DrugMAP Full Data Download File
Title - DrugMAP drug information in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
College of Pharmaceutical Sciences
Zhejiang University
https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)
ID: Drug ID
DN: Drug Name
HS: Highest Status
SN: Synonymous
CP: Company
TC: Therapeutic Class
DT: Drug Type
SQ: Sequence
PC: PubChem CID
MW: Molecular Weight
FM: Formula
IC: InChI
CS: Canonical SMILES
IK: InChIKey
IU: IUPAC Name
CA: CAS Number
CB: ChEBI ID
DE: Disease Entry
DMMHNU2 ID DMMHNU2
DMMHNU2 DN (S)-(+)-Dimethindene maleate
DMMHNU2 HS Approved
DMMHNU2 SN UNII-J43ZL3WTLN; J43ZL3WTLN; 136152-65-3; DSSTox_RID_83231; DSSTox_CID_28966; DSSTox_GSID_49040; Dimethindene maleate, (+)-; CAS-1217457-81-2; NCGC00025158-01; 121367-05-3; Dimethindene maleate, (S)-(+)-; DTXSID8049040; CHEMBL2356801; MolPort-023-276-095; HMS3267J12; Tox21_113582; AKOS024456589; Tox21_113582_1; NCGC00025158-02; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1S)-1-(2-pyridinyl)ethyl)-, (2Z)-2-butenedioate (1:1); B6734; (S)-(+)-Dimethindene maleate, > UNII-6LL60J9E0O component
DMMHNU2 TC Antiinflammatory Agents
DMMHNU2 DT Small molecular drug
DMMHNU2 PC 56972160
DMMHNU2 MW 408.5
DMMHNU2 FM C24H28N2O4
DMMHNU2 IC InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m1./s1
DMMHNU2 CS C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMMHNU2 IK SWECWXGUJQLXJF-HFNHQGOYSA-N
DMMHNU2 IU (Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1S)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
DMMHNU2 CA CAS 136152-65-3
DMMHNU2 DE Pruritus
DMIAHVU ID DMIAHVU
DMIAHVU DN 2-deoxyglucose
DMIAHVU HS Approved
DMIAHVU SN 154-17-6; Deoxyglucose; 2-Deoxy-D-mannose; 2-Deoxy-D-arabinohexose; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; arabino-Hexose, 2-deoxy-; D-Glucose, 2-deoxy-; 9G2MP84A8W; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; AK-44445; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; d-2-glucodesose; D-2dGlc; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; 2-INNo-D-AEIIC; SCHEMBL7670; AC1L33KH; KSC175S5P; 4-01-00-04282 (Beilstein Handbook Reference); Jsp003004; CHEMBL2074932; CTK0H5957; MolPort-002-317-302; 2-deoxy-D-glucose
DMIAHVU CP Threshold Pharmaceuticals
DMIAHVU DT Small molecular drug
DMIAHVU PC 108223
DMIAHVU MW 164.16
DMIAHVU FM C6H12O5
DMIAHVU IC InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
DMIAHVU CS C(C=O)[C@H]([C@@H]([C@@H](CO)O)O)O
DMIAHVU IK VRYALKFFQXWPIH-PBXRRBTRSA-N
DMIAHVU IU (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal
DMIAHVU CA CAS 154-17-6
DMIAHVU DE Solid tumour/cancer
DMYFBMS ID DMYFBMS
DMYFBMS DN 99mTc-fanolesomab
DMYFBMS HS Approved
DMYFBMS SN LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody
DMYFBMS CP Palatin Technologies
DMYFBMS DT Antibody
DMYFBMS DE Appendicitis
DMVZO01 ID DMVZO01
DMVZO01 DN 99mTc-sestamibi
DMVZO01 HS Approved
DMVZO01 SN Sestamibi; RP-30; Tc-MIBI; Technetium-99m sestamibi
DMVZO01 CP Bristol-Myers Squibb Pharma Co
DMVZO01 DT Small molecular drug
DMVZO01 PC 9832136
DMVZO01 MW 777.9
DMVZO01 FM C36H66N6O6Tc+7
DMVZO01 IC InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+7/i;;;;;;1+1
DMVZO01 CS CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc+7]
DMVZO01 IK ZGDBEIODOXIKGQ-KTTJZPQESA-N
DMVZO01 IU 1-isocyano-2-methoxy-2-methylpropane;technetium-99(7+)
DMVZO01 DE Breast cancer
DMMN36E ID DMMN36E
DMMN36E DN Abacavir
DMMN36E HS Approved
DMMN36E SN Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
DMMN36E CP GlaxoSmithKline
DMMN36E TC Anti-HIV Agents
DMMN36E DT Small molecular drug
DMMN36E PC 441300
DMMN36E MW 286.33
DMMN36E FM C14H18N6O
DMMN36E IC InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
DMMN36E CS C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO
DMMN36E IK MCGSCOLBFJQGHM-SCZZXKLOSA-N
DMMN36E IU [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
DMMN36E CA CAS 136470-78-5
DMMN36E CB CHEBI:421707
DMMN36E DE Human immunodeficiency virus infection
DMOERGM ID DMOERGM
DMOERGM DN Abaloparatide
DMOERGM HS Approved
DMOERGM SN Tymlos
DMOERGM CP Radius Health
DMOERGM DT Recombinant protein
DMOERGM SQ Abaloparatide N-terminal peptide sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA
DMOERGM PC 76943386
DMOERGM MW 3961
DMOERGM FM C174H300N56O49
DMOERGM IC InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
DMOERGM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMOERGM IK BVISQZFBLRSESR-XSCWXTNMSA-N
DMOERGM IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMOERGM CA CAS 247062-33-5
DMOERGM DE Postmenopausal osteoporosis
DM2RX0I ID DM2RX0I
DM2RX0I DN Abametapir
DM2RX0I HS Approved
DM2RX0I SN 5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl
DM2RX0I DT Small molecular drug
DM2RX0I PC 15664
DM2RX0I MW 184.24
DM2RX0I FM C12H12N2
DM2RX0I IC InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3
DM2RX0I CS CC1=CN=C(C=C1)C2=NC=C(C=C2)C
DM2RX0I IK PTRATZCAGVBFIQ-UHFFFAOYSA-N
DM2RX0I IU 5-methyl-2-(5-methylpyridin-2-yl)pyridine
DM2RX0I CA CAS 1762-34-1
DM2RX0I DE Head and body lice
DM5WFNP ID DM5WFNP
DM5WFNP DN Abarelix
DM5WFNP HS Approved
DM5WFNP SN Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10
DM5WFNP CP Speciality European Pharma
DM5WFNP TC Anticancer Agents
DM5WFNP DT Small molecular drug
DM5WFNP PC 16131215
DM5WFNP MW 1416.1
DM5WFNP FM C72H95ClN14O14
DM5WFNP IC InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
DM5WFNP CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM5WFNP IK AIWRTTMUVOZGPW-HSPKUQOVSA-N
DM5WFNP IU (2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DM5WFNP CA CAS 183552-38-7
DM5WFNP CB CHEBI:337298
DM5WFNP DE Prostate cancer
DMSA8RU ID DMSA8RU
DMSA8RU DN Abatacept
DMSA8RU HS Approved
DMSA8RU SN Orencia (TN)
DMSA8RU CP Bristol-Myers Squibb
DMSA8RU TC Antirheumatic Agents
DMSA8RU SQ Abatacept monomer sequence: MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSA8RU DE Rheumatoid arthritis
DMJO6GV ID DMJO6GV
DMJO6GV DN Abciximab
DMJO6GV HS Approved
DMJO6GV SN ReoPro (TN)
DMJO6GV CP Eli Lilly
DMJO6GV TC Anticoagulants
DMJO6GV DT Monoclonal antibody
DMJO6GV SQ 1TXV:H ReoPro-like antibody Heavy Chain 1: EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 1DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >1TXV:H ReoPro-like antibody Heavy Chain 2EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 2DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
DMJO6GV DE Angina pectoris
DM8V75C ID DM8V75C
DM8V75C DN ABIRATERONE
DM8V75C HS Approved
DM8V75C SN Abiraterone (AR inhibitor)
DM8V75C DT Small molecular drug
DM8V75C PC 132971
DM8V75C MW 349.5
DM8V75C FM C24H31NO
DM8V75C IC InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
DM8V75C CS C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
DM8V75C IK GZOSMCIZMLWJML-VJLLXTKPSA-N
DM8V75C IU (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8V75C CA CAS 154229-19-3
DM8V75C CB CHEBI:68642
DM8V75C DE Prostate cancer
DMANBZI ID DMANBZI
DMANBZI DN Abiraterone acetate
DMANBZI HS Approved
DMANBZI SN CB-7630; JNJ-212082; Zytiga
DMANBZI TC Anticancer Agents
DMANBZI DT Small molecular drug
DMANBZI PC 9821849
DMANBZI MW 391.5
DMANBZI FM C26H33NO2
DMANBZI IC InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
DMANBZI CS CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
DMANBZI IK UVIQSJCZCSLXRZ-UBUQANBQSA-N
DMANBZI IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMANBZI CA CAS 154229-18-2
DMANBZI CB CHEBI:68639
DMANBZI DE Prostate cancer
DMZT2P0 ID DMZT2P0
DMZT2P0 DN Abobotulinum toxin A
DMZT2P0 HS Approved
DMZT2P0 SN AbobotulinumtoxinA; Azzalure; Dysport; Reloxin; Abobotulinum toxin A for injection; CNT-52120
DMZT2P0 CP Ipsen
DMZT2P0 DE Cervical cancer
DM7GCVW ID DM7GCVW
DM7GCVW DN Acalabrutinib
DM7GCVW HS Approved
DM7GCVW SN Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
DM7GCVW CP AstraZeneca/Acerta Pharma
DM7GCVW PC 71226662
DM7GCVW MW 465.5
DM7GCVW FM C26H23N7O2
DM7GCVW IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM7GCVW CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM7GCVW IK WDENQIQQYWYTPO-IBGZPJMESA-N
DM7GCVW IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM7GCVW CA CAS 1420477-60-6
DM7GCVW DE Chronic lymphocytic leukaemia; Mantle cell lymphoma
DMO381I ID DMO381I
DMO381I DN Acamprosate
DMO381I HS Approved
DMO381I SN AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid
DMO381I TC Alcohol Deterrents
DMO381I DT Small molecular drug
DMO381I PC 71158
DMO381I MW 181.21
DMO381I FM C5H11NO4S
DMO381I IC InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)
DMO381I CS CC(=O)NCCCS(=O)(=O)O
DMO381I IK AFCGFAGUEYAMAO-UHFFFAOYSA-N
DMO381I IU 3-acetamidopropane-1-sulfonic acid
DMO381I CA CAS 77337-76-9
DMO381I CB CHEBI:51041
DMO381I DE Alcohol dependence
DMRM3AW ID DMRM3AW
DMRM3AW DN Acarbose
DMRM3AW HS Approved
DMRM3AW SN acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369
DMRM3AW CP Bayer
DMRM3AW TC Hypoglycemic Agents
DMRM3AW DT Small molecular drug
DMRM3AW PC 41774
DMRM3AW MW 645.6
DMRM3AW FM C25H43NO18
DMRM3AW IC InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1
DMRM3AW CS C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
DMRM3AW IK XUFXOAAUWZOOIT-UGEKTDRHSA-N
DMRM3AW IU (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
DMRM3AW CA CAS 56180-94-0
DMRM3AW CB CHEBI:2376
DMRM3AW DE Diabetic complication; Cardiovascular disease
DM0TI4U ID DM0TI4U
DM0TI4U DN Acebutolol
DM0TI4U HS Approved
DM0TI4U SN Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
DM0TI4U CP Promius Pharma Llc
DM0TI4U TC Antihypertensive Agents
DM0TI4U DT Small molecular drug
DM0TI4U PC 1978
DM0TI4U MW 336.4
DM0TI4U FM C18H28N2O4
DM0TI4U IC InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
DM0TI4U CS CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
DM0TI4U IK GOEMGAFJFRBGGG-UHFFFAOYSA-N
DM0TI4U IU N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide
DM0TI4U CA CAS 37517-30-9
DM0TI4U CB CHEBI:2379
DM0TI4U DE Hypertension
DMOLNCZ ID DMOLNCZ
DMOLNCZ DN ACECLIDINE
DMOLNCZ HS Approved
DMOLNCZ SN (-)-aceclidine; R-(-)-aceclidine; GTPL288; ZB016005; [(8R)-1-azoniabicyclo[2.2.2]octan-8-yl] acetate
DMOLNCZ DT Small molecular drug
DMOLNCZ PC 1979
DMOLNCZ MW 169.22
DMOLNCZ FM C9H15NO2
DMOLNCZ IC InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
DMOLNCZ CS CC(=O)OC1CN2CCC1CC2
DMOLNCZ IK WRJPSSPFHGNBMG-UHFFFAOYSA-N
DMOLNCZ IU 1-azabicyclo[2.2.2]octan-3-yl acetate
DMOLNCZ CA CAS 827-61-2
DMOLNCZ CB CHEBI:93847
DMOLNCZ DE Glaucoma/ocular hypertension
DMZDF0B ID DMZDF0B
DMZDF0B DN Aceclofenac
DMZDF0B HS Approved
DMZDF0B SN Airtal; Barracan; Biofenac; Bristaflam; Falcol; Gerbin; Preservex; YT-919
DMZDF0B CP Almirall Prodesfarma SA
DMZDF0B DT Small molecular drug
DMZDF0B PC 71771
DMZDF0B MW 354.2
DMZDF0B FM C16H13Cl2NO4
DMZDF0B IC InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
DMZDF0B CS C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMZDF0B IK MNIPYSSQXLZQLJ-UHFFFAOYSA-N
DMZDF0B IU 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid
DMZDF0B CA CAS 89796-99-6
DMZDF0B CB CHEBI:31159
DMZDF0B DE Inflammation
DMH75KV ID DMH75KV
DMH75KV DN Acenocoumarol
DMH75KV HS Approved
DMH75KV SN Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
DMH75KV TC Anticoagulants
DMH75KV DT Small molecular drug
DMH75KV PC 54676537
DMH75KV MW 353.3
DMH75KV FM C19H15NO6
DMH75KV IC InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
DMH75KV CS CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O
DMH75KV IK VABCILAOYCMVPS-UHFFFAOYSA-N
DMH75KV IU 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one
DMH75KV CA CAS 152-72-7
DMH75KV CB CHEBI:53766
DMH75KV DE Thrombosis
DM1SRQT ID DM1SRQT
DM1SRQT DN Aceprometazine
DM1SRQT HS Approved
DM1SRQT SN Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB
DM1SRQT TC Antihistamines
DM1SRQT DT Small molecular drug
DM1SRQT PC 26035
DM1SRQT MW 326.5
DM1SRQT FM C19H22N2OS
DM1SRQT IC InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
DM1SRQT CS CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C
DM1SRQT IK XLOQNFNTQIRSOX-UHFFFAOYSA-N
DM1SRQT IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone
DM1SRQT CA CAS 13461-01-3
DM1SRQT CB CHEBI:53770
DM1SRQT DE Sleep-wake disorder
DMUIE76 ID DMUIE76
DMUIE76 DN Acetaminophen
DMUIE76 HS Approved
DMUIE76 SN acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet
DMUIE76 CP Beximco Pharma
DMUIE76 TC Analgesics
DMUIE76 DT Small molecular drug
DMUIE76 PC 1983
DMUIE76 MW 151.16
DMUIE76 FM C8H9NO2
DMUIE76 IC InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
DMUIE76 CS CC(=O)NC1=CC=C(C=C1)O
DMUIE76 IK RZVAJINKPMORJF-UHFFFAOYSA-N
DMUIE76 IU N-(4-hydroxyphenyl)acetamide
DMUIE76 CA CAS 103-90-2
DMUIE76 CB CHEBI:46195
DMUIE76 DE Pain
DM1AF5U ID DM1AF5U
DM1AF5U DN Acetazolamide
DM1AF5U HS Approved
DM1AF5U SN Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox
DM1AF5U TC Anticonvulsants
DM1AF5U DT Small molecular drug
DM1AF5U PC 1986
DM1AF5U MW 222.3
DM1AF5U FM C4H6N4O3S2
DM1AF5U IC InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
DM1AF5U CS CC(=O)NC1=NN=C(S1)S(=O)(=O)N
DM1AF5U IK BZKPWHYZMXOIDC-UHFFFAOYSA-N
DM1AF5U IU N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
DM1AF5U CA CAS 59-66-5
DM1AF5U CB CHEBI:27690
DM1AF5U DE Glaucoma/ocular hypertension
DM4SJ5Y ID DM4SJ5Y
DM4SJ5Y DN Acetic Acid, Glacial
DM4SJ5Y HS Approved
DM4SJ5Y SN ethanoic acid; 64-19-7; Ethylic acid; Acetic acid glacial; Acetic acid, glacial; Methanecarboxylic acid; Glacial acetic acid; Vinegar acid; Acetasol; Acide acetique; Essigsaeure; Aci-jel; Azijnzuur; Vinegar; Kyselina octova; Acido acetico; Octowy kwas; Pyroligneous acid; HOAc; Azijnzuur [Dutch]; Ethanoic acid monomer; acetyl alcohol; Aceticum acidum; Essigsaeure [German]; ethoic acid; Caswell No 003; Otic Tridesilon; Octowy kwas [Polish]; Otic Domeboro; Acetic acid (natural); Kyselina octova [Czech]; Acide acetique [French]; Orlex; Vosol; Acetic Acid 025% In Plastic Container
DM4SJ5Y CP Actavis Mid Atlantic Llc
DM4SJ5Y TC Antiinfective Agents
DM4SJ5Y DT Small molecular drug
DM4SJ5Y PC 176
DM4SJ5Y MW 60.05
DM4SJ5Y FM C2H4O2
DM4SJ5Y IC InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
DM4SJ5Y CS CC(=O)O
DM4SJ5Y IK QTBSBXVTEAMEQO-UHFFFAOYSA-N
DM4SJ5Y IU acetic acid
DM4SJ5Y CA CAS 64-19-7
DM4SJ5Y CB CHEBI:15366
DM4SJ5Y DE infection in the ear canal
DMR6N7H ID DMR6N7H
DMR6N7H DN Acetohexamide
DMR6N7H HS Approved
DMR6N7H SN Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
DMR6N7H TC Hypoglycemic Agents
DMR6N7H DT Small molecular drug
DMR6N7H PC 1989
DMR6N7H MW 324.4
DMR6N7H FM C15H20N2O4S
DMR6N7H IC InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
DMR6N7H CS CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
DMR6N7H IK VGZSUPCWNCWDAN-UHFFFAOYSA-N
DMR6N7H IU 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
DMR6N7H CA CAS 968-81-0
DMR6N7H CB CHEBI:28052
DMR6N7H DE Diabetic complication
DMYX7NI ID DMYX7NI
DMYX7NI DN Acetohydroxamic Acid
DMYX7NI HS Approved
DMYX7NI SN AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)
DMYX7NI TC Antiinfective Agents
DMYX7NI DT Small molecular drug
DMYX7NI PC 1990
DMYX7NI MW 75.07
DMYX7NI FM C2H5NO2
DMYX7NI IC InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
DMYX7NI CS CC(=O)NO
DMYX7NI IK RRUDCFGSUDOHDG-UHFFFAOYSA-N
DMYX7NI IU N-hydroxyacetamide
DMYX7NI CA CAS 546-88-3
DMYX7NI CB CHEBI:27777
DMYX7NI DE Urinary tract infection
DMZV2PJ ID DMZV2PJ
DMZV2PJ DN Acetophenazine
DMZV2PJ HS Approved
DMZV2PJ SN Acephenazinum; Acetophenazina; Acetophenazinum; Tindal; Acetophenazine [INN]; Acetophenazina [INN-Spanish]; Acetophenazinum [INN-Latin]; Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine
DMZV2PJ TC Antipsychotic Agents
DMZV2PJ DT Small molecular drug
DMZV2PJ PC 17676
DMZV2PJ MW 411.6
DMZV2PJ FM C23H29N3O2S
DMZV2PJ IC InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3
DMZV2PJ CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMZV2PJ IK WNTYBHLDCKXEOT-UHFFFAOYSA-N
DMZV2PJ IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMZV2PJ CA CAS 2751-68-0
DMZV2PJ CB CHEBI:2401
DMZV2PJ DE Bipolar disorder
DMDF79Z ID DMDF79Z
DMDF79Z DN Acetylcholine
DMDF79Z HS Approved
DMDF79Z SN acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e
DMDF79Z CP Novartis Pharmaceuticals Corp
DMDF79Z TC Cardiovascular Agents
DMDF79Z DT Small molecular drug
DMDF79Z PC 187
DMDF79Z MW 146.21
DMDF79Z FM C7H16NO2+
DMDF79Z IC InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1
DMDF79Z CS CC(=O)OCC[N+](C)(C)C
DMDF79Z IK OIPILFWXSMYKGL-UHFFFAOYSA-N
DMDF79Z IU 2-acetyloxyethyl(trimethyl)azanium
DMDF79Z CA CAS 51-84-3
DMDF79Z CB CHEBI:15355
DMDF79Z DE Cataract
DMHAUO0 ID DMHAUO0
DMHAUO0 DN Acetyldigitoxin
DMHAUO0 HS Approved
DMHAUO0 SN Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CP Norvatis Phamaceuticals Corporation
DMHAUO0 TC Cardiotonic Agents
DMHAUO0 DT Small molecular drug
DMHAUO0 PC 5284512
DMHAUO0 MW 807
DMHAUO0 FM C43H66O14
DMHAUO0 IC InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
DMHAUO0 CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O
DMHAUO0 IK HPMZBILYSWLILX-UMDUKNJSSA-N
DMHAUO0 IU [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CA CAS 1111-39-3
DMHAUO0 CB CHEBI:53773
DMHAUO0 DE Congestive heart failure
DMYLOVR ID DMYLOVR
DMYLOVR DN Aciclovir
DMYLOVR HS Approved
DMYLOVR SN acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir
DMYLOVR CP GlaxoSmithKline
DMYLOVR TC Antiviral Agents
DMYLOVR DT Small molecular drug
DMYLOVR PC 135398513
DMYLOVR MW 225.2
DMYLOVR FM C8H11N5O3
DMYLOVR IC InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
DMYLOVR CS C1=NC2=C(N1COCCO)N=C(NC2=O)N
DMYLOVR IK MKUXAQIIEYXACX-UHFFFAOYSA-N
DMYLOVR IU 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one
DMYLOVR CA CAS 59277-89-3
DMYLOVR CB CHEBI:2453
DMYLOVR DE Virus infection; Herpes simplex virus infection
DM8BKU9 ID DM8BKU9
DM8BKU9 DN Acitretin
DM8BKU9 HS Approved
DM8BKU9 SN Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 TC Keratolytic Agents
DM8BKU9 DT Small molecular drug
DM8BKU9 PC 5284513
DM8BKU9 MW 326.4
DM8BKU9 FM C21H26O3
DM8BKU9 IC InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
DM8BKU9 CS CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC
DM8BKU9 IK IHUNBGSDBOWDMA-AQFIFDHZSA-N
DM8BKU9 IU (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 CA CAS 55079-83-9
DM8BKU9 CB CHEBI:50173
DM8BKU9 DE Psoriasis vulgaris
DMLFZHD ID DMLFZHD
DMLFZHD DN Aclarubicin
DMLFZHD HS Approved
DMLFZHD SN Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
DMLFZHD TC Anticancer Agents
DMLFZHD DT Small molecular drug
DMLFZHD PC 451415
DMLFZHD MW 811.9
DMLFZHD FM C42H53NO15
DMLFZHD IC InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
DMLFZHD CS CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
DMLFZHD IK USZYSDMBJDPRIF-SVEJIMAYSA-N
DMLFZHD IU methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
DMLFZHD CA CAS 57576-44-0
DMLFZHD CB CHEBI:77980
DMLFZHD DE Acute myeloid leukaemia
DM7JT24 ID DM7JT24
DM7JT24 DN Acocantherin
DM7JT24 HS Approved
DM7JT24 SN Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DM7JT24 TC Cardiotonic Agents
DM7JT24 DT Small molecular drug
DM7JT24 PC 439501
DM7JT24 MW 584.7
DM7JT24 FM C29H44O12
DM7JT24 IC InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DM7JT24 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DM7JT24 IK LPMXVESGRSUGHW-HBYQJFLCSA-N
DM7JT24 IU 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM7JT24 CA CAS 630-60-4
DM7JT24 CB CHEBI:472805
DM7JT24 DE Heart failure; Atrial fibrillation
DMTIGA0 ID DMTIGA0
DMTIGA0 DN Acrivastine
DMTIGA0 HS Approved
DMTIGA0 SN Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
DMTIGA0 CP Pfizer Pharmaceuticals
DMTIGA0 TC Antiinflammatory Agents
DMTIGA0 DT Small molecular drug
DMTIGA0 PC 5284514
DMTIGA0 MW 348.4
DMTIGA0 FM C22H24N2O2
DMTIGA0 IC InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
DMTIGA0 CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O
DMTIGA0 IK PWACSDKDOHSSQD-IUTFFREVSA-N
DMTIGA0 IU (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
DMTIGA0 CA CAS 87848-99-5
DMTIGA0 CB CHEBI:83168
DMTIGA0 DE Allergic rhinitis
DMQMV1B ID DMQMV1B
DMQMV1B DN Adalimumab
DMQMV1B HS Approved
DMQMV1B SN Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
DMQMV1B CP Abbott Laboratories
DMQMV1B TC Antirheumatic Agents
DMQMV1B DT Antibody
DMQMV1B SQ Light chain:: DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC > Heavy chain:EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
DMQMV1B DE Rheumatoid arthritis
DMX2358 ID DMX2358
DMX2358 DN Adapalene
DMX2358 HS Approved
DMX2358 SN Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
DMX2358 CP Galderma Laboratories
DMX2358 TC Dermatologic Agents
DMX2358 DT Small molecular drug
DMX2358 PC 60164
DMX2358 MW 412.5
DMX2358 FM C28H28O3
DMX2358 IC InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMX2358 CS COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMX2358 IK LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMX2358 IU 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMX2358 CA CAS 106685-40-9
DMX2358 CB CHEBI:31174
DMX2358 DE Acne vulgaris
DMM278X ID DMM278X
DMM278X DN Adefovir
DMM278X HS Approved
DMM278X SN ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
DMM278X DT Small molecular drug
DMM278X PC 60172
DMM278X MW 273.189
DMM278X FM C12H14Cl2N2
DMM278X IC InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
DMM278X CS C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O
DMM278X IK FIKAKWIAUPDISJ-UHFFFAOYSA-L
DMM278X IU 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
DMM278X CA CAS 106941-25-7
DMM278X CB CHEBI:2469
DMM278X DE Hepatitis B virus infection; Herpes simplex virus infection
DMMAWY1 ID DMMAWY1
DMMAWY1 DN Adefovir dipivoxil
DMMAWY1 HS Approved
DMMAWY1 SN Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV
DMMAWY1 CP Gilead Sciences
DMMAWY1 TC Antiviral Agents
DMMAWY1 DT Small molecular drug
DMMAWY1 PC 60871
DMMAWY1 MW 501.5
DMMAWY1 FM C20H32N5O8P
DMMAWY1 IC InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
DMMAWY1 CS CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C
DMMAWY1 IK WOZSCQDILHKSGG-UHFFFAOYSA-N
DMMAWY1 IU [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMMAWY1 CA CAS 142340-99-6
DMMAWY1 CB CHEBI:31175
DMMAWY1 DE Hepatitis B virus infection
DMYQDBO ID DMYQDBO
DMYQDBO DN Ademetionine
DMYQDBO HS Approved
DMYQDBO SN Ceritan; Samyr; Transmetil; Ademetionine butandisulphonate; Ademetionine disulfate tosylate; Ademetionine sulfate tosilate; FD-1561; FO-1561
DMYQDBO CP Bioresearch SpA
DMYQDBO DT Small molecular drug
DMYQDBO PC 34755
DMYQDBO MW 398.4
DMYQDBO FM C15H22N6O5S
DMYQDBO IC InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
DMYQDBO CS C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMYQDBO IK MEFKEPWMEQBLKI-AIRLBKTGSA-N
DMYQDBO IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate
DMYQDBO CA CAS 29908-03-0
DMYQDBO CB CHEBI:67040
DMYQDBO DE Cerebrovascular ischaemia; Hepatic fibrosis
DMZLHKJ ID DMZLHKJ
DMZLHKJ DN Adenine
DMZLHKJ HS Approved
DMZLHKJ SN ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine
DMZLHKJ TC Dietary supplement
DMZLHKJ DT Small molecular drug
DMZLHKJ PC 190
DMZLHKJ MW 135.13
DMZLHKJ FM C5H5N5
DMZLHKJ IC InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
DMZLHKJ CS C1=NC2=NC=NC(=C2N1)N
DMZLHKJ IK GFFGJBXGBJISGV-UHFFFAOYSA-N
DMZLHKJ IU 7H-purin-6-amine
DMZLHKJ CA CAS 73-24-5
DMZLHKJ CB CHEBI:16708
DMZLHKJ DE Malnutrition
DMM2NSK ID DMM2NSK
DMM2NSK DN Adenosine
DMM2NSK HS Approved
DMM2NSK SN Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
DMM2NSK TC Antiarrhythmic Agents
DMM2NSK DT Small molecular drug
DMM2NSK PC 60961
DMM2NSK MW 267.24
DMM2NSK FM C10H13N5O4
DMM2NSK IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMM2NSK CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMM2NSK IK OIRDTQYFTABQOQ-KQYNXXCUSA-N
DMM2NSK IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMM2NSK CA CAS 5536-17-4
DMM2NSK CB CHEBI:16335
DMM2NSK DE Paroxysmal supraventricular tachycardia
DMNIJT0 ID DMNIJT0
DMNIJT0 DN Adenosine monophosphate
DMNIJT0 HS Approved
DMNIJT0 SN ASMP; Adenovite; Adenyl; Adenylate; Cardiomone; Lycedan; Monophosphadenine; Muskeladenylsaeure; Myoston; PAdo; Phosaden; Phosphaden; Phosphentaside; AMP dianion; Adenine polynucleotides; Adenosine phosphate; Adenosini phosphas; Adenylic acid; Ergadenylic acid; Fosfato de adenosina; Muscle adenylic acid; POLY A; Polyadenylic acids; Vitamin B8; A-5mp; AMP (VAN); AMP (nucleotide); Adenosine Monophosphate (Amp); Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas [INN-Latin]; Adenyl (TN); Adenylic acid (VAN); Ado5'P; Fosfato de adenosina [INN-Spanish]; Muskeladenosin-phosphorsaeure; Phosphate d'adenosine; Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; My-B-Den; Phosphate d'adenosine [INN-French]; ADENOSINE-5'-PHOSPHATE; Adenosine 5'-(dihydrogen phosphate); Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5-monophosphate(2-); GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb
DMNIJT0 TC Dietary supplement
DMNIJT0 DT Small molecular drug
DMNIJT0 PC 6083
DMNIJT0 MW 347.22
DMNIJT0 FM C10H14N5O7P
DMNIJT0 IC InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMNIJT0 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMNIJT0 IK UDMBCSSLTHHNCD-KQYNXXCUSA-N
DMNIJT0 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMNIJT0 CA CAS 61-19-8
DMNIJT0 CB CHEBI:16027
DMNIJT0 DE Malnutrition
DM79F6G ID DM79F6G
DM79F6G DN Adenosine triphosphate
DM79F6G HS Approved
DM79F6G SN Adenylpyrophosphate; Triphosadenine; Triphosadenine (DCF); Adenosine 5'-triphosphate(4-); [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
DM79F6G TC Dietary supplement
DM79F6G DT Small molecular drug
DM79F6G PC 5957
DM79F6G MW 507.18
DM79F6G FM C10H16N5O13P3
DM79F6G IC InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DM79F6G CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DM79F6G IK ZKHQWZAMYRWXGA-KQYNXXCUSA-N
DM79F6G IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM79F6G CA CAS 56-65-5
DM79F6G CB CHEBI:15422
DM79F6G DE Bradycardia; Heart disease; Malnutrition
DMBHO9Y ID DMBHO9Y
DMBHO9Y DN Adinazolam
DMBHO9Y HS Approved
DMBHO9Y SN Adinazolamum; Deracyn; Adinazolam [USAN]; U 41123; Adinazolamum [INN-Latin]; Deracyn (TN); U 41,123;U-41123; Adinazolam (USAN/INN); Adinazolam [USAN:BAN:INN]; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
DMBHO9Y TC Antidepressants
DMBHO9Y DT Small molecular drug
DMBHO9Y PC 37632
DMBHO9Y MW 351.8
DMBHO9Y FM C19H18ClN5
DMBHO9Y IC InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
DMBHO9Y CS CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMBHO9Y IK GJSLOMWRLALDCT-UHFFFAOYSA-N
DMBHO9Y IU 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
DMBHO9Y CA CAS 37115-32-5
DMBHO9Y CB CHEBI:251412
DMBHO9Y DE Anxiety disorder
DMVWHTG ID DMVWHTG
DMVWHTG DN Afamelanotide
DMVWHTG HS Approved
DMVWHTG SN [Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH
DMVWHTG DT Small molecular drug
DMVWHTG PC 16197727
DMVWHTG MW 1646.8
DMVWHTG FM C78H111N21O19
DMVWHTG IC InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMVWHTG CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMVWHTG IK UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMVWHTG IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVWHTG CA CAS 75921-69-6
DMVWHTG DE Vitiligo; Erythropoietic porphyrias
DMT3D5I ID DMT3D5I
DMT3D5I DN Aflibercept
DMT3D5I HS Approved
DMT3D5I SN Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
DMT3D5I CP Sanofi
DMT3D5I SQ Protein sequence for aflibercept: SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMT3D5I DE Metastatic colorectal cancer
DMPOD47 ID DMPOD47
DMPOD47 DN Ajmalicine
DMPOD47 HS Approved
DMPOD47 SN MLS000111555; methyl 19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate; NSC72115; SMR000107477; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19.alpha.)-; 6474-90-4; WLN: T F6 D5 C666 EM ON SO TU& TTTJ R1 UVO1; Isoarteril; Oxayohimban-16-carboxylic acid,17-didehydro-19-methyl-, methyl ester, (19
DMPOD47 DT Small molecular drug
DMPOD47 PC 441975
DMPOD47 MW 352.4
DMPOD47 FM C21H24N2O3
DMPOD47 IC InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1
DMPOD47 CS C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMPOD47 IK GRTOGORTSDXSFK-XJTZBENFSA-N
DMPOD47 IU methyl (1S,15R,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMPOD47 CA CAS 483-04-5
DMPOD47 CB CHEBI:2524
DMPOD47 DE Circulatory disorder
DMDJW5K ID DMDJW5K
DMDJW5K DN Ajmaline
DMDJW5K HS Approved
DMDJW5K SN (17R,21
DMDJW5K DT Small molecular drug
DMDJW5K PC 6100671
DMDJW5K MW 326.4
DMDJW5K FM C20H26N2O2
DMDJW5K IC InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16-,17-,18+,19+,20+/m0/s1
DMDJW5K CS CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C
DMDJW5K IK CJDRUOGAGYHKKD-RQBLFBSQSA-N
DMDJW5K IU (1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMDJW5K CA CAS 4360-12-7
DMDJW5K DE Atrial fibrillation
DML6SRO ID DML6SRO
DML6SRO DN Alacepril
DML6SRO HS Approved
DML6SRO SN Cetapril (TN)
DML6SRO CP Dainippon
DML6SRO DT Small molecular drug
DML6SRO PC 71992
DML6SRO MW 406.5
DML6SRO FM C20H26N2O5S
DML6SRO IC InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
DML6SRO CS C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DML6SRO IK FHHHOYXPRDYHEZ-COXVUDFISA-N
DML6SRO IU (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DML6SRO CA CAS 74258-86-9
DML6SRO CB CHEBI:31182
DML6SRO DE Cardiovascular disease
DMYZ57N ID DMYZ57N
DMYZ57N DN Albendazole
DMYZ57N HS Approved
DMYZ57N SN Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
DMYZ57N CP GlaxoSmithKline
DMYZ57N TC Antiprotozoal Agents
DMYZ57N DT Small molecular drug
DMYZ57N PC 2082
DMYZ57N MW 265.33
DMYZ57N FM C12H15N3O2S
DMYZ57N IC InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMYZ57N CS CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMYZ57N IK HXHWSAZORRCQMX-UHFFFAOYSA-N
DMYZ57N IU methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
DMYZ57N CA CAS 54965-21-8
DMYZ57N CB CHEBI:16664
DMYZ57N DE Worm infection
DM1JEGF ID DM1JEGF
DM1JEGF DN Albiglutide
DM1JEGF HS Approved
DM1JEGF CP GSK
DM1JEGF SQ Albiglutide sequence: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
DM1JEGF PC 122173812
DM1JEGF MW 3284.6
DM1JEGF FM C148H223N39O46
DM1JEGF IC InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1
DM1JEGF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N
DM1JEGF IK OGWAVGNOAMXIIM-VTAHJYCESA-N
DM1JEGF IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1JEGF CB CHEBI:78425
DM1JEGF DE Type-2 diabetes
DM5JTPU ID DM5JTPU
DM5JTPU DN Albumin Human
DM5JTPU HS Approved
DM5JTPU SN Albumin (Human); Kedbumin
DM5JTPU CP Ge Healthcare
DM5JTPU DE Hypoalbuminemia
DM5J1NH ID DM5J1NH
DM5J1NH DN Alcaftadine
DM5J1NH HS Approved
DM5J1NH SN Lastacaft (TN)
DM5J1NH CP Vistakon Pharmaceuticals
DM5J1NH DT Small molecular drug
DM5J1NH PC 19371515
DM5J1NH MW 307.4
DM5J1NH FM C19H21N3O
DM5J1NH IC InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3
DM5J1NH CS CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1
DM5J1NH IK MWTBKTRZPHJQLH-UHFFFAOYSA-N
DM5J1NH IU 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
DM5J1NH CA CAS 147084-10-4
DM5J1NH CB CHEBI:71023
DM5J1NH DE Allergic conjunctivitis
DMAE84F ID DMAE84F
DMAE84F DN Alclometasone
DMAE84F HS Approved
DMAE84F SN Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone
DMAE84F CP GlaxoSmithKline
DMAE84F TC Antiinflammatory Agents
DMAE84F DT Small molecular drug
DMAE84F PC 5311000
DMAE84F MW 408.9
DMAE84F FM C22H29ClO5
DMAE84F IC InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
DMAE84F CS C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl
DMAE84F IK FJXOGVLKCZQRDN-PHCHRAKRSA-N
DMAE84F IU (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMAE84F CA CAS 67452-97-5
DMAE84F CB CHEBI:53776
DMAE84F DE Inflammation
DM2U4XQ ID DM2U4XQ
DM2U4XQ DN ALCURONIUM
DM2U4XQ HS Approved
DM2U4XQ SN Alcuronium
DM2U4XQ DT Small molecular drug
DM2U4XQ PC 21158560
DM2U4XQ MW 666.9
DM2U4XQ FM C44H50N4O2+2
DM2U4XQ IC InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1
DM2U4XQ CS C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\\CO)/C1)CC2
DM2U4XQ IK MUQUYTSLDVKIOF-CHJKCJHBSA-N
DM2U4XQ IU (2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol
DM2U4XQ CA CAS 23214-96-2
DM2U4XQ CB CHEBI:55313
DM2U4XQ DE Anaesthesia
DM4YMIS ID DM4YMIS
DM4YMIS DN Aldesleukin
DM4YMIS HS Approved
DM4YMIS SN Proleukin (TN)
DM4YMIS CP Chiron
DM4YMIS TC Anticancer Agents
DM4YMIS SQ Aldesleukin sequence: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DM4YMIS DE Renal cell carcinoma; Non-hodgkin lymphoma
DM9S2JW ID DM9S2JW
DM9S2JW DN Aldosterone
DM9S2JW HS Approved
DM9S2JW SN ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocortene; Aldocorten; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum; Aldosterona; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 18-Aldocorticosterone; Aldosterone [INN:BAN:DCF]; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB; Aldocorten; D-Aldosterone; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosterone, (+-)-Isomer; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
DM9S2JW TC Antihypertensive Agents
DM9S2JW DT Small molecular drug
DM9S2JW PC 5839
DM9S2JW MW 360.4
DM9S2JW FM C21H28O5
DM9S2JW IC InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
DM9S2JW CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O
DM9S2JW IK PQSUYGKTWSAVDQ-ZVIOFETBSA-N
DM9S2JW IU (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde
DM9S2JW CA CAS 52-39-1
DM9S2JW CB CHEBI:27584
DM9S2JW DE Hypertension
DMP1I6Y ID DMP1I6Y
DMP1I6Y DN Alectinib
DMP1I6Y HS Approved
DMP1I6Y SN 1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2; Alectinib; 9-ethyl-6,6-dimethyl-
DMP1I6Y DT Small molecular drug
DMP1I6Y PC 49806720
DMP1I6Y MW 482.6
DMP1I6Y FM C30H34N4O2
DMP1I6Y IC InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
DMP1I6Y CS CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C
DMP1I6Y IK KDGFLJKFZUIJMX-UHFFFAOYSA-N
DMP1I6Y IU 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
DMP1I6Y CA CAS 1256580-46-7
DMP1I6Y CB CHEBI:90936
DMP1I6Y DE Lung cancer; Non-small-cell lung cancer
DMMYPWO ID DMMYPWO
DMMYPWO DN Alefacept
DMMYPWO HS Approved
DMMYPWO SN Amevive (TN)
DMMYPWO TC Analgesics
DMMYPWO SQ Alefacept heavy chain : CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Alefacept light chainMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN
DMMYPWO DE Pain
DMZL3IV ID DMZL3IV
DMZL3IV DN Alemtuzumab
DMZL3IV HS Approved
DMZL3IV SN Campath (TN); MabCampath (TN); Campath-1H (TN)
DMZL3IV CP Bayer Schering Pharma
DMZL3IV TC Anticancer Agents
DMZL3IV DT Antibody
DMZL3IV SQ 1CE1:H CAMPATH-1H:Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 1DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1CE1:H CAMPATH-1H:Heavy Chain 2QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 2DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV >1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMZL3IV DE Chronic lymphocytic leukaemia; Multiple sclerosis
DMY2KX9 ID DMY2KX9
DMY2KX9 DN Alendronate
DMY2KX9 HS Approved
DMY2KX9 SN Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
DMY2KX9 CP Teva Pharmaceuticals
DMY2KX9 TC Bone Density Conservation Agents
DMY2KX9 DT Small molecular drug
DMY2KX9 PC 2088
DMY2KX9 MW 249.1
DMY2KX9 FM C4H13NO7P2
DMY2KX9 IC InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
DMY2KX9 CS C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
DMY2KX9 IK OGSPWJRAVKPPFI-UHFFFAOYSA-N
DMY2KX9 IU (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
DMY2KX9 CA CAS 66376-36-1
DMY2KX9 CB CHEBI:2567
DMY2KX9 DE Paget's disease; Osteoporosis
DMCKPUR ID DMCKPUR
DMCKPUR DN Alfaferone
DMCKPUR HS Approved
DMCKPUR SN Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha)
DMCKPUR CP Alfa Wassermann SpA
DMCKPUR DE Hairy cell leukaemia
DMVO0UB ID DMVO0UB
DMVO0UB DN Alfentanil
DMVO0UB HS Approved
DMVO0UB SN Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
DMVO0UB CP Janssen Pharmaceutica
DMVO0UB TC Anesthetics
DMVO0UB DT Small molecular drug
DMVO0UB PC 51263
DMVO0UB MW 416.5
DMVO0UB FM C21H32N6O3
DMVO0UB IC InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
DMVO0UB CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC
DMVO0UB IK IDBPHNDTYPBSNI-UHFFFAOYSA-N
DMVO0UB IU N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
DMVO0UB CA CAS 71195-58-9
DMVO0UB CB CHEBI:2569
DMVO0UB DE Anaesthesia
DMZVMKF ID DMZVMKF
DMZVMKF DN Alfuzosin
DMZVMKF HS Approved
DMZVMKF SN Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
DMZVMKF CP Sanofi-Aventis
DMZVMKF TC Antihypertensive Agents
DMZVMKF DT Small molecular drug
DMZVMKF PC 2092
DMZVMKF MW 389.4
DMZVMKF FM C19H27N5O4
DMZVMKF IC InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
DMZVMKF CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DMZVMKF IK WNMJYKCGWZFFKR-UHFFFAOYSA-N
DMZVMKF IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
DMZVMKF CA CAS 81403-80-7
DMZVMKF CB CHEBI:51141
DMZVMKF DE Benign prostatic hyperplasia
DM4LOD0 ID DM4LOD0
DM4LOD0 DN Alglucosidase alfa
DM4LOD0 HS Approved
DM4LOD0 SN Lumizyme (TN); Myozyme (TN)
DM4LOD0 CP Genzyme Corporation
DM4LOD0 TC Enzyme Replacement Agents
DM4LOD0 SQ Alglucosidase alfa: AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
DM4LOD0 DE Pompe disease
DM1BV7W ID DM1BV7W
DM1BV7W DN Aliskiren
DM1BV7W HS Approved
DM1BV7W SN Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]
DM1BV7W CP Norvatis Phamaceuticals Corporation
DM1BV7W TC Antihypertensive Agents
DM1BV7W DT Small molecular drug
DM1BV7W PC 5493444
DM1BV7W MW 551.8
DM1BV7W FM C30H53N3O6
DM1BV7W IC InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
DM1BV7W CS CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
DM1BV7W IK UXOWGYHJODZGMF-QORCZRPOSA-N
DM1BV7W IU (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
DM1BV7W CA CAS 173334-57-1
DM1BV7W CB CHEBI:601027
DM1BV7W DE Hypertension
DMME8LH ID DMME8LH
DMME8LH DN Alitretinoin
DMME8LH HS Approved
DMME8LH CP Ligand Pharmaceuticals
DMME8LH TC Anticancer Agents
DMME8LH DT Small molecular drug
DMME8LH PC 449171
DMME8LH MW 300.4
DMME8LH FM C20H28O2
DMME8LH IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+
DMME8LH CS CC1=C(C(CCC1)(C)C)/C=C/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C
DMME8LH IK SHGAZHPCJJPHSC-ZVCIMWCZSA-N
DMME8LH IU (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMME8LH CA CAS 5300-03-8
DMME8LH CB CHEBI:50648
DMME8LH DE Kaposi sarcoma
DMB4HFI ID DMB4HFI
DMB4HFI DN Alkavervir
DMB4HFI HS Approved
DMB4HFI CP 3m Pharmaceuticals Inc
DMB4HFI TC Cardiovascular Agents
DMB4HFI DE High blood pressure
DMNLHAC ID DMNLHAC
DMNLHAC DN Allopregnanolone
DMNLHAC HS Approved
DMNLHAC SN 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
DMNLHAC DT Small molecular drug
DMNLHAC PC 92786
DMNLHAC MW 318.5
DMNLHAC FM C21H34O2
DMNLHAC IC InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
DMNLHAC CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMNLHAC IK AURFZBICLPNKBZ-SYBPFIFISA-N
DMNLHAC IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMNLHAC CA CAS 516-54-1
DMNLHAC CB CHEBI:50169
DMNLHAC DE Postpartum depression; Essential tremor or related tremors; Status epilepticus seizure; Depression
DMLPAOB ID DMLPAOB
DMLPAOB DN Allopurinol
DMLPAOB HS Approved
DMLPAOB SN Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP
DMLPAOB CP GlaxoSmithKline
DMLPAOB TC Antimetabolites
DMLPAOB DT Small molecular drug
DMLPAOB PC 135401907
DMLPAOB MW 136.11
DMLPAOB FM C5H4N4O
DMLPAOB IC InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
DMLPAOB CS C1=NNC2=C1C(=O)NC=N2
DMLPAOB IK OFCNXPDARWKPPY-UHFFFAOYSA-N
DMLPAOB IU 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
DMLPAOB CA CAS 315-30-0
DMLPAOB CB CHEBI:40279
DMLPAOB DE Hyperuricaemia
DM0SYAN ID DM0SYAN
DM0SYAN DN Almitrine
DM0SYAN HS Approved
DM0SYAN SN Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN TC Antiinflammatory Agents
DM0SYAN DT Small molecular drug
DM0SYAN PC 33887
DM0SYAN MW 477.6
DM0SYAN FM C26H29F2N7
DM0SYAN IC InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
DM0SYAN CS C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DM0SYAN IK OBDOVFRMEYHSQB-UHFFFAOYSA-N
DM0SYAN IU 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN CA CAS 27469-53-0
DM0SYAN CB CHEBI:53778
DM0SYAN DE Chronic obstructive pulmonary disease
DM7I64Z ID DM7I64Z
DM7I64Z DN Almogran
DM7I64Z HS Approved
DM7I64Z SN Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
DM7I64Z CP Almirall Prodesfarma
DM7I64Z TC Antimigraine Agents
DM7I64Z DT Small molecular drug
DM7I64Z PC 123606
DM7I64Z MW 335.5
DM7I64Z FM C17H25N3O2S
DM7I64Z IC InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
DM7I64Z CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
DM7I64Z IK WKEMJKQOLOHJLZ-UHFFFAOYSA-N
DM7I64Z IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
DM7I64Z CA CAS 154323-57-6
DM7I64Z CB CHEBI:520985
DM7I64Z DE Migraine
DMFG5ST ID DMFG5ST
DMFG5ST DN Almotriptan malate
DMFG5ST HS Approved
DMFG5ST SN Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510
DMFG5ST PC 123607
DMFG5ST MW 469.6
DMFG5ST FM C21H31N3O7S
DMFG5ST IC QHATUKWEVNMHRY-UHFFFAOYSA-N
DMFG5ST CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O
DMFG5ST IK 1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)
DMFG5ST IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine;2-hydroxybutanedioic acid
DMFG5ST CA CAS 181183-52-8
DMFG5ST CB CHEBI:53781
DMFG5ST DE Migraine
DM8WI3R ID DM8WI3R
DM8WI3R DN Alogliptin
DM8WI3R HS Approved
DM8WI3R SN 850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203; UNII-JHC049LO86
DM8WI3R CP Takeda
DM8WI3R DT Small molecular drug
DM8WI3R PC 11450633
DM8WI3R MW 339.4
DM8WI3R FM C18H21N5O2
DM8WI3R IC InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
DM8WI3R CS CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
DM8WI3R IK ZSBOMTDTBDDKMP-OAHLLOKOSA-N
DM8WI3R IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
DM8WI3R CA CAS 850649-61-5
DM8WI3R CB CHEBI:72323
DM8WI3R DE Type-2 diabetes
DML2A03 ID DML2A03
DML2A03 DN Alosetron
DML2A03 HS Approved
DML2A03 SN Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
DML2A03 CP Prometheus Laboratories Inc
DML2A03 TC Gastrointestinal Agents
DML2A03 DT Small molecular drug
DML2A03 PC 2099
DML2A03 MW 294.35
DML2A03 FM C17H18N4O
DML2A03 IC InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
DML2A03 CS CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
DML2A03 IK JSWZEAMFRNKZNL-UHFFFAOYSA-N
DML2A03 IU 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DML2A03 CA CAS 122852-42-0
DML2A03 CB CHEBI:253342
DML2A03 DE Irritable bowel syndrome
DMEXMYK ID DMEXMYK
DMEXMYK DN Alpelisib
DMEXMYK HS Approved
DMEXMYK SN alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
DMEXMYK CP Novartis
DMEXMYK DT Small molecular drug
DMEXMYK PC 56649450
DMEXMYK MW 441.5
DMEXMYK FM C19H22F3N5O2S
DMEXMYK IC InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
DMEXMYK CS CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
DMEXMYK IK STUWGJZDJHPWGZ-LBPRGKRZSA-N
DMEXMYK IU (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
DMEXMYK CA CAS 1217486-61-7
DMEXMYK CB CHEBI:93752
DMEXMYK DE Solid tumour/cancer; Breast cancer
DMXC1K9 ID DMXC1K9
DMXC1K9 DN Alpha 1-PI
DMXC1K9 HS Approved
DMXC1K9 SN Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine
DMXC1K9 DT Small molecular drug
DMXC1K9 PC 3689
DMXC1K9 MW 325.4
DMXC1K9 FM C21H27NO2
DMXC1K9 IC InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
DMXC1K9 CS CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
DMXC1K9 IK UYNVMODNBIQBMV-UHFFFAOYSA-N
DMXC1K9 IU 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
DMXC1K9 CA CAS 23210-56-2
DMXC1K9 CB CHEBI:93829
DMXC1K9 DE Alpha-1 antitrypsin deficiency; Cancer related pain
DMAS02L ID DMAS02L
DMAS02L DN Alpha-acetyldigoxin
DMAS02L HS Approved
DMAS02L SN Dioxanin (TN); Lanatilin (TN); Sandolanid (TN)
DMAS02L DT Small molecular drug
DMAS02L PC 11765960
DMAS02L MW 823
DMAS02L FM C43H66O15
DMAS02L IC InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMAS02L CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)OC(=O)C)O
DMAS02L IK HWKJSYYYURVNQU-DXJNJSHLSA-N
DMAS02L IU [(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-3-hydroxy-2-methyloxan-4-yl] acetate
DMAS02L CA CAS 5511-98-8
DMAS02L DE Cardiovascular disease
DMN7Y9K ID DMN7Y9K
DMN7Y9K DN Alpidem
DMN7Y9K HS Approved
DMN7Y9K SN ALPIDEM; 82626-01-5; Ananxyl; Alpidemum [Latin]; UNII-I93SC245QZ; SL 80.0342-00; 2-(6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide; 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide; CHEMBL54349; I93SC245QZ; S-800342; NCGC00182850-01; 6-Chlor-2-(4-chlorphenyl)-N,N-dipropylimidazol(1,2-a)pyridin-3-acetamid; DSSTox_RID_83237; DSSTox_CID_28972; DSSTox_GSID_49046; Alpidemum; 6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide
DMN7Y9K DT Small molecular drug
DMN7Y9K PC 54897
DMN7Y9K MW 404.3
DMN7Y9K FM C21H23Cl2N3O
DMN7Y9K IC InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
DMN7Y9K CS CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMN7Y9K IK JRTIDHTUMYMPRU-UHFFFAOYSA-N
DMN7Y9K IU 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
DMN7Y9K CA CAS 82626-01-5
DMN7Y9K CB CHEBI:135649
DMN7Y9K DE Anxiety disorder
DMC7XDN ID DMC7XDN
DMC7XDN DN Alprazolam
DMC7XDN HS Approved
DMC7XDN SN Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CP Pfizer Pharmaceuticals
DMC7XDN TC Hypnotics and Sedatives
DMC7XDN DT Small molecular drug
DMC7XDN PC 2118
DMC7XDN MW 308.8
DMC7XDN FM C17H13ClN4
DMC7XDN IC InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
DMC7XDN CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMC7XDN IK VREFGVBLTWBCJP-UHFFFAOYSA-N
DMC7XDN IU 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CA CAS 28981-97-7
DMC7XDN CB CHEBI:2611
DMC7XDN DE Anxiety disorder; Epilepsy
DMWH7NQ ID DMWH7NQ
DMWH7NQ DN Alprostadil
DMWH7NQ HS Approved
DMWH7NQ SN Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
DMWH7NQ CP Pfizer Pharmaceuticals
DMWH7NQ TC Vasodilator Agents
DMWH7NQ DT Small molecular drug
DMWH7NQ PC 5280723
DMWH7NQ MW 354.5
DMWH7NQ FM C20H34O5
DMWH7NQ IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
DMWH7NQ CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMWH7NQ IK GMVPRGQOIOIIMI-DWKJAMRDSA-N
DMWH7NQ IU 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMWH7NQ CA CAS 745-65-3
DMWH7NQ CB CHEBI:15544
DMWH7NQ DE Erectile dysfunction; Diabetic foot ulcer
DMB47TQ ID DMB47TQ
DMB47TQ DN Alseroxylon
DMB47TQ HS Approved
DMB47TQ TC Antihypertensive Agents
DMB47TQ DE Hypertension
DMRJ3YX ID DMRJ3YX
DMRJ3YX DN Alteplase
DMRJ3YX HS Approved
DMRJ3YX SN Activase (TN)
DMRJ3YX CP Boehringer Ingelheim Ltd
DMRJ3YX TC Thrombolytic Agents
DMRJ3YX SQ Alteplase sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMRJ3YX DE Pulmonary embolism
DMKLAYG ID DMKLAYG
DMKLAYG DN Altretamine
DMKLAYG HS Approved
DMKLAYG SN Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG TC Anticancer Agents
DMKLAYG DT Small molecular drug
DMKLAYG PC 2123
DMKLAYG MW 210.28
DMKLAYG FM C9H18N6
DMKLAYG IC InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
DMKLAYG CS CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
DMKLAYG IK UUVWYPNAQBNQJQ-UHFFFAOYSA-N
DMKLAYG IU 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG CA CAS 645-05-6
DMKLAYG CB CHEBI:24564
DMKLAYG DE Ovarian cancer
DMO9WDS ID DMO9WDS
DMO9WDS DN Altropane
DMO9WDS HS Approved
DMO9WDS SN Carbon-11-Altropane; Iodine-123-Altropane; 11C-Altropane; 123I-Altropane
DMO9WDS CP Harvard University
DMO9WDS DT Small molecular drug
DMO9WDS PC 6440180
DMO9WDS MW 429.3
DMO9WDS FM C18H21FINO2
DMO9WDS IC InChI=1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1
DMO9WDS CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)F
DMO9WDS IK GTQLIPQFXVKRKJ-UNSMHXHVSA-N
DMO9WDS IU methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
DMO9WDS CA CAS 180468-34-2
DMO9WDS CB CHEBI:135696
DMO9WDS DE Attention deficit hyperactivity disorder
DM6ECN9 ID DM6ECN9
DM6ECN9 DN Aluminium
DM6ECN9 HS Approved
DM6ECN9 SN ALUMINUM; Adom; Aluminio; Metana; AO Al; Al alloy; Alaun [German]; Allbri aluminum paste and powder; Alumina fibre; Aluminium bronze; Aluminium flake; Aluminum alloy; Aluminum dehydrated; Aluminum dust; Aluminum metal; Aluminum powder; Aluminum production; Aluminum pyro powders; Aluminum soluble salts; Aluminum welding fumes; Emanay atomized aluminum powder; Metana aluminum paste; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminum; Noral aluminium; Noral aluminum; Noral ink grade aluminium; A 00; A 95; A 99; A 995; A 999; AA 1099; AA1199; AD 1; AD1M; AO A1; AV00; AV000; Aa1193; Aluminum 27; Aluminum A00; Aluminum hydride [UN2463] [Dangerous when wet]; JISC 3108; JISC 3110; L16; NA9260; Pigment metal 1; ALUMINUM, ATOMIZED; Al(0); Aluminium(0); Aluminium, elementar; Aluminum (dust or fume); Aluminum (fume or dust); Aluminum (metal); Aluminum metal, alkyls; Aluminum metal, pyro powders; Aluminum metal, respirable fraction; Aluminum metal, soluble salts; Aluminum metal, total dust; Aluminum metal, welding fumes; Aluminum powder, coated [UN1309] [Flammable solid]; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum, elemental; Aluminum, molten [NA9260] [Class 9]; Aluminum, pyro powders; Aluminum, soluble salts; Aluminum, welding fumes; C-Pigment 1; C-Pigment 1 [German]; Noral non-leafing grade; Aluminum, pyro powders/welding fumes; C.I. 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); ALUMINUM, 99.999%; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11008_ALDRICH; 11008_RIEDEL; 11009_ALDRICH; 11009_RIEDEL; 11010_ALDRICH; 11010_RIEDEL; 13Al
DM6ECN9 TC Antiinflammatory Agents
DM6ECN9 DT Small molecular drug
DM6ECN9 PC 5359268
DM6ECN9 MW 26.981
DM6ECN9 FM Al
DM6ECN9 IC InChI=1S/Al
DM6ECN9 CS [Al]
DM6ECN9 IK XAGFODPZIPBFFR-UHFFFAOYSA-N
DM6ECN9 IU aluminum
DM6ECN9 CA CAS 7429-90-5
DM6ECN9 CB CHEBI:28984
DM6ECN9 DE Hyperhidrosis
DMHR8KW ID DMHR8KW
DMHR8KW DN Alvimopan
DMHR8KW HS Approved
DMHR8KW SN Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CP GSK
DMHR8KW TC Analgesics
DMHR8KW DT Small molecular drug
DMHR8KW PC 5488548
DMHR8KW MW 424.5
DMHR8KW FM C25H32N2O4
DMHR8KW IC InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
DMHR8KW CS C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O
DMHR8KW IK UPNUIXSCZBYVBB-JVFUWBCBSA-N
DMHR8KW IU 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CA CAS 156053-89-3
DMHR8KW CB CHEBI:135686
DMHR8KW DE Gastrointestinal disease
DMS3YE9 ID DMS3YE9
DMS3YE9 DN Amantadine
DMS3YE9 HS Approved
DMS3YE9 SN Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane
DMS3YE9 TC Antiviral Agents
DMS3YE9 DT Small molecular drug
DMS3YE9 PC 2130
DMS3YE9 MW 151.25
DMS3YE9 FM C10H17N
DMS3YE9 IC InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
DMS3YE9 CS C1C2CC3CC1CC(C2)(C3)N
DMS3YE9 IK DKNWSYNQZKUICI-UHFFFAOYSA-N
DMS3YE9 IU adamantan-1-amine
DMS3YE9 CA CAS 768-94-5
DMS3YE9 CB CHEBI:2618
DMS3YE9 DE Influenza A virus infection
DMOP0BL ID DMOP0BL
DMOP0BL DN Ambenonium
DMOP0BL HS Approved
DMOP0BL SN Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
DMOP0BL CP Sanofi Aventis Us Llc
DMOP0BL TC Antiarrhythmic Agents
DMOP0BL DT Small molecular drug
DMOP0BL PC 2131
DMOP0BL MW 537.6
DMOP0BL FM C28H42Cl2N4O2+2
DMOP0BL IC InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
DMOP0BL CS CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl
DMOP0BL IK OMHBPUNFVFNHJK-UHFFFAOYSA-P
DMOP0BL IU (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium
DMOP0BL CA CAS 7648-98-8
DMOP0BL CB CHEBI:2627
DMOP0BL DE Myasthenia gravis
DMD1QXW ID DMD1QXW
DMD1QXW DN Ambrisentan
DMD1QXW HS Approved
DMD1QXW SN Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CP GSK
DMD1QXW DT Small molecular drug
DMD1QXW PC 6918493
DMD1QXW MW 378.4
DMD1QXW FM C22H22N2O4
DMD1QXW IC InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMD1QXW CS CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
DMD1QXW IK OUJTZYPIHDYQMC-LJQANCHMSA-N
DMD1QXW IU (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CA CAS 177036-94-1
DMD1QXW CB CHEBI:135949
DMD1QXW DE Pulmonary arterial hypertension
DMWJE9D ID DMWJE9D
DMWJE9D DN Ambroxol
DMWJE9D HS Approved
DMWJE9D SN Ambroxol hydrochloride; 23828-92-4; Ambroxol HCl; Mucosolvan; Mucoangin; Ambroxolhydrochloride; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; UNII-CC995ZMV90; Ambroxol hydrochloride; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; Ambroxol Hydrochloride [JAN]; CC995ZMV90; 15942-05-9; Ambroxol hydrochloride (JAN); 2-Amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride
DMWJE9D CP Exsar
DMWJE9D DT Small molecular drug
DMWJE9D PC 2132
DMWJE9D MW 378.1
DMWJE9D FM C13H18Br2N2O
DMWJE9D IC InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2
DMWJE9D CS C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
DMWJE9D IK JBDGDEWWOUBZPM-UHFFFAOYSA-N
DMWJE9D IU 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
DMWJE9D CA CAS 18683-91-5
DMWJE9D CB CHEBI:92994
DMWJE9D DE Bronchitis
DMM1JL9 ID DMM1JL9
DMM1JL9 DN Amcinonide
DMM1JL9 HS Approved
DMM1JL9 SN Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate
DMM1JL9 TC Antiinflammatory Agents
DMM1JL9 DT Small molecular drug
DMM1JL9 PC 443958
DMM1JL9 MW 502.6
DMM1JL9 FM C28H35FO7
DMM1JL9 IC InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
DMM1JL9 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6
DMM1JL9 IK ILKJAFIWWBXGDU-MOGDOJJUSA-N
DMM1JL9 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate
DMM1JL9 CA CAS 51022-69-6
DMM1JL9 CB CHEBI:31199
DMM1JL9 DE Inflammation
DMIG6FY ID DMIG6FY
DMIG6FY DN Amdinocillin
DMIG6FY HS Approved
DMIG6FY SN Coactin; Hexacillin; Mecilinamo; Mecillinam; Mecillinamum; Selexidin; Amdinocillin Mecillinam; Amdinocillin [USAN]; Penicillin HX; FL 1060; Ro 109070; Amdinocillin (USAN); Coactin (TN); FL-1060; Mecilinamo [INN-Spanish]; Mecillinam (INN); Mecillinamum [INN-Latin]; Ro 10-9070; Ro-10-9070; Rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid
DMIG6FY CP Leo Pharmaceutical
DMIG6FY TC Antibiotics
DMIG6FY DT Small molecular drug
DMIG6FY PC 36273
DMIG6FY MW 325.4
DMIG6FY FM C15H23N3O3S
DMIG6FY IC InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1
DMIG6FY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C
DMIG6FY IK BWWVAEOLVKTZFQ-NTZNESFSSA-N
DMIG6FY IU (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIG6FY CA CAS 32887-01-7
DMIG6FY DE Bacterial infection
DM6I2WQ ID DM6I2WQ
DM6I2WQ DN Amezinium
DM6I2WQ HS Approved
DM6I2WQ SN Amezinium methyl sulfate
DM6I2WQ DT Small molecular drug
DM6I2WQ PC 71927
DM6I2WQ MW 202.23
DM6I2WQ FM C11H12N3O+
DM6I2WQ IC InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
DM6I2WQ CS COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
DM6I2WQ IK VXROHTDSRBRJLN-UHFFFAOYSA-O
DM6I2WQ IU 6-methoxy-1-phenylpyridazin-1-ium-4-amine
DM6I2WQ CA CAS 41658-78-0
DM6I2WQ CB CHEBI:145698
DM6I2WQ DE Hypotension
DM9YSNQ ID DM9YSNQ
DM9YSNQ DN Amfepramone
DM9YSNQ HS Approved
DM9YSNQ SN Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone; Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone
DM9YSNQ DT Small molecular drug
DM9YSNQ PC 7029
DM9YSNQ MW 205.3
DM9YSNQ FM C13H19NO
DM9YSNQ IC InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
DM9YSNQ CS CCN(CC)C(C)C(=O)C1=CC=CC=C1
DM9YSNQ IK XXEPPPIWZFICOJ-UHFFFAOYSA-N
DM9YSNQ IU 2-(diethylamino)-1-phenylpropan-1-one
DM9YSNQ CA CAS 90-84-6
DM9YSNQ CB CHEBI:4530
DM9YSNQ DE Obesity; Migraine
DMK08L3 ID DMK08L3
DMK08L3 DN Amifampridine
DMK08L3 HS Approved
DMK08L3 SN 3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913
DMK08L3 CP Catalyst Pharmaceuticals
DMK08L3 PC 5918
DMK08L3 MW 109.13
DMK08L3 FM C5H7N3
DMK08L3 IC InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
DMK08L3 CS C1=CN=CC(=C1N)N
DMK08L3 IK OYTKINVCDFNREN-UHFFFAOYSA-N
DMK08L3 IU pyridine-3,4-diamine
DMK08L3 CA CAS 54-96-6
DMK08L3 CB CHEBI:135948
DMK08L3 DE LambertEaton myasthenic syndrome
DM5FL14 ID DM5FL14
DM5FL14 DN Amifostine
DM5FL14 HS Approved
DM5FL14 SN Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310
DM5FL14 CP Medimmune Oncology Inc
DM5FL14 DT Small molecular drug
DM5FL14 PC 2141
DM5FL14 MW 214.23
DM5FL14 FM C5H15N2O3PS
DM5FL14 IC InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
DM5FL14 CS C(CN)CNCCSP(=O)(O)O
DM5FL14 IK JKOQGQFVAUAYPM-UHFFFAOYSA-N
DM5FL14 IU 2-(3-aminopropylamino)ethylsulfanylphosphonic acid
DM5FL14 CA CAS 20537-88-6
DM5FL14 CB CHEBI:2636
DM5FL14 DE Mucositis
DM5PDRB ID DM5PDRB
DM5PDRB DN Amikacin
DM5PDRB HS Approved
DM5PDRB SN Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
DM5PDRB CP Abbott Laboratories
DM5PDRB TC Antibiotics
DM5PDRB DT Small molecular drug
DM5PDRB PC 37768
DM5PDRB MW 585.6
DM5PDRB FM C22H43N5O13
DM5PDRB IC InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
DM5PDRB CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DM5PDRB IK LKCWBDHBTVXHDL-RMDFUYIESA-N
DM5PDRB IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DM5PDRB CA CAS 37517-28-5
DM5PDRB CB CHEBI:2637
DM5PDRB DE Bacterial infection; Tuberculosis
DMRTSGP ID DMRTSGP
DMRTSGP DN Amiloride
DMRTSGP HS Approved
DMRTSGP SN Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)
DMRTSGP CP Tornett pharmaceutical
DMRTSGP TC Diuretics
DMRTSGP DT Small molecular drug
DMRTSGP PC 16231
DMRTSGP MW 229.63
DMRTSGP FM C6H8ClN7O
DMRTSGP IC InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
DMRTSGP CS C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
DMRTSGP IK XSDQTOBWRPYKKA-UHFFFAOYSA-N
DMRTSGP IU 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMRTSGP CA CAS 2609-46-3
DMRTSGP CB CHEBI:2639
DMRTSGP DE Congestive heart failure
DMFGND4 ID DMFGND4
DMFGND4 DN Aminocaproic acid
DMFGND4 HS Approved
DMFGND4 SN 6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
DMFGND4 CP Intelfarm Co.
DMFGND4 TC Antifibrinolytic Agents
DMFGND4 DT Small molecular drug
DMFGND4 PC 564
DMFGND4 MW 131.17
DMFGND4 FM C6H13NO2
DMFGND4 IC InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
DMFGND4 CS C(CCC(=O)O)CCN
DMFGND4 IK SLXKOJJOQWFEFD-UHFFFAOYSA-N
DMFGND4 IU 6-aminohexanoic acid
DMFGND4 CA CAS 60-32-2
DMFGND4 CB CHEBI:16586
DMFGND4 DE Bleeding disorder; Postoperative hemorrhage
DMWFHMZ ID DMWFHMZ
DMWFHMZ DN Aminoglutethimide
DMWFHMZ HS Approved
DMWFHMZ SN Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
DMWFHMZ CP Norvatis Phamaceuticals Corporation
DMWFHMZ TC Anticancer Agents
DMWFHMZ DT Small molecular drug
DMWFHMZ PC 2145
DMWFHMZ MW 232.28
DMWFHMZ FM C13H16N2O2
DMWFHMZ IC InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
DMWFHMZ CS CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMWFHMZ IK ROBVIMPUHSLWNV-UHFFFAOYSA-N
DMWFHMZ IU 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
DMWFHMZ CA CAS 125-84-8
DMWFHMZ CB CHEBI:2654
DMWFHMZ DE Cushing disease
DMS4BLQ ID DMS4BLQ
DMS4BLQ DN Aminolevulinic acid hci
DMS4BLQ HS Approved
DMS4BLQ SN Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)
DMS4BLQ DT Small molecular drug
DMS4BLQ PC 137
DMS4BLQ MW 131.13
DMS4BLQ FM C5H9NO3
DMS4BLQ IC InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
DMS4BLQ CS C(CC(=O)O)C(=O)CN
DMS4BLQ IK ZGXJTSGNIOSYLO-UHFFFAOYSA-N
DMS4BLQ IU 5-amino-4-oxopentanoic acid
DMS4BLQ CA CAS 106-60-5
DMS4BLQ CB CHEBI:17549
DMS4BLQ DE Acne vulgaris; Actinic keratosis
DMWNHPC ID DMWNHPC
DMWNHPC DN Aminolevulinic Acid Hydrochloride
DMWNHPC HS Approved
DMWNHPC SN Levulan; Levulan Kerastick
DMWNHPC CP Dusa Pharmaceuticals Inc
DMWNHPC DT Small molecular drug
DMWNHPC PC 123608
DMWNHPC MW 167.59
DMWNHPC FM C5H10ClNO3
DMWNHPC IC InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
DMWNHPC CS C(CC(=O)O)C(=O)CN.Cl
DMWNHPC IK ZLHFONARZHCSET-UHFFFAOYSA-N
DMWNHPC IU 5-amino-4-oxopentanoic acid;hydrochloride
DMWNHPC CA CAS 5451-09-2
DMWNHPC CB CHEBI:132969
DMWNHPC DE Actinic keratosis
DML2NIB ID DML2NIB
DML2NIB DN Aminophylline
DML2NIB HS Approved
DML2NIB SN Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
DML2NIB TC Bronchodilator Agents
DML2NIB DT Small molecular drug
DML2NIB PC 9433
DML2NIB MW 420.43
DML2NIB FM C16H24N10O4
DML2NIB IC InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
DML2NIB CS CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
DML2NIB IK FQPFAHBPWDRTLU-UHFFFAOYSA-N
DML2NIB IU 1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine
DML2NIB CA CAS 317-34-0
DML2NIB CB CHEBI:2659
DML2NIB DE Bronchial asthma; Asthma
DMENSL5 ID DMENSL5
DMENSL5 DN Aminosalicylic acid
DMENSL5 HS Approved
DMENSL5 SN 4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium
DMENSL5 CP Panray Corp Sub Ormont Drug And Chemical Co Inc
DMENSL5 DT Small molecular drug
DMENSL5 PC 4649
DMENSL5 MW 153.14
DMENSL5 FM C7H7NO3
DMENSL5 IC InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
DMENSL5 CS C1=CC(=C(C=C1N)O)C(=O)O
DMENSL5 IK WUBBRNOQWQTFEX-UHFFFAOYSA-N
DMENSL5 IU 4-amino-2-hydroxybenzoic acid
DMENSL5 CA CAS 65-49-6
DMENSL5 CB CHEBI:27565
DMENSL5 DE Pulmonary and extrapulmonary tuberculosis; Inflammatory bowel disease
DMUTEX3 ID DMUTEX3
DMUTEX3 DN Amiodarone
DMUTEX3 HS Approved
DMUTEX3 SN Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
DMUTEX3 CP Wyeth-Ayerst Laboratories
DMUTEX3 TC Antiarrhythmic Agents
DMUTEX3 DT Small molecular drug
DMUTEX3 PC 2157
DMUTEX3 MW 645.3
DMUTEX3 FM C25H29I2NO3
DMUTEX3 IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMUTEX3 CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMUTEX3 IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMUTEX3 IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMUTEX3 CA CAS 1951-25-3
DMUTEX3 CB CHEBI:2663
DMUTEX3 DE Tachyarrhythmias
DMSJVAM ID DMSJVAM
DMSJVAM DN Amisulpride
DMSJVAM HS Approved
DMSJVAM SN Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CP Sanofi-Aventis
DMSJVAM TC Antipsychotic Agents
DMSJVAM DT Small molecular drug
DMSJVAM PC 2159
DMSJVAM MW 369.5
DMSJVAM FM C17H27N3O4S
DMSJVAM IC InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
DMSJVAM CS CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMSJVAM IK NTJOBXMMWNYJFB-UHFFFAOYSA-N
DMSJVAM IU 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CA CAS 71675-85-9
DMSJVAM CB CHEBI:64045
DMSJVAM DE Schizophrenia
DMK7F9S ID DMK7F9S
DMK7F9S DN Amitriptyline
DMK7F9S HS Approved
DMK7F9S SN Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
DMK7F9S CP Hoffmann La Roche Inc
DMK7F9S TC Analgesics
DMK7F9S DT Small molecular drug
DMK7F9S PC 2160
DMK7F9S MW 277.4
DMK7F9S FM C20H23N
DMK7F9S IC InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
DMK7F9S CS CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DMK7F9S IK KRMDCWKBEZIMAB-UHFFFAOYSA-N
DMK7F9S IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DMK7F9S CA CAS 50-48-6
DMK7F9S CB CHEBI:2666
DMK7F9S DE Depression
DM0DQM5 ID DM0DQM5
DM0DQM5 DN Amlexanox
DM0DQM5 HS Approved
DM0DQM5 SN ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid
DM0DQM5 CP Access Pharmaceuticals
DM0DQM5 TC Antiulcer Agents
DM0DQM5 DT Small molecular drug
DM0DQM5 PC 2161
DM0DQM5 MW 298.29
DM0DQM5 FM C16H14N2O4
DM0DQM5 IC InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
DM0DQM5 CS CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
DM0DQM5 IK SGRYPYWGNKJSDL-UHFFFAOYSA-N
DM0DQM5 IU 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
DM0DQM5 CA CAS 68302-57-8
DM0DQM5 CB CHEBI:31205
DM0DQM5 DE Respiratory tract inflammation
DMBDAZV ID DMBDAZV
DMBDAZV DN Amlodipine
DMBDAZV HS Approved
DMBDAZV SN Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CP Dainippon Sumitomo
DMBDAZV TC Antihypertensive Agents
DMBDAZV DT Small molecular drug
DMBDAZV PC 2162
DMBDAZV MW 408.9
DMBDAZV FM C20H25ClN2O5
DMBDAZV IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
DMBDAZV CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DMBDAZV IK HTIQEAQVCYTUBX-UHFFFAOYSA-N
DMBDAZV IU 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CA CAS 88150-42-9
DMBDAZV CB CHEBI:2668
DMBDAZV DE Hypertension
DMOEVK6 ID DMOEVK6
DMOEVK6 DN Ammonia
DMOEVK6 HS Approved
DMOEVK6 SN Ammonia N13
DMOEVK6 CP Feinstein
DMOEVK6 DT Small molecular drug
DMOEVK6 PC 222
DMOEVK6 MW 17.031
DMOEVK6 FM H3N
DMOEVK6 IC InChI=1S/H3N/h1H3
DMOEVK6 CS N
DMOEVK6 IK QGZKDVFQNNGYKY-UHFFFAOYSA-N
DMOEVK6 IU azane
DMOEVK6 CA CAS 7664-41-7
DMOEVK6 CB CHEBI:16134
DMOEVK6 DE Coronary artery disease
DM0GQ8N ID DM0GQ8N
DM0GQ8N DN Amobarbital
DM0GQ8N HS Approved
DM0GQ8N SN AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
DM0GQ8N TC Hypnotics and Sedatives
DM0GQ8N DT Small molecular drug
DM0GQ8N PC 2164
DM0GQ8N MW 226.27
DM0GQ8N FM C11H18N2O3
DM0GQ8N IC InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DM0GQ8N CS CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
DM0GQ8N IK VIROVYVQCGLCII-UHFFFAOYSA-N
DM0GQ8N IU 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
DM0GQ8N CA CAS 57-43-2
DM0GQ8N CB CHEBI:2673
DM0GQ8N DE Insomnia
DME4RA8 ID DME4RA8
DME4RA8 DN Amodiaquine
DME4RA8 HS Approved
DME4RA8 SN Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751
DME4RA8 TC Antimalarials
DME4RA8 DT Small molecular drug
DME4RA8 PC 2165
DME4RA8 MW 355.9
DME4RA8 FM C20H22ClN3O
DME4RA8 IC InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DME4RA8 CS CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DME4RA8 IK OVCDSSHSILBFBN-UHFFFAOYSA-N
DME4RA8 IU 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DME4RA8 CA CAS 86-42-0
DME4RA8 CB CHEBI:2674
DME4RA8 DE Malaria
DML8QSZ ID DML8QSZ
DML8QSZ DN Amosulalol
DML8QSZ HS Approved
DML8QSZ SN Lowgan; LY-137224; YM-09538
DML8QSZ CP Yamanouchi Pharmaceutical Co Ltd
DML8QSZ DT Small molecular drug
DML8QSZ PC 2169
DML8QSZ MW 380.5
DML8QSZ FM C18H24N2O5S
DML8QSZ IC InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
DML8QSZ CS CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
DML8QSZ IK LVEXHFZHOIWIIP-UHFFFAOYSA-N
DML8QSZ IU 5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
DML8QSZ CA CAS 85320-68-9
DML8QSZ CB CHEBI:135592
DML8QSZ DE Hypertension
DMKITQE ID DMKITQE
DMKITQE DN Amoxapine
DMKITQE HS Approved
DMKITQE SN Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE TC Antidepressants
DMKITQE DT Small molecular drug
DMKITQE PC 2170
DMKITQE MW 313.8
DMKITQE FM C17H16ClN3O
DMKITQE IC InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
DMKITQE CS C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DMKITQE IK QWGDMFLQWFTERH-UHFFFAOYSA-N
DMKITQE IU 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE CA CAS 14028-44-5
DMKITQE CB CHEBI:2675
DMKITQE DE Major depressive disorder
DMUYNEI ID DMUYNEI
DMUYNEI DN Amoxicillin
DMUYNEI HS Approved
DMUYNEI SN AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMUYNEI CP AstraZeneca
DMUYNEI TC Antibiotics
DMUYNEI DT Small molecular drug
DMUYNEI PC 33613
DMUYNEI MW 365.4
DMUYNEI FM C16H19N3O5S
DMUYNEI IC InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
DMUYNEI CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
DMUYNEI IK LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DMUYNEI IU (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUYNEI CA CAS 26787-78-0
DMUYNEI CB CHEBI:2676
DMUYNEI DE Bacterial infection
DMSZQAK ID DMSZQAK
DMSZQAK DN Amphetamine
DMSZQAK HS Approved
DMSZQAK SN Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
DMSZQAK CP PharmacoFore Inc
DMSZQAK DT Small molecular drug
DMSZQAK PC 3007
DMSZQAK MW 135.21
DMSZQAK FM C9H13N
DMSZQAK IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
DMSZQAK CS CC(CC1=CC=CC=C1)N
DMSZQAK IK KWTSXDURSIMDCE-UHFFFAOYSA-N
DMSZQAK IU 1-phenylpropan-2-amine
DMSZQAK CA CAS 300-62-9
DMSZQAK CB CHEBI:2679
DMSZQAK DE Attention deficit hyperactivity disorder
DMTAJQE ID DMTAJQE
DMTAJQE DN Amphotericin B
DMTAJQE HS Approved
DMTAJQE SN ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)
DMTAJQE TC Antifungal Agents
DMTAJQE DT Small molecular drug
DMTAJQE PC 5280965
DMTAJQE MW 924.1
DMTAJQE FM C47H73NO17
DMTAJQE IC InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
DMTAJQE CS C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DMTAJQE IK APKFDSVGJQXUKY-INPOYWNPSA-N
DMTAJQE IU (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
DMTAJQE CA CAS 1397-89-3
DMTAJQE DE Fungal infection; Mycoses
DMHWE7P ID DMHWE7P
DMHWE7P DN Ampicillin
DMHWE7P HS Approved
DMHWE7P SN ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMHWE7P CP Stadapharm GmbH
DMHWE7P TC Antibiotics
DMHWE7P DT Small molecular drug
DMHWE7P PC 6249
DMHWE7P MW 349.4
DMHWE7P FM C16H19N3O4S
DMHWE7P IC InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
DMHWE7P CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
DMHWE7P IK AVKUERGKIZMTKX-NJBDSQKTSA-N
DMHWE7P IU (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHWE7P CA CAS 69-53-4
DMHWE7P CB CHEBI:28971
DMHWE7P DE Bacterial infection
DM5BS98 ID DM5BS98
DM5BS98 DN Ampiroxicam
DM5BS98 HS Approved
DM5BS98 SN Flucam; Nacyl; Nasil; CP-65703
DM5BS98 CP Pfizer Inc
DM5BS98 DT Small molecular drug
DM5BS98 PC 2176
DM5BS98 MW 447.5
DM5BS98 FM C20H21N3O7S
DM5BS98 IC InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
DM5BS98 CS CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
DM5BS98 IK LSNWBKACGXCGAJ-UHFFFAOYSA-N
DM5BS98 IU ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate
DM5BS98 CA CAS 99464-64-9
DM5BS98 CB CHEBI:31210
DM5BS98 DE Inflammation
DMLMXE0 ID DMLMXE0
DMLMXE0 DN Amprenavir
DMLMXE0 HS Approved
DMLMXE0 SN AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
DMLMXE0 CP GlaxoSmithKline
DMLMXE0 TC Anti-HIV Agents
DMLMXE0 DT Small molecular drug
DMLMXE0 PC 65016
DMLMXE0 MW 505.6
DMLMXE0 FM C25H35N3O6S
DMLMXE0 IC InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
DMLMXE0 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
DMLMXE0 IK YMARZQAQMVYCKC-OEMFJLHTSA-N
DMLMXE0 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMLMXE0 CA CAS 161814-49-9
DMLMXE0 CB CHEBI:40050
DMLMXE0 DE Human immunodeficiency virus infection
DMZKYIV ID DMZKYIV
DMZKYIV DN Amsacrine
DMZKYIV HS Approved
DMZKYIV SN Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
DMZKYIV CP Travenol Laboratories Inc
DMZKYIV TC Anticancer Agents
DMZKYIV DT Small molecular drug
DMZKYIV PC 2179
DMZKYIV MW 393.5
DMZKYIV FM C21H19N3O3S
DMZKYIV IC InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
DMZKYIV CS COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
DMZKYIV IK XCPGHVQEEXUHNC-UHFFFAOYSA-N
DMZKYIV IU N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
DMZKYIV CA CAS 51264-14-3
DMZKYIV CB CHEBI:2687
DMZKYIV DE Acute lymphoblastic leukaemia
DMAWU35 ID DMAWU35
DMAWU35 DN Amtolmetin guacil
DMAWU35 HS Approved
DMAWU35 SN Artromed; Atromed; Eufans; Amtolmetin guacyl; MED-15; ST-679
DMAWU35 CP Sigma-Tau Ind Farm Riunite SpA
DMAWU35 DT Small molecular drug
DMAWU35 PC 65655
DMAWU35 MW 420.5
DMAWU35 FM C24H24N2O5
DMAWU35 IC InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27)
DMAWU35 CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC
DMAWU35 IK CWJNMKKMGIAGDK-UHFFFAOYSA-N
DMAWU35 IU (2-methoxyphenyl) 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetate
DMAWU35 CA CAS 87344-06-7
DMAWU35 CB CHEBI:135678
DMAWU35 DE Inflammation
DMJKO05 ID DMJKO05
DMJKO05 DN Amyl nitrite
DMJKO05 HS Approved
DMJKO05 SN Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644
DMJKO05 DT Small molecular drug
DMJKO05 PC 10026
DMJKO05 MW 117.15
DMJKO05 FM C5H11NO2
DMJKO05 IC InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3
DMJKO05 CS CCCCCON=O
DMJKO05 IK CSDTZUBPSYWZDX-UHFFFAOYSA-N
DMJKO05 IU pentyl nitrite
DMJKO05 CA CAS 463-04-7
DMJKO05 CB CHEBI:55344
DMJKO05 DE Angina pectoris
DMJXIC9 ID DMJXIC9
DMJXIC9 DN Anagliptin
DMJXIC9 HS Approved
DMJXIC9 SN Anagliptin; 739366-20-2; UNII-K726J96838; suiny; CHEMBL1929396; (S)-N-(2-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; K726J96838; CHEMBL1929387; N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; Anagliptin [INN]; N-[2-({2-[(2s)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-A]pyrimidine-6-Carboxamide; Anagliptin (JAN/INN); SCHEMBL905393; sk-0403
DMJXIC9 CP Kowa Research Institute
DMJXIC9 DT Small molecular drug
DMJXIC9 PC 44513473
DMJXIC9 MW 383.4
DMJXIC9 FM C19H25N7O2
DMJXIC9 IC InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
DMJXIC9 CS CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
DMJXIC9 IK LDXYBEHACFJIEL-HNNXBMFYSA-N
DMJXIC9 IU N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
DMJXIC9 CA CAS 739366-20-2
DMJXIC9 CB CHEBI:136043
DMJXIC9 DE Type-2 diabetes
DMSQ8MD ID DMSQ8MD
DMSQ8MD DN Anagrelide
DMSQ8MD HS Approved
DMSQ8MD SN Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CP Shire Phamaceuticals
DMSQ8MD TC Antithrombotic Agents
DMSQ8MD DT Small molecular drug
DMSQ8MD PC 135409400
DMSQ8MD MW 256.079
DMSQ8MD FM C10H7Cl2N3O
DMSQ8MD IC InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
DMSQ8MD CS C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
DMSQ8MD IK OTBXOEAOVRKTNQ-UHFFFAOYSA-N
DMSQ8MD IU 6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CA CAS 68475-42-3
DMSQ8MD CB CHEBI:142290
DMSQ8MD DE Thrombocythemia; Essential thrombocythemia
DMU8KOD ID DMU8KOD
DMU8KOD DN Anakinra
DMU8KOD HS Approved
DMU8KOD SN Kineret; Kineret (TN); Anakinra (USAN/INN)
DMU8KOD CP Amgen Inc
DMU8KOD TC Antiinflammatory Agents
DMU8KOD SQ DB00026 sequence: MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
DMU8KOD DE Rheumatoid arthritis
DMV96ZH ID DMV96ZH
DMV96ZH DN Anapsos
DMV96ZH HS Approved
DMV96ZH SN Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
DMV96ZH CP ASAC Pharmaceutical International AIE
DMV96ZH DE Atopic dermatitis
DMNP60F ID DMNP60F
DMNP60F DN Anastrozole
DMNP60F HS Approved
DMNP60F SN Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CP AstraZeneca
DMNP60F TC Anticancer Agents
DMNP60F DT Small molecular drug
DMNP60F PC 2187
DMNP60F MW 293.4
DMNP60F FM C17H19N5
DMNP60F IC InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
DMNP60F CS CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
DMNP60F IK YBBLVLTVTVSKRW-UHFFFAOYSA-N
DMNP60F IU 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CA CAS 120511-73-1
DMNP60F CB CHEBI:2704
DMNP60F DE Breast cancer
DMLWQ27 ID DMLWQ27
DMLWQ27 DN Angiotensin Ii
DMLWQ27 HS Approved
DMLWQ27 SN Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]
DMLWQ27 CP La Jolla Pharmaceutical Company
DMLWQ27 DT Small molecular drug
DMLWQ27 PC 172198
DMLWQ27 MW 1046.2
DMLWQ27 FM C50H71N13O12
DMLWQ27 IC InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMLWQ27 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMLWQ27 IK CZGUSIXMZVURDU-JZXHSEFVSA-N
DMLWQ27 IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMLWQ27 CA CAS 4474-91-3
DMLWQ27 CB CHEBI:2719
DMLWQ27 DE Increase blood pressure
DM8QM5U ID DM8QM5U
DM8QM5U DN Anidulafungin
DM8QM5U HS Approved
DM8QM5U SN Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DM8QM5U CP Pfizer Pharmaceuticals
DM8QM5U TC Antifungal Agents
DM8QM5U DT Small molecular drug
DM8QM5U PC 166548
DM8QM5U MW 1140.2
DM8QM5U FM C58H73N7O17
DM8QM5U IC InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DM8QM5U CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DM8QM5U IK JHVAMHSQVVQIOT-MFAJLEFUSA-N
DM8QM5U IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DM8QM5U CA CAS 166663-25-8
DM8QM5U CB CHEBI:55346
DM8QM5U DE Convulsion
DMBAUED ID DMBAUED
DMBAUED DN Anileridine
DMBAUED HS Approved
DMBAUED SN Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester
DMBAUED TC Analgesics
DMBAUED DT Small molecular drug
DMBAUED PC 8944
DMBAUED MW 352.5
DMBAUED FM C22H28N2O2
DMBAUED IC InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
DMBAUED CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3
DMBAUED IK LKYQLAWMNBFNJT-UHFFFAOYSA-N
DMBAUED IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
DMBAUED CA CAS 144-14-9
DMBAUED CB CHEBI:61203
DMBAUED DE Pain
DMC128O ID DMC128O
DMC128O DN Anileridine Hydrochloride
DMC128O HS Approved
DMC128O SN Anileridine Phosphate; Leritine
DMC128O CP Merck And Co Inc
DMC128O TC Neurology Agents
DMC128O DT Small molecular drug
DMC128O PC 31338
DMC128O MW 425.4
DMC128O FM C22H30Cl2N2O2
DMC128O IC InChI=1S/C22H28N2O2.2ClH/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;;/h3-11H,2,12-17,23H2,1H3;2*1H
DMC128O CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3.Cl.Cl
DMC128O IK ZYTHLJLPPSSDIP-UHFFFAOYSA-N
DMC128O IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate;dihydrochloride
DMC128O CA CAS 126-12-5
DMC128O CB CHEBI:61208
DMC128O DE Pain
DMOIFW0 ID DMOIFW0
DMOIFW0 DN Aniracetam
DMOIFW0 HS Approved
DMOIFW0 SN aniracetam; 72432-10-1; Draganon; Sarpul; 1-(4-Methoxybenzoyl)-2-pyrrolidinone; Ampamet; 1-(4-methoxybenzoyl)pyrrolidin-2-one; 1-p-Anisoyl-2-pyrrolidinone; Ro 13-5057; Aniracetamun [INN-Latin]; Aniracetam [USAN:INN:JAN]; UNII-5L16LKN964; Ro 135057; BRN 4807205; Ro-13-5057; 1-p-anisoylpyrrolidin-2-one; 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-; CHEMBL36994; MLS000079240; CHEBI:47943; 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]; ZXNRTKGTQJPIJK-UHFFFAOYSA-N; 5L16LKN964; NCGC00015116-10; SMR000038438
DMOIFW0 DT Small molecular drug
DMOIFW0 PC 2196
DMOIFW0 MW 219.24
DMOIFW0 FM C12H13NO3
DMOIFW0 IC InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
DMOIFW0 CS COC1=CC=C(C=C1)C(=O)N2CCCC2=O
DMOIFW0 IK ZXNRTKGTQJPIJK-UHFFFAOYSA-N
DMOIFW0 IU 1-(4-methoxybenzoyl)pyrrolidin-2-one
DMOIFW0 CA CAS 72432-10-1
DMOIFW0 CB CHEBI:47943
DMOIFW0 DE Cerebrovascular ischaemia
DM2C48U ID DM2C48U
DM2C48U DN Anisindione
DM2C48U HS Approved
DM2C48U SN Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione
DM2C48U TC Anticoagulants
DM2C48U DT Small molecular drug
DM2C48U PC 2197
DM2C48U MW 252.26
DM2C48U FM C16H12O3
DM2C48U IC InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
DM2C48U CS COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2C48U IK XRCFXMGQEVUZFC-UHFFFAOYSA-N
DM2C48U IU 2-(4-methoxyphenyl)indene-1,3-dione
DM2C48U CA CAS 117-37-3
DM2C48U CB CHEBI:133809
DM2C48U DE Coagulation defect
DMW51AX ID DMW51AX
DMW51AX DN Anisodamine
DMW51AX HS Approved
DMW51AX SN anisodamine; racanisodamine; 55869-99-3; (6S)-6-Hydroxyhyoscyamine; (-)-Anisodamine; AC1O6SQS; AC1L4C7W; SCHEMBL620576; ZINC2112569; 8053AH; API0000388; 869A993; Q-100648; [(1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; (S)-((1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; [(1R,3S,5R,6R)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate
DMW51AX DT Small molecular drug
DMW51AX PC 6918612
DMW51AX MW 305.4
DMW51AX FM C17H23NO4
DMW51AX IC InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
DMW51AX CS CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3
DMW51AX IK WTQYWNWRJNXDEG-RBZJEDDUSA-N
DMW51AX IU [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMW51AX CA CAS 55869-99-3
DMW51AX DE Central and peripheral nervous disease
DMNOSWU ID DMNOSWU
DMNOSWU DN Anisodine
DMNOSWU HS Approved
DMNOSWU SN anisodine; 52646-92-1; SCHEMBL474045; AC1N31M8; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester
DMNOSWU DT Small molecular drug
DMNOSWU PC 11616712
DMNOSWU MW 319.4
DMNOSWU FM C17H21NO5
DMNOSWU IC InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1
DMNOSWU CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O
DMNOSWU IK JEJREKXHLFEVHN-QDXGGTILSA-N
DMNOSWU IU [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate
DMNOSWU CA CAS 52646-92-1
DMNOSWU DE Central and peripheral nervous disease
DMIJRF0 ID DMIJRF0
DMIJRF0 DN Anisotropine Methylbromide
DMIJRF0 HS Approved
DMIJRF0 SN Anisotropine; Endovalpin; Lytispasm; Valpin; Anisotropine methobromide; Anisotropine methyl bromide;Methyloctatropine bromide; Metilbromuro de octatropina; Octatropine methylbromide; Octatropini methylbromidum; Octatropone Bromide; Valpin 50; Anisotropine methylbromide (USAN); Anisotropine methylbromide [USAN:JAN]; Endovalpin (TN); Lytispasm (TN); Methylbromure d'octatropine; Methyloctatropine bromide (JAN); Metilbromuro de octatropina [INN-Spanish]; Octatropine methylbromide (INN); Octatropinimethylbromidum [INN-Latin]; Valpin (TN); Valpin 50 (TN); Methylbromure d'octatropine [INN-French]; Anisotropine methylbromide, (endo)-isomer; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 1-alpha-H,5-alpha-H-Tropanium,3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 2-Propylpentanoyltropinium methylbromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; 8-Methyltropinium bromide 2-propylpentanoate; 8-Methyltropinium bromide 2-propylvalerate
DMIJRF0 TC Anticholinergic Agents
DMIJRF0 DT Small molecular drug
DMIJRF0 PC 657201
DMIJRF0 MW 362.3
DMIJRF0 FM C17H32BrNO2
DMIJRF0 IC InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15+,16?;
DMIJRF0 CS CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-]
DMIJRF0 IK QSFKGMJOKUZAJM-JXMYBXCISA-M
DMIJRF0 IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide
DMIJRF0 CA CAS 80-50-2
DMIJRF0 DE Peptic ulcer
DM6Q4B0 ID DM6Q4B0
DM6Q4B0 DN Anistreplase
DM6Q4B0 HS Approved
DM6Q4B0 TC Thrombolytic Agents
DM6Q4B0 SQ DB00029 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DM6Q4B0 DE Acute coronary syndrome
DMUMOEV ID DMUMOEV
DMUMOEV DN Ansuvimab
DMUMOEV HS Approved
DMUMOEV DT Antibody
DMUMOEV DE Ebola virus infection
DMA04JS ID DMA04JS
DMA04JS DN Antazoline
DMA04JS HS Approved
DMA04JS SN Analergine; Antastan; Antasten; Antazolin; Antazolina; Antazolinum; Antihistal; Antistin; Antistine; Azalone; Histostab;Imidamin; Imidamine; Phenazolin; Phenazoline; Antazolina [Spanish]; Antazolinum [Latin]; Antazolina [INN-Spanish]; Antazoline (INN); Antazoline [INN:BAN]; Antazolinum [INN-Latin]; Ben-A-hist; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; 2-(N-Benzylanilinomethyl)-2-imidazoline; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 2-Phenyl-benzyl-amino-methylimidazolin; 2-Phenyl-benzyl-amino-methylimidazolin [German]; 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; 5512-M
DMA04JS DT Small molecular drug
DMA04JS PC 2200
DMA04JS MW 265.35
DMA04JS FM C17H19N3
DMA04JS IC InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
DMA04JS CS C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3
DMA04JS IK REYFJDPCWQRWAA-UHFFFAOYSA-N
DMA04JS IU N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
DMA04JS CA CAS 91-75-8
DMA04JS CB CHEBI:84115
DMA04JS DE Nasal congestion
DMNC64R ID DMNC64R
DMNC64R DN Antegren
DMNC64R HS Approved
DMNC64R DT Antibody
DMNC64R DE Multiple sclerosis
DMH4CFE ID DMH4CFE
DMH4CFE DN Antithymocyte globulin
DMH4CFE HS Approved
DMH4CFE SN Atgam (TN); Thymoglobulin (TN)
DMH4CFE CP Pfizer Pharmaceuticals
DMH4CFE TC Immunomodulatory Agents
DMH4CFE DE Aplastic anemia
DM89JLN ID DM89JLN
DM89JLN DN Apixaban
DM89JLN HS Approved
DM89JLN SN GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
DM89JLN CP Pfizer
DM89JLN DT Small molecular drug
DM89JLN PC 10182969
DM89JLN MW 459.5
DM89JLN FM C25H25N5O4
DM89JLN IC InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
DM89JLN CS COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
DM89JLN IK QNZCBYKSOIHPEH-UHFFFAOYSA-N
DM89JLN IU 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
DM89JLN CA CAS 503612-47-3
DM89JLN CB CHEBI:72296
DM89JLN DE Thrombosis
DMX38HQ ID DMX38HQ
DMX38HQ DN Apomorphine
DMX38HQ HS Approved
DMX38HQ SN Apomorphine (intranasal, Parkinson's disease)
DMX38HQ CP Archimedes Pharma Ltd
DMX38HQ DT Small molecular drug
DMX38HQ PC 6005
DMX38HQ MW 267.32
DMX38HQ FM C17H17NO2
DMX38HQ IC InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
DMX38HQ CS CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMX38HQ IK VMWNQDUVQKEIOC-CYBMUJFWSA-N
DMX38HQ IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMX38HQ CA CAS 58-00-4
DMX38HQ CB CHEBI:48538
DMX38HQ DE Parkinson disease; Sexual dysfunction; Idiopathic parkinson disease
DMO4PVE ID DMO4PVE
DMO4PVE DN Apraclonidine
DMO4PVE HS Approved
DMO4PVE SN Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine
DMO4PVE CP Alcon Canada Inc
DMO4PVE TC Antiglaucomic Agents
DMO4PVE DT Small molecular drug
DMO4PVE PC 2216
DMO4PVE MW 245.11
DMO4PVE FM C9H10Cl2N4
DMO4PVE IC InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
DMO4PVE CS C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl
DMO4PVE IK IEJXVRYNEISIKR-UHFFFAOYSA-N
DMO4PVE IU 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
DMO4PVE CA CAS 66711-21-5
DMO4PVE CB CHEBI:2788
DMO4PVE DE Intra ocular pressure reduction
DMTWS9E ID DMTWS9E
DMTWS9E DN Apremilast
DMTWS9E HS Approved
DMTWS9E SN Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
DMTWS9E CP Celgene
DMTWS9E DT Small molecular drug
DMTWS9E PC 11561674
DMTWS9E MW 460.5
DMTWS9E FM C22H24N2O7S
DMTWS9E IC InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
DMTWS9E CS CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
DMTWS9E IK IMOZEMNVLZVGJZ-QGZVFWFLSA-N
DMTWS9E IU N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
DMTWS9E CA CAS 608141-41-9
DMTWS9E CB CHEBI:78540
DMTWS9E DE Psoriasis vulgaris
DM053KT ID DM053KT
DM053KT DN Aprepitant
DM053KT HS Approved
DM053KT SN Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
DM053KT CP Merck & Co
DM053KT TC Antiemetics
DM053KT DT Small molecular drug
DM053KT PC 135413536
DM053KT MW 534.4
DM053KT FM C23H21F7N4O3
DM053KT IC InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1
DM053KT CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F
DM053KT IK ATALOFNDEOCMKK-OITMNORJSA-N
DM053KT IU 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DM053KT CA CAS 170729-80-3
DM053KT CB CHEBI:499361
DM053KT DE Depression; Nausea; Solid tumour/cancer
DMBXWU8 ID DMBXWU8
DMBXWU8 DN Aprindine
DMBXWU8 HS Approved
DMBXWU8 SN Aprindin; Aprindina; Aprindinum; Aprinidine; Fibocil; AC 1802; Aprindina [INN-Spanish]; Aprindinum [INN-Latin]; Aprindine (USAN/INN); Aprindine [USAN:BAN:INN]; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediaminemonohydrochloride; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine
DMBXWU8 TC Antiarrhythmic Agents
DMBXWU8 DT Small molecular drug
DMBXWU8 PC 2218
DMBXWU8 MW 322.5
DMBXWU8 FM C22H30N2
DMBXWU8 IC InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
DMBXWU8 CS CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3
DMBXWU8 IK NZLBHDRPUJLHCE-UHFFFAOYSA-N
DMBXWU8 IU N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine
DMBXWU8 CA CAS 37640-71-4
DMBXWU8 CB CHEBI:135370
DMBXWU8 DE Cardiac arrhythmias
DMOWK6B ID DMOWK6B
DMOWK6B DN Aprobarbital
DMOWK6B HS Approved
DMOWK6B SN Allional; Allonal; Allylisopropylmalonylurea; Allylpropymal; Allypropymal; Allypropymalum; Alurate; Aprobarbita; Aprobarbitale; Aprobarbitalum; Aprobarbitone; Aprozal; Numal; Allylisopropylbarbituric acid; Alurate elixir verdum; Aprobarbitale [DCIT]; Isopropylallylbarbituric acid; Alurate (TN); Aprobarbital (INN); Aprobarbital [INN:DCF]; Aprobarbitalum [INN-Latin]; Isonal (swedish); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-(9CI); 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-isopropylbarbiturate; 5-Allyl-5-isopropylbarbituricacid; 5-Isopropyl-5-allylbarbituric acid; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B TC Anticonvulsants
DMOWK6B DT Small molecular drug
DMOWK6B PC 6464
DMOWK6B MW 210.23
DMOWK6B FM C10H14N2O3
DMOWK6B IC InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)
DMOWK6B CS CC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DMOWK6B IK UORJNBVJVRLXMQ-UHFFFAOYSA-N
DMOWK6B IU 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B CA CAS 77-02-1
DMOWK6B CB CHEBI:2791
DMOWK6B DE Anaesthesia; Insomnia
DM0QD4W ID DM0QD4W
DM0QD4W DN Aprotinin
DM0QD4W HS Approved
DM0QD4W SN Trasylol; Zymofren; Trazinin; Iniprol; Riker 52G; Bayer A 128; UNII-04XPW8C0FL; 04XPW8C0FL; APROTININ; RP-9921; Aprotininum; Aprotinina; Aprotinine; Antilysine; Repulson; Antagosan; Pantinol; Onquinin; Trascolan; Protimbin; Inhibin; Contrykal; Antilysin; Antikrein; Fosten; Tzalol; Gordox; Kir richter; Trypsin inhibitor; Aprotinin solution; 9087-70-1; BPTI; APROTININ BOVINE; Basic protease inhibitor; Aprotininum [INN-Latin]; Aprotinine [INN-French]; Aprotinina [INN-Spanish]; Pancreatic trypsin inhibitor; Kunitz and Northrop inhibitor
DM0QD4W CP Novo Nordisk A/S
DM0QD4W DT Small molecular drug
DM0QD4W SQ Aprotinin (bovine pancreatic trypsin inhibitor): RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
DM0QD4W PC 146027575
DM0QD4W MW 6511
DM0QD4W FM C284H432N84O79S7
DM0QD4W IC InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147+,148-,149-,150+,151-,152-,153+,154+,167+,168-,169+,170+,171+,172+,173+,174-,175-,176+,177-,178+,179-,180+,181-,182+,183-,184+,185+,186+,187+,188+,189+,190-,191+,192+,193+,194+,195-,196+,197+,198+,199-,200+,201+,202-,203-,204+,205+,206+,221-,222+,223+,224-,225-,226-/m1/s1
DM0QD4W CS CC[C@@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N6CCC[C@@H]6C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CCC(=O)N)[C@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)[C@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@H](C)CC
DM0QD4W IK ZPNFWUPYTFPOJU-VKTQZXOTSA-N
DM0QD4W IU (3R)-4-[[(2S)-1-[[(1S,2aR,4R,5aR,8aR,11aR,13R,14aR,16S,17aS,19S,20aR,25S,26aR,29aR,31S,32aR,34S,35aS,37R,38aS,41aS,42R,44aS,45R,47aR,48S,50aS,51R,53aS,54R,56aR,57S,59aR,60S,62aS,63S,66S,69S,72S,75S,78S,81S,84S,87S,90S,93R)-29a,62a,69,84-tetrakis(4-aminobutyl)-35a,75,78-tris(2-amino-2-oxoethyl)-14a-(3-amino-3-oxopropyl)-8a,41a,72-tribenzyl-50a,53a-bis[(2R)-butan-2-yl]-47a,48,56a,81,90-pentakis(3-carbamimidamidopropyl)-31,60-bis(2-carboxyethyl)-42-[[2-[[2-[[(1R)-1-carboxyethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamoyl]-57-(carboxymethyl)-11a,45-bis[(1S)-1-hydroxyethyl]-13-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-2a,16,38a,44a-tetrakis[(4-hydroxyphenyl)methyl]-26a,32a,59a,63,87-pentamethyl-20a,34-bis(2-methylpropyl)-51-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,22a,24,25a,28a,30,31a,33,34a,36,37a,40a,43a,44,46a,47,49a,50,52a,53,55a,56,58a,59,61a,62,64a,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-5a-propan-2-yl-39,40,66a,67a,70a,71a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,21a,23,24a,27a,29,30a,32,33a,35,36a,39a,42a,43,45a,46,48a,49,51a,52,54a,55,57a,58,60a,61,63a,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazahexacyclo[91.71.4.454,117.04,8.019,23.025,29]doheptacontahectan-37-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid
DM0QD4W CA CAS 9087-70-1
DM0QD4W DE Bleeding disorder
DMHTXSL ID DMHTXSL
DMHTXSL DN Arbekacin
DMHTXSL HS Approved
DMHTXSL SN Habekacin (TN)
DMHTXSL CP Meiji Seika
DMHTXSL DT Small molecular drug
DMHTXSL PC 68682
DMHTXSL MW 552.6
DMHTXSL FM C22H44N6O10
DMHTXSL IC InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
DMHTXSL CS C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N
DMHTXSL IK MKKYBZZTJQGVCD-XTCKQBCOSA-N
DMHTXSL IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMHTXSL CA CAS 51025-85-5
DMHTXSL CB CHEBI:37922
DMHTXSL DE Bacterial infection
DMOQK8Z ID DMOQK8Z
DMOQK8Z DN Arbidol
DMOQK8Z HS Approved
DMOQK8Z SN Umifenovir; Arbidole; MC-101
DMOQK8Z CP Good Earth Medicine
DMOQK8Z DT Small molecular drug
DMOQK8Z PC 131411
DMOQK8Z MW 477.4
DMOQK8Z FM C22H25BrN2O3S
DMOQK8Z IC InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
DMOQK8Z CS CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3
DMOQK8Z IK KCFYEAOKVJSACF-UHFFFAOYSA-N
DMOQK8Z IU ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
DMOQK8Z CA CAS 131707-25-0
DMOQK8Z CB CHEBI:134730
DMOQK8Z DE Virus infection
DMCY8AF ID DMCY8AF
DMCY8AF DN Arbutamine
DMCY8AF HS Approved
DMCY8AF SN Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF TC Cardiotonic Agents
DMCY8AF DT Small molecular drug
DMCY8AF PC 60789
DMCY8AF MW 317.4
DMCY8AF FM C18H23NO4
DMCY8AF IC InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1
DMCY8AF CS C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O
DMCY8AF IK IIRWWTKISYTTBL-SFHVURJKSA-N
DMCY8AF IU 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF CA CAS 128470-16-6
DMCY8AF CB CHEBI:50580
DMCY8AF DE Coronary artery disease
DM9GH25 ID DM9GH25
DM9GH25 DN Arcitumomab
DM9GH25 HS Approved
DM9GH25 SN CEA-Scan; Arcitumomab (USAN/INN); Cea-Scan (TN)
DM9GH25 TC Diagnostic Agents
DM9GH25 DT Antibody
DM9GH25 DE Breast cancer
DMYRX8B ID DMYRX8B
DMYRX8B DN Ardeparin
DMYRX8B HS Approved
DMYRX8B SN Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
DMYRX8B CP Celcius Laboratories
DMYRX8B TC Anticoagulants
DMYRX8B DT Small molecular drug
DMYRX8B PC 772
DMYRX8B MW 1134.9
DMYRX8B FM C26H42N2O37S5
DMYRX8B IC InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
DMYRX8B CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
DMYRX8B IK HTTJABKRGRZYRN-UHFFFAOYSA-N
DMYRX8B IU 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DMYRX8B CA CAS 9005-49-6
DMYRX8B DE Venous thrombosis; Thrombosis; Deep vein thrombosis; Venous thromboembolism
DMVMY7K ID DMVMY7K
DMVMY7K DN Arepanrix
DMVMY7K HS Approved
DMVMY7K SN H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK
DMVMY7K CP GlaxoSmithKline plc
DMVMY7K DT Vaccine
DMVMY7K DE Influenza virus infection
DMYM974 ID DMYM974
DMYM974 DN Arformoterol
DMYM974 HS Approved
DMYM974 SN 67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate
DMYM974 CP Sepracor phamaceuticals
DMYM974 TC Bronchodilator Agents
DMYM974 DT Small molecular drug
DMYM974 PC 3083544
DMYM974 MW 344.4
DMYM974 FM C19H24N2O4
DMYM974 IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
DMYM974 CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O
DMYM974 IK BPZSYCZIITTYBL-YJYMSZOUSA-N
DMYM974 IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
DMYM974 CA CAS 67346-49-0
DMYM974 CB CHEBI:408174
DMYM974 DE Chronic obstructive pulmonary disease; Asthma
DMFI46A ID DMFI46A
DMFI46A DN Argatroban
DMFI46A HS Approved
DMFI46A SN Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
DMFI46A TC Anticoagulants
DMFI46A DT Small molecular drug
DMFI46A PC 92722
DMFI46A MW 508.6
DMFI46A FM C23H36N6O5S
DMFI46A IC InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
DMFI46A CS C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
DMFI46A IK KXNPVXPOPUZYGB-IOVMHBDKSA-N
DMFI46A IU (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
DMFI46A CA CAS 74863-84-6
DMFI46A CB CHEBI:94385
DMFI46A DE Thrombosis
DMRE4FC ID DMRE4FC
DMRE4FC DN Arginine
DMRE4FC HS Approved
DMRE4FC SN DL-Arginine hydrochloride; 32042-43-6; 2-Amino-5-guanidinopentanoic acid hydrochloride; argininhydrochlorid; DL-Arginine HCl; 220144-84-3; H-DL-Arg-OH.xHCl; DL-(+/-)-Arginine Hydrochloride; 1-Hydrochloride arginine; NSC7914; Arginine monochloride; 2-Amino-5-guanidinovaleric acid monohydrochloride; WLN: MUYZM3YZVQ & DL-Arginine hydrochloride, 98%, anhydrous; Arginine monohydrochloride, L-(+)-; ARGININE, (L); L(+)-Arginine hydrochloride; D-Arginine, hydrochloride (1:1); EINECS 250-903-0; EINECS 239-674-8
DMRE4FC DT Small molecular drug
DMRE4FC PC 6322
DMRE4FC MW 174.2
DMRE4FC FM C6H14N4O2
DMRE4FC IC InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
DMRE4FC CS C(C[C@@H](C(=O)O)N)CN=C(N)N
DMRE4FC IK ODKSFYDXXFIFQN-BYPYZUCNSA-N
DMRE4FC IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMRE4FC CA CAS 74-79-3
DMRE4FC CB CHEBI:16467
DMRE4FC DE Growth hormone deficiency
DM3NUMH ID DM3NUMH
DM3NUMH DN Aripiprazole
DM3NUMH HS Approved
DM3NUMH SN 129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
DM3NUMH CP Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
DM3NUMH TC Antipsychotic Agents
DM3NUMH DT Small molecular drug
DM3NUMH PC 60795
DM3NUMH MW 448.4
DM3NUMH FM C23H27Cl2N3O2
DM3NUMH IC InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
DM3NUMH CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
DM3NUMH IK CEUORZQYGODEFX-UHFFFAOYSA-N
DM3NUMH IU 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DM3NUMH CA CAS 129722-12-9
DM3NUMH CB CHEBI:31236
DM3NUMH DE Major depressive disorder; Schizophrenia; Bipolar disorder; Erythropoietic porphyrias
DMGB035 ID DMGB035
DMGB035 DN Armodafinil
DMGB035 HS Approved
DMGB035 SN Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 CP Cephalon
DMGB035 DT Small molecular drug
DMGB035 PC 9690109
DMGB035 MW 273.4
DMGB035 FM C15H15NO2S
DMGB035 IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
DMGB035 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
DMGB035 IK YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 IU 2-[(R)-benzhydrylsulfinyl]acetamide
DMGB035 CA CAS 112111-43-0
DMGB035 CB CHEBI:77590
DMGB035 DE Pediatric cancer
DMT81LZ ID DMT81LZ
DMT81LZ DN Arn-509
DMT81LZ HS Approved
DMT81LZ SN Arn-509 (AR inhibitor)
DMT81LZ CP Johnson & Johnson
DMT81LZ DT Small molecular drug
DMT81LZ PC 24872560
DMT81LZ MW 477.4
DMT81LZ FM C21H15F4N5O2S
DMT81LZ IC InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
DMT81LZ CS CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
DMT81LZ IK HJBWBFZLDZWPHF-UHFFFAOYSA-N
DMT81LZ IU 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide
DMT81LZ CA CAS 956104-40-8
DMT81LZ DE Acute myeloid leukaemia; Prostate cancer
DM1P6FR ID DM1P6FR
DM1P6FR DN Arry-162
DM1P6FR HS Approved
DM1P6FR SN 606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
DM1P6FR CP Array BioPharma
DM1P6FR DT Small molecular drug
DM1P6FR PC 10288191
DM1P6FR MW 441.2
DM1P6FR FM C17H15BrF2N4O3
DM1P6FR IC InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DM1P6FR CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
DM1P6FR IK ACWZRVQXLIRSDF-UHFFFAOYSA-N
DM1P6FR IU 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DM1P6FR CA CAS 606143-89-9
DM1P6FR CB CHEBI:145371
DM1P6FR DE Melanoma
DMTL2Y1 ID DMTL2Y1
DMTL2Y1 DN Arsenic
DMTL2Y1 HS Approved
DMTL2Y1 SN Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ
DMTL2Y1 PC 5359596
DMTL2Y1 MW 74.921
DMTL2Y1 FM As
DMTL2Y1 IC RQNWIZPPADIBDY-UHFFFAOYSA-N
DMTL2Y1 CS [As]
DMTL2Y1 IK 1S/As
DMTL2Y1 IU arsenic
DMTL2Y1 CA CAS 7440-38-2
DMTL2Y1 CB CHEBI:27563
DMTL2Y1 DE Acute myeloid leukaemia
DM61TA4 ID DM61TA4
DM61TA4 DN Arsenic trioxide
DM61TA4 HS Approved
DM61TA4 SN Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
DM61TA4 TC Anticancer Agents
DM61TA4 DT Small molecular drug
DM61TA4 PC 14888
DM61TA4 MW 197.841
DM61TA4 FM As2O3
DM61TA4 IC InChI=1S/2As.3O/q2*+3;3*-2
DM61TA4 CS [O-2].[O-2].[O-2].[As+3].[As+3]
DM61TA4 IK QTLQKAJBUDWPIB-UHFFFAOYSA-N
DM61TA4 IU arsenic(3+);oxygen(2-)
DM61TA4 CA CAS 1327-53-3
DM61TA4 DE Acute lymphoblastic leukaemia
DMQLX7O ID DMQLX7O
DMQLX7O DN Arteether
DMQLX7O HS Approved
DMQLX7O SN Beta arteether; Artecef (TN); Artemotil (TN)
DMQLX7O CP Artecef BV
DMQLX7O DT Small molecular drug
DMQLX7O PC 3000469
DMQLX7O MW 312.4
DMQLX7O FM C17H28O5
DMQLX7O IC InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
DMQLX7O CS CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](CC3)(OO4)C)C)C
DMQLX7O IK NLYNIRQVMRLPIQ-XQLAAWPRSA-N
DMQLX7O IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DMQLX7O CA CAS 75887-54-6
DMQLX7O CB CHEBI:135335
DMQLX7O DE Malaria
DM48QOT ID DM48QOT
DM48QOT DN Artemether
DM48QOT HS Approved
DM48QOT SN Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
DM48QOT DT Small molecular drug
DM48QOT PC 68911
DM48QOT MW 298.37
DM48QOT FM C16H26O5
DM48QOT IC InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
DM48QOT CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
DM48QOT IK SXYIRMFQILZOAM-HVNFFKDJSA-N
DM48QOT IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DM48QOT CA CAS 71963-77-4
DM48QOT CB CHEBI:195280
DM48QOT DE Malaria
DMOY7W3 ID DMOY7W3
DMOY7W3 DN Artemisinin
DMOY7W3 HS Approved
DMOY7W3 SN Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
DMOY7W3 DT Small molecular drug
DMOY7W3 PC 68827
DMOY7W3 MW 282.33
DMOY7W3 FM C15H22O5
DMOY7W3 IC InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
DMOY7W3 CS C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C
DMOY7W3 IK BLUAFEHZUWYNDE-NNWCWBAJSA-N
DMOY7W3 IU (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
DMOY7W3 CA CAS 63968-64-9
DMOY7W3 CB CHEBI:223316
DMOY7W3 DE Malaria
DMFETDK ID DMFETDK
DMFETDK DN Artemisinin SP
DMFETDK HS Approved
DMFETDK SN Isoguvacine; isoguvacine; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; 64603-90-3; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; UNII-YTF580771Y; CHEMBL39071; CHEBI:34799; YTF580771Y; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; AC1OEMUS; 1,2,3,6-tetrahydropyridinium-4-carboxylate; 1,2,3,6-tetrahydropyridin-1-ium-4-carboxylate; Tocris-0235; Spectrum_001974; Lopac-G-002; AC1L1GNT; Spectrum3_001869; Biomol-NT_000254; AC1Q5QG1; Lopac0_000561; KBioSS_002540; BSPBio_003318; DivK1c_000115
DMFETDK DT Small molecular drug
DMFETDK PC 3765
DMFETDK MW 127.14
DMFETDK FM C6H9NO2
DMFETDK IC InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h1,7H,2-4H2,(H,8,9)
DMFETDK CS C1CNCC=C1C(=O)O
DMFETDK IK KRVDMABBKYMBHG-UHFFFAOYSA-N
DMFETDK IU 1,2,3,6-tetrahydropyridine-4-carboxylic acid
DMFETDK CA CAS 64603-90-3
DMFETDK CB CHEBI:34799
DMFETDK DE Malaria
DMR27C8 ID DMR27C8
DMR27C8 DN Artesunate
DMR27C8 HS Approved
DMR27C8 SN Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
DMR27C8 DT Small molecular drug
DMR27C8 PC 6917864
DMR27C8 MW 384.4
DMR27C8 FM C19H28O8
DMR27C8 IC InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
DMR27C8 CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C
DMR27C8 IK FIHJKUPKCHIPAT-AHIGJZGOSA-N
DMR27C8 IU 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
DMR27C8 CA CAS 88495-63-0
DMR27C8 CB CHEBI:63918
DMR27C8 DE Malaria
DMOKCVI ID DMOKCVI
DMOKCVI DN ARZOXIFENE
DMOKCVI HS Approved
DMOKCVI SN Arzoxifene; 182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)
DMOKCVI DT Small molecular drug
DMOKCVI PC 179337
DMOKCVI MW 475.6
DMOKCVI FM C28H29NO4S
DMOKCVI IC InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
DMOKCVI CS COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5
DMOKCVI IK MCGDSOGUHLTADD-UHFFFAOYSA-N
DMOKCVI IU 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol
DMOKCVI CA CAS 182133-25-1
DMOKCVI DE Breast cancer
DMV05SW ID DMV05SW
DMV05SW DN As-1670542
DMV05SW HS Approved
DMV05SW SN AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542
DMV05SW CP Dova Pharmaceuticals
DMV05SW DT Small molecular drug
DMV05SW PC 9852519
DMV05SW MW 649.7
DMV05SW FM C29H34Cl2N6O3S2
DMV05SW IC InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)
DMV05SW CS C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
DMV05SW IK OFZJKCQENFPZBH-UHFFFAOYSA-N
DMV05SW IU 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
DMV05SW CA CAS 570406-98-3
DMV05SW DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMCZIHT ID DMCZIHT
DMCZIHT DN Asasantin
DMCZIHT HS Approved
DMCZIHT SN Aggrenox; Aspirin mixture with Dipyridamole; 87653-67-6; Asasantin Retard; Aspirin / Dipyridamole; aspirin, dipyridamole drug combination; TX-3301; TX 3301; C24H40N8O4.C9H8O4; Aspirin/extended-release dipyridamole; AC1L3AE0; SCHEMBL456521; DTXSID40236543; LS-178622; Benzoic acid, 2-(acetyloxy)-, mixt. with 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis(ethanol)
DMCZIHT CP Boehringer Ingelheim Corp
DMCZIHT DT Small molecular drug
DMCZIHT PC 137329
DMCZIHT MW 684.8
DMCZIHT FM C33H48N8O8
DMCZIHT IC InChI=1S/C24H40N8O4.C9H8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30;1-6(10)13-8-5-3-2-4-7(8)9(11)12/h33-36H,1-18H2;2-5H,1H3,(H,11,12)
DMCZIHT CS CC(=O)OC1=CC=CC=C1C(=O)O.C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMCZIHT IK NOHUXXDTQJPXSB-UHFFFAOYSA-N
DMCZIHT IU 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMCZIHT CA CAS 87653-67-6
DMCZIHT DE Cerebrovascular ischaemia
DMSQZE2 ID DMSQZE2
DMSQZE2 DN Asenapine
DMSQZE2 HS Approved
DMSQZE2 SN Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
DMSQZE2 CP Organon BioSciences
DMSQZE2 DT Small molecular drug
DMSQZE2 PC 3036780
DMSQZE2 MW 285.8
DMSQZE2 FM C17H16ClNO
DMSQZE2 IC InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
DMSQZE2 CS CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
DMSQZE2 IK VSWBSWWIRNCQIJ-GJZGRUSLSA-N
DMSQZE2 IU (2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DMSQZE2 CA CAS 65576-45-6
DMSQZE2 CB CHEBI:71246
DMSQZE2 DE Schizophrenia
DMM4FXA ID DMM4FXA
DMM4FXA DN Asfotase alfa
DMM4FXA HS Approved
DMM4FXA SN SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia
DMM4FXA CP Enobia Pharma Inc
DMM4FXA SQ Asfotase Alfa Sequence: LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD
DMM4FXA DE Genetic disease
DM672AH ID DM672AH
DM672AH DN Aspirin
DM672AH HS Approved
DM672AH SN ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
DM672AH CP Bayer Pharmaceuticals Corporation
DM672AH TC Analgesics
DM672AH DT Small molecular drug
DM672AH PC 2244
DM672AH MW 180.16
DM672AH FM C9H8O4
DM672AH IC InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
DM672AH CS CC(=O)OC1=CC=CC=C1C(=O)O
DM672AH IK BSYNRYMUTXBXSQ-UHFFFAOYSA-N
DM672AH IU 2-acetyloxybenzoic acid
DM672AH CA CAS 50-78-2
DM672AH CB CHEBI:15365
DM672AH DE Pain; Myocardial infarction; Cardiovascular disease
DMSYRBX ID DMSYRBX
DMSYRBX DN Atazanavir
DMSYRBX HS Approved
DMSYRBX SN 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
DMSYRBX CP Bristol-Myers Squibb
DMSYRBX TC Anti-HIV Agents
DMSYRBX DT Small molecular drug
DMSYRBX PC 148192
DMSYRBX MW 704.9
DMSYRBX FM C38H52N6O7
DMSYRBX IC InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
DMSYRBX CS CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMSYRBX IK AXRYRYVKAWYZBR-GASGPIRDSA-N
DMSYRBX IU methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMSYRBX CA CAS 198904-31-3
DMSYRBX CB CHEBI:37924
DMSYRBX DE Human immunodeficiency virus infection
DMNKG1Z ID DMNKG1Z
DMNKG1Z DN Atenolol
DMNKG1Z HS Approved
DMNKG1Z SN Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide
DMNKG1Z TC Antihypertensive Agents
DMNKG1Z DT Small molecular drug
DMNKG1Z PC 2249
DMNKG1Z MW 266.34
DMNKG1Z FM C14H22N2O3
DMNKG1Z IC InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
DMNKG1Z CS CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
DMNKG1Z IK METKIMKYRPQLGS-UHFFFAOYSA-N
DMNKG1Z IU 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMNKG1Z CA CAS 29122-68-7
DMNKG1Z CB CHEBI:2904
DMNKG1Z DE Hypertension
DMMF8U0 ID DMMF8U0
DMMF8U0 DN Atezolizumab
DMMF8U0 HS Approved
DMMF8U0 CP Genentech South San Francisco, CA
DMMF8U0 DT Monoclonal antibody
DMMF8U0 DE Melanoma; Breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancy; Myelodysplastic syndrome; Renal cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Acute myeloid leukaemia; Follicular lymphoma; Gastric adenocarcinoma; Multiple myeloma; Pancreatic cancer; Small-cell lung cancer; Solid tumour/cancer; Bronchioalveolar carcinoma; Ulcer; Non-small cell lung cancer
DM5L6HI ID DM5L6HI
DM5L6HI DN Atomoxetine
DM5L6HI HS Approved
DM5L6HI SN Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CP Eli Lilly
DM5L6HI DT Small molecular drug
DM5L6HI PC 54841
DM5L6HI MW 255.35
DM5L6HI FM C17H21NO
DM5L6HI IC InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
DM5L6HI CS CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
DM5L6HI IK VHGCDTVCOLNTBX-QGZVFWFLSA-N
DM5L6HI IU (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CA CAS 83015-26-3
DM5L6HI CB CHEBI:127342
DM5L6HI DE Attention deficit hyperactivity disorder
DMF28YC ID DMF28YC
DMF28YC DN Atorvastatin
DMF28YC HS Approved
DMF28YC SN Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
DMF28YC CP Pfizer Pharmaceuticals
DMF28YC TC Anticholesteremic Agents
DMF28YC DT Small molecular drug
DMF28YC PC 60823
DMF28YC MW 558.6
DMF28YC FM C33H35FN2O5
DMF28YC IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMF28YC CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMF28YC IK XUKUURHRXDUEBC-KAYWLYCHSA-N
DMF28YC IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMF28YC CA CAS 134523-00-5
DMF28YC CB CHEBI:39548
DMF28YC DE Cardiovascular disease
DMY4UMW ID DMY4UMW
DMY4UMW DN Atovaquone
DMY4UMW HS Approved
DMY4UMW SN Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
DMY4UMW CP GlaxoSmithKline
DMY4UMW TC Antifungal Agents
DMY4UMW DT Small molecular drug
DMY4UMW PC 74989
DMY4UMW MW 366.8
DMY4UMW FM C22H19ClO3
DMY4UMW IC InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2
DMY4UMW CS C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
DMY4UMW IK BSJMWHQBCZFXBR-UHFFFAOYSA-N
DMY4UMW IU 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
DMY4UMW CA CAS 94015-53-9
DMY4UMW CB CHEBI:575568
DMY4UMW DE Fungal infection
DM42HXN ID DM42HXN
DM42HXN DN Atracurium
DM42HXN HS Approved
DM42HXN SN Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CP Burroughs Wellcome Co
DM42HXN TC Neuromuscular Nondepolarizing Agents
DM42HXN DT Small molecular drug
DM42HXN PC 47319
DM42HXN MW 929.1
DM42HXN FM C53H72N2O12+2
DM42HXN IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
DM42HXN CS C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DM42HXN IK YXSLJKQTIDHPOT-UHFFFAOYSA-N
DM42HXN IU 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CA CAS 64228-79-1
DM42HXN CB CHEBI:2914
DM42HXN DE Anaesthesia
DMEN6X7 ID DMEN6X7
DMEN6X7 DN Atropine
DMEN6X7 HS Approved
DMEN6X7 SN dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
DMEN6X7 CP Pfizer Pharmaceuticals
DMEN6X7 TC Antiarrhythmic Agents
DMEN6X7 DT Small molecular drug
DMEN6X7 PC 174174
DMEN6X7 MW 289.4
DMEN6X7 FM C17H23NO3
DMEN6X7 IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
DMEN6X7 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
DMEN6X7 IK RKUNBYITZUJHSG-PJPHBNEVSA-N
DMEN6X7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMEN6X7 CA CAS 51-55-8
DMEN6X7 CB CHEBI:16684
DMEN6X7 DE Organophosphate poisoning; Poison intoxication
DM79Y2T ID DM79Y2T
DM79Y2T DN ATryn antithrombin
DM79Y2T HS Approved
DM79Y2T CP Revo biologics
DM79Y2T DE Multiple sclerosis
DMWE2N4 ID DMWE2N4
DMWE2N4 DN Auranofin
DMWE2N4 HS Approved
DMWE2N4 SN Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
DMWE2N4 TC Antirheumatic Agents
DMWE2N4 DT Small molecular drug
DMWE2N4 PC 24199313
DMWE2N4 MW 678.5
DMWE2N4 FM C20H34AuO9PS
DMWE2N4 IC InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
DMWE2N4 CS CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DMWE2N4 IK AUJRCFUBUPVWSZ-UHFFFAOYSA-M
DMWE2N4 IU gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
DMWE2N4 CA CAS 34031-32-8
DMWE2N4 DE Inflammatory arthritis
DM75CXN ID DM75CXN
DM75CXN DN Avanafil
DM75CXN HS Approved
DM75CXN SN Stendra (TN)
DM75CXN CP Vivus
DM75CXN DT Small molecular drug
DM75CXN PC 9869929
DM75CXN MW 483.9
DM75CXN FM C23H26ClN7O3
DM75CXN IC InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
DM75CXN CS COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
DM75CXN IK WEAJZXNPAWBCOA-INIZCTEOSA-N
DM75CXN IU 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
DM75CXN CA CAS 330784-47-9
DM75CXN CB CHEBI:66876
DM75CXN DE Erectile dysfunction
DMK2GZX ID DMK2GZX
DMK2GZX DN Avapritinib
DMK2GZX HS Approved
DMK2GZX SN 1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
DMK2GZX CP Blueprint Medicines Cambridge, MA
DMK2GZX PC 118023034
DMK2GZX MW 498.6
DMK2GZX FM C26H27FN10
DMK2GZX IC InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
DMK2GZX CS C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N
DMK2GZX IK DWYRIWUZIJHQKQ-SANMLTNESA-N
DMK2GZX IU (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine
DMK2GZX CA CAS 1703793-34-3
DMK2GZX DE Mast cell leukaemia; Systemic mastocytosis; Gastrointestinal stromal tumour
DMSZLJR ID DMSZLJR
DMSZLJR DN Avelumab
DMSZLJR HS Approved
DMSZLJR CP Merck KGaA/Pfizer
DMSZLJR DT Monoclonal antibody
DMSZLJR SQ Heavy chain: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMSZLJR DE Melanoma; Ovarian cancer; Solid tumour/cancer; Renal cell carcinoma; Merkel cell carcinoma
DM1AEH4 ID DM1AEH4
DM1AEH4 DN Avibactam
DM1AEH4 HS Approved
DM1AEH4 SN Avibactam; Avibactam (free acid); Avibactam [USAN:INN]; Avibactam free acid; AVE-1330A free acid; NXL 104; NXL104; Q15410251; SCHEMBL1666807; ZINC9302239; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; 1192500-31-4; 396731-14-9; BDBM50339145; CHEBI:85984; CHEMBL1689063; CS-0593; DB09060; HY-14879; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; UNII-7352665165
DM1AEH4 PC 9835049
DM1AEH4 MW 265.25
DM1AEH4 FM C7H11N3O6S
DM1AEH4 IC NDCUAPJVLWFHHB-UHNVWZDZSA-N
DM1AEH4 CS C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N
DM1AEH4 IK 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
DM1AEH4 IU [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DM1AEH4 CA CAS 396731-14-9
DM1AEH4 CB CHEBI:85984
DM1AEH4 DE Infectious cystitis
DMYHN59 ID DMYHN59
DMYHN59 DN Axicabtagene ciloleucel
DMYHN59 HS Approved
DMYHN59 CP Masonic Cancer Center, University of Minnesota
DMYHN59 DT CAR T Cell Therapy
DMYHN59 DE Acute lymphoblastic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; Large B-cell lymphoma
DMGVH6N ID DMGVH6N
DMGVH6N DN Axitinib
DMGVH6N HS Approved
DMGVH6N SN AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
DMGVH6N CP Pfizer
DMGVH6N TC Anticancer Agents
DMGVH6N DT Small molecular drug
DMGVH6N PC 6450551
DMGVH6N MW 386.5
DMGVH6N FM C22H18N4OS
DMGVH6N IC InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMGVH6N CS CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMGVH6N IK RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMGVH6N IU N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMGVH6N CA CAS 319460-85-0
DMGVH6N CB CHEBI:66910
DMGVH6N DE Renal cell carcinoma
DMTA5OE ID DMTA5OE
DMTA5OE DN Azacitidine
DMTA5OE HS Approved
DMTA5OE SN Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
DMTA5OE CP Celgene
DMTA5OE TC Anticancer Agents
DMTA5OE DT Small molecular drug
DMTA5OE PC 9444
DMTA5OE MW 244.2
DMTA5OE FM C8H12N4O5
DMTA5OE IC InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
DMTA5OE CS C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
DMTA5OE IK NMUSYJAQQFHJEW-KVTDHHQDSA-N
DMTA5OE IU 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMTA5OE CA CAS 320-67-2
DMTA5OE CB CHEBI:2038
DMTA5OE DE Myelodysplastic syndrome
DMZ80SB ID DMZ80SB
DMZ80SB DN Azatadine
DMZ80SB HS Approved
DMZ80SB SN Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
DMZ80SB TC Antihistamines
DMZ80SB DT Small molecular drug
DMZ80SB PC 19861
DMZ80SB MW 290.4
DMZ80SB FM C20H22N2
DMZ80SB IC InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3
DMZ80SB CS CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1
DMZ80SB IK SEBMTIQKRHYNIT-UHFFFAOYSA-N
DMZ80SB IU 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene
DMZ80SB CA CAS 3964-81-6
DMZ80SB CB CHEBI:2946
DMZ80SB DE Allergic rhinitis
DMMZSXQ ID DMMZSXQ
DMMZSXQ DN Azathioprine
DMMZSXQ HS Approved
DMMZSXQ SN Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
DMMZSXQ CP GlaxoSmithKline
DMMZSXQ TC Immunosuppressive Agents
DMMZSXQ DT Small molecular drug
DMMZSXQ PC 2265
DMMZSXQ MW 277.27
DMMZSXQ FM C9H7N7O2S
DMMZSXQ IC InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
DMMZSXQ CS CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
DMMZSXQ IK LMEKQMALGUDUQG-UHFFFAOYSA-N
DMMZSXQ IU 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
DMMZSXQ CA CAS 446-86-6
DMMZSXQ CB CHEBI:2948
DMMZSXQ DE Organ transplant rejection
DMHVL0J ID DMHVL0J
DMHVL0J DN Azelaic Acid
DMHVL0J HS Approved
DMHVL0J SN AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid
DMHVL0J TC Dermatologic Agents
DMHVL0J DT Small molecular drug
DMHVL0J PC 2266
DMHVL0J MW 188.22
DMHVL0J FM C9H16O4
DMHVL0J IC InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
DMHVL0J CS C(CCCC(=O)O)CCCC(=O)O
DMHVL0J IK BDJRBEYXGGNYIS-UHFFFAOYSA-N
DMHVL0J IU nonanedioic acid
DMHVL0J CA CAS 123-99-9
DMHVL0J CB CHEBI:48131
DMHVL0J DE Acne vulgaris
DMXTMBJ ID DMXTMBJ
DMXTMBJ DN Azelastine
DMXTMBJ HS Approved
DMXTMBJ SN Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CP Meda Pharmaceuticals Inc
DMXTMBJ TC Antiallergic Agents
DMXTMBJ DT Small molecular drug
DMXTMBJ PC 2267
DMXTMBJ MW 381.9
DMXTMBJ FM C22H24ClN3O
DMXTMBJ IC InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
DMXTMBJ CS CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
DMXTMBJ IK MBUVEWMHONZEQD-UHFFFAOYSA-N
DMXTMBJ IU 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CA CAS 58581-89-8
DMXTMBJ CB CHEBI:2950
DMXTMBJ DE Allergic conjunctivitis
DMOIX5S ID DMOIX5S
DMOIX5S DN Azilsartan
DMOIX5S HS Approved
DMOIX5S SN TAK 536; TAK-536; Azilsartan (INN/USAN)
DMOIX5S CP Takeda
DMOIX5S DT Small molecular drug
DMOIX5S PC 135415867
DMOIX5S MW 456.4
DMOIX5S FM C25H20N4O5
DMOIX5S IC InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
DMOIX5S CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
DMOIX5S IK KGSXMPPBFPAXLY-UHFFFAOYSA-N
DMOIX5S IU 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMOIX5S CA CAS 147403-03-0
DMOIX5S CB CHEBI:68850
DMOIX5S DE Hypertension
DMIR5QP ID DMIR5QP
DMIR5QP DN Azlocillin
DMIR5QP HS Approved
DMIR5QP SN Azlocilina; Azlocilline; Azlocillinum; Securopen; Bayer Brand of Azlocillin; Azlocilina [INN-Spanish]; Azlocillin Sodium (Sterile); Azlocilline [INN-French]; Azlocillinum [INN-Latin]; Bay-e 6905; Azlocillin (USAN/INN); Azlocillin [USAN:BAN:INN]; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
DMIR5QP CP Bayer Pharmaceuticals Corp
DMIR5QP TC Antibiotics
DMIR5QP DT Small molecular drug
DMIR5QP PC 6479523
DMIR5QP MW 461.5
DMIR5QP FM C20H23N5O6S
DMIR5QP IC InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1
DMIR5QP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
DMIR5QP IK JTWOMNBEOCYFNV-NFFDBFGFSA-N
DMIR5QP IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIR5QP CA CAS 37091-66-0
DMIR5QP CB CHEBI:2956
DMIR5QP DE Pseudomonas infection
DMDNJHG ID DMDNJHG
DMDNJHG DN Aztreonam
DMDNJHG HS Approved
DMDNJHG SN Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CP Bristol-Myers Squibb Company
DMDNJHG TC Antibiotics
DMDNJHG DT Small molecular drug
DMDNJHG PC 5742832
DMDNJHG MW 435.4
DMDNJHG FM C13H17N5O8S2
DMDNJHG IC InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
DMDNJHG CS C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
DMDNJHG IK WZPBZJONDBGPKJ-VEHQQRBSSA-N
DMDNJHG IU 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CA CAS 78110-38-0
DMDNJHG CB CHEBI:161680
DMDNJHG DE Bacterial infection
DMP54C7 ID DMP54C7
DMP54C7 DN Bacampicillin
DMP54C7 HS Approved
DMP54C7 SN Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester
DMP54C7 CP Pfizer Pharmaceuticals
DMP54C7 TC Antibiotics
DMP54C7 DT Small molecular drug
DMP54C7 PC 441397
DMP54C7 MW 465.5
DMP54C7 FM C21H27N3O7S
DMP54C7 IC InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1
DMP54C7 CS CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C
DMP54C7 IK PFOLLRNADZZWEX-FFGRCDKISA-N
DMP54C7 IU 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMP54C7 CA CAS 50972-17-3
DMP54C7 CB CHEBI:2968
DMP54C7 DE Bacterial infection
DM5OHYE ID DM5OHYE
DM5OHYE DN Bacitracin
DM5OHYE HS Approved
DM5OHYE SN Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA
DM5OHYE TC Antibiotics
DM5OHYE DT Small molecular drug
DM5OHYE PC 10909430
DM5OHYE MW 1422.7
DM5OHYE FM C66H103N17O16S
DM5OHYE IC InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
DM5OHYE CS CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
DM5OHYE IK CLKOFPXJLQSYAH-ABRJDSQDSA-N
DM5OHYE IU (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5OHYE CA CAS 1405-87-4
DM5OHYE CB CHEBI:35862
DM5OHYE DE Skin infection
DMD2871 ID DMD2871
DMD2871 DN Bacitracin
DMD2871 HS Approved
DMD2871 SN Bacillus subtilis; Bacitracin Zinc free sample; Bacitracin zinc [USP]; Bacitracins zinc complex; Bacitracins, zinc complex; EPA Pesticide Chemical Code 006309; SC-18930; SCHEMBL543112; Ziba-RX; Zinc bacitracin; 5-((1-((9-((4H-imidazol-4-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopent; AKOS015896384; Albac; Caswell No. 909A; EINECS 215-787-8; FT-0622546; FT-0654564
DMD2871 PC 3083711
DMD2871 MW 1488.1
DMD2871 FM C66H103N17O16SZn
DMD2871 IC QSNOBVJFKSQBBD-UHFFFAOYSA-N
DMD2871 CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3C=NC=N3)CC4=CC=CC=C4.[Zn]
DMD2871 IK 1S/C66H103N17O16S.Zn/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90;/h12-14,18-19,31,33-37,39-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88);
DMD2871 IU 4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(4H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid;zinc
DMD2871 CA CAS 1405-89-6
DMD2871 DE Pyothorax
DM0QV1J ID DM0QV1J
DM0QV1J DN Baclofen
DM0QV1J HS Approved
DM0QV1J SN Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA; ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid
DM0QV1J CP Norvatis Phamaceuticals Corporation
DM0QV1J TC Muscle Relaxants
DM0QV1J DT Small molecular drug
DM0QV1J PC 2284
DM0QV1J MW 213.66
DM0QV1J FM C10H12ClNO2
DM0QV1J IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DM0QV1J CS C1=CC(=CC=C1C(CC(=O)O)CN)Cl
DM0QV1J IK KPYSYYIEGFHWSV-UHFFFAOYSA-N
DM0QV1J IU 4-amino-3-(4-chlorophenyl)butanoic acid
DM0QV1J CA CAS 1134-47-0
DM0QV1J CB CHEBI:2972
DM0QV1J DE Multiple sclerosis; Fragile X syndrome
DMPWNDB ID DMPWNDB
DMPWNDB DN Balofloxacin
DMPWNDB HS Approved
DMPWNDB SN Baloxin; Balofloxacin [INN]; Q 35; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CP Chugai
DMPWNDB DT Small molecular drug
DMPWNDB PC 65958
DMPWNDB MW 389.4
DMPWNDB FM C20H24FN3O4
DMPWNDB IC InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)
DMPWNDB CS CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPWNDB IK MGQLHRYJBWGORO-UHFFFAOYSA-N
DMPWNDB IU 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CA CAS 127294-70-6
DMPWNDB DE Gram-positive bacterial infection
DM1UV7F ID DM1UV7F
DM1UV7F DN Baloxavir marboxil
DM1UV7F HS Approved
DM1UV7F SN UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527
DM1UV7F CP Shionogi/Roche
DM1UV7F PC 124081896
DM1UV7F MW 571.6
DM1UV7F FM C27H23F2N3O7S
DM1UV7F IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DM1UV7F CS COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DM1UV7F IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DM1UV7F IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DM1UV7F CA CAS 1985606-14-1
DM1UV7F DE Influenza virus infection
DMRJ9EN ID DMRJ9EN
DMRJ9EN DN Baloxavir marboxil
DMRJ9EN HS Approved
DMRJ9EN SN (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)
DMRJ9EN TC Antiviral Agents
DMRJ9EN DT Small molecular drug
DMRJ9EN PC 124081896
DMRJ9EN MW 571.552
DMRJ9EN FM C27H23F2N3O7S
DMRJ9EN IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DMRJ9EN CS COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DMRJ9EN IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DMRJ9EN IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DMRJ9EN CA CAS 1985606-14-1
DMRJ9EN DE Influenza A infection
DM7I1T9 ID DM7I1T9
DM7I1T9 DN Balsalazide
DM7I1T9 HS Approved
DM7I1T9 SN Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP
DM7I1T9 PC 54585
DM7I1T9 MW 357.32
DM7I1T9 FM C17H15N3O6
DM7I1T9 IC IPOKCKJONYRRHP-UHFFFAOYSA-N
DM7I1T9 CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DM7I1T9 IK 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DM7I1T9 IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DM7I1T9 CA CAS 80573-04-2
DM7I1T9 CB CHEBI:267413
DM7I1T9 DE Ulcerative colitis
DMO091F ID DMO091F
DMO091F DN Balsalazide
DMO091F HS Approved
DMO091F SN Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
DMO091F TC Antiinflammatory Agents
DMO091F DT Small molecular drug
DMO091F PC 54585
DMO091F MW 357.32
DMO091F FM C17H15N3O6
DMO091F IC InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DMO091F CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMO091F IK IPOKCKJONYRRHP-UHFFFAOYSA-N
DMO091F IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMO091F CA CAS 80573-04-2
DMO091F CB CHEBI:267413
DMO091F DE Inflammatory bowel disease
DMKLSHF ID DMKLSHF
DMKLSHF DN Bambuterol
DMKLSHF HS Approved
DMKLSHF SN Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
DMKLSHF CP AstraZeneca
DMKLSHF TC Bronchodilator Agents
DMKLSHF DT Small molecular drug
DMKLSHF PC 54766
DMKLSHF MW 367.4
DMKLSHF FM C18H29N3O5
DMKLSHF IC InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
DMKLSHF CS CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
DMKLSHF IK ANZXOIAKUNOVQU-UHFFFAOYSA-N
DMKLSHF IU [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate
DMKLSHF CA CAS 81732-65-2
DMKLSHF CB CHEBI:553827
DMKLSHF DE Asthma
DMXLHYN ID DMXLHYN
DMXLHYN DN Bamifylline
DMXLHYN HS Approved
DMXLHYN SN Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride
DMXLHYN DT Small molecular drug
DMXLHYN PC 16229
DMXLHYN MW 385.5
DMXLHYN FM C20H27N5O3
DMXLHYN IC InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3
DMXLHYN CS CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO
DMXLHYN IK VVUYEFBRTFASAH-UHFFFAOYSA-N
DMXLHYN IU 8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
DMXLHYN CA CAS 2016-63-9
DMXLHYN CB CHEBI:135605
DMXLHYN DE Chronic obstructive pulmonary disease
DME1DJX ID DME1DJX
DME1DJX DN Baquting
DME1DJX HS Approved
DME1DJX CP China Nuokang Bio-Pharmaceutical Inc
DME1DJX DE Bleeding disorder
DMJ8NMC ID DMJ8NMC
DMJ8NMC DN Barbital
DMJ8NMC HS Approved
DMJ8NMC SN Barbitale; Barbitalum; Barbitone; Barbitonum; DEBA; Diemal; Diemalum; Diethylbarbitone; Diethylmalonylurea; Dormileno; Dormonal; Ethylbarbital; Hypnogene; Malonal; Medinal; Sedeval; Uronal; Veroletten; Verolettin; Veronal; Vesperal; Barbital Faes Brand; Barbitale [DCIT]; Diethylbarbituric acid; Faes Brand of Barbital; Barbital (TN); Barbital (VAN); Barbital [INN:JAN]; Barbitalum [INN-Latin]; Veronal (TN); Barbital (JP15/INN); Kyselina 5,5-diethylbarbiturova; Kyselina 5,5-diethylbarbiturova [Czech]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-(9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethylbarbituric acid; 5,5-diethyl-1,3-diazinane-2,4,6-trione; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; 7979P
DMJ8NMC CP Schering-Plough
DMJ8NMC TC Hypnotics and Sedatives
DMJ8NMC DT Small molecular drug
DMJ8NMC PC 2294
DMJ8NMC MW 184.19
DMJ8NMC FM C8H12N2O3
DMJ8NMC IC InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
DMJ8NMC CS CCC1(C(=O)NC(=O)NC1=O)CC
DMJ8NMC IK FTOAOBMCPZCFFF-UHFFFAOYSA-N
DMJ8NMC IU 5,5-diethyl-1,3-diazinane-2,4,6-trione
DMJ8NMC CA CAS 57-44-3
DMJ8NMC CB CHEBI:31252
DMJ8NMC DE Insomnia
DMJIA6T ID DMJIA6T
DMJIA6T DN Barbiturate
DMJIA6T HS Approved
DMJIA6T SN Barbituric acid; BARBITURIC ACID; 67-52-7; Malonylurea; 6-Hydroxyuracil; 2,4,6(1H,3H,5H)-Pyrimidinetrione; Pyrimidinetrione; pyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6-Pyrimidinetrione; Malonylharnstoff; 2,4,6-Trioxohexahydropyrimidine; 1,3-diazinane-2,4,6-trione; Barbitursaeure; Hexahydropyrimidine-2,4,6-trione; Hydrouracil, 6-hydroxy-; Barbituric acid (VAN); Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; NSC 7889; UNII-WQ92Y2793G; 2,4,6-Pyrimidinetrione(1H,3H,5H); Barbituric acid (VAN) (8CI); CHEBI:16294; EINECS 200-658-0; Barbitursaeure; Pyrimidinetriol; Barbiturate anion; Sodiumbarbiturate; AG-670/31547005; Hexahydro-pyrimidine-2,4,6-trione; Pyrimidine-2,4,6(1H,3H,5H)-trione; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 11709_FLUKA; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Pyrimidinetriol; 2,4,6-Trihydroxypyrimidine; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; 4,6-dioxo-1H-pyrimidin-2-olate
DMJIA6T DT Small molecular drug
DMJIA6T PC 6211
DMJIA6T MW 128.09
DMJIA6T FM C4H4N2O3
DMJIA6T IC InChI=1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9)
DMJIA6T CS C1C(=O)NC(=O)NC1=O
DMJIA6T IK HNYOPLTXPVRDBG-UHFFFAOYSA-N
DMJIA6T IU 1,3-diazinane-2,4,6-trione
DMJIA6T CA CAS 67-52-7
DMJIA6T CB CHEBI:16294
DMJIA6T DE Depression; Anaesthesia
DM4ONW5 ID DM4ONW5
DM4ONW5 DN Baricitinib
DM4ONW5 HS Approved
DM4ONW5 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DM4ONW5 CP Incyte/Eli Lilly
DM4ONW5 DT Small molecular drug
DM4ONW5 PC 44205240
DM4ONW5 MW 371.4
DM4ONW5 FM C16H17N7O2S
DM4ONW5 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DM4ONW5 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM4ONW5 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N
DM4ONW5 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DM4ONW5 CA CAS 1187594-09-7
DM4ONW5 CB CHEBI:95341
DM4ONW5 DE Rheumatoid arthritis
DMWNRZT ID DMWNRZT
DMWNRZT DN Basiliximab
DMWNRZT HS Approved
DMWNRZT SN Simulect (TN)
DMWNRZT CP Norvatis Phamaceuticals Corporation
DMWNRZT TC Immunomodulatory Agents
DMWNRZT DT Monoclonal antibody
DMWNRZT SQ Basiliximab heavy chain: QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Basiliximab light chainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
DMWNRZT DE Organ transplant rejection
DMU9C8F ID DMU9C8F
DMU9C8F DN Bavencio
DMU9C8F HS Approved
DMU9C8F CP EMD Serono Rockland, MA Pfizer New York, NY
DMU9C8F DT Monoclonal antibody
DMU9C8F DE Melanoma; Merkel cell carcinoma; Breast cancer; Gastric adenocarcinoma; Haematological malignancy; Head and neck cancer; Squamous cell carcinoma; Urothelial carcinoma; Colon cancer; Testicular cancer
DMLOS5R ID DMLOS5R
DMLOS5R DN Bay 80-6946
DMLOS5R HS Approved
DMLOS5R SN Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS
DMLOS5R CP Bayer HealthCare Pharmaceuticals
DMLOS5R DT Small molecular drug
DMLOS5R PC 135565596
DMLOS5R MW 480.5
DMLOS5R FM C23H28N8O4
DMLOS5R IC InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
DMLOS5R CS COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
DMLOS5R IK MWYDSXOGIBMAET-UHFFFAOYSA-N
DMLOS5R IU 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide
DMLOS5R CA CAS 1032568-63-0
DMLOS5R DE Follicular lymphoma; Non-hodgkin lymphoma
DMY85QW ID DMY85QW
DMY85QW DN Bazedoxifene
DMY85QW HS Approved
DMY85QW SN Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424
DMY85QW CP Ligand Pharmaceuticals Inc
DMY85QW DT Small molecular drug
DMY85QW PC 154257
DMY85QW MW 470.6
DMY85QW FM C30H34N2O3
DMY85QW IC InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
DMY85QW CS CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
DMY85QW IK UCJGJABZCDBEDK-UHFFFAOYSA-N
DMY85QW IU 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
DMY85QW CA CAS 198481-32-2
DMY85QW CB CHEBI:135947
DMY85QW DE Osteopetrosis
DM1R5X4 ID DM1R5X4
DM1R5X4 DN Becaplermin
DM1R5X4 HS Approved
DM1R5X4 SN Regranex; Regranex (TN); Becaplermin (USAN/INN)
DM1R5X4 CP Ortho-McNeil Pharmaceutical
DM1R5X4 TC Antiulcer Agents
DM1R5X4 SQ DB00102 sequence: SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT
DM1R5X4 DE Diabetic complication
DMZPHIK ID DMZPHIK
DMZPHIK DN Beclomethasone
DMZPHIK HS Approved
DMZPHIK SN Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone
DMZPHIK CP Shire Pharmaceuticals
DMZPHIK TC Antiasthmatic Agents
DMZPHIK DT Small molecular drug
DMZPHIK PC 20469
DMZPHIK MW 408.9
DMZPHIK FM C22H29ClO5
DMZPHIK IC InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMZPHIK CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
DMZPHIK IK NBMKJKDGKREAPL-DVTGEIKXSA-N
DMZPHIK IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZPHIK CA CAS 4419-39-0
DMZPHIK CB CHEBI:3001
DMZPHIK DE Allergic rhinitis; Asthma
DM3906J ID DM3906J
DM3906J DN Bedaquiline
DM3906J HS Approved
DM3906J SN SIRTURO (TN)
DM3906J CP Johnson & Johnson
DM3906J DT Small molecular drug
DM3906J PC 5388906
DM3906J MW 555.5
DM3906J FM C32H31BrN2O2
DM3906J IC InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
DM3906J CS CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
DM3906J IK QUIJNHUBAXPXFS-XLJNKUFUSA-N
DM3906J IU (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol
DM3906J CA CAS 843663-66-1
DM3906J CB CHEBI:72292
DM3906J DE Multi-drug resistant tuberculosis
DM8WCXM ID DM8WCXM
DM8WCXM DN Befunolol hci
DM8WCXM HS Approved
DM8WCXM SN Bentox (TN)
DM8WCXM DT Small molecular drug
DM8WCXM PC 38286
DM8WCXM MW 327.8
DM8WCXM FM C16H22ClNO4
DM8WCXM IC InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
DM8WCXM CS CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-]
DM8WCXM IK TVVTWOGRPVJKDJ-UHFFFAOYSA-N
DM8WCXM IU [3-[(2-acetyl-1-benzofuran-7-yl)oxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride
DM8WCXM CA CAS 39543-79-8
DM8WCXM CB CHEBI:31254
DM8WCXM DE Glaucoma/ocular hypertension
DMBT3AI ID DMBT3AI
DMBT3AI DN Belantamab mafodotin
DMBT3AI HS Approved
DMBT3AI DT Antibody drug conjugate
DMBT3AI DE Multiple myeloma
DMXLYQF ID DMXLYQF
DMXLYQF DN Belatacept
DMXLYQF HS Approved
DMXLYQF SN Nulojix (TN); Belatacept (USAN/INN)
DMXLYQF CP Bristol-Myers Squibb
DMXLYQF SQ sequence for belatacept: MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMXLYQF DE Kidney transplant rejection; Heart transplant rejection
DM3OBQF ID DM3OBQF
DM3OBQF DN Belimumab
DM3OBQF HS Approved
DM3OBQF SN Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)
DM3OBQF CP GSK
DM3OBQF DT Antibody
DM3OBQF DE Systemic lupus erythematosus
DM2RBWK ID DM2RBWK
DM2RBWK DN Belladonna
DM2RBWK HS Approved
DM2RBWK DE Colitis
DM3SRJZ ID DM3SRJZ
DM3SRJZ DN Belotecan hydrocholoride
DM3SRJZ HS Approved
DM3SRJZ DE Small-cell lung cancer
DM1CI9R ID DM1CI9R
DM1CI9R DN Bempedoic acid
DM1CI9R HS Approved
DM1CI9R SN ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
DM1CI9R CP Esperion Therapeutics
DM1CI9R DT Small molecular drug
DM1CI9R PC 10472693
DM1CI9R MW 344.5
DM1CI9R FM C19H36O5
DM1CI9R IC InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
DM1CI9R CS CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
DM1CI9R IK HYHMLYSLQUKXKP-UHFFFAOYSA-N
DM1CI9R IU 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
DM1CI9R CA CAS 738606-46-7
DM1CI9R CB CHEBI:149601
DM1CI9R DE Cardiovascular disease; Familial hypercholesterolemia
DMH1M9B ID DMH1M9B
DMH1M9B DN Benazepril
DMH1M9B HS Approved
DMH1M9B SN Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CP Norvatis Phamaceuticals Corporation
DMH1M9B TC Antihypertensive Agents
DMH1M9B DT Small molecular drug
DMH1M9B PC 5362124
DMH1M9B MW 424.5
DMH1M9B FM C24H28N2O5
DMH1M9B IC InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
DMH1M9B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
DMH1M9B IK XPCFTKFZXHTYIP-PMACEKPBSA-N
DMH1M9B IU 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CA CAS 86541-75-5
DMH1M9B CB CHEBI:3011
DMH1M9B DE Hypertension
DMFH15Z ID DMFH15Z
DMFH15Z DN Bendamustine hydrochloride
DMFH15Z HS Approved
DMFH15Z SN Treanda (TN)
DMFH15Z CP Cephalon
DMFH15Z DT Small molecular drug
DMFH15Z PC 77082
DMFH15Z MW 394.7
DMFH15Z FM C16H22Cl3N3O2
DMFH15Z IC InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
DMFH15Z CS CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl
DMFH15Z IK ZHSKUOZOLHMKEA-UHFFFAOYSA-N
DMFH15Z IU 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
DMFH15Z CA CAS 3543-75-7
DMFH15Z DE leukaemia
DM7EVLC ID DM7EVLC
DM7EVLC DN Bendroflumethiazide
DM7EVLC HS Approved
DM7EVLC SN Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DM7EVLC CP Crescent Pharmaceuticals
DM7EVLC TC Antihypertensive Agents
DM7EVLC DT Small molecular drug
DM7EVLC PC 2315
DM7EVLC MW 421.4
DM7EVLC FM C15H14F3N3O4S2
DM7EVLC IC InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
DM7EVLC CS C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2
DM7EVLC IK HDWIHXWEUNVBIY-UHFFFAOYSA-N
DM7EVLC IU 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DM7EVLC CA CAS 73-48-3
DM7EVLC CB CHEBI:3013
DM7EVLC DE High blood pressure
DM7P1J4 ID DM7P1J4
DM7P1J4 DN Benralizumab
DM7P1J4 HS Approved
DM7P1J4 CP AstraZeneca
DM7P1J4 DT Monoclonal antibody
DM7P1J4 DE Asthma; Chronic obstructive pulmonary disease
DMRVBWU ID DMRVBWU
DMRVBWU DN Bentazepam
DMRVBWU HS Approved
DMRVBWU DT Small molecular drug
DMRVBWU PC 135412795
DMRVBWU MW 296.4
DMRVBWU FM C17H16N2OS
DMRVBWU IC InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)
DMRVBWU CS C1CCC2=C(C1)C3=C(S2)NC(=O)CN=C3C4=CC=CC=C4
DMRVBWU IK AIZFEOPQVZBNGH-UHFFFAOYSA-N
DMRVBWU IU 5-phenyl-1,3,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
DMRVBWU CA CAS 29462-18-8
DMRVBWU CB CHEBI:135252
DMRVBWU DE Anxiety disorder
DMF7EXL ID DMF7EXL
DMF7EXL DN Benzatropine
DMF7EXL HS Approved
DMF7EXL SN Benzatropina; Benzatropina [INN-Spanish]; Benzatropine; Benzatropinum; Benzatropinum [INN-Latin]; Benztropinum; Cobrentin; Cogentin; Cogentine; Akitan; Cogentinol; Tropine benzohydryl ether; benztropine; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 1NHL2J4X8K; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 86-13-5; CHEBI:3048; HSDB 3014; NCGC00159471-02; NK 02; UNII-1NHL2J4X8K
DMF7EXL PC 1201549
DMF7EXL MW 307.4
DMF7EXL FM C21H25NO
DMF7EXL IC GIJXKZJWITVLHI-YOFSQIOKSA-N
DMF7EXL CS CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMF7EXL IK 1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMF7EXL IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMF7EXL CA CAS 86-13-5
DMF7EXL CB CHEBI:3048
DMF7EXL DE Agitation/aggression
DMC3YUA ID DMC3YUA
DMC3YUA DN Benzbromarone
DMC3YUA HS Approved
DMC3YUA SN Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
DMC3YUA CP Labaz Laboratories
DMC3YUA DT Small molecular drug
DMC3YUA PC 2333
DMC3YUA MW 424.1
DMC3YUA FM C17H12Br2O3
DMC3YUA IC InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMC3YUA CS CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMC3YUA IK WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMC3YUA IU (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMC3YUA CA CAS 3562-84-3
DMC3YUA CB CHEBI:3023
DMC3YUA DE Gout
DMI18HW ID DMI18HW
DMI18HW DN Benzocaine
DMI18HW HS Approved
DMI18HW SN Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester
DMI18HW CP Wyeth Pharmaceuticals
DMI18HW TC Anesthetics
DMI18HW DT Small molecular drug
DMI18HW PC 2337
DMI18HW MW 165.19
DMI18HW FM C9H11NO2
DMI18HW IC InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
DMI18HW CS CCOC(=O)C1=CC=C(C=C1)N
DMI18HW IK BLFLLBZGZJTVJG-UHFFFAOYSA-N
DMI18HW IU ethyl 4-aminobenzoate
DMI18HW CA CAS 94-09-7
DMI18HW CB CHEBI:116735
DMI18HW DE Anaesthesia
DMKB9FI ID DMKB9FI
DMKB9FI DN Benzoic acid
DMKB9FI HS Approved
DMKB9FI SN Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1
DMKB9FI DT Small molecular drug
DMKB9FI PC 243
DMKB9FI MW 122.12
DMKB9FI FM C7H6O2
DMKB9FI IC InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)
DMKB9FI CS C1=CC=C(C=C1)C(=O)O
DMKB9FI IK WPYMKLBDIGXBTP-UHFFFAOYSA-N
DMKB9FI IU benzoic acid
DMKB9FI CA CAS 65-85-0
DMKB9FI CB CHEBI:30746
DMKB9FI DE Fungal infection
DM9U4FO ID DM9U4FO
DM9U4FO DN Benzonatate
DM9U4FO HS Approved
DM9U4FO SN Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
DM9U4FO TC Antitussives
DM9U4FO DT Small molecular drug
DM9U4FO PC 7699
DM9U4FO MW 603.7
DM9U4FO FM C30H53NO11
DM9U4FO IC InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3
DM9U4FO CS CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DM9U4FO IK MAFMQEKGGFWBAB-UHFFFAOYSA-N
DM9U4FO IU 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
DM9U4FO CA CAS 104-31-4
DM9U4FO CB CHEBI:3032
DM9U4FO DE Cough
DMIJATC ID DMIJATC
DMIJATC DN Benzphetamine
DMIJATC HS Approved
DMIJATC SN Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
DMIJATC CP Pharmacia
DMIJATC DT Small molecular drug
DMIJATC PC 5311017
DMIJATC MW 239.35
DMIJATC FM C17H21N
DMIJATC IC InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
DMIJATC CS C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
DMIJATC IK YXKTVDFXDRQTKV-HNNXBMFYSA-N
DMIJATC IU (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine
DMIJATC CA CAS 156-08-1
DMIJATC CB CHEBI:3044
DMIJATC DE Obesity
DMU4D5Y ID DMU4D5Y
DMU4D5Y DN Benzquinamide
DMU4D5Y HS Approved
DMU4D5Y SN Benzchinamid; Benzchinamide; Benzchinamidum; Benzochinamide; Benzoquinamida; Benzoquinamide; Benzquinamid; Benzquinamida; Benzquinamidum; Emeticon; Promecon; Quantril; Quantryl; P 2647; Benzoquinamida [INN-Spanish]; Benzquinamide (USAN); Benzquinamidum [INN-Latin]; Emete-con; P-2647; Benzquinamide [USAN:INN:BAN]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamideacetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-(9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate
DMU4D5Y TC Antiemetics
DMU4D5Y DT Small molecular drug
DMU4D5Y PC 2342
DMU4D5Y MW 404.5
DMU4D5Y FM C22H32N2O5
DMU4D5Y IC InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3
DMU4D5Y CS CCN(CC)C(=O)C1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C)OC)OC
DMU4D5Y IK JSZILQVIPPROJI-UHFFFAOYSA-N
DMU4D5Y IU [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate
DMU4D5Y CA CAS 63-12-7
DMU4D5Y CB CHEBI:27662
DMU4D5Y DE Nausea
DMQWZ0H ID DMQWZ0H
DMQWZ0H DN Benzthiazide
DMQWZ0H HS Approved
DMQWZ0H SN Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMQWZ0H TC Antihypertensive Agents
DMQWZ0H DT Small molecular drug
DMQWZ0H PC 2343
DMQWZ0H MW 431.9
DMQWZ0H FM C15H14ClN3O4S3
DMQWZ0H IC InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
DMQWZ0H CS C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N
DMQWZ0H IK NDTSRXAMMQDVSW-UHFFFAOYSA-N
DMQWZ0H IU 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMQWZ0H CA CAS 91-33-8
DMQWZ0H CB CHEBI:3047
DMQWZ0H DE High blood pressure
DMGZOVN ID DMGZOVN
DMGZOVN DN Benztropine
DMGZOVN HS Approved
DMGZOVN SN Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI)
DMGZOVN CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMGZOVN TC Antiparkinson Agents
DMGZOVN DT Small molecular drug
DMGZOVN PC 1201549
DMGZOVN MW 307.4
DMGZOVN FM C21H25NO
DMGZOVN IC InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMGZOVN CS CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMGZOVN IK GIJXKZJWITVLHI-YOFSQIOKSA-N
DMGZOVN IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMGZOVN CA CAS 86-13-5
DMGZOVN CB CHEBI:3048
DMGZOVN DE Parkinson disease
DMBVYDI ID DMBVYDI
DMBVYDI DN Benzyl alcohol
DMBVYDI HS Approved
DMBVYDI SN Ulesfia (TN)
DMBVYDI CP Sciele Pharma
DMBVYDI DT Small molecular drug
DMBVYDI PC 244
DMBVYDI MW 108.14
DMBVYDI FM C7H8O
DMBVYDI IC InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMBVYDI CS C1=CC=C(C=C1)CO
DMBVYDI IK WVDDGKGOMKODPV-UHFFFAOYSA-N
DMBVYDI IU phenylmethanol
DMBVYDI CA CAS 100-51-6
DMBVYDI CB CHEBI:17987
DMBVYDI DE Head and body lice
DMDPYI5 ID DMDPYI5
DMDPYI5 DN Benzyl benzoate
DMDPYI5 HS Approved
DMDPYI5 SN BENZYL BENZOATE; 120-51-4; Benylate; Ascabiol; Novoscabin; Benzoic acid, phenylmethyl ester; Benzoic acid benzyl ester; Scobenol; Scabitox; Ascabin; Benzyl phenylformate; Phenylmethyl benzoate; Scabiozon; Scabagen; Peruscabin; Colebenz; Scabanca; Benzylets; Benzoic acid, benzyl ester; Vanzoate; Scabide; Benzyl benzenecarboxylate; benzylbenzoate; Antiscabiosum; Benzylis benzoas; Benzyl alcohol benzoic ester; Peruscabina; Venzonate; Spasmodin; Benzylum benzoicum; Benzylester kyseliny benzoove; Benzoesaeurebenzylester; Caswell No. 082
DMDPYI5 DT Small molecular drug
DMDPYI5 PC 2345
DMDPYI5 MW 212.24
DMDPYI5 FM C14H12O2
DMDPYI5 IC InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2
DMDPYI5 CS C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2
DMDPYI5 IK SESFRYSPDFLNCH-UHFFFAOYSA-N
DMDPYI5 IU benzyl benzoate
DMDPYI5 CA CAS 120-51-4
DMDPYI5 CB CHEBI:41237
DMDPYI5 DE Infestations of lice and scabies
DMQHM2D ID DMQHM2D
DMQHM2D DN Benzylpenicilloyl Polylysine
DMQHM2D HS Approved
DMQHM2D SN Benzylpenicilloyl; Benzylpenicilloyl G; Benzylpenicilloyl G polylysine; Benzylpenicilloyl-polylysine; Penicilloyl-polylysine; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
DMQHM2D TC Analgesics
DMQHM2D DT Small molecular drug
DMQHM2D PC 45266800
DMQHM2D MW 626.8
DMQHM2D FM C28H46N6O8S
DMQHM2D IC InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
DMQHM2D CS CC1([C@@H](N[C@H](S1)C(C(=O)NCCCC[C@H](C(=O)O)N)NC(=O)CC2=CC=CC=C2)C(=O)O)C.C(CCN)C[C@H](C(=O)O)N
DMQHM2D IK IMPVZRLKKKXMKQ-SGDOCVTFSA-N
DMQHM2D IU (2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid;(2R)-2,6-diaminohexanoic acid
DMQHM2D CA CAS 31855-75-1
DMQHM2D CB CHEBI:59297
DMQHM2D DE Bacterial infection
DMXDZAQ ID DMXDZAQ
DMXDZAQ DN Bepotastine
DMXDZAQ HS Approved
DMXDZAQ SN Betotastine; Tau 284; TAU-284DS; Talion (TN); (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CP Tanabe Seiyaku Co
DMXDZAQ TC Antiallergic Agents
DMXDZAQ DT Small molecular drug
DMXDZAQ PC 164522
DMXDZAQ MW 388.9
DMXDZAQ FM C21H25ClN2O3
DMXDZAQ IC InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1
DMXDZAQ CS C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O
DMXDZAQ IK YWGDOWXRIALTES-NRFANRHFSA-N
DMXDZAQ IU 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CA CAS 125602-71-3
DMXDZAQ CB CHEBI:71204
DMXDZAQ DE Allergic rhinitis
DM0RKS4 ID DM0RKS4
DM0RKS4 DN Bepridil
DM0RKS4 HS Approved
DM0RKS4 SN Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline
DM0RKS4 TC Antiarrhythmic Agents
DM0RKS4 DT Small molecular drug
DM0RKS4 PC 2351
DM0RKS4 MW 366.5
DM0RKS4 FM C24H34N2O
DM0RKS4 IC InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
DM0RKS4 CS CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
DM0RKS4 IK UIEATEWHFDRYRU-UHFFFAOYSA-N
DM0RKS4 IU N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline
DM0RKS4 CA CAS 64706-54-3
DM0RKS4 CB CHEBI:3061
DM0RKS4 DE Chronic/stable angina
DMEBY2D ID DMEBY2D
DMEBY2D DN Beriplast-P
DMEBY2D HS Approved
DMEBY2D SN Fibrin sealant, Aventis Behring
DMEBY2D CP Aventis Behring LLC
DMEBY2D DE Wound healing
DMWA2DZ ID DMWA2DZ
DMWA2DZ DN Berotralstat
DMWA2DZ HS Approved
DMWA2DZ SN UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CP BioCryst Pharmaceuticals
DMWA2DZ DT Small molecular drug
DMWA2DZ PC 137528262
DMWA2DZ MW 562.6
DMWA2DZ FM C30H26F4N6O
DMWA2DZ IC InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
DMWA2DZ CS C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
DMWA2DZ IK UXNXMBYCBRBRFD-MUUNZHRXSA-N
DMWA2DZ IU 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CA CAS 1809010-50-1
DMWA2DZ DE Hereditary angioedema
DMPHXMI ID DMPHXMI
DMPHXMI DN Besifloxacin
DMPHXMI HS Approved
DMPHXMI SN Besivance (TN)
DMPHXMI CP Bausch & Lomb
DMPHXMI DT Small molecular drug
DMPHXMI PC 10178705
DMPHXMI MW 393.8
DMPHXMI FM C19H21ClFN3O3
DMPHXMI IC InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1
DMPHXMI CS C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPHXMI IK QFFGVLORLPOAEC-SNVBAGLBSA-N
DMPHXMI IU 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMPHXMI CA CAS 141388-76-3
DMPHXMI CB CHEBI:135622
DMPHXMI DE Ocular inflammation
DM8L9D4 ID DM8L9D4
DM8L9D4 DN Bestatin
DM8L9D4 HS Approved
DM8L9D4 SN Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
DM8L9D4 DT Small molecular drug
DM8L9D4 PC 72172
DM8L9D4 MW 308.37
DM8L9D4 FM C16H24N2O4
DM8L9D4 IC InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
DM8L9D4 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
DM8L9D4 IK VGGGPCQERPFHOB-RDBSUJKOSA-N
DM8L9D4 IU (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
DM8L9D4 CA CAS 58970-76-6
DM8L9D4 DE Acute myeloid leukaemia
DMI6GKT ID DMI6GKT
DMI6GKT DN Beta-acetyldigoxin
DMI6GKT HS Approved
DMI6GKT SN Novodigal (TN)
DMI6GKT DT Small molecular drug
DMI6GKT PC 10350481
DMI6GKT MW 823
DMI6GKT FM C43H66O15
DMI6GKT IC InChI=1S/C43H66O15/c1-20-38(55-23(4)44)30(45)17-36(53-20)57-40-22(3)54-37(18-32(40)47)58-39-21(2)52-35(16-31(39)46)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(48)42(6)27(10-12-43(28,42)50)24-13-34(49)51-19-24/h13,20-22,25-33,35-40,45-48,50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMI6GKT CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)O)O
DMI6GKT IK NREAGDHHMSOWKZ-DXJNJSHLSA-N
DMI6GKT IU [(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate
DMI6GKT CA CAS 5355-48-6
DMI6GKT CB CHEBI:135892
DMI6GKT DE Cardiovascular disease
DM0RXBT ID DM0RXBT
DM0RXBT DN Beta-carotene
DM0RXBT HS Approved
DM0RXBT SN beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]
DM0RXBT DT Small molecular drug
DM0RXBT PC 5280489
DM0RXBT MW 536.9
DM0RXBT FM C40H56
DM0RXBT IC InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+
DM0RXBT CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\\C)\\C)/C)/C
DM0RXBT IK OENHQHLEOONYIE-JLTXGRSLSA-N
DM0RXBT IU 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene
DM0RXBT CA CAS 7235-40-7
DM0RXBT CB CHEBI:17579
DM0RXBT DE Vitamin deficiency
DMGRZW2 ID DMGRZW2
DMGRZW2 DN Betaine
DMGRZW2 HS Approved
DMGRZW2 SN Cystadane
DMGRZW2 CP Rare Disease Therapeutics Inc
DMGRZW2 DT Small molecular drug
DMGRZW2 PC 247
DMGRZW2 MW 117.15
DMGRZW2 FM C5H11NO2
DMGRZW2 IC InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
DMGRZW2 CS C[N+](C)(C)CC(=O)[O-]
DMGRZW2 IK KWIUHFFTVRNATP-UHFFFAOYSA-N
DMGRZW2 IU 2-(trimethylazaniumyl)acetate
DMGRZW2 CA CAS 107-43-7
DMGRZW2 CB CHEBI:17750
DMGRZW2 DE Inborn error of metabolism
DMAHJEF ID DMAHJEF
DMAHJEF DN Betamethasone
DMAHJEF HS Approved
DMAHJEF SN betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
DMAHJEF TC Antiinflammatory Agents
DMAHJEF DT Small molecular drug
DMAHJEF PC 9782
DMAHJEF MW 392.5
DMAHJEF FM C22H29FO5
DMAHJEF IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMAHJEF CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMAHJEF IK UREBDLICKHMUKA-DVTGEIKXSA-N
DMAHJEF IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMAHJEF CA CAS 378-44-9
DMAHJEF CB CHEBI:3077
DMAHJEF DE Inflammation
DMRMS1A ID DMRMS1A
DMRMS1A DN Betamethasone Benzoate
DMRMS1A HS Approved
DMRMS1A SN Uticort
DMRMS1A CP Parke Davis Div Warner Lambert Co
DMRMS1A DT Small molecular drug
DMRMS1A PC 5282492
DMRMS1A MW 496.6
DMRMS1A FM C29H33FO6
DMRMS1A IC InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1
DMRMS1A CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C
DMRMS1A IK SOQJPQZCPBDOMF-YCUXZELOSA-N
DMRMS1A IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate
DMRMS1A CA CAS 22298-29-9
DMRMS1A CB CHEBI:135798
DMRMS1A DE Inflammation
DMMIAXO ID DMMIAXO
DMMIAXO DN Betamethasone valerate
DMMIAXO HS Approved
DMMIAXO SN Beta-val; Betaderm; Betatrex; Dermabet; Valnac
DMMIAXO CP Schering Corp Sub Schering Plough Corp
DMMIAXO DT Small molecular drug
DMMIAXO PC 16533
DMMIAXO MW 476.6
DMMIAXO FM C27H37FO6
DMMIAXO IC InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1
DMMIAXO CS CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO
DMMIAXO IK SNHRLVCMMWUAJD-SUYDQAKGSA-N
DMMIAXO IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DMMIAXO CA CAS 2152-44-5
DMMIAXO CB CHEBI:31277
DMMIAXO DE Dermatological disease
DM6EUL5 ID DM6EUL5
DM6EUL5 DN Betaxolol
DM6EUL5 HS Approved
DM6EUL5 SN Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CP Lorex Pharmaceuticals
DM6EUL5 TC Antihypertensive Agents
DM6EUL5 DT Small molecular drug
DM6EUL5 PC 2369
DM6EUL5 MW 307.4
DM6EUL5 FM C18H29NO3
DM6EUL5 IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
DM6EUL5 CS CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
DM6EUL5 IK NWIUTZDMDHAVTP-UHFFFAOYSA-N
DM6EUL5 IU 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CA CAS 63659-18-7
DM6EUL5 CB CHEBI:3082
DM6EUL5 DE Hypertension
DMUFGAY ID DMUFGAY
DMUFGAY DN Betazole
DMUFGAY HS Approved
DMUFGAY SN Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole
DMUFGAY CP Eli Lilly And Co
DMUFGAY TC Antihistamines
DMUFGAY DT Small molecular drug
DMUFGAY PC 7741
DMUFGAY MW 111.15
DMUFGAY FM C5H9N3
DMUFGAY IC InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)
DMUFGAY CS C1=C(NN=C1)CCN
DMUFGAY IK JXDFEQONERDKSS-UHFFFAOYSA-N
DMUFGAY IU 2-(1H-pyrazol-5-yl)ethanamine
DMUFGAY CA CAS 105-20-4
DMUFGAY CB CHEBI:59170
DMUFGAY DE Gastric secretory disorder
DMCLHO0 ID DMCLHO0
DMCLHO0 DN Bethanechol
DMCLHO0 HS Approved
DMCLHO0 SN Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium
DMCLHO0 CP Merck & Co
DMCLHO0 TC Parasympathomimetics
DMCLHO0 DT Small molecular drug
DMCLHO0 PC 2370
DMCLHO0 MW 161.22
DMCLHO0 FM C7H17N2O2+
DMCLHO0 IC InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
DMCLHO0 CS CC(C[N+](C)(C)C)OC(=O)N
DMCLHO0 IK NZUPCNDJBJXXRF-UHFFFAOYSA-O
DMCLHO0 IU 2-carbamoyloxypropyl(trimethyl)azanium
DMCLHO0 CA CAS 674-38-4
DMCLHO0 CB CHEBI:3084
DMCLHO0 DE Urinary retention
DM2C4RF ID DM2C4RF
DM2C4RF DN Betrixaban
DM2C4RF HS Approved
DM2C4RF SN Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3
DM2C4RF CP Portola Pharmaceuticals
DM2C4RF DT Small molecular drug
DM2C4RF PC 10275777
DM2C4RF MW 451.9
DM2C4RF FM C23H22ClN5O3
DM2C4RF IC InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
DM2C4RF CS CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
DM2C4RF IK XHOLNRLADUSQLD-UHFFFAOYSA-N
DM2C4RF IU N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
DM2C4RF CA CAS 330942-05-7
DM2C4RF CB CHEBI:140421
DM2C4RF DE Venous thromboembolism; Cerebrovascular ischaemia
DMSD1UN ID DMSD1UN
DMSD1UN DN Bevacizumab
DMSD1UN HS Approved
DMSD1UN SN Bevacizumab (ophthalmic slow-release tissue tablet)
DMSD1UN CP University of London
DMSD1UN DT Monoclonal antibody
DMSD1UN SQ Bevacizumab light chain: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >"Bevacizumab heavy chain"EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSD1UN DE Solid tumour/cancer; Colorectal cancer; Lung cancer; Metastatic colorectal cancer; Brain metastases; Ovarian cancer
DMZFICR ID DMZFICR
DMZFICR DN Bevantolol
DMZFICR HS Approved
DMZFICR SN Bevantololum; Bevantolol [INN:BAN]; Bevantololum [INN-Latin]; (+-)-bevantolol; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
DMZFICR TC Antihypertensive Agents
DMZFICR DT Small molecular drug
DMZFICR PC 2372
DMZFICR MW 345.4
DMZFICR FM C20H27NO4
DMZFICR IC InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
DMZFICR CS CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O
DMZFICR IK HXLAFSUPPDYFEO-UHFFFAOYSA-N
DMZFICR IU 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol
DMZFICR CA CAS 59170-23-9
DMZFICR CB CHEBI:238698
DMZFICR DE Hypertension
DMOBIKY ID DMOBIKY
DMOBIKY DN Bexarotene
DMOBIKY HS Approved
DMOBIKY SN Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
DMOBIKY CP Eisai Inc
DMOBIKY TC Anticancer Agents
DMOBIKY DT Small molecular drug
DMOBIKY PC 82146
DMOBIKY MW 348.5
DMOBIKY FM C24H28O2
DMOBIKY IC InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
DMOBIKY CS CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
DMOBIKY IK NAVMQTYZDKMPEU-UHFFFAOYSA-N
DMOBIKY IU 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
DMOBIKY CA CAS 153559-49-0
DMOBIKY CB CHEBI:50859
DMOBIKY DE Cutaneous T-cell lymphoma
DMZDCS0 ID DMZDCS0
DMZDCS0 DN Bezafibrate
DMZDCS0 HS Approved
DMZDCS0 SN Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 TC Antilipemic Agents
DMZDCS0 DT Small molecular drug
DMZDCS0 PC 39042
DMZDCS0 MW 361.8
DMZDCS0 FM C19H20ClNO4
DMZDCS0 IC InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
DMZDCS0 CS CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
DMZDCS0 IK IIBYAHWJQTYFKB-UHFFFAOYSA-N
DMZDCS0 IU 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 CA CAS 41859-67-0
DMZDCS0 CB CHEBI:47612
DMZDCS0 DE Hyperlipidaemia
DMTZC5G ID DMTZC5G
DMTZC5G DN Bezlotoxumab
DMTZC5G HS Approved
DMTZC5G SN CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava
DMTZC5G CP Merck & Co.
DMTZC5G DT Monoclonal antibody
DMTZC5G DE C. difficile infection
DMTKD7Q ID DMTKD7Q
DMTKD7Q DN BIBW 2992
DMTKD7Q HS Approved
DMTKD7Q SN Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens
DMTKD7Q CP Boehringer Ingelheim
DMTKD7Q DT Small molecular drug
DMTKD7Q PC 10184653
DMTKD7Q MW 485.9
DMTKD7Q FM C24H25ClFN5O3
DMTKD7Q IC InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
DMTKD7Q CS CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
DMTKD7Q IK ULXXDDBFHOBEHA-CWDCEQMOSA-N
DMTKD7Q IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
DMTKD7Q CA CAS 850140-72-6
DMTKD7Q CB CHEBI:61390
DMTKD7Q DE Non-small-cell lung cancer
DMZMSPF ID DMZMSPF
DMZMSPF DN Bicalutamide
DMZMSPF HS Approved
DMZMSPF SN Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
DMZMSPF CP AstraZeneca plc
DMZMSPF TC Anticancer Agents
DMZMSPF DT Small molecular drug
DMZMSPF PC 2375
DMZMSPF MW 430.4
DMZMSPF FM C18H14F4N2O4S
DMZMSPF IC InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
DMZMSPF CS CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
DMZMSPF IK LKJPYSCBVHEWIU-UHFFFAOYSA-N
DMZMSPF IU N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
DMZMSPF CA CAS 90357-06-5
DMZMSPF CB CHEBI:91617
DMZMSPF DE Prostate cancer
DMG0H8K ID DMG0H8K
DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K HS Approved
DMG0H8K SN S900007760; Bictegravir mixture with emtricitabine and tenofovir alafenamide
DMG0H8K CP Gilead Sciences
DMG0H8K PC 129626368
DMG0H8K MW 1173.1
DMG0H8K FM C50H57F4N12O13PS
DMG0H8K IC InChI=1S/C21H18F3N3O5.C21H29N6O5P.C8H10FN3O3S/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28;1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30);5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1,5-6,13H,2-3H2,(H2,10,11,14)/t10-,11+,16+;15-,16+,33+;5-,6+/m010/s1
DMG0H8K CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F.C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMG0H8K IK GMIGIKGMWTUBHA-UKQLQXPXSA-N
DMG0H8K IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMG0H8K DE Human immunodeficiency virus infection
DM3KN7V ID DM3KN7V
DM3KN7V DN Bifonazole
DM3KN7V HS Approved
DM3KN7V SN Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CP Bayer Pharmaceuticals Corporation
DM3KN7V TC Antifungal Agents
DM3KN7V DT Small molecular drug
DM3KN7V PC 2378
DM3KN7V MW 310.4
DM3KN7V FM C22H18N2
DM3KN7V IC InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
DM3KN7V CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4
DM3KN7V IK OCAPBUJLXMYKEJ-UHFFFAOYSA-N
DM3KN7V IU 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CA CAS 60628-96-8
DM3KN7V CB CHEBI:78692
DM3KN7V DE Fungal infection
DMX0E5B ID DMX0E5B
DMX0E5B DN Bimatoprost
DMX0E5B HS Approved
DMX0E5B SN Bimatoprost (topical, alopecia)
DMX0E5B CP Allergan Inc
DMX0E5B DT Small molecular drug
DMX0E5B PC 5311027
DMX0E5B MW 415.6
DMX0E5B FM C25H37NO4
DMX0E5B IC InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
DMX0E5B CS CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
DMX0E5B IK AQOKCDNYWBIDND-FTOWTWDKSA-N
DMX0E5B IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
DMX0E5B CA CAS 155206-00-1
DMX0E5B CB CHEBI:51230
DMX0E5B DE Alopecia; Glaucoma/ocular hypertension
DME78OA ID DME78OA
DME78OA DN Biperiden
DME78OA HS Approved
DME78OA SN Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol
DME78OA CP Knoll Pharma
DME78OA TC Antiparkinson Agents
DME78OA DT Small molecular drug
DME78OA PC 2381
DME78OA MW 311.5
DME78OA FM C21H29NO
DME78OA IC InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
DME78OA CS C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
DME78OA IK YSXKPIUOCJLQIE-UHFFFAOYSA-N
DME78OA IU 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
DME78OA CA CAS 514-65-8
DME78OA CB CHEBI:3112
DME78OA DE Parkinson disease
DMTKU46 ID DMTKU46
DMTKU46 DN Bismuth
DMTKU46 HS Approved
DMTKU46 SN Bismut; Bismuto; Wismut; Bismuth standard for AAS; Bismuth standard for ICP; LTBB002773; Bismuth(III) nitrate solution; Bismuth, elemental; Bismuth-209; BISMUTH, 99.95%; BISMUTH, 99.999%; 83Bi
DMTKU46 TC Antidiarrheals
DMTKU46 DT Small molecular drug
DMTKU46 PC 5359367
DMTKU46 MW 208.98
DMTKU46 FM Bi
DMTKU46 IC InChI=1S/Bi
DMTKU46 CS [Bi]
DMTKU46 IK JCXGWMGPZLAOME-UHFFFAOYSA-N
DMTKU46 IU bismuth
DMTKU46 CA CAS 7440-69-9
DMTKU46 CB CHEBI:33301
DMTKU46 DE Diarrhea
DM3UZ95 ID DM3UZ95
DM3UZ95 DN Bisoprolol
DM3UZ95 HS Approved
DM3UZ95 SN Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
DM3UZ95 TC Antihypertensive Agents
DM3UZ95 DT Small molecular drug
DM3UZ95 PC 2405
DM3UZ95 MW 325.4
DM3UZ95 FM C18H31NO4
DM3UZ95 IC InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
DM3UZ95 CS CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O
DM3UZ95 IK VHYCDWMUTMEGQY-UHFFFAOYSA-N
DM3UZ95 IU 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
DM3UZ95 CA CAS 66722-44-9
DM3UZ95 CB CHEBI:3127
DM3UZ95 DE Hypertension
DMK6XAV ID DMK6XAV
DMK6XAV DN Bitolterol
DMK6XAV HS Approved
DMK6XAV SN Tornalate
DMK6XAV CP Sanofi Aventis Us Llc
DMK6XAV DT Small molecular drug
DMK6XAV PC 35330
DMK6XAV MW 461.5
DMK6XAV FM C28H31NO5
DMK6XAV IC InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
DMK6XAV CS CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C
DMK6XAV IK FZGVEKPRDOIXJY-UHFFFAOYSA-N
DMK6XAV IU [4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate
DMK6XAV CA CAS 30392-40-6
DMK6XAV CB CHEBI:3133
DMK6XAV DE Chronic obstructive pulmonary disease; Asthma
DMECRX1 ID DMECRX1
DMECRX1 DN Bivalirudin
DMECRX1 HS Approved
DMECRX1 SN 128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
DMECRX1 TC Antithrombotic Agents
DMECRX1 DT Small molecular drug
DMECRX1 PC 16129704
DMECRX1 MW 2180.3
DMECRX1 FM C98H138N24O33
DMECRX1 IC InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1
DMECRX1 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N
DMECRX1 IK OIRCOABEOLEUMC-GEJPAHFPSA-N
DMECRX1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMECRX1 CA CAS 128270-60-0
DMECRX1 CB CHEBI:59173
DMECRX1 DE Thrombocytopenia
DMR8YD6 ID DMR8YD6
DMR8YD6 DN B-Lactams
DMR8YD6 HS Approved
DMR8YD6 SN Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 DT Small molecular drug
DMR8YD6 PC 5280445
DMR8YD6 MW 286.24
DMR8YD6 FM C15H10O6
DMR8YD6 IC InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMR8YD6 CS C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMR8YD6 IK IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMR8YD6 IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 CA CAS 491-70-3
DMR8YD6 CB CHEBI:15864
DMR8YD6 DE Bacterial infection
DMNER5S ID DMNER5S
DMNER5S DN Bleomycin
DMNER5S HS Approved
DMNER5S SN BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
DMNER5S CP Bristol-Myers Squibb
DMNER5S TC Anticancer Agents
DMNER5S DT Small molecular drug
DMNER5S PC 5360373
DMNER5S MW 1415.6
DMNER5S FM C55H84N17O21S3+
DMNER5S IC InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
DMNER5S CS CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
DMNER5S IK OYVAGSVQBOHSSS-WXFSZRTFSA-O
DMNER5S IU 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
DMNER5S CA CAS 11056-06-7
DMNER5S DE Hodgkin lymphoma
DMGECIJ ID DMGECIJ
DMGECIJ DN Blinatumomab
DMGECIJ HS Approved
DMGECIJ SN AMG 103; Blincyto
DMGECIJ CP Amgen
DMGECIJ DT Monoclonal antibody
DMGECIJ SQ single chain variable fragment fusion protein : DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH
DMGECIJ DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma
DMQTAGO ID DMQTAGO
DMQTAGO DN BMS-201038
DMQTAGO HS Approved
DMQTAGO SN AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01
DMQTAGO CP Bristol-Myers Squibb
DMQTAGO DT Small molecular drug
DMQTAGO PC 9853053
DMQTAGO MW 693.7
DMQTAGO FM C39H37F6N3O2
DMQTAGO IC InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
DMQTAGO CS C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMQTAGO IK MBBCVAKAJPKAKM-UHFFFAOYSA-N
DMQTAGO IU N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMQTAGO CA CAS 182431-12-5
DMQTAGO CB CHEBI:72297
DMQTAGO DE Familial hypercholesterolemia
DMBSHMF ID DMBSHMF
DMBSHMF DN Boceprevir
DMBSHMF HS Approved
DMBSHMF SN Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
DMBSHMF DT Small molecular drug
DMBSHMF PC 10324367
DMBSHMF MW 519.7
DMBSHMF FM C27H45N5O5
DMBSHMF IC InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMBSHMF CS CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMBSHMF IK LHHCSNFAOIFYRV-DOVBMPENSA-N
DMBSHMF IU (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMBSHMF CA CAS 394730-60-0
DMBSHMF CB CHEBI:68621
DMBSHMF DE Hepatitis C virus infection
DM2EXC5 ID DM2EXC5
DM2EXC5 DN BOL-303259-X
DM2EXC5 HS Approved
DM2EXC5 SN Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
DM2EXC5 CP Bausch and Lomb/Valeant Pharmaceuticals
DM2EXC5 DT Small molecular drug
DM2EXC5 PC 11156438
DM2EXC5 MW 507.6
DM2EXC5 FM C27H41NO8
DM2EXC5 IC InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
DM2EXC5 CS C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
DM2EXC5 IK LOVMMUBRQUFEAH-UIEAZXIASA-N
DM2EXC5 IU 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DM2EXC5 CA CAS 860005-21-6
DM2EXC5 DE Open-angle glaucoma; Renal cell carcinoma
DMIFYLX ID DMIFYLX
DMIFYLX DN Bopindolol
DMIFYLX HS Approved
DMIFYLX SN BOPINDOLOL; 62658-63-3; Sandonorm; (+-)-Bopindolol; 1-(tert-Butylamino)-3-((2-methyl-1H-indol-4-yl)oxy)propan-2-yl benzoate; Bopindololum [INN-Latin]; Bopindolol [INN]; UUOJIACWOAYWEZ-UHFFFAOYSA-N; Bopindolol (INN); Wandonorm; 69010-88-4; NCGC00163155-01; Sandonorm (TN); (+-)-4-(2-Benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole; DSSTox_CID_2684; DSSTox_RID_76690; (+-)-1-(tert-Butylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol benzoate (ester); DSSTox_GSID_22684
DMIFYLX DT Small molecular drug
DMIFYLX PC 44112
DMIFYLX MW 380.5
DMIFYLX FM C23H28N2O3
DMIFYLX IC InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
DMIFYLX CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
DMIFYLX IK UUOJIACWOAYWEZ-UHFFFAOYSA-N
DMIFYLX IU [1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate
DMIFYLX CA CAS 62658-63-3
DMIFYLX CB CHEBI:143782
DMIFYLX DE Hypertension
DMNO38U ID DMNO38U
DMNO38U DN Bortezomib
DMNO38U HS Approved
DMNO38U SN 179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
DMNO38U CP Takeda
DMNO38U TC Anticancer Agents
DMNO38U DT Small molecular drug
DMNO38U PC 387447
DMNO38U MW 384.2
DMNO38U FM C19H25BN4O4
DMNO38U IC InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
DMNO38U CS B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
DMNO38U IK GXJABQQUPOEUTA-RDJZCZTQSA-N
DMNO38U IU [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
DMNO38U CA CAS 179324-69-7
DMNO38U CB CHEBI:52717
DMNO38U DE Multiple myeloma; Non-hodgkin lymphoma; Mantle cell lymphoma
DMIOGBU ID DMIOGBU
DMIOGBU DN Bosentan
DMIOGBU HS Approved
DMIOGBU SN Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CP Actelion Pharmaceuticals
DMIOGBU TC Antihypertensive Agents
DMIOGBU DT Small molecular drug
DMIOGBU PC 104865
DMIOGBU MW 551.6
DMIOGBU FM C27H29N5O6S
DMIOGBU IC InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
DMIOGBU CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
DMIOGBU IK GJPICJJJRGTNOD-UHFFFAOYSA-N
DMIOGBU IU 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CA CAS 147536-97-8
DMIOGBU CB CHEBI:51450
DMIOGBU DE Pulmonary arterial hypertension
DMTI8YE ID DMTI8YE
DMTI8YE DN Bosutinib
DMTI8YE HS Approved
DMTI8YE SN SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)
DMTI8YE CP Wyeth Research
DMTI8YE TC Anticancer Agents
DMTI8YE DT Small molecular drug
DMTI8YE PC 5328940
DMTI8YE MW 530.4
DMTI8YE FM C26H29Cl2N5O3
DMTI8YE IC InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
DMTI8YE CS CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
DMTI8YE IK UBPYILGKFZZVDX-UHFFFAOYSA-N
DMTI8YE IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
DMTI8YE CA CAS 380843-75-4
DMTI8YE CB CHEBI:39112
DMTI8YE DE Breast cancer
DMW67MU ID DMW67MU
DMW67MU DN Botulinum Toxin Type A
DMW67MU HS Approved
DMW67MU SN Botox; Botulinum toxin type A (JAN)
DMW67MU SQ Botulinum Toxin Type A Sequence: MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
DMW67MU DE Blepharospasm
DM58QS1 ID DM58QS1
DM58QS1 DN Botulinum Toxin Type B
DM58QS1 HS Approved
DM58QS1 SN BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN)
DM58QS1 CP Allergan Inc
DM58QS1 TC Antidystonic Agents
DM58QS1 SQ Botulinum neurotoxin type B - Clostridium botulinum: MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE
DM58QS1 DE Parkinson disease
DM20LIM ID DM20LIM
DM20LIM DN Bremelanotide
DM20LIM HS Approved
DM20LIM SN Bremelanotide (USAN/INN); PT-141; Rekynda
DM20LIM CP Palatin Technol
DM20LIM DT Small molecular drug
DM20LIM PC 9941379
DM20LIM MW 1025.2
DM20LIM FM C50H68N14O10
DM20LIM IC InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DM20LIM CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
DM20LIM IK FFHBJDQSGDNCIV-MFVUMRCOSA-N
DM20LIM IU (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
DM20LIM CA CAS 189691-06-3
DM20LIM DE Erectile dysfunction; Hypoactive sexual desire dysfunction
DMWLC57 ID DMWLC57
DMWLC57 DN Brentuximab vedotin
DMWLC57 HS Approved
DMWLC57 SN Adcetris (TN)
DMWLC57 CP Millennium Pharmaceuticals; Seattle Genetics
DMWLC57 DT Monoclonal antibody
DMWLC57 DE Hodgkin lymphoma
DM1FX74 ID DM1FX74
DM1FX74 DN Bretylium
DM1FX74 HS Approved
DM1FX74 SN Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
DM1FX74 CP Hospira Inc
DM1FX74 TC Antiarrhythmic Agents
DM1FX74 DT Small molecular drug
DM1FX74 PC 2431
DM1FX74 MW 243.16
DM1FX74 FM C11H17BrN+
DM1FX74 IC InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
DM1FX74 CS CC[N+](C)(C)CC1=CC=CC=C1Br
DM1FX74 IK AAQOQKQBGPPFNS-UHFFFAOYSA-N
DM1FX74 IU (2-bromophenyl)methyl-ethyl-dimethylazanium
DM1FX74 CA CAS 59-41-6
DM1FX74 CB CHEBI:3172
DM1FX74 DE Ventricular fibrillation
DM7W94S ID DM7W94S
DM7W94S DN Brigatinib
DM7W94S HS Approved
DM7W94S SN 1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958
DM7W94S CP Ariad Pharmaceuticals/Takeda
DM7W94S DT Small molecular drug
DM7W94S PC 68165256
DM7W94S MW 584.1
DM7W94S FM C29H39ClN7O2P
DM7W94S IC InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
DM7W94S CS CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
DM7W94S IK AILRADAXUVEEIR-UHFFFAOYSA-N
DM7W94S IU 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine
DM7W94S CA CAS 1197953-54-0
DM7W94S DE Non-small-cell lung cancer; Anaplastic large cell lymphoma
DMBR01X ID DMBR01X
DMBR01X DN Brilinta
DMBR01X HS Approved
DMBR01X SN Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique
DMBR01X CP AstraZeneca
DMBR01X DT Small molecular drug
DMBR01X PC 9871419
DMBR01X MW 522.6
DMBR01X FM C23H28F2N6O4S
DMBR01X IC InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
DMBR01X CS CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
DMBR01X IK OEKWJQXRCDYSHL-FNOIDJSQSA-N
DMBR01X IU (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
DMBR01X CA CAS 274693-27-5
DMBR01X CB CHEBI:68558
DMBR01X DE Myocardial infarction; Arterial thrombosis; Thrombosis
DMQLT4N ID DMQLT4N
DMQLT4N DN Brimonidine
DMQLT4N HS Approved
DMQLT4N SN brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine
DMQLT4N CP PSivida Corp
DMQLT4N DT Small molecular drug
DMQLT4N PC 2435
DMQLT4N MW 292.13
DMQLT4N FM C11H10BrN5
DMQLT4N IC InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
DMQLT4N CS C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
DMQLT4N IK XYLJNLCSTIOKRM-UHFFFAOYSA-N
DMQLT4N IU 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMQLT4N CA CAS 59803-98-4
DMQLT4N CB CHEBI:3175
DMQLT4N DE Ocular hypertension; Glaucoma/ocular hypertension
DMBAPFG ID DMBAPFG
DMBAPFG DN Brinzolamide
DMBAPFG HS Approved
DMBAPFG SN Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
DMBAPFG CP Alcon Laboratories
DMBAPFG TC Antiglaucomic Agents
DMBAPFG DT Small molecular drug
DMBAPFG PC 68844
DMBAPFG MW 383.5
DMBAPFG FM C12H21N3O5S3
DMBAPFG IC InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
DMBAPFG CS CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMBAPFG IK HCRKCZRJWPKOAR-JTQLQIEISA-N
DMBAPFG IU (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMBAPFG CA CAS 138890-62-7
DMBAPFG CB CHEBI:3176
DMBAPFG DE Open-angle glaucoma
DMSEPK8 ID DMSEPK8
DMSEPK8 DN Brivaracetam
DMSEPK8 HS Approved
DMSEPK8 SN Rikelta; UCB-34714; Brivaracetam (USAN/INN)
DMSEPK8 CP UCB
DMSEPK8 DT Small molecular drug
DMSEPK8 PC 9837243
DMSEPK8 MW 212.29
DMSEPK8 FM C11H20N2O2
DMSEPK8 IC InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
DMSEPK8 CS CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
DMSEPK8 IK MSYKRHVOOPPJKU-BDAKNGLRSA-N
DMSEPK8 IU (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
DMSEPK8 CA CAS 357336-20-0
DMSEPK8 CB CHEBI:133013
DMSEPK8 DE Epilepsy; Pain; Complex partial seizure
DMASDQ6 ID DMASDQ6
DMASDQ6 DN Brodalumab
DMASDQ6 HS Approved
DMASDQ6 SN AMG 827
DMASDQ6 CP Valeant Pharmaceuticals
DMASDQ6 DT Monoclonal antibody
DMASDQ6 DE Plaque psoriasis; Asthma; Psoriasis vulgaris
DMW8QNG ID DMW8QNG
DMW8QNG DN Brolucizumab
DMW8QNG HS Approved
DMW8QNG CP Alcon
DMW8QNG DT Antibody
DMW8QNG DE Wet age-related macular degeneration; Diabetic macular edema
DMY9TCW ID DMY9TCW
DMY9TCW DN Bromazepam
DMY9TCW HS Approved
DMY9TCW SN Bromazepamum; Calmepam; Compedium; Compendium; Creosedin; Durazanil; Lectopam; Lekotam; Lexaurin; Lexilium; Lexomil; Lexotan; Lexotanil; Normoc; Somalium; Ultramidol; Bromazepamum [Latin]; LA Xvii; KL 001; Ro 53350; Apo-Bromazepam; Brazepam (TN); Bromaze (TN); Bromazepam(USAN; Bromazepamum [INN-Latin]; Gen-Bromazepam; KL-001; Lectopam (TN); Lexotan (TN); Novo-bromazepam; Nu-Bromazepam; Ro 4-9253; Ro 5-3350; Bromazepam (JP15/USAN/INN); Bromazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CP Hoffmann-La Roche pharmaceutical company
DMY9TCW TC Hypnotics and Sedatives
DMY9TCW DT Small molecular drug
DMY9TCW PC 2441
DMY9TCW MW 316.15
DMY9TCW FM C14H10BrN3O
DMY9TCW IC InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
DMY9TCW CS C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3
DMY9TCW IK VMIYHDSEFNYJSL-UHFFFAOYSA-N
DMY9TCW IU 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CA CAS 1812-30-2
DMY9TCW CB CHEBI:31302
DMY9TCW DE Panic attacks; Anxiety disorder
DMKB79O ID DMKB79O
DMKB79O DN Bromfenac
DMKB79O HS Approved
DMKB79O SN Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O TC Antiinflammatory Agents
DMKB79O DT Small molecular drug
DMKB79O PC 60726
DMKB79O MW 334.16
DMKB79O FM C15H12BrNO3
DMKB79O IC InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
DMKB79O CS C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
DMKB79O IK ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
DMKB79O IU 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O CA CAS 91714-94-2
DMKB79O CB CHEBI:240107
DMKB79O DE Postoperative inflammation; Inflammation
DMVE3TK ID DMVE3TK
DMVE3TK DN Bromocriptine
DMVE3TK HS Approved
DMVE3TK SN Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
DMVE3TK CP Norvatis Phamaceuticals Corporation
DMVE3TK TC Antiparkinson Agents
DMVE3TK DT Small molecular drug
DMVE3TK PC 31101
DMVE3TK MW 654.6
DMVE3TK FM C32H40BrN5O5
DMVE3TK IC InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
DMVE3TK CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
DMVE3TK IK OZVBMTJYIDMWIL-AYFBDAFISA-N
DMVE3TK IU (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMVE3TK CA CAS 25614-03-3
DMVE3TK CB CHEBI:3181
DMVE3TK DE Parkinson disease
DMNDJT5 ID DMNDJT5
DMNDJT5 DN Bromodiphenhydramine
DMNDJT5 HS Approved
DMNDJT5 SN Amodryl; Bromanautine; Bromazin; Bromazina; Bromazine; Bromazinum; Bromdiphenhydramine; Bromdiphenhydraminum; Deserol; Histabromamine; Ambodryl hydrochloride; Bromdiphenhydramine hydrochloride; Bromdiphenylhydramine hydrochloride; Bromodiphenhydramine hydrochloride; Ambrodyl (TN); Bromazina [INN-Spanish]; Bromazine [INN:BAN]; Bromazinum [INN-Latin]; Bromo-Benadryl; Bromo-Benzdryl; Neo-Benadryl; Beta-dimethylaminoethyl p-bromobenzhydryl ether; Beta-(p-Bromobenzhydryloxy)ethyldimethylamine; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine
DMNDJT5 TC Antihistamines
DMNDJT5 DT Small molecular drug
DMNDJT5 PC 2444
DMNDJT5 MW 334.2
DMNDJT5 FM C17H20BrNO
DMNDJT5 IC InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3
DMNDJT5 CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br
DMNDJT5 IK NUNIWXHYABYXKF-UHFFFAOYSA-N
DMNDJT5 IU 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine
DMNDJT5 CA CAS 118-23-0
DMNDJT5 CB CHEBI:59177
DMNDJT5 DE Hay fever
DM24XYQ ID DM24XYQ
DM24XYQ DN Bromperidol
DM24XYQ HS Approved
DM24XYQ SN bromperidol; 10457-90-6; Impromen; Bromoperidol; Tesoprel; Azurene; 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; UNII-LYH6F7I22E; Bromperidolum [INN-Latin]; R 11333; EINECS 233-943-3; 4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; CC 2489; BRN 1552256; LYH6F7I22E; 4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; RKLNONIVDFXQRX-UHFFFAOYSA-N; 4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; NCGC00016692-01; CAS-10457-90-6
DM24XYQ DT Small molecular drug
DM24XYQ PC 2448
DM24XYQ MW 420.3
DM24XYQ FM C21H23BrFNO2
DM24XYQ IC InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM24XYQ CS C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F
DM24XYQ IK RKLNONIVDFXQRX-UHFFFAOYSA-N
DM24XYQ IU 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM24XYQ CA CAS 10457-90-6
DM24XYQ CB CHEBI:31305
DM24XYQ DE Schizophrenia
DMFOVSD ID DMFOVSD
DMFOVSD DN Brompheniramine
DMFOVSD HS Approved
DMFOVSD SN Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
DMFOVSD CP Alpharma Us Pharmaceuticals Division
DMFOVSD TC Antiallergic Agents
DMFOVSD DT Small molecular drug
DMFOVSD PC 6834
DMFOVSD MW 319.24
DMFOVSD FM C16H19BrN2
DMFOVSD IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DMFOVSD CS CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMFOVSD IK ZDIGNSYAACHWNL-UHFFFAOYSA-N
DMFOVSD IU 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMFOVSD CA CAS 86-22-6
DMFOVSD CB CHEBI:3183
DMFOVSD DE Allergic rhinitis
DMXKZT3 ID DMXKZT3
DMXKZT3 DN Buclizine
DMXKZT3 HS Approved
DMXKZT3 SN Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CP McNeil Laboratories
DMXKZT3 TC Antihistamines
DMXKZT3 DT Small molecular drug
DMXKZT3 PC 6729
DMXKZT3 MW 433
DMXKZT3 FM C28H33ClN2
DMXKZT3 IC InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
DMXKZT3 CS CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMXKZT3 IK MOYGZHXDRJNJEP-UHFFFAOYSA-N
DMXKZT3 IU 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CA CAS 82-95-1
DMXKZT3 CB CHEBI:3205
DMXKZT3 DE Nausea
DMJIBAW ID DMJIBAW
DMJIBAW DN Budesonide
DMJIBAW HS Approved
DMJIBAW SN Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
DMJIBAW CP AstraZeneca
DMJIBAW TC Antiinflammatory Agents
DMJIBAW DT Small molecular drug
DMJIBAW PC 5281004
DMJIBAW MW 430.5
DMJIBAW FM C25H34O6
DMJIBAW IC InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
DMJIBAW CS CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
DMJIBAW IK VOVIALXJUBGFJZ-KWVAZRHASA-N
DMJIBAW IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMJIBAW CA CAS 51333-22-3
DMJIBAW CB CHEBI:3207
DMJIBAW DE Asthma
DMODHQI ID DMODHQI
DMODHQI DN Budipine
DMODHQI HS Approved
DMODHQI SN Parkinsan; BY-701
DMODHQI CP ALTANA Pharma AG
DMODHQI DT Small molecular drug
DMODHQI PC 68778
DMODHQI MW 293.4
DMODHQI FM C21H27N
DMODHQI IC InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
DMODHQI CS CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMODHQI IK QIHLUZAFSSMXHQ-UHFFFAOYSA-N
DMODHQI IU 1-tert-butyl-4,4-diphenylpiperidine
DMODHQI CA CAS 57982-78-2
DMODHQI CB CHEBI:135228
DMODHQI DE Migraine
DMG1OPF ID DMG1OPF
DMG1OPF DN Buflomedil
DMG1OPF HS Approved
DMG1OPF SN Loftyl; Buflomedil hydrochloride
DMG1OPF CP Laboratoire L Lafon SA
DMG1OPF DT Small molecular drug
DMG1OPF PC 2467
DMG1OPF MW 307.4
DMG1OPF FM C17H25NO4
DMG1OPF IC InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
DMG1OPF CS COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
DMG1OPF IK OWYLAEYXIQKAOL-UHFFFAOYSA-N
DMG1OPF IU 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one
DMG1OPF CA CAS 55837-25-7
DMG1OPF CB CHEBI:94538
DMG1OPF DE Peripheral vascular disease
DMX82DO ID DMX82DO
DMX82DO DN Buformin
DMX82DO HS Approved
DMX82DO SN Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224
DMX82DO PC 2468
DMX82DO MW 157.22
DMX82DO FM C6H15N5
DMX82DO IC InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
DMX82DO CS CCCCN=C(N)N=C(N)N
DMX82DO IK XSEUMFJMFFMCIU-UHFFFAOYSA-N
DMX82DO IU 2-butyl-1-(diaminomethylidene)guanidine
DMX82DO CA CAS 692-13-7
DMX82DO CB CHEBI:3209
DMX82DO DE Type 2 diabetes
DMJUVE6 ID DMJUVE6
DMJUVE6 DN Bulevirtide
DMJUVE6 HS Approved
DMJUVE6 SN Lipopeptide
DMJUVE6 CP MYR Pharma
DMJUVE6 DT Peptide
DMJUVE6 DE Hepatitis D virus infection
DMRV7H0 ID DMRV7H0
DMRV7H0 DN Bumetanide
DMRV7H0 HS Approved
DMRV7H0 SN Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
DMRV7H0 CP Hoffmann-La Roche pharmaceutical company
DMRV7H0 TC Diuretics
DMRV7H0 DT Small molecular drug
DMRV7H0 PC 2471
DMRV7H0 MW 364.4
DMRV7H0 FM C17H20N2O5S
DMRV7H0 IC InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
DMRV7H0 CS CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
DMRV7H0 IK MAEIEVLCKWDQJH-UHFFFAOYSA-N
DMRV7H0 IU 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
DMRV7H0 CA CAS 28395-03-1
DMRV7H0 CB CHEBI:3213
DMRV7H0 DE Congestive heart failure
DM4I8O7 ID DM4I8O7
DM4I8O7 DN Bunazosin
DM4I8O7 HS Approved
DM4I8O7 SN Andante; E 015; DE-070; Detantol-R; E-1015; E-643
DM4I8O7 CP Eisai Co Ltd
DM4I8O7 DT Small molecular drug
DM4I8O7 PC 2472
DM4I8O7 MW 373.4
DM4I8O7 FM C19H27N5O3
DM4I8O7 IC InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
DM4I8O7 CS CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DM4I8O7 IK RHLJLALHBZGAFM-UHFFFAOYSA-N
DM4I8O7 IU 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
DM4I8O7 CA CAS 80755-51-7
DM4I8O7 CB CHEBI:135576
DM4I8O7 DE Glaucoma/ocular hypertension
DM4PRFC ID DM4PRFC
DM4PRFC DN Bupivacaine
DM4PRFC HS Approved
DM4PRFC SN Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CP AstraZeneca
DM4PRFC TC Anesthetics
DM4PRFC DT Small molecular drug
DM4PRFC PC 2474
DM4PRFC MW 288.4
DM4PRFC FM C18H28N2O
DM4PRFC IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
DM4PRFC CS CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
DM4PRFC IK LEBVLXFERQHONN-UHFFFAOYSA-N
DM4PRFC IU 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CA CAS 38396-39-3
DM4PRFC CB CHEBI:77431
DM4PRFC DE Anaesthesia; Pain
DMPRI8G ID DMPRI8G
DMPRI8G DN Buprenorphine
DMPRI8G HS Approved
DMPRI8G SN Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M
DMPRI8G CP Reckitt; Colman
DMPRI8G TC Analgesics
DMPRI8G DT Small molecular drug
DMPRI8G PC 644073
DMPRI8G MW 467.6
DMPRI8G FM C29H41NO4
DMPRI8G IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
DMPRI8G CS C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMPRI8G IK RMRJXGBAOAMLHD-IHFGGWKQSA-N
DMPRI8G IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMPRI8G CA CAS 52485-79-7
DMPRI8G CB CHEBI:3216
DMPRI8G DE Pain; Migraine; Psychiatric disorder
DMBQEGT ID DMBQEGT
DMBQEGT DN Buprenorphine + naloxone
DMBQEGT HS Approved
DMBQEGT SN Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461
DMBQEGT CP Orexo
DMBQEGT DT Small molecular drug
DMBQEGT PC 6321408
DMBQEGT MW 467.6
DMBQEGT FM C29H41NO4
DMBQEGT IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1
DMBQEGT CS C[C@]([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMBQEGT IK RMRJXGBAOAMLHD-MLLHIGKASA-N
DMBQEGT IU (1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBQEGT CA CAS 52485-79-7
DMBQEGT DE Opioid dependence; Major depressive disorder
DM5PCS7 ID DM5PCS7
DM5PCS7 DN Bupropion
DM5PCS7 HS Approved
DM5PCS7 SN bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone
DM5PCS7 CP GlaxoSmithKline plc
DM5PCS7 DT Small molecular drug
DM5PCS7 PC 444
DM5PCS7 MW 239.74
DM5PCS7 FM C13H18ClNO
DM5PCS7 IC InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5PCS7 CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DM5PCS7 IK SNPPWIUOZRMYNY-UHFFFAOYSA-N
DM5PCS7 IU 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DM5PCS7 CA CAS 34911-55-2
DM5PCS7 CB CHEBI:3219
DM5PCS7 DE Smoking dependence
DMKUOQV ID DMKUOQV
DMKUOQV DN Burosumab
DMKUOQV HS Approved
DMKUOQV SN Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29
DMKUOQV CP Ultragenyx Pharmaceutical/Kyowa Hakko Kirin
DMKUOQV DT Antibody
DMKUOQV DE X-linked hypophosphataemia
DMBS632 ID DMBS632
DMBS632 DN Buspirone
DMBS632 HS Approved
DMBS632 SN Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CP Bristol-Myers Squibb
DMBS632 TC Antianxiety Agents
DMBS632 DT Small molecular drug
DMBS632 PC 2477
DMBS632 MW 385.5
DMBS632 FM C21H31N5O2
DMBS632 IC InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
DMBS632 CS C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
DMBS632 IK QWCRAEMEVRGPNT-UHFFFAOYSA-N
DMBS632 IU 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CA CAS 36505-84-7
DMBS632 CB CHEBI:3223
DMBS632 DE Anxiety disorder
DMXYJ9C ID DMXYJ9C
DMXYJ9C DN Busulfan
DMXYJ9C HS Approved
DMXYJ9C SN Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CP GlaxoSmithKline
DMXYJ9C TC Anticancer Agents
DMXYJ9C DT Small molecular drug
DMXYJ9C PC 2478
DMXYJ9C MW 246.3
DMXYJ9C FM C6H14O6S2
DMXYJ9C IC InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
DMXYJ9C CS CS(=O)(=O)OCCCCOS(=O)(=O)C
DMXYJ9C IK COVZYZSDYWQREU-UHFFFAOYSA-N
DMXYJ9C IU 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CA CAS 55-98-1
DMXYJ9C CB CHEBI:28901
DMXYJ9C DE Myeloproliferative syndrome
DMC5AST ID DMC5AST
DMC5AST DN Butabarbital
DMC5AST HS Approved
DMC5AST SN Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
DMC5AST TC Antianxiety Agents
DMC5AST DT Small molecular drug
DMC5AST PC 2479
DMC5AST MW 212.25
DMC5AST FM C10H16N2O3
DMC5AST IC InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
DMC5AST CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMC5AST IK ZRIHAIZYIMGOAB-UHFFFAOYSA-N
DMC5AST IU 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione
DMC5AST CA CAS 125-40-6
DMC5AST CB CHEBI:3228
DMC5AST DE Insomnia
DM584TM ID DM584TM
DM584TM DN Butacaine
DM584TM HS Approved
DM584TM SN Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1)
DM584TM DT Small molecular drug
DM584TM PC 2480
DM584TM MW 306.4
DM584TM FM C18H30N2O2
DM584TM IC InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
DM584TM CS CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N
DM584TM IK HQFWVSGBVLEQGA-UHFFFAOYSA-N
DM584TM IU 3-(dibutylamino)propyl 4-aminobenzoate
DM584TM CA CAS 149-16-6
DM584TM CB CHEBI:94820
DM584TM DE Pain
DM9J04X ID DM9J04X
DM9J04X DN Butalbital
DM9J04X HS Approved
DM9J04X SN Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
DM9J04X TC Analgesics
DM9J04X DT Small molecular drug
DM9J04X PC 2481
DM9J04X MW 224.26
DM9J04X FM C11H16N2O3
DM9J04X IC InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM9J04X CS CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
DM9J04X IK UZVHFVZFNXBMQJ-UHFFFAOYSA-N
DM9J04X IU 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM9J04X CA CAS 77-26-9
DM9J04X CB CHEBI:102524
DM9J04X DE Anxiety disorder; Headache
DMOJ4ZI ID DMOJ4ZI
DMOJ4ZI DN Butenafine
DMOJ4ZI HS Approved
DMOJ4ZI SN Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
DMOJ4ZI CP Schering-Plough
DMOJ4ZI TC Antifungal Agents
DMOJ4ZI DT Small molecular drug
DMOJ4ZI PC 2484
DMOJ4ZI MW 317.5
DMOJ4ZI FM C23H27N
DMOJ4ZI IC InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
DMOJ4ZI CS CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
DMOJ4ZI IK ABJKWBDEJIDSJZ-UHFFFAOYSA-N
DMOJ4ZI IU 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
DMOJ4ZI CA CAS 101828-21-1
DMOJ4ZI CB CHEBI:3238
DMOJ4ZI DE Dermatologic infection
DM7JHX0 ID DM7JHX0
DM7JHX0 DN Butethal
DM7JHX0 HS Approved
DM7JHX0 SN Aethylbutylbarbitursaeure; Budorm; Butabarbitol; Butobarbital; Butobarbitalum; Butobarbitone; Butobarbitural; Etoval; Hyperbutal; Longanoct; Meonal; Monodorm; Neonal; Sonerile; Soneryl; Butobarbital [BAN]; Butobarbital (BAN); Neonal (TN); Butyl,5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-(9CI); 5-BUTYL-5-ETHYLBARBITURIC ACID; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-butylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 TC Hypnotics and Sedatives
DM7JHX0 DT Small molecular drug
DM7JHX0 PC 6473
DM7JHX0 MW 212.25
DM7JHX0 FM C10H16N2O3
DM7JHX0 IC InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)
DM7JHX0 CS CCCCC1(C(=O)NC(=O)NC1=O)CC
DM7JHX0 IK STDBAQMTJLUMFW-UHFFFAOYSA-N
DM7JHX0 IU 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 CA CAS 77-28-1
DM7JHX0 CB CHEBI:134884
DM7JHX0 DE Insomnia
DM8SY60 ID DM8SY60
DM8SY60 DN Butoconazole
DM8SY60 HS Approved
DM8SY60 SN Butaconazole; Butoconazol; Butoconazolum; Femstat; Gynofort; Duplicate RN for parent cpd; RS 35887; Butoconazol [INN-Spanish]; Butoconazole (INN); Butoconazole [INN:BAN]; Butoconazolum [INN-Latin]; Gynofort (TN); RS 35887-10-3; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; (+/-)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; (-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; 1H-Imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate
DM8SY60 CP Roche Palo Alto Llc
DM8SY60 TC Antifungal Agents
DM8SY60 DT Small molecular drug
DM8SY60 PC 47472
DM8SY60 MW 411.8
DM8SY60 FM C19H17Cl3N2S
DM8SY60 IC InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2
DM8SY60 CS C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl
DM8SY60 IK SWLMUYACZKCSHZ-UHFFFAOYSA-N
DM8SY60 IU 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole
DM8SY60 CA CAS 64872-76-0
DM8SY60 CB CHEBI:3240
DM8SY60 DE Candidiasis
DM5KYPJ ID DM5KYPJ
DM5KYPJ DN Butorphanol
DM5KYPJ HS Approved
DM5KYPJ SN Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
DM5KYPJ CP Apotex Inc
DM5KYPJ TC Analgesics
DM5KYPJ DT Small molecular drug
DM5KYPJ PC 5361092
DM5KYPJ MW 327.5
DM5KYPJ FM C21H29NO2
DM5KYPJ IC InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
DM5KYPJ CS C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
DM5KYPJ IK IFKLAQQSCNILHL-QHAWAJNXSA-N
DM5KYPJ IU (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DM5KYPJ CA CAS 42408-82-2
DM5KYPJ CB CHEBI:3242
DM5KYPJ DE Pain
DMZKXB7 ID DMZKXB7
DMZKXB7 DN Butylscopolamine
DMZKXB7 HS Approved
DMZKXB7 SN AC1LCV8Y
DMZKXB7 DT Small molecular drug
DMZKXB7 PC 160883
DMZKXB7 MW 360.5
DMZKXB7 FM C21H30NO4+
DMZKXB7 IC InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1
DMZKXB7 CS CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DMZKXB7 IK YBCNXCRZPWQOBR-MWGADRMYSA-N
DMZKXB7 IU [(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMZKXB7 CA CAS 7182-53-8
DMZKXB7 CB CHEBI:145701
DMZKXB7 DE Dysmenorrhea
DMPAZHC ID DMPAZHC
DMPAZHC DN Cabazitaxel
DMPAZHC HS Approved
DMPAZHC SN Jevtana; Taxoid XRP6258; Jevtana (TN)
DMPAZHC CP Sanofi-Aventis
DMPAZHC DT Small molecular drug
DMPAZHC PC 9854073
DMPAZHC MW 835.9
DMPAZHC FM C45H57NO14
DMPAZHC IC InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
DMPAZHC CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
DMPAZHC IK BMQGVNUXMIRLCK-OAGWZNDDSA-N
DMPAZHC IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMPAZHC CA CAS 183133-96-2
DMPAZHC CB CHEBI:63584
DMPAZHC DE Breast cancer; Solid tumour/cancer
DMQ4HIN ID DMQ4HIN
DMQ4HIN DN Cabergoline
DMQ4HIN HS Approved
DMQ4HIN SN Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
DMQ4HIN CP Pfizer Pharmaceuticals
DMQ4HIN TC Anticancer Agents
DMQ4HIN DT Small molecular drug
DMQ4HIN PC 54746
DMQ4HIN MW 451.6
DMQ4HIN FM C26H37N5O2
DMQ4HIN IC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
DMQ4HIN CS CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
DMQ4HIN IK KORNTPPJEAJQIU-KJXAQDMKSA-N
DMQ4HIN IU (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMQ4HIN CA CAS 81409-90-7
DMQ4HIN CB CHEBI:3286
DMQ4HIN DE Hyperprolactinaemia
DMIYDT4 ID DMIYDT4
DMIYDT4 DN Cabozantinib
DMIYDT4 HS Approved
DMIYDT4 SN Cabometyx; Cometriq
DMIYDT4 CP Exelixis
DMIYDT4 DT Small molecular drug
DMIYDT4 PC 25102847
DMIYDT4 MW 501.5
DMIYDT4 FM C28H24FN3O5
DMIYDT4 IC InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
DMIYDT4 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DMIYDT4 IK ONIQOQHATWINJY-UHFFFAOYSA-N
DMIYDT4 IU 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMIYDT4 CA CAS 849217-68-1
DMIYDT4 CB CHEBI:72317
DMIYDT4 DE Thyroid cancer; Ovarian cancer
DMKBJWP ID DMKBJWP
DMKBJWP DN Caffeine
DMKBJWP HS Approved
DMKBJWP SN CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline
DMKBJWP CP Ben Venue Laboratories
DMKBJWP TC Antihypertensive Agents
DMKBJWP DT Small molecular drug
DMKBJWP PC 2519
DMKBJWP MW 194.19
DMKBJWP FM C8H10N4O2
DMKBJWP IC InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMKBJWP CS CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMKBJWP IK RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMKBJWP IU 1,3,7-trimethylpurine-2,6-dione
DMKBJWP CA CAS 58-08-2
DMKBJWP CB CHEBI:27732
DMKBJWP DE Orthostatic hypotension
DMQZBXI ID DMQZBXI
DMQZBXI DN Calaspargase pegol
DMQZBXI HS Approved
DMQZBXI SN UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
DMQZBXI CP Servier
DMQZBXI DT Antibody
DMQZBXI DE Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia
DMN4CV5 ID DMN4CV5
DMN4CV5 DN Calcidiol
DMN4CV5 HS Approved
DMN4CV5 SN Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
DMN4CV5 CP United Research Laboratories
DMN4CV5 TC Vitamins
DMN4CV5 DT Small molecular drug
DMN4CV5 PC 5283731
DMN4CV5 MW 400.6
DMN4CV5 FM C27H44O2
DMN4CV5 IC InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
DMN4CV5 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMN4CV5 IK JWUBBDSIWDLEOM-DTOXIADCSA-N
DMN4CV5 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMN4CV5 CA CAS 19356-17-3
DMN4CV5 CB CHEBI:17933
DMN4CV5 DE Vitamin D deficiency
DM03CP7 ID DM03CP7
DM03CP7 DN Calcipotriol
DM03CP7 HS Approved
DM03CP7 SN Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
DM03CP7 CP LEO Pharma Inc
DM03CP7 TC Antipsoriatic Agents
DM03CP7 DT Small molecular drug
DM03CP7 PC 5288783
DM03CP7 MW 412.6
DM03CP7 FM C27H40O3
DM03CP7 IC InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
DM03CP7 CS C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM03CP7 IK LWQQLNNNIPYSNX-UROSTWAQSA-N
DM03CP7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM03CP7 CA CAS 112965-21-6
DM03CP7 CB CHEBI:50749
DM03CP7 DE Psoriasis vulgaris
DM0N9WA ID DM0N9WA
DM0N9WA DN Calcitonin Human
DM0N9WA HS Approved
DM0N9WA CP Novartis Pharmaceuticals Corp
DM0N9WA TC Anticancer Agents
DM0N9WA PC 45055432
DM0N9WA MW 3417.9
DM0N9WA FM C151H226N40O45S3
DM0N9WA IC InChI=1S/C151H226N40O45S3/c1-17-75(8)118(144(229)163-67-114(205)183-117(74(6)7)143(228)162-64-112(203)165-77(10)150(235)190-50-29-38-106(190)124(158)209)185-125(210)76(9)166-145(230)120(79(12)194)186-131(216)92(45-47-109(155)200)170-142(227)107-39-30-51-191(107)151(236)103(58-85-35-25-20-26-36-85)180-148(233)122(81(14)196)188-139(224)99(59-87-63-159-71-164-87)176-133(218)96(55-83-31-21-18-22-32-83)174-128(213)90(37-27-28-49-152)168-136(221)101(61-111(157)202)177-134(219)97(56-84-33-23-19-24-34-84)175-137(222)102(62-116(207)208)178-129(214)91(44-46-108(154)199)171-147(232)121(80(13)195)187-138(223)98(57-86-40-42-88(198)43-41-86)179-146(231)119(78(11)193)184-115(206)66-161-127(212)94(53-72(2)3)172-130(215)93(48-52-237-16)169-141(226)105-70-239-238-69-89(153)126(211)160-65-113(204)167-100(60-110(156)201)135(220)173-95(54-73(4)5)132(217)181-104(68-192)140(225)189-123(82(15)197)149(234)182-105/h18-26,31-36,40-43,63,71-82,89-107,117-123,192-198H,17,27-30,37-39,44-62,64-70,152-153H2,1-16H3,(H2,154,199)(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,209)(H,159,164)(H,160,211)(H,161,212)(H,162,228)(H,163,229)(H,165,203)(H,166,230)(H,167,204)(H,168,221)(H,169,226)(H,170,227)(H,171,232)(H,172,215)(H,173,220)(H,174,213)(H,175,222)(H,176,218)(H,177,219)(H,178,214)(H,179,231)(H,180,233)(H,181,217)(H,182,234)(H,183,205)(H,184,206)(H,185,210)(H,186,216)(H,187,223)(H,188,224)(H,189,225)(H,207,208)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-,122-,123-/m0/s1
DM0N9WA CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N
DM0N9WA IK LDVRMNJZLWXJPL-JKQNMTHDSA-N
DM0N9WA IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM0N9WA CB CHEBI:135973
DM0N9WA DE Postmenopausal osteoporosis; Pain; Paget's disease
DM8ZVJ7 ID DM8ZVJ7
DM8ZVJ7 DN Calcitriol
DM8ZVJ7 HS Approved
DM8ZVJ7 SN calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
DM8ZVJ7 CP Cytotech Labs LLC
DM8ZVJ7 DT Small molecular drug
DM8ZVJ7 PC 5280453
DM8ZVJ7 MW 416.6
DM8ZVJ7 FM C27H44O3
DM8ZVJ7 IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
DM8ZVJ7 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM8ZVJ7 IK GMRQFYUYWCNGIN-NKMMMXOESA-N
DM8ZVJ7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM8ZVJ7 CA CAS 32222-06-3
DM8ZVJ7 CB CHEBI:17823
DM8ZVJ7 DE Congenital alopecia
DM3W15N ID DM3W15N
DM3W15N DN Calcium carbimide
DM3W15N HS Approved
DM3W15N SN Nitrolime; Alzodef; Aero cyanamid granular; USAF CY-2; Aero cyanamid special grade; Nitrolim; Cyanamid; Calcium cyanamid; Lime Nitroget; Cyanamid granular; NCI-C02937; CY-L 500; Cyanamid special grade; UN 1403, Nitrolime; WLN: CA NCN; NSC7078; NSC-7078
DM3W15N DT Small molecular drug
DM3W15N PC 56955933
DM3W15N MW 80.1
DM3W15N FM CCaN2
DM3W15N IC InChI=1S/CN2.Ca/c2-1-3;/q-2;+2
DM3W15N CS C(=[N-])=[N-].[Ca+2]
DM3W15N IK MYFXBBAEXORJNB-UHFFFAOYSA-N
DM3W15N IU calcium;azanidylidenemethylideneazanide
DM3W15N CA CAS 156-62-7
DM3W15N CB CHEBI:64301
DM3W15N DE Alcohol dependence
DMJ3CFY ID DMJ3CFY
DMJ3CFY DN Calcium phosphate dihydrate
DMJ3CFY HS Approved
DMJ3CFY SN Calcium phosphate dihydrate
DMJ3CFY DT Small molecular drug
DMJ3CFY PC 22340838
DMJ3CFY MW 346.204
DMJ3CFY FM Ca3H4O10P2
DMJ3CFY IC InChI=1S/3Ca.2H3O4P.2H2O/c;;;2*1-5(2,3)4;;/h;;;2*(H3,1,2,3,4);2*1H2/q3*+2;;;;/p-6
DMJ3CFY CS O.O.[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMJ3CFY IK WKMXOPXIVBEXRR-UHFFFAOYSA-H
DMJ3CFY IU tricalcium;diphosphate;dihydrate
DMJ3CFY DE Dental Caries
DMWIO46 ID DMWIO46
DMWIO46 DN Camphor
DMWIO46 HS Approved
DMWIO46 SN camphor; 76-22-2; 2-Camphanone; 2-Bornanone; DL-Camphor; (+)-Camphor; l-(-)-Camphor; (+/-)-Camphor; Root bark oil; 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one; Bornan-2-one; Alphanon; Kampfer; Gum camphor; Spirit of camphor; Formosa camphor; Laurel camphor; 2-Camphonone; Matricaria camphor; Camphor, synthetic; Bornane, 2-oxo-; 1,7,7-Trimethylnorcamphor; Root bark spirit; 2-Keto-1,7,7-trimethylnorcamphane; DL-Bornan-2-one; D-(+)-Camphor; Norcamphor, 1,7,7-trimethyl-; 21368-68-3; Camphor, (1R,4R)-(+)-; Bicyclo[2.2.1]heptan-2-one, 1,7,7-tri
DMWIO46 DT Small molecular drug
DMWIO46 PC 2537
DMWIO46 MW 152.23
DMWIO46 FM C10H16O
DMWIO46 IC InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3
DMWIO46 CS CC1(C2CCC1(C(=O)C2)C)C
DMWIO46 IK DSSYKIVIOFKYAU-UHFFFAOYSA-N
DMWIO46 IU 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
DMWIO46 CA CAS 76-22-2
DMWIO46 CB CHEBI:36773
DMWIO46 DE Acute or chronic pain
DMFRM1I ID DMFRM1I
DMFRM1I DN Canagliflozin
DMFRM1I HS Approved
DMFRM1I SN 842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0
DMFRM1I CP Johnson & Johnson
DMFRM1I DT Small molecular drug
DMFRM1I PC 24812758
DMFRM1I MW 444.5
DMFRM1I FM C24H25FO5S
DMFRM1I IC InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
DMFRM1I CS CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
DMFRM1I IK XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DMFRM1I IU (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMFRM1I CA CAS 842133-18-0
DMFRM1I CB CHEBI:73274
DMFRM1I DE Type-2 diabetes; Diabetic nephropathy; Type-1 diabetes
DM8HLO5 ID DM8HLO5
DM8HLO5 DN Canakinumab
DM8HLO5 HS Approved
DM8HLO5 SN Ilaris (TN)
DM8HLO5 CP Novartis
DM8HLO5 DT Antibody
DM8HLO5 SQ 8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|: QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HLO5 DE Vasculitis; Urticaria; Rheumatoid arthritis; Cryopyrin-associated periodic syndromes
DMRK8OT ID DMRK8OT
DMRK8OT DN Candesartan
DMRK8OT HS Approved
DMRK8OT SN candesartan; 139481-59-7; Blopress; Ratacand; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; UNII-S8Q36MD2XX; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEMBL1016; S8Q36MD2XX; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; CHEBI:3347; C24H20N6O3; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; NCGC00167474-01; AK-57139; Blopress; Candesartan [BAN]; CV11974; Amias (TN); Atacand (TN); Blopress (TN); Candesartan [USAN:INN]; KS-5003; Ratacand (TN); Candesartan (USAN/INN); Atacand, Blopress, Amias, Ratacand,Candesartan; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; [3H]candesartan
DMRK8OT CP AstraZeneca
DMRK8OT TC Antihypertensive Agents
DMRK8OT DT Small molecular drug
DMRK8OT PC 2541
DMRK8OT MW 440.5
DMRK8OT FM C24H20N6O3
DMRK8OT IC InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMRK8OT CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMRK8OT IK HTQMVQVXFRQIKW-UHFFFAOYSA-N
DMRK8OT IU 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMRK8OT CA CAS 139481-59-7
DMRK8OT CB CHEBI:3347
DMRK8OT DE Hypertension
DMNZSC1 ID DMNZSC1
DMNZSC1 DN Candicidin
DMNZSC1 HS Approved
DMNZSC1 SN (23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 TC Antibiotics
DMNZSC1 DT Small molecular drug
DMNZSC1 PC 10079874
DMNZSC1 MW 1109.3
DMNZSC1 FM C59H84N2O18
DMNZSC1 IC InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1
DMNZSC1 CS C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O
DMNZSC1 IK OPGSFDUODIJJGF-JBUZINEHSA-N
DMNZSC1 IU (23E,25E,27E,29E,31E,33E,35E)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-38-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 CA CAS 1403-17-4
DMNZSC1 CB CHEBI:3349
DMNZSC1 DE Bacterial infection
DM8JRH0 ID DM8JRH0
DM8JRH0 DN Cangrelor
DM8JRH0 HS Approved
DM8JRH0 SN Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
DM8JRH0 CP The Medicines Company
DM8JRH0 DT Small molecular drug
DM8JRH0 PC 9854012
DM8JRH0 MW 776.4
DM8JRH0 FM C17H25Cl2F3N5O12P3S2
DM8JRH0 IC InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
DM8JRH0 CS CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
DM8JRH0 IK PAEBIVWUMLRPSK-IDTAVKCVSA-N
DM8JRH0 IU [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
DM8JRH0 CA CAS 163706-06-7
DM8JRH0 CB CHEBI:90841
DM8JRH0 DE Thrombosis
DM0659E ID DM0659E
DM0659E DN Cannabidiol
DM0659E HS Approved
DM0659E SN cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E CP GW Pharmaceuticals
DM0659E DT Small molecular drug
DM0659E PC 644019
DM0659E MW 314.5
DM0659E FM C21H30O2
DM0659E IC InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
DM0659E CS CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
DM0659E IK QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E IU 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DM0659E CA CAS 13956-29-1
DM0659E CB CHEBI:69478
DM0659E DE LennoxGastaut syndrome; Dravet syndrome; Epilepsy; Infantile spasm
DMBP5N3 ID DMBP5N3
DMBP5N3 DN Cantharidin
DMBP5N3 HS Approved
DMBP5N3 SN DSSTox_CID_21752; DSSTox_RID_79835; DSSTox_GSID_41752; CAS-56-25-7; NCGC00016247-01; Spectrum_001114; SpecPlus_000537; Spectrum4_000920; Spectrum2_000630; Prestwick0_000885; Spectrum3_000621; Prestwick1_000885; Spectrum5_001618; Prestwick2_000885; KBioSS_001594; KBioGR_001420; BSPBio_002182; MLS002153505; SCHEMBL152261; DivK1c_006633; SPBio_002889; SPBio_000600; CHEMBL299846; DTXSID7041752; KBio2_006730; KBio3_001682; KBio2_004162; KBio2_001594; KBio1_001577; MolPort-003-665-556; HMS1570B12; Tox21_110326; CCG-39927; Tox21_110326_1
DMBP5N3 DT Small molecular drug
DMBP5N3 PC 5944
DMBP5N3 MW 196.2
DMBP5N3 FM C10H12O4
DMBP5N3 IC InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-
DMBP5N3 CS C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
DMBP5N3 IK DHZBEENLJMYSHQ-XCVPVQRUSA-N
DMBP5N3 IU (1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DMBP5N3 CA CAS 56-25-7
DMBP5N3 CB CHEBI:64213
DMBP5N3 DE Molluscum contagiosum infection
DMTS85L ID DMTS85L
DMTS85L DN Capecitabine
DMTS85L HS Approved
DMTS85L SN Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)
DMTS85L CP Roche
DMTS85L TC Anticancer Agents
DMTS85L DT Small molecular drug
DMTS85L PC 60953
DMTS85L MW 359.35
DMTS85L FM C15H22FN3O6
DMTS85L IC InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
DMTS85L CS CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O
DMTS85L IK GAGWJHPBXLXJQN-UORFTKCHSA-N
DMTS85L IU pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
DMTS85L CA CAS 154361-50-9
DMTS85L CB CHEBI:31348
DMTS85L DE Colorectal cancer; Breast cancer
DMPUKA7 ID DMPUKA7
DMPUKA7 DN Caplacizumab
DMPUKA7 HS Approved
DMPUKA7 DT Antibody
DMPUKA7 DE Thrombotic thrombocytopenic purpura
DMYCXKL ID DMYCXKL
DMYCXKL DN Capmatinib
DMYCXKL HS Approved
DMYCXKL SN 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O
DMYCXKL CP Incyte
DMYCXKL DT Small molecular drug
DMYCXKL PC 25145656
DMYCXKL MW 412.4
DMYCXKL FM C23H17FN6O
DMYCXKL IC InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
DMYCXKL CS CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
DMYCXKL IK LIOLIMKSCNQPLV-UHFFFAOYSA-N
DMYCXKL IU 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
DMYCXKL CA CAS 1029712-80-8
DMYCXKL DE Hepatocellular carcinoma; Recurrent glioblastoma; Non-small-cell lung cancer
DMNZBRY ID DMNZBRY
DMNZBRY DN Capreomycin
DMNZBRY HS Approved
DMNZBRY SN Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY TC Antibiotics
DMNZBRY DT Small molecular drug
DMNZBRY PC 3000502
DMNZBRY MW 1321.4
DMNZBRY FM C50H88N28O15
DMNZBRY IC InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1
DMNZBRY CS C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N
DMNZBRY IK VCOPTHOUUNAYKQ-WBTCAYNUSA-N
DMNZBRY IU (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY CA CAS 11003-38-6
DMNZBRY DE Bacterial infection; Mycobacterium infection
DM346QI ID DM346QI
DM346QI DN Capreomycin Sulfate
DM346QI HS Approved
DM346QI SN Capastat Sulfate
DM346QI CP Akorn Inc
DM346QI DE Tuberculosis
DMHERIJ ID DMHERIJ
DMHERIJ DN Capromab
DMHERIJ HS Approved
DMHERIJ SN Prostascint (TN)
DMHERIJ TC Imaging Agents
DMHERIJ DT Antibody
DMHERIJ DE Prostate cancer
DMGMF6V ID DMGMF6V
DMGMF6V DN Capsaicin
DMGMF6V HS Approved
DMGMF6V SN Capsaicin (transdermal patch formulation, neuropathic pain)
DMGMF6V CP Samyang Corp
DMGMF6V DT Small molecular drug
DMGMF6V PC 1548943
DMGMF6V MW 305.4
DMGMF6V FM C18H27NO3
DMGMF6V IC InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
DMGMF6V CS CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMGMF6V IK YKPUWZUDDOIDPM-SOFGYWHQSA-N
DMGMF6V IU (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
DMGMF6V CA CAS 404-86-4
DMGMF6V CB CHEBI:3374
DMGMF6V DE Neuropathic pain
DM458UM ID DM458UM
DM458UM DN Captopril
DM458UM HS Approved
DM458UM SN Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline
DM458UM CP Bristol-Myers Squibb
DM458UM TC Antihypertensive Agents
DM458UM DT Small molecular drug
DM458UM PC 44093
DM458UM MW 217.29
DM458UM FM C9H15NO3S
DM458UM IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DM458UM CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DM458UM IK FAKRSMQSSFJEIM-RQJHMYQMSA-N
DM458UM IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DM458UM CA CAS 62571-86-2
DM458UM CB CHEBI:3380
DM458UM DE Hypertension
DMX9K8F ID DMX9K8F
DMX9K8F DN Carbachol
DMX9K8F HS Approved
DMX9K8F SN Carbach; Carbacholin; Carbacholine; Carbacholinum; Carbacholum; Carbacol; Carbacolina; Carbacolo; Carbamiotin; Carbamoylcholine; Carbastat; Carbochol; Carbocholin; Carbocholine; Carbyl; Carcholin; Coletyl; Doryl; Jestryl; Karbachol; Lentin; Lentine; Miostat; Moryl; Rilentol; Vasoperif; CARBACHOL CHLORIDE; Carbachol hydrochloride; Carbacholine chloride; Carbacholini chloridum; Carbacholinium chloratum; Carbacholum chloratum; Carbacolo [DCIT]; Carbaminocholine chloride; Carbaminoylcholine chloride; Carbamoylcholine chloride; Carbamylcholine chloride; Choline carbamate chloride; Choline chloride carbamate; Choline chlorine carbamate; Isopto Carbachol; Karbachol [Czech]; Karbamoylcholin chlorid; Karbamoylcholin chlorid [Czech]; Lentine [French]; Mistura C; C 4382; TL 457; C-1770; Carbacholum [INN-Latin]; Carbacol [INN-Spanish]; Carbamic acid, ester with choline chloride; Carbamoylcholine-hydrochloride; Carbastat (TN); Carboptic (TN); Choline chloride, carbamate; Doryl (VAN); Doryl (pharmaceutical); Gamma-Carbamoyl choline chloride; Isopto Carbachol (TN); Miostat (TN); Carbachol [INN:BAN:JAN]; Choline, chloride carbamate(ester); Choline, chloride, carbamate; P. V. Carbachol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); (2-Carbamoyloxyethyl)trimethylammonium chloride; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; (2-Hydroxyethyl)trimethylammonium chloride carbamate; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride
DMX9K8F CP Norvatis Phamaceuticals Corporation
DMX9K8F TC Cardiotonic Agents
DMX9K8F DT Small molecular drug
DMX9K8F PC 5831
DMX9K8F MW 182.65
DMX9K8F FM C6H15ClN2O2
DMX9K8F IC InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
DMX9K8F CS C[N+](C)(C)CCOC(=O)N.[Cl-]
DMX9K8F IK AIXAANGOTKPUOY-UHFFFAOYSA-N
DMX9K8F IU 2-carbamoyloxyethyl(trimethyl)azanium;chloride
DMX9K8F CA CAS 51-83-2
DMX9K8F CB CHEBI:3385
DMX9K8F DE Glaucoma/ocular hypertension
DMZOLBI ID DMZOLBI
DMZOLBI DN Carbamazepine
DMZOLBI HS Approved
DMZOLBI SN Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
DMZOLBI CP Lundbeck Inc
DMZOLBI DT Small molecular drug
DMZOLBI PC 2554
DMZOLBI MW 236.27
DMZOLBI FM C15H12N2O
DMZOLBI IC InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
DMZOLBI CS C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
DMZOLBI IK FFGPTBGBLSHEPO-UHFFFAOYSA-N
DMZOLBI IU benzo[b][1]benzazepine-11-carboxamide
DMZOLBI CA CAS 298-46-4
DMZOLBI CB CHEBI:3387
DMZOLBI DE Gastric adenocarcinoma; Epilepsy; Type-1 diabetes
DMLEDNK ID DMLEDNK
DMLEDNK DN Carbenicillin
DMLEDNK HS Approved
DMLEDNK SN CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMLEDNK CP Roerig Div Pfizer Inc
DMLEDNK TC Antibiotics
DMLEDNK DT Small molecular drug
DMLEDNK PC 20824
DMLEDNK MW 378.4
DMLEDNK FM C17H18N2O6S
DMLEDNK IC InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1
DMLEDNK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C
DMLEDNK IK FPPNZSSZRUTDAP-UWFZAAFLSA-N
DMLEDNK IU (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMLEDNK CA CAS 4697-36-3
DMLEDNK CB CHEBI:3393
DMLEDNK DE Infection of the upper and lower urinary tract
DME2XG3 ID DME2XG3
DME2XG3 DN Carbenicillin Indanyl Sodium
DME2XG3 HS Approved
DME2XG3 SN Geocillin
DME2XG3 CP Pfizer Laboratories Div Pfizer Inc
DME2XG3 TC Antiinfective Agents
DME2XG3 DT Small molecular drug
DME2XG3 PC 23676503
DME2XG3 MW 516.5
DME2XG3 FM C26H25N2NaO6S
DME2XG3 IC InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
DME2XG3 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+]
DME2XG3 IK QFWPXOXWAUAYAB-XZVIDJSISA-M
DME2XG3 IU sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DME2XG3 CA CAS 26605-69-6
DME2XG3 CB CHEBI:31358
DME2XG3 DE Bacterial infection
DMUSLW3 ID DMUSLW3
DMUSLW3 DN Carbetocin
DMUSLW3 HS Approved
DMUSLW3 SN Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
DMUSLW3 CP Pfizer Pharmaceuticals
DMUSLW3 TC Antitocolytic Agents
DMUSLW3 DT Small molecular drug
DMUSLW3 PC 16681432
DMUSLW3 MW 988.2
DMUSLW3 FM C45H69N11O12S
DMUSLW3 IC InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
DMUSLW3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUSLW3 IK NSTRIRCPWQHTIA-DTRKZRJBSA-N
DMUSLW3 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
DMUSLW3 CA CAS 37025-55-1
DMUSLW3 CB CHEBI:59204
DMUSLW3 DE Postpartum haemorrhage
DMHRG8Q ID DMHRG8Q
DMHRG8Q DN Carbidopa
DMHRG8Q HS Approved
DMHRG8Q SN Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
DMHRG8Q TC Antiparkinson Agents
DMHRG8Q DT Small molecular drug
DMHRG8Q PC 34359
DMHRG8Q MW 226.23
DMHRG8Q FM C10H14N2O4
DMHRG8Q IC InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
DMHRG8Q CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
DMHRG8Q IK TZFNLOMSOLWIDK-JTQLQIEISA-N
DMHRG8Q IU (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
DMHRG8Q CA CAS 28860-95-9
DMHRG8Q CB CHEBI:39585
DMHRG8Q DE Parkinson disease
DMULAI4 ID DMULAI4
DMULAI4 DN Carbimazole
DMULAI4 HS Approved
DMULAI4 SN Athyromazole; Atirozidina; Basolest; Carbethoxymethimazole; Carbimazol; Carbimazolum; Carbinazole; Carbotiroid; Mertiran; Neomercazole; TYRAZOL; Thyrostat; Carbimazol henning; Carbimazol spofa; CG1; Cg 1; Carbimazol henning (TN); Carbimazole (INN); Carbimazolum [INN-Latin]; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Carbimazol [INN-Spanish, French]; Carbimazole [INN:BAN:DCF]; Ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester
DMULAI4 TC Antithyroid Agents
DMULAI4 DT Small molecular drug
DMULAI4 PC 31072
DMULAI4 MW 186.23
DMULAI4 FM C7H10N2O2S
DMULAI4 IC InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3
DMULAI4 CS CCOC(=O)N1C=CN(C1=S)C
DMULAI4 IK CFOYWRHIYXMDOT-UHFFFAOYSA-N
DMULAI4 IU ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate
DMULAI4 CA CAS 22232-54-8
DMULAI4 CB CHEBI:617099
DMULAI4 DE Hyperthyroidism
DMCT31R ID DMCT31R
DMCT31R DN Carbinoxamine
DMCT31R HS Approved
DMCT31R SN Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
DMCT31R CP McNeil Laboratories
DMCT31R TC Antihistamines
DMCT31R DT Small molecular drug
DMCT31R PC 2564
DMCT31R MW 290.79
DMCT31R FM C16H19ClN2O
DMCT31R IC InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
DMCT31R CS CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DMCT31R IK OJFSXZCBGQGRNV-UHFFFAOYSA-N
DMCT31R IU 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
DMCT31R CA CAS 486-16-8
DMCT31R CB CHEBI:3398
DMCT31R DE Vasomotor/allergic rhinitis
DMG281S ID DMG281S
DMG281S DN Carboplatin
DMG281S HS Approved
DMG281S SN Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
DMG281S CP Bristol-Myers Squibb
DMG281S TC Anticancer Agents
DMG281S DT Small molecular drug
DMG281S PC 426756
DMG281S MW 371.25
DMG281S FM C6H12N2O4Pt
DMG281S IC InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
DMG281S CS C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
DMG281S IK VSRXQHXAPYXROS-UHFFFAOYSA-N
DMG281S IU azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMG281S CA CAS 41575-94-4
DMG281S CB CHEBI:31355
DMG281S DE Ovarian cancer
DMS3508 ID DMS3508
DMS3508 DN Carboprost tromethamine
DMS3508 HS Approved
DMS3508 SN Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine
DMS3508 TC Abortifacient Agents
DMS3508 DT Small molecular drug
DMS3508 PC 5281074
DMS3508 MW 489.6
DMS3508 FM C25H47NO8
DMS3508 IC InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1
DMS3508 CS CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMS3508 IK UMMADZJLZAPZAW-XOWPVRJPSA-N
DMS3508 IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
DMS3508 CA CAS 58551-69-2
DMS3508 DE Abortion
DM48K0X ID DM48K0X
DM48K0X DN Carfilzomib
DM48K0X HS Approved
DM48K0X SN Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
DM48K0X CP Onyx Pharmaceuticals
DM48K0X DT Small molecular drug
DM48K0X PC 11556711
DM48K0X MW 719.9
DM48K0X FM C40H57N5O7
DM48K0X IC InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
DM48K0X CS CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
DM48K0X IK BLMPQMFVWMYDKT-NZTKNTHTSA-N
DM48K0X IU (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
DM48K0X CA CAS 868540-17-4
DM48K0X CB CHEBI:65347
DM48K0X DE Multiple myeloma; Small-cell lung cancer
DMCY0TI ID DMCY0TI
DMCY0TI DN Carglumic acid
DMCY0TI HS Approved
DMCY0TI SN Carbaglu (TN)
DMCY0TI CP Orphan Europe
DMCY0TI DT Small molecular drug
DMCY0TI PC 121396
DMCY0TI MW 190.15
DMCY0TI FM C6H10N2O5
DMCY0TI IC InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
DMCY0TI CS C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
DMCY0TI IK LCQLHJZYVOQKHU-VKHMYHEASA-N
DMCY0TI IU (2S)-2-(carbamoylamino)pentanedioic acid
DMCY0TI CA CAS 1188-38-1
DMCY0TI CB CHEBI:71028
DMCY0TI DE Acute hyperammonaemia
DMJYDVK ID DMJYDVK
DMJYDVK DN Cariprazine
DMJYDVK HS Approved
DMJYDVK SN Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH
DMJYDVK CP Forest Laboratories; Gedeon Richter
DMJYDVK DT Small molecular drug
DMJYDVK PC 11154555
DMJYDVK MW 427.4
DMJYDVK FM C21H32Cl2N4O
DMJYDVK IC InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)
DMJYDVK CS CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
DMJYDVK IK KPWSJANDNDDRMB-UHFFFAOYSA-N
DMJYDVK IU 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
DMJYDVK CA CAS 839712-12-8
DMJYDVK CB CHEBI:90933
DMJYDVK DE Bipolar disorder
DMWR1JC ID DMWR1JC
DMWR1JC DN Carisoprodol
DMWR1JC HS Approved
DMWR1JC SN carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol
DMWR1JC DT Small molecular drug
DMWR1JC PC 2576
DMWR1JC MW 260.329
DMWR1JC FM C12H24N2O4
DMWR1JC IC InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
DMWR1JC CS CCCC(C)(COC(=O)N)COC(=O)NC(C)C
DMWR1JC IK OFZCIYFFPZCNJE-UHFFFAOYSA-N
DMWR1JC IU [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
DMWR1JC CA CAS 78-44-4
DMWR1JC CB CHEBI:3419
DMWR1JC DE Musculoskeletal disorder
DMHTB31 ID DMHTB31
DMHTB31 DN Carphenazine
DMHTB31 HS Approved
DMHTB31 SN Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CP Wyeth Ayerst Laboratories
DMHTB31 TC Antipsychotic Agents
DMHTB31 DT Small molecular drug
DMHTB31 PC 18104
DMHTB31 MW 425.6
DMHTB31 FM C24H31N3O2S
DMHTB31 IC InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DMHTB31 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMHTB31 IK XZSMZRXAEFNJCU-UHFFFAOYSA-N
DMHTB31 IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CA CAS 2622-30-2
DMHTB31 DE Insomnia; Schizophrenia
DMHMP05 ID DMHMP05
DMHMP05 DN Carprofen
DMHMP05 HS Approved
DMHMP05 SN Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al
DMHMP05 CP Pfizer Pharmaceuticals
DMHMP05 TC Analgesics
DMHMP05 DT Small molecular drug
DMHMP05 PC 2581
DMHMP05 MW 273.71
DMHMP05 FM C15H12ClNO2
DMHMP05 IC InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
DMHMP05 CS CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O
DMHMP05 IK PUXBGTOOZJQSKH-UHFFFAOYSA-N
DMHMP05 IU 2-(6-chloro-9H-carbazol-2-yl)propanoic acid
DMHMP05 CA CAS 53716-49-7
DMHMP05 CB CHEBI:364453
DMHMP05 DE Pain
DMFMDOB ID DMFMDOB
DMFMDOB DN Carteolol
DMFMDOB HS Approved
DMFMDOB SN Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
DMFMDOB CP CIBA Vision Sterile Mfg
DMFMDOB TC Antihypertensive Agents
DMFMDOB DT Small molecular drug
DMFMDOB PC 2583
DMFMDOB MW 292.37
DMFMDOB FM C16H24N2O3
DMFMDOB IC InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
DMFMDOB CS CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O
DMFMDOB IK LWAFSWPYPHEXKX-UHFFFAOYSA-N
DMFMDOB IU 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
DMFMDOB CA CAS 51781-06-7
DMFMDOB CB CHEBI:3437
DMFMDOB DE Glaucoma/ocular hypertension
DMHTEAO ID DMHTEAO
DMHTEAO DN Carvedilol
DMHTEAO HS Approved
DMHTEAO SN Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
DMHTEAO CP GlaxoSmithKline plc
DMHTEAO TC Vasodilator Agents
DMHTEAO DT Small molecular drug
DMHTEAO PC 2585
DMHTEAO MW 406.5
DMHTEAO FM C24H26N2O4
DMHTEAO IC InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMHTEAO CS COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMHTEAO IK OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMHTEAO IU 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMHTEAO CA CAS 72956-09-3
DMHTEAO CB CHEBI:3441
DMHTEAO DE Congestive heart failure
DMZPXRC ID DMZPXRC
DMZPXRC DN Carzinophilin
DMZPXRC HS Approved
DMZPXRC SN CARZINOPHILIN; Cardinophyllin; Cardinophillin; Azinomycin; CARZINOPHILIN A; Carzinophyllin; NSC 20088; Antibiotic from Streptomyces Sahachiroi; BRN 5721373; C31H33N3O11; 1403-28-7; Carzinophilin (8CI); AC1MHU1X; Carzinophilin (8CI)(9CI); LS-52587; LS-52588; 11002-20-3; [(1S)-2-[[(1E)-1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[[(E)-1-hydroxy-3-oxobut-1-en-2-yl]amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate
DMZPXRC DT Small molecular drug
DMZPXRC PC 227922
DMZPXRC MW 639.6
DMZPXRC FM C31H33N3O12
DMZPXRC IC InChI=1S/C31H33N3O12/c1-14-7-6-8-18-19(14)9-17(43-5)10-20(18)26(40)32-13-30(4)24(39)28(41)45-31(46-30)25(23(38)22-11-34(22)16(3)37)44-27(33-29(31)42)21(12-35)15(2)36/h6-10,12,22-25,38-39H,11,13H2,1-5H3,(H,32,40)(H,33,42)
DMZPXRC CS CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C(C(=O)OC4(O3)C(OC(=C(C=O)C(=O)C)NC4=O)C(C5CN5C(=O)C)O)O)C)OC
DMZPXRC IK GNGRYODSYNVRFD-UHFFFAOYSA-N
DMZPXRC IU N-[[7-[(1-acetylaziridin-2-yl)-hydroxymethyl]-9-(1,3-dioxobutan-2-ylidene)-3-hydroxy-4-methyl-2,11-dioxo-1,5,8-trioxa-10-azaspiro[5.5]undecan-4-yl]methyl]-3-methoxy-5-methylnaphthalene-1-carboxamide
DMZPXRC DE Solid tumour/cancer
DMGQIPT ID DMGQIPT
DMGQIPT DN Caspofungin
DMGQIPT HS Approved
DMGQIPT SN CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
DMGQIPT CP Merck & Co
DMGQIPT TC Antifungal Agents
DMGQIPT DT Small molecular drug
DMGQIPT PC 2826718
DMGQIPT MW 1093.3
DMGQIPT FM C52H88N10O15
DMGQIPT IC InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
DMGQIPT CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O
DMGQIPT IK JYIKNQVWKBUSNH-OGZDCFRISA-N
DMGQIPT IU N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMGQIPT CA CAS 162808-62-0
DMGQIPT CB CHEBI:474180
DMGQIPT DE Fungal infection
DMRSZA5 ID DMRSZA5
DMRSZA5 DN Cefacetrile
DMRSZA5 HS Approved
DMRSZA5 SN Cefacetril; Cefacetrilo; Cefacetrilum; Celospor; Cephacetrile; Vetrimast [veterinary]; Cefacetrile (INN); Cefacetrilo [INN-Spanish]; Cefacetrilum [INN-Latin]; Celospor (TN); Celtol (TN); Cristacef (TN); Vetrimast [veterinary] (TN); C-36278-Ba; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); 7-Cyanacetylamino-cephalosporansaeure
DMRSZA5 TC Antibiotics
DMRSZA5 DT Small molecular drug
DMRSZA5 PC 91562
DMRSZA5 MW 339.33
DMRSZA5 FM C13H13N3O6S
DMRSZA5 IC InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
DMRSZA5 CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O
DMRSZA5 IK RRYMAQUWDLIUPV-BXKDBHETSA-N
DMRSZA5 IU (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMRSZA5 CA CAS 10206-21-0
DMRSZA5 CB CHEBI:135437
DMRSZA5 DE Bacterial infection
DMJXDGC ID DMJXDGC
DMJXDGC DN Cefaclor
DMJXDGC HS Approved
DMJXDGC SN Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
DMJXDGC CP Eli Lilly
DMJXDGC TC Antibiotics
DMJXDGC DT Small molecular drug
DMJXDGC PC 51039
DMJXDGC MW 367.8
DMJXDGC FM C15H14ClN3O4S
DMJXDGC IC InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
DMJXDGC CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DMJXDGC IK QYIYFLOTGYLRGG-GPCCPHFNSA-N
DMJXDGC IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJXDGC CA CAS 53994-73-3
DMJXDGC CB CHEBI:3478
DMJXDGC DE Bacterial infection
DMMC345 ID DMMC345
DMMC345 DN Cefadroxil
DMMC345 HS Approved
DMMC345 SN CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMMC345 CP Pharco B international
DMMC345 TC Antibiotics
DMMC345 DT Small molecular drug
DMMC345 PC 47965
DMMC345 MW 363.4
DMMC345 FM C16H17N3O5S
DMMC345 IC InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
DMMC345 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DMMC345 IK BOEGTKLJZSQCCD-UEKVPHQBSA-N
DMMC345 IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMC345 CA CAS 50370-12-2
DMMC345 CB CHEBI:3479
DMMC345 DE Bacterial infection
DMVYSLE ID DMVYSLE
DMVYSLE DN Cefalotin
DMVYSLE HS Approved
DMVYSLE SN Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid
DMVYSLE CP Eli Lilly
DMVYSLE TC Antibiotics
DMVYSLE DT Small molecular drug
DMVYSLE PC 6024
DMVYSLE MW 396.4
DMVYSLE FM C16H16N2O6S2
DMVYSLE IC InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1
DMVYSLE CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O
DMVYSLE IK XIURVHNZVLADCM-IUODEOHRSA-N
DMVYSLE IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVYSLE CA CAS 153-61-7
DMVYSLE CB CHEBI:124991
DMVYSLE DE Bacterial infection
DMNEXZF ID DMNEXZF
DMNEXZF DN Cefamandole
DMNEXZF HS Approved
DMNEXZF SN Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DMNEXZF CP Eli Lilly
DMNEXZF TC Antibiotics
DMNEXZF DT Small molecular drug
DMNEXZF PC 456255
DMNEXZF MW 462.5
DMNEXZF FM C18H18N6O5S2
DMNEXZF IC InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1
DMNEXZF CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O
DMNEXZF IK OLVCFLKTBJRLHI-AXAPSJFSSA-N
DMNEXZF IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMNEXZF CA CAS 34444-01-4
DMNEXZF CB CHEBI:3480
DMNEXZF DE Microorganisms infection
DMPDYFR ID DMPDYFR
DMPDYFR DN Cefazolin
DMPDYFR HS Approved
DMPDYFR SN CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
DMPDYFR CP Fujisawa Pharmaceutical Co
DMPDYFR TC Antibiotics
DMPDYFR DT Small molecular drug
DMPDYFR PC 33255
DMPDYFR MW 454.5
DMPDYFR FM C14H14N8O4S3
DMPDYFR IC InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
DMPDYFR CS CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O
DMPDYFR IK MLYYVTUWGNIJIB-BXKDBHETSA-N
DMPDYFR IU (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPDYFR CA CAS 25953-19-9
DMPDYFR CB CHEBI:474053
DMPDYFR DE Bacterial infection
DMJ7A0H ID DMJ7A0H
DMJ7A0H DN Cefdinir
DMJ7A0H HS Approved
DMJ7A0H SN CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMJ7A0H CP Abbott Laboratories
DMJ7A0H TC Antibiotics
DMJ7A0H DT Small molecular drug
DMJ7A0H PC 6915944
DMJ7A0H MW 395.4
DMJ7A0H FM C14H13N5O5S2
DMJ7A0H IC InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
DMJ7A0H CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O
DMJ7A0H IK RTXOFQZKPXMALH-GHXIOONMSA-N
DMJ7A0H IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJ7A0H CA CAS 91832-40-5
DMJ7A0H CB CHEBI:3485
DMJ7A0H DE Bacterial infection
DMSUVM1 ID DMSUVM1
DMSUVM1 DN Cefditoren
DMSUVM1 HS Approved
DMSUVM1 SN Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMSUVM1 CP Cornerstone BioPharma
DMSUVM1 TC Antibiotics
DMSUVM1 DT Small molecular drug
DMSUVM1 PC 9870843
DMSUVM1 MW 506.6
DMSUVM1 FM C19H18N6O5S3
DMSUVM1 IC InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
DMSUVM1 CS CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMSUVM1 IK KMIPKYQIOVAHOP-YLGJWRNMSA-N
DMSUVM1 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSUVM1 CA CAS 104145-95-1
DMSUVM1 CB CHEBI:59343
DMSUVM1 DE Bacterial infection
DMHVWIK ID DMHVWIK
DMHVWIK DN Cefepime
DMHVWIK HS Approved
DMHVWIK SN Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
DMHVWIK CP Bristol-Myers Squibb
DMHVWIK TC Antibiotics
DMHVWIK DT Small molecular drug
DMHVWIK PC 5479537
DMHVWIK MW 480.6
DMHVWIK FM C19H24N6O5S2
DMHVWIK IC InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
DMHVWIK CS C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
DMHVWIK IK HVFLCNVBZFFHBT-ZKDACBOMSA-N
DMHVWIK IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMHVWIK CA CAS 88040-23-7
DMHVWIK CB CHEBI:478164
DMHVWIK DE Bacterial infection
DMY60I8 ID DMY60I8
DMY60I8 DN Cefixime
DMY60I8 HS Approved
DMY60I8 SN CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMY60I8 CP Wyeth Pharmaceuticals
DMY60I8 TC Antibiotics
DMY60I8 DT Small molecular drug
DMY60I8 PC 5362065
DMY60I8 MW 453.5
DMY60I8 FM C16H15N5O7S2
DMY60I8 IC InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
DMY60I8 CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
DMY60I8 IK OKBVVJOGVLARMR-QSWIMTSFSA-N
DMY60I8 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY60I8 CA CAS 79350-37-1
DMY60I8 CB CHEBI:472657
DMY60I8 DE Bacterial infection
DMPLY7B ID DMPLY7B
DMPLY7B DN Cefmenoxime
DMPLY7B HS Approved
DMPLY7B SN Cefmax; Cefmenoxima; Cefmenoximum; Tacef; Cefmenoxime [INN]; A 50912; AB 50912; SCE 1365; Abbott-50192; Cefmenoxima [INN-Spanish]; Cefmenoxime (INN); Cefmenoximum [INN-Latin]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMPLY7B TC Antibiotics
DMPLY7B DT Small molecular drug
DMPLY7B PC 9570757
DMPLY7B MW 511.6
DMPLY7B FM C16H17N9O5S3
DMPLY7B IC InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
DMPLY7B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMPLY7B IK HJJDBAOLQAWBMH-YCRCPZNHSA-N
DMPLY7B IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPLY7B CA CAS 65085-01-0
DMPLY7B CB CHEBI:55490
DMPLY7B DE Bacterial infection
DM42W1B ID DM42W1B
DM42W1B DN Cefmetazole
DM42W1B HS Approved
DM42W1B SN CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DM42W1B CP Pharmacia And Upjohn Co
DM42W1B TC Antibiotics
DM42W1B DT Small molecular drug
DM42W1B PC 42008
DM42W1B MW 471.5
DM42W1B FM C15H17N7O5S3
DM42W1B IC InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1
DM42W1B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
DM42W1B IK SNBUBQHDYVFSQF-HIFRSBDPSA-N
DM42W1B IU (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM42W1B CA CAS 56796-20-4
DM42W1B CB CHEBI:3489
DM42W1B DE Bacterial infection
DMORSGU ID DMORSGU
DMORSGU DN Cefodizime
DMORSGU HS Approved
DMORSGU SN AC1NSFIB; CDZM; CHEBI:63214; CHEMBL2303613; Cefodizima; Cefodizima [INN-Spanish]; Cefodizime; Cefodizime (INN); Cefodizime Acid; Cefodizime [INN:BAN]; Cefodizimum; Cefodizimum [INN-Latin]; Cefodizme; DTXSID2022757; Diezime; EC 700-301-3; EX-A1379; HR 221 [AS SODIUM]; HR-221; HR-221 [As Sodium]; J-700161; Modivid; Neucef; S-771221B [As Sodium]; SCHEMBL151101; THR 221 [AS SODIUM]; THR-221; THR-221 [As Sodium]; Timecef; UNII-Z31298J4HQ; Z31298J4HQ
DMORSGU TC Anti-Bacterial Agents
DMORSGU DT Small molecular drug
DMORSGU PC 5361871
DMORSGU MW 584.655
DMORSGU FM C20H20N6O7S4
DMORSGU IC InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
DMORSGU CS CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O
DMORSGU IK XDZKBRJLTGRPSS-BGZQYGJUSA-N
DMORSGU IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMORSGU CA CAS 69739-16-8
DMORSGU CB CHEBI:63214
DMORSGU DE Bacterial infections
DMTX2BH ID DMTX2BH
DMTX2BH DN Cefonicid
DMTX2BH HS Approved
DMTX2BH SN Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CP Glaxosmithkline
DMTX2BH TC Antibiotics
DMTX2BH DT Small molecular drug
DMTX2BH PC 43594
DMTX2BH MW 542.6
DMTX2BH FM C18H18N6O8S3
DMTX2BH IC InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
DMTX2BH CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O
DMTX2BH IK DYAIAHUQIPBDIP-AXAPSJFSSA-N
DMTX2BH IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CA CAS 61270-58-4
DMTX2BH CB CHEBI:3491
DMTX2BH DE Bacterial infection
DM53PV8 ID DM53PV8
DM53PV8 DN Cefoperazone
DM53PV8 HS Approved
DM53PV8 SN Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
DM53PV8 CP Pfizer Pharmaceuticals
DM53PV8 TC Antibiotics
DM53PV8 DT Small molecular drug
DM53PV8 PC 44187
DM53PV8 MW 645.7
DM53PV8 FM C25H27N9O8S2
DM53PV8 IC InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
DM53PV8 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DM53PV8 IK GCFBRXLSHGKWDP-XCGNWRKASA-N
DM53PV8 IU (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM53PV8 CA CAS 62893-19-0
DM53PV8 CB CHEBI:3493
DM53PV8 DE Bacterial infection
DMSQVD6 ID DMSQVD6
DMSQVD6 DN Ceforanide
DMSQVD6 HS Approved
DMSQVD6 SN Ceforanido; Ceforanidum; Precef; Radacef; Bl s786; BL-S 786; BL-S786; Ceforanido [INN-Spanish]; Ceforanidum [INN-Latin]; Precef (TN); Ceforanide (USP/INN); Ceforanide [USAN:INN:BAN]; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
DMSQVD6 TC Antibiotics
DMSQVD6 DT Small molecular drug
DMSQVD6 PC 43507
DMSQVD6 MW 519.6
DMSQVD6 FM C20H21N7O6S2
DMSQVD6 IC InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
DMSQVD6 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O
DMSQVD6 IK SLAYUXIURFNXPG-CRAIPNDOSA-N
DMSQVD6 IU (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSQVD6 CA CAS 60925-61-3
DMSQVD6 CB CHEBI:3495
DMSQVD6 DE Bacterial infection
DMEB837 ID DMEB837
DMEB837 DN Cefotaxime
DMEB837 HS Approved
DMEB837 SN Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7
DMEB837 PC 5742673
DMEB837 MW 455.5
DMEB837 FM C16H17N5O7S2
DMEB837 IC GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMEB837 CS CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
DMEB837 IK 1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMEB837 IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEB837 CA CAS 60846-21-1
DMEB837 CB CHEBI:204928
DMEB837 DE Meningitis
DMMKHBJ ID DMMKHBJ
DMMKHBJ DN Cefotaxime
DMMKHBJ HS Approved
DMMKHBJ SN Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*)
DMMKHBJ CP Roussel Uclaf
DMMKHBJ TC Antibiotics
DMMKHBJ DT Small molecular drug
DMMKHBJ PC 5742673
DMMKHBJ MW 455.5
DMMKHBJ FM C16H17N5O7S2
DMMKHBJ IC InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMMKHBJ CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMMKHBJ IK GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMMKHBJ IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMKHBJ CA CAS 63527-52-6
DMMKHBJ CB CHEBI:204928
DMMKHBJ DE Bacterial infection
DM07TX3 ID DM07TX3
DM07TX3 DN Cefotetan
DM07TX3 HS Approved
DM07TX3 SN Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DM07TX3 CP AstraZeneca
DM07TX3 TC Antibiotics
DM07TX3 DT Small molecular drug
DM07TX3 PC 53025
DM07TX3 MW 575.6
DM07TX3 FM C17H17N7O8S4
DM07TX3 IC InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
DM07TX3 CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O
DM07TX3 IK SRZNHPXWXCNNDU-RHBCBLIFSA-N
DM07TX3 IU (6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07TX3 CA CAS 69712-56-7
DM07TX3 CB CHEBI:3499
DM07TX3 DE Bacterial infection
DMF5HU6 ID DMF5HU6
DMF5HU6 DN Cefotiam
DMF5HU6 HS Approved
DMF5HU6 SN Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
DMF5HU6 CP Takeda
DMF5HU6 TC Antibiotics
DMF5HU6 DT Small molecular drug
DMF5HU6 PC 43708
DMF5HU6 MW 525.6
DMF5HU6 FM C18H23N9O4S3
DMF5HU6 IC InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1
DMF5HU6 CS CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O
DMF5HU6 IK QYQDKDWGWDOFFU-IUODEOHRSA-N
DMF5HU6 IU (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMF5HU6 CA CAS 61622-34-2
DMF5HU6 CB CHEBI:355510
DMF5HU6 DE Respiratory tract infection
DMY8NC4 ID DMY8NC4
DMY8NC4 DN Cefoxitin
DMY8NC4 HS Approved
DMY8NC4 SN Cefoxitina; Cefoxitine; Cefoxitinum; Cefoxotin; Cenomycin; Mefoxin; Mefoxitin; Rephoxitin; cefoxitin; ceftoxitin; 35607-66-0; CEPHOXITIN; 4kow; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; 6OEV9DX57Y; AK118716; CAS-35607-66-0; CFX; CHEBI:209807; CHEMBL996; DSSTox_CID_2764; DSSTox_GSID_22764; DSSTox_RID_76721; NCGC00183034-01; UNII-6OEV9DX57Y
DMY8NC4 PC 441199
DMY8NC4 MW 427.5
DMY8NC4 FM C16H17N3O7S2
DMY8NC4 IC WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMY8NC4 CS COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMY8NC4 IK 1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMY8NC4 IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY8NC4 CA CAS 35607-66-0
DMY8NC4 CB CHEBI:209807
DMY8NC4 DE Peritonitis
DMYTXVR ID DMYTXVR
DMYTXVR DN Cefoxitin
DMYTXVR HS Approved
DMYTXVR SN Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMYTXVR CP Merck & Co
DMYTXVR TC Antibiotics
DMYTXVR DT Small molecular drug
DMYTXVR PC 441199
DMYTXVR MW 427.5
DMYTXVR FM C16H17N3O7S2
DMYTXVR IC InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMYTXVR CS CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMYTXVR IK WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMYTXVR IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYTXVR CA CAS 35607-66-0
DMYTXVR CB CHEBI:209807
DMYTXVR DE Bacterial infection
DMKBTFG ID DMKBTFG
DMKBTFG DN Cefozopran
DMKBTFG HS Approved
DMKBTFG SN CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
DMKBTFG CP Takeda
DMKBTFG DT Small molecular drug
DMKBTFG PC 9571080
DMKBTFG MW 515.5
DMKBTFG FM C19H17N9O5S2
DMKBTFG IC InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
DMKBTFG CS CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]
DMKBTFG IK QDUIJCOKQCCXQY-WHJQOFBOSA-N
DMKBTFG IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMKBTFG CA CAS 113359-04-9
DMKBTFG CB CHEBI:3502
DMKBTFG DE Gram-positive bacterial infection
DMZ2WL4 ID DMZ2WL4
DMZ2WL4 DN Cefpiramide
DMZ2WL4 HS Approved
DMZ2WL4 SN Cefpiramido; Cefpiramidum; WY 44635; Cefpiramide [USAN:INN]; Cefpiramido [INN-Spanish]; Cefpiramidum [INN-Latin]; WY44,635; Cefpiramide (USP/INN); (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe-nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMZ2WL4 CP Wyeth Ayerst Laboratories
DMZ2WL4 TC Antibiotics
DMZ2WL4 DT Small molecular drug
DMZ2WL4 PC 636405
DMZ2WL4 MW 612.6
DMZ2WL4 FM C25H24N8O7S2
DMZ2WL4 IC InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
DMZ2WL4 CS CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DMZ2WL4 IK PWAUCHMQEXVFJR-PMAPCBKXSA-N
DMZ2WL4 IU (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMZ2WL4 CA CAS 70797-11-4
DMZ2WL4 CB CHEBI:59213
DMZ2WL4 DE Bacterial infection
DMJUNY5 ID DMJUNY5
DMJUNY5 DN Cefpodoxime
DMJUNY5 HS Approved
DMJUNY5 SN CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CP Pfizer Pharmaceuticals
DMJUNY5 TC Antibiotics
DMJUNY5 DT Small molecular drug
DMJUNY5 PC 6335986
DMJUNY5 MW 427.5
DMJUNY5 FM C15H17N5O6S2
DMJUNY5 IC InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
DMJUNY5 CS COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMJUNY5 IK WYUSVOMTXWRGEK-HBWVYFAYSA-N
DMJUNY5 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CA CAS 80210-62-4
DMJUNY5 CB CHEBI:3504
DMJUNY5 DE Bacterial infection
DM7DSYP ID DM7DSYP
DM7DSYP DN Cefprozil
DM7DSYP HS Approved
DM7DSYP SN Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CP Bristol-Myers Squibb
DM7DSYP TC Antibiotics
DM7DSYP DT Small molecular drug
DM7DSYP PC 5281006
DM7DSYP MW 389.4
DM7DSYP FM C18H19N3O5S
DM7DSYP IC InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1
DM7DSYP CS C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DM7DSYP IK WDLWHQDACQUCJR-ZAMMOSSLSA-N
DM7DSYP IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CA CAS 92676-86-3
DM7DSYP CB CHEBI:3506
DM7DSYP DE Bacterial infection
DMUNSWV ID DMUNSWV
DMUNSWV DN Cefradine
DMUNSWV HS Approved
DMUNSWV SN Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
DMUNSWV CP Kent Pharms
DMUNSWV TC Antibiotics
DMUNSWV DT Small molecular drug
DMUNSWV PC 38103
DMUNSWV MW 349.4
DMUNSWV FM C16H19N3O4S
DMUNSWV IC InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMUNSWV CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O
DMUNSWV IK RDLPVSKMFDYCOR-UEKVPHQBSA-N
DMUNSWV IU (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMUNSWV CA CAS 38821-53-3
DMUNSWV CB CHEBI:3547
DMUNSWV DE Bacterial infection
DMQXLF3 ID DMQXLF3
DMQXLF3 DN Cefsulodin
DMQXLF3 HS Approved
DMQXLF3 SN cefsulodin; (6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1NR4MP; SCHEMBL65524; DTXSID6022769; Cefsulodin free acid (SCE-129), Antibiotic for Culture Media Use Only
DMQXLF3 DT Small molecular drug
DMQXLF3 PC 656575
DMQXLF3 MW 532.6
DMQXLF3 FM C22H20N4O8S2
DMQXLF3 IC InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
DMQXLF3 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N
DMQXLF3 IK SYLKGLMBLAAGSC-QLVMHMETSA-N
DMQXLF3 IU (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMQXLF3 CA CAS 62587-73-9
DMQXLF3 CB CHEBI:3507
DMQXLF3 DE Pseudomonas infection
DM41GRA ID DM41GRA
DM41GRA DN Ceftazidime
DM41GRA HS Approved
DM41GRA SN Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
DM41GRA CP GlaxoSmithKline
DM41GRA TC Antibiotics
DM41GRA DT Small molecular drug
DM41GRA PC 5481173
DM41GRA MW 546.6
DM41GRA FM C22H22N6O7S2
DM41GRA IC InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
DM41GRA CS CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
DM41GRA IK ORFOPKXBNMVMKC-DWVKKRMSSA-N
DM41GRA IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM41GRA CA CAS 72558-82-8
DM41GRA CB CHEBI:3508
DM41GRA DE Bacterial infection
DMWV2AG ID DMWV2AG
DMWV2AG DN Ceftibuten
DMWV2AG HS Approved
DMWV2AG SN CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMWV2AG CP Shionogi USA
DMWV2AG TC Antibiotics
DMWV2AG DT Small molecular drug
DMWV2AG PC 5282242
DMWV2AG MW 410.4
DMWV2AG FM C15H14N4O6S2
DMWV2AG IC InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1
DMWV2AG CS C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O
DMWV2AG IK UNJFKXSSGBWRBZ-BJCIPQKHSA-N
DMWV2AG IU (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWV2AG CA CAS 97519-39-6
DMWV2AG CB CHEBI:3510
DMWV2AG DE Chronic bronchitis
DMR2SOZ ID DMR2SOZ
DMR2SOZ DN Ceftiofur
DMR2SOZ HS Approved
DMR2SOZ SN Excede (TN)
DMR2SOZ CP Pfizer
DMR2SOZ DT Small molecular drug
DMR2SOZ PC 6328657
DMR2SOZ MW 523.6
DMR2SOZ FM C19H17N5O7S3
DMR2SOZ IC InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
DMR2SOZ CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O
DMR2SOZ IK ZBHXIWJRIFEVQY-IHMPYVIRSA-N
DMR2SOZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMR2SOZ CA CAS 80370-57-6
DMR2SOZ DE Bacterial infection
DM3VOGS ID DM3VOGS
DM3VOGS DN Ceftizoxime
DM3VOGS HS Approved
DM3VOGS SN Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid
DM3VOGS CP Fujisawa Pharmaceutical Co
DM3VOGS TC Antibiotics
DM3VOGS DT Small molecular drug
DM3VOGS PC 6533629
DM3VOGS MW 383.4
DM3VOGS FM C13H13N5O5S2
DM3VOGS IC InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
DM3VOGS CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O
DM3VOGS IK NNULBSISHYWZJU-LLKWHZGFSA-N
DM3VOGS IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM3VOGS CA CAS 68401-81-0
DM3VOGS CB CHEBI:553473
DM3VOGS DE Bacterial infection
DM9QWAH ID DM9QWAH
DM9QWAH DN Ceftolozane/tazobactam
DM9QWAH HS Approved
DM9QWAH SN CXA-101/tazobactam; CXA-201; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa
DM9QWAH TC Antiinfective Agents
DM9QWAH DE Discovery agent
DMCEW64 ID DMCEW64
DMCEW64 DN Ceftriaxone
DMCEW64 HS Approved
DMCEW64 SN Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMCEW64 CP Hoffmann-La Roche pharmaceutical company
DMCEW64 TC Antibiotics
DMCEW64 DT Small molecular drug
DMCEW64 PC 5479530
DMCEW64 MW 554.6
DMCEW64 FM C18H18N8O7S3
DMCEW64 IC InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
DMCEW64 CS CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMCEW64 IK VAAUVRVFOQPIGI-SPQHTLEESA-N
DMCEW64 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMCEW64 CA CAS 73384-59-5
DMCEW64 CB CHEBI:29007
DMCEW64 DE Bacterial infection
DMSIMD8 ID DMSIMD8
DMSIMD8 DN Cefuroxime
DMSIMD8 HS Approved
DMSIMD8 SN Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMSIMD8 CP GlaxoSmithKline
DMSIMD8 TC Antibiotics
DMSIMD8 DT Small molecular drug
DMSIMD8 PC 5479529
DMSIMD8 MW 424.4
DMSIMD8 FM C16H16N4O8S
DMSIMD8 IC InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
DMSIMD8 CS CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
DMSIMD8 IK JFPVXVDWJQMJEE-IZRZKJBUSA-N
DMSIMD8 IU (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSIMD8 CA CAS 55268-75-2
DMSIMD8 CB CHEBI:3515
DMSIMD8 DE Acute bronchitis
DM4CHN0 ID DM4CHN0
DM4CHN0 DN Cefuroxime axetil
DM4CHN0 HS Approved
DM4CHN0 SN cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef
DM4CHN0 PC 6321416
DM4CHN0 MW 510.5
DM4CHN0 FM C20H22N4O10S
DM4CHN0 IC InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
DM4CHN0 CS CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N
DM4CHN0 IK KEJCWVGMRLCZQQ-YJBYXUATSA-N
DM4CHN0 IU 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4CHN0 CA CAS 64544-07-6
DM4CHN0 CB CHEBI:3516
DM4CHN0 DE Bacterial infections
DM6LOQU ID DM6LOQU
DM6LOQU DN Celecoxib
DM6LOQU HS Approved
DM6LOQU SN CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CP Pfizer
DM6LOQU TC Analgesics
DM6LOQU DT Small molecular drug
DM6LOQU PC 2662
DM6LOQU MW 381.4
DM6LOQU FM C17H14F3N3O2S
DM6LOQU IC InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM6LOQU CS CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM6LOQU IK RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM6LOQU IU 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CA CAS 169590-42-5
DM6LOQU CB CHEBI:41423
DM6LOQU DE Rheumatoid arthritis; Pain
DMD5LBX ID DMD5LBX
DMD5LBX DN Celiprolol HCL
DMD5LBX HS Approved
DMD5LBX SN Selectol (TN)
DMD5LBX DT Small molecular drug
DMD5LBX PC 42373
DMD5LBX MW 416
DMD5LBX FM C20H34ClN3O4
DMD5LBX IC InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
DMD5LBX CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl
DMD5LBX IK VKJHTUVLJYWAEY-UHFFFAOYSA-N
DMD5LBX IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea;hydrochloride
DMD5LBX CA CAS 57470-78-7
DMD5LBX CB CHEBI:31385
DMD5LBX DE Hypertension
DMYT2FP ID DMYT2FP
DMYT2FP DN Cellulose Sodium Phosphate
DMYT2FP HS Approved
DMYT2FP SN Calcibind
DMYT2FP CP Mission Pharmacal Co
DMYT2FP DE Hypercalciuria
DMTIUFA ID DMTIUFA
DMTIUFA DN Celtura
DMTIUFA HS Approved
DMTIUFA SN A/H1N1v; A/H1N1v vaccine (influenza virus infection), Novartis; H1N1 pandemic influenza A vaccine (MF59-adjuvanted, cell culture), Novartis
DMTIUFA CP Novartis AG
DMTIUFA DT Vaccine
DMTIUFA DE Influenza virus infection
DMKMJHE ID DMKMJHE
DMKMJHE DN Cemiplimab
DMKMJHE HS Approved
DMKMJHE SN REGN2810; REGN-2810; REGN 2810
DMKMJHE CP Regeneron/Sanofi
DMKMJHE DT Monoclonal antibody
DMKMJHE DE Cutaneous squamous cell carcinoma
DM8Y2RU ID DM8Y2RU
DM8Y2RU DN Cenegermin
DM8Y2RU HS Approved
DM8Y2RU SN cenegermin; Cenegermin [INN]; UNII-B6E7K36KT8; B6E7K36KT8; Human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli nerve growth factor
DM8Y2RU CP Domp
DM8Y2RU DT Antibody
DM8Y2RU DE Neurotrophic keratitis
DMXQS7K ID DMXQS7K
DMXQS7K DN Cenestin
DMXQS7K HS Approved
DMXQS7K SN Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo
DMXQS7K CP Duramed Pharmaceuticals Inc
DMXQS7K DT Small molecular drug
DMXQS7K PC 23676225
DMXQS7K MW 370.4
DMXQS7K FM C18H19NaO5S
DMXQS7K IC InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1
DMXQS7K CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+]
DMXQS7K IK QTTMOCOWZLSYSV-QWAPEVOJSA-M
DMXQS7K IU sodium;[(9S,13S,14S)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMXQS7K CA CAS 12126-59-9
DMXQS7K CB CHEBI:32143
DMXQS7K DE Menopause symptom; Osteoporosis
DM8KLU9 ID DM8KLU9
DM8KLU9 DN Cenobamate
DM8KLU9 HS Approved
DM8KLU9 SN Cenobamate; Cenobamate (USAN/INN); Cenobamate [INN]; Cenobamate [USAN:INN]; P85X70RZWS; SCHEMBL1682643; YKP3089; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 913088-80-9; CHEMBL3989949; CS-0014686; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; HY-17607; UNII-P85X70RZWS
DM8KLU9 PC 11962412
DM8KLU9 MW 267.67
DM8KLU9 FM C10H10ClN5O2
DM8KLU9 IC GFHAXPJGXSQLPT-VIFPVBQESA-N
DM8KLU9 CS C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
DM8KLU9 IK 1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DM8KLU9 IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DM8KLU9 CA CAS 913088-80-9
DM8KLU9 DE Focal seizure
DMGOVHA ID DMGOVHA
DMGOVHA DN Cenobamate
DMGOVHA HS Approved
DMGOVHA SN Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352
DMGOVHA DT Small molecular drug
DMGOVHA PC 11962412
DMGOVHA MW 267.67
DMGOVHA FM C10H10ClN5O2
DMGOVHA IC InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DMGOVHA CS C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
DMGOVHA IK GFHAXPJGXSQLPT-VIFPVBQESA-N
DMGOVHA IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DMGOVHA CA CAS 913088-80-9
DMGOVHA DE Complex partial seizure
DMD5JU8 ID DMD5JU8
DMD5JU8 DN Cephalexin
DMD5JU8 HS Approved
DMD5JU8 SN Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
DMD5JU8 CP Eli Lilly
DMD5JU8 TC Antibiotics
DMD5JU8 DT Small molecular drug
DMD5JU8 PC 27447
DMD5JU8 MW 347.4
DMD5JU8 FM C16H17N3O4S
DMD5JU8 IC InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMD5JU8 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMD5JU8 IK ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
DMD5JU8 IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMD5JU8 CA CAS 15686-71-2
DMD5JU8 CB CHEBI:3534
DMD5JU8 DE Bacterial infection
DMYZITL ID DMYZITL
DMYZITL DN Cephaloglycin
DMYZITL HS Approved
DMYZITL SN CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
DMYZITL TC Antibiotics
DMYZITL DT Small molecular drug
DMYZITL PC 19150
DMYZITL MW 405.4
DMYZITL FM C18H19N3O6S
DMYZITL IC InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1
DMYZITL CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMYZITL IK FUBBGQLTSCSAON-PBFPGSCMSA-N
DMYZITL IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYZITL CA CAS 3577-01-3
DMYZITL CB CHEBI:34613
DMYZITL DE Bacterial infection
DM79XDW ID DM79XDW
DM79XDW DN Cephalosporin
DM79XDW HS Approved
DM79XDW SN Cephalothin (TN)
DM79XDW CP Eli Lilly
DM79XDW TC Antibiotics
DM79XDW DT Small molecular drug
DM79XDW PC 25058126
DM79XDW MW 387.4
DM79XDW FM C15H21N3O7S
DM79XDW IC InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1
DM79XDW CS C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N
DM79XDW IK JGKXEMYIHDYWCZ-JFUSQASVSA-N
DM79XDW IU (2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DM79XDW DE Bacterial infection
DM51Z9E ID DM51Z9E
DM51Z9E DN Cephalothin sodium
DM51Z9E HS Approved
DM51Z9E SN Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin In Plastic Container
DM51Z9E CP Eli Lilly And Co
DM51Z9E TC Antiinfective Agents
DM51Z9E DT Small molecular drug
DM51Z9E PC 23675321
DM51Z9E MW 418.4
DM51Z9E FM C16H15N2NaO6S2
DM51Z9E IC InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1
DM51Z9E CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[Na+]
DM51Z9E IK VUFGUVLLDPOSBC-XRZFDKQNSA-M
DM51Z9E IU sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM51Z9E CA CAS 58-71-9
DM51Z9E CB CHEBI:3542
DM51Z9E DE Bacterial infection
DMV2JNY ID DMV2JNY
DMV2JNY DN Cephapirin
DMV2JNY HS Approved
DMV2JNY SN CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid
DMV2JNY TC Antibiotics
DMV2JNY DT Small molecular drug
DMV2JNY PC 30699
DMV2JNY MW 423.5
DMV2JNY FM C17H17N3O6S2
DMV2JNY IC InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
DMV2JNY CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O
DMV2JNY IK UQLLWWBDSUHNEB-CZUORRHYSA-N
DMV2JNY IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMV2JNY CA CAS 21593-23-7
DMV2JNY CB CHEBI:554446
DMV2JNY DE Sepsis
DM9Y5JB ID DM9Y5JB
DM9Y5JB DN Cepharanthine
DM9Y5JB HS Approved
DM9Y5JB SN CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)
DM9Y5JB PC 10206
DM9Y5JB MW 606.7
DM9Y5JB FM C37H38N2O6
DM9Y5JB IC InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
DM9Y5JB CS CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DM9Y5JB IK YVPXVXANRNDGTA-WDYNHAJCSA-N
DM9Y5JB IU (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DM9Y5JB CA CAS 481-49-2
DM9Y5JB CB CHEBI:3546
DM9Y5JB DE Thrombocytopenia
DMB920Z ID DMB920Z
DMB920Z DN Ceritinib
DMB920Z HS Approved
DMB920Z SN ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
DMB920Z DT Small molecular drug
DMB920Z PC 57379345
DMB920Z MW 558.1
DMB920Z FM C28H36ClN5O3S
DMB920Z IC InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
DMB920Z CS CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
DMB920Z IK VERWOWGGCGHDQE-UHFFFAOYSA-N
DMB920Z IU 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
DMB920Z CA CAS 1032900-25-6
DMB920Z CB CHEBI:78432
DMB920Z DE Non-small-cell lung cancer
DMXCM7H ID DMXCM7H
DMXCM7H DN Cerivastatin
DMXCM7H HS Approved
DMXCM7H SN cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
DMXCM7H DT Small molecular drug
DMXCM7H PC 446156
DMXCM7H MW 459.5
DMXCM7H FM C26H34FNO5
DMXCM7H IC InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
DMXCM7H CS CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
DMXCM7H IK SEERZIQQUAZTOL-ANMDKAQQSA-N
DMXCM7H IU (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMXCM7H CA CAS 145599-86-6
DMXCM7H CB CHEBI:3558
DMXCM7H DE Hyperlipidaemia; Multiple myeloma
DM0HAC8 ID DM0HAC8
DM0HAC8 DN Cerliponase Alfa
DM0HAC8 HS Approved
DM0HAC8 SN Brineura
DM0HAC8 CP BioMarin Pharmaceutical
DM0HAC8 DT Recombinant protein
DM0HAC8 SQ Cerliponase alfa Sequence: SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
DM0HAC8 DE Tripeptidyl peptidase 1 deficiency; Neuronal ceroid lipofuscinosis
DM5CL9Z ID DM5CL9Z
DM5CL9Z DN Certolizumab
DM5CL9Z HS Approved
DM5CL9Z SN CDP-870; Cimzia; PHA-738144; Simziya
DM5CL9Z CP UCB
DM5CL9Z DT Monoclonal antibody
DM5CL9Z DE Rheumatoid arthritis
DMUR94J ID DMUR94J
DMUR94J DN Certoparin sodium
DMUR94J HS Approved
DMUR94J SN Alphaparin (TN)
DMUR94J DE Deep vein thrombosis
DM6N4PR ID DM6N4PR
DM6N4PR DN Cerulenin
DM6N4PR HS Approved
DM6N4PR SN Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide
DM6N4PR TC Antiinfective Agents
DM6N4PR DT Small molecular drug
DM6N4PR PC 5282054
DM6N4PR MW 223.27
DM6N4PR FM C12H17NO3
DM6N4PR IC InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1
DM6N4PR CS C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N
DM6N4PR IK GVEZIHKRYBHEFX-NQQPLRFYSA-N
DM6N4PR IU (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide
DM6N4PR CA CAS 17397-89-6
DM6N4PR CB CHEBI:171741
DM6N4PR DE Weight loss
DM2WE5K ID DM2WE5K
DM2WE5K DN Ceruletide
DM2WE5K HS Approved
DM2WE5K SN Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
DM2WE5K CP Pharmacia And Upjohn Co
DM2WE5K TC Diagnostic Agents
DM2WE5K DT Small molecular drug
DM2WE5K PC 16129675
DM2WE5K MW 1352.4
DM2WE5K FM C58H73N13O21S2
DM2WE5K IC InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1
DM2WE5K CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O
DM2WE5K IK YRALAIOMGQZKOW-HYAOXDFASA-N
DM2WE5K IU (3S)-3-[[(2S)-5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DM2WE5K CA CAS 17650-98-5
DM2WE5K CB CHEBI:59219
DM2WE5K DE Caerulein stimulated gastric and pancreatic secretion; Solid tumour/cancer
DMOMP9U ID DMOMP9U
DMOMP9U DN Cetirizine
DMOMP9U HS Approved
DMOMP9U SN Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CP Pfizer Pharmaceuticals
DMOMP9U TC Antiallergic Agents
DMOMP9U DT Small molecular drug
DMOMP9U PC 2678
DMOMP9U MW 388.9
DMOMP9U FM C21H25ClN2O3
DMOMP9U IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
DMOMP9U CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMOMP9U IK ZKLPARSLTMPFCP-UHFFFAOYSA-N
DMOMP9U IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CA CAS 83881-51-0
DMOMP9U CB CHEBI:3561
DMOMP9U DE Allergic rhinitis
DMSP4JX ID DMSP4JX
DMSP4JX DN Cetraxate
DMSP4JX HS Approved
DMSP4JX SN Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006
DMSP4JX CP Daiichi Seiyaku Co Ltd
DMSP4JX DT Small molecular drug
DMSP4JX PC 2680
DMSP4JX MW 305.4
DMSP4JX FM C17H23NO4
DMSP4JX IC InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20)
DMSP4JX CS C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O
DMSP4JX IK FHRSHSOEWXUORL-UHFFFAOYSA-N
DMSP4JX IU 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
DMSP4JX CA CAS 34675-84-8
DMSP4JX CB CHEBI:17340
DMSP4JX DE Peptic ulcer
DMFD9Q6 ID DMFD9Q6
DMFD9Q6 DN Cetrorelix
DMFD9Q6 HS Approved
DMFD9Q6 SN Cetrorelixum; Cetrorelix (INN); Cetrotide (TN); HS-2008; Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
DMFD9Q6 CP Merck Serono
DMFD9Q6 TC Infertility Agents
DMFD9Q6 DT Small molecular drug
DMFD9Q6 PC 25074887
DMFD9Q6 MW 1431
DMFD9Q6 FM C70H92ClN17O14
DMFD9Q6 IC InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1
DMFD9Q6 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMFD9Q6 IK SBNPWPIBESPSIF-MHWMIDJBSA-N
DMFD9Q6 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFD9Q6 CA CAS 120287-85-6
DMFD9Q6 CB CHEBI:59224
DMFD9Q6 DE Ovarian stimulation
DMLNCE0 ID DMLNCE0
DMLNCE0 DN Cetuximab
DMLNCE0 HS Approved
DMLNCE0 SN Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
DMLNCE0 CP Bristol-Myers Squibb
DMLNCE0 TC Anticancer Agents
DMLNCE0 DT Antibody
DMLNCE0 SQ Cetuximab heavy chain: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Cetuximab light chainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMLNCE0 DE Colorectal cancer
DMWSMND ID DMWSMND
DMWSMND DN Cevimeline
DMWSMND HS Approved
DMWSMND SN Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
DMWSMND CP Daiichi Sankyo Pharma Development
DMWSMND TC Parasympathomimetics
DMWSMND DT Small molecular drug
DMWSMND PC 83898
DMWSMND MW 199.32
DMWSMND FM C10H17NOS
DMWSMND IC InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
DMWSMND CS C[C@@H]1O[C@]2(CN3CCC2CC3)CS1
DMWSMND IK WUTYZMFRCNBCHQ-PSASIEDQSA-N
DMWSMND IU (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
DMWSMND CA CAS 107233-08-9
DMWSMND DE Sjogren syndrome
DMKN345 ID DMKN345
DMKN345 DN Charybdotoxin
DMKN345 HS Approved
DMKN345 SN ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus
DMKN345 DT Small molecular drug
DMKN345 PC 56842037
DMKN345 MW 4296
DMKN345 FM C176H277N57O55S7
DMKN345 IC InChI=1S/C176H277N57O55S7/c1-81(2)58-106-149(263)213-110(62-91-67-191-80-197-91)152(266)215-112(64-127(183)246)156(270)231-135(85(8)240)170(284)219-114(69-234)157(271)200-95(36-25-54-192-174(185)186)138(252)196-68-130(249)199-96(32-17-21-50-177)139(253)222-120-75-291-295-79-124(226-159(273)116(71-236)218-167(281)132(82(3)4)228-155(269)113(65-128(184)247)216-169(283)134(84(7)239)230-154(268)108(59-88-28-13-12-14-29-88)210-145(259)102-44-47-129(248)198-102)166(280)232-137(87(10)242)172(286)233-136(86(9)241)171(285)220-115(70-235)158(272)204-98(34-19-23-52-179)141(255)206-104(45-48-131(250)251)147(261)225-122-77-292-290-74-119(223-143(257)99(35-20-24-53-180)201-140(254)97(33-18-22-51-178)203-153(267)111(63-126(182)245)214-148(262)105(49-57-289-11)208-162(120)276)161(275)205-101(38-27-56-194-176(189)190)144(258)224-121(164(278)211-107(60-89-39-41-92(243)42-40-89)150(264)221-118(73-238)173(287)288)76-293-294-78-123(163(277)207-103(43-46-125(181)244)146(260)202-100(142(256)209-106)37-26-55-193-175(187)188)227-168(282)133(83(5)6)229-160(274)117(72-237)217-151(265)109(212-165(122)279)61-90-66-195-94-31-16-15-30-93(90)94/h12-16,28-31,39-42,66-67,80-87,95-124,132-137,195,234-243H,17-27,32-38,43-65,68-79,177-180H2,1-11H3,(H2,181,244)(H2,182,245)(H2,183,246)(H2,184,247)(H,191,197)(H,196,252)(H,198,248)(H,199,249)(H,200,271)(H,201,254)(H,202,260)(H,203,267)(H,204,272)(H,205,275)(H,206,255)(H,207,277)(H,208,276)(H,209,256)(H,210,259)(H,211,278)(H,212,279)(H,213,263)(H,214,262)(H,215,266)(H,216,283)(H,217,265)(H,218,281)(H,219,284)(H,220,285)(H,221,264)(H,222,253)(H,223,257)(H,224,258)(H,225,261)(H,226,273)(H,227,282)(H,228,269)(H,229,274)(H,230,268)(H,231,270)(H,232,280)(H,233,286)(H,250,251)(H,287,288)(H4,185,186,192)(H4,187,188,193)(H4,189,190,194)/t84-,85-,86-,87-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+/m1/s1
DMKN345 CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCCN)CCCCN)CC(=O)N)CCSC)CCCCN)CCCNC(=N)N)CO)[C@@H](C)O)CC(=O)N)CC6=CN=CN6)CC(C)C)CCCNC(=N)N)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC7=CNC8=CC=CC=C87)CO)C(C)C)C(=O)N[C@@H](CC9=CC=C(C=C9)O)C(=O)N[C@@H](CO)C(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CO)[C@@H](C)O)O
DMKN345 IK CNVQLPPZGABUCM-LIGYZCPXSA-N
DMKN345 IU (2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(1R,4S,7R,12R,15S,18S,21S,24S,27S,30S,33S,36S,42S,45R,50R,53S,56S,59S,62S,65S,68R,75S,78S,81S,84S,89S,92S,95S)-42,62,75,78-tetrakis(4-aminobutyl)-50-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-27,81-bis(2-amino-2-oxoethyl)-15-(3-amino-3-oxopropyl)-4,18,36-tris(3-carbamimidamidopropyl)-65-(2-carboxyethyl)-30,53,56-tris[(1R)-1-hydroxyethyl]-33,59,92-tris(hydroxymethyl)-24-(1H-imidazol-5-ylmethyl)-89-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-84-(2-methylsulfanylethyl)-2,5,13,16,19,22,25,28,31,34,37,40,43,51,54,57,60,63,66,74,77,80,83,86,87,90,93,96-octacosaoxo-95-propan-2-yl-9,10,47,48,70,71-hexathia-3,6,14,17,20,23,26,29,32,35,38,41,44,52,55,58,61,64,67,73,76,79,82,85,88,91,94,97-octacosazatricyclo[43.27.14.1112,68]heptanonacontane-7-carbonyl]amino]propanoyl]amino]propanoic acid
DMKN345 CA CAS 95751-30-7
DMKN345 DE Scorpion envenoming syndrome
DMQ8JIK ID DMQ8JIK
DMQ8JIK DN Chenodiol
DMQ8JIK HS Approved
DMQ8JIK SN 474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum
DMQ8JIK CP Sigma Tau Pharmaceuticals Inc
DMQ8JIK DT Small molecular drug
DMQ8JIK PC 10133
DMQ8JIK MW 392.6
DMQ8JIK FM C24H40O4
DMQ8JIK IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
DMQ8JIK CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMQ8JIK IK RUDATBOHQWOJDD-BSWAIDMHSA-N
DMQ8JIK IU (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMQ8JIK CA CAS 474-25-9
DMQ8JIK CB CHEBI:16755
DMQ8JIK DE Cholelithiasis
DMXGJEI ID DMXGJEI
DMXGJEI DN Chlophedianol
DMXGJEI HS Approved
DMXGJEI SN Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]
DMXGJEI CP 3m Pharmaceuticals Inc
DMXGJEI TC Anesthetics
DMXGJEI DT Small molecular drug
DMXGJEI PC 2795
DMXGJEI MW 289.8
DMXGJEI FM C17H20ClNO
DMXGJEI IC InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
DMXGJEI CS CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O
DMXGJEI IK WRCHFMBCVFFYEQ-UHFFFAOYSA-N
DMXGJEI IU 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
DMXGJEI CA CAS 791-35-5
DMXGJEI CB CHEBI:135207
DMXGJEI DE Dry cough; Anaesthesia
DMRKE63 ID DMRKE63
DMRKE63 DN Chlorambucil
DMRKE63 HS Approved
DMRKE63 SN Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)
DMRKE63 CP GlaxoSmithKline
DMRKE63 TC Anticancer Agents
DMRKE63 DT Small molecular drug
DMRKE63 PC 2708
DMRKE63 MW 304.2
DMRKE63 FM C14H19Cl2NO2
DMRKE63 IC InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
DMRKE63 CS C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
DMRKE63 IK JCKYGMPEJWAADB-UHFFFAOYSA-N
DMRKE63 IU 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
DMRKE63 CA CAS 305-03-3
DMRKE63 CB CHEBI:28830
DMRKE63 DE Chronic lymphocytic leukaemia
DMFXEWT ID DMFXEWT
DMFXEWT DN Chloramphenicol
DMFXEWT HS Approved
DMFXEWT SN Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol
DMFXEWT CP Aventis Pharmaceuticals Inc.
DMFXEWT TC Antibiotics
DMFXEWT DT Small molecular drug
DMFXEWT PC 5959
DMFXEWT MW 323.13
DMFXEWT FM C11H12Cl2N2O5
DMFXEWT IC InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
DMFXEWT CS C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
DMFXEWT IK WIIZWVCIJKGZOK-RKDXNWHRSA-N
DMFXEWT IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
DMFXEWT CA CAS 56-75-7
DMFXEWT CB CHEBI:17698
DMFXEWT DE Bacterial infection
DMTN5XI ID DMTN5XI
DMTN5XI DN Chlordiazepoxide
DMTN5XI HS Approved
DMTN5XI SN Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CP Patheon Pharmaceuticals Inc
DMTN5XI TC Antianxiety Agents
DMTN5XI DT Small molecular drug
DMTN5XI PC 2712
DMTN5XI MW 299.75
DMTN5XI FM C16H14ClN3O
DMTN5XI IC InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3
DMTN5XI CS CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
DMTN5XI IK BUCORZSTKDOEKQ-UHFFFAOYSA-N
DMTN5XI IU 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CA CAS 58-25-3
DMTN5XI CB CHEBI:3611
DMTN5XI DE Anxiety disorder
DMQ9MVG ID DMQ9MVG
DMQ9MVG DN Chlorhexidine
DMQ9MVG HS Approved
DMQ9MVG SN AVAGARD; Chlorhexidin; Chlorhexidinum; Cloresidina; Clorhexidina; Fimeil; Hexadol; Hibiclens; Hibispray; Hibistat;Nolvasan; Novalsan; Peridex; Periogard; Rotersept; Savloclens; Soretol; Sterido; Sterilon; Superspray; Tubulicid; Chlorhexidin [Czech]; Chlorhexidine Base; Chlorhexidine gluconate; Cloresidina [DCIT]; Decanoylacetaldehyde Sodium Sulfide; Dentisept [veterinary]; Savlon babycare; Sebidin A; Sodium Houttuyfonamide; Avagard (TN); BIOPATCH (TN); ChloraPrep (TN); Chlorhexamed (TN); Chlorhexidine (INN);Chlorhexidine [INN:BAN]; Chlorhexidinum [INN-Latin]; Chlorohex (TN); Clohex (TN); Clorexil (TN); Clorhexidina [INN-Spanish]; Corsodyl (TN); Dentisept [veterinary] (TN); Dexidin (TN); Exidine (TN); Hibiclens (TN); Hibiscrub (TN); MK-412A; Merfen-incolore; Oro-Clense; Oronine (TN); Perichlor (TN); Peridex (TN); Peridont (TN); Periochip (TN); Periogard Oral Rinse (TN); Perioxidina (TN); Savacol (TN); Suthol (TN); Dejavu-MW (TN); Merfen-incolore (TN); Lisium (*Dihydrochloride*); Nolvasan (*Diacetate*); SOLU-I.V (TN); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca-nediimidamide; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; 1,6-Di(N-p-chlorophenyldiguanido)hexane
DMQ9MVG CP G. D. Pharmaceuticals
DMQ9MVG TC Antibiotics
DMQ9MVG DT Small molecular drug
DMQ9MVG PC 9552079
DMQ9MVG MW 505.4
DMQ9MVG FM C22H30Cl2N10
DMQ9MVG IC InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)
DMQ9MVG CS C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl
DMQ9MVG IK GHXZTYHSJHQHIJ-UHFFFAOYSA-N
DMQ9MVG IU (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
DMQ9MVG CA CAS 55-56-1
DMQ9MVG CB CHEBI:3614
DMQ9MVG DE Bacterial infection
DMSF4PR ID DMSF4PR
DMSF4PR DN Chlormerodrin
DMSF4PR HS Approved
DMSF4PR SN Chlormerodrina; Chloromeridin; Neogidrin; Chlormerodrin Hg 197; Chlormerodrin Hg 203; Chlormerodrin (197Hg); Chlormerodrin (203Hg); Chlormerodrin Hg 197 (TN); Chlormerodrin Hg 197 (USAN); Chlormerodrin Hg 197 [USAN:USP XX]; Chlormerodrin Hg 203 (USAN); Hg-203 chlormerodrin; Loro-}; Neohydrin-203; Chlormerodrin (197Hg) (INN); Neohydrin-203 (TN); Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Urea, (2-methoxypropyl)-, mercury complex; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203; Chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; (3-(Chloromercuri)-2-methoxypropyl)urea; 3-Chloromercuri-2-methoxypropylurea; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride
DMSF4PR TC Diagnostic Agents
DMSF4PR DT Small molecular drug
DMSF4PR PC 25210
DMSF4PR MW 367.2
DMSF4PR FM C5H11ClHgN2O2
DMSF4PR IC InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1
DMSF4PR CS COC(CNC(=O)N)C[Hg]Cl
DMSF4PR IK BJFGVYCULWBXKF-UHFFFAOYSA-M
DMSF4PR IU [3-(carbamoylamino)-2-methoxypropyl]-chloromercury
DMSF4PR CA CAS 10375-56-1
DMSF4PR CB CHEBI:59445
DMSF4PR DE Diagnostic imaging
DMTWUXR ID DMTWUXR
DMTWUXR DN Chlormezanone
DMTWUXR HS Approved
DMTWUXR SN Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide
DMTWUXR TC Analgesics
DMTWUXR DT Small molecular drug
DMTWUXR PC 2717
DMTWUXR MW 273.74
DMTWUXR FM C11H12ClNO3S
DMTWUXR IC InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
DMTWUXR CS CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl
DMTWUXR IK WEQAYVWKMWHEJO-UHFFFAOYSA-N
DMTWUXR IU 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
DMTWUXR CA CAS 80-77-3
DMTWUXR CB CHEBI:3619
DMTWUXR DE Anxiety disorder
DMSOQK1 ID DMSOQK1
DMSOQK1 DN Chloroprocaine
DMSOQK1 HS Approved
DMSOQK1 SN Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester
DMSOQK1 CP Abbott Laboratories
DMSOQK1 TC Anesthetics
DMSOQK1 DT Small molecular drug
DMSOQK1 PC 8612
DMSOQK1 MW 270.75
DMSOQK1 FM C13H19ClN2O2
DMSOQK1 IC InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
DMSOQK1 CS CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl
DMSOQK1 IK VDANGULDQQJODZ-UHFFFAOYSA-N
DMSOQK1 IU 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
DMSOQK1 CA CAS 133-16-4
DMSOQK1 CB CHEBI:3636
DMSOQK1 DE Anaesthesia
DMSI5CB ID DMSI5CB
DMSI5CB DN Chloroquine
DMSI5CB HS Approved
DMSI5CB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMSI5CB CP Medreich Sterilab Ltd
DMSI5CB TC Antimalarials
DMSI5CB DT Small molecular drug
DMSI5CB PC 2719
DMSI5CB MW 319.9
DMSI5CB FM C18H26ClN3
DMSI5CB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMSI5CB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMSI5CB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMSI5CB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMSI5CB CA CAS 54-05-7
DMSI5CB CB CHEBI:3638
DMSI5CB DE Malaria
DMLHESP ID DMLHESP
DMLHESP DN Chlorothiazide
DMLHESP HS Approved
DMLHESP SN Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMLHESP CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMLHESP TC Antihypertensive Agents
DMLHESP DT Small molecular drug
DMLHESP PC 2720
DMLHESP MW 295.7
DMLHESP FM C7H6ClN3O4S2
DMLHESP IC InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
DMLHESP CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
DMLHESP IK JBMKAUGHUNFTOL-UHFFFAOYSA-N
DMLHESP IU 6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMLHESP CA CAS 58-94-6
DMLHESP CB CHEBI:3640
DMLHESP DE Congestive heart failure
DMFZBMQ ID DMFZBMQ
DMFZBMQ DN Chloroxine
DMFZBMQ HS Approved
DMFZBMQ SN chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2
DMFZBMQ DT Small molecular drug
DMFZBMQ PC 2722
DMFZBMQ MW 214.04
DMFZBMQ FM C9H5Cl2NO
DMFZBMQ IC InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DMFZBMQ CS C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1
DMFZBMQ IK WDFKMLRRRCGAKS-UHFFFAOYSA-N
DMFZBMQ IU 5,7-dichloroquinolin-8-ol
DMFZBMQ CA CAS 773-76-2
DMFZBMQ CB CHEBI:59477
DMFZBMQ DE Erythema
DM5URA2 ID DM5URA2
DM5URA2 DN Chlorpheniramine
DM5URA2 HS Approved
DM5URA2 SN Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
DM5URA2 CP Schering-Plough Corporation
DM5URA2 TC Antiallergic Agents
DM5URA2 DT Small molecular drug
DM5URA2 PC 2725
DM5URA2 MW 274.79
DM5URA2 FM C16H19ClN2
DM5URA2 IC InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DM5URA2 CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM5URA2 IK SOYKEARSMXGVTM-UHFFFAOYSA-N
DM5URA2 IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM5URA2 CA CAS 113-92-8
DM5URA2 CB CHEBI:52010
DM5URA2 DE Allergic rhinitis
DMQRPOS ID DMQRPOS
DMQRPOS DN Chlorphentermine hydrochloride
DMQRPOS HS Approved
DMQRPOS SN Pre-sate
DMQRPOS CP Parke Davis Div Warner Lambert Co
DMQRPOS DT Small molecular drug
DMQRPOS PC 65477
DMQRPOS MW 220.14
DMQRPOS FM C10H15Cl2N
DMQRPOS IC InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H
DMQRPOS CS CC(C)(CC1=CC=C(C=C1)Cl)N.Cl
DMQRPOS IK WEJDYJKJPUPMLH-UHFFFAOYSA-N
DMQRPOS IU 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride
DMQRPOS CA CAS 151-06-4
DMQRPOS DE Appetite suppressant
DM1IFGT ID DM1IFGT
DM1IFGT DN Chlorproguanil
DM1IFGT HS Approved
DM1IFGT SN Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide
DM1IFGT DT Small molecular drug
DM1IFGT PC 9571037
DM1IFGT MW 288.17
DM1IFGT FM C11H15Cl2N5
DM1IFGT IC InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
DM1IFGT CS CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl
DM1IFGT IK ISZNZKHCRKXXAU-UHFFFAOYSA-N
DM1IFGT IU (1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine
DM1IFGT CA CAS 537-21-3
DM1IFGT CB CHEBI:135192
DM1IFGT DE Malaria
DMBGZI3 ID DMBGZI3
DMBGZI3 DN Chlorpromazine
DMBGZI3 HS Approved
DMBGZI3 SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DMBGZI3 CP GlaxoSmithKline
DMBGZI3 TC Antipsychotic Agents
DMBGZI3 DT Small molecular drug
DMBGZI3 PC 2726
DMBGZI3 MW 318.9
DMBGZI3 FM C17H19ClN2S
DMBGZI3 IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DMBGZI3 CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMBGZI3 IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DMBGZI3 IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DMBGZI3 CA CAS 34468-21-8
DMBGZI3 CB CHEBI:3647
DMBGZI3 DE Schizophrenia
DMPHZQE ID DMPHZQE
DMPHZQE DN Chlorpropamide
DMPHZQE HS Approved
DMPHZQE SN Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
DMPHZQE TC Hypoglycemic Agents
DMPHZQE DT Small molecular drug
DMPHZQE PC 2727
DMPHZQE MW 276.74
DMPHZQE FM C10H13ClN2O3S
DMPHZQE IC InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
DMPHZQE CS CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
DMPHZQE IK RKWGIWYCVPQPMF-UHFFFAOYSA-N
DMPHZQE IU 1-(4-chlorophenyl)sulfonyl-3-propylurea
DMPHZQE CA CAS 94-20-2
DMPHZQE CB CHEBI:3650
DMPHZQE DE Non-insulin dependent diabetes
DMY0KGJ ID DMY0KGJ
DMY0KGJ DN Chlorprothixene
DMY0KGJ HS Approved
DMY0KGJ SN Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ TC Antipsychotic Agents
DMY0KGJ DT Small molecular drug
DMY0KGJ PC 667467
DMY0KGJ MW 315.9
DMY0KGJ FM C18H18ClNS
DMY0KGJ IC InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
DMY0KGJ CS CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMY0KGJ IK WSPOMRSOLSGNFJ-AUWJEWJLSA-N
DMY0KGJ IU (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ CA CAS 113-59-7
DMY0KGJ CB CHEBI:50931
DMY0KGJ DE Psychotic disorder
DM4DMBT ID DM4DMBT
DM4DMBT DN Chlorthalidone
DM4DMBT HS Approved
DM4DMBT SN Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
DM4DMBT TC Antihypertensive Agents
DM4DMBT DT Small molecular drug
DM4DMBT PC 2732
DM4DMBT MW 338.8
DM4DMBT FM C14H11ClN2O4S
DM4DMBT IC InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
DM4DMBT CS C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
DM4DMBT IK JIVPVXMEBJLZRO-UHFFFAOYSA-N
DM4DMBT IU 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
DM4DMBT CA CAS 77-36-1
DM4DMBT CB CHEBI:3654
DM4DMBT DE Edema; Hypertension
DMCYVDT ID DMCYVDT
DMCYVDT DN Chlorzoxazone
DMCYVDT HS Approved
DMCYVDT SN Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one
DMCYVDT TC Analgesics
DMCYVDT DT Small molecular drug
DMCYVDT PC 2733
DMCYVDT MW 169.56
DMCYVDT FM C7H4ClNO2
DMCYVDT IC InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
DMCYVDT CS C1=CC2=C(C=C1Cl)NC(=O)O2
DMCYVDT IK TZFWDZFKRBELIQ-UHFFFAOYSA-N
DMCYVDT IU 5-chloro-3H-1,3-benzoxazol-2-one
DMCYVDT CA CAS 95-25-0
DMCYVDT CB CHEBI:3655
DMCYVDT DE Acute pain
DMGU74E ID DMGU74E
DMGU74E DN Cholecalciferol
DMGU74E HS Approved
DMGU74E SN Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
DMGU74E TC Vitamins
DMGU74E DT Small molecular drug
DMGU74E PC 5280795
DMGU74E MW 384.6
DMGU74E FM C27H44O
DMGU74E IC InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMGU74E CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMGU74E IK QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMGU74E IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMGU74E CA CAS 67-97-0
DMGU74E CB CHEBI:28940
DMGU74E DE Vitamin D deficiency
DM7OKQV ID DM7OKQV
DM7OKQV DN Cholic acid
DM7OKQV HS Approved
DM7OKQV SN cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV DT Small molecular drug
DM7OKQV PC 221493
DM7OKQV MW 408.6
DM7OKQV FM C24H40O5
DM7OKQV IC InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
DM7OKQV CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM7OKQV IK BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV IU (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM7OKQV CA CAS 81-25-4
DM7OKQV CB CHEBI:16359
DM7OKQV DE Synthesis disorder; Peroxisomal disorder
DMOI1ZF ID DMOI1ZF
DMOI1ZF DN Choline alfoscerate
DMOI1ZF HS Approved
DMOI1ZF SN Delecit (TN)
DMOI1ZF DT Small molecular drug
DMOI1ZF PC 657272
DMOI1ZF MW 257.22
DMOI1ZF FM C8H20NO6P
DMOI1ZF IC InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMOI1ZF CS C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
DMOI1ZF IK SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMOI1ZF IU [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOI1ZF CA CAS 28319-77-9
DMOI1ZF CB CHEBI:16870
DMOI1ZF DE Amnesia
DM8P137 ID DM8P137
DM8P137 DN Choline salicylate
DM8P137 HS Approved
DM8P137 SN 2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1)
DM8P137 DT Small molecular drug
DM8P137 PC 54686350
DM8P137 MW 241.28
DM8P137 FM C12H19NO4
DM8P137 IC InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1
DM8P137 CS C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-]
DM8P137 IK UDKCHVLMFQVBAA-UHFFFAOYSA-M
DM8P137 IU 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium
DM8P137 CA CAS 2016-36-6
DM8P137 CB CHEBI:3668
DM8P137 DE Inflammation
DMFMZ3G ID DMFMZ3G
DMFMZ3G DN Choriogonadotropin alfa
DMFMZ3G HS Approved
DMFMZ3G TC Fertility Agents
DMFMZ3G SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMFMZ3G DE Female infertility
DMFT73E ID DMFT73E
DMFT73E DN Chorionic Gonadotropin
DMFT73E HS Approved
DMFT73E SN A.P.L.; Chorionic Gonadotropin; Follutein; Pregnyl
DMFT73E CP Ferring Pharmaceuticals Inc
DMFT73E DE Fertility problem
DM2NA4K ID DM2NA4K
DM2NA4K DN Ciclesonide
DM2NA4K HS Approved
DM2NA4K SN Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
DM2NA4K CP Altana Pharma
DM2NA4K TC Antiallergic Agents
DM2NA4K DT Small molecular drug
DM2NA4K PC 6918155
DM2NA4K MW 540.7
DM2NA4K FM C32H44O7
DM2NA4K IC InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
DM2NA4K CS CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6
DM2NA4K IK LUKZNWIVRBCLON-GXOBDPJESA-N
DM2NA4K IU [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
DM2NA4K CA CAS 126544-47-6
DM2NA4K CB CHEBI:31397
DM2NA4K DE Obstructive airway disease; Asthma
DMN5T2A ID DMN5T2A
DMN5T2A DN Ciclopirox
DMN5T2A HS Approved
DMN5T2A SN Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A TC Antifungal Agents
DMN5T2A DT Small molecular drug
DMN5T2A PC 2749
DMN5T2A MW 207.27
DMN5T2A FM C12H17NO2
DMN5T2A IC InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
DMN5T2A CS CC1=CC(=O)N(C(=C1)C2CCCCC2)O
DMN5T2A IK SCKYRAXSEDYPSA-UHFFFAOYSA-N
DMN5T2A IU 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A CA CAS 29342-05-0
DMN5T2A CB CHEBI:453011
DMN5T2A DE Fungal infection
DMAZJFX ID DMAZJFX
DMAZJFX DN Ciclosporin
DMAZJFX HS Approved
DMAZJFX SN Ciclosporin; Ciclosporin (Ciclosporin A); Ciclosporina; Ciclosporina [INN-Spanish]; Ciclosporine; Ciclosporine [INN-French]; Ciclosporinum; Ciclosporinum [INN-Latin]; Cipol N; Consupren; Cyclosporin; Cyclosporine A; Equoral; Antibiotic S 7481F1; Gengraf; Neoplanta; Neoral; Ramihyphin A; Restasis; S-Neoral; Sandimmun; Sandimmun Neoral; Sandimmune; Sang 35; Sang-35; SangCyA; Sigmasporin Microoral; cyclosporin A; cyclosporine; 59865-13-3; 83HN0GTJ6D; CHEBI:4031; CSA; DSSTox_CID_365; DSSTox_RID_75541; MFCD00274558; MLS001333756; UNII-83HN0GTJ6D
DMAZJFX PC 5284373
DMAZJFX MW 1202.6
DMAZJFX FM C62H111N11O12
DMAZJFX IC PMATZTZNYRCHOR-CGLBZJNRSA-N
DMAZJFX CS CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMAZJFX IK 1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
DMAZJFX IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMAZJFX CA CAS 59865-13-3
DMAZJFX CB CHEBI:4031
DMAZJFX DE Viral hepatitis
DMT2KRV ID DMT2KRV
DMT2KRV DN Ciclosporin
DMT2KRV HS Approved
DMT2KRV SN Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMT2KRV CP Sandoz
DMT2KRV TC Immunosuppressive Agents
DMT2KRV DT Protein/peptide drug
DMT2KRV PC 24883466
DMT2KRV MW 1202.6
DMT2KRV FM C62H111N11O12
DMT2KRV IC InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMT2KRV CS CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMT2KRV IK PMATZTZNYRCHOR-VJRYSDSKSA-N
DMT2KRV IU (3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMT2KRV CA CAS 59865-13-3
DMT2KRV DE Psoriasis vulgaris; Xerophthalmia; Brain injury
DMA13GD ID DMA13GD
DMA13GD DN Cidofovir
DMA13GD HS Approved
DMA13GD SN CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
DMA13GD CP Pfizer Pharmaceuticals
DMA13GD TC Anti-HIV Agents
DMA13GD DT Small molecular drug
DMA13GD PC 60613
DMA13GD MW 279.19
DMA13GD FM C8H14N3O6P
DMA13GD IC InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
DMA13GD CS C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
DMA13GD IK VWFCHDSQECPREK-LURJTMIESA-N
DMA13GD IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
DMA13GD CA CAS 113852-37-2
DMA13GD CB CHEBI:3696
DMA13GD DE Cytomegalovirus infection
DME2H5T ID DME2H5T
DME2H5T DN Cilastatin
DME2H5T HS Approved
DME2H5T SN Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CP Merck
DME2H5T TC Antibiotics
DME2H5T DT Small molecular drug
DME2H5T PC 6435415
DME2H5T MW 358.5
DME2H5T FM C16H26N2O5S
DME2H5T IC InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1
DME2H5T CS CC1(C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@@H](C(=O)O)N)/C(=O)O)C
DME2H5T IK DHSUYTOATWAVLW-WFVMDLQDSA-N
DME2H5T IU (Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CA CAS 82009-34-5
DME2H5T CB CHEBI:3697
DME2H5T DE Bacterial infection
DM4V6JA ID DM4V6JA
DM4V6JA DN Cilazapril
DM4V6JA HS Approved
DM4V6JA SN Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate
DM4V6JA TC Antihypertensive Agents
DM4V6JA DT Small molecular drug
DM4V6JA PC 56330
DM4V6JA MW 417.5
DM4V6JA FM C22H31N3O5
DM4V6JA IC InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
DM4V6JA CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O
DM4V6JA IK HHHKFGXWKKUNCY-FHWLQOOXSA-N
DM4V6JA IU (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
DM4V6JA CA CAS 88768-40-5
DM4V6JA CB CHEBI:3698
DM4V6JA DE Congestive heart failure
DMZMSCT ID DMZMSCT
DMZMSCT DN Cilostazol
DMZMSCT HS Approved
DMZMSCT SN cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
DMZMSCT CP Otsuka Pharmaceutical Co
DMZMSCT TC Vasodilator Agents
DMZMSCT DT Small molecular drug
DMZMSCT PC 2754
DMZMSCT MW 369.5
DMZMSCT FM C20H27N5O2
DMZMSCT IC InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
DMZMSCT CS C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
DMZMSCT IK RRGUKTPIGVIEKM-UHFFFAOYSA-N
DMZMSCT IU 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
DMZMSCT CA CAS 73963-72-1
DMZMSCT CB CHEBI:31401
DMZMSCT DE Intermittent claudication
DMH61ZB ID DMH61ZB
DMH61ZB DN Cimetidine
DMH61ZB HS Approved
DMH61ZB SN Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
DMH61ZB CP GlaxoSmithKline
DMH61ZB TC Antiulcer Agents
DMH61ZB DT Small molecular drug
DMH61ZB PC 2756
DMH61ZB MW 252.34
DMH61ZB FM C10H16N6S
DMH61ZB IC InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
DMH61ZB CS CC1=C(N=CN1)CSCCNC(=NC)NC#N
DMH61ZB IK AQIXAKUUQRKLND-UHFFFAOYSA-N
DMH61ZB IU 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMH61ZB CA CAS 51481-61-9
DMH61ZB CB CHEBI:3699
DMH61ZB DE Acid-reflux disorder
DMZHPNE ID DMZHPNE
DMZHPNE DN Cimetropium bromide
DMZHPNE HS Approved
DMZHPNE SN Alginor (TN)
DMZHPNE CP DeAngelini
DMZHPNE DT Small molecular drug
DMZHPNE PC 20054870
DMZHPNE MW 438.4
DMZHPNE FM C21H28BrNO4
DMZHPNE IC InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1
DMZHPNE CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5.[Br-]
DMZHPNE IK WDURTRGFUGAJHA-HNHWXVNLSA-M
DMZHPNE IU [(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMZHPNE CA CAS 51598-60-8
DMZHPNE DE Spasm; Gastric motility disorder
DMCX0K3 ID DMCX0K3
DMCX0K3 DN Cinacalcet
DMCX0K3 HS Approved
DMCX0K3 SN Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
DMCX0K3 CP Amgen
DMCX0K3 TC Calcimimetics
DMCX0K3 DT Small molecular drug
DMCX0K3 PC 156419
DMCX0K3 MW 357.4
DMCX0K3 FM C22H22F3N
DMCX0K3 IC InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
DMCX0K3 CS C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
DMCX0K3 IK VDHAWDNDOKGFTD-MRXNPFEDSA-N
DMCX0K3 IU N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
DMCX0K3 CA CAS 226256-56-0
DMCX0K3 CB CHEBI:48390
DMCX0K3 DE Hyperparathyroidism; Kidney disease
DMFIC0M ID DMFIC0M
DMFIC0M DN Cinalukast
DMFIC0M HS Approved
DMFIC0M SN Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M TC Antiarrhythmic Agents
DMFIC0M DT Small molecular drug
DMFIC0M PC 6436135
DMFIC0M MW 412.5
DMFIC0M FM C23H28N2O3S
DMFIC0M IC InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
DMFIC0M CS CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C3CCC3)C(=O)O
DMFIC0M IK BZMKNPGKXJAIDV-VAWYXSNFSA-N
DMFIC0M IU 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M CA CAS 128312-51-6
DMFIC0M CB CHEBI:126598
DMFIC0M DE Asthma
DM7U5QJ ID DM7U5QJ
DM7U5QJ DN Cinnarizine
DM7U5QJ HS Approved
DM7U5QJ SN Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine
DM7U5QJ CP Janssen Pharmaceutica
DM7U5QJ TC Antiallergic Agents
DM7U5QJ DT Small molecular drug
DM7U5QJ PC 1547484
DM7U5QJ MW 368.5
DM7U5QJ FM C26H28N2
DM7U5QJ IC InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
DM7U5QJ CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7U5QJ IK DERZBLKQOCDDDZ-JLHYYAGUSA-N
DM7U5QJ IU 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine
DM7U5QJ CA CAS 16699-20-0
DM7U5QJ CB CHEBI:31403
DM7U5QJ DE Vertigo meniere disease
DMDX1ZC ID DMDX1ZC
DMDX1ZC DN Cinolazepam
DMDX1ZC HS Approved
DMDX1ZC SN Cinolazepamum; Gerodorm; Cinolazepam [INN]; OX 373; Cinolazepam (INN); Cinolazepamum [INN-Latin]; Gerodorm (TN); OX-373;1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile
DMDX1ZC TC Anticonvulsants
DMDX1ZC DT Small molecular drug
DMDX1ZC PC 3033621
DMDX1ZC MW 357.8
DMDX1ZC FM C18H13ClFN3O2
DMDX1ZC IC InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
DMDX1ZC CS C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F
DMDX1ZC IK XAXMYHMKTCNRRZ-UHFFFAOYSA-N
DMDX1ZC IU 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile
DMDX1ZC CA CAS 75696-02-5
DMDX1ZC CB CHEBI:59514
DMDX1ZC DE Muscle spasm
DM4EWNS ID DM4EWNS
DM4EWNS DN Cinoxacin
DM4EWNS HS Approved
DM4EWNS SN Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS TC Antiinfective Agents
DM4EWNS DT Small molecular drug
DM4EWNS PC 2762
DM4EWNS MW 262.22
DM4EWNS FM C12H10N2O5
DM4EWNS IC InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
DM4EWNS CS CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
DM4EWNS IK VDUWPHTZYNWKRN-UHFFFAOYSA-N
DM4EWNS IU 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS CA CAS 28657-80-9
DM4EWNS CB CHEBI:3716
DM4EWNS DE Urinary tract infection
DMVIKJZ ID DMVIKJZ
DMVIKJZ DN Cinryze
DMVIKJZ HS Approved
DMVIKJZ DE Hereditary angioedema
DMGC5DB ID DMGC5DB
DMGC5DB DN Ciprofibrate
DMGC5DB HS Approved
DMGC5DB SN Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid
DMGC5DB TC Anticancer Agents
DMGC5DB DT Small molecular drug
DMGC5DB PC 2763
DMGC5DB MW 289.15
DMGC5DB FM C13H14Cl2O3
DMGC5DB IC InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
DMGC5DB CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
DMGC5DB IK KPSRODZRAIWAKH-UHFFFAOYSA-N
DMGC5DB IU 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
DMGC5DB CA CAS 52214-84-3
DMGC5DB CB CHEBI:50867
DMGC5DB DE Hyperlipoproteinemia
DM2NLS9 ID DM2NLS9
DM2NLS9 DN Ciprofloxacin XR
DM2NLS9 HS Approved
DM2NLS9 SN ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
DM2NLS9 CP Depomed Bayer
DM2NLS9 DT Small molecular drug
DM2NLS9 PC 2764
DM2NLS9 MW 331.34
DM2NLS9 FM C17H18FN3O3
DM2NLS9 IC InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
DM2NLS9 CS C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DM2NLS9 IK MYSWGUAQZAJSOK-UHFFFAOYSA-N
DM2NLS9 IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DM2NLS9 CA CAS 85721-33-1
DM2NLS9 CB CHEBI:100241
DM2NLS9 DE Bacterial infection; Gram-positive bacterial infection; Biliary cancer; Cystic fibrosis
DMZR26N ID DMZR26N
DMZR26N DN Ciprofloxacin+dexamethasone
DMZR26N HS Approved
DMZR26N SN CIPRODEX; Ciprofloxacin mixture with dexamethasone; 130244-48-3; Ciprodex Otic; Ciprofloxacin / dexamethasone; Ciprofloxacin and dexamethasone; Ciprofloxacin-dexamethasone Mixt.; SCHEMBL2523572; DTXSID50156420; NTRHYMXQWWPZDD-WKSAPEMMSA-N; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
DMZR26N CP Alcon
DMZR26N DT Small molecular drug
DMZR26N PC 9961920
DMZR26N MW 723.8
DMZR26N FM C39H47F2N3O8
DMZR26N IC InChI=1S/C22H29FO5.C17H18FN3O3/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;7-10,19H,1-6H2,(H,23,24)/t12-,15+,16+,17+,19+,20+,21+,22+;/m1./s1
DMZR26N CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DMZR26N IK NTRHYMXQWWPZDD-WKSAPEMMSA-N
DMZR26N IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZR26N CA CAS 130244-48-3
DMZR26N DE Otitis externa; Acute otitis media
DMY7PED ID DMY7PED
DMY7PED DN Cisapride
DMY7PED HS Approved
DMY7PED SN cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825; Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454
DMY7PED CP Janssen Pharmaceutica
DMY7PED TC Gastrointestinal Agents
DMY7PED DT Small molecular drug
DMY7PED PC 6917698
DMY7PED MW 465.9
DMY7PED FM C23H29ClFN3O4
DMY7PED IC InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
DMY7PED CS CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
DMY7PED IK DCSUBABJRXZOMT-IRLDBZIGSA-N
DMY7PED IU 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
DMY7PED CA CAS 81098-60-4
DMY7PED CB CHEBI:3720
DMY7PED DE Gastroesophageal reflux disease; Gastrointestinal disease
DMUZPJ5 ID DMUZPJ5
DMUZPJ5 DN Cisatracurium
DMUZPJ5 HS Approved
DMUZPJ5 SN Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free
DMUZPJ5 CP Abbvie Inc
DMUZPJ5 DT Small molecular drug
DMUZPJ5 PC 62887
DMUZPJ5 MW 929.1
DMUZPJ5 FM C53H72N2O12+2
DMUZPJ5 IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
DMUZPJ5 CS C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DMUZPJ5 IK YXSLJKQTIDHPOT-LJCJQEJUSA-N
DMUZPJ5 IU 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DMUZPJ5 CA CAS 96946-41-7
DMUZPJ5 CB CHEBI:140621
DMUZPJ5 DE Muscle spasm
DMRHGI9 ID DMRHGI9
DMRHGI9 DN Cisplatin
DMRHGI9 HS Approved
DMRHGI9 SN Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
DMRHGI9 CP Bristol-Myers Squibb
DMRHGI9 TC Anticancer Agents
DMRHGI9 DT Small molecular drug
DMRHGI9 PC 5702198
DMRHGI9 MW 300.05
DMRHGI9 FM Cl2H6N2Pt
DMRHGI9 IC InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
DMRHGI9 CS N.N.Cl[Pt]Cl
DMRHGI9 IK LXZZYRPGZAFOLE-UHFFFAOYSA-L
DMRHGI9 IU azane;dichloroplatinum
DMRHGI9 CA CAS 15663-27-1
DMRHGI9 DE Solid tumour/cancer; Osteosarcoma
DM2G9AE ID DM2G9AE
DM2G9AE DN Citalopram
DM2G9AE HS Approved
DM2G9AE SN Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CP Forest Laboratories, Inc
DM2G9AE TC Antidepressants
DM2G9AE DT Small molecular drug
DM2G9AE PC 2771
DM2G9AE MW 324.4
DM2G9AE FM C20H21FN2O
DM2G9AE IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DM2G9AE CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DM2G9AE IK WSEQXVZVJXJVFP-UHFFFAOYSA-N
DM2G9AE IU 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CA CAS 59729-33-8
DM2G9AE CB CHEBI:77397
DM2G9AE DE Depression
DMI4XBM ID DMI4XBM
DMI4XBM DN Citicoline
DMI4XBM HS Approved
DMI4XBM SN Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine
DMI4XBM CP Ferrer Internacional SA
DMI4XBM DT Small molecular drug
DMI4XBM PC 13804
DMI4XBM MW 488.32
DMI4XBM FM C14H26N4O11P2
DMI4XBM IC InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1
DMI4XBM CS C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O
DMI4XBM IK RZZPDXZPRHQOCG-OJAKKHQRSA-N
DMI4XBM IU [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
DMI4XBM CA CAS 987-78-0
DMI4XBM CB CHEBI:16436
DMI4XBM DE Cerebrovascular ischaemia
DMMEBWR ID DMMEBWR
DMMEBWR DN Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR HS Approved
DMMEBWR SN Prepopik (TN)
DMMEBWR CP Ferring Pharmaceuticals
DMMEBWR DT Small molecular drug
DMMEBWR PC 68654
DMMEBWR MW 481.4
DMMEBWR FM C18H13NNa2O8S2
DMMEBWR IC InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMMEBWR CS C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+]
DMMEBWR IK GOZDTZWAMGHLDY-UHFFFAOYSA-L
DMMEBWR IU disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate
DMMEBWR CA CAS 10040-45-6
DMMEBWR CB CHEBI:32147
DMMEBWR DE Crohn disease
DM3JDRP ID DM3JDRP
DM3JDRP DN Cladribine
DM3JDRP HS Approved
DM3JDRP SN Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
DM3JDRP CP EMD Serono Rockland, MA
DM3JDRP TC Anticancer Agents
DM3JDRP DT Small molecular drug
DM3JDRP PC 20279
DM3JDRP MW 285.69
DM3JDRP FM C10H12ClN5O3
DM3JDRP IC InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
DM3JDRP CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
DM3JDRP IK PTOAARAWEBMLNO-KVQBGUIXSA-N
DM3JDRP IU (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DM3JDRP CA CAS 4291-63-8
DM3JDRP CB CHEBI:567361
DM3JDRP DE Multiple sclerosis; Relapsing-remitting multiple sclerosis; Hairy cell leukaemia
DM4M1SG ID DM4M1SG
DM4M1SG DN Clarithromycin
DM4M1SG HS Approved
DM4M1SG SN Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
DM4M1SG CP Abbott Laboratories
DM4M1SG TC Antibiotics
DM4M1SG DT Small molecular drug
DM4M1SG PC 84029
DM4M1SG MW 748
DM4M1SG FM C38H69NO13
DM4M1SG IC InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DM4M1SG CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
DM4M1SG IK AGOYDEPGAOXOCK-KCBOHYOISA-N
DM4M1SG IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4M1SG CA CAS 81103-11-9
DM4M1SG CB CHEBI:3732
DM4M1SG DE Bacterial infection
DMPGR1E ID DMPGR1E
DMPGR1E DN Clascoterone
DMPGR1E HS Approved
DMPGR1E SN CB-03-01
DMPGR1E CP Cosmo Pharmaceuticals SpA
DMPGR1E DT Small molecular drug
DMPGR1E PC 11750009
DMPGR1E MW 402.5
DMPGR1E FM C24H34O5
DMPGR1E IC InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1
DMPGR1E CS CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
DMPGR1E IK GPNHMOZDMYNCPO-PDUMRIMRSA-N
DMPGR1E IU [(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate
DMPGR1E CA CAS 19608-29-8
DMPGR1E DE Acne vulgaris
DM2FGRT ID DM2FGRT
DM2FGRT DN Clavulanate
DM2FGRT HS Approved
DM2FGRT SN Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))
DM2FGRT CP GlaxoSmithKline
DM2FGRT TC Antibiotics
DM2FGRT DT Small molecular drug
DM2FGRT PC 5280980
DM2FGRT MW 199.16
DM2FGRT FM C8H9NO5
DM2FGRT IC InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
DM2FGRT CS C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O
DM2FGRT IK HZZVJAQRINQKSD-PBFISZAISA-N
DM2FGRT IU (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM2FGRT CA CAS 58001-44-8
DM2FGRT CB CHEBI:48947
DM2FGRT DE Bacterial infection
DMBZWQL ID DMBZWQL
DMBZWQL DN Clemastine
DMBZWQL HS Approved
DMBZWQL SN Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
DMBZWQL CP Norvatis Phamaceuticals Corporation
DMBZWQL TC Antiallergic Agents
DMBZWQL DT Small molecular drug
DMBZWQL PC 26987
DMBZWQL MW 343.9
DMBZWQL FM C21H26ClNO
DMBZWQL IC InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
DMBZWQL CS C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
DMBZWQL IK YNNUSGIPVFPVBX-NHCUHLMSSA-N
DMBZWQL IU (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
DMBZWQL CA CAS 15686-51-8
DMBZWQL CB CHEBI:3738
DMBZWQL DE Allergic rhinitis
DMCKYZ5 ID DMCKYZ5
DMCKYZ5 DN Clenbuterol
DMCKYZ5 HS Approved
DMCKYZ5 SN Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
DMCKYZ5 TC Bronchodilator Agents
DMCKYZ5 DT Small molecular drug
DMCKYZ5 PC 2783
DMCKYZ5 MW 277.19
DMCKYZ5 FM C12H18Cl2N2O
DMCKYZ5 IC InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
DMCKYZ5 CS CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
DMCKYZ5 IK STJMRWALKKWQGH-UHFFFAOYSA-N
DMCKYZ5 IU 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
DMCKYZ5 CA CAS 37148-27-9
DMCKYZ5 CB CHEBI:174690
DMCKYZ5 DE Chronic breathing disorder
DMW4M97 ID DMW4M97
DMW4M97 DN Clevidipine butyrate
DMW4M97 HS Approved
DMW4M97 SN Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3
DMW4M97 CP The Medicines Company
DMW4M97 DT Small molecular drug
DMW4M97 PC 153994
DMW4M97 MW 456.3
DMW4M97 FM C21H23Cl2NO6
DMW4M97 IC InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
DMW4M97 CS CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMW4M97 IK KPBZROQVTHLCDU-UHFFFAOYSA-N
DMW4M97 IU 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMW4M97 CA CAS 167221-71-8
DMW4M97 CB CHEBI:135738
DMW4M97 DE Hypertension
DMUMQZ0 ID DMUMQZ0
DMUMQZ0 DN Clidinium
DMUMQZ0 HS Approved
DMUMQZ0 SN clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,; Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CP Hoffmann La Roche Inc
DMUMQZ0 TC Analgesics
DMUMQZ0 DT Small molecular drug
DMUMQZ0 PC 2784
DMUMQZ0 MW 352.4
DMUMQZ0 FM C22H26NO3+
DMUMQZ0 IC InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1
DMUMQZ0 CS C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMUMQZ0 IK HOOSGZJRQIVJSZ-UHFFFAOYSA-N
DMUMQZ0 IU (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CA CAS 7020-55-5
DMUMQZ0 CB CHEBI:3743
DMUMQZ0 DE Irritable bowel syndrome; Abdominal stomach pain
DM15HL8 ID DM15HL8
DM15HL8 DN Clindamycin
DM15HL8 HS Approved
DM15HL8 SN Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
DM15HL8 CP Pharmacia And Upjohn Co
DM15HL8 TC Antibiotics
DM15HL8 DT Small molecular drug
DM15HL8 PC 446598
DM15HL8 MW 425
DM15HL8 FM C18H33ClN2O5S
DM15HL8 IC InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
DM15HL8 CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
DM15HL8 IK KDLRVYVGXIQJDK-AWPVFWJPSA-N
DM15HL8 IU (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DM15HL8 CA CAS 18323-44-9
DM15HL8 DE Acne vulgaris
DMW1OQ0 ID DMW1OQ0
DMW1OQ0 DN Clobazam - Lundbeck
DMW1OQ0 HS Approved
DMW1OQ0 SN Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410; Onfi
DMW1OQ0 TC Neurology Agents
DMW1OQ0 DT Small molecular drug
DMW1OQ0 PC 2789
DMW1OQ0 MW 300.74
DMW1OQ0 FM C16H13ClN2O2
DMW1OQ0 IC InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMW1OQ0 CS CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMW1OQ0 IK CXOXHMZGEKVPMT-UHFFFAOYSA-N
DMW1OQ0 IU 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
DMW1OQ0 CA CAS 22316-47-8
DMW1OQ0 CB CHEBI:31413
DMW1OQ0 DE Anxiety disorder; Epilepsy
DMUXP52 ID DMUXP52
DMUXP52 DN Clobetasol
DMUXP52 HS Approved
DMUXP52 SN Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
DMUXP52 CP Fougera Pharmaceuticals Inc
DMUXP52 TC Antiinflammatory Agents
DMUXP52 DT Small molecular drug
DMUXP52 PC 5311051
DMUXP52 MW 410.9
DMUXP52 FM C22H28ClFO4
DMUXP52 IC InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMUXP52 CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C
DMUXP52 IK FCSHDIVRCWTZOX-DVTGEIKXSA-N
DMUXP52 IU (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUXP52 CA CAS 25122-41-2
DMUXP52 CB CHEBI:205919
DMUXP52 DE Rosacea; Oral lichen planus
DM9ZMQH ID DM9ZMQH
DM9ZMQH DN Clocortolone
DM9ZMQH HS Approved
DM9ZMQH SN Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
DM9ZMQH CP Promius Pharma Llc
DM9ZMQH DT Small molecular drug
DM9ZMQH PC 5311052
DM9ZMQH MW 410.9
DM9ZMQH FM C22H28ClFO4
DM9ZMQH IC InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
DM9ZMQH CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)Cl)C)F
DM9ZMQH IK YMTMADLUXIRMGX-RFPWEZLHSA-N
DM9ZMQH IU (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM9ZMQH CA CAS 4828-27-7
DM9ZMQH CB CHEBI:59582
DM9ZMQH DE Rosacea
DM9Y6X7 ID DM9Y6X7
DM9Y6X7 DN Clodronate
DM9Y6X7 HS Approved
DM9Y6X7 SN Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)
DM9Y6X7 TC Antihypocalcemic Agents
DM9Y6X7 DT Small molecular drug
DM9Y6X7 PC 25419
DM9Y6X7 MW 244.89
DM9Y6X7 FM CH4Cl2O6P2
DM9Y6X7 IC InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
DM9Y6X7 CS C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
DM9Y6X7 IK ACSIXWWBWUQEHA-UHFFFAOYSA-N
DM9Y6X7 IU [dichloro(phosphono)methyl]phosphonic acid
DM9Y6X7 CA CAS 10596-23-3
DM9Y6X7 CB CHEBI:110423
DM9Y6X7 DE Hypercalcaemia
DMCVJ86 ID DMCVJ86
DMCVJ86 DN Clofarabine
DMCVJ86 HS Approved
DMCVJ86 SN CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
DMCVJ86 TC Anticancer Agents
DMCVJ86 DT Small molecular drug
DMCVJ86 PC 119182
DMCVJ86 MW 303.68
DMCVJ86 FM C10H11ClFN5O3
DMCVJ86 IC InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
DMCVJ86 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
DMCVJ86 IK WDDPHFBMKLOVOX-AYQXTPAHSA-N
DMCVJ86 IU (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
DMCVJ86 CA CAS 123318-82-1
DMCVJ86 CB CHEBI:681569
DMCVJ86 DE Acute lymphoblastic leukaemia; Myelodysplastic syndrome
DMEBOFW ID DMEBOFW
DMEBOFW DN Clofazimine
DMEBOFW HS Approved
DMEBOFW SN clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
DMEBOFW CP Norvatis Phamaceuticals Corporation
DMEBOFW TC Antiinflammatory Agents
DMEBOFW DT Small molecular drug
DMEBOFW PC 2794
DMEBOFW MW 473.4
DMEBOFW FM C27H22Cl2N4
DMEBOFW IC InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
DMEBOFW CS CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
DMEBOFW IK WDQPAMHFFCXSNU-UHFFFAOYSA-N
DMEBOFW IU N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
DMEBOFW CA CAS 2030-63-9
DMEBOFW CB CHEBI:3749
DMEBOFW DE Crohn disease; Mycobacterium infection
DMPC1J7 ID DMPC1J7
DMPC1J7 DN Clofibrate
DMPC1J7 HS Approved
DMPC1J7 SN Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate
DMPC1J7 CP Ayerst Laboratories Inc
DMPC1J7 TC Antilipemic Agents
DMPC1J7 DT Small molecular drug
DMPC1J7 PC 2796
DMPC1J7 MW 242.7
DMPC1J7 FM C12H15ClO3
DMPC1J7 IC InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
DMPC1J7 CS CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
DMPC1J7 IK KNHUKKLJHYUCFP-UHFFFAOYSA-N
DMPC1J7 IU ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
DMPC1J7 CA CAS 637-07-0
DMPC1J7 CB CHEBI:3750
DMPC1J7 DE Dysbetalipoproteinemia
DMKI7RB ID DMKI7RB
DMKI7RB DN Clomifene
DMKI7RB HS Approved
DMKI7RB SN Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine
DMKI7RB TC Fertility Agents
DMKI7RB DT Small molecular drug
DMKI7RB PC 1548953
DMKI7RB MW 406
DMKI7RB FM C26H28ClNO
DMKI7RB IC InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
DMKI7RB CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
DMKI7RB IK GKIRPKYJQBWNGO-OCEACIFDSA-N
DMKI7RB IU 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
DMKI7RB CA CAS 15690-57-0
DMKI7RB CB CHEBI:3752
DMKI7RB DE Female infertility
DMS51VC ID DMS51VC
DMS51VC DN Clomiphene citrate
DMS51VC HS Approved
DMS51VC SN Clomid; Milophene; Serophene
DMS51VC CP Sanofi Aventis Us Llc
DMS51VC DT Small molecular drug
DMS51VC PC 3033832
DMS51VC MW 598.1
DMS51VC FM C32H36ClNO8
DMS51VC IC InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
DMS51VC CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMS51VC IK PYTMYKVIJXPNBD-OQKDUQJOSA-N
DMS51VC IU 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMS51VC CA CAS 7619-53-6
DMS51VC DE Female infertility
DMINRKW ID DMINRKW
DMINRKW DN Clomipramine
DMINRKW HS Approved
DMINRKW SN Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)
DMINRKW CP Norvatis Phamaceuticals Corporation
DMINRKW TC Antidepressants
DMINRKW DT Small molecular drug
DMINRKW PC 2801
DMINRKW MW 314.9
DMINRKW FM C19H23ClN2
DMINRKW IC InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
DMINRKW CS CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMINRKW IK GDLIGKIOYRNHDA-UHFFFAOYSA-N
DMINRKW IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DMINRKW CA CAS 303-49-1
DMINRKW CB CHEBI:47780
DMINRKW DE Depression
DM0ZRMQ ID DM0ZRMQ
DM0ZRMQ DN Clomocycline
DM0ZRMQ HS Approved
DM0ZRMQ SN Chlormethylenecycline; Clomociclina; Clomocyclina; Clomocyclinum; Clomociclina [INN-Spanish]; Clomocycline (INN); Clomocycline [INN:BAN]; Clomocyclinum [INN-Latin]; N-2-Hydroxymethylchlortetracycline; N'-Methylolo-chlortetracycline; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
DM0ZRMQ TC Antibiotics
DM0ZRMQ DT Small molecular drug
DM0ZRMQ PC 54680675
DM0ZRMQ MW 508.9
DM0ZRMQ FM C23H25ClN2O9
DM0ZRMQ IC InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-29,32,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1
DM0ZRMQ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)NCO)N(C)C)O
DM0ZRMQ IK BXTHDFJCJQJHKD-KMVLDZISSA-N
DM0ZRMQ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DM0ZRMQ CA CAS 1181-54-0
DM0ZRMQ CB CHEBI:59589
DM0ZRMQ DE Bacterial infection
DMTO13J ID DMTO13J
DMTO13J DN Clonazepam
DMTO13J HS Approved
DMTO13J SN Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
DMTO13J CP Roche Pharmaceuticals
DMTO13J TC Anticonvulsants
DMTO13J DT Small molecular drug
DMTO13J PC 2802
DMTO13J MW 315.71
DMTO13J FM C15H10ClN3O3
DMTO13J IC InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
DMTO13J CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
DMTO13J IK DGBIGWXXNGSACT-UHFFFAOYSA-N
DMTO13J IU 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
DMTO13J CA CAS 1622-61-3
DMTO13J CB CHEBI:3756
DMTO13J DE Epilepsy; Seizure disorder
DM6RZ9Q ID DM6RZ9Q
DM6RZ9Q DN Clonidine
DM6RZ9Q HS Approved
DM6RZ9Q SN clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
DM6RZ9Q CP Intas Pharmaceuticals
DM6RZ9Q TC Antihypertensive Agents
DM6RZ9Q DT Small molecular drug
DM6RZ9Q PC 2803
DM6RZ9Q MW 230.09
DM6RZ9Q FM C9H9Cl2N3
DM6RZ9Q IC InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
DM6RZ9Q CS C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
DM6RZ9Q IK GJSURZIOUXUGAL-UHFFFAOYSA-N
DM6RZ9Q IU N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
DM6RZ9Q CA CAS 4205-90-7
DM6RZ9Q CB CHEBI:3757
DM6RZ9Q DE Hypertension; Diabetic neuropathy
DMOL54H ID DMOL54H
DMOL54H DN Clopidogrel
DMOL54H HS Approved
DMOL54H SN clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
DMOL54H CP Prism Pharmaceuticals Inc
DMOL54H DT Small molecular drug
DMOL54H PC 60606
DMOL54H MW 321.8
DMOL54H FM C16H16ClNO2S
DMOL54H IC InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
DMOL54H CS COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
DMOL54H IK GKTWGGQPFAXNFI-HNNXBMFYSA-N
DMOL54H IU methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
DMOL54H CA CAS 113665-84-2
DMOL54H CB CHEBI:37941
DMOL54H DE Thrombosis
DMC3JST ID DMC3JST
DMC3JST DN Clorazepate
DMC3JST HS Approved
DMC3JST SN Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CP Taro Pharmaceutical Industries Ltd
DMC3JST TC Hypnotics and Sedatives
DMC3JST DT Small molecular drug
DMC3JST PC 2809
DMC3JST MW 314.72
DMC3JST FM C16H11ClN2O3
DMC3JST IC InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
DMC3JST CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
DMC3JST IK XDDJGVMJFWAHJX-UHFFFAOYSA-N
DMC3JST IU 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CA CAS 23887-31-2
DMC3JST CB CHEBI:3761
DMC3JST DE Anxiety disorder
DMCEUJD ID DMCEUJD
DMCEUJD DN Clorgyline
DMCEUJD HS Approved
DMCEUJD SN Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD TC Antiparkinson Agents
DMCEUJD DT Small molecular drug
DMCEUJD PC 4380
DMCEUJD MW 272.17
DMCEUJD FM C13H15Cl2NO
DMCEUJD IC InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3
DMCEUJD CS CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C
DMCEUJD IK BTFHLQRNAMSNLC-UHFFFAOYSA-N
DMCEUJD IU 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD CA CAS 17780-72-2
DMCEUJD CB CHEBI:3763
DMCEUJD DE Skin imperfections; Parkinson disease
DM6K1OA ID DM6K1OA
DM6K1OA DN Clothiapine
DM6K1OA HS Approved
DM6K1OA SN Clothiapine; Clotiapine; 2058-52-8; Entumine; Entumin; Etumine; HF 2159; Clotiapinum [INN-Latin]; Clotiapina [INN-Spanish]; UNII-Z05HCY0X1T; S-805C; Clothiapine [USAN]; EINECS 218-162-8; LW 2159; C18H18ClN3S; BRN 0568276; Z05HCY0X1T; CHEMBL304902; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine; KAAZGXDPUNNEFN-UHFFFAOYSA-N; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; Clothiapine (USAN); HF-2159; NCGC00160387-01
DM6K1OA DT Small molecular drug
DM6K1OA PC 16351
DM6K1OA MW 343.9
DM6K1OA FM C18H18ClN3S
DM6K1OA IC InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM6K1OA CS CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM6K1OA IK KAAZGXDPUNNEFN-UHFFFAOYSA-N
DM6K1OA IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine
DM6K1OA CA CAS 2058-52-8
DM6K1OA CB CHEBI:31424
DM6K1OA DE Schizophrenia
DM59AZT ID DM59AZT
DM59AZT DN Clotiazepam
DM59AZT HS Approved
DM59AZT SN Clotiazepamum; Clozan; Distensan; Rise; Rize; Rizen; Tienor; Trecalmo; Veratran; Y 6047; Clotiazepam [INN:JAN]; Clotiazepamum [INN-Latin]; Clozan (TN); Distensan (TN); Rize (TN); Rizen (TN); Trecalmo (TN); Veratran (TN); Y-6047; Clotiazepam (JP15/INN); 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-(8CI); 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one
DM59AZT TC Hypnotics and Sedatives
DM59AZT DT Small molecular drug
DM59AZT PC 2811
DM59AZT MW 318.8
DM59AZT FM C16H15ClN2OS
DM59AZT IC InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3
DM59AZT CS CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C
DM59AZT IK CHBRHODLKOZEPZ-UHFFFAOYSA-N
DM59AZT IU 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one
DM59AZT CA CAS 33671-46-4
DM59AZT CB CHEBI:31425
DM59AZT DE Anxiety disorder
DMMFCIH ID DMMFCIH
DMMFCIH DN Clotrimazole
DMMFCIH HS Approved
DMMFCIH SN Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole
DMMFCIH CP Bayer Pharmaceuticals Corporation
DMMFCIH TC Antifungal Agents
DMMFCIH DT Small molecular drug
DMMFCIH PC 2812
DMMFCIH MW 344.8
DMMFCIH FM C22H17ClN2
DMMFCIH IC InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
DMMFCIH CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
DMMFCIH IK VNFPBHJOKIVQEB-UHFFFAOYSA-N
DMMFCIH IU 1-[(2-chlorophenyl)-diphenylmethyl]imidazole
DMMFCIH CA CAS 23593-75-1
DMMFCIH CB CHEBI:3764
DMMFCIH DE Fungal infection
DMUTL7O ID DMUTL7O
DMUTL7O DN Cloxacillin
DMUTL7O HS Approved
DMUTL7O SN Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
DMUTL7O CP Beecham phamaceuticals
DMUTL7O TC Antibiotics
DMUTL7O DT Small molecular drug
DMUTL7O PC 6098
DMUTL7O MW 435.9
DMUTL7O FM C19H18ClN3O5S
DMUTL7O IC InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1
DMUTL7O CS CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMUTL7O IK LQOLIRLGBULYKD-JKIFEVAISA-N
DMUTL7O IU (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUTL7O CA CAS 61-72-3
DMUTL7O CB CHEBI:49566
DMUTL7O DE Bacterial infection
DMFC71L ID DMFC71L
DMFC71L DN Clozapine
DMFC71L HS Approved
DMFC71L SN Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
DMFC71L CP Sandoz
DMFC71L TC Antipsychotic Agents
DMFC71L DT Small molecular drug
DMFC71L PC 135398737
DMFC71L MW 326.8
DMFC71L FM C18H19ClN4
DMFC71L IC InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DMFC71L CS CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMFC71L IK QZUDBNBUXVUHMW-UHFFFAOYSA-N
DMFC71L IU 3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DMFC71L CA CAS 5786-21-0
DMFC71L CB CHEBI:3766
DMFC71L DE Schizophrenia
DMPC2QY ID DMPC2QY
DMPC2QY DN CNTO-1959
DMPC2QY HS Approved
DMPC2QY SN Guselkumab
DMPC2QY CP Janssen/Johnson & Johnson
DMPC2QY DT Antibody
DMPC2QY SQ Heavy chain: EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMPC2QY DE Plaque psoriasis; Asthma
DM8HBJI ID DM8HBJI
DM8HBJI DN Coagulation Factor IX
DM8HBJI HS Approved
DM8HBJI TC Anticoagulants
DM8HBJI DE Haemophilia B
DM6L4H2 ID DM6L4H2
DM6L4H2 DN Cobicistat
DM6L4H2 HS Approved
DM6L4H2 SN 1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl
DM6L4H2 CP GILEAD
DM6L4H2 DT Small molecular drug
DM6L4H2 PC 25151504
DM6L4H2 MW 776
DM6L4H2 FM C40H53N7O5S2
DM6L4H2 IC InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
DM6L4H2 CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DM6L4H2 IK ZCIGNRJZKPOIKD-CQXVEOKZSA-N
DM6L4H2 IU 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DM6L4H2 CA CAS 1004316-88-4
DM6L4H2 CB CHEBI:72291
DM6L4H2 DE Human immunodeficiency virus infection
DMDKXTO ID DMDKXTO
DMDKXTO DN Cobicistat/darunavir
DMDKXTO HS Approved
DMDKXTO SN Prezcobix; Cobicistat / darunavir; Darunavir / Cobicistat; Cobicistat and darunavir; Cobicistat mixture with darunavir; Darunavir and cobicistat
DMDKXTO CP Gilead Sciences
DMDKXTO DT Small molecular drug
DMDKXTO PC 57327017
DMDKXTO MW 1323.7
DMDKXTO FM C67H90N10O12S3
DMDKXTO IC InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1
DMDKXTO CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DMDKXTO IK CXORHDVSJFELCV-HWDLLDTBSA-N
DMDKXTO IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMDKXTO DE Human immunodeficiency virus infection
DMSOX7I ID DMSOX7I
DMSOX7I DN Cocaine
DMSOX7I HS Approved
DMSOX7I SN Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
DMSOX7I TC Anesthetics
DMSOX7I DT Small molecular drug
DMSOX7I PC 446220
DMSOX7I MW 303.35
DMSOX7I FM C17H21NO4
DMSOX7I IC InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
DMSOX7I CS CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC
DMSOX7I IK ZPUCINDJVBIVPJ-LJISPDSOSA-N
DMSOX7I IU methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMSOX7I CA CAS 50-36-2
DMSOX7I CB CHEBI:27958
DMSOX7I DE Anaesthesia
DMJX6ZG ID DMJX6ZG
DMJX6ZG DN Codeine
DMJX6ZG HS Approved
DMJX6ZG SN codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate
DMJX6ZG CP Forest Pharmaceuticals
DMJX6ZG TC Analgesics
DMJX6ZG DT Small molecular drug
DMJX6ZG PC 5284371
DMJX6ZG MW 299.4
DMJX6ZG FM C18H21NO3
DMJX6ZG IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMJX6ZG CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
DMJX6ZG IK OROGSEYTTFOCAN-DNJOTXNNSA-N
DMJX6ZG IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMJX6ZG CA CAS 76-57-3
DMJX6ZG CB CHEBI:16714
DMJX6ZG DE Pain; Cough
DM2POTE ID DM2POTE
DM2POTE DN Colchicine
DM2POTE HS Approved
DM2POTE SN Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine
DM2POTE TC Gout Suppressants
DM2POTE DT Small molecular drug
DM2POTE PC 6167
DM2POTE MW 399.4
DM2POTE FM C22H25NO6
DM2POTE IC InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DM2POTE CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DM2POTE IK IAKHMKGGTNLKSZ-INIZCTEOSA-N
DM2POTE IU N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM2POTE CA CAS 64-86-8
DM2POTE CB CHEBI:27882
DM2POTE DE Acute gouty arthritis
DMJ01D8 ID DMJ01D8
DMJ01D8 DN Colforsin daropate hci
DMJ01D8 HS Approved
DMJ01D8 SN Adehl (TN); Adele (TN)
DMJ01D8 CP Nippon Kayaku
DMJ01D8 DT Small molecular drug
DMJ01D8 PC 444028
DMJ01D8 MW 546.1
DMJ01D8 FM C27H44ClNO8
DMJ01D8 IC InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1
DMJ01D8 CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl
DMJ01D8 IK VIRRLEDAYYYTOD-YHEOSNBFSA-N
DMJ01D8 IU [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 3-(dimethylamino)propanoate;hydrochloride
DMJ01D8 CA CAS 138605-00-2
DMJ01D8 CB CHEBI:31429
DMJ01D8 DE Asthma
DMZ9BMU ID DMZ9BMU
DMZ9BMU DN Colistimethate
DMZ9BMU HS Approved
DMZ9BMU SN Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable
DMZ9BMU TC Antibiotics
DMZ9BMU DT Small molecular drug
DMZ9BMU PC 216258
DMZ9BMU MW 1749.8
DMZ9BMU FM C58H105N16Na5O28S5
DMZ9BMU IC InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
DMZ9BMU CS CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
DMZ9BMU IK IQWHCHZFYPIVRV-UHFFFAOYSA-I
DMZ9BMU IU pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
DMZ9BMU CA CAS 8068-28-8
DMZ9BMU DE Respiratory tract infection
DMMD9QE ID DMMD9QE
DMMD9QE DN Colistin
DMMD9QE HS Approved
DMMD9QE SN Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)
DMMD9QE CP Parkdale Pharmaceuticals
DMMD9QE TC Antibiotics
DMMD9QE DT Small molecular drug
DMMD9QE PC 5311054
DMMD9QE MW 1155.4
DMMD9QE FM C52H98N16O13
DMMD9QE IC InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1
DMMD9QE CS CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O
DMMD9QE IK YKQOSKADJPQZHB-QNPLFGSASA-N
DMMD9QE IU N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
DMMD9QE CA CAS 1066-17-7
DMMD9QE DE Pseudomonas infection
DMFJ2OG ID DMFJ2OG
DMFJ2OG DN Collagenase
DMFJ2OG HS Approved
DMFJ2OG TC Antiulcer Agents
DMFJ2OG DE Skin burns; Dermal ulcers
DM1V329 ID DM1V329
DM1V329 DN Conivaptan
DM1V329 HS Approved
DM1V329 SN Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
DM1V329 CP Astellas Pharma Inc
DM1V329 DT Small molecular drug
DM1V329 PC 151171
DM1V329 MW 498.6
DM1V329 FM C32H26N4O2
DM1V329 IC InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
DM1V329 CS CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM1V329 IK IKENVDNFQMCRTR-UHFFFAOYSA-N
DM1V329 IU N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
DM1V329 CA CAS 210101-16-9
DM1V329 CB CHEBI:681850
DM1V329 DE Euvolemic hyponatremia
DMLT0E1 ID DMLT0E1
DMLT0E1 DN Conjugated estrogens
DMLT0E1 HS Approved
DMLT0E1 SN Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMLT0E1 CP Wyeth Pharmaceuticals
DMLT0E1 TC Estrogens
DMLT0E1 DT Small molecular drug
DMLT0E1 PC 45357473
DMLT0E1 MW 372.4
DMLT0E1 FM C18H21NaO5S
DMLT0E1 IC InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1
DMLT0E1 CS C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
DMLT0E1 IK VUCAHVBMSFIGAI-TWCWWGPMSA-M
DMLT0E1 IU sodium;[(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMLT0E1 DE Menopause symptom; Vasomotor symptom
DMTPIZC ID DMTPIZC
DMTPIZC DN Conjugated estrogens a
DMTPIZC HS Approved
DMTPIZC SN Conestin (TN)
DMTPIZC DE Hormone replacement therapy
DMU7SF8 ID DMU7SF8
DMU7SF8 DN Conjugated estrogens b
DMU7SF8 HS Approved
DMU7SF8 SN Enjuvia (TN)
DMU7SF8 DE Hormone replacement therapy
DMF29Q5 ID DMF29Q5
DMF29Q5 DN Connexyn
DMF29Q5 HS Approved
DMF29Q5 SN Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
DMF29Q5 DT Small molecular drug
DMF29Q5 PC 71401
DMF29Q5 MW 282.5
DMF29Q5 FM C9H10Cl3N3O
DMF29Q5 IC InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
DMF29Q5 CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl
DMF29Q5 IK DGFYECXYGUIODH-UHFFFAOYSA-N
DMF29Q5 IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
DMF29Q5 CA CAS 29110-48-3
DMF29Q5 CB CHEBI:5559
DMF29Q5 DE Attention deficit hyperactivity disorder
DM26KR1 ID DM26KR1
DM26KR1 DN Copper dotatate Cu-64
DM26KR1 HS Approved
DM26KR1 SN UNII-N3858377KC; N3858377KC; Copper 64-DOTA-tate; Copper Cu-64 dotatate; 1426155-87-4; Cuprate(2-)-64Cu, (N-(2-(4,10-bis((carboxy-kappaO)methyl)-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN7,kappaN10)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoni
DM26KR1 DT Radioactive diagnostic agent
DM26KR1 PC 124220636
DM26KR1 MW 1497.5
DM26KR1 FM C65H88CuN14O19S2
DM26KR1 IC InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0
DM26KR1 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2]
DM26KR1 IK IJRLLVFQGCCPPI-NVGRTJHCSA-L
DM26KR1 IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)
DM26KR1 CA CAS 1426155-87-4
DM26KR1 DE Diagnostic imaging
DMP9TWZ ID DMP9TWZ
DMP9TWZ DN Corticotropin
DMP9TWZ HS Approved
DMP9TWZ SN corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine
DMP9TWZ CP Questcor pharmaceuticals
DMP9TWZ SQ ACTH(1-39): SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF
DMP9TWZ PC 16132265
DMP9TWZ MW 4541
DMP9TWZ FM C207H308N56O58S
DMP9TWZ IC InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1
DMP9TWZ CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N
DMP9TWZ IK IDLFZVILOHSSID-OVLDLUHVSA-N
DMP9TWZ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMP9TWZ CA CAS 12427-33-7
DMP9TWZ CB CHEBI:3892
DMP9TWZ DE Diabetic nephropathy; Cushing disease
DMU5QZX ID DMU5QZX
DMU5QZX DN Cortisone
DMU5QZX HS Approved
DMU5QZX SN 11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone
DMU5QZX DT Small molecular drug
DMU5QZX PC 222786
DMU5QZX MW 360.4
DMU5QZX FM C21H28O5
DMU5QZX IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DMU5QZX CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C
DMU5QZX IK MFYSYFVPBJMHGN-ZPOLXVRWSA-N
DMU5QZX IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
DMU5QZX CA CAS 53-06-5
DMU5QZX CB CHEBI:16962
DMU5QZX DE Atopic dermatitis
DMG8K57 ID DMG8K57
DMG8K57 DN Cortisone acetate
DMG8K57 HS Approved
DMG8K57 SN Cortone
DMG8K57 CP Pharmacia And Upjohn Co
DMG8K57 TC Anticancer Agents
DMG8K57 DT Small molecular drug
DMG8K57 PC 5745
DMG8K57 MW 402.5
DMG8K57 FM C23H30O6
DMG8K57 IC InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
DMG8K57 CS CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMG8K57 IK ITRJWOMZKQRYTA-RFZYENFJSA-N
DMG8K57 IU [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMG8K57 CA CAS 50-04-4
DMG8K57 CB CHEBI:3897
DMG8K57 DE Solid tumour/cancer
DMUIASK ID DMUIASK
DMUIASK DN Cosyntropin
DMUIASK HS Approved
DMUIASK SN Cortrosyn; Tetracosactide; Cortrosyn (TN); Cosyntropin (USAN); Tetracosactide (INN)
DMUIASK CP Sandoz
DMUIASK TC Diagnostic Agents
DMUIASK PC 16129617
DMUIASK MW 2933.4
DMUIASK FM C136H210N40O31S
DMUIASK IC InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1
DMUIASK CS CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N
DMUIASK IK ZOEFCCMDUURGSE-CQVUSSRSSA-N
DMUIASK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
DMUIASK CA CAS 16960-16-0
DMUIASK DE Adrenocortical insufficiency
DMCEZ1B ID DMCEZ1B
DMCEZ1B DN Cotinine
DMCEZ1B HS Approved
DMCEZ1B SN cotinine; (-)-Cotinine; 486-56-6; Cotinina; Cotininum; (S)-(-)-Cotinine; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; Cotinine (-); (S)-Cotinine; UNII-K5161X06LL; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; CHEBI:68641; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; UIKROCXWUNQSPJ-VIFPVBQESA-N; K5161X06LL; Cotinine [INN]; MFCD00077696; Cotininum [INN-Latin]; Cotinina [INN-Spanish]; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B DT Small molecular drug
DMCEZ1B PC 854019
DMCEZ1B MW 176.21
DMCEZ1B FM C10H12N2O
DMCEZ1B IC InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1
DMCEZ1B CS CN1[C@@H](CCC1=O)C2=CN=CC=C2
DMCEZ1B IK UIKROCXWUNQSPJ-VIFPVBQESA-N
DMCEZ1B IU (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B CA CAS 486-56-6
DMCEZ1B CB CHEBI:68641
DMCEZ1B DE Insecticide
DMJ7IQX ID DMJ7IQX
DMJ7IQX DN Crestor/TriLipix
DMJ7IQX HS Approved
DMJ7IQX CP AstraZeneca
DMJ7IQX DE Dyslipidemia
DMNVKU6 ID DMNVKU6
DMNVKU6 DN Crisaborole
DMNVKU6 HS Approved
DMNVKU6 SN Crisaborole ointment 2%; PF-06930164
DMNVKU6 CP Pfizer/Anacor Pharmaceuticals
DMNVKU6 DT Small molecular drug
DMNVKU6 PC 44591583
DMNVKU6 MW 251.05
DMNVKU6 FM C14H10BNO3
DMNVKU6 IC InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
DMNVKU6 CS B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
DMNVKU6 IK USZAGAREISWJDP-UHFFFAOYSA-N
DMNVKU6 IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
DMNVKU6 CA CAS 906673-24-3
DMNVKU6 CB CHEBI:134677
DMNVKU6 DE Atopic dermatitis
DMAHOVJ ID DMAHOVJ
DMAHOVJ DN Crizanlizumab
DMAHOVJ HS Approved
DMAHOVJ SN SEG101
DMAHOVJ CP Novartis
DMAHOVJ DT Antibody
DMAHOVJ DE Vaso-occlusive crisis; Sickle-cell disorder
DM4F29C ID DM4F29C
DM4F29C DN Crizotinib
DM4F29C HS Approved
DM4F29C SN Xalkori (TN); novel ALK inhibitors
DM4F29C CP Pfizer New York, NY
DM4F29C DT Small molecular drug
DM4F29C PC 11626560
DM4F29C MW 450.3
DM4F29C FM C21H22Cl2FN5O
DM4F29C IC InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
DM4F29C CS C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
DM4F29C IK KTEIFNKAUNYNJU-GFCCVEGCSA-N
DM4F29C IU 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
DM4F29C CA CAS 877399-52-5
DM4F29C CB CHEBI:64310
DM4F29C DE Non-small-cell lung cancer
DM4AMQZ ID DM4AMQZ
DM4AMQZ DN Crofelemer
DM4AMQZ HS Approved
DM4AMQZ SN Fulyzaq (TN)
DM4AMQZ CP Salix
DM4AMQZ DT Small molecular drug
DM4AMQZ PC 17397714
DM4AMQZ MW 308.3
DM4AMQZ FM C18H16N2O3
DM4AMQZ IC InChI=1S/C18H16N2O3/c1-22-16-10-6-5-9-14(16)12-19-18(21)15-11-17(23-20-15)13-7-3-2-4-8-13/h2-11H,12H2,1H3,(H,19,21)
DM4AMQZ CS COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3
DM4AMQZ IK JDNAIBCYTQGWFC-UHFFFAOYSA-N
DM4AMQZ IU N-[(2-methoxyphenyl)methyl]-5-phenyl-1,2-oxazole-3-carboxamide
DM4AMQZ DE HIV-associated diarrhoea
DM74LZK ID DM74LZK
DM74LZK DN Cromoglicate
DM74LZK HS Approved
DM74LZK SN Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)
DM74LZK CP Zambon Group
DM74LZK TC Antiasthmatic Agents
DM74LZK DT Small molecular drug
DM74LZK PC 2882
DM74LZK MW 468.4
DM74LZK FM C23H16O11
DM74LZK IC InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
DM74LZK CS C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
DM74LZK IK IMZMKUWMOSJXDT-UHFFFAOYSA-N
DM74LZK IU 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
DM74LZK CA CAS 16110-51-3
DM74LZK CB CHEBI:59773
DM74LZK DE Asthma; Allergic rhinitis
DMHCTAL ID DMHCTAL
DMHCTAL DN Cryptenamine Acetates
DMHCTAL HS Approved
DMHCTAL SN Unitensen; Cryptenamine Tannates
DMHCTAL CP Medpointe Pharmaceuticals Medpointe Healthcare Inc
DMHCTAL TC Cardiovascular Agents
DMHCTAL DE Hypertension
DMB8PF3 ID DMB8PF3
DMB8PF3 DN CT-102
DMB8PF3 HS Approved
DMB8PF3 CP Curative Health Services
DMB8PF3 DE Diabetic foot ulcer
DMP0NFQ ID DMP0NFQ
DMP0NFQ DN Cupric Sulfate
DMP0NFQ HS Approved
DMP0NFQ SN Copper sulfate; 7758-98-7; CUPRIC SULFATE; Copper(II) sulfate; Cupric sulfate anhydrous; Copper sulphate; Copper(2+) sulfate; Cupricsulfate; Blue stone; Copper monosulfate; Copper II sulfate; Trinagle; Hylinec; Delcup; Cupric sulphate; Copper(ii) sulfate, anhydrous; Monocopper sulfate; Copper sulfate (1:1); Incracide 10A; Incracide E 51; Sulfuric acid copper(2+) salt (1:1); BCS copper fungicide; Blue copper (VAN); Copper Sulfate Powder; Bonide Root Destroyer; CuSO4; Kupfersulfat [German]; All Clear Root Destroyer; Copper sulfate (CuSO
DMP0NFQ CP Abraxis Pharmaceutical Products
DMP0NFQ TC Antiinfective Agents
DMP0NFQ DT Small molecular drug
DMP0NFQ PC 24462
DMP0NFQ MW 159.61
DMP0NFQ FM CuO4S
DMP0NFQ IC InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMP0NFQ CS [O-]S(=O)(=O)[O-].[Cu+2]
DMP0NFQ IK ARUVKPQLZAKDPS-UHFFFAOYSA-L
DMP0NFQ IU copper;sulfate
DMP0NFQ CA CAS 7758-98-7
DMP0NFQ CB CHEBI:23414
DMP0NFQ DE Pest attack; Fungal infection; Herbicide
DMHSJB4 ID DMHSJB4
DMHSJB4 DN Cyclacillin
DMHSJB4 HS Approved
DMHSJB4 SN Aminocyclohexylpenicillin; Bastcillin; Calthor; Ciclacilina; Ciclacillin; Ciclacilline; Ciclacillinum; Ciclacillum; Citosarin; Cyclapen; Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vipicil; Wyvital; Aminocyclohexyl penicillin; Cyclacillin [USAN]; AC 98; WY 4508; WY4508; C-12104; Ciclacilina [INN-Spanish]; Ciclacilline [INN-French]; Ciclacillinum [INN-Latin]; Cyclacillin (USAN); Cyclapen (TN); Cyclapen-W; Vastcillin (TN); Wy-4508; Ciclacillin (JP15/INN); Cyclapen-W (TN); (1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMHSJB4 TC Antibiotics
DMHSJB4 DT Small molecular drug
DMHSJB4 PC 19003
DMHSJB4 MW 341.4
DMHSJB4 FM C15H23N3O4S
DMHSJB4 IC InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1
DMHSJB4 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C
DMHSJB4 IK HGBLNBBNRORJKI-WCABBAIRSA-N
DMHSJB4 IU (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHSJB4 CA CAS 3485-14-1
DMHSJB4 CB CHEBI:31444
DMHSJB4 DE Bacterial infection
DMO0R76 ID DMO0R76
DMO0R76 DN Cyclandelate
DMO0R76 HS Approved
DMO0R76 SN cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207
DMO0R76 DT Small molecular drug
DMO0R76 PC 2893
DMO0R76 MW 276.4
DMO0R76 FM C17H24O3
DMO0R76 IC InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
DMO0R76 CS CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
DMO0R76 IK WZHCOOQXZCIUNC-UHFFFAOYSA-N
DMO0R76 IU (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate
DMO0R76 CA CAS 456-59-7
DMO0R76 CB CHEBI:3988
DMO0R76 DE Dementia
DM9G7BS ID DM9G7BS
DM9G7BS DN Cyclizine
DM9G7BS HS Approved
DM9G7BS SN Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine
DM9G7BS CP Seatrace Pharmaceuticals
DM9G7BS TC Antiemetics
DM9G7BS DT Small molecular drug
DM9G7BS PC 6726
DM9G7BS MW 266.4
DM9G7BS FM C18H22N2
DM9G7BS IC InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
DM9G7BS CS CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9G7BS IK UVKZSORBKUEBAZ-UHFFFAOYSA-N
DM9G7BS IU 1-benzhydryl-4-methylpiperazine
DM9G7BS CA CAS 82-92-8
DM9G7BS CB CHEBI:3994
DM9G7BS DE Nausea
DM1YBRM ID DM1YBRM
DM1YBRM DN Cyclobenzaprine
DM1YBRM HS Approved
DM1YBRM SN Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.
DM1YBRM CP Janssen Research And Development Llc
DM1YBRM TC Antidepressants
DM1YBRM DT Small molecular drug
DM1YBRM PC 2895
DM1YBRM MW 275.4
DM1YBRM FM C20H21N
DM1YBRM IC InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
DM1YBRM CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
DM1YBRM IK JURKNVYFZMSNLP-UHFFFAOYSA-N
DM1YBRM IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine
DM1YBRM CA CAS 303-53-7
DM1YBRM CB CHEBI:3996
DM1YBRM DE Depression
DMT5RMB ID DMT5RMB
DMT5RMB DN Cyclofenil
DMT5RMB HS Approved
DMT5RMB SN cyclofenil; 2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066
DMT5RMB DT Small molecular drug
DMT5RMB PC 2898
DMT5RMB MW 364.4
DMT5RMB FM C23H24O4
DMT5RMB IC InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3
DMT5RMB CS CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C
DMT5RMB IK GVOUFPWUYJWQSK-UHFFFAOYSA-N
DMT5RMB IU [4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate
DMT5RMB CA CAS 2624-43-3
DMT5RMB CB CHEBI:31446
DMT5RMB DE Infertility
DMA8LM5 ID DMA8LM5
DMA8LM5 DN Cyclopentolate
DMA8LM5 HS Approved
DMA8LM5 SN Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
DMA8LM5 CP Akorn Inc
DMA8LM5 TC Parasympatholytics
DMA8LM5 DT Small molecular drug
DMA8LM5 PC 2905
DMA8LM5 MW 291.4
DMA8LM5 FM C17H25NO3
DMA8LM5 IC InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
DMA8LM5 CS CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
DMA8LM5 IK SKYSRIRYMSLOIN-UHFFFAOYSA-N
DMA8LM5 IU 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
DMA8LM5 CA CAS 512-15-2
DMA8LM5 CB CHEBI:4024
DMA8LM5 DE Examination of eyes or vision
DM4O2Z7 ID DM4O2Z7
DM4O2Z7 DN Cyclophosphamide
DM4O2Z7 HS Approved
DM4O2Z7 SN ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
DM4O2Z7 CP Baxter International Inc
DM4O2Z7 TC Anticancer Agents
DM4O2Z7 DT Small molecular drug
DM4O2Z7 PC 2907
DM4O2Z7 MW 261.079
DM4O2Z7 FM C7H15Cl2N2O2P
DM4O2Z7 IC InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
DM4O2Z7 CS C1CNP(=O)(OC1)N(CCCl)CCCl
DM4O2Z7 IK CMSMOCZEIVJLDB-UHFFFAOYSA-N
DM4O2Z7 IU N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DM4O2Z7 CA CAS 50-18-0
DM4O2Z7 CB CHEBI:4027
DM4O2Z7 DE Solid tumour/cancer
DMT1I52 ID DMT1I52
DMT1I52 DN Cycloserine
DMT1I52 HS Approved
DMT1I52 SN D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
DMT1I52 TC Antiinfective Agents
DMT1I52 DT Small molecular drug
DMT1I52 PC 6234
DMT1I52 MW 102.09
DMT1I52 FM C3H6N2O2
DMT1I52 IC InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
DMT1I52 CS C1[C@H](C(=O)NO1)N
DMT1I52 IK DYDCUQKUCUHJBH-UWTATZPHSA-N
DMT1I52 IU (4R)-4-amino-1,2-oxazolidin-3-one
DMT1I52 CA CAS 68-41-7
DMT1I52 CB CHEBI:40009
DMT1I52 DE Tuberculosis; Bacterial infection; Obsessive compulsive disorder
DMJ4AWC ID DMJ4AWC
DMJ4AWC DN Cyclothiazide
DMJ4AWC HS Approved
DMJ4AWC SN Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMJ4AWC TC Antihypertensive Agents
DMJ4AWC DT Small molecular drug
DMJ4AWC PC 2910
DMJ4AWC MW 389.9
DMJ4AWC FM C14H16ClN3O4S2
DMJ4AWC IC InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
DMJ4AWC CS C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
DMJ4AWC IK BOCUKUHCLICSIY-UHFFFAOYSA-N
DMJ4AWC IU 3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMJ4AWC CA CAS 2259-96-3
DMJ4AWC CB CHEBI:31448
DMJ4AWC DE Congestive heart failure
DM8C43Q ID DM8C43Q
DM8C43Q DN Cycrimine
DM8C43Q HS Approved
DM8C43Q SN Cicrimina; Cycriminum; Pagitane; Cicrimina [INN-Spanish]; Cycriminum [INN-Latin]; Alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; (+-)-cycrimine; 1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q TC Antiparkinson Agents
DM8C43Q DT Small molecular drug
DM8C43Q PC 2911
DM8C43Q MW 287.4
DM8C43Q FM C19H29NO
DM8C43Q IC InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DM8C43Q CS C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O
DM8C43Q IK SWRUZBWLEWHWRI-UHFFFAOYSA-N
DM8C43Q IU 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q CA CAS 77-39-4
DM8C43Q CB CHEBI:59692
DM8C43Q DE Parkinson disease
DMUY2OR ID DMUY2OR
DMUY2OR DN Cynarin
DMUY2OR HS Approved
DMUY2OR SN 1,3-O-Dicaffeoylquinic acid; 19870-46-3; 1,3-Dicaffeoylquinic acid; Cynarin; 1,5-Dicaffeoylquinic acid; Cynarine; 1,5-di-O-Caffeoylquinic acid; 1,3-di-O-Caffeoylquinic acid; 30964-13-7; (1S,3R,4R,5R)-1,3-Bis[3-(3,4-dihydroxyphenyl)acryloyloxy]-4,5-dihydroxycyclohexanecarboxylic acid; (1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxy-cyclohexanecarboxylic acid; AC1O6FEM; 1,5-Dicaffeoylquinic-acid; 1,3-Dicaffeoyl quinic acid; 1,5-Dicaffeoylquinic acid ; CHEMBL478574; 1,5-DCQA
DMUY2OR DT Small molecular drug
DMUY2OR PC 5281769
DMUY2OR MW 516.4
DMUY2OR FM C25H24O12
DMUY2OR IC InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1
DMUY2OR CS C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O
DMUY2OR IK YDDUMTOHNYZQPO-RVXRWRFUSA-N
DMUY2OR IU (1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
DMUY2OR CA CAS 212891-05-9
DMUY2OR CB CHEBI:520
DMUY2OR DE Vibrio cholerae infection
DM92AH3 ID DM92AH3
DM92AH3 DN Cyproheptadine
DM92AH3 HS Approved
DM92AH3 SN Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
DM92AH3 CP Merck & Co
DM92AH3 TC Antihistamines
DM92AH3 DT Small molecular drug
DM92AH3 PC 2913
DM92AH3 MW 287.4
DM92AH3 FM C21H21N
DM92AH3 IC InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
DM92AH3 CS CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
DM92AH3 IK JJCFRYNCJDLXIK-UHFFFAOYSA-N
DM92AH3 IU 1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
DM92AH3 CA CAS 129-03-3
DM92AH3 CB CHEBI:4046
DM92AH3 DE Rhinitis
DMQXLD2 ID DMQXLD2
DMQXLD2 DN Cyproterone
DMQXLD2 HS Approved
DMQXLD2 SN Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
DMQXLD2 CP Schering-Plough
DMQXLD2 TC Anticancer Agents
DMQXLD2 DT Small molecular drug
DMQXLD2 PC 5284537
DMQXLD2 MW 374.9
DMQXLD2 FM C22H27ClO3
DMQXLD2 IC InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
DMQXLD2 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O
DMQXLD2 IK DUSHUSLJJMDGTE-ZJPMUUANSA-N
DMQXLD2 IU (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
DMQXLD2 CA CAS 2098-66-0
DMQXLD2 CB CHEBI:50742
DMQXLD2 DE Prostate cancer
DMSYFM8 ID DMSYFM8
DMSYFM8 DN Cysteamine
DMSYFM8 HS Approved
DMSYFM8 SN Becaptan; Cisteamina; Cystavision; Cysteamide; Cysteamin; Cysteinamine; Decarboxycysteine; Ethanethiolamine; Lambraten; Lambratene; MEA; Mecramine; Mercamin; Mercamine; Mercaptamin; Mercaptamina; Mercaptamine; Mercaptaminum; Mercaptoethylamine; Merkamin; Riacon; Thioethanolamine; Aminoethyl mercaptan; Cisteamina [Italian]; Cysteamine bitartate; L 1573; WR 347; Beta-Aminoethanethiol; Beta-Aminoethylthiol; Beta-MEA; Beta-Mercaptoethylamine; C-9500; Cysteamine (USAN); Cysteamine [USAN:BAN]; L-1573; MEA (mercaptan); Mercaptamina [INN-Spanish]; Mercaptamine (INN); Mercaptaminum [INN-Latin]; (2-Mercaptoethyl)amine; (Mercaptoethyl)ammonium toluene-p-sulphonate; 1-Amino-2-mercaptoethylamine; 2-AMINO-ETHANETHIOL; 2-Amino-1-ethanethiol; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; 2-Mercaptoethanamine; 2-Mercaptoethylamine; 2-Mercaptoethylamine, polymer-bound; 641022_ALDRICH
DMSYFM8 CP Mylan Pharmaceuticals Inc
DMSYFM8 TC Nephropathic cystinosis therapy
DMSYFM8 DT Small molecular drug
DMSYFM8 PC 6058
DMSYFM8 MW 77.15
DMSYFM8 FM C2H7NS
DMSYFM8 IC InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
DMSYFM8 CS C(CS)N
DMSYFM8 IK UFULAYFCSOUIOV-UHFFFAOYSA-N
DMSYFM8 IU 2-aminoethanethiol
DMSYFM8 CA CAS 60-23-1
DMSYFM8 CB CHEBI:17141
DMSYFM8 DE Nephropathic cystinosis
DMZD5QR ID DMZD5QR
DMZD5QR DN Cytarabine
DMZD5QR HS Approved
DMZD5QR SN Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
DMZD5QR CP Upjohn Corporation
DMZD5QR TC Anticancer Agents
DMZD5QR DT Small molecular drug
DMZD5QR PC 6253
DMZD5QR MW 243.22
DMZD5QR FM C9H13N3O5
DMZD5QR IC InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMZD5QR CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMZD5QR IK UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DMZD5QR IU 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMZD5QR CA CAS 147-94-4
DMZD5QR CB CHEBI:28680
DMZD5QR DE Acute lymphoblastic leukaemia
DMDI6R4 ID DMDI6R4
DMDI6R4 DN Dabigatran
DMDI6R4 HS Approved
DMDI6R4 SN Pradaxa (TN)
DMDI6R4 CP Boehringer Ingelheim
DMDI6R4 DT Small molecular drug
DMDI6R4 PC 216210
DMDI6R4 MW 471.5
DMDI6R4 FM C25H25N7O3
DMDI6R4 IC InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
DMDI6R4 CS CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
DMDI6R4 IK YBSJFWOBGCMAKL-UHFFFAOYSA-N
DMDI6R4 IU 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
DMDI6R4 CA CAS 211914-51-1
DMDI6R4 CB CHEBI:70752
DMDI6R4 DE Stroke
DMX6OE3 ID DMX6OE3
DMX6OE3 DN Dabrafenib
DMX6OE3 HS Approved
DMX6OE3 SN 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436
DMX6OE3 DT Small molecular drug
DMX6OE3 PC 44462760
DMX6OE3 MW 519.6
DMX6OE3 FM C23H20F3N5O2S2
DMX6OE3 IC InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
DMX6OE3 CS CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
DMX6OE3 IK BFSMGDJOXZAERB-UHFFFAOYSA-N
DMX6OE3 IU N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
DMX6OE3 CA CAS 1195765-45-7
DMX6OE3 CB CHEBI:75045
DMX6OE3 DE Melanoma
DMNPZL4 ID DMNPZL4
DMNPZL4 DN Dacarbazine
DMNPZL4 HS Approved
DMNPZL4 SN Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
DMNPZL4 CP Bayer Pharmaceuticals Corporation
DMNPZL4 TC Anticancer Agents
DMNPZL4 DT Small molecular drug
DMNPZL4 PC 135398738
DMNPZL4 MW 182.18
DMNPZL4 FM C6H10N6O
DMNPZL4 IC InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
DMNPZL4 CS CN(C)/N=N/C1=C(NC=N1)C(=O)N
DMNPZL4 IK FDKXTQMXEQVLRF-ZHACJKMWSA-N
DMNPZL4 IU 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
DMNPZL4 CA CAS 4342-03-4
DMNPZL4 CB CHEBI:94587
DMNPZL4 DE Melanoma
DMSFK9V ID DMSFK9V
DMSFK9V DN Daclatasvir
DMSFK9V HS Approved
DMSFK9V SN 1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
DMSFK9V CP Bristol-Myers Squibb
DMSFK9V DT Small molecular drug
DMSFK9V PC 25154714
DMSFK9V MW 738.9
DMSFK9V FM C40H50N8O6
DMSFK9V IC InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
DMSFK9V CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSFK9V IK FKRSSPOQAMALKA-CUPIEXAXSA-N
DMSFK9V IU methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSFK9V CA CAS 1009119-64-5
DMSFK9V CB CHEBI:82977
DMSFK9V DE Hepatitis C virus infection
DM6OZQV ID DM6OZQV
DM6OZQV DN Daclizumab
DM6OZQV HS Approved
DM6OZQV SN DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec
DM6OZQV CP Biogen
DM6OZQV DT Monoclonal antibody
DM6OZQV SQ Humanized Anti-CD25 Heavy Chain 1: QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Humanized Anti-CD25 Light Chain 1DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM6OZQV DE Multiple sclerosis
DMOH8VY ID DMOH8VY
DMOH8VY DN Dacomitinib
DMOH8VY HS Approved
DMOH8VY SN PF-00299804
DMOH8VY CP Pfizer
DMOH8VY DT Small molecular drug
DMOH8VY PC 11511120
DMOH8VY MW 469.9
DMOH8VY FM C24H25ClFN5O2
DMOH8VY IC InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
DMOH8VY CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
DMOH8VY IK LVXJQMNHJWSHET-AATRIKPKSA-N
DMOH8VY IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
DMOH8VY CA CAS 1110813-31-4
DMOH8VY CB CHEBI:91466
DMOH8VY DE Non-small-cell lung cancer
DM2YGNW ID DM2YGNW
DM2YGNW DN Dactinomycin
DM2YGNW HS Approved
DM2YGNW SN Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
DM2YGNW TC Anticancer Agents
DM2YGNW DT Small molecular drug
DM2YGNW PC 457193
DM2YGNW MW 1255.4
DM2YGNW FM C62H86N12O16
DM2YGNW IC InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
DM2YGNW CS C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
DM2YGNW IK RJURFGZVJUQBHK-IIXSONLDSA-N
DM2YGNW IU 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
DM2YGNW CA CAS 50-76-0
DM2YGNW CB CHEBI:27666
DM2YGNW DE Solid tumour/cancer
DMGMNH3 ID DMGMNH3
DMGMNH3 DN Dalbavancin
DMGMNH3 HS Approved
DMGMNH3 SN Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba
DMGMNH3 CP Pfizer
DMGMNH3 DT Small molecular drug
DMGMNH3 PC 16134627
DMGMNH3 MW 1816.7
DMGMNH3 FM C88H100Cl2N10O28
DMGMNH3 IC InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
DMGMNH3 CS CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
DMGMNH3 IK KGPGQDLTDHGEGT-SZUNQUCBSA-N
DMGMNH3 IU (2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid
DMGMNH3 CA CAS 171500-79-1
DMGMNH3 CB CHEBI:82721
DMGMNH3 DE Bacterial infection
DMM0PDO ID DMM0PDO
DMM0PDO DN Dalfampridine
DMM0PDO HS Approved
DMM0PDO SN Ampyra (TN)
DMM0PDO CP Acorda Therapeutics
DMM0PDO DT Small molecular drug
DMM0PDO PC 1727
DMM0PDO MW 94.11
DMM0PDO FM C5H6N2
DMM0PDO IC InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
DMM0PDO CS C1=CN=CC=C1N
DMM0PDO IK NUKYPUAOHBNCPY-UHFFFAOYSA-N
DMM0PDO IU pyridin-4-amine
DMM0PDO CA CAS 504-24-5
DMM0PDO CB CHEBI:34385
DMM0PDO DE Multiple sclerosis
DM4LTKV ID DM4LTKV
DM4LTKV DN Dalfopristin
DM4LTKV HS Approved
DM4LTKV SN 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE
DM4LTKV TC Antibiotics
DM4LTKV DT Small molecular drug
DM4LTKV PC 6323289
DM4LTKV MW 690.8
DM4LTKV FM C34H50N4O9S
DM4LTKV IC InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
DM4LTKV CS CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
DM4LTKV IK SUYRLXYYZQTJHF-VMBLUXKRSA-N
DM4LTKV IU (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
DM4LTKV CA CAS 112362-50-2
DM4LTKV CB CHEBI:4309
DM4LTKV DE Bacterial infection
DM6CLBN ID DM6CLBN
DM6CLBN DN Danaparoid
DM6CLBN HS Approved
DM6CLBN SN Orgaran (TN)
DM6CLBN CP Schering-Plough
DM6CLBN TC Anticoagulants
DM6CLBN DE Deep venous clot
DML8KTN ID DML8KTN
DML8KTN DN Danazol
DML8KTN HS Approved
DML8KTN SN Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
DML8KTN TC Fertility Agents
DML8KTN DT Small molecular drug
DML8KTN PC 28417
DML8KTN MW 337.5
DML8KTN FM C22H27NO2
DML8KTN IC InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
DML8KTN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
DML8KTN IK POZRVZJJTULAOH-LHZXLZLDSA-N
DML8KTN IU (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
DML8KTN CA CAS 17230-88-5
DML8KTN CB CHEBI:4315
DML8KTN DE Menorrhagia; Breast cancer
DM1D8XY ID DM1D8XY
DM1D8XY DN Dantrolene
DM1D8XY HS Approved
DM1D8XY SN Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CP Procter & Gamble
DM1D8XY TC Muscle Relaxants
DM1D8XY DT Small molecular drug
DM1D8XY PC 6914273
DM1D8XY MW 314.25
DM1D8XY FM C14H10N4O5
DM1D8XY IC InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
DM1D8XY CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]
DM1D8XY IK OZOMQRBLCMDCEG-VIZOYTHASA-N
DM1D8XY IU 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CA CAS 7261-97-4
DM1D8XY DE Hyperthermia
DM28UJG ID DM28UJG
DM28UJG DN Dapagliflozin
DM28UJG HS Approved
DM28UJG SN BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
DM28UJG CP AstraZeneca
DM28UJG DT Small molecular drug
DM28UJG PC 9887712
DM28UJG MW 408.9
DM28UJG FM C21H25ClO6
DM28UJG IC InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
DM28UJG CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
DM28UJG IK JVHXJTBJCFBINQ-ADAARDCZSA-N
DM28UJG IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM28UJG CA CAS 461432-26-8
DM28UJG CB CHEBI:85078
DM28UJG DE Type-2 diabetes
DM34TXO ID DM34TXO
DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO HS Approved
DM34TXO SN Saxagliptin Hydrochloride; Qtern
DM34TXO CP Astrazeneca
DM34TXO DT Small molecular drug
DM34TXO DE Type-2 diabetes
DMOXJKF ID DMOXJKF
DMOXJKF DN Dapiprazole
DMOXJKF HS Approved
DMOXJKF SN Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
DMOXJKF CP Abbott Laboratories
DMOXJKF TC Ophthalmologicals
DMOXJKF DT Small molecular drug
DMOXJKF PC 3033538
DMOXJKF MW 325.5
DMOXJKF FM C19H27N5
DMOXJKF IC InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
DMOXJKF CS CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
DMOXJKF IK RFWZESUMWJKKRN-UHFFFAOYSA-N
DMOXJKF IU 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
DMOXJKF CA CAS 72822-12-9
DMOXJKF CB CHEBI:51066
DMOXJKF DE Glaucoma/ocular hypertension
DM4LT8A ID DM4LT8A
DM4LT8A DN Dapsone
DM4LT8A HS Approved
DM4LT8A SN Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline
DM4LT8A TC Antiinflammatory Agents
DM4LT8A DT Small molecular drug
DM4LT8A PC 2955
DM4LT8A MW 248.3
DM4LT8A FM C12H12N2O2S
DM4LT8A IC InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
DM4LT8A CS C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
DM4LT8A IK MQJKPEGWNLWLTK-UHFFFAOYSA-N
DM4LT8A IU 4-(4-aminophenyl)sulfonylaniline
DM4LT8A CA CAS 80-08-0
DM4LT8A CB CHEBI:4325
DM4LT8A DE Pneumocystis pneumonia
DMFDQ3I ID DMFDQ3I
DMFDQ3I DN Daptomycin
DMFDQ3I HS Approved
DMFDQ3I SN Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102
DMFDQ3I PC 16134395
DMFDQ3I MW 1620.7
DMFDQ3I FM C72H101N17O26
DMFDQ3I IC DOAKLVKFURWEDJ-RWDRXURGSA-N
DMFDQ3I CS CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMFDQ3I IK 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMFDQ3I IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMFDQ3I CA CAS 103060-53-3
DMFDQ3I CB CHEBI:600103
DMFDQ3I DE Methicillin-resistant staphylococcus infection
DMKDU16 ID DMKDU16
DMKDU16 DN Daptomycin
DMKDU16 HS Approved
DMKDU16 SN Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox
DMKDU16 CP Cubist Pharmaceuticals
DMKDU16 TC Antibiotics
DMKDU16 DT Small molecular drug
DMKDU16 PC 16134395
DMKDU16 MW 1620.7
DMKDU16 FM C72H101N17O26
DMKDU16 IC InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMKDU16 CS CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMKDU16 IK DOAKLVKFURWEDJ-RWDRXURGSA-N
DMKDU16 IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMKDU16 CA CAS 103060-53-3
DMKDU16 CB CHEBI:600103
DMKDU16 DE Bacterial infection
DMKCIUZ ID DMKCIUZ
DMKCIUZ DN Daratumumab
DMKCIUZ HS Approved
DMKCIUZ CP Genmab Princeton, NJ
DMKCIUZ DT Antibody
DMKCIUZ DE Multiple myeloma
DMMJTYW ID DMMJTYW
DMMJTYW DN Darbepoetin alfa
DMMJTYW HS Approved
DMMJTYW SN Aranesp (TN)
DMMJTYW CP Amgen Inc
DMMJTYW TC Antianemic Agents
DMMJTYW SQ DB00012 sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DMMJTYW DE Anemia
DMWXLYZ ID DMWXLYZ
DMWXLYZ DN Darifenacin
DMWXLYZ HS Approved
DMWXLYZ SN Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)
DMWXLYZ CP Norvatis Phamaceuticals Corporation
DMWXLYZ TC Urinary antispasmodics
DMWXLYZ DT Small molecular drug
DMWXLYZ PC 444031
DMWXLYZ MW 426.5
DMWXLYZ FM C28H30N2O2
DMWXLYZ IC InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
DMWXLYZ CS C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
DMWXLYZ IK HXGBXQDTNZMWGS-RUZDIDTESA-N
DMWXLYZ IU 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
DMWXLYZ CA CAS 133099-04-4
DMWXLYZ CB CHEBI:391960
DMWXLYZ DE Overactive bladder
DMV7YFT ID DMV7YFT
DMV7YFT DN Darolutamide
DMV7YFT HS Approved
DMV7YFT SN 1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen
DMV7YFT CP Bayer Pharmaceuticals Whippany, NJ
DMV7YFT PC 67171867
DMV7YFT MW 398.8
DMV7YFT FM C19H19ClN6O2
DMV7YFT IC InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
DMV7YFT CS C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
DMV7YFT IK BLIJXOOIHRSQRB-PXYINDEMSA-N
DMV7YFT IU N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
DMV7YFT CA CAS 1297538-32-9
DMV7YFT DE Prostate cancer
DMN3GCH ID DMN3GCH
DMN3GCH DN Darunavir
DMN3GCH HS Approved
DMN3GCH SN 206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
DMN3GCH CP Tibotec
DMN3GCH TC Antiviral Agents
DMN3GCH DT Small molecular drug
DMN3GCH PC 213039
DMN3GCH MW 547.7
DMN3GCH FM C27H37N3O7S
DMN3GCH IC InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
DMN3GCH CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
DMN3GCH IK CJBJHOAVZSMMDJ-HEXNFIEUSA-N
DMN3GCH IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMN3GCH CA CAS 206361-99-1
DMN3GCH CB CHEBI:367163
DMN3GCH DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMJV2EK ID DMJV2EK
DMJV2EK DN Dasatinib
DMJV2EK HS Approved
DMJV2EK SN Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMJV2EK CP Bristol Myers Squibb
DMJV2EK TC Anticancer Agents
DMJV2EK DT Small molecular drug
DMJV2EK PC 3062316
DMJV2EK MW 488
DMJV2EK FM C22H26ClN7O2S
DMJV2EK IC InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMJV2EK CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMJV2EK IK ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMJV2EK IU N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMJV2EK CA CAS 302962-49-8
DMJV2EK CB CHEBI:49375
DMJV2EK DE Chronic myelogenous leukaemia; Multiple myeloma
DM74SVE ID DM74SVE
DM74SVE DN Dasiglucagon
DM74SVE HS Approved
DM74SVE SN UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha
DM74SVE CP Zealand Pharma
DM74SVE DT Peptide
DM74SVE PC 126961379
DM74SVE MW 3381.6
DM74SVE FM C152H222N38O50
DM74SVE IC InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1
DM74SVE CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DM74SVE IK RZRMFQMNPDPAIX-AJTOSFMRSA-N
DM74SVE IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-2-methylpropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM74SVE CA CAS 1544300-84-6
DM74SVE DE Hypoglycemia; Hyperinsulinemia
DMLDQFV ID DMLDQFV
DMLDQFV DN Dasotraline
DMLDQFV HS Approved
DMLDQFV SN SEP-225289; SEP-289; Triple reuptake inhibitors (depression), Sepracor
DMLDQFV CP Sunovion pharmaceuticals
DMLDQFV DT Small molecular drug
DMLDQFV PC 9947999
DMLDQFV MW 292.2
DMLDQFV FM C16H15Cl2N
DMLDQFV IC InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
DMLDQFV CS C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
DMLDQFV IK SRPXSILJHWNFMK-MEDUHNTESA-N
DMLDQFV IU (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DMLDQFV CA CAS 675126-05-3
DMLDQFV DE Mood disorder; Attention deficit hyperactivity disorder; Eating disorder
DMQUSBT ID DMQUSBT
DMQUSBT DN Daunorubicin
DMQUSBT HS Approved
DMQUSBT SN daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
DMQUSBT TC Anticancer Agents
DMQUSBT DT Small molecular drug
DMQUSBT PC 30323
DMQUSBT MW 527.5
DMQUSBT FM C27H29NO10
DMQUSBT IC InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
DMQUSBT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
DMQUSBT IK STQGQHZAVUOBTE-VGBVRHCVSA-N
DMQUSBT IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMQUSBT CA CAS 20830-81-3
DMQUSBT CB CHEBI:41977
DMQUSBT DE Acute myeloid leukaemia; Solid tumour/cancer; Kaposi sarcoma
DMC50ME ID DMC50ME
DMC50ME DN Debrisoquin
DMC50ME HS Approved
DMC50ME SN Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
DMC50ME TC Antihypertensive Agents
DMC50ME DT Small molecular drug
DMC50ME PC 2966
DMC50ME MW 175.23
DMC50ME FM C10H13N3
DMC50ME IC InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
DMC50ME CS C1CN(CC2=CC=CC=C21)C(=N)N
DMC50ME IK JWPGJSVJDAJRLW-UHFFFAOYSA-N
DMC50ME IU 3,4-dihydro-1H-isoquinoline-2-carboximidamide
DMC50ME CA CAS 1131-64-2
DMC50ME CB CHEBI:34665
DMC50ME DE Hypertension
DMSBRUW ID DMSBRUW
DMSBRUW DN Decamethonium
DMSBRUW HS Approved
DMSBRUW SN Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide
DMSBRUW TC Neuromuscular Depolarizing Agents
DMSBRUW DT Small molecular drug
DMSBRUW PC 2968
DMSBRUW MW 258.49
DMSBRUW FM C16H38N2+2
DMSBRUW IC InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
DMSBRUW CS C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DMSBRUW IK MTCUAOILFDZKCO-UHFFFAOYSA-N
DMSBRUW IU trimethyl-[10-(trimethylazaniumyl)decyl]azanium
DMSBRUW CA CAS 156-74-1
DMSBRUW CB CHEBI:41934
DMSBRUW DE Muscle spasm
DMQL8XJ ID DMQL8XJ
DMQL8XJ DN Decitabine
DMQL8XJ HS Approved
DMQL8XJ SN AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2′-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
DMQL8XJ TC Anticancer Agents
DMQL8XJ DT Small molecular drug
DMQL8XJ PC 451668
DMQL8XJ MW 228.21
DMQL8XJ FM C8H12N4O4
DMQL8XJ IC InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
DMQL8XJ CS C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
DMQL8XJ IK XAUDJQYHKZQPEU-KVQBGUIXSA-N
DMQL8XJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMQL8XJ CA CAS 2353-33-5
DMQL8XJ CB CHEBI:50131
DMQL8XJ DE Myelodysplastic syndrome
DM6ETS0 ID DM6ETS0
DM6ETS0 DN Deferasirox
DM6ETS0 HS Approved
DM6ETS0 SN Deferasirox; Deferasirox (Exjade); Deferasiroxum; Deferasiroxum [INN-Latin]; Exjade; V8G4MOF2V9; 201530-41-8; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; C21H15N3O4; CGP-72670; CHEBI:49005; DSSTox_CID_28522; DSSTox_RID_82794; ICL 670; ICL 670A; ICL-670; ICL-670A; ICL670; ICL670A; NCGC00181754-01; UNII-V8G4MOF2V9
DM6ETS0 PC 214348
DM6ETS0 MW 373.4
DM6ETS0 FM C21H15N3O4
DM6ETS0 IC BOFQWVMAQOTZIW-UHFFFAOYSA-N
DM6ETS0 CS C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IK C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DM6ETS0 CA C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 CB CHEBI:49005
DM6ETS0 DE Hyperphosphatemia
DMS2M7O ID DMS2M7O
DMS2M7O DN Deferiprone
DMS2M7O HS Approved
DMS2M7O SN Ferriprox (TN)
DMS2M7O CP ApoPharma
DMS2M7O DT Small molecular drug
DMS2M7O PC 2972
DMS2M7O MW 139.15
DMS2M7O FM C7H9NO2
DMS2M7O IC InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
DMS2M7O CS CC1=C(C(=O)C=CN1C)O
DMS2M7O IK TZXKOCQBRNJULO-UHFFFAOYSA-N
DMS2M7O IU 3-hydroxy-1,2-dimethylpyridin-4-one
DMS2M7O CA CAS 30652-11-0
DMS2M7O CB CHEBI:68554
DMS2M7O DE Thalassemia
DMTUKZH ID DMTUKZH
DMTUKZH DN Deferoxamine mesylate
DMTUKZH HS Approved
DMTUKZH SN Desferal
DMTUKZH CP Novartis Pharmaceuticals Corp
DMTUKZH DT Small molecular drug
DMTUKZH PC 62881
DMTUKZH MW 656.8
DMTUKZH FM C26H52N6O11S
DMTUKZH IC InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
DMTUKZH CS CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
DMTUKZH IK IDDIJAWJANBQLJ-UHFFFAOYSA-N
DMTUKZH IU N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid
DMTUKZH CA CAS 138-14-7
DMTUKZH CB CHEBI:31460
DMTUKZH DE Acute iron or aluminum toxicity
DMV0RNS ID DMV0RNS
DMV0RNS DN Deflazacort
DMV0RNS HS Approved
DMV0RNS SN C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927
DMV0RNS CP PTC Therapeutics
DMV0RNS DT Small molecular drug
DMV0RNS PC 189821
DMV0RNS MW 441.5
DMV0RNS FM C25H31NO6
DMV0RNS IC InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
DMV0RNS CS CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
DMV0RNS IK FBHSPRKOSMHSIF-GRMWVWQJSA-N
DMV0RNS IU [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
DMV0RNS CA CAS 14484-47-0
DMV0RNS CB CHEBI:135720
DMV0RNS DE Duchenne dystrophy
DM3O8QY ID DM3O8QY
DM3O8QY DN Degarelix
DM3O8QY HS Approved
DM3O8QY SN Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
DM3O8QY DT Small molecular drug
DM3O8QY PC 16136245
DM3O8QY MW 1632.3
DM3O8QY FM C82H103ClN18O16
DM3O8QY IC InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DM3O8QY CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DM3O8QY IK MEUCPCLKGZSHTA-XYAYPHGZSA-N
DM3O8QY IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM3O8QY CA CAS 214766-78-6
DM3O8QY CB CHEBI:135961
DM3O8QY DE Prostate cancer
DM4Q80H ID DM4Q80H
DM4Q80H DN Dehydroepiandrosterone sulfate
DM4Q80H HS Approved
DM4Q80H SN Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate
DM4Q80H PC 12594
DM4Q80H MW 368.5
DM4Q80H FM C19H28O5S
DM4Q80H IC InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DM4Q80H CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DM4Q80H IK CZWCKYRVOZZJNM-USOAJAOKSA-N
DM4Q80H IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DM4Q80H CA CAS 651-48-9
DM4Q80H CB CHEBI:16814
DM4Q80H DE Dyspareunia
DMVTU5Q ID DMVTU5Q
DMVTU5Q DN Delafloxacin Meglumine
DMVTU5Q HS Approved
DMVTU5Q SN Baxdela
DMVTU5Q CP Melinta Therapeutics
DMVTU5Q DT Small molecular drug
DMVTU5Q PC 11578213
DMVTU5Q MW 636
DMVTU5Q FM C25H29ClF3N5O9
DMVTU5Q IC InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
DMVTU5Q CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMVTU5Q IK AHJGUEMIZPMAMR-WZTVWXICSA-N
DMVTU5Q IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DMVTU5Q CA CAS 352458-37-8
DMVTU5Q DE Acute bacterial skin infection; Skin infection
DMXE76K ID DMXE76K
DMXE76K DN Delamanid
DMXE76K HS Approved
DMXE76K SN OPC-67683; Nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka; 2-nitroimidazole derivatives (tuberculosis), Otsuka
DMXE76K CP Otsuka pharmaceutical
DMXE76K DT Small molecular drug
DMXE76K PC 6480466
DMXE76K MW 534.5
DMXE76K FM C25H25F3N4O6
DMXE76K IC InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
DMXE76K CS C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
DMXE76K IK XDAOLTSRNUSPPH-XMMPIXPASA-N
DMXE76K IU (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole
DMXE76K CA CAS 681492-22-8
DMXE76K CB CHEBI:134742
DMXE76K DE Mycobacterium infection; Multi-drug resistant tuberculosis
DM7EUK3 ID DM7EUK3
DM7EUK3 DN Delapril
DM7EUK3 HS Approved
DM7EUK3 SN Adecut (TN)
DM7EUK3 CP Takeda
DM7EUK3 DT Small molecular drug
DM7EUK3 PC 5362116
DM7EUK3 MW 452.5
DM7EUK3 FM C26H32N2O5
DM7EUK3 IC InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1
DM7EUK3 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2
DM7EUK3 IK WOUOLAUOZXOLJQ-MBSDFSHPSA-N
DM7EUK3 IU 2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid
DM7EUK3 CA CAS 83435-66-9
DM7EUK3 CB CHEBI:135735
DM7EUK3 DE Cardiovascular disease
DM3NF5G ID DM3NF5G
DM3NF5G DN Delavirdine
DM3NF5G HS Approved
DM3NF5G SN DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
DM3NF5G CP Pfizer Pharmaceuticals
DM3NF5G TC Anti-HIV Agents
DM3NF5G DT Small molecular drug
DM3NF5G PC 5625
DM3NF5G MW 456.6
DM3NF5G FM C22H28N6O3S
DM3NF5G IC InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
DM3NF5G CS CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DM3NF5G IK WHBIGIKBNXZKFE-UHFFFAOYSA-N
DM3NF5G IU N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DM3NF5G CA CAS 136817-59-9
DM3NF5G CB CHEBI:119573
DM3NF5G DE Human immunodeficiency virus infection
DMAYEU1 ID DMAYEU1
DMAYEU1 DN Demecarium bromide
DMAYEU1 HS Approved
DMAYEU1 SN Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide
DMAYEU1 TC Parasympathomimetics
DMAYEU1 DT Small molecular drug
DMAYEU1 PC 5965
DMAYEU1 MW 716.6
DMAYEU1 FM C32H52Br2N4O4
DMAYEU1 IC InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2
DMAYEU1 CS CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-]
DMAYEU1 IK YHKBUDZECQDYBR-UHFFFAOYSA-L
DMAYEU1 IU trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide
DMAYEU1 CA CAS 56-94-0
DMAYEU1 CB CHEBI:4391
DMAYEU1 DE Open-angle glaucoma
DMZEPFJ ID DMZEPFJ
DMZEPFJ DN Demeclocycline
DMZEPFJ HS Approved
DMZEPFJ SN Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline
DMZEPFJ CP Patheon Pharmaceuticals Inc
DMZEPFJ TC Antibiotics
DMZEPFJ DT Small molecular drug
DMZEPFJ PC 54680690
DMZEPFJ MW 464.9
DMZEPFJ FM C21H21ClN2O8
DMZEPFJ IC InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1
DMZEPFJ CS CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMZEPFJ IK GUXHBMASAHGULD-SEYHBJAFSA-N
DMZEPFJ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMZEPFJ CA CAS 127-33-3
DMZEPFJ CB CHEBI:4392
DMZEPFJ DE Bronchitis; Acne vulgaris; Lyme disease
DMCZQGK ID DMCZQGK
DMCZQGK DN Demecolcine
DMCZQGK HS Approved
DMCZQGK SN colcemid; 1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one; demecolcine,colcemid, n-deacetyl-n-methylcolchicine, n-methyl-n-desacetylcolchicine; Demicolcine; NSC3096; 1,2,3,10-Tetramethoxy-7-(methylamino)-6,7-dihydrobenzo[a]heptalen-9(5H)-one; NCGC00166035-01; AC1L1EKK; MolMap_000011; SCHEMBL8160; AC1Q698E; CHEMBL433632; CTK8E8505; MolPort-003-846-192; 6,7-Dihydro-1,2,3,10-Tetramethoxy-7-(Methylamino) Benzo (alpha) Heptalen-9(5H)-one; HMS3374M04; HSCI1_000384; BBL027927; STL377913; CD0013
DMCZQGK DT Small molecular drug
DMCZQGK PC 220401
DMCZQGK MW 371.4
DMCZQGK FM C21H25NO5
DMCZQGK IC InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1
DMCZQGK CS CN[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DMCZQGK IK NNJPGOLRFBJNIW-HNNXBMFYSA-N
DMCZQGK IU (7S)-1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one
DMCZQGK CA CAS 477-30-5
DMCZQGK CB CHEBI:4393
DMCZQGK DE Solid tumour/cancer
DMMHR1U ID DMMHR1U
DMMHR1U DN Denileukin diftitox
DMMHR1U HS Approved
DMMHR1U CP Louisville
DMMHR1U TC Anticancer Agents
DMMHR1U SQ DB00004 sequence: MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DMMHR1U DE leukaemia; Non-small-cell lung cancer
DM8C3GN ID DM8C3GN
DM8C3GN DN Denopamine
DM8C3GN HS Approved
DM8C3GN SN Kalgut (TN)
DM8C3GN DT Small molecular drug
DM8C3GN PC 5311064
DM8C3GN MW 317.4
DM8C3GN FM C18H23NO4
DM8C3GN IC InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1
DM8C3GN CS COC1=C(C=C(C=C1)CCNC[C@@H](C2=CC=C(C=C2)O)O)OC
DM8C3GN IK VHSBBVZJABQOSG-INIZCTEOSA-N
DM8C3GN IU 4-[(1R)-2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol
DM8C3GN CA CAS 71771-90-9
DM8C3GN CB CHEBI:135359
DM8C3GN DE Cardiac disease
DMNI0KO ID DMNI0KO
DMNI0KO DN Denosumab
DMNI0KO HS Approved
DMNI0KO SN Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)
DMNI0KO CP Amgen
DMNI0KO DT Antibody
DMNI0KO SQ Denosumab OPGL-1 heavy chain sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Denosumab OPGL-1 light chain sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNI0KO DE Postmenopausal osteoporosis; Rheumatoid arthritis; Prostate cancer
DM3GYAL ID DM3GYAL
DM3GYAL DN Deoxycholic acid
DM3GYAL HS Approved
DM3GYAL SN (3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate
DM3GYAL DT Small molecular drug
DM3GYAL PC 222528
DM3GYAL MW 392.58
DM3GYAL FM C24H40O4
DM3GYAL IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM3GYAL CS CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
DM3GYAL IK KXGVEGMKQFWNSR-LLQZFEROSA-N
DM3GYAL IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3GYAL CA CAS 83-44-3
DM3GYAL CB CHEBI:28834
DM3GYAL DE Fat below the chin
DMYE5LJ ID DMYE5LJ
DMYE5LJ DN DEOXYCYTIDINE
DMYE5LJ HS Approved
DMYE5LJ SN Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
DMYE5LJ DT Small molecular drug
DMYE5LJ PC 13711
DMYE5LJ MW 227.22
DMYE5LJ FM C9H13N3O4
DMYE5LJ IC InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1
DMYE5LJ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O
DMYE5LJ IK CKTSBUTUHBMZGZ-SHYZEUOFSA-N
DMYE5LJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMYE5LJ CA CAS 951-77-9
DMYE5LJ CB CHEBI:15698
DMYE5LJ DE Acute myeloid leukaemia
DMRH7CV ID DMRH7CV
DMRH7CV DN Deserpidine
DMRH7CV HS Approved
DMRH7CV SN Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)
DMRH7CV TC Antihypertensive Agents
DMRH7CV DT Small molecular drug
DMRH7CV PC 8550
DMRH7CV MW 578.7
DMRH7CV FM C32H38N2O8
DMRH7CV IC InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
DMRH7CV CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DMRH7CV IK CVBMAZKKCSYWQR-WCGOZPBSSA-N
DMRH7CV IU methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMRH7CV CA CAS 131-01-1
DMRH7CV CB CHEBI:27478
DMRH7CV DE Hypertension
DM2TO9R ID DM2TO9R
DM2TO9R DN Desflurane
DM2TO9R HS Approved
DM2TO9R SN Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R TC Anesthetics
DM2TO9R DT Small molecular drug
DM2TO9R PC 42113
DM2TO9R MW 168.04
DM2TO9R FM C3H2F6O
DM2TO9R IC InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DM2TO9R CS C(C(F)(F)F)(OC(F)F)F
DM2TO9R IK DPYMFVXJLLWWEU-UHFFFAOYSA-N
DM2TO9R IU 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R CA CAS 57041-67-5
DM2TO9R CB CHEBI:4445
DM2TO9R DE Anaesthesia
DMT2FDC ID DMT2FDC
DMT2FDC DN Desipramine
DMT2FDC HS Approved
DMT2FDC SN Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
DMT2FDC CP Sanofi Aventis Us Llc
DMT2FDC TC Antidepressants
DMT2FDC DT Small molecular drug
DMT2FDC PC 2995
DMT2FDC MW 266.4
DMT2FDC FM C18H22N2
DMT2FDC IC InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
DMT2FDC CS CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DMT2FDC IK HCYAFALTSJYZDH-UHFFFAOYSA-N
DMT2FDC IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMT2FDC CA CAS 50-47-5
DMT2FDC CB CHEBI:47781
DMT2FDC DE Attention deficit hyperactivity disorder; Depression
DM2BTFN ID DM2BTFN
DM2BTFN DN Desirudin Recombinant
DM2BTFN HS Approved
DM2BTFN SN Iprivask
DM2BTFN CP Valeant Pharmaceuticals North America Llc
DM2BTFN TC Cardiovascular Agents
DM2BTFN DE Coagulation defect
DMB3ZSK ID DMB3ZSK
DMB3ZSK DN Deslanoside
DMB3ZSK HS Approved
DMB3ZSK SN Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
DMB3ZSK TC Antiarrhythmic Agents
DMB3ZSK DT Small molecular drug
DMB3ZSK PC 28620
DMB3ZSK MW 943.1
DMB3ZSK FM C47H74O19
DMB3ZSK IC InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
DMB3ZSK CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
DMB3ZSK IK OBATZBGFDSVCJD-LALPQLPRSA-N
DMB3ZSK IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMB3ZSK CA CAS 17598-65-1
DMB3ZSK CB CHEBI:31468
DMB3ZSK DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DM56YN7 ID DM56YN7
DM56YN7 DN Desloratadine
DM56YN7 HS Approved
DM56YN7 SN Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
DM56YN7 CP Schering-Plough
DM56YN7 TC Antiallergic Agents
DM56YN7 DT Small molecular drug
DM56YN7 PC 124087
DM56YN7 MW 310.8
DM56YN7 FM C19H19ClN2
DM56YN7 IC InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
DM56YN7 CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
DM56YN7 IK JAUOIFJMECXRGI-UHFFFAOYSA-N
DM56YN7 IU 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DM56YN7 CA CAS 100643-71-8
DM56YN7 CB CHEBI:291342
DM56YN7 DE Allergic rhinitis
DMS3GVE ID DMS3GVE
DMS3GVE DN Desmopressin
DMS3GVE HS Approved
DMS3GVE SN Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals
DMS3GVE CP Ferring Pharmaceuticals Inc
DMS3GVE DT Small molecular drug
DMS3GVE PC 5311065
DMS3GVE MW 1069.2
DMS3GVE FM C46H64N14O12S2
DMS3GVE IC InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
DMS3GVE CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMS3GVE IK NFLWUMRGJYTJIN-PNIOQBSNSA-N
DMS3GVE IU (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS3GVE CA CAS 16679-58-6
DMS3GVE CB CHEBI:4450
DMS3GVE DE Diabetic complication
DM27U4Y ID DM27U4Y
DM27U4Y DN Desogestrel
DM27U4Y HS Approved
DM27U4Y SN Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
DM27U4Y TC Contraceptive Agents
DM27U4Y DT Small molecular drug
DM27U4Y PC 40973
DM27U4Y MW 310.5
DM27U4Y FM C22H30O
DM27U4Y IC InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DM27U4Y CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
DM27U4Y IK RPLCPCMSCLEKRS-BPIQYHPVSA-N
DM27U4Y IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
DM27U4Y CA CAS 54024-22-5
DM27U4Y CB CHEBI:4453
DM27U4Y DE Contraception
DMTP2NJ ID DMTP2NJ
DMTP2NJ DN Desonide
DMTP2NJ HS Approved
DMTP2NJ SN Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide
DMTP2NJ TC Antiinflammatory Agents
DMTP2NJ DT Small molecular drug
DMTP2NJ PC 5311066
DMTP2NJ MW 416.5
DMTP2NJ FM C24H32O6
DMTP2NJ IC InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMTP2NJ CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O
DMTP2NJ IK WBGKWQHBNHJJPZ-LECWWXJVSA-N
DMTP2NJ IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMTP2NJ CA CAS 638-94-8
DMTP2NJ CB CHEBI:204734
DMTP2NJ DE Atopic dermatitis
DM4PXF6 ID DM4PXF6
DM4PXF6 DN Desoximetasone
DM4PXF6 HS Approved
DM4PXF6 SN Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
DM4PXF6 TC Antiinflammatory Agents
DM4PXF6 DT Small molecular drug
DM4PXF6 PC 5311067
DM4PXF6 MW 376.5
DM4PXF6 FM C22H29FO4
DM4PXF6 IC InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
DM4PXF6 CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
DM4PXF6 IK VWVSBHGCDBMOOT-IIEHVVJPSA-N
DM4PXF6 IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4PXF6 CA CAS 140218-14-0
DM4PXF6 CB CHEBI:691037
DM4PXF6 DE Inflammation
DMS0AFE ID DMS0AFE
DMS0AFE DN Desoxycorticosterone acetate
DMS0AFE HS Approved
DMS0AFE SN Doca
DMS0AFE CP Organon Usa Inc
DMS0AFE DT Small molecular drug
DMS0AFE PC 5952
DMS0AFE MW 372.5
DMS0AFE FM C23H32O4
DMS0AFE IC InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1
DMS0AFE CS CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMS0AFE IK VPGRYOFKCNULNK-ACXQXYJUSA-N
DMS0AFE IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMS0AFE CA CAS 56-47-3
DMS0AFE CB CHEBI:34671
DMS0AFE DE Discovery agent
DMSA4B3 ID DMSA4B3
DMSA4B3 DN Desoxycorticosterone pivalate
DMSA4B3 HS Approved
DMSA4B3 SN DOCP; DTMA; Cortexone M; Deoxycorticosterone pivalate; Deoxycorticosterone trimethylacetate; Deoxycortolone Pivalate; Deoxycortone pivalate; Deoxycortone trimethylacetate; Desoxycorticosterone trimethylacetate; Desoxycortone pivalate; Percorten M; Percorten Pivalate; Desoxycorticosterone pivalate (USP); Neodin-depositum; Percorten (TN); Corticosterone, deoxy-, pivalate (6CI,7CI); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; 11-Deoxycorticosterone pivalate; 11-Deoxycorticosterone, pivalate; 11-Deoxycorticosterone, pivalate (8CI); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate
DMSA4B3 TC Antiaddison Agents
DMSA4B3 DT Small molecular drug
DMSA4B3 PC 11876263
DMSA4B3 MW 414.6
DMSA4B3 FM C26H38O4
DMSA4B3 IC InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
DMSA4B3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C
DMSA4B3 IK VVOIQBFMTVCINR-WWMZEODYSA-N
DMSA4B3 IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMSA4B3 CA CAS 808-48-0
DMSA4B3 CB CHEBI:50782
DMSA4B3 DE Addison disease
DMEZFXR ID DMEZFXR
DMEZFXR DN Desoxyribonuclease
DMEZFXR HS Approved
DMEZFXR DE Female genital tract inflammation
DMJE6KO ID DMJE6KO
DMJE6KO DN Desvenalfaxine succinate
DMJE6KO HS Approved
DMJE6KO SN 386750-22-7; Desvenlafaxine succinate monohydrate; Desvenlafaxine (succinate hydrate); Desvenlafaxine succinate hydrate; Desvenlafaxine Succinate [USAN]; Desvenlafaxine succinate (USAN); O-desmethylvenlafaxine Succinate Monohydrate; Desvenlafaxine Succinate Monohydrate (O-Desmethylvenlafaxine Succinate Monohydrate); Pristiq (TN); AC1OCFPN; Desvenlafaxine(succinatehydrate); SCHEMBL1278407; CTK8E8387; HY-B0602A; MolPort-021-783-032
DMJE6KO CP Wyeth
DMJE6KO DT Small molecular drug
DMJE6KO PC 6918664
DMJE6KO MW 399.5
DMJE6KO FM C20H33NO7
DMJE6KO IC InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2
DMJE6KO CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O
DMJE6KO IK PWPDEXVGKDEKTE-UHFFFAOYSA-N
DMJE6KO IU butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate
DMJE6KO CA CAS 386750-22-7
DMJE6KO DE Fibromyalgia
DMHD4PE ID DMHD4PE
DMHD4PE DN Desvenlafaxine
DMHD4PE HS Approved
DMHD4PE SN Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233
DMHD4PE CP Wyeth
DMHD4PE DT Small molecular drug
DMHD4PE PC 125017
DMHD4PE MW 263.37
DMHD4PE FM C16H25NO2
DMHD4PE IC InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
DMHD4PE CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
DMHD4PE IK KYYIDSXMWOZKMP-UHFFFAOYSA-N
DMHD4PE IU 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
DMHD4PE CA CAS 93413-62-8
DMHD4PE CB CHEBI:83527
DMHD4PE DE Major depressive disorder; Menopause symptom
DMUPFLI ID DMUPFLI
DMUPFLI DN Deutetrabenazine
DMUPFLI HS Approved
DMUPFLI SN Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]
DMUPFLI CP Teva
DMUPFLI DT Small molecular drug
DMUPFLI PC 73437646
DMUPFLI MW 323.5
DMUPFLI FM C19H27NO3
DMUPFLI IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
DMUPFLI CS [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
DMUPFLI IK MKJIEFSOBYUXJB-VFJJUKLQSA-N
DMUPFLI IU (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMUPFLI CA CAS 1392826-25-3
DMUPFLI DE Tardive dyskinesia; Huntington disease
DMMWZET ID DMMWZET
DMMWZET DN Dexamethasone
DMMWZET HS Approved
DMMWZET SN Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
DMMWZET CP Swiss Pharma
DMMWZET TC Antiinflammatory Agents
DMMWZET DT Small molecular drug
DMMWZET PC 5743
DMMWZET MW 392.5
DMMWZET FM C22H29FO5
DMMWZET IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DMMWZET CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMMWZET IK UREBDLICKHMUKA-CXSFZGCWSA-N
DMMWZET IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMMWZET CA CAS 50-02-2
DMMWZET CB CHEBI:41879
DMMWZET DE Rheumatoid arthritis
DMIG8DW ID DMIG8DW
DMIG8DW DN Dexamethasone sodium phosphate
DMIG8DW HS Approved
DMIG8DW SN EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel
DMIG8DW CP Universita' Degli Studi Di Urbino
DMIG8DW DT Small molecular drug
DMIG8DW PC 16961
DMIG8DW MW 516.4
DMIG8DW FM C22H28FNa2O8P
DMIG8DW IC InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
DMIG8DW CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+]
DMIG8DW IK PLCQGRYPOISRTQ-FCJDYXGNSA-L
DMIG8DW IU disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
DMIG8DW CA CAS 2392-39-4
DMIG8DW CB CHEBI:4462
DMIG8DW DE Ataxia-telangiectasia
DMKVWGE ID DMKVWGE
DMKVWGE DN Dexbrompheniramine
DMKVWGE HS Approved
DMKVWGE SN Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine
DMKVWGE CP Schering Corp Sub Schering Plough Corp
DMKVWGE TC Antihistamines
DMKVWGE DT Small molecular drug
DMKVWGE PC 16960
DMKVWGE MW 319.24
DMKVWGE FM C16H19BrN2
DMKVWGE IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
DMKVWGE CS CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMKVWGE IK ZDIGNSYAACHWNL-HNNXBMFYSA-N
DMKVWGE IU (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMKVWGE CA CAS 132-21-8
DMKVWGE CB CHEBI:59269
DMKVWGE DE Hay fever
DMA8DPN ID DMA8DPN
DMA8DPN DN Dexchlorpheniramine maleate
DMA8DPN HS Approved
DMA8DPN SN Polaramine
DMA8DPN CP Schering Corp Sub Schering Plough Corp
DMA8DPN DT Small molecular drug
DMA8DPN PC 5281070
DMA8DPN MW 390.9
DMA8DPN FM C20H23ClN2O4
DMA8DPN IC InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1
DMA8DPN CS CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DMA8DPN IK DBAKFASWICGISY-DASCVMRKSA-N
DMA8DPN IU (Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMA8DPN CA CAS 2438-32-6
DMA8DPN CB CHEBI:4465
DMA8DPN DE Rhinitis
DMFYBD0 ID DMFYBD0
DMFYBD0 DN Dexibuprofen
DMFYBD0 HS Approved
DMFYBD0 SN (S)-(+)-Ibuprofen; 51146-56-6; DEXIBUPROFEN; S(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; d-Ibuproten; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (+)-(S)-p-Isobutylhydratropic acid; Seractil; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; UNII-671DKG7P5S; S-(+)-ibuprofen; (2S)-2-(4-isobutylphenyl)propanoic acid; CHEMBL175; 671DKG7P5S; CHEBI:43415; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; NCGC00016861-05
DMFYBD0 DT Small molecular drug
DMFYBD0 PC 39912
DMFYBD0 MW 206.28
DMFYBD0 FM C13H18O2
DMFYBD0 IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
DMFYBD0 CS C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
DMFYBD0 IK HEFNNWSXXWATRW-JTQLQIEISA-N
DMFYBD0 IU (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
DMFYBD0 CA CAS 51146-56-6
DMFYBD0 CB CHEBI:43415
DMFYBD0 DE Ankylosing spondylitis
DM1DBV5 ID DM1DBV5
DM1DBV5 DN Dexlansoprazole
DM1DBV5 HS Approved
DM1DBV5 SN dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole
DM1DBV5 CP Takeda
DM1DBV5 DT Small molecular drug
DM1DBV5 PC 9578005
DM1DBV5 MW 369.4
DM1DBV5 FM C16H14F3N3O2S
DM1DBV5 IC InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
DM1DBV5 CS CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DM1DBV5 IK MJIHNNLFOKEZEW-RUZDIDTESA-N
DM1DBV5 IU 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DM1DBV5 CA CAS 138530-94-6
DM1DBV5 CB CHEBI:135931
DM1DBV5 DE Non-erosive gastro-esophageal reflux disease; Erosive esophagitis; Peptic ulcer; NSAID-associated gastric ulcer
DM93L4X ID DM93L4X
DM93L4X DN Dexmedetomidine
DM93L4X HS Approved
DM93L4X SN Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CP Hospira
DM93L4X TC Hypnotics and Sedatives
DM93L4X DT Small molecular drug
DM93L4X PC 5311068
DM93L4X MW 200.28
DM93L4X FM C13H16N2
DM93L4X IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
DM93L4X CS CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C
DM93L4X IK CUHVIMMYOGQXCV-NSHDSACASA-N
DM93L4X IU 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CA CAS 113775-47-6
DM93L4X CB CHEBI:4466
DM93L4X DE Irritability
DMUQE2A ID DMUQE2A
DMUQE2A DN Dexmethylphenidate
DMUQE2A HS Approved
DMUQE2A SN Dexmethylphenidate; Dexmethylphenidate (INN); Dexmethylphenidate [INN]; Focalin; Focalin XR; M32RH9MFGP; Methyl D-phenidate; d-Methylphenidate; Attenade; Dex methylphenidate; d-threo-Methylphenidate; dex-methylphenidate; dexmethylphenidatum; dexmetilfenidato; threo-(+)-Methylphenidate; (+)-threo-Methylphenidate; 40431-64-9; CHEBI:51860; CHEMBL827; D-MPH; D-TMP; UNII-M32RH9MFGP; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
DMUQE2A PC 154101
DMUQE2A MW 233.31
DMUQE2A FM C14H19NO2
DMUQE2A IC DUGOZIWVEXMGBE-CHWSQXEVSA-N
DMUQE2A CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DMUQE2A IK 1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
DMUQE2A IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DMUQE2A CA CAS 40431-64-9
DMUQE2A CB CHEBI:51860
DMUQE2A DE Attention deficit hyperactivity disorder
DM8WBAH ID DM8WBAH
DM8WBAH DN Dexmethylphenidate hydrochloride
DM8WBAH HS Approved
DM8WBAH SN Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
DM8WBAH DT Small molecular drug
DM8WBAH PC 154100
DM8WBAH MW 269.77
DM8WBAH FM C14H20ClNO2
DM8WBAH IC InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
DM8WBAH CS COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
DM8WBAH IK JUMYIBMBTDDLNG-OJERSXHUSA-N
DM8WBAH IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
DM8WBAH CA CAS 19262-68-1
DM8WBAH DE Attention deficit hyperactivity disorder
DMD7X1O ID DMD7X1O
DMD7X1O DN Dexrazoxane
DMD7X1O HS Approved
DMD7X1O SN 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum; Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187
DMD7X1O CP Pfizer Pharmaceuticals
DMD7X1O TC Anticancer Agents
DMD7X1O DT Small molecular drug
DMD7X1O PC 71384
DMD7X1O MW 268.27
DMD7X1O FM C11H16N4O4
DMD7X1O IC InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
DMD7X1O CS C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
DMD7X1O IK BMKDZUISNHGIBY-ZETCQYMHSA-N
DMD7X1O IU 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
DMD7X1O CA CAS 24584-09-6
DMD7X1O CB CHEBI:50223
DMD7X1O DE Breast cancer; Chemoprotection; Respiratory tract disease
DMMIHVP ID DMMIHVP
DMMIHVP DN Dextroamphetamine
DMMIHVP HS Approved
DMMIHVP SN D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga
DMMIHVP CP GlaxoSmithKline
DMMIHVP TC Central Nervous System Stimulants
DMMIHVP DT Small molecular drug
DMMIHVP PC 5826
DMMIHVP MW 135.21
DMMIHVP FM C9H13N
DMMIHVP IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
DMMIHVP CS C[C@@H](CC1=CC=CC=C1)N
DMMIHVP IK KWTSXDURSIMDCE-QMMMGPOBSA-N
DMMIHVP IU (2S)-1-phenylpropan-2-amine
DMMIHVP CA CAS 51-64-9
DMMIHVP CB CHEBI:4469
DMMIHVP DE Narcolepsy; Attention deficit hyperactivity disorder
DMUDJZM ID DMUDJZM
DMUDJZM DN Dextromethorphan
DMUDJZM HS Approved
DMUDJZM SN Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)
DMUDJZM TC Analgesics
DMUDJZM DT Small molecular drug
DMUDJZM PC 5360696
DMUDJZM MW 271.4
DMUDJZM FM C18H25NO
DMUDJZM IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
DMUDJZM CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
DMUDJZM IK MKXZASYAUGDDCJ-NJAFHUGGSA-N
DMUDJZM IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMUDJZM CA CAS 125-71-3
DMUDJZM CB CHEBI:4470
DMUDJZM DE Cough
DMEHCY5 ID DMEHCY5
DMEHCY5 DN Dextromethorphan polistirex
DMEHCY5 HS Approved
DMEHCY5 CP Reckitt Benckiser Llc
DMEHCY5 PC 5464025
DMEHCY5 MW 352.3
DMEHCY5 FM C18H26BrNO
DMEHCY5 IC InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1
DMEHCY5 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br
DMEHCY5 IK MISZALMBODQYFT-URVXVIKDSA-N
DMEHCY5 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide
DMEHCY5 CA CAS 125-69-9
DMEHCY5 DE Dry cough
DM23HCX ID DM23HCX
DM23HCX DN Dextropropoxyphene
DM23HCX HS Approved
DM23HCX SN Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
DM23HCX TC Analgesics
DM23HCX DT Small molecular drug
DM23HCX PC 10100
DM23HCX MW 339.5
DM23HCX FM C22H29NO2
DM23HCX IC InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
DM23HCX CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C
DM23HCX IK XLMALTXPSGQGBX-GCJKJVERSA-N
DM23HCX IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
DM23HCX CA CAS 469-62-5
DM23HCX CB CHEBI:51173
DM23HCX DE Pain
DMBVEC7 ID DMBVEC7
DMBVEC7 DN Dextrothyroxine Sodium
DMBVEC7 HS Approved
DMBVEC7 SN Choloxin
DMBVEC7 CP Abbvie Inc
DMBVEC7 DT Small molecular drug
DMBVEC7 PC 23690433
DMBVEC7 MW 798.85
DMBVEC7 FM C15H10I4NNaO4
DMBVEC7 IC InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1
DMBVEC7 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)[O-])N.[Na+]
DMBVEC7 IK YDTFRJLNMPSCFM-UTONKHPSSA-M
DMBVEC7 IU sodium;(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
DMBVEC7 CA CAS 137-53-1
DMBVEC7 DE High blood cholesterol level
DMJDB0Y ID DMJDB0Y
DMJDB0Y DN Dezocine
DMJDB0Y HS Approved
DMJDB0Y SN SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol
DMJDB0Y TC Analgesics
DMJDB0Y DT Small molecular drug
DMJDB0Y PC 3033053
DMJDB0Y MW 245.36
DMJDB0Y FM C16H23NO
DMJDB0Y IC InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1
DMJDB0Y CS C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O
DMJDB0Y IK VTMVHDZWSFQSQP-VBNZEHGJSA-N
DMJDB0Y IU (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol
DMJDB0Y CA CAS 53648-55-8
DMJDB0Y CB CHEBI:4474
DMJDB0Y DE Pain
DMU3FGB ID DMU3FGB
DMU3FGB DN Dhaq diacetate
DMU3FGB HS Approved
DMU3FGB SN Mitoxantrone diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate
DMU3FGB TC Anticancer Agents
DMU3FGB DT Small molecular drug
DMU3FGB PC 51151
DMU3FGB MW 564.6
DMU3FGB FM C26H36N4O10
DMU3FGB IC InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4)
DMU3FGB CS CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO
DMU3FGB IK ZWCKUVMZBKQQRG-UHFFFAOYSA-N
DMU3FGB IU 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium;diacetate
DMU3FGB CA CAS 70711-41-0
DMU3FGB DE Solid tumour/cancer
DM08E9O ID DM08E9O
DM08E9O DN Diazepam
DM08E9O HS Approved
DM08E9O SN diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol; Diazepam (intranasal, epilepsy)
DM08E9O CP Archimedes Pharma Ltd
DM08E9O DT Small molecular drug
DM08E9O PC 3016
DM08E9O MW 284.74
DM08E9O FM C16H13ClN2O
DM08E9O IC InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DM08E9O CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DM08E9O IK AAOVKJBEBIDNHE-UHFFFAOYSA-N
DM08E9O IU 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM08E9O CA CAS 439-14-5
DM08E9O CB CHEBI:49575
DM08E9O DE Epilepsy
DML1538 ID DML1538
DML1538 DN Diazoxide
DML1538 HS Approved
DML1538 SN Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1
DML1538 TC Antihypertensive Agents
DML1538 DT Small molecular drug
DML1538 PC 3019
DML1538 MW 230.67
DML1538 FM C8H7ClN2O2S
DML1538 IC InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
DML1538 CS CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
DML1538 IK GDLBFKVLRPITMI-UHFFFAOYSA-N
DML1538 IU 7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DML1538 CA CAS 364-98-7
DML1538 CB CHEBI:4495
DML1538 DE Hypertension
DMF9G7L ID DMF9G7L
DMF9G7L DN Dibucaine
DMF9G7L HS Approved
DMF9G7L SN Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CP Novartis Pharmaceuticals Corp
DMF9G7L TC Anesthetics
DMF9G7L DT Small molecular drug
DMF9G7L PC 3025
DMF9G7L MW 343.5
DMF9G7L FM C20H29N3O2
DMF9G7L IC InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
DMF9G7L CS CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
DMF9G7L IK PUFQVTATUTYEAL-UHFFFAOYSA-N
DMF9G7L IU 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CA CAS 85-79-0
DMF9G7L CB CHEBI:247956
DMF9G7L DE Anaesthesia
DMH7IDQ ID DMH7IDQ
DMH7IDQ DN Dichlorphenamide
DMH7IDQ HS Approved
DMH7IDQ SN dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis; Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE
DMH7IDQ TC Antiglaucomic Agents
DMH7IDQ DT Small molecular drug
DMH7IDQ PC 3038
DMH7IDQ MW 305.2
DMH7IDQ FM C6H6Cl2N2O4S2
DMH7IDQ IC InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
DMH7IDQ CS C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
DMH7IDQ IK GJQPMPFPNINLKP-UHFFFAOYSA-N
DMH7IDQ IU 4,5-dichlorobenzene-1,3-disulfonamide
DMH7IDQ CA CAS 120-97-8
DMH7IDQ CB CHEBI:101085
DMH7IDQ DE Chronic glaucoma
DMPIHLS ID DMPIHLS
DMPIHLS DN Diclofenac
DMPIHLS HS Approved
DMPIHLS SN Diclofenac (sodium matrix patch, pain)
DMPIHLS CP Novartis Pharmaceuticals Corp
DMPIHLS TC Neurology Agents
DMPIHLS DT Small molecular drug
DMPIHLS PC 3033
DMPIHLS MW 296.1
DMPIHLS FM C14H11Cl2NO2
DMPIHLS IC InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
DMPIHLS CS C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMPIHLS IK DCOPUUMXTXDBNB-UHFFFAOYSA-N
DMPIHLS IU 2-[2-(2,6-dichloroanilino)phenyl]acetic acid
DMPIHLS CA CAS 15307-86-5
DMPIHLS CB CHEBI:47381
DMPIHLS DE Osteoarthritis
DM8EU0Z ID DM8EU0Z
DM8EU0Z DN Dicloxacillin
DM8EU0Z HS Approved
DM8EU0Z SN Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DM8EU0Z CP Sandoz Inc
DM8EU0Z TC Antibiotics
DM8EU0Z DT Small molecular drug
DM8EU0Z PC 18381
DM8EU0Z MW 470.3
DM8EU0Z FM C19H17Cl2N3O5S
DM8EU0Z IC InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DM8EU0Z CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DM8EU0Z IK YFAGHNZHGGCZAX-JKIFEVAISA-N
DM8EU0Z IU (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8EU0Z CA CAS 3116-76-5
DM8EU0Z CB CHEBI:4511
DM8EU0Z DE Bacterial infection
DMFQCB1 ID DMFQCB1
DMFQCB1 DN Dicumarol
DMFQCB1 HS Approved
DMFQCB1 SN Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3′-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin
DMFQCB1 TC Anticoagulants
DMFQCB1 DT Small molecular drug
DMFQCB1 PC 54676038
DMFQCB1 MW 336.3
DMFQCB1 FM C19H12O6
DMFQCB1 IC InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
DMFQCB1 CS C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
DMFQCB1 IK DOBMPNYZJYQDGZ-UHFFFAOYSA-N
DMFQCB1 IU 4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one
DMFQCB1 CA CAS 66-76-2
DMFQCB1 CB CHEBI:4513
DMFQCB1 DE Thrombosis; Bleeding disorder
DMZSDGX ID DMZSDGX
DMZSDGX DN Dicyclomine
DMZSDGX HS Approved
DMZSDGX SN Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride
DMZSDGX CP Peckforton Pharmaceuticals
DMZSDGX TC Anticholinergic Agents
DMZSDGX DT Small molecular drug
DMZSDGX PC 3042
DMZSDGX MW 309.5
DMZSDGX FM C19H35NO2
DMZSDGX IC InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
DMZSDGX CS CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
DMZSDGX IK CURUTKGFNZGFSE-UHFFFAOYSA-N
DMZSDGX IU 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
DMZSDGX CA CAS 77-19-0
DMZSDGX CB CHEBI:4514
DMZSDGX DE Functional bowel syndrome
DMI2QPE ID DMI2QPE
DMI2QPE DN Didanosine
DMI2QPE HS Approved
DMI2QPE SN didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927
DMI2QPE CP Bristol-Myers Squibb
DMI2QPE TC Anti-HIV Agents
DMI2QPE DT Small molecular drug
DMI2QPE PC 135398739
DMI2QPE MW 236.23
DMI2QPE FM C10H12N4O3
DMI2QPE IC InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
DMI2QPE CS C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
DMI2QPE IK BXZVVICBKDXVGW-NKWVEPMBSA-N
DMI2QPE IU 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMI2QPE CA CAS 69655-05-6
DMI2QPE CB CHEBI:490877
DMI2QPE DE Human immunodeficiency virus infection
DMBSXI0 ID DMBSXI0
DMBSXI0 DN Dienestrol
DMBSXI0 HS Approved
DMBSXI0 SN Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 TC Estrogens
DMBSXI0 DT Small molecular drug
DMBSXI0 PC 667476
DMBSXI0 MW 266.3
DMBSXI0 FM C18H18O2
DMBSXI0 IC InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+
DMBSXI0 CS C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\\C2=CC=C(C=C2)O
DMBSXI0 IK NFDFQCUYFHCNBW-SCGPFSFSSA-N
DMBSXI0 IU 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 CA CAS 13029-44-2
DMBSXI0 CB CHEBI:4518
DMBSXI0 DE Atrophic vaginitis
DM1TJ8F ID DM1TJ8F
DM1TJ8F DN Diethylcarbamazine
DM1TJ8F HS Approved
DM1TJ8F SN Bitirazine; Camin; Caracide; Carbamazine; Carbilazine; Caricide; Cypip; Decacide; Diaethylcarbamazinum; Diethylcarbamazinum; Dietilcarbamazina; Ethodryl; Luxuran; Notezine; Spatonin; Diethyl carbamazine; Ditrazine Base; Banocide (TN); Camin (TN); Carbilazine (TN); Caricide (TN); Cypip (TN); Diethylcarbamazine (INN); Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; Ethodryl (TN); FR-1031; Filaribits (TN); Forte (TN); Hetrazan (TN); Spatonin (TN); N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-diethyl-4-methylpiperazine-1-carboxamide; 1-Diethylcarbamyl-4-methylpiperazine; 84L
DM1TJ8F CP Lederle Laboratories Div American Cyanamid Co
DM1TJ8F TC Anthelmintics
DM1TJ8F DT Small molecular drug
DM1TJ8F PC 3052
DM1TJ8F MW 199.29
DM1TJ8F FM C10H21N3O
DM1TJ8F IC InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3
DM1TJ8F CS CCN(CC)C(=O)N1CCN(CC1)C
DM1TJ8F IK RCKMWOKWVGPNJF-UHFFFAOYSA-N
DM1TJ8F IU N,N-diethyl-4-methylpiperazine-1-carboxamide
DM1TJ8F CA CAS 90-89-1
DM1TJ8F CB CHEBI:4527
DM1TJ8F DE Lymphatic filariasis
DMN3UXQ ID DMN3UXQ
DMN3UXQ DN Diethylstilbestrol
DMN3UXQ HS Approved
DMN3UXQ SN Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol "2" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol
DMN3UXQ CP Bayer Pharmaceuticals Corp
DMN3UXQ TC Anticancer Agents
DMN3UXQ DT Small molecular drug
DMN3UXQ PC 448537
DMN3UXQ MW 268.3
DMN3UXQ FM C18H20O2
DMN3UXQ IC InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
DMN3UXQ CS CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
DMN3UXQ IK RGLYKWWBQGJZGM-ISLYRVAYSA-N
DMN3UXQ IU 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
DMN3UXQ CA CAS 56-53-1
DMN3UXQ CB CHEBI:41922
DMN3UXQ DE Gonorrheal vaginitis
DMI9PRJ ID DMI9PRJ
DMI9PRJ DN Diflorasone
DMI9PRJ HS Approved
DMI9PRJ SN Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
DMI9PRJ CP Pharmacia And Upjohn Co
DMI9PRJ TC Antiinflammatory Agents
DMI9PRJ DT Small molecular drug
DMI9PRJ PC 71415
DMI9PRJ MW 410.5
DMI9PRJ FM C22H28F2O5
DMI9PRJ IC InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
DMI9PRJ CS C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F
DMI9PRJ IK WXURHACBFYSXBI-XHIJKXOTSA-N
DMI9PRJ IU (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMI9PRJ CA CAS 2557-49-5
DMI9PRJ CB CHEBI:59750
DMI9PRJ DE Rosacea
DM7EN8I ID DM7EN8I
DM7EN8I DN Diflunisal
DM7EN8I HS Approved
DM7EN8I SN Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid
DM7EN8I CP Merck & Co
DM7EN8I TC Analgesics
DM7EN8I DT Small molecular drug
DM7EN8I PC 3059
DM7EN8I MW 250.2
DM7EN8I FM C13H8F2O3
DM7EN8I IC InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
DM7EN8I CS C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
DM7EN8I IK HUPFGZXOMWLGNK-UHFFFAOYSA-N
DM7EN8I IU 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
DM7EN8I CA CAS 22494-42-4
DM7EN8I CB CHEBI:39669
DM7EN8I DE Pain
DMMFVB3 ID DMMFVB3
DMMFVB3 DN Difluprednate
DMMFVB3 HS Approved
DMMFVB3 SN Durezol (TN)
DMMFVB3 CP Sirion
DMMFVB3 DT Small molecular drug
DMMFVB3 PC 443936
DMMFVB3 MW 508.5
DMMFVB3 FM C27H34F2O7
DMMFVB3 IC InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
DMMFVB3 CS CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C
DMMFVB3 IK WYQPLTPSGFELIB-JTQPXKBDSA-N
DMMFVB3 IU [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
DMMFVB3 CA CAS 23674-86-4
DMMFVB3 CB CHEBI:31485
DMMFVB3 DE Ocular pain
DMWVIGP ID DMWVIGP
DMWVIGP DN Digitoxin
DMWVIGP HS Approved
DMWVIGP SN Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]
DMWVIGP TC Antiarrhythmic Agents
DMWVIGP DT Small molecular drug
DMWVIGP PC 441207
DMWVIGP MW 764.9
DMWVIGP FM C41H64O13
DMWVIGP IC InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
DMWVIGP CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
DMWVIGP IK WDJUZGPOPHTGOT-XUDUSOBPSA-N
DMWVIGP IU 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMWVIGP CA CAS 71-63-6
DMWVIGP CB CHEBI:28544
DMWVIGP DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMQCTIH ID DMQCTIH
DMQCTIH DN Digoxin
DMQCTIH HS Approved
DMQCTIH SN digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin
DMQCTIH CP GlaxoSmithKline
DMQCTIH TC Antiarrhythmic Agents
DMQCTIH DT Small molecular drug
DMQCTIH PC 2724385
DMQCTIH MW 780.9
DMQCTIH FM C41H64O14
DMQCTIH IC InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
DMQCTIH CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
DMQCTIH IK LTMHDMANZUZIPE-PUGKRICDSA-N
DMQCTIH IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQCTIH CA CAS 20830-75-5
DMQCTIH CB CHEBI:4551
DMQCTIH DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMZIXU9 ID DMZIXU9
DMZIXU9 DN Dihydralazine
DMZIXU9 HS Approved
DMZIXU9 SN Dihydralazine sulfate; 7327-87-9; Dihydralazine sulphate; 1,4-Dihydrazinophthalazine sulfate; Depressan; Hydralazine sulfate; Ophthazin Sulfate; UNII-1C2B1W91NK; CCRIS 5386; Sulfate de dihydralazine [French]; 1,4-Dihydrazinylphthalazine Sulfate; EINECS 230-808-0; 1C2B1W91NK; Phthalazine, 1,4-dihydrazino-, sulfate (1:1); 1,4-Dihydrazinophthalazine hydrogen sulfate; W-104459; Sulfate de dihydralazine; 1,4-dihydrazinophthalazine sulfate(1:1); Dihydralazinsulfat; C8H10N6.H2O4S; Nepresol (TN); Dihydralazine Sulfate,(S); AC1Q6XE2
DMZIXU9 DT Small molecular drug
DMZIXU9 PC 10230
DMZIXU9 MW 190.21
DMZIXU9 FM C8H10N6
DMZIXU9 IC InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
DMZIXU9 CS C1=CC=C2C(=C1)C(=NN=C2NN)NN
DMZIXU9 IK VQKLRVZQQYVIJW-UHFFFAOYSA-N
DMZIXU9 IU (4-hydrazinylphthalazin-1-yl)hydrazine
DMZIXU9 CA CAS 484-23-1
DMZIXU9 CB CHEBI:134841
DMZIXU9 DE Hypertension
DMBXVMZ ID DMBXVMZ
DMBXVMZ DN Dihydroartemisinin
DMBXVMZ HS Approved
DMBXVMZ SN Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
DMBXVMZ DT Small molecular drug
DMBXVMZ PC 3000518
DMBXVMZ MW 284.35
DMBXVMZ FM C15H24O5
DMBXVMZ IC InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1
DMBXVMZ CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
DMBXVMZ IK BJDCWCLMFKKGEE-ISOSDAIHSA-N
DMBXVMZ IU (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
DMBXVMZ CA CAS 71939-50-9
DMBXVMZ CB CHEBI:135921
DMBXVMZ DE Malaria
DM5SQ1G ID DM5SQ1G
DM5SQ1G DN Dihydroergocristine
DM5SQ1G HS Approved
DM5SQ1G SN Nehydrin
DM5SQ1G CP Sanochemia Pharmazeutika AG
DM5SQ1G DT Small molecular drug
DM5SQ1G PC 107715
DM5SQ1G MW 611.7
DM5SQ1G FM C35H41N5O5
DM5SQ1G IC InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
DM5SQ1G CS CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5SQ1G IK DEQITUUQPICUMR-HJPBWRTMSA-N
DM5SQ1G IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5SQ1G CA CAS 17479-19-5
DM5SQ1G CB CHEBI:59912
DM5SQ1G DE Alcohol dependence
DM5IKUF ID DM5IKUF
DM5IKUF DN Dihydroergotamine
DM5IKUF HS Approved
DM5IKUF SN Migranal (TN)
DM5IKUF CP Pfizer Pharmaceuticals
DM5IKUF TC Antimigraine Agents
DM5IKUF DT Small molecular drug
DM5IKUF PC 10531
DM5IKUF MW 583.7
DM5IKUF FM C33H37N5O5
DM5IKUF IC InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
DM5IKUF CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5IKUF IK LUZRJRNZXALNLM-JGRZULCMSA-N
DM5IKUF IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5IKUF CA CAS 511-12-6
DM5IKUF CB CHEBI:4562
DM5IKUF DE Migraine
DM5D6WZ ID DM5D6WZ
DM5D6WZ DN Dihydroergotoxine
DM5D6WZ HS Approved
DM5D6WZ SN Ergotamine, dihydro, methanesulfonate (salt)
DM5D6WZ TC Vasodilator Agents
DM5D6WZ DT Small molecular drug
DM5D6WZ PC 6420006
DM5D6WZ MW 679.8
DM5D6WZ FM C34H41N5O8S
DM5D6WZ IC InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1
DM5D6WZ CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5CC6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
DM5D6WZ IK ADYPXRFPBQGGAH-WVVAGBSPSA-N
DM5D6WZ IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
DM5D6WZ CA CAS 11032-41-0
DM5D6WZ DE Alzheimer disease
DMFB97P ID DMFB97P
DMFB97P DN Dihydrotachysterol
DMFB97P HS Approved
DMFB97P SN Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol
DMFB97P TC Antihypoparathyroid Agents
DMFB97P DT Small molecular drug
DMFB97P PC 5311071
DMFB97P MW 398.7
DMFB97P FM C28H46O
DMFB97P IC InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1
DMFB97P CS C[C@H]\\1CC[C@@H](C/C1=C\\C=C\\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O
DMFB97P IK ILYCWAKSDCYMBB-OPCMSESCSA-N
DMFB97P IU (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
DMFB97P CA CAS 67-96-9
DMFB97P CB CHEBI:4591
DMFB97P DE Hypocalcemia
DMM1LG2 ID DMM1LG2
DMM1LG2 DN Dihydroxyacetone
DMM1LG2 HS Approved
DMM1LG2 SN 1,3-dihydroxyacetone; Dihydroxyacetone; 96-26-4; 1,3-Dihydroxypropan-2-one; Chromelin; 1,3-Dihydroxy-2-propanone; glycerone; Triulose; Viticolor; Soleal; Oxatone; Dihyxal; Oxantin; Otan; 2-Propanone, 1,3-dihydroxy-; 1,3-Dihydroxypropanone; 1,3-Dihydroxydimethyl ketone; NSC-24343; Ketochromin; Bis(hydroxymethyl) ketone; UNII-O10DDW6JOO; dihydroxy-acetone; 2-Propanone, 1,3-dihydroxy; BRN 1740268; CCRIS 4899; AI3-24477; Dihydroxyacetone [USP]; EINECS 202-494-5; O10DDW6JOO; 1,2-Dihydroxy-2-propanone; CHEBI:16016; RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 DT Small molecular drug
DMM1LG2 PC 670
DMM1LG2 MW 90.08
DMM1LG2 FM C3H6O3
DMM1LG2 IC InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2
DMM1LG2 CS C(C(=O)CO)O
DMM1LG2 IK RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 IU 1,3-dihydroxypropan-2-one
DMM1LG2 CA CAS 96-26-4
DMM1LG2 CB CHEBI:16016
DMM1LG2 DE Sunburn
DM8YXKW ID DM8YXKW
DM8YXKW DN Dihydroxyaluminium
DM8YXKW HS Approved
DM8YXKW SN (2-Aminoacetoxy)dihydroxyaluminum; Dihydroxyaluminium glycinate; Dihydroxyaluminum aminoacetate; 41354-48-7; Robalate; Prodexin; Hyperacid; Alilac; (Glycinato)dihydroxyaluminum; Alminate; (T-4)-(Glycinato-N,O)dihydroxyaluminum; Dihydroxyaluminum aminoacetate [USAN:USP]; C2H6AlNO4; Dihydroxoaluminium glycinat; Aluminum glycinate, AldrichCPR; DTXSID3044546; (Glycinato-N,O)dihydroxyaluminum; 51484-68-5 (proacid); MolPort-023-220-319; 13682-92-3 (Parent); (Glycinato)dihydroxyaluminum hydrate; EINECS 237-193-8; Aluminum, (glycinato-N
DM8YXKW TC Antiinflammatory Agents
DM8YXKW DT Small molecular drug
DM8YXKW PC 16683036
DM8YXKW MW 137.07
DM8YXKW FM C2H8AlNO4
DM8YXKW IC InChI=1S/C2H5NO2.Al.2H2O/c3-1-2(4)5;;;/h1,3H2,(H,4,5);;2*1H2/q;+1;;/p-1
DM8YXKW CS C(C(=O)O[Al])N.O.O
DM8YXKW IK RBNPZEHAODHBPZ-UHFFFAOYSA-M
DM8YXKW CA CAS 13682-92-3
DM8YXKW DE Skin inflammation
DMAI7ZV ID DMAI7ZV
DMAI7ZV DN Diltiazem
DMAI7ZV HS Approved
DMAI7ZV SN Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
DMAI7ZV CP Valeant International Barbados Srl
DMAI7ZV TC Antihypertensive Agents
DMAI7ZV DT Small molecular drug
DMAI7ZV PC 39186
DMAI7ZV MW 414.5
DMAI7ZV FM C22H26N2O4S
DMAI7ZV IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
DMAI7ZV CS CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMAI7ZV IK HSUGRBWQSSZJOP-RTWAWAEBSA-N
DMAI7ZV IU [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMAI7ZV CA CAS 56209-45-1
DMAI7ZV CB CHEBI:101278
DMAI7ZV DE Hypertension
DM264B3 ID DM264B3
DM264B3 DN Dimenhydrinate
DM264B3 HS Approved
DM264B3 SN Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
DM264B3 CP Carter-Horner Corp.
DM264B3 TC Antiemetics
DM264B3 DT Small molecular drug
DM264B3 PC 10660
DM264B3 MW 470
DM264B3 FM C24H28ClN5O3
DM264B3 IC InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)
DM264B3 CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DM264B3 IK NFLLKCVHYJRNRH-UHFFFAOYSA-N
DM264B3 IU 2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione
DM264B3 CA CAS 523-87-5
DM264B3 CB CHEBI:94848
DM264B3 DE Nausea
DM32YAI ID DM32YAI
DM32YAI DN Dimethindene
DM32YAI HS Approved
DM32YAI SN Dimethpyrindene; Dimethylpyrindene; Dimetindene; Dimetindeno; Dimetindenum; Fengel; Fenistil; Forhistal; Foristal; Pecofenil; Triten; Z 2001; Dimetindene (INN); Dimetindene [INN:BAN]; Dimetindeno [INN-Spanish]; Dimetindenum [INN-Latin]; Fenistil (TN); Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-(9CI); 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine
DM32YAI TC Antiallergic Agents
DM32YAI DT Small molecular drug
DM32YAI PC 21855
DM32YAI MW 292.4
DM32YAI FM C20H24N2
DM32YAI IC InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3
DM32YAI CS CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
DM32YAI IK MVMQESMQSYOVGV-UHFFFAOYSA-N
DM32YAI IU N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine
DM32YAI CA CAS 5636-83-9
DM32YAI CB CHEBI:135222
DM32YAI DE Respiratory allergy
DMXQKSL ID DMXQKSL
DMXQKSL DN Dinoprost Tromethamine
DMXQKSL HS Approved
DMXQKSL SN Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt
DMXQKSL TC Abortifacient Agents
DMXQKSL DT Small molecular drug
DMXQKSL PC 5282415
DMXQKSL MW 475.6
DMXQKSL FM C24H45NO8
DMXQKSL IC InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
DMXQKSL CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMXQKSL IK IYGXEHDCSOYNKY-RZHHZEQLSA-N
DMXQKSL IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DMXQKSL CA CAS 38562-01-5
DMXQKSL CB CHEBI:31502
DMXQKSL DE Abortion
DMTYOPD ID DMTYOPD
DMTYOPD DN Dinoprostone
DMTYOPD HS Approved
DMTYOPD SN Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
DMTYOPD CP Pfizer Pharmaceuticals
DMTYOPD TC Prostaglandins
DMTYOPD DT Small molecular drug
DMTYOPD PC 5280360
DMTYOPD MW 352.5
DMTYOPD FM C20H32O5
DMTYOPD IC InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
DMTYOPD CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMTYOPD IK XEYBRNLFEZDVAW-ARSRFYASSA-N
DMTYOPD IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMTYOPD CA CAS 363-24-6
DMTYOPD CB CHEBI:15551
DMTYOPD DE Medical abortion
DMXVU6D ID DMXVU6D
DMXVU6D DN Diphemanil Methylsulfate
DMXVU6D HS Approved
DMXVU6D SN Demotil; Diphemanil; Diphemanilum; Diphenatil; Diphenmethanil; Nivelon; Nivelona; Prantal; Prantil; Prentol; Talpran; Vagophemanil; Variton; Diphemanil methosulfate; Diphemanil methyl sulfate; Diphemanil methylsulphate; Diphemanil metilsulfate; Diphemanili metilsulfas; Diphenmanil methyl sulfate; Diphenmanil methylsulfate; Diphenmethanil methyl sulfate; Diphenmethanil methylsulfate; Metilsulfate de diphemanil; Metilsulfato de difemanilo; Prantal methylsulfate; Vagophemanil methyl sulfate; Ban-guard; Diphemanil methylsulfate [INN:BAN]; Diphemanil metilsulfate (INN); Diphemanili metilsulfas [INN-Latin]; Metilsulfate de diphemanil [INN-French]; Metilsulfato de difemanilo [INN-Spanish]; Prantal (TN); Ban-Guard (Veterinary); P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; P-(alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium
DMXVU6D TC Parasympatholytics
DMXVU6D DT Small molecular drug
DMXVU6D PC 6126
DMXVU6D MW 389.5
DMXVU6D FM C21H27NO4S
DMXVU6D IC InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMXVU6D CS C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-]
DMXVU6D IK BREMLQBSKCSNNH-UHFFFAOYSA-M
DMXVU6D IU 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium;methyl sulfate
DMXVU6D CA CAS 62-97-5
DMXVU6D CB CHEBI:59782
DMXVU6D DE Peptic ulcer
DMKQTBA ID DMKQTBA
DMKQTBA DN Diphenhydramine
DMKQTBA HS Approved
DMKQTBA SN diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl; Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM
DMKQTBA CP Johnson & Johnson
DMKQTBA TC Antiallergic Agents
DMKQTBA DT Small molecular drug
DMKQTBA PC 3100
DMKQTBA MW 255.35
DMKQTBA FM C17H21NO
DMKQTBA IC InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMKQTBA CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DMKQTBA IK ZZVUWRFHKOJYTH-UHFFFAOYSA-N
DMKQTBA IU 2-benzhydryloxy-N,N-dimethylethanamine
DMKQTBA CA CAS 58-73-1
DMKQTBA CB CHEBI:4636
DMKQTBA DE Meniere disease
DMHPWOM ID DMHPWOM
DMHPWOM DN Diphenidol
DMHPWOM HS Approved
DMHPWOM SN Avomol; Defenidol; Difenidol; Difenidolo; Difenidolum; Nometic; Vontrol; Difenidol HCl; Difenidolo [DCIT]; SKF 478; Difenidolum [INN-Latin]; Diphenidol [USAN:BAN]; SK-478; Diphenidol (USAN/INN); SK&F-478; Alpha,alpha-Diphenyl-1-piperidinebutanol; Diphenyl(3-(1-piperidyl)propyl)carbinol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride
DMHPWOM DT Small molecular drug
DMHPWOM PC 3055
DMHPWOM MW 309.4
DMHPWOM FM C21H27NO
DMHPWOM IC InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2
DMHPWOM CS C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMHPWOM IK OGAKLTJNUQRZJU-UHFFFAOYSA-N
DMHPWOM IU 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol
DMHPWOM CA CAS 972-02-1
DMHPWOM CB CHEBI:4638
DMHPWOM DE Nausea
DMO5SZX ID DMO5SZX
DMO5SZX DN Diphenoxylate
DMO5SZX HS Approved
DMO5SZX SN Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride
DMO5SZX CP Janssen Pharmaceutica
DMO5SZX TC Analgesics
DMO5SZX DT Small molecular drug
DMO5SZX PC 13505
DMO5SZX MW 452.6
DMO5SZX FM C30H32N2O2
DMO5SZX IC InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
DMO5SZX CS CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMO5SZX IK HYPPXZBJBPSRLK-UHFFFAOYSA-N
DMO5SZX IU ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
DMO5SZX CA CAS 915-30-0
DMO5SZX CB CHEBI:4639
DMO5SZX DE Diarrhea
DMW4X37 ID DMW4X37
DMW4X37 DN Diphenylpyraline
DMW4X37 HS Approved
DMW4X37 SN Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
DMW4X37 TC Antihistamines
DMW4X37 DT Small molecular drug
DMW4X37 PC 3103
DMW4X37 MW 281.4
DMW4X37 FM C19H23NO
DMW4X37 IC InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
DMW4X37 CS CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
DMW4X37 IK OWQUZNMMYNAXSL-UHFFFAOYSA-N
DMW4X37 IU 4-benzhydryloxy-1-methylpiperidine
DMW4X37 CA CAS 147-20-6
DMW4X37 CB CHEBI:59788
DMW4X37 DE Allergic rhinitis
DM0FSIM ID DM0FSIM
DM0FSIM DN Diphtheria-tetanus vaccine
DM0FSIM HS Approved
DM0FSIM SN Diphtheria-tetanus vaccine (im suspension), Finlay Institute
DM0FSIM CP Finlay Institute
DM0FSIM DT Vaccine
DM0FSIM DE Clostridium infection
DMH5W0G ID DMH5W0G
DMH5W0G DN Dipivefrin
DMH5W0G HS Approved
DMH5W0G SN AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
DMH5W0G CP Allergan Pharmaceutical
DMH5W0G TC Ophthalmologicals
DMH5W0G DT Small molecular drug
DMH5W0G PC 3105
DMH5W0G MW 351.4
DMH5W0G FM C19H29NO5
DMH5W0G IC InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3
DMH5W0G CS CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C
DMH5W0G IK OCUJLLGVOUDECM-UHFFFAOYSA-N
DMH5W0G IU [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
DMH5W0G CA CAS 52365-63-6
DMH5W0G CB CHEBI:4646
DMH5W0G DE Chronic open-angle glaucoma
DMXY30O ID DMXY30O
DMXY30O DN Dipyridamole
DMXY30O HS Approved
DMXY30O SN Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
DMXY30O CP FISCHER and ROCH
DMXY30O TC Vasodilator Agents
DMXY30O DT Small molecular drug
DMXY30O PC 3108
DMXY30O MW 504.6
DMXY30O FM C24H40N8O4
DMXY30O IC InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
DMXY30O CS C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMXY30O IK IZEKFCXSFNUWAM-UHFFFAOYSA-N
DMXY30O IU 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMXY30O CA CAS 58-32-2
DMXY30O CB CHEBI:4653
DMXY30O DE Hypertension
DM0D9YJ ID DM0D9YJ
DM0D9YJ DN Dirithromycin
DM0D9YJ HS Approved
DM0D9YJ SN Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin
DM0D9YJ TC Antibiotics
DM0D9YJ DT Small molecular drug
DM0D9YJ PC 6473883
DM0D9YJ MW 835.1
DM0D9YJ FM C42H78N2O14
DM0D9YJ IC InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1
DM0D9YJ CS CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O
DM0D9YJ IK WLOHNSSYAXHWNR-DWIOZXRMSA-N
DM0D9YJ IU (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
DM0D9YJ CA CAS 62013-04-1
DM0D9YJ CB CHEBI:474014
DM0D9YJ DE Bacterial infection
DM5SYZP ID DM5SYZP
DM5SYZP DN Disopyramide
DM5SYZP HS Approved
DM5SYZP SN Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CP Gd Searle Llc
DM5SYZP TC Antiarrhythmic Agents
DM5SYZP DT Small molecular drug
DM5SYZP PC 3114
DM5SYZP MW 339.5
DM5SYZP FM C21H29N3O
DM5SYZP IC InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
DM5SYZP CS CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
DM5SYZP IK UVTNFZQICZKOEM-UHFFFAOYSA-N
DM5SYZP IU 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CA CAS 3737-09-5
DM5SYZP CB CHEBI:4657
DM5SYZP DE Ventricular arrhythmias; Urinary incontinence
DMCL2OK ID DMCL2OK
DMCL2OK DN Disulfiram
DMCL2OK HS Approved
DMCL2OK SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMCL2OK CP Odyssey Pharmaceuticals
DMCL2OK TC Alcohol Deterrents
DMCL2OK DT Small molecular drug
DMCL2OK PC 3117
DMCL2OK MW 296.5
DMCL2OK FM C10H20N2S4
DMCL2OK IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMCL2OK CS CCN(CC)C(=S)SSC(=S)N(CC)CC
DMCL2OK IK AUZONCFQVSMFAP-UHFFFAOYSA-N
DMCL2OK IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMCL2OK CA CAS 97-77-8
DMCL2OK CB CHEBI:4659
DMCL2OK DE Alcohol dependence
DM4RK0G ID DM4RK0G
DM4RK0G DN Divalproex sodium
DM4RK0G HS Approved
DM4RK0G SN Delepsine; Depakote; Divalproate; Divalproex; Epilex; Epival; Sprinkle; Valcote; Valdisoval; Valparin; Depakote CP; Depakote ER; Depakote Sprinkle; Divalproex sodium [USAN]; Sodium divalproate; Sodium hydrogen divalproate; Valproate semisodique; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico; Valproato semisodico [Spanish]; Valproatum seminatricum; Valproatum seminatricum [Latin]; Abbott 50711; Abbott-50711; Depacon (TN); Depakote (TN); Depakote ER (TN); Divalproex sodium (USP); Epival (TN); Ergenyl Chrono (TN); Valance (TN); Valproate semisodium (INN); Divalproex sodium, Depakote, Epival; Natrium hydrogen bis(2-propylvalerat); Sodium hydrogen bis(2-propylpentanoate); Sodium hydrogen bis(2-propylvalerate); Valproic acid semisodium salt (2:1); Zalkote. (TN); Sodium hydrogen bis(2-propylvalerate), oligomer; Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1); Pentanoic acid, 2-propyl-, sodium salt (2:1); Pentanoic acid, 2-propyl-, sodium salt(2:1); 2-propylpentanoate
DM4RK0G CP Abbott Laboratories
DM4RK0G TC Anticonvulsants
DM4RK0G DT Small molecular drug
DM4RK0G PC 23663956
DM4RK0G MW 310.4
DM4RK0G FM C16H31NaO4
DM4RK0G IC InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1
DM4RK0G CS CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
DM4RK0G IK MSRILKIQRXUYCT-UHFFFAOYSA-M
DM4RK0G IU sodium;2-propylpentanoate;2-propylpentanoic acid
DM4RK0G CA CAS 76584-70-8
DM4RK0G CB CHEBI:4667
DM4RK0G DE Seizure disorder
DMD1B8Z ID DMD1B8Z
DMD1B8Z DN Dobutamine
DMD1B8Z HS Approved
DMD1B8Z SN Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CP Ben Venue Laboratories
DMD1B8Z TC Cardiotonic Agents
DMD1B8Z DT Small molecular drug
DMD1B8Z PC 36811
DMD1B8Z MW 301.4
DMD1B8Z FM C18H23NO3
DMD1B8Z IC InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
DMD1B8Z CS CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
DMD1B8Z IK JRWZLRBJNMZMFE-UHFFFAOYSA-N
DMD1B8Z IU 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CA CAS 34368-04-2
DMD1B8Z CB CHEBI:4670
DMD1B8Z DE Heart failure
DMS5IEB ID DMS5IEB
DMS5IEB DN Docarpamine
DMS5IEB HS Approved
DMS5IEB SN Tanadopa (TN)
DMS5IEB DT Small molecular drug
DMS5IEB PC 71137
DMS5IEB MW 470.5
DMS5IEB FM C21H30N2O8S
DMS5IEB IC InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
DMS5IEB CS CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC
DMS5IEB IK ZLVMAMIPILWYHQ-INIZCTEOSA-N
DMS5IEB IU [4-[2-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]ethyl]-2-ethoxycarbonyloxyphenyl] ethyl carbonate
DMS5IEB CA CAS 74639-40-0
DMS5IEB CB CHEBI:31513
DMS5IEB DE Hypertension
DMDI269 ID DMDI269
DMDI269 DN Docetaxel
DMDI269 HS Approved
DMDI269 SN EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
DMDI269 CP Sanofi-Aventis
DMDI269 TC Anticancer Agents
DMDI269 DT Small molecular drug
DMDI269 PC 148124
DMDI269 MW 807.9
DMDI269 FM C43H53NO14
DMDI269 IC InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
DMDI269 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
DMDI269 IK ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DMDI269 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDI269 CA CAS 114977-28-5
DMDI269 CB CHEBI:4672
DMDI269 DE Solid tumour/cancer
DMOHK1E ID DMOHK1E
DMOHK1E DN Docosanol
DMOHK1E HS Approved
DMOHK1E SN Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL
DMOHK1E CP Avanir Pharmaceuticals
DMOHK1E TC Antiviral Agents
DMOHK1E DT Small molecular drug
DMOHK1E PC 12620
DMOHK1E MW 326.6
DMOHK1E FM C22H46O
DMOHK1E IC InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DMOHK1E CS CCCCCCCCCCCCCCCCCCCCCCO
DMOHK1E IK NOPFSRXAKWQILS-UHFFFAOYSA-N
DMOHK1E IU docosan-1-ol
DMOHK1E CA CAS 661-19-8
DMOHK1E CB CHEBI:31000
DMOHK1E DE Herpes simplex virus infection
DMPN1TW ID DMPN1TW
DMPN1TW DN Dofetilide
DMPN1TW HS Approved
DMPN1TW SN Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE
DMPN1TW CP Pfizer Pharmaceuticals
DMPN1TW TC Antiarrhythmic Agents
DMPN1TW DT Small molecular drug
DMPN1TW PC 71329
DMPN1TW MW 441.6
DMPN1TW FM C19H27N3O5S2
DMPN1TW IC InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
DMPN1TW CS CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
DMPN1TW IK IXTMWRCNAAVVAI-UHFFFAOYSA-N
DMPN1TW IU N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
DMPN1TW CA CAS 115256-11-6
DMPN1TW CB CHEBI:4681
DMPN1TW DE Sinus rhythm disorder
DMMG26Z ID DMMG26Z
DMMG26Z DN Dolasetron
DMMG26Z HS Approved
DMMG26Z SN Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
DMMG26Z CP Aventis Pharmaceuticals Inc.
DMMG26Z TC Antiemetics
DMMG26Z DT Small molecular drug
DMMG26Z PC 3033818
DMMG26Z MW 324.4
DMMG26Z FM C19H20N2O3
DMMG26Z IC InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
DMMG26Z CS C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
DMMG26Z IK UKTAZPQNNNJVKR-AKJUYKBHSA-N
DMMG26Z IU [(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate
DMMG26Z CA CAS 115956-12-2
DMMG26Z CB CHEBI:94561
DMMG26Z DE Nausea
DMCZGRE ID DMCZGRE
DMCZGRE DN Dolutegravir
DMCZGRE HS Approved
DMCZGRE SN 1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
DMCZGRE CP GlaxoSmithKline
DMCZGRE DT Small molecular drug
DMCZGRE PC 54726191
DMCZGRE MW 419.4
DMCZGRE FM C20H19F2N3O5
DMCZGRE IC InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
DMCZGRE CS C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMCZGRE IK RHWKPHLQXYSBKR-BMIGLBTASA-N
DMCZGRE IU (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
DMCZGRE CA CAS 1051375-16-6
DMCZGRE CB CHEBI:76010
DMCZGRE DE Human immunodeficiency virus infection
DMBDPY0 ID DMBDPY0
DMBDPY0 DN Domperidone
DMBDPY0 HS Approved
DMBDPY0 SN Domperidon; Domperidona; Domperidonum; Motilium; Nauzelin; KW 5338; NCI299589; Costi (TN); D-122; Domperidona [INN-Spanish]; Domperidonum [INN-Latin]; HS-0067; KW-5338; Motilium (TN); Motillium (TN); Motinorm (TN); R 33,812; R-33812; R-33,812; Domperidone (JAN/USAN/INN); Domperidone [USAN:BAN:INN:JAN]; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CP Janssen Pharmaceutica
DMBDPY0 TC Antiemetics
DMBDPY0 DT Small molecular drug
DMBDPY0 PC 3151
DMBDPY0 MW 425.9
DMBDPY0 FM C22H24ClN5O2
DMBDPY0 IC InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
DMBDPY0 CS C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
DMBDPY0 IK FGXWKSZFVQUSTL-UHFFFAOYSA-N
DMBDPY0 IU 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CA CAS 57808-66-9
DMBDPY0 CB CHEBI:31515
DMBDPY0 DE Gastrointestinal disease
DMIYG7Z ID DMIYG7Z
DMIYG7Z DN Donepezil
DMIYG7Z HS Approved
DMIYG7Z SN Donepezil (transdermal patch, Alzheimer's disease)
DMIYG7Z CP Nitto Denko Corp
DMIYG7Z TC Neurology Agents
DMIYG7Z DT Small molecular drug
DMIYG7Z PC 3152
DMIYG7Z MW 379.5
DMIYG7Z FM C24H29NO3
DMIYG7Z IC InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
DMIYG7Z CS COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
DMIYG7Z IK ADEBPBSSDYVVLD-UHFFFAOYSA-N
DMIYG7Z IU 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
DMIYG7Z CA CAS 120014-06-4
DMIYG7Z CB CHEBI:53289
DMIYG7Z DE Alzheimer disease
DMPGUCF ID DMPGUCF
DMPGUCF DN Dopamine
DMPGUCF HS Approved
DMPGUCF SN Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
DMPGUCF CP Baxter Healthcare Corp Anesthesia And Critical Care
DMPGUCF TC Cardiotonic Agents
DMPGUCF DT Small molecular drug
DMPGUCF PC 681
DMPGUCF MW 153.18
DMPGUCF FM C8H11NO2
DMPGUCF IC InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
DMPGUCF CS C1=CC(=C(C=C1CCN)O)O
DMPGUCF IK VYFYYTLLBUKUHU-UHFFFAOYSA-N
DMPGUCF IU 4-(2-aminoethyl)benzene-1,2-diol
DMPGUCF CA CAS 51-61-6
DMPGUCF CB CHEBI:18243
DMPGUCF DE Parkinson disease; Hypotension
DMSCIKZ ID DMSCIKZ
DMSCIKZ DN Dopexamine
DMSCIKZ HS Approved
DMSCIKZ SN Dopacard (TN)
DMSCIKZ DT Small molecular drug
DMSCIKZ PC 55483
DMSCIKZ MW 356.5
DMSCIKZ FM C22H32N2O2
DMSCIKZ IC InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2
DMSCIKZ CS C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O
DMSCIKZ IK RYBJORHCUPVNMB-UHFFFAOYSA-N
DMSCIKZ IU 4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
DMSCIKZ CA CAS 86197-47-9
DMSCIKZ CB CHEBI:135507
DMSCIKZ DE Cardiac failure
DM9UCJK ID DM9UCJK
DM9UCJK DN Doripenem
DM9UCJK HS Approved
DM9UCJK SN Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CP Shionogi; penisula
DM9UCJK DT Small molecular drug
DM9UCJK PC 73303
DM9UCJK MW 420.5
DM9UCJK FM C15H24N4O6S2
DM9UCJK IC InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1
DM9UCJK CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O
DM9UCJK IK AVAACINZEOAHHE-VFZPANTDSA-N
DM9UCJK IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CA CAS 148016-81-3
DM9UCJK CB CHEBI:135928
DM9UCJK DE Urinary tract infection; Gram-positive bacterial infection
DM3XU74 ID DM3XU74
DM3XU74 DN Dornase Alfa
DM3XU74 HS Approved
DM3XU74 SN Pulmozyme (TN)
DM3XU74 CP Genentech
DM3XU74 TC Enzyme Replacement Agents
DM3XU74 SQ Dornase alfa sequence: LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK
DM3XU74 DE Cystic fibrosis
DMA17D0 ID DMA17D0
DMA17D0 DN Dorzolamide
DMA17D0 HS Approved
DMA17D0 SN Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
DMA17D0 CP Merck & Co
DMA17D0 TC Antihypertensive Agents
DMA17D0 DT Small molecular drug
DMA17D0 PC 5284549
DMA17D0 MW 324.4
DMA17D0 FM C10H16N2O4S3
DMA17D0 IC InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
DMA17D0 CS CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMA17D0 IK IAVUPMFITXYVAF-XPUUQOCRSA-N
DMA17D0 IU (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMA17D0 CA CAS 120279-96-1
DMA17D0 CB CHEBI:4702
DMA17D0 DE Open-angle glaucoma
DM78NWP ID DM78NWP
DM78NWP DN Dostarlimab
DM78NWP HS Approved
DM78NWP CP AnaptysBio; GlaxoSmithKline
DM78NWP DT Antibody
DM78NWP DE Endometrial cancer; Multiple myeloma; Breast cancer; Neoplasm
DMKE7L9 ID DMKE7L9
DMKE7L9 DN Doxacurium
DMKE7L9 HS Approved
DMKE7L9 SN Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride
DMKE7L9 CP Abbott Laboratories
DMKE7L9 TC Analgesics
DMKE7L9 DT Small molecular drug
DMKE7L9 PC 60169
DMKE7L9 MW 1035.2
DMKE7L9 FM C56H78N2O16+2
DMKE7L9 IC InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
DMKE7L9 CS C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C
DMKE7L9 IK GBLRQXKSCRCLBZ-UHFFFAOYSA-N
DMKE7L9 IU bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
DMKE7L9 CA CAS 133814-18-3
DMKE7L9 CB CHEBI:4706
DMKE7L9 DE Spasm
DMCYANK ID DMCYANK
DMCYANK DN Doxapram
DMCYANK HS Approved
DMCYANK SN Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)
DMCYANK TC Central Nervous System Stimulants
DMCYANK DT Small molecular drug
DMCYANK PC 3156
DMCYANK MW 378.5
DMCYANK FM C24H30N2O2
DMCYANK IC InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
DMCYANK CS CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
DMCYANK IK XFDJYSQDBULQSI-UHFFFAOYSA-N
DMCYANK IU 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
DMCYANK CA CAS 309-29-5
DMCYANK CB CHEBI:681848
DMCYANK DE Respiratory disease
DM9PLRH ID DM9PLRH
DM9PLRH DN Doxazosin
DM9PLRH HS Approved
DM9PLRH SN Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
DM9PLRH CP Pfizer Pharmaceuticals
DM9PLRH TC Antihypertensive Agents
DM9PLRH DT Small molecular drug
DM9PLRH PC 3157
DM9PLRH MW 451.5
DM9PLRH FM C23H25N5O5
DM9PLRH IC InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
DM9PLRH CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
DM9PLRH IK RUZYUOTYCVRMRZ-UHFFFAOYSA-N
DM9PLRH IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
DM9PLRH CA CAS 74191-85-8
DM9PLRH CB CHEBI:4708
DM9PLRH DE Hypertension
DMPI98T ID DMPI98T
DMPI98T DN Doxepin
DMPI98T HS Approved
DMPI98T SN Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin
DMPI98T CP Pfizer Pharmaceuticals
DMPI98T TC Antidepressants
DMPI98T DT Small molecular drug
DMPI98T PC 667477
DMPI98T MW 279.4
DMPI98T FM C19H21NO
DMPI98T IC InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
DMPI98T CS CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
DMPI98T IK ODQWQRRAPPTVAG-GZTJUZNOSA-N
DMPI98T IU (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
DMPI98T CA CAS 1668-19-5
DMPI98T DE Depression
DM6FG1P ID DM6FG1P
DM6FG1P DN Doxercalciferol
DM6FG1P HS Approved
DM6FG1P SN Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
DM6FG1P CP Genzyme
DM6FG1P DT Small molecular drug
DM6FG1P PC 5281107
DM6FG1P MW 412.6
DM6FG1P FM C28H44O2
DM6FG1P IC InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
DM6FG1P CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM6FG1P IK HKXBNHCUPKIYDM-CGMHZMFXSA-N
DM6FG1P IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM6FG1P CA CAS 54573-75-0
DM6FG1P CB CHEBI:4712
DM6FG1P DE Chronic kidney disease
DMEDKZH ID DMEDKZH
DMEDKZH DN Doxofylline
DMEDKZH HS Approved
DMEDKZH SN Ansimar (TN)
DMEDKZH CP ABC S.p.A.
DMEDKZH DT Small molecular drug
DMEDKZH PC 50942
DMEDKZH MW 266.25
DMEDKZH FM C11H14N4O4
DMEDKZH IC InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
DMEDKZH CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
DMEDKZH IK HWXIGFIVGWUZAO-UHFFFAOYSA-N
DMEDKZH IU 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
DMEDKZH CA CAS 69975-86-6
DMEDKZH CB CHEBI:94714
DMEDKZH DE Asthma
DMVP5YE ID DMVP5YE
DMVP5YE DN Doxorubicin
DMVP5YE HS Approved
DMVP5YE SN doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
DMVP5YE CP Sequus Pharmaceuticals Inc
DMVP5YE TC Anticancer Agents
DMVP5YE DT Small molecular drug
DMVP5YE PC 31703
DMVP5YE MW 543.5
DMVP5YE FM C27H29NO11
DMVP5YE IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
DMVP5YE CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMVP5YE IK AOJJSUZBOXZQNB-TZSSRYMLSA-N
DMVP5YE IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMVP5YE CA CAS 23214-92-8
DMVP5YE CB CHEBI:28748
DMVP5YE DE Solid tumour/cancer; Tumour; Breast cancer; Hepatocellular carcinoma
DM7ICNU ID DM7ICNU
DM7ICNU DN Doxycycline
DM7ICNU HS Approved
DM7ICNU SN Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline
DM7ICNU CP Collagenex
DM7ICNU TC Antiinflammatory Agents
DM7ICNU DT Small molecular drug
DM7ICNU PC 54671203
DM7ICNU MW 444.4
DM7ICNU FM C22H24N2O8
DM7ICNU IC InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
DM7ICNU CS C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DM7ICNU IK SGKRLCUYIXIAHR-AKNGSSGZSA-N
DM7ICNU IU (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM7ICNU CA CAS 564-25-0
DM7ICNU CB CHEBI:50845
DM7ICNU DE Chronic periodontitis; Advanced gum disease; Diabetic foot ulcer
DMKOXFE ID DMKOXFE
DMKOXFE DN Doxylamine
DMKOXFE HS Approved
DMKOXFE SN Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline
DMKOXFE CP Ion Healthcare
DMKOXFE TC Hypnotics and Sedatives
DMKOXFE DT Small molecular drug
DMKOXFE PC 3162
DMKOXFE MW 270.37
DMKOXFE FM C17H22N2O
DMKOXFE IC InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
DMKOXFE CS CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
DMKOXFE IK HCFDWZZGGLSKEP-UHFFFAOYSA-N
DMKOXFE IU N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
DMKOXFE CA CAS 469-21-6
DMKOXFE CB CHEBI:51380
DMKOXFE DE Morning sickness
DMGOXPQ ID DMGOXPQ
DMGOXPQ DN DP-VPA
DMGOXPQ HS Approved
DMGOXPQ SN TVA; RAP-valproate; SPD-421; Valproic acid prodrug, Shire; RAP-valproate, D-Pharm
DMGOXPQ CP D-Pharm Ltd
DMGOXPQ DE Bipolar disorder
DMF2JDG ID DMF2JDG
DMF2JDG DN Dromostanolone
DMF2JDG HS Approved
DMF2JDG SN Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone
DMF2JDG CP Eli Lilly And Co
DMF2JDG TC Anabolic Agents
DMF2JDG DT Small molecular drug
DMF2JDG PC 6011
DMF2JDG MW 304.5
DMF2JDG FM C20H32O2
DMF2JDG IC InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1
DMF2JDG CS C[C@@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)CC1=O)C
DMF2JDG IK IKXILDNPCZPPRV-RFMGOVQKSA-N
DMF2JDG IU (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMF2JDG CA CAS 58-19-5
DMF2JDG CB CHEBI:34838
DMF2JDG DE Mammary tumour
DMA8FS5 ID DMA8FS5
DMA8FS5 DN Dronedarone
DMA8FS5 HS Approved
DMA8FS5 SN Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
DMA8FS5 CP Sanofi-Synthelabo
DMA8FS5 DT Small molecular drug
DMA8FS5 PC 208898
DMA8FS5 MW 556.8
DMA8FS5 FM C31H44N2O5S
DMA8FS5 IC InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
DMA8FS5 CS CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
DMA8FS5 IK ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
DMA8FS5 IU N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
DMA8FS5 CA CAS 141626-36-0
DMA8FS5 CB CHEBI:50659
DMA8FS5 DE Angina pectoris; Atrial fibrillation
DM0DXA8 ID DM0DXA8
DM0DXA8 DN Droperidol
DM0DXA8 HS Approved
DM0DXA8 SN DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CP Janssen Pharmaceutica
DM0DXA8 TC Antipsychotic Agents
DM0DXA8 DT Small molecular drug
DM0DXA8 PC 3168
DM0DXA8 MW 379.4
DM0DXA8 FM C22H22FN3O2
DM0DXA8 IC InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
DM0DXA8 CS C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
DM0DXA8 IK RMEDXOLNCUSCGS-UHFFFAOYSA-N
DM0DXA8 IU 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CA CAS 548-73-2
DM0DXA8 CB CHEBI:4717
DM0DXA8 DE Nausea
DM1A9W3 ID DM1A9W3
DM1A9W3 DN Drospirenone
DM1A9W3 HS Approved
DM1A9W3 SN DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta
DM1A9W3 TC Contraceptive Agents
DM1A9W3 DT Small molecular drug
DM1A9W3 PC 68873
DM1A9W3 MW 366.5
DM1A9W3 FM C24H30O3
DM1A9W3 IC InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
DM1A9W3 CS C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C
DM1A9W3 IK METQSPRSQINEEU-HXCATZOESA-N
DM1A9W3 IU (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
DM1A9W3 CA CAS 67392-87-4
DM1A9W3 CB CHEBI:50838
DM1A9W3 DE Contraception
DM59JCN ID DM59JCN
DM59JCN DN Drotrecogin alfa
DM59JCN HS Approved
DM59JCN SN Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN)
DM59JCN CP Eli Lilly
DM59JCN TC Antisepsis Agents
DM59JCN SQ Heavy chain: LIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP >Light chainSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL
DM59JCN DE Cerebrovascular ischaemia; Severe sepsis
DM5YF4M ID DM5YF4M
DM5YF4M DN Droxidopa
DM5YF4M HS Approved
DM5YF4M SN droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-
DM5YF4M CP Chelsea Therapeutics
DM5YF4M DT Small molecular drug
DM5YF4M PC 92974
DM5YF4M MW 213.19
DM5YF4M FM C9H11NO5
DM5YF4M IC InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
DM5YF4M CS C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
DM5YF4M IK QXWYKJLNLSIPIN-JGVFFNPUSA-N
DM5YF4M IU (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
DM5YF4M CA CAS 23651-95-8
DM5YF4M CB CHEBI:31524
DM5YF4M DE Neurogenic orthostatic hypotension
DMXZRW0 ID DMXZRW0
DMXZRW0 DN DTI-015
DMXZRW0 HS Approved
DMXZRW0 SN Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics
DMXZRW0 CP Direct Therapeutics Inc
DMXZRW0 DT Small molecular drug
DMXZRW0 PC 2578
DMXZRW0 MW 214.05
DMXZRW0 FM C5H9Cl2N3O2
DMXZRW0 IC InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
DMXZRW0 CS C(CCl)NC(=O)N(CCCl)N=O
DMXZRW0 IK DLGOEMSEDOSKAD-UHFFFAOYSA-N
DMXZRW0 IU 1,3-bis(2-chloroethyl)-1-nitrosourea
DMXZRW0 CA CAS 154-93-8
DMXZRW0 CB CHEBI:3423
DMXZRW0 DE Liver cancer; Brain cancer
DMCIJBH ID DMCIJBH
DMCIJBH DN DU-176B
DMCIJBH HS Approved
DMCIJBH SN Edoxaban
DMCIJBH CP Daiichi Sankyo
DMCIJBH DT Small molecular drug
DMCIJBH PC 25022378
DMCIJBH MW 738.3
DMCIJBH FM C31H40ClN7O8S2
DMCIJBH IC InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
DMCIJBH CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O
DMCIJBH IK PSMMNJNZVZZNOI-SJILXJHISA-N
DMCIJBH IU N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate
DMCIJBH CA CAS 1229194-11-9
DMCIJBH CB CHEBI:85974
DMCIJBH DE Atrial fibrillation
DMYXBV3 ID DMYXBV3
DMYXBV3 DN Dulaglutide
DMYXBV3 HS Approved
DMYXBV3 SN GLP-1 analog
DMYXBV3 CP Eli Lilly
DMYXBV3 SQ Dulaglutide Sequence: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
DMYXBV3 DE Type-2 diabetes
DM9BI7M ID DM9BI7M
DM9BI7M DN Duloxetine
DM9BI7M HS Approved
DM9BI7M SN Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
DM9BI7M CP Eli Lilly
DM9BI7M TC Antidepressants
DM9BI7M DT Small molecular drug
DM9BI7M PC 60835
DM9BI7M MW 297.4
DM9BI7M FM C18H19NOS
DM9BI7M IC InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
DM9BI7M CS CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DM9BI7M IK ZEUITGRIYCTCEM-KRWDZBQOSA-N
DM9BI7M IU (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DM9BI7M CA CAS 116539-59-4
DM9BI7M CB CHEBI:36795
DM9BI7M DE Depression
DMOAD2Y ID DMOAD2Y
DMOAD2Y DN Dupilumab
DMOAD2Y HS Approved
DMOAD2Y SN REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
DMOAD2Y CP Regeneron/Sanofi
DMOAD2Y DT Antibody
DMOAD2Y DE Atopic dermatitis; Asthma
DM4PVDY ID DM4PVDY
DM4PVDY DN Durvalumab
DM4PVDY HS Approved
DM4PVDY CP AstraZeneca
DM4PVDY DT Monoclonal antibody
DM4PVDY SQ Durvalumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Durvalumab light chainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM4PVDY DE Pancreatic ductal carcinoma; Solid tumour/cancer; Biliary tract cancer; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Melanoma; Urothelial carcinoma
DMQ4TJK ID DMQ4TJK
DMQ4TJK DN Dutasteride
DMQ4TJK HS Approved
DMQ4TJK SN Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
DMQ4TJK CP GSK
DMQ4TJK TC Anticancer Agents
DMQ4TJK DT Small molecular drug
DMQ4TJK PC 6918296
DMQ4TJK MW 528.5
DMQ4TJK FM C27H30F6N2O2
DMQ4TJK IC InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
DMQ4TJK CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMQ4TJK IK JWJOTENAMICLJG-QWBYCMEYSA-N
DMQ4TJK IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMQ4TJK CA CAS 164656-23-9
DMQ4TJK CB CHEBI:521033
DMQ4TJK DE Benign prostatic hyperplasia; Prostate cancer
DMU6OFP ID DMU6OFP
DMU6OFP DN Dyclonine
DMU6OFP HS Approved
DMU6OFP SN Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone
DMU6OFP CP Astrazeneca Lp
DMU6OFP TC Anesthetics
DMU6OFP DT Small molecular drug
DMU6OFP PC 3180
DMU6OFP MW 289.4
DMU6OFP FM C18H27NO2
DMU6OFP IC InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
DMU6OFP CS CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
DMU6OFP IK BZEWSEKUUPWQDQ-UHFFFAOYSA-N
DMU6OFP IU 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
DMU6OFP CA CAS 586-60-7
DMU6OFP CB CHEBI:4724
DMU6OFP DE Pain
DMAKIDV ID DMAKIDV
DMAKIDV DN Dydrogesterone
DMAKIDV HS Approved
DMAKIDV SN Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI)
DMAKIDV CP Solvay Pharmaceuticals
DMAKIDV TC Progesterones
DMAKIDV DT Small molecular drug
DMAKIDV PC 9051
DMAKIDV MW 312.4
DMAKIDV FM C21H28O2
DMAKIDV IC InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1
DMAKIDV CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C
DMAKIDV IK JGMOKGBVKVMRFX-HQZYFCCVSA-N
DMAKIDV IU (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMAKIDV CA CAS 152-62-5
DMAKIDV CB CHEBI:31527
DMAKIDV DE Menstrual disorder
DM8DZC1 ID DM8DZC1
DM8DZC1 DN Dyphylline
DM8DZC1 HS Approved
DM8DZC1 SN Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline
DM8DZC1 TC Bronchodilator Agents
DM8DZC1 DT Small molecular drug
DM8DZC1 PC 3182
DM8DZC1 MW 254.24
DM8DZC1 FM C10H14N4O4
DM8DZC1 IC InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DM8DZC1 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DM8DZC1 IK KSCFJBIXMNOVSH-UHFFFAOYSA-N
DM8DZC1 IU 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DM8DZC1 CA CAS 479-18-5
DM8DZC1 CB CHEBI:4728
DM8DZC1 DE Acute bronchial asthma
DMJDYNQ ID DMJDYNQ
DMJDYNQ DN E-2007
DMJDYNQ HS Approved
DMJDYNQ SN Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
DMJDYNQ CP Eisai Co. Ltd.
DMJDYNQ DT Small molecular drug
DMJDYNQ PC 9924495
DMJDYNQ MW 349.4
DMJDYNQ FM C23H15N3O
DMJDYNQ IC InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
DMJDYNQ CS C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
DMJDYNQ IK PRMWGUBFXWROHD-UHFFFAOYSA-N
DMJDYNQ IU 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
DMJDYNQ CA CAS 380917-97-5
DMJDYNQ CB CHEBI:71013
DMJDYNQ DE Diabetic neuropathy; Parkinson disease
DMOF2C6 ID DMOF2C6
DMOF2C6 DN Ecallantide
DMOF2C6 HS Approved
DMOF2C6 SN FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea
DMOF2C6 CP Dyax Corp
DMOF2C6 DT Small molecular drug
DMOF2C6 PC 44152182
DMOF2C6 MW 7054
DMOF2C6 FM C305H442N88O91S8
DMOF2C6 IC InChI=1S/C305H442N88O91S8/c1-16-152(5)241-295(478)377-195(124-168-80-82-172(398)83-81-168)252(435)334-137-227(404)333-138-228(405)345-214-143-487-491-147-218-291(474)351-179(73-47-107-327-301(315)316)255(438)341-154(7)245(428)339-155(8)249(432)379-210(127-171-136-326-150-338-171)299(482)393-113-53-79-221(393)294(477)361-181(75-49-109-329-303(319)320)260(443)372-203(125-169-134-332-175-69-40-39-68-173(169)175)277(460)370-198(119-163-58-29-20-30-59-163)274(457)369-199(120-164-60-31-21-32-61-164)275(458)375-207(130-226(314)403)284(467)389-242(153(6)17-2)296(479)378-202(123-167-66-37-24-38-67-167)283(466)390-243(159(12)396)297(480)362-182(76-50-110-330-304(321)322)258(441)353-186(86-94-223(311)400)267(450)383-217(290(473)359-188(89-98-234(414)415)263(446)354-189(90-99-235(416)417)265(448)368-201(282(465)388-241)122-166-64-35-23-36-65-166)146-490-489-145-216(384-268(451)191(92-101-237(420)421)355-262(445)187(88-97-233(412)413)357-271(454)194(116-151(3)4)366-285(468)212(141-394)381-266(449)190(91-100-236(418)419)358-273(456)197(118-162-56-27-19-28-57-162)367-259(442)180(74-48-108-328-302(317)318)349-280(463)206(129-225(313)402)374-264(447)185(85-93-222(310)399)356-279(462)205(128-224(312)401)344-229(406)139-335-251(434)184(352-288(214)471)87-96-232(410)411)289(472)350-178(72-43-46-106-308)256(439)347-177(71-42-45-105-307)257(440)360-193(103-115-486-15)270(453)385-219(292(475)391-244(160(13)397)298(481)363-183(77-51-111-331-305(323)324)261(444)380-211(300(483)484)133-240(426)427)148-492-488-144-215(386-276(459)200(121-165-62-33-22-34-63-165)371-286(469)213(142-395)382-278(461)204(126-170-135-325-149-337-170)373-269(452)192(102-114-485-14)346-246(429)156(9)340-250(433)174(309)84-95-231(408)409)287(470)343-158(11)247(430)364-196(117-161-54-25-18-26-55-161)272(455)348-176(70-41-44-104-306)254(437)342-157(10)248(431)365-209(132-239(424)425)281(464)376-208(131-238(422)423)253(436)336-140-230(407)392-112-52-78-220(392)293(476)387-218/h18-40,54-69,80-83,134-136,149-160,174,176-221,241-244,332,394-398H,16-17,41-53,70-79,84-133,137-148,306-309H2,1-15H3,(H2,310,399)(H2,311,400)(H2,312,401)(H2,313,402)(H2,314,403)(H,325,337)(H,326,338)(H,333,404)(H,334,435)(H,335,434)(H,336,436)(H,339,428)(H,340,433)(H,341,438)(H,342,437)(H,343,470)(H,344,406)(H,345,405)(H,346,429)(H,347,439)(H,348,455)(H,349,463)(H,350,472)(H,351,474)(H,352,471)(H,353,441)(H,354,446)(H,355,445)(H,356,462)(H,357,454)(H,358,456)(H,359,473)(H,360,440)(H,361,477)(H,362,480)(H,363,481)(H,364,430)(H,365,431)(H,366,468)(H,367,442)(H,368,448)(H,369,457)(H,370,460)(H,371,469)(H,372,443)(H,373,452)(H,374,447)(H,375,458)(H,376,464)(H,377,478)(H,378,479)(H,379,432)(H,380,444)(H,381,449)(H,382,461)(H,383,450)(H,384,451)(H,385,453)(H,386,459)(H,387,476)(H,388,465)(H,389,467)(H,390,466)(H,391,475)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,483,484)(H4,315,316,327)(H4,317,318,328)(H4,319,320,329)(H4,321,322,330)(H4,323,324,331)/t152-,153-,154-,155-,156-,157-,158-,159-,160-,174-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,241-,242-,243-,244-/m0/s1
DMOF2C6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)[C@H](C)O)CC1=CC=CC=C1)[C@@H](C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O
DMOF2C6 IK VBGWSQKGUZHFPS-VGMMZINCSA-N
DMOF2C6 IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(1R,2aS,4S,5aS,8aS,11aR,13S,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,84S,87R,96S,99S)-22,42,45-tris(4-aminobutyl)-31-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-29a,72,78-tris(2-amino-2-oxoethyl)-14a,75-bis(3-amino-3-oxopropyl)-2a,23a,25,32a,35a,66-hexabenzyl-26a,99-bis[(2S)-butan-2-yl]-17a,41a,59a,69-tetrakis(3-carbamimidamidopropyl)-5a,8a,51,54,63,84-hexakis(2-carboxyethyl)-13,16-bis(carboxymethyl)-20a-[(1S)-1-hydroxyethyl]-60-(hydroxymethyl)-96-[(4-hydroxyphenyl)methyl]-50a-(1H-imidazol-5-ylmethyl)-38a-(1H-indol-3-ylmethyl)-19,28,53a,56a-tetramethyl-57-(2-methylpropyl)-39-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.04,8.0144,148]nonahexacontahectane-36-carbonyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]butanedioic acid
DMOF2C6 CA CAS 460738-38-9
DMOF2C6 DE Retina venous occlusion
DMSNVGB ID DMSNVGB
DMSNVGB DN Echothiophate Iodide
DMSNVGB HS Approved
DMSNVGB SN Echodide; Phospholine; Diethoxyphosphinylthiocholine iodide; ECOTHIOPATE IODIDE; Ecostigmini jodidum; Ecothiopati iodidum; Ecothiophate iodide; Ioduro de ecotiopato; Phospholine iodide; Diethoxyphosphoryl-thiocholine iodide; Echothiophate iodide (USP); Ecothiopati iodidum [INN-Latin]; Iodide, Echothiophate; Iodide, Ecothiopate; Iodide, Ecothiophate; Iodide, Phospholine; Iodure d'ecothiopate; Ioduro de ecotiopato [INN-Spanish]; Phospholine (the pharmaceutical); Phospholine Iodide (TN); Phospholine iodide (TN); Ecothiopate iodide (JP15/INN); Iodure d'ecothiopate [INN-French]; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; 217 MI; 217-mi
DMSNVGB CP Wyeth Pharmaceuticals
DMSNVGB TC Parasympathomimetics
DMSNVGB DT Small molecular drug
DMSNVGB PC 10547
DMSNVGB MW 383.23
DMSNVGB FM C9H23INO3PS
DMSNVGB IC InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1
DMSNVGB CS CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]
DMSNVGB IK OVXQHPWHMXOFRD-UHFFFAOYSA-M
DMSNVGB IU 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium;iodide
DMSNVGB CA CAS 513-10-0
DMSNVGB CB CHEBI:59849
DMSNVGB DE Chronic glaucoma
DMFSWGH ID DMFSWGH
DMFSWGH DN Econazole
DMFSWGH HS Approved
DMFSWGH SN Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMFSWGH CP Merz Pharmaceuticals Llc
DMFSWGH TC Antifungal Agents
DMFSWGH DT Small molecular drug
DMFSWGH PC 3198
DMFSWGH MW 381.7
DMFSWGH FM C18H15Cl3N2O
DMFSWGH IC InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2
DMFSWGH CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMFSWGH IK LEZWWPYKPKIXLL-UHFFFAOYSA-N
DMFSWGH IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMFSWGH CA CAS 27220-47-9
DMFSWGH CB CHEBI:82873
DMFSWGH DE Tinea versicolor; Cutaneous candidiasis; Tinea corporis; Tinea cruris; Tinea pedis
DMCRQHB ID DMCRQHB
DMCRQHB DN Edrophonium
DMCRQHB HS Approved
DMCRQHB SN EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium
DMCRQHB TC Antidotes
DMCRQHB DT Small molecular drug
DMCRQHB PC 3202
DMCRQHB MW 166.24
DMCRQHB FM C10H16NO+
DMCRQHB IC InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
DMCRQHB CS CC[N+](C)(C)C1=CC(=CC=C1)O
DMCRQHB IK VWLHWLSRQJQWRG-UHFFFAOYSA-O
DMCRQHB IU ethyl-(3-hydroxyphenyl)-dimethylazanium
DMCRQHB CA CAS 312-48-1
DMCRQHB CB CHEBI:251408
DMCRQHB DE Myasthenia gravis
DMCKL5V ID DMCKL5V
DMCKL5V DN Efalizumab
DMCKL5V HS Approved
DMCKL5V SN Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
DMCKL5V CP Roche
DMCKL5V TC Immunomodulatory Agents
DMCKL5V DT Antibody
DMCKL5V SQ Heavy Chain Variable Region: EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS >Light Chain Variable RegionDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR
DMCKL5V DE Psoriasis vulgaris; Renal transplantation
DMC0GSJ ID DMC0GSJ
DMC0GSJ DN Efavirenz
DMC0GSJ HS Approved
DMC0GSJ SN EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
DMC0GSJ TC Anti-HIV Agents
DMC0GSJ DT Small molecular drug
DMC0GSJ PC 64139
DMC0GSJ MW 315.67
DMC0GSJ FM C14H9ClF3NO2
DMC0GSJ IC InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
DMC0GSJ CS C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
DMC0GSJ IK XPOQHMRABVBWPR-ZDUSSCGKSA-N
DMC0GSJ IU (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
DMC0GSJ CA CAS 154598-52-4
DMC0GSJ CB CHEBI:119486
DMC0GSJ DE Human immunodeficiency virus infection
DMFA9MV ID DMFA9MV
DMFA9MV DN Efinaconazole
DMFA9MV HS Approved
DMFA9MV SN IDP-108; KP-103
DMFA9MV CP Dow
DMFA9MV DT Small molecular drug
DMFA9MV PC 489181
DMFA9MV MW 348.4
DMFA9MV FM C18H22F2N4O
DMFA9MV IC InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
DMFA9MV CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
DMFA9MV IK NFEZZTICAUWDHU-RDTXWAMCSA-N
DMFA9MV IU (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMFA9MV CA CAS 164650-44-6
DMFA9MV CB CHEBI:82718
DMFA9MV DE Fungal infection
DMJOQM3 ID DMJOQM3
DMJOQM3 DN Eflornithine
DMJOQM3 HS Approved
DMJOQM3 SN EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate
DMJOQM3 CP Sanofi-Aventis
DMJOQM3 TC Anticancer Agents
DMJOQM3 DT Small molecular drug
DMJOQM3 PC 3009
DMJOQM3 MW 182.17
DMJOQM3 FM C6H12F2N2O2
DMJOQM3 IC InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)
DMJOQM3 CS C(CC(C(F)F)(C(=O)O)N)CN
DMJOQM3 IK VLCYCQAOQCDTCN-UHFFFAOYSA-N
DMJOQM3 IU 2,5-diamino-2-(difluoromethyl)pentanoic acid
DMJOQM3 CA CAS 70052-12-9
DMJOQM3 CB CHEBI:41948
DMJOQM3 DE African trypanosomiasis; Trypanosomiasis
DMMUCG4 ID DMMUCG4
DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4 HS Approved
DMMUCG4 SN Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN); DOCOSAHEXAENOIC ACID
DMMUCG4 CP Omthera Pharmaceutials
DMMUCG4 DT Small molecular drug
DMMUCG4 PC 445580
DMMUCG4 MW 328.5
DMMUCG4 FM C22H32O2
DMMUCG4 IC InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMMUCG4 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMMUCG4 IK MBMBGCFOFBJSGT-KUBAVDMBSA-N
DMMUCG4 IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
DMMUCG4 CA CAS 6217-54-5
DMMUCG4 CB CHEBI:28125
DMMUCG4 DE Hypertriglyceridemia; Alzheimer disease
DMRDUC0 ID DMRDUC0
DMRDUC0 DN Elagolix sodium
DMRDUC0 HS Approved
DMRDUC0 SN Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336
DMRDUC0 CP AbbVie
DMRDUC0 PC 24785956
DMRDUC0 MW 653.6
DMRDUC0 FM C32H29F5N3NaO5
DMRDUC0 IC InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
DMRDUC0 CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
DMRDUC0 IK DQYGXRQUFSRDCH-UQIIZPHYSA-M
DMRDUC0 IU sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
DMRDUC0 CA CAS 832720-36-2
DMRDUC0 DE Endometriosis
DMS7OU8 ID DMS7OU8
DMS7OU8 DN Elapegademase
DMS7OU8 HS Approved
DMS7OU8 SN Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS
DMS7OU8 CP Leadiant Biosciences
DMS7OU8 DE Immunodeficiency; Adenosine deaminase defciency
DMJLE18 ID DMJLE18
DMJLE18 DN Elbasvir
DMJLE18 HS Approved
DMJLE18 SN Elbasvir; Elbasvir [USAN:INN]; Elbasvir(MK-8742); MK 8742; MK-8742; MK8742; SB16741; ZINC150588351; 1370468-36-2; 632L571YDK; A16855; CHEBI:132967; CHEMBL3039514; CS-5332; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; DB11574; EX-A2889; HY-15789; SCHEMBL17429773; UNII-632L571YDK
DMJLE18 PC 71661251
DMJLE18 MW 882
DMJLE18 FM C49H55N9O7
DMJLE18 IC BVAZQCUMNICBAQ-PZHYSIFUSA-N
DMJLE18 CS CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
DMJLE18 IK 1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
DMJLE18 IU methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMJLE18 CA CAS 1370468-36-2
DMJLE18 CB CHEBI:132967
DMJLE18 DE Viral hepatitis
DMW649X ID DMW649X
DMW649X DN Eletriptan
DMW649X HS Approved
DMW649X SN Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CP Pfizer Inc
DMW649X TC Antimigraine Agents
DMW649X DT Small molecular drug
DMW649X PC 77993
DMW649X MW 382.5
DMW649X FM C22H26N2O2S
DMW649X IC InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
DMW649X CS CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMW649X IK PWVXXGRKLHYWKM-LJQANCHMSA-N
DMW649X IU 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CA CAS 143322-58-1
DMW649X CB CHEBI:50922
DMW649X DE Migraine
DMSRZAO ID DMSRZAO
DMSRZAO DN Eliglustat tartrate
DMSRZAO HS Approved
DMSRZAO SN Fabrazyme (TN)
DMSRZAO CP Genzyme
DMSRZAO DT Small molecular drug
DMSRZAO PC 52918379
DMSRZAO MW 959.2
DMSRZAO FM C50H78N4O14
DMSRZAO IC InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1
DMSRZAO CS CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMSRZAO IK KUBARPMUNHKBIQ-VTHUDJRQSA-N
DMSRZAO IU N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid
DMSRZAO CA CAS 928659-70-5
DMSRZAO CB CHEBI:83353
DMSRZAO DE Metabolic disorder
DMZC6GT ID DMZC6GT
DMZC6GT DN Elliptinium acetate
DMZC6GT HS Approved
DMZC6GT SN Celiptium (TN)
DMZC6GT CP Sanofi
DMZC6GT DT Small molecular drug
DMZC6GT PC 42722
DMZC6GT MW 336.4
DMZC6GT FM C20H20N2O3
DMZC6GT IC InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4)
DMZC6GT CS CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-]
DMZC6GT IK BOMZMNZEXMAQQW-UHFFFAOYSA-N
DMZC6GT IU 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate
DMZC6GT CA CAS 58337-35-2
DMZC6GT DE Solid tumour/cancer
DMRCX8K ID DMRCX8K
DMRCX8K DN Eloctate
DMRCX8K HS Approved
DMRCX8K SN Recombinant human factor VIII-FC
DMRCX8K CP Biogen Idec
DMRCX8K DE Haemophilia A
DMA9REV ID DMA9REV
DMA9REV DN Elosulfase alfa
DMA9REV HS Approved
DMA9REV SN Vimizim
DMA9REV CP Biomarin
DMA9REV SQ Elosulfase-alfa: APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARNLLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLTFLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPFPGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWTVTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGKPNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARPQIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWWPPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQCLTPPESIPKKCLWSH
DMA9REV DE Mucopolysaccharidosis
DMEYHG9 ID DMEYHG9
DMEYHG9 DN Elotuzumab
DMEYHG9 HS Approved
DMEYHG9 SN BMS-901608
DMEYHG9 CP Bristol-Myers Squibb
DMEYHG9 DT Antibody
DMEYHG9 SQ Elotuzumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Elotuzumab light chainDIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMEYHG9 DE Multiple myeloma
DMOGFIX ID DMOGFIX
DMOGFIX DN Eltrombopag
DMOGFIX HS Approved
DMOGFIX SN Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
DMOGFIX CP GlaxoSmithKline
DMOGFIX DT Small molecular drug
DMOGFIX PC 135449332
DMOGFIX MW 442.5
DMOGFIX FM C25H22N4O4
DMOGFIX IC InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
DMOGFIX CS CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
DMOGFIX IK SVOQIEJWJCQGDQ-UHFFFAOYSA-N
DMOGFIX IU 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
DMOGFIX CA CAS 496775-61-2
DMOGFIX CB CHEBI:85010
DMOGFIX DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMYZ0P1 ID DMYZ0P1
DMYZ0P1 DN Eluxadoline
DMYZ0P1 HS Approved
DMYZ0P1 SN MuDelta
DMYZ0P1 CP Furiex pharmaceuticals
DMYZ0P1 DT Small molecular drug
DMYZ0P1 PC 11250029
DMYZ0P1 MW 569.6
DMYZ0P1 FM C32H35N5O5
DMYZ0P1 IC InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
DMYZ0P1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
DMYZ0P1 IK QFNHIDANIVGXPE-FNZWTVRRSA-N
DMYZ0P1 IU 5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
DMYZ0P1 CA CAS 864821-90-9
DMYZ0P1 CB CHEBI:85980
DMYZ0P1 DE Diarrhea-predominant irritable bowel syndrome
DMG9B1U ID DMG9B1U
DMG9B1U DN Elvitegravir
DMG9B1U HS Approved
DMG9B1U SN EVG
DMG9B1U DT Small molecular drug
DMG9B1U PC 5277135
DMG9B1U MW 447.9
DMG9B1U FM C23H23ClFNO5
DMG9B1U IC InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
DMG9B1U CS CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
DMG9B1U IK JUZYLCPPVHEVSV-LJQANCHMSA-N
DMG9B1U IU 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
DMG9B1U CA CAS 697761-98-1
DMG9B1U CB CHEBI:72289
DMG9B1U DE Human immunodeficiency virus infection
DMZG5WL ID DMZG5WL
DMZG5WL DN Emapalumab
DMZG5WL HS Approved
DMZG5WL SN emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
DMZG5WL CP Novimmune
DMZG5WL DT Antibody
DMZG5WL DE Primary haemophagocytic lymphohistiocytosis
DM36LAJ ID DM36LAJ
DM36LAJ DN Emedastine
DM36LAJ HS Approved
DM36LAJ SN Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
DM36LAJ TC Antiallergic Agents
DM36LAJ DT Small molecular drug
DM36LAJ PC 3219
DM36LAJ MW 302.4
DM36LAJ FM C17H26N4O
DM36LAJ IC InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
DM36LAJ CS CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
DM36LAJ IK KBUZBQVCBVDWKX-UHFFFAOYSA-N
DM36LAJ IU 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
DM36LAJ CA CAS 87233-61-2
DM36LAJ CB CHEBI:4779
DM36LAJ DE Allergic conjunctivitis
DMCOAVT ID DMCOAVT
DMCOAVT DN Emepronium
DMCOAVT HS Approved
DMCOAVT SN Emepronium Bromide; Restenacht; Cetiprin; Emeprone bromide; Emepron bromide; 3614-30-0; Emeproniumbromid [German]; Emepronium bromide [INN:BAN]; Emepronii bromidum [INN-Latin]; Bromure d'emepronium [INN-French]; Bromuro de emepronio [INN-Spanish]; EINECS 222-786-6; Ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide; Dimethylethyl(beta-benzhydrylisopropyl)ammonium bromide; C20H28N; Ammonium, ethyldimethyl(1-methyl-3,3-diphenylpropyl)-, bromide; Emeproniumbromid; Emepronii bromidum; Bromure d'emepronium; Bromuro de emep
DMCOAVT DT Small molecular drug
DMCOAVT PC 34055
DMCOAVT MW 282.4
DMCOAVT FM C20H28N+
DMCOAVT IC InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
DMCOAVT CS CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMCOAVT IK JEJBJBKVPOWOQK-UHFFFAOYSA-N
DMCOAVT IU 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium
DMCOAVT CA CAS 27892-33-7
DMCOAVT CB CHEBI:135169
DMCOAVT DE Urinary incontinence
DMCT2YF ID DMCT2YF
DMCT2YF DN Emetine
DMCT2YF HS Approved
DMCT2YF SN Emetine hydrochloride; EMETINE; 14198-59-5; MLS000028478; SMR000058444; NSC-33669; NSC33669; Emetine monohydrochloride; Opera_ID_1460; Cephaeline methyl ether HCl; AC1O7FP4; SCHEMBL636599; CHEMBL513000; DTXSID80424947; MolPort-004-964-890; Cephaeline methyl ether hydrochloride; NSC752340; AKOS024374935; NSC-752340; ST51014995; Emetan,7',10,11-tetramethoxy-, dihydrochloride; Q-100155; 10-[((1R)-6,7-dimethoxy(1,2,3,4-tetrahydroisoquinolyl))methyl](10S,11aS,9R)-9- ethyl-2,3-dimethoxy-5,6,7,11a-tetrahydropiperidino[2,1-a]isoquinolin
DMCT2YF DT Small molecular drug
DMCT2YF PC 10219
DMCT2YF MW 480.6
DMCT2YF FM C29H40N2O4
DMCT2YF IC InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1
DMCT2YF CS CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
DMCT2YF IK AUVVAXYIELKVAI-CKBKHPSWSA-N
DMCT2YF IU (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
DMCT2YF CA CAS 483-18-1
DMCT2YF CB CHEBI:4781
DMCT2YF DE Hepatitis virus infection
DM0AQ83 ID DM0AQ83
DM0AQ83 DN Emicizumab
DM0AQ83 HS Approved
DM0AQ83 CP Roche/Genentech
DM0AQ83 DT Antibody
DM0AQ83 DE Factor VIII deficiency
DMRF9YK ID DMRF9YK
DMRF9YK DN Empagliflozin
DMRF9YK HS Approved
DMRF9YK SN 864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
DMRF9YK CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMRF9YK DT Small molecular drug
DMRF9YK PC 11949646
DMRF9YK MW 450.9
DMRF9YK FM C23H27ClO7
DMRF9YK IC InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
DMRF9YK CS C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMRF9YK IK OBWASQILIWPZMG-QZMOQZSNSA-N
DMRF9YK IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9YK CA CAS 864070-44-0
DMRF9YK CB CHEBI:82720
DMRF9YK DE Type-1 diabetes
DMBMUWZ ID DMBMUWZ
DMBMUWZ DN Emtricitabine
DMBMUWZ HS Approved
DMBMUWZ SN Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
DMBMUWZ CP Gilead; Bristol-Myers Squibb
DMBMUWZ TC Anti-HIV Agents
DMBMUWZ DT Small molecular drug
DMBMUWZ PC 60877
DMBMUWZ MW 247.25
DMBMUWZ FM C8H10FN3O3S
DMBMUWZ IC InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
DMBMUWZ CS C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMBMUWZ IK XQSPYNMVSIKCOC-NTSWFWBYSA-N
DMBMUWZ IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMBMUWZ CA CAS 143491-57-0
DMBMUWZ CB CHEBI:31536
DMBMUWZ DE Human immunodeficiency virus infection; Hepatitis virus infection; Hepatitis B virus infection
DMNFUZR ID DMNFUZR
DMNFUZR DN Enalapril
DMNFUZR HS Approved
DMNFUZR SN Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CP Merck & Co
DMNFUZR TC Antihypertensive Agents
DMNFUZR DT Small molecular drug
DMNFUZR PC 5388962
DMNFUZR MW 376.4
DMNFUZR FM C20H28N2O5
DMNFUZR IC InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
DMNFUZR CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
DMNFUZR IK GBXSMTUPTTWBMN-XIRDDKMYSA-N
DMNFUZR IU (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CA CAS 75847-73-3
DMNFUZR CB CHEBI:4784
DMNFUZR DE Hypertension
DMFYAM1 ID DMFYAM1
DMFYAM1 DN Enalaprilat
DMFYAM1 HS Approved
DMFYAM1 SN Extract of ginger root; Ginger extract; Ginger root extract; Ginger, ext; LS-3194; Zingiber officinale extract; Zingiber officinale root extract; CCRIS 7641; EINECS 283-634-2; FEMA No. 2520; FEMA No. 2521; FEMA No. 2523; Ginger extract (Zingiber officinale); ginger, extract (zingiber officinale rosc.)
DMFYAM1 PC 6850776
DMFYAM1 MW 568.8
DMFYAM1 FM C35H52O6
DMFYAM1 IC QCVRFSPGUWEKFC-ILHSMLOTSA-N
DMFYAM1 CS CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC.CCCCCC(C)CC(=O)CCC1=CC(=C(C=C1)O)OC
DMFYAM1 IK 1S/C18H28O3.C17H24O3/c1-4-5-6-7-14(2)12-16(19)10-8-15-9-11-17(20)18(13-15)21-3;1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9,11,13-14,20H,4-8,10,12H2,1-3H3;7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b;8-7+
DMFYAM1 IU (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one;1-(4-hydroxy-3-methoxyphenyl)-5-methyldecan-3-one
DMFYAM1 CA CAS 84696-15-1
DMFYAM1 DE Essential hypertension
DMPRBQV ID DMPRBQV
DMPRBQV DN Enalaprilat
DMPRBQV HS Approved
DMPRBQV SN EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
DMPRBQV CP Merck & Co
DMPRBQV TC Antihypertensive Agents
DMPRBQV DT Small molecular drug
DMPRBQV PC 5462501
DMPRBQV MW 348.4
DMPRBQV FM C18H24N2O5
DMPRBQV IC InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
DMPRBQV CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O
DMPRBQV IK LZFZMUMEGBBDTC-QEJZJMRPSA-N
DMPRBQV IU (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMPRBQV CA CAS 76420-72-9
DMPRBQV CB CHEBI:4786
DMPRBQV DE Hypertension
DM8QXOC ID DM8QXOC
DM8QXOC DN Enasidenib
DM8QXOC HS Approved
DM8QXOC SN Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG
DM8QXOC PC 89683805
DM8QXOC MW 473.4
DM8QXOC FM C19H17F6N7O
DM8QXOC IC DYLUUSLLRIQKOE-UHFFFAOYSA-N
DM8QXOC CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DM8QXOC IK 1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DM8QXOC IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DM8QXOC CA CAS 1446502-11-9
DM8QXOC CB CHEBI:145374
DM8QXOC DE Acute myeloid leukaemia
DMPOU5H ID DMPOU5H
DMPOU5H DN ENASIDENIB MESYLATE
DMPOU5H HS Approved
DMPOU5H SN UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
DMPOU5H CP Celgene/Agios
DMPOU5H PC 90480031
DMPOU5H MW 569.5
DMPOU5H FM C20H21F6N7O4S
DMPOU5H IC InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
DMPOU5H CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
DMPOU5H IK ORZHZQZYWXEDDL-UHFFFAOYSA-N
DMPOU5H IU methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMPOU5H CA CAS 1650550-25-6
DMPOU5H DE Acute myeloid leukaemia
DM7RNP3 ID DM7RNP3
DM7RNP3 DN Enbrel
DM7RNP3 HS Approved
DM7RNP3 DE Arthritis
DM0YJSB ID DM0YJSB
DM0YJSB DN Enflurane
DM0YJSB HS Approved
DM0YJSB SN Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB TC Anesthetics
DM0YJSB DT Small molecular drug
DM0YJSB PC 3226
DM0YJSB MW 184.49
DM0YJSB FM C3H2ClF5O
DM0YJSB IC InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
DM0YJSB CS C(C(OC(F)F)(F)F)(F)Cl
DM0YJSB IK JPGQOUSTVILISH-UHFFFAOYSA-N
DM0YJSB IU 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB CA CAS 13838-16-9
DM0YJSB CB CHEBI:4792
DM0YJSB DE Anaesthesia
DMFS63G ID DMFS63G
DMFS63G DN Enfortumab
DMFS63G HS Approved
DMFS63G SN ASG-2ME
DMFS63G CP Astellas Northbrook, IL Seattle Genetics Bothell, WA
DMFS63G DT Antibody drug conjugate
DMFS63G DE Urothelial carcinoma
DM7YPM1 ID DM7YPM1
DM7YPM1 DN Enfuvirtide
DM7YPM1 HS Approved
DM7YPM1 SN Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd
DM7YPM1 CP Hoffmann-La Roche pharmaceutical company
DM7YPM1 TC Anti-HIV Agents
DM7YPM1 DT Small molecular drug
DM7YPM1 SQ DB00109 sequence: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
DM7YPM1 PC 24847866
DM7YPM1 MW 4565
DM7YPM1 FM C206H304N52O66
DM7YPM1 IC InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1
DM7YPM1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C
DM7YPM1 IK BWVBEUNZTQWGMR-CKVIKZOTSA-N
DM7YPM1 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM7YPM1 DE Human immunodeficiency virus infection
DMYTE6L ID DMYTE6L
DMYTE6L DN Enoxacin
DMYTE6L HS Approved
DMYTE6L SN Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L TC Antiinfective Agents
DMYTE6L DT Small molecular drug
DMYTE6L PC 3229
DMYTE6L MW 320.32
DMYTE6L FM C15H17FN4O3
DMYTE6L IC InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
DMYTE6L CS CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
DMYTE6L IK IDYZIJYBMGIQMJ-UHFFFAOYSA-N
DMYTE6L IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L CA CAS 74011-58-8
DMYTE6L CB CHEBI:157175
DMYTE6L DE Urinary tract infection
DMQVZJD ID DMQVZJD
DMQVZJD DN Enoximone
DMQVZJD HS Approved
DMQVZJD SN ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE
DMQVZJD TC Cardiotonic Agents
DMQVZJD DT Small molecular drug
DMQVZJD PC 53708
DMQVZJD MW 248.3
DMQVZJD FM C12H12N2O2S
DMQVZJD IC InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
DMQVZJD CS CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC
DMQVZJD IK ZJKNESGOIKRXQY-UHFFFAOYSA-N
DMQVZJD IU 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one
DMQVZJD CA CAS 77671-31-9
DMQVZJD CB CHEBI:135010
DMQVZJD DE Congestive heart failure
DMFYZKN ID DMFYZKN
DMFYZKN DN Enprofylline
DMFYZKN HS Approved
DMFYZKN SN Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione
DMFYZKN TC Antiinflammatory Agents
DMFYZKN DT Small molecular drug
DMFYZKN PC 1676
DMFYZKN MW 194.19
DMFYZKN FM C8H10N4O2
DMFYZKN IC InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
DMFYZKN CS CCCN1C2=C(C(=O)NC1=O)NC=N2
DMFYZKN IK SIQPXVQCUCHWDI-UHFFFAOYSA-N
DMFYZKN IU 3-propyl-7H-purine-2,6-dione
DMFYZKN CA CAS 41078-02-8
DMFYZKN CB CHEBI:126237
DMFYZKN DE Asthma
DMLBVKQ ID DMLBVKQ
DMLBVKQ DN Entacapone
DMLBVKQ HS Approved
DMLBVKQ SN Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
DMLBVKQ CP Norvatis Phamaceuticals Corporation
DMLBVKQ TC Antiparkinson Agents
DMLBVKQ DT Small molecular drug
DMLBVKQ PC 5281081
DMLBVKQ MW 305.29
DMLBVKQ FM C14H15N3O5
DMLBVKQ IC InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
DMLBVKQ CS CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N
DMLBVKQ IK JRURYQJSLYLRLN-BJMVGYQFSA-N
DMLBVKQ IU (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
DMLBVKQ CA CAS 130929-57-6
DMLBVKQ CB CHEBI:4798
DMLBVKQ DE Parkinson disease
DM7VTQO ID DM7VTQO
DM7VTQO DN Entecavir
DM7VTQO HS Approved
DM7VTQO SN Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
DM7VTQO CP Bristol-Myers Squibb
DM7VTQO TC Antiviral Agents
DM7VTQO DT Small molecular drug
DM7VTQO PC 135398508
DM7VTQO MW 277.28
DM7VTQO FM C12H15N5O3
DM7VTQO IC InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
DM7VTQO CS C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N
DM7VTQO IK QDGZDCVAUDNJFG-FXQIFTODSA-N
DM7VTQO IU 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one
DM7VTQO CA CAS 142217-69-4
DM7VTQO CB CHEBI:473990
DM7VTQO DE Hepatitis B virus infection
DMK659W ID DMK659W
DMK659W DN Enteric-coated mycophenolate sodium
DMK659W HS Approved
DMK659W SN Myfortic; Mycophenolate sodium; ERL-080; Enteric-coated MPA, Novartis; Enteric-coated mycophenolate sodium, Novartis
DMK659W CP Novartis AG
DMK659W DE Transplant rejection
DMMPTLH ID DMMPTLH
DMMPTLH DN Entrectinib
DMMPTLH HS Approved
DMMPTLH SN 1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
DMMPTLH CP Ignyta
DMMPTLH DT Small molecular drug
DMMPTLH PC 25141092
DMMPTLH MW 560.6
DMMPTLH FM C31H34F2N6O2
DMMPTLH IC InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)
DMMPTLH CS CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMMPTLH IK HAYYBYPASCDWEQ-UHFFFAOYSA-N
DMMPTLH IU N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
DMMPTLH CA CAS 1108743-60-7
DMMPTLH DE Solid tumour/cancer; Colorectal cancer; Neuroblastoma; Mammary analogue secretory carcinoma; Non-small cell lung cancer
DMGL19D ID DMGL19D
DMGL19D DN Enzalutamide
DMGL19D HS Approved
DMGL19D SN MDV3100; Enzalutamide (AR inhibitor)
DMGL19D CP Astellas Pharma
DMGL19D DT Small molecular drug
DMGL19D SQ 5'-CTCCAACATCAAGGAAGATGGCATTTCTAG
DMGL19D PC 15951529
DMGL19D MW 464.4
DMGL19D FM C21H16F4N4O2S
DMGL19D IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
DMGL19D CS CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
DMGL19D IK WXCXUHSOUPDCQV-UHFFFAOYSA-N
DMGL19D IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
DMGL19D CA CAS 915087-33-1
DMGL19D CB CHEBI:68534
DMGL19D DE Prostate cancer
DM5OGK0 ID DM5OGK0
DM5OGK0 DN Epalrestat
DM5OGK0 HS Approved
DM5OGK0 SN epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; Epalrestat [INN]; Epalrestatum [Latin]; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; ONO 2; UNII-424DV0807X; C15H13NO3S2; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 424DV0807X; Epalrestatum; Aldorin (TN); Kinedak (TN); Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; Ono 2
DM5OGK0 CP Eskayef Bangladesh Limited
DM5OGK0 TC Hypoglycemic Agents
DM5OGK0 DT Small molecular drug
DM5OGK0 PC 1549120
DM5OGK0 MW 319.4
DM5OGK0 FM C15H13NO3S2
DM5OGK0 IC InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
DM5OGK0 CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O
DM5OGK0 IK CHNUOJQWGUIOLD-NFZZJPOKSA-N
DM5OGK0 IU 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DM5OGK0 CA CAS 82159-09-9
DM5OGK0 CB CHEBI:31539
DM5OGK0 DE Diabetic neuropathy; Pain
DMHEAGL ID DMHEAGL
DMHEAGL DN Epanova
DMHEAGL HS Approved
DMHEAGL SN Omefas; Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera
DMHEAGL CP Tillotts Pharma AG
DMHEAGL DT Small molecular drug
DMHEAGL PC 56842239
DMHEAGL MW 909.4
DMHEAGL FM C60H92O6
DMHEAGL IC InChI=1S/C22H32O2.C20H30O2.C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;4-3-,7-6-,10-9-,13-12-,16-15-;4-3-,7-6-,10-9-
DMHEAGL CS CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMHEAGL IK QPEOIOLHJXXJFN-GNGJDXFDSA-N
DMHEAGL IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
DMHEAGL DE Hypertriglyceridemia
DMMV0KW ID DMMV0KW
DMMV0KW DN Ephedrine
DMMV0KW HS Approved
DMMV0KW SN Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin
DMMV0KW CP Ben Venue Laboratories Inc
DMMV0KW TC Central Nervous System Stimulants
DMMV0KW DT Small molecular drug
DMMV0KW PC 9294
DMMV0KW MW 165.23
DMMV0KW FM C10H15NO
DMMV0KW IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
DMMV0KW CS C[C@@H]([C@@H](C1=CC=CC=C1)O)NC
DMMV0KW IK KWGRBVOPPLSCSI-WPRPVWTQSA-N
DMMV0KW IU (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMMV0KW CA CAS 299-42-3
DMMV0KW CB CHEBI:15407
DMMV0KW DE Asthma
DMVONE6 ID DMVONE6
DMVONE6 DN Epidermal growth factor
DMVONE6 HS Approved
DMVONE6 SN 62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF
DMVONE6 DT Small molecular drug
DMVONE6 PC 56841751
DMVONE6 MW 6046
DMVONE6 FM C257H381N73O83S7
DMVONE6 IC InChI=1S/C257H381N73O83S7/c1-20-123(15)203(245(404)283-103-192(351)285-157(80-127-42-52-135(339)53-43-127)222(381)313-171(104-331)210(369)281-101-191(350)287-167(92-198(360)361)228(387)290-146(37-27-70-273-255(265)266)213(372)318-177(110-414)238(397)292-148(62-65-185(259)344)217(376)327-205(125(17)337)249(408)294-147(38-28-71-274-256(267)268)212(371)309-168(93-199(362)363)229(388)298-153(76-117(3)4)218(377)289-145(36-26-69-272-254(263)264)211(370)303-162(86-133-96-277-144-35-25-23-33-141(133)144)226(385)304-161(85-132-95-276-143-34-24-22-32-140(132)143)225(384)291-149(63-66-195(354)355)214(373)297-154(77-118(5)6)219(378)296-152(253(412)413)39-29-72-275-257(269)270)326-247(406)202(122(13)14)324-242(401)181(114-418)320-227(386)165(90-188(262)347)307-241(400)180(113-417)322-250(409)206(126(18)338)328-231(390)160(83-130-48-58-138(342)59-49-130)302-234(393)174(107-334)315-230(389)169(94-200(364)365)310-221(380)155(78-119(7)8)299-233(392)173(106-333)314-215(374)150(64-67-196(356)357)295-248(407)204(124(16)21-2)325-232(391)163(87-134-97-271-116-284-134)305-216(375)151(68-75-420-19)293-239(398)179(112-416)321-246(405)201(121(11)12)323-194(353)99-278-189(348)98-279-208(367)164(89-187(261)346)306-220(379)156(79-120(9)10)300-240(399)178(111-415)319-223(382)158(81-128-44-54-136(340)55-45-128)286-190(349)100-280-209(368)166(91-197(358)359)308-224(383)159(82-129-46-56-137(341)57-47-129)301-235(394)175(108-335)316-237(396)176(109-336)317-244(403)184-41-31-74-330(184)252(411)182(115-419)288-193(352)102-282-243(402)183-40-30-73-329(183)251(410)170(84-131-50-60-139(343)61-51-131)311-236(395)172(105-332)312-207(366)142(258)88-186(260)345/h22-25,32-35,42-61,95-97,116-126,142,145-184,201-206,276-277,331-343,414-419H,20-21,26-31,36-41,62-94,98-115,258H2,1-19H3,(H2,259,344)(H2,260,345)(H2,261,346)(H2,262,347)(H,271,284)(H,278,348)(H,279,367)(H,280,368)(H,281,369)(H,282,402)(H,283,404)(H,285,351)(H,286,349)(H,287,350)(H,288,352)(H,289,377)(H,290,387)(H,291,384)(H,292,397)(H,293,398)(H,294,408)(H,295,407)(H,296,378)(H,297,373)(H,298,388)(H,299,392)(H,300,399)(H,301,394)(H,302,393)(H,303,370)(H,304,385)(H,305,375)(H,306,379)(H,307,400)(H,308,383)(H,309,371)(H,310,380)(H,311,395)(H,312,366)(H,313,381)(H,314,374)(H,315,389)(H,316,396)(H,317,403)(H,318,372)(H,319,382)(H,320,386)(H,321,405)(H,322,409)(H,323,353)(H,324,401)(H,325,391)(H,326,406)(H,327,376)(H,328,390)(H,354,355)(H,356,357)(H,358,359)(H,360,361)(H,362,363)(H,364,365)(H,412,413)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t123-,124-,125+,126+,142-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,201-,202-,203-,204-,205-,206-/m0/s1
DMVONE6 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N
DMVONE6 IK VBEQCZHXXJYVRD-GACYYNSASA-N
DMVONE6 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMVONE6 CA CAS 62229-50-9
DMVONE6 DE Vulnerary; Wound healing
DMX0K3Q ID DMX0K3Q
DMX0K3Q DN Epinastine
DMX0K3Q HS Approved
DMX0K3Q SN Epinastina; Epinastinum; Purivist; Epinastina [Spanish]; Epinastine [INN]; Epinastinum [Latin]; WAL 80; WAL 801; WAL 801CL; Elestat (TN); Epinastine (INN); Purivist (TN); Relestat (TN); WAL-80 Cl; (+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine
DMX0K3Q CP Allergan Pharmaceuticals
DMX0K3Q TC Antihistamines
DMX0K3Q DT Small molecular drug
DMX0K3Q PC 3241
DMX0K3Q MW 249.31
DMX0K3Q FM C16H15N3
DMX0K3Q IC InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
DMX0K3Q CS C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
DMX0K3Q IK WHWZLSFABNNENI-UHFFFAOYSA-N
DMX0K3Q IU 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine
DMX0K3Q CA CAS 80012-43-7
DMX0K3Q CB CHEBI:51032
DMX0K3Q DE Allergic conjunctivitis
DM3KJBC ID DM3KJBC
DM3KJBC DN Epinephrine
DM3KJBC HS Approved
DM3KJBC SN ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC TC Vasoconstrictor Agents
DM3KJBC DT Small molecular drug
DM3KJBC PC 5816
DM3KJBC MW 183.2
DM3KJBC FM C9H13NO3
DM3KJBC IC InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
DM3KJBC CS CNC[C@@H](C1=CC(=C(C=C1)O)O)O
DM3KJBC IK UCTWMZQNUQWSLP-VIFPVBQESA-N
DM3KJBC IU 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC CA CAS 51-43-4
DM3KJBC CB CHEBI:28918
DM3KJBC DE Allergy
DMPDW6T ID DMPDW6T
DMPDW6T DN Epirubicin
DMPDW6T HS Approved
DMPDW6T SN Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
DMPDW6T CP Pfizer Pharmaceuticals
DMPDW6T TC Anticancer Agents
DMPDW6T DT Small molecular drug
DMPDW6T PC 41867
DMPDW6T MW 543.5
DMPDW6T FM C27H29NO11
DMPDW6T IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
DMPDW6T CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMPDW6T IK AOJJSUZBOXZQNB-VTZDEGQISA-N
DMPDW6T IU (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMPDW6T CA CAS 56420-45-2
DMPDW6T CB CHEBI:47898
DMPDW6T DE Solid tumour/cancer
DMF0NQR ID DMF0NQR
DMF0NQR DN Eplerenone
DMF0NQR HS Approved
DMF0NQR SN Epoxymexrenone; Inspra; Selara; CGP-30083; Inspra (TN); SC-66110; Eplerenone (JAN/USAN/INN); Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
DMF0NQR CP Pfizer Pharmaceuticals
DMF0NQR TC Antihypertensive Agents
DMF0NQR DT Small molecular drug
DMF0NQR PC 443872
DMF0NQR MW 414.5
DMF0NQR FM C24H30O6
DMF0NQR IC InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
DMF0NQR CS C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMF0NQR IK JUKPWJGBANNWMW-VWBFHTRKSA-N
DMF0NQR IU methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
DMF0NQR CA CAS 107724-20-9
DMF0NQR CB CHEBI:31547
DMF0NQR DE Heart failure
DMKWB73 ID DMKWB73
DMKWB73 DN Epoetin alfa
DMKWB73 HS Approved
DMKWB73 SN Epogen (TN); Procrit (TN)
DMKWB73 CP Amgen Inc
DMKWB73 TC Antianemic Agents
DMKWB73 DE Anemia
DMUTYR2 ID DMUTYR2
DMUTYR2 DN Epoprostenol
DMUTYR2 HS Approved
DMUTYR2 SN Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
DMUTYR2 TC Antihypertensive Agents
DMUTYR2 DT Small molecular drug
DMUTYR2 PC 5282411
DMUTYR2 MW 352.5
DMUTYR2 FM C20H32O5
DMUTYR2 IC InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1
DMUTYR2 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O
DMUTYR2 IK KAQKFAOMNZTLHT-OZUDYXHBSA-N
DMUTYR2 IU (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
DMUTYR2 CA CAS 35121-78-9
DMUTYR2 CB CHEBI:15552
DMUTYR2 DE Pulmonary hypertension
DM07K2I ID DM07K2I
DM07K2I DN Eprosartan
DM07K2I HS Approved
DM07K2I SN 133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan
DM07K2I CP Abbott Laboratories
DM07K2I TC Antihypertensive Agents
DM07K2I DT Small molecular drug
DM07K2I PC 5281037
DM07K2I MW 424.5
DM07K2I FM C23H24N2O4S
DM07K2I IC InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
DM07K2I CS CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\\CC3=CC=CS3)/C(=O)O
DM07K2I IK OROAFUQRIXKEMV-LDADJPATSA-N
DM07K2I IU 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid
DM07K2I CA CAS 133040-01-4
DM07K2I CB CHEBI:4814
DM07K2I DE Hypertension
DMQXTJS ID DMQXTJS
DMQXTJS DN Eptifibatide
DMQXTJS HS Approved
DMQXTJS SN Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS CP Millennium Pharmaceuticals
DMQXTJS TC Anticoagulants
DMQXTJS DT Small molecular drug
DMQXTJS PC 448812
DMQXTJS MW 832
DMQXTJS FM C35H49N11O9S2
DMQXTJS IC InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
DMQXTJS CS C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
DMQXTJS IK CZKPOZZJODAYPZ-LROMGURASA-N
DMQXTJS IU 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS CA CAS 188627-80-7
DMQXTJS CB CHEBI:291902
DMQXTJS DE Acute cardiac ischemic events
DM5LJCI ID DM5LJCI
DM5LJCI DN Eptinezumab
DM5LJCI HS Approved
DM5LJCI CP Alder Biopharmaceuticals Bothell, WA
DM5LJCI DE Migraine
DMI782S ID DMI782S
DMI782S DN Erdafitinib
DMI782S HS Approved
DMI782S SN 1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino
DMI782S CP Janssen Research & Development Raritan, NJ
DMI782S PC 67462786
DMI782S MW 446.5
DMI782S FM C25H30N6O2
DMI782S IC InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
DMI782S CS CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
DMI782S IK OLAHOMJCDNXHFI-UHFFFAOYSA-N
DMI782S IU N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine
DMI782S CA CAS 1346242-81-6
DMI782S DE Lymphoma; Urothelial carcinoma; Bladder cancer; Solid tumour/cancer
DM6QFSV ID DM6QFSV
DM6QFSV DN Erdosteine
DM6QFSV HS Approved
DM6QFSV SN Asdigan; Biopulmin; Dostin; Dostol; Drupsan; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdotin; Esteclin; Fluidasa; Flusten; Mucoflux; Mucofor; Mucotec; Mucothera; Mukial; Secresolv; Theovix; Tusselin; Vectrine; KW-9144; RV-144
DM6QFSV CP Edmond Pharma
DM6QFSV DT Small molecular drug
DM6QFSV PC 65632
DM6QFSV MW 249.3
DM6QFSV FM C8H11NO4S2
DM6QFSV IC InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
DM6QFSV CS C1CSC(=O)C1NC(=O)CSCC(=O)O
DM6QFSV IK QGFORSXNKQLDNO-UHFFFAOYSA-N
DM6QFSV IU 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid
DM6QFSV CA CAS 84611-23-4
DM6QFSV CB CHEBI:135014
DM6QFSV DE Bronchitis
DMWMCN0 ID DMWMCN0
DMWMCN0 DN Erenumab
DMWMCN0 HS Approved
DMWMCN0 SN Aimovig; Erenumab [USAN]; UNII-I5I8VB78VT; I5I8VB78VT
DMWMCN0 CP Amgen/Novartis
DMWMCN0 DE Hyperprolactinaemia
DMHO0AR ID DMHO0AR
DMHO0AR DN Ergocalciferol
DMHO0AR HS Approved
DMHO0AR SN Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
DMHO0AR CP Eli Lilly
DMHO0AR TC Vitamins
DMHO0AR DT Small molecular drug
DMHO0AR PC 5280793
DMHO0AR MW 396.6
DMHO0AR FM C28H44O
DMHO0AR IC InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
DMHO0AR CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMHO0AR IK MECHNRXZTMCUDQ-RKHKHRCZSA-N
DMHO0AR IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMHO0AR CA CAS 50-14-6
DMHO0AR CB CHEBI:28934
DMHO0AR DE Hypoparathyroidism
DMORPBA ID DMORPBA
DMORPBA DN Ergoloid mesylate
DMORPBA HS Approved
DMORPBA SN Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)
DMORPBA CP Sandoz
DMORPBA TC Vasodilator Agents
DMORPBA DT Small molecular drug
DMORPBA PC 592735
DMORPBA MW 591.7
DMORPBA FM C33H45N5O5
DMORPBA IC InChI=1S/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39)
DMORPBA CS CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O
DMORPBA IK YLXBZBPHTNJZQE-UHFFFAOYSA-N
DMORPBA IU N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMORPBA DE Alzheimer disease
DM0VEC1 ID DM0VEC1
DM0VEC1 DN Ergonovine
DM0VEC1 HS Approved
DM0VEC1 SN Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
DM0VEC1 CP Pfizer Pharmaceuticals
DM0VEC1 TC Oxytocics
DM0VEC1 DT Small molecular drug
DM0VEC1 PC 443884
DM0VEC1 MW 325.4
DM0VEC1 FM C19H23N3O2
DM0VEC1 IC InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
DM0VEC1 CS C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DM0VEC1 IK WVVSZNPYNCNODU-XTQGRXLLSA-N
DM0VEC1 IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM0VEC1 CA CAS 60-79-7
DM0VEC1 CB CHEBI:4822
DM0VEC1 DE Postpartum haemorrhage
DMKR3C5 ID DMKR3C5
DMKR3C5 DN Ergotamine
DMKR3C5 HS Approved
DMKR3C5 SN Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
DMKR3C5 CP Eli Lilly
DMKR3C5 TC Analgesics
DMKR3C5 DT Small molecular drug
DMKR3C5 PC 8223
DMKR3C5 MW 581.7
DMKR3C5 FM C33H35N5O5
DMKR3C5 IC InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
DMKR3C5 CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
DMKR3C5 IK XCGSFFUVFURLIX-VFGNJEKYSA-N
DMKR3C5 IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMKR3C5 CA CAS 379-79-3
DMKR3C5 CB CHEBI:64318
DMKR3C5 DE Headache
DM78IME ID DM78IME
DM78IME DN Ergotidine
DM78IME HS Approved
DM78IME SN Eramin; Ergamine; Histamine; Histaminum; Istamina; Theramine; Free histamine; Histamine Base; Histamine [USAN]; Istamina [Italian]; H7125_SIGMA; [3H]histamine; ALBB-005968; Beta-Aminoethylglyoxaline; Beta-Aminoethylimidazole; Beta-aminothethylglyoxaline; Histamine (DCF); Histamine, Free Base; Histaminum (TN); L-histamine; ZERO/004089; Imidazole-4-ethylamine; Beta-Imidazolyl-4-ethylamine; F411C768-A159-4FC0-A195-291A08BB03AA; 1H-Imidazole-4-ethanamine; 1H-Imidazole-5-ethanamine; 2-(1H-Imidazol-4-yl)ethanamine; 2-(1H-imidazol-4-yl)ethan-1-amine; 2-(1H-imidazol-5-yl)ethanamine; 2-(3H-Imidazol-4-yl)-ethylamine; 2-(4-Imidazolyl)ethylamine; 2-Imidazol-4-ylethylamine; 2-[4-Imidazolyl]ethylamine; 4-(2-Aminoethyl)-1H-imidazole; 4-Imidazoleethylamine; 5-Imidazoleethylamine
DM78IME TC Antiallergic Agents
DM78IME DT Small molecular drug
DM78IME PC 774
DM78IME MW 111.15
DM78IME FM C5H9N3
DM78IME IC InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)
DM78IME CS C1=C(NC=N1)CCN
DM78IME IK NTYJJOPFIAHURM-UHFFFAOYSA-N
DM78IME IU 2-(1H-imidazol-5-yl)ethanamine
DM78IME CA CAS 51-45-6
DM78IME CB CHEBI:18295
DM78IME DE Respiratory allergy
DM1DX4Q ID DM1DX4Q
DM1DX4Q DN Eribulin
DM1DX4Q HS Approved
DM1DX4Q CP Eisai
DM1DX4Q DT Small molecular drug
DM1DX4Q PC 11354606
DM1DX4Q MW 729.9
DM1DX4Q FM C40H59NO11
DM1DX4Q IC InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
DM1DX4Q CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
DM1DX4Q IK UFNVPOGXISZXJD-JBQZKEIOSA-N
DM1DX4Q IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
DM1DX4Q CA CAS 253128-41-5
DM1DX4Q CB CHEBI:63587
DM1DX4Q DE Breast cancer
DMCMBHA ID DMCMBHA
DMCMBHA DN Erlotinib
DMCMBHA HS Approved
DMCMBHA SN Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
DMCMBHA CP OSI Pharma
DMCMBHA TC Anticancer Agents
DMCMBHA DT Small molecular drug
DMCMBHA PC 176870
DMCMBHA MW 393.4
DMCMBHA FM C22H23N3O4
DMCMBHA IC InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
DMCMBHA CS COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
DMCMBHA IK AAKJLRGGTJKAMG-UHFFFAOYSA-N
DMCMBHA IU N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
DMCMBHA CA CAS 183321-74-6
DMCMBHA CB CHEBI:114785
DMCMBHA DE Non-small-cell lung cancer; Colon cancer; Pancreatic cancer
DM4S3O8 ID DM4S3O8
DM4S3O8 DN Ertapenem
DM4S3O8 HS Approved
DM4S3O8 SN Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8 CP Merck & Co
DM4S3O8 TC Antibiotics
DM4S3O8 DT Small molecular drug
DM4S3O8 PC 150610
DM4S3O8 MW 475.5
DM4S3O8 FM C22H25N3O7S
DM4S3O8 IC InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1
DM4S3O8 CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O
DM4S3O8 IK JUZNIMUFDBIJCM-ANEDZVCMSA-N
DM4S3O8 IU (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8 CA CAS 153832-46-3
DM4S3O8 CB CHEBI:404903
DM4S3O8 DE Bacterial infection
DMFGQ2S ID DMFGQ2S
DMFGQ2S DN Erythrityl Tetranitrate
DMFGQ2S HS Approved
DMFGQ2S SN Cardilate; Cardiloid; Cardivell; Cardiwell; Erythritetranitrat; Nitroerythrit; Nitroerythrite; Nitroerythrol; Tetranitrin; Tetranitrol; Eritritile tetranitrato; Eritritile tetranitrato [DCIT]; Eritrityl tetranitrate; Eritrityli tetranitras; Erythritol tetranitrate; Erythrityl tetranitrate [USAN]; Erythrol tetranitrate; Tetranitrato de eritritilo; Eritrityli tetranitras [INN-Latin]; Erythritol, tetranitrate; Meso-Erythritol tetranitrate; Tetranitrate d'erithrityle; Tetranitrate d'eritrityle; Tetranitrato de eritritilo [INN-Spanish]; Erythritol, tetranitrate (8CI); Tetranitrate d'eritrityle [INN-French]; 1,2,3,4-Butanetetralyl tetranitrate; 1,3,4-trinitrooxybutan-2-yl nitrate
DMFGQ2S TC Vasodilator Agents
DMFGQ2S DT Small molecular drug
DMFGQ2S PC 5284553
DMFGQ2S MW 302.11
DMFGQ2S FM C4H6N4O12
DMFGQ2S IC InChI=1S/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+
DMFGQ2S CS C([C@H]([C@H](CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMFGQ2S IK SNFOERUNNSHUGP-ZXZARUISSA-N
DMFGQ2S IU [(2R,3S)-1,3,4-trinitrooxybutan-2-yl] nitrate
DMFGQ2S CA CAS 7297-25-8
DMFGQ2S CB CHEBI:60072
DMFGQ2S DE Angina pectoris
DM4K7GQ ID DM4K7GQ
DM4K7GQ DN Erythromycin
DM4K7GQ HS Approved
DM4K7GQ SN Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
DM4K7GQ CP Eli Lilly
DM4K7GQ TC Antibiotics
DM4K7GQ DT Small molecular drug
DM4K7GQ PC 12560
DM4K7GQ MW 733.9
DM4K7GQ FM C37H67NO13
DM4K7GQ IC InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
DM4K7GQ CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
DM4K7GQ IK ULGZDMOVFRHVEP-RWJQBGPGSA-N
DM4K7GQ IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4K7GQ CA CAS 114-07-8
DM4K7GQ CB CHEBI:42355
DM4K7GQ DE Bacterial infection
DMFK9HG ID DMFK9HG
DMFK9HG DN Escitalopram
DMFK9HG HS Approved
DMFK9HG SN Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram
DMFK9HG CP Forest Laboratories
DMFK9HG TC Antidepressants
DMFK9HG DT Small molecular drug
DMFK9HG PC 146570
DMFK9HG MW 324.4
DMFK9HG FM C20H21FN2O
DMFK9HG IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
DMFK9HG CS CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DMFK9HG IK WSEQXVZVJXJVFP-FQEVSTJZSA-N
DMFK9HG IU (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DMFK9HG CA CAS 128196-01-0
DMFK9HG CB CHEBI:36791
DMFK9HG DE Major depressive disorder
DMZREFQ ID DMZREFQ
DMZREFQ DN Eslicarbazepine
DMZREFQ HS Approved
DMZREFQ SN Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix
DMZREFQ TC Neurology Agents
DMZREFQ DT Small molecular drug
DMZREFQ PC 9881504
DMZREFQ MW 254.28
DMZREFQ FM C15H14N2O2
DMZREFQ IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMZREFQ CS C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMZREFQ IK BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMZREFQ IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMZREFQ CA CAS 104746-04-5
DMZREFQ DE Seizure disorder
DMREUZV ID DMREUZV
DMREUZV DN Eslicarbazepine acetate
DMREUZV HS Approved
DMREUZV SN Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN)
DMREUZV PC 179344
DMREUZV MW 296.32
DMREUZV FM C17H16N2O3
DMREUZV IC InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
DMREUZV CS CC(=O)OC1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N
DMREUZV IK QIALRBLEEWJACW-INIZCTEOSA-N
DMREUZV IU [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate
DMREUZV CA CAS 236395-14-5
DMREUZV CB CHEBI:87016
DMREUZV DE Partial seizures
DM51TYR ID DM51TYR
DM51TYR DN Esmolol
DM51TYR HS Approved
DM51TYR SN ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
DM51TYR CP Bedford Laboratories
DM51TYR TC Antihypertensive Agents
DM51TYR DT Small molecular drug
DM51TYR PC 59768
DM51TYR MW 295.37
DM51TYR FM C16H25NO4
DM51TYR IC InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
DM51TYR CS CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
DM51TYR IK AQNDDEOPVVGCPG-UHFFFAOYSA-N
DM51TYR IU methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
DM51TYR CA CAS 81147-92-4
DM51TYR CB CHEBI:88206
DM51TYR DE Acute supraventricular tachycardia
DM7BN0X ID DM7BN0X
DM7BN0X DN Esomeprazole
DM7BN0X HS Approved
DM7BN0X SN Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
DM7BN0X CP AstraZeneca
DM7BN0X TC Antiulcer Agents
DM7BN0X DT Small molecular drug
DM7BN0X PC 9568614
DM7BN0X MW 345.4
DM7BN0X FM C17H19N3O3S
DM7BN0X IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
DM7BN0X CS CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC
DM7BN0X IK SUBDBMMJDZJVOS-DEOSSOPVSA-N
DM7BN0X IU 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM7BN0X CA CAS 119141-88-7
DM7BN0X CB CHEBI:50275
DM7BN0X DE Peptic ulcer
DMZGXUM ID DMZGXUM
DMZGXUM DN Estazolam
DMZGXUM HS Approved
DMZGXUM SN Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine
DMZGXUM TC Anticonvulsants
DMZGXUM DT Small molecular drug
DMZGXUM PC 3261
DMZGXUM MW 294.74
DMZGXUM FM C16H11ClN4
DMZGXUM IC InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2
DMZGXUM CS C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4
DMZGXUM IK CDCHDCWJMGXXRH-UHFFFAOYSA-N
DMZGXUM IU 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMZGXUM CA CAS 29975-16-4
DMZGXUM CB CHEBI:4858
DMZGXUM DE Insomnia
DM9KZDO ID DM9KZDO
DM9KZDO DN Esterified estrogens
DM9KZDO HS Approved
DM9KZDO DE Breast cancer
DMUNTE3 ID DMUNTE3
DMUNTE3 DN Estradiol
DMUNTE3 HS Approved
DMUNTE3 SN Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol
DMUNTE3 TC Estrogens
DMUNTE3 DT Small molecular drug
DMUNTE3 PC 5757
DMUNTE3 MW 272.4
DMUNTE3 FM C18H24O2
DMUNTE3 IC InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
DMUNTE3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
DMUNTE3 IK VOXZDWNPVJITMN-ZBRFXRBCSA-N
DMUNTE3 IU (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMUNTE3 CA CAS 17916-67-5
DMUNTE3 CB CHEBI:16469
DMUNTE3 DE Breast cancer
DM07U2A ID DM07U2A
DM07U2A DN Estradiol acetate
DM07U2A HS Approved
DM07U2A SN Femring
DM07U2A CP Warner Chilcott Ireland Ltd
DM07U2A DT Small molecular drug
DM07U2A PC 9818306
DM07U2A MW 314.4
DM07U2A FM C20H26O3
DM07U2A IC InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1
DM07U2A CS CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C
DM07U2A IK FHXBMXJMKMWVRG-SLHNCBLASA-N
DM07U2A IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate
DM07U2A CA CAS 4245-41-4
DM07U2A CB CHEBI:135981
DM07U2A DE Hormone replacement therapy
DM27Z5T ID DM27Z5T
DM27Z5T DN Estradiol cypionate
DM27Z5T HS Approved
DM27Z5T SN Depo-estradiol
DM27Z5T CP Pharmacia And Upjohn Co
DM27Z5T DT Small molecular drug
DM27Z5T PC 9403
DM27Z5T MW 396.6
DM27Z5T FM C26H36O3
DM27Z5T IC InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1
DM27Z5T CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O
DM27Z5T IK UOACKFBJUYNSLK-XRKIENNPSA-N
DM27Z5T IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DM27Z5T CA CAS 313-06-4
DM27Z5T CB CHEBI:34745
DM27Z5T DE Hormone replacement therapy
DM8MC6O ID DM8MC6O
DM8MC6O DN Estradiol valerate
DM8MC6O HS Approved
DM8MC6O SN Delestrogen
DM8MC6O CP Par Sterile Products Llc
DM8MC6O DT Small molecular drug
DM8MC6O PC 13791
DM8MC6O MW 356.5
DM8MC6O FM C23H32O3
DM8MC6O IC InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1
DM8MC6O CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C
DM8MC6O IK RSEPBGGWRJCQGY-RBRWEJTLSA-N
DM8MC6O IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DM8MC6O CA CAS 979-32-8
DM8MC6O CB CHEBI:31561
DM8MC6O DE Hormone replacement therapy
DMLNMEA ID DMLNMEA
DMLNMEA DN Estradiol valerate/dienogest
DMLNMEA HS Approved
DMLNMEA SN Climodien; Climodiene; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme
DMLNMEA DT Small molecular drug
DMLNMEA PC 9874560
DMLNMEA MW 667.9
DMLNMEA FM C43H57NO5
DMLNMEA IC InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1
DMLNMEA CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C.C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMLNMEA IK LRHSUZNWLAJWRT-GAJBHWORSA-N
DMLNMEA IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate;2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMLNMEA CA CAS 307334-58-3
DMLNMEA DE Discovery agent
DMWTAOI ID DMWTAOI
DMWTAOI DN Estramustine
DMWTAOI HS Approved
DMWTAOI SN Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]
DMWTAOI CP Pfizer Pharmaceuticals
DMWTAOI TC Anticancer Agents
DMWTAOI DT Small molecular drug
DMWTAOI PC 259331
DMWTAOI MW 440.4
DMWTAOI FM C23H31Cl2NO3
DMWTAOI IC InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1
DMWTAOI CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl
DMWTAOI IK FRPJXPJMRWBBIH-RBRWEJTLSA-N
DMWTAOI IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate
DMWTAOI CA CAS 2998-57-4
DMWTAOI CB CHEBI:4868
DMWTAOI DE Prostate cancer
DMOEM2I ID DMOEM2I
DMOEM2I DN Estriol
DMOEM2I HS Approved
DMOEM2I SN Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene
DMOEM2I CP Pipex Pharmaceuticals
DMOEM2I TC Estrogens
DMOEM2I DT Small molecular drug
DMOEM2I PC 5756
DMOEM2I MW 288.4
DMOEM2I FM C18H24O3
DMOEM2I IC InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1
DMOEM2I CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O
DMOEM2I IK PROQIPRRNZUXQM-ZXXIGWHRSA-N
DMOEM2I IU (8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
DMOEM2I CA CAS 50-27-1
DMOEM2I CB CHEBI:27974
DMOEM2I DE Hormone deficiency; Multiple sclerosis
DMGY0UT ID DMGY0UT
DMGY0UT DN Estrogen
DMGY0UT HS Approved
DMGY0UT DE Menopause symptom
DM5T6US ID DM5T6US
DM5T6US DN Estrone
DM5T6US HS Approved
DM5T6US SN Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one
DM5T6US TC Antimenopausal Agents
DM5T6US DT Small molecular drug
DM5T6US PC 5870
DM5T6US MW 270.4
DM5T6US FM C18H22O2
DM5T6US IC InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
DM5T6US CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
DM5T6US IK DNXHEGUUPJUMQT-CBZIJGRNSA-N
DM5T6US IU (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DM5T6US CA CAS 53-16-7
DM5T6US CB CHEBI:17263
DM5T6US DE Menopausal and postmenopausal disorder
DMVBIZL ID DMVBIZL
DMVBIZL DN Estrone sulfate
DMVBIZL HS Approved
DMVBIZL SN Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate
DMVBIZL DT Small molecular drug
DMVBIZL PC 3001028
DMVBIZL MW 350.429
DMVBIZL FM C18H22O5S
DMVBIZL IC InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
DMVBIZL CS CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
DMVBIZL IK JKKFKPJIXZFSSB-CBZIJGRNSA-N
DMVBIZL IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMVBIZL CA CAS 481-97-0
DMVBIZL CB CHEBI:17474
DMVBIZL DE Menopausal symptoms
DMRMDWA ID DMRMDWA
DMRMDWA DN Estropipate
DMRMDWA HS Approved
DMRMDWA SN Estropipate; 7280-37-7; Piperazine estrone sulfate; Harmogen; Ogen; Ortho-Est; UNII-SVI38UY019; Piperazine estronesulfate; Sulestrex; SVI38UY019; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1); OGEN 2.5; Estropipate (USP); OGEN 5; Ogen (TN); OGEN .625; OGEN 1.25; EINECS 230-696-3; piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate; Piperazine oestrone sulphate; Conjugated estrogens: piperazine estrone sulfate; Estrone hydrogen sulf
DMRMDWA DT Small molecular drug
DMRMDWA PC 5284555
DMRMDWA MW 436.6
DMRMDWA FM C22H32N2O5S
DMRMDWA IC InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1
DMRMDWA CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1
DMRMDWA IK HZEQBCVBILBTEP-ZFINNJDLSA-N
DMRMDWA IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine
DMRMDWA CA CAS 7280-37-7
DMRMDWA CB CHEBI:4873
DMRMDWA DE Hypogonadism
DM8RZ9H ID DM8RZ9H
DM8RZ9H DN Eszopiclone
DM8RZ9H HS Approved
DM8RZ9H SN Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester
DM8RZ9H CP GSK
DM8RZ9H TC Hypnotics and Sedatives
DM8RZ9H DT Small molecular drug
DM8RZ9H PC 969472
DM8RZ9H MW 388.8
DM8RZ9H FM C17H17ClN6O3
DM8RZ9H IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
DM8RZ9H CS CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DM8RZ9H IK GBBSUAFBMRNDJC-INIZCTEOSA-N
DM8RZ9H IU [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DM8RZ9H CA CAS 138729-47-2
DM8RZ9H CB CHEBI:53760
DM8RZ9H DE Insomnia
DMCV109 ID DMCV109
DMCV109 DN Etanercept
DMCV109 HS Approved
DMCV109 SN Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon
DMCV109 CP AstraZeneca
DMCV109 DT Monoclonal antibody
DMCV109 SQ Etanercept Sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMCV109 DE Arthritis; Pemphigus vulgaris; Sciatica
DMHP9BL ID DMHP9BL
DMHP9BL DN Etelcalcetide
DMHP9BL HS Approved
DMHP9BL SN Velcalcetide; Parsabiv; UNII-60ME133FJB; 1262780-97-1; 60ME133FJB; etelcalcetide HCl; Etelcalcetide [USAN:INN]; Etelcalcetide (USAN/INN); Etelcalcetide Hydrochloride(AMG-416)
DMHP9BL CP Amgen/Kai Pharmaceuticals
DMHP9BL DT Small molecular drug
DMHP9BL PC 71511839
DMHP9BL MW 1048.3
DMHP9BL FM C38H73N21O10S2
DMHP9BL IC InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1
DMHP9BL CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C
DMHP9BL IK ANIAZGVDEUQPRI-ZJQCGQFWSA-N
DMHP9BL IU (2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid
DMHP9BL CA CAS 1262780-97-1
DMHP9BL CB CHEBI:134700
DMHP9BL DE Secondary hyperparathyroidism; Myelodysplastic syndrome
DM2QBHP ID DM2QBHP
DM2QBHP DN Eteplirsen
DM2QBHP HS Approved
DM2QBHP SN AVI-4658
DM2QBHP CP Sarepta Therapeutics
DM2QBHP DE Duchenne dystrophy
DM5M4NT ID DM5M4NT
DM5M4NT DN Ethacrynate sodium
DM5M4NT HS Approved
DM5M4NT CP Aton Pharma Inc
DM5M4NT TC Cardiovascular Agents
DM5M4NT DT Small molecular drug
DM5M4NT PC 23668825
DM5M4NT MW 325.12
DM5M4NT FM C13H11Cl2NaO4
DM5M4NT IC InChI=1S/C13H12Cl2O4.Na/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17;/h4-5H,2-3,6H2,1H3,(H,16,17);/q;+1/p-1
DM5M4NT CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Na+]
DM5M4NT IK CWCSCNSKBSCYCS-UHFFFAOYSA-M
DM5M4NT IU sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate
DM5M4NT CA CAS 6500-81-8
DM5M4NT DE High blood pressure
DM60QMR ID DM60QMR
DM60QMR DN Ethacrynic acid
DM60QMR HS Approved
DM60QMR SN Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR TC Diuretics
DM60QMR DT Small molecular drug
DM60QMR PC 3278
DM60QMR MW 303.13
DM60QMR FM C13H12Cl2O4
DM60QMR IC InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
DM60QMR CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
DM60QMR IK AVOLMBLBETYQHX-UHFFFAOYSA-N
DM60QMR IU 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR CA CAS 58-54-8
DM60QMR CB CHEBI:4876
DM60QMR DE High blood pressure
DMR87LC ID DMR87LC
DMR87LC DN Ethambutol
DMR87LC HS Approved
DMR87LC SN Aethambutolum; Diambutol; EMB; Etambutol; Etambutolo; Ethambutolum; Etibi; Miambutol; Myambutol; Purderal; Servambutol; Tibutol; Etambutolo [DCIT]; CL 40881 (dihydrochloride); D-Ethambutol; Etambutol [INN-Spanish]; Ethambutol & EEP; Ethambutol & Propolis; Ethambutol (INN); Ethambutol [INN:BAN]; Ethambutol, meso form; Ethambutol, racemic mixture; Ethambutolum [INN-Latin]; Myambutol (TN); Myambutol (dihydrochloride); Servambutol (TN); Ethambutol, (-)-isomer; D,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-2,2'-(Ethylenediimino)bis(1-butanol); D-2,2'-(Ethylenediimino)di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-2,2'-(Ethylenediimino)di-1-butanol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-Ethambutol; (+)-ethambutol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (S,S)-ethambutol; 2,2'-(1,2-Ethylenediimino)-di-1-butanol; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol
DMR87LC CP Macleods Pharmaceutical. Ltd
DMR87LC TC Antitubercular Agents
DMR87LC DT Small molecular drug
DMR87LC PC 14052
DMR87LC MW 204.31
DMR87LC FM C10H24N2O2
DMR87LC IC InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
DMR87LC CS CC[C@@H](CO)NCCN[C@@H](CC)CO
DMR87LC IK AEUTYOVWOVBAKS-UWVGGRQHSA-N
DMR87LC IU (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol
DMR87LC CA CAS 74-55-5
DMR87LC CB CHEBI:4877
DMR87LC DE Pulmonary tuberculosis
DMDRQZU ID DMDRQZU
DMDRQZU DN Ethanol
DMDRQZU HS Approved
DMDRQZU SN Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA
DMDRQZU TC Analgesics
DMDRQZU DT Small molecular drug
DMDRQZU PC 702
DMDRQZU MW 46.07
DMDRQZU FM C2H6O
DMDRQZU IC InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
DMDRQZU CS CCO
DMDRQZU IK LFQSCWFLJHTTHZ-UHFFFAOYSA-N
DMDRQZU IU ethanol
DMDRQZU CA CAS 64-17-5
DMDRQZU CB CHEBI:16236
DMDRQZU DE Cystitis; Chronic pain
DM3B654 ID DM3B654
DM3B654 DN Ethanolamine oleate
DM3B654 HS Approved
DM3B654 SN Ethamolin (TN)
DM3B654 DT Small molecular drug
DM3B654 PC 5282489
DM3B654 MW 343.5
DM3B654 FM C20H41NO3
DM3B654 IC InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;
DM3B654 CS CCCCCCCC/C=C\\CCCCCCCC(=O)O.C(CO)N
DM3B654 IK KGWDUNBJIMUFAP-KVVVOXFISA-N
DM3B654 IU 2-aminoethanol;(Z)-octadec-9-enoic acid
DM3B654 CA CAS 2272-11-9
DM3B654 DE Bleeding disorder
DM53IP1 ID DM53IP1
DM53IP1 DN Ethchlorvynol
DM53IP1 HS Approved
DM53IP1 SN Alvinol; Arvynol; Etchlorvinolo; Etclorvinol; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethchlorvynolum;Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline; A 71; Aethyl-chlorvynol; Beta-Chlorovinyl ethyl ethynyl carbinol; Beta-Chlorvinyl ethyl ethynyl carbinol; Etclorvinol [INN-Spanish]; Ethchlorvynolum [INN-Latin]; Ethyl beta-chlorovinyl ethynyl carbinol; Placidyl (TN); Ethchlorvynol [USAN:INN:BAN]; Ethchlorvynol (JAN/USP/INN); (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; 1-Chloro-3-ethylpent-1-4-yn-3-ol; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol
DM53IP1 CP Abbott Laboratories
DM53IP1 TC Hypnotics and Sedatives
DM53IP1 DT Small molecular drug
DM53IP1 PC 5281077
DM53IP1 MW 144.6
DM53IP1 FM C7H9ClO
DM53IP1 IC InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
DM53IP1 CS CCC(/C=C/Cl)(C#C)O
DM53IP1 IK ZEHYJZXQEQOSON-AATRIKPKSA-N
DM53IP1 IU (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol
DM53IP1 CA CAS 113-18-8
DM53IP1 CB CHEBI:4882
DM53IP1 DE Insomnia
DMK57GB ID DMK57GB
DMK57GB DN Ethinamate
DMK57GB HS Approved
DMK57GB SN Ethinamat; Ethinamatum; Ethinimate; Etinamate; Etinamato; Valamid; Valamin; Valaminetta; Valaminettae; Valaminetten; Valmid; Valmidate; Volamin; Ethynylcyclohexyl carbamate; Carbamate de L'ethinylcyclohexanol; Carbamate de l'ethinylcyclohexanol [French]; Ethinamatum [INN-Latin]; Etinamato [INN-Spanish]; USAF EL-42; Valamin (TN); Valmid (TN); Aethinyl-cyclohexyl-carbamat; Aethinyl-cyclohexyl-carbamat [German]; Carbamic acid, 1-ethynylcyclohexyl ester; Ethinamate (JAN/INN); Ethinamate [INN:BAN:JAN]; Cyclohexanol, 1-ethynyl-, carbamate; Cyclohexanol, 1-ethynyl-, 1-carbamate; (1-ethynylcyclohexyl) carbamate; 1-Ethinylcyclohexyl carbamate; 1-Ethinylcyclohexyl carbonate; 1-Ethynylcyclohexanol carbamate; 1-Ethynylcyclohexyl carbamate; 1-ethynylcyclohexylcarbamate
DMK57GB TC Hypnotics and Sedatives
DMK57GB DT Small molecular drug
DMK57GB PC 3284
DMK57GB MW 167.2
DMK57GB FM C9H13NO2
DMK57GB IC InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)
DMK57GB CS C#CC1(CCCCC1)OC(=O)N
DMK57GB IK GXRZIMHKGDIBEW-UHFFFAOYSA-N
DMK57GB IU (1-ethynylcyclohexyl) carbamate
DMK57GB CA CAS 126-52-3
DMK57GB CB CHEBI:4884
DMK57GB DE Insomnia
DMODJ40 ID DMODJ40
DMODJ40 DN Ethinyl estradiol
DMODJ40 HS Approved
DMODJ40 SN Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta
DMODJ40 CP Schering-Plough
DMODJ40 TC Estrogens
DMODJ40 DT Small molecular drug
DMODJ40 PC 5991
DMODJ40 MW 296.4
DMODJ40 FM C20H24O2
DMODJ40 IC InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
DMODJ40 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
DMODJ40 IK BFPYWIDHMRZLRN-SLHNCBLASA-N
DMODJ40 IU (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMODJ40 CA CAS 57-63-6
DMODJ40 CB CHEBI:4903
DMODJ40 DE Female hypogonadism
DM8K3EI ID DM8K3EI
DM8K3EI DN Ethionamide
DM8K3EI HS Approved
DM8K3EI SN Aethionamidum; Aetina; Aetiva; Amidazin; Amidazine; Atina; Ethatyl; Ethimide; Ethina; Ethinamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etimid; Etiocidan; Etionamid; Etionamida; Etionamide; Etioniamid; Etionid; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isothin; Isotiamida; Itiocide; Nicotion; Nisotin; Nizotin; Rigenicid; Sertinon; Teberus; Thianid; Thianide; Thioamide; Thiomid; Thioniden; Tianid; Tiomid; Trecator; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Ethionamid prothionamid; Etionamide [DCIT]; Iridocin Bayer; Trecator SC; Wyeth Brand of Ethionamide; Bayer 5312; Bayer5312; E0695; TH 1314; Alpha-Ethylisonicotinic acid thioamide; Alpha-Ethylisonicotinoylthioamide; Alpha-Ethylisothionicotinamide; Alpha-Ethylthioisonicotinamide; Alpha-ethylt hioisonicotinamide; Ethina (VAN); Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Tio-Mid; Trecator-SC; Alpha-Ethyl-thioisonicotinamide; Trecator-SC (TN); Ethionamide (JP15/USP/INN); Ethionamide [USAN:INN:BAN:JAN]; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; 2-Ethyl-4-thioamidylpyridine; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 2-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethylisonicotinothioamide; 2-Ethylisonicotinoylthioamide; 2-Ethylisothionicotinamide; 2-Ethylthioisonicotinamide; 2-e thylisothionicotinamide; 2-ethyl-4-aminothiocarbonylpyridine; 2-ethylisonicotinic acid thiomide; 2-ethylpyridine-4-carbothioamide; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; 3-Ethylisothionicotinamide
DM8K3EI TC Antituberculosis Agents
DM8K3EI DT Small molecular drug
DM8K3EI PC 2761171
DM8K3EI MW 166.25
DM8K3EI FM C8H10N2S
DM8K3EI IC InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
DM8K3EI CS CCC1=NC=CC(=C1)C(=S)N
DM8K3EI IK AEOCXXJPGCBFJA-UHFFFAOYSA-N
DM8K3EI IU 2-ethylpyridine-4-carbothioamide
DM8K3EI CA CAS 536-33-4
DM8K3EI CB CHEBI:4885
DM8K3EI DE Tuberculosis
DM0N3L7 ID DM0N3L7
DM0N3L7 DN Ethopropazine
DM0N3L7 HS Approved
DM0N3L7 SN Aethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothiazine; Lysivane; Parcidol; Pardidol; Parfezine; Parkin; Parkisol; Parsidan; Parsidol; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamine; Profenaminum; Prophenamine; Prophenaminum; Rochipel; Rocipel; Rodipal; Profenamina [Italian]; RP 3356; SC 2538; SKF 2538; W 483; Parkin (TN); Parsidan (TN); Parsidol(TN); Profenamina [INN-Spanish]; Profenamine (INN); Profenamine [INN:BAN]; Profenaminum [INN-Latin]; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; 10-(2-Diethylaminopropyl)phenothiazine; 10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine; 10-[2-(Diethylamino)propyl]phenothiazine; 2-Diethylamino-1-propyl-N-dibenzoparathiazine
DM0N3L7 TC Antiparkinson Agents
DM0N3L7 DT Small molecular drug
DM0N3L7 PC 3290
DM0N3L7 MW 312.5
DM0N3L7 FM C19H24N2S
DM0N3L7 IC InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3
DM0N3L7 CS CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31
DM0N3L7 IK CDOZDBSBBXSXLB-UHFFFAOYSA-N
DM0N3L7 IU N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine
DM0N3L7 CA CAS 522-00-9
DM0N3L7 CB CHEBI:313639
DM0N3L7 DE Parkinson disease
DMDZ9LT ID DMDZ9LT
DMDZ9LT DN Ethosuximide
DMDZ9LT HS Approved
DMDZ9LT SN Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide
DMDZ9LT CP Pfizer
DMDZ9LT TC Analgesics
DMDZ9LT DT Small molecular drug
DMDZ9LT PC 3291
DMDZ9LT MW 141.17
DMDZ9LT FM C7H11NO2
DMDZ9LT IC InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
DMDZ9LT CS CCC1(CC(=O)NC1=O)C
DMDZ9LT IK HAPOVYFOVVWLRS-UHFFFAOYSA-N
DMDZ9LT IU 3-ethyl-3-methylpyrrolidine-2,5-dione
DMDZ9LT CA CAS 77-67-8
DMDZ9LT CB CHEBI:4887
DMDZ9LT DE Epilepsy
DMXWOCP ID DMXWOCP
DMXWOCP DN Ethotoin
DMXWOCP HS Approved
DMXWOCP SN Accenon; Ethotoine; Ethotoinum; Etotoina; Peganone; Pegoanone; Abbott brand of ethotoin; Accenon (TN); Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Peganone (TN); Ethotoin [INN:BAN:JAN]; Ethotoin (JAN/USP/INN); (+-)-3-Ethyl-5-phenylhydantoin; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenylhydantoin; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP CP Ovation Pharmaceuticals
DMXWOCP TC Anticonvulsants
DMXWOCP DT Small molecular drug
DMXWOCP PC 3292
DMXWOCP MW 204.22
DMXWOCP FM C11H12N2O2
DMXWOCP IC InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
DMXWOCP CS CCN1C(=O)C(NC1=O)C2=CC=CC=C2
DMXWOCP IK SZQIFWWUIBRPBZ-UHFFFAOYSA-N
DMXWOCP IU 3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP CA CAS 86-35-1
DMXWOCP CB CHEBI:4888
DMXWOCP DE Complex partial seizure
DMVO4ED ID DMVO4ED
DMVO4ED DN Ethoxzolamide
DMVO4ED HS Approved
DMVO4ED SN ethoxzolamide; Ethoxyzolamide; Ethoxazolamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-2-benzothiazolesulfonamide; 452-35-7; Glaucotensil; Diuretic C; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Mingoral; 2-Benzothiazolesulfonamide, 6-ethoxy-; Redupresin; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; C9H10N2O3S2; HSDB 3268; CHEMBL18; EINECS 207-199-5; BRN 0212240; MLS000028637; AI3-50805; Cardrase; EZL; Cardrase (TN); Ethoxzolamide (EZA); 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; 6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED TC Diuretics
DMVO4ED DT Small molecular drug
DMVO4ED PC 3295
DMVO4ED MW 258.3
DMVO4ED FM C9H10N2O3S2
DMVO4ED IC InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)
DMVO4ED CS CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N
DMVO4ED IK OUZWUKMCLIBBOG-UHFFFAOYSA-N
DMVO4ED IU 6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED CA CAS 452-35-7
DMVO4ED CB CHEBI:101096
DMVO4ED DE Glaucoma/ocular hypertension; Duodenal ulcer
DM20VMW ID DM20VMW
DM20VMW DN Ethylestrenol
DM20VMW HS Approved
DM20VMW SN Maxibolin
DM20VMW CP Organon Usa Inc
DM20VMW DT Small molecular drug
DM20VMW PC 13765
DM20VMW MW 288.5
DM20VMW FM C20H32O
DM20VMW IC InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM20VMW CS CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O
DM20VMW IK AOXRBFRFYPMWLR-XGXHKTLJSA-N
DM20VMW IU (8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM20VMW CA CAS 965-90-2
DM20VMW CB CHEBI:31578
DM20VMW DE Testosterone deficiency
DMZM84R ID DMZM84R
DMZM84R DN Ethynodiol diacetate
DMZM84R HS Approved
DMZM84R SN Cervicundin; Continuin; Femulen; Luteonorm; Metrodiol; Ethinodiol diacetate; Ethyndiol Diacetate; Ethynodiol diacetate [Progestins]; Ethynodiol diacetate [USAN]; Etynodiol Acetate; Metrodiol diacetate; Ovulen 50; SC 11800; Etynodiol di(acetate); Luto-metrodiol; SC-11800; Ethynodiol diacetate (JAN/USP);[(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diolDiacetate; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol diacetate; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17-alpha-Ethynyl-4-estrene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynylestr-4-ene-3-beta,17-beta-diol acetate; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17-beta-diol diacetate; 17alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17alpha-Ethynyl-4-estrene-3beta,17beta-diol diacetate; 17alpha-Ethynylestr-4-ene-3beta,17beta-diol acetate; 17alpha-ethynylestr-4-ene-3beta,17beta-diyl diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol, diacetate; 19-Nor-17alpha-pregn-4-en-20-yne-3beta,17-diol diacetate; 3-beta, 17-beta-Diacetoxy-17-alpha-ethynyl-4-oestrene; 3-beta,17-beta-Diacetoxy-19-nor-17-alpha-pregn-4-en-20-yne; 3beta, 17beta-Diacetoxy-17alpha-ethynyl-4-oestrene; 3beta,17beta-Diacetoxy-17alpha-ethynyl-4-estrene; 3beta,17beta-Diacetoxy-19-nor-17alpha-pregn-4-en-20-yne
DMZM84R TC Contraceptive Agents
DMZM84R DT Small molecular drug
DMZM84R PC 9270
DMZM84R MW 384.5
DMZM84R FM C24H32O4
DMZM84R IC InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
DMZM84R CS CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C
DMZM84R IK ONKUMRGIYFNPJW-KIEAKMPYSA-N
DMZM84R IU [(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMZM84R CA CAS 297-76-7
DMZM84R CB CHEBI:31580
DMZM84R DE Contraception
DMBIYNH ID DMBIYNH
DMBIYNH DN ETI-204
DMBIYNH HS Approved
DMBIYNH CP Elusys Therapeutics
DMBIYNH DT Antibody
DMBIYNH DE Anthrax
DMAWJIN ID DMAWJIN
DMAWJIN DN Etidronate Disodium
DMAWJIN HS Approved
DMAWJIN SN Didronel
DMAWJIN CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMAWJIN DT Small molecular drug
DMAWJIN PC 23894
DMAWJIN MW 249.99
DMAWJIN FM C2H6Na2O7P2
DMAWJIN IC InChI=1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
DMAWJIN CS CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DMAWJIN IK GWBBVOVXJZATQQ-UHFFFAOYSA-L
DMAWJIN IU disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate
DMAWJIN CA CAS 7414-83-7
DMAWJIN CB CHEBI:4906
DMAWJIN DE Osteoporosis
DM1XHYJ ID DM1XHYJ
DM1XHYJ DN Etidronic acid
DM1XHYJ HS Approved
DM1XHYJ SN EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL
DM1XHYJ TC Bone Density Conservation Agents
DM1XHYJ DT Small molecular drug
DM1XHYJ PC 3305
DM1XHYJ MW 206.03
DM1XHYJ FM C2H8O7P2
DM1XHYJ IC InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
DM1XHYJ CS CC(O)(P(=O)(O)O)P(=O)(O)O
DM1XHYJ IK DBVJJBKOTRCVKF-UHFFFAOYSA-N
DM1XHYJ IU (1-hydroxy-1-phosphonoethyl)phosphonic acid
DM1XHYJ CA CAS 2809-21-4
DM1XHYJ CB CHEBI:4907
DM1XHYJ DE Paget's disease
DM6WJO9 ID DM6WJO9
DM6WJO9 DN Etodolac
DM6WJO9 HS Approved
DM6WJO9 SN etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
DM6WJO9 CP Meda Pharmaceuticals
DM6WJO9 TC Analgesics
DM6WJO9 DT Small molecular drug
DM6WJO9 PC 3308
DM6WJO9 MW 287.35
DM6WJO9 FM C17H21NO3
DM6WJO9 IC InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
DM6WJO9 CS CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
DM6WJO9 IK NNYBQONXHNTVIJ-UHFFFAOYSA-N
DM6WJO9 IU 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
DM6WJO9 CA CAS 41340-25-4
DM6WJO9 CB CHEBI:4909
DM6WJO9 DE Pain
DMZI3WO ID DMZI3WO
DMZI3WO DN Etomidate
DMZI3WO HS Approved
DMZI3WO SN Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
DMZI3WO CP Janssen Pharmaceutica
DMZI3WO TC Analgesics
DMZI3WO DT Small molecular drug
DMZI3WO PC 667484
DMZI3WO MW 244.29
DMZI3WO FM C14H16N2O2
DMZI3WO IC InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
DMZI3WO CS CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2
DMZI3WO IK NPUKDXXFDDZOKR-LLVKDONJSA-N
DMZI3WO IU ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate
DMZI3WO CA CAS 33125-97-2
DMZI3WO CB CHEBI:4910
DMZI3WO DE Anaesthesia
DMKA8J4 ID DMKA8J4
DMKA8J4 DN Etonogestrel
DMKA8J4 HS Approved
DMKA8J4 SN Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel
DMKA8J4 TC Contraceptive Agents
DMKA8J4 DT Small molecular drug
DMKA8J4 PC 6917715
DMKA8J4 MW 324.5
DMKA8J4 FM C22H28O2
DMKA8J4 IC InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DMKA8J4 CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMKA8J4 IK GCKFUYQCUCGESZ-BPIQYHPVSA-N
DMKA8J4 IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMKA8J4 CA CAS 54048-10-1
DMKA8J4 CB CHEBI:50777
DMKA8J4 DE Contraception
DMNH3PG ID DMNH3PG
DMNH3PG DN Etoposide
DMNH3PG HS Approved
DMNH3PG SN etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
DMNH3PG CP Bristol Myers Squibb Co Pharmaceutical Research Institute
DMNH3PG TC Anticancer Agents
DMNH3PG DT Small molecular drug
DMNH3PG PC 36462
DMNH3PG MW 588.6
DMNH3PG FM C29H32O13
DMNH3PG IC InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
DMNH3PG CS C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
DMNH3PG IK VJJPUSNTGOMMGY-MRVIYFEKSA-N
DMNH3PG IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMNH3PG CA CAS 33419-42-0
DMNH3PG CB CHEBI:4911
DMNH3PG DE Solid tumour/cancer
DM6A4NW ID DM6A4NW
DM6A4NW DN Etoricoxib
DM6A4NW HS Approved
DM6A4NW SN Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH
DM6A4NW CP Merck & Co
DM6A4NW TC Antiinflammatory Agents
DM6A4NW DT Small molecular drug
DM6A4NW PC 123619
DM6A4NW MW 358.8
DM6A4NW FM C18H15ClN2O2S
DM6A4NW IC InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
DM6A4NW CS CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
DM6A4NW IK MNJVRJDLRVPLFE-UHFFFAOYSA-N
DM6A4NW IU 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
DM6A4NW CA CAS 202409-33-4
DM6A4NW CB CHEBI:6339
DM6A4NW DE Rheumatoid arthritis
DMGV8QU ID DMGV8QU
DMGV8QU DN Etravirine
DMGV8QU HS Approved
DMGV8QU SN Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR
DMGV8QU DT Small molecular drug
DMGV8QU PC 193962
DMGV8QU MW 435.3
DMGV8QU FM C20H15BrN6O
DMGV8QU IC InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
DMGV8QU CS CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
DMGV8QU IK PYGWGZALEOIKDF-UHFFFAOYSA-N
DMGV8QU IU 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
DMGV8QU CA CAS 269055-15-4
DMGV8QU CB CHEBI:63589
DMGV8QU DE Human immunodeficiency virus-1 infection
DM2CZFA ID DM2CZFA
DM2CZFA DN Etretinate
DM2CZFA HS Approved
DM2CZFA SN etretinate; 54350-48-0; Tegison; Ethyl etrinoate; Retinoid; Etretinatum; Etretinato; Ro 10-9359; Etretinatum [INN-Latin]; Etretinato [INN-Spanish]; UNII-65M2UDR9AG; CCRIS 3615; HSDB 7185; EINECS 259-119-3; NSC 297936; 65M2UDR9AG; Ro-10-9359; Tigason; CHEBI:4913; C23H30O3; Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethy
DM2CZFA DT Small molecular drug
DM2CZFA PC 5282375
DM2CZFA MW 354.5
DM2CZFA FM C23H30O3
DM2CZFA IC InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
DM2CZFA CS CCOC(=O)/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
DM2CZFA IK HQMNCQVAMBCHCO-DJRRULDNSA-N
DM2CZFA IU ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
DM2CZFA CA CAS 54350-48-0
DM2CZFA CB CHEBI:4913
DM2CZFA DE Keratosis
DM5GT1M ID DM5GT1M
DM5GT1M DN EVANS BLUE
DM5GT1M HS Approved
DM5GT1M SN tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-5-oxonaphthalene-1,3-disulfonate; AC1NUWHB; AC1O426Q; AN-23389; tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonato-2-naphthylidene)hydrazino]-3-methyl-phenyl]-2-methyl-phenyl]hydrazono]-5-oxo-naphthalene-1,3-disulfonate; 6,6-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid]tetrasodium sa
DM5GT1M DT Small molecular drug
DM5GT1M PC 9409
DM5GT1M MW 960.8
DM5GT1M FM C34H24N6Na4O14S4
DM5GT1M IC InChI=1S/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM5GT1M CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+]
DM5GT1M IK ATNOAWAQFYGAOY-UHFFFAOYSA-J
DM5GT1M IU tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate
DM5GT1M CA CAS 314-13-6
DM5GT1M CB CHEBI:82467
DM5GT1M DE Abdominal aortic aneurysm
DM8X2EH ID DM8X2EH
DM8X2EH DN Everolimus
DM8X2EH HS Approved
DM8X2EH SN Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
DM8X2EH CP Novartis
DM8X2EH TC Anticancer Agents
DM8X2EH DT Small molecular drug
DM8X2EH PC 6442177
DM8X2EH MW 958.2
DM8X2EH FM C53H83NO14
DM8X2EH IC InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DM8X2EH CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
DM8X2EH IK HKVAMNSJSFKALM-GKUWKFKPSA-N
DM8X2EH IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM8X2EH CA CAS 159351-69-6
DM8X2EH CB CHEBI:68478
DM8X2EH DE Renal cell carcinoma; Kidney cancer
DMBLX7U ID DMBLX7U
DMBLX7U DN Evinacumab
DMBLX7U HS Approved
DMBLX7U SN REGN1500; ANGPTL-1 antibody
DMBLX7U CP Regeneron Pharmaceuticals Tarrytown, NY
DMBLX7U DE Elevated C-reactive protein; Familial hypercholesterolemia; Hypercholesterolaemia
DM9HPW3 ID DM9HPW3
DM9HPW3 DN Exemestane
DM9HPW3 HS Approved
DM9HPW3 SN Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione
DM9HPW3 TC Anticancer Agents
DM9HPW3 DT Small molecular drug
DM9HPW3 PC 60198
DM9HPW3 MW 296.4
DM9HPW3 FM C20H24O2
DM9HPW3 IC InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
DM9HPW3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
DM9HPW3 IK BFYIZQONLCFLEV-DAELLWKTSA-N
DM9HPW3 IU (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
DM9HPW3 CA CAS 107868-30-4
DM9HPW3 CB CHEBI:4953
DM9HPW3 DE Hormonally-responsive breast cancer
DMYHBKN ID DMYHBKN
DMYHBKN DN Exenatide
DMYHBKN HS Approved
DMYHBKN SN Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide
DMYHBKN CP Eli Lilly
DMYHBKN TC Hypoglycemic Agents
DMYHBKN DT Small molecular drug
DMYHBKN SQ Exenatide: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
DMYHBKN PC 45588096
DMYHBKN MW 4187
DMYHBKN FM C184H282N50O60S
DMYHBKN IC InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1
DMYHBKN CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N
DMYHBKN IK HTQBXNHDCUEHJF-XWLPCZSASA-N
DMYHBKN IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMYHBKN CA CAS 141758-74-9
DMYHBKN DE Cardiovascular disease; Type-2 diabetes
DMHPRWG ID DMHPRWG
DMHPRWG DN Exjade
DMHPRWG HS Approved
DMHPRWG SN Deferasirox
DMHPRWG CP Novartis
DMHPRWG DT Small molecular drug
DMHPRWG PC 214348
DMHPRWG MW 373.4
DMHPRWG FM C21H15N3O4
DMHPRWG IC InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
DMHPRWG CS C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
DMHPRWG IK BOFQWVMAQOTZIW-UHFFFAOYSA-N
DMHPRWG IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DMHPRWG CA CAS 201530-41-8
DMHPRWG CB CHEBI:49005
DMHPRWG DE Iron overload disease
DM7A8TW ID DM7A8TW
DM7A8TW DN Ezetimibe
DM7A8TW HS Approved
DM7A8TW SN Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
DM7A8TW CP Schering-Plough
DM7A8TW TC Anticholesteremic Agents
DM7A8TW DT Small molecular drug
DM7A8TW PC 150311
DM7A8TW MW 409.4
DM7A8TW FM C24H21F2NO3
DM7A8TW IC InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
DM7A8TW CS C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O
DM7A8TW IK OLNTVTPDXPETLC-XPWALMASSA-N
DM7A8TW IU (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
DM7A8TW CA CAS 163222-33-1
DM7A8TW CB CHEBI:49040
DM7A8TW DE Hypercholesterolaemia
DMAB6PM ID DMAB6PM
DMAB6PM DN Factor 8
DMAB6PM HS Approved
DMAB6PM SN Wilate (TN)
DMAB6PM DE Hemophilia
DMZUW6P ID DMZUW6P
DMZUW6P DN Factor viia
DMZUW6P HS Approved
DMZUW6P SN Novoseven (TN)
DMZUW6P DE Hemophilia
DM3C5GZ ID DM3C5GZ
DM3C5GZ DN FADROZOLE
DM3C5GZ HS Approved
DM3C5GZ SN 102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-
DM3C5GZ DT Small molecular drug
DM3C5GZ PC 59693
DM3C5GZ MW 223.27
DM3C5GZ FM C14H13N3
DM3C5GZ IC InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2
DM3C5GZ CS C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N
DM3C5GZ IK CLPFFLWZZBQMAO-UHFFFAOYSA-N
DM3C5GZ IU 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
DM3C5GZ CA CAS 102676-47-1
DM3C5GZ CB CHEBI:94355
DM3C5GZ DE Breast cancer
DMBI9ZJ ID DMBI9ZJ
DMBI9ZJ DN Falecalcitrol
DMBI9ZJ HS Approved
DMBI9ZJ SN Falecalcitriol; falecalcitriol; Flocalcitriol; 83805-11-2; calcitriol hexafluoride; Hornel, Fulstan; Falecalcitriol [INN]; ST-630; ST 630; Fulstan; Ro 23-4194; UNII-G70A8514T8; C27H38F6O3; Hornel; 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3; G70A8514T8; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; Hexafluorocalcitriol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol,; Fulstan (TN); Horner (TN)
DMBI9ZJ DT Small molecular drug
DMBI9ZJ PC 5282190
DMBI9ZJ MW 524.6
DMBI9ZJ FM C27H38F6O3
DMBI9ZJ IC InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
DMBI9ZJ CS C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMBI9ZJ IK XPYGGHVSFMUHLH-UUSULHAXSA-N
DMBI9ZJ IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMBI9ZJ CA CAS 83805-11-2
DMBI9ZJ DE Hyperparathyroidism
DMJHLSD ID DMJHLSD
DMJHLSD DN Famciclovir
DMJHLSD HS Approved
DMJHLSD SN FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
DMJHLSD CP Schering-Plough
DMJHLSD TC Antiviral Agents
DMJHLSD DT Small molecular drug
DMJHLSD PC 3324
DMJHLSD MW 321.33
DMJHLSD FM C14H19N5O4
DMJHLSD IC InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)
DMJHLSD CS CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
DMJHLSD IK GGXKWVWZWMLJEH-UHFFFAOYSA-N
DMJHLSD IU [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate
DMJHLSD CA CAS 104227-87-4
DMJHLSD CB CHEBI:4974
DMJHLSD DE Virus infection
DMRL3AB ID DMRL3AB
DMRL3AB DN Famotidine
DMRL3AB HS Approved
DMRL3AB SN Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB CP Astellas Pharma
DMRL3AB TC Antiulcer Agents
DMRL3AB DT Small molecular drug
DMRL3AB PC 5702160
DMRL3AB MW 337.5
DMRL3AB FM C8H15N7O2S3
DMRL3AB IC InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
DMRL3AB CS C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
DMRL3AB IK XUFQPHANEAPEMJ-UHFFFAOYSA-N
DMRL3AB IU 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB CA CAS 76824-35-6
DMRL3AB CB CHEBI:4975
DMRL3AB DE Peptic ulcer
DMX7A5V ID DMX7A5V
DMX7A5V DN Faropenem
DMX7A5V HS Approved
DMX7A5V SN FPM; Fropenem; (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid
DMX7A5V CP Suntory
DMX7A5V TC Respiratory Agents
DMX7A5V DT Small molecular drug
DMX7A5V PC 65894
DMX7A5V MW 285.32
DMX7A5V FM C12H15NO5S
DMX7A5V IC InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1
DMX7A5V CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)[C@H]3CCCO3)C(=O)O)O
DMX7A5V IK HGGAKXAHAYOLDJ-FHZUQPTBSA-N
DMX7A5V IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMX7A5V CA CAS 106560-14-9
DMX7A5V CB CHEBI:51257
DMX7A5V DE Gram-positive bacterial infection
DMDEXQ0 ID DMDEXQ0
DMDEXQ0 DN Febuxostat
DMDEXQ0 HS Approved
DMDEXQ0 SN Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0 CP Takeda
DMDEXQ0 DT Small molecular drug
DMDEXQ0 PC 134018
DMDEXQ0 MW 316.4
DMDEXQ0 FM C16H16N2O3S
DMDEXQ0 IC InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
DMDEXQ0 CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
DMDEXQ0 IK BQSJTQLCZDPROO-UHFFFAOYSA-N
DMDEXQ0 IU 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0 CA CAS 144060-53-7
DMDEXQ0 CB CHEBI:31596
DMDEXQ0 DE Hyperuricaemia
DM4ZBK6 ID DM4ZBK6
DM4ZBK6 DN Fedratinib
DM4ZBK6 HS Approved
DM4ZBK6 SN TG101348
DM4ZBK6 CP Targen
DM4ZBK6 DT Small molecular drug
DM4ZBK6 PC 16722836
DM4ZBK6 MW 524.7
DM4ZBK6 FM C27H36N6O3S
DM4ZBK6 IC InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
DM4ZBK6 CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
DM4ZBK6 IK JOOXLOJCABQBSG-UHFFFAOYSA-N
DM4ZBK6 IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
DM4ZBK6 CA CAS 936091-26-8
DM4ZBK6 CB CHEBI:91408
DM4ZBK6 DE Myelofibrosis
DML2DCR ID DML2DCR
DML2DCR DN Fedratinib hydrochloride
DML2DCR HS Approved
DML2DCR SN Fedratinib hydrochloride (USAN); TG101348(2ClH.H2O); UH9J2HBQWJ; 1374744-69-0; BCP24783; D11296; Fedratinib dihydrochloride monohydrate; UNII-UH9J2HBQWJ
DML2DCR PC 67517580
DML2DCR MW 615.6
DML2DCR FM C27H40Cl2N6O4S
DML2DCR IC QAFZLTVOFJHYDF-UHFFFAOYSA-N
DML2DCR CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl
DML2DCR IK 1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2
DML2DCR IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride
DML2DCR CA CAS 1374744-69-0
DML2DCR DE Myelofibrosis
DM1V5ZS ID DM1V5ZS
DM1V5ZS DN Felbamate
DM1V5ZS HS Approved
DM1V5ZS SN Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate
DM1V5ZS CP MedPointe
DM1V5ZS TC Antiepileptic Agents
DM1V5ZS DT Small molecular drug
DM1V5ZS PC 3331
DM1V5ZS MW 238.24
DM1V5ZS FM C11H14N2O4
DM1V5ZS IC InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
DM1V5ZS CS C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
DM1V5ZS IK WKGXYQFOCVYPAC-UHFFFAOYSA-N
DM1V5ZS IU (3-carbamoyloxy-2-phenylpropyl) carbamate
DM1V5ZS CA CAS 25451-15-4
DM1V5ZS CB CHEBI:4995
DM1V5ZS DE Epilepsy
DMKZEIB ID DMKZEIB
DMKZEIB DN Felbinac
DMKZEIB HS Approved
DMKZEIB SN Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda
DMKZEIB CP Takeda Pharmaceutical Co Ltd
DMKZEIB DT Small molecular drug
DMKZEIB PC 3332
DMKZEIB MW 212.24
DMKZEIB FM C14H12O2
DMKZEIB IC InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)
DMKZEIB CS C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O
DMKZEIB IK QRZAKQDHEVVFRX-UHFFFAOYSA-N
DMKZEIB IU 2-(4-phenylphenyl)acetic acid
DMKZEIB CA CAS 5728-52-9
DMKZEIB CB CHEBI:31597
DMKZEIB DE Arthritis
DMOSW35 ID DMOSW35
DMOSW35 DN Felodipine
DMOSW35 HS Approved
DMOSW35 SN Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35 CP AstraZeneca
DMOSW35 TC Antihypertensive Agents
DMOSW35 DT Small molecular drug
DMOSW35 PC 3333
DMOSW35 MW 384.2
DMOSW35 FM C18H19Cl2NO4
DMOSW35 IC InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
DMOSW35 CS CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMOSW35 IK RZTAMFZIAATZDJ-UHFFFAOYSA-N
DMOSW35 IU 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35 CA CAS 72509-76-3
DMOSW35 CB CHEBI:585948
DMOSW35 DE Hypertension
DMHLP9C ID DMHLP9C
DMHLP9C DN Felypressin
DMHLP9C HS Approved
DMHLP9C SN Felipresina; Felipressina; Felypressine; Felypressinum; Octapressin; Octopressin; Phelypressin; Felipressina [DCIT]; Phenylalanine Lysine Vasopressin; Felipresina [INN-Spanish]; Felypressine [INN-French]; Felypressinum [INN-Latin]; Octapressin (TN); PLV-2; Felypressin [USAN:INN:BAN]; Vasopressin, Phenylalanyl-Lysyl; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; 2-(L-Phenylalanine)-8-L-lysinevasopressin; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C CP AstraZeneca
DMHLP9C TC Vasoconstrictor Agents
DMHLP9C DT Small molecular drug
DMHLP9C PC 14257662
DMHLP9C MW 1040.2
DMHLP9C FM C46H65N13O11S2
DMHLP9C IC InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMHLP9C CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMHLP9C IK SFKQVVDKFKYTNA-DZCXQCEKSA-N
DMHLP9C IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C CA CAS 56-59-7
DMHLP9C CB CHEBI:60564
DMHLP9C DE Localisation
DMXGDFK ID DMXGDFK
DMXGDFK DN Fenbufen
DMXGDFK HS Approved
DMXGDFK SN fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a
DMXGDFK DT Small molecular drug
DMXGDFK PC 3335
DMXGDFK MW 254.28
DMXGDFK FM C16H14O3
DMXGDFK IC InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
DMXGDFK CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCC(=O)O
DMXGDFK IK ZPAKPRAICRBAOD-UHFFFAOYSA-N
DMXGDFK IU 4-oxo-4-(4-phenylphenyl)butanoic acid
DMXGDFK CA CAS 36330-85-5
DMXGDFK CB CHEBI:31599
DMXGDFK DE Arthritis
DM0LRU9 ID DM0LRU9
DM0LRU9 DN Fendrix
DM0LRU9 HS Approved
DM0LRU9 SN Fendrix Extra Strength; New hepatitis B prophylactic vaccine, GlaxoSmithKline; HBV prophylactic vaccine (new), GlaxoSmithKline; Hepatitis B prophylactic vaccine (extra strength), GlaxoSmithKline; MPL hepatitis B vaccine, GSK/Corixa; SBAS4-adjuvanted hepatitis B vaccine, GlaxoSmithKline; SBAS4-adjuvanted hepatitis B vaccine, SmithKline Beecham; SBAS4/MPL (HBV vaccine), GlaxoSmithKline/Ribi; SBAS4/MPL (HBV vaccine), SmithKline Beecham/Ribi
DM0LRU9 CP GlaxoSmithKline Biologicals
DM0LRU9 DT Vaccine
DM0LRU9 DE Hepatitis B virus infection
DMFKXDY ID DMFKXDY
DMFKXDY DN Fenofibrate
DMFKXDY HS Approved
DMFKXDY SN Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
DMFKXDY CP Abbott Laboratories
DMFKXDY TC Antilipemic Agents
DMFKXDY DT Small molecular drug
DMFKXDY PC 3339
DMFKXDY MW 360.8
DMFKXDY FM C20H21ClO4
DMFKXDY IC InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
DMFKXDY CS CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMFKXDY IK YMTINGFKWWXKFG-UHFFFAOYSA-N
DMFKXDY IU propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
DMFKXDY CA CAS 49562-28-9
DMFKXDY CB CHEBI:5001
DMFKXDY DE High cholesterol level
DMGO2MC ID DMGO2MC
DMGO2MC DN Fenofibric acid
DMGO2MC HS Approved
DMGO2MC SN Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287
DMGO2MC DT Small molecular drug
DMGO2MC PC 64929
DMGO2MC MW 318.7
DMGO2MC FM C17H15ClO4
DMGO2MC IC InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
DMGO2MC CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMGO2MC IK MQOBSOSZFYZQOK-UHFFFAOYSA-N
DMGO2MC IU 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid
DMGO2MC CA CAS 42017-89-0
DMGO2MC CB CHEBI:83469
DMGO2MC DE Cardiovascular disease
DMFAOKP ID DMFAOKP
DMFAOKP DN Fenoldopam
DMFAOKP HS Approved
DMFAOKP SN Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP CP Ben Venue Laboratories
DMFAOKP TC Antihypertensive Agents
DMFAOKP DT Small molecular drug
DMFAOKP PC 3341
DMFAOKP MW 305.75
DMFAOKP FM C16H16ClNO3
DMFAOKP IC InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
DMFAOKP CS C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O
DMFAOKP IK TVURRHSHRRELCG-UHFFFAOYSA-N
DMFAOKP IU 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP CA CAS 67227-56-9
DMFAOKP CB CHEBI:5002
DMFAOKP DE Hypertension
DML5VQ0 ID DML5VQ0
DML5VQ0 DN Fenoprofen
DML5VQ0 HS Approved
DML5VQ0 SN Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid
DML5VQ0 CP Typharm Limited
DML5VQ0 TC Antiinflammatory Agents
DML5VQ0 DT Small molecular drug
DML5VQ0 PC 3342
DML5VQ0 MW 242.27
DML5VQ0 FM C15H14O3
DML5VQ0 IC InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
DML5VQ0 CS CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
DML5VQ0 IK RDJGLLICXDHJDY-UHFFFAOYSA-N
DML5VQ0 IU 2-(3-phenoxyphenyl)propanoic acid
DML5VQ0 CA CAS 29679-58-1
DML5VQ0 CB CHEBI:5004
DML5VQ0 DE Rheumatoid arthritis
DMIP3ZV ID DMIP3ZV
DMIP3ZV DN Fenoterol
DMIP3ZV HS Approved
DMIP3ZV SN Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol
DMIP3ZV CP Boehriger Ingelheim
DMIP3ZV TC Bronchodilator Agents
DMIP3ZV DT Small molecular drug
DMIP3ZV PC 3343
DMIP3ZV MW 303.35
DMIP3ZV FM C17H21NO4
DMIP3ZV IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
DMIP3ZV CS CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O
DMIP3ZV IK LSLYOANBFKQKPT-UHFFFAOYSA-N
DMIP3ZV IU 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
DMIP3ZV CA CAS 13392-18-2
DMIP3ZV CB CHEBI:149226
DMIP3ZV DE Asthma
DM8WAHT ID DM8WAHT
DM8WAHT DN Fentanyl
DM8WAHT HS Approved
DM8WAHT SN fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals
DM8WAHT CP Janssen Pharmaceuticals Inc
DM8WAHT TC Neurology Agents
DM8WAHT DT Small molecular drug
DM8WAHT PC 3345
DM8WAHT MW 336.5
DM8WAHT FM C22H28N2O
DM8WAHT IC InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
DM8WAHT CS CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
DM8WAHT IK PJMPHNIQZUBGLI-UHFFFAOYSA-N
DM8WAHT IU N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
DM8WAHT CA CAS 437-38-7
DM8WAHT CB CHEBI:119915
DM8WAHT DE Analgesia; Pain; Cancer related pain; Chronic pain
DM13495 ID DM13495
DM13495 DN Fesoterodine fumarate
DM13495 HS Approved
DM13495 SN Toviaz (TN)
DM13495 CP Pfizer
DM13495 DT Small molecular drug
DM13495 PC 9849808
DM13495 MW 527.6
DM13495 FM C30H41NO7
DM13495 IC InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1
DM13495 CS CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\\C(=O)O
DM13495 IK MWHXMIASLKXGBU-RNCYCKTQSA-N
DM13495 IU (E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
DM13495 CA CAS 286930-03-8
DM13495 DE Overactive bladder
DM17ONX ID DM17ONX
DM17ONX DN Fexofenadine
DM17ONX HS Approved
DM17ONX SN Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
DM17ONX CP Sanofi-Aventis
DM17ONX TC Antiallergic Agents
DM17ONX DT Small molecular drug
DM17ONX PC 3348
DM17ONX MW 501.7
DM17ONX FM C32H39NO4
DM17ONX IC InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
DM17ONX CS CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
DM17ONX IK RWTNPBWLLIMQHL-UHFFFAOYSA-N
DM17ONX IU 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
DM17ONX CA CAS 83799-24-0
DM17ONX CB CHEBI:5050
DM17ONX DE Allergic rhinitis
DM9Q8SO ID DM9Q8SO
DM9Q8SO DN Fibrinolysin
DM9Q8SO HS Approved
DM9Q8SO SQ Fibrinolysin heavy chain: DLLDDYVNTQGASLLSLSRKNLAGRSVEDCAAKCEEETDFVCRAFQYHSKEQQCVVMAENSKNTPVFRMRDVILYEKRIYLLECKTGNGQTYRGTTAETKSGVTCQKWSATSPHVPKFSPEKFPLAGLEENYCRNPDNDENGPWCYTTDPDKRYDYCDIPECEDKCMHCSGENYEGKIAKTMSGRDCQAWDSQSPHAHGYIPSKFPNKNLKMNYCRNPDGEPRPWCFTTDPQKRWEFCDIPRCTTPPPSSGPKYQCLKGTGKNYGGTVAVTESGHTCQRWSEQTPHKHNRTPENFPCKNLEENYCRNPNGEKAPWCYTTNSEVRWEYCTIPSCESSPLSTERMDVPVPPEQTPVPQDCYHGNGQSYRGTSSTTITGRKCQSWSSMTPHRHLKTPENYPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEFCNLKKCSETPEQVPAAPQAPGVENPPEADCMIGTGKSYRGKKATTVAGVPCQEWAAQEPHQHSIFTPETNPQSGLERNYCRNPDGDVNGPWCYTMNPRKPFDYCDVPQCESSFDCGKPKVEPKKCSGR >Fibrinolysin light chainIVGGCVSKPHSWPWQVSLRRSSRHFCGGTLISPKWVLTAAHCLDNILALSFYKVILGAHNEKVREQSVQEIPVSRLFREPSQADIALLKLSRPAIITKEVIPACLPPPNYMVAARTECYITGWGETQGTFGEGLLKEAHLPVIENKVCNRNEYLDGRVKPTELCAGHLIGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSPYVPWIEETMRRN
DM9Q8SO DE Wound healing
DMFP6MV ID DMFP6MV
DMFP6MV DN Fidaxomicin
DMFP6MV HS Approved
DMFP6MV SN Dificid (TN)
DMFP6MV CP Astellas
DMFP6MV DT Small molecular drug
DMFP6MV PC 10034073
DMFP6MV MW 1058
DMFP6MV FM C52H74Cl2O18
DMFP6MV IC InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
DMFP6MV CS CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\\C)\\C)[C@@H](C)O)\\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\\C
DMFP6MV IK ZVGNESXIJDCBKN-UUEYKCAUSA-N
DMFP6MV IU [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
DMFP6MV CA CAS 873857-62-6
DMFP6MV DE Clostridium difficile associated diarrhea
DMZEONG ID DMZEONG
DMZEONG DN Finafloxacin
DMZEONG HS Approved
DMZEONG SN Finafloxacin hydrochloride; Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature; Finafloxacin (iv, bacterial infection), MerLion/Alcon; Finafloxacin (oral, bacterial infection), MerLion/Alcon
DMZEONG CP Alcon
DMZEONG DT Small molecular drug
DMZEONG PC 11567473
DMZEONG MW 398.4
DMZEONG FM C20H19FN4O4
DMZEONG IC InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
DMZEONG CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
DMZEONG IK FYMHQCNFKNMJAV-HOTGVXAUSA-N
DMZEONG IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMZEONG CA CAS 209342-40-5
DMZEONG CB CHEBI:85176
DMZEONG DE Urinary tract infection
DMWV3TZ ID DMWV3TZ
DMWV3TZ DN Finasteride
DMWV3TZ HS Approved
DMWV3TZ SN Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
DMWV3TZ CP Merck
DMWV3TZ TC Antihyperplasia Agents
DMWV3TZ DT Small molecular drug
DMWV3TZ PC 57363
DMWV3TZ MW 372.5
DMWV3TZ FM C23H36N2O2
DMWV3TZ IC InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
DMWV3TZ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
DMWV3TZ IK DBEPLOCGEIEOCV-WSBQPABSSA-N
DMWV3TZ IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMWV3TZ CA CAS 98319-26-7
DMWV3TZ CB CHEBI:5062
DMWV3TZ DE Benign prostatic hyperplasia
DM5JVAN ID DM5JVAN
DM5JVAN DN Fingolimod
DM5JVAN HS Approved
DM5JVAN SN 2-Amino-2-(4-octylphenethyl)propane-1,3-diol
DM5JVAN CP Novartis
DM5JVAN DT Small molecular drug
DM5JVAN PC 107970
DM5JVAN MW 307.5
DM5JVAN FM C19H33NO2
DM5JVAN IC InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
DM5JVAN CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
DM5JVAN IK KKGQTZUTZRNORY-UHFFFAOYSA-N
DM5JVAN IU 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
DM5JVAN CA CAS 162359-55-9
DM5JVAN CB CHEBI:63115
DM5JVAN DE Primary progressive multiple sclerosis
DMKV4NL ID DMKV4NL
DMKV4NL DN Flavoxate
DMKV4NL HS Approved
DMKV4NL SN Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester
DMKV4NL CP Nippon Shinyaku
DMKV4NL TC Parasympatholytics
DMKV4NL DT Small molecular drug
DMKV4NL PC 3354
DMKV4NL MW 391.5
DMKV4NL FM C24H25NO4
DMKV4NL IC InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
DMKV4NL CS CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
DMKV4NL IK SPIUTQOUKAMGCX-UHFFFAOYSA-N
DMKV4NL IU 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
DMKV4NL CA CAS 15301-69-6
DMKV4NL CB CHEBI:5088
DMKV4NL DE Suprapubic pain; Nocturia; Urgency; Dysuria
DMSQDLE ID DMSQDLE
DMSQDLE DN Flecainide
DMSQDLE HS Approved
DMSQDLE SN flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide
DMSQDLE CP 3M pharmaceuticals
DMSQDLE TC Antiarrhythmic Agents
DMSQDLE DT Small molecular drug
DMSQDLE PC 3356
DMSQDLE MW 414.34
DMSQDLE FM C17H20F6N2O3
DMSQDLE IC InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
DMSQDLE CS C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
DMSQDLE IK DJBNUMBKLMJRSA-UHFFFAOYSA-N
DMSQDLE IU N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
DMSQDLE CA CAS 54143-55-4
DMSQDLE CB CHEBI:75984
DMSQDLE DE Tachyarrhythmias; Atrial fibrillation; Paroxysmal atrial fibrillation
DMXGQYZ ID DMXGQYZ
DMXGQYZ DN Fleroxacin
DMXGQYZ HS Approved
DMXGQYZ SN FLRX; Fleroxacine; Fleroxacino; Fleroxacinum; Fleroxicin; Megalocin; Megalone; Megalosin; Quinodis; Fleroxacine [French]; Fleroxacino [Spanish]; Fleroxacinum [Latin]; AM 833; F0646; AM-833; Megalocin (TN); Megalone (TN); Quinodis (TN); Ro 23-6240; Ro-236240; Ro 23-6240/000; Fleroxacin (JAN/USAN/INN); Fleroxacin [USAN:BAN:INN:JAN]; Ro-23-6240/000; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ TC Antiinfective Agents
DMXGQYZ DT Small molecular drug
DMXGQYZ PC 3357
DMXGQYZ MW 369.34
DMXGQYZ FM C17H18F3N3O3
DMXGQYZ IC InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
DMXGQYZ CS CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
DMXGQYZ IK XBJBPGROQZJDOJ-UHFFFAOYSA-N
DMXGQYZ IU 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ CA CAS 79660-72-3
DMXGQYZ CB CHEBI:31810
DMXGQYZ DE Bacterial infection
DM70DTN ID DM70DTN
DM70DTN DN Flibanserin
DM70DTN HS Approved
DM70DTN SN Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN CP Boehringer Ingelheim
DM70DTN DT Small molecular drug
DM70DTN PC 6918248
DM70DTN MW 390.4
DM70DTN FM C20H21F3N4O
DM70DTN IC InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
DM70DTN CS C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
DM70DTN IK PPRRDFIXUUSXRA-UHFFFAOYSA-N
DM70DTN IU 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN CA CAS 167933-07-5
DM70DTN CB CHEBI:90865
DM70DTN DE Mood disorder; Female sexual arousal dysfunction
DMJ8A3Z ID DMJ8A3Z
DMJ8A3Z DN Florbetapir F-18
DMJ8A3Z HS Approved
DMJ8A3Z SN Amyvid (TN)
DMJ8A3Z CP Avid Radiopharmaceuticals
DMJ8A3Z DT Small molecular drug
DMJ8A3Z PC 24822371
DMJ8A3Z MW 359.4
DMJ8A3Z FM C20H25FN2O3
DMJ8A3Z IC InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1
DMJ8A3Z CS CNC1=CC=C(C=C1)/C=C/C2=CN=C(C=C2)OCCOCCOCC[18F]
DMJ8A3Z IK YNDIAUKFXKEXSV-CRYLGTRXSA-N
DMJ8A3Z IU 4-[(E)-2-[6-[2-[2-(2-(18F)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline
DMJ8A3Z CA CAS 956103-76-7
DMJ8A3Z CB CHEBI:66880
DMJ8A3Z DE Diagnostic imaging
DM04LR2 ID DM04LR2
DM04LR2 DN Floxuridine
DM04LR2 HS Approved
DM04LR2 SN floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside; Sterile fudr (TN); Floxuridine/5-fluorouracil
DM04LR2 CP Heidelberger
DM04LR2 DT Small molecular drug
DM04LR2 PC 5790
DM04LR2 MW 246.19
DM04LR2 FM C9H11FN2O5
DM04LR2 IC InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DM04LR2 CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
DM04LR2 IK ODKNJVUHOIMIIZ-RRKCRQDMSA-N
DM04LR2 IU 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM04LR2 CA CAS 50-91-9
DM04LR2 CB CHEBI:60761
DM04LR2 DE Solid tumour/cancer; Colorectal cancer
DMNUWST ID DMNUWST
DMNUWST DN Flucloxacillin
DMNUWST HS Approved
DMNUWST SN FLOXACILLIN; Floxapen; Fluclox; Flucloxacilina; Flucloxacilline; Flucloxacillinum; Fluorochloroxacillin; MFIPC; Floxacillin [USAN]; Flucloxacillin sodium; BRL 2039; Flopen (TN); Floxacillin (USAN); Floxapen (TN); Flucloxacilina [INN-Spanish]; Flucloxacillin (INN); Flucloxacillin-Sodium; Flucloxacilline [INN-French]; Flucloxacillinum [INN-Latin]; Rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMNUWST CP GlaxoSmithKline
DMNUWST TC Antibiotics
DMNUWST DT Small molecular drug
DMNUWST PC 21319
DMNUWST MW 453.9
DMNUWST FM C19H17ClFN3O5S
DMNUWST IC InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DMNUWST CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMNUWST IK UIOFUWFRIANQPC-JKIFEVAISA-N
DMNUWST IU (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNUWST CA CAS 5250-39-5
DMNUWST CB CHEBI:5098
DMNUWST DE Bacterial infection
DMOWZ6B ID DMOWZ6B
DMOWZ6B DN Fluconazole
DMOWZ6B HS Approved
DMOWZ6B SN Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B CP Pfizer
DMOWZ6B TC Antifungal Agents
DMOWZ6B DT Small molecular drug
DMOWZ6B PC 3365
DMOWZ6B MW 306.27
DMOWZ6B FM C13H12F2N6O
DMOWZ6B IC InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
DMOWZ6B CS C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
DMOWZ6B IK RFHAOTPXVQNOHP-UHFFFAOYSA-N
DMOWZ6B IU 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B CA CAS 86386-73-4
DMOWZ6B CB CHEBI:46081
DMOWZ6B DE Fungal infection
DM13VTW ID DM13VTW
DM13VTW DN Flucytosine
DM13VTW HS Approved
DM13VTW SN Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P
DM13VTW TC Antifungal Agents
DM13VTW DT Small molecular drug
DM13VTW PC 3366
DM13VTW MW 129.09
DM13VTW FM C4H4FN3O
DM13VTW IC InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
DM13VTW CS C1=NC(=O)NC(=C1F)N
DM13VTW IK XRECTZIEBJDKEO-UHFFFAOYSA-N
DM13VTW IU 6-amino-5-fluoro-1H-pyrimidin-2-one
DM13VTW CA CAS 2022-85-7
DM13VTW CB CHEBI:5100
DM13VTW DE Endocarditis
DMVRLT7 ID DMVRLT7
DMVRLT7 DN Fludarabine
DMVRLT7 HS Approved
DMVRLT7 SN FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
DMVRLT7 CP Genzyme Corp
DMVRLT7 TC Anticancer Agents
DMVRLT7 DT Small molecular drug
DMVRLT7 PC 657237
DMVRLT7 MW 285.23
DMVRLT7 FM C10H12FN5O4
DMVRLT7 IC InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
DMVRLT7 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
DMVRLT7 IK HBUBKKRHXORPQB-FJFJXFQQSA-N
DMVRLT7 IU (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMVRLT7 CA CAS 21679-14-1
DMVRLT7 CB CHEBI:94701
DMVRLT7 DE Haematological malignancy
DMD2K4I ID DMD2K4I
DMD2K4I DN Fludiazepam
DMD2K4I HS Approved
DMD2K4I SN Erispan; Fludiazepamum; ID 540; Erispan (TN); Fludiazepam [INN:JAN]; Fludiazepamum [INN-Latin]; ID-540; Fludiazepam (JP15/INN); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-(9CI); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I CP Dainippon Sumitomo Pharma
DMD2K4I TC Antianxiety Agents
DMD2K4I DT Small molecular drug
DMD2K4I PC 3369
DMD2K4I MW 302.73
DMD2K4I FM C16H12ClFN2O
DMD2K4I IC InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
DMD2K4I CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMD2K4I IK ROYOYTLGDLIGBX-UHFFFAOYSA-N
DMD2K4I IU 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I CA CAS 3900-31-0
DMD2K4I CB CHEBI:31618
DMD2K4I DE Anxiety disorder
DMUDIR8 ID DMUDIR8
DMUDIR8 DN Fludrocortisone
DMUDIR8 HS Approved
DMUDIR8 SN fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone
DMUDIR8 TC Antiinflammatory Agents
DMUDIR8 DT Small molecular drug
DMUDIR8 PC 31378
DMUDIR8 MW 380.4
DMUDIR8 FM C21H29FO5
DMUDIR8 IC InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
DMUDIR8 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F
DMUDIR8 IK AAXVEMMRQDVLJB-BULBTXNYSA-N
DMUDIR8 IU (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUDIR8 CA CAS 127-31-1
DMUDIR8 CB CHEBI:50885
DMUDIR8 DE Cerebral salt-wasting syndrome
DMC8VNH ID DMC8VNH
DMC8VNH DN Flufenamic Acid
DMC8VNH HS Approved
DMC8VNH SN flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440
DMC8VNH DT Small molecular drug
DMC8VNH PC 3371
DMC8VNH MW 281.23
DMC8VNH FM C14H10F3NO2
DMC8VNH IC InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)
DMC8VNH CS C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F
DMC8VNH IK LPEPZBJOKDYZAD-UHFFFAOYSA-N
DMC8VNH IU 2-[3-(trifluoromethyl)anilino]benzoic acid
DMC8VNH CA CAS 530-78-9
DMC8VNH CB CHEBI:42638
DMC8VNH DE Dysmenorrhea
DMPCG2L ID DMPCG2L
DMPCG2L DN Flumazenil
DMPCG2L HS Approved
DMPCG2L SN flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N; FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus
DMPCG2L CP Coeruleus Ltd
DMPCG2L DT Small molecular drug
DMPCG2L PC 3373
DMPCG2L MW 303.29
DMPCG2L FM C15H14FN3O3
DMPCG2L IC InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
DMPCG2L CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C
DMPCG2L IK OFBIFZUFASYYRE-UHFFFAOYSA-N
DMPCG2L IU ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMPCG2L CA CAS 78755-81-4
DMPCG2L CB CHEBI:5103
DMPCG2L DE Benzodiazepine overdose
DMUNG4A ID DMUNG4A
DMUNG4A DN Flumethasone
DMUNG4A HS Approved
DMUNG4A SN Flucorticin; Flumetasona; Flumetasona [INN-Spanish]; Flumetasone; Flumetasone [INN]; Flumetasonum; Flumetasonum [INN-Latin]; Flumethason; Flumethasonum; Fluvet; LR3CD8SX89; Methagon; RS 2177; RS-2177; U-10974; flumethasone; 2135-17-3; Anaprime; Aniprime; Cortexilar; Flucort (Veterinary); 6-alpha-Fluorodexamethasone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone; 6alpha-Fluorodexamethasone; CHEBI:34764; MLS000028618; NSC 54702; UNII-LR3CD8SX89
DMUNG4A PC 16490
DMUNG4A MW 410.5
DMUNG4A FM C22H28F2O5
DMUNG4A IC WXURHACBFYSXBI-GQKYHHCASA-N
DMUNG4A CS CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F
DMUNG4A IK 1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMUNG4A IU (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUNG4A CA CAS 2135-17-3
DMUNG4A CB CHEBI:34764
DMUNG4A DE Atopic dermatitis
DMU0YP6 ID DMU0YP6
DMU0YP6 DN Flumethasone Pivalate
DMU0YP6 HS Approved
DMU0YP6 SN Locacorten; Locorten; Lorinden; Flumetasone pivalate; Flumethasone pivalate (USP); KS-1138; Locorten (TN); Flumetasone pivalate (JAN/BAN); Lpha.-methylpregna-1,4-diene-3,20-dione 21-pivalate; [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate; 6,9-Difluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pivalate; 6.Alpha.,9-Difluoro-11.beta.,17,21-trihydroxy-16.a; 6.Alpha.,9.alpha.-Difluoro-16.alpha.-methylprednisolone 21-pivalate; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate); 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate
DMU0YP6 TC Antiinflammatory Agents
DMU0YP6 DT Small molecular drug
DMU0YP6 PC 443980
DMU0YP6 MW 494.6
DMU0YP6 FM C27H36F2O6
DMU0YP6 IC InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,24+,25+,26+,27+/m1/s1
DMU0YP6 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
DMU0YP6 IK JWRMHDSINXPDHB-OJAGFMMFSA-N
DMU0YP6 IU [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMU0YP6 CA CAS 2002-29-1
DMU0YP6 CB CHEBI:31620
DMU0YP6 DE Contact dermatitis
DMZU5JP ID DMZU5JP
DMZU5JP DN Flunarizine
DMZU5JP HS Approved
DMZU5JP SN Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP CP Janssen Pharmaceutica
DMZU5JP TC Anticonvulsants
DMZU5JP DT Small molecular drug
DMZU5JP PC 941361
DMZU5JP MW 404.5
DMZU5JP FM C26H26F2N2
DMZU5JP IC InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
DMZU5JP CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMZU5JP IK SMANXXCATUTDDT-QPJJXVBHSA-N
DMZU5JP IU 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP CA CAS 52468-60-7
DMZU5JP CB CHEBI:92209
DMZU5JP DE Migraine
DMZSWQC ID DMZSWQC
DMZSWQC DN Flunisolide
DMZSWQC HS Approved
DMZSWQC SN Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
DMZSWQC TC Antiasthmatic Agents
DMZSWQC DT Small molecular drug
DMZSWQC PC 82153
DMZSWQC MW 434.5
DMZSWQC FM C24H31FO6
DMZSWQC IC InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMZSWQC CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O
DMZSWQC IK XSFJVAJPIHIPKU-XWCQMRHXSA-N
DMZSWQC IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMZSWQC CA CAS 3385-03-3
DMZSWQC CB CHEBI:5106
DMZSWQC DE Allergic rhinitis
DMGR5Z3 ID DMGR5Z3
DMGR5Z3 DN Flunitrazepam
DMGR5Z3 HS Approved
DMGR5Z3 SN Flunibeta; Flunimerck; Fluninoc; Flunitrazepamum; Fluridrazepam; Narcozep; Primun; Rohipnol; Rohypnol; Roipnol; Betapharm Brand of Flunitrazepam; Ct Arzneimittel Brand of Flunitrazepam; Flunitrazepam Teva; Flunitrazepam neuraxpharm; Flunitrazepam ratiopharm; Flunizep von ct; Hexal Brand of Flunitrazepam; Merck dura Brand ofFlunitrazepam; Neuraxpharm Brand of Flunitrazepam; Ratiopharm Brand of Flunitrazepam; Roche Brand of Flunitrazepam; Teva Brand of Flunitrazepam; Fluni 1A Pharma; RO54200; [3H]flunitrazepam; Ct-Arzneimittel Brand of Flunitrazepam; Darkene (TN); Flunipam (TN); Flunitrazepam-Teva; Flunitrazepam-neuraxpharm; Flunitrazepam-ratiopharm; Flunitrazepamum [INN-Latin]; Hipnosedon (TN); Hypnodorm (TN); Ilman(TN); Insom (TN); Nilium (TN); Ro 5-4200; Rohypnol (TN); Rufinol (TN); Silece (TN); Vulbegal (TN); RO-5-4200; Flunitrazepam (JP15/USAN/INN); Flunitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; 1A Brand of Flunitrazepam; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one
DMGR5Z3 CP Roche Laboratories Inc
DMGR5Z3 TC Hypnotics and Sedatives
DMGR5Z3 DT Small molecular drug
DMGR5Z3 PC 3380
DMGR5Z3 MW 313.28
DMGR5Z3 FM C16H12FN3O3
DMGR5Z3 IC InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3
DMGR5Z3 CS CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F
DMGR5Z3 IK PPTYJKAXVCCBDU-UHFFFAOYSA-N
DMGR5Z3 IU 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one
DMGR5Z3 CA CAS 1622-62-4
DMGR5Z3 CB CHEBI:31622
DMGR5Z3 DE Insomnia
DMG2KI4 ID DMG2KI4
DMG2KI4 DN Fluocinolone acetonide
DMG2KI4 HS Approved
DMG2KI4 SN Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide
DMG2KI4 TC Antiinflammatory Agents
DMG2KI4 DT Small molecular drug
DMG2KI4 PC 6215
DMG2KI4 MW 452.5
DMG2KI4 FM C24H30F2O6
DMG2KI4 IC InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMG2KI4 CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
DMG2KI4 IK FEBLZLNTKCEFIT-VSXGLTOVSA-N
DMG2KI4 IU (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMG2KI4 CA CAS 67-73-2
DMG2KI4 CB CHEBI:31623
DMG2KI4 DE Inflammation
DM65KL8 ID DM65KL8
DM65KL8 DN Fluocinonide
DM65KL8 HS Approved
DM65KL8 SN Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate
DM65KL8 CP Taro Pharmaceuticals Inc
DM65KL8 TC Antiinflammatory Agents
DM65KL8 DT Small molecular drug
DM65KL8 PC 9642
DM65KL8 MW 494.5
DM65KL8 FM C26H32F2O7
DM65KL8 IC InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
DM65KL8 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
DM65KL8 IK WJOHZNCJWYWUJD-IUGZLZTKSA-N
DM65KL8 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate
DM65KL8 CA CAS 356-12-7
DM65KL8 CB CHEBI:5109
DM65KL8 DE Inflammation
DMQTFAO ID DMQTFAO
DMQTFAO DN Fluorescein
DMQTFAO HS Approved
DMQTFAO SN Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070
DMQTFAO DT Small molecular drug
DMQTFAO PC 16850
DMQTFAO MW 332.3
DMQTFAO FM C20H12O5
DMQTFAO IC InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
DMQTFAO CS C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O
DMQTFAO IK GNBHRKFJIUUOQI-UHFFFAOYSA-N
DMQTFAO IU 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
DMQTFAO CA CAS 2321-07-5
DMQTFAO CB CHEBI:31624
DMQTFAO DE Ocular disease
DM2HKC4 ID DM2HKC4
DM2HKC4 DN Fluorometholone
DM2HKC4 HS Approved
DM2HKC4 SN Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
DM2HKC4 CP Alcon Laboratories
DM2HKC4 TC Antiallergic Agents
DM2HKC4 DT Small molecular drug
DM2HKC4 PC 9878
DM2HKC4 MW 376.5
DM2HKC4 FM C22H29FO4
DM2HKC4 IC InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
DM2HKC4 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
DM2HKC4 IK FAOZLTXFLGPHNG-KNAQIMQKSA-N
DM2HKC4 IU (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM2HKC4 CA CAS 426-13-1
DM2HKC4 CB CHEBI:31625
DM2HKC4 DE Chronic obstructive pulmonary disease
DMUM7HZ ID DMUM7HZ
DMUM7HZ DN Fluorouracil
DMUM7HZ HS Approved
DMUM7HZ SN 5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU
DMUM7HZ CP Hoffmann-La Roche pharmaceutical company
DMUM7HZ TC Immunosuppressive Agents
DMUM7HZ DT Small molecular drug
DMUM7HZ PC 3385
DMUM7HZ MW 130.08
DMUM7HZ FM C4H3FN2O2
DMUM7HZ IC InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
DMUM7HZ CS C1=C(C(=O)NC(=O)N1)F
DMUM7HZ IK GHASVSINZRGABV-UHFFFAOYSA-N
DMUM7HZ IU 5-fluoro-1H-pyrimidine-2,4-dione
DMUM7HZ CA CAS 51-21-8
DMUM7HZ CB CHEBI:46345
DMUM7HZ DE Solid tumour/cancer; Tumour; Colorectal cancer
DM3PD2C ID DM3PD2C
DM3PD2C DN Fluoxetine
DM3PD2C HS Approved
DM3PD2C SN Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
DM3PD2C CP Eli Lilly
DM3PD2C TC Antidepressants
DM3PD2C DT Small molecular drug
DM3PD2C PC 3386
DM3PD2C MW 309.33
DM3PD2C FM C17H18F3NO
DM3PD2C IC InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
DM3PD2C CS CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
DM3PD2C IK RTHCYVBBDHJXIQ-UHFFFAOYSA-N
DM3PD2C IU N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DM3PD2C CA CAS 54910-89-3
DM3PD2C CB CHEBI:86990
DM3PD2C DE Depression
DMUHCF1 ID DMUHCF1
DMUHCF1 DN Fluoxymesterone
DMUHCF1 HS Approved
DMUHCF1 SN Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one
DMUHCF1 TC Anabolic Agents
DMUHCF1 DT Small molecular drug
DMUHCF1 PC 6446
DMUHCF1 MW 336.4
DMUHCF1 FM C20H29FO3
DMUHCF1 IC InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
DMUHCF1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F
DMUHCF1 IK YLRFCQOZQXIBAB-RBZZARIASA-N
DMUHCF1 IU (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUHCF1 CA CAS 76-43-7
DMUHCF1 CB CHEBI:5120
DMUHCF1 DE Breast cancer
DM0DJ9O ID DM0DJ9O
DM0DJ9O DN Flupentixol
DM0DJ9O HS Approved
DM0DJ9O SN 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum
DM0DJ9O TC Antipsychotic Neuroleptic drug
DM0DJ9O DT Small molecular drug
DM0DJ9O PC 5281881
DM0DJ9O MW 434.521
DM0DJ9O FM C23H25F3N2OS
DM0DJ9O IC InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
DM0DJ9O CS C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DM0DJ9O IK NJMYODHXAKYRHW-DVZOWYKESA-N
DM0DJ9O IU 2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DM0DJ9O CA CAS 2709-56-0
DM0DJ9O CB CHEBI:10454
DM0DJ9O DE Depression; Schizophrenia
DMIT8LX ID DMIT8LX
DMIT8LX DN Fluphenazine
DMIT8LX HS Approved
DMIT8LX SN FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
DMIT8LX CP Bristol-Myers Squibb
DMIT8LX TC Antipsychotic Agents
DMIT8LX DT Small molecular drug
DMIT8LX PC 3372
DMIT8LX MW 437.5
DMIT8LX FM C22H26F3N3OS
DMIT8LX IC InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
DMIT8LX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMIT8LX IK PLDUPXSUYLZYBN-UHFFFAOYSA-N
DMIT8LX IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
DMIT8LX CA CAS 69-23-8
DMIT8LX CB CHEBI:5123
DMIT8LX DE Psychotic disorder
DMZWBKG ID DMZWBKG
DMZWBKG DN Fluprednisolone
DMZWBKG HS Approved
DMZWBKG SN Alphadrol
DMZWBKG CP Pharmacia And Upjohn Co
DMZWBKG DT Small molecular drug
DMZWBKG PC 5876
DMZWBKG MW 378.4
DMZWBKG FM C21H27FO5
DMZWBKG IC InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
DMZWBKG CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O
DMZWBKG IK MYYIMZRZXIQBGI-HVIRSNARSA-N
DMZWBKG IU (6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMZWBKG CA CAS 53-34-9
DMZWBKG CB CHEBI:34474
DMZWBKG DE Asthma
DMHCI9S ID DMHCI9S
DMHCI9S DN Flurandrenolide
DMHCI9S HS Approved
DMHCI9S SN Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide
DMHCI9S CP Watson Laboratories
DMHCI9S TC Antiinflammatory Agents
DMHCI9S DT Small molecular drug
DMHCI9S PC 15209
DMHCI9S MW 436.5
DMHCI9S FM C24H33FO6
DMHCI9S IC InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMHCI9S CS C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F
DMHCI9S IK POPFMWWJOGLOIF-XWCQMRHXSA-N
DMHCI9S IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMHCI9S CA CAS 1524-88-5
DMHCI9S CB CHEBI:5127
DMHCI9S DE Inflammation
DMAL4G0 ID DMAL4G0
DMAL4G0 DN Flurazepam
DMAL4G0 HS Approved
DMAL4G0 SN Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0 CP West-ward Pharmaceutical Corp
DMAL4G0 TC Hypnotics and Sedatives
DMAL4G0 DT Small molecular drug
DMAL4G0 PC 3393
DMAL4G0 MW 387.9
DMAL4G0 FM C21H23ClFN3O
DMAL4G0 IC InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
DMAL4G0 CS CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMAL4G0 IK SAADBVWGJQAEFS-UHFFFAOYSA-N
DMAL4G0 IU 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0 CA CAS 17617-23-1
DMAL4G0 CB CHEBI:5128
DMAL4G0 DE Insomnia
DMGN4BY ID DMGN4BY
DMGN4BY DN Flurbiprofen
DMGN4BY HS Approved
DMGN4BY SN Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
DMGN4BY CP Abbott Laboratories
DMGN4BY TC Antiinflammatory Agents
DMGN4BY DT Small molecular drug
DMGN4BY PC 3394
DMGN4BY MW 244.26
DMGN4BY FM C15H13FO2
DMGN4BY IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
DMGN4BY CS CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMGN4BY IK SYTBZMRGLBWNTM-UHFFFAOYSA-N
DMGN4BY IU 2-(3-fluoro-4-phenylphenyl)propanoic acid
DMGN4BY CA CAS 5104-49-4
DMGN4BY CB CHEBI:5130
DMGN4BY DE Rheumatoid arthritis
DMFO843 ID DMFO843
DMFO843 DN Fluspirilene
DMFO843 HS Approved
DMFO843 SN Fluspirilen; Fluspirileno; Fluspirilenum; Imap; Redeptin; Spirodiflamine; R 6218; F-100; Fluspirileno [INN-Spanish]; Fluspirilenum [INN-Latin]; Imap (TN); Spiropiperidine analogue, 1; Fluspirilene (USAN/INN); Fluspirilene [USAN:INN:BAN]; McN-JR-6218; 1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane; 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one; 8-[4,4-bis (p-fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4,5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one; 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one
DMFO843 CP Janssen Pharmaceutica
DMFO843 TC Antipsychotic Agents
DMFO843 DT Small molecular drug
DMFO843 PC 3396
DMFO843 MW 475.6
DMFO843 FM C29H31F2N3O
DMFO843 IC InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
DMFO843 CS C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMFO843 IK QOYHHIBFXOOADH-UHFFFAOYSA-N
DMFO843 IU 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMFO843 CA CAS 1841-19-6
DMFO843 CB CHEBI:93369
DMFO843 DE Schizophrenia
DMK0O7U ID DMK0O7U
DMK0O7U DN Flutamide
DMK0O7U HS Approved
DMK0O7U SN Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)
DMK0O7U CP Schering-Plough Corporation
DMK0O7U TC Anticancer Agents
DMK0O7U DT Small molecular drug
DMK0O7U PC 3397
DMK0O7U MW 276.21
DMK0O7U FM C11H11F3N2O3
DMK0O7U IC InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
DMK0O7U CS CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
DMK0O7U IK MKXKFYHWDHIYRV-UHFFFAOYSA-N
DMK0O7U IU 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMK0O7U CA CAS 13311-84-7
DMK0O7U CB CHEBI:5132
DMK0O7U DE Prostate cancer
DMGCSVF ID DMGCSVF
DMGCSVF DN Fluticasone
DMGCSVF HS Approved
DMGCSVF SN Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF CP Fougera Pharmaceuticals Inc
DMGCSVF TC Antiinflammatory Agents
DMGCSVF DT Small molecular drug
DMGCSVF PC 5311101
DMGCSVF MW 444.5
DMGCSVF FM C22H27F3O4S
DMGCSVF IC InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMGCSVF CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F
DMGCSVF IK MGNNYOODZCAHBA-GQKYHHCASA-N
DMGCSVF IU S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF CA CAS 90566-53-3
DMGCSVF CB CHEBI:5134
DMGCSVF DE Allergic rhinitis
DMRWLB2 ID DMRWLB2
DMRWLB2 DN Fluticasone propionate
DMRWLB2 HS Approved
DMRWLB2 SN FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W
DMRWLB2 PC 444036
DMRWLB2 MW 500.6
DMRWLB2 FM C25H31F3O5S
DMRWLB2 IC InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
DMRWLB2 CS CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
DMRWLB2 IK WMWTYOKRWGGJOA-CENSZEJFSA-N
DMRWLB2 IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMRWLB2 CA CAS 80474-14-2
DMRWLB2 CB CHEBI:31441
DMRWLB2 DE Asthma
DMU54C3 ID DMU54C3
DMU54C3 DN Flutropium bromide
DMU54C3 HS Approved
DMU54C3 SN Flubron (TN)
DMU54C3 DT Small molecular drug
DMU54C3 PC 656602
DMU54C3 MW 478.4
DMU54C3 FM C24H29BrFNO3
DMU54C3 IC InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22?,26?;
DMU54C3 CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.[Br-]
DMU54C3 IK FNUZASGZEHGWQM-QCERWEEGSA-M
DMU54C3 IU [(1S,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide
DMU54C3 CA CAS 63516-07-4
DMU54C3 CB CHEBI:31630
DMU54C3 DE Cough
DM4MDJY ID DM4MDJY
DM4MDJY DN Fluvastatin
DM4MDJY HS Approved
DM4MDJY SN Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY TC Anticholesteremic Agents
DM4MDJY DT Small molecular drug
DM4MDJY PC 446155
DM4MDJY MW 411.5
DM4MDJY FM C24H26FNO4
DM4MDJY IC InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1
DM4MDJY CS CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F
DM4MDJY IK FJLGEFLZQAZZCD-MCBHFWOFSA-N
DM4MDJY IU (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY CA CAS 93957-54-1
DM4MDJY CB CHEBI:38565
DM4MDJY DE Hypercholesterolaemia
DMQTJSX ID DMQTJSX
DMQTJSX DN Fluvoxamine
DMQTJSX HS Approved
DMQTJSX SN Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
DMQTJSX CP IVAX Pharmaceuticals
DMQTJSX TC Antidepressants
DMQTJSX DT Small molecular drug
DMQTJSX PC 5324346
DMQTJSX MW 318.33
DMQTJSX FM C15H21F3N2O2
DMQTJSX IC InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
DMQTJSX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F
DMQTJSX IK CJOFXWAVKWHTFT-XSFVSMFZSA-N
DMQTJSX IU 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMQTJSX CA CAS 54739-18-3
DMQTJSX CB CHEBI:5138
DMQTJSX DE Depression
DM2PSBE ID DM2PSBE
DM2PSBE DN Focetria A(H1N1)
DM2PSBE HS Approved
DM2PSBE SN Focetria (H1N1); H1N1 pandemic influenza A vaccine (MF59-adjuvanted, egg-based), Novartis
DM2PSBE CP Novartis AG
DM2PSBE DT Vaccine
DM2PSBE DE Influenza virus infection
DMEMBJC ID DMEMBJC
DMEMBJC DN Folic acid
DMEMBJC HS Approved
DMEMBJC SN folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; Folacid; PteGlu; Vitamin B9; Folvite; Pteroyl-L-glutamic acid; Vitamin Bc; Acifolic; Cytofol; Incafolic; Foliamin; Folsaure; Folicet; Millafol; Folipac; Folettes; Folsan; Folbal; Folsav; Vitamin Be; Pteroyl-L-monoglutamic acid; Mittafol; Folan; Facid; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Pteroylmonoglutamate; Acfol (Spain); Foldine; Folcysteine; Folasic (Australia); Folcidin; Folaemin [Netherlands]; Nifolin; [3H]folic acid
DMEMBJC TC Vitamins
DMEMBJC DT Small molecular drug
DMEMBJC PC 135398658
DMEMBJC MW 441.4
DMEMBJC FM C19H19N7O6
DMEMBJC IC InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
DMEMBJC CS C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMEMBJC IK OVBPIULPVIDEAO-LBPRGKRZSA-N
DMEMBJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMEMBJC CA CAS 59-30-3
DMEMBJC CB CHEBI:27470
DMEMBJC DE Vitamin deficiency; Folate-deficiency anemia
DM2JTS5 ID DM2JTS5
DM2JTS5 DN Follitropin beta
DM2JTS5 HS Approved
DM2JTS5 TC Fertility Agents
DM2JTS5 SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM2JTS5 DE Female infertility
DM6VOWQ ID DM6VOWQ
DM6VOWQ DN Fomepizole
DM6VOWQ HS Approved
DM6VOWQ SN Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride
DM6VOWQ TC Antidotes
DM6VOWQ DT Small molecular drug
DM6VOWQ PC 3406
DM6VOWQ MW 82.1
DM6VOWQ FM C4H6N2
DM6VOWQ IC InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)
DM6VOWQ CS CC1=CNN=C1
DM6VOWQ IK RIKMMFOAQPJVMX-UHFFFAOYSA-N
DM6VOWQ IU 4-methyl-1H-pyrazole
DM6VOWQ CA CAS 7554-65-6
DM6VOWQ CB CHEBI:5141
DM6VOWQ DE Athylene glycol or methanol poisoning
DMBEP7G ID DMBEP7G
DMBEP7G DN Fomivirsen sodium
DMBEP7G HS Approved
DMBEP7G SN Vitravene; Vitravene Preservative Free; DRG-0234; Vitravene (TN); DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), eicosasodium salt
DMBEP7G CP Novartis AG; Isis Pharmaceuticals
DMBEP7G TC Antisense
DMBEP7G DT Small molecular drug
DMBEP7G PC 71587550
DMBEP7G MW 7122
DMBEP7G FM C204H243N63Na20O114P20S20
DMBEP7G IC InChI=1S/C204H263N63O114P20S20.20Na/c1-80-44-253(195(291)237-169(80)270)145-31-98(119(349-145)62-328-387(306,407)367-97-30-144(252-22-16-137(210)226-194(252)290)348-118(97)61-327-400(319,420)380-109-42-157(266-78-219-162-167(266)230-187(214)235-182(162)283)361-131(109)74-340-398(317,418)378-107-40-154(262-53-89(10)178(279)246-204(262)300)357-127(107)70-336-395(314,415)375-104-37-151(259-50-86(7)175(276)243-201(259)297)355-125(104)68-334-396(315,416)376-105-38-152(260-51-87(8)176(277)244-202(260)298)358-128(105)71-337-401(320,421)381-110-43-158(267-79-220-163-168(267)231-188(215)236-183(163)284)359-129(110)72-338-388(307,408)368-93-26-140(248-18-12-133(206)222-190(248)286)343-113(93)56-322-383(302,403)362-91-24-155(341-111(91)54-268)264-76-217-160-165(264)228-185(212)233-180(160)281)369-389(308,409)323-58-115-94(27-141(345-115)249-19-13-134(207)223-191(249)287)364-384(303,404)329-63-120-101(34-148(350-120)256-47-83(4)172(273)240-198(256)294)372-392(311,412)332-66-123-99(32-146(353-123)254-45-81(2)170(271)238-196(254)292)370-390(309,410)324-59-116-95(28-142(346-116)250-20-14-135(208)224-192(250)288)365-385(304,405)330-64-121-102(35-149(351-121)257-48-84(5)173(274)241-199(257)295)373-393(312,413)333-67-124-100(33-147(354-124)255-46-82(3)171(272)239-197(255)293)371-391(310,411)325-60-117-96(29-143(347-117)251-21-15-136(209)225-193(251)289)366-386(305,406)331-65-122-103(36-150(352-122)258-49-85(6)174(275)242-200(258)296)374-394(313,414)335-69-126-106(39-153(356-126)261-52-88(9)177(278)245-203(261)299)377-397(316,417)339-73-130-108(41-156(360-130)265-77-218-161-166(265)229-186(213)234-181(161)282)379-399(318,419)326-57-114-92(25-139(344-114)247-17-11-132(205)221-189(247)285)363-382(301,402)321-55-112-90(269)23-138(342-112)263-75-216-159-164(263)227-184(211)232-179(159)280;;;;;;;;;;;;;;;;;;;;/h11-22,44-53,75-79,90-131,138-158,268-269H,23-43,54-74H2,1-10H3,(H,301,402)(H,302,403)(H,303,404)(H,304,405)(H,305,406)(H,306,407)(H,307,408)(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H2,205,221,285)(H2,206,222,286)(H2,207,223,287)(H2,208,224,288)(H2,209,225,289)(H2,210,226,290)(H,237,270,291)(H,238,271,292)(H,239,272,293)(H,240,273,294)(H,241,274,295)(H,242,275,296)(H,243,276,297)(H,244,277,298)(H,245,278,299)(H,246,279,300)(H3,211,227,232,280)(H3,212,228,233,281)(H3,213,229,234,282)(H3,214,230,235,283)(H3,215,231,236,284);;;;;;;;;;;;;;;;;;;;/q;20*+1/p-20/t90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,382?,383?,384?,385?,386?,387?,388?,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?;;;;;;;;;;;;;;;;;;;;/m0..................../s1
DMBEP7G CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMBEP7G IK DLKYYJFLRUUGHJ-SSJCJZGYSA-A
DMBEP7G IU icosasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMBEP7G CA CAS 160369-77-7
DMBEP7G DE Cytomegalovirus retinitis
DMWS3FH ID DMWS3FH
DMWS3FH DN Fondaparinux sodium
DMWS3FH HS Approved
DMWS3FH SN Arixtra; Quixidar; Fondaparin sodium; Arixtra (TN); GSK-576428; SR-90107; SR-90107A; Fondaparinux sodium (JAN/USAN/INN)
DMWS3FH CP GSK
DMWS3FH TC Anticoagulants
DMWS3FH DT Small molecular drug
DMWS3FH PC 636380
DMWS3FH MW 1728.1
DMWS3FH FM C31H43N3Na10O49S8
DMWS3FH IC InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1
DMWS3FH CS CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMWS3FH IK XEKSTYNIJLDDAZ-JASSWCPGSA-D
DMWS3FH IU decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate
DMWS3FH CA CAS 114870-03-0
DMWS3FH DE Venous thrombosis
DMRBJNZ ID DMRBJNZ
DMRBJNZ DN Forasartan
DMRBJNZ HS Approved
DMRBJNZ SN SC 52458; SC-52458; Forasartan (USAN/INN); 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine; 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ TC Antihypertensive Agents
DMRBJNZ DT Small molecular drug
DMRBJNZ PC 132706
DMRBJNZ MW 416.5
DMRBJNZ FM C23H28N8
DMRBJNZ IC InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
DMRBJNZ CS CCCCC1=NN(C(=N1)CCCC)CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMRBJNZ IK YONOBYIBNBCDSJ-UHFFFAOYSA-N
DMRBJNZ IU 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ CA CAS 145216-43-9
DMRBJNZ CB CHEBI:141552
DMRBJNZ DE Hypertension
DMSOURV ID DMSOURV
DMSOURV DN Formoterol
DMSOURV HS Approved
DMSOURV SN Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
DMSOURV CP Norvatis Phamaceuticals Corporation
DMSOURV TC Sympathomimetics
DMSOURV DT Small molecular drug
DMSOURV PC 3410
DMSOURV MW 344.4
DMSOURV FM C19H24N2O4
DMSOURV IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
DMSOURV CS CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
DMSOURV IK BPZSYCZIITTYBL-UHFFFAOYSA-N
DMSOURV IU N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide
DMSOURV CA CAS 73573-87-2
DMSOURV CB CHEBI:63082
DMSOURV DE Asthma
DM4W9B3 ID DM4W9B3
DM4W9B3 DN Fosamprenavir
DM4W9B3 HS Approved
DM4W9B3 SN Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
DM4W9B3 CP GlaxoSmithKline
DM4W9B3 TC Anti-HIV Agents
DM4W9B3 DT Small molecular drug
DM4W9B3 PC 131536
DM4W9B3 MW 585.6
DM4W9B3 FM C25H36N3O9PS
DM4W9B3 IC InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
DM4W9B3 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N
DM4W9B3 IK MLBVMOWEQCZNCC-OEMFJLHTSA-N
DM4W9B3 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
DM4W9B3 CA CAS 226700-79-4
DM4W9B3 CB CHEBI:82941
DM4W9B3 DE Human immunodeficiency virus infection
DM9KJLZ ID DM9KJLZ
DM9KJLZ DN Foscavir
DM9KJLZ HS Approved
DM9KJLZ SN Foscarmet; Foscarnet; Phosphonoformate; Triapten; Virudin; Carboxyphosphonic acid; Dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; FOSCARNET SODIUM; Forscarnet sodium; Foscarnet sodico; Foscarnet sodico [Spanish]; Foscarnet sodique; Foscarnet sodique [French]; Foscarnet sodium hexahydrate; Foscarnet sodium hydrate; Foscarneto sodico; Foscarnetum natricum; Foscarnetum natricum [Latin]; Phgosphonocarboxylic acid; Phosphonoformic acid; Phosphonomethanoic acid; Trisodium carboxyphosphate; Trisodium dioxidophosphanecarboxylate oxide; Trisodium dioxidophosphinecarboxylate oxide; Trisodium phosphonatoformate; Trisodium phosphonatoformate hexahydrate; Trisodium phosphonoformate; Trisodium phosphonoformate hexahydrate; Trisodium phosphonoformte hexahydrate; A 29622; EHB 776; A-29622; DRG-0017; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; EHB-776; Foscarnet sodique [INN-French]; Foscarnet sodium hydrate (JAN); Foscarneto sodico [INN-Spanish]; Foscarnetum natricum [INN-Latin]; Foscavir (TN); HS-0008; MSL & PFA; Phosphonoformic acid, trisodium salt; Trisodium carboxyphosphate (anhydrous); Trisodium phosphonoformate (anhydrous); Foscarnet & IFN-ALPHA; Foscarnet sodium (USAN/INN); Foscarnet sodium [USAN:INN:BAN]; Phosphonoformic acid & IFN-ALPHA; Phosphonoformic acid, trisodium salt, hexahydrate; PFA & rIFN.alpha.A; Phosphinecarboxylic acid, dihydroxy-, oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
DM9KJLZ CP AstraZeneca
DM9KJLZ TC Antiviral Agents
DM9KJLZ DT Small molecular drug
DM9KJLZ PC 44561
DM9KJLZ MW 191.95
DM9KJLZ FM CNa3O5P
DM9KJLZ IC InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
DM9KJLZ CS C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
DM9KJLZ IK DFHAXXVZCFXGOQ-UHFFFAOYSA-K
DM9KJLZ IU trisodium;phosphonatoformate
DM9KJLZ CA CAS 63585-09-1
DM9KJLZ CB CHEBI:141644
DM9KJLZ DE Cytomegalovirus retinitis
DMR0TYK ID DMR0TYK
DMR0TYK DN Fosdenopterin
DMR0TYK HS Approved
DMR0TYK SN CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
DMR0TYK CP Orphatec Pharmaceuticals GmbH
DMR0TYK DT Small molecular drug
DMR0TYK PC 135463437
DMR0TYK MW 363.22
DMR0TYK FM C10H14N5O8P
DMR0TYK IC InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1
DMR0TYK CS C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
DMR0TYK IK CZAKJJUNKNPTTO-AJFJRRQVSA-N
DMR0TYK IU (1R,10R,12S,17R)-5-amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-dien-7-one
DMR0TYK CA CAS 150829-29-1
DMR0TYK CB CHEBI:60210
DMR0TYK DE Encephalopathy; Molybdenum cofactor deficiency
DMD072M ID DMD072M
DMD072M DN Fosfestrol
DMD072M HS Approved
DMD072M SN fosfestrol; Diethylstilbestrol diphosphate; 522-40-7; Phosphestrol; Phosphoestrolum; Honvan; Stilbestrol diphosphate; Desdp; Diethylstilbestryl diphosphate; Diethylstilbesterol diphosphate; ST52-Asta; Fosfestrolum [INN-Latin]; UNII-A0E0NMA80F; CCRIS 2778; (E)-Hex-3-ene-3,4-diylbis(4,1-phenylene) bis(dihydrogen phosphate); C18H22O8P2; EINECS 208-328-8; A0E0NMA80F; CHEBI:4532; Diethylstilbestrol diphosphate [USP]; NCGC00181335-01; Stilphostrol (TN); alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol bis(dihydrogen phosphate)
DMD072M DT Small molecular drug
DMD072M PC 3032325
DMD072M MW 428.3
DMD072M FM C18H22O8P2
DMD072M IC InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+
DMD072M CS CC/C(=C(/CC)\\C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O
DMD072M IK NLORYLAYLIXTID-ISLYRVAYSA-N
DMD072M IU [4-[(E)-4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate
DMD072M CA CAS 522-40-7
DMD072M CB CHEBI:4532
DMD072M DE Solid tumour/cancer
DMVGPMX ID DMVGPMX
DMVGPMX DN Fosfomycin
DMVGPMX HS Approved
DMVGPMX SN FCM; Phosphomycin; Phosphonemycin; Phosphonomycin; Priomicina; Veramina; Disodium fosfomycin; Disodium phosphonomycin; Fosfocina disodium salt; Fosfomycin disodium; Fosfomycin disodium salt; Fosfomycin sodium; Fosfomycin sodium salt; Fosmicin S; Phosphomycin disodium salt; Phosphonomycin disodium salt; Phosphonomycin sodium; Sodium fosfomycin; MK 955; FOM-Na; Fosfomycin sodium (JP15); Fosmicin S (TN); Fosfomycin (USAN/INN); L-cis-1,2-epoxypropylphosphonic acid; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-(9CI); (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonicacid; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; (1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonate; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt
DMVGPMX TC Antibiotics
DMVGPMX DT Small molecular drug
DMVGPMX PC 446987
DMVGPMX MW 138.06
DMVGPMX FM C3H7O4P
DMVGPMX IC InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
DMVGPMX CS C[C@H]1[C@H](O1)P(=O)(O)O
DMVGPMX IK YMDXZJFXQJVXBF-STHAYSLISA-N
DMVGPMX IU [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
DMVGPMX CA CAS 23155-02-4
DMVGPMX CB CHEBI:28915
DMVGPMX DE Bacterial infection
DMDIC39 ID DMDIC39
DMDIC39 DN Fosfosal
DMDIC39 HS Approved
DMDIC39 SN Disdolen (TN)
DMDIC39 DT Small molecular drug
DMDIC39 PC 3418
DMDIC39 MW 218.1
DMDIC39 FM C7H7O6P
DMDIC39 IC InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)
DMDIC39 CS C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O
DMDIC39 IK FFKUDWZICMJVPA-UHFFFAOYSA-N
DMDIC39 IU 2-phosphonooxybenzoic acid
DMDIC39 CA CAS 6064-83-1
DMDIC39 CB CHEBI:94564
DMDIC39 DE Pain
DM9NJ52 ID DM9NJ52
DM9NJ52 DN Fosinopril
DM9NJ52 HS Approved
DM9NJ52 SN Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52 CP Bristol-Myers Squibb
DM9NJ52 TC Antihypertensive Agents
DM9NJ52 DT Small molecular drug
DM9NJ52 PC 55891
DM9NJ52 MW 563.7
DM9NJ52 FM C30H46NO7P
DM9NJ52 IC InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
DM9NJ52 CS CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3
DM9NJ52 IK BIDNLKIUORFRQP-FKDWWROVSA-N
DM9NJ52 IU (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52 CA CAS 98048-97-6
DM9NJ52 CB CHEBI:5163
DM9NJ52 DE Hypertension
DM7G0EP ID DM7G0EP
DM7G0EP DN Fosmidomycin
DM7G0EP HS Approved
DM7G0EP SN FOM; Fosmidomycina; Fosmidomycine; Fosmidomycinum; FR-31564; Fosmidomycina [INN-Spanish]; Fosmidomycine [INN-French]; Fosmidomycinum [INN-Latin]; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; (3-(N-Hydroxyformamido)propyl)phosphonic acid; 3-(Formyl-hydroxy-amino)propylphosphonic acid; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; 3-(N-hydroxyformamido)propylphosphonic acid; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID
DM7G0EP TC Antimalarials
DM7G0EP DT Small molecular drug
DM7G0EP PC 572
DM7G0EP MW 183.1
DM7G0EP FM C4H10NO5P
DM7G0EP IC InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
DM7G0EP CS C(CN(C=O)O)CP(=O)(O)O
DM7G0EP IK GJXWDTUCERCKIX-UHFFFAOYSA-N
DM7G0EP IU 3-[formyl(hydroxy)amino]propylphosphonic acid
DM7G0EP CA CAS 66508-53-0
DM7G0EP CB CHEBI:443725
DM7G0EP DE Malaria
DMOX3LB ID DMOX3LB
DMOX3LB DN Fosphenytoin
DMOX3LB HS Approved
DMOX3LB SN Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester
DMOX3LB CP Pfizer Pharmaceuticals
DMOX3LB TC Anticonvulsants
DMOX3LB DT Small molecular drug
DMOX3LB PC 56339
DMOX3LB MW 362.27
DMOX3LB FM C16H15N2O6P
DMOX3LB IC InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)
DMOX3LB CS C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3
DMOX3LB IK XWLUWCNOOVRFPX-UHFFFAOYSA-N
DMOX3LB IU (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate
DMOX3LB CA CAS 93390-81-9
DMOX3LB CB CHEBI:5165
DMOX3LB DE Epilepsy
DM8J5XT ID DM8J5XT
DM8J5XT DN Fospropofol
DM8J5XT HS Approved
DM8J5XT SN Fospropofol; Fospropofol [INN]; LZ257RZP7K; SCHEMBL3821874; ZINC2519740; 258516-89-1; AC1MI4YI; ACM258516891; CHEBI:135193; CHEMBL1201766; DB06716; DEA No. 2138; DTXSID50870295; FT-0727559; GTPL7475; UNII-LZ257RZP7K; [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT PC 3038498
DM8J5XT MW 288.28
DM8J5XT FM C13H21O5P
DM8J5XT IC QVNNONOFASOXQV-UHFFFAOYSA-N
DM8J5XT CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O
DM8J5XT IK 1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)
DM8J5XT IU [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT CA CAS 258516-89-1
DM8J5XT CB CHEBI:135193
DM8J5XT DE Neuropathic pain
DMKLJRD ID DMKLJRD
DMKLJRD DN Fospropofol disodium
DMKLJRD HS Approved
DMKLJRD SN Lusedra (TN)
DMKLJRD CP Eisai
DMKLJRD DT Small molecular drug
DMKLJRD PC 3038497
DMKLJRD MW 332.24
DMKLJRD FM C13H19Na2O5P
DMKLJRD IC InChI=1S/C13H21O5P.2Na/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16;;/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16);;/q;2*+1/p-2
DMKLJRD CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)([O-])[O-].[Na+].[Na+]
DMKLJRD IK LWYLQNWMSGFCOZ-UHFFFAOYSA-L
DMKLJRD IU disodium;[2,6-di(propan-2-yl)phenoxy]methyl phosphate
DMKLJRD CA CAS 258516-87-9
DMKLJRD DE Monitored anaesthesia care
DM6AUHV ID DM6AUHV
DM6AUHV DN Fostamatinib
DM6AUHV HS Approved
DM6AUHV SN 901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]
DM6AUHV CP Rigel Pharmaceuticals
DM6AUHV DT Small molecular drug
DM6AUHV PC 11671467
DM6AUHV MW 580.5
DM6AUHV FM C23H26FN6O9P
DM6AUHV IC InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
DM6AUHV CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C
DM6AUHV IK GKDRMWXFWHEQQT-UHFFFAOYSA-N
DM6AUHV IU [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
DM6AUHV CA CAS 901119-35-5
DM6AUHV DE Immune thrombocytopenic purpura; Rheumatoid arthritis
DM50ILT ID DM50ILT
DM50ILT DN Fostemsavir
DM50ILT HS Approved
DM50ILT SN BMS-216; BMS-248; BMS-378806; BMS-626529; BMS-705; BMS-806; BMS-806 series; BMS-853; HIV-1 attachment inhibitors, BMS; HIV-1 entry inhibitors, BMS; BMS-488043 follow-on compounds, BMS; HIV-1 attachment inhibitors, Bristol-Myers Squibb
DM50ILT CP Bristol-myers squibb
DM50ILT DT Small molecular drug
DM50ILT PC 11319217
DM50ILT MW 583.5
DM50ILT FM C25H26N7O8P
DM50ILT IC InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)
DM50ILT CS CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC
DM50ILT IK SWMDAPWAQQTBOG-UHFFFAOYSA-N
DM50ILT IU [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
DM50ILT CA CAS 864953-29-7
DM50ILT DE Human immunodeficiency virus infection
DMV62ED ID DMV62ED
DMV62ED DN Fotemustine
DMV62ED HS Approved
DMV62ED SN Fotemustine; 92118-27-9; Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Muphoran; Mustophorane; Servier-10036; Fotemustinum [Latin]; Fotemustina [Spanish]; S 10036; C9H19ClN3O5P; CCRIS 6337; S-10036; Fotemustinum; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Mustoforan; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Fotemustine [BAN:INN]
DMV62ED DT Small molecular drug
DMV62ED PC 104799
DMV62ED MW 315.69
DMV62ED FM C9H19ClN3O5P
DMV62ED IC InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
DMV62ED CS CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
DMV62ED IK YAKWPXVTIGTRJH-UHFFFAOYSA-N
DMV62ED IU 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea
DMV62ED CA CAS 92118-27-9
DMV62ED CB CHEBI:131852
DMV62ED DE Solid tumour/cancer
DMF8DNE ID DMF8DNE
DMF8DNE DN Framycetin
DMF8DNE HS Approved
DMF8DNE SN Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy
DMF8DNE TC Antibiotics
DMF8DNE DT Small molecular drug
DMF8DNE PC 8378
DMF8DNE MW 614.6
DMF8DNE FM C23H46N6O13
DMF8DNE IC InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DMF8DNE CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DMF8DNE IK PGBHMTALBVVCIT-VCIWKGPPSA-N
DMF8DNE IU (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
DMF8DNE CA CAS 119-04-0
DMF8DNE CB CHEBI:7508
DMF8DNE DE Alcoholic cirrhosis of liver; Acute liver failure; Bacterial infection
DMDZY54 ID DMDZY54
DMDZY54 DN Fremanezumab
DMDZY54 HS Approved
DMDZY54 SN Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429
DMDZY54 CP Teva
DMDZY54 DT Antibody
DMDZY54 DE Hyperprolactinaemia
DM7RE8P ID DM7RE8P
DM7RE8P DN Frovatriptan
DM7RE8P HS Approved
DM7RE8P SN Allegro; Auradol; Frova; Frovelan; Migard; Miguard; Rilamig; Allergo filmtabletten; SB 209509; Allergo filmtabletten(TN); Frova (TN); Frovatriptan (INN); SB-209509; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide
DM7RE8P CP Vernalis
DM7RE8P TC Antimigraine Agents
DM7RE8P DT Small molecular drug
DM7RE8P PC 77992
DM7RE8P MW 243.3
DM7RE8P FM C14H17N3O
DM7RE8P IC InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1
DM7RE8P CS CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N
DM7RE8P IK XPSQPHWEGNHMSK-SECBINFHSA-N
DM7RE8P IU (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
DM7RE8P CA CAS 158747-02-5
DM7RE8P CB CHEBI:134991
DM7RE8P DE Migraine
DM43AN2 ID DM43AN2
DM43AN2 DN Fructose
DM43AN2 HS Approved
DM43AN2 SN D-(-)-Fructose; 57-48-7; D(-)-Fructose; (3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one; 53188-23-1; D-(-)-Levulose; D-Levulose; Nevulose; Furucton; arabino-Hexulose; Sugar, fruit; Fructose, D-; Krystar 300; Hi-Fructo 970; keto-D-fructose; Fructose, pure; Fructose solution; CCRIS 3335; 30237-26-4; EINECS 200-333-3; AI3-23514; DL-Fructose; MFCD00148910; D(-)-Fructose, 99%; Fructon; D-(-)-Fructose, > Methose; Levulosa; Levulosa Baxter; Levulosa Braun; Apir Levulosa; Levulosa Mein; Levulosa Ibys; Levulosa Ife; Levulosado Braun; D-fructose
DM43AN2 DT Small molecular drug
DM43AN2 PC 2723872
DM43AN2 MW 180.16
DM43AN2 FM C6H12O6
DM43AN2 IC InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1
DM43AN2 CS C1[C@H]([C@H]([C@@H](C(O1)(CO)O)O)O)O
DM43AN2 IK LKDRXBCSQODPBY-VRPWFDPXSA-N
DM43AN2 IU (3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM43AN2 CA CAS 6347-01-9
DM43AN2 CB CHEBI:37714
DM43AN2 DE Vomiting
DM0YZC6 ID DM0YZC6
DM0YZC6 DN Fulvestrant
DM0YZC6 HS Approved
DM0YZC6 SN Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI
DM0YZC6 CP AstraZeneca
DM0YZC6 TC Anticancer Agents
DM0YZC6 DT Small molecular drug
DM0YZC6 PC 104741
DM0YZC6 MW 606.8
DM0YZC6 FM C32H47F5O3S
DM0YZC6 IC InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
DM0YZC6 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
DM0YZC6 IK VWUXBMIQPBEWFH-WCCTWKNTSA-N
DM0YZC6 IU (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM0YZC6 CA CAS 129453-61-8
DM0YZC6 CB CHEBI:31638
DM0YZC6 DE Breast cancer
DM3P6V7 ID DM3P6V7
DM3P6V7 DN Furazolidone
DM3P6V7 HS Approved
DM3P6V7 SN Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
DM3P6V7 CP GlaxoSmithKline
DM3P6V7 TC Antiinfective Agents
DM3P6V7 DT Small molecular drug
DM3P6V7 PC 5323714
DM3P6V7 MW 225.16
DM3P6V7 FM C8H7N3O5
DM3P6V7 IC InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
DM3P6V7 CS C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM3P6V7 IK PLHJDBGFXBMTGZ-WEVVVXLNSA-N
DM3P6V7 IU 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
DM3P6V7 CA CAS 67-45-8
DM3P6V7 CB CHEBI:5195
DM3P6V7 DE Diarrhea
DMMQ8ZG ID DMMQ8ZG
DMMQ8ZG DN Furosemide
DMMQ8ZG HS Approved
DMMQ8ZG SN Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
DMMQ8ZG CP Sanofi-Aventis
DMMQ8ZG TC Diuretics
DMMQ8ZG DT Small molecular drug
DMMQ8ZG PC 3440
DMMQ8ZG MW 330.74
DMMQ8ZG FM C12H11ClN2O5S
DMMQ8ZG IC InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
DMMQ8ZG CS C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
DMMQ8ZG IK ZZUFCTLCJUWOSV-UHFFFAOYSA-N
DMMQ8ZG IU 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
DMMQ8ZG CA CAS 54-31-9
DMMQ8ZG CB CHEBI:47426
DMMQ8ZG DE Congestive heart failure
DMWVCF3 ID DMWVCF3
DMWVCF3 DN Fusidic acid
DMWVCF3 HS Approved
DMWVCF3 SN FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
DMWVCF3 CP Leo Laboratories
DMWVCF3 TC Antibiotics
DMWVCF3 DT Small molecular drug
DMWVCF3 PC 3000226
DMWVCF3 MW 516.7
DMWVCF3 FM C31H48O6
DMWVCF3 IC InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
DMWVCF3 CS C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\\C(=O)O)OC(=O)C)C)O)C
DMWVCF3 IK IECPWNUMDGFDKC-MZJAQBGESA-N
DMWVCF3 IU (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
DMWVCF3 CA CAS 6990-06-3
DMWVCF3 CB CHEBI:29013
DMWVCF3 DE Bacterial infection; MRSA infection
DMZ0P95 ID DMZ0P95
DMZ0P95 DN Ga-68-DOTATOC
DMZ0P95 HS Approved
DMZ0P95 DT radioactive diagnostic agent
DMZ0P95 DE Diagnostic imaging
DM6T924 ID DM6T924
DM6T924 DN Gabapentin
DM6T924 HS Approved
DM6T924 SN Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924 CP Pfizer
DM6T924 TC Analgesics
DM6T924 DT Small molecular drug
DM6T924 PC 3446
DM6T924 MW 171.24
DM6T924 FM C9H17NO2
DM6T924 IC InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
DM6T924 CS C1CCC(CC1)(CC(=O)O)CN
DM6T924 IK UGJMXCAKCUNAIE-UHFFFAOYSA-N
DM6T924 IU 2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924 CA CAS 60142-96-3
DM6T924 CB CHEBI:42797
DM6T924 DE Complex partial seizure; Solid tumour/cancer
DMU9D2F ID DMU9D2F
DMU9D2F DN Gabexate
DMU9D2F HS Approved
DMU9D2F SN gabexate; Gabexate [INN]; 39492-01-8; Gabexatum [INN-Latin]; Gabexato [INN-Spanish]; UNII-4V7M9137X9; CHEMBL87563; C16H23N3O4; Gabexate (INN); 4V7M9137X9; Ethyl p-hydroxybenzoate 6-guanidinohexanoate; ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate; Gabexatum; Gabexato; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester; p-carbethoxyphenyl e-guanidinocaproate; AC1L1FYH; Prestwick3_001008; Prestwick2_001008; Prestwick0_001008; Prestwick1_001008; BSPBio_001135; SCHEMBL446024; SPBio_003016; GTPL7863
DMU9D2F DT Small molecular drug
DMU9D2F PC 3447
DMU9D2F MW 321.37
DMU9D2F FM C16H23N3O4
DMU9D2F IC InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
DMU9D2F CS CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N
DMU9D2F IK YKGYIDJEEQRWQH-UHFFFAOYSA-N
DMU9D2F IU ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
DMU9D2F CA CAS 39492-01-8
DMU9D2F CB CHEBI:93036
DMU9D2F DE Pancreatitis
DMI53FU ID DMI53FU
DMI53FU DN Gaboxadol
DMI53FU HS Approved
DMI53FU SN Gaboxadolum; Gaboxadolum [Latin]; LU 2030; Gaboxadol [USAN:INN]; Lu 02-030; MK-0928; Gaboxadol (USAN/INN); LU-2-030; Lu-02-030; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; 4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU CP Merck & Co
DMI53FU TC Hypnotics and Sedatives
DMI53FU DT Small molecular drug
DMI53FU PC 3448
DMI53FU MW 140.14
DMI53FU FM C6H8N2O2
DMI53FU IC InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
DMI53FU CS C1CNCC2=C1C(=O)NO2
DMI53FU IK ZXRVKCBLGJOCEE-UHFFFAOYSA-N
DMI53FU IU 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU CA CAS 64603-91-4
DMI53FU CB CHEBI:34373
DMI53FU DE Insomnia
DM4VAOG ID DM4VAOG
DM4VAOG DN Gadobenate dimeglumine
DM4VAOG HS Approved
DM4VAOG SN Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
DM4VAOG TC Contrast Media
DM4VAOG DT Small molecular drug
DM4VAOG PC 6918204
DM4VAOG MW 1058.1
DM4VAOG FM C36H62GdN5O21
DM4VAOG IC InChI=1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
DM4VAOG CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)O.[Gd+3]
DM4VAOG IK OCDAWJYGVOLXGZ-VPVMAENOSA-K
DM4VAOG IU 2-[2-[carboxylatomethyl-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]ethyl-(carboxymethyl)amino]-3-phenylmethoxypropanoate;gadolinium(3+);(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DM4VAOG CA CAS 127000-20-8
DM4VAOG DE Schizophrenia
DM5V9U1 ID DM5V9U1
DM5V9U1 DN Gadofosveset
DM5V9U1 HS Approved
DM5V9U1 SN Vasovist (TN)
DM5V9U1 CP Epix
DM5V9U1 DT Small molecular drug
DM5V9U1 PC 73415770
DM5V9U1 MW 891.9
DM5V9U1 FM C33H41GdN3O14P
DM5V9U1 IC InChI=1S/C33H44N3O14P.Gd/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);/q;+3/p-3/t26-;/m1./s1
DM5V9U1 CS [H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3]
DM5V9U1 IK ZSDLYSDDELEVDD-UFTMZEDQSA-K
DM5V9U1 IU 2-[[(2R)-2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron
DM5V9U1 CA CAS 201688-00-8
DM5V9U1 DE Imaging
DMEO794 ID DMEO794
DMEO794 DN Galantamine
DMEO794 HS Approved
DMEO794 SN GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
DMEO794 CP Janssen Pharmaceutica
DMEO794 TC Parasympathomimetics
DMEO794 DT Small molecular drug
DMEO794 PC 9651
DMEO794 MW 287.35
DMEO794 FM C17H21NO3
DMEO794 IC InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
DMEO794 CS CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
DMEO794 IK ASUTZQLVASHGKV-JDFRZJQESA-N
DMEO794 IU (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMEO794 CA CAS 357-70-0
DMEO794 CB CHEBI:42944
DMEO794 DE Alzheimer disease
DMIZ1E8 ID DMIZ1E8
DMIZ1E8 DN Galcanezumab
DMIZ1E8 HS Approved
DMIZ1E8 SN Galcanezumab [USAN:INN]; UNII-55KHL3P693; 55KHL3P693
DMIZ1E8 CP Eli Lilly
DMIZ1E8 DT Antibody
DMIZ1E8 DE Hyperprolactinaemia
DMPO0MS ID DMPO0MS
DMPO0MS DN Gallamine Triethiodide
DMPO0MS HS Approved
DMPO0MS SN Benzkurin; Flaxedil; Gallaflex; Parexyl; Pirolakson; Pyrolaxon; Relaxan; Remyolan; Retensin; Sincurarine; Syncurarine; Tricuran; Benzcurine iodide; Gallamin triethiodide; Gallamina triodoetilato; Gallamina triodoetilato [DCIT]; Gallamine iodide; Gallamine triethiodide [INN]; Gallamine triiodoethylate; Gallamini triethiodidum; Gallaminii iodidum; Gallaminum triaethjodidum; Gallaminum triaethoiodatum; Gallamone triethiodide; Gallamoni jodidum; Miowas G; Triethiodure de gallamine; Triethiodurode galamina; Triiodoethylate de gallamine; Triiodoethylate de gallamine [French]; F 2559; Fourneau 2559; G 8134; HL 8583; RP 3697; Flaxedil (TN); Gallamine triethiodide (USP); Gallamine-3ETI; Gallamini triethiodidum [INN-Latin]; Triethiodure de gallamine [INN-French]; Triethioduro de galamina [INN-Spanish]; Pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide); Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [French]; Triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [French]; Ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide; Ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide; Tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate; Ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl-, triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammonium iodide); (v-Phenenyltris(oxyethylene))tris(triethylammonium) triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammoniumiodide); 1,2,3-Tri(beta-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene tris(ethyliodide); 1,2,3-Tris(2-triethylammonium ethoxy)benzene triiodide; 1,2,3-Tris(diethylaminoethoxy)benzene triethiodide; 2,2',2''-(1,2,3-Benzenetriyltris(oxy))tris(N,N,N-triethylethanaminium) triiodide; 2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide; 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide
DMPO0MS TC Skeletal Muscle Relaxants
DMPO0MS DT Small molecular drug
DMPO0MS PC 6172
DMPO0MS MW 891.5
DMPO0MS FM C30H60I3N3O3
DMPO0MS IC InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3
DMPO0MS CS CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
DMPO0MS IK REEUVFCVXKWOFE-UHFFFAOYSA-K
DMPO0MS IU 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;triiodide
DMPO0MS CA CAS 65-29-2
DMPO0MS DE Stabilize muscle contraction
DMF9O6B ID DMF9O6B
DMF9O6B DN Gallium nitrate
DMF9O6B HS Approved
DMF9O6B SN Ganite (TN)
DMF9O6B TC Anticancer Agents
DMF9O6B DT Small molecular drug
DMF9O6B PC 61635
DMF9O6B MW 255.74
DMF9O6B FM GaN3O9
DMF9O6B IC InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1
DMF9O6B CS [N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ga+3]
DMF9O6B IK CHPZKNULDCNCBW-UHFFFAOYSA-N
DMF9O6B IU gallium;trinitrate
DMF9O6B CA CAS 13494-90-1
DMF9O6B DE Hypercalcaemia
DMER9YA ID DMER9YA
DMER9YA DN Galsulfase
DMER9YA HS Approved
DMER9YA SN Aryplase; Aryplase (TN); Galsulfase (genetical recombination); Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN)
DMER9YA TC Enzyme Replacement Agents
DMER9YA SQ Galsulfase: SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM
DMER9YA DE Mucopolysaccharidosis
DMGBKVD ID DMGBKVD
DMGBKVD DN Gamma hydroxybutyric acid
DMGBKVD HS Approved
DMGBKVD SN Anetamin; GHB; Hydroxyb; Oxybate; SHB; Somsanit; Xyrem; Gamma OH; Oxybate sodium; Utyric acid monosodium salt; EB 27; WY 3478; Gam-OH; Gamma-Hydroxy butyrate; Gamma-Hydroxy sodium butyrate; Gamma-Hydroxybutanoic acid; Gamma-Hydroxybutyrate sodium; Gamma-Hydroxybutyric acid; Gamma-Hydroxybutyric acid decomposition product; Gamma-Hydroxybutyric acid monosodium salt; Gamma-OH; Xyrem (TN); Gamma-Hydroxybutyric acid, sodium salt; Oxy-n-butyric acid; Sodium Oxybate (4-hydroxybutanoic acid); Sodium .gamma.-hydroxybutyrate; Sodium .gamma.-oxybutyrate; AA3E2AF0-AB7A-4A1E-A391-199C049D7162; Butanoic acid, 4-hydroxy-, monosodium salt; Butanoic acid, 4-hydroxy-, sodium salt; Butyric acid, 4-hydroxy-, monosodium salt; Butyric acid, 4-hydroxy-, sodium salt; 3-carboxypropoxy acid; 4 HB; 4-Hydroxy; 4-Hydroxyacid; 4-Hydroxyalkanoic acid; 4-Hydroxybutanoic acid; 4-Hydroxybuttersaeure; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid; 4-Hydroxybutyric acid monosodium salt; 4-Hydroxycarboxylic acid; 4-OHB; 4-hydroxy-butyric acid
DMGBKVD CP Jazz Pharmaceuticals
DMGBKVD TC Anesthetics
DMGBKVD DT Small molecular drug
DMGBKVD PC 10413
DMGBKVD MW 104.1
DMGBKVD FM C4H8O3
DMGBKVD IC InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)
DMGBKVD CS C(CC(=O)O)CO
DMGBKVD IK SJZRECIVHVDYJC-UHFFFAOYSA-N
DMGBKVD IU 4-hydroxybutanoic acid
DMGBKVD CA CAS 591-81-1
DMGBKVD CB CHEBI:30830
DMGBKVD DE Narcolepsy
DMSXKYG ID DMSXKYG
DMSXKYG DN Gamma-homolinolenic acid
DMSXKYG HS Approved
DMSXKYG SN DGLA; BML3-B11; Ro 12-1989; Star GLA (GNC); Bishomo-gamma-linolenic acid; C 20:3 n-6; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Homo-gamma-linolensaeure; Tona-lean 1000 CLA (Action Labs); Cis-8,11,14-Eicosatrienoic Acid; Eicosa-8Z,11Z,14Z-trienoic acid; All-cis-8,11,14-Eicosatrienoic acid; All-cis-8,11,14-icosatrienoic acid; All-cis-Eicosa-8,11,14-triensaeure; Cis,cis,cis-8,11,14-Eicosatrienoic acid; Cis-8,cis-11,cis-14-Eicosatrienoic acid; (8E,11E,14E)-8,11,14-Icosatrienoic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoicacid; 20:3, n-6,9,12 all-cis; 8, 11, 14-eicosatrienoic acid; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)-(9CI); 8,11,14-Eicosatrienoic acid, (Z,Z,Z)-(8CI); 8,11,14-Icosatrienoate; 8,11,14-all-cis-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 8c,11c,14c-eicosatrienoic acid
DMSXKYG TC Dietary supplement
DMSXKYG DT Small molecular drug
DMSXKYG PC 5280581
DMSXKYG MW 306.5
DMSXKYG FM C20H34O2
DMSXKYG IC InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-
DMSXKYG CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)O
DMSXKYG IK HOBAELRKJCKHQD-QNEBEIHSSA-N
DMSXKYG IU (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid
DMSXKYG CA CAS 1783-84-2
DMSXKYG CB CHEBI:53486
DMSXKYG DE Malnutrition
DMQN30Z ID DMQN30Z
DMQN30Z DN Gamolenic acid
DMQN30Z HS Approved
DMQN30Z SN gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; CCRIS 7668; UNII-78YC2MAX4O; Acidum gamolenicum [Latin]; Acido gamolenico [Spanish]; Acide gamolenique [French]; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; Gamolenic acid [INN:BAN]; (6,9,12)-linolenic acid; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; CHEMBL464982; CHEBI:28661; Epogam (TN); gamma-linolenic acid
DMQN30Z DT Small molecular drug
DMQN30Z PC 5280933
DMQN30Z MW 278.4
DMQN30Z FM C18H30O2
DMQN30Z IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
DMQN30Z CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O
DMQN30Z IK VZCCETWTMQHEPK-QNEBEIHSSA-N
DMQN30Z IU (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid
DMQN30Z CA CAS 506-26-3
DMQN30Z CB CHEBI:28661
DMQN30Z DE Allergy
DM1MBYQ ID DM1MBYQ
DM1MBYQ DN Ganciclovir
DM1MBYQ HS Approved
DM1MBYQ SN ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512
DM1MBYQ CP Bausch & Lomb Pharmaceuticals, Inc.
DM1MBYQ TC Antiviral Agents
DM1MBYQ DT Small molecular drug
DM1MBYQ PC 135398740
DM1MBYQ MW 255.23
DM1MBYQ FM C9H13N5O4
DM1MBYQ IC InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
DM1MBYQ CS C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
DM1MBYQ IK IRSCQMHQWWYFCW-UHFFFAOYSA-N
DM1MBYQ IU 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one
DM1MBYQ CA CAS 82410-32-0
DM1MBYQ CB CHEBI:465284
DM1MBYQ DE Virus infection
DMGMB30 ID DMGMB30
DMGMB30 DN Ganirelix
DMGMB30 HS Approved
DMGMB30 SN Ganirelixum; Orgalutran; Ganirelix acetate; Antagon (TN); Ganirelix (INN); Ganirelix [INN:BAN]; Ganirelixum [INN-Latin]; Orgalutran (TN); RS-26306
DMGMB30 CP Organon International
DMGMB30 TC Abortifacient Agents
DMGMB30 DT Small molecular drug
DMGMB30 PC 16130957
DMGMB30 MW 1570.3
DMGMB30 FM C80H113ClN18O13
DMGMB30 IC InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1
DMGMB30 CS CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC
DMGMB30 IK GJNXBNATEDXMAK-PFLSVRRQSA-N
DMGMB30 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGMB30 CA CAS 124904-93-4
DMGMB30 CB CHEBI:135910
DMGMB30 DE Ovulation dysfunction
DMSL679 ID DMSL679
DMSL679 DN Gatifloxacin
DMSL679 HS Approved
DMSL679 SN Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679 CP Bristol-Myers Squibb
DMSL679 TC Antiinfective Agents
DMSL679 DT Small molecular drug
DMSL679 PC 5379
DMSL679 MW 375.4
DMSL679 FM C19H22FN3O4
DMSL679 IC InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
DMSL679 CS CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMSL679 IK XUBOMFCQGDBHNK-UHFFFAOYSA-N
DMSL679 IU 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679 CA CAS 112811-59-3
DMSL679 CB CHEBI:5280
DMSL679 DE Respiratory tract infection
DMH0QKA ID DMH0QKA
DMH0QKA DN GDC-0199
DMH0QKA HS Approved
DMH0QKA CP AbbVie
DMH0QKA DT Small molecular drug
DMH0QKA PC 49846579
DMH0QKA MW 868.4
DMH0QKA FM C45H50ClN7O7S
DMH0QKA IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DMH0QKA CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DMH0QKA IK LQBVNQSMGBZMKD-UHFFFAOYSA-N
DMH0QKA IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DMH0QKA CA CAS 1257044-40-8
DMH0QKA CB CHEBI:133021
DMH0QKA DE Chronic lymphocytic leukaemia; Solid tumour/cancer
DM15F0X ID DM15F0X
DM15F0X DN Gefitinib
DM15F0X HS Approved
DM15F0X SN Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
DM15F0X CP AstraZeneca
DM15F0X TC Anticancer Agents
DM15F0X DT Small molecular drug
DM15F0X PC 123631
DM15F0X MW 446.9
DM15F0X FM C22H24ClFN4O3
DM15F0X IC InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
DM15F0X CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DM15F0X IK XGALLCVXEZPNRQ-UHFFFAOYSA-N
DM15F0X IU N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
DM15F0X CA CAS 184475-35-2
DM15F0X CB CHEBI:49668
DM15F0X DE Solid tumour/cancer; Urethral cancer; Head and neck cancer
DMSE3I7 ID DMSE3I7
DMSE3I7 DN Gemcitabine
DMSE3I7 HS Approved
DMSE3I7 SN Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)
DMSE3I7 CP Eli Lilly
DMSE3I7 TC Anticancer Agents
DMSE3I7 DT Small molecular drug
DMSE3I7 PC 60750
DMSE3I7 MW 263.2
DMSE3I7 FM C9H11F2N3O4
DMSE3I7 IC InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
DMSE3I7 CS C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
DMSE3I7 IK SDUQYLNIPVEERB-QPPQHZFASA-N
DMSE3I7 IU 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMSE3I7 CA CAS 95058-81-4
DMSE3I7 CB CHEBI:175901
DMSE3I7 DE Solid tumour/cancer
DMD8Q3J ID DMD8Q3J
DMD8Q3J DN Gemfibrozil
DMD8Q3J HS Approved
DMD8Q3J SN ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
DMD8Q3J CP Pfizer Pharmaceuticals
DMD8Q3J TC Antilipemic Agents
DMD8Q3J DT Small molecular drug
DMD8Q3J PC 3463
DMD8Q3J MW 250.33
DMD8Q3J FM C15H22O3
DMD8Q3J IC InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
DMD8Q3J CS CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
DMD8Q3J IK HEMJJKBWTPKOJG-UHFFFAOYSA-N
DMD8Q3J IU 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
DMD8Q3J CA CAS 25812-30-0
DMD8Q3J CB CHEBI:5296
DMD8Q3J DE Hyperlipidaemia
DMHT34O ID DMHT34O
DMHT34O DN Gemifloxacin
DMHT34O HS Approved
DMHT34O SN Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DMHT34O CP Oscient Pharmaceuticals
DMHT34O TC Antibiotics
DMHT34O DT Small molecular drug
DMHT34O PC 9571107
DMHT34O MW 389.4
DMHT34O FM C18H20FN5O4
DMHT34O IC InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
DMHT34O CS CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
DMHT34O IK ZRCVYEYHRGVLOC-HYARGMPZSA-N
DMHT34O IU 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMHT34O CA CAS 175463-14-6
DMHT34O CB CHEBI:101853
DMHT34O DE Bacterial infection
DMJ2O7B ID DMJ2O7B
DMJ2O7B DN Gemtuzumab ozogamicin
DMJ2O7B HS Approved
DMJ2O7B SN Mylotarg (TN)
DMJ2O7B CP Wyeth Pharmaceuticals
DMJ2O7B TC Anticancer Agents
DMJ2O7B DT Antibody
DMJ2O7B SQ Light Chain No. 1: QIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK > Light Chain No. 2DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPSRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK > Heavy Chain No. 1QVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS > Heavy Chain No. 2QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS
DMJ2O7B DE Acute myeloid leukaemia
DMKINJO ID DMKINJO
DMKINJO DN Gentamicin
DMKINJO HS Approved
DMKINJO SN Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside
DMKINJO CP Sandoz
DMKINJO TC Antibiotics
DMKINJO DT Small molecular drug
DMKINJO PC 3467
DMKINJO MW 477.6
DMKINJO FM C21H43N5O7
DMKINJO IC InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
DMKINJO CS CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
DMKINJO IK CEAZRRDELHUEMR-UHFFFAOYSA-N
DMKINJO IU 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMKINJO CA CAS 1403-66-3
DMKINJO DE Bacterial infection
DMBT7MI ID DMBT7MI
DMBT7MI DN Gentamicine sulfate
DMBT7MI HS Approved
DMBT7MI SN SCH-9724; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMBT7MI TC Antibiotics
DMBT7MI DT Small molecular drug
DMBT7MI PC 6419933
DMBT7MI MW 1488.8
DMBT7MI FM C60H125N15O25S
DMBT7MI IC InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9-,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8-,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1
DMBT7MI CS C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O.OS(=O)(=O)O
DMBT7MI IK RDEIXVOBVLKYNT-HDZPSJEVSA-N
DMBT7MI IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
DMBT7MI CA CAS 1405-41-0
DMBT7MI DE Bacterial infection
DMP0OVQ ID DMP0OVQ
DMP0OVQ DN Gestrinone
DMP0OVQ HS Approved
DMP0OVQ SN Dimetrose (TN)
DMP0OVQ CP Sarsa
DMP0OVQ DT Small molecular drug
DMP0OVQ PC 27812
DMP0OVQ MW 308.4
DMP0OVQ FM C21H24O2
DMP0OVQ IC InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1
DMP0OVQ CS CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O
DMP0OVQ IK BJJXHLWLUDYTGC-ANULTFPQSA-N
DMP0OVQ IU (8S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMP0OVQ CA CAS 16320-04-0
DMP0OVQ CB CHEBI:89642
DMP0OVQ DE Breast cancer
DMKGH0R ID DMKGH0R
DMKGH0R DN GHRP-2
DMKGH0R HS Approved
DMKGH0R SN Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy
DMKGH0R DT Small molecular drug
DMKGH0R PC 6918245
DMKGH0R MW 818
DMKGH0R FM C45H55N9O6
DMKGH0R IC InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
DMKGH0R CS C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N
DMKGH0R IK HRNLPPBUBKMZMT-RDRUQFPZSA-N
DMKGH0R IU (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMKGH0R CA CAS 158861-67-7
DMKGH0R CB CHEBI:135890
DMKGH0R DE Growth hormone deficiency
DMTI0ZO ID DMTI0ZO
DMTI0ZO DN Gilteritinib
DMTI0ZO HS Approved
DMTI0ZO SN 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; ASP 2215; Gilteritinib; Gilteritinib (ASP-2215); Gilteritinib (ASP2215); Gilteritinib (USAN/INN); Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Xospata
DMTI0ZO TC Anticancer Agents
DMTI0ZO DT Small molecular drug
DMTI0ZO PC 49803313
DMTI0ZO MW 552.724
DMTI0ZO FM C29H44N8O3
DMTI0ZO IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMTI0ZO CS CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N
DMTI0ZO IK GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMTI0ZO IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMTI0ZO CA CAS 1254053-43-4
DMTI0ZO DE Acute myeloid leukemia
DMWQ4MZ ID DMWQ4MZ
DMWQ4MZ DN Gilteritinib
DMWQ4MZ HS Approved
DMWQ4MZ SN UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199
DMWQ4MZ CP Astellas
DMWQ4MZ PC 49803313
DMWQ4MZ MW 552.7
DMWQ4MZ FM C29H44N8O3
DMWQ4MZ IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMWQ4MZ CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
DMWQ4MZ IK GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMWQ4MZ IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMWQ4MZ CA CAS 1254053-43-4
DMWQ4MZ CB CHEBI:145372
DMWQ4MZ DE Acute myeloid leukaemia
DM5PFIJ ID DM5PFIJ
DM5PFIJ DN Givosiran
DM5PFIJ HS Approved
DM5PFIJ SN 1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280
DM5PFIJ CP Alnylam Pharmaceuticals
DM5PFIJ DT Small interfering RNA
DM5PFIJ PC 119058042
DM5PFIJ MW 1711
DM5PFIJ FM C78H139N11O30
DM5PFIJ IC InChI=1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1
DM5PFIJ CS C[C@@H]1C[C@H](CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(=O)C)O
DM5PFIJ IK RUPXJRIDSUCQAN-PQNNUJSWSA-N
DM5PFIJ IU N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide
DM5PFIJ CA CAS 1639325-43-1
DM5PFIJ DE Acute intermittent hepatic porphyria
DM83MOK ID DM83MOK
DM83MOK DN Glassia
DM83MOK HS Approved
DM83MOK SN Glassia (TN)
DM83MOK CP Baxter
DM83MOK DE Emphysema
DMAPV1B ID DMAPV1B
DMAPV1B DN Glatiramer acetate
DMAPV1B HS Approved
DMAPV1B SN Glatiramer acetate; Copaxone; 147245-92-9; Copolymer 1; Copolymer-1; COP-1; Protiramer; Glatopa; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); (2S)-2,6-diaminohexanoic acid; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; AC1MIXQC; 5M691HL4BO
DMAPV1B CP Teva Pharmaceuticals
DMAPV1B TC Immunosuppressive Agents
DMAPV1B DT Small molecular drug
DMAPV1B SQ Example Glatiramer peptide: EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK
DMAPV1B PC 3081884
DMAPV1B MW 623.7
DMAPV1B FM C25H45N5O13
DMAPV1B IC InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
DMAPV1B CS C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N
DMAPV1B IK FHEAIOHRHQGZPC-KIWGSFCNSA-N
DMAPV1B IU acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid
DMAPV1B CA CAS 147245-92-9
DMAPV1B DE Multiple sclerosis
DM31YVO ID DM31YVO
DM31YVO DN Glecaprevir
DM31YVO HS Approved
DM31YVO SN Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; glecaprevirum; 1365970-03-1; A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CHEMBL3545363; CS-8098; D10814; DB13879; EX-A1940; HY-17634; UNII-K6BUU8J72P
DM31YVO PC 66828839
DM31YVO MW 838.9
DM31YVO FM C38H46F4N6O9S
DM31YVO IC MLSQGNCUYAMAHD-ITNVBOSISA-N
DM31YVO CS CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DM31YVO IK 1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DM31YVO IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DM31YVO CA CAS 1365970-03-1
DM31YVO DE Viral hepatitis
DMF6Z5T ID DMF6Z5T
DMF6Z5T DN Glecaprevir; pibrentasvir
DMF6Z5T HS Approved
DMF6Z5T SN pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520
DMF6Z5T CP AbbVie
DMF6Z5T DT Combination drug
DMF6Z5T PC 66828839; 58031952
DMF6Z5T DE Hepatitis C virus infection
DM8JXPZ ID DM8JXPZ
DM8JXPZ DN Glibenclamide
DM8JXPZ HS Approved
DM8JXPZ SN Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ CP Nigerian-German Chemicals
DM8JXPZ TC Hypoglycemic Agents
DM8JXPZ DT Small molecular drug
DM8JXPZ PC 3488
DM8JXPZ MW 494
DM8JXPZ FM C23H28ClN3O5S
DM8JXPZ IC InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
DM8JXPZ CS COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DM8JXPZ IK ZNNLBTZKUZBEKO-UHFFFAOYSA-N
DM8JXPZ IU 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ CA CAS 10238-21-8
DM8JXPZ CB CHEBI:5441
DM8JXPZ DE Diabetic complication; Stroke
DMN6QO5 ID DMN6QO5
DMN6QO5 DN Gliclazide
DMN6QO5 HS Approved
DMN6QO5 SN Diaikron; Diamicron; Gliclazida; Gliclazidum; Gliklazid; Glimicron; Glyclazide; Nordialex; S 1702; S 852; SE 1702; Diamicron (TN); Dianorm (TN); Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; Glimicron (TN); S-1702; S-852; Gliclazide (JAN/INN); Glubitor-OD (TN); Gliclazide [BAN:INN:DCF:JAN]; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
DMN6QO5 TC Hypoglycemic Agents
DMN6QO5 DT Small molecular drug
DMN6QO5 PC 3475
DMN6QO5 MW 323.4
DMN6QO5 FM C15H21N3O3S
DMN6QO5 IC InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
DMN6QO5 CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
DMN6QO5 IK BOVGTQGAOIONJV-UHFFFAOYSA-N
DMN6QO5 IU 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
DMN6QO5 CA CAS 21187-98-4
DMN6QO5 CB CHEBI:31654
DMN6QO5 DE Diabetic complication
DM5FSJA ID DM5FSJA
DM5FSJA DN Glimepiride
DM5FSJA HS Approved
DM5FSJA SN Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P
DM5FSJA CP Sanofi-Aventis
DM5FSJA TC Hypoglycemic Agents
DM5FSJA DT Small molecular drug
DM5FSJA PC 3476
DM5FSJA MW 490.6
DM5FSJA FM C24H34N4O5S
DM5FSJA IC InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
DM5FSJA CS CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
DM5FSJA IK WIGIZIANZCJQQY-UHFFFAOYSA-N
DM5FSJA IU 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
DM5FSJA CA CAS 261361-60-8
DM5FSJA CB CHEBI:5383
DM5FSJA DE Diabetic complication
DMZA5PQ ID DMZA5PQ
DMZA5PQ DN Glipizide
DMZA5PQ HS Approved
DMZA5PQ SN Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
DMZA5PQ CP Pfizer Pharmaceuticals
DMZA5PQ TC Hypoglycemic Agents
DMZA5PQ DT Small molecular drug
DMZA5PQ PC 3478
DMZA5PQ MW 445.5
DMZA5PQ FM C21H27N5O4S
DMZA5PQ IC InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
DMZA5PQ CS CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DMZA5PQ IK ZJJXGWJIGJFDTL-UHFFFAOYSA-N
DMZA5PQ IU N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide
DMZA5PQ CA CAS 29094-61-9
DMZA5PQ CB CHEBI:5384
DMZA5PQ DE Diabetic complication
DMB0EUX ID DMB0EUX
DMB0EUX DN Gliquidone
DMB0EUX HS Approved
DMB0EUX SN Beglynor; Beglynora; Glikvidon; Gliquidona; Gliquidonum; Glurenorm; Glycvidon; ARDF 26; ARDF 26 SE; AR-DF 26; Gliquidona [INN-Spanish]; Gliquidone (INN); Gliquidone [BAN:INN]; Gliquidonum [INN-Latin]; Glurenorm (TN); N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX CP Boehriger Ingelheim
DMB0EUX TC Hypoglycemic Agents
DMB0EUX DT Small molecular drug
DMB0EUX PC 91610
DMB0EUX MW 527.6
DMB0EUX FM C27H33N3O6S
DMB0EUX IC InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
DMB0EUX CS CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C
DMB0EUX IK LLJFMFZYVVLQKT-UHFFFAOYSA-N
DMB0EUX IU 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX CA CAS 33342-05-1
DMB0EUX CB CHEBI:93416
DMB0EUX DE Diabetic complication
DMJPR2B ID DMJPR2B
DMJPR2B DN Glisoxepide
DMJPR2B HS Approved
DMJPR2B SN Glisepin; Glisoxepid; Glisoxepida; Glisoxepidum; Glisoxepida [Spanish]; BS 4231; Bay B 4231; FBB 4231; RP22410; Glisoxepida [INN-Spanish]; Glisoxepide (INN); Glisoxepidum [INN-Latin]; Pro-Diaban; Glisoxepide [INN:BAN:DCF]; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea
DMJPR2B TC Hypoglycemic Agents
DMJPR2B DT Small molecular drug
DMJPR2B PC 32778
DMJPR2B MW 449.5
DMJPR2B FM C20H27N5O5S
DMJPR2B IC InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
DMJPR2B CS CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3
DMJPR2B IK ZKUDBRCEOBOWLF-UHFFFAOYSA-N
DMJPR2B IU N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
DMJPR2B CA CAS 25046-79-1
DMJPR2B CB CHEBI:135731
DMJPR2B DE Non-insulin dependent diabetes
DMFLUTR ID DMFLUTR
DMFLUTR DN Glucagon recombinant
DMFLUTR HS Approved
DMFLUTR SN Glucagon recombinant; GTPL1136; CHEMBL266481
DMFLUTR TC Antihypoglycemic Agents
DMFLUTR DT Small molecular drug
DMFLUTR SQ Glucagon for Injection Sequence : HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
DMFLUTR PC 44278361
DMFLUTR MW 3482.7
DMFLUTR FM C153H225N43O49S
DMFLUTR IC InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1
DMFLUTR CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DMFLUTR IK MASNOZXLGMXCHN-ZLPAWPGGSA-N
DMFLUTR IU (3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMFLUTR CB CHEBI:5391
DMFLUTR DE Hypoglycemia
DM6EL5Q ID DM6EL5Q
DM6EL5Q DN Glucarpidase
DM6EL5Q HS Approved
DM6EL5Q SN Voraxaze (TN)
DM6EL5Q CP BTG International
DM6EL5Q DT Small molecular drug
DM6EL5Q SQ Glucarpidase: ALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK
DM6EL5Q PC 21195079
DM6EL5Q MW 261.5
DM6EL5Q FM Zn4+8
DM6EL5Q IC InChI=1S/4Zn/q4*+2
DM6EL5Q CS [Zn+2].[Zn+2].[Zn+2].[Zn+2]
DM6EL5Q IK LZQXMCNBQHANEY-UHFFFAOYSA-N
DM6EL5Q IU zinc(2+)
DM6EL5Q DE Delayed methotrexate clearance
DM4ZLFD ID DM4ZLFD
DM4ZLFD DN Glucosamine
DM4ZLFD HS Approved
DM4ZLFD SN Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose
DM4ZLFD TC Antiinflammatory Agents
DM4ZLFD DT Small molecular drug
DM4ZLFD PC 439213
DM4ZLFD MW 179.17
DM4ZLFD FM C6H13NO5
DM4ZLFD IC InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1
DM4ZLFD CS C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O
DM4ZLFD IK MSWZFWKMSRAUBD-IVMDWMLBSA-N
DM4ZLFD IU (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
DM4ZLFD CA CAS 3416-24-8
DM4ZLFD CB CHEBI:47977
DM4ZLFD DE Osteoarthritis
DMAHMT9 ID DMAHMT9
DMAHMT9 DN Glutathione
DMAHMT9 HS Approved
DMAHMT9 SN glutathione; 70-18-8; Glutathion; Isethion; Tathion; Glutathione-SH; Glutinal; reduced glutathione; Neuthion; Deltathione; Copren; L-Glutathione reduced; Glutide; Tathione; Triptide; Ledac; Glutatione; GSH; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Glutathione (reduced); Agifutol S; L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; glutathione red; gamma-L-Glutamylcysteinylglycine; red. glutathione
DMAHMT9 DT Small molecular drug
DMAHMT9 PC 124886
DMAHMT9 MW 307.33
DMAHMT9 FM C10H17N3O6S
DMAHMT9 IC InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1
DMAHMT9 CS C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DMAHMT9 IK RWSXRVCMGQZWBV-WDSKDSINSA-N
DMAHMT9 IU (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
DMAHMT9 CA CAS 70-18-8
DMAHMT9 CB CHEBI:16856
DMAHMT9 DE Human immunodeficiency virus infection
DMGE0CW ID DMGE0CW
DMGE0CW DN Glutethimide
DMGE0CW HS Approved
DMGE0CW SN Alfimid; Doriden; Dorimide; Elrodorm; Gimid; Glimid; Glutathimid; Glutethimid; Glutethimidum; Glutetimid; Glutetimida; Glutetimide; Glutetimidu; Gluthetimide; Noxiron; Noxyron; Ondasil; Rigenox; Sarodormin; Glutetimide [DCIT]; Glutetimidu [Polish]; CC 11511; LT00114358; Doriden (TN); Doriden-sed; Glutethimide [INN:BAN]; Glutethimidum [INN-Latin]; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); Phenyl-aethyl-glutarsaeureimid; Phenyl-aethyl-glutarsaeureimid [German]; Alpha-Ethyl-alpha-phenylglutarimide; Alpha-Phenyl-alpha-ethylglutaric acid imide; Alpha-Phenyl-alpha-ethylglutarimide; 2-Ethyl-2-phenylglutarimide; 2-Phenyl-2-ethylglutaric acid imide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; 3-Ethyl-3-phenyl-2,6-piperidinedione; 3-Phenyl-3-ethyl-2,6-diketopiperidine; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; 3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW TC Hypnotics and Sedatives
DMGE0CW DT Small molecular drug
DMGE0CW PC 3487
DMGE0CW MW 217.26
DMGE0CW FM C13H15NO2
DMGE0CW IC InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)
DMGE0CW CS CCC1(CCC(=O)NC1=O)C2=CC=CC=C2
DMGE0CW IK JMBQKKAJIKAWKF-UHFFFAOYSA-N
DMGE0CW IU 3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW CA CAS 77-21-4
DMGE0CW CB CHEBI:5439
DMGE0CW DE Insomnia
DMDGRQO ID DMDGRQO
DMDGRQO DN Glycerol phenylbutyrate
DMDGRQO HS Approved
DMDGRQO SN GT4P; HPN-100; Glyceryl tri-(4-phenylbutyrate)
DMDGRQO CP Ucyclyd Pharma Inc
DMDGRQO DT Small molecular drug
DMDGRQO PC 10482134
DMDGRQO MW 530.6
DMDGRQO FM C33H38O6
DMDGRQO IC InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2
DMDGRQO CS C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
DMDGRQO IK ZSDBFLMJVAGKOU-UHFFFAOYSA-N
DMDGRQO IU 2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate
DMDGRQO CA CAS 611168-24-2
DMDGRQO CB CHEBI:134745
DMDGRQO DE Hepatic encephalopathy
DMIOZ29 ID DMIOZ29
DMIOZ29 DN Glycine
DMIOZ29 HS Approved
DMIOZ29 SN Aciport; Aminoazijnzuur; Aminoessigsaeure; Amitone; Corilin; Glicina; Glicoamin; Gly; Glycin; Glycinum; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Hgly; Leimzucker; Padil; Polyglycine; Acide aminoacetique; Acido aminoacetico; Acidum aminoaceticum; Aminoacetic acid; Aminoethanoic acid; An alpha amino acid ester; Glycine [INN]; Hampshire glycine; Polyglycine II; Sucre de gelatine; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; GLY (IUPAC abbrev); GLYCINE, ACS; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Gyn-hydralin; L-Glycine; S04-0135; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; GLYCINE 1.5% IN PLASTIC CONTAINER; Glycine (JP15/USP); Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; H-Gly-OH; H2N-CH2-COOH; L-alpha-amino acids; (1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid
DMIOZ29 TC Dietary supplement
DMIOZ29 DT Small molecular drug
DMIOZ29 PC 750
DMIOZ29 MW 75.07
DMIOZ29 FM C2H5NO2
DMIOZ29 IC InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)
DMIOZ29 CS C(C(=O)O)N
DMIOZ29 IK DHMQDGOQFOQNFH-UHFFFAOYSA-N
DMIOZ29 IU 2-aminoacetic acid
DMIOZ29 CA CAS 56-40-6
DMIOZ29 CB CHEBI:15428
DMIOZ29 DE Malnutrition
DM1WL9O ID DM1WL9O
DM1WL9O DN Glycodiazine
DM1WL9O HS Approved
DM1WL9O SN GLYMIDINE; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German]; Gondafon (TN); N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
DM1WL9O TC Hypoglycemic Agents
DM1WL9O DT Small molecular drug
DM1WL9O PC 9565
DM1WL9O MW 309.34
DM1WL9O FM C13H15N3O4S
DM1WL9O IC InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)
DM1WL9O CS COCCOC1=CN=C(N=C1)NS(=O)(=O)C2=CC=CC=C2
DM1WL9O IK QFWPJPIVLCBXFJ-UHFFFAOYSA-N
DM1WL9O IU N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
DM1WL9O CA CAS 339-44-6
DM1WL9O CB CHEBI:146188
DM1WL9O DE Diabetic complication
DM2M3ZA ID DM2M3ZA
DM2M3ZA DN Glycopyrrolate
DM2M3ZA HS Approved
DM2M3ZA SN GLYCOPYRROLATE; 596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide
DM2M3ZA CP Novartis
DM2M3ZA TC Anticholinergic Agents
DM2M3ZA DT Small molecular drug
DM2M3ZA PC 11693
DM2M3ZA MW 398.3
DM2M3ZA FM C19H28BrNO3
DM2M3ZA IC InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
DM2M3ZA CS C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DM2M3ZA IK VPNYRYCIDCJBOM-UHFFFAOYSA-M
DM2M3ZA IU (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DM2M3ZA CA CAS 596-51-0
DM2M3ZA CB CHEBI:90972
DM2M3ZA DE Anaesthesia; Chronic obstructive pulmonary disease
DMGVJLB ID DMGVJLB
DMGVJLB DN GMA-161
DMGVJLB HS Approved (orphan drug)
DMGVJLB CP MacroGenics & Genzyme
DMGVJLB DE Idiopathic thrombocytopenic purpura
DMHZV7X ID DMHZV7X
DMHZV7X DN Golimumab
DMHZV7X HS Approved
DMHZV7X SN Simponi (TN); Golimumab (USAN/INN)
DMHZV7X CP Takeda
DMHZV7X DT Antibody
DMHZV7X DE Rheumatoid arthritis; Inflammatory bowel disease
DMAQ469 ID DMAQ469
DMAQ469 DN Gonadorelin
DMAQ469 HS Approved
DMAQ469 SN Dirigestran; Factrel; Fertagyl; Gonadorelina; Gonadorelinum; Hypocrine; Kryptocur; LFRH; LHFSHRH; Luforan; Luliberin; Lutal; Lutamin; Lutrefact; Relefact; Relisorm; Dirigestran Spofa; Gonadoliberin I; Gonadotropin releasing hormone; LHFSH Releasing Hormone; LUTEINIZING HORMONE; Lutrepulse KIT; MammalianGnRH; Relisorm l; Synthetic LRF; Synthetic gonadoliberin; HOE 471; AY-24031; FSH-Releasing Hormone; Fertagyl (TN); GnRH-I; Gonadorelin (INN); Gonadorelin [INN:BAN]; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone I; Human LH-RH; LH-FSH Releasing Hormone; LH-Releasing hormone; Luteinizing hormone-releasing hormone; Mammalian LH-RH; Mammalian gonadotropin-releasing hormone; Ovine LH-RH; Ovine gonadotropin-releasing hormone; Porchine LH-RH; Porcine LH-releasing factor; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; Synthetic gonadotropin-releasing hormone; LH-RH (swine); LH-Releasing factor (pig); LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing factor (swine); Luteinizing hormone-releasing hormone (swin); Synthetic LH-FSH-RH; Synthetic decapeptide FSH/LH-RH; Follicle-stimulating hormone-releasing factor (pig); Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Synthetic LH-RH/FSH-RH; Synthetic LH-releasing hormone/FSH-releasing hormone; PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
DMAQ469 CP Hikma (Maple) Ltd
DMAQ469 TC Fertility Agents
DMAQ469 DT Small molecular drug
DMAQ469 PC 638793
DMAQ469 MW 1182.3
DMAQ469 FM C55H75N17O13
DMAQ469 IC InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMAQ469 CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAQ469 IK XLXSAKCOAKORKW-AQJXLSMYSA-N
DMAQ469 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAQ469 CA CAS 9034-40-6
DMAQ469 CB CHEBI:5520
DMAQ469 DE Hypothalamic hypogonadism
DMAT8CG ID DMAT8CG
DMAT8CG DN Goserelin
DMAT8CG HS Approved
DMAT8CG SN AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)
DMAT8CG CP Zeneca Pharmaceuticals
DMAT8CG TC Anticancer Agents
DMAT8CG DT Small molecular drug
DMAT8CG PC 5311128
DMAT8CG MW 1269.4
DMAT8CG FM C59H84N18O14
DMAT8CG IC InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
DMAT8CG CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAT8CG IK BLCLNMBMMGCOAS-URPVMXJPSA-N
DMAT8CG IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAT8CG CA CAS 65807-02-5
DMAT8CG CB CHEBI:5523
DMAT8CG DE Breast cancer
DMPT74U ID DMPT74U
DMPT74U DN Gramicidin D
DMPT74U HS Approved
DMPT74U SN Gramicidins; Gramoderm; Gramacidine S; Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidina D; Gramicidina S; Gramicidinum S; Neosporin Ophthalmic Solution; Gramicin S 1; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin [INN:BAN]; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S-A; Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); 1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine)
DMPT74U TC Antibiotics
DMPT74U DT Small molecular drug
DMPT74U PC 45267103
DMPT74U MW 1811.2
DMPT74U FM C96H135N19O16
DMPT74U IC InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1
DMPT74U CS C[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC=O
DMPT74U IK NDAYQJDHGXTBJL-MWWSRJDJSA-N
DMPT74U IU (2R)-2-[[2-[[(2S)-2-formamido-3-methylbutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-(2-hydroxyethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-4-methylpentanamide
DMPT74U CA CAS 1405-97-6
DMPT74U DE Bacterial infection
DMIUW25 ID DMIUW25
DMIUW25 DN Granisetron
DMIUW25 HS Approved
DMIUW25 SN BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
DMIUW25 CP Roche Pharmaceuticals
DMIUW25 TC Antiemetics
DMIUW25 DT Small molecular drug
DMIUW25 PC 5284566
DMIUW25 MW 312.4
DMIUW25 FM C18H24N4O
DMIUW25 IC InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+
DMIUW25 CS CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMIUW25 IK MFWNKCLOYSRHCJ-AGUYFDCRSA-N
DMIUW25 IU 1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
DMIUW25 CA CAS 109889-09-0
DMIUW25 CB CHEBI:5537
DMIUW25 DE Nausea and vomiting
DMGLX0T ID DMGLX0T
DMGLX0T DN Grepafloxacin
DMGLX0T HS Approved
DMGLX0T SN Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T CP GlaxoSmithKline
DMGLX0T TC Antibiotics
DMGLX0T DT Small molecular drug
DMGLX0T PC 72474
DMGLX0T MW 359.4
DMGLX0T FM C19H22FN3O3
DMGLX0T IC InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)
DMGLX0T CS CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
DMGLX0T IK AIJTTZAVMXIJGM-UHFFFAOYSA-N
DMGLX0T IU 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T CA CAS 119914-60-2
DMGLX0T CB CHEBI:5543
DMGLX0T DE Chronic bronchitis; Bacterial infection
DMK54YG ID DMK54YG
DMK54YG DN Griseofulvin
DMK54YG HS Approved
DMK54YG SN Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione
DMK54YG TC Antifungal Agents
DMK54YG DT Small molecular drug
DMK54YG PC 441140
DMK54YG MW 352.8
DMK54YG FM C17H17ClO6
DMK54YG IC InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1
DMK54YG CS C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
DMK54YG IK DDUHZTYCFQRHIY-RBHXEPJQSA-N
DMK54YG IU (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
DMK54YG CA CAS 126-07-8
DMK54YG CB CHEBI:27779
DMK54YG DE Ringworm infection
DM1ECNJ ID DM1ECNJ
DM1ECNJ DN GS-7340
DM1ECNJ HS Approved
DM1ECNJ SN Tenofovir alafenamide; Vemlidy
DM1ECNJ CP Gilead Sciences
DM1ECNJ DT Small molecular drug
DM1ECNJ PC 9574768
DM1ECNJ MW 476.5
DM1ECNJ FM C21H29N6O5P
DM1ECNJ IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DM1ECNJ CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3
DM1ECNJ IK LDEKQSIMHVQZJK-CAQYMETFSA-N
DM1ECNJ IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DM1ECNJ CA CAS 379270-37-8
DM1ECNJ CB CHEBI:90926
DM1ECNJ DE Human immunodeficiency virus infection; Hepatitis B virus infection
DM8QB0T ID DM8QB0T
DM8QB0T DN GSK2592984A
DM8QB0T HS Approved
DM8QB0T SN GSK-2340269A; GSK-2340272A; Pandemrix (H1N1); H1N1 pandemic influenzavaccine (AS03 adjuvanted) 1, GlaxoSmithKline; H1N1 pandemic influenza vaccine 1 (AS03 adjuvanted), GSK; Influenza vaccines (intramuscular, influenza virus infection), GlaxoSmithKline
DM8QB0T CP GlaxoSmithKline plc
DM8QB0T DT Vaccine
DM8QB0T DE Influenza virus infection
DM5QWEL ID DM5QWEL
DM5QWEL DN Guanabenz
DM5QWEL HS Approved
DM5QWEL SN GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL CP Eon Labs Manufacturing
DM5QWEL TC Sympatholytics
DM5QWEL DT Small molecular drug
DM5QWEL PC 5702063
DM5QWEL MW 231.08
DM5QWEL FM C8H8Cl2N4
DM5QWEL IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
DM5QWEL CS C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
DM5QWEL IK WDZVGELJXXEGPV-YIXHJXPBSA-N
DM5QWEL IU 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL CA CAS 60329-03-5
DM5QWEL CB CHEBI:5553
DM5QWEL DE High blood pressure
DM6S157 ID DM6S157
DM6S157 DN Guanadrel Sulfate
DM6S157 HS Approved
DM6S157 SN Hylorel; Hyloride; Guanadrel sulfate [USAN]; CL 1388R; U 28288D; CL-1388R; Guanadrel sulfate (USP); Hylorel (TN); U 28,288D; U-28288D; Guanadrel sulfate (2:1); Guanidine (1,4-dioxaspiro(4.5)dec-2-ylmethyl)-, sulfate (2:1); (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine sulfate (2:1); 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine
DM6S157 TC Antihypertensive Agents
DM6S157 DT Small molecular drug
DM6S157 PC 68552
DM6S157 MW 524.6
DM6S157 FM C20H40N6O8S
DM6S157 IC InChI=1S/2C10H19N3O2.H2O4S/c2*11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10;1-5(2,3)4/h2*8H,1-7H2,(H4,11,12,13);(H2,1,2,3,4)
DM6S157 CS C1CCC2(CC1)OCC(O2)CN=C(N)N.C1CCC2(CC1)OCC(O2)CN=C(N)N.OS(=O)(=O)O
DM6S157 IK RTEVGQJRTFFMLL-UHFFFAOYSA-N
DM6S157 IU 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine;sulfuric acid
DM6S157 CA CAS 22195-34-2
DM6S157 CB CHEBI:5556
DM6S157 DE Hypertension
DM9NSWT ID DM9NSWT
DM9NSWT DN Guanethidine
DM9NSWT HS Approved
DM9NSWT SN Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT CP Norvatis Phamaceuticals Corporation
DM9NSWT TC Antihypertensive Agents
DM9NSWT DT Small molecular drug
DM9NSWT PC 3518
DM9NSWT MW 198.31
DM9NSWT FM C10H22N4
DM9NSWT IC InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)
DM9NSWT CS C1CCCN(CCC1)CCN=C(N)N
DM9NSWT IK ACGDKVXYNVEAGU-UHFFFAOYSA-N
DM9NSWT IU 2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT CA CAS 55-65-2
DM9NSWT CB CHEBI:5557
DM9NSWT DE Moderate and severe hypertension
DMB1CZ8 ID DMB1CZ8
DMB1CZ8 DN Guanfacine extended release
DMB1CZ8 HS Approved
DMB1CZ8 SN Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0)
DMB1CZ8 CP Shire
DMB1CZ8 DT Small molecular drug
DMB1CZ8 PC 4671
DMB1CZ8 MW 299.5
DMB1CZ8 FM C18H37NO2
DMB1CZ8 IC InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
DMB1CZ8 CS CCCCCCCCCCCCCCCC(=O)NCCO
DMB1CZ8 IK HXYVTAGFYLMHSO-UHFFFAOYSA-N
DMB1CZ8 IU N-(2-hydroxyethyl)hexadecanamide
DMB1CZ8 CA CAS 544-31-0
DMB1CZ8 CB CHEBI:71464
DMB1CZ8 DE Attention deficit hyperactivity disorder
DM0P63W ID DM0P63W
DM0P63W DN Guanidine Hydrochloride
DM0P63W HS Approved
DM0P63W SN Guanidine hydrochloride; 1950/1/1; Guanidinium chloride; Guanidine, monohydrochloride; guanidine HCl; Aminoformamidine hydrochloride; Aminomethanamidine hydrochloride; GUANIDINE MONOHYDROCHLORIDE; Guanidine chloride; Iminourea hydrochloride; Carbamidine hydrochloride; Guanidinium hydrochloride; Guanidine (hydrochloride); UNII-3YQC9ZY4YB; Guanidium chloride; USAF EK-749; Guanidine, hydrochloride (1:1); EINECS 200-002-3; 3YQC9ZY4YB; AI3-19014; MFCD00013026; Guanidine Hydrochloride, ULTROL& Grade; Guanidinehydrochloride
DM0P63W CP Merck Sharp And Dohme Corp
DM0P63W TC Neurology Agents
DM0P63W DT Small molecular drug
DM0P63W PC 5742
DM0P63W MW 95.53
DM0P63W FM CH6ClN3
DM0P63W IC InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H
DM0P63W CS C(=N)(N)N.Cl
DM0P63W IK PJJJBBJSCAKJQF-UHFFFAOYSA-N
DM0P63W IU guanidine;hydrochloride
DM0P63W CA CAS 50-01-1
DM0P63W CB CHEBI:32735
DM0P63W DE Muscle fatigue
DMP7LK1 ID DMP7LK1
DMP7LK1 DN Guggulsterone
DMP7LK1 HS Approved
DMP7LK1 SN Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-; Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE
DMP7LK1 TC Antiinflammatory Agents
DMP7LK1 DT Small molecular drug
DMP7LK1 PC 6450278
DMP7LK1 MW 312.4
DMP7LK1 FM C21H28O2
DMP7LK1 IC InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1
DMP7LK1 CS C/C=C/1\\C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMP7LK1 IK WDXRGPWQVHZTQJ-OSJVMJFVSA-N
DMP7LK1 IU (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione
DMP7LK1 CA CAS 39025-23-5
DMP7LK1 CB CHEBI:135338
DMP7LK1 DE Osteoarthritis
DMV4KOA ID DMV4KOA
DMV4KOA DN GW642444
DMV4KOA HS Approved
DMV4KOA SN Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester
DMV4KOA CP GSK
DMV4KOA DT Small molecular drug
DMV4KOA PC 21880659
DMV4KOA MW 486.4
DMV4KOA FM C24H33Cl2NO5
DMV4KOA IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2
DMV4KOA CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl
DMV4KOA IK DAFYYTQWSAWIGS-UHFFFAOYSA-N
DMV4KOA IU 4-[2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMV4KOA DE Asthma
DML72VJ ID DML72VJ
DML72VJ DN GW685698X
DML72VJ HS Approved
DML72VJ SN Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
DML72VJ CP GSK
DML72VJ DT Small molecular drug
DML72VJ PC 9854489
DML72VJ MW 538.6
DML72VJ FM C27H29F3O6S
DML72VJ IC InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
DML72VJ CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
DML72VJ IK XTULMSXFIHGYFS-VLSRWLAYSA-N
DML72VJ IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
DML72VJ CA CAS 397864-44-7
DML72VJ CB CHEBI:74899
DML72VJ DE Asthma
DMFUAXT ID DMFUAXT
DMFUAXT DN H1N1 pandemic influenza A vaccine
DMFUAXT HS Approved
DMFUAXT SN Panflu; H1N1 pandemic influenza A vaccine, Sinovac; Panflu.1; Split viron vaccine (H1N1 influenza), Sinovac; Split viron vaccine + adjuvant (H1N1 influenza), Sinovac; Whole viron vaccine + adjuvant (H1N1 influenza), Sinovac
DMFUAXT CP Sinovac Biotech Ltd
DMFUAXT DT Vaccine
DMFUAXT DE Influenza virus infection
DMMHYLB ID DMMHYLB
DMMHYLB DN H5N1 influenza vaccine
DMMHYLB HS Approved
DMMHYLB SN IPSIV; Inactivated Polymer-Subunit H5N1 Influenza Vaccine; H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant); H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant), Microgen
DMMHYLB CP Glaxosmithkline; novavax; vaxart
DMMHYLB DT Vaccine
DMMHYLB DE Human immunodeficiency virus infection
DM7JNTV ID DM7JNTV
DM7JNTV DN Halaven
DM7JNTV HS Approved
DM7JNTV SN Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
DM7JNTV CP Eisai Woodcliff Lake, NJ
DM7JNTV PC 17755248
DM7JNTV MW 826
DM7JNTV FM C41H63NO14S
DM7JNTV IC InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1
DM7JNTV CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
DM7JNTV IK QAMYWGZHLCQOOJ-WRNBYXCMSA-N
DM7JNTV IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid
DM7JNTV CA CAS 441045-17-6
DM7JNTV CB CHEBI:70710
DM7JNTV DE Bladder cancer; Breast cancer
DMPFWO6 ID DMPFWO6
DMPFWO6 DN Halazepam
DMPFWO6 HS Approved
DMPFWO6 SN Halazepamum; Pacinone; Paxipam; Sch 12041; Schering 12041; Alapryl (TN); Halazepamum [INN-Latin]; Pacinone (TN); Paxipam (TN); Sch-12041; Halazepam (USAN/INN); Halazepam [USAN:BAN:INN]; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on
DMPFWO6 TC Antianxiety Agents
DMPFWO6 DT Small molecular drug
DMPFWO6 PC 31640
DMPFWO6 MW 352.7
DMPFWO6 FM C17H12ClF3N2O
DMPFWO6 IC InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
DMPFWO6 CS C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F
DMPFWO6 IK WYCLKVQLVUQKNZ-UHFFFAOYSA-N
DMPFWO6 IU 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one
DMPFWO6 CA CAS 23092-17-3
DMPFWO6 CB CHEBI:5603
DMPFWO6 DE Anxiety disorder
DMGLAX1 ID DMGLAX1
DMGLAX1 DN Halcinonide
DMGLAX1 HS Approved
DMGLAX1 SN Halog; Halog-e
DMGLAX1 CP Ranbaxy Laboratories Inc
DMGLAX1 DT Small molecular drug
DMGLAX1 PC 443943
DMGLAX1 MW 455
DMGLAX1 FM C24H32ClFO5
DMGLAX1 IC InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMGLAX1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F
DMGLAX1 IK MUQNGPZZQDCDFT-JNQJZLCISA-N
DMGLAX1 IU (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMGLAX1 CA CAS 3093-35-4
DMGLAX1 CB CHEBI:31663
DMGLAX1 DE Skin disease
DM3GB6S ID DM3GB6S
DM3GB6S DN Halobetasol propionate
DM3GB6S HS Approved
DM3GB6S SN Halobetasol; Miracorten; Ultravate; Halobetasol propionate [USAN]; Ulobetasol cream; Ulobetasol propionate; BMY 30056; CGP 14 458; CGP 14458; BMY-30056; CGP-14458; Halobetasol propionate (USAN); Ultravate (TN); [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; 6 alpha-fluoroclobetasol 17-propionate; 6-fluoroclobetasol 17-propionate
DM3GB6S TC Antiinflammatory Agents
DM3GB6S DT Small molecular drug
DM3GB6S PC 6918178
DM3GB6S MW 485
DM3GB6S FM C25H31ClF2O5
DM3GB6S IC InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
DM3GB6S CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl
DM3GB6S IK BDSYKGHYMJNPAB-LICBFIPMSA-N
DM3GB6S IU [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DM3GB6S CA CAS 66852-54-8
DM3GB6S CB CHEBI:135782
DM3GB6S DE Inflammation
DMOMK1V ID DMOMK1V
DMOMK1V DN Halofantrine
DMOMK1V HS Approved
DMOMK1V SN Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
DMOMK1V CP GlaxoSmithKline
DMOMK1V TC Antimalarials
DMOMK1V DT Small molecular drug
DMOMK1V PC 37393
DMOMK1V MW 500.4
DMOMK1V FM C26H30Cl2F3NO
DMOMK1V IC InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
DMOMK1V CS CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O
DMOMK1V IK FOHHNHSLJDZUGQ-UHFFFAOYSA-N
DMOMK1V IU 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
DMOMK1V CA CAS 69756-53-2
DMOMK1V CB CHEBI:94392
DMOMK1V DE Malaria
DM96SE0 ID DM96SE0
DM96SE0 DN Haloperidol
DM96SE0 HS Approved
DM96SE0 SN Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]
DM96SE0 CP Janssen Pharmaceutica
DM96SE0 TC Antipsychotic Agents
DM96SE0 DT Small molecular drug
DM96SE0 PC 3559
DM96SE0 MW 375.9
DM96SE0 FM C21H23ClFNO2
DM96SE0 IC InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM96SE0 CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
DM96SE0 IK LNEPOXFFQSENCJ-UHFFFAOYSA-N
DM96SE0 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM96SE0 CA CAS 52-86-8
DM96SE0 CB CHEBI:5613
DM96SE0 DE Schizophrenia
DMH4IVU ID DMH4IVU
DMH4IVU DN Haloprogin
DMH4IVU HS Approved
DMH4IVU SN Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
DMH4IVU TC Antifungal Agents
DMH4IVU DT Small molecular drug
DMH4IVU PC 3561
DMH4IVU MW 361.4
DMH4IVU FM C9H4Cl3IO
DMH4IVU IC InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
DMH4IVU CS C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
DMH4IVU IK CTETYYAZBPJBHE-UHFFFAOYSA-N
DMH4IVU IU 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene
DMH4IVU CA CAS 777-11-7
DMH4IVU CB CHEBI:5614
DMH4IVU DE Dermatophytosis; Candidiasis
DM80OZ5 ID DM80OZ5
DM80OZ5 DN Halothane
DM80OZ5 HS Approved
DM80OZ5 SN Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan
DM80OZ5 TC Anesthetics
DM80OZ5 DT Small molecular drug
DM80OZ5 PC 3562
DM80OZ5 MW 197.38
DM80OZ5 FM C2HBrClF3
DM80OZ5 IC InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
DM80OZ5 CS C(C(F)(F)F)(Cl)Br
DM80OZ5 IK BCQZXOMGPXTTIC-UHFFFAOYSA-N
DM80OZ5 IU 2-bromo-2-chloro-1,1,1-trifluoroethane
DM80OZ5 CA CAS 151-67-7
DM80OZ5 CB CHEBI:5615
DM80OZ5 DE Anaesthesia
DMN0S1G ID DMN0S1G
DMN0S1G DN HEGF
DMN0S1G HS Approved
DMN0S1G CP Bharat Biotech
DMN0S1G DE Diabetic foot ulcer
DMEVXY6 ID DMEVXY6
DMEVXY6 DN Heparin Calcium
DMEVXY6 HS Approved
DMEVXY6 SN Calciparine
DMEVXY6 CP Sanofi Aventis Us Llc
DMEVXY6 TC Cardiovascular Agents
DMEVXY6 DE Coagulation defect
DM9KHZL ID DM9KHZL
DM9KHZL DN Heparin Sodium
DM9KHZL HS Approved
DM9KHZL SN (2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container
DM9KHZL CP Hospira Inc
DM9KHZL TC Cardiovascular Agents
DM9KHZL PC 92044406
DM9KHZL MW 1157.9
DM9KHZL FM C26H42N2NaO37S5+
DM9KHZL IC InChI=1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1
DM9KHZL CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
DM9KHZL IK JRTRSJGZMRQDHI-UHFFFAOYSA-N
DM9KHZL IU sodium;6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KHZL DE Deep vein thrombosis; Coagulation defect
DMOB2F3 ID DMOB2F3
DMOB2F3 DN Heptabarbital
DMOB2F3 HS Approved
DMOB2F3 SN Cycloheptenylethylmalonylurea; Heptabarb; Heptabarbe; Heptabarbitone; Heptabarbo; Heptabarbum; Heptadorm; Heptamal; Heptamalum; Heptbarbital; Medapan; Medomin; Medomine; Noctyn; Cycloheptenylethylbarbituric acid; G 475; Heptabarbe [INN-French]; Heptabarbo [INN-Spanish]; Heptabarbum [INN-Latin]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl-(9CI); 5-(1-CYCLOHEPTEN-1-YL)-5-ETHYLBARBITURIC ACID; 5-(1-Cyclohepten-1-yl)-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cycloheptenyl)-5-ethylbarbitursaeure; 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione; 5-Ethyl-5-(1'-cycloheptenyl)-barbituric acid; 5-Ethyl-5-cycloheptenylbarbituric acid
DMOB2F3 DT Small molecular drug
DMOB2F3 PC 10518
DMOB2F3 MW 250.29
DMOB2F3 FM C13H18N2O3
DMOB2F3 IC InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)
DMOB2F3 CS CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2
DMOB2F3 IK PAZQYDJGLKSCSI-UHFFFAOYSA-N
DMOB2F3 IU 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
DMOB2F3 CA CAS 509-86-4
DMOB2F3 CB CHEBI:81297
DMOB2F3 DE Anaesthesia
DM6YWBF ID DM6YWBF
DM6YWBF DN Herbimycin A
DM6YWBF HS Approved
DM6YWBF SN Herbimycin; Herbimycin A from Streptomyces hygroscopicus; Antibiotic Tan 420F; [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12Z,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate
DM6YWBF TC Anticancer Agents
DM6YWBF DT Small molecular drug
DM6YWBF PC 5311102
DM6YWBF MW 574.7
DM6YWBF FM C30H42N2O9
DM6YWBF IC InChI=1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1
DM6YWBF CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)/C)OC)OC(=O)N)\\C)C)OC)OC
DM6YWBF IK MCAHMSDENAOJFZ-BVXDHVRPSA-N
DM6YWBF IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DM6YWBF CA CAS 70563-58-5
DM6YWBF CB CHEBI:5674
DM6YWBF DE Solid tumour/cancer
DMDBWHY ID DMDBWHY
DMDBWHY DN Heroin diacetylmorphine
DMDBWHY HS Approved
DMDBWHY SN Diamorphine (TN)
DMDBWHY CP Bayer company
DMDBWHY DT Small molecular drug
DMDBWHY PC 5462328
DMDBWHY MW 369.4
DMDBWHY FM C21H23NO5
DMDBWHY IC InChI=1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1
DMDBWHY CS CC(=O)O[C@H]1C=C[C@H]2[C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C
DMDBWHY IK GVGLGOZIDCSQPN-PVHGPHFFSA-N
DMDBWHY IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate
DMDBWHY CA CAS 561-27-3
DMDBWHY CB CHEBI:27808
DMDBWHY DE Neurological disorder
DMKER83 ID DMKER83
DMKER83 DN Hesperetin
DMKER83 HS Approved
DMKER83 SN Hesperin; Hesperitin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone
DMKER83 TC Anticholesteremic Agents
DMKER83 DT Small molecular drug
DMKER83 PC 72281
DMKER83 MW 302.28
DMKER83 FM C16H14O6
DMKER83 IC InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
DMKER83 CS COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMKER83 IK AIONOLUJZLIMTK-AWEZNQCLSA-N
DMKER83 IU (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMKER83 CA CAS 520-33-2
DMKER83 CB CHEBI:28230
DMKER83 DE High blood cholesterol level
DMI5DW1 ID DMI5DW1
DMI5DW1 DN Hesperidin
DMI5DW1 HS Approved
DMI5DW1 SN hesperidin; 520-26-3; Cirantin; Hesperidoside; Hesper bitabs; Hesperetin-rutinosid; Hesperidine; UNII-E750O06Y6O; CCRIS 3940; (S)-(-)-Hesperidin; EINECS 208-288-1; NSC 44184; BRN 0075140; Hesperidin, (2S)-; Hesperetin 7-rutinoside; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; CHEBI:28775; USAF CF-3; Hesperidin, (S)-(-)-; Hesperitin-7-rhamnoglucoside; E750O06Y6O; C28H34O15; HESPERIDINE
DMI5DW1 DT Small molecular drug
DMI5DW1 PC 10621
DMI5DW1 MW 610.6
DMI5DW1 FM C28H34O15
DMI5DW1 IC InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
DMI5DW1 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
DMI5DW1 IK QUQPHWDTPGMPEX-QJBIFVCTSA-N
DMI5DW1 IU (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMI5DW1 CA CAS 520-26-3
DMI5DW1 CB CHEBI:28775
DMI5DW1 DE Vascular purpura
DMPXITB ID DMPXITB
DMPXITB DN Hetacillin
DMPXITB HS Approved
DMPXITB SN Etacillina; Hetacilina; Hetacilline; Hetacillinum; Phenazacillin; Versapen; Etacillina [DCIT]; HETACILLIN POTASSIUM; BRL 804; BL-P 804; BRL-804; Hetacilina [INN-Spanish]; Hetacilline [INN-French]; Hetacillinum [INN-Latin]; Versapen (TN); Hetacillin (USAN/INN); Hetacillin [USAN:INN:BAN]; N,N'-Isopropylidene-A-amino-benzyl penicillin; (2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (2S,5R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure; 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
DMPXITB CP Bristol Laboratories Inc Div Bristol Myers Co
DMPXITB TC Antibiotics
DMPXITB DT Small molecular drug
DMPXITB PC 443387
DMPXITB MW 389.5
DMPXITB FM C19H23N3O4S
DMPXITB IC InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1
DMPXITB CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C
DMPXITB IK DXVUYOAEDJXBPY-NFFDBFGFSA-N
DMPXITB IU (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMPXITB CA CAS 3511-16-8
DMPXITB CB CHEBI:5683
DMPXITB DE Bacterial infection
DMGUC9T ID DMGUC9T
DMGUC9T DN HEV-239
DMGUC9T HS Approved
DMGUC9T SN Hecolin; Bacterially-expressed hepatitis E vaccine, Xiamen Innovax Biotech; Hepatitis E vaccine (recombinant), Xiamen Innovax Biotech; Hepatitis E vaccine (alum-adjuvanted), Xiamen Innovax Biotech
DMGUC9T CP Beijing Wantai Biological Pharmacy Enterprise Co Ltd
DMGUC9T DT Vaccine
DMGUC9T DE Hepatitis E virus infection
DMLKSE0 ID DMLKSE0
DMLKSE0 DN Hexachlorophene
DMLKSE0 HS Approved
DMLKSE0 SN Acigena; Almederm; Armohex; Bilevon; Bivelon; Cotofilm; Dermadex; Distodin; Eleven; Esaclorofene; Exofene; Fascol; Fomac; Fostril; Gamophen; Gamophene; Hexabalm; Hexachlorofen; Hexachlorophane; Hexachlorophen; Hexachlorophenum; Hexaclorofeno; Hexafen; Hexascrub; Hexide; Hexophene; Hexosan; Isobac; Nabac; PHisoHex; Phisodan; Ritosept; Septisol; Septofen; Steral; Steraskin; Surofene; TRICHLOROPHENE; Tersaseptic; Trisophen; Turgex; Blockade Anti Bacterial Finish; Brevity Blue Liquid Bacteriostatic Scouring Cream; Brevity Blue Liquid Sanitizing Scouring Cream; Enditch Pet Shampoo; Esaclorofene [DCIT]; Fo stril; Hexachlorofen [Czech]; Hexachlorophene [INN]; Hilo Cat Flea Powder; Hilo Flea Powder; Neosept V; Pedigree Dog Shampoo Bar; Scrubteam Surgical Spongebrush; Staphene O; AT 7; B 32; H3P; Hexachlorophene [UN2875] [Poison]; KUC106447N; M0219; Nabac 25 ec; AT-7; AT17 (TN); AT7 (TN); Acigena (TN); Almederm (TN); At-17; B & b Flea Kontroller for Dogs Only; B 32 (VAN); Bilevon (TN); E-Z Scrub; En-Viron D Concentrated Phenolic Disinfectant; Exofene (TN); Fesia-sin; Fostril (TN); G-11; G-Eleven; G-II; Gamophen (TN); Germa-Medica; Hexa-Germ; Hexachlorophene, Pharma; Hexachlorophenum [INN-Latin]; Hexaclorofeno [INN-Spanish]; Hexaphene-LV; Hexosan (TN); PRE-OP II; Phiso-Scrub; Phisohex(TN); Pre-Op; Septi-Soft; Septisol (TN); Solu-Heks; Soy-dome; Ster-zac; Surgi-Cen; Surgi-Cin; Surofene (TN); Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; G-11 (TN); GERMA-MEDICA (MG); Germa-Medica (TN); Hexachlorophene (USP/INN); KSC-19-051; Methylenebis(3,4,6-trichlorophenol); Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-Methylene bis(3,4,6-trichlorophenol); 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2'-Methylenebis[3,4,6-trichlorophenol]; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2-Methylene-bis-[3,4,6-trichlorophenol]; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0 TC Antiinfective Agents
DMLKSE0 DT Small molecular drug
DMLKSE0 PC 3598
DMLKSE0 MW 406.9
DMLKSE0 FM C13H6Cl6O2
DMLKSE0 IC InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2
DMLKSE0 CS C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl
DMLKSE0 IK ACGUYXCXAPNIKK-UHFFFAOYSA-N
DMLKSE0 IU 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0 CA CAS 70-30-4
DMLKSE0 CB CHEBI:5693
DMLKSE0 DE Bacterial infection
DMFY307 ID DMFY307
DMFY307 DN Hexafluronium bromide
DMFY307 HS Approved
DMFY307 SN Hexafluorenium; Milaxen; Mylaxen; Bromuro de hexafluronio; Esafluronio bromuro; Esafluronio bromuro [DCIT]; Hexafluorenium bromide; Hexafluorenium bromide [USAN]; Hexafluorenium dibromide; Hexafluorenium dibromide salt; Hexafluronii bromidum; Bromure d'hexafluronium; Bromuro de hexafluronio [INN-Spanish]; Hexafluorenium bromide (USAN); Hexafluronii bromidum [INN-Latin]; Hexafluronium bromide (INN); IN-117; Mylaxen (TN); Bromure d'hexafluronium [INN-French]; Hexamethylene bis(9-fluorenyldimethylammonium)dibromide; Hexamethylenebis(9-fluorenyldimethylammonium bromide); Hexamethylenebis(dimethyl-9-fluorenylammonium bromide); Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide; AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE; Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide; N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid); 1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide; 1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide
DMFY307 TC Analgesics
DMFY307 DT Small molecular drug
DMFY307 PC 9434
DMFY307 MW 662.5
DMFY307 FM C36H42Br2N2
DMFY307 IC InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
DMFY307 CS C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-]
DMFY307 IK WDEFPRUEZRUYNW-UHFFFAOYSA-L
DMFY307 IU 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide
DMFY307 CA CAS 317-52-2
DMFY307 DE Spasm
DMQ314B ID DMQ314B
DMQ314B DN Hexobarbital
DMQ314B HS Approved
DMQ314B SN Barbidorm; Citodon; Citopan; Cyclonal; Cyclopan; Dorico; Enhexymal; Enhexymalum; Esobarbitale; Evipal; Evipan; Hexabarbital;Hexobarbitalum; Hexobarbitone; Hexobarbitonum; Methexenyl; Methylhexabarbital; Methylhexabital; Narcosan; Noctivane; Sombucaps; Sombulex; Somnalert; Esobarbitale [DCIT]; Esobarbitale [Italian]; Hexanastab oral; Sodium hexobarbital; Citopan (TN); Evipan (TN); Hexenal (barbiturate); Hexobarbital (VAN); Hexobarbital [INN:JAN]; Hexobarbitalum [INN-Latin]; Hexobarbital (JAN/INN); N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; (+-)-Hexobarbital; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-(delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione
DMQ314B TC Hypnotics and Sedatives
DMQ314B DT Small molecular drug
DMQ314B PC 3608
DMQ314B MW 236.27
DMQ314B FM C12H16N2O3
DMQ314B IC InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
DMQ314B CS CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2
DMQ314B IK UYXAWHWODHRRMR-UHFFFAOYSA-N
DMQ314B IU 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
DMQ314B CA CAS 56-29-1
DMQ314B CB CHEBI:5706
DMQ314B DE Anaesthesia
DMEADRK ID DMEADRK
DMEADRK DN Hexylcaine
DMEADRK HS Approved
DMEADRK SN Hexilcaina; Hexylcainum; Osmocaine; Hexylcaine [INN]; Cyclaine (TN); Hexilcaina [INN-Spanish]; Hexylcainum [INN-Latin]; Osmocaine (TN); (2-Cyclohexylamino-1-methylethyl) benzoate; 1-(Cyclohexylamino)-2-propanol benzoate (ester); 1-(cyclohexylamino)propan-2-yl benzoate; 2-Propanol, 1-(cyclohexylamino)-, benzoate (ester)
DMEADRK CP Merck & Co
DMEADRK TC Anesthetics
DMEADRK DT Small molecular drug
DMEADRK PC 10770
DMEADRK MW 261.36
DMEADRK FM C16H23NO2
DMEADRK IC InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
DMEADRK CS CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2
DMEADRK IK DKLKMKYDWHYZTD-UHFFFAOYSA-N
DMEADRK IU 1-(cyclohexylamino)propan-2-yl benzoate
DMEADRK CA CAS 532-77-4
DMEADRK CB CHEBI:34791
DMEADRK DE Anaesthesia
DMV7IM6 ID DMV7IM6
DMV7IM6 DN Histamine Phosphate
DMV7IM6 HS Approved
DMV7IM6 SN Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
DMV7IM6 TC Diagnostic Agents
DMV7IM6 DT Small molecular drug
DMV7IM6 PC 65513
DMV7IM6 MW 307.14
DMV7IM6 FM C5H15N3O8P2
DMV7IM6 IC InChI=1S/C5H9N3.2H3O4P/c6-2-1-5-3-7-4-8-5;2*1-5(2,3)4/h3-4H,1-2,6H2,(H,7,8);2*(H3,1,2,3,4)
DMV7IM6 CS C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O
DMV7IM6 IK ZHIBQGJKHVBLJJ-UHFFFAOYSA-N
DMV7IM6 IU 2-(1H-imidazol-5-yl)ethanamine;phosphoric acid
DMV7IM6 CA CAS 51-74-1
DMV7IM6 CB CHEBI:51193
DMV7IM6 DE Diagnostic imaging
DMGBPSH ID DMGBPSH
DMGBPSH DN Homatropine Methylbromide
DMGBPSH HS Approved
DMGBPSH SN Arkitropin; Camatropine; Equipin; Esopin; Homapin; Homatromide; Malcotran; Mesopin; Methylhomatropine; Novatrin; Novatrine; Novatropine; Npvatropine; Sethyl; Homatropine methobromide; Homatropine methyl bromide; Homatropini methylbromidum; Humulon lead salt; Methyl Bromide Homatropine; Methylhomatropine bromide; Methylhomatropinum bromatum; Metilbromuro de homatropina; Omatropina metilbromuro; Omatropina metilbromuro [DCIT]; Tropinium methobromide mandelate; DL-Homatropine methyl bromide; DL-Methylbromide; Equipin (TN); Homapin-10; Homapin-5; Homatropine DL-methylbromide; Homatropine methylbromide (USP); Homatropine methylbromide [INN:BAN]; Homatropini methylbromidum [INN-Latin]; Hycodan, probilagol; Isopto Homatropine (TN); Methylbromure d'homatropine; Metilbromuro de homatropina [INN-Spanish]; N-Methylhomatropinium Bromide; Sed-Tems; Methylbromure d'homatropine [INN-French]; HOMATROPINIUM, 8-METHYL-, BROMIDE; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; 8-Methylhomatropinium bromide
DMGBPSH TC Antiulcer Agents
DMGBPSH DT Small molecular drug
DMGBPSH PC 10429215
DMGBPSH MW 370.3
DMGBPSH FM C17H24BrNO3
DMGBPSH IC InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15?,16?;
DMGBPSH CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-]
DMGBPSH IK FUFVKLQESJNNAN-ZZJGABIISA-M
DMGBPSH IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide
DMGBPSH CA CAS 80-49-9
DMGBPSH DE Uveitis; Peptic ulcer
DM78G6F ID DM78G6F
DM78G6F DN HTF 919
DM78G6F HS Approved
DM78G6F DT Small molecular drug
DM78G6F PC 60918
DM78G6F MW 301.39
DM78G6F FM C16H23N5O
DM78G6F IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)
DM78G6F CS CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC
DM78G6F IK IKBKZGMPCYNSLU-UHFFFAOYSA-N
DM78G6F IU 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM78G6F CA CAS 145158-71-0
DM78G6F DE Constipation
DMA5OBU ID DMA5OBU
DMA5OBU DN Human neutral insulin
DMA5OBU HS Approved
DMA5OBU DT Small molecular drug
DMA5OBU PC 16129672
DMA5OBU MW 5808
DMA5OBU FM C257H383N65O77S6
DMA5OBU IC InChI=1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1
DMA5OBU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMA5OBU IK PBGKTOXHQIOBKM-FHFVDXKLSA-N
DMA5OBU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMA5OBU DE Diabetic complication
DMPHVQ1 ID DMPHVQ1
DMPHVQ1 DN Human prothrombin complex concentrate
DMPHVQ1 HS Approved
DMPHVQ1 CP Octapharma usa
DMPHVQ1 SQ sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2: MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
DMPHVQ1 DE Bleeding disorder
DMMAWLU ID DMMAWLU
DMMAWLU DN Huperzine A
DMMAWLU HS Approved
DMMAWLU SN Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680
DMMAWLU DT Small molecular drug
DMMAWLU PC 854026
DMMAWLU MW 242.32
DMMAWLU FM C15H18N2O
DMMAWLU IC InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1
DMMAWLU CS C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3
DMMAWLU IK ZRJBHWIHUMBLCN-YQEJDHNASA-N
DMMAWLU IU (1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMMAWLU CA CAS 102518-79-6
DMMAWLU CB CHEBI:78330
DMMAWLU DE Alzheimer disease
DMX8M26 ID DMX8M26
DMX8M26 DN Hyaluronate sodium
DMX8M26 HS Approved
DMX8M26 DT Small molecular drug
DMX8M26 PC 3084049
DMX8M26 MW 799.6
DMX8M26 FM C28H44N2NaO23+
DMX8M26 IC InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1
DMX8M26 CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O.[Na+]
DMX8M26 IK YWIVKILSMZOHHF-QJZPQSOGSA-N
DMX8M26 IU sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMX8M26 CA CAS 9067-32-7
DMX8M26 DE Joint lubricant; Pancytopenia; Enthesopathy
DMETWAU ID DMETWAU
DMETWAU DN Hyaluronidase (ovine)
DMETWAU HS Approved
DMETWAU SN Hyaluronidase; Hydase; Vitragan; Vitrase; Hyaluronidase Injection; Hyaluronidase (vitreous hemorrhage), ISTA
DMETWAU CP PrimaPharm; Primapharm
DMETWAU SQ Hyaluronidase Sequence: MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPTYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVNVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWADRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS
DMETWAU DE Resorption of radiopaque agents
DMU8JGH ID DMU8JGH
DMU8JGH DN Hydralazine
DMU8JGH HS Approved
DMU8JGH SN Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine
DMU8JGH TC Antihypertensive Agents
DMU8JGH DT Small molecular drug
DMU8JGH PC 3637
DMU8JGH MW 160.18
DMU8JGH FM C8H8N4
DMU8JGH IC InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
DMU8JGH CS C1=CC=C2C(=C1)C=NN=C2NN
DMU8JGH IK RPTUSVTUFVMDQK-UHFFFAOYSA-N
DMU8JGH IU phthalazin-1-ylhydrazine
DMU8JGH CA CAS 86-54-4
DMU8JGH CB CHEBI:5775
DMU8JGH DE Hypertension
DMUSZHD ID DMUSZHD
DMUSZHD DN Hydrochlorothiazide
DMUSZHD HS Approved
DMUSZHD SN Acesistem; Acuilix; Acuretic; Aldazida; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Briazide; Caplaril; Carozide; Catiazida; Chlorizide; Chlorosulthiadil; Chlorzide; Chlothia; Cidrex; Clorana; Condiuren; Diaqua; Dichlorosal; Dichlorotride; Dichlothiazide; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Didral; Dihydran; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Disothiazid; Diurogen; Dixidrasi; Drenol; Esidrex; Esidrix; Esoidrina; Fluvin; HCT; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroclorotiazida; Hidroronol; Hidrosaluretil; Hidrotiazida; Hyclosid; Hydril; HydroDIURIL; Hydrochlorat; Hydrochlorot; Hydrochlorothiazid; Hydrochlorothiazidum; Hydrochlorthiazide; Hydrochlorthiazidum; Hydrocot; Hydrodiuretic; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hytrid; Idroclorotiazide; Idrotiazide; Indroclor; Ivaugan; Manuril; Maschitt; Medozide; Megadiuril; Microzide; Mictrin; Mikorten; Modurcen; Moduretic; Natrinax; Nefrix; Nefrol; Neoflumen; Newtolide; Novodiurex; Oretic; Pantemon; Panurin; Roxane; Saldiuril; Sectrazide; Selozide; Servithiazid; Spironazide; Tandiur; Thiaretic; Thiuretic; Thlaretic; Timolide; Unazid; Urodiazin; Urozide; Vaseretic; Vetidrex; Aquazide H; Chlorsulfonamidodihydrobenzothiadiazine dioxide; Component of Aldactazide; Component of Aldoril; Component of Butizide Prestabs; Component of Caplaril; Component of Cyclex; Component of Dyazide; Component of Esimil; Concor Plus; Diclot ride; Hydro Par; Hydrochlorothiazide Intensol; Idroclorotiazide [DCIT]; Lotensin HCT; Panurin dichloride; Raunova Plus; Diu 25 Vigt; H 4759; MaybridgeCompound 10; Mazide 25 mg; Su 5879; Aldactazide 25/25; Aldectazide 50/50; Apo-Hydro; Aquazide H (TN); Aquazide-H; Dichlotride (TN); Diu-melusin; Esidrex (TN); Esidrix (TN); HCT-Isis; Hidro-Niagrin; Hidroclorotiazida [INN-Spanish]; Hydrex-semi; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydro-Saluric; Hydro-T; Hydro-chlor; HydroSaluric (TN); Hydrochlorothiazidum [INN-Latin]; Hydrodiuril (TN); Hydrozide Injection, Veterinary; Jen-Diril; Microzide (TN); Neo-Flumen; Neo-Minzil; Neo-codema; Oretic (TN); Ro-hydrazide; AF-614/30832002; Apo-Hydro (TN); Hydrochlorothiazide [INN:BAN:JAN]; Hydrochlorothiazide (JP15/USP/INN); Dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; 3,4-Dihydrochlorothiazide; 6-Chloro-7-sulfamoyl-3, 4-dihy
DMUSZHD TC Diuretics
DMUSZHD DT Small molecular drug
DMUSZHD PC 3639
DMUSZHD MW 297.7
DMUSZHD FM C7H8ClN3O4S2
DMUSZHD IC InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
DMUSZHD CS C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
DMUSZHD IK JZUFKLXOESDKRF-UHFFFAOYSA-N
DMUSZHD IU 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMUSZHD CA CAS 58-93-5
DMUSZHD CB CHEBI:5778
DMUSZHD DE Hypertension
DMQ2JO5 ID DMQ2JO5
DMQ2JO5 DN Hydrocodone
DMQ2JO5 HS Approved
DMQ2JO5 SN HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug
DMQ2JO5 CP Abbott Laboratories
DMQ2JO5 TC Analgesics
DMQ2JO5 DT Small molecular drug
DMQ2JO5 PC 5284569
DMQ2JO5 MW 299.4
DMQ2JO5 FM C18H21NO3
DMQ2JO5 IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
DMQ2JO5 CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
DMQ2JO5 IK LLPOLZWFYMWNKH-CMKMFDCUSA-N
DMQ2JO5 IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMQ2JO5 CA CAS 125-29-1
DMQ2JO5 CB CHEBI:5779
DMQ2JO5 DE Pain
DMIAPBE ID DMIAPBE
DMIAPBE DN Hydrocodone bitartrate
DMIAPBE HS Approved
DMIAPBE SN Hydrocodon; Hydrocodone [INN:BAN]; Hydrocodone polistirex; Hydrocodonum; Hydrocodonum [INN-Latin]; Hydrocone; Hydroconum; Idrocodone; Idrocodone [DCIT]; Multacodin; hidrocodona; (-)-Dihydrocodeinone; 125-29-1; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; BRN 0094193; DICO; EINECS 204-733-9; HSDB 3097; UNII-6YKS4Y3WQ7; Bekadid; Codeinone, dihydro-; Codinovo; Dicodid; Dihydrocodeinone; HYDROCODONE; Hidrocodona [INN-Spanish]; HYDROCODONE BITARTRATE; OJHZNMVJJKMFGX-RNWHKREASA-N; SCHEMBL154972; .codon; 143-71-5; API0002943; CHEMBL2062267; MFCD00078557
DMIAPBE PC 20831824
DMIAPBE MW 449.4
DMIAPBE FM C22H27NO9
DMIAPBE IC OJHZNMVJJKMFGX-RNWHKREASA-N
DMIAPBE CS CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4.C(C(C(=O)O)O)(C(=O)O)O
DMIAPBE IK 1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;/m0./s1
DMIAPBE IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2,3-dihydroxybutanedioic acid
DMIAPBE CA CAS 143-71-5
DMIAPBE DE Neuropathic pain
DM8K1XO ID DM8K1XO
DM8K1XO DN Hydrocortamate
DM8K1XO HS Approved
DM8K1XO SN Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate
DM8K1XO TC Antiinflammatory Agents
DM8K1XO DT Small molecular drug
DM8K1XO PC 84088
DM8K1XO MW 475.6
DM8K1XO FM C27H41NO6
DM8K1XO IC InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1
DM8K1XO CS CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O
DM8K1XO IK FWFVLWGEFDIZMJ-FOMYWIRZSA-N
DM8K1XO IU [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate
DM8K1XO CA CAS 76-47-1
DM8K1XO CB CHEBI:50851
DM8K1XO DE Inflammation
DMGEMB7 ID DMGEMB7
DMGEMB7 DN Hydrocortisone
DMGEMB7 HS Approved
DMGEMB7 SN Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone
DMGEMB7 CP Merck And Co Inc
DMGEMB7 TC Antiinflammatory Agents
DMGEMB7 DT Small molecular drug
DMGEMB7 PC 5754
DMGEMB7 MW 362.5
DMGEMB7 FM C21H30O5
DMGEMB7 IC InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMGEMB7 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
DMGEMB7 IK JYGXADMDTFJGBT-VWUMJDOOSA-N
DMGEMB7 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMGEMB7 CA CAS 50-23-7
DMGEMB7 CB CHEBI:17650
DMGEMB7 DE Inflammation; Congenital adrenal hyperplasia
DMVPUQI ID DMVPUQI
DMVPUQI DN Hydroflumethiazide
DMVPUQI HS Approved
DMVPUQI SN Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DMVPUQI TC Diuretics
DMVPUQI DT Small molecular drug
DMVPUQI PC 3647
DMVPUQI MW 331.3
DMVPUQI FM C8H8F3N3O4S2
DMVPUQI IC InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
DMVPUQI CS C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1
DMVPUQI IK DMDGGSIALPNSEE-UHFFFAOYSA-N
DMVPUQI IU 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMVPUQI CA CAS 135-09-1
DMVPUQI CB CHEBI:5784
DMVPUQI DE Congestive heart failure
DM1NG5W ID DM1NG5W
DM1NG5W DN Hydrogen peroxide
DM1NG5W HS Approved
DM1NG5W SN perhydrol; oxydol; 7722-84-1; Superoxol; Interox; Hydrogen dioxide; hydroperoxide; Peroxaan; Inhibine; Kastone; Hioxyl; Albone; Albone 35; Dihydrogen dioxide; Albone DS; T-Stuff; Lensept; Perone; Elawox; Albone 70; Perone 50; Albone 50; Albone 35CG; Albone 70CG; Albone 50CG; H2O2; Hydrogen peroxide (H2O2); Peroxide; Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 35; Perone 30; Hydrogen peroxide, solution; Waterstofperoxyde; Wasserstoffperoxid; Hydrogen peroxide, 3%; Caswell No. 486AA
DM1NG5W DT Small molecular drug
DM1NG5W PC 784
DM1NG5W MW 34.015
DM1NG5W FM H2O2
DM1NG5W IC InChI=1S/H2O2/c1-2/h1-2H
DM1NG5W CS OO
DM1NG5W IK MHAJPDPJQMAIIY-UHFFFAOYSA-N
DM1NG5W IU hydrogen peroxide
DM1NG5W CA CAS 7722-84-1
DM1NG5W CB CHEBI:16240
DM1NG5W DE Infectious disease
DMHP21E ID DMHP21E
DMHP21E DN Hydromorphone
DMHP21E HS Approved
DMHP21E SN hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug
DMHP21E CP Knoll
DMHP21E TC Analgesics
DMHP21E DT Small molecular drug
DMHP21E PC 5284570
DMHP21E MW 285.34
DMHP21E FM C17H19NO3
DMHP21E IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
DMHP21E CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
DMHP21E IK WVLOADHCBXTIJK-YNHQPCIGSA-N
DMHP21E IU (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMHP21E CA CAS 466-99-9
DMHP21E CB CHEBI:5790
DMHP21E DE Pain; Chronic pain
DM6AVR4 ID DM6AVR4
DM6AVR4 DN Hydroquinone
DM6AVR4 HS Approved
DM6AVR4 SN hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; 1,4-Dihydroxybenzene; Quinol; p-Benzenediol; p-Hydroxyphenol; p-Hydroquinone; 4-Hydroxyphenol; Eldoquin; Benzoquinol; p-Dihydroxybenzene; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Hydroquinole; Dihydroquinone; Tecquinol; Idrochinone; Benzohydroquinone; Tequinol; Hidroquinone; Arctuvin; Dihydroxybenzene; Solaquin forte; Derma-Blanch; Tenox HQ; Hydrochinone; Hydrochinon; Artra; Eldoquin Forte; Eldopaque Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; Accutin
DM6AVR4 DT Small molecular drug
DM6AVR4 PC 785
DM6AVR4 MW 110.11
DM6AVR4 FM C6H6O2
DM6AVR4 IC InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H
DM6AVR4 CS C1=CC(=CC=C1O)O
DM6AVR4 IK QIGBRXMKCJKVMJ-UHFFFAOYSA-N
DM6AVR4 IU benzene-1,4-diol
DM6AVR4 CA CAS 123-31-9
DM6AVR4 CB CHEBI:17594
DM6AVR4 DE Melasma
DMGKV9D ID DMGKV9D
DMGKV9D DN Hydroxocobalamin
DMGKV9D HS Approved
DMGKV9D SN AlphaRedisol; Axion; Axlon; Cobalex; Codroxomin; Cyanokit; Depogamma; Docclan; Docelan; Docelvita; Docevita; Duradoce; Hidroxocobalamina; Hydrobamine; Hydrocobalamin; Hydrogrisevit; Hydrovit; Hydroxocobalaminacetat; Hydroxocobalamine; Hydroxocobalaminum; Hydroxocobemine; Hydroxomin; Hydroxycobalamin; Hydroxycobalamine; Hyxobamine; Idrogrisevit; Idrossocobalamina; Oxobemin; Vibeden; Vitadurin; Alpha Cobione; Ciplamin H; Hydro Cobex; Hydroxocobalamin acetate; Hydroxocobalamin monohydrochloride; Hydroxy Cobal; Idrossocobalamina [DCIT]; Primabalt RP; Hydroxocobalamin Vitamin B12; Hydroxy vitamin B12; Ohb12; Vitamin B12a; Vitamin B12b; Acti-B12; AlphaRedisol (TN); Benzimidazolyl ribofuranosyl phosphate deriv.; Cyanokit (TN); Ducobee-Hy; Duralta-12; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamine [INN-French]; Hydroxocobalaminum [INN-Latin]; Hydroxycob(lll)alamin; Lyovit-H; Neo-Betalin 12; Neo-cytamen; Neo-macrabin; Neo-rojamin; OH-Cbl; OH-Duphar; Oxolamine (arcum); Redisol-H; Sytobex-H; Vitamin B(sub 12a); Vitamin B-12b; Hydroxocobalamin (JAN/USP/INN); Hydroxocobalamin [USAN:INN:BAN:JAN]; Alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin(alkaline soln.), OH-replaces CN-in Cyanocobalamin); Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
DMGKV9D TC Vitamins
DMGKV9D DT Small molecular drug
DMGKV9D PC 70689311
DMGKV9D MW 1347.4
DMGKV9D FM C62H90CoN13O15P
DMGKV9D IC InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1
DMGKV9D CS CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@@]\\4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](C(=N7)/C=C\\8/C([C@@H](C(=N8)/C(=C4\\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2]
DMGKV9D IK DQOCFCZRZOAIBN-WZHZPDAFSA-L
DMGKV9D IU cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] phosphate;hydrate
DMGKV9D CA CAS 13422-51-0
DMGKV9D DE Vitamin B12 deficiency; Lung injury
DMJAS3O ID DMJAS3O
DMJAS3O DN Hydroxyamphetamine
DMJAS3O HS Approved
DMJAS3O SN Hydroxyamfetamine; Hydroxyamphetamide; Norpholedrine; Norveritol; Nov-Pholedrin; Oksamfetamin; Oxamfetamin; Oxamphetamine; Oxamphetaminium; Paradrine; Paredrine; Paredrinex; Pedrolon; Phenol, 4-(2-aminopropyl)-; Phenol, p-(2-aminopropyl)-; Phenol,4-(2-aminopropyl)-; Pulsoton; alpha-Methyltyramine; hydroxyamphetamine; p-(2-Aminopropyl)phenol; p-HYDROXYAMPHETAMINE; .alpha.-Methyltyramine; 1-p-Hydroxyphenyl-2-propylamine; 103-86-6; 2-Amino-1-(p-hydroxyphenyl)propane; 4-(2-Aminopropyl)phenol; 4-Hydroxyamphetamine
DMJAS3O PC 3651
DMJAS3O MW 151.21
DMJAS3O FM C9H13NO
DMJAS3O IC GIKNHHRFLCDOEU-UHFFFAOYSA-N
DMJAS3O CS CC(CC1=CC=C(C=C1)O)N
DMJAS3O IK 1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
DMJAS3O IU 4-(2-aminopropyl)phenol
DMJAS3O CA CAS 103-86-6
DMJAS3O CB CHEBI:103855
DMJAS3O DE Horner syndrome
DMQSGM0 ID DMQSGM0
DMQSGM0 DN Hydroxyamphetamine Hydrobromide
DMQSGM0 HS Approved
DMQSGM0 SN Paredrine; 4-hydroxyamphetamine
DMQSGM0 CP Pharmics Inc
DMQSGM0 DT Small molecular drug
DMQSGM0 PC 9377
DMQSGM0 MW 232.12
DMQSGM0 FM C9H14BrNO
DMQSGM0 IC InChI=1S/C9H13NO.BrH/c1-7(10)6-8-2-4-9(11)5-3-8;/h2-5,7,11H,6,10H2,1H3;1H
DMQSGM0 CS CC(CC1=CC=C(C=C1)O)N.Br
DMQSGM0 IK RZCJLMTXBMNRAD-UHFFFAOYSA-N
DMQSGM0 IU 4-(2-aminopropyl)phenol;hydrobromide
DMQSGM0 CA CAS 306-21-8
DMQSGM0 DE Horner syndrome
DMSIVND ID DMSIVND
DMSIVND DN Hydroxychloroquine
DMSIVND HS Approved
DMSIVND SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMSIVND CP Concordia Pharmaceuticals Inc
DMSIVND TC Antimalarials
DMSIVND DT Small molecular drug
DMSIVND PC 3652
DMSIVND MW 335.9
DMSIVND FM C18H26ClN3O
DMSIVND IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMSIVND CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMSIVND IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMSIVND IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMSIVND CA CAS 118-42-3
DMSIVND CB CHEBI:5801
DMSIVND DE Malaria
DMGIZF5 ID DMGIZF5
DMGIZF5 DN Hydroxyflutamide
DMGIZF5 HS Approved
DMGIZF5 SN HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5 TC Anticancer Agents
DMGIZF5 DT Small molecular drug
DMGIZF5 PC 91649
DMGIZF5 MW 292.21
DMGIZF5 FM C11H11F3N2O4
DMGIZF5 IC InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
DMGIZF5 CS CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O
DMGIZF5 IK YPQLFJODEKMJEF-UHFFFAOYSA-N
DMGIZF5 IU 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5 CA CAS 52806-53-8
DMGIZF5 DE Prostate cancer
DMIKQH5 ID DMIKQH5
DMIKQH5 DN Hydroxyprogesterone
DMIKQH5 HS Approved
DMIKQH5 SN Delalutin (TN); Proluton depot (TN)
DMIKQH5 CP Bristol Myers Squibb
DMIKQH5 DT Small molecular drug
DMIKQH5 PC 6238
DMIKQH5 MW 330.5
DMIKQH5 FM C21H30O3
DMIKQH5 IC InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
DMIKQH5 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMIKQH5 IK DBPWSSGDRRHUNT-CEGNMAFCSA-N
DMIKQH5 IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMIKQH5 CA CAS 68-96-2
DMIKQH5 CB CHEBI:17252
DMIKQH5 DE Solid tumour/cancer
DMR5QS6 ID DMR5QS6
DMR5QS6 DN Hydroxystilbamidine Isethionate
DMR5QS6 HS Approved
DMR5QS6 SN Hydroxystilbamide; Hydroxystilbamidine diisethionate; FluoroGold (TN); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1) (8CI); Benzenecarboximidamide, 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxy-, bis(2-hydroxyethanesulfonate) (salt); Ethanesulfonic acid, 2-hydroxy-, compd. with 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxybenzenecarboximidamide (2:1); (4E)-4-[2-[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene]ethylidene]-3-oxocyclohexa-1,5-diene-1-carboximidamide; 2-Hydroxy-4,4'-diamidinostilbene di(beta-hydroxyethanesulfonate); 2-Hydroxy-4,4'-diguanylstilbene diisethionate; 2-Hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulfonate) (salt); 2-Hydroxy-4,4'-stilbenedicarboxamidine diisethionate; 2-Hydroxyethanesulphonic acid, compoundwith 4-(2-(4-amidinophenyl)vinyl)-3-hydroxybenzenecarboxamidine (2:1); 2-Hydroxystilbamidine diisethionate; 2-Hydroxystilbamidine isethionate; 2-hydroxyethanesulfonic acid
DMR5QS6 TC Antifungal Agents
DMR5QS6 DT Small molecular drug
DMR5QS6 PC 135460345
DMR5QS6 MW 406.5
DMR5QS6 FM C18H22N4O5S
DMR5QS6 IC InChI=1S/C16H16N4O.C2H6O4S/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21;3-1-2-7(4,5)6/h1-9,21H,(H3,17,18)(H3,19,20);3H,1-2H2,(H,4,5,6)/b4-1+;
DMR5QS6 CS C1=CC(=CC=C1/C=C/C2=C(C=C(C=C2)C(=N)N)O)C(=N)N.C(CS(=O)(=O)O)O
DMR5QS6 IK HPLUMRXCPMTSQW-DYVSEJHDSA-N
DMR5QS6 IU 4-[(E)-2-(4-carbamimidoylphenyl)ethenyl]-3-hydroxybenzenecarboximidamide;2-hydroxyethanesulfonic acid
DMR5QS6 CA CAS 533-22-2
DMR5QS6 DE Blastomycosis
DMOQVU9 ID DMOQVU9
DMOQVU9 DN Hydroxyurea
DMOQVU9 HS Approved
DMOQVU9 SN Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
DMOQVU9 TC Anticancer Agents
DMOQVU9 DT Small molecular drug
DMOQVU9 PC 3657
DMOQVU9 MW 76.055
DMOQVU9 FM CH4N2O2
DMOQVU9 IC InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
DMOQVU9 CS C(=O)(N)NO
DMOQVU9 IK VSNHCAURESNICA-UHFFFAOYSA-N
DMOQVU9 IU hydroxyurea
DMOQVU9 CA CAS 127-07-1
DMOQVU9 CB CHEBI:44423
DMOQVU9 DE Chronic myelogenous leukaemia
DMF8Y74 ID DMF8Y74
DMF8Y74 DN Hydroxyzine
DMF8Y74 HS Approved
DMF8Y74 SN Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74 CP Pfizer Pharmaceuticals
DMF8Y74 TC Hypnotics and Sedatives
DMF8Y74 DT Small molecular drug
DMF8Y74 PC 3658
DMF8Y74 MW 374.9
DMF8Y74 FM C21H27ClN2O2
DMF8Y74 IC InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
DMF8Y74 CS C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMF8Y74 IK ZQDWXGKKHFNSQK-UHFFFAOYSA-N
DMF8Y74 IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74 CA CAS 68-88-2
DMF8Y74 CB CHEBI:5818
DMF8Y74 DE Anxiety disorder
DMVAIH4 ID DMVAIH4
DMVAIH4 DN Hylenex
DMVAIH4 HS Approved
DMVAIH4 CP Halozyme therapeutics; baxter healthcare
DMVAIH4 DE Solid tumour/cancer
DM804UR ID DM804UR
DM804UR DN Hyoscyamine
DM804UR HS Approved
DM804UR SN L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine
DM804UR TC Antiarrhythmic Agents
DM804UR DT Small molecular drug
DM804UR PC 154417
DM804UR MW 289.4
DM804UR FM C17H23NO3
DM804UR IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
DM804UR CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3
DM804UR IK RKUNBYITZUJHSG-VFSICIBPSA-N
DM804UR IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM804UR CA CAS 101-31-5
DM804UR CB CHEBI:17486
DM804UR DE Gastrointestinal disease
DM0RXF5 ID DM0RXF5
DM0RXF5 DN Hyqvia
DM0RXF5 HS Approved
DM0RXF5 SN Immunoglobulin infusion with recombinant hyaluronidase
DM0RXF5 CP Baxter
DM0RXF5 DE Immunodeficiency
DMV67QO ID DMV67QO
DMV67QO DN Ibalizumab
DMV67QO HS Approved
DMV67QO SN Hu5A8; TNX-355
DMV67QO CP TaiMed Biologics/Theratechnologies
DMV67QO DT Antibody
DMV67QO DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DM0QZBN ID DM0QZBN
DM0QZBN DN Ibandronate
DM0QZBN HS Approved
DM0QZBN SN BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate
DM0QZBN CP Roche; GlaxoSmithKline
DM0QZBN TC Bone Density Conservation Agents
DM0QZBN DT Small molecular drug
DM0QZBN PC 60852
DM0QZBN MW 319.23
DM0QZBN FM C9H23NO7P2
DM0QZBN IC InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
DM0QZBN CS CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
DM0QZBN IK MPBVHIBUJCELCL-UHFFFAOYSA-N
DM0QZBN IU [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
DM0QZBN CA CAS 114084-78-5
DM0QZBN DE Osteoporosis
DMGUX67 ID DMGUX67
DMGUX67 DN Ibopamine hci
DMGUX67 HS Approved
DMGUX67 SN Inopamil (TN); Scandine (TN)
DMGUX67 DT Small molecular drug
DMGUX67 PC 156320
DMGUX67 MW 343.8
DMGUX67 FM C17H26ClNO4
DMGUX67 IC InChI=1S/C17H25NO4.ClH/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4;/h6-7,10-12,18H,8-9H2,1-5H3;1H
DMGUX67 CS CC(C)C(=O)OC1=C(C=C(C=C1)CCNC)OC(=O)C(C)C.Cl
DMGUX67 IK ALIXRWKJZYLBJI-UHFFFAOYSA-N
DMGUX67 IU [4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride
DMGUX67 CA CAS 75011-65-3
DMGUX67 DE Cardiac disease
DMG594T ID DMG594T
DMG594T DN Ibritumomab
DMG594T HS Approved
DMG594T SN Zevalin (TN)
DMG594T CP Bayer Pharmaceuticals Corporation
DMG594T TC Anticancer Agents
DMG594T DT Antibody
DMG594T SQ Ibritumomab tiuxetan heavy chain: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR >Ibritumomab tiuxetan light chainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN
DMG594T DE Non-hodgkin lymphoma; Mantle cell lymphoma
DMHZCPO ID DMHZCPO
DMHZCPO DN Ibrutinib
DMHZCPO HS Approved
DMHZCPO SN PCI-32765; Ibrutinib (BTK inhibitor)
DMHZCPO CP Janssen Biotech; Pharmacyclics
DMHZCPO DT Small molecular drug
DMHZCPO PC 24821094
DMHZCPO MW 440.5
DMHZCPO FM C25H24N6O2
DMHZCPO IC InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
DMHZCPO CS C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHZCPO IK XYFPWWZEPKGCCK-GOSISDBHSA-N
DMHZCPO IU 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
DMHZCPO CA CAS 936563-96-1
DMHZCPO CB CHEBI:76612
DMHZCPO DE B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma; Pancreatic cancer; Solid tumour/cancer
DM4LSPN ID DM4LSPN
DM4LSPN DN Ibudilast
DM4LSPN HS Approved
DM4LSPN SN Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
DM4LSPN CP Avigen
DM4LSPN DT Small molecular drug
DM4LSPN PC 3671
DM4LSPN MW 230.31
DM4LSPN FM C14H18N2O
DM4LSPN IC InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
DM4LSPN CS CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C
DM4LSPN IK ZJVFLBOZORBYFE-UHFFFAOYSA-N
DM4LSPN IU 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
DM4LSPN CA CAS 50847-11-5
DM4LSPN CB CHEBI:31684
DM4LSPN DE Amyotrophic lateral sclerosis; Alcohol dependence; Methamphetamine dependence; Opioid dependence; Multiple sclerosis; Castleman's disease
DM8VCBE ID DM8VCBE
DM8VCBE DN Ibuprofen
DM8VCBE HS Approved
DM8VCBE SN ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN
DM8VCBE TC Analgesics
DM8VCBE DT Small molecular drug
DM8VCBE PC 3672
DM8VCBE MW 206.28
DM8VCBE FM C13H18O2
DM8VCBE IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
DM8VCBE CS CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
DM8VCBE IK HEFNNWSXXWATRW-UHFFFAOYSA-N
DM8VCBE IU 2-[4-(2-methylpropyl)phenyl]propanoic acid
DM8VCBE CA CAS 15687-27-1
DM8VCBE CB CHEBI:5855
DM8VCBE DE Pain
DMFJ8LT ID DMFJ8LT
DMFJ8LT DN Ibutamoren
DMFJ8LT HS Approved
DMFJ8LT SN L 163191; MK-0667; MK-677; 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT CP Merck
DMFJ8LT DT Small molecular drug
DMFJ8LT PC 178024
DMFJ8LT MW 528.7
DMFJ8LT FM C27H36N4O5S
DMFJ8LT IC InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1
DMFJ8LT CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N
DMFJ8LT IK UMUPQWIGCOZEOY-JOCHJYFZSA-N
DMFJ8LT IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT CA CAS 159634-47-6
DMFJ8LT DE Fibromyalgia
DMKXY2R ID DMKXY2R
DMKXY2R DN Ibutilide
DMKXY2R HS Approved
DMKXY2R SN Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate
DMKXY2R CP Pfizer Pharmaceuticals
DMKXY2R TC Antiarrhythmic Agents
DMKXY2R DT Small molecular drug
DMKXY2R PC 60753
DMKXY2R MW 384.6
DMKXY2R FM C20H36N2O3S
DMKXY2R IC InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
DMKXY2R CS CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DMKXY2R IK ALOBUEHUHMBRLE-UHFFFAOYSA-N
DMKXY2R IU N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
DMKXY2R CA CAS 122647-31-8
DMKXY2R CB CHEBI:5856
DMKXY2R DE Atrial fibrillation
DMQPTOZ ID DMQPTOZ
DMQPTOZ DN Icatibant
DMQPTOZ HS Approved
DMQPTOZ SN Firazyr; Icatibant [INN]; HOE 140; HOE140; JE049; WIN 65365; Hoe-140; WIN-65365; D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DMQPTOZ CP Jerini AG
DMQPTOZ TC Antiinflammatory Agents
DMQPTOZ DT Small molecular drug
DMQPTOZ PC 6918173
DMQPTOZ MW 1304.5
DMQPTOZ FM C59H89N19O13S
DMQPTOZ IC InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
DMQPTOZ CS C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMQPTOZ IK QURWXBZNHXJZBE-SKXRKSCCSA-N
DMQPTOZ IU (2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMQPTOZ CA CAS 130308-48-4
DMQPTOZ DE Hereditary angioedema
DM648X9 ID DM648X9
DM648X9 DN Icodextrin
DM648X9 HS Approved
DM648X9 SN Extraneal
DM648X9 CP Innovata plc
DM648X9 DT Small molecular drug
DM648X9 PC 3517
DM648X9 MW 231.08
DM648X9 FM C8H8Cl2N4
DM648X9 IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)
DM648X9 CS C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl
DM648X9 IK WDZVGELJXXEGPV-UHFFFAOYSA-N
DM648X9 IU 2-[(2,6-dichlorophenyl)methylideneamino]guanidine
DM648X9 CA CAS 5051-62-7
DM648X9 DE Kidney disease
DMJHN0A ID DMJHN0A
DMJHN0A DN Icosapent
DMJHN0A HS Approved
DMJHN0A TC Dietary supplement
DMJHN0A DT Small molecular drug
DMJHN0A PC 446284
DMJHN0A MW 302.5
DMJHN0A FM C20H30O2
DMJHN0A IC InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMJHN0A CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O
DMJHN0A IK JAZBEHYOTPTENJ-JLNKQSITSA-N
DMJHN0A IU (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
DMJHN0A CA CAS 10417-94-4
DMJHN0A CB CHEBI:28364
DMJHN0A DE Thrombin deficiency; Hyperglyceridemia; Hypertriglyceridemia
DMM0XGL ID DMM0XGL
DMM0XGL DN Idarubicin
DMM0XGL HS Approved
DMM0XGL SN DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
DMM0XGL CP Ben Venue Laboratories
DMM0XGL TC Anticancer Agents
DMM0XGL DT Small molecular drug
DMM0XGL PC 42890
DMM0XGL MW 497.5
DMM0XGL FM C26H27NO9
DMM0XGL IC InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
DMM0XGL CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
DMM0XGL IK XDXDZDZNSLXDNA-TZNDIEGXSA-N
DMM0XGL IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DMM0XGL CA CAS 58957-92-9
DMM0XGL CB CHEBI:42068
DMM0XGL DE Acute myeloid leukaemia
DMXEACF ID DMXEACF
DMXEACF DN Idarucizumab
DMXEACF HS Approved
DMXEACF SN Praxbind
DMXEACF CP Boehringer Ingelheim
DMXEACF DT Antibody
DMXEACF DE Reversal of the anticoagulant effects of dabigatran
DMQFDRC ID DMQFDRC
DMQFDRC DN Idebenone
DMQFDRC HS Approved
DMQFDRC SN idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; Idebenonum [Latin]; Idebenona [Spanish]; Idebenone [INN:JAN]; CV-2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; UNII-HB6PN45W4J; BRN 2001459; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; CHEBI:31687; JGPMMRGNQUBGND-UHFFFAOYSA-N; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; NCGC00160514-01; AK161748
DMQFDRC CP Santhera Pharmaceuticals
DMQFDRC DT Small molecular drug
DMQFDRC PC 3686
DMQFDRC MW 338.4
DMQFDRC FM C19H30O5
DMQFDRC IC InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3
DMQFDRC CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
DMQFDRC IK JGPMMRGNQUBGND-UHFFFAOYSA-N
DMQFDRC IU 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
DMQFDRC CA CAS 58186-27-9
DMQFDRC CB CHEBI:31687
DMQFDRC DE Cognitive impairment; Friedreich's ataxia
DMP1QTS ID DMP1QTS
DMP1QTS DN Idecabtagene vicleucel
DMP1QTS HS Approved
DMP1QTS SN Bb2121
DMP1QTS CP Celgene
DMP1QTS DT CAR T Cell Therapy
DMP1QTS DE Multiple myeloma
DM602WT ID DM602WT
DM602WT DN Idelalisib
DM602WT HS Approved
DM602WT SN Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
DM602WT CP Gilead Sciences
DM602WT DT Small molecular drug
DM602WT PC 11625818
DM602WT MW 415.4
DM602WT FM C22H18FN7O
DM602WT IC InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
DM602WT CS CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM602WT IK IFSDAJWBUCMOAH-HNNXBMFYSA-N
DM602WT IU 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
DM602WT CA CAS 870281-82-6
DM602WT CB CHEBI:82701
DM602WT DE Chronic lymphocytic leukaemia
DMDRT0E ID DMDRT0E
DMDRT0E DN Idoxuridine
DMDRT0E HS Approved
DMDRT0E SN Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU
DMDRT0E TC Antiviral Agents
DMDRT0E DT Small molecular drug
DMDRT0E PC 5905
DMDRT0E MW 354.1
DMDRT0E FM C9H11IN2O5
DMDRT0E IC InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DMDRT0E CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O
DMDRT0E IK XQFRJNBWHJMXHO-RRKCRQDMSA-N
DMDRT0E IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMDRT0E CA CAS 54-42-2
DMDRT0E CB CHEBI:147675
DMDRT0E DE Herpes simplex virus infection
DM30SXV ID DM30SXV
DM30SXV DN Idursulfase
DM30SXV HS Approved
DM30SXV SN Elaprase (TN)
DM30SXV SQ Idursulfase heavy chain: SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPG >Idursulfase light chainNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
DM30SXV DE Infertility; Hunter syndrome
DMCT3I8 ID DMCT3I8
DMCT3I8 DN Ifosfamide
DMCT3I8 HS Approved
DMCT3I8 SN Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
DMCT3I8 TC Anticancer Agents
DMCT3I8 DT Small molecular drug
DMCT3I8 PC 3690
DMCT3I8 MW 261.079
DMCT3I8 FM C7H15Cl2N2O2P
DMCT3I8 IC InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
DMCT3I8 CS C1CN(P(=O)(OC1)NCCCl)CCCl
DMCT3I8 IK HOMGKSMUEGBAAB-UHFFFAOYSA-N
DMCT3I8 IU N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMCT3I8 CA CAS 3778-73-2
DMCT3I8 CB CHEBI:5864
DMCT3I8 DE Solid tumour/cancer
DM6AUFY ID DM6AUFY
DM6AUFY DN Iloperidone
DM6AUFY HS Approved
DM6AUFY SN Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
DM6AUFY CP Vanda Pharmaceuticals
DM6AUFY DT Small molecular drug
DM6AUFY PC 71360
DM6AUFY MW 426.5
DM6AUFY FM C24H27FN2O4
DM6AUFY IC InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
DM6AUFY CS CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
DM6AUFY IK XMXHEBAFVSFQEX-UHFFFAOYSA-N
DM6AUFY IU 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
DM6AUFY CA CAS 133454-47-4
DM6AUFY CB CHEBI:65173
DM6AUFY DE Schizophrenia
DMVPZBE ID DMVPZBE
DMVPZBE DN Iloprost
DMVPZBE HS Approved
DMVPZBE SN Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
DMVPZBE CP Actelion Pharmaceuticals
DMVPZBE TC Antihypertensive Agents
DMVPZBE DT Small molecular drug
DMVPZBE PC 5311181
DMVPZBE MW 360.5
DMVPZBE FM C22H32O4
DMVPZBE IC InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
DMVPZBE CS CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
DMVPZBE IK HIFJCPQKFCZDDL-ACWOEMLNSA-N
DMVPZBE IU (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMVPZBE CA CAS 78919-13-8
DMVPZBE CB CHEBI:63916
DMVPZBE DE Pulmonary arterial hypertension
DM7RJXL ID DM7RJXL
DM7RJXL DN Imatinib
DM7RJXL HS Approved
DM7RJXL SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DM7RJXL CP Novartis AG
DM7RJXL TC Anticancer Agents
DM7RJXL DT Small molecular drug
DM7RJXL PC 5291
DM7RJXL MW 493.6
DM7RJXL FM C29H31N7O
DM7RJXL IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DM7RJXL CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7RJXL IK KTUFNOKKBVMGRW-UHFFFAOYSA-N
DM7RJXL IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DM7RJXL CA CAS 152459-95-5
DM7RJXL CB CHEBI:45783
DM7RJXL DE Chronic myelogenous leukaemia; Systemic mastocytosis; Lung cancer; Intestinal cancer; Acute lymphoblastic leukaemia
DMUL7T1 ID DMUL7T1
DMUL7T1 DN Imidapril
DMUL7T1 HS Approved
DMUL7T1 SN Tanatil (TN)
DMUL7T1 CP Tanabe
DMUL7T1 DT Small molecular drug
DMUL7T1 PC 5464343
DMUL7T1 MW 405.4
DMUL7T1 FM C20H27N3O6
DMUL7T1 IC InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMUL7T1 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O
DMUL7T1 IK KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMUL7T1 IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMUL7T1 CA 89371-37-9
DMUL7T1 DE Cardiovascular disease
DM3VS7Z ID DM3VS7Z
DM3VS7Z DN Imidazole salicylate
DM3VS7Z HS Approved
DM3VS7Z SN Salizolo; Selezen; ITF-182
DM3VS7Z CP Italfarmaco SpA
DM3VS7Z DT Small molecular drug
DM3VS7Z PC 37425
DM3VS7Z MW 206.2
DM3VS7Z FM C10H10N2O3
DM3VS7Z IC InChI=1S/C7H6O3.C3H4N2/c8-6-4-2-1-3-5(6)7(9)10;1-2-5-3-4-1/h1-4,8H,(H,9,10);1-3H,(H,4,5)
DM3VS7Z CS C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1
DM3VS7Z IK XCHHJFVNQPPLJK-UHFFFAOYSA-N
DM3VS7Z IU 2-hydroxybenzoic acid;1H-imidazole
DM3VS7Z CA CAS 36364-49-5
DM3VS7Z DE Inflammation
DMI9FBP ID DMI9FBP
DMI9FBP DN Imipenem
DMI9FBP HS Approved
DMI9FBP SN Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP CP Merck & Co
DMI9FBP TC Antibiotics
DMI9FBP DT Small molecular drug
DMI9FBP PC 104838
DMI9FBP MW 299.35
DMI9FBP FM C12H17N3O4S
DMI9FBP IC InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1
DMI9FBP CS C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O
DMI9FBP IK ZSKVGTPCRGIANV-ZXFLCMHBSA-N
DMI9FBP IU (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP CA CAS 64221-86-9
DMI9FBP CB CHEBI:471744
DMI9FBP DE Bacterial infection
DM2NUH3 ID DM2NUH3
DM2NUH3 DN Imipramine
DM2NUH3 HS Approved
DM2NUH3 SN Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)
DM2NUH3 CP Novartis Pharmaceuticals Corp
DM2NUH3 TC Antidepressants
DM2NUH3 DT Small molecular drug
DM2NUH3 PC 3696
DM2NUH3 MW 280.4
DM2NUH3 FM C19H24N2
DM2NUH3 IC InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
DM2NUH3 CS CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DM2NUH3 IK BCGWQEUPMDMJNV-UHFFFAOYSA-N
DM2NUH3 IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DM2NUH3 CA CAS 50-49-7
DM2NUH3 CB CHEBI:47499
DM2NUH3 DE Depression
DM1TMA3 ID DM1TMA3
DM1TMA3 DN Imiquimod
DM1TMA3 HS Approved
DM1TMA3 SN Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
DM1TMA3 CP INova Pharmaceuticals
DM1TMA3 TC Antiviral Agents
DM1TMA3 DT Small molecular drug
DM1TMA3 PC 57469
DM1TMA3 MW 240.3
DM1TMA3 FM C14H16N4
DM1TMA3 IC InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
DM1TMA3 CS CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
DM1TMA3 IK DOUYETYNHWVLEO-UHFFFAOYSA-N
DM1TMA3 IU 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
DM1TMA3 CA CAS 99011-02-6
DM1TMA3 CB CHEBI:36704
DM1TMA3 DE Skin cancer
DMRMFP4 ID DMRMFP4
DMRMFP4 DN Inamrinone Lactate
DMRMFP4 HS Approved
DMRMFP4 SN Amrinone; inamrinone; 60719-84-8; Wincoram; Inocor; Cordemcura; Cartonic; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Amrinonum [INN-Latin]; Amrinonum; Amrinona; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; Win-40680; Amcoral; 5-Amino-(3,4'-bipyridin)-6(1H)-one; WIN 40680; AWD 08-250; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; UNII-JUT23379TN; CCRIS 3794; Amrinone lactate; MLS000069829; EINECS 262-390-0; 5-amino-3,4'-bipyridin-6(1H)-one; BRN 0744819; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN; Amrinone Lactate
DMRMFP4 CP Sanofi Aventis Us Llc
DMRMFP4 TC Cardiovascular Agents
DMRMFP4 DT Small molecular drug
DMRMFP4 PC 3035194
DMRMFP4 MW 277.28
DMRMFP4 FM C13H15N3O4
DMRMFP4 IC InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)
DMRMFP4 CS CC(C(=O)O)O.C1=CN=CC=C1C2=CNC(=O)C(=C2)N
DMRMFP4 IK DOSIONJFGDSKCQ-UHFFFAOYSA-N
DMRMFP4 IU 3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid
DMRMFP4 CA CAS 75898-90-7
DMRMFP4 DE Congestive heart failure; Cardiac disease
DM3DSVJ ID DM3DSVJ
DM3DSVJ DN Incadronate
DM3DSVJ HS Approved
DM3DSVJ SN Incadronate; 138330-18-4; Disodium Cycloheptylaminomethylene diphosphonate; Bisphonal; Cimadronate sodium; AC1OCF1R; Incadronic acid sodium salt; C8H17NNa2O6P2; CTK8F9264; RT-012376; YM-21175-1; J-007120; disodium [(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ DT Small molecular drug
DM3DSVJ PC 6918123
DM3DSVJ MW 331.15
DM3DSVJ FM C8H17NNa2O6P2
DM3DSVJ IC InChI=1S/C8H19NO6P2.2Na/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7;;/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2
DM3DSVJ CS C1CCCC(CC1)NC(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DM3DSVJ IK PCSJAAWOSGCAFV-UHFFFAOYSA-L
DM3DSVJ IU disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ DE Hypercalcaemia
DMKE6YT ID DMKE6YT
DMKE6YT DN Incobotulinum toxin A
DMKE6YT HS Approved
DMKE6YT SN IncobotulinumtoxinA; Xeomin; NT-201; Botulinum toxin type A extract (blepharospasm), Merz/BioteCon
DMKE6YT CP Merz
DMKE6YT DE Cervical cancer
DM32GSJ ID DM32GSJ
DM32GSJ DN Incruse ellipta
DM32GSJ HS Approved
DM32GSJ SN Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; Incruse Ellipta; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2
DM32GSJ CP Glaxosmithkline
DM32GSJ DT Small molecular drug
DM32GSJ PC 11519069
DM32GSJ MW 508.5
DM32GSJ FM C29H34BrNO2
DM32GSJ IC InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
DM32GSJ CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
DM32GSJ IK PEJHHXHHNGORMP-UHFFFAOYSA-M
DM32GSJ IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
DM32GSJ CA CAS 869113-09-7
DM32GSJ CB CHEBI:79040
DM32GSJ DE Chronic obstructive pulmonary disease
DMQJHR7 ID DMQJHR7
DMQJHR7 DN Indacaterol
DMQJHR7 HS Approved
DMQJHR7 SN 312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone
DMQJHR7 CP Novartis
DMQJHR7 DT Small molecular drug
DMQJHR7 PC 6918554
DMQJHR7 MW 392.5
DMQJHR7 FM C24H28N2O3
DMQJHR7 IC InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
DMQJHR7 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
DMQJHR7 IK QZZUEBNBZAPZLX-QFIPXVFZSA-N
DMQJHR7 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMQJHR7 CA CAS 312753-06-3
DMQJHR7 CB CHEBI:68575
DMQJHR7 DE Chronic obstructive pulmonary disease; Asthma
DMGN1PW ID DMGN1PW
DMGN1PW DN Indapamide
DMGN1PW HS Approved
DMGN1PW SN Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW CP Servier Laboratories
DMGN1PW TC Antihypertensive Agents
DMGN1PW DT Small molecular drug
DMGN1PW PC 3702
DMGN1PW MW 365.8
DMGN1PW FM C16H16ClN3O3S
DMGN1PW IC InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
DMGN1PW CS CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
DMGN1PW IK NDDAHWYSQHTHNT-UHFFFAOYSA-N
DMGN1PW IU 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW CA CAS 26807-65-8
DMGN1PW CB CHEBI:5893
DMGN1PW DE Hypertension
DMUV8OR ID DMUV8OR
DMUV8OR DN Indecainide
DMUV8OR HS Approved
DMUV8OR SN Indecainida; Indecainidum; Ricainid; Ricainide; Indecainida [Spanish]; Indecainide [INN]; Indecainidum [Latin]; Decabid (TN); LY-135837; 9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid; 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR CP Eli Lilly And Co
DMUV8OR TC Antidysrhythmic Agents
DMUV8OR DT Small molecular drug
DMUV8OR PC 52195
DMUV8OR MW 308.4
DMUV8OR FM C20H24N2O
DMUV8OR IC InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)
DMUV8OR CS CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N
DMUV8OR IK UCEWGESNIULAGX-UHFFFAOYSA-N
DMUV8OR IU 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR CA CAS 74517-78-5
DMUV8OR CB CHEBI:135314
DMUV8OR DE Dysrhythmias
DMWO3N6 ID DMWO3N6
DMWO3N6 DN Indeloxazine
DMWO3N6 HS Approved
DMWO3N6 SN Elen; Noin; Indeloxazine hydrochloride; YM-08054
DMWO3N6 CP Yamanouchi Pharmaceutical Co Ltd
DMWO3N6 DT Small molecular drug
DMWO3N6 PC 3704
DMWO3N6 MW 231.29
DMWO3N6 FM C14H17NO2
DMWO3N6 IC InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2
DMWO3N6 CS C1COC(CN1)COC2=CC=CC3=C2CC=C3
DMWO3N6 IK MADRVGBADLFHMO-UHFFFAOYSA-N
DMWO3N6 IU 2-(3H-inden-4-yloxymethyl)morpholine
DMWO3N6 CA CAS 60929-23-9
DMWO3N6 CB CHEBI:5894
DMWO3N6 DE Dementia
DM0T3YH ID DM0T3YH
DM0T3YH DN Indinavir
DM0T3YH HS Approved
DM0T3YH SN Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH CP Merck & Co
DM0T3YH TC Anti-HIV Agents
DM0T3YH DT Small molecular drug
DM0T3YH PC 5362440
DM0T3YH MW 613.8
DM0T3YH FM C36H47N5O4
DM0T3YH IC InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
DM0T3YH CS CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
DM0T3YH IK CBVCZFGXHXORBI-PXQQMZJSSA-N
DM0T3YH IU (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH CA CAS 150378-17-9
DM0T3YH CB CHEBI:44032
DM0T3YH DE Human immunodeficiency virus infection
DMOPGHQ ID DMOPGHQ
DMOPGHQ DN Indiplon
DMOPGHQ HS Approved
DMOPGHQ SN NBI 34060; NBI-34060; Indiplon (USAN/INN); N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ CP Neurocrine Biosciences
DMOPGHQ DT Small molecular drug
DMOPGHQ PC 6450813
DMOPGHQ MW 376.4
DMOPGHQ FM C20H16N4O2S
DMOPGHQ IC InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3
DMOPGHQ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4
DMOPGHQ IK CBIAWPMZSFFRGN-UHFFFAOYSA-N
DMOPGHQ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ CA CAS 325715-02-4
DMOPGHQ DE Insomnia; Fibromyalgia
DM2NQUY ID DM2NQUY
DM2NQUY DN Indocyanine green
DM2NQUY HS Approved
DM2NQUY SN indocyanine green; Cardiogreen; 3599-32-4; AC1L2DMU; GTPL4844; KS-00000YFZ; MOLI001001; F9995-0163; sodium 4-(2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolium-3-yl)butane-1-sulfonate; sodium 4-[2-[(1E,3E,5E,7Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate; sodium 4-[2-[7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4
DM2NQUY DT Small molecular drug
DM2NQUY PC 11967809
DM2NQUY MW 775
DM2NQUY FM C43H47N2NaO6S2
DM2NQUY IC InChI=1S/C43H48N2O6S2.Na/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51;/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51);/q;+1/p-1
DM2NQUY CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+]
DM2NQUY IK MOFVSTNWEDAEEK-UHFFFAOYSA-M
DM2NQUY IU sodium;4-[(2E)-2-[(2E,4E,6E)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate
DM2NQUY CA CAS 3599-32-4
DM2NQUY DE Gastrointestinal disease
DMSC4A7 ID DMSC4A7
DMSC4A7 DN Indomethacin
DMSC4A7 HS Approved
DMSC4A7 SN Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
DMSC4A7 CP Recordati Rare Diseases Inc
DMSC4A7 TC Antiinflammatory Agents
DMSC4A7 DT Small molecular drug
DMSC4A7 PC 3715
DMSC4A7 MW 357.8
DMSC4A7 FM C19H16ClNO4
DMSC4A7 IC InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DMSC4A7 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
DMSC4A7 IK CGIGDMFJXJATDK-UHFFFAOYSA-N
DMSC4A7 IU 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
DMSC4A7 CA CAS 53-86-1
DMSC4A7 CB CHEBI:49662
DMSC4A7 DE Rheumatoid arthritis
DMI0RHA ID DMI0RHA
DMI0RHA DN Inebilizumab
DMI0RHA HS Approved
DMI0RHA CP MedImmune Gaithersburg, MD
DMI0RHA DE Neuromyelitis optica spectrum disorder
DMH7OIA ID DMH7OIA
DMH7OIA DN Infliximab
DMH7OIA HS Approved
DMH7OIA SN Remicade (TN)
DMH7OIA CP Samsung Bioepsis
DMH7OIA TC Immunosuppressive Agents
DMH7OIA DT Antibody
DMH7OIA DE Plaque psoriasis; Rheumatoid arthritis; Asthma
DMK1CZJ ID DMK1CZJ
DMK1CZJ DN Ingenol mebutate
DMK1CZJ HS Approved
DMK1CZJ SN Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A
DMK1CZJ CP LEO Pharma
DMK1CZJ DT Small molecular drug
DMK1CZJ PC 6918670
DMK1CZJ MW 430.5
DMK1CZJ FM C25H34O6
DMK1CZJ IC InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
DMK1CZJ CS C/C=C(/C)\\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C
DMK1CZJ IK VDJHFHXMUKFKET-WDUFCVPESA-N
DMK1CZJ IU [(1S,4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] (Z)-2-methylbut-2-enoate
DMK1CZJ CA CAS 75567-37-2
DMK1CZJ CB CHEBI:66913
DMK1CZJ DE Actinic keratosis; Melanoma
DMJ93CT ID DMJ93CT
DMJ93CT DN Inotersen
DMJ93CT HS Approved
DMJ93CT SN UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915
DMJ93CT CP Ionis Pharmaceuticals
DMJ93CT PC 121492004
DMJ93CT MW 7183
DMJ93CT FM C230H318N69O121P19S19
DMJ93CT IC InChI=1S/C230H318N69O121P19S19/c1-98-53-280(219(312)262-178(98)231)140-43-110(121(382-140)66-364-425(328,444)406-114-47-144(292-90-254-150-183(236)244-85-249-188(150)292)387-126(114)71-368-423(326,442)404-112-45-142(282-59-104(7)197(303)274-225(282)318)383-122(112)67-363-421(324,440)403-111-44-141(281-58-103(6)196(302)273-224(281)317)385-124(111)69-366-427(330,446)410-119-52-149(297-95-260-156-194(297)268-217(242)271-204(156)310)391-130(119)75-372-431(334,450)419-167-139(401-215(177(167)362-42-32-352-22)299-97-261-157-195(299)269-218(243)272-205(157)311)84-381-438(341,457)418-165-136(398-213(175(165)360-40-30-350-20)291-64-109(12)202(308)279-230(291)323)82-379-437(340,456)417-163-135(397-211(173(163)358-38-28-348-18)289-62-107(10)200(306)277-228(289)321)81-378-435(338,454)414-161-132(394-209(171(161)356-36-26-346-16)286-56-101(4)181(234)265-222(286)315)78-375-433(336,452)412-159-120(65-300)392-207(169(159)354-34-24-344-14)288-61-106(9)199(305)276-227(288)320)402-422(325,441)367-70-125-115(48-145(386-125)293-91-255-151-184(237)245-86-250-189(151)293)407-426(329,445)365-68-123-113(46-143(384-123)283-60-105(8)198(304)275-226(283)319)405-424(327,443)371-74-129-118(51-148(390-129)296-94-259-155-193(296)267-216(241)270-203(155)309)409-429(332,448)370-72-127-116(49-146(388-127)294-92-256-152-185(238)246-87-251-190(152)294)408-428(331,447)369-73-128-117(50-147(389-128)295-93-257-153-186(239)247-88-252-191(153)295)411-430(333,449)374-77-138-166(176(361-41-31-351-21)214(400-138)298-96-258-154-187(240)248-89-253-192(154)298)420-439(342,458)380-83-137-164(174(359-39-29-349-19)212(399-137)290-63-108(11)201(307)278-229(290)322)416-436(339,455)377-80-134-162(172(357-37-27-347-17)210(396-134)287-57-102(5)182(235)266-223(287)316)415-434(337,453)376-79-133-160(170(355-35-25-345-15)208(395-133)285-55-100(3)180(233)264-221(285)314)413-432(335,451)373-76-131-158(301)168(353-33-23-343-13)206(393-131)284-54-99(2)179(232)263-220(284)313/h53-64,85-97,110-149,158-177,206-215,300-301H,23-52,65-84H2,1-22H3,(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H,342,458)(H2,231,262,312)(H2,232,263,313)(H2,233,264,314)(H2,234,265,315)(H2,235,266,316)(H2,236,244,249)(H2,237,245,250)(H2,238,246,251)(H2,239,247,252)(H2,240,248,253)(H,273,302,317)(H,274,303,318)(H,275,304,319)(H,276,305,320)(H,277,306,321)(H,278,307,322)(H,279,308,323)(H3,241,267,270,309)(H3,242,268,271,310)(H3,243,269,272,311)/t110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,206+,207+,208+,209+,210+,211+,212+,213+,214+,215+,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?/m0/s1
DMJ93CT CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)O[C@@H]8[C@H](O[C@H]([C@@H]8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMJ93CT IK KLEGMTRDCCDFJK-XDQSQZFTSA-N
DMJ93CT IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJ93CT CA CAS 1492984-65-2
DMJ93CT DE Hereditary amyloidosis
DMAC130 ID DMAC130
DMAC130 DN Inotuzumab ozogamicin
DMAC130 HS Approved
DMAC130 CP Pfizer
DMAC130 DT Antibody
DMAC130 DE Acute lymphocytic leukaemia; Acute lymphoblastic leukaemia
DMB7CE0 ID DMB7CE0
DMB7CE0 DN Insulin
DMB7CE0 HS Approved
DMB7CE0 SN BrioDurance; Insulin (agglomerated vesicle technology, diabetes), Cense Biosciences; Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes); Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes), Cense Biosciences
DMB7CE0 CP Cense Biosciences Inc
DMB7CE0 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKT
DMB7CE0 DE Diabetic complication
DMPL395 ID DMPL395
DMPL395 DN Insulin degludec
DMPL395 HS Approved
DMPL395 SN Tresiba (TN)
DMPL395 CP Novo Nordisk
DMPL395 SQ A Chain: FVNQHLCGSHLVEALYLVCGERGFFYTPK >B ChainGIVEQCCTSICSLYQLENYCN
DMPL395 PC 118984462
DMPL395 MW 6104
DMPL395 FM C274H411N65O81S6
DMPL395 IC InChI=1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1
DMPL395 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMPL395 IK FYZPCMFQCNBYCY-WIWKJPBBSA-N
DMPL395 IU 16-[[(1S)-4-[[(5S)-5-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carboxypentyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid
DMPL395 CA CAS 844439-96-9
DMPL395 DE Type-1/2 diabetes
DM79NZ5 ID DM79NZ5
DM79NZ5 DN Insulin determir
DM79NZ5 HS Approved
DM79NZ5 SN Levemir (TN)
DM79NZ5 DE Diabetic complication
DM5XHVR ID DM5XHVR
DM5XHVR DN Insulin Lyspro recombinant
DM5XHVR HS Approved
DM5XHVR TC Hypoglycemic Agents
DM5XHVR DE Diabetic complication
DMYVP5G ID DMYVP5G
DMYVP5G DN Insulin recombinant
DMYVP5G HS Approved
DMYVP5G SN 9004-10-8; Exubera; Insulin recombinant; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system]
DMYVP5G TC Hypoglycemic Agents
DMYVP5G DT Small molecular drug
DMYVP5G PC 70678557
DMYVP5G MW 5794
DMYVP5G FM C256H381N65O77S6
DMYVP5G IC InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1
DMYVP5G CS CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN
DMYVP5G IK YAJCHEVQCOHZDC-QMMNLEPNSA-N
DMYVP5G IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-oxopropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2R)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1S)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2S)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMYVP5G CA CAS 9004-10-8
DMYVP5G DE Diabetic complication
DMW8KI7 ID DMW8KI7
DMW8KI7 DN Insulin Susp Isophane Recombinant Human
DMW8KI7 HS Approved
DMW8KI7 SN Nph Insulin; Nph Iletin I (Beef-pork); Nph Iletin Ii; Insulin Insulatard Nph Nordisk; Nph Iletin Ii (Pork); Nph Purified Pork Isophane Insulin; Humulin N; Novolin N; Insulatard Nph Human; Insulin Susp Isophane Beef; Insulin Susp Isophane Beef/Pork; Insulin Susp Isophane Purified Beef; Insulin Susp Isophane Purified Pork; Insulin Susp Isophane Semisynthetic Purified Human
DMW8KI7 CP Eli Lilly And Co
DMW8KI7 DE Diabetic complication
DM0NATE ID DM0NATE
DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork
DM0NATE HS Approved
DM0NATE SN Protamine Zinc & Iletin I (Beef-pork); Protamine Zinc And Iletin Ii; Protamine Zinc Insulin; Protamine Zinc And Iletin Ii (Pork); Insulin Susp Protamine Zinc Purified Beef; Insulin Susp Protamine Zinc Purified Pork
DM0NATE CP Eli Lilly And Co
DM0NATE DE Diabetic complication
DM6MO9X ID DM6MO9X
DM6MO9X DN Insulin Zinc Susp Recombinant Human
DM6MO9X HS Approved
DM6MO9X SN Humulin L; Humulin U; Lentard; Lente; Lente Iletin Ii; Lente Iletin Ii (Pork); Lente Insulin; Novolin L; Semilente; Semilente Insulin; Ultralente; Ultralente Insulin; Insulin Zinc Susp Beef; Insulin Zinc Susp Extended Beef; Insulin Zinc Susp Extended Purified Beef; Insulin Zinc Susp Extended Recombinant Human; Insulin Zinc Susp Prompt Beef; Insulin Zinc Susp Prompt Purified Pork; Insulin Zinc Susp Purified Beef; Insulin Zinc Susp Purified Beef/Pork; Insulin Zinc Susp Purified Pork; Insulin Zinc Susp Semisynthetic Purified Human
DM6MO9X CP Eli Lilly And Co
DM6MO9X DE Diabetic complication
DMO95XI ID DMO95XI
DMO95XI DN Insulin, porcine
DMO95XI HS Approved
DMO95XI SN Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox)
DMO95XI TC Hypoglycemic Agents
DMO95XI DT Small molecular drug
DMO95XI PC 16131098
DMO95XI MW 5778
DMO95XI FM C256H381N65O76S6
DMO95XI IC InChI=1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMO95XI CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMO95XI IK NOESYZHRGYRDHS-ZYCCASTOSA-N
DMO95XI IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S)-1-carboxyethyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMO95XI CA CAS 12584-58-6
DMO95XI DE Diabetic complication
DMX7V28 ID DMX7V28
DMX7V28 DN Insulin-aspart
DMX7V28 HS Approved
DMX7V28 SN Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human)
DMX7V28 TC Hypoglycemic Agents
DMX7V28 DT Small molecular drug
DMX7V28 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTDKT
DMX7V28 PC 118984445
DMX7V28 MW 5826
DMX7V28 FM C256H381N65O79S6
DMX7V28 IC InChI=1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMX7V28 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMX7V28 IK WEDIKSVWBUKTRA-WTKGVUNUSA-N
DMX7V28 IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMX7V28 CA CAS 116094-23-6
DMX7V28 DE Diabetic complication
DMOA4VW ID DMOA4VW
DMOA4VW DN Insulin-detemir
DMOA4VW HS Approved
DMOA4VW SN Insulin detemir; UNII-4FT78T86XV; 4FT78T86XV; NN-304; Levemir; Levemir Penfill; Levemir Insulin; Levemir Innolet; Levemir Flexpen; 169148-63-4; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human); 270588-25-5
DMOA4VW TC Hypoglycemic Agents
DMOA4VW DT Small molecular drug
DMOA4VW SQ GIVEQCCTSICSLYQLENYCNFVNQHLCGSHLVEALYLVCGERGFFYTPK
DMOA4VW PC 16137271
DMOA4VW MW 5917
DMOA4VW FM C267H402N64O76S6
DMOA4VW IC InChI=1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1
DMOA4VW CS CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC9=CNC=N9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)[C@@H](C)CC)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O
DMOA4VW IK UGOZVNFCFYTPAZ-IOXYNQHNSA-N
DMOA4VW IU (2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid
DMOA4VW CA CAS 169148-63-4
DMOA4VW DE Type-1/2 diabetes
DMR4HIW ID DMR4HIW
DMR4HIW DN Insulin-glargine
DMR4HIW HS Approved
DMR4HIW SN Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin
DMR4HIW TC Hypoglycemic Agents
DMR4HIW DT Small molecular drug
DMR4HIW SQ A chain: GIVEQCCTSICSLYQLENYCG >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR
DMR4HIW PC 118984454
DMR4HIW MW 6063
DMR4HIW FM C267H404N72O78S6
DMR4HIW IC InChI=1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1
DMR4HIW CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMR4HIW IK COCFEDIXXNGUNL-RFKWWTKHSA-N
DMR4HIW IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMR4HIW CA CAS 160337-95-1
DMR4HIW DE Malaria; Type-1 diabetes; Type-2 diabetes; Diabetic complication
DMQI0FU ID DMQI0FU
DMQI0FU DN Insulin-glulisine
DMQI0FU HS Approved
DMQI0FU TC Hypoglycemic Agents
DMQI0FU SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVKQHLCGSHLVEALYLVCGERGFFYTPET
DMQI0FU PC 16136701
DMQI0FU MW 5823
DMQI0FU FM C258H384N64O78S6
DMQI0FU IC InChI=1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1
DMQI0FU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMQI0FU IK RCHHVVGSTHAVPF-ZPHPLDECSA-N
DMQI0FU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQI0FU CA CAS 207748-29-6
DMQI0FU DE Diabetic complication
DM4O90W ID DM4O90W
DM4O90W DN Insulin-lispro
DM4O90W HS Approved
DM4O90W SN WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro
DM4O90W CP Eli Lilly
DM4O90W TC Hypoglycemic Agents
DM4O90W DT Small molecular drug
DM4O90W PC 16132438
DM4O90W MW 5814
DM4O90W FM C257H389N65O77S6
DM4O90W IC InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
DM4O90W CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
DM4O90W IK WNRQPCUGRUFHED-DETKDSODSA-N
DM4O90W IU (4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM4O90W CA CAS 133107-64-9
DM4O90W DE Diabetic complication
DMSTA36 ID DMSTA36
DMSTA36 DN Intedanib
DMSTA36 HS Approved
DMSTA36 SN Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate
DMSTA36 CP Boehringer Ingelheim Pharmaceuticals
DMSTA36 DT Small molecular drug
DMSTA36 PC 135423438
DMSTA36 MW 539.6
DMSTA36 FM C31H33N5O4
DMSTA36 IC InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
DMSTA36 CS CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
DMSTA36 IK CPMDPSXJELVGJG-UHFFFAOYSA-N
DMSTA36 IU methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate
DMSTA36 CA CAS 656247-17-5
DMSTA36 CB CHEBI:85164
DMSTA36 DE Colorectal cancer; Idiopathic pulmonary fibrosis; Ovarian cancer; Non-small-cell lung cancer; Mesothelioma
DMUTZ8S ID DMUTZ8S
DMUTZ8S DN Interferon Alfa-2a, Recombinant
DMUTZ8S HS Approved
DMUTZ8S SN Roferon A (TN)
DMUTZ8S TC Anticancer Agents
DMUTZ8S SQ DB00034 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMUTZ8S DE Chronic HCV-1 infection
DMWCQP4 ID DMWCQP4
DMWCQP4 DN Interferon alfa-2B
DMWCQP4 HS Approved
DMWCQP4 SN Intron A; Viraferon
DMWCQP4 CP Schering-plough
DMWCQP4 TC Anticancer Agents
DMWCQP4 DT Small molecular drug
DMWCQP4 PC 71306834
DMWCQP4 MW 746.5
DMWCQP4 FM C16H17Cl3I2N3NaO5S
DMWCQP4 IC InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1
DMWCQP4 CS CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
DMWCQP4 IK MIXCUJKCXRNYFM-UHFFFAOYSA-M
DMWCQP4 IU sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide
DMWCQP4 CA CAS 98530-12-2
DMWCQP4 DE Melanoma
DM3TPY8 ID DM3TPY8
DM3TPY8 DN Interferon Alfa-2b, Recombinant
DM3TPY8 HS Approved
DM3TPY8 SN Alpharona (TN); Genferon (TN); Gerpferon (TN); Grippferon (TN); Infagel (TN); Intron A (TN); Kipferon (TN); Realderon (TN); Recolin (TN); Teva (TN); Viferon (TN)
DM3TPY8 CP Schering-Plough
DM3TPY8 TC Anticancer Agents
DM3TPY8 SQ DB00105 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM3TPY8 DE Hairy cell leukaemia
DM90WJH ID DM90WJH
DM90WJH DN Interferon alfacon-1
DM90WJH HS Approved
DM90WJH SN Advaferon; Infergen; Advaferon (TN); Infergen (TN); Interferon alfacon-1 (genetical recombination); Interferon alfacon-1 (USAN/INN); Interferon alfacon-1 (genetical recombination) (JAN)
DM90WJH TC Anticancer Agents
DM90WJH SQ Interferon alfacon-1: MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE
DM90WJH DE Hepatitis C
DM4AK0Q ID DM4AK0Q
DM4AK0Q DN Interferon alfa-n1
DM4AK0Q HS Approved
DM4AK0Q SN Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN)
DM4AK0Q TC Antiviral Agents
DM4AK0Q SQ DB00011 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM4AK0Q DE Chronic myelogenous leukaemia
DMTZNQ9 ID DMTZNQ9
DMTZNQ9 DN Interferon alfa-n3
DMTZNQ9 HS Approved
DMTZNQ9 SN Alferon LDO; Interferon alfa-n3 (oral); Interferon alfa-n3 (oral), Hemispherx; Interferon alfa-n3 (oral), InterferonSciences
DMTZNQ9 CP Interferon Sciences Inc
DMTZNQ9 SQ DB00018 sequence (alpha-2A): CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2B)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2C)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMTZNQ9 DE Human immunodeficiency virus infection
DM1A6RV ID DM1A6RV
DM1A6RV DN Interferon beta-1a
DM1A6RV HS Approved
DM1A6RV SN Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN)
DM1A6RV TC Immunomodulatory Agents
DM1A6RV DT Protein/peptide drug
DM1A6RV SQ MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DM1A6RV DE Multiple sclerosis
DMCN61Z ID DMCN61Z
DMCN61Z DN Interferon beta-1b
DMCN61Z HS Approved
DMCN61Z SN Betaferon (TN); Betaseron (TN)
DMCN61Z TC Immunomodulatory Agents
DMCN61Z SQ DB00068 sequence: SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMCN61Z DE Multiple sclerosis
DMWUMRL ID DMWUMRL
DMWUMRL DN Interferon gamma-1b
DMWUMRL HS Approved
DMWUMRL TC Immunomodulatory Agents
DMWUMRL SQ DB00033 sequence: CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ
DMWUMRL DE Chronic granulomatous disease
DM1Y69Q ID DM1Y69Q
DM1Y69Q DN Interleukin-3
DM1Y69Q HS Approved
DM1Y69Q DE Aplastic anemia
DM1Y2JH ID DM1Y2JH
DM1Y2JH DN Inulin
DM1Y2JH HS Approved
DM1Y2JH SN Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27
DM1Y2JH TC Hypoglycemic Agents
DM1Y2JH DT Small molecular drug
DM1Y2JH PC 24763
DM1Y2JH MW 6179
DM1Y2JH FM C228H382O191
DM1Y2JH IC InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DM1Y2JH CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO[C@]8([C@H]([C@@H]([C@H](O8)CO)O)O)CO[C@]9([C@H]([C@@H]([C@H](O9)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO)O)O)O)O
DM1Y2JH IK JYJIGFIDKWBXDU-MNNPPOADSA-N
DM1Y2JH IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM1Y2JH CA CAS 9005-80-5
DM1Y2JH DE Measure kidney function
DMS6ZI0 ID DMS6ZI0
DMS6ZI0 DN Inulin
DMS6ZI0 HS Approved
DMS6ZI0 SN Inulin [BAN]; Inulin [USP:BAN]; Inulin and sodium chloride; Inulin-oligofructose enriched; JOS53KRJ01; LS-186416; LS-187349; Liquid Agave Inulin; Agave Inulin; Inulin - Liquid; Inulin Powder; 78089-EP2272846A1; 78089-EP2277868A1; 78089-EP2277869A1; 78089-EP2308866A1; 78089-EP2374791A1; AI3-19506; DB00638; EINECS 232-684-3; UNII-JOS53KRJ01
DMS6ZI0 PC 24763
DMS6ZI0 MW 6179
DMS6ZI0 FM C228H382O191
DMS6ZI0 IC JYJIGFIDKWBXDU-MNNPPOADSA-N
DMS6ZI0 CS C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O
DMS6ZI0 IK 1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DMS6ZI0 IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMS6ZI0 CA CAS 9005-80-5
DMS6ZI0 DE Acute kidney failure
DM80OEZ ID DM80OEZ
DM80OEZ DN Iobenguane I-123
DM80OEZ HS Approved
DM80OEZ SN Iobenguane (123I); UNII-P2TH1XYZ84; m-Iodobenzylguanidine-123I; P2TH1XYZ84; Adreview; Iobenguane I 123; 123I-MIBG; 2-[(3-iodanylphenyl)methyl]guanidine; 76924-93-1; Iodine-123 metaiodobenzylguanidine; m-(123I)Iodobenzylguanidine; Iobenguane I 123 [USAN]; MyoMIBG-I 123 (TN); (123I)-m-Iodobenzylguanidine; AC1L367T; AC1Q50E3; CHEMBL1615777; SCHEMBL13158600; (123)I-MIBG; CHEBI:135134; 123 iodine metaiodobenzylguanidine; MOLI000966; 3-Iodobenzylguanidine (123I) (JAN); Guanidine, ((3-iodo(123I)phenyl)methyl)-; D01729
DM80OEZ CP GE Healthcare
DM80OEZ DT Small molecular drug
DM80OEZ PC 135326
DM80OEZ MW 271.09
DM80OEZ FM C8H10IN3
DM80OEZ IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4
DM80OEZ CS C1=CC(=CC(=C1)[123I])CN=C(N)N
DM80OEZ IK PDWUPXJEEYOOTR-IUAIQHPESA-N
DM80OEZ IU 2-[(3-(123I)iodanylphenyl)methyl]guanidine
DM80OEZ CA CAS 76924-93-1
DM80OEZ CB CHEBI:135134
DM80OEZ DE Neuroendocrine cancer
DMXIQYS ID DMXIQYS
DMXIQYS DN Iodipamide
DMXIQYS HS Approved
DMXIQYS SN Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS TC Contrast Media
DMXIQYS DT Small molecular drug
DMXIQYS PC 3739
DMXIQYS MW 1139.8
DMXIQYS FM C20H14I6N2O6
DMXIQYS IC InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)
DMXIQYS CS C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I
DMXIQYS IK FFINMCNLQNTKLU-UHFFFAOYSA-N
DMXIQYS IU 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS CA CAS 606-17-7
DMXIQYS CB CHEBI:31176
DMXIQYS DE Gallbladder disease
DMNARJT ID DMNARJT
DMNARJT DN Ioflupane I-123
DMNARJT HS Approved
DMNARJT SN Datscan (TN)
DMNARJT CP GE Healthcare
DMNARJT DT Small molecular drug
DMNARJT PC 3086674
DMNARJT MW 427.3
DMNARJT FM C18H23FINO2
DMNARJT IC InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4
DMNARJT CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)[123I]
DMNARJT IK HXWLAJVUJSVENX-HFIFKADTSA-N
DMNARJT IU methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-(123I)iodanylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DMNARJT CA CAS 155798-07-5
DMNARJT CB CHEBI:68855
DMNARJT DE Parkinson disease
DMLZTP9 ID DMLZTP9
DMLZTP9 DN Ipecac
DMLZTP9 HS Approved
DMLZTP9 SN Ipecac syrup
DMLZTP9 DE Poison intoxication
DMWA24P ID DMWA24P
DMWA24P DN IPI-145
DMWA24P HS Approved
DMWA24P SN Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;
DMWA24P CP Verastem
DMWA24P DT Small molecular drug
DMWA24P PC 50905713
DMWA24P MW 416.9
DMWA24P FM C22H17ClN6O
DMWA24P IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DMWA24P CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DMWA24P IK SJVQHLPISAIATJ-ZDUSSCGKSA-N
DMWA24P IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DMWA24P CA CAS 1201438-56-3
DMWA24P CB CHEBI:131169
DMWA24P DE Small lymphocytic lymphoma; Follicular lymphoma; Arthritis
DMJTIYK ID DMJTIYK
DMJTIYK DN Ipilimumab
DMJTIYK HS Approved
DMJTIYK SN BMS-734016; MDX-010; MDX-101; Yervoy (TN)
DMJTIYK CP Bristol-Myers Squibb
DMJTIYK DT Monoclonal antibody
DMJTIYK SQ Ipilimumab heavy chain (patent appl. US20150283234) : QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Ipilimumab light chain EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMJTIYK DE Melanoma
DMFQ320 ID DMFQ320
DMFQ320 DN Ipratropium
DMFQ320 HS Approved
DMFQ320 SN Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane
DMFQ320 TC Bronchodilator Agents
DMFQ320 DT Small molecular drug
DMFQ320 PC 657309
DMFQ320 MW 332.5
DMFQ320 FM C20H30NO3+
DMFQ320 IC InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?
DMFQ320 CS CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
DMFQ320 IK OEXHQOGQTVQTAT-BZQJJPTISA-N
DMFQ320 IU [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMFQ320 CA CAS 60205-81-4
DMFQ320 CB CHEBI:5956
DMFQ320 DE Obstructive lung disease
DM0IO13 ID DM0IO13
DM0IO13 DN Ipriflavone
DM0IO13 HS Approved
DM0IO13 SN Osten (TN)
DM0IO13 DT Small molecular drug
DM0IO13 PC 3747
DM0IO13 MW 280.3
DM0IO13 FM C18H16O3
DM0IO13 IC InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
DM0IO13 CS CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
DM0IO13 IK SFBODOKJTYAUCM-UHFFFAOYSA-N
DM0IO13 IU 3-phenyl-7-propan-2-yloxychromen-4-one
DM0IO13 CA CAS 35212-22-7
DM0IO13 CB CHEBI:31719
DM0IO13 DE Osteoporosis
DMTP1DC ID DMTP1DC
DMTP1DC DN Irbesartan
DMTP1DC HS Approved
DMTP1DC SN irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan
DMTP1DC CP Bristol-Myers Squibb
DMTP1DC TC Antihypertensive Agents
DMTP1DC DT Small molecular drug
DMTP1DC PC 3749
DMTP1DC MW 428.5
DMTP1DC FM C25H28N6O
DMTP1DC IC InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
DMTP1DC CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMTP1DC IK YOSHYTLCDANDAN-UHFFFAOYSA-N
DMTP1DC IU 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
DMTP1DC CA CAS 138402-11-6
DMTP1DC CB CHEBI:5959
DMTP1DC DE Hypertension
DMP6SC2 ID DMP6SC2
DMP6SC2 DN Irinotecan
DMP6SC2 HS Approved
DMP6SC2 SN Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde
DMP6SC2 CP Pfizer Pharmaceuticals
DMP6SC2 TC Anticancer Agents
DMP6SC2 DT Small molecular drug
DMP6SC2 PC 60838
DMP6SC2 MW 586.7
DMP6SC2 FM C33H38N4O6
DMP6SC2 IC InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
DMP6SC2 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
DMP6SC2 IK UWKQSNNFCGGAFS-XIFFEERXSA-N
DMP6SC2 IU [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMP6SC2 CA CAS 97682-44-5
DMP6SC2 CB CHEBI:80630
DMP6SC2 DE Colorectal cancer
DMAP8MV ID DMAP8MV
DMAP8MV DN Iron
DMAP8MV HS Approved
DMAP8MV SN Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP
DMAP8MV TC Iron Supplement
DMAP8MV DT Small molecular drug
DMAP8MV PC 23925
DMAP8MV MW 55.84
DMAP8MV FM Fe
DMAP8MV IC InChI=1S/Fe
DMAP8MV CS [Fe]
DMAP8MV IK XEEYBQQBJWHFJM-UHFFFAOYSA-N
DMAP8MV IU iron
DMAP8MV CA CAS 7439-89-6
DMAP8MV CB CHEBI:18248
DMAP8MV DE Iron-deficiency anemia
DM5OY70 ID DM5OY70
DM5OY70 DN Iron Dextran
DM5OY70 HS Approved
DM5OY70 SN Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1)
DM5OY70 TC Iron Supplement
DM5OY70 DT Small molecular drug
DM5OY70 PC 105075
DM5OY70 MW 153.93
DM5OY70 FM FeH2O4S
DM5OY70 IC InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
DM5OY70 CS OS(=O)(=O)O.[Fe]
DM5OY70 IK MVZXTUSAYBWAAM-UHFFFAOYSA-N
DM5OY70 IU iron;sulfuric acid
DM5OY70 CA CAS 9004-66-4
DM5OY70 DE Iron-deficiency anemia
DMD45S9 ID DMD45S9
DMD45S9 DN Isavuconazonium
DMD45S9 HS Approved
DMD45S9 SN Isavuconazonium; Isavuconazonium (USAN); Isavuconazonium [USAN]; Isavuconazonium ion; VH2L779W8Q; 742049-41-8; AC1OCFMR; ACN-048059; BCP23773; BAL 8557-000; BAL-8557; BAL8557-000; CHEBI:85978; CHEMBL1183349; DB06636; DTXSID70225203; Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-1H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl ester; SCHEMBL13133195; UNII-VH2L779W8Q
DMD45S9 PC 6918606
DMD45S9 MW 717.8
DMD45S9 FM C35H35F2N8O5S+
DMD45S9 IC RSWOJTICKMKTER-QXLBVTBOSA-N
DMD45S9 CS CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O
DMD45S9 IK 1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1
DMD45S9 IU [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate
DMD45S9 CA CAS 742049-41-8
DMD45S9 CB CHEBI:85978
DMD45S9 DE Allergic bronchopulmonary aspergillosis
DMJ9G23 ID DMJ9G23
DMJ9G23 DN ISIS 1570
DMJ9G23 HS Approved
DMJ9G23 CP Isis Pharmaceuticals
DMJ9G23 DT Antisense drug
DMJ9G23 DE Lleum inflammation
DMAF1NB ID DMAF1NB
DMAF1NB DN Isocarboxazid
DMAF1NB HS Approved
DMAF1NB SN BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide
DMAF1NB CP Hoffmann-La Roche pharmaceutical company
DMAF1NB TC Antidepressants
DMAF1NB DT Small molecular drug
DMAF1NB PC 3759
DMAF1NB MW 231.25
DMAF1NB FM C12H13N3O2
DMAF1NB IC InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
DMAF1NB CS CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
DMAF1NB IK XKFPYPQQHFEXRZ-UHFFFAOYSA-N
DMAF1NB IU N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
DMAF1NB CA CAS 59-63-2
DMAF1NB CB CHEBI:93635
DMAF1NB DE Depression
DMITSEH ID DMITSEH
DMITSEH DN Isoetharine
DMITSEH HS Approved
DMITSEH SN Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH TC Bronchodilator Agents
DMITSEH DT Small molecular drug
DMITSEH PC 3762
DMITSEH MW 239.31
DMITSEH FM C13H21NO3
DMITSEH IC InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3
DMITSEH CS CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C
DMITSEH IK HUYWAWARQUIQLE-UHFFFAOYSA-N
DMITSEH IU 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH CA CAS 530-08-5
DMITSEH CB CHEBI:6005
DMITSEH DE Asthma
DMY6T31 ID DMY6T31
DMY6T31 DN Isoflurane
DMY6T31 HS Approved
DMY6T31 SN Aerrane; Forane; Forene; IsoFlo; Isoflurano; Isofluranum; AErrane (Veterinary); Forane (TN); Isoflurane [Anaesthetics, volatile]; Isoflurano [INN-Spanish]; Isofluranum [INN-Latin]; R-E 235dal; Isoflurane (JP15/USP/INN); Isoflurane [USAN:BAN:INN:JAN]; Isoflurane [USAN:INN:BAN:JAN]; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
DMY6T31 TC Anesthetics
DMY6T31 DT Small molecular drug
DMY6T31 PC 3763
DMY6T31 MW 184.49
DMY6T31 FM C3H2ClF5O
DMY6T31 IC InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DMY6T31 CS C(C(F)(F)F)(OC(F)F)Cl
DMY6T31 IK PIWKPBJCKXDKJR-UHFFFAOYSA-N
DMY6T31 IU 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
DMY6T31 CA CAS 26675-46-7
DMY6T31 CB CHEBI:6015
DMY6T31 DE Anaesthesia
DMBSK7X ID DMBSK7X
DMBSK7X DN Isoflurophate
DMBSK7X HS Approved
DMBSK7X SN DFP; DIFP; Diflupyl; Diflurophate; Diisopropylfluorfosfat; Diisopropylfluorophosphate; Diisopropylfluorphosphorsaeureester; Diisopropylphosphofluoridate; Diisopropylphosphorofluoridate; Dyflos; Floropryl; Fluoropryl; Fluorostigmine; Fluostigmine; Fluropryl; Isofluorophate; Isofluorphate; Isoflurophosphate; Neoglaucit; Di isopropylphosphorofluoridate; Diisopropoxyphosphoryl fluoride; Diisopropyl fluoridophosphate; Diisopropyl fluorophosphate; Diisopropyl fluorophosphonate; Diisopropyl phosphofluoridate; Diisopropyl phosphorofluoridate; Diisopropylfluorfosfat [Czech]; Diisopropylfluorophosphoric acid ester; Diisopropylfluorphosphorsaeureester [German]; Disiopropyl fluorophosphonate; Fluorodiisopropyl phosphate; Isoflurophate [USP]; Isopropyl fluophosphate; Isopropyl phosphorofluoridate; Merck Brand of Isoflurophate; Phosphoric acid diisopropyl ester fluoride; EA 1152; TL 466; DIISOPROPYL-FLUOROPHOSPHATE; Di-isopropylphosphorofluoridate; Floropryl (TN); Fluophosphoric acid, diisopropyl ester; Fluorophosphoric acid, diisopropyl ester; Isoflurophate (USP); PF-3; Phosphorofluoridic acid, diisopropyl ester; T-1703; Bis(1-methylethyl) Phosphorofluoridate; Dipropan-2-yl phosphorofluoridoate; O,O-Diisopropyl fluorophosphate; Bis(propan-2-yl) fluorophosphate; O,O'-Diisopropyl phosphoryl fluoride; Phosphorofluoridic acid, bis(1-methylethyl) ester; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X TC Antiglaucomic Agents
DMBSK7X DT Small molecular drug
DMBSK7X PC 5936
DMBSK7X MW 184.15
DMBSK7X FM C6H14FO3P
DMBSK7X IC InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3
DMBSK7X CS CC(C)OP(=O)(OC(C)C)F
DMBSK7X IK MUCZHBLJLSDCSD-UHFFFAOYSA-N
DMBSK7X IU 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X CA CAS 55-91-4
DMBSK7X CB CHEBI:17941
DMBSK7X DE Glaucoma/ocular hypertension
DM5JVS3 ID DM5JVS3
DM5JVS3 DN Isoniazid
DM5JVS3 HS Approved
DM5JVS3 SN Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.
DM5JVS3 CP Roche Pharmaceuticals
DM5JVS3 TC Antitubercular Agents
DM5JVS3 DT Small molecular drug
DM5JVS3 PC 3767
DM5JVS3 MW 137.14
DM5JVS3 FM C6H7N3O
DM5JVS3 IC InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
DM5JVS3 CS C1=CN=CC=C1C(=O)NN
DM5JVS3 IK QRXWMOHMRWLFEY-UHFFFAOYSA-N
DM5JVS3 IU pyridine-4-carbohydrazide
DM5JVS3 CA CAS 54-85-3
DM5JVS3 CB CHEBI:6030
DM5JVS3 DE Tuberculosis
DMQYV60 ID DMQYV60
DMQYV60 DN Isopropamide iodide
DMQYV60 HS Approved
DMQYV60 SN Isopropamide Iodide; 71-81-8; Darbid; Isoproponum iodide; Priamide Eupharma; Priamide; Tyrimide; Dipramide; Priazimide; Piaccamide; Sanulcin; Dipramid; Isamid; Marygin-M; UNII-E0KNA372SZ; Isopropamide ioduro [DCIT]; Isopropamidi iodidum [INN-Latin]; SKF 4740; Iodure d'isopropamide [INN-French]; EINECS 200-766-8; NSC 15521; Ioduro de isopropamida [INN-Spanish]; 5579 MD; E0KNA372SZ; R 79; MLS000069749; (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; Benzenepropanaminium, gamma-(aminocarbonyl)-N-methyl-N,N-bis(1-methyl
DMQYV60 DT Small molecular drug
DMQYV60 PC 6284
DMQYV60 MW 480.4
DMQYV60 FM C23H33IN2O
DMQYV60 IC InChI=1S/C23H32N2O.HI/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21;/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26);1H
DMQYV60 CS CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-]
DMQYV60 IK BFSMWENDZZIWPW-UHFFFAOYSA-N
DMQYV60 IU (4-amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium;iodide
DMQYV60 CA CAS 71-81-8
DMQYV60 CB CHEBI:6044
DMQYV60 DE Allergic rhinitis
DMK7MEY ID DMK7MEY
DMK7MEY DN Isoproterenol
DMK7MEY HS Approved
DMK7MEY SN isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409
DMK7MEY CP Abbott Laboratories
DMK7MEY TC Cardiotonic Agents
DMK7MEY DT Small molecular drug
DMK7MEY PC 3779
DMK7MEY MW 211.26
DMK7MEY FM C11H17NO3
DMK7MEY IC InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
DMK7MEY CS CC(C)NCC(C1=CC(=C(C=C1)O)O)O
DMK7MEY IK JWZZKOKVBUJMES-UHFFFAOYSA-N
DMK7MEY IU 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
DMK7MEY CA CAS 7683-59-2
DMK7MEY CB CHEBI:64317
DMK7MEY DE Heart block; Melanoma
DMBI4JG ID DMBI4JG
DMBI4JG DN Isosorbide dinitrate
DMBI4JG HS Approved
DMBI4JG SN Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol
DMBI4JG CP Biovail Corporation
DMBI4JG TC Vasodilator Agents
DMBI4JG DT Small molecular drug
DMBI4JG PC 6883
DMBI4JG MW 236.14
DMBI4JG FM C6H8N2O8
DMBI4JG IC InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
DMBI4JG CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]
DMBI4JG IK MOYKHGMNXAOIAT-JGWLITMVSA-N
DMBI4JG IU [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMBI4JG CA CAS 87-33-2
DMBI4JG CB CHEBI:6061
DMBI4JG DE Anal fissure; Angina pectoris
DMYLMU0 ID DMYLMU0
DMYLMU0 DN Isosorbide mononitrate
DMYLMU0 HS Approved
DMYLMU0 SN Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn
DMYLMU0 CP AstraZeneca
DMYLMU0 TC Vasodilator Agents
DMYLMU0 DT Small molecular drug
DMYLMU0 PC 27661
DMYLMU0 MW 191.14
DMYLMU0 FM C6H9NO6
DMYLMU0 IC InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
DMYLMU0 CS C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O
DMYLMU0 IK YWXYYJSYQOXTPL-SLPGGIOYSA-N
DMYLMU0 IU [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMYLMU0 CA CAS 16051-77-7
DMYLMU0 CB CHEBI:6062
DMYLMU0 DE Hydrocephalus
DM4QTBN ID DM4QTBN
DM4QTBN DN Isotretinoin
DM4QTBN HS Approved
DM4QTBN SN Accutane; Amnesteem; Claravis; Isotane; Isotretinoine; Isotretinoino; Isotretinoinum; Isotrex; Roaccutan; Roaccutane; Roacutan; Sotret; Teriosal; Neovitamin A acid; R 3255; Ro 4 3780; Ro 43780; Accutane (TN); Amnesteem (TN); BML2-E07; CIP-Isotretinoin; Claravi (TN); Clarus (TN); Decutan (TN); Isotane (TN); Isotretinoin (USP); Isotretinoin Zinc Salt, 13 cis Isomer; Isotretinoine [INN-French]; Isotretinoino [INN-Spanish]; Isotretinoinum [INN-Latin]; Izotek (TN); Oratane (TN); Ro 4-3780; Ro-43780; Roaccutane (TN); Sotret (TN); Isotretinoin [USAN:INN:BAN]; Ro-4-3780; Isotretinoin Zinc Salt, 13-cis-Isomer; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (7E,9E,11E,13Z)-retinoic acid; 13-RA; 13-cis RA; 13-cis-Vitamin A acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
DM4QTBN CP Roche Pharmaceuticals
DM4QTBN TC Antiacne Agents
DM4QTBN DT Small molecular drug
DM4QTBN PC 5282379
DM4QTBN MW 300.4
DM4QTBN FM C20H28O2
DM4QTBN IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DM4QTBN CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DM4QTBN IK SHGAZHPCJJPHSC-XFYACQKRSA-N
DM4QTBN IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM4QTBN CA CAS 4759-48-2
DM4QTBN CB CHEBI:6067
DM4QTBN DE Acne vulgaris
DMX7LKS ID DMX7LKS
DMX7LKS DN Isovanillin
DMX7LKS HS Approved
DMX7LKS SN Isovanilin; Isovanilline; Iso-Vanillin; Oxy-3 methoxy-4 benzaldehyde; Oxy-3 methoxy-4 benzaldehyde [French]; P-Anisaldehyde, 3-hydroxy-(8CI); 3-Hydroxy-4-methoxybenzaldehyde; 3-Hydroxy-p-anisaldehyde; 3-Hydroxyanisaldehyde; 3-hydroxy-4-anisaldehyde; 4-Methoxy-3-hydroxybenzaldehyde; 5-Formylguaiacol
DMX7LKS TC Anticancer Agents
DMX7LKS DT Small molecular drug
DMX7LKS PC 12127
DMX7LKS MW 152.15
DMX7LKS FM C8H8O3
DMX7LKS IC InChI=1S/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H3
DMX7LKS CS COC1=C(C=C(C=C1)C=O)O
DMX7LKS IK JVTZFYYHCGSXJV-UHFFFAOYSA-N
DMX7LKS IU 3-hydroxy-4-methoxybenzaldehyde
DMX7LKS CA CAS 621-59-0
DMX7LKS DE Solid tumour/cancer
DMJL10P ID DMJL10P
DMJL10P DN Isoxyl
DMJL10P HS Approved
DMJL10P SN Tiocarlide; Thiocarlide; Tiocarlid; 910-86-1; Disocarban; Datanil; Tiocarlidum [INN-Latin]; Tiocarlida [INN-Spanish]; 4,4'-Diisoamyloxythiocarbanilide; 4,4'-Bis(isopentyloxy)thiocarbanilide; Tiocarlide [INN:BAN:DCF]; UNII-43M23X81Y2; C23H32N2O2S; N,N'-Bis(4-(3-methylbutoxy)phenyl)thiourea; EINECS 213-006-5; CARBANILIDE, 4,4'-BIS(ISOPENTYLOXY)THIO-; BRN 2546347; Thiourea, N,N'-bis[4-(3-methylbutoxy)phenyl]-; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-; NSC742400; 43M23X81Y2; Amixyl; Disoxyl; Tiocarlida; Tiocarlidum; BRN2546347; Tiocarlide (INN); Tiocarlide [INN:DCF]; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-(9CI)
DMJL10P DT Small molecular drug
DMJL10P PC 3001386
DMJL10P MW 400.6
DMJL10P FM C23H32N2O2S
DMJL10P IC InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
DMJL10P CS CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C
DMJL10P IK BWBONKHPVHMQHE-UHFFFAOYSA-N
DMJL10P IU 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
DMJL10P CA CAS 910-86-1
DMJL10P CB CHEBI:135637
DMJL10P DE Bacterial infection
DMWCRN1 ID DMWCRN1
DMWCRN1 DN Ispaghula
DMWCRN1 HS Approved
DMWCRN1 SN Fiberall; Metamucil; PSYLLIUM; Plantaglucide; Psyllium Husk [USP]; Psyllium gum; Psyllium seed gum; Psyllium seed husk
DMWCRN1 CP Reckitt; Colman
DMWCRN1 DE Irritable bowel syndrome
DMA5XGH ID DMA5XGH
DMA5XGH DN Isradipine
DMA5XGH HS Approved
DMA5XGH SN Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
DMA5XGH CP Norvatis Phamaceuticals Corporation
DMA5XGH TC Antihypertensive Agents
DMA5XGH DT Small molecular drug
DMA5XGH PC 3784
DMA5XGH MW 371.4
DMA5XGH FM C19H21N3O5
DMA5XGH IC InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
DMA5XGH CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
DMA5XGH IK HMJIYCCIJYRONP-UHFFFAOYSA-N
DMA5XGH IU 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMA5XGH CA CAS 75695-93-1
DMA5XGH CB CHEBI:6073
DMA5XGH DE Hypertension; Herpes simplex virus infection
DM20VSK ID DM20VSK
DM20VSK DN Istradefylline
DM20VSK HS Approved
DM20VSK SN KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK CP Kyowa Hakko Pharmaceuticals
DM20VSK DT Small molecular drug
DM20VSK PC 5311037
DM20VSK MW 384.4
DM20VSK FM C20H24N4O4
DM20VSK IC InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
DM20VSK CS CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
DM20VSK IK IQVRBWUUXZMOPW-PKNBQFBNSA-N
DM20VSK IU 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK CA CAS 155270-99-8
DM20VSK CB CHEBI:134726
DM20VSK DE Substance use disorder; Parkinson disease
DMCR1MV ID DMCR1MV
DMCR1MV DN Itraconazole
DMCR1MV HS Approved
DMCR1MV SN Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
DMCR1MV CP Janssen Pharmaceutica
DMCR1MV TC Antifungal Agents
DMCR1MV DT Small molecular drug
DMCR1MV PC 55283
DMCR1MV MW 705.6
DMCR1MV FM C35H38Cl2N8O4
DMCR1MV IC InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
DMCR1MV CS CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
DMCR1MV IK VHVPQPYKVGDNFY-ZPGVKDDISA-N
DMCR1MV IU 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
DMCR1MV CA CAS 84625-61-6
DMCR1MV CB CHEBI:6076
DMCR1MV DE Fungal infection
DM0L594 ID DM0L594
DM0L594 DN Ivabradine
DM0L594 HS Approved
DM0L594 SN Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN]
DM0L594 CP Servier
DM0L594 DT Small molecular drug
DM0L594 PC 132999
DM0L594 MW 468.6
DM0L594 FM C27H36N2O5
DM0L594 IC InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
DM0L594 CS CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC
DM0L594 IK ACRHBAYQBXXRTO-OAQYLSRUSA-N
DM0L594 IU 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM0L594 CA CAS 155974-00-8
DM0L594 CB CHEBI:85966
DM0L594 DE Angina pectoris
DMZC1HS ID DMZC1HS
DMZC1HS DN Ivacaftor
DMZC1HS HS Approved
DMZC1HS SN Kalydeco (TN)
DMZC1HS CP Vertex
DMZC1HS DT Small molecular drug
DMZC1HS PC 16220172
DMZC1HS MW 392.5
DMZC1HS FM C24H28N2O3
DMZC1HS IC InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
DMZC1HS CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
DMZC1HS IK PURKAOJPTOLRMP-UHFFFAOYSA-N
DMZC1HS IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide
DMZC1HS CA CAS 873054-44-5
DMZC1HS CB CHEBI:66901
DMZC1HS DE Cystic fibrosis
DMDBX5F ID DMDBX5F
DMDBX5F DN Ivermectin
DMDBX5F HS Approved
DMDBX5F SN I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN)
DMDBX5F CP Merck & Co
DMDBX5F TC Antiprotozoal Agents
DMDBX5F DT Small molecular drug
DMDBX5F PC 6321424
DMDBX5F MW 875.1
DMDBX5F FM C48H74O14
DMDBX5F IC InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
DMDBX5F CS CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C
DMDBX5F IK AZSNMRSAGSSBNP-XPNPUAGNSA-N
DMDBX5F IU (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMDBX5F CA CAS 71827-03-7
DMDBX5F CB CHEBI:63941
DMDBX5F DE Intestinal strongyloidiasis due to nematode parasite
DM8S6T7 ID DM8S6T7
DM8S6T7 DN Ivosidenib
DM8S6T7 HS Approved
DM8S6T7 SN UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
DM8S6T7 CP Agios Pharmaceuticals
DM8S6T7 PC 71657455
DM8S6T7 MW 583
DM8S6T7 FM C28H22ClF3N6O3
DM8S6T7 IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DM8S6T7 CS C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DM8S6T7 IK WIJZXSAJMHAVGX-DHLKQENFSA-N
DM8S6T7 IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DM8S6T7 CA CAS 1448347-49-6
DM8S6T7 CB CHEBI:145430
DM8S6T7 DE Haematological malignancy; Acute myeloid leukaemia; Cholangiocarcinoma
DMRVITQ ID DMRVITQ
DMRVITQ DN Ivosidenib
DMRVITQ HS Approved
DMRVITQ SN (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo
DMRVITQ TC Anticancer Agents
DMRVITQ DT Small molecular drug
DMRVITQ PC 71657455
DMRVITQ MW 582.968
DMRVITQ FM C28H22ClF3N6O3
DMRVITQ IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DMRVITQ CS C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DMRVITQ IK WIJZXSAJMHAVGX-DHLKQENFSA-N
DMRVITQ IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DMRVITQ CA CAS 1448347-49-6
DMRVITQ DE Acute myeloid leukemia; Cholangiocarcinoma
DM2OZ3G ID DM2OZ3G
DM2OZ3G DN Ixabepilone
DM2OZ3G HS Approved
DM2OZ3G SN Azaepothilone B; BMS-247550; Ixempra (TN)
DM2OZ3G CP Bristol-Myers Squibb
DM2OZ3G DT Small molecular drug
DM2OZ3G PC 6445540
DM2OZ3G MW 506.7
DM2OZ3G FM C27H42N2O5S
DM2OZ3G IC InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
DM2OZ3G CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
DM2OZ3G IK FABUFPQFXZVHFB-PVYNADRNSA-N
DM2OZ3G IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
DM2OZ3G CA CAS 219989-84-1
DM2OZ3G CB CHEBI:63605
DM2OZ3G DE Breast cancer
DMXW92T ID DMXW92T
DMXW92T DN Ixekizumab
DMXW92T HS Approved
DMXW92T SN LY2439821
DMXW92T CP Eli Lilly
DMXW92T DT Monoclonal antibody
DMXW92T SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG >Light Chain SequenceDIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMXW92T DE Plaque psoriasis; Psoriatic arthritis
DMKJ8LB ID DMKJ8LB
DMKJ8LB DN Josamycin
DMKJ8LB HS Approved
DMKJ8LB SN Josacine; Josamicina; Josamycine; Josamycinum; EN 141; Kitasamycin A3; Leucomycin A3; Turimycin A5; Antibiotic yl-704 A3; Iosalide (TN); Josacine (TN); Josalid (TN); Josamicina [INN-Spanish]; Josamina (TN); Josamy (TN); Josamycin (TN); Josamycine [INN-French]; Josamycinum [INN-Latin]; Wilprafen (TN); Yl-704 A3; Josamycin [USAN:INN:JAN]; Josamycin (JP15/USAN/INN); Dro-2H-pyran-3-yl 3-methylbutanoate; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin V,3-acetate 4(sup beta)-(3-methylbutanoate)
DMKJ8LB TC Antibiotics
DMKJ8LB DT Small molecular drug
DMKJ8LB PC 5282165
DMKJ8LB MW 828
DMKJ8LB FM C42H69NO15
DMKJ8LB IC InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMKJ8LB CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O
DMKJ8LB IK XJSFLOJWULLJQS-NGVXBBESSA-N
DMKJ8LB IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate
DMKJ8LB CA CAS 16846-24-5
DMKJ8LB CB CHEBI:31739
DMKJ8LB DE Bacterial infection
DM2DMPO ID DM2DMPO
DM2DMPO DN Kanamycin
DM2DMPO HS Approved
DM2DMPO SN Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
DM2DMPO CP Sigma Chemical Company
DM2DMPO TC Antibiotics
DM2DMPO DT Small molecular drug
DM2DMPO PC 6032
DM2DMPO MW 484.5
DM2DMPO FM C18H36N4O11
DM2DMPO IC InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DM2DMPO CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
DM2DMPO IK SBUJHOSQTJFQJX-NOAMYHISSA-N
DM2DMPO IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DM2DMPO CA CAS 59-01-8
DM2DMPO CB CHEBI:17630
DM2DMPO DE Bacterial infection
DMITFB8 ID DMITFB8
DMITFB8 DN Kanamycin
DMITFB8 HS Approved
DMITFB8 SN Kanamicina; Kanamicina [Italian]; Kanamycin Base; EQK9Q303C5; KANAMYCIN A; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin sulfate; Kanamycine; Kanamycine [INN-French]; Kanamycinum; Kanamycinum [INN-Latin]; kanamycin; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; BRN 0061647; C18H36N4O11; CHEBI:17630; EINECS 200-411-7; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; HSDB 3107; KAN; UNII-EQK9Q303C5
DMITFB8 PC 6032
DMITFB8 MW 484.5
DMITFB8 FM C18H36N4O11
DMITFB8 IC SBUJHOSQTJFQJX-NOAMYHISSA-N
DMITFB8 CS C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N
DMITFB8 IK 1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DMITFB8 IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DMITFB8 CA CAS 59-01-8
DMITFB8 CB CHEBI:17630
DMITFB8 DE Pulmonary tuberculosis
DMT5HA4 ID DMT5HA4
DMT5HA4 DN Ketamine
DMT5HA4 HS Approved
DMT5HA4 SN Calypsol; Cetamina; Green; Ketaject; Ketalar; Ketaminum; Ketanest; Ketoject; Ketolar; Tekam; KETAMINE HCL; Ketalar base; Ketamine Base; Special K; Special K [street name]; CLSTA 20; T385; Cetamina [INN-Spanish]; Dl-Ketamine; Ketalar (TN); Ketamine (INN); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Ketanest (TN); Ketaset (TN); Tekam (TN); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-(9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-(9CI); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)-(8CI); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
DMT5HA4 CP Pfizer Pharmaceuticals
DMT5HA4 TC Analgesics
DMT5HA4 DT Small molecular drug
DMT5HA4 PC 3821
DMT5HA4 MW 237.72
DMT5HA4 FM C13H16ClNO
DMT5HA4 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
DMT5HA4 CS CNC1(CCCCC1=O)C2=CC=CC=C2Cl
DMT5HA4 IK YQEZLKZALYSWHR-UHFFFAOYSA-N
DMT5HA4 IU 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMT5HA4 CA CAS 6740-88-1
DMT5HA4 CB CHEBI:6121
DMT5HA4 DE Anaesthesia
DMVLMW6 ID DMVLMW6
DMVLMW6 DN Ketanserin
DMVLMW6 HS Approved
DMVLMW6 SN Ketanserina; Ketanserine; Ketanserinum; Ketaserin; Perketal; Serefrex; Sufrexal; Taseron; Ketanserina [INN-Spanish]; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; R 41,468; R-41468; [3H]-Ketanserin; Ketanserin (USAN/INN); Ketanserin [USAN:BAN:INN]; R-41,468; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione
DMVLMW6 CP Janssen Pharmaceutica
DMVLMW6 TC Antihypertensive Agents
DMVLMW6 DT Small molecular drug
DMVLMW6 PC 3822
DMVLMW6 MW 395.4
DMVLMW6 FM C22H22FN3O3
DMVLMW6 IC InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
DMVLMW6 CS C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O
DMVLMW6 IK FPCCSQOGAWCVBH-UHFFFAOYSA-N
DMVLMW6 IU 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione
DMVLMW6 CA CAS 74050-98-9
DMVLMW6 CB CHEBI:6123
DMVLMW6 DE Hypertension
DMM3L6Z ID DMM3L6Z
DMM3L6Z DN Ketobemidone
DMM3L6Z HS Approved
DMM3L6Z SN Ketobemidone hydrochloride; Cliradon hydrochloride; Ketobimedon hydrochloride; UNII-U9U6LTV80K; 5965-49-1; EINECS 227-749-8; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; Ketobemidone HCl; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; Ketogan (TN); AC1L2YOJ; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); AC1Q5G7W; SCHEMBL9706814; 469-79-4 (Parent); DTXSID00208327; LS-123062; D08101
DMM3L6Z DT Small molecular drug
DMM3L6Z PC 10101
DMM3L6Z MW 247.33
DMM3L6Z FM C15H21NO2
DMM3L6Z IC InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
DMM3L6Z CS CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O
DMM3L6Z IK ALFGKMXHOUSVAD-UHFFFAOYSA-N
DMM3L6Z IU 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
DMM3L6Z CA CAS 469-79-4
DMM3L6Z CB CHEBI:6125
DMM3L6Z DE Pain
DMPZI3Q ID DMPZI3Q
DMPZI3Q DN Ketoconazole
DMPZI3Q HS Approved
DMPZI3Q SN KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
DMPZI3Q CP Johnson & Johnson
DMPZI3Q TC Antifungal Agents
DMPZI3Q DT Small molecular drug
DMPZI3Q PC 456201
DMPZI3Q MW 531.4
DMPZI3Q FM C26H28Cl2N4O4
DMPZI3Q IC InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1
DMPZI3Q CS CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
DMPZI3Q IK XMAYWYJOQHXEEK-OZXSUGGESA-N
DMPZI3Q IU 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
DMPZI3Q CA CAS 65277-42-1
DMPZI3Q CB CHEBI:48336
DMPZI3Q DE Fungal infection
DMRKXPT ID DMRKXPT
DMRKXPT DN Ketoprofen
DMRKXPT HS Approved
DMRKXPT SN Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid
DMRKXPT CP ProEthic Pharmaceuticals
DMRKXPT TC Analgesics
DMRKXPT DT Small molecular drug
DMRKXPT PC 3825
DMRKXPT MW 254.28
DMRKXPT FM C16H14O3
DMRKXPT IC InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
DMRKXPT CS CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
DMRKXPT IK DKYWVDODHFEZIM-UHFFFAOYSA-N
DMRKXPT IU 2-(3-benzoylphenyl)propanoic acid
DMRKXPT CA CAS 22071-15-4
DMRKXPT CB CHEBI:6128
DMRKXPT DE Pain; Osteoarthritis; Musculoskeletal pain; Migraine
DMI4EL5 ID DMI4EL5
DMI4EL5 DN Ketorolac
DMI4EL5 HS Approved
DMI4EL5 SN Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5 CP Laboratorios Syntex SA
DMI4EL5 TC Analgesics
DMI4EL5 DT Small molecular drug
DMI4EL5 PC 3826
DMI4EL5 MW 255.27
DMI4EL5 FM C15H13NO3
DMI4EL5 IC InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
DMI4EL5 CS C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
DMI4EL5 IK OZWKMVRBQXNZKK-UHFFFAOYSA-N
DMI4EL5 IU 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5 CA CAS 74103-06-3
DMI4EL5 CB CHEBI:76223
DMI4EL5 DE Postoperative inflammation
DM74XKS ID DM74XKS
DM74XKS DN Ketotifen
DM74XKS HS Approved
DM74XKS SN Ketotifen [INN:BAN]; Ketotifene; Ketotifene [INN-French]; Ketotifeno; Ketotifeno [INN-Spanish]; Ketotifenum; Ketotifenum [INN-Latin]; HC 20-511; ZCVMWBYGMWKGHF-UHFFFAOYSA-N; Zaditor; ketotifen; 34580-13-7; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; BRN 3983897; CHEMBL534; EINECS 252-099-7; HSDB 7283; UNII-X49220T18G
DM74XKS PC 3827
DM74XKS MW 309.4
DM74XKS FM C19H19NOS
DM74XKS IC ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DM74XKS CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DM74XKS IK 1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DM74XKS IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DM74XKS CA CAS 34580-13-7
DM74XKS CB CHEBI:92511
DM74XKS DE Conjunctivitis
DMOVY05 ID DMOVY05
DMOVY05 DN Ketotifen
DMOVY05 HS Approved
DMOVY05 SN Ketotifene; Ketotifeno; Ketotifenum; Ketotifin; Ketotiphen; Ketotiphene; Zaditor; Ketotifene fumarate; Alaway (TN); HC 20-511; Ketotifen (INN); Ketotifen [INN:BAN]; Ketotifene [INN-French]; Ketotifeno [INN-Spanish]; Ketotifenum [INN-Latin]; Zaditor (TN); 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
DMOVY05 CP Norvatis Phamaceuticals Corporation
DMOVY05 TC Antiallergic Agents
DMOVY05 DT Small molecular drug
DMOVY05 PC 3827
DMOVY05 MW 309.4
DMOVY05 FM C19H19NOS
DMOVY05 IC InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DMOVY05 CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DMOVY05 IK ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DMOVY05 IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DMOVY05 CA CAS 34580-13-7
DMOVY05 CB CHEBI:92511
DMOVY05 DE Allergic conjunctivitis
DM0KAE6 ID DM0KAE6
DM0KAE6 DN Kombiglyze XR/Komboglyze FDC
DM0KAE6 HS Approved
DM0KAE6 SN Metformin mixture with saxagliptin; 1198772-17-6; Kombiglyze; Komboglyze; Kombiglyze XR; Saxagliptin / metformin; Metformin / saxagliptin
DM0KAE6 CP AstraZeneca
DM0KAE6 DT Small molecular drug
DM0KAE6 PC 56842229
DM0KAE6 MW 444.6
DM0KAE6 FM C22H36N8O2
DM0KAE6 IC InChI=1S/C18H25N3O2.C4H11N5/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;1-9(2)4(7)8-3(5)6/h10-15,23H,1-7,9,20H2;1-2H3,(H5,5,6,7,8)/t10?,11?,12?,13-,14-,15+,17?,18?;/m1./s1
DM0KAE6 CS CN(C)C(=N)N=C(N)N.C1[C@@H](N([C@H]2C1C2)C(=O)[C@@H](C34CC5CC(C3)CC(C5)(C4)O)N)C#N
DM0KAE6 IK QUKZWYNGKYRRKE-RIKNOMPASA-N
DM0KAE6 IU (1R,3R)-2-[(2R)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine
DM0KAE6 CA CAS 1198772-17-6
DM0KAE6 DE Diabetic complication
DMSA4HZ ID DMSA4HZ
DMSA4HZ DN KU-0058948
DMSA4HZ HS Approved
DMSA4HZ SN CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
DMSA4HZ DT Small molecular drug
DMSA4HZ PC 11291932
DMSA4HZ MW 380.4
DMSA4HZ FM C21H21FN4O2
DMSA4HZ IC InChI=1S/C21H21FN4O2/c22-18-7-6-14(12-17(18)21(28)26-10-3-8-23-9-11-26)13-19-15-4-1-2-5-16(15)20(27)25-24-19/h1-2,4-7,12,23H,3,8-11,13H2,(H,25,27)
DMSA4HZ CS C1CNCCN(C1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
DMSA4HZ IK HGEPGGJUGUMFHT-UHFFFAOYSA-N
DMSA4HZ IU 4-[[3-(1,4-diazepane-1-carbonyl)-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DMSA4HZ DE Ovarian cancer
DMK8U72 ID DMK8U72
DMK8U72 DN Labetalol
DMK8U72 HS Approved
DMK8U72 SN Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
DMK8U72 CP Allen & Handbury
DMK8U72 TC Antihypertensive Agents
DMK8U72 DT Small molecular drug
DMK8U72 PC 3869
DMK8U72 MW 328.4
DMK8U72 FM C19H24N2O3
DMK8U72 IC InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
DMK8U72 CS CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
DMK8U72 IK SGUAFYQXFOLMHL-UHFFFAOYSA-N
DMK8U72 IU 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
DMK8U72 CA CAS 36894-69-6
DMK8U72 CB CHEBI:6343
DMK8U72 DE Hypertension
DMVM6QR ID DMVM6QR
DMVM6QR DN Lacosamide
DMVM6QR HS Approved
DMVM6QR SN Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR CP Schwarz Pharma
DMVM6QR TC Analgesics
DMVM6QR DT Small molecular drug
DMVM6QR PC 219078
DMVM6QR MW 250.29
DMVM6QR FM C13H18N2O3
DMVM6QR IC InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
DMVM6QR CS CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1
DMVM6QR IK VPPJLAIAVCUEMN-GFCCVEGCSA-N
DMVM6QR IU (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR CA CAS 175481-36-4
DMVM6QR CB CHEBI:135939
DMVM6QR DE Convulsion; Diabetic neuropathy; Epilepsy
DMA7QTC ID DMA7QTC
DMA7QTC DN Lactoferrin
DMA7QTC HS Approved
DMA7QTC SN Lactoferroxin B; Lactoferroxin-B; AC1L4UTC; Arg-tyr-tyr-gly-tyr-och3; AC1Q5JP4; methyl n5-(diaminomethylidene)-l-ornithyl-l-tyrosyl-l-tyrosylglycyl-l-tyrosinate; 117667-26-2; L-Tyrosine, N-(N-(N-(N-L-arginyl-L-tyrosyl)-L-tyrosyl)glycyl)-, methyl ester; methyl (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoate
DMA7QTC DT Small molecular drug
DMA7QTC PC 126456119
DMA7QTC MW 3125.8
DMA7QTC FM C141H226N46O29S3
DMA7QTC IC InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1
DMA7QTC CS CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O
DMA7QTC IK CSSYQJWUGATIHM-IKGCZBKSSA-N
DMA7QTC IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid
DMA7QTC CA CAS 151186-19-5
DMA7QTC DE Solid tumour/cancer
DMV7OPN ID DMV7OPN
DMV7OPN DN Lactulose
DMV7OPN HS Approved
DMV7OPN SN Lactulosa; Lactulosa [INN-Spanish]; Lactulosa [Spanish]; Lactulosum; Lactulosum [INN-Latin]; Lactulosum [Latin]; Laevolac; Lattulosio [Italian]; Laxilose; Portalac; lactulose; 4-O-beta-D-Galactopyranosyl-D-fructofuranose; 4-O-beta-D-Galactopyranosyl-D-fructose; Acilac; Bifiteral; Cephulac; Cholac; Chronulac; Constilac; Constulose; D-Lactulose; Duphalac; Enulose; Generlac; Heptalac; Isolactose; 4-O-beta-D-galactopyranosyl-beta-D-fructofuranose; 9XH2P2N8EP; BRN 0093773; BRN 6278818; EINECS 225-027-7; UNII-9XH2P2N8EP
DMV7OPN PC 11333
DMV7OPN MW 342.3
DMV7OPN FM C12H22O11
DMV7OPN IC JCQLYHFGKNRPGE-FCVZTGTOSA-N
DMV7OPN CS C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O
DMV7OPN IK 1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1
DMV7OPN IU (2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMV7OPN CA CAS 4618-18-2
DMV7OPN CB CHEBI:6359
DMV7OPN DE Hepatic encephalopathy
DMZDN4W ID DMZDN4W
DMZDN4W DN L-alanine
DMZDN4W HS Approved
DMZDN4W SN ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine
DMZDN4W TC Dietary supplement
DMZDN4W DT Small molecular drug
DMZDN4W PC 5950
DMZDN4W MW 89.09
DMZDN4W FM C3H7NO2
DMZDN4W IC InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1
DMZDN4W CS C[C@@H](C(=O)O)N
DMZDN4W IK QNAYBMKLOCPYGJ-REOHCLBHSA-N
DMZDN4W IU (2S)-2-aminopropanoic acid
DMZDN4W CA CAS 56-41-7
DMZDN4W CB CHEBI:16977
DMZDN4W DE Glioma; Dietary shortage
DMANBR7 ID DMANBR7
DMANBR7 DN L-alanyl-l-glutamine
DMANBR7 HS Approved
DMANBR7 SN Dipeptiven (TN)
DMANBR7 DT Small molecular drug
DMANBR7 PC 123935
DMANBR7 MW 217.22
DMANBR7 FM C8H15N3O4
DMANBR7 IC InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1
DMANBR7 CS C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMANBR7 IK HJCMDXDYPOUFDY-WHFBIAKZSA-N
DMANBR7 IU (2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid
DMANBR7 CA CAS 39537-23-0
DMANBR7 CB CHEBI:73788
DMANBR7 DE Mucositis
DMI347A ID DMI347A
DMI347A DN Lamivudine
DMI347A HS Approved
DMI347A SN lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate
DMI347A CP Glaxo Smith Kline Pharmaceuticals
DMI347A TC Anti-HIV Agents
DMI347A DT Small molecular drug
DMI347A PC 60825
DMI347A MW 229.26
DMI347A FM C8H11N3O3S
DMI347A IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
DMI347A CS C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
DMI347A IK JTEGQNOMFQHVDC-NKWVEPMBSA-N
DMI347A IU 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMI347A CA CAS 134678-17-4
DMI347A CB CHEBI:63577
DMI347A DE Chronic HBV infection; Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DM8SXYG ID DM8SXYG
DM8SXYG DN Lamotrigine
DM8SXYG HS Approved
DM8SXYG SN Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG CP GSK
DM8SXYG TC Anticonvulsants
DM8SXYG DT Small molecular drug
DM8SXYG PC 3878
DM8SXYG MW 256.089
DM8SXYG FM C9H7Cl2N5
DM8SXYG IC InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
DM8SXYG CS C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
DM8SXYG IK PYZRQGJRPPTADH-UHFFFAOYSA-N
DM8SXYG IU 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG CA CAS 84057-84-1
DM8SXYG CB CHEBI:6367
DM8SXYG DE Bipolar disorder; Epilepsy
DMEH7YU ID DMEH7YU
DMEH7YU DN Lanadelumab
DMEH7YU HS Approved
DMEH7YU SN Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930
DMEH7YU CP Dyax/Shire
DMEH7YU DE Hereditary angioedema
DMG6ZU4 ID DMG6ZU4
DMG6ZU4 DN Lanreotide acetate
DMG6ZU4 HS Approved
DMG6ZU4 SN Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel
DMG6ZU4 CP Beaufour-Ipsen
DMG6ZU4 DT Small molecular drug
DMG6ZU4 PC 71349
DMG6ZU4 MW 1096.3
DMG6ZU4 FM C54H69N11O10S2
DMG6ZU4 IC InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
DMG6ZU4 CS CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
DMG6ZU4 IK PUDHBTGHUJUUFI-UHFFFAOYSA-N
DMG6ZU4 IU 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMG6ZU4 CA CAS 108736-35-2
DMG6ZU4 DE Acromegaly
DMXYLQ3 ID DMXYLQ3
DMXYLQ3 DN Lansoprazole
DMXYLQ3 HS Approved
DMXYLQ3 SN Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton
DMXYLQ3 PC 3883
DMXYLQ3 MW 369.4
DMXYLQ3 FM C16H14F3N3O2S
DMXYLQ3 IC MJIHNNLFOKEZEW-UHFFFAOYSA-N
DMXYLQ3 CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DMXYLQ3 IK 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
DMXYLQ3 IU 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMXYLQ3 CA CAS 103577-45-3
DMXYLQ3 CB CHEBI:6375
DMXYLQ3 DE Duodenal ulcer
DMMJQSH ID DMMJQSH
DMMJQSH DN Lanthanum carbonate
DMMJQSH HS Approved
DMMJQSH SN Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey
DMMJQSH CP Shire Pharm
DMMJQSH DT Small molecular drug
DMMJQSH PC 168924
DMMJQSH MW 457.84
DMMJQSH FM C3La2O9
DMMJQSH IC InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
DMMJQSH CS C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
DMMJQSH IK NZPIUJUFIFZSPW-UHFFFAOYSA-H
DMMJQSH IU lanthanum(3+);tricarbonate
DMMJQSH CA CAS 587-26-8
DMMJQSH DE Hypophosphatasia
DM3BH1Y ID DM3BH1Y
DM3BH1Y DN Lapatinib
DM3BH1Y HS Approved
DM3BH1Y SN FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
DM3BH1Y CP GlaxoSmithKline
DM3BH1Y TC Anticancer Agents
DM3BH1Y DT Small molecular drug
DM3BH1Y PC 208908
DM3BH1Y MW 581.1
DM3BH1Y FM C29H26ClFN4O4S
DM3BH1Y IC InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
DM3BH1Y CS CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
DM3BH1Y IK BCFGMOOMADDAQU-UHFFFAOYSA-N
DM3BH1Y IU N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
DM3BH1Y CA CAS 231277-92-2
DM3BH1Y CB CHEBI:49603
DM3BH1Y DE Breast cancer
DM26CQR ID DM26CQR
DM26CQR DN Larotrectinib
DM26CQR HS Approved
DM26CQR SN UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470
DM26CQR CP Loxo Oncology/Bayer
DM26CQR PC 46188928
DM26CQR MW 428.4
DM26CQR FM C21H22F2N6O2
DM26CQR IC InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
DM26CQR CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F
DM26CQR IK NYNZQNWKBKUAII-KBXCAEBGSA-N
DM26CQR IU (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
DM26CQR CA CAS 1223403-58-4
DM26CQR DE Solid tumour/cancer
DMSQ1JV ID DMSQ1JV
DMSQ1JV DN LAS-34273
DMSQ1JV HS Approved
DMSQ1JV SN Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide
DMSQ1JV CP Almirall
DMSQ1JV DT Small molecular drug
DMSQ1JV PC 11519741
DMSQ1JV MW 564.6
DMSQ1JV FM C26H30BrNO4S2
DMSQ1JV IC InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
DMSQ1JV CS C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-]
DMSQ1JV IK XLAKJQPTOJHYDR-QTQXQZBYSA-M
DMSQ1JV IU [(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DMSQ1JV CA CAS 320345-99-1
DMSQ1JV CB CHEBI:65344
DMSQ1JV DE Chronic obstructive pulmonary disease
DMXLVDT ID DMXLVDT
DMXLVDT DN Lasmiditan
DMXLVDT HS Approved
DMXLVDT SN COL-144; LY-573144; Migraine therapy, CoLucid
DMXLVDT CP Colucid pharmaceuticals
DMXLVDT DT Small molecular drug
DMXLVDT PC 11610526
DMXLVDT MW 377.4
DMXLVDT FM C19H18F3N3O2
DMXLVDT IC InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
DMXLVDT CS CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F
DMXLVDT IK XEDHVZKDSYZQBF-UHFFFAOYSA-N
DMXLVDT IU 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
DMXLVDT CA CAS 439239-90-4
DMXLVDT DE Migraine
DMHA18P ID DMHA18P
DMHA18P DN Lasofoxifene
DMHA18P HS Approved
DMHA18P SN Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202; Oporia; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639
DMHA18P CP Pfizer
DMHA18P DT Small molecular drug
DMHA18P PC 216416
DMHA18P MW 413.5
DMHA18P FM C28H31NO2
DMHA18P IC InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
DMHA18P CS C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5
DMHA18P IK GXESHMAMLJKROZ-IAPPQJPRSA-N
DMHA18P IU (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DMHA18P CA CAS 180916-16-9
DMHA18P CB CHEBI:135938
DMHA18P DE Osteoporosis; Virus infection
DMANL0D ID DMANL0D
DMANL0D DN Latamoxef
DMANL0D HS Approved
DMANL0D SN Festamoxin; LMOX; Lamoxactam; Latamoxefum; Moxalactam; Disodium Moxalactam; Lilly 127935; Ly127935; Sid 734787; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum [INN-Latin]; Oxa-cephem; S-6059; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid
DMANL0D TC Antibiotics
DMANL0D DT Small molecular drug
DMANL0D PC 47499
DMANL0D MW 520.5
DMANL0D FM C20H20N6O9S
DMANL0D IC InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
DMANL0D CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O
DMANL0D IK JWCSIUVGFCSJCK-CAVRMKNVSA-N
DMANL0D IU (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMANL0D CA CAS 64952-97-2
DMANL0D CB CHEBI:599928
DMANL0D DE Bacterial infection
DMI5OXG ID DMI5OXG
DMI5OXG DN Latanoprost
DMI5OXG HS Approved
DMI5OXG SN Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
DMI5OXG CP Pfizer Pharmaceuticals
DMI5OXG TC Antihypertensive Agents
DMI5OXG DT Small molecular drug
DMI5OXG PC 5311221
DMI5OXG MW 432.6
DMI5OXG FM C26H40O5
DMI5OXG IC InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
DMI5OXG CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMI5OXG IK GGXICVAJURFBLW-CEYXHVGTSA-N
DMI5OXG IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMI5OXG CA CAS 130209-82-4
DMI5OXG CB CHEBI:6384
DMI5OXG DE Open-angle glaucoma; Glaucoma/ocular hypertension; Ocular disease
DMLFX7K ID DMLFX7K
DMLFX7K DN LCZ696
DMLFX7K HS Approved
DMLFX7K SN DTXSID50239500
DMLFX7K CP Novartis Pharmaceuticals
DMLFX7K DT Small molecular drug
DMLFX7K PC 71300864
DMLFX7K MW 970
DMLFX7K FM C48H64N6Na3O11+3
DMLFX7K IC InChI=1S/C24H29N5O3.C24H29NO5.3Na.3H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;3*1H2/q;;3*+1;;;/t22-;17-,21+;;;;;;/m01....../s1
DMLFX7K CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O.O.O.O.[Na+].[Na+].[Na+]
DMLFX7K IK ACXLNSLRLQLEAL-HWSDWTSLSA-N
DMLFX7K IU trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;trihydrate
DMLFX7K DE Heart failure
DME6G97 ID DME6G97
DME6G97 DN Lefamulin
DME6G97 HS Approved
DME6G97 SN UNII-21904A5386; 1061337-51-6; CHEMBL3291398; 21904A5386; Lefamulin [INN]; Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester; Lefamulin(BC-3781); Lefamulin [USAN:INN]; Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten
DME6G97 CP Nabriva Therapeutics King of Prussia, PA
DME6G97 PC 25185057
DME6G97 MW 507.7
DME6G97 FM C28H45NO5S
DME6G97 IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1
DME6G97 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C
DME6G97 IK KPVIXBKIJXZQJX-FCEONZPQSA-N
DME6G97 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate
DME6G97 CA CAS 1061337-51-6
DME6G97 DE Acute bacterial skin infection; Community-acquired pneumonia
DMR8ONJ ID DMR8ONJ
DMR8ONJ DN Leflunomide
DMR8ONJ HS Approved
DMR8ONJ SN Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
DMR8ONJ CP Sanofi-Aventis
DMR8ONJ TC Antiinflammatory Agents
DMR8ONJ DT Small molecular drug
DMR8ONJ PC 3899
DMR8ONJ MW 270.21
DMR8ONJ FM C12H9F3N2O2
DMR8ONJ IC InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
DMR8ONJ CS CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
DMR8ONJ IK VHOGYURTWQBHIL-UHFFFAOYSA-N
DMR8ONJ IU 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
DMR8ONJ CA CAS 75706-12-6
DMR8ONJ CB CHEBI:6402
DMR8ONJ DE Arthritis; Multiple sclerosis
DM6Q7U4 ID DM6Q7U4
DM6Q7U4 DN Lenalidomide
DM6Q7U4 HS Approved
DM6Q7U4 SN Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
DM6Q7U4 CP Celgene Corporation
DM6Q7U4 TC Anticancer Agents
DM6Q7U4 DT Small molecular drug
DM6Q7U4 PC 216326
DM6Q7U4 MW 259.26
DM6Q7U4 FM C13H13N3O3
DM6Q7U4 IC InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
DM6Q7U4 CS C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
DM6Q7U4 IK GOTYRUGSSMKFNF-UHFFFAOYSA-N
DM6Q7U4 IU 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
DM6Q7U4 CA CAS 191732-72-6
DM6Q7U4 CB CHEBI:63791
DM6Q7U4 DE Multiple myeloma
DMB1IU4 ID DMB1IU4
DMB1IU4 DN Lenvatinib
DMB1IU4 HS Approved
DMB1IU4 SN E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
DMB1IU4 CP Eisai Co. Ltd.
DMB1IU4 DT Small molecular drug
DMB1IU4 PC 9823820
DMB1IU4 MW 426.9
DMB1IU4 FM C21H19ClN4O4
DMB1IU4 IC InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
DMB1IU4 CS COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
DMB1IU4 IK WOSKHXYHFSIKNG-UHFFFAOYSA-N
DMB1IU4 IU 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
DMB1IU4 CA CAS 417716-92-8
DMB1IU4 CB CHEBI:85994
DMB1IU4 DE Ovarian cancer; Hepatocellular carcinoma; Melanoma; Solid tumour/cancer; Non-small-cell lung cancer; Renal cell carcinoma; Thyroid cancer
DM1I3D5 ID DM1I3D5
DM1I3D5 DN Lepirudin
DM1I3D5 HS Approved
DM1I3D5 SN Refludan; Refludin; Aventis Behring Brand of Lepirudin; Aventis Brand Lepirudin; Aventis Pharma Brand of Lepirudin; Berlex Brand of Lepirudin; Hoechst Brand of Lepirudin; Lepirudin recombinant; Pharmion Brand of Lepirudin; Schering Brand of Lepirudin; Hbw 023; Hbw-023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudomedicinalis isoform HV1); 1-Leu-2-thr-63-desulfohirudin
DM1I3D5 TC Antithrombotic Agents
DM1I3D5 DT Small molecular drug
DM1I3D5 SQ DB00001 sequence: LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ
DM1I3D5 PC 118856773
DM1I3D5 MW 6979
DM1I3D5 FM C287H440N80O111S6
DM1I3D5 IC InChI=1S/C287H440N80O111S6/c1-24-132(17)225-280(470)345-162(87-126(5)6)236(426)306-111-209(396)320-181(116-370)267(457)344-176(101-220(416)417)238(428)307-105-203(390)316-152(61-74-213(402)403)243(433)321-146(40-29-32-80-288)241(431)339-171(96-198(298)385)259(449)326-153(56-69-194(294)381)250(440)351-186(121-482-479-118-183-240(430)310-107-202(389)313-148(54-67-192(292)379)233(423)303-108-206(393)317-170(95-197(297)384)258(448)322-147(41-30-33-81-289)242(432)350-187(272(462)359-225)122-483-480-119-184(269(459)323-150(60-73-212(400)401)235(425)304-110-208(395)319-180(115-369)266(456)342-174(99-201(301)388)265(455)357-223(130(13)14)278(468)355-183)352-254(444)165(90-129(11)12)335-270(460)185-120-481-484-123-188(354-263(453)178(103-222(420)421)347-283(473)230(137(22)375)362-264(454)168(93-141-48-52-144(378)53-49-141)346-282(472)228(135(20)373)361-232(422)145(291)86-125(3)4)273(463)363-229(136(21)374)281(471)330-158(65-78-217(410)411)249(439)348-179(114-368)239(429)309-106-204(391)315-151(55-68-193(293)380)244(434)340-172(97-199(299)386)260(450)334-164(89-128(9)10)253(443)353-185)271(461)358-224(131(15)16)279(469)364-227(134(19)372)277(467)311-112-205(392)314-149(59-72-211(398)399)234(424)305-113-210(397)356-231(138(23)376)286(476)367-85-37-45-191(367)276(466)331-160(42-31-34-82-290)284(474)365-83-35-43-189(365)274(464)328-154(57-70-195(295)382)248(438)349-182(117-371)268(458)338-169(94-142-104-302-124-312-142)257(447)341-173(98-200(300)387)261(451)343-175(100-219(414)415)237(427)308-109-207(394)318-177(102-221(418)419)262(452)337-166(91-139-38-27-26-28-39-139)255(445)327-155(62-75-214(404)405)245(435)325-159(66-79-218(412)413)251(441)360-226(133(18)25-2)285(475)366-84-36-44-190(366)275(465)329-157(64-77-216(408)409)246(436)324-156(63-76-215(406)407)247(437)336-167(92-140-46-50-143(377)51-47-140)256(446)333-163(88-127(7)8)252(442)332-161(287(477)478)58-71-196(296)383/h26-28,38-39,46-53,104,124-138,145-191,223-231,368-378H,24-25,29-37,40-45,54-103,105-123,288-291H2,1-23H3,(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H2,301,388)(H,302,312)(H,303,423)(H,304,425)(H,305,424)(H,306,426)(H,307,428)(H,308,427)(H,309,429)(H,310,430)(H,311,467)(H,313,389)(H,314,392)(H,315,391)(H,316,390)(H,317,393)(H,318,394)(H,319,395)(H,320,396)(H,321,433)(H,322,448)(H,323,459)(H,324,436)(H,325,435)(H,326,449)(H,327,445)(H,328,464)(H,329,465)(H,330,471)(H,331,466)(H,332,442)(H,333,446)(H,334,450)(H,335,460)(H,336,437)(H,337,452)(H,338,458)(H,339,431)(H,340,434)(H,341,447)(H,342,456)(H,343,451)(H,344,457)(H,345,470)(H,346,472)(H,347,473)(H,348,439)(H,349,438)(H,350,432)(H,351,440)(H,352,444)(H,353,443)(H,354,453)(H,355,468)(H,356,397)(H,357,455)(H,358,461)(H,359,462)(H,360,441)(H,361,422)(H,362,454)(H,363,463)(H,364,469)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,477,478)/t132-,133-,134+,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DM1I3D5 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DM1I3D5 IK FIBJDTSHOUXTKV-BRHMIFOHSA-N
DM1I3D5 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM1I3D5 CA CAS 138068-37-8
DM1I3D5 CB CHEBI:142437
DM1I3D5 DE Thrombocytopenia
DMPWSEM ID DMPWSEM
DMPWSEM DN Lercanidipine
DMPWSEM HS Approved
DMPWSEM SN Lercanil; Masnidipine; Lercanidipine [INN]; Lercanidipine (INN); Lercanil (TN); REC 15-2375; Zanidip (TN); REC-15-2375; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM CP Forest Laboratories
DMPWSEM TC Antihypertensive Agents
DMPWSEM DT Small molecular drug
DMPWSEM PC 65866
DMPWSEM MW 611.7
DMPWSEM FM C36H41N3O6
DMPWSEM IC InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
DMPWSEM CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMPWSEM IK ZDXUKAKRHYTAKV-UHFFFAOYSA-N
DMPWSEM IU 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM CA CAS 100427-26-7
DMPWSEM CB CHEBI:135930
DMPWSEM DE Hypertension
DMUR64T ID DMUR64T
DMUR64T DN Lesinurad
DMUR64T HS Approved
DMUR64T SN LESINURAD; 878672-00-5; RDEA594; Zurampic; RDEA 594; UNII-09ERP08I3W; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 09ERP08I3W; AK323774; C17H14BrN3O2S; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
DMUR64T CP Ardea Biosciences
DMUR64T DT Small molecular drug
DMUR64T PC 53465279
DMUR64T MW 404.3
DMUR64T FM C17H14BrN3O2S
DMUR64T IC InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
DMUR64T CS C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
DMUR64T IK FGQFOYHRJSUHMR-UHFFFAOYSA-N
DMUR64T IU 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
DMUR64T CA CAS 878672-00-5
DMUR64T CB CHEBI:90929
DMUR64T DE Hyperuricaemia
DMQ2AIJ ID DMQ2AIJ
DMQ2AIJ DN Lestaurtinib
DMQ2AIJ HS Approved (orphan drug)
DMQ2AIJ SN A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
DMQ2AIJ CP Cephalon; Kyowa Hakko Kogyo
DMQ2AIJ TC Anticancer Agents
DMQ2AIJ DT Small molecular drug
DMQ2AIJ PC 126565
DMQ2AIJ MW 439.5
DMQ2AIJ FM C26H21N3O4
DMQ2AIJ IC InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
DMQ2AIJ CS C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
DMQ2AIJ IK UIARLYUEJFELEN-LROUJFHJSA-N
DMQ2AIJ IU (15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
DMQ2AIJ CA CAS 111358-88-4
DMQ2AIJ CB CHEBI:91471
DMQ2AIJ DE Acute myeloid leukaemia; Psoriasis vulgaris; Myeloid leukaemia
DMH07Y3 ID DMH07Y3
DMH07Y3 DN Letrozole
DMH07Y3 HS Approved
DMH07Y3 SN Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3 TC Anticancer Agents
DMH07Y3 DT Small molecular drug
DMH07Y3 PC 3902
DMH07Y3 MW 285.3
DMH07Y3 FM C17H11N5
DMH07Y3 IC InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
DMH07Y3 CS C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
DMH07Y3 IK HPJKCIUCZWXJDR-UHFFFAOYSA-N
DMH07Y3 IU 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3 CA CAS 112809-51-5
DMH07Y3 CB CHEBI:6413
DMH07Y3 DE Hormonally-responsive breast cancer
DMUAZWG ID DMUAZWG
DMUAZWG DN Leucovorin
DMUAZWG HS Approved
DMUAZWG SN 5-formyltetrahydrofolate; Citrovorum factor; Folinic acid
DMUAZWG TC Vitamins
DMUAZWG DT Small molecular drug
DMUAZWG PC 135403648
DMUAZWG MW 473.446
DMUAZWG FM C20H23N7O7
DMUAZWG IC InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
DMUAZWG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUAZWG IK VVIAGPKUTFNRDU-ABLWVSNPSA-N
DMUAZWG IU (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMUAZWG CA CAS 58-05-9
DMUAZWG CB CHEBI:15640
DMUAZWG DE Colorectal cancer
DMNWZJG ID DMNWZJG
DMNWZJG DN Leucovorin Calcium
DMNWZJG HS Approved
DMNWZJG SN Leucovorin Calcium Preservative Free; Wellcovorin
DMNWZJG CP Hospira Inc
DMNWZJG TC Anticancer Agents
DMNWZJG DT Small molecular drug
DMNWZJG PC 135403647
DMNWZJG MW 511.5
DMNWZJG FM C20H21CaN7O7
DMNWZJG IC InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1
DMNWZJG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2]
DMNWZJG IK KVUAALJSMIVURS-ZEDZUCNESA-L
DMNWZJG IU calcium;(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioate
DMNWZJG CA CAS 1492-18-8
DMNWZJG CB CHEBI:31340
DMNWZJG DE Solid tumour/cancer
DMZT4N7 ID DMZT4N7
DMZT4N7 DN Leucovorin/5-fluorouracil
DMZT4N7 HS Approved
DMZT4N7 TC Vitamins
DMZT4N7 DT Small molecular drug
DMZT4N7 PC 54575
DMZT4N7 DE Colon cancer
DM5XPIJ ID DM5XPIJ
DM5XPIJ DN Leuprolide
DM5XPIJ HS Approved
DM5XPIJ SN Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
DM5XPIJ CP Abbott Laboratories
DM5XPIJ TC Anticancer Agents
DM5XPIJ DT Small molecular drug
DM5XPIJ SQ Leuprolide: PHWSYLLR
DM5XPIJ PC 657181
DM5XPIJ MW 1209.4
DM5XPIJ FM C59H84N16O12
DM5XPIJ IC InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
DM5XPIJ CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DM5XPIJ IK GFIJNRVAKGFPGQ-LIJARHBVSA-N
DM5XPIJ IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM5XPIJ CA CAS 53714-56-0
DM5XPIJ CB CHEBI:6427
DM5XPIJ DE Prostate cancer
DM15HAT ID DM15HAT
DM15HAT DN Leuprorelin acetate
DM15HAT HS Approved
DM15HAT SN Leuprolide acetate; Leuplin (TN); Leuprorelin acetate (JAN); 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
DM15HAT CP Takeda
DM15HAT DT Small molecular drug
DM15HAT PC 657180
DM15HAT MW 1269.4
DM15HAT FM C61H88N16O14
DM15HAT IC InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1
DM15HAT CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O
DM15HAT IK RGLRXNKKBLIBQS-XNHQSDQCSA-N
DM15HAT IU acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM15HAT CA CAS 74381-53-6
DM15HAT CB CHEBI:63597
DM15HAT DE Prostate cancer
DMJBOCR ID DMJBOCR
DMJBOCR DN Levacecarnine HCL
DMJBOCR HS Approved
DMJBOCR SN Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine; Nicetile (TN); L-Carnitine
DMJBOCR DT Small molecular drug
DMJBOCR PC 10917
DMJBOCR MW 161.2
DMJBOCR FM C7H15NO3
DMJBOCR IC InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
DMJBOCR CS C[N+](C)(C)C[C@@H](CC(=O)[O-])O
DMJBOCR IK PHIQHXFUZVPYII-ZCFIWIBFSA-N
DMJBOCR IU (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate
DMJBOCR CA CAS 541-15-1
DMJBOCR CB CHEBI:16347
DMJBOCR DE Nutritional deficiency; Cognitive impairment
DM5YBO1 ID DM5YBO1
DM5YBO1 DN Levalbuterol
DM5YBO1 HS Approved
DM5YBO1 SN Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
DM5YBO1 DT Small molecular drug
DM5YBO1 PC 123600
DM5YBO1 MW 239.31
DM5YBO1 FM C13H21NO3
DM5YBO1 IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1
DM5YBO1 CS CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O
DM5YBO1 IK NDAUXUAQIAJITI-LBPRGKRZSA-N
DM5YBO1 IU 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DM5YBO1 CA CAS 34391-04-3
DM5YBO1 CB CHEBI:8746
DM5YBO1 DE Asthma
DMCOLUP ID DMCOLUP
DMCOLUP DN Levallorphan
DMCOLUP HS Approved
DMCOLUP SN Levallofano; Levallorphane; Levallorphanum; Levalorfano; Naloxiphan; Levallofano [DCIT]; Levallorphan [INN:BAN]; Levallorphane [INN-French]; Levallorphanum [INN-Latin]; Levalorfano [INN-Spanish]; Lorfan (TN); Ro-1-7700; N-Allyl-3-hydroxymorphinan; L-N-Allyl-3-hydroxymorphinan; Levo-3-hydroxy-N-allyl morphinan; (-)-3-Hydroxy-N-allylmorphinan; 17-Allylmorphinan-3-ol; 17-prop-2-en-1-ylmorphinan-3-ol
DMCOLUP CP Hoffmann La Roche Inc
DMCOLUP TC Antinarcotic Agents
DMCOLUP DT Small molecular drug
DMCOLUP PC 5359371
DMCOLUP MW 283.4
DMCOLUP FM C19H25NO
DMCOLUP IC InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1
DMCOLUP CS C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMCOLUP IK OZYUPQUCAUTOBP-QXAKKESOSA-N
DMCOLUP IU (1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMCOLUP CA CAS 152-02-3
DMCOLUP CB CHEBI:6431
DMCOLUP DE Narcotic depression
DM5EN79 ID DM5EN79
DM5EN79 DN Levamisole
DM5EN79 HS Approved
DM5EN79 SN Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole
DM5EN79 CP Janssen Pharmaceutica
DM5EN79 TC Anticancer Agents
DM5EN79 DT Small molecular drug
DM5EN79 PC 26879
DM5EN79 MW 204.29
DM5EN79 FM C11H12N2S
DM5EN79 IC InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1
DM5EN79 CS C1CSC2=N[C@H](CN21)C3=CC=CC=C3
DM5EN79 IK HLFSDGLLUJUHTE-SNVBAGLBSA-N
DM5EN79 IU (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
DM5EN79 CA CAS 14769-73-4
DM5EN79 CB CHEBI:6432
DM5EN79 DE Parasitic infection; Colon cancer
DMTGDN8 ID DMTGDN8
DMTGDN8 DN Levetiracetam
DMTGDN8 HS Approved
DMTGDN8 SN 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam
DMTGDN8 CP UCB Pharmaceuticals Inc
DMTGDN8 TC Anticonvulsants
DMTGDN8 DT Small molecular drug
DMTGDN8 PC 5284583
DMTGDN8 MW 170.21
DMTGDN8 FM C8H14N2O2
DMTGDN8 IC InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
DMTGDN8 CS CC[C@@H](C(=O)N)N1CCCC1=O
DMTGDN8 IK HPHUVLMMVZITSG-LURJTMIESA-N
DMTGDN8 IU (2S)-2-(2-oxopyrrolidin-1-yl)butanamide
DMTGDN8 CA CAS 102767-28-2
DMTGDN8 CB CHEBI:6437
DMTGDN8 DE Fibromyalgia; Epilepsy
DMSREPX ID DMSREPX
DMSREPX DN Levobetaxolol
DMSREPX HS Approved
DMSREPX SN Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol
DMSREPX CP Alcon Pharmaceuticals Ltd
DMSREPX TC Cardiotonic Agents
DMSREPX DT Small molecular drug
DMSREPX PC 60657
DMSREPX MW 307.4
DMSREPX FM C18H29NO3
DMSREPX IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
DMSREPX CS CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O
DMSREPX IK NWIUTZDMDHAVTP-KRWDZBQOSA-N
DMSREPX IU (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMSREPX CA CAS 93221-48-8
DMSREPX CB CHEBI:59254
DMSREPX DE Chronic open-angle glaucoma
DMTNFCQ ID DMTNFCQ
DMTNFCQ DN Levobunolol
DMTNFCQ HS Approved
DMTNFCQ SN Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
DMTNFCQ CP Allergan Pharmaceuticals
DMTNFCQ TC Sympatholytics
DMTNFCQ DT Small molecular drug
DMTNFCQ PC 39468
DMTNFCQ MW 291.4
DMTNFCQ FM C17H25NO3
DMTNFCQ IC InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
DMTNFCQ CS CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
DMTNFCQ IK IXHBTMCLRNMKHZ-LBPRGKRZSA-N
DMTNFCQ IU 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
DMTNFCQ CA CAS 47141-42-4
DMTNFCQ CB CHEBI:6438
DMTNFCQ DE Open-angle glaucoma
DM783CH ID DM783CH
DM783CH DN Levobupivacaine
DM783CH HS Approved
DM783CH SN Novabupi; Chirocaine (TN); Levobupivacaine (INN); Levobupivacaine [INN:BAN]; Novabupi (TN); L(-)-Bupivacaine; L-(-)-bupivacaine; L-(-)-1-Butyl-2',6'-pipecoloxylidide; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (S)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine
DM783CH CP AstraZeneca
DM783CH TC Anesthetics
DM783CH DT Small molecular drug
DM783CH PC 92253
DM783CH MW 288.4
DM783CH FM C18H28N2O
DM783CH IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1
DM783CH CS CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DM783CH IK LEBVLXFERQHONN-INIZCTEOSA-N
DM783CH IU (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM783CH CA CAS 27262-47-1
DM783CH CB CHEBI:6149
DM783CH DE Anaesthesia
DMMZPWT ID DMMZPWT
DMMZPWT DN Levocabastine
DMMZPWT HS Approved
DMMZPWT SN Levocabastin; Levocabastina; Levocabastinum; Livostin; Levocabastina [Spanish]; Levocabastinum [Latin]; Levocabastine (INN); Levocabastine [INN:BAN]; Livostin (TN); (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid
DMMZPWT CP Janssen Pharmaceutica
DMMZPWT TC Antiallergic Agents
DMMZPWT DT Small molecular drug
DMMZPWT PC 54385
DMMZPWT MW 420.5
DMMZPWT FM C26H29FN2O2
DMMZPWT IC InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1
DMMZPWT CS C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F
DMMZPWT IK ZCGOMHNNNFPNMX-YHYDXASRSA-N
DMMZPWT IU (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
DMMZPWT CA CAS 79449-98-2
DMMZPWT CB CHEBI:92584
DMMZPWT DE Allergic conjunctivitis
DMQYLGP ID DMQYLGP
DMQYLGP DN Levocetirizine
DMQYLGP HS Approved
DMQYLGP SN (-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
DMQYLGP DT Small molecular drug
DMQYLGP PC 1549000
DMQYLGP MW 388.892
DMQYLGP FM C21H25ClN2O3
DMQYLGP IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
DMQYLGP CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMQYLGP IK ZKLPARSLTMPFCP-OAQYLSRUSA-N
DMQYLGP IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMQYLGP CA CAS 130018-77-8
DMQYLGP CB CHEBI:94559
DMQYLGP DE Allergy
DMW6ZJI ID DMW6ZJI
DMW6ZJI DN Levocetirizine dihydrochloride
DMW6ZJI HS Approved
DMW6ZJI SN Xyzal; Xyzall; Levocetirizine HCl; Levocetirizine dihydrochloride [USAN]; Levocetirizine hydrochloride; Levocetirizine 2HCl; KS-1177; Levocetirizine hydrochloride (JAN); Vozet (TN); Xozal (TN); Xusal (TN); Xuzal (TN); Xyzal (TN); Xyzall (TN); Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride; (2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
DMW6ZJI CP GlaxoSmithKline
DMW6ZJI TC Antiallergic Agents
DMW6ZJI DT Small molecular drug
DMW6ZJI PC 9955977
DMW6ZJI MW 461.8
DMW6ZJI FM C21H27Cl3N2O3
DMW6ZJI IC InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/m1../s1
DMW6ZJI CS C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
DMW6ZJI IK PGLIUCLTXOYQMV-GHVWMZMZSA-N
DMW6ZJI IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
DMW6ZJI CA CAS 130018-87-0
DMW6ZJI DE Allergic rhinitis
DMN3E57 ID DMN3E57
DMN3E57 DN Levodopa
DMN3E57 HS Approved
DMN3E57 SN Levodopa (optimized formulation, Parkinson's disease); More effective levodopa (Parkinson's disease), Orion; Levodopa (optimized formulation, Parkinson's disease), Orion
DMN3E57 CP Orion Corp
DMN3E57 DT Small molecular drug
DMN3E57 PC 6047
DMN3E57 MW 197.19
DMN3E57 FM C9H11NO4
DMN3E57 IC InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
DMN3E57 CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
DMN3E57 IK WTDRDQBEARUVNC-LURJTMIESA-N
DMN3E57 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
DMN3E57 CA CAS 59-92-7
DMN3E57 CB CHEBI:15765
DMN3E57 DE Parkinson disease
DMS60RB ID DMS60RB
DMS60RB DN Levofloxacin
DMS60RB HS Approved
DMS60RB SN Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin
DMS60RB CP Sanofi-Aventis
DMS60RB TC Antibiotics
DMS60RB DT Small molecular drug
DMS60RB PC 149096
DMS60RB MW 361.4
DMS60RB FM C18H20FN3O4
DMS60RB IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
DMS60RB CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DMS60RB IK GSDSWSVVBLHKDQ-JTQLQIEISA-N
DMS60RB IU (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMS60RB CA CAS 100986-85-4
DMS60RB CB CHEBI:63598
DMS60RB DE Bacterial infection
DMUV5JB ID DMUV5JB
DMUV5JB DN Levomefolic acid
DMUV5JB HS Approved
DMUV5JB SN Levomefolic acid; Levomefolinic acid; Metafolin; Metafolin (TN); L-5-Methyltetrahydrofolate; LEVOMEFOLATE; (6s)-5-methyltetrahydrofolic acid; (S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid; 31690-09-2; 5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID; 5-Methyltetrahydrofolate; 8S95DH25XC; C20H25N7O6; CHEBI:15641; LMSR; N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; UNII-8S95DH25XC; [(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate
DMUV5JB PC 135398561
DMUV5JB MW 459.5
DMUV5JB FM C20H25N7O6
DMUV5JB IC ZNOVTXRBGFNYRX-STQMWFEESA-N
DMUV5JB CS CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUV5JB IK 1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1
DMUV5JB IU (2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DMUV5JB CA CAS 31690-09-2
DMUV5JB CB CHEBI:15641
DMUV5JB DE Contraception
DMIKFEL ID DMIKFEL
DMIKFEL DN Levomepromazine
DMIKFEL HS Approved
DMIKFEL SN METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine
DMIKFEL CP Immunex Corp
DMIKFEL DT Small molecular drug
DMIKFEL PC 72287
DMIKFEL MW 328.5
DMIKFEL FM C19H24N2OS
DMIKFEL IC InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
DMIKFEL CS C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
DMIKFEL IK VRQVVMDWGGWHTJ-CQSZACIVSA-N
DMIKFEL IU (2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
DMIKFEL CA CAS 60-99-1
DMIKFEL CB CHEBI:6838
DMIKFEL DE Psychotic disorder; Bipolar disorder
DM06HG5 ID DM06HG5
DM06HG5 DN Levomethadyl Acetate
DM06HG5 HS Approved
DM06HG5 SN LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)
DM06HG5 CP Roxane Laboratories
DM06HG5 TC Analgesics
DM06HG5 DT Small molecular drug
DM06HG5 PC 15130
DM06HG5 MW 353.5
DM06HG5 FM C23H31NO2
DM06HG5 IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
DM06HG5 CS CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DM06HG5 IK XBMIVRRWGCYBTQ-AVRDEDQJSA-N
DM06HG5 IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DM06HG5 CA CAS 1477-40-3
DM06HG5 CB CHEBI:6441
DM06HG5 DE Opioid dependence
DM429AE ID DM429AE
DM429AE DN Levomethadyl acetate hydrochloride
DM429AE HS Approved
DM429AE SN Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol
DM429AE PC 39371
DM429AE MW 390
DM429AE FM C23H32ClNO2
DM429AE IC UXBPQRGCVJOTNT-COBSGTNCSA-N
DM429AE CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl
DM429AE IK 1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1
DM429AE IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride
DM429AE CA CAS 43033-72-3
DM429AE CB CHEBI:6442
DM429AE DE Opiate dependence
DMV26S8 ID DMV26S8
DMV26S8 DN Levomilnacipran
DMV26S8 HS Approved
DMV26S8 SN Fetzima; UNII-UGM0326TXX; Levomilnacipran HCl; 96847-54-0; UGM0326TXX; CHEMBL99946; F-2695; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran [USAN:INN]; Milnacipram; AC1OCEN8; F 2695; Levomilnacipran (USAN/INN); ZINC506; SCHEMBL1414867; GTPL7435; GJJFMKBJSRMPLA-DZGCQCFKSA-N; CHEBI:136040; BDBM50032379; SB17447; DB08918; f2-695; D10072
DMV26S8 CP Forest Laboratories
DMV26S8 DT Small molecular drug
DMV26S8 PC 6917779
DMV26S8 MW 246.35
DMV26S8 FM C15H22N2O
DMV26S8 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
DMV26S8 CS CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
DMV26S8 IK GJJFMKBJSRMPLA-DZGCQCFKSA-N
DMV26S8 IU (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMV26S8 CA CAS 96847-54-0
DMV26S8 CB CHEBI:136040
DMV26S8 DE Fibromyalgia
DM1DP7T ID DM1DP7T
DM1DP7T DN Levonorgestrel
DM1DP7T HS Approved
DM1DP7T SN norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme; Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS
DM1DP7T TC Contraceptive Agents
DM1DP7T DT Small molecular drug
DM1DP7T PC 13109
DM1DP7T MW 312.4
DM1DP7T FM C21H28O2
DM1DP7T IC InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM1DP7T CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DM1DP7T IK WWYNJERNGUHSAO-XUDSTZEESA-N
DM1DP7T IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM1DP7T CA CAS 797-63-7
DM1DP7T CB CHEBI:6443
DM1DP7T DE Contraception
DMECB4H ID DMECB4H
DMECB4H DN Levopropoxyphene Napsylate Anhydrous
DMECB4H HS Approved
DMECB4H SN Novrad
DMECB4H CP Eli Lilly Industries Inc
DMECB4H DT Small molecular drug
DMECB4H PC 6604497
DMECB4H MW 547.7
DMECB4H FM C32H37NO5S
DMECB4H IC InChI=1S/C22H29NO2.C10H8O3S/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13)/t18-,22+;/m0./s1
DMECB4H CS CCC(=O)O[C@@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O
DMECB4H IK VZPXFHVJUUSVLH-VNJAQMQMSA-N
DMECB4H IU [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;naphthalene-2-sulfonic acid
DMECB4H CA CAS 5714-90-9
DMECB4H DE Cough
DM2XVNI ID DM2XVNI
DM2XVNI DN Levormeloxifene
DM2XVNI HS Approved
DM2XVNI SN Centchroman; Centron; Levormeloxifene; Ormeloxifene; Saheli; NNC-46-0020; Non-steroidal (oral, contraception/cancer); Non-steroidal (oral, contraception/cancer), Central Drug Research Institute (CDRI)
DM2XVNI CP Novo Nordisk A/S; Central Drug Research Institute
DM2XVNI DT Small molecular drug
DM2XVNI PC 35805
DM2XVNI MW 457.6
DM2XVNI FM C30H35NO3
DM2XVNI IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
DM2XVNI CS CC1([C@H]([C@@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DM2XVNI IK XZEUAXYWNKYKPL-WDYNHAJCSA-N
DM2XVNI IU 1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DM2XVNI CA 78994-23-7
DM2XVNI DE Breast cancer
DMGS80V ID DMGS80V
DMGS80V DN Levorphanol
DMGS80V HS Approved
DMGS80V SN levorphanol; Levorphan; Methorphinan; Aromarone; Racemethorphanum; Dromoran; Cetarin; Antalgin; Levo-Dromoran; Racemic dromoran; Methorfinan [Czech]; Levorfanolo [DCIT]; Levorphanolum; Levorfanol; Orphan; Levorfanol [INN-Spanish]; Levorphanolum [INN-Latin]; Racemorfano [INN-Spanish]; 17-Methylmorphinan-3-ol; N-Methyl-3-hydroxymorphinan; Racemorphan; Racemorphan [INN:BAN]; Racemorphane [INN-French]; Racemorphanum [INN-Latin]; (-)-N-Methylmorphinan-3-ol; Morphinan-3-ol, 17-methyl-; Levorphanal; dl-3-Hydroxy-N-methylmorphinan; DEA No; Antalgin; DEXTRORPHAN; Levodroman; Levorfanolo; Methorfinan; Racemorfano; Racemorphane; Racemorphanum; NU 2206; L-Dromoran; Levorphanol (INN); Ro 1-5431; Levo-Dromoran (TN); Dl-3-Hydroxy-N-methylmorphinan; (+)-3-Hydroxy-17-methylmorphinan; (+-)-17-Methylmorphinan-3-ol; (+-)-3-Hydroxy-N-methylmorphinan; (-)-3-Hydroxy-N-methylmorphinan; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; 3-Hydroxy-N-methylmorphinan; Dextrorphan
DMGS80V CP Roxane Laboratories
DMGS80V TC Analgesics
DMGS80V DT Small molecular drug
DMGS80V PC 5359272
DMGS80V MW 257.37
DMGS80V FM C17H23NO
DMGS80V IC InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
DMGS80V CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMGS80V IK JAQUASYNZVUNQP-USXIJHARSA-N
DMGS80V IU (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMGS80V CA CAS 297-90-5
DMGS80V CB CHEBI:6444
DMGS80V DE Pain; Ischemic stroke
DMKBOS2 ID DMKBOS2
DMKBOS2 DN Levosimendan
DMKBOS2 HS Approved
DMKBOS2 SN Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2 CP Abbott Laboratories
DMKBOS2 TC Cardiotonic Agents
DMKBOS2 DT Small molecular drug
DMKBOS2 PC 3033825
DMKBOS2 MW 280.28
DMKBOS2 FM C14H12N6O
DMKBOS2 IC InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1
DMKBOS2 CS C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
DMKBOS2 IK WHXMKTBCFHIYNQ-SECBINFHSA-N
DMKBOS2 IU 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2 CA CAS 141505-33-1
DMKBOS2 CB CHEBI:50567
DMKBOS2 DE Cardiac output syndrome; Pulmonary hypertension; Congestive heart failure; Heart failure
DMHN027 ID DMHN027
DMHN027 DN Levothyroxine
DMHN027 HS Approved
DMHN027 SN Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5"-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine
DMHN027 CP Abbott Laboratories
DMHN027 TC Antithyroid Agents
DMHN027 DT Small molecular drug
DMHN027 PC 5819
DMHN027 MW 776.87
DMHN027 FM C15H11I4NO4
DMHN027 IC InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
DMHN027 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N
DMHN027 IK XUIIKFGFIJCVMT-LBPRGKRZSA-N
DMHN027 IU (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
DMHN027 CA CAS 51-48-9
DMHN027 CB CHEBI:18332
DMHN027 DE Hypothyroidism
DM4PUDW ID DM4PUDW
DM4PUDW DN L-glutamic acid
DM4PUDW HS Approved
DM4PUDW SN Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid
DM4PUDW TC Dietary supplement
DM4PUDW DT Small molecular drug
DM4PUDW PC 33032
DM4PUDW MW 147.13
DM4PUDW FM C5H9NO4
DM4PUDW IC InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DM4PUDW CS C(CC(=O)O)[C@@H](C(=O)O)N
DM4PUDW IK WHUUTDBJXJRKMK-VKHMYHEASA-N
DM4PUDW IU (2S)-2-aminopentanedioic acid
DM4PUDW CA CAS 56-86-0
DM4PUDW CB CHEBI:16015
DM4PUDW DE Schizophrenia
DM69G8X ID DM69G8X
DM69G8X DN L-glutamine
DM69G8X HS Approved
DM69G8X SN NutreStore; AES-14; Aesgen-14; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles
DM69G8X CP Nutritional Restart
DM69G8X DT Small molecular drug
DM69G8X PC 5961
DM69G8X MW 146.14
DM69G8X FM C5H10N2O3
DM69G8X IC InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
DM69G8X CS C(CC(=O)N)[C@@H](C(=O)O)N
DM69G8X IK ZDXPYRJPNDTMRX-VKHMYHEASA-N
DM69G8X IU (2S)-2,5-diamino-5-oxopentanoic acid
DM69G8X CA CAS 56-85-9
DM69G8X CB CHEBI:18050
DM69G8X DE Short bowel syndrome
DMNQXV8 ID DMNQXV8
DMNQXV8 DN LGX818
DMNQXV8 HS Approved
DMNQXV8 SN Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)
DMNQXV8 CP Array BioPharma
DMNQXV8 DT Small molecular drug
DMNQXV8 PC 50922675
DMNQXV8 MW 540
DMNQXV8 FM C22H27ClFN7O4S
DMNQXV8 IC InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
DMNQXV8 CS C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC
DMNQXV8 IK CMJCXYNUCSMDBY-ZDUSSCGKSA-N
DMNQXV8 IU methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
DMNQXV8 CA CAS 1269440-17-6
DMNQXV8 DE Melanoma
DML4ZOT ID DML4ZOT
DML4ZOT DN Lidocaine
DML4ZOT HS Approved
DML4ZOT SN Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
DML4ZOT CP Endo Pharmaceuticals
DML4ZOT TC Anesthetics
DML4ZOT DT Small molecular drug
DML4ZOT PC 3676
DML4ZOT MW 234.34
DML4ZOT FM C14H22N2O
DML4ZOT IC InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
DML4ZOT CS CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
DML4ZOT IK NNJVILVZKWQKPM-UHFFFAOYSA-N
DML4ZOT IU 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
DML4ZOT CA CAS 137-58-6
DML4ZOT CB CHEBI:6456
DML4ZOT DE Anaesthesia; Dysmenorrhea
DMV23GL ID DMV23GL
DMV23GL DN Lidoflazine
DMV23GL HS Approved
DMV23GL SN LIDOFLAZINE; Ordiflazine; Corflazine; Clinium; Lidoflazinum; Lidoflazin; 3416-26-0; Klinium; Angex; Lidoflazina [Italian]; McN-JR 7904; UNII-J4ZHN3HBTE; Lidoflazinum [INN-Latin]; Lidoflazina [INN-Spanish]; Lidoflazine [USAN:INN:BAN]; C30H35F2N3O; J4ZHN3HBTE; EINECS 222-312-8; R 7904; BRN 0904339; CHEMBL92870; MCN-JR-7904; 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide; 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-; NCGC00016627-01; NCGC00016627-04; CAS-3416-26-0
DMV23GL DT Small molecular drug
DMV23GL PC 3926
DMV23GL MW 491.6
DMV23GL FM C30H35F2N3O
DMV23GL IC InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
DMV23GL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMV23GL IK ZBIAKUMOEKILTF-UHFFFAOYSA-N
DMV23GL IU 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
DMV23GL CA CAS 3416-26-0
DMV23GL CB CHEBI:93095
DMV23GL DE Angina pectoris
DM4WVC5 ID DM4WVC5
DM4WVC5 DN Lifitegrast
DM4WVC5 HS Approved
DM4WVC5 SN Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1118; SAR-1119; SHP606; SPD606
DM4WVC5 CP Shire Pharmaceuticals
DM4WVC5 DT Small molecular drug
DM4WVC5 PC 11965427
DM4WVC5 MW 615.5
DM4WVC5 FM C29H24Cl2N2O7S
DM4WVC5 IC InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
DM4WVC5 CS CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
DM4WVC5 IK JFOZKMSJYSPYLN-QHCPKHFHSA-N
DM4WVC5 IU (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
DM4WVC5 CA CAS 1025967-78-5
DM4WVC5 CB CHEBI:133023
DM4WVC5 DE Dry eye disease; Allergic conjunctivitis
DM4EGV0 ID DM4EGV0
DM4EGV0 DN Linaclotide
DM4EGV0 HS Approved
DM4EGV0 SN Linaclotide (USAN)
DM4EGV0 CP Microbia
DM4EGV0 DT Small molecular drug
DM4EGV0 PC 16158208
DM4EGV0 MW 1526.8
DM4EGV0 FM C59H79N15O21S6
DM4EGV0 IC InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
DM4EGV0 CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
DM4EGV0 IK KXGCNMMJRFDFNR-WDRJZQOASA-N
DM4EGV0 IU (2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4EGV0 CA CAS 851199-59-2
DM4EGV0 CB CHEBI:68551
DM4EGV0 DE Irritable bowel syndrome
DMWFJTR ID DMWFJTR
DMWFJTR DN Linagliptin
DMWFJTR HS Approved
DMWFJTR SN Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
DMWFJTR CP Boehringer Ingelheim
DMWFJTR DT Small molecular drug
DMWFJTR PC 10096344
DMWFJTR MW 472.5
DMWFJTR FM C25H28N8O2
DMWFJTR IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMWFJTR CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMWFJTR IK LTXREWYXXSTFRX-QGZVFWFLSA-N
DMWFJTR IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMWFJTR CA CAS 668270-12-0
DMWFJTR CB CHEBI:68610
DMWFJTR DE Type-2 diabetes
DMVTHER ID DMVTHER
DMVTHER DN Lincomycin
DMVTHER HS Approved
DMVTHER SN Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside
DMVTHER TC Antibiotics
DMVTHER DT Small molecular drug
DMVTHER PC 3000540
DMVTHER MW 406.5
DMVTHER FM C18H34N2O6S
DMVTHER IC InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1
DMVTHER CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
DMVTHER IK OJMMVQQUTAEWLP-KIDUDLJLSA-N
DMVTHER IU (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DMVTHER CA CAS 154-21-2
DMVTHER CB CHEBI:6472
DMVTHER DE Gram-positive bacterial infection
DMB8CNL ID DMB8CNL
DMB8CNL DN Lindane
DMB8CNL HS Approved
DMB8CNL SN Aalindan; Aficide; Agrocide; Agronexit; Ameisenatod; Ameisentod; Aparasin; Aphtiria; Aphtitria; Aplidal; Arbitex; BBH; Benhexachlor; Benhexol; Benzanex; Benzex; Bexol; Celanex; Chloresene; Codechine; Devoran; Dolmix; Entomoxan; Esoderm; Exagama; Forlin; Gallogama; Gamacarbatox; Gamacid; Gamacide; Gamaphex; Gamene; Gamiso; Gammahexa; Gammahexane; Gammalin; Gammasan; Gammaterr; Gammex; Gammexane; Gammopaz; Gamtox; Geobilan; Gexane; Gyben; HCH; Hcch; Heclotox; Hecoltox; Hexa; Hexablanc; Hexachlor; Hexachloran; Hexachlorane; Hexamul; Hexapoudre; Hexatox; Hexaverm; Hexcidum; Hexicide; Hexit; Hexyclan; Hilbeech; Hortex; Inexit; Isatox; Isotox; Jacutin; Kokotine; Kwell; Lasochron; Lendine; Lentox; Lidenal; Lindafor; Lindagam; Lindagrain; Lindagranox; Lindalo; Lindamul; Lindan; Lindano; Lindanum; Lindapoudre; Lindaterra; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Mszycol; Nexit; Nicochloran; Novigam; Novigan; Omnitox; Ovadziak; Owadziak; PLK; Pedraczak; Pflanzol; Quellada; Scabene; Silvanol; Streunex; Submar; Viton; Agrocide III; Agrocide WP; Am eisenatod; Arcotal S; BHCor HCH; Borer Spray; DOL GRANULE; Eso derm; Gamma BHC; HCH [BSI]; HCH [ISO]; Hilbeec h; Isot ox; Lacco HI lin; Lindam ul; Mglawik L; New kotol; Nexen fb; PMS Lindane; Sang gamma; Agrocide 2; Agrocide6G; Agrocide 7; Bentox 10; Detox 25; Gamacide 20; Gammalin 20; Geolin G 3; Hungaria L7; Latka 666; Milbol 49; PS71_SUPELCO; TAP 85; Agrisol G-20; Alpha-BHC; Alpha-HCH; Ben-Hex; Beta-BHC; Beta-HCH; Beta-Lindane; Beta-isomer; D-BHC; Delta-BHC; Delta-HCH; ENT 7,796; ENT 8,601; ENT 9,232; ENT 9,233; ENT 9,234; Epsilon-HCH; Forst-nexen; Gamma-BHC; Gamma-HCH; Gamma-col; HCH (alpha); HCH (beta); KWELL (TN); Kwell-R; Nexen-fb; Nexi t-stark; Nexit-stark; Nexol-E; Sang-gamma; T-HCH; TRI-6; Trives-T
DMB8CNL CP Morton Grove Pharmaceuticals
DMB8CNL TC Antiscabies Agent
DMB8CNL DT Small molecular drug
DMB8CNL PC 727
DMB8CNL MW 290.8
DMB8CNL FM C6H6Cl6
DMB8CNL IC InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
DMB8CNL CS C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
DMB8CNL IK JLYXXMFPNIAWKQ-UHFFFAOYSA-N
DMB8CNL IU 1,2,3,4,5,6-hexachlorocyclohexane
DMB8CNL CB CHEBI:24536
DMB8CNL DE Infestations of lice and scabies
DMGFPU2 ID DMGFPU2
DMGFPU2 DN Linezolid
DMGFPU2 HS Approved
DMGFPU2 SN Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017
DMGFPU2 CP Pfizer Pharmaceuticals
DMGFPU2 TC Antibiotics
DMGFPU2 DT Small molecular drug
DMGFPU2 PC 441401
DMGFPU2 MW 337.35
DMGFPU2 FM C16H20FN3O4
DMGFPU2 IC InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
DMGFPU2 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
DMGFPU2 IK TYZROVQLWOKYKF-ZDUSSCGKSA-N
DMGFPU2 IU N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMGFPU2 CA CAS 165800-03-3
DMGFPU2 CB CHEBI:63607
DMGFPU2 DE Bacterial infection
DM6IR3P ID DM6IR3P
DM6IR3P DN Liothyronine
DM6IR3P HS Approved
DM6IR3P SN liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
DM6IR3P CP King Pharmaceuticals, Inc
DM6IR3P TC Hormone Replacement Agents
DM6IR3P DT Small molecular drug
DM6IR3P PC 5920
DM6IR3P MW 650.97
DM6IR3P FM C15H12I3NO4
DM6IR3P IC InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
DM6IR3P CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O
DM6IR3P IK AUYYCJSJGJYCDS-LBPRGKRZSA-N
DM6IR3P IU (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
DM6IR3P CA CAS 15785-49-6
DM6IR3P CB CHEBI:18258
DM6IR3P DE Hypothyroidism; Congestive heart failure
DMSTXWR ID DMSTXWR
DMSTXWR DN Liotrix
DMSTXWR HS Approved
DMSTXWR SN Liotrix; Novothyral; Thyrolar; Combithyrex; Diotroxin; Euthroid; W 1782; 8065-29-0; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; Levothyroxine Sodium mixture with Liothyronine Sodium; Liothyronine Sodium and Levothyroxine Sodium; Monosodium L-thyroxine hydrate mixt. with monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
DMSTXWR PC 71371
DMSTXWR MW 1471.8
DMSTXWR FM C30H21I7N2Na2O8
DMSTXWR IC LKYWLLWWYBVUPP-XOCLESOZSA-L
DMSTXWR CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+].[Na+]
DMSTXWR IK 1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1
DMSTXWR IU disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
DMSTXWR CA CAS 8065-29-0
DMSTXWR CB CHEBI:6485
DMSTXWR DE Hypothyroidism
DM3FXPS ID DM3FXPS
DM3FXPS DN Liraglutide
DM3FXPS HS Approved
DM3FXPS SN Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
DM3FXPS CP Novo Nordisk Massachusetts General Hospital
DM3FXPS DT Small molecular drug
DM3FXPS SQ Liraglutide Sequence: HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG
DM3FXPS PC 16134956
DM3FXPS MW 3751
DM3FXPS FM C172H265N43O51
DM3FXPS IC InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1
DM3FXPS CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
DM3FXPS IK YSDQQAXHVYUZIW-QCIJIYAXSA-N
DM3FXPS IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DM3FXPS CA CAS 204656-20-2
DM3FXPS CB CHEBI:71193
DM3FXPS DE Type-2 diabetes; Obesity
DM6W8V5 ID DM6W8V5
DM6W8V5 DN Lisdexamfetamine
DM6W8V5 HS Approved
DM6W8V5 SN NRP104; Lisdexamfetamine (INN); Vyvanse (TN)
DM6W8V5 CP New River Pharmaceuticals
DM6W8V5 DT Small molecular drug
DM6W8V5 PC 11597698
DM6W8V5 MW 263.38
DM6W8V5 FM C15H25N3O
DM6W8V5 IC InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
DM6W8V5 CS C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
DM6W8V5 IK VOBHXZCDAVEXEY-JSGCOSHPSA-N
DM6W8V5 IU (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
DM6W8V5 CA CAS 608137-32-2
DM6W8V5 CB CHEBI:135925
DM6W8V5 DE Attention deficit hyperactivity disorder
DMUOK4C ID DMUOK4C
DMUOK4C DN Lisinopril
DMUOK4C HS Approved
DMUOK4C SN Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
DMUOK4C CP Merck & Co
DMUOK4C TC Antihypertensive Agents
DMUOK4C DT Small molecular drug
DMUOK4C PC 5362119
DMUOK4C MW 405.5
DMUOK4C FM C21H31N3O5
DMUOK4C IC InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
DMUOK4C CS C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
DMUOK4C IK RLAWWYSOJDYHDC-BZSNNMDCSA-N
DMUOK4C IU (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
DMUOK4C CA CAS 76547-98-3
DMUOK4C CB CHEBI:43755
DMUOK4C DE Hypertension
DMP45ME ID DMP45ME
DMP45ME DN Lisocabtagene maraleucel
DMP45ME HS Approved
DMP45ME SN JCAR017
DMP45ME CP Celgene
DMP45ME DT CAR T Cell Therapy
DMP45ME DE Central nervous system lymphoma; Precursor B-lymphoblastic neoplasm; Follicular lymphoma; Richter syndrome; Non-hodgkin lymphoma; Large B-cell lymphoma
DMCME17 ID DMCME17
DMCME17 DN Lisuride
DMCME17 HS Approved
DMCME17 SN Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
DMCME17 CP IVAX Pharmaceuticals
DMCME17 TC Antiparkinson Agents
DMCME17 DT Small molecular drug
DMCME17 PC 28864
DMCME17 MW 338.4
DMCME17 FM C20H26N4O
DMCME17 IC InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
DMCME17 CS CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMCME17 IK BKRGVLQUQGGVSM-KBXCAEBGSA-N
DMCME17 IU 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMCME17 CA CAS 18016-80-3
DMCME17 CB CHEBI:51164
DMCME17 DE Parkinson disease; Fibrosis
DMX9PIA ID DMX9PIA
DMX9PIA DN Live attenuated influenza vaccine
DMX9PIA HS Approved
DMX9PIA SN Influenza vaccine, BioDiem; Influenza vaccine, St Petersburg Institute of Experimental Medicine; Live attenuated influenza vaccine (CoVaccine adjuvant); SCH-900795; Cold-adapted flu virus vaccine, St Petersburg Institute of Experimental Medicine; Influenza vaccine (live attenuated, nasal), BioDiem; Influenza vaccine, BioDiem/Merck & Co; LAIV (CoVaccine adjuvant), Nobilon/NV Organon; Live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India; Live attenuated influenza vaccine (CoVaccine adjuvant), Schering Plough/BioDiem; Live attenuated influenza vaccine (CoVaccine adjuvant), Merck & Co/BioDiem
DMX9PIA CP St Petersburg Institute of Experimental Medicine
DMX9PIA DT Vaccine
DMX9PIA DE Influenza virus infection
DM0QJDC ID DM0QJDC
DM0QJDC DN Lixisenatide
DM0QJDC HS Approved
DM0QJDC SN Lyxumia (TN)
DM0QJDC CP Sanofi
DM0QJDC DT Small molecular drug
DM0QJDC PC 90472060
DM0QJDC MW 4858
DM0QJDC FM C215H347N61O65S
DM0QJDC IC InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1
DM0QJDC CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N
DM0QJDC IK XVVOERDUTLJJHN-IAEQDCLQSA-N
DM0QJDC IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM0QJDC CA CAS 320367-13-3
DM0QJDC CB CHEBI:85662
DM0QJDC DE Type-2 diabetes
DMJPD06 ID DMJPD06
DMJPD06 DN Lmw heparin
DMJPD06 HS Approved
DMJPD06 SN Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)
DMJPD06 DT Small molecular drug
DMJPD06 PC 25244225
DMJPD06 MW 591.5
DMJPD06 FM C12H17NO20S3-4
DMJPD06 IC InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
DMJPD06 CS C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
DMJPD06 IK OHJKXVLJWUPWQG-IUYNYSEKSA-J
DMJPD06 IU (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
DMJPD06 DE Hematologic disease; Coagulation defect
DMHY3IP ID DMHY3IP
DMHY3IP DN Lobeglitazone
DMHY3IP HS Approved
DMHY3IP SN Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang
DMHY3IP CP Chong Kun Dang Pharmaceutical Corp
DMHY3IP DT Small molecular drug
DMHY3IP PC 9826451
DMHY3IP MW 480.5
DMHY3IP FM C24H24N4O5S
DMHY3IP IC InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
DMHY3IP CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC
DMHY3IP IK CHHXEZSCHQVSRE-UHFFFAOYSA-N
DMHY3IP IU 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMHY3IP CA CAS 607723-33-1
DMHY3IP CB CHEBI:136052
DMHY3IP DE Type-2 diabetes
DM1WXA6 ID DM1WXA6
DM1WXA6 DN Lofexidine
DM1WXA6 HS Approved
DM1WXA6 SN Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole
DM1WXA6 CP US WorldMeds
DM1WXA6 TC Antihypertensive Agents
DM1WXA6 DT Small molecular drug
DM1WXA6 PC 30668
DM1WXA6 MW 259.13
DM1WXA6 FM C11H12Cl2N2O
DM1WXA6 IC InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
DM1WXA6 CS CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl
DM1WXA6 IK KSMAGQUYOIHWFS-UHFFFAOYSA-N
DM1WXA6 IU 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
DM1WXA6 CA CAS 31036-80-3
DM1WXA6 CB CHEBI:51368
DM1WXA6 DE Opioid dependence; Heroin and opiate withdrawal
DMVRH9C ID DMVRH9C
DMVRH9C DN Lomefloxacin
DMVRH9C HS Approved
DMVRH9C SN LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride
DMVRH9C CP Pharmacia Corp
DMVRH9C TC Antibiotics
DMVRH9C DT Small molecular drug
DMVRH9C PC 3948
DMVRH9C MW 351.35
DMVRH9C FM C17H19F2N3O3
DMVRH9C IC InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
DMVRH9C CS CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
DMVRH9C IK ZEKZLJVOYLTDKK-UHFFFAOYSA-N
DMVRH9C IU 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMVRH9C CA CAS 98079-51-7
DMVRH9C CB CHEBI:116278
DMVRH9C DE Bacterial infection
DME0TC8 ID DME0TC8
DME0TC8 DN Lomerizine
DME0TC8 HS Approved
DME0TC8 SN lomerizine; 101477-55-8; Lomerizine [INN]; UNII-DEE37CY4VO; 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine; C27H30F2N2O3; DEE37CY4VO; CHEMBL29188; Terranas; 1-(Bis(p-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; 1-(Bis(p-fluorophenyl)-methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; NCGC00164543-01; iomerizine; 1-(2,3,4-trimethoxybenzyl)-4-[bis(4-fluorophenyl)methyl]piperazine; 1-(2,3,4-trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazine; AC1Q4NME
DME0TC8 DT Small molecular drug
DME0TC8 PC 3949
DME0TC8 MW 468.5
DME0TC8 FM C27H30F2N2O3
DME0TC8 IC InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3
DME0TC8 CS COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC
DME0TC8 IK JQSAYKKFZOSZGJ-UHFFFAOYSA-N
DME0TC8 IU 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
DME0TC8 CA CAS 101477-55-8
DME0TC8 CB CHEBI:94682
DME0TC8 DE Migraine
DMLB4PE ID DMLB4PE
DMLB4PE DN Lomitapide mesylate
DMLB4PE HS Approved
DMLB4PE SN Lomitapide (mesylate); Lomitapide mesylate; Lomitapide mesylate (USAN); Lomitapide mesylate [USAN]; X4S83CP54E; lomitapide-mesylate; 202914-84-9; BMS 201038-04; BMS-201038-04; CHEBI:72299; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate; UNII-X4S83CP54E; Juxtapid (TN)
DMLB4PE PC 11274333
DMLB4PE MW 789.8
DMLB4PE FM C40H41F6N3O5S
DMLB4PE IC QKVKOFVWUHNEBX-UHFFFAOYSA-N
DMLB4PE CS CS(=O)(=O)O.C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMLB4PE IK 1S/C39H37F6N3O2.CH4O3S/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45;1-5(2,3)4/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49);1H3,(H,2,3,4)
DMLB4PE IU methanesulfonic acid;N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMLB4PE CA CAS 202914-84-9
DMLB4PE CB CHEBI:72299
DMLB4PE DE Hypertriglyceridaemia
DMMWSUL ID DMMWSUL
DMMWSUL DN Lomustine
DMMWSUL HS Approved
DMMWSUL SN Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
DMMWSUL TC Anticancer Agents
DMMWSUL DT Small molecular drug
DMMWSUL PC 3950
DMMWSUL MW 233.69
DMMWSUL FM C9H16ClN3O2
DMMWSUL IC InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
DMMWSUL CS C1CCC(CC1)NC(=O)N(CCCl)N=O
DMMWSUL IK GQYIWUVLTXOXAJ-UHFFFAOYSA-N
DMMWSUL IU 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
DMMWSUL CA CAS 13010-47-4
DMMWSUL CB CHEBI:6520
DMMWSUL DE Brain cancer
DMGM2Z6 ID DMGM2Z6
DMGM2Z6 DN Lonafarnib
DMGM2Z6 HS Approved
DMGM2Z6 SN Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE
DMGM2Z6 CP Schering-Plough
DMGM2Z6 TC Anticancer Agents
DMGM2Z6 DT Small molecular drug
DMGM2Z6 PC 148195
DMGM2Z6 MW 638.8
DMGM2Z6 FM C27H31Br2ClN4O2
DMGM2Z6 IC InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
DMGM2Z6 CS C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
DMGM2Z6 IK DHMTURDWPRKSOA-RUZDIDTESA-N
DMGM2Z6 IU 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
DMGM2Z6 CA CAS 193275-84-2
DMGM2Z6 CB CHEBI:47097
DMGM2Z6 DE Non-small-cell lung cancer; Hepatitis D virus infection; Myelodysplastic syndrome; Hutchinson-Gilford progeria syndrome
DMXSVGI ID DMXSVGI
DMXSVGI DN Loncastuximab tesirine
DMXSVGI HS Approved
DMXSVGI CP ADC Therapeutics
DMXSVGI DT Antibody drug conjugate
DMXSVGI DE Diffuse large B-cell lymphoma; Follicular lymphoma
DMOJZQ9 ID DMOJZQ9
DMOJZQ9 DN Loperamide
DMOJZQ9 HS Approved
DMOJZQ9 SN Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide
DMOJZQ9 CP Janssen Pharmaceutica
DMOJZQ9 TC Antidiarrheals
DMOJZQ9 DT Small molecular drug
DMOJZQ9 PC 3955
DMOJZQ9 MW 477
DMOJZQ9 FM C29H33ClN2O2
DMOJZQ9 IC InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
DMOJZQ9 CS CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
DMOJZQ9 IK RDOIQAHITMMDAJ-UHFFFAOYSA-N
DMOJZQ9 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
DMOJZQ9 CA CAS 53179-11-6
DMOJZQ9 CB CHEBI:6532
DMOJZQ9 DE Diarrhea
DMITQS0 ID DMITQS0
DMITQS0 DN Lopinavir
DMITQS0 HS Approved
DMITQS0 SN AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
DMITQS0 CP Abbott Laboratories
DMITQS0 TC Anti-HIV Agents
DMITQS0 DT Small molecular drug
DMITQS0 PC 92727
DMITQS0 MW 628.8
DMITQS0 FM C37H48N4O5
DMITQS0 IC InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
DMITQS0 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
DMITQS0 IK KJHKTHWMRKYKJE-SUGCFTRWSA-N
DMITQS0 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
DMITQS0 CA CAS 192725-17-0
DMITQS0 CB CHEBI:31781
DMITQS0 DE Human immunodeficiency virus infection
DM4L8H3 ID DM4L8H3
DM4L8H3 DN Loracarbef
DM4L8H3 HS Approved
DM4L8H3 SN Lorabid; Loracarbefum; Lorafem; Loracarbef hydrate; KT-3777; LY-163892; Lorabid (TN); (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate
DM4L8H3 CP Eli Lilly
DM4L8H3 TC Antibiotics
DM4L8H3 DT Small molecular drug
DM4L8H3 PC 5284585
DM4L8H3 MW 349.77
DM4L8H3 FM C16H16ClN3O4
DM4L8H3 IC InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1
DM4L8H3 CS C1CC(=C(N2[C@H]1[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DM4L8H3 IK JAPHQRWPEGVNBT-UTUOFQBUSA-N
DM4L8H3 IU (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM4L8H3 CA CAS 76470-66-1
DM4L8H3 CB CHEBI:47544
DM4L8H3 DE Bacterial infection
DMF3AN7 ID DMF3AN7
DMF3AN7 DN Loratadine
DMF3AN7 HS Approved
DMF3AN7 SN Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
DMF3AN7 CP Schering-Plough Corporation
DMF3AN7 TC Antihistamines
DMF3AN7 DT Small molecular drug
DMF3AN7 PC 3957
DMF3AN7 MW 382.9
DMF3AN7 FM C22H23ClN2O2
DMF3AN7 IC InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
DMF3AN7 CS CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
DMF3AN7 IK JCCNYMKQOSZNPW-UHFFFAOYSA-N
DMF3AN7 IU ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
DMF3AN7 CA CAS 79794-75-5
DMF3AN7 CB CHEBI:6538
DMF3AN7 DE Allergy; Allergic rhinitis
DM84ZXF ID DM84ZXF
DM84ZXF DN Lorazepam
DM84ZXF HS Approved
DM84ZXF SN Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF CP Wyeth Pharmaceuticals
DM84ZXF TC Antianxiety Agents
DM84ZXF DT Small molecular drug
DM84ZXF PC 3958
DM84ZXF MW 321.2
DM84ZXF FM C15H10Cl2N2O2
DM84ZXF IC InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
DM84ZXF CS C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
DM84ZXF IK DIWRORZWFLOCLC-UHFFFAOYSA-N
DM84ZXF IU 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF CA CAS 846-49-1
DM84ZXF CB CHEBI:6539
DM84ZXF DE Anxiety disorder
DMG6OYJ ID DMG6OYJ
DMG6OYJ DN Lorcaserin
DMG6OYJ HS Approved
DMG6OYJ SN APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene
DMG6OYJ CP Arena Pharmaceuticals Inc.
DMG6OYJ DT Small molecular drug
DMG6OYJ PC 11658860
DMG6OYJ MW 195.69
DMG6OYJ FM C11H14ClN
DMG6OYJ IC InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
DMG6OYJ CS C[C@H]1CNCCC2=C1C=C(C=C2)Cl
DMG6OYJ IK XTTZERNUQAFMOF-QMMMGPOBSA-N
DMG6OYJ IU (5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
DMG6OYJ CA CAS 616202-92-7
DMG6OYJ CB CHEBI:65353
DMG6OYJ DE Obesity; Drug abuse
DMICDLV ID DMICDLV
DMICDLV DN Lorlatinib
DMICDLV HS Approved
DMICDLV SN Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39
DMICDLV CP Pfizer
DMICDLV PC 71731823
DMICDLV MW 406.4
DMICDLV FM C21H19FN6O2
DMICDLV IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMICDLV CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMICDLV IK IIXWYSCJSQVBQM-LLVKDONJSA-N
DMICDLV IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMICDLV CA CAS 1454846-35-5
DMICDLV CB CHEBI:143117
DMICDLV DE Non-small-cell lung cancer
DMYZFXN ID DMYZFXN
DMYZFXN DN Lornoxicam
DMYZFXN HS Approved
DMYZFXN SN CTX; Chlortenoxicam; Lorcam; Safem; Telos; Xefo; Xefo Rapid; HN-10000; TS-110; Ro-13-9297
DMYZFXN CP Roche Holding AG
DMYZFXN DT Small molecular drug
DMYZFXN PC 54690031
DMYZFXN MW 371.8
DMYZFXN FM C13H10ClN3O4S2
DMYZFXN IC InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
DMYZFXN CS CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3
DMYZFXN IK WLHQHAUOOXYABV-UHFFFAOYSA-N
DMYZFXN IU 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMYZFXN CA CAS 70374-39-9
DMYZFXN CB CHEBI:31783
DMYZFXN DE Migraine
DM72JXH ID DM72JXH
DM72JXH DN Losartan
DM72JXH HS Approved
DM72JXH SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DM72JXH CP Merck & Co
DM72JXH TC Antihypertensive Agents
DM72JXH DT Small molecular drug
DM72JXH PC 3961
DM72JXH MW 422.9
DM72JXH FM C22H23ClN6O
DM72JXH IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DM72JXH CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DM72JXH IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DM72JXH IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DM72JXH CA CAS 114798-26-4
DM72JXH CB CHEBI:6541
DM72JXH DE Hypertension
DM8QTJI ID DM8QTJI
DM8QTJI DN Loteprednol etabonate
DM8QTJI HS Approved
DM8QTJI SN Alrex; Locort; Loteflam; Lotemax; Loterox; CDDD-5604; HGP-1; IDR-90102; IDR-90103; Lotemax (TN); P-5604; Alrex, Lotemax, Loteprednol etabonate; Loteprednol etabonate (JAN/USAN); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI CP Bausch & Lomb Pharmaceuticals, Inc.
DM8QTJI TC Antiallergic Agents
DM8QTJI DT Small molecular drug
DM8QTJI PC 444025
DM8QTJI MW 466.9
DM8QTJI FM C24H31ClO7
DM8QTJI IC InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1
DM8QTJI CS CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
DM8QTJI IK DMKSVUSAATWOCU-HROMYWEYSA-N
DM8QTJI IU chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI CA CAS 82034-46-6
DM8QTJI CB CHEBI:31784
DM8QTJI DE Eye inflammation
DM9OZWQ ID DM9OZWQ
DM9OZWQ DN Lovastatin
DM9OZWQ HS Approved
DM9OZWQ SN lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
DM9OZWQ CP Atos Pharma
DM9OZWQ TC Anticholesteremic Agents
DM9OZWQ DT Small molecular drug
DM9OZWQ PC 53232
DM9OZWQ MW 404.5
DM9OZWQ FM C24H36O5
DM9OZWQ IC InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DM9OZWQ CS CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM9OZWQ IK PCZOHLXUXFIOCF-BXMDZJJMSA-N
DM9OZWQ IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM9OZWQ CA CAS 75330-75-5
DM9OZWQ CB CHEBI:40303
DM9OZWQ DE Hypercholesterolaemia; Cardiovascular disease
DMGCQ4E ID DMGCQ4E
DMGCQ4E DN Lovastatin acid
DMGCQ4E HS Approved
DMGCQ4E SN Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E PC 64727
DMGCQ4E MW 422.6
DMGCQ4E FM C24H38O6
DMGCQ4E IC InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DMGCQ4E CS CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DMGCQ4E IK QLJODMDSTUBWDW-BXMDZJJMSA-N
DMGCQ4E IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E CA CAS 75225-51-3
DMGCQ4E CB CHEBI:82985
DMGCQ4E DE Hypercholesterolemia
DM8AI9U ID DM8AI9U
DM8AI9U DN Loxapine
DM8AI9U HS Approved
DM8AI9U SN Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
DM8AI9U CP Watson Laboratories
DM8AI9U TC Antipsychotic Agents
DM8AI9U DT Small molecular drug
DM8AI9U PC 3964
DM8AI9U MW 327.8
DM8AI9U FM C18H18ClN3O
DM8AI9U IC InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM8AI9U CS CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DM8AI9U IK XJGVXQDUIWGIRW-UHFFFAOYSA-N
DM8AI9U IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DM8AI9U CA CAS 1977-10-2
DM8AI9U CB CHEBI:50841
DM8AI9U DE Schizophrenia
DMQMGXV ID DMQMGXV
DMQMGXV DN Loxoprofen gel
DMQMGXV HS Approved
DMQMGXV SN Loxonin; Loxoprofen; Loxonin Pap; Loxonin Tape; CS-600G; LX-A; LX-P; Loxonin Gel 1%; Lipoxin A, Daiichi Sankyo/Lead Chemical; Lipoxin A, Sankyo/ Lead Chemical; Loxoprofen (gel, pain/ inflammation), Daiichi Sankyo; Loxoprofen (gel, pain/ inflammation), Sankyo; Loxoprofen (patch, pain/inflammation), Daiichi Sankyo/ Lead Chemical; Loxoprofen (patch, pain/inflammation), Sankyo/ Lead Chemical
DMQMGXV CP Sankyo Co Ltd
DMQMGXV DT Small molecular drug
DMQMGXV PC 3965
DMQMGXV MW 246.3
DMQMGXV FM C15H18O3
DMQMGXV IC InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DMQMGXV CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DMQMGXV IK YMBXTVYHTMGZDW-UHFFFAOYSA-N
DMQMGXV IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DMQMGXV CA 68767-14-6
DMQMGXV DE Inflammation
DMQXI9F ID DMQXI9F
DMQXI9F DN L-Phenylalanine
DMQXI9F HS Approved
DMQXI9F SN Endophenyl; Fenilalanina; Phe; Phenylalanine; Phenylalaninum; Fenilalanina [Spanish]; Phenylalaninum [Latin]; Antibiotic FN 1636; CB 3208; NCI9959; Alpha-Aminohydrocinnamic acid; Beta-Phenylalanine; L-Antibiotic FN 1636; L-PHENYLALININE; N-Formylmelphalan; Phenylalanine (VAN); H-Phe-OH; L-Phenylalanine (JP15); Phenylalanine (USP/INN); Phenylalanine [USAN:INN:JAN]; Beta-Phenyl-L-alanine; N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl-(9CI); (2S)-2-amino-3-phenylpropanoic acid; (L)-Phenylalanine; (S)-(-)-Phenylalanine; (S)-2-Amino-3-phenylpropanoic acid; (S)-2-Amino-3-phenylpropionic acid; (S)-Phenylalanine; (S)-alpha-Amino-benzenepropanoic acid; (S)-alpha-Amino-beta-phenylpropionic acid; (S)-alpha-Aminohydrocinnamic acid; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 3-Phenyl-L-alanine; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
DMQXI9F TC Dietary supplement
DMQXI9F DT Small molecular drug
DMQXI9F PC 6140
DMQXI9F MW 165.19
DMQXI9F FM C9H11NO2
DMQXI9F IC InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
DMQXI9F CS C1=CC=C(C=C1)C[C@@H](C(=O)O)N
DMQXI9F IK COLNVLDHVKWLRT-QMMMGPOBSA-N
DMQXI9F IU (2S)-2-amino-3-phenylpropanoic acid
DMQXI9F CA CAS 63-91-2
DMQXI9F CB CHEBI:17295
DMQXI9F DE Malnutrition
DMKSTWR ID DMKSTWR
DMKSTWR DN L-Proline
DMKSTWR HS Approved
DMKSTWR SN Carboxypyrrolidine; Pro; Prolina; Prolinum; Prolina [Spanish]; Prolinum [Latin]; CB 1707; L-Prolin; PRO (IUPACabbreviation); Proline (USP); Proline (VAN); Proline [USAN:INN]; H-Pro-OH; L-Proline (JAN); L-Proline-15N; L-alpha-Pyrrolidinecarboxylic acid; L-Proline, labeled with carbon-14; L-Pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; (-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid
DMKSTWR TC Dietary supplement
DMKSTWR DT Small molecular drug
DMKSTWR PC 145742
DMKSTWR MW 115.13
DMKSTWR FM C5H9NO2
DMKSTWR IC InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
DMKSTWR CS C1C[C@H](NC1)C(=O)O
DMKSTWR IK ONIBWKKTOPOVIA-BYPYZUCNSA-N
DMKSTWR IU (2S)-pyrrolidine-2-carboxylic acid
DMKSTWR CA CAS 4305-67-3
DMKSTWR CB CHEBI:17203
DMKSTWR DE Malnutrition
DMIBH7M ID DMIBH7M
DMIBH7M DN L-tryptophan
DMIBH7M HS Approved
DMIBH7M SN Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine
DMIBH7M TC Antidepressants
DMIBH7M DT Small molecular drug
DMIBH7M PC 6305
DMIBH7M MW 204.22
DMIBH7M FM C11H12N2O2
DMIBH7M IC InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
DMIBH7M CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N
DMIBH7M IK QIVBCDIJIAJPQS-VIFPVBQESA-N
DMIBH7M IU (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
DMIBH7M CA CAS 73-22-3
DMIBH7M CB CHEBI:16828
DMIBH7M DE Depression
DM9O8DT ID DM9O8DT
DM9O8DT DN L-tyrosine
DM9O8DT HS Approved
DM9O8DT SN DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1
DM9O8DT TC Dietary supplement
DM9O8DT DT Small molecular drug
DM9O8DT PC 6057
DM9O8DT MW 181.19
DM9O8DT FM C9H11NO3
DM9O8DT IC InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
DM9O8DT CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)O
DM9O8DT IK OUYCCCASQSFEME-QMMMGPOBSA-N
DM9O8DT IU (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
DM9O8DT CA CAS 60-18-4
DM9O8DT CB CHEBI:17895
DM9O8DT DE Malnutrition
DMMJVXZ ID DMMJVXZ
DMMJVXZ DN LU302146
DMMJVXZ HS Approved
DMMJVXZ DE Pulmonary hypertension
DMJTEMW ID DMJTEMW
DMJTEMW DN Lubiprostone
DMJTEMW HS Approved
DMJTEMW SN Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW CP Takeda
DMJTEMW TC Anticonstipation Agents
DMJTEMW DT Small molecular drug
DMJTEMW PC 157920
DMJTEMW MW 390.5
DMJTEMW FM C20H32F2O5
DMJTEMW IC InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1
DMJTEMW CS CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F
DMJTEMW IK WGFOBBZOWHGYQH-MXHNKVEKSA-N
DMJTEMW IU 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW CA CAS 333963-40-9
DMJTEMW DE Chronic idiopathic constipation
DMZLBUO ID DMZLBUO
DMZLBUO DN Lucanthone
DMZLBUO HS Approved
DMZLBUO SN Lucanthon; Lucanthonum; Lucantona; Miracol; Nilodin; Scapuren; Tixantone; LUCANTHONE HYDROCHLORIDE; Lucanthone monohydrochloride; Miracil D; BW 57223; CBC 900139; DR-15771; Lucanthone [INN:BAN]; Lucanthonum [INN-Latin]; Lucantona [INN-Spanish]; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; 1-(2-diethylaminoethylamino)-4-methylthioxanthen-9-one; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-(9CI)
DMZLBUO CP Spectrum
DMZLBUO TC Anticancer Agents
DMZLBUO DT Small molecular drug
DMZLBUO PC 10180
DMZLBUO MW 340.5
DMZLBUO FM C20H24N2OS
DMZLBUO IC InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3
DMZLBUO CS CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O
DMZLBUO IK FBQPGGIHOFZRGH-UHFFFAOYSA-N
DMZLBUO IU 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one
DMZLBUO CA CAS 479-50-5
DMZLBUO CB CHEBI:51052
DMZLBUO DE Solid tumour/cancer
DMT73J8 ID DMT73J8
DMT73J8 DN Luliconazole
DMT73J8 HS Approved
DMT73J8 SN Lulicon; Lulifin; JA-004; JA-005; NND-502; PR-2699
DMT73J8 CP Medicis
DMT73J8 DT Small molecular drug
DMT73J8 PC 3003141
DMT73J8 MW 354.3
DMT73J8 FM C14H9Cl2N3S2
DMT73J8 IC InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1
DMT73J8 CS C1[C@H](S/C(=C(\\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl
DMT73J8 IK YTAOBBFIOAEMLL-REQDGWNSSA-N
DMT73J8 IU (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
DMT73J8 CA CAS 187164-19-8
DMT73J8 CB CHEBI:34825
DMT73J8 DE Tinea pedis; Dry eye disease
DMUPOGR ID DMUPOGR
DMUPOGR DN Lumacaftor + Ivacaftor
DMUPOGR HS Approved
DMUPOGR CP Vertex
DMUPOGR DE Cystic fibrosis; Acute lung injury
DMEBQAO ID DMEBQAO
DMEBQAO DN Lumasiran
DMEBQAO HS Approved
DMEBQAO CP Alnylam Pharmaceuticals
DMEBQAO DT Small interfering RNA
DMEBQAO DE Hyperoxaluria
DMQ8HOJ ID DMQ8HOJ
DMQ8HOJ DN lumateperone tosylate
DMQ8HOJ HS Approved
DMQ8HOJ SN lumateperone Tosylate; lumateperone (Tosylate); 1187020-80-9; UNII-JIE88N006O; ITI-007 tosylate; JIE88N006O; 1187020-80-9 (tosylate); ITI007; ITI 007; ITI-007; Lumateperone tosylate (USAN); Lumateperone tosylate [USAN]; CHEMBL3233142; 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one toluenesulfonic acid; Caplyta (TN); SCHEMBL1769664; CS-5540; HY-19733; D11170; Q27281520; 1-(4-Fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one tosylate salt
DMQ8HOJ DT Small molecular drug
DMQ8HOJ PC 44241743
DMQ8HOJ MW 565.7
DMQ8HOJ FM C31H36FN3O4S
DMQ8HOJ IC InChI=1S/C24H28FN3O.C7H8O3S/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17;1-6-2-4-7(5-3-6)11(8,9)10/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3;2-5H,1H3,(H,8,9,10)/t20-,21-;/m0./s1
DMQ8HOJ CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMQ8HOJ IK LHAPOGAFBLSJJQ-GUTACTQSSA-N
DMQ8HOJ IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic acid
DMQ8HOJ CA CAS 1187020-80-9
DMQ8HOJ DE Schizophrenia
DM29GAD ID DM29GAD
DM29GAD DN Lumefantrine
DM29GAD HS Approved
DM29GAD SN Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
DM29GAD DT Small molecular drug
DM29GAD PC 6437380
DM29GAD MW 528.9
DM29GAD FM C30H32Cl3NO
DM29GAD IC InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
DM29GAD CS CCCCN(CCCC)CC(C1=CC(=CC\\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O
DM29GAD IK DYLGFOYVTXJFJP-MYYYXRDXSA-N
DM29GAD IU 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
DM29GAD CA CAS 82186-77-4
DM29GAD CB CHEBI:156095
DM29GAD DE Malaria
DM1S4AG ID DM1S4AG
DM1S4AG DN Lumiracoxib
DM1S4AG HS Approved
DM1S4AG SN Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG CP Norvatis Phamaceuticals Corporation
DM1S4AG TC Antiinflammatory Agents
DM1S4AG DT Small molecular drug
DM1S4AG PC 151166
DM1S4AG MW 293.72
DM1S4AG FM C15H13ClFNO2
DM1S4AG IC InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
DM1S4AG CS CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
DM1S4AG IK KHPKQFYUPIUARC-UHFFFAOYSA-N
DM1S4AG IU 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG CA CAS 220991-20-8
DM1S4AG CB CHEBI:73044
DM1S4AG DE Knee osteoarthritis
DMCVPXO ID DMCVPXO
DMCVPXO DN Lurasidone hydrochloride
DMCVPXO HS Approved
DMCVPXO SN Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
DMCVPXO CP Sumitomo
DMCVPXO DT Small molecular drug
DMCVPXO PC 11237860
DMCVPXO MW 529.1
DMCVPXO FM C28H37ClN4O2S
DMCVPXO IC InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
DMCVPXO CS C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
DMCVPXO IK NEKCRUIRPWNMLK-SCIYSFAVSA-N
DMCVPXO IU (1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride
DMCVPXO CA CAS 367514-88-3
DMCVPXO CB CHEBI:70732
DMCVPXO DE Schizophrenia
DMEFRTZ ID DMEFRTZ
DMEFRTZ DN Lurbinectedin
DMEFRTZ HS Approved
DMEFRTZ SN UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B
DMEFRTZ CP PharmaMar
DMEFRTZ DT Small molecular drug
DMEFRTZ PC 57327016
DMEFRTZ MW 784.9
DMEFRTZ FM C41H44N4O10S
DMEFRTZ IC InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
DMEFRTZ CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMEFRTZ IK YDDMIZRDDREKEP-HWTBNCOESA-N
DMEFRTZ IU [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
DMEFRTZ CA CAS 497871-47-3
DMEFRTZ DE leukaemia; Solid tumour/cancer; Endometrial cancer; Ovarian cancer; Small-cell lung cancer
DMH6IKO ID DMH6IKO
DMH6IKO DN Lusutrombopag
DMH6IKO HS Approved
DMH6IKO SN LUSUTROMBOPAG; mulpleta; UNII-6LL5JFU42F; 6LL5JFU42F; 2-Propenoic acid, Lusutrombopag [USAN:INN]; SCHEMBL3062
DMH6IKO CP Shionogi
DMH6IKO PC 49843517
DMH6IKO MW 591.5
DMH6IKO FM C29H32Cl2N2O5S
DMH6IKO IC InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
DMH6IKO CS CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\\C)/C(=O)O)Cl
DMH6IKO IK NOZIJMHMKORZBA-KJCUYJGMSA-N
DMH6IKO IU (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
DMH6IKO CA CAS 1110766-97-6
DMH6IKO CB CHEBI:136051
DMH6IKO DE Thrombocytopenia; Liver disease
DMN1XVC ID DMN1XVC
DMN1XVC DN Lutetium Lu 177 dotatate
DMN1XVC HS Approved
DMN1XVC SN UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate
DMN1XVC CP Advanced Accelerator Applications/Novartis
DMN1XVC PC 132274234
DMN1XVC MW 1609.5
DMN1XVC FM C65H87LuN14O19S2
DMN1XVC IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMN1XVC CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMN1XVC IK MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMN1XVC IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMN1XVC CA CAS 437608-50-9
DMN1XVC DE Neuroendocrine cancer
DM7K5GD ID DM7K5GD
DM7K5GD DN Lutropin alfa
DM7K5GD HS Approved
DM7K5GD SN Luveris; Luveris (TN); Lutropin alfa (USAN/INN)
DM7K5GD TC Fertility Agents
DM7K5GD SQ Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta Chain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL
DM7K5GD DE Female infertility
DMJKROX ID DMJKROX
DMJKROX DN Luvox
DMJKROX HS Approved
DMJKROX SN FLUVOXAMINE MALEATE; 61718-82-9; Fevarin; Luvox CR; Fluvoxamine (maleate); UNII-5LGN83G74V; DU23000; DU-23000; SME 3110; 5LGN83G74V; MK-264; 54739-18-3; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1); 54739-20-7; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1); C19H25F3N2O6
DMJKROX DT Small molecular drug
DMJKROX PC 9560989
DMJKROX MW 434.4
DMJKROX FM C19H25F3N2O6
DMJKROX IC InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
DMJKROX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O
DMJKROX IK LFMYNZPAVPMEGP-PIDGMYBPSA-N
DMJKROX IU (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMJKROX CA CAS 61718-82-9
DMJKROX CB CHEBI:5139
DMJKROX DE Anxiety disorder
DM93VBZ ID DM93VBZ
DM93VBZ DN LY2835219
DM93VBZ HS Approved
DM93VBZ SN Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);
DM93VBZ CP Eli Lilly
DM93VBZ DT Small molecular drug
DM93VBZ PC 46220502
DM93VBZ MW 506.6
DM93VBZ FM C27H32F2N8
DM93VBZ IC InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
DM93VBZ CS CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
DM93VBZ IK UZWDCWONPYILKI-UHFFFAOYSA-N
DM93VBZ IU N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
DM93VBZ CA CAS 1231929-97-7
DM93VBZ DE Breast cancer; Solid tumour/cancer
DMOMLHJ ID DMOMLHJ
DMOMLHJ DN Lymecycline
DMOMLHJ HS Approved
DMOMLHJ SN Aureociclin; Aureomicina; Aurofac; Biovetin; Centraureo; Chlortetracyclin; Chrusomykine; Limeciclina; Lymecyclinum; Orospray; Acronize PD; Aurofac 10; Tetrlysal 300; Lymecycline (INN); Tetralysal 300 (TN); N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
DMOMLHJ CP Galderma
DMOMLHJ TC Antibiotics
DMOMLHJ DT Small molecular drug
DMOMLHJ PC 54707177
DMOMLHJ MW 602.6
DMOMLHJ FM C29H38N4O10
DMOMLHJ IC InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34-35,38,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1
DMOMLHJ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)N(C)C)O
DMOMLHJ IK PZTCVADFMACKLU-UEPZRUIBSA-N
DMOMLHJ IU (2S)-6-[[[(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid
DMOMLHJ CA CAS 992-21-2
DMOMLHJ CB CHEBI:59040
DMOMLHJ DE Bacterial infection
DM154EB ID DM154EB
DM154EB DN Lypressin
DM154EB HS Approved
DM154EB SN Lysine-vasopressin; Lysine-8-vasopressin
DM154EB DT Small molecular drug
DM154EB PC 644076
DM154EB MW 1056.2
DM154EB FM C46H65N13O12S2
DM154EB IC InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM154EB CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DM154EB IK BJFIDCADFRDPIO-DZCXQCEKSA-N
DM154EB IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM154EB CA CAS 50-57-7
DM154EB CB CHEBI:94802
DM154EB DE Amnesia
DMQYJIR ID DMQYJIR
DMQYJIR DN Macimorelin
DMQYJIR HS Approved
DMQYJIR SN Solorel; AEZS-130; ARD-07; ARD-0705; EP-01572; EP-1572; JMV-1843
DMQYJIR CP Aeterna Zentaris
DMQYJIR DT Small molecular drug
DMQYJIR PC 9804938
DMQYJIR MW 474.6
DMQYJIR FM C26H30N6O3
DMQYJIR IC InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
DMQYJIR CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N
DMQYJIR IK UJVDJAPJQWZRFR-DHIUTWEWSA-N
DMQYJIR IU 2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DMQYJIR CA CAS 381231-18-1
DMQYJIR DE Somatotropin deficiency; Growth hormone deficiency
DMP79A1 ID DMP79A1
DMP79A1 DN Macitentan
DMP79A1 HS Approved
DMP79A1 SN Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; Z9K9Y9WMVL; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Actelion-1; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; SCHEMBL1445625; GTPL7352; CHEMBL2103873; ZLA0005; EX-A544; DTXSID50196063
DMP79A1 CP Actelion Pharmaceuticals
DMP79A1 DT Small molecular drug
DMP79A1 PC 16004692
DMP79A1 MW 588.3
DMP79A1 FM C19H20Br2N6O4S
DMP79A1 IC InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
DMP79A1 CS CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
DMP79A1 IK JGCMEBMXRHSZKX-UHFFFAOYSA-N
DMP79A1 IU 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine
DMP79A1 CA CAS 441798-33-0
DMP79A1 CB CHEBI:76607
DMP79A1 DE Cardiovascular disease
DM3BS97 ID DM3BS97
DM3BS97 DN Macrolides
DM3BS97 HS Approved
DM3BS97 SN Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W
DM3BS97 DT Small molecular drug
DM3BS97 PC 5280440
DM3BS97 MW 916.1
DM3BS97 FM C46H77NO17
DM3BS97 IC InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1
DM3BS97 CS CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC
DM3BS97 IK WBPYTXDJUQJLPQ-VMXQISHHSA-N
DM3BS97 IU 2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM3BS97 CA CAS 1401-69-0
DM3BS97 CB CHEBI:17658
DM3BS97 DE Bacterial infection
DMU4ORS ID DMU4ORS
DMU4ORS DN Magnesium
DMU4ORS HS Approved
DMU4ORS SN Magnesio; Magnesio [Italian]; Magnesium Matrix Modifier; Magnesium modifier; Magnesium powdered; Magnesium preparation; Magnesium sheet; LTBB002624; Magnesium hydride [UN2010] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; Magnesium nitrate-nitric acid solution; Rieke's active magnesium; MAGNESIUM, ATOMIZED POWDER,18MICRON; Magnesium granules, coated particle size not50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L;12Mg
DMU4ORS CP AstraZeneca
DMU4ORS DT Small molecular drug
DMU4ORS PC 5462224
DMU4ORS MW 24.305
DMU4ORS FM Mg
DMU4ORS IC InChI=1S/Mg
DMU4ORS CS [Mg]
DMU4ORS IK FYYHWMGAXLPEAU-UHFFFAOYSA-N
DMU4ORS IU magnesium
DMU4ORS CA CAS 7439-95-4
DMU4ORS CB CHEBI:25107
DMU4ORS DE Ischemic stroke
DMVEK07 ID DMVEK07
DMVEK07 DN Magnesium Sulfate
DMVEK07 HS Approved
DMVEK07 SN Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt
DMVEK07 CP Mitsuwa Kinzoku Co
DMVEK07 TC Analgesics
DMVEK07 DT Small molecular drug
DMVEK07 PC 24083
DMVEK07 MW 120.37
DMVEK07 FM MgO4S
DMVEK07 IC InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMVEK07 CS [O-]S(=O)(=O)[O-].[Mg+2]
DMVEK07 IK CSNNHWWHGAXBCP-UHFFFAOYSA-L
DMVEK07 IU magnesium;sulfate
DMVEK07 CA CAS 7487-88-9
DMVEK07 CB CHEBI:32599
DMVEK07 DE Acute pain
DMXZ84M ID DMXZ84M
DMXZ84M DN Malathion
DMXZ84M HS Approved
DMXZ84M SN Calmathion; Camathion; Carbafos; Carbetovur; Carbetox; Carbofos; Carbophos; Celthion; Chemathion; Cimexan; Cleensheen; Cythion; Dorthion; Emmatos; Ethiolacar; Etiol; Extermathion; Flair; Forthion; Fosfothion; Fosfotion; Fyfanon; Hilthion; Karbofos; Kypfos; Malacide; Malafor; Malagran; Malakill; Malamar; Malaphele; Malaphos; Malasol; Malaspray; Malataf; Malathiazol; Malathione; Malathiozoo; Malathon; Malathyl; Malation; Malatol; Malatox; Maldison; Malmed; Malphos; Maltox; Mercaptothion; Mercaptotion; Moscarda; Oleophosphothion; Organoderm; Ovide; Paladin; Phosphothion; Prioderm; Sadofos; Sadophos; Sumitox; TAK; Taskil; Vetiol; Zithiol; Carbethoxy malathion; Detm ol ma; Detmol MA; Emmatos extra; Lice Rid;Malathion LV Concentrate; Malathion [USP]; Malation [Polish]; Maltox MLT; Mercaptosuccinic acid diethyl ester; Mercaptotion [Spanish]; Ortho Malathion; Siptox I; Vegfru malatox; AC 26691; EL 4049; Experimental insecticide 4049; Fog 3; Fosfotion 550; Hilthion 25wdp; IFO 13140; Latka 4049; Latka 4049 [Czech]; MET86C_SUPELCO; Malamar 50; Malathion 60; Malathion E50; OMS 1; PS86_SUPELCO; SF 60; Sadofos 30; American cyanamid 4,049; Derbac-M; ENT 17,034; Four thousand forty-nine; Insecticide no. 4049; Kop-Thionkypfosmalacide; Kop-thion; Malathion (USP); Malathion (old ID); Ovide (TN); Staeubol-Puder; Suleo-M; TM-4049; Kill-A-Mite; MALATHION, 96%; Malathion-2,3-14C; 8059HC
DMXZ84M TC Parasympathomimetics
DMXZ84M DT Small molecular drug
DMXZ84M PC 4004
DMXZ84M MW 330.4
DMXZ84M FM C10H19O6PS2
DMXZ84M IC InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3
DMXZ84M CS CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC
DMXZ84M IK JXSJBGJIGXNWCI-UHFFFAOYSA-N
DMXZ84M IU diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate
DMXZ84M CA CAS 121-75-5
DMXZ84M CB CHEBI:6651
DMXZ84M DE Pediculus capitis infestation
DMSCDY9 ID DMSCDY9
DMSCDY9 DN Mannitol
DMSCDY9 HS Approved
DMSCDY9 SN Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol
DMSCDY9 TC Sweetening Agents
DMSCDY9 DT Small molecular drug
DMSCDY9 PC 6251
DMSCDY9 MW 182.17
DMSCDY9 FM C6H14O6
DMSCDY9 IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
DMSCDY9 CS C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
DMSCDY9 IK FBPFZTCFMRRESA-KVTDHHQDSA-N
DMSCDY9 IU (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
DMSCDY9 CA CAS 69-65-8
DMSCDY9 CB CHEBI:16899
DMSCDY9 DE Bronchiectasis; Renal failure
DMPWB7T ID DMPWB7T
DMPWB7T DN Maprotiline
DMPWB7T HS Approved
DMPWB7T SN Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine
DMPWB7T CP Norvatis Phamaceuticals Corporation
DMPWB7T TC Antidepressants
DMPWB7T DT Small molecular drug
DMPWB7T PC 4011
DMPWB7T MW 277.4
DMPWB7T FM C20H23N
DMPWB7T IC InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
DMPWB7T CS CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
DMPWB7T IK QSLMDECMDJKHMQ-UHFFFAOYSA-N
DMPWB7T IU N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine
DMPWB7T CA CAS 10262-69-8
DMPWB7T CB CHEBI:6690
DMPWB7T DE Major depressive disorder
DMTL94F ID DMTL94F
DMTL94F DN Maraviroc
DMTL94F HS Approved
DMTL94F SN 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
DMTL94F CP Pfizer; AstraZeneca
DMTL94F TC Anti-HIV Agents
DMTL94F DT Small molecular drug
DMTL94F PC 3002977
DMTL94F MW 513.7
DMTL94F FM C29H41F2N5O
DMTL94F IC InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
DMTL94F CS CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
DMTL94F IK GSNHKUDZZFZSJB-HLMSNRGBSA-N
DMTL94F IU 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
DMTL94F CA CAS 376348-65-1
DMTL94F CB CHEBI:63608
DMTL94F DE Human immunodeficiency virus infection; Chronic obstructive pulmonary disease
DMKEY6S ID DMKEY6S
DMKEY6S DN Margetuximab
DMKEY6S HS Approved
DMKEY6S CP Macrogenics
DMKEY6S DT Antibody
DMKEY6S DE Gastrointestinal cancer; Gastric adenocarcinoma; HER2-positive breast cancer
DM70IK5 ID DM70IK5
DM70IK5 DN Marinol
DM70IK5 HS Approved
DM70IK5 SN Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP; Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol
DM70IK5 CP Unimed Pharmaceuticals
DM70IK5 TC Analgesics
DM70IK5 DT Small molecular drug
DM70IK5 PC 16078
DM70IK5 MW 314.5
DM70IK5 FM C21H30O2
DM70IK5 IC InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1
DM70IK5 CS CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DM70IK5 IK CYQFCXCEBYINGO-IAGOWNOFSA-N
DM70IK5 IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
DM70IK5 CA CAS 1972-08-3
DM70IK5 CB CHEBI:66964
DM70IK5 DE Anorexia nervosa cachexia; Chemotherapy-induced nausea
DMMVNZ0 ID DMMVNZ0
DMMVNZ0 DN Masoprocol
DMMVNZ0 HS Approved
DMMVNZ0 SN NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0 TC Anticancer Agents
DMMVNZ0 DT Small molecular drug
DMMVNZ0 PC 71398
DMMVNZ0 MW 302.4
DMMVNZ0 FM C18H22O4
DMMVNZ0 IC InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
DMMVNZ0 CS C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O
DMMVNZ0 IK HCZKYJDFEPMADG-TXEJJXNPSA-N
DMMVNZ0 IU 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0 CA CAS 27686-84-6
DMMVNZ0 CB CHEBI:73468
DMMVNZ0 DE Prostate cancer
DMZ36RN ID DMZ36RN
DMZ36RN DN Mazindol
DMZ36RN HS Approved
DMZ36RN SN mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547; Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol
DMZ36RN TC Central Nervous System Stimulants
DMZ36RN DT Small molecular drug
DMZ36RN PC 4020
DMZ36RN MW 284.74
DMZ36RN FM C16H13ClN2O
DMZ36RN IC InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
DMZ36RN CS C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
DMZ36RN IK ZPXSCAKFGYXMGA-UHFFFAOYSA-N
DMZ36RN IU 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
DMZ36RN CA CAS 22232-71-9
DMZ36RN CB CHEBI:6702
DMZ36RN DE Obesity
DM0R4Z5 ID DM0R4Z5
DM0R4Z5 DN MCB-3837
DM0R4Z5 HS Approved
DM0R4Z5 SN Oxaquin
DM0R4Z5 CP Biovertis
DM0R4Z5 DT Small molecular drug
DM0R4Z5 PC 44201350
DM0R4Z5 MW 706.6
DM0R4Z5 FM C31H33F2N4O11P
DM0R4Z5 IC InChI=1S/C31H33F2N4O11P/c1-17(38)34-13-20-14-37(30(42)47-20)19-4-5-27(24(33)10-19)46-16-31(48-49(43,44)45)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18/h4-5,10-12,15,18,20H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)(H2,43,44,45)/t20-/m0/s1
DM0R4Z5 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)OCC3(CCN(CC3)C4=C(C=C5C(=C4)N(C=C(C5=O)C(=O)O)C6CC6)F)OP(=O)(O)O)F
DM0R4Z5 IK MNABRWLVTSGIMU-FQEVSTJZSA-N
DM0R4Z5 IU 7-[4-[[4-[(5S)-5-(acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenoxy]methyl]-4-phosphonooxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM0R4Z5 CA CAS 790704-50-6
DM0R4Z5 DE Malaria
DM8ZHP1 ID DM8ZHP1
DM8ZHP1 DN MCI-186
DM8ZHP1 HS Approved
DM8ZHP1 SN Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1 CP Mitsubishi Tanabe
DM8ZHP1 DT Small molecular drug
DM8ZHP1 PC 4021
DM8ZHP1 MW 174.2
DM8ZHP1 FM C10H10N2O
DM8ZHP1 IC InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
DM8ZHP1 CS CC1=NN(C(=O)C1)C2=CC=CC=C2
DM8ZHP1 IK QELUYTUMUWHWMC-UHFFFAOYSA-N
DM8ZHP1 IU 5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1 CA CAS 89-25-8
DM8ZHP1 CB CHEBI:31530
DM8ZHP1 DE Amyotrophic lateral sclerosis
DM4IAKR ID DM4IAKR
DM4IAKR DN MD-1100
DM4IAKR HS Approved
DM4IAKR SN Linaclotide acetate; Linaclotide acetate (USAN); MM-416775
DM4IAKR CP Microbia
DM4IAKR DT Small molecular drug
DM4IAKR PC 16158207
DM4IAKR MW 1586.8
DM4IAKR FM C61H83N15O23S6
DM4IAKR IC InChI=1S/C59H79N15O21S6.C2H4O2/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29;1-2(3)4/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95);1H3,(H,3,4)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-;/m0./s1
DM4IAKR CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O.CC(=O)O
DM4IAKR IK KWFNVZFWXXEJKL-YZDVLOIKSA-N
DM4IAKR IU acetic acid;(2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4IAKR CA CAS 851199-60-5
DM4IAKR DE Constipation; Irritable bowel syndrome
DMO14SG ID DMO14SG
DMO14SG DN Mebendazole
DMO14SG HS Approved
DMO14SG SN Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
DMO14SG CP Janssen Pharmaceutica
DMO14SG TC Antinematodal Agents
DMO14SG DT Small molecular drug
DMO14SG PC 4030
DMO14SG MW 295.29
DMO14SG FM C16H13N3O3
DMO14SG IC InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
DMO14SG CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
DMO14SG IK OPXLLQIJSORQAM-UHFFFAOYSA-N
DMO14SG IU methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
DMO14SG CA CAS 31431-39-7
DMO14SG CB CHEBI:6704
DMO14SG DE Worm infection
DMNOBFQ ID DMNOBFQ
DMNOBFQ DN Mebeverine
DMNOBFQ HS Approved
DMNOBFQ SN Arluy; Mebeverina; Mebeverinum; Arluy (TN); Mebeverina [INN-Spanish]; Mebeverine (INN); Mebeverine [INN:BAN]; Mebeverinum [INN-Latin]; Mebeverine (USAN)(*hydrochloride*); Veratric acid, 4-[ethyl(p-me; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate;4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ CP Reckitt; Colman
DMNOBFQ DT Small molecular drug
DMNOBFQ PC 4031
DMNOBFQ MW 429.5
DMNOBFQ FM C25H35NO5
DMNOBFQ IC InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
DMNOBFQ CS CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC
DMNOBFQ IK VYVKHNNGDFVQGA-UHFFFAOYSA-N
DMNOBFQ IU 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ CA CAS 3625-06-7
DMNOBFQ CB CHEBI:91514
DMNOBFQ DE Irritable bowel syndrome
DM0KYI4 ID DM0KYI4
DM0KYI4 DN Mebutamate
DM0KYI4 HS Approved
DM0KYI4 SN Dormate
DM0KYI4 CP Medpointe Pharmaceuticals Medpointe Healthcare Inc
DM0KYI4 DT Small molecular drug
DM0KYI4 PC 6151
DM0KYI4 MW 232.28
DM0KYI4 FM C10H20N2O4
DM0KYI4 IC InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)
DM0KYI4 CS CCC(C)C(C)(COC(=O)N)COC(=O)N
DM0KYI4 IK LEROTMJVBFSIMP-UHFFFAOYSA-N
DM0KYI4 IU [2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate
DM0KYI4 CA CAS 64-55-1
DM0KYI4 CB CHEBI:31804
DM0KYI4 DE Anxiety disorder
DMGQFYB ID DMGQFYB
DMGQFYB DN Mecamylamine
DMGQFYB HS Approved
DMGQFYB SN Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane
DMGQFYB CP Mecamylamine
DMGQFYB TC Antihypertensive Agents
DMGQFYB DT Small molecular drug
DMGQFYB PC 4032
DMGQFYB MW 167.29
DMGQFYB FM C11H21N
DMGQFYB IC InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
DMGQFYB CS CC1(C2CCC(C2)C1(C)NC)C
DMGQFYB IK IMYZQPCYWPFTAG-UHFFFAOYSA-N
DMGQFYB IU N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
DMGQFYB CA CAS 60-40-2
DMGQFYB CB CHEBI:6706
DMGQFYB DE Essential hypertension
DM1O3BY ID DM1O3BY
DM1O3BY DN Mecasermin
DM1O3BY HS Approved
DM1O3BY SN Increlex (TN)
DM1O3BY TC Immunomodulatory Agents
DM1O3BY SQ Mecasermin: GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
DM1O3BY DE Growth failure
DM0CVXA ID DM0CVXA
DM0CVXA DN Mechlorethamine
DM0CVXA HS Approved
DM0CVXA SN Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA CP Recordati Rare Diseases Inc
DM0CVXA TC Anticancer Agents
DM0CVXA DT Small molecular drug
DM0CVXA PC 4033
DM0CVXA MW 156.05
DM0CVXA FM C5H11Cl2N
DM0CVXA IC InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3
DM0CVXA CS CN(CCCl)CCCl
DM0CVXA IK HAWPXGHAZFHHAD-UHFFFAOYSA-N
DM0CVXA IU 2-chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA CA CAS 51-75-2
DM0CVXA CB CHEBI:28925
DM0CVXA DE T-cell lymphoma; Hodgkin lymphoma
DMS7T13 ID DMS7T13
DMS7T13 DN Meclizine
DMS7T13 HS Approved
DMS7T13 SN Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine
DMS7T13 CP Citron Pharma Llc
DMS7T13 TC Antiallergic Agents
DMS7T13 DT Small molecular drug
DMS7T13 PC 4034
DMS7T13 MW 390.9
DMS7T13 FM C25H27ClN2
DMS7T13 IC InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
DMS7T13 CS CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMS7T13 IK OCJYIGYOJCODJL-UHFFFAOYSA-N
DMS7T13 IU 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine
DMS7T13 CA CAS 569-65-3
DMS7T13 CB CHEBI:6709
DMS7T13 DE Dizziness
DMSFQ8I ID DMSFQ8I
DMSFQ8I DN Meclocycline
DMSFQ8I HS Approved
DMSFQ8I SN Meclociclina; Meclocyclinum; Meclosorb; Samil; Meclociclina [Italian]; GS 2989; GS-2989; Meclociclina [INN-Spanish]; Meclocycline(USAN); Meclocyclinum [INN-Latin]; Meclocycline (USAN/INN); Meclocycline [USAN:INN:BAN]; (2E,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4aR,5S,5aS,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]-(9CI); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4aal; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-6-methylene-5-oxytetracycline; 7-Cloro-6-metilene-5-ossitetraciclina; 7-Cloro-6-metilene-5-ossitetraciclina [Italian]; 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide
DMSFQ8I CP Johnson And Johnson Consumer Companies Inc
DMSFQ8I TC Antibiotics
DMSFQ8I DT Small molecular drug
DMSFQ8I PC 54676539
DMSFQ8I MW 476.9
DMSFQ8I FM C22H21ClN2O8
DMSFQ8I IC InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26-28,31,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1
DMSFQ8I CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMSFQ8I IK RNIADBXQDMCFEN-IWVLMIASSA-N
DMSFQ8I IU (4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMSFQ8I CA CAS 2013-58-3
DMSFQ8I CB CHEBI:135772
DMSFQ8I DE Bacterial infection
DMNL98G ID DMNL98G
DMNL98G DN Meclofenamate sodium
DMNL98G HS Approved
DMNL98G CP Parke Davis Div Warner Lambert Co
DMNL98G DT Small molecular drug
DMNL98G PC 4038
DMNL98G MW 318.1
DMNL98G FM C14H10Cl2NNaO2
DMNL98G IC InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1
DMNL98G CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+]
DMNL98G IK OGPIIGMUPMPMNT-UHFFFAOYSA-M
DMNL98G IU sodium;2-(2,6-dichloro-3-methylanilino)benzoate
DMNL98G CA CAS 6385-02-0
DMNL98G CB CHEBI:6711
DMNL98G DE Arthritis
DM05FXR ID DM05FXR
DM05FXR DN Meclofenamic acid
DM05FXR HS Approved
DM05FXR SN Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
DM05FXR TC Analgesics
DM05FXR DT Small molecular drug
DM05FXR PC 4037
DM05FXR MW 296.1
DM05FXR FM C14H11Cl2NO2
DM05FXR IC InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
DM05FXR CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
DM05FXR IK SBDNJUWAMKYJOX-UHFFFAOYSA-N
DM05FXR IU 2-(2,6-dichloro-3-methylanilino)benzoic acid
DM05FXR CA CAS 644-62-2
DM05FXR CB CHEBI:6710
DM05FXR DE Ankylosing spondylitis; Joint pain
DMBGWPH ID DMBGWPH
DMBGWPH DN Medroxyprogesterone
DMBGWPH HS Approved
DMBGWPH SN Asconale; Colirest; Hematrol; Hydroxymethylprogesterone; Lunelle; Medrossiprogesterone; Medroxiprogesterona; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteronum; Methylhydroxyprogesterone; Adgyn Medro; Farlutal inyectable; Medroprogesterone Acetate; Medrossiprogesterone [DCIT]; Medroxyprogesteron acetate; Medroxyprogesterone Strakan Brand; Sodelut G; Strakan Brand of Medroxyprogesterone; MPA Gyn 5; U 8840; CBP-1011; Farlutal inyectable (TN); G-Farlutal; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone (INN); Medroxyprogesterone [INN:BAN]; Medroxyprogesteronum [INN-Latin]; Novo-Medrone; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-(9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-(9CI); (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 17-Hydroxy-6.alpha.-methylprogesterone; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylprogesterone; 6-Dihydromegestrol; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
DMBGWPH CP Pharmacia And Upjohn Co
DMBGWPH TC Contraceptive Agents
DMBGWPH DT Small molecular drug
DMBGWPH PC 10631
DMBGWPH MW 344.5
DMBGWPH FM C22H32O3
DMBGWPH IC InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1
DMBGWPH CS C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMBGWPH IK FRQMUZJSZHZSGN-HBNHAYAOSA-N
DMBGWPH IU (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMBGWPH CA CAS 520-85-4
DMBGWPH CB CHEBI:6715
DMBGWPH DE Solid tumour/cancer
DMJ90O5 ID DMJ90O5
DMJ90O5 DN Medrysone
DMJ90O5 HS Approved
DMJ90O5 SN Hydroxymesterone; Medrifar; Medritonic; Medrocort; Visudrisone; Medrysone (USAN); U-8471; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone
DMJ90O5 DT Small molecular drug
DMJ90O5 PC 247839
DMJ90O5 MW 344.5
DMJ90O5 FM C22H32O3
DMJ90O5 IC InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1
DMJ90O5 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C
DMJ90O5 IK GZENKSODFLBBHQ-ILSZZQPISA-N
DMJ90O5 IU (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMJ90O5 CA CAS 2668-66-8
DMJ90O5 CB CHEBI:34829
DMJ90O5 DE Eye inflammation
DMK7HFI ID DMK7HFI
DMK7HFI DN Mefenamic acid
DMK7HFI HS Approved
DMK7HFI SN ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid
DMK7HFI TC Antiinflammatory Agents
DMK7HFI DT Small molecular drug
DMK7HFI PC 4044
DMK7HFI MW 241.28
DMK7HFI FM C15H15NO2
DMK7HFI IC InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
DMK7HFI CS CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
DMK7HFI IK HYYBABOKPJLUIN-UHFFFAOYSA-N
DMK7HFI IU 2-(2,3-dimethylanilino)benzoic acid
DMK7HFI CA CAS 61-68-7
DMK7HFI CB CHEBI:6717
DMK7HFI DE Dysmenorrhea
DMWT905 ID DMWT905
DMWT905 DN Mefloquine
DMWT905 HS Approved
DMWT905 SN Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
DMWT905 CP Hoffmann-La Roche pharmaceutical company
DMWT905 TC Antimalarials
DMWT905 DT Small molecular drug
DMWT905 PC 4046
DMWT905 MW 378.31
DMWT905 FM C17H16F6N2O
DMWT905 IC InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
DMWT905 CS C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
DMWT905 IK XEEQGYMUWCZPDN-UHFFFAOYSA-N
DMWT905 IU [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
DMWT905 CA CAS 49752-90-1
DMWT905 CB CHEBI:63681
DMWT905 DE Malaria
DMDH9KX ID DMDH9KX
DMDH9KX DN Megestrol
DMDH9KX HS Approved
DMDH9KX SN Chronopil; Megestrolo; Megestrolo [DCIT]; Chronopil (TN); Megace (TN); Megestrol (INN); Megestrol [INN:BAN]; Megestrolum [INN-Latin]; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
DMDH9KX CP Bristol Myers Squibb
DMDH9KX TC Anticancer Agents
DMDH9KX DT Small molecular drug
DMDH9KX PC 19090
DMDH9KX MW 342.5
DMDH9KX FM C22H30O3
DMDH9KX IC InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1
DMDH9KX CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMDH9KX IK VXIMPSPISRVBPZ-NWUMPJBXSA-N
DMDH9KX IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMDH9KX CA CAS 3562-63-8
DMDH9KX DE Breast cancer
DM1OFHN ID DM1OFHN
DM1OFHN DN Meglitinides
DM1OFHN HS Approved
DM1OFHN DT Small molecular drug
DM1OFHN PC 3033769
DM1OFHN MW 347.2
DM1OFHN FM C15H20Cl2N2O3
DM1OFHN IC InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
DM1OFHN CS CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O
DM1OFHN IK WAOQONBSWFLFPE-VIFPVBQESA-N
DM1OFHN IU 3,5-dichloro-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
DM1OFHN CA CAS 84225-95-6
DM1OFHN CB CHEBI:92070
DM1OFHN DE Type-2 diabetes; Psychotic disorder
DMGUZ0W ID DMGUZ0W
DMGUZ0W DN MELARSOPROL
DMGUZ0W HS Approved
DMGUZ0W SN MELARSOPROL; Mel B; Arsobal; 494-79-1; Melarsoprolum [INN-Latin]; EINECS 207-793-4; Melarsoprol [INN:BAN:DCF]; RP 3854; CHEBI:6729; [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol; 1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-; Melarsoprolum; Melarsenoxid-BAL; 2-(p-(4,6-Diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol; C12H15AsN6OS2; Specia; UNII-ZF3786Q2E8; Melarsoprol (INN); AC1L1UXN; Mel B (TN); CHEMBL166; SCHEMBL61707; ZF3786Q2E8
DMGUZ0W DT Small molecular drug
DMGUZ0W PC 10311
DMGUZ0W MW 398.3
DMGUZ0W FM C12H15AsN6OS2
DMGUZ0W IC InChI=1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19)
DMGUZ0W CS C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO
DMGUZ0W IK JCYZMTMYPZHVBF-UHFFFAOYSA-N
DMGUZ0W IU [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol
DMGUZ0W CA CAS 494-79-1
DMGUZ0W CB CHEBI:6729
DMGUZ0W DE Trypanosomiasis
DMKWFBT ID DMKWFBT
DMKWFBT DN Melatonin
DMKWFBT HS Approved
DMKWFBT SN 73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; 5-Methoxy-N-acetyltryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Melatonex; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; UNII-JL5DK93RCL; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-acetyl-5-methoxy-tryptamine; NSC 113928; CCRIS 3472; CHEMBL45; EINECS 200-797-7; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; BRN 0205542; Circadin; Melapure; Melatonina; Posidorm; Vivitas; Night Rest; Pineal Hormone; Revital Melatonin; Rx Balance; Sleep Right; IN1244; M 5250; M1105; ML1; MT6; TNP00300; M-1200; M-1250; Mela-T; Melatonex, Melatonin; Melatonina (TN); NMR/14327425; Nature'S Harmony; PREVENTION 2 (MELATONIN); PREVENTION 3 (MELATONIN); PREVENTION 4 (MELATONIN); PREVENTION 5 (MELATONIN); PREVENTION 1 (MELATONIN) (PREVENTION 1); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-(6CI,8CI); N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-(9CI); Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI); 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; [3H]melatonin; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT TC Central Nervous System Stimulants
DMKWFBT DT Small molecular drug
DMKWFBT PC 896
DMKWFBT MW 232.28
DMKWFBT FM C13H16N2O2
DMKWFBT IC InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)
DMKWFBT CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
DMKWFBT IK DRLFMBDRBRZALE-UHFFFAOYSA-N
DMKWFBT IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT CA CAS 73-31-4
DMKWFBT CB CHEBI:16796
DMKWFBT DE Insomnia
DM2AR7L ID DM2AR7L
DM2AR7L DN Meloxicam
DM2AR7L HS Approved
DM2AR7L SN Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
DM2AR7L CP Iroko pharmaceuticals
DM2AR7L DT Small molecular drug
DM2AR7L PC 54677470
DM2AR7L MW 351.4
DM2AR7L FM C14H13N3O4S2
DM2AR7L IC InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
DM2AR7L CS CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
DM2AR7L IK ZRVUJXDFFKFLMG-UHFFFAOYSA-N
DM2AR7L IU 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
DM2AR7L CA CAS 71125-38-7
DM2AR7L CB CHEBI:6741
DM2AR7L DE Arthritis
DMOLNHF ID DMOLNHF
DMOLNHF DN Melphalan
DMOLNHF HS Approved
DMOLNHF SN Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
DMOLNHF TC Anticancer Agents
DMOLNHF DT Small molecular drug
DMOLNHF PC 460612
DMOLNHF MW 305.2
DMOLNHF FM C13H18Cl2N2O2
DMOLNHF IC InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
DMOLNHF CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl
DMOLNHF IK SGDBTWWWUNNDEQ-LBPRGKRZSA-N
DMOLNHF IU (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
DMOLNHF CA CAS 148-82-3
DMOLNHF CB CHEBI:28876
DMOLNHF DE Multiple myeloma; Intrahepatic cholangiocarcinoma
DMWF5R4 ID DMWF5R4
DMWF5R4 DN Melphalan flufenamide
DMWF5R4 HS Approved
DMWF5R4 SN J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
DMWF5R4 CP Oncopeptides AB
DMWF5R4 DT Small molecular drug
DMWF5R4 PC 9935639
DMWF5R4 MW 498.4
DMWF5R4 FM C24H30Cl2FN3O3
DMWF5R4 IC InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
DMWF5R4 CS CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N
DMWF5R4 IK YQZNKYXGZSVEHI-VXKWHMMOSA-N
DMWF5R4 IU ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate
DMWF5R4 CA CAS 380449-51-4
DMWF5R4 DE Ovarian cancer; Plasma cell myeloma; Multiple myeloma
DMD9WSC ID DMD9WSC
DMD9WSC DN Memantine
DMD9WSC HS Approved
DMD9WSC SN Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest
DMD9WSC CP Merz & Co GmbH
DMD9WSC DT Small molecular drug
DMD9WSC PC 4054
DMD9WSC MW 179.3
DMD9WSC FM C12H21N
DMD9WSC IC InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
DMD9WSC CS CC12CC3CC(C1)(CC(C3)(C2)N)C
DMD9WSC IK BUGYDGFZZOZRHP-UHFFFAOYSA-N
DMD9WSC IU 3,5-dimethyladamantan-1-amine
DMD9WSC CA CAS 19982-08-2
DMD9WSC CB CHEBI:64312
DMD9WSC DE Alzheimer disease
DMP9N85 ID DMP9N85
DMP9N85 DN Menadiol sodium diphosphate
DMP9N85 HS Approved
DMP9N85 SN Kappadione; Synkavit; Procoagulo; Synkavite; Thylokay; Kipca water soluble; Synkayvite; Menadiol sodium diphosphate; Menadione sodium phosphate; Sodium menadione diphosphate; Menadiol Sodium Diphosphate Anhydrous; UNII-R2L46WE615; Menadiol tetrasodium diphosphate; EINECS 205-012-1; Menadione diphosphate tetrasodium salt; 1:4-Naphthaquinol-bisdisodium phosphate; 131-13-5; Menadiol sodium diphosphate anhydrous [USAN]; R2L46WE615; 2-Methyl-1,4-naphthaquinol bis(disodium phosphate); Tetrasodium 2-methyl-1,4-naphthalenediol diphosp
DMP9N85 DT Small molecular drug
DMP9N85 PC 8555
DMP9N85 MW 422.08
DMP9N85 FM C11H8Na4O8P2
DMP9N85 IC InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4
DMP9N85 CS CC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
DMP9N85 IK GZBACHSOZNEZOG-UHFFFAOYSA-J
DMP9N85 IU tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate
DMP9N85 CA CAS 131-13-5
DMP9N85 DE Coagulation defect
DMSJDTY ID DMSJDTY
DMSJDTY DN Menadione
DMSJDTY HS Approved
DMSJDTY SN menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; 2-methylnaphthalene-1,4-dione; 2-Methylnaphthoquinone; Thyloquinone; Panosine; Klottone; Kayquinone; Kappaxin; Kayklot; Kolklot; 2-Methyl-1,4-naphthalenedione; Menaphthon; Menadion; Kipca; Kanone; Mitenone; Kativ-G; Kaergona; Aquinone; Prokayvit; Mitenon; Koaxin; Kaykot; Kareon; Hemodal; Aquakay; Synkay; Karcon; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Menaquinone 0; Vitamin K 3; Menaphtone; Menadionum; 2-Methyl-1,4-naphthochinon; Usaf; Aquakay; Klottone;Koaxin; Memodol; Methylnaphthoquinone; Vicasol; Menadione semiquinone; M0373; VK3; Kappaxan (VAN); Kappaxin (TN); Kipca, oil soluble; Menadione (K3); Menadione (USP); Menadione [USAN:BAN]; Usaf ek-5185; Vitamin-K3; Methyl-1,4-naphthalenedione; Methyl-1,4-naphthoquinone; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-,radical ion(1-); 2-Methyl-1,4-naftochinon; 2-Methyl-1,4-naftochinon [Czech]; 2-Methyl-1,4-naphthochinon [German]; 2-methyl-1,4-naphthoquinone, 5; 3-Methyl-1,4-naphthoquinone; Ascorbic acid/menadione; Triglycyl-lysine-vasopressin
DMSJDTY TC Vitamins
DMSJDTY DT Small molecular drug
DMSJDTY PC 4055
DMSJDTY MW 172.18
DMSJDTY FM C11H8O2
DMSJDTY IC InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3
DMSJDTY CS CC1=CC(=O)C2=CC=CC=C2C1=O
DMSJDTY IK MJVAVZPDRWSRRC-UHFFFAOYSA-N
DMSJDTY IU 2-methylnaphthalene-1,4-dione
DMSJDTY CA CAS 58-27-5
DMSJDTY CB CHEBI:28869
DMSJDTY DE Vitamin K deficiency; Prostate cancer
DM2SR1J ID DM2SR1J
DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine
DM2SR1J HS Approved
DM2SR1J SN Menveo (TN)
DM2SR1J CP Novartis
DM2SR1J DE Meningococcal infection
DM4CF18 ID DM4CF18
DM4CF18 DN Menotropins
DM4CF18 HS Approved
DM4CF18 SN Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP)
DM4CF18 TC Fertility Agents
DM4CF18 SQ AlphaChain (LH): APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL >AlphaChain (FSH)APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (FSH)NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM4CF18 DE Female infertility
DMG2KW7 ID DMG2KW7
DMG2KW7 DN Menthol
DMG2KW7 HS Approved
DMG2KW7 SN Hexahydrothymol; Levomenthol; Levomentholum; Menthacamphor; Menthomenthol; Neoisomenthol; Racementhol; Racementholum; Racementol; Headache crystals; Menthol natural; Menthol racemic; Menthol racemique; Menthol racemique [French]; Menthol solution; Menthyl alcohol; Peppermint camphor; Racemic menthol; Robitussin Cough Drops; M0321; M0545; D-Menthol; D-Neomenthol; Dl-Menthol; Fisherman's friend lozenges; L-Menthol; Levomenthol [INN:BAN]; Levomentholum [INN-Latin]; Menthol (USP); Menthol (VAN); Menthol natural, brazilian; NOOLISFMXDJSKH-KXUCPTDWBX; Rac-Menthol; Racementhol [INN:BAN]; Racementholum [INN-Latin]; Racementol [INN-Spanish]; Tra-kill tracheal mite killer; D,l-Menthol; Dl-Menthol (JP15); Fisherman's friendlozenges (TN); L-Menthol (JP15); L-Menthol (TN); L-Menthol (natural); Dl-3-p-Menthanol; P-Menthan-3-ol; RACEMIC MENTHOL U.S.P.; U.S.P. Menthol; D-(-)-Menthol; D-p-Menthan-3-ol; L-(-)-Menthol; Menthol, (1alpha,2beta,5alpha)-Isomer; Cis-1 ,3-trans-1,4-(+-)-menthol; Cis-1,3-trans-1,4-(+-)-menthol; (+)-Neo-menthol; (+)-p-Menthan-3-ol; (+-)-(1R*,3R*,4S*)-Menthol; (+-)-Menthol; (+/-)-Menthol; (+/-)-p-Menthan-3-ol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-p-Menthan-3-ol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-Menthol; (1R,3R,4S)-(-)-MENTHOL; (1S, 2S, 5R)-(+)-Neomenthol; (1S,2R,5R)-(+)-Isomenthol; (1S,2R,5S)-(+)-Menthol; (1S,2R,5S)-Menthol; (1r,2s,5r)-(-)-menthol; (L)-MENTHOL; (R)-(-)-Menthol; 2-Isopropyl-5-methylcyclohexanol; 3-p-Menthol; 4-Isopropyl-1-methylcyclohexan-3-ol; 5-Methyl-2-(1-methylethyl)-cyclohexanol; 5-Methyl-2-(1-methylethyl)cyclohexanol; 5-methyl-2-(propan-2-yl)cyclohexanol; 5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7 TC Antipruritics
DMG2KW7 DT Small molecular drug
DMG2KW7 PC 1254
DMG2KW7 MW 156.26
DMG2KW7 FM C10H20O
DMG2KW7 IC InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3
DMG2KW7 CS CC1CCC(C(C1)O)C(C)C
DMG2KW7 IK NOOLISFMXDJSKH-UHFFFAOYSA-N
DMG2KW7 IU 5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7 CA CAS 89-78-1
DMG2KW7 CB CHEBI:25187
DMG2KW7 DE Throat irritation
DM8YU2F ID DM8YU2F
DM8YU2F DN Mepenzolate
DM8YU2F HS Approved
DM8YU2F SN Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
DM8YU2F TC Parasympatholytics
DM8YU2F DT Small molecular drug
DM8YU2F PC 4057
DM8YU2F MW 340.4
DM8YU2F FM C21H26NO3+
DM8YU2F IC InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
DM8YU2F CS C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C
DM8YU2F IK GKNPSSNBBWDAGH-UHFFFAOYSA-N
DM8YU2F IU (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
DM8YU2F CA CAS 25990-43-6
DM8YU2F CB CHEBI:94411
DM8YU2F DE Gastrointestinal disease; Peptic ulcer
DMX4GND ID DMX4GND
DMX4GND DN Meperidine
DMX4GND HS Approved
DMX4GND SN Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
DMX4GND CP Apotex Inc
DMX4GND TC Anesthetics
DMX4GND DT Small molecular drug
DMX4GND PC 4058
DMX4GND MW 247.33
DMX4GND FM C15H21NO2
DMX4GND IC InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
DMX4GND CS CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2
DMX4GND IK XADCESSVHJOZHK-UHFFFAOYSA-N
DMX4GND IU ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
DMX4GND CA CAS 57-42-1
DMX4GND CB CHEBI:6754
DMX4GND DE Pain
DMFJH5Q ID DMFJH5Q
DMFJH5Q DN Mephentermine
DMFJH5Q HS Approved
DMFJH5Q SN Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
DMFJH5Q CP Baxter Healthcare Corp Anesthesia Critical Care
DMFJH5Q TC Vasoconstrictor Agents
DMFJH5Q DT Small molecular drug
DMFJH5Q PC 3677
DMFJH5Q MW 163.26
DMFJH5Q FM C11H17N
DMFJH5Q IC InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
DMFJH5Q CS CC(C)(CC1=CC=CC=C1)NC
DMFJH5Q IK RXQCGGRTAILOIN-UHFFFAOYSA-N
DMFJH5Q IU N,2-dimethyl-1-phenylpropan-2-amine
DMFJH5Q CA CAS 100-92-5
DMFJH5Q CB CHEBI:6755
DMFJH5Q DE High blood pressure
DM5UGDK ID DM5UGDK
DM5UGDK DN Mephenytoin
DM5UGDK HS Approved
DM5UGDK SN Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK CP Norvatis Phamaceuticals Corporation
DM5UGDK TC Anticonvulsants
DM5UGDK DT Small molecular drug
DM5UGDK PC 4060
DM5UGDK MW 218.25
DM5UGDK FM C12H14N2O2
DM5UGDK IC InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
DM5UGDK CS CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
DM5UGDK IK GMHKMTDVRCWUDX-UHFFFAOYSA-N
DM5UGDK IU 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK CA CAS 50-12-4
DM5UGDK CB CHEBI:6757
DM5UGDK DE Epilepsy
DMUDWP9 ID DMUDWP9
DMUDWP9 DN Mepindolol
DMUDWP9 HS Approved
DMUDWP9 SN Mepindolol Bio Tsd; PH-851; Mepindolol, Pharmed/SB
DMUDWP9 CP Pharmed Dr Liedtke GmbH
DMUDWP9 DT Small molecular drug
DMUDWP9 PC 71698
DMUDWP9 MW 262.35
DMUDWP9 FM C15H22N2O2
DMUDWP9 IC InChI=1S/C15H22N2O2/c1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14/h4-7,10,12,16-18H,8-9H2,1-3H3
DMUDWP9 CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)C)O
DMUDWP9 IK NXWGWUVGUSFQJC-UHFFFAOYSA-N
DMUDWP9 IU 1-[(2-methyl-1H-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol
DMUDWP9 CA CAS 23694-81-7
DMUDWP9 CB CHEBI:135082
DMUDWP9 DE Angina pectoris
DMH2NMY ID DMH2NMY
DMH2NMY DN Mepivacaine
DMH2NMY HS Approved
DMH2NMY SN Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE
DMH2NMY CP Eastman Kodak Co
DMH2NMY TC Anesthetics
DMH2NMY DT Small molecular drug
DMH2NMY PC 4062
DMH2NMY MW 246.35
DMH2NMY FM C15H22N2O
DMH2NMY IC InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
DMH2NMY CS CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
DMH2NMY IK INWLQCZOYSRPNW-UHFFFAOYSA-N
DMH2NMY IU N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
DMH2NMY CA CAS 96-88-8
DMH2NMY CB CHEBI:6759
DMH2NMY DE Analgesia
DMW2GEJ ID DMW2GEJ
DMW2GEJ DN Mepolizumab
DMW2GEJ HS Approved
DMW2GEJ SN Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
DMW2GEJ CP MedImmune
DMW2GEJ DT Monoclonal antibody
DMW2GEJ DE Severe asthma; Asthma
DMTL9IP ID DMTL9IP
DMTL9IP DN Meprednisone
DMTL9IP HS Approved
DMTL9IP SN Betapar
DMTL9IP CP Schering Corp Sub Schering Plough Corp
DMTL9IP DT Small molecular drug
DMTL9IP PC 5284587
DMTL9IP MW 372.5
DMTL9IP FM C22H28O5
DMTL9IP IC InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1
DMTL9IP CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C
DMTL9IP IK PIDANAQULIKBQS-RNUIGHNZSA-N
DMTL9IP IU (8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DMTL9IP CA CAS 1247-42-3
DMTL9IP CB CHEBI:135573
DMTL9IP DE Chronic obstructive pulmonary disease
DMHM93Y ID DMHM93Y
DMHM93Y DN Meprobamate
DMHM93Y HS Approved
DMHM93Y SN meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas; Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455
DMHM93Y CP Wyeth Pharmaceuticals
DMHM93Y TC Antianxiety Agents
DMHM93Y DT Small molecular drug
DMHM93Y PC 4064
DMHM93Y MW 218.25
DMHM93Y FM C9H18N2O4
DMHM93Y IC InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
DMHM93Y CS CCCC(C)(COC(=O)N)COC(=O)N
DMHM93Y IK NPPQSCRMBWNHMW-UHFFFAOYSA-N
DMHM93Y IU [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
DMHM93Y CA CAS 57-53-4
DMHM93Y CB CHEBI:6761
DMHM93Y DE Malaria; Anxiety disorder; Ischemic reperfusion injury
DMPSB8F ID DMPSB8F
DMPSB8F DN MEPTAZINOL
DMPSB8F HS Approved
DMPSB8F SN MEPTAZINOL HYDROCHLORIDE; 59263-76-2; Meptazinol HCl; Meptazinol (hydrochloride); 3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Meptazinol hydrochloride [USAN]; EINECS 261-683-0; WY-22811 hydrochloride; IL-22811 hydrochloride; WY 22811; IL 22811; 3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride; m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride; m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Phenol, m-(3-ethyl-1-methyl-hexahydro-1H-azepin-3-yl)-, hydrochloride
DMPSB8F DT Small molecular drug
DMPSB8F PC 41049
DMPSB8F MW 233.35
DMPSB8F FM C15H23NO
DMPSB8F IC InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
DMPSB8F CS CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O
DMPSB8F IK JLICHNCFTLFZJN-UHFFFAOYSA-N
DMPSB8F IU 3-(3-ethyl-1-methylazepan-3-yl)phenol
DMPSB8F CA CAS 54340-58-8
DMPSB8F CB CHEBI:91484
DMPSB8F DE Pain
DMB4SFH ID DMB4SFH
DMB4SFH DN Mepyramine
DMB4SFH HS Approved
DMB4SFH SN Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine
DMB4SFH TC Antiasthmatic Agents
DMB4SFH DT Small molecular drug
DMB4SFH PC 4992
DMB4SFH MW 285.4
DMB4SFH FM C17H23N3O
DMB4SFH IC InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3
DMB4SFH CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
DMB4SFH IK YECBIJXISLIIDS-UHFFFAOYSA-N
DMB4SFH IU N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMB4SFH CA CAS 91-84-9
DMB4SFH CB CHEBI:6762
DMB4SFH DE Allergy
DM7F5OW ID DM7F5OW
DM7F5OW DN Mepyramine maleate
DM7F5OW HS Approved
DM7F5OW SN Pyrilamine maleate; PYRILAMINE MALEATE; 59-33-6; Anisopyradamine; Histosol; Minihist; Diaminide maleate; Paraminyl maleate; Renstamin; Histatex; Pyraninyl; Pymafed; Paramal; Histine; Antihist; Histan; Pyramal maleate; Stangen maleate; Thylogen maleate; Anthisan maleate; Statomin maleate; Pyra-Maleate; Pyrilamine maleate salt; Neoantergan maleate; Pyranisamine maleate; Pyranilamine maleate; Kriptin maleate; Neo-Antergan maleate; Pyra maleate; Prefrin A; Dorantamin maleate; 2786 RP maleate; Histavet-P (veterinary); Mepyramine hydrogen; Enrumay; Pyma; Component of Pyrdex; Mepiramine maleate; Mepyramine hydrogen maleinate; Mepyramine maleate salt; Midol Maximum Strength PMS; Pyranilamine m aleate; Pyrilamine maleate [USAN]; P 5514; Component of Endotussin-NN; Histavet-P; Pymafed (TN); Pyrilamine maleate (USP); PYRILAMINE MALEATE (SEE ALSO PYRILAMINE, CAS 91-84-9); N-Dimethylaminoethyl-N-p-methoxy-alpha-aminopyridine maleate; N-(dimethylaminoethyl)-N-(p-methoxyphenyl)-alpha-aminopyridine maleate; N-(Dimethylamino)ethyl-N-(p-methoxy)-alpha-aminopyridine maleate; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1); N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine maleate; N-(p-me thoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-, maleate (1:1); N-(4-Methoxyphenyl)methyl-N inverted exclamation marka,Ninverted exclamation marka-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; N-(p-Methoxybenzyl)-N,N'-dimethyl-N-2-pyridyl-1,2-ethanediamine, maleic acid salt; N-(4-Methoxyphenyl)methyl-N',N'-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine but-2-enedioate; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine (2Z)-but-2-enedioate; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N1-((4-methoxyphenyl)methyl)-N2,N2-dimethyl-N1-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine bimaleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate (1:1); 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine bimaleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine maleate; Pyrilamine Maleate
DM7F5OW TC Antiasthmatic Agents
DM7F5OW DT Small molecular drug
DM7F5OW PC 5284451
DM7F5OW MW 401.5
DM7F5OW FM C21H27N3O5
DM7F5OW IC InChI=1S/C17H23N3O.C4H4O4/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15;5-3(6)1-2-4(7)8/h4-11H,12-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DM7F5OW CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DM7F5OW IK JXYWFNAQESKDNC-BTJKTKAUSA-N
DM7F5OW IU (Z)-but-2-enedioic acid;N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DM7F5OW CA CAS 59-33-6
DM7F5OW DE Headache; Allergy
DMAFBCY ID DMAFBCY
DMAFBCY DN Mequitazine
DMAFBCY HS Approved
DMAFBCY SN Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine
DMAFBCY CP Pierre Fabre SA
DMAFBCY TC Antihistamines
DMAFBCY DT Small molecular drug
DMAFBCY PC 4066
DMAFBCY MW 322.5
DMAFBCY FM C20H22N2S
DMAFBCY IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
DMAFBCY CS C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAFBCY IK HOKDBMAJZXIPGC-UHFFFAOYSA-N
DMAFBCY IU 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine
DMAFBCY CA CAS 29216-28-2
DMAFBCY CB CHEBI:31821
DMAFBCY DE Allergic rhinitis; Respiratory disease
DMTM2IK ID DMTM2IK
DMTM2IK DN Mercaptopurine
DMTM2IK HS Approved
DMTM2IK SN 6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)
DMTM2IK CP Novopharm
DMTM2IK TC Anticancer Agents
DMTM2IK DT Small molecular drug
DMTM2IK PC 667490
DMTM2IK MW 152.18
DMTM2IK FM C5H4N4S
DMTM2IK IC InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMTM2IK CS C1=NC2=C(N1)C(=S)N=CN2
DMTM2IK IK GLVAUDGFNGKCSF-UHFFFAOYSA-N
DMTM2IK IU 3,7-dihydropurine-6-thione
DMTM2IK CA CAS 50-44-2
DMTM2IK CB CHEBI:2208
DMTM2IK DE Acute lymphoblastic leukaemia; Crohn disease
DM0HS92 ID DM0HS92
DM0HS92 DN Merimepodib
DM0HS92 HS Approved
DM0HS92 SN Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
DM0HS92 CP GSK
DM0HS92 DT Small molecular drug
DM0HS92 PC 153241
DM0HS92 MW 452.5
DM0HS92 FM C23H24N4O6
DM0HS92 IC InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
DM0HS92 CS COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
DM0HS92 IK JBPUGFODGPKTDW-SFHVURJKSA-N
DM0HS92 IU [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
DM0HS92 CA CAS 198821-22-6
DM0HS92 DE Hepatitis C virus infection; Breast cancer; Hepatitis virus infection; Head and neck cancer; Gastric adenocarcinoma
DM62UHC ID DM62UHC
DM62UHC DN Meropenem
DM62UHC HS Approved
DM62UHC SN MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
DM62UHC CP AstraZeneca
DM62UHC TC Antibiotics
DM62UHC DT Small molecular drug
DM62UHC PC 441130
DM62UHC MW 383.5
DM62UHC FM C17H25N3O5S
DM62UHC IC InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
DM62UHC CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DM62UHC IK DMJNNHOOLUXYBV-PQTSNVLCSA-N
DM62UHC IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM62UHC CA CAS 96036-03-2
DM62UHC CB CHEBI:43968
DM62UHC DE Bacterial infection
DMOVAIX ID DMOVAIX
DMOVAIX DN Meropenem + vaborbactam
DMOVAIX HS Approved
DMOVAIX SN Vabomere; Meropenem / vaborbactam; Meropenem and vaborbactam; Meropenem mixture with vaborbactam; Carbavance
DMOVAIX CP The Medicines Company/Rempex Pharmaceuticals
DMOVAIX PC 86298703
DMOVAIX MW 680.6
DMOVAIX FM C29H41BN4O10S2
DMOVAIX IC InChI=1S/C17H25N3O5S.C12H16BNO5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t7-,8-,9+,10+,11-,12-;8-,10-/m10/s1
DMOVAIX CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O.C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DMOVAIX IK SDJYWZHQLNEXKV-SSHSFQATSA-N
DMOVAIX IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMOVAIX CA CAS 2031124-72-6
DMOVAIX DE Urinary tract infection; Intra-abdominal infection
DMOL5IU ID DMOL5IU
DMOL5IU DN Mesalazine
DMOL5IU HS Approved
DMOL5IU SN Apriso; Asacol; Asacolitin; Asacolon; Asalit; Ascolitin; Canasa; Claversal; Fisalamine; Fivasa; Iialda; Ipocol; Lialda; Lixacol; Mesacol; Mesalamine; Mesalazina; Mesalazinum; Mesasal; Mesavance; Mesavancol; Mezavant; Pentacol; Pentasa; Rowasa; Salofalk; Salozinal; SfRowasa; Allphar Brand of Mesalamine; Antigen Brand of Mesalamine; Asacol HD; Axcan Brand of Mesalamine; Byk Brand of Mesalamine; Celltech Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Ferring Brand of Mesalamine; GlaxoSmithKline Brand of Mesalamine; Henning Berlin Brand of Mesalamine; M Aminosalicylic Acid; Merckle Brand of Mesalamine; Mesalamine Hydrochloride; Mesalamine Monosodium Salt; Mesalamine [USAN]; Mesalazina[Spanish]; Mesalazine MMX; Mesalazinum [Latin]; Meta Aminosalicylic Acid; Mezavant XL; Minosalicylic acid; Norgine Brand of Mesalamine; Novopharm Brand of Mesalamine; Provalis Brand of Mesalamine; Sanofi Synthelabo Brand of Mesalamine; Schering Plough Brand of Mesalamine; SmithKline Brand of Mesalamine; Solvay Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Novo 5 ASA; Novo5 ASA; AJG-501; Apriso (TN); Asacol (TN); Canasa (TN); Hydrochloride, Mesalamine; Iialda (TN); Ipocal (TN); Lialda (TN); M-A; M-Aminosalicylic acid; MAX-002; MD-0901; Masacol (TN); Mesalamine (USP); Meta-AminosalicylicAcid; Monosodium Salt, Mesalamine; Novo-5 ASA; P-Aminosalicylsaeure; P-Aminosalicylsaeure [German]; Pentasa (TN); Procter & Gamble Brand of Mesalamine; Rowasa (TN); SPD-476; SPD-480; Salofalk (TN); Salofalk Granu-Stix; Schering-Plough Brand of Mesalamine; Z-206; Mesalazine (JAN/INN); Salicylic acid, 5-amino-(8CI); 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; 5 Aminosalicylate; 5 Aminosalicylic Acid; 5-AS; 5-ASA; 5-Amino-2-hydroxybenzoic acid; 5-Aminosalicylate; 5-Aminosalicylic acid; 5-amino-2-hydroxy-benzoic acid; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine
DMOL5IU TC Antiinflammatory Agents
DMOL5IU DT Small molecular drug
DMOL5IU PC 4075
DMOL5IU MW 153.14
DMOL5IU FM C7H7NO3
DMOL5IU IC InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
DMOL5IU CS C1=CC(=C(C=C1N)C(=O)O)O
DMOL5IU IK KBOPZPXVLCULAV-UHFFFAOYSA-N
DMOL5IU IU 5-amino-2-hydroxybenzoic acid
DMOL5IU CA CAS 89-57-6
DMOL5IU CB CHEBI:6775
DMOL5IU DE Ulcerative colitis
DM2ZGAN ID DM2ZGAN
DM2ZGAN DN Mesoridazine
DM2ZGAN HS Approved
DM2ZGAN SN Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN CP Norvatis Phamaceuticals Corporation
DM2ZGAN TC Antipsychotic Agents
DM2ZGAN DT Small molecular drug
DM2ZGAN PC 4078
DM2ZGAN MW 386.6
DM2ZGAN FM C21H26N2OS2
DM2ZGAN IC InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM2ZGAN CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
DM2ZGAN IK SLVMESMUVMCQIY-UHFFFAOYSA-N
DM2ZGAN IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN CA CAS 5588-33-0
DM2ZGAN CB CHEBI:6780
DM2ZGAN DE Schizophrenia
DMG3F94 ID DMG3F94
DMG3F94 DN Mestranol
DMG3F94 HS Approved
DMG3F94 SN Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol
DMG3F94 TC Estrogens
DMG3F94 DT Small molecular drug
DMG3F94 PC 6291
DMG3F94 MW 310.4
DMG3F94 FM C21H26O2
DMG3F94 IC InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1
DMG3F94 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC
DMG3F94 IK IMSSROKUHAOUJS-MJCUULBUSA-N
DMG3F94 IU (8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMG3F94 CA CAS 72-33-3
DMG3F94 CB CHEBI:6784
DMG3F94 DE Contraception
DMM4QOJ ID DMM4QOJ
DMM4QOJ DN Metadoxine
DMM4QOJ HS Approved
DMM4QOJ SN MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra
DMM4QOJ CP Alcobra
DMM4QOJ DT Small molecular drug
DMM4QOJ PC 115198
DMM4QOJ MW 298.29
DMM4QOJ FM C13H18N2O6
DMM4QOJ IC InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
DMM4QOJ CS CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)N[C@@H]1C(=O)O
DMM4QOJ IK RYKKQQUKJJGFMN-HVDRVSQOSA-N
DMM4QOJ IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid
DMM4QOJ CA CAS 74536-44-0
DMM4QOJ DE Multiple myeloma
DMTQS9A ID DMTQS9A
DMTQS9A DN Metaproterenol sulfate
DMTQS9A HS Approved
DMTQS9A SN Metaproterenol; metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Metaproterenol sulfate; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; Alupent; Orciprenaline
DMTQS9A CP Boehringer Ingelheim Pharmaceuticals Inc
DMTQS9A DT Small molecular drug
DMTQS9A PC 441333
DMTQS9A MW 520.6
DMTQS9A FM C22H36N2O10S
DMTQS9A IC InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4)
DMTQS9A CS CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O
DMTQS9A IK MKFFGUZYVNDHIH-UHFFFAOYSA-N
DMTQS9A IU 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid
DMTQS9A CA CAS 5874-97-5
DMTQS9A DE Asthma
DMWIX23 ID DMWIX23
DMWIX23 DN Metaraminol
DMWIX23 HS Approved
DMWIX23 SN Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23 CP Merck Sharp & Dohme Pharmaceuticals
DMWIX23 TC Antihypertensive Agents
DMWIX23 DT Small molecular drug
DMWIX23 PC 5906
DMWIX23 MW 167.2
DMWIX23 FM C9H13NO2
DMWIX23 IC InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
DMWIX23 CS C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N
DMWIX23 IK WXFIGDLSSYIKKV-RCOVLWMOSA-N
DMWIX23 IU 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23 CA CAS 54-49-9
DMWIX23 CB CHEBI:6794
DMWIX23 DE Hypotension
DMJFP6G ID DMJFP6G
DMJFP6G DN Metergolin
DMJFP6G HS Approved
DMJFP6G SN Metergoline; metergoline; Liserdol; 17692-51-2; Methergoline; Metergolina; Metergolinum; Metergolina [DCIT]; Metergolinum [Latin]; Metergolina [Spanish]; Substance 355/255; Metergoline [INN:BAN]; Metergolinum [INN-Latin]; 1-Methyl-N-carbobenzyloxydihydro-D-lysergamin; FI-6337; MLS000069437; UNII-1501393LY5; C25H29N3O2; AHR 3009; 1-Methyl-8-beta-carbobenzyloxyaminomethyl-10-alpha-ergoline; EINECS 241-686-3; 1,6-Dimethyl-8-beta-carbobenzyloxaminomethyl-10-alpha-ergoline; FI 6337; Liserdol (TN)
DMJFP6G DT Small molecular drug
DMJFP6G PC 28693
DMJFP6G MW 403.5
DMJFP6G FM C25H29N3O2
DMJFP6G IC InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1
DMJFP6G CS CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5
DMJFP6G IK WZHJKEUHNJHDLS-QTGUNEKASA-N
DMJFP6G IU benzyl N-[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate
DMJFP6G CA CAS 17692-51-2
DMJFP6G CB CHEBI:64216
DMJFP6G DE Hyperprolactinaemia
DM89QE1 ID DM89QE1
DM89QE1 DN Metformin
DM89QE1 HS Approved
DM89QE1 SN 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
DM89QE1 CP Bristol-Myers Squibb
DM89QE1 TC Hypoglycemic Agents
DM89QE1 DT Small molecular drug
DM89QE1 PC 4091
DM89QE1 MW 129.16
DM89QE1 FM C4H11N5
DM89QE1 IC InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
DM89QE1 CS CN(C)C(=N)N=C(N)N
DM89QE1 IK XZWYZXLIPXDOLR-UHFFFAOYSA-N
DM89QE1 IU 3-(diaminomethylidene)-1,1-dimethylguanidine
DM89QE1 CA CAS 657-24-9
DM89QE1 CB CHEBI:6801
DM89QE1 DE Type-2 diabetes
DMTPAM3 ID DMTPAM3
DMTPAM3 DN Metformin arginine-hemisuccinimide
DMTPAM3 HS Approved
DMTPAM3 SN Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria
DMTPAM3 CP Boehringer Ingelheim Pharmaceuticals; Merck; Depomed; Janssen Research & Development; AstraZeneca; Bristol-Myers Squibb
DMTPAM3 DE Type-2 diabetes
DMGS4QH ID DMGS4QH
DMGS4QH DN Methacholine Chloride
DMGS4QH HS Approved
DMGS4QH SN Methacholine; methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium; METHACHOLINE
DMGS4QH CP Methapharm Inc
DMGS4QH DT Small molecular drug
DMGS4QH PC 6114
DMGS4QH MW 195.69
DMGS4QH FM C8H18ClNO2
DMGS4QH IC InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1
DMGS4QH CS CC(C[N+](C)(C)C)OC(=O)C.[Cl-]
DMGS4QH IK JHPHVAVFUYTVCL-UHFFFAOYSA-M
DMGS4QH IU 2-acetyloxypropyl(trimethyl)azanium;chloride
DMGS4QH CA CAS 62-51-1
DMGS4QH CB CHEBI:50142
DMGS4QH DE bronchial hyperreactivity; Asthma
DMAY96V ID DMAY96V
DMAY96V DN Methacycline
DMAY96V HS Approved
DMAY96V SN Bialatan; Metaciclina; Metacycline; Metacyclinum; Methacyclin; Methacyclinum; Methylenecycline; Methyleneoxytetracycline; Rondomycin; Methacycline amphoteric; Methacycline base; GS 2876; GS-2876; Metaciclina [INN-Spanish]; Metacycline (INN); Metacyclinum [INN-Latin]; Methacycline (USAN); Methacycline [USAN:BAN]; Tri-methacycline; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; 6-Methylene-5-hydroxytetracycline; 6-Methylene-5-oxytetracycline; 6-Methyleneoxytetracycline
DMAY96V TC Antibiotics
DMAY96V DT Small molecular drug
DMAY96V PC 54675785
DMAY96V MW 442.4
DMAY96V FM C22H22N2O8
DMAY96V IC InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25-27,30,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1
DMAY96V CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O
DMAY96V IK XIYOPDCBBDCGOE-IWVLMIASSA-N
DMAY96V IU (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMAY96V CA CAS 914-00-1
DMAY96V CB CHEBI:6805
DMAY96V DE Bacterial infection
DMTW6IU ID DMTW6IU
DMTW6IU DN Methadone
DMTW6IU HS Approved
DMTW6IU SN Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone
DMTW6IU CP Eli Lilly
DMTW6IU TC Analgesics
DMTW6IU DT Small molecular drug
DMTW6IU PC 4095
DMTW6IU MW 309.4
DMTW6IU FM C21H27NO
DMTW6IU IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
DMTW6IU CS CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DMTW6IU IK USSIQXCVUWKGNF-UHFFFAOYSA-N
DMTW6IU IU 6-(dimethylamino)-4,4-diphenylheptan-3-one
DMTW6IU CA CAS 76-99-3
DMTW6IU CB CHEBI:6807
DMTW6IU DE Dry cough
DMIRMVB ID DMIRMVB
DMIRMVB DN Methadyl Acetate
DMIRMVB HS Approved
DMIRMVB SN ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate
DMIRMVB TC Narcotics
DMIRMVB DT Small molecular drug
DMIRMVB PC 10517
DMIRMVB MW 353.5
DMIRMVB FM C23H31NO2
DMIRMVB IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3
DMIRMVB CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DMIRMVB IK XBMIVRRWGCYBTQ-UHFFFAOYSA-N
DMIRMVB IU [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DMIRMVB CA CAS 509-74-0
DMIRMVB CB CHEBI:135491
DMIRMVB DE Opioid dependence
DMPM4SK ID DMPM4SK
DMPM4SK DN Methamphetamine
DMPM4SK HS Approved
DMPM4SK SN METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine
DMPM4SK CP Ovation Pharma
DMPM4SK TC Central Nervous System Stimulants
DMPM4SK DT Small molecular drug
DMPM4SK PC 10836
DMPM4SK MW 149.23
DMPM4SK FM C10H15N
DMPM4SK IC InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
DMPM4SK CS C[C@@H](CC1=CC=CC=C1)NC
DMPM4SK IK MYWUZJCMWCOHBA-VIFPVBQESA-N
DMPM4SK IU (2S)-N-methyl-1-phenylpropan-2-amine
DMPM4SK CA CAS 537-46-2
DMPM4SK CB CHEBI:6809
DMPM4SK DE Pain; Attention deficit hyperactivity disorder
DMO2JBC ID DMO2JBC
DMO2JBC DN Methamphetamine hydrochloride
DMO2JBC HS Approved
DMO2JBC SN Methamphetamine HCL; Methamphetamine hydrochloride; Methamphetaminium chloride; Methylamphetamine hydrochloride; Methylisomyn; Norodin hydrochloride; Adipex; Chestox; Deofed; Des-O-E; Desepin; Desodex; Desoxo-5; Desoxyfed; Desoxyne; Destim; Dexoval; Dexstim; Dextim; Dosoxy; Doxyfed; Drinalfa; Efroxine; Eufodrinal; Gerovit; Hyphet; Isophen; Isophen (VAN); Obedrin-LA; Pervitin; Philopon; Soxysympamine; Syndrox; Tonedron; d-Methaphetamine hydrochloride; (+)-Methamphetamine hydrochloride; 51-57-0; S-(+)-Methamphetamine hydrochloride
DMO2JBC PC 66124
DMO2JBC MW 185.69
DMO2JBC FM C10H16ClN
DMO2JBC IC TWXDDNPPQUTEOV-FVGYRXGTSA-N
DMO2JBC CS CC(CC1=CC=CC=C1)NC.Cl
DMO2JBC IK 1S/C10H15N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h3-7,9,11H,8H2,1-2H3;1H/t9-;/m0./s1
DMO2JBC IU (2S)-N-methyl-1-phenylpropan-2-amine;hydrochloride
DMO2JBC CA CAS 51-57-0
DMO2JBC CB CHEBI:35340
DMO2JBC DE Attention deficit hyperactivity disorder
DM8X4A1 ID DM8X4A1
DM8X4A1 DN Methantheline
DM8X4A1 HS Approved
DM8X4A1 SN Mantheline; Methanide; Methanthelinium; Methanthelinum; Banthine bromide; Gastrin I; Methanthine bromide; Gastrin-1 Human; Diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium
DM8X4A1 CP Shire Development Inc
DM8X4A1 TC Anticholinergic Agents
DM8X4A1 DT Small molecular drug
DM8X4A1 PC 4097
DM8X4A1 MW 340.4
DM8X4A1 FM C21H26NO3+
DM8X4A1 IC InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
DM8X4A1 CS CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13
DM8X4A1 IK GZHFODJQISUKAY-UHFFFAOYSA-N
DM8X4A1 IU diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM8X4A1 CA CAS 5818-17-7
DM8X4A1 CB CHEBI:6817
DM8X4A1 DE Gastritis; Pancreatitis; Irritable bowel syndrome; Peptic ulcer
DM5A38V ID DM5A38V
DM5A38V DN Metharbital
DM5A38V HS Approved
DM5A38V SN Endiemal; Endiemalum; Gemonal; Gemonil; Gemonit; Metabarbital; Metarbital; Metarbitale; Methabarbital; Methabarbitone; Metharbitalum; Metharbitone; Metharbutal; Methylbarbital; Metarbitale [DCIT]; AN 23; Sch 412; Gemonil (TN); Metarbital [INN-Spanish]; Metharbital [INN:JAN]; Metharbitalum [INN-Latin]; N-Methylbarbital; Metharbital (JAN/INN); 1-Methylbarbital; 5,5-Diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethyl-1-methylbarbituric acid; 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione; 5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione
DM5A38V CP Abbott Laboratories
DM5A38V TC Anticonvulsants
DM5A38V DT Small molecular drug
DM5A38V PC 4099
DM5A38V MW 198.22
DM5A38V FM C9H14N2O3
DM5A38V IC InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)
DM5A38V CS CCC1(C(=O)NC(=O)N(C1=O)C)CC
DM5A38V IK FWJKNZONDWOGMI-UHFFFAOYSA-N
DM5A38V IU 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione
DM5A38V CA CAS 50-11-3
DM5A38V CB CHEBI:31827
DM5A38V DE Epilepsy
DM7J2TA ID DM7J2TA
DM7J2TA DN Methazolamide
DM7J2TA HS Approved
DM7J2TA SN Methazolamide (oral, sustained release)
DM7J2TA CP Effcon Laboratories Inc
DM7J2TA DT Small molecular drug
DM7J2TA PC 4100
DM7J2TA MW 236.3
DM7J2TA FM C5H8N4O3S2
DM7J2TA IC InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
DM7J2TA CS CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
DM7J2TA IK FLOSMHQXBMRNHR-UHFFFAOYSA-N
DM7J2TA IU N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
DM7J2TA CA CAS 554-57-4
DM7J2TA CB CHEBI:6822
DM7J2TA DE Glaucoma/ocular hypertension
DMAUHQX ID DMAUHQX
DMAUHQX DN Methdilazine
DMAUHQX HS Approved
DMAUHQX SN Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine
DMAUHQX TC Antihistamines
DMAUHQX DT Small molecular drug
DMAUHQX PC 14677
DMAUHQX MW 296.4
DMAUHQX FM C18H20N2S
DMAUHQX IC InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
DMAUHQX CS CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
DMAUHQX IK HTMIBDQKFHUPSX-UHFFFAOYSA-N
DMAUHQX IU 10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine
DMAUHQX CA CAS 1982-37-2
DMAUHQX CB CHEBI:6823
DMAUHQX DE Allergic rhinitis
DM25FL8 ID DM25FL8
DM25FL8 DN Methimazole
DM25FL8 HS Approved
DM25FL8 SN methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Mercazolyl; 1-Methylimidazole-2-thiol; Thymidazole; Mercazole; Methimazol; Thymidazol; Thiamazol; Metazolo; Thycapzol; Metothyrine; Metothyrin; Merkazolil; Mercaptazole; Strumazol; Favistan; Basolan; Thycapsol; Metotirin; Danantizol; Thacapzol; Merkastan; Frentirox; Metizol; Tiamazol; Mercasolyl; 1-Methyl-1H-imidazole-2-thiol; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; Usaf el-30; Methimazolum; Mercazolylum; Tapuzole; Metimazol; Thimazole; Basolan; MMZ; Mercazol; Methamazole; Methizol; Methymazol; Metisol; Strumazole; Thiamazole; Thiamazolum; Thimazol; Thyrozol; Tiamazolo; Tirodril; EliLilly Brand of Methimazole; Estedi Brand of Methimazole; Henning Berlin Brand of Methimazole; Hexal Brand of Methimazole; Jones Brand of Methimazole; Merck Brand of Methimazole; Nourypharma Brand of Methimazole; Philopharm Brand of Methimazole; Sanofi Synthelabo Brand of Methimazole; Temmler Brand of Methimazole; Thiamazol Henning; Thiamazol Hexal; Tiamazolo [DCIT]; M0868; Henning, Thiamazol; Hexal, Thiamazol; Methimazole (USP); Methimazole [USAN:BAN]; Tapazole (TN); Thiamazol [INN-French]; Thiamazolum [INN-Latin]; Tiamazol [INN-Spanish]; Mestinon, Regonol, Pyridostigmine Bromide;Thiamazole (JP15/INN); N-Methyl-2-mercaptoimidazole; 1 Methyl 2 mercaptoimidazole; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-Imidazolethione; 1-Methyl-2-imidazolethiol; 1-Methyl-imidazole-2-thiol; 1-Methylimidazole-2(3H)-thione; 1-Metylo 2 merkaptoimidazolem; 1-Metylo 2 merkaptoimidazolem [Polish]; 2-Mercaptomethylimidazole; 3-methyl-1H-imidazole-2-thione
DM25FL8 TC Antithyroid Agents
DM25FL8 DT Small molecular drug
DM25FL8 PC 1349907
DM25FL8 MW 114.17
DM25FL8 FM C4H6N2S
DM25FL8 IC InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM25FL8 CS CN1C=CNC1=S
DM25FL8 IK PMRYVIKBURPHAH-UHFFFAOYSA-N
DM25FL8 IU 3-methyl-1H-imidazole-2-thione
DM25FL8 CA CAS 60-56-0
DM25FL8 CB CHEBI:50673
DM25FL8 DE Hyperthyroidism
DM3Z217 ID DM3Z217
DM3Z217 DN Methimazole
DM3Z217 HS Approved
DM3Z217 SN Mercaptazole; Mercasolyl; Mercazole; Mercazolyl; Mercazolylum; Merkastan; Merkazolil; Metazolo; Methiamazole; Methimazol; Methimazolum; Methylmercaptoimidazole; Metizol; Metothyrin; Metothyrine; Metotirin; Strumazol; Tapazole; Thacapzol; Basolan; Danantizol; Favistan; Frentirox; Thiamazol; Thycapsol; Thycapzol; Thymidazol; Thymidazole; Tiamazol; Usaf el-30; methimazole; thiamazole; 1-Methyl-1H-imidazole-2-thiol; 1-Methyl-2-mercaptoimidazole; 1-Methylimidazole-2-thiol; 2-Mercapto-1-methylimidazole; 3-methyl-1H-imidazole-2-thione; 60-56-0
DM3Z217 PC 1349907
DM3Z217 MW 114.17
DM3Z217 FM C4H6N2S
DM3Z217 IC PMRYVIKBURPHAH-UHFFFAOYSA-N
DM3Z217 CS CN1C=CNC1=S
DM3Z217 IK 1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM3Z217 IU 3-methyl-1H-imidazole-2-thione
DM3Z217 CA CAS 60-56-0
DM3Z217 CB CHEBI:50673
DM3Z217 DE Thyrotoxicosis
DM7YMIT ID DM7YMIT
DM7YMIT DN Methohexital
DM7YMIT HS Approved
DM7YMIT SN Brevital; Brietal; Enallynymall; Enallynymalum; Methodrexitone; Methohexitalum; Methohexitone; Metoesital; Metohexital; Metoesital [DCIT]; Brevital (TN); Methohexital, Monosodium Salt; Methohexitalum [INN-Latin]; Metohexital [INN-Spanish]; Methohexital (USP/INN); Alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituricacid; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT CP Par Sterile Products Llc
DM7YMIT TC Anesthetics
DM7YMIT DT Small molecular drug
DM7YMIT PC 9034
DM7YMIT MW 262.3
DM7YMIT FM C14H18N2O3
DM7YMIT IC InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
DM7YMIT CS CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C
DM7YMIT IK NZXKDOXHBHYTKP-UHFFFAOYSA-N
DM7YMIT IU 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT CA CAS 151-83-7
DM7YMIT CB CHEBI:102216
DM7YMIT DE Anaesthesia
DM2TEOL ID DM2TEOL
DM2TEOL DN Methotrexate
DM2TEOL HS Approved
DM2TEOL SN methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
DM2TEOL DT Small molecular drug
DM2TEOL PC 126941
DM2TEOL MW 454.4
DM2TEOL FM C20H22N8O5
DM2TEOL IC InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
DM2TEOL CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM2TEOL IK FBOZXECLQNJBKD-ZDUSSCGKSA-N
DM2TEOL IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
DM2TEOL CA CAS 59-05-2
DM2TEOL CB CHEBI:44185
DM2TEOL DE leukaemia; Solid tumour/cancer; Prostate cancer; Rheumatoid arthritis; Proliferative vitreoretinopathy
DM5XH2C ID DM5XH2C
DM5XH2C DN Methotrexate Sodium
DM5XH2C HS Approved
DM5XH2C SN Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE
DM5XH2C CP Hospira Inc
DM5XH2C TC Anticancer Agents
DM5XH2C DT Small molecular drug
DM5XH2C PC 11329481
DM5XH2C MW 498.4
DM5XH2C FM C20H20N8Na2O5
DM5XH2C IC InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1
DM5XH2C CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]
DM5XH2C IK DASQOOZCTWOQPA-GXKRWWSZSA-L
DM5XH2C IU disodium;(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioate
DM5XH2C CA CAS 7413-34-5
DM5XH2C CB CHEBI:50679
DM5XH2C DE Solid tumour/cancer
DMF5XQH ID DMF5XQH
DMF5XQH DN Methoxamine
DMF5XQH HS Approved
DMF5XQH SN Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol
DMF5XQH CP Glaxosmithkline
DMF5XQH TC Antihypertensive Agents
DMF5XQH DT Small molecular drug
DMF5XQH PC 6082
DMF5XQH MW 211.26
DMF5XQH FM C11H17NO3
DMF5XQH IC InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3
DMF5XQH CS CC(C(C1=C(C=CC(=C1)OC)OC)O)N
DMF5XQH IK WJAJPNHVVFWKKL-UHFFFAOYSA-N
DMF5XQH IU 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol
DMF5XQH CA CAS 390-28-3
DMF5XQH CB CHEBI:6839
DMF5XQH DE Hypertension
DME8FZ9 ID DME8FZ9
DME8FZ9 DN Methoxsalen
DME8FZ9 HS Approved
DME8FZ9 SN Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9 TC Anticancer Agents
DME8FZ9 DT Small molecular drug
DME8FZ9 PC 4114
DME8FZ9 MW 216.19
DME8FZ9 FM C12H8O4
DME8FZ9 IC InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3
DME8FZ9 CS COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
DME8FZ9 IK QXKHYNVANLEOEG-UHFFFAOYSA-N
DME8FZ9 IU 9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9 CA CAS 298-81-7
DME8FZ9 CB CHEBI:18358
DME8FZ9 DE Cutaneous T-cell lymphoma; Psoriasis vulgaris
DMK1LZD ID DMK1LZD
DMK1LZD DN Methoxy polyethylene glycol-epoetin beta
DMK1LZD HS Approved
DMK1LZD SN Mircera (TN)
DMK1LZD DE Kidney transplant rejection
DML0RAE ID DML0RAE
DML0RAE DN Methoxyflurane
DML0RAE HS Approved
DML0RAE SN Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether
DML0RAE TC Anesthetics
DML0RAE DT Small molecular drug
DML0RAE PC 4116
DML0RAE MW 164.96
DML0RAE FM C3H4Cl2F2O
DML0RAE IC InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
DML0RAE CS COC(C(Cl)Cl)(F)F
DML0RAE IK RFKMCNOHBTXSMU-UHFFFAOYSA-N
DML0RAE IU 2,2-dichloro-1,1-difluoro-1-methoxyethane
DML0RAE CA CAS 76-38-0
DML0RAE CB CHEBI:6843
DML0RAE DE Anaesthesia
DMHP8FI ID DMHP8FI
DMHP8FI DN Methscopolamine bromide
DMHP8FI HS Approved
DMHP8FI SN Pamine Forte
DMHP8FI CP Private Formulations Inc
DMHP8FI DT Small molecular drug
DMHP8FI PC 5459110
DMHP8FI MW 398.3
DMHP8FI FM C18H24BrNO4
DMHP8FI IC InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14-,15+,16-,17+;/m1./s1
DMHP8FI CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DMHP8FI IK CXYRUNPLKGGUJF-OZVSTBQFSA-M
DMHP8FI IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMHP8FI CA CAS 155-41-9
DMHP8FI CB CHEBI:61276
DMHP8FI DE Nausea and vomiting
DM6L5VO ID DM6L5VO
DM6L5VO DN Methsuximide
DM6L5VO HS Approved
DM6L5VO SN Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO CP Pfizer Pharmaceuticals
DM6L5VO TC Anticonvulsants
DM6L5VO DT Small molecular drug
DM6L5VO PC 6476
DM6L5VO MW 203.24
DM6L5VO FM C12H13NO2
DM6L5VO IC InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
DM6L5VO CS CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
DM6L5VO IK AJXPJJZHWIXJCJ-UHFFFAOYSA-N
DM6L5VO IU 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO CA CAS 77-41-8
DM6L5VO CB CHEBI:6846
DM6L5VO DE Epileptic seizures
DMN7SDE ID DMN7SDE
DMN7SDE DN Methyclothiazide
DMN7SDE HS Approved
DMN7SDE SN Aquaresen; Aquatensen; Duretic; Enduron; Enduronum; METHYLCLOTHIAZIDE; Methychlothiazide; Methyclothiazid; Methyclothiazidum;Methycyclothiazide; Methylchlorothiazide; Methylcyclothiazide; Meticlotiazida; Meticlotiazide; Naturon; Meticlotiazide [DCIT]; Ciba 7272-Su; Enduron (TN); Methyclothiazidum [INN-Latin]; Meticlotiazida [INN-Spanish]; Naturon (VAN); Methyclothiazide (JAN/USP/INN); Methyclothiazide [USAN:INN:BAN:JAN]; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1
DMN7SDE TC Antihypertensive Agents
DMN7SDE DT Small molecular drug
DMN7SDE PC 4121
DMN7SDE MW 360.2
DMN7SDE FM C9H11Cl2N3O4S2
DMN7SDE IC InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
DMN7SDE CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl
DMN7SDE IK CESYKOGBSMNBPD-UHFFFAOYSA-N
DMN7SDE IU 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMN7SDE CA CAS 135-07-9
DMN7SDE CB CHEBI:6847
DMN7SDE DE Edema; Hypertension
DMIUX3D ID DMIUX3D
DMIUX3D DN Methyl aminolevulinate
DMIUX3D HS Approved
DMIUX3D SN Metvix; Aminolevulinic acid methyl ester; Methyl 5-aminolevulinate; Methyl delta-aminolevulinate; Methyl5-amino-4-oxopentanoate; Levulinic acid, 5-amino-, methyl ester; Pentanoic acid, 5-amino-4-oxo-, methyl ester; 5-Aminolevulinic acid methyl ester
DMIUX3D TC Anticancer Agents
DMIUX3D DT Small molecular drug
DMIUX3D PC 157922
DMIUX3D MW 145.16
DMIUX3D FM C6H11NO3
DMIUX3D IC InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3
DMIUX3D CS COC(=O)CCC(=O)CN
DMIUX3D IK YUUAYBAIHCDHHD-UHFFFAOYSA-N
DMIUX3D IU methyl 5-amino-4-oxopentanoate
DMIUX3D CA CAS 33320-16-0
DMIUX3D CB CHEBI:724125
DMIUX3D DE Acne vulgaris
DM5I621 ID DM5I621
DM5I621 DN Methyldopa
DM5I621 HS Approved
DM5I621 SN AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine
DM5I621 CP Ivax pharmaceutical
DM5I621 TC Antihypertensive Agents
DM5I621 DT Small molecular drug
DM5I621 PC 38853
DM5I621 MW 211.21
DM5I621 FM C10H13NO4
DM5I621 IC InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1
DM5I621 CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
DM5I621 IK CJCSPKMFHVPWAR-JTQLQIEISA-N
DM5I621 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
DM5I621 CA CAS 555-30-6
DM5I621 CB CHEBI:61058
DM5I621 DE Hypertension
DM8XI09 ID DM8XI09
DM8XI09 DN Methyldopate Hydrochloride
DM8XI09 HS Approved
DM8XI09 CP Merck And Co Inc
DM8XI09 TC Cardiovascular Agents
DM8XI09 DT Small molecular drug
DM8XI09 PC 17276
DM8XI09 MW 275.73
DM8XI09 FM C12H18ClNO4
DM8XI09 IC InChI=1S/C12H17NO4.ClH/c1-3-17-11(16)12(2,13)7-8-4-5-9(14)10(15)6-8;/h4-6,14-15H,3,7,13H2,1-2H3;1H/t12-;/m0./s1
DM8XI09 CS CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N.Cl
DM8XI09 IK QSRVZCCJDKYRRF-YDALLXLXSA-N
DM8XI09 IU ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate;hydrochloride
DM8XI09 CA CAS 2508-79-4
DM8XI09 DE Hypertension
DMJAPE7 ID DMJAPE7
DMJAPE7 DN Methylene blue
DMJAPE7 HS Approved
DMJAPE7 SN methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium
DMJAPE7 PC 6099
DMJAPE7 MW 319.9
DMJAPE7 FM C16H18ClN3S
DMJAPE7 IC InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1
DMJAPE7 CS CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]
DMJAPE7 IK CXKWCBBOMKCUKX-UHFFFAOYSA-M
DMJAPE7 IU [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
DMJAPE7 CA CAS 61-73-4
DMJAPE7 CB CHEBI:6872
DMJAPE7 DE Acquired methemoglobinemia
DMBEX4O ID DMBEX4O
DMBEX4O DN Methylergonovine
DMBEX4O HS Approved
DMBEX4O SN Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide
DMBEX4O CP Edison Therapeutics Llc
DMBEX4O TC Oxytocics
DMBEX4O DT Small molecular drug
DMBEX4O PC 8226
DMBEX4O MW 339.4
DMBEX4O FM C20H25N3O2
DMBEX4O IC InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1
DMBEX4O CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMBEX4O IK UNBRKDKAWYKMIV-QWQRMKEZSA-N
DMBEX4O IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMBEX4O CA CAS 113-42-8
DMBEX4O CB CHEBI:92607
DMBEX4O DE Spontaneous abortion
DMZTGN2 ID DMZTGN2
DMZTGN2 DN Methylnaltrexone bromide
DMZTGN2 HS Approved
DMZTGN2 SN Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, > W-5330; CHIR-01020
DMZTGN2 CP Progenics
DMZTGN2 DT Small molecular drug
DMZTGN2 PC 5361917
DMZTGN2 MW 436.3
DMZTGN2 FM C21H26BrNO4
DMZTGN2 IC InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
DMZTGN2 CS C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-]
DMZTGN2 IK IFGIYSGOEZJNBE-KNLJMPJLSA-N
DMZTGN2 IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one;bromide
DMZTGN2 CA CAS 73232-52-7
DMZTGN2 DE Opioid-induced constipation; Obesity
DM7SJD6 ID DM7SJD6
DM7SJD6 DN Methylphenidate
DM7SJD6 HS Approved
DM7SJD6 SN Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester
DM7SJD6 CP Novartis
DM7SJD6 TC Central Nervous System Stimulants
DM7SJD6 DT Small molecular drug
DM7SJD6 PC 4158
DM7SJD6 MW 233.31
DM7SJD6 FM C14H19NO2
DM7SJD6 IC InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
DM7SJD6 CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DM7SJD6 IK DUGOZIWVEXMGBE-UHFFFAOYSA-N
DM7SJD6 IU methyl 2-phenyl-2-piperidin-2-ylacetate
DM7SJD6 CA CAS 113-45-1
DM7SJD6 CB CHEBI:84276
DM7SJD6 DE Attention deficit hyperactivity disorder; Traumatic brain injury
DMDSWAG ID DMDSWAG
DMDSWAG DN Methylphenobarbital
DMDSWAG HS Approved
DMDSWAG SN Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMDSWAG CP Ovation Pharmaceuticals
DMDSWAG TC Hypnotics and Sedatives
DMDSWAG DT Small molecular drug
DMDSWAG PC 8271
DMDSWAG MW 246.26
DMDSWAG FM C13H14N2O3
DMDSWAG IC InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
DMDSWAG CS CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2
DMDSWAG IK ALARQZQTBTVLJV-UHFFFAOYSA-N
DMDSWAG IU 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMDSWAG CA CAS 115-38-8
DMDSWAG CB CHEBI:6758
DMDSWAG DE Anxiety disorder
DM4BDON ID DM4BDON
DM4BDON DN Methylprednisolone
DM4BDON HS Approved
DM4BDON SN Depo-medrol; M-predrol; Medrol; Medrol Acetate
DM4BDON CP Pharmacia And Upjohn Co
DM4BDON TC Anticancer Agents
DM4BDON DT Small molecular drug
DM4BDON PC 6741
DM4BDON MW 374.5
DM4BDON FM C22H30O5
DM4BDON IC InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
DM4BDON CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
DM4BDON IK VHRSUDSXCMQTMA-PJHHCJLFSA-N
DM4BDON IU (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4BDON CA CAS 83-43-2
DM4BDON CB CHEBI:6888
DM4BDON DE Solid tumour/cancer; Spinal cord injury
DM5VWOB ID DM5VWOB
DM5VWOB DN Methylscopolamine
DM5VWOB HS Approved
DM5VWOB SN Methscopolamine; methscopolamine; N-Methylscopolamine; N-methyl scopolamine; UNII-VDR09VTQ8U; VDR09VTQ8U; 13265-10-6; CHEMBL376897; (1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane; Metylskopolamin; 56552-70-6; 3-Oxa-9-azoniatricyclo[33102,4]nonane, 7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b); HSDB 5420; [3H]N-methylscopolamine; [3H]N-methyl scopolamine; [3H]NMS; Methyl scopolamine; 3C0
DM5VWOB TC Anticholinergic Agents
DM5VWOB DT Small molecular drug
DM5VWOB PC 71183
DM5VWOB MW 318.4
DM5VWOB FM C18H24NO4+
DM5VWOB IC InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12?,13-,14-,15+,16-,17+/m1/s1
DM5VWOB CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DM5VWOB IK LZCOQTDXKCNBEE-XJMZPCNVSA-N
DM5VWOB IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM5VWOB CA CAS 13265-10-6
DM5VWOB CB CHEBI:135361
DM5VWOB DE Peptic ulcer
DMWLFGO ID DMWLFGO
DMWLFGO DN Methyltestosterone
DMWLFGO HS Approved
DMWLFGO SN Android (TN)
DMWLFGO CP Valeant Pharmaceuticals
DMWLFGO DT Small molecular drug
DMWLFGO PC 6010
DMWLFGO MW 302.5
DMWLFGO FM C20H30O2
DMWLFGO IC InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
DMWLFGO CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
DMWLFGO IK GCKMFJBGXUYNAG-HLXURNFRSA-N
DMWLFGO IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMWLFGO CA CAS 58-18-4
DMWLFGO CB CHEBI:27436
DMWLFGO DE Solid tumour/cancer
DMBW7VH ID DMBW7VH
DMBW7VH DN Methyprylon
DMBW7VH HS Approved
DMBW7VH SN Dimerin; Methprylon; Methyprolon; Methyprylone; Methyprylonum; Metiprilon; Metiprilona; Metiprilone; Noctan; Nodular; Noludar; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Metiprilona [INN-Spanish]; Noludar (TN); Ro 1-6463; Methyprylon (JAN/INN); 2,4-Dioxo-3,3-diethyl-5-methylpiperidine; 2,4-Dioxy-3,3-diethyl-5-methylpiperidine; 3,3-Diethyl-2,4-dioxo-5-methylpiperidine; 3,3-Diethyl-5-methyl-2,4-piperidinedione; 3,3-Diethyl-5-methylpiperidine-2,4-dione
DMBW7VH TC Sedatives and Hypnotics
DMBW7VH DT Small molecular drug
DMBW7VH PC 4162
DMBW7VH MW 183.25
DMBW7VH FM C10H17NO2
DMBW7VH IC InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)
DMBW7VH CS CCC1(C(=O)C(CNC1=O)C)CC
DMBW7VH IK SIDLZWOQUZRBRU-UHFFFAOYSA-N
DMBW7VH IU 3,3-diethyl-5-methylpiperidine-2,4-dione
DMBW7VH CA CAS 125-64-4
DMBW7VH CB CHEBI:31837
DMBW7VH DE Insomnia
DM1EF73 ID DM1EF73
DM1EF73 DN Methysergide
DM1EF73 HS Approved
DM1EF73 SN Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
DM1EF73 CP Norvatis Phamaceuticals Corporation
DM1EF73 TC Vasoconstrictor Agents
DM1EF73 DT Small molecular drug
DM1EF73 PC 9681
DM1EF73 MW 353.5
DM1EF73 FM C21H27N3O2
DM1EF73 IC InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1
DM1EF73 CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
DM1EF73 IK KPJZHOPZRAFDTN-ZRGWGRIASA-N
DM1EF73 IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
DM1EF73 CA CAS 361-37-5
DM1EF73 CB CHEBI:92629
DM1EF73 DE Migraine
DMIKHN0 ID DMIKHN0
DMIKHN0 DN Meticillin
DMIKHN0 HS Approved
DMIKHN0 SN Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid
DMIKHN0 CP Beecham phamaceuticals
DMIKHN0 TC Antibiotics
DMIKHN0 DT Small molecular drug
DMIKHN0 PC 6087
DMIKHN0 MW 380.4
DMIKHN0 FM C17H20N2O6S
DMIKHN0 IC InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1
DMIKHN0 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C
DMIKHN0 IK RJQXTJLFIWVMTO-TYNCELHUSA-N
DMIKHN0 IU (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIKHN0 CA CAS 61-32-5
DMIKHN0 CB CHEBI:6827
DMIKHN0 DE Bacterial infection; Neurological disorder
DMJMVKI ID DMJMVKI
DMJMVKI DN Metipranolol
DMJMVKI HS Approved
DMJMVKI SN Disorat; Methypranol; Metipranololum; Trimepranol; Turoptin; BM-01004; Betanol (TN); Disorat (TN); Metipranololum [INN-Latin]; OptiPranolol (TN); Trimepranol (TN); VUAB-6453; VUFB-6453; Metipranolol (USAN/INN); Metipranolol [USAN:BAN:INN]; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); Phenol,4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; 62164P
DMJMVKI TC Antihypertensive Agents
DMJMVKI DT Small molecular drug
DMJMVKI PC 31477
DMJMVKI MW 309.4
DMJMVKI FM C17H27NO4
DMJMVKI IC InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
DMJMVKI CS CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O
DMJMVKI IK BQIPXWYNLPYNHW-UHFFFAOYSA-N
DMJMVKI IU [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate
DMJMVKI CA CAS 22664-55-7
DMJMVKI CB CHEBI:6897
DMJMVKI DE Open-angle glaucoma
DM0JE6N ID DM0JE6N
DM0JE6N DN Metixene
DM0JE6N HS Approved
DM0JE6N SN Atosil; Contalyl; Dalpan; METHIXENE; Methixart; Methixen; Methyloxan; Metisene; Metixeno; Metixenum; Raunana; Tremaril;Tremarit; Tremonil; Tremoquil; Trest; Methixen [German]; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Tremaril hydrochloride; Metixene (INN); Metixene (TN); Metixene [INN:BAN]; Metixeno [INN-Spanish]; Metixenum [INN-Latin]; Methixene (*hydrochloride*); Metixene (*hydrochloride*); Tremonil (*hydrochloride*); 1-Methyl-3-(9H-thioxanthen-9-yl-methyl)piperidine; 1-Methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl) piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine; 1-methyl-3-(thioxanthen-9-ylmethyl)-piperidine hydrochloride; 60 SJ 1977; 60 SJ 1977 (*hydrochloride*); 9-(1'-Methylpiperidine-3'-methyl)thioxanthene
DM0JE6N CP Norvatis Phamaceuticals Corporation
DM0JE6N TC Antiparkinson Agents
DM0JE6N DT Small molecular drug
DM0JE6N PC 4167
DM0JE6N MW 309.5
DM0JE6N FM C20H23NS
DM0JE6N IC InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
DM0JE6N CS CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24
DM0JE6N IK MJFJKKXQDNNUJF-UHFFFAOYSA-N
DM0JE6N IU 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
DM0JE6N CA CAS 4969-02-2
DM0JE6N CB CHEBI:51024
DM0JE6N DE Parkinson disease
DMFA5MY ID DMFA5MY
DMFA5MY DN Metoclopramide
DMFA5MY HS Approved
DMFA5MY SN Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide
DMFA5MY CP Sanofi-Aventis
DMFA5MY TC Antiemetics
DMFA5MY DT Small molecular drug
DMFA5MY PC 4168
DMFA5MY MW 299.79
DMFA5MY FM C14H22ClN3O2
DMFA5MY IC InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
DMFA5MY CS CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
DMFA5MY IK TTWJBBZEZQICBI-UHFFFAOYSA-N
DMFA5MY IU 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
DMFA5MY CA CAS 364-62-5
DMFA5MY CB CHEBI:107736
DMFA5MY DE Nausea
DMZJYBW ID DMZJYBW
DMZJYBW DN Metocurine Iodide
DMZJYBW HS Approved
DMZJYBW SN Metokuriinijodidi; Metokurinjodid; Metubine; Dimethyl tubocurarine iodide; Dimethylchondrocurarine iodide; Dimethyltubocurarine Iodide; Metocurine diiodide; Metocurine iodide [USAN]; Metocurini Iodidum; Metubine iodide; Mutubine Iodide; Trimethyltubocurarine Iodide; Dimethylether of d-tubocurarine iodide; Dimetiltubocurarinio, ioduro de; Methyl-curarin; Methyl-curarin [German]; Metocurine iodide (USAN); Metubine iodide (TN); O,O'-Dimethylchondrocurarine diiodide; Tubocurarine, O,O'-dimethyl-, diiodide; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, diiodide; (+)-O,O'-Dimethylchondrocurarine Di-iodide; (+)-O,O'-Dimethylchondrocurarine diiodide; 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide; 6,6',7',12'-Tetramethoxy-2,2,2',2'-tetramethyltubocuraranium diiodide
DMZJYBW TC Anesthetics
DMZJYBW DT Small molecular drug
DMZJYBW PC 24244
DMZJYBW MW 906.6
DMZJYBW FM C40H48I2N2O6
DMZJYBW IC InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1
DMZJYBW CS C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-]
DMZJYBW IK DIGFQJFCDPKEPF-OIUSMDOTSA-L
DMZJYBW IU (1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;diiodide
DMZJYBW CA CAS 7601-55-0
DMZJYBW CB CHEBI:6901
DMZJYBW DE Anaesthesia
DMB39LO ID DMB39LO
DMB39LO DN Metolazone
DMB39LO HS Approved
DMB39LO SN Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO TC Antihypertensive Agents
DMB39LO DT Small molecular drug
DMB39LO PC 4170
DMB39LO MW 365.8
DMB39LO FM C16H16ClN3O3S
DMB39LO IC InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
DMB39LO CS CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
DMB39LO IK AQCHWTWZEMGIFD-UHFFFAOYSA-N
DMB39LO IU 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO CA CAS 17560-51-9
DMB39LO CB CHEBI:64354
DMB39LO DE Edema; Hypertension
DMOJ0V6 ID DMOJ0V6
DMOJ0V6 DN Metoprolol
DMOJ0V6 HS Approved
DMOJ0V6 SN Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
DMOJ0V6 CP AstraZeneca
DMOJ0V6 TC Antihypertensive Agents
DMOJ0V6 DT Small molecular drug
DMOJ0V6 PC 4171
DMOJ0V6 MW 267.36
DMOJ0V6 FM C15H25NO3
DMOJ0V6 IC InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
DMOJ0V6 CS CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
DMOJ0V6 IK IUBSYMUCCVWXPE-UHFFFAOYSA-N
DMOJ0V6 IU 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMOJ0V6 CA CAS 51384-51-1
DMOJ0V6 CB CHEBI:6904
DMOJ0V6 DE Hypertension
DM1NOEK ID DM1NOEK
DM1NOEK DN Metreleptin
DM1NOEK HS Approved
DM1NOEK CP Amylin Pharmaceuticals
DM1NOEK SQ Peptide Sequence : MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC
DM1NOEK DE Diabetic complication
DMTIVEN ID DMTIVEN
DMTIVEN DN Metronidazole
DMTIVEN HS Approved
DMTIVEN SN APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ
DMTIVEN CP Pfizer Pharmaceuticals
DMTIVEN TC Antiinfective Agents
DMTIVEN DT Small molecular drug
DMTIVEN PC 4173
DMTIVEN MW 171.15
DMTIVEN FM C6H9N3O3
DMTIVEN IC InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
DMTIVEN CS CC1=NC=C(N1CCO)[N+](=O)[O-]
DMTIVEN IK VAOCPAMSLUNLGC-UHFFFAOYSA-N
DMTIVEN IU 2-(2-methyl-5-nitroimidazol-1-yl)ethanol
DMTIVEN CA CAS 443-48-1
DMTIVEN CB CHEBI:6909
DMTIVEN DE Amoebiasis; Crohn disease; Perianal crohn disease
DMI7FVQ ID DMI7FVQ
DMI7FVQ DN Metyrapone
DMI7FVQ HS Approved
DMI7FVQ SN MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ CP Norvatis Phamaceuticals Corporation
DMI7FVQ TC Antimetabolites
DMI7FVQ DT Small molecular drug
DMI7FVQ PC 4174
DMI7FVQ MW 226.27
DMI7FVQ FM C14H14N2O
DMI7FVQ IC InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
DMI7FVQ CS CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
DMI7FVQ IK FJLBFSROUSIWMA-UHFFFAOYSA-N
DMI7FVQ IU 2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ CA CAS 54-36-4
DMI7FVQ CB CHEBI:44241
DMI7FVQ DE Cushing disease
DMBYCU0 ID DMBYCU0
DMBYCU0 DN Metyrosine
DMBYCU0 HS Approved
DMBYCU0 SN Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine
DMBYCU0 TC Anticancer Agents
DMBYCU0 DT Small molecular drug
DMBYCU0 PC 441350
DMBYCU0 MW 195.21
DMBYCU0 FM C10H13NO3
DMBYCU0 IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
DMBYCU0 CS C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
DMBYCU0 IK NHTGHBARYWONDQ-JTQLQIEISA-N
DMBYCU0 IU (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMBYCU0 CA CAS 672-87-7
DMBYCU0 CB CHEBI:6912
DMBYCU0 DE Pheochromocytoma
DMCTE9R ID DMCTE9R
DMCTE9R DN Mexiletine
DMCTE9R HS Approved
DMCTE9R SN Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
DMCTE9R CP Boehringer Ingelheim
DMCTE9R TC Antiarrhythmic Agents
DMCTE9R DT Small molecular drug
DMCTE9R PC 4178
DMCTE9R MW 179.26
DMCTE9R FM C11H17NO
DMCTE9R IC InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
DMCTE9R CS CC1=C(C(=CC=C1)C)OCC(C)N
DMCTE9R IK VLPIATFUUWWMKC-UHFFFAOYSA-N
DMCTE9R IU 1-(2,6-dimethylphenoxy)propan-2-amine
DMCTE9R CA CAS 31828-71-4
DMCTE9R CB CHEBI:6916
DMCTE9R DE Ventricular tachycardia
DMY5JEP ID DMY5JEP
DMY5JEP DN Mezlocillin
DMY5JEP HS Approved
DMY5JEP SN Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid
DMY5JEP TC Antibiotics
DMY5JEP DT Small molecular drug
DMY5JEP PC 656511
DMY5JEP MW 539.6
DMY5JEP FM C21H25N5O8S2
DMY5JEP IC InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1
DMY5JEP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C
DMY5JEP IK YPBATNHYBCGSSN-VWPFQQQWSA-N
DMY5JEP IU (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMY5JEP CA CAS 51481-65-3
DMY5JEP CB CHEBI:6919
DMY5JEP DE Urinary tract infection
DMVKA4O ID DMVKA4O
DMVKA4O DN Mianserin
DMVKA4O HS Approved
DMVKA4O SN Mianserina; Mianserine; Mianserinum; Mianseryna; Norval; Tolvan; Tolvon; Mianserin Monohydrochloride; Mianseryna [Polish]; Bolvidon (TN); Mianserin (INN); Mianserin [INN:BAN]; Mianserina [INN-Spanish]; Mianserine [INN-French]; Mianserinum [INN-Latin]; Norval (TN); Tolvin (TN); Tolvon (TN); 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
DMVKA4O CP GlaxoSmithKline
DMVKA4O TC Antidepressants
DMVKA4O DT Small molecular drug
DMVKA4O PC 4184
DMVKA4O MW 264.4
DMVKA4O FM C18H20N2
DMVKA4O IC InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
DMVKA4O CS CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
DMVKA4O IK UEQUQVLFIPOEMF-UHFFFAOYSA-N
DMVKA4O IU 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
DMVKA4O CA CAS 24219-97-4
DMVKA4O CB CHEBI:51137
DMVKA4O DE Depression
DM6Y3AN ID DM6Y3AN
DM6Y3AN DN Micafungin
DM6Y3AN HS Approved
DM6Y3AN SN Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM)
DM6Y3AN CP Astellas Pharma
DM6Y3AN TC Antifungal Agents
DM6Y3AN DT Small molecular drug
DM6Y3AN PC 477468
DM6Y3AN MW 1270.3
DM6Y3AN FM C56H71N9O23S
DM6Y3AN IC InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
DM6Y3AN CS CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O
DM6Y3AN IK PIEUQSKUWLMALL-YABMTYFHSA-N
DM6Y3AN IU [5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
DM6Y3AN CA CAS 235114-32-6
DM6Y3AN CB CHEBI:600520
DM6Y3AN DE Candidiasis
DM3O6CY ID DM3O6CY
DM3O6CY DN Micardis telmisartan
DM3O6CY HS Approved
DM3O6CY CP Boehringer-Ingelheim Pharmaceuticals
DM3O6CY DE Hypertension
DMPMYE8 ID DMPMYE8
DMPMYE8 DN Miconazole
DMPMYE8 HS Approved
DMPMYE8 SN Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMPMYE8 CP Janssen Pharmaceutica
DMPMYE8 TC Antifungal Agents
DMPMYE8 DT Small molecular drug
DMPMYE8 PC 4189
DMPMYE8 MW 416.1
DMPMYE8 FM C18H14Cl4N2O
DMPMYE8 IC InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
DMPMYE8 CS C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
DMPMYE8 IK BYBLEWFAAKGYCD-UHFFFAOYSA-N
DMPMYE8 IU 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
DMPMYE8 CA CAS 22916-47-8
DMPMYE8 CB CHEBI:82892
DMPMYE8 DE Fungal infection
DMXOELT ID DMXOELT
DMXOELT DN Midazolam
DMXOELT HS Approved
DMXOELT SN Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
DMXOELT CP Roche Pharmaceuticals
DMXOELT TC Hypnotics and Sedatives
DMXOELT DT Small molecular drug
DMXOELT PC 4192
DMXOELT MW 325.8
DMXOELT FM C18H13ClFN3
DMXOELT IC InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
DMXOELT CS CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F
DMXOELT IK DDLIGBOFAVUZHB-UHFFFAOYSA-N
DMXOELT IU 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
DMXOELT CA CAS 59467-70-8
DMXOELT CB CHEBI:6931
DMXOELT DE Irritability; Epilepsy
DME2PY5 ID DME2PY5
DME2PY5 DN Midodrine
DME2PY5 HS Approved
DME2PY5 SN Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
DME2PY5 CP Shire Canada Inc
DME2PY5 TC Vasoconstrictor Agents
DME2PY5 DT Small molecular drug
DME2PY5 PC 4195
DME2PY5 MW 254.28
DME2PY5 FM C12H18N2O4
DME2PY5 IC InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
DME2PY5 CS COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
DME2PY5 IK PTKSEFOSCHHMPD-UHFFFAOYSA-N
DME2PY5 IU 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
DME2PY5 CA CAS 42794-76-3
DME2PY5 CB CHEBI:6933
DME2PY5 DE Orthostatic hypotension
DMI6E0R ID DMI6E0R
DMI6E0R DN Midostaurin
DMI6E0R HS Approved
DMI6E0R SN PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251
DMI6E0R CP Novartis
DMI6E0R TC Anticancer Agents
DMI6E0R DT Small molecular drug
DMI6E0R PC 9829523
DMI6E0R MW 570.6
DMI6E0R FM C35H30N4O4
DMI6E0R IC InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
DMI6E0R CS C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
DMI6E0R IK BMGQWWVMWDBQGC-IIFHNQTCSA-N
DMI6E0R IU N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
DMI6E0R CA CAS 120685-11-2
DMI6E0R CB CHEBI:63452
DMI6E0R DE Acute myeloid leukaemia; Systemic mastocytosis; Colorectal cancer; Chronic myelomonocytic leukaemia
DMGZQEF ID DMGZQEF
DMGZQEF DN Mifepristone
DMGZQEF HS Approved
DMGZQEF SN Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma
DMGZQEF CP HRA Pharma
DMGZQEF DT Small molecular drug
DMGZQEF PC 55245
DMGZQEF MW 429.6
DMGZQEF FM C29H35NO2
DMGZQEF IC InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
DMGZQEF CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMGZQEF IK VKHAHZOOUSRJNA-GCNJZUOMSA-N
DMGZQEF IU (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMGZQEF CA CAS 84371-65-3
DMGZQEF CB CHEBI:50692
DMGZQEF DE Cushing disease
DMFIQ2H ID DMFIQ2H
DMFIQ2H DN Migalastat
DMFIQ2H HS Approved
DMFIQ2H SN DDIG; D-Galactitol, 1,5-dideoxy-1,5-imino; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-iminogalactitol; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride
DMFIQ2H CP Amicus Therapeutics
DMFIQ2H DT Small molecular drug
DMFIQ2H PC 176077
DMFIQ2H MW 163.17
DMFIQ2H FM C6H13NO4
DMFIQ2H IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1
DMFIQ2H CS C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O
DMFIQ2H IK LXBIFEVIBLOUGU-DPYQTVNSSA-N
DMFIQ2H IU (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMFIQ2H CA CAS 108147-54-2
DMFIQ2H CB CHEBI:135923
DMFIQ2H DE Fabry disease
DMXBQAM ID DMXBQAM
DMXBQAM DN Miglitol
DMXBQAM HS Approved
DMXBQAM SN Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM TC Hypoglycemic Agents
DMXBQAM DT Small molecular drug
DMXBQAM PC 441314
DMXBQAM MW 207.22
DMXBQAM FM C8H17NO5
DMXBQAM IC InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
DMXBQAM CS C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
DMXBQAM IK IBAQFPQHRJAVAV-ULAWRXDQSA-N
DMXBQAM IU (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM CA CAS 72432-03-2
DMXBQAM CB CHEBI:6935
DMXBQAM DE Diabetic complication
DM5J64S ID DM5J64S
DM5J64S DN Miglustat
DM5J64S HS Approved
DM5J64S SN BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol
DM5J64S TC Anti-HIV Agents
DM5J64S DT Small molecular drug
DM5J64S PC 51634
DM5J64S MW 219.28
DM5J64S FM C10H21NO4
DM5J64S IC InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
DM5J64S CS CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
DM5J64S IK UQRORFVVSGFNRO-UTINFBMNSA-N
DM5J64S IU (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
DM5J64S CA CAS 72599-27-0
DM5J64S CB CHEBI:50381
DM5J64S DE Type 1 gaucher disease
DMBFE74 ID DMBFE74
DMBFE74 DN Milnacipran
DMBFE74 HS Approved
DMBFE74 SN Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
DMBFE74 CP Silesia Laboratories
DMBFE74 TC Antidepressants
DMBFE74 DT Small molecular drug
DMBFE74 PC 65833
DMBFE74 MW 246.35
DMBFE74 FM C15H22N2O
DMBFE74 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1
DMBFE74 CS CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2
DMBFE74 IK GJJFMKBJSRMPLA-HIFRSBDPSA-N
DMBFE74 IU (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMBFE74 CA CAS 96847-55-1
DMBFE74 CB CHEBI:94468
DMBFE74 DE Depression
DM8TUPF ID DM8TUPF
DM8TUPF DN Milrinone
DM8TUPF HS Approved
DM8TUPF SN Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF CP Sanofi-Synthelabo Inc
DM8TUPF TC Cardiotonic Agents
DM8TUPF DT Small molecular drug
DM8TUPF PC 4197
DM8TUPF MW 211.22
DM8TUPF FM C12H9N3O
DM8TUPF IC InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
DM8TUPF CS CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
DM8TUPF IK PZRHRDRVRGEVNW-UHFFFAOYSA-N
DM8TUPF IU 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF CA CAS 78415-72-2
DM8TUPF CB CHEBI:50693
DM8TUPF DE Congestive heart failure
DMND304 ID DMND304
DMND304 DN Miltefosine
DMND304 HS Approved
DMND304 SN HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
DMND304 CP Aeterna Zentaris
DMND304 TC Antifungal Agents
DMND304 DT Small molecular drug
DMND304 PC 3599
DMND304 MW 407.6
DMND304 FM C21H46NO4P
DMND304 IC InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
DMND304 CS CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
DMND304 IK PQLXHQMOHUQAKB-UHFFFAOYSA-N
DMND304 IU hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
DMND304 CA CAS 58066-85-6
DMND304 CB CHEBI:75283
DMND304 DE Leishmaniasis; Visceral leishmaniasis
DM0EP7M ID DM0EP7M
DM0EP7M DN Minaprine
DM0EP7M HS Approved
DM0EP7M SN Brantur; Cantor; Minaprina; Minaprinum; Minaprine dihydrochloride; AGR 1240; CB 30038; Cantor (TN); Minaprina [INN-Spanish]; Minaprinum [INN-Latin]; Minaprine (USAN/INN); Minaprine [USAN:BAN:INN]; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M TC Antidepressants
DM0EP7M DT Small molecular drug
DM0EP7M PC 4199
DM0EP7M MW 298.4
DM0EP7M FM C17H22N4O
DM0EP7M IC InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
DM0EP7M CS CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
DM0EP7M IK LDMWSLGGVTVJPG-UHFFFAOYSA-N
DM0EP7M IU 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M CA CAS 25905-77-5
DM0EP7M CB CHEBI:51038
DM0EP7M DE Depression
DMVN5OH ID DMVN5OH
DMVN5OH DN Minocycline
DMVN5OH HS Approved
DMVN5OH SN Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline
DMVN5OH CP Lederle Laboratories
DMVN5OH TC Antibiotics
DMVN5OH DT Small molecular drug
DMVN5OH PC 54675783
DMVN5OH MW 457.5
DMVN5OH FM C23H27N3O7
DMVN5OH IC InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
DMVN5OH CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
DMVN5OH IK FFTVPQUHLQBXQZ-KVUCHLLUSA-N
DMVN5OH IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMVN5OH CA CAS 10118-90-8
DMVN5OH CB CHEBI:50694
DMVN5OH DE Bacterial infection; Rosacea
DM50PMY ID DM50PMY
DM50PMY DN Minodronate
DM50PMY HS Approved
DM50PMY SN Minodronic acid; 180064-38-4; (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; Recalbon; Bonoteo; BPH 261; ONO 5920; YH 529; Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-; UNII-40SGR63TGL; YM 529; 40SGR63TGL; Ono-5920; NSC725590; YH-529; 127657-42-5; NCGC00183829-01; AK119862; Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-; (1-hydroxy-2-{imidazo[1,2-a]pyridin-3-yl}-1-phosphonoethyl)phosphonic acid; minodronic acid
DM50PMY DT Small molecular drug
DM50PMY PC 130956
DM50PMY MW 322.15
DM50PMY FM C9H12N2O7P2
DM50PMY IC InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)
DM50PMY CS C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM50PMY IK VMMKGHQPQIEGSQ-UHFFFAOYSA-N
DM50PMY IU (1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid
DM50PMY CA CAS 180064-38-4
DM50PMY DE Osteoporosis
DMA2Z4F ID DMA2Z4F
DMA2Z4F DN Minoxidil
DMA2Z4F HS Approved
DMA2Z4F SN Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
DMA2Z4F CP Upjohn Corporation
DMA2Z4F TC Antihypertensive Agents
DMA2Z4F DT Small molecular drug
DMA2Z4F PC 4201
DMA2Z4F MW 209.25
DMA2Z4F FM C9H15N5O
DMA2Z4F IC InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
DMA2Z4F CS C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
DMA2Z4F IK ZIMGGGWCDYVHOY-UHFFFAOYSA-N
DMA2Z4F IU 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
DMA2Z4F CA CAS 38304-91-5
DMA2Z4F CB CHEBI:6942
DMA2Z4F DE Hypertension
DMGSRN1 ID DMGSRN1
DMGSRN1 DN Mipomersen
DMGSRN1 HS Approved
DMGSRN1 SN Mipomersen
DMGSRN1 CP Isis Pharmaceuticals
DMGSRN1 TC Antisense
DMGSRN1 DT Antisense drug
DMGSRN1 SQ 5'-GCCUCAGTCTGCTTCGCACC
DMGSRN1 PC 71301230
DMGSRN1 MW 7158
DMGSRN1 FM C230H305N67O122P19S19-19
DMGSRN1 IC InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-131(112(400-141)70-381-422(327,328)442-136-50-146(283-66-108(12)196(302)275-228(283)320)406-118(136)76-387-427(337,338)448-140-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)409-120(140)78-389-428(339,340)446-138-52-148(292-91-250-151-186(240)246-89-248-188(151)292)407-121(138)79-390-430(343,344)450-169-124(413-204(160(169)373-37-27-363-17)286-59-101(5)181(235)260-221(286)313)83-394-435(353,354)455-174-128(417-209(165(174)378-42-32-368-22)291-68-110(14)198(304)277-230(291)322)87-396-434(351,352)453-172-126(415-207(163(172)376-40-30-366-20)289-62-104(8)184(238)263-224(289)316)85-395-433(349,350)452-171-123(412-206(162(171)375-39-29-365-19)288-61-103(7)183(237)262-223(288)315)82-393-432(347,348)449-168-111(69-298)410-211(159(168)372-36-26-362-16)296-95-254-155-192(296)267-215(244)271-201(155)307)439-420(323,324)384-74-117-137(51-147(405-117)284-67-109(13)197(303)276-229(284)321)444-425(333,334)388-77-119-139(53-149(408-119)293-92-252-153-190(293)265-213(242)269-199(153)305)447-426(335,336)386-71-113-132(46-142(401-113)279-56-98(2)178(232)257-218(279)310)440-421(325,326)383-73-115-135(49-145(403-115)282-65-107(11)195(301)274-227(282)319)443-424(331,332)385-75-116-134(48-144(404-116)281-64-106(10)194(300)273-226(281)318)441-423(329,330)382-72-114-133(47-143(402-114)280-57-99(3)179(233)258-219(280)311)445-429(341,342)392-81-129-176(167(380-44-34-370-24)212(419-129)297-96-255-156-193(297)268-216(245)272-202(156)308)457-438(359,360)398-86-127-173(164(377-41-31-367-21)208(416-127)290-63-105(9)185(239)264-225(290)317)454-436(355,356)399-88-130-175(166(379-43-33-369-23)210(418-130)295-94-251-152-187(241)247-90-249-189(152)295)456-437(357,358)397-84-125-170(161(374-38-28-364-18)205(414-125)287-60-102(6)182(236)261-222(287)314)451-431(345,346)391-80-122-157(299)158(371-35-25-361-15)203(411-122)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/p-19/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123-,124-,125+,126-,127+,128-,129-,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,157+,158+,159-,160-,161+,162-,163-,164+,165-,166+,167-,168-,169-,170+,171-,172-,173+,174-,175+,176-,203+,204-,205+,206-,207-,208+,209-,210+,211-,212-/m1/s1
DMGSRN1 CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMGSRN1 IK TZRFSLHOCZEXCC-HIVFKXHNSA-A
DMGSRN1 IU [(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4R,5S)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4S,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-[(2R,3R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]sulfanylphosphinate
DMGSRN1 CA CAS 1000120-98-8
DMGSRN1 DE Familial hypercholesterolemia
DMS1GYT ID DMS1GYT
DMS1GYT DN Mirabegron
DMS1GYT HS Approved
DMS1GYT SN Myrbetriq (TN)
DMS1GYT CP Astellas
DMS1GYT DT Small molecular drug
DMS1GYT PC 9865528
DMS1GYT MW 396.5
DMS1GYT FM C21H24N4O2S
DMS1GYT IC InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
DMS1GYT CS C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
DMS1GYT IK PBAPPPCECJKMCM-IBGZPJMESA-N
DMS1GYT IU 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
DMS1GYT CA CAS 223673-61-8
DMS1GYT CB CHEBI:65349
DMS1GYT DE Overactive bladder
DML53ZJ ID DML53ZJ
DML53ZJ DN Mirtazapine
DML53ZJ HS Approved
DML53ZJ SN Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin
DML53ZJ CP Organon International
DML53ZJ TC Antidepressants
DML53ZJ DT Small molecular drug
DML53ZJ PC 4205
DML53ZJ MW 265.35
DML53ZJ FM C17H19N3
DML53ZJ IC InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
DML53ZJ CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DML53ZJ IK RONZAEMNMFQXRA-UHFFFAOYSA-N
DML53ZJ IU 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DML53ZJ CA CAS 85650-52-8
DML53ZJ CB CHEBI:6950
DML53ZJ DE Depression
DMHVJFK ID DMHVJFK
DMHVJFK DN Misoprostol
DMHVJFK HS Approved
DMHVJFK SN Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
DMHVJFK CP Pfizer Pharmaceuticals
DMHVJFK TC Abortifacient Agents
DMHVJFK DT Small molecular drug
DMHVJFK PC 5282381
DMHVJFK MW 382.5
DMHVJFK FM C22H38O5
DMHVJFK IC InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
DMHVJFK CS CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O
DMHVJFK IK OJLOPKGSLYJEMD-URPKTTJQSA-N
DMHVJFK IU methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
DMHVJFK CA CAS 59122-46-2
DMHVJFK CB CHEBI:94387
DMHVJFK DE Medical abortion
DMP8HEL ID DMP8HEL
DMP8HEL DN Mitiglinide
DMP8HEL HS Approved
DMP8HEL SN Mitiglinide calcium; Mitiglinide calcium hydrate; KAD 1229; S21403; Glufast (TN); Kad-1229; Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; Calcium (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate; (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid; 2-Benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate
DMP8HEL CP Elixir Pharmaceuticals
DMP8HEL TC Hypoglycemic Agents
DMP8HEL DT Small molecular drug
DMP8HEL PC 121891
DMP8HEL MW 315.4
DMP8HEL FM C19H25NO3
DMP8HEL IC InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
DMP8HEL CS C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O
DMP8HEL IK WPGGHFDDFPHPOB-BBWFWOEESA-N
DMP8HEL IU (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid
DMP8HEL CA CAS 145375-43-5
DMP8HEL CB CHEBI:135349
DMP8HEL DE Diabetic complication
DMH0ZJE ID DMH0ZJE
DMH0ZJE DN Mitomycin
DMH0ZJE HS Approved
DMH0ZJE SN Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free
DMH0ZJE TC Anticancer Agents
DMH0ZJE DT Small molecular drug
DMH0ZJE PC 5746
DMH0ZJE MW 334.33
DMH0ZJE FM C15H18N4O5
DMH0ZJE IC InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
DMH0ZJE CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
DMH0ZJE IK NWIBSHFKIJFRCO-WUDYKRTCSA-N
DMH0ZJE IU [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DMH0ZJE CA CAS 50-07-7
DMH0ZJE CB CHEBI:27504
DMH0ZJE DE Breast cancer; Gastrointestinal cancer; Solid tumour/cancer
DM4PF81 ID DM4PF81
DM4PF81 DN Mitomycin A
DM4PF81 HS Approved
DM4PF81 SN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester); [(1ar,8r,8as,8br)-6,8a-dimethoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))-(9CI)
DM4PF81 TC Anticancer Agents
DM4PF81 DT Small molecular drug
DM4PF81 PC 19972
DM4PF81 MW 349.34
DM4PF81 FM C16H19N3O6
DM4PF81 IC InChI=1S/C16H19N3O6/c1-6-11(20)10-9(12(21)13(6)23-2)7(5-25-15(17)22)16(24-3)14-8(18-14)4-19(10)16/h7-8,14,18H,4-5H2,1-3H3,(H2,17,22)/t7-,8+,14+,16-/m1/s1
DM4PF81 CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC
DM4PF81 IK HYFMSAFINFJTFH-NGSRAFSJSA-N
DM4PF81 IU [(4S,6S,7R,8S)-7,11-dimethoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DM4PF81 CA CAS 4055-39-4
DM4PF81 CB CHEBI:85412
DM4PF81 DE Solid tumour/cancer
DMU1GX0 ID DMU1GX0
DMU1GX0 DN Mitotane
DMU1GX0 HS Approved
DMU1GX0 SN Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
DMU1GX0 CP Bristol Myers Squibb
DMU1GX0 TC Anticancer Agents
DMU1GX0 DT Small molecular drug
DMU1GX0 PC 4211
DMU1GX0 MW 320
DMU1GX0 FM C14H10Cl4
DMU1GX0 IC InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
DMU1GX0 CS C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
DMU1GX0 IK JWBOIMRXGHLCPP-UHFFFAOYSA-N
DMU1GX0 IU 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
DMU1GX0 CA CAS 53-19-0
DMU1GX0 CB CHEBI:6954
DMU1GX0 DE Adrenocortical carcinoma
DMM39BF ID DMM39BF
DMM39BF DN Mitoxantrone
DMM39BF HS Approved
DMM39BF SN DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)
DMM39BF CP Serono
DMM39BF TC Analgesics
DMM39BF DT Small molecular drug
DMM39BF PC 4212
DMM39BF MW 444.5
DMM39BF FM C22H28N4O6
DMM39BF IC InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
DMM39BF CS C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
DMM39BF IK KKZJGLLVHKMTCM-UHFFFAOYSA-N
DMM39BF IU 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
DMM39BF CA CAS 65271-80-9
DMM39BF CB CHEBI:50729
DMM39BF DE Solid tumour/cancer; Non-hodgkin lymphoma
DM473VD ID DM473VD
DM473VD DN Mivacurium
DM473VD HS Approved
DM473VD SN Mivacron; Chlorure de mivacurium; Chlorure de mivacurium [French]; Cloruro de mivacurio; Cloruro de mivacurio [Spanish]; MIVACURIUM CHLORIDE; Mivacurii chloridum; Mivacurii chloridum [Latin]; BW B109OU dichloride; BWB109OU; BW-B1090U; BW-B109OU; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; Mivacron (TN); Mivacurium chloride(USAN/INN); Mivacurium chloride [USAN:INN:BAN]; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
DM473VD TC Neuromuscular Nondepolarizing Agents
DM473VD DT Small molecular drug
DM473VD PC 5281042
DM473VD MW 1029.3
DM473VD FM C58H80N2O14+2
DM473VD IC InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
DM473VD CS C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C
DM473VD IK ILVYCEVXHALBSC-OTBYEXOQSA-N
DM473VD IU bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
DM473VD CA CAS 133814-19-4
DM473VD CB CHEBI:6958
DM473VD DE Anaesthesia
DM1FDN8 ID DM1FDN8
DM1FDN8 DN Mizolastine
DM1FDN8 HS Approved
DM1FDN8 SN Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8 TC Antiallergic Agents
DM1FDN8 DT Small molecular drug
DM1FDN8 PC 65906
DM1FDN8 MW 432.5
DM1FDN8 FM C24H25FN6O
DM1FDN8 IC InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
DM1FDN8 CS CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
DM1FDN8 IK PVLJETXTTWAYEW-UHFFFAOYSA-N
DM1FDN8 IU 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8 CA CAS 108612-45-9
DM1FDN8 CB CHEBI:31857
DM1FDN8 DE Allergic rhinitis
DMW6F0S ID DMW6F0S
DMW6F0S DN Mizoribine
DMW6F0S HS Approved
DMW6F0S SN Bredinin; Bredinine; MZR; Mizoribina; Mizoribinum; M 3047; Bredinin (TN); HE-69; HS-0046; Mizoribina [INN-Spanish]; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribine (JAN/INN); Bredinin, HE 69, NSC 289637, MZB, Mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide;4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; 4-carbamoyl-1-b-d-ribofuranosylimidazolium-5-olate; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide
DMW6F0S TC Antimetabolites
DMW6F0S DT Small molecular drug
DMW6F0S PC 104762
DMW6F0S MW 259.22
DMW6F0S FM C9H13N3O6
DMW6F0S IC InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
DMW6F0S CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)N
DMW6F0S IK HZQDCMWJEBCWBR-UUOKFMHZSA-N
DMW6F0S IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide
DMW6F0S CA CAS 50924-49-7
DMW6F0S CB CHEBI:31858
DMW6F0S DE Transplant rejection
DM215WE ID DM215WE
DM215WE DN MK-1439
DM215WE HS Approved
DM215WE SN Doravirine; 1338225-97-0; UNII-913P6LK81M; MK1439; 913P6LK81M; MK 1439
DM215WE CP Merck & Co.
DM215WE DT Small molecular drug
DM215WE PC 58460047
DM215WE MW 425.7
DM215WE FM C17H11ClF3N5O3
DM215WE IC InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
DM215WE CS CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F
DM215WE IK ZIAOVIPSKUPPQW-UHFFFAOYSA-N
DM215WE IU 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile
DM215WE CA CAS 1338225-97-0
DM215WE DE Human immunodeficiency virus infection
DMBYNW0 ID DMBYNW0
DMBYNW0 DN MK-3475
DMBYNW0 HS Approved
DMBYNW0 CP Merck
DMBYNW0 DT Monoclonal antibody
DMBYNW0 DE Melanoma
DMOB58Q ID DMOB58Q
DMOB58Q DN MK-8228
DMOB58Q HS Approved
DMOB58Q SN Letermovir
DMOB58Q CP Merck & Co.
DMOB58Q DT Small molecular drug
DMOB58Q PC 45138674
DMOB58Q MW 572.5
DMOB58Q FM C29H28F4N4O4
DMOB58Q IC InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
DMOB58Q CS COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
DMOB58Q IK FWYSMLBETOMXAG-QHCPKHFHSA-N
DMOB58Q IU 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
DMOB58Q CA CAS 917389-32-3
DMOB58Q DE Cytomegalovirus Disease; Cytomegalovirus infection
DMP2LZ8 ID DMP2LZ8
DMP2LZ8 DN MLN0002
DMP2LZ8 HS Approved
DMP2LZ8 SN Vedolizumab
DMP2LZ8 CP Takeda
DMP2LZ8 SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceDVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMP2LZ8 DE Crohn disease
DMCMETN ID DMCMETN
DMCMETN DN MLN9708
DMCMETN HS Approved
DMCMETN CP Millennium Pharmaceuticals
DMCMETN DT Small molecular drug
DMCMETN PC 49867936
DMCMETN MW 517.1
DMCMETN FM C20H23BCl2N2O9
DMCMETN IC InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1
DMCMETN CS B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
DMCMETN IK YTXSYWAKVMZICI-PVCZSOGJSA-N
DMCMETN IU 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
DMCMETN CA CAS 1201902-80-8
DMCMETN DE Amyloidosis; Multiple myeloma
DMNZWL7 ID DMNZWL7
DMNZWL7 DN Moclobemide
DMNZWL7 HS Approved
DMNZWL7 SN Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
DMNZWL7 CP Hoffmann-La Roche pharmaceutical company
DMNZWL7 TC Antidepressants
DMNZWL7 DT Small molecular drug
DMNZWL7 PC 4235
DMNZWL7 MW 268.74
DMNZWL7 FM C13H17ClN2O2
DMNZWL7 IC InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
DMNZWL7 CS C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
DMNZWL7 IK YHXISWVBGDMDLQ-UHFFFAOYSA-N
DMNZWL7 IU 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
DMNZWL7 CA CAS 71320-77-9
DMNZWL7 CB CHEBI:83531
DMNZWL7 DE Skin imperfections; Depression
DMYILBE ID DMYILBE
DMYILBE DN Modafinil
DMYILBE HS Approved
DMYILBE SN Provigil; Modiodal
DMYILBE CP Cephalon Inc
DMYILBE TC Neurology Agents
DMYILBE DT Small molecular drug
DMYILBE PC 4236
DMYILBE MW 273.4
DMYILBE FM C15H15NO2S
DMYILBE IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)
DMYILBE CS C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
DMYILBE IK YFGHCGITMMYXAQ-UHFFFAOYSA-N
DMYILBE IU 2-benzhydrylsulfinylacetamide
DMYILBE CA CAS 68693-11-8
DMYILBE CB CHEBI:77585
DMYILBE DE Narcolepsy; Brain injury; Bipolar disorder
DM26E4B ID DM26E4B
DM26E4B DN Moexipril
DM26E4B HS Approved
DM26E4B SN Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B CP Ucb Inc
DM26E4B TC Antihypertensive Agents
DM26E4B DT Small molecular drug
DM26E4B PC 91270
DM26E4B MW 498.6
DM26E4B FM C27H34N2O7
DM26E4B IC InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
DM26E4B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC
DM26E4B IK UWWDHYUMIORJTA-HSQYWUDLSA-N
DM26E4B IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B CA CAS 103775-10-6
DM26E4B CB CHEBI:6960
DM26E4B DE Hypertension
DMISH0Z ID DMISH0Z
DMISH0Z DN Mogamulizumab
DMISH0Z HS Approved
DMISH0Z CP Kyowa Hakko Kirin
DMISH0Z DT Monoclonal antibody
DMISH0Z DE Cutaneous T-cell lymphoma; Solid tumour/cancer; T-cell leukaemia; Sezary syndrome; Mycosis fungoides
DMAH70G ID DMAH70G
DMAH70G DN Molindone
DMAH70G HS Approved
DMAH70G SN Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
DMAH70G TC Antipsychotic Agents
DMAH70G DT Small molecular drug
DMAH70G PC 23897
DMAH70G MW 276.37
DMAH70G FM C16H24N2O2
DMAH70G IC InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
DMAH70G CS CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
DMAH70G IK KLPWJLBORRMFGK-UHFFFAOYSA-N
DMAH70G IU 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
DMAH70G CA CAS 7416-34-4
DMAH70G CB CHEBI:6965
DMAH70G DE Schizophrenia
DM9MA8O ID DM9MA8O
DM9MA8O DN Molsidomine
DM9MA8O HS Approved
DM9MA8O SN molsidomine; morsydomine; Corvaton; 25717-80-0; Molsidolat; Motazomin; SIN-10; Sydnopharm; Morial; N-Ethoxycarbonyl-3-morpholinosydnonimine; Molsidominum [INN-Latin]; Molsidomina [INN-Spanish]; Molsidomin; MLS000028573; UNII-D46583G77X; CAS 276; EINECS 247-207-4; BRN 3999414; SMR000058990; Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-; N-Carboxy-3-morpholinosydnonimine ethyl ester; N-Carboxy-3-morpholinosydnone imine ethyl ester; N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine; Corvasal; Coruno; Sydnone imine, N-carboxy-3-m
DM9MA8O DT Small molecular drug
DM9MA8O PC 5353788
DM9MA8O MW 242.23
DM9MA8O FM C9H14N4O4
DM9MA8O IC InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
DM9MA8O CS CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-]
DM9MA8O IK XLFWDASMENKTKL-UHFFFAOYSA-N
DM9MA8O IU (1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
DM9MA8O CA CAS 25717-80-0
DM9MA8O CB CHEBI:92623
DM9MA8O DE Angina pectoris
DM45OJN ID DM45OJN
DM45OJN DN Mometasone
DM45OJN HS Approved
DM45OJN SN Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
DM45OJN CP Schering-Plough
DM45OJN TC Antiinflammatory Agents
DM45OJN DT Small molecular drug
DM45OJN PC 441335
DM45OJN MW 427.4
DM45OJN FM C22H28Cl2O4
DM45OJN IC InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DM45OJN CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C
DM45OJN IK QLIIKPVHVRXHRI-CXSFZGCWSA-N
DM45OJN IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM45OJN CA CAS 105102-22-5
DM45OJN CB CHEBI:6970
DM45OJN DE Skin allergy
DMVJS2K ID DMVJS2K
DMVJS2K DN Monobenzone
DMVJS2K HS Approved
DMVJS2K SN Agerite; Alba; Benoquin; Benzoquin; Carmifal; Depigman; Dermochinona; Leucodinine; Monobenzon; Monobenzona; Monobenzonum; PBP; Pigmex; Superlite; Agerite alba; Benzyl hydroquinone; Hydrochinon monobenzylether; Hydrochinon monobenzylether [Czech]; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; ICN brand of monobenzone; Monobenzone [INN]; Monobenzyl Ether of Hydroquinone; Monobenzyl ether hydroquinone; Monobenzyl hydroquinone; Alba-Dome; Benoquin (TN); Benoquin, Monobenzone; Benzyl p-hydroxyphenyl ether; Carmifal(TN); Depigman (TN); Dermochinona (TN); HYDROQUINONE MONOBENZYL ETHER, N F; Leucodinine (TN); Monobenzon (TN); Monobenzona [INN-Spanish]; Monobenzonum [INN-Latin]; Novo-depigman; P-BENZYLOXYPHENOL; P-Hydroxyphenyl benzyl ether; Pigmex (TN); Superlite (TN); Superlite (antioxidant); Monobenzone (USP/INN); P-(BENZYLOXY)PHENOL; 4-(Benzyl-Oxy)Phenol; 4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxyphenol; 4-benzyloxy phenol; 4-phenylmethoxy-phenol; 4-phenylmethoxyphenol
DMVJS2K TC Dermatologic Agents
DMVJS2K DT Small molecular drug
DMVJS2K PC 7638
DMVJS2K MW 200.23
DMVJS2K FM C13H12O2
DMVJS2K IC InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2
DMVJS2K CS C1=CC=C(C=C1)COC2=CC=C(C=C2)O
DMVJS2K IK VYQNWZOUAUKGHI-UHFFFAOYSA-N
DMVJS2K IU 4-phenylmethoxyphenol
DMVJS2K CA CAS 103-16-2
DMVJS2K CB CHEBI:34380
DMVJS2K DE Vitiligo
DMD157S ID DMD157S
DMD157S DN Montelukast
DMD157S HS Approved
DMD157S SN Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S CP Schering-Plough Corporation
DMD157S TC Antiasthmatic Agents
DMD157S DT Small molecular drug
DMD157S PC 5281040
DMD157S MW 586.2
DMD157S FM C35H36ClNO3S
DMD157S IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMD157S CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMD157S IK UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMD157S IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S CA CAS 158966-92-8
DMD157S CB CHEBI:50730
DMD157S DE Asthma
DM560Y3 ID DM560Y3
DM560Y3 DN Morantel tartrate
DM560Y3 HS Approved
DM560Y3 SN Paratect; Banminth II; MORANTEL TARTRATE SALT; Morantel tartrate [USAN]; Morantel tartrate hydrate; CP 12009-18; Morantel tartrate (USP); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; 2,3-dihydroxybutanedioic acid
DM560Y3 TC Anthelmintics
DM560Y3 DT Small molecular drug
DM560Y3 PC 6433951
DM560Y3 MW 370.4
DM560Y3 FM C16H22N2O6S
DM560Y3 IC InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1
DM560Y3 CS CC1=C(SC=C1)/C=C/C2=NCCCN2C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM560Y3 IK GGXQONWGCAQGNA-UUSVNAAPSA-N
DM560Y3 IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine
DM560Y3 CA CAS 26155-31-7
DM560Y3 DE Mature gastrointestinal nematode infection
DMOMBJW ID DMOMBJW
DMOMBJW DN Moricizine
DMOMBJW HS Approved
DMOMBJW SN Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester
DMOMBJW CP Shire Development Inc
DMOMBJW TC Antiarrhythmic Agents
DMOMBJW DT Small molecular drug
DMOMBJW PC 34633
DMOMBJW MW 427.5
DMOMBJW FM C22H25N3O4S
DMOMBJW IC InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)
DMOMBJW CS CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4
DMOMBJW IK FUBVWMNBEHXPSU-UHFFFAOYSA-N
DMOMBJW IU ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate
DMOMBJW CA CAS 31883-05-3
DMOMBJW CB CHEBI:6997
DMOMBJW DE Arrhythmia; Heart arrhythmia
DM9UTDE ID DM9UTDE
DM9UTDE DN Morniflumate
DM9UTDE HS Approved
DM9UTDE SN morniflumate; 65847-85-0; UNII-R133MWH7X1; 2-Morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate; R133MWH7X1; Morniflumatum; Morniflumato; 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate; Morniflumate [USAN:INN]; Morniflumatum [INN-Latin]; Morniflumato [INN-Spanish]; Nifluminsaeure 2-morpholinoethylester; UP 164; Morniflumate (USAN); Niflumic acid beta-morpholinoethyl ester; AC1Q4JLB; AC1L2HFJ; DSSTox_RID_97471; DSSTox_CID_31587; DSSTox_GSID_57798; SCHEMBL50683; CHEMBL2105059; DTXSID6057798
DM9UTDE DT Small molecular drug
DM9UTDE PC 72106
DM9UTDE MW 395.4
DM9UTDE FM C19H20F3N3O3
DM9UTDE IC InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
DM9UTDE CS C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F
DM9UTDE IK LDXSPUSKBDTEKA-UHFFFAOYSA-N
DM9UTDE IU 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
DM9UTDE CA CAS 65847-85-0
DM9UTDE CB CHEBI:136018
DM9UTDE DE Otitis media
DMRMS0L ID DMRMS0L
DMRMS0L DN Morphine
DMRMS0L HS Approved
DMRMS0L SN Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr
DMRMS0L CP Eurohealth International Sarl
DMRMS0L TC Analgesics
DMRMS0L DT Small molecular drug
DMRMS0L PC 5288826
DMRMS0L MW 285.34
DMRMS0L FM C17H19NO3
DMRMS0L IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
DMRMS0L CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
DMRMS0L IK BQJCRHHNABKAKU-KBQPJGBKSA-N
DMRMS0L IU (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DMRMS0L CA CAS 57-27-2
DMRMS0L CB CHEBI:17303
DMRMS0L DE Chronic pain
DMEJKRF ID DMEJKRF
DMEJKRF DN Motexafin gadolinium
DMEJKRF HS Approved
DMEJKRF SN Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)
DMEJKRF CP Pharmacyclics, Inc
DMEJKRF TC Anticancer Agents
DMEJKRF DT Small molecular drug
DMEJKRF PC 158385
DMEJKRF MW 1148.4
DMEJKRF FM C52H72GdN5O14
DMEJKRF IC InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2
DMEJKRF CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]
DMEJKRF IK VAZLWPAHMORDGR-UHFFFAOYSA-L
DMEJKRF IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;gadolinium(3+);diacetate
DMEJKRF CA CAS 246252-06-2
DMEJKRF DE Brain cancer; Human immunodeficiency virus infection
DMYKUNR ID DMYKUNR
DMYKUNR DN Moxalactam Disodium
DMYKUNR HS Approved
DMYKUNR SN Moxam; Shiomarin
DMYKUNR CP Eli Lilly And Co
DMYKUNR TC Antiinfective Agents
DMYKUNR DT Small molecular drug
DMYKUNR PC 441242
DMYKUNR MW 564.4
DMYKUNR FM C20H18N6Na2O9S
DMYKUNR IC InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1
DMYKUNR CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+]
DMYKUNR IK GRIXGZQULWMCLU-HUTAOCTPSA-L
DMYKUNR IU disodium;(6R,7R)-7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMYKUNR CA CAS 64953-12-4
DMYKUNR DE Bacterial infection
DMN63DZ ID DMN63DZ
DMN63DZ DN Moxetumomab pasudotox
DMN63DZ HS Approved
DMN63DZ SN CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)
DMN63DZ CP AstraZeneca
DMN63DZ TC Anticancer Agents
DMN63DZ DT Monoclonal antibody
DMN63DZ SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMN63DZ DE Haematological malignancy; Hairy cell leukaemia
DMYGHX5 ID DMYGHX5
DMYGHX5 DN Moxidectin
DMYGHX5 HS Approved
DMYGHX5 SN Moxidectin; ProHeart 6; UNII-NGU5H31YO9; Cydectin; NGU5H31YO9; Moxidectine [INN-French]; Moxidectinum [INN-Latin]; Moxidectina [INN-Spanish]; C37H53NO8; Moxidectina; Moxidectine; Moxidectinum; Moxidectin [USAN:INN:BAN]
DMYGHX5 CP Medicines Development for Global Health
DMYGHX5 PC 9832912
DMYGHX5 MW 639.8
DMYGHX5 FM C37H53NO8
DMYGHX5 IC InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
DMYGHX5 CS C[C@@H]\\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C
DMYGHX5 IK YZBLFMPOMVTDJY-LSGXYNIPSA-N
DMYGHX5 IU (1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMYGHX5 CA CAS 113507-06-5
DMYGHX5 DE River blindness; Onchocerciasis
DMU8V4S ID DMU8V4S
DMU8V4S DN Moxifloxacin
DMU8V4S HS Approved
DMU8V4S SN Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S CP Bayer AG
DMU8V4S TC Antibiotics
DMU8V4S DT Small molecular drug
DMU8V4S PC 152946
DMU8V4S MW 401.4
DMU8V4S FM C21H24FN3O4
DMU8V4S IC InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
DMU8V4S CS COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
DMU8V4S IK FABPRXSRWADJSP-MEDUHNTESA-N
DMU8V4S IU 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S CA CAS 151096-09-2
DMU8V4S CB CHEBI:63611
DMU8V4S DE Bacterial infection
DMFCLYW ID DMFCLYW
DMFCLYW DN Moxisylyte
DMFCLYW HS Approved
DMFCLYW SN Thymoxamine
DMFCLYW DT Small molecular drug
DMFCLYW PC 4260
DMFCLYW MW 279.37
DMFCLYW FM C16H25NO3
DMFCLYW IC InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
DMFCLYW CS CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C
DMFCLYW IK VRYMTAVOXVTQEF-UHFFFAOYSA-N
DMFCLYW IU [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate
DMFCLYW CA CAS 54-32-0
DMFCLYW CB CHEBI:94754
DMFCLYW DE Erectile dysfunction
DMGFB0E ID DMGFB0E
DMGFB0E DN MOXONIDINE
DMGFB0E HS Approved
DMGFB0E SN BDF-5895; BE-5895; Normoxin; AC1OCENE; SCHEMBL1230620; Moxonidine hydrochloride hydrate; moxonidine hydrochloride monohydrate; LY-326869; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine hydrate hydrochloride
DMGFB0E DT Small molecular drug
DMGFB0E PC 4810
DMGFB0E MW 241.68
DMGFB0E FM C9H12ClN5O
DMGFB0E IC InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
DMGFB0E CS CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
DMGFB0E IK WPNJAUFVNXKLIM-UHFFFAOYSA-N
DMGFB0E IU 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
DMGFB0E CA CAS 75438-57-2
DMGFB0E CB CHEBI:7009
DMGFB0E DE Alcohol dependence
DMZ905C ID DMZ905C
DMZ905C DN Mozavaptan
DMZ905C HS Approved
DMZ905C SN 137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260
DMZ905C DT Small molecular drug
DMZ905C PC 119369
DMZ905C MW 427.5
DMZ905C FM C27H29N3O2
DMZ905C IC InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
DMZ905C CS CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
DMZ905C IK WRNXUQJJCIZICJ-UHFFFAOYSA-N
DMZ905C IU N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide
DMZ905C CA CAS 137975-06-5
DMZ905C CB CHEBI:135694
DMZ905C DE Hyponatraemia
DMWX683 ID DMWX683
DMWX683 DN Mupirocin
DMWX683 HS Approved
DMWX683 SN Bactoderm; Bactroban; Centany; MRC; Mupirocina; Mupirocine; Mupirocinum; Plasimine; Bactroban Nasal; Mupirocina [Spanish]; Mupirocine [French]; Mupirocinum [Latin]; Pseudomonic acid; Pseudomonic acid A; BRL 4910A; BRL-4910A; Bactroban (TN); Centany (TN); Mupirocin (USP/INN); Mupirocin, 14C-Labeled; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S); 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683 CP GlaxoSmithKline
DMWX683 TC Antibiotics
DMWX683 DT Small molecular drug
DMWX683 PC 446596
DMWX683 MW 500.6
DMWX683 FM C26H44O9
DMWX683 IC InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
DMWX683 CS C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
DMWX683 IK MINDHVHHQZYEEK-HBBNESRFSA-N
DMWX683 IU 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683 CA CAS 12650-69-0
DMWX683 CB CHEBI:7025
DMWX683 DE Bacterial infection
DM8ANCF ID DM8ANCF
DM8ANCF DN Muromonab
DM8ANCF HS Approved
DM8ANCF TC Immunomodulatory Agents
DM8ANCF SQ Muromonab-CD3 light chain: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >Muromonab-CD3 heavy chainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSAKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DM8ANCF DE Organ transplant rejection
DMPQAGE ID DMPQAGE
DMPQAGE DN Mycophenolate mofetil
DMPQAGE HS Approved
DMPQAGE SN mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
DMPQAGE CP Roche
DMPQAGE TC Immunosuppressive Agents
DMPQAGE DT Small molecular drug
DMPQAGE PC 5281078
DMPQAGE MW 433.5
DMPQAGE FM C23H31NO7
DMPQAGE IC InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
DMPQAGE CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O
DMPQAGE IK RTGDFNSFWBGLEC-SYZQJQIISA-N
DMPQAGE IU 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
DMPQAGE CA CAS 128794-94-5
DMPQAGE CB CHEBI:8764
DMPQAGE DE Organ transplant rejection; Immune System disease; Pemphigus vulgaris
DMRBMAU ID DMRBMAU
DMRBMAU DN Mycophenolic acid
DMRBMAU HS Approved
DMRBMAU SN Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T
DMRBMAU PC 446541
DMRBMAU MW 320.3
DMRBMAU FM C17H20O6
DMRBMAU IC HPNSFSBZBAHARI-RUDMXATFSA-N
DMRBMAU CS CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
DMRBMAU IK 1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMRBMAU IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMRBMAU CA CAS 483-60-3
DMRBMAU CB CHEBI:168396
DMRBMAU DE Crohn disease
DMYTN18 ID DMYTN18
DMYTN18 DN Mycophenolic acid
DMYTN18 HS Approved
DMYTN18 SN (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T; mycophenolic acid
DMYTN18 DT Small molecular drug
DMYTN18 PC 446541
DMYTN18 MW 320.341
DMYTN18 FM C17H20O6
DMYTN18 IC InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMYTN18 CS CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC
DMYTN18 IK HPNSFSBZBAHARI-RUDMXATFSA-N
DMYTN18 IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMYTN18 CA CAS 483-60-3
DMYTN18 CB CHEBI:168396
DMYTN18 DE Organ transplant rejection
DMSOAJ2 ID DMSOAJ2
DMSOAJ2 DN N-0923
DMSOAJ2 HS Approved
DMSOAJ2 SN ent-Rotigotine; 92206-54-7; N-0437; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 112835-48-0; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PubChem16422; AC1Q7ALS; rotigotine transdermal patch; AC1L1N7C; SCHEMBL50425; CHEMBL104383; CTK8E7910
DMSOAJ2 CP National Cancer Institute (NCI)
DMSOAJ2 DT Small molecular drug
DMSOAJ2 PC 57537
DMSOAJ2 MW 315.5
DMSOAJ2 FM C19H25NOS
DMSOAJ2 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3
DMSOAJ2 CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMSOAJ2 IK KFQYTPMOWPVWEJ-UHFFFAOYSA-N
DMSOAJ2 IU 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMSOAJ2 CA CAS 92206-54-7
DMSOAJ2 DE Parkinson disease
DMHJVOL ID DMHJVOL
DMHJVOL DN Nabi-HB
DMHJVOL HS Approved
DMHJVOL SN Reformulated HBV therapy, Nabi; Hepatitis B virus immune globulin (intramuscular), Nabi; H-BIG 5%iv formulation, Nabi
DMHJVOL CP Nabi Biologics
DMHJVOL DE Hepatitis B virus infection
DMVRYT2 ID DMVRYT2
DMVRYT2 DN Nabilone
DMVRYT2 HS Approved
DMVRYT2 SN Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-
DMVRYT2 DT Small molecular drug
DMVRYT2 PC 5284592
DMVRYT2 MW 372.5
DMVRYT2 FM C24H36O3
DMVRYT2 IC InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
DMVRYT2 CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=O)CC[C@H]3C(OC2=C1)(C)C)O
DMVRYT2 IK GECBBEABIDMGGL-RTBURBONSA-N
DMVRYT2 IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
DMVRYT2 CA CAS 51022-71-0
DMVRYT2 DE Insomnia
DMAT2XH ID DMAT2XH
DMAT2XH DN Nabumetone
DMAT2XH HS Approved
DMAT2XH SN NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex
DMAT2XH CP Nobex Corp
DMAT2XH DT Small molecular drug
DMAT2XH PC 4409
DMAT2XH MW 228.29
DMAT2XH FM C15H16O2
DMAT2XH IC InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
DMAT2XH CS CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
DMAT2XH IK BLXXJMDCKKHMKV-UHFFFAOYSA-N
DMAT2XH IU 4-(6-methoxynaphthalen-2-yl)butan-2-one
DMAT2XH CA CAS 42924-53-8
DMAT2XH CB CHEBI:7443
DMAT2XH DE Pain
DM1XBWR ID DM1XBWR
DM1XBWR DN N-acetyl-D-glucosamine
DM1XBWR HS Approved
DM1XBWR SN Aflexa; GlcNAc; NAcGlc; NDG; Crab Shell Chitin; Glucosamine Complex; Maxi GS; Natures Blend Glucosamine; Pharmaceutical aid; JFD00446; SB01966; GS-500; N-Acetylchitosamine; N-Acetylchondrosamine; N-Acetylgalactosamine; N-Acetylhexosamine; Glucosamine, N-acetyl; N-Acetyl-D-Allosamine; N-Acetyl-D-galactosamine; N-Acetyl-D-hexosamine; N-acetyl-D-mannosamine; N-Acetyl-D-glucosamine-Agarose; N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosaminides; N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-(Acetylamino)-2-deoxyhexopyranose; 2-ACETAMIDO-2-DEOXY-D-ALLOSE; 2-Acetamido-2-deoxy-D-glucose; 2-Acetamido-2-deoxyglucose; 2-Acetamido-D-glucose; 2-acetamido-2-deoxy-D-glucopyranose; 2-acetamido-2-deoxyhexopyranose; 6-Acetamido-6-deoxy-.alpha.-D-glucopyranose; 6-Acetamido-6-deoxy-acpha-D-glucopyranose
DM1XBWR TC Antiinflammatory Agents
DM1XBWR DT Small molecular drug
DM1XBWR PC 439174
DM1XBWR MW 221.21
DM1XBWR FM C8H15NO6
DM1XBWR IC InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8?/m1/s1
DM1XBWR CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O
DM1XBWR IK OVRNDRQMDRJTHS-RTRLPJTCSA-N
DM1XBWR IU N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DM1XBWR CA CAS 72-87-7
DM1XBWR CB CHEBI:506227
DM1XBWR DE Autoimmune diabetes
DM5NM6E ID DM5NM6E
DM5NM6E DN NADH
DM5NM6E HS Approved
DM5NM6E SN DPNH; Dihydrodiphosphopyridine nucleotide; Dihydronicotinamide adenine dinucleotide; Diphosphopyridine nucleotide reduced; NADH dianion; Nicotinamide adenine dinucleotide reduced; Reduced Nicotinamide Adenine Dinucleotide; NADH2; Beta-DPNH; Beta-NADH; Coenzyme I, reduced; Cozymase I, reduced; Diphosphopyridine nucleotide,reduced form; NAD-reduced; Nicotinamide adenine dinucleotide, reduced form; Reduced nicotinamide-adenine dinucleotide; Beta-Nicotinamide adenine dinucleotide, reduced dipotassium salt; NADH+H+; Nicotinaminde-Adenine-Dinucleotide; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}; Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] diphosphate}; [5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid
DM5NM6E TC Dietary supplement
DM5NM6E DT Small molecular drug
DM5NM6E PC 439153
DM5NM6E MW 665.4
DM5NM6E FM C21H29N7O14P2
DM5NM6E IC InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM5NM6E CS C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DM5NM6E IK BOPGDPNILDQYTO-NNYOXOHSSA-N
DM5NM6E IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM5NM6E CA CAS 58-68-4
DM5NM6E CB CHEBI:16908
DM5NM6E DE Parkinson disease
DMW6GVL ID DMW6GVL
DMW6GVL DN Nadolol
DMW6GVL HS Approved
DMW6GVL SN Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
DMW6GVL CP Apotex Inc
DMW6GVL TC Antihypertensive Agents
DMW6GVL DT Small molecular drug
DMW6GVL PC 39147
DMW6GVL MW 309.4
DMW6GVL FM C17H27NO4
DMW6GVL IC InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
DMW6GVL CS CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O
DMW6GVL IK VWPOSFSPZNDTMJ-UCWKZMIHSA-N
DMW6GVL IU (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
DMW6GVL CA CAS 220045-89-6
DMW6GVL DE High blood pressure
DMBNKST ID DMBNKST
DMBNKST DN Nadroparin calcium
DMBNKST HS Approved
DMBNKST SN Fraxiparine (TN)
DMBNKST DE Coagulation defect
DMU1XOD ID DMU1XOD
DMU1XOD DN Nafamostat
DMU1XOD HS Approved
DMU1XOD SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DMU1XOD DT Small molecular drug
DMU1XOD PC 4413
DMU1XOD MW 347.4
DMU1XOD FM C19H17N5O2
DMU1XOD IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DMU1XOD CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DMU1XOD IK MQQNFDZXWVTQEH-UHFFFAOYSA-N
DMU1XOD IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DMU1XOD CA CAS 81525-10-2
DMU1XOD CB CHEBI:135466
DMU1XOD DE Pancreatitis; Sepsis
DMAHEFY ID DMAHEFY
DMAHEFY DN Nafarelin
DMAHEFY HS Approved
DMAHEFY SN Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)
DMAHEFY CP Pfizer Pharmaceuticals
DMAHEFY TC Fertility Agents
DMAHEFY DT Small molecular drug
DMAHEFY PC 25077405
DMAHEFY MW 1322.5
DMAHEFY FM C66H83N17O13
DMAHEFY IC InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1
DMAHEFY CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMAHEFY IK RWHUEXWOYVBUCI-ITQXDASVSA-N
DMAHEFY IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAHEFY CA CAS 76932-56-4
DMAHEFY DE Endometriosis
DMN9RPO ID DMN9RPO
DMN9RPO DN Nafcillin
DMN9RPO HS Approved
DMN9RPO SN Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMN9RPO TC Antibiotics
DMN9RPO DT Small molecular drug
DMN9RPO PC 8982
DMN9RPO MW 414.5
DMN9RPO FM C21H22N2O5S
DMN9RPO IC InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
DMN9RPO CS CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMN9RPO IK GPXLMGHLHQJAGZ-JTDSTZFVSA-N
DMN9RPO IU (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMN9RPO CA CAS 147-52-4
DMN9RPO CB CHEBI:7447
DMN9RPO DE Arthritis
DMVMQ1L ID DMVMQ1L
DMVMQ1L DN Nafronyl
DMVMQ1L HS Approved
DMVMQ1L SN Nafronyl oxalate; 3200-06-4; Naftidrofuryl oxalate; Nafronyl oxalate salt; 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-((tetrahydrofuran-2-yl)methyl)propanoate oxalate; Naftidrofuryl (oxalate); Dusodril; Dubimax; Praxilene; Iridus; LS-121; EU-1806; DSSTox_RID_80935; DSSTox_CID_25533; DSSTox_GSID_45533; naftidrofuryl hydrogen oxalate; CHEMBL1439099; alpha-[1-Naphthylmethyl]-2-tetrahydrofuranpropionic acid diethylaminoethyl ester; SMR000539007; Nafronyl oxalate salt, analytical standard; CAS-3200-06-4; NSC225233; LS 121
DMVMQ1L DT Small molecular drug
DMVMQ1L PC 4417
DMVMQ1L MW 383.5
DMVMQ1L FM C24H33NO3
DMVMQ1L IC InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
DMVMQ1L CS CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32
DMVMQ1L IK KBAFPSLPKGSANY-UHFFFAOYSA-N
DMVMQ1L IU 2-(diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate
DMVMQ1L CA CAS 31329-57-4
DMVMQ1L CB CHEBI:91817
DMVMQ1L DE Cerebrovascular ischaemia
DMHVBG1 ID DMHVBG1
DMHVBG1 DN Naftifine
DMHVBG1 HS Approved
DMHVBG1 SN Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1 CP Merz Pharmaceuticals Llc
DMHVBG1 TC Antifungal Agents
DMHVBG1 DT Small molecular drug
DMHVBG1 PC 47641
DMHVBG1 MW 287.4
DMHVBG1 FM C21H21N
DMHVBG1 IC InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+
DMHVBG1 CS CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32
DMHVBG1 IK OZGNYLLQHRPOBR-DHZHZOJOSA-N
DMHVBG1 IU (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1 CA CAS 65472-88-0
DMHVBG1 CB CHEBI:7451
DMHVBG1 DE Dermatomycosis
DMQ8R4E ID DMQ8R4E
DMQ8R4E DN Naftopidil
DMQ8R4E HS Approved
DMQ8R4E SN naftopidil; 57149-07-2; Flivas; KT-611; Naftopidil [INN]; Avishot; Naftopidilum [Latin]; Naftopidil (Flivas); BM-15275; Naftopidil (unspecified); BRN 0629965; CHEMBL142635; C24H28N2O3; 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol; NCGC00015718-06; (+-)-1-(4-(2-Methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol; 4-(2-Methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol; (RS)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol; DSSTox_RID_80725; DSSTox_CID_25176
DMQ8R4E DT Small molecular drug
DMQ8R4E PC 4418
DMQ8R4E MW 392.5
DMQ8R4E FM C24H28N2O3
DMQ8R4E IC InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
DMQ8R4E CS COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O
DMQ8R4E IK HRRBJVNMSRJFHQ-UHFFFAOYSA-N
DMQ8R4E IU 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol
DMQ8R4E CA CAS 57149-07-2
DMQ8R4E CB CHEBI:31891
DMQ8R4E DE Hypertension
DMOSQGU ID DMOSQGU
DMOSQGU DN Nalbuphine
DMOSQGU HS Approved
DMOSQGU SN Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
DMOSQGU CP Endo Pharmaceuticals
DMOSQGU TC Analgesics
DMOSQGU DT Small molecular drug
DMOSQGU PC 5311304
DMOSQGU MW 357.4
DMOSQGU FM C21H27NO4
DMOSQGU IC InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
DMOSQGU CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O
DMOSQGU IK NETZHAKZCGBWSS-CEDHKZHLSA-N
DMOSQGU IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMOSQGU CA CAS 20594-83-6
DMOSQGU CB CHEBI:7454
DMOSQGU DE Prurigo nodularis; Uremic pruritus; Pain
DMGD3YH ID DMGD3YH
DMGD3YH DN Naldemedine Tosylate
DMGD3YH HS Approved
DMGD3YH CP Shionogi
DMGD3YH DT Small molecular drug
DMGD3YH PC 56837137
DMGD3YH MW 742.8
DMGD3YH FM C39H42N4O9S
DMGD3YH IC InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1
DMGD3YH CS CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
DMGD3YH IK WCYDLROFMZJJLE-RTMHEQJQSA-N
DMGD3YH IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide;4-methylbenzenesulfonic acid
DMGD3YH CA CAS 1345728-04-2
DMGD3YH DE Opioid-induced constipation
DMA9DHW ID DMA9DHW
DMA9DHW DN Nalfurafine hcl
DMA9DHW HS Approved
DMA9DHW SN Nalfurafine hydrochloride; Nalfurafine HCl; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN)
DMA9DHW DT Small molecular drug
DMA9DHW PC 6918287
DMA9DHW MW 513
DMA9DHW FM C28H33ClN2O5
DMA9DHW IC InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1
DMA9DHW CS CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7.Cl
DMA9DHW IK DJSFYNINGIMKAG-FQJQBBMWSA-N
DMA9DHW IU (E)-N-[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]-3-(furan-3-yl)-N-methylprop-2-enamide;hydrochloride
DMA9DHW CA CAS 152658-17-8
DMA9DHW DE Uremic pruritus
DMRM0JV ID DMRM0JV
DMRM0JV DN Nalidixic acid
DMRM0JV HS Approved
DMRM0JV SN Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
DMRM0JV TC Antibiotics
DMRM0JV DT Small molecular drug
DMRM0JV PC 4421
DMRM0JV MW 232.23
DMRM0JV FM C12H12N2O3
DMRM0JV IC InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
DMRM0JV CS CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
DMRM0JV IK MHWLWQUZZRMNGJ-UHFFFAOYSA-N
DMRM0JV IU 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMRM0JV CA CAS 389-08-2
DMRM0JV CB CHEBI:100147
DMRM0JV DE Urinary tract infection
DM4YWCZ ID DM4YWCZ
DM4YWCZ DN Nalmefene
DM4YWCZ HS Approved
DM4YWCZ SN Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
DM4YWCZ CP Eurohealth International Sarl
DM4YWCZ TC Anticraving Agents
DM4YWCZ DT Small molecular drug
DM4YWCZ PC 5284594
DM4YWCZ MW 339.4
DM4YWCZ FM C21H25NO3
DM4YWCZ IC InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
DM4YWCZ CS C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
DM4YWCZ IK WJBLNOPPDWQMCH-MBPVOVBZSA-N
DM4YWCZ IU (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DM4YWCZ CA CAS 55096-26-9
DM4YWCZ CB CHEBI:7457
DM4YWCZ DE Opioid dependence
DML0B41 ID DML0B41
DML0B41 DN Naloxegol
DML0B41 HS Approved
DML0B41 SN NKTR-118
DML0B41 CP AstraZeneca
DML0B41 DT Small molecular drug
DML0B41 PC 56959087
DML0B41 MW 651.8
DML0B41 FM C34H53NO11
DML0B41 IC InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1
DML0B41 CS COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O
DML0B41 IK XNKCCCKFOQNXKV-ZRSCBOBOSA-N
DML0B41 IU (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DML0B41 CA CAS 854601-70-0
DML0B41 CB CHEBI:82975
DML0B41 DE Opioid-induced constipation
DM3FXMA ID DM3FXMA
DM3FXMA DN Naloxone
DM3FXMA HS Approved
DM3FXMA SN Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
DM3FXMA CP Bristol Meyers Squibb
DM3FXMA TC Antinarcotic Agents
DM3FXMA DT Small molecular drug
DM3FXMA PC 5284596
DM3FXMA MW 327.4
DM3FXMA FM C19H21NO4
DM3FXMA IC InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
DM3FXMA CS C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM3FXMA IK UZHSEJADLWPNLE-GRGSLBFTSA-N
DM3FXMA IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM3FXMA CA CAS 465-65-6
DM3FXMA CB CHEBI:7459
DM3FXMA DE Narcotic depression; Opioid dependence; Respiratory depression; Pruritus
DMUL45H ID DMUL45H
DMUL45H DN Naltrexone
DMUL45H HS Approved
DMUL45H SN Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
DMUL45H CP Tni biotech; DrugAbuse Sciences; Alkermes Inc
DMUL45H DT Small molecular drug
DMUL45H PC 5360515
DMUL45H MW 341.4
DMUL45H FM C20H23NO4
DMUL45H IC InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
DMUL45H CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMUL45H IK DQCKKXVULJGBQN-XFWGSAIBSA-N
DMUL45H IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMUL45H CA CAS 16590-41-3
DMUL45H CB CHEBI:7465
DMUL45H DE Alcohol dependence; Human immunodeficiency virus infection
DMFWKG1 ID DMFWKG1
DMFWKG1 DN Nandrolone
DMFWKG1 HS Approved
DMFWKG1 SN Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one
DMFWKG1 CP Aspen Global Inc
DMFWKG1 TC Anabolic Agents
DMFWKG1 DT Small molecular drug
DMFWKG1 PC 9904
DMFWKG1 MW 274.4
DMFWKG1 FM C18H26O2
DMFWKG1 IC InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
DMFWKG1 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34
DMFWKG1 IK NPAGDVCDWIYMMC-IZPLOLCNSA-N
DMFWKG1 IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
DMFWKG1 CA CAS 434-22-0
DMFWKG1 CB CHEBI:7466
DMFWKG1 DE Osteoporosis
DMJFZDL ID DMJFZDL
DMJFZDL DN Naphazoline
DMJFZDL HS Approved
DMJFZDL SN Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
DMJFZDL CP Allergan Inc
DMJFZDL TC Anticancer Agents
DMJFZDL DT Small molecular drug
DMJFZDL PC 4436
DMJFZDL MW 210.27
DMJFZDL FM C14H14N2
DMJFZDL IC InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
DMJFZDL CS C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
DMJFZDL IK CNIIGCLFLJGOGP-UHFFFAOYSA-N
DMJFZDL IU 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
DMJFZDL CA CAS 835-31-4
DMJFZDL CB CHEBI:93363
DMJFZDL DE Itching; Hyperaemia
DMZ5RGV ID DMZ5RGV
DMZ5RGV DN Naproxen
DMZ5RGV HS Approved
DMZ5RGV SN NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
DMZ5RGV CP Iroko pharmaceuticals; PLx Pharma; CeNeS Pharmaceuticals plc
DMZ5RGV DT Small molecular drug
DMZ5RGV PC 156391
DMZ5RGV MW 230.26
DMZ5RGV FM C14H14O3
DMZ5RGV IC InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
DMZ5RGV CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
DMZ5RGV IK CMWTZPSULFXXJA-VIFPVBQESA-N
DMZ5RGV IU (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
DMZ5RGV CA CAS 22204-53-1
DMZ5RGV CB CHEBI:7476
DMZ5RGV DE Osteoarthritis; Endometriosis; Pain
DMO50U2 ID DMO50U2
DMO50U2 DN Naratriptan
DMO50U2 HS Approved
DMO50U2 SN Colatan; Naramig; Naratriptanum; Amerge (TN); Naramig (TN); Naratriptan (INN); Amerge, Naramig,Naratriptan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
DMO50U2 CP GlaxoSmithKline
DMO50U2 TC Vasoconstrictor Agents
DMO50U2 DT Small molecular drug
DMO50U2 PC 4440
DMO50U2 MW 335.5
DMO50U2 FM C17H25N3O2S
DMO50U2 IC InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
DMO50U2 CS CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
DMO50U2 IK AMKVXSZCKVJAGH-UHFFFAOYSA-N
DMO50U2 IU N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
DMO50U2 CA CAS 121679-13-8
DMO50U2 CB CHEBI:7478
DMO50U2 DE Migraine
DMFEHXD ID DMFEHXD
DMFEHXD DN Natamycin
DMFEHXD HS Approved
DMFEHXD SN Delvocid; Delvolan; Delvopos; Mycophyt; Myprozine; Natacyn; Natafucin; Natamicina; Natamycine; Natamycinum; Pimafucin; Pimaricin; Pimaricine; Pimarizin; Synogil; Tennecetin; Natamycin preparation; Pimaricin preparation; Pimarizin [German]; CL 12625; Antibiotic A-5283; CL 12,625; CL-12625; Natacyn (TN); Natamicina [INN-Spanish]; Natamycine [INN-French]; Natamycinum [INN-Latin]; Pimaricin (JP15); Natamycin (USP/INN); Natamycin [USAN:INN:BAN]; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14
DMFEHXD TC Antifungal Agents
DMFEHXD DT Small molecular drug
DMFEHXD PC 5284447
DMFEHXD MW 665.7
DMFEHXD FM C33H47NO13
DMFEHXD IC InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1
DMFEHXD CS C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O
DMFEHXD IK NCXMLFZGDNKEPB-FFPOYIOWSA-N
DMFEHXD IU (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
DMFEHXD CA CAS 7681-93-8
DMFEHXD DE Conjunctivitis
DMLK2QH ID DMLK2QH
DMLK2QH DN Nateglinide
DMLK2QH HS Approved
DMLK2QH SN Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH CP Norvatis Phamaceuticals Corporation
DMLK2QH TC Hypoglycemic Agents
DMLK2QH DT Small molecular drug
DMLK2QH PC 5311309
DMLK2QH MW 317.4
DMLK2QH FM C19H27NO3
DMLK2QH IC InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
DMLK2QH CS CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
DMLK2QH IK OELFLUMRDSZNSF-OFLPRAFFSA-N
DMLK2QH IU (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH CA CAS 105816-04-4
DMLK2QH CB CHEBI:31897
DMLK2QH DE Diabetic complication
DM7F1PA ID DM7F1PA
DM7F1PA DN Nebivolol
DM7F1PA HS Approved
DM7F1PA SN Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
DM7F1PA CP Forest Laboratories
DM7F1PA TC Antihypertensive Agents
DM7F1PA DT Small molecular drug
DM7F1PA PC 71301
DM7F1PA MW 405.4
DM7F1PA FM C22H25F2NO4
DM7F1PA IC InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
DM7F1PA CS C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
DM7F1PA IK KOHIRBRYDXPAMZ-UHFFFAOYSA-N
DM7F1PA IU 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
DM7F1PA CA CAS 99200-09-6
DM7F1PA CB CHEBI:64019
DM7F1PA DE Hypertension
DMKOJSN ID DMKOJSN
DMKOJSN DN Necitumumab
DMKOJSN HS Approved
DMKOJSN SN LY3012211
DMKOJSN CP Lilly
DMKOJSN DT Monoclonal antibody
DMKOJSN SQ Sequence A: QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence A'QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence BEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Sequence B'EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMKOJSN DE Colorectal cancer
DM4ZS8M ID DM4ZS8M
DM4ZS8M DN Nefazodone
DM4ZS8M HS Approved
DM4ZS8M SN Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
DM4ZS8M CP Bristol-Myers Squibb
DM4ZS8M TC Antidepressants
DM4ZS8M DT Small molecular drug
DM4ZS8M PC 4449
DM4ZS8M MW 470
DM4ZS8M FM C25H32ClN5O2
DM4ZS8M IC InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
DM4ZS8M CS CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DM4ZS8M IK VRBKIVRKKCLPHA-UHFFFAOYSA-N
DM4ZS8M IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
DM4ZS8M CA CAS 83366-66-9
DM4ZS8M CB CHEBI:7494
DM4ZS8M DE Major depressive disorder; Depression
DMB6VEG ID DMB6VEG
DMB6VEG DN Nelarabine
DMB6VEG HS Approved
DMB6VEG SN Arranon; ArranonG; Atriance; Nelzarabine; Nelarabine [USAN]; Nelzarabine [USAN]; GW 506U78; GW506U78; U78; Arranon (GlaxoSmithKline); Arranon (TN); Arranon, Nelarabine; Atriance (TN); GW-506U; GW-506U78; Nelarabine (INN); Nelzarabine (USAN); O-Methoxydeoxyguanosine; O-Methylguanosine; Nelarabine (JAN/USAN); (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Amino-6-methoxypurine arabinoside; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; 6'-O-Methylguanosine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
DMB6VEG CP GlaxoSmithKline
DMB6VEG TC Anticancer Agents
DMB6VEG DT Small molecular drug
DMB6VEG PC 3011155
DMB6VEG MW 297.27
DMB6VEG FM C11H15N5O5
DMB6VEG IC InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
DMB6VEG CS COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DMB6VEG IK IXOXBSCIXZEQEQ-UHTZMRCNSA-N
DMB6VEG IU (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMB6VEG CA CAS 121032-29-9
DMB6VEG CB CHEBI:63612
DMB6VEG DE leukaemia
DMFX6G8 ID DMFX6G8
DMFX6G8 DN Nelfinavir mesylate
DMFX6G8 HS Approved
DMFX6G8 SN Nelfin; Nelfinavir (Mesylate); Nelfinavir Mesylate [USAN]; Nelfinavir Methanesulfonate; Nelfinavir mesilate; Nelfinavir mesylate; Nelfinavir mesylate hydrate; Nelfinavir; NELFINAVIR MESYLATE AG1343; Nelfinavir [INN:BAN]; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; 159989-64-7; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; C32H45N3O4S; CHEBI:7496; HO3OGH5D7I; NLF; UNII-HO3OGH5D7I; 98D603VP8V; C32H45N3O4S.CH4O3S; CHEBI:7497; CHEMBL1205; DSSTox_CID_10777; DSSTox_GSID_33736; DSSTox_RID_79093; HSDB 7159; MFCD00931436; Nelfinavir methanesulfonate hydrate; UNII-98D603VP8V
DMFX6G8 PC 64142
DMFX6G8 MW 663.9
DMFX6G8 FM C33H49N3O7S2
DMFX6G8 IC NQHXCOAXSHGTIA-SKXNDZRYSA-N
DMFX6G8 CS CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
DMFX6G8 IK 1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1
DMFX6G8 IU (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;methanesulfonic acid
DMFX6G8 CA CAS 159989-65-8
DMFX6G8 CB CHEBI:7497
DMFX6G8 DE Human immunodeficiency virus infection
DMY0EKH ID DMY0EKH
DMY0EKH DN Nemonapride
DMY0EKH HS Approved
DMY0EKH SN Emilace (TN); Nemonapride (JAN/INN); Nemonapride, (cis)-isomer
DMY0EKH CP Astellas
DMY0EKH DT Small molecular drug
DMY0EKH PC 156333
DMY0EKH MW 387.9
DMY0EKH FM C21H26ClN3O2
DMY0EKH IC InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1
DMY0EKH CS C[C@@H]1[C@@H](CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
DMY0EKH IK KRVOJOCLBAAKSJ-RDTXWAMCSA-N
DMY0EKH IU N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide
DMY0EKH CA CAS 187139-87-3
DMY0EKH CB CHEBI:64219
DMY0EKH DE Schizophrenia
DM0S9Z1 ID DM0S9Z1
DM0S9Z1 DN Nemonoxacin
DM0S9Z1 HS Approved
DM0S9Z1 SN Nemonoxacin; 378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
DM0S9Z1 CP TaiGen Biotechnology
DM0S9Z1 DT Small molecular drug
DM0S9Z1 PC 11993740
DM0S9Z1 MW 371.4
DM0S9Z1 FM C20H25N3O4
DM0S9Z1 IC InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
DM0S9Z1 CS C[C@H]1C[C@@H](CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N
DM0S9Z1 IK AVPQPGFLVZTJOR-RYUDHWBXSA-N
DM0S9Z1 IU 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
DM0S9Z1 CA CAS 378746-64-6
DM0S9Z1 CB CHEBI:136053
DM0S9Z1 DE infection associated with diabetic foot ulcers; Community-acquired pneumonia
DMPWCTH ID DMPWCTH
DMPWCTH DN Neocarzinostatin
DMPWCTH HS Approved
DMPWCTH SN ZINOSTATIN; Neocarzinostatin (JAN); Zinostatin (USAN/INN); SCHEMBL1347615; D02046; 33862-EP2311453A1; 33862-EP2298765A1; 33862-EP2295426A1; 33862-EP2298764A1; 33862-EP2298748A2; 33862-EP2295427A1; 33862-EP2295055A2; 33862-EP2272832A1; 33862-EP2311829A1; 33862-EP2305642A2; 33862-EP2275420A1; 33862-EP2311808A1; 33862-EP2298768A1; 33862-EP2295416A2; 120130-EP2272832A1
DMPWCTH DT Small molecular drug
DMPWCTH PC 5282473
DMPWCTH MW 661.6
DMPWCTH FM C35H35NO12
DMPWCTH IC InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1
DMPWCTH CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](C=C3C2CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O
DMPWCTH IK BLXZMHNVKCEIJX-PNKAXBHOSA-N
DMPWCTH IU [(4S,6R,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]tridec-1(13)-en-2,7-diyn-12-yl] 2-hydroxy-7-methoxy-5-methylnaphthalene-1-carboxylate
DMPWCTH CA CAS 9014-02-2
DMPWCTH DE Solid tumour/cancer
DM6T2J3 ID DM6T2J3
DM6T2J3 DN Neostigmine
DM6T2J3 HS Approved
DM6T2J3 SN Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium
DM6T2J3 TC Parasympathomimetics
DM6T2J3 DT Small molecular drug
DM6T2J3 PC 4456
DM6T2J3 MW 223.29
DM6T2J3 FM C12H19N2O2+
DM6T2J3 IC InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
DM6T2J3 CS CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
DM6T2J3 IK ALWKGYPQUAPLQC-UHFFFAOYSA-N
DM6T2J3 IU [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
DM6T2J3 CA CAS 59-99-4
DM6T2J3 CB CHEBI:7514
DM6T2J3 DE Myasthenia gravis
DMYK490 ID DMYK490
DMYK490 DN Nepafenac
DMYK490 HS Approved
DMYK490 SN Nevanac; AHR-9434; AL-6515
DMYK490 CP Alcon
DMYK490 DT Small molecular drug
DMYK490 PC 151075
DMYK490 MW 254.28
DMYK490 FM C15H14N2O2
DMYK490 IC InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
DMYK490 CS C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N
DMYK490 IK QEFAQIPZVLVERP-UHFFFAOYSA-N
DMYK490 IU 2-(2-amino-3-benzoylphenyl)acetamide
DMYK490 CA CAS 78281-72-8
DMYK490 CB CHEBI:75922
DMYK490 DE Osteoarthritis
DMEDU7B ID DMEDU7B
DMEDU7B DN NERATINIB MALEATE
DMEDU7B HS Approved
DMEDU7B SN Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892
DMEDU7B CP Puma Biotechnology
DMEDU7B PC 67307512
DMEDU7B MW 673.1
DMEDU7B FM C34H33ClN6O7
DMEDU7B IC InChI=1S/C30H29ClN6O3.C4H4O4/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22;5-3(6)1-2-4(7)8/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38);1-2H,(H,5,6)(H,7,8)/b9-7+;2-1-
DMEDU7B CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMEDU7B IK VXZCUHNJXSIJIM-MEBGWEOYSA-N
DMEDU7B IU (Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMEDU7B CA CAS 915942-22-2
DMEDU7B DE HER2/NEU overexpressing breast cancer
DMMPG5V ID DMMPG5V
DMMPG5V DN NERIDRONIC ACID
DMMPG5V HS Approved
DMMPG5V SN Neridronic acid; 79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis-
DMMPG5V DT Small molecular drug
DMMPG5V PC 71237
DMMPG5V MW 277.15
DMMPG5V FM C6H17NO7P2
DMMPG5V IC InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
DMMPG5V CS C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
DMMPG5V IK PUUSSSIBPPTKTP-UHFFFAOYSA-N
DMMPG5V IU (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid
DMMPG5V CA CAS 79778-41-9
DMMPG5V CB CHEBI:135145
DMMPG5V DE Bone disease; Complex regional pain syndrome
DMFOIA8 ID DMFOIA8
DMFOIA8 DN Nesiritide
DMFOIA8 HS Approved
DMFOIA8 SN Natrecor (TN)
DMFOIA8 CP Scios Llc
DMFOIA8 DT Small molecular drug
DMFOIA8 SQ DB04899: Natriuretic peptides B: SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
DMFOIA8 PC 71308561
DMFOIA8 MW 3464
DMFOIA8 FM C143H244N50O42S4
DMFOIA8 IC InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1
DMFOIA8 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO
DMFOIA8 IK HPNRHPKXQZSDFX-OAQDCNSJSA-N
DMFOIA8 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(4R,10S,16S,19S,22S,25S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMFOIA8 CB CHEBI:135919
DMFOIA8 DE Congestive heart failure
DM0LPI9 ID DM0LPI9
DM0LPI9 DN Netarsudil
DM0LPI9 HS Approved
DM0LPI9 SN UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4
DM0LPI9 CP Aerie Pharmaceuticals
DM0LPI9 PC 66599893
DM0LPI9 MW 453.5
DM0LPI9 FM C28H27N3O3
DM0LPI9 IC InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
DM0LPI9 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
DM0LPI9 IK OURRXQUGYQRVML-AREMUKBSSA-N
DM0LPI9 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
DM0LPI9 CA CAS 1254032-66-0
DM0LPI9 DE Open-angle glaucoma; Glaucoma/ocular hypertension
DMRD1QK ID DMRD1QK
DMRD1QK DN Netilmicin
DMRD1QK HS Approved
DMRD1QK SN NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside
DMRD1QK CP Abbott Laboratories
DMRD1QK TC Antibiotics
DMRD1QK DT Small molecular drug
DMRD1QK PC 441306
DMRD1QK MW 475.6
DMRD1QK FM C21H41N5O7
DMRD1QK IC InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1
DMRD1QK CS CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N
DMRD1QK IK CIDUJQMULVCIBT-MQDUPKMGSA-N
DMRD1QK IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMRD1QK CA CAS 56391-56-1
DMRD1QK DE Bacterial infection
DM6HX9B ID DM6HX9B
DM6HX9B DN Nevirapine
DM6HX9B HS Approved
DM6HX9B SN NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
DM6HX9B CP Boehringer Ingelheim
DM6HX9B TC Anti-HIV Agents
DM6HX9B DT Small molecular drug
DM6HX9B PC 4463
DM6HX9B MW 266.3
DM6HX9B FM C15H14N4O
DM6HX9B IC InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
DM6HX9B CS CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
DM6HX9B IK NQDJXKOVJZTUJA-UHFFFAOYSA-N
DM6HX9B IU 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
DM6HX9B CA CAS 129618-40-2
DM6HX9B CB CHEBI:63613
DM6HX9B DE Human immunodeficiency virus infection
DMCDYW7 ID DMCDYW7
DMCDYW7 DN Nicardipine
DMCDYW7 HS Approved
DMCDYW7 SN Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7 CP Chiesi Usa Inc
DMCDYW7 TC Antihypertensive Agents
DMCDYW7 DT Small molecular drug
DMCDYW7 PC 4474
DMCDYW7 MW 479.5
DMCDYW7 FM C26H29N3O6
DMCDYW7 IC InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
DMCDYW7 CS CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMCDYW7 IK ZBBHBTPTTSWHBA-UHFFFAOYSA-N
DMCDYW7 IU 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7 CA CAS 55985-32-5
DMCDYW7 CB CHEBI:7550
DMCDYW7 DE High blood pressure
DMBCM8L ID DMBCM8L
DMBCM8L DN Nicergoline
DMBCM8L HS Approved
DMBCM8L SN MNE; Nargoline; Nicergolin; Nicergolina; Nicergolinum; Nicotergoline; Nimergoline; Sermion; Nicergolin [German]; Nicergolina [DCIT]; Nimergoline base; FI 6714; RP 19651; Nicergolinum [INN-Latin]; Sermion (TN); Nicergoline (JP15/USAN/INN); Nicergoline [USAN:BAN:INN:JAN]; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline
DMBCM8L TC Vasodilator Agents
DMBCM8L DT Small molecular drug
DMBCM8L PC 34040
DMBCM8L MW 484.4
DMBCM8L FM C24H26BrN3O3
DMBCM8L IC InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
DMBCM8L CS CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br
DMBCM8L IK YSEXMKHXIOCEJA-FVFQAYNVSA-N
DMBCM8L IU [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
DMBCM8L CA CAS 27848-84-6
DMBCM8L CB CHEBI:31902
DMBCM8L DE Brain ischaemia; Senile dementia
DMJAGXQ ID DMJAGXQ
DMJAGXQ DN Niclosamide
DMJAGXQ HS Approved
DMJAGXQ SN niclosamide; 50-65-7; Niclocide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Tredemine; Bayluscid; Phenasal; Yomesan; Fenasal; Dichlosale; Helmiantin; Sagimid; Iomezan; Devermine; Atenase; Vermitid; Radeverm; Mansonil; Iomesan; Devermin; Cestocid; Sulqui; Lintex; Nasemo; Mato; Fedal-Telmin; Bayer 73; Radewerm; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; Chemagro 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; Niclosamidum [I
DMJAGXQ DT Small molecular drug
DMJAGXQ PC 4477
DMJAGXQ MW 327.12
DMJAGXQ FM C13H8Cl2N2O4
DMJAGXQ IC InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)
DMJAGXQ CS C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
DMJAGXQ IK RJMUSRYZPJIFPJ-UHFFFAOYSA-N
DMJAGXQ IU 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide
DMJAGXQ CA CAS 50-65-7
DMJAGXQ CB CHEBI:7553
DMJAGXQ DE Cestodes infection
DMIYJFV ID DMIYJFV
DMIYJFV DN Nicorandil
DMIYJFV HS Approved
DMIYJFV SN Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat
DMIYJFV CP Chugai; Roche; Sanofi-Aventis; Merk KGaA; Pfizer; 3M Pharmaceutical
DMIYJFV TC Vasodilator Agents
DMIYJFV DT Small molecular drug
DMIYJFV PC 47528
DMIYJFV MW 211.17
DMIYJFV FM C8H9N3O4
DMIYJFV IC InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
DMIYJFV CS C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
DMIYJFV IK LBHIOVVIQHSOQN-UHFFFAOYSA-N
DMIYJFV IU 2-(pyridine-3-carbonylamino)ethyl nitrate
DMIYJFV CA CAS 65141-46-0
DMIYJFV CB CHEBI:31905
DMIYJFV DE Angina pectoris
DMUPE07 ID DMUPE07
DMUPE07 DN Nicotinamide
DMUPE07 HS Approved
DMUPE07 SN Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide
DMUPE07 TC Antiinflammatory Agents
DMUPE07 DT Small molecular drug
DMUPE07 PC 936
DMUPE07 MW 122.12
DMUPE07 FM C6H6N2O
DMUPE07 IC InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
DMUPE07 CS C1=CC(=CN=C1)C(=O)N
DMUPE07 IK DFPAKSUCGFBDDF-UHFFFAOYSA-N
DMUPE07 IU pyridine-3-carboxamide
DMUPE07 CA CAS 98-92-0
DMUPE07 CB CHEBI:17154
DMUPE07 DE Inflammatory skin condition
DMWX5CO ID DMWX5CO
DMWX5CO DN Nicotine
DMWX5CO HS Approved
DMWX5CO SN Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO CP Upjohn Corporation
DMWX5CO DT Small molecular drug
DMWX5CO PC 89594
DMWX5CO MW 162.23
DMWX5CO FM C10H14N2
DMWX5CO IC InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1
DMWX5CO CS CN1CCC[C@H]1C2=CN=CC=C2
DMWX5CO IK SNICXCGAKADSCV-JTQLQIEISA-N
DMWX5CO IU 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO CA CAS 54-11-5
DMWX5CO CB CHEBI:17688
DMWX5CO DE Nicotine dependence; Tobacco dependence
DMSVOZT ID DMSVOZT
DMSVOZT DN Nifedipine
DMSVOZT HS Approved
DMSVOZT SN Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]
DMSVOZT CP Bayer
DMSVOZT TC Analgesics
DMSVOZT DT Small molecular drug
DMSVOZT PC 4485
DMSVOZT MW 346.3
DMSVOZT FM C17H18N2O6
DMSVOZT IC InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
DMSVOZT CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DMSVOZT IK HYIMSNHJOBLJNT-UHFFFAOYSA-N
DMSVOZT IU dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMSVOZT CA CAS 21829-25-4
DMSVOZT CB CHEBI:7565
DMSVOZT DE Angina pectoris
DMJ3I1Q ID DMJ3I1Q
DMJ3I1Q DN Niflumic acid
DMJ3I1Q HS Approved
DMJ3I1Q SN Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A
DMJ3I1Q TC Antiinflammatory Agents
DMJ3I1Q DT Small molecular drug
DMJ3I1Q PC 4488
DMJ3I1Q MW 282.22
DMJ3I1Q FM C13H9F3N2O2
DMJ3I1Q IC InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
DMJ3I1Q CS C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
DMJ3I1Q IK JZFPYUNJRRFVQU-UHFFFAOYSA-N
DMJ3I1Q IU 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid
DMJ3I1Q CA CAS 4394-00-7
DMJ3I1Q CB CHEBI:34888
DMJ3I1Q DE Rheumatoid arthritis
DMSQLZJ ID DMSQLZJ
DMSQLZJ DN Nifurtimox
DMSQLZJ HS Approved
DMSQLZJ SN NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide
DMSQLZJ CP Bayer healthcare pharmaceuticals
DMSQLZJ DT Small molecular drug
DMSQLZJ PC 6842999
DMSQLZJ MW 287.29
DMSQLZJ FM C10H13N3O5S
DMSQLZJ IC InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+
DMSQLZJ CS CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DMSQLZJ IK ARFHIAQFJWUCFH-IZZDOVSWSA-N
DMSQLZJ IU (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine
DMSQLZJ CA CAS 23256-30-6
DMSQLZJ CB CHEBI:7566
DMSQLZJ DE Trypanosomiasis; Chagas disease
DM7HXWT ID DM7HXWT
DM7HXWT DN Nilotinib
DM7HXWT HS Approved
DM7HXWT SN NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
DM7HXWT CP Novartis AG
DM7HXWT TC Anticancer Agents
DM7HXWT DT Small molecular drug
DM7HXWT PC 644241
DM7HXWT MW 529.5
DM7HXWT FM C28H22F3N7O
DM7HXWT IC InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
DM7HXWT CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7HXWT IK HHZIURLSWUIHRB-UHFFFAOYSA-N
DM7HXWT IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DM7HXWT CA CAS 641571-10-0
DM7HXWT CB CHEBI:52172
DM7HXWT DE Chronic myelogenous leukaemia
DMFN07X ID DMFN07X
DMFN07X DN Nilutamide
DMFN07X HS Approved
DMFN07X SN Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X CP Aventis Pharmaceuticals Inc.
DMFN07X TC Anticancer Agents
DMFN07X DT Small molecular drug
DMFN07X PC 4493
DMFN07X MW 317.22
DMFN07X FM C12H10F3N3O4
DMFN07X IC InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
DMFN07X CS CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
DMFN07X IK XWXYUMMDTVBTOU-UHFFFAOYSA-N
DMFN07X IU 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X CA CAS 63612-50-0
DMFN07X CB CHEBI:7573
DMFN07X DE Prostate cancer
DMQ0RKZ ID DMQ0RKZ
DMQ0RKZ DN Nimodipine
DMQ0RKZ HS Approved
DMQ0RKZ SN Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
DMQ0RKZ CP Bayer Pharmaceuticals Corporation
DMQ0RKZ TC Vasodilator Agents
DMQ0RKZ DT Small molecular drug
DMQ0RKZ PC 4497
DMQ0RKZ MW 418.4
DMQ0RKZ FM C21H26N2O7
DMQ0RKZ IC InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
DMQ0RKZ CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
DMQ0RKZ IK UIAGMCDKSXEBJQ-UHFFFAOYSA-N
DMQ0RKZ IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMQ0RKZ CA CAS 66085-59-4
DMQ0RKZ CB CHEBI:7575
DMQ0RKZ DE Cerebral vasospasm
DMA65ER ID DMA65ER
DMA65ER DN Nipradilol
DMA65ER HS Approved
DMA65ER SN Nipradilol; Nipradolol; Hypadil; 81486-22-8; Nipradilolum [Latin]; Nipradilol [INN:JAN]; UNII-FVM336I71Y; Hypadil (TN); CCRIS 2515; K 351; BRN 3566879; FVM336I71Y; 8-(2-Hydroxy-3-(isopropylamino)propoxy)chroman-3-yl nitrate; C15H22N2O6; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanyl nitrat; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanol 3-nitrate; K-351; 3,4-Dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran; 3,4-Dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2H-1-benzopyran-3-ol 3-nitra
DMA65ER DT Small molecular drug
DMA65ER PC 72006
DMA65ER MW 326.34
DMA65ER FM C15H22N2O6
DMA65ER IC InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3
DMA65ER CS CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O
DMA65ER IK OMCPLEZZPVJJIS-UHFFFAOYSA-N
DMA65ER IU [8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2H-chromen-3-yl] nitrate
DMA65ER CA CAS 81486-22-8
DMA65ER CB CHEBI:31682
DMA65ER DE Angina pectoris
DMLPSWQ ID DMLPSWQ
DMLPSWQ DN Niraparib Tosylate
DMLPSWQ HS Approved
DMLPSWQ SN 1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059
DMLPSWQ CP Tesaro
DMLPSWQ TC Antihypertensive Agents
DMLPSWQ DT Small molecular drug
DMLPSWQ PC 78357761
DMLPSWQ MW 492.6
DMLPSWQ FM C26H28N4O4S
DMLPSWQ IC InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
DMLPSWQ CS CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLPSWQ IK LCPFHXWLJMNKNC-PFEQFJNWSA-N
DMLPSWQ IU 4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLPSWQ CA CAS 1038915-73-9
DMLPSWQ DE Peritoneal cancer; Fallopian tube cancer
DM7ISKJ ID DM7ISKJ
DM7ISKJ DN Nisoldipine
DM7ISKJ HS Approved
DM7ISKJ SN Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ TC Antihypertensive Agents
DM7ISKJ DT Small molecular drug
DM7ISKJ PC 4499
DM7ISKJ MW 388.4
DM7ISKJ FM C20H24N2O6
DM7ISKJ IC InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
DM7ISKJ CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DM7ISKJ IK VKQFCGNPDRICFG-UHFFFAOYSA-N
DM7ISKJ IU 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ CA CAS 63675-72-9
DM7ISKJ CB CHEBI:76917
DM7ISKJ DE Hypertension
DMOWLVG ID DMOWLVG
DMOWLVG DN Nitazoxanide
DMOWLVG HS Approved
DMOWLVG SN Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
DMOWLVG CP Unimed Pharmaceuticals
DMOWLVG TC Antiparasitic Agents
DMOWLVG DT Small molecular drug
DMOWLVG PC 41684
DMOWLVG MW 307.28
DMOWLVG FM C12H9N3O5S
DMOWLVG IC InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
DMOWLVG CS CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]
DMOWLVG IK YQNQNVDNTFHQSW-UHFFFAOYSA-N
DMOWLVG IU [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
DMOWLVG CA CAS 55981-09-4
DMOWLVG CB CHEBI:94807
DMOWLVG DE Diarrhea
DMVS9WQ ID DMVS9WQ
DMVS9WQ DN Nitisinone
DMVS9WQ HS Approved
DMVS9WQ SN Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
DMVS9WQ TC Anticancer Agents
DMVS9WQ DT Small molecular drug
DMVS9WQ PC 115355
DMVS9WQ MW 329.23
DMVS9WQ FM C14H10F3NO5
DMVS9WQ IC InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2
DMVS9WQ CS C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
DMVS9WQ IK OUBCNLGXQFSTLU-UHFFFAOYSA-N
DMVS9WQ IU 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
DMVS9WQ CA CAS 104206-65-7
DMVS9WQ CB CHEBI:50378
DMVS9WQ DE Hereditary tyrosinemia type 1
DMEGIQ6 ID DMEGIQ6
DMEGIQ6 DN Nitrazepam
DMEGIQ6 HS Approved
DMEGIQ6 SN Alodorm; Apodorm; Benzalin; Calsamin; Calsmin; Cerson; Dormalon; Dumolid; Eatan; Epibenzalin; Epinelbon; Eunoctin; Eunoktin; Gerson; Hipnax; Hipsal; Ibrovek; Imadorm; Imeson; Imesont; Ipersed; Magadon; Megadon; Mitidin; Mogadan; Mogadon; Mogadone; Nelbon; Nelmat; Neozepam; Neuchlonic; Nitrados; Nitravet; Nitrazadon; Nitrazep; Nitrazepamum; Nitrempax; Nitrenpax; Nitrodiazepam; Noctesed; Novanox; Pacisyn; Paxisyn; Pelson; Persopit; Radedorm; Relact; Remnos; Serenade; Somitran; Somnased; Somnibel; Somnite; Sonebon; Sonnolin; Surem; Trazenin; Unisomnia; Aliud Brand of Nitrazepam; Allphar Brand of Nitrazepam; Alphapharma Brand of Nitrazepam; Alpharma Brand of Nitrazepam; Alter Brand of Nitrazepam; CSP Brand of Nitrazepam; DDSA Brand of Nitrazepam; Dermatech Brand of Nitrazepam; Desitin Brand of Nitrazepam; Dormicum Brand of Nitrazepam; Eatan N; ICN Brand of Nitrazepam; Neuraxpharm Brand of Nitrazepam; Nitrazepam AL; Norgine Brand of Nitrazepam; Pfleger Brand of Nitrazepam; Protea Brand of Nitrazepam; Rhoxalpharma Brand of Nitrazepam; Sandoz nitrazepam; Scheurich Brand of Nitrazepam; Sonebon Tofraniln A; Taurus Brandof Nitrazepam; United Drug Brand of Nitrazepam; Wernigerode Brand of Nitrazepam; LA 1; S 2000; Alodorm (TN); Apo-nitrazepam tablets BP; Apodorm (TN); Arem (TN); Benzalin (TN); Cavodan (TN); Ct-Arzneimittel Brand of Nitrazepam; Dima (TN); Dormalon (TN); Dormicum (anticonvulsant); Dormigen (TN); Dormin-5; Dormo-Puren; Dumolid (TN); Eatan N (TN); Eunoctin (TN); Hypnotex (TN); ISOPROPYLACETATE/NITRAZEPAM; Imeson (TN); Insoma (TN); Insomin (TN); Ipersed (TN); LA 1 (VAN); Mitidin (TN); Mogadan (TN); Mogadon (TN); N-Desmethylnimetazepam; Nitavan (TN); Nitepam (TN); Nitrados (TN); Nitrapan (TN); Nitravet (TN); Nitrazadon (TN); Nitrazep (TN); Nitrazepam (TN); Nitrazepam Capsules BP 1993 (TN); Nitrazepam Oral Suspension BP 1993 (TN); Nitrazepam Tablets BP 1993 (TN); Nitrazepam-10; Nitrazepam-5; Nitrazepam-neuraxpharm; Nitrazepamum [INN-Latin]; Nitrazepan (TN); Nitrazepol (TN); Nitredon (TN); Nitrosun (TN); Novanox (TN); Numbon (TN); Onirema (TN); Ormodon (TN); Pacisyn (TN); Paxadorm (TN); Pelson (TN); Pelsonfilina (TN); Protraz (TN); Radedorm (TN); Remnos (TN); Rhoxal-nitrazepam; Ro 4-5360; Ro 5-3059; Ro 53-60; Serenade (TN); Somnibel N (TN); Somnipar (TN); Somnite (TN); Sonebon (TN); Sonotrat (TN); Surem (TN); Tri (TN); Unisomnia (TN); Dormo-Puren (TN); Nitrazepam (JP15/USAN/INN); Nitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6 TC Antianxiety Agents
DMEGIQ6 DT Small molecular drug
DMEGIQ6 PC 4506
DMEGIQ6 MW 281.27
DMEGIQ6 FM C15H11N3O3
DMEGIQ6 IC InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
DMEGIQ6 CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
DMEGIQ6 IK KJONHKAYOJNZEC-UHFFFAOYSA-N
DMEGIQ6 IU 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6 CA CAS 146-22-5
DMEGIQ6 CB CHEBI:7581
DMEGIQ6 DE Epilepsy; Insomnia
DM21C09 ID DM21C09
DM21C09 DN Nitrendipine
DM21C09 HS Approved
DM21C09 SN Baylotensin; Bayotensin; Baypress; Bylotensin; Deiten; Gericin; Jutapress; Nidrel; Niprina; NitrePuren; Nitregamma; Nitrendepat; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipincorax; Nitrendipino; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Tensogradal; Trendinol; Vastensium; Nitre AbZ; Nitre Puren; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendi Biochemie; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipino Bayvit; Nitren 1A Pharma; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Ct, nitrendipin von; Heumann, Nitrendipin; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nitre-Puren; Nitrendipin-corax; Pharma, Nitren 1A; Stada, Nitrendipin; Von ct, nitrendipin; Bay-e-5009; 1A Pharma, Nitren
DM21C09 TC Antihypertensive Agents
DM21C09 DT Small molecular drug
DM21C09 PC 4507
DM21C09 MW 360.4
DM21C09 FM C18H20N2O6
DM21C09 IC InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
DM21C09 CS CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
DM21C09 IK PVHUJELLJLJGLN-UHFFFAOYSA-N
DM21C09 IU 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM21C09 CA CAS 39562-70-4
DM21C09 CB CHEBI:7582
DM21C09 DE Hypertension
DM1RBYG ID DM1RBYG
DM1RBYG DN Nitric Oxide
DM1RBYG HS Approved
DM1RBYG SN Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO; HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)
DM1RBYG CP NB therapeutics; University of Akron
DM1RBYG TC Bronchodilator Agents
DM1RBYG DT Small molecular drug
DM1RBYG PC 145068
DM1RBYG MW 30.006
DM1RBYG FM NO
DM1RBYG IC InChI=1S/NO/c1-2
DM1RBYG CS [N]=O
DM1RBYG IK MWUXSHHQAYIFBG-UHFFFAOYSA-N
DM1RBYG IU nitric oxide
DM1RBYG CA CAS 10102-43-9
DM1RBYG CB CHEBI:16480
DM1RBYG DE Respiratory failure; Solid tumour/cancer; Tinea pedis
DM7PQIK ID DM7PQIK
DM7PQIK DN Nitrofurantoin
DM7PQIK HS Approved
DM7PQIK SN Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin
DM7PQIK CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DM7PQIK TC Antiinfective Agents
DM7PQIK DT Small molecular drug
DM7PQIK PC 6604200
DM7PQIK MW 238.16
DM7PQIK FM C8H6N4O5
DM7PQIK IC InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
DM7PQIK CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM7PQIK IK NXFQHRVNIOXGAQ-YCRREMRBSA-N
DM7PQIK IU 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
DM7PQIK CA CAS 67-20-9
DM7PQIK CB CHEBI:71415
DM7PQIK DE Urinary tract infection
DMSM2KE ID DMSM2KE
DMSM2KE DN Nitrofurazone
DMSM2KE HS Approved
DMSM2KE SN nitrofurazone; Nitrofural; Furacilin; 59-87-0; Furacin; Furacillin; Furacine; Aldomycin; Furaldon; Nifuzon; Actin-N; Furacycline; Furacoccid; Otofuran; Nitrofurazan; Monafuracin; Furaziline; Furacinetten; Babrocid; Nitrozone; Mastofuran; Furazone; Chemofuran; Mammex; Amifur; Alfucin; Furesol; Furazol W; 5-Nitro-2-furaldehyde semicarbazone; Monofuracin; Dermofural; Monafuracis; Furaseptyl; Furatsilin; Nitrofurol; Fuvacillin; Furametral; Biofuracina; Becafurazone; Nifucin; Ibiofural; Hemofuran; Furalone; Furacort; Eldezol; Vadrocid; Vabrocid; Furazyme
DMSM2KE DT Small molecular drug
DMSM2KE PC 5447130
DMSM2KE MW 198.14
DMSM2KE FM C6H6N4O4
DMSM2KE IC InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+
DMSM2KE CS C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N
DMSM2KE IK IAIWVQXQOWNYOU-FPYGCLRLSA-N
DMSM2KE IU [(E)-(5-nitrofuran-2-yl)methylideneamino]urea
DMSM2KE CA CAS 59-87-0
DMSM2KE CB CHEBI:44368
DMSM2KE DE Skin burns; Bacterial infection
DMQ2491 ID DMQ2491
DMQ2491 DN Nitroglycerin
DMQ2491 HS Approved
DMQ2491 SN nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401
DMQ2491 TC Vasodilator Agents
DMQ2491 DT Small molecular drug
DMQ2491 PC 4510
DMQ2491 MW 227.09
DMQ2491 FM C3H5N3O9
DMQ2491 IC InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMQ2491 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMQ2491 IK SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMQ2491 IU 1,3-dinitrooxypropan-2-yl nitrate
DMQ2491 CA CAS 55-63-0
DMQ2491 CB CHEBI:28787
DMQ2491 DE Diabetic foot ulcer; Angina pectoris
DMLUA2J ID DMLUA2J
DMLUA2J DN Nitroprusside
DMLUA2J HS Approved
DMLUA2J SN Nitropress (TN); Nitroprusside sodium; Sodium nitroprusside (USP); Tox21_110314; Tox21_110314_1; 13755-38-9; 7304AF; A-8282; C07695; NITROPRUSSIDE SODIUM DIHYDRATE; C5FeN6O.2Na.2H2O; CAS-13755-38-9; CHEBI:9179; D00614; DSSTox_CID_21126; DSSTox_GSID_41126; DSSTox_RID_79630; DTXSID7041126; MFCD00149192; NCGC00166055-03; Na2[Fe(CN)5(NO)].2H2O; Sodium nitroferricyanide dihydrate, 99+%; Sodium nitroferricyanide dihydrate, reagent ACS; Sodium nitroferricyanide(III) dihydrate; Sodium nitroprusside hydrate (JAN)
DMLUA2J PC 11953895
DMLUA2J MW 297.95
DMLUA2J FM C5H4FeN6Na2O3
DMLUA2J IC XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMLUA2J CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMLUA2J IK 1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMLUA2J IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMLUA2J CA CAS 13755-38-9
DMLUA2J CB CHEBI:9179
DMLUA2J DE Congestive heart failure
DMM765C ID DMM765C
DMM765C DN Nitroprusside
DMM765C HS Approved
DMM765C SN C07269; LS-187044
DMM765C TC Antihypertensive Agents
DMM765C DT Small molecular drug
DMM765C PC 11953891
DMM765C MW 215.94
DMM765C FM C5FeN6O
DMM765C IC InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+6;-1
DMM765C CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+6]
DMM765C IK CDLSWOALPINAJL-UHFFFAOYSA-N
DMM765C IU iron(6+);nitroxyl anion;pentacyanide
DMM765C DE Hypertension
DMTHWBI ID DMTHWBI
DMTHWBI DN Nitrous oxide
DMTHWBI HS Approved
DMTHWBI SN Distickstoffmonoxid; Lachgas; Stickdioxyd; Dinitrogen monoxide; Dinitrogen oxide; Factitious air; Gaz hilarant; Hyponitrous acid anhydride; Laughing gas; Nitrogen hypoxide; Nitrogenium oxydulatum; Nitrous oxide [JAN]; Oxido nitroso; Oxido nitroso [Spanish]; Oxyde nitreux; Stickdioxyd [German]; N2O; Nitrous oxide [UN1070] [Nonflammable gas]; Diazyne 1-oxide; Gas, Laughing; NITROUS-OXIDE; Nitrogen oxide (N2O); Nitrous oxide (TN); Nitrous oxide [Anaesthetics, volatile]; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Oxide, Nitrous; Protoxyde d'azote; Protoxyde d'azote [French]; Nitrous oxide (JP15/USP); Oxidodinitrogen(N-N); Stickstoff(I)-oxid
DMTHWBI DT Small molecular drug
DMTHWBI PC 948
DMTHWBI MW 44.013
DMTHWBI FM N2O
DMTHWBI IC InChI=1S/N2O/c1-2-3
DMTHWBI CS [N-]=[N+]=O
DMTHWBI IK GQPLMRYTRLFLPF-UHFFFAOYSA-N
DMTHWBI IU nitrous oxide
DMTHWBI CA CAS 10024-97-2
DMTHWBI CB CHEBI:17045
DMTHWBI DE Anxiety disorder
DMAB9QE ID DMAB9QE
DMAB9QE DN Nivolumab
DMAB9QE HS Approved
DMAB9QE CP Bristol-Myers Squibb
DMAB9QE DT Monoclonal antibody
DMAB9QE SQ Heavy Chain Sequence: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMAB9QE DE Central nervous system lymphoma; Chronic myelogenous leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Malignant pleural mesothelioma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small-cell lung cancer; Esophageal cancer; Gastric adenocarcinoma; Recurrent glioblastoma; Renal cell carcinoma; Triple negative breast cancer; Melanoma; Non-small-cell lung cancer
DMGFV3Z ID DMGFV3Z
DMGFV3Z DN Nizatidine
DMGFV3Z HS Approved
DMGFV3Z SN Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DMGFV3Z CP Eli Lilly
DMGFV3Z TC Antiulcer Agents
DMGFV3Z DT Small molecular drug
DMGFV3Z PC 3033637
DMGFV3Z MW 331.5
DMGFV3Z FM C12H21N5O2S2
DMGFV3Z IC InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
DMGFV3Z CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
DMGFV3Z IK SGXXNSQHWDMGGP-IZZDOVSWSA-N
DMGFV3Z IU (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DMGFV3Z CA CAS 76963-41-2
DMGFV3Z CB CHEBI:7601
DMGFV3Z DE Acid-reflux disorder
DMRJ7D1 ID DMRJ7D1
DMRJ7D1 DN Nomegestrol acetate
DMRJ7D1 HS Approved
DMRJ7D1 SN Lutenyl (TN)
DMRJ7D1 CP Theramex
DMRJ7D1 DT Small molecular drug
DMRJ7D1 PC 91668
DMRJ7D1 MW 370.5
DMRJ7D1 FM C23H30O4
DMRJ7D1 IC InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
DMRJ7D1 CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4
DMRJ7D1 IK IIVBFTNIGYRNQY-YQLZSBIMSA-N
DMRJ7D1 IU [(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
DMRJ7D1 CA CAS 58652-20-3
DMRJ7D1 CB CHEBI:135564
DMRJ7D1 DE Breast cancer
DMOUC09 ID DMOUC09
DMOUC09 DN Norepinephrine
DMOUC09 HS Approved
DMOUC09 SN norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins
DMOUC09 CP Bedford Laboratories
DMOUC09 TC Vasoconstrictor Agents
DMOUC09 DT Small molecular drug
DMOUC09 PC 439260
DMOUC09 MW 169.18
DMOUC09 FM C8H11NO3
DMOUC09 IC InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1
DMOUC09 CS C1=CC(=C(C=C1[C@H](CN)O)O)O
DMOUC09 IK SFLSHLFXELFNJZ-QMMMGPOBSA-N
DMOUC09 IU 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
DMOUC09 CA CAS 51-41-2
DMOUC09 CB CHEBI:18357
DMOUC09 DE Sepsis
DMTY169 ID DMTY169
DMTY169 DN Norethindrone
DMTY169 HS Approved
DMTY169 SN Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one
DMTY169 CP Parke Davis Div Warner Lambert Co
DMTY169 TC Contraceptive Agents
DMTY169 DT Small molecular drug
DMTY169 PC 6230
DMTY169 MW 298.4
DMTY169 FM C20H26O2
DMTY169 IC InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DMTY169 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMTY169 IK VIKNJXKGJWUCNN-XGXHKTLJSA-N
DMTY169 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMTY169 CA CAS 68-22-4
DMTY169 CB CHEBI:7627
DMTY169 DE Solid tumour/cancer
DMDGCQP ID DMDGCQP
DMDGCQP DN Norethindrone acetate
DMDGCQP HS Approved
DMDGCQP SN Noresthisterone; Norethadrone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Norpregneninlone; Norpregneninolone; Primolut-N; Proluteasi; Synphase; Triella; Utovlan; Utovlar; norethindrone; 19-Nor-ethindrone; 19-Norethisterone; 68-22-4; Anovulatorio; Anovule; Camila; Ciclovulan; Conludaf; Conludag; Ethinylnortestosterone; Gestest; Microneth; Micronett; Micronor; Micronovum; Mini-Pe; Mini-pill; Minovlar; Nor-QD; Noralutin; Norcolut; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
DMDGCQP PC 5832
DMDGCQP MW 340.5
DMDGCQP FM C22H28O3
DMDGCQP IC IMONTRJLAWHYGT-ZCPXKWAGSA-N
DMDGCQP CS CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C
DMDGCQP IK 1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1
DMDGCQP IU [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMDGCQP CA CAS 51-98-9
DMDGCQP CB CHEBI:7628
DMDGCQP DE Menorrhagia
DMIZ6W2 ID DMIZ6W2
DMIZ6W2 DN Norfloxacin
DMIZ6W2 HS Approved
DMIZ6W2 SN Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2 TC Antibiotics
DMIZ6W2 DT Small molecular drug
DMIZ6W2 PC 4539
DMIZ6W2 MW 319.33
DMIZ6W2 FM C16H18FN3O3
DMIZ6W2 IC InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
DMIZ6W2 CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
DMIZ6W2 IK OGJPXUAPXNRGGI-UHFFFAOYSA-N
DMIZ6W2 IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2 CA CAS 70458-96-7
DMIZ6W2 CB CHEBI:100246
DMIZ6W2 DE Bacterial infection
DMYP4XC ID DMYP4XC
DMYP4XC DN Norgestimate
DMYP4XC HS Approved
DMYP4XC SN Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
DMYP4XC TC Contraceptive Agents
DMYP4XC DT Small molecular drug
DMYP4XC PC 6540478
DMYP4XC MW 369.5
DMYP4XC FM C23H31NO3
DMYP4XC IC InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1
DMYP4XC CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34
DMYP4XC IK KIQQMECNKUGGKA-NMYWJIRASA-N
DMYP4XC IU [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMYP4XC CA CAS 20799-27-3
DMYP4XC CB CHEBI:50815
DMYP4XC DE Contraception
DM4KDYJ ID DM4KDYJ
DM4KDYJ DN Nortriptyline
DM4KDYJ HS Approved
DM4KDYJ SN Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
DM4KDYJ TC Antidepressants
DM4KDYJ DT Small molecular drug
DM4KDYJ PC 4543
DM4KDYJ MW 263.4
DM4KDYJ FM C19H21N
DM4KDYJ IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
DM4KDYJ CS CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DM4KDYJ IK PHVGLTMQBUFIQQ-UHFFFAOYSA-N
DM4KDYJ IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DM4KDYJ CA CAS 72-69-5
DM4KDYJ CB CHEBI:7640
DM4KDYJ DE Depression
DMRFWGK ID DMRFWGK
DMRFWGK DN Novobiocin
DMRFWGK HS Approved
DMRFWGK SN Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one
DMRFWGK CP Pfizer Pharmaceuticals
DMRFWGK TC Antibiotics
DMRFWGK DT Small molecular drug
DMRFWGK PC 54675769
DMRFWGK MW 612.6
DMRFWGK FM C31H36N2O11
DMRFWGK IC InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1
DMRFWGK CS CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O
DMRFWGK IK YJQPYGGHQPGBLI-KGSXXDOSSA-N
DMRFWGK IU [(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate
DMRFWGK CA CAS 303-81-1
DMRFWGK CB CHEBI:28368
DMRFWGK DE Bacterial infection
DM6ZPLQ ID DM6ZPLQ
DM6ZPLQ DN Novolimus
DM6ZPLQ HS Approved
DM6ZPLQ CP Elixir Medical
DM6ZPLQ PC 9854320
DM6ZPLQ MW 900.1
DM6ZPLQ FM C50H77NO13
DM6ZPLQ IC InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)40(53)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-42(32(4)25-36-19-21-39(52)43(26-36)61-8)28-41(54)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-40,42-43,45-46,52-53,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11+,30-16+,34-24+/t29-,31-,32-,33-,35-,36+,37+,38+,39-,40+,42+,43-,45-,46+,50-/m1/s1
DM6ZPLQ CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)O
DM6ZPLQ IK ZHYGVVKSAGDVDY-QQQXYHJWSA-N
DM6ZPLQ IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18,30-trihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM6ZPLQ CA CAS 151519-50-5
DM6ZPLQ DE Artery stenosis
DMRSX53 ID DMRSX53
DMRSX53 DN nusinersen
DMRSX53 HS Approved
DMRSX53 SN BIIB 058; IONIS-SMNRx; ISIS-396443; Spinraza
DMRSX53 CP Biogen/Ionis Pharmaceuticals
DMRSX53 DT Antisense drug
DMRSX53 SQ 5'-UCACUUUCAUAAUGCUGG
DMRSX53 DE Spinal muscular atrophy
DM63QS9 ID DM63QS9
DM63QS9 DN Nystatin
DM63QS9 HS Approved
DM63QS9 SN Biofanal; Comycin; Diastatin; Fungicidin; Herniocid; Korostatin; Moronal; Myconystatin; Mycostatin; Mykinac; Mykostatyna; Nilstat; Nistatin; Nistatina; Nyamyc; Nyotran; Nystaform; Nystan; Nystatine; Nystatinum; Nystatyna; Nystavescent; Nystex; Nystop; Stamicin; Stamycin; Terrastatin; Candex Lotion; Mycostatin Pastilles; Nystatin A; Nystatin G; Nystatin preparation; Nystatyna [Polish]; Zydin E; Barstatin 100; Mycostatin 20; Nystatin A1; Nystatin A2; Nystatin A3; Animax (TN); Candio-hermal; Flagystatin II (TN); Infestat (TN); Korostatin (TN); Lystin (TN); Moronal (antibiotic); Mycostatin (TN); Mykacet (TN); Mykinac (TN); Mytrex (TN); Nidoflor (TN); Nilstat (TN); Nistatina (TN); Nistatina [INN-Spanish]; Nysert (TN);Nystaform (TN); Nystalocal (TN); Nystamont (TN); Nystan (TN); Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nystex (TN); Nystop (TN); O-V Statin; Myco-Triacet II (TN); Mycolog-II (TN); Nystatin A1, A2, A3 complex; Nystatin [INN:BAN:JAN]; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid
DM63QS9 CP Bristol-Myers Squibb
DM63QS9 TC Antifungal Agents
DM63QS9 DT Small molecular drug
DM63QS9 PC 6433272
DM63QS9 MW 926.1
DM63QS9 FM C47H75NO17
DM63QS9 IC InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
DM63QS9 CS C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DM63QS9 IK VQOXZBDYSJBXMA-RKEBNKJGSA-N
DM63QS9 IU (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
DM63QS9 CA CAS 1400-61-9
DM63QS9 CB CHEBI:473992
DM63QS9 DE Fungal infection
DM3Q1SM ID DM3Q1SM
DM3Q1SM DN Obeticholic acid
DM3Q1SM HS Approved
DM3Q1SM SN INT747; INT-747; 6-ethylchenodeoxycholic acid; 6-ECDCA; OCA; 6-Et CDCA
DM3Q1SM CP Intercept
DM3Q1SM DT Small molecular drug
DM3Q1SM PC 447715
DM3Q1SM MW 420.6
DM3Q1SM FM C26H44O4
DM3Q1SM IC InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
DM3Q1SM CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O
DM3Q1SM IK ZXERDUOLZKYMJM-ZWECCWDJSA-N
DM3Q1SM IU (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3Q1SM CA CAS 459789-99-2
DM3Q1SM CB CHEBI:43602
DM3Q1SM DE Primary biliary cholangitis; Insomnia
DM3BVAE ID DM3BVAE
DM3BVAE DN Obinutuzumab
DM3BVAE HS Approved
DM3BVAE SN GA101/RG7159
DM3BVAE CP Biogen Idec; Genentech
DM3BVAE DT Antibody
DM3BVAE DE Chronic lymphocytic leukaemia; Haematological malignancy
DMEZ2KH ID DMEZ2KH
DMEZ2KH DN Ocrelizumab
DMEZ2KH HS Approved
DMEZ2KH SN Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
DMEZ2KH CP Roche/Genentech
DMEZ2KH DT Antibody
DMEZ2KH DE Multiple sclerosis; Diffuse large B-cell lymphoma
DM7AVGW ID DM7AVGW
DM7AVGW DN Ocriplasmin
DM7AVGW HS Approved
DM7AVGW CP ThromboGenics
DM7AVGW SQ Protein sequence for the truncated heavy chain: APSFDCGKPQVEPKKCPGR >Protein sequence for the light chain VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
DM7AVGW DE Symptomatic vitreomacular adhesion
DMHIDCJ ID DMHIDCJ
DMHIDCJ DN Octreotide
DMHIDCJ HS Approved
DMHIDCJ SN Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ CP Norvatis Phamaceuticals Corporation
DMHIDCJ TC Anabolic Agents
DMHIDCJ DT Small molecular drug
DMHIDCJ PC 448601
DMHIDCJ MW 1019.2
DMHIDCJ FM C49H66N10O10S2
DMHIDCJ IC InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
DMHIDCJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
DMHIDCJ IK DEQANNDTNATYII-OULOTJBUSA-N
DMHIDCJ IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ CA CAS 83150-76-9
DMHIDCJ DE Acromegaly
DMZK0FQ ID DMZK0FQ
DMZK0FQ DN Oestradiol valerate and dienogest
DMZK0FQ HS Approved
DMZK0FQ SN Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)
DMZK0FQ CP Bayer
DMZK0FQ DT Small molecular drug
DMZK0FQ PC 68861
DMZK0FQ MW 311.4
DMZK0FQ FM C20H25NO2
DMZK0FQ IC InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1
DMZK0FQ CS C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMZK0FQ IK AZFLJNIPTRTECV-FUMNGEBKSA-N
DMZK0FQ IU 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMZK0FQ CA CAS 65928-58-7
DMZK0FQ CB CHEBI:70708
DMZK0FQ DE Endometriosis; Contraception
DM295PR ID DM295PR
DM295PR DN Ofatumumab
DM295PR HS Approved
DM295PR SN Arzerra (TN)
DM295PR CP GlaxoSmithKline
DM295PR DT Antibody
DM295PR SQ Ofatumumab Heavy Chain: EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP >Ofatumumab Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM295PR DE Chronic lymphocytic leukaemia; Rheumatoid arthritis; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DM0VQN3 ID DM0VQN3
DM0VQN3 DN Ofloxacin
DM0VQN3 HS Approved
DM0VQN3 SN Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
DM0VQN3 CP Janssen Pharmaceutica
DM0VQN3 TC Antibiotics
DM0VQN3 DT Small molecular drug
DM0VQN3 PC 4583
DM0VQN3 MW 361.4
DM0VQN3 FM C18H20FN3O4
DM0VQN3 IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
DM0VQN3 CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DM0VQN3 IK GSDSWSVVBLHKDQ-UHFFFAOYSA-N
DM0VQN3 IU 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DM0VQN3 CA CAS 82419-36-1
DM0VQN3 CB CHEBI:7731
DM0VQN3 DE Bacterial infection
DMQ4PKA ID DMQ4PKA
DMQ4PKA DN Olamufloxacin
DMQ4PKA HS Approved
DMQ4PKA SN Olamufloxacin; HSR-903; UNII-LJG8KL1435; HSR 903; LJG8KL1435; J-502473; (S)-5-Amino-7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-(-)-5-Amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid; 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-quinoline-3-carboxylic acid; Olamufloxacin [INN]; AC1Q5RCW; AC1L9XAZ; SCHEMBL1851976
DMQ4PKA PC 477670
DMQ4PKA MW 386.4
DMQ4PKA FM C20H23FN4O3
DMQ4PKA IC InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1
DMQ4PKA CS CC1=C2C(=C(C(=C1N3CC(C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O
DMQ4PKA IK LEILBPMISZFZQK-GFCCVEGCSA-N
DMQ4PKA IU 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid
DMQ4PKA CA CAS 167887-97-0
DMQ4PKA DE Bacterial infections
DMPFN6Y ID DMPFN6Y
DMPFN6Y DN Olanzapine
DMPFN6Y HS Approved
DMPFN6Y SN Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
DMPFN6Y CP Eli Lilly
DMPFN6Y TC Antipsychotic Agents
DMPFN6Y DT Small molecular drug
DMPFN6Y PC 135398745
DMPFN6Y MW 312.4
DMPFN6Y FM C17H20N4S
DMPFN6Y IC InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
DMPFN6Y CS CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
DMPFN6Y IK KVWDHTXUZHCGIO-UHFFFAOYSA-N
DMPFN6Y IU 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
DMPFN6Y CA CAS 132539-06-1
DMPFN6Y CB CHEBI:7735
DMPFN6Y DE Schizophrenia
DM0Y49P ID DM0Y49P
DM0Y49P DN Olanzapine/fluoxetine combination
DM0Y49P HS Approved
DM0Y49P SN Symbyax (Zyprexa/Prozac)
DM0Y49P CP Eli Lilly; Eli Lilly & Co
DM0Y49P DT Small molecular drug
DM0Y49P PC 24848071
DM0Y49P DE Depression
DM8QB1D ID DM8QB1D
DM8QB1D DN Olaparib
DM8QB1D HS Approved
DM8QB1D SN AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
DM8QB1D CP AstraZeneca
DM8QB1D DT Small molecular drug
DM8QB1D PC 23725625
DM8QB1D MW 434.5
DM8QB1D FM C24H23FN4O3
DM8QB1D IC InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
DM8QB1D CS C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
DM8QB1D IK FDLYAMZZIXQODN-UHFFFAOYSA-N
DM8QB1D IU 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DM8QB1D CA CAS 763113-22-0
DM8QB1D CB CHEBI:83766
DM8QB1D DE Ovarian cancer; Pancreatic cancer; Prostate cancer
DMNYOIX ID DMNYOIX
DMNYOIX DN Olaratumab
DMNYOIX HS Approved
DMNYOIX SN LY3012207
DMNYOIX CP Eli Lilly
DMNYOIX DT Monoclonal antibody
DMNYOIX SQ Heavy Chain: QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNYOIX DE Soft tissue sarcoma; Non-small-cell lung cancer
DM6MDCF ID DM6MDCF
DM6MDCF DN Oliceridine
DM6MDCF HS Approved
DM6MDCF SN TRV130A
DM6MDCF DT Small molecular drug
DM6MDCF PC 66553195
DM6MDCF MW 386.6
DM6MDCF FM C22H30N2O2S
DM6MDCF IC InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
DM6MDCF CS COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
DM6MDCF IK DMNOVGJWPASQDL-OAQYLSRUSA-N
DM6MDCF IU N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
DM6MDCF CA CAS 1401028-24-7
DM6MDCF DE Thyroid disease; Acute pain
DMWBHRY ID DMWBHRY
DMWBHRY DN Olmesartan medoxomil
DMWBHRY HS Approved
DMWBHRY SN Benevas; Benicar; Olmetec; Olvance; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Sankyo Brand of Olmesartan Medoxomil; Cs 866; Benicar (TN); Berlin-Chemie Brand of Olmesartan Medoxomil; CS-866; CS-866DM; CS-866RN; DE-092; KS-1182; Olmetec (TN); Benicar, Olmetec,Olmesartan; Olmesartan medoxomil (JAN/USAN); (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
DMWBHRY TC Antihypertensive Agents
DMWBHRY DT Small molecular drug
DMWBHRY PC 130881
DMWBHRY MW 558.6
DMWBHRY FM C29H30N6O6
DMWBHRY IC InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
DMWBHRY CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
DMWBHRY IK UQGKUQLKSCSZGY-UHFFFAOYSA-N
DMWBHRY IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
DMWBHRY CA CAS 144689-63-4
DMWBHRY CB CHEBI:31932
DMWBHRY DE High blood pressure
DM62B78 ID DM62B78
DM62B78 DN Olodaterol
DM62B78 HS Approved
DM62B78 SN BI-1744
DM62B78 CP Boehringer Ingelheim Pharmaceuticals
DM62B78 DT Small molecular drug
DM62B78 PC 11504295
DM62B78 MW 386.4
DM62B78 FM C21H26N2O5
DM62B78 IC InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1
DM62B78 CS CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O
DM62B78 IK COUYJEVMBVSIHV-SFHVURJKSA-N
DM62B78 IU 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one
DM62B78 CA CAS 868049-49-4
DM62B78 CB CHEBI:82700
DM62B78 DE Chronic obstructive pulmonary disease
DMKMWQG ID DMKMWQG
DMKMWQG DN Olopatadine
DMKMWQG HS Approved
DMKMWQG SN Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
DMKMWQG CP Alcon
DMKMWQG TC Antiallergic Agents
DMKMWQG DT Small molecular drug
DMKMWQG PC 5281071
DMKMWQG MW 337.4
DMKMWQG FM C21H23NO3
DMKMWQG IC InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
DMKMWQG CS CN(C)CC/C=C\\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
DMKMWQG IK JBIMVDZLSHOPLA-LSCVHKIXSA-N
DMKMWQG IU 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
DMKMWQG CA CAS 113806-05-6
DMKMWQG CB CHEBI:94593
DMKMWQG DE Allergic conjunctivitis; Ocular allergy
DMWBQKU ID DMWBQKU
DMWBQKU DN Olprinone
DMWBQKU HS Approved
DMWBQKU SN Olprinone; 106730-54-5; loprinone; Coretec; Olprinone [INN]; UNII-4Y8BMI9YGC; 4Y8BMI9YGC; C14H10N4O; Olprinone (INN); 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile; 1,2-Dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile; AC1L1IIG; AC1Q4Q1U; SCHEMBL27661; DTXSID1048461; CHEMBL1474900; KS-00000EYK; MolPort-006-394-808; JPAWFIIYTJQOKW-UHFFFAOYSA-N; CHEBI:135019; BCP09781; ZINC38192538; HY-14254A; 3950AH
DMWBQKU DT Small molecular drug
DMWBQKU PC 4593
DMWBQKU MW 250.25
DMWBQKU FM C14H10N4O
DMWBQKU IC InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)
DMWBQKU CS CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2
DMWBQKU IK JPAWFIIYTJQOKW-UHFFFAOYSA-N
DMWBQKU IU 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
DMWBQKU CA CAS 106730-54-5
DMWBQKU CB CHEBI:135019
DMWBQKU DE Heart failure
DMZW9HA ID DMZW9HA
DMZW9HA DN Olsalazine
DMZW9HA HS Approved
DMZW9HA SN Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine
DMZW9HA CP Pharmacia & Upjohn AB
DMZW9HA DT Small molecular drug
DMZW9HA PC 22419
DMZW9HA MW 302.24
DMZW9HA FM C14H10N2O6
DMZW9HA IC InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
DMZW9HA CS C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DMZW9HA IK QQBDLJCYGRGAKP-UHFFFAOYSA-N
DMZW9HA IU 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
DMZW9HA CA CAS 15722-48-2
DMZW9HA CB CHEBI:7770
DMZW9HA DE Ulcerative colitis
DMPU2WX ID DMPU2WX
DMPU2WX DN Omacetaxine mepesuccinate
DMPU2WX HS Approved
DMPU2WX SN Synribo (TN)
DMPU2WX CP Ivax
DMPU2WX DT Small molecular drug
DMPU2WX PC 285033
DMPU2WX MW 545.6
DMPU2WX FM C29H39NO9
DMPU2WX IC InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
DMPU2WX CS CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
DMPU2WX IK HYFHYPWGAURHIV-JFIAXGOJSA-N
DMPU2WX IU 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
DMPU2WX CA CAS 26833-87-4
DMPU2WX CB CHEBI:71019
DMPU2WX DE Chronic myeloid leukaemia
DMR2J95 ID DMR2J95
DMR2J95 DN Omadacycline
DMR2J95 HS Approved
DMR2J95 SN UNII-090IP5RV8F; 090IP5RV8F; Omadacycline [USAN:INN]; Omadacycline (USAN); AC1NUY3H; Amadacycline methanesulfonate; SCHEMBL152
DMR2J95 CP Paratek Pharmaceuticals
DMR2J95 PC 54697325
DMR2J95 MW 556.6
DMR2J95 FM C29H40N4O7
DMR2J95 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMR2J95 CS CC(C)(C)CNCC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMR2J95 IK VJYKVCURWJGLPG-IQZGDKDPSA-N
DMR2J95 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMR2J95 CA CAS 389139-89-3
DMR2J95 DE Acute bacterial skin infection; Bacterial pneumonia; Bacterial infection
DMU5G01 ID DMU5G01
DMU5G01 DN Omadacycline
DMU5G01 HS Approved
DMU5G01 SN Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer
DMU5G01 TC Antibiotics
DMU5G01 DT Small molecular drug
DMU5G01 PC 54697325
DMU5G01 MW 556.66
DMU5G01 FM C29H40N4O7
DMU5G01 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMU5G01 CS CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMU5G01 IK VJYKVCURWJGLPG-IQZGDKDPSA-N
DMU5G01 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMU5G01 CA CAS 389139-89-3
DMU5G01 DE Acute skin infections; Community-acquired bacterial pneumonia
DMETVFJ ID DMETVFJ
DMETVFJ DN Omalizumab
DMETVFJ HS Approved
DMETVFJ SN Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
DMETVFJ CP National University Hospital, Singapore|National University, Singapore
DMETVFJ TC Antiasthmatic Agents
DMETVFJ DT Monoclonal antibody
DMETVFJ SQ Omalizumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Omalizumab light chainDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMETVFJ DE Asthma; Chronic idiopathic urticaria
DML9TI0 ID DML9TI0
DML9TI0 DN Ombitasvir + paritaprevir + ritonavir
DML9TI0 HS Approved
DML9TI0 SN ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); Viekirax
DML9TI0 TC Antiinfective Agents
DML9TI0 DE Hepatitis C virus infection
DM471KJ ID DM471KJ
DM471KJ DN Omeprazole
DM471KJ HS Approved
DM471KJ SN Losec (TN)
DM471KJ CP AstraZeneca
DM471KJ TC Antiulcer Agents
DM471KJ DT Small molecular drug
DM471KJ PC 4594
DM471KJ MW 345.4
DM471KJ FM C17H19N3O3S
DM471KJ IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
DM471KJ CS CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
DM471KJ IK SUBDBMMJDZJVOS-UHFFFAOYSA-N
DM471KJ IU 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM471KJ CA CAS 73590-58-6
DM471KJ CB CHEBI:77260
DM471KJ DE Gastroesophageal reflux disease
DMOTQ1I ID DMOTQ1I
DMOTQ1I DN Ondansetron
DMOTQ1I HS Approved
DMOTQ1I SN DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I CP GlaxoSmithKline
DMOTQ1I TC Antiemetics
DMOTQ1I DT Small molecular drug
DMOTQ1I PC 4595
DMOTQ1I MW 293.4
DMOTQ1I FM C18H19N3O
DMOTQ1I IC InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
DMOTQ1I CS CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
DMOTQ1I IK FELGMEQIXOGIFQ-UHFFFAOYSA-N
DMOTQ1I IU 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I CA CAS 99614-02-5
DMOTQ1I CB CHEBI:7773
DMOTQ1I DE Chemotherapy-induced nausea; Alcohol dependence
DMHG57U ID DMHG57U
DMHG57U DN OPC-34712
DMHG57U HS Approved
DMHG57U SN Brexpiprazole
DMHG57U CP Lundbeck; Otsuka America Pharmaceutical
DMHG57U DT Small molecular drug
DMHG57U PC 11978813
DMHG57U MW 433.6
DMHG57U FM C25H27N3O2S
DMHG57U IC InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
DMHG57U CS C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
DMHG57U IK ZKIAIYBUSXZPLP-UHFFFAOYSA-N
DMHG57U IU 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
DMHG57U CA CAS 913611-97-9
DMHG57U CB CHEBI:134716
DMHG57U DE Major depressive disorder
DM1BKA6 ID DM1BKA6
DM1BKA6 DN Opicapone
DM1BKA6 HS Approved
DM1BKA6 SN BIA-9-1067
DM1BKA6 CP Portela & Ca SA
DM1BKA6 PC 135565903
DM1BKA6 MW 413.2
DM1BKA6 FM C15H10Cl2N4O6
DM1BKA6 IC InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
DM1BKA6 CS CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
DM1BKA6 IK ASOADIZOVZTJSR-UHFFFAOYSA-N
DM1BKA6 IU 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
DM1BKA6 CA CAS 923287-50-7
DM1BKA6 CB CHEBI:134699
DM1BKA6 DE Parkinson disease
DMPUOXF ID DMPUOXF
DMPUOXF DN Opipramol
DMPUOXF HS Approved
DMPUOXF SN Opipramolo; Opipramolum; Opipramol dihydrochloride; Opipramol hydrochloride; Opipramoli hydrochloridum; G 33 040
DMPUOXF DT Small molecular drug
DMPUOXF PC 9417
DMPUOXF MW 363.5
DMPUOXF FM C23H29N3O
DMPUOXF IC InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
DMPUOXF CS C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO
DMPUOXF IK YNZFUWZUGRBMHL-UHFFFAOYSA-N
DMPUOXF IU 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol
DMPUOXF CA CAS 315-72-0
DMPUOXF CB CHEBI:94614
DMPUOXF DE Anxiety disorder
DMTSRI6 ID DMTSRI6
DMTSRI6 DN Oprelvekin
DMTSRI6 HS Approved
DMTSRI6 SN Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN)
DMTSRI6 CP Wyeth Pharmaceuticals
DMTSRI6 TC Anticoagulants
DMTSRI6 SQ DB00038 sequence: GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL
DMTSRI6 DE Thrombocytopenia
DM28D05 ID DM28D05
DM28D05 DN Oritavancin
DM28D05 HS Approved
DM28D05 SN Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin
DM28D05 CP Eli Lilly
DM28D05 DT Small molecular drug
DM28D05 PC 16136912
DM28D05 MW 1793.1
DM28D05 FM C86H97Cl3N10O26
DM28D05 IC InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
DM28D05 CS C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
DM28D05 IK VHFGEBVPHAGQPI-LXKZPTCJSA-N
DM28D05 IU (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DM28D05 CA CAS 171099-57-3
DM28D05 CB CHEBI:82699
DM28D05 DE Bacterial infection; Gram-positive bacterial infection
DMRJSP8 ID DMRJSP8
DMRJSP8 DN Orlistat
DMRJSP8 HS Approved
DMRJSP8 SN orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247; Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN
DMRJSP8 CP GlaxoSmithKline plc
DMRJSP8 TC Antiobesity Agents
DMRJSP8 DT Small molecular drug
DMRJSP8 PC 3034010
DMRJSP8 MW 495.7
DMRJSP8 FM C29H53NO5
DMRJSP8 IC InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
DMRJSP8 CS CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
DMRJSP8 IK AHLBNYSZXLDEJQ-FWEHEUNISA-N
DMRJSP8 IU [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
DMRJSP8 CA CAS 96829-58-2
DMRJSP8 CB CHEBI:94686
DMRJSP8 DE Obesity
DM6QHDJ ID DM6QHDJ
DM6QHDJ DN Ornidazole
DM6QHDJ HS Approved
DM6QHDJ DT Small molecular drug
DM6QHDJ PC 28061
DM6QHDJ MW 219.62
DM6QHDJ FM C7H10ClN3O3
DM6QHDJ IC InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
DM6QHDJ CS CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-]
DM6QHDJ IK IPWKIXLWTCNBKN-UHFFFAOYSA-N
DM6QHDJ IU 1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DM6QHDJ CA CAS 16773-42-5
DM6QHDJ CB CHEBI:75176
DM6QHDJ DE Amoebiasis
DMW542E ID DMW542E
DMW542E DN Orphenadrine
DMW542E HS Approved
DMW542E SN Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine
DMW542E CP 3M Pharmaceuticals
DMW542E TC Antiparkinson Agents
DMW542E DT Small molecular drug
DMW542E PC 4601
DMW542E MW 269.4
DMW542E FM C18H23NO
DMW542E IC InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
DMW542E CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
DMW542E IK QVYRGXJJSLMXQH-UHFFFAOYSA-N
DMW542E IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
DMW542E CA CAS 83-98-7
DMW542E CB CHEBI:7789
DMW542E DE Parkinson disease
DMFIQ20 ID DMFIQ20
DMFIQ20 DN Orphenadrine citrate
DMFIQ20 HS Approved
DMFIQ20 SN Orfenadrina; Orfenadrina [INN-Spanish]; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrine [INN:BAN]; Orphenadrinum; Orphenadrinum [INN-Latin]; Orphenate; Orphenedrine; WS 2434; o-Methyldiphenhydramine; o-Monomethyldiphenhydramine; orphenadrine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine; 83-98-7; EINECS 201-509-2; HSDB 3139; Phenyl-o-tolylmethyl dimethyaminoethyl ether; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Biorphen; Brocadisipal; Brocasipal; Disipal; Invagesic; Mephenamine; Norgesic; Banflex; Euflex; Flexoject; Flexon; Flexor; Norflex; Norflex (pharmaceutical); Orphenadrine (Citrate); Orphenadrine citrate; Orphenadrine citrate (Norflex); Orphenadrine citrate [USP]; Orphenadrine citrate salt; Orphenadrine dihydrogen citrate; Plenactol; Tega-Flex; X-Otag; 2-hydroxypropane-1,2,3-tricarboxylic acid; 4596-23-0; 4682-36-4; CHEBI:7790; EINECS 225-137-5; N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1); NCGC00094745-01; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
DMFIQ20 PC 83823
DMFIQ20 MW 461.5
DMFIQ20 FM C24H31NO8
DMFIQ20 IC MMMNTDFSPSQXJP-UHFFFAOYSA-N
DMFIQ20 CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMFIQ20 IK 1S/C18H23NO.C6H8O7/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-12,18H,13-14H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMFIQ20 IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMFIQ20 CA CAS 4682-36-4
DMFIQ20 CB CHEBI:7790
DMFIQ20 DE Myalgia
DMGO72P ID DMGO72P
DMGO72P DN Oseltamivir
DMGO72P HS Approved
DMGO72P SN Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV
DMGO72P CP Hoffmann-La Roche pharmaceutical company
DMGO72P TC Antiviral Agents
DMGO72P DT Small molecular drug
DMGO72P PC 65028
DMGO72P MW 312.4
DMGO72P FM C16H28N2O4
DMGO72P IC InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
DMGO72P CS CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC
DMGO72P IK VSZGPKBBMSAYNT-RRFJBIMHSA-N
DMGO72P IU ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
DMGO72P CA CAS 196618-13-0
DMGO72P CB CHEBI:7798
DMGO72P DE Influenza virus infection
DMIJC9X ID DMIJC9X
DMIJC9X DN Osilodrostat
DMIJC9X HS Approved
DMIJC9X SN LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile
DMIJC9X CP Novartis Pharmaceuticals
DMIJC9X DT Small molecular drug
DMIJC9X PC 44139752
DMIJC9X MW 227.24
DMIJC9X FM C13H10FN3
DMIJC9X IC InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
DMIJC9X CS C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
DMIJC9X IK USUZGMWDZDXMDG-CYBMUJFWSA-N
DMIJC9X IU 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
DMIJC9X CA CAS 928134-65-0
DMIJC9X DE Cushing disease
DMRJLAT ID DMRJLAT
DMRJLAT DN Osimertinib
DMRJLAT HS Approved
DMRJLAT SN Tagrisso
DMRJLAT CP Astrazeneca
DMRJLAT DT Small molecular drug
DMRJLAT PC 71496458
DMRJLAT MW 499.6
DMRJLAT FM C28H33N7O2
DMRJLAT IC InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
DMRJLAT CS CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMRJLAT IK DUYJMQONPNNFPI-UHFFFAOYSA-N
DMRJLAT IU N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
DMRJLAT CA CAS 1421373-65-0
DMRJLAT CB CHEBI:90943
DMRJLAT DE Non-small-cell lung cancer; Melanoma
DMF5ZB3 ID DMF5ZB3
DMF5ZB3 DN OspA lipoprotein
DMF5ZB3 HS Approved
DMF5ZB3 TC Vaccines
DMF5ZB3 DT Vaccine
DMF5ZB3 SQ OspA lipoprotein: MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDNVDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKSTTEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVEIKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNGTITVQNYDSAGTKLEGSAAEIKKLDELKNALR
DMF5ZB3 DE Lyme disease
DMC4GEI ID DMC4GEI
DMC4GEI DN Ospemifene
DMC4GEI HS Approved
DMC4GEI SN Ospemifene; 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2
DMC4GEI CP Shionogi; QuatRx
DMC4GEI DT Small molecular drug
DMC4GEI PC 3036505
DMC4GEI MW 378.9
DMC4GEI FM C24H23ClO2
DMC4GEI IC InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
DMC4GEI CS C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)OCCO)/CCCl
DMC4GEI IK LUMKNAVTFCDUIE-VHXPQNKSSA-N
DMC4GEI IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol
DMC4GEI CA CAS 128607-22-7
DMC4GEI CB CHEBI:73275
DMC4GEI DE Dyspareunia; Postmenopausal vaginal atrophy
DM05968 ID DM05968
DM05968 DN Otilonium bromide
DM05968 HS Approved
DM05968 SN Otilonium Bromide; 26095-59-0; Octylonium bromide; Spasmomen; Octylonium; Otilonium (bromide); SP63; Ottilonio bromuro [Italian]; UNII-21HN3N72PV; Otilonium bromide [INN:BAN]; Otilonii bromidum [INN-Latin]; Bromure d'otilonium [INN-French]; Bromuro de otilonio [INN-Spanish]; EINECS 247-457-4; 21HN3N72PV; Diethyl(2-hydroxyethyl)methylammonium bromide p-(o-(octyloxy)benzamido)benzoate; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide; DSSTox_CID_26357; DSSTox_RID_81559
DM05968 CP Menarini
DM05968 DT Small molecular drug
DM05968 PC 72092
DM05968 MW 563.6
DM05968 FM C29H43BrN2O4
DM05968 IC InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H
DM05968 CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-]
DM05968 IK VWZPIJGXYWHBOW-UHFFFAOYSA-N
DM05968 IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide
DM05968 CA CAS 26095-59-0
DM05968 DE Gastric motility disorder
DMQNI7O ID DMQNI7O
DMQNI7O DN OTL-200
DMQNI7O HS Approved
DMQNI7O SN Libmeldy
DMQNI7O CP Orchard Therapeutics
DMQNI7O DT Gene therapy
DMQNI7O DE Metachromatic leukodystrophy
DME0F98 ID DME0F98
DME0F98 DN Ovine corticotropin-releasing hormone
DME0F98 HS Approved
DME0F98 SN Ovine CRF; Ovine CRH; Ovine CRF 41; Ovine corticotropin-releasing factor; Ovine ACTH releasing factor; 79804-71-0; Corticotropin-releasing factor (sheep); Sheep corticotropin-releasing factor (1-41); Corticotropin-releasing factor (sheep hypothalamus); Amunine; Amunin; Corticorelin ovine; oCRH; Corticorelin triflutate; AC1Q2C7A; CRF(OVINE)TRIFLUOROACETATE; Sheep corticotropin-releasing factor; Corticotropin-releasing hormone, ovine; Corticotropin-releasing f
DME0F98 DT Small molecular drug
DME0F98 PC 16132344
DME0F98 MW 4670
DME0F98 FM C205H339N59O63S
DME0F98 IC InChI=1S/C205H339N59O63S/c1-30-104(21)159(198(322)225-106(23)163(214)287)259-193(317)142(87-157(285)286)253-184(308)132(77-99(11)12)246-182(306)130(75-97(7)8)244-172(296)117(46-36-38-67-207)231-170(294)118(47-39-68-221-204(215)216)233-189(313)139(84-151(213)274)251-194(318)143(91-266)256-188(312)137(82-113-88-219-93-223-113)241-165(289)108(25)227-169(293)120(51-58-147(209)270)234-173(297)121(52-59-148(210)271)229-164(288)107(24)228-179(303)128(73-95(3)4)243-176(300)123(54-61-150(212)273)236-190(314)140(85-155(281)282)242-166(290)109(26)226-168(292)116(45-35-37-66-206)239-200(324)161(110(27)268)261-178(302)126(65-72-328-29)238-174(298)124(55-62-152(275)276)237-181(305)134(79-101(15)16)254-197(321)158(103(19)20)258-177(301)125(56-63-153(277)278)235-171(295)119(48-40-69-222-205(217)218)232-180(304)129(74-96(5)6)245-183(307)131(76-98(9)10)247-187(311)138(83-114-89-220-94-224-114)250-186(310)136(81-112-43-33-32-34-44-112)255-201(325)162(111(28)269)262-192(316)135(80-102(17)18)248-191(315)141(86-156(283)284)252-185(309)133(78-100(13)14)249-195(319)144(92-267)257-199(323)160(105(22)31-2)260-196(320)145-49-41-70-263(145)203(327)146-50-42-71-264(146)202(326)127(57-64-154(279)280)240-175(299)122(53-60-149(211)272)230-167(291)115(208)90-265/h32-34,43-44,88-89,93-111,115-146,158-162,265-269H,30-31,35-42,45-87,90-92,206-208H2,1-29H3,(H2,209,270)(H2,210,271)(H2,211,272)(H2,212,273)(H2,213,274)(H2,214,287)(H,219,223)(H,220,224)(H,225,322)(H,226,292)(H,227,293)(H,228,303)(H,229,288)(H,230,291)(H,231,294)(H,232,304)(H,233,313)(H,234,297)(H,235,295)(H,236,314)(H,237,305)(H,238,298)(H,239,324)(H,240,299)(H,241,289)(H,242,290)(H,243,300)(H,244,296)(H,245,307)(H,246,306)(H,247,311)(H,248,315)(H,249,319)(H,250,310)(H,251,318)(H,252,309)(H,253,308)(H,254,321)(H,255,325)(H,256,312)(H,257,323)(H,258,301)(H,259,317)(H,260,320)(H,261,302)(H,262,316)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,215,216,221)(H4,217,218,222)/t104-,105-,106-,107-,108-,109-,110+,111+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,158-,159-,160-,161-,162-/m0/s1
DME0F98 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N
DME0F98 IK QEEJLLNYQOBRRM-KSHGRFHLSA-N
DME0F98 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoic acid
DME0F98 CA CAS 79804-71-0
DME0F98 DE Cushing disease; Diagnostic imaging
DMTAFY4 ID DMTAFY4
DMTAFY4 DN Oxacillin
DMTAFY4 HS Approved
DMTAFY4 SN Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid
DMTAFY4 CP Sandoz Inc
DMTAFY4 TC Antibiotics
DMTAFY4 DT Small molecular drug
DMTAFY4 PC 6196
DMTAFY4 MW 401.4
DMTAFY4 FM C19H19N3O5S
DMTAFY4 IC InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
DMTAFY4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTAFY4 IK UWYHMGVUTGAWSP-JKIFEVAISA-N
DMTAFY4 IU (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTAFY4 CA CAS 66-79-5
DMTAFY4 CB CHEBI:7809
DMTAFY4 DE Bacterial infection
DMQNWRD ID DMQNWRD
DMQNWRD DN Oxaliplatin
DMQNWRD HS Approved
DMQNWRD SN Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
DMQNWRD CP Sanofi-Aventis
DMQNWRD TC Anticancer Agents
DMQNWRD DT Small molecular drug
DMQNWRD PC 9887053
DMQNWRD MW 397.29
DMQNWRD FM C8H14N2O4Pt
DMQNWRD IC InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
DMQNWRD CS C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
DMQNWRD IK DRMCATBEKSVAPL-BNTLRKBRSA-N
DMQNWRD IU [(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
DMQNWRD CA CAS 61825-94-3
DMQNWRD DE Colorectal cancer
DM2QDX1 ID DM2QDX1
DM2QDX1 DN Oxamniquine
DM2QDX1 HS Approved
DM2QDX1 SN Mansil; Oxaminiquine; Oxamniquina; Oxamniquinum; Vansil; UK 4261; UK 4271; Mansil (TN); Oxamniquina [INN-Spanish]; Oxamniquinum [INN-Latin]; UK-4271; Vansil (TN); Oxamniquine (USAN/INN); Oxamniquine [USAN:BAN:INN]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
DM2QDX1 CP Pfizer Pharmaceuticals
DM2QDX1 TC Schistosomicides
DM2QDX1 DT Small molecular drug
DM2QDX1 PC 4612
DM2QDX1 MW 279.33
DM2QDX1 FM C14H21N3O3
DM2QDX1 IC InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3
DM2QDX1 CS CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO
DM2QDX1 IK XCGYUJZMCCFSRP-UHFFFAOYSA-N
DM2QDX1 IU [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol
DM2QDX1 CA CAS 21738-42-1
DM2QDX1 CB CHEBI:78416
DM2QDX1 DE Schistosomiasis
DMU9MYJ ID DMU9MYJ
DMU9MYJ DN Oxandrolone
DMU9MYJ HS Approved
DMU9MYJ SN Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)
DMU9MYJ CP Pfizer Pharmaceuticals
DMU9MYJ DT Small molecular drug
DMU9MYJ PC 5878
DMU9MYJ MW 306.4
DMU9MYJ FM C19H30O3
DMU9MYJ IC InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
DMU9MYJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
DMU9MYJ IK QSLJIVKCVHQPLV-PEMPUTJUSA-N
DMU9MYJ IU (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
DMU9MYJ CA CAS 53-39-4
DMU9MYJ CB CHEBI:7820
DMU9MYJ DE Alcoholic hepatitis
DMZ30JT ID DMZ30JT
DMZ30JT DN Oxantel pamoate
DMZ30JT HS Approved
DMZ30JT SN Telopar; Oxantel embonate; CP-14445; Oxantel pamoate (USAN); Telopar (TN); CP-14445-16; Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (E)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt); 4,4'-Methylenebis(3-hydroxy-2-naphthoic) acid, compound with (E)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1)
DMZ30JT TC Anthelmintics
DMZ30JT DT Small molecular drug
DMZ30JT PC 5281086
DMZ30JT MW 604.6
DMZ30JT FM C36H32N2O7
DMZ30JT IC InChI=1S/C23H16O6.C13H16N2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-7,10,16H,3,8-9H2,1H3/b;7-6+
DMZ30JT CS CN1CCCN=C1/C=C/C2=CC(=CC=C2)O.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O
DMZ30JT IK CCOAINFUFGBHBA-UETGHTDLSA-N
DMZ30JT IU 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol
DMZ30JT CA CAS 68813-55-8
DMZ30JT CB CHEBI:7821
DMZ30JT DE Trichuris trichiura infection
DM9UB0P ID DM9UB0P
DM9UB0P DN Oxaprozin
DM9UB0P HS Approved
DM9UB0P SN Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid
DM9UB0P CP Gd Searle Llc
DM9UB0P TC Antiinflammatory Agents
DM9UB0P DT Small molecular drug
DM9UB0P PC 4614
DM9UB0P MW 293.3
DM9UB0P FM C18H15NO3
DM9UB0P IC InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
DM9UB0P CS C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
DM9UB0P IK OFPXSFXSNFPTHF-UHFFFAOYSA-N
DM9UB0P IU 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
DM9UB0P CA CAS 21256-18-8
DM9UB0P CB CHEBI:7822
DM9UB0P DE Rheumatoid arthritis
DM1F42Z ID DM1F42Z
DM1F42Z DN Oxatomide
DM1F42Z HS Approved
DM1F42Z SN Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z CP Janssen Pharmaceutica
DM1F42Z TC Antiallergic Agents
DM1F42Z DT Small molecular drug
DM1F42Z PC 4615
DM1F42Z MW 426.6
DM1F42Z FM C27H30N4O
DM1F42Z IC InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
DM1F42Z CS C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM1F42Z IK BAINIUMDFURPJM-UHFFFAOYSA-N
DM1F42Z IU 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z CA CAS 60607-34-3
DM1F42Z CB CHEBI:31943
DM1F42Z DE Hay fever
DMXNZM4 ID DMXNZM4
DMXNZM4 DN Oxazepam
DMXNZM4 HS Approved
DMXNZM4 SN Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4 CP Genus Pharms
DMXNZM4 TC Hypnotics and Sedatives
DMXNZM4 DT Small molecular drug
DMXNZM4 PC 4616
DMXNZM4 MW 286.71
DMXNZM4 FM C15H11ClN2O2
DMXNZM4 IC InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
DMXNZM4 CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
DMXNZM4 IK ADIMAYPTOBDMTL-UHFFFAOYSA-N
DMXNZM4 IU 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4 CA CAS 604-75-1
DMXNZM4 CB CHEBI:7823
DMXNZM4 DE Anxiety disorder
DM5PU6O ID DM5PU6O
DM5PU6O DN Oxcarbazepine
DM5PU6O HS Approved
DM5PU6O SN Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O CP Norvatis Phamaceuticals Corporation
DM5PU6O TC Anticonvulsants
DM5PU6O DT Small molecular drug
DM5PU6O PC 34312
DM5PU6O MW 252.27
DM5PU6O FM C15H12N2O2
DM5PU6O IC InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
DM5PU6O CS C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
DM5PU6O IK CTRLABGOLIVAIY-UHFFFAOYSA-N
DM5PU6O IU 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O CA CAS 28721-07-5
DM5PU6O CB CHEBI:7824
DM5PU6O DE Epilepsy
DME7KRM ID DME7KRM
DME7KRM DN Oxiconazole
DME7KRM HS Approved
DME7KRM SN Oxiconazol; Oxiconazolum; Oxyconazole; Oxiconazol [INN-Spanish]; Oxiconazole (INN); Oxiconazole [INN:BAN]; Oxiconazolum [INN-Latin]; Ro 13-8996; Sgd 301-76; RO-13-8996; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime)
DME7KRM CP Fougera Pharmaceuticals Inc
DME7KRM TC Antifungal Agents
DME7KRM DT Small molecular drug
DME7KRM PC 5353853
DME7KRM MW 429.1
DME7KRM FM C18H13Cl4N3O
DME7KRM IC InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+
DME7KRM CS C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl
DME7KRM IK QRJJEGAJXVEBNE-HKOYGPOVSA-N
DME7KRM IU (Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine
DME7KRM CA CAS 64211-45-6
DME7KRM CB CHEBI:7825
DME7KRM DE Tinea pedis
DM9EQC0 ID DM9EQC0
DM9EQC0 DN Oxidized glutathione
DM9EQC0 HS Approved
DM9EQC0 DT Small molecular drug
DM9EQC0 PC 65359
DM9EQC0 MW 612.6
DM9EQC0 FM C20H32N6O12S2
DM9EQC0 IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DM9EQC0 CS C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DM9EQC0 IK YPZRWBKMTBYPTK-BJDJZHNGSA-N
DM9EQC0 IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9EQC0 CA CAS 27025-41-8
DM9EQC0 CB CHEBI:17858
DM9EQC0 DE Breast cancer; Bacterial infection
DMRKOS1 ID DMRKOS1
DMRKOS1 DN Oxilofrine
DMRKOS1 HS Approved
DMRKOS1 SN Oxilofrine hydrochloride; Carnigen (TN)
DMRKOS1 DT Small molecular drug
DMRKOS1 PC 688009
DMRKOS1 MW 181.23
DMRKOS1 FM C10H15NO2
DMRKOS1 IC InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1
DMRKOS1 CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NC
DMRKOS1 IK OXFGTKPPFSCSMA-XVKPBYJWSA-N
DMRKOS1 IU 4-[(1R,2S)-1-hydroxy-2-(methylamino)propyl]phenol
DMRKOS1 CA CAS 365-26-4
DMRKOS1 CB CHEBI:134822
DMRKOS1 DE Orthostatic hypotension
DM9FKSR ID DM9FKSR
DM9FKSR DN Oxitropium bromide
DM9FKSR HS Approved
DM9FKSR SN Oxivent (TN)
DM9FKSR CP Dieckmann
DM9FKSR DT Small molecular drug
DM9FKSR PC 6917865
DM9FKSR MW 412.3
DM9FKSR FM C19H26BrNO4
DM9FKSR IC InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13?,14-,15-,16+,17-,18+,20?;/m1./s1
DM9FKSR CS CC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DM9FKSR IK LCELQERNWLBPSY-YAYGZGPXSA-M
DM9FKSR IU [(1R,2R,4S,5S)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DM9FKSR CA CAS 30286-75-0
DM9FKSR DE Asthma
DM51OQW ID DM51OQW
DM51OQW DN Oxprenolol
DM51OQW HS Approved
DM51OQW SN Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
DM51OQW TC Antihypertensive Agents
DM51OQW DT Small molecular drug
DM51OQW PC 4631
DM51OQW MW 265.35
DM51OQW FM C15H23NO3
DM51OQW IC InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
DM51OQW CS CC(C)NCC(COC1=CC=CC=C1OCC=C)O
DM51OQW IK CEMAWMOMDPGJMB-UHFFFAOYSA-N
DM51OQW IU 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
DM51OQW CA CAS 6452-71-7
DM51OQW CB CHEBI:91704
DM51OQW DE Hypertension
DMLHSE3 ID DMLHSE3
DMLHSE3 DN Oxtriphylline
DMLHSE3 HS Approved
DMLHSE3 SN Choledyl; Cholegyl; Cholinophyllin; Cholinophylline; Filoral; Oxtrimethylline; Sabidal; Soliphylline; Teofilcolina; Teokolin; Theoxylline; Choline theophylline salt; Cholini theophyllinas; Colina teofillinato; Colina teofillinato [DCIT]; Oxtriphylline [USAN]; Oxtriphylline pediatric; Teofilinato de colina; Theophyllinate de choline; Theophylline cholinate; Theophylline salt of choline; Choledyl SA 400; Zy 15061; Choledyl (TN); Cholini theophyllinas [INN-Latin]; Teofilinato de colina [INN-Spanish]; Theophyllinate de choline[INN-French]; Choline salt with theophylline (1:1); Theophylline, compd. with choline; Choline, compd. with theophylline (1:1); Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); (2-Hydroxyethyl)trimethylammonium compound with theophylline; 1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium
DMLHSE3 TC Bronchodilator Agents
DMLHSE3 DT Small molecular drug
DMLHSE3 PC 656652
DMLHSE3 MW 283.33
DMLHSE3 FM C12H21N5O3
DMLHSE3 IC InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1
DMLHSE3 CS CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO
DMLHSE3 IK SOELXOBIIIBLRJ-UHFFFAOYSA-M
DMLHSE3 IU 1,3-dimethyl-2-oxopurin-6-olate;2-hydroxyethyl(trimethyl)azanium
DMLHSE3 CA CAS 4499-40-5
DMLHSE3 DE Cough
DMI0GDH ID DMI0GDH
DMI0GDH DN Oxybuprocaine
DMI0GDH HS Approved
DMI0GDH SN Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]
DMI0GDH CP Norvatis Phamaceuticals Corporation
DMI0GDH TC Anesthetics
DMI0GDH DT Small molecular drug
DMI0GDH PC 4633
DMI0GDH MW 308.4
DMI0GDH FM C17H28N2O3
DMI0GDH IC InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
DMI0GDH CS CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N
DMI0GDH IK CMHHMUWAYWTMGS-UHFFFAOYSA-N
DMI0GDH IU 2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
DMI0GDH CA CAS 99-43-4
DMI0GDH CB CHEBI:309594
DMI0GDH DE Anaesthesia
DMF2KLU ID DMF2KLU
DMF2KLU DN Oxybutynin hydrochloride
DMF2KLU HS Approved
DMF2KLU SN HOB-294; Oxybutynin hydrochloride (transdermal patch, overactive bladder); Oxybutynin hydrochloride (transdermal patch, overactive bladder), Hisamitsu
DMF2KLU CP Watson Pharmaceuticals
DMF2KLU DT Small molecular drug
DMF2KLU PC 91505
DMF2KLU MW 393.9
DMF2KLU FM C22H32ClNO3
DMF2KLU IC InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
DMF2KLU CS CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
DMF2KLU IK SWIJYDAEGSIQPZ-UHFFFAOYSA-N
DMF2KLU IU 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride
DMF2KLU CA CAS 1508-65-2
DMF2KLU CB CHEBI:7857
DMF2KLU DE Urinary incontinence
DMXLKHV ID DMXLKHV
DMXLKHV DN Oxycodone
DMXLKHV HS Approved
DMXLKHV CP Watson Laboratories
DMXLKHV TC Analgesics
DMXLKHV DT Small molecular drug
DMXLKHV PC 5284603
DMXLKHV MW 315.4
DMXLKHV FM C18H21NO4
DMXLKHV IC InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
DMXLKHV CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
DMXLKHV IK BRUQQQPBMZOVGD-XFKAJCMBSA-N
DMXLKHV IU (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMXLKHV CA CAS 76-42-6
DMXLKHV CB CHEBI:7852
DMXLKHV DE Pain; Back pain
DM8ZXT6 ID DM8ZXT6
DM8ZXT6 DN Oxymetazoline
DM8ZXT6 HS Approved
DM8ZXT6 SN Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6 CP Schein Pharmaceutical
DM8ZXT6 TC Nasal Decongestants
DM8ZXT6 DT Small molecular drug
DM8ZXT6 PC 4636
DM8ZXT6 MW 260.37
DM8ZXT6 FM C16H24N2O
DM8ZXT6 IC InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)
DM8ZXT6 CS CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C
DM8ZXT6 IK WYWIFABBXFUGLM-UHFFFAOYSA-N
DM8ZXT6 IU 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6 CA CAS 1491-59-4
DM8ZXT6 CB CHEBI:7862
DM8ZXT6 DE Eye inflammation; Nasal congestion
DMFXUT8 ID DMFXUT8
DMFXUT8 DN Oxymetholone
DMFXUT8 HS Approved
DMFXUT8 SN oxymetholone; Anasterone; 434-07-1; HMS3393H15
DMFXUT8 CP Solvay Pharmaceuticals
DMFXUT8 DT Small molecular drug
DMFXUT8 PC 5281034
DMFXUT8 MW 332.5
DMFXUT8 FM C21H32O3
DMFXUT8 IC InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
DMFXUT8 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
DMFXUT8 IK ICMWWNHDUZJFDW-DHODBPELSA-N
DMFXUT8 IU (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMFXUT8 CA CAS 434-07-1
DMFXUT8 CB CHEBI:7864
DMFXUT8 DE Aplastic anemia
DM65AGJ ID DM65AGJ
DM65AGJ DN Oxymorphone
DM65AGJ HS Approved
DM65AGJ SN Oxymorphone (abuse-resistant, pain); Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals; Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer
DM65AGJ CP Pain Therapeutics Inc
DM65AGJ TC Neurology Agents
DM65AGJ DT Small molecular drug
DM65AGJ PC 5284604
DM65AGJ MW 301.34
DM65AGJ FM C17H19NO4
DM65AGJ IC InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
DM65AGJ CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM65AGJ IK UQCNKQCJZOAFTQ-ISWURRPUSA-N
DM65AGJ IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM65AGJ CA CAS 76-41-5
DM65AGJ CB CHEBI:7865
DM65AGJ DE Pain
DMPZS7U ID DMPZS7U
DMPZS7U DN Oxyphenbutazone
DMPZS7U HS Approved
DMPZS7U SN Tandearil
DMPZS7U CP Novartis Pharmaceuticals Corp
DMPZS7U DT Small molecular drug
DMPZS7U PC 4641
DMPZS7U MW 324.4
DMPZS7U FM C19H20N2O3
DMPZS7U IC InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
DMPZS7U CS CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMPZS7U IK HFHZKZSRXITVMK-UHFFFAOYSA-N
DMPZS7U IU 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
DMPZS7U CA CAS 129-20-4
DMPZS7U CB CHEBI:76258
DMPZS7U DE Arthritis
DM3TABW ID DM3TABW
DM3TABW DN Oxyphencyclimine
DM3TABW HS Approved
DM3TABW SN Antulcus; Caridan; Daricol; Manir; Naridan; Oxifencicliminum; Oxiphencycliminum; Oxyphencycliminum; Zamanil; Oxifencicliminum [INN-Spanish]; Oxyphencyclimine (INN); Oxyphencyclimine [INN:BAN]; Oxyphencycliminum [INN-Latin]; Benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester; (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate; (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat; 1-Methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat
DM3TABW CP Pfizer Laboratories Div Pfizer Inc
DM3TABW TC Anticholinergic Agents
DM3TABW DT Small molecular drug
DM3TABW PC 4642
DM3TABW MW 344.4
DM3TABW FM C20H28N2O3
DM3TABW IC InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3
DM3TABW CS CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O
DM3TABW IK DUDKAZCAISNGQN-UHFFFAOYSA-N
DM3TABW IU (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
DM3TABW CA CAS 125-53-1
DM3TABW CB CHEBI:7868
DM3TABW DE Peptic ulcer
DMMQHOZ ID DMMQHOZ
DMMQHOZ DN Oxyphenonium
DMMQHOZ HS Approved
DMMQHOZ SN Argicillin; Atrenyl; Hydroxymethylgramicidin; Methacin; Methocidin; Methocidine; Methocidinum; Metocidina; Oxiphenonum; Spastrex;Oxyphenonium Chloride; Oxyphenonium Iodide; Methocidin [DCF:INN]; Methocidine [INN-French]; Methocidinum [INN-Latin]; Metocidina [INN-Spanish]; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium
DMMQHOZ CP Novartis Pharmaceuticals Corp
DMMQHOZ TC Parasympatholytics
DMMQHOZ DT Small molecular drug
DMMQHOZ PC 5749
DMMQHOZ MW 348.5
DMMQHOZ FM C21H34NO3+
DMMQHOZ IC InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1
DMMQHOZ CS CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
DMMQHOZ IK GFRUPHOKLBPHTQ-UHFFFAOYSA-N
DMMQHOZ IU 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium
DMMQHOZ CA CAS 14214-84-7
DMMQHOZ CB CHEBI:94329
DMMQHOZ DE Visceral spasms
DMOVH1M ID DMOVH1M
DMOVH1M DN Oxytetracycline
DMOVH1M HS Approved
DMOVH1M SN Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline
DMOVH1M CP Pfizer Pharmaceuticals
DMOVH1M TC Antibiotics
DMOVH1M DT Small molecular drug
DMOVH1M PC 54675779
DMOVH1M MW 460.4
DMOVH1M FM C22H24N2O9
DMOVH1M IC InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1
DMOVH1M CS C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
DMOVH1M IK OWFJMIVZYSDULZ-PXOLEDIWSA-N
DMOVH1M IU (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMOVH1M CA CAS 2058-46-0
DMOVH1M CB CHEBI:27701
DMOVH1M DE Bacterial infection
DMDL27I ID DMDL27I
DMDL27I DN Oxytocin
DMDL27I HS Approved
DMDL27I SN OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior; Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat)
DMDL27I CP Pastorus Pharma Llc
DMDL27I DT Small molecular drug
DMDL27I SQ DB00107 sequence: CYIQNCPLG
DMDL27I PC 439302
DMDL27I MW 1007.2
DMDL27I FM C43H66N12O12S2
DMDL27I IC InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
DMDL27I CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDL27I IK XNOPRXBHLZRZKH-DSZYJQQASA-N
DMDL27I IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMDL27I CA CAS 50-56-6
DMDL27I CB CHEBI:7872
DMDL27I DE Autism spectrum disorder; Lactation failure
DM1YB0R ID DM1YB0R
DM1YB0R DN OZ277
DM1YB0R HS Approved
DM1YB0R SN Arterolane; UNII-3N1TN351VB; 664338-39-0; OZ277; 3N1TN351VB; OZ-277; C22H36N2O4; Arterolane [INN]; RBx11160; OZ 277; SCHEMBL4547841; CHEMBL404431; CHEMBL580910; CHEMBL221773; SCHEMBL12612733; CHEMBL1197433; SCHEMBL13951812; SCHEMBL11379522; SCHEMBL10307589; VXYZBLXGCYNIHP-BBMJWGJISA-N; VXYZBLXGCYNIHP-CAGINOIPSA-N; ZINC14191464; RBX-11160; NCGC00274173-01; HY-10852; Y1261
DM1YB0R DT Small molecular drug
DM1YB0R PC 10475633
DM1YB0R MW 392.5
DM1YB0R FM C22H36N2O4
DM1YB0R IC InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)
DM1YB0R CS CC(C)(CNC(=O)CC1CCC2(CC1)OC3(C4CC5CC(C4)CC3C5)OO2)N
DM1YB0R IK VXYZBLXGCYNIHP-UHFFFAOYSA-N
DM1YB0R CA CAS 664338-39-0
DM1YB0R CB CHEBI:136054
DM1YB0R DE Malaria
DMT6AM2 ID DMT6AM2
DMT6AM2 DN Ozanimod
DMT6AM2 HS Approved
DMT6AM2 SN 1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1
DMT6AM2 CP Receptos San Diego, CA
DMT6AM2 PC 52938427
DMT6AM2 MW 404.5
DMT6AM2 FM C23H24N4O3
DMT6AM2 IC InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
DMT6AM2 CS CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N
DMT6AM2 IK XRVDGNKRPOAQTN-FQEVSTJZSA-N
DMT6AM2 IU 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
DMT6AM2 CA CAS 1306760-87-1
DMT6AM2 DE Crohn disease; Ulcerative colitis; Non-small-cell lung cancer; Multiple sclerosis
DM6KZMG ID DM6KZMG
DM6KZMG DN Ozenoxacin
DM6KZMG HS Approved
DM6KZMG SN T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer
DM6KZMG CP Ferrer Internacional
DM6KZMG PC 9863827
DM6KZMG MW 363.4
DM6KZMG FM C21H21N3O3
DM6KZMG IC InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
DM6KZMG CS CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
DM6KZMG IK XPIJWUTXQAGSLK-UHFFFAOYSA-N
DM6KZMG IU 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
DM6KZMG CA CAS 245765-41-7
DM6KZMG CB CHEBI:136050
DM6KZMG DE Impetigo; Bacterial infection
DMNKT8Z ID DMNKT8Z
DMNKT8Z DN Pachycarpine
DMNKT8Z HS Approved
DMNKT8Z SN (+)-sparteine
DMNKT8Z DT Small molecular drug
DMNKT8Z PC 7014
DMNKT8Z MW 234.38
DMNKT8Z FM C15H26N2
DMNKT8Z IC InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m1/s1
DMNKT8Z CS C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4
DMNKT8Z IK SLRCCWJSBJZJBV-TUVASFSCSA-N
DMNKT8Z IU (1R,2S,9R,10R)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane
DMNKT8Z CA CAS 492-08-0
DMNKT8Z DE Postpartum haemorrhage
DMLB81S ID DMLB81S
DMLB81S DN Paclitaxel
DMLB81S HS Approved
DMLB81S SN 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
DMLB81S TC Anticancer Agents
DMLB81S DT Small molecular drug
DMLB81S PC 36314
DMLB81S MW 853.918
DMLB81S FM C47H51NO14
DMLB81S IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMLB81S CS CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMLB81S IK RCINICONZNJXQF-MZXODVADSA-N
DMLB81S IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMLB81S CA CAS 33069-62-4
DMLB81S CB ChEBI:45863
DMLB81S DE Breast cancer
DMD7L94 ID DMD7L94
DMD7L94 DN Palbociclib
DMD7L94 HS Approved
DMD7L94 SN 571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
DMD7L94 CP Onyx Pharmaceuticals; Pfizer
DMD7L94 TC Anticancer Agents
DMD7L94 DT Small molecular drug
DMD7L94 PC 5330286
DMD7L94 MW 447.5
DMD7L94 FM C24H29N7O2
DMD7L94 IC InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
DMD7L94 CS CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
DMD7L94 IK AHJRHEGDXFFMBM-UHFFFAOYSA-N
DMD7L94 IU 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
DMD7L94 CA CAS 571190-30-2
DMD7L94 CB CHEBI:85993
DMD7L94 DE Solid tumour/cancer; Schizophrenia; Breast cancer
DM9JOYP ID DM9JOYP
DM9JOYP DN Palifermin
DM9JOYP HS Approved
DM9JOYP SN Kepivance; Kepivance (TN); Palifermin (USAN/INN)
DM9JOYP TC Antimucositis Agents
DM9JOYP SQ Palifermin sequence: SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT
DM9JOYP DE Oral mucositis
DM7NPJS ID DM7NPJS
DM7NPJS DN Paliperidone
DM7NPJS HS Approved
DM7NPJS SN Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson
DM7NPJS CP Johnson & Johnson
DM7NPJS DT Small molecular drug
DM7NPJS PC 115237
DM7NPJS MW 426.5
DM7NPJS FM C23H27FN4O3
DM7NPJS IC InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
DM7NPJS CS CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DM7NPJS IK PMXMIIMHBWHSKN-UHFFFAOYSA-N
DM7NPJS IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DM7NPJS CA CAS 144598-75-4
DM7NPJS CB CHEBI:83804
DM7NPJS DE Schizophrenia
DMQM9S0 ID DMQM9S0
DMQM9S0 DN Palivizumab
DMQM9S0 HS Approved
DMQM9S0 SN Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN)
DMQM9S0 CP Medlmmune
DMQM9S0 TC Antiviral Agents
DMQM9S0 DT Monoclonal antibody
DMQM9S0 SQ VH region MEDI-493: QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS >VH RegionQVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
DMQM9S0 DE Respiratory syncytial virus infection
DMBHMOX ID DMBHMOX
DMBHMOX DN Palonosetron
DMBHMOX HS Approved
DMBHMOX SN Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
DMBHMOX CP Eisai Inc
DMBHMOX TC Antiemetics
DMBHMOX DT Small molecular drug
DMBHMOX PC 6337614
DMBHMOX MW 296.4
DMBHMOX FM C19H24N2O
DMBHMOX IC InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1
DMBHMOX CS C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5
DMBHMOX IK CPZBLNMUGSZIPR-NVXWUHKLSA-N
DMBHMOX IU (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one
DMBHMOX CA CAS 135729-61-2
DMBHMOX CB CHEBI:85161
DMBHMOX DE Nausea
DMK2PBD ID DMK2PBD
DMK2PBD DN Palonosetron + fosnetupitant
DMK2PBD HS Approved
DMK2PBD CP Helsinn Group
DMK2PBD DT Antibody
DMK2PBD DE Chemotherapy-induced nausea
DMB4AVP ID DMB4AVP
DMB4AVP DN Pamidronate
DMB4AVP HS Approved
DMB4AVP SN AHPrBP; Amidronate; Aminomux; Aminopropanehydroxydiphosphonate; Aredia; Ribodroat; Acide pamidronique; Acido pamidronico; Acidum pamidronicum; Aminohydroxypropylidene diphosphonate; Novartis brand of pamidronate disodium salt; PAMIDRONATE DISODIUM; PAMIDRONIC ACID; Pamidronate calcium; Pamidronate monosodium; Bisphosphonate 6; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; Pamidronic acid (INN); Pamidronic acid [INN:BAN]; Ribodroat (TN); Amino-1-hydroxypropane-1,1-diphosphonate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; 1-hydroxy-3-aminopropane-1,1-diphosphonic acid; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate
DMB4AVP TC Antiinflammatory Agents
DMB4AVP DT Small molecular drug
DMB4AVP PC 4674
DMB4AVP MW 235.07
DMB4AVP FM C3H11NO7P2
DMB4AVP IC InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
DMB4AVP CS C(CN)C(O)(P(=O)(O)O)P(=O)(O)O
DMB4AVP IK WRUUGTRCQOWXEG-UHFFFAOYSA-N
DMB4AVP IU (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
DMB4AVP CA CAS 40391-99-9
DMB4AVP CB CHEBI:7903
DMB4AVP DE Hypercalcaemia
DMB0VY8 ID DMB0VY8
DMB0VY8 DN Pancuronium
DMB0VY8 HS Approved
DMB0VY8 SN Mioblock; Pavulon; Bromure de pancuronium; Bromuro de pancuronio; PANCURONIUM BROMIDE; Pancuronii bromidum; Pancuronium dibromide; Poncuronium bromide; NA 97; ORG NA 97; P 1918; Bromure de pancuronium [INN-French]; Bromuro de pancuronio [INN-Spanish]; ORG-NA 97; Pancuronii bromidum [INN-Latin]; Pavulon (TN); Pancuronium bromide (JP15/USAN/INN); Pancuronium bromide [USAN:BAN:INN:JAN]; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate
DMB0VY8 CP Organon International
DMB0VY8 TC Neuromuscular Nondepolarizing Agents
DMB0VY8 DT Small molecular drug
DMB0VY8 PC 441289
DMB0VY8 MW 572.9
DMB0VY8 FM C35H60N2O4+2
DMB0VY8 IC InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMB0VY8 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMB0VY8 IK GVEAYVLWDAFXET-XGHATYIMSA-N
DMB0VY8 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMB0VY8 CA CAS 16974-53-1
DMB0VY8 CB CHEBI:7907
DMB0VY8 DE Anaesthesia
DMQPD1F ID DMQPD1F
DMQPD1F DN Panitumumab
DMQPD1F HS Approved
DMQPD1F SN Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)
DMQPD1F CP Amgen & Takeda
DMQPD1F TC Anticancer Agents
DMQPD1F DT Monoclonal antibody
DMQPD1F DE Colorectal cancer; Head and neck cancer
DM58WKG ID DM58WKG
DM58WKG DN Panobinostat
DM58WKG HS Approved
DM58WKG SN Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG CP Novartis
DM58WKG DT Small molecular drug
DM58WKG PC 6918837
DM58WKG MW 349.4
DM58WKG FM C21H23N3O2
DM58WKG IC InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
DM58WKG CS CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
DM58WKG IK FPOHNWQLNRZRFC-ZHACJKMWSA-N
DM58WKG IU (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG CA CAS 404950-80-7
DM58WKG CB CHEBI:85990
DM58WKG DE Multiple myeloma; Primary myelofibrosis; Type-2 diabetes
DMSVOCZ ID DMSVOCZ
DMSVOCZ DN Pantoprazole
DMSVOCZ HS Approved
DMSVOCZ SN Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ CP Wyeth; Altana; Solvay
DMSVOCZ TC Antiulcer Agents
DMSVOCZ DT Small molecular drug
DMSVOCZ PC 4679
DMSVOCZ MW 383.4
DMSVOCZ FM C16H15F2N3O4S
DMSVOCZ IC InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
DMSVOCZ CS COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
DMSVOCZ IK IQPSEEYGBUAQFF-UHFFFAOYSA-N
DMSVOCZ IU 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ CA CAS 102625-70-7
DMSVOCZ CB CHEBI:7915
DMSVOCZ DE Gastroesophageal reflux disease
DM091H2 ID DM091H2
DM091H2 DN Pantothenic acid
DM091H2 HS Approved
DM091H2 SN D-pantothenic acid; pantothenic acid; vitamin B5; 79-83-4; pantothenate; Chick antidermatitis factor; (+)-Pantothenic acid; PANTOTHENOIC ACID; (R)-pantothenate; (D)-(+)-Pantothenic acid; Kyselina pantothenova [Czech]; HSDB 1020; Pantothenic Acid [BAN]; D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-beta-alanine; BRN 1727064; UNII-19F5HK2737; (R)-pantothenic acid; beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-; EINECS 201-229-0; (D,+)-N(alpha-gamma-Dihydroxy-beta,beta-dimethylbutyryl)-beta-alanine
DM091H2 DT Small molecular drug
DM091H2 PC 6613
DM091H2 MW 219.23
DM091H2 FM C9H17NO5
DM091H2 IC InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1
DM091H2 CS CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O
DM091H2 IK GHOKWGTUZJEAQD-ZETCQYMHSA-N
DM091H2 IU 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
DM091H2 CA CAS 79-83-4
DM091H2 CB CHEBI:46905
DM091H2 DE Vitamin deficiency
DMCA9QP ID DMCA9QP
DMCA9QP DN Papaverine
DMCA9QP HS Approved
DMCA9QP SN papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE
DMCA9QP TC Vasodilator Agents
DMCA9QP DT Small molecular drug
DMCA9QP PC 4680
DMCA9QP MW 339.4
DMCA9QP FM C20H21NO4
DMCA9QP IC InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
DMCA9QP CS COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
DMCA9QP IK XQYZDYMELSJDRZ-UHFFFAOYSA-N
DMCA9QP IU 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
DMCA9QP CA CAS 58-74-2
DMCA9QP CB CHEBI:28241
DMCA9QP DE Spasm
DMOC1BX ID DMOC1BX
DMOC1BX DN Paraldehyde
DMOC1BX HS Approved
DMOC1BX SN UNII-S6M3YBG8QA; S6M3YBG8QA
DMOC1BX DT Small molecular drug
DMOC1BX PC 31264
DMOC1BX MW 132.16
DMOC1BX FM C6H12O3
DMOC1BX IC InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3
DMOC1BX CS CC1OC(OC(O1)C)C
DMOC1BX IK SQYNKIJPMDEDEG-UHFFFAOYSA-N
DMOC1BX IU 2,4,6-trimethyl-1,3,5-trioxane
DMOC1BX CA CAS 123-63-7
DMOC1BX CB CHEBI:27909
DMOC1BX DE Insomnia
DMR5ZUP ID DMR5ZUP
DMR5ZUP DN Paramethadione
DMR5ZUP HS Approved
DMR5ZUP SN Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione
DMR5ZUP TC Anticonvulsants
DMR5ZUP DT Small molecular drug
DMR5ZUP PC 8280
DMR5ZUP MW 157.17
DMR5ZUP FM C7H11NO3
DMR5ZUP IC InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
DMR5ZUP CS CCC1(C(=O)N(C(=O)O1)C)C
DMR5ZUP IK VQASKUSHBVDKGU-UHFFFAOYSA-N
DMR5ZUP IU 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
DMR5ZUP CA CAS 115-67-3
DMR5ZUP CB CHEBI:7921
DMR5ZUP DE Seizure disorder; Fetal trimethadione syndrome
DM6PR40 ID DM6PR40
DM6PR40 DN Paramethasone
DM6PR40 HS Approved
DM6PR40 SN Cassenne; Cortiden; Dillar; Flumethone; Metilar; Parametasona; Parametasone; Paramethasonum; Paramezone; Parametasone [DCIT]; CS 1483; Dillar (TN); Parametasona [INN-Spanish]; Paramethasone (INN); Paramethasone [INN:BAN]; Paramethasonum [INN-Latin]; (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 16alpha-Methyl-6alpha-fluoroprednisolone; 6alpha-Fluoro-16alpha-methylprednisolone
DM6PR40 CP Eli Lilly And Co
DM6PR40 TC Antiinflammatory Agents
DM6PR40 DT Small molecular drug
DM6PR40 PC 5875
DM6PR40 MW 392.5
DM6PR40 FM C22H29FO5
DM6PR40 IC InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1
DM6PR40 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)F
DM6PR40 IK MKPDWECBUAZOHP-AFYJWTTESA-N
DM6PR40 IU (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM6PR40 CA CAS 53-33-8
DM6PR40 CB CHEBI:7922
DM6PR40 DE Inflammation; Diabetic macular edema
DMM0HR1 ID DMM0HR1
DMM0HR1 DN Pargyline
DMM0HR1 HS Approved
DMM0HR1 SN Benzylmethylpropargylamine; Benzylmethylpropynylamine; Eudatin; Eutron; Methylbenzylpropynylamine; Paragyline; Pargilina; Pargylamine; Pargylin; Pargylinum; Supirdyl; A 19120; MO 911; Pargilina [INN-Spanish]; Pargyline (INN); Pargyline [INN:BAN]; Pargylinum [INN-Latin]; Benzyl-methyl-2-propinylamin; Benzyl-methyl-2-propinylamin [Czech]; N-Methyl-N-benzylpropynylamine; N-Methyl-N-propargylbenzylamine; N-Methyl-N-2-propynylbenzylamine; N-Benzyl-N-methyl-2-propynylamine; N-Benzyl-N-methyl-2-propyn-1; N-Benzyl-N-methyl-2-propyn-1-amine; N-benzyl-N-methylprop-2-yn-1-amine; N-methyl-N-(phenylmethyl)prop-2-yn-1-amine
DMM0HR1 CP Abbott Laboratories Pharmaceutical Products Div
DMM0HR1 TC Antihypertensive Agents
DMM0HR1 DT Small molecular drug
DMM0HR1 PC 4688
DMM0HR1 MW 159.23
DMM0HR1 FM C11H13N
DMM0HR1 IC InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
DMM0HR1 CS CN(CC#C)CC1=CC=CC=C1
DMM0HR1 IK DPWPWRLQFGFJFI-UHFFFAOYSA-N
DMM0HR1 IU N-benzyl-N-methylprop-2-yn-1-amine
DMM0HR1 CA CAS 555-57-7
DMM0HR1 CB CHEBI:7930
DMM0HR1 DE Skin imperfections; Muscular dystrophy; Hypertension
DMYBV3G ID DMYBV3G
DMYBV3G DN Paricalcitol
DMYBV3G HS Approved
DMYBV3G SN Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
DMYBV3G CP Abbott Laboratories
DMYBV3G TC Parasympathomimetics
DMYBV3G DT Small molecular drug
DMYBV3G PC 5281104
DMYBV3G MW 416.6
DMYBV3G FM C27H44O3
DMYBV3G IC InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
DMYBV3G CS C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMYBV3G IK BPKAHTKRCLCHEA-UBFJEZKGSA-N
DMYBV3G IU (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMYBV3G CA CAS 131918-61-1
DMYBV3G CB CHEBI:7931
DMYBV3G DE Hyperparathyroidism
DM1AGXN ID DM1AGXN
DM1AGXN DN Paromomycin
DM1AGXN HS Approved
DM1AGXN SN Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine
DM1AGXN CP King Pharmaceuticals
DM1AGXN TC Antibiotics
DM1AGXN DT Small molecular drug
DM1AGXN PC 165580
DM1AGXN MW 615.6
DM1AGXN FM C23H45N5O14
DM1AGXN IC InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DM1AGXN CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DM1AGXN IK UOZODPSAJZTQNH-LSWIJEOBSA-N
DM1AGXN IU (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
DM1AGXN CA CAS 7542-37-2
DM1AGXN CB CHEBI:7934
DM1AGXN DE Intestinal amebiasis
DM5PVQE ID DM5PVQE
DM5PVQE DN Paroxetine
DM5PVQE HS Approved
DM5PVQE SN Seroxat (TN)
DM5PVQE CP GlaxoSmithKline
DM5PVQE TC Antidepressants
DM5PVQE DT Small molecular drug
DM5PVQE PC 43815
DM5PVQE MW 329.4
DM5PVQE FM C19H20FNO3
DM5PVQE IC InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
DM5PVQE CS C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
DM5PVQE IK AHOUBRCZNHFOSL-YOEHRIQHSA-N
DM5PVQE IU (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
DM5PVQE CA CAS 61869-08-7
DM5PVQE CB CHEBI:7936
DM5PVQE DE Depression
DMHM7JS ID DMHM7JS
DMHM7JS DN Pasireotide
DMHM7JS HS Approved
DMHM7JS SN Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230
DMHM7JS CP Novartis
DMHM7JS DT Small molecular drug
DMHM7JS PC 9941444
DMHM7JS MW 1047.2
DMHM7JS FM C58H66N10O9
DMHM7JS IC InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1
DMHM7JS CS C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
DMHM7JS IK VMZMNAABQBOLAK-DBILLSOUSA-N
DMHM7JS IU [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
DMHM7JS CA CAS 396091-73-9
DMHM7JS CB CHEBI:72312
DMHM7JS DE Cushing disease
DMMIQ20 ID DMMIQ20
DMMIQ20 DN Patiromer calcium
DMMIQ20 HS Approved
DMMIQ20 SN Patiromer; RLY-5016; Potassium binder (hyperkalemia), Relypsa
DMMIQ20 CP Relypsa Inc
DMMIQ20 DE Hyperkalemia
DMWSA0V ID DMWSA0V
DMWSA0V DN Patisiran
DMWSA0V HS Approved
DMWSA0V SN Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
DMWSA0V CP Alnylam Pharmaceuticals
DMWSA0V DT siRNA drug
DMWSA0V SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMWSA0V DE Amyloidosis; Amyloid cardiomyopathy; Hereditary amyloidosis; Transthyretin familial amyloid cardiomyopathy
DMF57DM ID DMF57DM
DMF57DM DN Pazopanib
DMF57DM HS Approved
DMF57DM SN Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK
DMF57DM PC 10113978
DMF57DM MW 437.5
DMF57DM FM C21H23N7O2S
DMF57DM IC CUIHSIWYWATEQL-UHFFFAOYSA-N
DMF57DM CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
DMF57DM IK 1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
DMF57DM IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
DMF57DM CA CAS 444731-52-6
DMF57DM CB CHEBI:71219
DMF57DM DE Renal cell carcinoma
DM6U9CQ ID DM6U9CQ
DM6U9CQ DN Pazopanib HCl
DM6U9CQ HS Approved
DM6U9CQ SN Votrient (TN)
DM6U9CQ CP GlaxoSmithKline
DM6U9CQ DT Small molecular drug
DM6U9CQ PC 11525740
DM6U9CQ MW 474
DM6U9CQ FM C21H24ClN7O2S
DM6U9CQ IC InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
DM6U9CQ CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
DM6U9CQ IK MQHIQUBXFFAOMK-UHFFFAOYSA-N
DM6U9CQ IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
DM6U9CQ CA CAS 635702-64-6
DM6U9CQ CB CHEBI:71217
DM6U9CQ DE Renal cell carcinoma
DM49IGF ID DM49IGF
DM49IGF DN Pefloxacin
DM49IGF HS Approved
DM49IGF SN Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo
DM49IGF TC Antiinfective Agents
DM49IGF DT Small molecular drug
DM49IGF PC 51081
DM49IGF MW 333.36
DM49IGF FM C17H20FN3O3
DM49IGF IC InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)
DM49IGF CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
DM49IGF IK FHFYDNQZQSQIAI-UHFFFAOYSA-N
DM49IGF IU 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM49IGF CA CAS 70458-92-3
DM49IGF CB CHEBI:50199
DM49IGF DE Gonococcal urethritis
DMOWEBU ID DMOWEBU
DMOWEBU DN Pegaptanib
DMOWEBU HS Approved
DMOWEBU SN Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838
DMOWEBU CP Eyetech pharmaceuticals and Pfizer
DMOWEBU TC Antiangiogenic Agents
DMOWEBU DT Aptamer
DMOWEBU PC 56603655
DMOWEBU MW 541.6
DMOWEBU FM C22H44N3O10P
DMOWEBU IC InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)/t19-/m0/s1
DMOWEBU CS COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
DMOWEBU IK WLCZTRVUXYALDD-IBGZPJMESA-N
DMOWEBU IU 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid
DMOWEBU DE Neovascular age-related macular degeneration
DM7UP8X ID DM7UP8X
DM7UP8X DN Pegfilgrastim
DM7UP8X HS Approved
DM7UP8X SN Neulasta; Neulasta (TN); Pegfilgrastim (INN)
DM7UP8X CP Amgen Inc
DM7UP8X TC Immunomodulatory Agents
DM7UP8X DT Small molecular drug
DM7UP8X SQ Pegfilgrastim sequence: MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
DM7UP8X PC 70683024
DM7UP8X MW 730.7
DM7UP8X FM C27H46N4O19
DM7UP8X IC InChI=1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1
DM7UP8X CS C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C
DM7UP8X IK GAQMWPRWVIGRRV-IVDGIBIRSA-N
DM7UP8X IU (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DM7UP8X DE Malignant solid tumour
DMJI3BA ID DMJI3BA
DMJI3BA DN Peginterferon alfa-2a
DMJI3BA HS Approved
DMJI3BA SN Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a (USAN/INN); Peginterferon alfa-2a (genetical recombination) (JAN)
DMJI3BA CP Hoffmann-La Roche pharmaceutical company
DMJI3BA TC Anticancer Agents
DMJI3BA SQ Peginterferon alfa-2a sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMJI3BA DE Hairy cell leukaemia
DMAP58Y ID DMAP58Y
DMAP58Y DN Peginterferon alfa-2b
DMAP58Y HS Approved
DMAP58Y SN PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN)
DMAP58Y CP Schering-Plough
DMAP58Y TC Antiviral Agents
DMAP58Y SQ DB00022 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMAP58Y DE Hepatitis C virus infection
DMCLR6G ID DMCLR6G
DMCLR6G DN Pegloticase
DMCLR6G HS Approved
DMCLR6G SN Krystexxa (TN)
DMCLR6G CP Savient
DMCLR6G SQ Pegloticase: TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL
DMCLR6G DE Gout
DM6NZ2P ID DM6NZ2P
DM6NZ2P DN Pegvaliase
DM6NZ2P HS Approved
DM6NZ2P SN BMN 165; Pegvaliase [INN]; UNII-N6UAH27EUV; N6UAH27EUV
DM6NZ2P CP BioMarin Pharmaceutical
DM6NZ2P PC 86278362
DM6NZ2P MW 318.41
DM6NZ2P FM C15H30N2O5
DM6NZ2P IC InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
DM6NZ2P CS COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N
DM6NZ2P IK NPOCDVAOUKODSQ-ZDUSSCGKSA-N
DM6NZ2P IU (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid
DM6NZ2P CA CAS 1585984-95-7
DM6NZ2P DE Phenylketonuria
DMDEZI3 ID DMDEZI3
DMDEZI3 DN Pegvisomant
DMDEZI3 HS Approved
DMDEZI3 SN Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN)
DMDEZI3 CP Abbott Laboratories
DMDEZI3 TC Anabolic Agents
DMDEZI3 SQ DB00082 sequence: FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
DMDEZI3 DE Acromegaly
DMRH0D5 ID DMRH0D5
DMRH0D5 DN PEGylated IFN beta 1-a
DMRH0D5 HS Approved
DMRH0D5 SN BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec
DMRH0D5 CP Biogen idec
DMRH0D5 DE Type-2 diabetes
DM8DQV9 ID DM8DQV9
DM8DQV9 DN Pelubiprofen
DM8DQV9 HS Approved
DM8DQV9 SN Pelubi; Rubione; CS-670; DW-330; RS-2131
DM8DQV9 CP Sankyo Co Ltd
DM8DQV9 DT Small molecular drug
DM8DQV9 PC 5282203
DM8DQV9 MW 258.31
DM8DQV9 FM C16H18O3
DM8DQV9 IC InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+
DM8DQV9 CS CC(C1=CC=C(C=C1)/C=C/2\\CCCCC2=O)C(=O)O
DM8DQV9 IK AUZUGWXLBGZUPP-GXDHUFHOSA-N
DM8DQV9 IU 2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid
DM8DQV9 CA CAS 69956-77-0
DM8DQV9 DE Back pain
DMD1VZL ID DMD1VZL
DMD1VZL DN Pemafibrate
DMD1VZL HS Approved
DMD1VZL SN K-877
DMD1VZL CP Kowa Co Ltd
DMD1VZL PC 11526038
DMD1VZL MW 490.5
DMD1VZL FM C28H30N2O6
DMD1VZL IC InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
DMD1VZL CS CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
DMD1VZL IK ZHKNLJLMDFQVHJ-RUZDIDTESA-N
DMD1VZL IU (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid
DMD1VZL CA CAS 848259-27-8
DMD1VZL DE Lipid metabolism disorder; Cardiovascular disease; Hyperlipidemia
DMFQEA6 ID DMFQEA6
DMFQEA6 DN Pembrolizumab
DMFQEA6 HS Approved
DMFQEA6 CP Merck Kenilworth, NJ
DMFQEA6 DT Monoclonal antibody
DMFQEA6 SQ Heavy Chain Sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFQEA6 DE Solid tumour/cancer; Hepatocellular carcinoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Prostate cancer; Renal cell carcinoma; Small-cell lung cancer; Breast cancer; Colorectal cancer; Cutaneous squamous cell carcinoma; Esophageal cancer; Melanoma
DMMX2E6 ID DMMX2E6
DMMX2E6 DN Pemetrexed
DMMX2E6 HS Approved
DMMX2E6 SN Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
DMMX2E6 CP Eli Lilly
DMMX2E6 TC Anticancer Agents
DMMX2E6 DT Small molecular drug
DMMX2E6 PC 135410875
DMMX2E6 MW 427.4
DMMX2E6 FM C20H21N5O6
DMMX2E6 IC InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
DMMX2E6 CS C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMMX2E6 IK WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
DMMX2E6 IU (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
DMMX2E6 CA CAS 137281-23-3
DMMX2E6 CB CHEBI:63616
DMMX2E6 DE Malignant pleural mesothelioma
DM819JF ID DM819JF
DM819JF DN Pemigatinib
DM819JF HS Approved
DM819JF SN Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
DM819JF CP Incyte Wilmington, DE
DM819JF PC 86705695
DM819JF MW 487.5
DM819JF FM C24H27F2N5O4
DM819JF IC InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
DM819JF CS CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
DM819JF IK HCDMJFOHIXMBOV-UHFFFAOYSA-N
DM819JF IU 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
DM819JF CA CAS 1513857-77-6
DM819JF DE Bladder cancer; Myeloproliferative syndrome; Cholangiocarcinoma
DML97WV ID DML97WV
DML97WV DN Pemirolast
DML97WV HS Approved
DML97WV SN Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV TC Antiallergic Agents
DML97WV DT Small molecular drug
DML97WV PC 57697
DML97WV MW 228.21
DML97WV FM C10H8N6O
DML97WV IC InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)
DML97WV CS CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3
DML97WV IK HIANJWSAHKJQTH-UHFFFAOYSA-N
DML97WV IU 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV CA CAS 69372-19-6
DML97WV CB CHEBI:134936
DML97WV DE Allergic conjunctivitis
DM4ES8F ID DM4ES8F
DM4ES8F DN Penbutolol
DM4ES8F HS Approved
DM4ES8F SN Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol
DM4ES8F TC Antihypertensive Agents
DM4ES8F DT Small molecular drug
DM4ES8F PC 37464
DM4ES8F MW 291.4
DM4ES8F FM C18H29NO2
DM4ES8F IC InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1
DM4ES8F CS CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O
DM4ES8F IK KQXKVJAGOJTNJS-HNNXBMFYSA-N
DM4ES8F IU (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
DM4ES8F CA CAS 38363-40-5
DM4ES8F CB CHEBI:7954
DM4ES8F DE Hypertension
DMOUMDV ID DMOUMDV
DMOUMDV DN Penciclovir
DMOUMDV HS Approved
DMOUMDV SN penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
DMOUMDV TC Antiviral Agents
DMOUMDV DT Small molecular drug
DMOUMDV PC 135398748
DMOUMDV MW 253.26
DMOUMDV FM C10H15N5O3
DMOUMDV IC InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
DMOUMDV CS C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
DMOUMDV IK JNTOCHDNEULJHD-UHFFFAOYSA-N
DMOUMDV IU 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
DMOUMDV CA CAS 39809-25-1
DMOUMDV CB CHEBI:7956
DMOUMDV DE Human immunodeficiency virus infection
DMG1DTE ID DMG1DTE
DMG1DTE DN Penfluridol
DMG1DTE HS Approved
DMG1DTE SN PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates
DMG1DTE DT Small molecular drug
DMG1DTE PC 33630
DMG1DTE MW 524
DMG1DTE FM C28H27ClF5NO
DMG1DTE IC InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
DMG1DTE CS C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMG1DTE IK MDLAAYDRRZXJIF-UHFFFAOYSA-N
DMG1DTE IU 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
DMG1DTE CA CAS 26864-56-2
DMG1DTE CB CHEBI:92278
DMG1DTE DE Schizophrenia
DM40EF6 ID DM40EF6
DM40EF6 DN Penicillamine
DM40EF6 HS Approved
DM40EF6 SN D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Beta-Thiovaline; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; Beta,beta-Dimethylcysteine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine; D-penicillamine
DM40EF6 TC Antidotes
DM40EF6 DT Small molecular drug
DM40EF6 PC 5852
DM40EF6 MW 149.21
DM40EF6 FM C5H11NO2S
DM40EF6 IC InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1
DM40EF6 CS CC(C)([C@H](C(=O)O)N)S
DM40EF6 IK VVNCNSJFMMFHPL-VKHMYHEASA-N
DM40EF6 IU (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid
DM40EF6 CA CAS 771431-20-0
DM40EF6 CB CHEBI:7959
DM40EF6 DE Rheumatoid arthritis
DMNMHBV ID DMNMHBV
DMNMHBV DN Penicillin
DMNMHBV HS Approved
DMNMHBV SN Cillin; Pentids; 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Phenylmethyl)penicillin; 7005-30-3; NSC131815; (Phenylmethyl)penicillinic acid; 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1DHC; AC1Q5UVJ; Penicilline G sodium salt; Oprea1_713794; Oprea1_861345; CHEMBL300052; SCHEMBL2109546; CTK2H5530
DMNMHBV DT Small molecular drug
DMNMHBV PC 2349
DMNMHBV MW 334.4
DMNMHBV FM C16H18N2O4S
DMNMHBV IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)
DMNMHBV CS CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMNMHBV IK JGSARLDLIJGVTE-UHFFFAOYSA-N
DMNMHBV IU 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNMHBV CA CAS 61-33-6
DMNMHBV DE Bacterial infection
DM49VEW ID DM49VEW
DM49VEW DN Penicillin G Benzathine
DM49VEW HS Approved
DM49VEW SN Bicillin L-a; Permapen; Bicillin
DM49VEW CP King Pharmaceuticals Inc
DM49VEW TC Antiinfective Agents
DM49VEW DT Small molecular drug
DM49VEW PC 656811
DM49VEW MW 981.2
DM49VEW FM C48H64N6O12S2
DM49VEW IC InChI=1S/2C16H18N2O4S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1
DM49VEW CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCCNCC2=CC=CC=C2.O.O.O.O
DM49VEW IK WIDKTXGNSOORHA-CJHXQPGBSA-N
DM49VEW IU N,N'-dibenzylethane-1,2-diamine;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate
DM49VEW CA CAS 41372-02-5
DM49VEW DE Bacterial infection
DMU4JLB ID DMU4JLB
DMU4JLB DN Penicillin G Procaine
DMU4JLB HS Approved
DMU4JLB SN Duracillin A.S.; Pfizerpen-as
DMU4JLB CP Eli Lilly And Co
DMU4JLB TC Antiinfective Agents
DMU4JLB DT Small molecular drug
DMU4JLB PC 22502
DMU4JLB MW 588.7
DMU4JLB FM C29H40N4O7S
DMU4JLB IC InChI=1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3;1H2/t11-,12+,14-;;/m1../s1
DMU4JLB CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O
DMU4JLB IK KZDCMKVLEYCGQX-UDPGNSCCSA-N
DMU4JLB IU 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate
DMU4JLB CA CAS 6130-64-9
DMU4JLB DE Bacterial infection
DMY18XK ID DMY18XK
DMY18XK DN Penicillin G Sodium
DMY18XK HS Approved
DMY18XK SN Penicillin G sodium salt; 69-57-8; Benzylpenicillin sodium; Crystapen; American penicillin; Pencillin G sodium; Sodium penicillin G; BENZYLPENICILLIN SODIUM SALT; Sodium penicillin; Sodium benzylpenicillinate; Sodium penicillin II; Veticillin; Penilaryn; Mycofarm; Novocillin; Sodium benzylpenicillin; Kesso-Pen; Pen-A-Brasive; Sodium benzylpenicillin G; Monosodium benzylpenicillin; Benzylpenicillinic acid sodium salt; Sugracillin sodium salt; Penicillin G Sodium, Crystalline; Sodium benzylp
DMY18XK CP Bristol Myers Squibb Spa
DMY18XK TC Antiinfective Agents
DMY18XK DT Small molecular drug
DMY18XK PC 23668834
DMY18XK MW 356.4
DMY18XK FM C16H17N2NaO4S
DMY18XK IC InChI=1S/C16H18N2O4S.Na/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DMY18XK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)[O-])C.[Na+]
DMY18XK IK FCPVYOBCFFNJFS-LQDWTQKMSA-M
DMY18XK IU sodium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMY18XK CA CAS 69-57-8
DMY18XK CB CHEBI:51765
DMY18XK DE Bacterial infection
DMKVOYF ID DMKVOYF
DMKVOYF DN Penicillin V
DMKVOYF HS Approved
DMKVOYF SN Apocillin; Apopen; Beromycin; Calcipen; Fenacilin; Fenospen; Fenossimetilpenicillina; Fenoximetilpenicilina; Fenoxymethylpenicillin; Fenoxypen; Meropenin; Oracillin; Oratren; Ospen; PNV; PVA; Phenocillin; Phenomycilline; Phenopenicillin; Phenoximethylpenicillinum; Phenoxomethylpenicillanyl; Phenoxomethylpenicillin; Phenoxymethylpenicillanyl; Phenoxymethylpenicillin; Phenoxymethylpenicilline; Phenoxymethylpenicillinum; Robicillin; Rocilin; Stabicillin; Vebecillin; Vegacillin; Acipen V; Compocillin V; Crystapen V; Distaquaine V; Eskacillian V; Eskacillin V; Fenossimetilpenicillina [DCIT]; Penicillin V [USAN]; Penicillin phenoxymethyl; Phenoxymethyl penicillin; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillinic acid; Phenoxymethylpenicillinic acid potassium salt; Acipen-v; Beromycin, Penicillin; Berromycin, Penicillin; Fenoximetilpenicilina [INN-Spanish]; Pen-Oral; Pen-V; Pen-vee; Penicillin V (USP); Penicillin, Phenoxymethyl; Phenoxymethylpenicillin (INN); Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; V-Cil; V-Cillin; V-Cylina; V-Cyline; V-Tablopen; P-Mega-Tablinen; V-Cillin (TN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); 6-Phenoxyacetamidopenicillanic acid
DMKVOYF TC Antibiotics
DMKVOYF DT Small molecular drug
DMKVOYF PC 6869
DMKVOYF MW 350.4
DMKVOYF FM C16H18N2O5S
DMKVOYF IC InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMKVOYF CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C
DMKVOYF IK BPLBGHOLXOTWMN-MBNYWOFBSA-N
DMKVOYF IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMKVOYF CA CAS 87-08-1
DMKVOYF CB CHEBI:27446
DMKVOYF DE Bacterial infection
DM8LX76 ID DM8LX76
DM8LX76 DN Penicillin V Potassium
DM8LX76 HS Approved
DM8LX76 SN Ledercillin Vk; Pen-vee K; Pfizerpen Vk; Veetids; Veetids '125'; Veetids '250'; Uticillin Vk; Veetids '500'
DM8LX76 CP Glaxosmithkline
DM8LX76 TC Antiinfective Agents
DM8LX76 DT Small molecular drug
DM8LX76 PC 23676814
DM8LX76 MW 388.5
DM8LX76 FM C16H17KN2O5S
DM8LX76 IC InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DM8LX76 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+]
DM8LX76 IK HCTVWSOKIJULET-LQDWTQKMSA-M
DM8LX76 IU potassium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DM8LX76 CA CAS 132-98-9
DM8LX76 CB CHEBI:7967
DM8LX76 DE Bacterial infection
DMZ9MO5 ID DMZ9MO5
DMZ9MO5 DN Pentaerythritol tetranitrate
DMZ9MO5 HS Approved
DMZ9MO5 SN PENTAERYTHRITOL TETRANITRATE; PETN; Penthrite; Nitropentaerythrite; Nitropentaerythritol; Nitropenta; Pentaerithrityl tetranitrate; Vasodiatol; Pentanitrine; Pentanitrol; Quintrate; Corpent; Baritrate; Angicap; Perityl; Peritrate; Penthrit; Antora; Erinit; Peridex-LA; 78-11-5; Deltrate-20; Neopentanetetrayl nitrate; Tetrasule; Pergitral; Pentritol; Pentrite; Nitrotalans; Kaytrate; Duotrate; Subicard; Rythritol; Prevangor; Pentryate; Nitropenton; Nitropent; Pentrate; Pentitrate; Pentafin; Nitrinal; Niperyth; Mycardol; Metranil; Lowetrate; Arcotrate
DMZ9MO5 DT Small molecular drug
DMZ9MO5 PC 6518
DMZ9MO5 MW 316.14
DMZ9MO5 FM C5H8N4O12
DMZ9MO5 IC InChI=1S/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2
DMZ9MO5 CS C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-]
DMZ9MO5 IK TZRXHJWUDPFEEY-UHFFFAOYSA-N
DMZ9MO5 IU [3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate
DMZ9MO5 CA CAS 78-11-5
DMZ9MO5 CB CHEBI:25879
DMZ9MO5 DE Angina pectoris
DMRCLZB ID DMRCLZB
DMRCLZB DN Pentagastrin
DMRCLZB HS Approved
DMRCLZB SN Peptavlon; Peptavlon (TN); Pentagastrin (JAN/USAN/INN); (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB TC Diagnostic Agents
DMRCLZB DT Small molecular drug
DMRCLZB PC 9853654
DMRCLZB MW 767.9
DMRCLZB FM C37H49N7O9S
DMRCLZB IC InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
DMRCLZB CS CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
DMRCLZB IK NEYNJQRKHLUJRU-DZUOILHNSA-N
DMRCLZB IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB CA CAS 5534-95-2
DMRCLZB CB CHEBI:31974
DMRCLZB DE Diagnostic imaging
DMHZJCG ID DMHZJCG
DMHZJCG DN Pentamidine
DMHZJCG HS Approved
DMHZJCG SN Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG TC Antifungal Agents
DMHZJCG DT Small molecular drug
DMHZJCG PC 4735
DMHZJCG MW 340.4
DMHZJCG FM C19H24N4O2
DMHZJCG IC InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
DMHZJCG CS C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
DMHZJCG IK XDRYMKDFEDOLFX-UHFFFAOYSA-N
DMHZJCG IU 4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG CA CAS 100-33-4
DMHZJCG CB CHEBI:45081
DMHZJCG DE Fungal infection; Human immunodeficiency virus infection
DM1XBHS ID DM1XBHS
DM1XBHS DN Pentazocine
DM1XBHS HS Approved
DM1XBHS SN Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
DM1XBHS CP Sterling Drug Company
DM1XBHS TC Anesthetics
DM1XBHS DT Small molecular drug
DM1XBHS PC 441278
DM1XBHS MW 285.4
DM1XBHS FM C19H27NO
DM1XBHS IC InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
DM1XBHS CS C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O
DM1XBHS IK VOKSWYLNZZRQPF-GDIGMMSISA-N
DM1XBHS IU (1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM1XBHS CA CAS 359-83-1
DM1XBHS CB CHEBI:7982
DM1XBHS DE Pain
DMFNH7L ID DMFNH7L
DMFNH7L DN Pentobarbital
DMFNH7L HS Approved
DMFNH7L SN Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L CP Oak Pharmaceuticals Inc
DMFNH7L TC Hypnotics and Sedatives
DMFNH7L DT Small molecular drug
DMFNH7L PC 4737
DMFNH7L MW 226.27
DMFNH7L FM C11H18N2O3
DMFNH7L IC InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMFNH7L CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMFNH7L IK WEXRUCMBJFQVBZ-UHFFFAOYSA-N
DMFNH7L IU 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L CA CAS 76-74-4
DMFNH7L CB CHEBI:7983
DMFNH7L DE Insomnia
DM38VYQ ID DM38VYQ
DM38VYQ DN Pentolinium
DM38VYQ HS Approved
DM38VYQ SN Pentolineum; Pentolonium; Pentolonum; 1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium); 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ CP Wyeth Ayerst Laboratories
DM38VYQ TC Antihypertensive Agents
DM38VYQ DT Small molecular drug
DM38VYQ PC 5850
DM38VYQ MW 240.43
DM38VYQ FM C15H32N2+2
DM38VYQ IC InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
DM38VYQ CS C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C
DM38VYQ IK XSBSKEQEUFOSDD-UHFFFAOYSA-N
DM38VYQ IU 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ CA CAS 144-44-5
DM38VYQ CB CHEBI:347401
DM38VYQ DE Hypotension
DM2HRKE ID DM2HRKE
DM2HRKE DN Pentosan polysulfate
DM2HRKE HS Approved
DM2HRKE SN Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE CP Ortho-McNeil Pharmaceutical
DM2HRKE TC Anticoagulants
DM2HRKE DT Small molecular drug
DM2HRKE PC 37720
DM2HRKE MW 602.5
DM2HRKE FM C10H18O21S4
DM2HRKE IC InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
DM2HRKE CS C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O
DM2HRKE IK FCCNSUIJIOOXEZ-SJYYZXOBSA-N
DM2HRKE IU [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE CA CAS 37300-21-3
DM2HRKE DE Painful bladder syndrome; Interstitial cystitis
DM0HXDS ID DM0HXDS
DM0HXDS DN Pentostatin
DM0HXDS HS Approved
DM0HXDS SN Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin
DM0HXDS TC Anticancer Agents
DM0HXDS DT Small molecular drug
DM0HXDS PC 439693
DM0HXDS MW 268.27
DM0HXDS FM C11H16N4O4
DM0HXDS IC InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
DM0HXDS CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC=NC[C@H]3O)CO)O
DM0HXDS IK FPVKHBSQESCIEP-JQCXWYLXSA-N
DM0HXDS IU (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
DM0HXDS CA CAS 53910-25-1
DM0HXDS DE Hairy cell leukaemia
DMU3DNC ID DMU3DNC
DMU3DNC DN Pentoxifylline
DMU3DNC HS Approved
DMU3DNC SN Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC CP Aventis Pharmaceuticals Inc.
DMU3DNC TC Vasodilator Agents
DMU3DNC DT Small molecular drug
DMU3DNC PC 4740
DMU3DNC MW 278.31
DMU3DNC FM C13H18N4O3
DMU3DNC IC InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
DMU3DNC CS CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMU3DNC IK BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DMU3DNC IU 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC CA CAS 6493-05-6
DMU3DNC CB CHEBI:7986
DMU3DNC DE Intermittent claudication
DMNXY5K ID DMNXY5K
DMNXY5K DN Peramivir
DMNXY5K HS Approved
DMNXY5K SN PeramiFlu; S-021812; (1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; PRV
DMNXY5K CP BioCryst Pharmaceuticals
DMNXY5K DT Small molecular drug
DMNXY5K PC 154234
DMNXY5K MW 328.41
DMNXY5K FM C15H28N4O4
DMNXY5K IC InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
DMNXY5K CS CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C
DMNXY5K IK XRQDFNLINLXZLB-CKIKVBCHSA-N
DMNXY5K IU (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DMNXY5K CA CAS 330600-85-6
DMNXY5K CB CHEBI:85202
DMNXY5K DE Influenza virus infection
DM2AOTZ ID DM2AOTZ
DM2AOTZ DN Perazine
DM2AOTZ HS Approved
DM2AOTZ SN Perazine maleate; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, maleate; 84-97-9 (Parent); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (Z)-2-butenedioate; SCHEMBL220704; AC1O6123; LS-105593; 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ DT Small molecular drug
DM2AOTZ PC 4744
DM2AOTZ MW 339.5
DM2AOTZ FM C20H25N3S
DM2AOTZ IC InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
DM2AOTZ CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42
DM2AOTZ IK WEYVCQFUGFRXOM-UHFFFAOYSA-N
DM2AOTZ IU 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ CA CAS 84-97-9
DM2AOTZ CB CHEBI:59118
DM2AOTZ DE Psychotic disorder
DM14MAE ID DM14MAE
DM14MAE DN Pergolide
DM14MAE HS Approved
DM14MAE SN Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline
DM14MAE CP Valeant Pharmaceuticals
DM14MAE TC Antiparkinson Agents
DM14MAE DT Small molecular drug
DM14MAE PC 47811
DM14MAE MW 314.5
DM14MAE FM C19H26N2S
DM14MAE IC InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
DM14MAE CS CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
DM14MAE IK YEHCICAEULNIGD-MZMPZRCHSA-N
DM14MAE IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DM14MAE CA CAS 66104-22-1
DM14MAE CB CHEBI:63617
DM14MAE DE Parkinson disease
DM5GKOV ID DM5GKOV
DM5GKOV DN Pergolide mesylate
DM5GKOV HS Approved
DM5GKOV SN Pergolida; Pergolide (mesylate); Pergolide Methanesulfonate; Pergolide mesilate; Permax (TN); LY127809; PERGOLIDE MESYLATE; PERGOLIDE MESYLATE SALT; 55B9HQY616; 66104-23-2; 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate; 8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate; 8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate; CHEBI:8021; CHEMBL1275; CPD000058504; DSSTox_CID_20583; DSSTox_GSID_40583; DSSTox_RID_77029; MLS000069837; MPE; SMR000058504; UNII-55B9HQY616; LY-127,809; LY-127809; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum; Pergolidum [INN-Latin]; Permax; Prestwick0_000295; Prestwick1_000295; Prestwick2_000295; Prestwick3_000295; SR-01000721840; Spectrum2_001970; Spectrum4_000835; Spectrum5_001649; Spectrum_001647; TNP00315; pergolide; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; 24MJ822NZ9; 66104-22-1; CHEBI:63617; CHEMBL531; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; NCGC00017366-04; UNII-24MJ822NZ9
DM5GKOV PC 47812
DM5GKOV MW 410.6
DM5GKOV FM C20H30N2O3S2
DM5GKOV IC UWCVGPLTGZWHGS-ZORIOUSZSA-N
DM5GKOV CS CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O
DM5GKOV IK 1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1
DM5GKOV IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid
DM5GKOV CA CAS 66104-23-2
DM5GKOV CB CHEBI:8021
DM5GKOV DE Parkinsonism
DMINO7Z ID DMINO7Z
DMINO7Z DN Perhexiline
DMINO7Z HS Approved
DMINO7Z SN Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
DMINO7Z TC Vasodilator Agents
DMINO7Z DT Small molecular drug
DMINO7Z PC 4746
DMINO7Z MW 277.5
DMINO7Z FM C19H35N
DMINO7Z IC InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
DMINO7Z CS C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
DMINO7Z IK CYXKNKQEMFBLER-UHFFFAOYSA-N
DMINO7Z IU 2-(2,2-dicyclohexylethyl)piperidine
DMINO7Z CA CAS 39648-47-0
DMINO7Z CB CHEBI:35553
DMINO7Z DE Angina pectoris
DMOPZDT ID DMOPZDT
DMOPZDT DN Perindopril
DMOPZDT HS Approved
DMOPZDT SN ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
DMOPZDT TC Antihypertensive Agents
DMOPZDT DT Small molecular drug
DMOPZDT PC 107807
DMOPZDT MW 368.5
DMOPZDT FM C19H32N2O5
DMOPZDT IC InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
DMOPZDT CS CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O
DMOPZDT IK IPVQLZZIHOAWMC-QXKUPLGCSA-N
DMOPZDT IU (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DMOPZDT CA CAS 82834-16-0
DMOPZDT CB CHEBI:8024
DMOPZDT DE Hypertension
DMZ0Q1G ID DMZ0Q1G
DMZ0Q1G DN Permethrin
DMZ0Q1G HS Approved
DMZ0Q1G SN Ambush; PerFoam; Transpermethrin; Acticin Cream; Elimite Cream; Nix Cream Rinse; Transpermethrin [ISO];FMC 35171; NRDC 146; NRDC 148; PS758_SUPELCO; Permethrin (isomers); Permethrin (isomers) solution; Permethrine,c&t; Trans-(+-)-Permethrin; [3-(phenyloxy)phenyl]methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (+)-CIS-PERMETHRIN; (+)-trans-Permethrin; (+-)-cis-Fmc 33297; (+-)-cis-Permethrin; (+-)-trans-Permethrin; (3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate; 1RS,cis-Permethrin; 1RS-trans-Permethrin; 3-Phenoxybenzyle (1RS)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylate; 3-phenoxybenzyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
DMZ0Q1G TC Insecticides
DMZ0Q1G DT Small molecular drug
DMZ0Q1G PC 40326
DMZ0Q1G MW 391.3
DMZ0Q1G FM C21H20Cl2O3
DMZ0Q1G IC InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3
DMZ0Q1G CS CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C
DMZ0Q1G IK RLLPVAHGXHCWKJ-UHFFFAOYSA-N
DMZ0Q1G IU (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate
DMZ0Q1G CA CAS 52645-53-1
DMZ0Q1G CB CHEBI:34911
DMZ0Q1G DE Sarcoptes scabiei infection
DMVHJLX ID DMVHJLX
DMVHJLX DN Perospirone
DMVHJLX HS Approved
DMVHJLX SN Lullan; SM-9018
DMVHJLX CP Sumitomo Pharmaceuticals Co Ltd
DMVHJLX DT Small molecular drug
DMVHJLX PC 115368
DMVHJLX MW 426.6
DMVHJLX FM C23H30N4O2S
DMVHJLX IC InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+
DMVHJLX CS C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54
DMVHJLX IK FBVFZWUMDDXLLG-HDICACEKSA-N
DMVHJLX IU (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
DMVHJLX CA CAS 150915-41-6
DMVHJLX CB CHEBI:94777
DMVHJLX DE Psychotic disorder
DMA4MRX ID DMA4MRX
DMA4MRX DN Perphenazine
DMA4MRX HS Approved
DMA4MRX SN Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin;PZC; Perfenazina; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; Perfenazina [Italian]; Perphenazine [Trilafon]; Perphenazine maleate; P 6402; Sch 3940; Apo-Perphenazine; F-mon; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; SCH-3940; Siquil (TN); Triavil (TN); Perphenazine [INN:BAN:JAN]; Perphenazine (JP15/USP/INN); Gamma-[4-(beta-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; Gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
DMA4MRX CP Schering-Plough Corporation
DMA4MRX TC Antipsychotic Agents
DMA4MRX DT Small molecular drug
DMA4MRX PC 4748
DMA4MRX MW 404
DMA4MRX FM C21H26ClN3OS
DMA4MRX IC InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
DMA4MRX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMA4MRX IK RGCVKNLCSQQDEP-UHFFFAOYSA-N
DMA4MRX IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
DMA4MRX CA CAS 58-39-9
DMA4MRX CB CHEBI:8028
DMA4MRX DE Schizophrenia
DMHJV0X ID DMHJV0X
DMHJV0X DN Pertuzumab
DMHJV0X HS Approved
DMHJV0X SN Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
DMHJV0X CP Roche; Genentech
DMHJV0X DT Monoclonal antibody
DMHJV0X SQ Amino acid sequence for pertuzumab light chain : DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Amino acid sequence for pertuzumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMHJV0X DE Breast cancer
DMS2J0Z ID DMS2J0Z
DMS2J0Z DN Pexidartinib
DMS2J0Z HS Approved
DMS2J0Z SN PLX-3397
DMS2J0Z CP Plexxikon Inc
DMS2J0Z PC 25151352
DMS2J0Z MW 417.8
DMS2J0Z FM C20H15ClF3N5
DMS2J0Z IC InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)
DMS2J0Z CS C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F
DMS2J0Z IK JGWRKYUXBBNENE-UHFFFAOYSA-N
DMS2J0Z IU 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine
DMS2J0Z CA CAS 1029044-16-3
DMS2J0Z CB CHEBI:145373
DMS2J0Z DE Alzheimer disease; Pigmented villonodular synovitis; Neurofibromatosis type 1; Tenosynovial giant cell tumour
DMSB068 ID DMSB068
DMSB068 DN PF-04449913
DMSB068 HS Approved
DMSB068 SN Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2
DMSB068 CP Pfizer
DMSB068 DT Small molecular drug
DMSB068 PC 25166913
DMSB068 MW 374.4
DMSB068 FM C21H22N6O
DMSB068 IC InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1
DMSB068 CS CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N
DMSB068 IK SFNSLLSYNZWZQG-VQIMIIECSA-N
DMSB068 IU 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea
DMSB068 CA CAS 1095173-27-5
DMSB068 CB CHEBI:145428
DMSB068 DE Chronic myelomonocytic leukaemia; Solid tumour/cancer
DM79VXT ID DM79VXT
DM79VXT DN PF-04971729
DM79VXT HS Approved
DM79VXT SN Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7; PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729
DM79VXT CP Merck & Co./Pfizer
DM79VXT DT Small molecular drug
DM79VXT PC 44814423
DM79VXT MW 436.9
DM79VXT FM C22H25ClO7
DM79VXT IC InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
DM79VXT CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl
DM79VXT IK MCIACXAZCBVDEE-CUUWFGFTSA-N
DM79VXT IU (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
DM79VXT CA CAS 1210344-57-2
DM79VXT DE Type-2 diabetes
DMOHS9P ID DMOHS9P
DMOHS9P DN Phenacemide
DMOHS9P HS Approved
DMOHS9P SN Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea
DMOHS9P TC Anticonvulsants
DMOHS9P DT Small molecular drug
DMOHS9P PC 4753
DMOHS9P MW 178.19
DMOHS9P FM C9H10N2O2
DMOHS9P IC InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
DMOHS9P CS C1=CC=C(C=C1)CC(=O)NC(=O)N
DMOHS9P IK XPFRXWCVYUEORT-UHFFFAOYSA-N
DMOHS9P IU N-carbamoyl-2-phenylacetamide
DMOHS9P CA CAS 63-98-9
DMOHS9P CB CHEBI:8049
DMOHS9P DE Epilepsy
DM6TS1N ID DM6TS1N
DM6TS1N DN Phendimetrazine
DM6TS1N HS Approved
DM6TS1N SN Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine
DM6TS1N CP Sandoz Inc
DM6TS1N TC Anorexigenic Agents
DM6TS1N DT Small molecular drug
DM6TS1N PC 30487
DM6TS1N MW 191.27
DM6TS1N FM C12H17NO
DM6TS1N IC InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1
DM6TS1N CS C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2
DM6TS1N IK MFOCDFTXLCYLKU-CMPLNLGQSA-N
DM6TS1N IU (2S,3S)-3,4-dimethyl-2-phenylmorpholine
DM6TS1N CA CAS 634-03-7
DM6TS1N CB CHEBI:8059
DM6TS1N DE Obesity
DMHIDUE ID DMHIDUE
DMHIDUE DN Phenelzine
DMHIDUE HS Approved
DMHIDUE SN Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
DMHIDUE CP Parke Davis Div Warner Lambert Co
DMHIDUE TC Antidepressants
DMHIDUE DT Small molecular drug
DMHIDUE PC 3675
DMHIDUE MW 136.19
DMHIDUE FM C8H12N2
DMHIDUE IC InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DMHIDUE CS C1=CC=C(C=C1)CCNN
DMHIDUE IK RMUCZJUITONUFY-UHFFFAOYSA-N
DMHIDUE IU 2-phenylethylhydrazine
DMHIDUE CA CAS 51-71-8
DMHIDUE CB CHEBI:8060
DMHIDUE DE Skin imperfections; Depression
DMDTC7R ID DMDTC7R
DMDTC7R DN Phenindamine
DMDTC7R HS Approved
DMDTC7R SN Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R CP Amarin Pharmaceuticals
DMDTC7R TC Antihistamines
DMDTC7R DT Small molecular drug
DMDTC7R PC 11291
DMDTC7R MW 261.399
DMDTC7R FM C19H19N
DMDTC7R IC InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3
DMDTC7R CS CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4
DMDTC7R IK ISFHAYSTHMVOJR-UHFFFAOYSA-N
DMDTC7R IU 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R CA CAS 82-88-2
DMDTC7R CB CHEBI:8065
DMDTC7R DE Common cold
DM2PYNR ID DM2PYNR
DM2PYNR DN Phenindione
DM2PYNR HS Approved
DM2PYNR SN Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Fenindiona; Hedulin; Hemolidione; Indema; Indion; Indon; Phenhydren; Phenillin; Phenindionum; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol; Boots Brand of Phenindione; Goldshield Brand of Phenindione; Merck Lipha Sante Brand of Phenindione; P1029; P26406_ALDRICH; Fenindiona [INN-Spanish]; Hedulin (TN); Phenindione (INN); Phenindione [INN:BAN]; Phenindionum [INN-Latin]; 2 Phenyl 1,3 indandione; 2-Fenyloindandion-1,3; 2-Fenyloindandion-1,3 [Polish]; 2-Phenyl-1,3-diketohydrindene; 2-Phenyl-1,3-indandione; 2-Phenyl-1,3-indanedione; 2-Phenyl-1H-indene-1,3(2H)-dione; 2-Phenylindan-1,3-dione; 2-Phenylindandione; 2-phenyl-1,3(2H)-Indenedione; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; 2-phenylindene-1,3-dione
DM2PYNR TC Anticoagulants
DM2PYNR DT Small molecular drug
DM2PYNR PC 4760
DM2PYNR MW 222.24
DM2PYNR FM C15H10O2
DM2PYNR IC InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H
DM2PYNR CS C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2PYNR IK NFBAXHOPROOJAW-UHFFFAOYSA-N
DM2PYNR IU 2-phenylindene-1,3-dione
DM2PYNR CA CAS 83-12-5
DM2PYNR CB CHEBI:8066
DM2PYNR DE Coagulation defect; Pulmonary embolism
DMCH7RU ID DMCH7RU
DMCH7RU DN Pheniramine
DMCH7RU HS Approved
DMCH7RU SN Avil; Feniramina; Feniramine; Histapyridamine; Metron; Pheniraminum; Propheniramine; Prophenpyridamine; Pyriton; Trimeton; Tripoton; Pheniramine Bimaleate; Avil (TN); Feniramina [INN-Spanish]; P-Aminosalicylsaures salz; Pheniramine (INN); Pheniramine [INN:BAN]; Pheniraminum [INN-Latin]; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; 2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-(9CI); 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine
DMCH7RU CP Aventis Pharmaceuticals Inc.
DMCH7RU TC Antiallergic Agents
DMCH7RU DT Small molecular drug
DMCH7RU PC 4761
DMCH7RU MW 240.34
DMCH7RU FM C16H20N2
DMCH7RU IC InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
DMCH7RU CS CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2
DMCH7RU IK IJHNSHDBIRRJRN-UHFFFAOYSA-N
DMCH7RU IU N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine
DMCH7RU CA CAS 86-21-5
DMCH7RU CB CHEBI:91591
DMCH7RU DE Hay fever
DMXYTN9 ID DMXYTN9
DMXYTN9 DN Phenmetrazine
DMXYTN9 HS Approved
DMXYTN9 SN Cafilon; Defenmetrazin; Dexphenmetrazine; Fenmetrazin; Fenmetrazina; Oxazimedrine; Phenmetraline; Phenmetrazin; Phenmetrazinum; Preludin hydrochloride; A 66; Psychamine A 66; Defenmetrazin (TN); Fenmetrazin (TN); Fenmetrazina [INN-Spanish]; Oxazimedrine (TN); Phenmetraline (TN); Phenmetrazine [INN:BAN]; Phenmetrazinum [INN-Latin]; Dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Fenyl-3-methylmorfolin; 2-Fenyl-3-methylmorfolin [Czech]; 2-Phenyl-3-methylmorpholine; 3-Methyl-2-phenylmorpholine; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine
DMXYTN9 CP Boehringer Ingelheim GmbH
DMXYTN9 TC Appetite Depressants
DMXYTN9 DT Small molecular drug
DMXYTN9 PC 4762
DMXYTN9 MW 177.24
DMXYTN9 FM C11H15NO
DMXYTN9 IC InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3
DMXYTN9 CS CC1C(OCCN1)C2=CC=CC=C2
DMXYTN9 IK OOBHFESNSZDWIU-UHFFFAOYSA-N
DMXYTN9 IU 3-methyl-2-phenylmorpholine
DMXYTN9 CA CAS 134-49-6
DMXYTN9 CB CHEBI:8067
DMXYTN9 DE Obesity
DMXZOCG ID DMXZOCG
DMXZOCG DN Phenobarbital
DMXZOCG HS Approved
DMXZOCG SN Adonal; Aephenal; Agrypnal; Amylofene; Antrocol; Aphenylbarbit; Aphenyletten; Austrominal; Barbapil; Barbellen; Barbellon; Barbenyl; Barbilehae; Barbinal; Barbipenyl; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Donphen; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Ezibarbitur; Fenbital; Fenemal; Fenobarbital; Fenobarbitale; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nunol; PHOB; Parkotal; Pharmetten; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarb; Phenobarbitalum; Phenobarbitol; Phenobarbitone; Phenobarbitonum; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylaethylbarbitursaeure; Phenylethylbarbiturate; Phenylethylbarbitursaeure; Phenylethylmalonylurea; Phenyletten; Phenylral; Phenyral; Polcominal; Promptonal; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sedophen; Sevenal; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Theominal; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal; Aephe nal; Component of Antrocol; Component of Bronkotabs; Component of Hecadrol; Component of Primatene P; Component of Slowten; Component of Tedral; Elixir of phenobarbital; Fen osed; Fenobarbitale [DCIT]; Le phebar; Levsin PB Drops and Tablets; PUBERTAL PHENOBARBITAL STUDY; Pamine PB; Phenobarbitalum [INN]; Phenobarbituric acid; Phenylethyl barbituric acid; Phenylethylbarbituric acid; Solfoton talpheno; Stental Extentabs; Stental exte ntabs; Arco-Lase Plus; Barbilehae (barbilettae); Blu-phen; Chardonna-2; Component of Valpin 50-PB; Fenobarbital [INN-Spanish]; Gustase-Plus; Hypno-Tablinetten; Luminal (TN); Nova-Pheno; Phazyme-PB; Phen-Bar; Phenobarbital (PB); Phenobarbital, Monosodium Salt; Phenobarbitalum [INN-Latin]; SK-Phenobarbital; Seda-Tablinen; Seda-tabl inen; Sedonal (sedative); Solu-Barb; Valprin 50-PB; Phenobarbital [USAN:INN:JAN]; Phenyl-ethyl-barbituric acid; Acido 5-fenil-5-etilbarbiturico; Acido 5-fenil-5-etilbarbiturico [Italian]; Phenobarbital (JP15/USP/INN); 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMXZOCG CP FISCHER and ROCH
DMXZOCG TC Anticonvulsants
DMXZOCG DT Small molecular drug
DMXZOCG PC 4763
DMXZOCG MW 232.23
DMXZOCG FM C12H12N2O3
DMXZOCG IC InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
DMXZOCG CS CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DMXZOCG IK DDBREPKUVSBGFI-UHFFFAOYSA-N
DMXZOCG IU 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMXZOCG CA CAS 50-06-6
DMXZOCG CB CHEBI:8069
DMXZOCG DE Seizure disorder
DM8KSQH ID DM8KSQH
DM8KSQH DN Phenoxybenzamine
DM8KSQH HS Approved
DM8KSQH SN Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A
DM8KSQH CP Concordia Pharmaceuticals Inc
DM8KSQH TC Antihypertensive Agents
DM8KSQH DT Small molecular drug
DM8KSQH PC 4768
DM8KSQH MW 303.8
DM8KSQH FM C18H22ClNO
DM8KSQH IC InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
DM8KSQH CS CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2
DM8KSQH IK QZVCTJOXCFMACW-UHFFFAOYSA-N
DM8KSQH IU N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
DM8KSQH CA CAS 59-96-1
DM8KSQH CB CHEBI:8077
DM8KSQH DE Malignant essential hypertension
DMDO279 ID DMDO279
DMDO279 DN Phenprocoumon
DMDO279 HS Approved
DMDO279 SN Falithiom; Falithrom; Fencumar; Fenprocoumona; Fenprocumon; Fenprocumone; Liquamar; Marcoumar; Marcumar; Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumonum; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Roche Brand of Phenprocoumon; Worwag Brand of Phenprocoumon; U29342; Falithrom (TN); Fenprocoumona [INN-Spanish]; Liquamar (TN); Marcoumar (TN); Marcumar (TN); Phenprocoumone [INN-French]; Phenprocoumonum [INN-Latin]; Ro 1-4849; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
DMDO279 TC Anticoagulants
DMDO279 DT Small molecular drug
DMDO279 PC 54680692
DMDO279 MW 280.3
DMDO279 FM C18H16O3
DMDO279 IC InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
DMDO279 CS CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMDO279 IK DQDAYGNAKTZFIW-UHFFFAOYSA-N
DMDO279 IU 4-hydroxy-3-(1-phenylpropyl)chromen-2-one
DMDO279 CA CAS 435-97-2
DMDO279 CB CHEBI:50438
DMDO279 DE Thrombosis
DMG60XN ID DMG60XN
DMG60XN DN Phentermine
DMG60XN HS Approved
DMG60XN SN Duromine; Fastin; Fentermina; Inoamin; Ionamin; Ionamine; Linyl; Lipopill; Lonamin; Mirapront; Normephentermine; Obenix; Obermine; Omnibex; Ortetamin; Ortetamina; Ortetaminum; Phentercot; Phenterminum; Phentride; Phentrol; Wilpo; Zantryl; Ona Mast; Ortetamine [INN]; Phentermine HCl; Phentermine resin complex; AmbkkkkK744; Phentermine Resin 30; Phentrol 2; Phentrol 3; Phentrol 4; Adipex P (TN); Adipex-P; Alpha-Benzylisopropylamine; Duromine (TN); Fastin (TN); Fentermina [INN-Spanish]; Ionamin (TN); Mirapront (TN); Obenix (TN); Obephen (TN); Obermine (TN); Oby-Trim; Panbesy (TN); Phenterex (TN); Phentermine (TN); Phenterminum [INN-Latin]; Phentremene (TN); Phentrol (TN); Phentromin (TN); Pro-Fast; Redusa (TN); Sinpet (TN); Supremin (TN); Teramine (TN); Trenker (TN); Umine (TN); Weltmine (TN); Zantryl (TN); Alpha,alpha-Dimethylbenzeneethanamine; Alpha,alpha-Dimethylphenethylamine; Anoxine-AM (TN); Obestin-30 (TN); Oby-Trim (TN); Phentermine (USAN/INN); Phentermine [USAN:INN:BAN]; Phenyl-tert-butylamine; Phenyl-tertiary-butylamine; Pro-Fast SA (TN); Alpha,alpha-Dimethyl-beta-phenylethylamine; Alpha.,.alpha.-dimethyl-Benzeneethanamine; (alpha,alpha)-Dimethylphenethylamine; 1,1-Dimethyl-2-phenylethylamine; 1-(2-Methylphenyl)-2-propylamin; 1-(2-Tolyl)-2-propylamine; 2-Amino-2-methyl-1-phenylpropane; 2-Methyl-1-phenyl-2-propanamine; 2-Phenyl-tert-butylamine
DMG60XN CP Medeva Pharmaceuticals
DMG60XN TC Appetite Depressants
DMG60XN DT Small molecular drug
DMG60XN PC 4771
DMG60XN MW 149.23
DMG60XN FM C10H15N
DMG60XN IC InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
DMG60XN CS CC(C)(CC1=CC=CC=C1)N
DMG60XN IK DHHVAGZRUROJKS-UHFFFAOYSA-N
DMG60XN IU 2-methyl-1-phenylpropan-2-amine
DMG60XN CA CAS 122-09-8
DMG60XN CB CHEBI:8080
DMG60XN DE Obesity
DMXYJOB ID DMXYJOB
DMXYJOB DN Phentolamine
DMXYJOB HS Approved
DMXYJOB SN Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB CP Bedford Laboratories
DMXYJOB TC Antihypertensive Agents
DMXYJOB DT Small molecular drug
DMXYJOB PC 5775
DMXYJOB MW 281.35
DMXYJOB FM C17H19N3O
DMXYJOB IC InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
DMXYJOB CS CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
DMXYJOB IK MRBDMNSDAVCSSF-UHFFFAOYSA-N
DMXYJOB IU 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB CA CAS 50-60-2
DMXYJOB CB CHEBI:8081
DMXYJOB DE Dermal necrosis
DMQ95GE ID DMQ95GE
DMQ95GE DN Phenylacetic acid
DMQ95GE HS Approved
DMQ95GE SN .alpha.-Toluic acid; .omega.-Phenylacetic acid; 2-Phenylacetic acid; Acetic acid, phenyl-; Benzenacetic acid; Benzeneacetic acid; Benzylcarboxylic acid; Benzylformic acid; Kyselina fenyloctova; Kyselina fenyloctova [Czech]; PHENYL ACETIC ACID; PHENYL-ACETIC ACID; PHENYLACETIC ACID; Phenylacetic acid (natural); Phenylethanoic acid; Phenyllacetic acid; alpha-Toluic acid; omega-Phenylacetic acid; phenylacetate
DMQ95GE DT Small molecular drug
DMQ95GE PC 999
DMQ95GE MW 136.15
DMQ95GE FM C8H8O2
DMQ95GE IC InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)
DMQ95GE CS C1=CC=C(C=C1)CC(=O)O
DMQ95GE IK WLJVXDMOQOGPHL-UHFFFAOYSA-N
DMQ95GE IU 2-phenylacetic acid
DMQ95GE CA CAS 103-82-2
DMQ95GE CB ChEBI:30745
DMQ95GE DE Hyperammonemia
DMAYL0T ID DMAYL0T
DMAYL0T DN Phenylbutazone
DMAYL0T HS Approved
DMAYL0T SN Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
DMAYL0T TC Analgesics
DMAYL0T DT Small molecular drug
DMAYL0T PC 4781
DMAYL0T MW 308.4
DMAYL0T FM C19H20N2O2
DMAYL0T IC InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
DMAYL0T CS CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
DMAYL0T IK VYMDGNCVAMGZFE-UHFFFAOYSA-N
DMAYL0T IU 4-butyl-1,2-diphenylpyrazolidine-3,5-dione
DMAYL0T CA CAS 50-33-9
DMAYL0T CB CHEBI:48574
DMAYL0T DE Chronic pain
DMZHUO5 ID DMZHUO5
DMZHUO5 DN Phenylephrine
DMZHUO5 HS Approved
DMZHUO5 SN Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5 CP Alcon Canada Inc
DMZHUO5 TC Ophthalmologicals
DMZHUO5 DT Small molecular drug
DMZHUO5 PC 6041
DMZHUO5 MW 167.2
DMZHUO5 FM C9H13NO2
DMZHUO5 IC InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
DMZHUO5 CS CNC[C@@H](C1=CC(=CC=C1)O)O
DMZHUO5 IK SONNWYBIRXJNDC-VIFPVBQESA-N
DMZHUO5 IU 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5 CA CAS 61-76-7
DMZHUO5 CB CHEBI:8093
DMZHUO5 DE Fecal incontinence; Ophthalmic graves disease
DMKAEQW ID DMKAEQW
DMKAEQW DN Phenyltoloxamine
DMKAEQW HS Approved
DMKAEQW SN Bristamin hydrochloride; Phenyltoloxamine hydrochloride; HL 2153; (2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride; N,N-Dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride; ETHYLAMINE, 2-(o-BENZYLPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE; Ethylamine, N,N-dimethyl-2-((alpha-phenyl-o-tolyl)oxy)-, hydrochloride; N-(2'-Dimethylaminoaethyl)-(o-benzylphenol)-aether hydrochlorid [German]; AC1L2KJQ; 92-12-6 (Parent); LS-67923; 2-(2-benzylphenoxy)ethyl-dimethylazanium chloride
DMKAEQW DT Small molecular drug
DMKAEQW PC 7077
DMKAEQW MW 255.35
DMKAEQW FM C17H21NO
DMKAEQW IC InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMKAEQW CS CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2
DMKAEQW IK IZRPKIZLIFYYKR-UHFFFAOYSA-N
DMKAEQW IU 2-(2-benzylphenoxy)-N,N-dimethylethanamine
DMKAEQW CA CAS 92-12-6
DMKAEQW CB CHEBI:135047
DMKAEQW DE Allergy
DMNOKBV ID DMNOKBV
DMNOKBV DN Phenytoin
DMNOKBV HS Approved
DMNOKBV SN Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione
DMNOKBV CP Mylan Laboratories
DMNOKBV TC Anticonvulsants
DMNOKBV DT Small molecular drug
DMNOKBV PC 1775
DMNOKBV MW 252.27
DMNOKBV FM C15H12N2O2
DMNOKBV IC InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
DMNOKBV CS C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
DMNOKBV IK CXOFVDLJLONNDW-UHFFFAOYSA-N
DMNOKBV IU 5,5-diphenylimidazolidine-2,4-dione
DMNOKBV CA CAS 57-41-0
DMNOKBV CB CHEBI:8107
DMNOKBV DE Epilepsy
DMUKMC8 ID DMUKMC8
DMUKMC8 DN Phloroglucinol
DMUKMC8 HS Approved
DMUKMC8 SN phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157
DMUKMC8 DT Small molecular drug
DMUKMC8 PC 359
DMUKMC8 MW 126.11
DMUKMC8 FM C6H6O3
DMUKMC8 IC InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H
DMUKMC8 CS C1=C(C=C(C=C1O)O)O
DMUKMC8 IK QCDYQQDYXPDABM-UHFFFAOYSA-N
DMUKMC8 IU benzene-1,3,5-triol
DMUKMC8 CA CAS 108-73-6
DMUKMC8 CB CHEBI:16204
DMUKMC8 DE Urinary tract disease
DMUXQG7 ID DMUXQG7
DMUXQG7 DN Phosphate
DMUXQG7 HS Approved
DMUXQG7 SN orthophosphate; Phosphate ion; 14265-44-2; O-Phosphate; UNII-NK08V8K8HR; NK08V8K8HR; Phosphates; Phosphate ions; PO4; a phosphate group; tetraoxophosphate(V); tetraoxophosphate(3-); Phosphoric acid trianion; tetraoxidophosphate(3-); phosphoric acid, ion(3-); AC1L1AN2; DTXSID7039672; CHEBI:18367; CTK0H5978; NBIIXXVUZAFLBC-UHFFFAOYSA-K; BDBM50155537; AKOS015903596; PO4(3-); CREATINE PHOSPHATE; N-PHOSPHOCREATINE; [PO4](3-); I14-18227
DMUXQG7 DT Small molecular drug
DMUXQG7 PC 1061
DMUXQG7 MW 94.971
DMUXQG7 FM O4P-3
DMUXQG7 IC InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3
DMUXQG7 CS [O-]P(=O)([O-])[O-]
DMUXQG7 IK NBIIXXVUZAFLBC-UHFFFAOYSA-K
DMUXQG7 IU phosphate
DMUXQG7 CA CAS 14265-44-2
DMUXQG7 CB CHEBI:18367
DMUXQG7 DE Constipation
DM8HDOL ID DM8HDOL
DM8HDOL DN Phytonadione
DM8HDOL HS Approved
DM8HDOL SN Phyllochinon; Phyllohydroquinone; Phytomenadione; Fitomenadione [DCIT]; Phyllochinon [German]; LT00452032; Fitomenadiona [INN-Spanish]; Mephyton (TN); Phylloquinone (8CI); Phytomenadione (INN); Phytomenadionum [INN-Latin]; Phytonadione [USAN:JAN]; Vitamin K1 (TN); Vitamin K1 (VAN); Vitamin K1 (generic); Phythyl-menadion (GERMAN); Phytonadione (JP15/USP); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened-ione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 3-Phytylmenadione
DM8HDOL TC Vitamins
DM8HDOL DT Small molecular drug
DM8HDOL PC 5284607
DM8HDOL MW 450.7
DM8HDOL FM C31H46O2
DM8HDOL IC InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1
DM8HDOL CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C
DM8HDOL IK MBWXNTAXLNYFJB-NKFFZRIASA-N
DM8HDOL IU 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
DM8HDOL CA CAS 79083-00-4
DM8HDOL CB CHEBI:18067
DM8HDOL DE Bleeding disorder; Vitamin K deficiency
DM27BL1 ID DM27BL1
DM27BL1 DN Pibrentasvir
DM27BL1 HS Approved
DM27BL1 SN 2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L
DM27BL1 TC Antiviral Agent
DM27BL1 DT Small molecular drug
DM27BL1 PC 58031952
DM27BL1 MW 1113.201
DM27BL1 FM C57H65F5N10O8
DM27BL1 IC InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1
DM27BL1 CS CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC
DM27BL1 IK VJYSBPDEJWLKKJ-NLIMODCCSA-N
DM27BL1 IU methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
DM27BL1 CA CAS 1353900-92-1
DM27BL1 DE Hepatitis C virus infection
DMIBNG2 ID DMIBNG2
DMIBNG2 DN Picrotoxin
DMIBNG2 HS Approved
DMIBNG2 SN Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2
DMIBNG2 TC Central Nervous System Stimulants
DMIBNG2 DT Small molecular drug
DMIBNG2 PC 31304
DMIBNG2 MW 602.6
DMIBNG2 FM C30H34O13
DMIBNG2 IC InChI=1S/C15H18O7.C15H16O6/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9;1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h5-9,18-19H,4H2,1-3H3;6-10,18H,1,4H2,2-3H3/t5-,6+,7?,8?,9-,13-,14-,15+;6?,7-,8?,9?,10+,13+,14+,15-/m10/s1
DMIBNG2 CS CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(CC5[C@]4(O5)C(=O)O3)O)C.C[C@@]12[C@H]3C4[C@H](C([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O
DMIBNG2 IK VJKUPQSHOVKBCO-ZTYBEOBUSA-N
DMIBNG2 IU (1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
DMIBNG2 CA CAS 124-87-8
DMIBNG2 DE Respiratory distress syndrome
DMV9ADG ID DMV9ADG
DMV9ADG DN Pilocarpine
DMV9ADG HS Approved
DMV9ADG SN Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG CP Alcon Laboratories
DMV9ADG TC Cholinergic Agents
DMV9ADG DT Small molecular drug
DMV9ADG PC 5910
DMV9ADG MW 208.26
DMV9ADG FM C11H16N2O2
DMV9ADG IC InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
DMV9ADG CS CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C
DMV9ADG IK QCHFTSOMWOSFHM-WPRPVWTQSA-N
DMV9ADG IU (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG CA CAS 92-13-7
DMV9ADG CB CHEBI:8207
DMV9ADG DE Glaucoma/ocular hypertension
DMZ65K8 ID DMZ65K8
DMZ65K8 DN Pilsicainide
DMZ65K8 HS Approved
DMZ65K8 SN SUNRYTHM; Sunrhythm; Pilsicainide hydrochloride; DU-6552; SUN-1165; SUN-1165i
DMZ65K8 CP Suntory Ltd
DMZ65K8 DT Small molecular drug
DMZ65K8 PC 4820
DMZ65K8 MW 272.4
DMZ65K8 FM C17H24N2O
DMZ65K8 IC InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)
DMZ65K8 CS CC1=C(C(=CC=C1)C)NC(=O)CC23CCCN2CCC3
DMZ65K8 IK BCQTVJKBTWGHCX-UHFFFAOYSA-N
DMZ65K8 IU N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide
DMZ65K8 CA CAS 88069-67-4
DMZ65K8 CB CHEBI:135127
DMZ65K8 DE Heart arrhythmia
DMR7IVC ID DMR7IVC
DMR7IVC DN Pimavanserin
DMR7IVC HS Approved
DMR7IVC SN ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC CP Acadia Pharmaceuticals
DMR7IVC DT Small molecular drug
DMR7IVC PC 10071196
DMR7IVC MW 427.6
DMR7IVC FM C25H34FN3O2
DMR7IVC IC InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
DMR7IVC CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
DMR7IVC IK RKEWSXXUOLRFBX-UHFFFAOYSA-N
DMR7IVC IU 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC CA CAS 706779-91-1
DMR7IVC CB CHEBI:133017
DMR7IVC DE Parkinson disease
DMZLGRB ID DMZLGRB
DMZLGRB DN Pimecrolimus
DMZLGRB HS Approved
DMZLGRB SN Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
DMZLGRB CP Norvatis Phamaceuticals Corporation
DMZLGRB TC Dermatologic Agents
DMZLGRB DT Small molecular drug
DMZLGRB PC 6509979
DMZLGRB MW 810.4
DMZLGRB FM C43H68ClNO11
DMZLGRB IC InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
DMZLGRB CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)Cl)/C)O)C)OC)OC)C)\\C
DMZLGRB IK KASDHRXLYQOAKZ-XDSKOBMDSA-N
DMZLGRB IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZLGRB CA CAS 137071-32-0
DMZLGRB CB CHEBI:135888
DMZLGRB DE Atopic dermatitis
DMW83TP ID DMW83TP
DMW83TP DN Pimozide
DMW83TP HS Approved
DMW83TP SN Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP CP Janssen Pharmaceutica
DMW83TP TC Antipsychotic Agents
DMW83TP DT Small molecular drug
DMW83TP PC 16362
DMW83TP MW 461.5
DMW83TP FM C28H29F2N3O
DMW83TP IC InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
DMW83TP CS C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMW83TP IK YVUQSNJEYSNKRX-UHFFFAOYSA-N
DMW83TP IU 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP CA CAS 2062-78-4
DMW83TP CB CHEBI:8212
DMW83TP DE Schizophrenia
DMRADYL ID DMRADYL
DMRADYL DN Pinacidil
DMRADYL HS Approved
DMRADYL SN Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate
DMRADYL TC Antihypertensive Agents
DMRADYL DT Small molecular drug
DMRADYL PC 4826
DMRADYL MW 245.32
DMRADYL FM C13H19N5
DMRADYL IC InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)
DMRADYL CS CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1
DMRADYL IK IVVNZDGDKPTYHK-UHFFFAOYSA-N
DMRADYL IU 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine
DMRADYL CA CAS 60560-33-0
DMRADYL CB CHEBI:91706
DMRADYL DE High blood pressure
DMD2NV7 ID DMD2NV7
DMD2NV7 DN Pindolol
DMD2NV7 HS Approved
DMD2NV7 SN Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
DMD2NV7 CP Tocris Bioscience
DMD2NV7 TC Antihypertensive Agents
DMD2NV7 DT Small molecular drug
DMD2NV7 PC 4828
DMD2NV7 MW 248.32
DMD2NV7 FM C14H20N2O2
DMD2NV7 IC InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
DMD2NV7 CS CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
DMD2NV7 IK JZQKKSLKJUAGIC-UHFFFAOYSA-N
DMD2NV7 IU 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DMD2NV7 CA CAS 13523-86-9
DMD2NV7 CB CHEBI:8214
DMD2NV7 DE Hypertension
DMKJ485 ID DMKJ485
DMKJ485 DN Pioglitazone
DMKJ485 HS Approved
DMKJ485 SN 111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
DMKJ485 CP Takeda Pharmaceuticals
DMKJ485 TC Hypoglycemic Agents
DMKJ485 DT Small molecular drug
DMKJ485 PC 4829
DMKJ485 MW 356.4
DMKJ485 FM C19H20N2O3S
DMKJ485 IC InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
DMKJ485 CS CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMKJ485 IK HYAFETHFCAUJAY-UHFFFAOYSA-N
DMKJ485 IU 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMKJ485 CA CAS 111025-46-8
DMKJ485 CB CHEBI:8228
DMKJ485 DE Diabetic complication; Obesity; Type-2 diabetes
DM5F84A ID DM5F84A
DM5F84A DN Pipecuronium
DM5F84A HS Approved
DM5F84A SN Arduan; Pipecurium; Arduan (TN); Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A TC Analgesics
DM5F84A DT Small molecular drug
DM5F84A PC 50192
DM5F84A MW 602.9
DM5F84A FM C35H62N4O4+2
DM5F84A IC InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM5F84A CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C
DM5F84A IK OWWLUIWOFHMHOQ-XGHATYIMSA-N
DM5F84A IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A CA CAS 68399-58-6
DM5F84A CB CHEBI:8230
DM5F84A DE Spasm
DMGQU0Y ID DMGQU0Y
DMGQU0Y DN Piperacetazine
DMGQU0Y HS Approved
DMGQU0Y SN Quide
DMGQU0Y CP Dow Pharmaceutical Corp Sub Dow Chemical Co
DMGQU0Y DT Small molecular drug
DMGQU0Y PC 19675
DMGQU0Y MW 410.6
DMGQU0Y FM C24H30N2O2S
DMGQU0Y IC InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3
DMGQU0Y CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMGQU0Y IK BTFMCMVEUCGQDX-UHFFFAOYSA-N
DMGQU0Y IU 1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMGQU0Y CA CAS 3819-00-9
DMGQU0Y CB CHEBI:92293
DMGQU0Y DE Schizophrenia
DMTBKF3 ID DMTBKF3
DMTBKF3 DN Piperacillin
DMTBKF3 HS Approved
DMTBKF3 SN PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DMTBKF3 CP Wyeth
DMTBKF3 TC Antibiotics
DMTBKF3 DT Small molecular drug
DMTBKF3 PC 43672
DMTBKF3 MW 517.6
DMTBKF3 FM C23H27N5O7S
DMTBKF3 IC InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1
DMTBKF3 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTBKF3 IK IVBHGBMCVLDMKU-GXNBUGAJSA-N
DMTBKF3 IU (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTBKF3 CA CAS 61477-96-1
DMTBKF3 CB CHEBI:8232
DMTBKF3 DE Bacterial infection
DMT70RC ID DMT70RC
DMT70RC DN Piperaquine
DMT70RC HS Approved
DMT70RC SN Piperaquinoline; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-(9CI); 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC DT Small molecular drug
DMT70RC PC 122262
DMT70RC MW 535.5
DMT70RC FM C29H32Cl2N6
DMT70RC IC InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2
DMT70RC CS C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl
DMT70RC IK UCRHFBCYFMIWHC-UHFFFAOYSA-N
DMT70RC IU 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC CA CAS 4085-31-8
DMT70RC CB CHEBI:91231
DMT70RC DE Malaria
DMTY9LU ID DMTY9LU
DMTY9LU DN Piperazine
DMTY9LU HS Approved
DMTY9LU SN Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine
DMTY9LU CP Glaxosmithkline
DMTY9LU TC Antinematodal Agents
DMTY9LU DT Small molecular drug
DMTY9LU PC 4837
DMTY9LU MW 86.14
DMTY9LU FM C4H10N2
DMTY9LU IC InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2
DMTY9LU CS C1CNCCN1
DMTY9LU IK GLUUGHFHXGJENI-UHFFFAOYSA-N
DMTY9LU IU piperazine
DMTY9LU CA CAS 110-85-0
DMTY9LU CB CHEBI:28568
DMTY9LU DE Enterobiasis; Ascariasis
DMNL0E6 ID DMNL0E6
DMNL0E6 DN Pipobroman
DMNL0E6 HS Approved
DMNL0E6 SN Amedel; Pipobromanum; Vercyte; A 1803; A-8103; Pipobroman [USAN:INN]; Pipobromanum [INN-Latin]; VERCYTE (TN); Pipobroman (JAN/USAN/INN); N,N'-Bis(3-bromopropionyl)piperazine; N,N-Bis-(3-bromopropionyl)-piperazine; 1,4-Bis(3-bromopropanoyl)piperazine; 1,4-Bis(3-bromopropionyl)piperazine; 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6 TC Anticancer Agents
DMNL0E6 DT Small molecular drug
DMNL0E6 PC 4842
DMNL0E6 MW 356.05
DMNL0E6 FM C10H16Br2N2O2
DMNL0E6 IC InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2
DMNL0E6 CS C1CN(CCN1C(=O)CCBr)C(=O)CCBr
DMNL0E6 IK NJBFOOCLYDNZJN-UHFFFAOYSA-N
DMNL0E6 IU 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6 CA CAS 54-91-1
DMNL0E6 CB CHEBI:8242
DMNL0E6 DE Refractory chronic myeloid leukaemia
DMC68DF ID DMC68DF
DMC68DF DN Pipotiazine
DMC68DF HS Approved
DMC68DF SN Pipotiazine; Pipothiazine; Pipotiazina; Pipotiazinum; 39860-99-6; Piportil; Pipotiazinum [INN-Latin]; Pipotiazina [INN-Spanish]; UNII-L903J9JPYV; L903J9JPYV; 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide; Pipotiazine [INN:BAN]; Piportil depot; Piportil (TN); Pipotiazine (INN); EINECS 254-659-6; Pipotiazine; ; ; Piportil; AC1L1XY4; SCHEMBL123275; GTPL7557; CHEMBL398880; BDBM81798; DTXSID40192913; ZINC3813024; BCP23973; PDSP2_000525; PDSP1_000527; NSC_62867; AKOS030527554; DB01621; ACM39860996
DMC68DF DT Small molecular drug
DMC68DF PC 62867
DMC68DF MW 475.7
DMC68DF FM C24H33N3O3S2
DMC68DF IC InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
DMC68DF CS CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMC68DF IK JOMHSQGEWSNUKU-UHFFFAOYSA-N
DMC68DF IU 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide
DMC68DF CA CAS 39860-99-6
DMC68DF DE Schizophrenia
DMGTW1I ID DMGTW1I
DMGTW1I DN Pirarubicin
DMGTW1I HS Approved
DMGTW1I SN Pinorubicin (TN); Therarubucin (TN)
DMGTW1I CP Sanraku and Meiji Seika
DMGTW1I DT Small molecular drug
DMGTW1I PC 636397
DMGTW1I MW 627.6
DMGTW1I FM C32H37NO12
DMGTW1I IC InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
DMGTW1I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O[C@H]6CCCCO6
DMGTW1I IK KMSKQZKKOZQFFG-HSUXVGOQSA-N
DMGTW1I IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMGTW1I CA CAS 72496-41-4
DMGTW1I CB CHEBI:32011
DMGTW1I DE Breast cancer
DMI5678 ID DMI5678
DMI5678 DN Pirbuterol
DMI5678 HS Approved
DMI5678 SN Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678 CP 3M Pharmaceuticals
DMI5678 TC Bronchodilator Agents
DMI5678 DT Small molecular drug
DMI5678 PC 4845
DMI5678 MW 240.3
DMI5678 FM C12H20N2O3
DMI5678 IC InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
DMI5678 CS CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
DMI5678 IK VQDBNKDJNJQRDG-UHFFFAOYSA-N
DMI5678 IU 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678 CA CAS 38677-81-5
DMI5678 CB CHEBI:8245
DMI5678 DE Asthma
DMP6M1N ID DMP6M1N
DMP6M1N DN Pirenzepine
DMP6M1N HS Approved
DMP6M1N SN Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
DMP6M1N CP Boehringer Ingelheim
DMP6M1N TC Antiulcer Agents
DMP6M1N DT Small molecular drug
DMP6M1N PC 4848
DMP6M1N MW 351.4
DMP6M1N FM C19H21N5O2
DMP6M1N IC InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
DMP6M1N CS CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMP6M1N IK RMHMFHUVIITRHF-UHFFFAOYSA-N
DMP6M1N IU 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMP6M1N CA CAS 28797-61-7
DMP6M1N CB CHEBI:8247
DMP6M1N DE Peptic ulcer
DM6VZFQ ID DM6VZFQ
DM6VZFQ DN Pirfenidone
DM6VZFQ HS Approved
DM6VZFQ SN Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one
DM6VZFQ CP InterMune
DM6VZFQ DT Small molecular drug
DM6VZFQ PC 40632
DM6VZFQ MW 185.22
DM6VZFQ FM C12H11NO
DM6VZFQ IC InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
DM6VZFQ CS CC1=CN(C(=O)C=C1)C2=CC=CC=C2
DM6VZFQ IK ISWRGOKTTBVCFA-UHFFFAOYSA-N
DM6VZFQ IU 5-methyl-1-phenylpyridin-2-one
DM6VZFQ CA CAS 53179-13-8
DM6VZFQ CB CHEBI:32016
DM6VZFQ DE Idiopathic pulmonary fibrosis
DMBCYF5 ID DMBCYF5
DMBCYF5 DN Pirmenol
DMBCYF5 HS Approved
DMBCYF5 SN Pimenol; Pirmavar; Pirmenol hydrochloride
DMBCYF5 CP Pfizer Inc
DMBCYF5 DT Small molecular drug
DMBCYF5 PC 65502
DMBCYF5 MW 338.5
DMBCYF5 FM C22H30N2O
DMBCYF5 IC InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3/t18-,19+,22?
DMBCYF5 CS C[C@@H]1CCC[C@@H](N1CCCC(C2=CC=CC=C2)(C3=CC=CC=N3)O)C
DMBCYF5 IK APUDBKTWDCXQJA-QIDMFYOTSA-N
DMBCYF5 IU 4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol
DMBCYF5 CA CAS 68252-19-7
DMBCYF5 CB CHEBI:135436
DMBCYF5 DE Heart arrhythmia
DMTK234 ID DMTK234
DMTK234 DN Piroxicam
DMTK234 HS Approved
DMTK234 SN Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
DMTK234 CP Pfizer Pharmaceuticals
DMTK234 TC Analgesics
DMTK234 DT Small molecular drug
DMTK234 PC 54676228
DMTK234 MW 331.3
DMTK234 FM C15H13N3O4S
DMTK234 IC InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
DMTK234 CS CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
DMTK234 IK QYSPLQLAKJAUJT-UHFFFAOYSA-N
DMTK234 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
DMTK234 CA CAS 36322-90-4
DMTK234 CB CHEBI:8249
DMTK234 DE Pain
DMMOFHT ID DMMOFHT
DMMOFHT DN Pirprofen
DMMOFHT HS Approved
DMMOFHT SN Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei
DMMOFHT DT Small molecular drug
DMMOFHT PC 35935
DMMOFHT MW 251.71
DMMOFHT FM C13H14ClNO2
DMMOFHT IC InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
DMMOFHT CS CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
DMMOFHT IK PIDSZXPFGCURGN-UHFFFAOYSA-N
DMMOFHT IU 2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
DMMOFHT CA CAS 31793-07-4
DMMOFHT CB CHEBI:135028
DMMOFHT DE Dysmenorrhea
DMJH792 ID DMJH792
DMJH792 DN Pitavastatin
DMJH792 HS Approved
DMJH792 SN Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)
DMJH792 PC 5282452
DMJH792 MW 421.5
DMJH792 FM C25H24FNO4
DMJH792 IC InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
DMJH792 CS C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F
DMJH792 IK VGYFMXBACGZSIL-MCBHFWOFSA-N
DMJH792 IU (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMJH792 CA CAS 147511-69-1
DMJH792 CB CHEBI:32020
DMJH792 DE Primary hyperlipidemia and mixed dyslipidemia
DM1UJO0 ID DM1UJO0
DM1UJO0 DN Pitavastatin calcium
DM1UJO0 HS Approved
DM1UJO0 SN Livalo; Pitavastatin calcium; 147526-32-7; Pitavastatin hemicalcium; NK-104; Nisvastatin; UNII-IYD54XEG3W; Flovas; IYD54XEG3W; 2C25H23FNO4Ca; CHEBI:71258; NK 104 (acid); Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; AK-50694; Itavastatin calcium; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; Pitavastatin calcium (JAN); Alipza; Livazo; P-872441; P 872441; 6-Heptenoic acid,
DM1UJO0 DT Small molecular drug
DM1UJO0 PC 5282451
DM1UJO0 MW 881
DM1UJO0 FM C50H46CaF2N2O8
DM1UJO0 IC InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1
DM1UJO0 CS C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2]
DM1UJO0 IK RHGYHLPFVJEAOC-FFNUKLMVSA-L
DM1UJO0 IU calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
DM1UJO0 CA CAS 147526-32-7
DM1UJO0 CB CHEBI:71258
DM1UJO0 DE Dyslipidemia
DM8RFNJ ID DM8RFNJ
DM8RFNJ DN Pitolisant
DM8RFNJ HS Approved
DM8RFNJ SN Pitolisant; 362665-56-3; TIPROLISANT; BF2.649; UNII-4BC83L4PIY; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; Pitolisant (BF2.649); 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 4BC83L4PIY; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; CHEMBL462605; wakix; 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Tirolisant; Pitolisant (INN); tiprolisant [USAN]; Wakix (TN); Pitolisant [USAN:INN]; SCHEMBL117648; GTPL8924; CTK1B6404; HBS-101
DM8RFNJ CP Bioprojet; Ferrer
DM8RFNJ DT Small molecular drug
DM8RFNJ PC 9948102
DM8RFNJ MW 295.8
DM8RFNJ FM C17H26ClNO
DM8RFNJ IC InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
DM8RFNJ CS C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
DM8RFNJ IK NNACHAUCXXVJSP-UHFFFAOYSA-N
DM8RFNJ IU 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
DM8RFNJ CA CAS 362665-56-3
DM8RFNJ CB CHEBI:134709
DM8RFNJ DE Schizophrenia; Excessive daytime sleepiness
DMX8CVY ID DMX8CVY
DMX8CVY DN Pivampicillin
DMX8CVY HS Approved
DMX8CVY SN Pivaloylampicillin; Pivampicilina; Pivampicilline; Pivampicillinum; Pondocillin; Ampicillin Pivaloyl Ester; Ampicillin pivaloyloxymethyl ester; Pivaloyloxymethyl ampicillinate; Pivampicillin Monohydrochloride; MK 191; Pivampicilina [INN-Spanish]; Pivampicillin (INN); Pivampicillin [INN:BAN]; Pivampicilline [INN-French]; Pivampicillinum [INN-Latin]; Pondocillin (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY TC Antibiotics
DMX8CVY DT Small molecular drug
DMX8CVY PC 33478
DMX8CVY MW 463.5
DMX8CVY FM C22H29N3O6S
DMX8CVY IC InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1
DMX8CVY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C
DMX8CVY IK ZEMIJUDPLILVNQ-ZXFNITATSA-N
DMX8CVY IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY CA CAS 33817-20-8
DMX8CVY CB CHEBI:8255
DMX8CVY DE Bacterial infection
DMDU0BV ID DMDU0BV
DMDU0BV DN Pivmecillinam
DMDU0BV HS Approved
DMDU0BV SN Coactabs; PMPC; Pivamdinocillin; Pivmecilinamo; Pivmecillinamum; Selexid; Amdinocillin Pivoxil; Amdinocillin pivoxil [USAN]; Mecillinam Pivaloyl Ester; Amdinocillin pivoxil (USAN); Amdinocillin, pivaloyloxymethyl ester; Coactabs (TN); Penomax (TN); Pivmecilinamo [INN-Spanish]; Pivmecillinam (INN); Pivmecillinamum [INN-Latin]; Ro 10-9071; Selexid (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl(2s,5r,6r)-6-{[(e)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Hydroxymethyl (2S,5R,6R)-6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester); 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV TC Antibiotics
DMDU0BV DT Small molecular drug
DMDU0BV PC 115163
DMDU0BV MW 439.6
DMDU0BV FM C21H33N3O5S
DMDU0BV IC InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1
DMDU0BV CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C
DMDU0BV IK NPGNOVNWUSPMDP-HLLBOEOZSA-N
DMDU0BV IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV CA CAS 32886-97-8
DMDU0BV CB CHEBI:51210
DMDU0BV DE Urinary tract infection
DMV74ZH ID DMV74ZH
DMV74ZH DN Pizotyline
DMV74ZH HS Approved
DMV74ZH SN Pizotifen; PIZOTYLINE; 15574-96-6; Sandomigran; Litec; Sandomygran; Pizotifenum; Pizotifeno; Polomigran; Pizotifene; BC-105; BC 105; Pizotyline [USAN]; Pizotifan; Pizotifene [INN-French]; Pizotifenum [INN-Latin]; Pizotifeno [INN-Spanish]; UNII-0BY8440V3N; EINECS 239-632-9; BRN 0753534; C19H21NS; CHEBI:50212; FIADGNVRKBPQEU-UHFFFAOYSA-N; Pizotifen (INN); Pizotifen [INN]; 0BY8440V3N; Pizotyline (USAN); 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidine
DMV74ZH DT Small molecular drug
DMV74ZH PC 27400
DMV74ZH MW 295.4
DMV74ZH FM C19H21NS
DMV74ZH IC InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3
DMV74ZH CS CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1
DMV74ZH IK FIADGNVRKBPQEU-UHFFFAOYSA-N
DMV74ZH IU 1-methyl-4-(6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)piperidine
DMV74ZH CA CAS 15574-96-6
DMV74ZH CB CHEBI:50212
DMV74ZH DE Headache
DMKMBES ID DMKMBES
DMKMBES DN Plazomicin
DMKMBES HS Approved
DMKMBES SN ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,
DMKMBES CP Achaogen
DMKMBES DT Small molecular drug
DMKMBES PC 42613186
DMKMBES MW 592.7
DMKMBES FM C25H48N6O10
DMKMBES IC InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1
DMKMBES CS C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O
DMKMBES IK IYDYFVUFSPQPPV-PEXOCOHZSA-N
DMKMBES IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMKMBES CA CAS 1154757-24-0
DMKMBES DE Urinary tract infection; Prostate disease; Bronchitis; Pancreatic cancer
DMKEX7O ID DMKEX7O
DMKEX7O DN Plecanatide
DMKEX7O HS Approved
DMKEX7O SN Trulance
DMKEX7O CP Synergy Pharmaceuticals
DMKEX7O DT Small molecular drug
DMKEX7O PC 70693500
DMKEX7O MW 1681.9
DMKEX7O FM C65H104N18O26S4
DMKEX7O IC InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1
DMKEX7O CS C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
DMKEX7O IK NSPHQWLKCGGCQR-DLJDZFDSSA-N
DMKEX7O IU (2S)-2-[[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-10-(2-amino-2-oxoethyl)-25-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-22-(2-carboxyethyl)-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-3,6,9,12,15,18,21,24,30,33,36-undecaoxo-7,13-di(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecazabicyclo[14.13.13]dotetracontane-38-carbonyl]amino]-4-methylpentanoic acid
DMKEX7O CA CAS 467426-54-6
DMKEX7O DE Irritable bowel syndrome; Chronic idiopathic constipation; Crohn disease
DMAKXW9 ID DMAKXW9
DMAKXW9 DN PLEGRIDY
DMAKXW9 HS Approved
DMAKXW9 SN Peginterferon beta-1a
DMAKXW9 CP Biogen Idec
DMAKXW9 SQ Sequence: MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMAKXW9 DE Multiple sclerosis
DMCJN1P ID DMCJN1P
DMCJN1P DN Plerixafor
DMCJN1P HS Approved
DMCJN1P SN Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P CP Genzyme
DMCJN1P DT Small molecular drug
DMCJN1P PC 65015
DMCJN1P MW 502.8
DMCJN1P FM C28H54N8
DMCJN1P IC InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
DMCJN1P CS C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
DMCJN1P IK YIQPUIGJQJDJOS-UHFFFAOYSA-N
DMCJN1P IU 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P CA CAS 110078-46-1
DMCJN1P CB CHEBI:125354
DMCJN1P DE Non-hodgkin lymphoma
DM7C8YV ID DM7C8YV
DM7C8YV DN Plicamycin
DM7C8YV HS Approved
DM7C8YV SN A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
DM7C8YV DT Small molecular drug
DM7C8YV PC 163659
DM7C8YV MW 1085.1
DM7C8YV FM C52H76O24
DM7C8YV IC InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1
DM7C8YV CS C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O
DM7C8YV IK CFCUWKMKBJTWLW-BKHRDMLASA-N
DM7C8YV IU (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one
DM7C8YV CA CAS 18378-89-7
DM7C8YV CB CHEBI:31856
DM7C8YV DE Lung cancer; Ovarian cancer; Testicular cancer; Hypercalcaemia; Solid tumour/cancer
DMG8MLJ ID DMG8MLJ
DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine
DMG8MLJ HS Approved
DMG8MLJ SN Prevnar 13 (TN)
DMG8MLJ CP Pfizer
DMG8MLJ DE Streptococcus infection
DMT2EJP ID DMT2EJP
DMT2EJP DN Podofilox
DMT2EJP HS Approved
DMT2EJP SN podophyllotoxin; 518-28-5; Condylox; Condyline; Wartec; Podophyllotoxin 7; Podophyllinic acid lactone; Warticon; (-)-Podophyllotoxin; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; Podophyllotoxin, 95%; HSDB 7238; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; MLS000069495; AI3-50456; CHEBI:50305; Podofilox (USAN); L36H50F353; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,; Podophyllotoxin
DMT2EJP CP Actavis Laboratories Ut Inc
DMT2EJP DT Small molecular drug
DMT2EJP PC 10607
DMT2EJP MW 414.4
DMT2EJP FM C22H22O8
DMT2EJP IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
DMT2EJP CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMT2EJP IK YJGVMLPVUAXIQN-XVVDYKMHSA-N
DMT2EJP IU (5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMT2EJP CA CAS 518-28-5
DMT2EJP CB CHEBI:50305
DMT2EJP DE External genital and perianal wart; Condyloma; Verruca vulgaris
DMF6Y0L ID DMF6Y0L
DMF6Y0L DN Polatuzumab vedotin
DMF6Y0L HS Approved
DMF6Y0L CP Genentech
DMF6Y0L DT Antibody
DMF6Y0L DE Follicular lymphoma; Haematological malignancy; Diffuse large B-cell lymphoma
DMH1KMT ID DMH1KMT
DMH1KMT DN Polidocanol
DMH1KMT HS Approved
DMH1KMT SN Asclera (TN)
DMH1KMT CP Chemisch FBRK KRSSLR
DMH1KMT DT Small molecular drug
DMH1KMT PC 656641
DMH1KMT MW 582.8
DMH1KMT FM C30H62O10
DMH1KMT IC InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
DMH1KMT CS CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
DMH1KMT IK ONJQDTZCDSESIW-UHFFFAOYSA-N
DMH1KMT IU 2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
DMH1KMT CA CAS 3055-99-0
DMH1KMT CB CHEBI:46859
DMH1KMT DE Reticular veins; Spider veins
DMUCWEX ID DMUCWEX
DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
DMUCWEX HS Approved
DMUCWEX SN Aethoxysklerol; Asclera
DMUCWEX DT Small molecular drug
DMUCWEX PC 24750
DMUCWEX MW 230.39
DMUCWEX FM C14H30O2
DMUCWEX IC InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3
DMUCWEX CS CCCCCCCCCCCCOCCO
DMUCWEX IK SFNALCNOMXIBKG-UHFFFAOYSA-N
DMUCWEX IU 2-dodecoxyethanol
DMUCWEX CA CAS 4536-30-5
DMUCWEX CB CHEBI:78770
DMUCWEX DE Varicose veins
DM0PMGJ ID DM0PMGJ
DM0PMGJ DN Polyestradiol Phosphate
DM0PMGJ HS Approved
DM0PMGJ SN Estradurin
DM0PMGJ CP Wyeth Ayerst Laboratories
DM0PMGJ TC Anticancer Agents
DM0PMGJ DT Small molecular drug
DM0PMGJ PC 66435
DM0PMGJ MW 352.4
DM0PMGJ FM C18H25O5P
DM0PMGJ IC InChI=1S/C18H25O5P/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H2,20,21,22)/t14-,15-,16+,17+,18+/m1/s1
DM0PMGJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)O
DM0PMGJ IK BBWXLCKRYRQQPL-ZBRFXRBCSA-N
DM0PMGJ IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate
DM0PMGJ CA CAS 4995-43-1
DM0PMGJ DE Prostate cancer
DM4I1JP ID DM4I1JP
DM4I1JP DN Polyethylene glycol
DM4I1JP HS Approved
DM4I1JP SN ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F
DM4I1JP DT Small molecular drug
DM4I1JP PC 174
DM4I1JP MW 62.07
DM4I1JP FM C2H6O2
DM4I1JP IC InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2
DM4I1JP CS C(CO)O
DM4I1JP IK LYCAIKOWRPUZTN-UHFFFAOYSA-N
DM4I1JP IU ethane-1,2-diol
DM4I1JP CA CAS 107-21-1
DM4I1JP CB CHEBI:30742
DM4I1JP DE Constipation
DMN0LP8 ID DMN0LP8
DMN0LP8 DN Polymyxin B Sulfate
DMN0LP8 HS Approved
DMN0LP8 SN Aerosporin; Polimixina B; Polymixin B sulfate; Polymxin B sulfate; Polymyxin b; Polymyxine B; Polymyxinum B; Terramycin Ophthalmic; Polimixina B [INN-Spanish]; Polymyxin B Sulfate [USAN:JAN]; Polymyxin B, sulfate; Polymyxine B [INN-French]; Polymyxinum B [INN-Latin]; Aerosporin, PMB, Poly-RX,Polymyxin B sulphate; 4-amino-N-[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(2-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-4-hydroxy-1-oxobutan-2-yl]-2-formamidobutanamide
DMN0LP8 TC Antibiotics
DMN0LP8 DT Small molecular drug
DMN0LP8 PC 5702105
DMN0LP8 MW 1301.6
DMN0LP8 FM C56H100N16O17S
DMN0LP8 IC InChI=1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)
DMN0LP8 CS CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.OS(=O)(=O)O
DMN0LP8 IK HFMDLUQUEXNBOP-UHFFFAOYSA-N
DMN0LP8 IU N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid
DMN0LP8 CA CAS 1405-20-5
DMN0LP8 DE Pseudomonas infection
DMJAOT1 ID DMJAOT1
DMJAOT1 DN Polyoxidonium
DMJAOT1 HS Approved
DMJAOT1 CP Immutic Group
DMJAOT1 DE Infectious disease
DMCH80F ID DMCH80F
DMCH80F DN Polythiazide
DMCH80F HS Approved
DMCH80F SN Drenusil; Nephril; Politiazida; Polythiazidum; Renese; P 2525; P-2525; Politiazida [INN-Spanish]; Polythiazidum [INN-Latin]; Renese (TN); Polythiazide (JAN/USAN/INN); Polythiazide [USAN:INN:BAN:JAN]; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMCH80F TC Antihypertensive Agents
DMCH80F DT Small molecular drug
DMCH80F PC 4870
DMCH80F MW 439.9
DMCH80F FM C11H13ClF3N3O4S3
DMCH80F IC InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)
DMCH80F CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F
DMCH80F IK CYLWJCABXYDINA-UHFFFAOYSA-N
DMCH80F IU 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMCH80F CA CAS 346-18-9
DMCH80F CB CHEBI:8327
DMCH80F DE Edema; Hypertension
DMTGBAX ID DMTGBAX
DMTGBAX DN Pomalidomide
DMTGBAX HS Approved
DMTGBAX SN Actimid (TN); Pomalidomide (Immunomodulator)
DMTGBAX CP Celgene
DMTGBAX DT Small molecular drug
DMTGBAX PC 134780
DMTGBAX MW 273.24
DMTGBAX FM C13H11N3O4
DMTGBAX IC InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
DMTGBAX CS C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
DMTGBAX IK UVSMNLNDYGZFPF-UHFFFAOYSA-N
DMTGBAX IU 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DMTGBAX CA CAS 19171-19-8
DMTGBAX CB CHEBI:72690
DMTGBAX DE Systemic sclerosis
DMYGJQO ID DMYGJQO
DMYGJQO DN Ponatinib
DMYGJQO HS Approved
DMYGJQO SN Iclusig (TN)
DMYGJQO CP ARIAD Pharmaceuticals
DMYGJQO DT Small molecular drug
DMYGJQO PC 24826799
DMYGJQO MW 532.6
DMYGJQO FM C29H27F3N6O
DMYGJQO IC InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
DMYGJQO CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
DMYGJQO IK PHXJVRSECIGDHY-UHFFFAOYSA-N
DMYGJQO IU 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMYGJQO CA CAS 943319-70-8
DMYGJQO CB CHEBI:78543
DMYGJQO DE Acute lymphoblastic leukaemia
DMEAOYJ ID DMEAOYJ
DMEAOYJ DN Ponesimod
DMEAOYJ HS Approved
DMEAOYJ SN 854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
DMEAOYJ CP Actelion Pharmaceuticals South San Francisco, CA
DMEAOYJ DT Small molecular drug
DMEAOYJ PC 11363176
DMEAOYJ MW 461
DMEAOYJ FM C23H25ClN2O4S
DMEAOYJ IC InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
DMEAOYJ CS CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
DMEAOYJ IK LPAUOXUZGSBGDU-ULCCENQXSA-N
DMEAOYJ IU (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
DMEAOYJ CA CAS 854107-55-4
DMEAOYJ DE Psoriasis vulgaris; Multiple sclerosis
DM7ZWNY ID DM7ZWNY
DM7ZWNY DN Porfimer Sodium
DM7ZWNY HS Approved
DM7ZWNY SN Photofrin
DM7ZWNY CP Concordia Laboratories Inc
DM7ZWNY DT Small molecular drug
DM7ZWNY DE Non-small-cell lung cancer
DMUL5EW ID DMUL5EW
DMUL5EW DN Posaconazole
DMUL5EW HS Approved
DMUL5EW SN Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW CP Schering-Plough
DMUL5EW TC Antifungal Agents
DMUL5EW DT Small molecular drug
DMUL5EW PC 468595
DMUL5EW MW 700.8
DMUL5EW FM C37H42F2N8O4
DMUL5EW IC InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
DMUL5EW CS CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMUL5EW IK RAGOYPUPXAKGKH-XAKZXMRKSA-N
DMUL5EW IU 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW CA CAS 171228-49-2
DMUL5EW CB CHEBI:64355
DMUL5EW DE Aspergillosis
DMMTAJC ID DMMTAJC
DMMTAJC DN Potassium chloride
DMMTAJC HS Approved
DMMTAJC SN Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA
DMMTAJC TC Dietary supplement
DMMTAJC DT Small molecular drug
DMMTAJC PC 4873
DMMTAJC MW 74.55
DMMTAJC FM ClK
DMMTAJC IC InChI=1S/ClH.K/h1H;/q;+1/p-1
DMMTAJC CS [Cl-].[K+]
DMMTAJC IK WCUXLLCKKVVCTQ-UHFFFAOYSA-M
DMMTAJC IU potassium;chloride
DMMTAJC CA CAS 7447-40-7
DMMTAJC CB CHEBI:32588
DMMTAJC DE Hypokalemia
DMGLZ26 ID DMGLZ26
DMGLZ26 DN Practolol
DMGLZ26 HS Approved
DMGLZ26 SN Dalzic; Eraldin; Practololo; Practololum; Praktololu; Teranol; Eralzdin Practolol; Practololo [DCIT]; Praktololu [Polish]; AY 21011; Cardiol (TN); Cordialina (TN); Dalzic (TN); Eraldin (TN); Eraldina (TN); Practololum [INN-Latin]; Praktol (TN); Pralon (TN); Teranol (TN); Practolol [USAN:BAN:INN]; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; (+-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
DMGLZ26 TC Antiarrhythmic Agents
DMGLZ26 DT Small molecular drug
DMGLZ26 PC 4883
DMGLZ26 MW 266.34
DMGLZ26 FM C14H22N2O3
DMGLZ26 IC InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
DMGLZ26 CS CC(C)NCC(COC1=CC=C(C=C1)NC(=O)C)O
DMGLZ26 IK DURULFYMVIFBIR-UHFFFAOYSA-N
DMGLZ26 IU N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMGLZ26 CA CAS 6673-35-4
DMGLZ26 CB CHEBI:258351
DMGLZ26 DE Cardiac arrhythmias
DMAO80I ID DMAO80I
DMAO80I DN Pralatrexate
DMAO80I HS Approved
DMAO80I SN Folotyn (TN)
DMAO80I CP Allos Therapeutics
DMAO80I DT Small molecular drug
DMAO80I PC 148121
DMAO80I MW 477.5
DMAO80I FM C23H23N7O5
DMAO80I IC InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
DMAO80I CS C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMAO80I IK OGSBUKJUDHAQEA-WMCAAGNKSA-N
DMAO80I IU (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid
DMAO80I CA CAS 146464-95-1
DMAO80I CB CHEBI:71223
DMAO80I DE Breast cancer; Peripheral T-cell lymphoma
DMGQ0ZI ID DMGQ0ZI
DMGQ0ZI DN Pralidoxime chloride
DMGQ0ZI HS Approved
DMGQ0ZI SN Protopam Chloride
DMGQ0ZI CP Baxter Healthcare Corp Anesthesia And Critical Care
DMGQ0ZI DT Small molecular drug
DMGQ0ZI PC 135445761
DMGQ0ZI MW 172.61
DMGQ0ZI FM C7H9ClN2O
DMGQ0ZI IC InChI=1S/C7H8N2O.ClH/c1-9-5-3-2-4-7(9)6-8-10;/h2-6H,1H3;1H
DMGQ0ZI CS C[N+]1=CC=CC=C1/C=N/O.[Cl-]
DMGQ0ZI IK HIGSLXSBYYMVKI-UHFFFAOYSA-N
DMGQ0ZI IU (NE)-N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine;chloride
DMGQ0ZI CA CAS 51-15-0
DMGQ0ZI CB CHEBI:8355
DMGQ0ZI DE Poisoning due to pesticides and chemicals
DMWU0I2 ID DMWU0I2
DMWU0I2 DN Pralsetinib
DMWU0I2 HS Approved
DMWU0I2 SN GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2 CP Blueprint Medicines Cambridge, MA
DMWU0I2 PC 129073603
DMWU0I2 MW 533.6
DMWU0I2 FM C27H32FN9O2
DMWU0I2 IC InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
DMWU0I2 CS CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
DMWU0I2 IK GBLBJPZSROAGMF-SIYOEGHHSA-N
DMWU0I2 IU N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2 CA CAS 2097132-94-8
DMWU0I2 DE Solid tumour/cancer; Non-small-cell lung cancer
DMNMW9R ID DMNMW9R
DMNMW9R DN Pramipexole
DMNMW9R HS Approved
DMNMW9R SN Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole
DMNMW9R CP Intas Pharma
DMNMW9R TC Antiparkinson Agents
DMNMW9R DT Small molecular drug
DMNMW9R PC 119570
DMNMW9R MW 211.33
DMNMW9R FM C10H17N3S
DMNMW9R IC InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
DMNMW9R CS CCCN[C@H]1CCC2=C(C1)SC(=N2)N
DMNMW9R IK FASDKYOPVNHBLU-ZETCQYMHSA-N
DMNMW9R IU (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMNMW9R CA CAS 104632-26-0
DMNMW9R CB CHEBI:8356
DMNMW9R DE Parkinson disease
DM2FHG3 ID DM2FHG3
DM2FHG3 DN Pramiracetam
DM2FHG3 HS Approved (orphan drug)
DM2FHG3 SN Amacetam; Ectapram; Neupramir; Remen; Amacetam hydrochloride; Amacetam sulfate; Pramiracetam hydrochloride; Pramiracetam sulfate; CNS-1879
DM2FHG3 CP Warner-Lambert Co
DM2FHG3 DT Small molecular drug
DM2FHG3 PC 51712
DM2FHG3 MW 269.38
DM2FHG3 FM C14H27N3O2
DM2FHG3 IC InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)
DM2FHG3 CS CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
DM2FHG3 IK ZULJGOSFKWFVRX-UHFFFAOYSA-N
DM2FHG3 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
DM2FHG3 CA CAS 68497-62-1
DM2FHG3 CB CHEBI:135110
DM2FHG3 DE Brain disease
DM0EZ9Q ID DM0EZ9Q
DM0EZ9Q DN Pramlintide
DM0EZ9Q HS Approved
DM0EZ9Q SN Symlin; Triproamylin; Pramlintide [USAN]; Pramlintide acetate; Pramlintide acetate [USAN]; Pramlintide acetate hydrate; AC 0137
DM0EZ9Q CP Amylin Pharmaceuticals
DM0EZ9Q DT Small molecular drug
DM0EZ9Q SQ Pramlintide: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY
DM0EZ9Q PC 70691388
DM0EZ9Q MW 3949
DM0EZ9Q FM C171H267N51O53S2
DM0EZ9Q IC InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1
DM0EZ9Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DM0EZ9Q IK TZIRZGBAFTZREM-MKAGXXMWSA-N
DM0EZ9Q IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DM0EZ9Q CA CAS 151126-32-8
DM0EZ9Q CB CHEBI:135922
DM0EZ9Q DE Type-1/2 diabetes
DMYHDCA ID DMYHDCA
DMYHDCA DN Pranlukast
DMYHDCA HS Approved
DMYHDCA SN Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA TC Antiasthmatic Agents
DMYHDCA DT Small molecular drug
DMYHDCA PC 4887
DMYHDCA MW 481.5
DMYHDCA FM C27H23N5O4
DMYHDCA IC InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
DMYHDCA CS C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5
DMYHDCA IK NBQKINXMPLXUET-UHFFFAOYSA-N
DMYHDCA IU N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA CA CAS 103177-37-3
DMYHDCA CB CHEBI:94810
DMYHDCA DE Asthma
DM67VKL ID DM67VKL
DM67VKL DN Prasterone
DM67VKL HS Approved
DM67VKL SN Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone
DM67VKL DT Small molecular drug
DM67VKL PC 5881
DM67VKL MW 288.4
DM67VKL FM C19H28O2
DM67VKL IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
DM67VKL CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C
DM67VKL IK FMGSKLZLMKYGDP-USOAJAOKSA-N
DM67VKL IU (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DM67VKL CA CAS 53-43-0
DM67VKL CB CHEBI:28689
DM67VKL DE Chronic obstructive pulmonary disease; Cardiovascular disease
DM7MT6E ID DM7MT6E
DM7MT6E DN Prasugrel
DM7MT6E HS Approved
DM7MT6E SN Effient (TN)
DM7MT6E CP Lilly; Daiichi Sankyo
DM7MT6E DT Small molecular drug
DM7MT6E PC 6918456
DM7MT6E MW 373.4
DM7MT6E FM C20H20FNO3S
DM7MT6E IC InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
DM7MT6E CS CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
DM7MT6E IK DTGLZDAWLRGWQN-UHFFFAOYSA-N
DM7MT6E IU [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
DM7MT6E CA CAS 150322-43-3
DM7MT6E CB CHEBI:87723
DM7MT6E DE Acute coronary syndrome
DM6A0X7 ID DM6A0X7
DM6A0X7 DN Pravastatin
DM6A0X7 HS Approved
DM6A0X7 SN Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
DM6A0X7 CP Bristol-Myers Squibb
DM6A0X7 TC Anticholesteremic Agents
DM6A0X7 DT Small molecular drug
DM6A0X7 PC 54687
DM6A0X7 MW 424.5
DM6A0X7 FM C23H36O7
DM6A0X7 IC InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
DM6A0X7 CS CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
DM6A0X7 IK TUZYXOIXSAXUGO-PZAWKZKUSA-N
DM6A0X7 IU (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM6A0X7 CA CAS 81093-37-0
DM6A0X7 CB CHEBI:63618
DM6A0X7 DE Hypercholesterolaemia
DMEWC7N ID DMEWC7N
DMEWC7N DN Prazepam
DMEWC7N HS Approved
DMEWC7N SN Centrax; Demetrin; Lysanxia; Prazeene; Prazene; Prazepamum; Sedapran; Settima; Trepidan; Verstran; W 4020; Centrac (TN); Centrax (TN); Demetrin (TN); K-373; Lysanxia (TN); Mono Demetrin (TN); Pozapam (TN); Prasepine (TN); Prazene (TN); Prazepamum [INN-Latin]; Reapam (TN); Trepidan (TN); W-4020; Prazepam (JP15/USAN/INN); Prazepam [USAN:INN:BAN:JAN]; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N TC Antianxiety Agents
DMEWC7N DT Small molecular drug
DMEWC7N PC 4890
DMEWC7N MW 324.8
DMEWC7N FM C19H17ClN2O
DMEWC7N IC InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
DMEWC7N CS C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
DMEWC7N IK MWQCHHACWWAQLJ-UHFFFAOYSA-N
DMEWC7N IU 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N CA CAS 2955-38-6
DMEWC7N CB CHEBI:8362
DMEWC7N DE Anxiety disorder
DMOU1PK ID DMOU1PK
DMOU1PK DN Praziquantel
DMOU1PK HS Approved
DMOU1PK SN Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY
DMOU1PK CP Bayer Pharmaceuticals Corporation
DMOU1PK TC Anthelmintics
DMOU1PK DT Small molecular drug
DMOU1PK PC 4891
DMOU1PK MW 312.4
DMOU1PK FM C19H24N2O2
DMOU1PK IC InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
DMOU1PK CS C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
DMOU1PK IK FSVJFNAIGNNGKK-UHFFFAOYSA-N
DMOU1PK IU 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one
DMOU1PK CA CAS 55268-74-1
DMOU1PK CB CHEBI:91583
DMOU1PK DE Flatworm infection
DMCD9YG ID DMCD9YG
DMCD9YG DN Prazosin
DMCD9YG HS Approved
DMCD9YG SN Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
DMCD9YG CP Pfizer Pharmaceuticals
DMCD9YG TC Antihypertensive Agents
DMCD9YG DT Small molecular drug
DMCD9YG PC 4893
DMCD9YG MW 383.4
DMCD9YG FM C19H21N5O4
DMCD9YG IC InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
DMCD9YG CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
DMCD9YG IK IENZQIKPVFGBNW-UHFFFAOYSA-N
DMCD9YG IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
DMCD9YG CA CAS 19216-56-9
DMCD9YG CB CHEBI:8364
DMCD9YG DE Congestive heart failure; Benign prostatic hyperplasia; Hypertension
DMBUNVW ID DMBUNVW
DMBUNVW DN Prednicarbate
DMBUNVW HS Approved
DMBUNVW SN Dermatop; Peitel; Dermatop (TN); Hoe-777; S-77 0777; S-770777; Prednicarbate (USP/INN); [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW TC Antiinflammatory Agents
DMBUNVW DT Small molecular drug
DMBUNVW PC 6714002
DMBUNVW MW 488.6
DMBUNVW FM C27H36O8
DMBUNVW IC InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1
DMBUNVW CS CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC
DMBUNVW IK FNPXMHRZILFCKX-KAJVQRHHSA-N
DMBUNVW IU [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW CA CAS 73771-04-7
DMBUNVW CB CHEBI:135791
DMBUNVW DE Inflammation
DMQ8FR2 ID DMQ8FR2
DMQ8FR2 DN Prednisolone
DMQ8FR2 HS Approved
DMQ8FR2 SN Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
DMQ8FR2 CP Schering Corp Sub Schering Plough Corp
DMQ8FR2 TC Anticancer Agents
DMQ8FR2 DT Small molecular drug
DMQ8FR2 PC 5755
DMQ8FR2 MW 360.4
DMQ8FR2 FM C21H28O5
DMQ8FR2 IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMQ8FR2 CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
DMQ8FR2 IK OIGNJSKKLXVSLS-VWUMJDOOSA-N
DMQ8FR2 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMQ8FR2 CA CAS 50-24-8
DMQ8FR2 CB CHEBI:8378
DMQ8FR2 DE Solid tumour/cancer; Multiple sclerosis
DM2HG4X ID DM2HG4X
DM2HG4X DN Prednisone
DM2HG4X HS Approved
DM2HG4X SN Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
DM2HG4X CP Schering-Plough
DM2HG4X TC Antiinflammatory Agents
DM2HG4X DT Small molecular drug
DM2HG4X PC 5865
DM2HG4X MW 358.4
DM2HG4X FM C21H26O5
DM2HG4X IC InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DM2HG4X CS C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
DM2HG4X IK XOFYZVNMUHMLCC-ZPOLXVRWSA-N
DM2HG4X IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DM2HG4X CA CAS 53-03-2
DM2HG4X CB CHEBI:8382
DM2HG4X DE Atopic dermatitis; Eczema; Inflammation
DMDVP3B ID DMDVP3B
DMDVP3B DN Pregabalin
DMDVP3B HS Approved
DMDVP3B SN Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer
DMDVP3B CP Pfizer
DMDVP3B DT Small molecular drug
DMDVP3B PC 5486971
DMDVP3B MW 159.23
DMDVP3B FM C8H17NO2
DMDVP3B IC InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
DMDVP3B CS CC(C)C[C@@H](CC(=O)O)CN
DMDVP3B IK AYXYPKUFHZROOJ-ZETCQYMHSA-N
DMDVP3B IU (3S)-3-(aminomethyl)-5-methylhexanoic acid
DMDVP3B CA CAS 148553-50-8
DMDVP3B CB CHEBI:64356
DMDVP3B DE Chronic obstructive pulmonary disease
DMYQVGN ID DMYQVGN
DMYQVGN DN Premarin/Trimegestone
DMYQVGN HS Approved
DMYQVGN SN Conjugated estrogen tablets
DMYQVGN CP Wyeth
DMYQVGN DE Menopause symptom
DMDYA31 ID DMDYA31
DMDYA31 DN Pretomanid
DMDYA31 HS Approved
DMDYA31 SN PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011
DMDYA31 DT Small molecular drug
DMDYA31 PC 456199
DMDYA31 MW 359.26
DMDYA31 FM C14H12F3N3O5
DMDYA31 IC InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
DMDYA31 CS C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
DMDYA31 IK ZLHZLMOSPGACSZ-NSHDSACASA-N
DMDYA31 IU (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
DMDYA31 CA CAS 187235-37-6
DMDYA31 DE Mycobacterium infection; Tuberculosis
DMQ0C2Z ID DMQ0C2Z
DMQ0C2Z DN Prevnar
DMQ0C2Z HS Approved
DMQ0C2Z SN Prevenar; PNCRM7; PCV-7; Polyvalent pneumococcal vaccine, Praxis; Pneumococcus/CRM-197 conjugate vaccine, Pfizer; Vaccine (pneumococcal), Praxis/American Home Products; 7vPnC, Pfizer
DMQ0C2Z CP Pfizer Vaccines
DMQ0C2Z DT Vaccine
DMQ0C2Z DE Otitis media
DMMZB0K ID DMMZB0K
DMMZB0K DN Prifinium
DMMZB0K HS Approved
DMMZB0K SN Prifinium; 10236-81-4; 3-(Benzhydrylidene)-1,1-diethyl-2-methylpyrrolidinium; Prifinum; NCGC00183859-01; EINECS 233-568-5; AC1Q1ITK; AC1L1J7T; SCHEMBL14672576; 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium; CHEMBL1229214; CTK4A0968; 3-Diphenylmethylene-1,1-diethyl-2-methylpyrrolidinium
DMMZB0K DT Small molecular drug
DMMZB0K PC 4905
DMMZB0K MW 306.5
DMMZB0K FM C22H28N+
DMMZB0K IC InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1
DMMZB0K CS CC[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)C1C)CC
DMMZB0K IK ZYEPZINLLPPBMI-UHFFFAOYSA-N
DMMZB0K IU 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium
DMMZB0K CA CAS 10236-81-4
DMMZB0K DE Irritable bowel syndrome
DMI7DZ2 ID DMI7DZ2
DMI7DZ2 DN Prilocaine
DMI7DZ2 HS Approved
DMI7DZ2 SN Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide
DMI7DZ2 CP Astrazeneca Lp
DMI7DZ2 TC Anesthetics
DMI7DZ2 DT Small molecular drug
DMI7DZ2 PC 4906
DMI7DZ2 MW 220.31
DMI7DZ2 FM C13H20N2O
DMI7DZ2 IC InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)
DMI7DZ2 CS CCCNC(C)C(=O)NC1=CC=CC=C1C
DMI7DZ2 IK MVFGUOIZUNYYSO-UHFFFAOYSA-N
DMI7DZ2 IU N-(2-methylphenyl)-2-(propylamino)propanamide
DMI7DZ2 CA CAS 721-50-6
DMI7DZ2 CB CHEBI:8404
DMI7DZ2 DE Pain
DMWQ16I ID DMWQ16I
DMWQ16I DN Primaquine
DMWQ16I HS Approved
DMWQ16I SN Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline
DMWQ16I CP Sanofi-Aventis
DMWQ16I TC Antimalarials
DMWQ16I DT Small molecular drug
DMWQ16I PC 4908
DMWQ16I MW 259.35
DMWQ16I FM C15H21N3O
DMWQ16I IC InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
DMWQ16I CS CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
DMWQ16I IK INDBQLZJXZLFIT-UHFFFAOYSA-N
DMWQ16I IU 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
DMWQ16I CA CAS 90-34-6
DMWQ16I CB CHEBI:8405
DMWQ16I DE Malaria
DM0WX6I ID DM0WX6I
DM0WX6I DN Primidone
DM0WX6I HS Approved
DM0WX6I SN Cyral; Desoxyphenobarbital; Desoxyphenobarbitone; Hexadiona; Lepimidin; Lepsiral; Liskantin; Majsolin; Midone; Milepsin; Misodine; Misolyne; Mizodin; Mizolin; Myidone; Mylepsin; Mylepsinum; Mysedon; Mysoline; Neurosyn; Prilepsin; Primacione; Primaclone; Primacone; Primakton; Primidon; Primidona; Primidonum; Primoline; Prysoline; Resimatil; Sertan; Apotex Brand of Primidone; Astra Brand of Primidone; AstraZeneca Brand of Primidone; Desitin Brand of Primidone; Draxis Brand of Primidone; Holsten Brand of Primidone; Pms Primidone; Primidon Holsten; Primidone Methanol Solution; Xcel Brand of Primidone; Zeneca Brand of Primidone; P 7295; Roe 101; Apo-Primidone; Hexamidine (the antispasmodic); Hexamidine(the antispasmodic); Liskantin (TN); Medi-Pets; Mylepsinum (TN); Mysoline (TN); Primidona [INN-Spanish]; Primidone (primaclone); Primidonum [INN-Latin]; Prysoline (TN); Pyrimidone Medi-pets; Resimatil (TN); Sanofi-Synthelabo Brand of Primidone; Sertan (TN); Apo-Primidone (TN); Pyrimidone (Medi-pets); Primidone (JP15/USP/INN); Primidone [USAN:INN:BAN:JAN]; 2-Deoxyphenobarbital; 2-Desoxyphenobarbital; 4,4'-(Hexamethylenedioxy)dibenzamidine; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine
DM0WX6I CP Rekah Pharmaceutical
DM0WX6I TC Anticonvulsants
DM0WX6I DT Small molecular drug
DM0WX6I PC 4909
DM0WX6I MW 218.25
DM0WX6I FM C12H14N2O2
DM0WX6I IC InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)
DM0WX6I CS CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
DM0WX6I IK DQMZLTXERSFNPB-UHFFFAOYSA-N
DM0WX6I IU 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione
DM0WX6I CA CAS 125-33-7
DM0WX6I CB CHEBI:8412
DM0WX6I DE Epilepsy
DM9HOKG ID DM9HOKG
DM9HOKG DN Prinomastat
DM9HOKG HS Approved
DM9HOKG SN AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG CP Pfizer
DM9HOKG TC Anticancer Agents
DM9HOKG DT Small molecular drug
DM9HOKG PC 466151
DM9HOKG MW 423.5
DM9HOKG FM C18H21N3O5S2
DM9HOKG IC InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
DM9HOKG CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C
DM9HOKG IK YKPYIPVDTNNYCN-INIZCTEOSA-N
DM9HOKG IU (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG CA CAS 192329-42-3
DM9HOKG CB CHEBI:138885
DM9HOKG DE Lung cancer; Brain cancer
DMMFWOJ ID DMMFWOJ
DMMFWOJ DN Probenecid
DMMFWOJ HS Approved
DMMFWOJ SN Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid
DMMFWOJ TC Uricosuric Agents
DMMFWOJ DT Small molecular drug
DMMFWOJ PC 4911
DMMFWOJ MW 285.36
DMMFWOJ FM C13H19NO4S
DMMFWOJ IC InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
DMMFWOJ CS CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
DMMFWOJ IK DBABZHXKTCFAPX-UHFFFAOYSA-N
DMMFWOJ IU 4-(dipropylsulfamoyl)benzoic acid
DMMFWOJ CA CAS 57-66-9
DMMFWOJ CB CHEBI:8426
DMMFWOJ DE Hyperuricaemia; Gout
DMVZQ2M ID DMVZQ2M
DMVZQ2M DN Probucol
DMVZQ2M HS Approved
DMVZQ2M SN Biphenabid; Bisbid; Bisphenabid; Lesterol; Lorelco; Lursell; Lurselle; Panavir; Probucolum; Sinlestal; Superlipid; Almirall Brand of Probucol; Aventis Brand of Probucol; Hoechst Brand of Probucol; DH 581; DH581; DE-3872; DH-581; LORELCO (TN); Probucolum [INN-Latin]; ZERO/001429; Probucol (JAN/USP/INN); Probucol [USAN:BAN:INN:JAN]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]
DMVZQ2M TC Anticholesteremic Agents
DMVZQ2M DT Small molecular drug
DMVZQ2M PC 4912
DMVZQ2M MW 516.799
DMVZQ2M FM C31H48O2S2
DMVZQ2M IC InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
DMVZQ2M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
DMVZQ2M IK FYPMFJGVHOHGLL-UHFFFAOYSA-N
DMVZQ2M IU 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
DMVZQ2M CA CAS 23288-49-5
DMVZQ2M CB CHEBI:8427
DMVZQ2M DE Coronary artery disease
DMNMXR8 ID DMNMXR8
DMNMXR8 DN Procainamide
DMNMXR8 HS Approved
DMNMXR8 SN Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide
DMNMXR8 TC Antiarrhythmic Agents
DMNMXR8 DT Small molecular drug
DMNMXR8 PC 4913
DMNMXR8 MW 235.33
DMNMXR8 FM C13H21N3O
DMNMXR8 IC InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
DMNMXR8 CS CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
DMNMXR8 IK REQCZEXYDRLIBE-UHFFFAOYSA-N
DMNMXR8 IU 4-amino-N-[2-(diethylamino)ethyl]benzamide
DMNMXR8 CA CAS 51-06-9
DMNMXR8 CB CHEBI:8428
DMNMXR8 DE Ventricular arrhythmias
DM4LSNE ID DM4LSNE
DM4LSNE DN Procaine
DM4LSNE HS Approved
DM4LSNE SN Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester
DM4LSNE CP Wyeth Pharmaceuticals
DM4LSNE TC Anesthetics
DM4LSNE DT Small molecular drug
DM4LSNE PC 4914
DM4LSNE MW 236.31
DM4LSNE FM C13H20N2O2
DM4LSNE IC InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
DM4LSNE CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N
DM4LSNE IK MFDFERRIHVXMIY-UHFFFAOYSA-N
DM4LSNE IU 2-(diethylamino)ethyl 4-aminobenzoate
DM4LSNE CA CAS 59-46-1
DM4LSNE CB CHEBI:8430
DM4LSNE DE Anaesthesia
DMIK367 ID DMIK367
DMIK367 DN Procarbazine
DMIK367 HS Approved
DMIK367 SN Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367 CP Sigma-Tau Pharmaceuticals
DMIK367 TC Anticancer Agents
DMIK367 DT Small molecular drug
DMIK367 PC 4915
DMIK367 MW 221.3
DMIK367 FM C12H19N3O
DMIK367 IC InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
DMIK367 CS CC(C)NC(=O)C1=CC=C(C=C1)CNNC
DMIK367 IK CPTBDICYNRMXFX-UHFFFAOYSA-N
DMIK367 IU 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367 CA CAS 671-16-9
DMIK367 CB CHEBI:71417
DMIK367 DE Hodgkin lymphoma
DM1M0Q4 ID DM1M0Q4
DM1M0Q4 DN Procaterol
DM1M0Q4 HS Approved
DM1M0Q4 SN Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4 TC Bronchodilator Agents
DM1M0Q4 DT Small molecular drug
DM1M0Q4 PC 4916
DM1M0Q4 MW 290.36
DM1M0Q4 FM C16H22N2O3
DM1M0Q4 IC InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)
DM1M0Q4 CS CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C
DM1M0Q4 IK FKNXQNWAXFXVNW-UHFFFAOYSA-N
DM1M0Q4 IU 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4 CA CAS 60443-17-6
DM1M0Q4 CB CHEBI:91585
DM1M0Q4 DE Asthma
DM53SRA ID DM53SRA
DM53SRA DN Prochlorperazine
DM53SRA HS Approved
DM53SRA SN CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
DM53SRA CP GlaxoSmithKline
DM53SRA TC Antipsychotic Agents
DM53SRA DT Small molecular drug
DM53SRA PC 4917
DM53SRA MW 373.9
DM53SRA FM C20H24ClN3S
DM53SRA IC InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
DM53SRA CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM53SRA IK WIKYUJGCLQQFNW-UHFFFAOYSA-N
DM53SRA IU 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM53SRA CA CAS 58-38-8
DM53SRA CB CHEBI:8435
DM53SRA DE Nausea
DMHFJDT ID DMHFJDT
DMHFJDT DN Procyclidine
DMHFJDT HS Approved
DMHFJDT SN Arpicolin; Elorine; Kemadrin; Kemadrine; Lergine; Metanin; Osnervan; Prociclidina; Procidlidina; Procyclid; Procyclidinum; Procyklidin; Prosyklidin; Spamol; Triciclidina; Triciloid; Tricoloid; Tricyclamol; Vagosin; Prociclidina [INN-Spanish]; Procyclidine (INN); Procyclidine [INN:BAN]; Procyclidinum [INN-Latin]; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT TC Antiparkinson Agents
DMHFJDT DT Small molecular drug
DMHFJDT PC 4919
DMHFJDT MW 287.4
DMHFJDT FM C19H29NO
DMHFJDT IC InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DMHFJDT CS C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O
DMHFJDT IK WYDUSKDSKCASEF-UHFFFAOYSA-N
DMHFJDT IU 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT CA CAS 77-37-2
DMHFJDT CB CHEBI:8448
DMHFJDT DE Parkinson disease
DMF1X5P ID DMF1X5P
DMF1X5P DN Proflavine
DMF1X5P HS Approved
DMF1X5P SN PRL; Proflavin; Proflavina; Proflavinum; Profura; Progarmed; Isoflav base; Proflavine [INN]; Proflavine hemisulfate; Proflavina [INN-Spanish]; Proflavine Hemi-Sulfate; Proflavinum [INN-Latin]; AE-562/12222295; Acridine-3,6-diamine; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); 2,8-Diaminoacridinium; 3,6-ACRIDINEDIAMINE; 3,6-Acridinediamine hydrochloride; 3,6-Diamino-acridinium; 3,6-Diaminoacridine; 3,6-Diaminoacridine sulfate; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene
DMF1X5P TC Antiinfective Agents
DMF1X5P DT Small molecular drug
DMF1X5P PC 7099
DMF1X5P MW 209.25
DMF1X5P FM C13H11N3
DMF1X5P IC InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2
DMF1X5P CS C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N
DMF1X5P IK WDVSHHCDHLJJJR-UHFFFAOYSA-N
DMF1X5P IU acridine-3,6-diamine
DMF1X5P CA CAS 92-62-6
DMF1X5P CB CHEBI:8452
DMF1X5P DE Sepsis
DM671NG ID DM671NG
DM671NG DN Progabide
DM671NG HS Approved
DM671NG SN Gabren; Gabrene; Halogabide; Progabida; Progabidum; SL 76002; Gabren (TN); Gabrene (TN); Progabida [INN-Spanish]; Progabidum [INN-Latin]; SL 76-002; SL-76002; Progabide (USAN/INN); Progabide [USAN:BAN:INN]; Progabide [USAN:INN:BAN]; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
DM671NG CP Sanofi-Aventis
DM671NG TC Antidepressants
DM671NG DT Small molecular drug
DM671NG PC 44115
DM671NG MW 334.8
DM671NG FM C17H16ClFN2O2
DM671NG IC InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,22H,1-2,9H2,(H2,20,23)
DM671NG CS C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl
DM671NG IK IBALRBWGSVJPAP-UHFFFAOYSA-N
DM671NG IU 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
DM671NG CA CAS 62666-20-0
DM671NG CB CHEBI:135422
DM671NG DE Depression
DMUY35B ID DMUY35B
DMUY35B DN Progesterone
DMUY35B HS Approved
DMUY35B SN progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine
DMUY35B CP Lipocine Inc
DMUY35B DT Small molecular drug
DMUY35B PC 5994
DMUY35B MW 314.5
DMUY35B FM C21H30O2
DMUY35B IC InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
DMUY35B CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMUY35B IK RJKFOVLPORLFTN-LEKSSAKUSA-N
DMUY35B IU (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMUY35B CA CAS 57-83-0
DMUY35B CB CHEBI:17026
DMUY35B DE Premature labour; Contraception
DMBL79I ID DMBL79I
DMBL79I DN Proguanil
DMBL79I HS Approved
DMBL79I SN Bigumal; Chlorguanid; Chlorguanide; Chloriguane; Chloroguanide; Paludrin; Proguanile; Proguanilum; Proguanile [DCIT]; Diguanyl (hydrochloride); Drinupal (hydrochloride); Paludrine (TN); Paludrine (hydrochloride); Palusil (hydrochloride); Proguanil [INN:BAN]; Proguanilum [INN-Latin]; RP-3359; Tirian (hydrochloride); M-4888 (hydrochloride); SN-12837 (hydrochloride); N1-p-Chlorophenyl-N5-isopropylbiguanide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 1-(p-Chlorophenyl)-5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide
DMBL79I CP AstraZeneca
DMBL79I TC Antimalarials
DMBL79I DT Small molecular drug
DMBL79I PC 6178111
DMBL79I MW 253.73
DMBL79I FM C11H16ClN5
DMBL79I IC InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)
DMBL79I CS CC(C)N=C(N)/N=C(\\N)/NC1=CC=C(C=C1)Cl
DMBL79I IK SSOLNOMRVKKSON-UHFFFAOYSA-N
DMBL79I IU (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine
DMBL79I CA CAS 500-92-5
DMBL79I CB CHEBI:8455
DMBL79I DE Malaria
DMYSCIL ID DMYSCIL
DMYSCIL DN Prolastin
DMYSCIL HS Approved
DMYSCIL SN Prolastin-C; TAL-6004; Alpha-1 antitrypsin, Bayer; Alpha-1 antitrypsin, Talecris/Crucell; Alpha-1 proteinaseinhibitor (human), Bayer
DMYSCIL CP Bayer AG
DMYSCIL DE Alpha-1 antitrypsin deficiency
DMMJ1IS ID DMMJ1IS
DMMJ1IS DN Prolixin decanoate
DMMJ1IS HS Approved
DMMJ1IS SN Modecate; Dapotum D; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine decanoate; Fluphenazine depot; Moditen depot; Fluphenazine O-decanoate; Moditen-depo; Prolixin decanoate (TN); SQ 10,733; Fluphenazine decanoate (JAN/USP); Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS TC Antipsychotic Agents
DMMJ1IS DT Small molecular drug
DMMJ1IS PC 3388
DMMJ1IS MW 591.8
DMMJ1IS FM C32H44F3N3O2S
DMMJ1IS IC InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
DMMJ1IS CS CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMMJ1IS IK VIQCGTZFEYDQMR-UHFFFAOYSA-N
DMMJ1IS IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS CA CAS 5002-47-1
DMMJ1IS CB CHEBI:5124
DMMJ1IS DE Schizophrenia
DMZAL7W ID DMZAL7W
DMZAL7W DN Promazine
DMZAL7W HS Approved
DMZAL7W SN Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
DMZAL7W CP Wyeth Pharmaceuticals
DMZAL7W TC Antipsychotic Agents
DMZAL7W DT Small molecular drug
DMZAL7W PC 4926
DMZAL7W MW 284.4
DMZAL7W FM C17H20N2S
DMZAL7W IC InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
DMZAL7W CS CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
DMZAL7W IK ZGUGWUXLJSTTMA-UHFFFAOYSA-N
DMZAL7W IU N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
DMZAL7W CA CAS 58-40-2
DMZAL7W CB CHEBI:8459
DMZAL7W DE Psychomotor agitation
DMK4S8I ID DMK4S8I
DMK4S8I DN Promegestone
DMK4S8I HS Approved
DMK4S8I SN Surgestone (TN)
DMK4S8I CP Labs. Cassenne
DMK4S8I DT Small molecular drug
DMK4S8I PC 36709
DMK4S8I MW 326.5
DMK4S8I FM C22H30O2
DMK4S8I IC InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1
DMK4S8I CS CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C
DMK4S8I IK QFFCYTLOTYIJMR-XMGTWHOFSA-N
DMK4S8I IU (8S,13S,14S,17S)-13,17-dimethyl-17-propanoyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMK4S8I CA CAS 34184-77-5
DMK4S8I CB CHEBI:73390
DMK4S8I DE Gynecological disease
DMU92F8 ID DMU92F8
DMU92F8 DN Promestriene
DMU92F8 HS Approved
DMU92F8 SN BCP9000134; VA11593; A824465; I06-0300
DMU92F8 DT Small molecular drug
DMU92F8 PC 9883915
DMU92F8 MW 328.5
DMU92F8 FM C22H32O2
DMU92F8 IC InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1
DMU92F8 CS CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C
DMU92F8 IK IUWKNLFTJBHTSD-AANPDWTMSA-N
DMU92F8 IU (8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene
DMU92F8 CA CAS 39219-28-8
DMU92F8 CB CHEBI:135402
DMU92F8 DE Acne vulgaris
DM6I5GR ID DM6I5GR
DM6I5GR DN Promethazine
DM6I5GR HS Approved
DM6I5GR SN Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
DM6I5GR CP Wyeth Pharmaceuticals
DM6I5GR TC Antiallergic Agents
DM6I5GR DT Small molecular drug
DM6I5GR PC 4927
DM6I5GR MW 284.4
DM6I5GR FM C17H20N2S
DM6I5GR IC InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
DM6I5GR CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
DM6I5GR IK PWWVAXIEGOYWEE-UHFFFAOYSA-N
DM6I5GR IU N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
DM6I5GR CA CAS 60-87-7
DM6I5GR CB CHEBI:8461
DM6I5GR DE Nausea
DMPIBJK ID DMPIBJK
DMPIBJK DN Propafenone
DMPIBJK HS Approved
DMPIBJK SN Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK CP Reliant Pharmaceuticals
DMPIBJK TC Antiarrhythmic Agents
DMPIBJK DT Small molecular drug
DMPIBJK PC 4932
DMPIBJK MW 341.4
DMPIBJK FM C21H27NO3
DMPIBJK IC InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
DMPIBJK CS CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
DMPIBJK IK JWHAUXFOSRPERK-UHFFFAOYSA-N
DMPIBJK IU 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK CA CAS 54063-53-5
DMPIBJK CB CHEBI:63619
DMPIBJK DE Tachyarrhythmias
DM2EN6G ID DM2EN6G
DM2EN6G DN Propantheline
DM2EN6G HS Approved
DM2EN6G SN Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)
DM2EN6G TC Antispasmodics
DM2EN6G DT Small molecular drug
DM2EN6G PC 4934
DM2EN6G MW 368.5
DM2EN6G FM C23H30NO3+
DM2EN6G IC InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1
DM2EN6G CS CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C
DM2EN6G IK VVWYOYDLCMFIEM-UHFFFAOYSA-N
DM2EN6G IU methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM2EN6G CA CAS 298-50-0
DM2EN6G CB CHEBI:8481
DM2EN6G DE Stomach ulcer; Excessive sweating
DMLS39E ID DMLS39E
DMLS39E DN Proparacaine
DMLS39E HS Approved
DMLS39E SN Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester
DMLS39E TC Anesthetics
DMLS39E DT Small molecular drug
DMLS39E PC 4935
DMLS39E MW 294.39
DMLS39E FM C16H26N2O3
DMLS39E IC InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
DMLS39E CS CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N
DMLS39E IK KCLANYCVBBTKTO-UHFFFAOYSA-N
DMLS39E IU 2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
DMLS39E CA CAS 499-67-2
DMLS39E CB CHEBI:8485
DMLS39E DE Anaesthesia
DM6JQ2I ID DM6JQ2I
DM6JQ2I DN Propentofylline propionate
DM6JQ2I HS Approved
DM6JQ2I SN Hextol (TN)
DM6JQ2I DT Small molecular drug
DM6JQ2I PC 4938
DM6JQ2I MW 306.36
DM6JQ2I FM C15H22N4O3
DM6JQ2I IC InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
DM6JQ2I CS CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C
DM6JQ2I IK RBQOQRRFDPXAGN-UHFFFAOYSA-N
DM6JQ2I IU 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione
DM6JQ2I CA CAS 55242-55-2
DM6JQ2I CB CHEBI:32061
DM6JQ2I DE Alzheimer disease
DME9JNL ID DME9JNL
DME9JNL DN Propericiazine
DME9JNL HS Approved
DME9JNL SN Aolept; Nemactil; Neulactil; Neuleptil; PERICYAZINE; Periciazina; Periciazine; Periciazinum; Piperocyanomazine;Periciazine [INN]; Bayer 1409; IC 6002; RP 8908; WH 7508; Neulactil (TN); Neuleptil (TN); Periciazina [INN-Spanish]; Periciazinum [INN-Latin]; Propericiazine (JAN); Propericiazine(jan); SKF 20,716; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; 6909 RP
DME9JNL CP Sanofi-Aventis
DME9JNL TC Antipsychotic Agents
DME9JNL DT Small molecular drug
DME9JNL PC 4747
DME9JNL MW 365.5
DME9JNL FM C21H23N3OS
DME9JNL IC InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
DME9JNL CS C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N
DME9JNL IK LUALIOATIOESLM-UHFFFAOYSA-N
DME9JNL IU 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
DME9JNL CA CAS 2622-26-6
DME9JNL CB CHEBI:31981
DME9JNL DE Psychiatric disorder
DMWDHUZ ID DMWDHUZ
DMWDHUZ DN Propicillin
DMWDHUZ HS Approved
DMWDHUZ SN Propicillin; propicilline; Propicilina; Propicillinum; 551-27-9; UNII-8X1R260V33; phenoxypropylpenicillin; CHEBI:52429; 8X1R260V33; 6beta-(2-phenoxybutanamido)-2,2-dimethylpenam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (1-Phenoxypropyl)penicillin; Propicillinum [INN-Latin]; Propicilina [INN-Spanish]; Propicilline [INN-French]; Propicillin [INN:BAN:DCF]; Propicillin (BAN); EINECS 208-995-5; AC1Q5QWR; NCGC00160673-01; AC1L3P0Y
DMWDHUZ DT Small molecular drug
DMWDHUZ PC 92879
DMWDHUZ MW 378.4
DMWDHUZ FM C18H22N2O5S
DMWDHUZ IC InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1
DMWDHUZ CS CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3
DMWDHUZ IK HOCWPKXKMNXINF-XQERAMJGSA-N
DMWDHUZ IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxybutanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMWDHUZ CA CAS 551-27-9
DMWDHUZ CB CHEBI:52429
DMWDHUZ DE Bacterial infection
DMKY8V1 ID DMKY8V1
DMKY8V1 DN Propiomazine
DMKY8V1 HS Approved
DMKY8V1 SN Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine
DMKY8V1 CP Hikma Maple Ltd
DMKY8V1 TC Sedatives and Hypnotics
DMKY8V1 DT Small molecular drug
DMKY8V1 PC 4940
DMKY8V1 MW 340.5
DMKY8V1 FM C20H24N2OS
DMKY8V1 IC InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
DMKY8V1 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C
DMKY8V1 IK UVOIBTBFPOZKGP-UHFFFAOYSA-N
DMKY8V1 IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one
DMKY8V1 CA CAS 362-29-8
DMKY8V1 CB CHEBI:8491
DMKY8V1 DE Insomnia
DMUWBIJ ID DMUWBIJ
DMUWBIJ DN Propiverine
DMUWBIJ HS Approved
DMUWBIJ SN propiverine hydrochloride; 54556-98-8; Propiverine HCl; Mictonorm; Propiverine Hydrochlorride; UNII-DC4GZD10H3; (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride; DSSTox_RID_81957; DSSTox_CID_26847; DSSTox_GSID_46847; C23H29NO3.HCl; DC4GZD10H3; CAS-54556-98-8; NCGC00181103-01; Mictonetten; Pollarine; Mictonorm (TN); propiverin hydrochloride; Bup-4 (TN); AC1L9B4A; CHEBI:8494; SCHEMBL1034248; DTXSID1046847; CHEMBL2359059; Propiverine hydrochloride (JP17); KFUJMHHNLGCTIJ-UHFFFAOYSA-N; BCP09576; Tox21_112719; NSC172140
DMUWBIJ DT Small molecular drug
DMUWBIJ PC 4942
DMUWBIJ MW 367.5
DMUWBIJ FM C23H29NO3
DMUWBIJ IC InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
DMUWBIJ CS CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C
DMUWBIJ IK QPCVHQBVMYCJOM-UHFFFAOYSA-N
DMUWBIJ IU (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate
DMUWBIJ CA CAS 60569-19-9
DMUWBIJ CB CHEBI:8493
DMUWBIJ DE Urinary incontinence
DMB4OLE ID DMB4OLE
DMB4OLE DN Propofol
DMB4OLE HS Approved
DMB4OLE SN Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol
DMB4OLE CP AstraZeneca
DMB4OLE TC Hypnotics and Sedatives
DMB4OLE DT Small molecular drug
DMB4OLE PC 4943
DMB4OLE MW 178.27
DMB4OLE FM C12H18O
DMB4OLE IC InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
DMB4OLE CS CC(C)C1=C(C(=CC=C1)C(C)C)O
DMB4OLE IK OLBCVFGFOZPWHH-UHFFFAOYSA-N
DMB4OLE IU 2,6-di(propan-2-yl)phenol
DMB4OLE CA CAS 2078-54-8
DMB4OLE CB CHEBI:44915
DMB4OLE DE Anaesthesia
DMMSOLA ID DMMSOLA
DMMSOLA DN Propoxyphene Hydrochloride
DMMSOLA HS Approved
DMMSOLA SN Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate
DMMSOLA CP Xanodyne Pharmaceutics Inc
DMMSOLA TC Neurology Agents
DMMSOLA DT Small molecular drug
DMMSOLA PC 15424
DMMSOLA MW 375.9
DMMSOLA FM C22H30ClNO2
DMMSOLA IC InChI=1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1
DMMSOLA CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.Cl
DMMSOLA IK QMQBBUPJKANITL-MYXGOWFTSA-N
DMMSOLA IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;hydrochloride
DMMSOLA CA CAS 1639-60-7
DMMSOLA CB CHEBI:8498
DMMSOLA DE Pain
DM79NTF ID DM79NTF
DM79NTF DN Propranolol
DM79NTF HS Approved
DM79NTF SN Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
DM79NTF CP AstraZeneca plc
DM79NTF TC Antianxiety Agents
DM79NTF DT Small molecular drug
DM79NTF PC 4946
DM79NTF MW 259.339
DM79NTF FM C16H21NO2
DM79NTF IC InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
DM79NTF CS CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
DM79NTF IK AQHHHDLHHXJYJD-UHFFFAOYSA-N
DM79NTF IU 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
DM79NTF CA CAS 525-66-6
DM79NTF CB CHEBI:8499
DM79NTF DE Migraine
DMTBW2O ID DMTBW2O
DMTBW2O DN Propylhexedrine
DMTBW2O HS Approved
DMTBW2O SN Propylhexedrine hydrochloride; Eggobesin; Eventin hydrochloride; Benzedrex hydrochloride; Pernsator-wirkstoff; dl-Propylhexedrine Hydrochloride; 1007-33-6; Cyclohexylisopropylmethylamine hydrochloride; NSC 27110; NSC 170998; Cyclohexyl(isopropyl)methylammonium chloride; 1-Cyclohexyl-2-methylaminopropane hydrochloride; EINECS 213-753-7; (+-)-Propylhexedrine hydrochloride; N,alpha-Dimethylcyclohexaneethylamine hydrochloride; Propylhexedrine dl-form hydrochloride; Cyclohexaneethylamine, N,alpha-dimethyl-, hydrochloride
DMTBW2O DT Small molecular drug
DMTBW2O PC 7558
DMTBW2O MW 155.28
DMTBW2O FM C10H21N
DMTBW2O IC InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3
DMTBW2O CS CC(CC1CCCCC1)NC
DMTBW2O IK JCRIVQIOJSSCQD-UHFFFAOYSA-N
DMTBW2O IU 1-cyclohexyl-N-methylpropan-2-amine
DMTBW2O CA CAS 101-40-6
DMTBW2O CB CHEBI:134783
DMTBW2O DE Obesity
DM6D7N8 ID DM6D7N8
DM6D7N8 DN Propylthiouracil
DM6D7N8 HS Approved
DM6D7N8 SN propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil; Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile
DM6D7N8 TC Antithyroid Agents
DM6D7N8 DT Small molecular drug
DM6D7N8 PC 657298
DM6D7N8 MW 170.23
DM6D7N8 FM C7H10N2OS
DM6D7N8 IC InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)
DM6D7N8 CS CCCC1=CC(=O)NC(=S)N1
DM6D7N8 IK KNAHARQHSZJURB-UHFFFAOYSA-N
DM6D7N8 IU 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one
DM6D7N8 CA CAS 51-52-5
DM6D7N8 CB CHEBI:8502
DM6D7N8 DE Hyperthyroidism
DMX0EZJ ID DMX0EZJ
DMX0EZJ DN Prothionamide
DMX0EZJ HS Approved
DMX0EZJ SN Ektebin; Peteha; Prothionamidum; Protionamid; Protionamida; Protionamide; Protionamidum; Protionizina; Tebeform; Trevintix; Tuberex; RP 9778; TH 1321; Prothionamide (JP15); Protionamida [INN-Spanish]; Protionamide (INN); Protionamide [INN:DCF]; Protionamidum [INN-Latin]; TH-1321; Trevintix (TN); 2-Propyl-4-pyridinecarbothioamide; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-thioisonicotinamide; 2-Propylisonicotinylthioamide; 2-Propylthioisonicotinamide; 2-propylpyridine-4-carbothioamide; 4-Pyridinecarbothioamide, 2-propyl-(9CI); 9778 R.P; 9778 R.P.
DMX0EZJ TC Antituberculosis Agents
DMX0EZJ DT Small molecular drug
DMX0EZJ PC 666418
DMX0EZJ MW 180.27
DMX0EZJ FM C9H12N2S
DMX0EZJ IC InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
DMX0EZJ CS CCCC1=NC=CC(=C1)C(=S)N
DMX0EZJ IK VRDIULHPQTYCLN-UHFFFAOYSA-N
DMX0EZJ IU 2-propylpyridine-4-carbothioamide
DMX0EZJ CA CAS 14222-60-7
DMX0EZJ CB CHEBI:32066
DMX0EZJ DE Tuberculosis
DMGN5QD ID DMGN5QD
DMGN5QD DN Protirelin
DMGN5QD HS Approved
DMGN5QD SN 24305-27-9; Hirtonin; TRH-SR, Takeda; protirelin
DMGN5QD CP Abbott Laboratories Pharmaceutical Products Div
DMGN5QD TC Neurology Agents
DMGN5QD DT Small molecular drug
DMGN5QD PC 638678
DMGN5QD MW 362.38
DMGN5QD FM C16H22N6O4
DMGN5QD IC InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1
DMGN5QD CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N
DMGN5QD IK XNSAINXGIQZQOO-SRVKXCTJSA-N
DMGN5QD IU (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMGN5QD CA CAS 24305-27-9
DMGN5QD CB CHEBI:35940
DMGN5QD DE Central nervous system disease
DMAHZKR ID DMAHZKR
DMAHZKR DN Protokylol Hydrochloride
DMAHZKR HS Approved
DMAHZKR SN Ventaire
DMAHZKR CP Sanofi Aventis Us Llc
DMAHZKR DT Small molecular drug
DMAHZKR PC 8699
DMAHZKR MW 367.8
DMAHZKR FM C18H22ClNO5
DMAHZKR IC InChI=1S/C18H21NO5.ClH/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13;/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3;1H
DMAHZKR CS CC(CC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)O)O.Cl
DMAHZKR IK LOVXREQUMZKFCM-UHFFFAOYSA-N
DMAHZKR IU 4-[2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride
DMAHZKR CA CAS 136-69-6
DMAHZKR DE Asthma
DMNHTZI ID DMNHTZI
DMNHTZI DN Protriptyline
DMNHTZI HS Approved
DMNHTZI SN Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
DMNHTZI CP Teva Womens Health Inc
DMNHTZI TC Antidepressants
DMNHTZI DT Small molecular drug
DMNHTZI PC 4976
DMNHTZI MW 263.4
DMNHTZI FM C19H21N
DMNHTZI IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
DMNHTZI CS CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
DMNHTZI IK BWPIARFWQZKAIA-UHFFFAOYSA-N
DMNHTZI IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine
DMNHTZI CA CAS 438-60-8
DMNHTZI CB CHEBI:8597
DMNHTZI DE Depression
DMGKT2L ID DMGKT2L
DMGKT2L DN Pro-urokinase
DMGKT2L HS Approved
DMGKT2L SN Thrombolyse (TN)
DMGKT2L DE Thrombin deficiency
DMOK965 ID DMOK965
DMOK965 DN Prulifloxacin
DMOK965 HS Approved
DMOK965 SN 123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6
DMOK965 DT Small molecular drug
DMOK965 PC 65947
DMOK965 MW 461.5
DMOK965 FM C21H20FN3O6S
DMOK965 IC InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMOK965 CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMOK965 IK PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMOK965 IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMOK965 CA CAS 123447-62-1
DMOK965 CB CHEBI:32071
DMOK965 DE Urinary tract infection
DMIVJ0D ID DMIVJ0D
DMIVJ0D DN Pseudoephedrine
DMIVJ0D HS Approved
DMIVJ0D SN Balminil Decongestant Syrup; Dimetapp Decongestant; Dimetapp Decongestant Pediatric Drops; Drixoral Nasal Decongestant; Pseudoephedrine Ephedrine; Sudafed Decongestant Extra Strength; Triaminic AM Decongestant Formula; Triaminic Infant Oral Decongestant Drops; Efidac 24 PseudoephedrineHcl; Sudafed Decongestant 12 Hour; Pseudoefedrina [INN-Spanish]; Pseudoephedrine (INN); Pseudoephedrine [INN:BAN]; Pseudoephedrine d-form; Pseudoephedrinum [INN-Latin]; Sudafed (TN); Alpha-(1-(Methylamino)ethyl)benzyl alcohol; D-psi-2-Methylamino-1-phenyl-1-propanol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI); (+)-(1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; (1S,2S)-Pseudoephedrine; (1S,2S)-Pseudoephedrine, polymer-bound
DMIVJ0D CP Pfizer Pharmaceuticals
DMIVJ0D DT Small molecular drug
DMIVJ0D PC 7028
DMIVJ0D MW 165.23
DMIVJ0D FM C10H15NO
DMIVJ0D IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
DMIVJ0D CS C[C@@H]([C@H](C1=CC=CC=C1)O)NC
DMIVJ0D IK KWGRBVOPPLSCSI-WCBMZHEXSA-N
DMIVJ0D IU (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMIVJ0D CA CAS 90-82-4
DMIVJ0D CB CHEBI:51209
DMIVJ0D DE Nasal congestion
DMLSUWZ ID DMLSUWZ
DMLSUWZ DN PSI-7977
DMLSUWZ HS Approved
DMLSUWZ SN 1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,
DMLSUWZ CP Gilead Sciences
DMLSUWZ DT Small molecular drug
DMLSUWZ PC 45375808
DMLSUWZ MW 529.5
DMLSUWZ FM C22H29FN3O9P
DMLSUWZ IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMLSUWZ CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMLSUWZ IK TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMLSUWZ IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMLSUWZ CA CAS 1190307-88-0
DMLSUWZ CB CHEBI:85083
DMLSUWZ DE HCV 1-6 infection; Hepatitis C virus infection
DMWLTU2 ID DMWLTU2
DMWLTU2 DN PSMA-11 Ga-68
DMWLTU2 HS Approved
DMWLTU2 SN UNII-ZJ0EKR6M10; ZJ0EKR6M10; Prostamedix; (68Ga)Hbed-psma; 68ga-psma-hbed-cc; (68ga)psma-hbed-cc; 68Ga-Psma-11; Gallium Ga-68 gozetotide; Gallium gozetotide Ga-68; Ga-Psma-hbed-CC Ga-68; Gallium (68Ga) gozetotide; Ga-68-Labeled PSMA-11; Ga-68 PSMA-11; PSMA-11 Ga 68; DKFZ-PSMA-11 GA-68; Gallium (68Ga) gozetotide [INN]; Glu-urea-Lys(ahx)-hbed-CC Ga-68; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-Labelled Glu-urea-Lys(ahx)-hbed-CC; Glu-NH-CO-NH-Lys-(ahx)-(68Ga(hbed-CC)); (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC; Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC; 1906894-20-9
DMWLTU2 DT Radioactive diagnostic agent
DMWLTU2 PC 154572876
DMWLTU2 MW 1011.9
DMWLTU2 FM C44H59GaN6O17
DMWLTU2 IC InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2
DMWLTU2 CS [H+].C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)[O-])CC(=O)[O-])CC(=O)[O-])[O-].[68Ga+3]
DMWLTU2 IK AEBYHKKMCWUMKX-LNTZDJBBSA-K
DMWLTU2 IU 2-[[5-[3-[[6-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-3-oxopropyl]-2-oxidophenyl]methyl-[2-[[5-(2-carboxyethyl)-2-oxidophenyl]methyl-(carboxylatomethyl)amino]ethyl]amino]acetate;gallium-68(3+);hydron
DMWLTU2 CA CAS 1906894-20-9
DMWLTU2 DE Diagnostic imaging
DMG2X3E ID DMG2X3E
DMG2X3E DN Pyrantel
DMG2X3E HS Approved
DMG2X3E SN PYRANTEL; Pyrequan; 15686-83-6; Strongid; Pirantele [DCIT]; Pyrantelum; Pirantel; Pyrantel [INN:BAN]; Pyrantelum [INN-Latin]; Pirantel [INN-Spanish]; UNII-4QIH0N49E7; HSDB 3252; EINECS 239-774-1; CHEBI:8654; 4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; Pirantele; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; Pin-X
DMG2X3E DT Small molecular drug
DMG2X3E PC 708857
DMG2X3E MW 206.31
DMG2X3E FM C11H14N2S
DMG2X3E IC InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+
DMG2X3E CS CN1CCCN=C1/C=C/C2=CC=CS2
DMG2X3E IK YSAUAVHXTIETRK-AATRIKPKSA-N
DMG2X3E IU 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine
DMG2X3E CA CAS 15686-83-6
DMG2X3E CB CHEBI:8654
DMG2X3E DE Worm infection
DM4IF32 ID DM4IF32
DM4IF32 DN Pyrazinamide
DM4IF32 HS Approved
DM4IF32 SN Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine
DM4IF32 TC Antitubercular Agents
DM4IF32 DT Small molecular drug
DM4IF32 PC 1046
DM4IF32 MW 123.11
DM4IF32 FM C5H5N3O
DM4IF32 IC InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
DM4IF32 CS C1=CN=C(C=N1)C(=O)N
DM4IF32 IK IPEHBUMCGVEMRF-UHFFFAOYSA-N
DM4IF32 IU pyrazine-2-carboxamide
DM4IF32 CA CAS 98-96-4
DM4IF32 CB CHEBI:45285
DM4IF32 DE Mycobacterium infection
DM8HO1L ID DM8HO1L
DM8HO1L DN Pyridostigmine
DM8HO1L HS Approved
DM8HO1L SN Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium
DM8HO1L CP Valeant Pharmaceuticals
DM8HO1L TC Parasympathomimetics
DM8HO1L DT Small molecular drug
DM8HO1L PC 4991
DM8HO1L MW 181.21
DM8HO1L FM C9H13N2O2+
DM8HO1L IC InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1
DM8HO1L CS C[N+]1=CC=CC(=C1)OC(=O)N(C)C
DM8HO1L IK RVOLLAQWKVFTGE-UHFFFAOYSA-N
DM8HO1L IU (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate
DM8HO1L CA CAS 155-97-5
DM8HO1L CB CHEBI:8665
DM8HO1L DE Myasthenia gravis
DMO2K0J ID DMO2K0J
DMO2K0J DN Pyridoxal Phosphate
DMO2K0J HS Approved
DMO2K0J SN Pyridoxal phosphate; pyridoxal phosphate; Codecarboxylase; pyridoxal 5-phosphate; 54-47-7; pyridoxal 5'-phosphate; Pyridoxal P; Pyromijin; Hairoxal; Vitazechs; Biosechs; Pyridoxal-5'-phosphate; Hiadelon; Pidopidon; Himitan; Phosphopyridoxal; Sechvitan; Pydoxal; Piodel; Pyridoxyl phosphate; Apolon B6; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; HI-Pyridoxin; Pal-P; PYRIDOXAL-5-PHOSPHATE; pyridoxal-P; Phosphopyridoxal coenzyme; Vitahexin P; Hexermin P; Coenzyme B6; Pyridoxal monophosphate; Pyridoxaldehyde phosphate; Apolon B(sub 6); Biosechs; PLP; Pyrido; Phosphoridoxal coenzyme; Pyridoxal phosphate [JAN]; SRI 2392; VITAMIN B6 COMPLEX; Vitamin B6 phosphate; Hexermin-P; Pyridoxal 5-monophosphoric acid ester; Pyridoxal 5-phosphate; Pyridoxal phosphate (6CI); Pyridoxal-5P; Pyridoxal-P; Sechvitan, Vitahexin P; Vitahexin-P; Vitamin B6 phosphate (ester); Pyridoxal 5'-phosphate; Pyridoxal 5'-phosphate hydrate; Pyridoxal-5-Phosphate Hydrate; Pyridoxal-5-monophosphate; P-5'-P; Pyridoxal 5'-(dihydrogen phosphate); Pyridoxal 5'-phosphate monohydrate, vitamin B6; Pyridoxal 5'-phosphate monohydrate-Vitamin B6; Pyridoxal phosphate treated beta-lactoglobulin from bovine whey; Pyridoxal, 5-(dihydrogen phosphate); Pyridoxal, 5-(dihydrogenphosphate); Pyridoxal, 5-(dihydrogen phosphate) (8CI); Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-(9CI); Lepirudine
DMO2K0J TC Dietary supplement
DMO2K0J DT Small molecular drug
DMO2K0J PC 1051
DMO2K0J MW 247.14
DMO2K0J FM C8H10NO6P
DMO2K0J IC InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)
DMO2K0J CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O
DMO2K0J IK NGVDGCNFYWLIFO-UHFFFAOYSA-N
DMO2K0J IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
DMO2K0J CA CAS 54-47-7
DMO2K0J CB CHEBI:18405
DMO2K0J DE Malnutrition
DM5X7VY ID DM5X7VY
DM5X7VY DN Pyrimethamine
DM5X7VY HS Approved
DM5X7VY SN Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
DM5X7VY TC Antimalarials
DM5X7VY DT Small molecular drug
DM5X7VY PC 4993
DM5X7VY MW 248.71
DM5X7VY FM C12H13ClN4
DM5X7VY IC InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)
DM5X7VY CS CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl
DM5X7VY IK WKSAUQYGYAYLPV-UHFFFAOYSA-N
DM5X7VY IU 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
DM5X7VY CA CAS 58-14-0
DM5X7VY CB CHEBI:8673
DM5X7VY DE Malaria
DMNA8HM ID DMNA8HM
DMNA8HM DN Pyrithione Zinc
DMNA8HM HS Approved
DMNA8HM SN Head & Shoulders Conditioner
DMNA8HM CP Warner Chilcott Co Llc
DMNA8HM DT Small molecular drug
DMNA8HM PC 3005837
DMNA8HM MW 317.7
DMNA8HM FM C10H8N2O2S2Zn
DMNA8HM IC InChI=1S/2C5H4NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4H;/q2*-1;+2
DMNA8HM CS C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2]
DMNA8HM IK PICXIOQBANWBIZ-UHFFFAOYSA-N
DMNA8HM IU zinc;1-oxidopyridine-2-thione
DMNA8HM CA CAS 13463-41-7
DMNA8HM CB CHEBI:32076
DMNA8HM DE Seborrhoeic dermatitis
DMUWAM2 ID DMUWAM2
DMUWAM2 DN Pyronaridine
DMUWAM2 HS Approved
DMUWAM2 SN Malaridine; Pyronaridine phosphate salt; Benzonaphthyridine 7351; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2 DT Small molecular drug
DMUWAM2 PC 107771
DMUWAM2 MW 518
DMUWAM2 FM C29H32ClN5O2
DMUWAM2 IC InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
DMUWAM2 CS COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6
DMUWAM2 IK DJUFPMUQJKWIJB-UHFFFAOYSA-N
DMUWAM2 IU 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2 CA CAS 74847-35-1
DMUWAM2 CB CHEBI:135951
DMUWAM2 DE Malaria
DM7Q41G ID DM7Q41G
DM7Q41G DN Pyruvic acid
DM7Q41G HS Approved
DM7Q41G SN BTS; Brenztraubensaeure; Acetylformic acid; Acide pyruvique; Pyroracemic acid; CH3COCOOH; A-Ketopropionic acid; Alpha-Ketopropionic acid; Alpha-Oxopropionsaeure; Alpha-keto propionic acid; Alpha-ketopropionic acid; P-9250; Pyruvic acid (8CI); Pyruvic acid (natural); Propanoic acid, 2-oxo-(9CI); 2-Ketopropionic acid; 2-Oxopropanoate; 2-Oxopropanoic acid; 2-Oxopropansaeure; 2-Oxopropionic acid; 2-Oxopropionsaeure; 2-oxo(1-14c)propanoic acid; 2-oxo-propionic acid
DM7Q41G TC Dietary supplement
DM7Q41G DT Small molecular drug
DM7Q41G PC 1060
DM7Q41G MW 88.06
DM7Q41G FM C3H4O3
DM7Q41G IC InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)
DM7Q41G CS CC(=O)C(=O)O
DM7Q41G IK LCTONWCANYUPML-UHFFFAOYSA-N
DM7Q41G IU 2-oxopropanoic acid
DM7Q41G CA CAS 127-17-3
DM7Q41G CB CHEBI:32816
DM7Q41G DE Malnutrition
DMGAZHU ID DMGAZHU
DMGAZHU DN Quattvaxem
DMGAZHU HS Approved
DMGAZHU SN DTwPHib-CRM197 conjugate vaccine; DPT-Hib vaccine, Chiron; DTP-Hib vaccine, Chiron; Diphtheria, tetanus, pertussis, Haemophilus influenzae b vaccine (CRM-197 adjuvant), Chiron
DMGAZHU CP Chiron Corp
DMGAZHU DT Vaccine
DMGAZHU DE Bordetella pertussis infection
DMY4D87 ID DMY4D87
DMY4D87 DN Quazepam
DMY4D87 HS Approved
DMY4D87 SN Cetrane; Doral; Dormalin; Oniria; Prosedar; Quazapam; Quazepamum; Quazium; Selepam; Sch 16134; Doral (TN); Dormalin (TN); Quazepamum [INN-Latin]; Sch-161; Sch-16134; Quazepam (JAN/USP); Quazepam [USAN:BAN:INN]; Quazepam (JAN/USP/INN); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87 CP Schering-Plough
DMY4D87 TC Hypnotics and Sedatives
DMY4D87 DT Small molecular drug
DMY4D87 PC 4999
DMY4D87 MW 386.8
DMY4D87 FM C17H11ClF4N2S
DMY4D87 IC InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
DMY4D87 CS C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F
DMY4D87 IK IKMPWMZBZSAONZ-UHFFFAOYSA-N
DMY4D87 IU 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87 CA CAS 36735-22-5
DMY4D87 CB CHEBI:8694
DMY4D87 DE Insomnia
DM3NC4M ID DM3NC4M
DM3NC4M DN Quercetin
DM3NC4M HS Approved
DM3NC4M SN Kvercetin; Meletin; QUE; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; Xanthaurine; Flavin meletin; Kvercetin [Czech]; Quercetin content; Quercetin dihydrate; CI Natural Yellow 10; Cyanidelonon 1522; KUC104418N; KUC107684N; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; TNP00070; TNP00089; LIM-5662; LNS-5662; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; CU-01000012502-3; KSC-10-126; KSC-23-76; T-Gelb bzw. grun 1; C.I. Natural yellow 10 & 13; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one
DM3NC4M TC Hypoglycemic Agents
DM3NC4M DT Small molecular drug
DM3NC4M PC 5280343
DM3NC4M MW 302.23
DM3NC4M FM C15H10O7
DM3NC4M IC InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
DM3NC4M CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DM3NC4M IK REFJWTPEDVJJIY-UHFFFAOYSA-N
DM3NC4M IU 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DM3NC4M CA CAS 117-39-5
DM3NC4M CB CHEBI:16243
DM3NC4M DE Obesity
DM1N62C ID DM1N62C
DM1N62C DN Quetiapine
DM1N62C HS Approved
DM1N62C SN quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760
DM1N62C CP AstraZeneca
DM1N62C TC Antipsychotic Agents
DM1N62C DT Small molecular drug
DM1N62C PC 5002
DM1N62C MW 383.5
DM1N62C FM C21H25N3O2S
DM1N62C IC InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
DM1N62C CS C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
DM1N62C IK URKOMYMAXPYINW-UHFFFAOYSA-N
DM1N62C IU 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
DM1N62C CA CAS 111974-69-7
DM1N62C CB CHEBI:8707
DM1N62C DE Schizophrenia; Alcohol dependence
DM7WI4Q ID DM7WI4Q
DM7WI4Q DN Quinagolide
DM7WI4Q HS Approved
DM7WI4Q SN Norprolac; 87056-78-8; Quinagolidum; SDZ 205-502; Quinagolide (INN/BAN); AC1MJ64J; SCHEMBL143485; CHEMBL290962; CHEBI:135627; ZINC3778441; BDBM50225362; DB09097; D07217; 056Q788; UNII-80Q9QWN15M component GDFGTRDCCWFXTG-ZIFCJYIRSA-N; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q CP Ferring Pharmaceuticals
DM7WI4Q TC Fertility Agents
DM7WI4Q DT Small molecular drug
DM7WI4Q PC 3086401
DM7WI4Q MW 395.6
DM7WI4Q FM C20H33N3O3S
DM7WI4Q IC InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1
DM7WI4Q CS CCCN1C[C@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
DM7WI4Q IK GDFGTRDCCWFXTG-ZIFCJYIRSA-N
DM7WI4Q IU (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q CA CAS 87056-78-8
DM7WI4Q CB CHEBI:135627
DM7WI4Q DE Hyperprolactinaemia
DMR8H31 ID DMR8H31
DMR8H31 DN Quinapril
DMR8H31 HS Approved
DMR8H31 SN Ectren; Koretic; Quinaprilum; QUINAPRIL HCL; Quinaprilum [Latin]; Accupril (TN); Quinapril [INN:BAN]; Quinapril (USP/INN); [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
DMR8H31 CP Pfizer Pharmaceuticals
DMR8H31 TC Antihypertensive Agents
DMR8H31 DT Small molecular drug
DMR8H31 PC 54892
DMR8H31 MW 438.5
DMR8H31 FM C25H30N2O5
DMR8H31 IC InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
DMR8H31 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
DMR8H31 IK JSDRRTOADPPCHY-HSQYWUDLSA-N
DMR8H31 IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMR8H31 CA CAS 85441-61-8
DMR8H31 CB CHEBI:8713
DMR8H31 DE Hypertension
DMJ6H1Z ID DMJ6H1Z
DMJ6H1Z DN Quinestrol
DMJ6H1Z HS Approved
DMJ6H1Z SN EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol
DMJ6H1Z TC Anticancer Agents
DMJ6H1Z DT Small molecular drug
DMJ6H1Z PC 9046
DMJ6H1Z MW 364.5
DMJ6H1Z FM C25H32O2
DMJ6H1Z IC InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
DMJ6H1Z CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5
DMJ6H1Z IK PWZUUYSISTUNDW-VAFBSOEGSA-N
DMJ6H1Z IU (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMJ6H1Z CA CAS 152-43-2
DMJ6H1Z CB CHEBI:8716
DMJ6H1Z DE Breast cancer
DMWCOSR ID DMWCOSR
DMWCOSR DN Quinethazone
DMWCOSR HS Approved
DMWCOSR SN Aquamox; Chinetazone; Chinethazone; Chinethazonum; Hydromox; Idrokin; Quinetazona; Quinethazon; Quinethazonum; Chinetazone[DCIT]; CL 36010; Hydromox (TN); Quinetazona [INN-Spanish]; Quinethazone (aquamox); Quinethazonum [INN-Latin]; Quinethazone (JAN/INN); Quinethazone [INN:BAN:JAN]; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR TC Antihypertensive Agents
DMWCOSR DT Small molecular drug
DMWCOSR PC 6307
DMWCOSR MW 289.74
DMWCOSR FM C10H12ClN3O3S
DMWCOSR IC InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
DMWCOSR CS CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl
DMWCOSR IK AGMMTXLNIQSRCG-UHFFFAOYSA-N
DMWCOSR IU 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR CA CAS 73-49-4
DMWCOSR CB CHEBI:8717
DMWCOSR DE Hypertension
DMLPICK ID DMLPICK
DMLPICK DN Quinidine
DMLPICK HS Approved
DMLPICK SN Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL
DMLPICK PC 441074
DMLPICK MW 324.4
DMLPICK FM C20H24N2O2
DMLPICK IC LOUPRKONTZGTKE-LHHVKLHASA-N
DMLPICK CS COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
DMLPICK IK 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
DMLPICK IU (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMLPICK CA CAS 56-54-2
DMLPICK CB CHEBI:28593
DMLPICK DE Ventricular tachyarrhythmia
DMSWYF5 ID DMSWYF5
DMSWYF5 DN Quinine
DMSWYF5 HS Approved
DMSWYF5 SN Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine
DMSWYF5 CP Pfizer Pharmaceuticals
DMSWYF5 TC Antimalarials
DMSWYF5 DT Small molecular drug
DMSWYF5 PC 3034034
DMSWYF5 MW 324.4
DMSWYF5 FM C20H24N2O2
DMSWYF5 IC InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1
DMSWYF5 CS COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
DMSWYF5 IK LOUPRKONTZGTKE-WZBLMQSHSA-N
DMSWYF5 IU (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMSWYF5 CA CAS 72402-53-0
DMSWYF5 CB CHEBI:15854
DMSWYF5 DE Malaria
DM5GVHU ID DM5GVHU
DM5GVHU DN Quinolones
DM5GVHU HS Approved
DM5GVHU SN AC1MI0KP
DM5GVHU DT Small molecular drug
DM5GVHU PC 6038
DM5GVHU MW 145.16
DM5GVHU FM C9H7NO
DM5GVHU IC InChI=1S/C9H7NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H,(H,10,11)
DM5GVHU CS C1=CC=C2C(=C1)C=CC(=O)N2
DM5GVHU IK LISFMEBWQUVKPJ-UHFFFAOYSA-N
DM5GVHU IU 1H-quinolin-2-one
DM5GVHU CA CAS 59-31-4
DM5GVHU CB CHEBI:16365
DM5GVHU DE Bacterial infection; Tuberculosis
DMLKFC4 ID DMLKFC4
DMLKFC4 DN Quinupristin
DMLKFC4 HS Approved
DMLKFC4 SN Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA
DMLKFC4 TC Antibiotics
DMLKFC4 DT Small molecular drug
DMLKFC4 PC 5388937
DMLKFC4 MW 1022.2
DMLKFC4 FM C53H67N9O10S
DMLKFC4 IC InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1
DMLKFC4 CS CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C
DMLKFC4 IK WTHRRGMBUAHGNI-LCYNINFDSA-N
DMLKFC4 IU N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
DMLKFC4 CA CAS 120138-50-3
DMLKFC4 DE Bacterial infection
DMM4U9G ID DMM4U9G
DMM4U9G DN R0-93877
DMM4U9G HS Approved
DMM4U9G SN Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]
DMM4U9G CP Shire/Takeda
DMM4U9G DT Small molecular drug
DMM4U9G PC 3052762
DMM4U9G MW 367.9
DMM4U9G FM C18H26ClN3O3
DMM4U9G IC InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)
DMM4U9G CS COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
DMM4U9G IK ZPMNHBXQOOVQJL-UHFFFAOYSA-N
DMM4U9G IU 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
DMM4U9G CA CAS 179474-81-8
DMM4U9G CB CHEBI:135552
DMM4U9G DE Irritable bowel syndrome; Constipation
DMMZXIW ID DMMZXIW
DMMZXIW DN Rabeprazole
DMMZXIW HS Approved
DMMZXIW SN Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW CP Eisai; Johnson & Johnson
DMMZXIW TC Antiulcer Agents
DMMZXIW DT Small molecular drug
DMMZXIW PC 5029
DMMZXIW MW 359.4
DMMZXIW FM C18H21N3O3S
DMMZXIW IC InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
DMMZXIW CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
DMMZXIW IK YREYEVIYCVEVJK-UHFFFAOYSA-N
DMMZXIW IU 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW CA CAS 117976-89-3
DMMZXIW CB CHEBI:8768
DMMZXIW DE Bacterial infection
DMFOTZ7 ID DMFOTZ7
DMFOTZ7 DN Racecadotril
DMFOTZ7 HS Approved
DMFOTZ7 SN Acetorphan; Hidrasec; Tiorfan
DMFOTZ7 CP BioProjet; Societe Civile de Recherche
DMFOTZ7 DT Small molecular drug
DMFOTZ7 PC 107751
DMFOTZ7 MW 385.5
DMFOTZ7 FM C21H23NO4S
DMFOTZ7 IC InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25)
DMFOTZ7 CS CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2
DMFOTZ7 IK ODUOJXZPIYUATO-UHFFFAOYSA-N
DMFOTZ7 IU benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate
DMFOTZ7 CA CAS 81110-73-8
DMFOTZ7 CB CHEBI:91508
DMFOTZ7 DE Diarrhea
DMXTCVF ID DMXTCVF
DMXTCVF DN Radium-223-Dichloride
DMXTCVF HS Approved
DMXTCVF CP Bayer HealthCare Pharmaceuticals
DMXTCVF DE Prostate cancer
DMDKF3M ID DMDKF3M
DMDKF3M DN Raloxifene
DMDKF3M HS Approved
DMDKF3M SN Raloxifene (extended-release, CDT)
DMDKF3M CP SCOLR Pharma Inc
DMDKF3M DT Small molecular drug
DMDKF3M PC 5035
DMDKF3M MW 473.6
DMDKF3M FM C28H27NO4S
DMDKF3M IC InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
DMDKF3M CS C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DMDKF3M IK GZUITABIAKMVPG-UHFFFAOYSA-N
DMDKF3M IU [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
DMDKF3M CA CAS 84449-90-1
DMDKF3M CB CHEBI:8772
DMDKF3M DE Osteoporosis
DMYURI6 ID DMYURI6
DMYURI6 DN Raltegravir
DMYURI6 HS Approved
DMYURI6 SN RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
DMYURI6 CP Merck
DMYURI6 DT Small molecular drug
DMYURI6 PC 54671008
DMYURI6 MW 444.4
DMYURI6 FM C20H21FN6O5
DMYURI6 IC InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
DMYURI6 CS CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
DMYURI6 IK CZFFBEXEKNGXKS-UHFFFAOYSA-N
DMYURI6 IU N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
DMYURI6 CA CAS 518048-05-0
DMYURI6 DE Human immunodeficiency virus infection
DMT9K8G ID DMT9K8G
DMT9K8G DN Raltitrexed
DMT9K8G HS Approved
DMT9K8G SN Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482
DMT9K8G CP AstraZeneca
DMT9K8G TC Anticancer Agents
DMT9K8G DT Small molecular drug
DMT9K8G PC 135400182
DMT9K8G MW 458.5
DMT9K8G FM C21H22N4O6S
DMT9K8G IC InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
DMT9K8G CS CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1
DMT9K8G IK IVTVGDXNLFLDRM-HNNXBMFYSA-N
DMT9K8G IU (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid
DMT9K8G CA CAS 112887-68-0
DMT9K8G CB CHEBI:5847
DMT9K8G DE Rectal adenocarcinoma
DM7IW9J ID DM7IW9J
DM7IW9J DN Ramelteon
DM7IW9J HS Approved
DM7IW9J SN Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
DM7IW9J CP Takeda
DM7IW9J TC Hypnotics and Sedatives
DM7IW9J DT Small molecular drug
DM7IW9J PC 208902
DM7IW9J MW 259.339
DM7IW9J FM C16H21NO2
DM7IW9J IC InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
DM7IW9J CS CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3
DM7IW9J IK YLXDSYKOBKBWJQ-LBPRGKRZSA-N
DM7IW9J IU N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide
DM7IW9J CA CAS 196597-26-9
DM7IW9J CB CHEBI:109549
DM7IW9J DE Insomnia; Circadian rhythm sleep disorder
DM2R68E ID DM2R68E
DM2R68E DN Ramipril
DM2R68E HS Approved
DM2R68E SN Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
DM2R68E CP Sanofi-Aventis
DM2R68E TC Antihypertensive Agents
DM2R68E DT Small molecular drug
DM2R68E PC 5362129
DM2R68E MW 416.5
DM2R68E FM C23H32N2O5
DM2R68E IC InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
DM2R68E CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
DM2R68E IK HDACQVRGBOVJII-JBDAPHQKSA-N
DM2R68E IU (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
DM2R68E CA CAS 87333-19-5
DM2R68E CB CHEBI:8774
DM2R68E DE Congestive heart failure
DMH7GN8 ID DMH7GN8
DMH7GN8 DN Ramosetron
DMH7GN8 HS Approved
DMH7GN8 SN 132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060
DMH7GN8 DT Small molecular drug
DMH7GN8 PC 108000
DMH7GN8 MW 279.34
DMH7GN8 FM C17H17N3O
DMH7GN8 IC InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
DMH7GN8 CS CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
DMH7GN8 IK NTHPAPBPFQJABD-LLVKDONJSA-N
DMH7GN8 IU (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone
DMH7GN8 CA CAS 132036-88-5
DMH7GN8 CB CHEBI:135156
DMH7GN8 DE Nausea and vomiting; Irritable bowel syndrome
DMWUFQ4 ID DMWUFQ4
DMWUFQ4 DN Ramucirumab
DMWUFQ4 HS Approved
DMWUFQ4 SN LY3009806
DMWUFQ4 CP Lilly
DMWUFQ4 DT Monoclonal antibody
DMWUFQ4 SQ 9098_H|ramucirumab|Homo sapiens||H-GAMMA-1 (VH(1-116)+CH1(117-214)+HINGE-REGION(215-229)+CH2(230-339)+CH3(340-446))|||||||446||||MW 48696.0|MW 48696.0|: EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9098_L|ramucirumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(109-214))|||||||214||||MW 23124.7|MW 23124.7|DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMWUFQ4 DE Gastric adenocarcinoma
DMSYPNW ID DMSYPNW
DMSYPNW DN Ranibizumab
DMSYPNW HS Approved
DMSYPNW SN Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)
DMSYPNW CP Genentech Inc
DMSYPNW DT Antibody
DMSYPNW SQ Ranibizumab Light Chain: DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Ranibizumab Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL
DMSYPNW DE Hereditary hemorrhagic telangiectasia
DM0GUSX ID DM0GUSX
DM0GUSX DN Ranitidine
DM0GUSX HS Approved
DM0GUSX SN Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DM0GUSX CP GlaxoSmithKline
DM0GUSX TC Antiulcer Agents
DM0GUSX DT Small molecular drug
DM0GUSX PC 3001055
DM0GUSX MW 314.41
DM0GUSX FM C13H22N4O3S
DM0GUSX IC InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
DM0GUSX CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
DM0GUSX IK VMXUWOKSQNHOCA-UKTHLTGXSA-N
DM0GUSX IU (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DM0GUSX CA CAS 82530-72-1
DM0GUSX CB CHEBI:8776
DM0GUSX DE Peptic ulcer
DM0C9IL ID DM0C9IL
DM0C9IL DN Ranolazine
DM0C9IL HS Approved
DM0C9IL SN RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
DM0C9IL CP CV Therapeutics
DM0C9IL TC Analgesics
DM0C9IL DT Small molecular drug
DM0C9IL PC 56959
DM0C9IL MW 427.5
DM0C9IL FM C24H33N3O4
DM0C9IL IC InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
DM0C9IL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
DM0C9IL IK XKLMZUWKNUAPSZ-UHFFFAOYSA-N
DM0C9IL IU N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
DM0C9IL CA CAS 95635-55-5
DM0C9IL CB CHEBI:87690
DM0C9IL DE Chronic/stable angina; Paroxysmal atrial fibrillation
DM3WKQ4 ID DM3WKQ4
DM3WKQ4 DN Rasagiline
DM3WKQ4 HS Approved
DM3WKQ4 SN RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
DM3WKQ4 CP Teva Pharmaceutical Industries Ltd
DM3WKQ4 TC Antiparkinson Agents
DM3WKQ4 DT Small molecular drug
DM3WKQ4 PC 3052776
DM3WKQ4 MW 171.24
DM3WKQ4 FM C12H13N
DM3WKQ4 IC InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
DM3WKQ4 CS C#CCN[C@@H]1CCC2=CC=CC=C12
DM3WKQ4 IK RUOKEQAAGRXIBM-GFCCVEGCSA-N
DM3WKQ4 IU (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
DM3WKQ4 CA CAS 136236-51-6
DM3WKQ4 CB CHEBI:63620
DM3WKQ4 DE Skin cancer; Skin imperfections; Parkinson disease
DMWTVAN ID DMWTVAN
DMWTVAN DN Rauwolfia serpentina root
DMWTVAN HS Approved
DMWTVAN SN Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m
DMWTVAN DT Small molecular drug
DMWTVAN DE Discovery agent
DMSWNJF ID DMSWNJF
DMSWNJF DN Ravulizumab
DMSWNJF HS Approved
DMSWNJF SN Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
DMSWNJF CP Alexion
DMSWNJF DT Antibody
DMSWNJF DE Paroxysmal nocturnal haemoglobinuria
DM7QG0M ID DM7QG0M
DM7QG0M DN Raxibacumab
DM7QG0M HS Approved
DM7QG0M CP GlaxoSmithKline
DM7QG0M DT Monoclonal antibody
DM7QG0M DE Anthrax
DM26PRD ID DM26PRD
DM26PRD DN Reboxetine
DM26PRD HS Approved
DM26PRD SN 71620-89-8; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; AC1L2RJ0; SCHEMBL34533; CHEMBL383921; DTXSID1048257; MolPort-005-943-618; CHEBI:135342; ZINC3996032; BCP12060; AKOS015966368; DB00234; AN-34535; AK431803; AJ-47614
DM26PRD CP Pfizer Pharmaceuticals
DM26PRD TC Antidepressants
DM26PRD DT Small molecular drug
DM26PRD PC 127151
DM26PRD MW 313.4
DM26PRD FM C19H23NO3
DM26PRD IC InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
DM26PRD CS CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
DM26PRD IK CBQGYUDMJHNJBX-RTBURBONSA-N
DM26PRD IU (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
DM26PRD CA CAS 71620-89-8
DM26PRD CB CHEBI:135342
DM26PRD DE Depression
DMY7ESM ID DMY7ESM
DMY7ESM DN Recombinant Factor IX
DMY7ESM HS Approved
DMY7ESM SN RFIX, Baxter; Recombinant Factor IX, Baxter
DMY7ESM CP Baxter 1nternational
DMY7ESM DE Factor IX deficiency; Bleeding disorder
DMMPCFX ID DMMPCFX
DMMPCFX DN Recombinant human endostatin
DMMPCFX HS Approved
DMMPCFX SN Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
DMMPCFX CP Shandong Simcere Medgenn Bio- Pharmaceutical Co Ltd
DMMPCFX DE Solid tumour/cancer
DM76VHG ID DM76VHG
DM76VHG DN Regadenoson
DM76VHG HS Approved
DM76VHG SN Lexiscan (TN)
DM76VHG CP CV Therapeutics
DM76VHG DT Small molecular drug
DM76VHG PC 219024
DM76VHG MW 390.35
DM76VHG FM C15H18N8O5
DM76VHG IC InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
DM76VHG CS CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM76VHG IK LZPZPHGJDAGEJZ-AKAIJSEGSA-N
DM76VHG IU 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
DM76VHG CA CAS 313348-27-5
DM76VHG CB CHEBI:135613
DM76VHG DE Radionuclide imaging
DM87XSN ID DM87XSN
DM87XSN DN REGN-727
DM87XSN HS Approved
DM87XSN SN Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis
DM87XSN CP Sanofi; Novo Nordisk
DM87XSN DT Antibody
DM87XSN DE Familial hypercholesterolemia; Hypercholesterolaemia
DMHSY1I ID DMHSY1I
DMHSY1I DN Regorafenib
DMHSY1I HS Approved
DMHSY1I SN Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
DMHSY1I CP Bayer HealthCare Pharmaceuticals
DMHSY1I DT Small molecular drug
DMHSY1I PC 11167602
DMHSY1I MW 482.8
DMHSY1I FM C21H15ClF4N4O3
DMHSY1I IC InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
DMHSY1I CS CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
DMHSY1I IK FNHKPVJBJVTLMP-UHFFFAOYSA-N
DMHSY1I IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMHSY1I CA CAS 755037-03-7
DMHSY1I CB CHEBI:68647
DMHSY1I DE Metastatic colorectal cancer
DMK7IWL ID DMK7IWL
DMK7IWL DN Relugolix
DMK7IWL HS Approved
DMK7IWL SN 737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917
DMK7IWL CP Takeda
DMK7IWL DT Small molecular drug
DMK7IWL PC 10348973
DMK7IWL MW 623.6
DMK7IWL FM C29H27F2N7O5S
DMK7IWL IC InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
DMK7IWL CS CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
DMK7IWL IK AOMXMOCNKJTRQP-UHFFFAOYSA-N
DMK7IWL IU 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
DMK7IWL CA CAS 737789-87-6
DMK7IWL DE Endometriosis; Prostate cancer
DMBFZ6L ID DMBFZ6L
DMBFZ6L DN Remdesivir
DMBFZ6L HS Approved
DMBFZ6L SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DMBFZ6L CP Gilead Sciences, Foster City, CA
DMBFZ6L DT Small molecular drug
DMBFZ6L PC 121304016
DMBFZ6L MW 602.6
DMBFZ6L FM C27H35N6O8P
DMBFZ6L IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DMBFZ6L CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DMBFZ6L IK RWWYLEGWBNMMLJ-YSOARWBDSA-N
DMBFZ6L IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMBFZ6L CA CAS 1809249-37-3
DMBFZ6L CB CHEBI:145994
DMBFZ6L DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19)
DMZTXCH ID DMZTXCH
DMZTXCH DN Remifentanil
DMZTXCH HS Approved
DMZTXCH SN Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
DMZTXCH CP Abbott Laboratories
DMZTXCH TC Hypnotics and Sedatives
DMZTXCH DT Small molecular drug
DMZTXCH PC 60815
DMZTXCH MW 376.4
DMZTXCH FM C20H28N2O5
DMZTXCH IC InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
DMZTXCH CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC
DMZTXCH IK ZTVQQQVZCWLTDF-UHFFFAOYSA-N
DMZTXCH IU methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DMZTXCH CA CAS 132875-61-7
DMZTXCH CB CHEBI:8802
DMZTXCH DE Anaesthesia
DMNAKLY ID DMNAKLY
DMNAKLY DN Remikiren
DMNAKLY HS Approved
DMNAKLY SN REM; Remikiren [INN]; Remikiren (INN); Ro 42-5892; Ro-42-5892; (2R)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; 2-benzyl-3-tert-butylsulfonyl-N-[1-[(1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl)amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY CP Hoffmann-La Roche pharmaceutical company
DMNAKLY TC Antihypertensive Agents
DMNAKLY DT Small molecular drug
DMNAKLY PC 6324659
DMNAKLY MW 630.8
DMNAKLY FM C33H50N4O6S
DMNAKLY IC InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1
DMNAKLY CS CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O
DMNAKLY IK UXIGZRQVLGFTOU-VQXQMPIVSA-N
DMNAKLY IU (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY CA CAS 126222-34-2
DMNAKLY CB CHEBI:8803
DMNAKLY DE Hypertension
DMLVSYX ID DMLVSYX
DMLVSYX DN Remimazolam
DMLVSYX HS Approved
DMLVSYX SN CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK
DMLVSYX CP GlaxoSmithKline plc
DMLVSYX DT Small molecular drug
DMLVSYX PC 9867812
DMLVSYX MW 439.3
DMLVSYX FM C21H19BrN4O2
DMLVSYX IC InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
DMLVSYX CS CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
DMLVSYX IK CYHWMBVXXDIZNZ-KRWDZBQOSA-N
DMLVSYX IU methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
DMLVSYX CA CAS 308242-62-8
DMLVSYX DE Anaesthesia; Procedural sedation
DM5SXUV ID DM5SXUV
DM5SXUV DN Repaglinide
DM5SXUV HS Approved
DM5SXUV SN Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
DM5SXUV CP Novo Nordisk
DM5SXUV TC Hypoglycemic Agents
DM5SXUV DT Small molecular drug
DM5SXUV PC 65981
DM5SXUV MW 452.6
DM5SXUV FM C27H36N2O4
DM5SXUV IC InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
DM5SXUV CS CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
DM5SXUV IK FAEKWTJYAYMJKF-QHCPKHFHSA-N
DM5SXUV IU 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
DM5SXUV CA CAS 135062-02-1
DM5SXUV CB CHEBI:8805
DM5SXUV DE Diabetic complication
DM6KI0D ID DM6KI0D
DM6KI0D DN Repirinast
DM6KI0D HS Approved
DM6KI0D SN MY-1250; MY-5116; MY-6116
DM6KI0D CP Mitsubishi-Tokyo Pharmaceuticals Inc
DM6KI0D DT Small molecular drug
DM6KI0D PC 5050
DM6KI0D MW 355.4
DM6KI0D FM C20H21NO5
DM6KI0D IC InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23)
DM6KI0D CS CC1=C(C2=C(C=C1)C3=C(C(=O)C=C(O3)C(=O)OCCC(C)C)C(=O)N2)C
DM6KI0D IK NFQIAEMCQGTTIR-UHFFFAOYSA-N
DM6KI0D IU 3-methylbutyl 7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylate
DM6KI0D CA CAS 73080-51-0
DM6KI0D CB CHEBI:32092
DM6KI0D DE Asthma
DMG7SQK ID DMG7SQK
DMG7SQK DN Rescinnamine
DMG7SQK HS Approved
DMG7SQK SN Anapral; Anaprel; Apolon; Apoterin; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Moderil; Normorescina; Paresinan; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinamina; Rescinnamin; Rescinnamina; Rescinnaminum; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Tuareg; Apoterin S; Methyl trimethoxycinnamoylreserpate; Rescinnamina [DCIT]; Trimethoxy cinnamoyl reserpate de methyl; Trimethoxy cinnamoyl reserpate de methyl [French]; Trimethoxycinnamoyl methyl reserpate; Tsuruselpi S; Anaprel (TN); Cinnasil (TN); Moderil (TN); NP-011016; Rescinamina [INN-Spanish]; Rescinnamine (VAN); Rescinnaminum [INN-Latin]; Resepinine (C35 alkaloid); Reserpinine (C35 alkaloid); Reserpinine (VAN); Tsuruselpi S (TN); Rescinnamine (JAN/INN); Rescinnamine [BAN:INN:JAN]; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; 3,4,5-Trimethoxycinnamoyl methyl reserpate; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; 3,4,5-Trimethylcinnamoyl methyl reserpate
DMG7SQK TC Antihypertensive Agents
DMG7SQK DT Small molecular drug
DMG7SQK PC 5280954
DMG7SQK MW 634.7
DMG7SQK FM C35H42N2O9
DMG7SQK IC InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
DMG7SQK CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)/C=C/C6=CC(=C(C(=C6)OC)OC)OC
DMG7SQK IK SZLZWPPUNLXJEA-QEGASFHISA-N
DMG7SQK IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMG7SQK CA CAS 24815-24-5
DMG7SQK CB CHEBI:28572
DMG7SQK DE Hypertension
DM6VM38 ID DM6VM38
DM6VM38 DN Reserpine
DM6VM38 HS Approved
DM6VM38 SN Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L"-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp
DM6VM38 TC Antihypertensive Agents
DM6VM38 DT Small molecular drug
DM6VM38 PC 5770
DM6VM38 MW 608.7
DM6VM38 FM C33H40N2O9
DM6VM38 IC InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
DM6VM38 CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DM6VM38 IK QEVHRUUCFGRFIF-MDEJGZGSSA-N
DM6VM38 IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DM6VM38 CA CAS 50-55-5
DM6VM38 CB CHEBI:28487
DM6VM38 DE Hypertension
DM0AUCH ID DM0AUCH
DM0AUCH DN Reslizumab
DM0AUCH HS Approved
DM0AUCH CP Teva
DM0AUCH DT Monoclonal antibody
DM0AUCH DE Severe asthma; Asthma; Eosinophilic asthma
DM9JXB7 ID DM9JXB7
DM9JXB7 DN Retapamulin
DM9JXB7 HS Approved
DM9JXB7 SN Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN)
DM9JXB7 CP GlaxoSmithKline
DM9JXB7 TC Antibiotics
DM9JXB7 DT Small molecular drug
DM9JXB7 PC 6918462
DM9JXB7 MW 517.799
DM9JXB7 FM C30H47NO4S
DM9JXB7 IC InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1
DM9JXB7 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C
DM9JXB7 IK STZYTFJPGGDRJD-FJJJPKKESA-N
DM9JXB7 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
DM9JXB7 CA CAS 224452-66-8
DM9JXB7 CB CHEBI:166679
DM9JXB7 DE Impetigo
DML0D1P ID DML0D1P
DML0D1P DN Reteplase
DML0D1P HS Approved
DML0D1P SN Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)
DML0D1P TC Thrombolytic Agents
DML0D1P SQ DB00015 sequence: SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DML0D1P DE Heart attack
DMGNYIH ID DMGNYIH
DMGNYIH DN Retigabine
DMGNYIH HS Approved
DMGNYIH SN Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
DMGNYIH CP GSK
DMGNYIH TC Anticonvulsants
DMGNYIH DT Small molecular drug
DMGNYIH PC 121892
DMGNYIH MW 303.33
DMGNYIH FM C16H18FN3O2
DMGNYIH IC InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
DMGNYIH CS CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N
DMGNYIH IK PCOBBVZJEWWZFR-UHFFFAOYSA-N
DMGNYIH IU ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
DMGNYIH CA CAS 150812-12-7
DMGNYIH CB CHEBI:68584
DMGNYIH DE Epilepsy; Behcet disease
DMMP5SI ID DMMP5SI
DMMP5SI DN Revefenacin
DMMP5SI HS Approved
DMMP5SI SN UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7
DMMP5SI CP Theravance Biopharma/Mylan
DMMP5SI PC 11753673
DMMP5SI MW 597.7
DMMP5SI FM C35H43N5O4
DMMP5SI IC InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
DMMP5SI CS CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
DMMP5SI IK FYDWDCIFZSGNBU-UHFFFAOYSA-N
DMMP5SI IU [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DMMP5SI CA CAS 864750-70-9
DMMP5SI DE Chronic obstructive pulmonary disease
DM8LRU2 ID DM8LRU2
DM8LRU2 DN Revolade/Promacta
DM8LRU2 HS Approved
DM8LRU2 SN AC1OC7GM
DM8LRU2 CP GSK
DM8LRU2 DT Small molecular drug
DM8LRU2 PC 6913084
DM8LRU2 MW 330.9
DM8LRU2 FM C22H31Cl
DM8LRU2 IC InChI=1S/C22H31Cl/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20/h8,12,15-18,20H,1-7,9-11,13-14H2/b12-8-
DM8LRU2 CS C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl
DM8LRU2 IK NDXQJQCGBAIFER-WQLSENKSSA-N
DM8LRU2 IU [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane
DM8LRU2 DE Idiopathic thrombocytopenic purpura; Thrombocytopenia; Chronic liver disease
DM69XMQ ID DM69XMQ
DM69XMQ DN RG-7446
DM69XMQ HS Approved
DM69XMQ CP Genentech
DM69XMQ DT Monoclonal antibody
DM69XMQ DE Urothelial carcinoma; Bladder cancer
DMNF0G8 ID DMNF0G8
DMNF0G8 DN Rh-alphaglucosidase
DMNF0G8 HS Approved
DMNF0G8 SN Pompase (TN)
DMNF0G8 DE Pompe disease
DM3ADGP ID DM3ADGP
DM3ADGP DN Rhucin
DM3ADGP HS Approved
DM3ADGP SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
DM3ADGP CP Pfizer
DM3ADGP DT Small molecular drug
DM3ADGP PC 135398744
DM3ADGP MW 474.6
DM3ADGP FM C22H30N6O4S
DM3ADGP IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM3ADGP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM3ADGP IK BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM3ADGP IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM3ADGP CA CAS 139755-83-2
DM3ADGP CB CHEBI:9139
DM3ADGP DE Hereditary angioedema; Erectile dysfunction
DMALNG0 ID DMALNG0
DMALNG0 DN RHuEPO
DMALNG0 HS Approved
DMALNG0 CP Bio-Gal Advanced Biotechnology
DMALNG0 DE Solid tumour/cancer
DMEYLH9 ID DMEYLH9
DMEYLH9 DN Ribavirin
DMEYLH9 HS Approved
DMEYLH9 SN ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
DMEYLH9 CP Hoffmann-La Roche pharmaceutical company
DMEYLH9 TC Antiviral Agents
DMEYLH9 DT Small molecular drug
DMEYLH9 PC 37542
DMEYLH9 MW 244.2
DMEYLH9 FM C8H12N4O5
DMEYLH9 IC InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
DMEYLH9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMEYLH9 IK IWUCXVSUMQZMFG-AFCXAGJDSA-N
DMEYLH9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
DMEYLH9 CA CAS 36791-04-5
DMEYLH9 CB CHEBI:63580
DMEYLH9 DE Hepatitis C virus infection
DM9CIUW ID DM9CIUW
DM9CIUW DN Ribociclib succinate
DM9CIUW HS Approved
DM9CIUW SN 1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739
DM9CIUW CP Novartis
DM9CIUW DT Small molecular drug
DM9CIUW PC 57334219
DM9CIUW MW 552.6
DM9CIUW FM C27H36N8O5
DM9CIUW IC InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)
DM9CIUW CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O
DM9CIUW IK NHANOMFABJQAAH-UHFFFAOYSA-N
DM9CIUW IU butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DM9CIUW CA CAS 1374639-75-4
DM9CIUW DE Hormone receptor positive and HER2-negative advanced or metastatic breast cancer; Breast cancer
DM8YMWE ID DM8YMWE
DM8YMWE DN Riboflavin
DM8YMWE HS Approved
DM8YMWE SN riboflavin; vitamin B2; Lactoflavin; Riboflavine; Vitamin G; 83-88-5; Lactoflavine; (-)-riboflavin; Beflavine; Beflavin; Riboflavina; Flavaxin; Vitaflavine; Riboflavinum; Ribocrisina; Ribovel; Lactobene; Ribotone; Flaxain; Ribosyn; Riboderm; Ribipca; Flavin BB; Vitasan B2; Fiboflavin; Dermadram; Hyflavin; HYRE; Vitamin Bi; Aqua-Flave; 7,8-Dimethyl-10-ribitylisoalloxazine; Russupteridine Yellow III; 6,7-Dimethyl-9-D-ribitylisoalloxazine; Riboflavinequinone; Riboflavinum [INN-Latin]; Riboflavine [INN-French]; Riboflavina [INN-Spanish]
DM8YMWE DT Small molecular drug
DM8YMWE PC 493570
DM8YMWE MW 376.4
DM8YMWE FM C17H20N4O6
DM8YMWE IC InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1
DM8YMWE CS CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O
DM8YMWE IK AUNGANRZJHBGPY-SCRDCRAPSA-N
DM8YMWE IU 7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
DM8YMWE CA CAS 83-88-5
DM8YMWE CB CHEBI:17015
DM8YMWE DE Acne vulgaris
DMWH9CN ID DMWH9CN
DMWH9CN DN Ridogrel
DMWH9CN HS Approved
DMWH9CN SN Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN TC Gastrointestinal Agents
DMWH9CN DT Small molecular drug
DMWH9CN PC 5362391
DMWH9CN MW 366.3
DMWH9CN FM C18H17F3N2O3
DMWH9CN IC InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
DMWH9CN CS C1=CC(=CC(=C1)C(F)(F)F)/C(=N\\OCCCCC(=O)O)/C2=CN=CC=C2
DMWH9CN IK GLLPUTYLZIKEGF-HAVVHWLPSA-N
DMWH9CN IU 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN CA CAS 110140-89-1
DMWH9CN CB CHEBI:135542
DMWH9CN DE Acute myocardial infarction
DM1YBHK ID DM1YBHK
DM1YBHK DN Rifabutin
DM1YBHK HS Approved
DM1YBHK SN Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S
DM1YBHK CP Adria Laboratories
DM1YBHK TC Antibiotics
DM1YBHK DT Small molecular drug
DM1YBHK PC 135398743
DM1YBHK MW 847
DM1YBHK FM C46H62N4O11
DM1YBHK IC InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
DM1YBHK CS C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C
DM1YBHK IK ZWBTYMGEBZUQTK-PVLSIAFMSA-N
DM1YBHK IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate
DM1YBHK CA CAS 72559-06-9
DM1YBHK DE Mycobacterium infection; Tuberculosis
DM5DSFZ ID DM5DSFZ
DM5DSFZ DN Rifampicin
DM5DSFZ HS Approved
DM5DSFZ SN Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifamor; Rifampicin; Rifampicin SV; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Sinerdol; Tubocin; Archidyn; Arficin; Arzide; Benemicin; Dione 21-acetate; Doloresum; Eremfat; Fenampicin; L-5103 Lepetit; rifampin; 13292-46-1; Abrifam; Ba 41166/E; R/AMP; Rifa; Rifam
DM5DSFZ PC 135398735
DM5DSFZ MW 822.9
DM5DSFZ FM C43H58N4O12
DM5DSFZ IC JQXXHWHPUNPDRT-WLSIYKJHSA-N
DM5DSFZ CS CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C
DM5DSFZ IK 1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DM5DSFZ IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DM5DSFZ CA CAS 13292-46-1
DM5DSFZ CB CHEBI:27470
DM5DSFZ DE Osteoporosis
DMA8J1G ID DMA8J1G
DMA8J1G DN Rifampin
DMA8J1G HS Approved
DMA8J1G SN Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)
DMA8J1G CP Norvatis Phamaceuticals Corporation
DMA8J1G TC Antituberculosis Agents
DMA8J1G DT Small molecular drug
DMA8J1G PC 135398735
DMA8J1G MW 822.9
DMA8J1G FM C43H58N4O12
DMA8J1G IC InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DMA8J1G CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
DMA8J1G IK JQXXHWHPUNPDRT-WLSIYKJHSA-N
DMA8J1G IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMA8J1G CA CAS 13292-46-1
DMA8J1G CB CHEBI:28077
DMA8J1G DE Tuberculosis
DMEH3O7 ID DMEH3O7
DMEH3O7 DN Rifamycin
DMEH3O7 HS Approved
DMEH3O7 SN Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus
DMEH3O7 CP Cosmo Technologies
DMEH3O7 DT Small molecular drug
DMEH3O7 PC 6324616
DMEH3O7 MW 697.8
DMEH3O7 FM C37H47NO12
DMEH3O7 IC InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
DMEH3O7 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C
DMEH3O7 IK HJYYPODYNSCCOU-ODRIEIDWSA-N
DMEH3O7 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMEH3O7 CA CAS 6998-60-3
DMEH3O7 CB CHEBI:29673
DMEH3O7 DE Diarrhea; Infectious disease
DMCHV4I ID DMCHV4I
DMCHV4I DN Rifapentine
DMCHV4I HS Approved
DMCHV4I SN RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
DMCHV4I CP Sanofi-Aventis
DMCHV4I TC Antituberculosis Agents
DMCHV4I DT Small molecular drug
DMCHV4I PC 135403821
DMCHV4I MW 877
DMCHV4I FM C47H64N4O12
DMCHV4I IC InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1
DMCHV4I CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
DMCHV4I IK WDZCUPBHRAEYDL-GZAUEHORSA-N
DMCHV4I IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMCHV4I CA CAS 61379-65-5
DMCHV4I CB CHEBI:45304
DMCHV4I DE Tuberculosis; Macular degeneration
DMW1TV2 ID DMW1TV2
DMW1TV2 DN Rifaximin
DMW1TV2 HS Approved
DMW1TV2 SN RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals
DMW1TV2 CP Salix Pharmaceuticals Ltd
DMW1TV2 DT Small molecular drug
DMW1TV2 PC 6436173
DMW1TV2 MW 785.9
DMW1TV2 FM C43H51N3O11
DMW1TV2 IC InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
DMW1TV2 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C
DMW1TV2 IK NZCRJKRKKOLAOJ-XRCRFVBUSA-N
DMW1TV2 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
DMW1TV2 CA CAS 80621-81-4
DMW1TV2 CB CHEBI:75246
DMW1TV2 DE Bacterial infection
DM13PQW ID DM13PQW
DM13PQW DN Rilmenidine
DM13PQW HS Approved
DM13PQW SN Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid
DM13PQW DT Small molecular drug
DM13PQW PC 68712
DM13PQW MW 180.25
DM13PQW FM C10H16N2O
DM13PQW IC InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
DM13PQW CS C1CC1C(C2CC2)NC3=NCCO3
DM13PQW IK CQXADFVORZEARL-UHFFFAOYSA-N
DM13PQW IU N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
DM13PQW CA CAS 54187-04-1
DM13PQW CB CHEBI:8862
DM13PQW DE Hypertension
DMGLUQS ID DMGLUQS
DMGLUQS DN Rilonacept
DMGLUQS HS Approved
DMGLUQS SN Rilonacept (USAN/INN)
DMGLUQS CP Regeneron
DMGLUQS SQ 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|: SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMGLUQS DE Arthritis; Acute gout flare
DMJ0QOW ID DMJ0QOW
DMJ0QOW DN Rilpivirine
DMJ0QOW HS Approved
DMJ0QOW SN 500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin
DMJ0QOW DT Small molecular drug
DMJ0QOW PC 6451164
DMJ0QOW MW 366.4
DMJ0QOW FM C22H18N6
DMJ0QOW IC InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
DMJ0QOW CS CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N
DMJ0QOW IK YIBOMRUWOWDFLG-ONEGZZNKSA-N
DMJ0QOW IU 4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile
DMJ0QOW CA CAS 500287-72-9
DMJ0QOW CB CHEBI:68606
DMJ0QOW DE Human immunodeficiency virus infection; Pain
DMECBWN ID DMECBWN
DMECBWN DN Riluzole
DMECBWN HS Approved
DMECBWN SN Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine
DMECBWN CP Sanofi-Aventis
DMECBWN TC Anticonvulsants
DMECBWN DT Small molecular drug
DMECBWN PC 5070
DMECBWN MW 234.2
DMECBWN FM C8H5F3N2OS
DMECBWN IC InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
DMECBWN CS C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
DMECBWN IK FTALBRSUTCGOEG-UHFFFAOYSA-N
DMECBWN IU 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
DMECBWN CA CAS 1744-22-5
DMECBWN CB CHEBI:8863
DMECBWN DE Amyotrophic lateral sclerosis
DM5DWMU ID DM5DWMU
DM5DWMU DN Rimantadine
DM5DWMU HS Approved
DM5DWMU SN Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
DM5DWMU CP Forest Laboratories Inc
DM5DWMU TC Antiviral Agents
DM5DWMU DT Small molecular drug
DM5DWMU PC 5071
DM5DWMU MW 179.3
DM5DWMU FM C12H21N
DM5DWMU IC InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3
DM5DWMU CS CC(C12CC3CC(C1)CC(C3)C2)N
DM5DWMU IK UBCHPRBFMUDMNC-UHFFFAOYSA-N
DM5DWMU IU 1-(1-adamantyl)ethanamine
DM5DWMU CA CAS 13392-28-4
DM5DWMU CB CHEBI:94440
DM5DWMU DE Influenza A virus infection
DMHOAUG ID DMHOAUG
DMHOAUG DN Rimegepant
DMHOAUG HS Approved
DMHOAUG SN BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991
DMHOAUG CP Labrys Biologics
DMHOAUG DT Small molecular drug
DMHOAUG PC 51049968
DMHOAUG MW 534.6
DMHOAUG FM C28H28F2N6O3
DMHOAUG IC InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
DMHOAUG CS C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
DMHOAUG IK KRNAOFGYEFKHPB-ANJVHQHFSA-N
DMHOAUG IU [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
DMHOAUG CA CAS 1289023-67-1
DMHOAUG DE Migraine
DMTAREC ID DMTAREC
DMTAREC DN Rimexolone
DMTAREC HS Approved
DMTAREC SN Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)
DMTAREC CP Auritec Pharmaceuticals Inc
DMTAREC DT Small molecular drug
DMTAREC PC 5311412
DMTAREC MW 370.5
DMTAREC FM C24H34O3
DMTAREC IC InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1
DMTAREC CS CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C
DMTAREC IK QTTRZHGPGKRAFB-OOKHYKNYSA-N
DMTAREC IU (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMTAREC CA CAS 49697-38-3
DMTAREC CB CHEBI:135566
DMTAREC DE Arthritis
DMA47C6 ID DMA47C6
DMA47C6 DN Rimiterol
DMA47C6 HS Approved
DMA47C6 SN Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)
DMA47C6 DT Small molecular drug
DMA47C6 PC 36283
DMA47C6 MW 223.27
DMA47C6 FM C12H17NO3
DMA47C6 IC InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1
DMA47C6 CS C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O
DMA47C6 IK IYMMESGOJVNCKV-SKDRFNHKSA-N
DMA47C6 IU 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol
DMA47C6 CA CAS 32953-89-2
DMA47C6 DE Asthma
DMXBLMP ID DMXBLMP
DMXBLMP DN Riociguat
DMXBLMP HS Approved
DMXBLMP SN Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester
DMXBLMP CP Bayer HealthCare Pharmaceuticals
DMXBLMP DT Small molecular drug
DMXBLMP PC 11304743
DMXBLMP MW 422.4
DMXBLMP FM C20H19FN8O2
DMXBLMP IC InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
DMXBLMP CS CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC
DMXBLMP IK WXXSNCNJFUAIDG-UHFFFAOYSA-N
DMXBLMP IU methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate
DMXBLMP CA CAS 625115-55-1
DMXBLMP CB CHEBI:76018
DMXBLMP DE Pulmonary arterial hypertension
DM958QB ID DM958QB
DM958QB DN Ripretinib
DM958QB HS Approved
DM958QB SN 1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
DM958QB CP Deciphera Pharmaceuticals Waltham, MA
DM958QB PC 71584930
DM958QB MW 510.4
DM958QB FM C24H21BrFN5O2
DM958QB IC InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
DM958QB CS CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
DM958QB IK CEFJVGZHQAGLHS-UHFFFAOYSA-N
DM958QB IU 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
DM958QB CA CAS 1442472-39-0
DM958QB DE Glioma; Solid tumour/cancer; Systemic mastocytosis; Gastrointestinal stromal tumour
DMM32GT ID DMM32GT
DMM32GT DN Risankizumab
DMM32GT HS Approved
DMM32GT CP AbbVie North Chicago, IL Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DMM32GT DE Psoriatic arthritis; Plaque psoriasis
DMIMF8J ID DMIMF8J
DMIMF8J DN Risdiplam
DMIMF8J HS Approved
DMIMF8J SN UNII-76RS4S2ET1; 76RS4S2ET1; 1825352-65-5; Risdiplam [INN]; SCHEMBL17260852; EX-A2074; RG-7916; HY-109101; RO7034067; CS-0039501; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
DMIMF8J CP PTC Therapeutics South Plainfield, NJ Roche Basel, Switzerland
DMIMF8J PC 118513932
DMIMF8J MW 401.5
DMIMF8J FM C22H23N7O
DMIMF8J IC InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
DMIMF8J CS CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
DMIMF8J IK ASKZRYGFUPSJPN-UHFFFAOYSA-N
DMIMF8J IU 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one
DMIMF8J CA CAS 1825352-65-5
DMIMF8J DE Spinal muscular atrophy
DM5FLTY ID DM5FLTY
DM5FLTY DN Risedronate
DM5FLTY HS Approved
DM5FLTY SN Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
DM5FLTY CP Procter & Gamble; Sanofi-Aventis
DM5FLTY TC Bone Density Conservation Agents
DM5FLTY DT Small molecular drug
DM5FLTY PC 5245
DM5FLTY MW 283.11
DM5FLTY FM C7H11NO7P2
DM5FLTY IC InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
DM5FLTY CS C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM5FLTY IK IIDJRNMFWXDHID-UHFFFAOYSA-N
DM5FLTY IU (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DM5FLTY CA CAS 105462-24-6
DM5FLTY CB CHEBI:8869
DM5FLTY DE Paget's disease
DMN6DXL ID DMN6DXL
DMN6DXL DN Risperidone
DMN6DXL HS Approved
DMN6DXL SN Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
DMN6DXL CP Janssen-Cilag
DMN6DXL TC Antipsychotic Agents
DMN6DXL DT Small molecular drug
DMN6DXL PC 5073
DMN6DXL MW 410.5
DMN6DXL FM C23H27FN4O2
DMN6DXL IC InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
DMN6DXL CS CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DMN6DXL IK RAPZEAPATHNIPO-UHFFFAOYSA-N
DMN6DXL IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DMN6DXL CB CHEBI:8871
DMN6DXL DE Schizophrenia
DM4V6RL ID DM4V6RL
DM4V6RL DN Ritodrine
DM4V6RL HS Approved
DM4V6RL SN Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL TC Sympathomimetics
DM4V6RL DT Small molecular drug
DM4V6RL PC 33572
DM4V6RL MW 287.35
DM4V6RL FM C17H21NO3
DM4V6RL IC InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
DM4V6RL CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O
DM4V6RL IK IOVGROKTTNBUGK-SJCJKPOMSA-N
DM4V6RL IU 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL CA CAS 26652-09-5
DM4V6RL CB CHEBI:8872
DM4V6RL DE Premature labour
DMU764S ID DMU764S
DMU764S DN Ritonavir
DMU764S HS Approved
DMU764S SN Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT
DMU764S CP Abbott Laboratories
DMU764S TC Anti-HIV Agents
DMU764S DT Small molecular drug
DMU764S PC 392622
DMU764S MW 720.9
DMU764S FM C37H48N6O5S2
DMU764S IC InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
DMU764S CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMU764S IK NCDNCNXCDXHOMX-XGKFQTDJSA-N
DMU764S IU 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMU764S CA CAS 155213-67-5
DMU764S CB CHEBI:45409
DMU764S DE Human immunodeficiency virus infection
DM1YVZT ID DM1YVZT
DM1YVZT DN Rituximab
DM1YVZT HS Approved
DM1YVZT CP Genentech
DM1YVZT DT Antibody
DM1YVZT DE Non-hodgkin lymphoma; Pemphigus vulgaris
DMBUH26 ID DMBUH26
DMBUH26 DN Rituximab
DMBUH26 HS Approved
DMBUH26 SN MAbThera (TN)
DMBUH26 CP Roche
DMBUH26 TC Anticancer Agents
DMBUH26 DT Antibody
DMBUH26 SQ Rituximab heavy chain chimeric: QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Rituximab light chain chimericQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMBUH26 DE Non-hodgkin lymphoma; Haematological malignancy
DMQMBZ1 ID DMQMBZ1
DMQMBZ1 DN Rivaroxaban
DMQMBZ1 HS Approved
DMQMBZ1 SN XARELTO (TN)
DMQMBZ1 CP Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
DMQMBZ1 DT Small molecular drug
DMQMBZ1 PC 9875401
DMQMBZ1 MW 435.9
DMQMBZ1 FM C19H18ClN3O5S
DMQMBZ1 IC InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
DMQMBZ1 CS C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
DMQMBZ1 IK KGFYHTZWPPHNLQ-AWEZNQCLSA-N
DMQMBZ1 IU 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
DMQMBZ1 CA CAS 366789-02-8
DMQMBZ1 CB CHEBI:68579
DMQMBZ1 DE Deep vein thrombosis
DMG629M ID DMG629M
DMG629M DN Rivastigmine
DMG629M HS Approved
DMG629M SN Rivastigmine (transdermal patch)
DMG629M CP Samyang Corp
DMG629M DT Small molecular drug
DMG629M PC 77991
DMG629M MW 250.34
DMG629M FM C14H22N2O2
DMG629M IC InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
DMG629M CS CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
DMG629M IK XSVMFMHYUFZWBK-NSHDSACASA-N
DMG629M IU [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
DMG629M CA CAS 123441-03-2
DMG629M CB CHEBI:8874
DMG629M DE Alzheimer disease
DMDJMA3 ID DMDJMA3
DMDJMA3 DN Rizatriptan
DMDJMA3 HS Approved
DMDJMA3 SN Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3 CP Merck & Co
DMDJMA3 TC Antiinflammatory Agents
DMDJMA3 DT Small molecular drug
DMDJMA3 PC 5078
DMDJMA3 MW 269.34
DMDJMA3 FM C15H19N5
DMDJMA3 IC InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
DMDJMA3 CS CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3
DMDJMA3 IK ULFRLSNUDGIQQP-UHFFFAOYSA-N
DMDJMA3 IU N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3 CA CAS 144034-80-0
DMDJMA3 CB CHEBI:48273
DMDJMA3 DE Migraine
DMY9BMK ID DMY9BMK
DMY9BMK DN Rocuronium
DMY9BMK HS Approved
DMY9BMK SN Esmeron (TN); Zemuron (TN); (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK CP Gland Pharma Ltd
DMY9BMK TC Neuromuscular Nondepolarizing Agents
DMY9BMK DT Small molecular drug
DMY9BMK PC 441290
DMY9BMK MW 529.8
DMY9BMK FM C32H53N2O4+
DMY9BMK IC InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
DMY9BMK CS CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C
DMY9BMK IK YXRDKMPIGHSVRX-OOJCLDBCSA-N
DMY9BMK IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK CA CAS 143558-00-3
DMY9BMK CB CHEBI:8884
DMY9BMK DE Muscle spasm
DM3P5DA ID DM3P5DA
DM3P5DA DN Rofecoxib
DM3P5DA HS Approved
DM3P5DA SN Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
DM3P5DA CP Merck & Co
DM3P5DA TC Antiinflammatory Agents
DM3P5DA DT Small molecular drug
DM3P5DA PC 5090
DM3P5DA MW 314.4
DM3P5DA FM C17H14O4S
DM3P5DA IC InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
DM3P5DA CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
DM3P5DA IK RZJQGNCSTQAWON-UHFFFAOYSA-N
DM3P5DA IU 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
DM3P5DA CA CAS 162011-90-7
DM3P5DA CB CHEBI:8887
DM3P5DA DE Osteoarthritis
DMPGHY8 ID DMPGHY8
DMPGHY8 DN Roflumilast
DMPGHY8 HS Approved
DMPGHY8 SN 162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; DAXAS; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast
DMPGHY8 CP Nycomed US Inc; Altana
DMPGHY8 DT Small molecular drug
DMPGHY8 PC 449193
DMPGHY8 MW 403.2
DMPGHY8 FM C17H14Cl2F2N2O3
DMPGHY8 IC InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
DMPGHY8 CS C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
DMPGHY8 IK MNDBXUUTURYVHR-UHFFFAOYSA-N
DMPGHY8 IU 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
DMPGHY8 CA CAS 162401-32-3
DMPGHY8 CB CHEBI:47657
DMPGHY8 DE Asthma; Atopic dermatitis; Type-2 diabetes; Chronic obstructive pulmonary disease
DMCZWOK ID DMCZWOK
DMCZWOK DN Rokitamycin
DMCZWOK HS Approved
DMCZWOK SN Ricamycin (TN)
DMCZWOK CP Toyo Jozo Co Ltd
DMCZWOK DT Small molecular drug
DMCZWOK PC 5282211
DMCZWOK MW 828
DMCZWOK FM C42H69NO15
DMCZWOK IC InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMCZWOK CS CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C
DMCZWOK IK VYWWNRMSAPEJLS-MDWYKHENSA-N
DMCZWOK IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate
DMCZWOK CA CAS 74014-51-0
DMCZWOK CB CHEBI:32103
DMCZWOK DE Bacterial infection
DM8XP26 ID DM8XP26
DM8XP26 DN Rolapitant
DM8XP26 HS Approved
DM8XP26 SN Rolapitant; 552292-08-7; Sch 619734; Varubi; UNII-NLE429IZUC; SCH-619734; NLE429IZUC; 914462-92-3; (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one; Rolapitant [USAN:INN]; Varuby; Varubi (TN); Rolapitant (USAN/INN); Rolapitant(sch619734); SCHEMBL354305; GTPL5749; CHEMBL3707331; CHEBI:90908; DTXSID90203740; MolPort-035-942-975; EX-A1288; BCP09609; ZINC3816514
DM8XP26 CP TESARO
DM8XP26 DT Small molecular drug
DM8XP26 PC 10311306
DM8XP26 MW 500.5
DM8XP26 FM C25H26F6N2O2
DM8XP26 IC InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
DM8XP26 CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4
DM8XP26 IK FIVSJYGQAIEMOC-ZGNKEGEESA-N
DM8XP26 IU (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
DM8XP26 CA CAS 552292-08-7
DM8XP26 CB CHEBI:90908
DM8XP26 DE Chemotherapy-induced nausea
DMBR5Q7 ID DMBR5Q7
DMBR5Q7 DN Rolitetracycline
DMBR5Q7 HS Approved
DMBR5Q7 SN Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
DMBR5Q7 TC Antibiotics
DMBR5Q7 DT Small molecular drug
DMBR5Q7 PC 54682938
DMBR5Q7 MW 527.6
DMBR5Q7 FM C27H33N3O8
DMBR5Q7 IC InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31-32,35,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14-,15-,20-,26+,27-/m0/s1
DMBR5Q7 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCN5CCCC5)N(C)C)O
DMBR5Q7 IK IKQRPFTXKQQLJF-IAHYZSEUSA-N
DMBR5Q7 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-N-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMBR5Q7 CA CAS 751-97-3
DMBR5Q7 CB CHEBI:63334
DMBR5Q7 DE Acne vulgaris
DMT5GNL ID DMT5GNL
DMT5GNL DN Romidepsin
DMT5GNL HS Approved
DMT5GNL SN Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL CP Gloucester Pharmaceuticals; Fujisawa Pharmaceutical Ltd.
DMT5GNL DT Small molecular drug
DMT5GNL PC 5352062
DMT5GNL MW 540.7
DMT5GNL FM C24H36N4O6S2
DMT5GNL IC InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
DMT5GNL CS C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
DMT5GNL IK OHRURASPPZQGQM-GCCNXGTGSA-N
DMT5GNL IU (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL CA CAS 128517-07-7
DMT5GNL CB CHEBI:61080
DMT5GNL DE Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Renal cell carcinoma
DM3U7SZ ID DM3U7SZ
DM3U7SZ DN Romiplostim
DM3U7SZ HS Approved
DM3U7SZ CP Amgen
DM3U7SZ DT Small molecular drug
DM3U7SZ SQ Thrombopoietin receptor binding domain amino acid sequence : IEGPTLRQWLAARA >Amino acid sequence for Fc fusion compoundMDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA
DM3U7SZ PC 5329098
DM3U7SZ MW 238.28
DM3U7SZ FM C15H14N2O
DM3U7SZ IC InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
DM3U7SZ CS CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C
DM3U7SZ IK WUWDLXZGHZSWQZ-WQLSENKSSA-N
DM3U7SZ IU (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
DM3U7SZ CA CAS 194413-58-6
DM3U7SZ CB CHEBI:91083
DM3U7SZ DE Thrombocytopenia; Multiple myeloma; Myelodysplastic syndrome
DMFJZN0 ID DMFJZN0
DMFJZN0 DN Romosozumab
DMFJZN0 HS Approved
DMFJZN0 SN AMG 785
DMFJZN0 CP Amgen
DMFJZN0 DT Antibody
DMFJZN0 DE Postmenopausal osteoporosis
DMA6S1D ID DMA6S1D
DMA6S1D DN Ropinirole
DMA6S1D HS Approved
DMA6S1D SN Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D CP GlaxoSmithKline plc
DMA6S1D TC Antiparkinson Agents
DMA6S1D DT Small molecular drug
DMA6S1D PC 5095
DMA6S1D MW 260.37
DMA6S1D FM C16H24N2O
DMA6S1D IC InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
DMA6S1D CS CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
DMA6S1D IK UHSKFQJFRQCDBE-UHFFFAOYSA-N
DMA6S1D IU 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D CA CAS 91374-21-9
DMA6S1D CB CHEBI:8888
DMA6S1D DE Parkinson disease
DMSPJG2 ID DMSPJG2
DMSPJG2 DN Ropivacaine
DMSPJG2 HS Approved
DMSPJG2 SN Naropin; ROPIVACAINE HCl; Ropivacaine hydrochloride; Ropivacaine monohydrochloride; Naropin (TN); Ropivacaine monohydrochloride, (S)-isomer; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
DMSPJG2 CP AstraZeneca
DMSPJG2 TC Anesthetics
DMSPJG2 DT Small molecular drug
DMSPJG2 PC 175805
DMSPJG2 MW 274.4
DMSPJG2 FM C17H26N2O
DMSPJG2 IC InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1
DMSPJG2 CS CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DMSPJG2 IK ZKMNUMMKYBVTFN-HNNXBMFYSA-N
DMSPJG2 IU (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
DMSPJG2 CA CAS 84057-95-4
DMSPJG2 CB CHEBI:8890
DMSPJG2 DE Anaesthesia
DMILWZR ID DMILWZR
DMILWZR DN Rosiglitazone
DMILWZR HS Approved
DMILWZR PC 77999
DMILWZR FM C18H19N3O3S
DMILWZR IC InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMILWZR CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMILWZR IK YASAKCUCGLMORW-UHFFFAOYSA-N
DMILWZR IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMILWZR CA CAS 122320-73-4
DMILWZR CB CHEBI:50122
DMILWZR DE Type 2 diabetes
DMY6EAO ID DMY6EAO
DMY6EAO DN Rosiglitazone
DMY6EAO HS Approved
DMY6EAO SN Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122
DMY6EAO PC 77999
DMY6EAO MW 357.4
DMY6EAO FM C18H19N3O3S
DMY6EAO IC YASAKCUCGLMORW-UHFFFAOYSA-N
DMY6EAO CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMY6EAO IK 1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMY6EAO IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMY6EAO CA CAS 122320-73-4
DMY6EAO CB CHEBI:50122
DMY6EAO DE Diabetes mellitus
DMT45MU ID DMT45MU
DMT45MU DN Rosiglitazone XR
DMT45MU HS Approved
DMT45MU SN Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
DMT45MU CP GSK
DMT45MU DT Small molecular drug
DMT45MU PC 5281055
DMT45MU MW 473.5
DMT45MU FM C22H23N3O7S
DMT45MU IC InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMT45MU CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=C\\C(=O)O)\\C(=O)O
DMT45MU IK SUFUKZSWUHZXAV-BTJKTKAUSA-N
DMT45MU IU (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMT45MU CA CAS 155141-29-0
DMT45MU CB CHEBI:8892
DMT45MU DE Type-2 diabetes; Alzheimer disease
DMVOIK1 ID DMVOIK1
DMVOIK1 DN Rosoxacin
DMVOIK1 HS Approved
DMVOIK1 SN Acrosoxacin; Eracine; Eradacil; Eradacin; Rosoxacine; Rosoxacino; Rosoxacinum; Roxadyl; Winuron; PD 107522; WIN 35213;Eradacil (TN); Rosoxacin [USAN:INN]; Rosoxacine [INN-French]; Rosoxacino [INN-Spanish]; Rosoxacinum [INN-Latin]; Roxadyl (TN); Win 35,213; Win-35123; Rosoxacin (USAN/INN); 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1 CP Sanofi-Aventis
DMVOIK1 TC Antiinfective Agents
DMVOIK1 DT Small molecular drug
DMVOIK1 PC 287180
DMVOIK1 MW 294.3
DMVOIK1 FM C17H14N2O3
DMVOIK1 IC InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)
DMVOIK1 CS CCN1C=C(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O
DMVOIK1 IK XBPZXDSZHPDXQU-UHFFFAOYSA-N
DMVOIK1 IU 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1 CA CAS 40034-42-2
DMVOIK1 CB CHEBI:131715
DMVOIK1 DE Bacterial infection
DMMIQ7G ID DMMIQ7G
DMMIQ7G DN Rosuvastatin
DMMIQ7G HS Approved
DMMIQ7G SN Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)
DMMIQ7G CP AstraZeneca
DMMIQ7G TC Anticholesteremic Agents
DMMIQ7G DT Small molecular drug
DMMIQ7G PC 446157
DMMIQ7G MW 481.5
DMMIQ7G FM C22H28FN3O6S
DMMIQ7G IC InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
DMMIQ7G CS CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
DMMIQ7G IK BPRHUIZQVSMCRT-VEUZHWNKSA-N
DMMIQ7G IU (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
DMMIQ7G CA CAS 287714-41-4
DMMIQ7G CB CHEBI:38545
DMMIQ7G DE Hypercholesterolaemia; Elevated C-reactive protein
DMP7X6Q ID DMP7X6Q
DMP7X6Q DN Rotigotine
DMP7X6Q HS Approved
DMP7X6Q SN Rotigotine; Rotigotine CDS; Rotigotine CDS Patch; SPM 962; SPM-962; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; Leganto; N 0923; Neupro; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 87T4T8BO2E; 99755-59-6; C19H25NOS; CHEMBL1303; DSSTox_CID_26772; DSSTox_RID_81893; NCGC00168748-01; UNII-87T4T8BO2E
DMP7X6Q PC 59227
DMP7X6Q MW 315.5
DMP7X6Q FM C19H25NOS
DMP7X6Q IC KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMP7X6Q CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMP7X6Q IK 1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMP7X6Q IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMP7X6Q CA CAS 99755-59-6
DMP7X6Q CB CHEBI:135351
DMP7X6Q DE Parkinsonism
DM9PVX8 ID DM9PVX8
DM9PVX8 DN Rucaparib
DM9PVX8 HS Approved
DM9PVX8 SN RUCAPARIB; 283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
DM9PVX8 CP Clovis Oncology
DM9PVX8 DT Small molecular drug
DM9PVX8 PC 9931954
DM9PVX8 MW 323.4
DM9PVX8 FM C19H18FN3O
DM9PVX8 IC InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
DM9PVX8 CS CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
DM9PVX8 IK HMABYWSNWIZPAG-UHFFFAOYSA-N
DM9PVX8 IU 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
DM9PVX8 CA CAS 283173-50-2
DM9PVX8 CB CHEBI:94311
DM9PVX8 DE Ovarian cancer
DMWE60C ID DMWE60C
DMWE60C DN Rufinamide
DMWE60C HS Approved
DMWE60C SN 106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506; Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel
DMWE60C CP Eisai
DMWE60C DT Small molecular drug
DMWE60C PC 129228
DMWE60C MW 238.19
DMWE60C FM C10H8F2N4O
DMWE60C IC InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
DMWE60C CS C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
DMWE60C IK POGQSBRIGCQNEG-UHFFFAOYSA-N
DMWE60C IU 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
DMWE60C CA CAS 106308-44-5
DMWE60C CB CHEBI:134966
DMWE60C DE Seizure disorder; Pediatric lennox-gastaut syndrome; Epilepsy
DM7Q98D ID DM7Q98D
DM7Q98D DN Ruxolitinib
DM7Q98D HS Approved
DM7Q98D SN Ruxolitinib (JAK inhibitor)
DM7Q98D CP Incyte
DM7Q98D DT Small molecular drug
DM7Q98D PC 25126798
DM7Q98D MW 306.4
DM7Q98D FM C17H18N6
DM7Q98D IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM7Q98D CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM7Q98D IK HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM7Q98D IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM7Q98D CA CAS 941678-49-5
DM7Q98D CB CHEBI:66919
DM7Q98D DE High-risk myelofibrosis; Pancreatic cancer; Essential thrombocythemia; Atopic dermatitis; Vitiligo
DMOFP18 ID DMOFP18
DMOFP18 DN Ryzodeq
DMOFP18 HS Approved
DMOFP18 CP Novo nordisk
DMOFP18 DE Type-2 diabetes
DM0YWJC ID DM0YWJC
DM0YWJC DN Safinamide
DM0YWJC HS Approved
DM0YWJC SN 133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na
DM0YWJC CP Us Worldmeds
DM0YWJC DT Small molecular drug
DM0YWJC PC 131682
DM0YWJC MW 302.34
DM0YWJC FM C17H19FN2O2
DM0YWJC IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DM0YWJC CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
DM0YWJC IK NEMGRZFTLSKBAP-LBPRGKRZSA-N
DM0YWJC IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DM0YWJC CA CAS 133865-89-1
DM0YWJC CB CHEBI:134718
DM0YWJC DE Parkinson disease; Idiopathic parkinson disease
DM0J2ZT ID DM0J2ZT
DM0J2ZT DN Safinamide mesylate
DM0J2ZT HS Approved
DM0J2ZT SN Safinamide mesylate; Safinamide mesilate; PNU-151774E; UNII-YS90V3DTX0; FCE-28073; NW-1015; Safinamide mesylate [USAN]; YS90V3DTX0; FCE-28073(R-isomer); Safinamide mesylate (USAN); safinamide methanesulfonate; PNU 151774E; Xadago (TN); NW 1015; AC1MI4YU; Safinamide mesilate (JAN)
DM0J2ZT CP US WorldMeds
DM0J2ZT PC 3038502
DM0J2ZT MW 398.5
DM0J2ZT FM C18H23FN2O5S
DM0J2ZT IC InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1
DM0J2ZT CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F.CS(=O)(=O)O
DM0J2ZT IK YKOCHIUQOBQIAC-YDALLXLXSA-N
DM0J2ZT IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid
DM0J2ZT CA CAS 202825-46-5
DM0J2ZT DE Parkinson disease
DMN9CWF ID DMN9CWF
DMN9CWF DN Salbutamol
DMN9CWF HS Approved
DMN9CWF SN Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
DMN9CWF CP GlaxoSmithKline
DMN9CWF TC Bronchodilator Agents
DMN9CWF DT Small molecular drug
DMN9CWF PC 2083
DMN9CWF MW 239.31
DMN9CWF FM C13H21NO3
DMN9CWF IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
DMN9CWF CS CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
DMN9CWF IK NDAUXUAQIAJITI-UHFFFAOYSA-N
DMN9CWF IU 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMN9CWF CA CAS 18559-94-9
DMN9CWF CB CHEBI:2549
DMN9CWF DE Acute asthma
DM1T2LS ID DM1T2LS
DM1T2LS DN Salicin
DM1T2LS HS Approved
DM1T2LS SN salicin; 138-52-3; Salicoside; Salicine; Salicyl alcohol glucoside; D-(-)-Salicin; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; 2-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Saligenin beta-D-glucopyranoside; D-Salicin; Saligenin-beta-D-glucopyranoside; 2-(Hydroxymethyl)phenyl-beta-d-glucopyranoside; Salicin (6CI,8CI); D(-)-Salicin; o-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Benzyl alcohol, o-hydroxy-, o-glucoside; UNII-4649620TBZ; AI3-19099; alpha-Hydroxy-o-tolyl beta
DM1T2LS DT Small molecular drug
DM1T2LS PC 439503
DM1T2LS MW 286.28
DM1T2LS FM C13H18O7
DM1T2LS IC InChI=1S/C13H18O7/c14-5-7-3-1-2-4-8(7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1
DM1T2LS CS C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM1T2LS IK NGFMICBWJRZIBI-UJPOAAIJSA-N
DM1T2LS IU (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
DM1T2LS CA CAS 138-52-3
DM1T2LS CB CHEBI:17814
DM1T2LS DE Analgesia
DM2F8XZ ID DM2F8XZ
DM2F8XZ DN Salicyclic acid
DM2F8XZ HS Approved
DM2F8XZ SN Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE
DM2F8XZ TC Antiinflammatory Agents
DM2F8XZ DT Small molecular drug
DM2F8XZ PC 338
DM2F8XZ MW 138.12
DM2F8XZ FM C7H6O3
DM2F8XZ IC InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
DM2F8XZ CS C1=CC=C(C(=C1)C(=O)O)O
DM2F8XZ IK YGSDEFSMJLZEOE-UHFFFAOYSA-N
DM2F8XZ IU 2-hydroxybenzoic acid
DM2F8XZ CA CAS 69-72-7
DM2F8XZ CB CHEBI:16914
DM2F8XZ DE Seborrhoeic dermatitis
DMIEU69 ID DMIEU69
DMIEU69 DN Salmeterol
DMIEU69 HS Approved
DMIEU69 SN Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69 CP GlaxoSmithKline
DMIEU69 TC Bronchodilator Agents
DMIEU69 DT Small molecular drug
DMIEU69 PC 5152
DMIEU69 MW 415.6
DMIEU69 FM C25H37NO4
DMIEU69 IC InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
DMIEU69 CS C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O
DMIEU69 IK GIIZNNXWQWCKIB-UHFFFAOYSA-N
DMIEU69 IU 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69 CA CAS 89365-50-4
DMIEU69 CB CHEBI:64064
DMIEU69 DE Chronic obstructive pulmonary disease
DMEWUPF ID DMEWUPF
DMEWUPF DN Salmon Calcitonin
DMEWUPF HS Approved
DMEWUPF SN Astronin; Biocalcin; Bionocalcin; Cadens; Calciben; Calcihexal; Calcimar; Calcimonta; Calcinil; Calcioton; Calcitonina; Calcitoran; Calco; Calogen; Calsynar; Caltine; Casalm; Catonin; Cibacalcine; Citonina; Eptacalcin; Forcaltonin; Fortical; Ipocalcin; Kalsimin; Karil; Miacalcic; Miacalcin; Miracalcic; Oseototal; Osseocalcina; Osteobion; Osteovis; Ostosalm; Ostostabil; Porostenina; Prontocalcin; Quosten; Riostin; Rulicalcin; Salcat; Salcatonin; Salcatyn; Salmocalcin; Salmofar; Sical; Stalcin; Staporos; Steocin; Tonocalcin; Ucecal; Calcitonin salmon; Calcitonin vom lachs; Calcitonine de saumon; Calsynar Lyo L; Recombinant salmon calcitonin; Salmon calcitonin I; Synthetic salmon calcitonin; CALCITONIN, SALMON; Calcimar (TN); Calcitonin (salmon); Calcitonin salmon (synthesis); Calcitonin, salmar; Calcitonin,salmon; Calcitonin-salmon; Fortical (TN); Isi-calcin; Miacalcin (TN); TZ-CT; Thyrocalcitonin (salmon); Calcitonin salmon (USAN/INN); Calcitonin salmon (synthesis) (JAN); Calcitonin, salmon, for bioassay; Salmon calcitonin (1-32); Calcitonin [USAN:INN:BAN:JAN]; Salmon calcitonin-(I-32)
DMEWUPF TC Antiosteporotic Agents
DMEWUPF DT Small molecular drug
DMEWUPF SQ DB00017 sequence: CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP
DMEWUPF PC 16129616
DMEWUPF MW 3431.9
DMEWUPF FM C145H240N44O48S2
DMEWUPF IC InChI=1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)
DMEWUPF CS CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO
DMEWUPF IK BBBFJLBPOGFECG-UHFFFAOYSA-N
DMEWUPF IU 4-[[5-amino-2-[[2-[[2-[[6-amino-2-[[2-[[2-[[2-[[22-amino-16-(2-amino-2-oxoethyl)-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[1-[[1-[[6-amino-1-[[1-[[5-amino-1-[[1-[[1-[2-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[2-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMEWUPF CA CAS 9007-12-9
DMEWUPF DE Osteoporosis
DM13P4C ID DM13P4C
DM13P4C DN Salsalate
DM13P4C HS Approved
DM13P4C SN Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid
DM13P4C TC Antiinflammatory Agents
DM13P4C DT Small molecular drug
DM13P4C PC 5161
DM13P4C MW 258.23
DM13P4C FM C14H10O5
DM13P4C IC InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
DM13P4C CS C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
DM13P4C IK WVYADZUPLLSGPU-UHFFFAOYSA-N
DM13P4C IU 2-(2-hydroxybenzoyl)oxybenzoic acid
DM13P4C CA CAS 552-94-3
DM13P4C CB CHEBI:9014
DM13P4C DE Rheumatoid arthritis
DM62MUZ ID DM62MUZ
DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium
DM62MUZ HS Approved
DM62MUZ CP Lantheus Medical Imaging Inc
DM62MUZ TC Neurology Agents
DM62MUZ DT Small molecular drug
DM62MUZ PC 9810246
DM62MUZ MW 695.93
DM62MUZ FM C6H12N2Na5O12P4Sm
DM62MUZ IC InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3
DM62MUZ CS C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]
DM62MUZ IK SZZACTGRBZTAKY-NKNBZPHVSA-F
DM62MUZ IU pentasodium;samarium-153(3+);N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine
DM62MUZ DE Cancer related pain
DMDINFS ID DMDINFS
DMDINFS DN Sanguinarine
DMDINFS HS Approved
DMDINFS SN SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650
DMDINFS DT Small molecular drug
DMDINFS PC 5154
DMDINFS MW 332.3
DMDINFS FM C20H14NO4+
DMDINFS IC InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1
DMDINFS CS C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
DMDINFS IK INVGWHRKADIJHF-UHFFFAOYSA-N
DMDINFS IU 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene
DMDINFS CA CAS 2447-54-3
DMDINFS CB CHEBI:17183
DMDINFS DE Dental plaque
DM5VP0F ID DM5VP0F
DM5VP0F DN Saphris
DM5VP0F HS Approved
DM5VP0F SN Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, >=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116
DM5VP0F PC 6917875
DM5VP0F MW 401.8
DM5VP0F FM C21H20ClNO5
DM5VP0F IC InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1
DM5VP0F CS CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.C(=CC(=O)O)C(=O)O
DM5VP0F IK GMDCDXMAFMEDAG-CHHFXETESA-N
DM5VP0F IU (Z)-but-2-enedioic acid;(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DM5VP0F CA CAS 85650-56-2
DM5VP0F CB CHEBI:71248
DM5VP0F DE Schizophrenia
DM4087K ID DM4087K
DM4087K DN Saprisartan
DM4087K HS Approved
DM4087K SN Saprisartan potassium; GR 138950; GR-138950; GR-138950C; GR-138950X; 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K TC Antihypertensive Agents
DM4087K DT Small molecular drug
DM4087K PC 60921
DM4087K MW 611.4
DM4087K FM C25H22BrF3N4O4S
DM4087K IC InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
DM4087K CS CCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)C(=O)N)C5CC5
DM4087K IK DUEWVPTZCSAMNB-UHFFFAOYSA-N
DM4087K IU 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K CA CAS 146623-69-0
DM4087K DE Hypertension
DM90TJP ID DM90TJP
DM90TJP DN Sapropterin hydrochloride
DM90TJP HS Approved
DM90TJP SN Biopten (TN)
DM90TJP DT Small molecular drug
DM90TJP PC 135409471
DM90TJP MW 314.17
DM90TJP FM C9H17Cl2N5O3
DM90TJP IC InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1
DM90TJP CS C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl
DM90TJP IK RKSUYBCOVNCALL-NTVURLEBSA-N
DM90TJP IU (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one;dihydrochloride
DM90TJP CA CAS 69056-38-8
DM90TJP CB CHEBI:32120
DM90TJP DE Hyperphenylalaninemia
DMG814N ID DMG814N
DMG814N DN Saquinavir
DMG814N HS Approved
DMG814N SN Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
DMG814N CP Hoffmann-La Roche pharmaceutical company
DMG814N TC Anti-HIV Agents
DMG814N DT Small molecular drug
DMG814N PC 441243
DMG814N MW 670.8
DMG814N FM C38H50N6O5
DMG814N IC InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
DMG814N CS CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
DMG814N IK QWAXKHKRTORLEM-UGJKXSETSA-N
DMG814N IU (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
DMG814N CA CAS 127779-20-8
DMG814N CB CHEBI:63621
DMG814N DE Human immunodeficiency virus infection
DMKS1DV ID DMKS1DV
DMKS1DV DN SARALASIN
DMKS1DV HS Approved
DMKS1DV SN Saralasin; 34273-10-4; UNII-H2AFV2HE66; (Sar1,Val5,Ala8)-Angiotensin II; CHEMBL938; H2AFV2HE66; Saralasinum [INN-Latin]; Saralasin [INN:BAN]; Saralasine [INN-French]; Saralasina [INN-Spanish]; Saralasinum; Saralasine; Saralasina; (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-; NCGC00166135-01; N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine; SCHEMBL23; AC1O44IX; DSSTox_RID_81710
DMKS1DV DT Small molecular drug
DMKS1DV PC 6324663
DMKS1DV MW 912
DMKS1DV FM C42H65N13O10
DMKS1DV IC InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1
DMKS1DV CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMKS1DV IK PFGWGEPQIUAZME-NXSMLHPHSA-N
DMKS1DV IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMKS1DV CA CAS 34273-10-4
DMKS1DV CB CHEBI:135894
DMKS1DV DE Hypertension
DMKZROL ID DMKZROL
DMKZROL DN Saralasin Acetate
DMKZROL HS Approved
DMKZROL SN Saralasin acetate; Sarenin; Saralasin acetate [USAN]; Saralasin acetate (USAN); 39698-78-7; UNII-FO21Z580M4; Sarenin (TN); SCHEMBL2200145; CHEMBL1200670; FO21Z580M4; 34273-10-4 (Parent); D04126; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, >
DMKZROL CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMKZROL DT Small molecular drug
DMKZROL PC 11954381
DMKZROL MW 990.1
DMKZROL FM C44H71N13O13
DMKZROL IC InChI=1S/C42H65N13O10.C2H4O2.H2O/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65;1-2(3)4;/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47);1H3,(H,3,4);1H2/t24-,28-,29-,30-,31-,33-,34-;;/m0../s1
DMKZROL CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC.CC(=O)O.O
DMKZROL IK YBZYNINTWCLDQA-UHKVWXOHSA-N
DMKZROL IU acetic acid;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;hydrate
DMKZROL CA CAS 39698-78-7
DMKZROL DE Hypertension
DMLZNIQ ID DMLZNIQ
DMLZNIQ DN Sarecycline
DMLZNIQ HS Approved
DMLZNIQ SN Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666
DMLZNIQ CP Allergan
DMLZNIQ PC 54681908
DMLZNIQ MW 487.5
DMLZNIQ FM C24H29N3O8
DMLZNIQ IC InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1
DMLZNIQ CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC
DMLZNIQ IK AYUMVPHUMFKFPJ-SBAJWEJLSA-N
DMLZNIQ IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLZNIQ CA CAS 1035654-66-0
DMLZNIQ DE Acne vulgaris
DMY0M8J ID DMY0M8J
DMY0M8J DN Sargramostim
DMY0M8J HS Approved
DMY0M8J SN Leukine; Leukine (TN); Sargramostim (genetical recombination); Sargramostim (USAN/INN); Sargramostim (genetical recombination) (JAN)
DMY0M8J CP Bayer Pharmaceuticals Corporation
DMY0M8J TC Immunomodulatory Agents
DMY0M8J SQ DB00020 sequence: APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE
DMY0M8J DE Bone marrow transplantation
DMOGNXY ID DMOGNXY
DMOGNXY DN Sarilumab
DMOGNXY HS Approved
DMOGNXY SN Kevzara
DMOGNXY CP Sanofi/Regeneron
DMOGNXY DT Monoclonal antibody
DMOGNXY SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMOGNXY DE Rheumatoid arthritis
DMGLP6S ID DMGLP6S
DMGLP6S DN Sarpogrelate
DMGLP6S HS Approved
DMGLP6S SN Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
DMGLP6S TC Hypoglycemic Agents
DMGLP6S DT Small molecular drug
DMGLP6S PC 5160
DMGLP6S MW 429.5
DMGLP6S FM C24H31NO6
DMGLP6S IC InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
DMGLP6S CS CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O
DMGLP6S IK FFYNAVGJSYHHFO-UHFFFAOYSA-N
DMGLP6S IU 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
DMGLP6S CA CAS 125926-17-2
DMGLP6S CB CHEBI:135697
DMGLP6S DE Diabetic complication
DMRSKMZ ID DMRSKMZ
DMRSKMZ DN Satumomab Pendetide
DMRSKMZ HS Approved
DMRSKMZ TC Imaging Agents
DMRSKMZ DT Monoclonal antibody
DMRSKMZ DE Breast cancer
DMGXENV ID DMGXENV
DMGXENV DN Saxagliptin
DMGXENV HS Approved
DMGXENV SN Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3
DMGXENV CP Bristol-Myers Squibb; AstraZeneca
DMGXENV DT Small molecular drug
DMGXENV PC 11243969
DMGXENV MW 315.4
DMGXENV FM C18H25N3O2
DMGXENV IC InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
DMGXENV CS C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
DMGXENV IK QGJUIPDUBHWZPV-SGTAVMJGSA-N
DMGXENV IU (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
DMGXENV CA CAS 361442-04-8
DMGXENV CB CHEBI:71272
DMGXENV DE Type-2 diabetes
DMDK7T9 ID DMDK7T9
DMDK7T9 DN SBC-102
DMDK7T9 HS Approved
DMDK7T9 SN Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma
DMDK7T9 CP Synageva biopharma
DMDK7T9 SQ Sebelipase alfa protein sequence: SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ
DMDK7T9 DE Enzyme deficiency
DMOM8AL ID DMOM8AL
DMOM8AL DN Scopolamine
DMOM8AL HS Approved
DMOM8AL SN Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate
DMOM8AL CP Norvatis Phamaceuticals Corporation
DMOM8AL TC Antispasmodics
DMOM8AL DT Small molecular drug
DMOM8AL PC 3000322
DMOM8AL MW 303.35
DMOM8AL FM C17H21NO4
DMOM8AL IC InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1
DMOM8AL CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4
DMOM8AL IK STECJAGHUSJQJN-USLFZFAMSA-N
DMOM8AL IU [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMOM8AL CA CAS 114-49-8
DMOM8AL CB CHEBI:16794
DMOM8AL DE Addictive disorder; Nausea
DMJ18YL ID DMJ18YL
DMJ18YL DN Secnidazole
DMJ18YL HS Approved
DMJ18YL SN 3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539
DMJ18YL CP Lupin
DMJ18YL DT Small molecular drug
DMJ18YL PC 71815
DMJ18YL MW 185.18
DMJ18YL FM C7H11N3O3
DMJ18YL IC InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
DMJ18YL CS CC1=NC=C(N1CC(C)O)[N+](=O)[O-]
DMJ18YL IK KPQZUUQMTUIKBP-UHFFFAOYSA-N
DMJ18YL IU 1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DMJ18YL CA CAS 3366-95-8
DMJ18YL CB CHEBI:94433
DMJ18YL DE Bacterial vaginosis; Amoebiasis
DM14RF5 ID DM14RF5
DM14RF5 DN Secobarbital
DM14RF5 HS Approved
DM14RF5 SN Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5 CP Eli Lilly
DM14RF5 TC Hypnotics and Sedatives
DM14RF5 DT Small molecular drug
DM14RF5 PC 5193
DM14RF5 MW 238.28
DM14RF5 FM C12H18N2O3
DM14RF5 IC InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DM14RF5 CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM14RF5 IK KQPKPCNLIDLUMF-UHFFFAOYSA-N
DM14RF5 IU 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5 CA CAS 76-73-3
DM14RF5 CB CHEBI:9073
DM14RF5 DE Intractable insomnia
DMDKE4N ID DMDKE4N
DMDKE4N DN Secretin
DMDKE4N HS Approved
DMDKE4N SN SECREFLO; SecreFlow; Secrepan; Secretina; Secretine; Secretinum; Secretolin; Vitrum; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Human secretin; RG 1068; L-Valinamide; SECRETIN-FERRING; Secretin (human); Secretin (porcine); Secretin-Kabi; Secretina [INN-Spanish]; Secretine [INN-French]; Secretinum [INN-Latin]; Secretin [INN:BAN:DCF:JAN]
DMDKE4N TC Diagnostic Agents
DMDKE4N DT Small molecular drug
DMDKE4N SQ DB00021 sequence: HSDGTFTSELSRLRDSARLQRLLQGLV
DMDKE4N PC 16129665
DMDKE4N MW 3056.4
DMDKE4N FM C130H219N43O42
DMDKE4N IC InChI=1S/C130H219N43O42/c1-59(2)43-78(118(206)172-99(65(13)14)126(214)215)151-94(182)53-148-104(192)75(31-34-91(132)180)156-113(201)81(46-62(7)8)163-115(203)82(47-63(9)10)161-107(195)72(28-22-38-145-128(136)137)153-110(198)76(32-35-92(133)181)157-114(202)80(45-61(5)6)159-106(194)71(27-21-37-144-127(134)135)152-102(190)66(15)150-120(208)87(55-174)168-117(205)86(52-98(188)189)165-109(197)73(29-23-39-146-129(138)139)154-112(200)79(44-60(3)4)160-108(196)74(30-24-40-147-130(140)141)155-121(209)89(57-176)169-116(204)83(48-64(11)12)162-111(199)77(33-36-96(184)185)158-122(210)90(58-177)170-125(213)101(68(17)179)173-119(207)84(49-69-25-19-18-20-26-69)166-124(212)100(67(16)178)171-95(183)54-149-105(193)85(51-97(186)187)164-123(211)88(56-175)167-103(191)70(131)50-93-142-41-42-143-93/h18-20,25-26,41-42,59-68,70-90,99-101,174-179H,21-24,27-40,43-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H,142,143)(H,148,192)(H,149,193)(H,150,208)(H,151,182)(H,152,190)(H,153,198)(H,154,200)(H,155,209)(H,156,201)(H,157,202)(H,158,210)(H,159,194)(H,160,196)(H,161,195)(H,162,199)(H,163,203)(H,164,211)(H,165,197)(H,166,212)(H,167,191)(H,168,205)(H,169,204)(H,170,213)(H,171,183)(H,172,206)(H,173,207)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,134,135,144)(H4,136,137,145)(H4,138,139,146)(H4,140,141,147)
DMDKE4N CS CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=NC=CN2)N
DMDKE4N IK KKNIUBFRGPFELP-UHFFFAOYSA-N
DMDKE4N IU 5-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[5-amino-1-[[2-[[1-[(1-carboxy-2-methylpropyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-amino-3-(1H-imidazol-2-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMDKE4N CA CAS 1393-25-5
DMDKE4N DE Pancreatic exocrine dysfunction; Gastrinoma
DMFEGB0 ID DMFEGB0
DMFEGB0 DN Segesterone acetate; ethinyl estradiol
DMFEGB0 HS Approved
DMFEGB0 CP TherapeuticsMD
DMFEGB0 DE Contraception
DM6034S ID DM6034S
DM6034S DN Selegiline
DM6034S HS Approved
DM6034S SN selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic
DM6034S CP Syntropharma
DM6034S DT Small molecular drug
DM6034S PC 26757
DM6034S MW 187.28
DM6034S FM C13H17N
DM6034S IC InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
DM6034S CS C[C@H](CC1=CC=CC=C1)N(C)CC#C
DM6034S IK MEZLKOACVSPNER-GFCCVEGCSA-N
DM6034S IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
DM6034S CA CAS 14611-51-9
DM6034S CB CHEBI:9086
DM6034S DE Skin imperfections; Major depressive disorder; Chemotherapy-induced nausea
DM3VR1L ID DM3VR1L
DM3VR1L DN Selegiline hydrochloride
DM3VR1L HS Approved
DM3VR1L SN Selegiline hydrochloride; 14611-52-0; Selegiline Hcl; (-)-Deprenyl hydrochloride; l-Deprenyl hydrochloride; Jumex hydrochloride; Eldepryl hydrochloride; (-)-Deprenil hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; (-)-E-250 hydrochloride; UNII-6W731X367Q; HSDB 7183; R-(-)-Deprenyl (hydrochloride); FPF1100; (-)-Phenylisopropylmethylpropynylamine; 6W731X367Q; (-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride; Zydis selegiline
DM3VR1L CP Somerset Pharmaceuticals Inc
DM3VR1L TC Neurology Agents
DM3VR1L DT Small molecular drug
DM3VR1L PC 26758
DM3VR1L MW 223.74
DM3VR1L FM C13H18ClN
DM3VR1L IC InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
DM3VR1L CS C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl
DM3VR1L IK IYETZZCWLLUHIJ-UTONKHPSSA-N
DM3VR1L IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
DM3VR1L CA CAS 14611-52-0
DM3VR1L CB CHEBI:9087
DM3VR1L DE Parkinson disease; Motor symptoms
DM25CGV ID DM25CGV
DM25CGV DN Selenium
DM25CGV HS Approved
DM25CGV SN Selenium; Selenium alloy; Selenium and compounds; Selenium anhydride; Selenium base; Selenium dihydride; Selenium dust; Selenium elemental; Selenium homopolymer; Selenium hydride; Selenium metallicum; Selenium, colloidal; Selenium, elemental; Selenium, metallic; Vandex; selenio; 7782-49-2; CCRIS 4250; Caswell No. 732; EINECS 231-957-4; Colloidal selenium; Electronic E-2; Elemental selenium; Gray selenium; Hydrogen selenide (H2Se); SELENIUM ATOM; SELENIUM COMPOUNDS; SELENIUM POWDER; Selen [Polish]; HSDB 4493; Se; Selen; UNII-H6241UJ22B
DM25CGV PC 6326970
DM25CGV MW 78.97
DM25CGV FM Se
DM25CGV IC BUGBHKTXTAQXES-UHFFFAOYSA-N
DM25CGV CS [Se]
DM25CGV IK 1S/Se
DM25CGV IU selenium
DM25CGV CA CAS 7782-49-2
DM25CGV CB CHEBI:27568
DM25CGV DE Seborrhoeic dermatitis
DMAHSU0 ID DMAHSU0
DMAHSU0 DN Selexipag
DMAHSU0 HS Approved
DMAHSU0 SN Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)
DMAHSU0 CP Actelion Pharmaceuticals
DMAHSU0 DT Small molecular drug
DMAHSU0 PC 9913767
DMAHSU0 MW 496.6
DMAHSU0 FM C26H32N4O4S
DMAHSU0 IC InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
DMAHSU0 CS CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMAHSU0 IK QXWZQTURMXZVHJ-UHFFFAOYSA-N
DMAHSU0 IU 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
DMAHSU0 CA CAS 475086-01-2
DMAHSU0 CB CHEBI:90844
DMAHSU0 DE Pulmonary arterial hypertension
DMZR15V ID DMZR15V
DMZR15V DN Selpercatinib
DMZR15V HS Approved
DMZR15V SN MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636
DMZR15V CP Loxo Oncology Stamford, CT
DMZR15V PC 134823904
DMZR15V MW 542.6
DMZR15V FM C29H34N8O3
DMZR15V IC InChI=1S/C29H34N8O3/c1-19-9-34-37-17-23(40-18-24-11-30-5-6-39-24)8-25(29(19)37)26-12-32-27(13-31-26)35-15-21-7-22(16-35)36(21)14-20-3-4-28(38-2)33-10-20/h3-4,8-10,12-13,17,21-22,24,30H,5-7,11,14-16,18H2,1-2H3/t21?,22?,24-/m0/s1
DMZR15V CS CC1=C2C(=CC(=CN2N=C1)OC[C@@H]3CNCCO3)C4=CN=C(C=N4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC
DMZR15V IK MFOVQWYFURMVKU-IWAAJCSBSA-N
DMZR15V IU (2S)-2-[[4-[5-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyrazin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-yl]oxymethyl]morpholine
DMZR15V DE Non-small-cell lung cancer; Colon cancer; Thyroid cancer
DMAGFOD ID DMAGFOD
DMAGFOD DN Semaglutide
DMAGFOD HS Approved
DMAGFOD SN NN9535
DMAGFOD CP Novo Nordisk
DMAGFOD DT Small molecular drug
DMAGFOD PC 56843331
DMAGFOD MW 4114
DMAGFOD FM C187H291N45O59
DMAGFOD IC InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1
DMAGFOD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMAGFOD IK DLSWIYLPEUIQAV-CCUURXOWSA-N
DMAGFOD IU 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
DMAGFOD CA CAS 910463-68-2
DMAGFOD DE Type-2 diabetes
DM25HP1 ID DM25HP1
DM25HP1 DN Sermorelin
DM25HP1 HS Approved
DM25HP1 SN Sermorelina; Sermoreline; Sermorelinum; Sermorelina [Spanish]; Sermoreline [French]; Sermorelinum [Latin]; Geref (TN); Sermorelin (INN); Sermorelin [INN:BAN]; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
DM25HP1 CP Emd Serono Inc
DM25HP1 TC Hormone Replacement Agents
DM25HP1 DT Small molecular drug
DM25HP1 SQ DB00010 sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQ
DM25HP1 PC 16132413
DM25HP1 MW 3357.9
DM25HP1 FM C149H246N44O42S
DM25HP1 IC InChI=1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1
DM25HP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM25HP1 IK WGWPRVFKDLAUQJ-MITYVQBRSA-N
DM25HP1 IU (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DM25HP1 CA CAS 86168-78-7
DM25HP1 DE Pediatric growth disorder
DM1A9XO ID DM1A9XO
DM1A9XO DN Sertaconazole
DM1A9XO HS Approved
DM1A9XO SN Sertaconazol; Sertaconazolum; Sertaconazol [Spanish]; Sertaconazole [INN]; Sertaconazolum [Latin]; FI-7045; Sertaconazole (INN); (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; (inverted exclamation markA)-1-[2,4-dichloro-b-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole;1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish]
DM1A9XO TC Antifungal Agents
DM1A9XO DT Small molecular drug
DM1A9XO PC 65863
DM1A9XO MW 437.8
DM1A9XO FM C20H15Cl3N2OS
DM1A9XO IC InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
DM1A9XO CS C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl
DM1A9XO IK JLGKQTAYUIMGRK-UHFFFAOYSA-N
DM1A9XO IU 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DM1A9XO CA CAS 99592-32-2
DM1A9XO CB CHEBI:83682
DM1A9XO DE Fungal infection
DM0FB1J ID DM0FB1J
DM0FB1J DN Sertraline
DM0FB1J HS Approved
DM0FB1J SN Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
DM0FB1J CP Pfizer Inc
DM0FB1J TC Antidepressants
DM0FB1J DT Small molecular drug
DM0FB1J PC 68617
DM0FB1J MW 306.2
DM0FB1J FM C17H17Cl2N
DM0FB1J IC InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
DM0FB1J CS CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DM0FB1J IK VGKDLMBJGBXTGI-SJCJKPOMSA-N
DM0FB1J IU (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
DM0FB1J CA CAS 79617-96-2
DM0FB1J CB CHEBI:9123
DM0FB1J DE Depression
DMPVRN9 ID DMPVRN9
DMPVRN9 DN Setmelanotide
DMPVRN9 HS Approved
DMPVRN9 SN RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d
DMPVRN9 CP Rhythm Metabolics Boston, MA
DMPVRN9 PC 11993702
DMPVRN9 MW 1117.3
DMPVRN9 FM C49H68N18O9S2
DMPVRN9 IC InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
DMPVRN9 CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMPVRN9 IK HDHDTKMUACZDAA-PHNIDTBTSA-N
DMPVRN9 IU (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
DMPVRN9 CA CAS 920014-72-8
DMPVRN9 DE Diabetic complication; Obesity; Prader-Willi syndrome; Bardet biedl syndrome
DMC9O43 ID DMC9O43
DMC9O43 DN Sevoflurane
DMC9O43 HS Approved
DMC9O43 SN Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
DMC9O43 CP Abbott Laboratories
DMC9O43 TC Anesthetics
DMC9O43 DT Small molecular drug
DMC9O43 PC 5206
DMC9O43 MW 200.05
DMC9O43 FM C4H3F7O
DMC9O43 IC InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
DMC9O43 CS C(OC(C(F)(F)F)C(F)(F)F)F
DMC9O43 IK DFEYYRMXOJXZRJ-UHFFFAOYSA-N
DMC9O43 IU 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
DMC9O43 CA CAS 28523-86-6
DMC9O43 CB CHEBI:9130
DMC9O43 DE Anaesthesia
DMFJTDI ID DMFJTDI
DMFJTDI DN Sibutramine
DMFJTDI HS Approved
DMFJTDI SN Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI CP Abbott Laboratories
DMFJTDI TC Appetite Depressants
DMFJTDI DT Small molecular drug
DMFJTDI PC 5210
DMFJTDI MW 279.8
DMFJTDI FM C17H26ClN
DMFJTDI IC InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
DMFJTDI CS CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
DMFJTDI IK UNAANXDKBXWMLN-UHFFFAOYSA-N
DMFJTDI IU 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI CA CAS 106650-56-0
DMFJTDI CB CHEBI:9137
DMFJTDI DE Obesity
DM1BS03 ID DM1BS03
DM1BS03 DN Sifalimumab
DM1BS03 HS Approved
DM1BS03 SN Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DM1BS03 CP AstraZeneca; MedImmune
DM1BS03 DT Antibody
DM1BS03 DE Renal cell carcinoma; Systemic lupus erythematosus
DMSWJ5X ID DMSWJ5X
DMSWJ5X DN Sildenafil citrate
DMSWJ5X HS Approved
DMSWJ5X SN Sildenafil (citrate); Sildenafil citrate; Sildenafil citrate [USAN]; Sildenafil citrate salt; UK 92480; UK-92480-10; UNII-BW9B0ZE037; Sildenafilcitrate; Sildenafil; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; 139755-83-2; 3M7OB98Y7H; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; BNRNXUUZRGQAQC-UHFFFAOYSA-N; C22H30N6O4S; CHEBI:9139; CHEMBL192; HSDB 7305; Sildenafil [INN:BAN]; UK-92,480-10; UK-92480; UNII-3M7OB98Y7H; 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1); 171599-83-0; BW9B0ZE037; CHEBI:58987; Caverta; DSSTox_CID_26076; DSSTox_GSID_46076; DSSTox_RID_81321
DMSWJ5X PC 135413523
DMSWJ5X MW 666.7
DMSWJ5X FM C28H38N6O11S
DMSWJ5X IC DEIYFTQMQPDXOT-UHFFFAOYSA-N
DMSWJ5X CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMSWJ5X IK 1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMSWJ5X IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid
DMSWJ5X CA CAS 171599-83-0
DMSWJ5X CB CHEBI:31307
DMSWJ5X DE Erectile dysfunction
DMJSBT6 ID DMJSBT6
DMJSBT6 DN Silodosin
DMJSBT6 HS Approved
DMJSBT6 SN Silodosin; 160970-54-7; Rapaflo; Urief; Silodyx; Urorec; KMD-3213; Silodosin-d6; UNII-CUZ39LUY82; KMD 3213; KAD 3213; CUZ39LUY82; CHEMBL24778; KAD-3213; (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; Q-102517; Rapflo
DMJSBT6 DT Small molecular drug
DMJSBT6 PC 5312125
DMJSBT6 MW 495.5
DMJSBT6 FM C25H32F3N3O4
DMJSBT6 IC InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
DMJSBT6 CS C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
DMJSBT6 IK PNCPYILNMDWPEY-QGZVFWFLSA-N
DMJSBT6 IU 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
DMJSBT6 CA CAS 160970-54-7
DMJSBT6 CB CHEBI:135929
DMJSBT6 DE Benign prostatic hyperplasia
DMGEATB ID DMGEATB
DMGEATB DN Siltuximab
DMGEATB HS Approved
DMGEATB CP Janssen Biotech
DMGEATB DT Antibody
DMGEATB SQ Heavy Chain Sequence: EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceQIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMGEATB DE Anemia; Multiple myeloma
DMVTHWQ ID DMVTHWQ
DMVTHWQ DN Silver sulfadiazine
DMVTHWQ HS Approved
DMVTHWQ SN Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
DMVTHWQ TC Antiinfective Agents
DMVTHWQ DT Small molecular drug
DMVTHWQ PC 441244
DMVTHWQ MW 357.14
DMVTHWQ FM C10H9AgN4O2S
DMVTHWQ IC InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
DMVTHWQ CS C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+]
DMVTHWQ IK UEJSSZHHYBHCEL-UHFFFAOYSA-N
DMVTHWQ IU silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
DMVTHWQ CA CAS 22199-08-2
DMVTHWQ CB CHEBI:9142
DMVTHWQ DE Bacterial infection
DMLUA9D ID DMLUA9D
DMLUA9D DN Simeprevir
DMLUA9D HS Approved
DMLUA9D SN TMC436
DMLUA9D CP Johnson & Johnson
DMLUA9D TC Antiinfective Agents
DMLUA9D DT Small molecular drug
DMLUA9D PC 24873435
DMLUA9D MW 749.9
DMLUA9D FM C38H47N5O7S2
DMLUA9D IC InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1
DMLUA9D CS CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC
DMLUA9D IK JTZZSQYMACOLNN-VDWJNHBNSA-N
DMLUA9D IU (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide
DMLUA9D CA CAS 923604-59-5
DMLUA9D CB CHEBI:134743
DMLUA9D DE Chronic HCV-1 infection
DM30SGU ID DM30SGU
DM30SGU DN Simvastatin
DM30SGU HS Approved
DM30SGU SN Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
DM30SGU CP Merck & Co
DM30SGU TC Anticholesteremic Agents
DM30SGU DT Small molecular drug
DM30SGU PC 54454
DM30SGU MW 418.6
DM30SGU FM C25H38O5
DM30SGU IC InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM30SGU CS CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM30SGU IK RYMZZMVNJRMUDD-HGQWONQESA-N
DM30SGU IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
DM30SGU CA CAS 79902-63-9
DM30SGU CB CHEBI:9150
DM30SGU DE Hypercholesterolaemia
DMGWR0C ID DMGWR0C
DMGWR0C DN Sintilimab
DMGWR0C HS Approved
DMGWR0C SN Tyvyt
DMGWR0C CP Innovent Biologics
DMGWR0C DT Antibody
DMGWR0C DE Hodgkin lymphoma
DM2R86O ID DM2R86O
DM2R86O DN Siponimod
DM2R86O HS Approved
DM2R86O SN BAF312
DM2R86O CP Novartis
DM2R86O DT Small molecular drug
DM2R86O PC 44599207
DM2R86O MW 516.6
DM2R86O FM C29H35F3N2O3
DM2R86O IC InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DM2R86O CS CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O
DM2R86O IK KIHYPELVXPAIDH-HNSNBQBZSA-N
DM2R86O IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DM2R86O CA CAS 1230487-00-9
DM2R86O DE Hepatocellular carcinoma; Rheumatoid arthritis; Multiple sclerosis
DMVCMUJ ID DMVCMUJ
DMVCMUJ DN Siponimod
DMVCMUJ HS Approved
DMVCMUJ SN Siponimod; Siponimod [INN]; Siponimod [WHO-DD]; BAF-312; BAF312; BAF312 (Siponimod); RR6P8L282I; 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 1230487-00-9; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-; CHEMBL2336071; UNII-RR6P8L282I
DMVCMUJ PC 44599207
DMVCMUJ MW 516.6
DMVCMUJ FM C29H35F3N2O3
DMVCMUJ IC KIHYPELVXPAIDH-HNSNBQBZSA-N
DMVCMUJ CS CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O
DMVCMUJ IK 1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DMVCMUJ IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DMVCMUJ CA CAS 1230487-00-9
DMVCMUJ DE Multiple sclerosis
DMGW1ID ID DMGW1ID
DMGW1ID DN Sirolimus
DMGW1ID HS Approved
DMGW1ID SN 53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
DMGW1ID CP Wyeth
DMGW1ID TC Immunosuppressive Agents
DMGW1ID DT Small molecular drug
DMGW1ID PC 5284616
DMGW1ID MW 914.2
DMGW1ID FM C51H79NO13
DMGW1ID IC InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DMGW1ID CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DMGW1ID IK QFJCIRLUMZQUOT-HPLJOQBZSA-N
DMGW1ID IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMGW1ID CA CAS 53123-88-9
DMGW1ID CB CHEBI:9168
DMGW1ID DE Organ transplant rejection; Dutch elm disease; Multiple myeloma
DM92P0F ID DM92P0F
DM92P0F DN Sisomicin
DM92P0F HS Approved
DM92P0F SN Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ
DM92P0F PC 36119
DM92P0F MW 447.5
DM92P0F FM C19H37N5O7
DM92P0F IC URWAJWIAIPFPJE-YFMIWBNJSA-N
DM92P0F CS CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O
DM92P0F IK 1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
DM92P0F IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DM92P0F CA CAS 32385-11-8
DM92P0F CB CHEBI:9169
DM92P0F DE Infectious cystitis
DMGDKXN ID DMGDKXN
DMGDKXN DN Sitagliptin
DMGDKXN HS Approved
DMGDKXN SN 486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin
DMGDKXN CP Merck & Co
DMGDKXN TC Hypoglycemic Agents
DMGDKXN DT Small molecular drug
DMGDKXN PC 4369359
DMGDKXN MW 407.31
DMGDKXN FM C16H15F6N5O
DMGDKXN IC InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
DMGDKXN CS C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
DMGDKXN IK MFFMDFFZMYYVKS-SECBINFHSA-N
DMGDKXN IU (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
DMGDKXN CA CAS 486460-32-6
DMGDKXN CB CHEBI:40237
DMGDKXN DE Type-2 diabetes; Peripheral arterial disease
DMQ8E9R ID DMQ8E9R
DMQ8E9R DN SKI-758
DMQ8E9R HS Approved
DMQ8E9R SN SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile
DMQ8E9R DT Small molecular drug
DMQ8E9R PC 11341869
DMQ8E9R MW 552.4
DMQ8E9R FM C28H27Cl2N5O3
DMQ8E9R IC InChI=1S/C28H27Cl2N5O3/c1-34-4-6-35(7-5-34)15-19-8-17(16-38-19)20-9-24-21(10-26(20)36-2)28(18(13-31)14-32-24)33-25-12-27(37-3)23(30)11-22(25)29/h8-12,14,16H,4-7,15H2,1-3H3,(H,32,33)
DMQ8E9R CS CN1CCN(CC1)CC2=CC(=CO2)C3=C(C=C4C(=C3)N=CC(=C4NC5=CC(=C(C=C5Cl)Cl)OC)C#N)OC
DMQ8E9R IK ANUHLKPVOXDYSK-UHFFFAOYSA-N
DMQ8E9R IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile
DMQ8E9R DE Ischemia
DMDIZCS ID DMDIZCS
DMDIZCS DN S-licarbazepine
DMDIZCS HS Approved
DMDIZCS SN Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide
DMDIZCS PC 9881504
DMDIZCS MW 254.28
DMDIZCS FM 15H14N2O2
DMDIZCS IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMDIZCS CS C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMDIZCS IK BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMDIZCS IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMDIZCS CA CAS 104746-04-5
DMDIZCS DE Partial seizures
DMFX9O6 ID DMFX9O6
DMFX9O6 DN SM-101
DMFX9O6 HS Approved (orphan drug)
DMFX9O6 SN SMP-534
DMFX9O6 CP SuppreMol
DMFX9O6 DT Small molecular drug
DMFX9O6 PC 445629
DMFX9O6 DE Idiopathic thrombocytopenic purpura; Diabetic nephropathy; Systemic lupus erythematosus
DM1I93C ID DM1I93C
DM1I93C DN SMT-D002
DM1I93C HS Approved
DM1I93C SN DL-06003
DM1I93C CP DanioLabs Ltd
DM1I93C DE Seborrhea
DMH21E0 ID DMH21E0
DMH21E0 DN Sodium acetate anhydrous
DMH21E0 HS Approved
DMH21E0 SN Sodium Acetate In Plastic Container
DMH21E0 CP Hospira Inc
DMH21E0 DT Small molecular drug
DMH21E0 PC 517045
DMH21E0 MW 82.03
DMH21E0 FM C2H3NaO2
DMH21E0 IC InChI=1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
DMH21E0 CS CC(=O)[O-].[Na+]
DMH21E0 IK VMHLLURERBWHNL-UHFFFAOYSA-M
DMH21E0 IU sodium;acetate
DMH21E0 CA CAS 127-09-3
DMH21E0 CB CHEBI:32954
DMH21E0 DE Hyponatraemia
DMMU6BJ ID DMMU6BJ
DMMU6BJ DN Sodium bicarbonate
DMMU6BJ HS Approved
DMMU6BJ SN Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder
DMMU6BJ TC Antidiarrheals
DMMU6BJ DT Small molecular drug
DMMU6BJ PC 516892
DMMU6BJ MW 84.007
DMMU6BJ FM CHNaO3
DMMU6BJ IC InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
DMMU6BJ CS C(=O)(O)[O-].[Na+]
DMMU6BJ IK UIIMBOGNXHQVGW-UHFFFAOYSA-M
DMMU6BJ IU sodium;hydrogen carbonate
DMMU6BJ CA CAS 144-55-8
DMMU6BJ CB CHEBI:32139
DMMU6BJ DE Metabolic acidosis
DMM3950 ID DMM3950
DMM3950 DN Sodium chloride
DMM3950 HS Approved
DMM3950 SN sodium chloride; 7647-14-5; Halite; Salt; Table salt; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Top flake; Sodium chloride (NaCl); Hyposaline; Flexivial; Gingivyl; Iodized salt; Slow Sodium; Sea salt; SS salt; Sodium monochloride; Natriumchlorid; Hypersal; Adsorbanac; Trisodium trichloride; White crystal; NaCl; HG blending; Salt (ingredient); sodiumchloride; Colyte; Sodium chloride (Na4Cl4); Caswell No 754; Extra Fine 325 Salt; Extra Fine 200 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; sterling
DMM3950 DT Small molecular drug
DMM3950 PC 5234
DMM3950 MW 58.44
DMM3950 FM ClNa
DMM3950 IC InChI=1S/ClH.Na/h1H;/q;+1/p-1
DMM3950 CS [Na+].[Cl-]
DMM3950 IK FAPWRFPIFSIZLT-UHFFFAOYSA-M
DMM3950 IU sodium;chloride
DMM3950 CA CAS 7647-14-5
DMM3950 CB CHEBI:26710
DMM3950 DE Skin burns
DMLJ634 ID DMLJ634
DMLJ634 DN Sodium lauryl sulfate
DMLJ634 HS Approved
DMLJ634 SN Anticerumen; Dreft; Dupanal; Duponal; Duponol; Gardinol; Irium; NALS; Natriumlaurylsulfat; Neutrazyme; SDS; SLS; Syntapon; WAQE; Akyposal SDS; Aquarex ME; Aquarex methyl; Carsonol SLS; Carsonol SLS Paste B; Carsonol SLS Special; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Conco sulfate WA; Conco sulfate WN; DODECYL SULFATE; Dupanol WAQ; Duponal WAQE; Duponol C; Duponol Me; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Duponol WAQE; Duponol WAQM; Duponol methyl; Duponol qx; Duponol waqa; EMAL O; Empicol LPZ; Hexamol SLS; Incronol SLS; Laurylsiran sodny; Lauyl sodium sulfate; Maprobix NEU; Maprofix LK; Maprofix NEU; Maprofix WAC; Melanol CL; Montopol La Paste; Nikkol SLS; Orvus WA Paste; Perlandrol L; Perlankrol L; Richonol A; Richonol C; Richonol af; SDS Running Buffer; Sintapon L; Sipex OP; Sipex SP; Sipex UB; Sipex sb; Sipex sd; Sipon LS; Sipon LSB; Sipon PD; Sipon WD; Sodium Laurylsulfate; Solsol needles; Standapol WAQ; Stepanol ME; Stepanol ME Dry AW; Stepanol WA; Stepanol WA Paste; Stepanol me dry; Stepanol methyl; Stepanol wac; Stepanol waq; Sterling wa paste; Sulfotex wa; Texapon DL; Trepenol WA; Avirol 101; Avirol 118; Avirol 118 conc; Berol 452; CP 75424; Cycloryl 21; Cycloryl 31; Cycloryl 580; Cycloryl 585N; Detergent 66; Emal 10; Emersal 6400; Empicol LS 30; Empicol LX 28; Finasol osr2; MP SILICA RP 18; Maprofix 563; Melanol CL 30; Monagen Y 100; Monogen Y 100; Odoripon Al 95; Perklankrol ESD 60; Rewopol NLS 30; Sinnopon LS 100; Sinnopon LS 95; Sipon LS 100; Standapol 112; Standapol 112 conc; Standapol was 100; Steinapol NLS 90; Stepanol T 28; Sulfetal L 95; Sulfopon wa 1; Swascol 3L; Tarapon K 12; Tvm 474; Emulsifier no. 104; Finasol osr(sub 2); IPC-SDS;Jordanol SL-300; Lanette Wax-S; Maprofix WAC-LA; Product no. 161; Product no. 75; Quolac EX-UB; S-4600; Standapol wa-ac; Stepanol WA-100; Sterling WAQ-CH; Ultra sulfate sl-1
DMLJ634 DT Small molecular drug
DMLJ634 PC 3423265
DMLJ634 MW 288.38
DMLJ634 FM C12H25NaO4S
DMLJ634 IC InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1
DMLJ634 CS CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DMLJ634 IK DBMJMQXJHONAFJ-UHFFFAOYSA-M
DMLJ634 IU sodium;dodecyl sulfate
DMLJ634 CA CAS 151-21-3
DMLJ634 CB CHEBI:8984
DMLJ634 DE Constipation
DMGA9X0 ID DMGA9X0
DMGA9X0 DN Sodium nitroprusside
DMGA9X0 HS Approved
DMGA9X0 SN Nitroprusside (Sodium); Sodium nitroprusside anhydrous; 14402-89-2; C5FeN6O.2Na; Nitropruss; Nitroprusid-natrium; Sodium nitroprussate; Nitroprussidnatrium [German]; C5FeN6O.2H2O.2Na; Sodium nitroprusside [USAN]; Na2[Fe(CN)5(NO)]; Sodium nitroprussiate dihydrate; Sodium nitrosylpentacyanoferrate; SCHEMBL3020702; CCRIS 1912; Sodium Nitroprusside (anhydrous); Disodium nitrosylpentacyanoferrate; Disodium pentacyanonitrosylferrate; CHEBI:29321; Nitroprussiate de sodium [French]; MolPort-003-926-312; disodium pentacyanidonitrosylfer
DMGA9X0 DT Small molecular drug
DMGA9X0 PC 11953895
DMGA9X0 MW 297.95
DMGA9X0 FM C5H4FeN6Na2O3
DMGA9X0 IC InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMGA9X0 CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMGA9X0 IK XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMGA9X0 IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMGA9X0 CA CAS 13755-38-9
DMGA9X0 CB CHEBI:9179
DMGA9X0 DE Hypertension
DMCIWZL ID DMCIWZL
DMCIWZL DN Sodium oxybate
DMCIWZL HS Approved
DMCIWZL SN Sodium Oxybate [USAN]; Sodium gamma-hydroxybutyrate; Sodium oxybate; Sodium-4-hydroxybutyrate; Somsanit; gamma-Hydroxy sodium butyrate; Anetamin; Gamma OH; Natrium 4-hydroxybutyrat; Oxybate (sodium); Oxybate sodium; Sodium 4-hydroxybutyrate; gamma-Hydroxybutyrate sodium; gamma-Hydroxybutyrate sodium salt; sodium 4-hydroxybutanoate; 4-Hydroxybuttersaeure natriumsalz; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid sodium salt; 502-85-2; Butanoic acid, 4-hydroxy-, monosodium salt; EINECS 207-953-3; NSC 84223; UNII-7G33012534
DMCIWZL PC 23663870
DMCIWZL MW 126.09
DMCIWZL FM C4H7NaO3
DMCIWZL IC XYGBKMMCQDZQOZ-UHFFFAOYSA-M
DMCIWZL CS C(CC(=O)[O-])CO.[Na+]
DMCIWZL IK 1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1
DMCIWZL IU sodium;4-hydroxybutanoate
DMCIWZL CA CAS 502-85-2
DMCIWZL DE Narcolepsy
DMXLBCQ ID DMXLBCQ
DMXLBCQ DN Sodium phenylbutyrate
DMXLBCQ HS Approved
DMXLBCQ SN Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals
DMXLBCQ CP Ucyclyd Pharma Inc; Elan Corp plc
DMXLBCQ DT Small molecular drug
DMXLBCQ PC 5258
DMXLBCQ MW 186.18
DMXLBCQ FM C10H11NaO2
DMXLBCQ IC InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
DMXLBCQ CS C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
DMXLBCQ IK VPZRWNZGLKXFOE-UHFFFAOYSA-M
DMXLBCQ IU sodium;4-phenylbutanoate
DMXLBCQ CA CAS 1716-12-7
DMXLBCQ CB CHEBI:75316
DMXLBCQ DE Spinal muscular atrophy
DMKY27B ID DMKY27B
DMKY27B DN Sodium phosphate dibasic/sodium phosphate monobasic
DMKY27B HS Approved
DMKY27B SN Anhydrous sodium acid phosphate; Dipotassium phosphate anhydrous; Monobasic potassium acid phosphate; Monobasic sodium phosphate; Potassium phosphate; Sodium phosphate
DMKY27B DE Multiple sclerosis
DM4QFXJ ID DM4QFXJ
DM4QFXJ DN Sodium Tetradecyl Sulfate
DM4QFXJ HS Approved
DM4QFXJ SN STDS; Trombavar; Monotetradecylsulfate sodium salt; Natri tetradecylsulfas; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; Sotradecol Sodium; Tetradecyl sodium sulfate; Niaproof 4; Tesapon K 14; Texapon K 14; Myristyl sulfate, sodium salt; Natrii tetradecyclis sulfas [INN-Latin]; Tetradecilsulfato sodico [INN-Spanish]; Tetradecyl sulfate de sodium [INN-French]; Tetradecyl sulfate, sodium salt; Fibro-Vein (TN); S.T.D; Sulfuric acid, monotetradecyl ester, sodium salt; Sulfuric acid, myristyl ester, sodium salt; S.T.D.; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); 1-Tetradecanol, hydrogen sulfate, sodium salt
DM4QFXJ TC Sclerosing Agents
DM4QFXJ DT Small molecular drug
DM4QFXJ PC 23665770
DM4QFXJ MW 316.43
DM4QFXJ FM C14H29NaO4S
DM4QFXJ IC InChI=1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1
DM4QFXJ CS CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DM4QFXJ IK UPUIQOIQVMNQAP-UHFFFAOYSA-M
DM4QFXJ IU sodium;tetradecyl sulfate
DM4QFXJ CA CAS 1191-50-0
DM4QFXJ DE Hemangioma; Varicose and spider veins of leg
DMCSLZ4 ID DMCSLZ4
DMCSLZ4 DN Sodium zirconium cyclosilicate
DMCSLZ4 HS Approved
DMCSLZ4 SN UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7
DMCSLZ4 CP AstraZeneca
DMCSLZ4 PC 91799284
DMCSLZ4 MW 371.5
DMCSLZ4 FM H6Na2O9Si3Zr+2
DMCSLZ4 IC InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;
DMCSLZ4 CS O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr]
DMCSLZ4 IK CBTCHTJSGLCFMY-UHFFFAOYSA-N
DMCSLZ4 IU disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium
DMCSLZ4 CA CAS 17141-74-1
DMCSLZ4 DE Hyperkalemia
DMQI86A ID DMQI86A
DMQI86A DN Sofosbuvir
DMQI86A HS Approved
DMQI86A SN HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep
DMQI86A TC Antiviral Agents
DMQI86A DT Small molecular drug
DMQI86A PC 45375808
DMQI86A MW 529.458
DMQI86A FM C22H29FN3O9P
DMQI86A IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMQI86A CS CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMQI86A IK TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMQI86A IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMQI86A CA CAS 1190307-88-0
DMQI86A CB CHEBI:85083
DMQI86A DE Chronic hepatitis C infection
DM5F47O ID DM5F47O
DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O HS Approved
DM5F47O SN Vosevi; Sofosbuvir / velpatasvir / voxilaprevir; Sofosbuvir mixture with velpatasvir and voxilaprevir; S900007740
DM5F47O CP Gilead Sciences
DM5F47O PC 129011857
DM5F47O MW 2281.4
DM5F47O FM C111H135F5N17O26PS
DM5F47O IC InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1
DM5F47O CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC.C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DM5F47O IK FMWRYUBVSONSCK-ZYTFCPLVSA-N
DM5F47O IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide;methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate;propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5F47O DE Hepatitis C virus infection
DMG592Q ID DMG592Q
DMG592Q DN Solifenacin
DMG592Q HS Approved
DMG592Q SN Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
DMG592Q CP GlaxoSmithKline
DMG592Q TC Antispasmodics
DMG592Q DT Small molecular drug
DMG592Q PC 154059
DMG592Q MW 362.5
DMG592Q FM C23H26N2O2
DMG592Q IC InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
DMG592Q CS C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
DMG592Q IK FBOUYBDGKBSUES-VXKWHMMOSA-N
DMG592Q IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
DMG592Q CA CAS 242478-37-1
DMG592Q CB CHEBI:135530
DMG592Q DE Overactive bladder
DMZ9FAO ID DMZ9FAO
DMZ9FAO DN Somatomedin-1
DMZ9FAO HS Approved
DMZ9FAO SN Igef (TN)
DMZ9FAO DE Hormone deficiency
DMF3GM2 ID DMF3GM2
DMF3GM2 DN Somatropin recombinant
DMF3GM2 HS Approved
DMF3GM2 SN Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN)
DMF3GM2 CP Pfizer Pharmaceuticals
DMF3GM2 TC Hormone Replacement Agents
DMF3GM2 DE Growth hormone deficiency
DM72409 ID DM72409
DM72409 DN Sonidegib phosphate
DM72409 HS Approved
DM72409 SN Sonidegib phosphate; Sonidegib phosphate (USAN); Sonidegib phosphate [USAN:INN]; UNII-W421AI34UW; W421AI34UW; sonidegib bisphosphate; sonidegib diphosphate; 1218778-77-8; 3888AH; AKOS015994565; AOB87343; BCP11860; C26H26F3N3O3.2H3O4P; CHEBI:90864; CHEMBL3137317; CS-1175; DTXSID90669468; EX-A1556; Erismodegib Diphosphate; FE-0016; HY-16582; KS-00002WSZ; LDE-225 Diphosphate; LDE225 (Diphosphate); LDE225 Diphosphate; NVP-LDE225 Diphosphate; NVP-LDE225 Diphosphate salt; Odomzo (TN); SB16677
DM72409 PC 45138699
DM72409 MW 681.5
DM72409 FM C26H32F3N3O11P2
DM72409 IC RWIVSVMMGFFZIJ-VWDRLOGHSA-N
DM72409 CS CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O
DM72409 IK 1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;
DM72409 IU N-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide;phosphoric acid
DM72409 CA CAS 1218778-77-8
DM72409 CB CHEBI:90864
DM72409 DE Basal cell carcinoma
DMS8IFC ID DMS8IFC
DMS8IFC DN Sorafenib
DMS8IFC HS Approved
DMS8IFC SN Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
DMS8IFC CP Bayer AG; Onyx Pharmaceuticals
DMS8IFC TC Anticancer Agents
DMS8IFC DT Small molecular drug
DMS8IFC PC 216239
DMS8IFC MW 464.8
DMS8IFC FM C21H16ClF3N4O3
DMS8IFC IC InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
DMS8IFC CS CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
DMS8IFC IK MLDQJTXFUGDVEO-UHFFFAOYSA-N
DMS8IFC IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
DMS8IFC CA CAS 284461-73-0
DMS8IFC CB CHEBI:50924
DMS8IFC DE Renal cell carcinoma; Myelodysplastic syndrome; Hepatocellular carcinoma
DMAN0DE ID DMAN0DE
DMAN0DE DN Sorbitol
DMAN0DE HS Approved
DMAN0DE SN D-Sorbitol; sorbitol; D-Glucitol; 50-70-4; glucitol; L-Gulitol; (-)-Sorbitol; Glucarine; Sorbilande; Diakarmon; Sorbostyl; Multitol; Nivitin; Karion; Esasorb; Neosorb; D-(-)-Sorbitol; Sorbol; Cholaxine; Sorbite; Sionit; Sionite; Siosan; Sionon; Karion instant; Sorbitol F; Sorbitol FP; Sorbex Rp; Sorbitol syrup C; Sorbex X; Sorbex R; Sorbex M; Sorbex S; Sionit K; D-Sorbol; Hexahydric alcohol; Sorbicolan; Sorvilande; Neosorb P 60; D-Sorbite; Foodol D 70; Neosorb 20/60DC; Neosorb 70/70; Neosorb 70/02; Neosorb P 20/60; d-Sorbit; Karion (carbohydrate)
DMAN0DE CP Pharmaxis
DMAN0DE DT Small molecular drug
DMAN0DE PC 5780
DMAN0DE MW 182.17
DMAN0DE FM C6H14O6
DMAN0DE IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
DMAN0DE CS C([C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O
DMAN0DE IK FBPFZTCFMRRESA-JGWLITMVSA-N
DMAN0DE IU (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol
DMAN0DE CA CAS 50-70-4
DMAN0DE CB CHEBI:17924
DMAN0DE DE Constipation
DMUJGR1 ID DMUJGR1
DMUJGR1 DN Sorivudine
DMUJGR1 HS Approved
DMUJGR1 SN Usevir (TN)
DMUJGR1 DT Small molecular drug
DMUJGR1 PC 5282192
DMUJGR1 MW 349.13
DMUJGR1 FM C11H13BrN2O6
DMUJGR1 IC InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
DMUJGR1 CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br
DMUJGR1 IK GCQYYIHYQMVWLT-HQNLTJAPSA-N
DMUJGR1 IU 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMUJGR1 CA CAS 77181-69-2
DMUJGR1 CB CHEBI:32152
DMUJGR1 DE Virus infection
DML60TN ID DML60TN
DML60TN DN Sotalol
DML60TN HS Approved
DML60TN SN Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
DML60TN CP Bristol-Myers Squibb
DML60TN TC Antiarrhythmic Agents
DML60TN DT Small molecular drug
DML60TN PC 5253
DML60TN MW 272.37
DML60TN FM C12H20N2O3S
DML60TN IC InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
DML60TN CS CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DML60TN IK ZBMZVLHSJCTVON-UHFFFAOYSA-N
DML60TN IU N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
DML60TN CA CAS 3930-20-9
DML60TN CB CHEBI:63622
DML60TN DE Sinus rhythm disorder
DMB4HCT ID DMB4HCT
DMB4HCT DN Sparfloxacin
DMB4HCT HS Approved
DMB4HCT SN Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT CP Square pharma
DMB4HCT TC Antibiotics
DMB4HCT DT Small molecular drug
DMB4HCT PC 60464
DMB4HCT MW 392.4
DMB4HCT FM C19H22F2N4O3
DMB4HCT IC InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
DMB4HCT CS C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
DMB4HCT IK DZZWHBIBMUVIIW-DTORHVGOSA-N
DMB4HCT IU 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT CA CAS 110871-86-8
DMB4HCT CB CHEBI:9212
DMB4HCT DE Bacterial infection
DM0MQ35 ID DM0MQ35
DM0MQ35 DN Spectinomycin
DM0MQ35 HS Approved
DM0MQ35 SN Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt)
DM0MQ35 CP Pharmacia & Upjohn Company
DM0MQ35 TC Antibiotics
DM0MQ35 DT Small molecular drug
DM0MQ35 PC 15541
DM0MQ35 MW 332.35
DM0MQ35 FM C14H24N2O7
DM0MQ35 IC InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM0MQ35 CS C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O
DM0MQ35 IK UNFWWIHTNXNPBV-WXKVUWSESA-N
DM0MQ35 IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM0MQ35 CA CAS 1695-77-8
DM0MQ35 CB CHEBI:9215
DM0MQ35 DE Bacterial infection
DM6CMJD ID DM6CMJD
DM6CMJD DN Spectinomycin
DM6CMJD HS Approved
DM6CMJD SN Specitinomycin; Spectam; Spectinomicina; Spectinomicina [Italian]; Spectinomycin; Spectinomycin [INN:BAN]; Spectinomycin hydrochloride; Spectinomycine; Spectinomycine [INN-French]; Spectinomycinum; Spectinomycinum [INN-Latin]; Togamycin; Actinospectacina [Italian]; Antibiotic 2233wp; CHX-3101; Espectinomicina; Espectinomicina [INN-Spanish]; Trobicin; U 18409 E; UNFWWIHTNXNPBV-WXKVUWSESA-N; actinospectacin; 1695-77-8; 93AKI1U6QF; BRN 2171701; C14H24N2O7; CHEBI:9215; EINECS 216-911-3; M-141; SCM; UNII-93AKI1U6QF
DM6CMJD PC 15541
DM6CMJD MW 332.35
DM6CMJD FM C14H24N2O7
DM6CMJD IC UNFWWIHTNXNPBV-WXKVUWSESA-N
DM6CMJD CS CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O
DM6CMJD IK 1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM6CMJD IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM6CMJD CA CAS 1695-77-8
DM6CMJD CB CHEBI:9215
DM6CMJD DE Gonococcal infection
DM6XFHS ID DM6XFHS
DM6XFHS DN SPI-1005
DM6XFHS HS Approved
DM6XFHS SN Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
DM6XFHS TC Fibrinolytic Agents
DM6XFHS DT Small molecular drug
DM6XFHS PC 3194
DM6XFHS MW 274.19
DM6XFHS FM C13H9NOSe
DM6XFHS IC InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DM6XFHS CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DM6XFHS IK DYEFUKCXAQOFHX-UHFFFAOYSA-N
DM6XFHS IU 2-phenyl-1,2-benzoselenazol-3-one
DM6XFHS CA CAS 60940-34-3
DM6XFHS CB CHEBI:77543
DM6XFHS DE Reperfusion injury
DM0BQRS ID DM0BQRS
DM0BQRS DN Spinosad
DM0BQRS HS Approved
DM0BQRS SN Natroba (TN)
DM0BQRS CP ParaPRO
DM0BQRS DT Small molecular drug
DM0BQRS PC 24721309
DM0BQRS MW 732
DM0BQRS FM C41H65NO10
DM0BQRS IC InChI=1S/C41H65NO10/c1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t22-,23-,24+,25-,26+,27-,28+,29-,30-,31?,33+,34+,36+,38+,39-,40-,41+/m1/s1
DM0BQRS CS CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C
DM0BQRS IK SRJQTHAZUNRMPR-MGGCLMNKSA-N
DM0BQRS IU (2S,5S,7R,9R,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-14-methyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione
DM0BQRS CA CAS 168316-95-8
DM0BQRS DE Head and body lice
DM20R5F ID DM20R5F
DM20R5F DN Spiramycin
DM20R5F HS Approved
DM20R5F SN spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard
DM20R5F DT Small molecular drug
DM20R5F PC 6419898
DM20R5F MW 843.1
DM20R5F FM C43H74N2O14
DM20R5F IC InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1
DM20R5F CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
DM20R5F IK ACTOXUHEUCPTEW-JMRHEKERSA-N
DM20R5F IU 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM20R5F CA CAS 8025-81-8
DM20R5F DE Bacterial infection
DM5XLTY ID DM5XLTY
DM5XLTY DN Spirapril
DM5XLTY HS Approved
DM5XLTY SN Renormax; Sandopril; Setrilan; Espirapril [Spanish]; Not established; Spiraprilum [Latin]; Sch-33844; Spirapril (INN); Spirapril [INN:BAN]; TI-211-950; (2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid
DM5XLTY TC Antihypertensive Agents
DM5XLTY DT Small molecular drug
DM5XLTY PC 5311447
DM5XLTY MW 466.6
DM5XLTY FM C22H30N2O5S2
DM5XLTY IC InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
DM5XLTY CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3
DM5XLTY IK HRWCVUIFMSZDJS-SZMVWBNQSA-N
DM5XLTY IU (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
DM5XLTY CA CAS 83647-97-6
DM5XLTY CB CHEBI:135756
DM5XLTY DE Hypertension
DM2AQ5N ID DM2AQ5N
DM2AQ5N DN Spironolactone
DM2AQ5N HS Approved
DM2AQ5N SN Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
DM2AQ5N CP Pfizer Pharmaceuticals
DM2AQ5N TC Diuretics
DM2AQ5N DT Small molecular drug
DM2AQ5N PC 5833
DM2AQ5N MW 416.6
DM2AQ5N FM C24H32O4S
DM2AQ5N IC InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
DM2AQ5N CS CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
DM2AQ5N IK LXMSZDCAJNLERA-ZHYRCANASA-N
DM2AQ5N IU S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
DM2AQ5N CA CAS 52-01-7
DM2AQ5N CB CHEBI:9241
DM2AQ5N DE Congestive heart failure
DMCO5JZ ID DMCO5JZ
DMCO5JZ DN SR141716A
DMCO5JZ HS Approved
DMCO5JZ SN Riobant; Slimona; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
DMCO5JZ CP Sanofi-Aventis
DMCO5JZ TC Antiobesity Agents
DMCO5JZ DT Small molecular drug
DMCO5JZ PC 104850
DMCO5JZ MW 463.8
DMCO5JZ FM C22H21Cl3N4O
DMCO5JZ IC InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMCO5JZ CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMCO5JZ IK JZCPYUJPEARBJL-UHFFFAOYSA-N
DMCO5JZ IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMCO5JZ CA CAS 168273-06-1
DMCO5JZ CB CHEBI:34967
DMCO5JZ DE Obesity
DM6DEK9 ID DM6DEK9
DM6DEK9 DN Stavudine
DM6DEK9 HS Approved
DM6DEK9 SN DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T
DM6DEK9 CP Aurobindo Pharma
DM6DEK9 TC Anti-HIV Agents
DM6DEK9 DT Small molecular drug
DM6DEK9 PC 18283
DM6DEK9 MW 224.21
DM6DEK9 FM C10H12N2O4
DM6DEK9 IC InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
DM6DEK9 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
DM6DEK9 IK XNKLLVCARDGLGL-JGVFFNPUSA-N
DM6DEK9 IU 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DM6DEK9 CA CAS 3056-17-5
DM6DEK9 CB CHEBI:63581
DM6DEK9 DE Human immunodeficiency virus infection
DMMSDOY ID DMMSDOY
DMMSDOY DN Stiripentol
DMMSDOY HS Approved
DMMSDOY SN Diacomit; ME-2080; Stiripentol (oral); Stiripentol (oral), Laboratoires Biocodex
DMMSDOY CP Biocodex
DMMSDOY DT Small molecular drug
DMMSDOY PC 5311454
DMMSDOY MW 234.29
DMMSDOY FM C14H18O3
DMMSDOY IC InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
DMMSDOY CS CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O
DMMSDOY IK IBLNKMRFIPWSOY-FNORWQNLSA-N
DMMSDOY IU (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
DMMSDOY CA CAS 49763-96-4
DMMSDOY CB CHEBI:94435
DMMSDOY DE Dravet syndrome; Epilepsy
DM5JQ0D ID DM5JQ0D
DM5JQ0D DN Streptokinase
DM5JQ0D HS Approved
DM5JQ0D SN Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid
DM5JQ0D CP Alpes Selection
DM5JQ0D TC Thrombolytic Agents
DM5JQ0D DT Small molecular drug
DM5JQ0D SQ Streptokinase Sequence DB00086: MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK
DM5JQ0D PC 9815560
DM5JQ0D MW 197.27
DM5JQ0D FM C11H19NO2
DM5JQ0D IC InChI=1S/C11H19NO2/c13-11(14)10-6-9(7-12-10)8-4-2-1-3-5-8/h8-10,12H,1-7H2,(H,13,14)
DM5JQ0D CS C1CCC(CC1)C2CC(NC2)C(=O)O
DM5JQ0D IK XRZWVSXEDRYQGC-UHFFFAOYSA-N
DM5JQ0D IU 4-cyclohexylpyrrolidine-2-carboxylic acid
DM5JQ0D CA CAS 9002-01-1
DM5JQ0D DE Pulmonary embolism
DME1LQN ID DME1LQN
DME1LQN DN Streptomycin
DME1LQN HS Approved
DME1LQN SN Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
DME1LQN CP Merck & Co
DME1LQN TC Antibiotics
DME1LQN DT Small molecular drug
DME1LQN PC 19649
DME1LQN MW 581.6
DME1LQN FM C21H39N7O12
DME1LQN IC InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DME1LQN CS C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O
DME1LQN IK UCSJYZPVAKXKNQ-HZYVHMACSA-N
DME1LQN IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DME1LQN CA CAS 57-92-1
DME1LQN CB CHEBI:17076
DME1LQN DE Bacterial infection
DMSRXVM ID DMSRXVM
DMSRXVM DN Streptomycin
DMSRXVM HS Approved
DMSRXVM SN Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin [INN:BAN]; Streptomycin sulfate; Streptomycin sulphate; Streptomycine; Streptomycinum; Streptomyzin [German]; Agrept; Agrimycin; Chemform; Estreptomicina [INN-Spanish]; Hokko-mycin; Neodiestreptopab; Strepcen; Y45QSO73OB; streptomycin; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 57-92-1; CHEBI:17076; Caswell No. 804; Gerox; NSC-14083; UNII-Y45QSO73OB
DMSRXVM PC 19649
DMSRXVM MW 581.6
DMSRXVM FM C21H39N7O12
DMSRXVM IC UCSJYZPVAKXKNQ-HZYVHMACSA-N
DMSRXVM CS CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O
DMSRXVM IK 1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DMSRXVM IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DMSRXVM CA CAS 57-92-1
DMSRXVM CB CHEBI:17076
DMSRXVM DE Infectious endocarditis
DMOF7AT ID DMOF7AT
DMOF7AT DN Streptozocin
DMOF7AT HS Approved
DMOF7AT SN Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
DMOF7AT CP Pfizer Pharmaceuticals
DMOF7AT TC Anticancer Agents
DMOF7AT DT Small molecular drug
DMOF7AT PC 29327
DMOF7AT MW 265.22
DMOF7AT FM C8H15N3O7
DMOF7AT IC InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
DMOF7AT CS CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
DMOF7AT IK ZSJLQEPLLKMAKR-GKHCUFPYSA-N
DMOF7AT IU 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
DMOF7AT CA CAS 18883-66-4
DMOF7AT CB CHEBI:9288
DMOF7AT DE Pancreatic cancer
DME81IY ID DME81IY
DME81IY DN Succimer
DME81IY HS Approved
DME81IY SN Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure
DME81IY DT Small molecular drug
DME81IY PC 2724354
DME81IY MW 182.2
DME81IY FM C4H6O4S2
DME81IY IC InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+
DME81IY CS [C@@H]([C@@H](C(=O)O)S)(C(=O)O)S
DME81IY IK ACTRVOBWPAIOHC-XIXRPRMCSA-N
DME81IY IU (2S,3R)-2,3-bis(sulfanyl)butanedioic acid
DME81IY CA CAS 304-55-2
DME81IY CB CHEBI:63623
DME81IY DE Metal intoxication
DMDWICP ID DMDWICP
DMDWICP DN Succinic acid
DMDWICP HS Approved
DMDWICP SN Asuccin; Bernsteinsaeure; Bernsteinsaure; Butandisaeure; Katasuccin; SIN; Succ; Succinellite; Wormwood; Acid of amber; Acide butanedioique; Acide succinique; Acidum succinicum; Amber acid; Bernsteinsaure [German]; Butanedioic acid diammonium salt; Butanedionic acid; Dihydrofumaric acid; Ethanedicarboxylic acid; Ethylene dicarboxylic acid; Ethylene succinic acid; Ethylenesuccinic acid; Kyselina jantarova; Kyselina jantarova [Czech]; Potassium Succinate; Sal succini; Spirit of amber; Succinicum acidum; Succinicun acidum; Wormwood acid; A 12084; Butanedioic acid (9CI); SUCCINIC ACID, ACS; Succinate, 9; Succinic acid (8CI); Amber acid, Butanedioic acid, Ethylenesuccinic acid; 1,2-Ethanedicarboxylic acid; 1,4-BUTANEDIOIC ACID (SUCCINIC ACID); 1,4-Butanedioic acid
DMDWICP TC Dietary supplement
DMDWICP DT Small molecular drug
DMDWICP PC 1110
DMDWICP MW 118.09
DMDWICP FM C4H6O4
DMDWICP IC InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)
DMDWICP CS C(CC(=O)O)C(=O)O
DMDWICP IK KDYFGRWQOYBRFD-UHFFFAOYSA-N
DMDWICP IU butanedioic acid
DMDWICP CA CAS 110-15-6
DMDWICP CB CHEBI:15741
DMDWICP DE Malnutrition
DM2ET1M ID DM2ET1M
DM2ET1M DN Succinylcholine
DM2ET1M HS Approved
DM2ET1M SN Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
DM2ET1M CP Sandoz Canada Inc
DM2ET1M TC Analgesics
DM2ET1M DT Small molecular drug
DM2ET1M PC 5314
DM2ET1M MW 290.4
DM2ET1M FM C14H30N2O4+2
DM2ET1M IC InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
DM2ET1M CS C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
DM2ET1M IK AXOIZCJOOAYSMI-UHFFFAOYSA-N
DM2ET1M IU trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
DM2ET1M CA CAS 306-40-1
DM2ET1M CB CHEBI:45652
DM2ET1M DE Spasm
DMP9HBO ID DMP9HBO
DMP9HBO DN Sucralfate
DMP9HBO HS Approved
DMP9HBO SN SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova
DMP9HBO CP Scios Inc
DMP9HBO PC 121494085
DMP9HBO MW 1577.9
DMP9HBO FM C12H54Al9O55S8
DMP9HBO IC InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
DMP9HBO CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
DMP9HBO IK YZPQNHUVIVIUCT-JTJNLBSYSA-F
DMP9HBO CA CAS 54182-58-0
DMP9HBO DE Acne vulgaris
DMU7YEL ID DMU7YEL
DMU7YEL DN Sufentanil
DMU7YEL HS Approved
DMU7YEL SN Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
DMU7YEL CP Janssen Pharmaceutica
DMU7YEL TC Anesthetics
DMU7YEL DT Small molecular drug
DMU7YEL PC 41693
DMU7YEL MW 386.6
DMU7YEL FM C22H30N2O2S
DMU7YEL IC InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
DMU7YEL CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
DMU7YEL IK GGCSSNBKKAUURC-UHFFFAOYSA-N
DMU7YEL IU N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMU7YEL CA CAS 56030-54-7
DMU7YEL CB CHEBI:9316
DMU7YEL DE Analgesia
DMZ6VEY ID DMZ6VEY
DMZ6VEY DN Sulfacetamide
DMZ6VEY HS Approved
DMZ6VEY SN Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide
DMZ6VEY TC Antibiotics
DMZ6VEY DT Small molecular drug
DMZ6VEY PC 5320
DMZ6VEY MW 214.24
DMZ6VEY FM C8H10N2O3S
DMZ6VEY IC InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)
DMZ6VEY CS CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
DMZ6VEY IK SKIVFJLNDNKQPD-UHFFFAOYSA-N
DMZ6VEY IU N-(4-aminophenyl)sulfonylacetamide
DMZ6VEY CA CAS 144-80-9
DMZ6VEY CB CHEBI:63845
DMZ6VEY DE Acne vulgaris
DMKI2XC ID DMKI2XC
DMKI2XC DN Sulfacytine
DMKI2XC HS Approved
DMKI2XC SN Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC TC Antiinfective Agents
DMKI2XC DT Small molecular drug
DMKI2XC PC 5322
DMKI2XC MW 294.33
DMKI2XC FM C12H14N4O3S
DMKI2XC IC InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)
DMKI2XC CS CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N
DMKI2XC IK SIBQAECNSSQUOD-UHFFFAOYSA-N
DMKI2XC IU 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC CA CAS 17784-12-2
DMKI2XC CB CHEBI:135230
DMKI2XC DE Cystitis; Urinary tract infection
DMTW3R8 ID DMTW3R8
DMTW3R8 DN Sulfadiazine
DMTW3R8 HS Approved
DMTW3R8 SN Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ
DMTW3R8 CP Lilly
DMTW3R8 TC Antiinfective Agents
DMTW3R8 DT Small molecular drug
DMTW3R8 PC 5215
DMTW3R8 MW 250.28
DMTW3R8 FM C10H10N4O2S
DMTW3R8 IC InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
DMTW3R8 CS C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMTW3R8 IK SEEPANYCNGTZFQ-UHFFFAOYSA-N
DMTW3R8 IU 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
DMTW3R8 CA CAS 68-35-9
DMTW3R8 CB CHEBI:9328
DMTW3R8 DE Rheumatic fever
DMKM3SX ID DMKM3SX
DMKM3SX DN Sulfamerazine
DMKM3SX HS Approved
DMKM3SX SN Cremomerazine; Kelamerazine; Mebacid; Mesulfa; Methylpyrimal; Methylsulfadiazine; Methylsulfazin; Methylsulfazine;Metilsulfadiazin; Metilsulfazin; Percoccide; Pyralcid; Romezin; Septacil; Septosyl; Solfamerazina; Solumedin; Sulfameradine; Sulfamerazin; Sulfamerazina; Sulfamerazinum; Sulfamethyldiazine; Sulphamerazine; Sumedine; Pyrimal M; Solfamerazina [DCIT]; RP 2632; A-310; Debenal-M; Pirimal-M; Sulfamerazina [INN-Spanish]; Sulfamerazine (INN); Sulfamerazinum [INN-Latin]; Veta-Merazine; Sulfamerazine [USAN:INN:BAN]; N-(4-Methyl-2-pyrimidyl)sulfanilamide; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-(8CI); (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; 2-Sulfa-4-methylpyrimidine; 2-Sulfanilamido-4-methylpyrimidine; 2643-RP; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX TC Antiinfective Agents
DMKM3SX DT Small molecular drug
DMKM3SX PC 5325
DMKM3SX MW 264.31
DMKM3SX FM C11H12N4O2S
DMKM3SX IC InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
DMKM3SX CS CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMKM3SX IK QPPBRPIAZZHUNT-UHFFFAOYSA-N
DMKM3SX IU 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX CA CAS 127-79-7
DMKM3SX CB CHEBI:102130
DMKM3SX DE Bacterial infection
DMRGZ16 ID DMRGZ16
DMRGZ16 DN Sulfamethazine
DMRGZ16 HS Approved
DMRGZ16 SN Azolmetazin; Cremomethazine; Diazil; Dimezathine; Intradine; Kelametazine; Mermeth; Neasina; Neazina; Pirmazin; Primazin; Solfadimidina; Spanbolet; Sulfadimerazine; Sulfadimesin; Sulfadimesine; Sulfadimethyldiazine; Sulfadimethylpyrimidine; Sulfadimezin; Sulfadimezine; Sulfadimezinum; Sulfadimidin; Sulfadimidina; Sulfadimidine; Sulfadimidinum; Sulfadine; Sulfametazina; Sulfametazyny; Sulfamethiazine; Sulfamezathine; Sulfodimesin; Sulfodimezine; Sulphadimethylpyrimidine; Sulphadimidine; Sulphamethasine; Sulphamethazine; Sulphamezathine; Sulphamidine; Sulphodimezine; Superseptil; Superseptyl; Vertolan; Calfspan Tablets; Sa III; Solfadimidina [DCIT]; SulfaSURE SR Bolus; Sulfadimidine solution; Sulfametazina[Italian]; Sulfametazyny [Polish]; Sulfamethazine solution; Sulka S Boluses; BN 2409; HC210279; A-502; Diazil (the sulfanilamide); Dimidin-R; Hava-Span; Sulfa-Isodimerazine; Sulfadimidina [INN-Spanish]; Sulfadimidine (INN); Sulfadimidine [INN:BAN]; Sulfadimidinum [INN-Latin]; Sulfamethazine (USP); Sulfamezathine (TN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4,6-Dimethylsulfadiazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 4-Amino-N-[4,6-dimethyl-2-pyrimidinyl]-benzenesulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]
DMRGZ16 TC Antiinfective Agents
DMRGZ16 DT Small molecular drug
DMRGZ16 PC 5327
DMRGZ16 MW 278.33
DMRGZ16 FM C12H14N4O2S
DMRGZ16 IC InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)
DMRGZ16 CS CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
DMRGZ16 IK ASWVTGNCAZCNNR-UHFFFAOYSA-N
DMRGZ16 IU 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
DMRGZ16 CA CAS 57-68-1
DMRGZ16 CB CHEBI:102265
DMRGZ16 DE Bacterial infection
DMGCHDS ID DMGCHDS
DMGCHDS DN Sulfamethizole
DMGCHDS HS Approved
DMGCHDS SN Ayerlucil; Famet; Lucosil; Methazol; Microsul; Proklar; Renasul; Rufol; SULFAMETHIAZOLE; Salimol; Solfametizolo; Sulamethizole; Sulfamethazole; Sulfamethizol; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur;Thiosulfil; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; Solfametizolo [DCIT]; Sulfa gram; Thiosulfil Forte; RP 2145; VK 53; Sulfamethizolum [INN-Latin]; Sulfametizol [INN-Spanish]; Thiosulfil (TN); Sulfamethizole [USAN:INN:JAN]; Thiosulfil-A-Forte; Sulfamethizole (JP15/USP/INN); N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole
DMGCHDS TC Antiinfective Agents
DMGCHDS DT Small molecular drug
DMGCHDS PC 5328
DMGCHDS MW 270.3
DMGCHDS FM C9H10N4O2S2
DMGCHDS IC InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)
DMGCHDS CS CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N
DMGCHDS IK VACCAVUAMIDAGB-UHFFFAOYSA-N
DMGCHDS IU 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
DMGCHDS CA CAS 144-82-1
DMGCHDS CB CHEBI:9331
DMGCHDS DE Urinary tract infection
DMB08GE ID DMB08GE
DMB08GE DN Sulfamethoxazole
DMB08GE HS Approved
DMB08GE SN sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole
DMB08GE TC Antiinfective Agents
DMB08GE DT Small molecular drug
DMB08GE PC 5329
DMB08GE MW 253.28
DMB08GE FM C10H11N3O3S
DMB08GE IC InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
DMB08GE CS CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
DMB08GE IK JLKIGFTWXXRPMT-UHFFFAOYSA-N
DMB08GE IU 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
DMB08GE CA CAS 723-46-6
DMB08GE CB CHEBI:9332
DMB08GE DE Bacterial infection; Infection of P. falciparum
DMIO1K0 ID DMIO1K0
DMIO1K0 DN Sulfamylon
DMIO1K0 HS Approved
DMIO1K0 SN Mafenide; mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Maphenide; Maphenid; Malfamin; Homosul; Homonal; Benzamsulfonamide; Homosulfanilamide; Marprontil; Mesudrin; Septicid; Neofamid; Mesudin; Paramenyl; 4-Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Homosulfaminum; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; 4-sulfamoylbenzylamine; Bensulfamide; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(aminosulfonyl)benzylamine; Mafenide acetate; MAFENIDE
DMIO1K0 CP Mylan Inc
DMIO1K0 DT Small molecular drug
DMIO1K0 PC 3998
DMIO1K0 MW 186.23
DMIO1K0 FM C7H10N2O2S
DMIO1K0 IC InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
DMIO1K0 CS C1=CC(=CC=C1CN)S(=O)(=O)N
DMIO1K0 IK TYMRLRRVMHJFTF-UHFFFAOYSA-N
DMIO1K0 IU 4-(aminomethyl)benzenesulfonamide
DMIO1K0 CA CAS 138-39-6
DMIO1K0 CB CHEBI:6633
DMIO1K0 DE Bacterial infection
DMABVE9 ID DMABVE9
DMABVE9 DN Sulfanilamide
DMABVE9 HS Approved
DMABVE9 SN AAS; AVC; Albexan; Albosal; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Desseptyl; Dipron; Ergaseptine; Gerison; Gombardol; Infepan; Lusil; Lysococcine; Neococcyl; Orgaseptine; PABS; Prontalbin; Prontylin; Proseptal; Proseptine; Pysococcine; SAN; Sanamid; Septanilam; Septolix; Septoplex; Septoplix; Solfanilamide; Stramid; Strepamide; Streptagol; Streptamid; Streptocid; Streptocide; Streptocidum; Streptocom; Streptol; Strepton; Streptopan; Streptrocide; Sulfanilamida; Sulfanilamidum; Sulfocidin; Therapol; Tolder; Prontosil I; Prontosil White; Pronzin Album; Rubiazol A; Septamide Album; Solfanilamide [DCIT]; Stopton Album; Streptocid album; Streptocide White; Sulfanilamide Vaginal Cream; Sulphanilamide Extra Pure; Sulphanilamide Gr; White streptocide; F 1162; Fourneau 1162; Ro13354; A-349; AVC (TN); Aromatic/heteroaromatic sulfonamide 2; F-1162; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; Streptocid (TN); Streptocide (VAN); Sulfanilamida [INN-Spanish]; Sulfanilamide (INN); Sulfanilamide [INN:DCF]; Sulfanilamidum [INN-Latin]; Aniline-p-sulfonic amide; I.C. 56; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; N4,N4-Bis(2-bromoethyl)sulfanilamide; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-(9CI); Sulfanilamide, N4,N4-bis(2-bromoethyl)-(8CI); 1162 F; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; 4-Aminobenzene-1-Sulfonamide; 4-Aminophenylsulfonamide; 4-Sulfamoylaniline; 4-[bis(2-bromoethyl)amino]benzenesulfonamide
DMABVE9 TC Antibiotics
DMABVE9 DT Small molecular drug
DMABVE9 PC 5333
DMABVE9 MW 172.21
DMABVE9 FM C6H8N2O2S
DMABVE9 IC InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DMABVE9 CS C1=CC(=CC=C1N)S(=O)(=O)N
DMABVE9 IK FDDDEECHVMSUSB-UHFFFAOYSA-N
DMABVE9 IU 4-aminobenzenesulfonamide
DMABVE9 CA CAS 63-74-1
DMABVE9 CB CHEBI:45373
DMABVE9 DE Bacterial infection
DMFNAEM ID DMFNAEM
DMFNAEM DN Sulfaphenazole
DMFNAEM HS Approved
DMFNAEM SN Sulfabid
DMFNAEM CP Pharmaceutical Research Assoc Inc
DMFNAEM TC Antiinfective Agents
DMFNAEM DT Small molecular drug
DMFNAEM PC 5335
DMFNAEM MW 314.4
DMFNAEM FM C15H14N4O2S
DMFNAEM IC InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
DMFNAEM CS C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N
DMFNAEM IK QWCJHSGMANYXCW-UHFFFAOYSA-N
DMFNAEM IU 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide
DMFNAEM CA CAS 526-08-9
DMFNAEM CB CHEBI:77780
DMFNAEM DE Bacterial infection
DMIUYFH ID DMIUYFH
DMIUYFH DN Sulfapyridine
DMIUYFH HS Approved
DMIUYFH SN Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH TC Dermatologic Agents
DMIUYFH DT Small molecular drug
DMIUYFH PC 5336
DMIUYFH MW 249.29
DMIUYFH FM C11H11N3O2S
DMIUYFH IC InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
DMIUYFH CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMIUYFH IK GECHUMIMRBOMGK-UHFFFAOYSA-N
DMIUYFH IU 4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH CA CAS 144-83-2
DMIUYFH CB CHEBI:132842
DMIUYFH DE Dermatitis herpetiformis
DMICA9H ID DMICA9H
DMICA9H DN Sulfasalazine
DMICA9H HS Approved
DMICA9H SN sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine
DMICA9H CP Watson Laboratories
DMICA9H TC Antiinflammatory Agents
DMICA9H DT Small molecular drug
DMICA9H PC 5339
DMICA9H MW 398.4
DMICA9H FM C18H14N4O5S
DMICA9H IC InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
DMICA9H CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
DMICA9H IK NCEXYHBECQHGNR-UHFFFAOYSA-N
DMICA9H IU 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
DMICA9H CA CAS 599-79-1
DMICA9H CB CHEBI:9334
DMICA9H DE Rheumatoid arthritis; Irritable bowel syndrome
DMEV954 ID DMEV954
DMEV954 DN Sulfinpyrazone
DMEV954 HS Approved
DMEV954 SN Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954 TC Uricosuric Agents
DMEV954 DT Small molecular drug
DMEV954 PC 5342
DMEV954 MW 404.5
DMEV954 FM C23H20N2O3S
DMEV954 IC InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
DMEV954 CS C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
DMEV954 IK MBGGBVCUIVRRBF-UHFFFAOYSA-N
DMEV954 IU 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954 CA CAS 57-96-5
DMEV954 CB CHEBI:9342
DMEV954 DE Gout
DMXLT8C ID DMXLT8C
DMXLT8C DN Sulfisoxazole
DMXLT8C HS Approved
DMXLT8C SN Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole
DMXLT8C CP Hoffmann La Roche Inc
DMXLT8C TC Antiinfective Agents
DMXLT8C DT Small molecular drug
DMXLT8C PC 5344
DMXLT8C MW 267.31
DMXLT8C FM C11H13N3O3S
DMXLT8C IC InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
DMXLT8C CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
DMXLT8C IK NHUHCSRWZMLRLA-UHFFFAOYSA-N
DMXLT8C IU 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
DMXLT8C CA CAS 127-69-5
DMXLT8C CB CHEBI:102484
DMXLT8C DE Urinary tract infection
DM1YA7M ID DM1YA7M
DM1YA7M DN Sulfonamides
DM1YA7M HS Approved
DM1YA7M SN Sulfonamide Mixtures; Mixtures, Sulfonamide
DM1YA7M DT Small molecular drug
DM1YA7M PC 91392493
DM1YA7M MW 347.4
DM1YA7M FM C17H17NO5S
DM1YA7M IC InChI=1S/C17H17NO5S/c1-2-23-17(20)12-18(16-11-7-6-8-14(16)13-19)24(21,22)15-9-4-3-5-10-15/h3-11,13H,2,12H2,1H3
DM1YA7M CS CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2
DM1YA7M IK DFRPGUIKXDWHSA-UHFFFAOYSA-N
DM1YA7M IU ethyl 2-[N-(benzenesulfonyl)-2-formylanilino]acetate
DM1YA7M DE Bacterial infection
DMAYX6P ID DMAYX6P
DMAYX6P DN Sulfoxone
DMAYX6P HS Approved
DMAYX6P SN Aldapsone; Aldesulfon; Diamidin; Diason; Diazon; Novotrone; Adesulfone sodium; Diasone sodium enterab; Sodium aldesulphone; Sodium sulfoxone; [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid; [sulfonylbis(4,1-phenyleneimino)]dimethanesulfinic acid
DMAYX6P CP Abbvie Inc
DMAYX6P TC Antibiotics
DMAYX6P DT Small molecular drug
DMAYX6P PC 5351
DMAYX6P MW 404.5
DMAYX6P FM C14H16N2O6S3
DMAYX6P IC InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)
DMAYX6P CS C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O
DMAYX6P IK NEDPPCHNEOMTJV-UHFFFAOYSA-N
DMAYX6P IU [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid
DMAYX6P CA CAS 144-76-3
DMAYX6P CB CHEBI:135651
DMAYX6P DE Dermatitis herpetiformis
DM2QHZU ID DM2QHZU
DM2QHZU DN Sulindac
DM2QHZU HS Approved
DM2QHZU SN Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
DM2QHZU CP Merck & Co
DM2QHZU TC Antiinflammatory Agents
DM2QHZU DT Small molecular drug
DM2QHZU PC 1548887
DM2QHZU MW 356.4
DM2QHZU FM C20H17FO3S
DM2QHZU IC InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DM2QHZU CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
DM2QHZU IK MLKXDPUZXIRXEP-MFOYZWKCSA-N
DM2QHZU IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
DM2QHZU CA CAS 38194-50-2
DM2QHZU CB CHEBI:9352
DM2QHZU DE Rheumatoid arthritis
DMNUC42 ID DMNUC42
DMNUC42 DN Sulodexide
DMNUC42 HS Approved
DMNUC42 TC Antithrombotic Agents
DMNUC42 PC 6453528
DMNUC42 MW 295.29
DMNUC42 FM C12H17N5O4
DMNUC42 IC InChI=1S/C12H17N5O4/c1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(20-2)8(19)6(3-18)21-12/h4-6,8-9,12,18-19H,3H2,1-2H3,(H,13,14,15)/t6-,8-,9-,12-/m1/s1
DMNUC42 CS CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OC
DMNUC42 IK GRYSXUXXBDSYRT-WOUKDFQISA-N
DMNUC42 IU (2R,3R,4R,5R)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol
DMNUC42 CA CAS 57817-83-1
DMNUC42 DE Tinnitus
DMZI2UF ID DMZI2UF
DMZI2UF DN Sulphadoxine
DMZI2UF HS Approved
DMZI2UF SN 2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653
DMZI2UF DT Small molecular drug
DMZI2UF PC 17134
DMZI2UF MW 310.33
DMZI2UF FM C12H14N4O4S
DMZI2UF IC InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
DMZI2UF CS COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
DMZI2UF IK PJSFRIWCGOHTNF-UHFFFAOYSA-N
DMZI2UF IU 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
DMZI2UF CA CAS 2447-57-6
DMZI2UF CB CHEBI:9329
DMZI2UF DE Malaria
DMF54ZG ID DMF54ZG
DMF54ZG DN Sulpiride
DMF54ZG HS Approved
DMF54ZG SN Abilit; Aiglonyl; Alimoral; Arminol; Calmoflorine; Championyl; Coolspan; Darleton; Deponerton; Desisulpid; Desmenat; Digton; Dobren; Dogmatil; Dogmatyl; Dolmatil; Dresent; Eglonil; Eglonyl; Ekilid; Enimon; Equilid; Eusulpid; Fardalan; Fidelan; Guastil; Isnamide; Kylistro; Lebopride; Levobren; Levopraid; Levosulpirida; Levosulpiridum; Lisopiride; Mariastel; Meresa; Miradol; Mirbanil; Misulvan; Neogama; Norestran; Normum; Nufarol; Omiryl; Omperan; Ozoderpin; Pontiride; Psicocen; Pyrikappl; Pyrkappl; Restful; Sernevin; Splotin; Stamonevrol; Sulp; Sulperide; Sulpirid; Sulpirida; Sulpiridum; Sulpitil; Sulpivert; Sulpor; Sulpride; Sulpyrid; Suprium; Sursumid; Synedil; Tepavil; Valirem; Zemorcon; Allphar Brand of Sulpiride; Almirall Brand of Sulpiride; Areu Brand of Sulpiride; Centrum Brand of Sulpiride; Desitin Brand of Sulpiride; Dolorgiet Brand of Sulpiride; Erempharma Brand of Sulpiride; Fumouzer Brand of Sulpiride; Hennig Brand of Sulpiride; Hexal Brand of Sulpiride; Hoechst Brand of Sulpiride; Hormosan Brand of Sulpiride; Krewel Brand of Sulpiride; Levosulpiride [INN]; Magnetic resonance imaging sulpiride; Pharmacia Brand of Sulpiride; Psicofarma Brand of Sulpiride; Rosemont Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Spyfarma Brand of Sulpiride; Uriach Brand of Sulpiride; Vertigo Meresa; Vertigo neogama; RD 1403; S 8010; Bosnyl (TN); Dogmatil (TN); Dogmatyl (TN); Eglonyl (TN); Levosulpirida [INN-Spanish]; Levosulpiridum [INN-Latin]; Meresa (TN); Neuraxpharm (TN); RV-12309; Ratiopharm (TN); Sanofi-Synthelabo Brand of Sulpiride; Sulpirid (TN); Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpiryd (TN); Vertigo-Meresa; Vertigo-neogama; R. D. 1403; R.D. 1403; Sulpiride (JP15/USAN/INN); Sulpiride [USAN:INN:BAN:JAN]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (+/-)-Sulpiride; (RS)-(+/-)-sulpiride; (inverted question mark)-Sulpiride
DMF54ZG CP Arrow Generics
DMF54ZG TC Antipsychotic Agents
DMF54ZG DT Small molecular drug
DMF54ZG PC 5355
DMF54ZG MW 341.4
DMF54ZG FM C15H23N3O4S
DMF54ZG IC InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
DMF54ZG CS CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
DMF54ZG IK BGRJTUBHPOOWDU-UHFFFAOYSA-N
DMF54ZG IU N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
DMF54ZG CA CAS 15676-16-1
DMF54ZG CB CHEBI:32168
DMF54ZG DE Schizophrenia
DMVYXR8 ID DMVYXR8
DMVYXR8 DN Sumatriptan
DMVYXR8 HS Approved
DMVYXR8 SN Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
DMVYXR8 CP GlaxoSmithKline
DMVYXR8 TC Vasoconstrictor Agents
DMVYXR8 DT Small molecular drug
DMVYXR8 PC 5358
DMVYXR8 MW 295.4
DMVYXR8 FM C14H21N3O2S
DMVYXR8 IC InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
DMVYXR8 CS CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
DMVYXR8 IK KQKPFRSPSRPDEB-UHFFFAOYSA-N
DMVYXR8 IU 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DMVYXR8 CA CAS 103628-46-2
DMVYXR8 CB CHEBI:10650
DMVYXR8 DE Migraine
DMCBJSR ID DMCBJSR
DMCBJSR DN Sunitinib
DMCBJSR HS Approved
DMCBJSR SN Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
DMCBJSR CP Pfizer
DMCBJSR TC Anticancer Agents
DMCBJSR DT Small molecular drug
DMCBJSR PC 5329102
DMCBJSR MW 398.5
DMCBJSR FM C22H27FN4O2
DMCBJSR IC InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DMCBJSR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
DMCBJSR IK WINHZLLDWRZWRT-ATVHPVEESA-N
DMCBJSR IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMCBJSR CA CAS 557795-19-4
DMCBJSR CB CHEBI:38940
DMCBJSR DE Gastrointestinal stromal tumour; Gastrointestinal cancer
DMN8E5D ID DMN8E5D
DMN8E5D DN Sunitinib malate
DMN8E5D HS Approved
DMN8E5D SN (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73
DMN8E5D TC Anticancer Agents
DMN8E5D DT Small molecular drug
DMN8E5D PC 6456015
DMN8E5D MW 532.569
DMN8E5D FM C26H33FN4O7
DMN8E5D IC InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1
DMN8E5D CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
DMN8E5D IK LBWFXVZLPYTWQI-IPOVEDGCSA-N
DMN8E5D IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
DMN8E5D CA CAS 341031-54-7
DMN8E5D DE Gastrointestinal stromal tumor; Renal cell carcinoma
DMOGREH ID DMOGREH
DMOGREH DN Suplatast tosilate
DMOGREH HS Approved
DMOGREH SN IPD; IPD-1151T; YM-672
DMOGREH CP Taiho Pharmaceutical Co Ltd
DMOGREH DT Small molecular drug
DMOGREH PC 71773
DMOGREH MW 499.6
DMOGREH FM C23H33NO7S2
DMOGREH IC InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10)
DMOGREH CS CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DMOGREH IK RYVJQEZJUFRANT-UHFFFAOYSA-N
DMOGREH IU [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate
DMOGREH CA CAS 94055-76-2
DMOGREH DE Allergy
DMKXJZ7 ID DMKXJZ7
DMKXJZ7 DN Suprofen
DMKXJZ7 HS Approved
DMKXJZ7 SN Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure
DMKXJZ7 TC Antiinflammatory Agents
DMKXJZ7 DT Small molecular drug
DMKXJZ7 PC 5359
DMKXJZ7 MW 260.31
DMKXJZ7 FM C14H12O3S
DMKXJZ7 IC InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
DMKXJZ7 CS CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O
DMKXJZ7 IK MDKGKXOCJGEUJW-UHFFFAOYSA-N
DMKXJZ7 IU 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
DMKXJZ7 CA CAS 40828-46-4
DMKXJZ7 CB CHEBI:9362
DMKXJZ7 DE Miosis
DM0E6S3 ID DM0E6S3
DM0E6S3 DN Suvorexant
DM0E6S3 HS Approved
DM0E6S3 SN Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
DM0E6S3 DT Small molecular drug
DM0E6S3 PC 24965990
DM0E6S3 MW 450.9
DM0E6S3 FM C23H23ClN6O2
DM0E6S3 IC InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
DM0E6S3 CS C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
DM0E6S3 IK JYTNQNCOQXFQPK-MRXNPFEDSA-N
DM0E6S3 IU [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
DM0E6S3 CA CAS 1030377-33-3
DM0E6S3 CB CHEBI:82698
DM0E6S3 DE Insomnia
DM6S0HB ID DM6S0HB
DM6S0HB DN TachoComb
DM6S0HB HS Approved
DM6S0HB SN Collagen fleece, Nycomed; Collagen fleece, Torii; TO-193; Fibrin/thrombin/aprotinin collagen fleece, Nycomed/Torii
DM6S0HB CP Nycomed
DM6S0HB DE Wound healing
DM51FY6 ID DM51FY6
DM51FY6 DN Tacrine
DM51FY6 HS Approved
DM51FY6 SN Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine
DM51FY6 TC Parasympathomimetics
DM51FY6 DT Small molecular drug
DM51FY6 PC 1935
DM51FY6 MW 198.26
DM51FY6 FM C13H14N2
DM51FY6 IC InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
DM51FY6 CS C1CCC2=NC3=CC=CC=C3C(=C2C1)N
DM51FY6 IK YLJREFDVOIBQDA-UHFFFAOYSA-N
DM51FY6 IU 1,2,3,4-tetrahydroacridin-9-amine
DM51FY6 CA CAS 321-64-2
DM51FY6 CB CHEBI:45980
DM51FY6 DE Alzheimer disease
DMZ7XNQ ID DMZ7XNQ
DMZ7XNQ DN Tacrolimus
DMZ7XNQ HS Approved
DMZ7XNQ SN Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
DMZ7XNQ CP Fujisawa; Sucampo
DMZ7XNQ TC Immunosuppressive Agents
DMZ7XNQ DT Small molecular drug
DMZ7XNQ PC 445643
DMZ7XNQ MW 804
DMZ7XNQ FM C44H69NO12
DMZ7XNQ IC InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZ7XNQ CS C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
DMZ7XNQ IK QJJXYPPXXYFBGM-LFZNUXCKSA-N
DMZ7XNQ IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZ7XNQ CA CAS 104987-11-3
DMZ7XNQ CB CHEBI:61049
DMZ7XNQ DE Organ transplant rejection; Ocular allergy
DMJZHT1 ID DMJZHT1
DMJZHT1 DN Tadalafil
DMJZHT1 HS Approved
DMJZHT1 SN ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
DMJZHT1 CP Eli Lilly
DMJZHT1 TC Antiimpotence Agents
DMJZHT1 DT Small molecular drug
DMJZHT1 PC 110635
DMJZHT1 MW 389.4
DMJZHT1 FM C22H19N3O4
DMJZHT1 IC InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
DMJZHT1 CS CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
DMJZHT1 IK WOXKDUGGOYFFRN-IIBYNOLFSA-N
DMJZHT1 IU (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
DMJZHT1 CA CAS 171596-29-5
DMJZHT1 CB CHEBI:71940
DMJZHT1 DE Erectile dysfunction
DM1XT4N ID DM1XT4N
DM1XT4N DN Tafenoquine
DM1XT4N HS Approved
DM1XT4N SN 106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN
DM1XT4N CP Medicines for Malaria Venture/GlaxoSmithKline
DM1XT4N DT Small molecular drug
DM1XT4N PC 115358
DM1XT4N MW 463.5
DM1XT4N FM C24H28F3N3O3
DM1XT4N IC InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3
DM1XT4N CS CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
DM1XT4N IK LBHLFPGPEGDCJG-UHFFFAOYSA-N
DM1XT4N IU 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
DM1XT4N CA CAS 106635-80-7
DM1XT4N CB CHEBI:141487
DM1XT4N DE Plasmodium vivax malaria; Malaria
DMFC41K ID DMFC41K
DMFC41K DN Tafluprost
DMFC41K HS Approved
DMFC41K SN Zioptan (TN)
DMFC41K CP Merck
DMFC41K DT Small molecular drug
DMFC41K PC 9868491
DMFC41K MW 452.5
DMFC41K FM C25H34F2O5
DMFC41K IC InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1
DMFC41K CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O
DMFC41K IK WSNODXPBBALQOF-VEJSHDCNSA-N
DMFC41K IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
DMFC41K CA CAS 209860-87-7
DMFC41K CB CHEBI:66899
DMFC41K DE Glaucoma/ocular hypertension
DM9HQ5U ID DM9HQ5U
DM9HQ5U DN Tagraxofusp
DM9HQ5U HS Approved
DM9HQ5U SN Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DM9HQ5U CP Stemline Therapeutics
DM9HQ5U DE Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia
DM1KS78 ID DM1KS78
DM1KS78 DN Talazoparib
DM1KS78 HS Approved
DM1KS78 SN Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ
DM1KS78 CP Pfizer
DM1KS78 DT Small molecular drug
DM1KS78 PC 135565082
DM1KS78 MW 380.4
DM1KS78 FM C19H14F2N6O
DM1KS78 IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM1KS78 CS CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DM1KS78 IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM1KS78 IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM1KS78 CA CAS 1207456-01-6
DM1KS78 DE Breast cancer; Psoriatic arthritis
DM2M3OC ID DM2M3OC
DM2M3OC DN Talazoparib
DM2M3OC HS Approved
DM2M3OC SN (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN]
DM2M3OC TC Poly (ADP-ribose) polymerase (PARP) inhibitor
DM2M3OC DT Small molecular drug
DM2M3OC PC 135565082
DM2M3OC MW 380.359
DM2M3OC FM C19H14F2N6O
DM2M3OC IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM2M3OC CS CN1C(=NC=N1)C2C(NC3=C4C2=NNC(=O)C4=CC(=C3)F)C5=CC=C(C=C5)F
DM2M3OC IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM2M3OC IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM2M3OC CA CAS 1207456-01-6
DM2M3OC DE Breast cancer
DM214Q8 ID DM214Q8
DM214Q8 DN Talbutal
DM214Q8 HS Approved
DM214Q8 SN Lotusate; Profundol; Talbumalum; Talbutale; Talbutalum; Talbutal [INN]; Talbutale [DCIT]; WIN 5095; Lotusate (TN); Sec-Butyl allylbarbituric acid; Talbutal (INN); Talbutalum [INN-Latin]; 5-(1-Methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-(1-methylpropyl) barbituric acid; 5-Allyl-5-sec-butylbarbituric acid; 5-Isobutyl-5-allylbarbituric acid; 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8 TC Hypnotics and Sedatives
DM214Q8 DT Small molecular drug
DM214Q8 PC 8275
DM214Q8 MW 224.26
DM214Q8 FM C11H16N2O3
DM214Q8 IC InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM214Q8 CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM214Q8 IK BJVVMKUXKQHWJK-UHFFFAOYSA-N
DM214Q8 IU 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8 CA CAS 115-44-6
DM214Q8 CB CHEBI:134923
DM214Q8 DE Irritability
DM3PZXN ID DM3PZXN
DM3PZXN DN Taliglucerase alfa
DM3PZXN HS Approved
DM3PZXN SN Elelyso (TN)
DM3PZXN CP Pfizer
DM3PZXN DE Metabolic disorder
DMKBW5C ID DMKBW5C
DMKBW5C DN Talimogene Laherparepvec
DMKBW5C HS Approved
DMKBW5C SN IMLYGIC
DMKBW5C CP Amgen
DMKBW5C TC Anticancer Agents
DMKBW5C DT Vaccine
DMKBW5C DE Melanoma
DMLB0EZ ID DMLB0EZ
DMLB0EZ DN Tamoxifen
DMLB0EZ HS Approved
DMLB0EZ SN tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
DMLB0EZ CP AstraZeneca plc
DMLB0EZ TC Anticancer Agents
DMLB0EZ DT Small molecular drug
DMLB0EZ PC 2733526
DMLB0EZ MW 371.5
DMLB0EZ FM C26H29NO
DMLB0EZ IC InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
DMLB0EZ CS CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMLB0EZ IK NKANXQFJJICGDU-QPLCGJKRSA-N
DMLB0EZ IU 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMLB0EZ CA CAS 10540-29-1
DMLB0EZ CB CHEBI:41774
DMLB0EZ DE Breast cancer
DM5QF9V ID DM5QF9V
DM5QF9V DN Tamsulosin
DM5QF9V HS Approved
DM5QF9V SN Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
DM5QF9V CP Yamanouchi Pharmaceuticals
DM5QF9V TC Anticancer Agents
DM5QF9V DT Small molecular drug
DM5QF9V PC 129211
DM5QF9V MW 408.5
DM5QF9V FM C20H28N2O5S
DM5QF9V IC InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
DM5QF9V CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
DM5QF9V IK DRHKJLXJIQTDTD-OAHLLOKOSA-N
DM5QF9V IU 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM5QF9V CA CAS 106133-20-4
DM5QF9V CB CHEBI:9398
DM5QF9V DE Benign prostatic hyperplasia
DMPHWU6 ID DMPHWU6
DMPHWU6 DN Tandospirone
DMPHWU6 HS Approved
DMPHWU6 SN Sediel (TN)
DMPHWU6 DT Small molecular drug
DMPHWU6 PC 91273
DMPHWU6 MW 383.5
DMPHWU6 FM C21H29N5O2
DMPHWU6 IC InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
DMPHWU6 CS C1C[C@H]2C[C@@H]1[C@H]3[C@@H]2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5
DMPHWU6 IK CEIJFEGBUDEYSX-FZDBZEDMSA-N
DMPHWU6 IU (1S,2R,6S,7R)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
DMPHWU6 CA CAS 87760-53-0
DMPHWU6 CB CHEBI:145673
DMPHWU6 DE Anxiety disorder
DMXLSH3 ID DMXLSH3
DMXLSH3 DN Tapentadol hydrochloride
DMXLSH3 HS Approved
DMXLSH3 SN Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL
DMXLSH3 CP Ortho-McNell Pharmaceutical
DMXLSH3 DT Small molecular drug
DMXLSH3 PC 9838021
DMXLSH3 MW 257.8
DMXLSH3 FM C14H24ClNO
DMXLSH3 IC InChI=1S/C14H23NO.ClH/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;/h6-9,11,14,16H,5,10H2,1-4H3;1H/t11-,14+;/m0./s1
DMXLSH3 CS CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C.Cl
DMXLSH3 IK ZELFLGGRLLOERW-YECZQDJWSA-N
DMXLSH3 IU 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride
DMXLSH3 CA CAS 175591-09-0
DMXLSH3 DE Acute pain
DMLOQ1V ID DMLOQ1V
DMLOQ1V DN Tasimelteon
DMLOQ1V HS Approved
DMLOQ1V SN Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393
DMLOQ1V CP Vanda Pharmaceuticals
DMLOQ1V DT Small molecular drug
DMLOQ1V PC 10220503
DMLOQ1V MW 245.32
DMLOQ1V FM C15H19NO2
DMLOQ1V IC InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
DMLOQ1V CS CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
DMLOQ1V IK PTOIAAWZLUQTIO-GXFFZTMASA-N
DMLOQ1V IU N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
DMLOQ1V CA CAS 609799-22-6
DMLOQ1V CB CHEBI:79042
DMLOQ1V DE Insomnia
DMM13DI ID DMM13DI
DMM13DI DN Tasosartan
DMM13DI HS Approved
DMM13DI SN Verdia; ANA-756; WAY-126756; Tasosartan (USAN/INN); WAY-ANA-756; 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one; 2,4-dimethyl-8-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one
DMM13DI TC Antihypertensive Agents
DMM13DI DT Small molecular drug
DMM13DI PC 60919
DMM13DI MW 411.5
DMM13DI FM C23H21N7O
DMM13DI IC InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)
DMM13DI CS CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMM13DI IK ADXGNEYLLLSOAR-UHFFFAOYSA-N
DMM13DI IU 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
DMM13DI CA CAS 145733-36-4
DMM13DI CB CHEBI:135666
DMM13DI DE Hypertension
DM3ED1A ID DM3ED1A
DM3ED1A DN Tavaborole
DM3ED1A HS Approved
DM3ED1A SN Kerydin; AN2690; AN-2690; AN-2690); SCH-900340; Topical antifungal (onychomycosis), Merck & Co; Trichophyton-targeting antifungal (onychomycosis), Merck & Co; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor; Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
DM3ED1A CP Anacor; Anacor Pharmaceuticals Inc
DM3ED1A DT Small molecular drug
DM3ED1A PC 11499245
DM3ED1A MW 151.93
DM3ED1A FM C7H6BFO2
DM3ED1A IC InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
DM3ED1A CS B1(C2=C(CO1)C=C(C=C2)F)O
DM3ED1A IK LFQDNHWZDQTITF-UHFFFAOYSA-N
DM3ED1A IU 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
DM3ED1A CA CAS 174671-46-6
DM3ED1A CB CHEBI:77942
DM3ED1A DE Onychomycosis
DMUOT9V ID DMUOT9V
DMUOT9V DN Taxol
DMUOT9V HS Approved
DMUOT9V SN C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
DMUOT9V DT Small molecular drug
DMUOT9V PC 36314
DMUOT9V MW 853.9
DMUOT9V FM C47H51NO14
DMUOT9V IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMUOT9V CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMUOT9V IK RCINICONZNJXQF-MZXODVADSA-N
DMUOT9V IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMUOT9V CA CAS 33069-62-4
DMUOT9V CB CHEBI:45863
DMUOT9V DE Gastric adenocarcinoma; Ovarian cancer; Solid tumour/cancer; Breast cancer; Pancreatic cancer
DM8SMD1 ID DM8SMD1
DM8SMD1 DN Tazarotene
DM8SMD1 HS Approved
DM8SMD1 SN Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
DM8SMD1 CP Allergan Pharmaceuticals
DM8SMD1 TC Dermatologic Agents
DM8SMD1 DT Small molecular drug
DM8SMD1 PC 5381
DM8SMD1 MW 351.5
DM8SMD1 FM C21H21NO2S
DM8SMD1 IC InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
DM8SMD1 CS CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
DM8SMD1 IK OGQICQVSFDPSEI-UHFFFAOYSA-N
DM8SMD1 IU ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
DM8SMD1 CA CAS 118292-40-3
DM8SMD1 CB CHEBI:32184
DM8SMD1 DE Psoriasis vulgaris
DMWP1BH ID DMWP1BH
DMWP1BH DN Tazemetostat
DMWP1BH HS Approved
DMWP1BH SN EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
DMWP1BH CP Epizyme
DMWP1BH DT Small molecular drug
DMWP1BH PC 66558664
DMWP1BH MW 572.7
DMWP1BH FM C34H44N4O4
DMWP1BH IC InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
DMWP1BH CS CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
DMWP1BH IK NSQSAUGJQHDYNO-UHFFFAOYSA-N
DMWP1BH IU N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide
DMWP1BH CA CAS 1403254-99-8
DMWP1BH DE Malignant rhabdoid tumour; Brain and central nervous system tumour; Diffuse large B-cell lymphoma; Mesothelioma; Solid tumour/cancer; Synovial sarcoma; Follicular lymphoma
DM3XNUI ID DM3XNUI
DM3XNUI DN Tazobactam
DM3XNUI HS Approved
DM3XNUI SN TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
DM3XNUI CP Gepach International
DM3XNUI TC Antiinfective Agents
DM3XNUI DT Small molecular drug
DM3XNUI PC 123630
DM3XNUI MW 300.29
DM3XNUI FM C10H12N4O5S
DM3XNUI IC InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
DM3XNUI CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
DM3XNUI IK LPQZKKCYTLCDGQ-WEDXCCLWSA-N
DM3XNUI IU (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM3XNUI CA CAS 89786-04-9
DM3XNUI CB CHEBI:9421
DM3XNUI DE Bacterial infection
DML6OE7 ID DML6OE7
DML6OE7 DN Tbo-Filgrastim
DML6OE7 HS Approved
DML6OE7 SN Neutroval (TN)
DML6OE7 CP Sicor Biotech
DML6OE7 DE Neutropenia
DMQ5S6C ID DMQ5S6C
DMQ5S6C DN Tebipenem pivoxil
DMQ5S6C HS Approved
DMQ5S6C SN 161715-24-8; Orapenem; TBPM-PI; L-084; ME1211; UNII-95AK1A52I8; LJC 11,084; 95AK1A52I8; LJC-11084; ME-1211; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; Tebipenempivoxil; Tebipenem [INN]; (4R,5S,6S)-(Pivaloyloxy)methyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)-; Tebipenem pivoxil (L-084); Tebipenem pivoxil(L-084); Orapenem (TN); (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester; MLS006011128; SCHEMBL305541; Tebipenem pivoxil [USAN:INN]; CHEMBL2107486; GTPL10864; DTXSID00167228; CHEBI:135799; EX-A1256; HY-B0396; WHO 7924; ZINC4217736; Tebipenem pivoxil (JAN/USAN/INN); 2748AH; CT0255; LJC 11084; MFCD17215369; s2159; AKOS015899532; CCG-269673; LJC-11,084; NCGC00346570-01; NCGC00346570-04; (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; [(4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carbonyloxy]methyl 2,2-dimethylpropanoate; AC-22712; AS-75334; L-084;ME1211; SMR004702908; L 084; D09598; AB01566835_01; Q1623593; (4R,5R,6S)-3-((1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy) methyl ester; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C CP Meiji Seika Pharma
DMQ5S6C DT Small molecular drug
DMQ5S6C PC 9892071
DMQ5S6C MW 497.6
DMQ5S6C FM C22H31N3O6S2
DMQ5S6C IC InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3/t11-,12-,14-,15-/m1/s1
DMQ5S6C CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O
DMQ5S6C IK SNUDIPVBUUXCDG-QHSBEEBCSA-N
DMQ5S6C IU 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C CA CAS 161715-24-8
DMQ5S6C CB CHEBI:135799
DMQ5S6C DE Respiratory tract infection
DMYQCWT ID DMYQCWT
DMYQCWT DN Tecartus
DMYQCWT HS Approved
DMYQCWT SN Brexucabtagene autoleucel; KTE-X19
DMYQCWT CP Gilead Sciences; Kite Pharma
DMYQCWT DT CAR T Cell Therapy
DMYQCWT DE Mantle cell lymphoma
DM2OVDT ID DM2OVDT
DM2OVDT DN Tecfidera
DM2OVDT HS Approved
DM2OVDT SN DIMETHYL FUMARATE
DM2OVDT CP Biogen Idec
DM2OVDT DT Small molecular drug
DM2OVDT PC 637568
DM2OVDT MW 144.12
DM2OVDT FM C6H8O4
DM2OVDT IC InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
DM2OVDT CS COC(=O)/C=C/C(=O)OC
DM2OVDT IK LDCRTTXIJACKKU-ONEGZZNKSA-N
DM2OVDT IU dimethyl (E)-but-2-enedioate
DM2OVDT CA CAS 624-49-7
DM2OVDT CB CHEBI:76004
DM2OVDT DE Multiple sclerosis
DMUEWM3 ID DMUEWM3
DMUEWM3 DN Technetium (99MTC) mebrofenin
DMUEWM3 HS Approved
DMUEWM3 SN F2NQ468L52; Glycine, N-(2-((3-bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)-, technetium-99Tc salt; Mebrofenin / 99Tc; Mebrofenin / technetium-99Tc; Mebrofenin mixture with technetium-99Tc; TECHNETIUM TC-99M MEBROFENIN KIT; Technetium (99Mtc) Mebrofenin; Technetium TC-99M mebrofenin kit; Technetium Tc 99m DISIDA; Technetium Tc 99m diisopropyl-iminodiacetic acid; Technetium Tc 99m mebrofenin; Technetium Tc-99m mebrofenin; UNII-F2NQ468L52
DMUEWM3 TC Diagnostic Radiopharmaceutical Agents
DMUEWM3 DT Small molecular drug
DMUEWM3 PC 11431716
DMUEWM3 MW 486.136
DMUEWM3 FM C15H19BrN2O5Tc
DMUEWM3 IC InChI=1S/C15H19BrN2O5.Tc/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/i;1+1
DMUEWM3 CS CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C.[Tc]
DMUEWM3 IK JLJSYHOPCNWUNE-IEOVAKBOSA-N
DMUEWM3 IU 2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid;technetium-99
DMUEWM3 CA CAS 1415247-71-0
DMUEWM3 DE Imaging of liver and gallbladder
DMW5ML9 ID DMW5ML9
DMW5ML9 DN Tecovirimat
DMW5ML9 HS Approved
DMW5ML9 SN Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R; 816458-31-8; F925RR824R; ST-246; TPOXX; Tecovirimat [USAN:INN]; SIGA 246
DMW5ML9 CP SIGA Technologies
DMW5ML9 PC 16124688
DMW5ML9 MW 376.3
DMW5ML9 FM C19H15F3N2O3
DMW5ML9 IC InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+
DMW5ML9 CS C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F
DMW5ML9 IK CSKDFZIMJXRJGH-VWLPUNTISA-N
DMW5ML9 IU N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
DMW5ML9 CA CAS 869572-92-9
DMW5ML9 DE Virus infection; Smallpox
DMG2SKR ID DMG2SKR
DMG2SKR DN Tedizolid
DMG2SKR HS Approved
DMG2SKR SN Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855
DMG2SKR CP Bayer HealthCare Pharmaceuticals
DMG2SKR DT Small molecular drug
DMG2SKR PC 11234049
DMG2SKR MW 370.3
DMG2SKR FM C17H15FN6O3
DMG2SKR IC InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
DMG2SKR CS CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F
DMG2SKR IK XFALPSLJIHVRKE-GFCCVEGCSA-N
DMG2SKR IU (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
DMG2SKR CA CAS 856866-72-3
DMG2SKR CB CHEBI:82717
DMG2SKR DE Skin infection
DMYOAKS ID DMYOAKS
DMYOAKS DN Teduglutide
DMYOAKS HS Approved
DMYOAKS SN Gattex (TN)
DMYOAKS CP NPS
DMYOAKS DT Small molecular drug
DMYOAKS SQ Protein sequence for teduglutide: HGDGSFSDEMNTILDNLAARDFINWLIQTKITD
DMYOAKS PC 16139605
DMYOAKS MW 3752.1
DMYOAKS FM C164H252N44O55S
DMYOAKS IC InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1
DMYOAKS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N
DMYOAKS IK CILIXQOJUNDIDU-ASQIGDHWSA-N
DMYOAKS IU (2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanedioic acid
DMYOAKS CA CAS 197922-42-2
DMYOAKS DE Short bowel syndrome
DM31ZQM ID DM31ZQM
DM31ZQM DN Tegafur
DM31ZQM HS Approved
DM31ZQM SN Tegafur (Fluoropyrimidine)
DM31ZQM DT Small molecular drug
DM31ZQM PC 5386
DM31ZQM MW 200.17
DM31ZQM FM C8H9FN2O3
DM31ZQM IC InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
DM31ZQM CS C1CC(OC1)N2C=C(C(=O)NC2=O)F
DM31ZQM IK WFWLQNSHRPWKFK-UHFFFAOYSA-N
DM31ZQM IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
DM31ZQM CA CAS 17902-23-7
DM31ZQM CB CHEBI:32188
DM31ZQM DE Solid tumour/cancer
DM3XYD1 ID DM3XYD1
DM3XYD1 DN Tegaserod
DM3XYD1 HS Approved
DM3XYD1 SN Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine
DM3XYD1 CP Novartis
DM3XYD1 DT Small molecular drug
DM3XYD1 PC 135409453
DM3XYD1 MW 301.39
DM3XYD1 FM C16H23N5O
DM3XYD1 IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
DM3XYD1 CS CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC
DM3XYD1 IK IKBKZGMPCYNSLU-RGVLZGJSSA-N
DM3XYD1 IU 1-[(E)-(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM3XYD1 CA CAS 145158-71-0
DM3XYD1 CB CHEBI:51043
DM3XYD1 DE Irritable bowel syndrome; Gastro-oesophageal reflux; Dyspepsia
DMAQ2LK ID DMAQ2LK
DMAQ2LK DN Teicoplanin
DMAQ2LK HS Approved
DMAQ2LK SN Targocid (TN)
DMAQ2LK CP Sanofi-Aventis
DMAQ2LK DT Small molecular drug
DMAQ2LK PC 133065662
DMAQ2LK MW 1879.7
DMAQ2LK FM C88H97Cl2N9O33
DMAQ2LK IC InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
DMAQ2LK CS CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O
DMAQ2LK IK BJNLLBUOHPVGFT-CAYRISATSA-N
DMAQ2LK IU (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid
DMAQ2LK CA CAS 61036-62-2
DMAQ2LK DE Bacterial infection
DMMRV29 ID DMMRV29
DMMRV29 DN Telaprevir
DMMRV29 HS Approved
DMMRV29 SN 402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; Telavic; VX-950(Telaprevir); LY-570310; UNII-655M5O3W0U; VRT-111950; CHEMBL231813; CHEBI:68595; 655M5O3W0U; S-Telaprevir; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
DMMRV29 DT Small molecular drug
DMMRV29 PC 3010818
DMMRV29 MW 679.8
DMMRV29 FM C36H53N7O6
DMMRV29 IC InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1
DMMRV29 CS CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5
DMMRV29 IK BBAWEDCPNXPBQM-GDEBMMAJSA-N
DMMRV29 IU (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
DMMRV29 CA CAS 402957-28-2
DMMRV29 CB CHEBI:68595
DMMRV29 DE Hepatitis C virus infection
DM58VQX ID DM58VQX
DM58VQX DN Telavancin
DM58VQX HS Approved
DM58VQX SN telavancinum; telavancina; telavancine; 372151-71-8; UNII-XK134822Z0; CHEBI:71229; XK134822Z0; Telavancin [INN]; HSDB 8194; AC1MIWRX; SCHEMBL8287015; CHEMBL507870; DB06402; LS-192933; T-1455; Telavancin, Antibiotic for Culture Media Use Only; Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
DM58VQX DT Small molecular drug
DM58VQX PC 3081362
DM58VQX MW 1755.6
DM58VQX FM C80H106Cl2N11O27P
DM58VQX IC InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1
DM58VQX CS CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C
DM58VQX IK ONUMZHGUFYIKPM-MXNFEBESSA-N
DM58VQX IU (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
DM58VQX CA CAS 372151-71-8
DM58VQX CB CHEBI:71229
DM58VQX DE Staphylococcus infection
DMSWUGE ID DMSWUGE
DMSWUGE DN Telbivudine
DMSWUGE HS Approved
DMSWUGE SN Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine
DMSWUGE CP Idenix
DMSWUGE TC Antiviral Agents
DMSWUGE DT Small molecular drug
DMSWUGE PC 159269
DMSWUGE MW 242.23
DMSWUGE FM C10H14N2O5
DMSWUGE IC InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
DMSWUGE CS CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O
DMSWUGE IK IQFYYKKMVGJFEH-CSMHCCOUSA-N
DMSWUGE IU 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSWUGE CA CAS 3424-98-4
DMSWUGE CB CHEBI:63624
DMSWUGE DE Hepatitis B virus infection
DMZ4P3A ID DMZ4P3A
DMZ4P3A DN Telithromycin
DMZ4P3A HS Approved
DMZ4P3A SN Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
DMZ4P3A CP Sanofi-Aventis
DMZ4P3A TC Antibiotics
DMZ4P3A DT Small molecular drug
DMZ4P3A PC 3002190
DMZ4P3A MW 812
DMZ4P3A FM C43H65N5O10
DMZ4P3A IC InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
DMZ4P3A CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
DMZ4P3A IK LJVAJPDWBABPEJ-PNUFFHFMSA-N
DMZ4P3A IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMZ4P3A CA CAS 191114-48-4
DMZ4P3A CB CHEBI:29688
DMZ4P3A DE Bacterial infection
DMS3GX2 ID DMS3GX2
DMS3GX2 DN Telmisartan
DMS3GX2 HS Approved
DMS3GX2 SN Kinzal; Kinzalmono; Micardis; Pritor; Abbott brand of telmisartan; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; BIBR 277; BIBR 277SE; BIBR-277; BIBR-277SE; Bay 68-9291; Micardis (TN); Telmisartan [USAN:INN]; YM-086; BIBR-277-SE; Telmisartan (JAN/USAN/INN); Micardis, Targit, Temax, BIBR277, Telmisartan; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
DMS3GX2 CP Boehringer Ingelheim
DMS3GX2 TC Antihypertensive Agents
DMS3GX2 DT Small molecular drug
DMS3GX2 PC 65999
DMS3GX2 MW 514.6
DMS3GX2 FM C33H30N4O2
DMS3GX2 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMS3GX2 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMS3GX2 IK RMMXLENWKUUMAY-UHFFFAOYSA-N
DMS3GX2 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMS3GX2 CA CAS 144701-48-4
DMS3GX2 CB CHEBI:9434
DMS3GX2 DE Hypertension
DMDIYFZ ID DMDIYFZ
DMDIYFZ DN Telotristat ethyl
DMDIYFZ HS Approved
DMDIYFZ SN Telotristat; Telotristat etiprate; LP-778902; LX-1032; LX-1606; Serotonin modulator (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon; Tryptophan hydroxylase inhibitor (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon
DMDIYFZ CP Lexicon Pharmaceuticals
DMDIYFZ DT Small molecular drug
DMDIYFZ PC 25181577
DMDIYFZ MW 575
DMDIYFZ FM C27H26ClF3N6O3
DMDIYFZ IC InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1
DMDIYFZ CS CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N
DMDIYFZ IK MDSQOJYHHZBZKA-GBXCKJPGSA-N
DMDIYFZ IU ethyl (2S)-2-amino-3-[4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate
DMDIYFZ CA CAS 1033805-22-9
DMDIYFZ DE Carcinoid syndrome diarrhea; Carcinoid syndrome
DM02A65 ID DM02A65
DM02A65 DN Temazepam
DM02A65 HS Approved
DM02A65 SN Cerepax; Crisonar; Dasuen; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; Lenal; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; Nocturne; Nomapam; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temador; Temaz; Temaze; Temazepamum; Temtabs; Tenox; AHP Brand of Temazepam; Alphapharm Brand of Temazepam; Apo Temazepam; Apotex Brand of Temazepam; Ct Arzneimittel Brand of Temazepam; Desitin Brand of Temazepam; Gen Temazepam; Genopharm Brand of Temazepam; Genpharm Brand of Temazepam; ICN Brand of Temazepam; Katwijk Brand of Temazepam; Knoll Brand of Temazepam; Mallinckrodt Brand of Temazepam; Neodorm SP; Norkotral Tema; Norton Brand of Temazepam; Novartis Brand of Temazepam; Novo Temazepam; Novopharm Brand of Temazepam; Nu Pharm Brand of Temazepam; Nu Temazepam; Orion Brand of Temazepam; PMS Temazepam; Pharmascience Brand of Temazepam; Pronervon T; Scheffler Brand of Temazepam; Sigma Brand of Temazepam; Temazep von ct; Uvamin Retard; Wyeth Brand of Temazepam; ER 115; K3917; Pfizer Brand 1 of Temazepam; Pfizer Brand 2 of Temazepam; Ro 5 5345; Ro55345; SaH 47 603; SaH 47603; WY 2917; WY 3917; WY3917; Apo-Temazepam; Ct-Arzneimittel Brand of Temazepam; Euhypnos (TN); Gen-Temazepam; K-3917; N-Methyloxazepam; Norkotral (TN); Normison (TN); Novo-Temazepam; Nu-Pharm Brand of Temazepam; Nu-Temazepam; PMS-Temazepam; Remestan (TN); Restoril (TN); Ro 5-5345; SaH 47-603; Tema, Norkotral; Temazepam, pharmaceutical grade; Temazepamum [INN-Latin]; Temtabs (TN); Tenox (TN); Wy-3917; Ro-5-5345; Temazepam (USP/INN); Temazepam [USAN:INN:BAN]; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3 Hydroxydiazepam; 3-Hydroxydiazepam; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65 CP Mylan Inc
DM02A65 TC Hypnotics and Sedatives
DM02A65 DT Small molecular drug
DM02A65 PC 5391
DM02A65 MW 300.74
DM02A65 FM C16H13ClN2O2
DM02A65 IC InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
DM02A65 CS CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3
DM02A65 IK SEQDDYPDSLOBDC-UHFFFAOYSA-N
DM02A65 IU 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65 CA CAS 846-50-4
DM02A65 CB CHEBI:9435
DM02A65 DE Insomnia
DM1A79H ID DM1A79H
DM1A79H DN Temocapril
DM1A79H HS Approved
DM1A79H SN Temocapril; Temocaprilum; 2-((2S,6R)-6-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid; UNII-18IZ008EU6; 18IZ008EU6; Temocapril [INN:BAN]; Temocaprilum [INN-Latin]; C23H28N2O5S2; 2-((2S,6R)-6-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)-5-OXO-2-(THIOPHEN-2-YL)-1,4-THIAZEPAN-4-YL)ACETIC ACID; (2S-(2alpha,6beta(R*)))-6-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; Temocapril (INN); AC1L9FDI
DM1A79H PC 443874
DM1A79H MW 476.6
DM1A79H FM C23H28N2O5S2
DM1A79H IC InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
DM1A79H CS CCOC(=O)C(CCC1=CC=CC=C1)NC2CSC(CN(C2=O)CC(=O)O)C3=CC=CS3
DM1A79H IK FIQOFIRCTOWDOW-BJLQDIEVSA-N
DM1A79H IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
DM1A79H CA CAS 111902-57-9
DM1A79H CB CHEBI:135771
DM1A79H DE High blood pressure
DM0JXFL ID DM0JXFL
DM0JXFL DN Temocapril hydrochloride
DM0JXFL HS Approved
DM0JXFL SN Acecol (TN)
DM0JXFL CP Sankyo
DM0JXFL DT Small molecular drug
DM0JXFL PC 443873
DM0JXFL MW 513.1
DM0JXFL FM C23H29ClN2O5S2
DM0JXFL IC InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1
DM0JXFL CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl
DM0JXFL IK XDDQNOKKZKHBIX-ASBZXGSUSA-N
DM0JXFL IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;hydrochloride
DM0JXFL CA CAS 110221-44-8
DM0JXFL CB CHEBI:32190
DM0JXFL DE Cardiovascular disease
DMNX2QI ID DMNX2QI
DMNX2QI DN Temocaprilate
DMNX2QI HS Approved
DMNX2QI SN (+)-(2S,6R)-6-(((1S)-1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; 2-(4-Carboxymethyl-5-oxo-2-thiophen-2-yl-[1,4]thiazepan-6-ylamino)-4-phenyl-butyric acid; 2D6A12Q12R; AC1L9E45; AJ-48035; AK116088; AKOS016010295; API0000849; AX8152551; BDBM50024710; O437; RNH 5139; RNH-5139; RS 5139; RS-5139; RT-015901; SCHEMBL498916; TL8000320; Temocapril Diacid; Temocaprilat; Temocaprilat [INN:BAN]; ZINC4099102; temocaprilate
DMNX2QI PC 443151
DMNX2QI MW 448.552
DMNX2QI FM C21H24N2O5S2
DMNX2QI IC InChI=1S/C21H24N2O5S2/c24-19(25)12-23-11-18(17-7-4-10-29-17)30-13-16(20(23)26)22-15(21(27)28)9-8-14-5-2-1-3-6-14/h1-7,10,15-16,18,22H,8-9,11-13H2,(H,24,25)(H,27,28)/t15-,16-,18-/m0/s1
DMNX2QI CS C1C(SCC(C(=O)N1CC(=O)O)NC(CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3
DMNX2QI IK KZVWEOXAPZXAFB-BQFCYCMXSA-N
DMNX2QI IU (2S)-2-[[(2S,6R)-4-(carboxymethyl)-5-oxo-2-thiophen-2-yl-1,4-thiazepan-6-yl]amino]-4-phenylbutanoic acid
DMNX2QI CA CAS 110221-53-9
DMNX2QI CB CHEBI:9436
DMNX2QI DE High blood pressure
DMKECZD ID DMKECZD
DMKECZD DN Temozolomide
DMKECZD HS Approved
DMKECZD SN Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ
DMKECZD CP Schering-Plough
DMKECZD TC Anticancer Agents
DMKECZD DT Small molecular drug
DMKECZD PC 5394
DMKECZD MW 194.15
DMKECZD FM C6H6N6O2
DMKECZD IC InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
DMKECZD CS CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
DMKECZD IK BPEGJWRSRHCHSN-UHFFFAOYSA-N
DMKECZD IU 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
DMKECZD CA CAS 85622-93-1
DMKECZD CB CHEBI:72564
DMKECZD DE Grade IV astrocytoma
DMS104F ID DMS104F
DMS104F DN Temsirolimus
DMS104F HS Approved
DMS104F SN Torisel
DMS104F CP Wyeth
DMS104F DT Small molecular drug
DMS104F PC 6918289
DMS104F MW 1030.3
DMS104F FM C56H87NO16
DMS104F IC InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
DMS104F CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC
DMS104F IK CBPNZQVSJQDFBE-FUXHJELOSA-N
DMS104F IU [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DMS104F CA CAS 162635-04-3
DMS104F CB CHEBI:79699
DMS104F DE Renal cell carcinoma
DMCOZJY ID DMCOZJY
DMCOZJY DN Tenapanor
DMCOZJY HS Approved
DMCOZJY SN 1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
DMCOZJY CP AstraZeneca
DMCOZJY DT Small molecular drug
DMCOZJY PC 71587953
DMCOZJY MW 1145
DMCOZJY FM C50H66Cl4N8O10S2
DMCOZJY IC InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
DMCOZJY CS CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
DMCOZJY IK DNHPDWGIXIMXSA-CXNSMIOJSA-N
DMCOZJY IU 1-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea
DMCOZJY CA CAS 1234423-95-0
DMCOZJY DE Kidney disease; Constipation; Irritable bowel syndrome
DMJYN25 ID DMJYN25
DMJYN25 DN Tenecteplase
DMJYN25 HS Approved
DMJYN25 SN Tnkase; Tnkase (TN); Tenecteplase (USAN/INN)
DMJYN25 TC Thrombolytic Agents
DMJYN25 SQ DB00031 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMJYN25 DE Myocardial infarction
DMLW57T ID DMLW57T
DMLW57T DN Teniposide
DMLW57T HS Approved
DMLW57T SN PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
DMLW57T TC Anticancer Agents
DMLW57T DT Small molecular drug
DMLW57T PC 452548
DMLW57T MW 656.7
DMLW57T FM C32H32O13S
DMLW57T IC InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
DMLW57T CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O
DMLW57T IK NRUKOCRGYNPUPR-QBPJDGROSA-N
DMLW57T IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMLW57T CA CAS 29767-20-2
DMLW57T DE Acute lymphoblastic leukaemia
DM1IS6U ID DM1IS6U
DM1IS6U DN Tenofovir
DM1IS6U HS Approved
DM1IS6U SN Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA
DM1IS6U CP Gilead Sciences
DM1IS6U TC Anti-HIV Agents
DM1IS6U DT Small molecular drug
DM1IS6U PC 464205
DM1IS6U MW 287.21
DM1IS6U FM C9H14N5O4P
DM1IS6U IC InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
DM1IS6U CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
DM1IS6U IK SGOIRFVFHAKUTI-ZCFIWIBFSA-N
DM1IS6U IU [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
DM1IS6U CA CAS 147127-20-6
DM1IS6U CB CHEBI:63625
DM1IS6U DE Human immunodeficiency virus infection
DMTQF4A ID DMTQF4A
DMTQF4A DN Tenofovir alafenamide
DMTQF4A HS Approved
DMTQF4A SN Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy; Tenofovir; UNII-W4HFE001U5; W4HFE001U5; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-[2-(Phosphonomethoxy)propyl]adenine; (R)-PMPA; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; 147127-20-6; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Apropovir; CHEBI:63625; D,L-Tenofovir; GS-1278; PMPA; PMPA gel; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; 379270-37-8; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE
DMTQF4A PC 9574768
DMTQF4A MW 476.5
DMTQF4A FM C21H29N6O5P
DMTQF4A IC LDEKQSIMHVQZJK-CAQYMETFSA-N
DMTQF4A CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3
DMTQF4A IK 1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMTQF4A IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMTQF4A CA CAS 379270-37-8
DMTQF4A CB CHEBI:90926
DMTQF4A DE Viral hepatitis
DMSY4ZG ID DMSY4ZG
DMSY4ZG DN Tenofovir disoproxil fumarate
DMSY4ZG HS Approved
DMSY4ZG SN Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread
DMSY4ZG TC Antiinfective Agents
DMSY4ZG DT Small molecular drug
DMSY4ZG PC 6398764
DMSY4ZG MW 635.5
DMSY4ZG FM C23H34N5O14P
DMSY4ZG IC InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
DMSY4ZG CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\\C(=O)O
DMSY4ZG IK VCMJCVGFSROFHV-WZGZYPNHSA-N
DMSY4ZG IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid
DMSY4ZG CA CAS 202138-50-9
DMSY4ZG CB CHEBI:63718
DMSY4ZG DE Discovery agent
DMVAZP9 ID DMVAZP9
DMVAZP9 DN Tenoxicam
DMVAZP9 HS Approved
DMVAZP9 SN Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
DMVAZP9 CP Roche Laboratories Inc
DMVAZP9 TC Antiinflammatory Agents
DMVAZP9 DT Small molecular drug
DMVAZP9 PC 54677971
DMVAZP9 MW 337.4
DMVAZP9 FM C13H11N3O4S2
DMVAZP9 IC InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
DMVAZP9 CS CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3
DMVAZP9 IK LZNWYQJJBLGYLT-UHFFFAOYSA-N
DMVAZP9 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMVAZP9 CA CAS 59804-37-4
DMVAZP9 CB CHEBI:32192
DMVAZP9 DE Rheumatoid arthritis
DMUQ0E8 ID DMUQ0E8
DMUQ0E8 DN Tepotinib
DMUQ0E8 HS Approved
DMUQ0E8 SN 1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
DMUQ0E8 CP EMD Serono
DMUQ0E8 DT Small molecular drug
DMUQ0E8 PC 25171648
DMUQ0E8 MW 492.6
DMUQ0E8 FM C29H28N6O2
DMUQ0E8 IC InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
DMUQ0E8 CS CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
DMUQ0E8 IK AHYMHWXQRWRBKT-UHFFFAOYSA-N
DMUQ0E8 IU 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
DMUQ0E8 CA CAS 1100598-32-0
DMUQ0E8 DE Solid tumour/cancer; Hepatocellular carcinoma; Non-small cell lung cancer
DM4L59B ID DM4L59B
DM4L59B DN Teprotumumab
DM4L59B HS Approved
DM4L59B SN RV001
DM4L59B CP River vision
DM4L59B DE Diabetic macular edema; Graves disease
DM3JCVS ID DM3JCVS
DM3JCVS DN Terazosin
DM3JCVS HS Approved
DM3JCVS SN Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
DM3JCVS CP Abbott Laboratories
DM3JCVS TC Anticancer Agents
DM3JCVS DT Small molecular drug
DM3JCVS PC 5401
DM3JCVS MW 387.4
DM3JCVS FM C19H25N5O4
DM3JCVS IC InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
DM3JCVS CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
DM3JCVS IK VCKUSRYTPJJLNI-UHFFFAOYSA-N
DM3JCVS IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
DM3JCVS CA CAS 63590-64-7
DM3JCVS CB CHEBI:9445
DM3JCVS DE Benign prostatic hyperplasia
DMI6HUW ID DMI6HUW
DMI6HUW DN Terbinafine
DMI6HUW HS Approved
DMI6HUW SN Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
DMI6HUW CP Celtic Pharma
DMI6HUW TC Antifungal Agents
DMI6HUW DT Small molecular drug
DMI6HUW PC 1549008
DMI6HUW MW 291.4
DMI6HUW FM C21H25N
DMI6HUW IC InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
DMI6HUW CS CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
DMI6HUW IK DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DMI6HUW IU (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
DMI6HUW CA CAS 91161-71-6
DMI6HUW CB CHEBI:9448
DMI6HUW DE Fungal infection; Onychomycosis
DMD4381 ID DMD4381
DMD4381 DN Terbutaline
DMD4381 HS Approved
DMD4381 SN Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
DMD4381 CP Ben Venue Laboratories
DMD4381 TC Bronchodilator Agents
DMD4381 DT Small molecular drug
DMD4381 PC 5403
DMD4381 MW 225.28
DMD4381 FM C12H19NO3
DMD4381 IC InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
DMD4381 CS CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
DMD4381 IK XWTYSIMOBUGWOL-UHFFFAOYSA-N
DMD4381 IU 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
DMD4381 CA CAS 23031-25-6
DMD4381 CB CHEBI:9449
DMD4381 DE Asthma
DMVPWLZ ID DMVPWLZ
DMVPWLZ DN Terbutyline
DMVPWLZ HS Approved
DMVPWLZ DE Hypertension
DMJ13KI ID DMJ13KI
DMJ13KI DN Terconazole
DMJ13KI HS Approved
DMJ13KI SN Fungistat; Terazol; Terconazol; Terconazolum; Tercospor; Triaconazole; Zazole; R 42470; Terazol 3; Terazol 7; Terazol 73; Tetrazol 3; Tetrazol 7; Gyno-Terazol; R 42,470; R-42470; Terazol 3 (TN); Terazol 7 & 3; Terazol Cream & Suppositories; Terconazol [INN-Spanish]; Terconazolum [INN-Latin]; Terconazole (USAN/INN); Terconazole [USAN:INN:BAN]; Cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI TC Antifungal Agents
DMJ13KI DT Small molecular drug
DMJ13KI PC 441383
DMJ13KI MW 532.5
DMJ13KI FM C26H31Cl2N5O3
DMJ13KI IC InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
DMJ13KI CS CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl
DMJ13KI IK BLSQLHNBWJLIBQ-OZXSUGGESA-N
DMJ13KI IU 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI CA CAS 67915-31-5
DMJ13KI CB CHEBI:82980
DMJ13KI DE Candidiasis
DMQ2FKJ ID DMQ2FKJ
DMQ2FKJ DN Teriflunomide
DMQ2FKJ HS Approved
DMQ2FKJ CP Sanofi-Aventis
DMQ2FKJ DT Small molecular drug
DMQ2FKJ PC 54684141
DMQ2FKJ MW 270.21
DMQ2FKJ FM C12H9F3N2O2
DMQ2FKJ IC InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
DMQ2FKJ CS C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O
DMQ2FKJ IK UTNUDOFZCWSZMS-YFHOEESVSA-N
DMQ2FKJ IU (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
DMQ2FKJ CA CAS 163451-81-8
DMQ2FKJ CB CHEBI:68540
DMQ2FKJ DE Hyperlipidaemia; Multiple sclerosis; Hepatitis B virus infection; Rheumatoid arthritis
DMMC45B ID DMMC45B
DMMC45B DN Teriparatide
DMMC45B HS Approved
DMMC45B SN Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)
DMMC45B CP Eli Lilly
DMMC45B TC Bone Density Conservation Agents
DMMC45B DT Peptide
DMMC45B SQ Parathyroid hormone precursor - Homo sapiens (1-34): SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF
DMMC45B PC 16133850
DMMC45B MW 4118
DMMC45B FM C181H291N55O51S2
DMMC45B IC InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1
DMMC45B CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N
DMMC45B IK OGBMKVWORPGQRR-UMXFMPSGSA-N
DMMC45B IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMMC45B CA CAS 52232-67-4
DMMC45B CB CHEBI:135983
DMMC45B DE Osteogenesis imperfecta; Psoriatic disorder
DMT9FH3 ID DMT9FH3
DMT9FH3 DN Terlipressin
DMT9FH3 HS Approved
DMT9FH3 SN Glypressin; Lucassin; Terlipressina; Terlipressine; Terlipressinum; Glypressin (TN); HS-2028; Terlipressin [BAN:INN]; Terlipressina [INN-Spanish]; Terlipressine [INN-French]; Terlipressinum [INN-Latin]; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
DMT9FH3 CP Ferring Pharmaceuticals
DMT9FH3 TC Vasoconstrictor Agents
DMT9FH3 DT Small molecular drug
DMT9FH3 PC 72081
DMT9FH3 MW 1227.4
DMT9FH3 FM C52H74N16O15S2
DMT9FH3 IC InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
DMT9FH3 CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMT9FH3 IK BENFXAYNYRLAIU-QSVFAHTRSA-N
DMT9FH3 IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DMT9FH3 CA CAS 14636-12-5
DMT9FH3 CB CHEBI:135905
DMT9FH3 DE Hypertension
DM2L3D5 ID DM2L3D5
DM2L3D5 DN Tertatolol
DM2L3D5 HS Approved
DM2L3D5 SN (-)-tertatolol; (+)-Tertatolol; GTPL64; ZINC748; PDSP2_001696; PDSP1_001713; 117305-34-7; UNII-9ZO341YQXP component HTWFXPCUFWKXOP-CYBMUJFWSA-N
DM2L3D5 DT Small molecular drug
DM2L3D5 PC 36920
DM2L3D5 MW 295.4
DM2L3D5 FM C16H25NO2S
DM2L3D5 IC InChI=1S/C16H25NO2S/c1-16(2,3)17-10-13(18)11-19-14-8-4-6-12-7-5-9-20-15(12)14/h4,6,8,13,17-18H,5,7,9-11H2,1-3H3
DM2L3D5 CS CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O
DM2L3D5 IK HTWFXPCUFWKXOP-UHFFFAOYSA-N
DM2L3D5 IU 1-(tert-butylamino)-3-(3,4-dihydro-2H-thiochromen-8-yloxy)propan-2-ol
DM2L3D5 CA CAS 83688-84-0
DM2L3D5 CB CHEBI:135244
DM2L3D5 DE Hypertension
DM9GP85 ID DM9GP85
DM9GP85 DN Tesamorelin
DM9GP85 HS Approved
DM9GP85 SN Egrifta (TN)
DM9GP85 CP Theratechnologies
DM9GP85 DT Small molecular drug
DM9GP85 PC 16137828
DM9GP85 MW 5136
DM9GP85 FM C221H366N72O67S
DM9GP85 IC InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1
DM9GP85 CS CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N
DM9GP85 IK QBEPNUQJQWDYKU-BMGKTWPMSA-N
DM9GP85 IU (4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9GP85 CA CAS 804475-66-9
DM9GP85 DE HIV-associated lipodystrophy
DMVY4GN ID DMVY4GN
DMVY4GN DN Testolactone
DMVY4GN HS Approved
DMVY4GN SN Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
DMVY4GN TC Anticancer Agents
DMVY4GN DT Small molecular drug
DMVY4GN PC 13769
DMVY4GN MW 300.4
DMVY4GN FM C19H24O3
DMVY4GN IC InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
DMVY4GN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C
DMVY4GN IK BPEWUONYVDABNZ-DZBHQSCQSA-N
DMVY4GN IU (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
DMVY4GN CA CAS 968-93-4
DMVY4GN CB CHEBI:9460
DMVY4GN DE Breast cancer
DM7HUNW ID DM7HUNW
DM7HUNW DN Testosterone
DM7HUNW HS Approved
DM7HUNW SN AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one
DM7HUNW CP Ardana Bioscience
DM7HUNW DT Small molecular drug
DM7HUNW PC 6013
DM7HUNW MW 288.4
DM7HUNW FM C19H28O2
DM7HUNW IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
DM7HUNW CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C
DM7HUNW IK MUMGGOZAMZWBJJ-DYKIIFRCSA-N
DM7HUNW IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DM7HUNW CA CAS 58-22-0
DM7HUNW CB CHEBI:17347
DM7HUNW DE Osteoporosis; Male hormonal deficiency; Hormone deficiency
DMC1TEV ID DMC1TEV
DMC1TEV DN Testosterone cypionate
DMC1TEV HS Approved
DMC1TEV SN Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE
DMC1TEV PC 441404
DMC1TEV MW 412.6
DMC1TEV FM C27H40O3
DMC1TEV IC HPFVBGJFAYZEBE-ZLQWOROUSA-N
DMC1TEV CS CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C
DMC1TEV IK 1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1
DMC1TEV IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DMC1TEV CA CAS 58-20-8
DMC1TEV CB CHEBI:9463
DMC1TEV DE Testosterone deficiency
DMB6871 ID DMB6871
DMB6871 DN Testosterone enanthate
DMB6871 HS Approved
DMB6871 SN Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD
DMB6871 PC 9416
DMB6871 MW 400.6
DMB6871 FM C26H40O3
DMB6871 IC VOCBWIIFXDYGNZ-IXKNJLPQSA-N
DMB6871 CS CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
DMB6871 IK 1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1
DMB6871 IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
DMB6871 CA CAS 315-37-7
DMB6871 CB CHEBI:9464
DMB6871 DE Testosterone deficiency
DMZO10Y ID DMZO10Y
DMZO10Y DN Testosterone Undecanoate
DMZO10Y HS Approved
DMZO10Y SN Restandol (TN)
DMZO10Y CP Organon Greece
DMZO10Y DT Small molecular drug
DMZO10Y PC 65157
DMZO10Y MW 456.7
DMZO10Y FM C30H48O3
DMZO10Y IC InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
DMZO10Y CS CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMZO10Y IK UDSFVOAUHKGBEK-CNQKSJKFSA-N
DMZO10Y IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
DMZO10Y CA CAS 5949-44-0
DMZO10Y CB CHEBI:135741
DMZO10Y DE Hypogonadism
DMYWQ0O ID DMYWQ0O
DMYWQ0O DN Tetrabenazine
DMYWQ0O HS Approved
DMYWQ0O SN Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O TC Nephropathic cystinosis therapy
DMYWQ0O DT Small molecular drug
DMYWQ0O PC 6018
DMYWQ0O MW 317.4
DMYWQ0O FM C19H27NO3
DMYWQ0O IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
DMYWQ0O CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
DMYWQ0O IK MKJIEFSOBYUXJB-UHFFFAOYSA-N
DMYWQ0O IU 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O CA CAS 718635-93-9
DMYWQ0O CB CHEBI:64028
DMYWQ0O DE Hyperkinetic movement disorder; Huntington disease
DM9J6C2 ID DM9J6C2
DM9J6C2 DN Tetracaine
DM9J6C2 HS Approved
DM9J6C2 SN Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
DM9J6C2 TC Anesthetics
DM9J6C2 DT Small molecular drug
DM9J6C2 PC 5411
DM9J6C2 MW 264.36
DM9J6C2 FM C15H24N2O2
DM9J6C2 IC InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
DM9J6C2 CS CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
DM9J6C2 IK GKCBAIGFKIBETG-UHFFFAOYSA-N
DM9J6C2 IU 2-(dimethylamino)ethyl 4-(butylamino)benzoate
DM9J6C2 CA CAS 94-24-6
DM9J6C2 CB CHEBI:9468
DM9J6C2 DE Spinal anesthesia; Pain
DMZA017 ID DMZA017
DMZA017 DN Tetracycline
DMZA017 HS Approved
DMZA017 SN Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide
DMZA017 CP Pfizer Inc
DMZA017 TC Antibiotics
DMZA017 DT Small molecular drug
DMZA017 PC 54675776
DMZA017 MW 444.4
DMZA017 FM C22H24N2O8
DMZA017 IC InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
DMZA017 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DMZA017 IK NWXMGUDVXFXRIG-WESIUVDSSA-N
DMZA017 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMZA017 CA CAS 60-54-8
DMZA017 CB CHEBI:27902
DMZA017 DE Bacterial infection
DMINZ4W ID DMINZ4W
DMINZ4W DN Tetrahydrobiopterin
DMINZ4W HS Approved
DMINZ4W SN tetrahydrobiopterin; 17528-72-2; 5,6,7,8-tetrahydrobiopterin; BRN 0544742; CHEBI:15372; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; 5,6,7,8-erythro-tetrahydrobiopterin; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; Dapropterin; Phenoptin
DMINZ4W TC Dietary supplement
DMINZ4W DT Small molecular drug
DMINZ4W PC 135402045
DMINZ4W MW 241.25
DMINZ4W FM C9H15N5O3
DMINZ4W IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)
DMINZ4W CS CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMINZ4W IK FNKQXYHWGSIFBK-UHFFFAOYSA-N
DMINZ4W IU 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMINZ4W CA CAS 17528-72-2
DMINZ4W CB CHEBI:15372
DMINZ4W DE Malnutrition
DMH15UV ID DMH15UV
DMH15UV DN Tetrahydrofolic acid
DMH15UV HS Approved
DMH15UV SN Tetrahydrafolate; Tetrahydrofolate; Tetrahydropteroylglutamate; Tetrahydropteroylglutamic acid; BIT3012; FH4; H4PteGlu; Folate-H4; Th-folate; Tetra-H-folate; Tetrahydropteroyl mono-L-glutamate; N-(5,6,7,8-tetrahydropteroyl)-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)glutamic acid; N-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; N-[4-({[(6S)-2-AMINO-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID; N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid; (6S)-5,6,7,8-tetrahydropteroylglutamate; (6S)-H4folate; (6S)-THFA; (6S)-Tetrahydrofolic acid; (6S)-tetrahydrofolate; 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 5,6,7,8-Tetrahydropteroyl-L-glutamic acid; 5,6,7,8-tetrahydrofolate; 5,6,7,8-tetrahydrofolic acid
DMH15UV TC Dietary supplement
DMH15UV DT Small molecular drug
DMH15UV PC 135444742
DMH15UV MW 445.4
DMH15UV FM C19H23N7O6
DMH15UV IC InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1
DMH15UV CS C1C(NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMH15UV IK MSTNYGQPCMXVAQ-KIYNQFGBSA-N
DMH15UV IU (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMH15UV CA CAS 135-16-0
DMH15UV CB CHEBI:20506
DMH15UV DE Malnutrition
DMT57WC ID DMT57WC
DMT57WC DN Tetrahydrozoline
DMT57WC HS Approved
DMT57WC SN Tyzine
DMT57WC CP Fougera Pharmaceuticals Inc
DMT57WC DT Small molecular drug
DMT57WC PC 5419
DMT57WC MW 200.28
DMT57WC FM C13H16N2
DMT57WC IC InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
DMT57WC CS C1CC(C2=CC=CC=C2C1)C3=NCCN3
DMT57WC IK BYJAVTDNIXVSPW-UHFFFAOYSA-N
DMT57WC IU 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
DMT57WC CA CAS 84-22-0
DMT57WC CB CHEBI:28674
DMT57WC DE Ocular disease
DMWMPRG ID DMWMPRG
DMWMPRG DN Tetrodotoxin
DMWMPRG HS Approved
DMWMPRG SN Maculotoxin; Spheroidine; TTX; Tarichatoxin; Tetradotoxin; Tetrodontoxin; Tetrodotoxine; Tetrodoxin; Fugu Toxin; Fugu poison; BJT 1; Babylonia japonica toxin 1; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10adimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; (1R,5R,6R,7R,9S,11R,12R,13S,14S)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1(7,11).0(1,6)]tetradecane-5,9,12,13,14-pentol; (1r,5r,6r,9r,11s,13s,14s)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol(non-preferred name); (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol
DMWMPRG TC Antibiotics
DMWMPRG DT Small molecular drug
DMWMPRG PC 11174599
DMWMPRG MW 319.27
DMWMPRG FM C11H17N3O8
DMWMPRG IC InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1
DMWMPRG CS C([C@@]1([C@H]2[C@@H]3[C@H](N=C(N[C@@]34[C@@H]([C@@H]1O[C@]([C@H]4O)(O2)O)O)N)O)O)O
DMWMPRG IK CFMYXEVWODSLAX-QOZOJKKESA-N
DMWMPRG IU (1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol
DMWMPRG CA CAS 4368-28-9
DMWMPRG DE Bacterial infection
DMY62FC ID DMY62FC
DMY62FC DN Tezacaftor And Ivacaftor
DMY62FC HS Approved
DMY62FC SN Ivacaftor / Tezacaftor; Tezacaftor / Ivacaftor; Ivacaftor and Tezacaftor; Ivacaftor regimen with Tezacaftor
DMY62FC CP Vertex Pharmaceuticals
DMY62FC PC 72722243
DMY62FC MW 913
DMY62FC FM C50H55F3N4O9
DMY62FC IC InChI=1S/C26H27F3N2O6.C24H28N2O3/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35);7-13,27H,1-6H3,(H,25,28)(H,26,29)/t16-;/m1./s1
DMY62FC CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMY62FC IK NETGOEWJJZQLCO-PKLMIRHRSA-N
DMY62FC IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMY62FC CA CAS 1969264-35-4
DMY62FC DE Acute lung injury
DM70BU5 ID DM70BU5
DM70BU5 DN Thalidomide
DM70BU5 HS Approved
DM70BU5 SN Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
DM70BU5 TC Immunosuppressive Agents
DM70BU5 DT Small molecular drug
DM70BU5 PC 5426
DM70BU5 MW 258.23
DM70BU5 FM C13H10N2O4
DM70BU5 IC InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
DM70BU5 CS C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
DM70BU5 IK UEJJHQNACJXSKW-UHFFFAOYSA-N
DM70BU5 IU 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DM70BU5 CA CAS 50-35-1
DM70BU5 CB CHEBI:74947
DM70BU5 DE Multiple myeloma
DMM8D3F ID DMM8D3F
DMM8D3F DN Theobromine
DMM8D3F HS Approved
DMM8D3F SN theobromine; 83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332
DMM8D3F DT Small molecular drug
DMM8D3F PC 5429
DMM8D3F MW 180.16
DMM8D3F FM C7H8N4O2
DMM8D3F IC InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)
DMM8D3F CS CN1C=NC2=C1C(=O)NC(=O)N2C
DMM8D3F IK YAPQBXQYLJRXSA-UHFFFAOYSA-N
DMM8D3F IU 3,7-dimethylpurine-2,6-dione
DMM8D3F CA CAS 83-67-0
DMM8D3F CB CHEBI:28946
DMM8D3F DE Asthma
DMRJFN9 ID DMRJFN9
DMRJFN9 DN Theophylline
DMRJFN9 HS Approved
DMRJFN9 SN Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione
DMRJFN9 CP Purdue Pharma
DMRJFN9 TC Bronchodilator Agents
DMRJFN9 DT Small molecular drug
DMRJFN9 PC 2153
DMRJFN9 MW 180.16
DMRJFN9 FM C7H8N4O2
DMRJFN9 IC InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
DMRJFN9 CS CN1C2=C(C(=O)N(C1=O)C)NC=N2
DMRJFN9 IK ZFXYFBGIUFBOJW-UHFFFAOYSA-N
DMRJFN9 IU 1,3-dimethyl-7H-purine-2,6-dione
DMRJFN9 CA CAS 58-55-9
DMRJFN9 CB CHEBI:28177
DMRJFN9 DE Chronic obstructive pulmonary disease
DM7YCK3 ID DM7YCK3
DM7YCK3 DN Thiabendazole
DM7YCK3 HS Approved
DM7YCK3 SN Biogard; Bioguard; Bovizole; Cropasal; Drawipas; Eprofil; Equizole; Hymush; Lombristop; Mertec; Mertect; Mintesol; Mintezol; Mintezole; Minzolum; Mycozol; Nemacin; Nemapan; Omnizole; Ormogal; Pitrizet; Polival; RPH; Sistesan; Storite; Tbdz; Tebuzate; Tecto; Testo; Thiaben; Thiabendazol; Thiabendazolum; Thiabendole; Thiabenzazole; Thiabenzole; Thibendole; Thibenzol; Thibenzole; Thiprazole; Tiabenda; Tiabendazol; Tiabendazole; Tiabendazolum; Tobaz; Tresaderm; Triasox; Tubazole; Captan T; Equivet TZ; Equizole A; Helmindrax octelmin; Hokustar HP; Mertect lsp; RTU Flowable Fungicide; Tecto B; Tecto rph; Thibenzole att; Top Form Wormer; Chemviron TK 100; G 491; MK 360; Mertect 160; Mertect 340f; Metasol TK 100; Metasol tk 10; PS1057_SUPELCO; Sanaizol 100; Syntol M100; TBZ 6; TBZ 60W; Tecto 10P; Tecto 40F; Tecto 60; Thibenzole 200; Tibimix 20; APL-luster; Arbotect (TN); MK-360; Metasol TK-100; Mintezol (TN); TBZ-6; Thiabendazole (USP); Thiabendazole [BSI:ISO]; Thiabendazole [USAN:BAN]; Tiabendazolum [INN-Latin]; Tresaderm (TN); E-Z-Ex; Mintezol, Equizole, Thiabendazole; Tiabendazol [INN-Spanish, French]; Tiabendazole (JAN/INN); 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; 2-(1,3-Thiazol-4-yl)benzimidazole; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; 2-(4'-Thiazolyl)benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazole; 2-(4-Thiazolyl)benzimidazole; 2-(Thiazol-4-yl)benzimidazole; 2-Thiazol-4-yl-1H-benzoimidazole; 2-Thiazole-4-ylbenzimidazole; 2-[4-Thiazoly]benzimidazole; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; 4-(2-Benzimidazolyl)thiazole
DM7YCK3 TC Antinematodal Agents
DM7YCK3 DT Small molecular drug
DM7YCK3 PC 5430
DM7YCK3 MW 201.25
DM7YCK3 FM C10H7N3S
DM7YCK3 IC InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)
DM7YCK3 CS C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3
DM7YCK3 IK WJCNZQLZVWNLKY-UHFFFAOYSA-N
DM7YCK3 IU 4-(1H-benzimidazol-2-yl)-1,3-thiazole
DM7YCK3 CA CAS 148-79-8
DM7YCK3 CB CHEBI:45979
DM7YCK3 DE Helminth infection; Dutch elm disease
DMDRKH2 ID DMDRKH2
DMDRKH2 DN Thiamphenicol
DMDRKH2 HS Approved
DMDRKH2 SN thiamphenicol; 15318-45-3; Thiophenicol; Thiamcol; (+)-Thiamphenicol; Raceophenidol; Dextrosulphenidol; Thiamphenicolum; D-Thiocymetin; D-Thiophenicol; Thiocymetin (TN); Armai (TN); Thiocymetin; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Tiamfenicol [INN-Spanish]; Thiamphenicol (Thiophenicol); Macphenicol; C12H15Cl2NO5S; Urfamycine; Igralin; Hyrazin; Dexawin; Rincrol; Neomyson; Urfamicina; Thiamphenicolum [INN-Latin]; Descocin; Masatirin; Efnicol; SW 5063; Unaseran-D; Thiamphenicol [USAN:INN:BAN:JAN]; EINECS 239-355-3; RACEPHENICOL; WIN-5063-2
DMDRKH2 DT Small molecular drug
DMDRKH2 PC 27200
DMDRKH2 MW 356.2
DMDRKH2 FM C12H15Cl2NO5S
DMDRKH2 IC InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1
DMDRKH2 CS CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O
DMDRKH2 IK OTVAEFIXJLOWRX-NXEZZACHSA-N
DMDRKH2 IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide
DMDRKH2 CA CAS 15318-45-3
DMDRKH2 CB CHEBI:32215
DMDRKH2 DE Bacterial infection
DMHDF7B ID DMHDF7B
DMHDF7B DN Thiamylal
DMHDF7B HS Approved
DMHDF7B SN Surital; Thioquinalbarbitone; Thioseconal; Thiamylal [USAN]; Surital (TN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN) (8CI); Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-(9CI); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B TC Hypnotics and Sedatives
DMHDF7B DT Small molecular drug
DMHDF7B PC 3032285
DMHDF7B MW 254.35
DMHDF7B FM C12H18N2O2S
DMHDF7B IC InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DMHDF7B CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C
DMHDF7B IK XLOMZPUITCYLMJ-UHFFFAOYSA-N
DMHDF7B IU 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B CA CAS 77-27-0
DMHDF7B CB CHEBI:9536
DMHDF7B DE Anaesthesia
DMC1NBW ID DMC1NBW
DMC1NBW DN Thiazolidinedione
DMC1NBW HS Approved
DMC1NBW SN 2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487
DMC1NBW DT Small molecular drug
DMC1NBW PC 5437
DMC1NBW MW 117.13
DMC1NBW FM C3H3NO2S
DMC1NBW IC InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1H2,(H,4,5,6)
DMC1NBW CS C1C(=O)NC(=O)S1
DMC1NBW IK ZOBPZXTWZATXDG-UHFFFAOYSA-N
DMC1NBW IU 1,3-thiazolidine-2,4-dione
DMC1NBW CA CAS 2295-31-0
DMC1NBW CB CHEBI:50992
DMC1NBW DE Alzheimer disease
DMU3IET ID DMU3IET
DMU3IET DN Thiethylperazine
DMU3IET HS Approved
DMU3IET SN ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*)
DMU3IET CP Norvatis Phamaceuticals Corporation
DMU3IET TC Antiemetics
DMU3IET DT Small molecular drug
DMU3IET PC 5440
DMU3IET MW 399.6
DMU3IET FM C22H29N3S2
DMU3IET IC InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
DMU3IET CS CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C
DMU3IET IK XCTYLCDETUVOIP-UHFFFAOYSA-N
DMU3IET IU 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DMU3IET CA CAS 1420-55-9
DMU3IET CB CHEBI:9544
DMU3IET DE Nausea
DMEPWYA ID DMEPWYA
DMEPWYA DN THIOCOLCHICOSIDE
DMEPWYA HS Approved
DMEPWYA SN Thiocolchicoside; 602-41-5; Coltramyl; UNII-T1X8S697GT; Thiocolchicine 2-glucoside analog; NSC 147755; Musco-ril; T1X8S697GT; 10-Thiocolchicoside; Tiocolchicoside [DCIT]; Colchicoside, 10-thio-; Thiocolchicoside [INN:DCF]; Q-201823; Thiocolchicosidum [INN-Latin]; Tiocolchicosido [INN-Spanish]; C27H33NO10S; Tiocolchicosido; Tiocolchicoside; Muscoril; Thiocolchicosidum; EINECS 210-017-7; BRN 0072205; R. 271; 2-10-Di(demethoxy)-2-glucosyloxy-10-methylthiocolchicine; Miotens; Coltrax; NSC147755; Coltramyl (TN); NCGC00016519-01
DMEPWYA DT Small molecular drug
DMEPWYA PC 9915886
DMEPWYA MW 563.6
DMEPWYA FM C27H33NO10S
DMEPWYA IC InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
DMEPWYA CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMEPWYA IK LEQAKWQJCITZNK-AXHKHJLKSA-N
DMEPWYA IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMEPWYA CA CAS 602-41-5
DMEPWYA CB CHEBI:94557
DMEPWYA DE Muscle spasm
DM7NKEV ID DM7NKEV
DM7NKEV DN Thioguanine
DM7NKEV HS Approved
DM7NKEV SN 6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
DM7NKEV CP Glaxo Smith Kline Pharmaceuticals
DM7NKEV TC Anticancer Agents
DM7NKEV DT Small molecular drug
DM7NKEV PC 2723601
DM7NKEV MW 167.19
DM7NKEV FM C5H5N5S
DM7NKEV IC InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DM7NKEV CS C1=NC2=C(N1)C(=S)N=C(N2)N
DM7NKEV IK WYWHKKSPHMUBEB-UHFFFAOYSA-N
DM7NKEV IU 2-amino-3,7-dihydropurine-6-thione
DM7NKEV CA CAS 154-42-7
DM7NKEV CB CHEBI:9555
DM7NKEV DE Acute myeloid leukaemia
DMGP8AX ID DMGP8AX
DMGP8AX DN Thiopental
DMGP8AX HS Approved
DMGP8AX SN Intraval; Penthiobarbital; Pentothiobarbital; Thiomebumal; Thionembutal; Thiopentobarbital; Thiopentobarbitone; Thiopentone; Thiothal; Tiopentale; Trapanal; Thiopental [BAN]; Thiopental solution; Thiopentobarbituric acid; Tiopentale [Italian]; Sodium Pentothal (TN); Thiopental (TN); Thiopentone sodium (TN); Trapanal (TN); (+-)-Thiopental; (+/-)-THIOPENTAL; (+/-)-Thiopental solution; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-(9CI); 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX CP Abbott Laboratories
DMGP8AX TC Hypnotics and Sedatives
DMGP8AX DT Small molecular drug
DMGP8AX PC 3000715
DMGP8AX MW 242.34
DMGP8AX FM C11H18N2O2S
DMGP8AX IC InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMGP8AX CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC
DMGP8AX IK IUJDSEJGGMCXSG-UHFFFAOYSA-N
DMGP8AX IU 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX CA CAS 76-75-5
DMGP8AX CB CHEBI:102166
DMGP8AX DE Anaesthesia
DM35M8J ID DM35M8J
DM35M8J DN Thioridazine
DM35M8J HS Approved
DM35M8J SN Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
DM35M8J CP Norvatis Phamaceuticals Corporation
DM35M8J TC Antipsychotic Agents
DM35M8J DT Small molecular drug
DM35M8J PC 5452
DM35M8J MW 370.6
DM35M8J FM C21H26N2S2
DM35M8J IC InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM35M8J CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
DM35M8J IK KLBQZWRITKRQQV-UHFFFAOYSA-N
DM35M8J IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
DM35M8J CA CAS 50-52-2
DM35M8J CB CHEBI:9566
DM35M8J DE Schizophrenia
DMIZKOP ID DMIZKOP
DMIZKOP DN Thiotepa
DMIZKOP HS Approved
DMIZKOP SN thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosyl; Tiofosfamid; Thiofozil; Tiofozil; Thioplex; Tespamin; Oncotepa; Tespamine; Girostan; Thiotef; Stepa; Tio-tef; Thio-Tep; Oncotiotepa; Tifosyl; Oncothio-tepa; TESPA; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; N,N',N''-Triethylenethiophosphoramide; Tris(1-aziridinyl)phosphine sulfide; Thiophosphamidum; 1,1',1''-phosphorothioyltriaziridine; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide
DMIZKOP DT Small molecular drug
DMIZKOP PC 5453
DMIZKOP MW 189.22
DMIZKOP FM C6H12N3PS
DMIZKOP IC InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2
DMIZKOP CS C1CN1P(=S)(N2CC2)N3CC3
DMIZKOP IK FOCVUCIESVLUNU-UHFFFAOYSA-N
DMIZKOP IU tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane
DMIZKOP CA CAS 52-24-4
DMIZKOP CB CHEBI:9570
DMIZKOP DE Breast cancer
DMDINC4 ID DMDINC4
DMDINC4 DN Thiothixene
DMDINC4 HS Approved
DMDINC4 SN Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
DMDINC4 CP Pfizer Pharmaceuticals
DMDINC4 TC Antipsychotic Agents
DMDINC4 DT Small molecular drug
DMDINC4 PC 941651
DMDINC4 MW 443.6
DMDINC4 FM C23H29N3O2S2
DMDINC4 IC InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
DMDINC4 CS CN1CCN(CC1)CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
DMDINC4 IK GFBKORZTTCHDGY-UWVJOHFNSA-N
DMDINC4 IU (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
DMDINC4 CA CAS 3313-26-6
DMDINC4 CB CHEBI:9571
DMDINC4 DE Schizophrenia
DM2P6VD ID DM2P6VD
DM2P6VD DN Thrombin/fibrinogen matrix patch
DM2P6VD HS Approved
DM2P6VD SN Evicel; Thrombin; Biological Hemostatic Dressing; Fibrin Fleece; Fibrin Pad; Fibrin Patch; Fleece Fibrin Patch; Fibrin sealant, Omrix/ Ethicon; Fibrinogen, Omrix/Ethicon; Thrombin/fibrinogen matrix patch (surgical bleeding); Fibrin matrix patch (surgical bleeding), Omrix/Ethicon; Thrombin/fibrinogen matrixpatch (surgical bleeding), Omrix/Ethicon
DM2P6VD CP OMRIX Biopharmaceuticals SA
DM2P6VD DE Bleeding disorder
DMJ47QC ID DMJ47QC
DMJ47QC DN Thyrotropin
DMJ47QC HS Approved
DMJ47QC SN Thytropar
DMJ47QC CP Sanofi Aventis Us Llc
DMJ47QC DE Hypothyroidism
DMMYLTI ID DMMYLTI
DMMYLTI DN Thyrotropin Alfa
DMMYLTI HS Approved
DMMYLTI TC Diagnostic Agents
DMMYLTI SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY
DMMYLTI DE Thyroid cancer
DMKSQG0 ID DMKSQG0
DMKSQG0 DN Tiagabine
DMKSQG0 HS Approved
DMKSQG0 SN tiagabine; 115103-54-3; Gabitril; Tiagabinum; Tiagabina; (R)-Tiagabine; Tiagabinum [INN-Latin]; Tiagabina [INN-Spanish]; Tiagabine [INN:BAN]; Tiagabine [INN]; Abbott-70569; UNII-Z80I64HMNP; Tiagabine (INN); ABBOTT-70569-1; Gabitril (TN); CHEMBL1027; Z80I64HMNP; ABT-569; CHEBI:9586; NO-328; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; A-70569-1; (R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid; Gabatril; NO 329; Gabitril; NO-329; Tiagabina [INN-Spanish];Tiagabine (INN); N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; [3H]tiagabine
DMKSQG0 CP Cephalon
DMKSQG0 TC Anticonvulsants
DMKSQG0 DT Small molecular drug
DMKSQG0 PC 60648
DMKSQG0 MW 375.6
DMKSQG0 FM C20H25NO2S2
DMKSQG0 IC InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
DMKSQG0 CS CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C
DMKSQG0 IK PBJUNZJWGZTSKL-MRXNPFEDSA-N
DMKSQG0 IU (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid
DMKSQG0 CA CAS 115103-54-3
DMKSQG0 CB CHEBI:9586
DMKSQG0 DE Epilepsy; Anxiety disorder
DMYN8MA ID DMYN8MA
DMYN8MA DN Tianeptine
DMYN8MA HS Approved
DMYN8MA SN Tianeptina; Tianeptinum; Tianeptine Acid; Tianeptine [INN]; Stablon (TN); Tianeptine (INN); (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA DT Small molecular drug
DMYN8MA PC 68870
DMYN8MA MW 437
DMYN8MA FM C21H25ClN2O4S
DMYN8MA IC InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)
DMYN8MA CS CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O
DMYN8MA IK JICJBGPOMZQUBB-UHFFFAOYSA-N
DMYN8MA IU 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA CA CAS 72797-41-2
DMYN8MA CB CHEBI:91749
DMYN8MA DE Major depressive disorder
DMN6CAG ID DMN6CAG
DMN6CAG DN Tiapride
DMN6CAG HS Approved
DMN6CAG SN tiapride; 51012-32-9; Thiapride; Tiapridal; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; UNII-LAH70H9JPH; FLO 1347; Tiapride [INN:BAN:DCF]; Tiapride HCl; EINECS 256-907-9; LAH70H9JPH; BRN 2390588; JTVPZMFULRWINT-UHFFFAOYSA-N; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; Tiapridum; Tiaprida; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; NCGC00015996-02; SPI-860
DMN6CAG DT Small molecular drug
DMN6CAG PC 5467
DMN6CAG MW 328.4
DMN6CAG FM C15H24N2O4S
DMN6CAG IC InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
DMN6CAG CS CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
DMN6CAG IK JTVPZMFULRWINT-UHFFFAOYSA-N
DMN6CAG IU N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide
DMN6CAG CA CAS 51012-32-9
DMN6CAG CB CHEBI:94666
DMN6CAG DE Alcohol dependence; Neuropathic pain
DM23D7J ID DM23D7J
DM23D7J DN Tiaprofenic acid
DM23D7J HS Approved
DM23D7J SN Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid
DM23D7J TC Analgesics
DM23D7J DT Small molecular drug
DM23D7J PC 5468
DM23D7J MW 260.31
DM23D7J FM C14H12O3S
DM23D7J IC InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
DM23D7J CS CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O
DM23D7J IK GUHPRPJDBZHYCJ-UHFFFAOYSA-N
DM23D7J IU 2-(5-benzoylthiophen-2-yl)propanoic acid
DM23D7J CA CAS 33005-95-7
DM23D7J CB CHEBI:32221
DM23D7J DE Pain
DM5JWV9 ID DM5JWV9
DM5JWV9 DN Tiazofurin
DM5JWV9 HS Approved
DM5JWV9 SN Riboxamide; TCAR; TIZ; Tiazofurina; Tiazofurine; Tiazofurinum; Tiazole; Tiazofurin [USAN]; Tiazofurina [Spanish]; Tiazofurinum [Latin]; Cpd-5825; Tiazofurin (USAN); Tiazofurine (INN); 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide
DM5JWV9 TC Anticancer Agents
DM5JWV9 DT Small molecular drug
DM5JWV9 PC 457954
DM5JWV9 MW 260.269
DM5JWV9 FM C9H12N2O5S
DM5JWV9 IC InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1
DM5JWV9 CS C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DM5JWV9 IK FVRDYQYEVDDKCR-DBRKOABJSA-N
DM5JWV9 IU 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide
DM5JWV9 CA CAS 60084-10-8
DM5JWV9 CB CHEBI:90239
DM5JWV9 DE Solid tumour/cancer
DM78XFG ID DM78XFG
DM78XFG DN Tibolone
DM78XFG HS Approved
DM78XFG SN Livial (TN)
DM78XFG DT Small molecular drug
DM78XFG PC 444008
DM78XFG MW 312.4
DM78XFG FM C21H28O2
DM78XFG IC InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1
DM78XFG CS C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
DM78XFG IK WZDGZWOAQTVYBX-XOINTXKNSA-N
DM78XFG IU (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM78XFG CA CAS 5630-53-5
DM78XFG CB CHEBI:32223
DM78XFG DE Anabolic metabolism
DM4ME02 ID DM4ME02
DM4ME02 DN Ticarcillin
DM4ME02 HS Approved
DM4ME02 SN TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid
DM4ME02 CP GlaxoSmithKline
DM4ME02 TC Antibiotics
DM4ME02 DT Small molecular drug
DM4ME02 PC 36921
DM4ME02 MW 384.4
DM4ME02 FM C15H16N2O6S2
DM4ME02 IC InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1
DM4ME02 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C
DM4ME02 IK OHKOGUYZJXTSFX-KZFFXBSXSA-N
DM4ME02 IU (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM4ME02 CA CAS 34787-01-4
DM4ME02 CB CHEBI:9587
DM4ME02 DE Bacterial infection
DMO946V ID DMO946V
DMO946V DN Ticlopidine
DMO946V HS Approved
DMO946V SN Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V TC Fibrinolytic Agents
DMO946V DT Small molecular drug
DMO946V PC 5472
DMO946V MW 263.8
DMO946V FM C14H14ClNS
DMO946V IC InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
DMO946V CS C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
DMO946V IK PHWBOXQYWZNQIN-UHFFFAOYSA-N
DMO946V IU 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V CA CAS 55142-85-3
DMO946V CB CHEBI:9588
DMO946V DE Stroke
DMLE7IO ID DMLE7IO
DMLE7IO DN Tigecycline
DMLE7IO HS Approved
DMLE7IO SN Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline
DMLE7IO CP Wyeth Pharmaceuticals
DMLE7IO TC Antibiotics
DMLE7IO DT Small molecular drug
DMLE7IO PC 54686904
DMLE7IO MW 585.6
DMLE7IO FM C29H39N5O8
DMLE7IO IC InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
DMLE7IO CS CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMLE7IO IK SOVUOXKZCCAWOJ-HJYUBDRYSA-N
DMLE7IO IU (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLE7IO CA CAS 220620-09-7
DMLE7IO CB CHEBI:149836
DMLE7IO DE Skin infection
DMLW9HG ID DMLW9HG
DMLW9HG DN Tildrakizumab
DMLW9HG HS Approved
DMLW9HG SN UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222
DMLW9HG CP Sun Pharma
DMLW9HG DT Antibody
DMLW9HG DE Plaque psoriasis
DMJW0VS ID DMJW0VS
DMJW0VS DN Tilidine
DMJW0VS HS Approved
DMJW0VS SN Valoron; Tilidine hydrochloride hemihydrate; 255733-17-6; Tilidine hydrochloride hemihydrate [EP]; DTXSID70180262; Ethyl (1RS,2SR)-2-(dimethylamino)-1-phenylcyclohex-3-enecarboxylate hydrochloride hemihydrate; 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, hydrate (2:2:1), (1R,2S)-rel-; UNII-Y757T3419R component WHYVWQHDUOALSV-UMJMSJQKSA-N
DMJW0VS DT Small molecular drug
DMJW0VS PC 30131
DMJW0VS MW 273.37
DMJW0VS FM C17H23NO2
DMJW0VS IC InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
DMJW0VS CS CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2
DMJW0VS IK WDEFBBTXULIOBB-WBVHZDCISA-N
DMJW0VS IU ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate
DMJW0VS CA CAS 51931-66-9
DMJW0VS CB CHEBI:77822
DMJW0VS DE Pain
DM3NXRU ID DM3NXRU
DM3NXRU DN Timolol
DM3NXRU HS Approved
DM3NXRU SN Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol
DM3NXRU CP Merck Frosst
DM3NXRU TC Antiarrhythmic Agents
DM3NXRU DT Small molecular drug
DM3NXRU PC 33624
DM3NXRU MW 316.42
DM3NXRU FM C13H24N4O3S
DM3NXRU IC InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
DM3NXRU CS CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
DM3NXRU IK BLJRIMJGRPQVNF-JTQLQIEISA-N
DM3NXRU IU (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
DM3NXRU CA CAS 26839-75-8
DM3NXRU CB CHEBI:9599
DM3NXRU DE High blood pressure
DM3OWT4 ID DM3OWT4
DM3OWT4 DN Tindamax
DM3OWT4 HS Approved
DM3OWT4 SN Tinidazole (oral), Mission Pharmacal
DM3OWT4 CP Presutti Laboratories
DM3OWT4 DT Small molecular drug
DM3OWT4 PC 5479
DM3OWT4 MW 247.27
DM3OWT4 FM C8H13N3O4S
DM3OWT4 IC InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
DM3OWT4 CS CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
DM3OWT4 IK HJLSLZFTEKNLFI-UHFFFAOYSA-N
DM3OWT4 IU 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
DM3OWT4 CA CAS 148159-84-6
DM3OWT4 CB CHEBI:63627
DM3OWT4 DE Bacterial infection
DMNYPGS ID DMNYPGS
DMNYPGS DN Tioconazole
DMNYPGS HS Approved
DMNYPGS SN Fungibacid; GyneCure; Tioconazol; Tioconazolum; Trosyd; Trosyl; Vagistat; Zoniden; Trosyd AF; Trosyd J; Monistat 1; UK 20349; Gyno-trosyd; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK 20,349; UK-20349; Vagistat-1; Vagistat-1 (TN); Tioconazole (JAN/USP/INN); Tioconazole [USAN:BAN:INN:JAN]; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS TC Antifungal Agents
DMNYPGS DT Small molecular drug
DMNYPGS PC 5482
DMNYPGS MW 387.7
DMNYPGS FM C16H13Cl3N2OS
DMNYPGS IC InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2
DMNYPGS CS C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OCC3=C(SC=C3)Cl
DMNYPGS IK QXHHHPZILQDDPS-UHFFFAOYSA-N
DMNYPGS IU 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS CA CAS 65899-73-2
DMNYPGS CB CHEBI:77898
DMNYPGS DE Onychomycosis
DMFDC0Q ID DMFDC0Q
DMFDC0Q DN Tiotropium
DMFDC0Q HS Approved
DMFDC0Q SN 186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide
DMFDC0Q CP Boehringer Ingelheim
DMFDC0Q TC Bronchodilator Agents
DMFDC0Q DT Small molecular drug
DMFDC0Q PC 5487427
DMFDC0Q MW 392.5
DMFDC0Q FM C19H22NO4S2+
DMFDC0Q IC InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+
DMFDC0Q CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C
DMFDC0Q IK LERNTVKEWCAPOY-FPISHFTHSA-N
DMFDC0Q IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate
DMFDC0Q CA CAS 186691-13-4
DMFDC0Q CB CHEBI:90960
DMFDC0Q DE Chronic obstructive pulmonary disease
DM8HJX6 ID DM8HJX6
DM8HJX6 DN Tipranavir
DM8HJX6 HS Approved
DM8HJX6 SN Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
DM8HJX6 CP Boehriger Ingelheim
DM8HJX6 TC Anti-HIV Agents
DM8HJX6 DT Small molecular drug
DM8HJX6 PC 54682461
DM8HJX6 MW 602.7
DM8HJX6 FM C31H33F3N2O5S
DM8HJX6 IC InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
DM8HJX6 CS CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4
DM8HJX6 IK SUJUHGSWHZTSEU-FYBSXPHGSA-N
DM8HJX6 IU N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
DM8HJX6 CA CAS 174484-41-4
DM8HJX6 CB CHEBI:63628
DM8HJX6 DE Human immunodeficiency virus infection
DMJNV4O ID DMJNV4O
DMJNV4O DN Tirbanibulin
DMJNV4O HS Approved
DMJNV4O SN KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2
DMJNV4O CP Kinex Pharmaceuticals
DMJNV4O DT Small molecular drug
DMJNV4O PC 23635314
DMJNV4O MW 431.5
DMJNV4O FM C26H29N3O3
DMJNV4O IC InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)
DMJNV4O CS C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
DMJNV4O IK HUNGUWOZPQBXGX-UHFFFAOYSA-N
DMJNV4O IU N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide
DMJNV4O CA CAS 897016-82-9
DMJNV4O DE Prostate cancer; Actinic keratosis
DMQG17S ID DMQG17S
DMQG17S DN Tirofiban
DMQG17S HS Approved
DMQG17S SN AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S CP Medicure Pharma
DMQG17S TC Fibrinolytic Agents
DMQG17S DT Small molecular drug
DMQG17S PC 60947
DMQG17S MW 440.6
DMQG17S FM C22H36N2O5S
DMQG17S IC InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
DMQG17S CS CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O
DMQG17S IK COKMIXFXJJXBQG-NRFANRHFSA-N
DMQG17S IU (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S CA CAS 144494-65-5
DMQG17S CB CHEBI:9605
DMQG17S DE Acute coronary syndrome
DMM9BJD ID DMM9BJD
DMM9BJD DN Tisagenlecleucel
DMM9BJD HS Approved
DMM9BJD SN Tisagenlecleucel-T
DMM9BJD CP Novartis Pharmaceuticals East Hanover, NJ
DMM9BJD DT CAR T Cell Therapy
DMM9BJD DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Acute lymphoblastic leukaemia; Acute myeloid leukaemia
DMGVUO5 ID DMGVUO5
DMGVUO5 DN Tislelizumab
DMGVUO5 HS Approved
DMGVUO5 CP BeiGene
DMGVUO5 DT Monoclonal antibody
DMGVUO5 DE Hepatocellular carcinoma; Hodgkin lymphoma
DMUKC5L ID DMUKC5L
DMUKC5L DN Tivozanib
DMUKC5L HS Approved
DMUKC5L SN ASP4130/AV-951
DMUKC5L CP Astellas Pharma US; AVEO Pharmaceuticals
DMUKC5L DT Small molecular drug
DMUKC5L PC 9911830
DMUKC5L MW 454.9
DMUKC5L FM C22H19ClN4O5
DMUKC5L IC InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
DMUKC5L CS CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
DMUKC5L IK SPMVMDHWKHCIDT-UHFFFAOYSA-N
DMUKC5L IU 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
DMUKC5L CA CAS 475108-18-0
DMUKC5L CB CHEBI:91327
DMUKC5L DE Renal cell carcinoma
DMR2IQ4 ID DMR2IQ4
DMR2IQ4 DN Tizanidine
DMR2IQ4 HS Approved
DMR2IQ4 SN Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4 CP Elan Pharmaceuticals
DMR2IQ4 TC Analgesics
DMR2IQ4 DT Small molecular drug
DMR2IQ4 PC 5487
DMR2IQ4 MW 253.71
DMR2IQ4 FM C9H8ClN5S
DMR2IQ4 IC InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
DMR2IQ4 CS C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
DMR2IQ4 IK XFYDIVBRZNQMJC-UHFFFAOYSA-N
DMR2IQ4 IU 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4 CA CAS 51322-75-9
DMR2IQ4 CB CHEBI:63629
DMR2IQ4 DE Spasm
DMUI0CH ID DMUI0CH
DMUI0CH DN Tobramycin
DMUI0CH HS Approved
DMUI0CH SN Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B
DMUI0CH CP Bausch & Lomb Pharmaceuticals, Inc.
DMUI0CH TC Antibiotics
DMUI0CH DT Small molecular drug
DMUI0CH PC 36294
DMUI0CH MW 467.5
DMUI0CH FM C18H37N5O9
DMUI0CH IC InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMUI0CH CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
DMUI0CH IK NLVFBUXFDBBNBW-PBSUHMDJSA-N
DMUI0CH IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMUI0CH CA CAS 32986-56-4
DMUI0CH CB CHEBI:28864
DMUI0CH DE Bacterial infection
DMYNMDP ID DMYNMDP
DMYNMDP DN Tocainide
DMYNMDP HS Approved
DMYNMDP SN Taquidil; Tocainida; Tocainidum; Tonocard; Astra W 36095; Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; W-36095; Tocainide (USAN/INN); Tocainide [USAN:BAN:INN]; Alanyl-2,6-xylidide; N-(2,6-dimethylphenyl)alaninamide; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; 2-Amino-2',6'-propionoxylidide; 2-Amino-N-(2,6-dimethylphenyl)propionamid
DMYNMDP TC Antiarrhythmic Agents
DMYNMDP DT Small molecular drug
DMYNMDP PC 38945
DMYNMDP MW 192.26
DMYNMDP FM C11H16N2O
DMYNMDP IC InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)
DMYNMDP CS CC1=C(C(=CC=C1)C)NC(=O)C(C)N
DMYNMDP IK BUJAGSGYPOAWEI-UHFFFAOYSA-N
DMYNMDP IU 2-amino-N-(2,6-dimethylphenyl)propanamide
DMYNMDP CA CAS 41708-72-9
DMYNMDP CB CHEBI:9611
DMYNMDP DE Ventricular arrhythmias
DM7J6OR ID DM7J6OR
DM7J6OR DN Tocilizumab
DM7J6OR HS Approved
DM7J6OR SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DM7J6OR CP Roche; Genentech
DM7J6OR DT Monoclonal antibody
DM7J6OR DE Rheumatoid arthritis; Juvenile idiopathic arthritis
DM1UE67 ID DM1UE67
DM1UE67 DN TOCOTRIENOL
DM1UE67 HS Approved
DM1UE67 SN 2-Methyl-2-[[4,8,12-trimethyl-3(E),7(E),11(E)]-tridecatrienyl]-3,4-dihydro-2H-benzo[b]pyran-6-ol
DM1UE67 DT Small molecular drug
DM1UE67 PC 9929901
DM1UE67 MW 382.6
DM1UE67 FM C26H38O2
DM1UE67 IC InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+
DM1UE67 CS CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C
DM1UE67 IK GJJVAFUKOBZPCB-ZGRPYONQSA-N
DM1UE67 IU 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
DM1UE67 CA CAS 6829-55-6
DM1UE67 DE Hyperlipidaemia
DMBS370 ID DMBS370
DMBS370 DN Tofacitinib
DMBS370 HS Approved
DMBS370 SN Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)
DMBS370 CP Pfizer
DMBS370 DT Small molecular drug
DMBS370 PC 9926791
DMBS370 MW 312.37
DMBS370 FM C16H20N6O
DMBS370 IC InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
DMBS370 CS C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
DMBS370 IK UJLAWZDWDVHWOW-YPMHNXCESA-N
DMBS370 IU 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
DMBS370 CA CAS 477600-75-2
DMBS370 CB CHEBI:71200
DMBS370 DE Rheumatoid arthritis
DMIHRNA ID DMIHRNA
DMIHRNA DN Tolazamide
DMIHRNA HS Approved
DMIHRNA SN Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P
DMIHRNA TC Hypoglycemic Agents
DMIHRNA DT Small molecular drug
DMIHRNA PC 5503
DMIHRNA MW 311.4
DMIHRNA FM C14H21N3O3S
DMIHRNA IC InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
DMIHRNA CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
DMIHRNA IK OUDSBRTVNLOZBN-UHFFFAOYSA-N
DMIHRNA IU 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea
DMIHRNA CA CAS 1156-19-0
DMIHRNA CB CHEBI:9613
DMIHRNA DE Diabetic complication
DMI40NL ID DMI40NL
DMI40NL DN Tolazoline
DMI40NL HS Approved
DMI40NL SN Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
DMI40NL TC Vasodilator Agents
DMI40NL DT Small molecular drug
DMI40NL PC 5504
DMI40NL MW 160.22
DMI40NL FM C10H12N2
DMI40NL IC InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
DMI40NL CS C1CN=C(N1)CC2=CC=CC=C2
DMI40NL IK JIVZKJJQOZQXQB-UHFFFAOYSA-N
DMI40NL IU 2-benzyl-4,5-dihydro-1H-imidazole
DMI40NL CA CAS 59-98-3
DMI40NL CB CHEBI:28502
DMI40NL DE Pulmonary hypertension
DM02AWV ID DM02AWV
DM02AWV DN Tolbutamide
DM02AWV HS Approved
DM02AWV SN Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea
DM02AWV CP Pharmacia And Upjohn Co
DM02AWV TC Hypoglycemic Agents
DM02AWV DT Small molecular drug
DM02AWV PC 5505
DM02AWV MW 270.35
DM02AWV FM C12H18N2O3S
DM02AWV IC InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
DM02AWV CS CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
DM02AWV IK JLRGJRBPOGGCBT-UHFFFAOYSA-N
DM02AWV IU 1-butyl-3-(4-methylphenyl)sulfonylurea
DM02AWV CA CAS 64-77-7
DM02AWV CB CHEBI:27999
DM02AWV DE Non-insulin dependent diabetes
DM8MNVO ID DM8MNVO
DM8MNVO DN Tolcapone
DM8MNVO HS Approved
DM8MNVO SN Tasmar; Roche brand of tolcapone; Ro 40-7592; Tasmar (TN); Tolcapone [USAN:INN]; Ro-40-7592; Tolcapone (JAN/USAN/INN); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone
DM8MNVO TC Antiparkinson Agents
DM8MNVO DT Small molecular drug
DM8MNVO PC 4659569
DM8MNVO MW 273.24
DM8MNVO FM C14H11NO5
DM8MNVO IC InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
DM8MNVO CS CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DM8MNVO IK MIQPIUSUKVNLNT-UHFFFAOYSA-N
DM8MNVO IU (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
DM8MNVO CA CAS 134308-13-7
DM8MNVO CB CHEBI:63630
DM8MNVO DE Parkinson disease
DMWUIJE ID DMWUIJE
DMWUIJE DN Tolmetin
DMWUIJE HS Approved
DMWUIJE SN Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid
DMWUIJE CP Ortho Mcneil Janssen Pharmaceuticals Inc
DMWUIJE TC Antiinflammatory Agents
DMWUIJE DT Small molecular drug
DMWUIJE PC 5509
DMWUIJE MW 257.279
DMWUIJE FM C15H15NO3
DMWUIJE IC InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
DMWUIJE CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
DMWUIJE IK UPSPUYADGBWSHF-UHFFFAOYSA-N
DMWUIJE IU 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
DMWUIJE CA CAS 26171-23-3
DMWUIJE CB CHEBI:71941
DMWUIJE DE Rheumatoid arthritis
DM28MU7 ID DM28MU7
DM28MU7 DN Tolnaftate
DM28MU7 HS Approved
DM28MU7 SN Aftate; Breezee; Chinofungin; Dermoxin; Dungistop; Focusan; Fungistop; Genaspor; Micoisdin; Phytoderm; Pitrex; Separin; Sorgoa; Sporiline; Timoped; Tinactin; Tinaderm; Tinatox; Tinavet; Ting; Tniaderm; Tolnaftato; Tolnaftatum; Tolnaphthate; Tolsanil; Tonoftal; Tritin; ZeaSorb; Aftate for jock itch aerosol spray powder; Aftate for jock itch gel; Aftate for jock itch sprinkle powder; Bioglan Brand of Tolnaftate; Carter Wallace Brand of Tolnaftate; Chinosol Brand of Tolnaftate; Douglas Brand of Tolnaftate; Essex Brand of Tolnaftate; Genaspore cream; Insight Brand of Tolnaftate; Isdin Brand of Tolnaftate; Naphthiomate T; Ony Clear; Pitrex cream; Schering Brand of Tolnaftate; Stiefel Brand of Tolnaftate; Thompson Brand of Tolnaftate; Tinactin aerosol liquid; Tinactin aerosol powder; Tinactin antifungal deodorant powder aerosol; Tinactin cream; Tinactin jock itch aerosol powder; Tinactin jock itch cream;Tinactin jock itch spray powder; Tinactin plus aerosol powder; Tinactin plus powder; Tinactin powder; Tinactin solution; Ting Products; Ting antifungal cream; Ting antifungal powder; Ting antifungal spray liquid; Ting antifungal spray powder; Tolnaftat Purder N; Tolnaftate Douglas Brand; Tolnaftate Schering Brand; Tolnaftato [DCIT]; Wernigerode Brand of Tolnaftate; Zenith Brand of Tolnaftate; NP 27; NP27; Pedinol Brand 1 of Tolnaftate; Pedinol Brand 2 of Tolnaftate; Sch 10144; Absorbine (TN); Aftate (TN); Aftate for athlete's foot aerosol spray liquid; Aftate for athlete's foot aerosol spray powder; Aftate for athlete's foot gel; Aftate for athlete's foot sprinkle powder; Genaspor (TN); HI-Alazin; Hi-alarzin; Lamasil AF (TN); NP 27 (TN); NP-27 Cream; NP-27 Powder; NP-27 Solution; NP-27 Spray Powder; Naphthiomate-T; Odor Eaters (TN); Ony-Clear; Purder N, Tolnaftat; Schering-Plough Brand 1 of Tolnaftate; Schering-Plough Brand 2 of Tolnaftate; Scholl (TN); Separin (TN); Tinactin (TN); Tinavet (Veterinary); Ting (TN); Tolnaftate(USAN); Tolnaftato [INN-Spanish]; Tolnaftatum [INN-Latin]; Zeasorb-AF powder; Tolnaftate (JP14/USP); Tolnaftate (JP15/USP); Dr. Scholl's athlete's foot spray; Tolnaftate (JP15/USP/INN); Tolnaftate [USAN:BAN:INN:JAN]; Tolnaftate [USAN:INN:BAN:JAN]; M,N-Dimethylthiocarbanilic acid O-2-naphthyl ester; Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester; O-2-Naphthyl N,N-dimethylthiocarbanilate; O-2-Naphthyl m,N-dimethylthiocarbanilate; Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester; Methyl-[3-methylphenyl]-carbamothioic acid O-2-naphthyl ester; O-(2-Naphthyl) methyl(3-methylphenyl)thiocarbamate; O-naphthalen-2-yl methyl(3-methylphenyl)carbamothioate; Carbamothioic acid, methyl(3-methylphenyl)-, O-2-naphthalenyl ester; Carbanilic acid, N,m-dimethylthio-, O-2-naphthyl ester; Carbanilic acid, m,N-dimethylthio-, O-2-naphthyl ester; N-Methyl-(3-methylphenyl)-carbamothioic acid, O-2-naphthalenyl ester; O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate; Carbamothioic acid, N-methyl-N-(3-methylphenyl)-, O-2-naphthalenyl ester; 2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate
DM28MU7 CP Schering-Plough
DM28MU7 TC Antifungal Agents
DM28MU7 DT Small molecular drug
DM28MU7 PC 5510
DM28MU7 MW 307.4
DM28MU7 FM C19H17NOS
DM28MU7 IC InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3
DM28MU7 CS CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2
DM28MU7 IK FUSNMLFNXJSCDI-UHFFFAOYSA-N
DM28MU7 IU O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate
DM28MU7 CA CAS 2398-96-1
DM28MU7 CB CHEBI:9620
DM28MU7 DE Dermatophytosis; Jock itch
DMA2GHJ ID DMA2GHJ
DMA2GHJ DN Tolperisone
DMA2GHJ HS Approved
DMA2GHJ SN Agileo; Viveo; AV-650; SPH-3047; Tolperisone (controlled-release); Tolperisone (controlled-release), Sanochemia; Tolperisone (controlled-release), Sanochemia/Avigen
DMA2GHJ CP Sanochemia Pharmazeutika AG
DMA2GHJ DT Small molecular drug
DMA2GHJ PC 5511
DMA2GHJ MW 245.36
DMA2GHJ FM C16H23NO
DMA2GHJ IC InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3
DMA2GHJ CS CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DMA2GHJ IK FSKFPVLPFLJRQB-UHFFFAOYSA-N
DMA2GHJ IU 2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one
DMA2GHJ CA CAS 728-88-1
DMA2GHJ CB CHEBI:93835
DMA2GHJ DE Muscle spasm
DMSHPW8 ID DMSHPW8
DMSHPW8 DN Tolterodine
DMSHPW8 HS Approved
DMSHPW8 SN Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol
DMSHPW8 CP Pfizer Pharmaceuticals
DMSHPW8 TC Antispasmodics
DMSHPW8 DT Small molecular drug
DMSHPW8 PC 443879
DMSHPW8 MW 325.5
DMSHPW8 FM C22H31NO
DMSHPW8 IC InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
DMSHPW8 CS CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
DMSHPW8 IK OOGJQPCLVADCPB-HXUWFJFHSA-N
DMSHPW8 IU 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
DMSHPW8 CA CAS 124937-51-5
DMSHPW8 CB CHEBI:9622
DMSHPW8 DE Overactive bladder
DMIWFRL ID DMIWFRL
DMIWFRL DN Tolvaptan
DMIWFRL HS Approved
DMIWFRL SN Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
DMIWFRL CP Otsuka; Winston Laboratories & Otsuka
DMIWFRL DT Small molecular drug
DMIWFRL PC 216237
DMIWFRL MW 448.9
DMIWFRL FM C26H25ClN2O3
DMIWFRL IC InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
DMIWFRL CS CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
DMIWFRL IK GYHCTFXIZSNGJT-UHFFFAOYSA-N
DMIWFRL IU N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
DMIWFRL CA CAS 150683-30-0
DMIWFRL CB CHEBI:32246
DMIWFRL DE Hyponatraemia; Heart failure
DMAE6LK ID DMAE6LK
DMAE6LK DN Topetecan
DMAE6LK HS Approved
DMAE6LK SN TOPOTECAN HYDROCHLORIDE; 119413-54-6; Topotecan Hcl; Hycamptamine hydrochloride; Topotecan (Hydrochloride); Topotecan monohydrochloride; UNII-956S425ZCY; Topotecan hydrochloride [USAN]; Nogitecan hydrochloride; DRG-0288; F S-104864-A; NSC-609699; NSC 609699; NSC609699; 956S425ZCY; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione monohydrochloride; NCGC00095189-01; AK-48920; DSSTox_RID_81248; DSSTox_CID_25952
DMAE6LK CP GSK
DMAE6LK DT Small molecular drug
DMAE6LK PC 60699
DMAE6LK MW 457.9
DMAE6LK FM C23H24ClN3O5
DMAE6LK IC InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1
DMAE6LK CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl
DMAE6LK IK DGHHQBMTXTWTJV-BQAIUKQQSA-N
DMAE6LK IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydrochloride
DMAE6LK CA CAS 119413-54-6
DMAE6LK DE Small-cell lung cancer
DM82Z30 ID DM82Z30
DM82Z30 DN Topiramate
DM82Z30 HS Approved
DM82Z30 SN Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
DM82Z30 CP Ortho-McNell Pharmaceutical
DM82Z30 TC Anticonvulsants
DM82Z30 DT Small molecular drug
DM82Z30 PC 5284627
DM82Z30 MW 339.36
DM82Z30 FM C12H21NO8S
DM82Z30 IC InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
DM82Z30 CS CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C
DM82Z30 IK KJADKKWYZYXHBB-XBWDGYHZSA-N
DM82Z30 IU [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DM82Z30 CA CAS 97240-79-4
DM82Z30 CB CHEBI:63631
DM82Z30 DE Alcohol dependence; Epilepsy; Seizure disorder
DMP6G8T ID DMP6G8T
DMP6G8T DN Topotecan
DMP6G8T HS Approved
DMP6G8T SN Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
DMP6G8T CP GlaxoSmithKline
DMP6G8T TC Anticancer Agents
DMP6G8T DT Small molecular drug
DMP6G8T PC 60700
DMP6G8T MW 421.4
DMP6G8T FM C23H23N3O5
DMP6G8T IC InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
DMP6G8T CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
DMP6G8T IK UCFGDBYHRUNTLO-QHCPKHFHSA-N
DMP6G8T IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMP6G8T CA CAS 123948-87-8
DMP6G8T CB CHEBI:63632
DMP6G8T DE Small-cell lung cancer; Ovarian cancer; Solid tumour/cancer
DMXKJ6C ID DMXKJ6C
DMXKJ6C DN Torasemide
DMXKJ6C HS Approved
DMXKJ6C SN Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea
DMXKJ6C TC Diuretics
DMXKJ6C DT Small molecular drug
DMXKJ6C PC 41781
DMXKJ6C MW 348.4
DMXKJ6C FM C16H20N4O3S
DMXKJ6C IC InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
DMXKJ6C CS CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
DMXKJ6C IK NGBFQHCMQULJNZ-UHFFFAOYSA-N
DMXKJ6C IU 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
DMXKJ6C CA CAS 56211-40-6
DMXKJ6C CB CHEBI:9637
DMXKJ6C DE Congestive heart failure
DMQYUWG ID DMQYUWG
DMQYUWG DN Toremifene
DMQYUWG HS Approved
DMQYUWG SN Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
DMQYUWG CP Prostrakan Inc
DMQYUWG TC Anticancer Agents
DMQYUWG DT Small molecular drug
DMQYUWG PC 3005573
DMQYUWG MW 406
DMQYUWG FM C26H28ClNO
DMQYUWG IC InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
DMQYUWG CS CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
DMQYUWG IK XFCLJVABOIYOMF-QPLCGJKRSA-N
DMQYUWG IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMQYUWG CA CAS 89778-26-7
DMQYUWG CB CHEBI:9635
DMQYUWG DE Breast cancer
DMMYZ3D ID DMMYZ3D
DMMYZ3D DN Tositumomab
DMMYZ3D HS Approved
DMMYZ3D SN Bexxar (TN)
DMMYZ3D CP GlaxoSmithKline
DMMYZ3D TC Anticancer Agents
DMMYZ3D DT Antibody
DMMYZ3D SQ Mouse-Human chimeric Anti-CD20 Heavy Chain 1: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 1QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >Mouse-Human chimeric Anti-CD20 Heavy Chain 2QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 2QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMMYZ3D DE Non-hodgkin lymphoma
DM5A31S ID DM5A31S
DM5A31S DN TP-434
DM5A31S HS Approved
DM5A31S SN TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals
DM5A31S CP Tetraphase Pharmaceuticals
DM5A31S DT Small molecular drug
DM5A31S PC 54726192
DM5A31S MW 558.6
DM5A31S FM C27H31FN4O8
DM5A31S IC InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
DM5A31S CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
DM5A31S IK AKLMFDDQCHURPW-ISIOAQNYSA-N
DM5A31S IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM5A31S CA CAS 1207283-85-9
DM5A31S DE Intra-abdominal infection; Influenza virus infection
DMG3Y89 ID DMG3Y89
DMG3Y89 DN Trabectedin
DMG3Y89 HS Approved
DMG3Y89 SN Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
DMG3Y89 CP PharmaMar
DMG3Y89 DT Small molecular drug
DMG3Y89 PC 108150
DMG3Y89 MW 761.8
DMG3Y89 FM C39H43N3O11S
DMG3Y89 IC InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
DMG3Y89 CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMG3Y89 IK PKVRCIRHQMSYJX-AIFWHQITSA-N
DMG3Y89 IU [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
DMG3Y89 CA CAS 114899-77-3
DMG3Y89 CB CHEBI:84050
DMG3Y89 DE Solid tumour/cancer; Ovarian cancer
DMRQD04 ID DMRQD04
DMRQD04 DN Tramadol
DMRQD04 HS Approved
DMRQD04 SN Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram
DMRQD04 CP Chemie Grunenthal of Stolberg-am-Rhein
DMRQD04 TC Analgesics
DMRQD04 DT Small molecular drug
DMRQD04 PC 33741
DMRQD04 MW 263.37
DMRQD04 FM C16H25NO2
DMRQD04 IC InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
DMRQD04 CS CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
DMRQD04 IK TVYLLZQTGLZFBW-ZBFHGGJFSA-N
DMRQD04 IU (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
DMRQD04 CA CAS 123154-38-1
DMRQD04 CB CHEBI:75725
DMRQD04 DE Pain
DM2JGQ3 ID DM2JGQ3
DM2JGQ3 DN Trametinib
DM2JGQ3 HS Approved
DM2JGQ3 SN GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
DM2JGQ3 CP GlaxoSmithKline
DM2JGQ3 DT Small molecular drug
DM2JGQ3 PC 11707110
DM2JGQ3 MW 615.4
DM2JGQ3 FM C26H23FIN5O4
DM2JGQ3 IC InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
DM2JGQ3 CS CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
DM2JGQ3 IK LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DM2JGQ3 IU N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
DM2JGQ3 CA CAS 871700-17-3
DM2JGQ3 CB CHEBI:75998
DM2JGQ3 DE Melanoma
DM4L6EU ID DM4L6EU
DM4L6EU DN Trandolapril
DM4L6EU HS Approved
DM4L6EU SN Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
DM4L6EU CP Abbott Laboratories
DM4L6EU TC Antihypertensive Agents
DM4L6EU DT Small molecular drug
DM4L6EU PC 5484727
DM4L6EU MW 430.5
DM4L6EU FM C24H34N2O5
DM4L6EU IC InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
DM4L6EU CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O
DM4L6EU IK VXFJYXUZANRPDJ-WTNASJBWSA-N
DM4L6EU IU (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DM4L6EU CA CAS 87679-37-6
DM4L6EU CB CHEBI:9649
DM4L6EU DE Hypertension
DMFI8A7 ID DMFI8A7
DMFI8A7 DN Tranexamic acid
DMFI8A7 HS Approved
DMFI8A7 SN AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7 CP Daiichi Sankyo Pharma Development
DMFI8A7 TC Antifibrinolytic Agents
DMFI8A7 DT Small molecular drug
DMFI8A7 PC 5526
DMFI8A7 MW 157.21
DMFI8A7 FM C8H15NO2
DMFI8A7 IC InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
DMFI8A7 CS C1CC(CCC1CN)C(=O)O
DMFI8A7 IK GYDJEQRTZSCIOI-UHFFFAOYSA-N
DMFI8A7 IU 4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7 CA CAS 701-54-2
DMFI8A7 CB CHEBI:48669
DMFI8A7 DE Excessive bleeding
DME5Y64 ID DME5Y64
DME5Y64 DN Tranilast
DME5Y64 HS Approved
DME5Y64 SN tranilast; 53902-12-8; Rizaben; trans-Tranilast; Tranilastum; 70806-55-2; MK 341; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Tranilastum [INN-Latin]; Tranilast [USAN:INN:JAN]; Tranpro; UNII-HVF50SMY6E; SB-252218; MK-341; Tranilast (SB 252218); 3,4-DAA; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; HVF50SMY6E; MLS000028468; CHEBI:77572; C18H17NO5; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; NZHGWWWHIYHZNX-CSKARUKUSA-N; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid; MFCD00864787; T 0318; NU-3450; Rizaben (TN); Tranilast (JAN/USAN/INN); Rizaben, SB 252218, MK 341, Tranpro ,Tranilast; N-(3',4'-dimethoxycinnamoyl) anthranilic acid; N-(3′ -Dimethoxycinnamoyl)anthranilic Acid; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; Molecule 20
DME5Y64 CP Kissei
DME5Y64 DT Small molecular drug
DME5Y64 PC 5282230
DME5Y64 MW 327.3
DME5Y64 FM C18H17NO5
DME5Y64 IC InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
DME5Y64 CS COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
DME5Y64 IK NZHGWWWHIYHZNX-CSKARUKUSA-N
DME5Y64 IU 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid
DME5Y64 CA CAS 53902-12-8
DME5Y64 CB CHEBI:77572
DME5Y64 DE Ocular allergy
DMGB5RE ID DMGB5RE
DMGB5RE DN Tranylcypromine
DMGB5RE HS Approved
DMGB5RE SN GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine
DMGB5RE CP GlaxoSmithKline plc
DMGB5RE TC Antidepressants
DMGB5RE DT Small molecular drug
DMGB5RE PC 19493
DMGB5RE MW 133.19
DMGB5RE FM C9H11N
DMGB5RE IC InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
DMGB5RE CS C1[C@H]([C@@H]1N)C2=CC=CC=C2
DMGB5RE IK AELCINSCMGFISI-DTWKUNHWSA-N
DMGB5RE IU (1R,2S)-2-phenylcyclopropan-1-amine
DMGB5RE CA CAS 3721-26-4
DMGB5RE CB CHEBI:94631
DMGB5RE DE Prostate cancer; Major depressive disorder
DMZQOUX ID DMZQOUX
DMZQOUX DN Trastuzumab
DMZQOUX HS Approved
DMZQOUX SN Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
DMZQOUX CP Roche; Genentech
DMZQOUX TC Anticancer Agents
DMZQOUX DT Antibody
DMZQOUX SQ Anti-HER2 Light chain (1 and 2): DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Anti-HER2 Heavy chain (1 and 2)EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMZQOUX DE Breast cancer; Gastric adenocarcinoma; HER2-positive breast cancer
DM20K91 ID DM20K91
DM20K91 DN Travoprost
DM20K91 HS Approved
DM20K91 SN Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
DM20K91 CP Alcon Canada Inc
DM20K91 TC Ophthalmologicals
DM20K91 DT Small molecular drug
DM20K91 PC 5282226
DM20K91 MW 500.5
DM20K91 FM C26H35F3O6
DM20K91 IC InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
DM20K91 CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
DM20K91 IK MKPLKVHSHYCHOC-AHTXBMBWSA-N
DM20K91 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
DM20K91 CA CAS 157283-68-6
DM20K91 CB CHEBI:746859
DM20K91 DE Open-angle glaucoma
DMK1GBJ ID DMK1GBJ
DMK1GBJ DN Trazodone
DMK1GBJ HS Approved
DMK1GBJ SN Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride
DMK1GBJ CP Angelini research laboratories
DMK1GBJ TC Antidepressants
DMK1GBJ DT Small molecular drug
DMK1GBJ PC 5533
DMK1GBJ MW 371.9
DMK1GBJ FM C19H22ClN5O
DMK1GBJ IC InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
DMK1GBJ CS C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
DMK1GBJ IK PHLBKPHSAVXXEF-UHFFFAOYSA-N
DMK1GBJ IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one
DMK1GBJ CA CAS 19794-93-5
DMK1GBJ CB CHEBI:9654
DMK1GBJ DE Depression
DMTIQF3 ID DMTIQF3
DMTIQF3 DN Treprostinil
DMTIQF3 HS Approved
DMTIQF3 SN Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3 TC Antihypertensive Agents
DMTIQF3 DT Small molecular drug
DMTIQF3 PC 6918140
DMTIQF3 MW 390.5
DMTIQF3 FM C23H34O5
DMTIQF3 IC InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
DMTIQF3 CS CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
DMTIQF3 IK PAJMKGZZBBTTOY-ZFORQUDYSA-N
DMTIQF3 IU 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3 CA CAS 81846-19-7
DMTIQF3 CB CHEBI:50861
DMTIQF3 DE Pulmonary arterial hypertension
DM49DUI ID DM49DUI
DM49DUI DN Tretinoin
DM49DUI HS Approved
DM49DUI SN Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
DM49DUI CP Roche Pharmaceuticals
DM49DUI TC Keratolytic Agents
DM49DUI DT Small molecular drug
DM49DUI PC 444795
DM49DUI MW 300.4
DM49DUI FM C20H28O2
DM49DUI IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
DM49DUI CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DM49DUI IK SHGAZHPCJJPHSC-YCNIQYBTSA-N
DM49DUI IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM49DUI CA CAS 302-79-4
DM49DUI CB CHEBI:15367
DM49DUI DE Acne vulgaris; Acute promyelocytic leukaemia
DMU54QB ID DMU54QB
DMU54QB DN Treximet
DMU54QB HS Approved
DMU54QB SN Trexima; Naproxen mixture with sumatriptan; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan mixture with naproxen;Sumatriptan succinate and naproxen sodium; Sumatriptan succinate mixture with naproxen sodium; Naproxen / sumatriptan
DMU54QB CP GSK
DMU54QB DT Small molecular drug
DMU54QB PC 23709079
DMU54QB MW 665.7
DMU54QB FM C32H40N3NaO9S
DMU54QB IC InChI=1S/C14H21N3O2S.C14H14O3.C4H6O4.Na/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;5-3(6)1-2-4(7)8;/h4-5,8-9,15-16H,6-7,10H2,1-3H3;3-9H,1-2H3,(H,15,16);1-2H2,(H,5,6)(H,7,8);/q;;;+1/p-1/t;9-;;/m.0../s1
DMU54QB CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O.[Na+]
DMU54QB IK IGRAQVLKCQVBQA-DBQHITQZSA-M
DMU54QB IU sodium;butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMU54QB CA CAS 811794-26-0
DMU54QB DE Migraine
DM0AEPG ID DM0AEPG
DM0AEPG DN Triacetin
DM0AEPG HS Approved
DM0AEPG SN triacetin; 102-76-1; Glyceryl triacetate; Glycerol triacetate; Enzactin; Glycerin triacetate; Triacetine; Triacetylglycerol; Fungacetin; Glyped; Triacetyl glycerine; Vanay; Kesscoflex TRA; Kodaflex triacetin; 1,2,3-Propanetriol, triacetate; Acetin, tri-; Triacetinum; Triacetina; 1,2,3-triacetoxypropane; 1,2,3-Propanetriol triacetate; propane-1,2,3-triyl triacetate; Triacetyl glycerin; Triacetyl glycerol; 1,2,3-Propanetriyl triacetate; Triacetin [INN]; 1,2,3-Triacetylglycerol; 1,2,3-Propanetriol, 1,2,3-triacetate; FEMA Number 2007
DM0AEPG DT Small molecular drug
DM0AEPG PC 5541
DM0AEPG MW 218.2
DM0AEPG FM C9H14O6
DM0AEPG IC InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
DM0AEPG CS CC(=O)OCC(COC(=O)C)OC(=O)C
DM0AEPG IK URAYPUMNDPQOKB-UHFFFAOYSA-N
DM0AEPG IU 2,3-diacetyloxypropyl acetate
DM0AEPG CA CAS 102-76-1
DM0AEPG CB CHEBI:9661
DM0AEPG DE Onychomycosis
DM98IXF ID DM98IXF
DM98IXF DN Triamcinolone
DM98IXF HS Approved
DM98IXF SN Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
DM98IXF CP Aventis Pharmaceuticals Inc.
DM98IXF TC Antiinflammatory Agents
DM98IXF DT Small molecular drug
DM98IXF PC 31307
DM98IXF MW 394.4
DM98IXF FM C21H27FO6
DM98IXF IC InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
DM98IXF CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
DM98IXF IK GFNANZIMVAIWHM-OBYCQNJPSA-N
DM98IXF IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM98IXF CA CAS 124-94-7
DM98IXF CB CHEBI:9667
DM98IXF DE Allergic rhinitis
DM7LRKD ID DM7LRKD
DM7LRKD DN Triamcinolone diacetate
DM7LRKD HS Approved
DM7LRKD SN Aristocort diacetate; Polcortolon; Tedarol; Aristocort Forte; Triamcinolone 16,21-diacetate; Orion; Aristocort Parenterals; Kenacort Diacetate Syrup; Aristocort diacetate forte; Aristocort Forte Parenteral; TRIAMCINOLONE DIACETATE; UNII-A73MM2Q32P; Kenacourt; Aristocort syrup; CHEBI:9669; 357RP; EINECS 200-669-0; Triamcinolone 16-alpha,21-di(acetate); A73MM2Q32P; 16alpha-Hydroxy-9alpha-fluoroprednisolone diacetate; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone diacetate; NCGC00159320-03; delta1,9alpha-Fluoro-16alpha-hydroxyhydrocortisone diacetate; delta11,16alpha-Hydroxy-9alpha-fluorohydrocortisone diacetate; 16alpha,21-Diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione; 9-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; DSSTox_CID_28639; DSSTox_RID_82909; DSSTox_GSID_48713; Pregna-1,4-diene-3,20-dione, 16,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11beta,16alpha)-; Polcartolone; CAS-67-78-7; Triamcinolone diacetate [JAN]; Triamcinolone diacetate [USP:JAN]; SCHEMBL12549; 67-78-7
DM7LRKD PC 6216
DM7LRKD MW 478.5
DM7LRKD FM C25H31FO8
DM7LRKD IC XGMPVBXKDAHORN-RBWIMXSLSA-N
DM7LRKD CS CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O
DM7LRKD IK 1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1
DM7LRKD IU [2-[(8S,9R,10S,11S,13S,14S,16R,17S)-16-acetyloxy-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DM7LRKD CA CAS 67-78-7
DM7LRKD CB CHEBI:9669
DM7LRKD DE Allergy
DM2HU9I ID DM2HU9I
DM2HU9I DN Triamterene
DM2HU9I HS Approved
DM2HU9I SN Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine
DM2HU9I TC Diuretics
DM2HU9I DT Small molecular drug
DM2HU9I PC 5546
DM2HU9I MW 253.26
DM2HU9I FM C12H11N7
DM2HU9I IC InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
DM2HU9I CS C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
DM2HU9I IK FNYLWPVRPXGIIP-UHFFFAOYSA-N
DM2HU9I IU 6-phenylpteridine-2,4,7-triamine
DM2HU9I CA CAS 396-01-0
DM2HU9I CB CHEBI:9671
DM2HU9I DE Congestive heart failure; Edema; Hypertension
DMETYK5 ID DMETYK5
DMETYK5 DN Triazolam
DMETYK5 HS Approved
DMETYK5 SN Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5 CP Upjohn Corporation
DMETYK5 TC Hypnotics and Sedatives
DMETYK5 DT Small molecular drug
DMETYK5 PC 5556
DMETYK5 MW 343.2
DMETYK5 FM C17H12Cl2N4
DMETYK5 IC InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
DMETYK5 CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl
DMETYK5 IK JOFWLTCLBGQGBO-UHFFFAOYSA-N
DMETYK5 IU 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5 CA CAS 28911-01-5
DMETYK5 CB CHEBI:9674
DMETYK5 DE Insomnia
DMHAQCO ID DMHAQCO
DMHAQCO DN Trichlormethiazide
DMHAQCO HS Approved
DMHAQCO SN Achletin; Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Cretonin; Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naquasone; Schebitran; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazidum; Trichloromethiadiazide; Trichloromethiazide; Triclordiuride; Triclormetiazida; Triclormetiazide; Triflumen;American Urologicals Brand of Trichloromethiazide; Jones Brand of Trichloromethiazide; Schering Brand of Trichlormethiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Achletin (TN); Ciba 7057-Su; Diu-Hydrin; Flurese (VAN); Naqua (TN); Salurin (wadel); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum [INN-Latin]; Trichloromethiazide, 6; Triclormetiazida[INN-Spanish]; Triflumen (TN); Diu-Hydrin (TN); Trichlormethiazide (JP15/USP/INN); (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide
DMHAQCO CP Hoechst Marion Roussel
DMHAQCO TC Antihypertensive Agents
DMHAQCO DT Small molecular drug
DMHAQCO PC 5560
DMHAQCO MW 380.7
DMHAQCO FM C8H8Cl3N3O4S2
DMHAQCO IC InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
DMHAQCO CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
DMHAQCO IK LMJSLTNSBFUCMU-UHFFFAOYSA-N
DMHAQCO IU 6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMHAQCO CA CAS 133-67-5
DMHAQCO CB CHEBI:9683
DMHAQCO DE Hypertension
DMPWGBR ID DMPWGBR
DMPWGBR DN Triclabendazole
DMPWGBR HS Approved
DMPWGBR SN Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
DMPWGBR DT Small molecular drug
DMPWGBR PC 50248
DMPWGBR MW 359.7
DMPWGBR FM C14H9Cl3N2OS
DMPWGBR IC InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
DMPWGBR CS CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl
DMPWGBR IK NQPDXQQQCQDHHW-UHFFFAOYSA-N
DMPWGBR IU 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
DMPWGBR CA CAS 68786-66-3
DMPWGBR CB CHEBI:94759
DMPWGBR DE Helminth infection
DMZUR4N ID DMZUR4N
DMZUR4N DN Triclosan
DMZUR4N HS Approved
DMZUR4N SN triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001
DMZUR4N TC Antibiotics
DMZUR4N DT Small molecular drug
DMZUR4N PC 5564
DMZUR4N MW 289.5
DMZUR4N FM C12H7Cl3O2
DMZUR4N IC InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
DMZUR4N CS C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl
DMZUR4N IK XEFQLINVKFYRCS-UHFFFAOYSA-N
DMZUR4N IU 5-chloro-2-(2,4-dichlorophenoxy)phenol
DMZUR4N CA CAS 3380-34-5
DMZUR4N CB CHEBI:164200
DMZUR4N DE Trypanosomiasis; Infection of P. falciparum; Malaria
DMVLHNI ID DMVLHNI
DMVLHNI DN Tridihexethyl
DMVLHNI HS Approved
DMVLHNI SN Pathilon; Propethonum; (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium; 3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium
DMVLHNI TC Anticholinergic Agents
DMVLHNI DT Small molecular drug
DMVLHNI PC 20299
DMVLHNI MW 318.5
DMVLHNI FM C21H36NO+
DMVLHNI IC InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1
DMVLHNI CS CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O
DMVLHNI IK NPRHVSBSZMAEIN-UHFFFAOYSA-N
DMVLHNI IU (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium
DMVLHNI CA CAS 60-49-1
DMVLHNI CB CHEBI:9701
DMVLHNI DE Acquired nystagmus
DMD2WPG ID DMD2WPG
DMD2WPG DN Trientine
DMD2WPG HS Approved
DMD2WPG SN Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride
DMD2WPG DT Small molecular drug
DMD2WPG PC 5565
DMD2WPG MW 146.23
DMD2WPG FM C6H18N4
DMD2WPG IC InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2
DMD2WPG CS C(CNCCNCCN)N
DMD2WPG IK VILCJCGEZXAXTO-UHFFFAOYSA-N
DMD2WPG IU N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine
DMD2WPG CA CAS 112-24-3
DMD2WPG CB CHEBI:39501
DMD2WPG DE Inborn error of metabolism
DMOL793 ID DMOL793
DMOL793 DN Trifarotene
DMOL793 HS Approved
DMOL793 SN Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
DMOL793 CP Galderma
DMOL793 DT Small molecular drug
DMOL793 PC 11518241
DMOL793 MW 459.6
DMOL793 FM C29H33NO4
DMOL793 IC InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
DMOL793 CS CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
DMOL793 IK MFBCDACCJCDGBA-UHFFFAOYSA-N
DMOL793 IU 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
DMOL793 CA CAS 895542-09-3
DMOL793 DE Acne vulgaris
DMKBYWI ID DMKBYWI
DMKBYWI DN Trifluoperazine
DMKBYWI HS Approved
DMKBYWI SN Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
DMKBYWI CP GlaxoSmithKline plc
DMKBYWI TC Antipsychotic Agents
DMKBYWI DT Small molecular drug
DMKBYWI PC 5566
DMKBYWI MW 407.5
DMKBYWI FM C21H24F3N3S
DMKBYWI IC InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
DMKBYWI CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMKBYWI IK ZEWQUBUPAILYHI-UHFFFAOYSA-N
DMKBYWI IU 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
DMKBYWI CA CAS 117-89-5
DMKBYWI CB CHEBI:45951
DMKBYWI DE Schizophrenia
DMKFQJP ID DMKFQJP
DMKFQJP DN Triflupromazine
DMKFQJP HS Approved
DMKFQJP SN Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)
DMKFQJP CP Bristol-Myers Squibb
DMKFQJP TC Antipsychotic Agents
DMKFQJP DT Small molecular drug
DMKFQJP PC 5568
DMKFQJP MW 352.4
DMKFQJP FM C18H19F3N2S
DMKFQJP IC InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
DMKFQJP CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
DMKFQJP IK XSCGXQMFQXDFCW-UHFFFAOYSA-N
DMKFQJP IU N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
DMKFQJP CA CAS 146-54-3
DMKFQJP CB CHEBI:9711
DMKFQJP DE Psychotic disorder
DMG2YBD ID DMG2YBD
DMG2YBD DN Trifluridine
DMG2YBD HS Approved
DMG2YBD SN Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine
DMG2YBD CP Monarch Pharmaceuticals
DMG2YBD TC Antiviral Agents
DMG2YBD DT Small molecular drug
DMG2YBD PC 6256
DMG2YBD MW 296.2
DMG2YBD FM C10H11F3N2O5
DMG2YBD IC InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
DMG2YBD CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
DMG2YBD IK VSQQQLOSPVPRAZ-RRKCRQDMSA-N
DMG2YBD IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
DMG2YBD CA CAS 70-00-8
DMG2YBD CB CHEBI:75179
DMG2YBD DE Virus infection
DMB19L8 ID DMB19L8
DMB19L8 DN Trihexyphenidyl
DMB19L8 HS Approved
DMB19L8 SN trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959; Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA
DMB19L8 CP Lederle Laboratories Div American Cyanamid Co
DMB19L8 TC Antiparkinson Agents
DMB19L8 DT Small molecular drug
DMB19L8 PC 5572
DMB19L8 MW 301.5
DMB19L8 FM C20H31NO
DMB19L8 IC InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
DMB19L8 CS C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
DMB19L8 IK HWHLPVGTWGOCJO-UHFFFAOYSA-N
DMB19L8 IU 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DMB19L8 CA CAS 144-11-6
DMB19L8 CB CHEBI:9720
DMB19L8 DE Dystonia; Parkinson disease; Obesity
DMP5A4T ID DMP5A4T
DMP5A4T DN Trilaciclib
DMP5A4T HS Approved
DMP5A4T SN G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
DMP5A4T CP G1 Therapeutics Research Triangle Park, NC
DMP5A4T PC 68029831
DMP5A4T MW 446.5
DMP5A4T FM C24H30N8O
DMP5A4T IC InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
DMP5A4T CS CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMP5A4T IK PDGKHKMBHVFCMG-UHFFFAOYSA-N
DMP5A4T IU 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMP5A4T CA CAS 1374743-00-6
DMP5A4T DE Triple negative breast cancer; Small-cell lung cancer
DMQZ9GF ID DMQZ9GF
DMQZ9GF DN Trilostane
DMQZ9GF HS Approved
DMQZ9GF SN Desopan; Desopan (TN); Modrenal (TN); Vetoryl (TN); Vetoryl, Trilostane; Win-24540; Trilostane (JAN/USAN); (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile; 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile
DMQZ9GF CP Dechra Pharmaceuticals
DMQZ9GF DT Small molecular drug
DMQZ9GF PC 656583
DMQZ9GF MW 329.4
DMQZ9GF FM C20H27NO3
DMQZ9GF IC InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
DMQZ9GF CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C
DMQZ9GF IK KVJXBPDAXMEYOA-CXANFOAXSA-N
DMQZ9GF IU (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
DMQZ9GF CA CAS 13647-35-3
DMQZ9GF CB CHEBI:32260
DMQZ9GF DE Cushing disease
DM1QLST ID DM1QLST
DM1QLST DN Trimazosin
DM1QLST HS Approved
DM1QLST SN Trimazosin hydrochloride; Trimazosin HCl; 53746-46-6; UNII-827T79ILE7; Trimazosin hydrochloride [USAN]; 827T79ILE7; Trimazosin hydrochloride monohydrate; Trimazosin hydrochloride (USAN); 35795-16-5 (Parent); Cardovar; Supres; Trimazosin hydrochlorid-1-wasser; AC1Q3ECH; CP 19106-1; AC1L21UN; SCHEMBL10363255; CHEMBL3989848; DTXSID40202021; Trimazosin monohydrochloride monohydrate; 2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylate monohydrochloride monohydrate; 1-Piperazinecarboxylic aci
DM1QLST DT Small molecular drug
DM1QLST PC 37264
DM1QLST MW 435.5
DM1QLST FM C20H29N5O6
DM1QLST IC InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
DM1QLST CS CC(C)(COC(=O)N1CCN(CC1)C2=NC3=C(C(=C(C=C3C(=N2)N)OC)OC)OC)O
DM1QLST IK YNZXWQJZEDLQEG-UHFFFAOYSA-N
DM1QLST IU (2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
DM1QLST CA CAS 35795-16-5
DM1QLST CB CHEBI:135710
DM1QLST DE Congestive heart failure
DMPYQ7B ID DMPYQ7B
DMPYQ7B DN Trimebutine
DMPYQ7B HS Approved
DMPYQ7B SN Trimebutine maleate; Trimedat; Dromostat; Ibutin; Digerent polifarma; EINECS 251-845-9; TM 906; (1-Ethyl-1-phenyl-2-(3,4,5-trimethoxybenzoyloxy)ethyl)dimethylammonium hydrogen maleate; AC1O5HFA; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethylphenethyl ester, maleate (1:1); 34140-59-5; SCHEMBL1652810; C22H29NO5.C4H4O4; AKOS026750056; LS-38470; dimethyl-[2-phenyl-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium; (E)-4-hydroxy-4-oxobut-2-enoate; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethyl
DMPYQ7B DT Small molecular drug
DMPYQ7B PC 5573
DMPYQ7B MW 387.5
DMPYQ7B FM C22H29NO5
DMPYQ7B IC InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
DMPYQ7B CS CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
DMPYQ7B IK LORDFXWUHHSAQU-UHFFFAOYSA-N
DMPYQ7B IU [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
DMPYQ7B CA CAS 58997-89-0
DMPYQ7B CB CHEBI:94458
DMPYQ7B DE Irritable bowel syndrome
DMEMV9D ID DMEMV9D
DMEMV9D DN Trimeprazine
DMEMV9D HS Approved
DMEMV9D SN Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine
DMEMV9D CP Allergan Herbert Skin Care Div Allergan Inc
DMEMV9D TC Antihistamines
DMEMV9D DT Small molecular drug
DMEMV9D PC 5574
DMEMV9D MW 298.4
DMEMV9D FM C18H22N2S
DMEMV9D IC InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
DMEMV9D CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
DMEMV9D IK ZZHLYYDVIOPZBE-UHFFFAOYSA-N
DMEMV9D IU N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
DMEMV9D CA CAS 84-96-8
DMEMV9D CB CHEBI:9725
DMEMV9D DE Allergic rhinitis
DM0Q8MZ ID DM0Q8MZ
DM0Q8MZ DN Trimethadione
DM0Q8MZ HS Approved
DM0Q8MZ SN Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
DM0Q8MZ TC Anticonvulsants
DM0Q8MZ DT Small molecular drug
DM0Q8MZ PC 5576
DM0Q8MZ MW 143.14
DM0Q8MZ FM C6H9NO3
DM0Q8MZ IC InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
DM0Q8MZ CS CC1(C(=O)N(C(=O)O1)C)C
DM0Q8MZ IK IRYJRGCIQBGHIV-UHFFFAOYSA-N
DM0Q8MZ IU 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione
DM0Q8MZ CA CAS 127-48-0
DM0Q8MZ CB CHEBI:9727
DM0Q8MZ DE Pancreatic cancer; Epilepsy
DMHF4IQ ID DMHF4IQ
DMHF4IQ DN Trimethaphan
DMHF4IQ HS Approved
DMHF4IQ SN Thimethaphan; Trimetaphan; Trimetaphanum; Arfonad (TN); Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-(VAN); 1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium
DMHF4IQ CP Hoffmann La Roche Inc
DMHF4IQ TC Antihypertensive Agents
DMHF4IQ DT Small molecular drug
DMHF4IQ PC 23576
DMHF4IQ MW 365.5
DMHF4IQ FM C22H25N2OS+
DMHF4IQ IC InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
DMHF4IQ CS C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5
DMHF4IQ IK CHQOEHPMXSHGCL-UHFFFAOYSA-N
DMHF4IQ IU 3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one
DMHF4IQ CA CAS 7187-66-8
DMHF4IQ CB CHEBI:9728
DMHF4IQ DE Aneurysm; Hypertensive emergency
DMM7CHK ID DMM7CHK
DMM7CHK DN Trimethoprim
DMM7CHK HS Approved
DMM7CHK SN Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]
DMM7CHK CP GlaxoSmithKline
DMM7CHK TC Antiinfective Agents
DMM7CHK DT Small molecular drug
DMM7CHK PC 5578
DMM7CHK MW 290.32
DMM7CHK FM C14H18N4O3
DMM7CHK IC InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
DMM7CHK CS COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMM7CHK IK IEDVJHCEMCRBQM-UHFFFAOYSA-N
DMM7CHK IU 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMM7CHK CA CAS 738-70-5
DMM7CHK CB CHEBI:45924
DMM7CHK DE Urinary tract infection
DMDEA85 ID DMDEA85
DMDEA85 DN Trimetrexate
DMDEA85 HS Approved
DMDEA85 SN TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine
DMDEA85 CP Medimmune Oncology Inc
DMDEA85 TC Antifungal Agents
DMDEA85 DT Small molecular drug
DMDEA85 PC 5583
DMDEA85 MW 369.4
DMDEA85 FM C19H23N5O3
DMDEA85 IC InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
DMDEA85 CS CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC
DMDEA85 IK NOYPYLRCIDNJJB-UHFFFAOYSA-N
DMDEA85 IU 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
DMDEA85 CA CAS 52128-35-5
DMDEA85 CB CHEBI:9737
DMDEA85 DE Toxoplasmosis
DM1SC8M ID DM1SC8M
DM1SC8M DN Trimipramine
DM1SC8M HS Approved
DM1SC8M SN Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP
DM1SC8M CP Odyssey Pharmaceuticals Inc
DM1SC8M TC Antidepressants
DM1SC8M DT Small molecular drug
DM1SC8M PC 5584
DM1SC8M MW 294.4
DM1SC8M FM C20H26N2
DM1SC8M IC InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
DM1SC8M CS CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
DM1SC8M IK ZSCDBOWYZJWBIY-UHFFFAOYSA-N
DM1SC8M IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
DM1SC8M CA CAS 3564-75-8
DM1SC8M CB CHEBI:9738
DM1SC8M DE Major depressive disorder
DMZBU15 ID DMZBU15
DMZBU15 DN Tripelennamine
DMZBU15 HS Approved
DMZBU15 SN Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine
DMZBU15 CP Norvatis Phamaceuticals Corporation
DMZBU15 TC Antiallergic Agents
DMZBU15 DT Small molecular drug
DMZBU15 PC 5587
DMZBU15 MW 255.36
DMZBU15 FM C16H21N3
DMZBU15 IC InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMZBU15 CS CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
DMZBU15 IK UFLGIAIHIAPJJC-UHFFFAOYSA-N
DMZBU15 IU N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMZBU15 CA CAS 91-81-6
DMZBU15 CB CHEBI:9741
DMZBU15 DE Hypersensitivity
DM7SWIA ID DM7SWIA
DM7SWIA DN Triprolidine
DM7SWIA HS Approved
DM7SWIA SN Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
DM7SWIA TC Antiallergic Agents
DM7SWIA DT Small molecular drug
DM7SWIA PC 5282443
DM7SWIA MW 278.4
DM7SWIA FM C19H22N2
DM7SWIA IC InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
DM7SWIA CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC=N3
DM7SWIA IK CBEQULMOCCWAQT-WOJGMQOQSA-N
DM7SWIA IU 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine
DM7SWIA CA CAS 486-12-4
DM7SWIA CB CHEBI:84116
DM7SWIA DE Hay fever
DMTK4LS ID DMTK4LS
DMTK4LS DN Triptorelin
DMTK4LS HS Approved
DMTK4LS SN Gonapeptyl depot (TN)
DMTK4LS CP Tulane University
DMTK4LS DT Small molecular drug
DMTK4LS PC 25074470
DMTK4LS MW 1311.4
DMTK4LS FM C64H82N18O13
DMTK4LS IC InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
DMTK4LS CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMTK4LS IK VXKHXGOKWPXYNA-PGBVPBMZSA-N
DMTK4LS IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMTK4LS CA CAS 57773-63-4
DMTK4LS CB CHEBI:63633
DMTK4LS DE Solid tumour/cancer; Prostate cancer
DMHB2C3 ID DMHB2C3
DMHB2C3 DN Trofosfamide
DMHB2C3 HS Approved
DMHB2C3 SN Trofosfamide; Trophosphamide; Ixoten; 22089-22-1; Trofosfamid; Triphosphamide; Trilofosfamida; Trifosfamide; Trisfosfamide; Trilophosphamide; Trofosfamidum; Z 4828; Trofosfamide [INN]; ASTA Z 4828; Trofosfamida [Spanish]; A-4828; Trofosfamidum [INN-Latin]; NSC 109723; Trofosfamido [INN-Spanish]; MLS002704177; CCRIS 4442; Z-4828; EINECS 244-770-8; Trofosfamide (INN); BRN 0532530; N,N,3-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N,N-3'-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide
DMHB2C3 DT Small molecular drug
DMHB2C3 PC 65702
DMHB2C3 MW 323.6
DMHB2C3 FM C9H18Cl3N2O2P
DMHB2C3 IC InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
DMHB2C3 CS C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
DMHB2C3 IK UMKFEPPTGMDVMI-UHFFFAOYSA-N
DMHB2C3 IU N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMHB2C3 CA CAS 22089-22-1
DMHB2C3 CB CHEBI:135381
DMHB2C3 DE Non-hodgkin lymphoma
DM3VFPD ID DM3VFPD
DM3VFPD DN Troglitazone
DM3VFPD HS Approved
DM3VFPD SN Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
DM3VFPD CP Daiichi Sankyo Pharma Development
DM3VFPD TC Antiinflammatory Agents
DM3VFPD DT Small molecular drug
DM3VFPD PC 5591
DM3VFPD MW 441.5
DM3VFPD FM C24H27NO5S
DM3VFPD IC InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)
DM3VFPD CS CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
DM3VFPD IK GXPHKUHSUJUWKP-UHFFFAOYSA-N
DM3VFPD IU 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM3VFPD CA CAS 97322-87-7
DM3VFPD CB CHEBI:9753
DM3VFPD DE Diabetic complication
DMUZNIG ID DMUZNIG
DMUZNIG DN Troleandomycin
DMUZNIG HS Approved
DMUZNIG SN Aovine; Cyclamycin; Evramicina; Matromicina; Oleandocetin; Oleandocetine; TAO; Treolmicina; Triacetyloleandomycin; Triacetyloleandomycinum; Tribiocillina; Triocetin; Triolan; Troleandomicina; Troleandomycine; Troleandomycinum; Viamicina; Wytrion; Matromycin T; Oleandomycin triacetate; Oleandomycin triacetyl ester; Triacetyl ester of oleandomycin; WY 651; Tao (TN); Tao (VAN); Tekmisin (TN); Treis-Micina; Triacetyloleandomycin (JAN); Triocetin (TN); Troleandomicina [INN-Spanish]; Troleandomycin (TAO); Troleandomycin [USAN:INN]; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; Oleandomycin, triacetate (ester); T.A.O; Troleandomycin (USP/INN); T.A.O.
DMUZNIG CP Bayer Pharmaceuticals Corporation
DMUZNIG TC Antibiotics
DMUZNIG DT Small molecular drug
DMUZNIG PC 202225
DMUZNIG MW 814
DMUZNIG FM C41H67NO15
DMUZNIG IC InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1
DMUZNIG CS C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C
DMUZNIG IK LQCLVBQBTUVCEQ-QTFUVMRISA-N
DMUZNIG IU [(3R,5S,6S,7R,8S,9R,12R,13S,14S,15R)-6-[(2S,3R,4S,6R)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S)-5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate
DMUZNIG CA CAS 2751-09-9
DMUZNIG CB CHEBI:45735
DMUZNIG DE Bacterial infection
DMOBLGK ID DMOBLGK
DMOBLGK DN Tromethamine
DMOBLGK HS Approved
DMOBLGK SN Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane
DMOBLGK DT Small molecular drug
DMOBLGK PC 6503
DMOBLGK MW 121.14
DMOBLGK FM C4H11NO3
DMOBLGK IC InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
DMOBLGK CS C(C(CO)(CO)N)O
DMOBLGK IK LENZDBCJOHFCAS-UHFFFAOYSA-N
DMOBLGK IU 2-amino-2-(hydroxymethyl)propane-1,3-diol
DMOBLGK CA CAS 77-86-1
DMOBLGK CB CHEBI:9754
DMOBLGK DE Acidosis
DM1D90W ID DM1D90W
DM1D90W DN Tropicamide
DM1D90W HS Approved
DM1D90W SN Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
DM1D90W CP Alcon Laboratories Inc
DM1D90W TC Diagnostic Agents
DM1D90W DT Small molecular drug
DM1D90W PC 5593
DM1D90W MW 284.35
DM1D90W FM C17H20N2O2
DM1D90W IC InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
DM1D90W CS CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
DM1D90W IK BGDKAVGWHJFAGW-UHFFFAOYSA-N
DM1D90W IU N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide
DM1D90W CA CAS 1508-75-4
DM1D90W CB CHEBI:9757
DM1D90W DE Mydriasis
DMNSJ7V ID DMNSJ7V
DMNSJ7V DN Tropisetron
DMNSJ7V HS Approved
DMNSJ7V SN Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate
DMNSJ7V CP Novartis International AG
DMNSJ7V DT Small molecular drug
DMNSJ7V PC 656665
DMNSJ7V MW 284.35
DMNSJ7V FM C17H20N2O2
DMNSJ7V IC InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?
DMNSJ7V CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
DMNSJ7V IK ZNRGQMMCGHDTEI-FUNVUKJBSA-N
DMNSJ7V IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
DMNSJ7V CA CAS 89565-68-4
DMNSJ7V CB CHEBI:32269
DMNSJ7V DE Fibromyalgia
DMX6RTG ID DMX6RTG
DMX6RTG DN Trospium
DMX6RTG HS Approved
DMX6RTG SN Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
DMX6RTG CP Allergan Pharmaceuticals
DMX6RTG TC Parasympatholytics
DMX6RTG DT Small molecular drug
DMX6RTG PC 5284632
DMX6RTG MW 392.5
DMX6RTG FM C25H30NO3+
DMX6RTG IC InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23?
DMX6RTG CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O
DMX6RTG IK OYYDSUSKLWTMMQ-AIZNXBIQSA-N
DMX6RTG IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate
DMX6RTG CA CAS 47608-32-2
DMX6RTG CB CHEBI:145791
DMX6RTG DE Spasm; Overactive bladder
DM32XZT ID DM32XZT
DM32XZT DN Trospium chloride
DM32XZT HS Approved
DM32XZT SN Regurin; Sanctura
DM32XZT TC Respiratory Agents
DM32XZT DT Small molecular drug
DM32XZT PC 5284631
DM32XZT MW 428
DM32XZT FM C25H30ClNO3
DM32XZT IC InChI=1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23?;
DM32XZT CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-]
DM32XZT IK RVCSYOQWLPPAOA-DHWZJIOFSA-M
DM32XZT IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
DM32XZT CA CAS 10405-02-4
DM32XZT CB CHEBI:32270
DM32XZT DE Discovery agent
DM6AN32 ID DM6AN32
DM6AN32 DN Trovafloxacin
DM6AN32 HS Approved
DM6AN32 SN TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DM6AN32 CP Pfizer Pharmaceuticals
DM6AN32 TC Antiinfective Agents
DM6AN32 DT Small molecular drug
DM6AN32 PC 62959
DM6AN32 MW 416.4
DM6AN32 FM C20H15F3N4O3
DM6AN32 IC InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
DM6AN32 CS C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
DM6AN32 IK WVPSKSLAZQPAKQ-SOSAQKQKSA-N
DM6AN32 IU 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DM6AN32 CA CAS 147059-72-1
DM6AN32 CB CHEBI:9763
DM6AN32 DE Bacterial infection
DMDHCK9 ID DMDHCK9
DMDHCK9 DN Trumenba
DMDHCK9 HS Approved
DMDHCK9 SN Meningococcal Group B Vaccine
DMDHCK9 CP Wyeth; pfizer
DMDHCK9 DT Vaccine
DMDHCK9 DE Meningitis
DM4NTMO ID DM4NTMO
DM4NTMO DN TRYPAN BLUE
DM4NTMO HS Approved
DM4NTMO SN AC1O6WJ7; tetrasodium (3E)-5-amino-3-[[4-[4-[(2Z)-2-(8-amino-1-oxo-3,6-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-4-oxonaphthalene-2,7-disulfonate; 3,3',3,3'-[(3,3'-Dimethylbiphenyl-4,4'-diyl)bis(iminonitrilo)]bis(3,4-dihydro-4-oxo-5-amino-2,7-naphthalenedisulfonic acid disodium) salt
DM4NTMO DT Small molecular drug
DM4NTMO PC 6296
DM4NTMO MW 960.8
DM4NTMO FM C34H24N6Na4O14S4
DM4NTMO IC InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM4NTMO CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)C)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+]
DM4NTMO IK GLNADSQYFUSGOU-UHFFFAOYSA-J
DM4NTMO IU tetrasodium;5-amino-3-[[4-[4-[(8-amino-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate
DM4NTMO CA CAS 72-57-1
DM4NTMO CB CHEBI:78897
DM4NTMO DE Ophthalmic surgery injury
DMBZIVP ID DMBZIVP
DMBZIVP DN Tubocurarine
DMBZIVP HS Approved
DMBZIVP SN Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium
DMBZIVP TC Neuromuscular Nondepolarizing Agents
DMBZIVP DT Small molecular drug
DMBZIVP PC 6000
DMBZIVP MW 609.7
DMBZIVP FM C37H41N2O6+
DMBZIVP IC InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
DMBZIVP CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC
DMBZIVP IK JFJZZMVDLULRGK-URLMMPGGSA-O
DMBZIVP IU (1S,16R)-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-30-aza-15-azoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol
DMBZIVP CA CAS 57-95-4
DMBZIVP CB CHEBI:9774
DMBZIVP DE Anaesthesia; Smoking dependence
DMBESUA ID DMBESUA
DMBESUA DN Tucatinib
DMBESUA HS Approved
DMBESUA SN Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
DMBESUA CP Seattle Genetics Bothell, WA
DMBESUA PC 51039094
DMBESUA MW 480.5
DMBESUA FM C26H24N8O2
DMBESUA IC InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
DMBESUA CS CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
DMBESUA IK SDEAXTCZPQIFQM-UHFFFAOYSA-N
DMBESUA IU 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
DMBESUA CA CAS 937263-43-9
DMBESUA DE Gastric adenocarcinoma; HER2-positive breast cancer
DM749I3 ID DM749I3
DM749I3 DN Ubrogepant
DM749I3 HS Approved
DM749I3 SN 1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3 CP Merck
DM749I3 DT Small molecular drug
DM749I3 PC 68748835
DM749I3 MW 549.5
DM749I3 FM C29H26F3N5O3
DM749I3 IC InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
DM749I3 CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
DM749I3 IK DDOOFTLHJSMHLN-ZQHRPCGSSA-N
DM749I3 IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3 CA CAS 1374248-77-7
DM749I3 DE Migraine
DM1IQRP ID DM1IQRP
DM1IQRP DN Udenafil
DM1IQRP HS Approved
DM1IQRP SN Zydena; DA 8159; DA-8159; Zydena (TN); 3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
DM1IQRP CP Dong-A Pharmaceutical
DM1IQRP TC Vasodilator Agents
DM1IQRP DT Small molecular drug
DM1IQRP PC 135413547
DM1IQRP MW 516.7
DM1IQRP FM C25H36N6O4S
DM1IQRP IC InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
DM1IQRP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
DM1IQRP IK IYFNEFQTYQPVOC-UHFFFAOYSA-N
DM1IQRP IU 3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
DM1IQRP CA CAS 268203-93-6
DM1IQRP CB CHEBI:135926
DM1IQRP DE Erectile dysfunction
DMX3O0D ID DMX3O0D
DMX3O0D DN UFT
DMX3O0D HS Approved
DMX3O0D SN Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb
DMX3O0D CP Taiho Pharmaceutical Co Ltd
DMX3O0D DT Small molecular drug
DMX3O0D PC 104747
DMX3O0D MW 312.25
DMX3O0D FM C12H13FN4O5
DMX3O0D IC InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)
DMX3O0D CS C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O
DMX3O0D IK DHMYGZIEILLVNR-UHFFFAOYSA-N
DMX3O0D IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione
DMX3O0D CA CAS 74578-38-4
DMX3O0D DE Solid tumour/cancer
DMBNI20 ID DMBNI20
DMBNI20 DN Ulipristal
DMBNI20 HS Approved
DMBNI20 SN Ella (TN)
DMBNI20 CP HRA Pharma
DMBNI20 DT Small molecular drug
DMBNI20 PC 13559281
DMBNI20 MW 433.6
DMBNI20 FM C28H35NO3
DMBNI20 IC InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1
DMBNI20 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMBNI20 IK HKDLNTKNLJPAIY-WKWWZUSTSA-N
DMBNI20 IU (8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMBNI20 CA CAS 159811-51-5
DMBNI20 DE Contraception
DMYRBO1 ID DMYRBO1
DMYRBO1 DN Umbralisib
DMYRBO1 HS Approved
DMYRBO1 SN RP5264; TGR-1202
DMYRBO1 CP Tg therapeutics
DMYRBO1 PC 72950888
DMYRBO1 MW 571.5
DMYRBO1 FM C31H24F3N5O3
DMYRBO1 IC InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
DMYRBO1 CS C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
DMYRBO1 IK IUVCFHHAEHNCFT-INIZCTEOSA-N
DMYRBO1 IU 2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one
DMYRBO1 CA CAS 1532533-67-7
DMYRBO1 DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Marginal zone lymphoma
DM4E8O9 ID DM4E8O9
DM4E8O9 DN Umeclidinium
DM4E8O9 HS Approved
DM4E8O9 SN 573719
DM4E8O9 CP GlaxoSmithKline
DM4E8O9 DT Small molecular drug
DM4E8O9 PC 11519070
DM4E8O9 MW 428.6
DM4E8O9 FM C29H34NO2+
DM4E8O9 IC InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1
DM4E8O9 CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5
DM4E8O9 IK FVTWTVQXNAJTQP-UHFFFAOYSA-N
DM4E8O9 IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol
DM4E8O9 CA CAS 869185-19-3
DM4E8O9 CB CHEBI:79041
DM4E8O9 DE Chronic obstructive pulmonary disease
DMXNR04 ID DMXNR04
DMXNR04 DN Unoprostone
DMXNR04 HS Approved
DMXNR04 DT Small molecular drug
DMXNR04 PC 5311236
DMXNR04 MW 382.5
DMXNR04 FM C22H38O5
DMXNR04 IC InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1
DMXNR04 CS CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O
DMXNR04 IK TVHAZVBUYQMHBC-SNHXEXRGSA-N
DMXNR04 IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
DMXNR04 CA CAS 120373-36-6
DMXNR04 CB CHEBI:39455
DMXNR04 DE Glaucoma/ocular hypertension
DM32B5U ID DM32B5U
DM32B5U DN Upadacitinib
DM32B5U HS Approved
DM32B5U SN ABT-494
DM32B5U CP Abbvie
DM32B5U PC 58557659
DM32B5U MW 380.4
DM32B5U FM C17H19F3N6O
DM32B5U IC InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM32B5U CS CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM32B5U IK WYQFJHHDOKWSHR-MNOVXSKESA-N
DM32B5U IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM32B5U CA CAS 1310726-60-3
DM32B5U DE Atopic dermatitis; Psoriatic arthritis; Crohn disease; Ulcerative colitis; Rheumatoid arthritis
DM8T2OI ID DM8T2OI
DM8T2OI DN Upadacitinib
DM8T2OI HS Approved
DM8T2OI SN Upadacitinib, ABT-494; J3.590.729G; Rinvoq; SB19218; SCHEMBL9991056; Upadacitinib; Upadacitinib (USAN/INN); Upadacitinib [USAN:INN]; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; 1310726-59-0; 1310726-60-3; 4RA0KN46E0; ABT 494; ABT-494; ABT-494 enantiomer; AC-30326; BCP19011; CHEMBL3622821; CS-6150; D10994; EX-A1628; GTPL9246; HY-19569; MFCD30502663; UNII-4RA0KN46E0
DM8T2OI PC 58557659
DM8T2OI MW 380.4
DM8T2OI FM C17H19F3N6O
DM8T2OI IC WYQFJHHDOKWSHR-MNOVXSKESA-N
DM8T2OI CS CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM8T2OI IK 1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM8T2OI IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM8T2OI CA CAS 1310726-60-3
DM8T2OI DE Rheumatoid arthritis
DMHL7OB ID DMHL7OB
DMHL7OB DN Uracil mustard
DMHL7OB HS Approved
DMHL7OB SN Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
DMHL7OB TC Anticancer Agents
DMHL7OB DT Small molecular drug
DMHL7OB PC 6194
DMHL7OB MW 252.09
DMHL7OB FM C8H11Cl2N3O2
DMHL7OB IC InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)
DMHL7OB CS C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl
DMHL7OB IK IDPUKCWIGUEADI-UHFFFAOYSA-N
DMHL7OB IU 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione
DMHL7OB CA CAS 66-75-1
DMHL7OB CB CHEBI:9884
DMHL7OB DE Acute myeloid leukaemia
DMD59GI ID DMD59GI
DMD59GI DN Urapidil
DMD59GI HS Approved
DMD59GI SN urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc
DMD59GI DT Small molecular drug
DMD59GI PC 5639
DMD59GI MW 387.5
DMD59GI FM C20H29N5O3
DMD59GI IC InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
DMD59GI CS CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
DMD59GI IK ICMGLRUYEQNHPF-UHFFFAOYSA-N
DMD59GI IU 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione
DMD59GI CA CAS 34661-75-1
DMD59GI CB CHEBI:32278
DMD59GI DE Hypertension; Inflammation
DMUK75B ID DMUK75B
DMUK75B DN Urea
DMUK75B HS Approved
DMUK75B SN carbamide; 57-13-6; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Carbamimidic acid; Pseudourea; Ureaphil; Urevert; Carbaderm; Alphadrate; Keratinamin; Calmurid; Aquadrate; Carbonyl diamide; Pastaron; Urepearl; Carbamide resin; Ultra Mide; Varioform ii; Aqua Care; Prespersion, 75 urea; carmol; basodexan; Harnstoff; Nutraplus; Mocovina; Urea solution; Supercel 3000; Aqua Care HP; Ureacin-20; Ureacin-40 Creme; Ureacin-10 lotion; Polyurea; Panafil; Onychomal; Hyanit; Caswell No. 902; Carbonyl Diamine; Mocovina [Czech]; Harnstoff [Ge
DMUK75B DT Small molecular drug
DMUK75B PC 1176
DMUK75B MW 60.056
DMUK75B FM CH4N2O
DMUK75B IC InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)
DMUK75B CS C(=O)(N)N
DMUK75B IK XSQUKJJJFZCRTK-UHFFFAOYSA-N
DMUK75B IU urea
DMUK75B CA CAS 57-13-6
DMUK75B CB CHEBI:16199
DMUK75B DE Dermatological disease
DMQTREB ID DMQTREB
DMQTREB DN Uridine
DMQTREB HS Approved
DMQTREB SN uridine; 58-96-8; Uridin; Uracil riboside; beta-Uridine; d-uridine; CHEBI:16704; b-Uridine; UNII-WHI7HQ7H85; Urd; AI3-52690; EINECS 200-407-5; WHI7HQ7H85; MLS000069625; Uracil-1-beta-d-ribofuranoside; C9H12N2O6; DRTQHJPVMGBUCF-XVFCMESISA-N; SMR000058222; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-beta-D-ribofuranosylpyrimidine-2,4(1H,3H)-dione
DMQTREB DT Small molecular drug
DMQTREB PC 6029
DMQTREB MW 244.2
DMQTREB FM C9H12N2O6
DMQTREB IC InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
DMQTREB CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMQTREB IK DRTQHJPVMGBUCF-XVFCMESISA-N
DMQTREB IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMQTREB CA CAS 58-96-8
DMQTREB CB CHEBI:16704
DMQTREB DE Depression
DMG9HIA ID DMG9HIA
DMG9HIA DN Urofollitropin
DMG9HIA HS Approved
DMG9HIA SN Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin
DMG9HIA TC Fertility Agents
DMG9HIA DT Small molecular drug
DMG9HIA SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DMG9HIA PC 62819
DMG9HIA MW 980.2
DMG9HIA FM C42H65N11O12S2
DMG9HIA IC InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)
DMG9HIA CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
DMG9HIA IK ZDRRIRUAESZNIH-UHFFFAOYSA-N
DMG9HIA IU 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMG9HIA DE Female infertility
DM0GOUD ID DM0GOUD
DM0GOUD DN Urokinase
DM0GOUD HS Approved
DM0GOUD TC Thrombolytic Agents
DM0GOUD SQ DB00013 sequence: KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL
DM0GOUD DE Myocardial infarction
DMCUT21 ID DMCUT21
DMCUT21 DN Ursodeoxycholic acid
DMCUT21 HS Approved
DMCUT21 SN Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid
DMCUT21 CP Axcan Pharma
DMCUT21 TC Cholagogues and Choleretics
DMCUT21 DT Small molecular drug
DMCUT21 PC 31401
DMCUT21 MW 392.6
DMCUT21 FM C24H40O4
DMCUT21 IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
DMCUT21 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMCUT21 IK RUDATBOHQWOJDD-UZVSRGJWSA-N
DMCUT21 IU (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMCUT21 CA CAS 128-13-2
DMCUT21 CB CHEBI:9907
DMCUT21 DE Primary biliary cirrhosis
DMHTYK3 ID DMHTYK3
DMHTYK3 DN Ustekinumab
DMHTYK3 HS Approved
DMHTYK3 SN 6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)
DMHTYK3 CP Centocor Ortho Biotech
DMHTYK3 DT Antibody
DMHTYK3 DE Plaque psoriasis; Malaria; Inflammatory bowel disease; Psoriasis vulgaris
DMA630M ID DMA630M
DMA630M DN Vaccinia immune globulin
DMA630M HS Approved
DMA630M CP DynPort Vaccine Company LLC
DMA630M DE Vaccination
DMHKS94 ID DMHKS94
DMHKS94 DN Valaciclovir
DMHKS94 HS Approved
DMHKS94 SN Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate
DMHKS94 CP GlaxoSmithKline
DMHKS94 TC Antiviral Agents
DMHKS94 DT Small molecular drug
DMHKS94 PC 135398742
DMHKS94 MW 324.34
DMHKS94 FM C13H20N6O4
DMHKS94 IC InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1
DMHKS94 CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N
DMHKS94 IK HDOVUKNUBWVHOX-QMMMGPOBSA-N
DMHKS94 IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate
DMHKS94 CA CAS 124832-26-4
DMHKS94 CB CHEBI:35854
DMHKS94 DE Virus infection
DM5I1CE ID DM5I1CE
DM5I1CE DN Valacyclovir Hydrochloride
DM5I1CE HS Approved
DM5I1CE CP Glaxosmithkline
DM5I1CE TC Antiinfective Agents
DM5I1CE DT Small molecular drug
DM5I1CE PC 135398741
DM5I1CE MW 360.8
DM5I1CE FM C13H21ClN6O4
DM5I1CE IC InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1
DM5I1CE CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N.Cl
DM5I1CE IK ZCDDBUOENGJMLV-QRPNPIFTSA-N
DM5I1CE IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM5I1CE CA CAS 124832-27-5
DM5I1CE CB CHEBI:9919
DM5I1CE DE Herpes simplex virus infection
DMQSA2V ID DMQSA2V
DMQSA2V DN Valbenazine tosylate
DMQSA2V HS Approved
DMQSA2V SN Valbenazine ditosylate; UNII-5SML1T733B; 5SML1T733B; Valbenazine tosylate [USAN]; Valbenazine tosylate (USAN); 1639208-54-0; NBI-98854 ditosylate
DMQSA2V CP Neurocrine Biosciences
DMQSA2V DT Small molecular drug
DMQSA2V PC 92042922
DMQSA2V MW 763
DMQSA2V FM C38H54N2O10S2
DMQSA2V IC InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1
DMQSA2V CS CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMQSA2V IK BXGKAGLZHGYAMW-TZYFFPFWSA-N
DMQSA2V IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid
DMQSA2V CA CAS 1639208-54-0
DMQSA2V DE Tardive dyskinesia
DMAY7H4 ID DMAY7H4
DMAY7H4 DN Valdecoxib
DMAY7H4 HS Approved
DMAY7H4 SN Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
DMAY7H4 TC Antiinflammatory Agents
DMAY7H4 DT Small molecular drug
DMAY7H4 PC 119607
DMAY7H4 MW 314.4
DMAY7H4 FM C16H14N2O3S
DMAY7H4 IC InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
DMAY7H4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
DMAY7H4 IK LNPDTQAFDNKSHK-UHFFFAOYSA-N
DMAY7H4 IU 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
DMAY7H4 CA CAS 181695-72-7
DMAY7H4 CB CHEBI:63634
DMAY7H4 DE Osteoarthritis
DMS2IUH ID DMS2IUH
DMS2IUH DN Valganciclovir
DMS2IUH HS Approved
DMS2IUH SN Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
DMS2IUH CP Roche Laboratories Inc
DMS2IUH TC Antiviral Agents
DMS2IUH DT Small molecular drug
DMS2IUH PC 135413535
DMS2IUH MW 354.36
DMS2IUH FM C14H22N6O5
DMS2IUH IC InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
DMS2IUH CS CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
DMS2IUH IK WPVFJKSGQUFQAP-GKAPJAKFSA-N
DMS2IUH IU [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
DMS2IUH CA CAS 175865-60-8
DMS2IUH CB CHEBI:63635
DMS2IUH DE Virus infection
DMCFE9I ID DMCFE9I
DMCFE9I DN Valproate
DMCFE9I HS Approved
DMCFE9I SN 99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)
DMCFE9I CP Abbot Phamaceuticals
DMCFE9I TC Neurology Agents
DMCFE9I DT Small molecular drug
DMCFE9I PC 3121
DMCFE9I MW 144.21
DMCFE9I FM C8H16O2
DMCFE9I IC InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
DMCFE9I CS CCCC(CCC)C(=O)O
DMCFE9I IK NIJJYAXOARWZEE-UHFFFAOYSA-N
DMCFE9I IU 2-propylpentanoic acid
DMCFE9I CA CAS 99-66-1
DMCFE9I CB CHEBI:39867
DMCFE9I DE Epilepsy; Alcohol dependence
DMOYJFK ID DMOYJFK
DMOYJFK DN Valrubicin
DMOYJFK HS Approved
DMOYJFK SN Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
DMOYJFK TC Anticancer Agents
DMOYJFK DT Small molecular drug
DMOYJFK PC 454216
DMOYJFK MW 723.6
DMOYJFK FM C34H36F3NO13
DMOYJFK IC InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
DMOYJFK CS CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O
DMOYJFK IK ZOCKGBMQLCSHFP-KQRAQHLDSA-N
DMOYJFK IU [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
DMOYJFK CA CAS 56124-62-0
DMOYJFK CB CHEBI:135876
DMOYJFK DE Bladder cancer; Psoriasis vulgaris
DMREUQ6 ID DMREUQ6
DMREUQ6 DN Valsartan
DMREUQ6 HS Approved
DMREUQ6 SN valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis; Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan
DMREUQ6 CP Norvatis Phamaceuticals Corporation
DMREUQ6 TC Antihypertensive Agents
DMREUQ6 DT Small molecular drug
DMREUQ6 PC 60846
DMREUQ6 MW 435.5
DMREUQ6 FM C24H29N5O3
DMREUQ6 IC InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
DMREUQ6 CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
DMREUQ6 IK ACWBQPMHZXGDFX-QFIPXVFZSA-N
DMREUQ6 IU (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
DMREUQ6 CA CAS 137862-53-4
DMREUQ6 CB CHEBI:9927
DMREUQ6 DE Hypertension
DMK7T1Q ID DMK7T1Q
DMK7T1Q DN Vancomycin
DMK7T1Q HS Approved
DMK7T1Q SN Vancocin; Vancoled; Vancomicina; Vancomicina [INN-Spanish]; Vancomycin (USP); Vancomycin [USAN:INN:BAN]; Vancomycin [USP:INN:BAN]; Vancomycine; Vancomycine [INN-French]; Vancomycinum; Vancomycinum [INN-Latin]; Viomycin derivative; VANCOMYCIN; VANCOR; vancomicin; vanomycin; 1404-90-6; 6Q205EH1VU; C66H75Cl2N9O24; CHEBI:28001; CHEMBL262777; EINECS 215-772-6; HSDB 3262; UNII-6Q205EH1VU; Vancomycin hydrochloride from Streptomyces orientalis
DMK7T1Q PC 14969
DMK7T1Q MW 1449.2
DMK7T1Q FM C66H75Cl2N9O24
DMK7T1Q IC MYPYJXKWCTUITO-LYRMYLQWSA-N
DMK7T1Q CS CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMK7T1Q IK 1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
DMK7T1Q IU (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DMK7T1Q CA CAS 1404-90-6
DMK7T1Q CB CHEBI:28001
DMK7T1Q DE Methicillin-resistant staphylococcus infection
DMRICNP ID DMRICNP
DMRICNP DN Vandetanib
DMRICNP HS Approved
DMRICNP SN Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
DMRICNP CP AstraZeneca
DMRICNP TC Anticancer Agents
DMRICNP DT Small molecular drug
DMRICNP PC 3081361
DMRICNP MW 475.4
DMRICNP FM C22H24BrFN4O2
DMRICNP IC InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
DMRICNP CS CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
DMRICNP IK UHTHHESEBZOYNR-UHFFFAOYSA-N
DMRICNP IU N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
DMRICNP CA CAS 443913-73-3
DMRICNP CB CHEBI:49960
DMRICNP DE Solid tumour/cancer
DMTBGW8 ID DMTBGW8
DMTBGW8 DN Vardenafil
DMTBGW8 HS Approved
DMTBGW8 SN VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol
DMTBGW8 CP Bayer Pharmaceuticals Corporation
DMTBGW8 TC Antiimpotence Agents
DMTBGW8 DT Small molecular drug
DMTBGW8 PC 135400189
DMTBGW8 MW 488.6
DMTBGW8 FM C23H32N6O4S
DMTBGW8 IC InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
DMTBGW8 CS CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
DMTBGW8 IK SECKRCOLJRRGGV-UHFFFAOYSA-N
DMTBGW8 IU 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
DMTBGW8 CA CAS 224785-90-4
DMTBGW8 CB CHEBI:46295
DMTBGW8 DE Erectile dysfunction
DMMUOLJ ID DMMUOLJ
DMMUOLJ DN Varenicline
DMMUOLJ HS Approved
DMMUOLJ SN CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
DMMUOLJ CP Pfizer Pharmaceuticals
DMMUOLJ DT Small molecular drug
DMMUOLJ PC 170361
DMMUOLJ MW 211.26
DMMUOLJ FM C13H13N3
DMMUOLJ IC InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
DMMUOLJ CS C1C2CNCC1C3=CC4=NC=CN=C4C=C23
DMMUOLJ IK JQSHBVHOMNKWFT-UHFFFAOYSA-N
DMMUOLJ IU 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
DMMUOLJ CA CAS 249296-44-4
DMMUOLJ DE Smoking dependence
DMQ2FPC ID DMQ2FPC
DMQ2FPC DN Vasopressin
DMQ2FPC HS Approved
DMQ2FPC SN Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
DMQ2FPC CP Astellas Pharma
DMQ2FPC TC Vasoconstrictor Agents
DMQ2FPC DT Small molecular drug
DMQ2FPC PC 644077
DMQ2FPC MW 1084.2
DMQ2FPC FM C46H65N15O12S2
DMQ2FPC IC InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMQ2FPC CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMQ2FPC IK KBZOIRJILGZLEJ-LGYYRGKSSA-N
DMQ2FPC IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMQ2FPC CA CAS 113-79-1
DMQ2FPC CB CHEBI:34543
DMQ2FPC DE Diabetes insipidus; Polyuria; Enuresis
DMP0UK2 ID DMP0UK2
DMP0UK2 DN Vecuronium
DMP0UK2 HS Approved
DMP0UK2 SN Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2 CP Bedford Laboratories
DMP0UK2 TC Analgesics
DMP0UK2 DT Small molecular drug
DMP0UK2 PC 39765
DMP0UK2 MW 557.8
DMP0UK2 FM C34H57N2O4+
DMP0UK2 IC InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMP0UK2 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMP0UK2 IK BGSZAXLLHYERSY-XQIGCQGXSA-N
DMP0UK2 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2 CA CAS 86029-43-8
DMP0UK2 CB CHEBI:9939
DMP0UK2 DE Spasm
DMV3YMX ID DMV3YMX
DMV3YMX DN Vedolizmab
DMV3YMX HS Approved
DMV3YMX SN 4168-17-6
DMV3YMX CP Millennium Pharmaceuticals
DMV3YMX DT Monoclonal antibody
DMV3YMX DE Crohn disease; Ulcerative colitis
DM4BOAS ID DM4BOAS
DM4BOAS DN Velaglucerase alfa
DM4BOAS HS Approved
DM4BOAS SN Vpriv (TN)
DM4BOAS CP Shire
DM4BOAS SQ VPRIV Sequence: ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
DM4BOAS DE Metabolic disorder
DMGF8ZQ ID DMGF8ZQ
DMGF8ZQ DN Velpatasvir
DMGF8ZQ HS Approved
DMGF8ZQ SN Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
DMGF8ZQ PC 67683363
DMGF8ZQ MW 883
DMGF8ZQ FM C49H54N8O8
DMGF8ZQ IC FHCUMDQMBHQXKK-CDIODLITSA-N
DMGF8ZQ CS CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
DMGF8ZQ IK 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
DMGF8ZQ IU methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
DMGF8ZQ CA CAS 1377049-84-7
DMGF8ZQ CB CHEBI:133009
DMGF8ZQ DE Viral hepatitis
DM62UG5 ID DM62UG5
DM62UG5 DN Vemurafenib
DM62UG5 HS Approved
DM62UG5 SN PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
DM62UG5 CP Daiichi Sankyo group; Genentech
DM62UG5 DT Small molecular drug
DM62UG5 PC 42611257
DM62UG5 MW 489.9
DM62UG5 FM C23H18ClF2N3O3S
DM62UG5 IC InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
DM62UG5 CS CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
DM62UG5 IK GPXBXXGIAQBQNI-UHFFFAOYSA-N
DM62UG5 IU N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
DM62UG5 CA CAS 918504-65-1
DM62UG5 CB CHEBI:63637
DM62UG5 DE Melanoma
DM8I94Y ID DM8I94Y
DM8I94Y DN Venetoclax
DM8I94Y HS Approved
DM8I94Y SN Venclexta
DM8I94Y DT Small molecular drug
DM8I94Y PC 49846579
DM8I94Y MW 868.447
DM8I94Y FM C45H50ClN7O7S
DM8I94Y IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DM8I94Y CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DM8I94Y IK LQBVNQSMGBZMKD-UHFFFAOYSA-N
DM8I94Y IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DM8I94Y CA CAS 1257044-40-8
DM8I94Y CB CHEBI:133021
DM8I94Y DE Chronic lymphocytic leukemia
DMR6QH0 ID DMR6QH0
DMR6QH0 DN Venlafaxine
DMR6QH0 HS Approved
DMR6QH0 SN Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol
DMR6QH0 CP Wyeth
DMR6QH0 TC Antidepressants
DMR6QH0 DT Small molecular drug
DMR6QH0 PC 5656
DMR6QH0 MW 277.4
DMR6QH0 FM C17H27NO2
DMR6QH0 IC InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
DMR6QH0 CS CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
DMR6QH0 IK PNVNVHUZROJLTJ-UHFFFAOYSA-N
DMR6QH0 IU 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
DMR6QH0 CA CAS 93413-69-5
DMR6QH0 CB CHEBI:9943
DMR6QH0 DE Depression
DMA7PEW ID DMA7PEW
DMA7PEW DN Verapamil
DMA7PEW HS Approved
DMA7PEW SN Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)
DMA7PEW CP Pfizer Inc
DMA7PEW TC Analgesics
DMA7PEW DT Small molecular drug
DMA7PEW PC 2520
DMA7PEW MW 454.6
DMA7PEW FM C27H38N2O4
DMA7PEW IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DMA7PEW CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DMA7PEW IK SGTNSNPWRIOYBX-UHFFFAOYSA-N
DMA7PEW IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DMA7PEW CA CAS 52-53-9
DMA7PEW CB CHEBI:77733
DMA7PEW DE Hypertension
DM7MDBE ID DM7MDBE
DM7MDBE DN Vericiguat
DM7MDBE HS Approved
DM7MDBE SN Vericiguat; 1350653-20-1; UNII-LV66ADM269; BAY-1021189; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY1021189; LV66ADM269; MK-1242; Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate; methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)carbam
DM7MDBE CP Bayer HealthCare Pharmaceuticals
DM7MDBE DT Small molecular drug
DM7MDBE PC 54674461
DM7MDBE MW 426.4
DM7MDBE FM C19H16F2N8O2
DM7MDBE IC InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
DM7MDBE CS COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
DM7MDBE IK QZFHIXARHDBPBY-UHFFFAOYSA-N
DM7MDBE IU methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
DM7MDBE CA CAS 1350653-20-1
DM7MDBE CB CHEBI:142432
DM7MDBE DE Heart failure
DMIY6DB ID DMIY6DB
DMIY6DB DN Verteporfin
DMIY6DB HS Approved
DMIY6DB SN Visudyne (TN)
DMIY6DB DT Small molecular drug
DMIY6DB PC 11980904
DMIY6DB MW 1437.6
DMIY6DB FM C82H84N8O16
DMIY6DB IC InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1
DMIY6DB CS CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C
DMIY6DB IK NJLRKAMQPVVOIU-IDLGWYNRSA-N
DMIY6DB IU 3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid;3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-5-yl]propanoic acid
DMIY6DB DE Psoriasis vulgaris
DMBKX3C ID DMBKX3C
DMBKX3C DN VESNARINONE
DMBKX3C HS Approved
DMBKX3C SN vesnarinone; 81840-15-5; Arkin-Z; Piteranometozine; OPC-8212; Arkin; Vesnarinonum [Latin]; Vesnarinona [Spanish]; UNII-5COW40EV8M; OPC 8212; Vesnarinone [USAN:INN:JAN]; CCRIS 1451; DRG-0210; BRN 5644229; 5COW40EV8M; CHEMBL17423; 6-(4-(3,4-Dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1H)-; 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine; 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one; 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1H)-quinolinone
DMBKX3C DT Small molecular drug
DMBKX3C PC 5663
DMBKX3C MW 395.5
DMBKX3C FM C22H25N3O4
DMBKX3C IC InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
DMBKX3C CS COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
DMBKX3C IK ZVNYJIZDIRKMBF-UHFFFAOYSA-N
DMBKX3C IU 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
DMBKX3C CA CAS 81840-15-5
DMBKX3C CB CHEBI:31237
DMBKX3C DE Cardiac failure
DM4UHZF ID DM4UHZF
DM4UHZF DN Vestronidase alfa
DM4UHZF HS Approved
DM4UHZF CP Ultragenyx
DM4UHZF DE Mucopolysaccharidosis
DMFR201 ID DMFR201
DMFR201 DN Vibegron
DMFR201 HS Approved
DMFR201 SN MK-4618
DMFR201 CP Merck
DMFR201 PC 44472635
DMFR201 MW 444.5
DMFR201 FM C26H28N4O3
DMFR201 IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMFR201 CS C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O
DMFR201 IK DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMFR201 IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMFR201 CA CAS 1190389-15-1
DMFR201 CB CHEBI:142418
DMFR201 DE Overactive bladder
DM0N85H ID DM0N85H
DM0N85H DN Vidarabine
DM0N85H HS Approved
DM0N85H SN Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine
DM0N85H TC Antiviral Agents
DM0N85H DT Small molecular drug
DM0N85H PC 21704
DM0N85H MW 267.24
DM0N85H FM C10H13N5O4
DM0N85H IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
DM0N85H CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DM0N85H IK OIRDTQYFTABQOQ-UHTZMRCNSA-N
DM0N85H IU (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM0N85H CA CAS 5536-17-4
DM0N85H CB CHEBI:45327
DM0N85H DE Herpes simplex virus infection
DMYT0OG ID DMYT0OG
DMYT0OG DN Vigabatrin
DMYT0OG HS Approved
DMYT0OG SN GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid
DMYT0OG CP Ovation Pharma; Lundbeck
DMYT0OG TC Anticonvulsants
DMYT0OG DT Small molecular drug
DMYT0OG PC 5665
DMYT0OG MW 129.16
DMYT0OG FM C6H11NO2
DMYT0OG IC InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
DMYT0OG CS C=CC(CCC(=O)O)N
DMYT0OG IK PJDFLNIOAUIZSL-UHFFFAOYSA-N
DMYT0OG IU 4-aminohex-5-enoic acid
DMYT0OG CA CAS 68506-86-5
DMYT0OG CB CHEBI:63638
DMYT0OG DE Complex partial seizure; Infantile spasm; Epilepsy
DMF5EK1 ID DMF5EK1
DMF5EK1 DN Vilanterol
DMF5EK1 HS Approved
DMF5EK1 SN 503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair
DMF5EK1 CP GlaxoSmithKline
DMF5EK1 DT Small molecular drug
DMF5EK1 PC 10184665
DMF5EK1 MW 486.4
DMF5EK1 FM C24H33Cl2NO5
DMF5EK1 IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
DMF5EK1 CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl
DMF5EK1 IK DAFYYTQWSAWIGS-DEOSSOPVSA-N
DMF5EK1 IU 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMF5EK1 CA CAS 503068-34-6
DMF5EK1 CB CHEBI:75037
DMF5EK1 DE Chronic obstructive pulmonary disease
DM4LECQ ID DM4LECQ
DM4LECQ DN Vilazodone
DM4LECQ HS Approved
DM4LECQ SN Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
DM4LECQ CP Genaissance and Merck KGaA
DM4LECQ DT Small molecular drug
DM4LECQ PC 6918314
DM4LECQ MW 441.5
DM4LECQ FM C26H27N5O2
DM4LECQ IC InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
DM4LECQ CS C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
DM4LECQ IK SGEGOXDYSFKCPT-UHFFFAOYSA-N
DM4LECQ IU 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
DM4LECQ CA CAS 163521-12-8
DM4LECQ CB CHEBI:70707
DM4LECQ DE Major depressive disorder
DMYN59P ID DMYN59P
DMYN59P DN Vildagliptin
DMYN59P HS Approved
DMYN59P SN Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
DMYN59P CP Novartis
DMYN59P DT Small molecular drug
DMYN59P PC 6918537
DMYN59P MW 303.4
DMYN59P FM C17H25N3O2
DMYN59P IC InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
DMYN59P CS C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
DMYN59P IK SYOKIDBDQMKNDQ-XWTIBIIYSA-N
DMYN59P IU (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
DMYN59P CA CAS 274901-16-5
DMYN59P CB CHEBI:135285
DMYN59P DE Type-2 diabetes
DM5TVS3 ID DM5TVS3
DM5TVS3 DN Vinblastine
DM5TVS3 HS Approved
DM5TVS3 SN Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
DM5TVS3 CP Eli Lilly And Co
DM5TVS3 TC Anticancer Agents
DM5TVS3 DT Small molecular drug
DM5TVS3 PC 13342
DM5TVS3 MW 811
DM5TVS3 FM C46H58N4O9
DM5TVS3 IC InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
DM5TVS3 CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DM5TVS3 IK JXLYSJRDGCGARV-CFWMRBGOSA-N
DM5TVS3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DM5TVS3 CA CAS 865-21-4
DM5TVS3 DE Solid tumour/cancer
DMK1ZOR ID DMK1ZOR
DMK1ZOR DN Vincamine
DMK1ZOR HS Approved
DMK1ZOR SN vincamine; 1617-90-9; Pervincamine; Devincan; Minorine; Vincamidol; Novicet; Monorin; Methyl vincaminate; Arteriovinca; Vincasaunier; Vinkametrin; Devinkan; Decincan; Vincapront; Vincafolina; Vincadar; Tripervan; Angiopac; Anasclerol; (+)-Vincamine; Equipur; Pervone; Oxygeron; Vincafor; Perval; Ocu-vinc; Vincamina [DCIT]; Vincimax; Vincamine base; Vincaminum [INN-Latin]; UNII-996XVD0JHT; Vincamine [INN:BAN:DCF]; Minorin; Vincachron; Vincapan; Vincamin; Vincagil; Vinca; Vinodrel retard; Vinca-Minor; Vinca-Ecobi; HSDB 7150; Anasclerol (base)
DMK1ZOR DT Small molecular drug
DMK1ZOR PC 15376
DMK1ZOR MW 354.4
DMK1ZOR FM C21H26N2O3
DMK1ZOR IC InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
DMK1ZOR CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O
DMK1ZOR IK RXPRRQLKFXBCSJ-GIVPXCGWSA-N
DMK1ZOR IU methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
DMK1ZOR CA CAS 1617-90-9
DMK1ZOR CB CHEBI:9985
DMK1ZOR DE Cerebrovascular disease
DMINOX3 ID DMINOX3
DMINOX3 DN Vincristine
DMINOX3 HS Approved
DMINOX3 SN LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
DMINOX3 CP Mayne Pharma Limited
DMINOX3 TC Anticancer Agents
DMINOX3 DT Small molecular drug
DMINOX3 PC 5978
DMINOX3 MW 825
DMINOX3 FM C46H56N4O10
DMINOX3 IC InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
DMINOX3 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DMINOX3 IK OGWKCGZFUXNPDA-XQKSVPLYSA-N
DMINOX3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMINOX3 CA CAS 57-22-7
DMINOX3 CB CHEBI:28445
DMINOX3 DE Acute lymphoblastic leukaemia
DMVR628 ID DMVR628
DMVR628 DN Vindesine
DMVR628 HS Approved
DMVR628 SN DAVA; Vindesin; Vindesina; Vindesinum; Desacetylvinblastine amide; Lilly 112531; Vindesina [INN-Spanish]; Vindesinum [INN-Latin]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
DMVR628 TC Anticancer Agents
DMVR628 DT Small molecular drug
DMVR628 PC 40839
DMVR628 MW 753.9
DMVR628 FM C43H55N5O7
DMVR628 IC InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
DMVR628 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
DMVR628 IK HHJUWIANJFBDHT-KOTLKJBCSA-N
DMVR628 IU methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
DMVR628 CA CAS 53643-48-4
DMVR628 CB CHEBI:36373
DMVR628 DE Acute lymphoblastic leukaemia
DMVXFYE ID DMVXFYE
DMVXFYE DN Vinorelbine
DMVXFYE HS Approved
DMVXFYE SN Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
DMVXFYE CP GlaxoSmithKline
DMVXFYE TC Anticancer Agents
DMVXFYE DT Small molecular drug
DMVXFYE PC 5311497
DMVXFYE MW 778.9
DMVXFYE FM C45H54N4O8
DMVXFYE IC InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
DMVXFYE CS CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
DMVXFYE IK GBABOYUKABKIAF-IELIFDKJSA-N
DMVXFYE IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMVXFYE CA CAS 71486-22-1
DMVXFYE CB CHEBI:480999
DMVXFYE DE Solid tumour/cancer
DMVN2E6 ID DMVN2E6
DMVN2E6 DN Vinpocetine
DMVN2E6 HS Approved
DMVN2E6 SN Bravinton; Cavinton; Ceractin; Vinpocetinum; Apovincaminic acid ethyl ester; AY 27255; RGH 4405; TCV 3B; V 6383; V6383_SIGMA; AY 27,255; Apovincaminate d'ethyle; Apovincaminate d'ethyle [French]; Cavinton (TN); Cis-Apovincaminic acid ethyl ester; Intelectol (TN); RGH-4405; TCV-3B; Ultra-Vinca; Vinpocetine-ethyl apovincaminate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincamin-22-oate; Vinpocetine [USAN:INN:JAN]; Ethyl (+)-apovincaminate; Vinpocetine (JAN/USAN/INN); Ethyl(+)-cis-apovincaminate; Ethyl apovincaminate, (3alpha,16alpha)-isomer; Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (+)-Apovincaminic acid ethyl ester; (+)-cis-Apovincaminic acid ethyl ester; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; 3-alpha,16-alpha-Apovincaminic acid ethyl ester
DMVN2E6 TC Vasodilator Agents
DMVN2E6 DT Small molecular drug
DMVN2E6 PC 443955
DMVN2E6 MW 350.5
DMVN2E6 FM C22H26N2O2
DMVN2E6 IC InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
DMVN2E6 CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC
DMVN2E6 IK DDNCQMVWWZOMLN-IRLDBZIGSA-N
DMVN2E6 IU ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
DMVN2E6 CA CAS 42971-09-5
DMVN2E6 CB CHEBI:32297
DMVN2E6 DE Ischemic stroke
DMZYLFC ID DMZYLFC
DMZYLFC DN Viomycin sulfate
DMZYLFC HS Approved
DMZYLFC SN Viocin (TN)
DMZYLFC DT Small molecular drug
DMZYLFC PC 135524783
DMZYLFC MW 783.8
DMZYLFC FM C25H45N13O14S
DMZYLFC IC InChI=1S/C25H43N13O10.H2O4S/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;1-5(2,3)4/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);(H2,1,2,3,4)/b13-7-;/t10-,11+,12-,14-,15-,17-,18-;/m0./s1
DMZYLFC CS C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O
DMZYLFC IK AQONYROJHRNYQQ-QMAPKBLTSA-N
DMZYLFC IU (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide;sulfuric acid
DMZYLFC CA CAS 37883-00-4
DMZYLFC DE Bacterial infection
DM0REZS ID DM0REZS
DM0REZS DN Virulizin
DM0REZS HS Approved
DM0REZS SN Virulizin (TN)
DM0REZS CP Lorus Therapeutics
DM0REZS DE Breast cancer
DM5IXKQ ID DM5IXKQ
DM5IXKQ DN Vismodegib
DM5IXKQ HS Approved
DM5IXKQ SN 879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
DM5IXKQ CP Genentech
DM5IXKQ DT Small molecular drug
DM5IXKQ PC 24776445
DM5IXKQ MW 421.3
DM5IXKQ FM C19H14Cl2N2O3S
DM5IXKQ IC InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
DM5IXKQ CS CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
DM5IXKQ IK BPQMGSKTAYIVFO-UHFFFAOYSA-N
DM5IXKQ IU 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
DM5IXKQ CA CAS 879085-55-9
DM5IXKQ CB CHEBI:66903
DM5IXKQ DE Basal cell carcinoma; Primitive neuroectodermal tumour medulloblastoma
DMJ2AH4 ID DMJ2AH4
DMJ2AH4 DN Vitamin A
DMJ2AH4 HS Approved
DMJ2AH4 SN Retinol; retinol; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Oleovitamin A; Chocola A; Ophthalamin; Epiteliol; Biosterol; Aquasynth; Apostavit; Alphasterol; Veroftal; Testavol; Anatola; Prepalin; Myvpack; Agoncal; Agiolan; Vogan; Axerol; Vitpex; Avibon; Apexol; Aoral; Vaflol; Dofsol; Avitol; Vitamin A alcohol; Disatabs Tabs; Lard Factor; Bentavit A; Dohyfral A; all-trans-Retinyl alcohol; Alcovit A; Vogan-Neu; Anatola A; Plivit A; A-Mulsal; Vi-Alpha; A-Vitan; All-trans retinol; Atars; Vafol; trans-retinol; all-trans-Vitamin A; ACON; ATAV; Alin; Avita; Axerophtholum; Cylasphere; LPK; Retinolo; Retinolum; TROL; Thalasphere; Wachstumsvitamin; All Trans Retinol; Antixerophthalmic vitamin; Antixerophthalmisches Vitamin; Aquasol A Parenteral; Homagenets Aoral; Homagenets aorl; Hydrovit A; Mvc Plus; Retinol solution; Retinolo [DCIT]; Retrovitamin A; Sehkraft A; Super A; Testavol S; Vitamin A cryst; Vitamine A; Vitaminum A; Vitavel A; Zinosan N; Rovimix A 500; Vitamin A1 alcohol; A-Sol; Anti-infective vitamin; Beta-Retinol; Retinol [INN:BAN]; Retinolum [INN-Latin]; Solu-A; Trans-Vitamin A alcohol; Trans-retinol; Vi-a; Vi-alpha; Vio-A; Vitamin A (Feed); Vitamin A (USP); Vitamin A alcohol (VAN); Vitamin A1 alcohol, all trans; Vitamin-A; Vitamin-A alcohol; Vitamin-A alcohol solution; Vitamin-A1; Vitavel-A; Vogan-nu; A-Vi-Pel; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); All-trans-Retinol; All-trans-Retinyl alcohol; All-trans-Vitamin A; All-trans-Vitamin A alcohol; All-trans-Vitamin A1; Del-VI-A; Hi-A-Vita; Nio-A-Let; Ro-a-vit; Trans-Retinol acid (Vitamin A); Vi-Dom-A; [11,12-3H]-Retinol; MVC 9+3; MVI-12; Retinol, all-trans-(8CI); Retin-11,12-t2-ol (9CI); Retinol-(cellular-retinol-binding-protein); Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; All-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; Tricyclics
DMJ2AH4 TC Vitamins
DMJ2AH4 DT Small molecular drug
DMJ2AH4 PC 445354
DMJ2AH4 MW 286.5
DMJ2AH4 FM C20H30O
DMJ2AH4 IC InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DMJ2AH4 CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C
DMJ2AH4 IK FPIPGXGPPPQFEQ-OVSJKPMPSA-N
DMJ2AH4 IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
DMJ2AH4 CA CAS 11103-57-4
DMJ2AH4 CB CHEBI:17336
DMJ2AH4 DE Night blindness; Kinetoplastids
DMZ1WXJ ID DMZ1WXJ
DMZ1WXJ DN Vitamin B1
DMZ1WXJ HS Approved
DMZ1WXJ SN 59-43-8; Thiamine monochloride; Aneurine; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride; Tiamina; Oryzanin; Thiaminum; Oryzanine; Bethiamin; Vitaneurin; Beivon; Apatate drape; Thiamine, chloride; B-Amin; Thiamine [INN:BAN]; Tiamina [INN-Spanish]; Thiaminum [INN-Latin]; UNII-X66NSO3N35; CCRIS 5823; HSDB 220; thiamine(1+) chloride; EINECS 200-425-3; X66NSO3N35; CHEBI:33283; AK109288; Thiamine (Vit B1); Thiazolium,
DMZ1WXJ TC Vitamins
DMZ1WXJ DT Small molecular drug
DMZ1WXJ PC 6042
DMZ1WXJ MW 300.81
DMZ1WXJ FM C12H17ClN4OS
DMZ1WXJ IC InChI=1S/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1
DMZ1WXJ CS CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-]
DMZ1WXJ IK MYVIATVLJGTBFV-UHFFFAOYSA-M
DMZ1WXJ IU 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride
DMZ1WXJ CA CAS 59-43-8
DMZ1WXJ CB CHEBI:33283
DMZ1WXJ DE Vitamin B1 deficiency
DMQVRZH ID DMQVRZH
DMQVRZH DN Vitamin B3
DMQVRZH HS Approved
DMQVRZH SN Niacin (TN); Niacinamide (TN); Nicotinamide (TN)
DMQVRZH CP Anmar
DMQVRZH DT Small molecular drug
DMQVRZH PC 938
DMQVRZH MW 123.11
DMQVRZH FM C6H5NO2
DMQVRZH IC InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
DMQVRZH CS C1=CC(=CN=C1)C(=O)O
DMQVRZH IK PVNIIMVLHYAWGP-UHFFFAOYSA-N
DMQVRZH IU pyridine-3-carboxylic acid
DMQVRZH CA CAS 59-67-6
DMQVRZH CB CHEBI:15940
DMQVRZH DE Lipid metabolism disorder
DMDBZMV ID DMDBZMV
DMDBZMV DN Vitamin B6
DMDBZMV HS Approved
DMDBZMV SN Aderoxin; Alestrol; Becilan; Beesix; Benadon; Bonasanit; Godabion; Hexavibex; Hexermin; Hexermine; Hexobion; Nestrex; Paxadon; Pydox; Pyridipca; Pyridox; Spondylonal; Vitaped; Adermin hydrochloride; Adermine hydrochloride; Aderomine hydrochloride; Component of Alestrol; Hexabione hydrochloride; PN HCl; PYRIDOXINE HYDROCHLORIDE; Pyridoxin hydrochloride; Pyridoxine HCl; Pyridoxine chloride; Pyridoxine hydrogen chloride; Pyridoxine monohydrochloride; Pyridoxinium chloride; Pyridoxinum hydrochloricum; Pyridoxol hydrochloride; Rodex TD; AIDS006784; Campoviton 6; Vitamin V6; AIDS-006784; Cernevit-12; Pyridoxine (INN); Pyridoxine Hydrochloride (B6); Pyridoxine hydrochloride[USAN:JAN]; Pyridoxine, hydrochloride; Pyridoxine-HCl Microencapsulated; Pyridoxinum hydrochloricum (Hungarian); Pyridoxol, hydrochloride; Rodex (R); Vitamin B6-hydrochloride; Vitamin V6 (TN); Vitamin-B6 hydrochloride; Hexa-Betalin (R); Hexa-betalin (TN); Pyridoxine hydrochloride (JP15/USP); Tex Six T.R.; PYRIDOXINE HYDROCHLORIDE, U.S.P.; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 2-methyl-4,5-dimethylol-pyridin-3-ol; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; 4-Deoxypyridoxine 5'-phosphate; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
DMDBZMV TC Vitamins
DMDBZMV DT Small molecular drug
DMDBZMV PC 1054
DMDBZMV MW 169.18
DMDBZMV FM C8H11NO3
DMDBZMV IC InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
DMDBZMV CS CC1=NC=C(C(=C1O)CO)CO
DMDBZMV IK LXNHXLLTXMVWPM-UHFFFAOYSA-N
DMDBZMV IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
DMDBZMV CA CAS 65-23-6
DMDBZMV CB CHEBI:16709
DMDBZMV DE Vitamin B6 deficiency
DMXJ7O8 ID DMXJ7O8
DMXJ7O8 DN Vitamin C
DMXJ7O8 HS Approved
DMXJ7O8 SN l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid
DMXJ7O8 TC Vitamins
DMXJ7O8 DT Small molecular drug
DMXJ7O8 PC 54670067
DMXJ7O8 MW 176.12
DMXJ7O8 FM C6H8O6
DMXJ7O8 IC InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1
DMXJ7O8 CS C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
DMXJ7O8 IK CIWBSHSKHKDKBQ-JLAZNSOCSA-N
DMXJ7O8 IU (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one
DMXJ7O8 CA CAS 50-81-7
DMXJ7O8 CB CHEBI:29073
DMXJ7O8 DE Vitamin C deficiency; Urinary tract infection
DMWQUC9 ID DMWQUC9
DMWQUC9 DN Vitamin D
DMWQUC9 HS Approved
DMWQUC9 SN Vigantol; Vigorsan; Vitamin D3; Vitinc Dan-Dee-3; cholecalciferol; vitamin d-3; (+)-Vitamin D3; Activated 7-dehydrocholesterol; Arachitol; Calciol; Cholecalciferol, D3; Cholecalciferolum; Colecalciferol; Colecalciferolo [DCIT]; Colecalciferolum; Colecalciferolum [INN-Latin]; Colecalcipherol; D3-Vicotrat; D3-Vigantol; Delsterol; Deparal; Duphafral D3 1000; Ebivit; FeraCol; NEO Dohyfral D3; Oleovitamin D3; Quintox; Rampage; Ricketon; Trivitan; VITAMIN D; Vi-De3; Vi-de-3-hydrosol; 1406-16-2; 67-97-0; 7-Dehydrocholestrol, activated;; MFCD00078131
DMWQUC9 PC 5280795
DMWQUC9 MW 384.6
DMWQUC9 FM C27H44O
DMWQUC9 IC QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMWQUC9 CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
DMWQUC9 IK 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMWQUC9 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMWQUC9 CA CAS 67-97-0
DMWQUC9 CB CHEBI:28940
DMWQUC9 DE Hyperparathyroidism
DMZC90K ID DMZC90K
DMZC90K DN Vitamin E
DMZC90K HS Approved
DMZC90K SN Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol)
DMZC90K DT Small molecular drug
DMZC90K PC 14985
DMZC90K MW 430.7
DMZC90K FM C29H50O2
DMZC90K IC InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1
DMZC90K CS CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
DMZC90K IK GVJHHUAWPYXKBD-IEOSBIPESA-N
DMZC90K IU (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
DMZC90K CA CAS 59-02-9
DMZC90K CB CHEBI:18145
DMZC90K DE Cardiovascular disease
DMWIJTN ID DMWIJTN
DMWIJTN DN Voclosporin
DMWIJTN HS Approved
DMWIJTN SN Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Luveniq; Voclosporin [USAN]; R 1524; Trans-ISA 247; Trans-ISA-247; TrkA-IgG
DMWIJTN CP Isotechnika
DMWIJTN DT Small molecular drug
DMWIJTN PC 6918486
DMWIJTN MW 1214.6
DMWIJTN FM C63H111N11O12
DMWIJTN IC InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
DMWIJTN CS CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMWIJTN IK BICRTLVBTLFLRD-PTWUADNWSA-N
DMWIJTN IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMWIJTN CA CAS 515814-00-3
DMWIJTN CB CHEBI:135957
DMWIJTN DE Kidney disease; Psoriasis vulgaris; Lupus nephritis
DMUBP9O ID DMUBP9O
DMUBP9O DN Voglibose
DMUBP9O HS Approved
DMUBP9O SN Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol
DMUBP9O CP Takeda
DMUBP9O TC Hypoglycemic Agents
DMUBP9O DT Small molecular drug
DMUBP9O PC 444020
DMUBP9O MW 267.28
DMUBP9O FM C10H21NO7
DMUBP9O IC InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
DMUBP9O CS C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
DMUBP9O IK FZNCGRZWXLXZSZ-CIQUZCHMSA-N
DMUBP9O IU (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
DMUBP9O CA CAS 83480-29-9
DMUBP9O CB CHEBI:32300
DMUBP9O DE Diabetic complication
DM1YEPS ID DM1YEPS
DM1YEPS DN Volanesorsen
DM1YEPS HS Approved
DM1YEPS CP Akcea Therapeutics Cambridge, MA, Ionis Pharmaceuticals Carlsbad, CA
DM1YEPS DT Antisense oligonucleotide
DM1YEPS PC 121494123
DM1YEPS MW 7165
DM1YEPS FM C230H320N63O125P19S19
DM1YEPS IC InChI=1S/C230H320N63O125P19S19/c1-98-55-274(217(308)254-178(98)231)142-45-112(400-419(322,438)361-70-124-113(46-143(381-124)275-56-99(2)179(232)255-218(275)309)401-423(326,442)367-76-130-119(52-149(387-130)288-92-248-152-183(236)242-89-245-186(152)288)407-427(330,446)369-78-132-121(54-151(389-132)290-94-252-156-190(290)260-215(240)263-202(156)306)408-425(328,444)365-72-125-114(47-144(382-125)276-57-100(3)180(233)256-219(276)310)406-428(331,447)372-81-134-160(171(354-38-28-344-18)206(393-134)283-64-107(10)196(300)269-226(283)317)412-432(335,451)375-84-137-163(173(356-40-30-346-20)208(395-137)285-66-109(12)198(302)271-228(285)319)415-435(338,454)377-86-139-165(175(358-42-32-348-22)210(397-139)287-68-111(14)200(304)273-230(287)321)416-436(339,455)379-87-140-166(176(359-43-33-349-23)212(398-140)292-96-250-154-185(238)244-91-247-188(154)292)417-430(333,449)371-80-133-158(295)168(351-35-25-341-15)204(391-133)282-63-106(9)195(299)268-225(282)316)123(380-142)71-362-421(324,440)403-117-50-147(279-61-104(7)193(297)266-223(279)314)386-128(117)75-366-426(329,445)409-120-53-150(289-93-251-155-189(289)259-214(239)262-201(155)305)388-131(120)77-368-424(327,443)405-118-51-148(280-62-105(8)194(298)267-224(280)315)385-127(118)74-364-422(325,441)404-116-49-146(278-60-103(6)192(296)265-222(278)313)384-126(116)73-363-420(323,439)402-115-48-145(277-58-101(4)181(234)257-220(277)311)383-129(115)79-370-429(332,448)411-162-136(394-207(172(162)355-39-29-345-19)284-65-108(11)197(301)270-227(284)318)83-374-434(337,453)414-164-138(396-209(174(164)357-41-31-347-21)286-67-110(13)199(303)272-229(286)320)85-376-433(336,452)413-161-135(392-205(170(161)353-37-27-343-17)281-59-102(5)182(235)258-221(281)312)82-378-437(340,456)418-167-141(399-213(177(167)360-44-34-350-24)293-97-253-157-191(293)261-216(241)264-203(157)307)88-373-431(334,450)410-159-122(69-294)390-211(169(159)352-36-26-342-16)291-95-249-153-184(237)243-90-246-187(153)291/h55-68,89-97,112-151,158-177,204-213,294-295H,25-54,69-88H2,1-24H3,(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H2,231,254,308)(H2,232,255,309)(H2,233,256,310)(H2,234,257,311)(H2,235,258,312)(H2,236,242,245)(H2,237,243,246)(H2,238,244,247)(H,265,296,313)(H,266,297,314)(H,267,298,315)(H,268,299,316)(H,269,300,317)(H,270,301,318)(H,271,302,319)(H,272,303,320)(H,273,304,321)(H3,239,259,262,305)(H3,240,260,263,306)(H3,241,261,264,307)/t112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,204+,205+,206+,207+,208+,209+,210+,211+,212+,213+,419?,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?/m0/s1
DM1YEPS CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DM1YEPS IK IJUQCWMZCMFFJP-GQSLRNSLSA-N
DM1YEPS IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM1YEPS DE Familial chylomicronemia syndrome; Hyperlipoproteinemia; Hypertriglyceridemia
DMO6315 ID DMO6315
DMO6315 DN Vonoprazan
DMO6315 HS Approved
DMO6315 SN TAK-438
DMO6315 CP Takeda
DMO6315 DT Small molecular drug
DMO6315 PC 45375887
DMO6315 MW 461.5
DMO6315 FM C21H20FN3O6S
DMO6315 IC InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMO6315 CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\\C(=O)O
DMO6315 IK ROGSHYHKHPCCJW-WLHGVMLRSA-N
DMO6315 IU (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMO6315 CA CAS 881681-01-2
DMO6315 DE Gastroesophageal reflux disease; Helicobacter infection
DMI783H ID DMI783H
DMI783H DN Vonvendi
DMI783H HS Approved
DMI783H SN Vonicog alfa
DMI783H CP Vonvendi
DMI783H DT Recombinant protein
DMI783H DE Von willebrand disease
DMA16BR ID DMA16BR
DMA16BR DN Vorapaxar
DMA16BR HS Approved
DMA16BR SN Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny
DMA16BR CP Schering-Plough
DMA16BR DT Small molecular drug
DMA16BR PC 10077130
DMA16BR MW 492.6
DMA16BR FM C29H33FN2O4
DMA16BR IC InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
DMA16BR CS CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C
DMA16BR IK ZBGXUVOIWDMMJE-QHNZEKIYSA-N
DMA16BR IU ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
DMA16BR CA CAS 618385-01-6
DMA16BR CB CHEBI:82702
DMA16BR DE Myocardial infarction
DMAOL2S ID DMAOL2S
DMAOL2S DN Voriconazole
DMAOL2S HS Approved
DMAOL2S SN VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
DMAOL2S CP Pfizer
DMAOL2S TC Antifungal Agents
DMAOL2S DT Small molecular drug
DMAOL2S PC 71616
DMAOL2S MW 349.31
DMAOL2S FM C16H14F3N5O
DMAOL2S IC InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
DMAOL2S CS C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
DMAOL2S IK BCEHBSKCWLPMDN-MGPLVRAMSA-N
DMAOL2S IU (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMAOL2S CA CAS 188416-29-7
DMAOL2S CB CHEBI:10023
DMAOL2S DE Invasive aspergillosis
DMWMPD4 ID DMWMPD4
DMWMPD4 DN Vorinostat
DMWMPD4 HS Approved
DMWMPD4 SN NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)
DMWMPD4 CP Merck
DMWMPD4 TC Anticancer Agents
DMWMPD4 DT Small molecular drug
DMWMPD4 PC 5311
DMWMPD4 MW 264.32
DMWMPD4 FM C14H20N2O3
DMWMPD4 IC InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
DMWMPD4 CS C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
DMWMPD4 IK WAEXFXRVDQXREF-UHFFFAOYSA-N
DMWMPD4 IU N'-hydroxy-N-phenyloctanediamide
DMWMPD4 CA CAS 149647-78-9
DMWMPD4 CB CHEBI:45716
DMWMPD4 DE Cutaneous T-cell lymphoma
DM6F1PU ID DM6F1PU
DM6F1PU DN Vortioxetine
DM6F1PU HS Approved
DM6F1PU SN VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004
DM6F1PU CP Lundbeck; Takeda Pharmaceuticals
DM6F1PU DT Small molecular drug
DM6F1PU PC 9966051
DM6F1PU MW 298.4
DM6F1PU FM C18H22N2S
DM6F1PU IC InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
DM6F1PU CS CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
DM6F1PU IK YQNWZWMKLDQSAC-UHFFFAOYSA-N
DM6F1PU IU 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
DM6F1PU CA CAS 508233-74-7
DM6F1PU CB CHEBI:76016
DM6F1PU DE Major depressive disorder; Mood disorder
DMCS6M5 ID DMCS6M5
DMCS6M5 DN Voxelotor
DMCS6M5 HS Approved
DMCS6M5 SN Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S
DMCS6M5 CP Global Blood Therapeutics South San Francisco, CA
DMCS6M5 PC 71602803
DMCS6M5 MW 337.4
DMCS6M5 FM C19H19N3O3
DMCS6M5 IC InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
DMCS6M5 CS CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
DMCS6M5 IK FWCVZAQENIZVMY-UHFFFAOYSA-N
DMCS6M5 IU 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
DMCS6M5 CA CAS 1446321-46-5
DMCS6M5 DE Sickle-cell disorder
DMAI83D ID DMAI83D
DMAI83D DN Voxilaprevir
DMAI83D HS Approved
DMAI83D SN Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F; 1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359
DMAI83D PC 89921642
DMAI83D MW 868.9
DMAI83D FM C40H52F4N6O9S
DMAI83D IC MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMAI83D CS CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMAI83D IK 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMAI83D IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMAI83D CA CAS 1535212-07-7
DMAI83D DE Viral hepatitis
DMIO4V5 ID DMIO4V5
DMIO4V5 DN VRX496
DMIO4V5 HS Approved
DMIO4V5 SN Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV; NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
DMIO4V5 CP VIRxSYS Corporation
DMIO4V5 TC Antisense
DMIO4V5 DT Antisense drug
DMIO4V5 DE Acquired immune deficiency syndrome; Coronavirus infection
DMJYCVW ID DMJYCVW
DMJYCVW DN Warfarin
DMJYCVW HS Approved
DMJYCVW SN Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin
DMJYCVW CP Pharmaceutical Research Assoc Inc
DMJYCVW TC Anticoagulants
DMJYCVW DT Small molecular drug
DMJYCVW PC 54678486
DMJYCVW MW 308.3
DMJYCVW FM C19H16O4
DMJYCVW IC InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
DMJYCVW CS CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMJYCVW IK PJVWKTKQMONHTI-UHFFFAOYSA-N
DMJYCVW IU 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
DMJYCVW CA CAS 81-81-2
DMJYCVW CB CHEBI:87732
DMJYCVW DE Atrial fibrillation; Thrombosis
DMLHOA0 ID DMLHOA0
DMLHOA0 DN Xatral
DMLHOA0 HS Approved
DMLHOA0 SN Alfetim; Alfoten; Urion; Uroxatral; Alfuzosin HCl; Alfuzosin Hydrochloride; Alfuzosin hydrochloride [USAN]; Xatral OD; Xatral Retard; Xatral SR; Xatral XL; SL 77 499-10; SL 77499-10; SL-7749910; Uroxatral, Alfuzosin hydrochloride; Alfuzosin hydrochloride (JAN/USAN); SL-77499-10; SL-77.0499-10; N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride; N-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride
DMLHOA0 CP Sanofi-Aventis
DMLHOA0 DT Small molecular drug
DMLHOA0 PC 71764
DMLHOA0 MW 425.9
DMLHOA0 FM C19H28ClN5O4
DMLHOA0 IC InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
DMLHOA0 CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
DMLHOA0 IK YTNKWDJILNVLGX-UHFFFAOYSA-N
DMLHOA0 IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
DMLHOA0 CA CAS 81403-68-1
DMLHOA0 CB CHEBI:32286
DMLHOA0 DE Benign prostatic hyperplasia
DMU8ANS ID DMU8ANS
DMU8ANS DN Ximelegatran
DMU8ANS HS Approved
DMU8ANS SN Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632
DMU8ANS CP AstraZeneca
DMU8ANS DT Small molecular drug
DMU8ANS PC 448042
DMU8ANS MW 247.34
DMU8ANS FM C14H21N3O
DMU8ANS IC InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1
DMU8ANS CS C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
DMU8ANS IK IYOZTVGMEWJPKR-VOMCLLRMSA-N
DMU8ANS IU 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide
DMU8ANS CA CAS 146986-50-7
DMU8ANS CB CHEBI:75393
DMU8ANS DE Myocardial infarction; Asthma
DMAR467 ID DMAR467
DMAR467 DN Xylose
DMAR467 HS Approved
DMAR467 SN D-Xylose; D-Xylopyranose; Xyloside; D-xylopentose; (3R,4S,5R)-oxane-2,3,4,5-tetrol; 7261-26-9; CHEBI:53455; Xylopyranoside; D-Xylopyranoside; Xylomed; D-Xyl; 10257-31-5; (3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol; (3R,4S,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Xylose, > Xyl; Xylose (USP); Xylo-Pfan (TN); DSSTox_CID_3745; Epitope ID:114701; AC1L35YW; DSSTox_RID_77180; SCHEMBL39891; DSSTox_GSID_23745; MLS001361339; cid_135191; CHEMBL502135; DTXSID0023745; CTK0H1735; BDBM16234; MolPort-003-934-029; D-xylose
DMAR467 DT Small molecular drug
DMAR467 PC 135191
DMAR467 MW 150.13
DMAR467 FM C5H10O5
DMAR467 IC InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1
DMAR467 CS C1[C@H]([C@@H]([C@H](C(O1)O)O)O)O
DMAR467 IK SRBFZHDQGSBBOR-IOVATXLUSA-N
DMAR467 IU (3R,4S,5R)-oxane-2,3,4,5-tetrol
DMAR467 CA CAS 10257-31-5
DMAR467 CB CHEBI:53455
DMAR467 DE Gastrointestinal disease
DMDPM7R ID DMDPM7R
DMDPM7R DN Y-25130
DMDPM7R HS Approved
DMDPM7R SN Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R DT Small molecular drug
DMDPM7R PC 2264
DMDPM7R MW 349.8
DMDPM7R FM C17H20ClN3O3
DMDPM7R IC InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)
DMDPM7R CS CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4
DMDPM7R IK WUKZPHOXUVCQOR-UHFFFAOYSA-N
DMDPM7R IU N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R CA CAS 123040-69-7
DMDPM7R CB CHEBI:91712
DMDPM7R DE Nausea and vomiting
DMNZCI1 ID DMNZCI1
DMNZCI1 DN YM443
DMNZCI1 HS Approved
DMNZCI1 SN Acofide; Acotiamide
DMNZCI1 CP Astellas
DMNZCI1 DT Small molecular drug
DMNZCI1 PC 6918406
DMNZCI1 MW 541.1
DMNZCI1 FM C21H37ClN4O8S
DMNZCI1 IC InChI=1S/C21H30N4O5S.ClH.3H2O/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26;;;;/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27);1H;3*1H2
DMNZCI1 CS CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C.O.O.O.Cl
DMNZCI1 IK NPTDXIXCQCFGKC-UHFFFAOYSA-N
DMNZCI1 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;trihydrate;hydrochloride
DMNZCI1 CA CAS 773092-05-0
DMNZCI1 DE Functional dyspepsia
DMMP3Y2 ID DMMP3Y2
DMMP3Y2 DN Yn-968D1
DMMP3Y2 HS Approved
DMMP3Y2 SN Apatinib; Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang
DMMP3Y2 CP Advenchen Laboratories LLC
DMMP3Y2 DT Small molecular drug
DMMP3Y2 PC 45139106
DMMP3Y2 MW 493.6
DMMP3Y2 FM C25H27N5O4S
DMMP3Y2 IC InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)
DMMP3Y2 CS CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
DMMP3Y2 IK FYJROXRIVQPKRY-UHFFFAOYSA-N
DMMP3Y2 IU N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid
DMMP3Y2 CA CAS 1218779-75-9
DMMP3Y2 DE Breast cancer
DMJCP1Y ID DMJCP1Y
DMJCP1Y DN Yohimbine
DMJCP1Y HS Approved
DMJCP1Y SN APHRODINE; Actibine; Aphrodyne; Aphrosol; Corynine; Johimbin; Quebrachin; Quebrachine; Thybine; Yocon; Yohimar; Yohimbin; Yohimex; Yoman; Yovital; Dayto himbin; Yohimbic acid methyl ester; Baron-X; Trans-Quinolizidine yohimbine; Yohimbine (DCF); Methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-(9CI); Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; (+)-Yohimbin; (+)-Yohimbine; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
DMJCP1Y CP Palisades Pharmaceuticals Inc
DMJCP1Y TC Mydriatics
DMJCP1Y DT Small molecular drug
DMJCP1Y PC 8969
DMJCP1Y MW 354.4
DMJCP1Y FM C21H26N2O3
DMJCP1Y IC InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1
DMJCP1Y CS COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
DMJCP1Y IK BLGXFZZNTVWLAY-SCYLSFHTSA-N
DMJCP1Y IU methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMJCP1Y CA CAS 146-48-5
DMJCP1Y CB CHEBI:10093
DMJCP1Y DE Erectile dysfunction
DMHNQOG ID DMHNQOG
DMHNQOG DN Zafirlukast
DMHNQOG HS Approved
DMHNQOG SN Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
DMHNQOG CP AstraZeneca plc
DMHNQOG TC Antiasthmatic Agents
DMHNQOG DT Small molecular drug
DMHNQOG PC 5717
DMHNQOG MW 575.7
DMHNQOG FM C31H33N3O6S
DMHNQOG IC InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
DMHNQOG CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
DMHNQOG IK YEEZWCHGZNKEEK-UHFFFAOYSA-N
DMHNQOG IU cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
DMHNQOG CA CAS 107753-78-6
DMHNQOG CB CHEBI:10100
DMHNQOG DE Asthma
DMH7MUV ID DMH7MUV
DMH7MUV DN Zalcitabine
DMH7MUV HS Approved
DMH7MUV SN zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188; DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC
DMH7MUV CP Hoffmann-La Roche pharmaceutical company
DMH7MUV TC Anti-HIV Agents
DMH7MUV DT Small molecular drug
DMH7MUV PC 24066
DMH7MUV MW 211.22
DMH7MUV FM C9H13N3O3
DMH7MUV IC InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
DMH7MUV CS C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N
DMH7MUV IK WREGKURFCTUGRC-POYBYMJQSA-N
DMH7MUV IU 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMH7MUV CA CAS 7481-89-2
DMH7MUV CB CHEBI:10101
DMH7MUV DE Human immunodeficiency virus infection
DMGFWSM ID DMGFWSM
DMGFWSM DN Zaleplon
DMGFWSM HS Approved
DMGFWSM SN Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide
DMGFWSM CP King Pharm
DMGFWSM TC Hypnotics and Sedatives
DMGFWSM DT Small molecular drug
DMGFWSM PC 5719
DMGFWSM MW 305.33
DMGFWSM FM C17H15N5O
DMGFWSM IC InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
DMGFWSM CS CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
DMGFWSM IK HUNXMJYCHXQEGX-UHFFFAOYSA-N
DMGFWSM IU N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
DMGFWSM CA CAS 151319-34-5
DMGFWSM CB CHEBI:10102
DMGFWSM DE Insomnia
DMFMBZ4 ID DMFMBZ4
DMFMBZ4 DN Zanamivir
DMFMBZ4 HS Approved
DMFMBZ4 SN zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7; GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir
DMFMBZ4 CP GlaxoSmithKline
DMFMBZ4 TC Antiviral Agents
DMFMBZ4 DT Small molecular drug
DMFMBZ4 PC 60855
DMFMBZ4 MW 332.31
DMFMBZ4 FM C12H20N4O7
DMFMBZ4 IC InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
DMFMBZ4 CS CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N
DMFMBZ4 IK ARAIBEBZBOPLMB-UFGQHTETSA-N
DMFMBZ4 IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMFMBZ4 CA CAS 139110-80-8
DMFMBZ4 CB CHEBI:50663
DMFMBZ4 DE Influenza virus infection
DMJWRQP ID DMJWRQP
DMJWRQP DN Zanubrutinib
DMJWRQP HS Approved
DMJWRQP SN RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27
DMJWRQP CP BeiGene Cambridge, MA
DMJWRQP PC 135905454
DMJWRQP MW 471.5
DMJWRQP FM C27H29N5O3
DMJWRQP IC InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)
DMJWRQP CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMJWRQP IK RNOAOAWBMHREKO-UHFFFAOYSA-N
DMJWRQP IU 2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMJWRQP DE B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma; Waldenstrom macroglobulinemia; Mantle cell lymphoma
DMUR5NG ID DMUR5NG
DMUR5NG DN Zanubrutinib
DMUR5NG HS Approved
DMUR5NG SN Zanubrutinib; Zanubrutinib (USAN/INN); Zanubrutinib [INN]; Zanubrutinib [USAN]; compound 27b [US9447106]; (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; 1691249-45-2; BDBM250082; BGB3111; CHEMBL3936761; CS-0021869; D11422; GTPL9861; HY-101474A; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7S)-; SCHEMBL17842597; AG9MHG098Z; US9447106, 27b (peak 2); ZINC584641430; UNII-AG9MHG098Z
DMUR5NG PC 135565884
DMUR5NG MW 471.5
DMUR5NG FM C27H29N5O3
DMUR5NG IC RNOAOAWBMHREKO-QFIPXVFZSA-N
DMUR5NG CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMUR5NG IK 1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
DMUR5NG IU (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMUR5NG CA CAS 1691249-45-2
DMUR5NG DE Mantle cell lymphoma
DMA5QPM ID DMA5QPM
DMA5QPM DN Zemaira
DMA5QPM HS Approved
DMA5QPM SN Alpha-1-antitrypsin
DMA5QPM CP CSL Behring
DMA5QPM DT Recombinant protein
DMA5QPM DE Emphysema
DMSLJP4 ID DMSLJP4
DMSLJP4 DN Ziconotide
DMSLJP4 HS Approved
DMSLJP4 SN Prialt; Ziconotide [USAN]; SNX 111; DRG-0250; Omega-Conotoxin M VIIA; Omega-conotoxin MVIIA; Prialt (TN); SNX-111; Omega-ConopeptideMVIIA (Conus); Omega-Conotoxin mviia, conus magus; Omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide)
DMSLJP4 CP Neurox/Parke Davis
DMSLJP4 TC Analgesics
DMSLJP4 DT Small molecular drug
DMSLJP4 PC 16135415
DMSLJP4 MW 2639.2
DMSLJP4 FM C102H172N36O32S7
DMSLJP4 IC InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1
DMSLJP4 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
DMSLJP4 IK BPKIMPVREBSLAJ-QTBYCLKRSA-N
DMSLJP4 IU 2-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,54S,60S,63R,68R,71S,77S)-63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-[(1R)-1-hydroxyethyl]-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid
DMSLJP4 CA CAS 107452-89-1
DMSLJP4 CB CHEBI:135912
DMSLJP4 DE Pain; Traumatic brain injury
DM4KI7O ID DM4KI7O
DM4KI7O DN Zidovudine
DM4KI7O HS Approved
DM4KI7O SN zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S; AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422
DM4KI7O CP GlaxoSmithKline
DM4KI7O TC Anti-HIV Agents
DM4KI7O DT Small molecular drug
DM4KI7O PC 35370
DM4KI7O MW 267.24
DM4KI7O FM C10H13N5O4
DM4KI7O IC InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
DM4KI7O CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]
DM4KI7O IK HBOMLICNUCNMMY-XLPZGREQSA-N
DM4KI7O IU 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM4KI7O CA CAS 30516-87-1
DM4KI7O CB CHEBI:10110
DM4KI7O DE Human immunodeficiency virus infection; Virus infection
DMVRIC2 ID DMVRIC2
DMVRIC2 DN Zileuton
DMVRIC2 HS Approved
DMVRIC2 SN Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2 CP Cornerstone Therapeutics Inc
DMVRIC2 TC Antiinflammatory Agents
DMVRIC2 DT Small molecular drug
DMVRIC2 PC 60490
DMVRIC2 MW 236.29
DMVRIC2 FM C11H12N2O2S
DMVRIC2 IC InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
DMVRIC2 CS CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
DMVRIC2 IK MWLSOWXNZPKENC-UHFFFAOYSA-N
DMVRIC2 IU 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2 CA CAS 111406-87-2
DMVRIC2 CB CHEBI:10112
DMVRIC2 DE Asthma
DMZ4R3Q ID DMZ4R3Q
DMZ4R3Q DN Zinc salts
DMZ4R3Q HS Approved
DMZ4R3Q DE Arthritis
DMK4OL7 ID DMK4OL7
DMK4OL7 DN Zinostatin stimalamer
DMK4OL7 HS Approved
DMK4OL7 SN Smancs (TN)
DMK4OL7 DT Small molecular drug
DMK4OL7 PC 70682998
DMK4OL7 MW 657.7
DMK4OL7 FM C36H35NO11
DMK4OL7 IC InChI=1S/C36H35NO11/c1-17-9-10-22-18(2)13-21(42-5)15-24(22)28(17)33(40)45-25-14-20-11-12-36(27-16-43-35(41)46-27)26(48-36)8-6-7-23(20)32(25)47-34-29(37-4)31(39)30(38)19(3)44-34/h7,9-10,13-15,19,25-27,29-32,34,37-39H,16H2,1-5H3/b23-7+/t19-,25-,26-,27+,29-,30+,31-,32?,34-,36+/m1/s1
DMK4OL7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC\\2[C@@H](C=C3/C2=C\\C#C[C@@H]4[C@@](O4)(C#C3)[C@@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)C)NC)O)O
DMK4OL7 IK FYQZGCBXYVWXSP-STTFAQHVSA-N
DMK4OL7 IU [(4S,6R,9E,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate
DMK4OL7 DE Brain cancer
DMM58JY ID DMM58JY
DMM58JY DN Ziprasidone
DMM58JY HS Approved
DMM58JY SN 146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
DMM58JY CP Pfizer
DMM58JY TC Antipsychotic Agents
DMM58JY DT Small molecular drug
DMM58JY PC 60854
DMM58JY MW 412.9
DMM58JY FM C21H21ClN4OS
DMM58JY IC InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
DMM58JY CS C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
DMM58JY IK MVWVFYHBGMAFLY-UHFFFAOYSA-N
DMM58JY IU 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
DMM58JY CA CAS 146939-27-7
DMM58JY CB CHEBI:10119
DMM58JY DE Schizophrenia
DMN4H2O ID DMN4H2O
DMN4H2O DN Zithromax
DMN4H2O HS Approved
DMN4H2O SN azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955
DMN4H2O DT Small molecular drug
DMN4H2O PC 447043
DMN4H2O MW 749
DMN4H2O FM C38H72N2O12
DMN4H2O IC InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DMN4H2O CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
DMN4H2O IK MQTOSJVFKKJCRP-BICOPXKESA-N
DMN4H2O IU (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
DMN4H2O CA CAS 83905-01-5
DMN4H2O CB CHEBI:2955
DMN4H2O DE Syphilis infection
DMIXC7G ID DMIXC7G
DMIXC7G DN Zoledronate
DMIXC7G HS Approved
DMIXC7G SN Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
DMIXC7G CP Norvatis Phamaceuticals Corporation
DMIXC7G TC Bone Density Conservation Agents
DMIXC7G DT Small molecular drug
DMIXC7G PC 68740
DMIXC7G MW 272.09
DMIXC7G FM C5H10N2O7P2
DMIXC7G IC InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
DMIXC7G CS C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMIXC7G IK XRASPMIURGNCCH-UHFFFAOYSA-N
DMIXC7G IU (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
DMIXC7G CA CAS 118072-93-8
DMIXC7G CB CHEBI:46557
DMIXC7G DE Hypercalcaemia
DM57O90 ID DM57O90
DM57O90 DN Zolgensma
DM57O90 HS Approved
DM57O90 SN Onasemnogene abeparvovec-xioi
DM57O90 CP AveXis
DM57O90 DT Gene therapy
DM57O90 DE Spinal muscular atrophy
DM1IB4Q ID DM1IB4Q
DM1IB4Q DN Zolmitriptan
DM1IB4Q HS Approved
DM1IB4Q SN AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
DM1IB4Q CP AstraZeneca
DM1IB4Q TC Antimigraine Agents
DM1IB4Q DT Small molecular drug
DM1IB4Q PC 60857
DM1IB4Q MW 287.36
DM1IB4Q FM C16H21N3O2
DM1IB4Q IC InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
DM1IB4Q CS CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
DM1IB4Q IK ULSDMUVEXKOYBU-ZDUSSCGKSA-N
DM1IB4Q IU (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
DM1IB4Q CA CAS 139264-17-8
DM1IB4Q CB CHEBI:10124
DM1IB4Q DE Migraine
DMWOSKJ ID DMWOSKJ
DMWOSKJ DN Zolpidem
DMWOSKJ HS Approved
DMWOSKJ SN zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem
DMWOSKJ CP NovaDel Pharma Inc
DMWOSKJ DT Small molecular drug
DMWOSKJ PC 5732
DMWOSKJ MW 307.4
DMWOSKJ FM C19H21N3O
DMWOSKJ IC InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
DMWOSKJ CS CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
DMWOSKJ IK ZAFYATHCZYHLPB-UHFFFAOYSA-N
DMWOSKJ IU N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
DMWOSKJ CA CAS 82626-48-0
DMWOSKJ CB CHEBI:10125
DMWOSKJ DE Insomnia
DM0DTF7 ID DM0DTF7
DM0DTF7 DN Zonisamide
DM0DTF7 HS Approved
DM0DTF7 SN Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole
DM0DTF7 CP Eisai
DM0DTF7 TC Analgesics
DM0DTF7 DT Small molecular drug
DM0DTF7 PC 5734
DM0DTF7 MW 212.23
DM0DTF7 FM C8H8N2O3S
DM0DTF7 IC InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
DM0DTF7 CS C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
DM0DTF7 IK UBQNRHZMVUUOMG-UHFFFAOYSA-N
DM0DTF7 IU 1,2-benzoxazol-3-ylmethanesulfonamide
DM0DTF7 CA CAS 68291-97-4
DM0DTF7 DE Epilepsy
DMPI6Z0 ID DMPI6Z0
DMPI6Z0 DN Zopiclone
DMPI6Z0 HS Approved
DMPI6Z0 SN Amoban; Amovane; Imovance; Imovane; Limovan; Optidorm; Rhovane; Siaten; Sopivan; Ximovan; Zileze; Zimoclone; Zimovane; Zopicalm; Zopicalma; Zopiclodura; Zopiclona; Zopiclonum; Zopitan; Zorclone; AbZ brand of zopiclone; Aliud brand of zopiclone; Alpharma brand of zopiclone; Aventis Pharma brand of zopiclone; Aventis brand of zopiclone; Azupharma brand of zopiclone; Betapharm brand of zopiclone; Ciclum brand of zopiclone; Clonmel brand of zopiclone; Dolorgeit brand of zopiclone; Gerard brand of zopiclone; Hexal brand of zopiclone; Hormosan brand of zopiclone; Italfarmaco brand of zopiclone; Merck dura brand of zopiclone; Neuraxpharm brand of zopiclone; Norton brand of zopiclone; Opus brand of zopiclone; Pinewood brand of zopiclone; Ratiopharm brand of zopiclone; Rhodiapharm brand of zopiclone; Stadapharm brand of zopiclone; TAD brand of zopiclone; Temmler brand of zopiclone; Teva brand of zopiclone; Zopiclon AL; Zopiclon AZU; Zopiclon AbZ; Zopiclon Stada; Zopiclon TAD; Zopiclon beta; Zopiclon von ct; RP 27 267; RP 27267; Z 4900; Z4900_SIGMA; Amoban (TN); Ct-Arzneimittel brand of zopiclone; Imovane (TN); Novo-zopiclone; Nu-Pharm brand of zopiclone; Nu-Zopiclone; RP-27267; Ran-zopiclone; Ratio-Zopiclone; Rhone-Poulenc Rorer brand of zopiclone; Zimovane (TN); Zopi-Puren; Zopiclon-TEVA; Zopiclon-neuraxpharm; Zopiclon-ratiopharm; Zopiclona [INN-Spanish]; Zopiclone (TN); Zopiclonum [INN-Latin]; Zopinox (TN); Zopiclone (JAN/INN); Zopiclone [BAN:INN:JAN]; Zopiclone, Imovane, Zimovane, Lunesta; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo(3,4-b)pyrazin-5-one; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
DMPI6Z0 CP Sanofi-Aventis
DMPI6Z0 TC Hypnotics and Sedatives
DMPI6Z0 DT Small molecular drug
DMPI6Z0 PC 5735
DMPI6Z0 MW 388.8
DMPI6Z0 FM C17H17ClN6O3
DMPI6Z0 IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3
DMPI6Z0 CS CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DMPI6Z0 IK GBBSUAFBMRNDJC-UHFFFAOYSA-N
DMPI6Z0 IU [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DMPI6Z0 CA CAS 43200-80-2
DMPI6Z0 CB CHEBI:32315
DMPI6Z0 DE Insomnia
DMRMCXW ID DMRMCXW
DMRMCXW DN Zotarolimus
DMRMCXW HS Approved
DMRMCXW SN Abt-578; Zotarolimus (TN)
DMRMCXW CP Medtronic
DMRMCXW DT Small molecular drug
DMRMCXW PC 9876378
DMRMCXW MW 966.2
DMRMCXW FM C52H79N5O12
DMRMCXW IC InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1
DMRMCXW CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)C)/C)O)OC)C)C)/C)OC
DMRMCXW IK CGTADGCBEXYWNE-JUKNQOCSSA-N
DMRMCXW IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMRMCXW CA CAS 221877-54-9
DMRMCXW CB CHEBI:135897
DMRMCXW DE Solid tumour/cancer
DMF3VXA ID DMF3VXA
DMF3VXA DN Zotepine
DMF3VXA HS Approved
DMF3VXA SN zotepine; 26615-21-4; Nipolept; Lodopin; Zoleptil; Zotepina; Zotepinum; Compound-4; Zotepina [Spanish]; Zotepinum [INN-Latin]; Zotepina [INN-Spanish]; UNII-U29O83JAZW; 2-Chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin; 2-Chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin; C18H18ClNOS; BRN 1435710; U29O83JAZW; CHEMBL285802; CHEBI:32316; HDOZVRUNCMBHFH-UHFFFAOYSA-N; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine; 2-Chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine; NCGC00182081-02
DMF3VXA DT Small molecular drug
DMF3VXA PC 5736
DMF3VXA MW 331.9
DMF3VXA FM C18H18ClNOS
DMF3VXA IC InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3
DMF3VXA CS CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMF3VXA IK HDOZVRUNCMBHFH-UHFFFAOYSA-N
DMF3VXA IU 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine
DMF3VXA CA CAS 26615-21-4
DMF3VXA CB CHEBI:32316
DMF3VXA DE Anxiety disorder
DMKYD5N ID DMKYD5N
DMKYD5N DN Zuclopenthixol
DMKYD5N HS Approved
DMKYD5N SN Acuphase; CLOPENTHIXOL; Cisordinol; Clopenthixolum; Clopentixol; Clopixol; Zuclopenthixolum; Zuclopentixol; Alpha Clopenthixol; Zuclopenthixolum [Latin]; Zuclopentixol [Spanish]; Acuphase (TN); Alpha-Clopenthixol; Cisordinol (TN); Clopenthixol (USAN); Clopixol (TN); Zuclopenthixol (INN); Zuclopenthixol [BAN:INN]; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
DMKYD5N CP Lundbeck pharmaceutical company
DMKYD5N TC Antipsychotic Agents
DMKYD5N DT Small molecular drug
DMKYD5N PC 5311507
DMKYD5N MW 401
DMKYD5N FM C22H25ClN2OS
DMKYD5N IC InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
DMKYD5N CS C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMKYD5N IK WFPIAZLQTJBIFN-DVZOWYKESA-N
DMKYD5N IU 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol
DMKYD5N CA CAS 53772-83-1
DMKYD5N CB CHEBI:51364
DMKYD5N DE Schizophrenia
DMRCOU5 ID DMRCOU5
DMRCOU5 DN Dicycloplatin
DMRCOU5 HS Registered
DMRCOU5 CP Peking University
DMRCOU5 PC 44475103
DMRCOU5 MW 515.38
DMRCOU5 FM C12H20N2O8Pt
DMRCOU5 IC InChI=1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2
DMRCOU5 CS C1CC(C1)(C(=O)O)C(=O)O.C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]
DMRCOU5 IK IIJQICKYWPGJDT-UHFFFAOYSA-L
DMRCOU5 IU azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMRCOU5 CA CAS 287402-09-9
DMRCOU5 DE Prostate cancer
DMBZ27L ID DMBZ27L
DMBZ27L DN Favipiravir
DMBZ27L HS Registered
DMBZ27L SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DMBZ27L CP Toyama Chemical
DMBZ27L DT Small molecular drug
DMBZ27L PC 492405
DMBZ27L MW 157.1
DMBZ27L FM C5H4FN3O2
DMBZ27L IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DMBZ27L CS C1=C(N=C(C(=O)N1)C(=O)N)F
DMBZ27L IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DMBZ27L IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DMBZ27L CA CAS 259793-96-9
DMBZ27L CB CHEBI:134722
DMBZ27L DE Influenza virus infection
DMDWYUN ID DMDWYUN
DMDWYUN DN HBI-8000
DMDWYUN HS Registered
DMDWYUN SN CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
DMDWYUN CP HUYA Bioscience International; Quintiles
DMDWYUN DT Small molecular drug
DMDWYUN PC 12136798
DMDWYUN MW 390.4
DMDWYUN FM C22H19FN4O2
DMDWYUN IC InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
DMDWYUN CS C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
DMDWYUN IK SZMJVTADHFNAIS-BJMVGYQFSA-N
DMDWYUN IU N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
DMDWYUN CA CAS 1616493-44-7
DMDWYUN CB CHEBI:135918
DMDWYUN DE Solid tumour/cancer; Melanoma; Merkel cell carcinoma; Renal cell carcinoma; Non-small-cell lung cancer
DM5GFIK ID DM5GFIK
DM5GFIK DN Icotinib hydrochloride
DM5GFIK HS Registered
DM5GFIK SN Conmana; Conmanna; Icotinib; BPI-2009-H
DM5GFIK CP Beta Pharma Inc
DM5GFIK DT Small molecular drug
DM5GFIK PC 44609731
DM5GFIK MW 427.9
DM5GFIK FM C22H22ClN3O4
DM5GFIK IC InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H
DM5GFIK CS C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4.Cl
DM5GFIK IK PNNGXMJMUUJHAV-UHFFFAOYSA-N
DM5GFIK IU N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine;hydrochloride
DM5GFIK CA CAS 1204313-51-8
DM5GFIK DE Non-small-cell lung cancer
DM5GIWZ ID DM5GIWZ
DM5GIWZ DN Mirogabalin
DM5GIWZ HS Registered
DM5GIWZ SN Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303
DM5GIWZ DT Small molecular drug
DM5GIWZ PC 59509752
DM5GIWZ MW 209.28
DM5GIWZ FM C12H19NO2
DM5GIWZ IC InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
DM5GIWZ CS CCC1=C[C@@H]2[C@H](C1)C[C@@]2(CC(=O)O)CN
DM5GIWZ IK FTBQORVNHOIASH-CKYFFXLPSA-N
DM5GIWZ IU 2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid
DM5GIWZ CA CAS 1138245-13-2
DM5GIWZ DE Fibromyalgia; Cancer related pain; Cardiovascular disease; Peripheral neuropathy
DMY67U8 ID DMY67U8
DMY67U8 DN Trapidil
DMY67U8 HS Phase 4
DMY67U8 SN trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
DMY67U8 DT Small molecular drug
DMY67U8 PC 5531
DMY67U8 MW 205.26
DMY67U8 FM C10H15N5
DMY67U8 IC InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
DMY67U8 CS CCN(CC)C1=CC(=NC2=NC=NN12)C
DMY67U8 IK GSNOZLZNQMLSKJ-UHFFFAOYSA-N
DMY67U8 IU N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
DMY67U8 CA CAS 15421-84-8
DMY67U8 CB CHEBI:32254
DMY67U8 DE Multiple myeloma; Coronary artery disease; Acute coronary syndrome
DMVZL26 ID DMVZL26
DMVZL26 DN 3,4-Dihydroxycinnamic Acid
DMVZL26 HS Phase 4
DMVZL26 SN Caffeic acid; caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 3-(3,4-dihydroxyphenyl)acrylic acid; 501-16-6; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; 3,4-Dihydroxybenzeneacrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; trans-caffeic acid; trans-Caffeate; 3,4-Dihydroxy-trans-cinnamate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; Cinnamic acid, 3,4-dihydroxy-; 3-(3,4-Dihydroxyphenyl)propenoic acid; UNII-U2S3A33KVM; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene
DMVZL26 DT Small molecular drug
DMVZL26 PC 689043
DMVZL26 MW 180.16
DMVZL26 FM C9H8O4
DMVZL26 IC InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+
DMVZL26 CS C1=CC(=C(C=C1/C=C/C(=O)O)O)O
DMVZL26 IK QAIPRVGONGVQAS-DUXPYHPUSA-N
DMVZL26 IU (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
DMVZL26 CA CAS 331-39-5
DMVZL26 CB CHEBI:16433
DMVZL26 DE Thrombocytopenia
DML6CN4 ID DML6CN4
DML6CN4 DN Acemetacin
DML6CN4 HS Phase 4
DML6CN4 SN Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin
DML6CN4 PC 1981
DML6CN4 MW 415.8
DML6CN4 FM C21H18ClNO6
DML6CN4 IC FSQKKOOTNAMONP-UHFFFAOYSA-N
DML6CN4 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
DML6CN4 IK 1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
DML6CN4 IU 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid
DML6CN4 CA CAS 53164-05-9
DML6CN4 CB CHEBI:31162
DML6CN4 DE Osteoarthritis
DM4UE3K ID DM4UE3K
DM4UE3K DN Acetylcarnitine
DM4UE3K HS Phase 4
DM4UE3K SN (-)-Acetylcarnitine; (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate; (R)-Acetylcarnitine; 3040-38-8; 6DH1W9VH8Q; ALCAR; Acetyl-L-(-)-carnitine; Acetyl-L-carnitine; Acetylcarnitine, L-; CAR(2:0); CHEBI:57589; Carnitine, acetyl-, L-; HSDB 7587; L-ACETYLCARNITINE; L-Acetyl carnitine; L-Carnitine acetyl ester; L-O-Acetylcarnitine; Levocarnitine acetyl; Nicetile; O-Acetyl-L-carnitine; R-Acetylcarnitine; RDHQFKQIGNGIED-MRVPVSSYSA-N; UNII-6DH1W9VH8Q; acetyl l-carnitine; acetyl-carnitine; acetylcarnitine
DM4UE3K DT Small molecular drug
DM4UE3K PC 7045767
DM4UE3K MW 203.238
DM4UE3K FM C9H17NO4
DM4UE3K IC InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
DM4UE3K CS CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
DM4UE3K IK RDHQFKQIGNGIED-MRVPVSSYSA-N
DM4UE3K IU (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
DM4UE3K CA CAS 3040-38-8
DM4UE3K CB CHEBI:57589
DM4UE3K DE Migraine
DM1237M ID DM1237M
DM1237M DN Alfacalcidol
DM1237M HS Phase 4
DM1237M SN Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572
DM1237M PC 5282181
DM1237M MW 400.6
DM1237M FM C27H44O2
DM1237M IC OFHCOWSQAMBJIW-AVJTYSNKSA-N
DM1237M CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
DM1237M IK 1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
DM1237M IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM1237M CA CAS 41294-56-8
DM1237M CB CHEBI:31186
DM1237M DE Diabetes mellitus
DMY2AH1 ID DMY2AH1
DMY2AH1 DN Aminophenazone
DMY2AH1 HS Phase 4
DMY2AH1 SN AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1
DMY2AH1 PC 6009
DMY2AH1 MW 231.29
DMY2AH1 FM C13H17N3O
DMY2AH1 IC RMMXTBMQSGEXHJ-UHFFFAOYSA-N
DMY2AH1 CS CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C
DMY2AH1 IK 1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3
DMY2AH1 IU 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one
DMY2AH1 CA CAS 58-15-1
DMY2AH1 CB CHEBI:160246
DMY2AH1 DE Anaesthesia
DMWDEN0 ID DMWDEN0
DMWDEN0 DN Amylin
DMWDEN0 HS Phase 4
DMWDEN0 SN Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968
DMWDEN0 DT Small molecular drug
DMWDEN0 PC 16132430
DMWDEN0 MW 3903.3
DMWDEN0 FM C165H261N51O55S2
DMWDEN0 IC InChI=1S/C165H261N51O55S2/c1-22-75(12)124(159(266)200-95(47-71(4)5)140(247)203-108(64-219)153(260)206-110(66-221)154(261)216-129(84(21)226)163(270)202-105(58-119(174)234)147(254)209-122(73(8)9)157(264)181-61-121(236)187-106(62-217)150(257)198-103(56-117(172)232)148(255)215-128(83(20)225)162(269)190-93(130(175)237)49-87-38-40-89(227)41-39-87)211-132(239)76(13)183-120(235)60-180-136(243)97(50-85-32-25-23-26-33-85)194-144(251)101(54-115(170)230)196-145(252)102(55-116(171)231)197-151(258)107(63-218)205-152(259)109(65-220)204-142(249)99(52-88-59-178-69-182-88)201-158(265)123(74(10)11)210-146(253)96(48-72(6)7)193-141(248)98(51-86-34-27-24-28-35-86)195-143(250)100(53-114(169)229)191-131(238)77(14)184-139(246)94(46-70(2)3)192-137(244)91(37-31-45-179-165(176)177)188-138(245)92(42-43-113(168)228)189-161(268)126(81(18)223)212-133(240)78(15)185-155(262)111-67-272-273-68-112(207-135(242)90(167)36-29-30-44-166)156(263)199-104(57-118(173)233)149(256)214-125(80(17)222)160(267)186-79(16)134(241)213-127(82(19)224)164(271)208-111/h23-28,32-35,38-41,59,69-84,90-112,122-129,217-227H,22,29-31,36-37,42-58,60-68,166-167H2,1-21H3,(H2,168,228)(H2,169,229)(H2,170,230)(H2,171,231)(H2,172,232)(H2,173,233)(H2,174,234)(H2,175,237)(H,178,182)(H,180,243)(H,181,264)(H,183,235)(H,184,246)(H,185,262)(H,186,267)(H,187,236)(H,188,245)(H,189,268)(H,190,269)(H,191,238)(H,192,244)(H,193,248)(H,194,251)(H,195,250)(H,196,252)(H,197,258)(H,198,257)(H,199,263)(H,200,266)(H,201,265)(H,202,270)(H,203,247)(H,204,249)(H,205,259)(H,206,260)(H,207,242)(H,208,271)(H,209,254)(H,210,253)(H,211,239)(H,212,240)(H,213,241)(H,214,256)(H,215,255)(H,216,261)(H4,176,177,179)/t75-,76-,77-,78-,79-,80+,81+,82+,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,122-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMWDEN0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DMWDEN0 IK PLOPBXQQPZYQFA-AXPWDRQUSA-N
DMWDEN0 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DMWDEN0 CA CAS 106602-62-4
DM8EKSV ID DM8EKSV
DM8EKSV DN Anti-MIF antibodies
DM8EKSV HS Phase 4
DM8EKSV SN Antimacrophage inhibitory factor, Baxter; Anti-MIF antibodies (inflammation); Anti-MIF antibodies (inflammation), Baxter; Anti-MIF technology, Cytokine/IDEC; Anti-inflammatories, Cytokine/IDEC; Anti-macrophage inhibitory factor, Cytokine/IDEC
DM8EKSV CP Baxter healthcare
DM8EKSV DE Autoimmune diabetes
DML1VXW ID DML1VXW
DML1VXW DN Arotinolol
DML1VXW HS Phase 4
DML1VXW SN Arotinolol; Arotinolol (INN); Arotinolol [INN]; Arotinololum; Arotinololum [Latin]; (+-)-5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide; 2-(3-tert-Butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)thiazole; 5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamide; 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide; 68377-92-4; AK129719; C15H21N3O2S3; S-596
DML1VXW PC 2239
DML1VXW MW 371.5
DML1VXW FM C15H21N3O2S3
DML1VXW IC BHIAIPWSVYSKJS-UHFFFAOYSA-N
DML1VXW CS CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O
DML1VXW IK 1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
DML1VXW IU 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide
DML1VXW CA CAS 68377-92-4
DML1VXW CB CHEBI:135569
DML1VXW DE Essential tremor
DMB7WYM ID DMB7WYM
DMB7WYM DN ATOSIBAN
DMB7WYM HS Phase 4
DMB7WYM SN Atosiban; Tractocile; 90779-69-4; Atosiban acetate; Antocin; UNII-081D12SI0Z; Rwj 22164; Orf-22164; RWJ-22164; CHEMBL382301; 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin; dTVT; 081D12SI0Z; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; NCGC00165718-01; Atosibanum [INN-Latin]; ORF 22164; deTVT; Atosibanum; Antocin II; Atosiban [USAN:INN:BAN]; RWJ22164; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineox
DMB7WYM DT Small molecular drug
DMB7WYM PC 5311010
DMB7WYM MW 994.2
DMB7WYM FM C43H67N11O12S2
DMB7WYM IC InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
DMB7WYM CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
DMB7WYM IK VWXRQYYUEIYXCZ-OBIMUBPZSA-N
DMB7WYM IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMB7WYM CA CAS 90779-69-4
DMB7WYM CB CHEBI:135899
DMA12HL ID DMA12HL
DMA12HL DN Azelnidipine
DMA12HL HS Phase 4
DMA12HL SN Azelnidipine; Azelnidipine [INN]; Calblock; RS-9054; 123524-52-7; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-AMINO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-[1-(DIPHENYLMETHYL)-3-AZETIDINYL] 5-(1-METHYLETHYL) ESTER; 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; C33H34N4O6; CS 905; CS-905; DSSTox_CID_120; DSSTox_GSID_20120; DSSTox_RID_75382; MFCD00865803; NCGC00167436-01; NCGC00167436-02
DMA12HL PC 65948
DMA12HL MW 582.6
DMA12HL FM C33H34N4O6
DMA12HL IC ZKFQEACEUNWPMT-UHFFFAOYSA-N
DMA12HL CS CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C
DMA12HL IK 1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
DMA12HL IU 3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMA12HL CA CAS 123524-52-7
DMA12HL CB CHEBI:31247
DMA12HL DE Essential hypertension
DMJSDBE ID DMJSDBE
DMJSDBE DN Barnidipine
DMJSDBE HS Phase 4
DMJSDBE SN Barnidipine [INN]; Barnidipine HCl; Barnidipino; Barnidipino [INN-Spanish]; Barnidipinum; Barnidipinum [INN-Latin]; Libradin; Mepirodipine; VXMOONUMYLCFJD-DHLKQENFSA-N; Vasexten (TN); YM 09730; barnidipine; (S)-3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 104713-75-9; 2VBY96ASWJ; AC1L9FD3; BCP07244; C27H29N3O6; CHEBI:135793; CHEMBL2103761; CHEMBL2110040; CTK8B6661; SCHEMBL49302; UNII-2VBY96ASWJ
DMJSDBE PC 443869
DMJSDBE MW 491.5
DMJSDBE FM C27H29N3O6
DMJSDBE IC VXMOONUMYLCFJD-DHLKQENFSA-N
DMJSDBE CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMJSDBE IK 1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1
DMJSDBE IU 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJSDBE CA CAS 104713-75-9
DMJSDBE CB CHEBI:135793
DMJSDBE DE Essential hypertension
DMLKUG7 ID DMLKUG7
DMLKUG7 DN Beclabuvir
DMLKUG7 HS Phase 4
DMLKUG7 SN Beclabuvir; Beclabuvir (USAN/INN); Beclabuvir(BMS-791325); SB16521; 958002-33-0; BDBM50448498; BMS-791325; CHEMBL3126842; CS-6041; HY-12429; SCHEMBL11951525; cyclohexyl-N-(dimethylsulfamoyl)-methoxy-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)[?]carboxamide
DMLKUG7 PC 49773361
DMLKUG7 MW 659.8
DMLKUG7 FM C36H45N5O5S
DMLKUG7 IC ZTTKEBYSXUCBSE-VSBZUFFNSA-N
DMLKUG7 CS CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMLKUG7 IK 1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24?,25?,30-,36-/m0/s1
DMLKUG7 IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMLKUG7 CA CAS 958002-33-0
DMLKUG7 DE Viral hepatitis
DM5NW1E ID DM5NW1E
DM5NW1E DN Beclomethasone dipropionate
DM5NW1E HS Phase 4
DM5NW1E SN BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80
DM5NW1E PC 21700
DM5NW1E MW 521
DM5NW1E FM C28H37ClO7
DM5NW1E IC InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
DM5NW1E CS CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC
DM5NW1E IK KUVIULQEHSCUHY-XYWKZLDCSA-N
DM5NW1E IU [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DM5NW1E CA CAS 5534-09-8
DM5NW1E CB CHEBI:3002
DM5NW1E DE Allergic rhinitis
DMWNP6B ID DMWNP6B
DMWNP6B DN Benidipine
DMWNP6B HS Phase 4
DMWNP6B SN Benidipene; Benidipine; Benidipine (INN); Benidipine [INN]; Benidipino; Benidipino [Spanish]; Benidipinum; Benidipinum [Latin]; ZINC100014880; ZINC21992076; (+-)-(R*)-3-((R*)-1-Benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 105979-17-7; 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1LCVDP; AKOS015895389; C28H31N3O6; CHEMBL2105555; CHEMBL3303980; CTK8E8626; DTXSID0022648; NCGC00185768-01; SCHEMBL24516
DMWNP6B PC 656668
DMWNP6B MW 505.6
DMWNP6B FM C28H31N3O6
DMWNP6B IC QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
DMWNP6B CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMWNP6B IK 1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1
DMWNP6B IU 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMWNP6B CA CAS 105979-17-7
DMWNP6B DE Diabetic nephropathy
DMHKZX1 ID DMHKZX1
DMHKZX1 DN Benzethonium
DMHKZX1 HS Phase 4
DMHKZX1 SN Benzethonii chloridum [INN-Latin]; Benzetonio cloruro [DCIT]; Formula 144; Inactisol; Phemerol; Phemersol chloride; Sanizol; Antiseptol (quarternary compound); Solamin; benzethonium; 10172-60-8; 1VU15B70BP; 498-77-1; BZT (VAN); CCRIS 4748; CHEMBL221753; Caswell No. 614B; Chlorure de benzethonium [INN-French]; Cloruro de benzetonio [INN-Spanish]; EINECS 204-479-9; HSDB 567; NCI-C61494; NSC 20200; NSC20200; UNII-1VU15B70BP; benzyl-dimethyl-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]ammonium
DMHKZX1 PC 2335
DMHKZX1 MW 412.6
DMHKZX1 FM C27H42NO2+
DMHKZX1 IC SIYLLGKDQZGJHK-UHFFFAOYSA-N
DMHKZX1 CS CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2
DMHKZX1 IK 1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1
DMHKZX1 IU benzyl-dimethyl-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium
DMHKZX1 CA CAS 10172-60-8
DMHKZX1 CB CHEBI:94725
DMHKZX1 DE Methicillin-resistant staphylococcus infection
DML634R ID DML634R
DML634R DN Beraprost
DML634R HS Phase 4
DML634R SN Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593
DML634R PC 6917951
DML634R MW 398.5
DML634R FM C24H30O5
DML634R IC CTPOHARTNNSRSR-APJZLKAGSA-N
DML634R CS CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DML634R IK 1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1
DML634R IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DML634R CA CAS 88430-50-6
DML634R CB CHEBI:135633
DML634R DE Influenza virus infection
DMWL182 ID DMWL182
DMWL182 DN Beraprost
DMWL182 HS Phase 4
DMWL182 SN beraprost; 88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid
DMWL182 DT Small molecular drug
DMWL182 PC 5282428
DMWL182 MW 398.5
DMWL182 FM C24H30O5
DMWL182 IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+
DMWL182 CS CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMWL182 IK CTPOHARTNNSRSR-OUKQBFOZSA-N
DMWL182 IU 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMWL182 CA CAS 88430-50-6
DMWL182 DE Pulmonary hypertension
DMC5Q8X ID DMC5Q8X
DMC5Q8X DN Berberine
DMC5Q8X HS Phase 4
DMC5Q8X SN berberine; 2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE
DMC5Q8X DT Small molecular drug
DMC5Q8X PC 2353
DMC5Q8X MW 336.4
DMC5Q8X FM C20H18NO4+
DMC5Q8X IC InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1
DMC5Q8X CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
DMC5Q8X IK YBHILYKTIRIUTE-UHFFFAOYSA-N
DMC5Q8X IU 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMC5Q8X CA CAS 2086-83-1
DMC5Q8X CB CHEBI:16118
DMGXD5T ID DMGXD5T
DMGXD5T DN Brotizolam
DMGXD5T HS Phase 4
DMGXD5T SN Brotizolamum; Brotizolamum [INN-Latin]; Lendorm; Lendormin; Mederantil; Sintonal; UMSGKTJDUHERQW-UHFFFAOYSA-N; WE 941; WE-941; brotizolam; 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 2-Bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine; 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 57801-81-7; 5XZM1R3DKF; BRN 0839277; C15H10BrClN4S; CHEMBL32479; EINECS 260-964-5; NCGC00183872-01; UNII-5XZM1R3DKF
DMGXD5T PC 2451
DMGXD5T MW 393.7
DMGXD5T FM C15H10BrClN4S
DMGXD5T IC UMSGKTJDUHERQW-UHFFFAOYSA-N
DMGXD5T CS CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4Cl
DMGXD5T IK 1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
DMGXD5T IU 4-bromo-7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMGXD5T CA CAS 57801-81-7
DMGXD5T CB CHEBI:31308
DMGXD5T DE Insomnia
DMXZU73 ID DMXZU73
DMXZU73 DN Carbapenem
DMXZU73 HS Phase 4
DMXZU73 SN Carbapenem; Cis-carbapenem; (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one; 2,3-didehydro-1-carbapenam; 67836-EP2275424A1; 67836-EP2295402A2; 67836-EP2305219A1; 67836-EP2308874A1; CHEBI:46765; SCHEMBL37243
DMXZU73 PC 13293131
DMXZU73 MW 109.13
DMXZU73 FM C6H7NO
DMXZU73 IC YZBQHRLRFGPBSL-RXMQYKEDSA-N
DMXZU73 CS C1C=CN2C1CC2=O
DMXZU73 IK 1S/C6H7NO/c8-6-4-5-2-1-3-7(5)6/h1,3,5H,2,4H2/t5-/m1/s1
DMXZU73 IU (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one
DMXZU73 CB CHEBI:46765
DMXZU73 DE Infectious cystitis
DMJKWPZ ID DMJKWPZ
DMJKWPZ DN Cefpirome
DMJKWPZ HS Phase 4
DMJKWPZ SN Cefpiroma; Cefpiroma [Spanish]; Cefpirome (INN); Cefpirome [INN:BAN]; Cefpiromum; Cefpiromum [Latin]; Cefrom; Cerfpirome; Keiten; Broact; CEFPIROME; S72Q2F09HY; cefpirome sulfate; cefpirome sulphate; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 84957-29-9; C22H22N6O5S2; CHEBI:3503; HR 810; HR-810; NCGC00181339-01; UNII-S72Q2F09HY
DMJKWPZ PC 5479539
DMJKWPZ MW 514.6
DMJKWPZ FM C22H22N6O5S2
DMJKWPZ IC DKOQGJHPHLTOJR-WHRDSVKCSA-N
DMJKWPZ CS CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]
DMJKWPZ IK 1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
DMJKWPZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMJKWPZ CA CAS 84957-29-9
DMJKWPZ CB CHEBI:3503
DMJKWPZ DE Pseudomonas infection
DMPZTRC ID DMPZTRC
DMPZTRC DN Ceftazidine
DMPZTRC HS Phase 4
DMPZTRC SN Ceftazidine [INN]; Ceftazidine [USAN]; Ceftazidine [IBAN]; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC PC 13505813
DMPZTRC MW 564.6
DMPZTRC FM C22H24N6O8S2
DMPZTRC IC GCZOCVAKBHTGOL-ROMZVAKDSA-N
DMPZTRC CS CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)O.[OH-]
DMPZTRC IK 1S/C22H22N6O7S2.H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);1H2/b26-13-;/t14-,18-;/m1./s1
DMPZTRC IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC DE Meningitis
DMYGEH7 ID DMYGEH7
DMYGEH7 DN Ceftolozane sulfate
DMYGEH7 HS Phase 4
DMYGEH7 SN Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist
DMYGEH7 CP Fujisawa Pharmaceutical Co Ltd; Calixa Therapeutics Inc
DMYGEH7 DT Small molecular drug
DMYGEH7 PC 11592969
DMYGEH7 MW 764.8
DMYGEH7 FM C23H32N12O12S3
DMYGEH7 IC InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1
DMYGEH7 CS CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]
DMYGEH7 IK UJDQGRLTPBVSFN-GZGOMJRCSA-N
DMYGEH7 IU (6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate
DMYGEH7 DE Respiratory tract infection
DMYTGW0 ID DMYTGW0
DMYTGW0 DN Celiprolol
DMYTGW0 HS Phase 4
DMYTGW0 SN Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; celiprolol; 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; 56980-93-9; BRN 2776298; CCRIS 3400; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-
DMYTGW0 PC 2663
DMYTGW0 MW 379.5
DMYTGW0 FM C20H33N3O4
DMYTGW0 IC JOATXPAWOHTVSZ-UHFFFAOYSA-N
DMYTGW0 CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C
DMYTGW0 IK 1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)
DMYTGW0 IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea
DMYTGW0 CA CAS 56980-93-9
DMYTGW0 CB CHEBI:94461
DMYTGW0 DE Essential hypertension
DM6C4YJ ID DM6C4YJ
DM6C4YJ DN Chlorphenamine
DM6C4YJ HS Phase 4
DM6C4YJ SN Chloropheniramine; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamin; Chlorphenamine; Chlorphenaminum; Chlorpheniramine maleate; Chlorpheniramine polistirex; Chlorpheniraminum; Chlorprophenpyridamine; Clorfenamina; Clorfeniramina; Clorfeniramina [Italian]; Cloropiril; Aller-Chlor; Allergican; Allergisan; Antagonate; Chlor-trimeton; Haynon; Histadur; Kloromin; Phenetron; Polaramine; Polaronil; Telachlor; Teldrin; chlorpheniramine; 132-22-9; 4-Chloropheniramine
DM6C4YJ PC 2725
DM6C4YJ MW 274.79
DM6C4YJ FM C16H19ClN2
DM6C4YJ IC SOYKEARSMXGVTM-UHFFFAOYSA-N
DM6C4YJ CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM6C4YJ IK 1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m1/s1
DM6C4YJ IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM6C4YJ CA CAS 132-22-9
DM6C4YJ CB CHEBI:52010
DM6C4YJ DE Allergy
DM0N19Y ID DM0N19Y
DM0N19Y DN Chondroitin sulfate
DM0N19Y HS Phase 4
DM0N19Y SN Chondritinsulfate; Chondritinsulphate; Chondroitin 4 and 6 sulfate; Chondroitin 4-sulfate; Chondroitin 6-sulfate; Chondroitin polysulfate; Chondroitin sulfate; Chondroitin sulfuric acid; Chondroitin sulfuric acids; Chondroitin sulphate; Chondroitin, CHONDROITIN SULFATES; hydrogen sulfate; Chondroitine sulfate; Chondroitinsulfate C; Chondroitinsulfuric acids; Chondron; Chonsurid; Condrosan; Condrosulf; Sodium chondroitin sulfate; Structum; Uropol S; chondroitin sulfate C; 9007-28-7; EINECS 232-696-9; Gepan; UNII-6IC1M3OG5Z
DM0N19Y PC 24766
DM0N19Y MW 463.37
DM0N19Y FM C13H21NO15S
DM0N19Y IC KXKPYJOVDUMHGS-OSRGNVMNSA-N
DM0N19Y CS CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O
DM0N19Y IK 1S/C13H21NO15S/c1-2(15)14-3-8(7(19)13(28-11(3)22)29-30(23,24)25)26-12-6(18)4(16)5(17)9(27-12)10(20)21/h3-9,11-13,16-19,22H,1H3,(H,14,15)(H,20,21)(H,23,24,25)/t3-,4+,5+,6-,7-,8-,9+,11-,12-,13-/m1/s1
DM0N19Y IU (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM0N19Y CA CAS 9007-28-7
DM0N19Y DE Osteoarthritis
DMBG0N4 ID DMBG0N4
DMBG0N4 DN Cibenzoline
DMBG0N4 HS Phase 4
DMBG0N4 SN Cibenzolina; Cibenzolina [INN-Spanish]; Cibenzoline; Cibenzoline (INN); Cibenzoline [INN]; Cibenzolinum; Cibenzolinum [INN-Latin]; Cifenline; Cifenline (USAN); Cifenline [USAN]; Ro 22-7796; Ro 227796; UP 33901; (+-)-2-(2,2-Diphenylcyclopropyl)-2-imidazoline; 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)-; 2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole; 53267-01-9; C18H18N2; CHEMBL87045; EINECS 258-453-7
DMBG0N4 PC 2747
DMBG0N4 MW 262.3
DMBG0N4 FM C18H18N2
DMBG0N4 IC IPOBOOXFSRWSHL-UHFFFAOYSA-N
DMBG0N4 CS C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4
DMBG0N4 IK 1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)
DMBG0N4 IU 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole
DMBG0N4 CA CAS 53267-01-9
DMBG0N4 CB CHEBI:135083
DMBG0N4 DE Atrial fibrillation
DMSW5QP ID DMSW5QP
DMSW5QP DN Cotrimoxazole
DMSW5QP HS Phase 4
DMSW5QP SN Centran; Centrin; Cotrim.L.U.T; Eslectin; Insozalin; Biseptol-480; LS-2191; Metomide; Trimedin; Trimethoprim/Sulfamethoxazol; Trimezole; CHEMBL195591; Sulfamethoxazole-Trimethoprim Combination
DMSW5QP PC 24719
DMSW5QP MW 542.6
DMSW5QP FM C25H30N6O6S
DMSW5QP IC CTNTUFQBOKZSPI-UHFFFAOYSA-N
DMSW5QP CS CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMSW5QP IK 1S/C14H18N4O3.C11H12N2O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-8-6-10(13-16-8)7-17(14,15)11-4-2-9(12)3-5-11/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,7,12H2,1H3
DMSW5QP IU 4-[(5-methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMSW5QP DE Human immunodeficiency virus infection
DMLMOIJ ID DMLMOIJ
DMLMOIJ DN Cyproterone acetate
DMLMOIJ HS Phase 4
DMLMOIJ SN Cyprosterone acetate; Cyproteron acetate; Cyproteron-R acetate; Cyproterone 17-O-acetate; Cyproterone 17.alpha.-acetate; Cyproterone 17alpha-acetate; Cyproterone acetate [USAN:JAN]; Androcur; CYPROTERONE ACETATE; Cyproteroneacetate; SH 714; SH 80714; SH-714; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; 427-51-0; 4KM2BN5JHF; C24H29ClO4; CCRIS 4385; CHEBI:50743; CHEMBL139835; EINECS 207-048-3; HSDB 3592; MLS000859908; NSC 81430; NSC-81430; UNII-4KM2BN5JHF
DMLMOIJ PC 9880
DMLMOIJ MW 416.9
DMLMOIJ FM C24H29ClO4
DMLMOIJ IC UWFYSQMTEOIJJG-FDTZYFLXSA-N
DMLMOIJ CS CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C
DMLMOIJ IK 1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1
DMLMOIJ IU [(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate
DMLMOIJ CA CAS 427-51-0
DMLMOIJ CB CHEBI:50743
DMLMOIJ DE Polycystic ovary syndrome
DMV6KFY ID DMV6KFY
DMV6KFY DN Dapoxetine
DMV6KFY HS Phase 4
DMV6KFY SN Priligy (TN)
DMV6KFY CP Furiex pharmaceuticals
DMV6KFY DT Small molecular drug
DMV6KFY PC 71353
DMV6KFY MW 305.4
DMV6KFY FM C21H23NO
DMV6KFY IC InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
DMV6KFY CS CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3
DMV6KFY IK USRHYDPUVLEVMC-FQEVSTJZSA-N
DMV6KFY IU (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine
DMV6KFY CA CAS 119356-77-3
DMV6KFY CB CHEBI:135962
DMV6KFY DE Premature ejaculation
DMV5KTJ ID DMV5KTJ
DMV5KTJ DN Demegestone
DMV5KTJ HS Phase 4
DMV5KTJ SN Demegestona; Demegestona [INN-Spanish]; Demegestone; Demegestone (INN); Demegestone [INN:DCF]; Demegestonum; Demegestonum [INN-Latin]; Lutionex; R 2453; R-2453; RU 2453; SCHEMBL146550; ZINC4215548; 10116-22-0; 17-Methyl-19-norpregna-4,9-diene-3,20-dione; 17alpha-Methyl-19-demethylpregna-4,9-diene-3,20-dione; 19-Norpregna-4,9-diene-3,20-dione, 17-methyl- (8CI)(9CI); 6E89AM91SZ; AC1L3PEV; CHEBI:135339; CHEMBL2104231; D07223; DTXSID20878581; EINECS 233-320-6; NSC 118189; UNII-6E89AM91SZ
DMV5KTJ PC 93057
DMV5KTJ MW 312.4
DMV5KTJ FM C21H28O2
DMV5KTJ IC JWAHBTQSSMYISL-MHTWAQMVSA-N
DMV5KTJ CS CC(=O)C1(CCC2C1(CCC3=C4CCC(=O)C=C4CCC23)C)C
DMV5KTJ IK 1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1
DMV5KTJ IU (8S,13S,14S,17S)-17-acetyl-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMV5KTJ CA CAS 10116-22-0
DMV5KTJ CB CHEBI:135339
DMV5KTJ DE Corpus luteum cyst
DMN2Q5I ID DMN2Q5I
DMN2Q5I DN Diacerein
DMN2Q5I HS Phase 4
DMN2Q5I SN Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692
DMN2Q5I DT Small molecular drug
DMN2Q5I PC 26248
DMN2Q5I MW 368.3
DMN2Q5I FM C19H12O8
DMN2Q5I IC InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
DMN2Q5I CS CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O
DMN2Q5I IK TYNLGDBUJLVSMA-UHFFFAOYSA-N
DMN2Q5I IU 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid
DMN2Q5I CA CAS 13739-02-1
DMN2Q5I CB CHEBI:94708
DMTX0PZ ID DMTX0PZ
DMTX0PZ DN Dibekacin
DMTX0PZ HS Phase 4
DMTX0PZ SN Debecacin; Dibekacin sulfate; Dibekacina; Dibekacina [INN-Spanish]; Dibekacine; Dibekacine [INN-French]; Dibekacinum; Dibekacinum [INN-Latin]; Dideoxykanamycin B; Kappati; Panamicin; dibekacin; 3',4'-Dideoxykanamycin B; 34493-98-6; 45ZFO9E525; BRN 1441606; CHEBI:37945; DKB; DKM; EINECS 252-064-6; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; UNII-45ZFO9E525
DMTX0PZ PC 470999
DMTX0PZ MW 451.5
DMTX0PZ FM C18H37N5O8
DMTX0PZ IC JJCQSGDBDPYCEO-XVZSLQNASA-N
DMTX0PZ CS C1CC(C(OC1CN)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CO)O)N)O)N)N)N
DMTX0PZ IK 1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMTX0PZ IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMTX0PZ CA CAS 34493-98-6
DMTX0PZ CB CHEBI:37945
DMTX0PZ DE Acute lower respiratory infection
DMZ5Y1P ID DMZ5Y1P
DMZ5Y1P DN Dichloroacetate
DMZ5Y1P HS Phase 4
DMZ5Y1P SN 2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
DMZ5Y1P DT Small molecular drug
DMZ5Y1P PC 25975
DMZ5Y1P MW 127.93
DMZ5Y1P FM C2HCl2O2-
DMZ5Y1P IC InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DMZ5Y1P CS C(C(=O)[O-])(Cl)Cl
DMZ5Y1P IK JXTHNDFMNIQAHM-UHFFFAOYSA-M
DMZ5Y1P IU 2,2-dichloroacetate
DMZ5Y1P CA CAS 13425-80-4
DMZ5Y1P CB CHEBI:28240
DMZ5Y1P DE Pulmonary fibrosis; Pyruvate dehydrogenase complex deficiency; Insulin-resistant disorder
DMB0FWL ID DMB0FWL
DMB0FWL DN Dihydrocodeine
DMB0FWL HS Phase 4
DMB0FWL SN Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine
DMB0FWL CP Mundipharma AG
DMB0FWL DT Small molecular drug
DMB0FWL PC 5284543
DMB0FWL MW 301.4
DMB0FWL FM C18H23NO3
DMB0FWL IC InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMB0FWL CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
DMB0FWL IK RBOXVHNMENFORY-DNJOTXNNSA-N
DMB0FWL IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMB0FWL CA CAS 125-28-0
DMB0FWL CB CHEBI:135276
DMB0FWL DE Cancer related pain
DM3S8XC ID DM3S8XC
DM3S8XC DN Dihydrotestosterone
DM3S8XC HS Phase 4
DM3S8XC SN Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone
DM3S8XC DT Small molecular drug
DM3S8XC PC 10635
DM3S8XC MW 290.4
DM3S8XC FM C19H30O2
DM3S8XC IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
DM3S8XC CS C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
DM3S8XC IK NVKAWKQGWWIWPM-ABEVXSGRSA-N
DM3S8XC IU (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DM3S8XC CA CAS 521-18-6
DM3S8XC CB CHEBI:16330
DM3S8XC DE Prostate hyperplasia
DM3YH4I ID DM3YH4I
DM3YH4I DN D-Serine
DM3YH4I HS Phase 4
DM3YH4I SN D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine
DM3YH4I DT Small molecular drug
DM3YH4I PC 71077
DM3YH4I MW 105.09
DM3YH4I FM C3H7NO3
DM3YH4I IC InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1
DM3YH4I CS C([C@H](C(=O)O)N)O
DM3YH4I IK MTCFGRXMJLQNBG-UWTATZPHSA-N
DM3YH4I IU (2R)-2-amino-3-hydroxypropanoic acid
DM3YH4I CA CAS 312-84-5
DM3YH4I CB CHEBI:16523
DMH21D9 ID DMH21D9
DMH21D9 DN Ebastine
DMH21D9 HS Phase 4
DMH21D9 SN ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone
DMH21D9 PC 3191
DMH21D9 MW 469.7
DMH21D9 FM C32H39NO2
DMH21D9 IC InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMH21D9 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMH21D9 IK MJJALKDDGIKVBE-UHFFFAOYSA-N
DMH21D9 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMH21D9 CA CAS 90729-43-4
DMH21D9 CB CHEBI:31528
DMH21D9 DE Irritable bowel syndrome
DMQRX24 ID DMQRX24
DMQRX24 DN Ebastine
DMQRX24 HS Phase 4
DMQRX24 SN Ebastel; Ebastin; Ebastina [Spanish]; Ebastinum [Latin]; Estivan; Evastel; Kestin; Kestine; LAS W-090; RP 64305; Bactil; RP-64305; TQD7Q784P1; ebastine; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; 90729-43-4; C32H39NO2; CHEMBL305660; MFCD00865661; NCGC00164603-01; UNII-TQD7Q784P1
DMQRX24 PC 3191
DMQRX24 MW 469.7
DMQRX24 FM C32H39NO2
DMQRX24 IC MJJALKDDGIKVBE-UHFFFAOYSA-N
DMQRX24 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMQRX24 IK 1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMQRX24 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMQRX24 CA CAS 90729-43-4
DMQRX24 CB CHEBI:31528
DMQRX24 DE Irritable bowel syndrome
DM9WPIH ID DM9WPIH
DM9WPIH DN Ergonovine maleate
DM9WPIH HS Phase 4
DM9WPIH SN Ergomet; Ergometrin maleate; Ergometrine acid maleate; Ergometrine hydrogen maleate; Ergometrine maleate (1:1); Ergonovine hydrogen maleate; Ergonovine maleate; Ergonovine maleate (USP); Ergonovine maleate [USP]; Ergonovine maleate salt; Ergonovine, maleate (1:1); Ergonovine, maleate (1:1) (salt); Ergotocin maleate; Ermetrin; Metriclavin; Oxytocic; Cornocentin; Crude ergot; D-Ergonovine maleate; YMH3D0ZJWV; ergometrine maleate; 129-51-1; CHEBI:31554; EINECS 204-953-5; NSC 93752; UNII-YMH3D0ZJWV
DM9WPIH PC 6437065
DM9WPIH MW 441.5
DM9WPIH FM C23H27N3O6
DM9WPIH IC YREISLCRUMOYAY-IIPCNOPRSA-N
DM9WPIH CS CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O
DM9WPIH IK 1S/C19H23N3O2.C4H4O4/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;5-3(6)1-2-4(7)8/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24);1-2H,(H,5,6)(H,7,8)/b;2-1-/t11-,13+,17+;/m0./s1
DM9WPIH IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
DM9WPIH CA CAS 129-51-1
DM9WPIH CB CHEBI:31554
DM9WPIH DE Abnormal vaginal bleeding
DMKEGI3 ID DMKEGI3
DMKEGI3 DN Esmirtazapine
DMKEGI3 HS Phase 4
DMKEGI3 SN Esmirtazapine; Esmirtazapine [INN]; Org 44-20; Org-44-20; ZINC968310; (+)-Mirtazapine; (S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; 4685R51V7M; 61337-87-9; AC1MJ43F; BIDD:PXR0200; CHEMBL1366933; DB06678; EINECS 262-714-0; PDSP1_001530; PDSP2_001514; SCHEMBL49330; UNII-4685R51V7M
DMKEGI3 PC 3085218
DMKEGI3 MW 265.35
DMKEGI3 FM C17H19N3
DMKEGI3 IC RONZAEMNMFQXRA-MRXNPFEDSA-N
DMKEGI3 CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DMKEGI3 IK 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1
DMKEGI3 IU (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DMKEGI3 CA CAS 61337-87-9
DMKEGI3 DE Depression
DM7ITZK ID DM7ITZK
DM7ITZK DN Ethinylestradiol propanesulfonate
DM7ITZK HS Phase 4
DM7ITZK SN Ethinylestradiol propanesulfonate; Ethinyl estradiol isopropylsulfonate; SCHEMBL457480; Turisteron; Turisteron (TN); XF48685MYR; ethinylestradiol sulfonate; (17; 17-Hydroxy-19-norpregna-1(10),2,4-trien-20-yn-3-yl propane-2-sulfonate; 17alpha-Ethinyl-3-isopropylsulfonyloxyestradiol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17alpha)-; 28913-23-7; A)-17-ethynyl-17-hydroxyestra-1,3,5(10)-trien-3-yl propane-2-sulfonate; AC1L2A1G; AC1Q6XYI; CHEBI:135643; D07928; DTXSID20951545; J-96; UNII-XF48685MYR
DM7ITZK PC 68582
DM7ITZK MW 402.5
DM7ITZK FM C23H30O4S
DM7ITZK IC KPEUDULLQDHKAZ-VROINQGHSA-N
DM7ITZK CS CC(C)S(=O)(=O)OC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4(C#C)O)C
DM7ITZK IK 1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1
DM7ITZK IU [(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] propane-2-sulfonate
DM7ITZK CA CAS 28913-23-7
DM7ITZK CB CHEBI:135643
DM7ITZK DE Prostate cancer
DM8TNX3 ID DM8TNX3
DM8TNX3 DN Etizolam
DM8TNX3 HS Phase 4
DM8TNX3 SN Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37
DM8TNX3 PC 3307
DM8TNX3 MW 342.8
DM8TNX3 FM C17H15ClN4S
DM8TNX3 IC VMZUTJCNQWMAGF-UHFFFAOYSA-N
DM8TNX3 CS CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C
DM8TNX3 IK 1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
DM8TNX3 IU 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DM8TNX3 CA CAS 40054-69-1
DM8TNX3 CB CHEBI:31583
DM8TNX3 DE Insomnia
DMR7U8F ID DMR7U8F
DMR7U8F DN Etoperidone
DMR7U8F HS Phase 4
DMR7U8F SN Etoperidona; Etoperidona [INN-Spanish]; Etoperidona [Spanish]; Etoperidone [INN]; Etoperidonum; Etoperidonum [INN-Latin]; ETOPERIDONE; IZBNNCFOBMGTQX-UHFFFAOYSA-N; KAI6MVO39Z; L001188; ZINC3830815; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one; 52942-31-1; AC1L242J; AC1Q3SR1; ACM52942311; BDBM82438; CAS_52942-31-1; CHEBI:135589; CHEMBL1743259; DB09194; DTXSID0023034; NSC_40589; PDSP1_000523; PDSP2_000521; SCHEMBL49314; UNII-KAI6MVO39Z
DMR7U8F PC 40589
DMR7U8F MW 377.9
DMR7U8F FM C19H28ClN5O
DMR7U8F IC IZBNNCFOBMGTQX-UHFFFAOYSA-N
DMR7U8F CS CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl
DMR7U8F IK 1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
DMR7U8F IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one
DMR7U8F CA CAS 52942-31-1
DMR7U8F CB CHEBI:135589
DMR7U8F DE Depression
DM9R1YU ID DM9R1YU
DM9R1YU DN Gestodene
DM9R1YU HS Phase 4
DM9R1YU SN Gestinol; Gestoden; Gestodene [USAN:INN:BAN]; Gestodeno; Gestodeno [INN-Spanish]; Gestodenum; Gestodenum [INN-Latin]; SH B 331; GESTODENE; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 1664P6E6MI; 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; 60282-87-3; BRN 4237181; CCRIS 9189; DSSTox_CID_26478; DSSTox_GSID_46478; DSSTox_RID_81649; EINECS 262-145-8; HSDB 3594; UNII-1664P6E6MI
DM9R1YU PC 3033968
DM9R1YU MW 310.4
DM9R1YU FM C21H26O2
DM9R1YU IC SIGSPDASOTUPFS-XUDSTZEESA-N
DM9R1YU CS CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34
DM9R1YU IK 1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM9R1YU IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
DM9R1YU CA CAS 60282-87-3
DM9R1YU CB CHEBI:135323
DM9R1YU DE Contraception
DMDN4A1 ID DMDN4A1
DMDN4A1 DN Glitazone
DMDN4A1 HS Phase 4
DMDN4A1 SN 74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087
DMDN4A1 DT Small molecular drug
DMDN4A1 PC 10198397
DMDN4A1 MW 223.25
DMDN4A1 FM C10H9NO3S
DMDN4A1 IC InChI=1S/C10H9NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-4,8,12H,5H2,(H,11,13,14)
DMDN4A1 CS C1=CC(=CC=C1CC2C(=O)NC(=O)S2)O
DMDN4A1 IK NKOHRVBBQISBSB-UHFFFAOYSA-N
DMDN4A1 IU 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione
DMDN4A1 CA CAS 74772-78-4
DMF72W3 ID DMF72W3
DMF72W3 DN Glyceryl trinitrate
DMF72W3 HS Phase 4
DMF72W3 SN Gilustenon; Glycerol trinitrate; Glyceryl trinitrate; Lenitral; Minitran; Natispray; Nitro-Bid; Nitro-dur; Nitrocine; Nitroderm; Cordipatch; Corditrine; Epinitril; Nitroderm TTS; Nitroglicerina; Nitroglycerine; Nitroglycerol; Nitroglyn; Nitrolan; Nitrolingual; Nitronet; Nitrong; Nitroplast; Nitrorectal; Nitroretard; Nitrospan; Nitrostat; Perglottal; Perlinganit; Rectogesic; Susadrin; Sustonit; Transderm Nitro; Transderm-nitro; Tridil; Trinitrin; Trinitroglycerin; Trinitroglycerol; Trinitrolong; Trinitrosan; nitroglycerin; 55-63-0; Niong
DMF72W3 PC 4510
DMF72W3 MW 227.09
DMF72W3 FM C3H5N3O9
DMF72W3 IC SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMF72W3 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMF72W3 IK 1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMF72W3 IU 1,3-dinitrooxypropan-2-yl nitrate
DMF72W3 CA CAS 55-63-0
DMF72W3 CB CHEBI:28787
DMF72W3 DE Acute coronary syndrome
DM0OX31 ID DM0OX31
DM0OX31 DN Glypromate
DM0OX31 HS Phase 4
DM0OX31 SN Glypromate; Glycyl-prolyl-glutamic acid; Gly-Pro-Glu, >=98% (HPLC); Gly-pro-glu; SCHEMBL1170125; ZINC3776571; ZYK4RVV5LS; glycyl-l-prolyl-l-glutamic acid; 32302-76-4; CHEMBL371315; DB05633; DTXSID80186038; UNII-ZYK4RVV5LS
DM0OX31 PC 3080768
DM0OX31 MW 301.3
DM0OX31 FM C12H19N3O6
DM0OX31 IC JJGBXTYGTKWGAT-YUMQZZPRSA-N
DM0OX31 CS C1CC(N(C1)C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O
DM0OX31 IK 1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1
DM0OX31 IU (2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
DM0OX31 CA CAS 32302-76-4
DM0OX31 DE Epilepsy
DM9BPLW ID DM9BPLW
DM9BPLW DN Grazoprevir
DM9BPLW HS Phase 4
DM9BPLW SN Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J
DM9BPLW PC 44603531
DM9BPLW MW 766.9
DM9BPLW FM C38H50N6O9S
DM9BPLW IC OBMNJSNZOWALQB-NCQNOWPTSA-N
DM9BPLW CS CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1
DM9BPLW IK 1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
DM9BPLW IU (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DM9BPLW CA CAS 1350514-68-9
DM9BPLW CB CHEBI:132975
DM9BPLW DE Viral hepatitis
DMPN5IH ID DMPN5IH
DMPN5IH DN Guanfacine
DMPN5IH HS Phase 4
DMPN5IH SN GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043
DMPN5IH PC 3519
DMPN5IH MW 246.09
DMPN5IH FM C9H9Cl2N3O
DMPN5IH IC InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
DMPN5IH CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
DMPN5IH IK INJOMKTZOLKMBF-UHFFFAOYSA-N
DMPN5IH IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
DMPN5IH CA CAS 29110-47-2
DMPN5IH CB CHEBI:5558
DMPN5IH DE Primary liver cancer
DMLYXBF ID DMLYXBF
DMLYXBF DN Guanoxan
DMLYXBF HS Phase 4
DMLYXBF SN Guanoxan; Guanoxan [INN:BAN]; Guanoxane; Guanoxano; Guanoxano [INN-Spanish]; Guanoxanum; Guanoxanum [INN-Latin]; Guanoxon; ((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; (1,4-Benzodioxan-2-ylmethyl)guanidine; 2165-19-7; Envacar (Salt/Mix); BRN 1251616; DSSTox_CID_26166; DSSTox_RID_81397; GUANIDINE, (1,4-BENZODIOXAN-2-YLMETHYL)-; Guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; N-((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; N-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]guanidine; NCGC00160462-01
DMLYXBF PC 16564
DMLYXBF MW 207.23
DMLYXBF FM C10H13N3O2
DMLYXBF IC HIUVKVDQFXDZHU-UHFFFAOYSA-N
DMLYXBF CS C1C(OC2=CC=CC=C2O1)CN=C(N)N
DMLYXBF IK 1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)
DMLYXBF IU 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine
DMLYXBF CA CAS 2165-19-7
DMLYXBF CB CHEBI:134871
DMLYXBF DE Essential hypertension
DM4OQRD ID DM4OQRD
DM4OQRD DN HIF-1alpha
DM4OQRD HS Phase 4
DM4OQRD SN Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
DM4OQRD CP Enzon
DM4OQRD TC Anticancer Agents
DM4OQRD DT Small molecular drug
DM4OQRD PC 5328127
DM4OQRD MW 396.4
DM4OQRD FM C20H24N6O3
DM4OQRD IC InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27)
DM4OQRD CS CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC
DM4OQRD IK NHJSWORVNIOXIT-UHFFFAOYSA-N
DM4OQRD IU 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
DM4OQRD CA CAS 192705-79-6
DM4OQRD CB CHEBI:156259
DM4OQRD DE Lymphoma
DMYOC29 ID DMYOC29
DMYOC29 DN Hirudin
DMYOC29 HS Phase 4
DMYOC29 SN Hirudin (53-64); 135546-61-1; Hirudin 53-64; DTXSID20159463; L-Alanine, L-asparaginylglycyl-L-alpha-aspartyl-L-pheylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-
DMYOC29 DT Small molecular drug
DMYOC29 PC 72941487
DMYOC29 MW 7044
DMYOC29 FM C287H440N80O113S7
DMYOC29 IC InChI=1S/C287H440N80O113S7/c1-25-133(19)226-281(469)345-161(87-125(3)4)235(423)306-111-208(394)320-180(116-370)266(454)344-175(101-219(414)415)237(425)307-105-202(388)316-151(62-75-212(400)401)242(430)321-145(41-30-33-81-288)240(428)339-170(96-197(297)383)258(446)326-152(57-70-193(293)379)249(437)351-185(121-484-481-118-182-239(427)310-107-201(387)313-147(55-68-191(291)377)232(420)303-108-205(391)317-169(95-196(296)382)257(445)322-146(42-31-34-82-289)241(429)350-186(271(459)360-226)122-485-482-119-183(268(456)323-149(61-74-211(398)399)234(422)304-110-207(393)319-179(115-369)265(453)342-173(99-200(300)386)264(452)357-223(130(13)14)279(467)355-182)352-253(441)164(90-128(9)10)335-269(457)184-120-483-486-123-187(354-262(450)177(103-221(418)419)347-283(471)230(137(23)374)362-263(451)167(92-140-47-51-143(376)52-48-140)346-278(466)224(131(15)16)359-276(464)222(301)129(11)12)272(460)363-229(136(22)373)282(470)330-157(66-79-216(408)409)248(436)348-178(114-368)238(426)309-106-203(389)315-150(56-69-192(292)378)243(431)340-171(97-198(298)384)259(447)334-163(89-127(7)8)252(440)353-184)270(458)358-225(132(17)18)280(468)364-228(135(21)372)277(465)311-112-204(390)314-148(60-73-210(396)397)233(421)305-113-209(395)356-231(138(24)375)286(474)367-86-38-46-190(367)275(463)331-159(43-32-35-83-290)284(472)365-84-36-44-188(365)273(461)328-153(58-71-194(294)380)247(435)349-181(117-371)267(455)338-168(94-142-104-302-124-312-142)256(444)341-172(98-199(299)385)260(448)343-174(100-218(412)413)236(424)308-109-206(392)318-176(102-220(416)417)261(449)337-165(91-139-39-28-27-29-40-139)254(442)327-154(63-76-213(402)403)244(432)325-158(67-80-217(410)411)250(438)361-227(134(20)26-2)285(473)366-85-37-45-189(366)274(462)329-156(65-78-215(406)407)245(433)324-155(64-77-214(404)405)246(434)336-166(93-141-49-53-144(54-50-141)480-487(477,478)479)255(443)333-162(88-126(5)6)251(439)332-160(287(475)476)59-72-195(295)381/h27-29,39-40,47-54,104,124-138,145-190,222-231,368-376H,25-26,30-38,41-46,55-103,105-123,288-290,301H2,1-24H3,(H2,291,377)(H2,292,378)(H2,293,379)(H2,294,380)(H2,295,381)(H2,296,382)(H2,297,383)(H2,298,384)(H2,299,385)(H2,300,386)(H,302,312)(H,303,420)(H,304,422)(H,305,421)(H,306,423)(H,307,425)(H,308,424)(H,309,426)(H,310,427)(H,311,465)(H,313,387)(H,314,390)(H,315,389)(H,316,388)(H,317,391)(H,318,392)(H,319,393)(H,320,394)(H,321,430)(H,322,445)(H,323,456)(H,324,433)(H,325,432)(H,326,446)(H,327,442)(H,328,461)(H,329,462)(H,330,470)(H,331,463)(H,332,439)(H,333,443)(H,334,447)(H,335,457)(H,336,434)(H,337,449)(H,338,455)(H,339,428)(H,340,431)(H,341,444)(H,342,453)(H,343,448)(H,344,454)(H,345,469)(H,346,466)(H,347,471)(H,348,436)(H,349,435)(H,350,429)(H,351,437)(H,352,441)(H,353,440)(H,354,450)(H,355,467)(H,356,395)(H,357,452)(H,358,458)(H,359,464)(H,360,459)(H,361,438)(H,362,451)(H,363,460)(H,364,468)(H,396,397)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,475,476)(H,477,478,479)/t133-,134-,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DMYOC29 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DMYOC29 IK WQPDUTSPKFMPDP-OUMQNGNKSA-N
DMYOC29 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMYOC29 CA CAS 8001-27-2
DM0WD1V ID DM0WD1V
DM0WD1V DN Human calcitonin
DM0WD1V HS Phase 4
DM0WD1V SN Calcitonin (human synthetic); Calcitonin (human); Calcitonin human; Calcitonin, human; Calcitonin, human synthetic
DM0WD1V PC 16220016
DM0WD1V IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM0WD1V DE Hyperparathyroidism
DMABXOZ ID DMABXOZ
DMABXOZ DN Hyaluronic acid
DMABXOZ HS Phase 4
DMABXOZ SN Hyaluronic Acid [BAN]; Hylan G-F 20; Hyvisc; Luronit; Mucoitin; Amo Vitrax; Amvisc; Biolon; Etamucine; Sepracoat; Sofast; Synvisc; C33H54N2O23; EINECS 232-678-0; HSDB 7240; Hyaluronate Sodium (hyaluronic acid)
DMABXOZ PC 24847767
DMABXOZ MW 846.8
DMABXOZ FM C33H54N2O23
DMABXOZ IC BVOZFCOTOYGLGD-VPQOAABJSA-N
DMABXOZ CS CC(=O)NC1C(C(C(OC1COCC2C(OC(C(C2O)(C)O)OCC3C(C(OC(C3O)CO)O)NC(=O)C)C(=O)O)CO)O)COC4C(C(C(C(O4)C(=O)O)O)O)O
DMABXOZ IK 1S/C33H54N2O23/c1-10(38)34-18-12(7-53-31-24(44)22(42)23(43)26(57-31)29(48)49)20(40)15(4-36)55-17(18)9-52-6-14-25(28(46)47)58-32(33(3,51)27(14)45)54-8-13-19(35-11(2)39)30(50)56-16(5-37)21(13)41/h12-27,30-32,36-37,40-45,50-51H,4-9H2,1-3H3,(H,34,38)(H,35,39)(H,46,47)(H,48,49)/t12-,13-,14+,15?,16?,17-,18?,19?,20-,21-,22+,23-,24?,25?,26?,27+,30+,31+,32+,33?/m0/s1
DMABXOZ IU (3S,4R,6R)-3-[[(2R,4R,5S)-3-acetamido-4-[[(2R,4R,5S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxymethyl]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]methoxymethyl]-6-[[(2R,4R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]methoxy]-4,5-dihydroxy-5-methyloxane-2-carboxylic acid
DMABXOZ DE Osteoarthritis
DM8NWFD ID DM8NWFD
DM8NWFD DN Hypericum
DM8NWFD HS Phase 4
DM8NWFD SN 6-formamidopenicillanic acid; UNII-2TC14ZH3A5; CHEBI:59004; CTK2F8101; 6-formamido-2,2-dimethylpenam-3alpha-carboxylic acid; 2TC14ZH3A5; 64527-04-4; (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-Formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; PAB 141; 141a/2A; HIS-1201; Epitope ID:119700; SCHEMBL11176911; DTXSID90429524; 6beta-formylaminopenicillanic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-(formylamino)-3,3-d
DM8NWFD DT Small molecular drug
DM8NWFD PC 9548591
DM8NWFD MW 244.27
DM8NWFD FM C9H12N2O4S
DM8NWFD IC InChI=1S/C9H12N2O4S/c1-9(2)5(8(14)15)11-6(13)4(10-3-12)7(11)16-9/h3-5,7H,1-2H3,(H,10,12)(H,14,15)/t4-,5+,7-/m1/s1
DM8NWFD CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC=O)C(=O)O)C
DM8NWFD IK MDQGTDMBVJCTBN-JCGDXUMPSA-N
DM8NWFD IU (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8NWFD CA CAS 64527-04-4
DM8NWFD CB CHEBI:59004
DMVXLOD ID DMVXLOD
DMVXLOD DN Imrecoxib
DMVXLOD HS Phase 4
DMVXLOD SN Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ;
DMVXLOD DT Small molecular drug
DMVXLOD PC 11682175
DMVXLOD MW 369.5
DMVXLOD FM C21H23NO3S
DMVXLOD IC InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3
DMVXLOD CS CCCN1CC(=C(C1=O)C2=CC=C(C=C2)C)C3=CC=C(C=C3)S(=O)(=O)C
DMVXLOD IK AXMZZGKKZDJGAZ-UHFFFAOYSA-N
DMVXLOD IU 4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2H-pyrrol-5-one
DMVXLOD CA CAS 395683-14-4
DM2R496 ID DM2R496
DM2R496 DN Indenolol
DM2R496 HS Phase 4
DM2R496 SN Indenolol; Indenolol [INN]; Indenolol [BAN:INN]; Indenolol [INN:BAN]; Indenololum; Indenololum [INN-Latin]; Sch 28316 Z; Sch 28316Z; Securpres; 1-(4-Indenyloxy)-3-isopropylamino-2-propanol; 1-(Inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol; 106656-86-4; 2-Propanol, 1-(1H-inden-4-yloxy)-3-((1-methylethyl)amino)-; 2-Propanol, 1-(1H-inden-4-yloxy)-3-[(1-methylethyl)amino]-; 4-(2-Hydroxy-3-isopropylaminopropoxy)indene; 60607-68-3; AC1L2H51; AC1Q77JA; ACMC-20macf; C15H27NO2; CHEMBL153585; EINECS 262-323-5; SCHEMBL79021; YB-2
DM2R496 PC 71955
DM2R496 MW 247.33
DM2R496 FM C15H21NO2
DM2R496 IC MPGBPFMOOXKQRX-UHFFFAOYSA-N
DM2R496 CS CC(C)NCC(COC1=CC=CC2=C1C=CC2)O
DM2R496 IK 1S/C15H21NO2/c1-11(2)16-9-13(17)10-18-15-8-4-6-12-5-3-7-14(12)15/h3-4,6-8,11,13,16-17H,5,9-10H2,1-2H3
DM2R496 IU 1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DM2R496 CA CAS 60607-68-3
DM2R496 DE Cardiac arrhythmia
DMVPLNC ID DMVPLNC
DMVPLNC DN Ingrezza
DMVPLNC HS Phase 4
DMVPLNC SN Valbenazine; 1025504-45-3; UNII-54K37P50KH; Valbenazine free base; NBI 98854; 54K37P50KH; 1025504-45-3 (free base); (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; SB17456; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester
DMVPLNC CP Neurocrine Biosciences
DMVPLNC DT Small molecular drug
DMVPLNC PC 24795069
DMVPLNC MW 418.6
DMVPLNC FM C24H38N2O4
DMVPLNC IC InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
DMVPLNC CS CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMVPLNC IK GEJDGVNQKABXKG-CFKGEZKQSA-N
DMVPLNC IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate
DMVPLNC CA CAS 1025504-45-3
DMVPLNC DE Tourette syndrome; Tardive dyskinesia
DM7U58J ID DM7U58J
DM7U58J DN Isoflavone
DM7U58J HS Phase 4
DM7U58J SN Isoflavone; Isoflavone (8CI); Isoflavone skeleton; LS-191186; MCULE-2586547916; OVO2KUW8H8; SBB068618; SCHEMBL8028; ST098957; VN10014; ZINC895390; isoflavon; 3-Phenylchromone; 3-phenyl-4H-1-benzopyran-4-one; 3-phenyl-4H-chromen-4-one; 3-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 3-phenyl-; 574-12-9; AC-12802; AK114020; AKOS015918505; AX8135136; BCP22856; BCP9000133; CCG-214095; CHEBI:18220; CHEMBL366460; CS-W006405; DB12007; DS-6374; DTXSID90205986; KS-00000GFW; NSC 135405; NSC-135405; NSC135405; GOMNOOKGLZYEJT-UHFFFAOYSA-N; UNII-OVO2KUW8H8
DM7U58J PC 72304
DM7U58J MW 222.24
DM7U58J FM C15H10O2
DM7U58J IC GOMNOOKGLZYEJT-UHFFFAOYSA-N
DM7U58J CS C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O
DM7U58J IK 1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H
DM7U58J IU 3-phenylchromen-4-one
DM7U58J CA CAS 574-12-9
DM7U58J CB CHEBI:18220
DM7U58J DE Asthma
DM170OH ID DM170OH
DM170OH DN Ketazolam
DM170OH HS Phase 4
DM170OH SN Ketazolamum; Ketazolamum [INN-Latin]; Loftran; U 28774; U-28,774; Unakalm; Anseren; Ansieten; KETAZOLAM; 11-Chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)dione; 27223-35-4; 4H-(1,3)Oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)-dione, 8,12b-dihydro-11-chloro-2,8-dimethyl-12b-phenyl-; 4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-; Anxon; EINECS 248-346-3; NSC 338158
DM170OH PC 33746
DM170OH MW 368.8
DM170OH FM C20H17ClN2O3
DM170OH IC PWAJCNITSBZRBL-UHFFFAOYSA-N
DM170OH CS CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C
DM170OH IK 1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
DM170OH IU 11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione
DM170OH CA CAS 27223-35-4
DM170OH CB CHEBI:135556
DM170OH DE Anxiety disorder
DMQP5I3 ID DMQP5I3
DMQP5I3 DN Lacidipine
DMQP5I3 HS Phase 4
DMQP5I3 SN Lacidipine; Lacidipine (Lacipil, Motens); Lacidipino; Lacidipino [Spanish]; Lacidipinum [Latin]; Lacimen; Lacipil; Motens; trans Lacidipine; 103890-78-4; 260080034N; 4-(o-((E)-2-Carboxyvinyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 4-tert-butyl diethyl ester; C26H33NO6; DSSTox_CID_26429; DSSTox_GSID_46429; DSSTox_RID_81607; GR 43659 X; GR 43659X; GR-43659X; GX-1048; UNII-260080034N; diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3 PC 5311217
DMQP5I3 MW 455.5
DMQP5I3 FM C26H33NO6
DMQP5I3 IC GKQPCPXONLDCMU-CCEZHUSRSA-N
DMQP5I3 CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C
DMQP5I3 IK 1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
DMQP5I3 IU diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3 CA CAS 103890-78-4
DMQP5I3 CB CHEBI:94480
DMQP5I3 DE Essential hypertension
DM5FABJ ID DM5FABJ
DM5FABJ DN LAROPIPRANT
DM5FABJ HS Phase 4
DM5FABJ SN Laropiprant; 571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
DM5FABJ DT Small molecular drug
DM5FABJ PC 9867642
DM5FABJ MW 435.9
DM5FABJ FM C21H19ClFNO4S
DM5FABJ IC InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
DM5FABJ CS CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F
DM5FABJ IK NXFFJDQHYLNEJK-CYBMUJFWSA-N
DM5FABJ IU 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
DM5FABJ CA CAS 571170-77-9
DM5FABJ CB CHEBI:135942
DM5FABJ DE Arteriosclerosis; Coronary heart disease
DM92S6N ID DM92S6N
DM92S6N DN Levamlodipine
DM92S6N HS Phase 4
DM92S6N SN Levamlodipine (hypertension); S-amlodipine gentisate; Levamlodipine (hypertension), SK Chemicals; S-amlodipine (hypertension), SK Chemicals
DM92S6N CP SK Chemicals Co Ltd
DM92S6N DT Small molecular drug
DM92S6N PC 9822750
DM92S6N MW 408.9
DM92S6N FM C20H25ClN2O5
DM92S6N IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1
DM92S6N CS CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DM92S6N IK HTIQEAQVCYTUBX-KRWDZBQOSA-N
DM92S6N IU 3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DM92S6N CA CAS 103129-82-4
DM92S6N CB CHEBI:53796
DM92S6N DE Hypertension
DM82JP0 ID DM82JP0
DM82JP0 DN Lynestrenol
DM82JP0 HS Phase 4
DM82JP0 SN Linestrenol; Linestrenol [INN-Spanish]; Linestrenolo [DCIT]; Lynenol; Lynestrenolum [INN-Latin]; Lynoestrenol; Lynoestrenol [Progestins]; Lynstranol; Endometril; Ethinyl oestrenol; Ethinylestrenol; Ethinyloestranol; Ethynloestrenol; Ethynylestrenol; Exluten; Exlution; Exluton; Exlutona; IND 1006; LYNESTRENOL; Org 485-50; Orgametil; Orgametril; Orgametrol; 17-alpha-Ethynylestrenol; 17-alpha-Ethynyloestrenol; 17alpha-Ethynylestrenol; 3-Desoxynorlutin; 52-76-6; CCRIS 9093; EINECS 200-151-4; NSC 37725; NSC-37725; UNII-N2Z8ALG4U5
DM82JP0 PC 5857
DM82JP0 MW 284.4
DM82JP0 FM C20H28O
DM82JP0 IC YNVGQYHLRCDXFQ-XGXHKTLJSA-N
DM82JP0 CS CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34
DM82JP0 IK 1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM82JP0 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM82JP0 CA CAS 52-76-6
DM82JP0 CB CHEBI:31790
DM82JP0 DE Transsexualism
DM0UGYX ID DM0UGYX
DM0UGYX DN Medifoxamine
DM0UGYX HS Phase 4
DM0UGYX SN Medifoxamina; Medifoxamina [INN-Spanish]; Medifoxamine; Medifoxamine (INN); Medifoxamine [INN:DCF]; Medifoxaminum; Medifoxaminum [INN-Latin]; KWU7C2A1NT; ZX-AT022754; (Dimethylamino)acetaldehyde diphenyl acetal; 32359-34-5; AC1L1V3V; Acetaldehyde, (dimethylamino)-, diphenyl acetal; BRN 2054310; C16H19NO2; CHEBI:135061; CHEMBL85231; CTK4G8876; DTXSID80186078; EINECS 251-011-4; Ethanamine, N,N-dimethyl-2,2-diphenoxy-; N,N-Dimethyl-2,2-diphenoxyethanamine; N,N-Dimethyl-2,2-diphenoxyethylamine; SCHEMBL49319; UNII-KWU7C2A1NT
DM0UGYX PC 36109
DM0UGYX MW 257.329
DM0UGYX FM C16H19NO2
DM0UGYX IC QNMGHBMGNRQPNL-UHFFFAOYSA-N
DM0UGYX CS CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2
DM0UGYX IK 1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
DM0UGYX IU N,N-dimethyl-2,2-diphenoxyethanamine
DM0UGYX CA CAS 32359-34-5
DM0UGYX CB CHEBI:135061
DM0UGYX DE Depression
DME1X96 ID DME1X96
DME1X96 DN Mexazolam
DME1X96 HS Phase 4
DME1X96 SN Melex (TN); Mexazolam (JAN/INN); Mexazolam [INN:JAN]; Mexazolamum; Mexazolamum [INN-Latin]; Sedoxil; mexazolam; 10-Chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 10-Chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 31868-18-5; AC1L1HL4; BRN 1091849; C18H16Cl2N2O2; CHEBI:31842; CS 386; CS-386; DSSTox_CID_31504; Melex; Oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl-
DME1X96 PC 4177
DME1X96 MW 363.2
DME1X96 FM C18H16Cl2N2O2
DME1X96 IC ANUCDXCTICZJRH-UHFFFAOYSA-N
DME1X96 CS CC1COC2(N1CC(=O)NC3=C2C=C(C=C3)Cl)C4=CC=CC=C4Cl
DME1X96 IK 1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)
DME1X96 IU 10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
DME1X96 CA CAS 31868-18-5
DME1X96 CB CHEBI:31842
DME1X96 DE Anxiety disorder
DM2VOQ3 ID DM2VOQ3
DM2VOQ3 DN Mosapride
DM2VOQ3 HS Phase 4
DM2VOQ3 SN Mosapride; 112885-41-3; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; Mosapride [INN]; CHEMBL60889; Mosapride (INN); 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide; AK-41276; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; Q-201413; 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
DM2VOQ3 DT Small molecular drug
DM2VOQ3 PC 119584
DM2VOQ3 MW 421.9
DM2VOQ3 FM C21H25ClFN3O3
DM2VOQ3 IC InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
DM2VOQ3 CS CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
DM2VOQ3 IK YPELFRMCRYSPKZ-UHFFFAOYSA-N
DM2VOQ3 IU 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
DM2VOQ3 CA CAS 112885-41-3
DM2VOQ3 CB CHEBI:94373
DMVILAD ID DMVILAD
DMVILAD DN MOTILIN
DMVILAD HS Phase 4
DMVILAD SN Motilin (human, porcine); UNII-D85V250YSI; D85V250YSI; 9072-41-7; Human motilin; 52906-92-0; Motilin (swine); Motilin (human); Motilin (porcine); Motilin [MI]; Human motilin [MI]; Motilin porcine; h-Motilin; Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln; GTPL1458; CHEMBL525634; Motilin porcine, >
DMVILAD DT Small molecular drug
DMVILAD PC 16136567
DMVILAD MW 2699.1
DMVILAD FM C120H188N34O35S
DMVILAD IC InChI=1S/C120H188N34O35S/c1-9-64(6)97(152-114(184)86-31-22-53-154(86)117(187)96(63(4)5)151-99(169)70(123)56-66-23-12-10-13-24-66)115(185)150-84(57-67-25-14-11-15-26-67)113(183)153-98(65(7)155)116(186)149-83(58-68-32-34-69(156)35-33-68)101(171)135-60-91(161)136-75(39-45-93(163)164)105(175)147-82(55-62(2)3)111(181)145-77(37-43-88(125)158)106(176)140-73(29-20-51-132-119(128)129)103(173)146-80(48-54-190-8)110(180)142-76(36-42-87(124)157)107(177)144-79(41-47-95(167)168)108(178)139-72(28-17-19-50-122)102(172)143-78(40-46-94(165)166)109(179)141-74(30-21-52-133-120(130)131)104(174)148-85(59-90(127)160)112(182)138-71(27-16-18-49-121)100(170)134-61-92(162)137-81(118(188)189)38-44-89(126)159/h10-15,23-26,32-35,62-65,70-86,96-98,155-156H,9,16-22,27-31,36-61,121-123H2,1-8H3,(H2,124,157)(H2,125,158)(H2,126,159)(H2,127,160)(H,134,170)(H,135,171)(H,136,161)(H,137,162)(H,138,182)(H,139,178)(H,140,176)(H,141,179)(H,142,180)(H,143,172)(H,144,177)(H,145,181)(H,146,173)(H,147,175)(H,148,174)(H,149,186)(H,150,185)(H,151,169)(H,152,184)(H,153,183)(H,163,164)(H,165,166)(H,167,168)(H,188,189)(H4,128,129,132)(H4,130,131,133)/t64-,65+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,96-,97-,98-/m0/s1
DMVILAD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMVILAD IK LVRVABPNVHYXRT-BQWXUCBYSA-N
DMVILAD IU (2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMVILAD CA CAS 9072-41-7
DMHEAB1 ID DMHEAB1
DMHEAB1 DN Neupro
DMHEAB1 HS Phase 4
DMHEAB1 SN Rotigotine; 99755-59-6; Leganto; SPM 962; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-rotigotine; UNII-87T4T8BO2E; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-962; N 0923; CHEMBL1303; 87T4T8BO2E; 99755-59-6 (free base); (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; NCGC00168748-01; Rotigotine CDS Patch; (6s)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol; DSSTox_CID_26772; DSSTox_RID_81893; DSSTox_GSID_46772; C19H25NOS; Rotigotine CDS; (S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol; CAS-99755-59-6; Neupro (TN); N-0923; Rotigotine [USAN:INN:BAN]; (S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol; (S)-6-[Propyl[2-(thiophen-2-yl)ethyl]amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-936; SPM-937; PubChem16423; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; GTPL941; cc-129; Rotigotine (JAN/USAN/INN); (-)-N-0437; SCHEMBL1088585; ZINC4028; DTXSID5046772; HSDB 8254; (2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol; CHEBI:135351; HMS3885D17; EX-A1164; Tox21_112627; 2696AH; BDBM50123626; MFCD00870193; s4274; AKOS016340728; Tox21_112627_1; AC-3547; CCG-267650; CS-0376; DB05271; SB19528; SS-4572; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; NCGC00168748-02; HY-75502; AB0088886; SW220014-1; D05768; W-5179; 572R932; A846076; Q411985; J-502471; UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N; (6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (6S)-
DMHEAB1 CP UCB
DMHEAB1 DT Small molecular drug
DMHEAB1 PC 59227
DMHEAB1 MW 315.5
DMHEAB1 FM C19H25NOS
DMHEAB1 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMHEAB1 CS CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
DMHEAB1 IK KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMHEAB1 IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMHEAB1 CA CAS 99755-59-6
DMHEAB1 CB CHEBI:135351
DMHEAB1 DE Parkinson disease; Restless legs syndrome
DMRP8XB ID DMRP8XB
DMRP8XB DN Nomegestrol
DMRP8XB HS Phase 4
DMRP8XB SN Nomegestrol; Nomegestrol (USAN/INN); Nomegestrol [USAN:INN:BAN]; Nomegestrolum; Nomegestrolum [Latin]; SCHEMBL139763; Thermex; nomegestrol[inn]; Monaco; (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 10F89177CO; 17-Hydroxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione; 17-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione; 58691-88-6; AC1L2AFS; AC1Q6OH0; CHEBI:135993; CHEMBL2105722; UNII-10F89177CO
DMRP8XB PC 68783
DMRP8XB MW 328.4
DMRP8XB FM C21H28O3
DMRP8XB IC KZUIYQJTUIACIG-YBZCJVABSA-N
DMRP8XB CS CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4C1=CC(=O)CC4
DMRP8XB IK 1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1
DMRP8XB IU (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRP8XB CA CAS 58691-88-6
DMRP8XB CB CHEBI:135993
DMRP8XB DE Hypercoagulability
DMVAOME ID DMVAOME
DMVAOME DN Oleandomycin
DMVAOME HS Phase 4
DMVAOME SN Oleandomycin A; Amimycin; Landomycin; Matromycin; Antibiotic PA 105; LMPK04000007; P8ZQ646136; PA 105; Prestwick3_000152; RZPAKFUAFGMUPI-QESOVKLGSA-N; Romicil; SCHEMBL3717; ZINC85432018; oleandomycin; 3922-90-5; AB00513809; AC1L2I65; BDBM234401; BPBio1_000314; BSPBio_000284; C01946; CHEBI:16869; CHEMBL606258; CS-0063452; E704; HY-116010; NCGC00179617-01; UNII-P8ZQ646136
DMVAOME PC 72493
DMVAOME MW 687.9
DMVAOME FM C35H61NO12
DMVAOME IC RZPAKFUAFGMUPI-QESOVKLGSA-N
DMVAOME CS CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C)C)O)N(C)C
DMVAOME IK 1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1
DMVAOME IU (3R,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione
DMVAOME CA CAS 3922-90-5
DMVAOME CB CHEBI:16869
DMVAOME DE Acute upper respiratory infection
DMQIMTK ID DMQIMTK
DMQIMTK DN Ombitasvir
DMQIMTK HS Phase 4
DMQIMTK SN 2302768XJ8; ABT 267; ABT-267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; Ombitasvir; Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound>>ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; UNII-2302768XJ8; ZINC150601177; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
DMQIMTK TC Antiviral Agent
DMQIMTK DT Small molecular drug
DMQIMTK PC 54767916
DMQIMTK MW 894.127
DMQIMTK FM C50H67N7O8
DMQIMTK IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMQIMTK CS CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
DMQIMTK IK PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMQIMTK IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMQIMTK CA CAS 1258226-87-7
DMQIMTK CB CHEBI:85183
DMQIMTK DE Hepatitis C virus infection
DMPSKA5 ID DMPSKA5
DMPSKA5 DN Ortho-phosphate
DMPSKA5 HS Phase 4
DMPSKA5 SN Acide phosphorique; Acide phosphorique [French]; Acido fosforico; Acido fosforico [Italian]; Acidum phosphoricum; Fosforzuuroplossingen; Fosforzuuroplossingen [Dutch]; ORTHOPHOSPHORIC ACID; POLYPHOSPHORIC ACID; Phosphoric acid; Phosphoric acid 75%; Phosphoric acid, ortho-; Phosphorsaeure; Phosphorsaeureloesungen; Phosphorsaeureloesungen [German]; Superphosphoric acid; Wc-reiniger; White phosphoric acid; o-Phosphoric acid; ortho-phosphoric acid; 7664-38-2; Caswell No. 662; Evits; FEMA No. 2900; Sonac; UNII-E4GA8884NN
DMPSKA5 PC 1004
DMPSKA5 MW 97.995
DMPSKA5 FM H3O4P
DMPSKA5 IC NBIIXXVUZAFLBC-UHFFFAOYSA-N
DMPSKA5 CS OP(=O)(O)O
DMPSKA5 IK 1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
DMPSKA5 IU phosphoric acid
DMPSKA5 CA CAS 7664-38-2
DMPSKA5 CB CHEBI:26078.
DMPSKA5 DE Thyroid cancer
DMU1JVW ID DMU1JVW
DMU1JVW DN Otilonium
DMU1JVW HS Phase 4
DMU1JVW SN LS-187100; OTILONIUM; ZINC8214636; 105360-89-2; 6330179ARU; AB01566869_01; AC1L2HEM; AC1Q65RN; CHEBI:135780; CHEMBL1433361; CTK8G5037; DTXSID0048391; Diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-; N,N-Diethyl-N-methyl-2-(4-(2-(octyloxy)benzamido)benzoyloxy)ethanaminium; NCGC00163507-01; NCGC00163507-02; SCHEMBL20352274; UNII-6330179ARU
DMU1JVW PC 72093
DMU1JVW MW 483.7
DMU1JVW FM C29H43N2O4+
DMU1JVW IC NQHNLNLJPDMBFN-UHFFFAOYSA-O
DMU1JVW CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC
DMU1JVW IK 1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1
DMU1JVW IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium
DMU1JVW CA CAS 105360-89-2
DMU1JVW CB CHEBI:135780
DMU1JVW DE Irritable bowel syndrome
DMIGKA1 ID DMIGKA1
DMIGKA1 DN Ozagrel
DMIGKA1 HS Phase 4
DMIGKA1 SN Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika
DMIGKA1 CP Kissei Pharmaceutical Co Ltd
DMIGKA1 DT Small molecular drug
DMIGKA1 PC 5282440
DMIGKA1 MW 228.25
DMIGKA1 FM C13H12N2O2
DMIGKA1 IC InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
DMIGKA1 CS C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
DMIGKA1 IK SHZKQBHERIJWAO-AATRIKPKSA-N
DMIGKA1 IU (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
DMIGKA1 CA CAS 82571-53-7
DMIGKA1 CB CHEBI:92359
DMIGKA1 DE Chronic obstructive pulmonary disease; Xerophthalmia
DMY2AEF ID DMY2AEF
DMY2AEF DN PAI-1
DMY2AEF HS Phase 4
DMY2AEF SN PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
DMY2AEF DT Small molecular drug
DMY2AEF PC 3246941
DMY2AEF MW 297.39
DMY2AEF FM C16H27NO4
DMY2AEF IC InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)/t14-/m0/s1
DMY2AEF CS CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O
DMY2AEF IK PHSRRHGYXQCRPU-AWEZNQCLSA-N
DMY2AEF IU 3-oxo-N-[(3S)-2-oxooxolan-3-yl]dodecanamide
DMY2AEF CA CAS 168982-69-2
DMY2AEF CB CHEBI:44534
DMIV8CT ID DMIV8CT
DMIV8CT DN Parecoxib
DMIV8CT HS Phase 4
DMIV8CT SN Parecoxib; SC-69124; Dynastat; Valus-P; Vorth-P; SC 69124; UNII-9TUW81Y3CE; 9TUW81Y3CE; Parecoxib [USAN:INN:BAN]; CHEBI:73038; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; Parocoxib; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Valdecoxib Impurity J; Parecoxib (
DMIV8CT DT Small molecular drug
DMIV8CT PC 119828
DMIV8CT MW 370.4
DMIV8CT FM C19H18N2O4S
DMIV8CT IC InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
DMIV8CT CS CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
DMIV8CT IK TZRHLKRLEZJVIJ-UHFFFAOYSA-N
DMIV8CT IU N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide
DMIV8CT CA CAS 198470-84-7
DMIV8CT CB CHEBI:73038
DMQY873 ID DMQY873
DMQY873 DN Pentifylline
DMQY873 HS Phase 4
DMQY873 SN Pentifilina [INN-Spanish]; Pentifyllin; Pentifylline; Pentifylline [INN:BAN:DCF]; Pentifyllinum [INN-Latin]; Cosadon; Cosaldon; Hexyltheobromine; MBM1C4K26S; SK 7 (Pharmaceutical); Theobromine, 1-hexyl-; 1-Hexyl-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1-Hexyl-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione; 1-Hexyl-3,7-dimethylxanthine; 1-Hexyltheobromine; 1-n-hexyltheobromine; 1028-33-7; 3,7-Dimethyl-1-hexyl-1H,3H-purin-2,6-dione; BRN 0270632; C13H20N4O2; EINECS 213-842-0; MFCD00041424; SK 7; UNII-MBM1C4K26S
DMQY873 PC 70569
DMQY873 MW 264.32
DMQY873 FM C13H20N4O2
DMQY873 IC MRWQRJMESRRJJB-UHFFFAOYSA-N
DMQY873 CS CCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMQY873 IK 1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3
DMQY873 IU 1-hexyl-3,7-dimethylpurine-2,6-dione
DMQY873 CA CAS 1028-33-7
DMQY873 CB CHEBI:135091
DMQY873 DE Cerebrovascular dementia
DM4OIMZ ID DM4OIMZ
DM4OIMZ DN Pinaverium
DM4OIMZ HS Phase 4
DM4OIMZ SN Pinaverium; LS-176056; SCHEMBL312166; U2368VVE7O; 59995-65-2; AC1L24AP; BDBM50101975; C26H41BrNO4; CHEBI:135811; CHEMBL1909324; DB09090; Morpholinium, 4-((2-bromo-4,5-dimethoxyphenyl)methyl)-4-(2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-yl)ethoxy)ethyl)-; NCGC00181763-01; UNII-U2368VVE7O
DM4OIMZ PC 40704
DM4OIMZ MW 511.5
DM4OIMZ FM C26H41BrNO4+
DM4OIMZ IC DDHUTBKXLWCZCO-UHFFFAOYSA-N
DM4OIMZ CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C
DM4OIMZ IK 1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1
DM4OIMZ IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium
DM4OIMZ CA CAS 59995-65-2
DM4OIMZ CB CHEBI:135811
DM4OIMZ DE Irritable bowel syndrome
DMWRYUH ID DMWRYUH
DMWRYUH DN Prasterone sulfate
DMWRYUH HS Phase 4
DMWRYUH SN Prasterone sulfate; Prasterone sulphate; 17-Ketoandrost-5-en-3beta-yl sulfate; 3-O-Sulfodehydroepiandrosterone; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; 651-48-9; DEHYDROEPIANDROSTERONE SULFATE; DHEA sulfate; DHEA sulphate; DHEA-S; Dehydroandrosterone sulfate; Dehydroepiandrosterone 3-sulfate; Dehydroepiandrosterone monosulfate; Dehydroepiandrosterone sulphate; Dehydroisoandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; Androst-5-en-17-on-3beta-yl sulfuric acid; CCRIS 6746; DHEAS; UNII-57B09Q7FJR
DMWRYUH PC 12594
DMWRYUH MW 368.5
DMWRYUH FM C19H28O5S
DMWRYUH IC CZWCKYRVOZZJNM-USOAJAOKSA-N
DMWRYUH CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DMWRYUH IK 1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DMWRYUH IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMWRYUH CA CAS 651-48-9
DMWRYUH CB CHEBI:16814
DMWRYUH DE Adrenocortical deficiency
DM6VFO1 ID DM6VFO1
DM6VFO1 DN Pregnenolone
DM6VFO1 HS Phase 4
DM6VFO1 SN Pregnenolone (schizophrenia); Neurosteroid (schizophrenia), Neuroscience; Pregnenolone (schizophrenia), Neuroscience
DM6VFO1 CP Duke University
DM6VFO1 DT Small molecular drug
DM6VFO1 PC 8955
DM6VFO1 MW 316.5
DM6VFO1 FM C21H32O2
DM6VFO1 IC InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1
DM6VFO1 CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DM6VFO1 IK ORNBQBCIOKFOEO-QGVNFLHTSA-N
DM6VFO1 IU 1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DM6VFO1 CA CAS 145-13-1
DM6VFO1 CB CHEBI:16581
DM6VFO1 DE Schizophrenia
DM8PTSY ID DM8PTSY
DM8PTSY DN Prenylamine
DM8PTSY HS Phase 4
DM8PTSY SN Prenilamina; Prenilamina [INN-Spanish]; Prenylamine (vasodilator); Prenylamine [USAN:INN:BAN]; Prenylaminum; Prenylaminum [INN-Latin]; Bismethin; Carditin; Corontin; Corpax; DL-Prenylamine; Difril; Elecor; Falliocor; Hostaginan; PRENYLAMINE; SAN 13-194; Sandoz 13-194; Segontin; Synadrin; Valecor; 1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane; 390-64-7; B-436; BRN 2060323; CHEMBL24072; EINECS 206-869-4; N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine; N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
DM8PTSY PC 9801
DM8PTSY MW 329.5
DM8PTSY FM C24H27N
DM8PTSY IC IFFPICMESYHZPQ-UHFFFAOYSA-N
DM8PTSY CS CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DM8PTSY IK 1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3
DM8PTSY IU 3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine
DM8PTSY CA CAS 390-64-7
DM8PTSY CB CHEBI:8397
DM8PTSY DE Angina pectoris
DM37FKA ID DM37FKA
DM37FKA DN Primovist
DM37FKA HS Phase 4
DM37FKA SN Eovist; Primovist; gadoxate disodium; AC1L9OPS; gadolinium ethoxybenzyl-DTPA; MOLI000482; 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid; gadolinium(3+)
DM37FKA PC 450096
DM37FKA MW 684.8
DM37FKA FM C23H33GdN3O11+3
DM37FKA IC InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3
DM37FKA CS CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O.[Gd+3]
DM37FKA IK PCZHWPSNPWAQNF-UHFFFAOYSA-N
DM37FKA IU 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid;gadolinium(3+)
DM37FKA DE Lung cancer
DMXL43T ID DMXL43T
DMXL43T DN Prulifloxacin
DMXL43T HS Phase 4
DMXL43T SN Prulifloxacin; Prulifloxacin [INN]; Pruvel; Q-101929; Quisnon; NM 441; NM-441; 123447-62-1; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; AK144730; CCRIS 7686; DSSTox_CID_26480; DSSTox_GSID_46480; DSSTox_RID_81651; NCGC00164615-01; NM441; Sword
DMXL43T PC 65947
DMXL43T MW 461.5
DMXL43T FM C21H20FN3O6S
DMXL43T IC PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMXL43T CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMXL43T IK 1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMXL43T IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMXL43T CA CAS 123447-62-1
DMXL43T CB CHEBI:32071
DMXL43T DE Chronic obstructive pulmonary disease
DMF8CJ9 ID DMF8CJ9
DMF8CJ9 DN Pyridine
DMF8CJ9 HS Phase 4
DMF8CJ9 SN Azabenzene; 110-86-1; Azine; Pyridin; Pirydyna; Piridina; Pyridin [German]; Pirydyna [Polish]; Piridina [Italian]; RCRA waste number U196; NCI-C55301; Caswell No. 717; CCRIS 2926; HSDB 118; pyridine-ring; CHEBI:16227; FEMA Number 2966; CP 32; UNII-NH9L3PP67S; EINECS 203-809-9; UN1282; NSC 406123; FEMA No. 2966; RCRA waste no. U196; EPA Pesticide Chemical Code 069202; NH9L3PP67S; AI3-01240; pyridine fraction; JUJWROOIHBZHMG-UHFFFAOYSA-N; MFCD00011732; Pentadeuteropyridine; Pyridine [UN1282] [Flammable liquid]; 7291-22-7
DMF8CJ9 DT Small molecular drug
DMF8CJ9 PC 1049
DMF8CJ9 MW 79.1
DMF8CJ9 FM C5H5N
DMF8CJ9 IC InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H
DMF8CJ9 CS C1=CC=NC=C1
DMF8CJ9 IK JUJWROOIHBZHMG-UHFFFAOYSA-N
DMF8CJ9 IU pyridine
DMF8CJ9 CA CAS 110-86-1
DMF8CJ9 CB CHEBI:16227
DMBPN7T ID DMBPN7T
DMBPN7T DN Rupatadine
DMBPN7T HS Phase 4
DMBPN7T SN Rupatadine trihydrochloride; UNII-G61C8NZY2T; G61C8NZY2T; 156611-76-6; Rupatadine HCl; Rupatadine hydrochloride; UR 12592; AC1L320L; DTXSID90166109; BQFOTHHRVVHLEW-UHFFFAOYSA-N; 8-Chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine trihydrochloride; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, trihydrochloride
DMBPN7T DT Small molecular drug
DMBPN7T PC 133017
DMBPN7T MW 416
DMBPN7T FM C26H26ClN3
DMBPN7T IC InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
DMBPN7T CS CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2
DMBPN7T IK WUZYKBABMWJHDL-UHFFFAOYSA-N
DMBPN7T IU 13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DMBPN7T CA CAS 158876-82-5
DMBPN7T CB CHEBI:135673
DMXBYQR ID DMXBYQR
DMXBYQR DN Silymarin
DMXBYQR HS Phase 4
DMXBYQR SN Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one
DMXBYQR DT Small molecular drug
DMXBYQR PC 5213
DMXBYQR MW 482.4
DMXBYQR FM C25H22O10
DMXBYQR IC InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3
DMXBYQR CS COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
DMXBYQR IK SEBFKMXJBCUCAI-UHFFFAOYSA-N
DMXBYQR IU 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
DMXBYQR CA CAS 65666-07-1
DMXBYQR CB CHEBI:125451
DMOSJD0 ID DMOSJD0
DMOSJD0 DN Sivelestat sodium hydrate
DMOSJD0 HS Phase 4
DMOSJD0 SN sivelestat sodium hydrate; Sivelestat sodium tetrahydrate; 201677-61-4; Elaspol; Sodium sivelestat; EI546 sodium; UNII-737RR8Y409; Sivelestat (sodium tetrahydrate); LY544349 sodium; Sivelestat sodium [USAN]; Sivelestat sodium (USAN); 737RR8Y409; DSSTox_CID_26727; DSSTox_RID_81857; DSSTox_GSID_46727; sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY544349 Sodium Hydrate; Elaspol (TN); CAS-201677-61-4; NCGC00167577-01; AC1L4KMF; Sivelestat sodium hydrate (JAN); Sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; Sodium ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate tetrahydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate
DMOSJD0 CP ONO Pharmaceuticals
DMOSJD0 DT Small molecular drug
DMOSJD0 PC 23663985
DMOSJD0 MW 528.5
DMOSJD0 FM C20H29N2NaO11S
DMOSJD0 IC InChI=1S/C20H22N2O7S.Na.4H2O/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24;;;;;/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24);;4*1H2/q;+1;;;;/p-1
DMOSJD0 CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)[O-].O.O.O.O.[Na+]
DMOSJD0 IK PLHREJBSQUSUCW-UHFFFAOYSA-M
DMOSJD0 IU sodium;2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate;tetrahydrate
DMOSJD0 CA CAS 201677-61-4
DMOSJD0 CB CHEBI:32133
DMOSJD0 DE Community-acquired pneumonia; Acute lung injury
DMTV7XH ID DMTV7XH
DMTV7XH DN SPN-812
DMTV7XH HS Phase 4
DMTV7XH SN Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride
DMTV7XH CP Supernus Pharmaceuticals
DMTV7XH DT Small molecular drug
DMTV7XH PC 71424
DMTV7XH MW 273.75
DMTV7XH FM C13H20ClNO3
DMTV7XH IC InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
DMTV7XH CS CCOC1=CC=CC=C1OCC2CNCCO2.Cl
DMTV7XH IK HJOCKFVCMLCPTP-UHFFFAOYSA-N
DMTV7XH IU 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride
DMTV7XH CA CAS 35604-67-2
DMTV7XH DE Attention deficit hyperactivity disorder
DM4TX7J ID DM4TX7J
DM4TX7J DN Talipexole
DM4TX7J HS Phase 4
DM4TX7J SN Talipexole; 101626-70-4; Talipexole [INN]; Talipexolum [Latin]; Talipexol [Spanish]; UNII-7AM2J46Z1Y; Domin; 7AM2J46Z1Y; CHEMBL279085; Talipexole (INN); NCGC00163160-01; DSSTox_CID_26321; DSSTox_RID_81537; DSSTox_GSID_46321; Talipexolum; Talipexol; 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo(4,5-d)azepine; 6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-amine; 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine; 4H-Thiazolo[4,5-d]azepin-2-amine,5,6,7,8-tetrahydro-6-(2-propen-1-yl)-; BHT920
DM4TX7J DT Small molecular drug
DM4TX7J PC 5374
DM4TX7J MW 209.31
DM4TX7J FM C10H15N3S
DM4TX7J IC InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)
DM4TX7J CS C=CCN1CCC2=C(CC1)SC(=N2)N
DM4TX7J IK DHSSDEDRBUKTQY-UHFFFAOYSA-N
DM4TX7J IU 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine
DM4TX7J CA CAS 101626-70-4
DM4TX7J CB CHEBI:93327
DM62IPN ID DM62IPN
DM62IPN DN Tenofovir disoproxil
DM62IPN HS Phase 4
DM62IPN SN Tenofovir (Disoproxil); Tenofovir disoproxil; 201341-05-1; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; Bis(POC)PMPA; PMPA prodrug; CHEBI:63717; F4YU4LON7I; UNII-F4YU4LON7I; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; tenofovir bis(isopropyloxycarbonyloxymethyl) ester
DM62IPN PC 5481350
DM62IPN MW 519.4
DM62IPN FM C19H30N5O10P
DM62IPN IC JFVZFKDSXNQEJW-CQSZACIVSA-N
DM62IPN CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DM62IPN IK 1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DM62IPN IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DM62IPN CA CAS 201341-05-1
DM62IPN CB CHEBI:63717
DM62IPN DE Human immunodeficiency virus infection
DMC40UY ID DMC40UY
DMC40UY DN Tenofovir disoproxil
DMC40UY HS Phase 4
DMC40UY SN Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate
DMC40UY PC 5481350
DMC40UY MW 519.4
DMC40UY FM C19H30N5O10P
DMC40UY IC InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DMC40UY CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DMC40UY IK JFVZFKDSXNQEJW-CQSZACIVSA-N
DMC40UY IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DMC40UY CA CAS 201341-05-1
DMC40UY CB CHEBI:63717
DMC40UY DE Chronic hepatitis B infection
DM2M47Y ID DM2M47Y
DM2M47Y DN TKM-ApoB
DM2M47Y HS Phase 4
DM2M47Y CP Tekmira Pharmaceuticals
DM2M47Y DT siRNA drug
DM2M47Y DE Hypercholesterolaemia
DM7NSI0 ID DM7NSI0
DM7NSI0 DN Urethane
DM7NSI0 HS Phase 4
DM7NSI0 SN Uretan; Uretan etylowy; Uretano [DCIT]; Urethan; Urethanum; Urethanum [INN-Latin]; Aethylcarbamat; Aethylcarbamat [German]; Aethylurethan; Aethylurethan [German]; Carbamic acid ethyl ester; Carbamic acid, ethyl ester; Carbamidsaeure-aethylester; ETHYL CARBAMATE; Estane 5703; Ethyl urethan; Ethyl urethane; Ethylcarbamate; Ethylester kyseliny karbaminove; Ethylurethan; Ethylurethane; Leucethane; Leucothane; O-Ethyl urethane; O-Ethylurethane; Pracarbamin; Pracarbamine; U-Compound; ethyl aminoformate; urethane; 51-79-6; NSC 746
DM7NSI0 PC 5641
DM7NSI0 MW 89.09
DM7NSI0 FM C3H7NO2
DM7NSI0 IC JOYRKODLDBILNP-UHFFFAOYSA-N
DM7NSI0 CS CCOC(=O)N
DM7NSI0 IK 1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
DM7NSI0 IU ethyl carbamate
DM7NSI0 CA CAS 51-79-6
DM7NSI0 CB CHEBI:17967
DM7NSI0 DE Lung cancer
DMCOJPS ID DMCOJPS
DMCOJPS DN Vonoprazan
DMCOJPS HS Phase 4
DMCOJPS SN Vonoprazan; Vonoprazan [INN]; TAK-438 (free base); TAK-438 free base; SCHEMBL194487; 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{N}-methyl-methanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine; 1R5L3J156G; 881681-00-1; BCP13240; CHEBI:136048; CHEMBL2079130; DTXSID20236869; KS-00000TU1; UNII-1R5L3J156G
DMCOJPS PC 15981397
DMCOJPS MW 345.4
DMCOJPS FM C17H16FN3O2S
DMCOJPS IC BFDBKMOZYNOTPK-UHFFFAOYSA-N
DMCOJPS CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
DMCOJPS IK 1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
DMCOJPS IU 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMCOJPS CA CAS 881681-00-1
DMCOJPS CB CHEBI:136048
DMCOJPS DE Gastro-oesophageal reflux disease
DMKV32D ID DMKV32D
DMKV32D DN Xylometazoline
DMKV32D HS Phase 4
DMKV32D SN Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences
DMKV32D CP Fortune Apex Development Ltd
DMKV32D DT Small molecular drug
DMKV32D PC 5709
DMKV32D MW 244.37
DMKV32D FM C16H24N2
DMKV32D IC InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
DMKV32D CS CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C
DMKV32D IK HUCJFAOMUPXHDK-UHFFFAOYSA-N
DMKV32D IU 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
DMKV32D CA CAS 526-36-3
DMKV32D CB CHEBI:10082
DMKV32D DE Allergic rhinitis
DM9RJH7 ID DM9RJH7
DM9RJH7 DN Zaltoprofen
DM9RJH7 HS Phase 4
DM9RJH7 SN Zaltoprofen (unspecified); Zaltoprofene; Zaltoprofeno; Zaltoprofenum; CN 100; CN-100; Soleton; zaltoprofen; (+-)-2-(10,11-Dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic acid; 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; 2-(10,11-Dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid; 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid; 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid; 74711-43-6; 89482-00-8; AK-77321; C17H14O3S; EINECS 277-973-5; NCGC00183878-01; Peon
DM9RJH7 PC 5720
DM9RJH7 MW 298.4
DM9RJH7 FM C17H14O3S
DM9RJH7 IC MUXFZBHBYYYLTH-UHFFFAOYSA-N
DM9RJH7 CS CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O
DM9RJH7 IK 1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
DM9RJH7 IU 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid
DM9RJH7 CA CAS 74711-43-6
DM9RJH7 CB CHEBI:32306
DM9RJH7 DE Anaesthesia
DMXIRA0 ID DMXIRA0
DMXIRA0 DN RLX030
DMXIRA0 HS Approval submitted
DMXIRA0 SN Serelaxin
DMXIRA0 CP Novartis
DMXIRA0 DT Small molecular drug
DMXIRA0 PC 71300755
DMXIRA0 MW 5963
DMXIRA0 FM C256H408N74O74S8
DMXIRA0 IC InChI=1S/C256H408N74O74S8/c1-32-128(20)198-246(396)286-135(27)207(357)326-199(129(21)33-2)248(398)321-180(210(360)279-106-189(343)289-161(79-88-405-30)221(371)315-177(111-334)239(389)329-202(137(29)337)250(400)312-171(232(382)317-178(112-335)251(401)402)98-141-103-277-148-57-41-39-55-145(141)148)114-408-412-118-184(252(403)404)322-230(380)168(95-138-52-36-35-37-53-138)308-215(365)154(63-50-86-274-255(267)268)291-203(353)132(24)283-226(376)164(91-121(6)7)307-238(388)176(110-333)314-216(366)155(64-51-87-275-256(269)270)293-213(363)151(59-43-46-82-258)301-249(399)201(136(28)336)330-242(392)181-115-409-411-117-183(319-217(367)150(58-42-45-81-257)294-233(383)173(101-186(262)340)303-206(356)133(25)284-225(375)163(90-120(4)5)302-205(355)134(26)285-236(386)174(108-331)316-229(379)169(96-139-65-67-143(338)68-66-139)309-227(377)165(92-122(8)9)305-218(368)156-70-75-187(341)287-156)241(391)320-182(240(390)311-172(99-142-104-271-119-281-142)235(385)323-195(125(14)15)243(393)280-107-190(344)290-181)116-410-407-113-179(209(359)278-105-188(342)288-149(61-48-84-272-253(263)264)212(362)295-159(72-77-192(347)348)220(370)306-167(94-124(12)13)234(384)325-196(126(16)17)244(394)299-153(62-49-85-273-254(265)266)211(361)282-131(23)204(354)292-157(224(374)327-198)69-74-185(261)339)318-228(378)166(93-123(10)11)304-214(364)152(60-44-47-83-259)300-247(397)200(130(22)34-3)328-245(395)197(127(18)19)324-223(373)160(73-78-193(349)350)297-219(369)158(71-76-191(345)346)296-222(372)162(80-89-406-31)298-231(381)170(97-140-102-276-147-56-40-38-54-144(140)147)310-237(387)175(109-332)313-208(358)146(260)100-194(351)352/h35-41,52-57,65-68,102-104,119-137,146,149-184,195-202,276-277,331-338H,32-34,42-51,58-64,69-101,105-118,257-260H2,1-31H3,(H2,261,339)(H2,262,340)(H,271,281)(H,278,359)(H,279,360)(H,280,393)(H,282,361)(H,283,376)(H,284,375)(H,285,386)(H,286,396)(H,287,341)(H,288,342)(H,289,343)(H,290,344)(H,291,353)(H,292,354)(H,293,363)(H,294,383)(H,295,362)(H,296,372)(H,297,369)(H,298,381)(H,299,394)(H,300,397)(H,301,399)(H,302,355)(H,303,356)(H,304,364)(H,305,368)(H,306,370)(H,307,388)(H,308,365)(H,309,377)(H,310,387)(H,311,390)(H,312,400)(H,313,358)(H,314,366)(H,315,371)(H,316,379)(H,317,382)(H,318,378)(H,319,367)(H,320,391)(H,321,398)(H,322,380)(H,323,385)(H,324,373)(H,325,384)(H,326,357)(H,327,374)(H,328,395)(H,329,389)(H,330,392)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,401,402)(H,403,404)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t128-,129-,130-,131-,132-,133-,134-,135-,136+,137+,146-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,195-,196-,197-,198-,199-,200-,201-,202-/m0/s1
DMXIRA0 CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C)[C@@H](C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]7CCC(=O)N7)[C@@H](C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC9=CNC1=CC=CC=C19)C(=O)N[C@@H](CO)C(=O)O
DMXIRA0 IK DTLOVISJEFBXLX-REAFJZEQSA-N
DMXIRA0 IU (1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,80S,83S,88R)-6-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-88-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-68-(4-aminobutyl)-30-(3-amino-3-oxopropyl)-50-benzyl-33,39-bis[(2S)-butan-2-yl]-12,24,53,65-tetrakis(3-carbamimidamidopropyl)-15-(2-carboxyethyl)-42-[[2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamoyl]-71-[(1R)-1-hydroxyethyl]-62-(hydroxymethyl)-83-(1H-imidazol-5-ylmethyl)-27,36,56-trimethyl-18,59-bis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,80-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-47-carboxylic acid
DMXIRA0 CA CAS 99489-94-8
DMXIRA0 DE Acute heart failure
DMOML9Q ID DMOML9Q
DMOML9Q DN Pancrecarb
DMOML9Q HS NDA filed
DMOML9Q SN Pancrelipase (Digestive Care)
DMOML9Q CP Digestive Care Inc
DMOML9Q SQ Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL >Chymotrypsin BGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFCGGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNNDITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPLLSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCSTSSPGVYARVTKLIPWVQKILAAN >pancreatic triacylglycerol lipaseMLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC
DMOML9Q DE Pancreatic malfunction
DMF2O4T ID DMF2O4T
DMF2O4T DN (S)-FLURBIPROFEN
DMF2O4T HS Preregistration
DMF2O4T SN 51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac
DMF2O4T CP Taisho Pharmaceutical; TOKUHON
DMF2O4T DT Small molecular drug
DMF2O4T PC 72099
DMF2O4T MW 244.26
DMF2O4T FM C15H13FO2
DMF2O4T IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1
DMF2O4T CS C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMF2O4T IK SYTBZMRGLBWNTM-JTQLQIEISA-N
DMF2O4T IU (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMF2O4T CA CAS 51543-39-6
DMF2O4T CB CHEBI:42446
DMF2O4T DE Myalgia; Scapulohumeral periarthritis; Osteoarthritis
DMBRFUQ ID DMBRFUQ
DMBRFUQ DN B-cell lymphoma vaccine
DMBRFUQ HS Preregistration
DMBRFUQ SN BiovaxID (TN)
DMBRFUQ CP BioVest International
DMBRFUQ DT Vaccine
DMBRFUQ DE Follicular lymphoma
DMP5O1U ID DMP5O1U
DMP5O1U DN GSK2696273
DMP5O1U HS Preregistration
DMP5O1U CP Glaxosmithkline; molmed
DMP5O1U DE Chronic pain; Immunodeficiency
DMXSDJU ID DMXSDJU
DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine
DMXSDJU HS Preregistration
DMXSDJU SN Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma
DMXSDJU CP Allergy therapeutics
DMXSDJU DT Vaccine
DMXSDJU DE Allergy
DMLRKJX ID DMLRKJX
DMLRKJX DN Neugranin
DMLRKJX HS Preregistration
DMLRKJX SN Albugranin; CG-10639; Granulocyte colony stimulating factor (long-acting), CoGenesys; Granulocyte colony stimulating factor (long-acting), Teva Pharmaceutical; Long-acting G-CSF, HGS; Long-acting G-CSF, Teva Pharmaceutical; G-SCF (long-acting), CoGenesys
DMLRKJX CP Aventis Behring LLC
DMLRKJX DE Neutropenia
DMUY09W ID DMUY09W
DMUY09W DN SK-NBP601
DMUY09W HS Preregistration
DMUY09W SN NBP-601
DMUY09W CP SK Chemicals Co Ltd
DMUY09W DE Hemophilia
DM26I8H ID DM26I8H
DM26I8H DN TK-DLI
DM26I8H HS Preregistration
DM26I8H SN TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
DM26I8H CP Molmed
DM26I8H DE Graft-versus-host disease
DMYA6TR ID DMYA6TR
DMYA6TR DN Human coagulation factor X
DMYA6TR HS BLA submitted
DMYA6TR CP Bio products laboratory
DMYA6TR DE Renal cell carcinoma
DMNCY1I ID DMNCY1I
DMNCY1I DN (-)-Phenserine
DMNCY1I HS Phase 3
DMNCY1I SN (-)-Phenserine; CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
DMNCY1I DT Small molecular drug
DMNCY1I PC 192706
DMNCY1I MW 337.4
DMNCY1I FM C20H23N3O2
DMNCY1I IC InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1
DMNCY1I CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
DMNCY1I IK PBHFNBQPZCRWQP-QUCCMNQESA-N
DMNCY1I IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
DMNCY1I CA CAS 101246-66-6
DMNCY1I DE Alzheimer disease
DMLRHM5 ID DMLRHM5
DMLRHM5 DN [3H](R)-(-)-baclofen
DMLRHM5 HS Phase 3
DMLRHM5 SN AC1OCG0F; ZB000014
DMLRHM5 DT Small molecular drug
DMLRHM5 PC 44602
DMLRHM5 MW 213.66
DMLRHM5 FM C10H12ClNO2
DMLRHM5 IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
DMLRHM5 CS C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl
DMLRHM5 IK KPYSYYIEGFHWSV-QMMMGPOBSA-N
DMLRHM5 IU (3R)-4-amino-3-(4-chlorophenyl)butanoic acid
DMLRHM5 CA CAS 69308-37-8
DMLRHM5 DE Multiple sclerosis
DM3YEV0 ID DM3YEV0
DM3YEV0 DN 131I-labelled aCD45
DM3YEV0 HS Phase 3
DM3YEV0 CP Actinium Pharmaceuticals
DM3YEV0 DT Radiopharmaceutical therapy agent
DM3YEV0 DE Acute myeloid leukaemia
DMTZ1A5 ID DMTZ1A5
DMTZ1A5 DN 13-cis-retinoic acid
DMTZ1A5 HS Phase 3
DMTZ1A5 SN CRA, UCSD
DMTZ1A5 CP University of California San Diego
DMTZ1A5 DE Glioma; Infertility; Azoospermia
DMP5L8S ID DMP5L8S
DMP5L8S DN 177Lu-DOTA-octreotate
DMP5L8S HS Phase 3
DMP5L8S SN Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
DMP5L8S CP Advanced accelerator applications
DMP5L8S DE Melanoma; Neuroendocrine cancer
DMQ0IZ6 ID DMQ0IZ6
DMQ0IZ6 DN 177Lu-labelled PSMA-617
DMQ0IZ6 HS Phase 3
DMQ0IZ6 CP Novartis/Endocyte
DMQ0IZ6 DT Radiopharmaceutical therapy agent
DMQ0IZ6 DE Prostate cancer
DMMZS2T ID DMMZS2T
DMMZS2T DN 177-Lu-oxodotreotide
DMMZS2T HS Phase 3
DMMZS2T CP Millburn
DMMZS2T DT Small molecular drug
DMMZS2T DE Neuroendocrine cancer
DMX178V ID DMX178V
DMX178V DN 177-Lu-PSMA-617
DMX178V HS Phase 3
DMX178V CP Advanced Accelerator Applications
DMX178V DT Small molecular drug
DMX178V DE Prostate cancer
DME2A8X ID DME2A8X
DME2A8X DN 5-methoxypsoralen
DME2A8X HS Phase 3
DME2A8X SN 5-MOP
DME2A8X CP Oclassen Pharmaceuticals Inc
DME2A8X DT Small molecular drug
DME2A8X PC 2355
DME2A8X MW 216.19
DME2A8X FM C12H8O4
DME2A8X IC InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3
DME2A8X CS COC1=C2C=CC(=O)OC2=CC3=C1C=CO3
DME2A8X IK BGEBZHIAGXMEMV-UHFFFAOYSA-N
DME2A8X IU 4-methoxyfuro[3,2-g]chromen-7-one
DME2A8X CA CAS 484-20-8
DME2A8X CB CHEBI:18293
DME2A8X DE Psoriasis vulgaris
DM4OHMP ID DM4OHMP
DM4OHMP DN A-3309
DM4OHMP HS Phase 3
DM4OHMP SN Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca
DM4OHMP CP AstraZeneca plc
DM4OHMP DE Lipid metabolism disorder
DMJNSLU ID DMJNSLU
DMJNSLU DN AAV2-hRPE65v2
DMJNSLU HS Phase 3
DMJNSLU SN RPE65 AAV gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second University of Naples; RPE65 adeno-associated viral vector gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second Univerity of Naples
DMJNSLU CP Childrens Hospital of Philadelphia
DMJNSLU DE Ocular disease
DMPDQ8T ID DMPDQ8T
DMPDQ8T DN AB-103
DMPDQ8T HS Phase 3
DMPDQ8T SN Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem
DMPDQ8T CP Atoxbio; fast-track drugs & biologics
DMPDQ8T DT Small molecular drug
DMPDQ8T PC 16111
DMPDQ8T MW 281.25
DMPDQ8T FM C12H16N3O3P
DMPDQ8T IC InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17)
DMPDQ8T CS C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3
DMPDQ8T IK VFIUCBTYGKMLCM-UHFFFAOYSA-N
DMPDQ8T IU benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate
DMPDQ8T CA CAS 1980-45-6
DMPDQ8T DE Necrotizing soft tissue infection
DMUES7Y ID DMUES7Y
DMUES7Y DN AB154
DMUES7Y HS Phase 3
DMUES7Y SN Domvanalimab
DMUES7Y CP Arcus Biosciences; Gilead Sciences
DMUES7Y DT Antibody
DMUES7Y DE Solid tumour/cancer; Non-small cell lung cancer
DMMWO7V ID DMMWO7V
DMMWO7V DN ABBV-951
DMMWO7V HS Phase 3
DMMWO7V SN Foslevodopa; UNII-37NQZ0J76I; 37NQZ0J76I; 3-hydroxy-O-phosphono-L-tyrosine; 101141-95-1; 97321-87-4; Dopa 4-phosphate; Levodopa-4'-monophosphate; 3-Hydroxy-O-phosphonotyrosine; Foslevodopa (JAN/USAN/INN); CHEMBL4594379; SCHEMBL17685899; DTXSID70905957; HY-109132; CS-0086774; D11839; (S)-2-amino-3-(3-hydroxy-4-(phosphonooxy)phenyl)propanoic acid
DMMWO7V CP AbbVie
DMMWO7V DT Small molecular drug
DMMWO7V PC 127766
DMMWO7V MW 277.17
DMMWO7V FM C9H12NO7P
DMMWO7V IC InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
DMMWO7V CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
DMMWO7V IK YNDMEEULGSTYJT-LURJTMIESA-N
DMMWO7V IU (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid
DMMWO7V CA CAS 97321-87-4
DMMWO7V DE Parkinson disease
DMCKPG4 ID DMCKPG4
DMCKPG4 DN ABC294640
DMCKPG4 HS Phase 3
DMCKPG4 SN ABC294640; 915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8; ABC294640; 915385-81-8; ABC-294640
DMCKPG4 CP Apogee Biotechnology
DMCKPG4 DT Small molecular drug
DMCKPG4 PC 15604015
DMCKPG4 MW 380.9
DMCKPG4 FM C23H25ClN2O
DMCKPG4 IC InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
DMCKPG4 CS C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
DMCKPG4 IK CAOTVXGYTWCKQE-UHFFFAOYSA-N
DMCKPG4 IU 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
DMCKPG4 CA CAS 915385-81-8
DMCKPG4 CB CHEBI:124965
DMCKPG4 DE Advanced solid tumour; Hepatocellular carcinoma; Cholangiocarcinoma; Multiple myeloma
DM91LGU ID DM91LGU
DM91LGU DN Abexinostat
DM91LGU HS Phase 3
DM91LGU SN PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
DM91LGU CP Pharmacyclics
DM91LGU DT Small molecular drug
DM91LGU PC 11749858
DM91LGU MW 397.4
DM91LGU FM C21H23N3O5
DM91LGU IC InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
DM91LGU CS CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
DM91LGU IK MAUCONCHVWBMHK-UHFFFAOYSA-N
DM91LGU IU 3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide
DM91LGU CA CAS 783355-60-2
DM91LGU CB CHEBI:92223
DM91LGU DE Acute myeloid leukaemia; Breast cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Gynecologic cancer; Peripheral T-cell lymphoma; Solid tumour/cancer; Renal cell carcinoma
DMMF5K4 ID DMMF5K4
DMMF5K4 DN ABL 001
DMMF5K4 HS Phase 3
DMMF5K4 CP Novartis pharmaceuticals
DMMF5K4 DE leukaemia; Chronic myeloid leukaemia; Promyelocytic leukaemia
DM7EVUF ID DM7EVUF
DM7EVUF DN ABL001
DM7EVUF HS Phase 3
DM7EVUF SN asciminib; ABL-001; 1492952-76-7; Asciminib free base; ABL001-NX; UNII-L1F3R18W77; L1F3R18W77; NVP-ABL001; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; 1492952-76-7 (free base); N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Asciminib [USAN]; Asciminib (ABL001); Asciminib (USAN/INN); GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; ZINC150275965; CCG-269232; CS-7655; DB12597; NSC-789925; SB18878; BS-15538; HY-104010; D11403; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; AY7
DM7EVUF CP Novartis
DM7EVUF DT Small molecular drug
DM7EVUF PC 72165228
DM7EVUF MW 449.8
DM7EVUF FM C20H18ClF2N5O3
DM7EVUF IC InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1
DM7EVUF CS C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
DM7EVUF IK VOVZXURTCKPRDQ-CQSZACIVSA-N
DM7EVUF IU N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
DM7EVUF CA CAS 1492952-76-7
DM7EVUF DE Chronic myeloid leukaemia
DM2J4YB ID DM2J4YB
DM2J4YB DN ABP 501
DM2J4YB HS Phase 3
DM2J4YB CP Amgen
DM2J4YB DT Antibody
DM2J4YB DE Rheumatoid arthritis; Plaque psoriasis
DMDXE4I ID DMDXE4I
DMDXE4I DN ABP959
DMDXE4I HS Phase 3
DMDXE4I CP Amgen
DMDXE4I DT Small molecular drug
DMDXE4I DE Paroxysmal nocturnal haemoglobinuria
DMNE56X ID DMNE56X
DMNE56X DN ABT-263
DMNE56X HS Phase 3
DMNE56X SN Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
DMNE56X CP Roche; Genentech
DMNE56X DT Small molecular drug
DMNE56X PC 24978538
DMNE56X MW 974.6
DMNE56X FM C47H55ClF3N5O6S3
DMNE56X IC InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
DMNE56X CS CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
DMNE56X IK JLYAXFNOILIKPP-KXQOOQHDSA-N
DMNE56X IU 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
DMNE56X CA CAS 923564-51-6
DMNE56X CB CHEBI:94128
DMNE56X DE Relapsed or refractory chronic lymphocytic leukaemia; Solid tumour/cancer; Myelofibrosis
DMNQ869 ID DMNQ869
DMNQ869 DN ABT-267
DMNQ869 HS Phase 3
DMNQ869 SN HCV therapeutic, Abbott
DMNQ869 CP Abbott Laboratories
DMNQ869 DT Small molecular drug
DMNQ869 PC 54767916
DMNQ869 MW 894.1
DMNQ869 FM C50H67N7O8
DMNQ869 IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMNQ869 CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMNQ869 IK PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMNQ869 IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMNQ869 CA CAS 1258226-87-7
DMNQ869 CB CHEBI:85183
DMNQ869 DE Hepatitis C virus infection
DMJFD2I ID DMJFD2I
DMJFD2I DN ABT-492
DMJFD2I HS Phase 3
DMJFD2I SN Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN)
DMJFD2I DT Small molecular drug
DMJFD2I PC 487101
DMJFD2I MW 440.8
DMJFD2I FM C18H12ClF3N4O4
DMJFD2I IC InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
DMJFD2I CS C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMJFD2I IK DYDCPNMLZGFQTM-UHFFFAOYSA-N
DMJFD2I IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMJFD2I CA CAS 189279-58-1
DMJFD2I DE Bacterial infection
DM3FIC2 ID DM3FIC2
DM3FIC2 DN ABT-761
DM3FIC2 HS Phase 3
DM3FIC2 SN Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2 CP Abbott Laboratories
DM3FIC2 DT Small molecular drug
DM3FIC2 PC 3086671
DM3FIC2 MW 318.4
DM3FIC2 FM C16H15FN2O2S
DM3FIC2 IC InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1
DM3FIC2 CS C[C@H](C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O
DM3FIC2 IK MMSNEKOTSJRTRI-LLVKDONJSA-N
DM3FIC2 IU 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2 CA CAS 154355-76-7
DM3FIC2 DE Asthma
DMREDYP ID DMREDYP
DMREDYP DN ABT-869
DMREDYP HS Phase 3
DMREDYP SN Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea
DMREDYP CP Abbott Laboratories
DMREDYP TC Anticancer Agents
DMREDYP DT Small molecular drug
DMREDYP PC 11485656
DMREDYP MW 375.4
DMREDYP FM C21H18FN5O
DMREDYP IC InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
DMREDYP CS CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
DMREDYP IK MPVGZUGXCQEXTM-UHFFFAOYSA-N
DMREDYP IU 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea
DMREDYP CA CAS 796967-16-3
DMREDYP CB CHEBI:91435
DMREDYP DE Solid tumour/cancer
DMYHSO2 ID DMYHSO2
DMYHSO2 DN ABT-874
DMYHSO2 HS Phase 3
DMYHSO2 CP Abbott; Astra Zeneca
DMYHSO2 DE Crohn disease; Rheumatoid arthritis; Plaque psoriasis
DM4HYMS ID DM4HYMS
DM4HYMS DN ABT-888
DM4HYMS HS Phase 3
DM4HYMS SN Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
DM4HYMS DT Small molecular drug
DM4HYMS PC 45480520
DM4HYMS MW 317.21
DM4HYMS FM C13H18Cl2N4O
DM4HYMS IC InChI=1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
DM4HYMS CS C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
DM4HYMS IK DSBSVDCHFMEYBX-FFXKMJQXSA-N
DM4HYMS IU 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride
DM4HYMS CA CAS 912445-05-7
DM4HYMS DE Breast cancer; Epithelial ovarian cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer
DMQRL2Y ID DMQRL2Y
DMQRL2Y DN AC0010
DMQRL2Y HS Phase 3
DMQRL2Y SN Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-
DMQRL2Y CP ACEA BiosciencesSan Diego, CA
DMQRL2Y PC 72734520
DMQRL2Y MW 487.5
DMQRL2Y FM C26H26FN7O2
DMQRL2Y IC InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
DMQRL2Y CS CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
DMQRL2Y IK UOFYSRZSLXWIQB-UHFFFAOYSA-N
DMQRL2Y IU N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMQRL2Y CA CAS 1557267-42-1
DMQRL2Y DE Non-small-cell lung cancer
DMXZ9T3 ID DMXZ9T3
DMXZ9T3 DN AC-170
DMXZ9T3 HS Phase 3
DMXZ9T3 SN 88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D
DMXZ9T3 CP Aciex Therapeutics Inc
DMXZ9T3 DT Small molecular drug
DMXZ9T3 PC 5200169
DMXZ9T3 MW 188.02
DMXZ9T3 FM C6H6BrNO
DMXZ9T3 IC InChI=1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
DMXZ9T3 CS C1=CC(=NC=C1Br)CO
DMXZ9T3 IK RUCZFWMEACWFER-UHFFFAOYSA-N
DMXZ9T3 IU (5-bromopyridin-2-yl)methanol
DMXZ9T3 CA CAS 88139-91-7
DMXZ9T3 DE Allergic conjunctivitis
DM8Y4JS ID DM8Y4JS
DM8Y4JS DN AC220
DM8Y4JS HS Phase 3
DM8Y4JS SN Quizartinib
DM8Y4JS CP Ambit Biosciences; Astellas Pharma US
DM8Y4JS DT Small molecular drug
DM8Y4JS PC 24889392
DM8Y4JS MW 560.7
DM8Y4JS FM C29H32N6O4S
DM8Y4JS IC InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
DM8Y4JS CS CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
DM8Y4JS IK CVWXJKQAOSCOAB-UHFFFAOYSA-N
DM8Y4JS IU 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
DM8Y4JS CA CAS 950769-58-1
DM8Y4JS CB CHEBI:90217
DM8Y4JS DE leukaemia; Acute myeloid leukaemia
DM1RMF5 ID DM1RMF5
DM1RMF5 DN Acadesine
DM1RMF5 HS Phase 3
DM1RMF5 SN AICAR; Acadra; ADV-P1; ATH-001; Acadesine (intravenous formulation, leukemia); Acadesine (intravenous formulation, leukemia), Advanced In Vitro Cell Technologies
DM1RMF5 CP Schering-Plough
DM1RMF5 DT Small molecular drug
DM1RMF5 PC 17513
DM1RMF5 MW 258.23
DM1RMF5 FM C9H14N4O5
DM1RMF5 IC InChI=1S/C9H14N4O5/c10-7-4(8(11)17)12-2-13(7)9-6(16)5(15)3(1-14)18-9/h2-3,5-6,9,14-16H,1,10H2,(H2,11,17)/t3-,5-,6-,9-/m1/s1
DM1RMF5 CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N
DM1RMF5 IK RTRQQBHATOEIAF-UUOKFMHZSA-N
DM1RMF5 IU 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
DM1RMF5 CA CAS 2627-69-2
DM1RMF5 CB CHEBI:28498
DM1RMF5 DE Diabetic complication
DMY96O3 ID DMY96O3
DMY96O3 DN acelarin
DMY96O3 HS Phase 3
DMY96O3 SN NUC-1031
DMY96O3 DT Small molecular drug
DMY96O3 PC 11169170
DMY96O3 MW 580.5
DMY96O3 FM C25H27F2N4O8P
DMY96O3 IC InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1
DMY96O3 CS C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4
DMY96O3 IK NHTKGYOMICWFQZ-KKQYNPQSSA-N
DMY96O3 IU benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMY96O3 CA CAS 840506-29-8
DMY96O3 DE Alzheimer disease; Ovarian cancer; Biliary tract cancer
DM3UQ9K ID DM3UQ9K
DM3UQ9K DN Acolbifene
DM3UQ9K HS Phase 3
DM3UQ9K SN Acolbifene; EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol
DM3UQ9K CP EndoCeutics
DM3UQ9K DT Small molecular drug
DM3UQ9K PC 155435
DM3UQ9K MW 457.6
DM3UQ9K FM C29H31NO4
DM3UQ9K IC InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1
DM3UQ9K CS CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
DM3UQ9K IK DUYNJNWVGIWJRI-LJAQVGFWSA-N
DM3UQ9K IU (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol
DM3UQ9K CA CAS 182167-02-8
DM3UQ9K DE Breast cancer
DMXYRPO ID DMXYRPO
DMXYRPO DN Act1
DMXYRPO HS Phase 3
DMXYRPO SN 51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794
DMXYRPO DT Small molecular drug
DMXYRPO DE Wound healing
DMVLWG7 ID DMVLWG7
DMVLWG7 DN Ad5FGF-4
DMVLWG7 HS Phase 3
DMVLWG7 DE Angina pectoris
DMFIP35 ID DMFIP35
DMFIP35 DN Adhexil
DMFIP35 HS Phase 3
DMFIP35 CP OMRIX Biopharmaceuticals SA
DMFIP35 DE Injury
DMLBYRA ID DMLBYRA
DMLBYRA DN ADX N05
DMLBYRA HS Phase 3
DMLBYRA CP Aerial BioPharma
DMLBYRA DE Excessive daytime sleepiness; Mood disorder
DMAYO46 ID DMAYO46
DMAYO46 DN AEZS-108
DMAYO46 HS Phase 3
DMAYO46 SN Zoptarelin doxorubicin; AEZS-108; AN-152; UNII-27844X2J29; ZEN-008; 27844X2J29; Zoptrex; Zoptarelin doxorubicin [INN]; Zoptarelin doxorubicin [USAN]; AEZS 108; CHEMBL3544954; AN 152; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D-lysine)-, (2S-cis)-
DMAYO46 CP AEterna Zentaris
DMAYO46 DT Small molecular drug
DMAYO46 PC 16134409
DMAYO46 MW 1893
DMAYO46 FM C91H117N19O26
DMAYO46 IC InChI=1S/C91H117N19O26/c1-44(2)31-58(83(125)104-57(17-11-29-98-90(94)95)89(131)110-30-12-18-63(110)88(130)100-40-67(93)114)105-81(123)55(16-7-8-28-97-68(115)20-10-21-70(117)134-42-66(113)91(132)36-52-73(65(37-91)136-71-35-53(92)76(118)45(3)135-71)80(122)75-74(78(52)120)77(119)51-14-9-19-64(133-4)72(51)79(75)121)103-84(126)59(32-46-22-24-49(112)25-23-46)106-87(129)62(41-111)109-85(127)60(33-47-38-99-54-15-6-5-13-50(47)54)107-86(128)61(34-48-39-96-43-101-48)108-82(124)56-26-27-69(116)102-56/h5-6,9,13-15,19,22-25,38-39,43-45,53,55-63,65,71,76,99,111-112,118,120,122,132H,7-8,10-12,16-18,20-21,26-37,40-42,92H2,1-4H3,(H2,93,114)(H,96,101)(H,97,115)(H,100,130)(H,102,116)(H,103,126)(H,104,125)(H,105,123)(H,106,129)(H,107,128)(H,108,124)(H,109,127)(H4,94,95,98)/t45-,53-,55+,56-,57-,58-,59-,60-,61-,62-,63-,65-,71-,76+,91-/m0/s1
DMAYO46 CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O
DMAYO46 IK OOUACICUAVTCEC-LZHWUUGESA-N
DMAYO46 IU [2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
DMAYO46 CA CAS 139570-93-7
DMAYO46 DE Acute lymphoblastic leukaemia
DMS0ZBI ID DMS0ZBI
DMS0ZBI DN Ag-221
DMS0ZBI HS Phase 3
DMS0ZBI SN AG-221 (IDH2 inhibitor)
DMS0ZBI CP Agios pharmaceuticals; celgene
DMS0ZBI PC 89683805
DMS0ZBI MW 473.4
DMS0ZBI FM C19H17F6N7O
DMS0ZBI IC InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DMS0ZBI CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DMS0ZBI IK DYLUUSLLRIQKOE-UHFFFAOYSA-N
DMS0ZBI IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMS0ZBI CA CAS 1446502-11-9
DMS0ZBI CB CHEBI:145374
DMS0ZBI DE Acute myeloid leukaemia; Acute myelogenous leukaemia
DMIE1WY ID DMIE1WY
DMIE1WY DN AG-881
DMIE1WY HS Phase 3
DMIE1WY SN Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop
DMIE1WY CP Agios Pharmaceuticals Cambridge, MA Celgene Summit, NJ
DMIE1WY PC 117817422
DMIE1WY MW 414.74
DMIE1WY FM C14H13ClF6N6
DMIE1WY IC InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1
DMIE1WY CS C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F
DMIE1WY IK QCZAWDGAVJMPTA-RNFRBKRXSA-N
DMIE1WY IU 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine
DMIE1WY CA CAS 1644545-52-7
DMIE1WY DE Acute myeloid leukaemia; Glioma
DMYN3IH ID DMYN3IH
DMYN3IH DN AGI-1067
DMYN3IH HS Phase 3
DMYN3IH SN AGZ-1067; Succinic acid 2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxyphenylsulfanyl)-1-methylethylsulfanyl]phenyl monoester
DMYN3IH CP AtheroGenics
DMYN3IH DT Small molecular drug
DMYN3IH PC 216325
DMYN3IH MW 616.9
DMYN3IH FM C35H52O5S2
DMYN3IH IC InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
DMYN3IH CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C
DMYN3IH IK RKSMVPNZHBRNNS-UHFFFAOYSA-N
DMYN3IH IU 4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid
DMYN3IH CA CAS 216167-82-7
DMYN3IH DE Artery stenosis
DMJRQDG ID DMJRQDG
DMJRQDG DN AG-SPT201
DMJRQDG HS Phase 3
DMJRQDG SN SPT201; S-pantoprazole sodium trihydrate (ulcer), Ahn-Gook; (S)-pantoprazole sodium trihydrate
DMJRQDG CP Ahn-Gook Pharmaceuticals Co Ltd
DMJRQDG DE Ulcerative colitis
DMS2WV3 ID DMS2WV3
DMS2WV3 DN AIDSVAX
DMS2WV3 HS Phase 3
DMS2WV3 SN AIDSVAX B/B; AIDSVAX B/E; Bivalent gp120 HIV vaccines, GSID; Bivalent gp120 HIV vaccines, Global Solutions for Infectious Diseases; Bivalent gp120 HIV vaccines, VaxGen
DMS2WV3 CP DiaDexus Inc
DMS2WV3 DT Vaccine
DMS2WV3 DE Human immunodeficiency virus infection
DM8SYTE ID DM8SYTE
DM8SYTE DN AIR-insulin
DM8SYTE HS Phase 3
DM8SYTE SN HIIP
DM8SYTE CP Alkermes
DM8SYTE DE Diabetic complication
DM5K6J4 ID DM5K6J4
DM5K6J4 DN AJM-300
DM5K6J4 HS Phase 3
DM5K6J4 SN Alpha-4 integrin antagonist (inflammatory bowel disease), Ajinomoto
DM5K6J4 CP Ajinomoto Co Inc
DM5K6J4 DE Crohn disease; Ulcerative colitis
DM2EJM3 ID DM2EJM3
DM2EJM3 DN AKB-6548
DM2EJM3 HS Phase 3
DM2EJM3 CP Akebia therapeutics
DM2EJM3 PC 23634441
DM2EJM3 MW 306.7
DM2EJM3 FM C14H11ClN2O4
DM2EJM3 IC InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
DM2EJM3 CS C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DM2EJM3 IK JGRXMPYUTJLTKT-UHFFFAOYSA-N
DM2EJM3 IU 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DM2EJM3 CA CAS 1000025-07-9
DM2EJM3 DE Anaemia
DM3WP0N ID DM3WP0N
DM3WP0N DN Al3818
DM3WP0N HS Phase 3
DM3WP0N SN Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
DM3WP0N CP Advenchen Laboratories Moorpark, CA
DM3WP0N PC 25017411
DM3WP0N MW 407.4
DM3WP0N FM C23H22FN3O3
DM3WP0N IC InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
DM3WP0N CS CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM3WP0N IK KSMZEXLVHXZPEF-UHFFFAOYSA-N
DM3WP0N IU 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine
DM3WP0N CA CAS 1058156-90-3
DM3WP0N DE Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cavity cancer; Synovial sarcoma
DMK0QW6 ID DMK0QW6
DMK0QW6 DN Albinterferon alfa-2b
DMK0QW6 HS Phase 3
DMK0QW6 SN Albuferon; Joulferon; Zalbin; ABF-656; Albuferon-alpha; Interferon alpha-albumin fusion protein, HGS; Albumin-based fusion protein (viral disease), Principia; Interferon alpha-albumin fusion protein, HGS/Novartis
DMK0QW6 CP Human Genome Sciences
DMK0QW6 DE Hepatitis C virus infection
DMWAL73 ID DMWAL73
DMWAL73 DN Albutropin
DMWAL73 HS Phase 3
DMWAL73 SN Albumin-based fusion protein (growth deficiency), Teva Pharmaceutical; Recombinant human growth hormone (HGH, long acting),Human Genome Sciences; Albumin-based fusion protein (growth deficiency), Principia (HGS); Recombinant human growth hormone (HGH, long-acting), Teva Pharmaceutical
DMWAL73 CP Aventis Behring LLC
DMWAL73 DE Growth failure
DMHKCIS ID DMHKCIS
DMHKCIS DN Aldoxorubicin
DMHKCIS HS Phase 3
DMHKCIS SN 1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
DMHKCIS CP CytRx, Los Angeles, CA
DMHKCIS PC 9810709
DMHKCIS MW 750.7
DMHKCIS FM C37H42N4O13
DMHKCIS IC InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
DMHKCIS CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O
DMHKCIS IK OBMJQRLIQQTJLR-USGQOSEYSA-N
DMHKCIS IU N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
DMHKCIS CA CAS 1361644-26-9
DMHKCIS DE Soft tissue sarcoma; Pancreatic ductal carcinoma; Glioblastoma multiforme; Small-cell lung cancer; Solid tumour/cancer
DMPH1RK ID DMPH1RK
DMPH1RK DN Alferminogene tadenovec
DMPH1RK HS Phase 3
DMPH1RK SN Generx (TN)
DMPH1RK CP Cardium Therapeutics
DMPH1RK DE Heart disease; Angina pectoris
DMVHRL8 ID DMVHRL8
DMVHRL8 DN Alfimeprase
DMVHRL8 HS Phase 3
DMVHRL8 SN Thrombolytic fibrolase derivative (cardiovascular diseases), Nuvelo; Thrombolytic fibrolase derivative (cerebrovascular ischemia), Nuvelo; Thrombolytic fibrolase derivative (peripheral arterial occlusive diseases), Nuvelo
DMVHRL8 CP Nuvelo
DMVHRL8 SQ Alfimeprase Sequence: SFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEIWSNQDLITVTSVSHDTLASFGNWRETDLLRRQRHDNAQLLTAIDFDGDTVGLAYVGGMCQLKHSTGVIQDHSAINLLVALTMAHELGHNLGMNHDGNQCHCGANSCVMAAMLSDQPSKLFSDCSKKDYQTFLTVNNPQCILNKP
DMVHRL8 DE Peripheral vascular disease
DMBQK0X ID DMBQK0X
DMBQK0X DN Algenpantucel-L
DMBQK0X HS Phase 3
DMBQK0X SN HyperAcute pancreas (TN)
DMBQK0X CP NewLink Genetics
DMBQK0X DT Vaccine
DMBQK0X DE Pancreatic cancer
DMQ509J ID DMQ509J
DMQ509J DN Alicaforsen
DMQ509J HS Phase 3
DMQ509J SN Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)
DMQ509J CP ISIS & Atlantic Healthcare
DMQ509J TC Antisense
DMQ509J DT Antisense drug
DMQ509J PC 16197725
DMQ509J MW 6349
DMQ509J FM C192H225N75O98P19S19-19
DMQ509J IC InChI=1S/C192H244N75O98P19S19/c1-76-40-256(190(286)245-169(76)270)136-30-89(357-376(299,395)314-50-106-84(25-131(334-106)251-15-7-122(196)230-185(251)281)351-370(293,389)312-49-105-87(28-134(333-105)254-18-10-125(199)233-188(254)284)355-374(297,393)323-59-115-97(38-145(343-115)266-74-225-154-167(266)238-180(208)243-175(154)276)364-381(304,400)319-55-111-90(31-137(339-111)257-41-77(2)170(271)246-191(257)287)356-375(298,394)313-46-102-81(22-128(330-102)248-12-4-119(193)227-182(248)278)348-366(289,385)308-44-100-79(269)20-127(328-100)259-67-218-147-156(201)210-63-214-160(147)259)110(338-136)54-318-380(303,399)359-92-33-139(260-68-219-148-157(202)211-64-215-161(148)260)340-112(92)56-320-373(296,392)354-88-29-135(255-19-11-126(200)234-189(255)285)336-108(88)52-316-379(302,398)363-96-37-144(265-73-224-153-166(265)237-179(207)242-174(153)275)346-118(96)62-326-384(307,403)365-98-39-146(267-75-226-155-168(267)239-181(209)244-176(155)277)344-116(98)60-324-377(300,396)358-91-32-138(258-42-78(3)171(272)247-192(258)288)337-109(91)53-317-371(294,390)352-85-26-132(252-16-8-123(197)231-186(252)282)335-107(85)51-315-378(301,397)362-95-36-143(264-72-223-152-165(264)236-178(206)241-173(152)274)345-117(95)61-325-383(306,402)361-94-35-141(262-70-221-150-159(204)213-66-217-163(150)262)342-114(94)58-322-382(305,401)360-93-34-140(261-69-220-149-158(203)212-65-216-162(149)261)341-113(93)57-321-372(295,391)353-86-27-133(253-17-9-124(198)232-187(253)283)332-104(86)48-311-369(292,388)350-83-24-130(250-14-6-121(195)229-184(250)280)331-103(83)47-310-368(291,387)349-82-23-129(249-13-5-120(194)228-183(249)279)329-101(82)45-309-367(290,386)347-80-21-142(327-99(80)43-268)263-71-222-151-164(263)235-177(205)240-172(151)273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H2,193,227,278)(H2,194,228,279)(H2,195,229,280)(H2,196,230,281)(H2,197,231,282)(H2,198,232,283)(H2,199,233,284)(H2,200,234,285)(H2,201,210,214)(H2,202,211,215)(H2,203,212,216)(H2,204,213,217)(H,245,270,286)(H,246,271,287)(H,247,272,288)(H3,205,235,240,273)(H3,206,236,241,274)(H3,207,237,242,275)(H3,208,238,243,276)(H3,209,239,244,277)/p-19/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1
DMQ509J CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)O
DMQ509J IK ZMJWRJKGPUDEOX-LMXUULCNSA-A
DMQ509J IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMQ509J CA CAS 185229-68-9
DMQ509J DE Ulcerative colitis; Crohn disease; Lleum inflammation
DM9R2SD ID DM9R2SD
DM9R2SD DN Alilusem
DM9R2SD HS Phase 3
DM9R2SD SN M-12285; M-17000; M-17055; MD-31
DM9R2SD CP Mochida Pharmaceutical Co Ltd
DM9R2SD DT Small molecular drug
DM9R2SD PC 6338015
DM9R2SD MW 394.8
DM9R2SD FM C17H15ClN2O5S
DM9R2SD IC InChI=1S/C17H15ClN2O5S/c1-11-4-2-3-5-13(11)17(21)20-9-8-15(19-25-26(22,23)24)14-7-6-12(18)10-16(14)20/h2-7,10H,8-9H2,1H3,(H,22,23,24)/b19-15+
DM9R2SD CS CC1=CC=CC=C1C(=O)N2CC/C(=N\\OS(=O)(=O)O)/C3=C2C=C(C=C3)Cl
DM9R2SD IK QQCSUWGQBREWRO-XDJHFCHBSA-N
DM9R2SD IU [(E)-[7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4-ylidene]amino] hydrogen sulfate
DM9R2SD CA CAS 791024-52-7
DM9R2SD DE Diuretic vasodilator
DM83EBP ID DM83EBP
DM83EBP DN Alisporivir
DM83EBP HS Phase 3
DM83EBP SN DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
DM83EBP CP Novartis pharmaceuticals
DM83EBP DT Protein/peptide drug
DM83EBP PC 11513676
DM83EBP MW 1216.6
DM83EBP FM C63H113N11O12
DM83EBP IC InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
DM83EBP CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
DM83EBP IK OLROWHGDTNFZBH-XEMWPYQTSA-N
DM83EBP IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM83EBP CA CAS 254435-95-5
DM83EBP DE Duchenne dystrophy
DMCHA27 ID DMCHA27
DMCHA27 DN Almonertinib
DMCHA27 HS Phase 3
DMCHA27 SN HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27 CP EQRx
DMCHA27 DT Small molecular drug
DMCHA27 PC 121280087
DMCHA27 MW 525.6
DMCHA27 FM C30H35N7O2
DMCHA27 IC InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
DMCHA27 CS CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
DMCHA27 IK DOEOECWDNSEFDN-UHFFFAOYSA-N
DMCHA27 IU N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27 CA CAS 1899921-05-1
DMCHA27 DE Non-small-cell lung cancer
DMFUOM7 ID DMFUOM7
DMFUOM7 DN ALN-TTRsc
DMFUOM7 HS Phase 3
DMFUOM7 SN SAR438714
DMFUOM7 CP Alnylam pharmaceuticals
DMFUOM7 DE Cardiomyopathy
DMKLBHX ID DMKLBHX
DMKLBHX DN ALO-02
DMKLBHX HS Phase 3
DMKLBHX SN ALO-02 Oxycodone-naltrexone core
DMKLBHX CP Elite Pharmaceuticals; pfizer
DMKLBHX DE Pain
DM2RTGP ID DM2RTGP
DM2RTGP DN Alpha-glucosidase
DM2RTGP HS Phase 3
DM2RTGP SN Pompes disease therapy, Pharming; Alpha-glucosidase (transgenic); Alpha-glucosidase, Pharming; GD-halpha-GLU; Alpha-glucosidase (transgenic), Pharming/Genzyme
DM2RTGP CP Pharming Group NV
DM2RTGP DE Muscle disease
DM7EBH9 ID DM7EBH9
DM7EBH9 DN ALX-0081
DM7EBH9 HS Phase 3
DM7EBH9 CP Ablynx
DM7EBH9 DE Thrombocytopenia; Thrombotic thrombocytopenic purpura
DMG5BTD ID DMG5BTD
DMG5BTD DN ALZT-OP1
DMG5BTD HS Phase 3
DMG5BTD SN ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen
DMG5BTD CP AZTherapies Boston, MA
DMG5BTD DE Alzheimer disease
DMGMNUE ID DMGMNUE
DMGMNUE DN AM0010
DMGMNUE HS Phase 3
DMGMNUE CP Armo biosciences
DMGMNUE DE Solid tumour/cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Non-small-cell lung cancer; Pancreatic cancer
DM4E9PK ID DM4E9PK
DM4E9PK DN AM-111
DM4E9PK HS Phase 3
DM4E9PK SN UNII-FU288768DP; FU288768DP; XG102 peptide; AM111 peptide; D-JNKI-1; D-JNKI 1 peptide; XG 102; AM 111; D-JNKI 1; TAT-IB1 fusion peptide XG-102 (synthetic); HIV TAT-JIP-1 fusion peptide XG-102 (synthetic); 1198367-70-2; 1148126-36-6; Glycine, D-alpha-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-
DM4E9PK CP Auris Medical
DM4E9PK PC 72941992
DM4E9PK MW 3823.4
DM4E9PK FM C164H285N65O41
DM4E9PK IC InChI=1S/C164H285N65O41/c1-84(2)77-106(216-139(254)108(79-89-33-10-9-11-34-89)219-146(261)112-48-28-72-225(112)153(268)105(55-58-119(171)235)215-148(263)123(86(5)6)221-147(262)115-51-29-73-226(115)151(266)103(45-25-69-198-163(187)188)213-142(257)110(83-230)220-137(252)100(53-56-117(169)233)201-126(241)90(168)80-121(237)238)138(253)218-109(81-120(172)236)140(255)217-107(78-85(3)4)141(256)222-124(87(7)231)149(264)223-125(88(8)232)155(270)228-75-31-50-114(228)144(259)211-99(44-24-68-197-162(185)186)135(250)212-102(37-14-17-61-167)150(265)224-71-27-47-111(224)145(260)214-104(46-26-70-199-164(189)190)152(267)229-76-32-52-116(229)154(269)227-74-30-49-113(227)143(258)210-98(43-23-67-196-161(183)184)134(249)207-95(40-20-64-193-158(177)178)131(246)206-97(42-22-66-195-160(181)182)133(248)209-101(54-57-118(170)234)136(251)208-96(41-21-65-194-159(179)180)132(247)205-94(39-19-63-192-157(175)176)130(245)204-93(36-13-16-60-166)129(244)203-92(35-12-15-59-165)128(243)202-91(38-18-62-191-156(173)174)127(242)200-82-122(239)240/h9-11,33-34,84-88,90-116,123-125,230-232H,12-32,35-83,165-168H2,1-8H3,(H2,169,233)(H2,170,234)(H2,171,235)(H2,172,236)(H,200,242)(H,201,241)(H,202,243)(H,203,244)(H,204,245)(H,205,247)(H,206,246)(H,207,249)(H,208,251)(H,209,248)(H,210,258)(H,211,259)(H,212,250)(H,213,257)(H,214,260)(H,215,263)(H,216,254)(H,217,255)(H,218,253)(H,219,261)(H,220,252)(H,221,262)(H,222,256)(H,223,264)(H,237,238)(H,239,240)(H4,173,174,191)(H4,175,176,192)(H4,177,178,193)(H4,179,180,194)(H4,181,182,195)(H4,183,184,196)(H4,185,186,197)(H4,187,188,198)(H4,189,190,199)/t87-,88-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,123+,124+,125+/m0/s1
DM4E9PK CS C[C@@H]([C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N3CCC[C@@H]3C(=O)N4CCC[C@@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H]7CCCN7C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC(=O)O)N)O
DM4E9PK IK HRMVIAFZYCCHGF-BMCUWHFPSA-N
DM4E9PK IU (3R)-3-amino-4-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[(2R)-2-[[(2R)-1-[[(2R)-5-amino-1-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-4-amino-1-[[(2R)-1-[[(2R,3S)-1-[[(2R,3S)-1-[(2R)-2-[[(2R)-1-[[(2R)-6-amino-1-[(2R)-2-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-6-amino-1-[[(2R)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM4E9PK CA CAS 1198367-70-2
DM4E9PK DE Neurological disorder
DMVOY6B ID DMVOY6B
DMVOY6B DN AMD-070
DMVOY6B HS Phase 3
DMVOY6B SN AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
DMVOY6B CP Genzyme
DMVOY6B DT Small molecular drug
DMVOY6B PC 11256587
DMVOY6B MW 349.5
DMVOY6B FM C21H27N5
DMVOY6B IC InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
DMVOY6B CS C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
DMVOY6B IK WVLHHLRVNDMIAR-IBGZPJMESA-N
DMVOY6B IU N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
DMVOY6B CA CAS 558447-26-0
DMVOY6B CB CHEBI:138865
DMVOY6B DE Human immunodeficiency virus infection; Renal cell carcinoma; Melanoma; Merkel cell carcinoma; Solid tumour/cancer; Whim syndrome
DM4FPM3 ID DM4FPM3
DM4FPM3 DN Amediplase
DM4FPM3 HS Phase 3
DM4FPM3 SN Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3 CP Menarini
DM4FPM3 DT Small molecular drug
DM4FPM3 PC 154656
DM4FPM3 MW 346.4
DM4FPM3 FM C22H18O4
DM4FPM3 IC InChI=1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1
DM4FPM3 CS C1=CC=C2C(=C1)[C@@H]([C@H](C3=C2C=C4C=CC5=C(C4=C3)C=C[C@@H]([C@H]5O)O)O)O
DM4FPM3 IK YQINXCSNGCDFCQ-CMOCDZPBSA-N
DM4FPM3 IU (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3 CA CAS 151910-75-7
DM4FPM3 DE Thrombosis; Myocardial infarction
DMG324Y ID DMG324Y
DMG324Y DN AMG 145
DMG324Y HS Phase 3
DMG324Y CP Amgen Thousand
DMG324Y DE Hypercholesterolaemia
DMQJXL4 ID DMQJXL4
DMQJXL4 DN AMG 386
DMQJXL4 HS Phase 3
DMQJXL4 SN 7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
DMQJXL4 CP Amgen
DMQJXL4 DT Small molecular drug
DMQJXL4 PC 5360545
DMQJXL4 MW 22.989
DMQJXL4 FM Na
DMQJXL4 IC InChI=1S/Na
DMQJXL4 CS [Na]
DMQJXL4 IK KEAYESYHFKHZAL-UHFFFAOYSA-N
DMQJXL4 IU sodium
DMQJXL4 CA CAS 7440-23-5
DMQJXL4 CB CHEBI:26708
DMQJXL4 DE Alzheimer disease; Neuropathic pain; Sexual dysfunction; Breast cancer; Asthma
DMS1X67 ID DMS1X67
DMS1X67 DN Amitifadine
DMS1X67 HS Phase 3
DMS1X67 SN EB-1010
DMS1X67 CP Euthymics Bioscience
DMS1X67 DT Small molecular drug
DMS1X67 PC 11658655
DMS1X67 MW 228.11
DMS1X67 FM C11H11Cl2N
DMS1X67 IC InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1
DMS1X67 CS C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl
DMS1X67 IK BSMNRYCSBFHEMQ-KCJUWKMLSA-N
DMS1X67 IU (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
DMS1X67 CA CAS 410074-73-6
DMS1X67 DE Obesity; Alcohol dependence; Mood disorder
DMF50XJ ID DMF50XJ
DMF50XJ DN Amitriptyline+ketamine
DMF50XJ HS Phase 3
DMF50XJ SN AmiKet
DMF50XJ CP EpiCept Pharmaceuticals
DMF50XJ TC Analgesics
DMF50XJ DT Small molecular drug
DMF50XJ PC 24784105
DMF50XJ MW 412.9
DMF50XJ FM C20H17ClN4O2S
DMF50XJ IC InChI=1S/C20H16N4O2S.ClH/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18;/h3-12H,1-2H3;1H
DMF50XJ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4.Cl
DMF50XJ IK HPYLZBPCIBFRAI-UHFFFAOYSA-N
DMF50XJ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide;hydrochloride
DMF50XJ DE Neuropathic pain; Diabetic neuropathy; Postherpetic neuralgia
DMZ7AMY ID DMZ7AMY
DMZ7AMY DN Amivantamab
DMZ7AMY HS Phase 3
DMZ7AMY CP Janssen
DMZ7AMY DT Antibody
DMZ7AMY DE Non-small-cell lung cancer
DMB9587 ID DMB9587
DMB9587 DN Amocarzine
DMB9587 HS Phase 3
DMB9587 SN Phenthiourezine; Thiocarbamazine; CGP-6140; S-80016
DMB9587 CP Novartis AG
DMB9587 DT Small molecular drug
DMB9587 PC 5464102
DMB9587 MW 371.5
DMB9587 FM C18H21N5O2S
DMB9587 IC InChI=1S/C18H21N5O2S/c1-21-10-12-22(13-11-21)18(26)20-16-4-2-14(3-5-16)19-15-6-8-17(9-7-15)23(24)25/h2-9,19H,10-13H2,1H3,(H,20,26)
DMB9587 CS CN1CCN(CC1)C(=S)NC2=CC=C(C=C2)NC3=CC=C(C=C3)[N+](=O)[O-]
DMB9587 IK UFLRJROFPAGRPN-UHFFFAOYSA-N
DMB9587 IU 4-methyl-N-[4-(4-nitroanilino)phenyl]piperazine-1-carbothioamide
DMB9587 CA CAS 36590-19-9
DMB9587 CB CHEBI:38946
DMB9587 DE Helminth infection
DM6SGUB ID DM6SGUB
DM6SGUB DN Amrubicin
DM6SGUB HS Phase 3
DM6SGUB SN 110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB CP Celgene
DM6SGUB DT Small molecular drug
DM6SGUB PC 3035016
DM6SGUB MW 483.5
DM6SGUB FM C25H25NO9
DM6SGUB IC InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
DM6SGUB CS CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N
DM6SGUB IK VJZITPJGSQKZMX-XDPRQOKASA-N
DM6SGUB IU (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB CA CAS 110267-81-7
DM6SGUB CB CHEBI:135779
DM6SGUB DE Small-cell lung cancer
DM8QIRN ID DM8QIRN
DM8QIRN DN AMT-011
DM8QIRN HS Phase 3
DM8QIRN SN Alipogene tiparvovec
DM8QIRN CP Amsterdam Molecular Therapeutics
DM8QIRN DE Blood forming organ disorder
DMSO02K ID DMSO02K
DMSO02K DN AMT-061
DMSO02K HS Phase 3
DMSO02K SN etranacogene dezaparvovec
DMSO02K CP uniQure
DMSO02K DT Gene therapy
DMSO02K DE Haemophilia B
DMP2BFG ID DMP2BFG
DMP2BFG DN Anacetrapib
DMP2BFG HS Phase 3
DMP2BFG SN MK0859; Anacetrapib (USAN); MK-0859
DMP2BFG CP Merck
DMP2BFG DT Small molecular drug
DMP2BFG PC 11556427
DMP2BFG MW 637.5
DMP2BFG FM C30H25F10NO3
DMP2BFG IC InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
DMP2BFG CS C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMP2BFG IK MZZLGJHLQGUVPN-HAWMADMCSA-N
DMP2BFG IU (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
DMP2BFG CA CAS 875446-37-0
DMP2BFG DE Hyperlipidaemia; Arteriosclerosis
DM2F9YO ID DM2F9YO
DM2F9YO DN Anakinra
DM2F9YO HS Phase 3
DM2F9YO SN Antril
DM2F9YO TC Antiviral Agents
DM2F9YO DT Protein/peptide drug
DM2F9YO DE Coronavirus Disease 2019 (COVID-19)
DM6HXTS ID DM6HXTS
DM6HXTS DN Anamorelin
DM6HXTS HS Phase 3
DM6HXTS SN 249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036
DM6HXTS CP Sapphire Therape.
DM6HXTS DT Small molecular drug
DM6HXTS PC 9828911
DM6HXTS MW 546.7
DM6HXTS FM C31H42N6O3
DM6HXTS IC InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
DM6HXTS CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
DM6HXTS IK VQPFSIRUEPQQPP-MXBOTTGLSA-N
DM6HXTS IU 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DM6HXTS CA CAS 249921-19-5
DM6HXTS DE Carbohydrate metabolism disorder
DMK2Y4V ID DMK2Y4V
DMK2Y4V DN Ancrod
DMK2Y4V HS Phase 3
DMK2Y4V SN Arvin; Arwin; Venacil; Viprinex; Agkistrodon rhodostoma venom proteinase; Agkistrodon serine proteinase; Snake venom, Knoll
DMK2Y4V CP Knoll GmbH; Neurobiological Technologies
DMK2Y4V DE Blood forming organ disorder
DMLDB1X ID DMLDB1X
DMLDB1X DN Andecaliximab
DMLDB1X HS Phase 3
DMLDB1X CP Gilead Sciences Foster City, CA
DMLDB1X DE Solid tumour/cancer; Gastric adenocarcinoma
DMX36BH ID DMX36BH
DMX36BH DN Andolast
DMX36BH HS Phase 3
DMX36BH SN Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm
DMX36BH CP Rottapharm Madaus
DMX36BH DT Small molecular drug
DMX36BH PC 65970
DMX36BH MW 333.31
DMX36BH FM C15H11N9O
DMX36BH IC InChI=1S/C15H11N9O/c25-15(11-3-1-9(2-4-11)13-17-21-22-18-13)16-12-7-5-10(6-8-12)14-19-23-24-20-14/h1-8H,(H,16,25)(H,17,18,21,22)(H,19,20,23,24)
DMX36BH CS C1=CC(=CC=C1C2=NNN=N2)C(=O)NC3=CC=C(C=C3)C4=NNN=N4
DMX36BH IK VXEBMQZDPONDFB-UHFFFAOYSA-N
DMX36BH IU 4-(2H-tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]benzamide
DMX36BH CA CAS 132640-22-3
DMX36BH DE Rhinitis
DMITJAK ID DMITJAK
DMITJAK DN Androsterone
DMITJAK HS Phase 3
DMITJAK SN androsterone; 53-41-8; Androkinine; Androtine; 5alpha-Androsterone; Atromide ICI; 3alpha-Hydroxy-5alpha-androstan-17-one; 3-Epihydroxyetioallocholan-17-one; cis-Androsterone; 3alpha-Hydroxyetioallocholan-17-one; 5alpha-Androstane-3alpha-ol-17-one; 3alpha-Hydroxy-17-androstanone; Androstanon-3-alpha-ol-17-one; 3-alpha-Hydroxy-17-androstanone; 3-alpha-Hydroxyetioallocholan-17-one; 3-alpha-Hydroxy-5-alpha-androstan-17-one; 5-alpha-Androstan-3-alpha-ol-17-one; Caswell No. 051G; Androstan-17-one, 3-hydroxy-, (3alpha,5alpha)-
DMITJAK DT Small molecular drug
DMITJAK PC 5879
DMITJAK MW 290.4
DMITJAK FM C19H30O2
DMITJAK IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,18-,19-/m0/s1
DMITJAK CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMITJAK IK QGXBDMJGAMFCBF-HLUDHZFRSA-N
DMITJAK IU (3R,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMITJAK CA CAS 53-41-8
DMITJAK CB CHEBI:16032
DM76GZ0 ID DM76GZ0
DM76GZ0 DN Angiotensin-(1-7)
DM76GZ0 HS Phase 3
DM76GZ0 SN Ang (1-7); Angiotensin (1-7); Angiotensin-(1-7) (cancer); Angiotensin-(1-7) (cancer), Wake Forest University
DM76GZ0 CP Tarix pharmaceuticals
DM76GZ0 DT Small molecular drug
DM76GZ0 PC 123805
DM76GZ0 MW 899
DM76GZ0 FM C41H62N12O11
DM76GZ0 IC InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
DM76GZ0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DM76GZ0 IK PVHLMTREZMEJCG-GDTLVBQBSA-N
DM76GZ0 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DM76GZ0 CA CAS 39386-80-6
DM76GZ0 CB CHEBI:55438
DM76GZ0 DE Lymphoma; Chemotherapy-induced nausea; Sarcoma; Duchenne dystrophy; Muscular dystrophy
DM3FPAQ ID DM3FPAQ
DM3FPAQ DN Anifrolumab
DM3FPAQ HS Phase 3
DM3FPAQ CP MedImmune Gaithersburg, MD
DM3FPAQ DE Systemic lupus erythematosus
DMX0PWV ID DMX0PWV
DMX0PWV DN Anti-IL-23
DMX0PWV HS Phase 3
DMX0PWV SN Anti-IL-23 (chronic inflammation); Anti-IL-23 (chronic inflammation), Merck & Co; Anti-IL-23 (chronic inflammation), Schering-Plough; Anti-interleukin-23 antibody (chronic inflammation), Merck & Co
DMX0PWV CP Schering-Plough Corp
DMX0PWV DT Antibody
DMX0PWV DE Inflammation
DMUYOC8 ID DMUYOC8
DMUYOC8 DN AP12009
DMUYOC8 HS Phase 3
DMUYOC8 CP Antisense therapeutics
DMUYOC8 TC Antisense
DMUYOC8 DT Antisense drug
DMUYOC8 DE Colorectal cancer
DMD8QTC ID DMD8QTC
DMD8QTC DN Apadenoson
DMD8QTC HS Phase 3
DMD8QTC SN Stedivaze (TN)
DMD8QTC CP PGx Health
DMD8QTC DT Small molecular drug
DMD8QTC PC 9805430
DMD8QTC MW 486.5
DMD8QTC FM C23H30N6O6
DMD8QTC IC InChI=1S/C23H30N6O6/c1-3-25-21(32)18-16(30)17(31)22(35-18)29-11-26-15-19(24)27-14(28-20(15)29)6-4-5-12-7-9-13(10-8-12)23(33)34-2/h11-13,16-18,22,30-31H,3,5,7-10H2,1-2H3,(H,25,32)(H2,24,27,28)/t12?,13?,16-,17+,18-,22+/m0/s1
DMD8QTC CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CCC4CCC(CC4)C(=O)OC)N)O)O
DMD8QTC IK FLEVIENZILQUKB-DMJMAAGCSA-N
DMD8QTC IU methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate
DMD8QTC CA CAS 250386-15-3
DMD8QTC DE Coronary artery disease
DMVY0BU ID DMVY0BU
DMVY0BU DN Apaziquone
DMVY0BU HS Phase 3
DMVY0BU SN EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; Apaziquonum; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin
DMVY0BU CP Spectrum
DMVY0BU DT Small molecular drug
DMVY0BU PC 5813717
DMVY0BU MW 288.3
DMVY0BU FM C15H16N2O4
DMVY0BU IC InChI=1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+
DMVY0BU CS CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO
DMVY0BU IK MXPOCMVWFLDDLZ-NSCUHMNNSA-N
DMVY0BU IU 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione
DMVY0BU CA CAS 114560-48-4
DMVY0BU DE Non-muscle invasive bladder cancer; Bladder cancer
DMT0A3Y ID DMT0A3Y
DMT0A3Y DN APD-334
DMT0A3Y HS Phase 3
DMT0A3Y SN S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals
DMT0A3Y CP Arena Pharmaceuticals Inc
DMT0A3Y PC 44623998
DMT0A3Y MW 457.5
DMT0A3Y FM C26H26F3NO3
DMT0A3Y IC InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1
DMT0A3Y CS C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F
DMT0A3Y IK MVGWUTBTXDYMND-QGZVFWFLSA-N
DMT0A3Y IU 2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
DMT0A3Y CA CAS 1206123-37-6
DMT0A3Y DE Autoimmune diabetes; Pyoderma gangrenosum; Ulcerative colitis
DM4HQ52 ID DM4HQ52
DM4HQ52 DN APL-2
DM4HQ52 HS Phase 3
DM4HQ52 CP Apellis Pharmaceuticals
DM4HQ52 DE Paroxysmal nocturnal haemoglobinuria
DMBRQF5 ID DMBRQF5
DMBRQF5 DN ApoC-III
DMBRQF5 HS Phase 3
DM1K78U ID DM1K78U
DM1K78U DN Apricitabine
DM1K78U HS Phase 3
DM1K78U SN Apricitabine; 160707-69-7; AVX754; AVX 754; UNII-K1YX059ML1; BCH 10618; (-)-dOTC; (-)-BCH 10652; K1YX059ML1; AVX-754; SPD-754; BCH-10618; 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one; 4-Amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone; BCH-10652; 2(1H)-Pyrimidinone, 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-, (2R-cis)-; Apricitabine [INN]; SPD754; BCH-10619; SPD 754; AC1L9S1I; (+/-)dOTC
DM1K78U DT Small molecular drug
DM1K78U PC 455041
DM1K78U MW 229.26
DM1K78U FM C8H11N3O3S
DM1K78U IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1
DM1K78U CS C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N
DM1K78U IK RYMCFYKJDVMSIR-RNFRBKRXSA-N
DM1K78U IU 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one
DM1K78U CA CAS 160707-69-7
DM1K78U DE Human immunodeficiency virus infection
DM2YQK8 ID DM2YQK8
DM2YQK8 DN AR-301
DM2YQK8 HS Phase 3
DM2YQK8 CP Aridis Pharmaceuticals
DM2YQK8 DT Antibody
DM2YQK8 DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pneumonia
DMZB9RI ID DMZB9RI
DMZB9RI DN Arabaclofen
DMZB9RI HS Phase 3
DMZB9RI DT Small molecular drug
DMZB9RI DE Fragile X syndrome
DMO628K ID DMO628K
DMO628K DN Arbaclofen placarbil
DMO628K HS Phase 3
DMO628K SN AP; R-baclofen - XenoPort; XP-19986
DMO628K CP Genentech
DMO628K DT Small molecular drug
DMO628K PC 11281011
DMO628K MW 399.9
DMO628K FM C19H26ClNO6
DMO628K IC InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
DMO628K CS CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
DMO628K IK JXTAALBWJQJLGN-KSSFIOAISA-N
DMO628K IU (3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid
DMO628K CA CAS 847353-30-4
DMO628K DE Fragile X syndrome; Alcohol dependence
DMYNJHI ID DMYNJHI
DMYNJHI DN Arc029
DMYNJHI HS Phase 3
DMYNJHI SN Nilvadipine; nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino; NILVADIPINE
DMYNJHI CP Archer Pharmaceuticals
DMYNJHI DT Small molecular drug
DMYNJHI PC 4494
DMYNJHI MW 385.4
DMYNJHI FM C19H19N3O6
DMYNJHI IC InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
DMYNJHI CS CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
DMYNJHI IK FAIIFDPAEUKBEP-UHFFFAOYSA-N
DMYNJHI IU 3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMYNJHI CA CAS 75530-68-6
DMYNJHI CB CHEBI:31911
DMYNJHI DE Alzheimer disease
DM180DM ID DM180DM
DM180DM DN ARGX-113
DM180DM HS Phase 3
DM180DM CP Argenx
DM180DM DT Small molecular drug
DM180DM DE Myasthenia gravis
DM84AD1 ID DM84AD1
DM84AD1 DN Arofylline
DM84AD1 HS Phase 3
DM84AD1 SN Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1 CP Almiral Prodesfarma
DM84AD1 DT Small molecular drug
DM84AD1 PC 166553
DM84AD1 MW 304.73
DM84AD1 FM C14H13ClN4O2
DM84AD1 IC InChI=1S/C14H13ClN4O2/c1-2-7-18-13(20)11-12(17-8-16-11)19(14(18)21)10-5-3-9(15)4-6-10/h3-6,8H,2,7H2,1H3,(H,16,17)
DM84AD1 CS CCCN1C(=O)C2=C(N=CN2)N(C1=O)C3=CC=C(C=C3)Cl
DM84AD1 IK GVTLDPJNRVMCAL-UHFFFAOYSA-N
DM84AD1 IU 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1 CA CAS 136145-07-8
DM84AD1 DE Chronic obstructive pulmonary disease
DM02BVQ ID DM02BVQ
DM02BVQ DN ARQ-087
DM02BVQ HS Phase 3
DM02BVQ CP ArQule Inc
DM02BVQ PC 46834118
DM02BVQ MW 468.6
DM02BVQ FM C29H29FN4O
DM02BVQ IC InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
DM02BVQ CS COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
DM02BVQ IK KPJDVVCDVBFRMU-AREMUKBSSA-N
DM02BVQ IU (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
DM02BVQ CA CAS 1234356-69-4
DM02BVQ DE Solid tumour/cancer; Cholangiocarcinoma; Intrahepatic cholangiocarcinoma
DML61S4 ID DML61S4
DML61S4 DN ARQ-151
DML61S4 HS Phase 3
DML61S4 CP Arcutis Biotherapeutics
DML61S4 DT Small molecular drug
DML61S4 DE Plaque psoriasis; Psoriasis vulgaris; Atopic dermatitis
DMD7XWS ID DMD7XWS
DMD7XWS DN AS-013
DMD7XWS HS Phase 3
DMD7XWS SN Circulase; Ecraprost; Prostaglandin E1 (liposomal), Mitsubishi Pharma/Asahi Glass
DMD7XWS CP Taisho Pharmaceutical Co Ltd
DMD7XWS DT Small molecular drug
DMD7XWS PC 6917049
DMD7XWS MW 480.7
DMD7XWS FM C28H48O6
DMD7XWS IC InChI=1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1
DMD7XWS CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O
DMD7XWS IK HITYEEHTEOQBAC-OSIGYOHNSA-N
DMD7XWS IU butyl 7-[(4R,5R)-2-butanoyloxy-4-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate
DMD7XWS CA CAS 136892-64-3
DMD7XWS DE Thrombosis
DMIV1WR ID DMIV1WR
DMIV1WR DN AS-12141
DMIV1WR HS Phase 3
DMIV1WR SN D-GalNAc; GalNAc; N-Acetyl-D-Galactosamine; N-acetyl-galactosamine; N-Acetyl-Galactosamine; 14215-68-0; 2-Acetamido-2-Deoxy-D-Galactopyranose; 2-Acetamido-2-Deoxy-D-Galactopyranoside; 2-Acetamido-2-Deoxy-D-Galactose; 2-Acetamido-2-Deoxy-Galactopyranose; 2-Acetamido-2-Deoxy-Galactopyranoside; 2-Acetamido-2-Deoxy-Galactose; 2-Deoxy-2-Acetamido-D-Galactopyranose; 2-Deoxy-2-Acetamido-D-Galactopyranoside; 2-Deoxy-2-Acetamido-D-Galactose; 2-Deoxy-2-Acetamido-Galactopyranose; 2-Deoxy-2-Acetamido-Galactopyranoside; 2-Deoxy-2-Acetamido-Galactose
DMIV1WR PC 35717
DMIV1WR MW 221.21
DMIV1WR FM C8H15NO6
DMIV1WR IC OVRNDRQMDRJTHS-KEWYIRBNSA-N
DMIV1WR CS CC(=O)NC1C(C(C(OC1O)CO)O)O
DMIV1WR IK 1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1
DMIV1WR IU N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMIV1WR CA CAS 1136-42-1
DMIV1WR CB CHEBI:28037
DMIV1WR DE Gaucher disease
DMK09D4 ID DMK09D4
DMK09D4 DN ASC09 + ritonavir
DMK09D4 HS Phase 3
DMK09D4 SN TMC-310911 + norvir; ASC09F
DMK09D4 TC Antiviral Agents
DMK09D4 DT Combination drug
DMK09D4 DE Coronavirus Disease 2019 (COVID-19)
DMWE3SC ID DMWE3SC
DMWE3SC DN ASC09 + ritonavir + oseltamivir
DMWE3SC HS Phase 3
DMWE3SC SN TMC-310911 + norvir + tamiflu
DMWE3SC TC Antiviral Agents
DMWE3SC DT Combination drug
DMWE3SC DE Coronavirus Disease 2019 (COVID-19)
DMND3AB ID DMND3AB
DMND3AB DN Asimadoline
DMND3AB HS Phase 3
DMND3AB SN Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB CP Merck
DMND3AB DT Small molecular drug
DMND3AB PC 179340
DMND3AB MW 414.5
DMND3AB FM C27H30N2O2
DMND3AB IC InChI=1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3/t24-,25+/m0/s1
DMND3AB CS CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMND3AB IK JHLHNYVMZCADTC-LOSJGSFVSA-N
DMND3AB IU N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB CA CAS 153205-46-0
DMND3AB DE Diarrhea-predominant irritable bowel syndrome; Pruritus
DMVA8KU ID DMVA8KU
DMVA8KU DN ASP0113
DMVA8KU HS Phase 3
DMVA8KU SN VCL-CB01
DMVA8KU CP Astellas
DMVA8KU DT Vaccine
DMVA8KU DE Cytomegalovirus infection
DMZ1UOI ID DMZ1UOI
DMZ1UOI DN Asp-015K
DMZ1UOI HS Phase 3
DMZ1UOI SN Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A
DMZ1UOI CP Astellas Pharma Inc
DMZ1UOI DT Small molecular drug
DMZ1UOI PC 57928403
DMZ1UOI MW 326.4
DMZ1UOI FM C18H22N4O2
DMZ1UOI IC InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18?
DMZ1UOI CS C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O
DMZ1UOI IK DREIJXJRTLTGJC-JQCLMNFQSA-N
DMZ1UOI IU 4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
DMZ1UOI CA CAS 944118-01-8
DMZ1UOI DE Psoriasis vulgaris; Rheumatoid arthritis
DMR71ST ID DMR71ST
DMR71ST DN ASP1929
DMR71ST HS Phase 3
DMR71ST SN Cetuximab sarotalocan
DMR71ST CP Rakuten Medical
DMR71ST DT Antibody
DMR71ST DE Solid tumour/cancer; Head and neck cancer
DMGQ1TV ID DMGQ1TV
DMGQ1TV DN ASP1941
DMGQ1TV HS Phase 3
DMGQ1TV SN Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200
DMGQ1TV CP Astellas Pharma US
DMGQ1TV DT Small molecular drug
DMGQ1TV PC 10453870
DMGQ1TV MW 404.5
DMGQ1TV FM C21H21FO5S
DMGQ1TV IC InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
DMGQ1TV CS C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F
DMGQ1TV IK AHFWIQIYAXSLBA-RQXATKFSSA-N
DMGQ1TV IU (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMGQ1TV CA CAS 761423-87-4
DMGQ1TV CB CHEBI:134724
DMGQ1TV DE Liver disease
DM5N1OB ID DM5N1OB
DM5N1OB DN Asp-2151
DM5N1OB HS Phase 3
DM5N1OB SN Helicase-primase inhibitor (herpes infection), Astellas
DM5N1OB CP Astellas Pharma Inc
DM5N1OB DT Small molecular drug
DM5N1OB PC 11397521
DM5N1OB MW 482.6
DM5N1OB FM C24H26N4O5S
DM5N1OB IC InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
DM5N1OB CS CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
DM5N1OB IK MNHNIVNAFBSLLX-UHFFFAOYSA-N
DM5N1OB IU N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
DM5N1OB CA CAS 841301-32-4
DM5N1OB DE Herpes simplex virus infection
DMLY0H5 ID DMLY0H5
DMLY0H5 DN Astuprotimut-R
DMLY0H5 HS Phase 3
DMLY0H5 CP GlaxoSmithKline
DMLY0H5 DE Non-small-cell lung cancer
DM4HK8Z ID DM4HK8Z
DM4HK8Z DN ASTX727
DM4HK8Z HS Phase 3
DM4HK8Z CP Astex Pharmaceuticals Pleasanton, CA
DM4HK8Z DE Chronic myelogenous leukaemia; Myelodysplastic syndrome
DMRV4DT ID DMRV4DT
DMRV4DT DN AT1001
DMRV4DT HS Phase 3
DMRV4DT SN Larazotide acetate; Larazotide acetate [USAN]; AT-1001; 881851-50-9; Larazotide acetate (USAN); UNII-FO8S2IW40N; AT 1001; FO8S2IW40N; CHEMBL2103815; NYGCNONRVCGHAT-UFIKZEAMSA-N; HY-106268A; CS-8047; D09352; Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine acetate; Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate
DMRV4DT DT Small molecular drug
DMRV4DT PC 44146842
DMRV4DT MW 785.9
DMRV4DT FM C34H59N9O12
DMRV4DT IC InChI=1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1
DMRV4DT CS CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O
DMRV4DT IK NYGCNONRVCGHAT-UFIKZEAMSA-N
DMRV4DT IU acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
DMRV4DT CA CAS 881851-50-9
DMRV4DT DE Autoimmune diabetes
DMVJW0S ID DMVJW0S
DMVJW0S DN AT-406
DMVJW0S HS Phase 3
DMVJW0S SN 1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
DMVJW0S CP Ascenta Therapeutics; Debiopharm
DMVJW0S DT Small molecular drug
DMVJW0S PC 25022340
DMVJW0S MW 561.7
DMVJW0S FM C32H43N5O4
DMVJW0S IC InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
DMVJW0S CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC
DMVJW0S IK LSXUTRRVVSPWDZ-MKKUMYSQSA-N
DMVJW0S IU (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMVJW0S CA CAS 1071992-99-8
DMVJW0S DE Acute myeloid leukaemia; Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom
DMQ94CT ID DMQ94CT
DMQ94CT DN AT9283
DMQ94CT HS Phase 3
DMQ94CT CP Astex Therape.
DMQ94CT TC Anticancer Agents
DMQ94CT DT Small molecular drug
DMQ94CT PC 135398495
DMQ94CT MW 381.4
DMQ94CT FM C19H23N7O2
DMQ94CT IC InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)
DMQ94CT CS C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5
DMQ94CT IK LOLPPWBBNUVNQZ-UHFFFAOYSA-N
DMQ94CT IU 1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea
DMQ94CT CA CAS 896466-04-9
DMQ94CT CB CHEBI:125514
DMQ94CT DE Solid tumour/cancer
DM8GFEV ID DM8GFEV
DM8GFEV DN Atacicept
DM8GFEV HS Phase 3
DM8GFEV CP ZymoGenetics; Serono
DM8GFEV DE Multiple sclerosis; Rheumatoid arthritis; Lymphoma; Systemic lupus erythematosus; Lupus
DM4GXW3 ID DM4GXW3
DM4GXW3 DN Ataluren
DM4GXW3 HS Phase 3
DM4GXW3 SN Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124)
DM4GXW3 CP Genzyme; PTC Therapeutics
DM4GXW3 DT Small molecular drug
DM4GXW3 PC 11219835
DM4GXW3 MW 284.24
DM4GXW3 FM C15H9FN2O3
DM4GXW3 IC InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)
DM4GXW3 CS C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
DM4GXW3 IK OOUGLTULBSNHNF-UHFFFAOYSA-N
DM4GXW3 IU 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
DM4GXW3 CA CAS 775304-57-9
DM4GXW3 CB CHEBI:94805
DM4GXW3 DE Aniridia; Cystic fibrosis; Mucopolysaccharidosis; Dravet syndrome; Duchenne dystrophy; Muscular dystrophy
DM3QLK2 ID DM3QLK2
DM3QLK2 DN Atamestane + Toremifene
DM3QLK2 HS Phase 3
DM3QLK2 SN Atamestane-plus-toremifene
DM3QLK2 CP Intarcia Therapeutics
DM3QLK2 DE Breast cancer
DM4VJ5Q ID DM4VJ5Q
DM4VJ5Q DN ATG-Fresenius S
DM4VJ5Q HS Phase 3
DM4VJ5Q CP Enzon
DM4VJ5Q DT Antibody
DM4VJ5Q DE Transplant rejection
DMBR0QK ID DMBR0QK
DMBR0QK DN Atorvastatin
DMBR0QK HS Phase 3
DMBR0QK SN atorvastatin; 134523-00-5; Cardyl; Xavator; Tozalip; Lipitor; Torvast; Sotis; ATORVASTATIN CALCIUM; Atorvastatin [INN:BAN]; 110862-48-1; UNII-A0JWA85V8F; CCRIS 7159; C33H35FN2O5; HSDB 7039; CI 981; Lipitor (TN); CHEMBL1487; A0JWA85V8F; CHEBI:39548; (betaR,deltaR)-2-(p-Fluorophenyl)-b; Atorvastatin
DMBR0QK TC Antiviral Agents
DMBR0QK DT Small molecular drug
DMBR0QK PC 60823
DMBR0QK MW 558.6
DMBR0QK FM C33H35FN2O5
DMBR0QK IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMBR0QK CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMBR0QK IK XUKUURHRXDUEBC-KAYWLYCHSA-N
DMBR0QK IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMBR0QK CA CAS 134523-00-5
DMBR0QK CB CHEBI:39548
DMBR0QK DE Coronavirus Disease 2019 (COVID-19)
DMM74PK ID DMM74PK
DMM74PK DN Atrasentan
DMM74PK HS Phase 3
DMM74PK SN Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid
DMM74PK CP Abbott
DMM74PK DT Small molecular drug
DMM74PK PC 159594
DMM74PK MW 510.6
DMM74PK FM C29H38N2O6
DMM74PK IC InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
DMM74PK CS CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
DMM74PK IK MOTJMGVDPWRKOC-QPVYNBJUSA-N
DMM74PK IU (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
DMM74PK CA CAS 173937-91-2
DMM74PK CB CHEBI:135810
DMM74PK DE Prostate cancer; Diabetic nephropathy
DM64WYC ID DM64WYC
DM64WYC DN Atx-101
DM64WYC HS Phase 3
DM64WYC SN ATX-101, APIM Therapeutics; Proliferating cell nuclear antigen (peptide, cancer), APIM
DM64WYC CP Bayer HealthCare Pharmaceuticals
DM64WYC PC 222528
DM64WYC MW 392.6
DM64WYC FM C24H40O4
DM64WYC IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM64WYC CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DM64WYC IK KXGVEGMKQFWNSR-LLQZFEROSA-N
DM64WYC IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM64WYC CA CAS 83-44-3
DM64WYC CB CHEBI:28834
DM64WYC DE Obesity
DM0EQ9X ID DM0EQ9X
DM0EQ9X DN Av 133
DM0EQ9X HS Phase 3
DM0EQ9X CP Avid Radiopharmaceuticals
DM0EQ9X DE Alzheimer disease
DMPW5UF ID DMPW5UF
DMPW5UF DN Avalglucosidase alfa
DMPW5UF HS Phase 3
DMPW5UF CP Sanofi
DMPW5UF DT Recombinant protein
DMPW5UF DE Pompe disease
DMA86FL ID DMA86FL
DMA86FL DN Avastin+/-Tarceva
DMA86FL HS Phase 3
DMA86FL SN Juglone; juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS; JUGLONE
DMA86FL CP Genentech
DMA86FL DT Small molecular drug
DMA86FL PC 3806
DMA86FL MW 174.15
DMA86FL FM C10H6O3
DMA86FL IC InChI=1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H
DMA86FL CS C1=CC2=C(C(=O)C=CC2=O)C(=C1)O
DMA86FL IK KQPYUDDGWXQXHS-UHFFFAOYSA-N
DMA86FL IU 5-hydroxynaphthalene-1,4-dione
DMA86FL CA CAS 481-39-0
DMA86FL CB CHEBI:15794
DMA86FL DE Non-small-cell lung cancer; Nasopharyngeal carcinoma
DMRJK3U ID DMRJK3U
DMRJK3U DN Avotermin
DMRJK3U HS Phase 3
DMRJK3U SN Juvista; RN-1001; SPD-538; TGF3, Renovo; RN-1, Renovo
DMRJK3U CP Renovo, UK (Shire, UK)
DMRJK3U DE Sarcoidosis
DMV1SOR ID DMV1SOR
DMV1SOR DN AVP-786
DMV1SOR HS Phase 3
DMV1SOR CP Avanir pharmaceuticals
DMV1SOR PC 25052519
DMV1SOR MW 277.4
DMV1SOR FM C18H25NO
DMV1SOR IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1/i1D3,2D3
DMV1SOR CS [2H]C([2H])([2H])N1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC([2H])([2H])[2H]
DMV1SOR IK MKXZASYAUGDDCJ-QNNIAVNKSA-N
DMV1SOR IU (1S,9S,10S)-4-(trideuteriomethoxy)-17-(trideuteriomethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMV1SOR CA CAS 1079043-55-2
DMV1SOR DE Pain; Alzheimer disease; Neurobehavioral disorder; Schizophrenia
DM6WZG8 ID DM6WZG8
DM6WZG8 DN AXS-05
DM6WZG8 HS Phase 3
DM6WZG8 CP Axsome Therapeutics
DM6WZG8 DT Small molecular drug
DM6WZG8 DE Alzheimer disease; Depression
DMM6G5D ID DMM6G5D
DMM6G5D DN AZD0914
DMM6G5D HS Phase 3
DMM6G5D SN Zoliflodacin
DMM6G5D CP Astrazeneca
DMM6G5D PC 76685216
DMM6G5D MW 487.4
DMM6G5D FM C22H22FN5O7
DMM6G5D IC InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
DMM6G5D CS C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
DMM6G5D IK ZSWMIFNWDQEXDT-ZESJGQACSA-N
DMM6G5D IU (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
DMM6G5D CA CAS 1620458-09-4
DMM6G5D DE Bacterial infection; Neisseria gonorrhoeae infection
DM9SKW8 ID DM9SKW8
DM9SKW8 DN AZD5363
DM9SKW8 HS Phase 3
DM9SKW8 SN AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1
DM9SKW8 CP Astex Pharmaceuticals
DM9SKW8 DT Small molecular drug
DM9SKW8 PC 25227436
DM9SKW8 MW 428.9
DM9SKW8 FM C21H25ClN6O2
DM9SKW8 IC InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
DM9SKW8 CS C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
DM9SKW8 IK JDUBGYFRJFOXQC-KRWDZBQOSA-N
DM9SKW8 IU 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
DM9SKW8 CA CAS 1143532-39-1
DM9SKW8 DE Solid tumour/cancer; Triple negative breast cancer
DMLY9F1 ID DMLY9F1
DMLY9F1 DN Azetirelin
DMLY9F1 HS Phase 3
DMLY9F1 SN Azetirelin; YM-14673 (dihydrate); Nalpha-[(S)-2-Azetidinone-4-carbonyl]-L-histidyl-L-prolinamide
DMLY9F1 DT Small molecular drug
DMLY9F1 PC 65841
DMLY9F1 MW 348.36
DMLY9F1 FM C15H20N6O4
DMLY9F1 IC InChI=1S/C15H20N6O4/c16-13(23)11-2-1-3-21(11)15(25)10(4-8-6-17-7-18-8)20-14(24)9-5-12(22)19-9/h6-7,9-11H,1-5H2,(H2,16,23)(H,17,18)(H,19,22)(H,20,24)/t9-,10-,11-/m0/s1
DMLY9F1 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CC(=O)N3)C(=O)N
DMLY9F1 IK WBGUMUGCONUXFK-DCAQKATOSA-N
DMLY9F1 IU (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-4-oxoazetidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide
DMLY9F1 CA CAS 95729-65-0
DMLY9F1 DE Pain
DMUIBV8 ID DMUIBV8
DMUIBV8 DN Azimilide
DMUIBV8 HS Phase 3
DMUIBV8 SN Azimilide [INN:BAN]; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8 CP Procter & Gamble
DMUIBV8 DT Small molecular drug
DMUIBV8 PC 9571004
DMUIBV8 MW 458
DMUIBV8 FM C23H28ClN5O3
DMUIBV8 IC InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+
DMUIBV8 CS CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)/N=C/C3=CC=C(O3)C4=CC=C(C=C4)Cl
DMUIBV8 IK MREBEPTUUMTTIA-PCLIKHOPSA-N
DMUIBV8 IU 1-[(E)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8 CA CAS 149908-53-2
DMUIBV8 CB CHEBI:34545
DMUIBV8 DE Atrial fibrillation
DM5Y4Q2 ID DM5Y4Q2
DM5Y4Q2 DN Azithromycin + hydroxychloroquine
DM5Y4Q2 HS Phase 3
DM5Y4Q2 SN Zithromax + oxichloroquine
DM5Y4Q2 TC Antiviral Agents
DM5Y4Q2 DT Combination drug
DM5Y4Q2 DE Coronavirus Disease 2019 (COVID-19)
DMPV6B2 ID DMPV6B2
DMPV6B2 DN BA-058
DMPV6B2 HS Phase 3
DMPV6B2 SN BA-058 Microneedle Patch; BA-058 (transdermal microneedle patch, osteoporosis); BA-058 (transdermal microneedle patch, osteoporosis), Radius Health
DMPV6B2 CP Radius Health Inc
DMPV6B2 DE Osteoporosis
DMXBHR6 ID DMXBHR6
DMXBHR6 DN Balaglitazone
DMXBHR6 HS Phase 3
DMXBHR6 SN DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
DMXBHR6 CP Dr Reddy's Research Foundation
DMXBHR6 DT Small molecular drug
DMXBHR6 PC 9889200
DMXBHR6 MW 395.4
DMXBHR6 FM C20H17N3O4S
DMXBHR6 IC InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)
DMXBHR6 CS CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMXBHR6 IK IETKPTYAGKZLKY-UHFFFAOYSA-N
DMXBHR6 IU 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMXBHR6 CA CAS 199113-98-9
DMXBHR6 DE Type-1 diabetes
DMUOFAC ID DMUOFAC
DMUOFAC DN Balixafortide
DMUOFAC HS Phase 3
DMUOFAC SN 1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide
DMUOFAC CP Polyphor
DMUOFAC DT Peptide
DMUOFAC PC 91864511
DMUOFAC MW 1782
DMUOFAC FM C80H112N22O21S2
DMUOFAC IC InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1
DMUOFAC CS C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC=N7)C(=O)O)CC8=CC=C(C=C8)O)CCCNC(=N)N
DMUOFAC IK UUTLJGUXRVWOSI-YYXAXUJHSA-N
DMUOFAC IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(3S,6S,9R,14R,17S,20S,23S)-9-[[(2S)-2-aminopropanoyl]amino]-20-(3-carbamimidamidopropyl)-6-(hydroxymethyl)-17-[(4-hydroxyphenyl)methyl]-3-methyl-2,5,8,16,19,22-hexaoxo-11,12-dithia-1,4,7,15,18,21-hexazabicyclo[21.3.0]hexacosane-14-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMUOFAC DE Metastatic breast cancer
DMKMTDG ID DMKMTDG
DMKMTDG DN Balovaptan
DMKMTDG HS Phase 3
DMKMTDG SN 1228088-30-9; UNII-RAX5D5AGV6; RG7314; RAX5D5AGV6; RO5285119; 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-5-methyl-1-{trans-4-[(pyridin-2-yl)oxy]cyclohexyl}-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Balovaptan [INN]; Balovaptan [USAN]; Balovaptan (USAN/INN); Balovaptan [USAN:INN]; SCHEMBL2471320; SCHEMBL3329710; SCHEMBL3332136; CHEMBL4297183; GTPL10615; compound 1 [PMID: 31951127]; DB14823; RG-7314; SB19643; Ro-5285119; BS-14780; HY-109024; CS-0030526; D11476; 12-chloro-8-methyl-3-[(1r,4r)-4-(pyridin-2-yloxy)cyclohexyl]-2,4,5,8-tetraazatricyclo[8.4.0.0,tetradeca-1(10),3,5,11,13-pentaene; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-; 8-Chloro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-5,6-dihydro-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
DMKMTDG CP Genentech
DMKMTDG DT Small molecular drug
DMKMTDG PC 46200932
DMKMTDG MW 409.9
DMKMTDG FM C22H24ClN5O
DMKMTDG IC InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3
DMKMTDG CS CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1
DMKMTDG IK GMPZPHGHNDMRKL-UHFFFAOYSA-N
DMKMTDG IU 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMKMTDG CA CAS 1228088-30-9
DMKMTDG DE Autism spectrum disorder
DMHQ5GK ID DMHQ5GK
DMHQ5GK DN Bapineuzumab
DMHQ5GK HS Phase 3
DMHQ5GK SN AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan
DMHQ5GK CP Elan Corp plc
DMHQ5GK DT Antibody
DMHQ5GK DE Alzheimer disease
DMODA2X ID DMODA2X
DMODA2X DN Bardoxolone methyl
DMODA2X HS Phase 3
DMODA2X SN BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4
DMODA2X CP Reata Pharmaceuticals Irving, TX
DMODA2X DT Small molecular drug
DMODA2X PC 400769
DMODA2X MW 505.7
DMODA2X FM C32H43NO4
DMODA2X IC InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
DMODA2X CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC
DMODA2X IK WPTTVJLTNAWYAO-KPOXMGGZSA-N
DMODA2X IU methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate
DMODA2X CA CAS 218600-53-4
DMODA2X DE Mixed connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension
DMPRI14 ID DMPRI14
DMPRI14 DN Baricitinib
DMPRI14 HS Phase 3
DMPRI14 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DMPRI14 CP Incyte/Eli Lilly
DMPRI14 TC Antiviral Agents
DMPRI14 DT Small molecular drug
DMPRI14 PC 44205240
DMPRI14 MW 371.4
DMPRI14 FM C16H17N7O2S
DMPRI14 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DMPRI14 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DMPRI14 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N
DMPRI14 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMPRI14 CA CAS 1187594-09-7
DMPRI14 CB CHEBI:95341
DMPRI14 DE Asthma; Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; Coronavirus Disease 2019 (COVID-19)
DMB147A ID DMB147A
DMB147A DN BAX-817
DMB147A HS Phase 3
DMB147A CP Baxter International Inc
DMB147A DE Hemophilia
DM407I6 ID DM407I6
DM407I6 DN BAY 853934
DM407I6 HS Phase 3
DM407I6 SN Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H
DM407I6 CP Bayer
DM407I6 DT Small molecular drug
DM407I6 PC 59603622
DM407I6 MW 314.3
DM407I6 FM C13H14N8O2
DM407I6 IC InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
DM407I6 CS C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4
DM407I6 IK IJMBOKOTALXLKS-UHFFFAOYSA-N
DM407I6 IU 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one
DM407I6 CA CAS 1154028-82-6
DM407I6 DE Anaemia
DMPW5SB ID DMPW5SB
DMPW5SB DN Bay 86-9766
DMPW5SB HS Phase 3
DMPW5SB SN 923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333
DMPW5SB CP Ardea Biosciences
DMPW5SB DT Small molecular drug
DMPW5SB PC 44182295
DMPW5SB MW 572.3
DMPW5SB FM C19H20F3IN2O5S
DMPW5SB IC InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
DMPW5SB CS COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F
DMPW5SB IK RDSACQWTXKSHJT-NSHDSACASA-N
DMPW5SB IU N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
DMPW5SB CA CAS 923032-37-5
DMPW5SB DE Solid tumour/cancer
DM09M3H ID DM09M3H
DM09M3H DN BAY 94-9027
DM09M3H HS Phase 3
DM09M3H SN Peg rFVIII
DM09M3H CP Bayer HealthCare Pharmaceuticals
DM09M3H DE Stroke; Hemophilia
DMWYPZF ID DMWYPZF
DMWYPZF DN BAY-35-3377
DMWYPZF HS Phase 3
DMWYPZF SN BY-377; Gastroquinolone antibacterial, Altana; Gastroquinolone antibacterial, Bayer; Quinolone antibacterials, Bayer
DMWYPZF CP Bayer AG
DMWYPZF DT Small molecular drug
DMWYPZF PC 11662028
DMWYPZF MW 434.8
DMWYPZF FM C20H20ClFN4O4
DMWYPZF IC InChI=1S/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1
DMWYPZF CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O.Cl
DMWYPZF IK CQMSQUOHWYYEKM-MOGJOVFKSA-N
DMWYPZF IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMWYPZF CA CAS 209342-41-6
DMWYPZF DE Otitis media
DMQG7ZM ID DMQG7ZM
DMQG7ZM DN Belagenpumatucel-L
DMQG7ZM HS Phase 3
DMQG7ZM SN Lucanix (TN)
DMQG7ZM CP NovaRx
DMQG7ZM DT Vaccine
DMQG7ZM DE Small-cell lung cancer; Non-small-cell lung cancer
DM71CK8 ID DM71CK8
DM71CK8 DN Beloranib
DM71CK8 HS Phase 3
DM71CK8 SN 251111-30-5; CKD-732; UNII-FI471K8BU6; ZGN-433; FI471K8BU6; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; Beloranib [INN]; ZGN 433; AC1OCFID; ZGN-440(Beloranib); US9682965, Compound A; GTPL8445; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZINC3982162; AKOS027326543; DB12671; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(25)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; CKD-731; Fumagillin analogs, Chong Kun Dang; HRK-429; HRK-512
DM71CK8 CP Zafgen
DM71CK8 DT Small molecular drug
DM71CK8 PC 6918502
DM71CK8 MW 499.6
DM71CK8 FM C29H41NO6
DM71CK8 IC InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1
DM71CK8 CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C4=CC=C(C=C4)OCCN(C)C)OC)C
DM71CK8 IK ZEZFKUBILQRZCK-MJSCXXSSSA-N
DM71CK8 IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
DM71CK8 CA CAS 251111-30-5
DM71CK8 DE Obesity; Solid tumour/cancer
DMLU8NX ID DMLU8NX
DMLU8NX DN Benserazide
DMLU8NX HS Phase 3
DMLU8NX SN benserazide; Serazide; 322-35-0; Benseraszide; Benserazida; Benserazidum; Ro 4-4602; Ro 44602; DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide; Benserazidum [INN-Latin]; Benserazida [INN-Spanish]; Benserazide [USAN:INN:BAN]; DL-Seryltrihydroxybenzylhydrazine; C10H15N3O5; BRN 3984490; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; CHEBI:64187; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-; DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide
DMLU8NX DT Small molecular drug
DMLU8NX PC 2327
DMLU8NX MW 257.24
DMLU8NX FM C10H15N3O5
DMLU8NX IC InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)
DMLU8NX CS C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O
DMLU8NX IK BNQDCRGUHNALGH-UHFFFAOYSA-N
DMLU8NX IU 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
DMLU8NX CA CAS 322-35-0
DMLU8NX CB CHEBI:64187
DMS9503 ID DMS9503
DMS9503 DN Benzylpenicillin
DMS9503 HS Phase 3
DMS9503 SN penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid
DMS9503 DT Small molecular drug
DMS9503 PC 5904
DMS9503 MW 334.4
DMS9503 FM C16H18N2O4S
DMS9503 IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMS9503 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMS9503 IK JGSARLDLIJGVTE-MBNYWOFBSA-N
DMS9503 IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMS9503 CA CAS 61-33-6
DMS9503 CB CHEBI:18208
DM6RWBN ID DM6RWBN
DM6RWBN DN Beperminogene perplasmid
DM6RWBN HS Phase 3
DM6RWBN CP AnGes; Daiichi
DM6RWBN DE Heart disease; Critical limb ischemia
DMLVNTA ID DMLVNTA
DMLVNTA DN Besipirdine
DMLVNTA HS Phase 3
DMLVNTA SN Besipirdine hydrochloride; HP-749; P86-7480
DMLVNTA CP Hoechst Marion Roussel Inc
DMLVNTA DT Small molecular drug
DMLVNTA PC 60691
DMLVNTA MW 251.33
DMLVNTA FM C16H17N3
DMLVNTA IC InChI=1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3
DMLVNTA CS CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMLVNTA IK OTPPJICEBWOCKD-UHFFFAOYSA-N
DMLVNTA IU N-propyl-N-pyridin-4-ylindol-1-amine
DMLVNTA CA CAS 119257-34-0
DMLVNTA DE Cognitive impairment
DM0MI81 ID DM0MI81
DM0MI81 DN Bevacizumab + Erlotinib
DM0MI81 HS Phase 3
DM0MI81 CP Roche
DM0MI81 DE Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma
DM9EXGI ID DM9EXGI
DM9EXGI DN Bevacizumab + Rituximab
DM9EXGI HS Phase 3
DM9EXGI CP Roche
DM9EXGI DT Combination drug (Antibody)
DM9EXGI PC 24801580
DM9EXGI MW 396.2
DM9EXGI FM C14H18ILiN2O3
DM9EXGI IC InChI=1S/C14H19IN2O3.Li/c1-3-17(4-2)8-7-16-13(18)10-5-6-11(14(19)20)12(15)9-10;/h5-6,9H,3-4,7-8H2,1-2H3,(H,16,18)(H,19,20);/q;+1/p-1
DM9EXGI CS [Li+].CCN(CC)CCNC(=O)C1=CC(=C(C=C1)C(=O)[O-])I
DM9EXGI IK CNMYRBKJCDLCHB-UHFFFAOYSA-M
DM9EXGI IU lithium;4-[2-(diethylamino)ethylcarbamoyl]-2-iodobenzoate
DM9EXGI DE Non-hodgkin lymphoma; Lymphoma
DM9CEI5 ID DM9CEI5
DM9CEI5 DN Bevacizumab + Trastuzumab
DM9CEI5 HS Phase 3
DM9CEI5 SN Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,
DM9CEI5 CP Roche
DM9CEI5 DT Combination drug (Antibody)
DM9CEI5 PC 9903
DM9CEI5 MW 376.6
DM9CEI5 FM C24H40O3
DM9CEI5 IC InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
DM9CEI5 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C
DM9CEI5 IK SMEROWZSTRWXGI-HVATVPOCSA-N
DM9CEI5 IU (4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM9CEI5 CA CAS 434-13-9
DM9CEI5 DE Breast cancer
DMK56G0 ID DMK56G0
DMK56G0 DN Bexagliflozin
DMK56G0 HS Phase 3
DMK56G0 SN UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo
DMK56G0 CP Theracos Marlborough, MA
DMK56G0 PC 25195624
DMK56G0 MW 464.9
DMK56G0 FM C24H29ClO7
DMK56G0 IC InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
DMK56G0 CS C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMK56G0 IK BTCRKOKVYTVOLU-SJSRKZJXSA-N
DMK56G0 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMK56G0 CA CAS 1118567-05-7
DMK56G0 DE Type-2 diabetes
DM7NJYC ID DM7NJYC
DM7NJYC DN BGB-A317
DM7NJYC HS Phase 3
DM7NJYC CP BeiGene Cambridge, MA
DM7NJYC DE Hepatocellular carcinoma; Solid tumour/cancer; Squamous cell carcinoma
DMNKBEC ID DMNKBEC
DMNKBEC DN BGJ398
DMNKBEC HS Phase 3
DMNKBEC SN Infigratinib
DMNKBEC DT Small molecular drug
DMNKBEC PC 53235510
DMNKBEC MW 560.5
DMNKBEC FM C26H31Cl2N7O3
DMNKBEC IC InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
DMNKBEC CS CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
DMNKBEC IK QADPYRIHXKWUSV-UHFFFAOYSA-N
DMNKBEC IU 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
DMNKBEC CA CAS 872511-34-7
DMNKBEC CB CHEBI:63451
DMNKBEC DE Solid tumour/cancer; Cholangiocarcinoma
DM3MXT8 ID DM3MXT8
DM3MXT8 DN BI 201335
DM3MXT8 HS Phase 3
DM3MXT8 SN Faldaprevir; BI-201335; UNII-958X4J301A; CHEMBL1241348; 958X4J301A; N-[(Cyclopentyloxy)carbonyl]-3-Methyl-L-Valyl-(4r)-4-[(8-Bromo-7-Methoxy-2-{2-[(2-Methylpropanoyl)amino]-1,3-Thiazol-4-Yl}quinolin-4-Yl)oxy]-N-[(1r,2s)-1-Carboxy-2-Ethenylcyclopropyl]-L-Prolinamide; BI 201335; 801283-95-4; BI201335; Faldaprevir [USAN:INN]; SCHEMBL222429; BDBM50336545; SB16712; DB11808
DM3MXT8 CP Boehringer Ingelheim Pharma
DM3MXT8 DT Small molecular drug
DM3MXT8 PC 42601552
DM3MXT8 MW 869.8
DM3MXT8 FM C40H49BrN6O9S
DM3MXT8 IC InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
DM3MXT8 CS CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O
DM3MXT8 IK LLGDPTDZOVKFDU-XUHJSTDZSA-N
DM3MXT8 IU (1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylic acid
DM3MXT8 CA CAS 801283-95-4
DM3MXT8 DE Hepatitis C virus infection
DMH3XDR ID DMH3XDR
DMH3XDR DN BI 425809
DMH3XDR HS Phase 3
DMH3XDR CP Boehringer Ingelheim
DMH3XDR DT Small molecular drug
DMH3XDR DE Schizophrenia
DMBH4FL ID DMBH4FL
DMBH4FL DN BI 655066
DMBH4FL HS Phase 3
DMBH4FL CP Boehringer ingelheim pharmaceuticals
DMBH4FL DT Antibody
DMBH4FL DE Ankylosing spondylitis; Chronic plaque psoriasis; Crohn disease; Psoriatic arthritis
DM42GP9 ID DM42GP9
DM42GP9 DN Bicifadine
DM42GP9 HS Phase 3
DM42GP9 SN BICIFADINE; 71195-57-8; 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane; 1-p-tolyl-3-azabicyclo[3.1.0]hexane; 5-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-; CL-220075; PubChem18323; AC1L2J2O; SCHEMBL38793; AZA001; CHEMBL511099; OFYVIGTWSQPCLF-UHFFFAOYSA-N; NIH-9542; MCV-4147; BDBM50417944; AKOS006271730; DOV-220075; AN-3206; DB04889; KB-13207; 5-(p-tolyl)-3-azabicyclo[3.1.0]hexane; AM20041063; FT-0718156; 1-(p-tolyl)-3-azabicyclo[3.1.0]-hexane
DM42GP9 CP Dov Pharmaceutical
DM42GP9 TC Analgesics
DM42GP9 DT Small molecular drug
DM42GP9 PC 47953
DM42GP9 MW 173.25
DM42GP9 FM C12H15N
DM42GP9 IC InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3
DM42GP9 CS CC1=CC=C(C=C1)C23CC2CNC3
DM42GP9 IK OFYVIGTWSQPCLF-UHFFFAOYSA-N
DM42GP9 IU 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane
DM42GP9 CA CAS 71195-57-8
DM42GP9 DE Neuropathic pain; Chronic low back pain
DM57B9J ID DM57B9J
DM57B9J DN Biferonex
DM57B9J HS Phase 3
DM57B9J SN Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler
DM57B9J CP Dr Rentschler Biotechnologie GmbH
DM57B9J DE Multiple sclerosis
DM51JW4 ID DM51JW4
DM51JW4 DN BIIB037
DM51JW4 HS Phase 3
DM51JW4 CP Biogen Idec
DM51JW4 DE Alzheimer disease
DM0AEDT ID DM0AEDT
DM0AEDT DN BIIB067
DM0AEDT HS Phase 3
DM0AEDT SN IONIS-SOD1RX; Tofersen
DM0AEDT CP Ionis Pharmaceuticals
DM0AEDT DT Antisense oligonucleotide
DM0AEDT DE Amyotrophic lateral sclerosis
DMR9TF1 ID DMR9TF1
DMR9TF1 DN Bimekizumab
DMR9TF1 HS Phase 3
DMR9TF1 CP UCB Atlanta, GA
DMR9TF1 DE Psoriatic arthritis; Plaque psoriasis
DMS2GA1 ID DMS2GA1
DMS2GA1 DN Bindarit
DMS2GA1 HS Phase 3
DMS2GA1 SN Bindarit, Angelini Pharmaceuticals; CCL2 inhibitor (inflammatory disorders/kidney disease), Angelini Pharmaceuticals; MCP-1 inhibitor (inflammatory disorder/kidney disease), Angelini Pharmaceuticals
DMS2GA1 CP Angelini Pharmaceuticals SpA
DMS2GA1 DT Small molecular drug
DMS2GA1 PC 71354
DMS2GA1 MW 324.4
DMS2GA1 FM C19H20N2O3
DMS2GA1 IC InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)
DMS2GA1 CS CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3
DMS2GA1 IK MTHORRSSURHQPZ-UHFFFAOYSA-N
DMS2GA1 IU 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
DMS2GA1 CA CAS 130641-38-2
DMS2GA1 DE Nephritis
DMVHF8G ID DMVHF8G
DMVHF8G DN Binodenoson
DMVHF8G HS Phase 3
DMVHF8G SN CorVue; MRE-0470; MRE-0479; MRE-470; SHA-174; WRC-0470
DMVHF8G CP Aderis Pharmaceuticals Inc
DMVHF8G DT Small molecular drug
DMVHF8G PC 9576912
DMVHF8G MW 391.4
DMVHF8G FM C17H25N7O4
DMVHF8G IC InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1
DMVHF8G CS C1CCC(CC1)/C=N/NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMVHF8G IK XJFMHMFFBSOEPR-DNZQAUTHSA-N
DMVHF8G IU (2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMVHF8G CA CAS 144348-08-3
DMVHF8G DE Hypertension
DME76AP ID DME76AP
DME76AP DN Bis(olanzapine) pamoate monohydrate
DME76AP HS Phase 3
DME76AP SN Bis[2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine] 4,4'-methylenebis(3-hydroxynaphthalen-2-carboxylic acid) salt monohydrate
DME76AP DE Psychotic disorder
DMW34B1 ID DMW34B1
DMW34B1 DN BL-8040
DMW34B1 HS Phase 3
DMW34B1 CP BioLineRx
DMW34B1 DT Peptide
DMW34B1 PC 91865076
DMW34B1 MW 2159.5
DMW34B1 FM C97H144FN33O19S2
DMW34B1 IC InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
DMW34B1 CS C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
DMW34B1 IK JJVZSYKFCOBILL-MKMRYRNGSA-N
DMW34B1 IU (3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
DMW34B1 CA CAS 664334-36-5
DMW34B1 CB CHEBI:145536
DMW34B1 DE Acute myeloid leukaemia; Pancreatic cancer; Myelodysplastic syndrome; Multiple myeloma
DM7V9LH ID DM7V9LH
DM7V9LH DN Blisibimod
DM7V9LH HS Phase 3
DM7V9LH CP Anthera Pharmaceuticals Hayward, CA
DM7V9LH DE Systemic lupus erythematosus
DM36C17 ID DM36C17
DM36C17 DN Blonanserin
DM36C17 HS Phase 3
DM36C17 SN Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17 CP Dainippon
DM36C17 DT Small molecular drug
DM36C17 PC 125564
DM36C17 MW 367.5
DM36C17 FM C23H30FN3
DM36C17 IC InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
DM36C17 CS CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F
DM36C17 IK XVGOZDAJGBALKS-UHFFFAOYSA-N
DM36C17 IU 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17 CA CAS 132810-10-7
DM36C17 CB CHEBI:31296
DM36C17 DE Schizophrenia
DMBXR23 ID DMBXR23
DMBXR23 DN BMN-110
DMBXR23 HS Phase 3
DMBXR23 SN Enzyme replacement therapy (iv infusion, MPS IVA), BioMarin; Enzyme replacement therapy (iv infusion, Morquio A syndrome), BioMarin; Enzyme replacement therapy (iv infusion, mucopolysaccharidosis IVA), BioMarin; N-acetylgalactosamine-6-sulfatase (GALNS) (Morquio A syndrome), BioMarin
DMBXR23 CP Biomarin pharmaceutical
DMBXR23 DE Morquio syndrome
DMM9XL2 ID DMM9XL2
DMM9XL2 DN BMN-111
DMM9XL2 HS Phase 3
DMM9XL2 SN C-type natriuretic peptide analog (achondroplasia), BioMarin
DMM9XL2 CP Biomarin pharmaceutical
DMM9XL2 PC 119058036
DMM9XL2 MW 4103
DMM9XL2 FM C176H290N56O51S3
DMM9XL2 IC InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1
DMM9XL2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO
DMM9XL2 IK IGYWDDBBJPSOTG-WBAGYEQSSA-N
DMM9XL2 IU (4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-5-oxo-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31-(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,22-bis(hydroxymethyl)-10,37,43-tris(2-methylpropyl)-19-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid
DMM9XL2 CA CAS 1480724-61-5
DMM9XL2 DE Achondroplasia
DM94Y6O ID DM94Y6O
DM94Y6O DN BMN-701
DM94Y6O HS Phase 3
DM94Y6O SN IGF2-GAA; XC-701; ZC-701; Enzyme replacement therapy (GILT, Pompe disease), BioMarin/ZyStor
DM94Y6O CP Biomarin pharmaceutical
DM94Y6O DE Pompe disease; Type 2 glycogen storage disease
DMDAN8H ID DMDAN8H
DMDAN8H DN BMS-582664
DMDAN8H HS Phase 3
DMDAN8H SN Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
DMDAN8H CP Bristol Myers Squibb
DMDAN8H TC Anticancer Agents
DMDAN8H DT Small molecular drug
DMDAN8H PC 11154925
DMDAN8H MW 441.5
DMDAN8H FM C22H24FN5O4
DMDAN8H IC InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
DMDAN8H CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C
DMDAN8H IK LTEJRLHKIYCEOX-OCCSQVGLSA-N
DMDAN8H IU [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate
DMDAN8H CA CAS 649735-63-7
DMDAN8H DE Hepatocellular carcinoma
DMAR1YS ID DMAR1YS
DMAR1YS DN BMS-986165
DMAR1YS HS Phase 3
DMAR1YS CP Bristol-Myers Squibb Princeton, NJ
DMAR1YS PC 134821691
DMAR1YS MW 425.5
DMAR1YS FM C20H22N8O3
DMAR1YS IC InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
DMAR1YS CS [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
DMAR1YS IK BZZKEPGENYLQSC-FIBGUPNXSA-N
DMAR1YS IU 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
DMAR1YS CA CAS 1609392-27-9
DMAR1YS DE Plaque psoriasis; Psoriasis vulgaris
DM3MAYQ ID DM3MAYQ
DM3MAYQ DN BMS-986205
DM3MAYQ HS Phase 3
DM3MAYQ SN KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
DM3MAYQ CP Bristol-Myers Squibb Princeton, NJ
DM3MAYQ PC 121328278
DM3MAYQ MW 410.9
DM3MAYQ FM C24H24ClFN2O
DM3MAYQ IC InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16?,17?/m1/s1
DM3MAYQ CS C[C@H](C1CCC(CC1)C2=C3C=C(C=CC3=NC=C2)F)C(=O)NC4=CC=C(C=C4)Cl
DM3MAYQ IK KRTIYQIPSAGSBP-KLAILNCOSA-N
DM3MAYQ IU (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
DM3MAYQ CA CAS 1923833-60-6
DM3MAYQ DE Advanced cancer; Gastric adenocarcinoma; Melanoma; Renal cell carcinoma; Solid tumour/cancer
DM2OBNW ID DM2OBNW
DM2OBNW DN Bococizumab
DM2OBNW HS Phase 3
DM2OBNW CP Pfizer
DM2OBNW DT Antibody
DM2OBNW DE Chronic obstructive pulmonary disease
DM6KRLW ID DM6KRLW
DM6KRLW DN BQ788
DM6KRLW HS Phase 3
DM6KRLW SN (2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752
DM6KRLW DT Small molecular drug
DM6KRLW PC 16759603
DM6KRLW MW 663.8
DM6KRLW FM C34H50N5NaO7
DM6KRLW IC InChI=1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1
DM6KRLW CS CCCC[C@H](C(=O)[O-])NC(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C.[Na+]
DM6KRLW IK QCVIFBRTTLMEOV-FUKQNADPSA-M
DM6KRLW IU sodium;(2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoate
DM6KRLW CA CAS 156161-89-6
DM6KRLW DE Hypertension; Acute kidney injury; Encephalopathy; Myasthenia gravis; Neuromyelitis optica
DM942HP ID DM942HP
DM942HP DN Brivanib
DM942HP HS Phase 3
DM942HP SN Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
DM942HP CP Bristol-Myers Squibb
DM942HP DT Small molecular drug
DM942HP PC 11234052
DM942HP MW 370.4
DM942HP FM C19H19FN4O3
DM942HP IC InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
DM942HP CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
DM942HP IK WCWUXEGQKLTGDX-LLVKDONJSA-N
DM942HP IU (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
DM942HP CA CAS 649735-46-6
DM942HP CB CHEBI:94562
DM942HP DE Liver cancer; Breast cancer
DMM0VO3 ID DMM0VO3
DMM0VO3 DN BSI-201
DMM0VO3 HS Phase 3
DMM0VO3 SN Iniparib; NIBA; INO2BA; IND-71677; SAR-240550; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; 4-Iodo-3-nitrobenzamide; 4-iodo-3-nitro-benzamide
DMM0VO3 CP Sanofi-Aventis
DMM0VO3 DT Small molecular drug
DMM0VO3 PC 9796068
DMM0VO3 MW 292.03
DMM0VO3 FM C7H5IN2O3
DMM0VO3 IC InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
DMM0VO3 CS C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
DMM0VO3 IK MDOJTZQKHMAPBK-UHFFFAOYSA-N
DMM0VO3 IU 4-iodo-3-nitrobenzamide
DMM0VO3 CA CAS 160003-66-7
DMM0VO3 CB CHEBI:95067
DMM0VO3 DE Solid tumour/cancer
DM50SNX ID DM50SNX
DM50SNX DN Bucelipase alfa
DM50SNX HS Phase 3
DM50SNX SN Exinalda; Kiobrina; BSSL, Biovitrum; Bile salt stimulated lipase, Arexis; Bile salt stimulated lipase, Biovitrum; Bile salt stimulated lipase, PPL Therapeutics; HrBSSL, Biovitrum; Human recombinant bile salt stimulated lipase, Biovitrum; TgBSSL, PPL Therapeutics
DM50SNX CP Astra Hassle AB
DM50SNX DE Exocrine pancreatic insufficiency
DM1WEHC ID DM1WEHC
DM1WEHC DN Buparlisib
DM1WEHC HS Phase 3
DM1WEHC SN BKM120
DM1WEHC CP Novartis
DM1WEHC DT Small molecular drug
DM1WEHC PC 16654980
DM1WEHC MW 410.4
DM1WEHC FM C18H21F3N6O2
DM1WEHC IC InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
DM1WEHC CS C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DM1WEHC IK CWHUFRVAEUJCEF-UHFFFAOYSA-N
DM1WEHC IU 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
DM1WEHC CA CAS 944396-07-0
DM1WEHC CB CHEBI:71954
DM1WEHC DE Breast cancer
DMAR9ND ID DMAR9ND
DMAR9ND DN Bupropion+Naltrexone
DMAR9ND HS Phase 3
DMAR9ND SN Mysimba; Contrave; Naltrexone/bupropion; Naltrexone / bupropion; Bupropion / naltrexone; Bupropion mixture with naltrexone; SCHEMBL15633271; 1201668-08-7
DMAR9ND CP Orexigen Therapeutics
DMAR9ND DT Small molecular drug
DMAR9ND PC 11556075
DMAR9ND MW 581.1
DMAR9ND FM C33H41ClN2O5
DMAR9ND IC InChI=1S/C20H23NO4.C13H18ClNO/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h3-4,11,15,18,22,24H,1-2,5-10H2;5-9,15H,1-4H3/t15-,18+,19+,20-;/m1./s1
DMAR9ND CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMAR9ND IK KVNBDVQGENTICK-ITLPAZOVSA-N
DMAR9ND IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DMAR9ND CA CAS 1201668-08-7
DMAR9ND DE Obesity
DM6RUKX ID DM6RUKX
DM6RUKX DN BVT.2733
DM6RUKX HS Phase 3
DM6RUKX SN CHEMBL553071; AC1OCFOV; 376641-65-5; SCHEMBL5692696; MolPort-042-665-756; 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride
DM6RUKX DT Small molecular drug
DM6RUKX PC 6918651
DM6RUKX MW 429
DM6RUKX FM C17H21ClN4O3S2
DM6RUKX IC InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20)
DM6RUKX CS CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CC(=O)N3CCN(CC3)C
DM6RUKX IK YDPRNGAPPNPYQQ-UHFFFAOYSA-N
DM6RUKX IU 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide
DM6RUKX CA CAS 376640-41-4
DM6RUKX DE Non-insulin dependent diabetes; Lupus; Myasthenia gravis; Systemic lupus erythematosus
DM1ARHT ID DM1ARHT
DM1ARHT DN BYM338
DM1ARHT HS Phase 3
DM1ARHT CP Novartis
DM1ARHT DE Acute myeloid leukaemia; Inclusion body myositis; Muscle atrophy
DMPTCYB ID DMPTCYB
DMPTCYB DN Cadi-05
DMPTCYB HS Phase 3
DMPTCYB SN Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila
DMPTCYB CP Cadila Pharmaceuticals Ltd
DMPTCYB DT Vaccine
DMPTCYB DE Prostate cancer
DM6CHNJ ID DM6CHNJ
DM6CHNJ DN Camptothecin
DM6CHNJ HS Phase 3
DM6CHNJ SN camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat
DM6CHNJ DT Small molecular drug
DM6CHNJ PC 24360
DM6CHNJ MW 348.4
DM6CHNJ FM C20H16N2O4
DM6CHNJ IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
DM6CHNJ CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DM6CHNJ IK VSJKWCGYPAHWDS-FQEVSTJZSA-N
DM6CHNJ IU (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DM6CHNJ CA CAS 7689-03-4
DM6CHNJ CB CHEBI:27656
DM6CHNJ DE Solid tumour/cancer
DMHJCGV ID DMHJCGV
DMHJCGV DN Candoxatril
DMHJCGV HS Phase 3
DMHJCGV SN UK 79300; Candoxatril [USAN:INN:BAN]; UK-79,300; Candoxatril (JAN/USAN/INN); Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis); [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; Cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV TC Antihypertensive Agents
DMHJCGV DT Small molecular drug
DMHJCGV PC 5362417
DMHJCGV MW 515.6
DMHJCGV FM C29H41NO7
DMHJCGV IC InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
DMHJCGV CS COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3
DMHJCGV IK ZTWZVMIYIIVABD-RZMWZJFBSA-N
DMHJCGV IU 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV CA CAS 123122-55-4
DMHJCGV CB CHEBI:3353
DMHJCGV DE Hypertension
DM4FHQR ID DM4FHQR
DM4FHQR DN Canfosfamide
DM4FHQR HS Phase 3
DM4FHQR SN Telcyta (TN)
DM4FHQR CP Telik
DM4FHQR DT Small molecular drug
DM4FHQR PC 5312109
DM4FHQR MW 787.5
DM4FHQR FM C26H40Cl4N5O10PS
DM4FHQR IC InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1
DM4FHQR CS C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N
DM4FHQR IK OJLHWPALWODJPQ-QNWVGRARSA-N
DM4FHQR IU (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM4FHQR CA CAS 158382-37-7
DM4FHQR CB CHEBI:135883
DM4FHQR DE Solid tumour/cancer
DMMZDJ6 ID DMMZDJ6
DMMZDJ6 DN Captopril
DMMZDJ6 HS Phase 3
DMMZDJ6 SN captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Dilabar; Acepress; Captoril; Tenosbon; Hypertil; Garranil; Alopresin; Lopril; Acepril; Captoprilum; Aceplus; Acediur; Tensobon; Isopresol;Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; SQ 14,225; SA 333; Captopril
DMMZDJ6 TC Antiviral Agents
DMMZDJ6 DT Small molecular drug
DMMZDJ6 PC 44093
DMMZDJ6 MW 217.29
DMMZDJ6 FM C9H15NO3S
DMMZDJ6 IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DMMZDJ6 CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DMMZDJ6 IK FAKRSMQSSFJEIM-RQJHMYQMSA-N
DMMZDJ6 IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DMMZDJ6 CA CAS 62571-86-2
DMMZDJ6 CB CHEBI:3380
DMMZDJ6 DE Coronavirus Disease 2019 (COVID-19)
DMUVMWZ ID DMUVMWZ
DMUVMWZ DN Carebastine
DMUVMWZ HS Phase 3
DMUVMWZ SN Carebastina; Carebastinum; Carebastina [Spanish]; Carebastine [INN]; Carebastinum [Latin]; E00013; P-(4-(4-(Diphenylmethoxy)piperidino)butyryl)-alpha-methylhydratropic acid; 2-(4-(4-(4-Benzhydryloxypiperidino)butyryl)phenyl)-2-methylpropionsaeure; 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ CP Almirall Prodesfarma
DMUVMWZ DT Small molecular drug
DMUVMWZ PC 65820
DMUVMWZ MW 499.6
DMUVMWZ FM C32H37NO4
DMUVMWZ IC InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36)
DMUVMWZ CS CC(C)(C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O
DMUVMWZ IK XGHOVGYJHWQGCC-UHFFFAOYSA-N
DMUVMWZ IU 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ CA CAS 90729-42-3
DMUVMWZ DE Ocular allergy
DM4Y1SP ID DM4Y1SP
DM4Y1SP DN Carisbamate
DM4Y1SP HS Phase 3
DM4Y1SP SN Comfyde; JNJ 10234094; RWJ 333369; YKP 509; Carisbamate (USAN); JNJ-10234094; RWJ-333369; YKP-509; S-2-O-Carbamoyl-1-o-chlorophenyl-ethanol; [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP CP Johnson & Johnson
DM4Y1SP DT Small molecular drug
DM4Y1SP PC 6918474
DM4Y1SP MW 215.63
DM4Y1SP FM C9H10ClNO3
DM4Y1SP IC InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
DM4Y1SP CS C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
DM4Y1SP IK OLBWFRRUHYQABZ-MRVPVSSYSA-N
DM4Y1SP IU [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP CA CAS 194085-75-1
DM4Y1SP CB CHEBI:135966
DM4Y1SP DE Seizure disorder; Focal dystonia; Epilepsy
DMPG4OM ID DMPG4OM
DMPG4OM DN CAZ AVI
DMPG4OM HS Phase 3
DMPG4OM SN CAZ104
DMPG4OM CP AstraZeneca
DMPG4OM DE Serious infection
DM097UP ID DM097UP
DM097UP DN CBT-1
DM097UP HS Phase 3
DM097UP CP National Institutes of Health Clinical Center (CC)
DM097UP DE Non-small-cell lung cancer; Solid tumour/cancer
DMV7WSN ID DMV7WSN
DMV7WSN DN CC-25430
DMV7WSN HS Phase 3
DMV7WSN SN Caroverin; Caroverina; Caroverina [INN-Spanish]; Caroverine; Caroverine (INN); Caroverine [INN]; Caroverinum; Caroverinum [INN-Latin]; P 201-1; Spasmium; Spasmium (TN); Tox21_113512; XJ73B0K6KB; ZINC4212360; 1-Diethylaminoethyl-3-(p-methoxybenzyl)quinoxalone-2; 23465-76-1; AC1L23SW; BRD-K70161083-003-01-4; C-23692; CAS-23465-76-1; CC-25430; CHEBI:135541; CHEMBL1729803; D07098; DSSTox_CID_28936; DSSTox_GSID_49010; DSSTox_RID_83202; DTXSID6049010; FT-0716182; MFCD00865257; NCGC00186046-01; NCGC00186046-02; SCHEMBL25946; UNII-XJ73B0K6KB; P-201
DMV7WSN PC 65709
DMV7WSN MW 365.5
DMV7WSN FM C22H27N3O2
DMV7WSN IC MSPRUJDUTKRMLM-UHFFFAOYSA-N
DMV7WSN CS CCN(CC)CCN1C2=CC=CC=C2N=C(C1=O)CC3=CC=C(C=C3)OC
DMV7WSN IK 1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3
DMV7WSN IU 1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]quinoxalin-2-one
DMV7WSN CA CAS 23465-76-1
DMV7WSN CB CHEBI:135541
DMV7WSN DE Tinnitus
DMTNQB0 ID DMTNQB0
DMTNQB0 DN CC-486
DMTNQB0 HS Phase 3
DMTNQB0 SN AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
DMTNQB0 CP Celgene
DMTNQB0 DT Small molecular drug
DMTNQB0 PC 9840076
DMTNQB0 MW 320.4
DMTNQB0 FM C19H20N4O
DMTNQB0 IC InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)
DMTNQB0 CS CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O
DMTNQB0 IK SEKJSSBJKFLZIT-UHFFFAOYSA-N
DMTNQB0 IU 2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
DMTNQB0 CA CAS 328543-09-5
DMTNQB0 CB CHEBI:92015
DMTNQB0 DE Myelodysplastic syndrome; Acute myeloid leukaemia; Diffuse large B-cell lymphoma
DM5LQHB ID DM5LQHB
DM5LQHB DN CCX-168
DM5LQHB HS Phase 3
DM5LQHB SN Avacopan
DM5LQHB CP ChemoCentryx
DM5LQHB PC 49841217
DM5LQHB MW 581.6
DM5LQHB FM C33H35F4N3O2
DM5LQHB IC InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
DM5LQHB CS CC1=C(C(=CC=C1)F)C(=O)N2CCC[C@@H]([C@@H]2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F
DM5LQHB IK PUKBOVABABRILL-YZNIXAGQSA-N
DM5LQHB IU (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
DM5LQHB CA CAS 1346623-17-3
DM5LQHB DE Eosinophilic granulomatosis with polyangiitis; Hereditary haemolytic anemia; Anca-associated vasculitis
DMWO5ZR ID DMWO5ZR
DMWO5ZR DN Cediranib
DMWO5ZR HS Phase 3
DMWO5ZR SN Recentin; AZD 2171; AZD2171; M6294; AZD-2171; ZD-2171; AZD2171, Recentin, Cediranib; Cediranib (USAN/INN); 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
DMWO5ZR CP AstraZeneca
DMWO5ZR TC Anticancer Agents
DMWO5ZR DT Small molecular drug
DMWO5ZR PC 9933475
DMWO5ZR MW 450.5
DMWO5ZR FM C25H27FN4O3
DMWO5ZR IC InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
DMWO5ZR CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
DMWO5ZR IK XXJWYDDUDKYVKI-UHFFFAOYSA-N
DMWO5ZR IU 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
DMWO5ZR CA CAS 288383-20-0
DMWO5ZR CB CHEBI:94782
DMWO5ZR DE Peritoneal cavity cancer
DMLWIU4 ID DMLWIU4
DMLWIU4 DN Cefluprenam
DMLWIU4 HS Phase 3
DMLWIU4 SN E-1077
DMLWIU4 CP Eisai Co Ltd
DMLWIU4 DT Small molecular drug
DMLWIU4 PC 6536774
DMLWIU4 MW 556.6
DMLWIU4 FM C20H25FN8O6S2
DMLWIU4 IC InChI=1S/C20H25FN8O6S2/c1-3-29(2,7-11(22)30)6-4-5-10-8-36-18-13(17(32)28(18)14(10)19(33)34)24-16(31)12(26-35-9-21)15-25-20(23)37-27-15/h4-5,13,18H,3,6-9H2,1-2H3,(H5-,22,23,24,25,27,30,31,33,34)/b5-4+,26-12-/t13-,18-,29?/m1/s1
DMLWIU4 CS CC[N+](C)(C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCF)/C3=NSC(=N3)N)SC1)C(=O)[O-])CC(=O)N
DMLWIU4 IK XAKKNLNAJBNLPC-MAYKBZFQSA-N
DMLWIU4 IU (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMLWIU4 CA CAS 116853-25-9
DMLWIU4 CB CHEBI:3488
DMLWIU4 DE Bacterial infection
DMM76GL ID DMM76GL
DMM76GL DN Ceftobiprole
DMM76GL HS Phase 3
DMM76GL SN BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL CP Johnson & Johnson
DMM76GL DT Small molecular drug
DMM76GL PC 135413542
DMM76GL MW 534.6
DMM76GL FM C20H22N8O6S2
DMM76GL IC InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
DMM76GL CS C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
DMM76GL IK VOAZJEPQLGBXGO-SDAWRPRTSA-N
DMM76GL IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL CA CAS 209467-52-7
DMM76GL CB CHEBI:140407
DMM76GL DE Community-acquired pneumonia; Skin and skin-structure infection
DMWLF2X ID DMWLF2X
DMWLF2X DN Ceftobiprole medocaril
DMWLF2X HS Phase 3
DMWLF2X SN UNII-YXV28V1B07; YXV28V1B07; BAL5788; 376653-43-9; ceftobiprolemedocaril; Ceftobiprole Medocaril [INN]; SCHEMBL2671859; SCHEMBL19236293; CHEBI:135968; DB14733; 653C439; (6R,7R)-7-((2Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)((3'R)-1'-((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl)-2-oxo-(1,3'-bipyrrolidin)-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMWLF2X CP Basilea Pharmaceutica
DMWLF2X DT Small molecular drug
DMWLF2X PC 135413544
DMWLF2X MW 690.7
DMWLF2X FM C26H26N8O11S2
DMWLF2X IC InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
DMWLF2X CS CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O
DMWLF2X IK HFTSMHTWUFCYMJ-YIOMYIDASA-N
DMWLF2X IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWLF2X CA CAS 376653-43-9
DMWLF2X CB CHEBI:135968
DMWLF2X DE Skin and skin-structure infection
DMIGX84 ID DMIGX84
DMIGX84 DN Cethromycin
DMIGX84 HS Phase 3
DMIGX84 SN Restanza; Cethromycin [USAN]; ABT 773; A-195773; ABT-773; Abbott-195773; A-195773.0; Cethromycin (USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1S,2R,5R,7R,8R,9R,11R,13R,14R)-2-Ethyl-1,5,7,9,11,13-Hexamethyl-9-[3-(3-quinolyl)-2(E)-propenyloxy]-8-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-glucopyranosyloxy]-3,17-dioxa-15-azabicyclo[12.3.0]hepta; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15 hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15-hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone
DMIGX84 CP Advanced life sciences
DMIGX84 DT Small molecular drug
DMIGX84 PC 447451
DMIGX84 MW 765.9
DMIGX84 FM C42H59N3O10
DMIGX84 IC InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1
DMIGX84 CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/C4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C
DMIGX84 IK PENDGIOBPJLVBT-ONLVEXIXSA-N
DMIGX84 IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMIGX84 CA CAS 205110-48-1
DMIGX84 CB CHEBI:29506
DMIGX84 DE Bacterial infection; Pneumonia
DMWAHTN ID DMWAHTN
DMWAHTN DN Cetilistat
DMWAHTN HS Phase 3
DMWAHTN SN Cametor; Cetilistat [INN]; ATL 962; ATL962; ATL-962; Cetilistat (JAN/USAN/INN); 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
DMWAHTN CP Alizyme; Takeda; Norgine B.V.
DMWAHTN DT Small molecular drug
DMWAHTN PC 9952916
DMWAHTN MW 401.6
DMWAHTN FM C25H39NO3
DMWAHTN IC InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
DMWAHTN CS CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
DMWAHTN IK MVCQKIKWYUURMU-UHFFFAOYSA-N
DMWAHTN IU 2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one
DMWAHTN CA CAS 282526-98-1
DMWAHTN CB CHEBI:134721
DMWAHTN DE Obesity; Diabetic complication
DMX9K3W ID DMX9K3W
DMX9K3W DN Cetraxal Otic
DMX9K3W HS Phase 3
DMX9K3W SN Ciprofloxacin otic
DMX9K3W CP Salvat Laboratories
DMX9K3W DE Otitis externa
DMIKMA9 ID DMIKMA9
DMIKMA9 DN CG-100649
DMIKMA9 HS Phase 3
DMIKMA9 SN Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399
DMIKMA9 CP CG Pharmaceuticals
DMIKMA9 DT Small molecular drug
DMIKMA9 PC 9841854
DMIKMA9 MW 361.4
DMIKMA9 FM C18H16FNO4S
DMIKMA9 IC InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
DMIKMA9 CS CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C
DMIKMA9 IK IJWPAFMIFNSIGD-UHFFFAOYSA-N
DMIKMA9 IU 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide
DMIKMA9 CA CAS 301692-76-2
DMIKMA9 DE Arthritis
DM1TJXA ID DM1TJXA
DM1TJXA DN Chloride
DM1TJXA HS Phase 3
DM1TJXA SN chloride ion; 16887-00-6; Chloride(1-); Chloride anion; Chlorine, ion; UNII-Q32ZN48698; Hydrochloric acid, ion(1-); Chlorid; CHEMBL19429; Cl-; CHEBI:17996; Q32ZN48698; Chlorides; Chloride ions; Chloride (ion); Perchloride; Chlorine anion; Chlorine ion; Chloride (Cl-); Chlorine(1-); Chlorine ion(1-); Chloride ion (1-); Chlorine, ion (Cl1-); AC1L18YJ; Cl(-); CTK0H5734; BDBM26979; VEXZGXHMUGYJMC-UHFFFAOYSA-M; c0884; AKOS015903642; FT-0755769; 3-Carbamoyl-1-ethoxymethylpyridinium chloride; 1-Butoxymethyl-3-carbamoyl-pyridinium
DM1TJXA DT Small molecular drug
DM1TJXA PC 312
DM1TJXA MW 35.45
DM1TJXA FM Cl-
DM1TJXA IC InChI=1S/ClH/h1H/p-1
DM1TJXA CS [Cl-]
DM1TJXA IK VEXZGXHMUGYJMC-UHFFFAOYSA-M
DM1TJXA IU chloride
DM1TJXA CA CAS 16887-00-6
DM1TJXA CB CHEBI:17996
DM1TJXA DE Solid tumour/cancer
DMORSFB ID DMORSFB
DMORSFB DN Chloroquine
DMORSFB HS Phase 3
DMORSFB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMORSFB CP Medreich Sterilab Ltd
DMORSFB TC Antiviral Agents
DMORSFB DT Small molecular drug
DMORSFB PC 2719
DMORSFB MW 319.9
DMORSFB FM C18H26ClN3
DMORSFB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMORSFB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMORSFB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMORSFB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMORSFB CA CAS 54-05-7
DMORSFB CB CHEBI:3638
DMORSFB DE Malaria; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM5X7DJ ID DM5X7DJ
DM5X7DJ DN Chlorpromazine
DM5X7DJ HS Phase 3
DM5X7DJ SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DM5X7DJ CP GlaxoSmithKline
DM5X7DJ TC Antiviral Agents
DM5X7DJ DT Small molecular drug
DM5X7DJ PC 2726
DM5X7DJ MW 318.9
DM5X7DJ FM C17H19ClN2S
DM5X7DJ IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DM5X7DJ CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DM5X7DJ IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DM5X7DJ IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DM5X7DJ CA CAS 34468-21-8
DM5X7DJ CB CHEBI:3647
DM5X7DJ DE Schizophrenia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM0Q6CM ID DM0Q6CM
DM0Q6CM DN CIGB-300
DM0Q6CM HS Phase 3
DM0Q6CM SN P15; IGBC-300; P15-Tat
DM0Q6CM CP Center for Genetic Engineering and Biotechnology
DM0Q6CM PC 86290205
DM0Q6CM MW 3060.6
DM0Q6CM FM C127H215N53O30S3
DM0Q6CM IC InChI=1S/C127H215N53O30S3/c1-66(2)55-84-100(189)157-61-97(187)177-98(67(3)182)116(205)176-89(120(209)210)64-213-212-63-88(113(202)173-85(56-68-59-156-71-22-6-5-21-70(68)71)111(200)168-82(40-54-211-4)110(199)175-87(62-181)118(207)178-51-18-32-90(178)114(203)169-79(30-16-48-154-126(143)144)108(197)174-86(112(201)172-84)57-69-60-147-65-158-69)160-95(185)39-50-148-99(188)80(35-37-93(131)183)170-115(204)91-33-19-52-179(91)119(208)92-34-20-53-180(92)117(206)83(31-17-49-155-127(145)146)171-107(196)78(29-15-47-153-125(141)142)165-105(194)76(27-13-45-151-123(137)138)166-109(198)81(36-38-94(132)184)167-106(195)77(28-14-46-152-124(139)140)164-104(193)75(26-12-44-150-122(135)136)163-103(192)74(24-8-10-42-129)162-102(191)73(23-7-9-41-128)161-101(190)72(159-96(186)58-130)25-11-43-149-121(133)134/h5-6,21-22,59-60,65-67,72-92,98,156,181-182H,7-20,23-58,61-64,128-130H2,1-4H3,(H2,131,183)(H2,132,184)(H,147,158)(H,148,188)(H,157,189)(H,159,186)(H,160,185)(H,161,190)(H,162,191)(H,163,192)(H,164,193)(H,165,194)(H,166,198)(H,167,195)(H,168,200)(H,169,203)(H,170,204)(H,171,196)(H,172,201)(H,173,202)(H,174,197)(H,175,199)(H,176,205)(H,177,187)(H,209,210)(H4,133,134,149)(H4,135,136,150)(H4,137,138,151)(H4,139,140,152)(H4,141,142,153)(H4,143,144,154)(H4,145,146,155)/t67-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,98+/m1/s1
DM0Q6CM CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC(C)C)CC3=CNC=N3)CCCNC(=N)N)CO)CCSC)CC4=CNC5=CC=CC=C54)NC(=O)CCNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]6CCCN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)O)O
DM0Q6CM IK RNELHWXSRSKXRD-QNKYCTLBSA-N
DM0Q6CM IU (3S,6S,9S,12R,17R,20S,26S,29S,32S,35S)-12-[3-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]propanoylamino]-32-(3-carbamimidamidopropyl)-20-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-29-(1H-imidazol-4-ylmethyl)-9-(1H-indol-3-ylmethyl)-26-(2-methylpropyl)-6-(2-methylsulfanylethyl)-2,5,8,11,19,22,25,28,31,34-decaoxo-14,15-dithia-1,4,7,10,18,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontane-17-carboxylic acid
DM0Q6CM CB CHEBI:83696
DM0Q6CM DE Cervical cancer
DMP0NGX ID DMP0NGX
DMP0NGX DN Cilansetron
DMP0NGX HS Phase 3
DMP0NGX SN Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)
DMP0NGX CP Solvay Pharma
DMP0NGX DT Small molecular drug
DMP0NGX PC 6918107
DMP0NGX MW 319.4
DMP0NGX FM C20H21N3O
DMP0NGX IC InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1
DMP0NGX CS CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC5=C4N3CCC5
DMP0NGX IK NCNFDKWULDWJDS-OAHLLOKOSA-N
DMP0NGX IU (12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one
DMP0NGX CA CAS 120635-74-7
DMP0NGX DE Irritable bowel syndrome
DMEAOZ0 ID DMEAOZ0
DMEAOZ0 DN Cilengitide
DMEAOZ0 HS Phase 3
DMEAOZ0 SN Cilengitide; 188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)
DMEAOZ0 DT Small molecular drug
DMEAOZ0 PC 176873
DMEAOZ0 MW 588.7
DMEAOZ0 FM C27H40N8O7
DMEAOZ0 IC InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
DMEAOZ0 CS CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMEAOZ0 IK AMLYAMJWYAIXIA-VWNVYAMZSA-N
DMEAOZ0 IU 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMEAOZ0 CA CAS 188968-51-6
DMEAOZ0 DE Rheumatoid arthritis
DM1975O ID DM1975O
DM1975O DN Cilnidipine
DM1975O HS Phase 3
DM1975O SN Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O CP Fuji Viscera Pharmaceutical
DM1975O DT Small molecular drug
DM1975O PC 5282138
DM1975O MW 492.5
DM1975O FM C27H28N2O7
DM1975O IC InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
DM1975O CS CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC
DM1975O IK KJEBULYHNRNJTE-DHZHZOJOSA-N
DM1975O IU 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O CA CAS 132203-70-4
DM1975O CB CHEBI:31399
DM1975O DE High blood pressure
DMU2J7Y ID DMU2J7Y
DMU2J7Y DN Ciltacabtagene autoleucel
DMU2J7Y HS Phase 3
DMU2J7Y SN JNJ-68284528
DMU2J7Y CP Janssen
DMU2J7Y DT CAR T Cell Therapy
DMU2J7Y DE Multiple myeloma
DMEGFYD ID DMEGFYD
DMEGFYD DN Cinitapride
DMEGFYD HS Phase 3
DMEGFYD SN Cinitapride; 66564-14-5; Cidine; cinitapride tartrate; Blaston; Cinitapride [INN]; C21H30N4O4; Cinitapride hydrogen tartrate; Cinitapride (INN); 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; Cinitapridum; Cinitaprida; Paxapride; Cinitapridum [INN-Latin]; Cinitaprida [INN-Spanish]; cidin; Cintapro; Cinmove; UNII-R8I97I2L24; Paxapride (TN); AC1Q1YMD; AC1L2AM4; (non-labelled)Cinitapride-d5; SCHEMBL476454; SCHEMBL19235643; CHEMBL2104523; CHEBI:135642; R8I97I2L24; BCP04096; AKOS015909742; DB08810
DMEGFYD CP Eisai
DMEGFYD DT Small molecular drug
DMEGFYD PC 68867
DMEGFYD MW 402.5
DMEGFYD FM C21H30N4O4
DMEGFYD IC InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)
DMEGFYD CS CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N
DMEGFYD IK ZDLBNXXKDMLZMF-UHFFFAOYSA-N
DMEGFYD IU 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
DMEGFYD CA CAS 66564-14-5
DMEGFYD CB CHEBI:135642
DMEGFYD DE Functional dyspepsia
DM803GL ID DM803GL
DM803GL DN CIPEMASTAT
DM803GL HS Phase 3
DM803GL SN Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306
DM803GL DT Small molecular drug
DM803GL PC 9824350
DM803GL MW 436.5
DM803GL FM C22H36N4O5
DM803GL IC InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
DM803GL CS CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C
DM803GL IK GFUITADOEPNRML-SJORKVTESA-N
DM803GL IU (2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide
DM803GL CA CAS 190648-49-8
DM803GL DE Rheumatoid arthritis
DMJ9ZIY ID DMJ9ZIY
DMJ9ZIY DN CK-2017357
DMJ9ZIY HS Phase 3
DMJ9ZIY SN Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY CP Cytokinetics
DMJ9ZIY DT Small molecular drug
DMJ9ZIY PC 23729157
DMJ9ZIY MW 230.27
DMJ9ZIY FM C12H14N4O
DMJ9ZIY IC InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17)
DMJ9ZIY CS CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C
DMJ9ZIY IK RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY IU 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one
DMJ9ZIY CA CAS 1005491-05-3
DMJ9ZIY DE Muscle fatigue; Amyotrophic lateral sclerosis
DMTSONL ID DMTSONL
DMTSONL DN Claritin/Singulair
DMTSONL HS Phase 3
DMTSONL SN Loratadine/montelukast sodium
DMTSONL CP Schering-Plough
DMTSONL DE Allergic rhinitis
DMPQR1D ID DMPQR1D
DMPQR1D DN Claudiximab
DMPQR1D HS Phase 3
DMPQR1D SN IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
DMPQR1D CP Ganymed Pharmaceuticals AG
DMPQR1D DT Antibody
DMPQR1D DE Esophageal cancer; Gastric adenocarcinoma
DMQSBX4 ID DMQSBX4
DMQSBX4 DN Clazosentan
DMQSBX4 HS Phase 3
DMQSBX4 SN Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561
DMQSBX4 CP Actelion Pharmaceuticals
DMQSBX4 DT Small molecular drug
DMQSBX4 PC 6433095
DMQSBX4 MW 577.6
DMQSBX4 FM C25H23N9O6S
DMQSBX4 IC InChI=1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
DMQSBX4 CS CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
DMQSBX4 IK LFWCJABOXHSRGC-UHFFFAOYSA-N
DMQSBX4 IU N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
DMQSBX4 CA CAS 180384-56-9
DMQSBX4 DE Vasospasm; Cerebral vasospasm
DMR21Q3 ID DMR21Q3
DMR21Q3 DN Clevudine
DMR21Q3 HS Phase 3
DMR21Q3 SN Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)
DMR21Q3 CP Bukwang; Eisai
DMR21Q3 DT Small molecular drug
DMR21Q3 PC 73115
DMR21Q3 MW 260.22
DMR21Q3 FM C10H13FN2O5
DMR21Q3 IC InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
DMR21Q3 CS CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F
DMR21Q3 IK GBBJCSTXCAQSSJ-XQXXSGGOSA-N
DMR21Q3 IU 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR21Q3 CA CAS 163252-36-6
DMR21Q3 CB CHEBI:135964
DMR21Q3 DE Hepatitis B virus infection
DMSPN58 ID DMSPN58
DMSPN58 DN Clomethiazole
DMSPN58 HS Phase 3
DMSPN58 SN Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV
DMSPN58 DT Small molecular drug
DMSPN58 PC 10783
DMSPN58 MW 161.65
DMSPN58 FM C6H8ClNS
DMSPN58 IC InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3
DMSPN58 CS CC1=C(SC=N1)CCCl
DMSPN58 IK PCLITLDOTJTVDJ-UHFFFAOYSA-N
DMSPN58 IU 5-(2-chloroethyl)-4-methyl-1,3-thiazole
DMSPN58 CA CAS 533-45-9
DMSPN58 CB CHEBI:92875
DMSPN58 DE Stroke
DMFQ1WX ID DMFQ1WX
DMFQ1WX DN CLS006
DMFQ1WX HS Phase 3
DMFQ1WX CP Cutanea Wayne, PA
DMFQ1WX DE Verruca vulgaris
DMASPWR ID DMASPWR
DMASPWR DN CM-2395
DMASPWR HS Phase 3
DMASPWR CP Cenomed BioSciences
DMASPWR DE Schizophrenia
DMLMN2F ID DMLMN2F
DMLMN2F DN CM-AT
DMLMN2F HS Phase 3
DMLMN2F DE Autism spectrum disorder; Attention deficit hyperactivity disorder
DMC4X7L ID DMC4X7L
DMC4X7L DN CMS-024-02
DMC4X7L HS Phase 3
DMC4X7L SN Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
DMC4X7L CP Shenzhen Kangzhe Pharmaceutical Co Ltd
DMC4X7L PC 11303106
DMC4X7L MW 367.4
DMC4X7L FM C17H25N3O6
DMC4X7L IC InChI=1S/C17H25N3O6/c1-9(2)14(17(25)26)20-16(24)13(8-21)19-15(23)12(18)7-10-3-5-11(22)6-4-10/h3-6,9,12-14,21-22H,7-8,18H2,1-2H3,(H,19,23)(H,20,24)(H,25,26)/t12-,13-,14-/m0/s1
DMC4X7L CS CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMC4X7L IK TYFLVOUZHQUBGM-IHRRRGAJSA-N
DMC4X7L IU (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
DMC4X7L CA CAS 154039-16-4
DMC4X7L CB CHEBI:165974
DMC4X7L DE Solid tumour/cancer
DM9Y3B5 ID DM9Y3B5
DM9Y3B5 DN CMX-001
DM9Y3B5 HS Phase 3
DM9Y3B5 SN Brincidofovir; CMX001; 444805-28-1; Hexadecyloxypropyl-cidofovir; CMX 001; Hexadecyloxypropyl cidofovir; UNII-6794O900AX; 6794O900AX; HDP-Cidofovir; Cidofovir-HDP; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid; Brincidofovir [USAN:INN]; Hexadecyloxypropyl - cidofovir; Cidofovir prodrug; HDP-HPMPC; Brincidofovir (USAN); AC1LA8GF; 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)
DM9Y3B5 CP Chimerix
DM9Y3B5 DT Small molecular drug
DM9Y3B5 PC 483477
DM9Y3B5 MW 561.7
DM9Y3B5 FM C27H52N3O7P
DM9Y3B5 IC InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
DM9Y3B5 CS CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O
DM9Y3B5 IK WXJFKKQWPMNTIM-VWLOTQADSA-N
DM9Y3B5 IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
DM9Y3B5 CA CAS 444805-28-1
DM9Y3B5 DE Solid tumour/cancer
DMB4JPG ID DMB4JPG
DMB4JPG DN CNTX-4975
DMB4JPG HS Phase 3
DMB4JPG CP Centrexion Therapeutics Boston, MA
DMB4JPG DE Pain; Morton neuroma; Knee osteoarthritis
DMWZ2TU ID DMWZ2TU
DMWZ2TU DN CO-1686
DMWZ2TU HS Phase 3
DMWZ2TU SN 1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284
DMWZ2TU CP Clovis Oncology
DMWZ2TU DT Small molecular drug
DMWZ2TU PC 57335384
DMWZ2TU MW 555.6
DMWZ2TU FM C27H28F3N7O3
DMWZ2TU IC InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)
DMWZ2TU CS CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC
DMWZ2TU IK HUFOZJXAKZVRNJ-UHFFFAOYSA-N
DMWZ2TU IU N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMWZ2TU CA CAS 1374640-70-6
DMWZ2TU DE Lung cancer; Non-small-cell lung cancer
DMN9ETB ID DMN9ETB
DMN9ETB DN Contusugene ladenovec
DMN9ETB HS Phase 3
DMN9ETB SN Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
DMN9ETB CP Introgen Therapeutics
DMN9ETB DE Oral cancer; Liver metastasis
DMA0WEK ID DMA0WEK
DMA0WEK DN Coprexa
DMA0WEK HS Phase 3
DMA0WEK SN Tetrathiomolybdate
DMA0WEK CP Pipex Pharmaceuticals
DMA0WEK DT Small molecular drug
DMA0WEK PC 5245480
DMA0WEK MW 226.2
DMA0WEK FM H2MoS4-2
DMA0WEK IC InChI=1S/Mo.2H2S.2S/h;2*1H2;;/p-2
DMA0WEK CS [SH-].[SH-].S=[Mo]=S
DMA0WEK IK VVRHUOPINLMZBL-UHFFFAOYSA-L
DMA0WEK IU bis(sulfanylidene)molybdenum;sulfanide
DMA0WEK CA CAS 16330-92-0
DMA0WEK CB CHEBI:30703
DMA0WEK DE Neurological disorder
DMBS3UG ID DMBS3UG
DMBS3UG DN CORT-125134
DMBS3UG HS Phase 3
DMBS3UG SN relacorilant; Relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui
DMBS3UG CP Corcept TherapeuticsMenlo Park, CA
DMBS3UG PC 73051463
DMBS3UG MW 586.6
DMBS3UG FM C27H22F4N6O3S
DMBS3UG IC InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
DMBS3UG CS CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMBS3UG IK WANIDIGFXJFFEL-SANMLTNESA-N
DMBS3UG IU [(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMBS3UG CA CAS 1496510-51-0
DMBS3UG DE Alcohol dependence; Solid tumour/cancer; Cushing disease
DMMEAOL ID DMMEAOL
DMMEAOL DN Coversin
DMMEAOL HS Phase 3
DMMEAOL CP Akari Therapeutics
DMMEAOL DT Recombinant?protein
DMMEAOL DE Paroxysmal nocturnal haemoglobinuria
DMZIM37 ID DMZIM37
DMZIM37 DN CP-868596
DMZIM37 HS Phase 3
DMZIM37 SN Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37 CP Pfizer
DMZIM37 TC Anticancer Agents
DMZIM37 DT Small molecular drug
DMZIM37 PC 10366136
DMZIM37 MW 443.5
DMZIM37 FM C26H29N5O2
DMZIM37 IC InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3
DMZIM37 CS CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
DMZIM37 IK DYNHJHQFHQTFTP-UHFFFAOYSA-N
DMZIM37 IU 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37 CA CAS 670220-88-9
DMZIM37 CB CHEBI:145365
DMZIM37 DE Gastrointestinal cancer; Acute myelogenous leukaemia; Malignant glioma; Acute myeloid leukaemia; Gastrointestinal stromal tumour
DM2EO5M ID DM2EO5M
DM2EO5M DN CPC-211
DM2EO5M HS Phase 3
DM2EO5M SN Dichloracetate; Dichloroacetate; Dichloroacetate ion; Dichloroacetic acid ion(1-); LS-11597; STL483470; 13425-80-4; 2,2-bis(chloranyl)ethanoate; 2,2-dichloroacetate; 2q8h; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; ACETIC ACID, DICHLORO-, ION(1-); Acetic acid,2,2-dichloro-, ion(1-); BRN 3903873; CHEBI:28240; CTK4B9070; DCA; DTXSID40158610; GTPL4518; NCGC00241105-01
DM2EO5M PC 25975
DM2EO5M MW 127.93
DM2EO5M FM C2HCl2O2-
DM2EO5M IC JXTHNDFMNIQAHM-UHFFFAOYSA-M
DM2EO5M CS C(C(=O)[O-])(Cl)Cl
DM2EO5M IK 1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DM2EO5M IU 2,2-dichloroacetate
DM2EO5M CA CAS 13425-80-4
DM2EO5M CB CHEBI:28240
DM2EO5M DE Dehydrogenase PDC deficiency
DMPXOYJ ID DMPXOYJ
DMPXOYJ DN CPI-0610
DMPXOYJ HS Phase 3
DMPXOYJ CP Constellation pharmaceuticals
DMPXOYJ PC 57389999
DMPXOYJ MW 365.8
DMPXOYJ FM C20H16ClN3O2
DMPXOYJ IC InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
DMPXOYJ CS CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl
DMPXOYJ IK GCWIQUVXWZWCLE-INIZCTEOSA-N
DMPXOYJ IU 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide
DMPXOYJ CA CAS 1380087-89-7
DMPXOYJ DE Acute myeloid leukaemia; Myelodysplastic neoplasm; Myeloproliferative neoplasm; Myelofibrosis
DM5XUQL ID DM5XUQL
DM5XUQL DN CPI-613
DM5XUQL HS Phase 3
DM5XUQL SN CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
DM5XUQL CP Cornerstone Pharmaceuticals
DM5XUQL DT Small molecular drug
DM5XUQL PC 24770514
DM5XUQL MW 388.6
DM5XUQL FM C22H28O2S2
DM5XUQL IC InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
DM5XUQL CS C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
DM5XUQL IK ZYRLHJIMTROTBO-UHFFFAOYSA-N
DM5XUQL IU 6,8-bis(benzylsulfanyl)octanoic acid
DM5XUQL CA CAS 95809-78-2
DM5XUQL DE Acute myeloid leukaemia; Myelodysplastic syndrome; B-cell lymphoma; Metastatic colorectal cancer; Recurrent adult burkitt lymphoma; T-cell lymphoma; Pancreatic cancer
DM62E7C ID DM62E7C
DM62E7C DN CPL-7075
DM62E7C HS Phase 3
DM62E7C SN Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo
DM62E7C CP Cervelo Pharmaceuticals Ltd
DM62E7C DT Small molecular drug
DM62E7C PC 3083542
DM62E7C MW 400.5
DM62E7C FM C25H36O4
DM62E7C IC InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
DM62E7C CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C(=O)O)O
DM62E7C IK YCHYFHOSGQABSW-RTBURBONSA-N
DM62E7C IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
DM62E7C CA CAS 137945-48-3
DM62E7C DE Cystic fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis; Diffuse systemic sclerosis
DM60TVK ID DM60TVK
DM60TVK DN CQA 206-291
DM60TVK HS Phase 3
DM60TVK SN Cqa 206-291; Cqa-206-291; 93822-42-5; UNII-9I4I0M95U7; 9I4I0M95U7; N,N-Diethyl-N-(1-ethyl-6-methylergoline-8-yl)sulfamide; AC1L3TWB; SCHEMBL8195741; Sulfamide, N,N-diethyl-N'-((8alpha)-1-ethyl-6-methylergolin-8-yl)-
DM60TVK DT Small molecular drug
DM60TVK PC 9953076
DM60TVK MW 404.6
DM60TVK FM C21H32N4O2S
DM60TVK IC InChI=1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18+,20+/m0/s1
DM60TVK CS CCN1C=C2C[C@@H]3[C@H](C[C@@H](CN3C)NS(=O)(=O)N(CC)CC)C4=C2C1=CC=C4
DM60TVK IK ARTRTLXKTHJPRW-ILZDJORESA-N
DM60TVK IU (6aR,9S,10aR)-9-(diethylsulfamoylamino)-4-ethyl-7-methyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
DM60TVK CA CAS 93822-42-5
DM60TVK DE Parkinson disease
DMKD2BQ ID DMKD2BQ
DMKD2BQ DN Creatine ALS-08
DMKD2BQ HS Phase 3
DMKD2BQ SN Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena
DMKD2BQ CP Avicena Group Inc; Avicena
DMKD2BQ DT Small molecular drug
DMKD2BQ PC 586
DMKD2BQ MW 131.13
DMKD2BQ FM C4H9N3O2
DMKD2BQ IC InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)
DMKD2BQ CS CN(CC(=O)O)C(=N)N
DMKD2BQ IK CVSVTCORWBXHQV-UHFFFAOYSA-N
DMKD2BQ IU 2-[carbamimidoyl(methyl)amino]acetic acid
DMKD2BQ CA CAS 57-00-1
DMKD2BQ CB CHEBI:16919
DMKD2BQ DE Motor neurone disease
DM7QI29 ID DM7QI29
DM7QI29 DN Crenezumab
DM7QI29 HS Phase 3
DM7QI29 SN MABT5102A; RG7412
DM7QI29 CP Genentech
DM7QI29 DT Monoclonal antibody
DM7QI29 DE Alzheimer disease
DM5F24X ID DM5F24X
DM5F24X DN Crocin
DM5F24X HS Phase 3
DM5F24X DE Knee osteoarthritis
DM67P0F ID DM67P0F
DM67P0F DN CS-038
DM67P0F HS Phase 3
DM67P0F SN Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences
DM67P0F CP Shenzhen Chipscreen Biosciences Ltd
DM67P0F DT Small molecular drug
DM67P0F PC 71402018
DM67P0F MW 572.6
DM67P0F FM C36H29FN2O4
DM67P0F IC InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
DM67P0F CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
DM67P0F IK QNLWMPLUWMWDMQ-YTTGMZPUSA-N
DM67P0F IU (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid
DM67P0F CA CAS 743438-45-1
DM67P0F DE Type-2 diabetes
DMSY0NE ID DMSY0NE
DMSY0NE DN CS1001
DMSY0NE HS Phase 3
DMSY0NE CP CStone Pharmaceuticals
DMSY0NE DT Antibody
DMSY0NE DE Non-small cell lung cancer
DM1PV4Y ID DM1PV4Y
DM1PV4Y DN CS-600G
DM1PV4Y HS Phase 3
DM1PV4Y SN Koloxo; Loxoprofen; Loxoprofen (INN); Loxoprofen [INN]; Loxoprofen sodium hydrate; Loxoprofene; Loxoprofene [French]; Loxoprofeno; Loxoprofeno [Spanish]; Loxoprofenum; Loxoprofenum [Latin]; YMBXTVYHTMGZDW-UHFFFAOYSA-N; sodium loxoprofen; yl]-propionic acid; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; 68767-14-6; CHEBI:76172; CHEMBL19299; CS-600; MFCD00864331; Oxeno
DM1PV4Y PC 3965
DM1PV4Y MW 246.3
DM1PV4Y FM C15H18O3
DM1PV4Y IC YMBXTVYHTMGZDW-UHFFFAOYSA-N
DM1PV4Y CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DM1PV4Y IK 1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DM1PV4Y IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DM1PV4Y CA CAS 68767-14-6
DM1PV4Y CB CHEBI:76172
DM1PV4Y DE Epilepsy
DM4CSDH ID DM4CSDH
DM4CSDH DN CS-8958
DM4CSDH HS Phase 3
DM4CSDH SN Inavir; Laninamivir octanoate; R-118958
DM4CSDH CP Biota
DM4CSDH DT Small molecular drug
DM4CSDH PC 9847629
DM4CSDH MW 472.5
DM4CSDH FM C21H36N4O8
DM4CSDH IC InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1
DM4CSDH CS CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O
DM4CSDH IK UKTIJASCFRNWCB-RMIBSVFLSA-N
DM4CSDH IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4CSDH CA CAS 203120-46-1
DM4CSDH CB CHEBI:134741
DM4CSDH DE Influenza virus infection
DMV574J ID DMV574J
DMV574J DN CSL312
DMV574J HS Phase 3
DMV574J SN Garadacimab
DMV574J CP CSL Behring
DMV574J DT Antibody
DMV574J DE Hereditary angioedema
DMZJGVL ID DMZJGVL
DMZJGVL DN CSL-654
DMZJGVL HS Phase 3
DMZJGVL SN RIX-FP; Recombinant coagulation factor IX (iv, hemophilia B), CSL Behring; Recombinant coagulation factor IX (extended half-life, hemophilia B), CSL Behring
DMZJGVL CP Csl behring
DMZJGVL SQ DB00100 sequence: YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
DMZJGVL DE Factor IX deficiency
DMU2ZFK ID DMU2ZFK
DMU2ZFK DN CT-2584
DMU2ZFK HS Phase 3
DMU2ZFK SN Apra (Cell Therapeutics, US, US); 1-[11-(Dodecylamino)-10-hydroxyundecyl]-3,7-dimethylxanthine
DMU2ZFK CP Cell Therapeutics
DMU2ZFK DT Small molecular drug
DMU2ZFK PC 3081346
DMU2ZFK MW 533.8
DMU2ZFK FM C30H55N5O3
DMU2ZFK IC InChI=1S/C30H55N5O3/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38/h25-26,31,36H,4-24H2,1-3H3
DMU2ZFK CS CCCCCCCCCCCCNCC(CCCCCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMU2ZFK IK MZNMZWZGUGFQJP-UHFFFAOYSA-N
DMU2ZFK IU 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione
DMU2ZFK CA CAS 166981-13-1
DMU2ZFK DE Solid tumour/cancer
DMQPH29 ID DMQPH29
DMQPH29 DN Curcumin
DMQPH29 HS Phase 3
DMQPH29 SN curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
DMQPH29 DT Small molecular drug
DMQPH29 PC 969516
DMQPH29 MW 368.4
DMQPH29 FM C21H20O6
DMQPH29 IC InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
DMQPH29 CS COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
DMQPH29 IK VFLDPWHFBUODDF-FCXRPNKRSA-N
DMQPH29 IU (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
DMQPH29 CA CAS 458-37-7
DMQPH29 CB CHEBI:3962
DMQPH29 DE Solid tumour/cancer
DMIQ31Y ID DMIQ31Y
DMIQ31Y DN Custirsen
DMIQ31Y HS Phase 3
DMIQ31Y SN OGX-001/TV-1011; OGX-011
DMIQ31Y CP OncoGenex Pharmaceuticals
DMIQ31Y DT Small molecular drug
DMIQ31Y PC 72941942
DMIQ31Y MW 7346
DMIQ31Y FM C231H312N78O119P20S20
DMIQ31Y IC InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1
DMIQ31Y CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O)S
DMIQ31Y IK RCFZILUHCNXXFY-DEDWCYLFSA-N
DMIQ31Y IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMIQ31Y CA CAS 890056-27-6
DMIQ31Y DE Lung cancer; Breast cancer; Prostate cancer
DM0JA9N ID DM0JA9N
DM0JA9N DN Cyrtominetin
DM0JA9N HS Phase 3
DM0JA9N SN IdB-1031; D,L-5,7,3',4'-Tetrahydroxy-6,8-dimethylflavanone; Rac-5,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-6,8-dimethyl-2,3-dihydro-4H-1-benzopyran-4-one
DM0JA9N DT Small molecular drug
DM0JA9N PC 125309
DM0JA9N MW 316.3
DM0JA9N FM C17H16O6
DM0JA9N IC InChI=1S/C17H16O6/c1-7-15(21)8(2)17-14(16(7)22)12(20)6-13(23-17)9-3-4-10(18)11(19)5-9/h3-5,13,18-19,21-22H,6H2,1-2H3
DM0JA9N CS CC1=C(C(=C2C(=C1O)C(=O)CC(O2)C3=CC(=C(C=C3)O)O)C)O
DM0JA9N IK AESMRHCYHARBLU-UHFFFAOYSA-N
DM0JA9N IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydrochromen-4-one
DM0JA9N CA CAS 95272-99-4
DM0JA9N DE Phlegmy cough
DMUF0BJ ID DMUF0BJ
DMUF0BJ DN CYTISINE
DMUF0BJ HS Phase 3
DMUF0BJ SN CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98%
DMUF0BJ DT Small molecular drug
DMUF0BJ PC 10235
DMUF0BJ MW 190.24
DMUF0BJ FM C11H14N2O
DMUF0BJ IC InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1
DMUF0BJ CS C1[C@H]2CNC[C@@H]1C3=CC=CC(=O)N3C2
DMUF0BJ IK ANJTVLIZGCUXLD-DTWKUNHWSA-N
DMUF0BJ IU (1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
DMUF0BJ CA CAS 485-35-8
DMUF0BJ CB CHEBI:4055
DMUF0BJ DE Tobacco dependence
DMYJ2QB ID DMYJ2QB
DMYJ2QB DN D2A21
DMYJ2QB HS Phase 3
DMYJ2QB SN Demegel (Demegen, US, US); Alanyl-L-phenylalanyl-L-alanyl-L-phenylalanine
DMYJ2QB PC 16199213
DMYJ2QB MW 2775.4
DMYJ2QB FM C144H212N32O24
DMYJ2QB IC InChI=1S/C144H212N32O24/c1-91(155-128(183)105(154)83-97-49-15-7-16-50-97)122(177)161-106(65-31-40-74-145)129(184)165-111(70-36-45-79-150)134(189)172-117(86-100-55-21-10-22-56-100)139(194)156-93(3)124(179)163-108(67-33-42-76-147)131(186)167-114(73-39-48-82-153)137(192)175-120(89-103-61-27-13-28-62-103)143(198)169-110(69-35-44-78-149)132(187)168-113(72-38-47-81-152)136(191)174-119(88-102-59-25-12-26-60-102)140(195)157-92(2)123(178)162-107(66-32-41-75-146)130(185)166-112(71-37-46-80-151)135(190)173-118(87-101-57-23-11-24-58-101)141(196)158-94(4)125(180)164-109(68-34-43-77-148)133(188)171-116(85-99-53-19-9-20-54-99)142(197)159-95(5)126(181)170-115(84-98-51-17-8-18-52-98)138(193)160-96(6)127(182)176-121(144(199)200)90-104-63-29-14-30-64-104/h7-30,49-64,91-96,105-121H,31-48,65-90,145-154H2,1-6H3,(H,155,183)(H,156,194)(H,157,195)(H,158,196)(H,159,197)(H,160,193)(H,161,177)(H,162,178)(H,163,179)(H,164,180)(H,165,184)(H,166,185)(H,167,186)(H,168,187)(H,169,198)(H,170,181)(H,171,188)(H,172,189)(H,173,190)(H,174,191)(H,175,192)(H,176,182)(H,199,200)/t91-,92-,93-,94-,95-,96-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-/m0/s1
DMYJ2QB CS C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](C)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)O)NC(=O)[C@H](CC8=CC=CC=C8)N
DMYJ2QB IK WVRNJUBRGDUHNI-CPOCOYSOSA-N
DMYJ2QB IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoic acid
DMYJ2QB DE Burn and burn infection
DM9FAJM ID DM9FAJM
DM9FAJM DN D-5519
DM9FAJM HS Phase 3
DM9FAJM DE Asthma
DM6S4R2 ID DM6S4R2
DM6S4R2 DN DA-3031
DM6S4R2 HS Phase 3
DM6S4R2 SN Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A
DM6S4R2 CP Dong-A Pharmaceutical Co Ltd
DM6S4R2 DT Small molecular drug
DM6S4R2 PC 168302
DM6S4R2 MW 185.26
DM6S4R2 FM C10H19NO2
DM6S4R2 IC InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
DM6S4R2 CS CC(=C)C(=O)OCCN(C)C.C=C
DM6S4R2 IK PNMYDOBPCBCQIA-UHFFFAOYSA-N
DM6S4R2 IU 2-(dimethylamino)ethyl 2-methylprop-2-enoate;ethene
DM6S4R2 CA CAS 25134-54-7
DM6S4R2 DE Neutropenia
DMP2SGN ID DMP2SGN
DMP2SGN DN Dabelotine
DMP2SGN HS Phase 3
DMP2SGN SN Dabelotine mesilate; S-12024; S-12024-2
DMP2SGN CP Servier
DMP2SGN DT Small molecular drug
DMP2SGN PC 177949
DMP2SGN MW 262.35
DMP2SGN FM C15H22N2O2
DMP2SGN IC InChI=1S/C15H22N2O2/c1-17-8-3-5-12-4-2-6-14(15(12)17)19-11-13-10-16-7-9-18-13/h2,4,6,13,16H,3,5,7-11H2,1H3
DMP2SGN CS CN1CCCC2=C1C(=CC=C2)OCC3CNCCO3
DMP2SGN IK VXQWMLATWQSCBE-UHFFFAOYSA-N
DMP2SGN IU 2-[(1-methyl-3,4-dihydro-2H-quinolin-8-yl)oxymethyl]morpholine
DMP2SGN CA CAS 118976-38-8
DMP2SGN DE Cognitive impairment
DMRDZ4X ID DMRDZ4X
DMRDZ4X DN Dabigatran etexilate
DMRDZ4X HS Phase 3
DMRDZ4X SN BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
DMRDZ4X CP Boehringer Ingelheim Ridgefield, CT
DMRDZ4X PC 135565674
DMRDZ4X MW 627.7
DMRDZ4X FM C34H41N7O5
DMRDZ4X IC InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
DMRDZ4X CS CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4
DMRDZ4X IK KSGXQBZTULBEEQ-UHFFFAOYSA-N
DMRDZ4X IU ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
DMRDZ4X CA CAS 211915-06-9
DMRDZ4X DE Venous thromboembolism
DMKNCVM ID DMKNCVM
DMKNCVM DN Dalcetrapib
DMKNCVM HS Phase 3
DMKNCVM SN JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM CP Roche
DMKNCVM DT Small molecular drug
DMKNCVM PC 6918540
DMKNCVM MW 389.6
DMKNCVM FM C23H35NO2S
DMKNCVM IC InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
DMKNCVM CS CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
DMKNCVM IK YZQLWPMZQVHJED-UHFFFAOYSA-N
DMKNCVM IU S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM CA CAS 211513-37-0
DMKNCVM CB CHEBI:95001
DMKNCVM DE Hyperlipidaemia; Acute coronary syndrome
DM1C95G ID DM1C95G
DM1C95G DN DARE-BV1
DM1C95G HS Phase 3
DM1C95G CP Dare Bioscience
DM1C95G DT Small molecular drug
DM1C95G DE Bacterial vaginosis
DMR2JD4 ID DMR2JD4
DMR2JD4 DN Darotropium + 642444
DMR2JD4 HS Phase 3
DMR2JD4 CP GSK
DMR2JD4 DT Combination drug
DMR2JD4 PC 25195533; 642444
DMR2JD4 DE Chronic obstructive pulmonary disease
DM2FV5N ID DM2FV5N
DM2FV5N DN Darunavir + cobicistat
DM2FV5N HS Phase 3
DM2FV5N SN Prezcobix; Prezista + GS-9350
DM2FV5N TC Antiviral Agents
DM2FV5N DT Combination drug
DM2FV5N DE Coronavirus Disease 2019 (COVID-19)
DMF3V01 ID DMF3V01
DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01 HS Phase 3
DMF3V01 SN Prezista + norvir + T-705 + oxichloroquine
DMF3V01 TC Antiviral Agents
DMF3V01 DT Combination drug
DMF3V01 DE Coronavirus Disease 2019 (COVID-19)
DMN9BO3 ID DMN9BO3
DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3 HS Phase 3
DMN9BO3 SN Prezista + norvir + rseltamivir + oxichloroquine
DMN9BO3 TC Antiviral Agents
DMN9BO3 DT Combination drug
DMN9BO3 DE Coronavirus Disease 2019 (COVID-19)
DMN8DQH ID DMN8DQH
DMN8DQH DN Darusentan
DMN8DQH HS Phase 3
DMN8DQH SN Endothelin antagonist, BASF; HMR-4005; LU-127043; LU-135252
DMN8DQH CP Gilead Sciences; Knoll GmbH
DMN8DQH DT Small molecular drug
DMN8DQH PC 177236
DMN8DQH MW 410.4
DMN8DQH FM C22H22N2O6
DMN8DQH IC InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMN8DQH CS COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
DMN8DQH IK FEJVSJIALLTFRP-LJQANCHMSA-N
DMN8DQH IU (2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMN8DQH CA CAS 171714-84-4
DMN8DQH DE Hypotension
DMD7K9X ID DMD7K9X
DMD7K9X DN Davunetide
DMD7K9X HS Phase 3
DMD7K9X SN Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
DMD7K9X CP Allon Therapeutics Inc
DMD7K9X DE Cognitive impairment; Alzheimer disease
DMUX7Z8 ID DMUX7Z8
DMUX7Z8 DN DE-117
DMUX7Z8 HS Phase 3
DMUX7Z8 PC 44230999
DMUX7Z8 MW 520.6
DMUX7Z8 FM C26H28N6O4S
DMUX7Z8 IC InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
DMUX7Z8 CS CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4
DMUX7Z8 IK VIQCWEGEHRBLAC-UHFFFAOYSA-N
DMUX7Z8 IU propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
DMUX7Z8 CA CAS 1187451-19-9
DMUX7Z8 DE Glaucoma/ocular hypertension
DM0GUV2 ID DM0GUV2
DM0GUV2 DN DE-766
DM0GUV2 HS Phase 3
DM0GUV2 CP Daiichi Sankyo
DM0GUV2 DE Non-small-cell lung cancer; Gastric adenocarcinoma; Nasopharyngeal carcinoma
DM2R15Q ID DM2R15Q
DM2R15Q DN DENBUFYLLINE
DM2R15Q HS Phase 3
DM2R15Q SN denbufylline; 57076-71-8; Denbufyllinum [Latin]; Denbufilina [Spanish]; BRL 30892; BRL-30892; UNII-04B949KO6F; 1,3-Di-n-butyl-7-(2-oxopropyl)xanthine; CHEMBL277465; 7-Acetonyl-1,3-dibutylxanthine; C16H24N4O3; 04B949KO6F; 3,7-Dihydro-1,3-dibutyl-7-(2-oxopropyl)-1H-purine-2,6-dione; 1,3-Di-n-butyl-7-(2& -oxopropyl)xanthine; Denbufyllinum; Denbufilina; 1H-Purine-2,6-dione,1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-; Denbufylline [INN:BAN]; Denbufylline [BAN:INN
DM2R15Q DT Small molecular drug
DM2R15Q PC 2984
DM2R15Q MW 320.39
DM2R15Q FM C16H24N4O3
DM2R15Q IC InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3
DM2R15Q CS CCCCN1C2=C(C(=O)N(C1=O)CCCC)N(C=N2)CC(=O)C
DM2R15Q IK HJPRDDKCXVCFOH-UHFFFAOYSA-N
DM2R15Q IU 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione
DM2R15Q CA CAS 57076-71-8
DM2R15Q CB CHEBI:92669
DM2R15Q DE Cognitive impairment
DM2ATZB ID DM2ATZB
DM2ATZB DN Deoxynojirimycin
DM2ATZB HS Phase 3
DM2ATZB SN 1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; deoxynojirimycin; Moranoline; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; UNII-FZ56898FLE; D-1-deoxynojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; CHEMBL307429; C6H13NO4; FZ56898FLE; CHEBI:44369; 1-Deoxy-Nojirimycin; 5-Amino-1,5-dideoxy-D-glucopyranose; DNJ; AK151410; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-
DM2ATZB DT Small molecular drug
DM2ATZB PC 29435
DM2ATZB MW 163.17
DM2ATZB FM C6H13NO4
DM2ATZB IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1
DM2ATZB CS C1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O
DM2ATZB IK LXBIFEVIBLOUGU-JGWLITMVSA-N
DM2ATZB IU (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DM2ATZB CA CAS 19130-96-2
DM2ATZB CB CHEBI:44369
DM2ATZB DE Pompe disease
DMDLU4Z ID DMDLU4Z
DMDLU4Z DN Desmoteplase
DMDLU4Z HS Phase 3
DMDLU4Z CP Lundbeck Research
DMDLU4Z SQ P98119|URT1_DESRO Salivary plasminogen activator alpha 1 precursor - Desmodus rotundus: MVNTMKTKLLCVLLLCGAVFSLPRQETYRQLARGSRAYGVACKDEITQMTYRRQESWLRPEVRSKRVEHCQCDRGQARCHTVPVNSCSEPRCFNGGTCWQAVYFSDFVCQCPAGYTGKRCEVDTRATCYEGQGVTYRGTWSTAESRVECINWNSSLLTRRTYNGRMPDAFNLGLGNHNYCRNPNGAPKPWCYVIKAGKFTSESCSVPVCSKATCGLRKYKEPQLHSTGGLFTDITSHPWQAAIFAQNRRSSGERFLCGGILISSCWVLTAAHCFQESYLPDQLKVVLGRTYRVKPGEEEQTFKVKKYIVHKEFDDDTYNNDIALLQLKSDSPQCAQESDSVRAICLPEANLQLPDWTECELSGYGKHKSSSPFYSEQLKEGHVRLYPSSRCAPKFLFNKTVTNNMLCAGDTRSGEIYPNVHDACQGDSGGPLVCMNDNHMTLLGIISWGVGCGEKDVPGVYTKVTNYLGWIRDNMHL
DMDLU4Z DE Ischemic stroke
DMRH291 ID DMRH291
DMRH291 DN Dexanabinol
DMRH291 HS Phase 3
DMRH291 SN Sinnabidiol; HU 211; HU-211; PRS 211007-000; (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; 1,1-Dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; 11-Hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-Hydroxy-delta-8-dmh-thc; 11-Hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-OH-delta(8)-Thc-dmh; 5'(1,1-Dimethylheptyl)-7-hydroxyhexahydrocannabinol; 7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl
DMRH291 CP Pharmos
DMRH291 DT Small molecular drug
DMRH291 PC 107778
DMRH291 MW 386.6
DMRH291 FM C25H38O3
DMRH291 IC InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1
DMRH291 CS CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O
DMRH291 IK SSQJFGMEZBFMNV-PMACEKPBSA-N
DMRH291 IU (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMRH291 CA CAS 112924-45-5
DMRH291 DE Traumatic brain injury
DM1WNGJ ID DM1WNGJ
DM1WNGJ DN DFP-10917
DM1WNGJ HS Phase 3
DM1WNGJ CP Delta-Fly Pharma
DM1WNGJ DT Small molecular drug
DM1WNGJ PC 119184
DM1WNGJ MW 252.23
DM1WNGJ FM C10H12N4O4
DM1WNGJ IC InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
DM1WNGJ CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
DM1WNGJ IK DCYBPMFXJCWXNB-JWIUVKOKSA-N
DM1WNGJ IU (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
DM1WNGJ CA CAS 135598-68-4
DM1WNGJ CB CHEBI:145435
DM1WNGJ DE Acute lymphoblastic leukaemia; Solid tumour/cancer; Acute myeloid leukaemia
DMOUGX1 ID DMOUGX1
DMOUGX1 DN Diamyd
DMOUGX1 HS Phase 3
DMOUGX1 SN Oramyd; Human glutamate decarboxylase 65 kDa isoform; RhGAD-65; GAD65 (diabetes), Biosyn; GAD65 (diabetes), Diamyd; GAD65 (diabetes), OMJPI; GAD65 antigen-based therapy (diabetes), Johnson and Johnson; GAD65 (diabetes), Ortho-McNeil-Janssen Pharmaceuticals
DMOUGX1 CP Diamyd medical
DMOUGX1 DE Type-1 diabetes
DM4XBM7 ID DM4XBM7
DM4XBM7 DN DiaPep-277
DM4XBM7 HS Phase 3
DM4XBM7 SN Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor
DM4XBM7 CP Andromeda biotech
DM4XBM7 DT Small molecular drug
DM4XBM7 PC 16138701
DM4XBM7 MW 2390.7
DM4XBM7 FM C106H180N28O34
DM4XBM7 IC InChI=1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1
DM4XBM7 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N
DM4XBM7 IK VGGRNGOEDNBLPH-YJHCMWSWSA-N
DM4XBM7 IU (2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid
DM4XBM7 CA CAS 179822-83-4
DM4XBM7 DE Autoimmune diabetes
DMHZBEO ID DMHZBEO
DMHZBEO DN Difelikefalin
DMHZBEO HS Phase 3
DMHZBEO SN UNII-NA1U919MRO; NA1U919MRO; MR13A9; 1024828-77-0; FE202845; Difelikefalin [INN]; Difelikefalin [USAN:INN]; SEQ ID NO: 2; GTPL9044; CHEMBL3989915; SCHEMBL10316464; BDBM235785; DB11938; FE-202845; US9359399, 2; D-Phe-D-Phe-D-Leu-D-Lys-[gamma-(4-N-piperidinyl)amino carboxylic acid]; 4-Piperidinecarboylic acid, 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-; 4-Piperidinecarboxylic acid, N1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-amino-; 4-Piperidinecarboxylic acid, N1-(D
DMHZBEO CP Cara Therapeutics Stamford, CT
DMHZBEO PC 24794466
DMHZBEO MW 679.8
DMHZBEO FM C36H53N7O6
DMHZBEO IC InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1
DMHZBEO CS CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMHZBEO IK FWMNVWWHGCHHJJ-SKKKGAJSSA-N
DMHZBEO IU 4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid
DMHZBEO CA CAS 1024828-77-0
DMHZBEO DE Pruritus
DMU4T9Y ID DMU4T9Y
DMU4T9Y DN Dimesna
DMU4T9Y HS Phase 3
DMU4T9Y SN Tavocept (TN)
DMU4T9Y CP BioNumerik Pharmaceuticals
DMU4T9Y DT Small molecular drug
DMU4T9Y PC 65625
DMU4T9Y MW 326.4
DMU4T9Y FM C4H8Na2O6S4
DMU4T9Y IC InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2
DMU4T9Y CS C(CS(=O)(=O)[O-])SSCCS(=O)(=O)[O-].[Na+].[Na+]
DMU4T9Y IK KQYGMURBTJPBPQ-UHFFFAOYSA-L
DMU4T9Y IU disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate
DMU4T9Y CA CAS 16208-51-8
DMU4T9Y DE Diabetic nephropathy; Lung cancer
DM19CFZ ID DM19CFZ
DM19CFZ DN DIMS-0150
DM19CFZ HS Phase 3
DM19CFZ SN Kappaproct; Antisense NF-kBp65 oligonucleotide (IBD), InDex Pharmaceuticals; Antisense NF-kBp65 oligonucleotide (IBD), Serono; Antisense NF-kBp65 oligonucleotide (inflammatory bowel disease), Serono
DM19CFZ CP Karolinska Institute
DM19CFZ DT Antisense drug
DM19CFZ DE Ulcerative colitis
DMG8U6M ID DMG8U6M
DMG8U6M DN DIPROTEVERINE HYDROCHLORIDE
DMG8U6M HS Phase 3
DMG8U6M SN UNII-T587ZFV6UM; T587ZFV6UM; Isoquinoline, 3,4-dihydro-6,7-bis(1-methylethoxy)-1-((3,4-diethoxyphenyl)methyl)-, hydrochloride; 69373-88-2; 1-(3',4'-Diethoxybenzyl)-6,7-diisoprooxy-3,4-dihydroisoquinoline hydrochloride; DIPROTEVERINE HYDROCHLORIDE; AC1MHK6D; SCHEMBL7313181; DTXSID30219461; AWQPJKUSDUHYIX-UHFFFAOYSA-N; 69373-95-1 (Parent); LS-85505; 1-(3'4'-diethoxybenzyl)-6,7-diisopropoxy-3,4-dihydroisoquinoline hydrochloride; 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline hydrochloride
DMG8U6M DT Small molecular drug
DMG8U6M PC 3052867
DMG8U6M MW 462
DMG8U6M FM C26H36ClNO4
DMG8U6M IC InChI=1S/C26H35NO4.ClH/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22;/h9-10,14-18H,7-8,11-13H2,1-6H3;1H
DMG8U6M CS CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC(C)C)OC(C)C)OCC.Cl
DMG8U6M IK AWQPJKUSDUHYIX-UHFFFAOYSA-N
DMG8U6M IU 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline;hydrochloride
DMG8U6M CA CAS 69373-88-2
DMG8U6M DE Angina pectoris
DM64QG9 ID DM64QG9
DM64QG9 DN Diquafosol
DM64QG9 HS Phase 3
DM64QG9 SN UppppU; Diquafosol [INN]; KPY 998; Diquafosol [INN:BAN]; INS-365; P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate; P1,P4-Bis(5'-uridyl) tetraphosphate; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9 CP Santen Pharmaceutical
DM64QG9 DT Small molecular drug
DM64QG9 PC 148197
DM64QG9 MW 790.3
DM64QG9 FM C18H26N4O23P4
DM64QG9 IC InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
DM64QG9 CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DM64QG9 IK NMLMACJWHPHKGR-NCOIDOBVSA-N
DM64QG9 IU [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9 CA CAS 59985-21-6
DM64QG9 CB CHEBI:27791
DM64QG9 DE Dry eye disease
DMJS8V3 ID DMJS8V3
DMJS8V3 DN Disufenton sodium
DMJS8V3 HS Phase 3
DMJS8V3 SN Cerovive; ARL-16556; CPI-22; CXY-059; HPN-07; NXY-059; NXY-059G; OKN-007; S-PBN; Nitrones (cancer), Oklahoma Medical Research Foundation; Nitrones, Renovis/AstraZeneca; PBN derivatives, Renovis/AstraZeneca; Spin trap agents, Renovis/AstraZeneca
DMJS8V3 CP AstraZeneca
DMJS8V3 DT Small molecular drug
DMJS8V3 PC 6440181
DMJS8V3 MW 381.3
DMJS8V3 FM C11H13NNa2O7S2
DMJS8V3 IC InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;
DMJS8V3 CS CC(C)(C)/[N+](=C/C1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])/[O-].[Na+].[Na+]
DMJS8V3 IK XLZOVRYBVCMCGL-BPNVQINPSA-L
DMJS8V3 IU disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate
DMJS8V3 DE Ischemia; Recurrent glioblastoma
DMMKGBP ID DMMKGBP
DMMKGBP DN D-Methionine
DMMKGBP HS Phase 3
DMMKGBP SN D-Methionine-(methyl-13C); D-Methionine-(methyl-13C), 99 atom % 13C
DMMKGBP DT Small molecular drug
DMMKGBP PC 84815
DMMKGBP MW 149.21
DMMKGBP FM C5H11NO2S
DMMKGBP IC InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DMMKGBP CS CSCC[C@H](C(=O)O)N
DMMKGBP IK FFEARJCKVFRZRR-SCSAIBSYSA-N
DMMKGBP IU (2R)-2-amino-4-methylsulfanylbutanoic acid
DMMKGBP CA CAS 348-67-4
DMMKGBP CB CHEBI:16867
DMO7BQS ID DMO7BQS
DMO7BQS DN DMP-444
DMO7BQS HS Phase 3
DMO7BQS CP Bristol-Myers Squibb Pharma Co
DMO7BQS DE Coronary artery disease
DMQLSMB ID DMQLSMB
DMQLSMB DN Dociparstat sodium
DMQLSMB HS Phase 3
DMQLSMB SN DSTAT
DMQLSMB CP Chimerix
DMQLSMB DE Acute myeloid leukaemia
DMH8IT5 ID DMH8IT5
DMH8IT5 DN Donaperminogene seltoplasmid
DMH8IT5 HS Phase 3
DMH8IT5 SN VM202
DMH8IT5 CP ViroMed
DMH8IT5 DT Gene therapy
DMH8IT5 DE Amyotrophic lateral sclerosis; Diabetic foot ulcer; Diabetic neuropathy
DM97S10 ID DM97S10
DM97S10 DN DP-b99
DM97S10 HS Phase 3
DM97S10 SN DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid
DM97S10 CP D-Pharm
DM97S10 DT Small molecular drug
DM97S10 PC 9810955
DM97S10 MW 789
DM97S10 FM C42H64N2O12
DM97S10 IC InChI=1S/C42H64N2O12/c1-3-5-7-9-11-17-23-51-25-27-55-41(49)33-43(31-39(45)46)35-19-13-15-21-37(35)53-29-30-54-38-22-16-14-20-36(38)44(32-40(47)48)34-42(50)56-28-26-52-24-18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18,23-34H2,1-2H3,(H,45,46)(H,47,48)
DM97S10 CS CCCCCCCCOCCOC(=O)CN(CC(=O)O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(=O)O)CC(=O)OCCOCCCCCCCC
DM97S10 IK FTGBVHPWUIHWRH-UHFFFAOYSA-N
DM97S10 IU 2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-N-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid
DM97S10 CA CAS 343340-21-6
DM97S10 DE Stroke
DMWUN1S ID DMWUN1S
DMWUN1S DN Drisapersen
DMWUN1S HS Phase 3
DMWUN1S SN 2402968
DMWUN1S CP GlaxoSmithKline
DMWUN1S DT Antisense drug
DMWUN1S PC 121494119
DMWUN1S MW 6978
DMWUN1S FM C211H275N76O119P19S19
DMWUN1S IC InChI=1S/C211H275N76O119P19S19/c1-329-136-116(295)77(369-178(136)271-33-24-99(289)252-206(271)304)40-349-407(310,426)389-118-79(371-180(138(118)331-3)268-30-21-96(212)249-203(268)301)42-351-409(312,428)392-121-81(373-183(141(121)334-6)273-35-26-101(291)254-208(273)306)44-352-410(313,429)393-122-82(374-184(142(122)335-7)274-36-27-102(292)255-209(274)307)45-353-411(314,430)394-123-83(375-185(143(123)336-8)275-37-28-103(293)256-210(275)308)46-355-415(318,434)396-125-85(377-187(145(125)338-10)277-65-238-105-156(215)226-59-232-162(105)277)48-358-413(316,432)391-120-80(372-182(140(120)333-5)270-32-23-98(214)251-205(270)303)43-354-417(320,436)402-131-94(386-193(151(131)344-16)283-71-244-111-168(283)258-198(221)263-173(111)296)57-366-424(327,443)405-132-91(383-194(152(132)345-17)284-72-245-112-169(284)259-199(222)264-174(112)297)54-363-414(317,433)395-124-84(376-186(144(124)337-9)276-38-29-104(294)257-211(276)309)47-356-416(319,435)397-126-89(381-188(146(126)339-11)278-66-239-106-157(216)227-60-233-163(106)278)52-361-422(325,441)403-133-92(384-195(153(133)346-18)285-73-246-113-170(285)260-200(223)265-175(113)298)55-364-420(323,439)400-130-88(380-192(150(130)343-15)282-70-243-110-161(220)231-64-237-167(110)282)51-360-419(322,438)399-128-90(382-190(148(128)341-13)280-68-241-108-159(218)229-62-235-165(108)280)53-362-423(326,442)404-134-95(387-196(154(134)347-19)286-74-247-114-171(286)261-201(224)266-176(114)299)58-367-425(328,444)406-135-93(385-197(155(135)348-20)287-75-248-115-172(287)262-202(225)267-177(115)300)56-365-421(324,440)401-129-87(379-191(149(129)342-14)281-69-242-109-160(219)230-63-236-166(109)281)50-359-418(321,437)398-127-86(378-189(147(127)340-12)279-67-240-107-158(217)228-61-234-164(107)279)49-357-412(315,431)390-119-78(370-181(139(119)332-4)269-31-22-97(213)250-204(269)302)41-350-408(311,427)388-117-76(39-288)368-179(137(117)330-2)272-34-25-100(290)253-207(272)305/h21-38,59-95,116-155,178-197,288,295H,39-58H2,1-20H3,(H,310,426)(H,311,427)(H,312,428)(H,313,429)(H,314,430)(H,315,431)(H,316,432)(H,317,433)(H,318,434)(H,319,435)(H,320,436)(H,321,437)(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H2,212,249,301)(H2,213,250,302)(H2,214,251,303)(H2,215,226,232)(H2,216,227,233)(H2,217,228,234)(H2,218,229,235)(H2,219,230,236)(H2,220,231,237)(H,252,289,304)(H,253,290,305)(H,254,291,306)(H,255,292,307)(H,256,293,308)(H,257,294,309)(H3,221,258,263,296)(H3,222,259,264,297)(H3,223,260,265,298)(H3,224,261,266,299)(H3,225,262,267,300)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,407?,408?,409?,410?,411?,412?,413?,414?,415?,416?,417?,418?,419?,420?,421?,422?,423?,424?,425?/m1/s1
DMWUN1S CS CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=S)(O)O[C@@H]3[C@H](O[C@H]([C@@H]3OC)N4C=CC(=NC4=O)N)COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=CC(=O)NC8=O)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)CO)S)O
DMWUN1S IK HUGILZFVSVLCAO-XVKRXUDYSA-N
DMWUN1S IU 1-[(2R,3R,4R,5R)-5-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione
DMWUN1S CA CAS 1251830-50-8
DMWUN1S DE Duchenne dystrophy
DMM0HAE ID DMM0HAE
DMM0HAE DN DSC-127
DMM0HAE HS Phase 3
DMM0HAE SN aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; DSC-127; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine
DMM0HAE CP Derma Sciences
DMM0HAE DT Small molecular drug
DMM0HAE PC 9811551
DMM0HAE MW 913
DMM0HAE FM C42H64N12O11
DMM0HAE IC InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1
DMM0HAE CS CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMM0HAE IK RUBMHAHMIJSMHA-LBWFYSSPSA-N
DMM0HAE IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DMM0HAE CA CAS 227803-63-6
DMM0HAE DE Diabetic foot ulcer
DM6P8HU ID DM6P8HU
DM6P8HU DN Dutasteride + tamsulosin
DM6P8HU HS Phase 3
DM6P8HU SN Jalyn; Dutasteride / tamsulosin; Tamsulosin / Dutasteride; Dutasteride mixture with tamsulosin
DM6P8HU CP GSK
DM6P8HU DT Combination drug (small molecular drug)
DM6P8HU PC 11679580
DM6P8HU MW 937
DM6P8HU FM C47H58F6N4O7S
DM6P8HU IC InChI=1S/C27H30F6N2O2.C20H28N2O5S/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33;1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36);5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-,16-,17-,19+,21+,24-,25+;15-/m01/s1
DM6P8HU CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DM6P8HU IK SHHCJPKACHSWFP-NMXGMQNUSA-N
DM6P8HU IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM6P8HU DE Benign prostatic hyperplasia; Prostate cancer
DMM5VTA ID DMM5VTA
DMM5VTA DN Dutogliptin
DMM5VTA HS Phase 3
DMM5VTA SN Dutogliptin tartrate; PHX-1004; PHX-1149; PHX-1149T; DPP IV inhibitors (diabetes), Phenomix; DPP IV program (diabetes), Phenomix
DMM5VTA CP Phenomix Corp
DMM5VTA PC 11253490
DMM5VTA MW 241.1
DMM5VTA FM C10H20BN3O3
DMM5VTA IC InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
DMM5VTA CS B([C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2)(O)O
DMM5VTA IK DVJAMEIQRSHVKC-BDAKNGLRSA-N
DMM5VTA IU [(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid
DMM5VTA CA CAS 852329-66-9
DMM5VTA DE Type-2 diabetes
DMAFUIR ID DMAFUIR
DMAFUIR DN DWP-431
DMAFUIR HS Phase 3
DMAFUIR SN Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong
DMAFUIR CP Daewoong Pharmaceutical Co Ltd
DMAFUIR DE Bone development disorder
DMM1YC4 ID DMM1YC4
DMM1YC4 DN E-101
DMM1YC4 HS Phase 3
DMM1YC4 SN Myeloperoxidase; Glucose oxidase; Human myeloperoxidase, dimer; E-101 (infections); Myeloperoxidase formulations (nosocomial infections), Exoxemis; E-101 (infections), Exoxemis; MPO enzyme system (hospital-acquiredl infections), Exoxemis; Myeloperoxidase + glucose oxidase (infections), Exoxemis
DMM1YC4 CP Exoxemis
DMM1YC4 DT Small molecular drug
DMM1YC4 PC 11973707
DMM1YC4 MW 377.3
DMM1YC4 FM C17H26Cl2N2O3
DMM1YC4 IC InChI=1S/C17H25ClN2O3.ClH/c1-4-12-8-13(18)16(23-3)14(15(12)21)17(22)19-9-11-6-7-20(5-2)10-11;/h8,11,21H,4-7,9-10H2,1-3H3,(H,19,22);1H/t11-;/m0./s1
DMM1YC4 CS CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCN(C2)CC)OC)Cl.Cl
DMM1YC4 IK RDZXYWICCLALQM-MERQFXBCSA-N
DMM1YC4 IU 5-chloro-3-ethyl-N-[[(3S)-1-ethylpyrrolidin-3-yl]methyl]-2-hydroxy-6-methoxybenzamide;hydrochloride
DMM1YC4 DE Infectious disease
DMTNUJ8 ID DMTNUJ8
DMTNUJ8 DN E-2609
DMTNUJ8 HS Phase 3
DMTNUJ8 SN Beta secretase inhibitor (Alzheimer's disease), Eisai
DMTNUJ8 CP Eisai Co Ltd
DMTNUJ8 PC 57827330
DMTNUJ8 MW 437.4
DMTNUJ8 FM C19H18F3N5O2S
DMTNUJ8 IC InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1
DMTNUJ8 CS C[C@@H]1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N
DMTNUJ8 IK AACUJFVOHGRMTR-DPXNYUHVSA-N
DMTNUJ8 IU N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide
DMTNUJ8 CA CAS 1388651-30-6
DMTNUJ8 DE Alzheimer disease
DM42PFT ID DM42PFT
DM42PFT DN E-3810
DM42PFT HS Phase 3
DM42PFT SN Lucitanib; AL-3810; E-3810, EOS
DM42PFT CP Clovis oncology
DM42PFT DT Small molecular drug
DM42PFT PC 25031915
DM42PFT MW 443.5
DM42PFT FM C26H25N3O4
DM42PFT IC InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)
DM42PFT CS CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM42PFT IK CUDVHEFYRIWYQD-UHFFFAOYSA-N
DM42PFT IU 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide
DM42PFT CA CAS 1058137-23-7
DM42PFT CB CHEBI:65209
DM42PFT DE Solid tumour/cancer
DMUHS5Q ID DMUHS5Q
DMUHS5Q DN E-913
DMUHS5Q HS Phase 3
DMUHS5Q SN E913; E 913; 342394-93-8; 1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-; 11-butyl-9-(cyclohexylmethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-3,8,11-triazaspiro[5.5]undecane-7,10-dione; 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-; AC1LANMM; E-913; SCHEMBL1649664; GTPL3500; CHEMBL1196395; e9-13; BDBM50190513; LS-184716
DMUHS5Q DT Small molecular drug
DMUHS5Q PC 491774
DMUHS5Q MW 483.6
DMUHS5Q FM C28H41N3O4
DMUHS5Q IC InChI=1S/C28H41N3O4/c1-2-3-13-31-26(32)23(18-21-7-5-4-6-8-21)29-27(33)28(31)11-14-30(15-12-28)20-22-9-10-24-25(19-22)35-17-16-34-24/h9-10,19,21,23H,2-8,11-18,20H2,1H3,(H,29,33)
DMUHS5Q CS CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC4=C(C=C3)OCCO4)CC5CCCCC5
DMUHS5Q IK VBONNDPACFTZMX-UHFFFAOYSA-N
DMUHS5Q IU 1-butyl-3-(cyclohexylmethyl)-9-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane-2,5-dione
DMUHS5Q CA CAS 342394-93-8
DMUHS5Q DE Human immunodeficiency virus infection
DMLA1ER ID DMLA1ER
DMLA1ER DN EC20
DMLA1ER HS Phase 3
DMLA1ER SN Technetium Tc-99m etarfolatide
DMLA1ER CP Endocyte
DMLA1ER DT Small molecular drug
DMLA1ER PC 135428923
DMLA1ER MW 745.7
DMLA1ER FM C29H35N11O11S
DMLA1ER IC InChI=1S/C29H35N11O11S/c30-15(24(45)37-17(7-20(42)43)25(46)38-18(11-52)28(50)51)10-33-19(41)6-5-16(27(48)49)36-23(44)12-1-3-13(4-2-12)32-8-14-9-34-22-21(35-14)26(47)40-29(31)39-22/h1-4,9,15-18,32,52H,5-8,10-11,30H2,(H,33,41)(H,36,44)(H,37,45)(H,38,46)(H,42,43)(H,48,49)(H,50,51)(H3,31,34,39,40,47)/t15-,16+,17-,18-/m0/s1
DMLA1ER CS C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)NC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMLA1ER IK RKGPQAGUQDVJHG-MHORFTMASA-N
DMLA1ER IU (2R)-5-[[(2S)-2-amino-3-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]amino]-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-oxopentanoic acid
DMLA1ER CA CAS 479578-27-3
DMLA1ER DE Ovarian cancer
DMS9R43 ID DMS9R43
DMS9R43 DN Ecopipam
DMS9R43 HS Phase 3
DMS9R43 SN Sch-39166; Sch 39166; 112108-01-7; Ecopipam [INN]; Sch39166; UNII-0X748O646K; CHEMBL298406; 0X748O646K; DSSTox_RID_80075; DSSTox_CID_23814; 6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho(2,1b)azepine; DSSTox_GSID_43814; 5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-; (6aS,13bR)-11-chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol; 5H-Benzo[d]naphth[2,1-b]azepin-12-ol,; ecopipam (controlled-release, Lesch Nyhan syndrome/Tourette's syndrome/compulsive gambling). Psyadon Pharmaceuticals
DMS9R43 DT Small molecular drug
DMS9R43 PC 107930
DMS9R43 MW 313.8
DMS9R43 FM C19H20ClNO
DMS9R43 IC InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
DMS9R43 CS CN1CCC2=CC(=C(C=C2[C@@H]3[C@@H]1CCC4=CC=CC=C34)O)Cl
DMS9R43 IK DMJWENQHWZZWDF-PKOBYXMFSA-N
DMS9R43 IU (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol
DMS9R43 CA CAS 112108-01-7
DMS9R43 CB CHEBI:93645
DMS9R43 DE Cocaine addiction; Tourette syndrome
DMRLXAI ID DMRLXAI
DMRLXAI DN ED-71
DMRLXAI HS Phase 3
DMRLXAI SN Edirol; Eldecalcitol; (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; 104121-92-8; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3; 2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3; ED 71; ED-71; I2JP8UE90H; UNII-I2JP8UE90H
DMRLXAI PC 6918141
DMRLXAI MW 490.7
DMRLXAI FM C30H50O5
DMRLXAI IC FZEXGDDBXLBRTD-AYIMTCTASA-N
DMRLXAI CS CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C
DMRLXAI IK 1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1
DMRLXAI IU (1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
DMRLXAI CA CAS 104121-92-8
DMRLXAI CB CHEBI:73927
DMRLXAI DE Osteoporosis
DMYVBF6 ID DMYVBF6
DMYVBF6 DN Edasalonexent
DMYVBF6 HS Phase 3
DMYVBF6 SN UNII-AF3Z6434KS; AF3Z6434KS; 1204317-86-1; Edasalonexent [INN]; SCHEMBL1823117; CHEMBL3786673; JQLBBYLGWHUHRW-KUBAVDMBSA-N; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide; Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide
DMYVBF6 CP Catabasis Pharmaceuticals Cambridge, MA
DMYVBF6 PC 44626120
DMYVBF6 MW 490.7
DMYVBF6 FM C31H42N2O3
DMYVBF6 IC InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMYVBF6 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)NCCNC(=O)C1=CC=CC=C1O
DMYVBF6 IK JQLBBYLGWHUHRW-KUBAVDMBSA-N
DMYVBF6 IU N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
DMYVBF6 CA CAS 1204317-86-1
DMYVBF6 DE Duchenne dystrophy
DM3ZL7D ID DM3ZL7D
DM3ZL7D DN Edotecarin
DM3ZL7D HS Phase 3
DM3ZL7D SN ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DM3ZL7D CP Pfizer
DM3ZL7D DT Small molecular drug
DM3ZL7D PC 9808998
DM3ZL7D MW 608.6
DM3ZL7D FM C29H28N4O11
DM3ZL7D IC InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
DM3ZL7D CS C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O
DM3ZL7D IK QMVPQBFHUJZJCS-NTKFZFFISA-N
DM3ZL7D IU 13-(1,3-dihydroxypropan-2-ylamino)-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DM3ZL7D CA CAS 174402-32-5
DM3ZL7D DE Gastric adenocarcinoma
DMX7BM4 ID DMX7BM4
DMX7BM4 DN Efaproxyn
DMX7BM4 HS Phase 3
DMX7BM4 SN Efaproxiral; RSR13
DMX7BM4 CP Allos Therapeutics
DMX7BM4 DT Small molecular drug
DMX7BM4 PC 122335
DMX7BM4 MW 341.4
DMX7BM4 FM C20H23NO4
DMX7BM4 IC InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)
DMX7BM4 CS CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C
DMX7BM4 IK BNFRJXLZYUTIII-UHFFFAOYSA-N
DMX7BM4 IU 2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid
DMX7BM4 CA CAS 131179-95-8
DMX7BM4 DE Lung cancer
DMKA2PI ID DMKA2PI
DMKA2PI DN Efpeglenatide
DMKA2PI HS Phase 3
DMKA2PI SN Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5
DMKA2PI CP Sanofi US Bridgewater, NJ
DMKA2PI PC 86278345
DMKA2PI MW 403.5
DMKA2PI FM C19H37N3O6
DMKA2PI IC InChI=1S/C19H37N3O6/c20-16(18(23)24)6-1-2-8-21-9-4-12-27-14-15-28-13-5-11-22-10-3-7-17(22)19(25)26/h16-17,21H,1-15,20H2,(H,23,24)(H,25,26)/t16-,17-/m0/s1
DMKA2PI CS C1C[C@H](N(C1)CCCOCCOCCCNCCCC[C@@H](C(=O)O)N)C(=O)O
DMKA2PI IK OJQLGILETRTDGQ-IRXDYDNUSA-N
DMKA2PI IU (2S)-1-[3-[2-[3-[[(5S)-5-amino-5-carboxypentyl]amino]propoxy]ethoxy]propyl]pyrrolidine-2-carboxylic acid
DMKA2PI DE Type-2 diabetes
DMCMJRA ID DMCMJRA
DMCMJRA DN EGF816
DMCMJRA HS Phase 3
DMCMJRA CP Novartis pharmaceuticals
DMCMJRA PC 72703790
DMCMJRA MW 495
DMCMJRA FM C26H31ClN6O2
DMCMJRA IC InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
DMCMJRA CS CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl
DMCMJRA IK IOMMMLWIABWRKL-WUTDNEBXSA-N
DMCMJRA IU N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide
DMCMJRA CA CAS 1508250-71-2
DMCMJRA DE Non-small-cell lung cancer
DMB2C0E ID DMB2C0E
DMB2C0E DN Elagolix
DMB2C0E HS Phase 3
DMB2C0E SN Elagolix; 834153-87-6; UNII-5B2546MB5Z; NBI-56418; 5B2546MB5Z; NBI56418; NBI 56418; Elagolix [USAN:INN]; Orilissa; ELA gOLIX; Elagolix (USAN/INN); SCHEMBL1642523; GTPL8362; CHEMBL1208155; DTXSID40232348; ABT-620; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; EX-A1765; BCP08827; ZINC49888891; CS-5329; SB16700; DB11979; compound 10b [PMID 19006286]; HY-14789; AN-27202; D09335; Z-3253; 153E876; Butanoic acid, 4-(((1R)-2-(5-(2-flu
DMB2C0E CP Abbott Laboratories Abbott; Neurocrine Biosciences
DMB2C0E DT Small molecular drug
DMB2C0E PC 11250647
DMB2C0E MW 631.6
DMB2C0E FM C32H30F5N3O5
DMB2C0E IC InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
DMB2C0E CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F
DMB2C0E IK HEAUOKZIVMZVQL-VWLOTQADSA-N
DMB2C0E IU 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
DMB2C0E CA CAS 834153-87-6
DMB2C0E DE Uterine fibroids
DMW6C81 ID DMW6C81
DMW6C81 DN Eltoprazine
DMW6C81 HS Phase 3
DMW6C81 SN Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
DMW6C81 CP Amarantus bioscience; psychogenics
DMW6C81 DT Small molecular drug
DMW6C81 PC 65853
DMW6C81 MW 220.27
DMW6C81 FM C12H16N2O2
DMW6C81 IC InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
DMW6C81 CS C1CN(CCN1)C2=C3C(=CC=C2)OCCO3
DMW6C81 IK WVLHGCRWEHCIOT-UHFFFAOYSA-N
DMW6C81 IU 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine
DMW6C81 CA CAS 98224-03-4
DMW6C81 DE Non-hodgkin lymphoma; Alzheimer disease; Attention deficit hyperactivity disorder; Dyskinesia; Parkinson disease
DMZKTYJ ID DMZKTYJ
DMZKTYJ DN Enmetazobactam
DMZKTYJ HS Phase 3
DMZKTYJ SN AAI-101; AAI101; 1001404-83-6; UNII-80VUN7L00C; 80VUN7L00C; (2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide; CHEMBL4458276; SCHEMBL18110082; OCID-5090; CS-7557; HY-103095; J3.628.087E; (2S,3S,5R)-3-Methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate; (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1H-1,2,3-Triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt
DMZKTYJ CP Allecra Therapeutics
DMZKTYJ DT Small molecular drug
DMZKTYJ PC 23653540
DMZKTYJ MW 314.32
DMZKTYJ FM C11H14N4O5S
DMZKTYJ IC InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
DMZKTYJ CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C
DMZKTYJ IK HFZITXBUTWITPT-YWVKMMECSA-N
DMZKTYJ IU (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMZKTYJ CA CAS 1001404-83-6
DMZKTYJ DE Urinary tract infection
DMIKDCQ ID DMIKDCQ
DMIKDCQ DN Ensartinib
DMIKDCQ HS Phase 3
DMIKDCQ CP Xcovery Palm Beach Gardens, FL
DMIKDCQ PC 56960363
DMIKDCQ MW 561.4
DMIKDCQ FM C26H27Cl2FN6O3
DMIKDCQ IC InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1
DMIKDCQ CS C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N
DMIKDCQ IK GLYMPHUVMRFTFV-QLFBSQMISA-N
DMIKDCQ IU 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3S,5R)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide
DMIKDCQ CA CAS 1370651-20-9
DMIKDCQ DE Non-small-cell lung cancer
DM7EOBQ ID DM7EOBQ
DM7EOBQ DN Entacapone+levodopa+carbidopa
DM7EOBQ HS Phase 3
DM7EOBQ CP Orion; Novartis
DM7EOBQ DE Restless legs syndrome; Parkinson disease
DMTWLXY ID DMTWLXY
DMTWLXY DN Entresto
DMTWLXY HS Phase 3
DMTWLXY SN Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi
DMTWLXY CP Novartis East Hanover, NJ
DMTWLXY PC 71449007
DMTWLXY MW 1916
DMTWLXY FM C96H120N12Na6O21
DMTWLXY IC InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
DMTWLXY CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMTWLXY IK ZASXKEGREHRXDL-CAWNUZPDSA-H
DMTWLXY IU hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate
DMTWLXY CA CAS 936623-90-4
DMTWLXY DE Acute myocardial infarction; Heart failure
DM5H0R9 ID DM5H0R9
DM5H0R9 DN Enzastaurin
DM5H0R9 HS Phase 3
DM5H0R9 SN LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9 CP Eli Lilly
DM5H0R9 TC Anticancer Agents
DM5H0R9 DT Small molecular drug
DM5H0R9 PC 176167
DM5H0R9 MW 515.6
DM5H0R9 FM C32H29N5O2
DM5H0R9 IC InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
DM5H0R9 CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7
DM5H0R9 IK AXRCEOKUDYDWLF-UHFFFAOYSA-N
DM5H0R9 IU 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9 CA CAS 170364-57-5
DM5H0R9 CB CHEBI:91368
DM5H0R9 DE Central nervous system disease; Glioblastoma multiforme; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma
DMEX86V ID DMEX86V
DMEX86V DN Epcoritamab
DMEX86V HS Phase 3
DMEX86V CP Genmab
DMEX86V DT Antibody
DMEX86V DE Diffuse large B-cell lymphoma
DM1SMAI ID DM1SMAI
DM1SMAI DN Eperisone
DM1SMAI HS Phase 3
DM1SMAI SN EMPP; Myonal; Myorelark; E-0646; E-2000; E-646; Eperisone (transdermal patch); Eperisone (oral), Eisai; Eperisone (transdermalpatch), Eisai; E-2000 (oral), Eisai; E-2000 (transdermal patch), Eisai
DM1SMAI CP Eisai Co Ltd
DM1SMAI DT Small molecular drug
DM1SMAI PC 3236
DM1SMAI MW 259.399
DM1SMAI FM C17H25NO
DM1SMAI IC InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3
DM1SMAI CS CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DM1SMAI IK SQUNAWUMZGQQJD-UHFFFAOYSA-N
DM1SMAI IU 1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one
DM1SMAI CA CAS 64840-90-0
DM1SMAI CB CHEBI:77070
DM1SMAI DE Muscle spasm
DM08XIN ID DM08XIN
DM08XIN DN EPIANDROSTERONE
DM08XIN HS Phase 3
DM08XIN SN EPIANDROSTERONE; 481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2
DM08XIN DT Small molecular drug
DM08XIN PC 441302
DM08XIN MW 290.4
DM08XIN FM C19H30O2
DM08XIN IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,18-,19-/m0/s1
DM08XIN CS C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DM08XIN IK QGXBDMJGAMFCBF-LUJOEAJASA-N
DM08XIN IU (3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DM08XIN CA CAS 481-29-8
DM08XIN CB CHEBI:541975
DMCGWBJ ID DMCGWBJ
DMCGWBJ DN Epigallocatechin gallate
DMCGWBJ HS Phase 3
DMCGWBJ SN (-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE
DMCGWBJ CP Anagen Therapeutics Inc; Enzo Life Sciences
DMCGWBJ DT Small molecular drug
DMCGWBJ PC 65064
DMCGWBJ MW 458.4
DMCGWBJ FM C22H18O11
DMCGWBJ IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMCGWBJ CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMCGWBJ IK WMBWREPUVVBILR-WIYYLYMNSA-N
DMCGWBJ IU [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMCGWBJ CA CAS 989-51-5
DMCGWBJ CB CHEBI:4806
DMCGWBJ DE Hepatic fibrosis
DM9QPOU ID DM9QPOU
DM9QPOU DN Epoetin zeta
DM9QPOU HS Phase 3
DM9QPOU CP Hospira
DM9QPOU DE Anemia
DMITJRU ID DMITJRU
DMITJRU DN Epothilon
DMITJRU HS Phase 3
DMITJRU CP Bayer AG
DMITJRU DE Ovarian cancer
DMI1ZXV ID DMI1ZXV
DMI1ZXV DN Epratuzumab
DMI1ZXV HS Phase 3
DMI1ZXV SN LymphoCide; Lymphocide (TN); Epratuzumab (USAN/INN)
DMI1ZXV CP Immunomedics
DMI1ZXV DT Antibody
DMI1ZXV DE Graft rejection in heart transplantation; Systemic lupus erythematosus; Acute lymphoblastic leukaemia
DM35T1O ID DM35T1O
DM35T1O DN Epristeride
DM35T1O HS Phase 3
DM35T1O SN Zariflo; ONO-9302; SKB-105657; SKF-105657
DM35T1O CP SmithKline Beecham plc
DM35T1O DT Small molecular drug
DM35T1O PC 68741
DM35T1O MW 399.6
DM35T1O FM C25H37NO3
DM35T1O IC InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1
DM35T1O CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC=C4[C@@]3(CCC(=C4)C(=O)O)C
DM35T1O IK VAPSMQAHNAZRKC-PQWRYPMOSA-N
DM35T1O IU (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
DM35T1O CA CAS 119169-78-7
DM35T1O CB CHEBI:31552
DM35T1O DE Hirsutism
DMTV7ZM ID DMTV7ZM
DMTV7ZM DN Eptastigmine
DMTV7ZM HS Phase 3
DMTV7ZM SN heptastigmine; Heptylphysostigmine; Physostigmine heptyl; Eptastigmine [INN]; (-)-Heptylphysostigmine; Eptastigminum [INN-Latin]; Eptastigmina [INN-Spanish]; UNII-6PZZ52D76Q; N-Demethyl-N-heptylphysostigmine; 101246-68-8; BRN 4883778; CHEMBL433041; 6PZZ52D76Q; Heptylstigmine; heptyl-physostigmine; Eptastigminum; Eptastigmina; heptyl physostigmine; Carbamic acid, heptyl-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; AC1Q60XA; SCHEMBL195028; BDBM10972; Epiastigmine; Eptastigmine tartrate; Heptylstigmine tartrate; Heptyl-physostigmine; L-693487; MF-201; HEPTYPHYSOSTIGMINE
DMTV7ZM CP Consiglio Nazionale delle Ricerche
DMTV7ZM DT Small molecular drug
DMTV7ZM PC 65872
DMTV7ZM MW 359.5
DMTV7ZM FM C21H33N3O2
DMTV7ZM IC InChI=1S/C21H33N3O2/c1-5-6-7-8-9-13-22-20(25)26-16-10-11-18-17(15-16)21(2)12-14-23(3)19(21)24(18)4/h10-11,15,19H,5-9,12-14H2,1-4H3,(H,22,25)/t19-,21+/m1/s1
DMTV7ZM CS CCCCCCCNC(=O)OC1=CC2=C(C=C1)N([C@@H]3[C@]2(CCN3C)C)C
DMTV7ZM IK RRGMXBQMCUKRLH-CTNGQTDRSA-N
DMTV7ZM IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-heptylcarbamate
DMTV7ZM CA CAS 101246-68-8
DMTV7ZM DE Cognitive impairment
DM6BU57 ID DM6BU57
DM6BU57 DN Eraxis/Vfend
DM6BU57 HS Phase 3
DM6BU57 CP Pfizer
DM6BU57 DE Fungal infection
DM9YI2C ID DM9YI2C
DM9YI2C DN ErepoXen
DM9YI2C HS Phase 3
DM9YI2C CP Lipoxen plc
DM9YI2C DE Anemia
DMKQZ0L ID DMKQZ0L
DMKQZ0L DN ERITORAN
DMKQZ0L HS Phase 3
DMKQZ0L SN ERITORAN; UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287
DMKQZ0L DT Small molecular drug
DMKQZ0L PC 6912404
DMKQZ0L MW 1313.7
DMKQZ0L FM C66H126N2O19P2
DMKQZ0L IC InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1
DMKQZ0L CS CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC)NC(=O)CCCCCCCCC/C=C\\CCCCCC)O)OCCCCCCCCCC
DMKQZ0L IK BPSMYQFMCXXNPC-MFCPCZTFSA-N
DMKQZ0L IU [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate
DMKQZ0L CA CAS 185955-34-4
DMKQZ0L CB CHEBI:68609
DMKQZ0L DE Sepsis
DMVU687 ID DMVU687
DMVU687 DN Esketamine
DMVU687 HS Phase 3
DMVU687 SN (S)-Ketamine; l-Ketamine; (S)-(-)-Ketamine; 33643-46-8; S-Ketamine; UNII-50LFG02TXD; 50LFG02TXD; (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone; CHEBI:60799; esketamine HCl; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)-; 6740-88-1 (Parent); Esketamine [USAN:INN:BAN]; S-Ketamin; S-(-)-Ketamine; Esketamine (USAN/INN); AC1L4AD8; DSSTox_CID_27787; DSSTox_RID_82562; DSSTox_GSID_47810; SCHEMBL5512024; GTPL9152; CHEMBL395091; DTXSID6047810; YQEZ
DMVU687 CP Janssen Research & Development Raritan, NJ
DMVU687 PC 182137
DMVU687 MW 237.72
DMVU687 FM C13H16ClNO
DMVU687 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1
DMVU687 CS CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl
DMVU687 IK YQEZLKZALYSWHR-ZDUSSCGKSA-N
DMVU687 IU (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMVU687 CA CAS 33643-46-8
DMVU687 CB CHEBI:60799
DMVU687 DE Depression
DM8RBHJ ID DM8RBHJ
DM8RBHJ DN Esomeprazole magnesium + Aspirin
DM8RBHJ HS Phase 3
DM8RBHJ CP AstraZeneca
DM8RBHJ DE Peptic ulcer
DM4YGWA ID DM4YGWA
DM4YGWA DN Esonarimod
DM4YGWA HS Phase 3
DM4YGWA SN Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298
DM4YGWA CP Taisho Pharmaceutical Co Ltd
DM4YGWA DT Small molecular drug
DM4YGWA PC 127998
DM4YGWA MW 280.34
DM4YGWA FM C14H16O4S
DM4YGWA IC InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18)
DM4YGWA CS CC1=CC=C(C=C1)C(=O)CC(CSC(=O)C)C(=O)O
DM4YGWA IK YRSSFEUQNAXQMX-UHFFFAOYSA-N
DM4YGWA IU 2-(acetylsulfanylmethyl)-4-(4-methylphenyl)-4-oxobutanoic acid
DM4YGWA CA CAS 101973-77-7
DM4YGWA CB CHEBI:31559
DM4YGWA DE Arthritis
DMXLGED ID DMXLGED
DMXLGED DN esuberaprost
DMXLGED HS Phase 3
DMXLGED SN APS-314D free acid; BPS-314d
DMXLGED DT Small molecular drug
DMXLGED PC 10501053
DMXLGED MW 398.5
DMXLGED FM C24H30O5
DMXLGED IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15-,17-,19+,20+,21-,23-/m0/s1
DMXLGED CS CC#CC[C@H](C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMXLGED IK CTPOHARTNNSRSR-NOQAJONNSA-N
DMXLGED IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMXLGED CA CAS 94132-88-4
DMXLGED DE Gout; Pulmonary arterial hypertension
DMQHX1Y ID DMQHX1Y
DMQHX1Y DN Etirinotecan pegol
DMQHX1Y HS Phase 3
DMQHX1Y SN NKTR-102
DMQHX1Y CP Nektar Therapeutics
DMQHX1Y DT Small molecular drug
DMQHX1Y PC 56935717
DMQHX1Y MW 3047.4
DMQHX1Y FM C161H192N20O40
DMQHX1Y IC InChI=1S/C161H192N20O40/c1-9-105-109-69-101(214-153(198)174-53-37-97(38-54-174)170-45-21-17-22-46-170)29-33-125(109)166-141-113(105)81-178-129(141)73-121-117(145(178)190)85-210-149(194)158(121,13-5)218-137(186)77-162-133(182)89-202-61-65-206-93-157(94-207-66-62-203-90-134(183)163-78-138(187)219-159(14-6)122-74-130-142-114(82-179(130)146(191)118(122)86-211-150(159)195)106(10-2)110-70-102(30-34-126(110)167-142)215-154(199)175-55-39-98(40-56-175)171-47-23-18-24-48-171,95-208-67-63-204-91-135(184)164-79-139(188)220-160(15-7)123-75-131-143-115(83-180(131)147(192)119(123)87-212-151(160)196)107(11-3)111-71-103(31-35-127(111)168-143)216-155(200)176-57-41-99(42-58-176)172-49-25-19-26-50-172)96-209-68-64-205-92-136(185)165-80-140(189)221-161(16-8)124-76-132-144-116(84-181(132)148(193)120(124)88-213-152(161)197)108(12-4)112-72-104(32-36-128(112)169-144)217-156(201)177-59-43-100(44-60-177)173-51-27-20-28-52-173/h29-36,69-76,97-100H,9-28,37-68,77-96H2,1-8H3,(H,162,182)(H,163,183)(H,164,184)(H,165,185)/t158-,159-,160-,161-/m0/s1
DMQHX1Y CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)OC(=O)N3CCC(CC3)N3CCCCC3)N=C8C7=C6)CC)CC)(COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)OC(=O)N1CCC(CC1)N1CCCCC1
DMQHX1Y IK SELCJVNOEBVTAC-HLDPIHRNSA-N
DMQHX1Y IU [(19S)-19-[2-[[2-[2-[3-[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]-2,2-bis[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxymethyl]propoxy]ethoxy]acetyl]amino]acetyl]oxy-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMQHX1Y DE Breast cancer; Ovarian cancer
DMCDZ15 ID DMCDZ15
DMCDZ15 DN Evacetrapib
DMCDZ15 HS Phase 3
DMCDZ15 SN LY2484595
DMCDZ15 CP Lilly
DMCDZ15 DT Small molecular drug
DMCDZ15 PC 49836058
DMCDZ15 MW 638.6
DMCDZ15 FM C31H36F6N6O2
DMCDZ15 IC InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
DMCDZ15 CS CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C
DMCDZ15 IK IHIUGIVXARLYHP-UXNJHFGPSA-N
DMCDZ15 IU 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid
DMCDZ15 CA CAS 1186486-62-3
DMCDZ15 DE Cardiovascular disease
DMG4UJ6 ID DMG4UJ6
DMG4UJ6 DN EVK-001
DMG4UJ6 HS Phase 3
DMG4UJ6 CP Evoke Pharma
DMG4UJ6 DE Diabetic gastroparesis
DMLQO7F ID DMLQO7F
DMLQO7F DN EVP-6124
DMLQO7F HS Phase 3
DMLQO7F SN Encenicline; EVP-6124; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626
DMLQO7F CP EnVivo Pharmaceuticals
DMLQO7F DT Small molecular drug
DMLQO7F PC 46196517
DMLQO7F MW 320.8
DMLQO7F FM C16H17ClN2OS
DMLQO7F IC InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1
DMLQO7F CS C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl
DMLQO7F IK SSRDSYXGYPJKRR-ZDUSSCGKSA-N
DMLQO7F IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
DMLQO7F CA CAS 550999-75-2
DMLQO7F DE Schizophrenia; Alzheimer disease
DMCA7FN ID DMCA7FN
DMCA7FN DN Exatecan
DMCA7FN HS Phase 3
DMCA7FN SN Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
DMCA7FN CP Daiichi Seiyaku Co Ltd
DMCA7FN DT Small molecular drug
DMCA7FN PC 151115
DMCA7FN MW 435.4
DMCA7FN FM C24H22FN3O4
DMCA7FN IC InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
DMCA7FN CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
DMCA7FN IK ZVYVPGLRVWUPMP-FYSMJZIKSA-N
DMCA7FN IU (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione
DMCA7FN CA CAS 171335-80-1
DMCA7FN CB CHEBI:135709
DMCA7FN DE Solid tumour/cancer
DMBY56U ID DMBY56U
DMBY56U DN EXISULIND
DMBY56U HS Phase 3
DMBY56U SN Aposulind; Aptosyn; Sulindac sulfone; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid
DMBY56U CP OSI Pharmaceuticals
DMBY56U DT Small molecular drug
DMBY56U PC 5472495
DMBY56U MW 372.4
DMBY56U FM C20H17FO4S
DMBY56U IC InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DMBY56U CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
DMBY56U IK MVGSNCBCUWPVDA-MFOYZWKCSA-N
DMBY56U IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid
DMBY56U CA CAS 59973-80-7
DMBY56U CB CHEBI:64212
DMBY56U DE Colorectal cancer
DMOKT7Y ID DMOKT7Y
DMOKT7Y DN FARGLITAZAR
DMOKT7Y HS Phase 3
DMOKT7Y SN Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-
DMOKT7Y DT Small molecular drug
DMOKT7Y PC 170364
DMOKT7Y MW 546.6
DMOKT7Y FM C34H30N2O5
DMOKT7Y IC InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1
DMOKT7Y CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)C5=CC=CC=C5
DMOKT7Y IK ZZCHHVUQYRMYLW-HKBQPEDESA-N
DMOKT7Y IU (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
DMOKT7Y CA CAS 196808-45-4
DMOKT7Y DE Type-1 diabetes
DM83SEB ID DM83SEB
DM83SEB DN Faricimab
DM83SEB HS Phase 3
DM83SEB SN RO6867461; RG7716
DM83SEB DT Antibody
DM83SEB DE Diabetic macular edema
DMFLWX1 ID DMFLWX1
DMFLWX1 DN Farletuzumab
DMFLWX1 HS Phase 3
DMFLWX1 CP Morphotek
DMFLWX1 DT Monoclonal antibody
DMFLWX1 SQ 9067_H|farletuzumab|||H-GAMMA-1 (VH(1-119)+CH1(120-217)+HINGE-REGION(218-232)+CH2(233-342)+CH3(343-449))|||||||449||||MW 48946.2|MW 48946.2|: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9067_L|farletuzumab|||L-KAPPA (V-KAPPA(1-110)+C-KAPPA(111-217))|||||||217||||MW 23755.2|MW 23755.2|DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFLWX1 DE Ovarian cancer; Non-small-cell lung cancer
DMTGYSO ID DMTGYSO
DMTGYSO DN Fasiglifam hemihydrate
DMTGYSO HS Phase 3
DMTGYSO SN Fasiglifam hemihydrate; 1374598-80-7; UNII-8LDT91CH8A; 8LDT91CH8A; TAK-875 Hemihydrate; Fasiglifam hydrate (JAN); DTXSID80160191; MolPort-035-395-707; EX-A2165; s2637; AKOS025404925; 3-Benzofuranacetic acid, 6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)(1,1'-biphenyl)-3-yl)methoxy)-2,3-dihydro-, hydrate (2:1), (3S)-; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hydrate; SC-95595; BC600332; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)
DMTGYSO CP Apollo Scientific
DMTGYSO DT Small molecular drug
DMTGYSO PC 57339446
DMTGYSO MW 1067.3
DMTGYSO FM C58H66O15S2
DMTGYSO IC InChI=1S/2C29H32O7S.H2O/c2*1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24;/h2*4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31);1H2/t2*23-;/m11./s1
DMTGYSO CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.O
DMTGYSO IK OJXYMYYDAVXPIK-IWKNALKQSA-N
DMTGYSO IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid;hydrate
DMTGYSO CA CAS 1374598-80-7
DMTGYSO DE Type-2 diabetes
DM5PRLA ID DM5PRLA
DM5PRLA DN Fasinumab
DM5PRLA HS Phase 3
DM5PRLA CP Regeneron Pharmaceuticals Tarrytown, NY Teva Pharmaceuticals USA North Wales, PA
DM5PRLA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis
DM8E51L ID DM8E51L
DM8E51L DN FASORACETAM
DM8E51L HS Phase 3
DM8E51L SN LAM-105; NS-105; Fasoracetam; (R)-1-[(5-Oxo-2-pyrrolidinyl)carbonyl]piperidine; (R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one
DM8E51L DT Small molecular drug
DM8E51L PC 198695
DM8E51L MW 196.25
DM8E51L FM C10H16N2O2
DM8E51L IC InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
DM8E51L CS C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2
DM8E51L IK GOWRRBABHQUJMX-MRVPVSSYSA-N
DM8E51L IU (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
DM8E51L CA CAS 110958-19-5
DM8E51L CB CHEBI:31592
DM8E51L DE Cognitive impairment
DM35GBS ID DM35GBS
DM35GBS DN Favipiravir
DM35GBS HS Phase 3
DM35GBS SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DM35GBS CP Toyama Chemical
DM35GBS TC Antiviral Agents
DM35GBS DT Small molecular drug
DM35GBS PC 492405
DM35GBS MW 157.1
DM35GBS FM C5H4FN3O2
DM35GBS IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DM35GBS CS C1=C(N=C(C(=O)N1)C(=O)N)F
DM35GBS IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DM35GBS IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DM35GBS CA CAS 259793-96-9
DM35GBS CB CHEBI:134722
DM35GBS DE Influenza virus infection; Coronavirus Disease 2019 (COVID-19)
DM0762O ID DM0762O
DM0762O DN Fenfluramine
DM0762O HS Phase 3
DM0762O SN Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
DM0762O CP Zogenix Emeryville, CA
DM0762O DT Small molecular drug
DM0762O PC 3337
DM0762O MW 231.26
DM0762O FM C12H16F3N
DM0762O IC InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
DM0762O CS CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
DM0762O IK DBGIVFWFUFKIQN-UHFFFAOYSA-N
DM0762O IU N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DM0762O CA CAS 458-24-2
DM0762O CB CHEBI:5000
DM0762O DE Dravet syndrome; LennoxGastaut syndrome; Obesity
DMRD5SP ID DMRD5SP
DMRD5SP DN Fenretinide
DMRD5SP HS Phase 3
DMRD5SP SN RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR
DMRD5SP CP Sirion Therapeutics; cerrx; Sytera Inc
DMRD5SP DT Small molecular drug
DMRD5SP PC 5288209
DMRD5SP MW 391.5
DMRD5SP FM C26H33NO2
DMRD5SP IC InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
DMRD5SP CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C
DMRD5SP IK AKJHMTWEGVYYSE-FXILSDISSA-N
DMRD5SP IU (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
DMRD5SP CA CAS 65646-68-6
DMRD5SP CB CHEBI:42588
DMRD5SP DE Lymphoma; Peripheral T-cell lymphoma; Solid tumour/cancer; Tumour; Macular degeneration
DM4NX0C ID DM4NX0C
DM4NX0C DN Fevipiprant
DM4NX0C HS Phase 3
DM4NX0C SN 872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; Fevipiprant; NVP-QAW039; QAW039; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY
DM4NX0C CP Novartis
DM4NX0C DT Small molecular drug
DM4NX0C PC 23582412
DM4NX0C MW 426.4
DM4NX0C FM C19H17F3N2O4S
DM4NX0C IC InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
DM4NX0C CS CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
DM4NX0C IK GFPPXZDRVCSVNR-UHFFFAOYSA-N
DM4NX0C IU 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid
DM4NX0C CA CAS 872365-14-5
DM4NX0C DE Asthma
DM4XSQ2 ID DM4XSQ2
DM4XSQ2 DN FG-4592
DM4XSQ2 HS Phase 3
DM4XSQ2 SN FG-4592; 808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid
DM4XSQ2 CP FibroGen
DM4XSQ2 DT Small molecular drug
DM4XSQ2 PC 11256664
DM4XSQ2 MW 352.3
DM4XSQ2 FM C19H16N2O5
DM4XSQ2 IC InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
DM4XSQ2 CS CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
DM4XSQ2 IK YOZBGTLTNGAVFU-UHFFFAOYSA-N
DM4XSQ2 IU 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
DM4XSQ2 CA CAS 808118-40-3
DM4XSQ2 CB CHEBI:132774
DM4XSQ2 DE Kidney disease; Anaemia
DMFZ81T ID DMFZ81T
DMFZ81T DN Fidanacogene elaparvovec
DMFZ81T HS Phase 3
DMFZ81T SN AAV8-hFIX19
DMFZ81T CP Pfizer
DMFZ81T DT Gene therapy
DMFZ81T DE Haemophilia B
DMZL1I8 ID DMZL1I8
DMZL1I8 DN Fidarestat
DMZL1I8 HS Phase 3
DMZL1I8 SN Aldos; FID; Fidaresstat; SK 860; Snk 860; Aldos (TN); SNK-860; Fidarestat (JAN/INN); (+)-(2S,4S)-6-Fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (+)-(2s,4s)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; (2S,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; (2S,4S)-6-Fluoro-2',5'-dioxospiro(3,4-dihydro-2H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8 CP Sanwa Kagaku
DMZL1I8 DT Small molecular drug
DMZL1I8 PC 160024
DMZL1I8 MW 279.22
DMZL1I8 FM C12H10FN3O4
DMZL1I8 IC InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
DMZL1I8 CS C1[C@H](OC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N
DMZL1I8 IK WAAPEIZFCHNLKK-UFBFGSQYSA-N
DMZL1I8 IU (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8 CA CAS 136087-85-9
DMZL1I8 DE Diabetic complication
DMM4FJ3 ID DMM4FJ3
DMM4FJ3 DN Finerenone
DMM4FJ3 HS Phase 3
DMM4FJ3 SN UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
DMM4FJ3 CP Bayer HealthCare Pharmaceuticals, Plainsboro, NJ
DMM4FJ3 PC 60150535
DMM4FJ3 MW 378.4
DMM4FJ3 FM C21H22N4O3
DMM4FJ3 IC InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
DMM4FJ3 CS CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
DMM4FJ3 IK BTBHLEZXCOBLCY-QGZVFWFLSA-N
DMM4FJ3 IU (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
DMM4FJ3 CA CAS 1050477-31-0
DMM4FJ3 DE Diabetic nephropathy
DMMQ7BY ID DMMQ7BY
DMMQ7BY DN Fitusiran
DMMQ7BY HS Phase 3
DMMQ7BY SN ALN-AT3SC
DMMQ7BY CP Sanofi
DMMQ7BY DT Small interfering RNA
DMMQ7BY DE Hemophilia
DM6R2XF ID DM6R2XF
DM6R2XF DN FKB238
DM6R2XF HS Phase 3
DM6R2XF CP Fujifilm; Centus Biotherapeutics
DM6R2XF DT Antibody
DM6R2XF DE Non-small-cell lung cancer
DMPSG4D ID DMPSG4D
DMPSG4D DN Flobufen
DMPSG4D HS Phase 3
DMPSG4D SN VUFB-16066; VUFB-17203
DMPSG4D CP VUFB
DMPSG4D DT Small molecular drug
DMPSG4D PC 159476
DMPSG4D MW 304.29
DMPSG4D FM C17H14F2O3
DMPSG4D IC InChI=1S/C17H14F2O3/c1-10(17(21)22)8-16(20)12-4-2-11(3-5-12)14-7-6-13(18)9-15(14)19/h2-7,9-10H,8H2,1H3,(H,21,22)
DMPSG4D CS CC(CC(=O)C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)C(=O)O
DMPSG4D IK FIKVYIRIUOFLLR-UHFFFAOYSA-N
DMPSG4D IU 4-[4-(2,4-difluorophenyl)phenyl]-2-methyl-4-oxobutanoic acid
DMPSG4D CA CAS 112344-52-2
DMPSG4D DE Rheumatoid arthritis
DMKL5AT ID DMKL5AT
DMKL5AT DN Flurpiridaz F 18
DMKL5AT HS Phase 3
DMKL5AT SN Flurpiridaz (18F); PET myocardial perfusion imaging agents, Bristol-Myers Squibb Medical Imaging; RP-1003-18; RP-1004-18; RP-1005-18; [18F]-RP-1003; [18F]-RP-1004; [18F]-RP-1005; [18F]-labeled PET myocardial perfusion imaging agents, Lantheus Medical Imaging; BMS-747158-02-[18F]; Fluorine-18-BMS-747158; [18F]-labeled MC-1 inhibitors (MPIAs), Lantheus Medical Imaging; [18F]-labeled MC-1 inhibitors, Bristol-Myers Squibb Medical Imaging; [18fluorine]-labeled mitochondrial complex-1 inhibitors, Bristol-Myers Squibb Medical Imaging; 18F-BMS-747158-02
DMKL5AT CP Lantheus medical imaging
DMKL5AT DT Small molecular drug
DMKL5AT PC 11405965
DMKL5AT MW 367.8
DMKL5AT FM C18H22ClFN2O3
DMKL5AT IC InChI=1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1
DMKL5AT CS CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCC[18F])Cl
DMKL5AT IK RMXZKEPDYBTFOS-LRFGSCOBSA-N
DMKL5AT IU 2-tert-butyl-4-chloro-5-[[4-(2-(18F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one
DMKL5AT CA CAS 863887-89-2
DMKL5AT DE Myocardial disease
DM5S4DL ID DM5S4DL
DM5S4DL DN Forigerimod
DM5S4DL HS Phase 3
DM5S4DL SN CEP-33457
DM5S4DL CP Cephalon
DM5S4DL DT Small molecular drug
DM5S4DL PC 56841982
DM5S4DL MW 2638.9
DM5S4DL FM C117H181N34O32PS
DM5S4DL IC InChI=1S/C117H181N34O32PS/c1-9-64(5)94(148-99(163)75(120)24-18-47-128-115(121)122)112(176)144-85(56-71-57-127-62-132-71)106(170)139-80(44-51-185-8)103(167)147-93(63(3)4)110(174)143-83(54-69-32-38-73(154)39-33-69)105(169)146-87(60-152)108(172)138-78(25-14-16-45-118)101(165)137-76(27-19-48-129-116(123)124)96(160)97(161)88(150-184(180,181)182)61-183-133-59-91(157)135-81(26-15-17-46-119)113(177)151-50-21-29-89(151)109(173)140-77(28-20-49-130-117(125)126)100(164)131-58-90(156)136-82(53-68-30-36-72(153)37-31-68)104(168)134-66(7)98(162)142-84(52-67-22-12-11-13-23-67)107(171)149-95(65(6)10-2)111(175)141-79(42-43-92(158)159)102(166)145-86(114(178)179)55-70-34-40-74(155)41-35-70/h11-13,22-23,30-41,57,62-66,75-89,93-95,133,152-155H,9-10,14-21,24-29,42-56,58-61,118-120H2,1-8H3,(H,127,132)(H,131,164)(H,134,168)(H,135,157)(H,136,156)(H,137,165)(H,138,172)(H,139,170)(H,140,173)(H,141,175)(H,142,162)(H,143,174)(H,144,176)(H,145,166)(H,146,169)(H,147,167)(H,148,163)(H,149,171)(H,158,159)(H,178,179)(H4,121,122,128)(H4,123,124,129)(H4,125,126,130)(H3,150,180,181,182)/t64-,65-,66-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,93-,94-,95-/m0/s1
DM5S4DL CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)O)NP(=O)(O)O)NC(=O)[C@H](CCCNC(=N)N)N
DM5S4DL IK LSLBZWAEEUGETG-GGVFYUGVSA-N
DM5S4DL IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S,5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-8-carbamimidamido-3,4-dioxo-2-(phosphonoamino)octoxy]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxopentanoic acid
DM5S4DL CA CAS 497156-60-2
DM5S4DL DE Systemic lupus erythematosus
DM8L3JU ID DM8L3JU
DM8L3JU DN Fosclin
DM8L3JU HS Phase 3
DM8L3JU SN Fosmidomycin + clindamycin (oral, malaria), Jomaa; Fosmidomycin + clindamycin fixed-dose combination (oral, malaria), Jomaa
DM8L3JU CP Jomaa Pharma GmbH
DM8L3JU DE Malaria
DM3274D ID DM3274D
DM3274D DN Fostamatinib disodium
DM3274D HS Phase 3
DM3274D SN 1025687-58-4; R788(prodrug of R406); R788 (Fostamatinib) Disodium; UNII-X9417132K8; R 788 sodium; R788(Fostamatinib disodium); R 935788 sodium; R935788 (Fostamatinib disodium, R788); R788 disodium; X9417132K8; R788 disodium hexahydrate; R788 SODIUM; R-788 disodium; R788, Fostamatinib; Tube731; sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate; Disodium (6-(5-fluoro-2-(3
DM3274D CP Rigel Pharmaceuticals South San Francisco, CA
DM3274D PC 25008120
DM3274D MW 624.4
DM3274D FM C23H24FN6Na2O9P
DM3274D IC InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
DM3274D CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+]
DM3274D IK HSYBQXDGYCYSGA-UHFFFAOYSA-L
DM3274D IU disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate
DM3274D CA CAS 1025687-58-4
DM3274D DE Thrombocytopenia
DM823WQ ID DM823WQ
DM823WQ DN FP-1201
DM823WQ HS Phase 3
DM823WQ SN Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical
DM823WQ CP Faron Pharmaceuticals Ltd
DM823WQ DE Acute lung injury
DMGF8MZ ID DMGF8MZ
DMGF8MZ DN FPL-62064
DMGF8MZ HS Phase 3
DMGF8MZ SN N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine
DMGF8MZ DT Small molecular drug
DMGF8MZ PC 128268
DMGF8MZ MW 265.31
DMGF8MZ FM C16H15N3O
DMGF8MZ IC InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)
DMGF8MZ CS COC1=CC=C(C=C1)NC2=NN(C=C2)C3=CC=CC=C3
DMGF8MZ IK WKLGNFJHVJIZPK-UHFFFAOYSA-N
DMGF8MZ IU N-(4-methoxyphenyl)-1-phenylpyrazol-3-amine
DMGF8MZ CA CAS 103141-09-9
DMGF8MZ DE Inflammation
DMHOSCQ ID DMHOSCQ
DMHOSCQ DN Fruquintinib
DMHOSCQ HS Phase 3
DMHOSCQ SN HMPL-013
DMHOSCQ CP Hutchison Medipharma Enterprises Ltd
DMHOSCQ PC 44480399
DMHOSCQ MW 393.4
DMHOSCQ FM C21H19N3O5
DMHOSCQ IC InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
DMHOSCQ CS CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC
DMHOSCQ IK BALLNEJQLSTPIO-UHFFFAOYSA-N
DMHOSCQ IU 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide
DMHOSCQ CA CAS 1194506-26-7
DMHOSCQ DE Solid tumour/cancer
DM1YVLM ID DM1YVLM
DM1YVLM DN FST-201
DM1YVLM HS Phase 3
DM1YVLM SN Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics
DM1YVLM CP Foresight Biotherapeutics Inc
DM1YVLM DE Otitis externa
DMDKYVE ID DMDKYVE
DMDKYVE DN FT-0624878
DMDKYVE HS Phase 3
DMDKYVE SN Cellulosepulver; DEAE-CELLULOSE; DEAE-Sephacel(R); Diethylaminoethyl cellulose; Diethylaminoethyl-Sephacel(R); SBB058705; SC-21746; cellulose; 9004-34-6; AKOS015895024; Cellulose, 2-(diethylamino)ethyl ether; Diethylaminoethyl-Sephacel(R), aqueous ethanol suspension, 40-160 mum (wet), exclusion limit ~1,000,000 Da; Express-Ion(TM) exchanger?? D free base, 60-130 mum; FT-0624878; M158
DMDKYVE PC 16211032
DMDKYVE MW 342.3
DMDKYVE FM C12H22O11
DMDKYVE IC GUBGYTABKSRVRQ-WFVLMXAXSA-N
DMDKYVE CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DMDKYVE IK 1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3?,4?,5?,6?,7?,8?,9?,10-,11?,12+/m1/s1
DMDKYVE IU (6S)-2-(hydroxymethyl)-6-[(3S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMDKYVE CA CAS 9004-34-6
DMDKYVE DE Human immunodeficiency virus infection
DMF4I1V ID DMF4I1V
DMF4I1V DN FT-0710230
DMF4I1V HS Phase 3
DMF4I1V SN Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2
DMF4I1V PC 10347
DMF4I1V IU 3-hydroxy-4-oxopyran-2,6-dicarboxylic acid
DMF4I1V DE Opiate dependence
DMK38MV ID DMK38MV
DMK38MV DN Fulranumab
DMK38MV HS Phase 3
DMK38MV CP Johnson & Johnson Pharmaceutical Research & Development
DMK38MV DT Monoclonal antibody
DMK38MV DE Cancer related pain; Back pain; Arthralgia
DMP83UZ ID DMP83UZ
DMP83UZ DN Fumaric acid
DMP83UZ HS Phase 3
DMP83UZ SN Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)
DMP83UZ CP Biogen Idec
DMP83UZ DT Small molecular drug
DMP83UZ PC 444972
DMP83UZ MW 116.07
DMP83UZ FM C4H4O4
DMP83UZ IC InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+
DMP83UZ CS C(=C/C(=O)O)\\C(=O)O
DMP83UZ IK VZCYOOQTPOCHFL-OWOJBTEDSA-N
DMP83UZ IU (E)-but-2-enedioic acid
DMP83UZ CA CAS 110-17-8
DMP83UZ CB CHEBI:18012
DMP83UZ DE Multiple sclerosis; Pustular palmoplantar psoriasis
DMZARP1 ID DMZARP1
DMZARP1 DN FV-100
DMZARP1 HS Phase 3
DMZARP1 SN CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy
DMZARP1 CP Welsh School of Pharmacy
DMZARP1 DT Small molecular drug
DMZARP1 PC 71587897
DMZARP1 MW 534
DMZARP1 FM C27H36ClN3O6
DMZARP1 IC InChI=1S/C27H35N3O6.ClH/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3;/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3;1H/t20-,22+,23+,24-;/m0./s1
DMZARP1 CS CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O.Cl
DMZARP1 IK CAHTYTZOAVUCIU-ZMQZINMSSA-N
DMZARP1 IU [(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DMZARP1 CA CAS 956483-03-7
DMZARP1 DE Varicella zoster virus infection
DMMNP2F ID DMMNP2F
DMMNP2F DN G17DT
DMMNP2F HS Phase 3
DMMNP2F SN Gastrimmune; Insegia
DMMNP2F CP Receptor Biologix
DMMNP2F DT Antibody
DMMNP2F DE Gastric adenocarcinoma
DMXJMKF ID DMXJMKF
DMXJMKF DN Ganaxolone
DMXJMKF HS Phase 3
DMXJMKF SN Ganaxolone [USAN]; CCD 1042; CCD-1042; Ganaxolone (USAN/INN); (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one
DMXJMKF CP Marinus
DMXJMKF DT Small molecular drug
DMXJMKF PC 6918305
DMXJMKF MW 332.5
DMXJMKF FM C22H36O2
DMXJMKF IC InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1
DMXJMKF CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C
DMXJMKF IK PGTVWKLGGCQMBR-FLBATMFCSA-N
DMXJMKF IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMXJMKF CA CAS 38398-32-2
DMXJMKF DE Postpartum depression; Complex partial seizure
DMWX90U ID DMWX90U
DMWX90U DN Gantenerumab
DMWX90U HS Phase 3
DMWX90U SN RG1450
DMWX90U CP Roche
DMWX90U DT Monoclonal antibody
DMWX90U DE Alzheimer disease
DMO3ITF ID DMO3ITF
DMO3ITF DN GASTRAZOLE
DMO3ITF HS Phase 3
DMO3ITF SN JB-95008; 5-[N-[5-[N-(Cycloheptylmethyl)carbamoyl]-1H-benzimidazol-6-ylcarbonyl]-2-fluoro-L-phenylalanylamino]isophthalic acid
DMO3ITF DT Small molecular drug
DMO3ITF PC 71587829
DMO3ITF MW 687.6
DMO3ITF FM C34H32FN5Na2O7
DMO3ITF IC InChI=1S/C34H34FN5O7.2Na/c35-26-10-6-5-9-20(26)14-29(32(43)39-23-12-21(33(44)45)11-22(13-23)34(46)47)40-31(42)25-16-28-27(37-18-38-28)15-24(25)30(41)36-17-19-7-3-1-2-4-8-19;;/h5-6,9-13,15-16,18-19,29H,1-4,7-8,14,17H2,(H,36,41)(H,37,38)(H,39,43)(H,40,42)(H,44,45)(H,46,47);;/q;2*+1/p-2/t29-;;/m0../s1
DMO3ITF CS C1CCCC(CC1)CNC(=O)C2=CC3=C(C=C2C(=O)N[C@@H](CC4=CC=CC=C4F)C(=O)NC5=CC(=CC(=C5)C(=O)[O-])C(=O)[O-])N=CN3.[Na+].[Na+]
DMO3ITF IK VHAXHRARUCKASM-UJXPALLWSA-L
DMO3ITF IU disodium;5-[[(2S)-2-[[6-(cycloheptylmethylcarbamoyl)-1H-benzimidazole-5-carbonyl]amino]-3-(2-fluorophenyl)propanoyl]amino]benzene-1,3-dicarboxylate
DMO3ITF CA CAS 862583-15-1
DMO3ITF DE Duodenal ulcer
DMT4QHD ID DMT4QHD
DMT4QHD DN GDC-0032
DMT4QHD HS Phase 3
DMT4QHD SN Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD CP Genentech
DMT4QHD DT Small molecular drug
DMT4QHD PC 51001932
DMT4QHD MW 460.5
DMT4QHD FM C24H28N8O2
DMT4QHD IC InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
DMT4QHD CS CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
DMT4QHD IK BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD IU 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
DMT4QHD CA CAS 1282512-48-4
DMT4QHD DE Solid tumour/cancer; Breast cancer
DMWBZJD ID DMWBZJD
DMWBZJD DN GDC-0068
DMWBZJD HS Phase 3
DMWBZJD SN RG7440
DMWBZJD CP Genentech
DMWBZJD DT Small molecular drug
DMWBZJD PC 24788740
DMWBZJD MW 458
DMWBZJD FM C24H32ClN5O2
DMWBZJD IC InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
DMWBZJD CS C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O
DMWBZJD IK GRZXWCHAXNAUHY-NSISKUIASA-N
DMWBZJD IU (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
DMWBZJD CA CAS 1001264-89-6
DMWBZJD CB CHEBI:95089
DMWBZJD DE Solid tumour/cancer; Breast cancer; Colorectal cancer; Gastric adenocarcinoma; Prostate cancer
DMBEL3Q ID DMBEL3Q
DMBEL3Q DN GDC-0853
DMBEL3Q HS Phase 3
DMBEL3Q SN Fenebrutinib
DMBEL3Q CP GenentechSouth San Francisco, CA
DMBEL3Q PC 86567195
DMBEL3Q MW 664.8
DMBEL3Q FM C37H44N8O4
DMBEL3Q IC InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1
DMBEL3Q CS C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8
DMBEL3Q IK WNEODWDFDXWOLU-QHCPKHFHSA-N
DMBEL3Q IU 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one
DMBEL3Q CA CAS 1434048-34-6
DMBEL3Q DE Solid tumour/cancer; Autoimmune disease; Chronic idiopathic urticaria; Multiple sclerosis
DMTUV7L ID DMTUV7L
DMTUV7L DN GED-0301
DMTUV7L HS Phase 3
DMTUV7L SN SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani
DMTUV7L CP Giuliani SpA
DMTUV7L DE Crohn disease; Ulcerative colitis
DM4GWL7 ID DM4GWL7
DM4GWL7 DN Gefapixant
DM4GWL7 HS Phase 3
DM4GWL7 SN UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid
DM4GWL7 CP Merck, Roche
DM4GWL7 PC 24764487
DM4GWL7 MW 353.4
DM4GWL7 FM C14H19N5O4S
DM4GWL7 IC InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
DM4GWL7 CS CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
DM4GWL7 IK HLWURFKMDLAKOD-UHFFFAOYSA-N
DM4GWL7 IU 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
DM4GWL7 CA CAS 1015787-98-0
DM4GWL7 DE Overactive bladder; Cough
DMZKGPV ID DMZKGPV
DMZKGPV DN Gemigliptin
DMZKGPV HS Phase 3
DMZKGPV SN 911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-
DMZKGPV CP LG Life Sciences Ltd
DMZKGPV DT Small molecular drug
DMZKGPV PC 11953153
DMZKGPV MW 489.4
DMZKGPV FM C18H19F8N5O2
DMZKGPV IC InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1
DMZKGPV CS C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
DMZKGPV IK ZWPRRQZNBDYKLH-VIFPVBQESA-N
DMZKGPV IU 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
DMZKGPV CA CAS 911637-19-9
DMZKGPV CB CHEBI:134731
DMZKGPV DE Diabetic complication; Type-2 diabetes
DM1WMOK ID DM1WMOK
DM1WMOK DN Generx
DM1WMOK HS Phase 3
DM1WMOK SN Alferminogene tadenovec
DM1WMOK CP Angionetics
DM1WMOK DT Gene therapy
DM1WMOK DE Angina pectoris
DM7ZOAE ID DM7ZOAE
DM7ZOAE DN GFT-505
DM7ZOAE HS Phase 3
DM7ZOAE SN GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit
DM7ZOAE CP Genfit SA
DM7ZOAE PC 9864881
DM7ZOAE MW 384.5
DM7ZOAE FM C22H24O4S
DM7ZOAE IC InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
DM7ZOAE CS CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
DM7ZOAE IK AFLFKFHDSCQHOL-IZZDOVSWSA-N
DM7ZOAE IU 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
DM7ZOAE CA CAS 923978-27-2
DM7ZOAE DE Type-2 diabetes; Non-alcoholic steatohepatitis
DMR6YH3 ID DMR6YH3
DMR6YH3 DN GLP-1
DMR6YH3 HS Phase 3
DMR6YH3 SN Glucagon-like peptide 1; Glucagon-like-peptide-1; Glucagon-like peptide-1; Proglucagon (72-108); Proglucagon (78-107)amide; Glucagon-related peptide I; 89750-14-1; GLP-1 (7-36) amide (human, bovine, guinea pig, mouse,; Oral GLP (diabetes, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes); Glucagon-like peptides (oral, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes), Emisphere; NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2
DMR6YH3 CP Emisphere Technologies Inc
DMR6YH3 PC 16135499
DMR6YH3 MW 3297.6
DMR6YH3 FM C149H226N40O45
DMR6YH3 IC InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMR6YH3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMR6YH3 IK DTHNMHAUYICORS-KTKZVXAJSA-N
DMR6YH3 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMR6YH3 CA CAS 89750-14-1
DMR6YH3 DE Diabetic complication
DMEFCTP ID DMEFCTP
DMEFCTP DN Glufosfamide
DMEFCTP HS Phase 3
DMEFCTP SN Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP CP Threshold Pharmaceuticals
DMEFCTP DT Small molecular drug
DMEFCTP PC 123628
DMEFCTP MW 383.16
DMEFCTP FM C10H21Cl2N2O7P
DMEFCTP IC InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
DMEFCTP CS C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMEFCTP IK PSVUJBVBCOISSP-SPFKKGSWSA-N
DMEFCTP IU (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP CA CAS 132682-98-5
DMEFCTP DE Ovarian cancer; Pancreatic cancer
DMOUT89 ID DMOUT89
DMOUT89 DN Glutamic acid
DMOUT89 HS Phase 3
DMOUT89 SN D(-)-Glutamic acid; D-(-)-Glutamic acid; D-2-Aminoglutaric acid; D-2-Aminopentanedioic acid; D-Glutamicacid; D-Glutaminic acid; D-Glutaminsaeure; D-glutamate; D-glutamic acid; Gamma-D-Glutamic Acid; Glutamic acid D-form; Glutamic acid, D-; H-D-Glu-OH; L(+)-Glutamic acid; Lopac-G-2128; Q479989WEA; R-(-)-Glutamic acid; Tocris-0217; WHUUTDBJXJRKMK-GSVOUGTGSA-N; glutamate; (2R)-2-aminopentanedioic acid; (R)-2-aminopentanedioic acid; (r)-glutamic acid; 6893-26-1; CHEBI:15966; CHEMBL76232; D-Glu; DGL; MFCD00063112; UNII-Q479989WEA
DMOUT89 PC 23327
DMOUT89 MW 147.13
DMOUT89 FM C5H9NO4
DMOUT89 IC WHUUTDBJXJRKMK-GSVOUGTGSA-N
DMOUT89 CS C(CC(=O)O)C(C(=O)O)N
DMOUT89 IK 1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1
DMOUT89 IU (2R)-2-aminopentanedioic acid
DMOUT89 CA CAS 6893-26-1
DMOUT89 CB CHEBI:15966
DMOUT89 DE Follicular lymphoma
DM8M2N3 ID DM8M2N3
DM8M2N3 DN Glycyrrhizin
DM8M2N3 HS Phase 3
DM8M2N3 SN Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-
DM8M2N3 DT Small molecular drug
DM8M2N3 PC 14982
DM8M2N3 MW 822.9
DM8M2N3 FM C42H62O16
DM8M2N3 IC InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
DM8M2N3 CS C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O
DM8M2N3 IK LPLVUJXQOOQHMX-QWBHMCJMSA-N
DM8M2N3 IU (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM8M2N3 CA CAS 1405-86-3
DM8M2N3 CB CHEBI:15939
DM8M2N3 DE Influenza virus infection
DMQCZ4N ID DMQCZ4N
DMQCZ4N DN Glyminox
DMQCZ4N HS Phase 3
DMQCZ4N SN Savvy
DMQCZ4N CP Biosyn Inc
DMQCZ4N DT Small molecular drug
DMQCZ4N PC 56842993
DMQCZ4N MW 599
DMQCZ4N FM C36H74N2O4
DMQCZ4N IC InChI=1S/C20H39NO3.C16H35NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(22)21(2,3)18-20(23)24;1-4-5-6-7-8-9-10-11-12-13-14-15-16-17(2,3)18/h4-18H2,1-3H3;4-16H2,1-3H3
DMQCZ4N CS CCCCCCCCCCCCCCCC(=O)[N+](C)(C)CC(=O)[O-].CCCCCCCCCCCCCC[N+](C)(C)[O-]
DMQCZ4N IK KALYGJOYPFFBRF-UHFFFAOYSA-N
DMQCZ4N IU N,N-dimethyltetradecan-1-amine oxide;2-[hexadecanoyl(dimethyl)azaniumyl]acetate
DMQCZ4N CA CAS 664323-11-9
DMQCZ4N DE Sexually transmitted infection
DMOHUR2 ID DMOHUR2
DMOHUR2 DN GLYX-13
DMOHUR2 HS Phase 3
DMOHUR2 SN Rapastinel; 117928-94-6; GLYX-13; GLYX 13; GLYX13; UNII-6A1X56B95E; L-Threoninamide, L-threonyl-L-prolyl-L-prolyl-; 6A1X56B95E; (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate; TPPT-amide; GLYX-13 peptide; Rapastinel [USAN:INN]; GLYX13;Rapastinel; Rapastinel(GLYX-13); L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate
DMOHUR2 CP Naurex
DMOHUR2 DT Small molecular drug
DMOHUR2 PC 14539800
DMOHUR2 MW 413.5
DMOHUR2 FM C18H31N5O6
DMOHUR2 IC InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
DMOHUR2 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DMOHUR2 IK GIBQQARAXHVEGD-BSOLPCOYSA-N
DMOHUR2 IU (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMOHUR2 CA CAS 117928-94-6
DMOHUR2 DE Major depressive disorder
DMQIE7U ID DMQIE7U
DMQIE7U DN GMA102
DMQIE7U HS Phase 3
DMQIE7U CP Gmax Biopharm
DMQIE7U DT Antibody
DMQIE7U DE Type-2 diabetes; Obesity
DM2XSG0 ID DM2XSG0
DM2XSG0 DN GMA105
DM2XSG0 HS Phase 3
DM2XSG0 CP Gmax Biopharm
DM2XSG0 DT Antibody
DM2XSG0 DE Type-2 diabetes; Obesity
DMJ432G ID DMJ432G
DMJ432G DN GMI-1070
DMJ432G HS Phase 3
DMJ432G SN GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics
DMJ432G CP Glycomimetics; pfizer
DMJ432G DT Small molecular drug
DMJ432G PC 44232546
DMJ432G MW 1447.4
DMJ432G FM C58H74N6O31S3
DMJ432G IC InChI=1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1
DMJ432G CS C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](C[C@H](C[C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O
DMJ432G IK VXBNTHRZPJLRSS-PTCSXESPSA-N
DMJ432G IU (2S)-2-[(2R,3R,4S,5S,6R)-3-benzoyloxy-2-[(1R,2R,3S,5R)-3-[(2,4-dioxo-1H-pyrimidine-6-carbonyl)amino]-5-[2-[[2-[2-[2-oxo-2-[(3,6,8-trisulfonaphthalen-1-yl)amino]ethoxy]ethoxy]acetyl]amino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMJ432G CA CAS 927881-99-0
DMJ432G DE Asthma; Vaso-occlusive crisis
DMDTGWQ ID DMDTGWQ
DMDTGWQ DN GMI-1271
DMDTGWQ HS Phase 3
DMDTGWQ SN Uproleselan
DMDTGWQ CP Glycomimetics
DMDTGWQ DT ?
DMDTGWQ PC 71600085
DMDTGWQ MW 1304.5
DMDTGWQ FM C60H109N3O27
DMDTGWQ IC InChI=1S/C60H109N3O27/c1-5-44-38-45(39-46(55(44)90-60-54(70)53(69)51(67)41(2)86-60)88-59-50(63-42(3)65)56(52(68)48(40-64)89-59)87-47(58(72)73)37-43-9-7-6-8-10-43)57(71)62-13-12-61-49(66)11-14-75-17-18-77-21-22-79-25-26-81-29-30-83-33-34-85-36-35-84-32-31-82-28-27-80-24-23-78-20-19-76-16-15-74-4/h41,43-48,50-56,59-60,64,67-70H,5-40H2,1-4H3,(H,61,66)(H,62,71)(H,63,65)(H,72,73)/t41-,44-,45+,46+,47-,48+,50+,51+,52-,53+,54-,55+,56+,59+,60-/m0/s1
DMDTGWQ CS CC[C@H]1C[C@H](C[C@H]([C@@H]1O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)C)O)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DMDTGWQ IK LYSYOXNOOPBOSC-NGSKMYNLSA-N
DMDTGWQ IU (2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMDTGWQ CA CAS 1983970-12-2
DMDTGWQ DE Multiple myeloma; Acute myeloid leukaemia
DM0LQ94 ID DM0LQ94
DM0LQ94 DN GnRH
DM0LQ94 HS Phase 3
DM0LQ94 SN Lutrepatch; GnRH (Lutrepatch, female fertility); GnRH (Lutrepatch, female fertility), Ferring; GnRH (Lutrepatch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Vyteris/Ferring; Iontophoretic anti-infertility peptide (Smart Patch), Ferring/Vyteris; Iontophoretic anti-infertility peptide (Smart Patch), Vyteris/Ferring; Anti-infertility peptide (iontophoretic/Smart Patch), Ferring/Vyteris; Anti-infertility peptide (iontophoretic/Smart Patch), Vyteris/Ferring; Gonadotropin-releasing hormone (Smart Patch, female infertility), Ferring/Vyteris; Gonadotropin-releasing hormone (Smart Patch, female infertility), Vyteris/Ferring
DM0LQ94 CP Ferring Pharmaceuticals Inc
DM0LQ94 PC 16132914
DM0LQ94 MW 1212.3
DM0LQ94 FM C60H73N15O13
DM0LQ94 IC InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84)
DM0LQ94 CS CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
DM0LQ94 IK NMJREATYWWNIKX-UHFFFAOYSA-N
DM0LQ94 IU N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM0LQ94 DE Female infertility
DMKWV4B ID DMKWV4B
DMKWV4B DN Golnerminogene pradenovac
DMKWV4B HS Phase 3
DMKWV4B SN TNFerade (TN)
DMKWV4B CP GenVec
DMKWV4B DE Esophageal cancer
DMZS2R7 ID DMZS2R7
DMZS2R7 DN Granexin gel
DMZS2R7 HS Phase 3
DMZS2R7 SN alphaCT1
DMZS2R7 CP FirstString Research
DMZS2R7 DE Diabetic foot ulcer; Keloidal surgical scar; Radiation syndrome
DM4Y7WV ID DM4Y7WV
DM4Y7WV DN GRASPA
DM4Y7WV HS Phase 3
DM4Y7WV SN L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
DM4Y7WV CP Erytech Pharma
DM4Y7WV DT Protein
DM4Y7WV SQ Elspar Sequence: QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDETHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMERVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTGGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAEACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTVATQ >sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
DM4Y7WV DE Pancreatic cancer; Acute lymphoblastic leukaemia
DM71GPM ID DM71GPM
DM71GPM DN Grippol Plus
DM71GPM HS Phase 3
DM71GPM SN Egg-based adjuvanted seasonal influenza vaccine, Solvay
DM71GPM CP Solvay SA
DM71GPM DT Vaccine
DM71GPM DE Influenza virus infection
DMB34TZ ID DMB34TZ
DMB34TZ DN Grippol TC
DMB34TZ HS Phase 3
DMB34TZ SN Grippol; Grippol Neo; Cell-based adjuvanted seasonal influenza vaccine, Solvay/Petrovax; Seasonal influenza vaccine (tissue culture), Solvay/Petrovax
DMB34TZ CP Solvay SA
DMB34TZ DT Vaccine
DMB34TZ DE Influenza virus infection
DMHN3PG ID DMHN3PG
DMHN3PG DN GRT-6005
DMHN3PG HS Phase 3
DMHN3PG SN Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183; Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06
DMHN3PG CP Forest laboratories
DMHN3PG DT Small molecular drug
DMHN3PG PC 11848225
DMHN3PG MW 378.5
DMHN3PG FM C24H27FN2O
DMHN3PG IC InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3
DMHN3PG CS CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5
DMHN3PG IK CSMVOZKEWSOFER-UHFFFAOYSA-N
DMHN3PG IU 6-fluoro-N,N-dimethyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
DMHN3PG CA CAS 863513-91-1
DMHN3PG DE Diabetic neuropathy
DMNZO7M ID DMNZO7M
DMNZO7M DN GS-441524
DMNZO7M HS Phase 3
DMNZO7M SN EVO984; EVO-984; EVO 984; GS 441524; GS441524
DMNZO7M TC Antiviral Agents
DMNZO7M DT Small molecular drug
DMNZO7M PC 44468216
DMNZO7M MW 291.26
DMNZO7M FM C12H13N5O4
DMNZO7M IC InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1
DMNZO7M CS C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N
DMNZO7M IK BRDWIEOJOWJCLU-LTGWCKQJSA-N
DMNZO7M IU (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile
DMNZO7M CA CAS 1191237-69-0
DMNZO7M CB CHEBI:147281
DMNZO7M DE Coronavirus Disease 2019 (COVID-19)
DMP8MDW ID DMP8MDW
DMP8MDW DN GS-5745
DMP8MDW HS Phase 3
DMP8MDW CP GILEAD
DMP8MDW PC 56776542
DMP8MDW MW 250.02
DMP8MDW FM C7H5BrFNO3
DMP8MDW IC InChI=1S/C7H5BrFNO3/c1-13-5-3-2-4(8)6(9)7(5)10(11)12/h2-3H,1H3
DMP8MDW CS COC1=C(C(=C(C=C1)Br)F)[N+](=O)[O-]
DMP8MDW IK LJJAOMRFFXQENV-UHFFFAOYSA-N
DMP8MDW IU 1-bromo-2-fluoro-4-methoxy-3-nitrobenzene
DMP8MDW CA CAS 1352317-80-6
DMP8MDW DE Ulcerative colitis; Solid tumour/cancer; Crohn disease; Gastric adenocarcinoma; Rheumatoid arthritis
DMGJQVI ID DMGJQVI
DMGJQVI DN GS-6615
DMGJQVI HS Phase 3
DMGJQVI SN Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C
DMGJQVI CP GILEAD
DMGJQVI DT Small molecular drug
DMGJQVI PC 71183216
DMGJQVI MW 415.4
DMGJQVI FM C21H16F3N3O3
DMGJQVI IC InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
DMGJQVI CS C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4
DMGJQVI IK YNUAEEJQYHYLMS-UHFFFAOYSA-N
DMGJQVI IU 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DMGJQVI CA CAS 1443211-72-0
DMGJQVI DE Ischemic heart disease; Long QT syndrome
DM936V7 ID DM936V7
DM936V7 DN GS-9674
DM936V7 HS Phase 3
DM936V7 SN Cilofexor; 1418274-28-8; UNII-YUN2306954; PX104; 1418274-28-8 (free acid); YUN2306954; 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxyazetidin-1-yl)isonicotinic acid; GS 9674; 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid; Cilofexor [INN]; Cilofexor (GS(c)\\9674); CHEMBL4297613; SCHEMBL14641986; GTPL10644; BCP29283; BDBM50511109; GS9674; s6547; DB15168; example 13/9 [US10485795B2]; HY-109083; CS-0039260; 2-(3-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-4-pyridinecarboxylic acid; 4-Pyridinecarboxylic acid, 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-
DM936V7 DT Small molecular drug
DM936V7 PC 71228883
DM936V7 MW 586.8
DM936V7 FM C28H22Cl3N3O5
DM936V7 IC InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
DM936V7 CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl
DM936V7 IK KZSKGLFYQAYZCO-UHFFFAOYSA-N
DM936V7 IU 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid
DM936V7 CA CAS 1418274-28-8
DM936V7 DE Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
DMT8J0I ID DMT8J0I
DMT8J0I DN GSK1265744
DMT8J0I HS Phase 3
DMT8J0I SN Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265
DMT8J0I CP GSK
DMT8J0I DT Small molecular drug
DMT8J0I PC 54713659
DMT8J0I MW 405.4
DMT8J0I FM C19H17F2N3O5
DMT8J0I IC InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
DMT8J0I CS C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMT8J0I IK WCWSTNLSLKSJPK-LKFCYVNXSA-N
DMT8J0I IU (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
DMT8J0I CA CAS 1051375-10-0
DMT8J0I DE Human immunodeficiency virus infection
DMRNGD2 ID DMRNGD2
DMRNGD2 DN GSK1278863
DMRNGD2 HS Phase 3
DMRNGD2 SN Daprodustat; 960539-70-2; GSK1278863; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat; GSK1278863; Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874
DMRNGD2 CP GSK
DMRNGD2 DT Small molecular drug
DMRNGD2 PC 91617630
DMRNGD2 MW 393.4
DMRNGD2 FM C19H27N3O6
DMRNGD2 IC InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
DMRNGD2 CS C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
DMRNGD2 IK RUEYEZADQJCKGV-UHFFFAOYSA-N
DMRNGD2 IU 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid
DMRNGD2 CA CAS 960539-70-2
DMRNGD2 DE Autism spectrum disorder; Diabetic foot ulcer; Anaemia
DMSMFN2 ID DMSMFN2
DMSMFN2 DN GSK2140944
DMSMFN2 HS Phase 3
DMSMFN2 SN Gepotidacin
DMSMFN2 CP Glaxosmithkline
DMSMFN2 PC 25101874
DMSMFN2 MW 448.5
DMSMFN2 FM C24H28N6O3
DMSMFN2 IC InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
DMSMFN2 CS C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6
DMSMFN2 IK PZFAZQUREQIODZ-LJQANCHMSA-N
DMSMFN2 IU (3R)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
DMSMFN2 CA CAS 1075236-89-3
DMSMFN2 DE Acute bacterial skin infection; Urinary tract infection; Neisseria gonorrhoeae infection
DMWL2XD ID DMWL2XD
DMWL2XD DN GSK2402968
DMWL2XD HS Phase 3
DMWL2XD CP GlaxoSmithKline; Prosensa
DMWL2XD DE Duchenne dystrophy
DMUVZAO ID DMUVZAO
DMUVZAO DN GSK642444
DMUVZAO HS Phase 3
DMUVZAO SN threo isoleucyl thiazolidide, 1; BDBM17299
DMUVZAO CP Theravance; GlaxoSmithKline
DMUVZAO DT Small molecular drug
DMUVZAO PC 23647689
DMUVZAO MW 203.33
DMUVZAO FM C9H19N2OS+
DMUVZAO IC InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/p+1/t7-,8-/m0/s1
DMUVZAO CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)[NH3+]
DMUVZAO IK WCRLBFHWFPELKW-YUMQZZPRSA-O
DMUVZAO IU [(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3-yl)pentan-2-yl]azanium
DMUVZAO DE Chronic obstructive pulmonary disease
DMPS7U2 ID DMPS7U2
DMPS7U2 DN GTPL-9088
DMPS7U2 HS Phase 3
DMPS7U2 SN Clobetasona; Clobetasona [INN-Spanish]; Clobetasone; Clobetasone (INN); Clobetasone [INN:BAN]; Clobetasonum; Clobetasonum [INN-Latin]; LT69WY1J6D; SCHEMBL3581; XXIFVOHLGBURIG-OZCCCYNHSA-N; ZINC5752185; (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione; 21-Chlor-9-fluor-17-hydroxy-16beta-methyl-1,4-pregnadien-3,11,20-trion; 54063-32-0; AC1L2G2H; API0002061; D07717; DB13158; EINECS 258-953-5; GTPL9088; UNII-LT69WY1J6D
DMPS7U2 PC 71387
DMPS7U2 MW 408.9
DMPS7U2 FM C22H26ClFO4
DMPS7U2 IC XXIFVOHLGBURIG-OZCCCYNHSA-N
DMPS7U2 CS CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(=O)CC2(C1(C(=O)CCl)O)C)F)C
DMPS7U2 IK 1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
DMPS7U2 IU (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione
DMPS7U2 CA CAS 54063-32-0
DMPS7U2 DE Atopic dermatitis
DM9Y3EG ID DM9Y3EG
DM9Y3EG DN Guadecitabine
DM9Y3EG HS Phase 3
DM9Y3EG SN UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
DM9Y3EG CP Astex Pharmaceuticals Pleasanton, CA
DM9Y3EG PC 135564655
DM9Y3EG MW 557.4
DM9Y3EG FM C18H24N9O10P
DM9Y3EG IC InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1
DM9Y3EG CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O
DM9Y3EG IK GUWXKKAWLCENJA-WGWHJZDNSA-N
DM9Y3EG IU [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DM9Y3EG CA CAS 929901-49-5
DM9Y3EG DE Myelodysplastic syndrome
DMN4E7T ID DMN4E7T
DMN4E7T DN Guaiacol
DMN4E7T HS Phase 3
DMN4E7T SN guaiacol; 2-Methoxyphenol; 90-05-1; o-Methoxyphenol; 2-Hydroxyanisole; Phenol, 2-methoxy-; Pyrocatechol monomethyl ether; Methylcatechol; Guaiastil; Guaicol; 1-Hydroxy-2-methoxybenzene; Pyroguaiac acid; o-Guaiacol; o-Hydroxyanisole; Guaicolina; Guajol; Guasol; Anastil; Phenol, o-methoxy-; Catechol monomethyl ether; O-Methyl catechol; CREOSOTE, WOOD; Methoxyphenol; Guajakol; Wood creosote; 2-Methoxy-Phenol; Creosote, beechwood; Guajacol; Methyl Catechol; Phenol, methoxy-; Guajakol [Czech]; Guaiacol (natural); 8021-39-4; Methylcatachol
DMN4E7T DT Small molecular drug
DMN4E7T PC 460
DMN4E7T MW 124.14
DMN4E7T FM C7H8O2
DMN4E7T IC InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3
DMN4E7T CS COC1=CC=CC=C1O
DMN4E7T IK LHGVFZTZFXWLCP-UHFFFAOYSA-N
DMN4E7T IU 2-methoxyphenol
DMN4E7T CA CAS 8021-39-4
DMN4E7T CB CHEBI:28591
DMIWLJE ID DMIWLJE
DMIWLJE DN Guanine
DMIWLJE HS Phase 3
DMIWLJE DT Small molecular drug
DMIWLJE PC 135398634
DMIWLJE MW 151.13
DMIWLJE FM C5H5N5O
DMIWLJE IC InChI=1S/C5H5N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DMIWLJE CS C1=NC2=C(N1)C(=O)NC(=N2)N
DMIWLJE IK UYTPUPDQBNUYGX-UHFFFAOYSA-N
DMIWLJE IU 2-amino-1,7-dihydropurin-6-one
DMIWLJE CA CAS 73-40-5
DMIWLJE CB CHEBI:16235
DMHULRK ID DMHULRK
DMHULRK DN GV1001
DMHULRK HS Phase 3
DMHULRK SN GV1001
DMHULRK CP KAEL-GemVax
DMHULRK DT Vaccine
DMHULRK DE Pancreatic cancer
DMAXTFO ID DMAXTFO
DMAXTFO DN H1N1 influenza vaccine
DMAXTFO HS Phase 3
DMAXTFO SN Humenza; H1N1 influenza vaccine (AF-03-adjuvanted, EU market); H1N1 influenza vaccine (AF-03-adjuvanted, EU market), Sanofi Pasteur
DMAXTFO CP Sanofi Pasteur
DMAXTFO DT Vaccine
DMAXTFO DE Influenza virus infection
DM9CMI3 ID DM9CMI3
DM9CMI3 DN H5N1 influenza vaccine
DM9CMI3 HS Phase 3
DM9CMI3 SN KIB-PIA; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted); Avian influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato
DM9CMI3 CP Kitasato Institute
DM9CMI3 DT Vaccine
DM9CMI3 DE Influenza virus infection
DMQ38JZ ID DMQ38JZ
DMQ38JZ DN HB-AS02V
DMQ38JZ HS Phase 3
DMQ38JZ SN HBV vaccine (adjuvanted), Henogen; Hepatitis B virus vaccine (adjuvanted), Henogen
DMQ38JZ CP Henogen SA
DMQ38JZ DT Vaccine
DMQ38JZ DE Hepatitis B virus infection
DMB06MU ID DMB06MU
DMB06MU DN HC-1119
DMB06MU HS Phase 3
DMB06MU SN Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-
DMB06MU CP Hinova Pharmaceuticals
DMB06MU DT Small molecular drug
DMB06MU PC 71580408
DMB06MU MW 467.5
DMB06MU FM C21H16F4N4O2S
DMB06MU IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
DMB06MU CS [2H]C([2H])([2H])NC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)F
DMB06MU IK WXCXUHSOUPDCQV-HPRDVNIFSA-N
DMB06MU IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-(trideuteriomethyl)benzamide
DMB06MU CA CAS 1443331-82-5
DMB06MU DE Prostate cancer
DMB9U5E ID DMB9U5E
DMB9U5E DN HE3286
DMB9U5E HS Phase 3
DMB9U5E SN Triolex; HE3286; UNII-PH8858757I; PH8858757I; 1004264-32-7; HE 3286; HE-3286; 1001100-69-1; SCHEMBL512549; 3beta,7beta,17beta-Trihydroxy-17alpha-ethynylandrost-5-ene; DB05212; Pregn-5-en-20-yne-3,7,17-triol, (3beta,7beta,17alpha)-
DMB9U5E CP Hollis-Eden Pharmaceuticals
DMB9U5E DT Small molecular drug
DMB9U5E PC 16739648
DMB9U5E MW 330.5
DMB9U5E FM C21H30O3
DMB9U5E IC InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
DMB9U5E CS C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O
DMB9U5E IK JJKOQZHWYLMASZ-FJWDNACWSA-N
DMB9U5E IU (3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol
DMB9U5E CA CAS 1001100-69-1
DMB9U5E DE Type-2 diabetes
DMQTLVB ID DMQTLVB
DMQTLVB DN Hebergel
DMQTLVB HS Phase 3
DMQTLVB SN Interferon alpha 2b gel (viral infection), CIGB
DMQTLVB CP Center for Genetic Engineering and Biotechnology
DMQTLVB DE Virus infection
DMUE843 ID DMUE843
DMUE843 DN Hematide
DMUE843 HS Phase 3
DMUE843 CP Affymax Inc; Takeda Pharmaceutical Co Ltd.
DMUE843 DE Anemia
DMGFULM ID DMGFULM
DMGFULM DN Heparin low molecular weight
DMGFULM HS Phase 3
DMGFULM SN Heparin low molecular weight, Watson Laboratories; Heparin transmucosal, TheraTech
DMGFULM CP Watson Laboratories Inc
DMGFULM DE Thrombosis
DMXAZ47 ID DMXAZ47
DMXAZ47 DN HGH-CTP
DMXAZ47 HS Phase 3
DMXAZ47 SN MOD-401; MOD-4023; Human growth hormone (injectable, CTP, growth disorder), Modigene; Long-acting hGH (injectable, CTP, growth disorder), Modigene
DMXAZ47 CP Prolor biotech; chiasma
DMXAZ47 DE Growth hormone deficiency
DM6QOVN ID DM6QOVN
DM6QOVN DN HKI-272
DM6QOVN HS Phase 3
DM6QOVN SN Neratinib (ERBB2 inhibitor)
DM6QOVN CP Wyeth Research
DM6QOVN TC Anticancer Agents
DM6QOVN DT Small molecular drug
DM6QOVN PC 9915743
DM6QOVN MW 557
DM6QOVN FM C30H29ClN6O3
DM6QOVN IC InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
DM6QOVN CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C
DM6QOVN IK JWNPDZNEKVCWMY-VQHVLOKHSA-N
DM6QOVN IU (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DM6QOVN CA CAS 698387-09-6
DM6QOVN CB CHEBI:61397
DM6QOVN DE Breast cancer
DM29XGY ID DM29XGY
DM29XGY DN HMPL-004
DM29XGY HS Phase 3
DM29XGY SN Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
DM29XGY CP Hutchison Medipharma Enterprises Ltd
DM29XGY DE Inflammatory bowel disease
DMAVIPZ ID DMAVIPZ
DMAVIPZ DN HSR-803
DMAVIPZ HS Phase 3
DMAVIPZ SN Ganaton; ITOPRIDE HCl; Itopride (hydrochloride); Q-201260; itopride hydrochloride; 122892-31-3; 2H9NV66W0I; C20H27ClN2O4; DSSTox_CID_26693; DSSTox_GSID_46693; DSSTox_RID_81827; HSR-803; HSR803; Hsr 803; Itax; MFCD00881710; N-((4-(2-(Dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxidebenzamide hydrochloride; N-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide; UNII-2H9NV66W0I; n-[4-(2-dimethylaminoethoxy)benzyl]-3,4-dimethoxybenzamide hcl
DMAVIPZ PC 129791
DMAVIPZ MW 394.9
DMAVIPZ FM C20H27ClN2O4
DMAVIPZ IC ZTOUXLLIPWWHSR-UHFFFAOYSA-N
DMAVIPZ CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC.Cl
DMAVIPZ IK 1S/C20H26N2O4.ClH/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4;/h5-10,13H,11-12,14H2,1-4H3,(H,21,23);1H
DMAVIPZ IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide;hydrochloride
DMAVIPZ CA CAS 122892-31-3
DMAVIPZ DE Functional nausea/vomiting
DMBER0Q ID DMBER0Q
DMBER0Q DN Hu5F9-G4
DMBER0Q HS Phase 3
DMBER0Q CP Forty Seven Menlo Park, CA
DMBER0Q DE Solid tumour/cancer; Acute myeloid leukaemia; Colorectal cancer; B-cell non-hodgkin lymphoma; Myelodysplastic syndrome
DMXZAL2 ID DMXZAL2
DMXZAL2 DN Hydroxychloroquine
DMXZAL2 HS Phase 3
DMXZAL2 SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMXZAL2 CP Concordia Pharmaceuticals Inc
DMXZAL2 TC Antiviral Agents
DMXZAL2 DT Small molecular drug
DMXZAL2 PC 3652
DMXZAL2 MW 335.9
DMXZAL2 FM C18H26ClN3O
DMXZAL2 IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMXZAL2 CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMXZAL2 IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMXZAL2 IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMXZAL2 CA CAS 118-42-3
DMXZAL2 CB CHEBI:5801
DMXZAL2 DE Malaria; Coronavirus Disease 2019 (COVID-19)
DMIGFOR ID DMIGFOR
DMIGFOR DN I3C
DMIGFOR HS Phase 3
DMIGFOR SN Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165
DMIGFOR DT Small molecular drug
DMIGFOR PC 3712
DMIGFOR MW 147.17
DMIGFOR FM C9H9NO
DMIGFOR IC InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2
DMIGFOR CS C1=CC=C2C(=C1)C(=CN2)CO
DMIGFOR IK IVYPNXXAYMYVSP-UHFFFAOYSA-N
DMIGFOR IU 1H-indol-3-ylmethanol
DMIGFOR CA CAS 700-06-1
DMIGFOR CB CHEBI:24814
DMIGFOR DE Breast cancer
DM5KL8E ID DM5KL8E
DM5KL8E DN IBI-308
DM5KL8E HS Phase 3
DM5KL8E CP Innovent Biologics
DM5KL8E DT Monoclonal antibody
DM5KL8E DE Bronchioalveolar carcinoma
DM9G5XD ID DM9G5XD
DM9G5XD DN IB-MECA
DM9G5XD HS Phase 3
DM9G5XD SN IB-Meca; 152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide; 3-IB-MECA
DM9G5XD DT Small molecular drug
DM9G5XD PC 123683
DM9G5XD MW 510.3
DM9G5XD FM C18H19IN6O4
DM9G5XD IC InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
DM9G5XD CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O
DM9G5XD IK HUJXGQILHAUCCV-MOROJQBDSA-N
DM9G5XD IU (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DM9G5XD CA CAS 152918-18-8
DM9G5XD CB CHEBI:73286
DM9G5XD DE Solid tumour/cancer; Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis
DMT67EH ID DMT67EH
DMT67EH DN Ibodutant
DMT67EH HS Phase 3
DMT67EH SN MEN-15596; Tachykinin NK2 receptor antagonist (irritable bowel syndrome), Menarini
DMT67EH CP The Menarini Group
DMT67EH DT Small molecular drug
DMT67EH PC 11527495
DMT67EH MW 644.9
DMT67EH FM C37H48N4O4S
DMT67EH IC InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1
DMT67EH CS CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6
DMT67EH IK YQYSVMKCMIUCHY-WJOKGBTCSA-N
DMT67EH IU 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4-yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
DMT67EH CA CAS 522664-63-7
DMT67EH DE Irritable bowel syndrome
DMOJQGT ID DMOJQGT
DMOJQGT DN ICARIIN
DMOJQGT HS Phase 3
DMOJQGT SN Icariin; 489-32-7; Ieariline; UNII-VNM47R2QSQ; CHEBI:78420; VNM47R2QSQ; Icariine; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Icarin; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(be
DMOJQGT DT Small molecular drug
DMOJQGT PC 5318997
DMOJQGT MW 676.7
DMOJQGT FM C33H40O15
DMOJQGT IC InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1
DMOJQGT CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O
DMOJQGT IK TZJALUIVHRYQQB-XLRXWWTNSA-N
DMOJQGT IU 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMOJQGT CA CAS 489-32-7
DMOJQGT CB CHEBI:78420
DM3OU54 ID DM3OU54
DM3OU54 DN ICI 118,551
DM3OU54 HS Phase 3
DM3OU54 SN Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
DM3OU54 DT Small molecular drug
DM3OU54 PC 3682
DM3OU54 MW 277.4
DM3OU54 FM C17H27NO2
DM3OU54 IC InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3
DM3OU54 CS CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
DM3OU54 IK VFIDUCMKNJIJTO-UHFFFAOYSA-N
DM3OU54 IU 1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
DM3OU54 CB CHEBI:91879
DM3OU54 DE Gastric adenocarcinoma; HER2-positive breast cancer
DM7YNV9 ID DM7YNV9
DM7YNV9 DN Iclaprim
DM7YNV9 HS Phase 3
DM7YNV9 SN 192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine
DM7YNV9 CP Arpida
DM7YNV9 DT Small molecular drug
DM7YNV9 PC 213043
DM7YNV9 MW 354.4
DM7YNV9 FM C19H22N4O3
DM7YNV9 IC InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
DM7YNV9 CS COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
DM7YNV9 IK HWJPWWYTGBZDEG-UHFFFAOYSA-N
DM7YNV9 IU 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine
DM7YNV9 CA CAS 192314-93-5
DM7YNV9 CB CHEBI:131751
DM7YNV9 DE Pneumonia; Bacterial infection; Acute bacterial skin infection
DMU72KL ID DMU72KL
DMU72KL DN ICP-022
DMU72KL HS Phase 3
DMU72KL SN Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
DMU72KL CP InnoCare Pharma
DMU72KL DT Small molecular drug
DMU72KL PC 91667513
DMU72KL MW 427.5
DMU72KL FM C26H25N3O3
DMU72KL IC InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
DMU72KL CS C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
DMU72KL IK MZPVEMOYADUARK-UHFFFAOYSA-N
DMU72KL IU 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
DMU72KL CA CAS 1655504-04-3
DMU72KL DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMBIZ7H ID DMBIZ7H
DMBIZ7H DN ICT-107
DMBIZ7H HS Phase 3
DMBIZ7H CP ImmunoCellular Therapeutics
DMBIZ7H DT Vaccine
DMBIZ7H DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma
DMSP0X8 ID DMSP0X8
DMSP0X8 DN IDAZOXAN HYDROCHLORIDE
DMSP0X8 HS Phase 3
DMSP0X8 SN IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d
DMSP0X8 DT Small molecular drug
DMSP0X8 PC 154494
DMSP0X8 MW 240.68
DMSP0X8 FM C11H13ClN2O2
DMSP0X8 IC InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
DMSP0X8 CS C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl
DMSP0X8 IK MYUBYOVCLMEAOH-UHFFFAOYSA-N
DMSP0X8 IU 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride
DMSP0X8 CA CAS 79944-56-2
DMSP0X8 DE Neurological disorder
DMV3DHQ ID DMV3DHQ
DMV3DHQ DN IDDBCP161883
DMV3DHQ HS Phase 3
DMV3DHQ CP Mitsubishi Tanabe
DMV3DHQ DE Type-2 diabetes
DM3A701 ID DM3A701
DM3A701 DN IDP-122
DM3A701 HS Phase 3
DM3A701 CP Valeant Pharmaceuticals Bridgewater, NJ
DM3A701 DE Plaque psoriasis
DMRLVUD ID DMRLVUD
DMRLVUD DN Imagabalin
DMRLVUD HS Phase 3
DMRLVUD SN Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
DMRLVUD CP Pfizer Inc
DMRLVUD DT Small molecular drug
DMRLVUD PC 10236037
DMRLVUD MW 173.25
DMRLVUD FM C9H19NO2
DMRLVUD IC InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
DMRLVUD CS CCC[C@@H](C)C[C@@H](CC(=O)O)N
DMRLVUD IK JXEHXYFSIOYTAH-SFYZADRCSA-N
DMRLVUD IU (3S,5R)-3-amino-5-methyloctanoic acid
DMRLVUD CA CAS 610300-07-7
DMRLVUD DE Generalized anxiety disorder
DMM9JEF ID DMM9JEF
DMM9JEF DN Imatinib
DMM9JEF HS Phase 3
DMM9JEF SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DMM9JEF CP Novartis AG
DMM9JEF TC Antiviral Agents
DMM9JEF DT Small molecular drug
DMM9JEF PC 5291
DMM9JEF MW 493.6
DMM9JEF FM C29H31N7O
DMM9JEF IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DMM9JEF CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DMM9JEF IK KTUFNOKKBVMGRW-UHFFFAOYSA-N
DMM9JEF IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMM9JEF CA CAS 152459-95-5
DMM9JEF CB CHEBI:45783
DMM9JEF DE Chronic myelogenous leukaemia; Intestinal cancer; Lung cancer; Systemic mastocytosis; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7BCWT ID DM7BCWT
DM7BCWT DN Imiglitazar
DM7BCWT HS Phase 3
DM7BCWT SN TAK-559
DM7BCWT CP Takeda Pharmaceutical Co Ltd
DM7BCWT DT Small molecular drug
DM7BCWT PC 9890879
DM7BCWT MW 470.5
DM7BCWT FM C28H26N2O5
DM7BCWT IC InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+
DM7BCWT CS CC1=C(N=C(O1)C2=CC=CC=C2)COC3=CC=C(C=C3)CO/N=C(\\CCC(=O)O)/C4=CC=CC=C4
DM7BCWT IK ULVDFHLHKNJICZ-QCWLDUFUSA-N
DM7BCWT IU (4E)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid
DM7BCWT CA CAS 250601-04-8
DM7BCWT DE Type-2 diabetes
DM735FA ID DM735FA
DM735FA DN IMO-2125
DM735FA HS Phase 3
DM735FA CP Idera Pharmaceuticals
DM735FA DE Hepatitis C virus infection; Melanoma; Solid tumour/cancer
DMIJGT9 ID DMIJGT9
DMIJGT9 DN INCB24360
DMIJGT9 HS Phase 3
DMIJGT9 SN Epacadostat
DMIJGT9 CP Incyte
DMIJGT9 DT Small molecular drug
DMIJGT9 PC 135564890
DMIJGT9 MW 438.24
DMIJGT9 FM C11H13BrFN7O4S
DMIJGT9 IC InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
DMIJGT9 CS C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F
DMIJGT9 IK FBKMWOJEPMPVTQ-UHFFFAOYSA-N
DMIJGT9 IU N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide
DMIJGT9 CA CAS 1204669-58-8
DMIJGT9 DE Recurrent glioblastoma; Melanoma; B-cell lymphoma; Colorectal cancer; Head and neck cancer; Lung cancer; Lymphoma; Merkel cell carcinoma; Ovarian cancer; Solid tumour/cancer; Urothelial carcinoma
DMZA2K0 ID DMZA2K0
DMZA2K0 DN INCSHR1210
DMZA2K0 HS Phase 3
DMZA2K0 SN Camrelizumab
DMZA2K0 CP Incyte Wilmington, DE
DMZA2K0 DT Monoclonal antibody
DMZA2K0 DE Solid tumour/cancer; Bronchioalveolar carcinoma; Esophageal squamous cell carcinoma
DMLG96Z ID DMLG96Z
DMLG96Z DN INM-176
DMLG96Z HS Phase 3
DMLG96Z SN WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn
DMLG96Z CP Scigenic & Scigen Harvest Co Ltd
DMLG96Z DE Alzheimer disease
DM5L8QT ID DM5L8QT
DM5L8QT DN INO-1001
DM5L8QT HS Phase 3
DM5L8QT SN Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
DM5L8QT CP Inotek Pharma.
DM5L8QT TC Anticancer Agents
DM5L8QT DT Small molecular drug
DM5L8QT PC 6708742
DM5L8QT DE Brain cancer
DMUS1F8 ID DMUS1F8
DMUS1F8 DN Inolimomab
DMUS1F8 HS Phase 3
DMUS1F8 CP EUSA Pharma
DMUS1F8 DT Monoclonal antibody
DMUS1F8 DE Heart transplant rejection
DMOTH6V ID DMOTH6V
DMOTH6V DN Interferon alpha 2a
DMOTH6V HS Phase 3
DMOTH6V SN LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS
DMOTH6V CP LG Life Sciences Ltd
DMOTH6V DE Hepatitis C virus infection
DMZA47Y ID DMZA47Y
DMZA47Y DN Iomab-B
DMZA47Y HS Phase 3
DMZA47Y SN Iomab-B (TN)
DMZA47Y CP Actinium Pharmaceuticals
DMZA47Y DT Antibody
DMZA47Y DE Acute myeloid leukaemia; Bone marrow transplantation
DMSV12M ID DMSV12M
DMSV12M DN Isavuconazole
DMSV12M HS Phase 3
DMSV12M SN Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; 60UTO373KE; Isavuconazole(BAL-4815; RO-0094815); RO 0094815; CHEBI:85979; Isavuconazole (INN); RO-0094815; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 1286730-05-9; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M CP Astellas
DMSV12M DT Small molecular drug
DMSV12M PC 6918485
DMSV12M MW 437.5
DMSV12M FM C22H17F2N5OS
DMSV12M IC InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
DMSV12M CS C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O
DMSV12M IK DDFOUSQFMYRUQK-RCDICMHDSA-N
DMSV12M IU 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M CA CAS 241479-67-4
DMSV12M CB CHEBI:85979
DMSV12M DE Invasive aspergillosis; Invasive candidiasis; Candidemia
DMQZI7K ID DMQZI7K
DMQZI7K DN ISIS 23722
DMQZI7K HS Phase 3
DMQZI7K CP Isis Pharmaceuticals
DMQZI7K SQ TGTGCTATTCTGTGAATT
DMQZI7K DE Solid tumour/cancer
DMKWBJR ID DMKWBJR
DMKWBJR DN ISIS-PKK
DMKWBJR HS Phase 3
DMKWBJR SN ISIS-PKKRx
DMKWBJR DT Antisense drug
DMKWBJR DE Amyloid cardiomyopathy
DM4U5NF ID DM4U5NF
DM4U5NF DN ISIS-TTR
DM4U5NF HS Phase 3
DM4U5NF CP ISIS Pharm
DM4U5NF DT Antisense drug
DM4U5NF DE Amyloidosis
DMBJTVL ID DMBJTVL
DMBJTVL DN Isotretinoin
DMBJTVL HS Phase 3
DMBJTVL SN Accutane; 13-cis-Retinoic acid; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; isotretinoino; Isotretinoinum; Isotretinoine; Roaccutan; 13-RA; Roacutan; Absorica; ISOTRETINON; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; CCRIS 4286; HSDB 3929
DMBJTVL TC Antiviral Agents
DMBJTVL DT Small molecular drug
DMBJTVL PC 5282379
DMBJTVL MW 300.4
DMBJTVL FM C20H28O2
DMBJTVL IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DMBJTVL CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DMBJTVL IK SHGAZHPCJJPHSC-XFYACQKRSA-N
DMBJTVL IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMBJTVL CA CAS 4759-48-2
DMBJTVL CB CHEBI:6067
DMBJTVL DE Coronavirus Disease 2019 (COVID-19)
DMP61YB ID DMP61YB
DMP61YB DN ISRAPAFANT
DMP61YB HS Phase 3
DMP61YB SN Y-24180; Israpafant; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
DMP61YB DT Small molecular drug
DMP61YB PC 119175
DMP61YB MW 489.1
DMP61YB FM C28H29ClN4S
DMP61YB IC InChI=1S/C28H29ClN4S/c1-17(2)15-21-11-9-20(10-12-21)13-14-22-16-24-26(23-7-5-6-8-25(23)29)30-18(3)27-32-31-19(4)33(27)28(24)34-22/h5-12,16-18H,13-15H2,1-4H3
DMP61YB CS CC1C2=NN=C(N2C3=C(C=C(S3)CCC4=CC=C(C=C4)CC(C)C)C(=N1)C5=CC=CC=C5Cl)C
DMP61YB IK RMSWMRJVUJSDGN-UHFFFAOYSA-N
DMP61YB IU 7-(2-chlorophenyl)-9,13-dimethyl-4-[2-[4-(2-methylpropyl)phenyl]ethyl]-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMP61YB CA CAS 117279-73-9
DMP61YB DE Asthma
DMNDGWE ID DMNDGWE
DMNDGWE DN IT-101
DMNDGWE HS Phase 3
DMNDGWE CP Insert Therapeutics
DMNDGWE DE Solid tumour/cancer
DMFZBNE ID DMFZBNE
DMFZBNE DN ITF2357
DMFZBNE HS Phase 3
DMFZBNE SN Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
DMFZBNE CP Italfarmaco
DMFZBNE DT Small molecular drug
DMFZBNE PC 9804992
DMFZBNE MW 421.5
DMFZBNE FM C24H27N3O4
DMFZBNE IC InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
DMFZBNE CS CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO
DMFZBNE IK YALNUENQHAQXEA-UHFFFAOYSA-N
DMFZBNE IU [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
DMFZBNE CA CAS 497833-27-9
DMFZBNE CB CHEBI:94187
DMFZBNE DE Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Duchenne dystrophy
DMUQ1DO ID DMUQ1DO
DMUQ1DO DN ITI-007
DMUQ1DO HS Phase 3
DMUQ1DO CP Intra-Cellular Therapies
DMUQ1DO DT Small molecular drug
DMUQ1DO PC 21302490
DMUQ1DO MW 393.5
DMUQ1DO FM C24H28FN3O
DMUQ1DO IC InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1
DMUQ1DO CS CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMUQ1DO IK HOIIHACBCFLJET-SFTDATJTSA-N
DMUQ1DO IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one
DMUQ1DO CA CAS 313369-37-8
DMUQ1DO DE Insomnia; Schizophrenia; Depression; Major depressive disorder
DMGWVLX ID DMGWVLX
DMGWVLX DN Itolizumab
DMGWVLX HS Phase 3
DMGWVLX SN T-1h-mAb; T-1h-mAb); Anti-CD6 humanized monoclonal antibody, Center of Molecular Immunology/Biocon Biopharmaceuticals; Anti-CD6 humanized monoclonal antibody (rheumatoid arthritis/ psoriasis/ T-cell lymphoma), CIM/Biocon Biopharmaceuticals
DMGWVLX CP Dermatology; The Center of Molecular Immunology
DMGWVLX DT Antibody
DMGWVLX DE Type-1 diabetes
DM7MLTR ID DM7MLTR
DM7MLTR DN Itopride
DM7MLTR HS Phase 3
DM7MLTR SN Itopride; Itopride (INN); Itopride [INN]; QQQIECGTIMUVDS-UHFFFAOYSA-N; SCHEMBL311309; SR-01000763470; 122898-67-3; 81BMQ80QRL; AC1L1GQ2; AC1Q5DLT; DTXSID7048320; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide; N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide; N-[4-[2-(Dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide; N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide; NCGC00167529-01; UNII-81BMQ80QRL; n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4-dimethoxybenzamide
DM7MLTR PC 3792
DM7MLTR MW 358.4
DM7MLTR FM C20H26N2O4
DM7MLTR IC QQQIECGTIMUVDS-UHFFFAOYSA-N
DM7MLTR CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC
DM7MLTR IK 1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)
DM7MLTR IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide
DM7MLTR CA CAS 122898-67-3
DM7MLTR CB CHEBI:94809
DM7MLTR DE Functional nausea/vomiting
DMNORK8 ID DMNORK8
DMNORK8 DN Jakafi
DMNORK8 HS Phase 3
DMNORK8 SN Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka
DMNORK8 CP Incyte, Wilmington, DE
DMNORK8 PC 25127112
DMNORK8 MW 404.4
DMNORK8 FM C17H21N6O4P
DMNORK8 IC InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
DMNORK8 CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
DMNORK8 IK JFMWPOCYMYGEDM-XFULWGLBSA-N
DMNORK8 IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
DMNORK8 CA CAS 1092939-17-7
DMNORK8 CB CHEBI:66917
DMNORK8 DE Essential thrombocythemia
DM8FSPV ID DM8FSPV
DM8FSPV DN JTZ-951
DM8FSPV HS Phase 3
DM8FSPV PC 50899324
DM8FSPV MW 340.33
DM8FSPV FM C17H16N4O4
DM8FSPV IC InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
DM8FSPV CS C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
DM8FSPV IK FJYRBJKWDXVHHO-UHFFFAOYSA-N
DM8FSPV IU 2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid
DM8FSPV CA CAS 1262132-81-9
DM8FSPV DE Anaemia
DM5WCV4 ID DM5WCV4
DM5WCV4 DN JX-594
DM5WCV4 HS Phase 3
DM5WCV4 SN Pexastimogene devacirepvec
DM5WCV4 CP Jennerex Biotherapeutics
DM5WCV4 DE Liver cancer; Colorectal cancer; Hepatocellular carcinoma
DM9J0KD ID DM9J0KD
DM9J0KD DN K-103-IP
DM9J0KD HS Phase 3
DM9J0KD DE Pain
DMCRGY4 ID DMCRGY4
DMCRGY4 DN Karenitecin
DMCRGY4 HS Phase 3
DMCRGY4 SN Karenitecin (TN)
DMCRGY4 CP BioNumerik Pharmaceuticals
DMCRGY4 DT Small molecular drug
DMCRGY4 PC 148202
DMCRGY4 MW 448.6
DMCRGY4 FM C25H28N2O4Si
DMCRGY4 IC InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
DMCRGY4 CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O
DMCRGY4 IK POADTFBBIXOWFJ-VWLOTQADSA-N
DMCRGY4 IU (19S)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMCRGY4 CA CAS 203923-89-1
DMCRGY4 DE Lung cancer; Ovarian cancer
DM8VO16 ID DM8VO16
DM8VO16 DN KH-902
DM8VO16 HS Phase 3
DM8VO16 SN Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies
DM8VO16 CP Chengdu Kanghong Biotechnologies Co Ltd
DM8VO16 DE Diabetic macular edema
DMSDBPG ID DMSDBPG
DMSDBPG DN KN046
DMSDBPG HS Phase 3
DMSDBPG CP Alphamab Oncology
DMSDBPG DT Antibody
DMSDBPG DE Non-small-cell lung cancer
DMP5G1K ID DMP5G1K
DMP5G1K DN KPS-0373
DMP5G1K HS Phase 3
DMP5G1K SN S-0373; TSH release modulator (spinocerebellar ataxia), Kissei; Thyrotropin-releasing hormone derivative (spinocerebellarataxia), Shionogi; Thyrotropin-releasing hormone derivative (Parkinson's disease), Shionogi
DMP5G1K CP Shionogi & Co Ltd
DMP5G1K DE Parkinson disease
DMM2LTC ID DMM2LTC
DMM2LTC DN KSI-301
DMM2LTC HS Phase 3
DMM2LTC CP Kodiak Sciences
DMM2LTC DT Antibody biopolymer conjugate
DMM2LTC DE Diabetic macular edema
DMP3GI2 ID DMP3GI2
DMP3GI2 DN KW-3357
DMP3GI2 HS Phase 3
DMP3GI2 SN Coagulation factor inhibitor (iv, blood clotting disorder), Kyowa; Recombinant antithrombin (iv, blooding clottingdisorder), Kyowa Hakko Kirin
DMP3GI2 CP Kyowa Hakko Kogyo Co Ltd
DMP3GI2 DE Coagulation defect
DMF0NA9 ID DMF0NA9
DMF0NA9 DN KX-01
DMF0NA9 HS Phase 3
DMF0NA9 CP Athenex Buffalo, NY
DMF0NA9 DE Actinic keratosis
DMWTPCA ID DMWTPCA
DMWTPCA DN L-651582
DMWTPCA HS Phase 3
DMWTPCA SN Carboxyamidotriazole (CAI)
DMWTPCA CP National Cancer Institute
DMWTPCA DT Small molecular drug
DMWTPCA PC 108144
DMWTPCA MW 424.7
DMWTPCA FM C17H12Cl3N5O2
DMWTPCA IC InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
DMWTPCA CS C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl
DMWTPCA IK WNRZHQBJSXRYJK-UHFFFAOYSA-N
DMWTPCA IU 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide
DMWTPCA CA CAS 99519-84-3
DMWTPCA DE Solid tumour/cancer
DMI3YLK ID DMI3YLK
DMI3YLK DN LA-EP2006
DMI3YLK HS Phase 3
DMI3YLK CP Sandoz
DMI3YLK DE Neutropenia
DMA2NYS ID DMA2NYS
DMA2NYS DN Lampalizumab
DMA2NYS HS Phase 3
DMA2NYS CP Genentech
DMA2NYS DT Antibody
DMA2NYS DE Geographic retinal atrophy
DMFJLB6 ID DMFJLB6
DMFJLB6 DN Lanabecestat
DMFJLB6 HS Phase 3
DMFJLB6 SN 1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane
DMFJLB6 CP AstraZeneca Wilmington, DE; Eli Lilly Indianapolis, IN
DMFJLB6 PC 67979346
DMFJLB6 MW 412.5
DMFJLB6 FM C26H28N4O
DMFJLB6 IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1
DMFJLB6 CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4([C@]35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMFJLB6 IK WKDNQONLGXOZRG-BOPKNSRXSA-N
DMFJLB6 CA CAS 1383982-64-6
DMFJLB6 DE Alzheimer disease
DM4EGPN ID DM4EGPN
DM4EGPN DN Lanperisone
DM4EGPN HS Phase 3
DM4EGPN SN NK-433
DM4EGPN CP Nippon Kayaku Co Ltd
DM4EGPN DT Small molecular drug
DM4EGPN PC 198707
DM4EGPN MW 285.3
DM4EGPN FM C15H18F3NO
DM4EGPN IC InChI=1S/C15H18F3NO/c1-11(10-19-8-2-3-9-19)14(20)12-4-6-13(7-5-12)15(16,17)18/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1
DM4EGPN CS C[C@H](CN1CCCC1)C(=O)C2=CC=C(C=C2)C(F)(F)F
DM4EGPN IK RYZCWZZJFAKYHX-LLVKDONJSA-N
DM4EGPN IU (2R)-2-methyl-3-pyrrolidin-1-yl-1-[4-(trifluoromethyl)phenyl]propan-1-one
DM4EGPN CA CAS 116287-14-0
DM4EGPN DE Musculoskeletal disorder
DMMA0C7 ID DMMA0C7
DMMA0C7 DN Laquinamod
DMMA0C7 HS Phase 3
DMMA0C7 SN Laquinimod sodium; Laquinimod Sodium Salt; 248282-07-7; UNII-4H914M0CSP; Laquinimod sodium [USAN]; TV-5600; 4H914M0CSP; ABR-215062 SODIUM; Laquinimod sodium (USAN); sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate; SAIK-MS compound; ABR 215062 Sodium; SCHEMBL1991182; CHEMBL2103814; DTXSID50179538; QCR-166; JWHPPWBIIQMBQC-UHFFFAOYSA-M; AKOS027326368; TV 5600; FT-0670730; D08938; Sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin- 4-olate; 3-Quinolinecarboxamide, 5-chlo
DMMA0C7 CP Active Biotech; Teva
DMMA0C7 DT Small molecular drug
DMMA0C7 PC 23697158
DMMA0C7 MW 378.8
DMMA0C7 FM C19H16ClN2NaO3
DMMA0C7 IC InChI=1S/C19H17ClN2O3.Na/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24;/h4-11,23H,3H2,1-2H3;/q;+1/p-1
DMMA0C7 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+]
DMMA0C7 IK JWHPPWBIIQMBQC-UHFFFAOYSA-M
DMMA0C7 IU sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate
DMMA0C7 CA CAS 248282-07-7
DMMA0C7 DE Multiple sclerosis
DM3IWS8 ID DM3IWS8
DM3IWS8 DN Laquinimod
DM3IWS8 HS Phase 3
DM3IWS8 SN Laquinimod; 248281-84-7; 5-CHLORO-N-ETHYL-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE; ABR-215062; ABR 215062; 5-Chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-amide; UNII-908SY76S4G; CIVENTICHEM CV-4057; Laquinimod (ABR-215062); 908SY76S4G; N-Ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide; 5-chloro-n-ethyl-2-hydroxy-1-methyl-4-oxo-n-phenyl-1,4-dihydroquinoline-3-carboxamide; C19H17ClN2O3
DM3IWS8 CP Teva Neuroscience
DM3IWS8 DT Small molecular drug
DM3IWS8 PC 54677946
DM3IWS8 MW 356.8
DM3IWS8 FM C19H17ClN2O3
DM3IWS8 IC InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3
DM3IWS8 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
DM3IWS8 IK GKWPCEFFIHSJOE-UHFFFAOYSA-N
DM3IWS8 IU 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DM3IWS8 CA CAS 248281-84-7
DM3IWS8 CB CHEBI:134738
DM3IWS8 DE Lupus; Multiple sclerosis; Huntington disease; Primary progressive multiple sclerosis
DMH2EA1 ID DMH2EA1
DMH2EA1 DN Laromustine
DMH2EA1 HS Phase 3
DMH2EA1 SN Cloretazine; Onrigin; Alkylating agents, Vion; SHP, Vion; Sulfonyl hydrazine prodrugs, Vion; VN-40101M; VNP-40101M; VNP-4090-CE; 90CE
DMH2EA1 CP Vion Pharmaceuticals Inc
DMH2EA1 DT Small molecular drug
DMH2EA1 PC 3081349
DMH2EA1 MW 307.8
DMH2EA1 FM C6H14ClN3O5S2
DMH2EA1 IC InChI=1S/C6H14ClN3O5S2/c1-8-6(11)10(17(3,14)15)9(5-4-7)16(2,12)13/h4-5H2,1-3H3,(H,8,11)
DMH2EA1 CS CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C
DMH2EA1 IK PVCULFYROUOVGJ-UHFFFAOYSA-N
DMH2EA1 IU 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea
DMH2EA1 CA CAS 173424-77-6
DMH2EA1 DE Solid tumour/cancer
DMAJM12 ID DMAJM12
DMAJM12 DN LATIN T1D
DMAJM12 HS Phase 3
DMAJM12 SN NN9211
DMAJM12 CP Novo Nordisk
DMAJM12 DE Type-1 diabetes
DM09RKB ID DM09RKB
DM09RKB DN LC-150444
DM09RKB HS Phase 3
DM09RKB SN LCD15-0444; Dipeptidyl peptidase IV inhibitors (oral, type 2 diabetes), LG Life Sciences
DM09RKB CP LG Life Sciences Ltd
DM09RKB DE Type-2 diabetes
DMT4K0Z ID DMT4K0Z
DMT4K0Z DN L-citrulline
DMT4K0Z HS Phase 3
DMT4K0Z SN L-citrulline; citrulline; 372-75-8; H-cit-oh; delta-Ureidonorvaline; Sitrulline; N5-Carbamoyl-L-ornithine; L-Cytrulline; L(+)-citrulline; N5-(Aminocarbonyl)ornithine; N(delta)-Carbamylornithine; Citrulline, L-; alpha-Amino-delta-ureidovaleric acid; (S)-2-Amino-5-ureidopentanoic acid; N5-carbamoylornithine; d-ureidonorvaline; Ornithine, N5-(aminocarbonyl)-; L-2-Amino-5-ureidovaleric acid; L-Ornithine, N5-(aminocarbonyl)-; L-(+)-Citrulline; 2-Amino-5-ureidovaleric acid; L-citrullin; (2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z DT Small molecular drug
DMT4K0Z PC 9750
DMT4K0Z MW 175.19
DMT4K0Z FM C6H13N3O3
DMT4K0Z IC InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1
DMT4K0Z CS C(C[C@@H](C(=O)O)N)CNC(=O)N
DMT4K0Z IK RHGKLRLOHDJJDR-BYPYZUCNSA-N
DMT4K0Z IU (2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z CA CAS 372-75-8
DMT4K0Z CB CHEBI:16349
DMT4K0Z DE Acute lung injury
DMFLJHQ ID DMFLJHQ
DMFLJHQ DN LCQ908
DMFLJHQ HS Phase 3
DMFLJHQ SN Pradigastat; LCQ-908; 956136-95-1; UNII-2U23G6VNUZ; LCQ908; 2U23G6VNUZ; LCQ 908; Pradigastat [USAN:INN]; LCQ 908NXA; 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid; 2-{4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid; Pradigastat (USAN); LCQ908-NXA; SCHEMBL180536; GTPL7830; SCHEMBL1289309; CHEMBL2364624; SCHEMBL18286769; SCHEMBL16104874; GXALXAKNHIROPE-UHFFFAOYSA-N; BCP21089; ZINC253387875; AKOS027338695; DB12866; SB16971; CS-1222
DMFLJHQ CP Novartis
DMFLJHQ DT Small molecular drug
DMFLJHQ PC 53387035
DMFLJHQ MW 455.5
DMFLJHQ FM C25H24F3N3O2
DMFLJHQ IC InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)
DMFLJHQ CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F
DMFLJHQ IK GXALXAKNHIROPE-UHFFFAOYSA-N
DMFLJHQ IU 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid
DMFLJHQ CA CAS 956136-95-1
DMFLJHQ DE Hepatitis C virus infection; Familial chylomicronemia syndrome; Hypertriglyceridemia
DMQP0X5 ID DMQP0X5
DMQP0X5 DN Lebrikizumab
DMQP0X5 HS Phase 3
DMQP0X5 SN RG3637
DMQP0X5 CP Aerovance
DMQP0X5 DT Monoclonal antibody
DMQP0X5 DE Chronic obstructive pulmonary disease; Severe asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis
DMMX75K ID DMMX75K
DMMX75K DN LEE011
DMMX75K HS Phase 3
DMMX75K SN Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013
DMMX75K CP Novartis AG
DMMX75K DT Small molecular drug
DMMX75K PC 44631912
DMMX75K MW 434.5
DMMX75K FM C23H30N8O
DMMX75K IC InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
DMMX75K CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5
DMMX75K IK RHXHGRAEPCAFML-UHFFFAOYSA-N
DMMX75K IU 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DMMX75K CA CAS 1211441-98-3
DMMX75K DE Solid tumour/cancer; Breast cancer
DMSCGM8 ID DMSCGM8
DMSCGM8 DN LentiGlobin
DMSCGM8 HS Phase 3
DMSCGM8 SN Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), Genetix; Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), bluebird
DMSCGM8 CP Bluebird bio
DMSCGM8 DE Sickle-cell disorder; Beta thalassemia
DMSRIT4 ID DMSRIT4
DMSRIT4 DN Lenzilumab
DMSRIT4 HS Phase 3
DMSRIT4 SN lenzilumab; GTPL8935; KB003; KB-003
DMSRIT4 TC Antiviral Agents
DMSRIT4 DT Monoclonal antibody
DMSRIT4 DE Coronavirus Disease 2019 (COVID-19)
DMOTCIU ID DMOTCIU
DMOTCIU DN Lerisetron
DMOTCIU HS Phase 3
DMOTCIU SN Lerisetron[inn]; 1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU CP FAES Farma
DMOTCIU DT Small molecular drug
DMOTCIU PC 65997
DMOTCIU MW 292.4
DMOTCIU FM C18H20N4
DMOTCIU IC InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2
DMOTCIU CS C1CN(CCN1)C2=NC3=CC=CC=C3N2CC4=CC=CC=C4
DMOTCIU IK PWWDCRQZITYKDV-UHFFFAOYSA-N
DMOTCIU IU 1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU CA CAS 143257-98-1
DMOTCIU DE Vomiting; Testicular germ cell tumour; Nausea
DMAYC76 ID DMAYC76
DMAYC76 DN Levomequitazine
DMAYC76 HS Phase 3
DMAYC76 SN V-0114; V-0114CP
DMAYC76 CP Pierre Fabre SA
DMAYC76 DT Small molecular drug
DMAYC76 PC 6992284
DMAYC76 MW 322.5
DMAYC76 FM C20H22N2S
DMAYC76 IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2/t16-/m0/s1
DMAYC76 CS C1CN2CCC1[C@@H](C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAYC76 IK HOKDBMAJZXIPGC-INIZCTEOSA-N
DMAYC76 IU 10-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine
DMAYC76 CA CAS 88598-74-7
DMAYC76 DE Seasonal allergic rhinitis
DM103O8 ID DM103O8
DM103O8 DN Ligelizumab
DM103O8 HS Phase 3
DM103O8 SN QGE031
DM103O8 CP Novartis
DM103O8 DT Antibody
DM103O8 DE Chronic idiopathic urticaria
DMNM93X ID DMNM93X
DMNM93X DN Linagliptin
DMNM93X HS Phase 3
DMNM93X SN Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin
DMNM93X TC Antiviral Agents
DMNM93X DT Small molecular drug
DMNM93X PC 10096344
DMNM93X MW 472.5
DMNM93X FM C25H28N8O2
DMNM93X IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMNM93X CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMNM93X IK LTXREWYXXSTFRX-QGZVFWFLSA-N
DMNM93X IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMNM93X CA CAS 668270-12-0
DMNM93X CB CHEBI:68610
DMNM93X DE Coronavirus Disease 2019 (COVID-19)
DM0ZOGX ID DM0ZOGX
DM0ZOGX DN Linopirdine
DM0ZOGX HS Phase 3
DM0ZOGX SN AVIVA; Linopirine; DuP-996
DM0ZOGX CP Bristol-Myers Squibb Pharma Co
DM0ZOGX DT Small molecular drug
DM0ZOGX PC 3932
DM0ZOGX MW 391.5
DM0ZOGX FM C26H21N3O
DM0ZOGX IC InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2
DM0ZOGX CS C1=CC=C(C=C1)N2C3=CC=CC=C3C(C2=O)(CC4=CC=NC=C4)CC5=CC=NC=C5
DM0ZOGX IK YEJCDKJIEMIWRQ-UHFFFAOYSA-N
DM0ZOGX IU 1-phenyl-3,3-bis(pyridin-4-ylmethyl)indol-2-one
DM0ZOGX CA CAS 105431-72-9
DM0ZOGX CB CHEBI:34823
DM0ZOGX DE Cognitive impairment
DMNF4UH ID DMNF4UH
DMNF4UH DN Liprotamase
DMNF4UH HS Phase 3
DMNF4UH SN LY3031642
DMNF4UH CP Lilly
DMNF4UH DE Cystic fibrosis
DMKZRBP ID DMKZRBP
DMKZRBP DN Litoxetine
DMKZRBP HS Phase 3
DMKZRBP SN Litoxetine; 86811-09-8; 4-(2-Naphthylmethoxy)piperidine; UNII-9980ST005G; CHEMBL471036; 9980ST005G; Litoxetinum; Litoxetina; Litoxetine [INN]; Litoxetinum [INN-Latin]; Litoxetina [INN-Spanish]; AC1L23OW; SCHEMBL119884; ZINC3647; CTK3E8854; DTXSID30235828; BDBM50278564; 4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP DT Small molecular drug
DMKZRBP PC 65650
DMKZRBP MW 241.33
DMKZRBP FM C16H19NO
DMKZRBP IC InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2
DMKZRBP CS C1CNCCC1OCC2=CC3=CC=CC=C3C=C2
DMKZRBP IK MJJDYOLPMGIWND-UHFFFAOYSA-N
DMKZRBP IU 4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP CA CAS 86811-09-8
DMKZRBP DE Mood disorder
DMDN4ZP ID DMDN4ZP
DMDN4ZP DN Lixivaptan
DMDN4ZP HS Phase 3
DMDN4ZP SN 168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1
DMDN4ZP CP Wyeth-Ayerst; Cardiokine
DMDN4ZP DT Small molecular drug
DMDN4ZP PC 172997
DMDN4ZP MW 473.9
DMDN4ZP FM C27H21ClFN3O2
DMDN4ZP IC InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
DMDN4ZP CS CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
DMDN4ZP IK PPHTXRNHTVLQED-UHFFFAOYSA-N
DMDN4ZP IU N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
DMDN4ZP CA CAS 168079-32-1
DMDN4ZP DE Skin infection; Congestive heart failure; Hyponatraemia
DM4OAIU ID DM4OAIU
DM4OAIU DN LMI070
DM4OAIU HS Phase 3
DM4OAIU SN branaplam; Branaplam; 1562338-42-4; NVS-SM1; UNII-P12R69543A; LMI-070; P12R69543A; 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol; Branaplam [INN]; SCHEMBL15475826; LMI070 (NVS-SM1); STWTUEAWRAIWJG-UHFFFAOYSA-N; BCP19909; ZINC146605125; AKOS030526592; CS-5319; HY-19620; Phenol, 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethyl-4-piperidinyl)oxy)-3-pyridazinyl)-
DM4OAIU CP Novartis Pharmaceuticals East Hanover, NJ
DM4OAIU PC 135565042
DM4OAIU MW 393.5
DM4OAIU FM C22H27N5O2
DM4OAIU IC InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)
DM4OAIU CS CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C
DM4OAIU IK STWTUEAWRAIWJG-UHFFFAOYSA-N
DM4OAIU IU 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol
DM4OAIU CA CAS 1562338-42-4
DM4OAIU DE Spinal muscular atrophy
DMOFIBM ID DMOFIBM
DMOFIBM DN LMT-X
DMOFIBM HS Phase 3
DMOFIBM SN Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
DMOFIBM CP TauRx Therapeutics Pte Ltd
DMOFIBM DE Acute myeloid leukaemia; Alzheimer disease
DM9EZM0 ID DM9EZM0
DM9EZM0 DN LNP023
DM9EZM0 HS Phase 3
DM9EZM0 SN Iptacopan; LNP-023; UNII-8E05T07Z6W; 8E05T07Z6W; 1644670-37-0; 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid; 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; Iptacopan [INN]; CHEMBL4594448; SCHEMBL16400416; GTPL10710; US9682968, Example-26a; BDBM160475; ZINC223246892; compound 41 [PMID: 32073845]; HY-127105; CS-0093107; 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid; Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-; JGQ
DM9EZM0 CP Novartis
DM9EZM0 DT Small molecular drug
DM9EZM0 PC 90467622
DM9EZM0 MW 422.5
DM9EZM0 FM C25H30N2O4
DM9EZM0 IC InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
DM9EZM0 CS CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
DM9EZM0 IK RENRQMCACQEWFC-UGKGYDQZSA-N
DM9EZM0 IU 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
DM9EZM0 CA CAS 1644670-37-0
DM9EZM0 DE IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
DMQNVR8 ID DMQNVR8
DMQNVR8 DN Lopinavir + ritonavir
DMQNVR8 HS Phase 3
DMQNVR8 SN Aluviran + norvir; Kaletra
DMQNVR8 TC Antiviral Agents
DMQNVR8 DT Combination drug
DMQNVR8 PC 11979606
DMQNVR8 MW 1349.7
DMQNVR8 FM C74H96N10O10S2
DMQNVR8 IC InChI=1S/C37H48N6O5S2.C37H48N4O5/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30;1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46);5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t28-,31-,32-,33-;30-,31-,32-,34-/m00/s1
DMQNVR8 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMQNVR8 IK OFFWOVJBSQMVPI-RMLGOCCBSA-N
DMQNVR8 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMQNVR8 CA CAS 369372-47-4
DMQNVR8 DE Coronavirus Disease 2019 (COVID-19)
DMX0O9U ID DMX0O9U
DMX0O9U DN Lopinavir + ritonavir + favipiravir
DMX0O9U HS Phase 3
DMX0O9U SN Aluviran + norvir + T-705
DMX0O9U TC Antiviral Agents
DMX0O9U DT Combination drug
DMX0O9U DE Coronavirus Disease 2019 (COVID-19)
DMNY05F ID DMNY05F
DMNY05F DN Lopinavir + ritonavir + oseltamivir
DMNY05F HS Phase 3
DMNY05F SN Aluviran + norvir + tamiflu
DMNY05F TC Antiviral Agents
DMNY05F DT Combination drug
DMNY05F DE Coronavirus Disease 2019 (COVID-19)
DMTL5Q0 ID DMTL5Q0
DMTL5Q0 DN Losartan
DMTL5Q0 HS Phase 3
DMTL5Q0 SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DMTL5Q0 CP Merck & Co
DMTL5Q0 TC Antiviral Agents
DMTL5Q0 DT Small molecular drug
DMTL5Q0 PC 3961
DMTL5Q0 MW 422.9
DMTL5Q0 FM C22H23ClN6O
DMTL5Q0 IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DMTL5Q0 CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DMTL5Q0 IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DMTL5Q0 IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DMTL5Q0 CA CAS 114798-26-4
DMTL5Q0 CB CHEBI:6541
DMTL5Q0 DE Discovery agent; Hypertension; Coronavirus Disease 2019 (COVID-19)
DMIL37Z ID DMIL37Z
DMIL37Z DN Losmapimod
DMIL37Z HS Phase 3
DMIL37Z SN 585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod pound> HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587
DMIL37Z CP GSK
DMIL37Z DT Small molecular drug
DMIL37Z PC 11552706
DMIL37Z MW 383.5
DMIL37Z FM C22H26FN3O2
DMIL37Z IC InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
DMIL37Z CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C
DMIL37Z IK KKYABQBFGDZVNQ-UHFFFAOYSA-N
DMIL37Z IU 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
DMIL37Z CA CAS 585543-15-3
DMIL37Z CB CHEBI:131167
DMIL37Z DE Acute coronary syndrome
DMWGRQD ID DMWGRQD
DMWGRQD DN LU AE58054
DMWGRQD HS Phase 3
DMWGRQD SN Idalopirdine; Lu AE58054; 467459-31-0; LU-AE58054; UNII-59WCJ0YNWM; LU AE 58054; 59WCJ0YNWM; 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine; 1H-Indole-3-ethanamine,6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; 1H-Indole-3-ethanamine, 6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; Idalopirdine [USAN:INN]; Idlopirdine; Idalopirdine (USAN/INN); Lu AE58054;Idalopirdine; SCHEMBL762762; Idalopirdine(Lu-AE-58054); GTPL8689; CHEMBL3286580; C20H19F5N2O; EX-A844
DMWGRQD CP Lundbeck
DMWGRQD DT Small molecular drug
DMWGRQD PC 21071390
DMWGRQD MW 398.4
DMWGRQD FM C20H19F5N2O
DMWGRQD IC InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
DMWGRQD CS C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F
DMWGRQD IK YBAWYTYNMZWMMJ-UHFFFAOYSA-N
DMWGRQD IU 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine
DMWGRQD CA CAS 467459-31-0
DMWGRQD DE Schizophrenia
DMNAYUJ ID DMNAYUJ
DMNAYUJ DN Lu AF35700
DMNAYUJ HS Phase 3
DMNAYUJ CP Lundbeck Deerfield, IL
DMNAYUJ DE Schizophrenia
DMMLXA9 ID DMMLXA9
DMMLXA9 DN LX-4211
DMMLXA9 HS Phase 3
DMMLXA9 SN Sotagliflozin; 1018899-04-1; LX-4211; LX4211; UNII-6B4ZBS263Y; 6B4ZBS263Y; AK170751; (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol; b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-; Sotagliflozin [USAN:INN]; beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-; LX 4211; Tube103; LP 802034
DMMLXA9 CP Lexicon Pharmaceuticals
DMMLXA9 DT Small molecular drug
DMMLXA9 PC 24831714
DMMLXA9 MW 424.9
DMMLXA9 FM C21H25ClO5S
DMMLXA9 IC InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
DMMLXA9 CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
DMMLXA9 IK QKDRXGFQVGOQKS-CRSSMBPESA-N
DMMLXA9 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
DMMLXA9 CA CAS 1018899-04-1
DMMLXA9 DE Type-2 diabetes; Cardiovascular disease; Type-1 diabetes
DM1BXMY ID DM1BXMY
DM1BXMY DN LY2605541
DM1BXMY HS Phase 3
DM1BXMY SN UNII-6Y83I5F10I; Insulin peglispro [USAN:INN]; INSULIN PEGLISPRO; LY2605541; 6Y83I5F10I; 1200440-65-8; LY 2605541; Polyethylene glycol 20,000 pegylated insulin lispro:(28B-(6-N-((omega-methoxypoly(oxyethylene))carbonyl)-L-lysine),29B-L-proline)human insulin; Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 28B-ester with 28B-(N6-carboxy-L- lysine)-29B-L-prolineinsulin (human)
DM1BXMY CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DM1BXMY DT Small molecular drug
DM1BXMY PC 71301236
DM1BXMY MW 5892
DM1BXMY FM C261H387N65O79S6
DM1BXMY IC InChI=1S/C261H387N65O79S6/c1-30-134(23)208(317-196(343)107-262)255(397)321-207(133(21)22)251(393)290-160(76-83-203(353)354)219(361)285-157(72-79-192(265)339)223(365)312-186-119-409-410-120-187-246(388)309-181(114-328)243(385)297-164(91-126(7)8)226(368)298-170(98-143-54-62-149(333)63-55-143)229(371)286-155(70-77-190(263)337)220(362)293-163(90-125(5)6)224(366)288-159(75-82-202(351)352)222(364)306-177(104-193(266)340)236(378)301-172(100-145-58-66-151(335)67-59-145)232(374)313-185-118-408-407-117-184(216(358)276-110-197(344)281-154(73-80-200(347)348)218(360)284-153(52-43-85-273-260(269)270)214(356)275-111-198(345)282-168(95-140-45-35-32-36-46-140)228(370)300-169(96-141-47-37-33-38-48-141)231(373)302-174(101-146-60-68-152(336)69-61-146)241(383)323-210(137(26)330)256(398)291-161(51-41-42-84-274-261(403)405-88-87-404-29)258(400)326-86-44-53-189(326)249(391)325-212(139(28)332)259(401)402)315-253(395)206(132(19)20)319-238(380)166(93-128(11)12)295-230(372)171(99-144-56-64-150(334)65-57-144)299-225(367)162(89-124(3)4)292-213(355)136(25)280-217(359)158(74-81-201(349)350)289-250(392)204(130(15)16)318-239(381)167(94-129(13)14)296-234(376)176(103-148-109-272-123-279-148)305-242(384)180(113-327)283-199(346)112-277-215(357)183(116-406-411-121-188(314-247(186)389)248(390)324-211(138(27)331)257(399)310-182(115-329)244(386)322-209(135(24)31-2)254(396)316-187)311-227(369)165(92-127(9)10)294-233(375)175(102-147-108-271-122-278-147)304-221(363)156(71-78-191(264)338)287-235(377)179(106-195(268)342)308-252(394)205(131(17)18)320-240(382)173(97-142-49-39-34-40-50-142)303-237(379)178(105-194(267)341)307-245(185)387/h32-40,45-50,54-69,108-109,122-139,153-189,204-212,327-336H,30-31,41-44,51-53,70-107,110-121,262H2,1-29H3,(H2,263,337)(H2,264,338)(H2,265,339)(H2,266,340)(H2,267,341)(H2,268,342)(H,271,278)(H,272,279)(H,274,403)(H,275,356)(H,276,358)(H,277,357)(H,280,359)(H,281,344)(H,282,345)(H,283,346)(H,284,360)(H,285,361)(H,286,371)(H,287,377)(H,288,366)(H,289,392)(H,290,393)(H,291,398)(H,292,355)(H,293,362)(H,294,375)(H,295,372)(H,296,376)(H,297,385)(H,298,368)(H,299,367)(H,300,370)(H,301,378)(H,302,373)(H,303,379)(H,304,363)(H,305,384)(H,306,364)(H,307,387)(H,308,394)(H,309,388)(H,310,399)(H,311,369)(H,312,365)(H,313,374)(H,314,389)(H,315,395)(H,316,396)(H,317,343)(H,318,381)(H,319,380)(H,320,382)(H,321,397)(H,322,386)(H,323,383)(H,324,390)(H,325,391)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,401,402)(H4,269,270,273)/t134-,135-,136-,137+,138+,139+,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,204-,205-,206-,207-,208-,209-,210-,211-,212-/m0/s1
DM1BXMY CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC4=CN=CN4)CCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC6=CC=C(C=C6)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC7=CC=C(C=C7)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)OCCOC)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC2=CC=C(C=C2)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DM1BXMY IK UFIPGFMPJACHTH-HXDLXPBZSA-N
DM1BXMY IU (4S)-4-[[2-[[(aS,1R,3aS,6R,6aS,9S,12S,13aR,15S,18R,21S,24S,27S,30S,33S,36S,39S,42S,45R,50R,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,88S,91S,94S,97S)-13a-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6a,39,97-tris(2-amino-2-oxoethyl)-30,94-bis(3-amino-3-oxopropyl)-3a-benzyl-15-[(2S)-butan-2-yl]-36,68-bis(2-carboxyethyl)-9-[(1R)-1-hydroxyethyl]-12,21,80-tris(hydroxymethyl)-27,42,59-tris[(4-hydroxyphenyl)methyl]-77,91-bis(1H-imidazol-5-ylmethyl)-65-methyl-24,33,56,62,74,88-hexakis(2-methylpropyl)-2a,5a,7,8a,10,13,14a,16,19,22,25,28,31,34,37,40,43,52,55,58,61,64,67,70,73,76,79,82,85,87,90,93,96,99-tetratriacontaoxo-a,53,71-tri(propan-2-yl)-3,4,10a,11a,47,48-hexathia-1a,4a,7a,8,11,14,15a,17,20,23,26,29,32,35,38,41,44,51,54,57,60,63,66,69,72,75,78,81,84,86,89,92,95,98-tetratriacontazatricyclo[43.40.23.76,18]pentadecahectane-50-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-6-(2-methoxyethoxycarbonylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM1BXMY DE Type-1/2 diabetes
DMEZ0H5 ID DMEZ0H5
DMEZ0H5 DN LY2963016
DMEZ0H5 HS Phase 3
DMEZ0H5 CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMEZ0H5 DE Type-1/2 diabetes
DMWZIRJ ID DMWZIRJ
DMWZIRJ DN LY404039
DMWZIRJ HS Phase 3
DMWZIRJ SN LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid
DMWZIRJ CP Eli Lilly
DMWZIRJ DT Small molecular drug
DMWZIRJ PC 9834591
DMWZIRJ MW 235.22
DMWZIRJ FM C7H9NO6S
DMWZIRJ IC InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
DMWZIRJ CS C1[C@]([C@@H]2[C@H]([C@@H]2S1(=O)=O)C(=O)O)(C(=O)O)N
DMWZIRJ IK AVDUGNCTZRCAHH-MDASVERJSA-N
DMWZIRJ IU (1R,4S,5S,6S)-4-amino-2,2-dioxo-2lambda6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMWZIRJ CA CAS 635318-11-5
DMWZIRJ CB CHEBI:94640
DMWZIRJ DE Schizophrenia
DM7WORZ ID DM7WORZ
DM7WORZ DN LY-686017
DM7WORZ HS Phase 3
DM7WORZ SN NK1 antagonist (anxiety/alcoholism), Eli Lilly
DM7WORZ CP Eli Lilly & Co
DM7WORZ DT Small molecular drug
DM7WORZ PC 9916461
DM7WORZ MW 587.9
DM7WORZ FM C28H16ClF6N5O
DM7WORZ IC InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
DM7WORZ CS C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl
DM7WORZ IK CAVRKWRKTNINFF-UHFFFAOYSA-N
DM7WORZ IU [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone
DM7WORZ CA CAS 622370-35-8
DM7WORZ DE Alcohol dependence; Atopic dermatitis
DM6LVCQ ID DM6LVCQ
DM6LVCQ DN LY-CoV555
DM6LVCQ HS Phase 3
DM6LVCQ SN LY3819253
DM6LVCQ CP Lilly; AbCellera
DM6LVCQ DT Antibody
DM6LVCQ DE Coronavirus Disease 2019 (COVID-19)
DMGNC6T ID DMGNC6T
DMGNC6T DN M-0011
DMGNC6T HS Phase 3
DMGNC6T SN N-0011; RhLAMAN, Zymenex; Recombinant human alpha-mannosidase (alpha mannosidosis), Zymenex
DMGNC6T CP Zymenex A/S
DMGNC6T DE Alpha-mannosidosis
DM7ZFBA ID DM7ZFBA
DM7ZFBA DN M100907
DM7ZFBA HS Phase 3
DM7ZFBA SN Volinanserin; 139290-65-6; UNII-EW71EE171J; (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol; CHEMBL74355; EW71EE171J; (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL; M-100907; (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol; Volinanserin [INN]; Serotonin 5-HT2 Receptor Antagonists; VOLINANSERIN
DM7ZFBA DT Small molecular drug
DM7ZFBA PC 5311271
DM7ZFBA MW 373.5
DM7ZFBA FM C22H28FNO3
DM7ZFBA IC InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
DM7ZFBA CS COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DM7ZFBA IK HXTGXYRHXAGCFP-OAQYLSRUSA-N
DM7ZFBA IU (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
DM7ZFBA CA CAS 139290-65-6
DM7ZFBA DE Sleep-wake disorder
DMZ6VD5 ID DMZ6VD5
DMZ6VD5 DN M-518101
DMZ6VD5 HS Phase 3
DMZ6VD5 CP Maruho Co Ltd
DMZ6VD5 DE Psoriasis vulgaris; Plaque psoriasis
DM1PRT6 ID DM1PRT6
DM1PRT6 DN M710
DM1PRT6 HS Phase 3
DM1PRT6 SN 637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)
DM1PRT6 CP Momenta Pharmaceuticals; Mylan
DM1PRT6 DT Small molecular drug
DM1PRT6 PC 71561
DM1PRT6 MW 237.17
DM1PRT6 FM C10H18Cl2N2
DM1PRT6 IC InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
DM1PRT6 CS CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
DM1PRT6 IK FBHKTSXMTASXFJ-UHFFFAOYSA-N
DM1PRT6 IU 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride
DM1PRT6 CA CAS 637-01-4
DM1PRT6 DE Diabetic macular edema
DM8D13S ID DM8D13S
DM8D13S DN MABp1
DM8D13S HS Phase 3
DM8D13S CP Xbiotech Austin, TX
DM8D13S DE Type-2 diabetes; Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Pyoderma gangrenosum; Colorectal cancer; Peripheral vascular disease
DMVXUR0 ID DMVXUR0
DMVXUR0 DN Magrolimab
DMVXUR0 HS Phase 3
DMVXUR0 SN GS-4721
DMVXUR0 CP Gilead Sciences
DMVXUR0 DT Antibody
DMVXUR0 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMJPGUA ID DMJPGUA
DMJPGUA DN Manidipine
DMJPGUA HS Phase 3
DMJPGUA SN manidipine; 89226-50-6; Franidipine; 120092-68-4; Manidipine 6300; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Iperten; Artedil; Manidipine [INN]; Manidipine (Manyper); C35H38N4O6; CHEMBL312176; Manidipine (INN); 2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin
DMJPGUA DT Small molecular drug
DMJPGUA PC 4008
DMJPGUA MW 610.7
DMJPGUA FM C35H38N4O6
DMJPGUA IC InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3
DMJPGUA CS CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMJPGUA IK ANEBWFXPVPTEET-UHFFFAOYSA-N
DMJPGUA IU 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJPGUA CA CAS 89226-50-6
DMJPGUA CB CHEBI:135849
DMR23M1 ID DMR23M1
DMR23M1 DN Mapracorat
DMR23M1 HS Phase 3
DMR23M1 SN BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb
DMR23M1 CP Bayer Schering Pharma AG
DMR23M1 DT Small molecular drug
DMR23M1 PC 24795088
DMR23M1 MW 462.5
DMR23M1 FM C25H26F4N2O2
DMR23M1 IC InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
DMR23M1 CS CC1=NC2=C(C=C1)C(=CC=C2)NC[C@](CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O
DMR23M1 IK VJGFOYBQOIPQFY-XMMPIXPASA-N
DMR23M1 IU (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
DMR23M1 CA CAS 887375-26-0
DMR23M1 DE Ocular disease
DMJCF1O ID DMJCF1O
DMJCF1O DN Maralixibat
DMJCF1O HS Phase 3
DMJCF1O SN Lopixibat; UNII-UYB6UOF69L; Maralixibat [USAN]; 716313-53-0; UYB6UOF69L; CHEMBL363392; Maralixibat (USAN); Lopixibat cation; CHEMBL17879; 1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium; LUM001 CATION; LUM-001 CATION; SCHEMBL10013954; BDBM50140282; 4-Aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-; D10951; Q27291331; (4R,5R)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1$l^{6}-benzothiepin-4-ol; 1-{4-[4-((4R,5R)-3,3-Dibutyl-7-dimethylamino-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1lambda*6*-benzo[b]thiepin-5-yl)-phenoxymethyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; chloride
DMJCF1O CP Mirum Pharmaceuticals
DMJCF1O DT Small molecular drug
DMJCF1O PC 9831643
DMJCF1O MW 675
DMJCF1O FM C40H56N3O4S+
DMJCF1O IC InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1
DMJCF1O CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC
DMJCF1O IK STPKWKPURVSAJF-LJEWAXOPSA-N
DMJCF1O IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol
DMJCF1O CA CAS 716313-53-0
DMJCF1O DE Alagille syndrome; Progressive familial intrahepatic cholestasis
DM3GTAL ID DM3GTAL
DM3GTAL DN Maribavir
DM3GTAL HS Phase 3
DM3GTAL SN 176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea
DM3GTAL DT Small molecular drug
DM3GTAL PC 471161
DM3GTAL MW 376.2
DM3GTAL FM C15H19Cl2N3O4
DM3GTAL IC InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
DM3GTAL CS CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl
DM3GTAL IK KJFBVJALEQWJBS-XUXIUFHCSA-N
DM3GTAL IU (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM3GTAL CA CAS 176161-24-3
DM3GTAL DE Cytomegalovirus infection
DM6V34C ID DM6V34C
DM6V34C DN Marimastat
DM6V34C HS Phase 3
DM6V34C SN Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
DM6V34C CP British Biotech plc; Schering-Plough
DM6V34C TC Anticancer Agents
DM6V34C DT Small molecular drug
DM6V34C PC 119031
DM6V34C MW 331.41
DM6V34C FM C15H29N3O5
DM6V34C IC InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
DM6V34C CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DM6V34C IK OCSMOTCMPXTDND-OUAUKWLOSA-N
DM6V34C IU (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide
DM6V34C CA CAS 154039-60-8
DM6V34C CB CHEBI:50662
DM6V34C DE Lung cancer; Pancreatic cancer
DME9QGW ID DME9QGW
DME9QGW DN Marizomib
DME9QGW HS Phase 3
DME9QGW SN MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
DME9QGW CP Nereus Pharmaceuticals
DME9QGW DT Small molecular drug
DME9QGW PC 11347535
DME9QGW MW 313.77
DME9QGW FM C15H20ClNO4
DME9QGW IC InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
DME9QGW CS C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl
DME9QGW IK NGWSFRIPKNWYAO-SHTIJGAHSA-N
DME9QGW IU (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
DME9QGW CA CAS 437742-34-2
DME9QGW CB CHEBI:48045
DME9QGW DE Solid tumour/cancer; Malignant glioma; Multiple myeloma; Glioblastoma of brain
DMRSNEU ID DMRSNEU
DMRSNEU DN Masitinib
DMRSNEU HS Phase 3
DMRSNEU SN Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
DMRSNEU CP AB Science
DMRSNEU DT Small molecular drug
DMRSNEU PC 10074640
DMRSNEU MW 498.6
DMRSNEU FM C28H30N6OS
DMRSNEU IC InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
DMRSNEU CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5
DMRSNEU IK WJEOLQLKVOPQFV-UHFFFAOYSA-N
DMRSNEU IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
DMRSNEU CA CAS 790299-79-5
DMRSNEU CB CHEBI:63450
DMRSNEU DE Amyotrophic lateral sclerosis; Metastatic gastric or gastroesophageal junction cancer; Multiple sclerosis; Gastrointestinal stromal tumour; Ovarian cancer; Pancreatic cancer
DMK9BP2 ID DMK9BP2
DMK9BP2 DN Mavacamten
DMK9BP2 HS Phase 3
DMK9BP2 SN SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461
DMK9BP2 CP MyoKardia South San Francisco, CA Sanofi Bridgewater, NJ
DMK9BP2 PC 117761397
DMK9BP2 MW 273.33
DMK9BP2 FM C15H19N3O2
DMK9BP2 IC InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
DMK9BP2 CS C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
DMK9BP2 IK RLCLASQCAPXVLM-NSHDSACASA-N
DMK9BP2 IU 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
DMK9BP2 CA CAS 1642288-47-8
DMK9BP2 DE Obstructive hypertrophic cardiomyopathy
DMBPY9Z ID DMBPY9Z
DMBPY9Z DN MBG453
DMBPY9Z HS Phase 3
DMBPY9Z CP Novartis Oncology East Hanover, NJ
DMBPY9Z DE Solid tumour/cancer; Myelodysplastic syndrome
DMVZ57G ID DMVZ57G
DMVZ57G DN MD1003
DMVZ57G HS Phase 3
DMVZ57G CP MedDay Pharmaceuticals Paris, France
DMVZ57G DE Multiple sclerosis
DM5X849 ID DM5X849
DM5X849 DN MEDI4736
DM5X849 HS Phase 3
DM5X849 CP AstraZeneca
DM5X849 DT Monoclonal antibody
DM5X849 DE Solid tumour/cancer
DM4W8RE ID DM4W8RE
DM4W8RE DN Melagatran
DM4W8RE HS Phase 3
DM4W8RE SN Melagatran; 159776-70-2; UNII-2A9QP32MD4; Melagatran [INN]; 2A9QP32MD4; CHEBI:43966; MELAGATRAN (ASTRA-ZENECA); C22H31N5O4; Melagatran (INN); N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID; MEL; H-319/68; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine
DM4W8RE DT Small molecular drug
DM4W8RE PC 183797
DM4W8RE MW 429.5
DM4W8RE FM C22H31N5O4
DM4W8RE IC InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
DM4W8RE CS C1CCC(CC1)[C@H](C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
DM4W8RE IK DKWNMCUOEDMMIN-PKOBYXMFSA-N
DM4W8RE IU 2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid
DM4W8RE CA CAS 159776-70-2
DM4W8RE CB CHEBI:43966
DMQEC6Z ID DMQEC6Z
DMQEC6Z DN Melanoma vaccine
DMQEC6Z HS Phase 3
DMQEC6Z SN NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie
DMQEC6Z CP Institut Curie
DMQEC6Z DT Vaccine
DMQEC6Z DE Melanoma
DM8Z0I3 ID DM8Z0I3
DM8Z0I3 DN MF-101
DM8Z0I3 HS Phase 3
DM8Z0I3 SN DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo
DM8Z0I3 CP Bionovo Inc; Daewon Pharm Co Ltd
DM8Z0I3 DE Hepatitis virus infection
DMRKTCP ID DMRKTCP
DMRKTCP DN MGA012
DMRKTCP HS Phase 3
DMRKTCP SN INCMGA0012; Retifanlimab
DMRKTCP CP MacroGenics
DMRKTCP DT Antibody
DMRKTCP DE Solid tumour/cancer; Metastatic colorectal cancer; Non-small-cell lung cancer; Merkel cell carcinoma; Penile squamous cancer
DMCJRL1 ID DMCJRL1
DMCJRL1 DN MGN-1703
DMCJRL1 HS Phase 3
DMCJRL1 SN TLR-9 agonist (cancer), Mologen
DMCJRL1 CP Mologen Holding AG
DMCJRL1 DE Colorectal cancer; Solid tumour/cancer
DMZHN5B ID DMZHN5B
DMZHN5B DN MIM-D3
DMZHN5B HS Phase 3
DMZHN5B SN TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
DMZHN5B CP Mimetogen Pharmaceuticals Inc
DMZHN5B DT Small molecular drug
DMZHN5B PC 9808372
DMZHN5B MW 580.5
DMZHN5B FM C24H32N6O11
DMZHN5B IC InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
DMZHN5B CS C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
DMZHN5B IK DVJXNXPFYJIACK-ULQDDVLXSA-N
DMZHN5B IU 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
DMZHN5B CA CAS 263251-78-1
DMZHN5B DE Alzheimer disease
DMCJY35 ID DMCJY35
DMCJY35 DN MIN-101
DMCJY35 HS Phase 3
DMCJY35 SN Roluperidone
DMCJY35 CP Minerva neurosciences
DMCJY35 PC 9799284
DMCJY35 MW 366.4
DMCJY35 FM C22H23FN2O2
DMCJY35 IC InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
DMCJY35 CS C1CN(CCC1CN2CC3=CC=CC=C3C2=O)CC(=O)C4=CC=C(C=C4)F
DMCJY35 IK RNRYULFRLCBRQS-UHFFFAOYSA-N
DMCJY35 IU 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
DMCJY35 CA CAS 359625-79-9
DMCJY35 DE Schizophrenia
DM7R3N5 ID DM7R3N5
DM7R3N5 DN Mirikizumab
DM7R3N5 HS Phase 3
DM7R3N5 CP Eli Lilly Indianapolis, IN
DM7R3N5 DE Psoriasis vulgaris
DM5S4LX ID DM5S4LX
DM5S4LX DN Mirvetuximab soravtansine
DM5S4LX HS Phase 3
DM5S4LX SN ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489
DM5S4LX CP ImmunoGen Waltham, MA
DM5S4LX PC 91810695
DM5S4LX MW 977.6
DM5S4LX FM C42H61ClN4O14S3
DM5S4LX IC InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1
DM5S4LX CS C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\\C)OC)(NC(=O)O2)O
DM5S4LX IK ZOHXWSHGANNQGO-DSIKUUPMSA-N
DM5S4LX IU 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid
DM5S4LX DE Endometrial cancer; Ovarian cancer
DM3PSUF ID DM3PSUF
DM3PSUF DN MK-3102
DM3PSUF HS Phase 3
DM3PSUF SN Omarigliptin
DM3PSUF CP Merck
DM3PSUF DT Small molecular drug
DM3PSUF PC 46209133
DM3PSUF MW 398.4
DM3PSUF FM C17H20F2N4O3S
DM3PSUF IC InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
DM3PSUF CS CS(=O)(=O)N1C=C2CN(CC2=N1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DM3PSUF IK MKMPWKUAHLTIBJ-ISTRZQFTSA-N
DM3PSUF IU (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine
DM3PSUF CA CAS 1226781-44-7
DM3PSUF CB CHEBI:134735
DM3PSUF DE Type-2 diabetes
DMQBF7O ID DMQBF7O
DMQBF7O DN MK-3222
DMQBF7O HS Phase 3
DMQBF7O CP Merck
DMQBF7O DT Antibody
DMQBF7O DE Psoriasis vulgaris; Hairy cell leukaemia; Plaque psoriasis
DMGNHC2 ID DMGNHC2
DMGNHC2 DN MK-3415A
DMGNHC2 HS Phase 3
DMGNHC2 SN Actoxumab/bezlotoxumab
DMGNHC2 CP Merck
DMGNHC2 DT Antibody
DMGNHC2 DE Malaria; Clostridium infection
DMA25NO ID DMA25NO
DMA25NO DN MK-4214
DMA25NO HS Phase 3
DMA25NO SN INS-19; Recombinant human GCSF (biosimilar), Insmed
DMA25NO CP Insmed Inc
DMA25NO DE Neutropenia
DMLYGH4 ID DMLYGH4
DMLYGH4 DN MK-4827
DMLYGH4 HS Phase 3
DMLYGH4 SN 1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
DMLYGH4 CP Merck
DMLYGH4 DT Small molecular drug
DMLYGH4 PC 24958200
DMLYGH4 MW 320.4
DMLYGH4 FM C19H20N4O
DMLYGH4 IC InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
DMLYGH4 CS C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLYGH4 IK PCHKPVIQAHNQLW-CQSZACIVSA-N
DMLYGH4 IU 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLYGH4 CA CAS 1038915-60-4
DMLYGH4 DE Ewing sarcoma; Ovarian cancer; Breast cancer
DM84LO5 ID DM84LO5
DM84LO5 DN MK-8109
DM84LO5 HS Phase 3
DM84LO5 CP Merck
DM84LO5 DE Ovarian cancer
DMK301H ID DMK301H
DMK301H DN MK-8742
DMK301H HS Phase 3
DMK301H CP Merck
DMK301H DE Hepatitis C virus infection
DMT8IAJ ID DMT8IAJ
DMT8IAJ DN MK-8808
DMT8IAJ HS Phase 3
DMT8IAJ CP Merck
DMT8IAJ DE Rheumatoid arthritis; Follicular lymphoma
DMP36KD ID DMP36KD
DMP36KD DN MLN4924
DMP36KD HS Phase 3
DMP36KD SN Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
DMP36KD CP Takeda
DMP36KD DT Small molecular drug
DMP36KD PC 16720766
DMP36KD MW 443.5
DMP36KD FM C21H25N5O4S
DMP36KD IC InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1
DMP36KD CS C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N
DMP36KD IK MPUQHZXIXSTTDU-QXGSTGNESA-N
DMP36KD IU [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate
DMP36KD CA CAS 905579-51-3
DMP36KD CB CHEBI:95028
DMP36KD DE Advanced malignancy; Myelodysplastic syndrome; Acute myelogenous leukaemia; Nasopharyngeal carcinoma
DMO8PT9 ID DMO8PT9
DMO8PT9 DN MLN8237
DMO8PT9 HS Phase 3
DMO8PT9 SN Alisertib
DMO8PT9 TC Anticancer Agents
DMO8PT9 DT Small molecular drug
DMO8PT9 PC 24771867
DMO8PT9 MW 518.9
DMO8PT9 FM C27H20ClFN4O4
DMO8PT9 IC InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
DMO8PT9 CS COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC
DMO8PT9 IK ZLHFILGSQDJULK-UHFFFAOYSA-N
DMO8PT9 IU 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
DMO8PT9 CA CAS 1028486-01-2
DMO8PT9 CB CHEBI:125628
DMO8PT9 DE Solid tumour/cancer; Small-cell lung cancer
DMFWE9S ID DMFWE9S
DMFWE9S DN Mobocertinib
DMFWE9S HS Phase 3
DMFWE9S SN 1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S CP Takeda
DMFWE9S DT Small molecular drug
DMFWE9S PC 118607832
DMFWE9S MW 585.7
DMFWE9S FM C32H39N7O4
DMFWE9S IC InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)
DMFWE9S CS CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMFWE9S IK AZSRSNUQCUDCGG-UHFFFAOYSA-N
DMFWE9S IU propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S CA CAS 1847461-43-1
DMFWE9S DE Non-small cell lung cancer
DM2TNJ1 ID DM2TNJ1
DM2TNJ1 DN Molgramostim
DM2TNJ1 HS Phase 3
DM2TNJ1 SN Genfulin; Molgramostim (topical, wound healing); Molgramostim (topical, wound healing), GeneScience; GM-CSF (topical, woundhealing), GeneScience; Granulocyte-macrophage colony stimulating factor (topical, wound healing), GeneScience
DM2TNJ1 CP GeneScience Pharmaceuticals Co Ltd
DM2TNJ1 DE Wound healing; Autoimmune pulmonary alveolar proteinosis
DMF98Q0 ID DMF98Q0
DMF98Q0 DN Momelotinib
DMF98Q0 HS Phase 3
DMF98Q0 SN Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
DMF98Q0 CP Gilead Sciences
DMF98Q0 DT Small molecular drug
DMF98Q0 PC 25062766
DMF98Q0 MW 414.5
DMF98Q0 FM C23H22N6O2
DMF98Q0 IC InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
DMF98Q0 CS C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
DMF98Q0 IK ZVHNDZWQTBEVRY-UHFFFAOYSA-N
DMF98Q0 IU N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
DMF98Q0 CA CAS 1056634-68-4
DMF98Q0 CB CHEBI:91407
DMF98Q0 DE Myelofibrosis; Polycythemia vera; Thrombocythemia
DMQ1FU8 ID DMQ1FU8
DMQ1FU8 DN Montelukast
DMQ1FU8 HS Phase 3
DMQ1FU8 SN Singulair; Montelukast [INN:BAN]; UNII-MHM278SD3E; MK 0476; CHEMBL787; MHM278SD3E; CHEBI:50730; 142522-28-9; Aerokast; Brondilat (TN)
DMQ1FU8 TC Antiviral Agents
DMQ1FU8 DT Small molecular drug
DMQ1FU8 PC 5281040
DMQ1FU8 MW 586.2
DMQ1FU8 FM C35H36ClNO3S
DMQ1FU8 IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMQ1FU8 CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMQ1FU8 IK UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMQ1FU8 IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMQ1FU8 CA CAS 158966-92-8
DMQ1FU8 CB CHEBI:50730
DMQ1FU8 DE Coronavirus Disease 2019 (COVID-19)
DMPVW6H ID DMPVW6H
DMPVW6H DN Morphine-6-glucuronide
DMPVW6H HS Phase 3
DMPVW6H SN Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide
DMPVW6H TC Analgesics
DMPVW6H DT Small molecular drug
DMPVW6H PC 5360621
DMPVW6H MW 461.5
DMPVW6H FM C23H27NO9
DMPVW6H IC InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22+,23-/m0/s1
DMPVW6H CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O
DMPVW6H IK GNJCUHZOSOYIEC-GAROZEBRSA-N
DMPVW6H IU (2S,3S,4S,5R,6R)-6-[[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DMPVW6H CA CAS 20290-10-2
DMPVW6H CB CHEBI:80581
DMPVW6H DE Pain
DM15ZIB ID DM15ZIB
DM15ZIB DN Mosunetuzumab
DM15ZIB HS Phase 3
DM15ZIB SN RG7828; RO7030816; BTCT4465A
DM15ZIB DT Antibody
DM15ZIB DE Follicular lymphoma
DMB24H7 ID DMB24H7
DMB24H7 DN Motavizumab
DMB24H7 HS Phase 3
DMB24H7 SN MEDI-524; Motavizumab (USAN/INN)
DMB24H7 CP AstraZeneca
DMB24H7 DT Monoclonal antibody
DMB24H7 DE Respiratory syncytial virus infection
DM8K5Z6 ID DM8K5Z6
DM8K5Z6 DN Motexafin lutetium
DM8K5Z6 HS Phase 3
DM8K5Z6 SN Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24
DM8K5Z6 CP Pharmacyclics
DM8K5Z6 DT Small molecular drug
DM8K5Z6 PC 3081907
DM8K5Z6 MW 1184.1
DM8K5Z6 FM C52H74LuN5O15
DM8K5Z6 IC InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2
DM8K5Z6 CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].O.[Lu+3]
DM8K5Z6 IK WIQKYZYFTAEWBF-UHFFFAOYSA-L
DM8K5Z6 IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;lutetium(3+);diacetate;hydrate
DM8K5Z6 CA CAS 156436-90-7
DM8K5Z6 DE Artery stenosis
DM9K3LM ID DM9K3LM
DM9K3LM DN MPDL-3280A
DM9K3LM HS Phase 3
DM9K3LM CP Genentech
DM9K3LM DT Monoclonal antibody
DM9K3LM DE Melanoma
DMNDCFY ID DMNDCFY
DMNDCFY DN MPL-S
DMNDCFY HS Phase 3
DMNDCFY CP Ribi ImmunoChem Research Inc
DMNDCFY DE Endotoxic shock
DMDV4EP ID DMDV4EP
DMDV4EP DN MRTX849
DMDV4EP HS Phase 3
DMDV4EP SN 2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX-849; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
DMDV4EP CP Mirati Therapeutics
DMDV4EP DT Small molecular drug
DMDV4EP PC 138611145
DMDV4EP MW 604.1
DMDV4EP FM C32H35ClFN7O2
DMDV4EP IC InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
DMDV4EP CS CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
DMDV4EP IK PEMUGDMSUDYLHU-ZEQRLZLVSA-N
DMDV4EP IU 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
DMDV4EP CA CAS 2326521-71-3
DMDV4EP DE Non-small-cell lung cancer
DMUNBMA ID DMUNBMA
DMUNBMA DN MT-1621
DMUNBMA HS Phase 3
DMUNBMA CP Modis Therapeutics
DMUNBMA DT Deoxynucleoside
DMUNBMA DE Thymidine kinase 2 deficiency
DMZPEHY ID DMZPEHY
DMZPEHY DN Multi-epitope peptide melanoma vaccine
DMZPEHY HS Phase 3
DMZPEHY SN Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
DMZPEHY CP University of Pittsburgh
DMZPEHY DT Vaccine
DMZPEHY DE Melanoma
DMG3NFZ ID DMG3NFZ
DMG3NFZ DN Muraglitazar
DMG3NFZ HS Phase 3
DMG3NFZ SN Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ DT Small molecular drug
DMG3NFZ PC 206044
DMG3NFZ MW 516.5
DMG3NFZ FM C29H28N2O7
DMG3NFZ IC InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
DMG3NFZ CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC
DMG3NFZ IK IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ IU 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
DMG3NFZ CA CAS 331741-94-7
DMUQ390 ID DMUQ390
DMUQ390 DN Murepavadin
DMUQ390 HS Phase 3
DMUQ390 SN UNII-0D02GRY87Z; 0D02GRY87Z; 944252-63-5; Murepavadin [INN]; Murepavadin [USAN:INN]; Murepavadin (USAN/INN); CHEMBL3946483; Cyclo(L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl); RO7033877; D10957
DMUQ390 CP Polyphor
DMUQ390 PC 91824766
DMUQ390 MW 1553.8
DMUQ390 FM C73H112N22O16
DMUQ390 IC InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1
DMUQ390 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
DMUQ390 IK RIDRXGOBXZLKHZ-NZUANIILSA-N
DMUQ390 IU (3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21,39-bis(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone
DMUQ390 CA CAS 944252-63-5
DMUQ390 DE Ventilator-associated pneumonia
DMS9GE1 ID DMS9GE1
DMS9GE1 DN MyoCell SDF-1
DMS9GE1 HS Phase 3
DMS9GE1 SN Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart
DMS9GE1 CP Bioheart
DMS9GE1 DE Heart failure
DMY60DT ID DMY60DT
DMY60DT DN N8-GP
DMY60DT HS Phase 3
DMY60DT SN NN7088
DMY60DT CP Novo Nordisk
DMY60DT DE Factor VIII deficiency
DMHKJ5I ID DMHKJ5I
DMHKJ5I DN Nabiximols
DMHKJ5I HS Phase 3
DMHKJ5I SN Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02
DMHKJ5I CP Otsuka America Pharmaceutical
DMHKJ5I DT Small molecular drug
DMHKJ5I PC 44148067
DMHKJ5I MW 628.9
DMHKJ5I FM C42H60O4
DMHKJ5I IC InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1
DMHKJ5I CS CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DMHKJ5I IK SSNHGLKFJISNTR-FWUPRJFYSA-N
DMHKJ5I IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DMHKJ5I CA CAS 56575-23-6
DMHKJ5I DE Cancer related pain; Muscle spasm
DMDZ6Q3 ID DMDZ6Q3
DMDZ6Q3 DN Napabucasin
DMDZ6Q3 HS Phase 3
DMDZ6Q3 SN 83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
DMDZ6Q3 CP Boston Biomedical Cambridge, MA
DMDZ6Q3 PC 10331844
DMDZ6Q3 MW 240.21
DMDZ6Q3 FM C14H8O4
DMDZ6Q3 IC InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3
DMDZ6Q3 CS CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O
DMDZ6Q3 IK DPHUWDIXHNQOSY-UHFFFAOYSA-N
DMDZ6Q3 IU 2-acetylbenzo[f][1]benzofuran-4,9-dione
DMDZ6Q3 CA CAS 83280-65-3
DMDZ6Q3 DE Pancreatic cancer; Colorectal cancer; Advanced malignancy; Solid tumour/cancer; Gastrointestinal cancer; Haematological malignancy; Hepatocellular carcinoma; Recurring respiratory infection; Recurrent glioblastoma
DMKP45D ID DMKP45D
DMKP45D DN Naproxcinod
DMKP45D HS Phase 3
DMKP45D SN Beprana; Nitronaproxen; AR-P900758XX; AZD-3582; HCT-3012; Nitronaproxen, NicOx; NO-naproxen, AstraZeneca; NO-naproxen, NicOx; NO-NSAID, NicOx/AstraZeneca; Nitric oxide-donating derivative of naproxen (oral, osteoarthritis), NicOx
DMKP45D CP NicOx SA
DMKP45D DT Small molecular drug
DMKP45D PC 9884642
DMKP45D MW 347.4
DMKP45D FM C18H21NO6
DMKP45D IC InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1
DMKP45D CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-]
DMKP45D IK AKFJWRDCWYYTIG-ZDUSSCGKSA-N
DMKP45D IU 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMKP45D CA CAS 163133-43-5
DMKP45D CB CHEBI:76254
DMKP45D DE Inflammation
DMIC56X ID DMIC56X
DMIC56X DN NASVAC
DMIC56X HS Phase 3
DMIC56X SN NASTERAP; HBV vaccine (intranasal), CIGB
DMIC56X CP Center for Genetic Engineering and Biotechnology
DMIC56X DT Vaccine
DMIC56X DE Hepatitis B virus infection
DMRSI1M ID DMRSI1M
DMRSI1M DN NAV5001
DMRSI1M HS Phase 3
DMRSI1M CP Navidea biopharmaceuticals
DMRSI1M DE Dementia
DMVO1C0 ID DMVO1C0
DMVO1C0 DN NBI-98854
DMVO1C0 HS Phase 3
DMVO1C0 SN NBI-98782; Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine; VMAT-2 inhibitor (CNS disease), Neurocrine
DMVO1C0 CP Neurocrine biosciences
DMVO1C0 DT Small molecular drug
DMVO1C0 PC 123836
DMVO1C0 MW 319.4
DMVO1C0 FM C19H29NO3
DMVO1C0 IC InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3
DMVO1C0 CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC
DMVO1C0 IK WEQLWGNDNRARGE-UHFFFAOYSA-N
DMVO1C0 IU 9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
DMVO1C0 CA CAS 3466-75-9
DMVO1C0 DE Movement disorder; Tourette syndrome
DMFD249 ID DMFD249
DMFD249 DN Nebracetam
DMFD249 HS Phase 3
DMFD249 SN Memolog; WEB-1881; WEB-1881-FU
DMFD249 CP Boehringer Ingelheim Corp
DMFD249 DT Small molecular drug
DMFD249 PC 65926
DMFD249 MW 204.27
DMFD249 FM C12H16N2O
DMFD249 IC InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2
DMFD249 CS C1C(CN(C1=O)CC2=CC=CC=C2)CN
DMFD249 IK LCAFGJGYCUMTGS-UHFFFAOYSA-N
DMFD249 IU 4-(aminomethyl)-1-benzylpyrrolidin-2-one
DMFD249 CA CAS 97205-34-0
DMFD249 DE Parkinson disease
DMDBY30 ID DMDBY30
DMDBY30 DN Nelipepimut S
DMDBY30 HS Phase 3
DMDBY30 SN E75
DMDBY30 CP Galena biopharma
DMDBY30 DT Small molecular drug
DMDBY30 PC 9941306
DMDBY30 MW 995.2
DMDBY30 FM C50H78N10O11
DMDBY30 IC InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1
DMDBY30 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N
DMDBY30 IK AHOKKYCUWBLDST-QYULHYBRSA-N
DMDBY30 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMDBY30 CA CAS 160212-35-1
DMDBY30 DE Non-hodgkin lymphoma; Breast cancer; Gastric adenocarcinoma
DMH9EUA ID DMH9EUA
DMH9EUA DN Nemolizumab
DMH9EUA HS Phase 3
DMH9EUA CP Galderma Fort Worth, TX
DMH9EUA DE Atopic dermatitis
DMIPNBG ID DMIPNBG
DMIPNBG DN Nemonaxacin
DMIPNBG HS Phase 3
DMIPNBG CP Warner Chilcott plc
DMIPNBG DE Methicillin-resistant staphylococci infection
DMVP7HI ID DMVP7HI
DMVP7HI DN Nestorone
DMVP7HI HS Phase 3
DMVP7HI SN Nestorone; Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux
DMVP7HI CP Population Council; Population Council Center for Biomedical Research
DMVP7HI DT Small molecular drug
DMVP7HI PC 108059
DMVP7HI MW 370.5
DMVP7HI FM C23H30O4
DMVP7HI IC InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1
DMVP7HI CS CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C
DMVP7HI IK CKFBRGLGTWAVLG-GOMYTPFNSA-N
DMVP7HI IU [(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMVP7HI CA 7759-35-5
DMVP7HI DE Endometriosis
DMTKRY1 ID DMTKRY1
DMTKRY1 DN Netivudine
DMTKRY1 HS Phase 3
DMTKRY1 SN Zonavir; BW-882; BW-882C; 882-C-87; 882C
DMTKRY1 CP Burroughs Wellcome Inc
DMTKRY1 DT Small molecular drug
DMTKRY1 PC 55281
DMTKRY1 MW 282.25
DMTKRY1 FM C12H14N2O6
DMTKRY1 IC InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1
DMTKRY1 CS CC#CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMTKRY1 IK QLOCVMVCRJOTTM-SDNRWEOFSA-N
DMTKRY1 IU 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione
DMTKRY1 CA CAS 84558-93-0
DMTKRY1 DE Virus infection
DMEKAYI ID DMEKAYI
DMEKAYI DN Netupitant
DMEKAYI HS Phase 3
DMEKAYI SN R-1124; NK1 antagonist (emesis), Roche; Ro-67-3189
DMEKAYI CP Helsinn Therapeutics
DMEKAYI DT Small molecular drug
DMEKAYI PC 6451149
DMEKAYI MW 578.6
DMEKAYI FM C30H32F6N4O
DMEKAYI IC InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
DMEKAYI CS CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
DMEKAYI IK WAXQNWCZJDTGBU-UHFFFAOYSA-N
DMEKAYI IU 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
DMEKAYI CA CAS 290297-26-6
DMEKAYI CB CHEBI:85155
DMEKAYI DE Chemotherapy-induced nausea
DME617W ID DME617W
DME617W DN Neucardin
DME617W HS Phase 3
DME617W SN Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun
DME617W CP Zensun (Shanghai) Sci-Tech Co Ltd
DME617W DE Heart failure; Chronic heart failure
DMYTC4I ID DMYTC4I
DMYTC4I DN NeuVax
DMYTC4I HS Phase 3
DMYTC4I SN NeuVax (TN)
DMYTC4I CP Galena Biopharma
DMYTC4I DT Vaccine
DMYTC4I DE Breast cancer
DMJ2KIE ID DMJ2KIE
DMJ2KIE DN NI-101
DMJ2KIE HS Phase 3
DMJ2KIE SN BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec
DMJ2KIE CP Neurimmune Therapeutics AG
DMJ2KIE DT Antibody
DMJ2KIE DE Alzheimer disease
DMFBNA3 ID DMFBNA3
DMFBNA3 DN Nicaraven
DMFBNA3 HS Phase 3
DMFBNA3 SN AVS; Antevan; Antevas
DMFBNA3 CP Chugai Pharmaceutical
DMFBNA3 DT Small molecular drug
DMFBNA3 PC 71234
DMFBNA3 MW 284.31
DMFBNA3 FM C15H16N4O2
DMFBNA3 IC InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
DMFBNA3 CS CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2
DMFBNA3 IK KTXBOOWDLPUROC-UHFFFAOYSA-N
DMFBNA3 IU N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide
DMFBNA3 CA CAS 79455-30-4
DMFBNA3 DE Cerebrovascular disease
DM376WT ID DM376WT
DM376WT DN NKTR 214
DM376WT HS Phase 3
DM376WT CP Nektar Therapeutics San Francisco, CA
DM376WT DE Bladder cancer; Colorectal cancer; Melanoma; Renal cell carcinoma; Solid tumour/cancer; Sarcoma
DM45DS8 ID DM45DS8
DM45DS8 DN NKTR-181
DM45DS8 HS Phase 3
DM45DS8 CP Nektar therapeutics
DM45DS8 PC 73673720
DM45DS8 MW 595.7
DM45DS8 FM C31H49NO10
DM45DS8 IC InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1
DM45DS8 CS CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O)OCCOCCOCCOCCOCCOCCOC
DM45DS8 IK RQHILGKAOIGUHU-XPLSERNMSA-N
DM45DS8 IU (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol
DM45DS8 CA CAS 1211231-76-3
DM45DS8 DE Neuropathic pain; Chronic low back pain; Pain
DMACYW6 ID DMACYW6
DMACYW6 DN NKTR-214
DMACYW6 HS Phase 3
DMACYW6 SN bempegaldesleukin
DMACYW6 CP Nektar Therapeutics
DMACYW6 DT Recombinant protein
DMACYW6 DE Melanoma
DMDJLY9 ID DMDJLY9
DMDJLY9 DN NM-702
DMDJLY9 HS Phase 3
DMDJLY9 SN NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride
DMDJLY9 CP Nissan Chemical America
DMDJLY9 DT Small molecular drug
DMDJLY9 PC 9848253
DMDJLY9 MW 486.2
DMDJLY9 FM C19H19BrCl2N4O2
DMDJLY9 IC InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H
DMDJLY9 CS C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl
DMDJLY9 IK QWGUGDYWUADMGB-UHFFFAOYSA-N
DMDJLY9 IU 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
DMDJLY9 CA CAS 878796-94-2
DMDJLY9 DE Angina pectoris
DMDGK83 ID DMDGK83
DMDGK83 DN NN1841
DMDGK83 HS Phase 3
DMDGK83 SN NovoThirteen (TN)
DMDGK83 CP Novo Nordisk
DMDGK83 DE Hemophilia
DM0QV27 ID DM0QV27
DM0QV27 DN NN5401
DM0QV27 HS Phase 3
DM0QV27 SN Insulin degludec and insulin aspart; Ryzodeg (TN)
DM0QV27 CP Novo Nordisk
DM0QV27 DE Diabetic complication
DM1PI9G ID DM1PI9G
DM1PI9G DN NN8717
DM1PI9G HS Phase 3
DM1PI9G CP Novo Nordisk
DM1PI9G DE Graft-versus-host disease
DMOF0CA ID DMOF0CA
DMOF0CA DN Nolatrexed
DMOF0CA HS Phase 3
DMOF0CA SN Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS
DMOF0CA CP Agouron Pharmaceuticals Inc
DMOF0CA DT Small molecular drug
DMOF0CA PC 135400184
DMOF0CA MW 284.34
DMOF0CA FM C14H12N4OS
DMOF0CA IC InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)
DMOF0CA CS CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3
DMOF0CA IK XHWRWCSCBDLOLM-UHFFFAOYSA-N
DMOF0CA IU 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one
DMOF0CA CA CAS 147149-76-6
DMOF0CA DE Solid tumour/cancer
DMMC3Y8 ID DMMC3Y8
DMMC3Y8 DN NPC-01
DMMC3Y8 HS Phase 3
DMMC3Y8 SN LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma
DMMC3Y8 CP Nobelpharma Co Ltd
DMMC3Y8 DE Dysmenorrhea
DMCMIJ1 ID DMCMIJ1
DMCMIJ1 DN NT0202
DMCMIJ1 HS Phase 3
DMCMIJ1 SN Amphetamine polistirex
DMCMIJ1 CP Neos therapeutics
DMCMIJ1 DE Attention deficit hyperactivity disorder
DMA16IL ID DMA16IL
DMA16IL DN NU-100
DMA16IL HS Phase 3
DMA16IL SN BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech
DMA16IL CP Nuron biotech
DMA16IL PC 21987656
DMA16IL MW 378.5
DMA16IL FM C24H30N2O2
DMA16IL IC InChI=1S/C24H30N2O2/c27-23(25-21-7-3-1-4-8-21)19-13-11-18-16-20(14-12-17(18)15-19)24(28)26-22-9-5-2-6-10-22/h11-16,21-22H,1-10H2,(H,25,27)(H,26,28)
DMA16IL CS C1CCC(CC1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=O)NC4CCCCC4
DMA16IL IK MBSRTKPGZKQXQR-UHFFFAOYSA-N
DMA16IL IU 2-N,6-N-dicyclohexylnaphthalene-2,6-dicarboxamide
DMA16IL CA CAS 153250-52-3
DMA16IL DE Multiple sclerosis
DM8JWNA ID DM8JWNA
DM8JWNA DN NVP-LAQ824
DM8JWNA HS Phase 3
DM8JWNA SN Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; Dacinostat; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
DM8JWNA CP Corcept Therapeutics
DM8JWNA DT Small molecular drug
DM8JWNA PC 6445533
DM8JWNA MW 379.5
DM8JWNA FM C22H25N3O3
DM8JWNA IC InChI=1S/C22H25N3O3/c26-14-13-25(12-11-19-15-23-21-4-2-1-3-20(19)21)16-18-7-5-17(6-8-18)9-10-22(27)24-28/h1-10,15,23,26,28H,11-14,16H2,(H,24,27)/b10-9+
DM8JWNA CS C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO
DM8JWNA IK BWDQBBCUWLSASG-MDZDMXLPSA-N
DM8JWNA IU (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
DM8JWNA CA CAS 404951-53-7
DM8JWNA CB CHEBI:94063
DM8JWNA DE leukaemia; Multiple myeloma; Mood disorder
DM3L2GT ID DM3L2GT
DM3L2GT DN O6-Benzylguanine alkylade
DM3L2GT HS Phase 3
DM3L2GT SN KRX-0402; O6-Benzylguanine (BG)
DM3L2GT CP Wiley-Liss; Keryx Biopharmaceuticals
DM3L2GT DE Sarcoma
DMENDP6 ID DMENDP6
DMENDP6 DN OBI-1
DMENDP6 HS Phase 3
DMENDP6 SN Porcine rFVIII, Ipsen/Inspiration; Porcine rFVIII, Octagen/Ipsen; Porcine rFactor VIII, Ipsen/Inspiration; Porcine rFactor VIII, Octagen/Ipsen; Recombinant porcine Factor VIII, Ipsen/Inspiration; Recombinant porcine Factor VIII, Octagen/Ipsen
DMENDP6 CP Baxter international; inspiration biopharmaceuticals
DMENDP6 DE Factor VIII deficiency
DM7KI4E ID DM7KI4E
DM7KI4E DN Oblimersen
DM7KI4E HS Phase 3
DM7KI4E CP Genta Incorp
DM7KI4E PC 118984457
DM7KI4E MW 6058
DM7KI4E FM C172H204N62Na17O91P17S17
DM7KI4E IC InChI=1S/C172H221N62O91P17S17.17Na/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254;;;;;;;;;;;;;;;;;/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244);;;;;;;;;;;;;;;;;/q;17*+1/p-17/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?;;;;;;;;;;;;;;;;;/m0................./s1
DM7KI4E CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)[S-])N1C=NC2=C(N=CN=C21)N)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM7KI4E IK IBXPAFBDJCXCDW-MHFPCNPESA-A
DM7KI4E IU heptadecasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfidophosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM7KI4E CA CAS 190977-41-4
DM7KI4E DE Multiple myeloma; Melanoma
DMEDSVJ ID DMEDSVJ
DMEDSVJ DN Ociperlimab
DMEDSVJ HS Phase 3
DMEDSVJ SN BGB-A1217
DMEDSVJ CP BeiGene
DMEDSVJ DT Antibody
DMEDSVJ DE Cervical cancer; Non-small-cell lung cancer
DM1EO3G ID DM1EO3G
DM1EO3G DN Odanacatib
DM1EO3G HS Phase 3
DM1EO3G SN MK 0822; MK0822; MK-0822A; Odanacatib (USAN)
DM1EO3G CP Merck
DM1EO3G DT Small molecular drug
DM1EO3G PC 10152654
DM1EO3G MW 525.6
DM1EO3G FM C25H27F4N3O3S
DM1EO3G IC InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
DM1EO3G CS CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
DM1EO3G IK FWIVDMJALNEADT-SFTDATJTSA-N
DM1EO3G IU (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
DM1EO3G CA CAS 603139-19-1
DM1EO3G DE Osteoporosis
DMYN391 ID DMYN391
DMYN391 DN Odevixibat
DMYN391 HS Phase 3
DMYN391 SN 501692-44-0; UNII-2W150K0UUC; 2W150K0UUC; A4250; AZD8294; 501692-44-0 (free base); Odevixibat (USAN); Odevixibat [USAN]; AR-H064974; A-4250; (S)-2-((R)-2-(2-((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid; SCHEMBL946468; CHEMBL4297588; BDBM77040; GTPL11194; AZD-8294; example 5 [US9694018B1]; WHO 10706; HY-109120; Unk-D-nTyr-Abu-OH (IUPAC condensed name); CS-0078340; D11716; US9694018, 5; (2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid; (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid; Butanoic acid, 2-(((2R)-((((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)(4-hydroxyphenyl)acetyl)amino)-, (2S)-; Butanoic acid, 2-(((2R)-2-((2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)-, (2S)-
DMYN391 CP Albireo Pharma
DMYN391 DT Small molecular drug
DMYN391 PC 10153627
DMYN391 MW 740.9
DMYN391 FM C37H48N4O8S2
DMYN391 IC InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1
DMYN391 CS CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC
DMYN391 IK XULSCZPZVQIMFM-IPZQJPLYSA-N
DMYN391 IU (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid
DMYN391 CA CAS 501692-44-0
DMYN391 DE Alagille syndrome
DMBWO5T ID DMBWO5T
DMBWO5T DN ODT-8
DMBWO5T HS Phase 3
DMBWO5T SN H-c(Cys3-Phe6-Phe7-DTrp8-Lys9-Thr10-Phe11-Cys14)-OH; CHEMBL266477; BDBM50136824; (4R,7S,10S,13S,16R,19S,22S,25R)-16-((1H-indol-3-yl)methyl)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-((R)-1-hydroxyethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptaazacyclohexacosane-4-carboxylic acid
DMBWO5T PC 11251755
DMBWO5T MW 1079.3
DMBWO5T FM C54H66N10O10S2
DMBWO5T IC InChI=1S/C54H66N10O10S2/c1-32(65)46-53(72)62-43(27-35-19-9-4-10-20-35)51(70)63-45(54(73)74)31-76-75-30-38(56)47(66)59-41(25-33-15-5-2-6-16-33)49(68)60-42(26-34-17-7-3-8-18-34)50(69)61-44(28-36-29-57-39-22-12-11-21-37(36)39)52(71)58-40(48(67)64-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,57,65H,13-14,23-28,30-31,55-56H2,1H3,(H,58,71)(H,59,66)(H,60,68)(H,61,69)(H,62,72)(H,63,70)(H,64,67)(H,73,74)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1
DMBWO5T CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CC6=CC=CC=C6)O
DMBWO5T IK PJRZZHKHLDKTKL-OCZUONHDSA-N
DMBWO5T IU (4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxylic acid
DM1FBZ7 ID DM1FBZ7
DM1FBZ7 DN Olodaterol/tiotropium bromide
DM1FBZ7 HS Phase 3
DM1FBZ7 SN 136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0
DM1FBZ7 CP Boehringer Ingelheim Pharmaceuticals
DM1FBZ7 DT Small molecular drug
DM1FBZ7 PC 5487426
DM1FBZ7 MW 472.4
DM1FBZ7 FM C19H22BrNO4S2
DM1FBZ7 IC InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+;
DM1FBZ7 CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
DM1FBZ7 IK DQHNAVOVODVIMG-RGECMCKFSA-M
DM1FBZ7 IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DM1FBZ7 CA CAS 136310-93-5
DM1FBZ7 CB CHEBI:90959
DM1FBZ7 DE Chronic obstructive pulmonary disease
DM4Z9QI ID DM4Z9QI
DM4Z9QI DN Olokizumab
DM4Z9QI HS Phase 3
DM4Z9QI CP UCB
DM4Z9QI DT Monoclonal antibody
DM4Z9QI DE Rheumatoid arthritis
DM624TW ID DM624TW
DM624TW DN Omecamtiv mecarbil
DM624TW HS Phase 3
DM624TW SN Omecamtiv mecarbil; 873697-71-3; Omecamtiv mecarbil (CK-1827452); CK-1827452; CK1827452; UNII-2M19539ERK; CK 1827452; methyl 4-(2-fluoro-3-(3-(6-Methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate; CHEMBL1800955; AMG-423; 2M19539ERK; Methyl 4-(2-Fluoro-3-{[(6-Methylpyridin-3-Yl)carbamoyl]amino}benzyl)piperazine-1-Carboxylate; Methyl 4-[[2-fluoro-3-[n'-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate; Omecamtiv mecarbil [USAN:INN]; omecamtiv mercarbil; MLS006011266; SCHEMBL400544; Omecamtiv Mecarbil;
DM624TW CP Amgen
DM624TW DT Small molecular drug
DM624TW PC 11689883
DM624TW MW 401.4
DM624TW FM C20H24FN5O3
DM624TW IC InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
DM624TW CS CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC
DM624TW IK RFUBTTPMWSKEIW-UHFFFAOYSA-N
DM624TW IU methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
DM624TW CA CAS 873697-71-3
DM624TW DE Heart failure
DMBWY8V ID DMBWY8V
DMBWY8V DN Omega-6-FA
DMBWY8V HS Phase 3
DMBWY8V SN Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398
DMBWY8V PC 56842208
DMBWY8V MW 584.9
DMBWY8V FM C38H64O4
DMBWY8V IC ZCDMRPMKAQLWAO-PZLFCYFRSA-N
DMBWY8V CS CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCC=CCC=CCC=CCC=CCCCC(=O)O
DMBWY8V IK 1S/C20H32O2.C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22);6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-,16-15-;7-6-,10-9-
DMBWY8V IU (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid
DMBWY8V DE Attention deficit hyperactivity disorder
DMK6QBZ ID DMK6QBZ
DMK6QBZ DN OMS721
DMK6QBZ HS Phase 3
DMK6QBZ CP Omeros, Seattle, WA
DMK6QBZ DE Thrombotic microangiopathy; Glomerulonephritis; Lupus; Atypical hemolytic uremic syndrome
DMU86DM ID DMU86DM
DMU86DM DN ONO-1101
DMU86DM HS Phase 3
DMU86DM SN Landiolol; Landiolol [INN]; ONO-1101; Ono 1101; (S-(R*,R*))-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-(2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)benzenepropanoate; 133242-30-5; 62NWQ924LH; Benzenepropanoic acid, 4-((2S)-2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)-, ((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; UNII-62NWQ924LH; [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM PC 114905
DMU86DM MW 509.6
DMU86DM FM C25H39N3O8
DMU86DM IC WMDSZGFJQKSLLH-RBBKRZOGSA-N
DMU86DM CS CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C
DMU86DM IK 1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
DMU86DM IU [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM CA CAS 133242-30-5
DMU86DM CB CHEBI:135809
DMU86DM DE Atrial fibrillation
DM06KRC ID DM06KRC
DM06KRC DN Oregovomab
DM06KRC HS Phase 3
DM06KRC CP Quest PharmaTech
DM06KRC DT Monoclonal antibody
DM06KRC DE Ovarian cancer; Epithelial ovarian cancer
DMWD3IV ID DMWD3IV
DMWD3IV DN Oseltamivir + hydroxychloroquine
DMWD3IV HS Phase 3
DMWD3IV SN Tamiflu + oxichloroquine
DMWD3IV TC Antiviral Agents
DMWD3IV DT Combination drug
DMWD3IV DE Coronavirus Disease 2019 (COVID-19)
DMHKZLF ID DMHKZLF
DMHKZLF DN OSI-906
DMHKZLF HS Phase 3
DMHKZLF SN Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906
DMHKZLF DT Small molecular drug
DMHKZLF PC 11640390
DMHKZLF MW 421.5
DMHKZLF FM C26H23N5O
DMHKZLF IC InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)
DMHKZLF CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O
DMHKZLF IK PKCDDUHJAFVJJB-UHFFFAOYSA-N
DMHKZLF IU 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DMHKZLF CA CAS 867160-71-2
DMHKZLF CB CHEBI:91402
DMHKZLF DE Solid tumour/cancer
DM7R145 ID DM7R145
DM7R145 DN Otesaconazole
DM7R145 HS Phase 3
DM7R145 SN Oteseconazole; 1340593-59-0; VT-1161; UNII-VHH774W97N; VHH774W97N; CHEMBL3311228; (R)-2-(2,4-Difluorophenyl)-1,1-Difluoro-3-(1h-Tetrazol-1-Yl)-1-(5-(4-(2,2,2-Trifluoroethoxy)phenyl)pyridin-2-Yl)propan-2-Ol; Oteseconazole [USAN]; Oteseconazole (USAN/INN); SCHEMBL17113021; BDBM50046187; WHO 10138; DB13055; SB17420; HY-17643; CS-0016914; D11785; Q27291837; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol; 2-Pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphaR)-
DM7R145 CP Mycovia Pharmaceuticals
DM7R145 DT Small molecular drug
DM7R145 PC 77050711
DM7R145 MW 527.4
DM7R145 FM C23H16F7N5O2
DM7R145 IC InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1
DM7R145 CS C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
DM7R145 IK IDUYJRXRDSPPRC-NRFANRHFSA-N
DM7R145 IU (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
DM7R145 CA CAS 1340593-59-0
DM7R145 DE Onychomycosis; Vulvovaginal Candidiasis
DMLMS6J ID DMLMS6J
DMLMS6J DN OTL-101
DMLMS6J HS Phase 3
DMLMS6J CP Orchard Therapeutics
DMLMS6J DT Gene therapy
DMLMS6J DE Severe combined immunodeficiency
DM3BK2Y ID DM3BK2Y
DM3BK2Y DN OTL-103
DM3BK2Y HS Phase 3
DM3BK2Y CP Orchard Therapeutics
DM3BK2Y DT Gene therapy
DM3BK2Y DE Wiskott-Aldrich syndrome
DM5DRMY ID DM5DRMY
DM5DRMY DN P1101
DM5DRMY HS Phase 3
DM5DRMY SN N-Phenylethylenediamine; 1664-40-0; N1-Phenylethane-1,2-diamine; N-(2-Aminoethyl)aniline; 1,2-Ethanediamine, N-phenyl-; Ethylenediamine, N-phenyl-; N-Phenyl-1,2-ethanediamine; 1,2-Ethanediamine, N1-phenyl-; Benzenamine, N-(2-aminoethyl)-; N'-phenylethane-1,2-diamine; N-phenylethane-1,2-diamine; n1-phenyl-1,2-ethanediamine; MFCD00008162; (2-aminoethyl)phenylamine; N-Phenylethylenediamine, 99%; NSC84247; phenylethylenediamine; EINECS 216-773-4; NSC 84247; 2-phenylaminoethylamine; phenyl ethylene diamine; ACMC-209duf; N -phenylethylenediamine; N-phenyl ethylenediamine; N-phenyl ethylene diamine; N-phenyl-ethylene-diamine; N-(2-aminoethyl)-aniline; N-phenyl ethyl-ene diamine; n2-phenyl-1,2-ethanediamine; N-phenyl-ethane-1,2-diamine; SCHEMBL307775; N-Phenylethylenediamine, 98%; N'-phenyl-ethane-1,2-diamine; N1-phenyl-ethane-1,2-diamine; DTXSID1061861; OCIDXARMXNJACB-UHFFFAOYSA-; Ethylenediamine, N-phenyl- (8CI); STR05027; ZINC1736738; 8473AA; ANW-22213; NSC-84247; SBB004200; STL257388; AKOS005135725; LS10740; MCULE-5870561171; NE53436; AC-25457; AK122216; SY009366; DB-043652; CS-0045385; FT-0629102; ST45237853; EN300-81504; J-010281
DM5DRMY CP PharmaEssentia
DM5DRMY DT Small molecular drug
DM5DRMY PC 74270
DM5DRMY MW 136.19
DM5DRMY FM C8H12N2
DM5DRMY IC InChI=1S/C8H12N2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DM5DRMY CS C1=CC=C(C=C1)NCCN
DM5DRMY IK OCIDXARMXNJACB-UHFFFAOYSA-N
DM5DRMY IU N'-phenylethane-1,2-diamine
DM5DRMY CA CAS 1664-40-0
DM5DRMY DE Polycythemia vera
DM7WYXJ ID DM7WYXJ
DM7WYXJ DN P-1101
DM7WYXJ HS Phase 3
DM7WYXJ SN Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b
DM7WYXJ CP Hanall biopharma; medtronic
DM7WYXJ DE Hepatitis B virus infection; Essential thrombocythemia; Myelofibrosis
DM9PVHX ID DM9PVHX
DM9PVHX DN P2B-001
DM9PVHX HS Phase 3
DM9PVHX SN Fixed-dose combination therapy (Parkinsons diease), Pharma Two B
DM9PVHX CP Pharma Two B Ltd
DM9PVHX DE Parkinson disease
DM1T6ZN ID DM1T6ZN
DM1T6ZN DN Pacritinib
DM1T6ZN HS Phase 3
DM1T6ZN SN JAK inhibitor (alone or in combination)s
DM1T6ZN CP Cell Therapeutics
DM1T6ZN DT Small molecular drug
DM1T6ZN PC 46216796
DM1T6ZN MW 472.6
DM1T6ZN FM C28H32N4O3
DM1T6ZN IC InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
DM1T6ZN CS C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2
DM1T6ZN IK HWXVIOGONBBTBY-ONEGZZNKSA-N
DM1T6ZN IU (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
DM1T6ZN CA CAS 937272-79-2
DM1T6ZN DE Myelofibrosis
DMFKOR9 ID DMFKOR9
DMFKOR9 DN Pafuramidine
DMFKOR9 HS Phase 3
DMFKOR9 SN Pafuramidine maleate; DB-289; DB-290; DB-75 prodrug, Immtech; Pafuramidine maleate (oral formulation), Strativa
DMFKOR9 CP Immtech International; University of North Carolina
DMFKOR9 DT Small molecular drug
DMFKOR9 PC 5480200
DMFKOR9 MW 364.4
DMFKOR9 FM C20H20N4O3
DMFKOR9 IC InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24)
DMFKOR9 CS CO/N=C(\\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N
DMFKOR9 IK UKOQVLAXCBRRGH-UHFFFAOYSA-N
DMFKOR9 IU N'-methoxy-4-[5-[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide
DMFKOR9 CA CAS 186953-56-0
DMFKOR9 DE Malaria
DMAD2OZ ID DMAD2OZ
DMAD2OZ DN Palovarotene
DMAD2OZ HS Phase 3
DMAD2OZ SN R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074
DMAD2OZ CP Roche
DMAD2OZ DT Small molecular drug
DMAD2OZ PC 10295295
DMAD2OZ MW 414.5
DMAD2OZ FM C27H30N2O2
DMAD2OZ IC InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
DMAD2OZ CS CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C
DMAD2OZ IK YTFHCXIPDIHOIA-DHZHZOJOSA-N
DMAD2OZ IU 4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid
DMAD2OZ CA CAS 410528-02-8
DMAD2OZ DE Emphysema; Fibrodysplasia ossificans progressiva
DM4SKYI ID DM4SKYI
DM4SKYI DN PAMAQUESIDE
DM4SKYI HS Phase 3
DM4SKYI SN CP-148623; Pamaqueside < Prop INN; 11-Ketotigogenyl beta-O-cellobioside
DM4SKYI DT Small molecular drug
DM4SKYI PC 9918516
DM4SKYI MW 754.9
DM4SKYI FM C39H62O14
DM4SKYI IC InChI=1S/C39H62O14/c1-17-7-10-39(48-16-17)18(2)27-24(53-39)12-22-21-6-5-19-11-20(8-9-37(19,3)28(21)23(42)13-38(22,27)4)49-35-33(47)31(45)34(26(15-41)51-35)52-36-32(46)30(44)29(43)25(14-40)50-36/h17-22,24-36,40-41,43-47H,5-16H2,1-4H3/t17-,18+,19+,20+,21+,22+,24+,25-,26-,27+,28-,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1
DM4SKYI CS C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC(=O)[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1
DM4SKYI IK VWMZIGBYZQUQOA-QEEMJVPDSA-N
DM4SKYI IU (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-11-one
DM4SKYI CA CAS 150332-35-7
DM4SKYI DE Hyperlipidaemia
DMIRYU9 ID DMIRYU9
DMIRYU9 DN Pancopride
DMIRYU9 HS Phase 3
DMIRYU9 SN LAS-30451
DMIRYU9 CP Almirall Prodesfarma SA
DMIRYU9 DT Small molecular drug
DMIRYU9 PC 71342
DMIRYU9 MW 349.9
DMIRYU9 FM C18H24ClN3O2
DMIRYU9 IC InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)
DMIRYU9 CS C1CC1COC2=CC(=C(C=C2C(=O)NC3CN4CCC3CC4)Cl)N
DMIRYU9 IK DBQMQBCSKXTCIJ-UHFFFAOYSA-N
DMIRYU9 IU 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide
DMIRYU9 DE Nausea
DMEW5Z8 ID DMEW5Z8
DMEW5Z8 DN PARABEN
DMEW5Z8 HS Phase 3
DM3H2U4 ID DM3H2U4
DM3H2U4 DN Patrome
DM3H2U4 HS Phase 3
DM3H2U4 CP GlaxoSmithKline
DM3H2U4 DE Parkinson disease
DMHXTAQ ID DMHXTAQ
DMHXTAQ DN Pazufloxacin
DMHXTAQ HS Phase 3
DMHXTAQ SN 127045-41-4; T-3761; UNII-4CZ1R38NDI; 4CZ1R38NDI; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; Pazufloxacin [INN]; SMR000466380; CCRIS 7312; CAS-127045-41-4; T 3761; 127046-18-8; PZFX; Pazufloxacin (JAN/INN); SCHEMBL34460; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; MLS000759513; MLS001424116; CHEMBL240163; DTXSID5046697; CHEBI:94700; HY-B0724B; HMS2051B05; HMS2090H07; BCP12954; LSM-5745; RKL10069; ZINC3779726; Tox21_112531; BDBM50248017; MFCD00865012; AKOS015900451; Tox21_112531_1; AC-3506; CCG-100919; DB11774; GM-1171; KS-5008; NC00169; NCGC00167534-02; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-; AB0012715; D01153; AB00639918-07; AB00639918-09; AB00639918_10; Pazufloxacin, VETRANAL(TM), analytical standard; SR-01000759348; J-005457; Q3898423; SR-01000759348-4; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-
DMHXTAQ DT Small molecular drug
DMHXTAQ PC 65957
DMHXTAQ MW 318.3
DMHXTAQ FM C16H15FN2O4
DMHXTAQ IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMHXTAQ CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMHXTAQ IK XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMHXTAQ IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMHXTAQ CA CAS 127045-41-4
DMHXTAQ CB CHEBI:94700
DMHXTAQ DE Conjunctivitis
DMP3G0W ID DMP3G0W
DMP3G0W DN Pazufloxacin
DMP3G0W HS Phase 3
DMP3G0W SN Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
DMP3G0W PC 65957
DMP3G0W MW 318.3
DMP3G0W FM C16H15FN2O4
DMP3G0W IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMP3G0W CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMP3G0W IK XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMP3G0W IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMP3G0W CA CAS 127045-41-4
DMP3G0W CB CHEBI:94700
DMP3G0W DE Bacterial conjunctivitis
DMJBHO0 ID DMJBHO0
DMJBHO0 DN PC-DAC:Insulin
DMJBHO0 HS Phase 3
DMJBHO0 SN Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea
DMJBHO0 CP Lipoxen plc; Aradigm; Translational Research Ltd; Diabetology Ltd; Coremed Inc; Nobex Corp; Altea Therapeutics; ConjuChem Biotechnologies Inc; Bioglan Pharmaceuticals Co; Epic Therapeutics Inc; NOD Pharmaceuticals Inc; Andaris Group Ltd; Emisphere Technologies Inc; halozyme therapeutics
DMJBHO0 DE Type-1 diabetes; Type-2 diabetes
DMMBC5W ID DMMBC5W
DMMBC5W DN PDGF-BB
DMMBC5W HS Phase 3
DMMBC5W SN PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns)
DMMBC5W CP Adocia SAS
DMMBC5W DE Diabetic foot ulcer
DM53J6B ID DM53J6B
DM53J6B DN PDR001
DM53J6B HS Phase 3
DM53J6B CP Novartis Oncology East Hanover, NJ
DM53J6B DT Antibody
DM53J6B DE Lymphoma; Neuroendocrine cancer; Solid tumour/cancer; Melanoma; Esophageal squamous cell carcinoma
DMBKWAF ID DMBKWAF
DMBKWAF DN Peg-G-CSF
DMBKWAF HS Phase 3
DMBKWAF SN Peg-G-CSF (chemotherapy induced side effects)
DMBKWAF CP Phage Biotechnology Corp
DMBKWAF DE Solid tumour/cancer
DMK6OFY ID DMK6OFY
DMK6OFY DN Peginterferon lambda-1a
DMK6OFY HS Phase 3
DMK6OFY SN BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
DMK6OFY CP Bristol-myers squibb
DMK6OFY DE Acute myeloid leukaemia
DMESAZK ID DMESAZK
DMESAZK DN Peretinoin
DMESAZK HS Phase 3
DMESAZK SN Polyprenoic acid; E-5166; NIK-333; Peretinoin (oral); Peretinoin (oral), Kowa; Peretinoin (oral formulation, hepatocellular carcinoma), Kowa Pharmaceutical
DMESAZK CP Kowa Pharmaceutical Co Ltd; Eisai Co Ltd
DMESAZK DT Small molecular drug
DMESAZK PC 6437836
DMESAZK MW 302.5
DMESAZK FM C20H30O2
DMESAZK IC InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+
DMESAZK CS CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C
DMESAZK IK UUBHZHZSIKRVIV-KCXSXWJSSA-N
DMESAZK IU (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid
DMESAZK CA CAS 81485-25-8
DMESAZK DE Hepatocellular carcinoma
DMUP5Z0 ID DMUP5Z0
DMUP5Z0 DN PF-03084014
DMUP5Z0 HS Phase 3
DMUP5Z0 SN Nirogacestat; 1290543-63-3; PF-03084014; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01
DMUP5Z0 CP Pfizer
DMUP5Z0 DT Small molecular drug
DMUP5Z0 PC 46224413
DMUP5Z0 MW 489.6
DMUP5Z0 FM C27H41F2N5O
DMUP5Z0 IC InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1
DMUP5Z0 CS CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F
DMUP5Z0 IK VFCRKLWBYMDAED-REWPJTCUSA-N
DMUP5Z0 IU (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide
DMUP5Z0 CA CAS 1290543-63-3
DMUP5Z0 DE Alzheimer disease; Solid tumour/cancer; Desmoid tumour
DM0TWCY ID DM0TWCY
DM0TWCY DN PF-04950615
DM0TWCY HS Phase 3
DM0TWCY CP Pfizer New York, NY
DM0TWCY DT Antibody
DM0TWCY DE Hypercholesterolaemia
DM8J29L ID DM8J29L
DM8J29L DN PF-04965842
DM8J29L HS Phase 3
DM8J29L PC 78323835
DM8J29L MW 323.42
DM8J29L FM C14H21N5O2S
DM8J29L IC InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)
DM8J29L CS CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
DM8J29L IK IUEWXNHSKRWHDY-UHFFFAOYSA-N
DM8J29L IU N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
DM8J29L CA CAS 1622902-68-4
DM8J29L DE Lupus; Atopic dermatitis
DM23BUP ID DM23BUP
DM23BUP DN PF-05280014
DM23BUP HS Phase 3
DM23BUP CP Pfizer
DM23BUP DE Breast cancer
DMNZOCK ID DMNZOCK
DMNZOCK DN PF-05280586
DMNZOCK HS Phase 3
DMNZOCK CP Pfizer
DMNZOCK DE Cluster headache; Follicular lymphoma
DM2GF14 ID DM2GF14
DM2GF14 DN PF-06410293
DM2GF14 HS Phase 3
DM2GF14 CP Pfizer
DM2GF14 DT Antibody
DM2GF14 DE Rheumatoid arthritis
DMM4C95 ID DMM4C95
DMM4C95 DN PF-06438179
DMM4C95 HS Phase 3
DMM4C95 CP Pfizer
DMM4C95 DE Rheumatoid arthritis
DMVHZDP ID DMVHZDP
DMVHZDP DN PF-06439535
DMVHZDP HS Phase 3
DMVHZDP CP Pfizer
DMVHZDP DT Antibody
DMVHZDP DE Solid tumour/cancer; Non-small-cell lung cancer
DMW63TQ ID DMW63TQ
DMW63TQ DN PF-06741086
DMW63TQ HS Phase 3
DMW63TQ SN marstacimab
DMW63TQ CP Pfizer
DMW63TQ DT Antibody
DMW63TQ DE Hemophilia
DMWPA4L ID DMWPA4L
DMWPA4L DN PF-07055480
DMWPA4L HS Phase 3
DMWPA4L SN giroctocogene fitelparvovec
DMWPA4L CP Pfizer
DMWPA4L DT Gene therapy
DMWPA4L DE Haemophilia A
DMS1EQ7 ID DMS1EQ7
DMS1EQ7 DN PF-1228305
DMS1EQ7 HS Phase 3
DMS1EQ7 SN Sitaxentan sodium; Sitaxsentan sodium
DMS1EQ7 CP Pfizer
DMS1EQ7 DT Small molecular drug
DMS1EQ7 PC 11477084
DMS1EQ7 MW 476.9
DMS1EQ7 FM C18H14ClN2NaO6S2
DMS1EQ7 IC InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
DMS1EQ7 CS CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+]
DMS1EQ7 IK MDTNUYUCUYPIHE-UHFFFAOYSA-N
DMS1EQ7 IU sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide
DMS1EQ7 CA CAS 210421-74-2
DMS1EQ7 DE Pulmonary hypertension
DMJ7IKW ID DMJ7IKW
DMJ7IKW DN PF-4494700
DMJ7IKW HS Phase 3
DMJ7IKW SN PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer
DMJ7IKW CP Transtech pharma
DMJ7IKW DT Small molecular drug
DMJ7IKW PC 11180124
DMJ7IKW MW 532.1
DMJ7IKW FM C32H38ClN3O2
DMJ7IKW IC InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
DMJ7IKW CS CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC
DMJ7IKW IK KJNNWYBAOPXVJY-UHFFFAOYSA-N
DMJ7IKW IU 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine
DMJ7IKW CA CAS 603148-36-3
DMJ7IKW DE Dementia; Alzheimer disease
DM5DAP3 ID DM5DAP3
DM5DAP3 DN PGF2ALPHA-IE
DM5DAP3 HS Phase 3
DM5DAP3 SN Prostaglandin F2alpha isopropyl ester; (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid isopropyl ester
DM5DAP3 DT Small molecular drug
DM5DAP3 PC 5283077
DM5DAP3 MW 396.6
DM5DAP3 FM C23H40O5
DM5DAP3 IC InChI=1S/C23H40O5/c1-4-5-8-11-18(24)14-15-20-19(21(25)16-22(20)26)12-9-6-7-10-13-23(27)28-17(2)3/h6,9,14-15,17-22,24-26H,4-5,7-8,10-13,16H2,1-3H3/b9-6-,15-14+/t18-,19+,20+,21-,22+/m0/s1
DM5DAP3 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)OC(C)C)O)O)O
DM5DAP3 IK FPABVZYYTCHNMK-YNRDDPJXSA-N
DM5DAP3 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate
DM5DAP3 CA CAS 53764-90-2
DM5DAP3 CB CHEBI:165336
DM5DAP3 DE Glaucoma/ocular hypertension
DM8Y12A ID DM8Y12A
DM8Y12A DN PH-80
DM8Y12A HS Phase 3
DM8Y12A SN Vomeropherin (premenstrual syndrome), Pherin; Vomeropherin (premenstrual syndrome), Pherin/ Organon
DM8Y12A CP Pherin Corp
DM8Y12A DE Premenstrual syndrome
DMDC7OH ID DMDC7OH
DMDC7OH DN PH94B NS
DMDC7OH HS Phase 3
DMDC7OH SN Aloradine IN; Aloradine NS
DMDC7OH CP Pherin Pharmaceuticals Los Altos, CA
DMDC7OH DE Social anxiety disorder
DMVEHM4 ID DMVEHM4
DMVEHM4 DN Phentermine+topiramate
DMVEHM4 HS Phase 3
DMVEHM4 SN Qnexa (TN)
DMVEHM4 CP Vivus
DMVEHM4 DT Small molecular drug
DMVEHM4 PC 56842108
DMVEHM4 MW 488.6
DMVEHM4 FM C22H36N2O8S
DMVEHM4 IC InChI=1S/C12H21NO8S.C10H15N/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;1-10(2,11)8-9-6-4-3-5-7-9/h7-9H,5-6H2,1-4H3,(H2,13,14,15);3-7H,8,11H2,1-2H3/t7-,8-,9?,12+;/m1./s1
DMVEHM4 CS CC1(O[C@@H]2CO[C@@]3(C([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C.CC(C)(CC1=CC=CC=C1)N
DMVEHM4 IK PWDLDBWXTVILPC-QGGVPXFVSA-N
DMVEHM4 IU 2-methyl-1-phenylpropan-2-amine;[(1R,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DMVEHM4 CA CAS 960078-81-3
DMVEHM4 DE Obesity
DMGZPX6 ID DMGZPX6
DMGZPX6 DN PI-88
DMGZPX6 HS Phase 3
DMGZPX6 SN CHEMBL603733
DMGZPX6 CP Progen Industries
DMGZPX6 TC Anticancer Agents
DMGZPX6 DT Small molecular drug
DMGZPX6 PC 46233427
DMGZPX6 MW 2516.5
DMGZPX6 FM C30H35Na15O77PS16-3
DMGZPX6 IC InChI=1S/C30H53O77PS16.15Na/c31-108(32,33)82-1-6-14(99-116(55,56)57)20(102-119(64,65)66)25(106-123(76,77)78)29(87-6)94-17-12(97-114(49,50)51)8(3-84-110(37,38)39)89-27(23(17)104-121(70,71)72)92-16-11(96-113(46,47)48)7(2-83-109(34,35)36)88-26(22(16)103-120(67,68)69)93-18-13(98-115(52,53)54)9(4-85-111(40,41)42)90-28(24(18)105-122(73,74)75)95-21-19(101-118(61,62)63)15(100-117(58,59)60)10(5-86-112(43,44)45)91-30(21)107-124(79,80)81;;;;;;;;;;;;;;;/h6-30H,1-5H2,(H2,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81);;;;;;;;;;;;;;;/q;15*+1/p-18/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-;;;;;;;;;;;;;;;/m1.............../s1
DMGZPX6 CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O[C@H]2[C@@H]([C@H](O[C@@H]([C@H]2OS(=O)(=O)[O-])O[C@H]3[C@@H]([C@H](O[C@@H]([C@H]3OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H](O[C@@H]([C@H]4OS(=O)(=O)[O-])O[C@H]5[C@H]([C@@H]([C@H](O[C@@H]5OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMGZPX6 IK FIYNUMVQYZZZCH-JSZMYKOGSA-A
DMGZPX6 IU pentadecasodium;[(2R,3R,4S,5S,6R)-6-[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5R,6R)-2-[(2R,3R,4S,5S,6R)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2R,3S,4R,5R,6R)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,4,5-trisulfonatooxyoxan-2-yl]methyl phosphate
DMGZPX6 DE Prostate cancer; Hepatocellular carcinoma
DM7OSHC ID DM7OSHC
DM7OSHC DN Pinaverium bromide
DM7OSHC HS Phase 3
DM7OSHC SN Dicetel; Bromure de pinaverium; Bromuro de pinaverio; Pinaverii bromidum; Pinaverium bromide [INN]; LAT 1717; Bromure de pinaverium [INN-French]; Bromuro de pinaverio [INN-Spanish]; Dicetel (TN); Pinaverii bromidum [INN-Latin]; Pinaverium bromide (INN); Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide; 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide; 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide
DM7OSHC CP Solvay
DM7OSHC DT Small molecular drug
DM7OSHC PC 40703
DM7OSHC MW 591.4
DM7OSHC FM C26H41Br2NO4
DM7OSHC IC InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1
DM7OSHC CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-]
DM7OSHC IK IKGXLCMLVINENI-UHFFFAOYSA-M
DM7OSHC IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium;bromide
DM7OSHC CA CAS 53251-94-8
DM7OSHC DE Irritable bowel syndrome
DMRG1X3 ID DMRG1X3
DMRG1X3 DN Pirtobrutinib
DMRG1X3 HS Phase 3
DMRG1X3 SN BTK inhibitor 16; 2101700-15-4; Pirtobrutinib [USAN]; UNII-JNA39I7ZVB; JNA39I7ZVB; LOXO-305; SCHEMBL19014257; WHO 11681; HY-131328; LY3527727; CS-0133286; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-
DMRG1X3 CP LOXO Oncology
DMRG1X3 DT Small molecular drug
DMRG1X3 PC 129269915
DMRG1X3 MW 479.4
DMRG1X3 FM C22H21F4N5O3
DMRG1X3 IC InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
DMRG1X3 CS C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N
DMRG1X3 IK FWZAWAUZXYCBKZ-NSHDSACASA-N
DMRG1X3 IU 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
DMRG1X3 CA CAS 2101700-15-4
DMRG1X3 DE Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMQGR45 ID DMQGR45
DMQGR45 DN Pixantrone
DMQGR45 HS Phase 3
DMQGR45 SN Pixuvri (TN)
DMQGR45 CP Cell Therapeutics
DMQGR45 DT Small molecular drug
DMQGR45 PC 134019
DMQGR45 MW 325.4
DMQGR45 FM C17H19N5O2
DMQGR45 IC InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
DMQGR45 CS C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN
DMQGR45 IK PEZPMAYDXJQYRV-UHFFFAOYSA-N
DMQGR45 IU 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
DMQGR45 CA CAS 144510-96-3
DMQGR45 CB CHEBI:135945
DMQGR45 DE Multiple sclerosis; Follicular lymphoma; Diffuse large B-cell lymphoma; Pediatric cancer
DMCA6BW ID DMCA6BW
DMCA6BW DN Pixykine
DMCA6BW HS Phase 3
DMCA6BW SN Milodistim; Plasmid Immunex yeast 321; PIXY-321
DMCA6BW CP Immunex Corp
DMCA6BW DE Human immunodeficiency virus infection
DM1RWMY ID DM1RWMY
DM1RWMY DN Plasma derived factor VIII PEGylated liposomal
DM1RWMY HS Phase 3
DM1RWMY SN LongAte; NecLip-pdFVIII; Plasma derived factor VIII (PEGylated liposomal (NecLip), hemophilia A), Recoly
DM1RWMY CP Recoly NV
DM1RWMY DE Factor VIII deficiency
DMD7L48 ID DMD7L48
DMD7L48 DN Plinabulin
DMD7L48 HS Phase 3
DMD7L48 SN NPI-2358
DMD7L48 CP Nereus Pharmaceuticals
DMD7L48 DT Small molecular drug
DMD7L48 PC 9949641
DMD7L48 MW 336.4
DMD7L48 FM C19H20N4O2
DMD7L48 IC InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
DMD7L48 CS CC(C)(C)C1=C(N=CN1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2
DMD7L48 IK UNRCMCRRFYFGFX-TYPNBTCFSA-N
DMD7L48 IU (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]piperazine-2,5-dione
DMD7L48 CA CAS 714272-27-2
DMD7L48 DE Non-small-cell lung cancer
DMJ8AUE ID DMJ8AUE
DMJ8AUE DN Plitidepsin
DMJ8AUE HS Phase 3
DMJ8AUE SN Aplidin (TN)
DMJ8AUE CP PharmaMar
DMJ8AUE DT Small molecular drug
DMJ8AUE PC 9812534
DMJ8AUE MW 1110.3
DMJ8AUE FM C57H87N7O15
DMJ8AUE IC InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
DMJ8AUE CS CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
DMJ8AUE IK UUSZLLQJYRSZIS-LXNNNBEUSA-N
DMJ8AUE IU (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
DMJ8AUE CA CAS 137219-37-5
DMJ8AUE CB CHEBI:90205
DMJ8AUE DE Multiple myeloma; Angioimmunoblastic T-cell Lymphoma
DMV8EXG ID DMV8EXG
DMV8EXG DN PolyHeme
DMV8EXG HS Phase 3
DMV8EXG SN Oxygen-carrying blood substitute, Northfield Laboratories
DMV8EXG CP Northfield Laboratories
DMV8EXG PC 72941846
DMV8EXG MW 347.26
DMV8EXG FM C13H18NO8P
DMV8EXG IC InChI=1S/C8H10NO6P.C5H8O2/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;6-4-2-1-3-5-7/h2-3,11H,4H2,1H3,(H2,12,13,14);4-5H,1-3H2
DMV8EXG CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.C(CC=O)CC=O
DMV8EXG IK SKKYPUWZZNPUMG-UHFFFAOYSA-N
DMV8EXG IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;pentanedial
DMV8EXG DE Blood forming organ disorder
DMTD7AB ID DMTD7AB
DMTD7AB DN Pracinostat
DMTD7AB HS Phase 3
DMTD7AB SN Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-
DMTD7AB CP MEI Pharma
DMTD7AB DT Small molecular drug
DMTD7AB PC 49855250
DMTD7AB MW 358.5
DMTD7AB FM C20H30N4O2
DMTD7AB IC InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
DMTD7AB CS CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO
DMTD7AB IK JHDKZFFAIZKUCU-ZRDIBKRKSA-N
DMTD7AB IU (E)-3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide
DMTD7AB CA CAS 929016-96-6
DMTD7AB CB CHEBI:95071
DMTD7AB DE Myelofibrosis; Myelodysplastic syndrome; Acute myeloid leukaemia
DM2ZYX9 ID DM2ZYX9
DM2ZYX9 DN Pradaxa
DM2ZYX9 HS Phase 3
DM2ZYX9 SN Dabigatran etexilate mesylate; 872728-81-9; XETBXHPXHHOLOE-UHFFFAOYSA-N; CP0128; FT-0660872; ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulphonate; 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide mesylate
DM2ZYX9 CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM2ZYX9 PC 11434065
DM2ZYX9 MW 723.8
DM2ZYX9 FM C35H45N7O8S
DM2ZYX9 IC InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)
DM2ZYX9 CS CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\\N.CS(=O)(=O)O
DM2ZYX9 IK XETBXHPXHHOLOE-UHFFFAOYSA-N
DM2ZYX9 IU ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
DM2ZYX9 CA CAS 872728-81-9
DM2ZYX9 DE Stroke
DMOMDXI ID DMOMDXI
DMOMDXI DN Pratosartan
DMOMDXI HS Phase 3
DMOMDXI SN KD3-671; KT3-671
DMOMDXI CP Kotobuki Pharmaceutical Co Ltd
DMOMDXI DT Small molecular drug
DMOMDXI PC 9802561
DMOMDXI MW 426.5
DMOMDXI FM C25H26N6O
DMOMDXI IC InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
DMOMDXI CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)CCCC2
DMOMDXI IK KCTFTBCZZUBAKN-UHFFFAOYSA-N
DMOMDXI IU 2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6,7,8-tetrahydrocyclohepta[d]imidazol-4-one
DMOMDXI CA CAS 153804-05-8
DMOMDXI CB CHEBI:32041
DMOMDXI DE Hypertension
DMLSOB7 ID DMLSOB7
DMLSOB7 DN Premarin/Pravachol
DMLSOB7 HS Phase 3
DMLSOB7 SN Estrogen/Eptastatin
DMLSOB7 CP Bristol-Myers Squibb
DMLSOB7 DE Hyperlipidaemia
DMX9YLR ID DMX9YLR
DMX9YLR DN Pridopidine
DMX9YLR HS Phase 3
DMX9YLR SN PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149; Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co
DMX9YLR CP Teva pharmaceutical
DMX9YLR DT Small molecular drug
DMX9YLR PC 9795739
DMX9YLR MW 281.4
DMX9YLR FM C15H23NO2S
DMX9YLR IC InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3
DMX9YLR CS CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
DMX9YLR IK YGKUEOZJFIXDGI-UHFFFAOYSA-N
DMX9YLR IU 4-(3-methylsulfonylphenyl)-1-propylpiperidine
DMX9YLR CA CAS 346688-38-8
DMX9YLR DE Huntington disease
DMD1FTP ID DMD1FTP
DMD1FTP DN PRO-140
DMD1FTP HS Phase 3
DMD1FTP SN PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals
DMD1FTP CP Progenics Pharmaceuticals Inc
DMD1FTP DE Human immunodeficiency virus infection
DM5FZH4 ID DM5FZH4
DM5FZH4 DN ProstaVac
DM5FZH4 HS Phase 3
DM5FZH4 SN Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis); Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis), AmVac
DM5FZH4 CP AmVac AG
DM5FZH4 DT Vaccine
DM5FZH4 DE Prostate hyperplasia
DMVU8RW ID DMVU8RW
DMVU8RW DN PRT4445
DMVU8RW HS Phase 3
DMVU8RW CP Portola pharmaceuticals
DMVU8RW DE Bleeding disorder
DMEH641 ID DMEH641
DMEH641 DN PRX-302
DMEH641 HS Phase 3
DMEH641 CP Sophiris
DMEH641 DE Prostate cancer
DMIZJ8M ID DMIZJ8M
DMIZJ8M DN Psoralen
DMIZJ8M HS Phase 3
DMIZJ8M SN Psoralen; 66-97-7; 7H-Furo[3,2-g]chromen-7-one; Ficusin; Furocoumarin; Psoralene; 7H-Furo[3,2-g][1]benzopyran-7-one; Psorline-P; 6,7-Furanocoumarin; furo[3,2-g]chromen-7-one; Furo[3,2-g]coumarin; Furo(4',5',6,7)coumarin; Furo(2',3',7,6)coumarin; Furo(3,2-g)-coumarin; Furo[4',5':6,7]coumarin; Furo[2',3':7,6]coumarin; NSC 404562; UNII-KTZ7ZCN2EX; 7H-Furo(3,2-g)(1)benzopyran-7-one; 7H-Furo[3,2-g]benzopyran-7-one; CCRIS 4343; Furo[2'.3':7.6]coumarin; HSDB 3528; KTZ7ZCN2EX; EINECS 200-639-7; 6-Hydroxy-5-benzofuranacrylic acid beta-lacto
DMIZJ8M DT Small molecular drug
DMIZJ8M PC 6199
DMIZJ8M MW 186.16
DMIZJ8M FM C11H6O3
DMIZJ8M IC InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
DMIZJ8M CS C1=CC(=O)OC2=CC3=C(C=CO3)C=C21
DMIZJ8M IK ZCCUUQDIBDJBTK-UHFFFAOYSA-N
DMIZJ8M IU furo[3,2-g]chromen-7-one
DMIZJ8M CA CAS 66-97-7
DMIZJ8M CB CHEBI:27616
DMTSN8L ID DMTSN8L
DMTSN8L DN PT005
DMTSN8L HS Phase 3
DMTSN8L SN Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005
DMTSN8L CP Pearl Therapeutics
DMTSN8L DT Small molecular drug
DMTSN8L PC 6917983
DMTSN8L MW 822.9
DMTSN8L FM C42H54N4O13
DMTSN8L IC InChI=1S/2C19H24N2O4.C4H4O4.H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);1H2/b;;2-1+;/t2*13-,19+;;/m11../s1
DMTSN8L CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\\C(=O)O.O
DMTSN8L IK BPXZSHHCUKRDHD-HTLUESNNSA-N
DMTSN8L IU (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate
DMTSN8L DE Chronic obstructive pulmonary disease
DML1KTO ID DML1KTO
DML1KTO DN PT2977
DML1KTO HS Phase 3
DML1KTO SN MK-6482
DML1KTO CP Peloton Therapeutics Dallas, TX
DML1KTO PC 117947097
DML1KTO MW 383.3
DML1KTO FM C17H12F3NO4S
DML1KTO IC InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
DML1KTO CS CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
DML1KTO IK LOMMPXLFBTZENJ-ZACQAIPSSA-N
DML1KTO IU 3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile
DML1KTO CA CAS 1672668-24-4
DML1KTO DE Solid tumour/cancer; Von hippel-lindau disease; Renal cell carcinoma
DMMJ63A ID DMMJ63A
DMMJ63A DN PT-304
DMMJ63A HS Phase 3
DMMJ63A SN 149486-04-4; Thiourea, N-(2-(3-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(3-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 3; AC1MHDMA; SCHEMBL6964163; CHEMBL253995; BDBM1896; DTXSID20164299; 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030941; 1-(2-Thiazolyl)-3-[3-fluorophenethyl]thiourea; N-(2-(3-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DMMJ63A DT Small molecular drug
DMMJ63A PC 3001163
DMMJ63A MW 281.4
DMMJ63A FM C12H12FN3S2
DMMJ63A IC InChI=1S/C12H12FN3S2/c13-10-3-1-2-9(8-10)4-5-14-11(17)16-12-15-6-7-18-12/h1-3,6-8H,4-5H2,(H2,14,15,16,17)
DMMJ63A CS C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=CS2
DMMJ63A IK NDHSDDFIIZKISX-UHFFFAOYSA-N
DMMJ63A IU 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMMJ63A CA CAS 149486-04-4
DMVDCGZ ID DMVDCGZ
DMVDCGZ DN Pyridoxamine
DMVDCGZ HS Phase 3
DMVDCGZ SN Pyridorin (TN)
DMVDCGZ CP Nephrogenex
DMVDCGZ DT Small molecular drug
DMVDCGZ PC 1052
DMVDCGZ MW 168.19
DMVDCGZ FM C8H12N2O2
DMVDCGZ IC InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
DMVDCGZ CS CC1=NC=C(C(=C1O)CN)CO
DMVDCGZ IK NHZMQXZHNVQTQA-UHFFFAOYSA-N
DMVDCGZ IU 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
DMVDCGZ CA CAS 85-87-0
DMVDCGZ CB CHEBI:16410
DMVDCGZ DE Diabetic nephropathy; Diabetic kidney disease
DMPCFXN ID DMPCFXN
DMPCFXN DN QAW-039
DMPCFXN HS Phase 3
DMPCFXN DE Asthma
DMDU5Y2 ID DMDU5Y2
DMDU5Y2 DN QPI-1002
DMDU5Y2 HS Phase 3
DMDU5Y2 CP Quark Pharmaceuticals
DMDU5Y2 TC siRNA
DMDU5Y2 DT siRNA drug
DMDU5Y2 DE Renal artery disease; Renal transplantation
DMUWXEB ID DMUWXEB
DMUWXEB DN QPI-1007
DMUWXEB HS Phase 3
DMUWXEB SN SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
DMUWXEB CP Quark pharmaceuticals
DMUWXEB DT siRNA drug
DMUWXEB DE Glaucoma/ocular hypertension; Ischemic optic neuropathy; Non-arteritic anterior ischemic optic neuropathy
DMDCQW0 ID DMDCQW0
DMDCQW0 DN Quinotolast
DMDCQW0 HS Phase 3
DMDCQW0 SN Aslock; Quinotalast; FK-021; FR-71021
DMDCQW0 CP Fujisawa Pharmaceutical Co Ltd
DMDCQW0 DT Small molecular drug
DMDCQW0 PC 65871
DMDCQW0 MW 348.32
DMDCQW0 FM C17H12N6O3
DMDCQW0 IC InChI=1S/C17H12N6O3/c24-15(18-17-19-21-22-20-17)12-10-14(26-11-6-2-1-3-7-11)13-8-4-5-9-23(13)16(12)25/h1-10H,(H2,18,19,20,21,22,24)
DMDCQW0 CS C1=CC=C(C=C1)OC2=C3C=CC=CN3C(=O)C(=C2)C(=O)NC4=NNN=N4
DMDCQW0 IK ZUPLNRDTYQWUHP-UHFFFAOYSA-N
DMDCQW0 IU 4-oxo-1-phenoxy-N-(2H-tetrazol-5-yl)quinolizine-3-carboxamide
DMDCQW0 CA CAS 101193-40-2
DMDCQW0 DE Asthma
DMSFX75 ID DMSFX75
DMSFX75 DN QVA-149
DMSFX75 HS Phase 3
DMSFX75 SN Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol
DMSFX75 CP Sosei; Vectura; Novartis
DMSFX75 DT Small molecular drug
DMSFX75 PC 11564052
DMSFX75 MW 790.8
DMSFX75 FM C43H56BrN3O6
DMSFX75 IC InChI=1S/C24H28N2O3.C19H28NO3.BrH/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q;+1;/p-1/t22-;;/m0../s1
DMSFX75 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMSFX75 IK GCUZFFAPBPDIFM-IKXQUJFKSA-M
DMSFX75 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMSFX75 CA CAS 1262431-94-6
DMSFX75 DE Chronic obstructive pulmonary disease
DM4K9WH ID DM4K9WH
DM4K9WH DN R1678
DM4K9WH HS Phase 3
DM4K9WH SN R-1678; RG-1678
DM4K9WH CP Roche
DM4K9WH DT Small molecular drug
DM4K9WH PC 137905
DM4K9WH MW 342.3
DM4K9WH FM C22H14O4
DM4K9WH IC InChI=1S/C22H14O4/c23-19(15-7-3-1-4-8-15)21(25)17-11-13-18(14-12-17)22(26)20(24)16-9-5-2-6-10-16/h1-14H
DM4K9WH CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)C(=O)C3=CC=CC=C3
DM4K9WH IK FUEGWHHUYNHBNI-UHFFFAOYSA-N
DM4K9WH IU 1-[4-(2-oxo-2-phenylacetyl)phenyl]-2-phenylethane-1,2-dione
DM4K9WH CA CAS 3363-97-1
DM4K9WH DE Schizophrenia
DM9Z4N5 ID DM9Z4N5
DM9Z4N5 DN RA101495
DM9Z4N5 HS Phase 3
DM9Z4N5 SN Zilucoplan
DM9Z4N5 CP Ra Pharmaceuticals Cambridge, MA
DM9Z4N5 PC 133083018
DM9Z4N5 MW 3562
DM9Z4N5 FM C172H278N24O55
DM9Z4N5 IC InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1
DM9Z4N5 CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O
DM9Z4N5 IK JDXCOXKBIGBZSK-PSNKNOTQSA-N
DM9Z4N5 IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid
DM9Z4N5 CA CAS 1841136-73-9
DM9Z4N5 DE Paroxysmal nocturnal haemoglobinuria; Myasthenia gravis
DM8RLJ5 ID DM8RLJ5
DM8RLJ5 DN RAD-1901
DM8RLJ5 HS Phase 3
DM8RLJ5 SN ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius
DM8RLJ5 CP Eisai Co Ltd
DM8RLJ5 PC 23642301
DM8RLJ5 MW 458.6
DM8RLJ5 FM C30H38N2O2
DM8RLJ5 IC InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
DM8RLJ5 CS CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O
DM8RLJ5 IK SIFNOOUKXBRGGB-AREMUKBSSA-N
DM8RLJ5 IU (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DM8RLJ5 CA CAS 722533-56-4
DM8RLJ5 DE Breast cancer
DMN1ZEU ID DMN1ZEU
DMN1ZEU DN Radiosensitizer gene therapy
DMN1ZEU HS Phase 3
DMN1ZEU SN Radiosensitizer gene therapy (prostate cancer)
DMN1ZEU CP Advantagene
DMN1ZEU DE Pancreatic cancer
DMWA74Y ID DMWA74Y
DMWA74Y DN Radotinib
DMWA74Y HS Phase 3
DMWA74Y SN IY-5511; IY-GV50205; Anticancer, Il-yang
DMWA74Y CP Il-Yang Pharmaceutical Co
DMWA74Y DT Small molecular drug
DMWA74Y PC 16063245
DMWA74Y MW 530.5
DMWA74Y FM C27H21F3N8O
DMWA74Y IC InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
DMWA74Y CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5
DMWA74Y IK DUPWHXBITIZIKZ-UHFFFAOYSA-N
DMWA74Y IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
DMWA74Y CA CAS 926037-48-1
DMWA74Y DE leukaemia
DMFSHEM ID DMFSHEM
DMFSHEM DN Ragaglitazar
DMFSHEM HS Phase 3
DMFSHEM SN Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid
DMFSHEM DT Small molecular drug
DMFSHEM PC 447458
DMFSHEM MW 419.5
DMFSHEM FM C25H25NO5
DMFSHEM IC InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1
DMFSHEM CS CCO[C@@H](CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMFSHEM IK WMUIIGVAWPWQAW-DEOSSOPVSA-N
DMFSHEM IU (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid
DMFSHEM CA CAS 222834-30-2
DMFSHEM DE Type-1 diabetes
DMUNMY0 ID DMUNMY0
DMUNMY0 DN Ralfinamide
DMUNMY0 HS Phase 3
DMUNMY0 SN Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0 CP Newron
DMUNMY0 TC Analgesics
DMUNMY0 DT Small molecular drug
DMUNMY0 PC 5745207
DMUNMY0 MW 302.34
DMUNMY0 FM C17H19FN2O2
DMUNMY0 IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMUNMY0 CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F
DMUNMY0 IK BHJIBOFHEFDSAU-LBPRGKRZSA-N
DMUNMY0 IU (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0 CA CAS 133865-88-0
DMUNMY0 DE Neuropathic pain
DMD5QRS ID DMD5QRS
DMD5QRS DN Ranirestat
DMD5QRS HS Phase 3
DMD5QRS SN AS-3201
DMD5QRS CP Eisai
DMD5QRS DT Small molecular drug
DMD5QRS PC 153948
DMD5QRS MW 420.2
DMD5QRS FM C17H11BrFN3O4
DMD5QRS IC InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
DMD5QRS CS C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
DMD5QRS IK QCVNMNYRNIMDKV-QGZVFWFLSA-N
DMD5QRS IU (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
DMD5QRS CA CAS 147254-64-6
DMD5QRS DE Diabetic neuropathy
DMVKL3B ID DMVKL3B
DMVKL3B DN Ravulizumab
DMVKL3B HS Phase 3
DMVKL3B SN Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2
DMVKL3B TC Antiviral Agents
DMVKL3B DT Monoclonal antibody
DMVKL3B DE Coronavirus Disease 2019 (COVID-19)
DMPJTZ1 ID DMPJTZ1
DMPJTZ1 DN RBP-7000
DMPJTZ1 HS Phase 3
DMPJTZ1 CP Reckitt benckiser pharmaceutical
DMPJTZ1 DE Non-small-cell lung cancer; Schizophrenia
DMDZW8K ID DMDZW8K
DMDZW8K DN RBT-101
DMDZW8K HS Phase 3
DMDZW8K SN RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec
DMDZW8K CP Redbiotec AG
DMDZW8K DE Influenza virus infection; Heart failure; Respiratory tract infection
DM2GHCR ID DM2GHCR
DM2GHCR DN Rebamipide
DM2GHCR HS Phase 3
DM2GHCR SN rebamipide; 90098-04-7; Mucosta; Proamipide; 111911-87-6; OPC-12759; Rebamipidum; Pramipide; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; Rebamipida [INN-Spanish]; OPC 12759; CCRIS 3585; Rebamipide hydrate; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 139344-42-6; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; Mucosta hydrate; NCGC00095161-01; Proamipide hydrate; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid
DM2GHCR DT Small molecular drug
DM2GHCR PC 5042
DM2GHCR MW 370.8
DM2GHCR FM C19H15ClN2O4
DM2GHCR IC InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
DM2GHCR CS C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl
DM2GHCR IK ALLWOAVDORUJLA-UHFFFAOYSA-N
DM2GHCR IU 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
DM2GHCR CA CAS 90098-04-7
DM2GHCR CB CHEBI:93814
DM2GHCR DE Peptic ulcer
DM8HVNR ID DM8HVNR
DM8HVNR DN Recombinant acidic fibroblast growth factor
DM8HVNR HS Phase 3
DM8HVNR SN AFGF; Rh-aFGF; Recombinant acidic fibroblast growth factor (ulcer/burns); Recombinant acidic fibroblast growth factor (ulcer/burns), SinoBiomed; Recombinant acidic fibroplast growth factor (ulcer/burns), SinoBiomed
DM8HVNR CP SinoBiomed Inc
DM8HVNR DE Skin burns
DMOWQAF ID DMOWQAF
DMOWQAF DN Recombinant human iduronate-2-sulfatase
DMOWQAF HS Phase 3
DMOWQAF SN GC-1111; Recombinant human iduronate-2-sulfatase (Hunter syndrome); Recombinant human iduronate-2-sulfatase (Hunter syndrome), Green Cross
DMOWQAF CP Green Cross Corp
DMOWQAF DE Hunter syndrome
DM7JFDO ID DM7JFDO
DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO HS Phase 3
DM7JFDO SN Willebrand factor/recombinant Factor VIII complex; Recombinant von Willebrand factor/recombinant Factor VIII complex (von Willebrand disease)
DM7JFDO CP Csl behring
DM7JFDO DE Von willebrand disease
DM34GOF ID DM34GOF
DM34GOF DN REL-1017
DM34GOF HS Phase 3
DM34GOF SN Dextromethadone; d-Methadone; S-Methadone; (S)-methadone; (+)-Methadone; S-(+)-Methadone; 6S-Methadone; 5653-80-5; L-(+)-Methadone; (6S)-Methadone; l-Methadone; (S)-(+)-Methadone; UNII-S95RZH8AMH; d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; S95RZH8AMH; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; CHEMBL350719; (S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; 3-14-00-00279 (Beilstein Handbook Reference); Methadone, (+)-; BRN 3213667; (+)-(S)-Methadone; (+)-(6S)-Methadone; SCHEMBL24294; (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; CHEBI:167308; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (S)-; ZINC1530707; BDBM50223640; DB15198; SB18896; (S)-6-Dimethylamino4,4-diphenylheptan-3-on; Q15634047; (+)-(S)-6-(dimethylamino)-4,4-diphenyl-3-heptanone; 3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)-; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-KRWDZBQOSA-N; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-QGZVFWFLSA-N; 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)- (9CI); 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (S)- (8CI)
DM34GOF CP Relmada Therapeutics
DM34GOF DT Small molecular drug
DM34GOF PC 643985
DM34GOF MW 309.4
DM34GOF FM C21H27NO
DM34GOF IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m0/s1
DM34GOF CS CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DM34GOF IK USSIQXCVUWKGNF-KRWDZBQOSA-N
DM34GOF IU (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one
DM34GOF CA CAS 5653-80-5
DM34GOF CB CHEBI:167308
DM34GOF DE Neuropathic pain; Major depressive disorder
DMOWINT ID DMOWINT
DMOWINT DN Reloxaliase
DMOWINT HS Phase 3
DMOWINT SN ALLN-177
DMOWINT CP Allena Pharmaceuticals
DMOWINT DT Protein
DMOWINT DE Hyperoxaluria
DM3YXP8 ID DM3YXP8
DM3YXP8 DN Remacemide
DM3YXP8 HS Phase 3
DM3YXP8 SN Remacemida; Remacemidum; Remacemide [INN]; FPL 12924; FPL 12924AA; FPL 14144; FPL 14145; FPL-12944AA; PR 1032-644; PR 934-423; PR1032-646; Remacemida [INN-Spanish]; Remacemidum [INN-Latin]; PR-934-423; Remacemide monohydrochloride, (+-)-isomer; (+)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (+-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide; 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide
DM3YXP8 CP Astra Zeneca
DM3YXP8 DT Small molecular drug
DM3YXP8 PC 60511
DM3YXP8 MW 268.35
DM3YXP8 FM C17H20N2O
DM3YXP8 IC InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
DM3YXP8 CS CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN
DM3YXP8 IK YSGASDXSLKIKOD-UHFFFAOYSA-N
DM3YXP8 IU 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide
DM3YXP8 CA CAS 128298-28-2
DM3YXP8 CB CHEBI:91654
DM3YXP8 DE Pain
DM49IGE ID DM49IGE
DM49IGE DN Remdesivir
DM49IGE HS Phase 3
DM49IGE SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DM49IGE CP Gilead Sciences, Foster City, CA
DM49IGE TC Antiviral Agents
DM49IGE DT Small molecular drug
DM49IGE PC 121304016
DM49IGE MW 602.6
DM49IGE FM C27H35N6O8P
DM49IGE IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DM49IGE CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DM49IGE IK RWWYLEGWBNMMLJ-YSOARWBDSA-N
DM49IGE IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM49IGE CA CAS 1809249-37-3
DM49IGE CB CHEBI:145994
DM49IGE DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7HQNX ID DM7HQNX
DM7HQNX DN Renzapride
DM7HQNX HS Phase 3
DM7HQNX SN Renzaprida; Renzapridum; Renzaprida [INN-Spanish]; Renzapridum [INN-Latin]; 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX CP Alizyme
DM7HQNX DT Small molecular drug
DM7HQNX PC 119574
DM7HQNX MW 323.82
DM7HQNX FM C16H22ClN3O2
DM7HQNX IC InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1
DM7HQNX CS COC1=CC(=C(C=C1C(=O)N[C@@H]2CCN3CCC[C@H]2C3)Cl)N
DM7HQNX IK GZSKEXSLDPEFPT-IINYFYTJSA-N
DM7HQNX IU 4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX CA CAS 112727-80-7
DM7HQNX DE Irritable bowel syndrome
DMVBA7I ID DMVBA7I
DMVBA7I DN Reparixin
DMVBA7I HS Phase 3
DMVBA7I SN reparixin; repertaxin; 266359-83-5; UNII-U604E1NB3K; CHEMBL191413; U604E1NB3K; DF 1681Y; (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide; Reparixin [USAN:INN]; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; (2R)-2-(4-(2-Methylpropyl)phenyl)-N-methylsulfonylpropanamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; Reparixin (USAN/INN); DSSTox_RID_81678; DSSTox_CID_26509; DSSTox_GSID_46509; ZINC8717; SCHEMBL1884299; GTPL8498; DTXSID6046509; EX-A2461; DF-1681Y; BCP10635; Tox21_112272; BDBM50169045; Repertaxin; Reparixin [INN]; Reparixin (INN/USAN); (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; RAPARIXIN
DMVBA7I CP Dompe s.p.a.
DMVBA7I DT Small molecular drug
DMVBA7I PC 9838712
DMVBA7I MW 283.39
DMVBA7I FM C14H21NO3S
DMVBA7I IC InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
DMVBA7I CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C
DMVBA7I IK KQDRVXQXKZXMHP-LLVKDONJSA-N
DMVBA7I IU (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide
DMVBA7I CA CAS 266359-83-5
DMVBA7I DE Graft rejection in heart transplantation; lung transplantation; Ischemia-reperfusion injury; Pancreatic islet transplantation failure
DMDEJX9 ID DMDEJX9
DMDEJX9 DN Reproxalap
DMDEJX9 HS Phase 3
DMDEJX9 SN 2-(3-Amino-6-chloroquinolin-2-yl)propan-2-ol; 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol; Reproxalap [USAN]; UNII-F0GIZ22IJH; F0GIZ22IJH; SCHEMBL12228833; ALD-102; ADX-102; 2-Quinolinemethanol, 3-amino-6-chloro-alpha,alpha-dimethyl-; NS2
DMDEJX9 CP Aldeyra Therapeutics Lexington, MA
DMDEJX9 PC 16088030
DMDEJX9 MW 236.7
DMDEJX9 FM C12H13ClN2O
DMDEJX9 IC InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3
DMDEJX9 CS CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O
DMDEJX9 IK GUHFUVLKYSQIOQ-UHFFFAOYSA-N
DMDEJX9 IU 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol
DMDEJX9 CA CAS 916056-79-6
DMDEJX9 DE Sjogren-Larsson syndrome
DMFMWYC ID DMFMWYC
DMFMWYC DN Resatorvid
DMFMWYC HS Phase 3
DMFMWYC SN Resatorvid; TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC CP Takeda
DMFMWYC DT Small molecular drug
DMFMWYC PC 11703255
DMFMWYC MW 361.8
DMFMWYC FM C15H17ClFNO4S
DMFMWYC IC InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
DMFMWYC CS CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl
DMFMWYC IK LEEIJTHMHDMWLJ-CQSZACIVSA-N
DMFMWYC IU ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC CA CAS 243984-11-4
DMFMWYC DE Sepsis
DM3RWXL ID DM3RWXL
DM3RWXL DN Resveratrol
DM3RWXL HS Phase 3
DM3RWXL SN Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
DM3RWXL CP Sirtris Pharma
DM3RWXL DT Small molecular drug
DM3RWXL PC 445154
DM3RWXL MW 228.24
DM3RWXL FM C14H12O3
DM3RWXL IC InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
DM3RWXL CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
DM3RWXL IK LUKBXSAWLPMMSZ-OWOJBTEDSA-N
DM3RWXL IU 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
DM3RWXL CA CAS 501-36-0
DM3RWXL CB CHEBI:45713
DM3RWXL DE Colorectal cancer; Giant cell arteritis; Rheumatoid arthritis; Systemic sclerosis
DMOYGZF ID DMOYGZF
DMOYGZF DN Retosiban
DMOYGZF HS Phase 3
DMOYGZF SN 820957-38-8; UNII-GIE06H28OX; GSK221149A; GSK-221149A; GIE06H28OX; CHEMBL429736; Retosiban [USAN:INN]; Retosiban (USAN); GSK 221149A; SCHEMBL230301; GTPL8403; DTXSID00231559; PLVGDGRBPMVYPB-FDUHJNRSSA-N; ZINC6718496; BDBM50372608; GSK-221,149-A; SB16762; DB11818; HY-14778; CS-0003555; J3.542.064I; D08986; 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-
DMOYGZF CP GlaxoSmithKline
DMOYGZF DT Small molecular drug
DMOYGZF PC 11340891
DMOYGZF MW 494.6
DMOYGZF FM C27H34N4O5
DMOYGZF IC InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
DMOYGZF CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DMOYGZF IK PLVGDGRBPMVYPB-FDUHJNRSSA-N
DMOYGZF IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DMOYGZF CA CAS 820957-38-8
DMOYGZF DE Preterm labour
DM5E73H ID DM5E73H
DM5E73H DN Revusiran
DM5E73H HS Phase 3
DM5E73H DT siRNA drug
DM5E73H DE Amyloidosis
DMQ4CSX ID DMQ4CSX
DMQ4CSX DN Rezafungin
DMQ4CSX HS Phase 3
DMQ4CSX SN CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-]
DMQ4CSX CP Cidara Therapeutics
DMQ4CSX DT Small molecular drug
DMQ4CSX PC 78318119
DMQ4CSX MW 1226.4
DMQ4CSX FM C63H85N8O17+
DMQ4CSX IC InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1
DMQ4CSX CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O
DMQ4CSX IK LNFCWEXGZIEGJW-TXSVMFMRSA-O
DMQ4CSX IU 2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
DMQ4CSX DE Candidiasis
DMTQJE0 ID DMTQJE0
DMTQJE0 DN RG3638
DMTQJE0 HS Phase 3
DMTQJE0 SN Onartuzumab
DMTQJE0 CP Roche
DMTQJE0 DE Non-small-cell lung cancer; Gastric adenocarcinoma
DMER75Y ID DMER75Y
DMER75Y DN RG6013
DMER75Y HS Phase 3
DMER75Y DT Antibody
DMER75Y DE Haemophilia A
DMJRFYB ID DMJRFYB
DMJRFYB DN RG7201
DMJRFYB HS Phase 3
DMJRFYB CP Roche
DMJRFYB DE Type-2 diabetes
DMF5GZI ID DMF5GZI
DMF5GZI DN RG7388
DMF5GZI HS Phase 3
DMF5GZI SN Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856
DMF5GZI CP Roche
DMF5GZI DT Small molecular drug
DMF5GZI PC 53358942
DMF5GZI MW 616.5
DMF5GZI FM C31H29Cl2F2N3O4
DMF5GZI IC InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1
DMF5GZI CS CC(C)(C)C[C@H]1[C@]([C@H]([C@@H](N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F
DMF5GZI IK TVTXCJFHQKSQQM-LJQIRTBHSA-N
DMF5GZI IU 4-[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid
DMF5GZI CA CAS 1229705-06-9
DMF5GZI DE Haematological malignancy; Solid tumour/cancer; Polycythemia vera; Acute myeloid leukaemia
DMDVAFP ID DMDVAFP
DMDVAFP DN RG7601
DMDVAFP HS Phase 3
DMDVAFP CP Abbott; Roche
DMDVAFP DE Chronic lymphocytic leukaemia
DMGOTK4 ID DMGOTK4
DMGOTK4 DN Rhumab Beta7
DMGOTK4 HS Phase 3
DMGOTK4 CP Roche; Genentech
DMGOTK4 DT Antibody
DMGOTK4 DE Ulcerative colitis
DMLHEU7 ID DMLHEU7
DMLHEU7 DN Ridaforolimus
DMLHEU7 HS Phase 3
DMLHEU7 SN Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus
DMLHEU7 CP Merck
DMLHEU7 DT Small molecular drug
DMLHEU7 PC 11520894
DMLHEU7 MW 990.2
DMLHEU7 FM C53H84NO14P
DMLHEU7 IC InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DMLHEU7 CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC
DMLHEU7 IK BUROJSBIWGDYCN-GAUTUEMISA-N
DMLHEU7 IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-dimethylphosphoryloxy-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMLHEU7 CA CAS 572924-54-0
DMLHEU7 CB CHEBI:79700
DMLHEU7 DE Sarcoma
DMYXOHV ID DMYXOHV
DMYXOHV DN Rifalazil
DMYXOHV HS Phase 3
DMYXOHV DT Small molecular drug
DMYXOHV PC 135431094
DMYXOHV MW 941.1
DMYXOHV FM C51H64N4O13
DMYXOHV IC InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,58-60,62H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29+,34-,42-,43+,46+,51-/m0/s1
DMYXOHV CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C
DMYXOHV IK IXSVOCGZBUJEPI-HTQYORAHSA-N
DMYXOHV IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate
DMYXOHV CA CAS 129791-92-0
DMYXOHV DE Bacterial infection
DMKTS2M ID DMKTS2M
DMKTS2M DN Rifaximin DR
DMKTS2M HS Phase 3
DMKTS2M CP Salix Pharmaceuticals Raleigh, NC
DMKTS2M DE Crohn disease
DMOSTXF ID DMOSTXF
DMOSTXF DN Rigosertib
DMOSTXF HS Phase 3
DMOSTXF SN Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a
DMOSTXF CP Onconova Therapeutics
DMOSTXF DT Small molecular drug
DMOSTXF PC 6918736
DMOSTXF MW 451.5
DMOSTXF FM C21H25NO8S
DMOSTXF IC InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
DMOSTXF CS COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
DMOSTXF IK OWBFCJROIKNMGD-BQYQJAHWSA-N
DMOSTXF IU 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid
DMOSTXF CA CAS 592542-59-1
DMOSTXF CB CHEBI:124939
DMOSTXF DE Solid tumour/cancer; Myelodysplastic syndrome
DMGTCI0 ID DMGTCI0
DMGTCI0 DN Rilimogene galvacirepvec
DMGTCI0 HS Phase 3
DMGTCI0 SN Prostvac (TN)
DMGTCI0 CP BM ImmunoTherapeutics
DMGTCI0 DE Prostate cancer
DMP6IMQ ID DMP6IMQ
DMP6IMQ DN Rindopepimut
DMP6IMQ HS Phase 3
DMP6IMQ CP Celldex Therapeutics
DMP6IMQ DE Glioblastoma multiforme; Brain cancer
DMYX7VI ID DMYX7VI
DMYX7VI DN Rintatolimod
DMYX7VI HS Phase 3
DMYX7VI CP Hemispherx Biopharma
DMYX7VI DT siRNA drug
DMYX7VI DE Human immunodeficiency virus infection
DM13V0P ID DM13V0P
DM13V0P DN Rivoceranib
DM13V0P HS Phase 3
DM13V0P CP Elevar Therapeutics
DM13V0P DT Small molecular drug
DM13V0P DE Gastric adenocarcinoma; Solid tumour/cancer; Sarcoma
DMBY31K ID DMBY31K
DMBY31K DN Rivoglitazone
DMBY31K HS Phase 3
DMBY31K SN CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
DMBY31K CP Sankyo Co Ltd
DMBY31K DT Small molecular drug
DMBY31K PC 3055168
DMBY31K MW 397.4
DMBY31K FM C20H19N3O4S
DMBY31K IC InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
DMBY31K CS CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMBY31K IK XMSXOLDPMGMWTH-UHFFFAOYSA-N
DMBY31K IU 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMBY31K CA CAS 185428-18-6
DMBY31K DE Ocular inflammation
DMVQ5X1 ID DMVQ5X1
DMVQ5X1 DN Roclatan
DMVQ5X1 HS Phase 3
DMVQ5X1 SN PG324
DMVQ5X1 CP Aerie pharmaceuticals
DMVQ5X1 PC 118984471
DMVQ5X1 MW 886.1
DMVQ5X1 FM C54H67N3O8
DMVQ5X1 IC InChI=1S/C28H27N3O3.C26H40O5/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b;8-3-/t26-;21-,22+,23+,24-,25+/m10/s1
DMVQ5X1 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C.CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMVQ5X1 IK QILUCPOIAVKEBG-GCBPXYGZSA-N
DMVQ5X1 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMVQ5X1 DE Glaucoma/ocular hypertension
DMSZPR3 ID DMSZPR3
DMSZPR3 DN Rolofylline
DMSZPR3 HS Phase 3
DMSZPR3 SN KW 3902; HMR-4902; KW-3902; MK-7418; Rolofylline (USAN); 1,3-Dipropyl-8-(3-noradamantyl)xanthine; 1,3-Dnax; 8-(3-Noradamantyl)-1,3-dipropylxanthine; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione
DMSZPR3 CP Merck
DMSZPR3 DT Small molecular drug
DMSZPR3 PC 64627
DMSZPR3 MW 356.5
DMSZPR3 FM C20H28N4O2
DMSZPR3 IC InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)
DMSZPR3 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)CC4C5
DMSZPR3 IK PJBFVWGQFLYWCB-UHFFFAOYSA-N
DMSZPR3 IU 1,3-dipropyl-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione
DMSZPR3 CA CAS 136199-02-5
DMSZPR3 DE Heart failure
DMPIDXT ID DMPIDXT
DMPIDXT DN Rosiglitazone + metformin
DMPIDXT HS Phase 3
DMPIDXT SN Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]
DMPIDXT CP GSK
DMPIDXT DT Combination drug (small molecular drug)
DMPIDXT PC 5329099
DMPIDXT MW 310.3
DMPIDXT FM C18H18N2O3
DMPIDXT IC InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
DMPIDXT CS CC1=C(NC(=C1CCC(=O)O)C)/C=C\\2/C3=CC=CC=C3NC2=O
DMPIDXT IK NHFDRBXTEDBWCZ-ZROIWOOFSA-N
DMPIDXT IU 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
DMPIDXT CA CAS 210644-62-5
DMPIDXT DE Advanced solid tumour; Diabetic complication
DM18B72 ID DM18B72
DM18B72 DN Rosiglitazone + simvastatin
DM18B72 HS Phase 3
DM18B72 CP GSK
DM18B72 DT Combination drug (small molecular drug)
DM18B72 PC 23644561
DM18B72 MW 241.24
DM18B72 FM C13H11N3O2
DM18B72 IC InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-8H,1H3,(H,16,17)/b11-4-
DM18B72 CS COC1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3C=NC=N3
DM18B72 IK KKGJVFQBVRACGR-WCIBSUBMSA-N
DM18B72 IU (3Z)-3-(4H-imidazol-4-ylmethylidene)-5-methoxy-1H-indol-2-one
DM18B72 DE Type-2 diabetes
DMNGCAD ID DMNGCAD
DMNGCAD DN Rova-T
DMNGCAD HS Phase 3
DMNGCAD SN rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9
DMNGCAD CP StemcentRx South San Francisco, CA
DMNGCAD PC 131954443
DMNGCAD MW 1617.8
DMNGCAD FM C78H108N10O25S
DMNGCAD IC InChI=1S/C78H108N10O25S/c1-49(2)70(84-68(90)16-21-103-23-25-105-27-29-107-31-33-109-35-36-110-34-32-108-30-28-106-26-24-104-22-17-80-67(89)15-18-85-69(91)43-66(76(85)97)114-48-58(79)77(98)99)72(93)82-52(5)71(92)83-54-13-11-53(12-14-54)47-113-78(100)88-60-42-65(63(102-7)40-57(60)74(95)87-46-51(4)38-61(87)75(88)96)112-20-10-8-9-19-111-64-41-59-56(39-62(64)101-6)73(94)86-45-50(3)37-55(86)44-81-59/h11-14,39-42,44-46,49,52,55,58,61,66,70,75,96H,8-10,15-38,43,47-48,79H2,1-7H3,(H,80,89)(H,82,93)(H,83,92)(H,84,90)(H,98,99)/t52-,55-,58-,61-,66+,70-,75-/m0/s1
DMNGCAD CS CC1=CN2[C@@H](C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N([C@H]([C@@H]6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)C[C@H](C8=O)SC[C@@H](C(=O)O)N)OC
DMNGCAD IK NQUUPTGRJYIXSL-YPDXTJLXSA-N
DMNGCAD IU (2R)-3-[(3R)-1-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[4-[[(6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DMNGCAD CA CAS 1613313-09-9
DMNGCAD DE Small-cell lung cancer; Neuroendocrine cancer
DM9T8OF ID DM9T8OF
DM9T8OF DN RQ-00000004
DM9T8OF HS Phase 3
DM9T8OF SN PF-03716556; RQ-00000774; RQ-4; Acid pump inhibitor (GERD), Pfizer; Acid pump inhibitor (GERD), RaQualia;Acid pump inhibitor (gastroesophageal reflux), Pfizer; Acid pump inhibitor (gastroesophageal reflux), RaQualia
DM9T8OF CP Pfizer Inc
DM9T8OF DE Gastroesophageal reflux disease
DMQM2FH ID DMQM2FH
DMQM2FH DN RRx-001
DMQM2FH HS Phase 3
DMQM2FH SN RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015
DMQM2FH CP RadioRx
DMQM2FH DT Small molecular drug
DMQM2FH PC 15950826
DMQM2FH MW 268.02
DMQM2FH FM C5H6BrN3O5
DMQM2FH IC InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2
DMQM2FH CS C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-]
DMQM2FH IK JODKFOVZURLVTG-UHFFFAOYSA-N
DMQM2FH IU 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
DMQM2FH CA CAS 925206-65-1
DMQM2FH DE Lymphoma; Anaplastic glioma; Neuroendocrine cancer; Ovarian epithelial cancer; Solid tumour/cancer; Non-small-cell lung cancer; Small-cell lung cancer
DM62QTW ID DM62QTW
DM62QTW DN RTB101
DM62QTW HS Phase 3
DM62QTW CP ResTORbio
DM62QTW DT Small molecular drug
DM62QTW DE Coronavirus Disease 2019 (COVID-19); Respiratory tract infection
DMDWU1S ID DMDWU1S
DMDWU1S DN Rubitecan
DMDWU1S HS Phase 3
DMDWU1S SN 9-Nitrocamptothecin; 91421-42-0; Orathecin; 9-nitro-20(S)-camptothecin; Camptogen; 9-NC; RFS 2000; RFS-2000; UNII-H19C446XXB; Nitrocamptothecin; H19C446XXB; CHEBI:90225; C20H15N3O6; (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NCGC00167969-01; (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; 9NC; Q-100889; (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin; 9-Nitrocamptothecin (9-NC)
DMDWU1S CP SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center
DMDWU1S DT Small molecular drug
DMDWU1S PC 472335
DMDWU1S MW 393.3
DMDWU1S FM C20H15N3O6
DMDWU1S IC InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
DMDWU1S CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O
DMDWU1S IK VHXNKPBCCMUMSW-FQEVSTJZSA-N
DMDWU1S IU (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMDWU1S CA CAS 91421-42-0
DMDWU1S CB CHEBI:90225
DMDWU1S DE Human immunodeficiency virus infection
DMQOCD8 ID DMQOCD8
DMQOCD8 DN RUBOXISTAURIN HYDROCHLORIDE
DMQOCD8 HS Phase 3
DMQOCD8 SN LY-333531.HCl; Ruboxistaurin hydrochloride; 9(S)-(Dimethylaminomethyl)-5,6,7,9,10,11,12,17,18,19,20,21-dodecahydro-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione hydrochloride
DMQOCD8 PC 9870785
DMQOCD8 MW 505
DMQOCD8 FM C28H29ClN4O3
DMQOCD8 IC InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
DMQOCD8 CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl
DMQOCD8 IK NYQIEYDJYFVLPO-FERBBOLQSA-N
DMQOCD8 IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione;hydrochloride
DMQOCD8 CA CAS 169939-93-9
DMQOCD8 DE Lymphoma
DM25TMP ID DM25TMP
DM25TMP DN Rubraca rucaparib
DM25TMP HS Phase 3
DM25TMP CP Clovis Oncology Boulder, CO
DM25TMP DE Prostate cancer; Ovarian cancer
DM20KYR ID DM20KYR
DM20KYR DN Ruxolitinib
DM20KYR HS Phase 3
DM20KYR SN Ruxolitinib (JAK inhibitor)
DM20KYR CP Incyte
DM20KYR TC Antiviral Agents
DM20KYR DT Small molecular drug
DM20KYR PC 25126798
DM20KYR MW 306.4
DM20KYR FM C17H18N6
DM20KYR IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM20KYR CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM20KYR IK HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM20KYR IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM20KYR CA CAS 941678-49-5
DM20KYR CB CHEBI:66919
DM20KYR DE Essential thrombocythemia; High-risk myelofibrosis; Nasopharyngeal carcinoma; Pancreatic cancer; Coronavirus Disease 2019 (COVID-19)
DMAYTIH ID DMAYTIH
DMAYTIH DN S-06911
DMAYTIH HS Phase 3
DMAYTIH SN Strontium ranelate + vitamin D3 (osteoporosis), Servier; Strontium ranelate + vitamin D3 (fixed-dose combination, osteoporosis), Servier
DMAYTIH CP Servier
DMAYTIH DE Osteoporosis
DMXY34J ID DMXY34J
DMXY34J DN S-110
DMXY34J HS Phase 3
DMXY34J SN DNA demethylating agent (myelodysplastic syndrome), Supergen
DMXY34J CP SuperGen Inc
DMXY34J DE Acute myeloid leukaemia; Chronic myelogenous leukaemia; Solid tumour/cancer
DM408GM ID DM408GM
DM408GM DN S-474474
DM408GM HS Phase 3
DM408GM CP Shionogi
DM408GM DE Metabolic syndrome x
DM7F2VG ID DM7F2VG
DM7F2VG DN SA-237
DM7F2VG HS Phase 3
DM7F2VG SN Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
DM7F2VG CP Chugai Pharmaceutical Co Ltd
DM7F2VG DE Rheumatoid arthritis; Encephalopathy; Neuromyelitis optica
DMGR98T ID DMGR98T
DMGR98T DN SAGE-217
DMGR98T HS Phase 3
DMGR98T SN HARRKNSQXBRBGZ-GVKWWOCJSA-N; SCHEMBL16189866; HY-103040; CS-0023489; 1632051-40-1
DMGR98T CP Sage Therapeutics Cambridge, MA
DMGR98T PC 86294073
DMGR98T MW 409.6
DMGR98T FM C25H35N3O2
DMGR98T IC InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
DMGR98T CS C[C@]1(CC[C@H]2[C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CN5C=C(C=N5)C#N)C)O
DMGR98T IK HARRKNSQXBRBGZ-GVKWWOCJSA-N
DMGR98T IU 1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile
DMGR98T CA CAS 1632051-40-1
DMGR98T DE Essential tremor or related tremors; Major depressive disorder; Parkinson disease; Postpartum depression
DMI1R5S ID DMI1R5S
DMI1R5S DN SAIT101
DMI1R5S HS Phase 3
DMI1R5S CP Archigen Biotech
DMI1R5S DT Antibody
DMI1R5S DE Follicular lymphoma
DMKHLRT ID DMKHLRT
DMKHLRT DN SAND-26
DMKHLRT HS Phase 3
DMKHLRT SN Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
DMKHLRT CP ADIENNE Pharma & Biotech
DMKHLRT DT Antibody
DMKHLRT DE Autoimmune diabetes
DMXAO4J ID DMXAO4J
DMXAO4J DN SAR153191
DMXAO4J HS Phase 3
DMXAO4J CP Sanofi-Aventis
DMXAO4J DE Ankylosing spondylitis
DMHFBOG ID DMHFBOG
DMHFBOG DN SAR231893
DMHFBOG HS Phase 3
DMHFBOG CP Sanofi
DMHFBOG DE Atopic dermatitis; Asthma
DMR0EWV ID DMR0EWV
DMR0EWV DN SAR342434
DMR0EWV HS Phase 3
DMR0EWV DE Diabetic complication; Type-1 diabetes; Type-2 diabetes
DMXGE3O ID DMXGE3O
DMXGE3O DN SAR408701
DMXGE3O HS Phase 3
DMXGE3O CP Sanofi
DMXGE3O DT Antibody drug conjugate
DMXGE3O DE Solid tumour/cancer; Non-small-cell lung cancer
DMDMAE4 ID DMDMAE4
DMDMAE4 DN SAR438584
DMDMAE4 HS Phase 3
DMDMAE4 SN REGN2222
DMDMAE4 DT Antibody
DMDMAE4 DE Respiratory syncytial virus infection
DM8HCFD ID DM8HCFD
DM8HCFD DN Sarilumab
DM8HCFD HS Phase 3
DM8HCFD SN Kevzara
DM8HCFD CP Sanofi/Regeneron
DM8HCFD TC Antiviral Agents
DM8HCFD DT Monoclonal antibody
DM8HCFD SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HCFD DE Rheumatoid arthritis; Severely active rheumatoid arthritis; Coronavirus Disease 2019 (COVID-19)
DMUVSG4 ID DMUVSG4
DMUVSG4 DN Sasanlimab
DMUVSG4 HS Phase 3
DMUVSG4 SN PF-06801591
DMUVSG4 CP Pfizer
DMUVSG4 DT Antibody
DMUVSG4 DE Non-muscle invasive bladder cancer
DME5PN3 ID DME5PN3
DME5PN3 DN Satavaptan
DME5PN3 HS Phase 3
DME5PN3 CP Sanofi-Aventis
DME5PN3 DT Small molecular drug
DME5PN3 PC 158348
DME5PN3 MW 643.8
DME5PN3 FM C33H45N3O8S
DME5PN3 IC InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)
DME5PN3 CS CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)OCCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC
DME5PN3 IK QKXJWFOKVQWEDZ-UHFFFAOYSA-N
DME5PN3 IU N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
DME5PN3 CA CAS 185913-78-4
DME5PN3 DE Acute and chronic heart failure
DMALFKX ID DMALFKX
DMALFKX DN Savolitinib
DMALFKX HS Phase 3
DMALFKX SN 1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
DMALFKX CP AstraZeneca Wilmington, DE
DMALFKX PC 68289010
DMALFKX MW 345.4
DMALFKX FM C17H15N9
DMALFKX IC InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
DMALFKX CS C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
DMALFKX IK XYDNMOZJKOGZLS-NSHDSACASA-N
DMALFKX IU 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
DMALFKX CA CAS 1313725-88-0
DMALFKX DE Solid tumour/cancer; Renal cell carcinoma
DMAPRWV ID DMAPRWV
DMAPRWV DN SaxaDapa FDC
DMAPRWV HS Phase 3
DMAPRWV CP AstraZeneca
DMAPRWV DE Diabetic complication
DMME6GJ ID DMME6GJ
DMME6GJ DN SB12
DMME6GJ HS Phase 3
DMME6GJ CP Samsung Bioepis
DMME6GJ DT Antibody
DMME6GJ DE Paroxysmal nocturnal haemoglobinuria
DM6L4ZT ID DM6L4ZT
DM6L4ZT DN SB-742457
DM6L4ZT HS Phase 3
DM6L4ZT SN GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline
DM6L4ZT CP GlaxoSmithKline
DM6L4ZT DT Small molecular drug
DM6L4ZT PC 11256720
DM6L4ZT MW 353.4
DM6L4ZT FM C19H19N3O2S
DM6L4ZT IC InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
DM6L4ZT CS C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4
DM6L4ZT IK JJZFWROHYSMCMU-UHFFFAOYSA-N
DM6L4ZT IU 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline
DM6L4ZT CA CAS 607742-69-8
DM6L4ZT DE Alzheimer disease
DM6XNJR ID DM6XNJR
DM6XNJR DN SC-46553
DM6XNJR HS Phase 3
DM6XNJR SN Ginsenoside 20-Glc-Rf; PubChem13034; SC-46553; ZINC238808898; ginsenoside-Rd; 705G938; CHEMBL525935; S597; Ginsenoside Rd
DM6XNJR PC 24721561
DM6XNJR MW 963.2
DM6XNJR FM C48H82O19
DM6XNJR IC FBFMBWCLBGQEBU-RXMALORBSA-N
DM6XNJR CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C
DM6XNJR IK 1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)64-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(53)44(3,4)40(45)24(17-47(28,46)7)62-43-39(36(59)33(56)27(20-51)65-43)66-41-37(60)34(57)31(54)25(18-49)63-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
DM6XNJR IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM6XNJR DE Cerebral stroke
DMK1IPV ID DMK1IPV
DMK1IPV DN SCY-078
DMK1IPV HS Phase 3
DMK1IPV SN Ibrexafungerp
DMK1IPV CP Scynexis
DMK1IPV DT Small molecular drug
DMK1IPV PC 46871657
DMK1IPV MW 730
DMK1IPV FM C44H67N5O4
DMK1IPV IC InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1
DMK1IPV CS C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
DMK1IPV IK BODYFEUFKHPRCK-ZCZMVWJSSA-N
DMK1IPV IU (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid
DMK1IPV CA CAS 1207753-03-4
DMK1IPV DE Fungal infection; Invasive candidiasis
DMAMTGI ID DMAMTGI
DMAMTGI DN SD-101
DMAMTGI HS Phase 3
DMAMTGI SN HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
DMAMTGI CP Scioderm
DMAMTGI DT Oligonucleotide
DMAMTGI DE Hepatitis C virus infection; Melanoma; Skin disease; Squamous cell carcinoma; Squamous head and neck cell carcinom
DM9DEYL ID DM9DEYL
DM9DEYL DN SD-6010
DM9DEYL HS Phase 3
DM9DEYL CP Pfizer New York, NY
DM9DEYL DE Osteoarthritis
DMBD4K3 ID DMBD4K3
DMBD4K3 DN Selinexor
DMBD4K3 HS Phase 3
DMBD4K3 SN Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
DMBD4K3 CP Karyopharm therapeutics
DMBD4K3 DT Small molecular drug
DMBD4K3 PC 71481097
DMBD4K3 MW 443.3
DMBD4K3 FM C17H11F6N7O
DMBD4K3 IC InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
DMBD4K3 CS C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMBD4K3 IK DEVSOMFAQLZNKR-RJRFIUFISA-N
DMBD4K3 IU (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
DMBD4K3 CA CAS 1393477-72-9
DMBD4K3 DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Acute myeloid leukaemia; Multiple myeloma; Liposarcoma; Neuroendocrine cancer; Recurrent glioblastoma
DMC7W6R ID DMC7W6R
DMC7W6R DN Selumetinib
DMC7W6R HS Phase 3
DMC7W6R SN Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
DMC7W6R CP AstraZeneca
DMC7W6R DT Small molecular drug
DMC7W6R PC 10127622
DMC7W6R MW 457.7
DMC7W6R FM C17H15BrClFN4O3
DMC7W6R IC InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DMC7W6R CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
DMC7W6R IK CYOHGALHFOKKQC-UHFFFAOYSA-N
DMC7W6R IU 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DMC7W6R CA CAS 606143-52-6
DMC7W6R CB CHEBI:90227
DMC7W6R DE Non-small-cell lung cancer; Melanoma; Thyroid cancer; Solid tumour/cancer
DML83IW ID DML83IW
DML83IW DN Semagacestat
DML83IW HS Phase 3
DML83IW SN DAPT; AN-37124; AN-44989; LY-374973; LY-411575; LY-424354; LY-450139; LY-4501395; Gamma-secretase inhibitors (Alzheimer's disease), Elan Pharmaceuticals/Eli Lilly
DML83IW CP Eli Lilly & Co
DML83IW DT Small molecular drug
DML83IW PC 9843750
DML83IW MW 361.4
DML83IW FM C19H27N3O4
DML83IW IC InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
DML83IW CS C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
DML83IW IK PKXWXXPNHIWQHW-RCBQFDQVSA-N
DML83IW IU (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide
DML83IW CA CAS 425386-60-3
DML83IW CB CHEBI:131158
DML83IW DE Parkinson disease
DMKL9QO ID DMKL9QO
DMKL9QO DN Seocalcitol
DMKL9QO HS Phase 3
DMKL9QO SN Seocalcitol; 134404-52-7; UNII-Q0OZ0D9223; EB-1089; Q0OZ0D9223; EB1089; EB 1089; Seocalcitol [INN:BAN]; CB-1089; (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO DT Small molecular drug
DMKL9QO PC 5288149
DMKL9QO MW 454.7
DMKL9QO FM C30H46O3
DMKL9QO IC InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
DMKL9QO CS CCC(CC)(/C=C/C=C/[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O
DMKL9QO IK LVLLALCJVJNGQQ-SEODYNFXSA-N
DMKL9QO IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO CA CAS 134404-52-7
DMKL9QO DE Rickets
DMG2QP4 ID DMG2QP4
DMG2QP4 DN SEP-363856
DMG2QP4 HS Phase 3
DMG2QP4 CP Sunovion
DMG2QP4 PC 89532783
DMG2QP4 MW 183.27
DMG2QP4 FM C9H13NOS
DMG2QP4 IC InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1
DMG2QP4 CS CNC[C@H]1C2=C(CCO1)C=CS2
DMG2QP4 IK ABDDQTDRAHXHOC-QMMMGPOBSA-N
DMG2QP4 IU 1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine
DMG2QP4 CA CAS 1310426-33-5
DMG2QP4 DE Major depressive disorder; Parkinson disease; Schizophrenia
DM5VH6U ID DM5VH6U
DM5VH6U DN Serlopitant
DM5VH6U HS Phase 3
DM5VH6U SN VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U CP Menlo Therapeutics Redwood City, CA
DM5VH6U PC 23653789
DM5VH6U MW 555.5
DM5VH6U FM C29H28F7NO2
DM5VH6U IC InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
DM5VH6U CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
DM5VH6U IK FLNYCRJBCNNHRH-OIYLJQICSA-N
DM5VH6U IU 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U CA CAS 860642-69-9
DM5VH6U DE Prurigo nodularis; Psoriasis vulgaris
DMZ61IA ID DMZ61IA
DMZ61IA DN Setipiprant
DMZ61IA HS Phase 3
DMZ61IA SN ACT-129968
DMZ61IA CP Actelion Pharmaceuticals
DMZ61IA DT Small molecular drug
DMZ61IA PC 49843471
DMZ61IA MW 402.4
DMZ61IA FM C24H19FN2O3
DMZ61IA IC InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)
DMZ61IA CS C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54
DMZ61IA IK IHAXLPDVOWLUOS-UHFFFAOYSA-N
DMZ61IA IU 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
DMZ61IA CA CAS 866460-33-5
DMZ61IA DE Asthma
DM1NQDW ID DM1NQDW
DM1NQDW DN SGI110
DM1NQDW HS Phase 3
DM1NQDW CP Astex Pharmaceuticals
DM1NQDW PC 137295284
DM1NQDW MW 581.4
DM1NQDW FM C18H25N9NaO10P
DM1NQDW IC InChI=1S/C18H24N9O10P.Na.H/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30;;/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30);;/q;+1;-1/t7?,8-,9+,10+,11?,12+;;/m0../s1
DM1NQDW CS [H-].C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)OP(=O)(O)OC[C@@H]3C(CC(O3)N4C=NC5=C4N=C(NC5=O)N)O.[Na+]
DM1NQDW IK AYXRQJHOBFJIHP-ZWBDGAAVSA-N
DM1NQDW IU sodium;[(2R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate;hydride
DM1NQDW DE Acute myeloid leukaemia
DM4N1SP ID DM4N1SP
DM4N1SP DN Shigamabs
DM4N1SP HS Phase 3
DM4N1SP SN C-Stx1; C-Stx2; Ca-Stx1; Ca-Stx2; Anti-Shiga toxin monoclonal antibodies, Thallion; Anti-Shiga toxin monoclonals, Sunol;Monoclonal antibodies (HUS), Sunol; Monoclonal antibodies (HUS), Thallion
DM4N1SP CP Bellus Health
DM4N1SP DT Monoclonal antibody
DM4N1SP DE Haemolytic uraemic syndrome; Bacterial infection
DMEWRXA ID DMEWRXA
DMEWRXA DN SHP647
DMEWRXA HS Phase 3
DMEWRXA CP inhibitor, Lexington, MA
DMEWRXA DE Crohn disease; Ulcerative colitis
DMMIWCE ID DMMIWCE
DMMIWCE DN Sifuvirtide
DMMIWCE HS Phase 3
DMMIWCE SN FS-0101; HIV fusion inhibitor (oral), FusoGen; HIV gp41 protein inhibitor (oral), FusoGen; Sifuvirtide (oral, HIV); Sifuvirtide (oral, HIV), FusoGen
DMMIWCE CP FusoGen Pharmaceuticals Inc
DMMIWCE PC 49769437
DMMIWCE MW 4686
DMMIWCE FM C201H307N59O71
DMMIWCE IC InChI=1S/C201H307N59O71/c1-15-93(10)156(257-177(311)124(54-67-151(285)286)235-162(296)109(31-22-70-219-197(209)210)226-168(302)119(49-62-146(275)276)237-184(318)133(81-101-87-225-108-30-21-19-28-105(101)108)254-195(329)160(97(14)264)259-178(312)125(55-68-152(287)288)239-183(317)132(244-161(295)106(202)88-261)80-100-86-224-107-29-20-18-27-104(100)107)191(325)242-123(53-66-150(283)284)173(307)249-135(83-144(208)272)186(320)247-131(79-99-38-42-103(266)43-39-99)189(323)260-159(96(13)263)194(328)241-112(34-25-73-222-200(215)216)163(297)232-117(47-60-142(206)270)176(310)258-158(95(12)17-3)193(327)253-130(78-98-36-40-102(265)41-37-98)182(316)229-113(35-26-74-223-201(217)218)175(309)256-157(94(11)16-2)192(326)252-129(77-92(8)9)179(313)236-121(51-64-148(279)280)171(305)234-122(52-65-149(281)282)174(308)255-138(89-262)190(324)240-115(45-58-140(204)268)167(301)233-118(48-61-145(273)274)170(304)230-114(44-57-139(203)267)166(300)231-116(46-59-141(205)269)172(306)251-136(84-154(291)292)187(321)228-111(33-24-72-221-199(213)214)164(298)248-134(82-143(207)271)185(319)238-120(50-63-147(277)278)169(303)227-110(32-23-71-220-198(211)212)165(299)250-137(85-155(293)294)188(322)246-128(76-91(6)7)181(315)245-127(75-90(4)5)180(314)243-126(196(330)331)56-69-153(289)290/h18-21,27-30,36-43,86-87,90-97,106,109-138,156-160,224-225,261-266H,15-17,22-26,31-35,44-85,88-89,202H2,1-14H3,(H2,203,267)(H2,204,268)(H2,205,269)(H2,206,270)(H2,207,271)(H2,208,272)(H,226,302)(H,227,303)(H,228,321)(H,229,316)(H,230,304)(H,231,300)(H,232,297)(H,233,301)(H,234,305)(H,235,296)(H,236,313)(H,237,318)(H,238,319)(H,239,317)(H,240,324)(H,241,328)(H,242,325)(H,243,314)(H,244,295)(H,245,315)(H,246,322)(H,247,320)(H,248,298)(H,249,307)(H,250,299)(H,251,306)(H,252,326)(H,253,327)(H,254,329)(H,255,308)(H,256,309)(H,257,311)(H,258,310)(H,259,312)(H,260,323)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,330,331)(H4,209,210,219)(H4,211,212,220)(H4,213,214,221)(H4,215,216,222)(H4,217,218,223)/t93-,94-,95-,96+,97+,106-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,156-,157-,158-,159-,160-/m0/s1
DMMIWCE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)N
DMMIWCE IK WIOOVJJJJQAZGJ-ISHQQBGZSA-N
DMMIWCE IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]pentanedioic acid
DMMIWCE DE Human immunodeficiency virus infection
DM4YDAJ ID DM4YDAJ
DM4YDAJ DN Sildenafil
DM4YDAJ HS Phase 3
DM4YDAJ SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N; Sildenafil
DM4YDAJ TC Antiviral Agents
DM4YDAJ DT Small molecular drug
DM4YDAJ PC 135398744
DM4YDAJ MW 474.6
DM4YDAJ FM C22H30N6O4S
DM4YDAJ IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM4YDAJ CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM4YDAJ IK BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM4YDAJ IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM4YDAJ CA CAS 139755-83-2
DM4YDAJ CB CHEBI:9139
DM4YDAJ DE Coronavirus Disease 2019 (COVID-19)
DMVO7UW ID DMVO7UW
DMVO7UW DN Siltuximab
DMVO7UW HS Phase 3
DMVO7UW SN Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1
DMVO7UW TC Antiviral Agents
DMVO7UW DT Monoclonal antibody
DMVO7UW DE Coronavirus Disease 2019 (COVID-19)
DM18QHT ID DM18QHT
DM18QHT DN Simvastatin acid
DM18QHT HS Phase 3
DM18QHT SN Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid
DM18QHT PC 64718
DM18QHT MW 436.6
DM18QHT FM C25H40O6
DM18QHT IC InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM18QHT CS CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DM18QHT IK XWLXKKNPFMNSFA-HGQWONQESA-N
DM18QHT IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM18QHT CA CAS 121009-77-6
DM18QHT DE Chronic obstructive pulmonary disease
DMK8AQP ID DMK8AQP
DMK8AQP DN Sirukumab
DMK8AQP HS Phase 3
DMK8AQP CP GlaxoSmithKline
DMK8AQP DT Monoclonal antibody
DMK8AQP DE Rheumatoid arthritis; Cutaneous lupus erythematosus; Giant cell arteritis; Major depressive disorder
DM6BZCV ID DM6BZCV
DM6BZCV DN Sivelestat
DM6BZCV HS Phase 3
DM6BZCV SN 127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine
DM6BZCV DT Small molecular drug
DM6BZCV PC 107706
DM6BZCV MW 434.5
DM6BZCV FM C20H22N2O7S
DM6BZCV IC InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)
DM6BZCV CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
DM6BZCV IK BTGNGJJLZOIYID-UHFFFAOYSA-N
DM6BZCV IU 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid
DM6BZCV CA CAS 127373-66-4
DM6BZCV CB CHEBI:135704
DM6BZCV DE Anterior uveitis; Pyoderma gangrenosum; Axial spondyloarthritis; Crohn disease; Multiple sclerosis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
DMWOF1E ID DMWOF1E
DMWOF1E DN SKY59
DMWOF1E HS Phase 3
DMWOF1E SN Crovalimab; RO7112689
DMWOF1E CP Roche
DMWOF1E DT Antibody
DMWOF1E DE Haemolytic uraemic syndrome
DMH7W9X ID DMH7W9X
DMH7W9X DN SNDX-275
DMH7W9X HS Phase 3
DMH7W9X SN Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
DMH7W9X CP Bayer Schering
DMH7W9X DT Small molecular drug
DMH7W9X PC 4261
DMH7W9X MW 376.4
DMH7W9X FM C21H20N4O3
DMH7W9X IC InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
DMH7W9X CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
DMH7W9X IK INVTYAOGFAGBOE-UHFFFAOYSA-N
DMH7W9X IU pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
DMH7W9X CA CAS 209783-80-2
DMH7W9X CB CHEBI:132082
DMH7W9X DE Colorectal cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer; Breast cancer
DMOQKAD ID DMOQKAD
DMOQKAD DN SNF472
DMOQKAD HS Phase 3
DMOQKAD SN Hexasodium phytate; UNII-ZBX50UG81V; 34367-89-0(Hexasodium phytate); ZBX50UG81V; 34367-89-0; sodium cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen phosphate); Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo-; Myo-inositol, hexakis(dihydrogen phosphate), hexasodium salt; Q27295268; scyllo-inositol,1,2,3,4,5,6-hexakis(dihydrogenphosphate),hexasodiumsalt; (1R,2R,3S,4S,5S,6S)-cyclohexane-(1,2,3,4,5,6)-hexaylhexakis(hydrogenphosphate),hexasodiumsalt
DMOQKAD CP Sanifit
DMOQKAD DT Small molecular drug
DMOQKAD PC 91667962
DMOQKAD MW 791.93
DMOQKAD FM C6H12Na6O24P6
DMOQKAD IC InChI=1S/C6H18O24P6.6Na/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;;;;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;;;;;/q;6*+1/p-6
DMOQKAD CS C1(C(C(C(C(C1OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMOQKAD IK DHZIAGCFFSRULK-UHFFFAOYSA-H
DMOQKAD IU hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate
DMOQKAD CA CAS 34367-89-0
DMOQKAD DE Calciphylaxis; Calcific uremic arteriolopathy
DMZE2JO ID DMZE2JO
DMZE2JO DN SNS-595
DMZE2JO HS Phase 3
DMZE2JO SN Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO CP Sunesis Pharmaceuticals Inc
DMZE2JO DT Small molecular drug
DMZE2JO PC 9952884
DMZE2JO MW 401.4
DMZE2JO FM C18H19N5O4S
DMZE2JO IC InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
DMZE2JO CS CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O
DMZE2JO IK XZAFZXJXZHRNAQ-STQMWFEESA-N
DMZE2JO IU 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO CA CAS 175414-77-4
DMZE2JO DE Ovarian cancer; Acute myeloid leukaemia
DMPBA0D ID DMPBA0D
DMPBA0D DN Sofpironium bromide
DMPBA0D HS Phase 3
DMPBA0D SN BBI-4000; 1628106-94-4; Sofpironium bromide [USAN]; CHEMBL3707223; Sofpironium bromide (JAN/USAN/INN); D10989; Pyrrolidinium, 3-(((2R)-2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy)-1-(2-ethoxy-2-oxoethyl)-1-methyl-, bromide (1:1), (3R)-
DMPBA0D CP Brickell Biotech Boulder, CO
DMPBA0D PC 86301316
DMPBA0D MW 470.4
DMPBA0D FM C22H32BrNO5
DMPBA0D IC InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
DMPBA0D CS CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMPBA0D IK FIAFMTCUJCWADZ-JOFREBOKSA-M
DMPBA0D IU [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMPBA0D CA CAS 1628106-94-4
DMPBA0D DE Primary axillary hyperhidrosis
DM0HIU5 ID DM0HIU5
DM0HIU5 DN Solanezumab
DM0HIU5 HS Phase 3
DM0HIU5 CP Eli Lilly
DM0HIU5 DT Monoclonal antibody
DM0HIU5 DE Alzheimer disease
DM6QZIA ID DM6QZIA
DM6QZIA DN Solithromycin
DM6QZIA HS Phase 3
DM6QZIA SN Solithromycin; CEM-101; OP-1068; OPT-1068; Solithromycin (iv, bacterial pneumonia), Cempra; Solithromycin (malaria), Cempra/Medicines for Malaria Venture; Solithromycin (oral, bacterial pneumonia), Cempra; CEM-101 (iv, bacterial pneumonia), Cempra; CEM-101 (malaria), Cempra/Medicines for Malaria Venture; CEM-101 (oral, bacterial pneumonia), Cempra
DM6QZIA CP Cempra pharmaceuticals
DM6QZIA DT Small molecular drug
DM6QZIA PC 25242512
DM6QZIA MW 845
DM6QZIA FM C43H65FN6O10
DM6QZIA IC InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
DM6QZIA CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C
DM6QZIA IK IXXFZUPTQVDPPK-ZAWHAJPISA-N
DM6QZIA IU (1S,2R,5S,7R,8R,9R,11R,13R,14R)-15-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DM6QZIA CA 760981-83-7
DM6QZIA DE Bacillus anthracis infection
DMLAYTP ID DMLAYTP
DMLAYTP DN Soluble ferric pyrophosphate
DMLAYTP HS Phase 3
DMLAYTP SN Ferric pyrophosphate; Soluble ferric pyrophosphate (anemia)
DMLAYTP CP Rockwell Medical Inc
DMLAYTP DT Small molecular drug
DMLAYTP PC 24877
DMLAYTP MW 745.21
DMLAYTP FM Fe4O21P6
DMLAYTP IC InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12
DMLAYTP CS [O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3]
DMLAYTP IK CADNYOZXMIKYPR-UHFFFAOYSA-B
DMLAYTP IU iron(3+);phosphonato phosphate
DMLAYTP CA CAS 10058-44-3
DMLAYTP CB CHEBI:132767
DMLAYTP DE Iron-deficiency anemia
DMIG4OX ID DMIG4OX
DMIG4OX DN SOTB07
DMIG4OX HS Phase 3
DMIG4OX DE Asthma
DMLSV74 ID DMLSV74
DMLSV74 DN Sotorasib
DMLSV74 HS Phase 3
DMLSV74 SN AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; AMG510 ; AMG 510; AMG-510; AMG510; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
DMLSV74 CP Amgen
DMLSV74 DT Small molecular drug
DMLSV74 PC 137278711
DMLSV74 MW 560.6
DMLSV74 FM C30H30F2N6O3
DMLSV74 IC InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1
DMLSV74 CS C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
DMLSV74 IK NXQKSXLFSAEQCZ-SFHVURJKSA-N
DMLSV74 IU 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
DMLSV74 CA CAS 2252403-56-6
DMLSV74 DE Non-small-cell lung cancer
DMMP51W ID DMMP51W
DMMP51W DN sparsentan
DMMP51W HS Phase 3
DMMP51W SN Sparsentan; RE-021; 254740-64-2; UNII-9242RO5URM; PS433540; PS-433540; CHEMBL539423; 9242RO5URM; BMS-346567; retrophin; Sparsentan [USAN]; compound 7 [PMID 15634011]; PS 33540; Sparsentan (RE-021); Sparsentan(PS433540); SCHEMBL535109; GTPL8448; BCP23969; BDBM50175523; SB16876; DB12548; CS-7947; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); HY-17621; L023324; 4'-((2-butyl-4-oxo-1,3-diazaspiro[44]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; RE-021
DMMP51W DT Small molecular drug
DMMP51W PC 10257882
DMMP51W MW 592.8
DMMP51W FM C32H40N4O5S
DMMP51W IC InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
DMMP51W CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
DMMP51W IK WRFHGDPIDHPWIQ-UHFFFAOYSA-N
DMMP51W IU 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
DMMP51W CA CAS 254740-64-2
DMMP51W DE Myocardial infarction; Hypertension; Focal segmental glomerulosclerosis
DM4TOEQ ID DM4TOEQ
DM4TOEQ DN Spartalizumab
DM4TOEQ HS Phase 3
DM4TOEQ CP Novartis
DM4TOEQ DT Monoclonal antibody
DM4TOEQ DE Melanoma
DM7NV1I ID DM7NV1I
DM7NV1I DN SPD-465
DM7NV1I HS Phase 3
DM7NV1I SN Triple-bead MAS, Shire; Triple-bead mixed amphetamine salts (oral, attention deficit hyperactivity disorder ADHD), Shire
DM7NV1I CP Shire plc
DM7NV1I DE Attention deficit hyperactivity disorder
DMVJNFI ID DMVJNFI
DMVJNFI DN Spermidine
DMVJNFI HS Phase 3
DMVJNFI SN Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0
DMVJNFI DT Small molecular drug
DMVJNFI PC 1102
DMVJNFI MW 145.25
DMVJNFI FM C7H19N3
DMVJNFI IC InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2
DMVJNFI CS C(CCNCCCN)CN
DMVJNFI IK ATHGHQPFGPMSJY-UHFFFAOYSA-N
DMVJNFI IU N'-(3-aminopropyl)butane-1,4-diamine
DMVJNFI CA CAS 124-20-9
DMVJNFI CB CHEBI:16610
DMVJNFI DE Plaque psoriasis; Rheumatoid arthritis
DMACVEI ID DMACVEI
DMACVEI DN SPI-2012
DMACVEI HS Phase 3
DMACVEI CP SPECTRUM pharmaceuticals
DMACVEI DE Breast cancer
DM3PS2E ID DM3PS2E
DM3PS2E DN Squalamine
DM3PS2E HS Phase 3
DM3PS2E SN Squalamine; 148717-90-2; Squalamine [INN]; UNII-F8PO54Z4V7; F8PO54Z4V7; CHEBI:80765; 3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate; (3beta,5alpha,7alpha,24R)-3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate); 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-; Cholestane-7,24-diol, 3-((3-(4-(aminobutyl)amino)propyl)amio)-, 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-
DM3PS2E CP OHR Pharmaceutical
DM3PS2E DT Small molecular drug
DM3PS2E PC 72495
DM3PS2E MW 628
DM3PS2E FM C34H65N3O5S
DM3PS2E IC InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
DM3PS2E CS C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCN)C)O)C
DM3PS2E IK UIRKNQLZZXALBI-MSVGPLKSSA-N
DM3PS2E IU [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
DM3PS2E CA CAS 148717-90-2
DM3PS2E CB CHEBI:80765
DM3PS2E DE Solid tumour/cancer; Diabetic macular edema
DM1ODMR ID DM1ODMR
DM1ODMR DN SR46349B
DM1ODMR HS Phase 3
DM1ODMR SN Eplivanserin fumarate; SR 46349; SR 46349B; SR-46349B; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one
DM1ODMR CP Sanofi-Aventis
DM1ODMR DT Small molecular drug
DM1ODMR PC 135456189
DM1ODMR MW 772.8
DM1ODMR FM C42H46F2N4O8
DM1ODMR IC InChI=1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
DM1ODMR CS CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.C(=C/C(=O)O)\\C(=O)O
DM1ODMR IK RNLKLYQQDLHHBH-ABDBJYMXSA-N
DM1ODMR IU (E)-but-2-enedioic acid;4-[(E,3Z)-3-[2-(dimethylamino)ethoxyimino]-3-(2-fluorophenyl)prop-1-enyl]phenol
DM1ODMR CA CAS 130580-02-8
DM1ODMR DE Schizophrenia; Primary insomnia; Sleep-wake disorder
DMT71EX ID DMT71EX
DMT71EX DN SSR-126517E
DMT71EX HS Phase 3
DMT71EX CP Sanofi-aventis
DMT71EX DE Thrombosis
DMVLKDX ID DMVLKDX
DMVLKDX DN Streptokinase rectal suppository
DMVLKDX HS Phase 3
DMVLKDX SN Proctokinase; Streptokinase rectal suppository (hemorrhoids); Streptokinase rectal suppository (hemorrhoids), CIGB
DMVLKDX CP Center for Genetic Engineering and Biotechnology
DMVLKDX DE Hemorrhoids
DMPOTM4 ID DMPOTM4
DMPOTM4 DN Sulfatinib
DMPOTM4 HS Phase 3
DMPOTM4 SN Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison
DMPOTM4 CP Hutchison Medipharma Enterprises Ltd
DMPOTM4 PC 52920501
DMPOTM4 MW 480.6
DMPOTM4 FM C24H28N6O3S
DMPOTM4 IC InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
DMPOTM4 CS CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
DMPOTM4 IK TTZSNFLLYPYKIL-UHFFFAOYSA-N
DMPOTM4 IU N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
DMPOTM4 CA CAS 1308672-74-3
DMPOTM4 DE Solid tumour/cancer; Neuroendocrine cancer
DMMD856 ID DMMD856
DMMD856 DN Sulopenem
DMMD856 HS Phase 3
DMMD856 SN CP-70,429; PF-03709270; PF-3,709,270
DMMD856 TC Antiinfective Agents
DMMD856 DT Small molecular drug
DMMD856 PC 9950244
DMMD856 MW 349.5
DMMD856 FM C12H15NO5S3
DMMD856 IC InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
DMMD856 CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O
DMMD856 IK FLSUCZWOEMTFAQ-PRBGKLEPSA-N
DMMD856 IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMMD856 CA CAS 120788-07-0
DMMD856 DE Urinary tract infection
DM07653 ID DM07653
DM07653 DN SULTHIAME
DM07653 HS Phase 3
DM07653 SN sultiame; SULTHIAME; Ospolot; sultiam; Sulphenyltame; Sulthiamine; Contravul; Trolone; 61-56-3; Sultiamum; Elisal; Conadil; Riker 594; Bayer A-168; Sultiamum [INN-Latin]; Sultiamo [INN-Spanish]; Sulthiame [USAN]; 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide; UNII-I00Q766CZ2; RP-10284; R-594; EINECS 200-511-0; p-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide, S,S-dioxide; BRN 1222219; Benzenesulfonamide, 4-(tetrahydro-2H-1,2-thiazin-2-yl)-, S,S-dioxide; RP 10284; 4-(1,1-Dioxido-1,2-thiazinan-2-yl)benzenesulfonamide; CHEMBL328560
DM07653 DT Small molecular drug
DM07653 PC 5356
DM07653 MW 290.4
DM07653 FM C10H14N2O4S2
DM07653 IC InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)
DM07653 CS C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N
DM07653 IK HMHVCUVYZFYAJI-UHFFFAOYSA-N
DM07653 IU 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide
DM07653 CA CAS 61-56-3
DM07653 CB CHEBI:32171
DMYHV17 ID DMYHV17
DMYHV17 DN Sumanirole
DMYHV17 HS Phase 3
DMYHV17 SN PNU 95666; U 95666E; PNU-95666; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-, 2-naphthalenesulfonate (salt); 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1)
DMYHV17 CP Pfizer
DMYHV17 DT Small molecular drug
DMYHV17 PC 9818479
DMYHV17 MW 203.24
DMYHV17 FM C11H13N3O
DMYHV17 IC InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1
DMYHV17 CS CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1
DMYHV17 IK RKZSNTNMEFVBDT-MRVPVSSYSA-N
DMYHV17 IU (10R)-10-(methylamino)-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-2-one
DMYHV17 CA CAS 179386-43-7
DMYHV17 DE Parkinson disease
DMXNZQK ID DMXNZQK
DMXNZQK DN SUN-101
DMXNZQK HS Phase 3
DMXNZQK CP Sunovion
DMXNZQK DE Chronic obstructive pulmonary disease
DMH2FN1 ID DMH2FN1
DMH2FN1 DN Suronacrine maleate
DMH2FN1 HS Phase 3
DMH2FN1 SN HP-128; Suronacrine maleate < Rec INNM; Rac-9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol maleate
DMH2FN1 DT Small molecular drug
DMH2FN1 PC 9953907
DMH2FN1 MW 420.5
DMH2FN1 FM C24H24N2O5
DMH2FN1 IC InChI=1S/C20H20N2O.C4H4O4/c23-18-12-6-11-17-19(18)20(15-9-4-5-10-16(15)22-17)21-13-14-7-2-1-3-8-14;5-3(6)1-2-4(7)8/h1-5,7-10,18,23H,6,11-13H2,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMH2FN1 CS C1CC(C2=C(C3=CC=CC=C3N=C2C1)NCC4=CC=CC=C4)O.C(=C\\C(=O)O)\\C(=O)O
DMH2FN1 IK JRQSVNSUJOFXHC-BTJKTKAUSA-N
DMH2FN1 IU 9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol;(Z)-but-2-enedioic acid
DMH2FN1 CA CAS 113108-86-4
DMH2FN1 DE Cognitive impairment
DMY7WH1 ID DMY7WH1
DMY7WH1 DN Sutimlimab
DMY7WH1 HS Phase 3
DMY7WH1 CP Sanofi
DMY7WH1 DT Antibody
DMY7WH1 DE Cold type autoimmune haemolytic anemia
DM3BO8G ID DM3BO8G
DM3BO8G DN SUVN-G3031
DM3BO8G HS Phase 3
DM3BO8G SN LNXDUSQEXVQFGP-UHFFFAOYSA-N; UNII-65V47O9NOP; 65V47O9NOP; SCHEMBL12484542; N-[4-(1-Cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; 1394808-82-2
DM3BO8G CP Suven Life Sciences Hyderabad, India
DM3BO8G PC 60151477
DM3BO8G MW 373.5
DM3BO8G FM C21H31N3O3
DM3BO8G IC InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25)
DM3BO8G CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4
DM3BO8G IK LNXDUSQEXVQFGP-UHFFFAOYSA-N
DM3BO8G IU N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide
DM3BO8G CA CAS 1394808-82-2
DM3BO8G DE Cognitive impairment
DMOVEDH ID DMOVEDH
DMOVEDH DN SYM-004
DMOVEDH HS Phase 3
DMOVEDH SN Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
DMOVEDH CP Symphogen A/S
DMOVEDH DT Antibody
DMOVEDH DE Head and neck cancer; Colorectal cancer; Metastatic colorectal cancer; Recurrent glioblastoma; Non-small-cell lung cancer
DMRUEKC ID DMRUEKC
DMRUEKC DN Synthetic conjugated estrogen
DMRUEKC HS Phase 3
DMRUEKC SN Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva
DMRUEKC CP Duramed Pharmaceuticals Inc
DMRUEKC DE Vaginal disease
DMXU4ON ID DMXU4ON
DMXU4ON DN Synthetic hypericin
DMXU4ON HS Phase 3
DMXU4ON SN Hypericin; VIMRxyn; Synthetic hypericin, Nexell
DMXU4ON CP Nexell Therapeutics Inc
DMXU4ON DE Virus infection
DM9L1AC ID DM9L1AC
DM9L1AC DN SYR-472
DM9L1AC HS Phase 3
DM9L1AC SN Trelagliptin succinate; TRELAGLIPTIN SUCCINATE; 1029877-94-8; Trelagliptin (succinate); UNII-4118932Z90; AK198895; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile; 4118932Z90; SYR-472 succinate; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate; SYR 111472 succinate; Trelagliptin succinate [USAN]; SYR111472 SUCCINATE; SYR 472; SYR472; Zafatek (TN); Trelagliptin succinat; SYR472 succinate; syr; Trelagliptin Succinate
DM9L1AC CP Takeda
DM9L1AC DT Small molecular drug
DM9L1AC PC 15983988
DM9L1AC MW 357.4
DM9L1AC FM C18H20FN5O2
DM9L1AC IC InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
DM9L1AC CS CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N
DM9L1AC IK IWYJYHUNXVAVAA-OAHLLOKOSA-N
DM9L1AC IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
DM9L1AC CA CAS 865759-25-7
DM9L1AC CB CHEBI:134715
DM9L1AC DE Non-insulin dependent diabetes; Metabolic disorder
DMR32KN ID DMR32KN
DMR32KN DN TA-6366
DMR32KN HS Phase 3
DMR32KN SN Hipertene (TN); Imidapril (INN); Imidapril HCl; Imidapril [BAN:INN]; Imidapril [INN:BAN]; Imidaprilum; Imidaprilum [INN-Latin]; Novaloc; Tanatril; imidapril; lmidaprfil; (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid; (S)-3-(N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid; 89371-37-9; BW7H1TJS22; C20H27N3O6; CHEMBL317094; MFCD00923828; NCGC00181342-01; UNII-BW7H1TJS22
DMR32KN PC 5464343
DMR32KN MW 405.4
DMR32KN FM C20H27N3O6
DMR32KN IC KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMR32KN CS CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O
DMR32KN IK 1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMR32KN IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMR32KN CA CAS 89371-37-9
DMR32KN CB CHEBI:135654
DMR32KN DE Essential hypertension
DMKSAG1 ID DMKSAG1
DMKSAG1 DN Tabalumab
DMKSAG1 HS Phase 3
DMKSAG1 SN LY2127399
DMKSAG1 CP Lilly
DMKSAG1 DT Monoclonal antibody
DMKSAG1 DE Multiple myeloma
DMW5PHL ID DMW5PHL
DMW5PHL DN Taberminogene vadenovec
DMW5PHL HS Phase 3
DMW5PHL SN Trinam (TN)
DMW5PHL CP Ark Therapeutics
DMW5PHL DE Vascular restinosis
DM1NTVQ ID DM1NTVQ
DM1NTVQ DN Tadekinig alfa
DM1NTVQ HS Phase 3
DM1NTVQ CP AB2 Bio
DM1NTVQ DT Recombinant protein
DM1NTVQ DE XIAP deficiency
DMCF6SX ID DMCF6SX
DMCF6SX DN TAK-491
DMCF6SX HS Phase 3
DMCF6SX SN TAK 491
DMCF6SX CP Takeda
DMCF6SX DT Small molecular drug
DMCF6SX PC 135409642
DMCF6SX MW 568.5
DMCF6SX FM C30H24N4O8
DMCF6SX IC InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
DMCF6SX CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
DMCF6SX IK QJFSABGVXDWMIW-UHFFFAOYSA-N
DMCF6SX IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
DMCF6SX CA CAS 863031-21-4
DMCF6SX CB CHEBI:68845
DMCF6SX DE Hypertension
DM2H8FZ ID DM2H8FZ
DM2H8FZ DN TAK-700
DM2H8FZ HS Phase 3
DM2H8FZ SN Orteronel
DM2H8FZ CP Millennium Pharmaceuticals
DM2H8FZ DT Small molecular drug
DM2H8FZ PC 9883029
DM2H8FZ MW 307.3
DM2H8FZ FM C18H17N3O2
DM2H8FZ IC InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)
DM2H8FZ CS CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O
DM2H8FZ IK OZPFIJIOIVJZMN-UHFFFAOYSA-N
DM2H8FZ IU 6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide
DM2H8FZ CB CHEBI:94965
DM2H8FZ DE Prostate cancer
DMIM5AP ID DMIM5AP
DMIM5AP DN TAK-875
DMIM5AP HS Phase 3
DMIM5AP SN TAK-875; Fasiglifam; 1000413-72-8; TAK875; TAK 875; UNII-GLP1W4JXAH; GLP1W4JXAH; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; CHEMBL1829174; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; J-501277
DMIM5AP CP Takeda Pharmaceuticals U.S.A.
DMIM5AP DT Small molecular drug
DMIM5AP PC 24857286
DMIM5AP MW 524.6
DMIM5AP FM C29H32O7S
DMIM5AP IC InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
DMIM5AP CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C
DMIM5AP IK BZCALJIHZVNMGJ-HSZRJFAPSA-N
DMIM5AP IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid
DMIM5AP CA CAS 1000413-72-8
DMIM5AP DE Type-2 diabetes
DM1IZ5D ID DM1IZ5D
DM1IZ5D DN Talabostat
DM1IZ5D HS Phase 3
DM1IZ5D SN Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro
DM1IZ5D CP Point Therapeutics; Tufts University School of Medicine
DM1IZ5D DT Small molecular drug
DM1IZ5D PC 6918572
DM1IZ5D MW 214.07
DM1IZ5D FM C9H19BN2O3
DM1IZ5D IC InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1
DM1IZ5D CS B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O
DM1IZ5D IK FKCMADOPPWWGNZ-YUMQZZPRSA-N
DM1IZ5D IU [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid
DM1IZ5D CA CAS 149682-77-9
DM1IZ5D DE Constitutional neutropenia; Solid tumour/cancer
DMV7T64 ID DMV7T64
DMV7T64 DN Talactoferrin
DMV7T64 HS Phase 3
DMV7T64 SN Talactoferrin (topical)
DMV7T64 CP Agennix AG
DMV7T64 DE Diabetic foot ulcer
DM3G74J ID DM3G74J
DM3G74J DN Tamibarotene
DM3G74J HS Phase 3
DM3G74J SN Tamibarotene (oral, Alzheimer's disease)
DM3G74J CP Research Foundation Itsuu Laboratory
DM3G74J DT Small molecular drug
DM3G74J PC 108143
DM3G74J MW 351.4
DM3G74J FM C22H25NO3
DM3G74J IC InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DM3G74J CS CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
DM3G74J IK MUTNCGKQJGXKEM-UHFFFAOYSA-N
DM3G74J IU 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
DM3G74J CA CAS 94497-51-5
DM3G74J CB CHEBI:32181
DM3G74J DE Alzheimer disease; T-cell leukaemia
DMJKWMA ID DMJKWMA
DMJKWMA DN Tanezumab
DMJKWMA HS Phase 3
DMJKWMA CP Pfizer New York, NY
DMJKWMA DT Monoclonal antibody
DMJKWMA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis; Cancer related pain
DMWM4D0 ID DMWM4D0
DMWM4D0 DN TAS-120
DMWM4D0 HS Phase 3
DMWM4D0 CP Taiho oncology
DMWM4D0 PC 71621331
DMWM4D0 MW 418.4
DMWM4D0 FM C22H22N6O3
DMWM4D0 IC InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1
DMWM4D0 CS COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC
DMWM4D0 IK KEIPNCCJPRMIAX-HNNXBMFYSA-N
DMWM4D0 IU 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
DMWM4D0 CA CAS 1448169-71-8
DMWM4D0 DE Multiple myeloma; Solid tumour/cancer; Cholangiocarcinoma
DMPYET9 ID DMPYET9
DMPYET9 DN Taspoglutide
DMPYET9 HS Phase 3
DMPYET9 SN BIM-51077; BIM-51079; BIM-51182; Glucagon agonists, Ipsen; ITM-077; R-1583; RG-1583; RO-5073031; Glucagon agonists, Beaufour-Ipsen
DMPYET9 CP Ipsen
DMPYET9 PC 56842233
DMPYET9 MW 3339.7
DMPYET9 FM C152H232N40O45
DMPYET9 IC InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1
DMPYET9 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMPYET9 IK WRGVLTAWMNZWGT-VQSPYGJZSA-N
DMPYET9 IU (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DMPYET9 CA CAS 275371-94-3
DMPYET9 DE Type-1 diabetes
DM9GSVQ ID DM9GSVQ
DM9GSVQ DN Tasquinimod
DM9GSVQ HS Phase 3
DM9GSVQ SN TASQ
DM9GSVQ CP Active Biotech
DM9GSVQ DT Small molecular drug
DM9GSVQ PC 54682876
DM9GSVQ MW 406.4
DM9GSVQ FM C20H17F3N2O4
DM9GSVQ IC InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
DM9GSVQ CS CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
DM9GSVQ IK ONDYALNGTUAJDX-UHFFFAOYSA-N
DM9GSVQ IU 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide
DM9GSVQ CA CAS 254964-60-8
DM9GSVQ DE Prostate cancer
DMD6AUX ID DMD6AUX
DMD6AUX DN Tat-NR2B9c
DMD6AUX HS Phase 3
DMD6AUX SN NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita
DMD6AUX CP Nono inc
DMD6AUX DT Peptide
DMD6AUX PC 44568939
DMD6AUX MW 2518.9
DMD6AUX FM C105H188N42O30
DMD6AUX IC InChI=1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1
DMD6AUX CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMD6AUX IK XWQVQFBTSBCKLI-FKXNDIMNSA-N
DMD6AUX IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMD6AUX CA CAS 500992-11-0
DMD6AUX DE Cerebrovascular ischaemia; Stroke
DML6GAN ID DML6GAN
DML6GAN DN Taxol/Paraplatin/Herceptin
DML6GAN HS Phase 3
DML6GAN SN Paclitaxel/carboplatin/trastuzumab
DML6GAN CP Bristol-Myers Squibb
DML6GAN DE Breast cancer
DMGKBZH ID DMGKBZH
DMGKBZH DN TD-1792
DMGKBZH HS Phase 3
DMGKBZH CP Theravance
DMGKBZH DT Small molecular drug
DMGKBZH PC 76960417
DMGKBZH MW 1983.3
DMGKBZH FM C87H95Cl3N16O28S2
DMGKBZH IC InChI=1S/C87H95Cl3N16O28S2/c1-33(2)20-45(94-5)74(117)100-62-66(112)36-11-14-49(43(88)22-36)130-51-24-38-25-52(70(51)134-85-71(69(115)68(114)53(31-107)132-85)133-55-29-87(4,93)72(116)34(3)129-55)131-50-15-12-37(23-44(50)89)67(113)63-81(124)99-59(42-26-40(108)27-48(110)56(42)41-21-35(10-13-47(41)109)57(77(120)101-63)98-78(121)58(38)97-75(118)46(28-54(91)111)96-80(62)123)76(119)95-16-9-19-128-104-61(60-73(90)136-86(92)103-60)79(122)102-64-82(125)106-65(84(126)127)39(32-135-83(64)106)30-105-17-7-6-8-18-105/h6-8,10-15,17-18,21-27,33-34,45-46,53,55,57-59,62-64,66-69,71-72,83,85,94,107,112-116H,9,16,19-20,28-32,93H2,1-5H3,(H15-,91,92,95,96,97,98,99,100,101,102,103,104,108,109,110,111,117,118,119,120,121,122,123,124,126,127)/t34-,45+,46-,53+,55-,57+,58+,59-,62+,63-,64+,66+,67+,68+,69-,71+,72+,83+,85-,87-/m0/s1
DMGKBZH CS C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)NCCCO/N=C(/C1=C(SC(=N1)N)Cl)\\C(=O)N[C@H]1[C@@H]2N(C1=O)C(=C(CS2)C[N+]1=CC=CC=C1)C(=O)[O-])CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMGKBZH IK OGUAFUAJSPORAH-KHCCTVBNSA-N
DMGKBZH IU (6R,7R)-7-[[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[3-[[(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carbonyl]amino]propoxyimino]acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMGKBZH CA CAS 722454-12-8
DMGKBZH DE Gram-positive bacterial infection; Skin infection
DMVSX6O ID DMVSX6O
DMVSX6O DN Tebipenem
DMVSX6O HS Phase 3
DMVSX6O SN Tebipenem [INN]
DMVSX6O CP Sanofi-Aventis
DMVSX6O DT Small molecular drug
DMVSX6O PC 9800194
DMVSX6O MW 383.5
DMVSX6O FM C16H21N3O4S2
DMVSX6O IC InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1
DMVSX6O CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O
DMVSX6O IK GXXLUDOKHXEFBQ-YJFSRANCSA-N
DMVSX6O IU (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMVSX6O CA CAS 161715-21-5
DMVSX6O DE Obesity; Nicotine dependence; Urinary tract infection
DMTCR2O ID DMTCR2O
DMTCR2O DN Tecarfarin
DMTCR2O HS Phase 3
DMTCR2O SN ATI-5923
DMTCR2O CP ARYx Therapeutics
DMTCR2O DT Small molecular drug
DMTCR2O PC 54718618
DMTCR2O MW 460.3
DMTCR2O FM C21H14F6O5
DMTCR2O IC InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
DMTCR2O CS CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
DMTCR2O IK QFLNTQDOVCLQKW-UHFFFAOYSA-N
DMTCR2O IU (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
DMTCR2O CA CAS 867257-26-9
DMTCR2O DE Cerebrovascular ischaemia; Thrombosis
DMKE187 ID DMKE187
DMKE187 DN Telmisartan
DMKE187 HS Phase 3
DMKE187 SN Telmisartan; 144701-48-4; Micardis; Pritor; BIBR 277; Kinzalmono; BIBR-277; BIBR 277SE; Telmisattan; Targit; Telmisartan [INN]; UNII-U5SYW473RQ; BIBR-277SE; BIBR-277-SE; U5SYW473RQ; CHEMBL1017; CHEBI:9434; Telmisartan
DMKE187 TC Antiviral Agents
DMKE187 DT Small molecular drug
DMKE187 PC 65999
DMKE187 MW 514.6
DMKE187 FM C33H30N4O2
DMKE187 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMKE187 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMKE187 IK RMMXLENWKUUMAY-UHFFFAOYSA-N
DMKE187 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMKE187 CA CAS 144701-48-4
DMKE187 CB CHEBI:9434
DMKE187 DE Coronavirus Disease 2019 (COVID-19)
DMHQRYE ID DMHQRYE
DMHQRYE DN Tenidap
DMHQRYE HS Phase 3
DMHQRYE DT Small molecular drug
DMHQRYE PC 60712
DMHQRYE MW 320.8
DMHQRYE FM C14H9ClN2O3S
DMHQRYE IC InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20)
DMHQRYE CS C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O
DMHQRYE IK IZSFDUMVCVVWKW-UHFFFAOYSA-N
DMHQRYE IU 5-chloro-2-hydroxy-3-(thiophene-2-carbonyl)indole-1-carboxamide
DMHQRYE CA CAS 120210-48-2
DMHQRYE CB CHEBI:35847
DMHQRYE DE Rheumatoid arthritis
DMHOV7D ID DMHOV7D
DMHOV7D DN Tenofovir alafenamide
DMHOV7D HS Phase 3
DMHOV7D SN (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy
DMHOV7D TC Antiviral Agent
DMHOV7D DT Small molecular drug
DMHOV7D PC 9574768
DMHOV7D MW 476.474
DMHOV7D FM C21H29N6O5P
DMHOV7D IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMHOV7D CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OC3=CC=CC=C3
DMHOV7D IK LDEKQSIMHVQZJK-CAQYMETFSA-N
DMHOV7D IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMHOV7D CA CAS 379270-37-8
DMHOV7D CB CHEBI:90926
DMHOV7D DE Chronic hepatitis B infection; Human immunodeficiency virus infection
DMZ3P6C ID DMZ3P6C
DMZ3P6C DN Teplizumab
DMZ3P6C HS Phase 3
DMZ3P6C CP MacroGenics
DMZ3P6C DT Antibody
DMZ3P6C DE Type-1 diabetes; Melanoma
DM4MZXE ID DM4MZXE
DM4MZXE DN Terodiline
DM4MZXE HS Phase 3
DM4MZXE SN Bicor; Microl; Mictrol; Micturin; Micturol; Terolin; Terodiline hydrochloride; TD-758
DM4MZXE CP Pharmacia & Upjohn AB
DM4MZXE DT Small molecular drug
DM4MZXE PC 23480
DM4MZXE MW 281.4
DM4MZXE FM C20H27N
DM4MZXE IC InChI=1S/C20H27N/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19,21H,15H2,1-4H3
DM4MZXE CS CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C
DM4MZXE IK UISARWKNNNHPGI-UHFFFAOYSA-N
DM4MZXE IU N-tert-butyl-4,4-diphenylbutan-2-amine
DM4MZXE CA CAS 15793-40-5
DM4MZXE CB CHEBI:135168
DM4MZXE DE Urinary incontinence
DMGRBN5 ID DMGRBN5
DMGRBN5 DN TESAGLITAZAR
DMGRBN5 HS Phase 3
DMGRBN5 SN Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5 DT Small molecular drug
DMGRBN5 PC 208901
DMGRBN5 MW 408.5
DMGRBN5 FM C20H24O7S
DMGRBN5 IC InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
DMGRBN5 CS CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
DMGRBN5 IK CXGTZJYQWSUFET-IBGZPJMESA-N
DMGRBN5 IU (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5 CA CAS 251565-85-2
DMGRBN5 DE Type-1 diabetes
DMMTKC6 ID DMMTKC6
DMMTKC6 DN TEV-48125
DMMTKC6 HS Phase 3
DMMTKC6 DT Antibody
DMMTKC6 DE Migraine
DM9R5J6 ID DM9R5J6
DM9R5J6 DN Tezepelumab
DM9R5J6 HS Phase 3
DM9R5J6 CP Amgen; AstraZeneca
DM9R5J6 DT Antibody
DM9R5J6 DE Severe asthma
DMLCXPD ID DMLCXPD
DMLCXPD DN TG-C
DMLCXPD HS Phase 3
DMLCXPD SN 3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC
DMLCXPD DT Small molecular drug
DMLCXPD PC 24768536
DMLCXPD MW 899.7
DMLCXPD FM C25H40N7O19P3S2
DMLCXPD IC InChI=1S/C25H40N7O19P3S2/c1-25(2,20(38)23(39)28-4-3-14(33)27-5-6-56-16(36)9-55-8-15(34)35)10-48-54(45,46)51-53(43,44)47-7-13-19(50-52(40,41)42)18(37)24(49-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,18-20,24,37-38H,3-10H2,1-2H3,(H,27,33)(H,28,39)(H,34,35)(H,43,44)(H,45,46)(H2,26,29,30)(H2,40,41,42)/t13-,18-,19-,20+,24-/m1/s1
DMLCXPD CS CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CSCC(=O)O)O
DMLCXPD IK GKSSRSUPHZUOQO-ITIYDSSPSA-N
DMLCXPD IU 2-[2-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoethyl]sulfanylacetic acid
DMLCXPD DE Arthritis
DMPGH7N ID DMPGH7N
DMPGH7N DN ThermoProfen
DMPGH7N HS Phase 3
DMPGH7N CP ZARS Pharma
DMPGH7N DE Pain
DM3PA8H ID DM3PA8H
DM3PA8H DN THVD-201
DM3PA8H HS Phase 3
DM3PA8H SN Tolterodine + pilocarpine (overactive bladder/urinary incontinence), TheraVida
DM3PA8H CP TheraVida Inc
DM3PA8H DE Overactive bladder
DM3DG5C ID DM3DG5C
DM3DG5C DN THX-TS01
DM3DG5C HS Phase 3
DM3DG5C CP Therapix Biosciences Givatayim, Israel
DM3DG5C DE Tourette syndrome
DMMO6P0 ID DMMO6P0
DMMO6P0 DN Tifacogin
DMMO6P0 HS Phase 3
DMMO6P0 SN LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron
DMMO6P0 CP GD Searle & Co; Chiron
DMMO6P0 DT Small molecular drug
DMMO6P0 PC 961320
DMMO6P0 MW 203.31
DMMO6P0 FM C12H13NS
DMMO6P0 IC InChI=1S/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2
DMMO6P0 CS C1=CC=C(C=C1)CNCC2=CC=CS2
DMMO6P0 IK GEWKIDGKZRKUFB-UHFFFAOYSA-N
DMMO6P0 IU 1-phenyl-N-(thiophen-2-ylmethyl)methanamine
DMMO6P0 CA CAS 73325-61-8
DMMO6P0 DE Sepsis
DMZBGI8 ID DMZBGI8
DMZBGI8 DN Tilarginine acetate
DMZBGI8 HS Phase 3
DMZBGI8 SN 53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99%
DMZBGI8 CP ArgiNOx
DMZBGI8 DT Small molecular drug
DMZBGI8 PC 135242
DMZBGI8 MW 248.28
DMZBGI8 FM C9H20N4O4
DMZBGI8 IC InChI=1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1
DMZBGI8 CS CC(=O)O.CN=C(N)NCCC[C@@H](C(=O)O)N
DMZBGI8 IK IKPNWIGTWUZCKM-JEDNCBNOSA-N
DMZBGI8 IU acetic acid;(2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid
DMZBGI8 CA CAS 53308-83-1
DMZBGI8 DE Angina pectoris; Myocardial infarction
DMGYK2N ID DMGYK2N
DMGYK2N DN Tilsotolimod
DMGYK2N HS Phase 3
DMGYK2N SN IMO-2125
DMGYK2N CP Idera Pharmaceuticals
DMGYK2N DT Oligonucleotide
DMGYK2N DE Melanoma
DMBFE4K ID DMBFE4K
DMBFE4K DN Tirapazamine
DMBFE4K HS Phase 3
DMBFE4K SN TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075
DMBFE4K CP Sri international
DMBFE4K DT Small molecular drug
DMBFE4K PC 135413511
DMBFE4K MW 178.15
DMBFE4K FM C7H6N4O2
DMBFE4K IC InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
DMBFE4K CS C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]
DMBFE4K IK ORYDPOVDJJZGHQ-UHFFFAOYSA-N
DMBFE4K IU 1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
DMBFE4K CA CAS 27314-97-2
DMBFE4K CB CHEBI:78887
DMBFE4K DE Alzheimer disease; Hepatocellular carcinoma
DMQNMAT ID DMQNMAT
DMQNMAT DN Tirzepatide
DMQNMAT HS Phase 3
DMQNMAT CP Eli Lilly
DMQNMAT DE Type 2 diabetes
DM95IPS ID DM95IPS
DM95IPS DN Tivanisiran
DM95IPS HS Phase 3
DM95IPS CP Sylentis
DM95IPS DT Small interfering RNA
DM95IPS DE Dry eye disease
DMNVP8Q ID DMNVP8Q
DMNVP8Q DN Tivantinib
DMNVP8Q HS Phase 3
DMNVP8Q SN Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
DMNVP8Q CP ArQule; Daiichi Sankyo
DMNVP8Q DT Small molecular drug
DMNVP8Q PC 11494412
DMNVP8Q MW 369.4
DMNVP8Q FM C23H19N3O2
DMNVP8Q IC InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
DMNVP8Q CS C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
DMNVP8Q IK UCEQXRCJXIVODC-PMACEKPBSA-N
DMNVP8Q IU (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
DMNVP8Q CA CAS 905854-02-6
DMNVP8Q CB CHEBI:91398
DMNVP8Q DE Solid tumour/cancer; Hepatocellular carcinoma
DMYLT67 ID DMYLT67
DMYLT67 DN TKI258
DMYLT67 HS Phase 3
DMYLT67 SN Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
DMYLT67 CP Novartis & Chiron Corp
DMYLT67 TC Anticancer Agents
DMYLT67 DT Small molecular drug
DMYLT67 PC 135611162
DMYLT67 MW 500.5
DMYLT67 FM C24H29FN6O5
DMYLT67 IC InChI=1S/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2
DMYLT67 CS CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N.O
DMYLT67 IK QDPVYZNVVQQULH-UHFFFAOYSA-N
DMYLT67 IU 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid;hydrate
DMYLT67 CA CAS 915769-50-5
DMYLT67 DE Endometrial cancer; Renal cell carcinoma; Triple negative breast cancer
DMO1234 ID DMO1234
DMO1234 DN TNX-102
DMO1234 HS Phase 3
DMO1234 SN Cyclobenzaprine very low dose
DMO1234 CP TONIX Pharmaceuticals
DMO1234 DT Small molecular drug
DMO1234 PC 22576
DMO1234 MW 311.8
DMO1234 FM C20H22ClN
DMO1234 IC InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H
DMO1234 CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl
DMO1234 IK VXEAYBOGHINOKW-UHFFFAOYSA-N
DMO1234 IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine;hydrochloride
DMO1234 CA CAS 6202-23-9
DMO1234 CB CHEBI:3997
DMO1234 DE Fibromyalgia; Post-traumatic stress disorder
DMYA41S ID DMYA41S
DMYA41S DN TNX-355
DMYA41S HS Phase 3
DMYA41S CP Tanox; Biogen
DMYA41S DE Human immunodeficiency virus infection
DMFDNT0 ID DMFDNT0
DMFDNT0 DN Tocilizumab
DMFDNT0 HS Phase 3
DMFDNT0 SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DMFDNT0 CP Roche; Genentech
DMFDNT0 TC Antiviral Agents
DMFDNT0 DT Monoclonal antibody
DMFDNT0 DE Juvenile idiopathic arthritis; Rheumatoid arthritis; Systemic sclerosis; Coronavirus Disease 2019 (COVID-19)
DMATC14 ID DMATC14
DMATC14 DN Tozadenant
DMATC14 HS Phase 3
DMATC14 SN Ro-2; SYN-115; A2a receptor antagonists (Parkinson's disease), Synosia/Roche; Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche
DMATC14 CP Biotie therapies
DMATC14 DT Small molecular drug
DMATC14 PC 11618368
DMATC14 MW 406.5
DMATC14 FM C19H26N4O4S
DMATC14 IC InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
DMATC14 CS CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O
DMATC14 IK XNBRWUQWSKXMPW-UHFFFAOYSA-N
DMATC14 IU 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide
DMATC14 CA CAS 870070-55-6
DMATC14 DE Parkinson disease
DMLKI2B ID DMLKI2B
DMLKI2B DN Trafermin
DMLKI2B HS Phase 3
DMLKI2B SN Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
DMLKI2B CP Johnson & Johnson Licensee; Kaken Pharmaceutical
DMLKI2B DE Periodontitis
DM6ENSJ ID DM6ENSJ
DM6ENSJ DN Tralokinumab
DM6ENSJ HS Phase 3
DM6ENSJ SN CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
DM6ENSJ CP Ception Therapeutics
DM6ENSJ DT Monoclonal antibody
DM6ENSJ DE Asthma; Ulcerative colitis; Atopic dermatitis
DM7BSRH ID DM7BSRH
DM7BSRH DN Tramiprosate
DM7BSRH HS Phase 3
DM7BSRH SN Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS
DM7BSRH CP Neurochem
DM7BSRH DT Small molecular drug
DM7BSRH PC 1646
DM7BSRH MW 139.18
DM7BSRH FM C3H9NO3S
DM7BSRH IC InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)
DM7BSRH CS C(CN)CS(=O)(=O)O
DM7BSRH IK SNKZJIOFVMKAOJ-UHFFFAOYSA-N
DM7BSRH IU 3-aminopropane-1-sulfonic acid
DM7BSRH CA CAS 3687-18-1
DM7BSRH CB CHEBI:1457
DM7BSRH DE Alzheimer disease
DMLB3I4 ID DMLB3I4
DMLB3I4 DN Trastuzumab-DM1
DMLB3I4 HS Phase 3
DMLB3I4 CP Genentech
DMLB3I4 DT Antibody drug conjugate
DMLB3I4 DE Breast cancer
DM1874J ID DM1874J
DM1874J DN TRC105
DM1874J HS Phase 3
DM1874J DT Monoclonal antibody
DM1874J DE Breast cancer; Lung cancer; Ovarian cancer; Macular degeneration; Peritoneal cancer; Fallopian tube cancer; Soft tissue sarcoma; Gestational trophoblastic neoplasia; Hemangiosarcoma; Hepatocellular carcinoma; Renal cell carcinoma; Recurrent glioblastoma; Angiosarcoma
DMOG2X1 ID DMOG2X1
DMOG2X1 DN Trebananib
DMOG2X1 HS Phase 3
DMOG2X1 CP Amgen
DMOG2X1 DT Recombinant protein
DMOG2X1 DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer
DMOQ9H1 ID DMOQ9H1
DMOQ9H1 DN Tremelimumab
DMOQ9H1 HS Phase 3
DMOQ9H1 CP AstraZeneca
DMOQ9H1 DT Monoclonal antibody
DMOQ9H1 DE Solid tumour/cancer; Malignant mesothelioma
DMS57DJ ID DMS57DJ
DMS57DJ DN Trimegestone/ethinyl estradiol
DMS57DJ HS Phase 3
DMS57DJ CP Wyeth
DMS57DJ DE Contraception
DMCMDVR ID DMCMDVR
DMCMDVR DN Triptolide
DMCMDVR HS Phase 3
DMCMDVR SN triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
DMCMDVR DT Small molecular drug
DMCMDVR PC 107985
DMCMDVR MW 360.4
DMCMDVR FM C20H24O6
DMCMDVR IC InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
DMCMDVR CS CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C
DMCMDVR IK DFBIRQPKNDILPW-CIVMWXNOSA-N
DMCMDVR IU (1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
DMCMDVR CA CAS 38748-32-2
DMCMDVR CB CHEBI:9747
DMCMDVR DE Autoimmune diabetes
DMHDNK0 ID DMHDNK0
DMHDNK0 DN TroVax
DMHDNK0 HS Phase 3
DMHDNK0 SN TroVax (TN)
DMHDNK0 CP Oxford BioMedica
DMHDNK0 DT Vaccine
DMHDNK0 DE Prostate cancer
DM0QNF4 ID DM0QNF4
DM0QNF4 DN TRx0237
DM0QNF4 HS Phase 3
DM0QNF4 SN 951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide
DM0QNF4 CP TauRx Therapeutics
DM0QNF4 DT Small molecular drug
DM0QNF4 PC 23651551
DM0QNF4 MW 447.2
DM0QNF4 FM C16H21Br2N3S
DM0QNF4 IC InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H
DM0QNF4 CS CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.Br.Br
DM0QNF4 IK JAUPSVVTGFBHTN-UHFFFAOYSA-N
DM0QNF4 IU 3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine;dihydrobromide
DM0QNF4 CA CAS 951131-15-0
DM0QNF4 DE Alzheimer disease
DMAFPHB ID DMAFPHB
DMAFPHB DN TRYPTAMINE
DMAFPHB HS Phase 3
DMAFPHB SN tryptamine; 61-54-1; 2-(1H-Indol-3-yl)ethanamine; 3-(2-aminoethyl)indole; 1H-Indole-3-ethanamine; 2-(3-Indolyl)ethylamine; Indol-3-ethylamine; Indole, 3-(2-aminoethyl)-; 2-(Indol-3-yl)ethylamine; 2-(1H-Indol-3-Yl)Ethan-1-Amine; 3-Indoleethylamine; Tryptamin; 2-(1H-indol-3-yl)ethylamine; 2-Indol-3-ylethylamine; 2-(1H-INDOL-3-YL)-ETHYLAMINE; UNII-422ZU9N5TV; (Amino-2 ethyl)-3 indole; (Amino-2 ethyl)-3 indole [French]; Tryptamine, 98%; BRN 0125513; EINECS 200-510-5; CHEMBL6640; 422ZU9N5TV; CHEBI:16765; APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB DT Small molecular drug
DMAFPHB PC 1150
DMAFPHB MW 160.22
DMAFPHB FM C10H12N2
DMAFPHB IC InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2
DMAFPHB CS C1=CC=C2C(=C1)C(=CN2)CCN
DMAFPHB IK APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB IU 2-(1H-indol-3-yl)ethanamine
DMAFPHB CA CAS 61-54-1
DMAFPHB CB CHEBI:16765
DMPBJ8W ID DMPBJ8W
DMPBJ8W DN Turoctocog alfa
DMPBJ8W HS Phase 3
DMPBJ8W SN NN7008
DMPBJ8W CP Novo Nordisk
DMPBJ8W DE Haemophilia A
DM71ZL6 ID DM71ZL6
DM71ZL6 DN TZTX-001
DM71ZL6 HS Phase 3
DM71ZL6 SN Teverelix LA; TX 12-001-HR
DM71ZL6 CP Ardana Bioscience
DM71ZL6 DE Endometriosis
DMN72OM ID DMN72OM
DMN72OM DN U300
DMN72OM HS Phase 3
DMN72OM SN Methyl 3,5-dinitrobenzoate; 2702-58-1; Benzoic acid, 3,5-dinitro-, methyl ester; POGCCFLNFPIIGW-UHFFFAOYSA-N; 3,5-dinitro-benzoic acid methyl ester; Methyl 3,5-Dinitrobenzoate,99%; Methyl-3,5-dinitrobenzoate; U300; ACMC-1CR6Q; AC1L5B8W; AC1Q5AI0; KSC494Q3H; SCHEMBL418416; Jsp005266; CHEMBL2252127; CTK3J4833; KS-00000ZZJ; NSC7317; MolPort-001-012-121; Methyl 3,5-dinitrobenzoate, 99%; ALBB-024845; NSC-7317; ZINC1683476; METHYL-3,5-DINITRO BENZOATE; BBL000013; ANW-44565; SBB068882; MFCD00017016; STK386186; 3,5-Dinitrobenzoic acid methyl e
DMN72OM CP Sanofi us
DMN72OM DT Small molecular drug
DMN72OM PC 222067
DMN72OM MW 226.14
DMN72OM FM C8H6N2O6
DMN72OM IC InChI=1S/C8H6N2O6/c1-16-8(11)5-2-6(9(12)13)4-7(3-5)10(14)15/h2-4H,1H3
DMN72OM CS COC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-]
DMN72OM IK POGCCFLNFPIIGW-UHFFFAOYSA-N
DMN72OM IU methyl 3,5-dinitrobenzoate
DMN72OM CA CAS 2702-58-1
DMN72OM DE Type-2 diabetes
DMHTY9W ID DMHTY9W
DMHTY9W DN Ublituximab
DMHTY9W HS Phase 3
DMHTY9W SN TG-1101
DMHTY9W CP TG Therapeutics
DMHTY9W DT Antibody
DMHTY9W DE Chronic lymphocytic leukaemia; Lymphoma; Multiple sclerosis; Nodal marginal zone lymphoma
DMKUOVP ID DMKUOVP
DMKUOVP DN Ublituximab + umbralisib
DMKUOVP HS Phase 3
DMKUOVP CP TG Therapeutics New York, NY
DMKUOVP DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DM90AG2 ID DM90AG2
DM90AG2 DN Ularitide
DM90AG2 HS Phase 3
DM90AG2 SN Urodilatin; 115966-23-9; Atriopeptin (95-126); Human urodilatin; Urodilatin human; Ularitide [INN]; Urodilatin ularitide; Anf (95-126); Anp (95-126); ANP 95-126; Atrial natriuretic peptide (95-126); CHEMBL2103920; Urodilatin human, > AKOS030213250; DB05034; CDD 95-126; LS-187531; LS-186876; Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide; atrial natriuretic factor prohormone (95-126)
DM90AG2 CP EKR Therapeutics
DM90AG2 DT Small molecular drug
DM90AG2 PC 16132416
DM90AG2 MW 3505.9
DM90AG2 FM C145H234N52O44S3
DM90AG2 IC InChI=1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1
DM90AG2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
DM90AG2 IK IUCCYQIEZNQWRS-DWWHXVEHSA-N
DM90AG2 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM90AG2 CA CAS 118812-69-4
DM90AG2 DE Heart failure; Acute heart failure
DMIQCFG ID DMIQCFG
DMIQCFG DN Ulinastatin
DMIQCFG HS Phase 3
DMIQCFG SN Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p
DMIQCFG DT Small molecular drug
DMIQCFG PC 105102
DMIQCFG MW 220.26
DMIQCFG FM C13H16O3
DMIQCFG IC InChI=1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2
DMIQCFG CS C1CC2(CC=C1)COC(OC2)C3=CC=CO3
DMIQCFG IK ODVKSTFPQDVPJZ-UHFFFAOYSA-N
DMIQCFG IU 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
DMIQCFG CA CAS 80449-32-7
DMIQCFG DE Premature labour
DM6PMNR ID DM6PMNR
DM6PMNR DN Ulocuplumab
DM6PMNR HS Phase 3
DM6PMNR CP Bristol-myers squibb
DM6PMNR DT Monoclonal antibody
DM6PMNR DE Haematological malignancy; Multiple myeloma
DMCWM03 ID DMCWM03
DMCWM03 DN Unfractionated heparin
DMCWM03 HS Phase 3
DMCWM03 SN Elaprin; UFH (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen); SNAC/heparin capsule (solid oral), Emisphere; SNAD/heparin tablet (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen), Emisphere
DMCWM03 CP Emisphere Technologies Inc
DMCWM03 DE Thrombosis
DM0DIEZ ID DM0DIEZ
DM0DIEZ DN UNI-rhIL-11
DM0DIEZ HS Phase 3
DM0DIEZ SN Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group
DM0DIEZ CP Uni-Bio Science Group Limited
DM0DIEZ DE Thrombocytopenia
DMM2OZH ID DMM2OZH
DMM2OZH DN Ushercell
DMM2OZH HS Phase 3
DMM2OZH SN Cellulose sulfate gel, Polydex
DMM2OZH CP Polydex Pharmaceuticals Ltd
DMM2OZH DT Small molecular drug
DMM2OZH PC 154413
DMM2OZH MW 457.6
DMM2OZH FM C30H35NO3
DMM2OZH IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1
DMM2OZH CS CC1([C@@H]([C@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DMM2OZH IK XZEUAXYWNKYKPL-URLMMPGGSA-N
DMM2OZH IU 1-[2-[4-[(3S,4S)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DMM2OZH CA CAS 31477-60-8
DMM2OZH DE Bacterial infection
DMD2O0L ID DMD2O0L
DMD2O0L DN UX-001
DMD2O0L HS Phase 3
DMD2O0L CP Ultragenyx Pharmaceutical
DMD2O0L DT Small molecular drug
DMD2O0L PC 656387
DMD2O0L MW 309.27
DMD2O0L FM C11H19NO9
DMD2O0L IC InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6-,7+,8-,9+,11+/m0/s1
DMD2O0L CS CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@H]([C@H](CO)O)O)(C(=O)O)O)O
DMD2O0L IK SQVRNKJHWKZAKO-USOVHJGOSA-N
DMD2O0L IU (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMD2O0L DE Myopathy; Hereditary inclusion body myositis
DMDCFXJ ID DMDCFXJ
DMDCFXJ DN Vaborbactam
DMDCFXJ HS Phase 3
DMDCFXJ SN RPX-7009; 1360457-46-0; RPX7009; UNII-1C75676F8V; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; CHEMBL3317857; 1C75676F8V; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; Vaborbactam [INN]; RPX 7009; Vaborbactam. RPX7009; Vaborbactam (USAN/INN); Vaborbactam [USAN:INN]; SCHEMBL620289; GTPL10871; Vabomere (vaborbactam + meropenem); EX-A2589; BDBM50089084; MFCD28502176; AKOS032961376; CS-6445; DB12107; SB17184; 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-; compound 9f [PMID: 25782055]; NCGC00510003-01; HY-19930; 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-; D10998; Q27252228; {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; 1,2-Oxaborinane-6-acetic acid
DMDCFXJ DT Small molecular drug
DMDCFXJ PC 56649692
DMDCFXJ MW 297.14
DMDCFXJ FM C12H16BNO5S
DMDCFXJ IC InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
DMDCFXJ CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
DMDCFXJ IK IOOWNWLVCOUUEX-WPRPVWTQSA-N
DMDCFXJ IU 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMDCFXJ CA CAS 1360457-46-0
DMDCFXJ DE Urinary tract infection
DM9LH10 ID DM9LH10
DM9LH10 DN Vadastuximab talirine
DM9LH10 HS Phase 3
DM9LH10 SN vadastuximab talirine; Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5
DM9LH10 CP Seattle Genetics Bothell, WA
DM9LH10 PC 122706909
DM9LH10 MW 1210.4
DM9LH10 FM C63H71N9O14S
DM9LH10 IC InChI=1S/C63H71N9O14S/c1-35(2)57(69-55(73)11-8-7-9-20-70-56(74)29-54(62(70)79)87-34-47(64)63(80)81)59(76)67-36(3)58(75)68-41-16-12-37(13-17-41)39-23-42-30-65-48-27-52(50(83-5)25-45(48)60(77)71(42)32-39)85-21-10-22-86-53-28-49-46(26-51(53)84-6)61(78)72-33-40(24-43(72)31-66-49)38-14-18-44(82-4)19-15-38/h12-19,25-28,30-33,35-36,42-43,47,54,57H,7-11,20-24,29,34,64H2,1-6H3,(H,67,76)(H,68,75)(H,69,73)(H,80,81)/t36-,42-,43-,47-,54+,57-/m0/s1
DM9LH10 CS C[C@@H](C(=O)NC1=CC=C(C=C1)C2=CN3[C@@H](C2)C=NC4=CC(=C(C=C4C3=O)OC)OCCCOC5=C(C=C6C(=C5)N=C[C@@H]7CC(=CN7C6=O)C8=CC=C(C=C8)OC)OC)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN9C(=O)C[C@H](C9=O)SC[C@@H](C(=O)O)N
DM9LH10 IK BNJNAEJASPUJTO-DUOHOMBCSA-N
DM9LH10 IU (2R)-3-[(3R)-1-[6-[[(2S)-1-[[(2S)-1-[4-[(6aS)-3-[3-[[(6aS)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DM9LH10 CA CAS 1436390-64-5
DM9LH10 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DM9J5Q4 ID DM9J5Q4
DM9J5Q4 DN VAL-083
DM9J5Q4 HS Phase 3
DM9J5Q4 SN VAL-083; Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6
DM9J5Q4 CP Del Mar Pharmaceuticals
DM9J5Q4 DT Small molecular drug
DM9J5Q4 PC 15942827
DM9J5Q4 MW 146.14
DM9J5Q4 FM C6H10O4
DM9J5Q4 IC InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-
DM9J5Q4 CS C1[C@@H](O1)[C@@H]([C@@H]([C@@H]2CO2)O)O
DM9J5Q4 IK AAFJXZWCNVJTMK-GUCUJZIJSA-N
DM9J5Q4 IU (1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol
DM9J5Q4 CA CAS 23261-20-3
DM9J5Q4 DE Grade IV malignant glioma; Acute myeloid leukaemia; Recurrent glioblastoma; Recurring respiratory infection
DMMKE2H ID DMMKE2H
DMMKE2H DN Valoctocogene roxaparvovec
DMMKE2H HS Phase 3
DMMKE2H SN BMN 270
DMMKE2H CP BioMarin Pharmaceutical
DMMKE2H DT Gene therapy
DMMKE2H DE Haemophilia A
DMQL0KF ID DMQL0KF
DMQL0KF DN Vanadate
DMQL0KF HS Phase 3
DMQL0KF SN Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3
DMQL0KF DT Small molecular drug
DMQL0KF PC 516859
DMQL0KF MW 116.978
DMQL0KF FM H4NO3V
DMQL0KF IC InChI=1S/H3N.3O.V/h1H3;;;;/q;;;-1;/p+1
DMQL0KF CS [NH4+].[O-][V](=O)=O
DMQL0KF IK UNTBPXHCXVWYOI-UHFFFAOYSA-O
DMQL0KF IU azanium;oxido(dioxo)vanadium
DMQL0KF CA CAS 7803-55-6
DMQL0KF DE Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
DMLIMEA ID DMLIMEA
DMLIMEA DN Varespladib methyl
DMLIMEA HS Phase 3
DMLIMEA SN A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera
DMLIMEA CP Shionogi & Co Ltd
DMLIMEA DT Small molecular drug
DMLIMEA PC 9886917
DMLIMEA MW 394.4
DMLIMEA FM C22H22N2O5
DMLIMEA IC InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
DMLIMEA CS CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N
DMLIMEA IK VJYDOJXJUCJUHL-UHFFFAOYSA-N
DMLIMEA IU methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
DMLIMEA CA CAS 172733-08-3
DMLIMEA DE Rheumatoid arthritis
DMANKTO ID DMANKTO
DMANKTO DN Vatreptacog alfa (activated)
DMANKTO HS Phase 3
DMANKTO SN NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
DMANKTO CP Novo Nordisk A/S
DMANKTO DE Bleeding disorder
DMX04CA ID DMX04CA
DMX04CA DN VB-111
DMX04CA HS Phase 3
DMX04CA CP VBL Therapeutics
DMX04CA DE Glioblastoma multiforme; Malignant glioma; Ovarian cancer; Recurrent glioblastoma
DMXHI89 ID DMXHI89
DMXHI89 DN Velac Gel
DMXHI89 HS Phase 3
DMXHI89 SN Clindamycin/tretinoin
DMXHI89 CP Stiefel Laboratories
DMXHI89 DE Acne vulgaris
DMJBU9V ID DMJBU9V
DMJBU9V DN Velimogene aliplasmid
DMJBU9V HS Phase 3
DMJBU9V SN Allovectin (TN)
DMJBU9V CP Vical
DMJBU9V DE Melanoma
DM6L5ZQ ID DM6L5ZQ
DM6L5ZQ DN Vercirnon
DM6L5ZQ HS Phase 3
DM6L5ZQ SN 1605786
DM6L5ZQ CP GlaxoSmithKline
DM6L5ZQ DT Small molecular drug
DM6L5ZQ PC 10343454
DM6L5ZQ MW 444.9
DM6L5ZQ FM C22H21ClN2O4S
DM6L5ZQ IC InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3
DM6L5ZQ CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-]
DM6L5ZQ IK JRWROCIMSDXGOZ-UHFFFAOYSA-N
DM6L5ZQ IU 4-tert-butyl-N-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide
DM6L5ZQ CA CAS 698394-73-9
DM6L5ZQ DE Crohn disease
DMOQ81Y ID DMOQ81Y
DMOQ81Y DN Vernakalant
DMOQ81Y HS Phase 3
DMOQ81Y SN Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
DMOQ81Y CP Cardiome Pharma; Merck
DMOQ81Y DT Small molecular drug
DMOQ81Y PC 9930049
DMOQ81Y MW 349.5
DMOQ81Y FM C20H31NO4
DMOQ81Y IC InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
DMOQ81Y CS COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
DMOQ81Y IK VBHQKCBVWWUUKN-KZNAEPCWSA-N
DMOQ81Y IU (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
DMOQ81Y CA CAS 794466-70-9
DMOQ81Y CB CHEBI:135956
DMOQ81Y DE Atrial fibrillation
DM4CGH5 ID DM4CGH5
DM4CGH5 DN verubecestat
DM4CGH5 HS Phase 3
DM4CGH5 SN example 25 (US8940748)
DM4CGH5 DT Small molecular drug
DM4CGH5 PC 51352361
DM4CGH5 MW 409.4
DM4CGH5 FM C17H17F2N5O3S
DM4CGH5 IC InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
DM4CGH5 CS C[C@]1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F
DM4CGH5 IK YHYKUSGACIYRML-KRWDZBQOSA-N
DM4CGH5 IU N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DM4CGH5 CA CAS 1286770-55-5
DM4CGH5 DE Alzheimer disease
DMMQ2U9 ID DMMQ2U9
DMMQ2U9 DN VGX-3100
DMMQ2U9 HS Phase 3
DMMQ2U9 CP Inovio Pharmaceuticals
DMMQ2U9 DE Human papillomavirus infection; Cervical Intraepithelial neoplasia; Vulvar squamous intraepithelial lesion; Dysplasia; Vulvar intraepithelial neoplasia
DMCWNZG ID DMCWNZG
DMCWNZG DN Vibegron
DMCWNZG HS Phase 3
DMCWNZG SN Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum
DMCWNZG DT Small molecular drug
DMCWNZG PC 44472635
DMCWNZG MW 444.535
DMCWNZG FM C26H28N4O3
DMCWNZG IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMCWNZG CS C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
DMCWNZG IK DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMCWNZG IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMCWNZG CA CAS 1190389-15-1
DMCWNZG CB ChEBI:142418
DMCWNZG DE Overactive bladder disorder
DMLO0KD ID DMLO0KD
DMLO0KD DN Vicineum
DMLO0KD HS Phase 3
DMLO0KD SN Oportuzumab monatox
DMLO0KD CP Sesen Bio
DMLO0KD DT Recombinant protein
DMLO0KD DE Bladder cancer
DMMTW9K ID DMMTW9K
DMMTW9K DN Vicriviroc
DMMTW9K HS Phase 3
DMMTW9K SN SchD; Sch 417690; PRO 140 & Vicrivirac; SCH-417690; SCH-D; SCH-D690; Sch-D compound; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine
DMMTW9K CP Schering-Plough
DMMTW9K DT Small molecular drug
DMMTW9K PC 3009355
DMMTW9K MW 533.6
DMMTW9K FM C28H38F3N5O2
DMMTW9K IC InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1
DMMTW9K CS C[C@H]1CN(CCN1[C@@H](COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C
DMMTW9K IK CNPVJJQCETWNEU-CYFREDJKSA-N
DMMTW9K IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMTW9K CA CAS 306296-47-9
DMMTW9K CB CHEBI:94843
DMMTW9K DE Human immunodeficiency virus infection
DMJFNR9 ID DMJFNR9
DMJFNR9 DN Viramidine
DMJFNR9 HS Phase 3
DMJFNR9 SN Ribamidine; Prodrug of Ribavirin; Ribavirin amidine; Taribavirin hydrochloride; ICN 3142; AVS-000206; AVS-206;ICN-3142; Taribavirin hydrochloride (USAN); Viramidine (TN); 1-.Beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine hydrochloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide hydrochloride; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine
DMJFNR9 CP Valeant Pharmaceuticals International
DMJFNR9 DT Small molecular drug
DMJFNR9 PC 451448
DMJFNR9 MW 243.22
DMJFNR9 FM C8H13N5O4
DMJFNR9 IC InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1
DMJFNR9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N
DMJFNR9 IK NHKZSTHOYNWEEZ-AFCXAGJDSA-N
DMJFNR9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide
DMJFNR9 CA CAS 119567-79-2
DMJFNR9 CB CHEBI:134989
DMJFNR9 DE Hepatitis C virus infection
DMXYM1H ID DMXYM1H
DMXYM1H DN Visilizumab
DMXYM1H HS Phase 3
DMXYM1H SN Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
DMXYM1H CP PDL BioPharma Inc; PDL BioPharma
DMXYM1H DT Antibody
DMXYM1H DE Graft-versus-host disease
DMQGV5P ID DMQGV5P
DMQGV5P DN VLB-01
DMQGV5P HS Phase 3
DMQGV5P CP Marco Polo Pharmaceuticals SA
DMQGV5P DE Epilepsy
DMSW80U ID DMSW80U
DMSW80U DN VM-202
DMSW80U HS Phase 3
DMSW80U CP ViroMed
DMSW80U DE Angina pectoris; Amyotrophic lateral sclerosis; Peripheral neuropathy; Diabetic foot ulcer; Peripheral arterial disease
DM4P5UJ ID DM4P5UJ
DM4P5UJ DN VM-501
DM4P5UJ HS Phase 3
DM4P5UJ SN IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed
DM4P5UJ CP ViroMed Co Ltd
DM4P5UJ DE Thrombocytopenia
DMOFH1M ID DMOFH1M
DMOFH1M DN Volasertib
DMOFH1M HS Phase 3
DMOFH1M SN Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
DMOFH1M CP Boehringer Ingelheim
DMOFH1M DT Small molecular drug
DMOFH1M PC 10461508
DMOFH1M MW 618.8
DMOFH1M FM C34H50N8O3
DMOFH1M IC InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
DMOFH1M CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
DMOFH1M IK SXNJFOWDRLKDSF-XKHVUIRMSA-N
DMOFH1M IU N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide
DMOFH1M CA CAS 755038-65-4
DMOFH1M DE Acute myeloid leukaemia
DM5T4IS ID DM5T4IS
DM5T4IS DN VP-102
DM5T4IS HS Phase 3
DM5T4IS CP Verrica Pharmaceuticals West Chester, PA
DM5T4IS DE Common wart; Molluscum contagiosum infection
DMWMT5N ID DMWMT5N
DMWMT5N DN VRS-317
DMWMT5N HS Phase 3
DMWMT5N SN HGH-XTEN; Human growth hormone-XTEN; RPEG HGH (injectable, growth deficiency), Versartis; Recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis
DMWMT5N CP Versartis
DMWMT5N DE Growth hormone deficiency
DMM1Z9G ID DMM1Z9G
DMM1Z9G DN Vutrisiran
DMM1Z9G HS Phase 3
DMM1Z9G SN ALN-TTRsc02
DMM1Z9G CP Alnylam Pharmaceuticals
DMM1Z9G DT Small interfering RNA
DMM1Z9G DE Transthyretin familial amyloid cardiomyopathy
DMJBXO3 ID DMJBXO3
DMJBXO3 DN VX-661
DMJBXO3 HS Phase 3
DMJBXO3 CP Vertex Pharmaceuticals Inc
DMJBXO3 DT Small molecular drug
DMJBXO3 PC 46199646
DMJBXO3 MW 520.5
DMJBXO3 FM C26H27F3N2O6
DMJBXO3 IC InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
DMJBXO3 CS CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMJBXO3 IK MJUVRTYWUMPBTR-MRXNPFEDSA-N
DMJBXO3 IU 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMJBXO3 CA CAS 1152311-62-0
DMJBXO3 DE Cystic fibrosis
DMM2JXP ID DMM2JXP
DMM2JXP DN VX-787
DMM2JXP HS Phase 3
DMM2JXP SN Pimodivir
DMM2JXP CP Vertex pharmaceuticals
DMM2JXP DT Small molecular drug
DMM2JXP PC 67286591
DMM2JXP MW 399.4
DMM2JXP FM C20H19F2N5O2
DMM2JXP IC InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
DMM2JXP CS C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O
DMM2JXP IK JGPXDNKSIXAZEQ-SBBZOCNPSA-N
DMM2JXP IU (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
DMM2JXP CA CAS 1629869-44-8
DMM2JXP DE Influenza A virus infection
DM1JCW8 ID DM1JCW8
DM1JCW8 DN Xaliproden
DM1JCW8 HS Phase 3
DM1JCW8 SN Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
DM1JCW8 CP Sanofi-Aventis
DM1JCW8 DT Small molecular drug
DM1JCW8 PC 128919
DM1JCW8 MW 381.4
DM1JCW8 FM C24H22F3N
DM1JCW8 IC InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2
DM1JCW8 CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
DM1JCW8 IK WJJYZXPHLSLMGE-UHFFFAOYSA-N
DM1JCW8 IU 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DM1JCW8 CA CAS 135354-02-8
DM1JCW8 CB CHEBI:48520
DM1JCW8 DE Lateral sclerosis; Peripheral sensory neuropathies; Alzheimer disease; Juvenile idiopathic arthritis; Plaque psoriasis
DMK34MZ ID DMK34MZ
DMK34MZ DN Xilonix
DMK34MZ HS Phase 3
DMK34MZ CP Xbiotech
DMK34MZ DE Non-small-cell lung cancer; Influenza virus infection; Colorectal cancer
DMJ6F5C ID DMJ6F5C
DMJ6F5C DN XL019
DMJ6F5C HS Phase 3
DMJ6F5C SN XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe
DMJ6F5C DT Small molecular drug
DMJ6F5C PC 57990869
DMJ6F5C MW 444.5
DMJ6F5C FM C25H28N6O2
DMJ6F5C IC InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)/t23-/m0/s1
DMJ6F5C CS C1C[C@H](NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5
DMJ6F5C IK ISOCDPQFIXDIMS-QHCPKHFHSA-N
DMJ6F5C IU (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide
DMJ6F5C CA CAS 945755-56-6
DMJ6F5C DE Polycythemia vera; Solid tumour/cancer
DMOKQV7 ID DMOKQV7
DMOKQV7 DN XOMA 052
DMOKQV7 HS Phase 3
DMOKQV7 SN Gevokizumab
DMOKQV7 CP XOMA
DMOKQV7 DT Antibody
DMOKQV7 DE Type-2 diabetes
DMOLR5W ID DMOLR5W
DMOLR5W DN Yttrium (90Y) clivatuzumab tetraxetan
DMOLR5W HS Phase 3
DMOLR5W SN PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
DMOLR5W CP Immunomedics; Garden State Cancer Center; Immunomedics
DMOLR5W DT Antibody
DMOLR5W DE Pancreatic cancer
DMEY1F3 ID DMEY1F3
DMEY1F3 DN Zabofloxacin
DMEY1F3 HS Phase 3
DMEY1F3 SN DW-224a; DW-224aa; PB-101; Zabofloxacin (oral), IASO Pharma/DHP
DMEY1F3 CP Dong Wha Pharmaceutical Co Ltd
DMEY1F3 DT Small molecular drug
DMEY1F3 PC 10388396
DMEY1F3 MW 401.4
DMEY1F3 FM C19H20FN5O4
DMEY1F3 IC InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14+
DMEY1F3 CS CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F
DMEY1F3 IK ZNPOCLHDJCAZAH-OEAKJJBVSA-N
DMEY1F3 IU 1-cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMEY1F3 DE Pneumonia
DM52QEZ ID DM52QEZ
DM52QEZ DN Zalutumumab
DM52QEZ HS Phase 3
DM52QEZ CP Genmab
DM52QEZ DT Antibody
DM52QEZ SQ Zalutumumab (A chain): QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Zalutumumab (B chain)AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM52QEZ DE Head and neck cancer
DMKB4ZY ID DMKB4ZY
DMKB4ZY DN Zanolimumab
DMKB4ZY HS Phase 3
DMKB4ZY CP Emergent BioSolutions
DMKB4ZY DT Antibody
DMKB4ZY DE Lymphoma
DM9HUYP ID DM9HUYP
DM9HUYP DN ZANOTERONE
DM9HUYP HS Phase 3
DM9HUYP SN ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
DM9HUYP DT Small molecular drug
DM9HUYP PC 9844827
DM9HUYP MW 416.6
DM9HUYP FM C23H32N2O3S
DM9HUYP IC InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
DM9HUYP CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(CC5=CN(N=C5C4)S(=O)(=O)C)C
DM9HUYP IK MHDDZDPNIDVLNK-ZGIWMXSJSA-N
DM9HUYP IU (1S,2S,10S,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-6-methylsulfonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol
DM9HUYP CA CAS 107000-34-0
DM9HUYP DE Prostate hyperplasia
DMF30HL ID DMF30HL
DMF30HL DN Zarnestra
DMF30HL HS Phase 3
DMF30HL SN JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
DMF30HL CP Johnson & Johnson
DMF30HL TC Anticancer Agents
DMF30HL DT Small molecular drug
DMF30HL PC 159324
DMF30HL MW 489.4
DMF30HL FM C27H22Cl2N4O
DMF30HL IC InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1
DMF30HL CS CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
DMF30HL IK PLHJCIYEEKOWNM-HHHXNRCGSA-N
DMF30HL IU 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one
DMF30HL CA CAS 192185-72-1
DMF30HL CB CHEBI:141969
DMF30HL DE Colorectal cancer; Pancreatic cancer; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Human papillomavirus infection; Peripheral T-cell lymphoma; Acute myeloid leukaemia
DMWDEFC ID DMWDEFC
DMWDEFC DN Zatosetron maleate
DMWDEFC HS Phase 3
DMWDEFC SN LY-277359 maleate; Zatosetron maleate < Rec INNM; Endo-5-Chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydrobenzofuran-7-carboxamide maleate
DMWDEFC DT Small molecular drug
DMWDEFC PC 6918153
DMWDEFC MW 464.9
DMWDEFC FM C23H29ClN2O6
DMWDEFC IC InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13?,14-,15+;
DMWDEFC CS CC1(CC2=C(O1)C(=CC(=C2)Cl)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C.C(=C\\C(=O)O)\\C(=O)O
DMWDEFC IK HAFQATMFFHYNPN-BSLJCGBVSA-N
DMWDEFC IU (Z)-but-2-enedioic acid;5-chloro-2,2-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-1-benzofuran-7-carboxamide
DMWDEFC CA CAS 123482-23-5
DMWDEFC DE Anxiety disorder
DMP8ESD ID DMP8ESD
DMP8ESD DN Zicronapine
DMP8ESD HS Phase 3
DMP8ESD SN Zicronapine; 170381-16-5; UNII-QZV11V7G6A; QZV11V7G6A; Zicronapine [USAN:INN]; Zicronapine (USAN/INN); SCHEMBL904402; CHEMBL3039528; DTXSID30168849; Lu31-130; AKOS032946690; DB12188; 4-((1R,3S)-6-Chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine; LU-31130; D10329; Piperazine, 4-((1R,3S)-6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl)-1,2,2-trimethyl-
DMP8ESD CP Lundbeck
DMP8ESD DT Small molecular drug
DMP8ESD PC 11465618
DMP8ESD MW 354.9
DMP8ESD FM C22H27ClN2
DMP8ESD IC InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
DMP8ESD CS CC1(CN(CCN1C)[C@@H]2C[C@H](C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C
DMP8ESD IK BYPMJBXPNZMNQD-PZJWPPBQSA-N
DMP8ESD IU 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
DMP8ESD CA CAS 170381-16-5
DMP8ESD DE Schizophrenia
DM09TVB ID DM09TVB
DM09TVB DN Zimura
DM09TVB HS Phase 3
DM09TVB SN ARC-1905
DM09TVB CP Ophthotech Corp
DM09TVB DT Oligonucleotide
DM09TVB DE Macular degeneration
DMFWMKZ ID DMFWMKZ
DMFWMKZ DN ZK-93423
DMFWMKZ HS Phase 3
DMFWMKZ SN ZK 93423; 83910-44-5; ZK93423; ZK 93 423; 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-6-(phenylmethoxy)-, ethyl ester; ALBKMJDFBZVHAK-UHFFFAOYSA-N; PDSP1_001754; AC1L3TNV; AC1Q64YI; CHEMBL10947; GTPL4346; SCHEMBL7117282; CHEMBL1518572; BDBM85039; CHEBI:92593; ZINC5857871; PDSP2_001737; PDSP1_001771; ethyl 6-(benzyloxy)-4-(methoxymethyl)-9h-; BDBM50007553; PDSP2_001754; CAS_121926; NSC_121926
DMFWMKZ DT Small molecular drug
DMFWMKZ PC 121926
DMFWMKZ MW 390.4
DMFWMKZ FM C23H22N2O4
DMFWMKZ IC InChI=1S/C23H22N2O4/c1-3-28-23(26)22-18(14-27-2)21-17-11-16(29-13-15-7-5-4-6-8-15)9-10-19(17)25-20(21)12-24-22/h4-12,25H,3,13-14H2,1-2H3
DMFWMKZ CS CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4
DMFWMKZ IK ALBKMJDFBZVHAK-UHFFFAOYSA-N
DMFWMKZ IU ethyl 4-(methoxymethyl)-6-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMFWMKZ CA CAS 83910-44-5
DMFWMKZ CB CHEBI:92593
DMFWMKZ DE Epileptic seizures
DM5ST9Z ID DM5ST9Z
DM5ST9Z DN Zolbetuximab
DM5ST9Z HS Phase 3
DM5ST9Z SN IMAB362
DM5ST9Z CP Astellas Pharma
DM5ST9Z DT Antibody
DM5ST9Z DE Pancreatic cancer; Gastric adenocarcinoma; Esophagogastric junction neoplasm
DM8L7JD ID DM8L7JD
DM8L7JD DN Zoniporide hydrochloride
DM8L7JD HS Phase 3
DM8L7JD SN CP-597396; EMD-392426; Zoniporide hydrochloride < Prop INNM; N''-[5-Cyclopropyl-1-(5-quinolyl)-1H-pyrazol-4-ylcarbonyl]guanidine hydrochloride monohydrate
DM8L7JD DT Small molecular drug
DM8L7JD PC 11962997
DM8L7JD MW 356.8
DM8L7JD FM C17H17ClN6O
DM8L7JD IC InChI=1S/C17H16N6O.ClH/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);1H
DM8L7JD CS C1CC1C2=C(C=NN2C3=CC=CC4=C3C=CC=N4)C(=O)N=C(N)N.Cl
DM8L7JD IK JTEXNYIOROVPIR-UHFFFAOYSA-N
DM8L7JD IU 5-cyclopropyl-N-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide;hydrochloride
DM8L7JD CA CAS 241800-97-5
DM8L7JD DE Angina pectoris
DMMBJYC ID DMMBJYC
DMMBJYC DN ZYH-1
DMMBJYC HS Phase 3
DMMBJYC SN Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
DMMBJYC CP Zydus-Cadila Group
DMMBJYC DE Lipid metabolism disorder
DM12UX6 ID DM12UX6
DM12UX6 DN 131 I-omburtamab
DM12UX6 HS Phase 2/3
DM12UX6 CP Y-mAbs Therapeutics
DM12UX6 DT Antibody
DM12UX6 DE Neuroblastoma; Brain and central nervous system tumour
DMZ0T24 ID DMZ0T24
DMZ0T24 DN Abagovomab
DMZ0T24 HS Phase 2/3
DMZ0T24 CP Menarini
DMZ0T24 DT Monoclonal antibody
DMZ0T24 DE Ovarian cancer
DMKY9GI ID DMKY9GI
DMKY9GI DN Activated recombinant FVII-albumin fusion protein
DMKY9GI HS Phase 2/3
DMKY9GI SN CSL-689; Activated recombinant FVII-albumin fusion protein (hemophilia); Activated recombinant FVII-albumin fusion protein (hemophilia), CSL Behring; RVIIa-FP (hemophilia), CSL Behring; Recombinant factor VIIa/human albumin fusion protein (hemophilia), CSL Behring
DMKY9GI CP Csl behring
DMKY9GI DE Hemophilia
DM6GTMD ID DM6GTMD
DM6GTMD DN ADX-48621
DM6GTMD HS Phase 2/3
DM6GTMD SN Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621
DM6GTMD CP Addex Pharma.
DM6GTMD DT Small molecular drug
DM6GTMD PC 44557636
DM6GTMD MW 265.28
DM6GTMD FM C16H12FN3
DM6GTMD IC InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
DM6GTMD CS C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F
DM6GTMD IK LZXMUJCJAWVHPZ-UHFFFAOYSA-N
DM6GTMD IU 6-fluoro-2-(4-pyridin-2-ylbut-3-ynyl)imidazo[1,2-a]pyridine
DM6GTMD CA CAS 872363-17-2
DM6GTMD DE Mood disorder; Dyskinesia; Parkinson disease
DMMHSLC ID DMMHSLC
DMMHSLC DN Afq056
DMMHSLC HS Phase 2/3
DMMHSLC SN Mavoglurant
DMMHSLC CP Novartis
DMMHSLC DT Small molecular drug
DMMHSLC PC 9926832
DMMHSLC MW 313.4
DMMHSLC FM C19H23NO3
DMMHSLC IC InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
DMMHSLC CS CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
DMMHSLC IK ZFPZEYHRWGMJCV-ZHALLVOQSA-N
DMMHSLC IU methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
DMMHSLC CA CAS 543906-09-8
DMMHSLC DE Fragile X syndrome
DMGC970 ID DMGC970
DMGC970 DN AG-013
DMGC970 HS Phase 2/3
DMGC970 SN ActoBiotic (oral mucositis), ActoGenix; TFF-producing Lactococci lactis (mucositis), ActoGenix/VIB/University of Ghent; Trefoil factor producing micro-organisms (TopAct, oral, mucositis), ActoGenix
DMGC970 CP Flanders Interuniversity Institute for Biotechnology (VIB)
DMGC970 DE Oral mucositis
DMD741P ID DMD741P
DMD741P DN Alagebrium chloride
DMD741P HS Phase 2/3
DMD741P SN PTB; Tetrazolium chloride; ALT-711; ALT-766; N-phenacylthiazolium bromide; Advanced glycosylation end product (AGE)breakers, Alteon; Advanced glycosylation end product (AGE) breakers, Synvista
DMD741P CP Synvista Therapeutics Inc
DMD741P DT Small molecular drug
DMD741P PC 216306
DMD741P MW 267.77
DMD741P FM C13H14ClNOS
DMD741P IC InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1
DMD741P CS CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C.[Cl-]
DMD741P IK MKOMESMZHZNBIZ-UHFFFAOYSA-M
DMD741P IU 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;chloride
DMD741P CA CAS 341028-37-3
DMD741P DE Hypotension
DM36HBS ID DM36HBS
DM36HBS DN ALXN1101
DM36HBS HS Phase 2/3
DM36HBS CP Alexion pharmaceuticals
DM36HBS DE Molybdenum cofactor deficiency
DMBFOAZ ID DMBFOAZ
DMBFOAZ DN AMG520
DMBFOAZ HS Phase 2/3
DMBFOAZ SN CNP520
DMBFOAZ CP Amgen Thousand Oaks, CA Novartis East Hanover, NJ
DMBFOAZ DE Alzheimer disease
DMN6F1W ID DMN6F1W
DMN6F1W DN Amiodarone
DMN6F1W HS Phase 2/3
DMN6F1W SN amiodarone; 1951-25-3; Cordarone; Amiodarona; Amiodaronum; Amjodaronum; Amiodaronum [INN-Latin]; Amiodarona [INN-Spanish]; Pacerone; L 3428; L-3428; UNII-N3RQ532IUT; C25H29I2NO3; SKF 33134-A; EINECS 217-772-1; CHEMBL633; BRN 1271711; N3RQ532; Amiodarone
DMN6F1W TC Antiviral Agents
DMN6F1W DT Small molecular drug
DMN6F1W PC 2157
DMN6F1W MW 645.3
DMN6F1W FM C25H29I2NO3
DMN6F1W IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMN6F1W CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMN6F1W IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMN6F1W IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMN6F1W CA CAS 1951-25-3
DMN6F1W CB CHEBI:2663
DMN6F1W DE Coronavirus Disease 2019 (COVID-19)
DMJRU3A ID DMJRU3A
DMJRU3A DN AMO-02
DMJRU3A HS Phase 2/3
DMJRU3A CP AMO Pharma Berwyn, PA
DMJRU3A DE Myotonic dystrophy
DMDLGRO ID DMDLGRO
DMDLGRO DN Aramchol
DMDLGRO HS Phase 2/3
DMDLGRO SN Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed
DMDLGRO CP Galmed Medical Research Ltd
DMDLGRO DT Small molecular drug
DMDLGRO PC 18738120
DMDLGRO MW 702.1
DMDLGRO FM C44H79NO5
DMDLGRO IC InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
DMDLGRO CS CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C
DMDLGRO IK SHKXZIQNFMOPBS-OOMQYRRCSA-N
DMDLGRO IU (4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMDLGRO CA CAS 246529-22-6
DMDLGRO DE Lipid metabolism disorder
DMS8QF9 ID DMS8QF9
DMS8QF9 DN Arimoclomol
DMS8QF9 HS Phase 2/3
DMS8QF9 SN BRX-345
DMS8QF9 CP Biorex Research and Development Co
DMS8QF9 DT Small molecular drug
DMS8QF9 PC 9568077
DMS8QF9 MW 313.78
DMS8QF9 FM C14H20ClN3O3
DMS8QF9 IC InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14-/t13-/m1/s1
DMS8QF9 CS C1CCN(CC1)C[C@H](CO/N=C(/C2=C[N+](=CC=C2)[O-])\\Cl)O
DMS8QF9 IK SGEIEGAXKLMUIZ-XUVDNFPMSA-N
DMS8QF9 IU (3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride
DMS8QF9 CA CAS 289893-25-0
DMS8QF9 DE Cerebrovascular ischaemia; Inclusion body myositis
DM15VBJ ID DM15VBJ
DM15VBJ DN Artemisone
DM15VBJ HS Phase 2/3
DM15VBJ SN Artemifone; Artemisone, Medicines For Malaria Venture; MMV-00/1007; Artemisinin derviative, Bayer/WHO/Hong Kong University; Artemisone, Bayer/WHO/Hong Kong University; Semi-synthetic endoperoxide, Bayer/WHO/Hong Kong University
DM15VBJ CP Hong Kong University of Science & Technology
DM15VBJ DT Small molecular drug
DM15VBJ PC 11531457
DM15VBJ MW 401.5
DM15VBJ FM C19H31NO6S
DM15VBJ IC InChI=1S/C19H31NO6S/c1-12-4-5-15-13(2)16(20-8-10-27(21,22)11-9-20)23-17-19(15)14(12)6-7-18(3,24-17)25-26-19/h12-17H,4-11H2,1-3H3/t12-,13-,14+,15+,16-,17-,18-,19-/m1/s1
DM15VBJ CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)N5CCS(=O)(=O)CC5)C
DM15VBJ IK FDMUNKXWYMSZIR-NQWKWHCYSA-N
DM15VBJ IU 4-[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]-1,4-thiazinane 1,1-dioxide
DM15VBJ CA CAS 255730-18-8
DM15VBJ DE Malaria
DMZGKXW ID DMZGKXW
DMZGKXW DN Atogepant
DMZGKXW HS Phase 2/3
DMZGKXW SN UNII-7CRV8RR151; 7CRV8RR151; AGN-241689; MK-8031; 1374248-81-3; Atogepant [INN]; Atogepant [WHO-DD]; Atogepant [USAN:INN]; SCHEMBL4570348; GTPL9730; CHEMBL3991065; example 4 [US20120122911]; Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3'S)-; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1
DMZGKXW CP Allergan Parsippany, NJ
DMZGKXW PC 72163100
DMZGKXW MW 603.5
DMZGKXW FM C29H23F6N5O3
DMZGKXW IC InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
DMZGKXW CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F
DMZGKXW IK QIVUCLWGARAQIO-OLIXTKCUSA-N
DMZGKXW IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DMZGKXW CA CAS 1374248-81-3
DMZGKXW DE Migraine
DMVB4OS ID DMVB4OS
DMVB4OS DN AVN 211
DMVB4OS HS Phase 2/3
DMVB4OS CP Avineuro Pharmaceuticals
DMVB4OS DE Schizophrenia
DM5YHU2 ID DM5YHU2
DM5YHU2 DN Avoralstat
DM5YHU2 HS Phase 2/3
DM5YHU2 SN TUWMKPVJGGWGNL-UHFFFAOYSA-N; UNII-UX17773O15; UX17773O15; 918407-35-9; Avoralstat [INN]; 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid; SCHEMBL17513082; AKOS030629101; DB12120; CS-7551; 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-met
DM5YHU2 CP BioCryst Pharmaceuticals Durham, NC
DM5YHU2 PC 86566678
DM5YHU2 MW 513.5
DM5YHU2 FM C28H27N5O5
DM5YHU2 IC InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37)
DM5YHU2 CS COC1=CC(=C(C=C1C=C)C(=O)NC2=CC=C(C=C2)C(=N)N)C3=C(N=C(C=C3)C(=O)NCC4CC4)C(=O)O
DM5YHU2 IK TUWMKPVJGGWGNL-UHFFFAOYSA-N
DM5YHU2 IU 3-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl]-6-(cyclopropylmethylcarbamoyl)pyridine-2-carboxylic acid
DM5YHU2 CA CAS 918407-35-9
DM5YHU2 DE Hereditary angioedema
DMJQHXD ID DMJQHXD
DMJQHXD DN AZD3293
DMJQHXD HS Phase 2/3
DMJQHXD SN CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099
DMJQHXD CP AstraZeneca
DMJQHXD DT Small molecular drug
DMJQHXD PC 57404290
DMJQHXD MW 412.5
DMJQHXD FM C26H28N4O
DMJQHXD IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)
DMJQHXD CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMJQHXD IK WKDNQONLGXOZRG-UHFFFAOYSA-N
DMJQHXD DE Alzheimer disease
DM3827C ID DM3827C
DM3827C DN AZD4547
DM3827C HS Phase 2/3
DM3827C SN AZD4547; 1035270-39-3; AZD-4547; AZD 4547; UNII-2167OG1EKJ; 2167OG1EKJ; CHEBI:63453; KB-74810; N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-rel-3,5-dimethylpiperazin-1-yl)benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(cis-3,5-dimethylpiperazin-1-yl)benzamide; rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C CP AstraZeneca
DM3827C DT Small molecular drug
DM3827C PC 51039095
DM3827C MW 463.6
DM3827C FM C26H33N5O3
DM3827C IC InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
DM3827C CS C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
DM3827C IK VRQMAABPASPXMW-HDICACEKSA-N
DM3827C IU N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C CA CAS 1035270-39-3
DM3827C CB CHEBI:63453
DM3827C DE Solid tumour/cancer
DMHWE5R ID DMHWE5R
DMHWE5R DN Batabulin
DMHWE5R HS Phase 2/3
DMHWE5R SN T-138067; T-138068; T-67
DMHWE5R CP Tularik Inc
DMHWE5R DT Small molecular drug
DMHWE5R PC 216324
DMHWE5R MW 371.26
DMHWE5R FM C13H7F6NO3S
DMHWE5R IC InChI=1S/C13H7F6NO3S/c1-23-7-3-2-5(4-6(7)14)20-24(21,22)13-11(18)9(16)8(15)10(17)12(13)19/h2-4,20H,1H3
DMHWE5R CS COC1=C(C=C(C=C1)NS(=O)(=O)C2=C(C(=C(C(=C2F)F)F)F)F)F
DMHWE5R IK ROZCIVXTLACYNY-UHFFFAOYSA-N
DMHWE5R IU 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide
DMHWE5R CA CAS 195533-53-0
DMHWE5R DE Solid tumour/cancer
DMKT16N ID DMKT16N
DMKT16N DN Bevacizumab
DMKT16N HS Phase 2/3
DMKT16N SN Bevacizumab (ophthalmic slow-release tissue tablet); Avastin
DMKT16N TC Antiviral Agents
DMKT16N DT Monoclonal antibody
DMKT16N DE Metastatic colorectal cancer; Coronavirus Disease 2019 (COVID-19)
DMUSJ3D ID DMUSJ3D
DMUSJ3D DN BIIB-088
DMUSJ3D HS Phase 2/3
DMUSJ3D SN AGTC 501
DMUSJ3D CP Applied Genetic Technologies
DMUSJ3D DT Gene therapy
DMUSJ3D DE Retinitis pigmentosa
DMYFQJL ID DMYFQJL
DMYFQJL DN BNV-222
DMYFQJL HS Phase 2/3
DMYFQJL SN Diepalrestat choline; UNII-16AHE7410O; 16AHE7410O; CHEMBL4297277; Q27251797; 1665300-21-9; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate (1:1:1)
DMYFQJL CP BioNevia Pharmaceuticals
DMYFQJL DT Small molecular drug
DMYFQJL PC 117587644
DMYFQJL MW 742
DMYFQJL FM C35H39N3O7S4
DMYFQJL IC InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;
DMYFQJL CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O.C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)[O-].C[N+](C)(C)CCO
DMYFQJL IK WKSNHZZSMLFYFI-UROVXFGGSA-M
DMYFQJL IU 2-hydroxyethyl(trimethyl)azanium;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetate;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DMYFQJL CA CAS 1665300-21-9
DMYFQJL DE Diabetic neuropathy
DMV52CP ID DMV52CP
DMV52CP DN Bucindolol
DMV52CP HS Phase 2/3
DMV52CP SN Bucindolol; 71119-11-4; Bucindolol [INN:BAN]; Bucindololum [INN-Latin]; CHEMBL321582; C22H25N3O2; NCGC00167817-01; 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile; DSSTox_RID_81872; DSSTox_CID_26744; DSSTox_GSID_46744; Bucindololum; 2-[2-Hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile; Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-; 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
DMV52CP DT Small molecular drug
DMV52CP PC 51045
DMV52CP MW 363.5
DMV52CP FM C22H25N3O2
DMV52CP IC InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
DMV52CP CS CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
DMV52CP IK FBMYKMYQHCBIGU-UHFFFAOYSA-N
DMV52CP IU 2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
DMV52CP CA CAS 71119-11-4
DMV52CP DE Hypertension; Atrial fibrillation
DM31VZT ID DM31VZT
DM31VZT DN CAD-106
DM31VZT HS Phase 2/3
DM31VZT SN Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis
DM31VZT CP Cytos Biotechnology AG
DM31VZT DT Vaccine
DM31VZT DE Alzheimer disease
DMVLXMG ID DMVLXMG
DMVLXMG DN Camostat mesylate
DMVLXMG HS Phase 2/3
DMVLXMG SN Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164
DMVLXMG TC Antiviral Agents
DMVLXMG DT Small molecular drug
DMVLXMG PC 5284360
DMVLXMG MW 494.5
DMVLXMG FM C21H26N4O8S
DMVLXMG IC InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
DMVLXMG CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O
DMVLXMG IK FSEKIHNIDBATFG-UHFFFAOYSA-N
DMVLXMG IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
DMVLXMG CA CAS 59721-29-8
DMVLXMG CB CHEBI:31347
DMVLXMG DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMST3FM ID DMST3FM
DMST3FM DN CART-19
DMST3FM HS Phase 2/3
DMST3FM CP Fujian Medical University
DMST3FM DT CAR T Cell Therapy
DMST3FM DE Acute lymphoblastic leukaemia
DM45Z3P ID DM45Z3P
DM45Z3P DN CD123/CLL1 CAR-T Cells
DM45Z3P HS Phase 2/3
DM45Z3P CP Fujian Medical University
DM45Z3P DT CAR T Cell Therapy (Dual specific)
DM45Z3P DE Acute myeloid leukaemia
DM32148 ID DM32148
DM32148 DN CD19 CAR T cells
DM32148 HS Phase 2/3
DM32148 CP Fujian Medical University
DM32148 DT CAR T Cell Therapy
DM32148 DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMFCLT6 ID DMFCLT6
DMFCLT6 DN CE-224535
DMFCLT6 HS Phase 2/3
DMFCLT6 SN CP-23575
DMFCLT6 CP Pfizer Inc
DMFCLT6 DT Small molecular drug
DMFCLT6 PC 11547499
DMFCLT6 MW 480.9
DMFCLT6 FM C22H29ClN4O6
DMFCLT6 IC InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1
DMFCLT6 CS COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O
DMFCLT6 IK FUCKCIVGBCBZNP-MRXNPFEDSA-N
DMFCLT6 IU 2-chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide
DMFCLT6 CA CAS 724424-43-5
DMFCLT6 DE Arthralgia
DMXCD69 ID DMXCD69
DMXCD69 DN CEP1347
DMXCD69 HS Phase 2/3
DMXCD69 SN AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403
DMXCD69 DT Small molecular drug
DMXCD69 PC 9917013
DMXCD69 MW 615.8
DMXCD69 FM C33H33N3O5S2
DMXCD69 IC InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1
DMXCD69 CS CCSCC1=CC2=C(C=C1)N3[C@H]4C[C@@]([C@](O4)(N5C6=C(C=C(C=C6)CSCC)C7=C8CNC(=O)C8=C2C3=C75)C)(C(=O)OC)O
DMXCD69 IK SCMLRESZJCKCTC-KMYQRJGFSA-N
DMXCD69 IU methyl (15S,16R,18R)-10,23-bis(ethylsulfanylmethyl)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboxylate
DMXCD69 CA CAS 156177-65-0
DMXCD69 DE Asthma
DMUOMBZ ID DMUOMBZ
DMUOMBZ DN CLL1 CAR-T Cell
DMUOMBZ HS Phase 2/3
DMUOMBZ CP Fujian Medical University
DMUOMBZ DT CAR T Cell Therapy (Dual specific)
DMUOMBZ DE Acute myeloid leukaemia
DMX9V8K ID DMX9V8K
DMX9V8K DN Contigoside B
DMX9V8K HS Phase 2/3
DMX9V8K SN Isoquercitrin; Isoquercetin; 482-35-9; Hirsutrin; 3-Glucosylquercetin; Glucosyl 3-quercetin; Quercetin 3-glucoside; Quercetol 3-glucoside; Quercetin 3-o-glucopyranoside; Quercetin 3-D-glucoside; Quercetol 3-monoglucoside; Quercetin 3-monoglucoside; Isotrifoliin; Quercetin 3-beta-glucoside; Quercetin 3-O-glucoside; quercetin-3-glucoside; Quercetin 3-beta-O-glucoside; Quercetin-3-O-glucopyranoside; UNII-6HN2PC637T; quercetin-3-O-glucoside; NSC 115918; BRN 0100989; CHEMBL250450; 6HN2PC637T; CHEBI:68352; quercetin 3-O-beta-D-glucopyran
DMX9V8K DT Small molecular drug
DMX9V8K PC 5280804
DMX9V8K MW 464.4
DMX9V8K FM C21H20O12
DMX9V8K IC InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15-,17+,18-,21+/m1/s1
DMX9V8K CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
DMX9V8K IK OVSQVDMCBVZWGM-QSOFNFLRSA-N
DMX9V8K IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMX9V8K CA CAS 482-35-9
DMX9V8K CB CHEBI:68352
DMX9V8K DE Thrombosis
DMJYTUQ ID DMJYTUQ
DMJYTUQ DN CR-845
DMJYTUQ HS Phase 2/3
DMJYTUQ SN Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring
DMJYTUQ CP Cara Therapeutics Inc; cara therapeutics
DMJYTUQ DE Pain; Chronic pain
DMSR7D2 ID DMSR7D2
DMSR7D2 DN CX-516
DMSR7D2 HS Phase 2/3
DMSR7D2 SN Ampalex; BDP 12; CX 516; CX516; BDP-12; SPD-420; Piperidin-1-yl(quinoxalin-6-yl)methanone; 1-(6-Quinoxalinylcarbonyl)piperidine; 1-(6-quinoxalinylcarbonyl)-Piperidine; 1-(quinoxalin-6-ylcarbonyl)piperidine; 6-(piperidin-1-ylcarbonyl)quinoxaline
DMSR7D2 CP Cortex
DMSR7D2 DT Small molecular drug
DMSR7D2 PC 148184
DMSR7D2 MW 241.29
DMSR7D2 FM C14H15N3O
DMSR7D2 IC InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
DMSR7D2 CS C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2
DMSR7D2 IK ANDGGVOPIJEHOF-UHFFFAOYSA-N
DMSR7D2 IU piperidin-1-yl(quinoxalin-6-yl)methanone
DMSR7D2 CA CAS 154235-83-3
DMSR7D2 CB CHEBI:34605
DMSR7D2 DE Pervasive developmental disorder; Schizophrenia
DML906E ID DML906E
DML906E DN CY-1503
DML906E HS Phase 2/3
DML906E SN Cylexin
DML906E CP Epimmune Inc
DML906E DE Hypertension
DMYVKM5 ID DMYVKM5
DMYVKM5 DN Darbufelone
DMYVKM5 HS Phase 2/3
DMYVKM5 SN PD-136095
DMYVKM5 CP Parke-Davis & Co
DMYVKM5 DT Small molecular drug
DMYVKM5 PC 6444826
DMYVKM5 MW 332.5
DMYVKM5 FM C18H24N2O2S
DMYVKM5 IC InChI=1S/C18H24N2O2S/c1-17(2,3)11-7-10(8-12(14(11)21)18(4,5)6)9-13-15(22)20-16(19)23-13/h7-9,21H,1-6H3,(H2,19,20,22)/b13-9-
DMYVKM5 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N=C(S2)N
DMYVKM5 IK AKTXOQVMWSFEBQ-LCYFTJDESA-N
DMYVKM5 IU (5Z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one
DMYVKM5 CA CAS 139226-28-1
DMYVKM5 DE Asthma
DMZV3SY ID DMZV3SY
DMZV3SY DN Denagliptin
DMZV3SY HS Phase 2/3
DMZV3SY SN GW 823093; GW823093; (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoro-pyrrolidine-2-carbonitrile
DMZV3SY CP Glaxo Smithkline
DMZV3SY DT Small molecular drug
DMZV3SY PC 9887755
DMZV3SY MW 373.4
DMZV3SY FM C20H18F3N3O
DMZV3SY IC InChI=1S/C20H18F3N3O/c21-14-5-1-12(2-6-14)18(13-3-7-15(22)8-4-13)19(25)20(27)26-11-16(23)9-17(26)10-24/h1-8,16-19H,9,11,25H2/t16-,17-,19-/m0/s1
DMZV3SY CS C1[C@@H](CN([C@@H]1C#N)C(=O)[C@H](C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)N)F
DMZV3SY IK URRAHSMDPCMOTH-LNLFQRSKSA-N
DMZV3SY IU (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile
DMZV3SY CA CAS 483369-58-0
DMZV3SY DE Type-2 diabetes
DMVSIN2 ID DMVSIN2
DMVSIN2 DN Emapalumab
DMVSIN2 HS Phase 2/3
DMVSIN2 SN emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501
DMVSIN2 TC Antiviral Agents
DMVSIN2 DT Monoclonal antibody
DMVSIN2 DE Coronavirus Disease 2019 (COVID-19)
DMH8VMP ID DMH8VMP
DMH8VMP DN Emixustat
DMH8VMP HS Phase 2/3
DMH8VMP SN EMIXUSTAT; UNII-02DZ1HBF0M; 1141777-14-1; 02DZ1HBF0M; Emixustat [USAN:INN]; (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol; Incemixustat; ACU 4229; A3V; Emixustat (USAN); SCHEMBL966515; CHEMBL2107821; DTXSID50150665; WJIGGYYSZBWCGC-MRXNPFEDSA-N; ZINC59126886; AKOS032945088; CS-6177; DB12608; HY-19720; D10348; (r)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol; 3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1(R)-ol hydro -chloride
DMH8VMP CP Acucela Seattle, WA
DMH8VMP DT Small molecular drug
DMH8VMP PC 25221720
DMH8VMP MW 263.37
DMH8VMP FM C16H25NO2
DMH8VMP IC InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1
DMH8VMP CS C1CCC(CC1)COC2=CC=CC(=C2)[C@@H](CCN)O
DMH8VMP IK WJIGGYYSZBWCGC-MRXNPFEDSA-N
DMH8VMP IU (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol
DMH8VMP CA CAS 1141777-14-1
DMH8VMP DE Age-related macular degeneration; Proliferative diabetic retinopathy
DMOYE70 ID DMOYE70
DMOYE70 DN Fexinidazole
DMOYE70 HS Phase 2/3
DMOYE70 SN Fexinidazole (human African trypanosomiasis); Fexinidazole (African sleeping sickness), Drugs for Neglected Diseases initiative; Fexinidazole (HAT), Drugs for Neglected Diseases initiative; Fexinidazole (human African trypanosomiasis), Drugs for Neglected Diseases initiative
DMOYE70 CP Drugs for Neglected Diseases initiative
DMOYE70 DT Small molecular drug
DMOYE70 PC 68792
DMOYE70 MW 279.32
DMOYE70 FM C12H13N3O3S
DMOYE70 IC InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3
DMOYE70 CS CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-]
DMOYE70 IK MIWWSGDADVMLTG-UHFFFAOYSA-N
DMOYE70 IU 1-methyl-2-[(4-methylsulfanylphenoxy)methyl]-5-nitroimidazole
DMOYE70 CA CAS 59729-37-2
DMOYE70 DE Trypanosomiasis
DMH7CSQ ID DMH7CSQ
DMH7CSQ DN Gavilimomab
DMH7CSQ HS Phase 2/3
DMH7CSQ SN ABX-CBL; CBL-1
DMH7CSQ CP Abgenix Inc
DMH7CSQ DT Antibody
DMH7CSQ DE Graft-versus-host disease
DM0JETC ID DM0JETC
DM0JETC DN Genistein
DM0JETC HS Phase 2/3
DM0JETC SN Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC CP DSM Nutritional Products
DM0JETC DT Small molecular drug
DM0JETC PC 5280961
DM0JETC MW 270.24
DM0JETC FM C15H10O5
DM0JETC IC InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
DM0JETC CS C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
DM0JETC IK TZBJGXHYKVUXJN-UHFFFAOYSA-N
DM0JETC IU 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC CA CAS 446-72-0
DM0JETC CB CHEBI:28088
DM0JETC DE Prostate cancer; Menopause symptom
DMW7TZV ID DMW7TZV
DMW7TZV DN GS-6207
DMW7TZV HS Phase 2/3
DMW7TZV SN 2189684-45-3; N-[(1R)-1-[3-[4-Chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV CP Gilead Sciences
DMW7TZV DT Small molecular drug
DMW7TZV PC 138059678
DMW7TZV MW 958.3
DMW7TZV FM C41H36ClF8N7O5S2
DMW7TZV IC InChI=1S/C41H36ClF8N7O5S2/c1-40(2,63(3,59)60)11-10-22-4-7-24(25-8-9-28(42)33-36(25)56(17-30(45)46)54-39(33)55-64(61,62)23-5-6-23)34(51-22)29(14-19-12-20(43)15-21(44)13-19)52-31(58)18-57-37-32(35(53-57)38(47)48)26-16-27(26)41(37,49)50/h4,7-9,12-13,15,23,26-27,29-30,38H,5-6,14,16-18H2,1-3H3,(H,52,58)(H,54,55)/t26-,27+,29-/m1/s1
DMW7TZV CS CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)F)NS(=O)(=O)C4CC4)[C@@H](CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C([C@@H]8C[C@@H]8C7(F)F)C(=N6)C(F)F)S(=O)(=O)C
DMW7TZV IK CPCUUUACFKQOHY-IUAQSZDVSA-N
DMW7TZV IU N-[(1R)-1-[3-[4-chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV DE Human immunodeficiency virus infection
DMMTL7V ID DMMTL7V
DMMTL7V DN Hemoglobin raffimer
DMMTL7V HS Phase 2/3
DMMTL7V SN Hemolink; Cross-linked hemoglobin, Hemosol
DMMTL7V CP Ontario Inc
DMMTL7V DE Anemia
DMPLQ1V ID DMPLQ1V
DMPLQ1V DN IFX-1
DMPLQ1V HS Phase 2/3
DMPLQ1V SN IFX-1 mab
DMPLQ1V TC Antiviral Agents
DMPLQ1V DT Monoclonal antibody
DMPLQ1V DE Coronavirus Disease 2019 (COVID-19)
DMONWJ4 ID DMONWJ4
DMONWJ4 DN Imetelstat
DMONWJ4 HS Phase 2/3
DMONWJ4 SN Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448
DMONWJ4 CP Geron
DMONWJ4 DT Small molecular drug
DMONWJ4 PC 71587831
DMONWJ4 MW 4610
DMONWJ4 FM C148H211N68O53P13S13
DMONWJ4 IC InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)/t69?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,270?,271?,272?,273?,274?,275?,276?,277?,278?,279?,280?,281?,282?/m0/s1
DMONWJ4 CS CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OC[C@@H]9[C@H](C[C@@H](O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)N)S)O
DMONWJ4 IK LVZYXEALRXBLJZ-ISQYCPACSA-N
DMONWJ4 IU N-[3-[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-amino-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-sulfanylphosphoryl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2-hydroxypropyl]hexadecanamide
DMONWJ4 CA CAS 868169-64-6
DMONWJ4 DE Multiple myeloma; Breast cancer; Non-small-cell lung cancer; Essential thrombocythemia; Myelodysplastic syndrome; Myelofibrosis
DMIUA3M ID DMIUA3M
DMIUA3M DN Imprime PGG
DMIUA3M HS Phase 2/3
DMIUA3M SN Imprime PGG (TN)
DMIUA3M CP Biothera
DMIUA3M DE Breast cancer; Colorectal cancer; Head and neck cancer; Melanoma; Non-hodgkin lymphoma
DM5UJ9P ID DM5UJ9P
DM5UJ9P DN IMU-838
DM5UJ9P HS Phase 2/3
DM5UJ9P SN Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus
DM5UJ9P TC Antiviral Agents
DM5UJ9P DT Small molecular drug
DM5UJ9P PC 9820008
DM5UJ9P MW 355.4
DM5UJ9P FM C20H18FNO4
DM5UJ9P IC InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
DM5UJ9P CS COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
DM5UJ9P IK XPRDUGXOWVXZLL-UHFFFAOYSA-N
DM5UJ9P IU 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
DM5UJ9P CA CAS 717824-30-1
DM5UJ9P DE Coronavirus Disease 2019 (COVID-19)
DMC3794 ID DMC3794
DMC3794 DN Indium-111
DMC3794 HS Phase 2/3
DMC3794 SN ABT-806
DMC3794 CP Abbott Laboratories Abbott
DMC3794 DT Antibody
DMC3794 DE Solid tumour/cancer
DMGPJ5U ID DMGPJ5U
DMGPJ5U DN JNJ-54861911
DMGPJ5U HS Phase 2/3
DMGPJ5U CP Janssen research & development
DMGPJ5U PC 68254185
DMGPJ5U MW 367.4
DMGPJ5U FM C18H14FN5OS
DMGPJ5U IC InChI=1S/C18H14FN5OS/c1-18(6-7-26-17(21)24-18)13-8-12(3-4-14(13)19)23-16(25)15-5-2-11(9-20)10-22-15/h2-8,10H,1H3,(H2,21,24)(H,23,25)/t18-/m0/s1
DMGPJ5U CS C[C@]1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMGPJ5U IK VLLFGVHGKLDDLW-SFHVURJKSA-N
DMGPJ5U IU N-[3-[(4S)-2-amino-4-methyl-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMGPJ5U CA CAS 1200493-78-2
DMGPJ5U DE Alzheimer disease
DMBJ4IZ ID DMBJ4IZ
DMBJ4IZ DN LECOZOTAN HYDROCHLORIDE
DMBJ4IZ HS Phase 2/3
DMBJ4IZ SN Lecozotan hydrochloride < USAN; SRA-333; 4-Cyano-N-[2(R)-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-(2-pyridyl)benzamide hydrochloride
DMBJ4IZ DT Small molecular drug
DMBJ4IZ PC 11156648
DMBJ4IZ MW 520
DMBJ4IZ FM C28H30ClN5O3
DMBJ4IZ IC InChI=1S/C28H29N5O3.ClH/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23;/h2-12,21H,13-18,20H2,1H3;1H/t21-;/m1./s1
DMBJ4IZ CS C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5.Cl
DMBJ4IZ IK GXYZREDEYDFJPT-ZMBIFBSDSA-N
DMBJ4IZ IU 4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride
DMBJ4IZ CA CAS 433282-68-9
DMBJ4IZ DE Cognitive impairment
DMEUGZL ID DMEUGZL
DMEUGZL DN Legumain-cleavable doxorubicin prodrugs
DMEUGZL HS Phase 2/3
DMEUGZL SN Legubicin; LEG-2; LEG-3; Legumain-cleavable doxorubicin prodrugs (cancer); Legumain-cleavabledoxorubicin prodrugs (cancer), Affinity Pharmaceuticals
DMEUGZL CP Scripps Research Institute
DMEUGZL DE Solid tumour/cancer
DM4OYXE ID DM4OYXE
DM4OYXE DN LIAROZOLE
DM4OYXE HS Phase 2/3
DM4OYXE SN Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277
DM4OYXE DT Small molecular drug
DM4OYXE PC 60652
DM4OYXE MW 308.8
DM4OYXE FM C17H13ClN4
DM4OYXE IC InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
DM4OYXE CS C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
DM4OYXE IK UGFHIPBXIWJXNA-UHFFFAOYSA-N
DM4OYXE IU 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole
DM4OYXE CA CAS 115575-11-6
DM4OYXE CB CHEBI:135316
DM4OYXE DE Dermatological disease
DMI215P ID DMI215P
DMI215P DN Lopinavir + ritonavir + interferon beta-1b
DMI215P HS Phase 2/3
DMI215P SN Aluviran + norvir + betaseron
DMI215P TC Antiviral Agents
DMI215P DT Combination drug
DMI215P DE Middle East Respiratory Syndrome (MERS)
DMP8HW1 ID DMP8HW1
DMP8HW1 DN LY2157299
DMP8HW1 HS Phase 2/3
DMP8HW1 SN Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1 CP Eli Lilly
DMP8HW1 DT Small molecular drug
DMP8HW1 PC 10090485
DMP8HW1 MW 369.4
DMP8HW1 FM C22H19N5O
DMP8HW1 IC InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
DMP8HW1 CS CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N
DMP8HW1 IK IVRXNBXKWIJUQB-UHFFFAOYSA-N
DMP8HW1 IU 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1 CA CAS 700874-72-2
DMP8HW1 CB CHEBI:137064
DMP8HW1 DE Arteriosclerosis; Glioma; Hepatocellular carcinoma; Pancreatic cancer; Solid tumour/cancer; Non-small-cell lung cancer
DMUQWRD ID DMUQWRD
DMUQWRD DN LYS-SAF302
DMUQWRD HS Phase 2/3
DMUQWRD SN SRP-9002
DMUQWRD CP Lysogene; Sarepta Therapeutics
DMUQWRD DT Gene therapy
DMUQWRD DE Mucopolysaccharidosis
DM948AP ID DM948AP
DM948AP DN MAb114
DM948AP HS Phase 2/3
DM948AP CP Ridgeback Biotherapeutics
DM948AP DT Antibody
DM948AP DE Ebola virus infection
DMONYS9 ID DMONYS9
DMONYS9 DN MBX-102
DMONYS9 HS Phase 2/3
DMONYS9 SN Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV
DMONYS9 CP Metabolex
DMONYS9 DT Small molecular drug
DMONYS9 PC 12082259
DMONYS9 MW 415.8
DMONYS9 FM C19H17ClF3NO4
DMONYS9 IC InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1
DMONYS9 CS CC(=O)NCCOC(=O)[C@@H](C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
DMONYS9 IK BJBCSGQLZQGGIQ-QGZVFWFLSA-N
DMONYS9 IU 2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate
DMONYS9 CA CAS 24136-23-0
DMONYS9 DE Gout
DMNTCV4 ID DMNTCV4
DMNTCV4 DN MBX-8025
DMNTCV4 HS Phase 2/3
DMNTCV4 SN Ppar; A agonist 2; SCHEMBL4950228; CHEMBL3545019; XJHXZGHPCAKRFK-UHFFFAOYSA-N; HY-100120; CS-0018099; {2-Methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid
DMNTCV4 CP Metabolex
DMNTCV4 DT Small molecular drug
DMNTCV4 PC 11236126
DMNTCV4 MW 444.5
DMNTCV4 FM C21H23F3O5S
DMNTCV4 IC InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
DMNTCV4 CS CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
DMNTCV4 IK JWHYSEDOYMYMNM-QGZVFWFLSA-N
DMNTCV4 IU 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
DMNTCV4 CA CAS 851528-79-5
DMNTCV4 DE Obesity; Familial hypercholesterolemia; Primary biliary cholangitis
DMBIO6E ID DMBIO6E
DMBIO6E DN Meclinertant
DMBIO6E HS Phase 2/3
DMBIO6E SN Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E CP Sanofi-aventis
DMBIO6E TC Anticancer Agents
DMBIO6E DT Small molecular drug
DMBIO6E PC 119192
DMBIO6E MW 587.1
DMBIO6E FM C32H31ClN4O5
DMBIO6E IC InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)
DMBIO6E CS COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
DMBIO6E IK DYLJVOXRWLXDIG-UHFFFAOYSA-N
DMBIO6E IU 2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E CA CAS 146362-70-1
DMBIO6E CB CHEBI:125516
DMBIO6E DE Inflammatory bowel disease
DMFE0P1 ID DMFE0P1
DMFE0P1 DN Metformin glycinate
DMFE0P1 HS Phase 2/3
DMFE0P1 SN DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes
DMFE0P1 CP Laboratorios Silanes SA De CV
DMFE0P1 DT Small molecular drug
DMFE0P1 PC 44520175
DMFE0P1 MW 204.23
DMFE0P1 FM C6H16N6O2
DMFE0P1 IC InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5)
DMFE0P1 CS CN(C)C(=N)N=C(N)N.C(C(=O)O)N
DMFE0P1 IK KOFRCHIVYXPUNL-UHFFFAOYSA-N
DMFE0P1 IU 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine
DMFE0P1 CA CAS 121369-64-0
DMFE0P1 DE Type-2 diabetes
DM752PU ID DM752PU
DM752PU DN MGCD516
DM752PU HS Phase 2/3
DM752PU SN Sitravatinib
DM752PU CP Mirati therapeutics
DM752PU PC 25212148
DM752PU MW 629.7
DM752PU FM C33H29F2N5O4S
DM752PU IC InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
DM752PU CS COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DM752PU IK WLAVZAAODLTUSW-UHFFFAOYSA-N
DM752PU IU 1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DM752PU CA CAS 1123837-84-2
DM752PU DE Non-small-cell lung cancer; Solid tumour/cancer; Breast cancer
DM2YNMI ID DM2YNMI
DM2YNMI DN MK-1654
DM2YNMI HS Phase 2/3
DM2YNMI CP Merck
DM2YNMI DT Antibody
DM2YNMI DE Respiratory syncytial virus infection
DMDQOWT ID DMDQOWT
DMDQOWT DN MOR-208
DMDQOWT HS Phase 2/3
DMDQOWT SN XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
DMDQOWT CP Morphosys
DMDQOWT DT Antibody
DMDQOWT DE Autoimmune diabetes; Diffuse large B-cell lymphoma; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DMKMZW2 ID DMKMZW2
DMKMZW2 DN MTC-DOX
DMKMZW2 HS Phase 2/3
DMKMZW2 SN MTC-doxorubicin
DMKMZW2 CP FeRx
DMKMZW2 DE Liver cancer
DM16PWF ID DM16PWF
DM16PWF DN N1-methylnicotinamide
DM16PWF HS Phase 2/3
DM16PWF SN Trigonellinamide; 1-methylnicotinamide; N(1)-Methylnicotinamide; N1-Methylnicotinamide; 3-(Aminocarbonyl)-1-methylpyridinium; 1-Methyl nicotinamide; 3-carbamoyl-1-methylpyridinium; 3106-60-3; Pyridinium, 3-carbamoyl-1-methyl-; UNII-UM47085BXC; N(sup 1)-Methylnicotinamide; 3-carbamoyl-1-methylpyridin-1-ium; BRN 3540351; 1-methylpyridine-3-carboxamide; UM47085BXC; CHEBI:16797; 1-methylpyridin-1-ium-3-carboxamide; CHEMBL1209652; Trigonellamide; Pyridinium, 3-(aminocarbonyl)-1-methyl-; 1-methyl-3-carbamoylpyridinium; 8GC; I-methyl n
DM16PWF DT Small molecular drug
DM16PWF PC 457
DM16PWF MW 137.16
DM16PWF FM C7H9N2O+
DM16PWF IC InChI=1S/C7H8N2O/c1-9-4-2-3-6(5-9)7(8)10/h2-5H,1H3,(H-,8,10)/p+1
DM16PWF CS C[N+]1=CC=CC(=C1)C(=O)N
DM16PWF IK LDHMAVIPBRSVRG-UHFFFAOYSA-O
DM16PWF IU 1-methylpyridin-1-ium-3-carboxamide
DM16PWF CA CAS 3106-60-3
DM16PWF CB CHEBI:16797
DM16PWF DE Hyperlipidemia
DM8D6O2 ID DM8D6O2
DM8D6O2 DN Nafamostat
DM8D6O2 HS Phase 2/3
DM8D6O2 SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DM8D6O2 TC Antiviral Agents
DM8D6O2 DT Small molecular drug
DM8D6O2 PC 4413
DM8D6O2 MW 347.4
DM8D6O2 FM C19H17N5O2
DM8D6O2 IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DM8D6O2 CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DM8D6O2 IK MQQNFDZXWVTQEH-UHFFFAOYSA-N
DM8D6O2 IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DM8D6O2 CA CAS 81525-10-2
DM8D6O2 CB CHEBI:135466
DM8D6O2 DE Pancreatitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS)
DMD5AEB ID DMD5AEB
DMD5AEB DN NAL-GLU
DMD5AEB HS Phase 2/3
DMD5AEB SN [Ac-D2Nal1,D4ClPhe2,D3Pal3,Arg5,DGlu5(anisole adduct),DAla10]-GnRH; Acetyl-D-2-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-arginyl-[4-(4-methoxybenzoyl)-D-2-aminobutyryl]-L-leucyl-L-arginyl-L-prolyl-D-alanylamide; N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-arginyl-5-(4-methoxyphenyl)-5-oxo-D-norvalyl-L-leucyl-L-arginyl-L-prolyl-D-alanylamide
DMD5AEB PC 44412112
DMD5AEB MW 343.4
DMD5AEB FM C18H21N3O4
DMD5AEB IC InChI=1S/C18H21N3O4/c19-14(17(23)21-15(18(24)25)7-8-16(20)22)10-11-5-6-12-3-1-2-4-13(12)9-11/h1-6,9,14-15H,7-8,10,19H2,(H2,20,22)(H,21,23)(H,24,25)/t14-,15-/m0/s1
DMD5AEB CS C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMD5AEB IK VSZVSSYQFUFEQG-GJZGRUSLSA-N
DMD5AEB IU (2S)-5-amino-2-[[(2S)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid
DMD5AEB DE Prostate cancer
DM901ZW ID DM901ZW
DM901ZW DN Naptumomab estafenatox
DM901ZW HS Phase 2/3
DM901ZW CP Active Biotech
DM901ZW DE Solid tumour/cancer
DM3MJUS ID DM3MJUS
DM3MJUS DN NBTX-001
DM3MJUS HS Phase 2/3
DM3MJUS CP Nobilis Therapeutics Portland, OR
DM3MJUS DE Panic disorder; Post-traumatic stress disorder
DM0798Z ID DM0798Z
DM0798Z DN NLG8189
DM0798Z HS Phase 2/3
DM0798Z SN 1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
DM0798Z CP NewLink Genetics
DM0798Z DT Small molecular drug
DM0798Z PC 405012
DM0798Z MW 218.25
DM0798Z FM C12H14N2O2
DM0798Z IC InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
DM0798Z CS CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)O)N
DM0798Z IK ZADWXFSZEAPBJS-SNVBAGLBSA-N
DM0798Z IU (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid
DM0798Z CA CAS 110117-83-4
DM0798Z DE Acute myeloid leukaemia; Melanoma; Brain cancer; Pancreatic cancer; Prostate cancer
DM4H78P ID DM4H78P
DM4H78P DN NT-501
DM4H78P HS Phase 2/3
DM4H78P SN NTC-201E; CNTF cell implant (ECT), Neurotech; CNTF ophthalmic cell implant (retinitis pigmentosa), Neurotech; Cell implant (ciliary neurotrophic factor), Neurotech; Cell implant (retinitis pigmentosa, ECT), Neurotech
DM4H78P CP Amgen Inc
DM4H78P DE Ocular inflammation; Macular telangiectasia type 2; Retinitis pigmentosa
DMT13UA ID DMT13UA
DMT13UA DN Olokizumab
DMT13UA HS Phase 2/3
DMT13UA SN OLOKIZUMAB; CHEMBL1743050; CDP-6038
DMT13UA TC Antiviral Agents
DMT13UA DT Monoclonal antibody
DMT13UA DE Coronavirus Disease 2019 (COVID-19)
DMTIESG ID DMTIESG
DMTIESG DN Omburtamab
DMTIESG HS Phase 2/3
DMTIESG CP Y-mAbs Therapeutics
DMTIESG DT Antibody
DMTIESG DE Neuroblastoma
DMPDA17 ID DMPDA17
DMPDA17 DN Omburtamab I-131
DMPDA17 HS Phase 2/3
DMPDA17 CP Y-mAbs Therapeutics New York, NY
DMPDA17 DE Small round cell desmoplastic tumour; Neuroblastoma
DMCA2PJ ID DMCA2PJ
DMCA2PJ DN ONO-2506
DMCA2PJ HS Phase 2/3
DMCA2PJ SN (2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO; Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175
DMCA2PJ CP Ono Pharmaceuticals
DMCA2PJ DT Small molecular drug
DMCA2PJ PC 208925
DMCA2PJ MW 186.29
DMCA2PJ FM C11H22O2
DMCA2PJ IC InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1
DMCA2PJ CS CCCCCC[C@@H](CCC)C(=O)O
DMCA2PJ IK YCYMCMYLORLIJX-SNVBAGLBSA-N
DMCA2PJ IU (2R)-2-propyloctanoic acid
DMCA2PJ CA CAS 185517-21-9
DMCA2PJ DE Stroke; Type-2 diabetes
DMCTRLN ID DMCTRLN
DMCTRLN DN OT-101
DMCTRLN HS Phase 2/3
DMCTRLN CP Mateon/Oncotelic
DMCTRLN DT Antisense oligonucleotide
DMCTRLN DE Melanoma; Merkel cell carcinoma; Pancreatic cancer; Recurrent glioblastoma; Coronavirus Disease 2019 (COVID-19)
DMURH4X ID DMURH4X
DMURH4X DN Oxypurinol
DMURH4X HS Phase 2/3
DMURH4X SN Oxypurinol (intravenous)
DMURH4X CP Johns Hopkins University
DMURH4X DT Small molecular drug
DMURH4X PC 135398752
DMURH4X MW 152.11
DMURH4X FM C5H4N4O2
DMURH4X IC InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)
DMURH4X CS C1=NNC2=C1C(=O)NC(=O)N2
DMURH4X IK HXNFUBHNUDHIGC-UHFFFAOYSA-N
DMURH4X IU 1,7-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione
DMURH4X CA CAS 2465-59-0
DMURH4X CB CHEBI:28315
DMURH4X DE Heart failure
DM0NZDT ID DM0NZDT
DM0NZDT DN Pactimibe
DM0NZDT HS Phase 2/3
DM0NZDT SN Pactimibe; 189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309
DM0NZDT DT Small molecular drug
DM0NZDT PC 3081927
DM0NZDT MW 416.6
DM0NZDT FM C25H40N2O3
DM0NZDT IC InChI=1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29)
DM0NZDT CS CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C
DM0NZDT IK TXIIZHHIOHVWJD-UHFFFAOYSA-N
DM0NZDT IU 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid
DM0NZDT CA CAS 189198-30-9
DM0NZDT DE Arteriosclerosis
DMRZ1F2 ID DMRZ1F2
DMRZ1F2 DN Padsevonil
DMRZ1F2 HS Phase 2/3
DMRZ1F2 SN 1294000-61-5; UNII-0R1HN52K0N; UCB0942; UCB1415943-000; (R)-4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one; Padsevonil [INN]; Padsevonil [USAN]; Padsevonil (JAN/USAN); SCHEMBL1672843; CHEMBL4297521; UCB-0942; WHO 10384; DB14977; SB18725; HY-109009; CS-0030507; D11842; Q27237119; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)-
DMRZ1F2 CP UCB
DMRZ1F2 DT Small molecular drug
DMRZ1F2 PC 52911611
DMRZ1F2 MW 432.8
DMRZ1F2 FM C14H14ClF5N4O2S
DMRZ1F2 IC InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1
DMRZ1F2 CS COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
DMRZ1F2 IK DCXFIOLWWRXEQH-SSDOTTSWSA-N
DMRZ1F2 IU (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
DMRZ1F2 CA CAS 1294000-61-5
DMRZ1F2 DE Epilepsy
DMHWY2G ID DMHWY2G
DMHWY2G DN Pagoclone
DMHWY2G HS Phase 2/3
DMHWY2G SN IP-456; RP-59037; RP-62955
DMHWY2G CP Rhone-Poulenc SA
DMHWY2G DT Small molecular drug
DMHWY2G PC 131664
DMHWY2G MW 407.9
DMHWY2G FM C23H22ClN3O2
DMHWY2G IC InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3
DMHWY2G CS CC(C)CCC(=O)CC1C2=CC=CC=C2C(=O)N1C3=NC4=C(C=C3)C=CC(=N4)Cl
DMHWY2G IK HIUPRQPBWVEQJJ-UHFFFAOYSA-N
DMHWY2G IU 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one
DMHWY2G CA CAS 133737-32-3
DMHWY2G DE Anxiety disorder
DMBJ15R ID DMBJ15R
DMBJ15R DN Pexacerfont
DMBJ15R HS Phase 2/3
DMBJ15R SN PEXACERFONT; 459856-18-9; UNII-LF1VBG4ZUK; CRF1 ANTAGONIST; LF1VBG4ZUK; BMS-562086; Pexacerfont [USAN:INN]; BMS 562086; Pexacerfont (USAN/INN); CHEMBL482950; SCHEMBL5235999; BDBM29490; DTXSID60196675; CS-6630; DB12572; HY-12127; D10022; Pyrazolo[1,5-a]-1,3,5-triazine, 13-15; BMS562086;BMS 562086;BMS-562086; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-((1R)-1-methylpropyl)-
DMBJ15R CP Bristol-Myers Squibb
DMBJ15R DT Small molecular drug
DMBJ15R PC 9884366
DMBJ15R MW 340.4
DMBJ15R FM C18H24N6O
DMBJ15R IC InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1
DMBJ15R CS CC[C@@H](C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C
DMBJ15R IK LBWQSAZEYIZZCE-SNVBAGLBSA-N
DMBJ15R IU N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMBJ15R CA CAS 459856-18-9
DMBJ15R DE Anxiety disorder
DMYKNME ID DMYKNME
DMYKNME DN PF-06651600
DMYKNME HS Phase 2/3
DMYKNME SN CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME CP Pfizer New York, NY
DMYKNME PC 118115473
DMYKNME MW 285.34
DMYKNME FM C15H19N5O
DMYKNME IC InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
DMYKNME CS C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
DMYKNME IK CBRJPFGIXUFMTM-WDEREUQCSA-N
DMYKNME IU 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME CA CAS 1792180-81-4
DMYKNME DE Asthma; Crohn disease; Alopecia
DM1QSM3 ID DM1QSM3
DM1QSM3 DN Phenol
DM1QSM3 HS Phase 2/3
DM1QSM3 SN carbolic acid; 108-95-2; Hydroxybenzene; Phenic acid; Oxybenzene; Phenylic acid; Benzenol; Phenyl hydrate; Monophenol; Phenyl hydroxide; Phenylic alcohol; PhOH; Monohydroxybenzene; Phenole; Paoscle; Phenyl alcohol; Phenol alcohol; Izal; Phenol, liquefied; Acide carbolique; Fenolo; Phenosmolin; Fenosmoline; Fenosmolin; Carbolsaure; Fenol; Liquid phenol; Carbolic oil; Phenol, pure; Phenol homopolymer; Phenole [German]; Fenolo [Italian]; Benzene, hydroxy-; Rcra waste number U188; Campho-Phenique Gel; Phenic; Carbolsaure [German]
DM1QSM3 DT Small molecular drug
DM1QSM3 PC 996
DM1QSM3 MW 94.11
DM1QSM3 FM C6H6O
DM1QSM3 IC InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H
DM1QSM3 CS C1=CC=C(C=C1)O
DM1QSM3 IK ISWSIDIOOBJBQZ-UHFFFAOYSA-N
DM1QSM3 IU phenol
DM1QSM3 CA CAS 108-95-2
DM1QSM3 CB CHEBI:15882
DM1SV8I ID DM1SV8I
DM1SV8I DN PHN-131
DM1SV8I HS Phase 2/3
DM1SV8I SN NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h
DM1SV8I CP PhytoHealth Corp
DM1SV8I DT Small molecular drug
DM1SV8I PC 5360733
DM1SV8I MW 393.9
DM1SV8I FM C21H28ClNO4
DM1SV8I IC InChI=1S/C21H27NO4.ClH/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12;/h4-5,12,15-16,19,23-25H,1-3,6-11H2;1H/t15-,16+,19-,20-,21+;/m0./s1
DM1SV8I CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl
DM1SV8I IK YZLZPSJXMWGIFH-BCXQGASESA-N
DM1SV8I IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
DM1SV8I CA CAS 23277-43-2
DM1SV8I CB CHEBI:7455
DM1SV8I DE Pain
DMPWH30 ID DMPWH30
DMPWH30 DN Pimagedine HCl
DMPWH30 HS Phase 2/3
DMPWH30 CP Synvista Therapeutics
DMPWH30 DT Small molecular drug
DMPWH30 PC 85468708
DMPWH30 MW 110.55
DMPWH30 FM CH7ClN4
DMPWH30 IC InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H
DMPWH30 CS C(=[NH+]N)(N)N.[Cl-]
DMPWH30 IK UBDZFAGVPPMTIT-UHFFFAOYSA-N
DMPWH30 IU amino(diaminomethylidene)azanium;chloride
DMPWH30 CA CAS 16139-18-7
DMPWH30 DE Diabetic kidney disease
DM0EFQS ID DM0EFQS
DM0EFQS DN Plasminogen
DM0EFQS HS Phase 2/3
DM0EFQS CP Kedrion
DM0EFQS DE Alzheimer disease
DMCGK6X ID DMCGK6X
DMCGK6X DN PRO 140
DMCGK6X HS Phase 2/3
DMCGK6X CP CytoDyn
DMCGK6X DT Antibody
DMCGK6X DE Human immunodeficiency virus-1 infection
DMZI4OV ID DMZI4OV
DMZI4OV DN QLT-091001
DMZI4OV HS Phase 2/3
DMZI4OV SN Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY
DMZI4OV PC 638034
DMZI4OV MW 328.5
DMZI4OV FM C22H32O2
DMZI4OV IC QGNJRVVDBSJHIZ-QHLGVNSISA-N
DMZI4OV CS CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C
DMZI4OV IK 1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9+,18-14+
DMZI4OV IU [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] acetate
DMZI4OV CA CAS 127-47-9
DMZI4OV CB CHEBI:32095
DMZI4OV DE Barrett esophagus
DMB8UQ3 ID DMB8UQ3
DMB8UQ3 DN Ramatroban
DMB8UQ3 HS Phase 2/3
DMB8UQ3 SN 116649-85-5; Baynas; BAY u3405; Bay u-3405; Bay u 3406; Bay-u-3405; Bay u 3405; BAY-u 3405; UNII-P1ALI72U6C; C21H21FN2O4S; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; P1ALI72U6C; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; CHEMBL361812; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; NCGC00167519-01; EN-137774; DSSTox_RID_81819; Baynas (TN); Ramatroban (JAN/INN); [3H]ramatroban
DMB8UQ3 CP Bayer Yakuhin
DMB8UQ3 DT Small molecular drug
DMB8UQ3 PC 123879
DMB8UQ3 MW 416.5
DMB8UQ3 FM C21H21FN2O4S
DMB8UQ3 IC InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
DMB8UQ3 CS C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
DMB8UQ3 IK LDXDSHIEDAPSSA-OAHLLOKOSA-N
DMB8UQ3 IU 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
DMB8UQ3 CA CAS 116649-85-5
DMB8UQ3 CB CHEBI:32087
DMB8UQ3 DE Perennial allergic rhinitis
DM1LFUN ID DM1LFUN
DM1LFUN DN Ravidasvir
DM1LFUN HS Phase 2/3
DM1LFUN SN PPI-668 free base; UNII-AL3G001BI8; AL3G001BI8; 1242087-93-9; Methyl N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamate; Ravidasvir [USAN]; Ravidasvir free base; BL-238630; SCHEMBL7603463; CHEMBL3121849; SCHEMBL12075676; BDBM243443; methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; SB19743; Carbamic acid, N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-benzimidazol-6-yl)-2-naphthalenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester; Methyl N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)naphthalen-2-yl)-1H-benzimidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate; BI 238630; BI-238630; US9427428, 3; Q27273972; methyl ((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((s)-1-((s)-2-(5-(6-(2((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-4-yl)naphthalen-2-yl)-1h-benzo[d]imidazol-2-yl) pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
DM1LFUN CP Presidio Pharmaceuticals
DM1LFUN DT Small molecular drug
DM1LFUN PC 52918888
DM1LFUN MW 762.9
DM1LFUN FM C42H50N8O6
DM1LFUN IC InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
DM1LFUN CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM1LFUN IK LCHMHYPWGWYXEL-ZYADHFCISA-N
DM1LFUN IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM1LFUN CA CAS 1242087-93-9
DM1LFUN DE Hepatitis C
DML9FD4 ID DML9FD4
DML9FD4 DN Rinfabate
DML9FD4 HS Phase 2/3
DML9FD4 SN RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed
DML9FD4 CP Insmed Inc
DML9FD4 DE Solid tumour/cancer
DMWZ6DK ID DMWZ6DK
DMWZ6DK DN Roledumab
DMWZ6DK HS Phase 2/3
DMWZ6DK SN DMATRIA; LFB-R593; R-297; R-593; Anti-D human monoclonal antibody, Laboratoire Francais du Fractionnement et des Biotechnologies; R297 antibody (hematological disease), LFB; R297 antibody (hematological disease), Laboratoire Francais du Fractionnement et des Biotechnologies; Anti-RhD antibody (hematological disease), LFB; Anti-rhesus D mAB (hematological disease), LFB
DMWZ6DK CP LFB Biotechnologies
DMWZ6DK DT Antibody
DMWZ6DK DE Anemia
DMNIYSZ ID DMNIYSZ
DMNIYSZ DN RP101
DMNIYSZ HS Phase 2/3
DMNIYSZ SN SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
DMNIYSZ CP RESprotect
DMNIYSZ DT Small molecular drug
DMNIYSZ PC 446727
DMNIYSZ MW 333.13
DMNIYSZ FM C11H13BrN2O5
DMNIYSZ IC InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1
DMNIYSZ CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O
DMNIYSZ IK ODZBBRURCPAEIQ-PIXDULNESA-N
DMNIYSZ IU 5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMNIYSZ CA CAS 69304-47-8
DMNIYSZ DE Pancreatic cancer; Infectious disease
DMOJLCV ID DMOJLCV
DMOJLCV DN SAR164877
DMOJLCV HS Phase 2/3
DMOJLCV CP Sanofi-Aventis
DMOJLCV TC Analgesics
DMOJLCV DE Pain
DMH7IPW ID DMH7IPW
DMH7IPW DN Sarizotan
DMH7IPW HS Phase 2/3
DMH7IPW SN Sarizotan [INN]; EMD 128130; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW CP EMD Serono
DMH7IPW DT Small molecular drug
DMH7IPW PC 6918388
DMH7IPW MW 348.4
DMH7IPW FM C22H21FN2O
DMH7IPW IC InChI=1S/C22H21FN2O/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2/t21-/m1/s1
DMH7IPW CS C1CC2=CC=CC=C2O[C@H]1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F
DMH7IPW IK HKFMQJUJWSFOLY-OAQYLSRUSA-N
DMH7IPW IU 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW CA CAS 351862-32-3
DMH7IPW DE Parkinson disease; Rett syndrome
DM31L9K ID DM31L9K
DM31L9K DN Sepofarsen
DM31L9K HS Phase 2/3
DM31L9K SN QR-110
DM31L9K CP ProQR Therapeutics
DM31L9K DT Oligonucleotide
DM31L9K DE Leber congenital amaurosis
DMTV5XC ID DMTV5XC
DMTV5XC DN Sitafloxacin
DMTV5XC HS Phase 2/3
DMTV5XC SN Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid
DMTV5XC PC 461399
DMTV5XC MW 409.8
DMTV5XC FM C19H18ClF2N3O3
DMTV5XC IC InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
DMTV5XC CS C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F
DMTV5XC IK PNUZDKCDAWUEGK-CYZMBNFOSA-N
DMTV5XC IU 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
DMTV5XC CA CAS 127254-12-0
DMTV5XC CB CHEBI:4304
DMTV5XC DE Escherichia Coli Infections
DM30JWZ ID DM30JWZ
DM30JWZ DN SM04554
DM30JWZ HS Phase 2/3
DM30JWZ CP Samumed San Diego,CA
DM30JWZ DT Small molecular drug
DM30JWZ DE Alopecia
DMD9ISG ID DMD9ISG
DMD9ISG DN SM-88
DMD9ISG HS Phase 2/3
DMD9ISG CP Tyme Technologies New York, NY
DMD9ISG PC 3125
DMD9ISG MW 195.21
DMD9ISG FM C10H13NO3
DMD9ISG IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)
DMD9ISG CS CC(CC1=CC=C(C=C1)O)(C(=O)O)N
DMD9ISG IK NHTGHBARYWONDQ-UHFFFAOYSA-N
DMD9ISG IU 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMD9ISG CA CAS 658-48-0
DMD9ISG DE Prostate cancer; Pancreatic cancer
DM5WQ2U ID DM5WQ2U
DM5WQ2U DN SR-123781A
DM5WQ2U HS Phase 2/3
DM5WQ2U CP Sanofi-aventis
DM5WQ2U PC 145996625
DM5WQ2U MW 4854
DM5WQ2U FM C127H201Na19O134S17
DM5WQ2U IC InChI=1S/C127H220O134S17.19Na/c1-183-32-46-60(235-114-95(203-21)76(192-10)62(48(223-114)34-185-3)237-116-97(205-23)78(194-12)64(50(225-116)36-187-5)239-118-99(207-25)80(196-14)66(52(227-118)38-189-7)241-120-101(209-27)82(198-16)68(55(229-120)41-216-264(138,139)140)244-124-106(258-275(171,172)173)89(254-271(159,160)161)71(57(231-124)43-218-266(144,145)146)246-125-107(259-276(174,175)176)90(255-272(162,163)164)72(58(232-125)44-219-267(147,148)149)247-126-109(261-278(180,181)182)91(256-273(165,166)167)73(252-269(153,154)155)59(234-126)45-220-268(150,151)152)74(190-8)94(202-20)113(222-46)236-61-47(33-184-2)224-115(96(204-22)75(61)191-9)238-63-49(35-186-4)226-117(98(206-24)77(63)193-11)240-65-51(37-188-6)228-119(100(208-26)79(65)195-13)242-67-54(40-215-263(135,136)137)230-121(102(210-28)81(67)197-15)248-86-84(200-18)104(212-30)123(251-92(86)110(128)129)245-70-56(42-217-265(141,142)143)233-127(108(260-277(177,178)179)88(70)253-270(156,157)158)249-87-85(201-19)103(211-29)122(250-93(87)111(130)131)243-69-53(39-214-262(132,133)134)221-112(213-31)105(83(69)199-17)257-274(168,169)170;;;;;;;;;;;;;;;;;;;/h46-109,112-127H,32-45H2,1-31H3,(H,128,129)(H,130,131)(H,132,133,134)(H,135,136,137)(H,138,139,140)(H,141,142,143)(H,144,145,146)(H,147,148,149)(H,150,151,152)(H,153,154,155)(H,156,157,158)(H,159,160,161)(H,162,163,164)(H,165,166,167)(H,168,169,170)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67+,68-,69-,70-,71-,72-,73-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104-,105+,106-,107-,108-,109-,112+,113-,114+,115+,116+,117-,118+,119+,120-,121-,122-,123-,124+,125-,126-,127-;;;;;;;;;;;;;;;;;;;/m1.................../s1
DM5WQ2U CS COC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3OC)OC)O[C@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)[O-])O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]7[C@@H]([C@@H]([C@@H](O[C@H]7C(=O)[O-])O[C@@H]8[C@H](O[C@@H]([C@H]([C@H]8OC)OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])COC)COC)OC)OC)O[C@@H]9[C@@H]([C@H]([C@@H]([C@H](O9)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)OC)OC)OC)OC)OC)OC)OC)OC)OC.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM5WQ2U IK RRHHPXJSGSYSHW-ZURHXDBDSA-A
DM5WQ2U IU nonadecasodium;(2R,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5S,6R)-2-carboxylato-6-[(2R,3R,4S,5S,6S)-4,6-dimethoxy-5-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-3,4-disulfonatooxy-6-(sulfonatooxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-disulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylate
DM5WQ2U CA CAS 232602-93-6
DM5WQ2U DE Venous thrombosis
DMKGQF0 ID DMKGQF0
DMKGQF0 DN Suvodirsen
DMKGQF0 HS Phase 2/3
DMKGQF0 SN WVE-210201
DMKGQF0 CP Wave Life Sciences
DMKGQF0 DT Antisense oligonucleotide
DMKGQF0 DE Duchenne dystrophy
DMWE3GB ID DMWE3GB
DMWE3GB DN TG-4010
DMWE3GB HS Phase 2/3
DMWE3GB SN MVA-Muc1-IL-2; MVA-TG-9931 (frozen suspension); MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene
DMWE3GB CP Transgene
DMWE3GB DE Bipolar disorder; Non-small-cell lung cancer
DMVDTR2 ID DMVDTR2
DMVDTR2 DN Thymoquinone
DMVDTR2 HS Phase 2/3
DMVDTR2 SN 490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
DMVDTR2 DT Small molecular drug
DMVDTR2 PC 10281
DMVDTR2 MW 164.2
DMVDTR2 FM C10H12O2
DMVDTR2 IC InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
DMVDTR2 CS CC1=CC(=O)C(=CC1=O)C(C)C
DMVDTR2 IK KEQHJBNSCLWCAE-UHFFFAOYSA-N
DMVDTR2 IU 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione
DMVDTR2 CA CAS 490-91-5
DMVDTR2 CB CHEBI:113532
DMVDTR2 DE Polycystic ovarian syndrome
DM23ARP ID DM23ARP
DM23ARP DN V-710
DM23ARP HS Phase 2/3
DM23ARP SN Vaccine (Staphylococcus aureus), Intercell; Vaccine (Staphylococcus aureus), Merck & Co; Iron surface determinant B-based vaccine (Staphylococcus aureus infection), Merck & Co; IsdB-based vaccine (Staphylococcus aureus infection), Merck & Co
DM23ARP CP Intercell AG
DM23ARP DT Vaccine
DM23ARP DE Staphylococcus infection
DMDG8Q3 ID DMDG8Q3
DMDG8Q3 DN Varlitinib
DMDG8Q3 HS Phase 2/3
DMDG8Q3 SN VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3 CP ASLAN Pharmaceuticals
DMDG8Q3 DT Small molecular drug
DMDG8Q3 PC 42642648
DMDG8Q3 MW 466.9
DMDG8Q3 FM C22H19ClN6O2S
DMDG8Q3 IC InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1
DMDG8Q3 CS C[C@@H]1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl
DMDG8Q3 IK UWXSAYUXVSFDBQ-CYBMUJFWSA-N
DMDG8Q3 IU 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3 CA CAS 845272-21-1
DMDG8Q3 DE Breast cancer; Metastatic biliary tract neoplasms
DMTROUI ID DMTROUI
DMTROUI DN Vazegepant
DMTROUI HS Phase 2/3
DMTROUI SN UNII-ODU3ZAZ94J; ODU3ZAZ94J; BHV-3500; BDBM50436107
DMTROUI TC Antiviral Agents
DMTROUI DT Small molecular drug
DMTROUI PC 53472683
DMTROUI MW 638.8
DMTROUI FM C36H46N8O3
DMTROUI IC InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
DMTROUI CS CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
DMTROUI IK JJVAPHYEOZSKJZ-JGCGQSQUSA-N
DMTROUI IU N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide
DMTROUI CA CAS 1337918-83-8
DMTROUI DE Coronavirus Disease 2019 (COVID-19)
DMGKRAJ ID DMGKRAJ
DMGKRAJ DN VB4-845
DMGKRAJ HS Phase 2/3
DMGKRAJ CP Viventia Biotechnologies
DMGKRAJ DT Antibody
DMGKRAJ SQ 9045_H|oportuzumab monatox|||SCFV-KAPPA-HEAVY-TOXIN (V-KAPPA(7-118)+LINKER(119-144)+VH(145-260)+TOX-DOMAIN(281-637))|||||||647||||MW 69566.3|MW 69566.3|: HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRATPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL
DMGKRAJ DE Head and neck cancer
DM0ASTP ID DM0ASTP
DM0ASTP DN Verapamil
DM0ASTP HS Phase 2/3
DM0ASTP SN VERAPAMIL; Iproveratril; 52-53-9; Vasolan; Dilacoran; Isoptin; Falicard; Isoptine; Isoptimo; Finoptin; Calan; Verapamilo; Verapamilum; Verapamilum [INN-Latin]; Lekoptin; Verapamilo [INN-Spanish]; Isotopin; Calcan; Tarka; D-365; Securon; Verelan; Izoptin; Verapamil [USAN:INN:BAN]; CP-16533-1; Covera-HS; Verpamil; CCRIS 6749; Verelan PM; Isoptin SR; C; Verapamil
DM0ASTP TC Antiviral Agents
DM0ASTP DT Small molecular drug
DM0ASTP PC 2520
DM0ASTP MW 454.6
DM0ASTP FM C27H38N2O4
DM0ASTP IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DM0ASTP CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM0ASTP IK SGTNSNPWRIOYBX-UHFFFAOYSA-N
DM0ASTP IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM0ASTP CA CAS 52-53-9
DM0ASTP CB CHEBI:77733
DM0ASTP DE Coronavirus Disease 2019 (COVID-19)
DM4WQBO ID DM4WQBO
DM4WQBO DN VM-1500
DM4WQBO HS Phase 2/3
DM4WQBO SN VM-1500 (topical gel formulation, HIV infection)
DM4WQBO CP Viriom Ltd
DM4WQBO DE Human immunodeficiency virus infection
DM5G1NT ID DM5G1NT
DM5G1NT DN VX-210
DM5G1NT HS Phase 2/3
DM5G1NT SN BA-210; VX210
DM5G1NT CP Vertex Pharmaceuticals Boston, MA
DM5G1NT DE Spinal cord injury
DM2U3MX ID DM2U3MX
DM2U3MX DN VX-509
DM2U3MX HS Phase 2/3
DM2U3MX SN Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK
DM2U3MX CP Vertex Pharmaceuticals
DM2U3MX DT Small molecular drug
DM2U3MX PC 59422203
DM2U3MX MW 392.4
DM2U3MX FM C18H19F3N6O
DM2U3MX IC InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
DM2U3MX CS CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3
DM2U3MX IK ASUGUQWIHMTFJL-QGZVFWFLSA-N
DM2U3MX IU (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
DM2U3MX CA CAS 944842-54-0
DM2U3MX DE Rheumatoid arthritis
DMHXJ68 ID DMHXJ68
DMHXJ68 DN WVE-210201
DMHXJ68 HS Phase 2/3
DMHXJ68 CP WaVe Life Sciences Cambridge, MA
DMHXJ68 DE Duchenne dystrophy
DM78DOT ID DM78DOT
DM78DOT DN AllerB
DM78DOT HS Phase 2b
DM78DOT CP Anergis SA
DM78DOT DE Allergy
DMJM9LZ ID DMJM9LZ
DMJM9LZ DN LB80380
DMJM9LZ HS Phase 2b
DMJM9LZ SN LB80380; UNII-S9I9P4J8IU; LB 80380; S9I9P4J8IU; LB-80380; 441785-26-8; PMCDG dipivoxil; AC1O59EP; SCHEMBL4270816; CHEMBL1652128; ANA-380; DTXSID90196062; J3.616.617G; [[1-[(2-aminopurin-9-yl)methyl]cyclopropoxy]methyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; [({[(2-Aminopurin-9-yl)methyl]cyclopropoxy}methyl)[(2,2-dimethylpropanoyloxy)methoxy]carbonyloxy]methyl 2,2-dimethylpropanoate; 872968-04-2
DMJM9LZ CP LG Life Sciences
DMJM9LZ DT Small molecular drug
DMJM9LZ PC 6480442
DMJM9LZ MW 527.5
DMJM9LZ FM C22H34N5O8P
DMJM9LZ IC InChI=1S/C22H34N5O8P/c1-20(2,3)17(28)31-12-34-36(30,35-13-32-18(29)21(4,5)6)14-33-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26)
DMJM9LZ CS CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)CN2C=NC3=CN=C(N=C32)N)OCOC(=O)C(C)(C)C
DMJM9LZ IK JLKJXDOWBVVABZ-UHFFFAOYSA-N
DMJM9LZ IU [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMJM9LZ CA CAS 441785-26-8
DMJM9LZ DE Hepatitis B virus infection
DMXB4NL ID DMXB4NL
DMXB4NL DN MEDI4893
DMXB4NL HS Phase 2b
DMXB4NL CP AstraZeneca
DMXB4NL DT Antibody
DMXB4NL DE Hospital-acquired pneumonia; Ventilator-associated pneumonia
DMEARCM ID DMEARCM
DMEARCM DN OrM3
DMEARCM HS Phase 2b
DMEARCM CP Merck Research Laboratories
DMEARCM DE Chronic obstructive pulmonary disease
DMOE582 ID DMOE582
DMOE582 DN TZP-101
DMOE582 HS Phase 2b
DMOE582 SN Ulimorelin; TZP-101; TZP 101; UNII-LGI67MCW2S; 842131-33-3; LGI67MCW2S; CHEMBL1923502; Ulimorelin [USAN:INN]; Ulimorelin (USAN/INN); SCHEMBL804500; TZP101; GTPL3535; CHEMBL1963249; DTXSID00233139; BDBM50359256; DB12128; D09981; (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione; D-Phenylalanine, (2S)-N-((2R)-2-(2-(3-aminopropyl)phenoxy)propyl)-2- cyclopropylglycyl-N-methyl-D-alanyl-4-fluoro-, (3-1)-lactam
DMOE582 CP Tranzyme
DMOE582 DT Small molecular drug
DMOE582 PC 11526696
DMOE582 MW 538.7
DMOE582 FM C30H39FN4O4
DMOE582 IC InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1
DMOE582 CS C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4
DMOE582 IK WGYPAJVJMXQXTR-ABNZCKJZSA-N
DMOE582 IU (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
DMOE582 CA CAS 842131-33-3
DMOE582 DE Gastrointestinal disease; Gastroparesis; Ileus
DMUB8WN ID DMUB8WN
DMUB8WN DN Aerovant
DMUB8WN HS Phase 2a
DMUB8WN CP Aerovance
DMUB8WN DE Asthma
DMSC8YW ID DMSC8YW
DMSC8YW DN ANA773
DMSC8YW HS Phase 2a
DMSC8YW CP Anadys Pharmaceuticals
DMSC8YW DE Hepatitis C virus infection
DMJBDL0 ID DMJBDL0
DMJBDL0 DN BIIB104
DMJBDL0 HS Phase 2a
DMJBDL0 CP Biogen
DMJBDL0 DE Cognitive impairment
DM0TH9A ID DM0TH9A
DM0TH9A DN Bimosiamose
DM0TH9A HS Phase 2a
DM0TH9A SN TBC 1269; TBC-1269
DM0TH9A CP Encysive Pharma
DM0TH9A DT Small molecular drug
DM0TH9A PC 9811353
DM0TH9A MW 862.9
DM0TH9A FM C46H54O16
DM0TH9A IC InChI=1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
DM0TH9A CS C1=CC(=CC(=C1)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=CC(=C5)CC(=O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)CC(=O)O
DM0TH9A IK RYWCQJDEHXJHRI-XJMXIVSISA-N
DM0TH9A IU 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid
DM0TH9A CA CAS 187269-40-5
DM0TH9A DE Atopic dermatitis; Psoriatic disorder; Chronic obstructive pulmonary disease; Asthma
DMR6LXM ID DMR6LXM
DMR6LXM DN CAP-232
DMR6LXM HS Phase 2a
DMR6LXM SN TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01
DMR6LXM TC Anticancer Agents
DMR6LXM DT Small molecular drug
DMR6LXM PC 6918265
DMR6LXM MW 947.1
DMR6LXM FM C45H58N10O9S2
DMR6LXM IC InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
DMR6LXM CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)O
DMR6LXM IK SNAJPQVDGYDQSW-DYCFWDQMSA-N
DMR6LXM IU (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMR6LXM CA CAS 147159-51-1
DMR6LXM DE Pain; Renal cell carcinoma
DMLQ3PO ID DMLQ3PO
DMLQ3PO DN INCB13739
DMLQ3PO HS Phase 2a
DMLQ3PO SN Phenylarsine oxide; phenylarsine oxide; Oxophenylarsine; 637-03-6; Arzene; Phenylarsenoxide; Arsenosobenzene; ARSINE, OXOPHENYL-; Phenyl arsine oxide; Benzene, arsenoso-; arsorosobenzene; Fenylarsinoxid; Caswell No 060; Fenylarsinoxid [Czech]; C6H5AsO; Phenyl arsenoxide; UNII-0HUR2WY345; PAO; EINECS 211-275-3; NSC 42470; EPA Pesticide Chemical Code 007101; BRN 2935227; 0HUR2WY345; CHEBI:75253; MFCD00001990; Phenylarsine oxide, 97%; Phenylarsine Oxide Solution; oxo(phenyl)arsan; Phenylarsinoxyd; oxo(phenyl)arsine; oxo(phenyl)arsane; PhAsO; phenylarsenious
DMLQ3PO CP Incyte
DMLQ3PO DT Small molecular drug
DMLQ3PO PC 11502183
DMLQ3PO MW 398.9
DMLQ3PO FM C19H27ClN2O3S
DMLQ3PO IC InChI=1S/C19H27ClN2O3S/c1-14-17(20)10-5-11-18(14)26(24,25)22-12-6-7-15(13-22)19(23)21-16-8-3-2-4-9-16/h5,10-11,15-16H,2-4,6-9,12-13H2,1H3,(H,21,23)
DMLQ3PO CS CC1=C(C=CC=C1Cl)S(=O)(=O)N2CCCC(C2)C(=O)NC3CCCCC3
DMLQ3PO IK ODRPEKCTTLECBX-UHFFFAOYSA-N
DMLQ3PO IU 1-(3-chloro-2-methylphenyl)sulfonyl-N-cyclohexylpiperidine-3-carboxamide
DMLQ3PO DE Diabetic complication; Type-2 diabetes
DMMWC6F ID DMMWC6F
DMMWC6F DN INCB9471
DMMWC6F HS Phase 2a
DMMWC6F SN INCB-9471; UNII-C5D4W25708; INCB9471; CHEMBL1688243; INCB009471; C5D4W25708; INCB-009471; INCB 9471; INCB0 09471; 869769-98-2; SCHEMBL3676335; ZINC43171152; BDBM50339033; DB12960; 925701-76-4; Piperidine, 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-((3S)-4-((1R,2R)-2-ethoxy-2,3-dihydro-5-(trifluoromethyl)-1H-inden-1-yl)-3-methyl-1-piperazinyl)-4-methyl-; 5-((4-(4-(2-Ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine
DMMWC6F CP Incyte
DMMWC6F DT Small molecular drug
DMMWC6F PC 49871007
DMMWC6F MW 559.7
DMMWC6F FM C30H40F3N5O2
DMMWC6F IC InChI=1S/C30H40F3N5O2/c1-6-40-25-16-22-15-23(30(31,32)33)7-8-24(22)27(25)38-14-13-37(17-19(38)2)29(5)9-11-36(12-10-29)28(39)26-20(3)34-18-35-21(26)4/h7-8,15,18-19,25,27H,6,9-14,16-17H2,1-5H3/t19-,25+,27+/m0/s1
DMMWC6F CS CCO[C@@H]1CC2=C([C@H]1N3CCN(C[C@@H]3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F
DMMWC6F IK ZMCJFJZOSKEMOM-DNKZPPIMSA-N
DMMWC6F IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMWC6F CA CAS 869769-98-2
DMMWC6F DE Human immunodeficiency virus infection; Infectious disease
DMYZU6G ID DMYZU6G
DMYZU6G DN MEM-1003
DMYZU6G HS Phase 2a
DMYZU6G SN SCHEMBL1191960; SCHEMBL16332975
DMYZU6G CP Bayer
DMYZU6G DT Small molecular drug
DMYZU6G PC 9802887
DMYZU6G MW 432.9
DMYZU6G FM C22H25ClN2O5
DMYZU6G IC InChI=1S/C22H25ClN2O5/c1-12(2)30-22(27)18-14(4)25-13(3)17(21(26)29-10-9-28-5)19(18)16-8-6-7-15(11-24)20(16)23/h6-8,12,19,25H,9-10H2,1-5H3
DMYZU6G CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC(=C2Cl)C#N)C(=O)OCCOC
DMYZU6G IK GTIKSQYSAKETQA-UHFFFAOYSA-N
DMYZU6G IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 4-(2-chloro-3-cyanophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMYZU6G DE Dementia; Bipolar disorder
DMGM1IR ID DMGM1IR
DMGM1IR DN RhuDex
DMGM1IR HS Phase 2a
DMGM1IR CP MediGene AG
DMGM1IR DE Rheumatoid arthritis
DMKJDR6 ID DMKJDR6
DMKJDR6 DN VX-702
DMKJDR6 HS Phase 2a
DMKJDR6 SN ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6 CP Vertex Pharma
DMKJDR6 DT Small molecular drug
DMKJDR6 PC 10341154
DMKJDR6 MW 404.3
DMKJDR6 FM C19H12F4N4O2
DMKJDR6 IC InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
DMKJDR6 CS C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
DMKJDR6 IK FYSRKRZDBHOFAY-UHFFFAOYSA-N
DMKJDR6 IU 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6 CA CAS 745833-23-2
DMKJDR6 CB CHEBI:94489
DMKJDR6 DE Coronary artery disease; Rheumatoid arthritis; Inflammation
DMAV426 ID DMAV426
DMAV426 DN (S)-oxybutynin
DMAV426 HS Phase 2
DMAV426 CP Sepracor
DMAV426 PC 206530
DMAV426 MW 357.5
DMAV426 FM C22H31NO3
DMAV426 IC InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1
DMAV426 CS CCN(CC)CC#CCOC(=O)[C@](C1CCCCC1)(C2=CC=CC=C2)O
DMAV426 IK XIQVNETUBQGFHX-JOCHJYFZSA-N
DMAV426 IU 4-(diethylamino)but-2-ynyl (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate
DMAV426 CA CAS 119618-22-3
DMAV426 CB CHEBI:51329
DMAV426 DE Urinary incontinence
DMGDOS2 ID DMGDOS2
DMGDOS2 DN (Z)-endoxifen
DMGDOS2 HS Phase 2
DMGDOS2 SN Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645
DMGDOS2 PC 10090750
DMGDOS2 MW 373.5
DMGDOS2 FM C25H27NO2
DMGDOS2 IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMGDOS2 CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3
DMGDOS2 IK MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMGDOS2 IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMGDOS2 CA CAS 112093-28-4
DMGDOS2 CB CHEBI:80555
DMGDOS2 DE Breast cancer
DMV86DY ID DMV86DY
DMV86DY DN [131I]-BC8
DMV86DY HS Phase 2
DMV86DY DT Antibody
DMV86DY DE leukaemia
DM4VWXI ID DM4VWXI
DM4VWXI DN [131I]-Metuximab
DM4VWXI HS Phase 2
DM4VWXI CP Elsevier
DM4VWXI DT Antibody
DM4VWXI DE Liver cancer
DMSLMY7 ID DMSLMY7
DMSLMY7 DN 11C-PBR-28
DMSLMY7 HS Phase 2
DMSLMY7 SN Radiolabeled benzodiazepine receptor ligands, NIH; Carbon-11-PBR-101; Carbon-11-PBR-28; Fluorine-18-PBR-06; 11C-PBR-01; 18F-PBR-06
DMSLMY7 CP National Institutes of Health
DMSLMY7 PC 11653141
DMSLMY7 MW 347.4
DMSLMY7 FM C21H20N2O3
DMSLMY7 IC InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3/i2-1
DMSLMY7 CS CC(=O)N(CC1=CC=CC=C1O[11CH3])C2=C(C=CN=C2)OC3=CC=CC=C3
DMSLMY7 IK DHZBNHMEIOBPAE-JVVVGQRLSA-N
DMSLMY7 IU N-[(2-(111C)methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
DMSLMY7 CA CAS 1005325-43-8
DMSLMY7 DE Brain disease
DMTIED1 ID DMTIED1
DMTIED1 DN 131I-TM-601
DMTIED1 HS Phase 2
DMTIED1 SN Glioma therapy, Transmolecular; Solid tumor imaging, TransMolecular; TM-602; TM-603; TM-803; Toxin-based anticancers, Transmolecular; Iodine-131-TM-601
DMTIED1 CP TransMolecular Inc
DMTIED1 DE Glioma
DM4EP6Y ID DM4EP6Y
DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y HS Phase 2
DM4EP6Y SN GPX-100; (8R,10S)-10-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 13-Deoxydoxorubicin hydrochloride
DM4EP6Y CP Access Pharmaceuticals
DM4EP6Y PC 9829418
DM4EP6Y MW 566
DM4EP6Y FM C27H32ClNO10
DM4EP6Y IC InChI=1S/C27H31NO10.ClH/c1-11-22(30)14(28)8-17(37-11)38-16-10-27(35,6-7-29)9-13-19(16)26(34)21-20(24(13)32)23(31)12-4-3-5-15(36-2)18(12)25(21)33;/h3-5,11,14,16-17,22,29-30,32,34-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17-,22+,27-;/m0./s1
DM4EP6Y CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(CCO)O)N)O.Cl
DM4EP6Y IK YZSQITAPLDJGKS-RYQLBYGJSA-N
DM4EP6Y IU (7S,9R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
DM4EP6Y CA CAS 65360-29-4
DM4EP6Y DE Solid tumour/cancer
DMNF38S ID DMNF38S
DMNF38S DN 16,16-dimethyl-PGE2
DMNF38S HS Phase 2
DMNF38S SN 16,16-dimethylprostaglandin E2
DMNF38S DT Small molecular drug
DMNF38S PC 5283066
DMNF38S MW 380.5
DMNF38S FM C22H36O5
DMNF38S IC InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)/b8-6-,13-12+/t16-,17-,19-,20-/m1/s1
DMNF38S CS CCCCC(C)(C)[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMNF38S IK QAOBBBBDJSWHMU-WMBBNPMCSA-N
DMNF38S IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMNF38S CA CAS 39746-25-3
DMNF38S CB CHEBI:141046
DMNF38S DE Stem cell engraftment
DMT8GVU ID DMT8GVU
DMT8GVU DN 177Lu-DOTATATE
DMT8GVU HS Phase 2
DMT8GVU CP Advanced accelerator applications
DMT8GVU PC 76966897
DMT8GVU MW 1609.5
DMT8GVU FM C65H87LuN14O19S2
DMT8GVU IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMT8GVU CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMT8GVU IK MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMT8GVU IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMT8GVU CA CAS 437608-50-9
DMT8GVU DE Hepatitis C virus infection
DM2TSMD ID DM2TSMD
DM2TSMD DN 177Lu-labelled NeoBOMB1
DM2TSMD HS Phase 2
DM2TSMD CP Novartis/AAA
DM2TSMD DT Radiopharmaceutical therapy agent
DM2TSMD DE Solid tumour/cancer
DM8JVIB ID DM8JVIB
DM8JVIB DN 18F-LMI-1195
DM8JVIB HS Phase 2
DM8JVIB SN Flourine-18-LMI-1195; Fluorine-18-based PET imaging agent (intravenous, heart failure), Lantheus; 18F-based PET imaging agent (intravenous, heart failure), Lantheus
DM8JVIB CP Lantheus medical imaging
DM8JVIB DE Heart failure
DMZWNQF ID DMZWNQF
DMZWNQF DN 2'3'-Dideoxyinosine
DMZWNQF HS Phase 2
DMZWNQF DT Small molecular drug
DMZWNQF PC 16219192
DMBOL4K ID DMBOL4K
DMBOL4K DN 264W94
DMBOL4K HS Phase 2
DMBOL4K SN GW-264
DMBOL4K CP Glaxo Wellcome plc
DMBOL4K DT Small molecular drug
DMBOL4K PC 9823277
DMBOL4K MW 417.6
DMBOL4K FM C23H31NO4S
DMBOL4K IC InChI=1S/C23H31NO4S/c1-5-7-13-23(6-2)16-29(25,26)21-15-20(28-4)19(27-3)14-18(21)22(24-23)17-11-9-8-10-12-17/h8-12,14-15,22,24H,5-7,13,16H2,1-4H3/t22-,23-/m1/s1
DMBOL4K CS CCCC[C@@]1(CS(=O)(=O)C2=CC(=C(C=C2[C@H](N1)C3=CC=CC=C3)OC)OC)CC
DMBOL4K IK CKFWDLFFXXVSBJ-DHIUTWEWSA-N
DMBOL4K IU (3R,5R)-3-butyl-3-ethyl-7,8-dimethoxy-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepine 1,1-dioxide
DMBOL4K CA CAS 178259-25-1
DMBOL4K DE Hyperlipidaemia
DMGBPME ID DMGBPME
DMGBPME DN 2-Methoxyestradiol
DMGBPME HS Phase 2
DMGBPME SN ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
DMGBPME CP EntreMed
DMGBPME DT Small molecular drug
DMGBPME PC 66414
DMGBPME MW 302.4
DMGBPME FM C19H26O3
DMGBPME IC InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
DMGBPME CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O
DMGBPME IK CQOQDQWUFQDJMK-SSTWWWIQSA-N
DMGBPME IU (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMGBPME CA CAS 362-07-2
DMGBPME CB CHEBI:28955
DMGBPME DE Pulmonary arterial hypertension
DMX9MSL ID DMX9MSL
DMX9MSL DN 2X-121
DMX9MSL HS Phase 2
DMX9MSL CP 2X Oncology Cambridge, MA
DMX9MSL DE Breast cancer
DML8M5T ID DML8M5T
DML8M5T DN 3,5-diiodothyropropionic acid
DML8M5T HS Phase 2
DML8M5T SN DITPA)
DML8M5T CP Titan Pharmaceuticals
DML8M5T DT Small molecular drug
DML8M5T PC 160565
DML8M5T MW 510.06
DML8M5T FM C15H12I2O4
DML8M5T IC InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)
DML8M5T CS C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CCC(=O)O)I
DML8M5T IK WONYMNWUJVKVII-UHFFFAOYSA-N
DML8M5T IU 3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
DML8M5T CA CAS 1158-10-7
DML8M5T CB CHEBI:134267
DML8M5T DE Cardiovascular disease; Congestive heart failure
DMTLR6Y ID DMTLR6Y
DMTLR6Y DN 3K3A-APC
DMTLR6Y HS Phase 2
DMTLR6Y CP Zz biotech
DMTLR6Y DE Cerebrovascular ischaemia; Ischemic stroke
DMPFVJB ID DMPFVJB
DMPFVJB DN 5-hydroxymethyl-2-furfural
DMPFVJB HS Phase 2
DMPFVJB SN Aes-103; 5-HMF; 5-hydroxymethylfurfural
DMPFVJB CP Aesrx
DMPFVJB DT Small molecular drug
DMPFVJB PC 237332
DMPFVJB MW 126.11
DMPFVJB FM C6H6O3
DMPFVJB IC InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2
DMPFVJB CS C1=C(OC(=C1)C=O)CO
DMPFVJB IK NOEGNKMFWQHSLB-UHFFFAOYSA-N
DMPFVJB IU 5-(hydroxymethyl)furan-2-carbaldehyde
DMPFVJB CA 67-47-0
DMPFVJB DE Anemia
DMHBN8X ID DMHBN8X
DMHBN8X DN 60P002
DMHBN8X HS Phase 2
DMHBN8X CP 60 Degrees Pharmaceuticals
DMHBN8X DT Small molecular drug
DMHBN8X DE Dengue
DMOV0AP ID DMOV0AP
DMOV0AP DN 842166X
DMOV0AP HS Phase 2
DMOV0AP SN GW842166X; 666260-75-9; GW 842166X; GW-842166X; UNII-VL1I6P2DZ8; VL1I6P2DZ8; GW842166; GW 842166; CHEMBL225411; 2-((2,4-dichlorophenyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide; TWQYWUXBZHPIIV-UHFFFAOYSA-N; 842166X; MLS006010287; C18H17Cl2F3N4O2; SCHEMBL3015040; DTXSID60216786; MolPort-009-019-316; HMS3656P06; BCP05306; ZINC3947932; BDBM50211843; s2778; 2455AH; AKOS032945128; DB11903; BCP9000755; CS-7768; SB19546; API0013938; GW-842,166X; NCGC00346697-05; NCGC00346697-01; KB-77649; HY-14167
DMOV0AP DT Small molecular drug
DMOV0AP PC 10253143
DMOV0AP MW 449.3
DMOV0AP FM C18H17Cl2F3N4O2
DMOV0AP IC InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27)
DMOV0AP CS C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl
DMOV0AP IK TWQYWUXBZHPIIV-UHFFFAOYSA-N
DMOV0AP IU 2-(2,4-dichloroanilino)-N-(oxan-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide
DMOV0AP CA CAS 666260-75-9
DMOV0AP DE Pain
DML4GU1 ID DML4GU1
DML4GU1 DN 99mTc-MIP-1404
DML4GU1 HS Phase 2
DML4GU1 CP Molecular Insight Pharmaceuticals Inc
DML4GU1 DT ?
DML4GU1 PC 71300957
DML4GU1 MW 1176.3
DML4GU1 FM C40H53ClN10O23Tc
DML4GU1 IC InChI=1S/C37H50N10O20.3CHO.ClH.Tc/c48-26(6-4-22(35(63)64)41-37(67)42-23(36(65)66)5-7-29(51)52)40-21(34(61)62)3-1-2-10-43(13-24-38-8-11-44(24)15-27(49)46(17-30(53)54)18-31(55)56)14-25-39-9-12-45(25)16-28(50)47(19-32(57)58)20-33(59)60;3*1-2;;/h8-9,11-12,21-23H,1-7,10,13-20H2,(H,40,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,41,42,67);3*1H;1H;/q;3*-1;;+4/p-1/t21-,22-,23-;;;;;/m0...../s1/i;;;;;1+1
DML4GU1 CS [CH-]=O.[CH-]=O.[CH-]=O.C1=CN(C(=N1)CN(CCCC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CC2=NC=CN2CC(=O)N(CC(=O)O)CC(=O)O)CC(=O)N(CC(=O)O)CC(=O)O.[Cl-].[99Tc+4]
DML4GU1 IK XOJYSFPEJAILJZ-LCERUKBVSA-M
DML4GU1 IU (2S)-2-[[(1S)-4-[[(1S)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid;methanone;technetium-99(4+);chloride
DML4GU1 CA CAS 1333117-95-5
DML4GU1 DE Prostate cancer
DMX2LO3 ID DMX2LO3
DMX2LO3 DN 99mTc-RP-128
DMX2LO3 HS Phase 2
DMX2LO3 SN (SP-5-25)-Hydrogen [N,N-dimethylglycyl-kappaN-L-seryl-kappaN-L-cysteinyl-kappaN,kappaS-glycyl-L-threonyl-L-lysyl-L-prolyl-L-prolyl-L-argininato(4-)]oxotechnetate(1-)-99Tc; 186037-48-9
DMX2LO3 DE Diagnostic imaging
DMQXYRG ID DMQXYRG
DMQXYRG DN 9-AMINOCAMPTOTHECIN
DMQXYRG HS Phase 2
DMQXYRG SN IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin
DMQXYRG DT Small molecular drug
DMQXYRG PC 72402
DMQXYRG MW 363.4
DMQXYRG FM C20H17N3O4
DMQXYRG IC InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
DMQXYRG CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O
DMQXYRG IK FUXVKZWTXQUGMW-FQEVSTJZSA-N
DMQXYRG IU (19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQXYRG CA CAS 91421-43-1
DMQXYRG CB CHEBI:80755
DMQXYRG DE Acquired immune deficiency syndrome
DM57TY3 ID DM57TY3
DM57TY3 DN 9-ING-41
DM57TY3 HS Phase 2
DM57TY3 SN 1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione
DM57TY3 CP Actuate Therapeutics
DM57TY3 DT Small molecular drug
DM57TY3 PC 44582816
DM57TY3 MW 404.3
DM57TY3 FM C22H13FN2O5
DM57TY3 IC InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
DM57TY3 CS CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F
DM57TY3 IK FARXPFGGGGLENU-UHFFFAOYSA-N
DM57TY3 IU 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
DM57TY3 CA CAS 1034895-42-5
DM57TY3 DE Solid tumour/cancer; Myelofibrosis
DM6ZIES ID DM6ZIES
DM6ZIES DN A-6
DM6ZIES HS Phase 2
DM6ZIES SN Angstrom-6; CD44 binding peptide (cancer), Angstrom
DM6ZIES CP Angstrom pharmaceuticals
DM6ZIES DE Macular degeneration
DMHOLB7 ID DMHOLB7
DMHOLB7 DN A-85380
DMHOLB7 HS Phase 2
DMHOLB7 SN A-85380; A 85380; 161416-98-4; CHEMBL59986; (S)-3-(AZETIDIN-2-YLMETHOXY)PYRIDINE; AC1NSJQT; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-; SCHEMBL676026; A-159470; GTPL5460; ZINC3805142; 3-(2(s)-azetidinylmethoxy)pyridine; BDBM50049750; AKOS030230435; NCGC00387223-01; 3-[(2S)-azetidin-2-ylmethoxy]pyridine; 3-[[(2S)-azetidin-2-yl]methoxy]pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-pyridine; Pyridine, 3-(2-azetidinylmethoxy)-, (S)-
DMHOLB7 DT Small molecular drug
DMHOLB7 PC 5310969
DMHOLB7 MW 164.2
DMHOLB7 FM C9H12N2O
DMHOLB7 IC InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1
DMHOLB7 CS C1CN[C@@H]1COC2=CN=CC=C2
DMHOLB7 IK XKFMBGWHHBCWCD-QMMMGPOBSA-N
DMHOLB7 IU 3-[[(2S)-azetidin-2-yl]methoxy]pyridine
DMHOLB7 CA CAS 161416-98-4
DMOGDCQ ID DMOGDCQ
DMOGDCQ DN Ab-01
DMOGDCQ HS Phase 2
DMOGDCQ SN Ab-02; IL-21 receptor-targeted human monoclonal antibodies (inflammation); Anti-IL-21R mAb (inflammation), Pfizer; IL-21 receptor-targeted human monoclonal antibodies (inflammation), Pfizer
DMOGDCQ CP Pfizer Inc
DMOGDCQ DT Antibody
DMOGDCQ DE Inflammation
DMEW62S ID DMEW62S
DMEW62S DN AB-106
DMEW62S HS Phase 2
DMEW62S SN DS6051b; GTPL11198; AB106
DMEW62S CP AnHeart Therapeutics
DMEW62S DT Small molecular drug
DMEW62S PC 154699459
DMEW62S MW 405.5
DMEW62S FM C23H24FN5O
DMEW62S IC InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)
DMEW62S CS CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N
DMEW62S IK HEVHTYMYEMEBPX-UHFFFAOYSA-N
DMEW62S IU 3-[4-(2-aminopropoxy)phenyl]-N-[1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DMEW62S DE Non-small cell lung cancer
DM48DPS ID DM48DPS
DM48DPS DN AB-729
DM48DPS HS Phase 2
DM48DPS CP Arbutus Biopharma
DM48DPS DT Small interfering RNA
DM48DPS DE Hepatitis B virus infection
DM4ZLTY ID DM4ZLTY
DM4ZLTY DN ABBV-2222
DM4ZLTY HS Phase 2
DM4ZLTY SN QVDYQHXNAQHIKH-YMBRHYMPSA-N; ABBV 2222; 1918143-53-9; BCP25130
DM4ZLTY CP AbbVie
DM4ZLTY PC 121301049
DM4ZLTY MW 559.5
DM4ZLTY FM C28H21F4NO7
DM4ZLTY IC InChI=1S/C28H21F4NO7/c29-26(30)37-17-6-7-18-19(13-21(38-22(18)12-17)14-1-3-15(4-2-14)24(34)35)33-25(36)27(9-10-27)16-5-8-20-23(11-16)40-28(31,32)39-20/h1-8,11-12,19,21,26H,9-10,13H2,(H,33,36)(H,34,35)/t19-,21-/m1/s1
DM4ZLTY CS C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)N[C@@H]4C[C@@H](OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O
DM4ZLTY IK QVDYQHXNAQHIKH-TZIWHRDSSA-N
DM4ZLTY IU 4-[(2R,4R)-4-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid
DM4ZLTY CA CAS 1918143-53-9
DM4ZLTY DE Cystic fibrosis
DMT6H3J ID DMT6H3J
DMT6H3J DN AbGn-168
DMT6H3J HS Phase 2
DMT6H3J SN AbGn-168H; Antibody 168 (autoimmune diseases), Boehringer Ingelheim/AbGenomics; Anti-CD162 mAb (psoriasis), Boehringer/AbGenomics
DMT6H3J CP Abgenomics international
DMT6H3J DT Antibody
DMT6H3J DE Allergy
DMQ6KZM ID DMQ6KZM
DMQ6KZM DN ABI-009
DMQ6KZM HS Phase 2
DMQ6KZM CP Celgene
DMQ6KZM DE Solid tumour/cancer; Malignant perivascular epithelioid cell tumour; Non-muscle invasive bladder cancer; Pulmonary arterial hypertension
DM59OJ2 ID DM59OJ2
DM59OJ2 DN Abicipar pegol
DM59OJ2 HS Phase 2
DM59OJ2 CP Allergan Parsippany, NJ Molecular Partners Zurich, Switzerland
DM59OJ2 DE Diabetic macular edema
DMX1KDM ID DMX1KDM
DMX1KDM DN ABI-H0731
DMX1KDM HS Phase 2
DMX1KDM SN Vebicorvir; UNII-16F6055SMG; 16F6055SMG; 11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide; 2090064-66-5; Vebicorvir [INN]; Vebicorvir [USAN]; SCHEMBL21250344; WHO 11201; Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide
DMX1KDM CP Assembly Biosciences
DMX1KDM DT Small molecular drug
DMX1KDM PC 139394142
DMX1KDM MW 467.4
DMX1KDM FM C19H12F3N3O4S2
DMX1KDM IC InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27)
DMX1KDM CS C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F
DMX1KDM IK LBJVBJYMZKEREY-UHFFFAOYSA-N
DMX1KDM IU 6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide
DMX1KDM CA CAS 2090064-66-5
DMX1KDM DE Hepatitis B
DM6X70G ID DM6X70G
DM6X70G DN ABI-H2158
DM6X70G HS Phase 2
DM6X70G CP Assembly Biosciences
DM6X70G DT Small molecular drug
DM6X70G DE Hepatitis B
DMTCXSG ID DMTCXSG
DMTCXSG DN Abituzumab
DMTCXSG HS Phase 2
DMTCXSG CP Emd serono
DMTCXSG DT Antibody
DMTCXSG DE Colorectal cancer
DM23UQ9 ID DM23UQ9
DM23UQ9 DN ABT-122
DM23UQ9 HS Phase 2
DM23UQ9 CP AbbVie
DM23UQ9 DT Monoclonal antibody
DM23UQ9 DE Rheumatoid arthritis; Psoriatic arthritis
DM2OS51 ID DM2OS51
DM2OS51 DN ABT-126
DM2OS51 HS Phase 2
DM2OS51 CP Abbott Laboratories
DM2OS51 PC 24987875
DM2OS51 MW 313.4
DM2OS51 FM C17H19N3OS
DM2OS51 IC InChI=1S/C17H19N3OS/c1-2-4-12(5-3-1)16-18-19-17(22-16)21-15-13-6-11-7-14(15)10-20(8-11)9-13/h1-5,11,13-15H,6-10H2
DM2OS51 CS C1C2CC3CN(C2)CC1C3OC4=NN=C(S4)C5=CC=CC=C5
DM2OS51 IK QZDCYUCETTWCMO-UHFFFAOYSA-N
DM2OS51 IU 2-(1-azatricyclo[3.3.1.13,7]decan-4-yloxy)-5-phenyl-1,3,4-thiadiazole
DM2OS51 CA CAS 1026687-03-5
DM2OS51 DE Schizophrenia; Alzheimer disease
DMN3S1B ID DMN3S1B
DMN3S1B DN ABT-229
DMN3S1B HS Phase 2
DMN3S1B SN Alemcinal; ABT-229; UNII-5DS173ODI4; 5DS173ODI4; ABBOTT-81229.0; 150785-53-8; A-81229; Alemcinal (USAN/INN); CHEMBL300049; ABT229; GTPL1444; BDBM86685; ABT 229; D02801; 8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin
DMN3S1B DT Small molecular drug
DMN3S1B PC 9918079
DMN3S1B MW 697.9
DMN3S1B FM C38H67NO10
DMN3S1B IC InChI=1S/C38H67NO10/c1-14-28-23(6)30(40)24(7)32-20(3)17-38(11,49-32)34(48-36-31(41)27(39(12)15-2)16-21(4)45-36)25(8)33(26(9)35(42)46-28)47-29-19-37(10,43-13)18-22(5)44-29/h21-31,33-34,36,40-41H,14-19H2,1-13H3/t21-,22+,23+,24-,25+,26-,27+,28-,29+,30+,31-,33+,34-,36+,37+,38-/m1/s1
DMN3S1B CS CC[C@@H]1[C@@H]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)C
DMN3S1B IK IWTSXJNGTTXMFK-KTQUSEMZSA-N
DMN3S1B IU (2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMN3S1B CA CAS 150785-53-8
DMN3S1B DE Pain
DM7X54F ID DM7X54F
DM7X54F DN ABT-288
DM7X54F HS Phase 2
DM7X54F SN ABT-288; UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4
DM7X54F CP Abbott Laboratories
DM7X54F DT Small molecular drug
DM7X54F PC 24743471
DM7X54F MW 372.5
DM7X54F FM C23H24N4O
DM7X54F IC InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
DM7X54F CS CN1C[C@H]2CCN([C@H]2C1)C3=CC=C(C=C3)C4=CC=C(C=C4)N5C(=O)C=CC=N5
DM7X54F IK GNIRITULTPTAQW-KNQAVFIVSA-N
DM7X54F IU 2-[4-[4-[(3aR,6aR)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one
DM7X54F CA CAS 948845-91-8
DM7X54F DE Alzheimer disease
DM6WN2D ID DM6WN2D
DM6WN2D DN ABT-308
DM6WN2D HS Phase 2
DM6WN2D DE Asthma; Eosinophilic esophagitis
DMMZOYN ID DMMZOYN
DMMZOYN DN ABT-348
DMMZOYN HS Phase 2
DMMZOYN SN ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea
DMMZOYN CP Abbott Laboratories Abbott
DMMZOYN DT Small molecular drug
DMMZOYN PC 46207586
DMMZOYN MW 488.5
DMMZOYN FM C25H21FN6O2S
DMMZOYN IC InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)
DMMZOYN CS C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N
DMMZOYN IK WPHKIQPVPYJNAX-UHFFFAOYSA-N
DMMZOYN IU 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea
DMMZOYN CA CAS 1227939-82-3
DMMZOYN DE Haematological malignancy
DM7XW5Y ID DM7XW5Y
DM7XW5Y DN ABT-384
DM7XW5Y HS Phase 2
DM7XW5Y SN ABT-384; UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide
DM7XW5Y CP Abbott Laboratories
DM7XW5Y DT Small molecular drug
DM7XW5Y PC 11670435
DM7XW5Y MW 493.6
DM7XW5Y FM C25H34F3N5O2
DM7XW5Y IC InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35)
DM7XW5Y CS CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)C(=O)N)N4CCN(CC4)C5=NC=C(C=C5)C(F)(F)F
DM7XW5Y IK CLHMYBJIOZXCEX-UHFFFAOYSA-N
DM7XW5Y IU 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
DM7XW5Y CA CAS 868623-40-9
DM7XW5Y DE Alzheimer disease; Hepatitis C virus infection
DMGUTPN ID DMGUTPN
DMGUTPN DN ABT-414
DMGUTPN HS Phase 2
DMGUTPN CP Abbvie
DMGUTPN DT Antibody
DMGUTPN DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma
DMNAU1V ID DMNAU1V
DMNAU1V DN ABT-436
DMNAU1V HS Phase 2
DMNAU1V CP Abbott Laboratories
DMNAU1V DE Anxiety disorder
DMFW860 ID DMFW860
DMFW860 DN ABT-450
DMFW860 HS Phase 2
DMFW860 CP Abbott; Enanta
DMFW860 PC 45110509
DMFW860 MW 765.9
DMFW860 FM C40H43N7O7S
DMFW860 IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DMFW860 CS CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DMFW860 IK UAUIUKWPKRJZJV-QPLHLKROSA-N
DMFW860 IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DMFW860 CA CAS 1216941-48-8
DMFW860 DE Hepatitis C virus infection
DMPDVM8 ID DMPDVM8
DMPDVM8 DN ABT-510
DMPDVM8 HS Phase 2
DMPDVM8 SN N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide
DMPDVM8 CP Abbott Laboratories
DMPDVM8 DT Small molecular drug
DMPDVM8 PC 6918562
DMPDVM8 MW 994.2
DMPDVM8 FM C46H83N13O11
DMPDVM8 IC InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1
DMPDVM8 CS CCC[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C
DMPDVM8 IK RIWLPSIAFBLILR-WVNGMBSFSA-N
DMPDVM8 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R,3S)-2-[[(2S)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide
DMPDVM8 CA CAS 251579-55-2
DMPDVM8 DE Solid tumour/cancer
DMEWQ4X ID DMEWQ4X
DMEWQ4X DN ABT-639
DMEWQ4X HS Phase 2
DMEWQ4X SN ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide
DMEWQ4X DT Small molecular drug
DMEWQ4X PC 46851313
DMEWQ4X MW 455.9
DMEWQ4X FM C20H20ClF2N3O3S
DMEWQ4X IC InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1
DMEWQ4X CS C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F
DMEWQ4X IK AGPIHNZOZNKRGT-CYBMUJFWSA-N
DMEWQ4X IU 5-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide
DMEWQ4X CA CAS 1235560-28-7
DMEWQ4X DE Pain
DMLEO2Z ID DMLEO2Z
DMLEO2Z DN ABT-652
DMLEO2Z HS Phase 2
DMLEO2Z CP Abbott Laboratories
DMLEO2Z DE Musculoskeletal pain; Diabetic neuropathy
DMNG35S ID DMNG35S
DMNG35S DN ABT-751
DMNG35S HS Phase 2
DMNG35S SN ABT-751; 141430-65-1; ABT 751; E-7010; ABT751; ABT-751 (E7010); UNII-WDT5V5OB9F; E 7010; WDT5V5OB9F; N-[2-[(4-HYDROXYPHENYL)AMINO]-3-PYRIDYL]-4-METHOXYBENZENESULFONAMIDE; CHEMBL20684; N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide; N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide; Benzenesulfonamide,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-; N-(2-(4-hydroxyphenylamino)pyridin-3-yl)-4-methoxybenzenesulfonamide
DMNG35S DT Small molecular drug
DMNG35S PC 3035714
DMNG35S MW 371.4
DMNG35S FM C18H17N3O4S
DMNG35S IC InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)
DMNG35S CS COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O
DMNG35S IK URCVCIZFVQDVPM-UHFFFAOYSA-N
DMNG35S IU N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide
DMNG35S CA CAS 141430-65-1
DMNG35S CB CHEBI:95043
DMNG35S DE Solid tumour/cancer
DM6PTIX ID DM6PTIX
DM6PTIX DN ABT-981
DM6PTIX HS Phase 2
DM6PTIX CP AbbVie
DM6PTIX DT Monoclonal antibody
DM6PTIX DE Osteoarthritis
DM9Y1XB ID DM9Y1XB
DM9Y1XB DN ABT-RTA-408
DM9Y1XB HS Phase 2
DM9Y1XB CP Abbvie; reata pharmaceuticals
DM9Y1XB DE Non-small-cell lung cancer
DM91U0R ID DM91U0R
DM91U0R DN ABX-EGF
DM91U0R HS Phase 2
DM91U0R DT Antibody
DMCZFMS ID DMCZFMS
DMCZFMS DN ABX-IL8
DMCZFMS HS Phase 2
DMCZFMS DT Antibody
DMCZFMS DE Melanoma
DMNVFZA ID DMNVFZA
DMNVFZA DN AC-1202
DMNVFZA HS Phase 2
DMNVFZA SN Ketasyn
DMNVFZA CP Accera
DMNVFZA DT Small molecular drug
DMNVFZA PC 10850
DMNVFZA MW 470.7
DMNVFZA FM C27H50O6
DMNVFZA IC InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
DMNVFZA CS CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
DMNVFZA IK VLPFTAMPNXLGLX-UHFFFAOYSA-N
DMNVFZA IU 2,3-di(octanoyloxy)propyl octanoate
DMNVFZA CA CAS 538-23-8
DMNVFZA CB CHEBI:76978
DMNVFZA DE Memory loss
DMB0TNL ID DMB0TNL
DMB0TNL DN AC-201
DMB0TNL HS Phase 2
DMB0TNL CP TWi Biotechnology Taipei, Taiwan
DMB0TNL DE Type-2 diabetes
DM3TUBR ID DM3TUBR
DM3TUBR DN Acalabrutinib
DM3TUBR HS Phase 2
DM3TUBR SN Acalabrutinib; 1420477-60-6; ACP-196; Calquence; UNII-I42748ELQW; I42748ELQW; Benzamide; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Acalabrutinib (ACP-196); Calquence (TN); Benzamide, ACP-196; Acalabrutinib; Acalabrutinib(ACP196); GTPL8912; CHEMBL3707348; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; ACP 196; WDENQI; Acalabrutinib
DM3TUBR TC Antiviral Agents
DM3TUBR DT Small molecular drug
DM3TUBR PC 71226662
DM3TUBR MW 465.5
DM3TUBR FM C26H23N7O2
DM3TUBR IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM3TUBR CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM3TUBR IK WDENQIQQYWYTPO-IBGZPJMESA-N
DM3TUBR IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM3TUBR CA CAS 1420477-60-6
DM3TUBR DE Coronavirus Disease 2019 (COVID-19)
DM0FGDO ID DM0FGDO
DM0FGDO DN ACCLAIM
DM0FGDO HS Phase 2
DM0FGDO SN Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester
DM0FGDO CP Angiogenix
DM0FGDO DT Small molecular drug
DM0FGDO PC 47938
DM0FGDO MW 361.8
DM0FGDO FM C18H16ClNO5
DM0FGDO IC InChI=1S/C18H16ClNO5/c1-3-22-17(21)11(2)23-13-5-7-14(8-6-13)24-18-20-15-9-4-12(19)10-16(15)25-18/h4-11H,3H2,1-2H3
DM0FGDO CS CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl
DM0FGDO IK PQKBPHSEKWERTG-UHFFFAOYSA-N
DM0FGDO IU ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate
DM0FGDO CA CAS 66441-23-4
DM0FGDO CB CHEBI:5008
DM0FGDO DE Coronary artery disease; Angina pectoris
DMZ8PY0 ID DMZ8PY0
DMZ8PY0 DN ACE-031
DMZ8PY0 HS Phase 2
DMZ8PY0 CP Acceleron Pharma
DMZ8PY0 DE Duchenne dystrophy
DMIVUFL ID DMIVUFL
DMIVUFL DN ACH-1625
DMIVUFL HS Phase 2
DMIVUFL SN SOVAPREVIR; 1001667-23-7; UNII-2ND9V3MN6O; ACH-0141625; 2ND9V3MN6O; Sovaprevir [USAN:INN]; Sovaprevir (USAN); Prodrug of ACH-1095; SCHEMBL1462843; CHEMBL2105750; DTXSID00142994; DB12069; SB16836; D10166; 2-Pyrrolidinecarboxamide, N-((1R,2S)-1-(((cyclopropylsulfonyl)amino)carbonyl)-2- ethenylcyclopropyl)-1-((2S)-3,3-dimethyl-1-oxo-2-(2-oxo-2-(1-piperidinyl)ethyl)butyl)-4-
DMIVUFL CP Achillion
DMIVUFL DT Small molecular drug
DMIVUFL PC 53362096
DMIVUFL MW 800
DMIVUFL FM C43H53N5O8S
DMIVUFL IC InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
DMIVUFL CS CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
DMIVUFL IK MHFMTUBUVQZIRE-WINRQGAFSA-N
DMIVUFL IU (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide
DMIVUFL CA CAS 1001667-23-7
DMIVUFL DE Hepatitis C virus infection
DM0RPY5 ID DM0RPY5
DM0RPY5 DN ACH-3102
DM0RPY5 HS Phase 2
DM0RPY5 CP Achillion pharmaceuticals
DM0RPY5 PC 71474517
DM0RPY5 MW 1001.3
DM0RPY5 FM C60H72N8O6
DM0RPY5 IC InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1
DM0RPY5 CS CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM0RPY5 IK LSYBRGMTRKJATA-IVEWBXRVSA-N
DM0RPY5 IU methyl N-[(2S)-1-[(2S,3aS,7aS)-2-[6-[11-[2-[(2S,3aS,7aS)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl]-1H-benzimidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM0RPY5 CA CAS 1415119-52-6
DM0RPY5 DE Hepatitis C virus infection
DMLVCZR ID DMLVCZR
DMLVCZR DN ACH-4471
DMLVCZR HS Phase 2
DMLVCZR SN PIBARDGJJAGJAJ-NQIIRXRSSA-N; UNII-JM8C1SFX0U; JM8C1SFX0U; SCHEMBL17024981; 1903768-17-1; (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR CP Achillion Pharmaceuticals New Haven, CT
DMLVCZR PC 118323590
DMLVCZR MW 580.4
DMLVCZR FM C26H23BrFN7O3
DMLVCZR IC InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1
DMLVCZR CS CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F
DMLVCZR IK PIBARDGJJAGJAJ-NQIIRXRSSA-N
DMLVCZR IU (2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR CA CAS 1903768-17-1
DMLVCZR DE Glomerulonephritis; Anaemia
DMPR8E9 ID DMPR8E9
DMPR8E9 DN ACP-001
DMPR8E9 HS Phase 2
DMPR8E9 SN TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma
DMPR8E9 CP Ascendis Pharma A/S
DMPR8E9 DE Growth hormone deficiency
DMMG61B ID DMMG61B
DMMG61B DN ACT-GRO-777
DMMG61B HS Phase 2
DMMG61B SN AGRO-100; AS-1411; Anticancer aptamers, Aptamera; GRO-26B; AGRO-100 derivatives, Aptamera; Nucleolin inhibitors (cancer), Aptamera; Nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics
DMMG61B CP Aptamera Inc
DMMG61B DT Aptamer
DMMG61B DE Solid tumour/cancer
DMKBIPR ID DMKBIPR
DMKBIPR DN Actimab-A
DMKBIPR HS Phase 2
DMKBIPR CP Actinium Pharmaceuticals New York, NY
DMKBIPR DE Acute myeloid leukaemia
DM9GRTK ID DM9GRTK
DM9GRTK DN ACYLINE
DM9GRTK HS Phase 2
DM9GRTK SN Acyline; UNII-S3439D3B35; CHEMBL262747; S3439D3B35; BDBM50102456; DB11906; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-(acetylamino)-L-phenylalanyl-4-(acetylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; Z-3146; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(Ac)]-D-[Aph(Ac)]-Leu-ILys-Pro-DAla-NH2
DM9GRTK PC 16137348
DM9GRTK MW 1533.2
DM9GRTK FM C80H102ClN15O14
DM9GRTK IC InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,70+/m1/s1
DM9GRTK CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9GRTK IK ZWNUQDJANZGVFO-YHSALVGYSA-N
DM9GRTK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM9GRTK CA CAS 170157-13-8
DM9GRTK DE Prostate cancer
DMLV9GS ID DMLV9GS
DMLV9GS DN AD04
DMLV9GS HS Phase 2
DMLV9GS CP ADial Pharmaceuticals Charlottesville, VA
DMLV9GS DE Alcohol dependence; Opioid dependence
DMMFLXN ID DMMFLXN
DMMFLXN DN AD-452
DMMFLXN HS Phase 2
DMMFLXN SN RS(+)-mefloquine; (+)-erythro-mefloquine
DMMFLXN CP Sosei R&D Ltd
DMMFLXN DE Rheumatoid arthritis
DM8GHIX ID DM8GHIX
DM8GHIX DN ADC-3680
DM8GHIX HS Phase 2
DM8GHIX SN ADC-3680B; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Pulmagen; Prostaglandin D2 receptor antagonists (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery
DM8GHIX CP Argenta Discovery Ltd
DM8GHIX DE Allergic rhinitis
DM821BS ID DM821BS
DM821BS DN Adipiplon
DM821BS HS Phase 2
DM821BS SN GABA modulator (insomnia), Neurogen; NG-2-73
DM821BS CP Neurogen Corporation
DM821BS DT Small molecular drug
DM821BS PC 11198924
DM821BS MW 351.4
DM821BS FM C18H18FN7
DM821BS IC InChI=1S/C18H18FN7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11H,3,5,10H2,1-2H3
DM821BS CS CCCC1=C(N=CN2C1=NC(=N2)C)CN3C=CN=C3C4=C(C=CC=N4)F
DM821BS IK UAMAIHOEGLEXSV-UHFFFAOYSA-N
DM821BS IU 7-[[2-(3-fluoropyridin-2-yl)imidazol-1-yl]methyl]-2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidine
DM821BS CA CAS 840486-93-3
DM821BS DE Sleep-wake disorder
DMMUPTN ID DMMUPTN
DMMUPTN DN ADL-5747
DMMUPTN HS Phase 2
DMMUPTN CP Pfizer
DMMUPTN DT Small molecular drug
DMMUPTN PC 76967747
DMMUPTN MW 428.9
DMMUPTN FM C24H29ClN2O3
DMMUPTN IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22;/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3;1H
DMMUPTN CS CCN(CC)C(=O)C1=CC(=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42)O.Cl
DMMUPTN IK XROFSGVHHSJMMG-UHFFFAOYSA-N
DMMUPTN IU N,N-diethyl-3-hydroxy-4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide;hydrochloride
DMMUPTN CA CAS 1187653-56-0
DMMUPTN DE Pain
DMDQH9A ID DMDQH9A
DMDQH9A DN ADL-5859
DMDQH9A HS Phase 2
DMDQH9A SN PF-04856880
DMDQH9A CP Pfizer
DMDQH9A DT Small molecular drug
DMDQH9A PC 46931003
DMDQH9A MW 428.9
DMDQH9A FM C24H29ClN2O3
DMDQH9A IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21;/h5-11,16,25,27H,3-4,12-15H2,1-2H3;1H
DMDQH9A CS CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC(=C42)O.Cl
DMDQH9A IK ZFNLSWREIULTDO-UHFFFAOYSA-N
DMDQH9A IU N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide;hydrochloride
DMDQH9A CA CAS 850173-95-4
DMDQH9A DE Rheumatoid arthritis
DM819CO ID DM819CO
DM819CO DN ADMVA
DM819CO HS Phase 2
DM819CO SN RMVA vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankara vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankaravaccine (HIV-1), Aaron Diamond AIDS Research Center; DNA vaccine (gag, pol, env, tat, nef), ADARC; DNA vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center; HIV-1 vaccine (gag, pol, env, tat, nef), ADARC; HIV-1 vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center
DM819CO CP Aaron Diamond AIDS Research Center
DM819CO DT Vaccine
DM819CO DE Diabetic complication
DMJSWXL ID DMJSWXL
DMJSWXL DN Ad-p53
DMJSWXL HS Phase 2
DMJSWXL SN P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
DMJSWXL CP Transgene SA
DMJSWXL DE Colorectal cancer; Solid tumour/cancer
DMRYH3M ID DMRYH3M
DMRYH3M DN ADP-A2M4
DMRYH3M HS Phase 2
DMRYH3M CP Adaptimmune
DMRYH3M DE Solid tumour/cancer; Synovial sarcoma
DME384W ID DME384W
DME384W DN AdPEDR
DME384W HS Phase 2
DME384W CP GenVec
DME384W DT Small molecular drug
DME384W PC 11557063
DME384W MW 964.7
DME384W FM C38H41IN14O9
DME384W IC InChI=1S/C20H22N8O5.C18H19IN6O4/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t13-;12-,13+,14-,18+/m00/s1
DME384W CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O.CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DME384W IK BDNQEWFVMDIRTE-VXJTWHGRSA-N
DME384W IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DME384W DE Exudative age-related macular degeneration
DMCNTFW ID DMCNTFW
DMCNTFW DN Ad-RTS-hIL-12
DMCNTFW HS Phase 2
DMCNTFW CP Ziopharm Oncology
DMCNTFW DT Gene therapy
DMCNTFW DE Melanoma; Malignant glioma; Recurrent glioblastoma; Glioblastoma of brain
DMM6B2Y ID DMM6B2Y
DMM6B2Y DN ADU- S100
DMM6B2Y HS Phase 2
DMM6B2Y DT Small molecular drug
DMM6B2Y DE Head and neck cancer
DM8HBUI ID DM8HBUI
DM8HBUI DN ADU-S100
DM8HBUI HS Phase 2
DM8HBUI SN MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885
DM8HBUI CP Aduro Biotech Berkeley, CANovartis Oncology East Hanover, NJ
DM8HBUI PC 135390762
DM8HBUI MW 734.5
DM8HBUI FM C20H22N10Na2O10P2S2
DM8HBUI IC InChI=1S/C20H24N10O10P2S2.2Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30;;/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26);;/q;2*+1/p-2/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?;;/m1../s1
DM8HBUI CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)[S-])[O-])O.[Na+].[Na+]
DM8HBUI IK GDWOOOCBNOMMTL-QYUKNOIISA-L
DM8HBUI IU disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3-oxido-12-oxo-3-sulfanylidene-12-sulfido-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol
DM8HBUI CA CAS 1638750-95-4
DM8HBUI DE Solid tumour/cancer; Head and neck cancer
DMGVKHQ ID DMGVKHQ
DMGVKHQ DN ADX10059
DMGVKHQ HS Phase 2
DMGVKHQ CP Addex Pharma.
DMGVKHQ DE Anxiety disorder
DMC8NAO ID DMC8NAO
DMC8NAO DN ADXS-HPV
DMC8NAO HS Phase 2
DMC8NAO CP Advaxis
DMC8NAO DT Vaccine
DMC8NAO DE Cervical Intraepithelial neoplasia; Cervical cancer
DMJVN89 ID DMJVN89
DMJVN89 DN AEB07
DMJVN89 HS Phase 2
DMJVN89 CP Novartis
DMJVN89 DT Small molecular drug
DMJVN89 PC 9963383
DMJVN89 MW 1078.3
DMJVN89 FM C52H71N9O12S2
DMJVN89 IC InChI=1S/C27H36N4O5S.C24H31N5O4.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-3-16-6-8-19(27-23(16)25-2)9-7-17-10-12-29(24(17)33)15-21(30)28-20(13-22(31)32)18-5-4-11-26-14-18;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);4-6,8,11,14,17,20H,3,7,9-10,12-13,15H2,1-2H3,(H,25,27)(H,28,30)(H,31,32);1H3,(H,2,3,4)/t22-;17-,20-;/m10./s1
DMJVN89 CS CCC1=C(N=C(C=C1)CC[C@H]2CCN(C2=O)CC(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3)NC.CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O
DMJVN89 IK XAOWMNBAVQDQSR-WQDYQDSXSA-N
DMJVN89 IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;(3S)-3-[[2-[(3S)-3-[2-[5-ethyl-6-(methylamino)pyridin-2-yl]ethyl]-2-oxopyrrolidin-1-yl]acetyl]amino]-3-pyridin-3-ylpropanoic acid;methanesulfonic acid
DMJVN89 DE Transplant rejection
DMQ1GH4 ID DMQ1GH4
DMQ1GH4 DN AEF0117
DMQ1GH4 HS Phase 2
DMQ1GH4 CP Aelis Farma
DMQ1GH4 DT Small molecular drug
DMQ1GH4 DE Marijuana use disorder
DMSBLOU ID DMSBLOU
DMSBLOU DN AEG-33773
DMSBLOU HS Phase 2
DMSBLOU CP Aegera Therapeutics Inc
DMSBLOU DE Diabetic neuropathy
DMI5TXZ ID DMI5TXZ
DMI5TXZ DN AEM-28
DMI5TXZ HS Phase 2
DMI5TXZ SN Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX
DMI5TXZ CP Lipimetix development
DMI5TXZ DE Hyperlipidaemia; Familial hypercholesterolemia
DMNO7BC ID DMNO7BC
DMNO7BC DN AeroLEF
DMNO7BC HS Phase 2
DMNO7BC DE Pain
DMFO2G5 ID DMFO2G5
DMFO2G5 DN Afabicin
DMFO2G5 HS Phase 2
DMFO2G5 SN UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-
DMFO2G5 CP Debiopharm Lausanne, Switzerland
DMFO2G5 PC 72696796
DMFO2G5 MW 485.4
DMFO2G5 FM C23H24N3O7P
DMFO2G5 IC InChI=1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+
DMFO2G5 CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O
DMFO2G5 IK HFYMDQMXVPJNTH-VQHVLOKHSA-N
DMFO2G5 IU [6-[(E)-3-[methyl-[(3-methyl-1-benzofuran-2-yl)methyl]amino]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]methyl dihydrogen phosphate
DMFO2G5 CA CAS 1518800-35-5
DMFO2G5 DE Acute bacterial skin infection
DMFORDT ID DMFORDT
DMFORDT DN Afimoxifene
DMFORDT HS Phase 2
DMFORDT SN 4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
DMFORDT CP ASCEND Therapeutics
DMFORDT DT Small molecular drug
DMFORDT PC 449459
DMFORDT MW 387.5
DMFORDT FM C26H29NO2
DMFORDT IC InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
DMFORDT CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMFORDT IK TXUZVZSFRXZGTL-QPLCGJKRSA-N
DMFORDT IU 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMFORDT CA CAS 68047-06-3
DMFORDT CB CHEBI:44616
DMFORDT DE Breast cancer; Ductal carcinoma
DMN45IC ID DMN45IC
DMN45IC DN AFM13
DMN45IC HS Phase 2
DMN45IC CP Affimed Therapeutics
DMN45IC DT Antibody
DMN45IC DE Hodgkin lymphoma; Lymphoma; Peripheral T-cell lymphoma; Mycosis fungoides
DMTFE9Y ID DMTFE9Y
DMTFE9Y DN AFN-1252
DMTFE9Y HS Phase 2
DMTFE9Y SN API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium
DMTFE9Y CP Affinium pharmaceuticals
DMTFE9Y DT Small molecular drug
DMTFE9Y PC 10407120
DMTFE9Y MW 375.4
DMTFE9Y FM C22H21N3O3
DMTFE9Y IC InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+
DMTFE9Y CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
DMTFE9Y IK QXTWSUQCXCWEHF-JXMROGBWSA-N
DMTFE9Y IU (E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
DMTFE9Y CA CAS 620175-39-5
DMTFE9Y DE Staphylococcus infection
DM6AJKC ID DM6AJKC
DM6AJKC DN AFN-1720
DM6AJKC HS Phase 2
DM6AJKC CP Affinium pharmaceuticals
DM6AJKC DE Bacterial infection
DM1FJ2B ID DM1FJ2B
DM1FJ2B DN AFP464
DM1FJ2B HS Phase 2
DM1FJ2B SN UNII-73JNH95XPX; AFP464; 73JNH95XPX; 468719-53-1; AFP 464; AFP-464; Hexanamide, 2,6-diamino-N-(4-(5-amino-6,8-difluoro-7-methyl-4-oxo-4H-1-benzopyran-2-yl)-2-fluorophenyl)-, (2S)-, dimethanesulfonate
DM1FJ2B CP Kirax
DM1FJ2B DT Small molecular drug
DM1FJ2B PC 399587
DM1FJ2B MW 544.5
DM1FJ2B FM C23H27F3N4O6S
DM1FJ2B IC InChI=1S/C22H23F3N4O3.CH4O3S/c1-10-18(24)20(28)17-15(30)9-16(32-21(17)19(10)25)11-5-6-14(12(23)8-11)29-22(31)13(27)4-2-3-7-26;1-5(2,3)4/h5-6,8-9,13H,2-4,7,26-28H2,1H3,(H,29,31);1H3,(H,2,3,4)/t13-;/m0./s1
DM1FJ2B CS CC1=C(C(=C2C(=O)C=C(OC2=C1F)C3=CC(=C(C=C3)NC(=O)[C@H](CCCCN)N)F)N)F.CS(=O)(=O)O
DM1FJ2B IK MJVICFBYAVBBOA-ZOWNYOTGSA-N
DM1FJ2B IU (2S)-2,6-diamino-N-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide;methanesulfonic acid
DM1FJ2B CA CAS 468719-53-1
DM1FJ2B DE Breast cancer
DMD3XMG ID DMD3XMG
DMD3XMG DN AFTVac
DMD3XMG HS Phase 2
DMD3XMG SN Autologous fixed tumor vaccine (AFTVac) therapy; Autologous vaccine (cancer), Cell-Medicine; GM-CSF agonist/IL-2 agonist containing-vaccine; Fixed autologous tumor derivatives + microparticles encapsulating GM-CSF and IL-2, Cell-Medicine
DMD3XMG CP Cell-Medicine Inc
DMD3XMG DT Vaccine
DMD3XMG DE Glioblastoma multiforme
DMA9FKY ID DMA9FKY
DMA9FKY DN AG140699
DMA9FKY HS Phase 2
DMA9FKY CP Pfizer
DMA9FKY TC Anticancer Agents
DMA9FKY DE Melanoma
DMNQ5T2 ID DMNQ5T2
DMNQ5T2 DN AG-858
DMNQ5T2 HS Phase 2
DMNQ5T2 SN Chronic myeloid leukemia therapy, Antigenics; HSP-70 cancer vaccine, Antigenics; HSPPC-70 (cancer); HSPPC-70-C
DMNQ5T2 CP Agenus Inc; Antigenics
DMNQ5T2 DT Vaccine
DMNQ5T2 DE leukaemia
DMPO7UG ID DMPO7UG
DMPO7UG DN AGEN2034
DMPO7UG HS Phase 2
DMPO7UG CP AgenusLexington, MA
DMPO7UG DT Monoclonal antibody
DMPO7UG DE Solid tumour/cancer; Cervical cancer
DMP5Y1A ID DMP5Y1A
DMP5Y1A DN AGN-199981
DMP5Y1A HS Phase 2
DMP5Y1A CP Allergan
DMP5Y1A TC Analgesics
DMP5Y1A DE Neuropathic pain
DM4KOAC ID DM4KOAC
DM4KOAC DN AGN-241751
DM4KOAC HS Phase 2
DM4KOAC CP Allergan
DM4KOAC DT Small molecular drug
DM4KOAC DE Major depressive disorder
DMLQRFO ID DMLQRFO
DMLQRFO DN AGN-2979
DMLQRFO HS Phase 2
DMLQRFO SN BTG-1501; SC-48274; AGN-2979 (free base); 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione; 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione monohydrochloride
DMLQRFO DT Small molecular drug
DMLQRFO PC 40914
DMLQRFO MW 332.4
DMLQRFO FM C19H28N2O3
DMLQRFO IC InChI=1S/C19H28N2O3/c1-18(2)13-16(22)20-17(23)19(18,10-7-11-21(3)4)14-8-6-9-15(12-14)24-5/h6,8-9,12H,7,10-11,13H2,1-5H3,(H,20,22,23)
DMLQRFO CS CC1(CC(=O)NC(=O)C1(CCCN(C)C)C2=CC(=CC=C2)OC)C
DMLQRFO IK UJFNSGBGJMRZKS-UHFFFAOYSA-N
DMLQRFO IU 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione
DMLQRFO CA CAS 53873-21-5
DMLQRFO DE Psychotic disorder
DMMGAUK ID DMMGAUK
DMMGAUK DN AGN-XX/YY
DMMGAUK HS Phase 2
DMMGAUK SN Rezatomidine
DMMGAUK CP ACADIA Pharmaceuticals
DMMGAUK DT Small molecular drug
DMMGAUK PC 11287722
DMMGAUK MW 232.35
DMMGAUK FM C13H16N2S
DMMGAUK IC InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
DMMGAUK CS CC1=C(C(=CC=C1)[C@H](C)C2=CNC(=S)N2)C
DMMGAUK IK WQXVKEDUCPMRRI-JTQLQIEISA-N
DMMGAUK IU 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydroimidazole-2-thione
DMMGAUK CA CAS 847829-38-3
DMMGAUK DE Fibromyalgia; Diabetic nephropathy
DM2POHA ID DM2POHA
DM2POHA DN AGS-16C3F
DM2POHA HS Phase 2
DM2POHA CP AgensysSanta Monica, CA
DM2POHA DE Renal cell carcinoma
DMMKASG ID DMMKASG
DMMKASG DN AGTC-0106
DMMKASG HS Phase 2
DMMKASG SN Alpha-1 antitrypsin deficiency gene therapy, AGTC; RAAV1-CB-hAAT; Gene therapy (alpha-1 antitrypsin deficiency), Applied Genetic Technologies
DMMKASG CP Agtc; applied genetic technologies
DMMKASG DE Alpha-1 antitrypsin deficiency
DMXJ8Z4 ID DMXJ8Z4
DMXJ8Z4 DN AK104
DMXJ8Z4 HS Phase 2
DMXJ8Z4 CP Akeso Biopharma
DMXJ8Z4 DT Antibody
DMXJ8Z4 DE Cervical cancer; Hepatocellular carcinoma
DMKNRYH ID DMKNRYH
DMKNRYH DN AKB-9778
DMKNRYH HS Phase 2
DMKNRYH CP Aerpio Therapeutics
DMKNRYH PC 46700782
DMKNRYH MW 586.7
DMKNRYH FM C26H26N4O6S3
DMKNRYH IC InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
DMKNRYH CS COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4
DMKNRYH IK KWJDHELCGJFUHW-SFTDATJTSA-N
DMKNRYH IU [4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
DMKNRYH CA CAS 1008510-37-9
DMKNRYH DE Peripheral arterial disease; Diabetic macular edema
DMR8W7Y ID DMR8W7Y
DMR8W7Y DN AKCEA-ANGPTL3-LRX
DMR8W7Y HS Phase 2
DMR8W7Y CP Akcea Therapeutics Cambridge, MA
DMR8W7Y DE Cardiovascular disease
DMCTWIB ID DMCTWIB
DMCTWIB DN AL102
DMCTWIB HS Phase 2
DMCTWIB CP Ayala Pharmaceuticals
DMCTWIB DT Small molecular drug
DMCTWIB DE Desmoid tumour
DM3P91Z ID DM3P91Z
DM3P91Z DN Alacizumab pegol
DM3P91Z HS Phase 2
DM3P91Z SN CDP-791
DM3P91Z CP UCB Celltech
DM3P91Z DT Antibody
DM3P91Z DE Non-small-cell lung cancer
DM2U530 ID DM2U530
DM2U530 DN ALD-401
DM2U530 HS Phase 2
DM2U530 SN ALD-401, Aldagen; ALDH-expressing stem cell therapy (ischemic stroke), Aldagen
DM2U530 CP Cytomedix
DM2U530 DE Cerebrovascular ischaemia
DM6RBYT ID DM6RBYT
DM6RBYT DN ALD-403
DM6RBYT HS Phase 2
DM6RBYT SN MAb (migraine), Alder
DM6RBYT CP Alder biopharmaceuticals
DM6RBYT DE Migraine
DMPWSBL ID DMPWSBL
DMPWSBL DN ALD-518
DMPWSBL HS Phase 2
DMPWSBL DE Rheumatoid arthritis; Psoriatic arthritis
DMUA0XC ID DMUA0XC
DMUA0XC DN ALF-5755
DMUA0XC HS Phase 2
DMUA0XC SN HIP/PAP; Hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
DMUA0XC CP INSERM
DMUA0XC DE Liver failure
DMR2YPF ID DMR2YPF
DMR2YPF DN ALG-1001
DMR2YPF HS Phase 2
DMR2YPF CP Allegro Ophthalmics
DMR2YPF PC 130476723
DMR2YPF MW 637.7
DMR2YPF FM C22H39N9O11S
DMR2YPF IC InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1
DMR2YPF CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O
DMR2YPF IK MYZAXBZLEILEBR-RVFOSREFSA-N
DMR2YPF IU (2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMR2YPF CA CAS 1307293-62-4
DMR2YPF DE Diabetic macular edema
DME3ZYC ID DME3ZYC
DME3ZYC DN ALKS 4230
DME3ZYC HS Phase 2
DME3ZYC CP Alkermes
DME3ZYC DT Protein
DME3ZYC DE Solid tumour/cancer
DMF3QN1 ID DMF3QN1
DMF3QN1 DN ALKS33
DMF3QN1 HS Phase 2
DMF3QN1 SN Samidorphan
DMF3QN1 CP Alkermes
DMF3QN1 DT Small molecular drug
DMF3QN1 PC 11667832
DMF3QN1 MW 370.4
DMF3QN1 FM C21H26N2O4
DMF3QN1 IC InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
DMF3QN1 CS C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O
DMF3QN1 IK RYIDHLJADOKWFM-MAODMQOUSA-N
DMF3QN1 IU (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide
DMF3QN1 CA CAS 852626-89-2
DMF3QN1 DE Alcohol dependence
DMWYMJN ID DMWYMJN
DMWYMJN DN ALN-CC5
DMWYMJN HS Phase 2
DMWYMJN CP Alnylam Pharmaceuticals: Cemdisiran
DMWYMJN DT Antisense oligonucleotide
DMWYMJN DE Haemolytic uraemic syndrome
DMEYNQA ID DMEYNQA
DMEYNQA DN ALN-RSV01
DMEYNQA HS Phase 2
DMEYNQA DT siRNA drug
DMEYNQA DE Respiratory infection; Respiratory syncytial virus infection
DMJPV5X ID DMJPV5X
DMJPV5X DN Alovudine
DMJPV5X HS Phase 2
DMJPV5X SN Alovudine; 25526-93-6; FddT; 3'-DEOXY-3'-FLUOROTHYMIDINE; FddThD; 3'-Fluoro-3'-deoxythymidine; Thymidine, 3'-deoxy-3'-fluoro-; 3'F-TdR; 3'-FddT; Alovudine [USAN:INN]; UNII-PG53R0DWDQ; 3'-Fluorothymidine; 3'-FLT; DRG-0097; PG53R0DWDQ; NSC 140025; BRN 0754299; 3'-Fluorodeoxythymidine; CL 184824; CHEMBL105318; FLT; 1-((2R,4S,5R)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; C10H13FN2O4; MIV-310; 1-(3'-Deoxy-3'-fluoro-beta-D-pentofuranosyl)thymine; CL-184824; DSSTox_RID_81738; DSSTox_CID_26579
DMJPV5X DT Small molecular drug
DMJPV5X PC 33039
DMJPV5X MW 244.22
DMJPV5X FM C10H13FN2O4
DMJPV5X IC InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1
DMJPV5X CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F
DMJPV5X IK UXCAQJAQSWSNPQ-XLPZGREQSA-N
DMJPV5X IU 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJPV5X CA CAS 25526-93-6
DMJPV5X DE Breast cancer
DM5EFXZ ID DM5EFXZ
DM5EFXZ DN Alpha-1 antitrypsin
DM5EFXZ HS Phase 2
DM5EFXZ SN AAT, Transgene; Alpha-1 antitrypsin, Transgene
DM5EFXZ CP Transgene SA
DM5EFXZ DE Bacillus anthracis infection; Coagulation defect
DMLBWT1 ID DMLBWT1
DMLBWT1 DN ALRN-6924
DMLBWT1 HS Phase 2
DMLBWT1 CP Aileron Therapeutics Cambridge, MA
DMLBWT1 DE Acute myeloid leukaemia; Haematological malignancy; Myelodysplastic syndrome; Solid tumour/cancer
DM9KL7P ID DM9KL7P
DM9KL7P DN ALT-801
DM9KL7P HS Phase 2
DM9KL7P SN ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
DM9KL7P CP Altor bioscience
DM9KL7P DE Acute myeloid leukaemia; Bladder cancer; Non-muscle invasive bladder cancer
DMK3U1X ID DMK3U1X
DMK3U1X DN ALT-803
DMK3U1X HS Phase 2
DMK3U1X SN IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
DMK3U1X CP Altor bioscience
DMK3U1X DE Human immunodeficiency virus infection; Solid tumour/cancer; Non-hodgkin lymphoma; Pancreatic cancer; Non-small-cell lung cancer; Bladder cancer; Multiple myeloma; Acute myeloid leukaemia
DMGJ71F ID DMGJ71F
DMGJ71F DN ALT-836
DMGJ71F HS Phase 2
DMGJ71F CP Altor BioScience
DMGJ71F DE Adult respiratory distress syndrome
DMLSK01 ID DMLSK01
DMLSK01 DN Altrakincept
DMLSK01 HS Phase 2
DMLSK01 CP Novartis
DMLSK01 DT Monoclonal antibody
DMLSK01 DE Asthma
DMXSFA0 ID DMXSFA0
DMXSFA0 DN ALV-003
DMXSFA0 HS Phase 2
DMXSFA0 SN Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine
DMXSFA0 CP Alvine Pharmaceuticals Inc
DMXSFA0 DE Coeliac disease
DMO1VHC ID DMO1VHC
DMO1VHC DN ALX-0061
DMO1VHC HS Phase 2
DMO1VHC SN Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
DMO1VHC CP Ablynx NV
DMO1VHC DT Antibody
DMO1VHC DE Autoimmune diabetes; Rheumatoid arthritis; Systemic lupus erythematosus
DMCAFXM ID DMCAFXM
DMCAFXM DN ALX-101
DMCAFXM HS Phase 2
DMCAFXM SN Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy
DMCAFXM CP Ralexar Therapeutics Malvern, PA
DMCAFXM PC 89792952
DMCAFXM MW 452.4
DMCAFXM FM C21H19F3N2O4S
DMCAFXM IC InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3
DMCAFXM CS CCOC(=O)CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C
DMCAFXM IK ZUMNJDGBYXHASJ-UHFFFAOYSA-N
DMCAFXM IU ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate
DMCAFXM CA CAS 1454288-88-0
DMCAFXM DE Atopic dermatitis
DMV934L ID DMV934L
DMV934L DN ALX-40-4C
DMV934L HS Phase 2
DMV934L SN AV-9
DMV934L CP NPS Allelix Corp
DMV934L DT Small molecular drug
DMV934L PC 25077385
DMV934L MW 1464.7
DMV934L FM C56H113N37O10
DMV934L IC InChI=1S/C56H113N37O10/c1-29(94)85-31(12-3-21-77-49(60)61)40(96)87-33(14-5-23-79-51(64)65)42(98)89-35(16-7-25-81-53(68)69)44(100)91-37(18-9-27-83-55(72)73)46(102)93-38(19-10-28-84-56(74)75)47(103)92-36(17-8-26-82-54(70)71)45(101)90-34(15-6-24-80-52(66)67)43(99)88-32(13-4-22-78-50(62)63)41(97)86-30(39(57)95)11-2-20-76-48(58)59/h30-38H,2-28H2,1H3,(H2,57,95)(H,85,94)(H,86,97)(H,87,96)(H,88,99)(H,89,98)(H,90,101)(H,91,100)(H,92,103)(H,93,102)(H4,58,59,76)(H4,60,61,77)(H4,62,63,78)(H4,64,65,79)(H4,66,67,80)(H4,68,69,81)(H4,70,71,82)(H4,72,73,83)(H4,74,75,84)/t30-,31-,32-,33-,34-,35-,36-,37-,38-/m1/s1
DMV934L CS CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N
DMV934L IK LGLVVVCSQBZONM-HCCLCSBVSA-N
DMV934L IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMV934L CA CAS 153127-49-2
DMV934L DE Human immunodeficiency virus infection
DMH5LFR ID DMH5LFR
DMH5LFR DN ALXN6000
DMH5LFR HS Phase 2
DMH5LFR SN Samalizumab
DMH5LFR CP Alexion Pharmaceuticals
DMH5LFR DT Antibody
DMH5LFR DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer
DM7ZQAT ID DM7ZQAT
DM7ZQAT DN ALZ-801
DM7ZQAT HS Phase 2
DM7ZQAT CP Alzheon
DM7ZQAT PC 25008296
DM7ZQAT MW 238.31
DM7ZQAT FM C8H18N2O4S
DM7ZQAT IC InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
DM7ZQAT CS CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
DM7ZQAT IK NRZRFNYKMSAZBI-ZETCQYMHSA-N
DM7ZQAT IU 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
DM7ZQAT CA CAS 1034190-08-3
DM7ZQAT DE Alzheimer disease
DM9UMSJ ID DM9UMSJ
DM9UMSJ DN AM001
DM9UMSJ HS Phase 2
DM9UMSJ SN MLS000562506; CHEMBL1407569; HMS2222P08; SMR000453693
DM9UMSJ CP AmDerma Pharmaceuticals
DM9UMSJ DT Small molecular drug
DM9UMSJ PC 16745944
DM9UMSJ MW 369.4
DM9UMSJ FM C19H19N3O5
DM9UMSJ IC InChI=1S/C19H19N3O5/c1-2-10-26-14-11-17(27-15(14)12-23)22-9-8-16(21-19(22)25)20-18(24)13-6-4-3-5-7-13/h1,3-9,14-15,17,23H,10-12H2,(H,20,21,24,25)/t14-,15-,17-/m1/s1
DM9UMSJ CS C#CCO[C@@H]1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3
DM9UMSJ IK VUDFTOHJBXWAGS-BFYDXBDKSA-N
DM9UMSJ IU N-[1-[(2R,4R,5R)-5-(hydroxymethyl)-4-prop-2-ynoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
DM9UMSJ DE Actinic keratosis
DMGVQI8 ID DMGVQI8
DMGVQI8 DN AM-001
DMGVQI8 HS Phase 2
DMGVQI8 SN AM-001 (topical); AM-001 (topical), DermAct
DMGVQI8 CP DermAct Pharmaceutical Inc
DMGVQI8 DE Dermatological disease; Actinic keratosis
DMBWNX5 ID DMBWNX5
DMBWNX5 DN AMA-76
DMBWNX5 HS Phase 2
DMBWNX5 CP Amakem
DMBWNX5 DE Glaucoma/ocular hypertension
DMEB3T9 ID DMEB3T9
DMEB3T9 DN Amdoxovir
DMEB3T9 HS Phase 2
DMEB3T9 SN Amdoxovir; DAPD; 145514-04-1; DAPD cpd; UNII-54I81H0M9C; (-)-DAPD; beta-D-2,6-Diaminopurine-dioxolane; 54I81H0M9C; [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol; (2R-cis)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (2R,4R)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (-)-(2R,4R)-2-Amino-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)adenine; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R-cis)-; Amdoxovir [USAN]
DMEB3T9 DT Small molecular drug
DMEB3T9 PC 124088
DMEB3T9 MW 252.23
DMEB3T9 FM C9H12N6O3
DMEB3T9 IC InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1
DMEB3T9 CS C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N
DMEB3T9 IK RLAHNGKRJJEIJL-RFZPGFLSSA-N
DMEB3T9 IU [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
DMEB3T9 CA CAS 145514-04-1
DMEB3T9 DE Hepatitis B virus infection
DMIVZ3M ID DMIVZ3M
DMIVZ3M DN AME-133v
DMIVZ3M HS Phase 2
DMIVZ3M SN Ocaratuzumab
DMIVZ3M CP MENTRIK Biotech
DMIVZ3M DT Antibody
DMIVZ3M DE Non-hodgkin lymphoma
DMUMCB9 ID DMUMCB9
DMUMCB9 DN Amelubant
DMUMCB9 HS Phase 2
DMUMCB9 SN Amelubant [INN]; BIIL 283 BS; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester
DMUMCB9 CP Boehringer Ingelheim
DMUMCB9 DT Small molecular drug
DMUMCB9 PC 135564996
DMUMCB9 MW 538.6
DMUMCB9 FM C33H34N2O5
DMUMCB9 IC InChI=1S/C33H34N2O5/c1-4-38-32(37)35-31(34)25-8-16-29(17-9-25)39-21-23-6-5-7-24(20-23)22-40-30-18-12-27(13-19-30)33(2,3)26-10-14-28(36)15-11-26/h5-20,36H,4,21-22H2,1-3H3,(H2,34,35,37)
DMUMCB9 CS CCOC(=O)NC(=N)C1=CC=C(C=C1)OCC2=CC(=CC=C2)COC3=CC=C(C=C3)C(C)(C)C4=CC=C(C=C4)O
DMUMCB9 IK SBVYURPQULDJTI-UHFFFAOYSA-N
DMUMCB9 IU ethyl N-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidoyl]carbamate
DMUMCB9 CA CAS 346735-24-8
DMUMCB9 DE Cystic fibrosis; Pulmonary disease
DMGOFL3 ID DMGOFL3
DMGOFL3 DN AMG 151
DMGOFL3 HS Phase 2
DMGOFL3 CP Amgen
DMGOFL3 DE Type-2 diabetes
DMPQHOR ID DMPQHOR
DMPQHOR DN AMG 208
DMPQHOR HS Phase 2
DMPQHOR SN AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8
DMPQHOR CP Amgen Thousand
DMPQHOR DT Small molecular drug
DMPQHOR PC 24864821
DMPQHOR MW 383.4
DMPQHOR FM C22H17N5O2
DMPQHOR IC InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
DMPQHOR CS COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5
DMPQHOR IK HEAIZQNMNCHNFD-UHFFFAOYSA-N
DMPQHOR IU 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
DMPQHOR CA CAS 1002304-34-8
DMPQHOR CB CHEBI:90626
DMPQHOR DE Solid tumour/cancer
DM65PTO ID DM65PTO
DM65PTO DN AMG 232
DM65PTO HS Phase 2
DM65PTO SN KRT-232
DM65PTO CP Amgen
DM65PTO PC 58573469
DM65PTO MW 568.6
DM65PTO FM C28H35Cl2NO5S
DM65PTO IC InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1
DM65PTO CS CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl
DM65PTO IK DRLCSJFKKILATL-YWCVFVGNSA-N
DM65PTO IU 2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid
DM65PTO CA CAS 1352066-68-2
DM65PTO DE Solid tumour/cancer; Merkel cell carcinoma
DMO72IF ID DMO72IF
DMO72IF DN AMG 301
DMO72IF HS Phase 2
DMO72IF CP Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ
DMO72IF DE Migraine; Hyperprolactinaemia
DMI3WFG ID DMI3WFG
DMI3WFG DN AMG 334
DMI3WFG HS Phase 2
DMI3WFG CP Amgen
DMI3WFG DE Migraine
DMIOUEY ID DMIOUEY
DMIOUEY DN AMG 337
DMIOUEY HS Phase 2
DMIOUEY PC 44181686
DMIOUEY MW 463.5
DMIOUEY FM C23H22FN7O3
DMIOUEY IC InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
DMIOUEY CS C[C@H](C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC
DMIOUEY IK DWHXUGDWKAIASB-CQSZACIVSA-N
DMIOUEY IU 6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one
DMIOUEY CA CAS 1173699-31-4
DMIOUEY DE Solid tumour/cancer; Clear cell sarcoma
DM0DRAZ ID DM0DRAZ
DM0DRAZ DN AMG 479
DM0DRAZ HS Phase 2
DM0DRAZ CP Amgen
DM0DRAZ DE Breast cancer
DME6QH1 ID DME6QH1
DME6QH1 DN AMG 557
DME6QH1 HS Phase 2
DME6QH1 CP Amgen Thousand
DME6QH1 DE Systemic lupus erythematosus; Sjogren syndrome
DMY1XJH ID DMY1XJH
DMY1XJH DN AMG 570
DMY1XJH HS Phase 2
DMY1XJH CP Amgen
DMY1XJH DT Small molecular drug
DMY1XJH DE Systemic lupus erythematosus
DMFXN2T ID DMFXN2T
DMFXN2T DN AMG 745
DMFXN2T HS Phase 2
DMFXN2T CP Amgen
DMFXN2T DE Muscle atrophy
DMWPGB8 ID DMWPGB8
DMWPGB8 DN Amg 747
DMWPGB8 HS Phase 2
DMWPGB8 CP Amgen
DMWPGB8 DE Schizophrenia
DM973N4 ID DM973N4
DM973N4 DN AMG 853
DM973N4 HS Phase 2
DM973N4 SN VIDUPIPRANT; 1169483-24-2; AMG 853; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238
DM973N4 CP Amgen Thousand
DM973N4 DT Small molecular drug
DM973N4 PC 42641863
DM973N4 MW 609.5
DM973N4 FM C28H27Cl2FN2O6S
DM973N4 IC InChI=1S/C28H27Cl2FN2O6S/c1-28(2,3)32-27(36)17-6-8-23(39-24-14-21(31)18(11-19(24)29)13-26(34)35)22(12-17)33-40(37,38)25-9-7-16(10-20(25)30)15-4-5-15/h6-12,14-15,33H,4-5,13H2,1-3H3,(H,32,36)(H,34,35)
DM973N4 CS CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl
DM973N4 IK PFWVGKROPKKEDW-UHFFFAOYSA-N
DM973N4 IU 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid
DM973N4 CA CAS 1169483-24-2
DM973N4 DE Asthma
DM3H0IX ID DM3H0IX
DM3H0IX DN AMG 890
DM3H0IX HS Phase 2
DM3H0IX SN Olpasiran
DM3H0IX CP Amgen
DM3H0IX DT Small interfering RNA
DM3H0IX DE Cardiac fibrosis
DMODJTX ID DMODJTX
DMODJTX DN AMG-181
DMODJTX HS Phase 2
DMODJTX SN Inflammatory bowel disease therapeutics, Amgen
DMODJTX CP Amgen; astrazeneca
DMODJTX DT Antibody
DMODJTX DE Crohn disease; Ulcerative colitis
DM1T3KQ ID DM1T3KQ
DM1T3KQ DN AMG-714
DM1T3KQ HS Phase 2
DM1T3KQ CP Genmab; Amgen
DM1T3KQ DT Antibody
DM1T3KQ DE Rheumatoid arthritis; Coeliac disease
DMJ4GPR ID DMJ4GPR
DMJ4GPR DN AMP-579
DMJ4GPR HS Phase 2
DMJ4GPR SN RPR-100579; (1S,2R,3S,4R)-4-[7-[1(R)-(3-Chloro-2-thienylmethyl)propylamino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR DT Small molecular drug
DMJ4GPR PC 72941762
DMJ4GPR MW 478
DMJ4GPR FM C22H28ClN5O3S
DMJ4GPR IC InChI=1S/C22H28ClN5O3S/c1-3-12(9-17-15(23)6-8-32-17)27-20-13-5-7-28(21(13)26-11-25-20)16-10-14(18(29)19(16)30)22(31)24-4-2/h5-8,11-12,14,16,18-19,29-30H,3-4,9-10H2,1-2H3,(H,24,31)(H,25,26,27)/t12-,14+,16-,18-,19+/m1/s1
DMJ4GPR CS CC[C@H](CC1=C(C=CS1)Cl)NC2=C3C=CN(C3=NC=N2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC
DMJ4GPR IK CKQOOYMMAAPDKH-QODLLSGVSA-N
DMJ4GPR IU (1S,2R,3S,4R)-4-[4-[[(2R)-1-(3-chlorothiophen-2-yl)butan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR CA CAS 213453-89-5
DMJ4GPR DE Hyperlipidaemia
DMGE8FK ID DMGE8FK
DMGE8FK DN AMR-001
DMGE8FK HS Phase 2
DMGE8FK CP Amorcyte; Progenitor Cell Therapy
DMGE8FK DE Heart failure
DMOB01U ID DMOB01U
DMOB01U DN Amsilarotene
DMOB01U HS Phase 2
DMOB01U SN Am-555S; TAC-101; Anticancer retinoic acid receptor antagonist (oral), Taiho
DMOB01U CP Taiho Pharmaceutical Co Ltd
DMOB01U DT Small molecular drug
DMOB01U PC 9800306
DMOB01U MW 385.6
DMOB01U FM C20H27NO3Si2
DMOB01U IC InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24)
DMOB01U CS C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C
DMOB01U IK VVTNSTLJOVCBDL-UHFFFAOYSA-N
DMOB01U IU 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
DMOB01U CA CAS 125973-56-0
DMOB01U DE Solid tumour/cancer
DMS0GA6 ID DMS0GA6
DMS0GA6 DN AMY-101
DMS0GA6 HS Phase 2
DMS0GA6 SN UNII-4Z4DFR9BX7; 4Z4DFR9BX7; 1427001-89-5 (free base); Compstatin 40; Compstatin analog peptide CP40; CHEMBL4297260; 1427001-89-5; L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3->13)-disulfide; S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)
DMS0GA6 CP Amyndas
DMS0GA6 DT Peptide
DMS0GA6 PC 131634231
DMS0GA6 MW 1789.1
DMS0GA6 FM C83H117N23O18S2
DMS0GA6 IC InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1
DMS0GA6 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN(C3=CC=CC=C32)C)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@@H](CC7=CC=C(C=C7)O)N
DMS0GA6 IK MUSGYEMSJUFFHT-UWABRSFTSA-N
DMS0GA6 IU 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMS0GA6 CA CAS 1427001-89-5
DMS0GA6 DE Gingivitis
DMT3S10 ID DMT3S10
DMT3S10 DN AN0128
DMT3S10 HS Phase 2
DMT3S10 SN Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane
DMT3S10 CP Anacor Pharma.
DMT3S10 DT Small molecular drug
DMT3S10 PC 11704019
DMT3S10 MW 400.1
DMT3S10 FM C20H16BCl2NO3
DMT3S10 IC InChI=1S/C20H16BCl2NO3/c1-12-5-7-14(10-16(12)22)21(15-8-6-13(2)17(23)11-15)27-20(26)19-18(25)4-3-9-24-19/h3-11,25H,1-2H3
DMT3S10 CS B(C1=CC(=C(C=C1)C)Cl)(C2=CC(=C(C=C2)C)Cl)OC(=O)C3=C(C=CC=N3)O
DMT3S10 IK ZTLSOLUCMQEGEA-UHFFFAOYSA-N
DMT3S10 IU bis(3-chloro-4-methylphenyl)boranyl 3-hydroxypyridine-2-carboxylate
DMT3S10 CA CAS 872044-70-7
DMT3S10 DE Psoriatic disorder; Atopic dermatitis
DMJ7QP8 ID DMJ7QP8
DMJ7QP8 DN AN-019
DMJ7QP8 HS Phase 2
DMJ7QP8 SN NRC-19; NRC-24; NRC-AN-015; NRC-AN-019; Bcr-Abl inhibitors (CML), Natco
DMJ7QP8 CP Natco Pharma Ltd
DMJ7QP8 DE Chronic myelogenous leukaemia
DM3JNXS ID DM3JNXS
DM3JNXS DN AN-1792
DM3JNXS HS Phase 2
DM3JNXS SN Betabloc; AIP-001
DM3JNXS CP Elan Pharmaceutical Research
DM3JNXS DT Small molecular drug
DM3JNXS PC 15176
DM3JNXS MW 283.83
DM3JNXS FM C16H26ClNO
DM3JNXS IC InChI=1S/C16H25NO.ClH/c1-3-12(2)17-11-16(18)15-9-8-13-6-4-5-7-14(13)10-15;/h8-10,12,16-18H,3-7,11H2,1-2H3;1H
DM3JNXS CS CCC(C)[NH2+]CC(C1=CC2=C(CCCC2)C=C1)O.[Cl-]
DM3JNXS IK KHBXORBAOCQNMC-UHFFFAOYSA-N
DM3JNXS IU butan-2-yl-[2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]azanium;chloride
DM3JNXS CA CAS 1506-12-3
DM3JNXS DE Alzheimer disease
DMDK7CL ID DMDK7CL
DMDK7CL DN AN-2898
DMDK7CL HS Phase 2
DMDK7CL SN PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
DMDK7CL CP Anacor Pharmaceuticals Inc
DMDK7CL PC 24806574
DMDK7CL MW 276.06
DMDK7CL FM C15H9BN2O3
DMDK7CL IC InChI=1S/C15H9BN2O3/c17-7-10-1-2-13(5-11(10)8-18)21-14-3-4-15-12(6-14)9-20-16(15)19/h1-6,19H,9H2
DMDK7CL CS B1(C2=C(CO1)C=C(C=C2)OC3=CC(=C(C=C3)C#N)C#N)O
DMDK7CL IK UBMGTTRDNUKZMT-UHFFFAOYSA-N
DMDK7CL IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzene-1,2-dicarbonitrile
DMDK7CL CA CAS 906673-33-4
DMDK7CL DE Atopic dermatitis
DMG7IEN ID DMG7IEN
DMG7IEN DN Anatibant
DMG7IEN HS Phase 2
DMG7IEN SN Anatibant [INN]; (2S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide
DMG7IEN CP Fournier Pharma
DMG7IEN DT Small molecular drug
DMG7IEN PC 9831652
DMG7IEN MW 711.7
DMG7IEN FM C34H36Cl2N6O5S
DMG7IEN IC InChI=1S/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)/t27-/m0/s1
DMG7IEN CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)C5=CC=C(C=C5)C(=N)N)Cl)C
DMG7IEN IK XUHBBTKJWIBQMY-MHZLTWQESA-N
DMG7IEN IU (2S)-N-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carboxamide
DMG7IEN CA CAS 209733-45-9
DMG7IEN CB CHEBI:138828
DMG7IEN DE Traumatic brain injury
DMTG2O0 ID DMTG2O0
DMTG2O0 DN Anrukinzumab
DMTG2O0 HS Phase 2
DMTG2O0 SN Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
DMTG2O0 CP Genentech
DMTG2O0 DT Monoclonal antibody
DMTG2O0 DE Ulcerative colitis; Asthma
DMHVZ27 ID DMHVZ27
DMHVZ27 DN Anti-CD137
DMHVZ27 HS Phase 2
DMHVZ27 SN BMS-663513
DMHVZ27 CP Bristol-Myers Squibb
DMHVZ27 DT Antibody
DMHVZ27 DE Solid tumour/cancer
DMPRIHK ID DMPRIHK
DMPRIHK DN Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
DMPRIHK HS Phase 2
DMPRIHK SN Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
DMPRIHK CP Transtarget; barbara ann karmanos cancer institute
DMPRIHK DT Antibody
DMPRIHK DE Breast cancer
DMVQHBK ID DMVQHBK
DMVQHBK DN Anti-GD2 CART
DMVQHBK HS Phase 2
DMVQHBK CP Zhujiang Hospital
DMVQHBK DT CAR T Cell Therapy
DMVQHBK DE Neuroblastoma
DMVRNAO ID DMVRNAO
DMVRNAO DN Anti-IP10
DMVRNAO HS Phase 2
DMVRNAO CP Bristol-myers squibb
DMVRNAO DT Antibody
DMVRNAO DE Ulcerative colitis; Crohn disease
DMJO402 ID DMJO402
DMJO402 DN Anti-LAG3
DMJO402 HS Phase 2
DMJO402 CP Bristol-Myers Squibb Princeton, NJ
DMJO402 DE Gastric adenocarcinoma; Renal cell carcinoma; Non-small-cell lung cancer
DMQ58YH ID DMQ58YH
DMQ58YH DN Anti-LT alpha
DMQ58YH HS Phase 2
DMQ58YH CP Genentech
DMQ58YH DT Antibody
DMQ58YH DE Rheumatoid arthritis
DMQFU1R ID DMQFU1R
DMQFU1R DN Anti-M1 prime
DMQFU1R HS Phase 2
DMQFU1R CP Genentech
DMQFU1R DT Antibody
DMQFU1R DE Asthma
DMJPZDC ID DMJPZDC
DMJPZDC DN Anti-PSCA mab
DMJPZDC HS Phase 2
DMJPZDC CP Agensys
DMJPZDC DT Monoclonal antibody
DMJPZDC DE Pancreatic cancer
DMDKRS3 ID DMDKRS3
DMDKRS3 DN Antistasin
DMDKRS3 HS Phase 2
DMDKRS3 DE Attention deficit hyperactivity disorder
DMRGQVZ ID DMRGQVZ
DMRGQVZ DN Antroquinonol
DMRGQVZ HS Phase 2
DMRGQVZ SN Hocena; Fungal extract (cancer), Golden Biotechnology
DMRGQVZ CP Golden biotechnology
DMRGQVZ PC 24875259
DMRGQVZ MW 390.6
DMRGQVZ FM C24H38O4
DMRGQVZ IC InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1
DMRGQVZ CS C[C@@H]1[C@H]([C@H](C(=C(C1=O)OC)OC)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMRGQVZ IK LJTSIMVOOOLKOL-FNRDIUJOSA-N
DMRGQVZ IU (4R,5R,6R)-4-hydroxy-2,3-dimethoxy-6-methyl-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]cyclohex-2-en-1-one
DMRGQVZ CA CAS 1010081-09-0
DMRGQVZ CB CHEBI:65415
DMRGQVZ DE Non-small-cell lung cancer; Pancreatic cancer
DMMJOZD ID DMMJOZD
DMMJOZD DN ANW-32821
DMMJOZD HS Phase 2
DMMJOZD SN Cholest-5-en-3-beta-ol; Cholesterol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; Hydrocerin; Kathro; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.; cholesterol; (-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 57-88-5; 5:6-Cholesten-3beta-ol; CCRIS 2834; Lanol
DMMJOZD PC 5997
DMMJOZD MW 386.664
DMMJOZD FM C27H46O
DMMJOZD IC HVYWMOMLDIMFJA-DPAQBDIFSA-N
DMMJOZD CS CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C
DMMJOZD IK InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMMJOZD IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMMJOZD CA CAS 17528-72-2
DMMJOZD CB ChEBI:15372
DMMJOZD DE Cone rod dystrophy
DMYBQEF ID DMYBQEF
DMYBQEF DN AP26113
DMYBQEF HS Phase 2
DMYBQEF SN 1197958-12-5; ALK-IN-1; UNII-3DGD69C6PV; 3DGD69C6PV; CHEMBL3397300; (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine; 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine; AP26113-analog; Tube723; compound 11q [PMID: 27144831]
DMYBQEF DT Small molecular drug
DMYBQEF PC 57390074
DMYBQEF MW 529
DMYBQEF FM C26H34ClN6O2P
DMYBQEF IC InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)
DMYBQEF CS CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC
DMYBQEF IK OVDSPTSBIQCAIN-UHFFFAOYSA-N
DMYBQEF IU 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine
DMYBQEF CA CAS 1197958-12-5
DMYBQEF DE Solid tumour/cancer
DM3ICYL ID DM3ICYL
DM3ICYL DN AP-301-IH
DM3ICYL HS Phase 2
DM3ICYL SN AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico
DM3ICYL CP Apeptico Forschung und Entwicklung GmbH
DM3ICYL DE Pneumonia
DMISQOZ ID DMISQOZ
DMISQOZ DN AP-761
DMISQOZ HS Phase 2
DMISQOZ SN BI-671800
DMISQOZ CP Actimis Pharmaceuticals Inc
DMISQOZ DT Small molecular drug
DMISQOZ PC 45270144
DMISQOZ MW 501.5
DMISQOZ FM C25H26F3N5O3
DMISQOZ IC InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)
DMISQOZ CS CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O
DMISQOZ IK XEOSTBFUCNZKGS-UHFFFAOYSA-N
DMISQOZ IU 2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid
DMISQOZ CA CAS 1093108-50-9
DMISQOZ DE Asthma
DM1B8IT ID DM1B8IT
DM1B8IT DN Apadoline
DM1B8IT HS Phase 2
DM1B8IT SN ACMC-20mvlw; SCHEMBL7518667; CTK8G8521; 10H-Phenothiazine-2-carboxamide,10-[(1R)-1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-; KXMAIWXPZGQNCR-UHFFFAOYSA-N; L001386; N-propyl-10-[1-(pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide; N-propyl-10-[1-(1-pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide
DM1B8IT CP Rhone-Poulenc SA
DM1B8IT DT Small molecular drug
DM1B8IT PC 179334
DM1B8IT MW 395.6
DM1B8IT FM C23H29N3OS
DM1B8IT IC InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1
DM1B8IT CS CCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2[C@H](C)CN4CCCC4
DM1B8IT IK KXMAIWXPZGQNCR-QGZVFWFLSA-N
DM1B8IT IU N-propyl-10-[(2R)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide
DM1B8IT CA CAS 135003-30-4
DM1B8IT DE Pain
DMQMV9F ID DMQMV9F
DMQMV9F DN Apaxifylline
DMQMV9F HS Phase 2
DMQMV9F SN BIIP-20; U-98950; BIIP-20-XX
DMQMV9F CP Boehringer Ingelheim Corp
DMQMV9F DT Small molecular drug
DMQMV9F PC 60949
DMQMV9F MW 318.37
DMQMV9F FM C16H22N4O3
DMQMV9F IC InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1
DMQMV9F CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3CCC(=O)C3
DMQMV9F IK RUHGOZFOVBMWOO-JTQLQIEISA-N
DMQMV9F IU 8-[(1S)-3-oxocyclopentyl]-1,3-dipropyl-7H-purine-2,6-dione
DMQMV9F CA CAS 151581-23-6
DMQMV9F DE Cognitive impairment
DM3VP19 ID DM3VP19
DM3VP19 DN APC-8015F
DM3VP19 HS Phase 2
DM3VP19 SN CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon
DM3VP19 CP Dendreon Corp
DM3VP19 DE Prostate cancer
DMNQ7DV ID DMNQ7DV
DMNQ7DV DN APD-209
DMNQ7DV HS Phase 2
DMNQ7DV SN Undisclosed cachexia therapy (oral fixed-dose combination), Acacia
DMNQ7DV CP Acacia Pharma Ltd
DMNQ7DV PC 49837938
DMNQ7DV MW 1042.3
DMNQ7DV FM C54H95N3O16
DMNQ7DV IC InChI=1S/C54H95N3O16/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-25-28-48(62)56-31-34-68-36-38-70-40-42-71-41-39-69-37-35-67-33-29-49(63)55-30-26-24-27-32-72-54(53(65)66)43-46(60)50(57-45(2)59)52(73-54)51(64)47(61)44-58/h46-47,50-52,58,60-61,64H,3-13,18-44H2,1-2H3,(H,55,63)(H,56,62)(H,57,59)(H,65,66)/t46-,47+,50+,51+,52+,54+/m0/s1
DMNQ7DV CS CCCCCCCCCCCCC#CC#CCCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NCCCCCO[C@@]1(C[C@@H]([C@H]([C@@H](O1)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O
DMNQ7DV IK VRJMVFQLUBTBKF-HBJHFNNESA-N
DMNQ7DV IU (2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-[5-[3-[2-[2-[2-[2-[2-(pentacosa-10,12-diynoylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]pentoxy]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMNQ7DV CA CAS 1261156-82-4
DMNQ7DV DE Cachexia
DM3XT5V ID DM3XT5V
DM3XT5V DN APD371
DM3XT5V HS Phase 2
DM3XT5V SN Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci
DM3XT5V CP Arena Pharmaceuticals San Diego, CA
DM3XT5V PC 60164925
DM3XT5V MW 357.4
DM3XT5V FM C18H23N5O3
DM3XT5V IC InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1
DM3XT5V CS CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-]
DM3XT5V IK ACSQLTBPYZSGBA-GMXVVIOVSA-N
DM3XT5V IU (2S,4S)-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-9-(4-oxidopyrazin-4-ium-2-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide
DM3XT5V CA CAS 1268881-20-4
DM3XT5V DE Crohn disease
DM1VITS ID DM1VITS
DM1VITS DN APD-403
DM1VITS HS Phase 2
DM1VITS CP Acacia Pharma Ltd
DM1VITS DE Vomiting
DM9LZ0M ID DM9LZ0M
DM9LZ0M DN APD-515
DM9LZ0M HS Phase 2
DM9LZ0M SN ACA-1515
DM9LZ0M CP Acacia Pharma Ltd
DM9LZ0M DE Xerostomia
DM0FXMZ ID DM0FXMZ
DM0FXMZ DN APG-101
DM0FXMZ HS Phase 2
DM0FXMZ SN CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
DM0FXMZ CP Apogenix GmbH
DM0FXMZ DE Cerebrovascular ischaemia
DMIFA0L ID DMIFA0L
DMIFA0L DN APG-115
DMIFA0L HS Phase 2
DMIFA0L SN 15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
DMIFA0L CP Ascentage Pharma Rockville, MD
DMIFA0L PC 91972012
DMIFA0L MW 642.6
DMIFA0L FM C34H38Cl2FN3O4
DMIFA0L IC InChI=1S/C34H38Cl2FN3O4/c1-2-40-27(28(41)39-32-16-13-31(14-17-32,15-18-32)30(43)44)25(21-7-6-8-23(36)26(21)37)34(33(40)11-4-3-5-12-33)22-10-9-20(35)19-24(22)38-29(34)42/h6-10,19,25,27H,2-5,11-18H2,1H3,(H,38,42)(H,39,41)(H,43,44)/t25-,27+,31?,32?,34+/m0/s1
DMIFA0L CS CCN1[C@H]([C@@H]([C@]2(C13CCCCC3)C4=C(C=C(C=C4)Cl)NC2=O)C5=C(C(=CC=C5)Cl)F)C(=O)NC67CCC(CC6)(CC7)C(=O)O
DMIFA0L IK YJCZPJQGFSSFOL-MNZPCBJKSA-N
DMIFA0L CA CAS 1818393-16-6
DMIFA0L DE Solid tumour/cancer; Prolymphocytic leukaemia
DM756GE ID DM756GE
DM756GE DN APH-0812
DM756GE HS Phase 2
DM756GE SN Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios
DM756GE CP Aphios Corp
DM756GE DE Human immunodeficiency virus-1 infection; Human immunodeficiency virus infection
DMHIS6Z ID DMHIS6Z
DMHIS6Z DN Apilimod
DMHIS6Z HS Phase 2
DMHIS6Z SN Apilimod; STA 5326; STA-5326; GFW2K84S4L; STA5326; Apilimod [INN]; EX-A908
DMHIS6Z TC Antiviral Agents
DMHIS6Z DT Small molecular drug
DMHIS6Z PC 10173277
DMHIS6Z MW 418.5
DMHIS6Z FM C23H26N6O2
DMHIS6Z IC InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
DMHIS6Z CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
DMHIS6Z IK HSKAZIJJKRAJAV-KOEQRZSOSA-N
DMHIS6Z IU N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMHIS6Z CA CAS 541550-19-0
DMHIS6Z DE Coronavirus Disease 2019 (COVID-19)
DM4N2O0 ID DM4N2O0
DM4N2O0 DN Apilimod dimesylate
DM4N2O0 HS Phase 2
DM4N2O0 CP LAM Therapeutics Guilford, CT
DM4N2O0 PC 11527330
DM4N2O0 MW 610.7
DM4N2O0 FM C25H34N6O8S2
DM4N2O0 IC InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28);2*1H3,(H,2,3,4)/b25-17+;;
DM4N2O0 CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4.CS(=O)(=O)O.CS(=O)(=O)O
DM4N2O0 IK GAJWNIKZLYZYSY-OKUPSQOASA-N
DM4N2O0 IU methanesulfonic acid;N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DM4N2O0 CA CAS 870087-36-8
DM4N2O0 DE Non-hodgkin lymphoma
DM7IGO9 ID DM7IGO9
DM7IGO9 DN Apimostinel
DM7IGO9 HS Phase 2
DM7IGO9 SN UNII-TTT1F11FZB; TTT1F11FZB; 1421866-48-9; Apimostinel [USAN]; SCHEMBL14682282; CHEMBL3989872; DB11784; Threonyl-prolyl-2R-(2-benzyl)-prolyl-threonine amide; L-Threoninamide, L-threonyl-L-prolyl-2-(phenylmethyl)-L-prolyl-
DM7IGO9 CP Allergan Parsippany, NJ
DM7IGO9 PC 71249967
DM7IGO9 MW 503.6
DM7IGO9 FM C25H37N5O6
DM7IGO9 IC InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1
DM7IGO9 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@@]2(CC3=CC=CC=C3)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DM7IGO9 IK DVBUEXCIEIAXPM-PJUQSVSOSA-N
DM7IGO9 IU (2R)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide
DM7IGO9 CA CAS 1421866-48-9
DM7IGO9 DE Major depressive disorder
DMP0LST ID DMP0LST
DMP0LST DN APL-101
DMP0LST HS Phase 2
DMP0LST SN Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine
DMP0LST CP Apollomics
DMP0LST DT Small molecular drug
DMP0LST PC 72202701
DMP0LST MW 424.4
DMP0LST FM C20H15F3N8
DMP0LST IC InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
DMP0LST CS CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
DMP0LST IK QHXLXUIZUCJRKV-UHFFFAOYSA-N
DMP0LST IU 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
DMP0LST CA CAS 1440964-89-5
DMP0LST DE Non-small cell lung cancer
DMGJ1X2 ID DMGJ1X2
DMGJ1X2 DN Aplindore fumarate
DMGJ1X2 HS Phase 2
DMGJ1X2 SN Aplindore; Aplindore fumarate (USAN); WAY-DAB-452; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one; 8H-1,4-Dioxino(2,3-e)indol-8-one,2,3,7,9-tetrahydro-2-(((phenylmethyl)amino)methyl)-,2(S)-, (2E)-2-butenediotate (1:1)
DMGJ1X2 CP Wyeth
DMGJ1X2 DT Small molecular drug
DMGJ1X2 PC 6440763
DMGJ1X2 MW 426.4
DMGJ1X2 FM C22H22N2O7
DMGJ1X2 IC InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1
DMGJ1X2 CS C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O
DMGJ1X2 IK GELJVTSEGKGLDF-QDSMGTAFSA-N
DMGJ1X2 IU (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(E)-but-2-enedioic acid
DMGJ1X2 CA CAS 189681-71-8
DMGJ1X2 DE Schizophrenia
DMGNFBC ID DMGNFBC
DMGNFBC DN APN301
DMGNFBC HS Phase 2
DMGNFBC SN MAb hu14.18 linked with IL-2
DMGNFBC CP Apeiron Biologics
DMGNFBC DT Antibody
DMGNFBC DE Neuroblastoma
DM32YTJ ID DM32YTJ
DM32YTJ DN APN-301
DM32YTJ HS Phase 2
DM32YTJ SN EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
DM32YTJ CP Apeiron biologics
DM32YTJ DE Melanoma; Neuroblastoma
DMEXN7V ID DMEXN7V
DMEXN7V DN APN401
DMEXN7V HS Phase 2
DMEXN7V SN APN-411; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer); Cbl-b modulators (cancer), Apeiron Biologics; E3 ubiquitin ligase casitas B cell lymphoma-b silencing siRNA therapeutics (cancer), Apeiron Biologics; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer), Apeiron Biologics
DMEXN7V CP Apeiron Biologics
DMEXN7V DT Small interfering RNA
DMEXN7V DE Solid tumour/cancer
DMKVP7E ID DMKVP7E
DMKVP7E DN Apolizumab
DMKVP7E HS Phase 2
DMKVP7E SN Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma
DMKVP7E CP PDL BioPharma
DMKVP7E DT Monoclonal antibody
DMKVP7E DE Solid tumour/cancer
DM6B9HP ID DM6B9HP
DM6B9HP DN Apomine
DM6B9HP HS Phase 2
DM6B9HP SN Apomine; SR-45023A; UNII-JQ95208805; JQ95208805; SR-9223i; SR 45023A; APB-231-A2; SKF 99085; F-99085; 126411-13-0; SCHEMBL1648488; AC1L423G; DB12276; 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol; tetraisopropyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-biphosphonate; Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl); SK&F-99085; 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonic acid tetraisopropyl ester; SR-45023A (Apomine)
DM6B9HP CP Genzyme
DM6B9HP DT Small molecular drug
DM6B9HP PC 176405
DM6B9HP MW 562.7
DM6B9HP FM C28H52O7P2
DM6B9HP IC InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3
DM6B9HP CS CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OC(C)C)OC(C)C)OC(C)C
DM6B9HP IK YLJOVCWVJCDPLN-UHFFFAOYSA-N
DM6B9HP IU 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol
DM6B9HP CA CAS 126411-13-0
DM6B9HP DE Osteopetrosis
DMNFADH ID DMNFADH
DMNFADH DN APR-246
DMNFADH HS Phase 2
DMNFADH SN Eprenetapopt
DMNFADH CP Aprea Therapeutics
DMNFADH DT Small molecular drug
DMNFADH PC 52918385
DMNFADH MW 199.25
DMNFADH FM C10H17NO3
DMNFADH IC InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3
DMNFADH CS COCC1(C(=O)C2CCN1CC2)CO
DMNFADH IK BGBNULCRKBVAKL-UHFFFAOYSA-N
DMNFADH IU 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
DMNFADH CA CAS 5291-32-7
DMNFADH DE Solid tumour/cancer; Ovarian cancer; Esophageal cancer; Myelodysplastic syndrome; Bladder cancer; Gastric adenocarcinoma
DM8W4N9 ID DM8W4N9
DM8W4N9 DN Apratastat
DM8W4N9 HS Phase 2
DM8W4N9 SN TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, > MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst
DM8W4N9 CP Wyeth Research
DM8W4N9 DT Small molecular drug
DM8W4N9 PC 11452716
DM8W4N9 MW 414.5
DM8W4N9 FM C17H22N2O6S2
DM8W4N9 IC InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)/t15-/m0/s1
DM8W4N9 CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C
DM8W4N9 IK MAVDNGWEBZTACC-HNNXBMFYSA-N
DM8W4N9 IU (3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide
DM8W4N9 CA CAS 287405-51-0
DM8W4N9 DE Rheumatoid arthritis
DMEJICQ ID DMEJICQ
DMEJICQ DN Aprocitentan
DMEJICQ HS Phase 2
DMEJICQ SN ACT-132577; UNII-MZI81HV01P; 1103522-45-7; Despropyl Macitentan; MZI81HV01P; CHEMBL2165326; CHEBI:76609; Macitentan metabolite; ACT 132577; SCHEMBL3646065; ZINC95553608; BDBM50395672; AKOS028114466; CS-2687; HY-15895; BC600808; 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide
DMEJICQ CP Idorsia Pharmaceuticals Allschwil, Switzerland Janssen Biotech Horsham, PA
DMEJICQ PC 25099191
DMEJICQ MW 546.2
DMEJICQ FM C16H14Br2N6O4S
DMEJICQ IC InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
DMEJICQ CS C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
DMEJICQ IK DKULOVKANLVDEA-UHFFFAOYSA-N
DMEJICQ IU 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
DMEJICQ CA CAS 1103522-45-7
DMEJICQ CB CHEBI:76609
DMEJICQ DE Hypertension
DMX2P5G ID DMX2P5G
DMX2P5G DN APX005M
DMX2P5G HS Phase 2
DMX2P5G CP Apexigen San Carlos, CA
DMX2P5G DT Antibody
DMX2P5G DE Solid tumour/cancer; Brain cancer; Chronic lymphocytic leukaemia; Melanoma
DMU6NBO ID DMU6NBO
DMU6NBO DN APX3330
DMU6NBO HS Phase 2
DMU6NBO SN E3330; 136164-66-4; E-3330; E 3330; CHEMBL578390; UNII-11267UI968; 11267UI968; (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid; (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid; (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid; SCHEMBL3758716; SCHEMBL3758719; HMS3886N15; APX 3330; EX-A2212; BDBM50303955; s7445; ZINC14252145; CCG-268389; HY-19357; B5875; CS-0015424; E3330, >=98% (HPLC); A14440; (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid; (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid; Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)-
DMU6NBO CP Apexian Pharmaceuticals
DMU6NBO DT Small molecular drug
DMU6NBO PC 6439397
DMU6NBO MW 378.5
DMU6NBO FM C21H30O6
DMU6NBO IC InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h13H,5-12H2,1-4H3,(H,24,25)/b15-13+
DMU6NBO CS CCCCCCCCC/C(=C\\C1=C(C(=O)C(=C(C1=O)OC)OC)C)/C(=O)O
DMU6NBO IK AALSSIXXBDPENJ-FYWRMAATSA-N
DMU6NBO IU (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid
DMU6NBO CA CAS 136164-66-4
DMU6NBO DE Solid tumour/cancer; Diabetic retinopathy
DM1USXR ID DM1USXR
DM1USXR DN AQ-13
DM1USXR HS Phase 2
DM1USXR SN AQ-13 Dihydrochloride; 169815-40-1; UNII-PKT9732S5K; AQ 13; PKT9732S5K; DTXSID10168761; (N1-(7-Chloroquinolin-4-yl)-3-(N3,N3-diethylamino)propylamine) dihydrochloride; HY-100358; CS-0018673; 1,3-Propanediamine, N'-(7-chloro-4-quinolinyl)-N,N-diethyl-, dihydrochloride
DM1USXR CP Tulane University
DM1USXR DT Small molecular drug
DM1USXR PC 9820475
DM1USXR MW 364.7
DM1USXR FM C16H24Cl3N3
DM1USXR IC InChI=1S/C16H22ClN3.2ClH/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16;;/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19);2*1H
DM1USXR CS CCN(CC)CCCNC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl
DM1USXR IK ZNHBPWZRWNFJPN-UHFFFAOYSA-N
DM1USXR IU N-(7-chloroquinolin-4-yl)-N',N'-diethylpropane-1,3-diamine;dihydrochloride
DM1USXR CA CAS 169815-40-1
DM1USXR DE Malaria
DMD2RFO ID DMD2RFO
DMD2RFO DN AQW-051
DMD2RFO HS Phase 2
DMD2RFO SN AQW-051; 669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
DMD2RFO CP Novartis AG
DMD2RFO DT Small molecular drug
DMD2RFO PC 50914822
DMD2RFO MW 294.4
DMD2RFO FM C19H22N2O
DMD2RFO IC InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
DMD2RFO CS CC1=CC=C(C=C1)C2=NC=C(C=C2)O[C@H]3CN4CCC3CC4
DMD2RFO IK NPDLTEZXGWRMLQ-IBGZPJMESA-N
DMD2RFO IU (3R)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane
DMD2RFO DE Alzheimer disease
DMCH3G5 ID DMCH3G5
DMCH3G5 DN AQX-1125
DMCH3G5 HS Phase 2
DMCH3G5 SN AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox
DMCH3G5 CP Aquinox Pharmaceuticals Inc
DMCH3G5 DT Small molecular drug
DMCH3G5 PC 76965484
DMCH3G5 MW 321.5
DMCH3G5 FM C20H35NO2
DMCH3G5 IC InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1
DMCH3G5 CS C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C
DMCH3G5 IK MDEJTPWQNNMAQF-BVMLLJBZSA-N
DMCH3G5 IU (1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol
DMCH3G5 CA CAS 782487-28-9
DMCH3G5 DE Chronic obstructive pulmonary disease
DM93CTQ ID DM93CTQ
DM93CTQ DN AR08
DM93CTQ HS Phase 2
DM93CTQ CP Arbor pharmaceuticals
DM93CTQ DE Attention deficit hyperactivity disorder
DM5TC43 ID DM5TC43
DM5TC43 DN AR-12286
DM5TC43 HS Phase 2
DM5TC43 SN AR-11236; AR-12080; AR-12132; CF-286-03; CF-286-04
DM5TC43 CP Aerie Pharmaceuticals Inc
DM5TC43 PC 66906051
DM5TC43 MW 327.4
DM5TC43 FM C17H17N3O2S
DM5TC43 IC InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)
DM5TC43 CS CN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3
DM5TC43 IK VDYRZXYYQMMFJW-UHFFFAOYSA-N
DM5TC43 IU 2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide
DM5TC43 CA CAS 1414854-42-4
DM5TC43 DE Glaucoma/ocular hypertension
DM8A71F ID DM8A71F
DM8A71F DN AR-67
DM8A71F HS Phase 2
DM8A71F SN AR-67; Silatecan; 220913-32-6; DB-67; UNII-3YEA04NV6H; 3YEA04NV6H; DB67; AR67; AR 67; (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; NCI60_038363; C26H30N2O5Si; SCHEMBL1266162; CHEMBL412309; GTPL8919; DTXSID00176592; DB 67; BCP19768; 7555AD; NSC708298; ZINC170020689; AKOS030627314; DB12384; NSC-708298; compound 14 [PMID:11052802]; KB-74723; Z3398; Z-3160; 1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9-dihydroxy-, (4S)-
DM8A71F CP Arno Therapeutics
DM8A71F DT Small molecular drug
DM8A71F PC 6712744
DM8A71F MW 478.6
DM8A71F FM C26H30N2O5Si
DM8A71F IC InChI=1S/C26H30N2O5Si/c1-7-26(32)18-11-20-21-16(12-28(20)23(30)17(18)13-33-24(26)31)22(34(5,6)25(2,3)4)15-10-14(29)8-9-19(15)27-21/h8-11,29,32H,7,12-13H2,1-6H3/t26-/m0/s1
DM8A71F CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O
DM8A71F IK XUSKJHCMMWAAHV-SANMLTNESA-N
DM8A71F IU (19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DM8A71F CA CAS 220913-32-6
DM8A71F DE Myelodysplastic syndrome; Glioblastoma multiforme
DMJHA6Q ID DMJHA6Q
DMJHA6Q DN Ar9281
DMJHA6Q HS Phase 2
DMJHA6Q SN 1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
DMJHA6Q CP Ar te Therapeutics
DMJHA6Q DT Small molecular drug
DMJHA6Q PC 12000797
DMJHA6Q MW 319.4
DMJHA6Q FM C18H29N3O2
DMJHA6Q IC InChI=1S/C18H29N3O2/c1-12(22)21-4-2-16(3-5-21)19-17(23)20-18-9-13-6-14(10-18)8-15(7-13)11-18/h13-16H,2-11H2,1H3,(H2,19,20,23)
DMJHA6Q CS CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMJHA6Q IK HUDQLWBKJOMXSZ-UHFFFAOYSA-N
DMJHA6Q IU 1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea
DMJHA6Q CA CAS 913548-29-5
DMJHA6Q DE Hypertension
DM7PCLY ID DM7PCLY
DM7PCLY DN ARC1779
DM7PCLY HS Phase 2
DM7PCLY CP Archemix
DM7PCLY DT Small molecular drug
DM7PCLY DE Intracranial embolism
DM9LNXS ID DM9LNXS
DM9LNXS DN ARI-3037MO
DM9LNXS HS Phase 2
DM9LNXS CP Arisaph Pharmaceuticals
DM9LNXS DE Dyslipidemia; Cardiovascular disease; Hypertriglyceridemia
DML3PJF ID DML3PJF
DML3PJF DN ARN-810
DML3PJF HS Phase 2
DML3PJF CP Seragon pharmaceuticals
DML3PJF PC 56941241
DML3PJF MW 446.9
DML3PJF FM C26H20ClFN2O2
DML3PJF IC InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+
DML3PJF CS CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl
DML3PJF IK BURHGPHDEVGCEZ-KJGLQBJMSA-N
DML3PJF IU (E)-3-[4-[(E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid
DML3PJF CA CAS 1365888-06-7
DML3PJF DE Breast cancer
DM2UP6Z ID DM2UP6Z
DM2UP6Z DN ARO-AAT
DM2UP6Z HS Phase 2
DM2UP6Z CP Arrowhead Pharmaceuticals
DM2UP6Z DT Small interfering RNA
DM2UP6Z DE Alpha-1 antitrypsin deficiency; Alopecia
DM5WK0J ID DM5WK0J
DM5WK0J DN ARQ 092
DM5WK0J HS Phase 2
DM5WK0J SN Miransertib
DM5WK0J CP ArQule; Daiichi
DM5WK0J PC 53262401
DM5WK0J MW 432.5
DM5WK0J FM C27H24N6
DM5WK0J IC InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
DM5WK0J CS C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N
DM5WK0J IK HNFMVVHMKGFCMB-UHFFFAOYSA-N
DM5WK0J IU 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine
DM5WK0J CA CAS 1313881-70-7
DM5WK0J DE Solid tumour/cancer; Proteus syndrome
DMRG0A3 ID DMRG0A3
DMRG0A3 DN ARQ 531
DMRG0A3 HS Phase 2
DMRG0A3 SN JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol
DMRG0A3 CP ArQule Burlington, MA
DMRG0A3 PC 129045720
DMRG0A3 MW 478.9
DMRG0A3 FM C25H23ClN4O4
DMRG0A3 IC InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1
DMRG0A3 CS C1C[C@H](OC[C@@H]1NC2=NC=NC3=C2C(=CN3)C(=O)C4=C(C=C(C=C4)OC5=CC=CC=C5)Cl)CO
DMRG0A3 IK JSFCZQSJQXFJDS-QAPCUYQASA-N
DMRG0A3 IU (2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone
DMRG0A3 CA CAS 2095393-15-8
DMRG0A3 DE Hematologic tumour
DMH5CAL ID DMH5CAL
DMH5CAL DN ARQ 761
DMH5CAL HS Phase 2
DMH5CAL CP ArQule
DMH5CAL DE Solid tumour/cancer; Pancreatic cancer
DMYEIOH ID DMYEIOH
DMYEIOH DN ARQ-154
DMYEIOH HS Phase 2
DMYEIOH CP Arcutis Biotherapeutics
DMYEIOH DT Small molecular drug
DMYEIOH DE Plaque psoriasis
DM0VGDC ID DM0VGDC
DM0VGDC DN ARRY-382
DM0VGDC HS Phase 2
DM0VGDC CP Array BioPharma; Celgene
DM0VGDC DE Solid tumour/cancer
DM17469 ID DM17469
DM17469 DN ARRY-502
DM17469 HS Phase 2
DM17469 CP Array BioPharma
DM17469 PC 131633366
DM17469 MW 516.4
DM17469 FM C26H23Cl2NO6
DM17469 IC InChI=1S/C26H23Cl2NO6/c1-33-22-12-17(27)5-2-15(22)8-10-29-25(30)16-3-6-18(7-4-16)35-24-14-23-20(13-21(24)28)19(26(31)32)9-11-34-23/h2-7,12-14,19H,8-11H2,1H3,(H,29,30)(H,31,32)/t19-/m0/s1
DM17469 CS COC1=C(C=CC(=C1)Cl)CCNC(=O)C2=CC=C(C=C2)OC3=C(C=C4[C@H](CCOC4=C3)C(=O)O)Cl
DM17469 IK QIDYUNXQPQEJEC-IBGZPJMESA-N
DM17469 IU (4S)-6-chloro-7-[4-[2-(4-chloro-2-methoxyphenyl)ethylcarbamoyl]phenoxy]-3,4-dihydro-2H-chromene-4-carboxylic acid
DM17469 CA CAS 1202891-16-4
DM17469 DE Allergic asthma
DMTOI7S ID DMTOI7S
DMTOI7S DN ARRY-520
DMTOI7S HS Phase 2
DMTOI7S SN Filanesib; ARRY-520; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; ARRY-520; Filanesib; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04
DMTOI7S CP Array BioPharma.
DMTOI7S TC Anticancer Agents
DMTOI7S DT Small molecular drug
DMTOI7S PC 44224257
DMTOI7S MW 420.5
DMTOI7S FM C20H22F2N4O2S
DMTOI7S IC InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3/t20-/m0/s1
DMTOI7S CS CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC
DMTOI7S IK LLXISKGBWFTGEI-FQEVSTJZSA-N
DMTOI7S IU (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide
DMTOI7S CA CAS 885060-09-3
DMTOI7S DE Solid tumour/cancer; Multiple myeloma
DMJ48AB ID DMJ48AB
DMJ48AB DN ARRY-797
DMJ48AB HS Phase 2
DMJ48AB SN CHEMBL1088750; ARRY-797; SCHEMBL222635; ARRY-371797; BDBM50314072
DMJ48AB CP Array BioPharma.
DMJ48AB TC Analgesics
DMJ48AB DT Small molecular drug
DMJ48AB PC 46883775
DMJ48AB MW 416.5
DMJ48AB FM C22H26F2N4O2
DMJ48AB IC InChI=1S/C22H26F2N4O2/c1-14(2)13-28-19-11-17(22(29)25-7-8-27(3)4)21(9-15(19)12-26-28)30-20-6-5-16(23)10-18(20)24/h5-6,9-12,14H,7-8,13H2,1-4H3,(H,25,29)
DMJ48AB CS CC(C)CN1C2=CC(=C(C=C2C=N1)OC3=C(C=C(C=C3)F)F)C(=O)NCCN(C)C
DMJ48AB IK IFGWYHGYNVGVRB-UHFFFAOYSA-N
DMJ48AB IU 5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide
DMJ48AB DE Pain; Osteoarthritis; Dilated cardiomyopathy
DML27AE ID DML27AE
DML27AE DN Arverapamil
DML27AE HS Phase 2
DML27AE SN Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE CP AGI Therapeutics
DML27AE DT Small molecular drug
DML27AE PC 15593907
DML27AE MW 440.6
DML27AE FM C26H36N2O4
DML27AE IC InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1
DML27AE CS CC(C)[C@@](CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DML27AE IK UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE IU (2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile
DML27AE CA CAS 123932-43-4
DML27AE CB CHEBI:134082
DML27AE DE Irritable bowel syndrome
DMMX1EJ ID DMMX1EJ
DMMX1EJ DN AS-1402
DMMX1EJ HS Phase 2
DMMX1EJ SN Therex; R-1550; HuHMFG1 derivative, ICRF/Antisoma/Roche; Anti-mucin MAb, ICRF/Antisoma/Roche
DMMX1EJ CP Antisoma
DMMX1EJ DT Antibody
DMMX1EJ DE Breast cancer
DMTUMYX ID DMTUMYX
DMTUMYX DN AS-902330
DMTUMYX HS Phase 2
DMTUMYX SN Sprifermin; Zfgf5; FGF-18, Merck Serono; FGF-18, ZymoGenetics
DMTUMYX CP Emd serono
DMTUMYX DE Arthropathy
DMNVU28 ID DMNVU28
DMNVU28 DN ASB17061
DMNVU28 HS Phase 2
DMNVU28 CP Daiichi Sankyo
DMNVU28 DE Atopic dermatitis
DMMBVCJ ID DMMBVCJ
DMMBVCJ DN ASCJ-9
DMMBVCJ HS Phase 2
DMMBVCJ SN Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience
DMMBVCJ CP AndroScience
DMMBVCJ DE Alopecia; Acne vulgaris
DMDQS4W ID DMDQS4W
DMDQS4W DN ASC-J9
DMDQS4W HS Phase 2
DMDQS4W SN Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9
DMDQS4W CP AndroScience
DMDQS4W DT Small molecular drug
DMDQS4W PC 6477182
DMDQS4W MW 396.4
DMDQS4W FM C23H24O6
DMDQS4W IC InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-
DMDQS4W CS COC1=C(C=C(C=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)/O)OC
DMDQS4W IK ZMGUKFHHNQMKJI-CIOHCNBKSA-N
DMDQS4W IU (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
DMDQS4W CA CAS 52328-98-0
DMDQS4W DE Thrombosis; End-stage renal disease
DMZF68E ID DMZF68E
DMZF68E DN Ascrolimus
DMZF68E HS Phase 2
DMZF68E SN A-86281; ABT-281; ZK-248258
DMZF68E CP Abbott Laboratories
DMZF68E PC 9919023
DMZF68E MW 844
DMZF68E FM C44H69N5O11
DMZF68E IC InChI=1S/C44H69N5O11/c1-10-31-18-25(2)17-26(3)19-37(57-8)40-38(58-9)21-28(5)44(55,60-40)41(52)42(53)48-16-12-11-13-33(48)43(54)59-39(29(6)34(50)23-35(31)51)27(4)20-30-14-15-32(36(22-30)56-7)49-24-45-46-47-49/h18,20,24,26,28-34,36-40,50,55H,10-17,19,21-23H2,1-9H3/b25-18+,27-20+/t26-,28+,29+,30-,31+,32-,33-,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZF68E CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)/C)O)C)OC)OC)C)\\C
DMZF68E IK HIEKJRVYXXINKH-ADVKXBNGSA-N
DMZF68E IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZF68E CA CAS 148147-65-3
DMZF68E DE Psoriasis vulgaris
DM1CLKO ID DM1CLKO
DM1CLKO DN ASKP-1240
DM1CLKO HS Phase 2
DM1CLKO SN Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kirin/Astellas; Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kyowa Hakko Kirin/Astellas; 4D11
DM1CLKO CP Astellas pharma us; kyowa hakko kirin pharma
DM1CLKO DT Antibody
DM1CLKO DE Transplant rejection
DM35S2I ID DM35S2I
DM35S2I DN ASM-024
DM35S2I HS Phase 2
DM35S2I CP Asmacure Lt |e
DM35S2I PC 117587641
DM35S2I MW 404.6
DM35S2I FM C22H32N2O3S
DM35S2I IC InChI=1S/C15H25N2.C7H8O3S/c1-3-17(4-2)13-8-11-16(12-14-17)15-9-6-5-7-10-15;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,9-10H,3-4,8,11-14H2,1-2H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1
DM35S2I CS CC[N+]1(CCCN(CC1)C2=CC=CC=C2)CC.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DM35S2I IK PXRYYARWCNIUKT-UHFFFAOYSA-M
DM35S2I IU 1,1-diethyl-4-phenyl-1,4-diazepan-1-ium;4-methylbenzenesulfonate
DM35S2I CA CAS 1609534-90-8
DM35S2I DE Asthma
DMTHR4U ID DMTHR4U
DMTHR4U DN ASM8
DMTHR4U HS Phase 2
DMTHR4U CP Pharmaxis
DMTHR4U DT Antisense drug
DMTHR4U DE Allergic asthma
DM92X7N ID DM92X7N
DM92X7N DN ASN002
DM92X7N HS Phase 2
DM92X7N SN POAZPIKWEFFCBP-UHFFFAOYSA-N; GTPL10000; 2-[1-(4-{[4-(4-hydroxypiperazin-1-yl)phenyl]amino}-5-oxo-5H,6H-pyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl]acetonitrile
DM92X7N CP Asana BioSciences Lawrenceville, NJ
DM92X7N PC 71269142
DM92X7N MW 460.5
DM92X7N FM C24H28N8O2
DM92X7N IC InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)
DM92X7N CS C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O
DM92X7N IK NLFLXLJXEIUQDL-UHFFFAOYSA-N
DM92X7N IU 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6H-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile
DM92X7N CA CAS 1425381-60-7
DM92X7N DE Eczema; Lymphoma; Solid tumour/cancer
DMWPGLS ID DMWPGLS
DMWPGLS DN ASN100
DMWPGLS HS Phase 2
DMWPGLS CP Arsanis
DMWPGLS DT Monoclonal antibody
DMWPGLS DE Ventilator-associated pneumonia; Hospital-acquired pneumonia
DM6HJ3V ID DM6HJ3V
DM6HJ3V DN ASP0819
DM6HJ3V HS Phase 2
DM6HJ3V CP Astellas Pharma
DM6HJ3V DT Small molecular drug
DM6HJ3V DE Fibromyalgia
DME8XD7 ID DME8XD7
DME8XD7 DN ASP-1707
DME8XD7 HS Phase 2
DME8XD7 CP Astellas Pharma Inc
DME8XD7 DE Endometriosis
DMBADQV ID DMBADQV
DMBADQV DN ASP-3291
DMBADQV HS Phase 2
DMBADQV CP Astellas Pharma Inc
DMBADQV DE Ulcerative colitis
DM4KTN6 ID DM4KTN6
DM4KTN6 DN ASP-3652
DM4KTN6 HS Phase 2
DM4KTN6 SN FK-175; Beta 3 adrenoceptor agonists (overactive bladder), Astellas
DM4KTN6 CP Astellas Pharma Inc
DM4KTN6 DE Overactive bladder
DMZUAH2 ID DMZUAH2
DMZUAH2 DN ASP-4901
DMZUAH2 HS Phase 2
DMZUAH2 CP Astellas Pharma
DMZUAH2 DE Genitourinary disease
DMTF24A ID DMTF24A
DMTF24A DN ASP-7035
DMTF24A HS Phase 2
DMTF24A CP Astellas Pharma Inc
DMTF24A PC 11478371
DMTF24A MW 548.4
DMTF24A FM C25H23F7N2O4
DMTF24A IC InChI=1S/C25H23F7N2O4/c1-14(26)13-38-16-3-4-17(20(11-16)25(30,31)32)23(37)34-8-6-24(28,29)19(12-22(36)33-7-9-35)18-10-15(27)2-5-21(18)34/h2-5,10-12,14,35H,6-9,13H2,1H3,(H,33,36)/b19-12-/t14-/m1/s1
DMTF24A CS C[C@H](COC1=CC(=C(C=C1)C(=O)N2CCC(/C(=C\\C(=O)NCCO)/C3=C2C=CC(=C3)F)(F)F)C(F)(F)F)F
DMTF24A IK VSXSHTIGQAUGMW-VCRXTVNUSA-N
DMTF24A IU (2Z)-N-(2-hydroxyethyl)-2-[4,4,7-trifluoro-1-[4-[(2R)-2-fluoropropoxy]-2-(trifluoromethyl)benzoyl]-2,3-dihydro-1-benzazepin-5-ylidene]acetamide
DMTF24A CA CAS 790694-26-7
DMTF24A DE Nocturia
DMGDF2X ID DMGDF2X
DMGDF2X DN ASP-7147
DMGDF2X HS Phase 2
DMGDF2X CP Astellas Pharma Inc
DMGDF2X DE Irritable bowel syndrome
DM3TN1A ID DM3TN1A
DM3TN1A DN ASP7991
DM3TN1A HS Phase 2
DM3TN1A CP Astellas
DM3TN1A DE Hyperparathyroidism
DMR1MIV ID DMR1MIV
DMR1MIV DN ASP8062
DMR1MIV HS Phase 2
DMR1MIV CP Astellas Northbrook, IL
DMR1MIV DE Fibromyalgia
DMYK1JU ID DMYK1JU
DMYK1JU DN ASP8232
DMYK1JU HS Phase 2
DMYK1JU CP Astellas
DMYK1JU DE Diabetic nephropathy; Diabetic macular edema
DMHLXUY ID DMHLXUY
DMHLXUY DN ASP8273
DMHLXUY HS Phase 2
DMHLXUY CP Astellas pharma us
DMHLXUY PC 71667668
DMHLXUY MW 562.7
DMHLXUY FM C30H42N8O3
DMHLXUY IC InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1
DMHLXUY CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
DMHLXUY IK QKDCLUARMDUUKN-XMMPIXPASA-N
DMHLXUY IU 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide
DMHLXUY CA CAS 1448232-80-1
DMHLXUY DE Non-small-cell lung cancer
DMBZQS7 ID DMBZQS7
DMBZQS7 DN ASP-8477
DMBZQS7 HS Phase 2
DMBZQS7 CP Astellas Pharma Inc
DMBZQS7 DE Neuropathic pain
DM2MSGF ID DM2MSGF
DM2MSGF DN ASP9831
DM2MSGF HS Phase 2
DM2MSGF CP Astellas
DM2MSGF DT Small molecular drug
DM2MSGF DE Steatohepatitis; Non-alcoholic steatohepatitis
DMMKW8L ID DMMKW8L
DMMKW8L DN ASTX660
DMMKW8L HS Phase 2
DMMKW8L SN YCXOHEXZVKOGEV-DNRQZRRGSA-N; 1799328-86-1; SCHEMBL16830758; CS-8216; HY-109565; 1-(6-(4-fluorobenzyl)-5-(hydroxymethyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((R)-3-methylmorpholino)methyl)piperazin-1-yl)ethan-1-one
DMMKW8L CP Astex Pharmaceuticals Pleasanton, CA
DMMKW8L PC 118169620
DMMKW8L MW 539.7
DMMKW8L FM C30H42FN5O3
DMMKW8L IC InChI=1S/C30H42FN5O3/c1-20-14-35(25(13-32-20)15-34-9-10-39-18-21(34)2)16-28(38)36-19-30(3,4)29-27(36)12-23(26(17-37)33-29)11-22-5-7-24(31)8-6-22/h5-8,12,20-21,25,32,37H,9-11,13-19H2,1-4H3/t20-,21-,25-/m1/s1
DMMKW8L CS C[C@@H]1CN([C@H](CN1)CN2CCOC[C@H]2C)CC(=O)N3CC(C4=C3C=C(C(=N4)CO)CC5=CC=C(C=C5)F)(C)C
DMMKW8L IK YCXOHEXZVKOGEV-DNRQZRRGSA-N
DMMKW8L IU 1-[6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-2H-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-[[(3R)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone
DMMKW8L CA CAS 1799328-86-1
DMMKW8L DE Solid tumour/cancer; Lymphoma
DMARIQK ID DMARIQK
DMARIQK DN AT-527
DMARIQK HS Phase 2
DMARIQK SN AT527; SCHEMBL18061556; GTPL11295; 2241337-84-6; propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK CP Atea Pharmaceuticals
DMARIQK DT Small molecular drug
DMARIQK PC 122527270
DMARIQK MW 581.5
DMARIQK FM C24H33FN7O7P
DMARIQK IC InChI=1S/C24H33FN7O7P/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33H,11H2,1-5H3,(H,31,35)(H3,26,27,29,30)/t14-,16?,18+,22+,24+,40-/m0/s1
DMARIQK CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
DMARIQK IK OISLSHLAXHALQZ-ZXWZJMKMSA-N
DMARIQK IU propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK DE Coronavirus Disease 2019 (COVID-19)
DM35KDA ID DM35KDA
DM35KDA DN Ataciguat
DM35KDA HS Phase 2
DM35KDA SN Ataciguat [INN]; HMR 1766; HMR-1766; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA CP Sanofi-Aventis
DM35KDA TC Analgesics
DM35KDA DT Small molecular drug
DM35KDA PC 213037
DM35KDA MW 576.5
DM35KDA FM C21H19Cl2N3O6S3
DM35KDA IC InChI=1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)
DM35KDA CS C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl
DM35KDA IK PQHLRGARXNPFCF-UHFFFAOYSA-N
DM35KDA IU 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA CA CAS 254877-67-3
DM35KDA DE Neuropathic pain
DM6ABD9 ID DM6ABD9
DM6ABD9 DN ATHX-105
DM6ABD9 HS Phase 2
DM6ABD9 SN ATH-88651; 5-HT2c receptor agonists (obesity), Athersys Inc
DM6ABD9 CP Athersys
DM6ABD9 DE Obesity
DMWP59B ID DMWP59B
DMWP59B DN ATI-2042
DMWP59B HS Phase 2
DMWP59B SN Budiodarone
DMWP59B CP ARYx Therapeutics
DMWP59B DT Small molecular drug
DMWP59B PC 9833332
DMWP59B MW 703.3
DMWP59B FM C27H31I2NO5
DMWP59B IC InChI=1S/C27H31I2NO5/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3/t17-/m0/s1
DMWP59B CS CC[C@H](C)OC(=O)CC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMWP59B IK ZXOSVKYCXLTVGS-KRWDZBQOSA-N
DMWP59B IU [(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate
DMWP59B CA CAS 335148-45-3
DMWP59B DE Atrial fibrillation
DMT5QYJ ID DMT5QYJ
DMT5QYJ DN ATI-2173
DMT5QYJ HS Phase 2
DMT5QYJ CP Antios Therapeutics
DMT5QYJ DT Small molecular drug
DMT5QYJ DE Hepatitis B
DMTY6OF ID DMTY6OF
DMTY6OF DN ATI-501
DMTY6OF HS Phase 2
DMTY6OF CP Aclaris Therapeutics
DMTY6OF DT Small molecular drug
DMTY6OF DE Alopecia
DM8NODR ID DM8NODR
DM8NODR DN ATI-502
DM8NODR HS Phase 2
DM8NODR SN ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
DM8NODR CP Aclaris Therapeutics
DM8NODR DT Small molecular drug
DM8NODR PC 46851625
DM8NODR MW 395.4
DM8NODR FM C20H18FN5O3
DM8NODR IC InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26)
DM8NODR CS CC1=CC(=CC(=C1F)OC)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(=O)N4)C
DM8NODR IK OYFMQDVLFYKOPZ-UHFFFAOYSA-N
DM8NODR IU 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one
DM8NODR CA CAS 1236667-40-5
DM8NODR DE Atopic dermatitis; Alopecia
DMK3VYU ID DMK3VYU
DMK3VYU DN ATI-502
DMK3VYU HS Phase 2
DMK3VYU CP Aclaris Therapeutics Wayne, PA
DMK3VYU DE Atopic dermatitis; Vitiligo
DMYAQV2 ID DMYAQV2
DMYAQV2 DN ATL101
DMYAQV2 HS Phase 2
DMYAQV2 CP Atlab pharma; weill medical college
DMYAQV2 DE Influenza virus infection
DMD0I29 ID DMD0I29
DMD0I29 DN ATL-104
DMD0I29 HS Phase 2
DMD0I29 DE Solid tumour/cancer
DM3POT6 ID DM3POT6
DM3POT6 DN ATL1102
DM3POT6 HS Phase 2
DM3POT6 CP ISIS Pharm; Antisense Therapeutics
DM3POT6 DE Multiple sclerosis
DM7I56B ID DM7I56B
DM7I56B DN ATM AVI
DM7I56B HS Phase 2
DM7I56B CP AstraZeneca
DM7I56B DE Bacterial infection
DM4T9RS ID DM4T9RS
DM4T9RS DN ATN-161
DM4T9RS HS Phase 2
DM4T9RS SN PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan
DM4T9RS CP University of Michigan
DM4T9RS DT Small molecular drug
DM4T9RS PC 9960285
DM4T9RS MW 597.6
DM4T9RS FM C23H35N9O8S
DM4T9RS IC InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1
DM4T9RS CS CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N
DM4T9RS IK MMHDBUJXLOFTLC-WOYTXXSLSA-N
DM4T9RS IU (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide
DM4T9RS CA CAS 262438-43-7
DM4T9RS DE Renal cell carcinoma
DMQJ5DV ID DMQJ5DV
DMQJ5DV DN ATN-224
DMQJ5DV HS Phase 2
DMQJ5DV SN Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
DMQJ5DV CP University of Michigan
DMQJ5DV DT Small molecular drug
DMQJ5DV PC 18442052
DMQJ5DV MW 434.6
DMQJ5DV FM C10H30MoN2O2S4
DMQJ5DV IC InChI=1S/2C5H14NO.Mo.2H2S.2S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;2*1H2;;/q2*+1;;;;;/p-2
DMQJ5DV CS C[N+](C)(C)CCO.C[N+](C)(C)CCO.[SH-].[SH-].S=[Mo]=S
DMQJ5DV IK FSWNJZRQQVVVJT-UHFFFAOYSA-L
DMQJ5DV IU bis(sulfanylidene)molybdenum;2-hydroxyethyl(trimethyl)azanium;sulfanide
DMQJ5DV CA CAS 649749-10-0
DMQJ5DV DE Solid tumour/cancer
DMUXO3Z ID DMUXO3Z
DMUXO3Z DN AUS-131
DMUXO3Z HS Phase 2
DMUXO3Z SN AUS-131; S-Equol; (-)-(S)-Equol; (-)-Equol; (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol; (3S)-3-(4-hydroxyphenyl)chroman-7-ol; (S)-(-)-4',7-Isoflavandiol; (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; (S)-3-(4-Hydroxyphenyl)chroman-7-ol; (S)-Equol; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-; 2T6D2HPX7Q; 4',7-Dihydroxyisoflavan; 4',7-Isoflavandiol; 531-95-3; 7,4'-dihydroxyisoflavan; CCRIS 9222; CHEBI:34741; CHEMBL198877; EINECS 208-522-2; Equol; UNII-2T6D2HPX7Q
DMUXO3Z PC 91469
DMUXO3Z MW 242.27
DMUXO3Z FM C15H14O3
DMUXO3Z IC ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMUXO3Z IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMUXO3Z DE Prostatic hyperplasia
DMZMSQJ ID DMZMSQJ
DMZMSQJ DN AUS-131
DMZMSQJ HS Phase 2
DMZMSQJ CP Ausio Pharmaceuticals
DMZMSQJ PC 91469
DMZMSQJ MW 242.27
DMZMSQJ FM C15H14O3
DMZMSQJ IC InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
DMZMSQJ CS C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
DMZMSQJ IK ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMZMSQJ IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMZMSQJ CA CAS 531-95-3
DMZMSQJ CB CHEBI:34741
DMZMSQJ DE Hot flushes; Alzheimer disease
DMN7VK1 ID DMN7VK1
DMN7VK1 DN AV-101
DMN7VK1 HS Phase 2
DMN7VK1 SN Anti-epileptic, VistaGen; L-4-chlorokynurenine; NMDA receptor antagonists, University of Maryland/VistaGen; 4-Cl-kynurenine, NIH/VistaGen; 7-Chlorokynurenic acid; 7-Cl-KYN; 7-Cl-KYNA, NIH
DMN7VK1 CP Vistagen therapeutics
DMN7VK1 PC 9859632
DMN7VK1 MW 242.66
DMN7VK1 FM C10H11ClN2O3
DMN7VK1 IC InChI=1S/C10H11ClN2O3/c11-5-1-2-6(7(12)3-5)9(14)4-8(13)10(15)16/h1-3,8H,4,12-13H2,(H,15,16)/t8-/m0/s1
DMN7VK1 CS C1=CC(=C(C=C1Cl)N)C(=O)C[C@@H](C(=O)O)N
DMN7VK1 IK HQLHZNDJQSRKDT-QMMMGPOBSA-N
DMN7VK1 IU (2S)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid
DMN7VK1 CA CAS 153152-32-0
DMN7VK1 DE Neuropathic pain; Major depressive disorder
DMDL9WU ID DMDL9WU
DMDL9WU DN AV-201
DMDL9WU HS Phase 2
DMDL9WU SN AAV (amino acid decarboxylase), Avigen; AAV (tyrosine hydroxylase), Avigen; AAV gene therapy (Parkinsons), Avigen; AAV vector (AADC), Avigen; AAV vector (TH), Avigen; AAV-hAADC-2; Gene therapy (PD), Avigen; Gene therapy (Parkinsons disease), Avigen; Gene therapy (L-aromatic amino acid decarboxylase), Avigen
DMDL9WU CP Avigen Inc
DMDL9WU DE Parkinson disease
DMASRP3 ID DMASRP3
DMASRP3 DN AVA-101
DMASRP3 HS Phase 2
DMASRP3 CP Avalanche biotechnologies
DMASRP3 DE Age-related macular degeneration
DMORJD4 ID DMORJD4
DMORJD4 DN AVB-500
DMORJD4 HS Phase 2
DMORJD4 CP Aravive
DMORJD4 DT Protein
DMORJD4 DE IgA nephropathy
DMLAOHX ID DMLAOHX
DMLAOHX DN Avdoralimab
DMLAOHX HS Phase 2
DMLAOHX SN IPH5401
DMLAOHX TC Antiviral Agents
DMLAOHX DT Monoclonal antibody
DMLAOHX DE Coronavirus Disease 2019 (COVID-19)
DMESMHU ID DMESMHU
DMESMHU DN AVE-0657
DMESMHU HS Phase 2
DMESMHU SN IDDBCP219683
DMESMHU CP Sanofi
DMESMHU DE Cheyne-stokes respiration
DMA42BV ID DMA42BV
DMA42BV DN AVE-2268
DMA42BV HS Phase 2
DMA42BV CP Aventis SA
DMA42BV DE Diabetic complication
DMQGI73 ID DMQGI73
DMQGI73 DN AVI-4557
DMQGI73 HS Phase 2
DMQGI73 CP AVI BioPharma
DMQGI73 DT Antisense drug
DMQGI73 DE Anxiety disorder
DMUOYQR ID DMUOYQR
DMUOYQR DN AVI-5126
DMUOYQR HS Phase 2
DMUOYQR SN Resten-CP; NeuGene (CABG), AVI
DMUOYQR CP AVI BioPharma
DMUOYQR DT Antisense drug
DMUOYQR DE Coronary artery disease
DMJFLBC ID DMJFLBC
DMJFLBC DN AVN 101
DMJFLBC HS Phase 2
DMJFLBC CP Avineuro Pharmaceuticals
DMJFLBC DE Anxiety disorder; Alzheimer disease; Cognitive impairment
DMK2LGM ID DMK2LGM
DMK2LGM DN AVN 322
DMK2LGM HS Phase 2
DMK2LGM CP Avineuro Pharmaceuticals
DMK2LGM DE Alzheimer disease; Cognitive impairment
DMOGFNI ID DMOGFNI
DMOGFNI DN AVN-101
DMOGFNI HS Phase 2
DMOGFNI SN 1061354-48-0; UNII-XML910S5X8; XML910S5X8; 2,8-Dimethyl-5-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride; AVN-101 hydrochloride; AVN-101 HCl; SB18759; 1H-Pyrido(4,3-b)indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-phenylethyl)-, hydrochloride (1:1)
DMOGFNI CP Avineuro
DMOGFNI DT Small molecular drug
DMOGFNI PC 126843189
DMOGFNI MW 340.9
DMOGFNI FM C21H25ClN2
DMOGFNI IC InChI=1S/C21H24N2.ClH/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17;/h3-9,14H,10-13,15H2,1-2H3;1H
DMOGFNI CS CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4.Cl
DMOGFNI IK RKLJJDFIWWRTEJ-UHFFFAOYSA-N
DMOGFNI IU 2,8-dimethyl-5-(2-phenylethyl)-3,4-dihydro-1H-pyrido[4,3-b]indole;hydrochloride
DMOGFNI CA CAS 1061354-48-0
DMOGFNI DE Cognitive impairment
DMVADGZ ID DMVADGZ
DMVADGZ DN AWD-12-281
DMVADGZ HS Phase 2
DMVADGZ SN GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline; 842470
DMVADGZ CP ASTA Medica AG
DMVADGZ DT Small molecular drug
DMVADGZ PC 6918428
DMVADGZ MW 458.3
DMVADGZ FM C22H14Cl2FN3O3
DMVADGZ IC InChI=1S/C22H14Cl2FN3O3/c23-17-8-26-9-18(24)20(17)27-22(31)21(30)16-11-28(10-12-1-3-13(25)4-2-12)19-6-5-14(29)7-15(16)19/h1-9,11,29H,10H2,(H,26,27,31)
DMVADGZ CS C1=CC(=CC=C1CN2C=C(C3=C2C=CC(=C3)O)C(=O)C(=O)NC4=C(C=NC=C4Cl)Cl)F
DMVADGZ IK DPHDSIQHVGSITN-UHFFFAOYSA-N
DMVADGZ IU N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide
DMVADGZ CA CAS 257892-33-4
DMVADGZ DE Rhinitis
DMTAEMB ID DMTAEMB
DMTAEMB DN AX-200
DMTAEMB HS Phase 2
DMTAEMB SN Filgrastim (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (intravenous, peripheral arterial occlusive disease/spinal cord injury/stroke/Parkinsons disease), Axaron; G-CSF (protein recombinant/iv, stroke/ALS/PAO/PD/SCI), Sygnis
DMTAEMB CP SYGNIS Bioscience GmbH & Co KG
DMTAEMB DE Cardiovascular disease
DMTQ1Y3 ID DMTQ1Y3
DMTQ1Y3 DN AXL-1717
DMTQ1Y3 HS Phase 2
DMTQ1Y3 SN BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum
DMTQ1Y3 CP Axelar AB
DMTQ1Y3 DT Small molecular drug
DMTQ1Y3 PC 72435
DMTQ1Y3 MW 414.4
DMTQ1Y3 FM C22H22O8
DMTQ1Y3 IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1
DMTQ1Y3 CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMTQ1Y3 IK YJGVMLPVUAXIQN-HAEOHBJNSA-N
DMTQ1Y3 IU (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMTQ1Y3 CA CAS 477-47-4
DMTQ1Y3 CB CHEBI:75251
DMTQ1Y3 DE Solid tumour/cancer
DM4CJNE ID DM4CJNE
DM4CJNE DN AYX-1
DM4CJNE HS Phase 2
DM4CJNE DE Pain
DMHFUJT ID DMHFUJT
DMHFUJT DN AZ-01, PEGylated interferon-beta
DMHFUJT HS Phase 2
DMHFUJT SN PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne
DMHFUJT CP Allozyne Inc
DMHFUJT DE Multiple sclerosis
DM9LKYP ID DM9LKYP
DM9LKYP DN AZ-40140
DM9LKYP HS Phase 2
DM9LKYP CP Asahi Kasei
DM9LKYP DE Type-2 diabetes; Obesity
DMM0N1F ID DMM0N1F
DMM0N1F DN AZD-0865
DMM0N1F HS Phase 2
DMM0N1F SN AR-H044277
DMM0N1F CP AstraZeneca plc
DMM0N1F DT Small molecular drug
DMM0N1F PC 9951066
DMM0N1F MW 366.5
DMM0N1F FM C21H26N4O2
DMM0N1F IC InChI=1S/C21H26N4O2/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27)
DMM0N1F CS CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO
DMM0N1F IK GHVIMBCFLRTFHI-UHFFFAOYSA-N
DMM0N1F IU 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
DMM0N1F CA CAS 248919-64-4
DMM0N1F DE Gastrointestinal disease
DM7B1AR ID DM7B1AR
DM7B1AR DN AZD-1446
DM7B1AR HS Phase 2
DM7B1AR SN TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca
DM7B1AR CP Targacept Inc
DM7B1AR DT Small molecular drug
DM7B1AR PC 96568204
DM7B1AR MW 240.68
DM7B1AR FM C11H13ClN2O2
DM7B1AR IC InChI=1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2/t7-,8+
DM7B1AR CS C1[C@@H]2CN(C[C@@H]2CN1)C(=O)C3=CC=C(O3)Cl
DM7B1AR IK GTUIQNHJSXQMKW-OCAPTIKFSA-N
DM7B1AR IU [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone
DM7B1AR CA CAS 1025007-04-8
DM7B1AR DE Alzheimer disease
DMLK59M ID DMLK59M
DMLK59M DN AZD1480
DMLK59M HS Phase 2
DMLK59M SN RET inhibitors
DMLK59M CP AstraZeneca
DMLK59M DT Small molecular drug
DMLK59M PC 16659841
DMLK59M MW 348.76
DMLK59M FM C14H14ClFN8
DMLK59M IC InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1
DMLK59M CS CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F
DMLK59M IK PDOQBOJDRPLBQU-QMMMGPOBSA-N
DMLK59M IU 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
DMLK59M CA CAS 935666-88-9
DMLK59M DE Myeloproliferative syndrome
DMUE90I ID DMUE90I
DMUE90I DN AZD1656
DMUE90I HS Phase 2
DMUE90I SN AZD1656; AZD-1656; FJEJHJINOKKDCW-INIZCTEOSA-N; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide; SCHEMBL321593; GTPL7701; UNII-660M185X4D; CHEMBL3219124; AZD 1656; 660M185X4D; 89961-EP2305674A1; 89961-EP2301929A1; 89961-EP2301935A1; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I CP AstraZeneca
DMUE90I DT Small molecular drug
DMUE90I PC 16039797
DMUE90I MW 478.5
DMUE90I FM C24H26N6O5
DMUE90I IC InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
DMUE90I CS CC1=CN=C(C=N1)NC(=O)C2=CC(=CC(=C2)O[C@@H](C)COC)OC3=NC=C(N=C3)C(=O)N4CCC4
DMUE90I IK FJEJHJINOKKDCW-INIZCTEOSA-N
DMUE90I IU 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I CA CAS 919783-22-5
DMUE90I DE Diabetic complication
DMX5SG7 ID DMX5SG7
DMX5SG7 DN AZD1772//RDX5791
DMX5SG7 HS Phase 2
DMX5SG7 CP Ardelyx; astrazeneca
DMX5SG7 DE Chronic kidney disease
DMMCL9F ID DMMCL9F
DMMCL9F DN AZD1981
DMMCL9F HS Phase 2
DMMCL9F SN AZD1981; 802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603
DMMCL9F DT Small molecular drug
DMMCL9F PC 11292191
DMMCL9F MW 388.9
DMMCL9F FM C19H17ClN2O3S
DMMCL9F IC InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
DMMCL9F CS CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl
DMMCL9F IK JWYIGNODXSRKGP-UHFFFAOYSA-N
DMMCL9F IU 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid
DMMCL9F CA CAS 802904-66-1
DMMCL9F DE Chronic obstructive pulmonary disease
DMOEARH ID DMOEARH
DMOEARH DN Azd2014
DMOEARH HS Phase 2
DMOEARH SN AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)
DMOEARH CP AstraZeneca
DMOEARH DT Small molecular drug
DMOEARH PC 25262792
DMOEARH MW 462.5
DMOEARH FM C25H30N6O3
DMOEARH IC InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1
DMOEARH CS C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C
DMOEARH IK JUSFANSTBFGBAF-IRXDYDNUSA-N
DMOEARH IU 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide
DMOEARH CA CAS 1009298-59-2
DMOEARH DE Solid tumour/cancer
DMGQSVX ID DMGQSVX
DMGQSVX DN AZD-2115
DMGQSVX HS Phase 2
DMGQSVX SN Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca
DMGQSVX CP AstraZeneca
DMGQSVX DE Chronic obstructive pulmonary disease
DM8FZOG ID DM8FZOG
DM8FZOG DN AZD-2327
DM8FZOG HS Phase 2
DM8FZOG SN Opioid receptor delta agonist (anxiety, depression), AstraZeneca
DM8FZOG CP AstraZeneca plc
DM8FZOG DT Small molecular drug
DM8FZOG PC 11525765
DM8FZOG MW 474.6
DM8FZOG FM C29H35FN4O
DM8FZOG IC InChI=1S/C29H35FN4O/c1-3-33(4-2)29(35)24-12-10-23(11-13-24)28(25-6-5-7-27(31)20-25)34-18-16-32(17-19-34)21-22-8-14-26(30)15-9-22/h5-15,20,28H,3-4,16-19,21,31H2,1-2H3/t28-/m1/s1
DM8FZOG CS CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)N)N3CCN(CC3)CC4=CC=C(C=C4)F
DM8FZOG IK XGFLMBBZEPJGHY-MUUNZHRXSA-N
DM8FZOG IU 4-[(R)-(3-aminophenyl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-N,N-diethylbenzamide
DM8FZOG CA CAS 875647-81-7
DM8FZOG DE Anxiety disorder
DMF34UY ID DMF34UY
DMF34UY DN AZD-2423
DMF34UY HS Phase 2
DMF34UY SN CCR2b antagonist (pain, COPD), AstraZeneca
DMF34UY CP AstraZeneca plc
DMF34UY DT Small molecular drug
DMF34UY PC 46213922
DMF34UY MW 425.9
DMF34UY FM C20H29ClFN5O2
DMF34UY IC InChI=1S/C20H29ClFN5O2/c1-20(2,3)27-7-6-23-17(13-27)18(28)25-8-10-26(11-9-25)19(29)24-14-4-5-15(21)16(22)12-14/h4-5,12,17,23H,6-11,13H2,1-3H3,(H,24,29)/t17-/m1/s1
DMF34UY CS CC(C)(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F
DMF34UY IK SRWQVWAIVQXPJY-QGZVFWFLSA-N
DMF34UY IU 4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
DMF34UY CA CAS 1229603-37-5
DMF34UY DE Chronic obstructive pulmonary disease
DMZLGQV ID DMZLGQV
DMZLGQV DN AZD2624
DMZLGQV HS Phase 2
DMZLGQV SN Pavinetant; AZD-2624; MLE4901; 941690-55-7; UNII-3U471ZVC5K; 3U471ZVC5K; AZ124752520; pavinetantum; Pavinetant [USAN]; SCHEMBL3587478; GTPL5775; CHEMBL3545233; CHEBI:140478; QYTBBBAHNIWFOD-NRFANRHFSA-N; BDBM50180193; AKOS032946112; DB11692; CS-7979; 4-Quinolinecarboxamide, 3-((methylsulfonyl)amino)-2-phenyl-N-((1S)-1-phenylpropyl)-; HY-14432; KB-74807; 3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; 3-[(methanesulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV CP AstraZeneca
DMZLGQV DT Small molecular drug
DMZLGQV PC 23649245
DMZLGQV MW 459.6
DMZLGQV FM C26H25N3O3S
DMZLGQV IC InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
DMZLGQV CS CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)NS(=O)(=O)C
DMZLGQV IK QYTBBBAHNIWFOD-NRFANRHFSA-N
DMZLGQV IU 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV CA CAS 941690-55-7
DMZLGQV CB CHEBI:140478
DMZLGQV DE Schizophrenia; Multiple sclerosis; .
DMYUNXP ID DMYUNXP
DMYUNXP DN AZD2811
DMYUNXP HS Phase 2
DMYUNXP CP AstraZeneca
DMYUNXP DT Small molecular drug
DMYUNXP DE Small-cell lung cancer
DM6AI9N ID DM6AI9N
DM6AI9N DN AZD-2927
DM6AI9N HS Phase 2
DM6AI9N SN AZD2927
DM6AI9N CP AstraZenec, UK
DM6AI9N DT Small molecular drug
DM6AI9N PC 57345449
DM6AI9N MW 308.4
DM6AI9N FM C17H25FN2O2
DM6AI9N IC InChI=1S/C17H25FN2O2/c1-11(2)16(10-20-8-14(21)9-20)19(4)17(22)13-5-6-15(18)12(3)7-13/h5-7,11,14,16,21H,8-10H2,1-4H3/t16-/m1/s1
DM6AI9N CS CC1=C(C=CC(=C1)C(=O)N(C)[C@H](CN2CC(C2)O)C(C)C)F
DM6AI9N IK GAHPWXLXWUVMIV-MRXNPFEDSA-N
DM6AI9N IU 4-fluoro-N-[(2S)-1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl]-N,3-dimethylbenzamide
DM6AI9N DE Atrial fibrillation
DME8Z5M ID DME8Z5M
DME8Z5M DN AZD-3199
DME8Z5M HS Phase 2
DME8Z5M PC 16035068
DME8Z5M MW 578.8
DME8Z5M FM C32H42N4O4S
DME8Z5M IC InChI=1S/C32H42N4O4S/c1-3-35(4-2)20-21-36(19-18-33-17-14-26-12-13-28(37)30-31(26)41-32(39)34-30)29(38)16-23-40-22-15-25-10-7-9-24-8-5-6-11-27(24)25/h5-13,33,37H,3-4,14-23H2,1-2H3,(H,34,39)
DME8Z5M CS CCN(CC)CCN(CCNCCC1=C2C(=C(C=C1)O)NC(=O)S2)C(=O)CCOCCC3=CC=CC4=CC=CC=C43
DME8Z5M IK ZVULMJYRVAVKCP-UHFFFAOYSA-N
DME8Z5M IU N-[2-(diethylamino)ethyl]-N-[2-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide
DME8Z5M CA CAS 925243-19-2
DME8Z5M DE Asthma
DMANC59 ID DMANC59
DMANC59 DN AZD-3241
DMANC59 HS Phase 2
DMANC59 SN Parkinson's disease therapeutic, AstraZeneca
DMANC59 CP AstraZeneca plc
DMANC59 PC 11528958
DMANC59 MW 253.32
DMANC59 FM C11H15N3O2S
DMANC59 IC InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17)
DMANC59 CS CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2
DMANC59 IK FVJCUZCRPIMVLB-UHFFFAOYSA-N
DMANC59 IU 1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one
DMANC59 CA CAS 890655-80-8
DMANC59 DE Parkinson disease
DML9M5S ID DML9M5S
DML9M5S DN AZD-4017
DML9M5S HS Phase 2
DML9M5S SN AZD-4017 (oral tablet, ocular hypertension)
DML9M5S CP AstraZeneca plc
DML9M5S DT Small molecular drug
DML9M5S PC 24946280
DML9M5S MW 419.6
DML9M5S FM C22H33N3O3S
DML9M5S IC InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1
DML9M5S CS CCCSC1=C(C=CC(=N1)N2CCC[C@H](C2)CC(=O)O)C(=O)NC3CCCCC3
DML9M5S IK NCDZABJPWMBMIQ-INIZCTEOSA-N
DML9M5S IU 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
DML9M5S CA CAS 1024033-43-9
DML9M5S DE Ocular hypertension
DM8SVIY ID DM8SVIY
DM8SVIY DN AZD4635
DM8SVIY HS Phase 2
DM8SVIY SN NCWQLHHDGDXIJN-UHFFFAOYSA-N; AZD-4635; 1321514-06-0; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; SCHEMBL2320714; EX-A1681; AC-30333; HY-101980; CS-0022379; 5-(4-fluorophenyl)-6-(2-chloro-6-methyl-pyridin-4-yl)-1,2,4-triazin-3-amine
DM8SVIY CP AstraZeneca Wilmington, DE
DM8SVIY PC 86676119
DM8SVIY MW 315.73
DM8SVIY FM C15H11ClFN5
DM8SVIY IC InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)
DM8SVIY CS CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F
DM8SVIY IK NCWQLHHDGDXIJN-UHFFFAOYSA-N
DM8SVIY IU 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
DM8SVIY CA CAS 1321514-06-0
DM8SVIY DE Solid tumour/cancer; Prostate cancer
DMFVL5J ID DMFVL5J
DMFVL5J DN AZD-4877
DMFVL5J HS Phase 2
DMFVL5J SN Anticancer therapeutic (solid tumors), AstraZeneca
DMFVL5J CP AstraZeneca plc
DMFVL5J DT Small molecular drug
DMFVL5J PC 10368812
DMFVL5J MW 503.7
DMFVL5J FM C28H33N5O2S
DMFVL5J IC InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
DMFVL5J CS CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C
DMFVL5J IK SMFXSYMLJDHGIE-UHFFFAOYSA-N
DMFVL5J IU N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide
DMFVL5J CA CAS 1176760-49-8
DMFVL5J DE Acute myeloid leukaemia
DM3JSFK ID DM3JSFK
DM3JSFK DN AZD-5069
DM3JSFK HS Phase 2
DM3JSFK SN CXCR2 inhibitor (COPD), Astrazeneca
DM3JSFK CP AstraZeneca plc
DM3JSFK PC 56645576
DM3JSFK MW 476.5
DM3JSFK FM C18H22F2N4O5S2
DM3JSFK IC InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1
DM3JSFK CS C[C@H]([C@H](CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F
DM3JSFK IK QZECRCLSIGFCIO-RISCZKNCSA-N
DM3JSFK IU N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide
DM3JSFK CA CAS 878385-84-3
DM3JSFK DE Asthma
DMOZ04X ID DMOZ04X
DMOZ04X DN AZD-5213
DMOZ04X HS Phase 2
DMOZ04X CP AstraZeneca plc
DMOZ04X PC 53342708
DMOZ04X MW 327.4
DMOZ04X FM C19H25N3O2
DMOZ04X IC InChI=1S/C19H25N3O2/c20-18(23)14-6-4-13(5-7-14)16-12-17(16)19(24)22-10-8-21(9-11-22)15-2-1-3-15/h4-7,15-17H,1-3,8-12H2,(H2,20,23)/t16-,17+/m1/s1
DMOZ04X CS C1CC(C1)N2CCN(CC2)C(=O)[C@H]3C[C@@H]3C4=CC=C(C=C4)C(=O)N
DMOZ04X IK VCQZCDSEWSFTPO-SJORKVTESA-N
DMOZ04X IU 4-[(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide
DMOZ04X CA CAS 1119807-02-1
DMOZ04X DE Alzheimer disease
DMJ8V3K ID DMJ8V3K
DMJ8V3K DN AZD5312
DMJ8V3K HS Phase 2
DMJ8V3K CP Astrazeneca; isis pharmaceuticals
DMJ8V3K DE Prostate cancer
DM0PFNC ID DM0PFNC
DM0PFNC DN AZD6738
DM0PFNC HS Phase 2
DM0PFNC CP Astrazeneca; eagle pharmaceuticals
DM0PFNC DT Small molecular drug
DM0PFNC PC 54761306
DM0PFNC MW 412.5
DM0PFNC FM C20H24N6O2S
DM0PFNC IC InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
DM0PFNC CS C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4
DM0PFNC IK OHUHVTCQTUDPIJ-JYCIKRDWSA-N
DM0PFNC IU imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
DM0PFNC DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Small-cell lung cancer
DMIBXK0 ID DMIBXK0
DMIBXK0 DN AZD-7009
DMIBXK0 HS Phase 2
DMIBXK0 SN AR-H065522XX; AZD-7009 (iv formulation, atrial fibrillation conversion)
DMIBXK0 CP AstraZeneca plc
DMIBXK0 DT Small molecular drug
DMIBXK0 PC 72440971
DMIBXK0 MW 496.9
DMIBXK0 FM C22H23ClF2N4O5
DMIBXK0 IC InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)
DMIBXK0 CS CON=C(C1=CC=C(C=C1)CNC(=O)C2CCN2C(=O)C(C3=CC(=CC(=C3)Cl)OC(F)F)O)N
DMIBXK0 IK XSNMGLZVFNDDPW-UHFFFAOYSA-N
DMIBXK0 IU 1-[2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(N'-methoxycarbamimidoyl)phenyl]methyl]azetidine-2-carboxamide
DMIBXK0 DE Atrial fibrillation
DMC48SP ID DMC48SP
DMC48SP DN AZD-7268
DMC48SP HS Phase 2
DMC48SP SN Enkephalinergic receptor modulator (oral, depression, anxiety), AstraZeneca
DMC48SP CP AstraZeneca plc
DMC48SP DT Small molecular drug
DMC48SP PC 24772484
DMC48SP MW 498.6
DMC48SP FM C29H30N4O2S
DMC48SP IC InChI=1S/C29H30N4O2S/c1-32(16-17-34)29(35)24-9-7-21(8-10-24)27(26-6-2-4-23-5-3-13-30-28(23)26)22-11-14-33(15-12-22)18-25-19-36-20-31-25/h2-10,13,19-20,34H,11-12,14-18H2,1H3
DMC48SP CS CN(CCO)C(=O)C1=CC=C(C=C1)C(=C2CCN(CC2)CC3=CSC=N3)C4=CC=CC5=C4N=CC=C5
DMC48SP IK ZJKUETLEJYCOBO-UHFFFAOYSA-N
DMC48SP IU N-(2-hydroxyethyl)-N-methyl-4-[quinolin-8-yl-[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]benzamide
DMC48SP CA CAS 1018988-00-5
DMC48SP DE Anxiety disorder
DMXF26Y ID DMXF26Y
DMXF26Y DN AZD7325
DMXF26Y HS Phase 2
DMXF26Y SN AZD-7325; UNII-KNM216XOUH; KNM216XOUH; CHEMBL1783282; 942437-37-8; AZD7325; KYDURMHFWXCKMW-UHFFFAOYSA-N; SCHEMBL1962584; GTPL7712; AZD 7325; BDBM50418481; SB17497; 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide; 4-Amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y CP AstraZeneca
DMXF26Y DT Small molecular drug
DMXF26Y PC 23581869
DMXF26Y MW 354.4
DMXF26Y FM C19H19FN4O2
DMXF26Y IC InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
DMXF26Y CS CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC
DMXF26Y IK KYDURMHFWXCKMW-UHFFFAOYSA-N
DMXF26Y IU 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y CA CAS 942437-37-8
DMXF26Y DE Anxiety disorder
DMEW3K9 ID DMEW3K9
DMEW3K9 DN AZD7624
DMEW3K9 HS Phase 2
DMEW3K9 CP Astrazeneca
DMEW3K9 PC 25143624
DMEW3K9 MW 491.6
DMEW3K9 FM C27H30FN5O3
DMEW3K9 IC InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)
DMEW3K9 CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)N3C=CN=C(C3=O)NC4(CC4)C5=CC=CC=C5OCCNC
DMEW3K9 IK NNKPHNTWNILINE-UHFFFAOYSA-N
DMEW3K9 IU N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide
DMEW3K9 CA CAS 1095004-78-6
DMEW3K9 DE Chronic obstructive pulmonary disease
DMLXFM6 ID DMLXFM6
DMLXFM6 DN AZD-8683
DMLXFM6 HS Phase 2
DMLXFM6 CP AstraZeneca plc
DMLXFM6 DE Chronic obstructive pulmonary disease
DM0M7QW ID DM0M7QW
DM0M7QW DN AZD-8848
DM0M7QW HS Phase 2
DM0M7QW SN AZ-12441970; DSP-3025; SM-324405; TLR7 agonist (allergy), Dainippon/AstraZeneca
DM0M7QW CP Dainippon Sumitomo Pharma Co Ltd
DM0M7QW PC 11592228
DM0M7QW MW 569.7
DM0M7QW FM C29H43N7O5
DM0M7QW IC InChI=1S/C29H43N7O5/c1-3-4-16-41-28-32-26(30)25-27(33-28)36(29(38)31-25)13-7-12-35(11-6-10-34-14-17-40-18-15-34)21-23-9-5-8-22(19-23)20-24(37)39-2/h5,8-9,19H,3-4,6-7,10-18,20-21H2,1-2H3,(H,31,38)(H2,30,32,33)
DM0M7QW CS CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N
DM0M7QW IK FEFIBEHSXLKJGI-UHFFFAOYSA-N
DM0M7QW IU methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate
DM0M7QW CA CAS 866269-28-5
DM0M7QW DE Allergic rhinitis
DMFLCW4 ID DMFLCW4
DMFLCW4 DN AZD8931
DMFLCW4 HS Phase 2
DMFLCW4 SN Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline
DMFLCW4 CP AstraZeneca
DMFLCW4 DT Small molecular drug
DMFLCW4 PC 11488320
DMFLCW4 MW 473.9
DMFLCW4 FM C23H25ClFN5O3
DMFLCW4 IC InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
DMFLCW4 CS CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC
DMFLCW4 IK DFJSJLGUIXFDJP-UHFFFAOYSA-N
DMFLCW4 IU 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide
DMFLCW4 CA CAS 848942-61-0
DMFLCW4 CB CHEBI:132986
DMFLCW4 DE Breast cancer
DMJGYPK ID DMJGYPK
DMJGYPK DN AZD9056
DMJGYPK HS Phase 2
DMJGYPK SN AZD-9056; AZD9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide
DMJGYPK CP AstraZeneca
DMJGYPK DT Small molecular drug
DMJGYPK PC 10161381
DMJGYPK MW 419
DMJGYPK FM C24H35ClN2O2
DMJGYPK IC InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)
DMJGYPK CS C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=CC(=C4)CCCNCCCO)Cl
DMJGYPK IK HSQAARMBHJCUOK-UHFFFAOYSA-N
DMJGYPK IU N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide
DMJGYPK CA CAS 345304-65-6
DMJGYPK DE Chronic obstructive pulmonary disease
DMVKPEZ ID DMVKPEZ
DMVKPEZ DN AZD-9164
DMVKPEZ HS Phase 2
DMVKPEZ SN IDDBCP239717
DMVKPEZ CP AstraZeneca plc
DMVKPEZ PC 44517831
DMVKPEZ MW 465.6
DMVKPEZ FM C29H38FN2O2+
DMVKPEZ IC InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1
DMVKPEZ CS C[C@](C1=CC=CC=C1)(C(=O)O[C@H]2C[N+]3(CCC2CC3)CCC4=CC=C(C=C4)F)N5CCCCC5
DMVKPEZ IK FNYFFCOCVNTJCD-NNMXADRKSA-N
DMVKPEZ IU [(3R)-1-[2-(4-fluorophenyl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2S)-2-phenyl-2-piperidin-1-ylpropanoate
DMVKPEZ CA CAS 1034978-04-5
DMVKPEZ DE Chronic obstructive pulmonary disease
DMB87M3 ID DMB87M3
DMB87M3 DN AZD9668
DMB87M3 HS Phase 2
DMB87M3 SN Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
DMB87M3 CP AstraZeneca
DMB87M3 DT Small molecular drug
DMB87M3 PC 46861623
DMB87M3 MW 545.5
DMB87M3 FM C25H22F3N5O4S
DMB87M3 IC InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)
DMB87M3 CS CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C
DMB87M3 IK QNQZWEGMKJBHEM-UHFFFAOYSA-N
DMB87M3 IU 6-methyl-5-(2-methylpyrazol-3-yl)-N-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
DMB87M3 CA CAS 848141-11-7
DMB87M3 DE Chronic obstructive pulmonary disease; Bronchiectasis
DMQOTHP ID DMQOTHP
DMQOTHP DN AZD9833
DMQOTHP HS Phase 2
DMQOTHP SN AZD-9833; UNII-JUP57A8EPZ; JUP57A8EPZ; 2222844-89-3; Camizestrant; Camizestrant [USAN]; SCHEMBL20089710; NSC828717; WHO 11592; NSC-828717; HY-136255; AZ14066724; CS-0121043; 3-Pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo(4,3-F)isoquinolin-6-yl)-
DMQOTHP CP AstraZeneca
DMQOTHP DT Small molecular drug
DMQOTHP PC 134453496
DMQOTHP MW 476.5
DMQOTHP FM C24H28F4N6
DMQOTHP IC InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
DMQOTHP CS C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
DMQOTHP IK WDHOIABIERMLGY-CMJOXMDJSA-N
DMQOTHP IU N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
DMQOTHP CA CAS 2222844-89-3
DMQOTHP DE ER-positive breast cancer
DME0JMV ID DME0JMV
DME0JMV DN AZX-100
DME0JMV HS Phase 2
DME0JMV CP AzERx Inc
DME0JMV DE Asthma
DMOMDA4 ID DMOMDA4
DMOMDA4 DN B-701
DMOMDA4 HS Phase 2
DMOMDA4 SN VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
DMOMDA4 CP BioClin Therapeutics San Ramon, CA
DMOMDA4 PC 95987
DMOMDA4 MW 355.6
DMOMDA4 FM C10H22Cl3N2O3P
DMOMDA4 IC InChI=1S/C10H22Cl3N2O3P/c11-3-1-10-18-19(17,14-6-2-9-16)15(7-4-12)8-5-13/h16H,1-10H2,(H,14,17)
DMOMDA4 CS C(CNP(=O)(N(CCCl)CCCl)OCCCCl)CO
DMOMDA4 IK VKRFJPYJBOIVPD-UHFFFAOYSA-N
DMOMDA4 IU 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol
DMOMDA4 CA CAS 78218-88-9
DMOMDA4 DE Bladder cancer; Urothelial carcinoma
DM7586F ID DM7586F
DM7586F DN Bafetinib
DM7586F HS Phase 2
DM7586F SN Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide
DM7586F CP CytRx
DM7586F DT Small molecular drug
DM7586F PC 11387605
DM7586F MW 576.6
DM7586F FM C30H31F3N8O
DM7586F IC InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1
DM7586F CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5
DM7586F IK ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
DM7586F IU 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
DM7586F CA CAS 859212-16-1
DM7586F DE Bone disease
DM4C7E6 ID DM4C7E6
DM4C7E6 DN BAICALEIN
DM4C7E6 HS Phase 2
DM4C7E6 SN baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761
DM4C7E6 DT Small molecular drug
DM4C7E6 PC 5281605
DM4C7E6 MW 270.24
DM4C7E6 FM C15H10O5
DM4C7E6 IC InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H
DM4C7E6 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O
DM4C7E6 IK FXNFHKRTJBSTCS-UHFFFAOYSA-N
DM4C7E6 IU 5,6,7-trihydroxy-2-phenylchromen-4-one
DM4C7E6 CA CAS 491-67-8
DM4C7E6 CB CHEBI:2979
DM4C7E6 DE Influenza virus infection
DM3WCL4 ID DM3WCL4
DM3WCL4 DN Baltaleucel-T
DM3WCL4 HS Phase 2
DM3WCL4 CP Cell Medica Houston, TX
DM3WCL4 DE Diffuse large B-cell lymphoma; Hodgkin lymphoma; Lymphoma; Post-transplant lymphoproliferative disorder
DMSZOXQ ID DMSZOXQ
DMSZOXQ DN Baminercept
DMSZOXQ HS Phase 2
DMSZOXQ SN BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec
DMSZOXQ CP Biogen Idec
DMSZOXQ DE Rheumatoid arthritis
DM0TZEP ID DM0TZEP
DM0TZEP DN Bamosiran
DM0TZEP HS Phase 2
DM0TZEP SN SYL040012
DM0TZEP CP Sylentis
DM0TZEP DT Small interfering RNA
DM0TZEP DE Glaucoma/ocular hypertension
DMW03YD ID DMW03YD
DMW03YD DN BAN2401
DMW03YD HS Phase 2
DMW03YD CP BioArtic Neuroscience
DMW03YD DE Alzheimer disease
DMWI0X3 ID DMWI0X3
DMWI0X3 DN Barusiban
DMWI0X3 HS Phase 2
DMWI0X3 SN FE-200440
DMWI0X3 CP Ferring Pharmaceuticals Inc
DMWI0X3 DT Small molecular drug
DMWI0X3 PC 9832431
DMWI0X3 MW 830.1
DMWI0X3 FM C40H63N9O8S
DMWI0X3 IC InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1
DMWI0X3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC
DMWI0X3 IK UGNGRKKDUVKQDF-IHOMMZCZSA-N
DMWI0X3 IU (4S,7S,10S,13S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-10-[(2R)-butan-2-yl]-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMWI0X3 CA CAS 285571-64-4
DMWI0X3 DE Androgen deficiency
DMQ8J0U ID DMQ8J0U
DMQ8J0U DN Basmisanil
DMQ8J0U HS Phase 2
DMQ8J0U SN 1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha
DMQ8J0U CP Roche
DMQ8J0U PC 57336276
DMQ8J0U MW 445.5
DMQ8J0U FM C21H20FN3O5S
DMQ8J0U IC InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3
DMQ8J0U CS CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
DMQ8J0U IK VCGRFBXVSFAGGA-UHFFFAOYSA-N
DMQ8J0U IU (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
DMQ8J0U CA CAS 1159600-41-5
DMQ8J0U DE Alzheimer disease; Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation
DM6CVZ5 ID DM6CVZ5
DM6CVZ5 DN Bavisant
DM6CVZ5 HS Phase 2
DM6CVZ5 SN JNJ-31001074
DM6CVZ5 CP Johnson & Johnson Pharmaceutical Research & Development
DM6CVZ5 DT Small molecular drug
DM6CVZ5 PC 16061509
DM6CVZ5 MW 329.4
DM6CVZ5 FM C19H27N3O2
DM6CVZ5 IC InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
DM6CVZ5 CS C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4
DM6CVZ5 IK BGBVSGSIXIIREO-UHFFFAOYSA-N
DM6CVZ5 IU (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
DM6CVZ5 CA CAS 929622-08-2
DM6CVZ5 DE Attention deficit hyperactivity disorder
DM4JGNH ID DM4JGNH
DM4JGNH DN BAY 1067197
DM4JGNH HS Phase 2
DM4JGNH CP Bayer HealthCare Pharmaceuticals
DM4JGNH DE Heart failure
DMHKTGX ID DMHKTGX
DMHKTGX DN BAY 1142524
DMHKTGX HS Phase 2
DMHKTGX SN Fulacimstat; UNII-VIR72PP4ZU; VIR72PP4ZU; BAY1142524; 1488354-15-9; 1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-; 2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-; Fulacimstat [INN]; Fulacimstat; BAY1142524; Fulacimstat(BAY 1142524); CHEMBL4297596; SCHEMBL16701233; EX-A2732; DB15085; BAY-1142524; HY-109059; CS-0032987; (R)-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-3-(4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(2,3-Dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxylic acid; 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-((1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 5-Pyrimidinecarboxylic acid, 1-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-
DMHKTGX CP Bayer
DMHKTGX DT Small molecular drug
DMHKTGX PC 91758792
DMHKTGX MW 487.4
DMHKTGX FM C23H16F3N3O6
DMHKTGX IC InChI=1S/C23H16F3N3O6/c1-27-17-7-5-11(9-18(17)35-22(27)34)28-10-14(20(31)32)19(30)29(21(28)33)16-8-6-12-13(16)3-2-4-15(12)23(24,25)26/h2-5,7,9-10,16H,6,8H2,1H3,(H,31,32)/t16-/m1/s1
DMHKTGX CS CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)[C@@H]4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O
DMHKTGX IK JDARDSVOVYVQST-MRXNPFEDSA-N
DMHKTGX IU 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid
DMHKTGX CA CAS 1488354-15-9
DMHKTGX DE Myocardial infarction
DM8SNEM ID DM8SNEM
DM8SNEM DN BAY 11-42524
DM8SNEM HS Phase 2
DM8SNEM CP Bayer healthcare pharmaceuticals
DM8SNEM DE Heart failure; Left ventricular dysfunction
DM450XS ID DM450XS
DM450XS DN BAY 2253651
DM450XS HS Phase 2
DM450XS CP Bayer
DM450XS DT Small molecular drug
DM450XS DE Obstructive sleep apnea
DMSUB64 ID DMSUB64
DMSUB64 DN BAY 57-1293
DMSUB64 HS Phase 2
DMSUB64 SN Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742
DMSUB64 DT Small molecular drug
DMSUB64 PC 491941
DMSUB64 MW 402.5
DMSUB64 FM C18H18N4O3S2
DMSUB64 IC InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
DMSUB64 CS CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
DMSUB64 IK IVZKZONQVYTCKC-UHFFFAOYSA-N
DMSUB64 IU N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
DMSUB64 CA CAS 348086-71-5
DMSUB64 DE Herpes simplex virus infection
DMA75FG ID DMA75FG
DMA75FG DN BAY 794980
DMA75FG HS Phase 2
DMA75FG SN BAY-794980; Kogenate FS liposome; Kogenate liposomal; NecLip-rFVIII; PEGLip-formulated exogenous FVIII - Bayer/Zilip-Pharma; PEGLip-FVIII FS - Bayer/Zilip-Pharma; PEGylated octocog alfa sucrose - Bayer/Zilip-Pharma
DMA75FG DE Discovery agent
DMCPUKG ID DMCPUKG
DMCPUKG DN BAY 85-8501
DMCPUKG HS Phase 2
DMCPUKG CP Bayer HealthCare Pharmaceuticals
DMCPUKG PC 66601502
DMCPUKG MW 474.5
DMCPUKG FM C22H17F3N4O3S
DMCPUKG IC InChI=1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1
DMCPUKG CS CC1=C([C@H](N(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C)C3=C(C=C(C=C3)C#N)S(=O)(=O)C)C#N
DMCPUKG IK YAJWYFPMASPAMM-HXUWFJFHSA-N
DMCPUKG IU (4S)-4-(4-cyano-2-methylsulfonylphenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile
DMCPUKG CA CAS 1161921-82-9
DMCPUKG DE Bronchiectasis
DMRZLU4 ID DMRZLU4
DMRZLU4 DN BAY 86-5044
DMRZLU4 HS Phase 2
DMRZLU4 SN Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE; Lonaprisan
DMRZLU4 CP Bayer HealthCare Pharmaceuticals
DMRZLU4 DT Small molecular drug
DMRZLU4 PC 6918548
DMRZLU4 MW 508.5
DMRZLU4 FM C28H29F5O3
DMRZLU4 IC InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1
DMRZLU4 CS CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C(C(F)(F)F)(F)F)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C
DMRZLU4 IK VHZPUDNSVGRVMB-RXDLHWJPSA-N
DMRZLU4 IU (8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRZLU4 CA CAS 211254-73-8
DMRZLU4 DE Breast cancer
DMCSGJ2 ID DMCSGJ2
DMCSGJ2 DN BAY1163877
DMCSGJ2 HS Phase 2
DMCSGJ2 SN Rogaratinib
DMCSGJ2 CP Bayer healthcare pharmaceuticals
DMCSGJ2 PC 71611869
DMCSGJ2 MW 466.6
DMCSGJ2 FM C23H26N6O3S
DMCSGJ2 IC InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)
DMCSGJ2 CS CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N
DMCSGJ2 IK HNLRRJSKGXOYNO-UHFFFAOYSA-N
DMCSGJ2 IU 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one
DMCSGJ2 CA CAS 1443530-05-9
DMCSGJ2 DE Solid tumour/cancer; Bladder cancer
DM83IYE ID DM83IYE
DM83IYE DN BAY1193397
DM83IYE HS Phase 2
DM83IYE CP Bayer HealthCare Pharmaceuticals Whippany, NJ
DM83IYE DE Peripheral arterial disease
DMYSQMW ID DMYSQMW
DMYSQMW DN BAY-1902607
DMYSQMW HS Phase 2
DMYSQMW CP Bayer
DMYSQMW DE Cough
DMM7Q68 ID DMM7Q68
DMM7Q68 DN BAY-2253651
DMM7Q68 HS Phase 2
DMM7Q68 CP Bayer
DMM7Q68 DE Obstructive sleep apnea
DMVA5NS ID DMVA5NS
DMVA5NS DN BAY-57-9352
DMVA5NS HS Phase 2
DMVA5NS SN Telatinib; Bay 57-9352
DMVA5NS CP Bayer AG
DMVA5NS TC Anticancer Agents
DMVA5NS DT Small molecular drug
DMVA5NS PC 9808844
DMVA5NS MW 409.8
DMVA5NS FM C20H16ClN5O3
DMVA5NS IC InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
DMVA5NS CS CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl
DMVA5NS IK QFCXANHHBCGMAS-UHFFFAOYSA-N
DMVA5NS IU 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide
DMVA5NS CA CAS 332012-40-5
DMVA5NS DE Solid tumour/cancer; Gastric adenocarcinoma
DM7NHLC ID DM7NHLC
DM7NHLC DN BAY-85-3934
DM7NHLC HS Phase 2
DM7NHLC SN Hypoxia-inducible factor prolyl hydroxylase inhibitors (anemia); HIF-PH inhibitors (anemia), Bayer
DM7NHLC CP Bayer HealthCare Pharmaceuticals
DM7NHLC DT Small molecular drug
DM7NHLC PC 69669724
DM7NHLC MW 336.28
DM7NHLC FM C13H13N8NaO2
DM7NHLC IC InChI=1S/C13H14N8O2.Na/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19;/h1-2,7-9,22H,3-6H2;/q;+1/p-1
DM7NHLC CS C1COCCN1C2=NC=NC(=C2)N3C(=C(C=N3)N4C=CN=N4)[O-].[Na+]
DM7NHLC IK VYRQLKYGGSWDNH-UHFFFAOYSA-M
DM7NHLC IU sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate
DM7NHLC DE Anemia
DM2XE80 ID DM2XE80
DM2XE80 DN BAY-X-7195
DM2XE80 HS Phase 2
DM2XE80 SN BAY-X-7195; UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid
DM2XE80 CP Bayer AG
DM2XE80 DT Small molecular drug
DM2XE80 PC 6442328
DM2XE80 MW 520.6
DM2XE80 FM C30H32O6S
DM2XE80 IC InChI=1S/C30H32O6S/c31-29(32)20-19-27(37-28-17-13-24(14-18-28)30(33)34)10-6-7-23-11-15-26(16-12-23)36-22-5-4-21-35-25-8-2-1-3-9-25/h1-3,6,8-18,27H,4-5,7,19-22H2,(H,31,32)(H,33,34)/b10-6-/t27-/m1/s1
DM2XE80 CS C1=CC=C(C=C1)OCCCCOC2=CC=C(C=C2)C/C=C\\[C@H](CCC(=O)O)SC3=CC=C(C=C3)C(=O)O
DM2XE80 IK MHKAEITVUICXRN-BPGQXAFDSA-N
DM2XE80 IU 4-[(Z,3S)-1-carboxy-6-[4-(4-phenoxybutoxy)phenyl]hex-4-en-3-yl]sulfanylbenzoic acid
DM2XE80 CA CAS 143538-27-6
DM2XE80 DE Asthma
DMLO18H ID DMLO18H
DMLO18H DN BAY-Y-5959
DMLO18H HS Phase 2
DMLO18H CP Bayer AG
DMLO18H PC 9910240
DMLO18H MW 424.5
DMLO18H FM C26H24N4O2
DMLO18H IC InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1
DMLO18H CS CC1=C([C@H](C(=C(N1)N)C(=O)OC(C)C)C2=C3C=C(C=NC3=CC=C2)C4=CC=CC=C4)C#N
DMLO18H IK PHJVBZVDUNTGNR-HSZRJFAPSA-N
DMLO18H IU propan-2-yl (4R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate
DMLO18H CA CAS 146136-94-9
DMLO18H DE Cardiovascular disease
DMB0UF9 ID DMB0UF9
DMB0UF9 DN Bb2121
DMB0UF9 HS Phase 2
DMB0UF9 CP bluebird bioCambridge, MACelgeneSummit, NJ
DMB0UF9 DT CAR T Cell Therapy
DMB0UF9 DE Multiple myeloma
DMR59I4 ID DMR59I4
DMR59I4 DN BBI-5000
DMR59I4 HS Phase 2
DMR59I4 CP Brickell Biotech
DMR59I4 DT Small molecular drug
DMR59I4 DE Alopecia
DMDSNIR ID DMDSNIR
DMDSNIR DN BBI503
DMDSNIR HS Phase 2
DMDSNIR CP Boston Biomedical
DMDSNIR PC 25190990
DMDSNIR MW 539.7
DMDSNIR FM C31H33N5O2S
DMDSNIR IC InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
DMDSNIR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
DMDSNIR IK QDWKGEFGLQMDAM-ULJHMMPZSA-N
DMDSNIR IU N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
DMDSNIR CA CAS 1129403-56-0
DMDSNIR DE Ovarian cancer; Hepatocellular carcinoma; Cholangiocarcinoma; Solid tumour/cancer
DMY1UGV ID DMY1UGV
DMY1UGV DN Bc-3781 intravenous
DMY1UGV HS Phase 2
DMY1UGV SN BC-3781 (intravenous), Nabriva; BC-3781 (oral), Nabriva
DMY1UGV CP Nabriva therapeutics
DMY1UGV DT Small molecular drug
DMY1UGV PC 52918381
DMY1UGV MW 507.7
DMY1UGV FM C28H45NO5S
DMY1UGV IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18?,20?,21?,22-,24+,25+,26-,27+,28+/m1/s1
DMY1UGV CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C
DMY1UGV IK KPVIXBKIJXZQJX-IJUBVZAWSA-N
DMY1UGV IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate
DMY1UGV CA CAS 1061872-97-6
DMY1UGV DE Bacterial infection
DMMKCJ6 ID DMMKCJ6
DMMKCJ6 DN BC-7013
DMMKCJ6 HS Phase 2
DMMKCJ6 SN Pleuromutilin (topical, dermatological infection), Nabriva
DMMKCJ6 CP Nabriva Therapeutics AG
DMMKCJ6 DE Skin infection
DM2BO9W ID DM2BO9W
DM2BO9W DN BCP-13498
DM2BO9W HS Phase 2
DM2BO9W SN Propacetamol; Pro-Dafalgan; Propacetamol (INN); Propacetamol [INN:BAN]; Propacetamol [INN]; Propacetamolum; Propacetamolum [Latin]; Tox21_113811; ZINC55161176; (4-acetamidophenyl) 2-(diethylamino)acetate; 5CHW4JMR82; 66532-85-2; AC1L2ALY; AC1Q6199; AKOS015890722; BCP13498; CHEBI:135089; CHEMBL1851805; DB09288; DSSTox_CID_31589; DSSTox_GSID_57800; DSSTox_RID_97473; DTXSID3057800; EINECS 266-390-1; Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester; N,N-Diethylglycine, ester with 4'-hydroxyacetanilide; SCHEMBL26155; UNII-5CHW4JMR82
DM2BO9W PC 68865
DM2BO9W MW 264.32
DM2BO9W FM C14H20N2O3
DM2BO9W IC QTGAJCQTLIRCFL-UHFFFAOYSA-N
DM2BO9W CS CCN(CC)CC(=O)OC1=CC=C(C=C1)NC(=O)C
DM2BO9W IK 1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)
DM2BO9W IU (4-acetamidophenyl) 2-(diethylamino)acetate
DM2BO9W CA CAS 66532-85-2
DM2BO9W CB CHEBI:135089
DM2BO9W DE Anaesthesia
DMUFY4K ID DMUFY4K
DMUFY4K DN BCT303
DMUFY4K HS Phase 2
DMUFY4K SN Liothyronine sustained release
DMUFY4K CP Intellectual property executives
DMUFY4K DE Hypothyroidism
DMRSG31 ID DMRSG31
DMRSG31 DN BCX-3408
DMRSG31 HS Phase 2
DMRSG31 SN ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine
DMRSG31 DT Small molecular drug
DMRSG31 PC 135449518
DMRSG31 MW 264.28
DMRSG31 FM C12H16N4O3
DMRSG31 IC InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
DMRSG31 CS C1[C@@H]([C@H](CN1CC2=CNC3=C2N=CNC3=O)O)CO
DMRSG31 IK AFNHHLILYQEHKK-BDAKNGLRSA-N
DMRSG31 IU 7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMRSG31 CA CAS 548486-59-5
DMRSG31 DE Plaque psoriasis; Gout; Autoimmune diabetes
DMKFJXP ID DMKFJXP
DMKFJXP DN BDB001
DMKFJXP HS Phase 2
DMKFJXP CP Birdie Biopharmaceuticals; Seven and Eight Biopharmaceuticals
DMKFJXP DT Antibody
DMKFJXP DE Solid tumour/cancer
DM2Q50G ID DM2Q50G
DM2Q50G DN Belnacasan
DM2Q50G HS Phase 2
DM2Q50G SN Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)
DM2Q50G CP MedKoo Biosciences; vertex pharmaceuticals
DM2Q50G DT Small molecular drug
DM2Q50G PC 11398092
DM2Q50G MW 509
DM2Q50G FM C24H33ClN4O6
DM2Q50G IC InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1
DM2Q50G CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl
DM2Q50G IK SJDDOCKBXFJEJB-MOKWFATOSA-N
DM2Q50G IU (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
DM2Q50G CA CAS 273404-37-8
DM2Q50G DE Epilepsy
DMWNYIE ID DMWNYIE
DMWNYIE DN Bemarituzumab
DMWNYIE HS Phase 2
DMWNYIE CP Five Prime Therapeutics South San Francisco, CA
DMWNYIE DE Gastric adenocarcinoma
DM0YCPL ID DM0YCPL
DM0YCPL DN Bemcentinib
DM0YCPL HS Phase 2
DM0YCPL SN R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine
DM0YCPL CP Rigel Pharmaceuticals; BerGen BIO
DM0YCPL DT Small molecular drug
DM0YCPL PC 46215462
DM0YCPL MW 506.6
DM0YCPL FM C30H34N8
DM0YCPL IC InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1
DM0YCPL CS C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76
DM0YCPL IK KXMZDGSRSGHMMK-VWLOTQADSA-N
DM0YCPL IU 1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
DM0YCPL CA CAS 1037624-75-1
DM0YCPL DE Non-small-cell lung cancer; Myelodysplastic syndrome; Triple negative breast cancer
DMUL6GY ID DMUL6GY
DMUL6GY DN BEMORADAN
DMUL6GY HS Phase 2
DMUL6GY SN Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one
DMUL6GY DT Small molecular drug
DMUL6GY PC 5362399
DMUL6GY MW 259.26
DMUL6GY FM C13H13N3O3
DMUL6GY IC InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)
DMUL6GY CS CC1CC(=O)NN=C1C2=CC3=C(C=C2)NC(=O)CO3
DMUL6GY IK XZPGINPFWXLYNW-UHFFFAOYSA-N
DMUL6GY IU 7-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-4H-1,4-benzoxazin-3-one
DMUL6GY CA CAS 112018-01-6
DMUL6GY DE Heart failure
DMRC0EQ ID DMRC0EQ
DMRC0EQ DN Bertilimumab
DMRC0EQ HS Phase 2
DMRC0EQ SN CAT-213; ICo-008
DMRC0EQ CP Cambridge Antibody Technology
DMRC0EQ DT Monoclonal antibody
DMRC0EQ DE Ocular allergy; Bullous pemphigoid; Psoriasis vulgaris; Ulcerative colitis
DMJ2REU ID DMJ2REU
DMJ2REU DN Berubicin
DMJ2REU HS Phase 2
DMJ2REU SN Berubicin hydrochloride; RTA-744; RTA-769; WP-744; WP-769; Anthracycline derivative topoisomerase II inhibitor (cancer), MD Anderson; Anthracycline derivative topoisomerase II inhibitor (cancer), Reata; Berubicin (intravenous), Reata Pharmaceuticals; Berubicin (oral, cancer); Anthracycline topoisomerase II inhibitor (oral, cancer), MD Anderson Cancer Center; Anthracycline topoisomerase II inhibitor (oral, cancer), Reata Pharmaceuticals; Berubicin (oral, cancer), Reata Pharmaceuticals
DMJ2REU CP MD Anderson Cancer Center
DMJ2REU DT Small molecular drug
DMJ2REU PC 9874592
DMJ2REU MW 633.6
DMJ2REU FM C34H35NO11
DMJ2REU IC InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1
DMJ2REU CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6
DMJ2REU IK FIGNGSHKNAHTSH-JJMFXPFOSA-N
DMJ2REU IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMJ2REU CA CAS 677017-23-1
DMJ2REU DE Solid tumour/cancer
DM7583A ID DM7583A
DM7583A DN Beta-caryophyllene
DM7583A HS Phase 2
DM7583A SN BETA-CARYOPHYLLENE; Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; L-Caryophyllene; (-)-beta-caryophyllene; trans-Caryophyllene; (E)-Caryophyllene; (E)-beta-caryophyllene; b-caryophyllene; trans-beta-caryophyllene; Beta-Caryophylene; (-)-Caryophyllene; beta-Caryophyllen; beta-Caryophyllene; CHEBI:10357; (E)-beta-caryophylene; beta-(E)-Caryophyllene; beta-Caryophyllen; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; MFCD00075925; UNII-BHW853AU9H; g-Caryophyllene; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; NSC 11906; E-.beta.-caryophyllene; BHW853AU9H; beta-Caryophyllene, (-); Tincturoid; NSC11906; Caryophyllene B; beta-cariofillene; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; beta-caryophillene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; E-beta-caryophyllene; Caryophyllene, (E); beta-(e)-caryophyllene; beta-trans-caryophyllene; (-)- -caryophyllene; (-)-(E)-Caryophyllene; DSSTox_CID_4739; beta-trans-Caryophyllene; trans-.beta.-Caryophyllene; (-)-I(2)-caryophyllene; DSSTox_RID_77517; DSSTox_GSID_24739; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; CHEMBL445740; DTXSID8024739; HY-N1415; ZINC8234282; Tox21_301497; BDBM50529607; s6058; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; AKOS024283988; trans-(1R,9S)-8-Methylene-4,11,11-trimethylbicyclo[7.2.0]undec-4-ene; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; ST072181; (-)-trans-Caryophyllene, analytical standard; CS-0016839; V0915; C09629; Q421614; W-109317; UNII-K4H93P747O component NPNUFJAVOOONJE-GFUGXAQUSA-N; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]-
DM7583A DT Small molecular drug
DM7583A PC 5281515
DM7583A MW 204.35
DM7583A FM C15H24
DM7583A IC InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1
DM7583A CS C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C
DM7583A IK NPNUFJAVOOONJE-GFUGXAQUSA-N
DM7583A IU (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
DM7583A CA CAS 87-44-5
DM7583A CB CHEBI:10357
DM7583A DE Pain
DMMI84K ID DMMI84K
DMMI84K DN Beta-lapachone
DMMI84K HS Phase 2
DMMI84K SN ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione
DMMI84K CP Roche
DMMI84K DT Small molecular drug
DMMI84K PC 3885
DMMI84K MW 242.27
DMMI84K FM C15H14O3
DMMI84K IC InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3
DMMI84K CS CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C
DMMI84K IK QZPQTZZNNJUOLS-UHFFFAOYSA-N
DMMI84K IU 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione
DMMI84K CA CAS 4707-32-8
DMMI84K CB CHEBI:10429
DMMI84K DE Solid tumour/cancer
DML2D8Q ID DML2D8Q
DML2D8Q DN Bevirimat
DML2D8Q HS Phase 2
DML2D8Q SN DSB; Bevirimat dimeglumine; DSB 2NMG; MPC-4326; PA-457; PA-103001-01; PA-103001-04; PA-457 di-NMG; Viral maturation inhibitor (HIV), Myrexis; Viral maturation inhibitor (HIV), Myriad; Viral maturation inhibitor (HIV), Panacos; YK-FH-312; 3-O-(3' 3'-dimethylsuccinyl)-betulinic acid
DML2D8Q CP Panacos
DML2D8Q DT Small molecular drug
DML2D8Q PC 457928
DML2D8Q MW 584.8
DML2D8Q FM C36H56O6
DML2D8Q IC InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1
DML2D8Q CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O
DML2D8Q IK YJEJKUQEXFSVCJ-WRFMNRASSA-N
DML2D8Q IU (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DML2D8Q CA CAS 174022-42-5
DML2D8Q CB CHEBI:65484
DML2D8Q DE Human immunodeficiency virus infection
DMKBRDL ID DMKBRDL
DMKBRDL DN BEZ235
DMKBRDL HS Phase 2
DMKBRDL SN BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
DMKBRDL CP Novartis
DMKBRDL DT Small molecular drug
DMKBRDL PC 11977753
DMKBRDL MW 469.5
DMKBRDL FM C30H23N5O
DMKBRDL IC InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3
DMKBRDL CS CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
DMKBRDL IK JOGKUKXHTYWRGZ-UHFFFAOYSA-N
DMKBRDL IU 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
DMKBRDL CA CAS 915019-65-7
DMKBRDL CB CHEBI:71952
DMKBRDL DE Solid tumour/cancer
DMVUX1C ID DMVUX1C
DMVUX1C DN BFH-772
DMVUX1C HS Phase 2
DMVUX1C SN NVP-BFH-772
DMVUX1C CP Novartis AG
DMVUX1C PC 24756034
DMVUX1C MW 439.4
DMVUX1C FM C23H16F3N3O3
DMVUX1C IC InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)
DMVUX1C CS C1=CC(=CC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=NC=NC(=C4)CO)C(F)(F)F
DMVUX1C IK JNLSTLQFDDAULK-UHFFFAOYSA-N
DMVUX1C IU 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
DMVUX1C CA CAS 890128-81-1
DMVUX1C DE Psoriasis vulgaris
DMRO6XT ID DMRO6XT
DMRO6XT DN BGB-290
DMRO6XT HS Phase 2
DMRO6XT SN Pamiparib
DMRO6XT PC 135565554
DMRO6XT MW 298.31
DMRO6XT FM C16H15FN4O
DMRO6XT IC InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
DMRO6XT CS C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
DMRO6XT IK DENYZIUJOTUUNY-MRXNPFEDSA-N
DMRO6XT IU (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
DMRO6XT CA CAS 1446261-44-4
DMRO6XT DE Recurrent glioblastoma; Solid tumour/cancer; Ovarian cancer
DMQCFSM ID DMQCFSM
DMQCFSM DN BGB-3112
DMQCFSM HS Phase 2
DMQCFSM CP BeiGene Cambridge, MA
DMQCFSM DE Follicular lymphoma
DMDI43Y ID DMDI43Y
DMDI43Y DN BGB-324
DMDI43Y HS Phase 2
DMDI43Y SN BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio
DMDI43Y CP BergenBio AS
DMDI43Y DT siRNA drug
DMDI43Y DE Metastatic malignant neoplasm; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndrome
DM1X3L0 ID DM1X3L0
DM1X3L0 DN BGB-3245
DM1X3L0 HS Phase 2
DM1X3L0 CP BeiGene
DM1X3L0 DT Small molecular drug
DM1X3L0 DE Solid tumour/cancer
DMS2MQ5 ID DMS2MQ5
DMS2MQ5 DN BGC-20-1531
DMS2MQ5 HS Phase 2
DMS2MQ5 SN AH-22921; EP4 antagonist, BTG; EP4 antagonist, Pharmagene; Migraine therapy, BTG; Migraine therapy, Pharmagene; PGN-1531; EP4 receptor antagonists (migraine), Asterand; R-4 (migraine), Pharmagene
DMS2MQ5 CP Pharmagene plc
DMS2MQ5 DT Small molecular drug
DMS2MQ5 PC 25209437
DMS2MQ5 MW 514.5
DMS2MQ5 FM C26H23N2NaO6S
DMS2MQ5 IC InChI=1S/C26H24N2O6S.Na/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23;/h4-15H,16H2,1-3H3,(H,28,29);/q;+1/p-1
DMS2MQ5 CS CC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+]
DMS2MQ5 IK TVDHMDXPKGMXRT-UHFFFAOYSA-M
DMS2MQ5 IU sodium;[4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methylfuran-2-carbonyl]-(2-methylphenyl)sulfonylazanide
DMS2MQ5 DE Migraine
DMYDM68 ID DMYDM68
DMYDM68 DN BGP-15
DMYDM68 HS Phase 2
DMYDM68 SN 66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride
DMYDM68 CP N-Gene Research Laboratories
DMYDM68 DT Small molecular drug
DMYDM68 PC 9884807
DMYDM68 MW 351.3
DMYDM68 FM C14H24Cl2N4O2
DMYDM68 IC InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
DMYDM68 CS C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\N)O.Cl.Cl
DMYDM68 IK ISGGVCWFTPTHIX-UHFFFAOYSA-N
DMYDM68 IU N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride
DMYDM68 CA CAS 66611-37-8
DMYDM68 DE Type-2 diabetes
DMO4MNQ ID DMO4MNQ
DMO4MNQ DN BGS-649
DMO4MNQ HS Phase 2
DMO4MNQ CP Novartis AG
DMO4MNQ DE Endometriosis
DMSROM4 ID DMSROM4
DMSROM4 DN BHQ880
DMSROM4 HS Phase 2
DMSROM4 SN BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
DMSROM4 CP Novartis
DMSROM4 DT Antibody
DMSROM4 DE Multiple myeloma
DM7ZM1H ID DM7ZM1H
DM7ZM1H DN BHT-3009
DM7ZM1H HS Phase 2
DM7ZM1H CP Bayhill Therapeutics
DM7ZM1H DT Vaccine
DM7ZM1H DE Multiple sclerosis
DM740BS ID DM740BS
DM740BS DN BI 1358894
DM740BS HS Phase 2
DM740BS CP Boehringer Ingelheim
DM740BS DT Small molecular drug
DM740BS DE Depression
DMMSGAT ID DMMSGAT
DMMSGAT DN BI 207127
DMMSGAT HS Phase 2
DMMSGAT SN Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic; Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1
DMMSGAT CP Boehringer Ingelheim Pharma
DMMSGAT DT Small molecular drug
DMMSGAT PC 56948249
DMMSGAT MW 653.6
DMMSGAT FM C34H33BrN6O3
DMMSGAT IC InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+
DMMSGAT CS CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7
DMMSGAT IK BMAIGAHXAJEULY-UKTHLTGXSA-N
DMMSGAT IU (E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid
DMMSGAT CA CAS 863884-77-9
DMMSGAT DE Hepatitis C virus infection
DMJSADP ID DMJSADP
DMJSADP DN BI 2536
DMJSADP HS Phase 2
DMJSADP SN BI2536, BI 2536
DMJSADP CP Boehringer Ingelheim
DMJSADP TC Anticancer Agents
DMJSADP DT Small molecular drug
DMJSADP PC 11364421
DMJSADP MW 521.7
DMJSADP FM C28H39N7O3
DMJSADP IC InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
DMJSADP CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
DMJSADP IK XQVVPGYIWAGRNI-JOCHJYFZSA-N
DMJSADP IU 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DMJSADP CA CAS 755038-02-9
DMJSADP DE Acute myeloid leukaemia
DM1NMGJ ID DM1NMGJ
DM1NMGJ DN BI 456906
DM1NMGJ HS Phase 2
DM1NMGJ CP Boehringer Ingelheim; Zealand Pharma
DM1NMGJ DT Small molecular drug
DM1NMGJ DE Type 2 diabetes
DMF86P2 ID DMF86P2
DMF86P2 DN BI 655064
DMF86P2 HS Phase 2
DMF86P2 CP Boehringer ingelheim pharmaceuticals
DMF86P2 DT Antibody
DMF86P2 DE Rheumatoid arthritis; Lupus; Thrombocytopenia
DMJFDS0 ID DMJFDS0
DMJFDS0 DN BI-409306
DMJFDS0 HS Phase 2
DMJFDS0 CP Boehringer Ingelheim Pharmaceuticals
DMJFDS0 PC 135908617
DMJFDS0 MW 311.34
DMJFDS0 FM C16H17N5O2
DMJFDS0 IC InChI=1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22)
DMJFDS0 CS C1COCCC1N2C3=C(C=N2)C(=O)NC(=N3)CC4=CC=CC=N4
DMJFDS0 IK BZTIJCSHNVZMES-UHFFFAOYSA-N
DMJFDS0 IU 1-(oxan-4-yl)-6-(pyridin-2-ylmethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMJFDS0 CA CAS 1189767-28-9
DMJFDS0 DE Psychiatric disorder; Alzheimer disease; Schizophrenia
DMZR9OU ID DMZR9OU
DMZR9OU DN BI-44370
DMZR9OU HS Phase 2
DMZR9OU SN BI-44370; Calcitonin gene-related peptide antagonist (migraine), Boehringer Ingelheim
DMZR9OU CP Boehringer Ingelheim Corp
DMZR9OU DE Migraine
DMSZQHX ID DMSZQHX
DMSZQHX DN BI-505
DMSZQHX HS Phase 2
DMSZQHX CP BioInvent International
DMSZQHX DT Antibody
DMSZQHX DE Multiple myeloma
DM9FZYT ID DM9FZYT
DM9FZYT DN BI-655130
DM9FZYT HS Phase 2
DM9FZYT CP Boehringer Ingelheim Ridgefield, CT
DM9FZYT DE Plaque psoriasis; Palmoplantar pustulosis
DMWH7Z5 ID DMWH7Z5
DMWH7Z5 DN BI-836826
DMWH7Z5 HS Phase 2
DMWH7Z5 CP Boehringer Ingelheim Pharmaceuticals
DMWH7Z5 DT Antibody
DMWH7Z5 DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMUVMY9 ID DMUVMY9
DMUVMY9 DN BI-836858
DMUVMY9 HS Phase 2
DMUVMY9 CP Boehringer Ingelheim Pharmaceuticals
DMUVMY9 DT Antibody
DMUVMY9 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMG3ON2 ID DMG3ON2
DMG3ON2 DN BIA 3-202
DMG3ON2 HS Phase 2
DMG3ON2 SN Nebicapone; 274925-86-9; UNII-NM2KXJ990T; NM2KXJ990T; CHEMBL160038; Ethanone, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-; BIA 3-202; Nebicapone [INN]; 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone; SCHEMBL132167; ZINC8750; 1-(3,4-dihydroxy-5-nitro-phenyl)-2-phenyl-ethanone; CTK8H9559; DTXSID30181912; BIA-3-202; BDBM50108878; AKOS028111881; ACM274925869; FT-0703128
DMG3ON2 DT Small molecular drug
DMG3ON2 PC 9838389
DMG3ON2 MW 273.24
DMG3ON2 FM C14H11NO5
DMG3ON2 IC InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
DMG3ON2 CS C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DMG3ON2 IK MRFOLGFFTUGAEB-UHFFFAOYSA-N
DMG3ON2 IU 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
DMG3ON2 CA CAS 274925-86-9
DMG3ON2 DE Parkinson disease
DMHYZEK ID DMHYZEK
DMHYZEK DN BIBH 1
DMHYZEK HS Phase 2
DMHYZEK CP Boehringer Ingelheim
DMHYZEK DT Antibody
DMHYZEK DE Solid tumour/cancer
DM9OXEJ ID DM9OXEJ
DM9OXEJ DN BIIB 023
DM9OXEJ HS Phase 2
DM9OXEJ CP Biogen Idec
DM9OXEJ DE Rheumatoid arthritis
DM293JT ID DM293JT
DM293JT DN BIIB 033
DM293JT HS Phase 2
DM293JT DT Antibody
DM293JT DE Multiple sclerosis
DMH7RJ1 ID DMH7RJ1
DMH7RJ1 DN BIIB014
DMH7RJ1 HS Phase 2
DMH7RJ1 SN V2006
DMH7RJ1 CP Biogen Idec
DMH7RJ1 DT Small molecular drug
DMH7RJ1 PC 21874557
DMH7RJ1 MW 321.34
DMH7RJ1 FM C16H15N7O
DMH7RJ1 IC InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
DMH7RJ1 CS CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N
DMH7RJ1 IK HQSBCDPYXDGTCL-UHFFFAOYSA-N
DMH7RJ1 IU 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
DMH7RJ1 CA CAS 442908-10-3
DMH7RJ1 DE Parkinson disease
DMPAJ41 ID DMPAJ41
DMPAJ41 DN BIIB-021
DMPAJ41 HS Phase 2
DMPAJ41 SN CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma
DMPAJ41 CP Conforma Therapeutics Corp
DMPAJ41 DT Small molecular drug
DMPAJ41 PC 16736529
DMPAJ41 MW 318.76
DMPAJ41 FM C14H15ClN6O
DMPAJ41 IC InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)
DMPAJ41 CS CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N
DMPAJ41 IK QULDDKSCVCJTPV-UHFFFAOYSA-N
DMPAJ41 IU 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine
DMPAJ41 CA CAS 848695-25-0
DMPAJ41 CB CHEBI:90687
DMPAJ41 DE Breast cancer
DMZO2SY ID DMZO2SY
DMZO2SY DN BIIB054
DMZO2SY HS Phase 2
DMZO2SY CP Biogen Cambridge, MA
DMZO2SY DE Parkinson disease
DMLV1ET ID DMLV1ET
DMLV1ET DN BIIB074
DMLV1ET HS Phase 2
DMLV1ET SN CNV1014082; BC600719; HY-12796; B5927; (5R)-5-(4-[2-
DMLV1ET CP Biogen
DMLV1ET PC 16046068
DMLV1ET MW 314.4
DMLV1ET FM C18H19FN2O2
DMLV1ET IC InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
DMLV1ET CS C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
DMLV1ET IK JESCETIFNOFKEU-SJORKVTESA-N
DMLV1ET IU (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
DMLV1ET CA CAS 934240-30-9
DMLV1ET DE Lumbosacral radiculopathy; Trigeminal neuralgia; Bipolar disorder
DM263RP ID DM263RP
DM263RP DN BIIB092
DM263RP HS Phase 2
DM263RP CP Biogen Cambridge, MA
DM263RP DE Alzheimer disease; Progressive supranuclear palsy
DM2J36F ID DM2J36F
DM2J36F DN BILN-2061
DM2J36F HS Phase 2
DM2J36F SN Ciluprevir; BILN-2061; 300832-84-2; BILN 2061; UNII-75C8DU40T0; CHEMBL297884; 75C8DU40T0; Ciluprevir [USAN:INN]; Ciluprevir (BILN-2061); BILN 2061 ZW; BILN2061; SCHEMBL2524642; BILN-2061-ZW; C40H50N6O8S; (cyclopentoxycarbonylamino)-[[2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy]-dioxo-[ ]carboxylic acid; BDBM50142916; 3548AH; ZINC150339466; AKOS024627485; CS-0339; DB05868; BILN 2061; ; ; BILN 2061ZW; HY-10242; W-5515; F2145-0237
DM2J36F TC Antiviral Agents
DM2J36F DT Small molecular drug
DM2J36F PC 9853710
DM2J36F MW 774.9
DM2J36F FM C40H50N6O8S
DM2J36F IC InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1
DM2J36F CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O
DM2J36F IK PJZPDFUUXKKDNB-KNINVFKUSA-N
DM2J36F IU (1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
DM2J36F CA CAS 300832-84-2
DM2J36F DE Hepatitis virus infection
DMAG4SX ID DMAG4SX
DMAG4SX DN BILR-355
DMAG4SX HS Phase 2
DMAG4SX SN BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
DMAG4SX DE Human immunodeficiency virus infection
DM6EIZG ID DM6EIZG
DM6EIZG DN BIM23A760
DM6EIZG HS Phase 2
DM6EIZG SN Lonapalene; LONAPALENE; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene
DM6EIZG CP Ipsen
DM6EIZG DT Small molecular drug
DM6EIZG PC 56237
DM6EIZG MW 338.74
DM6EIZG FM C16H15ClO6
DM6EIZG IC InChI=1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
DM6EIZG CS CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC
DM6EIZG IK IFWMVQUGSGWCRP-UHFFFAOYSA-N
DM6EIZG IU (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate
DM6EIZG CA CAS 91431-42-4
DM6EIZG DE Acromegaly; Carcinoid syndrome; Psoriasis vulgaris
DMH7Q4E ID DMH7Q4E
DMH7Q4E DN Bimagrumab
DMH7Q4E HS Phase 2
DMH7Q4E CP Novartis
DMH7Q4E DT Antibody
DMH7Q4E DE Type 2 diabetes
DMBRL19 ID DMBRL19
DMBRL19 DN Bimakalim
DMBRL19 HS Phase 2
DMBRL19 SN EMD-52692; SR-44866
DMBRL19 CP Merck KGaA
DMBRL19 DT Small molecular drug
DMBRL19 PC 60674
DMBRL19 MW 278.3
DMBRL19 FM C17H14N2O2
DMBRL19 IC InChI=1S/C17H14N2O2/c1-17(2)10-14(19-8-4-3-5-16(19)20)13-9-12(11-18)6-7-15(13)21-17/h3-10H,1-2H3
DMBRL19 CS CC1(C=C(C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)C
DMBRL19 IK JTVSKASWNROQQF-UHFFFAOYSA-N
DMBRL19 IU 2,2-dimethyl-4-(2-oxopyridin-1-yl)chromene-6-carbonitrile
DMBRL19 CA CAS 117545-11-6
DMBRL19 DE Angina pectoris
DMB9LRJ ID DMB9LRJ
DMB9LRJ DN Bintrafusp alfa
DMB9LRJ HS Phase 2
DMB9LRJ CP EMD Serono; GlaxoSmithKline
DMB9LRJ DT Recombinant protein
DMB9LRJ DE Non-small cell lung cancer
DM6N05H ID DM6N05H
DM6N05H DN BIO-11006
DM6N05H HS Phase 2
DM6N05H CP BioMarck Pharmaceuticals
DM6N05H DE Chronic obstructive pulmonary disease; Non-small-cell lung cancer
DMPNYXQ ID DMPNYXQ
DMPNYXQ DN BIO-11006
DMPNYXQ HS Phase 2
DMPNYXQ SN UNII-609AWV0US2; 609AWV0US2; DB14886; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid; 901117-03-1
DMPNYXQ CP BioMarck Pharmaceuticals
DMPNYXQ DT Small molecular drug
DMPNYXQ PC 11622197
DMPNYXQ MW 1050.2
DMPNYXQ FM C46H75N13O15
DMPNYXQ IC InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1
DMPNYXQ CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)C)O
DMPNYXQ IK KCSNGWMKFYVMKF-HGYIIGRXSA-N
DMPNYXQ IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid
DMPNYXQ CA CAS 901117-03-1
DMPNYXQ DE Non-small-cell lung cancer
DMKICA3 ID DMKICA3
DMKICA3 DN BIO-1211
DMKICA3 HS Phase 2
DMKICA3 SN BIO-1211; BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-
DMKICA3 DT Small molecular drug
DMKICA3 PC 9961766
DMKICA3 MW 708.8
DMKICA3 FM C36H48N6O9
DMKICA3 IC InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1
DMKICA3 CS CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O
DMKICA3 IK NVVGCQABIHSJSQ-KFZSMJGVSA-N
DMKICA3 IU (2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMKICA3 CA CAS 187735-94-0
DMKICA3 DE Asthma
DM7PT8R ID DM7PT8R
DM7PT8R DN BioE-743
DM7PT8R HS Phase 2
DM7PT8R CP BioElectron Technology Mountain View, CA
DM7PT8R DE Leigh syndrome; Pontocerebellar hypoplasia type 6
DM6PBUM ID DM6PBUM
DM6PBUM DN Birinapant
DM6PBUM HS Phase 2
DM6PBUM SN Birinapant; 1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM CP TetraLogic Pharmaceuticals
DM6PBUM DT Small molecular drug
DM6PBUM PC 49836020
DM6PBUM MW 806.9
DM6PBUM FM C42H56F2N8O6
DM6PBUM IC InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
DM6PBUM CS CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC
DM6PBUM IK PKWRMUKBEYJEIX-DXXQBUJASA-N
DM6PBUM IU (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM CA CAS 1260251-31-7
DM6PBUM DE Lymphoma; Solid tumour/cancer
DMW76V0 ID DMW76V0
DMW76V0 DN Bisantrene
DMW76V0 HS Phase 2
DMW76V0 SN 39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K
DMW76V0 DT Small molecular drug
DMW76V0 PC 5351322
DMW76V0 MW 398.474
DMW76V0 FM C22H22N8
DMW76V0 IC InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
DMW76V0 CS C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5
DMW76V0 IK NJSMWLQOCQIOPE-OCHFTUDZSA-N
DMW76V0 IU N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine
DMW76V0 CA CAS 78186-34-2
DMW76V0 DE Acute myelogenous leukemia
DMVDO93 ID DMVDO93
DMVDO93 DN BL-1020
DMVDO93 HS Phase 2
DMVDO93 SN BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
DMVDO93 CP BioLineRx
DMVDO93 DT Small molecular drug
DMVDO93 PC 11203271
DMVDO93 MW 489.1
DMVDO93 FM C25H33ClN4O2S
DMVDO93 IC InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2
DMVDO93 CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN
DMVDO93 IK BABFYCSPNDKXRI-UHFFFAOYSA-N
DMVDO93 IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
DMVDO93 CA CAS 751477-01-7
DMVDO93 DE Schizophrenia
DM8R71T ID DM8R71T
DM8R71T DN BL-22
DM8R71T HS Phase 2
DM8R71T SN CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
DM8R71T CP National Cancer Institute
DM8R71T DT Antibody
DM8R71T DE Acute lymphoblastic leukaemia
DMSBPJI ID DMSBPJI
DMSBPJI DN BL-7040
DMSBPJI HS Phase 2
DMSBPJI SN Monarsen; EN-101; TLR-9 activator (oral, inflammatory bowel disease), BioLineRx; TLR-9 activator (oral, inflammatory bowel disease), Hebrew University of Jerusalem
DMSBPJI CP Yissum Research Development Co
DMSBPJI DT Small molecular drug
DMSBPJI PC 56841946
DMSBPJI MW 6375
DMSBPJI FM C194H253N64O106P19S19
DMSBPJI IC InChI=1S/C194H253N64O106P19S19/c1-78-45-248(189(279)233-165(78)261)137-35-91(108(333-137)58-307-365(285,384)346-84-28-130(326-101(84)51-259)239-19-10-121(195)218-180(239)270)357-375(295,394)321-66-116-98(42-144(341-116)255-74-215-149-162(255)227-177(206)230-171(149)267)360-378(298,397)312-56-106-85(29-131(331-106)240-20-11-122(196)219-181(240)271)347-366(286,385)308-52-102-88(32-134(327-102)243-23-14-125(199)222-184(243)274)350-369(289,388)319-64-114-97(41-143(339-114)254-73-213-147-158(204)209-71-211-160(147)254)359-377(297,396)311-55-105-89(33-135(330-105)244-24-15-126(200)223-185(244)275)351-370(290,389)320-65-115-100(44-146(340-115)257-76-217-151-164(257)229-179(208)232-173(151)269)362-380(300,399)318-63-113-95(39-141(338-113)252-49-82(5)169(265)237-193(252)283)356-374(294,393)316-61-111-93(37-139(336-111)250-47-80(3)167(263)235-191(250)281)354-372(292,391)310-54-104-86(30-132(329-104)241-21-12-123(197)220-182(241)272)348-367(287,386)314-59-109-92(36-138(334-109)249-46-79(2)166(262)234-190(249)280)353-371(291,390)309-53-103-87(31-133(328-103)242-22-13-124(198)221-183(242)273)349-368(288,387)315-60-110-94(38-140(335-110)251-48-81(4)168(264)236-192(251)282)355-373(293,392)317-62-112-96(40-142(337-112)253-50-83(6)170(266)238-194(253)284)358-376(296,395)322-67-117-99(43-145(342-117)256-75-216-150-163(256)228-178(207)231-172(150)268)361-379(299,398)313-57-107-90(34-136(332-107)245-25-16-127(201)224-186(245)276)352-381(301,400)324-69-120-154(157(306-9)176(345-120)258-77-214-148-159(205)210-72-212-161(148)258)364-383(303,402)325-70-119-153(156(305-8)175(344-119)247-27-18-129(203)226-188(247)278)363-382(302,401)323-68-118-152(260)155(304-7)174(343-118)246-26-17-128(202)225-187(246)277/h10-27,45-50,71-77,84-120,130-146,152-157,174-176,259-260H,28-44,51-70H2,1-9H3,(H,285,384)(H,286,385)(H,287,386)(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H2,195,218,270)(H2,196,219,271)(H2,197,220,272)(H2,198,221,273)(H2,199,222,274)(H2,200,223,275)(H2,201,224,276)(H2,202,225,277)(H2,203,226,278)(H2,204,209,211)(H2,205,210,212)(H,233,261,279)(H,234,262,280)(H,235,263,281)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H3,206,227,230,267)(H3,207,228,231,268)(H3,208,229,232,269)
DMSBPJI CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3CO)N4C=CC(=NC4=O)N)OP(=S)(O)OCC5C(CC(O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)(O)OCC8C(CC(O8)N9C=CC(=NC9=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMSBPJI IK QJYMZHMIZZYHBI-UHFFFAOYSA-N
DMSBPJI IU 1-[4-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSBPJI DE Inflammatory bowel disease
DMKO0BQ ID DMKO0BQ
DMKO0BQ DN BLD-2660
DMKO0BQ HS Phase 2
DMKO0BQ SN BLD 2660
DMKO0BQ TC Antiviral Agents
DMKO0BQ DT Small molecular drug
DMKO0BQ DE Coronavirus Disease 2019 (COVID-19)
DMYK1DR ID DMYK1DR
DMYK1DR DN BLI-1005
DMYK1DR HS Phase 2
DMYK1DR CP BioLite Taipei, Taiwan
DMYK1DR DE Major depressive disorder
DMG1LVA ID DMG1LVA
DMG1LVA DN BLZ-945
DMG1LVA HS Phase 2
DMG1LVA SN CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis
DMG1LVA CP Novartis Institutes for BioMedical Research Inc
DMG1LVA DT Small molecular drug
DMG1LVA PC 46184986
DMG1LVA MW 398.5
DMG1LVA FM C20H22N4O3S
DMG1LVA IC InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1
DMG1LVA CS CNC(=O)C1=NC=CC(=C1)OC2=CC3=C(C=C2)N=C(S3)N[C@@H]4CCCC[C@H]4O
DMG1LVA IK ADZBMFGQQWPHMJ-RHSMWYFYSA-N
DMG1LVA IU 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide
DMG1LVA CA CAS 953769-46-5
DMG1LVA DE Solid tumour/cancer; Amyotrophic lateral sclerosis
DMQI43G ID DMQI43G
DMQI43G DN BMS 650032
DMQI43G HS Phase 2
DMQI43G SN Asunaprevir; 630420-16-5; BMS-650032; UNII-S9X0KRJ00S; BMS 650032; S9X0KRJ00S; Asunaprevir (BMS-650032); N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; Asunaprevir [USAN:INN]; Sunvepra (TN); tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; 2R9
DMQI43G CP Bristol-Myers Squibb
DMQI43G DT Small molecular drug
DMQI43G PC 16076883
DMQI43G MW 748.3
DMQI43G FM C35H46ClN5O9S
DMQI43G IC InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
DMQI43G CS CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
DMQI43G IK XRWSZZJLZRKHHD-WVWIJVSJSA-N
DMQI43G IU tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMQI43G CA CAS 630420-16-5
DMQI43G CB CHEBI:134723
DMQI43G DE Hepatitis C virus infection
DMKH4PI ID DMKH4PI
DMKH4PI DN BMS 791325
DMKH4PI HS Phase 2
DMKH4PI SN BMS-791325
DMKH4PI CP Bristol-Myers Squibb
DMKH4PI DT Small molecular drug
DMKH4PI PC 56934415
DMKH4PI MW 659.8
DMKH4PI FM C36H45N5O5S
DMKH4PI IC InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1
DMKH4PI CS CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMKH4PI IK ZTTKEBYSXUCBSE-QDFUAKMASA-N
DMKH4PI IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1S,5R)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMKH4PI CA CAS 958002-33-0
DMKH4PI DE Hepatitis C virus infection
DMDPLEM ID DMDPLEM
DMDPLEM DN BMS-184476
DMDPLEM HS Phase 2
DMDPLEM SN 10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 7-O-(Methylsulfanylmethyl)paclitaxel
DMDPLEM DT Small molecular drug
DMDPLEM PC 6918461
DMDPLEM MW 914
DMDPLEM FM C49H55NO14S
DMDPLEM IC InChI=1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1
DMDPLEM CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OCSC)C)OC(=O)C
DMDPLEM IK UBJAHGAUPNGZFF-XOVTVWCYSA-N
DMDPLEM IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDPLEM CA CAS 160237-25-2
DMDPLEM DE Solid tumour/cancer
DML1CK2 ID DML1CK2
DML1CK2 DN BMS-188797
DML1CK2 HS Phase 2
DML1CK2 SN 11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 4-O-Deacetyl-4-O-(methoxycarbonyl)paclitaxel
DML1CK2 DT Small molecular drug
DML1CK2 PC 6918494
DML1CK2 MW 869.9
DML1CK2 FM C47H51NO15
DML1CK2 IC InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1
DML1CK2 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)OC)O)C)OC(=O)C
DML1CK2 IK GMJWGJSDPOAZTP-MIDYMNAOSA-N
DML1CK2 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DML1CK2 CA CAS 172481-83-3
DML1CK2 DE Solid tumour/cancer
DMJUV6C ID DMJUV6C
DMJUV6C DN BMS-223131
DMJUV6C HS Phase 2
DMJUV6C SN 4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
DMJUV6C PC 9951995
DMJUV6C MW 383.7
DMJUV6C FM C18H13ClF3NO3
DMJUV6C IC InChI=1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26)
DMJUV6C CS C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O
DMJUV6C IK QESHSZWKJULSAR-UHFFFAOYSA-N
DMJUV6C IU 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-quinolin-2-one
DMJUV6C CA CAS 275375-69-4
DMJUV6C DE Erectile dysfunction
DMQL3VS ID DMQL3VS
DMQL3VS DN BMS-275183
DMQL3VS HS Phase 2
DMQL3VS SN BMS-198246; Oral taxane (cancer), BMS; Oral taxane (cancer), Bristol-Myers Squibb
DMQL3VS CP Bristol-Myers Squibb Co
DMQL3VS DT Small molecular drug
DMQL3VS PC 6918594
DMQL3VS MW 845.9
DMQL3VS FM C43H59NO16
DMQL3VS IC InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1
DMQL3VS CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C(C)(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)OC)O)C)OC(=O)C
DMQL3VS IK AHXICHPPXIGCBN-GPWPDEGDSA-N
DMQL3VS IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]oxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMQL3VS CA CAS 355113-98-3
DMQL3VS DE Solid tumour/cancer
DMGYXFP ID DMGYXFP
DMGYXFP DN BMS-582949
DMGYXFP HS Phase 2
DMGYXFP SN BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446
DMGYXFP CP Bristol-Myers Squibb
DMGYXFP DT Small molecular drug
DMGYXFP PC 10409068
DMGYXFP MW 406.5
DMGYXFP FM C22H26N6O2
DMGYXFP IC InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)
DMGYXFP CS CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C
DMGYXFP IK GDTQLZHHDRRBEB-UHFFFAOYSA-N
DMGYXFP IU 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
DMGYXFP CA CAS 623152-17-0
DMGYXFP DE Psoriasis vulgaris; Atherosclerosis
DMDPQV5 ID DMDPQV5
DMDPQV5 DN BMS-599626
DMDPQV5 HS Phase 2
DMDPQV5 SN BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703
DMDPQV5 CP Bristol Myers Squibb
DMDPQV5 TC Anticancer Agents
DMDPQV5 DT Small molecular drug
DMDPQV5 PC 10437018
DMDPQV5 MW 530.6
DMDPQV5 FM C27H27FN8O3
DMDPQV5 IC InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1
DMDPQV5 CS CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F
DMDPQV5 IK LUJZZYWHBDHDQX-QFIPXVFZSA-N
DMDPQV5 IU [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate
DMDPQV5 CA CAS 714971-09-2
DMDPQV5 DE Solid tumour/cancer
DMX302C ID DMX302C
DMX302C DN BMS-690514
DMX302C HS Phase 2
DMX302C SN BMS 690514; BMS690514
DMX302C DT Small molecular drug
DMX302C PC 11349170
DMX302C MW 368.4
DMX302C FM C19H24N6O2
DMX302C IC InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMX302C CS COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CC[C@H]([C@@H](C4)O)N
DMX302C IK CSGQVNMSRKWUSH-IAGOWNOFSA-N
DMX302C IU (3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DMX302C CA CAS 859853-30-8
DMX302C DE Chronic pain
DM51LTG ID DM51LTG
DM51LTG DN BMS-708163
DM51LTG HS Phase 2
DM51LTG SN Avagacestat
DM51LTG CP Bristol-Myers Squibb
DM51LTG DT Small molecular drug
DM51LTG PC 46883536
DM51LTG MW 520.9
DM51LTG FM C20H17ClF4N4O4S
DM51LTG IC InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1
DM51LTG CS C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl
DM51LTG IK XEAOPVUAMONVLA-QGZVFWFLSA-N
DM51LTG IU (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
DM51LTG CA CAS 1146699-66-2
DM51LTG DE Alzheimer disease
DMTVGY7 ID DMTVGY7
DMTVGY7 DN BMS-770767
DMTVGY7 HS Phase 2
DMTVGY7 CP Bristol-Myers Squibb
DMTVGY7 DE Hypercholesterolaemia
DMKY638 ID DMKY638
DMKY638 DN BMS-813160
DMKY638 HS Phase 2
DMKY638 SN BMS-585059; CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS; CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb; CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb
DMKY638 CP Bristol-myers squibb
DMKY638 PC 51039119
DMKY638 MW 484.6
DMKY638 FM C25H40N8O2
DMKY638 IC InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1
DMKY638 CS CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N2CC[C@@H](C2=O)NC3=NC=NC4=CC(=NN43)C(C)(C)C)NC(C)(C)C
DMKY638 IK CMVHFGNTABZQJU-HCXYKTFWSA-N
DMKY638 IU N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-[(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino]-2-oxopyrrolidin-1-yl]cyclohexyl]acetamide
DMKY638 CA CAS 1286279-29-5
DMKY638 DE Diabetic nephropathy; Solid tumour/cancer
DMT8L6P ID DMT8L6P
DMT8L6P DN BMS-817399
DMT8L6P HS Phase 2
DMT8L6P CP Bristol-Myers Squibb
DMT8L6P PC 44537841
DMT8L6P MW 454
DMT8L6P FM C23H36ClN3O4
DMT8L6P IC InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1
DMT8L6P CS CC(C)[C@H](C(=O)N1CC[C@@](C(C1)(C)C)(C2=CC=C(C=C2)Cl)O)NC(=O)NCC(C)(C)O
DMT8L6P IK GTDPZONCGOCXOD-JPYJTQIMSA-N
DMT8L6P IU 1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea
DMT8L6P CA CAS 1202400-18-7
DMT8L6P DE Rheumatoid arthritis
DMF46PD ID DMF46PD
DMF46PD DN BMS-911543
DMF46PD HS Phase 2
DMF46PD SN BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD CP Bristol-Myers Squibb
DMF46PD DT Small molecular drug
DMF46PD PC 50922691
DMF46PD MW 432.5
DMF46PD FM C23H28N8O
DMF46PD IC InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)
DMF46PD CS CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6
DMF46PD IK JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD IU N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide
DMF46PD CA CAS 1271022-90-2
DMF46PD DE Myelofibrosis
DMN28WK ID DMN28WK
DMN28WK DN BMS-919373
DMN28WK HS Phase 2
DMN28WK CP Bristol-myers squibb
DMN28WK PC 51030730
DMN28WK MW 468.5
DMN28WK FM C25H20N6O2S
DMN28WK IC InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31)
DMN28WK CS C1=CC=C(C=C1)C2=C3C(=CC=C2)N=C(N=C3NCC4=CC=CC=N4)C5=CC(=CN=C5)S(=O)(=O)N
DMN28WK IK XGKULQQVQWCASY-UHFFFAOYSA-N
DMN28WK IU 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
DMN28WK CA CAS 1272353-82-8
DMN28WK DE Atrial fibrillation
DMUTS1W ID DMUTS1W
DMUTS1W DN BMS-936557
DMUTS1W HS Phase 2
DMUTS1W SN Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex
DMUTS1W CP Medarex Inc
DMUTS1W DT Antibody
DMUTS1W DE Immune System disease
DM7XV4R ID DM7XV4R
DM7XV4R DN BMS-954561
DM7XV4R HS Phase 2
DM7XV4R SN AGN-001; AGN-209323; AGN-2XXXXX; AGN-323; EHT-001; EHT/AGN-0001; EHT/AGN-001; GABA/nicotinic modulator (neuroscience), BMS; Neuropathic pain therapy, ExonHit/Allergan/Bristol-Myers Squibb
DM7XV4R CP Exonhit
DM7XV4R DE Diabetic neuropathy
DMMEAGO ID DMMEAGO
DMMEAGO DN BMS-955176
DMMEAGO HS Phase 2
DMMEAGO CP Bristol-myers squibb
DMMEAGO DE Human immunodeficiency virus-1 infection
DMVJXOH ID DMVJXOH
DMVJXOH DN BMS-986012
DMVJXOH HS Phase 2
DMVJXOH CP Bristol-Myers Squibb
DMVJXOH DT Antibody
DMVJXOH DE Small-cell lung cancer; Solid tumour/cancer
DMHMV6E ID DMHMV6E
DMHMV6E DN BMS-986020
DMHMV6E HS Phase 2
DMHMV6E SN GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl
DMHMV6E CP Bristol-Myers SquibbPrinceton, NJ
DMHMV6E PC 49792850
DMHMV6E MW 482.5
DMHMV6E FM C29H26N2O5
DMHMV6E IC InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
DMHMV6E CS CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
DMHMV6E IK GQBRZBHEPUQRPL-LJQANCHMSA-N
DMHMV6E IU 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
DMHMV6E CA CAS 1257213-50-5
DMHMV6E DE Psoriasis vulgaris; Scleroderma
DMIZKEC ID DMIZKEC
DMIZKEC DN BMS-986036
DMIZKEC HS Phase 2
DMIZKEC CP Bristol-Myers Squibb Princeton, NJ
DMIZKEC DE Type-2 diabetes
DMTKDIP ID DMTKDIP
DMTKDIP DN BMS-986141
DMTKDIP HS Phase 2
DMTKDIP SN UNII-W530IRZ40G; W530IRZ40G; UDM-003183; 1478711-48-6; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N,N-dimethylbenzamide; CHEMBL3716552; SCHEMBL15348940; BDBM176003; DB14942; US9688695, 36; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide; Benzamide, 4-(4-(((6-methoxy-2-(2-methoxyimidazo(2,1-b)-1,3,4-thiadiazol-6-yl)-4-benzofuranyl)oxy)methyl)-2-thiazolyl)-N,N-dimethyl-
DMTKDIP CP Bristol-Myers Squibb
DMTKDIP DT Small molecular drug
DMTKDIP PC 72188743
DMTKDIP MW 561.6
DMTKDIP FM C27H23N5O5S2
DMTKDIP IC InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3
DMTKDIP CS CN(C)C(=O)C1=CC=C(C=C1)C2=NC(=CS2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC
DMTKDIP IK KEEBLYWBELVGPQ-UHFFFAOYSA-N
DMTKDIP IU 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide
DMTKDIP CA CAS 1478711-48-6
DMTKDIP DE Thrombosis
DMZB8AJ ID DMZB8AJ
DMZB8AJ DN BMS-986142
DMZB8AJ HS Phase 2
DMZB8AJ SN Unii-pjx9GH268R; UNII-PJX9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ CP Bristol-Myers SquibbPrinceton, NJ
DMZB8AJ PC 86582336
DMZB8AJ MW 572.6
DMZB8AJ FM C32H30F2N4O4
DMZB8AJ IC InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)/t16-/m0/s1
DMZB8AJ CS CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)C[C@H](CC6)C(C)(C)O)C(=O)N)F
DMZB8AJ IK ZRYMMWAJAFUANM-INIZCTEOSA-N
DMZB8AJ IU (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ CA CAS 1643368-58-4
DMZB8AJ DE Rheumatoid arthritis
DM4QHZS ID DM4QHZS
DM4QHZS DN BMS-986177
DM4QHZS HS Phase 2
DM4QHZS SN Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
DM4QHZS CP Bristol-Myers Squibb
DM4QHZS DT Small molecular drug
DM4QHZS PC 118277544
DM4QHZS MW 626.4
DM4QHZS FM C28H23Cl2F2N9O2
DM4QHZS IC InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
DM4QHZS CS C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl
DM4QHZS IK FSWFYCYPTDLKON-CMJOXMDJSA-N
DM4QHZS IU (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
DM4QHZS CA CAS 1802425-99-5
DM4QHZS DE Thrombosis; Cerebral ischemia
DM42B0C ID DM42B0C
DM42B0C DN BMS-986253
DM42B0C HS Phase 2
DM42B0C CP Bristol-Myers Squibb
DM42B0C DT Antibody
DM42B0C DE Solid tumour/cancer; Coronavirus Disease 2019 (COVID-19)
DM5OU2W ID DM5OU2W
DM5OU2W DN BMS-986253
DM5OU2W HS Phase 2
DM5OU2W SN Humax-inflam; HuMax-IL8; Humax-IL-8; UNII-N0YWS8X3S9; N0YWS8X3S9; MDX-018; BMS-986253; anti-Il-8 monoclonal antibody humax-IL8; 2231258-73-2
DM5OU2W TC Antiviral Agents
DM5OU2W DT Monoclonal antibody
DM5OU2W DE Coronavirus Disease 2019 (COVID-19)
DMSRVXO ID DMSRVXO
DMSRVXO DN BMS-986263
DMSRVXO HS Phase 2
DMSRVXO SN ND L02 s0201
DMSRVXO CP Bristol-Myers Squibb
DMSRVXO DT Small interfering RNA
DMSRVXO DE Hepatic fibrosis
DMUM2KA ID DMUM2KA
DMUM2KA DN BN82451
DMUM2KA HS Phase 2
DMUM2KA SN UNII-531B661QBY; 335242-75-6; BN-82451; 531B661QBY; 4-(2-(Aminomethyl)-1,3-thiazol-4-yl)-2,6-di(tert-butyl)phenol; Phenol,4-2-(aminomethyl)-4-thiazolyl-2,6-bis(1,1-dimethyl ethyl)-; 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)phenol; SCHEMBL197161; HAQOEWGSBVQDHB-UHFFFAOYSA-N; Phenol, 4-(2-(aminomethyl)-4-thiazolyl)-2,6-bis(1,1-dimethylethyl)-; SB17395; KB-59536
DMUM2KA CP Ipsen
DMUM2KA DT Small molecular drug
DMUM2KA PC 72941952
DMUM2KA MW 354.9
DMUM2KA FM C18H27ClN2OS
DMUM2KA IC InChI=1S/C18H26N2OS.ClH/c1-17(2,3)12-7-11(14-10-22-15(9-19)20-14)8-13(16(12)21)18(4,5)6;/h7-8,10,21H,9,19H2,1-6H3;1H
DMUM2KA CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CSC(=N2)CN.Cl
DMUM2KA IK WPWBWGUPSJCKKF-UHFFFAOYSA-N
DMUM2KA IU 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol;hydrochloride
DMUM2KA CA CAS 918656-59-4
DMUM2KA DE Parkinson disease
DMJC8DR ID DMJC8DR
DMJC8DR DN BNC-105
DMJC8DR HS Phase 2
DMJC8DR SN BNC-105P; IL-0035; IL-0049; Combretastatin A4 analogs (cancer), Bionomics; VDAs (cancer), Bionomics; Vascular disruption agents (cancer), Bionomics; Vascular targeting agents (cancer), Bionomics
DMJC8DR CP Iliad Chemicals Pty Ltd
DMJC8DR DT Small molecular drug
DMJC8DR PC 24786555
DMJC8DR MW 372.4
DMJC8DR FM C20H20O7
DMJC8DR IC InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3
DMJC8DR CS CC1=C(C2=C(O1)C(=C(C=C2)OC)O)C(=O)C3=CC(=C(C(=C3)OC)OC)OC
DMJC8DR IK RADMJHVVIZTENA-UHFFFAOYSA-N
DMJC8DR IU (7-hydroxy-6-methoxy-2-methyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone
DMJC8DR CA CAS 945771-74-4
DMJC8DR DE Mesothelioma
DMEGDWA ID DMEGDWA
DMEGDWA DN BNC-210
DMEGDWA HS Phase 2
DMEGDWA SN BNC-10002; GABA-A modulators (oral, anxiety), Bionomics
DMEGDWA CP Bionomics Ltd
DMEGDWA DE Anxiety disorder
DMRWG8B ID DMRWG8B
DMRWG8B DN BNT321
DMRWG8B HS Phase 2
DMRWG8B SN MVT-5873
DMRWG8B CP BioNTech
DMRWG8B DT Antibody
DMRWG8B DE Pancreatic cancer
DM8JQZC ID DM8JQZC
DM8JQZC DN BNZ-1
DM8JQZC HS Phase 2
DM8JQZC CP Bioniz Therapeutics
DM8JQZC DT Peptide
DM8JQZC DE Cutaneous T-cell lymphoma; T-cell leukaemia; Large granular lymphocytic leukemia
DMZ70GE ID DMZ70GE
DMZ70GE DN BOS-228
DMZ70GE HS Phase 2
DMZ70GE CP Boston Pharmaceuticals
DMZ70GE DT Small molecular drug
DMZ70GE DE Bacterial infection
DMKDGI8 ID DMKDGI8
DMKDGI8 DN BP-100-1-01
DMKDGI8 HS Phase 2
DMKDGI8 CP Bio-Path Ogden, Utah
DMKDGI8 DE Myelodysplastic syndrome; Hematologic tumour; Chronic myelogenous leukaemia; Acute myeloid leukaemia; Acute lymphoblastic leukaemia
DMWVPO0 ID DMWVPO0
DMWVPO0 DN BPN14770
DMWVPO0 HS Phase 2
DMWVPO0 SN KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide
DMWVPO0 CP Tetra Discovery Partners Grand Rapids, MI
DMWVPO0 PC 90111638
DMWVPO0 MW 405.8
DMWVPO0 FM C21H15ClF3NO2
DMWVPO0 IC InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28)
DMWVPO0 CS C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F
DMWVPO0 IK LTSUMTMGJHPGFX-UHFFFAOYSA-N
DMWVPO0 IU 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
DMWVPO0 CA CAS 1606974-33-7
DMWVPO0 DE Alzheimer disease
DMDYZRS ID DMDYZRS
DMDYZRS DN BPS-804
DMDYZRS HS Phase 2
DMDYZRS SN Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis
DMDYZRS CP Novartis AG
DMDYZRS DT Antibody
DMDYZRS DE Metabolic bone disease
DM0MO8I ID DM0MO8I
DM0MO8I DN BQ-123
DM0MO8I HS Phase 2
DM0MO8I SN BQ-123; 136553-81-6; BQ123; BQ 123; Cyclo(D-trp-D-asp-pro-D-val-leu); UNII-S2A8YZM151; CHEBI:2965; S2A8YZM151; CHEMBL314691; cyclo[D-Trp-D-Asp-Pro-D-Val-Leu]; cyclo(D-Asp-Pro-D-Val-Leu-D-Trp); cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu); cyclo-[D-Asp-Pro-d-Val-Leu-d-Trp]; cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp); Cyclo(D-trp-D-asp-L-pro-D-val-L-leu); Cyclo[D-trp-D-asp-L-pro-D-val-L-leu]; cyclo[(D)Trp-(D)Asp-Pro-(D)Val-Leu]; cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]; cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp)
DM0MO8I DT Small molecular drug
DM0MO8I PC 443289
DM0MO8I MW 610.7
DM0MO8I FM C31H42N6O7
DM0MO8I IC InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1
DM0MO8I CS CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43
DM0MO8I IK VYCMAAOURFJIHD-PJNXIOHISA-N
DM0MO8I IU 2-[(3R,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM0MO8I CA CAS 136553-81-6
DM0MO8I CB CHEBI:2965
DM0MO8I DE Pulmonary arterial hypertension
DMNFKVW ID DMNFKVW
DMNFKVW DN BR-4628
DMNFKVW HS Phase 2
DMNFKVW CP Bayer HealthCare Pharmaceuticals
DMNFKVW PC 60168629
DMNFKVW MW 381.4
DMNFKVW FM C22H23NO5
DMNFKVW IC InChI=1S/C22H23NO5/c1-6-27-22(26)19-13(4)23-12(3)18(14(5)24)20(19)16-9-7-8-15-17(25)10-11(2)28-21(15)16/h7-10,20,23H,6H2,1-5H3/t20-/m1/s1
DMNFKVW CS CCOC(=O)C1=C(NC(=C([C@H]1C2=CC=CC3=C2OC(=CC3=O)C)C(=O)C)C)C
DMNFKVW IK DXCPBIXBBLLGOZ-HXUWFJFHSA-N
DMNFKVW IU ethyl (4R)-5-acetyl-2,6-dimethyl-4-(2-methyl-4-oxochromen-8-yl)-1,4-dihydropyridine-3-carboxylate
DMNFKVW DE Heart failure
DM3TRF7 ID DM3TRF7
DM3TRF7 DN Brasofensine
DM3TRF7 HS Phase 2
DM3TRF7 SN Brasofensine [INN]
DM3TRF7 CP Lundbeck
DM3TRF7 DT Small molecular drug
DM3TRF7 PC 9554198
DM3TRF7 MW 327.2
DM3TRF7 FM C16H20Cl2N2O
DM3TRF7 IC InChI=1S/C16H20Cl2N2O/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3/b19-9+/t11?,12-,13-,16?/m1/s1
DM3TRF7 CS CN1C2CCC1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)/C=N/OC
DM3TRF7 IK NRLIFEGHTNUYFL-MTKJPOGLSA-N
DM3TRF7 IU (E)-1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine
DM3TRF7 CA CAS 171655-91-7
DM3TRF7 DE Parkinson disease
DMKGM42 ID DMKGM42
DMKGM42 DN BREQUINAR
DMKGM42 HS Phase 2
DMKGM42 SN Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum
DMKGM42 DT Small molecular drug
DMKGM42 PC 57030
DMKGM42 MW 375.4
DMKGM42 FM C23H15F2NO2
DMKGM42 IC InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
DMKGM42 CS CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
DMKGM42 IK PHEZJEYUWHETKO-UHFFFAOYSA-N
DMKGM42 IU 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
DMKGM42 CA CAS 96187-53-0
DMKGM42 DE Acute myeloid leukaemia; Coronavirus Disease 2019 (COVID-19)
DMXI9BP ID DMXI9BP
DMXI9BP DN Brilacidin
DMXI9BP HS Phase 2
DMXI9BP SN UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)-
DMXI9BP CP Cellceutix
DMXI9BP DT Small molecular drug
DMXI9BP PC 25023695
DMXI9BP MW 936.9
DMXI9BP FM C40H50F6N14O6
DMXI9BP IC InChI=1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
DMXI9BP CS C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N
DMXI9BP IK QPDYBCZNGUJZDK-DNQXCXABSA-N
DMXI9BP IU 4-N,6-N-bis[3-[5-(diaminomethylideneamino)pentanoylamino]-2-[(3R)-pyrrolidin-3-yl]oxy-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide
DMXI9BP CA CAS 1224095-98-0
DMXI9BP DE Infectious disease; Acute bacterial skin infection
DMLD80M ID DMLD80M
DMLD80M DN Brivoligide
DMLD80M HS Phase 2
DMLD80M SN AYX1
DMLD80M CP Adynxx
DMLD80M DT Oligonucleotide
DMLD80M DE Postoperative pain
DMLFGHX ID DMLFGHX
DMLFGHX DN BRL 35135
DMLFGHX HS Phase 2
DMLFGHX SN Brl35135A; BRL 35135; Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate; Brl-35135; 91097-81-3; C20H24ClNO4; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester; AC1Q3M3M; AC1L3U5A; CHEMBL49289; SCHEMBL4611391; CTK5G8940; ZFLBZHXQAMUEFS-UHFFFAOYSA-N; LS-178136; L003499; methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate; [4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester; methyl 2-[4-[2-[[2-(3-chloroph
DMLFGHX DT Small molecular drug
DMLFGHX PC 122186
DMLFGHX MW 377.9
DMLFGHX FM C20H24ClNO4
DMLFGHX IC InChI=1S/C20H24ClNO4/c1-14(22-12-19(23)16-4-3-5-17(21)11-16)10-15-6-8-18(9-7-15)26-13-20(24)25-2/h3-9,11,14,19,22-23H,10,12-13H2,1-2H3
DMLFGHX CS CC(CC1=CC=C(C=C1)OCC(=O)OC)NCC(C2=CC(=CC=C2)Cl)O
DMLFGHX IK ZFLBZHXQAMUEFS-UHFFFAOYSA-N
DMLFGHX IU methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate
DMLFGHX CA CAS 91097-81-3
DMLFGHX DE Diabetic complication
DMUI5PA ID DMUI5PA
DMUI5PA DN Brostallicin
DMUI5PA HS Phase 2
DMUI5PA SN Brostallicin; UNII-RPC6R41K4I; 203258-60-0; RPC6R41K4I; PNU-166196A; Brostallicin [INN]; AC1OCFEA; SCHEMBL3678233; CHEMBL1189025; DTXSID70174222; ZINC3979512; Z-3228; 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA CP Cell Therapeutics
DMUI5PA DT Small molecular drug
DMUI5PA PC 6918408
DMUI5PA MW 723.6
DMUI5PA FM C30H35BrN12O5
DMUI5PA IC InChI=1S/C30H35BrN12O5/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35)
DMUI5PA CS CN1C=C(C=C1C(=O)NCCN=C(N)N)NC(=O)C2=CC(=CN2C)NC(=O)C3=CC(=CN3C)NC(=O)C4=CC(=CN4C)NC(=O)C(=C)Br
DMUI5PA IK RXOVOXFAAGIKDQ-UHFFFAOYSA-N
DMUI5PA IU 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA CA CAS 203258-60-0
DMUI5PA DE Breast cancer
DM1ZOCK ID DM1ZOCK
DM1ZOCK DN Bryostatin-1
DM1ZOCK HS Phase 2
DM1ZOCK SN Bryostatin 1; 83314-01-6
DM1ZOCK DT Small molecular drug
DM1ZOCK PC 5280757
DM1ZOCK MW 905
DM1ZOCK FM C47H68O17
DM1ZOCK IC InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1
DM1ZOCK CS CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)/C[C@H]2C[C@@H](OC(=O)C[C@@H](C[C@@H]3C[C@@H](C([C@@](O3)(C[C@@H]4C/C(=C/C(=O)OC)/C[C@@H](O4)/C=C/C([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O
DM1ZOCK IK MJQUEDHRCUIRLF-TVIXENOKSA-N
DM1ZOCK IU [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate
DM1ZOCK CA CAS 83314-01-6
DM1ZOCK CB CHEBI:88353
DM1ZOCK DE Alzheimer disease
DM2LZIY ID DM2LZIY
DM2LZIY DN BT-061
DM2LZIY HS Phase 2
DM2LZIY CP Biotest
DM2LZIY DT Antibody
DM2LZIY DE Asthma; Psoriasis vulgaris
DMYO185 ID DMYO185
DMYO185 DN BT-062
DMYO185 HS Phase 2
DMYO185 CP Biotest Pharmaceuticals; ImmunoGen
DMYO185 DT Antibody
DMYO185 DE Multiple myeloma
DMDWP0U ID DMDWP0U
DMDWP0U DN BTA-798
DMDWP0U HS Phase 2
DMDWP0U SN Capsid-binding inhibitors, Biota; Capsid-binding (anti-rhinovirus) agents, Biota
DMDWP0U CP Biota pharmaceuticals
DMDWP0U DE Rhinovirus infection
DMS6ZA0 ID DMS6ZA0
DMS6ZA0 DN BTD-001
DMS6ZA0 HS Phase 2
DMS6ZA0 CP Balance Therapeutics San Bruno, CA
DMS6ZA0 DE Narcolepsy
DMY5IX4 ID DMY5IX4
DMY5IX4 DN BTL-TML-001
DMY5IX4 HS Phase 2
DMY5IX4 SN Influenza virus infection, Beech Tree Labs
DMY5IX4 CP Beech Tree Labs Inc
DMY5IX4 DE Influenza virus infection; Herpes simplex labialis
DMA9238 ID DMA9238
DMA9238 DN BTRX-246040
DMA9238 HS Phase 2
DMA9238 CP BlackThorn Therapeutics San Francisco, CA
DMA9238 DE Major depressive disorder
DMWPDUZ ID DMWPDUZ
DMWPDUZ DN BTRX-335140
DMWPDUZ HS Phase 2
DMWPDUZ SN CYM-53093; UNII-XK5ILZ28KI; XK5ILZ28KI; 2244614-14-8; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine; CHEMBL4592045; SCHEMBL20670520; GTPL10452; BTRX335140; BCP32121; CYM53093; BDBM50531908; compound 58 [PMID: 30707578]; HY-124754; CS-0087593; BTRX 335140; BTRX335140; CYM-53093; CYM 53093; CYM53093; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine; 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine; 4-Piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-N-(tetrahydro-2H-pyran-4-yl)-
DMWPDUZ CP BlackThorn Therapeutics
DMWPDUZ DT Small molecular drug
DMWPDUZ PC 137434175
DMWPDUZ MW 453.6
DMWPDUZ FM C25H32FN5O2
DMWPDUZ IC InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
DMWPDUZ CS CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
DMWPDUZ IK CQOJHAJWCDJEAT-UHFFFAOYSA-N
DMWPDUZ IU 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
DMWPDUZ CA CAS 2244614-14-8
DMWPDUZ DE Major depressive disorder
DMIEPJG ID DMIEPJG
DMIEPJG DN BTT-1023
DMIEPJG HS Phase 2
DMIEPJG SN SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
DMIEPJG CP BioTie Therapies Corp
DMIEPJG DT Antibody
DMIEPJG DE Psoriasis vulgaris
DMZC4V0 ID DMZC4V0
DMZC4V0 DN Buproprion+zonisamide
DMZC4V0 HS Phase 2
DMZC4V0 SN Empatic (TN)
DMZC4V0 CP Orexigen Therapeutics
DMZC4V0 DE Obesity
DMNB4XK ID DMNB4XK
DMNB4XK DN BVD-523
DMNB4XK HS Phase 2
DMNB4XK CP Biomed valley discoveries
DMNB4XK PC 11719003
DMNB4XK MW 433.3
DMNB4XK FM C21H22Cl2N4O2
DMNB4XK IC InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
DMNB4XK CS CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl
DMNB4XK IK KSERXGMCDHOLSS-LJQANCHMSA-N
DMNB4XK IU N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
DMNB4XK CA CAS 869886-67-9
DMNB4XK DE Solid tumour/cancer; Pancreatic cancer; Melanoma
DM8CWL0 ID DM8CWL0
DM8CWL0 DN BVT.28949
DM8CWL0 HS Phase 2
DM8CWL0 CP Biovitrum
DM8CWL0 DE Glaucoma/ocular hypertension
DMD8GNB ID DMD8GNB
DMD8GNB DN BXT-51072
DMD8GNB HS Phase 2
DMD8GNB SN ALT-2074; SYI-2074
DMD8GNB CP Synvista Therapeutics
DMD8GNB DT Small molecular drug
DMD8GNB PC 130165
DMD8GNB MW 226.19
DMD8GNB FM C10H13NSe
DMD8GNB IC InChI=1S/C10H13NSe/c1-10(2)7-11-12-9-6-4-3-5-8(9)10/h3-6,11H,7H2,1-2H3
DMD8GNB CS CC1(CN[Se]C2=CC=CC=C21)C
DMD8GNB IK FXRYWOJYVGJZLE-UHFFFAOYSA-N
DMD8GNB IU 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine
DMD8GNB CA CAS 173026-17-0
DMD8GNB DE Cardiovascular disease
DMTRONK ID DMTRONK
DMTRONK DN BZL-101
DMTRONK HS Phase 2
DMTRONK CP Bionovo
DMTRONK DE Breast cancer
DMGE058 ID DMGE058
DMGE058 DN Cabiralizumab
DMGE058 HS Phase 2
DMGE058 CP Bristol-Myers Squibb Princeton, NJFive Prime Therapeutics South San Francisco, CA
DMGE058 DE Solid tumour/cancer; Pancreatic cancer
DMGXCY9 ID DMGXCY9
DMGXCY9 DN Calcium phosphate
DMGXCY9 HS Phase 2
DMGXCY9 SN Bonarka; Calcigenol simple; Calcium orthophosphate; Calcium phosphate; Calcium phosphate (3:2); Calcium phosphate (Ca3(PO4)2); Calcium phosphate tribasic; Calcium tertiary phosphate; Natural whitlockite; Phosphoric acid, calcium salt; Phosphoric acid, calcium salt (2:3); Synthos; TRICALCIUM PHOSPHATE; Tertiary calcium phosphate; Tribasic calcium phosphate; Tricalcium diphosphate; Tricalcium orthophosphate; beta-TCP; beta-Tricalcium phosphate
DMGXCY9 DT Small molecular drug
DMGXCY9 PC 24456
DMGXCY9 MW 310.174
DMGXCY9 FM Ca3O8P2
DMGXCY9 IC InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
DMGXCY9 CS [O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMGXCY9 IK QORWJWZARLRLPR-UHFFFAOYSA-H
DMGXCY9 IU tricalcium;diphosphate
DMGXCY9 CA CAS 7758-87-410103-46-5
DMGXCY9 CB ChEBI:9679
DMGXCY9 DE Osteoporosis
DMDV8MK ID DMDV8MK
DMDV8MK DN CALDARET HYDRATE
DMDV8MK HS Phase 2
DMDV8MK SN MCC-135; Caldaret hydrate; 5-Methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate
DMDV8MK CP Mitsubishi Pharma
DMDV8MK DT Small molecular drug
DMDV8MK PC 9816981
DMDV8MK MW 274.34
DMDV8MK FM C11H18N2O4S
DMDV8MK IC InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2
DMDV8MK CS CC1=CC(=C(C=C1)N2CCNCC2)S(=O)(=O)O.O
DMDV8MK IK ZRQKZWAOIRVBFD-UHFFFAOYSA-N
DMDV8MK IU 5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate
DMDV8MK CA CAS 192509-24-3
DMDV8MK DE Cardiovascular disease
DMAKSMX ID DMAKSMX
DMAKSMX DN Camicinal
DMAKSMX HS Phase 2
DMAKSMX SN 962040
DMAKSMX CP GlaxoSmithKline
DMAKSMX DT Small molecular drug
DMAKSMX PC 15984937
DMAKSMX MW 424.6
DMAKSMX FM C25H33FN4O
DMAKSMX IC InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1
DMAKSMX CS C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F
DMAKSMX IK RZKDEGZIFSJVNA-IBGZPJMESA-N
DMAKSMX IU 1-[4-(3-fluoroanilino)piperidin-1-yl]-2-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone
DMAKSMX CA CAS 923565-21-3
DMAKSMX DE Delayed gastric emptying; Diabetic gastroparesis
DMQ7UL8 ID DMQ7UL8
DMQ7UL8 DN Camostat
DMQ7UL8 HS Phase 2
DMQ7UL8 SN Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N
DMQ7UL8 DT Small molecular drug
DMQ7UL8 PC 2536
DMQ7UL8 MW 398.4
DMQ7UL8 FM C20H22N4O5
DMQ7UL8 IC InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
DMQ7UL8 CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
DMQ7UL8 IK XASIMHXSUQUHLV-UHFFFAOYSA-N
DMQ7UL8 IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
DMQ7UL8 CA CAS 59721-28-7
DMQ7UL8 CB CHEBI:135632
DMQ7UL8 DE Cystic fibrosis
DMEZLFT ID DMEZLFT
DMEZLFT DN Camsirubicin
DMEZLFT HS Phase 2
DMEZLFT SN UNII-VI79RD8VNN; VI79RD8VNN; 236095-26-4; (8R,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one; 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-
DMEZLFT CP Monopar Therapeutics
DMEZLFT DT Small molecular drug
DMEZLFT PC 135446069
DMEZLFT MW 528.5
DMEZLFT FM C27H32N2O9
DMEZLFT IC InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1
DMEZLFT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O
DMEZLFT IK GNCWGPLZJLZZPI-KUIJCEFOSA-N
DMEZLFT IU (8R,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one
DMEZLFT CA CAS 236095-26-4
DMEZLFT DE Soft tissue sarcoma
DMEYIVW ID DMEYIVW
DMEYIVW DN CAP1-6D
DMEYIVW HS Phase 2
DMEYIVW SN Modified CEA peptide (pancreatic cancer), University of Chicago
DMEYIVW CP University of Chicago
DMEYIVW DT Small molecular drug
DMEYIVW PC 396060
DMEYIVW MW 965.1
DMEYIVW FM C43H68N10O15
DMEYIVW IC InChI=1S/C43H68N10O15/c1-20(2)12-27(49-37(61)26(44)15-24-8-10-25(55)11-9-24)40(64)53-32(19-54)38(62)46-18-34(57)47-23(7)36(60)48-30(17-35(58)59)42(66)50-28(13-21(3)4)39(63)51-29(16-33(45)56)41(65)52-31(43(67)68)14-22(5)6/h8-11,20-23,26-32,54-55H,12-19,44H2,1-7H3,(H2,45,56)(H,46,62)(H,47,57)(H,48,60)(H,49,61)(H,50,66)(H,51,63)(H,52,65)(H,53,64)(H,58,59)(H,67,68)
DMEYIVW CS CC(C)CC(C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N
DMEYIVW IK SNKUSVNHTCUELQ-UHFFFAOYSA-N
DMEYIVW IU 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid
DMEYIVW DE Pancreatic cancer
DMJKLHU ID DMJKLHU
DMJKLHU DN CAP-7.1
DMJKLHU HS Phase 2
DMJKLHU CP CellAct Pharma GmbH
DMJKLHU PC 154701729
DMJKLHU DE Solid tumour/cancer
DMYWO62 ID DMYWO62
DMYWO62 DN Capadenoson
DMYWO62 HS Phase 2
DMYWO62 SN Capadenoson; 544417-40-5; UNII-O519NVW73R; O519NVW73R; CHEMBL3235279; BAY 68-4986; 2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-Pyridinedicarbonitrile; C25H18ClN5O2S2; Capadenoson [INN]; 2-amino-6-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)pyridine-3,5-dicarbonitrile; 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile; SCHEMBL174016; Capadenoson;BAY 68-4986
DMYWO62 CP Bayer HealthCare Pharmaceuticals
DMYWO62 DT Small molecular drug
DMYWO62 PC 9936489
DMYWO62 MW 520
DMYWO62 FM C25H18ClN5O2S2
DMYWO62 IC InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
DMYWO62 CS C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO
DMYWO62 IK CITWCLNVRIKQAF-UHFFFAOYSA-N
DMYWO62 IU 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile
DMYWO62 CA CAS 544417-40-5
DMYWO62 DE Atrial fibrillation
DMY4OMS ID DMY4OMS
DMY4OMS DN Carabersat
DMY4OMS HS Phase 2
DMY4OMS SN SB-204268; SB-204269; SB-258339
DMY4OMS CP SmithKline Beecham plc
DMY4OMS DT Small molecular drug
DMY4OMS PC 193943
DMY4OMS MW 357.4
DMY4OMS FM C20H20FNO4
DMY4OMS IC InChI=1S/C20H20FNO4/c1-11(23)13-6-9-16-15(10-13)17(18(24)20(2,3)26-16)22-19(25)12-4-7-14(21)8-5-12/h4-10,17-18,24H,1-3H3,(H,22,25)/t17-,18+/m0/s1
DMY4OMS CS CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC=C(C=C3)F)O)(C)C
DMY4OMS IK RCLXAPJEFHPYEG-ZWKOTPCHSA-N
DMY4OMS IU N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide
DMY4OMS CA CAS 184653-84-7
DMY4OMS DE Epileptic seizures
DMN5JCX ID DMN5JCX
DMN5JCX DN Carboxyamidotriazole orotate
DMN5JCX HS Phase 2
DMN5JCX CP Tactical Therapeutics
DMN5JCX PC 154732136
DMN5JCX DE Glioblastoma multiforme
DM7ADGX ID DM7ADGX
DM7ADGX DN Carfentanil
DM7ADGX HS Phase 2
DM7ADGX SN CARFENTANIL; Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester
DM7ADGX DT Small molecular drug
DM7ADGX PC 62156
DM7ADGX MW 394.5
DM7ADGX FM C24H30N2O3
DM7ADGX IC InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3
DM7ADGX CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC
DM7ADGX IK YDSDEBIZUNNPOB-UHFFFAOYSA-N
DM7ADGX IU methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DM7ADGX CA CAS 59708-52-0
DM7ADGX CB CHEBI:61084
DMAUN15 ID DMAUN15
DMAUN15 DN Carlumab
DMAUN15 HS Phase 2
DMAUN15 SN CCL-2; CNTO-888; Anti-MCP1 monoclonal antibodies, Centocor; CCL2 monoclonal antibody (infusion, cancer), Centocor
DMAUN15 CP Janssen biotech
DMAUN15 DT Antibody
DMAUN15 DE Pulmonary fibrosis
DMN6TKI ID DMN6TKI
DMN6TKI DN Carmoterol
DMN6TKI HS Phase 2
DMN6TKI SN 147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1
DMN6TKI CP Chiesi
DMN6TKI DT Small molecular drug
DMN6TKI PC 63952
DMN6TKI MW 368.4
DMN6TKI FM C21H24N2O4
DMN6TKI IC InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
DMN6TKI CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O
DMN6TKI IK IHOXNOQMRZISPV-YJYMSZOUSA-N
DMN6TKI IU 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
DMN6TKI CA CAS 147568-66-9
DMN6TKI DE Chronic obstructive pulmonary disease
DMTBFXW ID DMTBFXW
DMTBFXW DN CART 19
DMTBFXW HS Phase 2
DMTBFXW CP University of Pennsylvania
DMTBFXW DT CAR T Cell Therapy
DMTBFXW DE Acute lymphoblastic leukaemia; Pancreatic cancer
DM28A5D ID DM28A5D
DM28A5D DN CAR-T cells targeting CD19
DM28A5D HS Phase 2
DM28A5D CP The First Affiliated Hospital of Soochow University
DM28A5D DT CAR T Cell Therapy
DM28A5D DE Non-hodgkin lymphoma
DM3RU0A ID DM3RU0A
DM3RU0A DN CAR-T cells targeting CD20
DM3RU0A HS Phase 2
DM3RU0A CP The First Affiliated Hospital of Soochow University
DM3RU0A DT CAR T Cell Therapy
DM3RU0A DE Non-hodgkin lymphoma
DM6XN4C ID DM6XN4C
DM6XN4C DN CAR-T cells targeting CD22
DM6XN4C HS Phase 2
DM6XN4C CP The First Affiliated Hospital of Soochow University
DM6XN4C DT CAR T Cell Therapy
DM6XN4C DE Non-hodgkin lymphoma
DML0KWM ID DML0KWM
DML0KWM DN CAR-T cells targeting CD30
DML0KWM HS Phase 2
DML0KWM CP The First Affiliated Hospital of Soochow University
DML0KWM DT CAR T Cell Therapy
DML0KWM DE Non-hodgkin lymphoma
DMHQKN6 ID DMHQKN6
DMHQKN6 DN CART-19
DMHQKN6 HS Phase 2
DMHQKN6 CP University of Pennsylvania
DMHQKN6 DT CAR T Cell Therapy
DMHQKN6 DE Non-hodgkin lymphoma; B-cell lymphoma; leukaemia; Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia
DMZUV7T ID DMZUV7T
DMZUV7T DN CART-19 cells
DMZUV7T HS Phase 2
DMZUV7T CP University of Pennsylvania
DMZUV7T DT CAR T Cell Therapy
DMZUV7T DE Acute lymphocytic leukaemia; Multiple myeloma
DMQBP7R ID DMQBP7R
DMQBP7R DN CAT 1004
DMQBP7R HS Phase 2
DMQBP7R CP Catabasis Pharmaceuticals
DMQBP7R DE Type-2 diabetes; Duchenne dystrophy
DM2IFYZ ID DM2IFYZ
DM2IFYZ DN CB-10-01
DM2IFYZ HS Phase 2
DM2IFYZ CP Cosmo Pharmaceuticals
DM2IFYZ DT Vaccine
DM2IFYZ DE Melanoma
DM094UH ID DM094UH
DM094UH DN CB-839
DM094UH HS Phase 2
DM094UH PC 71577426
DM094UH MW 571.6
DM094UH FM C26H24F3N7O3S
DM094UH IC InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
DM094UH CS C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F
DM094UH IK PRAAPINBUWJLGA-UHFFFAOYSA-N
DM094UH IU N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
DM094UH CA CAS 1439399-58-2
DM094UH DE leukaemia; Breast cancer; Renal cell carcinoma; Solid tumour/cancer
DMK4FRU ID DMK4FRU
DMK4FRU DN CBLB-502
DMK4FRU HS Phase 2
DMK4FRU SN CBLB-501; Mini-flagellin, Cleveland BioLabs; Recombinant flagellin proteins (injury protection), Cleveland BioLabs
DMK4FRU CP Cleveland BioLabs Inc
DMK4FRU DE Acute radiation syndrome
DMSBNTZ ID DMSBNTZ
DMSBNTZ DN CBX-129801
DMSBNTZ HS Phase 2
DMSBNTZ SN Ersatta; C-peptide (depot formulation), Cebix; Long-acting synthetic C-peptide, Cebix; PEGylated C-peptide (diabetic complications), Cebix
DMSBNTZ CP Cebix
DMSBNTZ DE Diabetic complication
DMQ874W ID DMQ874W
DMQ874W DN CC-1088
DMQ874W HS Phase 2
DMQ874W SN CDC801; CC-1088; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5
DMQ874W DT Small molecular drug
DMQ874W PC 9844338
DMQ874W MW 408.4
DMQ874W FM C23H24N2O5
DMQ874W IC InChI=1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26)
DMQ874W CS COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCCC4
DMQ874W IK DDYUBCCTNHWSQM-UHFFFAOYSA-N
DMQ874W IU 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide
DMQ874W CA CAS 192819-27-5
DMQ874W DE Crohn disease
DMNE7L3 ID DMNE7L3
DMNE7L3 DN CC-220
DMNE7L3 HS Phase 2
DMNE7L3 SN AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266
DMNE7L3 DT Small molecular drug
DMNE7L3 PC 67335295
DMNE7L3 MW 449.5
DMNE7L3 FM C25H27N3O5
DMNE7L3 IC InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
DMNE7L3 CS C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
DMNE7L3 IK IXZOHGPZAQLIBH-NRFANRHFSA-N
DMNE7L3 IU (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
DMNE7L3 CA CAS 1323403-33-3
DMNE7L3 DE Sarcoidosis; Multiple myeloma; Systemic lupus erythematosus
DMJR9H0 ID DMJR9H0
DMJR9H0 DN CC-292
DMJR9H0 HS Phase 2
DMJR9H0 SN AVL-292; 1202757-89-8; spebrutinib; cc-292; UNII-DRU6NG543J; CC-292 (AVL-292); DRU6NG543J; AVL292; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; AK198940; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; Btk inhibitor CC-292; Spebrutinib [USAN:INN]; Spebrutinib (USAN/INN); SCHEMBL626216; GTPL7837; CHEMBL3301625; EX-A255; AVL 292
DMJR9H0 CP Celgene
DMJR9H0 DT Small molecular drug
DMJR9H0 PC 59174488
DMJR9H0 MW 423.4
DMJR9H0 FM C22H22FN5O3
DMJR9H0 IC InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)
DMJR9H0 CS COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F
DMJR9H0 IK KXBDTLQSDKGAEB-UHFFFAOYSA-N
DMJR9H0 IU N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMJR9H0 CA CAS 1202757-89-8
DMJR9H0 DE Chronic lymphocytic leukaemia
DMPMO6G ID DMPMO6G
DMPMO6G DN CC-401
DMPMO6G HS Phase 2
DMPMO6G SN CC-401; 395104-30-0; UNII-NOE38VQA1W; NOE38VQA1W; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole; 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE; CC 401; C22H24N6O; PubChem22434; SCHEMBL4604749; CHEMBL1614713; CHEBI:91437; DTXSID40192650; MolPort-044-561-531; MolPort-021-804-942; BCPP000298; BCP01960; ZINC38836256; RS0046; HY-13022A; AKOS027251057; AKOS027336636; DB12432; BCP9000495; CS-1955
DMPMO6G TC Anticancer Agents
DMPMO6G DT Small molecular drug
DMPMO6G PC 10430360
DMPMO6G MW 388.5
DMPMO6G FM C22H24N6O
DMPMO6G IC InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
DMPMO6G CS C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5
DMPMO6G IK XDJCLCLBSGGNKS-UHFFFAOYSA-N
DMPMO6G IU 3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole
DMPMO6G CA CAS 395104-30-0
DMPMO6G CB CHEBI:91437
DMPMO6G DE Solid tumour/cancer
DM0EDHJ ID DM0EDHJ
DM0EDHJ DN CC-90011
DM0EDHJ HS Phase 2
DM0EDHJ SN UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y
DM0EDHJ CP Bristol-Myers Squibb
DM0EDHJ DT Small molecular drug
DM0EDHJ PC 118483201
DM0EDHJ MW 451.5
DM0EDHJ FM C24H23F2N5O2
DM0EDHJ IC InChI=1S/C24H23F2N5O2/c1-30-23(32)21(14-5-6-20(33-2)19(26)11-14)22(15-3-4-16(13-27)18(25)12-15)29-24(30)31-9-7-17(28)8-10-31/h3-6,11-12,17H,7-10,28H2,1-2H3
DM0EDHJ CS CN1C(=O)C(=C(N=C1N2CCC(CC2)N)C3=CC(=C(C=C3)C#N)F)C4=CC(=C(C=C4)OC)F
DM0EDHJ IK NBAIXBAUHIQQGF-UHFFFAOYSA-N
DM0EDHJ IU 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile
DM0EDHJ CA CAS 1821307-10-1
DM0EDHJ DE Lymphoma; Non-hodgkin lymphoma
DMHVEGJ ID DMHVEGJ
DMHVEGJ DN CC-930
DMHVEGJ HS Phase 2
DMHVEGJ SN TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
DMHVEGJ CP Celgene
DMHVEGJ DT Small molecular drug
DMHVEGJ PC 11597537
DMHVEGJ MW 448.4
DMHVEGJ FM C21H23F3N6O2
DMHVEGJ IC InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
DMHVEGJ CS C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O
DMHVEGJ IK IBGLGMOPHJQDJB-MOKVOYLWSA-N
DMHVEGJ IU 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
DMHVEGJ CA CAS 899805-25-5
DMHVEGJ DE Discoid lupus erythematosus; Idiopathic pulmonary fibrosis
DMJ9XCO ID DMJ9XCO
DMJ9XCO DN CCX-140
DMJ9XCO HS Phase 2
DMJ9XCO SN CCX-140-B; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx
DMJ9XCO CP Chemocentryx
DMJ9XCO PC 25134303
DMJ9XCO MW 495.9
DMJ9XCO FM C20H13ClF3N5O3S
DMJ9XCO IC InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28)
DMJ9XCO CS CC1=CC(=C(N=C1)C(=O)C2=C3C=CNC3=NC=N2)NS(=O)(=O)C4=CC(=C(C=C4)Cl)C(F)(F)F
DMJ9XCO IK LUUMLYXKTPBTQR-UHFFFAOYSA-N
DMJ9XCO IU 4-chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide
DMJ9XCO CA CAS 1100318-47-5
DMJ9XCO DE Diabetic nephropathy
DMSHV9C ID DMSHV9C
DMSHV9C DN CCX-354
DMSHV9C HS Phase 2
DMSHV9C SN CCX-354-C; GSK2941266
DMSHV9C CP ChemoCentryx Inc
DMSHV9C PC 135565361
DMSHV9C MW 451.9
DMSHV9C FM C22H22ClN7O2
DMSHV9C IC InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25)
DMSHV9C CS COC1=C(C=CC(=C1)N2CCN(CC2)C(=O)CN3C4=C(C=CC=N4)C(=N3)C5=NC=CN5)Cl
DMSHV9C IK ZIMLRKWQDLVPEK-UHFFFAOYSA-N
DMSHV9C IU 1-[4-(4-chloro-3-methoxyphenyl)piperazin-1-yl]-2-[3-(1H-imidazol-2-yl)pyrazolo[3,4-b]pyridin-1-yl]ethanone
DMSHV9C CA CAS 1010073-75-2
DMSHV9C DE Autoimmune diabetes; Rheumatoid arthritis
DMPVAUT ID DMPVAUT
DMPVAUT DN CCX872
DMPVAUT HS Phase 2
DMPVAUT CP Chemocentryx
DMPVAUT DE Diabetic nephropathy; Pancreatic tumour
DMEK580 ID DMEK580
DMEK580 DN CD19 CAR T cells
DMEK580 HS Phase 2
DMEK580 CP Southwest Hospital, China
DMEK580 DT CAR T Cell Therapy
DMEK580 DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMQJBUK ID DMQJBUK
DMQJBUK DN CD19-targeting CAR T cells
DMQJBUK HS Phase 2
DMQJBUK CP Uppsala University
DMQJBUK DT CAR T Cell Therapy
DMQJBUK DE B-cell lymphoma; leukaemia
DMQGI8R ID DMQGI8R
DMQGI8R DN CD20 CAR T cells
DMQGI8R HS Phase 2
DMQGI8R CP Southwest Hospital, China
DMQGI8R DT CAR T Cell Therapy
DMQGI8R DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMXYLTI ID DMXYLTI
DMXYLTI DN CDP323
DMXYLTI HS Phase 2
DMXYLTI SN Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01
DMXYLTI CP UCB; Biogen Idec
DMXYLTI DT Small molecular drug
DMXYLTI PC 23394557
DMXYLTI MW 549.5
DMXYLTI FM C28H29BrN4O3
DMXYLTI IC InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1
DMXYLTI CS CCOC(=O)[C@H](CC1=CC=C(C=C1)NC2=NC=CC3=C2C=NC=C3)NC4=C(C(=O)C45CCCCC5)Br
DMXYLTI IK QCYAXXZCQKMTMO-QFIPXVFZSA-N
DMXYLTI IU ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate
DMXYLTI CA CAS 455264-30-9
DMXYLTI DE Rheumatoid arthritis; Multiple sclerosis
DM3YB2C ID DM3YB2C
DM3YB2C DN CDP-6038
DM3YB2C HS Phase 2
DM3YB2C DE Rheumatoid arthritis
DM8UQJG ID DM8UQJG
DM8UQJG DN CDX-1307
DM8UQJG HS Phase 2
DM8UQJG SN BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
DM8UQJG CP Medarex Inc
DM8UQJG DT Vaccine
DM8UQJG DE Bladder cancer
DMCGNJ6 ID DMCGNJ6
DMCGNJ6 DN CDX-1401
DMCGNJ6 HS Phase 2
DMCGNJ6 CP Celldex Therapeutics
DMCGNJ6 DE Solid tumour/cancer; Ovarian cancer
DMKRFCO ID DMKRFCO
DMKRFCO DN CDX-301
DMKRFCO HS Phase 2
DMKRFCO DE Hematopoietic stem cell transplantation; Solid tumour/cancer; Multiple myeloma
DM5GKYD ID DM5GKYD
DM5GKYD DN CDX-3379
DM5GKYD HS Phase 2
DM5GKYD CP Celldex Therapeutics Hampton, NJ
DM5GKYD DE Solid tumour/cancer; Squamous cell carcinoma
DM6Z9BV ID DM6Z9BV
DM6Z9BV DN CeaVac
DM6Z9BV HS Phase 2
DM6Z9BV SN Idiotypic vaccine (CEA), Titan; Monoclonal antibody (cancer), Titan
DM6Z9BV CP Titan Pharmaceuticals
DM6Z9BV DT Vaccine
DM6Z9BV DE Colorectal cancer
DM1S2FZ ID DM1S2FZ
DM1S2FZ DN Cemdisiran
DM1S2FZ HS Phase 2
DM1S2FZ CP Alnylam Pharmaceuticals
DM1S2FZ DT Small interfering RNA
DM1S2FZ DE Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome
DMCT8EY ID DMCT8EY
DMCT8EY DN Cenderitide
DMCT8EY HS Phase 2
DMCT8EY CP Nile Therapeutics
DMCT8EY DE Heart failure; Heart disease
DMU3P1K ID DMU3P1K
DMU3P1K DN Cenerimod
DMU3P1K HS Phase 2
DMU3P1K SN 1262414-04-9; UNII-Y333RS1786; ACT-334441; Y333RS1786; Cenerimod [INN]; Cenerimod [USAN]; SCHEMBL2671193; GTPL9824; MolPort-044-723-844; KS-000006AE; ZINC167253016; AKOS030630068; CS-6364; DB12705; 1,2-Propanediol, 3-(4-(5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-, (2S)-; (S)-3-((4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)(1,2,4)oxadiazol-3-yl)-2-ethyl-6-methylphenyl)oxy)propane-1,2-diol; HY-17606; AS-35045; (S)-3-(4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol
DMU3P1K CP Actelion Pharmaceuticals South San Francisco, CA
DMU3P1K PC 49871973
DMU3P1K MW 453.5
DMU3P1K FM C25H31N3O5
DMU3P1K IC InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1
DMU3P1K CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OC[C@H](CO)O
DMU3P1K IK KJKKMMMRWISKRF-FQEVSTJZSA-N
DMU3P1K IU (2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol
DMU3P1K CA CAS 1262414-04-9
DMU3P1K DE Systemic lupus erythematosus
DMMN21R ID DMMN21R
DMMN21R DN Cenersen
DMMN21R HS Phase 2
DMMN21R CP Eleos
DMMN21R DT Antisense drug
DMMN21R PC 56841947
DMMN21R MW 6415
DMMN21R FM C195H253N66O106P19S19
DMMN21R IC InChI=1S/C195H253N66O106P19S19/c1-77-43-250(190(282)236-165(77)264)134-32-89(107(336-134)56-317-370(290,389)351-85-28-130(244-20-12-122(198)222-184(244)276)332-103(85)52-313-375(295,394)357-91-34-136(252-45-79(3)167(266)238-192(252)284)340-111(91)60-321-382(302,401)364-99-42-144(260-75-219-150-164(260)231-181(209)235-174(150)273)344-115(99)64-324-378(298,397)360-94-37-139(255-48-82(6)170(269)241-195(255)287)339-110(94)59-320-381(301,400)361-95-38-140(256-71-214-145-157(204)210-69-212-159(145)256)341-112(95)61-322-372(292,391)353-87-30-132(246-22-14-124(200)224-186(246)278)333-104(87)53-314-379(299,398)363-98-41-143(259-74-218-149-163(259)230-180(208)234-173(149)272)345-116(98)65-325-383(303,402)365-96-39-141(257-72-216-147-161(257)228-178(206)232-171(147)270)342-113(96)62-310-368(288,387)349-83-26-128(329-100(83)49-262)242-18-10-120(196)220-182(242)274)355-373(293,392)311-50-101-84(27-129(330-101)243-19-11-121(197)221-183(243)275)350-369(289,388)316-55-106-90(33-135(335-106)251-44-78(2)166(265)237-191(251)283)356-374(294,393)312-51-102-86(29-131(331-102)245-21-13-123(199)223-185(245)277)352-371(291,390)318-57-108-92(35-137(337-108)253-46-80(4)168(267)239-193(253)285)358-376(296,395)319-58-109-93(36-138(338-109)254-47-81(5)169(268)240-194(254)286)359-377(297,396)323-63-114-97(40-142(343-114)258-73-217-148-162(258)229-179(207)233-172(148)271)362-380(300,399)315-54-105-88(31-133(334-105)247-23-15-125(201)225-187(247)279)354-384(304,403)327-67-119-153(156(309-9)177(348-119)261-76-215-146-158(205)211-70-213-160(146)261)367-386(306,405)328-68-118-152(155(308-8)176(347-118)249-25-17-127(203)227-189(249)281)366-385(305,404)326-66-117-151(263)154(307-7)175(346-117)248-24-16-126(202)226-188(248)280/h10-25,43-48,69-76,83-119,128-144,151-156,175-177,262-263H,26-42,49-68H2,1-9H3,(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H,304,403)(H,305,404)(H,306,405)(H2,196,220,274)(H2,197,221,275)(H2,198,222,276)(H2,199,223,277)(H2,200,224,278)(H2,201,225,279)(H2,202,226,280)(H2,203,227,281)(H2,204,210,212)(H2,205,211,213)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H,239,267,285)(H,240,268,286)(H,241,269,287)(H3,206,228,232,270)(H3,207,229,233,271)(H3,208,230,234,272)(H3,209,231,235,273)
DMMN21R CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMMN21R IK UTNSIDJKCKLZLN-UHFFFAOYSA-N
DMMN21R IU 1-[5-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMMN21R DE Acute myeloid leukaemia
DM4V8WF ID DM4V8WF
DM4V8WF DN Cenicriviroc
DM4V8WF HS Phase 2
DM4V8WF SN Cenicriviroc; 497223-25-3; TBR-652; TAK-652; Cenicriviroc mesylate; UNII-15C116UA4Y; TAK652; 15C116UA4Y; TBR652; Cenicriviroc (USAN/INN); SCHEMBL3157768; SCHEMBL3157748; CHEMBL2110727; MolPort-044-723-655; MolPort-044-649-359; EX-A1608; BDBM50422828; AKOS027250788; CS-6148; DB11758; SB16976; HY-14882; AS-35184; D09878; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-
DM4V8WF CP Tobira Therapeutics
DM4V8WF DT Small molecular drug
DM4V8WF PC 11285792
DM4V8WF MW 696.9
DM4V8WF FM C41H52N4O4S
DM4V8WF IC InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1
DM4V8WF CS CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C
DM4V8WF IK PNDKCRDVVKJPKG-WHERJAGFSA-N
DM4V8WF IU (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide
DM4V8WF CA CAS 497223-25-3
DM4V8WF CB CHEBI:149636
DM4V8WF DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMWUQI9 ID DMWUQI9
DMWUQI9 DN CER-001
DMWUQI9 HS Phase 2
DMWUQI9 CP Cerenis Therapeutics
DMWUQI9 DE Acute coronary syndrome; Cardiovascular disease
DMSABRI ID DMSABRI
DMSABRI DN CERC-301
DMSABRI HS Phase 2
DMSABRI CP Cerecor
DMSABRI PC 11394238
DMSABRI MW 358.4
DMSABRI FM C19H23FN4O2
DMSABRI IC InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMSABRI CS CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3
DMSABRI IK RECBFDWSXWAXHY-IAGOWNOFSA-N
DMSABRI IU (4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate
DMSABRI CA CAS 808733-05-3
DMSABRI DE Major depressive disorder
DM3SZ7P ID DM3SZ7P
DM3SZ7P DN CERC-801
DM3SZ7P HS Phase 2
DM3SZ7P SN D-(+)-Galactose Anhydrous; D-Galactopyranose; D-Galactopyranoside; D-Galactose; D-Galactose (9CI); D-Glucose-2-13C; Echocon; Echovist; Galactopyranose; Galactopyranoside; Galactose; Galactose, D- (8CI); Galactose, pure; Shu 450; Shu 454; Shu-454; brain sugar; cerebrose; dl-Galactose; 10257-28-0; AC1L1LNU; AC1Q28DZ; AI3-18440; CHEBI:4139; D-Gal; DSSTox_CID_3088; DSSTox_GSID_23088; DSSTox_RID_76869; EINECS 233-595-2; Epitope ID:141794; Gal; MLS001335983; MLS001335984; NCGC00159442-02; SCHEMBL38935; SMR000857326
DM3SZ7P PC 6036
DM3SZ7P MW 180.16
DM3SZ7P FM C6H12O6
DM3SZ7P IC WQZGKKKJIJFFOK-SVZMEOIVSA-N
DM3SZ7P CS C(C1C(C(C(C(O1)O)O)O)O)O
DM3SZ7P IK 1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1
DM3SZ7P IU (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM3SZ7P CA CAS 10257-28-0
DM3SZ7P CB CHEBI:4139
DM3SZ7P DE Glycosylation disorder
DMSCR2H ID DMSCR2H
DMSCR2H DN Cerdulatinib
DMSCR2H HS Phase 2
DMSCR2H SN PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
DMSCR2H CP Portola Pharmaceuticals Inc; portola pharmaceuticals
DMSCR2H PC 44595079
DMSCR2H MW 445.5
DMSCR2H FM C20H27N7O3S
DMSCR2H IC InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
DMSCR2H CS CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
DMSCR2H IK BGLPECHZZQDNCD-UHFFFAOYSA-N
DMSCR2H IU 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
DMSCR2H CA CAS 1198300-79-6
DMSCR2H DE Non-hodgkin lymphoma; Atopic dermatitis; B-cell lymphoma; Vitiligo
DMNW5I9 ID DMNW5I9
DMNW5I9 DN CERE-110
DMNW5I9 HS Phase 2
DMNW5I9 CP Ceregene
DMNW5I9 DE Alzheimer disease
DMS01AX ID DMS01AX
DMS01AX DN CERE-120
DMS01AX HS Phase 2
DMS01AX SN Neurturin; NeuroRescue PD; AAV-NTN; AAV2-NRTN; AAV2-Neurturin; NTN gene therapy, Ceregene; Neurological gene therapy, Ceregene; Neurturin gene therapy, Ceregene; Neurturin, Genentech; Parkinsons disease gene therapy, Ceregene; GDNF agonist, StemCells/Genentech; NTN gene-expressing AAV vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme; Neurturin gene-expressing adeno-associated virus vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme
DMS01AX CP Ceregene
DMS01AX DE Parkinson disease
DMAWKSM ID DMAWKSM
DMAWKSM DN CetuGEX
DMAWKSM HS Phase 2
DMAWKSM CP Glycotope GmbH
DMAWKSM DT Antibody
DMAWKSM DE Solid tumour/cancer
DMP56WJ ID DMP56WJ
DMP56WJ DN CF102
DMP56WJ HS Phase 2
DMP56WJ SN 2-Cl-IB-Meca; 163042-96-4; Cl-IB-MECA; Namodenoson; C-Ibza-MU; CF-102; CI-IB-MECA; (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide; UNII-Z07JR07J6C; 2Cl-IB-MECA; 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE; CHEMBL431733; Z07JR07J6C; CF102; 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
DMP56WJ CP Can-Fite BioPharm
DMP56WJ DT Small molecular drug
DMP56WJ PC 3035850
DMP56WJ MW 544.7
DMP56WJ FM C18H18ClIN6O4
DMP56WJ IC InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
DMP56WJ CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
DMP56WJ IK IPSYPUKKXMNCNQ-PFHKOEEOSA-N
DMP56WJ IU (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DMP56WJ CA CAS 163042-96-4
DMP56WJ DE Hepatitis C virus infection; Hepatocellular carcinoma
DM3BN4W ID DM3BN4W
DM3BN4W DN CFI-400945
DM3BN4W HS Phase 2
DM3BN4W SN CFI 400945; CFI400945
DM3BN4W DT Small molecular drug
DM3BN4W PC 58486178
DM3BN4W MW 534.6
DM3BN4W FM C33H34N4O3
DM3BN4W IC InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1
DM3BN4W CS C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
DM3BN4W IK DADASRPKWOGKCU-FVTQAUBDSA-N
DM3BN4W IU (2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one
DM3BN4W CA CAS 1338806-73-7
DM3BN4W DE Breast cancer
DM1TWIE ID DM1TWIE
DM1TWIE DN CFZ533
DM1TWIE HS Phase 2
DM1TWIE CP Novartis pharmaceuticals
DM1TWIE DE Rheumatoid arthritis; Graves disease; Myasthenia gravis; Sjogren syndrome
DMWY609 ID DMWY609
DMWY609 DN CG201
DMWY609 HS Phase 2
DMWY609 SN Bevonium methyl sulfate; BEVONIUM METILSULFATE; Bevonium methylsulfate; 5205-82-3; Bevonium methylsulphate; Piribenzil methyl sulfate; Bevonii metilsulfas [INN-Latin]; EINECS 226-001-8; CG 201; Metilsulfato de bevonio [INN-Spanish]; Metilsulfate de bevonium [INN-French]; Bevonium metilsulfate [INN]; L-99; 2-(Hydroxymethyl)-1,1-dimethylpiperidinium methyl sulfate benzilate; Piperidinium, 2-(hydroxymethyl)-1,1-dimethyl-, methyl sulfate, benzilate; alpha-Phenylmandelic acid N,N-dimethylpiperidinium-2-methyl ester methylsulfa
DMWY609 CP CG Therapeutics
DMWY609 DT Small molecular drug
DMWY609 PC 31799
DMWY609 MW 465.6
DMWY609 FM C23H31NO7S
DMWY609 IC InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMWY609 CS C[N+]1(CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.COS(=O)(=O)[O-]
DMWY609 IK AXKJGGRSAVLXTE-UHFFFAOYSA-M
DMWY609 IU (1,1-dimethylpiperidin-1-ium-2-yl)methyl 2-hydroxy-2,2-diphenylacetate;methyl sulfate
DMWY609 CA CAS 5205-82-3
DMWY609 CB CHEBI:31283
DMWY609 DE Solid tumour/cancer
DMFAKGR ID DMFAKGR
DMFAKGR DN CG-400549
DMFAKGR HS Phase 2
DMFAKGR SN CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics
DMFAKGR CP Cg pharmaceuticals
DMFAKGR DT Small molecular drug
DMFAKGR PC 11844916
DMFAKGR MW 340.4
DMFAKGR FM C19H20N2O2S
DMFAKGR IC InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
DMFAKGR CS CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3
DMFAKGR IK YCLREGRRHGLOAK-UHFFFAOYSA-N
DMFAKGR IU 1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one
DMFAKGR CA CAS 934628-27-0
DMFAKGR DE Bacterial infection
DM17JSI ID DM17JSI
DM17JSI DN CGC-11047
DM17JSI HS Phase 2
DM17JSI SN UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)-
DM17JSI CP Progen Pharmaceuticals
DM17JSI DT Small molecular drug
DM17JSI PC 6475492
DM17JSI MW 256.43
DM17JSI FM C14H32N4
DM17JSI IC InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
DM17JSI CS CCNCCCNC/C=C\\CNCCCNCC
DM17JSI IK XFWLTFZLLXVKDY-WAYWQWQTSA-N
DM17JSI IU (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM17JSI CA CAS 308145-19-9
DM17JSI DE Prostate cancer
DMYNTQV ID DMYNTQV
DMYNTQV DN CGP-28014
DMYNTQV HS Phase 2
DMYNTQV SN Cgp 28014; 111757-17-6; Methanimidamide, N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropyl-; N-(2-Oxopyridin-6-yl)-N',N'-di-n-propylformamidine; N'-(1,6-Dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide; CGP-28014; N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine; cgp28014; CHEBI:79969; LS-90457
DMYNTQV CP Novartis AG
DMYNTQV DT Small molecular drug
DMYNTQV PC 159470
DMYNTQV MW 221.3
DMYNTQV FM C12H19N3O
DMYNTQV IC InChI=1S/C12H19N3O/c1-3-8-15(9-4-2)10-13-11-6-5-7-12(16)14-11/h5-7,10H,3-4,8-9H2,1-2H3,(H,14,16)
DMYNTQV CS CCCN(CCC)C=NC1=CC=CC(=O)N1
DMYNTQV IK MEYPAYJYAZKERR-UHFFFAOYSA-N
DMYNTQV IU N'-(6-oxo-1H-pyridin-2-yl)-N,N-dipropylmethanimidamide
DMYNTQV CA CAS 111757-17-6
DMYNTQV DE Major depressive disorder
DMKS7RJ ID DMKS7RJ
DMKS7RJ DN CGS-15873A
DMKS7RJ HS Phase 2
DMKS7RJ SN Rac-trans-7-Hydroxy-4-propyl-1,2,3,4a,5,10b-hexahydro-4H-[1]benzopyrano[3,4-b]pyridine monohydrochloride
DMKS7RJ DT Small molecular drug
DMKS7RJ PC 195284
DMKS7RJ MW 283.79
DMKS7RJ FM C15H22ClNO2
DMKS7RJ IC InChI=1S/C15H21NO2.ClH/c1-2-8-16-9-4-6-11-12-5-3-7-14(17)15(12)18-10-13(11)16;/h3,5,7,11,13,17H,2,4,6,8-10H2,1H3;1H/t11-,13-;/m0./s1
DMKS7RJ CS CCCN1CCC[C@@H]2[C@@H]1COC3=C2C=CC=C3O.Cl
DMKS7RJ IK CEVXGMUELSDOPY-JZKFLRDJSA-N
DMKS7RJ IU (4aR,10bS)-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridin-7-ol;hydrochloride
DMKS7RJ CA CAS 118929-49-0
DMKS7RJ DE Psychotic disorder
DMLQRYH ID DMLQRYH
DMLQRYH DN CH-4051
DMLQRYH HS Phase 2
DMLQRYH CP Chelsea Therapeutics
DMLQRYH PC 11532464
DMLQRYH MW 449.5
DMLQRYH FM C23H23N5O5
DMLQRYH IC InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)/t18-/m0/s1
DMLQRYH CS C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CC3=C(C=C2)N=C(N=C3N)N)C(=O)O
DMLQRYH IK NAWXUBYGYWOOIX-SFHVURJKSA-N
DMLQRYH IU (2S)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
DMLQRYH DE Rheumatoid arthritis
DMQ2O8V ID DMQ2O8V
DMQ2O8V DN CHF-3381
DMQ2O8V HS Phase 2
DMQ2O8V SN Indantadol; UNII-Z3867B9SQP; Z3867B9SQP; Indantadol [INN]; CHF 3381; N-(2-Indanyl)glycinamide hydrochloride; 2-(2-indanylamino)acetamide; SCHEMBL399565; ZINC9005; MolPort-015-094-768; MNLULKBKWKTZPE-UHFFFAOYSA-N; AKOS009549166
DMQ2O8V CP Chiesi
DMQ2O8V TC Analgesics
DMQ2O8V DT Small molecular drug
DMQ2O8V PC 10198454
DMQ2O8V MW 226.7
DMQ2O8V FM C11H15ClN2O
DMQ2O8V IC InChI=1S/C11H14N2O.ClH/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10;/h1-4,10,13H,5-7H2,(H2,12,14);1H
DMQ2O8V CS C1C(CC2=CC=CC=C21)NCC(=O)N.Cl
DMQ2O8V IK JPNNIRXUJSPGRM-UHFFFAOYSA-N
DMQ2O8V IU 2-(2,3-dihydro-1H-inden-2-ylamino)acetamide;hydrochloride
DMQ2O8V CA CAS 202914-18-9
DMQ2O8V DE Neuropathic pain
DMTE071 ID DMTE071
DMTE071 DN CHF-5074
DMTE071 HS Phase 2
DMTE071 SN CHF 5074; CHF5074; 749269-83-8; CHF-5074; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261
DMTE071 CP Chiesi Pharmaceuticals
DMTE071 DT Small molecular drug
DMTE071 PC 9996409
DMTE071 MW 325.2
DMTE071 FM C16H11Cl2FO2
DMTE071 IC InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)
DMTE071 CS C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O
DMTE071 IK LIYLTQQDABRNRX-UHFFFAOYSA-N
DMTE071 IU 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid
DMTE071 CA CAS 749269-83-8
DMTE071 DE Alzheimer disease; Cognitive impairment
DMALN2M ID DMALN2M
DMALN2M DN Cholyl lysyl fluorescein
DMALN2M HS Phase 2
DMALN2M PC 44470395
DMALN2M FM C51H63N3O11S
DMALN2M IC InChI=1S/C51H63N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,46,55,57-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1
DMALN2M CS CC(CCC(=O)NC(CCCCNC(=S)NC1=CC(=C(C=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O)C(=O)O)C5CCC6C5(C(CC7C6C(CC8C7(CCC(C8)O)C)O)O)C
DMALN2M IK ZUJFMZPBQQCXQR-TZCNZRNCSA-N
DMALN2M IU 5-[[(5S)-5-carboxy-5-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]pentyl]carbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
DMALN2M DE Hepatitis virus infection
DMULZ4W ID DMULZ4W
DMULZ4W DN CHR-2797
DMULZ4W HS Phase 2
DMULZ4W SN Tosedostat; Tosedostat, CHR2797, CHR-2797
DMULZ4W CP Chroma Therape.
DMULZ4W TC Anticancer Agents
DMULZ4W DT Small molecular drug
DMULZ4W PC 15547703
DMULZ4W MW 406.5
DMULZ4W FM C21H30N2O6
DMULZ4W IC InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1
DMULZ4W CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2
DMULZ4W IK FWFGIHPGRQZWIW-SQNIBIBYSA-N
DMULZ4W IU cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate
DMULZ4W CA CAS 238750-77-1
DMULZ4W CB CHEBI:95044
DMULZ4W DE Acute myeloid leukaemia; Myelodysplastic syndrome; Inflammation
DMMRKPF ID DMMRKPF
DMMRKPF DN CHS-131
DMMRKPF HS Phase 2
DMMRKPF CP Coherus Biosciences Redwood City, CA
DMMRKPF DE Multiple sclerosis
DMLRTN1 ID DMLRTN1
DMLRTN1 DN CI-1012
DMLRTN1 HS Phase 2
DMLRTN1 SN NCS-675753; PD-161374; HIV replication inhibitor, Parke-Davis/NIAID
DMLRTN1 CP Parke-Davis & Co Ltd
DMLRTN1 DT Small molecular drug
DMLRTN1 PC 72552
DMLRTN1 MW 304.4
DMLRTN1 FM C14H12N2O2S2
DMLRTN1 IC InChI=1S/C14H12N2O2S2/c15-13(17)9-5-1-3-7-11(9)19-20-12-8-4-2-6-10(12)14(16)18/h1-8H,(H2,15,17)(H2,16,18)
DMLRTN1 CS C1=CC=C(C(=C1)C(=O)N)SSC2=CC=CC=C2C(=O)N
DMLRTN1 IK OEEHSSKRJOGQMP-UHFFFAOYSA-N
DMLRTN1 IU 2-[(2-carbamoylphenyl)disulfanyl]benzamide
DMLRTN1 CA CAS 2527-57-3
DMLRTN1 DE Acquired immune deficiency syndrome
DMSI8N3 ID DMSI8N3
DMSI8N3 DN CI-1033
DMSI8N3 HS Phase 2
DMSI8N3 SN Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride
DMSI8N3 CP Pfizer
DMSI8N3 TC Anticancer Agents
DMSI8N3 DT Small molecular drug
DMSI8N3 PC 156414
DMSI8N3 MW 485.9
DMSI8N3 FM C24H25ClFN5O3
DMSI8N3 IC InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
DMSI8N3 CS C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DMSI8N3 IK OMZCMEYTWSXEPZ-UHFFFAOYSA-N
DMSI8N3 IU N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
DMSI8N3 CA CAS 267243-28-7
DMSI8N3 CB CHEBI:61399
DMSI8N3 DE Lymphoma
DMCFLRH ID DMCFLRH
DMCFLRH DN Cibinetide
DMCFLRH HS Phase 2
DMCFLRH SN UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam
DMCFLRH CP Araim Pharmaceuticals Tarrytown, NY
DMCFLRH PC 91810664
DMCFLRH MW 1257.3
DMCFLRH FM C51H84N16O21
DMCFLRH IC InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMCFLRH CS C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
DMCFLRH IK WZTIQQBMSJTRBR-WYKNNRPVSA-N
DMCFLRH IU (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
DMCFLRH CA CAS 1208243-50-8
DMCFLRH DE Depression; Diabetic macular edema; Neuropathic pain; Sarcoidosis; Peripheral neuropathy
DMGTZLW ID DMGTZLW
DMGTZLW DN Cicletanine
DMGTZLW HS Phase 2
DMGTZLW SN Cicletanine; Cycletanide; Tenstaten; 89943-82-8; Justar; BN-1270; Win-90000; cicletanide; BN 1270; Cicletaninum; Cicletanina; Cicletaninum [Latin]; Cicletanina [Spanish]; Cicletanine [USAN:INN:BAN]; Win 90,000; ACMC-20mckj; ACMC-20mcin; AC1Q3NNY; Cicletanine (USAN/INN); (+-)-BN-1270; AC1L1HZ3; SCHEMBL49794; CHEMBL191886; (R)-(-)-CICLETANINE; CHEBI:135078; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (S)-; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (R)-; CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW CP Gilead Sciences
DMGTZLW DT Small molecular drug
DMGTZLW PC 54910
DMGTZLW MW 261.7
DMGTZLW FM C14H12ClNO2
DMGTZLW IC InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
DMGTZLW CS CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl
DMGTZLW IK CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW IU 3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
DMGTZLW CA CAS 89943-82-8
DMGTZLW CB CHEBI:135078
DMGTZLW DE Pulmonary arterial hypertension
DMTKSVA ID DMTKSVA
DMTKSVA DN CIMICOXIB
DMTKSVA HS Phase 2
DMTKSVA SN Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105
DMTKSVA DT Small molecular drug
DMTKSVA PC 213053
DMTKSVA MW 381.8
DMTKSVA FM C16H13ClFN3O3S
DMTKSVA IC InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
DMTKSVA CS COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F
DMTKSVA IK KYXDNECMRLFQMZ-UHFFFAOYSA-N
DMTKSVA IU 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
DMTKSVA CA CAS 265114-23-6
DMTKSVA CB CHEBI:76127
DMTKSVA DE Pain
DMGEAM6 ID DMGEAM6
DMGEAM6 DN Cinaciguat
DMGEAM6 HS Phase 2
DMGEAM6 SN Cinaciguat; 329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794
DMGEAM6 DT Small molecular drug
DMGEAM6 PC 9808022
DMGEAM6 MW 565.7
DMGEAM6 FM C36H39NO5
DMGEAM6 IC InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
DMGEAM6 CS C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O
DMGEAM6 IK WPYWMXNXEZFMAK-UHFFFAOYSA-N
DMGEAM6 IU 4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
DMGEAM6 CA CAS 329773-35-5
DMGEAM6 CB CHEBI:142433
DMGEAM6 DE Acute decompensated heart failure
DM98RW0 ID DM98RW0
DM98RW0 DN Cirmtuzumab
DM98RW0 HS Phase 2
DM98RW0 SN UC-961
DM98RW0 CP Oncternal Therapeutics San Diego, CA
DM98RW0 DE Mantle cell lymphoma; Chronic lymphocytic leukaemia
DMNRYPF ID DMNRYPF
DMNRYPF DN Cixutumumab
DMNRYPF HS Phase 2
DMNRYPF SN LY3012217
DMNRYPF CP Lilly
DMNRYPF DT Monoclonal antibody
DMNRYPF DE Non-small-cell lung cancer; Liver cancer
DMOFTRE ID DMOFTRE
DMOFTRE DN Cizolirtine
DMOFTRE HS Phase 2
DMOFTRE SN Cizolirtine [INN]; N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; N,N-dimethyl-2-[(R)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE CP Esteve Laboratories
DMOFTRE TC Analgesics
DMOFTRE DT Small molecular drug
DMOFTRE PC 132412
DMOFTRE MW 259.35
DMOFTRE FM C15H21N3O
DMOFTRE IC InChI=1S/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3
DMOFTRE CS CN1C(=CC=N1)C(C2=CC=CC=C2)OCCN(C)C
DMOFTRE IK DCMJBKFKXGPPMT-UHFFFAOYSA-N
DMOFTRE IU N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE CA CAS 142155-43-9
DMOFTRE DE Neuropathic pain
DMTSVJM ID DMTSVJM
DMTSVJM DN CJM112
DMTSVJM HS Phase 2
DMTSVJM CP Novartis Pharmaceuticals East Hanover, NJ
DMTSVJM DE Chronic plaque psoriasis; Multiple myeloma; Plaque psoriasis; Solid tumour/cancer; Acne vulgaris
DM9FHV8 ID DM9FHV8
DM9FHV8 DN CK-2127107
DM9FHV8 HS Phase 2
DM9FHV8 CP Cytokinetics
DM9FHV8 PC 67454400
DM9FHV8 MW 384.4
DM9FHV8 FM C19H18F2N6O
DM9FHV8 IC InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26)
DM9FHV8 CS C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F
DM9FHV8 IK MQXWPWOCXGARRK-UHFFFAOYSA-N
DM9FHV8 IU 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide
DM9FHV8 CA CAS 1345410-31-2
DM9FHV8 DE Muscle atrophy; Amyotrophic lateral sclerosis; Spinal muscular atrophy
DMW9F1G ID DMW9F1G
DMW9F1G DN CKD602
DMW9F1G HS Phase 2
DMW9F1G SN Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022
DMW9F1G DT Small molecular drug
DMW9F1G PC 6456014
DMW9F1G MW 433.5
DMW9F1G FM C25H27N3O4
DMW9F1G IC InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1
DMW9F1G CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O
DMW9F1G IK LNHWXBUNXOXMRL-VWLOTQADSA-N
DMW9F1G IU (19S)-19-ethyl-19-hydroxy-10-[2-(propan-2-ylamino)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMW9F1G CA CAS 256411-32-2
DMW9F1G CB CHEBI:135702
DMW9F1G DE Solid tumour/cancer
DMXH1KC ID DMXH1KC
DMXH1KC DN CL-316,243
DMXH1KC HS Phase 2
DMXH1KC SN UNII-52H8DB0TKX; 52H8DB0TKX; 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid; CL-316243; 5-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid; CL 316243; CL316,243; Cl-316243 Free diacid; AC1NUOLQ; Lopac0_000295; SCHEMBL2345491; GTPL3462; CHEMBL1204876; BDBM25763; ZINC1493298; 183720-02-7; 1,3-Benzodioxole-2,2-dicarboxylic acid, 5-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-; LS-187111
DMXH1KC DT Small molecular drug
DMXH1KC PC 5312115
DMXH1KC MW 465.8
DMXH1KC FM C20H18ClNNa2O7
DMXH1KC IC InChI=1S/C20H20ClNO7.2Na/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27;;/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27);;/q;2*+1/p-2/t11-,15+;;/m1../s1
DMXH1KC CS C[C@H](CC1=CC2=C(C=C1)OC(O2)(C(=O)[O-])C(=O)[O-])NC[C@@H](C3=CC(=CC=C3)Cl)O.[Na+].[Na+]
DMXH1KC IK FUZBPOHHSBDTJQ-CFOQQKEYSA-L
DMXH1KC IU disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
DMXH1KC CA CAS 138908-40-4
DMXH1KC DE Obesity
DMSF7WJ ID DMSF7WJ
DMSF7WJ DN CL-329167
DMSF7WJ HS Phase 2
DMSF7WJ SN 2-Butyl-6-(1-methoxy-1-methylethyl)-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]quinazolin-4(3H)-one
DMSF7WJ DT Small molecular drug
DMSF7WJ PC 6918269
DMSF7WJ MW 508.6
DMSF7WJ FM C30H32N6O2
DMSF7WJ IC InChI=1S/C30H32N6O2/c1-5-6-11-27-31-26-17-16-22(30(2,3)38-4)18-25(26)29(37)36(27)19-20-12-14-21(15-13-20)23-9-7-8-10-24(23)28-32-34-35-33-28/h7-10,12-18H,5-6,11,19H2,1-4H3,(H,32,33,34,35)
DMSF7WJ CS CCCCC1=NC2=C(C=C(C=C2)C(C)(C)OC)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMSF7WJ IK XZCUIMYYMKTCBA-UHFFFAOYSA-N
DMSF7WJ IU 2-butyl-6-(2-methoxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one
DMSF7WJ DE Hypertension
DM6ZOUV ID DM6ZOUV
DM6ZOUV DN Clazakizumab
DM6ZOUV HS Phase 2
DM6ZOUV SN Clazakizumab; ALD518; CHEMBL2108589; BMS-945429
DM6ZOUV TC Antiviral Agents
DM6ZOUV DT Monoclonal antibody
DM6ZOUV DE Coronavirus Disease 2019 (COVID-19)
DMAIW6C ID DMAIW6C
DMAIW6C DN Clazakizumab
DMAIW6C HS Phase 2
DMAIW6C CP Bristol-myers squibb; alder biopharmaceuticals
DMAIW6C DT Monoclonal antibody
DMAIW6C DE Crohn disease; Rheumatoid arthritis
DMU6R3O ID DMU6R3O
DMU6R3O DN CLG561
DMU6R3O HS Phase 2
DMU6R3O CP Alcon
DMU6R3O DT Antibody
DMU6R3O DE Geographic retinal atrophy
DMH2VS0 ID DMH2VS0
DMH2VS0 DN CLP-1001
DMH2VS0 HS Phase 2
DMH2VS0 SN Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics
DMH2VS0 CP Sorbent therapeutics
DMH2VS0 DE Chronic heart failure
DMAW4EL ID DMAW4EL
DMAW4EL DN CLR-1404
DMAW4EL HS Phase 2
DMAW4EL SN CLR-1501; CLR-1502
DMAW4EL CP Cellectar LLC
DMAW4EL DE Solid tumour/cancer
DM3Z6IQ ID DM3Z6IQ
DM3Z6IQ DN CLR-3001
DM3Z6IQ HS Phase 2
DM3Z6IQ CP Clera Inc
DM3Z6IQ DE Major depressive disorder
DMQSIY1 ID DMQSIY1
DMQSIY1 DN CLS003
DMQSIY1 HS Phase 2
DMQSIY1 SN Furosemide/digoxin; ICVT; Ionic contra viral therapy
DMQSIY1 CP Cutanea Wayne, PA
DMQSIY1 DE Plantar wart
DM1NCUY ID DM1NCUY
DM1NCUY DN CMI-392
DM1NCUY HS Phase 2
DM1NCUY SN LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea
DM1NCUY CP Millennium Pharmaceuticals
DM1NCUY DT Small molecular drug
DM1NCUY PC 6918268
DM1NCUY MW 633.2
DM1NCUY FM C31H37ClN2O8S
DM1NCUY IC InChI=1S/C31H37ClN2O8S/c1-34(36)31(35)33-18-21-14-19(15-26(37-2)29(21)41-12-13-43-23-8-6-22(32)7-9-23)24-10-11-25(42-24)20-16-27(38-3)30(40-5)28(17-20)39-4/h6-9,14-17,24-25,36H,10-13,18H2,1-5H3,(H,33,35)/t24-,25-/m0/s1
DM1NCUY CS CN(C(=O)NCC1=C(C(=CC(=C1)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC)OCCSC4=CC=C(C=C4)Cl)O
DM1NCUY IK LZVBMKDVEPGGFK-DQEYMECFSA-N
DM1NCUY IU 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea
DM1NCUY DE Psoriasis vulgaris
DM7GELO ID DM7GELO
DM7GELO DN CMVpp65-A0201
DM7GELO HS Phase 2
DM7GELO SN CMV vaccine (pp65 antigen), City of Hope
DM7GELO CP City of Hope
DM7GELO DT Vaccine
DM7GELO DE Cytomegalovirus infection
DMPSCVY ID DMPSCVY
DMPSCVY DN CMX-2043
DMPSCVY HS Phase 2
DMPSCVY CP Ischemix
DMPSCVY PC 49802864
DMPSCVY MW 406.5
DMPSCVY FM C16H26N2O6S2
DMPSCVY IC InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1
DMPSCVY CS C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1
DMPSCVY IK MQXRTCVZPIHBLD-TUAOUCFPSA-N
DMPSCVY IU (4S)-5-[[(1S)-1-carboxyethyl]amino]-4-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-5-oxopentanoic acid
DMPSCVY CA CAS 910627-26-8
DMPSCVY DE Myocardial reperfusion injury; Cardiac disease
DM0MTP8 ID DM0MTP8
DM0MTP8 DN CN-105
DM0MTP8 HS Phase 2
DM0MTP8 SN 5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905
DM0MTP8 CP AegisCN Raleigh, NC
DM0MTP8 PC 69085
DM0MTP8 MW 174.16
DM0MTP8 FM C9H6N2O2
DM0MTP8 IC InChI=1S/C9H6N2O2/c12-11(13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H
DM0MTP8 CS C1=CC2=C(C=CN=C2)C(=C1)[N+](=O)[O-]
DM0MTP8 IK PYGMPFQCCWBTJQ-UHFFFAOYSA-N
DM0MTP8 IU 5-nitroisoquinoline
DM0MTP8 CA CAS 607-32-9
DM0MTP8 DE Nontraumatic intracerebral hemorrhage
DM16KJ3 ID DM16KJ3
DM16KJ3 DN CNS-5161
DM16KJ3 HS Phase 2
DM16KJ3 SN CNS5161; 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine; 2-[2-chloro-5-(methylsulfanyl)phenyl]-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine
DM16KJ3 CP CeNeS
DM16KJ3 TC Analgesics
DM16KJ3 DT Small molecular drug
DM16KJ3 PC 192711
DM16KJ3 MW 351.9
DM16KJ3 FM C16H18ClN3S2
DM16KJ3 IC InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
DM16KJ3 CS CN(C1=CC(=CC=C1)SC)C(=NC2=C(C=CC(=C2)SC)Cl)N
DM16KJ3 IK JHVHEDNLONERHY-UHFFFAOYSA-N
DM16KJ3 IU 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine
DM16KJ3 CA CAS 160754-76-7
DM16KJ3 DE Neuropathic pain
DM2PEU5 ID DM2PEU5
DM2PEU5 DN CNSB-001
DM2PEU5 HS Phase 2
DM2PEU5 SN Flupirtine + opioid (fixed dose, diabetic neuropathic pain), CNSBio; Flupirtine + opioid (fixed dose, diabetic neuropathic pain), Relevare
DM2PEU5 CP Relevare Pharmaceuticals Ltd
DM2PEU5 DE Neuropathic pain
DMOR8SY ID DMOR8SY
DMOR8SY DN CNT0-1959
DMOR8SY HS Phase 2
DMOR8SY CP Janssen biotech
DMOR8SY DT Antibody
DMOR8SY DE Rheumatoid arthritis
DM6RQXB ID DM6RQXB
DM6RQXB DN CNTO-6785
DM6RQXB HS Phase 2
DM6RQXB CP Janssen research & development
DM6RQXB DT Antibody
DM6RQXB DE Rheumatoid arthritis
DMLT7JV ID DMLT7JV
DMLT7JV DN CNV-2197944
DMLT7JV HS Phase 2
DMLT7JV SN GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals
DMLT7JV CP GlaxoSmithKline plc
DMLT7JV PC 44595848
DMLT7JV MW 427.4
DMLT7JV FM C19H20F3N3O3S
DMLT7JV IC InChI=1S/C19H20F3N3O3S/c1-13-12-24(10-11-25(13)18(26)17-4-3-9-23-14(17)2)29(27,28)16-7-5-15(6-8-16)19(20,21)22/h3-9,13H,10-12H2,1-2H3/t13-/m0/s1
DMLT7JV CS C[C@H]1CN(CCN1C(=O)C2=C(N=CC=C2)C)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F
DMLT7JV IK BLFJGFDZMABYMY-ZDUSSCGKSA-N
DMLT7JV IU (2-methylpyridin-3-yl)-[(2S)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone
DMLT7JV CA CAS 1204535-44-3
DMLT7JV DE Pain
DMH5GQU ID DMH5GQU
DMH5GQU DN CO-101
DMH5GQU HS Phase 2
DMH5GQU SN methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
DMH5GQU CP Clovis Oncology
DMH5GQU DT Small molecular drug
DMH5GQU PC 9828310
DMH5GQU MW 527.6
DMH5GQU FM C27H43F2N3O5
DMH5GQU IC InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1
DMH5GQU CS CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O
DMH5GQU IK HESSNRGIEVBPRB-QDDPNBLJSA-N
DMH5GQU IU [(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
DMH5GQU CA CAS 210829-30-4
DMH5GQU DE Pancreatic cancer
DMF4MX9 ID DMF4MX9
DMF4MX9 DN Cobomarsen
DMF4MX9 HS Phase 2
DMF4MX9 SN MRG-106
DMF4MX9 CP miRagen Therapeutics Boulder, CO
DMF4MX9 DE Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Cutaneous T-cell lymphoma
DMDWG36 ID DMDWG36
DMDWG36 DN Codrituzumab
DMDWG36 HS Phase 2
DMDWG36 CP GenentechSouth San Francisco, CA
DMDWG36 DE Hepatic metastasis
DMO0VGH ID DMO0VGH
DMO0VGH DN Coenzyme Q10 analog
DMO0VGH HS Phase 2
DMO0VGH SN Coenzyme Q10 analog (mitochondrial disease); Coenzyme Q10 analog (mitochondrial disease), Edison Pharmaceuticals
DMO0VGH CP Edison Pharmaceuticals Inc
DMO0VGH DE Huntington disease; Leigh syndrome; Mitochondrial respiratory chain disease; Rett syndrome
DMNC76I ID DMNC76I
DMNC76I DN COL-1077
DMNC76I HS Phase 2
DMNC76I CP Columbia Laboratories Inc
DMNC76I DE Pain
DMSGFOY ID DMSGFOY
DMSGFOY DN Coltuximab ravtansine
DMSGFOY HS Phase 2
DMSGFOY CP ImmunoGen Waltham, MA
DMSGFOY DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMI2GSK ID DMI2GSK
DMI2GSK DN Coluracetam
DMI2GSK HS Phase 2
DMI2GSK SN BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells
DMI2GSK CP Mitsubishi Pharma Corp
DMI2GSK DT Small molecular drug
DMI2GSK PC 214346
DMI2GSK MW 341.4
DMI2GSK FM C19H23N3O3
DMI2GSK IC InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23)
DMI2GSK CS CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C
DMI2GSK IK PSPGQHXMUKWNDI-UHFFFAOYSA-N
DMI2GSK IU N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
DMI2GSK CA CAS 135463-81-9
DMI2GSK DE Alzheimer disease
DMGCTX5 ID DMGCTX5
DMGCTX5 DN Combined PR1/WT1 vaccine
DMGCTX5 HS Phase 2
DMGCTX5 SN Combined PR1/WT1 vaccine (leukemia); Combined PR1/WT1 vaccine (leukemia), NIH; Proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH
DMGCTX5 CP National Institutes of Health
DMGCTX5 DT Vaccine
DMGCTX5 DE Myeloid leukaemia
DM2UOSN ID DM2UOSN
DM2UOSN DN Conatumumab
DM2UOSN HS Phase 2
DM2UOSN CP Amgen; Takeda
DM2UOSN DT Monoclonal antibody
DM2UOSN DE Pain; Colorectal cancer
DMZ0F65 ID DMZ0F65
DMZ0F65 DN Contezolid
DMZ0F65 HS Phase 2
DMZ0F65 SN MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796
DMZ0F65 CP MicuRx Pharmaceuticals Hayward, CA
DMZ0F65 PC 25184541
DMZ0F65 MW 408.3
DMZ0F65 FM C18H15F3N4O4
DMZ0F65 IC InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
DMZ0F65 CS C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
DMZ0F65 IK SULYVXZZUMRQAX-NSHDSACASA-N
DMZ0F65 IU (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one
DMZ0F65 CA CAS 1112968-42-9
DMZ0F65 DE MRSA infection; Skin infection
DMMOHUA ID DMMOHUA
DMMOHUA DN Contezolid acefosamil
DMMOHUA HS Phase 2
DMMOHUA SN JANNTEAGZXJITO-BTQNPOSSSA-M; UNII-T79C086548; T79C086548; Contezolid acefosamil [USAN]; CHEMBL3989966; Acetic acid, anhydride with N-(((5R)-3-(4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-2,3,5-trifluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-N-3-isoxazolylphosphoramidic acid, sodium salt (1:1:1); Acetic (5R)-isoxazol-3yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidic anhydride, sodium salt (1:1); 1807365-35-0
DMMOHUA CP MicuRx Pharmaceuticals Hayward, CA
DMMOHUA PC 131750213
DMMOHUA MW 552.3
DMMOHUA FM C20H17F3N4NaO8P
DMMOHUA IC InChI=1S/C20H18F3N4O8P.Na/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25;/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32);/q;+1/p-1/t13-;/m1./s1
DMMOHUA CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)[O-].[Na+]
DMMOHUA IK JANNTEAGZXJITO-BTQNPOSSSA-M
DMMOHUA IU sodium;acetyloxy-[1,2-oxazol-3-yl-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]amino]phosphinate
DMMOHUA CA CAS 1807365-35-0
DMMOHUA DE Acute bacterial skin infection
DMER82Z ID DMER82Z
DMER82Z DN COR-1
DMER82Z HS Phase 2
DMER82Z CP Corimmun GmbH
DMER82Z DE Heart failure
DMHBOUX ID DMHBOUX
DMHBOUX DN CORT125281
DMHBOUX HS Phase 2
DMHBOUX SN Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-
DMHBOUX CP Corcept Therapeutics Menlo Park, CA
DMHBOUX PC 118092367
DMHBOUX MW 589.6
DMHBOUX FM C26H23F4N7O3S
DMHBOUX IC InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1
DMHBOUX CS CN1N=CC(=N1)S(=O)(=O)N2CC[C@H]3CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMHBOUX IK HWJYJKAURRIWJM-GKVSMKOHSA-N
DMHBOUX IU [(4aR,8aS)-1-(4-fluorophenyl)-6-(2-methyltriazol-4-yl)sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMHBOUX CA CAS 1781244-77-6
DMHBOUX DE Prostate cancer
DMVKW0N ID DMVKW0N
DMVKW0N DN Coumate
DMVKW0N HS Phase 2
DMVKW0N DT Small molecular drug
DMVKW0N PC 9859866
DMVKW0N MW 255.25
DMVKW0N FM C10H9NO5S
DMVKW0N IC InChI=1S/C10H9NO5S/c1-6-4-10(12)15-9-5-7(2-3-8(6)9)16-17(11,13)14/h2-5H,1H3,(H2,11,13,14)
DMVKW0N CS CC1=CC(=O)OC2=C1C=CC(=C2)OS(=O)(=O)N
DMVKW0N IK UFGBGFMPBMEVMI-UHFFFAOYSA-N
DMVKW0N IU (4-methyl-2-oxochromen-7-yl) sulfamate
DMVKW0N CA CAS 136167-05-0
DMVKW0N DE Breast cancer
DM2K5VP ID DM2K5VP
DM2K5VP DN Coxsackievirus A21
DM2K5VP HS Phase 2
DM2K5VP SN Cavatak (TN)
DM2K5VP CP Viralytics
DM2K5VP DE Bladder cancer; Lung cancer; Melanoma; Prostate cancer; Glioblastoma multiforme
DM8X5Q1 ID DM8X5Q1
DM8X5Q1 DN CP101
DM8X5Q1 HS Phase 2
DM8X5Q1 CP Finch Therapeutics
DM8X5Q1 DT Small molecular drug
DM8X5Q1 DE Autism spectrum disorder; Clostridium infection
DMIU19E ID DMIU19E
DMIU19E DN CP-101,606
DMIU19E HS Phase 2
DMIU19E SN SCHEMBL5888841; CHEMBL321758; AKOS030627610; CP-101581; (1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 1-((1R,2R)-Rel-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol
DMIU19E TC Analgesics
DMIU19E DT Small molecular drug
DMIU19E PC 219101
DMIU19E MW 327.4
DMIU19E FM C20H25NO3
DMIU19E IC InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1
DMIU19E CS C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O
DMIU19E IK QEMSVZNTSXPFJA-HNAYVOBHSA-N
DMIU19E IU 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol
DMIU19E CA CAS 134234-12-1
DMIU19E DE Ischemic stroke; Parkinson disease
DMSWLM5 ID DMSWLM5
DMSWLM5 DN CP-122721
DMSWLM5 HS Phase 2
DMSWLM5 SN CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine
DMSWLM5 DT Small molecular drug
DMSWLM5 PC 9821217
DMSWLM5 MW 380.4
DMSWLM5 FM C20H23F3N2O2
DMSWLM5 IC InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19-/m0/s1
DMSWLM5 CS COC1=C(C=C(C=C1)OC(F)(F)F)CN[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMSWLM5 IK ZIWFCOIGUNPHPM-HKUYNNGSSA-N
DMSWLM5 IU (2S,3S)-N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine
DMSWLM5 CA CAS 145742-28-5
DMSWLM5 DE Major depressive disorder
DMVO5DR ID DMVO5DR
DMVO5DR DN CP-331684
DMVO5DR HS Phase 2
DMVO5DR SN 2-[4-[2-[2(R)-(6-Amino-3-pyridinyl)-2-hydroxyethylamino]ethoxy]phenyl]acetic acid
DMVO5DR DT Small molecular drug
DMVO5DR PC 9840517
DMVO5DR MW 331.4
DMVO5DR FM C17H21N3O4
DMVO5DR IC InChI=1S/C17H21N3O4/c18-16-6-3-13(10-20-16)15(21)11-19-7-8-24-14-4-1-12(2-5-14)9-17(22)23/h1-6,10,15,19,21H,7-9,11H2,(H2,18,20)(H,22,23)/t15-/m0/s1
DMVO5DR CS C1=CC(=CC=C1CC(=O)O)OCCNC[C@@H](C2=CN=C(C=C2)N)O
DMVO5DR IK GZJZZQHTBTUBEL-HNNXBMFYSA-N
DMVO5DR IU 2-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]acetic acid
DMVO5DR CA CAS 207922-70-1
DMVO5DR DE Diabetic complication
DMEYMTX ID DMEYMTX
DMEYMTX DN CP-461
DMEYMTX HS Phase 2
DMEYMTX SN CP-461; OSI 461; UNII-68OJX9I7DT; CP 461; 68OJX9I7DT; 1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, monohydrochloride, (1Z)-; 227619-96-7; N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide hydrochloride; AC1O6379; 279238-68-5
DMEYMTX DT Small molecular drug
DMEYMTX PC 6445781
DMEYMTX MW 420.9
DMEYMTX FM C25H22ClFN2O
DMEYMTX IC InChI=1S/C25H21FN2O.ClH/c1-17-22(13-18-9-11-27-12-10-18)21-8-7-20(26)14-24(21)23(17)15-25(29)28-16-19-5-3-2-4-6-19;/h2-14H,15-16H2,1H3,(H,28,29);1H/b22-13-;
DMEYMTX CS CC\\1=C(C2=C(/C1=C\\C3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=C4.Cl
DMEYMTX IK KGXPDNOBLLACKL-BWLGBDCWSA-N
DMEYMTX IU N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydrochloride
DMEYMTX CA CAS 227619-96-7
DMEYMTX DE Inflammatory bowel disease
DMZEJLB ID DMZEJLB
DMZEJLB DN CP-533536
DMZEJLB HS Phase 2
DMZEJLB SN Evatanepag; CP-533,536; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid
DMZEJLB CP Pfizer
DMZEJLB DT Small molecular drug
DMZEJLB PC 9890801
DMZEJLB MW 468.6
DMZEJLB FM C25H28N2O5S
DMZEJLB IC InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)
DMZEJLB CS CC(C)(C)C1=CC=C(C=C1)CN(CC2=CC(=CC=C2)OCC(=O)O)S(=O)(=O)C3=CN=CC=C3
DMZEJLB IK WOHRHWDYFNWPNG-UHFFFAOYSA-N
DMZEJLB IU 2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid
DMZEJLB CA CAS 223488-57-1
DMZEJLB DE Osteoporosis
DMX054A ID DMX054A
DMX054A DN CP-547632
DMX054A HS Phase 2
DMX054A SN BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
DMX054A CP OSI Pharmaceuticals
DMX054A TC Anticancer Agents
DMX054A DT Small molecular drug
DMX054A PC 9811611
DMX054A MW 532.4
DMX054A FM C20H24BrF2N5O3S
DMX054A IC InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30)
DMX054A CS C1CCN(C1)CCCCNC(=O)NC2=C(C(=NS2)OCC3=C(C=C(C=C3F)Br)F)C(=O)N
DMX054A IK HXHAJRMTJXHJJZ-UHFFFAOYSA-N
DMX054A IU 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide
DMX054A CA CAS 252003-65-9
DMX054A DE Solid tumour/cancer; Ovarian cancer; Non-small-cell lung cancer
DMKJFDM ID DMKJFDM
DMKJFDM DN CP-601927
DMKJFDM HS Phase 2
DMKJFDM SN CP-601932; Alpha4beta2 nAchR partial agonists (depression), Pfizer
DMKJFDM CP Pfizer Inc
DMKJFDM DT Small molecular drug
DMKJFDM PC 11498153
DMKJFDM MW 227.22
DMKJFDM FM C12H12F3N
DMKJFDM IC InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1
DMKJFDM CS C1[C@H]2CNC[C@@H]1C3=C2C=CC(=C3)C(F)(F)F
DMKJFDM IK RNOBTWYQAWEZHH-JGVFFNPUSA-N
DMKJFDM IU (1S,8R)-4-(trifluoromethyl)-10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene
DMKJFDM CA CAS 357425-02-6
DMKJFDM DE Gastrointestinal disease
DMUJ0W7 ID DMUJ0W7
DMUJ0W7 DN CP-724714
DMUJ0W7 HS Phase 2
DMUJ0W7 SN CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
DMUJ0W7 CP Pfizer
DMUJ0W7 TC Anticancer Agents
DMUJ0W7 DT Small molecular drug
DMUJ0W7 PC 9874913
DMUJ0W7 MW 469.5
DMUJ0W7 FM C27H27N5O3
DMUJ0W7 IC InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
DMUJ0W7 CS CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)/C=C/CNC(=O)COC)C
DMUJ0W7 IK LLVZBTWPGQVVLW-SNAWJCMRSA-N
DMUJ0W7 IU 2-methoxy-N-[(E)-3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-enyl]acetamide
DMUJ0W7 CA CAS 845680-17-3
DMUJ0W7 CB CHEBI:91331
DMUJ0W7 DE Lymphoma
DMT3ORQ ID DMT3ORQ
DMT3ORQ DN CP-80794
DMT3ORQ HS Phase 2
DMT3ORQ DT Small molecular drug
DMT3ORQ PC 64922
DMT3ORQ MW 620.8
DMT3ORQ FM C31H48N4O7S
DMT3ORQ IC InChI=1S/C31H48N4O7S/c1-21(2)42-30(39)27(36)24(18-22-10-6-4-7-11-22)32-29(38)26(20-43-3)33-28(37)25(19-23-12-8-5-9-13-23)34-31(40)35-14-16-41-17-15-35/h5,8-9,12-13,21-22,24-27,36H,4,6-7,10-11,14-20H2,1-3H3,(H,32,38)(H,33,37)(H,34,40)/t24-,25-,26-,27+/m0/s1
DMT3ORQ CS CC(C)OC(=O)[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CSC)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)N3CCOCC3)O
DMT3ORQ IK UZQBKCWYZBHBOW-YIPNQBBMSA-N
DMT3ORQ IU propan-2-yl (2R,3S)-4-cyclohexyl-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[[(2S)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate
DMT3ORQ CA CAS 119625-78-4
DMT3ORQ DE Hypertension
DM6MUCX ID DM6MUCX
DM6MUCX DN CpG-10101
DM6MUCX HS Phase 2
DM6MUCX SN Actilon; Anti-HCV therapy, Coley
DM6MUCX CP Coley Pharmaceutical Group Inc; Coley Pharmaceutical
DM6MUCX DE Hepatitis C virus infection
DMK9NQI ID DMK9NQI
DMK9NQI DN CPP-115
DMK9NQI HS Phase 2
DMK9NQI SN GABA aminotransferase inhibitors (oral), Northwestern University/Catalyst Pharmaceutical Partners; Vigabatrin derivatives (oral, neurological diseases), Northwestern University; Vigabatrin derivatives (oral, drug addiction/epilepsy/neuropathic pain), Catalyst Pharmaceutical Partners
DMK9NQI CP Catalyst pharmaceutical partners
DMK9NQI DT Small molecular drug
DMK9NQI PC 9794014
DMK9NQI MW 177.15
DMK9NQI FM C7H9F2NO2
DMK9NQI IC InChI=1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1
DMK9NQI CS C1[C@H](CC(=C(F)F)[C@H]1N)C(=O)O
DMK9NQI IK CBSRETZPFOBWNG-UCORVYFPSA-N
DMK9NQI IU (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
DMK9NQI CA CAS 640897-20-7
DMK9NQI DE Substance use disorder; Infantile spasm; Tourette syndrome
DMK7DFM ID DMK7DFM
DMK7DFM DN CPX-POM
DMK7DFM HS Phase 2
DMK7DFM CP CicloMed
DMK7DFM DT Small molecular drug
DMK7DFM DE Solid tumour/cancer; Bladder cancer
DMHJEZS ID DMHJEZS
DMHJEZS DN CR-3294
DMHJEZS HS Phase 2
DMHJEZS CP Rottapharm Madaus
DMHJEZS DE Diarrhea
DMNC1AF ID DMNC1AF
DMNC1AF DN CR-665
DMNC1AF HS Phase 2
DMNC1AF SN CR665; UNII-3BX9UG06GG; 3BX9UG06GG; 228546-92-7; CR-665; CR 665; FE 200665; FE-200665; SCHEMBL4451321; DTXSID30177395; jnj-38488502; DB05155; D-Argininamide, D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-
DMNC1AF CP Ferring Pharmaceuticals Inc
DMNC1AF DT Small molecular drug
DMNC1AF PC 25030387
DMNC1AF MW 671.8
DMNC1AF FM C36H49N9O4
DMNC1AF IC InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1
DMNC1AF CS CCCC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC1=CC=NC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMNC1AF IK DBOGGOVKHSCMNB-OMRVPHBLSA-N
DMNC1AF IU (2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-5-(diaminomethylideneamino)-1-oxo-1-(pyridin-4-ylmethylamino)pentan-2-yl]hexanamide
DMNC1AF CA CAS 228546-92-7
DMNC1AF DE Pain
DMQ47U6 ID DMQ47U6
DMQ47U6 DN CR8020
DMQ47U6 HS Phase 2
DMQ47U6 SN H3N2 and H7N7 influenza monoclonal antibody therapy, Crucell
DMQ47U6 CP Crucell
DMQ47U6 DT Antibody
DMQ47U6 DE Influenza A virus infection; Influenza virus infection
DMO1ZGX ID DMO1ZGX
DMO1ZGX DN CRILVASTATIN
DMO1ZGX HS Phase 2
DMO1ZGX SN Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester
DMO1ZGX DT Small molecular drug
DMO1ZGX PC 22845140
DMO1ZGX MW 253.34
DMO1ZGX FM C14H23NO3
DMO1ZGX IC InChI=1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1
DMO1ZGX CS CC1CC(CC(C1)(C)C)OC(=O)[C@@H]2CCC(=O)N2
DMO1ZGX IK FXAAOALUHHXBSO-ILDUYXDCSA-N
DMO1ZGX IU (3,3,5-trimethylcyclohexyl) (2S)-5-oxopyrrolidine-2-carboxylate
DMO1ZGX CA CAS 120551-59-9
DMO1ZGX DE Hyperlipidaemia
DMQUWXY ID DMQUWXY
DMQUWXY DN CRLX101
DMQUWXY HS Phase 2
DMQUWXY CP Cerulean Pharma
DMQUWXY PC 184196
DMQUWXY MW 348.4
DMQUWXY FM C20H16N2O4
DMQUWXY IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m1/s1
DMQUWXY CS CC[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DMQUWXY IK VSJKWCGYPAHWDS-HXUWFJFHSA-N
DMQUWXY IU (19R)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQUWXY CA CAS 110351-92-3
DMQUWXY DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer; Non-small-cell lung cancer
DM85WID ID DM85WID
DM85WID DN Crobenetine
DM85WID HS Phase 2
DM85WID SN CROBENETINE; CROBENETINE); BIII-890-CL; Crobenetine; Crobenetine hydrochloride; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol hydrochloride
DM85WID DT Small molecular drug
DM85WID PC 9886143
DM85WID MW 379.5
DM85WID FM C25H33NO2
DM85WID IC InChI=1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1
DM85WID CS C[C@@H](CN1CC[C@]2(C3=C(C[C@@H]1C2(C)C)C(=CC=C3)O)C)OCC4=CC=CC=C4
DM85WID IK VCCBCXVFGHTDQN-UODBTFMRSA-N
DM85WID IU (1S,9R)-1,13,13-trimethyl-10-[(2S)-2-phenylmethoxypropyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-6-ol
DM85WID CA 221019-25-6
DM85WID DE Pain
DM129T7 ID DM129T7
DM129T7 DN CROMOGLYCATE LISETIL HYDROCHLORIDE
DM129T7 HS Phase 2
DM129T7 SN Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556; Cromoglycate lisetil hydrochloride
DM129T7 DT Small molecular drug
DM129T7 PC 196639
DM129T7 MW 652.6
DM129T7 FM C33H36N2O12
DM129T7 IC InChI=1S/C33H36N2O12/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3/t20-/m0/s1
DM129T7 CS CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)[C@H](CCCCN)N
DM129T7 IK NGJJDHCBOKNREV-FQEVSTJZSA-N
DM129T7 IU ethyl 5-[2-[(2S)-2,6-diaminohexanoyl]oxy-3-(2-ethoxycarbonyl-4-oxochromen-5-yl)oxypropoxy]-4-oxochromene-2-carboxylate
DM129T7 CA CAS 110816-79-0
DM129T7 CB CHEBI:31438
DM129T7 DE Asthma
DMXU5LZ ID DMXU5LZ
DMXU5LZ DN CRS-207
DMXU5LZ HS Phase 2
DMXU5LZ CP Aduro BioTech
DMXU5LZ DT Vaccine
DMXU5LZ DE Pancreatic cancer; Ovarian cancer; Gastric adenocarcinoma; Mesothelioma
DM16IMT ID DM16IMT
DM16IMT DN CRYPTOPHYCIN 52
DM16IMT HS Phase 2
DM16IMT SN LY-355703; [3S-(3alpha,10beta,13E,16beta)]-10-(3-Chloro-4-methoxybenzyl)-16-[2(R*),3(R*)-epoxy-1(R)-methyl-3-phenylpropyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone
DM16IMT DT Small molecular drug
DM16IMT PC 9939639
DM16IMT MW 669.2
DM16IMT FM C36H45ClN2O8
DM16IMT IC InChI=1S/C36H45ClN2O8/c1-21(2)17-29-34(42)45-27(22(3)31-32(47-31)24-11-8-7-9-12-24)13-10-14-30(40)39-26(19-23-15-16-28(44-6)25(37)18-23)33(41)38-20-36(4,5)35(43)46-29/h7-12,14-16,18,21-22,26-27,29,31-32H,13,17,19-20H2,1-6H3,(H,38,41)(H,39,40)/b14-10+/t22-,26+,27-,29-,31+,32+/m0/s1
DM16IMT CS C[C@@H]([C@@H]1C/C=C/C(=O)N[C@@H](C(=O)NCC(C(=O)O[C@H](C(=O)O1)CC(C)C)(C)C)CC2=CC(=C(C=C2)OC)Cl)[C@@H]3[C@H](O3)C4=CC=CC=C4
DM16IMT IK LSXOBYNBRKOTIQ-RQUBOUMQSA-N
DM16IMT IU (3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
DM16IMT CA CAS 186256-67-7
DM16IMT DE Solid tumour/cancer
DMZCG91 ID DMZCG91
DMZCG91 DN CSL-112
DMZCG91 HS Phase 2
DMZCG91 SN Reconstituted HDL (acute coronary syndrome), CSL
DMZCG91 CP Csl
DMZCG91 DE Arteriosclerosis; Cardiovascular disease
DMQXL1T ID DMQXL1T
DMQXL1T DN CT 327
DMQXL1T HS Phase 2
DMQXL1T CP Creabilis Therapeutics
DMQXL1T DE Psoriasis vulgaris; Plaque psoriasis
DMBRKZ7 ID DMBRKZ7
DMBRKZ7 DN CT1812
DMBRKZ7 HS Phase 2
DMBRKZ7 SN Elayta
DMBRKZ7 CP Cognition Therapeutics Pittsburgh, PA
DMBRKZ7 PC 118278088
DMBRKZ7 MW 431.6
DMBRKZ7 FM C24H33NO4S
DMBRKZ7 IC InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
DMBRKZ7 CS CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
DMBRKZ7 IK ISQAPFMBJFZOLG-UHFFFAOYSA-N
DMBRKZ7 IU 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol
DMBRKZ7 CA CAS 1802632-22-9
DMBRKZ7 DE Alzheimer disease
DMSGYNP ID DMSGYNP
DMSGYNP DN CTK0H-9987
DMSGYNP HS Phase 2
DMSGYNP SN Neoprontosil; Neoprontosil, disodium salt; Neoprontsil; PRONTOCIL; ZINC261161909; ZINC28863804; AZOSULFAMIDE; 132-38-7; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-((4-(aminosulfonyl)phenyl)azo)-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-, disodium salt; AABSSN; BDBM50221406; CHEMBL237251; CTK0H9987; DTXSID0074500
DMSGYNP PC 8625
DMSGYNP MW 544.5
DMSGYNP FM C18H16N4O10S3
DMSGYNP IC RALNLQYPLYWQRT-UHFFFAOYSA-N
DMSGYNP CS CC(=O)NC1=C(C=C2C=C(C(=C(C2=C1)O)N=NC3=CC=C(C=C3)S(=O)(=O)N)S(=O)(=O)O)S(=O)(=O)O
DMSGYNP IK 1S/C18H16N4O10S3/c1-9(23)20-14-8-13-10(6-15(14)34(27,28)29)7-16(35(30,31)32)17(18(13)24)22-21-11-2-4-12(5-3-11)33(19,25)26/h2-8,24H,1H3,(H,20,23)(H2,19,25,26)(H,27,28,29)(H,30,31,32)
DMSGYNP IU 6-acetamido-4-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]naphthalene-2,7-disulfonic acid
DMSGYNP DE Trachoma
DMMPC6W ID DMMPC6W
DMMPC6W DN CTL019
DMMPC6W HS Phase 2
DMMPC6W CP Novartis Pharmaceuticals
DMMPC6W DT CAR T Cell Therapy
DMMPC6W DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia
DM3SYOK ID DM3SYOK
DM3SYOK DN CTP-543
DM3SYOK HS Phase 2
DM3SYOK CP Concert Pharmaceuticals Lexington, MA
DM3SYOK DE Asthma
DMBT46Y ID DMBT46Y
DMBT46Y DN CTP-543
DMBT46Y HS Phase 2
DMBT46Y SN Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-
DMBT46Y CP Concert Pharmaceuticals
DMBT46Y DT Small molecular drug
DMBT46Y PC 72704611
DMBT46Y MW 314.41
DMBT46Y FM C17H18N6
DMBT46Y IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
DMBT46Y CS [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]
DMBT46Y IK HFNKQEVNSGCOJV-FBXGHSCESA-N
DMBT46Y IU (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DMBT46Y CA CAS 1513883-39-0
DMBT46Y DE Alopecia
DMYPXQ2 ID DMYPXQ2
DMYPXQ2 DN CVBT-141H
DMYPXQ2 HS Phase 2
DMYPXQ2 SN CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics
DMYPXQ2 CP CardioVascular BioTherapeutics Inc; CardioVascular Biotherapeutics
DMYPXQ2 DE Coronary artery disease; Peripheral arterial disease; Coronary heart disease
DMCN9GX ID DMCN9GX
DMCN9GX DN CVX-045
DMCN9GX HS Phase 2
DMCN9GX SN CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer
DMCN9GX CP CovX Pharmaceuticals Inc
DMCN9GX DE Solid tumour/cancer
DMVZT2I ID DMVZT2I
DMVZT2I DN CX-072
DMVZT2I HS Phase 2
DMVZT2I CP CytomX Therapeutics South San Francisco, CA
DMVZT2I DT Antibody
DMVZT2I DE Solid tumour/cancer; Advanced malignancy; Lymphoma; Medulloblastoma
DMS2WB5 ID DMS2WB5
DMS2WB5 DN CX157
DMS2WB5 HS Phase 2
DMS2WB5 SN CX157; O6L62LZJ0Q; CX-157; CX 157; 205187-53-7; UNII-O6L62LZJ0Q; SCHEMBL235650; DTXSID40174517; PDIMOTRDGUQMNY-UHFFFAOYSA-N; HY-100178; CS-0018174; 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide; Phenoxathiin, 3-fluoro-7-(2,2,2-trifluoroethoxy)-, 10,10-dioxide
DMS2WB5 CP CeNeRx Pharma
DMS2WB5 DT Small molecular drug
DMS2WB5 PC 18687754
DMS2WB5 MW 348.27
DMS2WB5 FM C14H8F4O4S
DMS2WB5 IC InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2
DMS2WB5 CS C1=CC2=C(C=C1OCC(F)(F)F)OC3=C(S2(=O)=O)C=CC(=C3)F
DMS2WB5 IK PDIMOTRDGUQMNY-UHFFFAOYSA-N
DMS2WB5 IU 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
DMS2WB5 CA CAS 205187-53-7
DMS2WB5 DE Mood disorder
DMJD7H4 ID DMJD7H4
DMJD7H4 DN CX-1739
DMJD7H4 HS Phase 2
DMJD7H4 SN CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant
DMJD7H4 CP Cortex Pharmaceuticals Inc
DMJD7H4 DE Attention deficit hyperactivity disorder
DMA5D6T ID DMA5D6T
DMA5D6T DN CX1789
DMA5D6T HS Phase 2
DMA5D6T CP RespireRx Pharmaceuticals Glen Rock, NJ
DMA5D6T DE Obstructive sleep apnea
DMU62I8 ID DMU62I8
DMU62I8 DN CX2009
DMU62I8 HS Phase 2
DMU62I8 CP CytomX Therapeutics
DMU62I8 DT Probody drug conjugate
DMU62I8 DE Solid tumour/cancer; Neoplasm
DMWE7B9 ID DMWE7B9
DMWE7B9 DN CX-4945
DMWE7B9 HS Phase 2
DMWE7B9 SN 1009820-21-6; Silmitasertib; CX-4945; 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid; 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid; C6RWP0N0L2; CHEMBL1230165; AK-82006; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid; 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid; C19H12ClN3O2; W-204393
DMWE7B9 CP Cylene Pharmaceuticals
DMWE7B9 DT Small molecular drug
DMWE7B9 PC 24748573
DMWE7B9 MW 349.8
DMWE7B9 FM C19H12ClN3O2
DMWE7B9 IC InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
DMWE7B9 CS C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4
DMWE7B9 IK MUOKSQABCJCOPU-UHFFFAOYSA-N
DMWE7B9 IU 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid
DMWE7B9 CA CAS 1009820-21-6
DMWE7B9 DE Solid tumour/cancer; Cholangiocarcinoma; Coronavirus infection
DMM65W1 ID DMM65W1
DMM65W1 DN CX-717
DMM65W1 HS Phase 2
DMM65W1 SN CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex
DMM65W1 CP University of California
DMM65W1 DT Small molecular drug
DMM65W1 PC 3323368
DMM65W1 MW 233.22
DMM65W1 FM C11H11N3O3
DMM65W1 IC InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2
DMM65W1 CS C1COCCN1C(=O)C2=CC3=NON=C3C=C2
DMM65W1 IK KFRQROSRKSVROW-UHFFFAOYSA-N
DMM65W1 IU 2,1,3-benzoxadiazol-5-yl(morpholin-4-yl)methanone
DMM65W1 CA CAS 211735-82-9
DMM65W1 DE Alzheimer disease; Spinal cord injury
DM3GEHC ID DM3GEHC
DM3GEHC DN CX-8998
DM3GEHC HS Phase 2
DM3GEHC CP Cavion Charlottesville, VA
DM3GEHC DE Epilepsy; Essential tremor or related tremors; Parkinson disease
DMM7Z6K ID DMM7Z6K
DMM7Z6K DN CXA10
DMM7Z6K HS Phase 2
DMM7Z6K CP Complexa
DMM7Z6K DT Small molecular drug
DMM7Z6K DE Pulmonary arterial hypertension; Focal segmental glomerulosclerosis
DM3JFZ2 ID DM3JFZ2
DM3JFZ2 DN CXL
DM3JFZ2 HS Phase 2
DM3JFZ2 SN CYCLOHEXANOL; 108-93-0; Cyclohexyl alcohol; Hexahydrophenol; Hydrophenol; Hydroxycyclohexane; Hexalin; 1-Cyclohexanol; Hydralin; Adronal; Naxol; Adronol; Anol; Cykloheksanol; Cicloesanolo; Phenol, hexahydro-; Cicloesanolo [Italian]; Cykloheksanol [Polish]; Cyclohexanone cyclohexanol mixture; Cyclohexan-1-ol; HSDB 61; NSC 403656; UNII-8E7S519M3P; CCRIS 5896; EINECS 203-630-6; BRN 0906744; AI3-00040; CHEBI:18099; HPXRVTGHNJAIIH-UHFFFAOYSA-N; 8E7S519M3P; MFCD00003855; Cyclohexanol, 98%; CXL; Cyclohexanols; DSSTox_CID_1894; DSSTox_RID_76390
DM3JFZ2 CP AstraZeneca
DM3JFZ2 DT Small molecular drug
DM3JFZ2 PC 7966
DM3JFZ2 MW 100.16
DM3JFZ2 FM C6H12O
DM3JFZ2 IC InChI=1S/C6H12O/c7-6-4-2-1-3-5-6/h6-7H,1-5H2
DM3JFZ2 CS C1CCC(CC1)O
DM3JFZ2 IK HPXRVTGHNJAIIH-UHFFFAOYSA-N
DM3JFZ2 IU cyclohexanol
DM3JFZ2 CA CAS 108-93-0
DM3JFZ2 CB CHEBI:18099
DM3JFZ2 DE Methicillin-resistant staphylococci infection
DMXR8WN ID DMXR8WN
DMXR8WN DN CYCLOPLATAM
DMXR8WN HS Phase 2
DMXR8WN SN Ammine(cyclopentanamine)[(S)-hydroxybutanedioato(2-)-O1,O4]platinum; (S)-(-)-Malatoammine(cyclopentylamine)platinum (II)
DMXR8WN DT Small molecular drug
DMXR8WN PC 3035239
DMXR8WN MW 429.33
DMXR8WN FM C9H18N2O5Pt
DMXR8WN IC InChI=1S/C5H11N.C4H6O5.H3N.Pt/c6-5-3-1-2-4-5;5-2(4(8)9)1-3(6)7;;/h5H,1-4,6H2;2,5H,1H2,(H,6,7)(H,8,9);1H3;/q;;;+2/p-2
DMXR8WN CS C1CCC(C1)N.C(C(C(=O)[O-])O)C(=O)[O-].N.[Pt+2]
DMXR8WN IK OPWOOOGFNULJAQ-UHFFFAOYSA-L
DMXR8WN IU azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+)
DMXR8WN CA CAS 109837-67-4
DMXR8WN DE Solid tumour/cancer
DM0DT45 ID DM0DT45
DM0DT45 DN CYSTEMUSTINE
DM0DT45 HS Phase 2
DM0DT45 SN CMSO2EN2; N-(2-Chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitrosourea
DM0DT45 DT Small molecular drug
DM0DT45 PC 119545
DM0DT45 MW 257.7
DM0DT45 FM C6H12ClN3O4S
DM0DT45 IC InChI=1S/C6H12ClN3O4S/c1-15(13,14)5-3-8-6(11)10(9-12)4-2-7/h2-5H2,1H3,(H,8,11)
DM0DT45 CS CS(=O)(=O)CCNC(=O)N(CCCl)N=O
DM0DT45 IK IUOVOJHLRFQQNS-UHFFFAOYSA-N
DM0DT45 IU 1-(2-chloroethyl)-3-(2-methylsulfonylethyl)-1-nitrosourea
DM0DT45 CA CAS 79955-36-5
DM0DT45 DE Solid tumour/cancer
DMMWIHC ID DMMWIHC
DMMWIHC DN CYT 99007
DMMWIHC HS Phase 2
DMMWIHC CP Cytheris
DMMWIHC TC Anticancer Agents
DMMWIHC DE Acquired immune deficiency syndrome
DM4LJH8 ID DM4LJH8
DM4LJH8 DN CYT003
DM4LJH8 HS Phase 2
DM4LJH8 DE Asthma
DMIRSWE ID DMIRSWE
DMIRSWE DN CYT-006-AngQb
DMIRSWE HS Phase 2
DMIRSWE SN AngQb; Immunodrug vaccines (hypertension), Cytos
DMIRSWE CP Cytos Biotechnology AG
DMIRSWE DT Vaccine
DMIRSWE DE Hypertension
DMUDMHA ID DMUDMHA
DMUDMHA DN CZEN-002
DMUDMHA HS Phase 2
DMUDMHA SN Bis(N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-L-valinamide) disulfide
DMUDMHA DT Small molecular drug
DMUDMHA PC 16133793
DMUDMHA MW 1664.9
DMUDMHA FM C77H109N21O19S
DMUDMHA IC InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1
DMUDMHA CS CC(C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMUDMHA IK WHNFPRLDDSXQCL-UAZQEYIDSA-N
DMUDMHA IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMUDMHA CA CAS 581-05-5
DMUDMHA DE Fungal infection
DMP6MH9 ID DMP6MH9
DMP6MH9 DN DA-8031
DMP6MH9 HS Phase 2
DMP6MH9 SN Serotonin transporter inhibitor (premature ejaculation), Dong A
DMP6MH9 CP Dong-A Pharmaceutical Co Ltd
DMP6MH9 DE Premature ejaculation
DMACTBM ID DMACTBM
DMACTBM DN DAC-060
DMACTBM HS Phase 2
DMACTBM SN DAC-0060; DAC-60; HDAC inhibitor (topical, skin cancer/actinic keratosis), DAC
DMACTBM CP DAC Srl
DMACTBM DE Keratosis
DM2U45Q ID DM2U45Q
DM2U45Q DN Danegaptide
DM2U45Q HS Phase 2
DM2U45Q SN SCHEMBL2399760; BCP17534; ZP 1609
DM2U45Q CP Pfizer; Zealand Pharma
DM2U45Q DT Small molecular drug
DM2U45Q PC 16656685
DM2U45Q MW 291.3
DM2U45Q FM C14H17N3O4
DM2U45Q IC InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1
DM2U45Q CS C1[C@H](CN([C@@H]1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2
DM2U45Q IK BIZKIHUJGMSVFD-MNOVXSKESA-N
DM2U45Q IU (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
DM2U45Q CA CAS 943134-39-2
DM2U45Q DE Atrial fibrillation
DM20MDU ID DM20MDU
DM20MDU DN Danoprevir
DM20MDU HS Phase 2
DM20MDU SN 850876-88-9; Danoprevir (USAN/INN)
DM20MDU CP InterMune; Genentech
DM20MDU DT Small molecular drug
DM20MDU PC 11285588
DM20MDU MW 731.8
DM20MDU FM C35H46FN5O9S
DM20MDU IC InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1
DM20MDU CS CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
DM20MDU IK ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
DM20MDU IU [(1S,4R,6S,7Z,14S,18R)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
DM20MDU CA CAS 850876-88-9
DM20MDU DE Hepatitis C virus infection
DM7IH48 ID DM7IH48
DM7IH48 DN Dapansutrile
DM7IH48 HS Phase 2
DM7IH48 SN 54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073
DM7IH48 CP Olatec Therapeutics New York, NY
DM7IH48 PC 12714644
DM7IH48 MW 133.17
DM7IH48 FM C4H7NO2S
DM7IH48 IC InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3
DM7IH48 CS CS(=O)(=O)CCC#N
DM7IH48 IK LQFRYKBDZNPJSW-UHFFFAOYSA-N
DM7IH48 IU 3-methylsulfonylpropanenitrile
DM7IH48 CA CAS 54863-37-5
DM7IH48 DE Acute gout flare; Musculoskeletal pain
DMIYFWA ID DMIYFWA
DMIYFWA DN Dapirolizumab pegol
DMIYFWA HS Phase 2
DMIYFWA CP Biogen Cambridge, MAUCBSmyrna, GA
DMIYFWA DE Systemic lupus erythematosus
DMR5J6K ID DMR5J6K
DMR5J6K DN DAPITANT
DMR5J6K HS Phase 2
DMR5J6K SN CHEMBL2103951
DMR5J6K DT Small molecular drug
DMR5J6K PC 132961
DMR5J6K MW 561.7
DMR5J6K FM C37H39NO4
DMR5J6K IC InChI=1S/C37H39NO4/c1-26(29-18-10-12-20-33(29)41-2)35(39)38-24-31-32(25-38)37(40,30-19-11-13-21-34(30)42-3)23-22-36(31,27-14-6-4-7-15-27)28-16-8-5-9-17-28/h4-21,26,31-32,40H,22-25H2,1-3H3/t26-,31-,32+,37+/m0/s1
DMR5J6K CS C[C@@H](C1=CC=CC=C1OC)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@]3(C4=CC=CC=C4OC)O)(C5=CC=CC=C5)C6=CC=CC=C6
DMR5J6K IK CCIWVEMVBWEMCY-RCFOMQFPSA-N
DMR5J6K IU (2S)-1-[(3aS,4S,7aS)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one
DMR5J6K CA CAS 153438-49-4
DMR5J6K DE Pain
DMCU74R ID DMCU74R
DMCU74R DN Daporinad
DMCU74R HS Phase 2
DMCU74R SN APO-866; FK-866; WK-175
DMCU74R CP Astellas Pharma GmbH
DMCU74R DT Small molecular drug
DMCU74R PC 6914657
DMCU74R MW 391.5
DMCU74R FM C24H29N3O2
DMCU74R IC InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+
DMCU74R CS C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3
DMCU74R IK KPBNHDGDUADAGP-VAWYXSNFSA-N
DMCU74R IU (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide
DMCU74R CA CAS 658084-64-1
DMCU74R CB CHEBI:94671
DMCU74R DE leukaemia
DM0Y8JP ID DM0Y8JP
DM0Y8JP DN DAS-181
DM0Y8JP HS Phase 2
DM0Y8JP SN Fludase; NEX-DAS-181; Enzyme-based therapy (Tosap, influenza), NexBio
DM0Y8JP CP Nexbio
DM0Y8JP DE Influenza virus infection
DMM3BPL ID DMM3BPL
DMM3BPL DN DAS-431
DMM3BPL HS Phase 2
DMM3BPL CP DrugAbuse Sciences
DMM3BPL DE Dementia
DM7JV4O ID DM7JV4O
DM7JV4O DN DB-041901
DM7JV4O HS Phase 2
DM7JV4O SN Pursennid; Senekot; Senna-lax; Sennaglucosides; Sennosides; Sennoside A&B; Sennoside [JAN]; Sennosides A and B; sennoside; (9,9'-Bianthracene)-2,2'-dicarboxylic acid, 5,5'-bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-; 5,5'-Bis(beta-D-glucopyranosyloxy)-4,4'-dihydroxy(9,9'-bianthrachinon)-2,2'-dicarbonsaeure; 5,5'-Bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid; 517-43-1; C42H38O20; EINECS 208-238-9; SENNA
DM7JV4O PC 5199
DM7JV4O MW 862.7
DM7JV4O FM C42H38O20
DM7JV4O IC IPQVTOJGNYVQEO-UHFFFAOYSA-N
DM7JV4O CS C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O
DM7JV4O IK 1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)
DM7JV4O IU 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
DM7JV4O CA CAS 517-43-1
DM7JV4O DE Opioid-induced constipation
DMQRCX5 ID DMQRCX5
DMQRCX5 DN DCDS-4501A
DMQRCX5 HS Phase 2
DMQRCX5 CP Genentech
DMQRCX5 DT Antibody
DMQRCX5 DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMCHWX1 ID DMCHWX1
DMCHWX1 DN DCR-PHXC
DMCHWX1 HS Phase 2
DMCHWX1 SN nedosiran
DMCHWX1 CP Dicerna Pharmaceuticals
DMCHWX1 DT Small interfering RNA
DMCHWX1 DE Hyperoxaluria
DM9REBL ID DM9REBL
DM9REBL DN DDP-225
DM9REBL HS Phase 2
DM9REBL SN AA-10021; AA-10025; AA-10026; 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine hydrate hydrochloride
DM9REBL CP Dynogen
DM9REBL DT Small molecular drug
DM9REBL PC 6918194
DM9REBL MW 382.9
DM9REBL FM C17H20ClFN4OS
DM9REBL IC InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2
DM9REBL CS CC1=CC2=C(N=C(N=C2S1)N3CCNCC3)C4=CC=CC=C4F.O.Cl
DM9REBL IK SAURKKOJWIFYSR-UHFFFAOYSA-N
DM9REBL IU 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride
DM9REBL CA CAS 476148-82-0
DM9REBL DE Chronic functional vomiting; Irritable bowel syndrome
DM5XT3G ID DM5XT3G
DM5XT3G DN DE-098
DM5XT3G HS Phase 2
DM5XT3G SN ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen
DM5XT3G CP Centocor Ortho Biotech Inc
DM5XT3G DT Antibody
DM5XT3G DE Rheumatoid arthritis
DMCQL5I ID DMCQL5I
DMCQL5I DN DE-110
DMCQL5I HS Phase 2
DMCQL5I SN Selective glucocorticoid receptor agonist (allergy), Santen
DMCQL5I CP Santen Pharmaceutical Co Ltd
DMCQL5I DE Xerophthalmia
DMZW50O ID DMZW50O
DMZW50O DN Debio 1347
DMZW50O HS Phase 2
DMZW50O CP Debiopharm
DMZW50O PC 66555680
DMZW50O MW 356.4
DMZW50O FM C20H16N6O
DMZW50O IC InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)
DMZW50O CS CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
DMZW50O IK BEMNJULZEQTDJY-UHFFFAOYSA-N
DMZW50O IU [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone
DMZW50O CA CAS 1265229-25-1
DMZW50O DE Breast cancer; Solid tumour/cancer
DM1H7UK ID DM1H7UK
DM1H7UK DN Dectrekumab
DM1H7UK HS Phase 2
DM1H7UK SN QAX-576
DM1H7UK DT Antibody
DM1H7UK DE Idiopathic pulmonary fibrosis
DMX4DQH ID DMX4DQH
DMX4DQH DN Delanzomib
DMX4DQH HS Phase 2
DMX4DQH SN ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
DMX4DQH CP Cephalon
DMX4DQH DT Small molecular drug
DMX4DQH PC 24800541
DMX4DQH MW 413.3
DMX4DQH FM C21H28BN3O5
DMX4DQH IC InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1
DMX4DQH CS B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
DMX4DQH IK SJFBTAPEPRWNKH-CCKFTAQKSA-N
DMX4DQH IU [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
DMX4DQH CA CAS 847499-27-8
DMX4DQH CB CHEBI:141530
DMX4DQH DE Multiple myeloma
DMS2WIN ID DMS2WIN
DMS2WIN DN Delphinidin
DMS2WIN HS Phase 2
DMS2WIN SN IdB-1056; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride;3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrilium chloride
DMS2WIN DT Small molecular drug
DMS2WIN PC 68245
DMS2WIN MW 338.69
DMS2WIN FM C15H11ClO7
DMS2WIN IC InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H
DMS2WIN CS C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]
DMS2WIN IK FFNDMZIBVDSQFI-UHFFFAOYSA-N
DMS2WIN IU 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride
DMS2WIN CA CAS 8012-95-1
DMS2WIN CB CHEBI:38701
DMS2WIN DE Cardiovascular disease
DM5CB8U ID DM5CB8U
DM5CB8U DN DELTIBANT
DM5CB8U HS Phase 2
DM5CB8U SN CP-0127; Deltibant < Prop INN; SB-238592; Bradycor (Cortech, US); S,S'-(Hexane-1,6-diyl)bis(succinimide-1,3-diyl)bis[D-arginyl-L-arginyl-L-prolyl-(4-hydroxy)-L-prolyl-glycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine]
DM5CB8U PC 70697628
DM5CB8U MW 2805.3
DM5CB8U FM C128H194N40O28S2
DM5CB8U IC InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1
DM5CB8U CS CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(C2=O)CCCCCCN3C(=O)C[C@@H](C3=O)SC[C@@H](C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@H](CN9C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O
DM5CB8U IK JKUYFMHGTOPVMR-WQVVEKGHSA-N
DM5CB8U IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[(3S)-1-[6-[(3R)-3-[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoic acid
DM5CB8U CA CAS 140661-97-8
DM5CB8U DE Sepsis
DML4PMG ID DML4PMG
DML4PMG DN Dendritic cell vaccine
DML4PMG HS Phase 2
DML4PMG SN Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn
DML4PMG CP University of Bonn
DML4PMG DT Vaccine
DML4PMG DE Ovarian cancer
DM7GPMB ID DM7GPMB
DM7GPMB DN Depatuxizumab
DM7GPMB HS Phase 2
DM7GPMB CP AbbVieNorth Chicago, IL
DM7GPMB DE Solid tumour/cancer; Glioblastoma of brain
DMH96JW ID DMH96JW
DMH96JW DN Dersalazine
DMH96JW HS Phase 2
DMH96JW SN UR-12715; UR-12746
DMH96JW CP Grupo Uriach
DMH96JW DT Small molecular drug
DMH96JW PC 135484128
DMH96JW MW 600.7
DMH96JW FM C35H32N6O4
DMH96JW IC InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38?
DMH96JW CS CC1=NC2=C(N1CC3CCN(CC3)C(=O)/C=C(/C4=CC=CC=C4)\\C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)O)C=CN=C2
DMH96JW IK AYEAMZDTWLXZIJ-JEFTWCRZSA-N
DMH96JW IU 2-hydroxy-5-[[4-[(Z)-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazenyl]benzoic acid
DMH96JW CA CAS 188913-58-8
DMH96JW DE Inflammatory bowel disease
DM63P1W ID DM63P1W
DM63P1W DN Descartes-08
DM63P1W HS Phase 2
DM63P1W CP Cartesian Therapeutics
DM63P1W DT CAR T Cell Therapy
DM63P1W DE Multiple myeloma
DM1UO4S ID DM1UO4S
DM1UO4S DN Descartes-11
DM1UO4S HS Phase 2
DM1UO4S CP Cartesian Therapeutics
DM1UO4S DT CAR T Cell Therapy
DM1UO4S DE Multiple myeloma
DMTY4KN ID DMTY4KN
DMTY4KN DN Dexefaroxan
DMTY4KN HS Phase 2
DMTY4KN SN Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN CP Pierre Fabre
DMTY4KN DT Small molecular drug
DMTY4KN PC 208820
DMTY4KN MW 216.28
DMTY4KN FM C13H16N2O
DMTY4KN IC InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1
DMTY4KN CS CC[C@@]1(CC2=CC=CC=C2O1)C3=NCCN3
DMTY4KN IK RATZLMXRALDSJW-CYBMUJFWSA-N
DMTY4KN IU 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN CA CAS 143249-88-1
DMTY4KN DE Schizophrenia; Parkinson disease
DM52HUD ID DM52HUD
DM52HUD DN Dexloxiglumide
DM52HUD HS Phase 2
DM52HUD SN Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119
DM52HUD DT Small molecular drug
DM52HUD PC 65937
DM52HUD MW 461.4
DM52HUD FM C21H30Cl2N2O5
DM52HUD IC InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1
DM52HUD CS CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DM52HUD IK QNQZBKQEIFTHFZ-GOSISDBHSA-N
DM52HUD IU (4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
DM52HUD CA CAS 119817-90-2
DM52HUD CB CHEBI:135747
DM52HUD DE Pancreatic malfunction
DM9L15R ID DM9L15R
DM9L15R DN Dextofisopam
DM9L15R HS Phase 2
DM9L15R SN R-Tofisopam; Dextofisopam (USAN/INN); (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R CP Vela Pharmaceuticals
DM9L15R DT Small molecular drug
DM9L15R PC 204105
DM9L15R MW 382.5
DM9L15R FM C22H26N2O4
DM9L15R IC InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1
DM9L15R CS CC[C@H]1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DM9L15R IK RUJBDQSFYCKFAA-HNNXBMFYSA-N
DM9L15R IU (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R CA CAS 82059-50-5
DM9L15R DE Irritable bowel syndrome
DMFI5J4 ID DMFI5J4
DMFI5J4 DN Dextromethorphan+quinidine
DMFI5J4 HS Phase 2
DMFI5J4 SN Dextromethorphan hydrobromide monohydrate; 6700-34-1; Dextromethorphan hydrobromide; Methorate; Drixoral Cough; PediaCare 1; Dextromethorphan hydrobromide hydrate; Dextromethorphan (hydrobromide hydrate); Hold; St. Joseph Cough Syrup; Chloraseptic DM; UNII-9D2RTI9KYH; Romilar; Tylenol Cough Liquid; Endotussin-NN Pediatric; Robitussin Cough Calmers; Robitussin Pediatric Cough; 9D2RTI9KYH; Dextromethorphan hydrobromide OROS Tablets; Drixoral Cough & Sore Throat; Robitussin Maximum Strength Cough
DMFI5J4 CP Avanir
DMFI5J4 DT Small molecular drug
DMFI5J4 PC 5462351
DMFI5J4 MW 370.3
DMFI5J4 FM C18H28BrNO2
DMFI5J4 IC InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1
DMFI5J4 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.O.Br
DMFI5J4 IK STTADZBLEUMJRG-IKNOHUQMSA-N
DMFI5J4 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide
DMFI5J4 CA CAS 6700-34-1
DMFI5J4 CB CHEBI:4471
DMFI5J4 DE Diabetic neuropathy
DMS9Y1T ID DMS9Y1T
DMS9Y1T DN DG-17
DMS9Y1T HS Phase 2
DMS9Y1T SN DG-35; Nar DG-35 Prodrug; DG-35-VIII
DMS9Y1T CP Narhex Life Sciences Ltd
DMS9Y1T DE Human immunodeficiency virus infection
DMK6FYR ID DMK6FYR
DMK6FYR DN DiabeCell
DMK6FYR HS Phase 2
DMK6FYR SN Porcine pancreatic islet cell therapy (Immupel encapsulated, type 1 diabetes), LCT; Porcine pancreatic islet celltherapy (alginate encapsulated, type 1 diabetes), LCT
DMK6FYR CP Living Cell Technologies Ltd
DMK6FYR DE Insulin-dependent diabetes
DMTJOEL ID DMTJOEL
DMTJOEL DN DIADENOSINE TETRAPHOSPHATE
DMTJOEL HS Phase 2
DMTJOEL SN Ap4A; F-1500 (tetraNa salt); Diadenosine 5',5''-P1,P4-tetraphosphate
DMTJOEL DT Small molecular drug
DMTJOEL PC 21706
DMTJOEL MW 836.4
DMTJOEL FM C20H28N10O19P4
DMTJOEL IC InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-50(35,36)47-52(39,40)49-53(41,42)48-51(37,38)44-2-8-12(32)14(34)20(46-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
DMTJOEL CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N
DMTJOEL IK YOAHKNVSNCMZGQ-XPWFQUROSA-N
DMTJOEL IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMTJOEL CA CAS 5542-28-9
DMTJOEL CB CHEBI:17422
DMTJOEL DE Cardiac arrhythmias
DM7AFJ8 ID DM7AFJ8
DM7AFJ8 DN Diannexin
DM7AFJ8 HS Phase 2
DM7AFJ8 CP Altavita Pharmaceuticals; Astellas Pharma
DM7AFJ8 DE Myocardial reperfusion injury
DM20ATW ID DM20ATW
DM20ATW DN Diflomotecan
DM20ATW HS Phase 2
DM20ATW SN BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
DM20ATW DT Small molecular drug
DM20ATW PC 219023
DM20ATW MW 398.4
DM20ATW FM C21H16F2N2O4
DM20ATW IC InChI=1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1
DM20ATW CS CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O
DM20ATW IK LFQCJSBXBZRMTN-OAQYLSRUSA-N
DM20ATW IU (20R)-20-ethyl-6,7-difluoro-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2(11),3,5,7,9,15(21)-heptaene-14,18-dione
DM20ATW CA CAS 220997-97-7
DM20ATW CB CHEBI:144046
DM20ATW DE Solid tumour/cancer
DMTLB92 ID DMTLB92
DMTLB92 DN DI-Leu16-IL2
DMTLB92 HS Phase 2
DMTLB92 CP Alopexx Oncology
DMTLB92 DT Recombinant protein
DMTLB92 DE B-cell lymphoma; Non-hodgkin lymphoma
DMBYJ92 ID DMBYJ92
DMBYJ92 DN Dilmapimod
DMBYJ92 HS Phase 2
DMBYJ92 SN Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323
DMBYJ92 CP GSK
DMBYJ92 TC Analgesics
DMBYJ92 DT Small molecular drug
DMBYJ92 PC 10297982
DMBYJ92 MW 456.4
DMBYJ92 FM C23H19F3N4O3
DMBYJ92 IC InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
DMBYJ92 CS CC1=C(C=CC(=C1)F)C2=C3C=CC(=O)N(C3=NC(=N2)NC(CO)CO)C4=C(C=CC=C4F)F
DMBYJ92 IK ORVNHOYNEHYKJG-UHFFFAOYSA-N
DMBYJ92 IU 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one
DMBYJ92 CA CAS 444606-18-2
DMBYJ92 DE Acute lung injury
DMCATH2 ID DMCATH2
DMCATH2 DN Dilpacimab
DMCATH2 HS Phase 2
DMCATH2 SN ABT-165
DMCATH2 DT Antibody
DMCATH2 DE Solid tumour/cancer
DM96NHM ID DM96NHM
DM96NHM DN Dimiracetam
DM96NHM HS Phase 2
DM96NHM SN BND-11624; Dimiracetam, Neurotune; NT-11624; NMDA receptor antagonist (oral, neuropathic pain/osteoarthritic pain), Neurotune
DM96NHM CP Brane Discovery Srl
DM96NHM DT Small molecular drug
DM96NHM PC 65955
DM96NHM MW 140.14
DM96NHM FM C6H8N2O2
DM96NHM IC InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)
DM96NHM CS C1CC(=O)N2C1NC(=O)C2
DM96NHM IK XTXXOHPHLNROBN-UHFFFAOYSA-N
DM96NHM IU 3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione
DM96NHM CA CAS 126100-97-8
DM96NHM DE Neuropathic pain
DM2QBDS ID DM2QBDS
DM2QBDS DN Disitertide
DM2QBDS HS Phase 2
DM2QBDS SN NAFB-001; Disitertide cream (skin disorders), Digna
DM2QBDS CP University of Navarra
DM2QBDS PC 9833838
DM2QBDS MW 1580.8
DM2QBDS FM C68H109N17O22S2
DM2QBDS IC InChI=1S/C68H109N17O22S2/c1-12-32(5)53(85-67(105)54(33(6)13-2)84-64(102)48(30-87)82-56(94)35(8)74-61(99)45(27-51(91)92)79-62(100)43(24-31(3)4)78-63(101)47(29-86)83-65(103)52(71)36(9)88)66(104)80-44(25-37-28-72-39-17-15-14-16-38(37)39)60(98)73-34(7)55(93)75-41(20-22-108-10)58(96)77-42(21-23-109-11)59(97)76-40(18-19-49(69)89)57(95)81-46(68(106)107)26-50(70)90/h14-17,28,31-36,40-48,52-54,72,86-88H,12-13,18-27,29-30,71H2,1-11H3,(H2,69,89)(H2,70,90)(H,73,98)(H,74,99)(H,75,93)(H,76,97)(H,77,96)(H,78,101)(H,79,100)(H,80,104)(H,81,95)(H,82,94)(H,83,103)(H,84,102)(H,85,105)(H,91,92)(H,106,107)/t32-,33-,34-,35-,36+,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-,53-,54-/m0/s1
DM2QBDS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)N
DM2QBDS IK IUYPEUHIWDMJLM-SWHDLQTQSA-N
DM2QBDS IU (2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM2QBDS CA CAS 272105-42-7
DM2QBDS DE Macular degeneration
DMYC2LE ID DMYC2LE
DMYC2LE DN Disufenton
DMYC2LE HS Phase 2
DMYC2LE SN 168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726
DMYC2LE CP Oblato
DMYC2LE DT Small molecular drug
DMYC2LE PC 151179
DMYC2LE MW 337.4
DMYC2LE FM C11H15NO7S2
DMYC2LE IC InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)
DMYC2LE CS CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-]
DMYC2LE IK OVTCHWSLKGENKP-UHFFFAOYSA-N
DMYC2LE IU N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide
DMYC2LE CA CAS 168021-77-0
DMYC2LE DE Recurrent glioblastoma
DMBMKV8 ID DMBMKV8
DMBMKV8 DN Disulfiram
DMBMKV8 HS Phase 2
DMBMKV8 SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMBMKV8 CP Odyssey Pharmaceuticals
DMBMKV8 TC Antiviral Agents
DMBMKV8 DT Small molecular drug
DMBMKV8 PC 3117
DMBMKV8 MW 296.5
DMBMKV8 FM C10H20N2S4
DMBMKV8 IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMBMKV8 CS CCN(CC)C(=S)SSC(=S)N(CC)CC
DMBMKV8 IK AUZONCFQVSMFAP-UHFFFAOYSA-N
DMBMKV8 IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMBMKV8 CA CAS 97-77-8
DMBMKV8 CB CHEBI:4659
DMBMKV8 DE Alcoholism; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMOHT5V ID DMOHT5V
DMOHT5V DN DKN-01
DMOHT5V HS Phase 2
DMOHT5V CP Leap Therapeutics
DMOHT5V DT Antibody
DMOHT5V DE Multiple myeloma; Cholangiocarcinoma; Esophageal cancer; Biliary tract cancer; Endometrial cancer; Oesophagogastric junction cancer; Ovarian cancer; Prostate cancer
DMDJUWG ID DMDJUWG
DMDJUWG DN DLX-105
DMDJUWG HS Phase 2
DMDJUWG SN DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech
DMDJUWG CP ESBATech AG
DMDJUWG DT Antibody
DMDJUWG DE Osteoarthritis
DM0157T ID DM0157T
DM0157T DN DM199
DM0157T HS Phase 2
DM0157T CP DiaMedica Therapeutics
DM0157T DT Recombinant?protein
DM0157T DE Autoimmune diabetes; Ischemic stroke; Diabetic nephropathy; Cerebral ischemia
DMMSIG7 ID DMMSIG7
DMMSIG7 DN DM-71
DMMSIG7 HS Phase 2
DMMSIG7 SN Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica
DMMSIG7 CP DiaMedica Inc
DMMSIG7 DE Type-2 diabetes
DM1HG3U ID DM1HG3U
DM1HG3U DN DM-99
DM1HG3U HS Phase 2
DM1HG3U CP DiaMedica Inc
DM1HG3U DE Alzheimer disease
DMBC7HZ ID DMBC7HZ
DMBC7HZ DN DM-CHOC-PEN
DMBC7HZ HS Phase 2
DMBC7HZ CP Dekk-Tec
DMBC7HZ PC 16126905
DMBC7HZ MW 724
DMBC7HZ FM C35H48Cl5NO4
DMBC7HZ IC InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1
DMBC7HZ CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)OC5=C(C(=NC(=C5Cl)OC)C(Cl)(Cl)Cl)Cl)C)C
DMBC7HZ IK ZJUUIXYKTPSIOH-LEZJFEBPSA-N
DMBC7HZ IU [3,5-dichloro-2-methoxy-6-(trichloromethyl)pyridin-4-yl] [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate
DMBC7HZ CA CAS 942149-56-6
DMBC7HZ DE Brain cancer; Brain metastases
DM725UG ID DM725UG
DM725UG DN DN24-02
DM725UG HS Phase 2
DM725UG SN Lapuleucel-T
DM725UG CP Dendreon
DM725UG DE Urogenital cancer; Colorectal cancer
DMDTVYC ID DMDTVYC
DMDTVYC DN DNCB
DMDTVYC HS Phase 2
DMDTVYC SN 1-Chloro-2,4-dinitrobenzene
DMDTVYC DT Small molecular drug
DMDTVYC PC 6
DMDTVYC MW 202.55
DMDTVYC FM C6H3ClN2O4
DMDTVYC IC InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H
DMDTVYC CS C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl
DMDTVYC IK VYZAHLCBVHPDDF-UHFFFAOYSA-N
DMDTVYC IU 1-chloro-2,4-dinitrobenzene
DMDTVYC CA CAS 97-00-7
DMDTVYC CB CHEBI:34718
DMDTVYC DE Immune System disease
DM89D6C ID DM89D6C
DM89D6C DN DNL758
DM89D6C HS Phase 2
DM89D6C SN SAR443122
DM89D6C CP Denali Therapeutics
DM89D6C DT Small molecular drug
DM89D6C DE Cutaneous lupus erythematosus
DM0QDC9 ID DM0QDC9
DM0QDC9 DN Dolastatin 10
DM0QDC9 HS Phase 2
DM0QDC9 SN Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-
DM0QDC9 PC 9810929
DM0QDC9 MW 785.1
DM0QDC9 FM C42H68N6O6S
DM0QDC9 IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DM0QDC9 CS CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C
DM0QDC9 IK OFDNQWIFNXBECV-VFSYNPLYSA-N
DM0QDC9 IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DM0QDC9 CA CAS 110417-88-4
DM0QDC9 CB CHEBI:67357
DM0QDC9 DE Leukemia
DMDUV1S ID DMDUV1S
DMDUV1S DN DOLASTATIN-10
DMDUV1S HS Phase 2
DMDUV1S DT Small molecular drug
DMDUV1S PC 9810929
DMDUV1S MW 785.1
DMDUV1S FM C42H68N6O6S
DMDUV1S IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DMDUV1S CS CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C
DMDUV1S IK OFDNQWIFNXBECV-VFSYNPLYSA-N
DMDUV1S IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DMDUV1S CA CAS 110417-88-4
DMDUV1S CB CHEBI:67357
DMDUV1S DE Solid tumour/cancer
DMCT08V ID DMCT08V
DMCT08V DN Domagrozumab
DMCT08V HS Phase 2
DMCT08V CP Pfizer New York, NY
DMCT08V DE Duchenne dystrophy
DM8VWPH ID DM8VWPH
DM8VWPH DN Doxorubicin-eluting beads
DM8VWPH HS Phase 2
DM8VWPH SN DC Bead (TN)
DM8VWPH CP Bayer HealthCare Pharmaceuticals; Biocompatibles
DM8VWPH DE Liver cancer
DM059CZ ID DM059CZ
DM059CZ DN DPK-060
DM059CZ HS Phase 2
DM059CZ SN DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen
DM059CZ CP DermaGen AB
DM059CZ DE Atopic dermatitis
DMMC3XR ID DMMC3XR
DMMC3XR DN DPV-001
DMMC3XR HS Phase 2
DMMC3XR CP Ubivac
DMMC3XR DE Non-small-cell lung cancer; Prostate cancer
DMGD3XT ID DMGD3XT
DMGD3XT DN DRL-17822
DMGD3XT HS Phase 2
DMGD3XT SN CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's
DMGD3XT CP Dr Reddy's Laboratories Ltd
DMGD3XT PC 58689743
DMGD3XT MW 603.6
DMGD3XT FM C30H31F6N7
DMGD3XT IC InChI=1S/C30H31F6N7/c1-18-4-3-5-22-12-23(27(37-26(18)22)42(14-19-6-7-19)15-20-8-9-20)17-43(28-38-40-41(2)39-28)16-21-10-24(29(31,32)33)13-25(11-21)30(34,35)36/h3-5,10-13,19-20H,6-9,14-17H2,1-2H3
DMGD3XT CS CC1=C2C(=CC=C1)C=C(C(=N2)N(CC3CC3)CC4CC4)CN(CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)C6=NN(N=N6)C
DMGD3XT IK OCNBSSLDAIWTKS-UHFFFAOYSA-N
DMGD3XT IU 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N,N-bis(cyclopropylmethyl)-8-methylquinolin-2-amine
DMGD3XT CA CAS 898911-09-6
DMGD3XT DE Arteriosclerosis
DM8WU3O ID DM8WU3O
DM8WU3O DN Drug 2862277
DM8WU3O HS Phase 2
DM8WU3O SN 2862277
DM8WU3O DT Antibody
DM8WU3O DE Acute lung injury
DMI69E5 ID DMI69E5
DMI69E5 DN DS-3201b
DMI69E5 HS Phase 2
DMI69E5 SN Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
DMI69E5 CP Daiichi Sankyo
DMI69E5 DT Small molecular drug
DMI69E5 PC 126481870
DMI69E5 MW 488
DMI69E5 FM C26H34ClN3O4
DMI69E5 IC InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1
DMI69E5 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C
DMI69E5 IK SSDRNUPMYCFXGM-ZZHSESOFSA-N
DMI69E5 IU (2R)-7-chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
DMI69E5 CA CAS 1809336-39-7
DMI69E5 DE Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Urothelial carcinoma; Renal cell carcinoma; Small-cell lung cancer; T-cell leukaemia
DMUXIRM ID DMUXIRM
DMUXIRM DN DS-8500
DMUXIRM HS Phase 2
DMUXIRM CP Daiichi Sankyo
DMUXIRM PC 74889211
DMUXIRM MW 153.18
DMUXIRM FM C8H11NO2
DMUXIRM IC InChI=1S/C8H11NO2/c1-3-7-6(4-5-9-7)8(10)11-2/h4-5,9H,3H2,1-2H3
DMUXIRM CS CCC1=C(C=CN1)C(=O)OC
DMUXIRM IK FWZOVQKKSCXOHE-UHFFFAOYSA-N
DMUXIRM IU methyl 2-ethyl-1H-pyrrole-3-carboxylate
DMUXIRM DE Diabetic complication; Type-2 diabetes
DM6UGHA ID DM6UGHA
DM6UGHA DN DSP-6952
DM6UGHA HS Phase 2
DM6UGHA SN Serotonin 4 receptor partial agonist (constipation), Dainippon Sumitomo
DM6UGHA CP Dainippon Sumitomo Pharma Co Ltd
DM6UGHA DE Constipation
DMU2GP4 ID DMU2GP4
DMU2GP4 DN DT-1687
DMU2GP4 HS Phase 2
DMU2GP4 SN DT-1386; MGluR4 PAM (neurological disease/psychiatric disorder), Domain Therapeutics; MGluR4 PAM (neurological disease/psychiatric disorder), Merck Serono
DMU2GP4 CP Domain Therapeutics SA
DMU2GP4 PC 135565465
DMU2GP4 MW 421.5
DMU2GP4 FM C23H23N3O3S
DMU2GP4 IC InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+
DMU2GP4 CS C1COCCN1CCCC2=CC\\3=C(C=C2)OC(=C/C3=N\\O)C4=NC=C5C=CSC5=C4
DMU2GP4 IK ZTEDNASHAWNBKQ-NCELDCMTSA-N
DMU2GP4 IU (NE)-N-[6-(3-morpholin-4-ylpropyl)-2-thieno[3,2-c]pyridin-6-ylchromen-4-ylidene]hydroxylamine
DMU2GP4 CA CAS 1883329-53-0
DMU2GP4 DE Neurological disorder; Parkinson disease
DMV84OK ID DMV84OK
DMV84OK DN DTI-0009
DMV84OK HS Phase 2
DMV84OK SN Selodenosan
DMV84OK CP Aderis Pharmaceuticals
DMV84OK DE Atrial fibrillation
DMX27IT ID DMX27IT
DMX27IT DN DTRM-555
DMX27IT HS Phase 2
DMX27IT CP Zhejiang DTRM Biopharma
DMX27IT DT Small molecular drug
DMX27IT DE Chronic lymphocytic leukaemia
DM1ZJYS ID DM1ZJYS
DM1ZJYS DN Dusigitumab
DM1ZJYS HS Phase 2
DM1ZJYS CP MedImmune Gaithersburg, MD
DM1ZJYS DE Breast cancer
DM7USVA ID DM7USVA
DM7USVA DN Duvelisib
DM7USVA HS Phase 2
DM7USVA SN Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib
DM7USVA TC Antiviral Agents
DM7USVA DT Small molecular drug
DM7USVA PC 50905713
DM7USVA MW 416.9
DM7USVA FM C22H17ClN6O
DM7USVA IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DM7USVA CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM7USVA IK SJVQHLPISAIATJ-ZDUSSCGKSA-N
DM7USVA IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DM7USVA CA CAS 1201438-56-3
DM7USVA CB CHEBI:131169
DM7USVA DE Coronavirus Disease 2019 (COVID-19)
DMUGBQK ID DMUGBQK
DMUGBQK DN DVC1-0101
DMUGBQK HS Phase 2
DMUGBQK SN Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
DMUGBQK CP DNAVEC Corp
DMUGBQK DE Arteriosclerosis
DMQKU2F ID DMQKU2F
DMQKU2F DN DWP-05195
DMQKU2F HS Phase 2
DMQKU2F SN DWJ-204; DWP-0519
DMQKU2F CP Daewoong Pharmaceutical Co Ltd
DMQKU2F DE Neuropathic pain
DMBFZET ID DMBFZET
DMBFZET DN DX-890
DMBFZET HS Phase 2
DMBFZET CP Dyax Corp.
DMBFZET PC 56841753
DMBFZET MW 6231
DMBFZET FM C282H412N74O75S6
DMBFZET IC InChI=1S/C282H412N74O75S6/c1-21-150(15)229-273(424)312-154(19)232(383)328-185(117-157-58-30-24-31-59-157)255(406)339-196(123-160-64-36-27-37-65-160)277(428)353-110-52-76-205(353)267(418)324-177(74-50-108-300-282(296)297)246(397)332-189(124-164-129-301-170-67-39-38-66-168(164)170)250(401)310-153(18)231(382)327-184(116-156-56-28-23-29-57-156)253(404)334-193(128-224(380)381)251(402)311-155(20)234(385)347-225(146(7)8)270(421)325-171(68-40-44-102-283)236(387)304-132-215(367)313-173(69-41-45-103-284)242(393)344-202-142-436-435-141-201-262(413)319-176(73-49-107-299-281(294)295)244(395)321-180(95-100-222(376)377)248(399)330-188(121-163-84-90-167(360)91-85-163)257(408)342-198(241(392)307-135-218(370)346-228(149(13)14)278(429)356-113-55-79-208(356)279(430)431)138-432-434-140-200(341-233(384)152(17)309-235(386)169(287)92-98-220(372)373)263(414)333-192(127-212(291)364)259(410)337-194(115-145(5)6)275(426)355-112-54-78-207(355)269(420)351-230(151(16)22-2)274(425)349-227(148(11)12)271(422)326-172(72-48-106-298-280(292)293)237(388)308-136-219(371)352-109-51-75-204(352)266(417)345-203(265(416)350-229)143-437-433-139-199(316-214(366)131-302-213(365)130-303-239(390)183(119-161-80-86-165(358)87-81-161)335-268(419)206-77-53-111-354(206)276(427)195(122-159-62-34-26-35-63-159)338-252(403)182(114-144(3)4)336-272(423)226(147(9)10)348-264(202)415)261(412)320-178(93-97-209(288)361)238(389)305-133-216(368)314-190(125-210(289)362)240(391)306-134-217(369)315-191(126-211(290)363)258(409)318-175(71-43-47-105-286)245(396)329-186(118-158-60-32-25-33-61-158)254(405)331-187(120-162-82-88-166(359)89-83-162)256(407)340-197(137-357)260(411)323-179(94-99-221(374)375)247(398)317-174(70-42-46-104-285)243(394)322-181(249(400)343-201)96-101-223(378)379/h23-39,56-67,80-91,129,144-155,169,171-208,225-230,301,357-360H,21-22,40-55,68-79,92-128,130-143,283-287H2,1-20H3,(H2,288,361)(H2,289,362)(H2,290,363)(H2,291,364)(H,302,365)(H,303,390)(H,304,387)(H,305,389)(H,306,391)(H,307,392)(H,308,388)(H,309,386)(H,310,401)(H,311,402)(H,312,424)(H,313,367)(H,314,368)(H,315,369)(H,316,366)(H,317,398)(H,318,409)(H,319,413)(H,320,412)(H,321,395)(H,322,394)(H,323,411)(H,324,418)(H,325,421)(H,326,422)(H,327,382)(H,328,383)(H,329,396)(H,330,399)(H,331,405)(H,332,397)(H,333,414)(H,334,404)(H,335,419)(H,336,423)(H,337,410)(H,338,403)(H,339,406)(H,340,407)(H,341,384)(H,342,408)(H,343,400)(H,344,393)(H,345,417)(H,346,370)(H,347,385)(H,348,415)(H,349,425)(H,350,416)(H,351,420)(H,372,373)(H,374,375)(H,376,377)(H,378,379)(H,380,381)(H,430,431)(H4,292,293,298)(H4,294,295,299)(H4,296,297,300)/t150-,151-,152-,153-,154-,155-,169-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,225-,226-,227-,228-,229-,230-/m0/s1
DMBFZET CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=CC=C7)CC(C)C)C(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)CC)C)CC9=CC=CC=C9)CC2=CC=CC=C2)CCCNC(=N)N)CC2=CNC3=CC=CC=C32)C)CC2=CC=CC=C2)CC(=O)O)C)C(C)C)CCCCN)CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)O)CC1=CC=C(C=C1)O)CCC(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CCC(=O)O)CO)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CCCCN)CC(=O)N)CC(=O)N)CCC(=O)N)CCCNC(=N)N)C(C)C
DMBFZET IK CARVNSROHCBVAO-BUGJESOBSA-N
DMBFZET IU (2S)-1-[(2S)-2-[[2-[[(1R,2aS,4S,8aS,11aS,13S,14aS,16S,17aR,19S,20aS,22S,26aS,28S,29aS,31S,32aS,34R,35aS,38aS,39R,41aS,42S,44aS,45S,47aS,48S,50aS,51R,54S,56aS,57S,59aS,60S,62aS,63S,65aS,66S,69S,72S,75S,81S,87S,90R,99S)-20a,26a,57,72-tetrakis(4-aminobutyl)-34-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-31,75,81-tris(2-amino-2-oxoethyl)-87-(3-amino-3-oxopropyl)-8a,38a,56a,59a,69-pentabenzyl-19,65a-bis[(2S)-butan-2-yl]-13,47a,48-tris(3-carbamimidamidopropyl)-45,54,60-tris(2-carboxyethyl)-35a-(carboxymethyl)-63-(hydroxymethyl)-42,66,99-tris[(4-hydroxyphenyl)methyl]-44a-(1H-indol-3-ylmethyl)-32a,41a,62a-trimethyl-11a,28-bis(2-methylpropyl)-1a,3,7a,9,10a,12,13a,15,16a,18,19a,21,22a,25a,27,28a,30,31a,33,34a,37a,40a,41,43a,44,46a,47,49a,50,53,55a,56,58a,59,61a,62,64a,65,67a,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-14a,16,29a-tri(propan-2-yl)-36,37,69a,70a,73a,74a-hexathia-a,2,6a,8,9a,11,12a,14,15a,17,18a,20,21a,24a,26,27a,29,30a,32,33a,36a,39a,40,42a,43,45a,46,48a,49,52,54a,55,57a,58,60a,61,63a,64,66a,67,70,73,76,79,82,85,88,91,94,97-pentacontazaheptacyclo[88.77.4.451,117.04,8.022,26.0102,106.0150,154]pentaheptacontahectane-39-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMBFZET CA CAS 506433-25-6
DMBFZET DE Acute lung injury
DMDYWM8 ID DMDYWM8
DMDYWM8 DN E-10030
DMDYWM8 HS Phase 2
DMDYWM8 SN PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix
DMDYWM8 CP Archemix Corp
DMDYWM8 DE Macular degeneration
DMLS269 ID DMLS269
DMLS269 DN E-1224
DMLS269 HS Phase 2
DMLS269 SN BMS-292655; BMS-315801; BMS-379224; Ravuconazole prodrugs, BMS; Ravuconazole back-up compounds, Eisai; Ravuconazole prodrug (fungal infection), Brain Factory; Ravuconazole prodrugs, Bristol-Myers Squibb
DMLS269 CP Bristol-Myers Squibb Co
DMLS269 DT Small molecular drug
DMLS269 PC 57416740
DMLS269 MW 273.14
DMLS269 FM C15H20BNO3
DMLS269 IC InChI=1S/C15H20BNO3/c1-11(18)13-12(7-6-10-17-13)8-9-16-19-14(2,3)15(4,5)20-16/h6-10H,1-5H3/b9-8+
DMLS269 CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(N=CC=C2)C(=O)C
DMLS269 IK DAQLKAUMCVWOCH-CMDGGOBGSA-N
DMLS269 IU 1-[3-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-yl]ethanone
DMLS269 DE Fungal infection
DMK8SY6 ID DMK8SY6
DMK8SY6 DN E2027
DMK8SY6 HS Phase 2
DMK8SY6 CP Eisai
DMK8SY6 DT Small molecular drug
DMK8SY6 DE Alzheimer disease; Parkinson disease; Lewy body dementia
DMC5PB2 ID DMC5PB2
DMC5PB2 DN E-4716
DMC5PB2 HS Phase 2
DMC5PB2 SN Mapinastine
DMC5PB2 CP Laboratorios Dr Esteve SA
DMC5PB2 DE Respiratory disease
DMQERC6 ID DMQERC6
DMQERC6 DN E5555
DMQERC6 HS Phase 2
DMQERC6 SN Atopaxar
DMQERC6 CP Eisai
DMQERC6 DT Small molecular drug
DMQERC6 PC 10459564
DMQERC6 MW 527.6
DMQERC6 FM C29H38FN3O5
DMQERC6 IC InChI=1S/C29H38FN3O5/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32/h13-15,31H,7-12,16-17H2,1-6H3
DMQERC6 CS CCOC1=C(C(=C2C(=C1)CN(C2=N)CC(=O)C3=CC(=C(C(=C3)N4CCOCC4)OC)C(C)(C)C)F)OCC
DMQERC6 IK QWKAUGRRIXBIPO-UHFFFAOYSA-N
DMQERC6 IU 1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone
DMQERC6 CA CAS 751475-53-3
DMQERC6 DE Acute coronary syndrome
DM1S489 ID DM1S489
DM1S489 DN E6005
DM1S489 HS Phase 2
DM1S489 SN Lotamilast; 947620-48-6; E6005; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7
DM1S489 CP Eisai
DM1S489 DT Small molecular drug
DM1S489 PC 24864553
DM1S489 MW 472.5
DM1S489 FM C26H24N4O5
DM1S489 IC InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)
DM1S489 CS CNC1=NC2=CC(=C(C=C2C(=N1)C3=CC(=CC=C3)NC(=O)C4=CC=C(C=C4)C(=O)OC)OC)OC
DM1S489 IK BBTFKAOFCSOZMB-UHFFFAOYSA-N
DM1S489 IU methyl 4-[[3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl]carbamoyl]benzoate
DM1S489 CA CAS 947620-48-6
DM1S489 DE Atopic dermatitis
DMOSL9P ID DMOSL9P
DMOSL9P DN E6201
DMOSL9P HS Phase 2
DMOSL9P SN novel MEK inhibitors
DMOSL9P CP Eisai Ltd.
DMOSL9P DT Small molecular drug
DMOSL9P PC 10172827
DMOSL9P MW 389.4
DMOSL9P FM C21H27NO6
DMOSL9P IC InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1
DMOSL9P CS CCNC1=CC\\2=C(C(=C1)O)C(=O)O[C@H]([C@@H](/C=C\\C(=O)[C@H]([C@H](C/C=C2)O)O)C)C
DMOSL9P IK MWUFVYLAWAXDHQ-HMNLTAHHSA-N
DMOSL9P IU (4S,5R,6Z,9S,10S,12E)-16-(ethylamino)-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione
DMOSL9P CA CAS 603987-35-5
DMOSL9P DE Psoriasis vulgaris
DMUWJI4 ID DMUWJI4
DMUWJI4 DN E-6700
DMUWJI4 HS Phase 2
DMUWJI4 PC 9843006
DMUWJI4 MW 383.4
DMUWJI4 FM C22H25NO5
DMUWJI4 IC InChI=1S/C22H25NO5/c1-14-18(19(24)15(2)21(28-3)20(14)25)12-17(22(26)27)10-6-4-5-8-16-9-7-11-23-13-16/h7,9,11-13H,4-6,8,10H2,1-3H3,(H,26,27)/b17-12+
DMUWJI4 CS CC1=C(C(=O)C(=C(C1=O)OC)C)/C=C(\\CCCCCC2=CN=CC=C2)/C(=O)O
DMUWJI4 IK WWYFKRSBSWBEGV-SFQUDFHCSA-N
DMUWJI4 IU (2E)-2-[(4-methoxy-2,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]-7-pyridin-3-ylheptanoic acid
DMUWJI4 DE Asthma
DMAHGKE ID DMAHGKE
DMAHGKE DN E7016
DMAHGKE HS Phase 2
DMAHGKE SN UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; E7016; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016
DMAHGKE CP Eisai
DMAHGKE DT Small molecular drug
DMAHGKE PC 11660296
DMAHGKE MW 349.4
DMAHGKE FM C20H19N3O3
DMAHGKE IC InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
DMAHGKE CS C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
DMAHGKE IK HAVFFEMDLROBGI-UHFFFAOYSA-N
DMAHGKE IU 4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one
DMAHGKE CA CAS 902128-92-1
DMAHGKE DE Melanoma
DMZRXTL ID DMZRXTL
DMZRXTL DN E7820
DMZRXTL HS Phase 2
DMZRXTL SN E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075
DMZRXTL CP Eisai
DMZRXTL DT Small molecular drug
DMZRXTL PC 196970
DMZRXTL MW 336.4
DMZRXTL FM C17H12N4O2S
DMZRXTL IC InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
DMZRXTL CS CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N
DMZRXTL IK LWGUASZLXHYWIV-UHFFFAOYSA-N
DMZRXTL IU 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
DMZRXTL CA CAS 289483-69-8
DMZRXTL DE Solid tumour/cancer; Colorectal cancer
DM8K5IF ID DM8K5IF
DM8K5IF DN E7850
DM8K5IF HS Phase 2
DM8K5IF SN Irofulven
DM8K5IF CP Eisai
DM8K5IF DT Small molecular drug
DM8K5IF PC 148189
DM8K5IF MW 246.3
DM8K5IF FM C15H18O3
DM8K5IF IC InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DM8K5IF CS CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO
DM8K5IF IK NICJCIQSJJKZAH-AWEZNQCLSA-N
DM8K5IF IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DM8K5IF CA CAS 158440-71-2
DM8K5IF CB CHEBI:135002
DM8K5IF DE Solid tumour/cancer
DM753H8 ID DM753H8
DM753H8 DN EB8018
DM753H8 HS Phase 2
DM753H8 SN Sibofimloc; 1616113-45-1; Antibiotic-202; VRT-1353385; UNII-00OF00QZC4; 1-[2,7-Bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; 1-[2,7-bis({2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl})spiro[fluorene-9,4'-piperidine]-1'-yl]ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; Sibofimloc [INN]; Sibofimloc [USAN]; Sibofimloc (USAN/INN); CHEMBL4594305; SCHEMBL15836795; EX-A750; Antibiotic-202;VRT-1353385; MFCD28144726; WHO 10950; ZINC209678340; ACN-052475; CS-5487; DA-43714; HY-12820; B5896; D11825; J-690221; 1-(2,7-Bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol-8-yl)spiro(fluorene-9,4'-piperidin)-1'-yl)ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4a?piperidine]-1a?yl]ethanone; 8,8'-(1'-Acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol); D-Glycero-D-manno-oct-7-ynitol, 8,8'-(1'-acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-
DM753H8 CP Enterome Biosciences
DM753H8 DT Small molecular drug
DM753H8 PC 76684239
DM753H8 MW 649.7
DM753H8 FM C35H39NO11
DM753H8 IC InChI=1S/C35H39NO11/c1-18(39)36-12-10-35(11-13-36)23-14-19(4-8-25-29(40)33(44)31(42)27(16-37)46-25)2-6-21(23)22-7-3-20(15-24(22)35)5-9-26-30(41)34(45)32(43)28(17-38)47-26/h2-3,6-7,14-15,25-34,37-38,40-45H,10-13,16-17H2,1H3/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m1/s1
DM753H8 CS CC(=O)N1CCC2(CC1)C3=C(C=CC(=C3)C#C[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=C2C=C(C=C5)C#C[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O
DM753H8 IK SFHMWDMKUYVSQJ-VECBPBMLSA-N
DM753H8 IU 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone
DM753H8 CA CAS 1616113-45-1
DM753H8 DE Crohn disease
DM0KVJC ID DM0KVJC
DM0KVJC DN EC-145
DM0KVJC HS Phase 2
DM0KVJC SN EC-0255; EC-0260
DM0KVJC CP Endocyte; Merck
DM0KVJC PC 25014653
DM0KVJC MW 1917
DM0KVJC FM C86H109N21O26S2
DM0KVJC IC InChI=1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1
DM0KVJC CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O
DM0KVJC IK KUZYSQSABONDME-QRLOMCMNSA-N
DM0KVJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM0KVJC CA CAS 742092-03-1
DM0KVJC DE Solid tumour/cancer
DM1LDIP ID DM1LDIP
DM1LDIP DN Econail
DM1LDIP HS Phase 2
DM1LDIP SN Econazole/SEPA
DM1LDIP CP MacroChem Corporation
DM1LDIP DT Small molecular drug
DM1LDIP PC 68589
DM1LDIP MW 444.7
DM1LDIP FM C18H16Cl3N3O4
DM1LDIP IC InChI=1S/C18H15Cl3N2O.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4)
DM1LDIP CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-]
DM1LDIP IK DDXORDQKGIZAME-UHFFFAOYSA-N
DM1LDIP IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid
DM1LDIP CA CAS 24169-02-6
DM1LDIP DE Fungal infection
DMKAUM9 ID DMKAUM9
DMKAUM9 DN Eculizumab
DMKAUM9 HS Phase 2
DMKAUM9 SN Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
DMKAUM9 CP Alexion Pharmaceuticals Inc
DMKAUM9 TC Antiviral Agents
DMKAUM9 DT Monoclonal antibody
DMKAUM9 DE Age-related macular degeneration; Coronavirus Disease 2019 (COVID-19)
DMQ08AJ ID DMQ08AJ
DMQ08AJ DN Edotreotide
DMQ08AJ HS Phase 2
DMQ08AJ SN Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DMQ08AJ PC 158782
DMQ08AJ MW 1421.6
DMQ08AJ FM C65H92N14O18S2
DMQ08AJ IC InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
DMQ08AJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O
DMQ08AJ IK RZHKDBRREKOZEW-AAXZNHDCSA-N
DMQ08AJ IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
DMQ08AJ CA CAS 204318-14-9
DMQ08AJ DE Acromegaly
DMGJYZ8 ID DMGJYZ8
DMGJYZ8 DN EDP-305
DMGJYZ8 HS Phase 2
DMGJYZ8 DT Small molecular drug
DMGJYZ8 DE Non-alcoholic steatohepatitis; Primary biliary cholangitis
DM5WZ0O ID DM5WZ0O
DM5WZ0O DN EDP-420
DM5WZ0O HS Phase 2
DM5WZ0O SN EP-013420
DM5WZ0O CP Enanta
DM5WZ0O DT Small molecular drug
DM5WZ0O PC 9875927
DM5WZ0O MW 841
DM5WZ0O FM C43H64N6O11
DM5WZ0O IC InChI=1S/C43H64N6O11/c1-12-33-43(9,54)39-26(4)35(46-29(7)50)24(2)19-42(8,56-23-31(22-55-39)47-57-21-30-14-15-34(44-20-30)49-17-13-16-45-49)38(27(5)36(51)28(6)40(53)59-33)60-41-37(52)32(48(10)11)18-25(3)58-41/h13-17,20,24-28,32-33,37-39,41,52,54H,12,18-19,21-23H2,1-11H3/b46-35?,47-31+/t24-,25-,26+,27+,28-,32+,33-,37-,38-,39-,41+,42-,43-/m1/s1
DM5WZ0O CS CC[C@@H]1[C@@]([C@H]2[C@H](C(=NC(=O)C)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(OC/C(=N/OCC4=CN=C(C=C4)N5C=CC=N5)/CO2)C)C)C)(C)O
DM5WZ0O IK WLGSYOKBEDVHQB-ZIJNRMRWSA-N
DM5WZ0O IU N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,18R)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2-hydroxy-2,6,8,10,16,18-hexamethyl-5,7-dioxo-13-[(6-pyrazol-1-ylpyridin-3-yl)methoxyimino]-4,11,15-trioxabicyclo[8.5.4]nonadecan-17-ylidene]acetamide
DM5WZ0O CA CAS 736992-12-4
DM5WZ0O DE Bacterial infection
DM32UOC ID DM32UOC
DM32UOC DN EDP-938
DM32UOC HS Phase 2
DM32UOC CP Enanta Pharmaceuticals
DM32UOC DT Small molecular drug
DM32UOC DE Respiratory syncytial virus infection
DMX4RSD ID DMX4RSD
DMX4RSD DN EFEGATRAN SULFATE HYDRATE
DMX4RSD HS Phase 2
DMX4RSD SN Efegatran sulfate hydrate < Rec INNM; N-Methyl-D-phenylalanyl-L-prolyl-L-arginal sulfate hydrate; N-Methyl-D-phenylalanyl-N-[4-guanidino-1(S)-formylbutyl]-L-prolinamide sulfate hydrate
DMX4RSD DT Small molecular drug
DMX4RSD PC 6918161
DMX4RSD MW 532.6
DMX4RSD FM C21H36N6O8S
DMX4RSD IC InChI=1S/C21H32N6O3.H2O4S.H2O/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23;1-5(2,3)4;/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25);(H2,1,2,3,4);1H2/t16-,17+,18-;;/m0../s1
DMX4RSD CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O.O.OS(=O)(=O)O
DMX4RSD IK JJJFZLGPEFEADH-VWRRVXQQSA-N
DMX4RSD IU (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid;hydrate
DMX4RSD DE Myocardial infarction
DMX6RZG ID DMX6RZG
DMX6RZG DN EFT508
DMX6RZG HS Phase 2
DMX6RZG SN Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG CP eFFECTOR Therapeutics San Diego, CA
DMX6RZG PC 118598754
DMX6RZG MW 340.4
DMX6RZG FM C17H20N6O2
DMX6RZG IC InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
DMX6RZG CS CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3
DMX6RZG IK HKTBYUWLRDZAJK-UHFFFAOYSA-N
DMX6RZG IU 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG CA CAS 1849590-01-7
DMX6RZG DE Solid tumour/cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Triple negative breast cancer
DMBHP56 ID DMBHP56
DMBHP56 DN Efungumab
DMBHP56 HS Phase 2
DMBHP56 SN Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec
DMBHP56 CP University of Manchester
DMBHP56 DT Antibody
DMBHP56 DE Breast cancer
DM6L5TR ID DM6L5TR
DM6L5TR DN EGEN-001
DM6L5TR HS Phase 2
DM6L5TR CP EGEN
DM6L5TR DE Ovarian cancer; Peritoneal cancer; Fallopian tube cancer
DMN1SWB ID DMN1SWB
DMN1SWB DN EGS-21
DMN1SWB HS Phase 2
DMN1SWB SN Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem
DMN1SWB CP Enzo Biochem Inc
DMN1SWB DT Small molecular drug
DMN1SWB PC 6475228
DMN1SWB MW 812.3
DMN1SWB FM C48H93NO8
DMN1SWB IC InChI=1S/C48H93NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,41-43,45-48,50-51,53-55H,3-34,36,38-40H2,1-2H3,(H,49,52)/b37-35+/t41-,42+,43+,45+,46-,47+,48+/m0/s1
DMN1SWB CS CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O
DMN1SWB IK POQRWMRXUOPCLD-GZXCKHLVSA-N
DMN1SWB IU N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide
DMN1SWB CB CHEBI:84744
DMN1SWB DE Crohn disease
DML7WP0 ID DML7WP0
DML7WP0 DN Eldacimibe
DML7WP0 HS Phase 2
DML7WP0 SN ACA-147; WAY-ACA-147
DML7WP0 CP Wyeth
DML7WP0 DT Small molecular drug
DML7WP0 PC 170321
DML7WP0 MW 634.9
DML7WP0 FM C39H58N2O5
DML7WP0 IC InChI=1S/C39H58N2O5/c1-13-14-15-16-21-41(25-27-19-17-26(18-20-27)24-36(2,3)4)33(31-34(43)45-39(11,12)46-35(31)44)40-28-22-29(37(5,6)7)32(42)30(23-28)38(8,9)10/h17-20,22-23,40,42H,13-16,21,24-25H2,1-12H3
DML7WP0 CS CCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=C2C(=O)OC(OC2=O)(C)C)NC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C
DML7WP0 IK HGLFNRGXRCKGSW-UHFFFAOYSA-N
DML7WP0 IU 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione
DML7WP0 CA CAS 141993-70-6
DML7WP0 DE Hyperlipidaemia
DMCSXI4 ID DMCSXI4
DMCSXI4 DN Elezanumab
DMCSXI4 HS Phase 2
DMCSXI4 CP AbbVie
DMCSXI4 DT Antibody
DMCSXI4 DE Multiple sclerosis; Spinal cord injury
DMIOGZM ID DMIOGZM
DMIOGZM DN ELIPRODIL
DMIOGZM HS Phase 2
DMIOGZM SN Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM DT Small molecular drug
DMIOGZM PC 60703
DMIOGZM MW 347.9
DMIOGZM FM C20H23ClFNO
DMIOGZM IC InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
DMIOGZM CS C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O
DMIOGZM IK GGUSQTSTQSHJAH-UHFFFAOYSA-N
DMIOGZM IU 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM CA CAS 119431-25-3
DMIOGZM CB CHEBI:91784
DMIOGZM DE Multiple sclerosis
DMB38KH ID DMB38KH
DMB38KH DN Elisidepsin
DMB38KH HS Phase 2
DMB38KH SN Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
DMB38KH CP PharmaMar SA
DMB38KH PC 9855343
DMB38KH MW 1477.9
DMB38KH FM C75H124N14O16
DMB38KH IC InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1
DMB38KH CS CC[C@H](C)CCC(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]2[C@H](OC(=O)[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)[C@@H](C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C
DMB38KH IK ZNVCPJPCKSJWDH-UCTDCHLSSA-N
DMB38KH IU (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2R)-3-methyl-2-[[(4S)-4-methylhexanoyl]amino]butanoyl]amino]butanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxamide
DMB38KH CB CHEBI:83152
DMB38KH DE Psoriasis vulgaris
DMR50I7 ID DMR50I7
DMR50I7 DN Elsamitrucin
DMR50I7 HS Phase 2
DMR50I7 SN Elsamicin; Elsamitrucina; Elsamitrucine; Elsamitrucinum; Chartreusin analog; Elsamicin A; Antibiotic BBM 2478A; BBM 2478A; BMY 28090; SPI 28090; BBM-2478A; BMS-181171; BMY-28090; BU-2478A; Elsamitrucin [USAN:INN]; Elsamitrucina [INN-Spanish]; Elsamitrucine [INN-French]; Elsamitrucinum [INN-Latin]; E-87/025; 10-O-Elsaminosylelsarosylchartarin; 2-Amino-2,6-dideoxy-3-O-methyl-D-galactose
DMR50I7 CP Spectrum
DMR50I7 DT Small molecular drug
DMR50I7 PC 5362259
DMR50I7 MW 653.6
DMR50I7 FM C33H35NO13
DMR50I7 IC InChI=1S/C33H35NO13/c1-11-9-10-16-19-17(11)29(38)46-25-18-14(24(36)21(20(19)25)30(39)44-16)7-6-8-15(18)45-32-28(33(4,40)27(37)13(3)43-32)47-31-22(34)26(41-5)23(35)12(2)42-31/h6-10,12-13,22-23,26-28,31-32,35-37,40H,34H2,1-5H3/t12-,13-,22-,23+,26-,27+,28+,31-,32+,33+/m1/s1
DMR50I7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](O[C@@H]([C@@H]([C@]2(C)O)O)C)OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=O)C6=C4O)N)OC)O
DMR50I7 IK MGQRRMONVLMKJL-KWJIQSIXSA-N
DMR50I7 IU 3-[(2S,3R,4S,5S,6R)-3-[(2R,3R,4R,5S,6R)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione
DMR50I7 CA CAS 97068-30-9
DMR50I7 DE Solid tumour/cancer
DMB7CPG ID DMB7CPG
DMB7CPG DN Elsiglutide
DMB7CPG HS Phase 2
DMB7CPG SN Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma
DMB7CPG CP Zealand Pharma A/S
DMB7CPG DE Diarrhea
DMYOUB6 ID DMYOUB6
DMYOUB6 DN EMA-401
DMYOUB6 HS Phase 2
DMYOUB6 SN Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex
DMYOUB6 CP Spinifex pharmaceuticals
DMYOUB6 DT Small molecular drug
DMYOUB6 PC 9937291
DMYOUB6 MW 507.6
DMYOUB6 FM C32H29NO5
DMYOUB6 IC InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
DMYOUB6 CS COC1=C(C2=C(CN([C@@H](C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5
DMYOUB6 IK GHBCIXGRCZIPNQ-MHZLTWQESA-N
DMYOUB6 IU (3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMYOUB6 CA CAS 1316755-16-4
DMYOUB6 DE Postherpetic neuralgia; Peripheral neuropathy
DMCLT2F ID DMCLT2F
DMCLT2F DN Emepepimut-S
DMCLT2F HS Phase 2
DMCLT2F CP EMD Serono; Oncothyreon
DMCLT2F DT Vaccine
DMCLT2F DE Non-small-cell lung cancer
DMT4MKF ID DMT4MKF
DMT4MKF DN Emibetuzumab
DMT4MKF HS Phase 2
DMT4MKF CP Eli Lilly Indianapolis, IN
DMT4MKF DE Solid tumour/cancer
DMQH1NV ID DMQH1NV
DMQH1NV DN Emivirine
DMQH1NV HS Phase 2
DMQH1NV SN Emivirine; Coactinon; MKC-442; 149950-60-7; I-EBU; 6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil; 1EtOMe6Bz5i-Pr-U; Emivirine [USAN:INN]; Mkc 442; UNII-X87G8IX72O; 6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL; DRG-0302; CHEMBL35033; X87G8IX72O; CHEBI:44143; 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil; 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione; 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)
DMQH1NV DT Small molecular drug
DMQH1NV PC 65013
DMQH1NV MW 302.37
DMQH1NV FM C17H22N2O3
DMQH1NV IC InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)
DMQH1NV CS CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2
DMQH1NV IK MLILORUFDVLTSP-UHFFFAOYSA-N
DMQH1NV IU 6-benzyl-1-(ethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
DMQH1NV CA CAS 149950-60-7
DMQH1NV CB CHEBI:44143
DMQH1NV DE Human immunodeficiency virus infection
DMDEL3F ID DMDEL3F
DMDEL3F DN EMZ701
DMDEL3F HS Phase 2
DMDEL3F SN Interferon enhancing therapy
DMDEL3F CP Transition Therapeutics
DMDEL3F DE Hepatitis B virus infection
DMGFZOL ID DMGFZOL
DMGFZOL DN Enadoline
DMGFZOL HS Phase 2
DMGFZOL SN ENADOLINE; 124378-77-4; UNII-KJL283326C; CI-977; 2-(Benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]decan-8-yl)acetamide; CHEMBL318859; KJL283326C; CI 977; 4-Benzofuranacetamide, N-methyl-N-((5R,7S,8S)-7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-; [3H]enadoline; Enadoline [INN]; [3H]-enadoline; C24H32N2O3; 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[45]decan-8-yl]acetamide; [3H]CI977; [3H]CI-977; [3H]-CI977; AC1L1TVT; AC1Q5HUV; DSSTox_CID_27258; DSSTox_RID_82216; Enadoline hydrochloride; PD-129290
DMGFZOL CP Parke-Davis & Co
DMGFZOL DT Small molecular drug
DMGFZOL PC 60768
DMGFZOL MW 396.5
DMGFZOL FM C24H32N2O3
DMGFZOL IC InChI=1S/C24H32N2O3/c1-25(23(27)16-18-6-4-7-22-19(18)9-15-28-22)20-8-11-24(10-5-14-29-24)17-21(20)26-12-2-3-13-26/h4,6-7,9,15,20-21H,2-3,5,8,10-14,16-17H2,1H3/t20-,21-,24-/m0/s1
DMGFZOL CS CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=C5C=COC5=CC=C4
DMGFZOL IK JMBYBVLCYODBJQ-HFMPRLQTSA-N
DMGFZOL IU 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DMGFZOL CA CAS 124378-77-4
DMGFZOL DE Pain
DMM8Z3Q ID DMM8Z3Q
DMM8Z3Q DN Encequidar
DMM8Z3Q HS Phase 2
DMM8Z3Q SN 849675-66-7; HM-30181-A; HM-30181; HM30181; UNII-K4I4I996O4; K4I4I996O4; 849675-66-7 (free base); HM 30181A; N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; HM30181A; Encequidar [USAN]; HM-30181A; Encequidar (USAN/INN); HM-30181 free base; CHEMBL4594298; SCHEMBL13822558; EX-A3429A; BCP25240; MFCD25976625; WHO 10861; ZINC68014383; CS-6194; DB14070; SB18921; 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide; AS-35283; HY-13646; D11782; Q27281950; 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide; 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-; N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q CP Athenex Oncology
DMM8Z3Q DT Small molecular drug
DMM8Z3Q PC 11399764
DMM8Z3Q MW 688.7
DMM8Z3Q FM C38H36N6O7
DMM8Z3Q IC InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)
DMM8Z3Q CS COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC
DMM8Z3Q IK AHJUHHDDCJQACA-UHFFFAOYSA-N
DMM8Z3Q IU N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q CA CAS 849675-66-7
DMM8Z3Q DE Metastatic breast cancer
DM8NLDI ID DM8NLDI
DM8NLDI DN Endostatin
DM8NLDI HS Phase 2
DM8NLDI CP EntreMed
DM8NLDI PC 187888
DM8NLDI MW 178.19
DM8NLDI FM C9H10N2O2
DM8NLDI IC InChI=1S/C9H10N2O2/c1-11(10-13)7-9(12)8-5-3-2-4-6-8/h2-6H,7H2,1H3
DM8NLDI CS CN(CC(=O)C1=CC=CC=C1)N=O
DM8NLDI IK AAFYOVPTFNNVDN-UHFFFAOYSA-N
DM8NLDI IU N-methyl-N-phenacylnitrous amide
DM8NLDI CA CAS 55984-52-6
DM8NLDI DE Solid tumour/cancer
DMTX8IZ ID DMTX8IZ
DMTX8IZ DN Endoxifen
DMTX8IZ HS Phase 2
DMTX8IZ SN Endoxifen (topical formulation, cancer); Endoxifen (topical formulation, cancer), Jina Pharmaceuticals; Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals
DMTX8IZ CP Jina Pharmaceuticals Inc
DMTX8IZ DT Small molecular drug
DMTX8IZ PC 10090750
DMTX8IZ MW 373.5
DMTX8IZ FM C25H27NO2
DMTX8IZ IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMTX8IZ CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3
DMTX8IZ IK MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMTX8IZ IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMTX8IZ CA CAS 112093-28-4
DMTX8IZ CB CHEBI:80555
DMTX8IZ DE Breast cancer
DMMIHSO ID DMMIHSO
DMMIHSO DN ENERGI-F701
DMMIHSO HS Phase 2
DMMIHSO CP Energenesis Biomedical
DMMIHSO DT Small molecular drug
DMMIHSO DE Alopecia
DM96NCR ID DM96NCR
DM96NCR DN Eniluracil
DM96NCR HS Phase 2
DM96NCR SN Eniluracil; 5-ETHYNYLURACIL; 59989-18-3; 5-ethynylpyrimidine-2,4(1H,3H)-dione; Compound 776C; GW776C85; 5-Ethynylpyrimidine-2,4-diol; 776C85; UNII-2E2W0W5XIU; 5-ethynyl-1H-pyrimidine-2,4-dione; 5-Ethynyl-2,4(1H,3H)-pyrimidinedione; 5-Ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-6-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(3H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(1H)-one; 5-Ethynyl-2,4(1H,3H)pyrimidinedione; 2E2W0W5XIU; 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-; CHEMBL355200; C6H4N2O2; Eniluracil [USAN]
DM96NCR CP Adherex Technologies
DM96NCR DT Small molecular drug
DM96NCR PC 43157
DM96NCR MW 136.11
DM96NCR FM C6H4N2O2
DM96NCR IC InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)
DM96NCR CS C#CC1=CNC(=O)NC1=O
DM96NCR IK JOZGNYDSEBIJDH-UHFFFAOYSA-N
DM96NCR IU 5-ethynyl-1H-pyrimidine-2,4-dione
DM96NCR CA CAS 59989-18-3
DM96NCR DE Hyperlipidaemia
DMJZVPB ID DMJZVPB
DMJZVPB DN ENMD-2076
DMJZVPB HS Phase 2
DMJZVPB SN ENMD-2076; 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159
DMJZVPB CP Entremed
DMJZVPB DT Small molecular drug
DMJZVPB PC 16041424
DMJZVPB MW 375.5
DMJZVPB FM C21H25N7
DMJZVPB IC InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
DMJZVPB CS CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C
DMJZVPB IK BLQYVHBZHAISJM-CMDGGOBGSA-N
DMJZVPB IU 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
DMJZVPB CA CAS 934353-76-1
DMJZVPB DE Acute myeloid leukaemia; Fibrolamellar liver cancer; Hepatocellular carcinoma; Triple negative breast cancer
DMDS20X ID DMDS20X
DMDS20X DN Enoblituzumab
DMDS20X HS Phase 2
DMDS20X CP MacroGenics Rockville, MD
DMDS20X DE Solid tumour/cancer; Prostate cancer
DMLPRZJ ID DMLPRZJ
DMLPRZJ DN Ensaculin hydrochloride
DMLPRZJ HS Phase 2
DMLPRZJ SN Anseculin hydrochloride; Ensaculin hydrochloride; KA-672.HCl; 7-Methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-one hydrochloride
DMLPRZJ DT Small molecular drug
DMLPRZJ PC 6918282
DMLPRZJ MW 489
DMLPRZJ FM C26H33ClN2O5
DMLPRZJ IC InChI=1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H
DMLPRZJ CS CC1=C(C(=O)OC2=CC(=C(C=C12)OCCCN3CCN(CC3)C4=CC=CC=C4OC)OC)C.Cl
DMLPRZJ IK XMONKHCPLIYQCY-UHFFFAOYSA-N
DMLPRZJ IU 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;hydrochloride
DMLPRZJ DE Parkinson disease
DM69NF1 ID DM69NF1
DM69NF1 DN EP-101
DM69NF1 HS Phase 2
DM69NF1 SN 106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; EP-101; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409
DM69NF1 CP Elevation Pharmaceuticals
DM69NF1 DT Small molecular drug
DM69NF1 PC 7832
DM69NF1 MW 124.18
DM69NF1 FM C8H12O
DM69NF1 IC InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2
DM69NF1 CS C=CC1CCC2C(C1)O2
DM69NF1 IK SLJFKNONPLNAPF-UHFFFAOYSA-N
DM69NF1 IU 3-ethenyl-7-oxabicyclo[4.1.0]heptane
DM69NF1 CA CAS 106-86-5
DM69NF1 DE Chronic obstructive pulmonary disease; Breast cancer
DMPC4EK ID DMPC4EK
DMPC4EK DN EP-217609
DMPC4EK HS Phase 2
DMPC4EK SN Neutralizable NAPAP analog (thrombosis), Endotis; Neutralizable NAPAP analog (thrombosis), Organon; Fondaparinux analog + thrombin inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Organon
DMPC4EK CP Organon BioSciences
DMPC4EK PC 11686894
DMPC4EK MW 2647.8
DMPC4EK FM C95H151N11O59S8
DMPC4EK IC InChI=1S/C95H151N11O59S8/c1-48-41-57(138-4)49(2)50(3)83(48)167(118,119)105-54(86(111)102-55(87(112)106-32-18-13-19-33-106)42-51-25-27-52(28-26-51)84(96)97)43-64(109)99-30-20-24-63(108)101-53(21-16-17-29-98-62(107)23-15-14-22-61-65-56(47-166-61)103-95(117)104-65)85(110)100-31-34-147-35-36-148-37-38-149-39-40-150-66-58(44-151-168(120,121)122)155-91(78(143-9)69(66)139-5)159-73-71(141-7)80(145-11)93(162-76(73)88(113)114)158-68-60(46-153-170(126,127)128)156-94(82(165-173(135,136)137)75(68)163-171(129,130)131)160-74-72(142-8)79(144-10)92(161-77(74)89(115)116)157-67-59(45-152-169(123,124)125)154-90(146-12)81(70(67)140-6)164-172(132,133)134/h25-28,41,53-56,58-61,65-82,90-94,105H,13-24,29-40,42-47H2,1-12H3,(H3,96,97)(H,98,107)(H,99,109)(H,100,110)(H,101,108)(H,102,111)(H,113,114)(H,115,116)(H2,103,104,117)(H,120,121,122)(H,123,124,125)(H,126,127,128)(H,129,130,131)(H,132,133,134)(H,135,136,137)/t53-,54-,55+,56-,58+,59+,60+,61-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,76-,77+,78+,79+,80+,81+,82+,90-,91+,92+,93+,94+/m0/s1
DMPC4EK CS CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@H]2[C@@H]3[C@H](CS2)NC(=O)N3)C(=O)NCCOCCOCCOCCO[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]7[C@@H]([C@H]([C@@H](O[C@H]7C(=O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC9=CC=C(C=C9)C(=N)N)C(=O)N1CCCCC1)C)C)OC
DMPC4EK IK QIBHGITUGYXJDF-UDLCEBFESA-N
DMPC4EK IU (2S,3S,4S,5R,6R)-3-[(2R,3R,4S,5R,6R)-5-[2-[2-[2-[2-[[(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[4-[[(3S)-4-[[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-4-oxobutanoyl]amino]butanoylamino]hexanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3,4-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-6-[(2R,3R,4S,5R,6S)-4,6-dimethoxy-5-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid
DMPC4EK CA CAS 894494-99-6
DMPC4EK DE Thrombosis
DMZT7EP ID DMZT7EP
DMZT7EP DN EPI 589
DMZT7EP HS Phase 2
DMZT7EP SN (R)-troloxamide quinone; EPI-589
DMZT7EP CP BioElectron Technology Mountain View, CA Sumitomo Dainippon Pharma Osaka, Japan
DMZT7EP DE Amyotrophic lateral sclerosis; Parkinson disease
DMWK26Q ID DMWK26Q
DMWK26Q DN EPX-200
DMWK26Q HS Phase 2
DMWK26Q CP Epygenix Therapeutics Paramus, NJ
DMWK26Q DE Dravet syndrome
DMUXDGZ ID DMUXDGZ
DMUXDGZ DN EPX-300
DMUXDGZ HS Phase 2
DMUXDGZ CP Epygenix Therapeutics Paramus, NJ
DMD4YRG ID DMD4YRG
DMD4YRG DN EQ-917
DMD4YRG HS Phase 2
DMD4YRG CP Equispharm Co Ltd
DMD4YRG DE Solid tumour/cancer
DMCEPUA ID DMCEPUA
DMCEPUA DN ERB-041
DMCEPUA HS Phase 2
DMCEPUA SN 2-(3-Fluoro-4-hydroxyphenyl)-7-vinylbenzoxazol-5-ol
DMCEPUA DT Small molecular drug
DMCEPUA PC 656954
DMCEPUA MW 271.24
DMCEPUA FM C15H10FNO3
DMCEPUA IC InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
DMCEPUA CS C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC(=C(C=C3)O)F
DMCEPUA IK MQIMZDXIAHJKQP-UHFFFAOYSA-N
DMCEPUA IU 7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMCEPUA CA CAS 524684-52-4
DMCEPUA DE Inflammatory bowel disease
DMU1XZD ID DMU1XZD
DMU1XZD DN Erteberel
DMU1XZD HS Phase 2
DMU1XZD SN LY-500307; SERBA-1; ER beta agonist (BPH), Lilly; Lead estrogen receptor beta agonists (benign prostatic hyperplasia),Eli Lilly
DMU1XZD CP Eli Lilly & Co
DMU1XZD DT Small molecular drug
DMU1XZD PC 10286159
DMU1XZD MW 282.3
DMU1XZD FM C18H18O3
DMU1XZD IC InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1
DMU1XZD CS C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O
DMU1XZD IK XIESSJVMWNJCGZ-VKJFTORMSA-N
DMU1XZD IU (3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
DMU1XZD CA CAS 533884-09-2
DMU1XZD DE Prostate hyperplasia
DM5Z3VP ID DM5Z3VP
DM5Z3VP DN Ertumaxomab
DM5Z3VP HS Phase 2
DM5Z3VP SN Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
DM5Z3VP CP Trion
DM5Z3VP DT Antibody
DM5Z3VP DE Breast cancer
DMYZWDC ID DMYZWDC
DMYZWDC DN ESBA-105
DMYZWDC HS Phase 2
DMYZWDC SN ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech
DMYZWDC CP ESBATech AG
DMYZWDC DT Antibody
DMYZWDC DE Ocular disease
DMTB63Q ID DMTB63Q
DMTB63Q DN Estetrol
DMTB63Q HS Phase 2
DMTB63Q SN Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer); Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer), Pantarhei; Estrogen receptor modulator (oral, contraception/hormone deficiency/autoimmune disease/breast cancer/prostate cancer/osteoporosis/cardiovascular disease), Pantarhei
DMTB63Q CP Pantarhei Bioscience BV
DMTB63Q DT Small molecular drug
DMTB63Q PC 27125
DMTB63Q MW 304.4
DMTB63Q FM C18H24O4
DMTB63Q IC InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1
DMTB63Q CS C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O
DMTB63Q IK AJIPIJNNOJSSQC-NYLIRDPKSA-N
DMTB63Q IU (8R,9S,13S,14S,15R,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,15,16,17-tetrol
DMTB63Q CA CAS 15183-37-6
DMTB63Q CB CHEBI:142773
DMTB63Q DE Autoimmune diabetes
DM71BZV ID DM71BZV
DM71BZV DN Etamicastat
DM71BZV HS Phase 2
DM71BZV SN BIA-5453; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), BIAL; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), Portela
DM71BZV CP Portela & Ca SA
DM71BZV DT Small molecular drug
DM71BZV PC 10450387
DM71BZV MW 311.35
DM71BZV FM C14H15F2N3OS
DM71BZV IC InChI=1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1
DM71BZV CS C1[C@H](COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCN
DM71BZV IK CWWWTTYMUOYSQA-LLVKDONJSA-N
DM71BZV IU 4-(2-aminoethyl)-3-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1H-imidazole-2-thione
DM71BZV CA CAS 760173-05-5
DM71BZV DE Heart failure
DMOCID7 ID DMOCID7
DMOCID7 DN Etazolate
DMOCID7 HS Phase 2
DMOCID7 SN Etazolate hydrochloride; EHT-0202; SQ-20009
DMOCID7 CP Exonhit
DMOCID7 DT Small molecular drug
DMOCID7 PC 3277
DMOCID7 MW 289.33
DMOCID7 FM C14H19N5O2
DMOCID7 IC InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18)
DMOCID7 CS CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC
DMOCID7 IK OPQRBXUBWHDHPQ-UHFFFAOYSA-N
DMOCID7 IU ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate
DMOCID7 CA CAS 51022-77-6
DMOCID7 CB CHEBI:93135
DMOCID7 DE Neurodegenerative disorder
DM68K39 ID DM68K39
DM68K39 DN ETIPREDNOL DICLOACETATE
DM68K39 HS Phase 2
DM68K39 SN BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester
DM68K39 CP Teva Pharmaceutical USA
DM68K39 DT Small molecular drug
DM68K39 PC 9935073
DM68K39 MW 485.4
DM68K39 FM C24H30Cl2O6
DM68K39 IC InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1
DM68K39 CS CCOC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)C(Cl)Cl
DM68K39 IK QAIOVDNCIZSSSF-RFAJLIJZSA-N
DM68K39 IU ethyl (8S,9S,10R,11S,13S,14S,17R)-17-(2,2-dichloroacetyl)oxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM68K39 CA CAS 199331-40-3
DM68K39 CB CHEBI:135783
DM68K39 DE Rhinitis
DMV96BY ID DMV96BY
DMV96BY DN ETS-6218
DMV96BY HS Phase 2
DMV96BY SN Antihistamine+antiviral (fibromyalgia), e-Therapeutics
DMV96BY CP E-Therapeutics Ltd
DMV96BY DE Fibromyalgia
DMZOA2L ID DMZOA2L
DMZOA2L DN ETX-9101
DMZOA2L HS Phase 2
DMZOA2L CP E-Therapeutics Ltd
DMZOA2L DE Asthma
DM1FCDH ID DM1FCDH
DM1FCDH DN EV-077
DM1FCDH HS Phase 2
DM1FCDH SN EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
DM1FCDH CP Evolva SA
DM1FCDH DE Type-2 diabetes
DMWB94K ID DMWB94K
DMWB94K DN Evenamide
DMWB94K HS Phase 2
DMWB94K SN 1092977-61-1; 2-((3-Butoxyphenethyl)amino)-N,N-dimethylacetamide; UNII-ON5S6N53JS; ON5S6N53JS; MFCD28502433; 2-[(3-Butoxyphenethyl)amino]-N,N-dimethylacetamide; Evenamide [INN]; SCHEMBL3025285; CHEMBL3678076; 2-((2-(3-Butoxyphenyl)ethyl)amino)-N,N-dimethylacetamide; Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-N,N-dimethyl-; BDBM161090; NW-3509; SB18910; AS-48527; HY-17612; SY244487; CS-0014697; Q21098995; 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide; US9051240, 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide
DMWB94K CP Newron Pharmaceuticals
DMWB94K DT Small molecular drug
DMWB94K PC 25105689
DMWB94K MW 278.39
DMWB94K FM C16H26N2O2
DMWB94K IC InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
DMWB94K CS CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
DMWB94K IK GRHBODILPPXVKN-UHFFFAOYSA-N
DMWB94K IU 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
DMWB94K CA CAS 1092977-61-1
DMWB94K DE Schizophrenia
DM8QXEY ID DM8QXEY
DM8QXEY DN Evt201
DM8QXEY HS Phase 2
DM8QXEY CP Evotec
DM8QXEY DT Small molecular drug
DM8QXEY DE Sleep-wake disorder
DMQGBM1 ID DMQGBM1
DMQGBM1 DN EVT-201
DMQGBM1 HS Phase 2
DMQGBM1 SN IDDBCP221837
DMQGBM1 CP Roche Holding AG
DMQGBM1 PC 9885841
DMQGBM1 MW 372.8
DMQGBM1 FM C17H17ClN6O2
DMQGBM1 IC InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
DMQGBM1 CS CN1CC2=C(N=CN2C3=C(C1=O)C(=CC=C3)Cl)C4=NOC(=N4)CN(C)C
DMQGBM1 IK JCYLWUVDHLVGER-UHFFFAOYSA-N
DMQGBM1 IU 7-chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMQGBM1 CA CAS 308239-86-3
DMQGBM1 DE Insomnia
DM73XNG ID DM73XNG
DM73XNG DN EVT302
DM73XNG HS Phase 2
DM73XNG CP Evotec Princeton, NJ
DM73XNG DE Alzheimer disease
DM4FBUH ID DM4FBUH
DM4FBUH DN EXC 001
DM4FBUH HS Phase 2
DM4FBUH CP ISIS Pharm; Excaliard
DM4FBUH DT Antisense drug
DM4FBUH DE Fibrosis
DMC1I56 ID DMC1I56
DMC1I56 DN Exherin
DMC1I56 HS Phase 2
DMC1I56 SN Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541
DMC1I56 CP Adherex Technol.
DMC1I56 TC Anticancer Agents
DMC1I56 DT Small molecular drug
DMC1I56 PC 9916058
DMC1I56 MW 570.7
DMC1I56 FM C22H34N8O6S2
DMC1I56 IC InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1
DMC1I56 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C
DMC1I56 IK FQVLRGLGWNWPSS-BXBUPLCLSA-N
DMC1I56 IU (4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMC1I56 CA CAS 229971-81-7
DMC1I56 DE Solid tumour/cancer
DM5PBLM ID DM5PBLM
DM5PBLM DN EYP001
DM5PBLM HS Phase 2
DM5PBLM SN Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM CP ENYO Pharma
DM5PBLM DT Small molecular drug
DM5PBLM PC 67202717
DM5PBLM MW 489.8
DM5PBLM FM C19H15Cl3N2O5S
DM5PBLM IC InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
DM5PBLM CS C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl
DM5PBLM IK XLGQSYUNOIJBNR-UHFFFAOYSA-N
DM5PBLM IU 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM CA CAS 1192171-69-9
DM5PBLM DE Non-alcoholic steatohepatitis
DM2L9CO ID DM2L9CO
DM2L9CO DN Ezatiostat
DM2L9CO HS Phase 2
DM2L9CO SN Telintra (TN)
DM2L9CO CP Telik
DM2L9CO DT Small molecular drug
DM2L9CO PC 5310939
DM2L9CO MW 529.6
DM2L9CO FM C27H35N3O6S
DM2L9CO IC InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1
DM2L9CO CS CCOC(=O)[C@H](CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@H](C2=CC=CC=C2)C(=O)OCC)N
DM2L9CO IK GWEJFLVSOGNLSS-WPFOTENUSA-N
DM2L9CO IU ethyl (2S)-2-amino-5-[[(2R)-3-benzylsulfanyl-1-[[(1R)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate
DM2L9CO CA CAS 168682-53-9
DM2L9CO DE Myelodysplastic syndrome
DMJ4BKT ID DMJ4BKT
DMJ4BKT DN F-16-IL-2 fusion protein
DMJ4BKT HS Phase 2
DMJ4BKT SN Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen
DMJ4BKT CP Philogen SpA
DMJ4BKT DE Solid tumour/cancer
DMKP3SJ ID DMKP3SJ
DMKP3SJ DN F-351
DMKP3SJ HS Phase 2
DMKP3SJ SN Liver cirrhosis, Gene Networks International; Liver cirrhosis, Shanghai; Liver fibrosis therapy, Shanghai Genomics; Liver fibrosis, Gene Networks International; Liver fibrosis, Shanghai
DMKP3SJ CP GNI Ltd
DMKP3SJ DT Small molecular drug
DMKP3SJ PC 11217901
DMKP3SJ MW 201.22
DMKP3SJ FM C12H11NO2
DMKP3SJ IC InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3
DMKP3SJ CS CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O
DMKP3SJ IK NETTXQJYJRFTFS-UHFFFAOYSA-N
DMKP3SJ IU 1-(4-hydroxyphenyl)-5-methylpyridin-2-one
DMKP3SJ CA CAS 851518-71-3
DMKP3SJ DE Liver disease
DM6UQNW ID DM6UQNW
DM6UQNW DN F4co vaccine
DM6UQNW HS Phase 2
DM6UQNW SN F4co vaccine (AIDS/HIV infection)
DM6UQNW CP GlaxoSmithKline plc
DM6UQNW DT Vaccine
DM6UQNW DE Human immunodeficiency virus infection
DMDNJ18 ID DMDNJ18
DMDNJ18 DN F-627
DMDNJ18 HS Phase 2
DMDNJ18 SN Recombinant human G-CSF dimer (neutropenia), Generon (Shanghai) Corporation Ltd
DMDNJ18 CP Generon
DMDNJ18 DE Neutropenia
DMBFPO1 ID DMBFPO1
DMBFPO1 DN F-8-IL-10 fusion protein
DMBFPO1 HS Phase 2
DMBFPO1 SN Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
DMBFPO1 CP Pfizer
DMBFPO1 DE Endometriosis; Inflammatory bowel disease; Rheumatoid arthritis
DM2CUS0 ID DM2CUS0
DM2CUS0 DN F901318
DM2CUS0 HS Phase 2
DM2CUS0 SN Olorofim; F-901318; UNII-T34SH2H9HI; T34SH2H9HI; 1928707-56-5; 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide; CHEMBL4297609; SCHEMBL17767345; BCP25872; BDBM50526857; DB15245; SB19827; F901318; F 901318; Olorofim; HY-104029; CS-0025660; Q27896127; CN1C(=C(C=C1C)C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C=N1)F)=O; 1H-Pyrrole-2-acetamide, N-(4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)phenyl)-1,5-dimethyl-alpha-oxo-3-phenyl-; 2-(1,5-Dimethyl-3-phenyl-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxo-acetamide
DM2CUS0 CP F2G
DM2CUS0 DT Small molecular drug
DM2CUS0 PC 91885568
DM2CUS0 MW 498.6
DM2CUS0 FM C28H27FN6O2
DM2CUS0 IC InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37)
DM2CUS0 CS CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5
DM2CUS0 IK SUFPWYYDCOKDLL-UHFFFAOYSA-N
DM2CUS0 IU 2-(1,5-dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide
DM2CUS0 CA CAS 1928707-56-5
DM2CUS0 DE Fungal infection
DMXB6KG ID DMXB6KG
DMXB6KG DN FAD-104
DMXB6KG HS Phase 2
DMXB6KG SN ME-2303; (8S,10S)-8-(6-Carboxyhexanoyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone-14-O-hemipimelate; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)pimelyladryamycinone
DMXB6KG DT Small molecular drug
DMXB6KG PC 115362
DMXB6KG MW 704.6
DMXB6KG FM C34H37FO15
DMXB6KG IC InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1
DMXB6KG CS C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O
DMXB6KG IK PQMIPLRIRFVQJZ-QBYYVRQOSA-N
DMXB6KG IU 7-[2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethoxy]-7-oxoheptanoic acid
DMXB6KG CA CAS 116521-53-0
DMXB6KG DE Solid tumour/cancer
DM6RKG3 ID DM6RKG3
DM6RKG3 DN Fadolmidine
DM6RKG3 HS Phase 2
DM6RKG3 SN Fadolmidine hydrochloride; MPV-2426
DM6RKG3 CP Orion Corp
DM6RKG3 DT Small molecular drug
DM6RKG3 PC 6433098
DM6RKG3 MW 214.26
DM6RKG3 FM C13H14N2O
DM6RKG3 IC InChI=1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15)
DM6RKG3 CS C1CC2=C(C1CC3=CN=CN3)C=C(C=C2)O
DM6RKG3 IK VTZPAJGVRWKMAG-UHFFFAOYSA-N
DM6RKG3 IU 3-(1H-imidazol-5-ylmethyl)-2,3-dihydro-1H-inden-5-ol
DM6RKG3 CA CAS 189353-31-9
DM6RKG3 DE Pain; Neuropathic pain
DMSFWT7 ID DMSFWT7
DMSFWT7 DN Famitinib
DMSFWT7 HS Phase 2
DMSFWT7 SN Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui
DMSFWT7 CP Shanghai Hengrui Pharmaceutical Co Ltd; Jiangsu Hengrui Medicine Co Ltd
DMSFWT7 DT Small molecular drug
DMSFWT7 PC 16662431
DMSFWT7 MW 410.5
DMSFWT7 FM C23H27FN4O2
DMSFWT7 IC InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
DMSFWT7 CS CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O)C
DMSFWT7 IK GKEYKDOLBLYGRB-LGMDPLHJSA-N
DMSFWT7 IU 5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one
DMSFWT7 CA CAS 945380-27-8
DMSFWT7 DE Solid tumour/cancer
DM563NC ID DM563NC
DM563NC DN Fasitibant chloride
DM563NC HS Phase 2
DM563NC SN MEN-16132; Bradykinin B2 antagonist (inflammation), Menarini; MEN-11270 analogs, Menarini
DM563NC CP The Menarini Group
DM563NC DT Small molecular drug
DM563NC PC 11535140
DM563NC MW 800.2
DM563NC FM C36H49Cl3N6O6S
DM563NC IC InChI=1S/C36H49Cl2N6O6S.ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;1H/q+1;/p-1/t29-;/m0./s1
DM563NC CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@H](CCC[N+](C)(C)C)N)Cl)C.[Cl-]
DM563NC IK ZNHJDJYKDVGQSH-JMAPEOGHSA-M
DM563NC IU [(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium;chloride
DM563NC DE Osteoarthritis
DMR3952 ID DMR3952
DMR3952 DN FBS-0701
DMR3952 HS Phase 2
DMR3952 SN Desferrithiocin analog (oral, iron overload), FerroKin Biosciences; Iron chelator (oral, iron overload), FerroKin Biosciences
DMR3952 CP FerroKin BioSciences Inc
DMR3952 DT Small molecular drug
DMR3952 PC 135565672
DMR3952 MW 399.5
DMR3952 FM C18H25NO7S
DMR3952 IC InChI=1S/C18H25NO7S/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2/h3-5,20H,6-12H2,1-2H3,(H,21,22)/t18-/m1/s1
DMR3952 CS C[C@@]1(CSC(=N1)C2=C(C(=CC=C2)OCCOCCOCCOC)O)C(=O)O
DMR3952 IK AWHIMFSHNAAMBM-GOSISDBHSA-N
DMR3952 IU (4S)-2-[2-hydroxy-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid
DMR3952 CA CAS 945635-15-4
DMR3952 DE Iron overload disease
DM3CVHQ ID DM3CVHQ
DM3CVHQ DN FE-202158
DM3CVHQ HS Phase 2
DM3CVHQ SN V1a agonist (septic shock), Ferring; Vasopressin 1a agonist (septic shock), Ferring
DM3CVHQ CP Ferring Pharmaceuticals Inc
DM3CVHQ PC 53330936
DM3CVHQ MW 1048.3
DM3CVHQ FM C46H73N13O11S2
DM3CVHQ IC InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1
DM3CVHQ CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N
DM3CVHQ IK JCVQBJTWWDYUFQ-MRUTUVJXSA-N
DM3CVHQ IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-5-(propan-2-ylamino)pentan-2-yl]pyrrolidine-2-carboxamide
DM3CVHQ CA CAS 876296-47-8
DM3CVHQ DE Sepsis
DMDGZ1C ID DMDGZ1C
DMDGZ1C DN FE-202767
DMDGZ1C HS Phase 2
DMDGZ1C SN Oxytocin agonists (erectile dysfunction), Ferring
DMDGZ1C CP Ferring Pharmaceuticals Inc
DMDGZ1C PC 102341060
DMDGZ1C MW 1042.2
DMDGZ1C FM C48H68FN11O12S
DMDGZ1C IC InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27?,32-,33-,34-,35-,36-,42-/m0/s1
DMDGZ1C CS CCC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N(CC3=CC=C(C=C3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDGZ1C IK PVVHQWISMVJHFK-JWKDVPIGSA-N
DMDGZ1C IU (3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-butan-2-yl-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
DMDGZ1C DE Erectile dysfunction
DMICMXE ID DMICMXE
DMICMXE DN Ferroquine
DMICMXE HS Phase 2
DMICMXE SN Ferroquine; UNII-8D81JS19ET; 8D81JS19ET; SSR97193; Ferroquine [INN]; 185055-67-8
DMICMXE CP Sanofi
DMICMXE DT Small molecular drug
DMICMXE PC 56841801
DMICMXE MW 433.8
DMICMXE FM C23H24ClFeN3
DMICMXE IC InChI=1S/C18H19ClN3.C5H5.Fe/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18;1-2-4-5-3-1;/h4,6-10H,5,11-12H2,1-2H3,(H,20,21);1-3H,4H2;/q2*-1;+2
DMICMXE CS CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2]
DMICMXE IK DLYPREQTTOHKSM-UHFFFAOYSA-N
DMICMXE IU 7-chloro-N-[[2-[(dimethylamino)methyl]cyclopenta-1,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+)
DMICMXE CA CAS 185055-67-8
DMICMXE DE Malaria
DMJX2P4 ID DMJX2P4
DMJX2P4 DN Fezakinumab
DMJX2P4 HS Phase 2
DMJX2P4 SN Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
DMJX2P4 CP Wyeth; pfizer
DMJX2P4 DT Antibody
DMJX2P4 DE Psoriasis vulgaris
DM7RYL4 ID DM7RYL4
DM7RYL4 DN FG-2216
DM7RYL4 HS Phase 2
DM7RYL4 PC 6914666
DM7RYL4 MW 280.66
DM7RYL4 FM C12H9ClN2O4
DM7RYL4 IC InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17)
DM7RYL4 CS C1=CC=C2C(=C1)C(=C(N=C2Cl)C(=O)NCC(=O)O)O
DM7RYL4 IK OUQVKRKGTAUJQA-UHFFFAOYSA-N
DM7RYL4 IU 2-[(1-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid
DM7RYL4 CA CAS 223387-75-5
DM7RYL4 DE Kidney disease
DMXMC8I ID DMXMC8I
DMXMC8I DN FGF-1
DMXMC8I HS Phase 2
DMXMC8I CP CardioVascular BioTherape.
DMXMC8I DE Coronary heart disease
DMCIGRB ID DMCIGRB
DMCIGRB DN Fialuridine
DMCIGRB HS Phase 2
DMCIGRB SN FIAU
DMCIGRB CP Oclassen Pharmaceuticals Inc
DMCIGRB DT Small molecular drug
DMCIGRB PC 50313
DMCIGRB MW 372.09
DMCIGRB FM C9H10FIN2O5
DMCIGRB IC InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1
DMCIGRB CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I
DMCIGRB IK IPVFGAYTKQKGBM-BYPJNBLXSA-N
DMCIGRB IU 1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMCIGRB CA CAS 69123-98-4
DMCIGRB DE Hepatitis B virus infection
DMG65WH ID DMG65WH
DMG65WH DN Ficlatuzumab
DMG65WH HS Phase 2
DMG65WH SN AV-299
DMG65WH CP AVEO Pharmaceuticals
DMG65WH DT Monoclonal antibody
DMG65WH DE Non-small-cell lung cancer; Multiple myeloma; Acute myeloid leukaemia; Pancreatic cancer; Squamous cell carcinoma
DMNSYXB ID DMNSYXB
DMNSYXB DN Filibuvir
DMNSYXB HS Phase 2
DMNSYXB SN Filibuvir; 877130-28-4; PF-00868554; UNII-198J479Y2L; 198J479Y2L; (6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; Filibuvir [USAN:INN]; 3frz
DMNSYXB CP Pfizer
DMNSYXB DT Small molecular drug
DMNSYXB PC 54708673
DMNSYXB MW 503.6
DMNSYXB FM C29H37N5O3
DMNSYXB IC InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1
DMNSYXB CS CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5
DMNSYXB IK SLVAPEZTBDBAPI-GDLZYMKVSA-N
DMNSYXB IU (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one
DMNSYXB CA CAS 877130-28-4
DMNSYXB DE Hepatitis C virus infection
DMG439E ID DMG439E
DMG439E DN Fipamezole
DMG439E HS Phase 2
DMG439E SN Fipamezole; 150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole
DMG439E DT Small molecular drug
DMG439E PC 213041
DMG439E MW 230.28
DMG439E FM C14H15FN2
DMG439E IC InChI=1S/C14H15FN2/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14/h3-5,8-9H,2,6-7H2,1H3,(H,16,17)
DMG439E CS CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3
DMG439E IK KXSUAWAUCNFBQJ-UHFFFAOYSA-N
DMG439E IU 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole
DMG439E CA CAS 150586-58-6
DMG439E DE Acute myeloid leukaemia
DMW2QYT ID DMW2QYT
DMW2QYT DN Firategrast
DMW2QYT HS Phase 2
DMW2QYT SN SB 683699; Firategrast (USAN); SB-683699; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid
DMW2QYT CP GSK
DMW2QYT DT Small molecular drug
DMW2QYT PC 9935681
DMW2QYT MW 499.5
DMW2QYT FM C27H27F2NO6
DMW2QYT IC InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
DMW2QYT CS CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC
DMW2QYT IK YLFZHHDVRSYTKT-NRFANRHFSA-N
DMW2QYT IU (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid
DMW2QYT CA CAS 402567-16-2
DMW2QYT DE Multiple sclerosis
DMJSD5W ID DMJSD5W
DMJSD5W DN FK-070
DMJSD5W HS Phase 2
DMJSD5W SN KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride
DMJSD5W DT Small molecular drug
DMJSD5W PC 6442424
DMJSD5W MW 500.4
DMJSD5W FM C22H27Cl2N3O4S
DMJSD5W IC InChI=1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1
DMJSD5W CS C1[C@H](CN([C@@H]1/C=C\\CCCC(=O)O)CC2=CN=CC=C2)NS(=O)(=O)C3=CC=C(C=C3)Cl.Cl
DMJSD5W IK JGCFJVFIRFTRKJ-YOLZMAEBSA-N
DMJSD5W IU (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid;hydrochloride
DMJSD5W CA CAS 130047-30-2
DMJSD5W DE Angina pectoris
DMEL15U ID DMEL15U
DMEL15U DN FK-143
DMEL15U HS Phase 2
DMEL15U SN FK-143; Fk 143; CHEMBL25083; 163136-03-6; 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; 4-[3-[3-(bis[4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; SCHEMBL3504489; AC1L435G; CTK0H5706; DTXSID80167524; LACIBZRFAYFTOV-UHFFFAOYSA-N; BDBM50057477; 1H-Indole-1-butanoicacid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-; 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U DT Small molecular drug
DMEL15U PC 178077
DMEL15U MW 600.8
DMEL15U FM C40H44N2O3
DMEL15U IC InChI=1S/C40H44N2O3/c1-27(2)23-29-14-18-31(19-15-29)39(32-20-16-30(17-21-32)24-28(3)4)41-34-10-7-9-33(25-34)40(45)36-26-42(22-8-13-38(43)44)37-12-6-5-11-35(36)37/h5-7,9-12,14-21,25-28,39,41H,8,13,22-24H2,1-4H3,(H,43,44)
DMEL15U CS CC(C)CC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC(C)C)NC3=CC=CC(=C3)C(=O)C4=CN(C5=CC=CC=C54)CCCC(=O)O
DMEL15U IK LACIBZRFAYFTOV-UHFFFAOYSA-N
DMEL15U IU 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U CA CAS 163136-03-6
DMEL15U DE Prostate disease
DML5AE4 ID DML5AE4
DML5AE4 DN FK-3311
DML5AE4 HS Phase 2
DML5AE4 SN 116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474
DML5AE4 CP Fujisawa Pharmaceutical Co Ltd
DML5AE4 DT Small molecular drug
DML5AE4 PC 164009
DML5AE4 MW 341.3
DML5AE4 FM C15H13F2NO4S
DML5AE4 IC InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3
DML5AE4 CS CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F
DML5AE4 IK DIIYLGZNZGPXRR-UHFFFAOYSA-N
DML5AE4 IU N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide
DML5AE4 CA CAS 116686-15-8
DML5AE4 DE Rheumatoid arthritis
DMKVXYS ID DMKVXYS
DMKVXYS DN FK-409
DMKVXYS HS Phase 2
DMKVXYS SN nor-3; 3-Hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-; 92454-83-6; 163180-49-2; ACMC-20eif3; AC1OAT8P; 4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide; CTK3H0114; CTK4D1460
DMKVXYS CP Fujisawa Pharmaceutical Co Ltd
DMKVXYS DT Small molecular drug
DMKVXYS PC 6413529
DMKVXYS MW 215.21
DMKVXYS FM C8H13N3O4
DMKVXYS IC InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)/b6-4+,10-7-
DMKVXYS CS CC/C(=C\\C(=N\\O)\\C(=O)N)/C(C)[N+](=O)[O-]
DMKVXYS IK MZAGXDHQGXUDDX-JSRXJHBZSA-N
DMKVXYS IU (E,2Z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide
DMKVXYS CA CAS 92454-60-9
DMKVXYS DE Angina pectoris
DMGROQP ID DMGROQP
DMGROQP DN FK-505
DMGROQP HS Phase 2
DMGROQP SN FR-76505; 2-[3-(4-Bromo-2-fluorobenzyl)-7-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl]acetic acid
DMGROQP DT Small molecular drug
DMGROQP PC 3086955
DMGROQP MW 425.2
DMGROQP FM C17H11BrF2N2O4
DMGROQP IC InChI=1S/C17H11BrF2N2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
DMGROQP CS C1=CC2=C(C=C1F)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DMGROQP IK XLOHSVVOWVIPFC-UHFFFAOYSA-N
DMGROQP IU 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-fluoro-2,4-dioxoquinazolin-1-yl]acetic acid
DMGROQP CA CAS 112733-08-1
DMGROQP DE Hyperuricaemia
DMY61TJ ID DMY61TJ
DMY61TJ DN FK-614
DMY61TJ HS Phase 2
DMY61TJ SN ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus
DMY61TJ CP Fujisawa Pharmaceutical Co Ltd; aestus therapeutics
DMY61TJ DT Small molecular drug
DMY61TJ PC 9869229
DMY61TJ MW 468.4
DMY61TJ FM C21H23Cl2N3O3S
DMY61TJ IC InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
DMY61TJ CS CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C
DMY61TJ IK UYGZODVVDUIDDQ-UHFFFAOYSA-N
DMY61TJ IU 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
DMY61TJ CA CAS 193012-35-0
DMY61TJ DE Type-2 diabetes
DMV0MZ3 ID DMV0MZ3
DMV0MZ3 DN FK-962
DMV0MZ3 HS Phase 2
DMV0MZ3 SN FK-960 analog, Fujisawa
DMV0MZ3 CP Fujisawa Pharmaceutical Co Ltd
DMV0MZ3 DT Small molecular drug
DMV0MZ3 PC 56842107
DMV0MZ3 MW 263.31
DMV0MZ3 FM C15H18FNO2
DMV0MZ3 IC InChI=1S/C15H18FNO2/c1-10(18)11-4-8-14(9-5-11)17-15(19)12-2-6-13(16)7-3-12/h2-3,6-7,11,14H,4-5,8-9H2,1H3,(H,17,19)
DMV0MZ3 CS CC(=O)C1CCC(CC1)NC(=O)C2=CC=C(C=C2)F
DMV0MZ3 IK PYMCWQVGVQEZNO-UHFFFAOYSA-N
DMV0MZ3 IU N-(4-acetylcyclohexyl)-4-fluorobenzamide
DMV0MZ3 CA CAS 283167-06-6
DMV0MZ3 DE Alzheimer disease
DM2O7NM ID DM2O7NM
DM2O7NM DN FKB01MD
DM2O7NM HS Phase 2
DM2O7NM CP Fabre-Kramer Pharmaceuticals Houston, TX
DMPXH7N ID DMPXH7N
DMPXH7N DN FKW00GA
DMPXH7N HS Phase 2
DMPXH7N CP Fabre-Kramer Pharmaceuticals Houston, TX
DMPXH7N DE Social phobia
DMKSUOI ID DMKSUOI
DMKSUOI DN Flavopiridol
DMKSUOI HS Phase 2
DMKSUOI SN FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI CP Sanofi-Aventis
DMKSUOI DT Small molecular drug
DMKSUOI PC 5287969
DMKSUOI MW 401.8
DMKSUOI FM C21H20ClNO5
DMKSUOI IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1
DMKSUOI CS CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMKSUOI IK BIIVYFLTOXDAOV-YVEFUNNKSA-N
DMKSUOI IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI CA CAS 146426-40-6
DMKSUOI CB CHEBI:47344
DMKSUOI DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia
DMCN4H6 ID DMCN4H6
DMCN4H6 DN Flezelastine
DMCN4H6 HS Phase 2
DMCN4H6 SN D-18024
DMCN4H6 CP ASTA Medica AG
DMCN4H6 DT Small molecular drug
DMCN4H6 PC 60432
DMCN4H6 MW 455.6
DMCN4H6 FM C29H30FN3O
DMCN4H6 IC InChI=1S/C29H30FN3O/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22/h1-5,7-8,10-15,25H,6,9,16-21H2
DMCN4H6 CS C1CC(CCN(C1)CCC2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)F
DMCN4H6 IK HQFSNUYUXXPVKL-UHFFFAOYSA-N
DMCN4H6 IU 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one
DMCN4H6 CA CAS 135381-77-0
DMCN4H6 DE Asthma
DMVR6OM ID DMVR6OM
DMVR6OM DN Flotetuzumab
DMVR6OM HS Phase 2
DMVR6OM CP MacroGenics Rockville, MD
DMVR6OM DE Myelodysplastic syndrome; Acute myeloid leukaemia; Acute biphenotypic leukaemia
DMMQ1YU ID DMMQ1YU
DMMQ1YU DN FLUASTERONE
DMMQ1YU HS Phase 2
DMMQ1YU SN HE-2500; 16alpha-Fluoroandrost-5-en-17-one; 8354
DMMQ1YU CP Aeson Therapeutics
DMMQ1YU DT Small molecular drug
DMMQ1YU PC 133967
DMMQ1YU MW 290.4
DMMQ1YU FM C19H27FO
DMMQ1YU IC InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
DMMQ1YU CS C[C@]12CCCCC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)F)C
DMMQ1YU IK VHZXNQKVFDBFIK-NBBHSKLNSA-N
DMMQ1YU IU (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DMMQ1YU CA CAS 112859-71-9
DMMQ1YU DE Arthritis
DME01HT ID DME01HT
DME01HT DN Fluciclatide F-18
DME01HT HS Phase 2
DME01HT CP GE Healthcare; National Cancer Institute
DME01HT DT Small molecular drug
DME01HT PC 139033064
DME01HT MW 1815
DME01HT FM C75H115FN18O27S3
DME01HT IC InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39-/t53-,54-,55-,56-,57-,58-,59-/m0/s1/i76-1
DME01HT CS C1[C@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@@H](CSCC(=O)N[C@H](C(=O)N2)CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C\\C3=CC=C(C=C3)[18F])C(=O)NCCOCCOCCOCCNC(=O)COCC(=O)N)CC4=CC=CC=C4)CC(=O)O)CCCN=C(N)N
DME01HT IK VXFFXZSNVKXXIB-SOFHUQNMSA-N
DME01HT IU 2-[(1R,4S,10R,13S,16R,19S,25S)-10-[2-[2-[2-[2-[[2-(2-amino-2-oxoethoxy)acetyl]amino]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]-13-benzyl-25-[3-(diaminomethylideneamino)propyl]-4-[4-[[2-[2-[2-[2-[2-[2-[2-[2-[[2-[(Z)-(4-(18F)fluoranylphenyl)methylideneamino]oxyacetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]butyl]-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octazabicyclo[14.11.4]hentriacontan-19-yl]acetic acid
DME01HT DE Solid tumour/cancer
DM0G5O6 ID DM0G5O6
DM0G5O6 DN Flumatinib
DM0G5O6 HS Phase 2
DM0G5O6 SN HH-GV-678
DM0G5O6 CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM0G5O6 DT Small molecular drug
DM0G5O6 PC 46848036
DM0G5O6 MW 562.6
DM0G5O6 FM C29H29F3N8O
DM0G5O6 IC InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
DM0G5O6 CS CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
DM0G5O6 IK BJCJYEYYYGBROF-UHFFFAOYSA-N
DM0G5O6 IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
DM0G5O6 CA CAS 895519-90-1
DM0G5O6 DE Chronic myelogenous leukaemia
DMCEUOH ID DMCEUOH
DMCEUOH DN Fluoropeptide vaccine
DMCEUOH HS Phase 2
DMCEUOH SN FP-01; Fluoropeptide vaccine (influenza); Fluoropeptide vaccine (influenza), Immune Targeting Systems
DMCEUOH CP Immune Targeting Systems Ltd
DMCEUOH DT Vaccine
DMCEUOH DE Influenza virus infection
DMPBV9D ID DMPBV9D
DMPBV9D DN Flupirtine
DMPBV9D HS Phase 2
DMPBV9D SN Flupirtine; 56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami
DMPBV9D CP Adeona Pharmaceuticals; MI Meda Pharmaceuticals
DMPBV9D DT Small molecular drug
DMPBV9D PC 53276
DMPBV9D MW 304.32
DMPBV9D FM C15H17FN4O2
DMPBV9D IC InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)
DMPBV9D CS CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N
DMPBV9D IK JUUFBMODXQKSTD-UHFFFAOYSA-N
DMPBV9D IU ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
DMPBV9D CA CAS 56995-20-1
DMPBV9D CB CHEBI:94646
DMPBV9D DE Fibromyalgia; Cancer related pain
DMQX5UA ID DMQX5UA
DMQX5UA DN FLX-787
DMQX5UA HS Phase 2
DMQX5UA CP Flex Pharma, Boston, MA
DMQX5UA DE Amyotrophic lateral sclerosis; Multiple sclerosis; Muscle spasm
DMB9ADM ID DMB9ADM
DMB9ADM DN FolateImmune
DMB9ADM HS Phase 2
DMB9ADM SN Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5
DMB9ADM CP Endocyte Inc
DMB9ADM DT Small molecular drug
DMB9ADM PC 135564966
DMB9ADM MW 872.9
DMB9ADM FM C42H36N10O10S
DMB9ADM IC InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1
DMB9ADM CS C1=CC(=CC=C1C(=O)N(CCNC(=S)NC2=CC3=C(C=C2)C4(C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O)OC3=O)[C@@H](CCC(=O)N)C(=O)O)NCC7=CN=C8C(=N7)C(=O)NC(=N8)N
DMB9ADM IK ZMTAPBHUSYTHBY-PMERELPUSA-N
DMB9ADM IU (2S)-5-amino-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]-[2-[(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)carbamothioylamino]ethyl]amino]-5-oxopentanoic acid
DMB9ADM CA CAS 583037-91-6
DMB9ADM DE Renal cell carcinoma; Solid tumour/cancer
DMJNO3D ID DMJNO3D
DMJNO3D DN Follicle stimulating hormone
DMJNO3D HS Phase 2
DMJNO3D SN FSH-GEX; Follicle stimulating hormone (GEX, inferticlity); GT-GP 2.4 GEX; Follicle stimulating hormone (GEX, inferticlity), Glycotope
DMJNO3D CP Glycotope GmbH
DMJNO3D DE Infertility
DMUAXS5 ID DMUAXS5
DMUAXS5 DN FP-1039
DMUAXS5 HS Phase 2
DMUAXS5 SN FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
DMUAXS5 CP FivePrime Therapeutics Inc
DMUAXS5 DE Solid tumour/cancer; Endometrial cancer
DMC1F2T ID DMC1F2T
DMC1F2T DN FP-1097
DMC1F2T HS Phase 2
DMC1F2T SN Urinary incontinence therapy, FemmePharma
DMC1F2T CP FemmePharma Inc
DMC1F2T DE Urinary incontinence
DMXOTMP ID DMXOTMP
DMXOTMP DN FPI-01
DMXOTMP HS Phase 2
DMXOTMP SN WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals
DMXOTMP CP Formula pharmaceuticals
DMXOTMP DT Vaccine
DMXOTMP DE Acute myeloid leukaemia
DMEL5SV ID DMEL5SV
DMEL5SV DN FR139317
DMEL5SV HS Phase 2
DMEL5SV SN D-Alanine, N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl-1-methyl-D-tryptophyl-3-(2-pyridinyl)-; FR 139317; 142375-60-8; CHEMBL352396; 2-((1-(Hexahydro-1H-azepinyl)carbonyl)amino-4-methylpentanoyl)-3-(-(1-methyl-1H-indolyl)propionyl)amino-3-(2-pyridyl)propionic acid; D-Alanine, N-(N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-1-methyl-D-tryptophyl)-3-(2-pyridinyl)-; GSK424887
DMEL5SV DT Small molecular drug
DMEL5SV PC 107810
DMEL5SV MW 604.7
DMEL5SV FM C33H44N6O5
DMEL5SV IC InChI=1S/C33H44N6O5/c1-22(2)18-26(37-33(44)39-16-10-4-5-11-17-39)30(40)35-27(19-23-21-38(3)29-14-7-6-13-25(23)29)31(41)36-28(32(42)43)20-24-12-8-9-15-34-24/h6-9,12-15,21-22,26-28H,4-5,10-11,16-20H2,1-3H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)/t26-,27+,28+/m0/s1
DMEL5SV CS CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=CC=N3)C(=O)O)NC(=O)N4CCCCCC4
DMEL5SV IK LIOKMIQQPDDTNO-UPRLRBBYSA-N
DMEL5SV IU (2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-pyridin-2-ylpropanoic acid
DMEL5SV CA CAS 142375-60-8
DMEL5SV DE Anxiety disorder; Depression; Hypertension
DMGO45I ID DMGO45I
DMGO45I DN FR-146687
DMGO45I HS Phase 2
DMGO45I SN FK-687; TF-505; 4-[1-[4-[1(S)-(4-Isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid
DMGO45I DE Prostate disease
DMFZ084 ID DMFZ084
DMFZ084 DN Fresolimumab
DMFZ084 HS Phase 2
DMFZ084 SN GC-1008
DMFZ084 DT Antibody
DMFZ084 DE Brain cancer
DM9ORUW ID DM9ORUW
DM9ORUW DN FRM-0962
DM9ORUW HS Phase 2
DM9ORUW CP Forum pharmaceuticals
DM9ORUW DE Alzheimer disease
DMPQFTA ID DMPQFTA
DMPQFTA DN Fucoxanthin
DMPQFTA HS Phase 2
DMPQFTA SN Fucoxanthin; UNII-06O0TC0VSM; CCRIS 4055; all-trans-Fucoxanthin; BRN 0073179; 06O0TC0VSM; beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one
DMPQFTA PC 5281239
DMPQFTA MW 658.9
DMPQFTA FM C42H58O6
DMPQFTA IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMPQFTA CS CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C
DMPQFTA IK SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMPQFTA IU nan
DMPQFTA CA CAS 3351-86-8
DMPQFTA CB CHEBI:5186
DMPQFTA DE Metabolic syndrome
DMZLBAW ID DMZLBAW
DMZLBAW DN Fucoxanthin
DMZLBAW HS Phase 2
DMZLBAW SN 3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-
DMZLBAW DT Small molecular drug
DMZLBAW PC 5281239
DMZLBAW MW 658.9
DMZLBAW FM C42H58O6
DMZLBAW IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMZLBAW CS C/C(=C\\C=C\\C=C(/C)\\C=C\\C=C(/C)\\C(=O)C[C@]12[C@](O1)(C[C@H](CC2(C)C)O)C)/C=C/C=C(\\C)/C=C=C3[C@](C[C@H](CC3(C)C)OC(=O)C)(C)O
DMZLBAW IK SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMZLBAW CA CAS 3351-86-8
DMZLBAW DE Metabolic syndrome x
DMKHNXA ID DMKHNXA
DMKHNXA DN G100
DMKHNXA HS Phase 2
DMKHNXA SN Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; CAFFEINE, 8-((3-METHOXYPROPYL)AMINO)-; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992
DMKHNXA CP Immune Design Seattle, WA
DMKHNXA PC 56998
DMKHNXA MW 281.31
DMKHNXA FM C12H19N5O3
DMKHNXA IC InChI=1S/C12H19N5O3/c1-15-8-9(14-11(15)13-6-5-7-20-4)16(2)12(19)17(3)10(8)18/h5-7H2,1-4H3,(H,13,14)
DMKHNXA CS CN1C2=C(N=C1NCCCOC)N(C(=O)N(C2=O)C)C
DMKHNXA IK ZZQHGKMTMAORFI-UHFFFAOYSA-N
DMKHNXA IU 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione
DMKHNXA CA CAS 95982-26-6
DMKHNXA DE Non-hodgkin lymphoma
DMQO2IT ID DMQO2IT
DMQO2IT DN G1T38
DMQO2IT HS Phase 2
DMQO2IT SN YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4
DMQO2IT CP G1 Therapeutics Research Tringle Park, NC
DMQO2IT PC 86269224
DMQO2IT MW 474.6
DMQO2IT FM C26H34N8O
DMQO2IT IC InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)
DMQO2IT CS CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMQO2IT IK YPJRHEKCFKOVRT-UHFFFAOYSA-N
DMQO2IT IU 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMQO2IT CA CAS 1628256-23-4
DMQO2IT DE Breast cancer; Non-small-cell lung cancer
DMQR9I8 ID DMQR9I8
DMQR9I8 DN G-202
DMQR9I8 HS Phase 2
DMQR9I8 SN UNII-Q032I35QMX; Q032I35QMX; 1245732-48-2; Mipsagargin [USAN:INN]; Mipsagargin (USAN/INN); CHEMBL3989865; DB11813; D10715
DMQR9I8 CP GenSpera
DMQR9I8 PC 24772106
DMQR9I8 MW 1409.5
DMQR9I8 FM C66H100N6O27
DMQR9I8 IC InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1
DMQR9I8 CS CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCCCCCCCCCCNC(=O)C[C@@H](C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)N)([C@](C(=O)O3)(C)O)O
DMQR9I8 IK UPYNTAIBQVNPIH-ODMLWHIESA-N
DMQR9I8 IU (2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(2S)-4-[[12-[[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-7-octanoyloxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-4-yl]oxy]-12-oxododecyl]amino]-2-amino-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
DMQR9I8 CA CAS 1245732-48-2
DMQR9I8 DE Solid tumour/cancer; Adenocarcinoma
DMJY2TM ID DMJY2TM
DMJY2TM DN Gabapentin enacarbil
DMJY2TM HS Phase 2
DMJY2TM SN 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512
DMJY2TM TC Neurology Agents
DMJY2TM DT Small molecular drug
DMJY2TM PC 9883933
DMJY2TM MW 329.39
DMJY2TM FM C16H27NO6
DMJY2TM IC InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
DMJY2TM CS CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
DMJY2TM IK TZDUHAJSIBHXDL-UHFFFAOYSA-N
DMJY2TM IU 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
DMJY2TM CA CAS 478296-72-9
DMJY2TM CB CHEBI:68840
DMJY2TM DE Alcohol dependence
DMTXCUS ID DMTXCUS
DMTXCUS DN Galiximab
DMTXCUS HS Phase 2
DMTXCUS CP Biogen Idec
DMTXCUS DT Antibody
DMTXCUS DE Lymphoma
DMXBR27 ID DMXBR27
DMXBR27 DN Gallopamil
DMXBR27 HS Phase 2
DMXBR27 SN 16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406
DMXBR27 DT Small molecular drug
DMXBR27 PC 1234
DMXBR27 MW 484.6
DMXBR27 FM C28H40N2O5
DMXBR27 IC InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
DMXBR27 CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC
DMXBR27 IK XQLWNAFCTODIRK-UHFFFAOYSA-N
DMXBR27 IU 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DMXBR27 CA CAS 16662-47-8
DMXBR27 CB CHEBI:34772
DMXBR27 DE Hypertension; Asthma
DMAEWS1 ID DMAEWS1
DMAEWS1 DN GAM-501
DMAEWS1 HS Phase 2
DMAEWS1 SN Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company
DMAEWS1 CP Selective Genetics Inc
DMAEWS1 DE Diabetic foot ulcer
DM2IFJQ ID DM2IFJQ
DM2IFJQ DN GBL-310
DM2IFJQ HS Phase 2
DM2IFJQ SN Anti-hyperproliferative (topical, actinic keratosis), Grannus
DM2IFJQ CP Grannus BioSciences Ltd
DM2IFJQ DE Keratosis
DM2VO9T ID DM2VO9T
DM2VO9T DN GBR 830
DM2VO9T HS Phase 2
DM2VO9T CP Glenmark Pharmaceuticals Mumbai, India
DM2VO9T DE Atopic dermatitis
DMYS6MW ID DMYS6MW
DMYS6MW DN GCS-100
DMYS6MW HS Phase 2
DMYS6MW CP La jolla pharmaceutical
DMYS6MW DE Chronic kidney disease
DMY6WUV ID DMY6WUV
DMY6WUV DN GDC-0077
DMY6WUV HS Phase 2
DMY6WUV SN RG6114; SGEUNORSOZVTOL-CABZTGNLSA-N; UNII-L4C1UY2NYH; L4C1UY2NYH; 2060571-02-8; GDC0077; GTPL9636; SCHEMBL18360780; EX-A2685; ZINC669678973; Ro7113755; CS-6459; HY-101562; Propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2S)-; (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide; (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxa
DMY6WUV CP GenentechSouth San Francisco, CA
DMY6WUV PC 124173720
DMY6WUV MW 407.4
DMY6WUV FM C18H19F2N5O4
DMY6WUV IC InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
DMY6WUV CS C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F
DMY6WUV IK SGEUNORSOZVTOL-CABZTGNLSA-N
DMY6WUV IU (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
DMY6WUV CA CAS 2060571-02-8
DMY6WUV DE Breast cancer; Solid tumour/cancer
DMA9SEY ID DMA9SEY
DMA9SEY DN GDC-0084
DMA9SEY HS Phase 2
DMA9SEY SN GDC-0084/RG7666
DMA9SEY CP Genentech
DMA9SEY PC 57384863
DMA9SEY MW 382.4
DMA9SEY FM C18H22N8O2
DMA9SEY IC InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
DMA9SEY CS CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C
DMA9SEY IK LGWACEZVCMBSKW-UHFFFAOYSA-N
DMA9SEY IU 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine
DMA9SEY CA CAS 1382979-44-3
DMA9SEY DE Glioblastoma of brain
DM1YAK6 ID DM1YAK6
DM1YAK6 DN GDC0941
DM1YAK6 HS Phase 2
DM1YAK6 SN Pictilisib; GDC-0941; 957054-30-7; PICTILISIB; Pictrelisib; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; ICY00EMP8P; Pictilisib (GDC-0941); CHEBI:65326; AK-40872; Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-; GD9; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
DM1YAK6 CP Genentech
DM1YAK6 DT Small molecular drug
DM1YAK6 PC 17755052
DM1YAK6 MW 513.6
DM1YAK6 FM C23H27N7O3S2
DM1YAK6 IC InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
DM1YAK6 CS CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
DM1YAK6 IK LHNIIDJUOCFXAP-UHFFFAOYSA-N
DM1YAK6 IU 4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
DM1YAK6 CA CAS 957054-30-7
DM1YAK6 CB CHEBI:65326
DM1YAK6 DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer
DMF3MV1 ID DMF3MV1
DMF3MV1 DN GDC-0980/RG7422
DMF3MV1 HS Phase 2
DMF3MV1 SN Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
DMF3MV1 CP Genentech; Roche
DMF3MV1 DT Small molecular drug
DMF3MV1 PC 25254071
DMF3MV1 MW 498.6
DMF3MV1 FM C23H30N8O3S
DMF3MV1 IC InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
DMF3MV1 CS CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O
DMF3MV1 IK YOVVNQKCSKSHKT-HNNXBMFYSA-N
DMF3MV1 IU (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one
DMF3MV1 CA CAS 1032754-93-0
DMF3MV1 DE Non-hodgkin lymphoma; Solid tumour/cancer
DMMQY0O ID DMMQY0O
DMMQY0O DN GED-0507-34-Levo
DMMQY0O HS Phase 2
DMMQY0O SN GED-0507; GED-0507-34; GED-0507-34E2
DMMQY0O CP Giuliani SpA
DMMQY0O PC 67008033
DMMQY0O MW 195.21
DMMQY0O FM C10H13NO3
DMMQY0O IC InChI=1S/C10H13NO3/c1-14-9(10(12)13)6-7-2-4-8(11)5-3-7/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
DMMQY0O CS CO[C@@H](CC1=CC=C(C=C1)N)C(=O)O
DMMQY0O IK QLJYLJGYIDIJPT-VIFPVBQESA-N
DMMQY0O IU (2S)-3-(4-aminophenyl)-2-methoxypropanoic acid
DMMQY0O CA CAS 921195-93-9
DMMQY0O DE Inflammatory bowel disease
DMJN09S ID DMJN09S
DMJN09S DN GEN-1
DMJN09S HS Phase 2
DMJN09S CP Celsion
DMJN09S DT Gene therapy
DMJN09S DE Ovarian cancer
DMO9WU8 ID DMO9WU8
DMO9WU8 DN Gepirone
DMO9WU8 HS Phase 2
DMO9WU8 SN Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q
DMO9WU8 PC 55191
DMO9WU8 MW 359.5
DMO9WU8 FM C19H29N5O2
DMO9WU8 IC InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
DMO9WU8 CS CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
DMO9WU8 IK QOIGKGMMAGJZNZ-UHFFFAOYSA-N
DMO9WU8 IU 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMO9WU8 CA CAS 83928-76-1
DMO9WU8 CB CHEBI:135990
DMO9WU8 DE Cocaine related disorders
DMD3RU8 ID DMD3RU8
DMD3RU8 DN GFT14
DMD3RU8 HS Phase 2
DMD3RU8 CP Genfit
DMD3RU8 DE Hyperlipidaemia
DMTY4PG ID DMTY4PG
DMTY4PG DN GI-4000
DMTY4PG HS Phase 2
DMTY4PG CP GlobeImmune
DMTY4PG DT Vaccine
DMTY4PG DE Colorectal cancer; Pancreatic cancer
DMQ0XZE ID DMQ0XZE
DMQ0XZE DN GI-4000 + gemcitabine
DMQ0XZE HS Phase 2
DMQ0XZE CP GlobeImmune
DMQ0XZE DE Pancreatic cancer
DM72O6F ID DM72O6F
DM72O6F DN GI-6207
DM72O6F HS Phase 2
DM72O6F CP GlobeImmune
DM72O6F DE Thyroid cancer
DMOMS7R ID DMOMS7R
DMOMS7R DN GI-6301
DMOMS7R HS Phase 2
DMOMS7R CP GlobeImmune
DMOMS7R DT Vaccine
DMOMS7R DE Solid tumour/cancer; Advanced cancer; Chordoma
DMSKMET ID DMSKMET
DMSKMET DN Gimatecan
DMSKMET HS Phase 2
DMSKMET SN LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin
DMSKMET CP Sigma-Tau Ind Farm Riunite SpA
DMSKMET DT Small molecular drug
DMSKMET PC 9577124
DMSKMET MW 447.5
DMSKMET FM C25H25N3O5
DMSKMET IC InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1
DMSKMET CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OC(C)(C)C)O
DMSKMET IK UIVFUQKYVFCEKJ-OPTOVBNMSA-N
DMSKMET IU (19S)-19-ethyl-19-hydroxy-10-[(E)-(2-methylpropan-2-yl)oxyiminomethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMSKMET CA CAS 292618-32-7
DMSKMET DE Breast cancer
DMG3O2Z ID DMG3O2Z
DMG3O2Z DN Girentuximab I-124
DMG3O2Z HS Phase 2
DMG3O2Z SN Redectane (TN)
DMG3O2Z CP Wilex
DMG3O2Z DT Monoclonal antibody
DMG3O2Z DE Renal cell carcinoma
DMLFSMX ID DMLFSMX
DMLFSMX DN GK1-399
DMLFSMX HS Phase 2
DMLFSMX SN TTP-399
DMLFSMX CP Forest Laboratories
DMLFSMX DE Diabetic complication; Type-2 diabetes
DMOVB3Y ID DMOVB3Y
DMOVB3Y DN GKT-137831
DMOVB3Y HS Phase 2
DMOVB3Y SN GKT-01; NADPH oxidase inhibitor (oral, renal cancer/ idiopathic pulmonary fibrosis), GenKyoTex
DMOVB3Y CP Genkyotex innovation
DMOVB3Y DT Small molecular drug
DMOVB3Y PC 58496428
DMOVB3Y MW 394.9
DMOVB3Y FM C21H19ClN4O2
DMOVB3Y IC InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3
DMOVB3Y CS CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl
DMOVB3Y IK RGYQPQARIQKJKH-UHFFFAOYSA-N
DMOVB3Y IU 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione
DMOVB3Y CA CAS 1218942-37-0
DMOVB3Y DE Fibrosis
DM17OZM ID DM17OZM
DM17OZM DN GL-0817
DM17OZM HS Phase 2
DM17OZM SN 912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
DM17OZM CP Gliknik
DM17OZM DT Small molecular drug
DM17OZM PC 122706930
DM17OZM MW 5758
DM17OZM FM C261H449N91O56
DM17OZM IC InChI=1S/C261H449N91O56/c1-30-147(26)204(249(406)339-186(124-153-70-38-33-39-71-153)234(391)342-190(131-354)238(395)322-159(75-43-49-99-263)210(367)309-149(28)207(364)341-189(130-353)240(397)344-192(133-356)241(398)343-191(132-355)239(396)335-180(118-137(6)7)230(387)324-175(93-96-195(270)358)223(380)331-178(116-135(2)3)228(385)320-168(84-58-108-298-255(279)280)218(375)313-160(76-44-50-100-264)212(369)312-161(77-45-51-101-265)213(370)314-165(81-55-105-295-252(273)274)216(373)315-167(83-57-107-297-254(277)278)219(376)323-174(92-95-194(269)357)222(379)318-166(82-56-106-296-253(275)276)217(374)316-169(85-59-109-299-256(281)282)220(377)329-177(250(407)408)90-64-114-304-261(291)292)351-248(405)203(146(24)25)348-225(382)171(87-61-111-301-258(285)286)319-215(372)163(79-47-53-103-267)327-245(402)200(143(18)19)347-227(384)173(89-63-113-303-260(289)290)328-246(403)201(144(20)21)349-236(393)182(120-139(10)11)330-206(363)148(27)308-211(368)164(80-54-104-294-251(271)272)325-242(399)193-91-65-115-352(193)196(359)129-306-209(366)187(125-154-127-305-158-74-41-40-72-156(154)158)338-231(388)181(119-138(8)9)334-232(389)184(122-151-66-34-31-35-67-151)336-221(378)170(86-60-110-300-257(283)284)317-214(371)162(78-46-52-102-266)326-244(401)199(142(16)17)346-226(383)172(88-62-112-302-259(287)288)321-229(386)179(117-136(4)5)333-233(390)185(123-152-68-36-32-37-69-152)337-235(392)188(126-155-128-293-134-307-155)340-247(404)202(145(22)23)350-237(394)183(121-140(12)13)332-224(381)176(94-97-197(360)361)311-205(362)150(29)310-243(400)198(141(14)15)345-208(365)157(268)73-42-48-98-262/h31-41,66-72,74,127-128,134-150,157,159-193,198-204,305,353-356H,30,42-65,73,75-126,129-133,262-268H2,1-29H3,(H2,269,357)(H2,270,358)(H,293,307)(H,306,366)(H,308,368)(H,309,367)(H,310,400)(H,311,362)(H,312,369)(H,313,375)(H,314,370)(H,315,373)(H,316,374)(H,317,371)(H,318,379)(H,319,372)(H,320,385)(H,321,386)(H,322,395)(H,323,376)(H,324,387)(H,325,399)(H,326,401)(H,327,402)(H,328,403)(H,329,377)(H,330,363)(H,331,380)(H,332,381)(H,333,390)(H,334,389)(H,335,396)(H,336,378)(H,337,392)(H,338,388)(H,339,406)(H,340,404)(H,341,364)(H,342,391)(H,343,398)(H,344,397)(H,345,365)(H,346,383)(H,347,384)(H,348,382)(H,349,393)(H,350,394)(H,351,405)(H,360,361)(H,407,408)(H4,271,272,294)(H4,273,274,295)(H4,275,276,296)(H4,277,278,297)(H4,279,280,298)(H4,281,282,299)(H4,283,284,300)(H4,285,286,301)(H4,287,288,302)(H4,289,290,303)(H4,291,292,304)/t147-,148-,149-,150-,157-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,198-,199-,200-,201-,202-,203-,204-/m0/s1
DM17OZM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N
DM17OZM IK SSOORFWOBGFTHL-OTEJMHTDSA-N
DM17OZM IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DM17OZM CA CAS 911338-45-9
DM17OZM DE Head and neck cancer; Squamous cell carcinoma; Multiple myeloma; Oral cavity squamous cell carcinoma
DMSVBND ID DMSVBND
DMSVBND DN Glecaprevir
DMSVBND HS Phase 2
DMSVBND SN A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum
DMSVBND TC Antiviral Agent
DMSVBND DT Small molecular drug
DMSVBND PC 66828839
DMSVBND MW 838.873
DMSVBND FM C38H46F4N6O9S
DMSVBND IC InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DMSVBND CS CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND IK CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DMSVBND CA CAS 1365970-03-1
DMSVBND DE Chronic hepatitis C infection
DMPHCDL ID DMPHCDL
DMPHCDL DN GLPG-0634
DMPHCDL HS Phase 2
DMPHCDL SN Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
DMPHCDL CP Abbvie; galapagos
DMPHCDL DT Small molecular drug
DMPHCDL PC 49831257
DMPHCDL MW 425.5
DMPHCDL FM C21H23N5O3S
DMPHCDL IC InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
DMPHCDL CS C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
DMPHCDL IK RIJLVEAXPNLDTC-UHFFFAOYSA-N
DMPHCDL IU N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMPHCDL CA CAS 1206161-97-8
DMPHCDL DE Rheumatoid arthritis; Crohn disease; Cutaneous lupus erythematosus
DMXO4T8 ID DMXO4T8
DMXO4T8 DN GLPG0974
DMXO4T8 HS Phase 2
DMXO4T8 SN compound 99 [PMID 25380412]
DMXO4T8 DT Small molecular drug
DMXO4T8 PC 57520598
DMXO4T8 MW 485
DMXO4T8 FM C25H25ClN2O4S
DMXO4T8 IC InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1
DMXO4T8 CS C[C@@]1(CCN1C(=O)C2=CSC3=CC=CC=C32)C(=O)N(CCCC(=O)O)CC4=CC(=CC=C4)Cl
DMXO4T8 IK MPMKMQHJHDHPBE-RUZDIDTESA-N
DMXO4T8 IU 4-[[(2R)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid
DMXO4T8 CA CAS 1391076-61-1
DMXO4T8 DE Abortion
DMOCRYB ID DMOCRYB
DMOCRYB DN GLPG-1837
DMOCRYB HS Phase 2
DMOCRYB SN GHTGYZMBQPXTCQ-UHFFFAOYSA-N; GLPG1837; 1654725-02-6; SCHEMBL16444982; GLPG 1837; EX-A1819; BCP23611; GLPG-1837(ABBV-974); HY-111099; CS-0034220; N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide
DMOCRYB CP Galapagos, AbbVie
DMOCRYB PC 117857370
DMOCRYB MW 348.4
DMOCRYB FM C16H20N4O3S
DMOCRYB IC InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22)
DMOCRYB CS CC1(CC2=C(C(O1)(C)C)SC(=C2C(=O)N)NC(=O)C3=CC=NN3)C
DMOCRYB IK GHTGYZMBQPXTCQ-UHFFFAOYSA-N
DMOCRYB IU N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide
DMOCRYB DE Cystic fibrosis
DMJ85FS ID DMJ85FS
DMJ85FS DN Glutathione-S-S-glutathione
DMJ85FS HS Phase 2
DMJ85FS SN oxiglutatione; glutathione disulfide; GSSG; oxidized glutathione; Glutathione disulphide; L-Glutathione oxidized; Glutathione-ssg; Glutathione, oxidized; Oxigluthione; glutathione oxidized; Glutathone disulfide; Bi(glutathion-S-yl); Oxidized L-glutathione; L-Oxidized glutathione; L(-)-Glutathione; Oxiglutatione [INN]; S,S'-Ethylenebis(glutathione); Oxiglutationum [INN-Latin]; Oxiglutationa [INN-Spanish]; CCRIS 780; OXIDIZED GLUTATHIONE DISULFIDE; Glutathiol; UNII-ULW86O013H
DMJ85FS PC 65359
DMJ85FS MW 612.6
DMJ85FS FM C20H32N6O12S2
DMJ85FS IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DMJ85FS CS C(CC(=O)NC(CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)C(=O)NCC(=O)O)C(C(=O)O)N
DMJ85FS IK YPZRWBKMTBYPTK-BJDJZHNGSA-N
DMJ85FS IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMJ85FS CA CAS 27025-41-8
DMJ85FS CB CHEBI:17858
DMJ85FS DE Ovarian cancer
DML6PO5 ID DML6PO5
DML6PO5 DN GM-CSF cancer vaccine
DML6PO5 HS Phase 2
DML6PO5 CP Thomas Jefferson University
DML6PO5 DT Vaccine
DML6PO5 DE Solid tumour/cancer
DMLWKZ7 ID DMLWKZ7
DMLWKZ7 DN GO-203-2c
DMLWKZ7 HS Phase 2
DMLWKZ7 CP Genus Oncology
DMLWKZ7 DE Solid tumour/cancer; Acute myeloid leukaemia
DMKZN3A ID DMKZN3A
DMKZN3A DN Golotimod
DMKZN3A HS Phase 2
DMKZN3A SN 229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta
DMKZN3A CP Verta Ltd; SciClone Pharmaceuticals
DMKZN3A DT Small molecular drug
DMKZN3A PC 6992140
DMKZN3A MW 333.34
DMKZN3A FM C16H19N3O5
DMKZN3A IC InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1
DMKZN3A CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N
DMKZN3A IK CATMPQFFVNKDEY-YPMHNXCESA-N
DMKZN3A IU (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
DMKZN3A CA CAS 229305-39-9
DMKZN3A DE Inflammation; Immune System disease
DMYWA0Z ID DMYWA0Z
DMYWA0Z DN GORALATIDE
DMYWA0Z HS Phase 2
DMYWA0Z SN AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline
DMYWA0Z DT Small molecular drug
DMYWA0Z PC 65938
DMYWA0Z MW 487.5
DMYWA0Z FM C20H33N5O9
DMYWA0Z IC InChI=1S/C20H33N5O9/c1-11(27)22-14(10-26)18(31)24-13(9-16(28)29)17(30)23-12(5-2-3-7-21)19(32)25-8-4-6-15(25)20(33)34/h12-15,26H,2-10,21H2,1H3,(H,22,27)(H,23,30)(H,24,31)(H,28,29)(H,33,34)/t12-,13-,14-,15-/m0/s1
DMYWA0Z CS CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O
DMYWA0Z IK HJDRXEQUFWLOGJ-AJNGGQMLSA-N
DMYWA0Z IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
DMYWA0Z CA CAS 120081-14-3
DMYWA0Z DE Constitutional neutropenia
DMJWE3I ID DMJWE3I
DMJWE3I DN Gossypol
DMJWE3I HS Phase 2
DMJWE3I SN gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
DMJWE3I DT Small molecular drug
DMJWE3I PC 3503
DMJWE3I MW 518.6
DMJWE3I FM C30H30O8
DMJWE3I IC InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3
DMJWE3I CS CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O
DMJWE3I IK QBKSWRVVCFFDOT-UHFFFAOYSA-N
DMJWE3I IU 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
DMJWE3I CA CAS 20300-26-9
DMJWE3I DE Prostate cancer
DM38ARE ID DM38ARE
DM38ARE DN Gp100:209-217(210M) peptide vaccine
DM38ARE HS Phase 2
DM38ARE SN Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI
DM38ARE CP National Cancer Institute
DM38ARE DT Vaccine
DM38ARE DE Melanoma
DMOHAS2 ID DMOHAS2
DMOHAS2 DN GPC-3298306
DMOHAS2 HS Phase 2
DMOHAS2 SN GPC3 peptide vaccine (hepatocellular carcinoma), Japanese National Cancer Center
DMOHAS2 CP Japanese National Cancer Center
DMOHAS2 DT Vaccine
DMOHAS2 DE Hepatocellular carcinoma
DMOQ7YI ID DMOQ7YI
DMOQ7YI DN GPD-1116
DMOQ7YI HS Phase 2
DMOQ7YI PC 9841417
DMOQ7YI MW 352.4
DMOQ7YI FM C22H16N4O
DMOQ7YI IC InChI=1S/C22H16N4O/c27-22-19-18(14-15-8-3-1-4-9-15)24-25-20(19)17-12-7-13-23-21(17)26(22)16-10-5-2-6-11-16/h1-13H,14H2,(H,24,25)
DMOQ7YI CS C1=CC=C(C=C1)CC2=C3C(=NN2)C4=C(N=CC=C4)N(C3=O)C5=CC=CC=C5
DMOQ7YI IK NOZMPLJNURLIAQ-UHFFFAOYSA-N
DMOQ7YI IU 3-benzyl-5-phenyl-2H-pyrazolo[4,3-c][1,8]naphthyridin-4-one
DMOQ7YI DE Asthma
DM64ZYM ID DM64ZYM
DM64ZYM DN GPI-1485
DM64ZYM HS Phase 2
DM64ZYM SN 186268-78-0; GPI-1485; UNII-0709BVY57W; (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; (2S)-1-(1,2-DIOXO-3,3-DIMETHYLPENTYL)-2-PYRROLIDINECARBOXYLIC ACID; 0709BVY57W; (S)-1-(3,3-Dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-; GPI 1485; SCHEMBL2006950; CTK6C7007; FOPALECPEUVCTL-QMMMGPOBSA-N; MolPort-023-219-569; ZX-RL003437; 1-(1,2-Dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2S; ZINC33979157; 6256AD; AKOS015991368; DB05814; EG-0058
DM64ZYM CP Eisai
DM64ZYM DT Small molecular drug
DM64ZYM PC 9837656
DM64ZYM MW 241.28
DM64ZYM FM C12H19NO4
DM64ZYM IC InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1
DM64ZYM CS CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)O
DM64ZYM IK FOPALECPEUVCTL-QMMMGPOBSA-N
DM64ZYM IU (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
DM64ZYM CA CAS 186268-78-0
DM64ZYM DE Parkinson disease
DMHNIGB ID DMHNIGB
DMHNIGB DN GPX-150D
DMHNIGB HS Phase 2
DMHNIGB SN CNDO-101; CNDO-101); GPX-150; Doxorubicin analog (cancer), Coronado; 5-imino-13-deoxy-doxorubicin
DMHNIGB CP Gem Pharmaceuticals LLC
DMHNIGB DE Breast cancer; Soft tissue sarcoma
DMMZQ7V ID DMMZQ7V
DMMZQ7V DN Granotapide
DMMZQ7V HS Phase 2
DMMZQ7V SN JTT-130
DMMZQ7V CP Japan Tobacco Inc
DMMZQ7V DT Small molecular drug
DMMZQ7V PC 11607299
DMMZQ7V MW 718.7
DMMZQ7V FM C39H37F3N2O8
DMMZQ7V IC InChI=1S/C39H37F3N2O8/c1-5-50-36(48)38(37(49)51-6-2,27-12-8-7-9-13-27)24-52-33(45)23-25-16-21-32(31(22-25)35(47)44(3)4)43-34(46)30-15-11-10-14-29(30)26-17-19-28(20-18-26)39(40,41)42/h7-22H,5-6,23-24H2,1-4H3,(H,43,46)
DMMZQ7V CS CCOC(=O)C(COC(=O)CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)C(=O)N(C)C)(C4=CC=CC=C4)C(=O)OCC
DMMZQ7V IK FPUQGCOBYOXAED-UHFFFAOYSA-N
DMMZQ7V IU diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate
DMMZQ7V CA CAS 594842-13-4
DMMZQ7V DE Hyperlipidaemia
DMWXJSZ ID DMWXJSZ
DMWXJSZ DN GRC-15300
DMWXJSZ HS Phase 2
DMWXJSZ CP Glenmark Pharmaceuticals Ltd
DMWXJSZ DE Pain
DM9QF65 ID DM9QF65
DM9QF65 DN GR-MD-02
DM9QF65 HS Phase 2
DM9QF65 SN Belapectin
DM9QF65 CP Galectin therapeutics
DM9QF65 DT Protein
DM9QF65 DE Melanoma; Plaque psoriasis; Non-alcoholic steatohepatitis; Hypertension
DMAHOEP ID DMAHOEP
DMAHOEP DN GRNVAC1
DMAHOEP HS Phase 2
DMAHOEP CP Argos Therapeutics
DMAHOEP DT Vaccine
DMAHOEP DE Acute myeloid leukaemia
DMHQV6R ID DMHQV6R
DMHQV6R DN GS-4059
DMHQV6R HS Phase 2
DMHQV6R SN tirabrutinib; Tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno
DMHQV6R CP Gilead Sciences Foster City, CA
DMHQV6R PC 54755438
DMHQV6R MW 454.5
DMHQV6R FM C25H22N6O3
DMHQV6R IC InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1
DMHQV6R CS CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHQV6R IK SEJLPXCPMNSRAM-GOSISDBHSA-N
DMHQV6R IU 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one
DMHQV6R CA CAS 1351636-18-4
DMHQV6R DE B-cell lymphoma; Rheumatoid arthritis
DMBDFN7 ID DMBDFN7
DMBDFN7 DN GS-4977
DMBDFN7 HS Phase 2
DMBDFN7 CP Gilead sciences
DMBDFN7 DE Diabetic nephropathy
DMNABMU ID DMNABMU
DMNABMU DN GS-4997
DMNABMU HS Phase 2
DMNABMU PC 71245288
DMNABMU MW 445.5
DMNABMU FM C24H24FN7O
DMNABMU IC InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
DMNABMU CS CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F
DMNABMU IK YIDDLAAKOYYGJG-UHFFFAOYSA-N
DMNABMU IU 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide
DMNABMU CA CAS 1448428-04-3
DMNABMU DE Diabetic nephropathy; Pulmonary arterial hypertension
DMDAHL6 ID DMDAHL6
DMDAHL6 DN GS-5806
DMDAHL6 HS Phase 2
DMDAHL6 CP GILEAD
DMDAHL6 DT Small molecular drug
DMDAHL6 PC 58029842
DMDAHL6 MW 532.1
DMDAHL6 FM C24H30ClN7O3S
DMDAHL6 IC InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
DMDAHL6 CS CC1=CN2C(=CC(=N2)[C@@H]3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CC[C@@H](C5)N
DMDAHL6 IK GOFXWTVKPWJNGD-UWJYYQICSA-N
DMDAHL6 IU N-[2-[(2S)-2-[5-[(3S)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide
DMDAHL6 CA CAS 1353625-73-6
DMDAHL6 DE Respiratory syncytial virus infection
DMSL3DX ID DMSL3DX
DMSL3DX DN GS-5885
DMSL3DX HS Phase 2
DMSL3DX SN Ledipasvir; 1256388-51-8; GS-5885; UNII-013TE6E4WV; GS5885; GS 5885; WHO 9796; Ledipasvir (GS5885); 013TE6E4WV; CHEBI:85089; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; SCHEMBL15116943; CHEMBL2374220; EX-A411; DTXSID90154829; MolPort-039-138-665
DMSL3DX CP Gilead Sciences Inc
DMSL3DX DT Small molecular drug
DMSL3DX PC 67505836
DMSL3DX MW 889
DMSL3DX FM C49H54F2N8O6
DMSL3DX IC InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
DMSL3DX CS CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSL3DX IK VRTWBAAJJOHBQU-KMWAZVGDSA-N
DMSL3DX IU methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSL3DX CA CAS 1256388-51-8
DMSL3DX CB CHEBI:85089
DMSL3DX DE Hepatitis C virus infection
DMV7ZU0 ID DMV7ZU0
DMV7ZU0 DN GS-6624
DMV7ZU0 HS Phase 2
DMV7ZU0 CP Gilead Sciences
DMV7ZU0 DT Antibody
DMV7ZU0 DE Colorectal cancer
DMCZH5B ID DMCZH5B
DMCZH5B DN GS-9256
DMCZH5B HS Phase 2
DMCZH5B SN GS-9256; UNII-8V42Y78HRU; 1001094-46-7; GS 9256; 8V42Y78HRU; [[8-chloro-2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy-(cyclopentoxycarbonylamino)-dioxo-[ ]yl]-[(2,6-difluorophenyl)methyl]phosphinic acid; GS9256; SCHEMBL9987287; CHEMBL1956820; DTXSID70142946; DB12876
DMCZH5B CP Gilead
DMCZH5B DT Small molecular drug
DMCZH5B PC 24823649
DMCZH5B MW 957.5
DMCZH5B FM C46H56ClF2N6O8PS
DMCZH5B IC InChI=1S/C46H56ClF2N6O8PS/c1-26(2)50-44-52-36(25-65-44)35-21-39(30-18-19-38(61-3)40(47)41(30)51-35)62-29-20-37-42(56)54-46(64(59,60)24-31-32(48)15-11-16-33(31)49)22-27(46)12-7-5-4-6-8-17-34(43(57)55(37)23-29)53-45(58)63-28-13-9-10-14-28/h11,15-16,18-19,21,25-29,34,37H,4-10,12-14,17,20,22-24H2,1-3H3,(H,50,52)(H,53,58)(H,54,56)(H,59,60)/t27-,29-,34+,37+,46+/m1/s1
DMCZH5B CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Cl)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6CCCCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)P(=O)(CC8=C(C=CC=C8F)F)O
DMCZH5B IK RFGUWOCFYCYEDM-ZOMNBDOOSA-N
DMCZH5B IU [(1S,4S,6R,14S,18R)-18-[8-chloro-7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-14-(cyclopentyloxycarbonylamino)-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadecan-4-yl]-[(2,6-difluorophenyl)methyl]phosphinic acid
DMCZH5B CA CAS 1001094-46-7
DMCZH5B DE Hepatitis C virus infection
DMF910Q ID DMF910Q
DMF910Q DN GS-9451
DMF910Q HS Phase 2
DMF910Q SN Vedroprevir; GS-9451; 1098189-15-1; UNII-KGD958X2B9; KGD958X2B9; CHEMBL2013174; Cyclopropanecarboxylic acid, N-[[(1a,3b,5a)-bicyclo[3.1.0]hex-3-yloxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-chloro-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-7-[2-(4-morpholinyl)ethoxy]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethyl-, (1R,2R)-; 1310824-24-8; Vedroprevir [USAN:INN]; GS 9451; GS9451; Vedroprevir (USAN); SCHEMBL10082460; SCHEMBL16241357; BDBM50379653; SB16765; DB12037; D10408
DMF910Q CP GILEAD
DMF910Q DT Small molecular drug
DMF910Q PC 25167947
DMF910Q MW 910.5
DMF910Q FM C45H60ClN7O9S
DMF910Q IC InChI=1S/C45H60ClN7O9S/c1-7-27-21-45(27,41(56)57)51-39(54)33-19-29(22-53(33)40(55)38(44(4,5)6)50-43(58)62-28-17-25-16-26(25)18-28)61-35-20-31(32-23-63-42(49-32)47-24(2)3)48-37-30(35)8-9-34(36(37)46)60-15-12-52-10-13-59-14-11-52/h8-9,20,23-29,33,38H,7,10-19,21-22H2,1-6H3,(H,47,49)(H,50,58)(H,51,54)(H,56,57)/t25-,26+,27-,28?,29-,33+,38-,45-/m1/s1
DMF910Q CS CC[C@@H]1C[C@@]1(C(=O)O)NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](C(C)(C)C)NC(=O)OC3C[C@H]4C[C@H]4C3)OC5=CC(=NC6=C5C=CC(=C6Cl)OCCN7CCOCC7)C8=CSC(=N8)NC(C)C
DMF910Q IK OTXAMWFYPMNDME-OPUYQWCOSA-N
DMF910Q IU (1R,2R)-1-[[(2S,4R)-1-[(2S)-2-[[(1S,5R)-3-bicyclo[3.1.0]hexanyl]oxycarbonylamino]-3,3-dimethylbutanoyl]-4-[8-chloro-7-(2-morpholin-4-ylethoxy)-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxypyrrolidine-2-carbonyl]amino]-2-ethylcyclopropane-1-carboxylic acid
DMF910Q CA CAS 1098189-15-1
DMF910Q DE Chronic HCV-1 infection
DMG5C8D ID DMG5C8D
DMG5C8D DN GS-9620
DMG5C8D HS Phase 2
DMG5C8D SN GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191
DMG5C8D CP GILEAD
DMG5C8D DT Small molecular drug
DMG5C8D PC 46241268
DMG5C8D MW 410.5
DMG5C8D FM C22H30N6O2
DMG5C8D IC InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26)
DMG5C8D CS CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N
DMG5C8D IK VFOKSTCIRGDTBR-UHFFFAOYSA-N
DMG5C8D IU 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one
DMG5C8D CA CAS 1228585-88-3
DMG5C8D DE Hepatitis B virus infection; Human immunodeficiency virus infection
DMYU6P5 ID DMYU6P5
DMYU6P5 DN GS-9857
DMYU6P5 HS Phase 2
DMYU6P5 DT Small molecular drug
DMYU6P5 PC 89921642
DMYU6P5 MW 868.9
DMYU6P5 FM C40H52F4N6O9S
DMYU6P5 IC InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMYU6P5 CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMYU6P5 IK MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMYU6P5 IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMYU6P5 CA CAS 1535212-07-7
DMYU6P5 DE Hepatitis C virus infection
DM9Q2B6 ID DM9Q2B6
DM9Q2B6 DN GS-9876
DM9Q2B6 HS Phase 2
DM9Q2B6 SN XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr
DM9Q2B6 CP Gilead Sciences Foster City, CA
DM9Q2B6 PC 118161062
DM9Q2B6 MW 443.5
DM9Q2B6 FM C23H25N9O
DM9Q2B6 IC InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)
DM9Q2B6 CS C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
DM9Q2B6 IK XCIGZBVOUQVIPI-UHFFFAOYSA-N
DM9Q2B6 IU 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine
DM9Q2B6 CA CAS 1800046-95-0
DM9Q2B6 DE Cutaneous lupus erythematosus; Rheumatoid arthritis
DMKWCTR ID DMKWCTR
DMKWCTR DN GS-9973
DMKWCTR HS Phase 2
DMKWCTR SN Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385
DMKWCTR CP Gilead Sciences
DMKWCTR DT Small molecular drug
DMKWCTR PC 59473233
DMKWCTR MW 411.5
DMKWCTR FM C23H21N7O
DMKWCTR IC InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
DMKWCTR CS C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6
DMKWCTR IK XSMSNFMDVXXHGJ-UHFFFAOYSA-N
DMKWCTR IU 6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
DMKWCTR CA CAS 1229208-44-9
DMKWCTR DE B-cell lymphoma; Acute myeloid leukaemia; Haematological malignancy
DMQGPLO ID DMQGPLO
DMQGPLO DN GSK-1070806
DMQGPLO HS Phase 2
DMQGPLO SN Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
DMQGPLO CP GlaxoSmithKline
DMQGPLO DT Antibody
DMQGPLO DE Type-2 diabetes
DMDMXKQ ID DMDMXKQ
DMDMXKQ DN GSK1292263
DMDMXKQ HS Phase 2
DMDMXKQ CP GSK
DMDMXKQ DT Small molecular drug
DMDMXKQ PC 24996872
DMDMXKQ MW 456.6
DMDMXKQ FM C23H28N4O4S
DMDMXKQ IC InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
DMDMXKQ CS CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C
DMDMXKQ IK AYJRTVVIBJSSKN-UHFFFAOYSA-N
DMDMXKQ IU 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole
DMDMXKQ CA CAS 1032823-75-8
DMDMXKQ DE Type-2 diabetes; Gastric adenocarcinoma
DM1EPMF ID DM1EPMF
DM1EPMF DN GSK1322322
DM1EPMF HS Phase 2
DM1EPMF SN GSK-1322322
DM1EPMF CP GlaxoSmithKline
DM1EPMF PC 52918384
DM1EPMF MW 479.5
DM1EPMF FM C22H34FN7O4
DM1EPMF IC InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1
DM1EPMF CS CC1=NC(=C(C(=N1)N2CCN3CCOC[C@@H]3C2)F)NNC(=O)[C@H](CC4CCCC4)CN(C=O)O
DM1EPMF IK SWHNZGMQMGFQGW-MSOLQXFVSA-N
DM1EPMF IU N-[(2R)-3-[2-[6-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-5-fluoro-2-methylpyrimidin-4-yl]hydrazinyl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
DM1EPMF CA CAS 1152107-25-9
DM1EPMF DE Bacterial infection
DMA6RBF ID DMA6RBF
DMA6RBF DN GSK1325756
DMA6RBF HS Phase 2
DMA6RBF SN Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF CP GlaxoSmithKline
DMA6RBF DT Small molecular drug
DMA6RBF PC 24780598
DMA6RBF MW 441.9
DMA6RBF FM C19H21ClFN3O4S
DMA6RBF IC InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
DMA6RBF CS CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O
DMA6RBF IK NGYNBSHYFOFVLS-LBPRGKRZSA-N
DMA6RBF IU 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF CA CAS 954126-98-8
DMA6RBF DE Chronic obstructive pulmonary disease
DM6HBGN ID DM6HBGN
DM6HBGN DN GSK-1399686
DM6HBGN HS Phase 2
DM6HBGN SN 1399686
DM6HBGN CP GlaxoSmithKline plc
DM6HBGN DE Inflammatory bowel disease
DMZHB37 ID DMZHB37
DMZHB37 DN GSK2110183
DMZHB37 HS Phase 2
DMZHB37 CP GlaxoSmithKline
DMZHB37 DT Small molecular drug
DMZHB37 PC 46843057
DMZHB37 MW 427.3
DMZHB37 FM C18H17Cl2FN4OS
DMZHB37 IC InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
DMZHB37 CS CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl
DMZHB37 IK AFJRDFWMXUECEW-LBPRGKRZSA-N
DMZHB37 IU N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide
DMZHB37 CA CAS 1047644-62-1
DMZHB37 CB CHEBI:131168
DMZHB37 DE Multiple myeloma; leukaemia; Solid tumour/cancer
DMSHE70 ID DMSHE70
DMSHE70 DN GSK2141795
DMSHE70 HS Phase 2
DMSHE70 SN Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70 CP GlaxoSmithKline
DMSHE70 DT Small molecular drug
DMSHE70 PC 51042438
DMSHE70 MW 429.2
DMSHE70 FM C18H16Cl2F2N4O2
DMSHE70 IC InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1
DMSHE70 CS CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl
DMSHE70 IK AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70 IU N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide
DMSHE70 CA CAS 1047634-65-0
DMSHE70 DE Lymphoma; Colorectal cancer
DMBWPZJ ID DMBWPZJ
DMBWPZJ DN GSK2245035
DMBWPZJ HS Phase 2
DMBWPZJ SN GSK-2245035
DMBWPZJ CP GlaxoSmithKline
DMBWPZJ DT Small molecular drug
DMBWPZJ PC 44623937
DMBWPZJ MW 390.5
DMBWPZJ FM C20H34N6O2
DMBWPZJ IC InChI=1S/C20H34N6O2/c1-3-10-15(2)28-19-23-17(21)16-18(24-19)26(20(27)22-16)14-9-5-8-13-25-11-6-4-7-12-25/h15H,3-14H2,1-2H3,(H,22,27)(H2,21,23,24)/t15-/m0/s1
DMBWPZJ CS CCC[C@H](C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N
DMBWPZJ IK LFMPVTVPXHNXOT-HNNXBMFYSA-N
DMBWPZJ IU 6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one
DMBWPZJ CA CAS 1207629-49-9
DMBWPZJ DE Asthma
DMG7YQL ID DMG7YQL
DMG7YQL DN GSK2245840
DMG7YQL HS Phase 2
DMG7YQL SN Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,
DMG7YQL CP GSK
DMG7YQL DT Small molecular drug
DMG7YQL PC 25108829
DMG7YQL MW 516.6
DMG7YQL FM C26H24N6O2S2
DMG7YQL IC InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
DMG7YQL CS CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
DMG7YQL IK LAMQVIQMVKWXOC-UHFFFAOYSA-N
DMG7YQL IU 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide
DMG7YQL CA CAS 1093403-33-8
DMG7YQL DE Chronic obstructive pulmonary disease
DMLFI7Q ID DMLFI7Q
DMLFI7Q DN GSK-2251052
DMLFI7Q HS Phase 2
DMLFI7Q SN ABX; AN-3365; GSK '052; Boron-based LeuRS inhibitors (Gram-negative bacterial infection), Anacor/GSK; Boron-based leucyl-tRNA synthetase inhibitors (bacterial infection), Anacor/GSK
DMLFI7Q CP Anacor Pharmaceuticals Inc
DMLFI7Q DT Small molecular drug
DMLFI7Q PC 46836890
DMLFI7Q MW 237.06
DMLFI7Q FM C11H16BNO4
DMLFI7Q IC InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1
DMLFI7Q CS B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O
DMLFI7Q IK FXQIIDINBDJDKL-SNVBAGLBSA-N
DMLFI7Q IU 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol
DMLFI7Q CA CAS 1093643-37-8
DMLFI7Q DE Urinary tract infection
DMIN0SV ID DMIN0SV
DMIN0SV DN GSK2269557
DMIN0SV HS Phase 2
DMIN0SV CP Glaxosmithkline
DMIN0SV PC 49784002
DMIN0SV MW 440.5
DMIN0SV FM C26H28N6O
DMIN0SV IC InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)
DMIN0SV CS CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5
DMIN0SV IK MCIDWGZGWVSZMK-UHFFFAOYSA-N
DMIN0SV IU 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole
DMIN0SV CA CAS 1254036-71-9
DMIN0SV DE Asthma
DM4BTH8 ID DM4BTH8
DM4BTH8 DN GSK2330672
DM4BTH8 HS Phase 2
DM4BTH8 CP GlaxoSmithKline
DM4BTH8 PC 53492727
DM4BTH8 MW 546.7
DM4BTH8 FM C28H38N2O7S
DM4BTH8 IC InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
DM4BTH8 CS CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
DM4BTH8 IK CZGVOBIGEBDYTP-VSGBNLITSA-N
DM4BTH8 IU 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid
DM4BTH8 CA CAS 1345982-69-5
DM4BTH8 DE Type-2 diabetes; Pruritus
DMB0CXT ID DMB0CXT
DMB0CXT DN GSK2330811
DMB0CXT HS Phase 2
DMB0CXT CP GlaxoSmithKline Research Triangle Park, NC
DMB0CXT DE Systemic sclerosis; Crohn disease
DMXUCG3 ID DMXUCG3
DMXUCG3 DN GSK233705
DMXUCG3 HS Phase 2
DMXUCG3 CP GlaxoSmithKline
DMXUCG3 DE Chronic obstructive pulmonary disease
DMRA3T2 ID DMRA3T2
DMRA3T2 DN GSK2339345
DMRA3T2 HS Phase 2
DMRA3T2 SN GSK-2339345
DMRA3T2 CP GlaxoSmithKline
DMRA3T2 DE Cough
DMBJMZC ID DMBJMZC
DMBJMZC DN GSK239512
DMBJMZC HS Phase 2
DMBJMZC SN 720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; GSK239512; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K
DMBJMZC CP GSK
DMBJMZC DT Small molecular drug
DMBJMZC PC 9976892
DMBJMZC MW 377.5
DMBJMZC FM C23H27N3O2
DMBJMZC IC InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
DMBJMZC CS C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
DMBJMZC IK YFRBKEVUUCQYOW-UHFFFAOYSA-N
DMBJMZC IU 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
DMBJMZC CA CAS 720691-69-0
DMBJMZC DE Dementia; Alzheimer disease
DMFAU3Z ID DMFAU3Z
DMFAU3Z DN GSK249320
DMFAU3Z HS Phase 2
DMFAU3Z CP GlaxoSmithKline
DMFAU3Z DT Antibody
DMFAU3Z DE Stroke
DMMAIY2 ID DMMAIY2
DMMAIY2 DN GSK-256073
DMMAIY2 HS Phase 2
DMMAIY2 SN GPCR agonists (hyperlipidemia), GSK; GSK-256073-A; HM74A receptor agonists (hyperlipidemia), GSK; G protein-coupled receptor agonists (hyperlipidemia), GSK
DMMAIY2 CP GlaxoSmithKline plc
DMMAIY2 DT Small molecular drug
DMMAIY2 PC 46215799
DMMAIY2 MW 256.69
DMMAIY2 FM C10H13ClN4O2
DMMAIY2 IC InChI=1S/C10H13ClN4O2/c1-2-3-4-5-15-7-6(12-9(11)13-7)8(16)14-10(15)17/h2-5H2,1H3,(H,12,13)(H,14,16,17)
DMMAIY2 CS CCCCCN1C2=C(C(=O)NC1=O)NC(=N2)Cl
DMMAIY2 IK CGAMDQCXAAOFSR-UHFFFAOYSA-N
DMMAIY2 IU 8-chloro-3-pentyl-7H-purine-2,6-dione
DMMAIY2 CA CAS 862892-90-8
DMMAIY2 DE Hyperlipidaemia
DMA2IXQ ID DMA2IXQ
DMA2IXQ DN GSK2586184
DMA2IXQ HS Phase 2
DMA2IXQ SN GSK-2586184
DMA2IXQ CP GlaxoSmithKline
DMA2IXQ PC 44603362
DMA2IXQ MW 389.4
DMA2IXQ FM C22H23N5O2
DMA2IXQ IC InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)
DMA2IXQ CS CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
DMA2IXQ IK MPYACSQFXVMWNO-UHFFFAOYSA-N
DMA2IXQ IU N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMA2IXQ CA CAS 1206163-45-2
DMA2IXQ DE Arthritis; Systemic lupus erythematosus
DMU5EVR ID DMU5EVR
DMU5EVR DN GSK2586881
DMU5EVR HS Phase 2
DMU5EVR SN GSK-2586881
DMU5EVR CP GlaxoSmithKline
DMU5EVR DE Acute lung injury; Pulmonary arterial hypertension
DM7V96W ID DM7V96W
DM7V96W DN GSK2798745
DM7V96W HS Phase 2
DM7V96W CP GlaxoSmithKline Research Triangle Park, NC
DM7V96W DE Heart failure
DMCIGRW ID DMCIGRW
DMCIGRW DN GSK2838232
DMCIGRW HS Phase 2
DMCIGRW CP GlaxoSmithKline
DMCIGRW DT Small molecular drug
DMCIGRW DE Human immunodeficiency virus-1 infection
DMT5YK7 ID DMT5YK7
DMT5YK7 DN GSK2890457
DMT5YK7 HS Phase 2
DMT5YK7 SN GSK-2890457
DMT5YK7 CP GlaxoSmithKline
DMT5YK7 DE Obesity
DM25YLM ID DM25YLM
DM25YLM DN GSK2981278
DM25YLM HS Phase 2
DM25YLM SN ROR gama modulator 1; 1474110-21-8; UNII-L49V5G013I; L49V5G013I; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide; GTPL9661; SCHEMBL15352875; LZLBRISQTJVZNP-UHFFFAOYSA-N; MolPort-044-561-790; EX-A1179; ZINC142250256; AKOS030526564; CS-5449; GSK-2981278; HY-19770; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide; Benzenesulfonamide, N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-((tetrahydro-2H-pyran-4-yl)
DM25YLM CP GlaxoSmithKline Research Triangle Park, NC
DM25YLM PC 89875987
DM25YLM MW 461.6
DM25YLM FM C25H35NO5S
DM25YLM IC InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3
DM25YLM CS CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO
DM25YLM IK LZLBRISQTJVZNP-UHFFFAOYSA-N
DM25YLM IU N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide
DM25YLM CA CAS 1474110-21-8
DM25YLM DE Plaque psoriasis
DM7HNFV ID DM7HNFV
DM7HNFV DN GSK2982772
DM7HNFV HS Phase 2
DM7HNFV SN LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr
DM7HNFV CP GlaxoSmithKline Research Triangle Park, NC
DM7HNFV PC 77108121
DM7HNFV MW 377.4
DM7HNFV FM C20H19N5O3
DM7HNFV IC InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1
DM7HNFV CS CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
DM7HNFV IK LYPAFUINURXJSG-AWEZNQCLSA-N
DM7HNFV IU 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
DM7HNFV CA CAS 1622848-92-3
DM7HNFV DE Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis; Ulcerative colitis
DMCDAVK ID DMCDAVK
DMCDAVK DN GSK3036656
DMCDAVK HS Phase 2
DMCDAVK SN GSK656 HCl; GSK656; 2131798-13-3; UNII-P83HS633ZK; P83HS633ZK; CHEMBL4082159; 2131798-13-3 (HCl); GSK-656; GSK-070; BCP29367; EX-A3128; BDBM50241779; GSK-3036656; GSK3036656; GSK070 hydrochloride; HY-107775; CS-0030140; (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride; (S)3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)ol hydrochloride; (S)a?-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)a'ol hydrochloride; Ethanol, 2-(((3S)-3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)oxy)-, hydrochloride (1:1)
DMCDAVK CP GlaxoSmithKline
DMCDAVK DT Small molecular drug
DMCDAVK PC 134691736
DMCDAVK MW 293.94
DMCDAVK FM C10H14BCl2NO4
DMCDAVK IC InChI=1S/C10H13BClNO4.ClH/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15;/h1-2,8,14-15H,3-5,13H2;1H/t8-;/m1./s1
DMCDAVK CS B1(C2=C(C=CC(=C2[C@H](O1)CN)Cl)OCCO)O.Cl
DMCDAVK IK FUOKBESTQMGROA-DDWIOCJRSA-N
DMCDAVK IU 2-[[(3S)-3-(aminomethyl)-4-chloro-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]ethanol;hydrochloride
DMCDAVK CA CAS 2131798-13-3
DMCDAVK DE Tuberculosis
DMEXKF4 ID DMEXKF4
DMEXKF4 DN GSK3196165
DMEXKF4 HS Phase 2
DMEXKF4 CP GlaxoSmithKline Research Triangle Park, NC
DMEXKF4 DE Rheumatoid arthritis
DMPBK8N ID DMPBK8N
DMPBK8N DN GSK3228836
DMPBK8N HS Phase 2
DMPBK8N SN IONIS-HBVRX; GSK'836
DMPBK8N CP GlaxoSmithKline
DMPBK8N DT Antisense oligonucleotide
DMPBK8N DE Hepatitis B
DMJRD7A ID DMJRD7A
DMJRD7A DN GSK3326595
DMJRD7A HS Phase 2
DMJRD7A SN JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
DMJRD7A CP GlaxoSmithKline Research Triangle Park, NC
DMJRD7A PC 90241742
DMJRD7A MW 452.5
DMJRD7A FM C24H32N6O3
DMJRD7A IC InChI=1S/C24H32N6O3/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28)/t21-/m0/s1
DMJRD7A CS CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC[C@@H](CN3CCC4=CC=CC=C4C3)O
DMJRD7A IK JLCCNYVTIWRPIZ-NRFANRHFSA-N
DMJRD7A IU 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide
DMJRD7A CA CAS 1616392-22-3
DMJRD7A DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer
DMO5JS3 ID DMO5JS3
DMO5JS3 DN GSK3389404
DMO5JS3 HS Phase 2
DMO5JS3 SN IONIS-HBV-LRX
DMO5JS3 CP GlaxoSmithKline
DMO5JS3 DT Antisense oligonucleotide
DMO5JS3 DE Hepatitis B
DMMOWT9 ID DMMOWT9
DMMOWT9 DN GSK3640254
DMMOWT9 HS Phase 2
DMMOWT9 SN GSK'254
DMMOWT9 CP ViiV Healthcare
DMMOWT9 DE Human immunodeficiency virus infection
DMV3TO4 ID DMV3TO4
DMV3TO4 DN GSK3810109
DMV3TO4 HS Phase 2
DMV3TO4 CP ViiV Healthcare
DMV3TO4 DT Antibody
DMV3TO4 DE Human immunodeficiency virus-1 infection
DMV6SNU ID DMV6SNU
DMV6SNU DN GSK4069889
DMV6SNU HS Phase 2
DMV6SNU SN TSR-022
DMV6SNU CP AnaptysBio
DMV6SNU DT Antibody
DMV6SNU DE Non-small cell lung cancer
DM3ZL2O ID DM3ZL2O
DM3ZL2O DN GSK-557296
DM3ZL2O HS Phase 2
DM3ZL2O SN Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline
DM3ZL2O CP GlaxoSmithKline plc
DM3ZL2O DT Small molecular drug
DM3ZL2O PC 11634973
DM3ZL2O MW 518.6
DM3ZL2O FM C30H38N4O4
DM3ZL2O IC InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1
DM3ZL2O CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DM3ZL2O IK UWHCWRQFNKUYCG-QUZACWSFSA-N
DM3ZL2O IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DM3ZL2O CA CAS 872599-83-2
DM3ZL2O DE Premature ejaculation
DMEVARK ID DMEVARK
DMEVARK DN GSK561679
DMEVARK HS Phase 2
DMEVARK SN VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695
DMEVARK CP GSK
DMEVARK DT Small molecular drug
DMEVARK PC 11596613
DMEVARK MW 406.5
DMEVARK FM C22H26N6O2
DMEVARK IC InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/s1
DMEVARK CS CC[C@@H](C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C
DMEVARK IK VKHVAUKFLBBZFJ-SFHVURJKSA-N
DMEVARK IU 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
DMEVARK CA CAS 885220-61-1
DMEVARK DE Major depressive disorder; Alcohol dependence
DMGU05N ID DMGU05N
DMGU05N DN GSK598809
DMGU05N HS Phase 2
DMGU05N CP GSK
DMGU05N PC 24743758
DMGU05N MW 481.5
DMGU05N FM C22H23F4N5OS
DMGU05N IC InChI=1S/C22H23F4N5OS/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3
DMGU05N CS CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=C(C=C(C=C5)C(F)(F)F)F
DMGU05N IK ZKRWPAYTJMRKLJ-UHFFFAOYSA-N
DMGU05N IU 5-[5-[3-[1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole
DMGU05N DE Drug abuse
DMTW79H ID DMTW79H
DMTW79H DN GSK683699
DMTW79H HS Phase 2
DMTW79H SN 4-Aminobutanoic acid; 4-aminobutyric acid; GABA; gamma-aminobutyric acid; 1956/12/2; Piperidic acid; Piperidinic acid; Aminalon; Mielogen; Gammalon; Gaballon; butanoic acid, 4-amino-; Mielomade; Gammalone; Gamarex; Gammasol; Gammar; Reanal; Immu-G; gamma-amino-n-butyric acid; gamma-Aminobutanoic acid; Butyric acid, 4-amino-; Gamastan; Gammagee; Gamulin; 4-aminobutyrate; omega-Aminobutyric acid; gamma-Aminobutyric acid; 3-Carboxypropylamine; gamma-Aminobuttersaeure; 4-amino-butanoic acid; gamma-Amino butyric acid; GAMMA-AMINO-BUTANOIC ACID
DMTW79H CP GSK; Tanabe
DMTW79H DT Small molecular drug
DMTW79H PC 119
DMTW79H MW 103.12
DMTW79H FM C4H9NO2
DMTW79H IC InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)
DMTW79H CS C(CC(=O)O)CN
DMTW79H IK BTCSSZJGUNDROE-UHFFFAOYSA-N
DMTW79H IU 4-aminobutanoic acid
DMTW79H CA CAS 56-12-2
DMTW79H CB CHEBI:16865
DMTW79H DE Inflammatory bowel disease
DMPLKAH ID DMPLKAH
DMPLKAH DN GSK-706769
DMPLKAH HS Phase 2
DMPLKAH SN GSK-163929; GSK-929; CCR5 antagonist (HIV), GSK; CCR5 antagonist (HIV), ViiV; CCR5 chemokine antagonists (HIV-1 infection),GlaxoSmithKline
DMPLKAH CP GlaxoSmithKline plc
DMPLKAH DE Human immunodeficiency virus infection
DMIEXUM ID DMIEXUM
DMIEXUM DN GSK768974
DMIEXUM HS Phase 2
DMIEXUM SN PTH analog, GlaxoSmithKline/Unigene; Parathyroid hormone analog (oral, Enteripep), Unigene/GlaxoSmithKline
DMIEXUM CP Unigene Laboratories Inc
DMIEXUM DE Osteoporosis
DMX27Q1 ID DMX27Q1
DMX27Q1 DN GSK933776A
DMX27Q1 HS Phase 2
DMX27Q1 CP GlaxoSmithKline
DMX27Q1 DE Macular degeneration; Alzheimer disease
DM6DKF9 ID DM6DKF9
DM6DKF9 DN GSK961081
DM6DKF9 HS Phase 2
DM6DKF9 SN CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate
DM6DKF9 CP GSK
DM6DKF9 DT Small molecular drug
DM6DKF9 PC 10372836
DM6DKF9 MW 740.2
DM6DKF9 FM C40H42ClN5O7
DM6DKF9 IC InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1
DM6DKF9 CS COC1=CC(=C(C=C1CNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)Cl)NC(=O)CCN4CCC(CC4)OC(=O)NC5=CC=CC=C5C6=CC=CC=C6
DM6DKF9 IK URWYQGVSPQJGGB-DHUJRADRSA-N
DM6DKF9 IU [1-[3-[2-chloro-4-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DM6DKF9 CA CAS 743461-65-6
DM6DKF9 DE Chronic obstructive pulmonary disease
DM8N3OQ ID DM8N3OQ
DM8N3OQ DN GT-AADC
DM8N3OQ HS Phase 2
DM8N3OQ CP PTC Therapeutics
DM8N3OQ DT Gene therapy
DM8N3OQ DE Aromatic L-amino acid decarboxylase deficiency
DMN6IDO ID DMN6IDO
DMN6IDO DN GTP-010
DMN6IDO HS Phase 2
DMN6IDO CP Gastrotech Pharma
DMN6IDO DE Dyspepsia; Irritable bowel syndrome
DM03NQS ID DM03NQS
DM03NQS DN GTP-200
DM03NQS HS Phase 2
DM03NQS DE Solid tumour/cancer
DMEN5KA ID DMEN5KA
DMEN5KA DN GTS-21
DMEN5KA HS Phase 2
DMEN5KA SN Gts-21; DMXBA; Gts 21; DMXB-Anabaseine; GTS-21 (dihydrochloride); DMXB-A; (E)-3-((2,4-Dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-2,3'-bipyridine dihydrochloride; 2,3'-Bipyridine, 3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-, dihydrochloride, (E)-; DMBX-anabaseine; DMBX-A; AC1O5PJQ; SCHEMBL2561893; SCHEMBL12274790; HY-14564A; CS-5486; SB16826; BC654014; AN-16572; GTS-21, > LS-173500; 3-(2,4-Dimethoxybenzylidene)anabaseine dihydrochloride
DMEN5KA DT Small molecular drug
DMEN5KA PC 5310985
DMEN5KA MW 308.4
DMEN5KA FM C19H20N2O2
DMEN5KA IC InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+
DMEN5KA CS COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC
DMEN5KA IK RPYWXZCFYPVCNQ-RVDMUPIBSA-N
DMEN5KA IU 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine
DMEN5KA CA CAS 148372-04-7
DMEN5KA DE Parkinson disease
DMDWYZS ID DMDWYZS
DMDWYZS DN GTx-758
DMDWYZS HS Phase 2
DMDWYZS CP GTx
DMDWYZS PC 46861578
DMDWYZS MW 341.3
DMDWYZS FM C19H13F2NO3
DMDWYZS IC InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H
DMDWYZS CS C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
DMDWYZS IK FBCQEUMZZNVQKD-UHFFFAOYSA-N
DMDWYZS IU 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide
DMDWYZS CA CAS 938067-78-8
DMDWYZS DE Prostate cancer
DMY53PL ID DMY53PL
DMY53PL DN GW 597599
DMY53PL HS Phase 2
DMY53PL SN Vestipitant mesylate < USAN; N-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2(S)-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide methanesulfonate
DMY53PL CP GlaxoSmithKline
DMY53PL DT Small molecular drug
DMY53PL PC 24969622
DMY53PL MW 587.6
DMY53PL FM C24H28F7N3O4S
DMY53PL IC InChI=1S/C23H24F7N3O.CH4O3S/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30;1-5(2,3)4/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3;1H3,(H,2,3,4)/t14-,20-;/m1./s1
DMY53PL CS CC1=C(C=CC(=C1)F)[C@H]2CNCCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F.CS(=O)(=O)O
DMY53PL IK BHECXGHXWKHZOY-DXPOFMJKSA-N
DMY53PL IU (2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide;methanesulfonic acid
DMY53PL CA CAS 334476-64-1
DMY53PL DE Mood disorder; Major depressive disorder
DMZMCB1 ID DMZMCB1
DMZMCB1 DN GW274150
DMZMCB1 HS Phase 2
DMZMCB1 SN GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1 DT Small molecular drug
DMZMCB1 PC 9797017
DMZMCB1 MW 219.31
DMZMCB1 FM C8H17N3O2S
DMZMCB1 IC InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
DMZMCB1 CS CC(=NCCSCC[C@@H](C(=O)O)N)N
DMZMCB1 IK MOLOJNHYNHBPCW-ZETCQYMHSA-N
DMZMCB1 IU (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1 CA CAS 210354-22-6
DMZMCB1 DE Asthma
DMY3KSU ID DMY3KSU
DMY3KSU DN GW-42004
DMY3KSU HS Phase 2
DMY3KSU SN CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals
DMY3KSU CP GW Pharmaceuticals plc
DMY3KSU DE Lipid metabolism disorder
DMBX9C0 ID DMBX9C0
DMBX9C0 DN GW-427353
DMBX9C0 HS Phase 2
DMBX9C0 SN UNII-GU14FR8D4A; GU14FR8D4A; GW427353B; Solabegron hydrochloride [USAN]; Solabegron hydrochloride (USAN); GW 427353B; Solabegron Hydrochloride; Solabegron HCl; SCHEMBL565177; CHEMBL2107299; PMXCGBVBIRYFPR-FTBISJDPSA-N; BCP28076; 3'-[(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]biphenyl-3-carboxylic acid hydrochloride; D05879; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-, hydrochloride
DMBX9C0 CP GSK
DMBX9C0 DT Small molecular drug
DMBX9C0 PC 9887812
DMBX9C0 MW 410.9
DMBX9C0 FM C23H23ClN2O3
DMBX9C0 IC InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1
DMBX9C0 CS C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O
DMBX9C0 IK LLDXOPKUNJTIRF-QFIPXVFZSA-N
DMBX9C0 IU 3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid
DMBX9C0 CA CAS 252920-94-8
DMBX9C0 CB CHEBI:141346
DMBX9C0 DE Urinary incontinence
DMH0C8J ID DMH0C8J
DMH0C8J DN GW-813893
DMH0C8J HS Phase 2
DMH0C8J SN Factor Xa inhibitors, GSK; Factor Xa inhibitors, GlaxoSmithKline; 813893
DMH0C8J CP GlaxoSmithKline plc
DMH0C8J PC 9911502
DMH0C8J MW 448
DMH0C8J FM C17H22ClN3O5S2
DMH0C8J IC InChI=1S/C17H22ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,5,11-12,14,19H,4,6-10H2,1H3/b11-5+/t12-,14-/m0/s1
DMH0C8J CS C[C@@H](C(=O)N1CCOCC1)N2CC[C@@H](C2=O)NS(=O)(=O)/C=C/C3=CC=C(S3)Cl
DMH0C8J IK ACEFOQMQINFMRW-DYCFVMESSA-N
DMH0C8J IU (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-morpholin-4-yl-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide
DMH0C8J CA CAS 478644-12-1
DMH0C8J DE Thrombosis
DM489FT ID DM489FT
DM489FT DN GW-870086-X
DM489FT HS Phase 2
DM489FT SN GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline
DM489FT CP GlaxoSmithKline plc
DM489FT DE Atopic dermatitis
DMQEC9P ID DMQEC9P
DMQEC9P DN GW-870086-X
DMQEC9P HS Phase 2
DMQEC9P SN Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline
DMQEC9P CP GlaxoSmithKline plc
DMQEC9P DE Asthma
DM8XH3S ID DM8XH3S
DM8XH3S DN H-1152
DM8XH3S HS Phase 2
DM8XH3S SN 451462-58-1; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; CHEBI:88220; H-1152P; (S)-H-1152 (hydrochloride); H52; dimethyl fasudil; 4-methyl-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline; 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline; 2gnh; 2gnl; 1q8u; AC1L9LJA; H 1152; SCHEMBL124161; CHEMBL406821; ZINC22706; BDBM14028; BCP16935; 3714AH; AKOS027263830; DB07876; CS-1536; HY-15720; LS-193100; W-5343; 4-methyl-5-[(2S)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline
DM8XH3S CP CoTherix
DM8XH3S DT Small molecular drug
DM8XH3S PC 448043
DM8XH3S MW 319.4
DM8XH3S FM C16H21N3O2S
DM8XH3S IC InChI=1S/C16H21N3O2S/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3/t13-/m0/s1
DM8XH3S CS C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C
DM8XH3S IK AWDORCFLUJZUQS-ZDUSSCGKSA-N
DM8XH3S IU 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline
DM8XH3S CA CAS 451462-58-1
DM8XH3S CB CHEBI:88220
DM8XH3S DE Pulmonary arterial hypertension
DMO4I61 ID DMO4I61
DMO4I61 DN H5N1 influenza vaccine
DMO4I61 HS Phase 2
DMO4I61 SN Daronrix; GSK-1119711A; H5N1 influenza vaccine (inactivated whole virus adjuvanted); Avian influenzavaccine (inactivated whole virus adjuvanted), GlaxoSmithKline; H5N1 influenza vaccine (inactivated whole virus adjuvanted), GlaxoSmithKline
DMO4I61 CP GlaxoSmithKline plc
DMO4I61 DT Vaccine
DMO4I61 DE Influenza virus infection
DM74ZKN ID DM74ZKN
DM74ZKN DN HBI-3000
DM74ZKN HS Phase 2
DM74ZKN SN Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA
DM74ZKN CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM74ZKN DE Heart arrhythmia; Atrial fibrillation
DMSMCXN ID DMSMCXN
DMSMCXN DN HBV vaccine
DMSMCXN HS Phase 2
DMSMCXN SN HBV vaccine (adjuvanted); HBV vaccine (adjuvanted), GlaxoSmithKline Biologicals
DMSMCXN CP GlaxoSmithKline Biologicals
DMSMCXN DT Vaccine
DMSMCXN DE Hepatitis B virus infection
DMX8C6J ID DMX8C6J
DMX8C6J DN HCB1019
DMX8C6J HS Phase 2
DMX8C6J CP OcuNexus Therapeutics
DMX8C6J DT Small molecular drug
DMX8C6J DE Diabetic macular edema
DMRQGMZ ID DMRQGMZ
DMRQGMZ DN HD-003
DMRQGMZ HS Phase 2
DMRQGMZ SN NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki
DMRQGMZ CP Nippon Zoki Pharmaceutical Co Ltd
DMRQGMZ DE Kidney disease
DMAX632 ID DMAX632
DMAX632 DN HDV-interferon
DMAX632 HS Phase 2
DMAX632 SN HDV-interferon (sc, HCV infection); HDV-IFN (sc, HCV infection), Hepasome Pharmaceuticals; HDV-interferon (sc, HCV infection), Hepasome Pharmaceuticals
DMAX632 CP Hepasome Pharmaceuticals
DMAX632 DE Hepatitis C virus infection
DMV50R1 ID DMV50R1
DMV50R1 DN HE3235
DMV50R1 HS Phase 2
DMV50R1 SN Apoptone; HE3235; UNII-891O182ZP5; 183387-50-0; HE 3235; 891O182ZP5; SCHEMBL3402872; Pregn-20-yne-3,17-diol, (3alpha,5alpha,17alpha)-; DTXSID70171418; MolPort-044-561-946; ZINC5921098
DMV50R1 CP Harbor Therapeutics
DMV50R1 DT Small molecular drug
DMV50R1 PC 42611099
DMV50R1 MW 316.5
DMV50R1 FM C21H32O2
DMV50R1 IC InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1
DMV50R1 CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O
DMV50R1 IK CKAXZOYFIHQCBN-JRRMKBMNSA-N
DMV50R1 IU (3R,5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
DMV50R1 CA CAS 183387-50-0
DMV50R1 DE Breast cancer
DM9OZU5 ID DM9OZU5
DM9OZU5 DN Heat shock protein vaccine
DM9OZU5 HS Phase 2
DM9OZU5 CP Agenus
DM9OZU5 DT Vaccine
DM9OZU5 DE Meningococcal infection
DM8QGPE ID DM8QGPE
DM8QGPE DN HepaStem
DM8QGPE HS Phase 2
DM8QGPE CP Promethera Biosciences SA/NV
DM8QGPE DE Liver failure
DMX6B95 ID DMX6B95
DMX6B95 DN HER1-VSSP vaccine
DMX6B95 HS Phase 2
DMX6B95 SN HER1-VSSP vaccine (cancer)
DMX6B95 CP The Center of Molecular Immunology
DMX6B95 DT Vaccine
DMX6B95 DE Solid tumour/cancer
DM8TOS0 ID DM8TOS0
DM8TOS0 DN HER-2 Protein AutoVac
DM8TOS0 HS Phase 2
DM8TOS0 CP Pharmexa
DM8TOS0 DE Breast cancer
DMISETH ID DMISETH
DMISETH DN HER2/neu peptide vaccine
DMISETH HS Phase 2
DMISETH SN HER2/neu peptide vaccine (intradermal, breast cancer)
DMISETH CP Fred Hutchinson Cancer Research Center
DMISETH DT Vaccine
DMISETH DE Breast cancer
DMQTREC ID DMQTREC
DMQTREC DN Her2-targeted autologous T-cell therapy
DMQTREC HS Phase 2
DMQTREC SN Her2-targeted autologous T-cell therapy (cancer)
DMQTREC CP Baylor College of Medicine
DMQTREC DE Glioblastoma multiforme
DMI4C90 ID DMI4C90
DMI4C90 DN HF-0220
DMI4C90 HS Phase 2
DMI4C90 SN Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming
DMI4C90 CP Hunter-Fleming Ltd
DMI4C90 PC 9836181
DMI4C90 MW 306.4
DMI4C90 FM C19H30O3
DMI4C90 IC InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1
DMI4C90 CS C[C@]12CC[C@@H](C[C@@H]1C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O)O
DMI4C90 IK VFPMCLQMAUVEHD-UCPSWNCLSA-N
DMI4C90 IU (3S,5R,7S,8R,9S,10S,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMI4C90 CA CAS 25848-69-5
DMI4C90 DE Alzheimer disease
DMDZE3B ID DMDZE3B
DMDZE3B DN HGT-1111
DMDZE3B HS Phase 2
DMDZE3B SN Metazym; M-0001; Recombinant arylsulfatase A (lysosomal storage disease), Shire; Recombinant arylsulfatase A (lysosomal storage disease), Zymenex; Recombinant arylsulfatase A (metachromatic leukodystrophy), Shire; Lysosomal arylsulfatase A replacement therapy (FGE, metachromatic leukodystrophy), Shire; Lysosomal asa replacement therapy (FGE, metachromatic leukodystrophy), Shire
DMDZE3B CP Zymenex A/S
DMDZE3B DE Metachromatic leukodystrophy
DMHZ4JI ID DMHZ4JI
DMHZ4JI DN HGT-1410
DMHZ4JI HS Phase 2
DMHZ4JI SN Intrathecal sulfamidase replacement therapy (FGE, Sanfilippo syndrome), Shire; Intrathecal heparin n-sulfamidase (FGE, Sanfilippo syndrome), Shire
DMHZ4JI CP Shire Human Genetic Therapies Inc
DMHZ4JI DE Sanfilippo syndrome
DM0LA6E ID DM0LA6E
DM0LA6E DN HGTV43
DM0LA6E HS Phase 2
DM0LA6E CP Enzo Biochem
DM0LA6E TC Antisense
DM0LA6E DT Antisense drug
DM0LA6E DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMO10JI ID DMO10JI
DMO10JI DN HibTITER
DMO10JI HS Phase 2
DMO10JI SN Haemophilus vaccine II, Praxis; Conjugate vaccine (Haemophilus influenzae type B/ meningitis), Nuron Biotech
DMO10JI CP Nuron biotech
DMO10JI DT Vaccine
DMO10JI DE Pneumococcal infection
DMLQDBH ID DMLQDBH
DMLQDBH DN HM-5016504
DMLQDBH HS Phase 2
DMLQDBH SN C-Met inhibitor (cancer), Hutchison
DMLQDBH CP Hutchison Medipharma Enterprises Ltd
DMLQDBH DE Solid tumour/cancer
DMZ3BER ID DMZ3BER
DMZ3BER DN HM-78136B
DMZ3BER HS Phase 2
DMZ3BER SN Pan-Her/EGFR inhibitors (cancer), Hanmi
DMZ3BER CP Hanmi Pharmaceutical Co Ltd
DMZ3BER DT Small molecular drug
DMZ3BER PC 25127713
DMZ3BER MW 491.3
DMZ3BER FM C23H21Cl2FN4O3
DMZ3BER IC InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
DMZ3BER CS COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
DMZ3BER IK LPFWVDIFUFFKJU-UHFFFAOYSA-N
DMZ3BER IU 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
DMZ3BER CA CAS 1092364-38-9
DMZ3BER DE Solid tumour/cancer; HER2-positive breast cancer; Non-small-cell lung cancer
DMMQZ3I ID DMMQZ3I
DMMQZ3I DN HMR59
DMMQZ3I HS Phase 2
DMMQZ3I SN AAVCAGsCD59
DMMQZ3I CP Hemera Biosciences
DMMQZ3I DT Gene therapy
DMMQZ3I DE Wet age-related macular degeneration; Dry age-related macular degeneration; Geographic retinal atrophy
DMA6HQJ ID DMA6HQJ
DMA6HQJ DN HO/03/03
DMA6HQJ HS Phase 2
DMA6HQJ SN PKC modulator (topical peptide, DU/VU/PU), HealOr
DMA6HQJ CP HealOr Ltd
DMA6HQJ DE Diabetic foot ulcer
DMNOMV2 ID DMNOMV2
DMNOMV2 DN HP-184
DMNOMV2 HS Phase 2
DMNOMV2 SN Nerispirdine; Nerispirdine hydrochloride; HP 184; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride
DMNOMV2 CP Sanofi-Aventis
DMNOMV2 DT Small molecular drug
DMNOMV2 PC 3081185
DMNOMV2 MW 283.34
DMNOMV2 FM C17H18FN3
DMNOMV2 IC InChI=1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3
DMNOMV2 CS CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C
DMNOMV2 IK BTDHTARYCBHHPJ-UHFFFAOYSA-N
DMNOMV2 IU N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine
DMNOMV2 CA CAS 119229-65-1
DMNOMV2 DE Multiple sclerosis
DMNZ35F ID DMNZ35F
DMNZ35F DN HP-228
DMNZ35F HS Phase 2
DMNZ35F SN HP 228; Ac-Nle-gln-his-D-phe-arg-D-trp-gly-NH2; AC1L2XO7; 109022-88-0; Acetyl-norleucyl-glutaminyl-histidyl-phenylalanyl-arginyl-tryptophyl-glycinamide; L-Norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycinamide; Glycinamide, L-norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-
DMNZ35F CP LION bioscience Inc
DMNZ35F DT Small molecular drug
DMNZ35F PC 9876430
DMNZ35F MW 984.1
DMNZ35F FM C47H65N15O9
DMNZ35F IC InChI=1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)/t33-,34-,35-,36+,37+,38-/m0/s1
DMNZ35F CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N)NC(=O)C
DMNZ35F IK UHKZNDVUBSEJJO-XAYNKGEHSA-N
DMNZ35F IU (2S)-2-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide
DMNZ35F DE Postoperative pain
DM3WSL2 ID DM3WSL2
DM3WSL2 DN HPH-116
DM3WSL2 HS Phase 2
DM3WSL2 SN Azocarbonamide; Azodicarbonamide; ADA, Hubriphar; Azodicarbonamide, H-Phar
DM3WSL2 CP H-Phar Co
DM3WSL2 DE Human immunodeficiency virus infection
DM25PQB ID DM25PQB
DM25PQB DN HPPH
DM25PQB HS Phase 2
DM25PQB SN CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752
DM25PQB PC 148160
DM25PQB MW 636.8
DM25PQB FM C39H48N4O4
DM25PQB IC InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,42,44H,8-16H2,1-7H3,(H,45,46)/t21-,24?,26-/m0/s1
DM25PQB CS CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C
DM25PQB IK PUUBADHCONCMPA-USOGPTGWSA-N
DM25PQB IU 3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
DM25PQB CA CAS 149402-51-7
DM25PQB DE Lung cancer
DM7QUN0 ID DM7QUN0
DM7QUN0 DN HQK-1001
DM7QUN0 HS Phase 2
DM7QUN0 SN Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest
DM7QUN0 CP Hemaquest pharmaceuticals
DM7QUN0 DT Small molecular drug
DM7QUN0 PC 53247304
DM7QUN0 MW 138.14
DM7QUN0 FM C6H11NaO2
DM7QUN0 IC InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1
DM7QUN0 CS CCC(C)(C)C(=O)[O-].[Na+]
DM7QUN0 IK OOPXYEYPPHJHSE-UHFFFAOYSA-M
DM7QUN0 IU sodium;2,2-dimethylbutanoate
DM7QUN0 CA CAS 3934-02-9
DM7QUN0 DE Beta thalassemia
DM3WX0K ID DM3WX0K
DM3WX0K DN HQK-1004
DM3WX0K HS Phase 2
DM3WX0K SN Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest
DM3WX0K CP HemaQuest Pharmaceuticals Inc; Vertex Pharmaceuticals Inc
DM3WX0K PC 23622962
DM3WX0K MW 875
DM3WX0K FM C34H74N12O14
DM3WX0K IC InChI=1S/3C6H14N4O2.4C4H8O2/c3*7-4(5(11)12)2-1-3-10-6(8)9;4*1-2-3-4(5)6/h3*4H,1-3,7H2,(H,11,12)(H4,8,9,10);4*2-3H2,1H3,(H,5,6)/t3*4-;;;;/m000..../s1
DM3WX0K CS CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N
DM3WX0K IK ZVEMACCDKBQNGX-KALODSIISA-N
DM3WX0K IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid
DM3WX0K CA CAS 80407-72-3
DM3WX0K DE Solid tumour/cancer
DMQ30X2 ID DMQ30X2
DMQ30X2 DN HQP1351
DMQ30X2 HS Phase 2
DMQ30X2 SN GZD824; 1257628-77-5; GZD-824; 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; UNII-KV1M7Q3CBP; KV1M7Q3CBP; 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide; CHEMBL2316582; Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-; HQP-1351; olverembatinib; 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide; Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-; HQP1351 free base; HQP-1351 free base; SCHEMBL3424528; GTPL10630; EX-A829; AOB87323; BCP07502; BDBM50425780; ZINC95594040; AKOS026750647; CS-1444; SB16617; compound 10a [PMID: 23301703]; NCGC00351607-06; AK547162; AS-75170; HY-15666; D-824; FT-0700150; A16264; W-6136; J-690110; 4-Methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
DMQ30X2 CP Ascentage Pharma
DMQ30X2 DT Small molecular drug
DMQ30X2 PC 51038269
DMQ30X2 MW 532.6
DMQ30X2 FM C29H27F3N6O
DMQ30X2 IC InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
DMQ30X2 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4
DMQ30X2 IK TZKBVRDEOITLRB-UHFFFAOYSA-N
DMQ30X2 IU 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
DMQ30X2 CA CAS 1257628-77-5
DMQ30X2 DE Chronic myeloid leukaemia
DML4RCG ID DML4RCG
DML4RCG DN HS-110
DML4RCG HS Phase 2
DML4RCG CP Heat Biologics
DML4RCG DT Vaccine
DML4RCG DE Non-small-cell lung cancer
DM2WP8F ID DM2WP8F
DM2WP8F DN HT-0712
DM2WP8F HS Phase 2
DM2WP8F SN IPL-455903; Small-molecule PDE4 inhibitors (memory disorders), Inflazyme/Helicon
DM2WP8F CP Dart neuroscience
DM2WP8F DT Small molecular drug
DM2WP8F PC 9865375
DM2WP8F MW 393.5
DM2WP8F FM C25H31NO3
DM2WP8F IC InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1
DM2WP8F CS CC1=CC(=CC=C1)C[C@@H]2C[C@H](CNC2=O)C3=CC(=C(C=C3)OC)OC4CCCC4
DM2WP8F IK ABEJDMOBAFLQNJ-NHCUHLMSSA-N
DM2WP8F IU (3S,5S)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3-[(3-methylphenyl)methyl]piperidin-2-one
DM2WP8F CA CAS 617720-02-2
DM2WP8F DE Cognitive impairment
DM2QIN1 ID DM2QIN1
DM2QIN1 DN HT-100
DM2QIN1 HS Phase 2
DM2QIN1 SN Halofunginone
DM2QIN1 CP Halo therapeutics
DM2QIN1 DT Small molecular drug
DM2QIN1 PC 62894
DM2QIN1 MW 414.7
DM2QIN1 FM C16H17BrClN3O3
DM2QIN1 IC InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2
DM2QIN1 CS C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
DM2QIN1 IK LVASCWIMLIKXLA-UHFFFAOYSA-N
DM2QIN1 IU 7-bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4-one
DM2QIN1 CA CAS 55837-20-2
DM2QIN1 DE Duchenne dystrophy
DMURXMJ ID DMURXMJ
DMURXMJ DN HTI-101
DMURXMJ HS Phase 2
DMURXMJ CP Hemodynamic Therapeutics
DMURXMJ DE Obesity
DM9MKQ5 ID DM9MKQ5
DM9MKQ5 DN Hu3F8 mAb
DM9MKQ5 HS Phase 2
DM9MKQ5 CP Y-mAbs Therapeutics New York, NY
DM9MKQ5 DE Neuroblastoma; Osteosarcoma
DMKQ3MC ID DMKQ3MC
DMKQ3MC DN Human interferon alpha oral
DMKQ3MC HS Phase 2
DMKQ3MC CP Amarillo biosciences
DMKQ3MC DE Hepatitis C virus infection
DM0NJWG ID DM0NJWG
DM0NJWG DN Human interleukin-2
DM0NJWG HS Phase 2
DM0NJWG SN Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice
DM0NJWG CP Immunservice GmbH
DM0NJWG DE Renal cell carcinoma
DMOPWSX ID DMOPWSX
DMOPWSX DN Ibrolipim
DMOPWSX HS Phase 2
DMOPWSX SN Ibrolipim < Prop INN; NO-1886; OPF-009; 4-[N-(4-Bromo-2-cyanophenyl)carbamoyl]benzylphosphonic acid diethyl ester
DMOPWSX CP TAP Pharmaceuticals
DMOPWSX DT Small molecular drug
DMOPWSX PC 131601
DMOPWSX MW 451.2
DMOPWSX FM C19H20BrN2O4P
DMOPWSX IC InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
DMOPWSX CS CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC
DMOPWSX IK KPRTURMJVWXURQ-UHFFFAOYSA-N
DMOPWSX IU N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide
DMOPWSX CA CAS 133208-93-2
DMOPWSX DE Hyperlipidaemia
DM37CX4 ID DM37CX4
DM37CX4 DN IC14
DM37CX4 HS Phase 2
DM37CX4 SN CD14 antibody
DM37CX4 TC Antiviral Agents
DM37CX4 DT Monoclonal antibody
DM37CX4 DE Coronavirus Disease 2019 (COVID-19)
DMUFCQG ID DMUFCQG
DMUFCQG DN IC14
DMUFCQG HS Phase 2
DMUFCQG DT Antibody
DMUFCQG DE Sepsis
DMB1UYV ID DMB1UYV
DMB1UYV DN IC-485
DMB1UYV HS Phase 2
DMB1UYV CP ICOS
DMB1UYV DT Small molecular drug
DMB1UYV PC 23724885
DMB1UYV DE Chronic obstructive pulmonary disease
DMP925B ID DMP925B
DMP925B DN ICA-105665
DMP925B HS Phase 2
DMP925B CP Icagen
DMP925B DE Epilepsy
DMRFY7I ID DMRFY7I
DMRFY7I DN ICA-17043
DMRFY7I HS Phase 2
DMRFY7I SN Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215; Senicapoc
DMRFY7I CP Icagen
DMRFY7I DT Small molecular drug
DMRFY7I PC 216327
DMRFY7I MW 323.3
DMRFY7I FM C20H15F2NO
DMRFY7I IC InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
DMRFY7I CS C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
DMRFY7I IK SCTZUZTYRMOMKT-UHFFFAOYSA-N
DMRFY7I IU 2,2-bis(4-fluorophenyl)-2-phenylacetamide
DMRFY7I CA CAS 289656-45-7
DMRFY7I DE Constitutional neutropenia; Alzheimer disease
DMGHQ37 ID DMGHQ37
DMGHQ37 DN Icaritin
DMGHQ37 HS Phase 2
DMGHQ37 SN Icaritin; 118525-40-9; UNII-UFE666UELY; UFE666UELY; CHEMBL498485; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; Icartin; Anhydroicaritin; AC1NSXIV; Icaritin(Anhydroicaritin); MLS006010055; BIDD:ER0021; SCHEMBL4223542; Icaritin, > DTXSID00152154; MolPort-020-006-012; TUUXBSASAQJECY-UHFFFAOYSA-N; HY-N0678; ZINC14762797; BDBM50272527; AKOS015896858; CS-3679; DB12672; NCGC00345813-01; AK168251; SMR004701218
DMGHQ37 DT Small molecular drug
DMGHQ37 PC 5318980
DMGHQ37 MW 368.4
DMGHQ37 FM C21H20O6
DMGHQ37 IC InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
DMGHQ37 CS CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C
DMGHQ37 IK TUUXBSASAQJECY-UHFFFAOYSA-N
DMGHQ37 IU 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DMGHQ37 CA CAS 118525-40-9
DMGHQ37 DE Breast cancer
DMC13BQ ID DMC13BQ
DMC13BQ DN ICO-25
DMC13BQ HS Phase 2
DMC13BQ SN Imuteran; Anti-MUC1 monoclonal antibodies, P Hertzen Moscow Cancer Research Institute; Anti-AG-4 antibodies, P Hertzen Moscow Cancer Research Institute
DMC13BQ CP Russian National Cancer Research Center
DMC13BQ DT Antibody
DMC13BQ DE Breast cancer
DMTXNZK ID DMTXNZK
DMTXNZK DN Icofungipen
DMTXNZK HS Phase 2
DMTXNZK SN PLD-118; 198022-65-0; UNII-I20202Q8M8; BAY-10-8888; I20202Q8M8; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)-; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylene-cyclopentanecarboxylic acid; PLD118; PLD 118; 156292-16-9; BAY 10-8888; (1r,2s)-2-amino-4-methylidenecyclopentanecarboxylic acid; AC1Q5QVF; AC1L50CI; 2-amino-4-methylenecyclopentane-1-carboxylic acid; SCHEMBL117349; CHEMBL343803; CTK0H0639; DTXSID90173515; RKOUGZGFAYMUIO-RITPCOANSA-N; (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylenecyclopentane-1-carboxylic acid; AHMA
DMTXNZK TC Antifungal Agents
DMTXNZK DT Small molecular drug
DMTXNZK PC 216240
DMTXNZK MW 141.17
DMTXNZK FM C7H11NO2
DMTXNZK IC InChI=1S/C7H11NO2/c1-4-2-5(7(9)10)6(8)3-4/h5-6H,1-3,8H2,(H,9,10)/t5-,6+/m1/s1
DMTXNZK CS C=C1C[C@H]([C@H](C1)N)C(=O)O
DMTXNZK IK RKOUGZGFAYMUIO-RITPCOANSA-N
DMTXNZK IU (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid
DMTXNZK CA CAS 198022-65-0
DMTXNZK DE Fungal infection
DM524GR ID DM524GR
DM524GR DN ICP-192
DM524GR HS Phase 2
DM524GR CP InnoCare Pharma
DM524GR DE Bladder cancer
DM7XIAJ ID DM7XIAJ
DM7XIAJ DN ID-93/GLA-SE
DM7XIAJ HS Phase 2
DM7XIAJ CP Infectious disease research institute; aeras global tb vaccine foundation
DM7XIAJ DE Tuberculosis
DMABRXY ID DMABRXY
DMABRXY DN IDM-2101
DMABRXY HS Phase 2
DMABRXY CP Biotech Synergy
DMABRXY DT Vaccine
DMABRXY DE Colorectal cancer
DMSRC5D ID DMSRC5D
DMSRC5D DN IDX899
DMSRC5D HS Phase 2
DMSRC5D SN Fosdevirine; IDX-899; IDX899; GSK2248761; GSK-2248761; 1018450-26-4; UNII-Z4I0C281BJ; Z4I0C281BJ; Fosdevirine [USAN:INN]; GSK2248761A; GSK 2248761A; Fosdevirine (USAN/INN); SCHEMBL1035677; CHEMBL2104968; IDX 899; 1097733-15-7; IDX-12899; GSK 2248761; D09906
DMSRC5D CP GSK
DMSRC5D DT Small molecular drug
DMSRC5D PC 23583058
DMSRC5D MW 413.8
DMSRC5D FM C20H17ClN3O3P
DMSRC5D IC InChI=1S/C20H17ClN3O3P/c1-12-8-13(4-3-7-22)10-15(9-12)28(26,27-2)19-16-11-14(21)5-6-17(16)24-18(19)20(23)25/h3-6,8-11,24H,1-2H3,(H2,23,25)/b4-3+
DMSRC5D CS CC1=CC(=CC(=C1)P(=O)(C2=C(NC3=C2C=C(C=C3)Cl)C(=O)N)OC)/C=C/C#N
DMSRC5D IK CGBYTKOSZYQOPV-ONEGZZNKSA-N
DMSRC5D IU 5-chloro-3-[[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1H-indole-2-carboxamide
DMSRC5D DE Human immunodeficiency virus infection
DMGWNCJ ID DMGWNCJ
DMGWNCJ DN Ifabotuzumab
DMGWNCJ HS Phase 2
DMGWNCJ CP Humanigen Brisbane, CA Olivia Newton-John Cancer Research Institute Heidelberg, Australia
DMGWNCJ DE Acute myeloid leukaemia; Myelodysplastic syndrome; Recurrent glioblastoma
DMZP84Y ID DMZP84Y
DMZP84Y DN Ifetroban sodium
DMZP84Y HS Phase 2
DMZP84Y SN BMS-180291 sodium salt; BMS-180291-02
DMZP84Y CP Bristol-Myers Squibb
DMZP84Y DT Small molecular drug
DMZP84Y PC 23663994
DMZP84Y MW 462.5
DMZP84Y FM C25H31N2NaO5
DMZP84Y IC InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20-,21+,23-;/m0./s1
DMZP84Y CS CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]
DMZP84Y IK WOHSQDNIXPEQAE-QBKVZTCDSA-M
DMZP84Y IU sodium;3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
DMZP84Y DE Thrombosis
DM4H8EZ ID DM4H8EZ
DM4H8EZ DN IFN-alpha
DM4H8EZ HS Phase 2
DM4H8EZ SN Hanferon; HL-143; IFN-alpha (sc injection, HCV infection); Belerofon (subcutaneous, HCV infection), Nautilus/HanAll; IFN-alpha (sc injection, HCV infection), HanAll; IFN-alpha (subcutaneous, HCV infection), Nautilus/HanAll; Interferon-alpha (subcutaneous, HCV infection), Nautilus/HanAll
DM4H8EZ CP Hanall biopharma
DM4H8EZ DE Hepatitis C virus infection; Hepatocellular carcinoma
DMHI36A ID DMHI36A
DMHI36A DN IFX-1
DMHI36A HS Phase 2
DMHI36A SN XZAPEHKCHWMSPW-MTALQEDYSA-N; Ifx-1; J3.560.481B
DMHI36A CP InflaRx Planegg, Germany
DMHI36A PC 137254326
DMHI36A MW 672.9
DMHI36A FM C43H60O6
DMHI36A IC InChI=1S/C43H60O6/c1-30(17-14-18-31(2)19-21-39-42(9,10)27-37(49-33(4)45)28-43(39,11)48)15-12-13-16-32(3)23-35(46)24-34(29-44)20-22-38-40(5,6)25-36(47)26-41(38,7)8/h12-24,29,36-38,47-48H,25-28H2,1-11H3/b15-12?,16-13?,18-14?,22-20+,30-17?,31-19?,32-23?,34-24-,39-21?/t36?,37-,38?,43-/m1/s1
DMHI36A CS CC(=CC=CC(=CC=C1[C@](C[C@@H](CC1(C)C)OC(=O)C)(C)O)C)C=CC=CC(=CC(=O)/C=C(/C=C/C2C(CC(CC2(C)C)O)(C)C)\\C=O)C
DMHI36A IK XZAPEHKCHWMSPW-MTALQEDYSA-N
DMHI36A IU [(1R,3R)-4-[(15Z,17E)-16-formyl-18-(4-hydroxy-2,2,6,6-tetramethylcyclohexyl)-3,7,12-trimethyl-14-oxooctadeca-2,4,6,8,10,12,15,17-octaenylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl] acetate
DMHI36A DE Hidradenitis suppurativa
DMH97XA ID DMH97XA
DMH97XA DN Igmesine
DMH97XA HS Phase 2
DMH97XA SN Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen
DMH97XA DT Small molecular drug
DMH97XA PC 6438340
DMH97XA MW 319.5
DMH97XA FM C23H29N
DMH97XA IC InChI=1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3/b13-10+
DMH97XA CS CCC(C/C=C/C1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3
DMH97XA IK VCZSWYIFCKGTJI-JLHYYAGUSA-N
DMH97XA IU (E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine
DMH97XA CA CAS 140850-73-3
DMH97XA DE Cystic fibrosis; Chronic obstructive pulmonary disease; Major depressive disorder
DMIHQ5G ID DMIHQ5G
DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G HS Phase 2
DMIHQ5G SN Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte
DMIHQ5G CP Baylor College of Medicine
DMIHQ5G DT Vaccine
DMIHQ5G DE Chronic lymphocytic leukaemia
DM1E4VP ID DM1E4VP
DM1E4VP DN IL-21
DM1E4VP HS Phase 2
DM1E4VP SN BMS-982470
DM1E4VP CP Bristol-Myers Squibb
DM1E4VP DE Colorectal cancer
DMYEGRH ID DMYEGRH
DMYEGRH DN IL-4R
DMYEGRH HS Phase 2
DMDNHRA ID DMDNHRA
DMDNHRA DN Ilodecakin
DMDNHRA HS Phase 2
DMDNHRA SN Prevascar; Ilodecakin, Renovo; Recombinant IL-10 (scarring), Renovo
DMDNHRA CP Renovo Group plc
DMDNHRA DE Sarcoidosis
DMUJ1WV ID DMUJ1WV
DMUJ1WV DN IMCgp100
DMUJ1WV HS Phase 2
DMUJ1WV CP Immunocore
DMUJ1WV DT Monoclonal antibody
DMUJ1WV DE Melanoma; Cutaneous melanoma
DMU1MR9 ID DMU1MR9
DMU1MR9 DN IMD-1041
DMU1MR9 HS Phase 2
DMU1MR9 SN IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD
DMU1MR9 CP Institute of Medicinal Molecular Design Inc
DMU1MR9 DE Alzheimer disease
DMMQFG2 ID DMMQFG2
DMMQFG2 DN Imeglimin
DMMQFG2 HS Phase 2
DMMQFG2 SN 775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771
DMMQFG2 CP Merck KGaA
DMMQFG2 DT Small molecular drug
DMMQFG2 PC 24812808
DMMQFG2 MW 155.2
DMMQFG2 FM C6H13N5
DMMQFG2 IC InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
DMMQFG2 CS C[C@@H]1N=C(NC(=N1)N(C)C)N
DMMQFG2 IK GFICWFZTBXUVIG-SCSAIBSYSA-N
DMMQFG2 IU (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
DMMQFG2 CA CAS 775351-65-0
DMMQFG2 DE Type-2 diabetes; Diabetic complication
DML9AVG ID DML9AVG
DML9AVG DN IMG-7289
DML9AVG HS Phase 2
DML9AVG SN KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
DML9AVG CP Imago BioSciences San Carlos, CA
DML9AVG PC 122460381
DML9AVG MW 519.6
DML9AVG FM C28H34FN7O2
DML9AVG IC InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1
DML9AVG CS CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5
DML9AVG IK KQKBMHGOHXOHTD-KKUQBAQOSA-N
DML9AVG IU N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide
DML9AVG CA CAS 1990504-34-1
DML9AVG DE Acute myeloid leukaemia; Myelodysplastic syndrome; Myelofibrosis
DMNJ491 ID DMNJ491
DMNJ491 DN IMGN529
DMNJ491 HS Phase 2
DMNJ491 CP ImmunoGen
DMNJ491 DT Antibody
DMNJ491 DE Metastatic non-hodgkin's lymphoma; Non-hodgkin lymphoma
DMIUC3M ID DMIUC3M
DMIUC3M DN IMGN901
DMIUC3M HS Phase 2
DMIUC3M SN Lorvotuzumab mertansine
DMIUC3M CP ImmunoGen
DMIUC3M DE Solid tumour/cancer
DME3POC ID DME3POC
DME3POC DN Imisopasem manganese
DME3POC HS Phase 2
DME3POC SN KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore
DME3POC CP MetaPhore Pharmaceuticals
DME3POC DT Small molecular drug
DME3POC PC 6918487
DME3POC MW 483.4
DME3POC FM C21H35Cl2MnN5
DME3POC IC InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1
DME3POC CS C1CC[C@@H]2[C@@H](C1)NCCN[C@@H]3CCCC[C@H]3NCC4=CC=CC(=N4)CN2.Cl[Mn]Cl
DME3POC IK WXEMWBBXVXHEPU-XNPJUPKFSA-L
DME3POC IU dichloromanganese;(4R,9R,14R,19R)-3,10,13,20,26-pentazatetracyclo[20.3.1.04,9.014,19]hexacosa-1(26),22,24-triene
DME3POC DE Pain
DM6IQ3V ID DM6IQ3V
DM6IQ3V DN IMO-2055
DM6IQ3V HS Phase 2
DM6IQ3V CP Idera Pharmaceuticals
DM6IQ3V DE Solid tumour/cancer; Renal cell carcinoma
DMM549D ID DMM549D
DMM549D DN IMO-3100
DMM549D HS Phase 2
DMM549D CP Idera Pharmaceuticals
DMM549D DE Autoimmune diabetes; Psoriasis vulgaris
DMDPNCJ ID DMDPNCJ
DMDPNCJ DN IMO-8400
DMDPNCJ HS Phase 2
DMDPNCJ SN Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M
DMDPNCJ CP Idera Pharmaceuticals Cambridge, MA
DMDPNCJ SQ CTATCTNNNNTTCTCTNN
DMDPNCJ PC 119058029
DMDPNCJ MW 5801
DMDPNCJ FM C179H233N52O101P17S17
DMDPNCJ IC InChI=1S/C179H233N52O101P17S17/c1-71-41-221(172(252)200-143(71)184)123-32-85(106(303-123)62-293-347(274,364)330-136-109(313-160(140(136)278-10)220-26-19-117(234)199-171(220)251)66-297-349(276,366)332-138-111(315-162(142(138)280-12)231-70-193-134-148(231)203-165(188)206-158(134)245)65-296-346(273,363)328-92-39-130(228-48-78(8)155(242)213-179(228)259)310-105(92)60-289-337(264,354)320-84-31-122(218-24-17-115(183)197-169(218)249)302-98(84)53-285-341(268,358)324-89-36-127(225-45-75(5)152(239)210-176(225)256)308-103(89)58-291-344(271,361)329-93-40-131(229-68-191-132-144(185)189-67-190-146(132)229)311-107(93)61-292-343(270,360)326-86-33-124(222-42-72(2)149(236)207-173(222)253)304-99(86)54-281-333(260,350)316-80-27-119(298-94(80)49-232)215-21-14-112(180)194-166(215)246)321-338(265,355)282-50-95-81(28-118(299-95)214-20-13-79-145(214)201-163(186)204-156(79)243)317-334(261,351)286-55-100-90(37-128(305-100)226-46-76(6)153(240)211-177(226)257)325-342(269,359)290-57-102-88(35-126(307-102)224-44-74(4)151(238)209-175(224)255)323-340(267,357)284-51-96-82(29-120(300-96)216-22-15-113(181)195-167(216)247)318-335(262,352)287-56-101-87(34-125(306-101)223-43-73(3)150(237)208-174(223)254)322-339(266,356)283-52-97-83(30-121(301-97)217-23-16-114(182)196-168(217)248)319-336(263,353)288-59-104-91(38-129(309-104)227-47-77(7)154(241)212-178(227)258)327-345(272,362)295-64-110-137(141(279-11)161(314-110)230-69-192-133-147(230)202-164(187)205-157(133)244)331-348(275,365)294-63-108-135(235)139(277-9)159(312-108)219-25-18-116(233)198-170(219)250/h13-26,41-48,67-70,80-111,118-131,135-142,159-162,232,235H,27-40,49-66H2,1-12H3,(H,260,350)(H,261,351)(H,262,352)(H,263,353)(H,264,354)(H,265,355)(H,266,356)(H,267,357)(H,268,358)(H,269,359)(H,270,360)(H,271,361)(H,272,362)(H,273,363)(H,274,364)(H,275,365)(H,276,366)(H2,180,194,246)(H2,181,195,247)(H2,182,196,248)(H2,183,197,249)(H2,184,200,252)(H2,185,189,190)(H,198,233,250)(H,199,234,251)(H,207,236,253)(H,208,237,254)(H,209,238,255)(H,210,239,256)(H,211,240,257)(H,212,241,258)(H,213,242,259)(H3,186,201,204,243)(H3,187,202,205,244)(H3,188,203,206,245)/t80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,135+,136+,137+,138+,139+,140+,141+,142+,159+,160+,161+,162+,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?,343?,344?,345?,346?,347?,348?,349?/m0/s1
DMDPNCJ CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=NC9=C8N=C(NC9=O)N)COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=O)(O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1CO)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)S)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=CC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)O
DMDPNCJ IK HDRGJRSISASRAJ-WKPMUQCKSA-N
DMDPNCJ IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMDPNCJ CA CAS 1378549-07-5
DMDPNCJ DE Diffuse large B-cell lymphoma; Rheumatoid arthritis; Waldenstrom macroglobulinemia
DMTN16K ID DMTN16K
DMTN16K DN Implitapide
DMTN16K HS Phase 2
DMTN16K SN Implitapide [INN]; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K CP MRL international
DMTN16K DT Small molecular drug
DMTN16K PC 5745206
DMTN16K MW 531.7
DMTN16K FM C35H37N3O2
DMTN16K IC InChI=1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1
DMTN16K CS CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)[C@H](C5CCCC5)C(=O)N[C@@H](CO)C6=CC=CC=C6)C
DMTN16K IK AMNXBQPRODZJQR-DITALETJSA-N
DMTN16K IU (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K CA CAS 177469-96-4
DMTN16K DE Hyperlipidaemia
DMB1N6P ID DMB1N6P
DMB1N6P DN Impoyz
DMB1N6P HS Phase 2
DMB1N6P SN Clobetasol propionate; CLOBETASOL PROPIONATE; 25122-46-7; Clobetasol 17-propionate; Clobex; Temovate; Dermovate; Embeline; Embeline E; Clobesol; Cormax; Olux; Temovate E; Olux-E; clobetasol 17-propanoate; GR 2/925; C25H32ClFO5; MLS000028708; Clobestasol propionate; Clobetasol propionate [USAN:JAN]; CGP 9555; CCI 4725; EINECS 246-634-3; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; UNII-779619577M; [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12
DMB1N6P CP Promius Pharma Princeton, NJ
DMB1N6P PC 32798
DMB1N6P MW 467
DMB1N6P FM C25H32ClFO5
DMB1N6P IC InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
DMB1N6P CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
DMB1N6P IK CBGUOGMQLZIXBE-XGQKBEPLSA-N
DMB1N6P IU [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMB1N6P CA CAS 25122-46-7
DMB1N6P CB CHEBI:31414
DMB1N6P DE Plaque psoriasis
DM15MRZ ID DM15MRZ
DM15MRZ DN IMR-687
DM15MRZ HS Phase 2
DM15MRZ SN Tovinontrine; UNII-W248Y1AKOR; W248Y1AKOR; 2062661-53-2; a]pyrazin-8(7H)-one; CHEMBL4297290; SCHEMBL20358493; BDBM426313; US10513524, Compound (P3; 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-; yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-; 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one; Imidazo(1,5-a)pyrazin-8(7H)-one, 6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2H-pyran-4-yl)-
DM15MRZ CP Imara
DM15MRZ DT Small molecular drug
DM15MRZ PC 124220601
DM15MRZ MW 394.5
DM15MRZ FM C21H26N6O2
DM15MRZ IC InChI=1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1
DM15MRZ CS C[C@@H]1CN(C[C@H]1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM15MRZ IK GWGNPYYVGANHRJ-GDBMZVCRSA-N
DM15MRZ IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one
DM15MRZ CA CAS 2062661-53-2
DM15MRZ DE Sickle-cell disorder
DMNUXKA ID DMNUXKA
DMNUXKA DN INCAGN01876
DMNUXKA HS Phase 2
DMNUXKA CP Agenis; Incyte
DMNUXKA DT Antibody
DMNUXKA DE Solid tumour/cancer
DMK7OHI ID DMK7OHI
DMK7OHI DN INCAGN01949
DMK7OHI HS Phase 2
DMK7OHI CP Agenis; Incyte
DMK7OHI DT Antibody
DMK7OHI DE Advanced malignancy; Metastatic malignant neoplasm
DMFG8TI ID DMFG8TI
DMFG8TI DN INCB00928
DMFG8TI HS Phase 2
DMFG8TI CP Incyte
DMFG8TI DT Small molecular drug
DMFG8TI DE Multiple myeloma; Myelodysplastic syndrome; Anemia
DMD9RV3 ID DMD9RV3
DMD9RV3 DN INCB039110
DMD9RV3 HS Phase 2
DMD9RV3 SN Examlpe 294 [WO2011112662]
DMD9RV3 DT Small molecular drug
DMD9RV3 PC 53380437
DMD9RV3 MW 553.5
DMD9RV3 FM C26H23F4N9O
DMD9RV3 IC InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
DMD9RV3 CS C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F
DMD9RV3 IK KTBSXLIQKWEBRB-UHFFFAOYSA-N
DMD9RV3 IU 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMD9RV3 CA CAS 1334298-90-6
DMD9RV3 DE Malignant neoplasm; Non-small-cell lung cancer
DMZJP2T ID DMZJP2T
DMZJP2T DN INCB50465
DMZJP2T HS Phase 2
DMZJP2T CP Incyte Wilmington, DE
DMZJP2T DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Marginal zone lymphoma
DMDK0HX ID DMDK0HX
DMDK0HX DN INCB54707
DMDK0HX HS Phase 2
DMDK0HX CP Incyte Wilmington, DE
DMDK0HX DE Hidradenitis suppurativa
DMJN9PU ID DMJN9PU
DMJN9PU DN INCB86550
DMJN9PU HS Phase 2
DMJN9PU CP Incyte
DMJN9PU DT Small molecular drug
DMJN9PU DE Solid tumour/cancer
DM6OFJ8 ID DM6OFJ8
DM6OFJ8 DN Indibulin
DM6OFJ8 HS Phase 2
DM6OFJ8 SN Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642
DM6OFJ8 CP ZioPharm
DM6OFJ8 DT Small molecular drug
DM6OFJ8 PC 2929
DM6OFJ8 MW 389.8
DM6OFJ8 FM C22H16ClN3O2
DM6OFJ8 IC InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)
DM6OFJ8 CS C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4
DM6OFJ8 IK SOLIIYNRSAWTSQ-UHFFFAOYSA-N
DM6OFJ8 IU 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide
DM6OFJ8 CA CAS 204205-90-3
DM6OFJ8 DE Advanced sarcoma
DM9SX6Y ID DM9SX6Y
DM9SX6Y DN Indisulam
DM9SX6Y HS Phase 2
DM9SX6Y SN Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN]
DM9SX6Y DT Small molecular drug
DM9SX6Y PC 216468
DM9SX6Y MW 385.8
DM9SX6Y FM C14H12ClN3O4S2
DM9SX6Y IC InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
DM9SX6Y CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
DM9SX6Y IK SETFNECMODOHTO-UHFFFAOYSA-N
DM9SX6Y IU 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
DM9SX6Y CA CAS 165668-41-7
DM9SX6Y CB CHEBI:145431
DM9SX6Y DE Lymphoma
DMU5SZP ID DMU5SZP
DMU5SZP DN Inecalcitol oral
DMU5SZP HS Phase 2
DMU5SZP SN Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; Inecalcitol; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics; 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin D3
DMU5SZP CP Catholic University of Leuven; Hybrigenics
DMU5SZP DT Small molecular drug
DMU5SZP PC 6915835
DMU5SZP MW 400.6
DMU5SZP FM C26H40O3
DMU5SZP IC InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1
DMU5SZP CS C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMU5SZP IK HHGRMHMXKPQNGF-WNSNRMDMSA-N
DMU5SZP IU (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMU5SZP CA CAS 163217-09-2
DMU5SZP DE Prostate cancer; Acute myeloid leukaemia
DMEO9Y7 ID DMEO9Y7
DMEO9Y7 DN INGAP peptide
DMEO9Y7 HS Phase 2
DMEO9Y7 CP Exsulin
DMEO9Y7 DE Type-1/2 diabetes
DMF7J6D ID DMF7J6D
DMF7J6D DN INGN-225
DMF7J6D HS Phase 2
DMF7J6D SN Cancer vaccine (p53), Introgen
DMF7J6D CP Introgen Therapeutics
DMF7J6D DT Vaccine
DMF7J6D DE Head and neck cancer
DM6P91T ID DM6P91T
DM6P91T DN INGN-241
DM6P91T HS Phase 2
DM6P91T SN AD-IL-24, Introgen; AD-mda-7, Introgen; Adenovirus-IL-24, Introgen; Adenovirus-mda-7, Introgen
DM6P91T CP Multivir; Introgen Therapeutics
DM6P91T DE Solid tumour/cancer
DMGO7QT ID DMGO7QT
DMGO7QT DN INK128
DMGO7QT HS Phase 2
DMGO7QT SN 1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
DMGO7QT CP Intellikine; MMRC
DMGO7QT DT Small molecular drug
DMGO7QT PC 45375953
DMGO7QT MW 309.33
DMGO7QT FM C15H15N7O
DMGO7QT IC InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
DMGO7QT CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
DMGO7QT IK GYLDXIAOMVERTK-UHFFFAOYSA-N
DMGO7QT IU 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
DMGO7QT CA CAS 1224844-38-5
DMGO7QT CB CHEBI:91450
DMGO7QT DE Multiple myeloma; Breast cancer
DMKRGVJ ID DMKRGVJ
DMKRGVJ DN INS-1
DMKRGVJ HS Phase 2
DMKRGVJ SN Diabetes therapeutics, Insmed; Inositol phosphoglycans, Insmed; D-chiro-inositol, Insmed
DMKRGVJ CP Insmed Inc
DMKRGVJ DE Metabolic disorder
DMF93RQ ID DMF93RQ
DMF93RQ DN INS-37217
DMF93RQ HS Phase 2
DMF93RQ SN Denufosol tetrasodium; DCp4U; INS 37217; INS37217; Up4dC; Denufosol tetrasodium (USAN); Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMF93RQ CP Inspire Pharmaceuticals
DMF93RQ DT Small molecular drug
DMF93RQ PC 10219163
DMF93RQ MW 861.3
DMF93RQ FM C18H23N5Na4O21P4
DMF93RQ IC InChI=1S/C18H27N5O21P4.4Na/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29;;;;/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29);;;;/q;4*+1/p-4/t8-,9+,10+,13+,14+,15+,16+;;;;/m0..../s1
DMF93RQ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O.[Na+].[Na+].[Na+].[Na+]
DMF93RQ IK PASYJVRFGUDDEW-WMUGRWSXSA-J
DMF93RQ IU tetrasodium;[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
DMF93RQ CA CAS 318250-11-2
DMF93RQ DE Cystic fibrosis
DMKZUVC ID DMKZUVC
DMKZUVC DN INS-50589
DMKZUVC HS Phase 2
DMKZUVC SN Regrelor; UNII-Q6C8TY6SW1; Q6C8TY6SW1; CHEMBL1162175; INS-50589; 787548-03-2; Regrelor [INN]; GTPL1770; DTXSID80229272; INS 50589; BDBM50371580; [(2S,3aR,4R,6R,6aR)-6-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[4,3-d][1,3]dioxol-4-yl]methyl dihydrogen phosphate
DMKZUVC CP Inspire Pharmaceuticals
DMKZUVC DT Small molecular drug
DMKZUVC PC 11273179
DMKZUVC MW 532.4
DMKZUVC FM C22H25N6O8P
DMKZUVC IC InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
DMKZUVC CS CCNC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)COP(=O)(O)O)O[C@@H](O4)/C=C/C5=CC=CC=C5
DMKZUVC IK NXHAXEBZOXCDKD-XIXRRVGJSA-N
DMKZUVC IU [(2S,3aR,4R,6R,6aR)-4-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl dihydrogen phosphate
DMKZUVC CA CAS 787548-03-2
DMKZUVC DE Cardiovascular disease
DMNKAFQ ID DMNKAFQ
DMNKAFQ DN Instiladrin
DMNKAFQ HS Phase 2
DMNKAFQ CP Fkd therapies
DMNKAFQ DE Bladder cancer
DMYTKF5 ID DMYTKF5
DMYTKF5 DN Interferon
DMYTKF5 HS Phase 2
DMYTKF5 CP Amarillo biosciences
DMYTKF5 DE Human papillomavirus infection; Hepatitis C virus infection
DMVACTU ID DMVACTU
DMVACTU DN Interferon alpha-2b
DMVACTU HS Phase 2
DMVACTU SN IFN-alpha-XL; IFN-alpha (Medusa), Flamel; Interferon alpha-2b (subcutaneous/controlled release, Medusa); Interferon alpha-2b (subcutaneous/controlled release, Medusa), Flamel
DMVACTU CP Hanall biopharma; medtronic
DMVACTU DE Hepatitis C virus infection
DMQSA7H ID DMQSA7H
DMQSA7H DN Interferon beta 1a
DMQSA7H HS Phase 2
DMQSA7H SN Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001
DMQSA7H TC Respiratory Agents
DMQSA7H DE Discovery agent
DM8YF01 ID DM8YF01
DM8YF01 DN Interferon-alpha lozenge
DM8YF01 HS Phase 2
DM8YF01 SN Veldona (TN)
DM8YF01 CP Amarillo Biosciences
DM8YF01 DE Fibromyalgia; Chronic obstructive pulmonary disease; Behcet disease
DMBXEG9 ID DMBXEG9
DMBXEG9 DN Intetumumab
DMBXEG9 HS Phase 2
DMBXEG9 CP Janssen Biotech
DMBXEG9 DT Monoclonal antibody
DMBXEG9 DE Prostate cancer
DMSTJ6Q ID DMSTJ6Q
DMSTJ6Q DN INX-189
DMSTJ6Q HS Phase 2
DMSTJ6Q SN INX-08032; INX-08189; INX-108; Nucleoside polymerase inhibitors (HCV infection), Cardiff University/Rega Institute; Nucleoside polymerase inhibitors (oral, HCV infection), Inhibitex
DMSTJ6Q CP Cardiff University
DMSTJ6Q DT Small molecular drug
DMSTJ6Q PC 46700744
DMSTJ6Q MW 658.6
DMSTJ6Q FM C30H39N6O9P
DMSTJ6Q IC InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)/t17-,21+,23+,27+,30+,46?/m0/s1
DMSTJ6Q CS C[C@@H](C(=O)OCC(C)(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=NC3=C2N=C(N=C3OC)N)(C)O)O)OC4=CC=CC5=CC=CC=C54
DMSTJ6Q IK YFXGICNMLCGLHJ-RSKRLRQZSA-N
DMSTJ6Q IU 2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
DMSTJ6Q CA CAS 1234490-83-5
DMSTJ6Q DE Hepatitis C virus infection
DMNW0DG ID DMNW0DG
DMNW0DG DN Iodine-131-tositumomab
DMNW0DG HS Phase 2
DMNW0DG DT Antibody
DM5F0QY ID DM5F0QY
DM5F0QY DN IONIS-416858
DM5F0QY HS Phase 2
DM5F0QY SN IONIS-FXI-LRx
DM5F0QY CP Ionis Pharmaceuticals
DM5F0QY DT Antisense oligonucleotide
DM5F0QY DE Thrombosis
DM6PDX2 ID DM6PDX2
DM6PDX2 DN IONIS-C9Rx
DM6PDX2 HS Phase 2
DM6PDX2 SN BIIB078
DM6PDX2 CP Ionis Pharmaceuticals
DM6PDX2 DT Antisense oligonucleotide
DM6PDX2 DE Amyotrophic lateral sclerosis
DM5LM3O ID DM5LM3O
DM5LM3O DN IONIS-DNM2-2.5Rx
DM5LM3O HS Phase 2
DM5LM3O CP Ionis Pharmaceuticals
DM5LM3O DT Antisense oligonucleotide
DM5LM3O DE Centronuclear myopathy
DMJ2763 ID DMJ2763
DMJ2763 DN IONIS-FB-LRx
DMJ2763 HS Phase 2
DMJ2763 CP Ionis Pharmaceuticals
DMJ2763 DT Antisense oligonucleotide
DMJ2763 DE IgA nephropathy
DMWV2N1 ID DMWV2N1
DMWV2N1 DN IONIS-GCCRRX
DMWV2N1 HS Phase 2
DMWV2N1 CP onis Pharmaceuticals Carlsbad, CA
DMWV2N1 DE Type-2 diabetes
DMB4GD9 ID DMB4GD9
DMB4GD9 DN IONIS-GCGR-Rx
DMB4GD9 HS Phase 2
DMB4GD9 CP Ionis Pharmaceuticals
DMB4GD9 DT Antisense oligonucleotide
DMB4GD9 DE Type-2 diabetes; Type 2 diabetes
DMGTJUP ID DMGTJUP
DMGTJUP DN IONIS-PTP1BRX
DMGTJUP HS Phase 2
DMGTJUP CP onis Pharmaceuticals Carlsbad, CA
DMGTJUP DE Type-2 diabetes
DM7VJE1 ID DM7VJE1
DM7VJE1 DN IONIS-TMPRSS6-LRx
DM7VJE1 HS Phase 2
DM7VJE1 CP Ionis Pharmaceuticals
DM7VJE1 DT Antisense oligonucleotide
DM7VJE1 DE Beta thalassemia
DM5TMYC ID DM5TMYC
DM5TMYC DN iOWH032
DM5TMYC HS Phase 2
DM5TMYC SN IOWH-032; CFTR inhibitors (diarrhea), BioFocus
DM5TMYC CP The Institute for OneWorld Health
DM5TMYC PC 135565181
DM5TMYC MW 545.2
DM5TMYC FM C22H15Br2N3O4
DM5TMYC IC InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)
DM5TMYC CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=NO3)C4=CC(=C(C(=C4)Br)O)Br
DM5TMYC IK DSFNLJXHXBIKDS-UHFFFAOYSA-N
DM5TMYC IU 3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide
DM5TMYC CA CAS 1191252-49-9
DM5TMYC DE Diarrhea
DMANRGW ID DMANRGW
DMANRGW DN IP10 C8
DMANRGW HS Phase 2
DMANRGW SN IP10C8
DMANRGW DE Psoriasis vulgaris
DMDUVCZ ID DMDUVCZ
DMDUVCZ DN IPH-2101
DMDUVCZ HS Phase 2
DMDUVCZ CP Innate Pharma
DMDUVCZ DE Multiple myeloma
DMPBR0D ID DMPBR0D
DMPBR0D DN IPH-2102
DMPBR0D HS Phase 2
DMPBR0D CP Innate Pharma SA
DMPBR0D DE Acute myeloid leukaemia
DMQH2SF ID DMQH2SF
DMQH2SF DN IPH4102
DMQH2SF HS Phase 2
DMQH2SF CP Innate Pharma Marseille, France
DMQH2SF DE T-cell lymphoma
DMG5Q7F ID DMG5Q7F
DMG5Q7F DN IPI-549
DMG5Q7F HS Phase 2
DMG5Q7F SN XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
DMG5Q7F CP Infinity Pharmaceuticals Cambridge, MA
DMG5Q7F PC 91933883
DMG5Q7F MW 528.6
DMG5Q7F FM C30H24N8O2
DMG5Q7F IC InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
DMG5Q7F CS C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
DMG5Q7F IK XUMALORDVCFWKV-IBGZPJMESA-N
DMG5Q7F IU 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMG5Q7F CA CAS 1693758-51-8
DMG5Q7F DE Adrenocortical carcinoma; Breast cancer; Head and neck cancer; Melanoma; Mesothelioma; Solid tumour/cancer; Bladder cancer
DMW2IF9 ID DMW2IF9
DMW2IF9 DN IR502
DMW2IF9 HS Phase 2
DMW2IF9 SN Zorcell
DMW2IF9 CP Orchestra Therapeutics
DMW2IF9 DE Psoriatic disorder; Plaque psoriasis; Psoriasis vulgaris
DMQ3RWN ID DMQ3RWN
DMQ3RWN DN Iralukast
DMQ3RWN HS Phase 2
DMQ3RWN SN CGP-45715A
DMQ3RWN CP Novartis AG
DMQ3RWN DT Small molecular drug
DMQ3RWN PC 6913104
DMQ3RWN MW 710.8
DMQ3RWN FM C38H37F3O8S
DMQ3RWN IC InChI=1S/C38H37F3O8S/c1-3-11-29-31(18-17-27(23(2)42)36(29)45)48-19-9-7-5-4-6-8-14-34(35(44)24-12-10-13-25(20-24)38(39,40)41)50-26-15-16-28-30(43)22-33(37(46)47)49-32(28)21-26/h4,6,8,10,12-18,20-22,34-35,44-45H,3,5,7,9,11,19H2,1-2H3,(H,46,47)/b6-4-,14-8+/t34-,35+/m0/s1
DMQ3RWN CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCC/C=C\\C=C\\[C@@H]([C@@H](C2=CC(=CC=C2)C(F)(F)F)O)SC3=CC4=C(C=C3)C(=O)C=C(O4)C(=O)O
DMQ3RWN IK IXJCHVMUTFCRBH-SDUHDBOFSA-N
DMQ3RWN IU 7-[(1R,2S,3E,5Z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid
DMQ3RWN CA CAS 151581-24-7
DMQ3RWN DE Asthma
DMI874B ID DMI874B
DMI874B DN Iratumumab
DMI874B HS Phase 2
DMI874B SN MDX-060; Anti-CD30 antibody, Medarex; 5F11
DMI874B CP Medarex
DMI874B DT Antibody
DMI874B DE Lymphoma
DMCAFVN ID DMCAFVN
DMCAFVN DN IRT-102
DMCAFVN HS Phase 2
DMCAFVN CP Tni biotech
DMCAFVN DT Small molecular drug
DMCAFVN PC 42785
DMCAFVN MW 573.7
DMCAFVN FM C27H35N5O7S
DMCAFVN IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)
DMCAFVN CS CSCCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N
DMCAFVN IK YFGBQHOOROIVKG-UHFFFAOYSA-N
DMCAFVN IU 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMCAFVN CA CAS 58569-55-4
DMCAFVN DE Pancreatic cancer
DMODLN7 ID DMODLN7
DMODLN7 DN IRX-2
DMODLN7 HS Phase 2
DMODLN7 CP IRX Therapeutics
DMODLN7 DE Head and neck cancer; Acute myeloid leukaemia; Breast cancer; Squamous cell carcinoma; leukaemia
DMHOJ8W ID DMHOJ8W
DMHOJ8W DN Isatoribine
DMHOJ8W HS Phase 2
DMHOJ8W SN 7-Thia-8-oxoguanosine; ANA245; 122970-40-5; UNII-2DNT962H92; ANA-245; 2DNT962H92; Immusine; Isatoribine [USAN:INN]; 7-TOG; Immunosine; Satoribine; N10146; 7-Deaza-7-thia-8-oxoguanosine; AC1L2HO7; SCHEMBL127980; AC1Q6N18; SCHEMBL12592999; CHEMBL2105116; ANA 245; TZYVRXZQAWPIAB-FCLHUMLKSA-N; ZINC8214713; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; DB04860; 5-amino-3-(; A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; BRD-K87535339-001-01-6
DMHOJ8W CP Anadys Pharmaceuticals
DMHOJ8W DT Small molecular drug
DMHOJ8W PC 135409474
DMHOJ8W MW 316.29
DMHOJ8W FM C10H12N4O6S
DMHOJ8W IC InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1
DMHOJ8W CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)SC2=O)O)O)O
DMHOJ8W IK TZYVRXZQAWPIAB-FCLHUMLKSA-N
DMHOJ8W IU 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
DMHOJ8W CA CAS 122970-40-5
DMHOJ8W DE Hepatitis C virus infection
DMBZK3P ID DMBZK3P
DMBZK3P DN ISF35
DMBZK3P HS Phase 2
DMBZK3P CP Memgen
DMBZK3P DE Small lymphocytic lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukaemia
DMUPD4G ID DMUPD4G
DMUPD4G DN ISIS 113715
DMUPD4G HS Phase 2
DMUPD4G CP ISIS
DMUPD4G TC Antisense
DMUPD4G DT Antisense drug
DMUPD4G SQ GCTCCTTCCACTGATCCTGC
DMUPD4G DE Type-2 diabetes
DMQ3C05 ID DMQ3C05
DMQ3C05 DN ISIS-APO(a)
DMQ3C05 HS Phase 2
DMQ3C05 DT Antisense drug
DMQ3C05 DE Coronary artery disease
DML84CN ID DML84CN
DML84CN DN ISIS-CRPRx
DML84CN HS Phase 2
DML84CN CP ISIS pharmaceuticals
DML84CN DE Coronary artery disease
DMRN543 ID DMRN543
DMRN543 DN ISIS-EIF4E
DMRN543 HS Phase 2
DMRN543 CP ISIS Pharm
DMRN543 DT Antisense drug
DMRN543 DE Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer
DMNVZDT ID DMNVZDT
DMNVZDT DN ISIS-FGFR4
DMNVZDT HS Phase 2
DMNVZDT CP ISIS Pharm
DMNVZDT DT Antisense drug
DMNVZDT DE Obesity
DMHETPI ID DMHETPI
DMHETPI DN ISIS-FXI
DMHETPI HS Phase 2
DMHETPI CP ISIS Pharm
DMHETPI DT Antisense drug
DMHETPI DE Coagulation defect
DMICMNU ID DMICMNU
DMICMNU DN ISIS-GCCR
DMICMNU HS Phase 2
DMICMNU CP ISIS Pharm
DMICMNU DT Antisense drug
DMICMNU DE Diabetic complication; Type-2 diabetes
DMHNYWP ID DMHNYWP
DMHNYWP DN ISIS-GCGR
DMHNYWP HS Phase 2
DMHNYWP CP ISIS Pharm
DMHNYWP DT Antisense drug
DMHNYWP DE Diabetic complication; Type-2 diabetes
DM4RXDQ ID DM4RXDQ
DM4RXDQ DN ISIS-HBV
DM4RXDQ HS Phase 2
DM4RXDQ DT Antisense drug
DM4RXDQ DE Hepatitis B virus infection
DMJGVXT ID DMJGVXT
DMJGVXT DN ISIS-PTP1Brx
DMJGVXT HS Phase 2
DMJGVXT CP Isis Pharmaceuticals
DMJGVXT DT Antisense drug
DMJGVXT DE Type-2 diabetes
DM2RS0V ID DM2RS0V
DM2RS0V DN Isofagomine tartrate
DM2RS0V HS Phase 2
DM2RS0V SN Plicera; Afegostat tartrate; AT-2101; HGT-3410; Plicera (TN); NN-42-1007
DM2RS0V CP Amicus Therape.
DM2RS0V DT Small molecular drug
DM2RS0V PC 23581846
DM2RS0V MW 297.26
DM2RS0V FM C10H19NO9
DM2RS0V IC InChI=1S/C6H13NO3.C4H6O6/c8-3-4-1-7-2-5(9)6(4)10;5-1(3(7)8)2(6)4(9)10/h4-10H,1-3H2;1-2,5-6H,(H,7,8)(H,9,10)/t4-,5-,6-;1-,2-/m11/s1
DM2RS0V CS C1[C@@H]([C@H]([C@@H](CN1)O)O)CO.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM2RS0V IK ULBPPCHRAVUQMC-MUMXBIPUSA-N
DM2RS0V IU (2R,3R)-2,3-dihydroxybutanedioic acid;(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
DM2RS0V CA CAS 919364-56-0
DM2RS0V DE Metabolic disorder
DMP2BWX ID DMP2BWX
DMP2BWX DN Ispinesib
DMP2BWX HS Phase 2
DMP2BWX SN SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX CP Cytokinetics
DMP2BWX TC Anticancer Agents
DMP2BWX DT Small molecular drug
DMP2BWX PC 6851740
DMP2BWX MW 517.1
DMP2BWX FM C30H33ClN4O2
DMP2BWX IC InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1
DMP2BWX CS CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C
DMP2BWX IK QJZRFPJCWMNVAV-HHHXNRCGSA-N
DMP2BWX IU N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX CA CAS 336113-53-2
DMP2BWX CB CHEBI:94692
DMP2BWX DE Solid tumour/cancer; Ovarian cancer; Renal cell carcinoma; Head and neck cancer
DMCY9PO ID DMCY9PO
DMCY9PO DN Itarnafloxin
DMCY9PO HS Phase 2
DMCY9PO SN Quarfloxin; CX-3385; CX-3543; Quadruplex DNA oncogene inhibitor (cancer), Cylene; C-Myc/VEGF oncogene inhibitor (cancer), Cylene
DMCY9PO CP Cylene Pharmaceuticals Inc
DMCY9PO DT Small molecular drug
DMCY9PO PC 11635763
DMCY9PO MW 604.7
DMCY9PO FM C35H33FN6O3
DMCY9PO IC InChI=1S/C35H33FN6O3/c1-40-13-4-7-24(40)8-10-39-35(44)26-20-42-29-15-21-5-2-3-6-22(21)16-30(29)45-34-31(42)25(33(26)43)17-27(36)32(34)41-14-9-23(19-41)28-18-37-11-12-38-28/h2-3,5-6,11-12,15-18,20,23-24H,4,7-10,13-14,19H2,1H3,(H,39,44)/t23?,24-/m0/s1
DMCY9PO CS CN1CCC[C@H]1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O
DMCY9PO IK WOQIDNWTQOYDLF-CGAIIQECSA-N
DMCY9PO IU 15-fluoro-N-[2-[(2S)-1-methylpyrrolidin-2-yl]ethyl]-18-oxo-14-(3-pyrazin-2-ylpyrrolidin-1-yl)-12-oxa-1-azapentacyclo[11.7.1.02,11.04,9.017,21]henicosa-2,4,6,8,10,13(21),14,16,19-nonaene-19-carboxamide
DMCY9PO CA CAS 865311-47-3
DMCY9PO DE leukaemia
DMDZWPL ID DMDZWPL
DMDZWPL DN ITCA-638
DMDZWPL HS Phase 2
DMDZWPL SN Omega DUROS, BioMedicines/ ALZA; Omega DUROS, Intarcia/ALZA; Omega IFN (sustained release), BioMedicines/ ALZA; Omega IFN (sustained release, hepatitis C), Intarcia/ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), BioMedicines/ ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), Intarcia/ALZA
DMDZWPL CP Intarcia Therapeutics Inc
DMDZWPL DE Hepatitis C virus infection
DM5UFRO ID DM5UFRO
DM5UFRO DN Itriglumide
DM5UFRO HS Phase 2
DM5UFRO SN CR-2945
DM5UFRO CP Rottapharm Madaus
DM5UFRO DT Small molecular drug
DM5UFRO PC 6604121
DM5UFRO MW 526.7
DM5UFRO FM C33H38N2O4
DM5UFRO IC InChI=1S/C33H38N2O4/c1-22-18-23(2)31(28(19-22)32(39)35-16-14-33(15-17-35)12-5-6-13-33)34-29(36)20-25(21-30(37)38)27-11-7-9-24-8-3-4-10-26(24)27/h3-4,7-11,18-19,25H,5-6,12-17,20-21H2,1-2H3,(H,34,36)(H,37,38)/t25-/m1/s1
DM5UFRO CS CC1=CC(=C(C(=C1)C(=O)N2CCC3(CCCC3)CC2)NC(=O)C[C@H](CC(=O)O)C4=CC=CC5=CC=CC=C54)C
DM5UFRO IK MFOOVZCXWVAWOV-RUZDIDTESA-N
DM5UFRO IU (3R)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid
DM5UFRO CA CAS 201605-51-8
DM5UFRO DE Anxiety disorder
DMCJX79 ID DMCJX79
DMCJX79 DN ITV-1
DMCJX79 HS Phase 2
DMCJX79 CP Immunotech Laboratories
DMCJX79 DT Vaccine
DMCJX79 DE Human immunodeficiency virus infection
DMJV3AX ID DMJV3AX
DMJV3AX DN IVA337
DMJV3AX HS Phase 2
DMJV3AX SN Lanifibranor; 927961-18-0; IVA-337; UNII-28Q8AG0PYL; 28Q8AG0PYL; CHEMBL4091374; CPD1537; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; Lanifbranor; Libfranor; Lanifbranor [INN]; Lanifibranor(IVA-337); SCHEMBL3528615; AMY16813; EX-A1511; BDBM50244350; s8770; DB14801; SB18746; AC-31451; AK689102; BS-17993; HY-104049; CS-0027586; Q27896056; 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic Acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; BJB
DMJV3AX DT Small molecular drug
DMJV3AX PC 68677842
DMJV3AX MW 434.9
DMJV3AX FM C19H15ClN2O4S2
DMJV3AX IC InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
DMJV3AX CS C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
DMJV3AX IK OQDQIFQRNZIEEJ-UHFFFAOYSA-N
DMJV3AX IU 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
DMJV3AX CA CAS 927961-18-0
DMJV3AX DE Non-alcoholic steatohepatitis
DM0OYLQ ID DM0OYLQ
DM0OYLQ DN I-vation
DM0OYLQ HS Phase 2
DM0OYLQ SN Triamcinolone implant
DM0OYLQ CP SurModics
DM0OYLQ DE Diabetic retinopathy
DM457XO ID DM457XO
DM457XO DN IW-1701
DM457XO HS Phase 2
DM457XO SN Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO CP Cyclerion Therapeutics
DM457XO DT Small molecular drug
DM457XO PC 90445883
DM457XO MW 509.4
DM457XO FM C21H16F5N7O3
DM457XO IC InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1
DM457XO CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
DM457XO IK YWQFJNWMWZMXRW-HXUWFJFHSA-N
DM457XO IU (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO CA CAS 1628732-62-6
DM457XO DE Sickle-cell disorder
DMK2T7J ID DMK2T7J
DMK2T7J DN IW-1973
DMK2T7J HS Phase 2
DMK2T7J SN Praliciguat; UNII-R1S0H458SA; R1S0H458SA; 1628730-49-3; Praliciguat [INN]; GTPL9900; SCHEMBL16082414; IW1973; 1,1,1-trifluoro-3-[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1H-pyrazol-3-yl}pyrimidin-4-yl)amino]-2-(trifluoromethyl)propan-2-ol; 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(3-isoxazolyl)-1H-pyrazol-3-yl)-4-pyrimidinyl)amino)methyl)-
DMK2T7J CP Ironwood Pharmaceuticals Cambridge, MA
DMK2T7J PC 86269973
DMK2T7J MW 534.4
DMK2T7J FM C21H14F8N6O2
DMK2T7J IC InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32)
DMK2T7J CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(F)(F)F)(C(F)(F)F)O)F)C4=NOC=C4)F
DMK2T7J IK CYSJNTQNMDWAJV-UHFFFAOYSA-N
DMK2T7J IU 1,1,1,3,3,3-hexafluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]propan-2-ol
DMK2T7J CA CAS 1628730-49-3
DMK2T7J CB CHEBI:142431
DMK2T7J DE Heart failure
DMP42W1 ID DMP42W1
DMP42W1 DN IW-6118
DMP42W1 HS Phase 2
DMP42W1 CP Ironwood Pharmaceuticals Inc
DMP42W1 DE Inflammation
DM3WSDR ID DM3WSDR
DM3WSDR DN IXT-m200
DM3WSDR HS Phase 2
DM3WSDR CP InterveXion Therapeutics
DM3WSDR DT Antibody
DM3WSDR DE Methamphetamine use disorder
DM9XKJU ID DM9XKJU
DM9XKJU DN J 591 Lu-177
DM9XKJU HS Phase 2
DM9XKJU CP BZL Biologics
DM9XKJU DE Prostate cancer
DMKU6MW ID DMKU6MW
DMKU6MW DN JB991
DMKU6MW HS Phase 2
DMKU6MW CP Synphora
DMKU6MW DE Sarcoidosis; Skin infection
DM89ASO ID DM89ASO
DM89ASO DN JCAR015
DM89ASO HS Phase 2
DM89ASO CP Juno Therapeutics, Inc.
DM89ASO DT CAR T Cell Therapy
DM89ASO DE B-cell lymphoma; Acute lymphoblastic leukaemia
DMM02VJ ID DMM02VJ
DMM02VJ DN JI-101
DMM02VJ HS Phase 2
DMM02VJ SN JI-101; 900573-88-8; CGI-1842; UNII-980M4N37DH; 980M4N37DH; 1-(1-((2-AMINOPYRIDIN-4-YL)METHYL)-1H-INDOL-4-YL)-3-(5-BROMO-2-METHOXYPHENYL)UREA; SCHEMBL5585996; CHEMBL3545155; MolPort-044-567-620; BCP16892; EX-A2371; JI 101; ZINC38255464; AKOS030526978; SB16904; DB12744; CS-5636; Urea, N-(1-((2-amino-4-pyridinyl)methyl)-1H-indol-4-yl)-N'-(5-bromo-2-methoxyphenyl)-; KB-77988; HY-16265
DMM02VJ CP Jubilant Biosys
DMM02VJ DT Small molecular drug
DMM02VJ PC 11691242
DMM02VJ MW 466.3
DMM02VJ FM C22H20BrN5O2
DMM02VJ IC InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)
DMM02VJ CS COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N
DMM02VJ IK ZXBFYBLSJMEBEP-UHFFFAOYSA-N
DMM02VJ IU 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
DMM02VJ CA CAS 900573-88-8
DMM02VJ DE Solid tumour/cancer
DMARQ0H ID DMARQ0H
DMARQ0H DN JKB-122
DMARQ0H HS Phase 2
DMARQ0H SN Opioid receptor modulator (liver disease), Jenken Bioscience
DMARQ0H CP Jenken Biosciences
DMARQ0H DE Hepatitis virus infection
DMJSVRL ID DMJSVRL
DMJSVRL DN JM216
DMJSVRL HS Phase 2
DMJSVRL SN 129580-63-8; JM 216; satraplatin(jm216); Satraplatin (USAN/INN); C081294; YHI-601; C6H13N.C4H6Cl2O4Pt.H3N; Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-; 4023AH; AKOS015914237; BMS-182751; BC679462; FT-0601550; D05807; Bis(acetato-O)amminedichloro(cyclohexanamine)-pt; 580S638; I14-43013; Platinum (lV) cis-dichloro-trans-bis(acetato-O)ammine(cyclohexanamine)
DMJSVRL DT Small molecular drug
DMJSVRL PC 6918220
DMJSVRL MW 502.3
DMJSVRL FM C10H24Cl2N2O4Pt
DMJSVRL IC InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+2/p-2
DMJSVRL CS CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl
DMJSVRL IK TWEQNPPRXJRHHM-UHFFFAOYSA-L
DMJSVRL IU acetic acid;azane;cyclohexanamine;dichloroplatinum
DMJSVRL DE Solid tumour/cancer
DMBXWJ5 ID DMBXWJ5
DMBXWJ5 DN JNJ 63723283
DMBXWJ5 HS Phase 2
DMBXWJ5 CP Janssen Research & Development Raritan, NJ
DMBXWJ5 DT Monoclonal antibody
DMBXWJ5 DE Solid tumour/cancer; Multiple myeloma; Prostate cancer; Ulcerative colitis
DMY7Q3I ID DMY7Q3I
DMY7Q3I DN JNJ-10229570
DMY7Q3I HS Phase 2
DMY7Q3I SN JNJ-10229570-AAA; MC5R antagonist (topical, acne), Johnson & Johnson; Melanocortin-5 receptor antagonist (topical, acne), Johnson & Johnson
DMY7Q3I CP Johnson & Johnson
DMY7Q3I PC 10110895
DMY7Q3I MW 389.5
DMY7Q3I FM C22H19N3O2S
DMY7Q3I IC InChI=1S/C22H19N3O2S/c1-26-19-14-8-6-12-17(19)21-24-22(23-16-10-4-3-5-11-16)28-25(21)18-13-7-9-15-20(18)27-2/h3-15H,1-2H3
DMY7Q3I CS COC1=CC=CC=C1C2=NC(=NC3=CC=CC=C3)SN2C4=CC=CC=C4OC
DMY7Q3I IK XTHRTBCPBWJYRO-UHFFFAOYSA-N
DMY7Q3I IU 2,3-bis(2-methoxyphenyl)-N-phenyl-1,2,4-thiadiazol-5-imine
DMY7Q3I CA CAS 524923-88-4
DMY7Q3I DE Acne vulgaris
DM7OTQS ID DM7OTQS
DM7OTQS DN JNJ-10311795
DM7OTQS HS Phase 2
DM7OTQS SN JNJ-10311795; CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS DT Small molecular drug
DM7OTQS PC 10146470
DM7OTQS MW 670.7
DM7OTQS FM C40H35N2O6P
DM7OTQS IC InChI=1S/C40H35N2O6P/c1-41(32-19-21-42(22-20-32)39(44)31-18-17-26-9-2-3-11-28(26)23-31)40(45)36-25-30-13-5-4-12-29(30)24-35(36)37(43)38(49(46,47)48)34-16-8-14-27-10-6-7-15-33(27)34/h2-18,23-25,32,38H,19-22H2,1H3,(H2,46,47,48)
DM7OTQS CS CN(C1CCN(CC1)C(=O)C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC5=CC=CC=C5C=C4C(=O)C(C6=CC=CC7=CC=CC=C76)P(=O)(O)O
DM7OTQS IK XUJQPDQURBZEGJ-UHFFFAOYSA-N
DM7OTQS IU [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS CA CAS 518062-14-1
DM7OTQS DE Chronic obstructive pulmonary disease
DMPFG7H ID DMPFG7H
DMPFG7H DN JNJ-16269110
DMPFG7H HS Phase 2
DMPFG7H SN SCHEMBL803531; CHEMBL2103860
DMPFG7H CP Janssen Research & Development
DMPFG7H DT Small molecular drug
DMPFG7H PC 56842069
DMPFG7H MW 572.6
DMPFG7H FM C34H31F3N2O3
DMPFG7H IC InChI=1S/C34H31F3N2O3/c1-42-33(41)31(26-7-3-2-4-8-26)39-21-19-24(20-22-39)23-13-17-28(18-14-23)38-32(40)30-10-6-5-9-29(30)25-11-15-27(16-12-25)34(35,36)37/h2-18,24,31H,19-22H2,1H3,(H,38,40)/t31-/m1/s1
DMPFG7H CS COC(=O)[C@@H](C1=CC=CC=C1)N2CCC(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4C5=CC=C(C=C5)C(F)(F)F
DMPFG7H IK WSYALRNYQFNNGP-WJOKGBTCSA-N
DMPFG7H IU methyl (2R)-2-phenyl-2-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]piperidin-1-yl]acetate
DMPFG7H CA CAS 403989-79-7
DMPFG7H DE Type-2 diabetes
DM1GRCU ID DM1GRCU
DM1GRCU DN JNJ-17216498
DM1GRCU HS Phase 2
DM1GRCU SN Histamine H3 antagonist (oral, narcolepsy) J&J
DM1GRCU CP Johnson & Johnson
DM1GRCU DE Narcolepsy
DMV1T59 ID DMV1T59
DMV1T59 DN JNJ-18038683
DMV1T59 HS Phase 2
DMV1T59 SN Serotonin 7 antagonist (depression), Johnson & Johnson; 5-HT 7 antagonist (depression), Johnson & Johnson
DMV1T59 CP Johnson & Johnson
DMV1T59 DT Small molecular drug
DMV1T59 PC 11151899
DMV1T59 MW 337.8
DMV1T59 FM C20H20ClN3
DMV1T59 IC InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2
DMV1T59 CS C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMV1T59 IK UKJPMZGILXATGT-UHFFFAOYSA-N
DMV1T59 IU 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine
DMV1T59 CA CAS 851373-91-6
DMV1T59 DE Major depressive disorder
DMKIE9C ID DMKIE9C
DMKIE9C DN JNJ-26481585
DMKIE9C HS Phase 2
DMKIE9C SN 875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide
DMKIE9C CP Janssen Research & Development
DMKIE9C DT Small molecular drug
DMKIE9C PC 11538455
DMKIE9C MW 394.5
DMKIE9C FM C21H26N6O2
DMKIE9C IC InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
DMKIE9C CS CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
DMKIE9C IK PAWIYAYFNXQGAP-UHFFFAOYSA-N
DMKIE9C IU N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
DMKIE9C CA CAS 875320-29-9
DMKIE9C CB CHEBI:94771
DMKIE9C DE Advanced stage follicular lymphoma; Solid tumour/cancer
DMQD1GN ID DMQD1GN
DMQD1GN DN JNJ-32729463
DMQD1GN HS Phase 2
DMQD1GN SN Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661
DMQD1GN DT Small molecular drug
DMQD1GN PC 67311433
DMQD1GN MW 455.9
DMQD1GN FM C21H24ClF2N3O4
DMQD1GN IC InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+;
DMQD1GN CS COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
DMQD1GN IK RDXCNSOGHLLWDV-YFMOEUEHSA-N
DMQD1GN IU 7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMQD1GN CA CAS 1001162-01-1
DMQD1GN DE Community-acquired pneumonia
DMV41P5 ID DMV41P5
DMV41P5 DN JNJ-37822681
DMV41P5 HS Phase 2
DMV41P5 SN UNII-GJB2URS7NJ; JNJ-37822681; GJB2URS7NJ; CHEMBL3234237; 935776-74-2; SCHEMBL1022639; MolPort-039-267-898; BDBM50003063; ZINC34951380; DB12579; 3-Pyridazinamine, N-(1-((3,4-difluorophenyl)methyl)-4-piperidinyl)-6-(trifluoromethyl)-; NCGC00386644-01; Z1558691527
DMV41P5 CP Johnson & Johnson Pharmaceutical Research & Development
DMV41P5 DT Small molecular drug
DMV41P5 PC 16058752
DMV41P5 MW 372.34
DMV41P5 FM C17H17F5N4
DMV41P5 IC InChI=1S/C17H17F5N4/c18-13-2-1-11(9-14(13)19)10-26-7-5-12(6-8-26)23-16-4-3-15(24-25-16)17(20,21)22/h1-4,9,12H,5-8,10H2,(H,23,25)
DMV41P5 CS C1CN(CCC1NC2=NN=C(C=C2)C(F)(F)F)CC3=CC(=C(C=C3)F)F
DMV41P5 IK UVUYWJWYRLJHEN-UHFFFAOYSA-N
DMV41P5 IU N-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine
DMV41P5 CA CAS 935776-74-2
DMV41P5 DE Schizophrenia
DM9UMIO ID DM9UMIO
DM9UMIO DN JNJ-38518168
DM9UMIO HS Phase 2
DM9UMIO CP Janssen research & development
DM9UMIO PC 23650961
DM9UMIO MW 392.5
DM9UMIO FM C23H32N6
DM9UMIO IC InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
DM9UMIO CS CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C
DM9UMIO IK FCRFVPZAXGJLPW-UHFFFAOYSA-N
DM9UMIO IU 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
DM9UMIO CA CAS 952494-46-1
DM9UMIO DE Rheumatoid arthritis; Plaque psoriasis
DM0WY3H ID DM0WY3H
DM0WY3H DN JNJ-39220675
DM0WY3H HS Phase 2
DM0WY3H SN Histamine H3 receptor antagonist (allergic rhinitis/alcoholism), Johnson & Johnson
DM0WY3H CP Johnson & Johnson Pharmaceutical Research & Development LLC
DM0WY3H DT Small molecular drug
DM0WY3H PC 24771368
DM0WY3H MW 369.4
DM0WY3H FM C21H24FN3O2
DM0WY3H IC InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2
DM0WY3H CS C1CC(C1)N2CCCN(CC2)C(=O)C3=CN=C(C=C3)OC4=CC=C(C=C4)F
DM0WY3H IK IQOWHZHNGJXGHG-UHFFFAOYSA-N
DM0WY3H IU (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(4-fluorophenoxy)pyridin-3-yl]methanone
DM0WY3H CA CAS 959740-39-7
DM0WY3H DE Alcohol dependence
DMUOEKM ID DMUOEKM
DMUOEKM DN JNJ-39393406
DMUOEKM HS Phase 2
DMUOEKM SN JNJ-39393406; UNII-T930SOU82P; T930SOU82P; JNJ 39393406; 953428-73-4; SCHEMBL827762; CHEMBL3545291; DB11867; 1H-1,2,4-Triazole-1-propanamide, 3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N,N-dimethyl-5-(4-pyridinyl)-
DMUOEKM CP Janssen Pharmaceutica NV
DMUOEKM DT Small molecular drug
DMUOEKM PC 16755766
DMUOEKM MW 416.4
DMUOEKM FM C19H18F2N6O3
DMUOEKM IC InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
DMUOEKM CS CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4
DMUOEKM IK IURMHZBQEYNQOH-UHFFFAOYSA-N
DMUOEKM IU 3-[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide
DMUOEKM CA CAS 953428-73-4
DMUOEKM DE Cognitive impairment; Depression; Tobacco dependence
DM219SF ID DM219SF
DM219SF DN JNJ-40346527
DM219SF HS Phase 2
DM219SF CP Janssen Research & Development
DM219SF PC 25230468
DM219SF MW 461.6
DM219SF FM C27H35N5O2
DM219SF IC InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
DM219SF CS CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C
DM219SF IK BNVPFDRNGHMRJS-UHFFFAOYSA-N
DM219SF IU 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide
DM219SF CA CAS 1142363-52-7
DM219SF DE Hodgkin lymphoma
DM72GZO ID DM72GZO
DM72GZO DN JNJ-42165279
DM72GZO HS Phase 2
DM72GZO CP Janssen research & development
DM72GZO PC 54576693
DM72GZO MW 410.8
DM72GZO FM C18H17ClF2N4O3
DM72GZO IC InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
DM72GZO CS C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
DM72GZO IK YWGYNGCRVZLMCS-UHFFFAOYSA-N
DM72GZO IU N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
DM72GZO CA CAS 1346528-50-4
DM72GZO DE Anxiety disorder; Social anxiety disorder
DMJ1FXL ID DMJ1FXL
DMJ1FXL DN JNJ-53718678
DMJ1FXL HS Phase 2
DMJ1FXL SN Rilematovir; JNJ-678; UNII-NQ99E8OH3P; NQ99E8OH3P; 1383450-81-4; 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one; 3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One; Rilematovir [INN]; CHEMBL4437054; SCHEMBL17529353; HY-112180; CS-0043622; C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C; 2H-Imidazo(4,5-C)pyridin-2-one, 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; 3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one; 6YA
DMJ1FXL CP Janssen
DMJ1FXL DT Small molecular drug
DMJ1FXL PC 118892432
DMJ1FXL MW 500.9
DMJ1FXL FM C21H20ClF3N4O3S
DMJ1FXL IC InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
DMJ1FXL CS CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F
DMJ1FXL IK GTQTUABHRCWVLL-UHFFFAOYSA-N
DMJ1FXL IU 3-[[5-chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyridin-2-one
DMJ1FXL CA CAS 1383450-81-4
DMJ1FXL DE Respiratory syncytial virus infection
DM9RW6H ID DM9RW6H
DM9RW6H DN JNJ-56136379
DM9RW6H HS Phase 2
DM9RW6H SN JNJ-6379
DM9RW6H CP Janssen
DM9RW6H DT Antibody
DM9RW6H DE Hepatitis B
DME2S4D ID DME2S4D
DME2S4D DN JNJ-61393215
DME2S4D HS Phase 2
DME2S4D SN Q66977422
DME2S4D CP Janssen
DME2S4D DT Small molecular drug
DME2S4D PC 139030979
DME2S4D MW 460.4
DME2S4D FM C23H18F4N4O2
DME2S4D IC InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
DME2S4D CS [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
DME2S4D IK HUKWIAXQBOHZIX-USKNZQBOSA-N
DME2S4D IU [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
DME2S4D DE Major depressive disorder
DMVSUH1 ID DMVSUH1
DMVSUH1 DN JNJ-64565111
DMVSUH1 HS Phase 2
DMVSUH1 CP Janssen Research & Development Raritan, NJ
DMVSUH1 DE Type-2 diabetes; Obesity
DM3ICO6 ID DM3ICO6
DM3ICO6 DN JNJ-74494550
DM3ICO6 HS Phase 2
DM3ICO6 SN Cusatuzumab
DM3ICO6 CP Argen Boston; Janssen
DM3ICO6 DT Antibody
DM3ICO6 DE Myelodysplastic syndrome
DMXTKCR ID DMXTKCR
DMXTKCR DN JT02
DMXTKCR HS Phase 2
DMXTKCR CP JYANT Technologies Marietta, GA
DMXTKCR DE Inflammatory bowel disease
DM2LBHN ID DM2LBHN
DM2LBHN DN JTE-051
DM2LBHN HS Phase 2
DM2LBHN DE Allergy; Plaque psoriasis
DM1945H ID DM1945H
DM1945H DN JTT-251
DM1945H HS Phase 2
DM1945H CP Akros pharma
DM1945H DE Type-2 diabetes; Pulmonary arterial hypertension
DMGLVBI ID DMGLVBI
DMGLVBI DN JTT-302
DMGLVBI HS Phase 2
DMGLVBI SN CETP inhibitor (oral, dyslipidemia), Japan Tobacco
DMGLVBI CP Japan Tobacco Inc
DMGLVBI DE Lipid metabolism disorder
DM50M2R ID DM50M2R
DM50M2R DN JTT-654
DM50M2R HS Phase 2
DM50M2R SN 11-beta HSD1 inhibitor (oral, type 2 diabetes), Japan Tobacco; 11-beta hydroxysteroid dehydrogenase (oral, type 2 diabetes), Japan Tobacco
DM50M2R CP Japan Tobacco Inc
DM50M2R DE Type-2 diabetes
DMED5J6 ID DMED5J6
DMED5J6 DN JTT-851
DMED5J6 HS Phase 2
DMED5J6 SN GPCR 40 agonist (type 2 diabetes) Japan Tobacco
DMED5J6 CP Akros pharma
DMED5J6 DE Type-2 diabetes
DMGXTOP ID DMGXTOP
DMGXTOP DN JTX-2011
DMGXTOP HS Phase 2
DMGXTOP CP Jounce Therapeutics Cambridge, MA
DMGXTOP DE Solid tumour/cancer
DMOT0M7 ID DMOT0M7
DMOT0M7 DN JTX-4014
DMOT0M7 HS Phase 2
DMOT0M7 SN Pimivalimab
DMOT0M7 CP Jounce Therapeutics
DMOT0M7 DT Antibody
DMOT0M7 DE Non-small-cell lung cancer
DMZKYNO ID DMZKYNO
DMZKYNO DN Juvidex
DMZKYNO HS Phase 2
DMZKYNO SN Adaprev; Mannose-6-phosphate (scarring), Renovo
DMZKYNO CP Renovo Group plc
DMZKYNO PC 6101690
DMZKYNO MW 260.14
DMZKYNO FM C6H13O9P
DMZKYNO IC InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4-,5-,6-/m1/s1
DMZKYNO CS C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)OP(=O)(O)O
DMZKYNO IK VFRROHXSMXFLSN-KVTDHHQDSA-N
DMZKYNO IU [(2R,3R,4S,5S)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
DMZKYNO CA CAS 3672-15-9
DMZKYNO CB CHEBI:48042
DMZKYNO DE Sarcoidosis
DMPMU38 ID DMPMU38
DMPMU38 DN JVRS-100
DMPMU38 HS Phase 2
DMPMU38 CP Colby Pharmaceutical
DMPMU38 DT Vaccine
DMPMU38 DE leukaemia
DMD4OK0 ID DMD4OK0
DMD4OK0 DN K-134
DMD4OK0 HS Phase 2
DMD4OK0 SN SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104
DMD4OK0 CP Kowa Pharmaceuticals America
DMD4OK0 DT Small molecular drug
DMD4OK0 PC 9908900
DMD4OK0 MW 399.5
DMD4OK0 FM C22H29N3O4
DMD4OK0 IC InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1
DMD4OK0 CS C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O
DMD4OK0 IK ULGNGSQNNMKROG-WOJBJXKFSA-N
DMD4OK0 IU 1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea
DMD4OK0 CA CAS 189362-06-9
DMD4OK0 DE Arteriosclerosis
DMZCVD7 ID DMZCVD7
DMZCVD7 DN K-201
DMZCVD7 HS Phase 2
DMZCVD7 SN DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519
DMZCVD7 CP Moberg Derma AB
DMZCVD7 DT Small molecular drug
DMZCVD7 PC 9868902
DMZCVD7 MW 461.1
DMZCVD7 FM C25H33ClN2O2S
DMZCVD7 IC InChI=1S/C25H32N2O2S.ClH/c1-29-23-7-8-24-22(18-23)19-27(15-16-30-24)25(28)11-14-26-12-9-21(10-13-26)17-20-5-3-2-4-6-20;/h2-8,18,21H,9-17,19H2,1H3;1H
DMZCVD7 CS COC1=CC2=C(C=C1)SCCN(C2)C(=O)CCN3CCC(CC3)CC4=CC=CC=C4.Cl
DMZCVD7 IK DKKLXCRMAXNIJF-UHFFFAOYSA-N
DMZCVD7 IU 3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one;hydrochloride
DMZCVD7 CA CAS 1038410-88-6
DMZCVD7 DE Atopic dermatitis
DMQVN6P ID DMQVN6P
DMQVN6P DN K-604
DMQVN6P HS Phase 2
DMQVN6P SN BDBM86691
DMQVN6P CP Kowa Pharmaceuticals America
DMQVN6P DT Small molecular drug
DMQVN6P PC 9892288
DMQVN6P MW 502.7
DMQVN6P FM C23H30N6OS3
DMQVN6P IC InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30)
DMQVN6P CS CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC
DMQVN6P IK VGGMTOYKEDKFLN-UHFFFAOYSA-N
DMQVN6P IU 2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide
DMQVN6P CA CAS 561023-90-3
DMQVN6P DE Arteriosclerosis
DMJLNZQ ID DMJLNZQ
DMJLNZQ DN K-828-AB
DMJLNZQ HS Phase 2
DMJLNZQ SN GABA transaminase inhibitor (oral, dementia), Kowa
DMJLNZQ CP Kowa Co Ltd
DMJLNZQ DE Dementia
DMMSTCF ID DMMSTCF
DMMSTCF DN K-832
DMMSTCF HS Phase 2
DMMSTCF SN 10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9
DMMSTCF CP Kowa
DMMSTCF DT Small molecular drug
DMMSTCF PC 9844960
DMMSTCF MW 418.9
DMMSTCF FM C24H19ClN2OS
DMMSTCF IC InChI=1S/C24H19ClN2OS/c1-29-21-13-9-19(10-14-21)24-22(18-7-11-20(25)12-8-18)15-23(28)27(26-24)16-17-5-3-2-4-6-17/h2-15H,16H2,1H3
DMMSTCF CS CSC1=CC=C(C=C1)C2=NN(C(=O)C=C2C3=CC=C(C=C3)Cl)CC4=CC=CC=C4
DMMSTCF IK HEUAVAATAFEENP-UHFFFAOYSA-N
DMMSTCF IU 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one
DMMSTCF DE Rheumatoid arthritis
DMTMCPZ ID DMTMCPZ
DMTMCPZ DN KB001A
DMTMCPZ HS Phase 2
DMTMCPZ CP Sanofi
DMTMCPZ DT Antibody
DMTMCPZ DE Infectious disease; Cystic fibrosis
DM60G5O ID DM60G5O
DM60G5O DN KB002/003
DM60G5O HS Phase 2
DM60G5O CP KaloBios Pharmaceuticals
DM60G5O DE Rheumatoid arthritis
DM74KIM ID DM74KIM
DM74KIM DN KB-003
DM74KIM HS Phase 2
DM74KIM SN KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios
DM74KIM CP Kalobios pharmaceuticals
DM74KIM DT Antibody
DM74KIM DE Severe asthma
DMZ4MCG ID DMZ4MCG
DMZ4MCG DN KB-6806
DMZ4MCG HS Phase 2
DMZ4MCG SN Prucalopride succinate; 179474-85-2; Prucalopride Succinat; Prucalopride (succinate); UNII-4V2G75E1CK; R-108512; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; Prucalopride succinate [USAN]; 4V2G75E1CK; R 108512; AK175654; Prucalopride succinate (USAN); resotran; Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1); Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-
DMZ4MCG CP Kanebo
DMZ4MCG DT Small molecular drug
DMZ4MCG PC 3073291
DMZ4MCG MW 307.82
DMZ4MCG FM C15H22ClN5
DMZ4MCG IC InChI=1S/C15H22ClN5/c1-10(2)21-14-9-12(17)11(16)8-13(14)18-15(21)20-6-4-19(3)5-7-20/h8-10H,4-7,17H2,1-3H3
DMZ4MCG CS CC(C)N1C2=C(C=C(C(=C2)N)Cl)N=C1N3CCN(CC3)C
DMZ4MCG IK QEANRFDFBNUCJR-UHFFFAOYSA-N
DMZ4MCG IU 6-chloro-2-(4-methylpiperazin-1-yl)-3-propan-2-ylbenzimidazol-5-amine
DMZ4MCG CA CAS 148014-93-1
DMZ4MCG DE Chemotherapy-induced nausea
DMEFW3G ID DMEFW3G
DMEFW3G DN KD019
DMEFW3G HS Phase 2
DMEFW3G SN Tesevatinib; XL647; XL-647; 781613-23-8; EXEL-7647; UNII-F6XM2TN5A1; KD-019; XL 647; F6XM2TN5A1; 651031-01-5; 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine; Tesevatinib [USAN:INN]; EXEL 7647; 874286-84-7; KD 019; 1000599-06-3; SCHEMBL721994; SCHEMBL721993; SCHEMBL721992; C24H25Cl2FN4O2; GTPL7944; CHEMBL3544983; EX-A172; QCR-153; MolPort-044-724-458; BCP23438; ZINC38912363; 2809AH; AKOS027255007
DMEFW3G CP Kadmon Pharmaceuticals
DMEFW3G DT Small molecular drug
DMEFW3G PC 10458325
DMEFW3G MW 491.4
DMEFW3G FM C24H25Cl2FN4O2
DMEFW3G IC InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
DMEFW3G CS CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC
DMEFW3G IK HVXKQKFEHMGHSL-GOOCMWNKSA-N
DMEFW3G IU 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
DMEFW3G CA CAS 781613-23-8
DMEFW3G DE Non-small-cell lung cancer; Polycystic kidney disease; Brain metastases; Meningioma metastases; Recurrent glioblastoma
DM548TK ID DM548TK
DM548TK DN KD025
DM548TK HS Phase 2
DM548TK CP Kadmon
DM548TK PC 11950170
DM548TK MW 452.5
DM548TK FM C26H24N6O2
DM548TK IC InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)
DM548TK CS CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
DM548TK IK GKHIVNAUVKXIIY-UHFFFAOYSA-N
DM548TK IU 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
DM548TK CA CAS 911417-87-3
DM548TK DE Rheumatoid arthritis; Psoriasis vulgaris; Psoriatic arthritis; Scleroderma; Systemic lupus erythematosus
DME1WV2 ID DME1WV2
DME1WV2 DN KD-7040
DME1WV2 HS Phase 2
DME1WV2 CP Kalypsys Inc
DME1WV2 DE Pain
DMFO6MH ID DMFO6MH
DMFO6MH DN Kevetrin
DMFO6MH HS Phase 2
DMFO6MH CP Cellceutix Corp
DMFO6MH DT Small molecular drug
DMFO6MH PC 437740
DMFO6MH MW 143.21
DMFO6MH FM C5H9N3S
DMFO6MH IC InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8)
DMFO6MH CS C(CC#N)CSC(=N)N
DMFO6MH IK PRDJGNVQBVXXEO-UHFFFAOYSA-N
DMFO6MH IU 3-cyanopropyl carbamimidothioate
DMFO6MH CA CAS 500863-50-3
DMFO6MH DE Solid tumour/cancer; Ovarian cancer
DMF6CTI ID DMF6CTI
DMF6CTI DN KHK-6188
DMF6CTI HS Phase 2
DMF6CTI CP Kyowa Hakko Kirin Co Ltd
DMF6CTI DE Neuropathic pain
DM40HOY ID DM40HOY
DM40HOY DN KLH-2109
DM40HOY HS Phase 2
DM40HOY CP Kissei Pharmaceutical Co Ltd
DM40HOY PC 16656889
DM40HOY MW 508.4
DM40HOY FM C22H15F3N2O7S
DM40HOY IC InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
DM40HOY CS COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC
DM40HOY IK BMAAMIIYNNPHAB-UHFFFAOYSA-N
DM40HOY IU 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid
DM40HOY CA CAS 935283-04-8
DM40HOY DE Endometriosis
DM05TBE ID DM05TBE
DM05TBE DN KLS-0611
DM05TBE HS Phase 2
DM05TBE SN Mucin stimulator (dry eye), Kissei
DM05TBE CP Kissei Pharmaceutical Co Ltd
DM05TBE DE Xerophthalmia
DMNLH9W ID DMNLH9W
DMNLH9W DN KN026
DMNLH9W HS Phase 2
DMNLH9W CP Alphamab Oncology
DMNLH9W DT Antibody
DMNLH9W DE Breast cancer
DMKLMG6 ID DMKLMG6
DMKLMG6 DN KN035
DMKLMG6 HS Phase 2
DMKLMG6 SN Envafolimab
DMKLMG6 CP TRACON Pharmaceuticals
DMKLMG6 DT Antibody
DMKLMG6 DE Advanced malignancy; Solid tumour/cancer; Pleomorphic sarcoma
DMQZ5HF ID DMQZ5HF
DMQZ5HF DN KNI-272
DMQZ5HF HS Phase 2
DMQZ5HF SN NSC651714; NSC-651714; AC1Q5L2H; (4r)-n-tert-butyl-3-[2-hydroxy-3-({n-[(isoquinolin-5-yloxy)acetyl]-s-methyl-l-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide; AC1L88B1; KNI 272; 3-(3,4-Dimethoxyphenyl)propionamide; NCI60_018063; 4-Thiazolidinecarboxamide,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*,3S*(R*)],4R*]]
DMQZ5HF DT Small molecular drug
DMQZ5HF PC 60927
DMQZ5HF MW 667.8
DMQZ5HF FM C33H41N5O6S2
DMQZ5HF IC InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1
DMQZ5HF CS CC(C)(C)NC(=O)[C@@H]1CSCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O
DMQZ5HF IK NJBBLOIWMSYVCQ-VZTVMPNDSA-N
DMQZ5HF IU (4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
DMQZ5HF CA CAS 147318-81-8
DMQZ5HF CB CHEBI:80006
DMQZ5HF DE Human immunodeficiency virus infection
DMCO8UZ ID DMCO8UZ
DMCO8UZ DN KP-496
DMCO8UZ HS Phase 2
DMCO8UZ DE Asthma
DM4WHOS ID DM4WHOS
DM4WHOS DN KPP203
DM4WHOS HS Phase 2
DM4WHOS CP Novartis PharmaceuticalsEast Hanover, NJ
DM4WHOS DE Subacute cutaneous lupus erythematosus
DMQDLVW ID DMQDLVW
DMQDLVW DN KRP-104
DMQDLVW HS Phase 2
DMQDLVW SN Antigen inhibitor
DMQDLVW CP ActivX Biosciences
DMQDLVW DE Type-2 diabetes
DMOW9X2 ID DMOW9X2
DMOW9X2 DN KRP-203
DMOW9X2 HS Phase 2
DMOW9X2 SN KNF-299; KRP-203-P prodrug, Kyorin
DMOW9X2 CP Kyorin Pharmaceutical Co Ltd
DMOW9X2 DT Small molecular drug
DMOW9X2 PC 11155873
DMOW9X2 MW 480.4
DMOW9X2 FM C24H27Cl2NO3S
DMOW9X2 IC InChI=1S/C24H26ClNO3S.ClH/c25-23-14-22(10-9-19(23)11-12-24(26,16-27)17-28)30-21-8-4-7-20(13-21)29-15-18-5-2-1-3-6-18;/h1-10,13-14,27-28H,11-12,15-17,26H2;1H
DMOW9X2 CS C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl.Cl
DMOW9X2 IK MYIFLDFUXIHOCJ-UHFFFAOYSA-N
DMOW9X2 IU 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride
DMOW9X2 CA CAS 509088-69-1
DMOW9X2 DE Cutaneous lupus erythematosus
DM08F12 ID DM08F12
DM08F12 DN KT6-971
DM08F12 HS Phase 2
DM08F12 SN Cholesterol absorption inhibitor, Kotobuki
DM08F12 CP Kotobuki Pharmaceutical Co Ltd
DM08F12 DE Hypercholesterolaemia
DMZL48U ID DMZL48U
DMZL48U DN KUR-111
DMZL48U HS Phase 2
DMZL48U SN I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter
DMZL48U CP Kuros Biosurgery AG
DMZL48U DE Bone disease
DM2N0Z3 ID DM2N0Z3
DM2N0Z3 DN KUR-211
DM2N0Z3 HS Phase 2
DM2N0Z3 CP Baxter international; kuros biosurgery
DM2N0Z3 DE Ulcer
DMB4HCY ID DMB4HCY
DMB4HCY DN KUR-212
DMB4HCY HS Phase 2
DMB4HCY SN I-020502; Fibrin-PDGF (wound healing), Baxter/Kuros; Fibrin-recombinant human platelet-derived growth factor (wound healing), Baxter/Kuros
DMB4HCY CP Baxter International Inc
DMB4HCY DE Wound healing
DMK4VOU ID DMK4VOU
DMK4VOU DN KVD001
DMK4VOU HS Phase 2
DMK4VOU CP KalVista Pharmaceuticals Cambridge, MA
DMK4VOU DE Diabetic macular edema
DM5N4OA ID DM5N4OA
DM5N4OA DN KVD824
DM5N4OA HS Phase 2
DM5N4OA CP KalVista Pharmaceuticals
DM5N4OA DE Diabetic macular edema
DMJGL72 ID DMJGL72
DMJGL72 DN KW-2478
DMJGL72 HS Phase 2
DMJGL72 SN KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72 CP Kyowa Hakko Kirin
DMJGL72 DT Small molecular drug
DMJGL72 PC 23116322
DMJGL72 MW 574.7
DMJGL72 FM C30H42N2O9
DMJGL72 IC InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3
DMJGL72 CS CCC1=C(C(=C(C=C1O)O)C(=O)C2=CC(=C(C=C2)OCCN3CCOCC3)OC)CC(=O)N(CCOC)CCOC
DMJGL72 IK VFUXSYAXEKYYMB-UHFFFAOYSA-N
DMJGL72 IU 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72 CA CAS 819812-04-9
DMJGL72 DE Solid tumour/cancer
DM15RZO ID DM15RZO
DM15RZO DN KYMRIAH
DM15RZO HS Phase 2
DM15RZO CP Masonic Cancer Center, University of Minnesota
DM15RZO DT CAR T Cell Therapy
DM15RZO DE Acute lymphoblastic leukaemia
DMLHPVW ID DMLHPVW
DMLHPVW DN L1-79
DMLHPVW HS Phase 2
DMLHPVW SN alpha-methylparatyrosine
DMLHPVW CP Yamo Pharmaceuticals
DMLHPVW DE Autism spectrum disorder
DMI2XP1 ID DMI2XP1
DMI2XP1 DN L19-IL-2 fusion protein
DMI2XP1 HS Phase 2
DMI2XP1 SN Darleukin; Immunocytokine fusion protein, Bayer Schering; Immunocytokine fusion protein, Philogen; L19-IL-2 fusion protein, Bayer Schering; L19-IL-2 fusion protein, Philogen
DMI2XP1 CP Philogen SpA
DMI2XP1 DT Antibody
DMI2XP1 DE Lymphoma
DMW6NMP ID DMW6NMP
DMW6NMP DN L19-TNF-alpha
DMW6NMP HS Phase 2
DMW6NMP SN Fibromun
DMW6NMP CP Philogen SpA
DMW6NMP DT Antibody
DMW6NMP DE Colorectal cancer
DMA0DSJ ID DMA0DSJ
DMA0DSJ DN L-694,458
DMA0DSJ HS Phase 2
DMA0DSJ SN DMP 777; 157341-41-8; DMP-777; UNII-3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide; DMP777; CHEMBL310871; L-694458; 3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide (3.5% w/w solution); L-694,458; L 694458; SCHEMBL6538142; AC1L433D; CTK4C9348; DTXSID00166251; MolPort-023-332-820; C31H40N4O6; ZINC3936307; KS-00001E6Q; BCP02269
DMA0DSJ DT Small molecular drug
DMA0DSJ PC 177992
DMA0DSJ MW 564.7
DMA0DSJ FM C31H40N4O6
DMA0DSJ IC InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1
DMA0DSJ CS CCC[C@H](C1=CC2=C(C=C1)OCO2)NC(=O)N3[C@H](C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C
DMA0DSJ IK ZSDCIRYNTCVTMF-GIGWZHCTSA-N
DMA0DSJ IU (2S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-4-oxoazetidine-1-carboxamide
DMA0DSJ CA CAS 157341-41-8
DMA0DSJ DE Cystic fibrosis
DMB7WT1 ID DMB7WT1
DMB7WT1 DN L-697,661
DMB7WT1 HS Phase 2
DMB7WT1 SN L-697661; L-697,661; 135525-78-9; L 697661; 3-(((4,7-Dichloro-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one; CHEMBL268871; UNII-4660N666EZ; 4660N666EZ; 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone, 3-(((4,7-dichloro-2-benzoxazolyl)methyl)amino)-5-ethyl-6-methyl-; ACMC-20mvsm; SCHEMBL599639; BDBM1317; AC1Q69B2; AC1L22E2; CTK0H5173; DTXSID10159457; AKOS030539285; LS-186956; LS-187602; L697,661; L 697,661
DMB7WT1 DT Small molecular drug
DMB7WT1 PC 65002
DMB7WT1 MW 352.2
DMB7WT1 FM C16H15Cl2N3O2
DMB7WT1 IC InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22)
DMB7WT1 CS CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C
DMB7WT1 IK WHFRDXVXYMGAJD-UHFFFAOYSA-N
DMB7WT1 IU 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one
DMB7WT1 CA CAS 135525-78-9
DMB7WT1 DE Human immunodeficiency virus infection
DMTGR25 ID DMTGR25
DMTGR25 DN L-745,870
DMTGR25 HS Phase 2
DMTGR25 SN 158985-00-3; L-745870; UNII-J3OLN3XSX7; J3OLN3XSX7; L-745,870; CHEMBL267014; L 745,870; 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine; CPMPP-3; Tocris-1002; Lopac-L-131; Biomol-NT_000049; AC1NSK75; L745870; Lopac0_000791; GTPL3303; BPBio1_001299; SCHEMBL1059886; CHEBI:92099
DMTGR25 DT Small molecular drug
DMTGR25 PC 5311200
DMTGR25 MW 326.8
DMTGR25 FM C18H19ClN4
DMTGR25 IC InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
DMTGR25 CS C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl
DMTGR25 IK OGJGQVFWEPNYSB-UHFFFAOYSA-N
DMTGR25 IU 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DMTGR25 CA CAS 158985-00-3
DMTGR25 CB CHEBI:92099
DMTGR25 DE Psychotic disorder
DMNO5UE ID DMNO5UE
DMNO5UE DN Labetuzumab I-131
DMNO5UE HS Phase 2
DMNO5UE SN IMMU-111
DMNO5UE CP Immunomedics
DMNO5UE DT Antibody
DMNO5UE DE Colorectal cancer
DM7063I ID DM7063I
DM7063I DN LADIRUBICIN
DM7063I HS Phase 2
DM7063I SN FCE-28729; PNU-159548; Ladirubicin; 3'-(1-Aziridinyl)-3'-deamino-4-demethoxy-4'-O-(methanesulfonyl)daunomycin
DM7063I DT Small molecular drug
DM7063I PC 216232
DM7063I MW 601.6
DM7063I FM C29H31NO11S
DM7063I IC InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1
DM7063I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C
DM7063I IK VMDWTZZCNDEKIO-CBNJBKGYSA-N
DM7063I IU [(2S,3S,4S,6R)-6-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-4-(aziridin-1-yl)-2-methyloxan-3-yl] methanesulfonate
DM7063I CA CAS 171047-47-5
DM7063I DE Breast cancer
DMJSY3Q ID DMJSY3Q
DMJSY3Q DN Ladostigil
DMJSY3Q HS Phase 2
DMJSY3Q SN Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326
DMJSY3Q CP Hebrew University of Jerusalem
DMJSY3Q DT Small molecular drug
DMJSY3Q PC 208907
DMJSY3Q MW 272.34
DMJSY3Q FM C16H20N2O2
DMJSY3Q IC InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1
DMJSY3Q CS CCN(C)C(=O)OC1=CC2=C(CC[C@H]2NCC#C)C=C1
DMJSY3Q IK LHXOCOHMBFOVJS-OAHLLOKOSA-N
DMJSY3Q IU [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
DMJSY3Q CA CAS 209394-27-4
DMJSY3Q DE Alzheimer disease
DMSIGAB ID DMSIGAB
DMSIGAB DN L-alanosine
DMSIGAB HS Phase 2
DMSIGAB SN SDX-102
DMSIGAB CP Salmedix
DMSIGAB DT Small molecular drug
DMSIGAB PC 135409347
DMSIGAB MW 149.11
DMSIGAB FM C3H7N3O4
DMSIGAB IC InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,9H,1,4H2,(H,7,8)/b6-5-/t2-/m0/s1
DMSIGAB CS C([C@@H](C(=O)O)N)/[N+](=N/O)/[O-]
DMSIGAB IK ZGNLFUXWZJGETL-YUSKDDKASA-N
DMSIGAB IU (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium
DMSIGAB CA CAS 5854-93-3
DMSIGAB DE Brain cancer
DMR0N74 ID DMR0N74
DMR0N74 DN LAM-002
DMR0N74 HS Phase 2
DMR0N74 CP LAM Therapeutics Guilford, CT
DMR0N74 DE B-cell non-hodgkin lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia
DM7MBV6 ID DM7MBV6
DM7MBV6 DN Lancovutide
DM7MBV6 HS Phase 2
DM7MBV6 SN Duramycin; Lancovutide; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio
DM7MBV6 CP Lantibio Inc
DM7MBV6 PC 86289378
DM7MBV6 MW 2013.3
DM7MBV6 FM C89H125N23O25S3
DM7MBV6 IC InChI=1S/C89H125N23O25S3/c1-44(2)67-85(131)107-60-42-138-41-59-80(126)106-61-43-140-46(4)69(87(133)103-56(76(122)108-67)35-49-23-12-7-13-24-49)109-77(123)55(34-48-21-10-6-11-22-48)102-83(129)62-27-18-32-112(62)66(116)39-96-73(119)54(33-47-19-8-5-9-20-47)101-79(125)58(104-81(61)127)37-94-31-17-15-26-53(88(134)135)100-86(132)68(110-78(124)57(36-64(93)114)97-65(115)38-95-84(130)70(111-82(60)128)71(117)89(136)137)45(3)139-40-50(91)72(118)98-51(25-14-16-30-90)74(120)99-52(75(121)105-59)28-29-63(92)113/h5-13,19-24,44-46,50-62,67-71,94,117H,14-18,25-43,90-91H2,1-4H3,(H2,92,113)(H2,93,114)(H,95,130)(H,96,119)(H,97,115)(H,98,118)(H,99,120)(H,100,132)(H,101,125)(H,102,129)(H,103,133)(H,104,127)(H,105,121)(H,106,126)(H,107,131)(H,108,122)(H,109,123)(H,110,124)(H,111,128)(H,134,135)(H,136,137)/t45?,46-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61-,62-,67-,68+,69+,70-,71+/m0/s1
DM7MBV6 CS C[C@H]1[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSC[C@@H]4C(=O)N[C@@H](CS1)C(=O)N[C@@H](CNCCCC[C@H](NC(=O)[C@@H](C(SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CCCCN)N)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC3=O)[C@H](C(=O)O)O)CC(=O)N)C(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N2)CC6=CC=CC=C6)CC7=CC=CC=C7)C(C)C)CC8=CC=CC=C8
DM7MBV6 IK SFWLDKQAUHFCBS-WWXQEMPQSA-N
DM7MBV6 IU (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-37-(2-amino-2-oxoethyl)-50-(3-amino-3-oxopropyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-41,70-dimethyl-2,5,8,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-octadecaoxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptacontane-65-carboxylic acid
DM7MBV6 DE Chronic obstructive pulmonary disease
DM1VK96 ID DM1VK96
DM1VK96 DN LANEPITANT
DM1VK96 HS Phase 2
DM1VK96 SN LY-303870; LY-302654 (racemate); Lanepitant; N-[1(R)-(1H-Indol-3-ylmethyl)-2-[N-(2-methoxybenzyl)acetamido]ethyl]-2-[4-(1-piperidinyl)piperidin-1-yl]acetamide
DM1VK96 DT Small molecular drug
DM1VK96 PC 3086681
DM1VK96 MW 559.7
DM1VK96 FM C33H45N5O3
DM1VK96 IC InChI=1S/C33H45N5O3/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40)/t28-/m1/s1
DM1VK96 CS CC(=O)N(CC1=CC=CC=C1OC)C[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CN4CCC(CC4)N5CCCCC5
DM1VK96 IK CVXJAPZTZWLRBP-MUUNZHRXSA-N
DM1VK96 IU N-[(2R)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1H-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide
DM1VK96 CA CAS 170566-84-4
DM1VK96 DE Pain
DMPRZX4 ID DMPRZX4
DMPRZX4 DN LAS 100977
DMPRZX4 HS Phase 2
DMPRZX4 SN LABA
DMPRZX4 CP Almirall; Forest Laboratories
DMPRZX4 DT Small molecular drug
DMPRZX4 PC 11962616
DMPRZX4 MW 460.5
DMPRZX4 FM C25H30F2N2O4
DMPRZX4 IC InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
DMPRZX4 CS C1=CC=C(C=C1)C(COCCCCCCNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)(F)F
DMPRZX4 IK SFYAXIFVXBKRPK-QFIPXVFZSA-N
DMPRZX4 IU 5-[(1R)-2-[6-(2,2-difluoro-2-phenylethoxy)hexylamino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMPRZX4 CA CAS 915133-65-2
DMPRZX4 CB CHEBI:142077
DMPRZX4 DE Chronic obstructive pulmonary disease
DM3WY0B ID DM3WY0B
DM3WY0B DN LAS-41002
DM3WY0B HS Phase 2
DM3WY0B SN Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall
DM3WY0B CP Almirall Prodesfarma SA
DM3WY0B DE Eczema
DMC04SR ID DMC04SR
DMC04SR DN LB-100
DMC04SR HS Phase 2
DMC04SR DT Small molecular drug
DMC04SR PC 3578572
DMC04SR MW 268.31
DMC04SR FM C13H20N2O4
DMC04SR IC InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)
DMC04SR CS CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3
DMC04SR IK JUQMLSGOTNKJKI-UHFFFAOYSA-N
DMC04SR IU 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
DMC04SR DE Solid tumour/cancer; Astrocytoma
DM0OHX3 ID DM0OHX3
DM0OHX3 DN LB-30870
DM0OHX3 HS Phase 2
DM0OHX3 SN N-(Carboxymethyl)-D-diphenylalanyl-L-proline 5-amidinothien-2-ylmethyl amide bis(trifluoroacetate)
DM0OHX3 PC 9871765
DM0OHX3 MW 533.6
DM0OHX3 FM C28H31N5O4S
DM0OHX3 IC InChI=1S/C28H31N5O4S/c29-26(30)22-14-13-20(38-22)16-32-27(36)21-12-7-15-33(21)28(37)25(31-17-23(34)35)24(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-6,8-11,13-14,21,24-25,31H,7,12,15-17H2,(H3,29,30)(H,32,36)(H,34,35)/t21-,25+/m0/s1
DM0OHX3 CS C1C[C@H](N(C1)C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NCC(=O)O)C(=O)NCC4=CC=C(S4)C(=N)N
DM0OHX3 IK BIHPYGVYKSQDLA-SQJMNOBHSA-N
DM0OHX3 IU 2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid
DM0OHX3 CA CAS 280780-95-2
DM0OHX3 DE Myocardial infarction
DMQZJNA ID DMQZJNA
DMQZJNA DN LCAR-B38M CAR-T Cell
DMQZJNA HS Phase 2
DMQZJNA CP Nanjing Legend Biotech Co.
DMQZJNA DT CAR T Cell Therapy
DMQZJNA DE Multiple myeloma
DMY4IWC ID DMY4IWC
DMY4IWC DN LCB-2183
DMY4IWC HS Phase 2
DMY4IWC PC 135418284
DMY4IWC MW 206.2
DMY4IWC FM C9H10N4O2
DMY4IWC IC InChI=1S/C9H10N4O2/c1-2-15-5-6-12-8-7(9(14)13-6)10-3-4-11-8/h3-4H,2,5H2,1H3,(H,11,12,13,14)
DMY4IWC CS CCOCC1=NC2=NC=CN=C2C(=O)N1
DMY4IWC IK SFWVULIFVPNTOF-UHFFFAOYSA-N
DMY4IWC IU 2-(ethoxymethyl)-3H-pteridin-4-one
DMY4IWC CA CAS 133914-85-9
DMY4IWC DE Asthma
DMTM4QA ID DMTM4QA
DMTM4QA DN LCL161
DMTM4QA HS Phase 2
DMTM4QA CP Novartis
DMTM4QA PC 24737642
DMTM4QA MW 500.6
DMTM4QA FM C26H33FN4O3S
DMTM4QA IC InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1
DMTM4QA CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC
DMTM4QA IK UFPFGVNKHCLJJO-SSKFGXFMSA-N
DMTM4QA IU (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide
DMTM4QA CA CAS 1005342-46-0
DMTM4QA DE Solid tumour/cancer; Breast cancer; Multiple myeloma; Myelofibrosis
DMM9F25 ID DMM9F25
DMM9F25 DN LDE225
DMM9F25 HS Phase 2
DMM9F25 SN Erismodegib
DMM9F25 CP Novartis Pharmaceuticals
DMM9F25 DT Small molecular drug
DMM9F25 PC 24775005
DMM9F25 MW 485.5
DMM9F25 FM C26H26F3N3O3
DMM9F25 IC InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
DMM9F25 CS C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F
DMM9F25 IK VZZJRYRQSPEMTK-CALCHBBNSA-N
DMM9F25 IU N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide
DMM9F25 CA CAS 956697-53-3
DMM9F25 CB CHEBI:90863
DMM9F25 DE Skin cancer; Medulloblastoma
DMIEZUB ID DMIEZUB
DMIEZUB DN L-DOS47
DMIEZUB HS Phase 2
DMIEZUB CP Helix BioPharma
DMIEZUB DE Lung cancer; Non-small-cell lung cancer; Non-small cell lung cancer
DMS6E9J ID DMS6E9J
DMS6E9J DN Lefitolimod
DMS6E9J HS Phase 2
DMS6E9J SN MGN1703
DMS6E9J CP Mologen
DMS6E9J DE Human immunodeficiency virus-1 infection
DMV2YDK ID DMV2YDK
DMV2YDK DN LEISH-F1
DMV2YDK HS Phase 2
DMV2YDK SN LeIF adjuvant, Corixa; Leish-111f; Leishmanial eukaryotic initiation factor, Corixa; Leishmaniasis vaccine (LeIF), Corixa; Leishmaniasis vaccine, Corixa/ Infectious Disease Research Institute; Vaccine (leishmania), Corixa; LeIF enhanced T-cell vaccine, Corixa, Infectious Disease Research Institute
DMV2YDK CP Infectious Disease Research Institute
DMV2YDK DT Vaccine
DMV2YDK DE Leishmania infection
DMZKBMG ID DMZKBMG
DMZKBMG DN Lenapenem hydrochloride hydrate
DMZKBMG HS Phase 2
DMZKBMG SN BO-2727; L-739428
DMZKBMG CP MSD Japan
DMZKBMG DT Small molecular drug
DMZKBMG PC 443100
DMZKBMG MW 454
DMZKBMG FM C18H32ClN3O6S
DMZKBMG IC InChI=1S/C18H29N3O5S.ClH.H2O/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3;;/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26);1H;1H2/t8-,9-,10+,11+,12-,13-,14-;;/m1../s1
DMZKBMG CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O.O.Cl
DMZKBMG IK FNSICOGCVDQJPU-HCRFUVGVSA-N
DMZKBMG IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate;hydrochloride
DMZKBMG CA CAS 149882-71-3
DMZKBMG DE Bacterial infection
DMWAD93 ID DMWAD93
DMWAD93 DN Leniolisib
DMWAD93 HS Phase 2
DMWAD93 SN 1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib; CDZ173; Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
DMWAD93 CP Novartis
DMWAD93 DT Small molecular drug
DMWAD93 PC 57495353
DMWAD93 MW 450.5
DMWAD93 FM C21H25F3N6O2
DMWAD93 IC InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1
DMWAD93 CS CCC(=O)N1CC[C@@H](C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F
DMWAD93 IK MWKYMZXCGYXLPL-ZDUSSCGKSA-N
DMWAD93 IU 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
DMWAD93 CA CAS 1354690-24-6
DMWAD93 DE Sjogren syndrome
DMR1MQW ID DMR1MQW
DMR1MQW DN Lenzilumab
DMR1MQW HS Phase 2
DMR1MQW CP Humanigen Brisbane, CA
DMR1MQW DE Chronic myelogenous leukaemia; Coronavirus Disease 2019 (COVID-19)
DM7W0JE ID DM7W0JE
DM7W0JE DN LEO 124249
DM7W0JE HS Phase 2
DM7W0JE SN delgocitinib; Delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile
DM7W0JE CP LEO Pharma Madison, NJ
DM7W0JE PC 50914062
DM7W0JE MW 310.35
DM7W0JE FM C16H18N6O
DM7W0JE IC InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
DM7W0JE CS C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
DM7W0JE IK LOWWYYZBZNSPDT-ZBEGNZNMSA-N
DM7W0JE IU 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
DM7W0JE CA CAS 1263774-59-9
DM7W0JE DE Asthma; Eczema
DMZ6Y0T ID DMZ6Y0T
DMZ6Y0T DN LEO-32731
DMZ6Y0T HS Phase 2
DMZ6Y0T SN LP0058
DMZ6Y0T CP LEO Pharma A/S
DMZ6Y0T PC 54765967
DMZ6Y0T MW 510.3
DMZ6Y0T FM C19H15Cl2F2NO7S
DMZ6Y0T IC InChI=1S/C19H15Cl2F2NO7S/c20-12-8-24(26)9-13(21)11(12)7-14(25)10-1-2-15(29-18(22)23)17-16(10)30-19(31-17)3-5-32(27,28)6-4-19/h1-2,8-9,18H,3-7H2
DMZ6Y0T CS C1CS(=O)(=O)CCC12OC3=C(C=CC(=C3O2)OC(F)F)C(=O)CC4=C(C=[N+](C=C4Cl)[O-])Cl
DMZ6Y0T IK ZININGNRPUGNSL-UHFFFAOYSA-N
DMZ6Y0T IU 2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-[7-(difluoromethoxy)-1',1'-dioxospiro[1,3-benzodioxole-2,4'-thiane]-4-yl]ethanone
DMZ6Y0T CA CAS 1353546-86-7
DMZ6Y0T DE Psoriasis vulgaris; Plaque psoriasis
DM6DL5K ID DM6DL5K
DM6DL5K DN Leridistim
DM6DL5K HS Phase 2
DM6DL5K SN MPO, Searle; MPO-1; SC-70935; Myelopoietin (1), Searle
DM6DL5K CP GD Searle & Co
DM6DL5K DE Immune System disease
DMMQ6VT ID DMMQ6VT
DMMQ6VT DN Leronlimab
DMMQ6VT HS Phase 2
DMMQ6VT SN PRO 140
DMMQ6VT TC Antiviral Agents
DMMQ6VT DT Monoclonal antibody
DMMQ6VT DE Coronavirus Disease 2019 (COVID-19)
DMSEVBH ID DMSEVBH
DMSEVBH DN Lersivirine
DMSEVBH HS Phase 2
DMSEVBH SN cc-718; Lersivirine (UK-453061)
DMSEVBH CP ViiV Healthcare
DMSEVBH DT Small molecular drug
DMSEVBH PC 16739244
DMSEVBH MW 310.35
DMSEVBH FM C17H18N4O2
DMSEVBH IC InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3
DMSEVBH CS CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N
DMSEVBH IK MCPUZZJBAHRIPO-UHFFFAOYSA-N
DMSEVBH IU 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile
DMSEVBH CA CAS 473921-12-9
DMSEVBH DE Human immunodeficiency virus infection
DMW50NF ID DMW50NF
DMW50NF DN LE-SN38
DMW50NF HS Phase 2
DMW50NF SN 7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; 7-Ethyl-10-hydroxy-camptothecin; SN 38; 10-Hydroxy-7-ethylcamptothecin; 7-Ethyl-10-hydroxycamptothecine; SN38; 7-Ethyl-10-hydroxy-20(S)-camptothecin; UNII-0H43101T0J; Captothecin, 7-ethyl-10-hydroxy-; CHEBI:8988; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-Ethyl-10-hydroxy camptothecin; NSC673596; 0H43101T0J; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; 113015-38-6
DMW50NF CP NeoPharm
DMW50NF DT Small molecular drug
DMW50NF PC 104842
DMW50NF MW 392.4
DMW50NF FM C22H20N2O5
DMW50NF IC InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
DMW50NF CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O
DMW50NF IK FJHBVJOVLFPMQE-QFIPXVFZSA-N
DMW50NF IU (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMW50NF CA CAS 86639-52-3
DMW50NF CB CHEBI:8988
DMW50NF DE Solid tumour/cancer; Colorectal cancer
DMIFGLY ID DMIFGLY
DMIFGLY DN Leukemia cancer vaccine
DMIFGLY HS Phase 2
DMIFGLY CP BioSante Pharmaceuticals
DMIFGLY DT Vaccine
DMIFGLY DE Acute myeloid leukaemia
DM5LQEI ID DM5LQEI
DM5LQEI DN Leuvectin
DM5LQEI HS Phase 2
DM5LQEI SN IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical
DM5LQEI CP Vical Inc
DM5LQEI DE Melanoma
DMOS5JZ ID DMOS5JZ
DMOS5JZ DN Lexatumumab
DMOS5JZ HS Phase 2
DMOS5JZ SN HGS-ETR2; TRAIL receptor-2 monoclonal antibodies (cancer), HGS/CAT; TRAIL-R2 mAbs (cancer), Human Genome Sciences/Cambridge Antibody Technology; TNF-related apoptosis-inducing ligand receptor-2 mAbs (cancer), HGS/CAT
DMOS5JZ CP Cambridge Antibody Technology Group plc
DMOS5JZ DT Antibody
DMOS5JZ DE Solid tumour/cancer
DMLEX1D ID DMLEX1D
DMLEX1D DN Lexibulin
DMLEX1D HS Phase 2
DMLEX1D SN Lexibulin; CYT-997; Microtubule inhibitor (oral, solid tumors) Cytopia; VDA anticancer program (iv), Cytopia; Lexibulin (iv infusion, cancer), YM BioSciences; Lexibulin (oral capsule, cancer), YM Biosciences; CYT-997 (iv infusion, cancer), Cytopia; CYT-997 (iv infusion, cancer), YM BioSciences; CYT-997 (oral capsule, cancer), Cytopia; CYT-997 (oral capsule, cancer), YM Biosciences; Vascular disrupting agent/ tubulin inhibitor (iv, cancer), Cytopia; Vascular disrupting agent/tubulin inhibitor (oral, cancer), Cytopia; Vascular targeting agent/ tubulin inhibitor (iv, cancer), Cytopia
DMLEX1D CP Cytopia Ltd; Cytopia
DMLEX1D DE Glioblastoma multiforme
DMZ2YBE ID DMZ2YBE
DMZ2YBE DN Lexipafant
DMZ2YBE HS Phase 2
DMZ2YBE SN LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
DMZ2YBE DT Small molecular drug
DMZ2YBE PC 9804204
DMZ2YBE MW 458.6
DMZ2YBE FM C23H30N4O4S
DMZ2YBE IC InChI=1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1
DMZ2YBE CS CCOC(=O)[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
DMZ2YBE IK AQRXDPFOYJSPMP-QFIPXVFZSA-N
DMZ2YBE IU ethyl (2S)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
DMZ2YBE CA CAS 139133-26-9
DMZ2YBE DE Hepatovirus infection; Nerve injury
DMCT1RQ ID DMCT1RQ
DMCT1RQ DN LFG-316
DMCT1RQ HS Phase 2
DMCT1RQ CP Novartis AG
DMCT1RQ DT Antibody
DMCT1RQ DE Macular degeneration
DM9T8A2 ID DM9T8A2
DM9T8A2 DN LGD-4665
DM9T8A2 HS Phase 2
DM9T8A2 CP Ligand
DM9T8A2 DE Immune thrombocytopenic purpura
DMPL9KG ID DMPL9KG
DMPL9KG DN LGD-6972
DMPL9KG HS Phase 2
DMPL9KG SN MB-11262
DMPL9KG CP Ligand pharmaceuticals
DMPL9KG PC 44625560
DMPL9KG MW 702.9
DMPL9KG FM C43H46N2O5S
DMPL9KG IC InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)/t39-/m1/s1
DMPL9KG CS CC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C
DMPL9KG IK HKJMCBYPVCGZFB-LDLOPFEMSA-N
DMPL9KG IU 2-[[4-[(2R)-2-[4-(4-tert-butylphenyl)phenyl]-3-oxo-3-[4-(2,4,6-trimethylphenyl)anilino]propyl]benzoyl]amino]ethanesulfonic acid
DMPL9KG CA CAS 1207989-09-0
DMPL9KG DE Type-2 diabetes; Non-insulin dependent diabetes
DMA0RI9 ID DMA0RI9
DMA0RI9 DN LIDORESTAT
DMA0RI9 HS Phase 2
DMA0RI9 SN Lidorestat; 245116-90-9; IDD-676; UNII-R3734K0M7L; IDD-000676-01; {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID; CHEMBL363387; R3734K0M7L; 1H-Indole-1-aceticacid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 3-[(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL]INDOLE-N-ACETIC ACID; 3NA; Lidorestat [USAN:INN]; 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 1H-Indole-1-acetic acid, 3-((4,5,7-trifluor
DMA0RI9 DT Small molecular drug
DMA0RI9 PC 157839
DMA0RI9 MW 376.4
DMA0RI9 FM C18H11F3N2O2S
DMA0RI9 IC InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25)
DMA0RI9 CS C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F
DMA0RI9 IK KYHVTMFADJNSGS-UHFFFAOYSA-N
DMA0RI9 IU 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid
DMA0RI9 CA CAS 245116-90-9
DMA0RI9 DE Diabetic complication
DM32NWD ID DM32NWD
DM32NWD DN LIK-066
DM32NWD HS Phase 2
DM32NWD CP Novartis AG
DM32NWD PC 52913524
DM32NWD MW 416.5
DM32NWD FM C23H28O7
DM32NWD IC InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
DM32NWD CS CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4
DM32NWD IK XFJAMQQAAMJFGB-ZQGJOIPISA-N
DM32NWD IU (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM32NWD CA CAS 1291094-73-9
DM32NWD DE Type-2 diabetes; Heart failure
DM9ZHRS ID DM9ZHRS
DM9ZHRS DN LIM-0705
DM9ZHRS HS Phase 2
DM9ZHRS CP Limerick Biopharma
DM9ZHRS PC 20833257
DM9ZHRS MW 382.21
DM9ZHRS FM C15H11O10P
DM9ZHRS IC InChI=1S/C15H11O10P/c16-7-4-9(18)12-11(5-7)24-15(14(20)13(12)19)6-1-2-8(17)10(3-6)25-26(21,22)23/h1-5,16-18,20H,(H2,21,22,23)
DM9ZHRS CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)OP(=O)(O)O)O
DM9ZHRS IK UWJBYNLLMAPJMM-UHFFFAOYSA-N
DM9ZHRS IU [2-hydroxy-5-(3,5,7-trihydroxy-4-oxochromen-2-yl)phenyl] dihydrogen phosphate
DM9ZHRS CA CAS 1111616-69-3
DM9ZHRS DE Insulin-resistant disorder
DMSHGWN ID DMSHGWN
DMSHGWN DN Lintopride
DMSHGWN HS Phase 2
DMSHGWN SN SL-920075
DMSHGWN CP Synthelabo
DMSHGWN DT Small molecular drug
DMSHGWN PC 65900
DMSHGWN MW 310.78
DMSHGWN FM C14H19ClN4O2
DMSHGWN IC InChI=1S/C14H19ClN4O2/c1-3-19-5-4-17-13(19)8-18-14(20)9-6-10(15)11(16)7-12(9)21-2/h6-7H,3-5,8,16H2,1-2H3,(H,18,20)
DMSHGWN CS CCN1CCN=C1CNC(=O)C2=CC(=C(C=C2OC)N)Cl
DMSHGWN IK MJCKISCWHDATBN-UHFFFAOYSA-N
DMSHGWN IU 4-amino-5-chloro-N-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide
DMSHGWN CA CAS 107429-63-0
DMSHGWN DE Nausea
DMWY0V1 ID DMWY0V1
DMWY0V1 DN LIPO-5
DMWY0V1 HS Phase 2
DMWY0V1 SN HIV vaccine (lipoprotein), ANRS/Aventis Pasteur
DMWY0V1 CP Sanofi Pasteur
DMWY0V1 DT Vaccine
DMWY0V1 DE Human immunodeficiency virus infection
DMNGT89 ID DMNGT89
DMNGT89 DN Lirilumab
DMNGT89 HS Phase 2
DMNGT89 CP Bristol-Myers Squibb
DMNGT89 DT Monoclonal antibody
DMNGT89 DE Acute myeloid leukaemia; Solid tumour/cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome
DMD4KAU ID DMD4KAU
DMD4KAU DN LIRIMILAST
DMD4KAU HS Phase 2
DMD4KAU SN Lirimilast; Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester
DMD4KAU DT Small molecular drug
DMD4KAU PC 6433118
DMD4KAU MW 443.3
DMD4KAU FM C17H12Cl2N2O6S
DMD4KAU IC InChI=1S/C17H12Cl2N2O6S/c1-28(24,25)27-9-3-5-11-13(7-9)26-16(14(11)21-17(20)23)15(22)10-4-2-8(18)6-12(10)19/h2-7H,1H3,(H3,20,21,23)
DMD4KAU CS CS(=O)(=O)OC1=CC2=C(C=C1)C(=C(O2)C(=O)C3=C(C=C(C=C3)Cl)Cl)NC(=O)N
DMD4KAU IK YPFLFUJKZDAXRA-UHFFFAOYSA-N
DMD4KAU IU [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate
DMD4KAU CA CAS 329306-27-6
DMD4KAU DE Chronic obstructive pulmonary disease
DMVU9X1 ID DMVU9X1
DMVU9X1 DN Lisofylline
DMVU9X1 HS Phase 2
DMVU9X1 SN LISOFYLLINE; (R)-Lisofylline; 100324-81-0; CT-1501R; ProTec; Lisophylline; NSMXQKNUPPXBRG-SECBINFHSA-N; (R)-Lisophylline; 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; UNII-L1F2Q2X956; 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione; L1F2Q2X956; ProTec (TN); AC1L9UOZ; Lisofylline (USAN/INN); CHEMBL1411; SCHEMBL39131; GTPL9225; DTXSID7058709; CTK8E6838; CT1501R; MolPort-005-943-169; ZINC1887263; LSF; 1836AH; AKOS025394050; SB18959; DB12406; NCGC00186630-01; FT-0670822
DMVU9X1 CP DiaKine Therapeutics
DMVU9X1 DT Small molecular drug
DMVU9X1 PC 501254
DMVU9X1 MW 280.32
DMVU9X1 FM C13H20N4O3
DMVU9X1 IC InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
DMVU9X1 CS C[C@H](CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMVU9X1 IK NSMXQKNUPPXBRG-SECBINFHSA-N
DMVU9X1 IU 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
DMVU9X1 CA CAS 100324-81-0
DMVU9X1 CB CHEBI:143527
DMVU9X1 DE Type-1 diabetes
DMZ3OU6 ID DMZ3OU6
DMZ3OU6 DN Lithium
DMZ3OU6 HS Phase 2
DMZ3OU6 SN 7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
DMZ3OU6 DT Small molecular drug
DMZ3OU6 PC 3028194
DMZ3OU6 MW 7
DMZ3OU6 FM Li
DMZ3OU6 IC InChI=1S/Li
DMZ3OU6 CS [Li]
DMZ3OU6 IK WHXSMMKQMYFTQS-UHFFFAOYSA-N
DMZ3OU6 IU lithium
DMZ3OU6 CA CAS 7439-93-2
DMZ3OU6 CB CHEBI:30145
DMZ3OU6 DE Fragile X syndrome
DM3XRUH ID DM3XRUH
DM3XRUH DN LJN452
DM3XRUH HS Phase 2
DM3XRUH SN Tropifexor; 1383816-29-2; UNII-NMZ08KM76Z; NMZ08KM76Z; CPD1549; Tropifexor [INN]; GTPL9725; SCHEMBL19178329; SCHEMBL17848159; LJN-452; EX-A1934; CS-8153; compound 1 [PMID: 29148806]; ACN-053193; AC-30341; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; HY-107418; 2-((1R,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorob
DM3XRUH CP Novartis Pharmaceuticals East Hanover, NJ
DM3XRUH PC 121418176
DM3XRUH MW 603.6
DM3XRUH FM C29H25F4N3O5S
DM3XRUH IC InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18?
DM3XRUH CS C1C[C@H]2CC(C[C@@H]1N2C3=NC4=C(C=C(C=C4S3)C(=O)O)F)OCC5=C(ON=C5C6=CC=CC=C6OC(F)(F)F)C7CC7
DM3XRUH IK VYLOOGHLKSNNEK-JWTNVVGKSA-N
DM3XRUH IU 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
DM3XRUH CA CAS 1383816-29-2
DM3XRUH DE Primary biliary cholangitis
DMVM13R ID DMVM13R
DMVM13R DN LJPC-401
DMVM13R HS Phase 2
DMVM13R CP La Jolla Pharmaceutical
DMVM13R DT Peptide
DMVM13R DE Hemochromatosis; Beta thalassemia
DMCFGP3 ID DMCFGP3
DMCFGP3 DN LKA651
DMCFGP3 HS Phase 2
DMCFGP3 SN 9-Nov
DMCFGP3 CP Novartis
DMCFGP3 DT Antibody
DMCFGP3 DE Diabetic macular edema
DMSJOE3 ID DMSJOE3
DMSJOE3 DN LM-030
DMSJOE3 HS Phase 2
DMSJOE3 CP LifeMax Laboratories Palo Alto, CA
DMSJOE3 DE Congenital ichthyosiform erythroderma
DMW6VA0 ID DMW6VA0
DMW6VA0 DN LM-1507.NA
DMW6VA0 HS Phase 2
DMW6VA0 SN MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt
DMW6VA0 DE Asthma
DMG7RAV ID DMG7RAV
DMG7RAV DN LMB-2
DMG7RAV HS Phase 2
DMG7RAV SN LMB-2a; AntiTac(Fv)-PE38; Immunotoxin (cancer), National Cancer Institute
DMG7RAV CP National Cancer Institute
DMG7RAV DE Chronic lymphocytic leukaemia
DMQOXNL ID DMQOXNL
DMQOXNL DN LMB763
DMQOXNL HS Phase 2
DMQOXNL SN Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-
DMQOXNL CP Novartis
DMQOXNL DT Small molecular drug
DMQOXNL PC 118063735
DMQOXNL MW 487.9
DMQOXNL FM C27H22ClN3O4
DMQOXNL IC InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
DMQOXNL CS CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
DMQOXNL IK JYTIXGYXBIBOMN-UHFFFAOYSA-N
DMQOXNL IU 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid
DMQOXNL CA CAS 1773489-72-7
DMQOXNL DE Non-alcoholic steatohepatitis; Diabetic nephropathy
DM01SR6 ID DM01SR6
DM01SR6 DN L-NAME
DM01SR6 HS Phase 2
DM01SR6 SN N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate
DM01SR6 CP Registry Operator
DM01SR6 DT Small molecular drug
DM01SR6 PC 39836
DM01SR6 MW 233.23
DM01SR6 FM C7H15N5O4
DM01SR6 IC InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1
DM01SR6 CS COC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N
DM01SR6 IK KCWZGJVSDFYRIX-YFKPBYRVSA-N
DM01SR6 IU methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate
DM01SR6 CA CAS 50903-99-6
DM01SR6 CB CHEBI:7549
DM01SR6 DE Hypertension
DMT3KB4 ID DMT3KB4
DMT3KB4 DN Lobeline
DMT3KB4 HS Phase 2
DMT3KB4 SN lobeline; Lobelin; Inflatine; Lobeline [INN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; EINECS 202-012-3; BRN 0091533; AC1LEL62; ZINC56446; Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; LS-88107
DMT3KB4 DT Small molecular drug
DMT3KB4 PC 101616
DMT3KB4 MW 337.5
DMT3KB4 FM C22H27NO2
DMT3KB4 IC InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1
DMT3KB4 CS CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMT3KB4 IK MXYUKLILVYORSK-HBMCJLEFSA-N
DMT3KB4 IU 2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone
DMT3KB4 CA CAS 90-69-7
DMT3KB4 CB CHEBI:48723
DMT3KB4 DE Substance use disorder
DMN0VS2 ID DMN0VS2
DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2 HS Phase 2
DMN0VS2 SN Aluviran + norvir + rebetol + betaseron
DMN0VS2 TC Antiviral Agents
DMN0VS2 DT Combination drug
DMN0VS2 DE Coronavirus Disease 2019 (COVID-19)
DM0GZTD ID DM0GZTD
DM0GZTD DN L-ornithine phenylacetate
DM0GZTD HS Phase 2
DM0GZTD SN L-ornthine phenylacetate; OCR-002; UCL-L1V; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy); Nitrogen metabolism modulator (injectable, AHE), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), UCL; Nitrogen metabolism modulator (injectable, hyperammonemia), Ocera; L-ornithine phenylacetate (injectable, AHE), Ocera; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy), Ocera; L-ornithine phenylacetate (injectable, hyperammonemia), Ocera
DM0GZTD CP Ocera therapeutics
DM0GZTD DT Small molecular drug
DM0GZTD PC 44247677
DM0GZTD MW 268.31
DM0GZTD FM C13H20N2O4
DM0GZTD IC InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1
DM0GZTD CS C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN
DM0GZTD IK LRSYFEZBIMVWRY-VWMHFEHESA-N
DM0GZTD IU (2S)-2,5-diaminopentanoic acid;2-phenylacetic acid
DM0GZTD CA CAS 952154-79-9
DM0GZTD DE Acute liver failure
DME8O5K ID DME8O5K
DME8O5K DN LOU064
DME8O5K HS Phase 2
DME8O5K CP Novartis Pharmaceuticals East Hanover, NJ
DME8O5K DE Chronic idiopathic urticaria
DMIV9ZE ID DMIV9ZE
DMIV9ZE DN LOXORIBINE
DMIV9ZE HS Phase 2
DMIV9ZE SN AOG; Loxoribine < Rec INN; RWJ-21757; 7-(2-Propenyl)-8-oxo-7,8-dihydroguanosine; 7-Allyl-2-amino-9-beta-D-ribofuranosylpurine-6,8(1H,9H)-dione; 7-Allyl-8-oxo-7,8-dihydroguanosine; 7A8OGua
DMIV9ZE DT Small molecular drug
DMIV9ZE PC 135410906
DMIV9ZE MW 339.3
DMIV9ZE FM C13H17N5O6
DMIV9ZE IC InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s1
DMIV9ZE CS C=CCN1C2=C(N=C(NC2=O)N)N(C1=O)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMIV9ZE IK VDCRFBBZFHHYGT-IOSLPCCCSA-N
DMIV9ZE IU 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-1H-purine-6,8-dione
DMIV9ZE CA CAS 121288-39-9
DMIV9ZE DE Immune System disease
DM7BN5W ID DM7BN5W
DM7BN5W DN LPN023
DM7BN5W HS Phase 2
DM7BN5W CP Novartis
DM7BN5W DT Small molecular drug
DM7BN5W DE IgA nephropathy
DMZQBCL ID DMZQBCL
DMZQBCL DN LR3001
DMZQBCL HS Phase 2
DMZQBCL CP Genta
DMZQBCL TC Anticancer Agents
DMZQBCL DT Antisense drug
DMZQBCL DE Myeloid leukaemia
DM0TZPL ID DM0TZPL
DM0TZPL DN LS-71719
DM0TZPL HS Phase 2
DM0TZPL SN Galactooligosaccharide; LS-71719; NOCAS_276547; 4'-Galactooligosaccharide; D-Glucose, O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-; DTXSID60276547; SCHEMBL12362685
DM0TZPL PC 165512
DM0TZPL MW 504.4
DM0TZPL FM C18H32O16
DM0TZPL IC RXVWSYJTUUKTEA-DSOVBJLESA-N
DM0TZPL CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC(C(CO)O)C(C(C=O)O)O)CO)O)O)O)O
DM0TZPL IK 1S/C18H32O16/c19-1-5(23)9(25)15(6(24)2-20)33-18-14(30)12(28)16(8(4-22)32-18)34-17-13(29)11(27)10(26)7(3-21)31-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10-,11-,12+,13+,14+,15+,16-,17-,18-/m0/s1
DM0TZPL IU (2R,3R,4R,5R)-4-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal
DM0TZPL CA CAS 6587-31-1
DM0TZPL DE Anxiety disorder
DME26RS ID DME26RS
DME26RS DN LTB4
DME26RS HS Phase 2
DME26RS SN Leukotriene B4; LEUKOTRIENE B4; 5,12-Dihete; 71160-24-2; 5,12-Hete; UNII-1HGW4DR56D; (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; 1HGW4DR56D; CHEMBL65061; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; CHEBI:15647; VNYSSYRCGWBHLG-AMOLWHMGSA-N; [5S,12R]-Dihydroxy-[6Z,8E,10E,14Z]-eicosatetraenoic acid; Leukotriene B; 5(S),12(R)-Dihydroxy-6-cis-8-trans-10-trans-14-cis-eicosatetraenoic Acid; (S-(R*,S*-(E,Z,E,Z)))-5,12-Dihydroxy-6,8,10,14-eicosatetraenoic acid; 6,8,10,14-Eicosatetraenoic acid,; Leukotriene B4 agonist (HIV infection), LTB4 Sweden AB; LEUKOTRIENE_B4
DME26RS CP LTB4 Sweden AB
DME26RS DT Small molecular drug
DME26RS PC 5280492
DME26RS MW 336.5
DME26RS FM C20H32O4
DME26RS IC InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1
DME26RS CS CCCCC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
DME26RS IK VNYSSYRCGWBHLG-AMOLWHMGSA-N
DME26RS IU (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DME26RS CA CAS 71160-24-2
DME26RS CB CHEBI:15647
DME26RS DE Human immunodeficiency virus infection
DMXEQ0R ID DMXEQ0R
DMXEQ0R DN LTX-109
DMXEQ0R HS Phase 2
DMXEQ0R SN Lytixar
DMXEQ0R CP Lytix Biopharma AS
DMXEQ0R DT Small molecular drug
DMXEQ0R PC 25242323
DMXEQ0R MW 788.1
DMXEQ0R FM C43H69N11O3
DMXEQ0R IC InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
DMXEQ0R CS CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
DMXEQ0R IK ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
DMXEQ0R IU (2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
DMXEQ0R CA CAS 1166254-80-3
DMXEQ0R CB CHEBI:77752
DMXEQ0R DE Bacterial infection
DMJOYNZ ID DMJOYNZ
DMJOYNZ DN Lu AF11167
DMJOYNZ HS Phase 2
DMJOYNZ CP Lundbeck
DMJOYNZ DT Small molecular drug
DMJOYNZ DE Schizophrenia
DM2ZUXK ID DM2ZUXK
DM2ZUXK DN Lu-AA34893
DM2ZUXK HS Phase 2
DM2ZUXK CP H Lundbeck A/S
DM2ZUXK DE Anxiety disorder
DM34FWR ID DM34FWR
DM34FWR DN Lu-AA39959
DM34FWR HS Phase 2
DM34FWR CP H Lundbeck A/S
DM34FWR DE Bipolar disorder
DMY2L7V ID DMY2L7V
DMY2L7V DN Lucatumumab
DMY2L7V HS Phase 2
DMY2L7V SN HDC122
DMY2L7V CP Novartis Pharmaceuticals
DMY2L7V DT Monoclonal antibody
DMY2L7V DE Lymphoma
DMCKNBA ID DMCKNBA
DMCKNBA DN Lufironil
DMCKNBA HS Phase 2
DMCKNBA SN Hoe-077
DMCKNBA CP Hoechst AG
DMCKNBA DT Small molecular drug
DMCKNBA PC 60788
DMCKNBA MW 281.31
DMCKNBA FM C13H19N3O4
DMCKNBA IC InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18)
DMCKNBA CS COCCNC(=O)C1=CC(=NC=C1)C(=O)NCCOC
DMCKNBA IK JUCNGMPTCXPMNB-UHFFFAOYSA-N
DMCKNBA IU 2-N,4-N-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide
DMCKNBA CA CAS 128075-79-6
DMCKNBA DE Liver cirrhosis
DMGWZ93 ID DMGWZ93
DMGWZ93 DN Lulizumab pegol
DMGWZ93 HS Phase 2
DMGWZ93 CP Bristol-Myers SquibbPrinceton, NJ
DMGWZ93 DE Systemic lupus erythematosus
DMQZXDW ID DMQZXDW
DMQZXDW DN Lum001
DMQZXDW HS Phase 2
DMQZXDW SN SHP625
DMQZXDW CP Lumena pharmaceuticals
DMQZXDW PC 9831642
DMQZXDW MW 710.4
DMQZXDW FM C40H56ClN3O4S
DMQZXDW IC InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1
DMQZXDW CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
DMQZXDW IK POMVPJBWDDJCMP-RUKDTIIFSA-M
DMQZXDW IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol;chloride
DMQZXDW CA CAS 228113-66-4
DMQZXDW DE Primary biliary cirrhosis; Primary biliary cholangitis; Primary sclerosing cholangitis; Progressive familial intrahepatic cholestasis; Structural developmental anomalies of liver
DMCLWDJ ID DMCLWDJ
DMCLWDJ DN Lumacaftor
DMCLWDJ HS Phase 2
DMCLWDJ SN VRT-325; VRT-422; VRT-532; VX-809
DMCLWDJ CP Vertex Pharmaceuticals Inc
DMCLWDJ DT Small molecular drug
DMCLWDJ PC 16678941
DMCLWDJ MW 452.4
DMCLWDJ FM C24H18F2N2O5
DMCLWDJ IC InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
DMCLWDJ CS CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
DMCLWDJ IK UFSKUSARDNFIRC-UHFFFAOYSA-N
DMCLWDJ IU 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
DMCLWDJ CA CAS 936727-05-8
DMCLWDJ CB CHEBI:90951
DMCLWDJ DE Cystic fibrosis
DMLTI39 ID DMLTI39
DMLTI39 DN Lumiliximab
DMLTI39 HS Phase 2
DMLTI39 SN Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
DMLTI39 CP IDEC Pharmaceuticals Corp; Biogen Idec
DMLTI39 DT Antibody
DMLTI39 DE leukaemia
DMLRU9I ID DMLRU9I
DMLRU9I DN Lunacalcipol
DMLRU9I HS Phase 2
DMLRU9I SN CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
DMLRU9I CP Johns Hopkins University
DMLRU9I DT Small molecular drug
DMLRU9I PC 10672195
DMLRU9I MW 474.7
DMLRU9I FM C28H42O4S
DMLRU9I IC InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1
DMLRU9I CS C[C@H](C/C=C/S(=O)(=O)C(C)(C)C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMLRU9I IK RFQHCLMGLJGZNV-UXXOMSPDSA-N
DMLRU9I IU (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMLRU9I CA CAS 250384-82-8
DMLRU9I DE Psoriasis vulgaris
DMZ2XAP ID DMZ2XAP
DMZ2XAP DN LX-1031
DMZ2XAP HS Phase 2
DMZ2XAP SN LG-103; LP-389924; LP-507518; LP-533401; LP-615819; TPH inhibitor (IBS), Lexicon; Tryptophan 5-hydroxylase inhibitor(IBS), Lexicon
DMZ2XAP CP Lexicon Pharmaceuticals Inc
DMZ2XAP DT Small molecular drug
DMZ2XAP PC 23633604
DMZ2XAP MW 538.5
DMZ2XAP FM C28H25F3N4O4
DMZ2XAP IC InChI=1S/C28H25F3N4O4/c1-38-21-4-2-3-20(14-21)17-9-11-19(12-10-17)25(28(29,30)31)39-24-15-23(34-27(33)35-24)18-7-5-16(6-8-18)13-22(32)26(36)37/h2-12,14-15,22,25H,13,32H2,1H3,(H,36,37)(H2,33,34,35)/t22-,25+/m0/s1
DMZ2XAP CS COC1=CC=CC(=C1)C2=CC=C(C=C2)[C@H](C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N
DMZ2XAP IK XNMUICFMGGQSMZ-WIOPSUGQSA-N
DMZ2XAP IU (2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
DMZ2XAP CA CAS 945976-76-1
DMZ2XAP DE Irritable bowel syndrome
DMLA8H3 ID DMLA8H3
DMLA8H3 DN LX2931
DMLA8H3 HS Phase 2
DMLA8H3 CP Lexicon Pharmaceuticals
DMLA8H3 DT Small molecular drug
DMLA8H3 PC 135564845
DMLA8H3 MW 245.23
DMLA8H3 FM C9H15N3O5
DMLA8H3 IC InChI=1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,13-17H,3H2,1H3,(H,10,11)/b12-4+/t6-,7-,8-/m1/s1
DMLA8H3 CS C/C(=N\\O)/C1=NC=C(N1)[C@H]([C@@H]([C@@H](CO)O)O)O
DMLA8H3 IK AMXVYJYMZLDINS-RSWLNLDNSA-N
DMLA8H3 IU (1R,2S,3R)-1-[2-[(E)-N-hydroxy-C-methylcarbonimidoyl]-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
DMLA8H3 CA CAS 948840-25-3
DMLA8H3 DE Rheumatoid arthritis; Hereditary acantholytic dermatoses
DMLBD5I ID DMLBD5I
DMLBD5I DN LXE408
DMLBD5I HS Phase 2
DMLBD5I SN SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
DMLBD5I CP Novartis
DMLBD5I DT Small molecular drug
DMLBD5I PC 118162630
DMLBD5I MW 443.4
DMLBD5I FM C23H18FN7O2
DMLBD5I IC InChI=1S/C23H18FN7O2/c1-12-5-4-8-25-19(12)15-10-26-23-29-21(30-31(23)11-15)17-9-16(6-7-18(17)24)28-22(32)20-13(2)27-14(3)33-20/h4-11H,1-3H3,(H,28,32)
DMLBD5I CS CC1=C(N=CC=C1)C2=CN3C(=NC(=N3)C4=C(C=CC(=C4)NC(=O)C5=C(N=C(O5)C)C)F)N=C2
DMLBD5I IK GNVVPYCWVLCWKV-UHFFFAOYSA-N
DMLBD5I IU N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide
DMLBD5I DE Visceral leishmaniasis
DM5IX9M ID DM5IX9M
DM5IX9M DN LY-156735
DM5IX9M HS Phase 2
DM5IX9M SN LY 156735; N-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide
DM5IX9M CP Phase 2 Discovery
DM5IX9M DT Small molecular drug
DM5IX9M PC 219018
DM5IX9M MW 280.75
DM5IX9M FM C14H17ClN2O2
DM5IX9M IC InChI=1S/C14H17ClN2O2/c1-8(6-16-9(2)18)11-7-17-13-5-12(15)14(19-3)4-10(11)13/h4-5,7-8,17H,6H2,1-3H3,(H,16,18)/t8-/m0/s1
DM5IX9M CS C[C@@H](CNC(=O)C)C1=CNC2=CC(=C(C=C21)OC)Cl
DM5IX9M IK RKHCTAKUYDTFHE-QMMMGPOBSA-N
DM5IX9M IU N-[(2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide
DM5IX9M CA CAS 118702-11-7
DM5IX9M DE Anxiety disorder
DMTBFE4 ID DMTBFE4
DMTBFE4 DN LY2090314
DMTBFE4 HS Phase 2
DMTBFE4 SN 603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, >
DMTBFE4 CP Eli Lilly
DMTBFE4 DT Small molecular drug
DMTBFE4 PC 10029385
DMTBFE4 MW 512.5
DMTBFE4 FM C28H25FN6O3
DMTBFE4 IC InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
DMTBFE4 CS C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
DMTBFE4 IK HRJWTAWVFDCTGO-UHFFFAOYSA-N
DMTBFE4 IU 3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione
DMTBFE4 CA CAS 603288-22-8
DMTBFE4 DE Acute myeloid leukaemia
DMU81BH ID DMU81BH
DMU81BH DN LY-2189102
DMU81BH HS Phase 2
DMU81BH SN Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
DMU81BH CP Eli lilly
DMU81BH DT Antibody
DMU81BH DE Cardiovascular disease
DMH3YKJ ID DMH3YKJ
DMH3YKJ DN LY2382770
DMH3YKJ HS Phase 2
DMH3YKJ CP Eli Lilly & Co
DMH3YKJ DT Antibody
DMH3YKJ DE Diabetic nephropathy; Diabetic kidney disease
DMZOIP4 ID DMZOIP4
DMZOIP4 DN LY-2409021
DMZOIP4 HS Phase 2
DMZOIP4 SN Oral glucagon receptor antagonist (type 2 diabetes), Eli Lilly
DMZOIP4 CP Eli Lilly & Co
DMZOIP4 PC 91933867
DMZOIP4 MW 555.6
DMZOIP4 FM C32H36F3NO4
DMZOIP4 IC InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
DMZOIP4 CS CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)O[C@@H](CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O
DMZOIP4 IK FASLTMSUPQDLIB-MHZLTWQESA-N
DMZOIP4 IU 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid
DMZOIP4 CA CAS 1488363-78-5
DMZOIP4 DE Type-2 diabetes
DMKYMS2 ID DMKYMS2
DMKYMS2 DN LY-2428757
DMKYMS2 HS Phase 2
DMKYMS2 SN GLP-PEG, Eli Lilly; GLP1-PEG, Eli Lilly
DMKYMS2 CP Eli Lilly & Co
DMKYMS2 DE Type-2 diabetes
DMLTSDC ID DMLTSDC
DMLTSDC DN LY-2456302
DMLTSDC HS Phase 2
DMLTSDC SN Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly
DMLTSDC CP Eli Lilly & Co
DMLTSDC DT Small molecular drug
DMLTSDC PC 44129648
DMLTSDC MW 418.5
DMLTSDC FM C26H27FN2O2
DMLTSDC IC InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1
DMLTSDC CS CC1=CC(=CC(=C1)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C
DMLTSDC IK ZHPMYDSXGRRERG-DEOSSOPVSA-N
DMLTSDC IU 4-[4-[[(2S)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide
DMLTSDC CA CAS 1174130-61-0
DMLTSDC DE Alcohol dependence; Major depressive disorder
DMM5JAN ID DMM5JAN
DMM5JAN DN LY2495655
DMM5JAN HS Phase 2
DMM5JAN CP Eli Lilly
DMM5JAN DE Disuse muscle atrophy
DMCV602 ID DMCV602
DMCV602 DN LY2523355
DMCV602 HS Phase 2
DMCV602 SN Litronesib
DMCV602 CP Lilly
DMCV602 DT Small molecular drug
DMCV602 PC 25167017
DMCV602 MW 511.7
DMCV602 FM C23H37N5O4S2
DMCV602 IC InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1
DMCV602 CS CCNCCS(=O)(=O)NC[C@@]1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2
DMCV602 IK YVAFBXLHPINSIK-QHCPKHFHSA-N
DMCV602 IU N-[(5R)-4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethylsulfonylamino]methyl]-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethylpropanamide
DMCV602 CA CAS 910634-41-2
DMCV602 DE Acute myeloid leukaemia
DMTVU2Q ID DMTVU2Q
DMTVU2Q DN LY2541546
DMTVU2Q HS Phase 2
DMTVU2Q CP Eli Lilly
DMTVU2Q DT Antibody
DMTVU2Q DE Osteoporosis
DM81UJW ID DM81UJW
DM81UJW DN LY-2590443
DM81UJW HS Phase 2
DM81UJW CP Eli Lilly & Co
DM81UJW DE Migraine
DMMI0RH ID DMMI0RH
DMMI0RH DN LY-2599506
DMMI0RH HS Phase 2
DMMI0RH SN PSN-010
DMMI0RH CP Prosidion Ltd
DMMI0RH PC 11517248
DMMI0RH MW 415.5
DMMI0RH FM C21H25N3O4S
DMMI0RH IC InChI=1S/C21H25N3O4S/c25-21(24-20-14-22-9-10-23-20)19(13-15-7-11-28-12-8-15)16-1-3-17(4-2-16)29(26,27)18-5-6-18/h1-4,9-10,14-15,18-19H,5-8,11-13H2,(H,23,24,25)/t19-/m1/s1
DMMI0RH CS C1CC1S(=O)(=O)C2=CC=C(C=C2)[C@@H](CC3CCOCC3)C(=O)NC4=NC=CN=C4
DMMI0RH IK DQIITKNITDKAJZ-LJQANCHMSA-N
DMMI0RH IU (2R)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-N-pyrazin-2-ylpropanamide
DMMI0RH CA CAS 745051-65-4
DMMI0RH DE Diabetic complication
DMCXRZF ID DMCXRZF
DMCXRZF DN LY2603618
DMCXRZF HS Phase 2
DMCXRZF SN LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
DMCXRZF CP Eli Lilly
DMCXRZF DT Small molecular drug
DMCXRZF PC 11955855
DMCXRZF MW 436.3
DMCXRZF FM C18H22BrN5O3
DMCXRZF IC InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
DMCXRZF CS CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3
DMCXRZF IK SYYBDNPGDKKJDU-ZDUSSCGKSA-N
DMCXRZF IU 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
DMCXRZF CA CAS 911222-45-2
DMCXRZF CB CHEBI:124917
DMCXRZF DE Pancreatic cancer
DM4XMF7 ID DM4XMF7
DM4XMF7 DN LY2606368
DM4XMF7 HS Phase 2
DM4XMF7 SN prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
DM4XMF7 CP Eli Lilly, Indianapolis, IN
DM4XMF7 PC 46700756
DM4XMF7 MW 365.4
DM4XMF7 FM C18H19N7O2
DM4XMF7 IC InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)
DM4XMF7 CS COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N
DM4XMF7 IK DOTGPNHGTYJDEP-UHFFFAOYSA-N
DM4XMF7 IU 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile
DM4XMF7 CA CAS 1234015-52-1
DM4XMF7 DE Head and neck cancer; Ovarian cancer; Small-cell lung cancer; Squamous cell anal carcinoma; Solid tumour/cancer
DM4EF9Y ID DM4EF9Y
DM4EF9Y DN LY-2608204
DM4EF9Y HS Phase 2
DM4EF9Y SN Glucokinase activator (type 2 diabetes), Eli Lilly
DM4EF9Y CP Eli Lilly & Co
DM4EF9Y DT Small molecular drug
DM4EF9Y PC 46832368
DM4EF9Y MW 559.8
DM4EF9Y FM C28H37N3O3S3
DM4EF9Y IC InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1
DM4EF9Y CS C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6
DM4EF9Y IK QIIVJLHCZUTGSD-CUBQBAPOSA-N
DM4EF9Y IU (1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
DM4EF9Y CA CAS 1234703-40-2
DM4EF9Y DE Type-2 diabetes
DMFGNB4 ID DMFGNB4
DMFGNB4 DN LY-2623091
DMFGNB4 HS Phase 2
DMFGNB4 SN Chronic renal disease therapy, Eli Lilly
DMFGNB4 CP Eli Lilly & Co
DMFGNB4 PC 42636651
DMFGNB4 MW 527.6
DMFGNB4 FM C30H30FN5O3
DMFGNB4 IC InChI=1S/C30H30FN5O3/c1-19(17-35-10-12-38-13-11-35)36-27-9-6-20(15-26(27)33-30(36)34-29(32)37)14-25-23-5-3-2-4-21(23)18-39-28-16-22(31)7-8-24(25)28/h2-9,14-16,19H,10-13,17-18H2,1H3,(H3,32,33,34,37)/b25-14+/t19-/m1/s1
DMFGNB4 CS C[C@H](CN1CCOCC1)N2C3=C(C=C(C=C3)/C=C\\4/C5=C(C=C(C=C5)F)OCC6=CC=CC=C64)N=C2NC(=O)N
DMFGNB4 IK YPCLDHGBEKZGEB-RUDKWAFVSA-N
DMFGNB4 IU [5-[(E)-(3-fluoro-6H-benzo[c][1]benzoxepin-11-ylidene)methyl]-1-[(2R)-1-morpholin-4-ylpropan-2-yl]benzimidazol-2-yl]urea
DMFGNB4 CA CAS 1162264-07-4
DMFGNB4 DE Chronic kidney disease
DMTPQUA ID DMTPQUA
DMTPQUA DN LY-2624803
DMTPQUA HS Phase 2
DMTPQUA SN HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly
DMTPQUA CP Hypnion
DMTPQUA PC 11567064
DMTPQUA MW 379.5
DMTPQUA FM C22H25N3O3
DMTPQUA IC InChI=1S/C22H25N3O3/c1-22(2,21(26)27)15-24-11-13-25(14-12-24)20-16-7-3-5-9-18(16)28-19-10-6-4-8-17(19)23-20/h3-10H,11-15H2,1-2H3,(H,26,27)
DMTPQUA CS CC(C)(CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMTPQUA IK UEFWDVMEDFCHGW-UHFFFAOYSA-N
DMTPQUA IU 3-(4-benzo[b][1,4]benzoxazepin-6-ylpiperazin-1-yl)-2,2-dimethylpropanoic acid
DMTPQUA CA CAS 879409-35-5
DMTPQUA DE Insomnia
DMZASMP ID DMZASMP
DMZASMP DN LY2784544
DMZASMP HS Phase 2
DMZASMP SN LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP CP Eli Lilly
DMZASMP DT Small molecular drug
DMZASMP PC 46213929
DMZASMP MW 469.9
DMZASMP FM C23H25ClFN7O
DMZASMP IC InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
DMZASMP CS CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
DMZASMP IK SQSZANZGUXWJEA-UHFFFAOYSA-N
DMZASMP IU 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP CA CAS 1229236-86-5
DMZASMP DE Breast cancer; Myeloproliferative neoplasm
DM0KJDY ID DM0KJDY
DM0KJDY DN LY2801653
DM0KJDY HS Phase 2
DM0KJDY SN Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY CP Lilly
DM0KJDY DT Small molecular drug
DM0KJDY PC 44603533
DM0KJDY MW 552.5
DM0KJDY FM C30H22F2N6O3
DM0KJDY IC InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)
DM0KJDY CS CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F
DM0KJDY IK QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY IU N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide
DM0KJDY CA CAS 1206799-15-6
DM0KJDY DE Solid tumour/cancer; Biliary tract cancer
DMO8IEZ ID DMO8IEZ
DMO8IEZ DN LY-2828360
DMO8IEZ HS Phase 2
DMO8IEZ CP Eli Lilly & Co
DMO8IEZ DE Pain
DMZ0DMY ID DMZ0DMY
DMZ0DMY DN LY2874455
DMZ0DMY HS Phase 2
DMZ0DMY SN LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051
DMZ0DMY CP Lilly
DMZ0DMY DT Small molecular drug
DMZ0DMY PC 46944259
DMZ0DMY MW 444.3
DMZ0DMY FM C21H19Cl2N5O2
DMZ0DMY IC InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1
DMZ0DMY CS C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO
DMZ0DMY IK GKJCVYLDJWTWQU-CXLRFSCWSA-N
DMZ0DMY IU 2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol
DMZ0DMY CA CAS 1254473-64-7
DMZ0DMY DE Solid tumour/cancer
DMQV1OU ID DMQV1OU
DMQV1OU DN LY-2875358
DMQV1OU HS Phase 2
DMQV1OU SN C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly
DMQV1OU CP Eli lilly
DMQV1OU DT Antibody
DMQV1OU DE Solid tumour/cancer
DMV14LM ID DMV14LM
DMV14LM DN LY2886721
DMV14LM HS Phase 2
DMV14LM SN LY2886721; 1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475
DMV14LM CP Lilly
DMV14LM DT Small molecular drug
DMV14LM PC 49837968
DMV14LM MW 390.4
DMV14LM FM C18H16F2N4O2S
DMV14LM IC InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1
DMV14LM CS C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N
DMV14LM IK NIDRNVHMMDAAIK-YPMLDQLKSA-N
DMV14LM IU N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DMV14LM CA CAS 1262036-50-9
DMV14LM DE Alzheimer disease
DMRDEKZ ID DMRDEKZ
DMRDEKZ DN LY2928057
DMRDEKZ HS Phase 2
DMRDEKZ CP Lilly
DMRDEKZ DE Anaemia
DM4N6EK ID DM4N6EK
DM4N6EK DN LY293558
DM4N6EK HS Phase 2
DM4N6EK SN Tezampanel; 154652-83-2; LY-293558; LY293558; Ted-isoquinoline-3-cooh; LY 293558; UNII-GA36S2O9C2; CHEMBL14935; GA36S2O9C2; 150131-78-5; Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid; 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; Tezampanel [INN]
DM4N6EK CP Eli Lilly
DM4N6EK TC Analgesics
DM4N6EK DT Small molecular drug
DM4N6EK PC 127894
DM4N6EK MW 279.34
DM4N6EK FM C13H21N5O2
DM4N6EK IC InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
DM4N6EK CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O
DM4N6EK IK ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
DM4N6EK IU (3S,4aR,6R,8aR)-6-[2-(2H-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DM4N6EK CA CAS 154652-83-2
DM4N6EK DE Pain
DMB5L6Q ID DMB5L6Q
DMB5L6Q DN LY-2940094
DMB5L6Q HS Phase 2
DMB5L6Q CP Eli Lilly & Co
DMB5L6Q PC 52914971
DMB5L6Q MW 481
DMB5L6Q FM C22H23ClF2N4O2S
DMB5L6Q IC InChI=1S/C22H23ClF2N4O2S/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30H,4-5,7-8,10,12-13H2,1H3
DMB5L6Q CS CC1=NN(C=C1CN2CCC3(CC2)C4=C(C=C(S4)Cl)C(CO3)(F)F)C5=C(C=CC=N5)CO
DMB5L6Q IK NKQHBJNRBKHUQR-UHFFFAOYSA-N
DMB5L6Q IU [2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol
DMB5L6Q CA CAS 1307245-86-8
DMB5L6Q DE Major depressive disorder
DML6XWR ID DML6XWR
DML6XWR DN LY2944876
DML6XWR HS Phase 2
DML6XWR PC 121494121
DML6XWR MW 405.5
DML6XWR FM C16H27N3O7S
DML6XWR IC InChI=1S/C16H27N3O7S/c1-25-7-8-26-6-2-4-18-13(20)3-5-19-14(21)9-12(15(19)22)27-10-11(17)16(23)24/h11-12H,2-10,17H2,1H3,(H,18,20)(H,23,24)/t11-,12?/m0/s1
DML6XWR CS COCCOCCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N
DML6XWR IK DLVAZTPQKCTPLB-PXYINDEMSA-N
DML6XWR IU (2R)-2-amino-3-[1-[3-[3-(2-methoxyethoxy)propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
DML6XWR CA CAS 1492924-65-8
DML6XWR DE Diabetic complication
DMRVEHY ID DMRVEHY
DMRVEHY DN LY3012212
DMRVEHY HS Phase 2
DMRVEHY SN Icrucumab
DMRVEHY CP Lilly
DMRVEHY DE Bladder cancer; Arteriosclerosis
DMFMKQ3 ID DMFMKQ3
DMFMKQ3 DN LY3015014
DMFMKQ3 HS Phase 2
DMFMKQ3 CP Eli lilly
DMFMKQ3 DT Antibody
DMFMKQ3 DE Cardiovascular disease
DMD9KYF ID DMD9KYF
DMD9KYF DN LY3023414
DMD9KYF HS Phase 2
DMD9KYF CP Lilly
DMD9KYF PC 57519748
DMD9KYF MW 406.5
DMD9KYF FM C23H26N4O3
DMD9KYF IC InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1
DMD9KYF CS C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC
DMD9KYF IK ACCFLVVUVBJNGT-AWEZNQCLSA-N
DMD9KYF IU 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one
DMD9KYF CA CAS 1386874-06-1
DMD9KYF DE Solid tumour/cancer; Prostate cancer
DMDFZK8 ID DMDFZK8
DMDFZK8 DN LY3113593
DMDFZK8 HS Phase 2
DMDFZK8 CP Eli Lilly
DMDFZK8 DT Antibody
DMDFZK8 DE Anaemia
DMAC457 ID DMAC457
DMAC457 DN LY3127804
DMAC457 HS Phase 2
DMAC457 TC Antiviral Agents
DMAC457 DT Monoclonal antibody
DMAC457 DE Coronavirus Disease 2019 (COVID-19)
DM7IFNB ID DM7IFNB
DM7IFNB DN LY3202626
DM7IFNB HS Phase 2
DM7IFNB CP Eli Lilly Indianapolis, IN
DM7IFNB DE Alzheimer disease
DMGMC8H ID DMGMC8H
DMGMC8H DN LY333531
DMGMC8H HS Phase 2
DMGMC8H SN Ruboxistaurin; 169939-94-0; LY-333531; Ruboxistaurin [INN]; LY 333531; UNII-721809WQCP; 721809WQCP; K00587a; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; CHEMBL432130; (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; Br-WR99210
DMGMC8H DT Small molecular drug
DMGMC8H PC 153999
DMGMC8H MW 468.5
DMGMC8H FM C28H28N4O3
DMGMC8H IC InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
DMGMC8H CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
DMGMC8H IK ZCBUQCWBWNUWSU-SFHVURJKSA-N
DMGMC8H IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
DMGMC8H CA CAS 169939-94-0
DMGMC8H DE Solid tumour/cancer
DM43O9N ID DM43O9N
DM43O9N DN LY-334370
DM43O9N HS Phase 2
DM43O9N SN LY334370; LY-334370; 182563-08-2; UNII-5Q7I1WL2UY; 5Q7I1WL2UY; LY 334370; CHEMBL101690; LY-334,370; 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide; 4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide; 4-Fluoro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzamide; AC1NSKBH; GTPL20; GTPL151; SCHEMBL6911508; DTXSID40415518; ZINC1488294; BCP29131; BDBM50130461; NCGC00378776-02; [3H]LY334370; HY-103107; CS-0025021; L000364; 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1h-indol-5-yl]-benzamide
DM43O9N DT Small molecular drug
DM43O9N PC 5311258
DM43O9N MW 351.4
DM43O9N FM C21H22FN3O
DM43O9N IC InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)
DM43O9N CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F
DM43O9N IK MDMJLMDBRQXOOI-UHFFFAOYSA-N
DM43O9N IU 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
DM43O9N CA CAS 182563-08-2
DM43O9N DE Migraine
DMD09CT ID DMD09CT
DMD09CT DN LY-362884
DMD09CT HS Phase 2
DMD09CT CP Eli Lilly
DMD09CT PC 9870239
DMD09CT MW 491.5
DMD09CT FM C26H29N5O5
DMD09CT IC InChI=1S/C26H29N5O5/c1-26(2,29-14-18(32)15-35-21-5-3-4-20-23(21)31-25(34)30-20)12-16-6-9-19(10-7-16)36-22-11-8-17(13-28-22)24(27)33/h3-11,13,18,29,32H,12,14-15H2,1-2H3,(H2,27,33)(H2,30,31,34)
DMD09CT CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NCC(COC3=CC=CC4=C3NC(=O)N4)O
DMD09CT IK RLYDBONATWKYQX-UHFFFAOYSA-N
DMD09CT IU 6-[4-[2-[[2-hydroxy-3-[(2-oxo-1,3-dihydrobenzimidazol-4-yl)oxy]propyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMD09CT DE Type-2 diabetes; Obesity
DMZCU7I ID DMZCU7I
DMZCU7I DN LY-377604
DMZCU7I HS Phase 2
DMZCU7I SN Ethanolamine analogs, Lilly; Obesity therapeutics, Lilly; Beta-3 adrenoceptor agonists, Lilly
DMZCU7I CP Eli Lilly & Co
DMZCU7I DT Small molecular drug
DMZCU7I PC 9849699
DMZCU7I MW 524.6
DMZCU7I FM C31H32N4O4
DMZCU7I IC InChI=1S/C31H32N4O4/c1-31(2,16-20-10-13-23(14-11-20)39-28-15-12-21(17-33-28)30(32)37)34-18-22(36)19-38-27-9-5-8-26-29(27)24-6-3-4-7-25(24)35-26/h3-15,17,22,34-36H,16,18-19H2,1-2H3,(H2,32,37)/t22-/m0/s1
DMZCU7I CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NC[C@@H](COC3=CC=CC4=C3C5=CC=CC=C5N4)O
DMZCU7I IK RBSGUQYXRDKPAE-QFIPXVFZSA-N
DMZCU7I IU 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMZCU7I CA CAS 204592-94-9
DMZCU7I DE Obesity
DM8OG0J ID DM8OG0J
DM8OG0J DN LY-517717
DM8OG0J HS Phase 2
DM8OG0J SN SCHEMBL676862
DM8OG0J CP Eli Lilly
DM8OG0J DT Small molecular drug
DM8OG0J PC 9939865
DM8OG0J MW 459.6
DM8OG0J FM C27H33N5O2
DM8OG0J IC InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1
DM8OG0J CS CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5
DM8OG0J IK VYNKVNDKAOGAAQ-RUZDIDTESA-N
DM8OG0J IU N-[(1R)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide
DM8OG0J CA CAS 313489-71-3
DM8OG0J DE Thrombosis
DMBM2I9 ID DMBM2I9
DMBM2I9 DN LY-518674
DMBM2I9 HS Phase 2
DMBM2I9 SN LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid
DMBM2I9 CP Eli Lilly
DMBM2I9 DT Small molecular drug
DMBM2I9 PC 135449333
DMBM2I9 MW 409.5
DMBM2I9 FM C23H27N3O4
DMBM2I9 IC InChI=1S/C23H27N3O4/c1-16-7-9-18(10-8-16)15-26-22(29)24-20(25-26)6-4-5-17-11-13-19(14-12-17)30-23(2,3)21(27)28/h7-14H,4-6,15H2,1-3H3,(H,27,28)(H,24,25,29)
DMBM2I9 CS CC1=CC=C(C=C1)CN2C(=O)NC(=N2)CCCC3=CC=C(C=C3)OC(C)(C)C(=O)O
DMBM2I9 IK PNHFDVSKDSLUFH-UHFFFAOYSA-N
DMBM2I9 IU 2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-4H-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid
DMBM2I9 CA CAS 425671-29-0
DMBM2I9 DE Diabetic complication
DMMSBW5 ID DMMSBW5
DMMSBW5 DN LY-545694
DMMSBW5 HS Phase 2
DMMSBW5 SN Lead iGluR5 antagonist (pain), Eli Lilly
DMMSBW5 CP Eli Lilly & Co
DMMSBW5 DE Neuropathic pain
DMP05GL ID DMP05GL
DMP05GL DN LYC-30937
DMP05GL HS Phase 2
DMP05GL CP Lycera Ann Arbor, MI
DMP05GL DE Plaque psoriasis; Ulcerative colitis
DMV8WU9 ID DMV8WU9
DMV8WU9 DN LYC-55716
DMV8WU9 HS Phase 2
DMV8WU9 SN Cintirorgon; UNII-LPN433P0EA; LPN433P0EA; 2055536-64-4; Cintirorgon [INN]; cintirorgon (proposed INN); SCHEMBL18302870; GTPL10045; LYC55716; BCP28882; EX-A2635; LYC 55716; CS-7496; compound 32J [WO2016201225A1]; HY-104037; 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9 CP Lycera Ann Arbor, MI
DMV8WU9 PC 124126348
DMV8WU9 MW 603.5
DMV8WU9 FM C27H23F6NO6S
DMV8WU9 IC InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
DMV8WU9 CS CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
DMV8WU9 IK GULSIMHVQYBADX-FQEVSTJZSA-N
DMV8WU9 IU 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9 CA CAS 2055536-64-4
DMV8WU9 DE Solid tumour/cancer; Non-small-cell lung cancer
DM23Y6K ID DM23Y6K
DM23Y6K DN LYS228
DM23Y6K HS Phase 2
DM23Y6K SN 1810051-96-7 (free acid); 1-((((Z)-1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropane-1-carboxylic acid; SCHEMBL17094584; 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid; l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid
DM23Y6K DT Small molecular drug
DM23Y6K PC 118380292
DM23Y6K MW 518.5
DM23Y6K FM C16H18N6O10S2
DM23Y6K IC InChI=1S/C16H18N6O10S2/c17-14-18-7(6-33-14)9(20-32-16(1-2-16)13(25)26)11(23)19-10-8(5-21-3-4-31-15(21)27)22(12(10)24)34(28,29)30/h6,8,10H,1-5H2,(H2,17,18)(H,19,23)(H,25,26)(H,28,29,30)/b20-9+/t8-,10+/m1/s1
DM23Y6K CS C1CC1(C(=O)O)O/N=C(\\C2=CSC(=N2)N)/C(=O)N[C@H]3[C@H](N(C3=O)S(=O)(=O)O)CN4CCOC4=O
DM23Y6K IK FWTGYTRQUBRVDW-UWGJAOEXSA-N
DM23Y6K IU 1-[(E)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-[[(3S,4R)-2-oxo-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1-sulfoazetidin-3-yl]amino]ethylidene]amino]oxycyclopropane-1-carboxylic acid
DM23Y6K DE Urinary tract infection
DML0I2Z ID DML0I2Z
DML0I2Z DN M118
DML0I2Z HS Phase 2
DML0I2Z SN Adomiparin
DML0I2Z CP Momenta Pharmaceuticals
DML0I2Z DT Small molecular drug
DML0I2Z PC 21156139
DML0I2Z MW 801.9
DML0I2Z FM C34H42Cl4N8O2Zn
DML0I2Z IC InChI=1S/2C17H20N4O.4ClH.Zn/c2*1-4-21(5-2)11-6-7-14-15(8-11)22-17-10(3)12(18)9-13(19)16(17)20-14;;;;;/h2*6-9H,4-5H2,1-3H3,(H3,18,19);4*1H;/q;;;;;;+2/p-2
DML0I2Z CS CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.Cl[Zn-2](Cl)(Cl)Cl
DML0I2Z IK JJKNZNYHIUJGIC-UHFFFAOYSA-L
DML0I2Z IU (7,9-diamino-6-methylphenoxazin-3-ylidene)-diethylazanium;tetrachlorozinc(2-)
DML0I2Z DE Acute coronary syndrome
DMZ7YX3 ID DMZ7YX3
DMZ7YX3 DN M-16209
DMZ7YX3 HS Phase 2
DMZ7YX3 SN 1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin
DMZ7YX3 DT Small molecular drug
DMZ7YX3 PC 164260
DMZ7YX3 MW 359.15
DMZ7YX3 FM C11H7BrN2O5S
DMZ7YX3 IC InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
DMZ7YX3 CS C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br
DMZ7YX3 IK ZJSUDHQFSBHLDV-UHFFFAOYSA-N
DMZ7YX3 IU 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione
DMZ7YX3 CA CAS 128851-36-5
DMZ7YX3 DE Diabetic complication
DMC5MQD ID DMC5MQD
DMC5MQD DN M2951
DMC5MQD HS Phase 2
DMC5MQD SN evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin
DMC5MQD CP EMD Serono Rockland, MA
DMC5MQD PC 71479709
DMC5MQD MW 429.5
DMC5MQD FM C25H27N5O2
DMC5MQD IC InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
DMC5MQD CS C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
DMC5MQD IK QUIWHXQETADMGN-UHFFFAOYSA-N
DMC5MQD IU 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
DMC5MQD CA CAS 1415823-73-2
DMC5MQD DE Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
DMJCULI ID DMJCULI
DMJCULI DN M7824
DMJCULI HS Phase 2
DMJCULI CP EMD SeronoRockland, MA
DMJCULI DT Antibody
DMJCULI DE Solid tumour/cancer
DMQOBH4 ID DMQOBH4
DMQOBH4 DN mab 1-7F9
DMQOBH4 HS Phase 2
DMQOBH4 CP CeMines
DMQOBH4 DT Antibody
DMQOBH4 DE Multiple myeloma
DMBYDNE ID DMBYDNE
DMBYDNE DN Managlinat dialanetil
DMBYDNE HS Phase 2
DMBYDNE SN CS-917; GP-3034; MB-05032; MB-06322; MB-06633; MB-6322; R-132917; Type 2 diabetes therapeutic, Gensia/Sankyo; Type 2 diabetes therapeutic, SICOR/Sankyo; Diabetes therapeutics, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, Gensia/Sankyo/Daiichi Sankyo; Purine nucleotide analogs, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, SICOR/Sankyo/Daiichi Sankyo
DMBYDNE CP Metabasis Therapeutics Inc
DMBYDNE PC 73014123
DMBYDNE MW 484.6
DMBYDNE FM C21H33N4O5PS
DMBYDNE IC InChI=1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1
DMBYDNE CS CCOC(=O)[C@H](C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)N[C@@H](C)C(=O)OCC
DMBYDNE IK JGCMEVUWRCNKKE-KBPBESRZSA-N
DMBYDNE IU ethyl (2S)-2-[[[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphanyl]amino]propanoate
DMBYDNE DE Type-2 diabetes
DMB4A8I ID DMB4A8I
DMB4A8I DN MANOALIDE
DMB4A8I HS Phase 2
DMB4A8I SN manoalide; UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975
DMB4A8I DT Small molecular drug
DMB4A8I PC 6437368
DMB4A8I MW 416.5
DMB4A8I FM C25H36O5
DMB4A8I IC InChI=1S/C25H36O5/c1-16(10-12-20-17(2)8-6-14-25(20,3)4)7-5-9-18-11-13-21(29-23(18)27)19-15-22(26)30-24(19)28/h7,11,15,21,23-24,27-28H,5-6,8-10,12-14H2,1-4H3/b16-7+/t21-,23-,24-/m1/s1
DMB4A8I CS CC1=C(C(CCC1)(C)C)CC/C(=C/CCC2=CC[C@@H](O[C@H]2O)C3=CC(=O)O[C@H]3O)/C
DMB4A8I IK FGJIDQWRRLDGDB-CPIXEKRISA-N
DMB4A8I IU (2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
DMB4A8I CA CAS 75088-80-1
DMB4A8I CB CHEBI:66666
DMB4A8I DE Arthritis
DMGQ175 ID DMGQ175
DMGQ175 DN Mapatumumab
DMGQ175 HS Phase 2
DMGQ175 CP Human Genome Sciences
DMGQ175 DT Monoclonal antibody
DMGQ175 DE Non-small-cell lung cancer
DMDTI0L ID DMDTI0L
DMDTI0L DN Masilukast
DMDTI0L HS Phase 2
DMDTI0L SN D-3523; MCC-847; ZD-3523
DMDTI0L CP Zeneca Group plc
DMDTI0L DT Small molecular drug
DMDTI0L PC 204056
DMDTI0L MW 615.7
DMDTI0L FM C31H32F3N3O5S
DMDTI0L IC InChI=1S/C31H32F3N3O5S/c1-19(16-31(32,33)34)17-35-29(38)22-11-12-26-25(14-22)24(18-37(26)3)13-21-9-10-23(15-27(21)42-4)30(39)36-43(40,41)28-8-6-5-7-20(28)2/h5-12,14-15,18-19H,13,16-17H2,1-4H3,(H,35,38)(H,36,39)/t19-/m1/s1
DMDTI0L CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)C(=O)NC[C@H](C)CC(F)(F)F)C)OC
DMDTI0L IK ULMFXAMQUGLVGA-LJQANCHMSA-N
DMDTI0L IU 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-N-[(2R)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide
DMDTI0L CA CAS 136564-68-6
DMDTI0L DE Asthma
DM2458E ID DM2458E
DM2458E DN Matuzumab
DM2458E HS Phase 2
DM2458E SN EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
DM2458E CP Merck KgaA; Merck KGaA
DM2458E DT Antibody
DM2458E SQ 3c08_H|Fab72000|Humanized||VH-CH1 (VH(1-115)+CH1(116-213))|||||||223||||MW 24063.8|MW 24063.8|: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS >3c08_L|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-101)+C-KAPPA(102-206))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_B|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-106)+C-KAPPA(107-175))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_C|Fab72000|Humanized||VH-CH1 (VH(1-121)+CH1(122-191))|||||||223||||MW 24019.8|MW 24019.8|QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
DM2458E DE Gastric adenocarcinoma
DMMVFRC ID DMMVFRC
DMMVFRC DN Mavrilimumab
DMMVFRC HS Phase 2
DMMVFRC CP MedImmune
DMMVFRC DT Antibody
DMMVFRC DE Rheumatoid arthritis
DMWLIPJ ID DMWLIPJ
DMWLIPJ DN MAXY-G34
DMWLIPJ HS Phase 2
DMWLIPJ SN Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen
DMWLIPJ CP Maxygen
DMWLIPJ DE Neutropenia
DMJKHVX ID DMJKHVX
DMJKHVX DN Mazapertine succinate
DMJKHVX HS Phase 2
DMJKHVX SN RWJ-37796
DMJKHVX CP RW Johnson Pharmaceutical Research Institute
DMJKHVX DT Small molecular drug
DMJKHVX PC 60819
DMJKHVX MW 539.7
DMJKHVX FM C30H41N3O6
DMJKHVX IC InChI=1S/C26H35N3O2.C4H6O4/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29;5-3(6)1-2-4(7)8/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
DMJKHVX CS CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4.C(CC(=O)O)C(=O)O
DMJKHVX IK WAHFGTZTVZRLEY-UHFFFAOYSA-N
DMJKHVX IU butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMJKHVX CA CAS 134208-18-7
DMJKHVX DE Psychotic disorder
DMHU8SJ ID DMHU8SJ
DMHU8SJ DN MB07803
DMHU8SJ HS Phase 2
DMHU8SJ SN MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester
DMHU8SJ CP Metabasis Therape
DMHU8SJ DT Small molecular drug
DMHU8SJ PC 24770445
DMHU8SJ MW 556.6
DMHU8SJ FM C24H37N4O7PS
DMHU8SJ IC InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)
DMHU8SJ CS CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC
DMHU8SJ IK CTKZZUXRWBCFEI-UHFFFAOYSA-N
DMHU8SJ IU ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate
DMHU8SJ CA CAS 882757-24-6
DMHU8SJ DE Type-2 diabetes
DM6JTSZ ID DM6JTSZ
DM6JTSZ DN MB-07811
DM6JTSZ HS Phase 2
DM6JTSZ SN CHEMBL471897; MB-07811; SCHEMBL3147495; BDBM50242404
DM6JTSZ CP Ligand Pharmaceuticals
DM6JTSZ DT Small molecular drug
DM6JTSZ PC 15942005
DM6JTSZ MW 515
DM6JTSZ FM C28H32ClO5P
DM6JTSZ IC InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1
DM6JTSZ CS CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl
DM6JTSZ IK LGGPZDRLTDGYSQ-JADSYQMUSA-N
DM6JTSZ IU 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol
DM6JTSZ CA CAS 852948-13-1
DM6JTSZ DE Hyperlipidaemia
DMLPNVS ID DMLPNVS
DMLPNVS DN MB-102
DMLPNVS HS Phase 2
DMLPNVS SN Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0
DMLPNVS CP Mustang Bio New York, NY
DMLPNVS PC 53389120
DMLPNVS MW 372.29
DMLPNVS FM C12H16N6O8
DMLPNVS IC InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
DMLPNVS CS C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O
DMLPNVS IK XHNJXRDGTITISI-QWWZWVQMSA-N
DMLPNVS IU (2R)-2-[[3,6-diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid
DMLPNVS CA CAS 1313706-17-0
DMLPNVS DE Acute myeloid leukaemia; Acute kidney injury
DM3RBJW ID DM3RBJW
DM3RBJW DN MB-11055
DM3RBJW HS Phase 2
DM3RBJW SN Cryptotanshinone, MD BioAlpha; Cryptotanshinone, Mazence; AMP activated protein kinase stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; AMPK stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; Lipid metabolism stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence
DM3RBJW CP Mazence Inc
DM3RBJW DE Fatty liver disease
DMRSN2C ID DMRSN2C
DMRSN2C DN MB-12066
DMRSN2C HS Phase 2
DMRSN2C SN B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence
DMRSN2C CP Mazence Inc
DMRSN2C DE Obesity
DM0AOID ID DM0AOID
DM0AOID DN MB-CART19.1
DM0AOID HS Phase 2
DM0AOID CP Shanghai Children's Medical Center
DM0AOID DT CAR T Cell Therapy
DM0AOID DE Precursor B-lymphoblastic neoplasm
DMJVU7Y ID DMJVU7Y
DMJVU7Y DN MBL-HCV1
DMJVU7Y HS Phase 2
DMJVU7Y SN Anti-HCV antibody, MassBiologics
DMJVU7Y CP Massbiologics
DMJVU7Y DE Hepatitis C virus infection
DMQMTO1 ID DMQMTO1
DMQMTO1 DN MBX-2044
DMQMTO1 HS Phase 2
DMQMTO1 SN MBX-102 analogs, Metabolex
DMQMTO1 CP Metabolex Inc
DMQMTO1 DE Type-2 diabetes
DM0W3R7 ID DM0W3R7
DM0W3R7 DN MCLA-128
DM0W3R7 HS Phase 2
DM0W3R7 CP MerusUtrecht, Netherlands
DM0W3R7 DE Breast cancer
DM0CL4I ID DM0CL4I
DM0CL4I DN MCS-110
DM0CL4I HS Phase 2
DM0CL4I SN Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis
DM0CL4I CP Novartis pharmaceuticals
DM0CL4I DE Bone metastases; Advanced malignancy; Breast cancer; Tenosynovial giant cell tumour; Triple negative breast cancer
DMX4U0B ID DMX4U0B
DMX4U0B DN MCS-18
DMX4U0B HS Phase 2
DMX4U0B SN Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur
DMX4U0B CP DoNatur GmbH
DMX4U0B DE Autoimmune diabetes
DMDR2SZ ID DMDR2SZ
DMDR2SZ DN MCT-125
DMDR2SZ HS Phase 2
DMDR2SZ CP Laxdale Ltd
DMDR2SZ DE Fatigue
DM5DSGJ ID DM5DSGJ
DM5DSGJ DN MD-0727
DM5DSGJ HS Phase 2
DM5DSGJ CP Ironwood Pharmaceuticals
DM5DSGJ PC 11586434
DM5DSGJ MW 193.2
DM5DSGJ FM C10H11NO3
DM5DSGJ IC InChI=1S/C10H11NO3/c1-3-14-10(13)9-6-4-5-8(11-9)7(2)12/h4-6H,3H2,1-2H3
DM5DSGJ CS CCOC(=O)C1=CC=CC(=N1)C(=O)C
DM5DSGJ IK COYXIUHSZNHMAS-UHFFFAOYSA-N
DM5DSGJ IU ethyl 6-acetylpyridine-2-carboxylate
DM5DSGJ CA CAS 114578-70-0
DM5DSGJ DE Hypercholesterolaemia
DM9FXU7 ID DM9FXU7
DM9FXU7 DN MDL-27192
DM9FXU7 HS Phase 2
DM9FXU7 SN 3-(4-Chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one; 5-(4-Chlorophenyl)-4-ethyl-3,4-dihydro-2H-1,2,4-triazol-3-one
DM9FXU7 PC 35793
DM9FXU7 MW 223.66
DM9FXU7 FM C10H10ClN3O
DM9FXU7 IC InChI=1S/C10H10ClN3O/c1-2-14-9(12-13-10(14)15)7-3-5-8(11)6-4-7/h3-6H,2H2,1H3,(H,13,15)
DM9FXU7 CS CCN1C(=NNC1=O)C2=CC=C(C=C2)Cl
DM9FXU7 IK PXINDYJACXPZIN-UHFFFAOYSA-N
DM9FXU7 IU 3-(4-chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5-one
DM9FXU7 CA CAS 31409-32-2
DM9FXU7 DE Epileptic seizures
DMCK8SX ID DMCK8SX
DMCK8SX DN MDX-1097
DMCK8SX HS Phase 2
DMCK8SX SN CKap; MKap; K-1-21; Mab therapy, Immune System therapeutics/Medarex; Monoclonal antibody (multiple myeloma, humanized/murine/chimeric), PacMab/Medarex
DMCK8SX CP Immune System Therapeutics Ltd
DMCK8SX DT Antibody
DMCK8SX DE Haematological malignancy
DM0EZWI ID DM0EZWI
DM0EZWI DN MDX-1100
DM0EZWI HS Phase 2
DM0EZWI CP Medarex
DM0EZWI DT Antibody
DM0EZWI DE Crohn disease
DMKMSC4 ID DMKMSC4
DMKMSC4 DN MDX-1342
DMKMSC4 HS Phase 2
DMKMSC4 SN Anti-CD19 (cancer), MDX/BMS; Anti-CD19 antibody (cancer), Medarex/BMS
DMKMSC4 CP Medarex
DMKMSC4 DT Antibody
DMKMSC4 DE leukaemia
DMO84TL ID DMO84TL
DMO84TL DN ME-3407
DMO84TL HS Phase 2
DMO84TL SN EF-4040; 2-(Butoxycarbonylmethylsulfinyl)thiazolo[5,4-b]pyridine; 2-(Thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetic acid butyl ester
DMO84TL DT Small molecular drug
DMO84TL PC 6918179
DMO84TL MW 298.4
DMO84TL FM C12H14N2O3S2
DMO84TL IC InChI=1S/C12H14N2O3S2/c1-2-3-7-17-10(15)8-19(16)12-14-9-5-4-6-13-11(9)18-12/h4-6H,2-3,7-8H2,1H3
DMO84TL CS CCCCOC(=O)CS(=O)C1=NC2=C(S1)N=CC=C2
DMO84TL IK BUXNKFNNJJTLOS-UHFFFAOYSA-N
DMO84TL IU butyl 2-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetate
DMO84TL DE Duodenal ulcer
DMX9Y7V ID DMX9Y7V
DMX9Y7V DN MEDETOMIDINE
DMX9Y7V HS Phase 2
DMX9Y7V DT Small molecular drug
DMX9Y7V PC 68602
DMX9Y7V MW 200.28
DMX9Y7V FM C13H16N2
DMX9Y7V IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
DMX9Y7V CS CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C
DMX9Y7V IK CUHVIMMYOGQXCV-UHFFFAOYSA-N
DMX9Y7V IU 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DMX9Y7V CA CAS 86347-14-0
DMX9Y7V CB CHEBI:48552
DMX9Y7V DE Pain
DMSV60C ID DMSV60C
DMSV60C DN MEDI0382
DMSV60C HS Phase 2
DMSV60C SN Cotadutide; UNII-QL6A9B13HW; QL6A9B13HW; Cotadutide [INN]; Cotadutide [USAN]; MEDI-0382; MEDI 0382 [WHO-DD]; 1686108-82-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-(gamma-glupalmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp- Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly; Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl
DMSV60C CP MedImmune Gaithersburg, MD
DMSV60C PC 134694273
DMSV60C MW 3728
DMSV60C FM C167H252N42O55
DMSV60C IC InChI=1S/C167H252N42O55/c1-13-14-15-16-17-18-19-20-21-22-23-24-31-47-125(219)186-109(165(263)264)53-58-124(218)175-62-35-34-44-102(189-153(251)116(72-131(228)229)201-161(259)122(83-213)206-164(262)137(92(12)215)209-157(255)114(68-94-40-29-26-30-41-94)202-163(261)136(91(11)214)207-127(221)78-181-142(240)105(52-57-123(169)217)190-158(256)119(80-210)203-141(239)100(168)71-97-76-174-84-182-97)146(244)204-120(81-211)159(257)193-108(56-61-130(226)227)148(246)197-112(69-95-48-50-98(216)51-49-95)151(249)195-111(66-86(4)5)150(248)200-118(74-133(232)233)155(253)205-121(82-212)160(258)192-107(55-60-129(224)225)147(245)188-103(45-36-63-176-166(170)171)143(241)184-89(9)139(237)187-104(46-37-64-177-167(172)173)145(243)199-117(73-132(230)231)154(252)198-113(67-93-38-27-25-28-39-93)156(254)208-135(87(6)7)162(260)185-90(10)140(238)194-115(70-96-75-178-101-43-33-32-42-99(96)101)152(250)196-110(65-85(2)3)149(247)191-106(54-59-128(222)223)144(242)183-88(8)138(236)180-77-126(220)179-79-134(234)235/h25-30,32-33,38-43,48-51,75-76,84-92,100,102-122,135-137,178,210-216H,13-24,31,34-37,44-47,52-74,77-83,168H2,1-12H3,(H2,169,217)(H,174,182)(H,175,218)(H,179,220)(H,180,236)(H,181,240)(H,183,242)(H,184,241)(H,185,260)(H,186,219)(H,187,237)(H,188,245)(H,189,251)(H,190,256)(H,191,247)(H,192,258)(H,193,257)(H,194,238)(H,195,249)(H,196,250)(H,197,246)(H,198,252)(H,199,243)(H,200,248)(H,201,259)(H,202,261)(H,203,239)(H,204,244)(H,205,253)(H,206,262)(H,207,221)(H,208,254)(H,209,255)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,263,264)(H4,170,171,176)(H4,172,173,177)/t88-,89-,90-,91+,92+,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-/m0/s1
DMSV60C CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)N)C(=O)O
DMSV60C IK YEKUUBPJRPXMBM-PTCFZACGSA-N
DMSV60C IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DMSV60C CA CAS 1686108-82-6
DMSV60C DE Type-2 diabetes
DMOXKIC ID DMOXKIC
DMOXKIC DN MEDI3902
DMOXKIC HS Phase 2
DMOXKIC CP AstraZeneca
DMOXKIC DT Antibody
DMOXKIC DE Pseudomonas infection; Ventilator-associated pneumonia
DMDYVN8 ID DMDYVN8
DMDYVN8 DN MEDI-528
DMDYVN8 HS Phase 2
DMDYVN8 CP MedImmune
DMDYVN8 DT Monoclonal antibody
DMDYVN8 DE Asthma
DMPKWR3 ID DMPKWR3
DMPKWR3 DN MEDI-546
DMPKWR3 HS Phase 2
DMPKWR3 CP AstraZeneca
DMPKWR3 DE Ovarian cancer
DMBTVFE ID DMBTVFE
DMBTVFE DN MEDI-551
DMBTVFE HS Phase 2
DMBTVFE CP MedImmune
DMBTVFE DT Antibody
DMBTVFE DE Chronic lymphocytic leukaemia; Encephalopathy; Neuromyelitis optica
DMI9WVM ID DMI9WVM
DMI9WVM DN MEDI-575
DMI9WVM HS Phase 2
DMI9WVM CP MedImmune
DMI9WVM DT Antibody
DMI9WVM DE Glioblastoma multiforme
DMU4CS8 ID DMU4CS8
DMU4CS8 DN MEDI6012
DMU4CS8 HS Phase 2
DMU4CS8 SN RhLCAT; ACP-501
DMU4CS8 DE Acute coronary syndrome; Coronary artery disease
DMGD1YP ID DMGD1YP
DMGD1YP DN MEDI9929
DMGD1YP HS Phase 2
DMGD1YP CP AstraZeneca
DMGD1YP DE Asthma
DM2C1YN ID DM2C1YN
DM2C1YN DN MEGF0444A
DM2C1YN HS Phase 2
DM2C1YN CP Genentech
DM2C1YN DE Non-small-cell lung cancer; Metastatic colorectal cancer
DMHOF7T ID DMHOF7T
DMHOF7T DN MEHD-7945A
DMHOF7T HS Phase 2
DMHOF7T SN RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech
DMHOF7T CP Genentech Inc
DMHOF7T DE Colorectal cancer; Solid tumour/cancer
DMVJ6WS ID DMVJ6WS
DMVJ6WS DN Melogliptin
DMVJ6WS HS Phase 2
DMVJ6WS CP Glenmark pharma
DMVJ6WS PC 11623906
DMVJ6WS MW 320.37
DMVJ6WS FM C15H21FN6O
DMVJ6WS IC InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1
DMVJ6WS CS C1C[C@H](C[C@H]1CN2C=NC=N2)NCC(=O)N3C[C@H](C[C@H]3C#N)F
DMVJ6WS IK JSYGLDMGERSRPC-FQUUOJAGSA-N
DMVJ6WS IU (2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
DMVJ6WS CA CAS 868771-57-7
DMVJ6WS DE Type-2 diabetes
DMPNDYU ID DMPNDYU
DMPNDYU DN MEM-3454
DMPNDYU HS Phase 2
DMPNDYU CP Memory Pharmaceuticals
DMPNDYU DT Small molecular drug
DMPNDYU PC 10380472
DMPNDYU MW 306.79
DMPNDYU FM C15H19ClN4O
DMPNDYU IC InChI=1S/C15H18N4O.ClH/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19;/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18);1H/t13-;/m1./s1
DMPNDYU CS C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43.Cl
DMPNDYU IK CMRLNEYJEPELSM-BTQNPOSSSA-N
DMPNDYU IU N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide;hydrochloride
DMPNDYU CA CAS 677305-02-1
DMPNDYU DE Schizophrenia
DMUMCWS ID DMUMCWS
DMUMCWS DN MEMP1972A
DMUMCWS HS Phase 2
DMUMCWS SN RG7449
DMUMCWS CP Genentech
DMUMCWS DE Allergic rhinitis; Asthma
DMIVR9K ID DMIVR9K
DMIVR9K DN MER-3001
DMIVR9K HS Phase 2
DMIVR9K SN Insulin B chain therapeutics (type 1 diabetes), Mercia Pharma/Joslin Diabetes Center
DMIVR9K CP Mercia Pharma Inc
DMIVR9K DE Type-1 diabetes; Type-2 diabetes
DM89QXT ID DM89QXT
DM89QXT DN MET409
DM89QXT HS Phase 2
DM89QXT CP Metacrine
DM89QXT DT Small molecular drug
DM89QXT DE Non-alcoholic steatohepatitis
DMNST69 ID DMNST69
DMNST69 DN Metaiodobenzylguanidine I-131
DMNST69 HS Phase 2
DMNST69 SN Azedra (TN)
DMNST69 CP Molecular Insights Pharmaceuticals
DMNST69 DT Small molecular drug
DMNST69 PC 71184
DMNST69 MW 279.09
DMNST69 FM C8H10IN3
DMNST69 IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9+4
DMNST69 CS C1=CC(=CC(=C1)[131I])CN=C(N)N
DMNST69 IK PDWUPXJEEYOOTR-JRGAVVOBSA-N
DMNST69 IU 2-[(3-(131I)iodanylphenyl)methyl]guanidine
DMNST69 CA CAS 77679-27-7
DMNST69 CB CHEBI:135997
DMNST69 DE Neuroblastoma; Neuroendocrine cancer; Pheochromocytoma
DMSZFTP ID DMSZFTP
DMSZFTP DN Met-enkephalin
DMSZFTP HS Phase 2
DMSZFTP SN MET-enkephalin; H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic
DMSZFTP DT Small molecular drug
DMSZFTP PC 443363
DMSZFTP MW 573.7
DMSZFTP FM C27H35N5O7S
DMSZFTP IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1
DMSZFTP CS CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMSZFTP IK YFGBQHOOROIVKG-FKBYEOEOSA-N
DMSZFTP IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMSZFTP CA CAS 58569-55-4
DMSZFTP CB CHEBI:6618
DMSZFTP DE Pain
DMS7FRI ID DMS7FRI
DMS7FRI DN Methanesulfonyl fluoride
DMS7FRI HS Phase 2
DMS7FRI SN Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)
DMS7FRI CP University of Texas
DMS7FRI DT Small molecular drug
DMS7FRI PC 11207
DMS7FRI MW 98.1
DMS7FRI FM CH3FO2S
DMS7FRI IC InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
DMS7FRI CS CS(=O)(=O)F
DMS7FRI IK KNWQLFOXPQZGPX-UHFFFAOYSA-N
DMS7FRI IU methanesulfonyl fluoride
DMS7FRI CA CAS 558-25-8
DMS7FRI DE Alzheimer disease
DMHSL87 ID DMHSL87
DMHSL87 DN Methoxyestradiol
DMHSL87 HS Phase 2
DMHSL87 SN SCHEMBL18733359; CHEMBL1473145; HMS3229K11
DMHSL87 DT Small molecular drug
DMHSL87 PC 129631909
DMHSL87 MW 302.4
DMHSL87 FM C19H26O3
DMHSL87 IC InChI=1S/C19H26O3/c1-19-8-7-14-13(15(19)5-6-17(19)21)4-3-11-9-12(20)10-16(22-2)18(11)14/h9-10,13-15,17,20-21H,3-8H2,1-2H3/t13-,14-,15-,17-,19-/m0/s1
DMHSL87 CS C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2O)CCC4=C3C(=CC(=C4)O)OC
DMHSL87 IK PJCUYTOXKIUJSL-SARNLOFESA-N
DMHSL87 IU (8R,9S,13S,14S,17S)-1-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM5GQD7 ID DM5GQD7
DM5GQD7 DN Metoprine
DM5GQD7 HS Phase 2
DM5GQD7 SN METOPRINE; Methodichlorophen; DDMP; 7761-45-7; Metoprine [USAN]; BW-197U; TCMDC-123931; NSC-19494; SK 5265; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; U 197; NSC7364; U-197; UNII-2L9RKX796Q; Metoprine (USAN); BW 50-197; METOPRINE, METHODICHLOROPHEN; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; NSC 7364; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; NSC 19494; BW50197; BRN 0223622; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892; DDMP; BW 197 U; BW 1970; BW 197U; BW 50197; BW 50,197; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; Chloroaniline 1
DM5GQD7 CP Werkheiser
DM5GQD7 DT Small molecular drug
DM5GQD7 PC 24466
DM5GQD7 MW 269.13
DM5GQD7 FM C11H10Cl2N4
DM5GQD7 IC InChI=1S/C11H10Cl2N4/c1-5-9(10(14)17-11(15)16-5)6-2-3-7(12)8(13)4-6/h2-4H,1H3,(H4,14,15,16,17)
DM5GQD7 CS CC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)Cl)Cl
DM5GQD7 IK VQJHOPSWBGJHQS-UHFFFAOYSA-N
DM5GQD7 IU 5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine
DM5GQD7 CA CAS 7761-45-7
DM5GQD7 DE Advanced cancer
DMIXT2Y ID DMIXT2Y
DMIXT2Y DN MGAH22
DMIXT2Y HS Phase 2
DMIXT2Y CP MacroGenics
DMIXT2Y DE Solid tumour/cancer
DMPBTVK ID DMPBTVK
DMPBTVK DN MGB-BP-3
DMPBTVK HS Phase 2
DMPBTVK SN 1000277-08-6; MGB-BP3; UNII-532PWU9738; 532PWU9738; J2.725.402K; (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide; 4-((4-(4-((E)-2-(3-Quinolyl)vinyl)benzoylamino)-1-methyl-1H-pyrrole-2-yl)carbonylamino)-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 4-[[4-[4-[(E)-2-(3-Quinolyl)vinyl]benzoylamino]-1-methyl-1H-pyrrole-2-yl]carbonylamino]-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; CHEMBL236345; SCHEMBL2398755; GTPL10996; HY-U00035; ZINC28864451; CS-6785; DB12892; SB19161; compound 50 [PMID: 17960927]; Q27261055; 1H-Pyrrole-2-carboxamide, 1-methyl-N-(1-methyl-5-(((2-(4-morpholinyl)ethyl)amino)carbonyl)-1H-pyrrol-3-yl)-4-((4-((1E)-2-(3-quinolinyl)ethenyl)benzoyl)amino)-
DMPBTVK CP MGB Biopharma
DMPBTVK DT Small molecular drug
DMPBTVK PC 23730143
DMPBTVK MW 631.7
DMPBTVK FM C36H37N7O4
DMPBTVK IC InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
DMPBTVK CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5
DMPBTVK IK OEKXCVYZBVOWBR-BQYQJAHWSA-N
DMPBTVK IU 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide
DMPBTVK CA CAS 1000277-08-6
DMPBTVK DE Clostridium infection
DM726HX ID DM726HX
DM726HX DN MGCD-0103
DM726HX HS Phase 2
DM726HX SN Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
DM726HX CP MethylGene Inc
DM726HX TC Anticancer Agents
DM726HX DT Small molecular drug
DM726HX PC 9865515
DM726HX MW 396.4
DM726HX FM C23H20N6O
DM726HX IC InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
DM726HX CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
DM726HX IK HRNLUBSXIHFDHP-UHFFFAOYSA-N
DM726HX IU N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
DM726HX CA CAS 726169-73-9
DM726HX CB CHEBI:94525
DM726HX DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Melanoma; Non-small-cell lung cancer
DMRPCF2 ID DMRPCF2
DMRPCF2 DN MGCD265
DMRPCF2 HS Phase 2
DMRPCF2 SN MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
DMRPCF2 CP MethylGene
DMRPCF2 DT Small molecular drug
DMRPCF2 PC 24901704
DMRPCF2 MW 517.6
DMRPCF2 FM C26H20FN5O2S2
DMRPCF2 IC InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
DMRPCF2 CS CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F
DMRPCF2 IK UFICVEHDQUKCEA-UHFFFAOYSA-N
DMRPCF2 IU N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide
DMRPCF2 CA CAS 875337-44-3
DMRPCF2 CB CHEBI:91393
DMRPCF2 DE Non-small-cell lung cancer; Solid tumour/cancer
DMRSK2I ID DMRSK2I
DMRSK2I DN MGCD290
DMRSK2I HS Phase 2
DMRSK2I CP Mirati Therapeutics
DMRSK2I DT Small molecular drug
DMRSK2I DE Vulvovaginal Candidiasis
DMNYPW7 ID DMNYPW7
DMNYPW7 DN MGI-114
DMNYPW7 HS Phase 2
DMNYPW7 SN Irofulven; Irofulven [USAN:INN]; MGI 114; MGI-114; (R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5H)inden)-7'(6'H)-one; (R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'H)-one; 158440-71-2; 6-(Hydroxymethyl)acylfulvene; 6-Hydroxymethylacylfulvene; 6B799IH05A; Acylfulvene, 6-(hydroxymethyl)-; HMAF; NSC 683863; NSC-683863; Spiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (R)-; UNII-6B799IH05A
DMNYPW7 PC 148189
DMNYPW7 MW 246.3
DMNYPW7 FM C15H18O3
DMNYPW7 IC NICJCIQSJJKZAH-AWEZNQCLSA-N
DMNYPW7 CS CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO
DMNYPW7 IK 1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DMNYPW7 IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DMNYPW7 CA CAS 158440-71-2
DMNYPW7 CB CHEBI:135002
DMNYPW7 DE Lung cancer
DM1HC9R ID DM1HC9R
DM1HC9R DN MGL-3196
DM1HC9R HS Phase 2
DM1HC9R CP Madrigal pharmaceuticals
DM1HC9R PC 15981237
DM1HC9R MW 435.2
DM1HC9R FM C17H12Cl2N6O4
DM1HC9R IC InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
DM1HC9R CS CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
DM1HC9R IK FDBYIYFVSAHJLY-UHFFFAOYSA-N
DM1HC9R IU 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
DM1HC9R CA CAS 920509-32-6
DM1HC9R DE Hyperlipidaemia; Familial hypercholesterolemia; Hypercholesterolaemia
DME5CSV ID DME5CSV
DME5CSV DN Mibampator
DME5CSV HS Phase 2
DME5CSV SN LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly
DME5CSV CP Eli Lilly & Co
DME5CSV DT Small molecular drug
DME5CSV PC 9889366
DME5CSV MW 438.6
DME5CSV FM C21H30N2O4S2
DME5CSV IC InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1
DME5CSV CS C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C
DME5CSV IK ULRDYYKSPCRXAJ-KRWDZBQOSA-N
DME5CSV IU N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide
DME5CSV CA CAS 375345-95-2
DME5CSV DE Alzheimer disease
DMGCRKY ID DMGCRKY
DMGCRKY DN Midismase
DMGCRKY HS Phase 2
DMGCRKY SN PC-01; SI-3501; PC-SOD (intravenous), LTT; Lecithin-bound superoxide dismutase (ulcerative colitis), LTT Bio-Pharma
DMGCRKY CP Asahi Glass Co Ltd
DMGCRKY DE Cerebral infarction
DMN45RI ID DMN45RI
DMN45RI DN MIJ821
DMN45RI HS Phase 2
DMN45RI SN CAD 9271
DMN45RI CP Novartis; Cadent Therapeutics
DMN45RI DE Major depressive disorder
DM50Z4U ID DM50Z4U
DM50Z4U DN Milataxel
DM50Z4U HS Phase 2
DM50Z4U SN M-10; MAC-321; Milataxel (oral); TL-00139; TL-139; Milataxel (oral), Taxolog; MAC-321 (injectable), Taxolog/Wyeth; MAC-321 (oral), Taxolog/Wyeth; TL-00139 (injectable), Taxolog/Wyeth; TL-00139 (oral), Taxolog/Wyeth; TL-139 (injectable), Taxolog/Wyeth; TL-139 (oral), Taxolog/Wyeth
DM50Z4U CP Taxolog Inc
DM50Z4U DT Small molecular drug
DM50Z4U PC 6918589
DM50Z4U MW 853.9
DM50Z4U FM C44H55NO16
DM50Z4U IC InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1
DM50Z4U CS CCC(=O)O[C@H]1C[C@@H]2[C@@](CO2)([C@@H]3[C@@]1(C(=O)[C@@H](C4=C([C@H](C[C@@]([C@H]3OC(=O)C5=CC=CC=C5)(C4(C)C)O)OC(=O)[C@@H]([C@H](C6=CC=CO6)NC(=O)OC(C)(C)C)O)C)O)C)OC(=O)C
DM50Z4U IK XIVMHSNIQAICTR-UQYHODNASA-N
DM50Z4U IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3R)-3-(furan-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]oxy-1,12-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-propanoyloxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DM50Z4U CA CAS 352425-37-7
DM50Z4U DE Solid tumour/cancer
DMSLIW6 ID DMSLIW6
DMSLIW6 DN MIN-117
DMSLIW6 HS Phase 2
DMSLIW6 CP Minerva neurosciences
DMSLIW6 PC 74424169
DMSLIW6 MW 538.8
DMSLIW6 FM C25H26Cl3N3O4
DMSLIW6 IC InChI=1S/C25H25Cl2N3O4.ClH/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17;/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3;1H
DMSLIW6 CS CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OCC(CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O.Cl
DMSLIW6 IK HRNDUKHBCUTNAL-UHFFFAOYSA-N
DMSLIW6 IU 1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride
DMSLIW6 DE Major depressive disorder
DMZFW8V ID DMZFW8V
DMZFW8V DN MIN-202
DMZFW8V HS Phase 2
DMZFW8V SN Seltorexant; 1293281-49-8; Seltorexant [USAN]; SCHEMBL1671257; GTPL9308; CHEMBL3597971; JNJ-922; SQOCEMCKYDVLMM-UHFFFAOYSA-N; BDBM118454; Methanone, (5-(4,6-dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)-; AKOS032954213; US8653263, 107; [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone; ((3aR,6aS)-5-(4,6-dimethylpyrimidin- 2-yl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2
DMZFW8V CP Minerva Neurosciences Waltham, MA
DMZFW8V PC 67116280
DMZFW8V MW 407.4
DMZFW8V FM C21H22FN7O
DMZFW8V IC InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3
DMZFW8V CS CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C
DMZFW8V IK SQOCEMCKYDVLMM-UHFFFAOYSA-N
DMZFW8V IU [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone
DMZFW8V CA CAS 1293281-49-8
DMZFW8V DE Major depressive disorder
DMWJMFZ ID DMWJMFZ
DMWJMFZ DN Miravirsen
DMWJMFZ HS Phase 2
DMWJMFZ SN Miravirsen; Miravirsen [INN]; SPC3649 Parent Acid; UNII-Q083AJW7VS; Q083AJW7VS; 1072874-90-8; RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C)
DMWJMFZ CP Santaris Pharma A/S
DMWJMFZ DT Small molecular drug
DMWJMFZ PC 56843415
DMWJMFZ MW 4897
DMWJMFZ FM C151H185N49O83P14S14
DMWJMFZ IC InChI=1S/C151H185N49O83P14S14/c1-60-26-193(140(215)182-119(60)203)87-21-66(74(258-87)34-245-290(225,304)281-110-102-130(199-58-171-94-114(161)165-55-168-117(94)199)268-150(110,44-239-102)50-252-291(226,305)272-65-20-86(187-13-6-79(153)174-134(187)209)256-72(65)33-243-286(221,300)277-105-97-125(262-144(105,37-201)38-234-97)189-15-8-81(155)176-136(189)211)271-285(220,299)241-30-73-67(22-88(257-73)194-27-61(2)120(204)183-141(194)216)273-293(228,307)253-51-151-45-240-103(131(269-151)200-59-172-95-118(200)180-132(162)181-123(95)207)111(151)283-297(232,311)254-52-149-43-238-101(129(267-149)196-29-63(4)122(206)185-143(196)218)109(149)280-289(224,303)244-32-71-64(19-85(255-71)186-12-5-78(152)173-133(186)208)270-284(219,298)242-31-76-69(24-90(260-76)197-56-169-92-112(159)163-53-166-115(92)197)275-294(229,308)249-47-147-41-236-99(127(265-147)191-17-10-83(157)178-138(191)213)107(147)279-288(223,302)247-36-77-70(25-91(261-77)198-57-170-93-113(160)164-54-167-116(93)198)276-295(230,309)250-48-146-40-235-98(126(264-146)190-16-9-82(156)177-137(190)212)106(146)278-287(222,301)246-35-75-68(23-89(259-75)195-28-62(3)121(205)184-142(195)217)274-292(227,306)251-49-148-42-237-100(128(266-148)192-18-11-84(158)179-139(192)214)108(148)282-296(231,310)248-46-145-39-233-96(104(145)202)124(263-145)188-14-7-80(154)175-135(188)210/h5-18,26-29,53-59,64-77,85-91,96-111,124-131,201-202H,19-25,30-52H2,1-4H3,(H,219,298)(H,220,299)(H,221,300)(H,222,301)(H,223,302)(H,224,303)(H,225,304)(H,226,305)(H,227,306)(H,228,307)(H,229,308)(H,230,309)(H,231,310)(H,232,311)(H2,152,173,208)(H2,153,174,209)(H2,154,175,210)(H2,155,176,211)(H2,156,177,212)(H2,157,178,213)(H2,158,179,214)(H2,159,163,166)(H2,160,164,167)(H2,161,165,168)(H,182,203,215)(H,183,204,216)(H,184,205,217)(H,185,206,218)(H3,162,180,181,207)
DMWJMFZ CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3C4C(OC3(CO4)COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6C7C(OC6(CO7)CO)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC4=C(N=CN=C41)N)OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=NC5=C(N=CN=C51)N)OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC16COC(C1OP(=S)(O)OCC17COC(C1O)C(O7)N1C=CC(=NC1=O)N)C(O6)N1C=CC(=NC1=O)N)C(O5)N1C=CC(=NC1=O)N)C(O4)N1C=CC(=NC1=O)N)C(O3)N1C=C(C(=O)NC1=O)C)C(O2)N1C=NC2=C1N=C(NC2=O)N
DMWJMFZ IK OSOOBMBDIGGTCP-UHFFFAOYSA-N
DMWJMFZ IU 1-[4-[[3-[[3-(2-amino-6-oxo-1H-purin-9-yl)-7-[[7-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-3-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[1-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[3-(4-amino-2-oxopyrimidin-1-yl)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-3-(6-aminopurin-9-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMWJMFZ CA CAS 1072874-90-8
DMWJMFZ DE Hepatitis C virus infection
DM7K4YR ID DM7K4YR
DM7K4YR DN MIS-416
DM7K4YR HS Phase 2
DM7K4YR SN Microparticle adjuvant (anthrax), Virionyx; Microparticle adjuvant (iv, autoimmune disease/cancer/anthrax), Innate Therapeutics
DM7K4YR CP Innate Therapeutics Ltd
DM7K4YR DE Bacillus anthracis infection; Autoimmune diabetes
DMOJ7QA ID DMOJ7QA
DMOJ7QA DN Mitemcinal fumarate
DMOJ7QA HS Phase 2
DMOJ7QA SN (2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA CP Roche
DMOJ7QA DT Small molecular drug
DMOJ7QA PC 11513721
DMOJ7QA MW 1628
DMOJ7QA FM C84H142N2O28
DMOJ7QA IC InChI=1S/2C40H69NO12.C4H4O4/c2*1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29;5-3(6)1-2-4(7)8/h2*20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-;/m11./s1
DMOJ7QA CS CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.C(=C/C(=O)O)\\C(=O)O
DMOJ7QA IK KQRXEQGYUDDPNW-QXRSSOOUSA-N
DMOJ7QA IU (E)-but-2-enedioic acid;(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA CA CAS 154802-96-7
DMOJ7QA DE Pain
DMIRPSA ID DMIRPSA
DMIRPSA DN Mitoglitazone
DMIRPSA HS Phase 2
DMIRPSA SN MSDC-0160; Mitoglitazone (TN)
DMIRPSA CP Metabolic Solutions Development
DMIRPSA DT Small molecular drug
DMIRPSA PC 10429242
DMIRPSA MW 370.4
DMIRPSA FM C19H18N2O4S
DMIRPSA IC InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
DMIRPSA CS CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMIRPSA IK IRNJSRAGRIZIHD-UHFFFAOYSA-N
DMIRPSA IU 5-[[4-[2-(5-ethylpyridin-2-yl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMIRPSA CA CAS 146062-49-9
DMIRPSA CB CHEBI:94409
DMIRPSA DE Type-2 diabetes; Alzheimer disease
DMKPZ0Q ID DMKPZ0Q
DMKPZ0Q DN Mitoquinone
DMKPZ0Q HS Phase 2
DMKPZ0Q SN mitoquinone; Mitoquinone cation; 444890-41-9; UNII-47BYS17IY0; 47BYS17IY0; MitoQ; 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium; Mito-Q; Mitoquinone ion; MitoQ; MitoQ10; CHEMBL1229093; SCHEMBL12135674; EX-A926; BCP19134; HY-100116; CS-0018095; A17092; Q27259044; (10-(2,5-Dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl)triphenyl phosphonium
DMKPZ0Q DT Small molecular drug
DMKPZ0Q PC 11388332
DMKPZ0Q MW 583.7
DMKPZ0Q FM C37H44O4P+
DMKPZ0Q IC InChI=1S/C37H44O4P/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3/q+1
DMKPZ0Q CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMKPZ0Q IK OIIMUKXVVLRCAF-UHFFFAOYSA-N
DMKPZ0Q IU 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium
DMKPZ0Q CA CAS 444890-41-9
DMKPZ0Q DE Hepatitis C virus infection
DM2NF6X ID DM2NF6X
DM2NF6X DN MIV-210
DM2NF6X HS Phase 2
DM2NF6X CP Medivir; Daewoong
DM2NF6X DT Small molecular drug
DM2NF6X PC 135431817
DM2NF6X MW 269.23
DM2NF6X FM C10H12FN5O3
DM2NF6X IC InChI=1S/C10H12FN5O3/c11-4-1-6(19-5(4)2-17)16-3-13-7-8(16)14-10(12)15-9(7)18/h3-6,17H,1-2H2,(H3,12,14,15,18)/t4-,5+,6+/m0/s1
DM2NF6X CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)CO)F
DM2NF6X IK RTJUXLYUUDBAJN-KVQBGUIXSA-N
DM2NF6X IU 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM2NF6X CA CAS 92562-88-4
DM2NF6X DE Hepatitis B virus infection
DMWFTRJ ID DMWFTRJ
DMWFTRJ DN MK-0354
DMWFTRJ HS Phase 2
DMWFTRJ SN MK-0354; 851776-28-8; UNII-4U62D8JYIQ; 4U62D8JYIQ; CHEMBL456145; 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole; 1,4,5,6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; LTQYSJKGRPGMPO-UHFFFAOYSA-N; SCHEMBL1875705; GTPL5784; MolPort-009-683-033; 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)Cyclopentapyrazole; BCP18112; ZINC38312374; BDBM50273099; AKOS030526928; MK 0354; CS-4589
DMWFTRJ DT Small molecular drug
DMWFTRJ PC 11159621
DMWFTRJ MW 176.18
DMWFTRJ FM C7H8N6
DMWFTRJ IC InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13)
DMWFTRJ CS C1CC2=C(C1)NN=C2C3=NNN=N3
DMWFTRJ IK LTQYSJKGRPGMPO-UHFFFAOYSA-N
DMWFTRJ IU 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole
DMWFTRJ CA CAS 851776-28-8
DMLTAES ID DMLTAES
DMLTAES DN MK-0752
DMLTAES HS Phase 2
DMLTAES SN MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635
DMLTAES CP Merck
DMLTAES DT Small molecular drug
DMLTAES PC 9803433
DMLTAES MW 442.9
DMLTAES FM C21H21ClF2O4S
DMLTAES IC InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)
DMLTAES CS C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl
DMLTAES IK XCGJIFAKUZNNOR-UHFFFAOYSA-N
DMLTAES IU 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid
DMLTAES CA CAS 471905-41-6
DMLTAES DE Alzheimer disease
DM2CJB4 ID DM2CJB4
DM2CJB4 DN MK-0773
DM2CJB4 HS Phase 2
DM2CJB4 SN C-8500; MK-773
DM2CJB4 CP Merck & Co Inc
DM2CJB4 DT Small molecular drug
DM2CJB4 PC 11950726
DM2CJB4 MW 479.6
DM2CJB4 FM C27H34FN5O2
DM2CJB4 IC InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1
DM2CJB4 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NCC4=NC5=C(N4)C=CC=N5)CC[C@@H]6[C@@]3(C=C(C(=O)N6C)F)C
DM2CJB4 IK GBEUKTWTUSPHEE-JWJWXJQQSA-N
DM2CJB4 IU (1S,3aS,3bS,5aR,9aS,9bS,11aS)-8-fluoro-N-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DM2CJB4 CA CAS 606101-58-0
DM2CJB4 DE Osteoporosis
DMRT8K4 ID DMRT8K4
DMRT8K4 DN MK-0812
DMRT8K4 HS Phase 2
DMRT8K4 SN C-6448; MK-812; CCR2 antagonist (rheumatoid arthritis/multiple sclerosis), Merck
DMRT8K4 CP Merck & Co Inc
DMRT8K4 DT Small molecular drug
DMRT8K4 PC 11180808
DMRT8K4 MW 469.5
DMRT8K4 FM C24H34F3N3O3
DMRT8K4 IC InChI=1S/C24H34F3N3O3/c1-15(2)23(7-4-18(11-23)29-20-6-9-33-14-21(20)32-3)22(31)30-8-5-19-16(13-30)10-17(12-28-19)24(25,26)27/h10,12,15,18,20-21,29H,4-9,11,13-14H2,1-3H3/t18-,20+,21-,23+/m1/s1
DMRT8K4 CS CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F
DMRT8K4 IK MTMDXAIUENDNDL-RJSMDTJLSA-N
DMRT8K4 IU [(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone
DMRT8K4 CA CAS 624733-88-6
DMRT8K4 DE Multiple sclerosis
DM0568C ID DM0568C
DM0568C DN MK-0873
DM0568C HS Phase 2
DM0568C SN MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co
DM0568C CP Merck & Co Inc
DM0568C DT Small molecular drug
DM0568C PC 9919680
DM0568C MW 422.4
DM0568C FM C25H18N4O3
DM0568C IC InChI=1S/C25H18N4O3/c30-23-21-7-2-12-26-24(21)29(16-22(23)25(31)27-19-10-11-19)20-6-1-4-17(14-20)8-9-18-5-3-13-28(32)15-18/h1-7,12-16,19H,10-11H2,(H,27,31)
DM0568C CS C1CC1NC(=O)C2=CN(C3=C(C2=O)C=CC=N3)C4=CC=CC(=C4)C#CC5=C[N+](=CC=C5)[O-]
DM0568C IK JJWKQXNHYDJXKF-UHFFFAOYSA-N
DM0568C IU N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide
DM0568C CA CAS 500355-52-2
DM0568C DE Psoriasis vulgaris
DM8ZTW7 ID DM8ZTW7
DM8ZTW7 DN MK-1029
DM8ZTW7 HS Phase 2
DM8ZTW7 DE Asthma
DMEDITW ID DMEDITW
DMEDITW DN MK-1454
DMEDITW HS Phase 2
DMEDITW CP Merck
DMEDITW DE Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom
DM3WDZ5 ID DM3WDZ5
DM3WDZ5 DN MK-1775
DM3WDZ5 HS Phase 2
DM3WDZ5 SN MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
DM3WDZ5 CP Merck
DM3WDZ5 DT Small molecular drug
DM3WDZ5 PC 24856436
DM3WDZ5 MW 500.6
DM3WDZ5 FM C27H32N8O2
DM3WDZ5 IC InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
DM3WDZ5 CS CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
DM3WDZ5 IK BKWJAKQVGHWELA-UHFFFAOYSA-N
DM3WDZ5 IU 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
DM3WDZ5 CA CAS 955365-80-7
DM3WDZ5 CB CHEBI:91414
DM3WDZ5 DE Ovarian cancer; Solid tumour/cancer
DMVJB09 ID DMVJB09
DMVJB09 DN MK-1903
DMVJB09 HS Phase 2
DMVJB09 SN Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co
DMVJB09 CP Arena Pharmaceuticals Inc
DMVJB09 DT Small molecular drug
DMVJB09 PC 49763030
DMVJB09 MW 164.16
DMVJB09 FM C8H8N2O2
DMVJB09 IC InChI=1S/C8H8N2O2/c11-8(12)7-5-2-3-1-4(3)6(5)9-10-7/h3-4H,1-2H2,(H,9,10)(H,11,12)/t3-,4-/m1/s1
DMVJB09 CS C1[C@H]2[C@@H]1C3=C(C2)C(=NN3)C(=O)O
DMVJB09 IK CUTZNERBKDMLAP-QWWZWVQMSA-N
DMVJB09 IU (2R,4R)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxylic acid
DMVJB09 CA CAS 1268882-43-4
DMVJB09 DE Arteriosclerosis
DMT1OZ6 ID DMT1OZ6
DMT1OZ6 DN MK-2206
DMT1OZ6 HS Phase 2
DMT1OZ6 SN MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
DMT1OZ6 CP Merck
DMT1OZ6 DT Small molecular drug
DMT1OZ6 PC 24964624
DMT1OZ6 MW 407.5
DMT1OZ6 FM C25H21N5O
DMT1OZ6 IC InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
DMT1OZ6 CS C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N
DMT1OZ6 IK ULDXWLCXEDXJGE-UHFFFAOYSA-N
DMT1OZ6 IU 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
DMT1OZ6 CA CAS 1032349-93-1
DMT1OZ6 CB CHEBI:67271
DMT1OZ6 DE Rectal adenocarcinoma; Nasopharyngeal carcinoma
DM1M57I ID DM1M57I
DM1M57I DN MK-2578
DM1M57I HS Phase 2
DM1M57I CP Merck Bioventures
DM1M57I DE Anemia
DM6OLGC ID DM6OLGC
DM6OLGC DN MK-3207
DM6OLGC HS Phase 2
DM6OLGC SN 957116-20-0; MK-3207 Hydrochloride; MK-3207 (Hydrochloride); MK-3207 HCl; MK-3207 HCl salt; 2-((R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-Pyrrolo[2,3-b]pyridin]-5-yl)acetamide hydrochloride; MK3207; (8R)-8-(3,5-Difluorophenyl)-10-oxo-n-[(2r)-1,1',2',3-tetrahydro-2'-oxospiro[2h-indene-2,3'-[3h]pyrrolo[2,3-b]pyridin]-5-yl]-6,9-diazaspiro[4.5]decane-9-acetamide hydrochloride; MK 3207 hydrochloride; MK-3207(Hydrochloride); MK3207 HCl
DM6OLGC CP Merck & Co Inc
DM6OLGC DT Small molecular drug
DM6OLGC PC 25019940
DM6OLGC MW 557.6
DM6OLGC FM C31H29F2N5O3
DM6OLGC IC InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)/t25-,30+/m0/s1
DM6OLGC CS C1CCC2(C1)C(=O)N([C@@H](CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(C[C@@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4
DM6OLGC IK AZAANWYREOQRFB-SETSBSEESA-N
DM6OLGC IU 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
DM6OLGC CA CAS 957118-49-9
DM6OLGC DE Migraine
DM347TQ ID DM347TQ
DM347TQ DN MK-3697
DM347TQ HS Phase 2
DM347TQ CP Merck
DM347TQ PC 46190695
DM347TQ MW 447.5
DM347TQ FM C23H21N5O3S
DM347TQ IC InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)
DM347TQ CS CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4
DM347TQ IK VSOUDUXMPUHJEU-UHFFFAOYSA-N
DM347TQ IU N-[(5,6-dimethoxypyridin-2-yl)methyl]-2-(5-methylpyridin-3-yl)-5-(1,3-thiazol-2-yl)pyridine-4-carboxamide
DM347TQ CA CAS 1224846-01-8
DM347TQ DE Insomnia
DMSPWX6 ID DMSPWX6
DMSPWX6 DN MK-5172
DMSPWX6 HS Phase 2
DMSPWX6 SN UNII-RU4QU6O6X6; 1206524-85-7; RU4QU6O6X6; (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid; 8H-7,10-Methanocyclopropa(18,19)(1,10,3,6)dioxadiazacyclononadecino(11,12-b)quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aR,5S,8S,10R,22aR)-
DMSPWX6 CP Merck
DMSPWX6 DT Small molecular drug
DMSPWX6 PC 46930991
DMSPWX6 MW 554.6
DMSPWX6 FM C29H38N4O7
DMSPWX6 IC InChI=1S/C29H38N4O7/c1-29(2,3)24-26(34)33-15-18(14-22(33)27(35)36)39-25-20(30-19-11-10-17(38-4)13-21(19)31-25)9-7-5-6-8-16-12-23(16)40-28(37)32-24/h10-11,13,16,18,22-24H,5-9,12,14-15H2,1-4H3,(H,32,37)(H,35,36)/t16-,18-,22+,23-,24-/m1/s1
DMSPWX6 CS CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)O)OC3=NC4=C(C=CC(=C4)OC)N=C3CCCCC[C@@H]5C[C@H]5OC(=O)N1
DMSPWX6 IK IVROMYPOGKZNLP-FDOFPDFBSA-N
DMSPWX6 IU (1R,18R,20R,24S,27S)-24-tert-butyl-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxylic acid
DMSPWX6 CA CAS 1206524-85-7
DMSPWX6 DE Hepatitis C virus infection
DMHTIGU ID DMHTIGU
DMHTIGU DN MK-5442
DMHTIGU HS Phase 2
DMHTIGU CP Merck
DMHTIGU PC 46917559
DMHTIGU MW 514
DMHTIGU FM C29H33ClFNO4
DMHTIGU IC InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1
DMHTIGU CS CC1=C(C=CC(=C1)C2=CC=CC=C2[C@@H](C)OC[C@@H](CNC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O
DMHTIGU IK UNFHDRVFEQPUEL-DENIHFKCSA-N
DMHTIGU IU 4-[2-[(1R)-1-[(2R)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid
DMHTIGU CA CAS 787583-71-5
DMHTIGU DE Osteoporosis
DMLMV0O ID DMLMV0O
DMLMV0O DN MK-7655
DMLMV0O HS Phase 2
DMLMV0O SN Relebactam; 1174018-99-5; Relebactam anhydrous; MK-7655; UNII-1OQF7TT3PF; 1OQF7TT3PF; CHEMBL3112741; Sulfuric acid, mono[(1R,2S,5R)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester; Relebactam [INN]; MK7655; MK 7655; (-)-Relebactam anhydrous; BDBM1858; SCHEMBL3721178; EX-A864; SMOBCLHAZXOKDQ-ZJUUUORDSA-N; MolPort-044-723-879; MK-7655A; ZINC43206319; BDBM50447651; AKOS027338697; SB16968; DB12377; CS-5391; Sulfuric acid mono-((2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) est
DMLMV0O CP Merck
DMLMV0O DT Small molecular drug
DMLMV0O PC 44129647
DMLMV0O MW 348.38
DMLMV0O FM C12H20N4O6S
DMLMV0O IC InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
DMLMV0O CS C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
DMLMV0O IK SMOBCLHAZXOKDQ-ZJUUUORDSA-N
DMLMV0O IU [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DMLMV0O CA CAS 1174018-99-5
DMLMV0O DE Bacterial infection
DMG6KXB ID DMG6KXB
DMG6KXB DN MK-8245
DMG6KXB HS Phase 2
DMG6KXB SN MK-8245; 1030612-90-8; MK8245; MK 8245; UNII-537E7QE8LX; 537E7QE8LX; CHEMBL1938870; 5-[3-[4-(2-Bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-2H-tetrazole-2-acetic acid; 2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-;2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-; 2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid; UJEAABFSXKCSGI-UHFFFAOYSA-N; C17H16BrFN6O4; MLS006011144
DMG6KXB DT Small molecular drug
DMG6KXB PC 24988881
DMG6KXB MW 467.2
DMG6KXB FM C17H16BrFN6O4
DMG6KXB IC InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)
DMG6KXB CS C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O
DMG6KXB IK UJEAABFSXKCSGI-UHFFFAOYSA-N
DMG6KXB IU 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid
DMG6KXB CA CAS 1030612-90-8
DMG6KXB DE Type-2 diabetes
DMD6E5W ID DMD6E5W
DMD6E5W DN MK-8342
DMD6E5W HS Phase 2
DMD6E5W CP Merck
DMD6E5W DE Contraception
DMVNAYE ID DMVNAYE
DMVNAYE DN MK-8521
DMVNAYE HS Phase 2
DMVNAYE CP Merck
DMVNAYE DE Type-2 diabetes
DMQHS6B ID DMQHS6B
DMQHS6B DN MK-866
DMQHS6B HS Phase 2
DMQHS6B TC Anticancer Agents
DMQHS6B DE Discovery agent
DMXKOW6 ID DMXKOW6
DMXKOW6 DN MKC-1106-MT
DMXKOW6 HS Phase 2
DMXKOW6 SN Melanoma vaccine (MART-1/tyrosinase), Mannkind
DMXKOW6 CP Colby pharmaceuticals
DMXKOW6 DE Melanoma
DM3I71U ID DM3I71U
DM3I71U DN MKT-077
DM3I71U HS Phase 2
DM3I71U SN FJ-776 (formerly); SDZ-MKT-077; 1-Ethyl-2-[3-ethyl-5-(3-methyl-2,3-dihydrobenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidenemethyl]pyridinium chloride
DM3I71U DT Small molecular drug
DM3I71U PC 6444403
DM3I71U MW 432
DM3I71U FM C21H22ClN3OS2
DM3I71U IC InChI=1S/C21H22N3OS2.ClH/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21;/h6-14H,4-5H2,1-3H3;1H/q+1;/p-1/b21-19+;
DM3I71U CS CCN1/C(=C/C2=CC=CC=[N+]2CC)/S/C(=C/3\\N(C4=CC=CC=C4S3)C)/C1=O.[Cl-]
DM3I71U IK VSKYOTRJSLYFHX-UXJRWBAGSA-M
DM3I71U IU (2Z,5E)-3-ethyl-2-[(1-ethylpyridin-1-ium-2-yl)methylidene]-5-(3-methyl-1,3-benzothiazol-2-ylidene)-1,3-thiazolidin-4-one;chloride
DM3I71U CA CAS 147366-41-4
DM3I71U DE Solid tumour/cancer
DMQSO4L ID DMQSO4L
DMQSO4L DN ML-04
DMQSO4L HS Phase 2
DMQSO4L SN BTL-cg; HP-4; ML-04A; Urological therapeutics, Milkhaus; Human chorionic gonadotropin (benign prostate hyperplasia/prostatitis/cancer), Beech Tree Labs
DMQSO4L CP Milkhaus Laboratory Inc
DMQSO4L DE Myelodysplastic syndrome
DMI4E9K ID DMI4E9K
DMI4E9K DN MLN0264
DMI4E9K HS Phase 2
DMI4E9K CP Millenium; The Takeda oncology company
DMI4E9K DE Gastrointestinal cancer
DM24SOL ID DM24SOL
DM24SOL DN MLN1202
DM24SOL HS Phase 2
DM24SOL SN UNNCHYARSNZOPF-UHFFFAOYSA-L; RFI-641; UNII-FR2W015BG1; FR2W015BG1; WAY-154641; CHEMBL425633; SCHEMBL20741446; RF-1461
DM24SOL CP Novartis & Millenium
DM24SOL DT Small molecular drug
DM24SOL PC 16156223
DM24SOL MW 1683.6
DM24SOL FM C58H60N24Na2O22S6
DM24SOL IC InChI=1S/C58H62N24O22S6.2Na/c59-45(83)23-79(24-46(60)84)105(91,92)37-9-1-5-31(17-37)67-53-73-54(68-32-6-2-10-38(18-32)106(93,94)80(25-47(61)85)26-48(62)86)76-57(75-53)71-35-13-15-41(43(21-35)109(99,100)101)42-16-14-36(22-44(42)110(102,103)104)72-58-77-55(69-33-7-3-11-39(19-33)107(95,96)81(27-49(63)87)28-50(64)88)74-56(78-58)70-34-8-4-12-40(20-34)108(97,98)82(29-51(65)89)30-52(66)90;;/h1-22H,23-30H2,(H2,59,83)(H2,60,84)(H2,61,85)(H2,62,86)(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,90)(H,99,100,101)(H,102,103,104)(H3,67,68,71,73,75,76)(H3,69,70,72,74,77,78);;/q;2*+1/p-2
DM24SOL CS C1=CC(=CC(=C1)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CC(=O)N)CC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CC(=O)N)CC(=O)N.[Na+].[Na+]
DM24SOL IK UNNCHYARSNZOPF-UHFFFAOYSA-L
DM24SOL IU disodium;5-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate
DM24SOL CA CAS 197366-24-8
DM24SOL DE Multiple sclerosis; Metastatic cancer; Respiratory syncytial virus infection
DMBR8NF ID DMBR8NF
DMBR8NF DN MLN2480
DMBR8NF HS Phase 2
DMBR8NF SN VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819
DMBR8NF CP Millennium Pharmaceuticals
DMBR8NF DT Small molecular drug
DMBR8NF PC 25161177
DMBR8NF MW 506.3
DMBR8NF FM C17H12Cl2F3N7O2S
DMBR8NF IC InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1
DMBR8NF CS C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl
DMBR8NF IK VWMJHAFYPMOMGF-ZCFIWIBFSA-N
DMBR8NF IU 2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
DMBR8NF CA CAS 1096708-71-2
DMBR8NF DE Solid tumour/cancer; Melanoma
DMJHVZC ID DMJHVZC
DMJHVZC DN MLN-591RL
DMJHVZC HS Phase 2
DMJHVZC SN HuJ591; J591; MLN-5591RL; MLN-591; ATG-J591:RC; Anti-PSMA, Millennium; Lutetium-177-J591; Yttrium-90-J591; Anti-PSMA, Millennium/BZL Biologics; Lutetium-177-MLN-591; Yttrium-90-MLN-591; 111In-J591; 177Lu-J591; 177Lu-MLN-591; 90Y-J591; 90Y-MLN-591
DMJHVZC CP Millennium Pharmaceuticals
DMJHVZC DT Antibody
DMJHVZC DE Prostate cancer
DMXJWNS ID DMXJWNS
DMXJWNS DN MM-093
DMXJWNS HS Phase 2
DMXJWNS SN ABI-001; Recombinant human alpha fetoprotein (autoimmune diseases), Merrimack; RhAFP (autoimmune diseases), Merrimack; Recombinant human alpha-fetoprotein (autoimmune disease), GTC Biotherapeutics
DMXJWNS CP Merrimack Pharmaceuticals
DMXJWNS SQ >Q4QR90|Q4QR90_RAT Alpha-fetoprotein - Rattus norvegicus (Rat).: MKQPATMKWSASISFLLLLNFAEPRVLHTNEFGIESTLDSSQCPTEKNMFNVATIVVAQFVQDATKAEVNKMSSDALAAMKENTGDGCLENQLSVFLDEICHETELFNKYGFSGCCNQSGVERHQCLLARKKTAPDSVPPFHFPETAESCPAYEENRAMSINTFIYDVSKRNPFLYAPTILYLAAQYDKAVPACCKADNMEECFQTKRASMAKELREGSMLNEHVCAVIRKFGSRNLQAVLIIKLSQKFPKANITEIRKLALDVAHIHEQCCHGNAMECLQDGESVMTHICSQQEILSSKTAECCKLPTIELGYCIIHAENGDKPEGLTLNPSEFLGDRNFAQFSSEEKLLFMASFLHEYSRNHPNLPVSVILKTAKSYQEILEKCSQSETPSKCQDNMEEELQKHIQESQALAKQSCDLYQKLGPYYLQNLFLIGYTRKAPQLTSAELIDLTGKMVSIASMCCQLSEEKRSACGEGLADIYIGHLCLRHEANPVNSGINHCCSSSYSNRRLCITSFLRDETYVPPPFSEDKFIFHKDLCQAQGRALQTMKQELLINLVKQKPEMTEEQHAAVTADFSGLLEKCCKDQDQEACFAKEGPKLISKTREALGV
DMXJWNS DE Autoimmune diabetes
DMO7MBS ID DMO7MBS
DMO7MBS DN MM-111
DMO7MBS HS Phase 2
DMO7MBS CP Merrimack
DMO7MBS DT Monoclonal antibody
DMO7MBS DE Gastric adenocarcinoma; Breast cancer
DMDJRU1 ID DMDJRU1
DMDJRU1 DN MM-121
DMDJRU1 HS Phase 2
DMDJRU1 SN SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis
DMDJRU1 CP Merrimack pharmaceuticals; sanofi us
DMDJRU1 DE Breast cancer; Non-small-cell lung cancer
DM2RJ4D ID DM2RJ4D
DM2RJ4D DN MM-141
DM2RJ4D HS Phase 2
DM2RJ4D DE Solid tumour/cancer; Pancreatic cancer
DM6VPIO ID DM6VPIO
DM6VPIO DN MM36
DM6VPIO HS Phase 2
DM6VPIO SN CHEMBL225555
DM6VPIO CP Medimetriks Pharmaceuticals Fairfield, NJ
DM6VPIO DT Small molecular drug
DM6VPIO PC 57855696
DM6VPIO MW 446.4
DM6VPIO FM C23H24F2N2O5
DM6VPIO IC InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
DM6VPIO CS CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C
DM6VPIO IK VFBILHPIHUPBPZ-UHFFFAOYSA-N
DM6VPIO IU N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
DM6VPIO CA CAS 937782-05-3
DM6VPIO DE Atopic dermatitis
DMBX2RE ID DMBX2RE
DMBX2RE DN MN-221
DMBX2RE HS Phase 2
DMBX2RE SN Bedoradrine
DMBX2RE CP MediciNova
DMBX2RE DT Small molecular drug
DMBX2RE PC 9963056
DMBX2RE MW 955.1
DMBX2RE FM C48H66N4O14S
DMBX2RE IC InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1
DMBX2RE CS CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.OS(=O)(=O)O
DMBX2RE IK VPCOODFYDJWLHD-YMZXMBPUSA-N
DMBX2RE IU 2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid
DMBX2RE CA CAS 194785-31-4
DMBX2RE DE Exacerbation of acute asthma; Aging skin
DMUGN4B ID DMUGN4B
DMUGN4B DN MN-305
DMUGN4B HS Phase 2
DMUGN4B SN Osemozotan hydrochloride; Mkc 242; MCI-242; MKC-242; 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine hydrochloride; 5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
DMUGN4B CP MediciNova
DMUGN4B DT Small molecular drug
DMUGN4B PC 198746
DMUGN4B MW 379.8
DMUGN4B FM C19H22ClNO5
DMUGN4B IC InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
DMUGN4B CS C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl
DMUGN4B IK GGNCUSDIUUCNKE-RSAXXLAASA-N
DMUGN4B IU 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride
DMUGN4B CA CAS 137275-80-0
DMUGN4B DE Mood disorder
DMQA3MV ID DMQA3MV
DMQA3MV DN MNX-100
DMQA3MV HS Phase 2
DMQA3MV CP MetronomX
DMQA3MV DE Solid tumour/cancer; Medulloblastoma
DMGK1JE ID DMGK1JE
DMGK1JE DN MORAb-004
DMGK1JE HS Phase 2
DMGK1JE CP Eisai
DMGK1JE DE Sarcoma; Melanoma; Colorectal cancer; Merkel cell carcinoma
DMCXNIP ID DMCXNIP
DMCXNIP DN MORAb-009
DMCXNIP HS Phase 2
DMCXNIP SN Amatuximab
DMCXNIP CP Eisai
DMCXNIP DT Antibody
DMCXNIP DE Mesothelioma
DMYCITZ ID DMYCITZ
DMYCITZ DN MP-101
DMYCITZ HS Phase 2
DMYCITZ CP Mediti Pharma
DMYCITZ DE Alzheimer disease
DMELUAK ID DMELUAK
DMELUAK DN MP470
DMELUAK HS Phase 2
DMELUAK SN Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)
DMELUAK CP SuperGen
DMELUAK TC Anticancer Agents
DMELUAK DT Small molecular drug
DMELUAK PC 11282283
DMELUAK MW 447.5
DMELUAK FM C23H21N5O3S
DMELUAK IC InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
DMELUAK CS C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6
DMELUAK IK FOFDIMHVKGYHRU-UHFFFAOYSA-N
DMELUAK IU N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide
DMELUAK CA CAS 850879-09-3
DMELUAK CB CHEBI:91389
DMELUAK DE Solid tumour/cancer
DMMRYEK ID DMMRYEK
DMMRYEK DN MPSK3169A
DMMRYEK HS Phase 2
DMMRYEK SN RG7652
DMMRYEK CP Genentech
DMMRYEK DE Metabolic disorder; Cardiovascular disease
DMQR23W ID DMQR23W
DMQR23W DN MRE-0094
DMQR23W HS Phase 2
DMQR23W SN SCHEMBL13010610; MRE 0094
DMQR23W CP Aderis Pharmaceuticals Licensee; King Pharmaceuticals
DMQR23W DT Small molecular drug
DMQR23W PC 9910098
DMQR23W MW 421.8
DMQR23W FM C18H20ClN5O5
DMQR23W IC InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1
DMQR23W CS C1=CC(=CC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)Cl
DMQR23W IK WUCQGGOGHZRELS-LSCFUAHRSA-N
DMQR23W IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMQR23W CA CAS 131865-88-8
DMQR23W DE Diabetic foot ulcer
DMJK8L1 ID DMJK8L1
DMJK8L1 DN MRG002
DMJK8L1 HS Phase 2
DMJK8L1 CP Miracogen
DMJK8L1 DT Antibody drug conjugate
DMJK8L1 DE Urothelial carcinoma
DM9M5WV ID DM9M5WV
DM9M5WV DN MRG-201
DM9M5WV HS Phase 2
DM9M5WV CP miRagen Therapeutics Boulder, CO
DM9M5WV DE Scleroderma; Keloid
DMQZWYE ID DMQZWYE
DMQZWYE DN MRX-4
DMQZWYE HS Phase 2
DMQZWYE SN Non-steroidal multifunctional anti-inflammatory drug (MFAID) (nasal spray, allergic rhinitis), Morria
DMQZWYE CP Morria Biopharmaceuticals plc
DMQZWYE PC 91864617
DMQZWYE MW 530.3
DMQZWYE FM C20H18F3N4O8P
DMQZWYE IC InChI=1S/C20H18F3N4O8P/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32)/t13-/m1/s1
DMQZWYE CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)O
DMQZWYE IK YCRAGJLWFBGKFE-CYBMUJFWSA-N
DMQZWYE IU acetyloxy-N-(1,2-oxazol-3-yl)-N-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]phosphonamidic acid
DMQZWYE CA CAS 1807497-11-5
DMQZWYE DE Allergic rhinitis
DMLVQKF ID DMLVQKF
DMLVQKF DN MRX-6
DMLVQKF HS Phase 2
DMLVQKF SN CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria
DMLVQKF CP Morria Biopharmaceuticals plc
DMLVQKF DE Contact dermatitis
DMH1DYU ID DMH1DYU
DMH1DYU DN MSC1936369B
DMH1DYU HS Phase 2
DMH1DYU SN Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; UNII-6ON9RK82AL; AS 703026; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; 6ON9RK82AL; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; 1204531-26-9; C15H15FIN3O3; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; Pimasertib [USAN:INN]
DMH1DYU CP EMD Serono
DMH1DYU DT Small molecular drug
DMH1DYU PC 44187362
DMH1DYU MW 431.2
DMH1DYU FM C15H15FIN3O3
DMH1DYU IC InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
DMH1DYU CS C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NC[C@@H](CO)O
DMH1DYU IK VIUAUNHCRHHYNE-JTQLQIEISA-N
DMH1DYU IU N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
DMH1DYU CA CAS 1204531-26-9
DMH1DYU CB CHEBI:94793
DMH1DYU DE Colorectal cancer
DMGUI51 ID DMGUI51
DMGUI51 DN MSDC-0602
DMGUI51 HS Phase 2
DMGUI51 SN MSDC-0602; 1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993
DMGUI51 CP Metabolic Solutions Development
DMGUI51 DT Small molecular drug
DMGUI51 PC 25230266
DMGUI51 MW 371.4
DMGUI51 FM C19H17NO5S
DMGUI51 IC InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
DMGUI51 CS COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMGUI51 IK YAUMOGALQJYOJQ-UHFFFAOYSA-N
DMGUI51 IU 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMGUI51 CA CAS 1133819-87-0
DMGUI51 DE Type-2 diabetes
DMUM370 ID DMUM370
DMUM370 DN MSH-1001
DMUM370 HS Phase 2
DMUM370 SN DNB-001; KR-31378; KR-31378); K+ channel activating compounds, Dongbu/KRICT
DMUM370 CP Danube Pharmaceuticals Inc; Korea Research Institute of Chemical Technology
DMUM370 PC 9823724
DMUM370 MW 425.5
DMUM370 FM C22H27N5O4
DMUM370 IC InChI=1S/C22H27N5O4/c1-22(20(29-2)30-3)19(28)18(16-11-15(24)9-10-17(16)31-22)27-21(26-13-23)25-12-14-7-5-4-6-8-14/h4-11,18-20,28H,12,24H2,1-3H3,(H2,25,26,27)/t18-,19+,22+/m1/s1
DMUM370 CS C[C@]1([C@H]([C@@H](C2=C(O1)C=CC(=C2)N)NC(=NCC3=CC=CC=C3)NC#N)O)C(OC)OC
DMUM370 IK OZHUPJHJQIEDFA-DXIQSLLYSA-N
DMUM370 IU 1-[(2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3-hydroxy-2-methyl-3,4-dihydrochromen-4-yl]-2-benzyl-3-cyanoguanidine
DMUM370 DE Ocular hypertension
DMSE9TH ID DMSE9TH
DMSE9TH DN MT-1303
DMSE9TH HS Phase 2
DMSE9TH CP Mitsubishi Tanabe Pharma Corp
DMSE9TH DT Small molecular drug
DMSE9TH PC 67418070
DMSE9TH MW 413.9
DMSE9TH FM C19H31ClF3NO3
DMSE9TH IC InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H
DMSE9TH CS CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl
DMSE9TH IK GEDVJGOVRLHFQG-UHFFFAOYSA-N
DMSE9TH IU 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol;hydrochloride
DMSE9TH CA CAS 942398-84-7
DMSE9TH DE Multiple sclerosis; Crohn disease
DM7I0MT ID DM7I0MT
DM7I0MT DN MT203
DM7I0MT HS Phase 2
DM7I0MT SN Namilumab
DM7I0MT CP National Institute of Allergy and Infectious Diseases (NIAID)
DM7I0MT DT Monoclonal antibody
DM7I0MT DE Plaque psoriasis
DMCNL7Z ID DMCNL7Z
DMCNL7Z DN MT-3724
DMCNL7Z HS Phase 2
DMCNL7Z CP Molecular Templates
DMCNL7Z DT Recombinant?protein
DMCNL7Z DE B-cell chronic lymphocytic leukaemia; B-cell lymphoma; B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMXSZA4 ID DMXSZA4
DMXSZA4 DN MT-3995
DMXSZA4 HS Phase 2
DMXSZA4 CP Mitsubishi tanabe pharma
DMXSZA4 DE Diabetic nephropathy
DM7VG8L ID DM7VG8L
DM7VG8L DN MTC-896
DM7VG8L HS Phase 2
DM7VG8L SN MC-5 antagonists (dermatological disease), Mimetica
DM7VG8L CP Mimetica Pty Ltd
DM7VG8L DE Seborrhea
DMT0K4F ID DMT0K4F
DMT0K4F DN MTR105
DMT0K4F HS Phase 2
DMT0K4F SN UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1
DMT0K4F CP Meditor Pharmaceuticals
DMT0K4F DT Small molecular drug
DMT0K4F PC 210823
DMT0K4F MW 258.279
DMT0K4F FM C7H19N2O4PS
DMT0K4F IC InChI=1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5)
DMT0K4F CS CCOP(=O)(O)OCC.CCSC(=N)N
DMT0K4F IK CSYSULGPHGCBQD-UHFFFAOYSA-N
DMT0K4F IU diethyl hydrogen phosphate;ethyl carbamimidothioate
DMT0K4F CA CAS 21704-46-1
DMT0K4F DE Hypotension
DML7N4B ID DML7N4B
DML7N4B DN MUC1-Poly-ICLC
DML7N4B HS Phase 2
DML7N4B SN Mucin1 peptide vaccine (cancer), University of Pittsburgh
DML7N4B CP University of Pittsburgh
DML7N4B DT Vaccine
DML7N4B DE Colorectal cancer
DMN68ZL ID DMN68ZL
DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL HS Phase 2
DMN68ZL SN Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering
DMN68ZL CP Memorial Sloan-Kettering Cancer Center
DMN68ZL DT Vaccine
DMN68ZL DE Melanoma
DMM6KZR ID DMM6KZR
DMM6KZR DN Mutant ras vaccine
DMM6KZR HS Phase 2
DMM6KZR SN Mutant ras vaccine, NCI; Ras peptide vaccine, NCI; 13 mer ras peptide, NCI
DMM6KZR CP National Cancer Institute
DMM6KZR DT Vaccine
DMM6KZR DE Solid tumour/cancer
DMKDN1C ID DMKDN1C
DMKDN1C DN MVA-85A
DMKDN1C HS Phase 2
DMKDN1C SN AERAS-485; MVA-AG85A; MVA-85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC; MVA-Ag85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC
DMKDN1C CP University of Oxford
DMKDN1C DT Vaccine
DMKDN1C DE Mycobacterium infection
DMDN6FO ID DMDN6FO
DMDN6FO DN MVI-816
DMDN6FO HS Phase 2
DMDN6FO CP Madison vaccines
DMDN6FO DE Prostate cancer
DM25VY8 ID DM25VY8
DM25VY8 DN Mydicar
DM25VY8 HS Phase 2
DM25VY8 SN Mydicar (TN)
DM25VY8 CP Celladon; Targeted Genetics
DM25VY8 DE Heart failure
DMO1XUK ID DMO1XUK
DMO1XUK DN Myeloma cancer vaccine
DMO1XUK HS Phase 2
DMO1XUK CP BioSante Pharmaceuticals
DMO1XUK DT Vaccine
DMO1XUK DE Multiple myeloma
DM9BREJ ID DM9BREJ
DM9BREJ DN MYK-491
DM9BREJ HS Phase 2
DM9BREJ SN Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl-
DM9BREJ CP MyoKardia; Sanofi
DM9BREJ DT Small molecular drug
DM9BREJ PC 122424426
DM9BREJ MW 435.4
DM9BREJ FM C16H20F3N5O4S
DM9BREJ IC InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
DM9BREJ CS C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
DM9BREJ IK NREKKBAMVWQRES-MRXNPFEDSA-N
DM9BREJ IU 4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide
DM9BREJ CA CAS 1970972-74-7
DM9BREJ DE Dilated cardiomyopathy
DMQKSGI ID DMQKSGI
DMQKSGI DN Myo-inositol
DMQKSGI HS Phase 2
DMQKSGI SN Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite
DMQKSGI DT Small molecular drug
DMQKSGI PC 892
DMQKSGI MW 180.16
DMQKSGI FM C6H12O6
DMQKSGI IC InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H
DMQKSGI CS C1(C(C(C(C(C1O)O)O)O)O)O
DMQKSGI IK CDAISMWEOUEBRE-UHFFFAOYSA-N
DMQKSGI IU cyclohexane-1,2,3,4,5,6-hexol
DMQKSGI CA CAS 551-72-4
DMQKSGI CB CHEBI:17268
DMQKSGI DE Alzheimer disease
DMUK6HC ID DMUK6HC
DMUK6HC DN N-5984
DMUK6HC HS Phase 2
DMUK6HC SN N-5984; SCHEMBL364457; XSOXUIXLUNBLJA-RNRVQEDPSA-N; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino)-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino )-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid
DMUK6HC CP Nisshin Kyorin
DMUK6HC DT Small molecular drug
DMUK6HC PC 9865284
DMUK6HC MW 391.8
DMUK6HC FM C20H22ClNO5
DMUK6HC IC InChI=1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1
DMUK6HC CS C[C@H](CC1=CC2=C(C=C1)O[C@H](CO2)C(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O
DMUK6HC IK XSOXUIXLUNBLJA-RNRVQEDPSA-N
DMUK6HC IU (2R)-6-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid
DMUK6HC DE Type-2 diabetes; Obesity
DMN7EUO ID DMN7EUO
DMN7EUO DN N6022
DMN7EUO HS Phase 2
DMN7EUO SN N6022; 1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206
DMN7EUO DT Small molecular drug
DMN7EUO PC 44623946
DMN7EUO MW 414.5
DMN7EUO FM C24H22N4O3
DMN7EUO IC InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30)
DMN7EUO CS CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O
DMN7EUO IK YVPGZQLRPAGKLA-UHFFFAOYSA-N
DMN7EUO IU 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid
DMN7EUO CA CAS 1208315-24-5
DMN7EUO DE Asthma
DM7P0WR ID DM7P0WR
DM7P0WR DN NAI-acne
DM7P0WR HS Phase 2
DM7P0WR CP Vicuron Pharmaceuticals Inc
DM7P0WR DE Acne vulgaris
DMSWUNX ID DMSWUNX
DMSWUNX DN Naratuximab emtansine
DMSWUNX HS Phase 2
DMSWUNX SN DEBIO 1562
DMSWUNX CP Debiopharm
DMSWUNX DT Antibody
DMSWUNX DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMD0E8U ID DMD0E8U
DMD0E8U DN Naveglitazar
DMD0E8U HS Phase 2
DMD0E8U SN LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand
DMD0E8U CP Ligand Pharmaceuticals
DMD0E8U DT Small molecular drug
DMD0E8U PC 9888484
DMD0E8U MW 422.5
DMD0E8U FM C25H26O6
DMD0E8U IC InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
DMD0E8U CS CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O
DMD0E8U IK OKJHGOPITGTTIM-DEOSSOPVSA-N
DMD0E8U IU (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid
DMD0E8U CA CAS 476436-68-7
DMD0E8U DE Diabetic complication
DMH9JFZ ID DMH9JFZ
DMH9JFZ DN NBI-5788
DMH9JFZ HS Phase 2
DMH9JFZ SN Tiplimotide; CGP-77116; MSP-771; MSP-771A; APL (multiple sclerosis), Neurocrine/Novartis; Altered peptide ligand (MS), Neurocrine/Novartis
DMH9JFZ CP Neurocrine Biosciences Inc
DMH9JFZ PC 25084501
DMH9JFZ MW 1860.2
DMH9JFZ FM C87H142N24O21
DMH9JFZ IC InChI=1S/C87H142N24O21/c1-15-47(10)67(82(127)105-66(46(8)9)81(126)108-69(51(14)113)84(129)110-35-23-29-60(110)77(122)97-54(28-21-33-94-87(91)92)72(117)107-68(50(13)112)85(130)111-36-24-31-62(111)86(131)132)106-76(121)59(40-63(90)114)99-71(116)49(12)96-73(118)57(38-52-25-17-16-18-26-52)101-74(119)56(37-43(2)3)100-75(120)58(39-53-41-93-42-95-53)102-79(124)64(44(4)5)104-80(125)65(45(6)7)103-78(123)61-30-22-34-109(61)83(128)55(27-19-20-32-88)98-70(115)48(11)89/h16-18,25-26,41-51,54-62,64-69,112-113H,15,19-24,27-40,88-89H2,1-14H3,(H2,90,114)(H,93,95)(H,96,118)(H,97,122)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,124)(H,103,123)(H,104,125)(H,105,127)(H,106,121)(H,107,117)(H,108,126)(H,131,132)(H4,91,92,94)/t47?,48-,49+,50?,51?,54+,55+,56+,57+,58+,59+,60+,61+,62+,64+,65+,66+,67+,68+,69+/m1/s1
DMH9JFZ CS CCC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N
DMH9JFZ IK NITUEMISTORFON-OOMTWUQISA-N
DMH9JFZ IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMH9JFZ DE Multiple sclerosis
DMT6O2E ID DMT6O2E
DMT6O2E DN NC318
DMT6O2E HS Phase 2
DMT6O2E CP NextCure
DMT6O2E DT Antibody
DMT6O2E DE Non-small cell lung cancer
DMVQKB3 ID DMVQKB3
DMVQKB3 DN NCI-C50000
DMVQKB3 HS Phase 2
DMVQKB3 SN Levomenthol; D-(-)-Menthol; Headache crystals; Hexahydrothymol; I-menthol; Levomentholum; Menthacamphor; Menthol (VAN); Menthol natural; Menthol racemic; Menthomenthol; Peppermint camphor; Racementhol; U.S.P. Menthol; d,l-Menthol; l-(-)-Menthol; l-Menthol; l-Menthol (natural); p-Menthan-3-ol; (+-)-Menthol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; (1r,2s,5r)-(-)-menthol; (R)-(-)-Menthol; 1-Menthol; 2216-51-5; 89-78-1
DMVQKB3 PC 16666
DMVQKB3 MW 156.26
DMVQKB3 FM C10H20O
DMVQKB3 IC NOOLISFMXDJSKH-KXUCPTDWSA-N
DMVQKB3 CS CC1CCC(C(C1)O)C(C)C
DMVQKB3 IK 1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1
DMVQKB3 IU (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol
DMVQKB3 CA CAS 89-78-1
DMVQKB3 CB CHEBI:15409
DMVQKB3 DE Pruritus
DM4W28K ID DM4W28K
DM4W28K DN NCX 1022
DM4W28K HS Phase 2
DM4W28K CP NicOx SA
DM4W28K DE Atopic dermatitis
DM2YIZH ID DM2YIZH
DM2YIZH DN NCX-1000
DM2YIZH HS Phase 2
DM2YIZH SN Nitric oxide ursodiol derivative, NicOx/Axcan; UDCA derivative, NicOx/Axcan; Ursodeoxycholic acid derivative, NicOx/Axcan
DM2YIZH CP NicOx SA
DM2YIZH DT Small molecular drug
DM2YIZH PC 129628949
DM2YIZH MW 685.8
DM2YIZH FM C38H55NO10
DM2YIZH IC InChI=1S/C38H55NO10/c1-24(28-10-11-29-36-30(16-18-38(28,29)3)37(2)17-15-27(40)22-26(37)23-31(36)41)7-13-35(43)49-32-12-8-25(21-33(32)46-4)9-14-34(42)47-19-5-6-20-48-39(44)45/h8-9,12,14,21,24,26-31,36,40-41H,5-7,10-11,13,15-20,22-23H2,1-4H3/b14-9+/t24-,26+,27-,28-,29+,30+,31+,36+,37+,38-/m1/s1
DM2YIZH CS C[C@H](CCC(=O)OC1=C(C=C(C=C1)/C=C/C(=O)OCCCCO[N+](=O)[O-])OC)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C
DM2YIZH IK WTAVOESJEWSDJC-OBOLPPCUSA-N
DM2YIZH IU [2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
DM2YIZH CA CAS 401519-96-8
DM2YIZH DE Cardiovascular disease
DMOX1CU ID DMOX1CU
DMOX1CU DN NCX-4016
DMOX1CU HS Phase 2
DMOX1CU SN Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate
DMOX1CU CP NiCox SA
DMOX1CU TC Analgesics
DMOX1CU DT Small molecular drug
DMOX1CU PC 119032
DMOX1CU MW 331.28
DMOX1CU FM C16H13NO7
DMOX1CU IC InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3
DMOX1CU CS CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]
DMOX1CU IK IOJUJUOXKXMJNF-UHFFFAOYSA-N
DMOX1CU IU [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate
DMOX1CU CA CAS 175033-36-0
DMOX1CU CB CHEBI:125482
DMOX1CU DE Claudication; Nephropathy; Type-2 diabetes; Inflammation
DM6S83X ID DM6S83X
DM6S83X DN NDDP
DM6S83X HS Phase 2
DM6S83X SN Cis-Bis(2,2-dimethyloctanoato)[trans-1(R),2(R)-diaminocyclohexane]platinum (II)
DM6S83X DT Small molecular drug
DM6S83X PC 56841091
DM6S83X MW 649.8
DM6S83X FM C26H50N2O4Pt
DM6S83X IC InChI=1S/2C10H20O2.C6H12N2.Pt/c2*1-10(2,3)8-6-4-5-7-9(11)12;7-5-3-1-2-4-6(5)8;/h2*4-8H2,1-3H3,(H,11,12);5-8H,1-4H2;/q;;-2;+4/p-2
DM6S83X CS CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)[NH-])[NH-].[Pt+4]
DM6S83X IK ALPHSAWEOKVWID-UHFFFAOYSA-L
DM6S83X IU (2-azanidylcyclohexyl)azanide;7,7-dimethyloctanoate;platinum(4+)
DM6S83X CA CAS 113427-19-3
DM6S83X DE Solid tumour/cancer
DMVIRN3 ID DMVIRN3
DMVIRN3 DN N-DESMETHYLCLOZAPINE
DMVIRN3 HS Phase 2
DMVIRN3 DT Small molecular drug
DMVIRN3 PC 135409468
DMVIRN3 MW 312.8
DMVIRN3 FM C17H17ClN4
DMVIRN3 IC InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2
DMVIRN3 CS C1CN(CCN1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMVIRN3 IK JNNOSTQEZICQQP-UHFFFAOYSA-N
DMVIRN3 IU 3-chloro-6-piperazin-1-yl-11H-benzo[b][1,4]benzodiazepine
DMVIRN3 CA CAS 6104-71-8
DMVIRN3 CB CHEBI:64050
DMVIRN3 DE Schizoaffective disorder; Schizophrenia
DMUPZFO ID DMUPZFO
DMUPZFO DN Neihulizumab
DMUPZFO HS Phase 2
DMUPZFO CP AbGenomics International Los Altos, CA
DMUPZFO DE Psoriatic arthritis
DMSVWI7 ID DMSVWI7
DMSVWI7 DN Neladenoson bialanate
DMSVWI7 HS Phase 2
DMSVWI7 SN UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate
DMSVWI7 CP Bayer HealthCare Pharmaceuticals Whippany, NJ
DMSVWI7 PC 56848985
DMSVWI7 MW 716.3
DMSVWI7 FM C35H34ClN7O4S2
DMSVWI7 IC InChI=1S/C35H34ClN7O4S2/c1-21(39)32(44)40-22(2)35(45)47-16-15-46-27-11-7-23(8-12-27)30-28(17-37)31(43-13-3-4-14-43)42-34(29(30)18-38)49-20-26-19-48-33(41-26)24-5-9-25(36)10-6-24/h5-12,19,21-22H,3-4,13-16,20,39H2,1-2H3,(H,40,44)/t21-,22-/m0/s1
DMSVWI7 CS C[C@@H](C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N5CCCC5)C#N)N
DMSVWI7 IK WESNEIGKOAXSGX-VXKWHMMOSA-N
DMSVWI7 IU 2-[4-[2-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-3,5-dicyano-6-pyrrolidin-1-ylpyridin-4-yl]phenoxy]ethyl (2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoate
DMSVWI7 CA CAS 1239309-58-0
DMSVWI7 DE Chronic heart failure
DM4LKFO ID DM4LKFO
DM4LKFO DN NELOTANSERIN
DM4LKFO HS Phase 2
DM4LKFO SN NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555
DM4LKFO DT Small molecular drug
DM4LKFO PC 11683556
DM4LKFO MW 437.2
DM4LKFO FM C18H15BrF2N4O2
DM4LKFO IC InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
DM4LKFO CS CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC
DM4LKFO IK COSPVUFTLGQDQL-UHFFFAOYSA-N
DM4LKFO IU 1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
DM4LKFO CA CAS 839713-36-9
DM4LKFO DE Sleep-wake disorder; Lewy body dementia
DMNM9DZ ID DMNM9DZ
DMNM9DZ DN Nepicastat oral
DMNM9DZ HS Phase 2
DMNM9DZ SN SYN117
DMNM9DZ CP Biotie Therapies
DMNM9DZ DT Small molecular drug
DMNM9DZ PC 9840545
DMNM9DZ MW 331.8
DMNM9DZ FM C14H16ClF2N3S
DMNM9DZ IC InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1
DMNM9DZ CS C1CC2=C(C[C@H]1N3C(=CNC3=S)CN)C=C(C=C2F)F.Cl
DMNM9DZ IK DIPDUAJWNBEVOY-PPHPATTJSA-N
DMNM9DZ IU 4-(aminomethyl)-3-[(2S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-imidazole-2-thione;hydrochloride
DMNM9DZ CA CAS 170151-24-3
DMNM9DZ DE Post-traumatic stress disorder
DM3ORVD ID DM3ORVD
DM3ORVD DN Neramexane
DM3ORVD HS Phase 2
DM3ORVD SN Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD CP Merz Pharmaceuticals GmbH
DM3ORVD TC Analgesics
DM3ORVD DT Small molecular drug
DM3ORVD PC 6433106
DM3ORVD MW 169.31
DM3ORVD FM C11H23N
DM3ORVD IC InChI=1S/C11H23N/c1-9(2)6-10(3,4)8-11(5,12)7-9/h6-8,12H2,1-5H3
DM3ORVD CS CC1(CC(CC(C1)(C)N)(C)C)C
DM3ORVD IK OGZQTTHDGQBLBT-UHFFFAOYSA-N
DM3ORVD IU 1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD CA CAS 219810-59-0
DM3ORVD DE Cancer related pain
DMBJ3GL ID DMBJ3GL
DMBJ3GL DN Nerenone
DMBJ3GL HS Phase 2
DMBJ3GL CP Bayer healthcare pharmaceuticals
DMBJ3GL DE Diabetic nephropathy
DM8H7OA ID DM8H7OA
DM8H7OA DN Netoglitazone
DM8H7OA HS Phase 2
DM8H7OA SN Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA CP Mitsubishi Pharma
DM8H7OA DT Small molecular drug
DM8H7OA PC 204109
DM8H7OA MW 381.4
DM8H7OA FM C21H16FNO3S
DM8H7OA IC InChI=1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25)
DM8H7OA CS C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F
DM8H7OA IK PKWDZWYVIHVNKS-UHFFFAOYSA-N
DM8H7OA IU 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA CA CAS 161600-01-7
DM8H7OA DE Non-alcoholic fatty liver disease
DMOZW4C ID DMOZW4C
DMOZW4C DN Neublastin
DMOZW4C HS Phase 2
DMOZW4C CP Biogen Idec
DMOZW4C DE Pain
DMIQDFW ID DMIQDFW
DMIQDFW DN Neu-P11
DMIQDFW HS Phase 2
DMIQDFW SN Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; NEU-P11; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819
DMIQDFW CP Neurim Pharmaceuticals
DMIQDFW DT Small molecular drug
DMIQDFW PC 24815904
DMIQDFW MW 312.32
DMIQDFW FM C17H16N2O4
DMIQDFW IC InChI=1S/C17H16N2O4/c1-22-13-2-3-15-14(9-13)11(10-19-15)4-6-18-17(21)16-8-12(20)5-7-23-16/h2-3,5,7-10,19H,4,6H2,1H3,(H,18,21)
DMIQDFW CS COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3
DMIQDFW IK PNTNBIHOAPJYDB-UHFFFAOYSA-N
DMIQDFW IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxopyran-2-carboxamide
DMIQDFW CA CAS 946846-83-9
DMIQDFW DE Insomnia; Alzheimer disease; Dementia
DMINQP1 ID DMINQP1
DMINQP1 DN NEUROPEPTIDE-Y
DMINQP1 HS Phase 2
DMINQP1 SN XKWCTHKJQNUFOQ-HRPSIEBRSA-N; Neuropeptide Y
DMINQP1 DT Small molecular drug
DMINQP1 PC 91928728
DMINQP1 MW 4254
DMINQP1 FM C190H287N55O57
DMINQP1 IC InChI=1S/C190H287N55O57/c1-16-94(9)149(180(296)235-129(81-141(194)255)169(285)227-124(74-93(7)8)172(288)240-150(95(10)17-2)181(297)241-151(100(15)248)182(298)222-116(32-23-67-209-190(203)204)156(272)221-118(57-60-140(193)254)161(277)219-114(30-21-65-207-188(199)200)157(273)224-121(152(196)268)76-102-39-49-108(250)50-40-102)239-173(289)127(79-105-45-55-111(253)56-46-105)230-168(284)128(80-106-86-205-90-211-106)231-159(275)115(31-22-66-208-189(201)202)220-165(281)123(73-92(5)6)225-155(271)97(12)213-174(290)134(88-246)237-167(283)126(78-104-43-53-110(252)54-44-104)229-166(282)125(77-103-41-51-109(251)52-42-103)228-158(274)113(29-20-64-206-187(197)198)217-153(269)96(11)212-163(279)122(72-91(3)4)226-170(286)131(84-147(264)265)233-162(278)119(59-62-145(260)261)218-154(270)98(13)214-177(293)137-34-25-68-242(137)183(299)99(14)215-164(280)130(83-146(262)263)232-160(276)117(58-61-144(258)259)216-143(257)87-210-176(292)136-33-24-70-244(136)186(302)133(82-142(195)256)236-171(287)132(85-148(266)267)234-178(294)139-36-27-71-245(139)185(301)120(28-18-19-63-191)223-175(291)135(89-247)238-179(295)138-35-26-69-243(138)184(300)112(192)75-101-37-47-107(249)48-38-101/h37-56,86,90-100,112-139,149-151,246-253H,16-36,57-85,87-89,191-192H2,1-15H3,(H2,193,254)(H2,194,255)(H2,195,256)(H2,196,268)(H,205,211)(H,210,292)(H,212,279)(H,213,290)(H,214,293)(H,215,280)(H,216,257)(H,217,269)(H,218,270)(H,219,277)(H,220,281)(H,221,272)(H,222,298)(H,223,291)(H,224,273)(H,225,271)(H,226,286)(H,227,285)(H,228,274)(H,229,282)(H,230,284)(H,231,275)(H,232,276)(H,233,278)(H,234,294)(H,235,296)(H,236,287)(H,237,283)(H,238,295)(H,239,289)(H,240,288)(H,241,297)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)(H4,203,204,209)/t94-,95-,96-,97-,98-,99-,100+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,149-,150-,151-/m0/s1
DMINQP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]9CCCN9C(=O)[C@H](CC1=CC=C(C=C1)O)N
DMINQP1 IK URPYMXQQVHTUDU-OFGSCBOVSA-N
DMINQP1 IU (4S)-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoic acid
DML5S71 ID DML5S71
DML5S71 DN Nexopamil
DML5S71 HS Phase 2
DML5S71 SN LU-49938
DML5S71 CP BASF AG
DML5S71 DT Small molecular drug
DML5S71 PC 65984
DML5S71 MW 404.6
DML5S71 FM C24H40N2O3
DML5S71 IC InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
DML5S71 CS CCCCCCN(C)CCC[C@@](C#N)(C1=CC(=C(C(=C1)OC)OC)OC)C(C)C
DML5S71 IK SKDZEFVVFACNLS-DEOSSOPVSA-N
DML5S71 IU (2S)-5-[hexyl(methyl)amino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DML5S71 CA CAS 136033-49-3
DML5S71 DE Hypertension
DMJKBAY ID DMJKBAY
DMJKBAY DN NGX-267
DMJKBAY HS Phase 2
DMJKBAY SN 503431-81-0; AF267B; (2S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4,5]DECAN-3-ONE; UNII-8D3PZX7G73; AF 267B; 8D3PZX7G73; (S)-2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one; NGX-267; NGX267; NGX 267; SCHEMBL3651146; CTK1G8674; DTXSID40198399; AF-267B; PHOZOHFUXHPOCK-QMMMGPOBSA-N; ZINC13816318; AKOS025295388; NCGC00162382-01; RT-005412; FT-0668336; (S)-2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one; 1-Thia-4,8-diazaspiro(4.5)decan-3-one, 2-ethyl-8-methyl-, (2S)-
DMJKBAY DT Small molecular drug
DMJKBAY PC 10013505
DMJKBAY MW 214.33
DMJKBAY FM C10H18N2OS
DMJKBAY IC InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)/t8-/m0/s1
DMJKBAY CS CC[C@H]1C(=O)NC2(S1)CCN(CC2)C
DMJKBAY IK PHOZOHFUXHPOCK-QMMMGPOBSA-N
DMJKBAY IU (2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one
DMJKBAY CA CAS 503431-81-0
DMJKBAY DE Schizophrenia
DMDY01J ID DMDY01J
DMDY01J DN NHS-IL2-LT
DMDY01J HS Phase 2
DMDY01J SN Selectikine; EMD-521873; Immunocytokine (solid tumors), Merck Serono
DMDY01J CP Merck Serono SA
DMDY01J DE Solid tumour/cancer
DMRQUH4 ID DMRQUH4
DMRQUH4 DN NI-0801
DMRQUH4 HS Phase 2
DMRQUH4 SN Anti-interferon inducible protein 10, NovImmune
DMRQUH4 CP NovImmune SA
DMRQUH4 DT Antibody
DMRQUH4 DE Autoimmune diabetes
DMKLJMI ID DMKLJMI
DMKLJMI DN NIC-002
DMKLJMI HS Phase 2
DMKLJMI SN NicQb; Nicotine-Qbeta; CYT-002-NicQb; Nicotine vaccine, Cytos/Novartis; Immunodrug (nicotine addiction), Cytos/Novartis
DMKLJMI CP Cytos Biotechnology AG
DMKLJMI DT Vaccine
DMKLJMI DE Nicotine dependence
DMG7XOC ID DMG7XOC
DMG7XOC DN NIC5-15
DMG7XOC HS Phase 2
DMG7XOC SN D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336
DMG7XOC CP Humanetics Minneapolis, MN
DMG7XOC DT Small molecular drug
DMG7XOC PC 164619
DMG7XOC MW 194.18
DMG7XOC FM C7H14O6
DMG7XOC IC InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5-,6+,7?/m0/s1
DMG7XOC CS COC1[C@@H]([C@H](C([C@@H]([C@@H]1O)O)O)O)O
DMG7XOC IK DSCFFEYYQKSRSV-FEPQRWDDSA-N
DMG7XOC IU (1S,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol
DMG7XOC CA CAS 484-68-4
DMG7XOC CB CHEBI:28548
DMG7XOC DE Alzheimer disease
DM21Z68 ID DM21Z68
DM21Z68 DN Nimacimab
DM21Z68 HS Phase 2
DM21Z68 SN Namacizumab
DM21Z68 CP Bird Rock Bio
DM21Z68 DT Antibody
DM21Z68 DE Diabetic nephropathy
DMPER4A ID DMPER4A
DMPER4A DN NIR178
DMPER4A HS Phase 2
DMPER4A CP Novartis Oncology East Hanover,
DMPER4A DE Non-hodgkin lymphoma; Solid tumour/cancer
DM81SDB ID DM81SDB
DM81SDB DN Niravoline
DM81SDB HS Phase 2
DM81SDB SN AC1L24CB; AC1Q1ZY1; N-methyl-2-(3-nitrophenyl)-N-[(2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB DT Small molecular drug
DM81SDB PC 9821174
DM81SDB MW 379.5
DM81SDB FM C22H25N3O3
DM81SDB IC InChI=1S/C22H25N3O3/c1-23(21(26)14-16-7-6-9-18(13-16)25(27)28)22-19-10-3-2-8-17(19)15-20(22)24-11-4-5-12-24/h2-3,6-10,13,20,22H,4-5,11-12,14-15H2,1H3/t20-,22-/m0/s1
DM81SDB CS CN([C@@H]1[C@H](CC2=CC=CC=C12)N3CCCC3)C(=O)CC4=CC(=CC=C4)[N+](=O)[O-]
DM81SDB IK ZSDAQBWGAOKTSI-UNMCSNQZSA-N
DM81SDB IU N-methyl-2-(3-nitrophenyl)-N-[(1S,2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB CA CAS 130610-93-4
DM81SDB DE Pain
DM8LBYT ID DM8LBYT
DM8LBYT DN NIS793
DM8LBYT HS Phase 2
DM8LBYT CP Novartis Oncology East Hanover,
DM8LBYT DE Solid tumour/cancer; Pancreatic ductal carcinoma
DMQHBSX ID DMQHBSX
DMQHBSX DN NITD609
DMQHBSX HS Phase 2
DMQHBSX SN Cipargamin; 1193314-23-6; NITD-609; NITD 609; UNII-Z7Q4FWA04P; (1'R,3'S)-5,7'-Dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyrido[3,4-b]indol]-2-one; Z7Q4FWA04P; CHEMBL1082723; Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one, 5,7'-dichloro-6'-fluoro-2',3',4',9'-tetrahydro-3'-methyl-, (1'R,3'S)-; Cipargamin [INN]; 1252008-89-1; GTPL9721; SCHEMBL1306342; DTXSID70152424; MolPort-039-337-269; ZINC49037032; BDBM50318666; AKOS027253851; SB16518; DB12306; CS-7486; NCGC00263785-01
DMQHBSX DT Small molecular drug
DMQHBSX PC 44469321
DMQHBSX MW 390.2
DMQHBSX FM C19H14Cl2FN3O
DMQHBSX IC InChI=1S/C19H14Cl2FN3O/c1-8-4-11-10-6-14(22)13(21)7-16(10)23-17(11)19(25-8)12-5-9(20)2-3-15(12)24-18(19)26/h2-3,5-8,23,25H,4H2,1H3,(H,24,26)/t8-,19+/m0/s1
DMQHBSX CS C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl
DMQHBSX IK CKLPLPZSUQEDRT-WPCRTTGESA-N
DMQHBSX IU (3R,3'S)-5,7'-dichloro-6'-fluoro-3'-methylspiro[1H-indole-3,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-2-one
DMQHBSX CA CAS 1193314-23-6
DMQHBSX DE Malaria
DMAOUZV ID DMAOUZV
DMAOUZV DN Nivatrotamab
DMAOUZV HS Phase 2
DMAOUZV CP Memorial Sloan Kettering; Y-mAbs Therapeutics
DMAOUZV DT Antibody
DMAOUZV DE Solid tumour/cancer; Small-cell lung cancer
DMUX8JZ ID DMUX8JZ
DMUX8JZ DN Nivocasan
DMUX8JZ HS Phase 2
DMUX8JZ SN GS-9450; LB-84451
DMUX8JZ CP LG Life Sciences Ltd
DMUX8JZ PC 11633038
DMUX8JZ MW 415.4
DMUX8JZ FM C21H22FN3O5
DMUX8JZ IC InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
DMUX8JZ CS CC(C)[C@]1(CC(=NO1)C2=NC=CC3=CC=CC=C32)C(=O)N[C@H]4CC(=O)O[C@@]4(CF)O
DMUX8JZ IK VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
DMUX8JZ IU (5R)-N-[(2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-3-isoquinolin-1-yl-5-propan-2-yl-4H-1,2-oxazole-5-carboxamide
DMUX8JZ CA CAS 908253-63-4
DMUX8JZ DE Fibrosis
DMTVGMZ ID DMTVGMZ
DMTVGMZ DN NKP 608
DMTVGMZ HS Phase 2
DMTVGMZ SN AV608)
DMTVGMZ CP Novartis; Avera Pharmaceuticals
DMTVGMZ PC 9917079
DMTVGMZ MW 620
DMTVGMZ FM C31H24ClF6N3O2
DMTVGMZ IC InChI=1S/C31H24ClF6N3O2/c32-22-7-5-18(6-8-22)13-24-17-23(40-28(42)26-9-11-39-27-4-2-1-3-25(26)27)10-12-41(24)29(43)19-14-20(30(33,34)35)16-21(15-19)31(36,37)38/h1-9,11,14-16,23-24H,10,12-13,17H2,(H,40,42)/t23-,24+/m0/s1
DMTVGMZ CS C1CN([C@@H](C[C@H]1NC(=O)C2=CC=NC3=CC=CC=C23)CC4=CC=C(C=C4)Cl)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DMTVGMZ IK NXLUTEDAEFXMQR-BJKOFHAPSA-N
DMTVGMZ IU N-[(2R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide
DMTVGMZ CA CAS 177707-12-9
DMTVGMZ DE Mood disorder
DMKD5ZO ID DMKD5ZO
DMKD5ZO DN NN-8226
DMKD5ZO HS Phase 2
DMKD5ZO SN NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk
DMKD5ZO CP ZymoGenetics Inc
DMKD5ZO DT Antibody
DMKD5ZO DE Psoriasis vulgaris
DM3IEHP ID DM3IEHP
DM3IEHP DN NN8555
DM3IEHP HS Phase 2
DM3IEHP CP Novo Nordisk
DM3IEHP DE Rheumatoid arthritis; Crohn disease
DMCFPBE ID DMCFPBE
DMCFPBE DN NN8765
DMCFPBE HS Phase 2
DMCFPBE CP Novo Nordisk
DMCFPBE DE Rheumatoid arthritis
DMDTNOS ID DMDTNOS
DMDTNOS DN NNC-0123-0000-0338
DMDTNOS HS Phase 2
DMDTNOS CP Novo Nordisk A/S
DMDTNOS DE Diabetic complication
DMU3KOH ID DMU3KOH
DMU3KOH DN NNC-0151-0000-0000
DMU3KOH HS Phase 2
DMU3KOH SN Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk
DMU3KOH CP G2 Therapies Ltd
DMU3KOH DT Antibody
DMU3KOH DE Rheumatoid arthritis
DMPZ97S ID DMPZ97S
DMPZ97S DN NNZ-2566
DMPZ97S HS Phase 2
DMPZ97S SN Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren
DMPZ97S CP Neuren pharmaceuticals
DMPZ97S DT Small molecular drug
DMPZ97S PC 11318905
DMPZ97S MW 315.32
DMPZ97S FM C13H21N3O6
DMPZ97S IC InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
DMPZ97S CS C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMPZ97S IK BUSXWGRAOZQTEY-SDBXPKJASA-N
DMPZ97S IU (2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMPZ97S CA CAS 853400-76-7
DMPZ97S DE Fragile X syndrome; Rett syndrome; Traumatic brain injury; Type-1 diabetes
DME8IFQ ID DME8IFQ
DME8IFQ DN Noberastine
DME8IFQ HS Phase 2
DME8IFQ SN Flamizole; R-64947; R-72075
DME8IFQ CP Janssen Pharmaceutica NV
DME8IFQ DT Small molecular drug
DME8IFQ PC 60531
DME8IFQ MW 311.4
DME8IFQ FM C17H21N5O
DME8IFQ IC InChI=1S/C17H21N5O/c1-12-4-5-14(23-12)11-22-16-15(3-2-8-19-16)21-17(22)20-13-6-9-18-10-7-13/h2-5,8,13,18H,6-7,9-11H2,1H3,(H,20,21)
DME8IFQ CS CC1=CC=C(O1)CN2C3=C(C=CC=N3)N=C2NC4CCNCC4
DME8IFQ IK VNIOQSAWKLOGLY-UHFFFAOYSA-N
DME8IFQ IU 3-[(5-methylfuran-2-yl)methyl]-N-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine
DME8IFQ CA CAS 110588-56-2
DME8IFQ DE Asthma
DMEHOI1 ID DMEHOI1
DMEHOI1 DN Novaferon
DMEHOI1 HS Phase 2
DMEHOI1 SN Recombinant interferon-like protein, Genova/Novagenetics/Novagen; Recombinant huIFN-alpha-like protein (cancer, viral infection), Genova/Novagenetics/Novagen
DMEHOI1 CP Novagenetics Inc
DMEHOI1 DE Colorectal cancer
DMHG3UR ID DMHG3UR
DMHG3UR DN NOX-E36
DMHG3UR HS Phase 2
DMHG3UR SN Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON
DMHG3UR CP NOXXON Pharma AG
DMHG3UR DE Diabetic complication
DM5HPZU ID DM5HPZU
DM5HPZU DN NOX-H94
DM5HPZU HS Phase 2
DM5HPZU CP NOXXON Pharma AG; Avant Immunotherapeutics
DM5HPZU DE Anemia
DMP1W9Z ID DMP1W9Z
DMP1W9Z DN NP-01
DMP1W9Z HS Phase 2
DMP1W9Z SN Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis
DMP1W9Z CP Medesis Pharma SA
DMP1W9Z DE Type-2 diabetes
DMLMZ6Q ID DMLMZ6Q
DMLMZ6Q DN NP-2
DMLMZ6Q HS Phase 2
DMLMZ6Q SN NP2 Enkephalin; NPE-1; NPE-2; Enkephalin-expressing gene therapy (HSV carrier, pain), Diamyd; Enkephalin-expressinggene therapy (HSV carrier/NTDDS, pain), Nurel
DMLMZ6Q CP Periphagen holdings
DMLMZ6Q DT Small molecular drug
DMLMZ6Q PC 16130887
DMLMZ6Q MW 3855
DMLMZ6Q FM C161H282N62O36S6
DMLMZ6Q IC InChI=1S/C161H282N62O36S6/c1-20-84(15)120(148(254)206-91(38-25-51-182-153(163)164)125(231)192-70-115(224)197-92(39-26-52-183-154(165)166)132(238)220-121(85(16)21-2)149(255)212-106(67-90-68-181-77-193-90)151(257)223-61-35-48-114(223)145(251)210-103(64-80(7)8)136(242)215-112(76-265)143(249)217-110(74-263)141(247)203-97(44-31-57-188-159(175)176)130(236)207-100(152(258)259)46-33-59-190-161(179)180)221-133(239)98(45-32-58-189-160(177)178)204-140(246)109(73-262)216-137(243)104(66-89-36-23-22-24-37-89)198-116(225)69-191-122(228)86(17)194-126(232)93(40-27-53-184-155(167)168)199-128(234)95(42-29-55-186-157(171)172)201-131(237)99(49-50-117(226)227)205-134(240)102(63-79(5)6)209-144(250)113-47-34-60-222(113)150(256)105(65-81(9)10)211-142(248)111(75-264)214-135(241)101(62-78(3)4)208-123(229)87(18)195-127(233)94(41-28-54-185-156(169)170)200-129(235)96(43-30-56-187-158(173)174)202-139(245)108(72-261)213-124(230)88(19)196-138(244)107(71-260)218-147(253)119(83(13)14)219-146(252)118(162)82(11)12/h22-24,36-37,68,77-88,91-114,118-121,260-265H,20-21,25-35,38-67,69-76,162H2,1-19H3,(H,181,193)(H,191,228)(H,192,231)(H,194,232)(H,195,233)(H,196,244)(H,197,224)(H,198,225)(H,199,234)(H,200,235)(H,201,237)(H,202,245)(H,203,247)(H,204,246)(H,205,240)(H,206,254)(H,207,236)(H,208,229)(H,209,250)(H,210,251)(H,211,248)(H,212,255)(H,213,230)(H,214,241)(H,215,242)(H,216,243)(H,217,249)(H,218,253)(H,219,252)(H,220,238)(H,221,239)(H,226,227)(H,258,259)(H4,163,164,182)(H4,165,166,183)(H4,167,168,184)(H4,169,170,185)(H4,171,172,186)(H4,173,174,187)(H4,175,176,188)(H4,177,178,189)(H4,179,180,190)/t84-,85-,86-,87-,88-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,118-,119-,120-,121-/m0/s1
DMLMZ6Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N
DMLMZ6Q IK AEUKDPKXTPNBNY-XEYRWQBLSA-N
DMLMZ6Q IU (4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMLMZ6Q CA CAS 88086-40-2
DMLMZ6Q DE Influenza A virus infection
DME6KAF ID DME6KAF
DME6KAF DN NPC-15199
DME6KAF HS Phase 2
DME6KAF SN 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; F-L-Leu; CHEMBL294989; PPARgamma Activator, Fmoc-Leu; 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; Fmoc-DL-leucine; N-alpha-Fmoc-L-leucine; NSC334290; ACMC-209iik; AC1L1HVH; n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucin; ACMC-2099ky; AC1Q5SK7; 126727-03-5; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; (2S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-4-methylpentanoic acid; GTPL2705; SCHEMBL1002861; CHEBI:91726; CTK8G6077; MolPort-003-700-319; HMS3266H19; SBB056939; IN1334; BDBM50034787; AKOS017268980
DME6KAF CP Scios Inc
DME6KAF DT Small molecular drug
DME6KAF PC 1549133
DME6KAF MW 353.4
DME6KAF FM C21H23NO4
DME6KAF IC InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1
DME6KAF CS CC(C)C[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
DME6KAF IK CBPJQFCAFFNICX-IBGZPJMESA-N
DME6KAF IU (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid
DME6KAF CA CAS 35661-60-0
DME6KAF DE Inflammation
DM9VEAL ID DM9VEAL
DM9VEAL DN NPC-1C
DM9VEAL HS Phase 2
DM9VEAL SN Ensituximab
DM9VEAL CP Neogenix Oncology
DM9VEAL DT Antibody
DM9VEAL DE Colorectal cancer; Pancreatic tumour; Pancreatic cancer
DM3DQXG ID DM3DQXG
DM3DQXG DN NPSP-795
DM3DQXG HS Phase 2
DM3DQXG SN NPSP-790; SB-423557; SB-423557A; SB-423562; SB-423562A
DM3DQXG CP GlaxoSmithKline plc
DM3DQXG PC 9910902
DM3DQXG MW 436.5
DM3DQXG FM C26H32N2O4
DM3DQXG IC InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1
DM3DQXG CS CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C=CC(=C3)CCC(=O)O)C#N)O
DM3DQXG IK NJBFJCJKWWIKRD-HSZRJFAPSA-N
DM3DQXG IU 3-[4-cyano-3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]phenyl]propanoic acid
DM3DQXG CA CAS 351490-27-2
DM3DQXG DE Osteoporosis
DMYXOU2 ID DMYXOU2
DMYXOU2 DN NRX-4204
DMYXOU2 HS Phase 2
DMYXOU2 SN AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
DMYXOU2 CP Allergan Ligand Retinoid Therapeutics Inc
DMYXOU2 DT Small molecular drug
DMYXOU2 PC 9863342
DMYXOU2 MW 352.5
DMYXOU2 FM C24H32O2
DMYXOU2 IC InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+
DMYXOU2 CS C/C(=C\\C(=O)O)/C=C/C1CC1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DMYXOU2 IK BOOOLEGQBVUTKC-YWRSBGDESA-N
DMYXOU2 IU (2E,4E)-3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid
DMYXOU2 DE Diabetic complication
DM9EFH0 ID DM9EFH0
DM9EFH0 DN NS 1209
DM9EFH0 HS Phase 2
DM9EFH0 CP NeuroSearch
DM9EFH0 TC Analgesics
DM9EFH0 DT Small molecular drug
DM9EFH0 PC 135456058
DM9EFH0 MW 516.6
DM9EFH0 FM C24H28N4O7S
DM9EFH0 IC InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)
DM9EFH0 CS CN1CCC2=C(C1)C3=C(C=C2C4=CC=C(C=C4)S(=O)(=O)N(C)C)/C(=N/OC(CCO)C(=O)O)/C(=O)N3
DM9EFH0 IK CFJRSKULEDUDKL-UHFFFAOYSA-N
DM9EFH0 IU 2-[(Z)-[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid
DM9EFH0 CA CAS 245063-59-6
DM9EFH0 DE Neuropathic pain; Epilepsy
DMI5HFU ID DMI5HFU
DMI5HFU DN NS 2359
DMI5HFU HS Phase 2
DMI5HFU SN FPTPUYCHSWIWIB-FUTJPDQTSA-N; SCHEMBL2640060; (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo-[321]octane; GSK372475
DMI5HFU CP GlaxoSmithKline
DMI5HFU DT Small molecular drug
DMI5HFU PC 68470595
DMI5HFU MW 314.2
DMI5HFU FM C16H21Cl2NO
DMI5HFU IC InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
DMI5HFU CS CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC
DMI5HFU IK PGYDXVBZYKQYCS-VPWBDBDCSA-N
DMI5HFU IU (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
DMI5HFU CA CAS 195875-68-4
DMI5HFU DE Cocaine addiction; Attention deficit hyperactivity disorder; Mood disorder
DMMUR6V ID DMMUR6V
DMMUR6V DN NS-2710
DMMUR6V HS Phase 2
DMMUR6V SN ME-3127
DMMUR6V CP NeuroSearch A/S
DMMUR6V DT Small molecular drug
DMMUR6V PC 9863520
DMMUR6V MW 356.4
DMMUR6V FM C22H20N4O
DMMUR6V IC InChI=1S/C22H20N4O/c1-3-27-25-16(2)17-9-10-22-21(13-17)24-15-26(22)20-8-4-6-18(12-20)19-7-5-11-23-14-19/h4-15H,3H2,1-2H3/b25-16+
DMMUR6V CS CCO/N=C(\\C)/C1=CC2=C(C=C1)N(C=N2)C3=CC=CC(=C3)C4=CN=CC=C4
DMMUR6V IK NHJFEXZXSCFYRX-PCLIKHOPSA-N
DMMUR6V IU (E)-N-ethoxy-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanimine
DMMUR6V CA CAS 184220-36-8
DMMUR6V DE Anxiety disorder
DM3H82Q ID DM3H82Q
DM3H82Q DN NS-7
DM3H82Q HS Phase 2
DM3H82Q SN (3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide; DB08305; NS7
DM3H82Q TC Analgesics
DM3H82Q DT Small molecular drug
DM3H82Q PC 9800750
DM3H82Q MW 393.9
DM3H82Q FM C21H29ClFN3O
DM3H82Q IC InChI=1S/C21H28FN3O.ClH/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25;/h8-11,16H,2-7,12-15H2,1H3;1H
DM3H82Q CS CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F.Cl
DM3H82Q IK VLYZLIWXMLUPLD-UHFFFAOYSA-N
DM3H82Q IU 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine;hydrochloride
DM3H82Q CA CAS 178429-67-9
DM3H82Q DE Nerve injury
DMPJQZG ID DMPJQZG
DMPJQZG DN NSC-645809
DMPJQZG HS Phase 2
DMPJQZG SN XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate
DMPJQZG DT Small molecular drug
DMPJQZG PC 132127
DMPJQZG MW 350.4
DMPJQZG FM C20H22N4O2
DMPJQZG IC InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
DMPJQZG CS CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O
DMPJQZG IK CUNDRHORZHFPLY-UHFFFAOYSA-N
DMPJQZG IU 10-[2-(diethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMPJQZG CA CAS 138154-39-9
DMPJQZG DE Breast cancer
DMRYLBW ID DMRYLBW
DMRYLBW DN NTO-1151
DMRYLBW HS Phase 2
DMRYLBW CP Nanotherapeutics; national cancer institute
DMRYLBW DE Cervical cancer
DMORNVB ID DMORNVB
DMORNVB DN NU-172
DMORNVB HS Phase 2
DMORNVB CP ARCA biopharma
DMORNVB DE Thrombosis
DMO0C5R ID DMO0C5R
DMO0C5R DN NU300
DMO0C5R HS Phase 2
DMO0C5R CP Nuron biotech
DMO0C5R DE Influenza virus infection
DMOJA5G ID DMOJA5G
DMOJA5G DN Nuplazid
DMOJA5G HS Phase 2
DMOJA5G SN Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate
DMOJA5G CP ACADIA Pharmaceuticals
DMOJA5G DT Small molecular drug
DMOJA5G PC 11672491
DMOJA5G MW 1005.2
DMOJA5G FM C54H74F2N6O10
DMOJA5G IC InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
DMOJA5G CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMOJA5G IK RGSULKHNAKTFIZ-CEAXSRTFSA-N
DMOJA5G IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMOJA5G CA CAS 706782-28-7
DMOJA5G CB CHEBI:133014
DMOJA5G DE Alzheimer disease
DMTYXQF ID DMTYXQF
DMTYXQF DN NVP-AUY922
DMTYXQF HS Phase 2
DMTYXQF SN Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
DMTYXQF CP Vernalis; Novartis
DMTYXQF TC Anticancer Agents
DMTYXQF DT Small molecular drug
DMTYXQF PC 135539077
DMTYXQF MW 465.5
DMTYXQF FM C26H31N3O5
DMTYXQF IC InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
DMTYXQF CS CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C
DMTYXQF IK NDAZATDQFDPQBD-UHFFFAOYSA-N
DMTYXQF IU 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide
DMTYXQF CA CAS 747412-49-3
DMTYXQF CB CHEBI:83656
DMTYXQF DE Multiple myeloma; Solid tumour/cancer
DM2UJ1H ID DM2UJ1H
DM2UJ1H DN NW-3509
DM2UJ1H HS Phase 2
DM2UJ1H SN NW-3381; Sodium channel blockers (epilepsy/pain/mania), Newron
DM2UJ1H CP Newron pharmaceuticals
DM2UJ1H DE Schizophrenia
DMMBAIH ID DMMBAIH
DMMBAIH DN NXN-188
DMMBAIH HS Phase 2
DMMBAIH SN 6634-56-6; 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid; NSC51920; AC1Q5VTF; AC1L6AFP; CTK5C4317; ZINC4721635; NSC-51920; AKOS030583716; KB-274877
DMMBAIH CP Neuraxon
DMMBAIH DT Small molecular drug
DMMBAIH PC 242911
DMMBAIH MW 484.6
DMMBAIH FM C27H36N2O6
DMMBAIH IC InChI=1S/C27H36N2O6/c1-27(7-6-26(32)33,22-2-4-24(30)20(16-22)18-28-8-12-34-13-9-28)23-3-5-25(31)21(17-23)19-29-10-14-35-15-11-29/h2-5,16-17,30-31H,6-15,18-19H2,1H3,(H,32,33)
DMMBAIH CS CC(CCC(=O)O)(C1=CC(=C(C=C1)O)CN2CCOCC2)C3=CC(=C(C=C3)O)CN4CCOCC4
DMMBAIH IK JWNUBAIGCVTLMJ-UHFFFAOYSA-N
DMMBAIH IU 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid
DMMBAIH CA CAS 6634-56-6
DMMBAIH DE Migraine
DMWVBS2 ID DMWVBS2
DMWVBS2 DN NXN-462
DMWVBS2 HS Phase 2
DMWVBS2 SN NNOS inhibitor (chronic headache), Neuraxon; NNOS inhibitor (neuropathic pain), NeurAxon
DMWVBS2 CP Neuraxon
DMWVBS2 DE Headache
DM1P60V ID DM1P60V
DM1P60V DN NYX-2925
DM1P60V HS Phase 2
DM1P60V CP Aptinyx Evanston, IL
DM1P60V DE Peripheral neuropathy; Fibromyalgia
DMX04O8 ID DMX04O8
DMX04O8 DN NYX-2925
DMX04O8 HS Phase 2
DMX04O8 SN 2012536-16-0
DMX04O8 CP Aptinyx
DMX04O8 DT Small molecular drug
DMX04O8 PC 134820579
DMX04O8 MW 297.35
DMX04O8 FM C14H23N3O4
DMX04O8 IC InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m0/s1
DMX04O8 CS C[C@@H]([C@H](C(=O)N)N1C[C@]2(C1=O)CCCN2C(=O)C(C)C)O
DMX04O8 IK NFXPEHLDVKVVKA-RBZYPMLTSA-N
DMX04O8 IU (2R,3S)-3-hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
DMX04O8 DE Diabetic neuropathy; Fibromyalgia
DMAVM2E ID DMAVM2E
DMAVM2E DN NYX-783
DMAVM2E HS Phase 2
DMAVM2E CP Aptinyx
DMAVM2E DT Small molecular drug
DMAVM2E DE Post-traumatic stress disorder
DMXM34I ID DMXM34I
DMXM34I DN O-304
DMXM34I HS Phase 2
DMXM34I SN 1261289-04-6; O304; 4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide; SCHEMBL1050337; BCP29039; EX-A1990; MFCD31657425; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; BS-14854; HY-112233; CS-0044210; O 304; S0795
DMXM34I CP Betagenon
DMXM34I DT Small molecular drug
DMXM34I PC 50923806
DMXM34I MW 380.2
DMXM34I FM C16H11Cl2N3O2S
DMXM34I IC InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23)
DMXM34I CS C1=CC(=CC=C1CN2C(=O)N=C(S2)NC(=O)C3=CC=C(C=C3)Cl)Cl
DMXM34I IK WEDWLYRQKUTOAX-UHFFFAOYSA-N
DMXM34I IU 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide
DMXM34I DE Type 2 diabetes
DMPF9ZM ID DMPF9ZM
DMPF9ZM DN Obatoclax
DMPF9ZM HS Phase 2
DMPF9ZM SN CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7
DMPF9ZM CP Cephalon
DMPF9ZM DT Small molecular drug
DMPF9ZM PC 11404337
DMPF9ZM MW 317.4
DMPF9ZM FM C20H19N3O
DMPF9ZM IC InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21,23H,1-3H3/b18-17-,19-10-
DMPF9ZM CS CC1=CC(=C(N1)/C=C\\2/C(=C/C(=C/3\\C=C4C=CC=CC4=N3)/N2)OC)C
DMPF9ZM IK CVCLJVVBHYOXDC-IAZSKANUSA-N
DMPF9ZM IU (2Z)-2-[(5Z)-5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole
DMPF9ZM CA CAS 803712-67-6
DMPF9ZM DE Solid tumour/cancer
DMJIBSG ID DMJIBSG
DMJIBSG DN OBE-101
DMJIBSG HS Phase 2
DMJIBSG CP OBEcure
DMJIBSG DE Obesity
DM5D6Y7 ID DM5D6Y7
DM5D6Y7 DN OBI-3424
DM5D6Y7 HS Phase 2
DM5D6Y7 SN UNII-X6SH5T8H76; X6SH5T8H76; CHEMBL4297474; SCHEMBL20870529; 2097713-68-1; 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide; Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-(3-(3-((dimethylamino)carbonyl)phenoxy)-4-nitrophenyl)ethyl ester
DM5D6Y7 CP OBI Pharma
DM5D6Y7 DT Small molecular drug
DM5D6Y7 PC 126961329
DM5D6Y7 MW 460.4
DM5D6Y7 FM C21H25N4O6P
DM5D6Y7 IC InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1
DM5D6Y7 CS C[C@H](C1=CC(=C(C=C1)[N+](=O)[O-])OC2=CC=CC(=C2)C(=O)N(C)C)OP(=O)(N3CC3)N4CC4
DM5D6Y7 IK NWGZZGNICQFUHV-OAHLLOKOSA-N
DM5D6Y7 IU 3-[5-[(1R)-1-[bis(aziridin-1-yl)phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide
DM5D6Y7 CA CAS 2097713-68-1
DM5D6Y7 DE Hepatocellular carcinoma; Prostate cancer; Solid tumour/cancer; Acute lymphoblastic leukaemia
DMVXZC4 ID DMVXZC4
DMVXZC4 DN OBP-601
DMVXZC4 HS Phase 2
DMVXZC4 SN Festinavir; Ed4T; Nucleoside reverse transcriptase inhibitor (HIV infection), Oncolys; Nucleoside reverse transcriptase inhibitor (HIV infection), Yale; 4'-Ed4T; 4'-ethynylstavudine
DMVXZC4 CP Bristol-myers squibb
DMVXZC4 DT Small molecular drug
DMVXZC4 PC 3008897
DMVXZC4 MW 248.23
DMVXZC4 FM C12H12N2O4
DMVXZC4 IC InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
DMVXZC4 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
DMVXZC4 IK OSYWBJSVKUFFSU-SKDRFNHKSA-N
DMVXZC4 IU 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
DMVXZC4 CA CAS 634907-30-5
DMVXZC4 DE Human immunodeficiency virus-1 infection
DM1JBD8 ID DM1JBD8
DM1JBD8 DN OC-000459
DM1JBD8 HS Phase 2
DM1JBD8 SN OC-1768; OC-2125; OC-2184; OC-459; OC-499; ODC-9101; CRTH2 antagonists (asthma/allergy), Oxagen
DM1JBD8 CP Oxagen Ltd
DM1JBD8 DT Small molecular drug
DM1JBD8 PC 11462174
DM1JBD8 MW 348.4
DM1JBD8 FM C21H17FN2O2
DM1JBD8 IC InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)
DM1JBD8 CS CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3
DM1JBD8 IK FATGTHLOZSXOBC-UHFFFAOYSA-N
DM1JBD8 IU 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid
DM1JBD8 CA CAS 851723-84-7
DM1JBD8 DE Allergy
DMP6B59 ID DMP6B59
DMP6B59 DN Ocaperidone
DMP6B59 HS Phase 2
DMP6B59 SN Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
DMP6B59 CP Johnson & Johnson
DMP6B59 DT Small molecular drug
DMP6B59 PC 71351
DMP6B59 MW 420.5
DMP6B59 FM C24H25FN4O2
DMP6B59 IC InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
DMP6B59 CS CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
DMP6B59 IK ZZQNEJILGNNOEP-UHFFFAOYSA-N
DMP6B59 IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
DMP6B59 CA CAS 129029-23-8
DMP6B59 DE Schizoaffective disorder; Schizophrenia; Idiopathic pulmonary fibrosis; Type-2 diabetes; Diabetic nephropathy; Pancreatic cancer
DM8TDBY ID DM8TDBY
DM8TDBY DN OCFENTANIL
DM8TDBY HS Phase 2
DM8TDBY SN Ocfentanil < Rec INN; A-3217 (hydrochloride); N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide; 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; 2'-Fluoro-2-methoxy-N-(1-phenethyl-4-piperidinyl)acetanilide
DM8TDBY DT Small molecular drug
DM8TDBY PC 60575
DM8TDBY MW 370.5
DM8TDBY FM C22H27FN2O2
DM8TDBY IC InChI=1S/C22H27FN2O2/c1-27-17-22(26)25(21-10-6-5-9-20(21)23)19-12-15-24(16-13-19)14-11-18-7-3-2-4-8-18/h2-10,19H,11-17H2,1H3
DM8TDBY CS COCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3F
DM8TDBY IK NYISTOZKVCMVEL-UHFFFAOYSA-N
DM8TDBY IU N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide
DM8TDBY CA CAS 101343-69-5
DM8TDBY DE Pain
DMT9QI2 ID DMT9QI2
DMT9QI2 DN OCV-101
DMT9QI2 HS Phase 2
DMT9QI2 SN OTS-11101
DMT9QI2 CP OncoTherapy Science Inc
DMT9QI2 DE Pancreatic cancer
DMK0MJP ID DMK0MJP
DMK0MJP DN Odelepran
DMK0MJP HS Phase 2
DMK0MJP SN Odelepran hydrochloride; LY2196044 HCl; LY-2196044; OpRA (alcohol dependence), Eli Lilly; OpRA II (alcoholism), Eli Lilly; Opioid receptor antagonist (alcoholism), Eli Lilly
DMK0MJP CP Eli Lilly & Co
DMK0MJP DT Small molecular drug
DMK0MJP PC 10457387
DMK0MJP MW 373.4
DMK0MJP FM C20H24FN3O3
DMK0MJP IC InChI=1S/C20H24FN3O3/c21-17-11-15(12-23-8-5-14-6-9-26-10-7-14)1-3-18(17)27-19-4-2-16(13-24-19)20(22)25/h1-4,11,13-14,23H,5-10,12H2,(H2,22,25)
DMK0MJP CS C1COCCC1CCNCC2=CC(=C(C=C2)OC3=NC=C(C=C3)C(=O)N)F
DMK0MJP IK QWNDOCKIKKQJNN-UHFFFAOYSA-N
DMK0MJP IU 6-[2-fluoro-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyridine-3-carboxamide
DMK0MJP CA CAS 676501-25-0
DMK0MJP DE Alcohol dependence
DMJL4A7 ID DMJL4A7
DMJL4A7 DN O-desulfated heparin
DMJL4A7 HS Phase 2
DMJL4A7 SN Intravenous
DMJL4A7 CP ParinGenix
DMJL4A7 DE Chronic obstructive pulmonary disease
DMWCBY7 ID DMWCBY7
DMWCBY7 DN Odiparcil
DMWCBY7 HS Phase 2
DMWCBY7 SN SB-424323
DMWCBY7 CP GlaxoSmithKline
DMWCBY7 DT Small molecular drug
DMWCBY7 PC 216385
DMWCBY7 MW 324.4
DMWCBY7 FM C15H16O6S
DMWCBY7 IC InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1
DMWCBY7 CS CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O
DMWCBY7 IK JRHNIQQUVJOPQC-AQNFWKISSA-N
DMWCBY7 IU 4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one
DMWCBY7 CA CAS 137215-12-4
DMWCBY7 DE Cardiovascular disease
DMVC90W ID DMVC90W
DMVC90W DN Oglemilast
DMVC90W HS Phase 2
DMVC90W SN GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark
DMVC90W CP Glenmark Pharmaceuticals Ltd
DMVC90W DT Small molecular drug
DMVC90W PC 11387409
DMVC90W MW 516.299
DMVC90W FM C20H13Cl2F2N3O5S
DMVC90W IC InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)
DMVC90W CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F
DMVC90W IK OKFDRAHPFKMAJH-UHFFFAOYSA-N
DMVC90W IU N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
DMVC90W CA CAS 778576-62-8
DMVC90W DE Asthma
DMJTU8D ID DMJTU8D
DMJTU8D DN OGX-427
DMJTU8D HS Phase 2
DMJTU8D CP Isis Pharmaceuticals & OncoGenex
DMJTU8D TC Antisense
DMJTU8D DT Antisense drug
DMJTU8D PC 71710946
DMJTU8D MW 7157
DMJTU8D FM C224H304N79O116P19S19
DMJTU8D IC InChI=1S/C224H304N79O116P19S19/c1-88-46-284(216(318)257-168(88)225)129-34-97(401-420(327,439)363-60-114-102(39-134(386-114)289-52-94(7)187(306)281-222(289)324)406-421(328,440)362-56-110-98(35-130(381-110)285-47-89(2)169(226)258-217(285)319)402-422(329,441)368-63-119-107(44-139(390-119)297-81-252-147-182(297)267-211(237)276-194(147)313)411-430(337,449)372-66-121-108(45-140(392-121)298-82-253-148-183(298)268-212(238)277-195(148)314)412-431(338,450)375-69-123-154(163(357-29-21-349-13)201(396-123)292-54-96(9)189(308)283-224(292)326)414-435(342,454)377-70-124-155(162(356-28-20-348-12)200(395-124)290-51-93(6)173(230)262-221(290)323)415-436(343,455)378-72-126-157(165(359-31-23-351-15)203(398-126)300-84-247-142-175(232)243-76-245-177(142)300)417-433(340,452)374-68-122-152(305)160(354-26-18-346-10)199(394-122)291-53-95(8)188(307)282-223(291)325)111(382-129)57-364-426(333,445)407-103-40-135(293-77-248-143-178(293)263-207(233)272-190(143)309)387-116(103)61-367-423(330,442)403-99-36-131(286-48-90(3)170(227)259-218(286)320)384-113(99)59-366-428(335,447)409-105-42-137(295-79-250-145-180(295)265-209(235)274-192(145)311)391-120(105)65-371-429(336,448)410-106-43-138(296-80-251-146-181(296)266-210(236)275-193(146)312)389-118(106)62-369-424(331,443)404-100-37-132(287-49-91(4)171(228)260-219(287)321)383-112(100)58-365-427(334,446)408-104-41-136(294-78-249-144-179(294)264-208(234)273-191(144)310)388-117(104)64-370-425(332,444)405-101-38-133(288-50-92(5)172(229)261-220(288)322)385-115(101)67-373-432(339,451)416-156-125(397-202(164(156)358-30-22-350-14)299-83-246-141-174(231)242-75-244-176(141)299)71-379-437(344,456)419-159-128(400-206(167(159)361-33-25-353-17)303-87-256-151-186(303)271-215(241)280-198(151)317)74-380-438(345,457)418-158-127(399-205(166(158)360-32-24-352-16)302-86-255-150-185(302)270-214(240)279-197(150)316)73-376-434(341,453)413-153-109(55-304)393-204(161(153)355-27-19-347-11)301-85-254-149-184(301)269-213(239)278-196(149)315/h46-54,75-87,97-140,152-167,199-206,304-305H,18-45,55-74H2,1-17H3,(H,327,439)(H,328,440)(H,329,441)(H,330,442)(H,331,443)(H,332,444)(H,333,445)(H,334,446)(H,335,447)(H,336,448)(H,337,449)(H,338,450)(H,339,451)(H,340,452)(H,341,453)(H,342,454)(H,343,455)(H,344,456)(H,345,457)(H2,225,257,318)(H2,226,258,319)(H2,227,259,320)(H2,228,260,321)(H2,229,261,322)(H2,230,262,323)(H2,231,242,244)(H2,232,243,245)(H,281,306,324)(H,282,307,325)(H,283,308,326)(H3,233,263,272,309)(H3,234,264,273,310)(H3,235,265,274,311)(H3,236,266,275,312)(H3,237,267,276,313)(H3,238,268,277,314)(H3,239,269,278,315)(H3,240,270,279,316)(H3,241,271,280,317)/t97?,98?,99?,100?,101?,102?,103?,104?,105?,106?,107?,108?,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,152?,153?,154?,155?,156?,157?,158?,159?,160?,161?,162?,163?,164?,165?,166?,167?,199-,200-,201-,202-,203-,204-,205-,206-,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m1/s1
DMJTU8D CS CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)COP(=S)(O)OC3C[C@@H](O[C@@H]3COP(=S)(O)OC4C[C@@H](O[C@@H]4COP(=S)(O)OC5C[C@@H](O[C@@H]5COP(=S)(O)OC6C[C@@H](O[C@@H]6COP(=S)(O)OC7C[C@@H](O[C@@H]7COP(=S)(O)OC8C[C@@H](O[C@@H]8COP(=O)(OC9C[C@@H](O[C@@H]9COP(=S)(O)OC1C[C@@H](O[C@@H]1COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=NC2=C1N=CNC2=N)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DMJTU8D IK RMTMMKNSPRRFHW-SVAVBUBPSA-N
DMJTU8D IU 1-[(2R,5R)-5-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[hydroxy-[[(2R,5R)-3-[hydroxy-[[(2R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(6-imino-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJTU8D CA CAS 1002331-21-6
DMJTU8D DE Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer
DMNEHY1 ID DMNEHY1
DMNEHY1 DN OI338GT
DMNEHY1 HS Phase 2
DMNEHY1 CP Novo Nordisk
DMNEHY1 DE Type-1/2 diabetes; Type-1 diabetes; Type-2 diabetes
DMVW5KR ID DMVW5KR
DMVW5KR DN Olcegepant
DMVW5KR HS Phase 2
DMVW5KR SN Olcegepant [INN]; BIBN 4096; BIBN 4096 BS; BIBN-4096; BIBN-4096BS; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR CP Boehringer Ingelheim
DMVW5KR DT Small molecular drug
DMVW5KR PC 6918509
DMVW5KR MW 869.6
DMVW5KR FM C38H47Br2N9O5
DMVW5KR IC InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1
DMVW5KR CS C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6
DMVW5KR IK ITIXDWVDFFXNEG-JHOUSYSJSA-N
DMVW5KR IU N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR CA CAS 204697-65-4
DMVW5KR DE Migraine
DM0RA8F ID DM0RA8F
DM0RA8F DN Oleoyl-estrone
DM0RA8F HS Phase 2
DM0RA8F SN Anti-obesity hormone-based therapy, Manhattan
DM0RA8F CP Oleoyl-Estrone Developments
DM0RA8F DT Small molecular drug
DM0RA8F PC 6918373
DM0RA8F MW 534.8
DM0RA8F FM C36H54O3
DM0RA8F IC InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1
DM0RA8F CS CCCCCCCC/C=C\\CCCCCCCC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C
DM0RA8F IK IMIPDPVHGGHVNH-YWVHRCQQSA-N
DM0RA8F IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate
DM0RA8F CA CAS 180003-17-2
DM0RA8F DE Obesity; Alzheimer disease; Psychotic disorder
DMXL7HO ID DMXL7HO
DMXL7HO DN OLX10010
DMXL7HO HS Phase 2
DMXL7HO SN OLX 101A
DMXL7HO CP Olix Pharmaceuticals
DMXL7HO DT Small interfering RNA
DMXL7HO DE Hypertrophic scars
DMLMNFX ID DMLMNFX
DMLMNFX DN Omaveloxolone
DMLMNFX HS Phase 2
DMLMNFX SN RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
DMLMNFX CP Reata Pharmaceuticals Irving, TX
DMLMNFX DT Small molecular drug
DMLMNFX PC 71811910
DMLMNFX MW 554.7
DMLMNFX FM C33H44F2N2O3
DMLMNFX IC InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
DMLMNFX CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
DMLMNFX IK RJCWBNBKOKFWNY-IDPLTSGASA-N
DMLMNFX IU N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
DMLMNFX CA CAS 1474034-05-3
DMLMNFX DE Friedreich's ataxia; Melanoma; Psychiatric disorder
DMH9RTV ID DMH9RTV
DMH9RTV DN Omigapil
DMH9RTV HS Phase 2
DMH9RTV SN Omigapil); CGP-3466; CGP-3499B; Neuroprotectant, Novartis; Neuroprotectant, Santhera; Nootropic agent, Novartis; Nootropicagent, Santhera; SNT-317; TCH-346; TCH-346B
DMH9RTV CP Novartis AG
DMH9RTV DT Small molecular drug
DMH9RTV PC 6419718
DMH9RTV MW 275.3
DMH9RTV FM C19H17NO
DMH9RTV IC InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3
DMH9RTV CS CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31
DMH9RTV IK QLMMOGWZCFQAPU-UHFFFAOYSA-N
DMH9RTV IU N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine
DMH9RTV CA CAS 181296-84-4
DMH9RTV CB CHEBI:41778
DMH9RTV DE Lateral sclerosis; Muscular dystrophy
DMWC36Y ID DMWC36Y
DMWC36Y DN OMS405
DMWC36Y HS Phase 2
DMWC36Y CP Omeros
DMWC36Y DE Nicotine dependence; Opioid dependence
DMA4OGL ID DMA4OGL
DMA4OGL DN OMS824
DMA4OGL HS Phase 2
DMA4OGL SN OMS-824
DMA4OGL CP Omeros
DMA4OGL DE Huntington disease
DMT6E5N ID DMT6E5N
DMT6E5N DN Onapristone
DMT6E5N HS Phase 2
DMT6E5N SN Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-
DMT6E5N CP Context Therapeutics
DMT6E5N DT Small molecular drug
DMT6E5N PC 5311505
DMT6E5N MW 449.6
DMT6E5N FM C29H39NO3
DMT6E5N IC InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
DMT6E5N CS C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C
DMT6E5N IK IEXUMDBQLIVNHZ-YOUGDJEHSA-N
DMT6E5N IU (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMT6E5N CA CAS 96346-61-1
DMT6E5N DE Breast cancer
DMM5SCF ID DMM5SCF
DMM5SCF DN ONC201
DMM5SCF HS Phase 2
DMM5SCF SN Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
DMM5SCF CP Oncoceutics Philadelphia, PA
DMM5SCF PC 73777259
DMM5SCF MW 386.5
DMM5SCF FM C24H26N4O
DMM5SCF IC InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
DMM5SCF CS CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5
DMM5SCF IK VLULRUCCHYVXOH-UHFFFAOYSA-N
DMM5SCF IU 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
DMM5SCF CA CAS 1616632-77-9
DMM5SCF DE Glioma; Endometrial cancer; leukaemia; Lymphoma; Multiple myeloma; Neuroendocrine cancer; Recurring respiratory infection; Solid tumour/cancer
DMKIZAL ID DMKIZAL
DMKIZAL DN ONO-1603
DMKIZAL HS Phase 2
DMKIZAL SN N-(4-Chlorobenzyl)-4-[2(S)-formylpyrrolidin-1-yl]-4-oxobutyramide
DMKIZAL DT Small molecular drug
DMKIZAL PC 9797271
DMKIZAL MW 322.78
DMKIZAL FM C16H19ClN2O3
DMKIZAL IC InChI=1S/C16H19ClN2O3/c17-13-5-3-12(4-6-13)10-18-15(21)7-8-16(22)19-9-1-2-14(19)11-20/h3-6,11,14H,1-2,7-10H2,(H,18,21)/t14-/m0/s1
DMKIZAL CS C1C[C@H](N(C1)C(=O)CCC(=O)NCC2=CC=C(C=C2)Cl)C=O
DMKIZAL IK KGDFDVHLEYUZLN-AWEZNQCLSA-N
DMKIZAL IU N-[(4-chlorophenyl)methyl]-4-[(2S)-2-formylpyrrolidin-1-yl]-4-oxobutanamide
DMKIZAL DE Cognitive impairment
DMOT0WR ID DMOT0WR
DMOT0WR DN ONO-2333Ms
DMOT0WR HS Phase 2
DMOT0WR SN Corticotropin-releasing factor-1 antagonist (oral, anxiety/depression), Ono
DMOT0WR CP Ono Pharmaceutical Co Ltd
DMOT0WR PC 9801039
DMOT0WR MW 398.9
DMOT0WR FM C22H27ClN4O
DMOT0WR IC InChI=1S/C22H27ClN4O/c1-5-14(6-2)24-21-17-8-7-9-19(17)25-22-20(13(3)26-27(21)22)16-11-10-15(28-4)12-18(16)23/h10-12,14,24H,5-9H2,1-4H3
DMOT0WR CS CCC(CC)NC1=C2CCCC2=NC3=C(C(=NN31)C)C4=C(C=C(C=C4)OC)Cl
DMOT0WR IK LDIOUQIXNSSOGU-UHFFFAOYSA-N
DMOT0WR IU 10-(2-chloro-4-methoxyphenyl)-11-methyl-N-pentan-3-yl-1,8,12-triazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-2-amine
DMOT0WR CA CAS 441060-02-2
DMOT0WR DE Anxiety disorder
DMOGYQ0 ID DMOGYQ0
DMOGYQ0 DN ONO-2952
DMOGYQ0 HS Phase 2
DMOGYQ0 SN Translocator protein 18kDr (TSPO) antagonist (irritable bowel syndrome), Ono Pharmaceutical
DMOGYQ0 CP Ono Pharmaceutical Co Ltd
DMOGYQ0 PC 11524127
DMOGYQ0 MW 398.9
DMOGYQ0 FM C22H20ClFN2O2
DMOGYQ0 IC InChI=1S/C22H20ClFN2O2/c1-12(27)26-11-22(8-9-22)19-18-15(24)4-3-5-16(18)25-20(19)21(26)14-7-6-13(23)10-17(14)28-2/h3-7,10,21,25H,8-9,11H2,1-2H3/t21-/m0/s1
DMOGYQ0 CS CC(=O)N1CC2(CC2)C3=C([C@@H]1C4=C(C=C(C=C4)Cl)OC)NC5=C3C(=CC=C5)F
DMOGYQ0 IK ZBQMTQGDBFZUBG-NRFANRHFSA-N
DMOGYQ0 IU 1-[(1S)-1-(4-chloro-2-methoxyphenyl)-5-fluorospiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,1'-cyclopropane]-2-yl]ethanone
DMOGYQ0 CA CAS 895169-20-7
DMOGYQ0 DE Irritable bowel syndrome
DMQGO74 ID DMQGO74
DMQGO74 DN ONO-3307
DMQGO74 HS Phase 2
DMQGO74 SN 4-Guanidinobenzoic acid 4-sulfamoylphenyl ester methanesulfonate
DMQGO74 DT Small molecular drug
DMQGO74 PC 127139
DMQGO74 MW 334.35
DMQGO74 FM C14H14N4O4S
DMQGO74 IC InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21)
DMQGO74 CS C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)S(=O)(=O)N)N=C(N)N
DMQGO74 IK YFUQTMNUQVFBBS-UHFFFAOYSA-N
DMQGO74 IU (4-sulfamoylphenyl) 4-(diaminomethylideneamino)benzoate
DMQGO74 CA CAS 76472-28-1
DMQGO74 DE Coagulation defect
DMX4MVP ID DMX4MVP
DMX4MVP DN ONO-4053
DMX4MVP HS Phase 2
DMX4MVP SN PGD2 receptor antagonist (allergic rhinitis), Ono Pharmaceutical; Prostaglandin D2 receptor antagonists (allergy/inflammation), Ono Pharmaceutical
DMX4MVP CP Ono Pharmaceutical Co Ltd
DMX4MVP DE Allergic rhinitis
DMLUM3Y ID DMLUM3Y
DMLUM3Y DN ONO-4641
DMLUM3Y HS Phase 2
DMLUM3Y SN Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono
DMLUM3Y CP Emd serono
DMLUM3Y PC 11502996
DMLUM3Y MW 435.6
DMLUM3Y FM C27H33NO4
DMLUM3Y IC InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
DMLUM3Y CS CCCC1=CC(=C(C=C1)COC2=CC3=C(C=C2)C(=C(CC3)CN4CC(C4)C(=O)O)C)OC
DMLUM3Y IK QDDQIPUKAXBMBX-UHFFFAOYSA-N
DMLUM3Y IU 1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid
DMLUM3Y CA CAS 891859-12-4
DMLUM3Y DE Rheumatoid arthritis
DMFX3P1 ID DMFX3P1
DMFX3P1 DN ONO-5129
DMFX3P1 HS Phase 2
DMFX3P1 SN Dual PPAR alpha/gamma agonist (metabolic disorder), Ono
DMFX3P1 CP Ono Pharmaceutical Co Ltd
DMFX3P1 DE Diabetic complication
DMRT28X ID DMRT28X
DMRT28X DN ONO-6126
DMRT28X HS Phase 2
DMRT28X SN 21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709
DMRT28X CP Ono Pharmaceuticals
DMRT28X DT Small molecular drug
DMRT28X PC 9864321
DMRT28X MW 373.4
DMRT28X FM C20H27N3O4
DMRT28X IC InChI=1S/C20H27N3O4/c1-26-17-7-6-15(12-18(17)27-16-4-2-3-5-16)20(14-21)8-10-23(11-9-20)13-19(24)22-25/h6-7,12,16,25H,2-5,8-11,13H2,1H3,(H,22,24)
DMRT28X CS COC1=C(C=C(C=C1)C2(CCN(CC2)CC(=O)NO)C#N)OC3CCCC3
DMRT28X IK VXYDHPDQMSVQCU-UHFFFAOYSA-N
DMRT28X IU 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-N-hydroxyacetamide
DMRT28X CA CAS 401519-28-6
DMRT28X DE Chronic obstructive pulmonary disease
DM5O6GC ID DM5O6GC
DM5O6GC DN ONO-9054
DM5O6GC HS Phase 2
DM5O6GC CP Ono pharmaceutical
DM5O6GC DE Glaucoma/ocular hypertension
DMCUGI8 ID DMCUGI8
DMCUGI8 DN ONO-AE1-437
DMCUGI8 HS Phase 2
DMCUGI8 SN 16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1
DMCUGI8 DT Small molecular drug
DMCUGI8 PC 9824353
DMCUGI8 MW 436.6
DMCUGI8 FM C23H32O6S
DMCUGI8 IC InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1
DMCUGI8 CS COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)O)O)O
DMCUGI8 IK ORSJUPRAHPZYRL-XHTUOEPPSA-N
DMCUGI8 IU 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoic acid
DMCUGI8 CA CAS 256382-23-7
DMCUGI8 DE Asthma
DMS8Q7A ID DMS8Q7A
DMS8Q7A DN Ontazolast
DMS8Q7A HS Phase 2
DMS8Q7A SN Ontazolast; UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-
DMS8Q7A CP Boehringer Ingelheim Corp
DMS8Q7A DT Small molecular drug
DMS8Q7A PC 71458
DMS8Q7A MW 335.4
DMS8Q7A FM C21H25N3O
DMS8Q7A IC InChI=1S/C21H25N3O/c1-15-10-11-20-19(13-15)24-21(25-20)23-18(17-9-5-6-12-22-17)14-16-7-3-2-4-8-16/h5-6,9-13,16,18H,2-4,7-8,14H2,1H3,(H,23,24)/t18-/m0/s1
DMS8Q7A CS CC1=CC2=C(C=C1)OC(=N2)N[C@@H](CC3CCCCC3)C4=CC=CC=N4
DMS8Q7A IK RVXKHAITGKBBAC-SFHVURJKSA-N
DMS8Q7A IU N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine
DMS8Q7A CA CAS 147432-77-7
DMS8Q7A DE Asthma
DM0FJIE ID DM0FJIE
DM0FJIE DN Ontuxizumab
DM0FJIE HS Phase 2
DM0FJIE SN Amatuximab
DM0FJIE CP EisaiWoodcliff Lake, NJ MorphotekExton, PA
DM0FJIE DT Antibody
DM0FJIE DE Melanoma; Merkel cell carcinoma; Soft tissue sarcoma; Colorectal cancer
DMB1WF3 ID DMB1WF3
DMB1WF3 DN OPC-14523
DMB1WF3 HS Phase 2
DMB1WF3 SN OPC-14523; UNII-1981OTB4DS; 1981OTB4DS; CHEMBL294144; 145969-30-8; OPC-14523 free base; SCHEMBL5022801; ZINC598353; BDBM50005656; 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-methoxy-3,4-dihydro-2-quinolinone; L001554; 2(1H)-Quinolinone, 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy-
DMB1WF3 CP Otsuka Pharmaceutical and Vela Pharmaceuticals; Pharmos and Otsaku
DMB1WF3 DT Small molecular drug
DMB1WF3 PC 9892540
DMB1WF3 MW 413.9
DMB1WF3 FM C23H28ClN3O2
DMB1WF3 IC InChI=1S/C23H28ClN3O2/c1-29-22-8-3-7-21-20(22)9-10-23(28)27(21)12-4-11-25-13-15-26(16-14-25)19-6-2-5-18(24)17-19/h2-3,5-8,17H,4,9-16H2,1H3
DMB1WF3 CS COC1=CC=CC2=C1CCC(=O)N2CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DMB1WF3 IK TZZGTNZBLPCBIS-UHFFFAOYSA-N
DMB1WF3 IU 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one
DMB1WF3 CA CAS 145969-30-8
DMB1WF3 DE Mood disorder; Bulimia nervosa; Female sexual arousal dysfunction
DMIK2AD ID DMIK2AD
DMIK2AD DN OPC-64005
DMIK2AD HS Phase 2
DMIK2AD CP Otsuka Pharmaceutical
DMIK2AD DE Attention deficit hyperactivity disorder
DML6TAS ID DML6TAS
DML6TAS DN OPI-1002
DML6TAS HS Phase 2
DML6TAS CP Quark Pharm; Pfizer
DML6TAS DT siRNA drug
DML6TAS DE Acute kidney injury
DM1IBRT ID DM1IBRT
DM1IBRT DN OPN-305
DM1IBRT HS Phase 2
DM1IBRT SN OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona
DM1IBRT CP Opsona therapeutics
DM1IBRT DT Antibody
DM1IBRT DE Myelodysplastic syndrome
DMYG1ZQ ID DMYG1ZQ
DMYG1ZQ DN OPNT001
DMYG1ZQ HS Phase 2
DMYG1ZQ CP Opiant Pharmaceuticals Santa Monica, CA
DMYG1ZQ DE Eating disorder
DM16RIC ID DM16RIC
DM16RIC DN Oprozomib
DM16RIC HS Phase 2
DM16RIC CP Onyx Pharmaceuticals
DM16RIC DT Small molecular drug
DM16RIC PC 25067547
DM16RIC MW 532.6
DM16RIC FM C25H32N4O7S
DM16RIC IC InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
DM16RIC CS CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
DM16RIC IK SWZXEVABPLUDIO-WSZYKNRRSA-N
DM16RIC IU N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
DM16RIC CA CAS 935888-69-0
DM16RIC DE Solid tumour/cancer; Hodgkin lymphoma; Multiple myeloma; Haematological malignancy
DMS4XFI ID DMS4XFI
DMS4XFI DN OPT-302
DMS4XFI HS Phase 2
DMS4XFI CP Opthea
DMS4XFI DE Diabetic macular edema
DMR3P98 ID DMR3P98
DMR3P98 DN ORG 34517/34850
DMR3P98 HS Phase 2
DMR3P98 SN Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]
DMR3P98 CP Organon
DMR3P98 DT Small molecular drug
DMR3P98 PC 9576789
DMR3P98 MW 230.27
DMR3P98 FM C11H14N6
DMR3P98 IC InChI=1S/C11H14N6/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17)/b16-9+
DMR3P98 CS C1C/C(=N\\N=C(N)N)/C2=C1C(=CC=C2)C(=N)N
DMR3P98 IK CYPGNVSXMAUSJY-CXUHLZMHSA-N
DMR3P98 IU (1E)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide
DMR3P98 CA CAS 149400-88-4
DMR3P98 DE Solid tumour/cancer; Mood disorder
DMAWXJT ID DMAWXJT
DMAWXJT DN ORG-13011
DMAWXJT HS Phase 2
DMAWXJT SN FIBOFLAPON; 936350-00-4; UNII-Y1NA96IX3T; Y1NA96IX3T; CHEMBL1922660; Fiboflapon [USAN:INN]; AM803; Fiboflapon (USAN); AM-803; AM 803; SCHEMBL11820; DTXSID20239496; DFQGDHBGRSTTHX-UHFFFAOYSA-N; GSK2190915B; ZINC68247071; BDBM50359080; AKOS030527019; SB16524; CS-3604; Fiboflapon; NCGC00485966-01; HY-15874; 1H-Indole-2-propanoic acid, 3-((1,1-dimethylethyl)thio)-1-((4-(6-ethoxy-3-pyridinyl)phenyl)methyl)-alpha,alpha-Dimethyl-5-((5-methyl-2-pyridinyl)methoxy)-; D10069
DMAWXJT DT Small molecular drug
DMAWXJT PC 9907401
DMAWXJT MW 370.4
DMAWXJT FM C18H25F3N4O
DMAWXJT IC InChI=1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2
DMAWXJT CS C1CC(=O)N(C1)CCCCN2CCN(CC2)C3=NC=CC(=C3)C(F)(F)F
DMAWXJT IK YKJJCYZZWWSBEW-UHFFFAOYSA-N
DMAWXJT IU 1-[4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]butyl]pyrrolidin-2-one
DMAWXJT CA CAS 142494-12-0
DMAWXJT DE Psychotic disorder; Anxiety disorder; Major depressive disorder
DMWN2EC ID DMWN2EC
DMWN2EC DN ORG-25935
DMWN2EC HS Phase 2
DMWN2EC SN Cis-N-(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-N-methylglycine hydrochloride
DMWN2EC DT Small molecular drug
DMWN2EC PC 11717074
DMWN2EC MW 339.4
DMWN2EC FM C21H25NO3
DMWN2EC IC InChI=1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1
DMWN2EC CS CN(C[C@H]1CCC2=C([C@H]1C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O
DMWN2EC IK UEBBYLJZCHTLEG-UTKZUKDTSA-N
DMWN2EC IU 2-[[(1R,2S)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino]acetic acid
DMWN2EC CA CAS 1147011-84-4
DMWN2EC DE Psychotic disorder
DMDZ4R2 ID DMDZ4R2
DMDZ4R2 DN Org-30029
DMDZ4R2 HS Phase 2
DMDZ4R2 SN Org-30029; Org 30029; 101041-95-6; N'-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide hydrochloride; DTXSID50143698; AKOS015848621; Benzo(b)thiophene-2-carboximidamide, N-hydroxy-5,6-dimethoxy-, monohydrochloride; (Z)-N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide hydrochloride
DMDZ4R2 CP Organon BioSciences
DMDZ4R2 DT Small molecular drug
DMDZ4R2 PC 9576838
DMDZ4R2 MW 288.75
DMDZ4R2 FM C11H13ClN2O3S
DMDZ4R2 IC InChI=1S/C11H12N2O3S.ClH/c1-15-7-3-6-4-10(11(12)13-14)17-9(6)5-8(7)16-2;/h3-5,14H,1-2H3,(H2,12,13);1H
DMDZ4R2 CS COC1=C(C=C2C(=C1)C=C(S2)/C(=N/O)/N)OC.Cl
DMDZ4R2 IK DVWBMWJOYIFITF-UHFFFAOYSA-N
DMDZ4R2 IU N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride
DMDZ4R2 CA CAS 101041-95-6
DMDZ4R2 DE Heart failure
DMIO59F ID DMIO59F
DMIO59F DN ORG-34517
DMIO59F HS Phase 2
DMIO59F SN 11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
DMIO59F CP Organon
DMIO59F DT Small molecular drug
DMIO59F PC 9867361
DMIO59F MW 430.5
DMIO59F FM C28H30O4
DMIO59F IC InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1
DMIO59F CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC6=C(C=C5)OCO6)C)O
DMIO59F IK DFELGYQKEOCHOA-BZAFBGKRSA-N
DMIO59F IU (8S,11R,13S,14S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMIO59F CA CAS 189035-07-2
DMIO59F DE Depression
DM8ARQW ID DM8ARQW
DM8ARQW DN ORM-12741
DM8ARQW HS Phase 2
DM8ARQW SN Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion
DM8ARQW CP Orion Corp
DM8ARQW DT Small molecular drug
DM8ARQW PC 71301276
DM8ARQW MW 285.4
DM8ARQW FM C18H23NO2
DM8ARQW IC InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1
DM8ARQW CS C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC
DM8ARQW IK OCUKPFWNSAAHRP-QZTJIDSGSA-N
DM8ARQW IU (1S,12bS)-1-(methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine
DM8ARQW CA CAS 610782-82-6
DM8ARQW DE Alzheimer disease
DMRIO6D ID DMRIO6D
DMRIO6D DN ORMD-0901
DMRIO6D HS Phase 2
DMRIO6D SN Exenatide-4 (oral, diabetes), Oramed; GLP1-analog (oral, non-insulin dependent diabetes), Oramed Pharmaceuticals
DMRIO6D CP Oramed Pharmaceuticals Inc
DMRIO6D DE Type-2 diabetes
DM1EK5D ID DM1EK5D
DM1EK5D DN Ortataxel
DM1EK5D HS Phase 2
DM1EK5D SN UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,; Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155
DM1EK5D CP Spectrum
DM1EK5D DT Small molecular drug
DM1EK5D PC 6918412
DM1EK5D MW 871.9
DM1EK5D FM C44H57NO17
DM1EK5D IC InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1
DM1EK5D CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C
DM1EK5D IK BWKDAMBGCPRVPI-ZQRPHVBESA-N
DM1EK5D IU [(1S,2S,3R,4S,7R,9S,10S,12R,15R,16S)-4,12-diacetyloxy-9-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benzoate
DM1EK5D CA CAS 186348-23-2
DM1EK5D DE Solid tumour/cancer; Heart transplant rejection
DMSO846 ID DMSO846
DMSO846 DN Orvepitant
DMSO846 HS Phase 2
DMSO846 SN Orvepitant; UNII-IIU6V0W3JD; 579475-18-6; GW823296X; IIU6V0W3JD; GW823296; Orvepitant [USAN:INN]; Orvepitant (USAN/INN); SCHEMBL1421784; CHEMBL2105667; XWNBGDJPEXZSQM-VZOBGQTKSA-N; BDBM50442585; ZINC56898864; AKOS030231272; SB17117; DB12427; NCGC00386593-01; (2R,4S)-N-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-4-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)piperidine-1-c; D09650
DMSO846 CP GSK
DMSO846 DT Small molecular drug
DMSO846 PC 9852175
DMSO846 MW 628.6
DMSO846 FM C31H35F7N4O2
DMSO846 IC InChI=1S/C31H35F7N4O2/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3/t19-,24+,25+,27-/m1/s1
DMSO846 CS CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5[C@H](C4)CCC5=O
DMSO846 IK XWNBGDJPEXZSQM-VZOBGQTKSA-N
DMSO846 IU (2R,4S)-4-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
DMSO846 CA CAS 579475-18-6
DMSO846 DE Anxiety disorder; Depression
DMJX3O8 ID DMJX3O8
DMJX3O8 DN OSI-027
DMJX3O8 HS Phase 2
DMJX3O8 CP OSI
DMJX3O8 DT Small molecular drug
DMJX3O8 PC 135398516
DMJX3O8 MW 406.4
DMJX3O8 FM C21H22N6O3
DMJX3O8 IC InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)
DMJX3O8 CS COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N
DMJX3O8 IK JROFGZPOBKIAEW-UHFFFAOYSA-N
DMJX3O8 IU 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid
DMJX3O8 CA CAS 936890-98-1
DMJX3O8 CB CHEBI:91363
DMJX3O8 DE Renal cell carcinoma
DMBVI6E ID DMBVI6E
DMBVI6E DN Ostabolin-C
DMBVI6E HS Phase 2
DMBVI6E CP Zelos Therape.
DMBVI6E DE Osteoporosis
DMHKIOF ID DMHKIOF
DMHKIOF DN OT551
DMHKIOF HS Phase 2
DMHKIOF CP Colby Pharmaceuticals
DMHKIOF DT Small interfering RNA
DMHKIOF DE Age-related macular degeneration
DMTNOXQ ID DMTNOXQ
DMTNOXQ DN OT-551
DMTNOXQ HS Phase 2
DMTNOXQ SN Tempol-H prodrug, Othera
DMTNOXQ CP Othera Pharmaceuticals Inc
DMTNOXQ DT Small molecular drug
DMTNOXQ PC 10131000
DMTNOXQ MW 241.33
DMTNOXQ FM C13H23NO3
DMTNOXQ IC InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3
DMTNOXQ CS CC1(CC(CC(N1O)(C)C)OC(=O)C2CC2)C
DMTNOXQ IK ZWEXEKJLDHNLLA-UHFFFAOYSA-N
DMTNOXQ IU (1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate
DMTNOXQ CA CAS 627085-11-4
DMTNOXQ DE Ocular inflammation
DMFNDBC ID DMFNDBC
DMFNDBC DN Otelixizumab
DMFNDBC HS Phase 2
DMFNDBC CP GSK
DMFNDBC DT Monoclonal antibody
DMFNDBC DE Type-1 diabetes
DM1AQLW ID DM1AQLW
DM1AQLW DN Otilimab
DM1AQLW HS Phase 2
DM1AQLW SN Otilimab [USAN]; UNII-Y8127R3VCH; Y8127R3VCH; MOR103; GSK3196165; 1638332-55-4; human monoclonal antibody
DM1AQLW TC Antiviral Agents
DM1AQLW DT Monoclonal antibody
DM1AQLW DE Coronavirus Disease 2019 (COVID-19)
DMAZIND ID DMAZIND
DMAZIND DN Otlertuzumab
DMAZIND HS Phase 2
DMAZIND CP Aptevo Therapeutics Seattle, WA
DMAZIND DE Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma
DM5Q9RY ID DM5Q9RY
DM5Q9RY DN OX-914
DM5Q9RY HS Phase 2
DM5Q9RY CP Inflazyme Pharmaceuticals
DM5Q9RY DE Asthma
DMBM47Z ID DMBM47Z
DMBM47Z DN Oxazolidinones
DMBM47Z HS Phase 2
DMBM47Z SN 2-Oxazolidone; Oxazolidin-2-one; 2-Oxazolidinone; 497-25-6; 1,3-Oxazolidin-2-one; Oxazolidinone; Oxazolidone; UNII-Z4D49W92PP; EINECS 207-840-9; NSC 35382; BRN 0106251; AI3-38980; CHEBI:1237; Z4D49W92PP; IZXIZTKNFFYFOF-UHFFFAOYSA-N; Carbamic acid, (2-hydroxyethyl)-, gamma-lactone; MFCD00005268; 2-Oxazolidone, 98%; WLN: T5MVOTJ; 51667-26-6; Carbamic acid, .gamma.-lactone; Oxazolidinones; SMR000857362; oxazolodinone; hydroxyoxazoline; 2-oxazolidinon; hydroxy-oxazoline; 2-Oxazolidine; oxazolidine-2-one; PubChem8624; ACMC-209upq; AC1Q6HSI
DMBM47Z DT Small molecular drug
DMBM47Z PC 73949
DMBM47Z MW 87.08
DMBM47Z FM C3H5NO2
DMBM47Z IC InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)
DMBM47Z CS C1COC(=O)N1
DMBM47Z IK IZXIZTKNFFYFOF-UHFFFAOYSA-N
DMBM47Z IU 1,3-oxazolidin-2-one
DMBM47Z CA CAS 497-25-6
DMBM47Z CB CHEBI:1237
DMBM47Z DE Gram-positive bacterial infection
DMSNL51 ID DMSNL51
DMSNL51 DN Oxfendazole
DMSNL51 HS Phase 2
DMSNL51 SN Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)
DMSNL51 PC 40854
DMSNL51 MW 315.3
DMSNL51 FM C15H13N3O3S
DMSNL51 IC InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)
DMSNL51 CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3
DMSNL51 IK BEZZFPOZAYTVHN-UHFFFAOYSA-N
DMSNL51 IU methyl N-[6-(benzenesulfinyl)-1H-benzimidazol-2-yl]carbamate
DMSNL51 CA CAS 53716-50-0
DMSNL51 CB CHEBI:35812
DMSNL51 DE Trichuris infection
DMC3PJS ID DMC3PJS
DMC3PJS DN Oxytrex
DMC3PJS HS Phase 2
DMC3PJS DE Pain
DMEGTH1 ID DMEGTH1
DMEGTH1 DN Ozarelix
DMEGTH1 HS Phase 2
DMEGTH1 CP Spectrum
DMEGTH1 PC 25080293
DMEGTH1 MW 1459.1
DMEGTH1 FM C72H96ClN17O14
DMEGTH1 IC InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1
DMEGTH1 CS CCCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMEGTH1 IK KATZUZNTRINHDT-HALMFYTRSA-N
DMEGTH1 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMEGTH1 CA CAS 295350-45-7
DMEGTH1 DE Prostate disease
DMEYQPN ID DMEYQPN
DMEYQPN DN P-1736
DMEYQPN HS Phase 2
DMEYQPN SN Pyyy; GPR40 modulators (diabetes), Nicholas Piramal; GPR40 modulators (diabetes), Piramal Life Sciences; P-1736-05; GPR40 modulators (diabetes), NPIL Research & Development
DMEYQPN CP Piramal Healthcare Ltd
DMEYQPN DE Diabetic complication
DMMJUHD ID DMMJUHD
DMMJUHD DN P-276
DMMJUHD HS Phase 2
DMMJUHD SN CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development
DMMJUHD CP Piramal Healthcare Ltd
DMMJUHD DT Small molecular drug
DMMJUHD PC 23643976
DMMJUHD MW 401.8
DMMJUHD FM C21H20ClNO5
DMMJUHD IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1
DMMJUHD CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMMJUHD IK QLUYMIVVAYRECT-OCCSQVGLSA-N
DMMJUHD IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one
DMMJUHD DE Breast cancer
DM9DJL2 ID DM9DJL2
DM9DJL2 DN P276-00
DM9DJL2 HS Phase 2
DM9DJL2 SN CHEMBL2312181; SCHEMBL1180418
DM9DJL2 CP Nicholas Piramal
DM9DJL2 DT Small molecular drug
DM9DJL2 PC 23643975
DM9DJL2 MW 438.3
DM9DJL2 FM C21H21Cl2NO5
DM9DJL2 IC InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1
DM9DJL2 CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
DM9DJL2 IK OOVTUOCTLAERQD-OJMBIDBESA-N
DM9DJL2 IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
DM9DJL2 CA CAS 920113-03-7
DM9DJL2 DE Mantle cell lymphoma
DMW1OI6 ID DMW1OI6
DMW1OI6 DN P32/98
DMW1OI6 HS Phase 2
DMW1OI6 SN Isoleucine-thiazolidide; AC1OCFGS; MolPort-044-561-375
DMW1OI6 DT Small molecular drug
DMW1OI6 PC 6918464
DMW1OI6 MW 318.39
DMW1OI6 FM C13H22N2O5S
DMW1OI6 IC InChI=1S/C9H18N2OS.C4H4O4/c1-3-7(2)8(10)9(12)11-4-5-13-6-11;5-3(6)1-2-4(7)8/h7-8H,3-6,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t7-,8-;/m0./s1
DMW1OI6 CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)N.C(=C/C(=O)O)\\C(=O)O
DMW1OI6 IK ZSOPWZQRZHWYFY-NUXPJIRBSA-N
DMW1OI6 IU (2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(E)-but-2-enedioic acid
DMW1OI6 DE Autism spectrum disorder
DMCBEYH ID DMCBEYH
DMCBEYH DN P54
DMCBEYH HS Phase 2
DMCBEYH DE Solid tumour/cancer
DMG8NLI ID DMG8NLI
DMG8NLI DN P-9808
DMG8NLI HS Phase 2
DMG8NLI SN Porphogen; Porphozym; PBGD, HemeBiotech; PBGD, Zymenex; Recombinant porphobilinogen deaminase, HemeBiotech; Recombinant porphobilinogen deaminase, Zymenex
DMG8NLI CP Zymenex A/S
DMG8NLI DE Porphyria
DM3816P ID DM3816P
DM3816P DN PAC-14028
DM3816P HS Phase 2
DM3816P CP Pacific Pharmaceuticals Co Ltd
DM3816P PC 56649347
DM3816P MW 491.5
DM3816P FM C21H22F5N3O3S
DM3816P IC InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1
DM3816P CS CCCC1=C(C=CC(=N1)C(F)(F)F)/C=C/C(=O)N[C@H](C)C2=CC(=C(C(=C2)F)NS(=O)(=O)C)F
DM3816P IK UKGJZDSUJSPAJL-YPUOHESYSA-N
DM3816P IU (E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide
DM3816P CA CAS 1005168-10-4
DM3816P DE Atopic dermatitis
DMMIYZ7 ID DMMIYZ7
DMMIYZ7 DN Palifosfamide
DMMIYZ7 HS Phase 2
DMMIYZ7 SN ZIO-201
DMMIYZ7 CP ZIOPHARM Oncology
DMMIYZ7 DT Small molecular drug
DMMIYZ7 PC 100427
DMMIYZ7 MW 221.02
DMMIYZ7 FM C4H11Cl2N2O2P
DMMIYZ7 IC InChI=1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10)
DMMIYZ7 CS C(CCl)NP(=O)(NCCCl)O
DMMIYZ7 IK BKCJZNIZRWYHBN-UHFFFAOYSA-N
DMMIYZ7 IU bis(2-chloroethylamino)phosphinic acid
DMMIYZ7 CA CAS 31645-39-3
DMMIYZ7 CB CHEBI:80566
DMMIYZ7 DE Soft tissue sarcoma
DMX8ZAQ ID DMX8ZAQ
DMX8ZAQ DN Paliroden
DMX8ZAQ HS Phase 2
DMX8ZAQ SN SR-57667; SR-57667B
DMX8ZAQ CP Sanofi-aventis
DMX8ZAQ DT Small molecular drug
DMX8ZAQ PC 11567682
DMX8ZAQ MW 407.5
DMX8ZAQ FM C26H24F3N
DMX8ZAQ IC InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2
DMX8ZAQ CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4
DMX8ZAQ IK CNEWKIDCGDXBDE-UHFFFAOYSA-N
DMX8ZAQ IU 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DMX8ZAQ CA CAS 188396-77-2
DMX8ZAQ DE Parkinson disease
DMAZ460 ID DMAZ460
DMAZ460 DN Pankomab-GEX
DMAZ460 HS Phase 2
DMAZ460 SN GT-MAB 2.5 GEX; PankoMab (GlycoExpress, cancer), Glycotope
DMAZ460 CP Glycotope GmbH
DMAZ460 DT Antibody
DMAZ460 DE Solid tumour/cancer
DMV27SP ID DMV27SP
DMV27SP DN Panobacumab
DMV27SP HS Phase 2
DMV27SP SN KBPA-101; Human monoclonal antibody (Pseudomonas aeruginosa), Berna; MAb (Pseudomonas aeruginosa), Berna
DMV27SP CP Aridis Pharmaceuticals
DMV27SP DT Monoclonal antibody
DMV27SP DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pseudomonas infection
DMPO4M1 ID DMPO4M1
DMPO4M1 DN Paquinimod
DMPO4M1 HS Phase 2
DMPO4M1 SN ABR-215757; ABR-25757; Project 57-57, Active Biotech
DMPO4M1 CP Active Biotech AB
DMPO4M1 DT Small molecular drug
DMPO4M1 PC 54684617
DMPO4M1 MW 350.4
DMPO4M1 FM C21H22N2O3
DMPO4M1 IC InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
DMPO4M1 CS CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C
DMPO4M1 IK DIKSYHCCYVYKRO-UHFFFAOYSA-N
DMPO4M1 IU N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DMPO4M1 CA CAS 248282-01-1
DMPO4M1 DE Lupus
DMD275X ID DMD275X
DMD275X DN Pardoprunox
DMD275X HS Phase 2
DMD275X SN Pardoprunox (USAN/INN); 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one; 7-(4-methylpiperazin-1-yl)-3H-benzooxazol-2-one
DMD275X CP Solvay
DMD275X DT Small molecular drug
DMD275X PC 6918525
DMD275X MW 233.27
DMD275X FM C12H15N3O2
DMD275X IC InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)
DMD275X CS CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3
DMD275X IK YVPUUUDAZYFFQT-UHFFFAOYSA-N
DMD275X IU 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
DMD275X CA CAS 269718-84-5
DMD275X DE Parkinson disease
DM4N7BT ID DM4N7BT
DM4N7BT DN Paritaprevir
DM4N7BT HS Phase 2
DM4N7BT SN (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
DM4N7BT TC Antiviral Agent
DM4N7BT DT Small molecular drug
DM4N7BT PC 45110509
DM4N7BT MW 765.886
DM4N7BT FM C40H43N7O7S
DM4N7BT IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DM4N7BT CS CC1=NC=C(N=C1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DM4N7BT IK UAUIUKWPKRJZJV-QPLHLKROSA-N
DM4N7BT IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DM4N7BT CA CAS 1216941-48-8
DM4N7BT DE Hepatitis C virus infection
DMYBIFS ID DMYBIFS
DMYBIFS DN Parsaclisib
DMYBIFS HS Phase 2
DMYBIFS SN INCB050465; Parsaclisib free base; UNII-OS7097575K; 1426698-88-5 (free base); OS7097575K; 1426698-88-5; (4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one; INCB-050465; (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; Parsaclisib [INN]; Parsaclisib [USAN]; Parsaclisib (USAN/INN); Parsaclisib [USAN:INN]; INCB050465 free base; INCB-050465 free base; CHEMBL4297615; SCHEMBL14736228; BDBM272573; EX-A2638; WHO 10589; DB14867; US10065963, 32c; HY-109068; CS-0033435; D11437; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)-
DMYBIFS CP Incyte
DMYBIFS DT Small molecular drug
DMYBIFS PC 86677874
DMYBIFS MW 432.9
DMYBIFS FM C20H22ClFN6O2
DMYBIFS IC InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
DMYBIFS CS CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
DMYBIFS IK ZQPDJCIXJHUERQ-QWRGUYRKSA-N
DMYBIFS IU (4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
DMYBIFS CA CAS 1426698-88-5
DMYBIFS DE Follicular lymphoma
DMCQBFT ID DMCQBFT
DMCQBFT DN Parthenolide
DMCQBFT HS Phase 2
DMCQBFT SN parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, > MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21
DMCQBFT DT Small molecular drug
DMCQBFT PC 7251185
DMCQBFT MW 248.32
DMCQBFT FM C15H20O3
DMCQBFT IC InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
DMCQBFT CS C/C/1=C\\CC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C
DMCQBFT IK KTEXNACQROZXEV-PVLRGYAZSA-N
DMCQBFT IU (1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one
DMCQBFT CA CAS 20554-84-1
DMCQBFT CB CHEBI:7939
DMU3XJP ID DMU3XJP
DMU3XJP DN Pascolizumab
DMU3XJP HS Phase 2
DMU3XJP SN SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
DMU3XJP CP Novartis
DMU3XJP DT Monoclonal antibody
DMU3XJP DE Asthma
DM2NJYC ID DM2NJYC
DM2NJYC DN Patidegib
DM2NJYC HS Phase 2
DM2NJYC SN Patidegib hydrochloride; UNII-ZL14FCA5PK; 1169829-40-6; ZL14FCA5PK; IPI-926 Hydrochloride; Saridegib HCl; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Saridegib hydrochloride (USAN); CHEMBL2105764; D10325; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)-
DM2NJYC CP PellePharm San Francisco, CA
DM2NJYC PC 25027363
DM2NJYC MW 504.8
DM2NJYC FM C29H48N2O3S
DM2NJYC IC InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1
DM2NJYC CS C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
DM2NJYC IK HZLFFNCLTRVYJG-WWGOJCOQSA-N
DM2NJYC IU N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide
DM2NJYC CA CAS 1037210-93-7
DM2NJYC DE Basal cell carcinoma; Basal cell nevus syndrome; Chondrosarcoma
DMU0812 ID DMU0812
DMU0812 DN PAZ-320
DMU0812 HS Phase 2
DMU0812 CP Boston Therapeutics
DMU0812 DE Type-2 diabetes
DMVJD2W ID DMVJD2W
DMVJD2W DN Pazopanib + Tyverb/Tykerb
DMVJD2W HS Phase 2
DMVJD2W CP GSK
DMVJD2W DT Combination drug
DMVJD2W PC 10113978; 9941095
DMVJD2W DE Inflammatory breast cancer
DMZCI04 ID DMZCI04
DMZCI04 DN PB-1023
DMZCI04 HS Phase 2
DMZCI04 CP PhaseBio Pharmaceuticals
DMZCI04 DE Type-2 diabetes
DM8MJ3F ID DM8MJ3F
DM8MJ3F DN PB1046
DM8MJ3F HS Phase 2
DM8MJ3F SN Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
DM8MJ3F CP Phasebio pharmaceuticals
DM8MJ3F DT Recombinant protein
DM8MJ3F DE Hypertension; Cardiomyopathy; Duchenne dystrophy; Heart failure; Pulmonary arterial hypertension
DM05WIU ID DM05WIU
DM05WIU DN PBI-05204
DM05WIU HS Phase 2
DM05WIU CP Phoenix Biotechnology
DM05WIU PC 11541511
DM05WIU MW 576.7
DM05WIU FM C32H48O9
DM05WIU IC InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
DM05WIU CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O
DM05WIU IK JLPDBLFIVFSOCC-XYXFTTADSA-N
DM05WIU IU [(3S,5R,8R,9S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate
DM05WIU CA CAS 465-16-7
DM05WIU CB CHEBI:59030
DM05WIU DE Solid tumour/cancer; Pancreatic cancer
DMPXK27 ID DMPXK27
DMPXK27 DN PBI-4050
DMPXK27 HS Phase 2
DMPXK27 SN setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887
DMPXK27 CP Liminal BioSciences
DMPXK27 DT Small molecular drug
DMPXK27 PC 24749700
DMPXK27 MW 206.28
DMPXK27 FM C13H18O2
DMPXK27 IC InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)
DMPXK27 CS CCCCCC1=CC(=CC=C1)CC(=O)O
DMPXK27 IK PEGQOIGYZLJMIB-UHFFFAOYSA-N
DMPXK27 IU 2-(3-pentylphenyl)acetic acid
DMPXK27 CA CAS 1002101-19-0
DMPXK27 DE Idiopathic pulmonary fibrosis
DMKWGS1 ID DMKWGS1
DMKWGS1 DN PBT-2
DMKWGS1 HS Phase 2
DMKWGS1 SN AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
DMKWGS1 CP Prana biotechnology
DMKWGS1 DT Small molecular drug
DMKWGS1 PC 10016012
DMKWGS1 MW 271.14
DMKWGS1 FM C12H12Cl2N2O
DMKWGS1 IC InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
DMKWGS1 CS CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
DMKWGS1 IK YZPOQCQXOSEMAZ-UHFFFAOYSA-N
DMKWGS1 IU 5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
DMKWGS1 CA CAS 747408-78-2
DMKWGS1 DE Alzheimer disease; Huntington disease
DMYRIHZ ID DMYRIHZ
DMYRIHZ DN PCL-016
DMYRIHZ HS Phase 2
DMYRIHZ CP Novactyl
DMYRIHZ DE Acne vulgaris
DMYFRTB ID DMYFRTB
DMYFRTB DN PCM-075
DMYFRTB HS Phase 2
DMYFRTB SN Onvansertib
DMYFRTB CP TrovaGene San Diego, CA
DMYFRTB PC 49792852
DMYFRTB MW 532.5
DMYFRTB FM C24H27F3N8O3
DMYFRTB IC InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
DMYFRTB CS CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO
DMYFRTB IK QHLVBNKYJGBCQJ-UHFFFAOYSA-N
DMYFRTB IU 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
DMYFRTB CA CAS 1034616-18-6
DMYFRTB DE Acute myeloid leukaemia; Solid tumour/cancer; Prostate cancer
DMUHDX3 ID DMUHDX3
DMUHDX3 DN PC-SOD
DMUHDX3 HS Phase 2
DMUHDX3 SN PC-SOD (inhaled)
DMUHDX3 CP LTT Bio-Pharma Co Ltd
DMUHDX3 DE Interstitial lung disease
DM27D4J ID DM27D4J
DM27D4J DN PD-0325901
DM27D4J HS Phase 2
DM27D4J SN PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
DM27D4J CP Pfizer
DM27D4J TC Anticancer Agents
DM27D4J DT Small molecular drug
DM27D4J PC 9826528
DM27D4J MW 482.19
DM27D4J FM C16H14F3IN2O4
DM27D4J IC InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
DM27D4J CS C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O
DM27D4J IK SUDAHWBOROXANE-SECBINFHSA-N
DM27D4J IU N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
DM27D4J CA CAS 391210-10-9
DM27D4J CB CHEBI:88249
DM27D4J DE Breast cancer
DMXAH4G ID DMXAH4G
DMXAH4G DN PD-143188
DMXAH4G HS Phase 2
DMXAH4G SN PD-147693; PD-149394; PD-155144; PD-163637; PD-163639
DMXAH4G CP Parke-Davis & Co
DMXAH4G DT Small molecular drug
DMXAH4G PC 101650979
DMXAH4G MW 329.5
DMXAH4G FM C24H27N
DMXAH4G IC InChI=1S/C24H27N/c1-3-9-21(10-4-1)23-14-16-25(17-15-23)19-20-8-7-13-24(18-20)22-11-5-2-6-12-22/h1-7,9-14,20,24H,8,15-19H2/t20-,24?/m1/s1
DMXAH4G CS C1CN(CC=C1C2=CC=CC=C2)C[C@@H]3CC=CC(C3)C4=CC=CC=C4
DMXAH4G IK SDOHTVBFDDPWNE-CGHJUBPDSA-N
DMXAH4G IU 4-phenyl-1-[[(1R)-5-phenylcyclohex-3-en-1-yl]methyl]-3,6-dihydro-2H-pyridine
DMXAH4G DE Psychotic disorder
DMWVBTQ ID DMWVBTQ
DMWVBTQ DN PD-145065
DMWVBTQ HS Phase 2
DMWVBTQ SN N-Acetyl-2-D-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan
DMWVBTQ DT Small molecular drug
DMWVBTQ PC 123959
DMWVBTQ MW 950.1
DMWVBTQ FM C52H67N7O10
DMWVBTQ IC InChI=1S/C52H67N7O10/c1-8-29(5)44(49(65)57-41(52(68)69)25-34-27-53-38-21-15-14-18-35(34)38)59-50(66)45(30(6)9-2)58-48(64)40(26-42(61)62)55-47(63)39(24-28(3)4)56-51(67)46(54-31(7)60)43-36-19-12-10-16-32(36)22-23-33-17-11-13-20-37(33)43/h10-21,27-30,39-41,43-46,53H,8-9,22-26H2,1-7H3,(H,54,60)(H,55,63)(H,56,67)(H,57,65)(H,58,64)(H,59,66)(H,61,62)(H,68,69)/t29-,30-,39-,40-,41-,44-,45-,46+/m0/s1
DMWVBTQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C3C4=CC=CC=C4CCC5=CC=CC=C35)NC(=O)C
DMWVBTQ IK HRAQSWKGRRUBDJ-OMUAVVNCSA-N
DMWVBTQ IU (3S)-3-[[(2S)-2-[[(2R)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMWVBTQ CA CAS 153049-49-1
DMWVBTQ DE Hypertension
DMPW28M ID DMPW28M
DMPW28M DN PD-200390
DMPW28M HS Phase 2
DMPW28M SN AC1L4NQF; SCHEMBL9494809; YPPRSIHNTQEZCJ-UHFFFAOYSA-N; 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide; 3-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-[2-(2-pyridyl)ethyl]-N-methylpropanamide; 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]propanamide
DMPW28M CP Pfizer
DMPW28M DT Small molecular drug
DMPW28M PC 188931
DMPW28M MW 428.6
DMPW28M FM C25H36N2O2S
DMPW28M IC InChI=1S/C25H36N2O2S/c1-24(2,3)20-16-19(17-21(23(20)29)25(4,5)6)30-15-12-22(28)27(7)14-11-18-10-8-9-13-26-18/h8-10,13,16-17,29H,11-12,14-15H2,1-7H3
DMPW28M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SCCC(=O)N(C)CCC2=CC=CC=N2
DMPW28M IK YPPRSIHNTQEZCJ-UHFFFAOYSA-N
DMPW28M IU 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide
DMPW28M DE Insomnia
DM6F5EV ID DM6F5EV
DM6F5EV DN PD-360324
DM6F5EV HS Phase 2
DM6F5EV SN PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer
DM6F5EV CP Pfizer
DM6F5EV DE Rheumatoid arthritis
DMGP9VN ID DMGP9VN
DMGP9VN DN PDC-1421
DMGP9VN HS Phase 2
DMGP9VN CP BioLite
DMGP9VN DE Attention deficit hyperactivity disorder
DM6OC53 ID DM6OC53
DM6OC53 DN PDX-101
DM6OC53 HS Phase 2
DM6OC53 SN Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684
DM6OC53 CP National Cancer Institute (NCI)
DM6OC53 TC Anticancer Agents
DM6OC53 DT Small molecular drug
DM6OC53 PC 6918638
DM6OC53 MW 318.3
DM6OC53 FM C15H14N2O4S
DM6OC53 IC InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
DM6OC53 CS C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
DM6OC53 IK NCNRHFGMJRPRSK-MDZDMXLPSA-N
DM6OC53 IU (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
DM6OC53 CA CAS 866323-14-0
DM6OC53 CB CHEBI:61076
DM6OC53 DE Solid tumour/cancer; Haematological malignancy; Peripheral T-cell lymphoma
DMFL96Z ID DMFL96Z
DMFL96Z DN Pegamotecan
DMFL96Z HS Phase 2
DMFL96Z SN Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
DMFL96Z CP Enzon Pharmaceuticals Inc
DMFL96Z DT Small molecular drug
DMFL96Z PC 11297617
DMFL96Z MW 981
DMFL96Z FM C52H48N6O14
DMFL96Z IC InChI=1S/C52H48N6O14/c1-5-51(35-19-39-43-31(17-29-11-7-9-13-37(29)55-43)21-57(39)45(61)33(35)23-69-49(51)65)71-47(63)27(3)53-41(59)25-67-15-16-68-26-42(60)54-28(4)48(64)72-52(6-2)36-20-40-44-32(18-30-12-8-10-14-38(30)56-44)22-58(40)46(62)34(36)24-70-50(52)66/h7-14,17-20,27-28H,5-6,15-16,21-26H2,1-4H3,(H,53,59)(H,54,60)/t27-,28-,51-,52-/m0/s1
DMFL96Z CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]6(C7=C(COC6=O)C(=O)N8CC9=CC1=CC=CC=C1N=C9C8=C7)CC
DMFL96Z IK DZNNFZGDBUXWMV-ZUWDIFAMSA-N
DMFL96Z IU [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[2-[2-[2-[[(2S)-1-[[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-1-oxopropan-2-yl]amino]-2-oxoethoxy]ethoxy]acetyl]amino]propanoate
DMFL96Z CA CAS 581079-18-7
DMFL96Z DE Esophageal cancer
DMPD3X6 ID DMPD3X6
DMPD3X6 DN Pegmusirudin
DMPD3X6 HS Phase 2
DMPD3X6 SN BSF-87981; LU-57291; LU-87981; Polyethylene glycol hirudin, Knoll; SPP-200; PEG-hirudin, Knoll
DMPD3X6 CP Knoll GmbH
DMPD3X6 PC 56841834
DMPD3X6 MW 7266
DMPD3X6 FM C299H462N84O115S6
DMPD3X6 IC InChI=1S/C299H462N84O115S6/c1-27-142(21)234-289(485)361-171(97-134(5)6)244(440)323-120-216(410)335-188(124-385)273(469)337-154(45-34-36-86-317-298(493)497-95-93-495-29-3)240(436)319-114-210(404)332-161(67-80-221(418)419)250(446)338-156(47-38-88-315-296(310)311)248(444)356-180(106-205(305)399)266(462)343-162(61-74-201(301)395)257(453)367-194(130-502-499-127-191-247(443)326-116-209(403)329-157(64-77-218(412)413)241(437)320-117-213(407)333-179(105-204(304)398)265(461)339-155(46-35-37-87-318-299(494)498-96-94-496-30-4)249(445)366-195(279(475)376-234)131-503-500-128-192(276(472)340-159(66-79-220(416)417)243(439)321-119-215(409)336-189(125-386)274(470)359-183(109-208(308)402)272(468)373-231(139(15)16)287(483)371-191)368-261(457)174(100-137(11)12)352-277(473)193-129-501-504-132-196(370-270(466)186(112-229(434)435)363-291(487)238(146(25)390)378-271(467)177(103-150-54-58-153(393)59-55-150)362-286(482)232(140(17)18)375-284(480)230(309)138(13)14)280(476)379-237(145(24)389)290(486)347-167(71-84-225(426)427)256(452)364-187(123-384)246(442)325-115-211(405)331-160(60-73-200(300)394)251(447)357-181(107-206(306)400)267(463)351-173(99-136(9)10)260(456)369-193)278(474)374-233(141(19)20)288(484)380-236(144(23)388)285(481)327-121-212(406)330-158(65-78-219(414)415)242(438)322-122-217(411)372-239(147(26)391)294(490)383-92-42-51-199(383)283(479)348-169(48-39-89-316-297(312)313)292(488)381-90-40-49-197(381)281(477)345-163(62-75-202(302)396)255(451)365-190(126-387)275(471)355-178(104-151-113-314-133-328-151)264(460)358-182(108-207(307)401)268(464)360-184(110-227(430)431)245(441)324-118-214(408)334-185(111-228(432)433)269(465)354-175(101-148-43-32-31-33-44-148)262(458)344-164(68-81-222(420)421)252(448)342-168(72-85-226(428)429)258(454)377-235(143(22)28-2)293(489)382-91-41-50-198(382)282(478)346-166(70-83-224(424)425)253(449)341-165(69-82-223(422)423)254(450)353-176(102-149-52-56-152(392)57-53-149)263(459)350-172(98-135(7)8)259(455)349-170(295(491)492)63-76-203(303)397/h31-33,43-44,52-59,113,133-147,154-199,230-239,384-393H,27-30,34-42,45-51,60-112,114-132,309H2,1-26H3,(H2,300,394)(H2,301,395)(H2,302,396)(H2,303,397)(H2,304,398)(H2,305,399)(H2,306,400)(H2,307,401)(H2,308,402)(H,314,328)(H,317,493)(H,318,494)(H,319,436)(H,320,437)(H,321,439)(H,322,438)(H,323,440)(H,324,441)(H,325,442)(H,326,443)(H,327,481)(H,329,403)(H,330,406)(H,331,405)(H,332,404)(H,333,407)(H,334,408)(H,335,410)(H,336,409)(H,337,469)(H,338,446)(H,339,461)(H,340,472)(H,341,449)(H,342,448)(H,343,462)(H,344,458)(H,345,477)(H,346,478)(H,347,486)(H,348,479)(H,349,455)(H,350,459)(H,351,463)(H,352,473)(H,353,450)(H,354,465)(H,355,471)(H,356,444)(H,357,447)(H,358,460)(H,359,470)(H,360,464)(H,361,485)(H,362,482)(H,363,487)(H,364,452)(H,365,451)(H,366,445)(H,367,453)(H,368,457)(H,369,456)(H,370,466)(H,371,483)(H,372,411)(H,373,468)(H,374,474)(H,375,480)(H,376,475)(H,377,454)(H,378,467)(H,379,476)(H,380,484)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,428,429)(H,430,431)(H,432,433)(H,434,435)(H,491,492)(H4,310,311,315)(H4,312,313,316)/t142-,143-,144+,145+,146+,147+,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-/m0/s1
DMPD3X6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCNC(=O)OCCOCC)CC(=O)N)CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CCC(=O)O)CCCCNC(=O)OCCOCC)CO)CC(C)C
DMPD3X6 IK MFPRYDMAZLLTGM-IJDGSQHYSA-N
DMPD3X6 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-15-(3-carbamimidamidopropyl)-18,47,67-tris(2-carboxyethyl)-24,76-bis[4-(2-ethoxyethoxycarbonylamino)butyl]-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMPD3X6 DE Angina pectoris
DM26YJ1 ID DM26YJ1
DM26YJ1 DN PEGPH20
DM26YJ1 HS Phase 2
DM26YJ1 CP Halozyme Therapeutics San Diego, CA
DM26YJ1 DE Pancreatic cancer; Gallbladder disease; Gastric adenocarcinoma; Non-small-cell lung cancer
DMX9ZM4 ID DMX9ZM4
DMX9ZM4 DN PEG-SN38
DMX9ZM4 HS Phase 2
DMX9ZM4 SN EZN-2208
DMX9ZM4 CP Enzon pharmaceuticals
DMX9ZM4 DT Small molecular drug
DMX9ZM4 PC 59443782
DMX9ZM4 MW 2300.3
DMX9ZM4 FM C118H122N12O37
DMX9ZM4 IC InChI=1S/C118H122N12O37/c1-9-67-71-33-61(131)17-21-87(71)123-103-75(67)45-127-91(103)37-83-79(107(127)143)53-160-111(147)115(83,13-5)164-99(139)41-119-95(135)57-153-27-25-151-49-65(158-31-29-155-59-97(137)121-43-101(141)166-117(15-7)85-39-93-105-77(47-129(93)109(145)81(85)55-162-113(117)149)69(11-3)73-35-63(133)19-23-89(73)125-105)51-157-52-66(159-32-30-156-60-98(138)122-44-102(142)167-118(16-8)86-40-94-106-78(48-130(94)110(146)82(86)56-163-114(118)150)70(12-4)74-36-64(134)20-24-90(74)126-106)50-152-26-28-154-58-96(136)120-42-100(140)165-116(14-6)84-38-92-104-76(46-128(92)108(144)80(84)54-161-112(116)148)68(10-2)72-34-62(132)18-22-88(72)124-104/h17-24,33-40,65-66,131-134H,9-16,25-32,41-60H2,1-8H3,(H,119,135)(H,120,136)(H,121,137)(H,122,138)/t65?,66?,115-,116-,117-,118-/m0/s1
DMX9ZM4 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)O)N=C8C7=C6)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)O
DMX9ZM4 IK CXWRXYDTWCBSJF-DPTNTHPESA-N
DMX9ZM4 IU [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[[2-[2-[3-[2,3-bis[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]-2-[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]ethoxy]acetyl]amino]acetate
DMX9ZM4 CA CAS 946062-05-1
DMX9ZM4 DE Metastatic colorectal cancer; Breast cancer
DMTDANB ID DMTDANB
DMTDANB DN Pegsunercept
DMTDANB HS Phase 2
DMTDANB SN STNF-R1
DMTDANB CP Amgen
DMTDANB DE Rheumatoid arthritis
DMBPJ9U ID DMBPJ9U
DMBPJ9U DN PEGylated pitrakinra
DMBPJ9U HS Phase 2
DMBPJ9U SN Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance
DMBPJ9U CP Aerovance
DMBPJ9U DT Monoclonal antibody
DMBPJ9U DE Allergy; Asthma
DMOMN31 ID DMOMN31
DMOMN31 DN PEITC
DMOMN31 HS Phase 2
DMOMN31 SN Phenethyl-isothiocyanate
DMOMN31 CP New York University
DMOMN31 DT Small molecular drug
DMOMN31 PC 16741
DMOMN31 MW 163.24
DMOMN31 FM C9H9NS
DMOMN31 IC InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
DMOMN31 CS C1=CC=C(C=C1)CCN=C=S
DMOMN31 IK IZJDOKYDEWTZSO-UHFFFAOYSA-N
DMOMN31 IU 2-isothiocyanatoethylbenzene
DMOMN31 CA CAS 2257-09-2
DMOMN31 CB CHEBI:351346
DMOMN31 DE Prostate cancer
DMIW453 ID DMIW453
DMIW453 DN Pelitinib
DMIW453 HS Phase 2
DMIW453 SN EKB-569; EKI-569; WAY-EKB-569
DMIW453 CP Wyeth
DMIW453 DT Small molecular drug
DMIW453 PC 6445562
DMIW453 MW 467.9
DMIW453 FM C24H23ClFN5O2
DMIW453 IC InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+
DMIW453 CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)/C=C/CN(C)C
DMIW453 IK WVUNYSQLFKLYNI-AATRIKPKSA-N
DMIW453 IU (E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMIW453 CA CAS 257933-82-7
DMIW453 CB CHEBI:38927
DMIW453 DE Lymphoma
DMR6USG ID DMR6USG
DMR6USG DN PELITREXOL
DMR6USG HS Phase 2
DMR6USG SN AG-2037; Pelitrexol < USAN; AG-2032 (racemate); AG-2038 ((6R)-isomer); N-[5-[2-[2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6(S)-yl]ethyl]-4-methylthien-2-ylcarbonyl]-L-glutamic acid
DMR6USG DT Small molecular drug
DMR6USG PC 135431074
DMR6USG MW 463.5
DMR6USG FM C20H25N5O6S
DMR6USG IC InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
DMR6USG CS CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N
DMR6USG IK QXOPTIPQEVJERB-JQWIXIFHSA-N
DMR6USG IU (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid
DMR6USG CA CAS 446022-33-9
DMR6USG DE Solid tumour/cancer
DMGY5JC ID DMGY5JC
DMGY5JC DN Pentacea
DMGY5JC HS Phase 2
DMGY5JC SN HMN14-734; Bispecific CEA antibody (radiotherapeutic pretargeting), IBC; Anti-CEA/anti-In-DTPA antibody, IBC
DMGY5JC CP IBC Pharmaceuticals Inc
DMGY5JC DT Antibody
DMGY5JC DE Small-cell lung cancer
DMNU48O ID DMNU48O
DMNU48O DN Peptide YY 3-36
DMNU48O HS Phase 2
DMNU48O SN YY 3-36; Peptide YY 3-36 (oral, eligen)
DMNU48O CP Emisphere Technologies Inc
DMNU48O DE Obesity
DMFM6OU ID DMFM6OU
DMFM6OU DN PerioPatch
DMFM6OU HS Phase 2
DMFM6OU CP Izun Pharmaceuticals Corp
DMFM6OU DE Periodontal disease
DMNM4CK ID DMNM4CK
DMNM4CK DN PF-00734200
DMNM4CK HS Phase 2
DMNM4CK SN GOSOGLIPTIN; 869490-23-3; UNII-GI718UO477; PF-00734200; PF-734200; CHEMBL515387; GI718UO477; 2-(4-{(3s,5s)-5-[(3,3-Difluoropyrrolidin-1-Yl)carbonyl]pyrrolidin-3-Yl}piperazin-1-Yl)pyrimidine; 869490-47-1; (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone; (3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone; (3,3-DIFLUOROPYRROLIDIN-1-YL)[(2S,4S)-4-[4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL]PYRROLIDIN-2-YL]METHANONE; Gosogliptin [USAN:
DMNM4CK DT Small molecular drug
DMNM4CK PC 11516136
DMNM4CK MW 366.4
DMNM4CK FM C17H24F2N6O
DMNM4CK IC InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
DMNM4CK CS C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4
DMNM4CK IK QWEWGXUTRTXFRF-KBPBESRZSA-N
DMNM4CK IU (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone
DMNM4CK CA CAS 869490-23-3
DMNM4CK DE Type-2 diabetes
DMJPE61 ID DMJPE61
DMJPE61 DN PF-02545920
DMJPE61 HS Phase 2
DMJPE61 SN 1037309-45-7; 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate; UNII-TJ5KAZ8T5G; TJ5KAZ8T5G; PF-2545920 succinate; SCHEMBL439127; CTK8C0559; DTXSID90647726; ANW-64894; AKOS016005150; KB-80291; Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1); AX8234870; TC-153639; Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt; 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline
DMJPE61 CP Pfizer
DMJPE61 DT Small molecular drug
DMJPE61 PC 11581936
DMJPE61 MW 392.5
DMJPE61 FM C25H20N4O
DMJPE61 IC InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3
DMJPE61 CS CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5
DMJPE61 IK AZEXWHKOMMASPA-UHFFFAOYSA-N
DMJPE61 IU 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline
DMJPE61 CA CAS 898562-94-2
DMJPE61 DE Schizophrenia; Huntington disease
DMTJWNE ID DMTJWNE
DMTJWNE DN PF-03446962
DMTJWNE HS Phase 2
DMTJWNE CP Pfizer New York, NY
DMTJWNE DE Solid tumour/cancer
DM826SW ID DM826SW
DM826SW DN PF-04236921
DM826SW HS Phase 2
DM826SW CP Pfizer New York, NY
DM826SW DE Systemic lupus erythematosus; Crohn disease
DMPRYU1 ID DMPRYU1
DMPRYU1 DN PF-04457845
DMPRYU1 HS Phase 2
DMPRYU1 SN PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
DMPRYU1 DT Small molecular drug
DMPRYU1 PC 24771824
DMPRYU1 MW 455.4
DMPRYU1 FM C23H20F3N5O2
DMPRYU1 IC InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)
DMPRYU1 CS C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4
DMPRYU1 IK BATCTBJIJJEPHM-UHFFFAOYSA-N
DMPRYU1 IU N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide
DMPRYU1 CA CAS 1020315-31-4
DMPRYU1 DE Liver disease
DMZMUIL ID DMZMUIL
DMZMUIL DN PF-04518600
DMZMUIL HS Phase 2
DMZMUIL CP Pfizer New York, NY
DMZMUIL DE Solid tumour/cancer
DMA9MBR ID DMA9MBR
DMA9MBR DN PF-04523655
DMA9MBR HS Phase 2
DMA9MBR CP Pfizer; Quark Pharmaceuticals
DMA9MBR TC siRNA
DMA9MBR DT siRNA drug
DMA9MBR DE Diabetic macular edema
DMS610L ID DMS610L
DMS610L DN PF-04691502
DMS610L HS Phase 2
DMS610L SN PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L CP Pfizer New York, NY
DMS610L DT Small molecular drug
DMS610L PC 25033539
DMS610L MW 425.5
DMS610L FM C22H27N5O4
DMS610L IC InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)
DMS610L CS CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC
DMS610L IK XDLYKKIQACFMJG-UHFFFAOYSA-N
DMS610L IU 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L CA CAS 1013101-36-4
DMS610L DE Endometrial cancer
DMQMF4O ID DMQMF4O
DMQMF4O DN PF-04937319
DMQMF4O HS Phase 2
DMQMF4O CP Pfizer
DMQMF4O PC 46916694
DMQMF4O MW 432.4
DMQMF4O FM C22H20N6O4
DMQMF4O IC InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)
DMQMF4O CS CC1=CC2=C(O1)C=C(C=C2OC3=CN=C(N=C3)C(=O)N(C)C)C(=O)NC4=NC=C(N=C4)C
DMQMF4O IK MASKQITXHVYVFL-UHFFFAOYSA-N
DMQMF4O IU N,N-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide
DMQMF4O CA CAS 1245603-92-2
DMQMF4O DE Type-2 diabetes
DMRAFBK ID DMRAFBK
DMRAFBK DN PF-04958242
DMRAFBK HS Phase 2
DMRAFBK CP Pfizer
DMRAFBK PC 49853967
DMRAFBK MW 392.5
DMRAFBK FM C18H20N2O4S2
DMRAFBK IC InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
DMRAFBK CS CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
DMRAFBK IK TTYKUKSFWHEBLI-DLBZAZTESA-N
DMRAFBK IU N-[(3S,4S)-4-[4-(5-cyanothiophen-2-yl)phenoxy]oxolan-3-yl]propane-2-sulfonamide
DMRAFBK CA CAS 1258963-59-5
DMRAFBK DE Schizophrenia
DM94NBE ID DM94NBE
DM94NBE DN PF-04991532
DM94NBE HS Phase 2
DM94NBE CP Pfizer
DM94NBE PC 46181428
DM94NBE MW 396.4
DM94NBE FM C18H19F3N4O3
DM94NBE IC InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
DM94NBE CS C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F
DM94NBE IK GKMLFBRLRVQVJO-ZDUSSCGKSA-N
DM94NBE IU 6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid
DM94NBE CA CAS 1215197-37-7
DM94NBE DE Diabetic complication
DMD74BJ ID DMD74BJ
DMD74BJ DN PF-05089771
DMD74BJ HS Phase 2
DMD74BJ SN Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer
DMD74BJ CP Pfizer
DMD74BJ PC 46840946
DMD74BJ MW 500.4
DMD74BJ FM C18H12Cl2FN5O3S2
DMD74BJ IC InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
DMD74BJ CS C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
DMD74BJ IK ZYSCOUXLBXGGIM-UHFFFAOYSA-N
DMD74BJ IU 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide
DMD74BJ CA CAS 1235403-62-9
DMD74BJ DE Chronic pain
DMLQ3OK ID DMLQ3OK
DMLQ3OK DN PF-05175157
DMLQ3OK HS Phase 2
DMLQ3OK CP Pfizer
DMLQ3OK PC 52934180
DMLQ3OK MW 405.5
DMLQ3OK FM C23H27N5O2
DMLQ3OK IC InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)
DMLQ3OK CS CC1=NC2=C(N1)C=C(C=C2)C(=O)N3CCC4(CC3)CC5=C(C(=O)C4)N(N=C5)C(C)C
DMLQ3OK IK BDXXSFOJPYSYOC-UHFFFAOYSA-N
DMLQ3OK IU 1'-(2-methyl-3H-benzimidazole-5-carbonyl)-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-7-one
DMLQ3OK CA CAS 1301214-47-0
DMLQ3OK DE Type-2 diabetes
DMPVQYR ID DMPVQYR
DMPVQYR DN PF-05212377
DMPVQYR HS Phase 2
DMPVQYR SN SAM-760
DMPVQYR CP Pfizer New York, NY
DMPVQYR DE Alzheimer disease
DMBL3VD ID DMBL3VD
DMBL3VD DN PF-05212384
DMBL3VD HS Phase 2
DMBL3VD SN PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
DMBL3VD CP Pfizer New York, NY
DMBL3VD DT Small molecular drug
DMBL3VD PC 44516953
DMBL3VD MW 615.7
DMBL3VD FM C32H41N9O4
DMBL3VD IC InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)
DMBL3VD CS CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
DMBL3VD IK DWZAEMINVBZMHQ-UHFFFAOYSA-N
DMBL3VD IU 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
DMBL3VD CA CAS 1197160-78-3
DMBL3VD DE Solid tumour/cancer
DMQLZOF ID DMQLZOF
DMQLZOF DN PF-06252616
DMQLZOF HS Phase 2
DMQLZOF CP Pfizer
DMQLZOF DT Antibody
DMQLZOF DE Muscular dystrophy; Duchenne dystrophy
DMUAOFM ID DMUAOFM
DMUAOFM DN PF-06290510
DMUAOFM HS Phase 2
DMUAOFM CP Pfizer
DMUAOFM DT Vaccine
DMUAOFM DE Staphylococcus infection; Major depressive disorder
DMN94QM ID DMN94QM
DMN94QM DN PF-06291874
DMN94QM HS Phase 2
DMN94QM CP Pfizer
DMN94QM PC 60151939
DMN94QM MW 503.5
DMN94QM FM C26H28F3N3O4
DMN94QM IC InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1
DMN94QM CS CCC[C@@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC(=C(C(=C2)C)N3C=C(C=N3)C(F)(F)F)C
DMN94QM IK IBDYYOQKQCCSDP-QFIPXVFZSA-N
DMN94QM IU 3-[[4-[(1S)-1-[3,5-dimethyl-4-[4-(trifluoromethyl)pyrazol-1-yl]phenoxy]butyl]benzoyl]amino]propanoic acid
DMN94QM CA CAS 1393124-08-7
DMN94QM DE Type-2 diabetes
DMKM7EW ID DMKM7EW
DMKM7EW DN PF-06463922
DMKM7EW HS Phase 2
DMKM7EW SN SCHEMBL15274056
DMKM7EW CP Pfizer
DMKM7EW DT Small molecular drug
DMKM7EW PC 71731823
DMKM7EW MW 406.4
DMKM7EW FM C21H19FN6O2
DMKM7EW IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMKM7EW CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMKM7EW IK IIXWYSCJSQVBQM-LLVKDONJSA-N
DMKM7EW IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMKM7EW CA CAS 1454846-35-5
DMKM7EW CB CHEBI:143117
DMKM7EW DE Solid tumour/cancer; Non-small-cell lung cancer
DM9S3P7 ID DM9S3P7
DM9S3P7 DN PF-06473871
DM9S3P7 HS Phase 2
DM9S3P7 CP Pfizer
DM9S3P7 DT Antisense oligonucleotide
DM9S3P7 DE Hypertrophic scars
DMMGSFV ID DMMGSFV
DMMGSFV DN PF-06700841
DMMGSFV HS Phase 2
DMMGSFV SN BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMMGSFV CP Pfizer New York, NY
DMMGSFV PC 118878093
DMMGSFV MW 389.4
DMMGSFV FM C18H21F2N7O
DMMGSFV IC InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1
DMMGSFV CS CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F
DMMGSFV IK BUWBRTXGQRBBHG-MJBXVCDLSA-N
DMMGSFV IU [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
DMMGSFV CA CAS 1883299-62-4
DMMGSFV DE Asthma; Plaque psoriasis; Psoriasis vulgaris
DM8C1H4 ID DM8C1H4
DM8C1H4 DN PF-06823859
DM8C1H4 HS Phase 2
DM8C1H4 CP Pfizer, New York, NY
DM8C1H4 DE Lupus; Rheumatoid arthritis; Dermatomycosis
DM5H8V1 ID DM5H8V1
DM5H8V1 DN PF-06826647
DM5H8V1 HS Phase 2
DM5H8V1 SN Tyk2-IN-8; 2127109-84-4; Tyk2-IN-9; (1r,3r)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Ropsacitinib; Ropsacitinib [USAN]; UNII-HY5SOV7O0Q; HY5SOV7O0Q; CHEMBL4459585; SCHEMBL19253418; SCHEMBL19253420; SCHEMBL19271747; SCHEMBL19276506; BDBM305820; BDBM305821; BCP33615; EX-A4020; US10144738, Example 19; US10144738, Example 20; MFCD32197240; s9676; WHO 11834; HY-126290A; HY-126290; CS-0101462; CS-0114967; (1s,3s)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)-, trans-; trans-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutanecarbonitrile; trans-3-Cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1H-pyrazol-1-yl)-cyclobutaneacetonitrile
DM5H8V1 CP Pfizer
DM5H8V1 DT Small molecular drug
DM5H8V1 PC 130339268
DM5H8V1 MW 383.4
DM5H8V1 FM C20H17N9
DM5H8V1 IC InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3
DM5H8V1 CS CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N
DM5H8V1 IK XPLZTJWZDBFWDE-UHFFFAOYSA-N
DM5H8V1 IU 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile
DM5H8V1 CA CAS 2127109-84-4
DM5H8V1 DE Plaque psoriasis
DM7EJ8S ID DM7EJ8S
DM7EJ8S DN PF-06882961
DM7EJ8S HS Phase 2
DM7EJ8S SN 2230198-02-2; UNII-DN9IUI24GP; DN9IUI24GP; 2230198-02-2 (free acid); (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid; 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid; Danuglipron; UK4; Danuglipron [USAN]; CHEMBL4518483; SCHEMBL20266351; BDBM349662; EX-A3607; WHO 11630; US10208019, Example 1A-09; US10208019, Example 4A-01; 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid; AC-31472; PF6882961; Q63141738; 1H-Benzimidazole-6-carboxylic acid, 2-((4-(6-((4-cyano-2-fluorophenyl)methoxy)-2-pyridinyl)-1-piperidinyl)methyl)-1-((2S)-2-oxetanylmethyl)-; 2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F
DM7EJ8S CP Pfizer
DM7EJ8S DT Small molecular drug
DM7EJ8S PC 134611040
DM7EJ8S MW 555.6
DM7EJ8S FM C31H30FN5O4
DM7EJ8S IC InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
DM7EJ8S CS C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
DM7EJ8S IK HYBAKUMPISVZQP-DEOSSOPVSA-N
DM7EJ8S IU 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
DM7EJ8S CA CAS 2230198-02-2
DM7EJ8S DE Type 2 diabetes
DM8T6KQ ID DM8T6KQ
DM8T6KQ DN PF-232798
DM8T6KQ HS Phase 2
DM8T6KQ SN PF-00232798
DM8T6KQ CP Pfizer Inc
DM8T6KQ DT Small molecular drug
DM8T6KQ PC 53316710
DM8T6KQ MW 509.7
DM8T6KQ FM C29H40FN5O2
DM8T6KQ IC InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25?,26-/m0/s1
DM8T6KQ CS CC1=NC2=C(N1C3C[C@H]4CC[C@@H](C3)N4CC[C@@H](C5=CC(=CC=C5)F)NC(=O)C)CCN(C2)C(=O)C(C)C
DM8T6KQ IK QETUKYDWZIRTEI-HLMSNRGBSA-N
DM8T6KQ IU N-[(1S)-1-(3-fluorophenyl)-3-[(1R,5S)-3-[2-methyl-5-(2-methylpropanoyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]octan-8-yl]propyl]acetamide
DM8T6KQ CA CAS 849753-15-7
DM8T6KQ DE Human immunodeficiency virus infection
DMO02LU ID DMO02LU
DMO02LU DN PF-3463275
DMO02LU HS Phase 2
DMO02LU SN PF-03463275
DMO02LU CP Pfizer Inc
DMO02LU PC 44156901
DMO02LU MW 376.9
DMO02LU FM C19H22ClFN4O
DMO02LU IC InChI=1S/C19H22ClFN4O/c1-23-7-13-14(8-23)15(13)9-25(19(26)18-10-24(2)11-22-18)6-12-3-4-17(21)16(20)5-12/h3-5,10-11,13-15H,6-9H2,1-2H3/t13-,14+,15?
DMO02LU CS CN1C[C@@H]2[C@H](C1)C2CN(CC3=CC(=C(C=C3)F)Cl)C(=O)C4=CN(C=N4)C
DMO02LU IK KYLOBHXXQOZRKK-YIONKMFJSA-N
DMO02LU IU N-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-N-[[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide
DMO02LU CA CAS 1173239-39-8
DMO02LU DE Schizophrenia
DMC2FAL ID DMC2FAL
DMC2FAL DN PF-3893787
DMC2FAL HS Phase 2
DMC2FAL SN PF-03893787; PF-3826719
DMC2FAL CP Pfizer Inc
DMC2FAL DT Small molecular drug
DMC2FAL PC 24745335
DMC2FAL MW 262.35
DMC2FAL FM C13H22N6
DMC2FAL IC InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
DMC2FAL CS CN[C@@H]1CCN(C1)C2=NC(=NC(=C2)NCC3CC3)N
DMC2FAL IK ISBHYKVAFKTATD-SNVBAGLBSA-N
DMC2FAL IU 4-N-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
DMC2FAL CA CAS 943057-12-3
DMC2FAL DE Asthma; Atopic dermatitis; Plaque psoriasis
DM3DWKN ID DM3DWKN
DM3DWKN DN PF-4191834
DM3DWKN HS Phase 2
DM3DWKN SN PF-04191834
DM3DWKN CP Pfizer Inc
DM3DWKN DT Small molecular drug
DM3DWKN PC 24986635
DM3DWKN MW 393.5
DM3DWKN FM C22H23N3O2S
DM3DWKN IC InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
DM3DWKN CS CN1C(=CC=N1)C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
DM3DWKN IK DVNQWYLVSNPCJZ-UHFFFAOYSA-N
DM3DWKN IU 4-[3-[4-(2-methylpyrazol-3-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
DM3DWKN CA CAS 1029317-21-2
DM3DWKN DE Asthma
DM81D4I ID DM81D4I
DM81D4I DN PF-4447943
DM81D4I HS Phase 2
DM81D4I SN BCP16255
DM81D4I CP Pfizer Inc
DM81D4I DT Small molecular drug
DM81D4I PC 135564558
DM81D4I MW 395.5
DM81D4I FM C20H25N7O2
DM81D4I IC InChI=1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)/t13-,16-/m1/s1
DM81D4I CS C[C@@H]1CN(C[C@H]1C2=NC3=C(C=NN3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM81D4I IK IWXUVYOOUMLUTQ-CZUORRHYSA-N
DM81D4I IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(oxan-4-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DM81D4I CA CAS 1082744-20-4
DM81D4I DE Alzheimer disease; Sickle-cell disorder
DML38VU ID DML38VU
DML38VU DN PF-446687
DML38VU HS Phase 2
DML38VU SN PF-00446687; PF-2336652
DML38VU CP Pfizer Inc
DML38VU DE Female sexual arousal dysfunction
DM3YIKR ID DM3YIKR
DM3YIKR DN PF-4523655
DM3YIKR HS Phase 2
DM3YIKR CP Quark Pharm; Pfizer
DM3YIKR DT siRNA drug
DM3YIKR DE Age-related macular degeneration; Diabetic macular degeneration
DM24I0N ID DM24I0N
DM24I0N DN PF-4878691
DM24I0N HS Phase 2
DM24I0N SN PF-04878691; PF-4171455
DM24I0N CP Pfizer Inc
DM24I0N PC 10309114
DM24I0N MW 361.5
DM24I0N FM C17H23N5O2S
DM24I0N IC InChI=1S/C17H23N5O2S/c1-3-14-21-15-16(12-8-4-5-9-13(12)20-17(15)18)22(14)11-7-6-10-19-25(2,23)24/h4-5,8-9,19H,3,6-7,10-11H2,1-2H3,(H2,18,20)
DM24I0N CS CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N
DM24I0N IK YZOQZEXYFLXNKA-UHFFFAOYSA-N
DM24I0N IU N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
DM24I0N CA CAS 532959-63-0
DM24I0N DE Hepatitis C virus infection; Melanoma
DM3C8GQ ID DM3C8GQ
DM3C8GQ DN PF-489791
DM3C8GQ HS Phase 2
DM3C8GQ SN UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
DM3C8GQ CP Pfizer New York, NY
DM3C8GQ DT Small molecular drug
DM3C8GQ PC 11465695
DM3C8GQ MW 476.6
DM3C8GQ FM C20H28N8O4S
DM3C8GQ IC InChI=1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
DM3C8GQ CS CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(=O)C)CCOCC
DM3C8GQ IK ZUHZNKJIJDAJFD-UHFFFAOYSA-N
DM3C8GQ IU 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-N-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide
DM3C8GQ CA CAS 853003-48-2
DM3C8GQ DE Raynaud disease; Chronic obstructive pulmonary disease
DM0KRLJ ID DM0KRLJ
DM0KRLJ DN PF-885706
DM0KRLJ HS Phase 2
DM0KRLJ SN PF-00885706
DM0KRLJ CP Pfizer Inc
DM0KRLJ DE Gastroesophageal reflux disease
DMF5YEN ID DMF5YEN
DMF5YEN DN PG-102
DMF5YEN HS Phase 2
DMF5YEN SN TNX-100; 5-D12
DMF5YEN CP PanGenetics BV
DMF5YEN DE Autoimmune diabetes
DMJTYO4 ID DMJTYO4
DMJTYO4 DN PGL-2
DMJTYO4 HS Phase 2
DMJTYO4 CP ProSci
DMJTYO4 DE Endometriosis
DMKA705 ID DMKA705
DMKA705 DN PGL-2001
DMKA705 HS Phase 2
DMKA705 SN Steroid sulfatase inhibitor (endometriosis), PregLem
DMKA705 CP Ipsen
DMKA705 PC 6918339
DMKA705 MW 351.5
DMKA705 FM C18H25NO4S
DMKA705 IC InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
DMKA705 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMKA705 IK YXYXCSOJKUAPJI-ZBRFXRBCSA-N
DMKA705 IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
DMKA705 CA CAS 172377-52-5
DMKA705 DE Endometriosis
DM9JGTQ ID DM9JGTQ
DM9JGTQ DN PH10 nasal spray
DM9JGTQ HS Phase 2
DM9JGTQ CP Pherin Pharmaceuticals Los Altos, CA
DM9JGTQ DE Major depressive disorder
DM71HVW ID DM71HVW
DM71HVW DN PH-794428
DM71HVW HS Phase 2
DM71HVW SN PHA-794428
DM71HVW CP Pfizer
DM71HVW DE Growth hormone deficiency
DMGYBZI ID DMGYBZI
DMGYBZI DN PHA-739358
DMGYBZI HS Phase 2
DMGYBZI SN Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d
DMGYBZI CP Pfizer; Nerviano
DMGYBZI DT Small molecular drug
DMGYBZI PC 11442891
DMGYBZI MW 474.6
DMGYBZI FM C26H30N6O3
DMGYBZI IC InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1
DMGYBZI CS CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)[C@@H](C5=CC=CC=C5)OC
DMGYBZI IK XKFTZKGMDDZMJI-HSZRJFAPSA-N
DMGYBZI IU N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
DMGYBZI CA CAS 827318-97-8
DMGYBZI CB CHEBI:94490
DMGYBZI DE Prostate cancer
DMS2Q9G ID DMS2Q9G
DMS2Q9G DN PHA848125
DMS2Q9G HS Phase 2
DMS2Q9G SN Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide
DMS2Q9G CP Nerviano Medical Services
DMS2Q9G DT Small molecular drug
DMS2Q9G PC 16718576
DMS2Q9G MW 460.6
DMS2Q9G FM C25H32N8O
DMS2Q9G IC InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
DMS2Q9G CS CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C
DMS2Q9G IK RXZMYLDMFYNEIM-UHFFFAOYSA-N
DMS2Q9G IU N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
DMS2Q9G CA CAS 802539-81-7
DMS2Q9G DE Thymic cancer
DMRP3CV ID DMRP3CV
DMRP3CV DN Phenylalanine hydroxylase
DMRP3CV HS Phase 2
DMRP3CV SN Oralase; Phenylase; AvPAL-PEG; Phenylalanine hydroxylase, BioMarin; Phenylalanine hydroxylase, IBEX; Poly ethylene glycol-phenylalanine ammonia lyase; Phenylketonuria therapy (enzyme), BioMarin
DMRP3CV CP Biomarin pharmaceutical
DMRP3CV DE Autoimmune diabetes
DMBHPDW ID DMBHPDW
DMBHPDW DN Phenylbutyrate
DMBHPDW HS Phase 2
DMBHPDW SN Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate
DMBHPDW CP Scandinavian
DMBHPDW DT Small molecular drug
DMBHPDW PC 4775
DMBHPDW MW 164.2
DMBHPDW FM C10H12O2
DMBHPDW IC InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
DMBHPDW CS C1=CC=C(C=C1)CCCC(=O)O
DMBHPDW IK OBKXEAXTFZPCHS-UHFFFAOYSA-N
DMBHPDW IU 4-phenylbutanoic acid
DMBHPDW CA CAS 1821-12-1
DMBHPDW CB CHEBI:41500
DMBHPDW DE Urea cycle disorder
DMJWD62 ID DMJWD62
DMJWD62 DN phorbol 12-myristate 13-acetate
DMJWD62 HS Phase 2
DMJWD62 SN TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate
DMJWD62 DT Small molecular drug
DMJWD62 PC 27924
DMJWD62 MW 616.8
DMJWD62 FM C36H56O8
DMJWD62 IC InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1
DMJWD62 CS CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C
DMJWD62 IK PHEDXBVPIONUQT-RGYGYFBISA-N
DMJWD62 IU [(1S,2S,6R,10S,11R,13S,14R,15R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate
DMJWD62 CA CAS 16561-29-8
DMJWD62 CB CHEBI:37537
DMJWD62 DE Acute myeloid leukaemia; Hodgkin lymphoma
DM4FIWC ID DM4FIWC
DM4FIWC DN PI-88/Taxotere
DM4FIWC HS Phase 2
DM4FIWC SN PI-88/docetaxel
DM4FIWC CP Progen Industries
DM4FIWC DE Solid tumour/cancer
DM3ZEYL ID DM3ZEYL
DM3ZEYL DN Piboserod
DM3ZEYL HS Phase 2
DM3ZEYL SN Piboserod; 152811-62-6; UNII-4UQ3S81B25; SB-207266; SB207256; 4UQ3S81B25; N-((1-butylpiperidin-4-yl)methyl)-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; SB 207266; N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxamide; N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; Piboserod [INN:BAN]; Serotonin 5-HT4 Receptor Antagonists; SB207266(Piboserod); AC1L42OO; GTPL225; SCHEMBL467339; CHEMBL356359; BDBM85026; DTXSID60165129
DM3ZEYL DT Small molecular drug
DM3ZEYL PC 177336
DM3ZEYL MW 369.5
DM3ZEYL FM C22H31N3O2
DM3ZEYL IC InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)
DM3ZEYL CS CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42
DM3ZEYL IK KVCSJPATKXABRQ-UHFFFAOYSA-N
DM3ZEYL IU N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
DM3ZEYL CA CAS 152811-62-6
DM3ZEYL DE Atrial fibrillation
DMYL7VR ID DMYL7VR
DMYL7VR DN Piclamilast
DMYL7VR HS Phase 2
DMYL7VR SN Piclamilast; 144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL
DMYL7VR DT Small molecular drug
DMYL7VR PC 154575
DMYL7VR MW 381.2
DMYL7VR FM C18H18Cl2N2O3
DMYL7VR IC InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
DMYL7VR CS COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3
DMYL7VR IK RRRUXBQSQLKHEL-UHFFFAOYSA-N
DMYL7VR IU 3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
DMYL7VR CA CAS 144035-83-6
DMYL7VR CB CHEBI:47619
DMYL7VR DE Rheumatoid arthritis
DMMO46E ID DMMO46E
DMMO46E DN Pidilizumab
DMMO46E HS Phase 2
DMMO46E SN CT-011
DMMO46E CP CureTech
DMMO46E DT Monoclonal antibody
DMMO46E DE Diffuse large B-cell lymphoma
DMAFZ84 ID DMAFZ84
DMAFZ84 DN PIKAMILONE
DMAFZ84 HS Phase 2
DMAFZ84 SN N-Nicotinoyl-gamma-aminobutyric acid sodium salt; N-(3-Pyridylcarbonyl)-4-aminobutyric acid sodium salt
DMAFZ84 DT Small molecular drug
DMAFZ84 PC 60608
DMAFZ84 MW 208.21
DMAFZ84 FM C10H12N2O3
DMAFZ84 IC InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)
DMAFZ84 CS C1=CC(=CN=C1)C(=O)NCCCC(=O)O
DMAFZ84 IK NAJVRARAUNYNDX-UHFFFAOYSA-N
DMAFZ84 IU 4-(pyridine-3-carbonylamino)butanoic acid
DMAFZ84 CA CAS 34562-97-5
DMAFZ84 DE Anxiety disorder
DM96VWD ID DM96VWD
DM96VWD DN PINOCEMBRIN
DM96VWD HS Phase 2
DM96VWD SN Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-
DM96VWD DT Small molecular drug
DM96VWD PC 68071
DM96VWD MW 256.25
DM96VWD FM C15H12O4
DM96VWD IC InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1
DM96VWD CS C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3
DM96VWD IK URFCJEUYXNAHFI-ZDUSSCGKSA-N
DM96VWD IU (2S)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM96VWD CA CAS 480-39-7
DM96VWD CB CHEBI:28157
DM276N1 ID DM276N1
DM276N1 DN Piritrexim
DM276N1 HS Phase 2
DM276N1 SN Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
DM276N1 DT Small molecular drug
DM276N1 PC 54369
DM276N1 MW 325.4
DM276N1 FM C17H19N5O2
DM276N1 IC InChI=1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22)
DM276N1 CS CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N
DM276N1 IK VJXSSYDSOJBUAV-UHFFFAOYSA-N
DM276N1 IU 6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
DM276N1 CA CAS 72732-56-0
DM276N1 DE Bladder cancer
DMC3T2S ID DMC3T2S
DMC3T2S DN PIRODOMAST
DMC3T2S HS Phase 2
DMC3T2S SN Sch-37224; Pirodomast; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one
DMC3T2S DT Small molecular drug
DMC3T2S PC 54680204
DMC3T2S MW 307.3
DMC3T2S FM C18H17N3O2
DMC3T2S IC InChI=1S/C18H17N3O2/c22-16-14-9-6-10-19-17(14)21(13-7-2-1-3-8-13)18(23)15(16)20-11-4-5-12-20/h1-3,6-10,22H,4-5,11-12H2
DMC3T2S CS C1CCN(C1)C2=C(C3=C(N=CC=C3)N(C2=O)C4=CC=CC=C4)O
DMC3T2S IK ULGABHCZIJXUFO-UHFFFAOYSA-N
DMC3T2S IU 4-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-2-one
DMC3T2S CA CAS 108310-20-9
DMC3T2S DE Asthma
DMHI6GE ID DMHI6GE
DMHI6GE DN Pirsidomine
DMHI6GE HS Phase 2
DMHI6GE SN C87-3754; CAS-936
DMHI6GE CP Hoechst Marion Roussel Inc
DMHI6GE DT Small molecular drug
DMHI6GE PC 9571076
DMHI6GE MW 330.4
DMHI6GE FM C17H22N4O3
DMHI6GE IC InChI=1S/C17H22N4O3/c1-12-5-4-6-13(2)21(12)20-11-16(24-19-20)18-17(22)14-7-9-15(23-3)10-8-14/h7-13H,4-6H2,1-3H3/t12-,13+
DMHI6GE CS C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)/N=C(/C3=CC=C(C=C3)OC)\\[O-])C
DMHI6GE IK TXPUBJSOHAMNEI-BETUJISGSA-N
DMHI6GE IU (1Z)-N-[3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzenecarboximidate
DMHI6GE CA CAS 132722-74-8
DMHI6GE DE Angina pectoris
DMKEV7N ID DMKEV7N
DMKEV7N DN PK1
DMKEV7N HS Phase 2
DMKEV7N SN FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin
DMKEV7N DT Small molecular drug
DMKEV7N PC 59235249
DMKEV7N MW 381.3
DMKEV7N FM C17H14Cl2N2O2S
DMKEV7N IC InChI=1S/C17H14Cl2N2O2S/c1-17(10-3-6-12(22)7-4-10)15(23)21(16(24)20(17)2)11-5-8-13(18)14(19)9-11/h3-9,22H,1-2H3/t17-/m1/s1
DMKEV7N CS C[C@]1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)O
DMKEV7N IK YPONBLYNQFHCLA-QGZVFWFLSA-N
DMKEV7N IU (5R)-3-(3,4-dichlorophenyl)-5-(4-hydroxyphenyl)-1,5-dimethyl-2-sulfanylideneimidazolidin-4-one
DMKEV7N DE Solid tumour/cancer
DMHUCQS ID DMHUCQS
DMHUCQS DN PL-3994
DMHUCQS HS Phase 2
DMHUCQS PC 121488161
DMHUCQS MW 1875.2
DMHUCQS FM C82H127N27O20S2
DMHUCQS IC InChI=1S/C82H127N27O20S2/c1-6-9-11-15-25-62(112)98-59-41-130-131-42-60(76(126)104-56(34-47-26-28-49(111)29-27-47)79(129)109-39-57(66(83)116)105-77(127)61(109)24-18-32-93-82(88)89)107-74(124)58(40-110)106-78(128)65(44(4)8-3)108-70(120)52(23-17-31-92-81(86)87)100-73(123)55(36-64(114)115)103-69(119)51(21-10-7-2)99-68(118)50(22-16-30-91-80(84)85)97-63(113)38-94-67(117)45(5)96-71(121)53(33-46-19-13-12-14-20-46)101-72(122)54(102-75(59)125)35-48-37-90-43-95-48/h12-14,19-20,26-29,37,43-45,50-61,65,110-111H,6-11,15-18,21-25,30-36,38-42H2,1-5H3,(H2,83,116)(H,90,95)(H,94,117)(H,96,121)(H,97,113)(H,98,112)(H,99,118)(H,100,123)(H,101,122)(H,102,125)(H,103,119)(H,104,126)(H,105,127)(H,106,128)(H,107,124)(H,108,120)(H,114,115)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t44-,45+,50-,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,65-/m0/s1
DMHUCQS CS CCCCCCC(=O)N[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CNC=N2)CC3=CC=CC=C3)C)CCCNC(=N)N)CCCC)CC(=O)O)CCCNC(=N)N)[C@@H](C)CC)CO)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5C[C@@H](NC(=O)[C@@H]5CCCNC(=N)N)C(=O)N
DMHUCQS IK HSHVZRILAMZYHY-WXSGKXQHSA-N
DMHUCQS IU 2-[(4R,7S,10S,13S,16S,19R,22S,28R,31S,34S,37S)-31-benzyl-10-[(2S)-butan-2-yl]-19-butyl-13,22-bis(3-carbamimidamidopropyl)-4-[[(2S)-1-[(2S,5R)-2-(3-carbamimidamidopropyl)-5-carbamoyl-3-oxopiperazin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-37-(heptanoylamino)-7-(hydroxymethyl)-34-(1H-imidazol-4-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacont-16-yl]acetic acid
DMHUCQS CA CAS 952295-80-6
DMHUCQS DE Hypertension; Congestive heart failure; Asthma
DMYUO6B ID DMYUO6B
DMYUO6B DN PlaMavax
DMYUO6B HS Phase 2
DMYUO6B SN AdCh63-ME-TRAP; MVA-ME-TRAP; ME-TRAP fusion antigen adenoviral vector vaccine (Malaria), Okairos
DMYUO6B CP University of Oxford
DMYUO6B DT Vaccine
DMYUO6B DE Malaria
DMOB1EM ID DMOB1EM
DMOB1EM DN Plasmin
DMOB1EM HS Phase 2
DMOB1EM SN Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke); Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke), Talecris Biotherapeutics
DMOB1EM CP Grifols therapeutics
DMOB1EM DE Occlusive disease; Peripheral arterial disease
DMK10ZC ID DMK10ZC
DMK10ZC DN PLECONARIL
DMK10ZC HS Phase 2
DMK10ZC SN Picovir; Pleconaril < Prop INN; SR-263843; SR-63843; VP-63843; Win-63843; 3-[3,5-Dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC CP ViroPharma
DMK10ZC DT Small molecular drug
DMK10ZC PC 1684
DMK10ZC MW 381.3
DMK10ZC FM C18H18F3N3O3
DMK10ZC IC InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3
DMK10ZC CS CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F
DMK10ZC IK KQOXLKOJHVFTRN-UHFFFAOYSA-N
DMK10ZC IU 3-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC CA CAS 153168-05-9
DMK10ZC DE Virus infection
DM7Y60I ID DM7Y60I
DM7Y60I DN Plevitrexed
DM7Y60I HS Phase 2
DM7Y60I SN ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
DM7Y60I CP BTG
DM7Y60I DT Small molecular drug
DM7Y60I PC 135430970
DM7Y60I MW 532.5
DM7Y60I FM C26H25FN8O4
DM7Y60I IC InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1
DM7Y60I CS CC1=CC2=C(C=C1CN(CC#C)C3=CC(=C(C=C3)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O)F)C(=O)NC(=N2)C
DM7Y60I IK IEJSCSAMMLUINT-NRFANRHFSA-N
DM7Y60I IU (2S)-2-[[4-[(2,7-dimethyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
DM7Y60I CA CAS 153537-73-6
DM7Y60I DE Gastric adenocarcinoma
DMTL39C ID DMTL39C
DMTL39C DN Plevitrexed (R)-isomer
DMTL39C HS Phase 2
DMTL39C SN YW3548
DMTL39C CP BTG
DMTL39C DT Small molecular drug
DMTL39C PC 213022
DMTL39C DE Gastric adenocarcinoma
DMRTD7I ID DMRTD7I
DMRTD7I DN PLX8394
DMRTD7I HS Phase 2
DMRTD7I CP Daiichi sankyo parsippany
DMRTD7I PC 90116675
DMRTD7I MW 542.5
DMRTD7I FM C25H21F3N6O3S
DMRTD7I IC InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1
DMRTD7I CS C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F
DMRTD7I IK YYACLQUDUDXAPA-MRXNPFEDSA-N
DMRTD7I IU (3R)-N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide
DMRTD7I CA CAS 1393466-87-9
DMRTD7I DE Melanoma; Solid tumour/cancer
DMMKOPX ID DMMKOPX
DMMKOPX DN PM-00104
DMMKOPX HS Phase 2
DMMKOPX SN Zalypsis; PM00104; UNII-C21EZR41AY; C21EZR41AY; PM-00104; 308359-57-1; (6aS,7R,13S,14S,16R)-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-16-[({(2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl}amino)methyl]-6,7,12,13,14,16-hexahydro-6aH-7,13-epimino[1,3]dioxolo[7,8]isoquino[3,2-b][3]benzazocin-5-yl acetate; SCHEMBL7975282; DTXSID0044026; NOCAS_44026; DB12454; CS-1940; HY-16401; 2-Propenamide, N-(((6aS,7R,13S,14S,16R)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo
DMMKOPX CP PharmaMar
DMMKOPX DT Small molecular drug
DMMKOPX PC 16061448
DMMKOPX MW 709.7
DMMKOPX FM C37H38F3N3O8
DMMKOPX IC InChI=1S/C37H38F3N3O8/c1-17-11-21-13-25-36(47)43-24(30(42(25)4)28(21)31(46)32(17)48-5)14-23-29(35-34(49-16-50-35)18(2)33(23)51-19(3)44)26(43)15-41-27(45)10-9-20-7-6-8-22(12-20)37(38,39)40/h6-12,24-26,30,36,46-47H,13-16H2,1-5H3,(H,41,45)/b10-9+/t24-,25-,26-,30-,36-/m0/s1
DMMKOPX CS CC1=CC2=C([C@@H]3[C@@H]4CC5=C(C(=C6C(=C5[C@@H](N4[C@H]([C@H](C2)N3C)O)CNC(=O)/C=C/C7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O
DMMKOPX IK VPAHZSUNBOYNQY-DLVGLDQCSA-N
DMMKOPX IU [(1R,2S,13R,15S,16S)-15,22-dihydroxy-21-methoxy-6,20,24-trimethyl-13-[[[(E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl]amino]methyl]-8,10-dioxa-14,24-diazahexacyclo[14.7.1.02,14.04,12.07,11.018,23]tetracosa-4,6,11,18(23),19,21-hexaen-5-yl] acetate
DMMKOPX CA CAS 308359-57-1
DMMKOPX DE Solid tumour/cancer
DMS34YO ID DMS34YO
DMS34YO DN PM184
DMS34YO HS Phase 2
DMS34YO CP PharmaMar Madrid, Spain
DMS34YO DE Colorectal cancer
DM0OVZ2 ID DM0OVZ2
DM0OVZ2 DN PMID27841036-Compound-37
DM0OVZ2 HS Phase 2
DM0OVZ2 SN 2X-121
DM0OVZ2 CP EISAI INC. XU, Weizheng DELAHANTY, Greg WEI, Ling ZHANG, Jie
DM0OVZ2 DT Small molecular drug
DM0OVZ2 PC 135565981
DM0OVZ2 MW 317.3
DM0OVZ2 FM C18H15N5O
DM0OVZ2 IC InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7H,8-10H2,(H,22,24)(H,19,20,21)
DM0OVZ2 CS C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3
DM0OVZ2 IK JLFSBHQQXIAQEC-UHFFFAOYSA-N
DM0OVZ2 IU 11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one
DM0OVZ2 CA CAS 1140964-99-3
DM0OVZ2 DE Ovarian cancer
DMZUAJ4 ID DMZUAJ4
DMZUAJ4 DN PMX-53
DMZUAJ4 HS Phase 2
DMZUAJ4 SN YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam
DMZUAJ4 DT Small molecular drug
DMZUAJ4 PC 6918468
DMZUAJ4 MW 896.1
DMZUAJ4 FM C47H65N11O7
DMZUAJ4 IC InChI=1S/C47H65N11O7/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51)/t35-,36-,37-,38+,39-,40-/m0/s1
DMZUAJ4 CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CCCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]3CCCN3C2=O)CC4CCCCC4)CC5=CNC6=CC=CC=C65)CCCN=C(N)N
DMZUAJ4 IK YOKBGCTZYPOSQM-HPSWDUTRSA-N
DMZUAJ4 IU (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
DMZUAJ4 DE Atopic dermatitis
DMWT73D ID DMWT73D
DMWT73D DN PMX-60056
DMWT73D HS Phase 2
DMWT73D SN PMX-150; PMX-60054; PMX-60065; PMX-60077; PMX-60079; PMX-60087; PMX-640; PMX-686; PMX-747; PMX-801; Heparin andlow molecular weight heparin (LMWH) reversing agents, PolyMedix
DMWT73D CP PolyMedix Inc
DMWT73D DT Small molecular drug
DMWT73D PC 51349239
DMWT73D MW 1126.3
DMWT73D FM C56H79N13O12
DMWT73D IC InChI=1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1
DMWT73D CS COC1=C(C=C(C=C1)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCCN)C(=O)NC2=CC(=C(C=C2)OC)C(=O)N[C@@H](CCCCN)C(=O)NC3=CC(=C(C=C3)OC)C(=O)N[C@@H](CCCCN)C(=O)NC4=CC(=C(C=C4)OC)C(=O)N
DMWT73D IK PWFIFNGOPQUNIT-ITMZJIMRSA-N
DMWT73D IU N-[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-(3-carbamoyl-4-methoxyanilino)-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]-5-[[(2S)-2,6-diaminohexanoyl]amino]-2-methoxybenzamide
DMWT73D CA CAS 872454-31-4
DMWT73D DE Coagulation defect
DMUVON0 ID DMUVON0
DMUVON0 DN PNT-2258
DMUVON0 HS Phase 2
DMUVON0 CP ProNAi Therapeutics Inc
DMUVON0 DT Antisense drug
DMUVON0 DE Solid tumour/cancer; Diffuse large B-cell lymphoma
DMM8IAQ ID DMM8IAQ
DMM8IAQ DN PNU-142731A
DMM8IAQ HS Phase 2
DMM8IAQ SN 9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride
DMM8IAQ PC 9846800
DMM8IAQ MW 455
DMM8IAQ FM C24H31ClN6O
DMM8IAQ IC InChI=1S/C24H30N6O.ClH/c31-20(27-11-3-4-12-27)17-30-19-10-2-1-9-18(19)21-22(28-13-5-6-14-28)25-24(26-23(21)30)29-15-7-8-16-29;/h1-2,9-10H,3-8,11-17H2;1H
DMM8IAQ CS C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CC(=O)N5CCCC5)N6CCCC6.Cl
DMM8IAQ IK RLFYAIUQWFELJD-UHFFFAOYSA-N
DMM8IAQ IU 2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)-1-pyrrolidin-1-ylethanone;hydrochloride
DMM8IAQ CA CAS 214212-38-1
DMM8IAQ DE Asthma
DM4OT29 ID DM4OT29
DM4OT29 DN POL-6326
DM4OT29 HS Phase 2
DM4OT29 SN CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor
DM4OT29 CP Polyphor Ltd
DM4OT29 DE Human immunodeficiency virus infection; Breast cancer
DMFCIKN ID DMFCIKN
DMFCIKN DN Polivy
DMFCIKN HS Phase 2
DMFCIKN SN Polatuzumab vedotin-piiq
DMFCIKN CP Roche/Genentech
DMFCIKN DT Antibody
DMFCIKN DE Mantle cell lymphoma
DMUXEBQ ID DMUXEBQ
DMUXEBQ DN Polyamine
DMUXEBQ HS Phase 2
DMUXEBQ DE Subjective cognitive decline
DMXROM7 ID DMXROM7
DMXROM7 DN Polyglutamate camptothecin
DMXROM7 HS Phase 2
DMXROM7 SN CT-2106; PG-interferon; Polyglutamate camptothecin, Cell Therapeutics; Polyglutamate-camptothecin; CPT-Gly-PG; Camptothecin-glycine-polyglutamate; PG-CPT, Cell Therapeutics; PG-camptothecin, CT; Polyglutamate-linked anticancer agents, Cell Therapeutics; PG-G-CSF, Cell Therapeutics
DMXROM7 CP Cell Therapeutics Inc
DMXROM7 DE Solid tumour/cancer
DM2570B ID DM2570B
DM2570B DN Poly-ICLC
DM2570B HS Phase 2
DM2570B CP Oncovir
DM2570B DT Small molecular drug
DM2570B PC 136033680
DM2570B MW 879.6
DM2570B FM C26H43N9O21P2
DM2570B IC InChI=1S/C10H13N4O8P.C9H14N3O8P.C5H12N2O2.C2H4O3/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;6-3-1-2-4-7-5(8)9;3-1-2(4)5/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);7H,1-4,6H2,(H,8,9);3H,1H2,(H,4,5)
DM2570B CS C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O
DM2570B IK MRYYMYCQXMFJNE-UHFFFAOYSA-N
DM2570B IU 4-aminobutylcarbamic acid;[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate;2-hydroxyacetic acid
DM2570B DE Glioblastoma multiforme; Recurrent glioblastoma; Solid tumour/cancer
DM3QDA6 ID DM3QDA6
DM3QDA6 DN Polynoma-1
DM3QDA6 HS Phase 2
DM3QDA6 SN Polyvalent melanoma vaccine, Vaccinoma
DM3QDA6 CP Vaccinoma Inc
DM3QDA6 DT Vaccine
DM3QDA6 DE Melanoma
DMIAZ13 ID DMIAZ13
DMIAZ13 DN Ponezumab
DMIAZ13 HS Phase 2
DMIAZ13 SN Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
DMIAZ13 CP Rinat Neuroscience Corp
DMIAZ13 DT Antibody
DMIAZ13 DE Alzheimer disease
DM5HMTB ID DM5HMTB
DM5HMTB DN Porphobilinogen
DM5HMTB HS Phase 2
DM5HMTB SN porphobilinogen; 487-90-1; 3-[5-(AMINOMETHYL)-4-(CARBOXYMETHYL)-1H-PYRROL-3-YL]PROPANOIC ACID; UNII-74KHC72QXK; 1H-Pyrrole-3-propanoic acid, 5-(aminomethyl)-4-(carboxymethyl)-; 2-aminomethylpyrrol-3-acetic acid 4-propionic acid; 74KHC72QXK; PBG; CHEBI:17381; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propanoic acid; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid; 3-(5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl)propanoic acid; 5-(aminomethyl)-4-(carboxymethyl)-pyrrole-3-propionic acid
DM5HMTB DT Small molecular drug
DM5HMTB PC 1021
DM5HMTB MW 226.23
DM5HMTB FM C10H14N2O4
DM5HMTB IC InChI=1S/C10H14N2O4/c11-4-8-7(3-10(15)16)6(5-12-8)1-2-9(13)14/h5,12H,1-4,11H2,(H,13,14)(H,15,16)
DM5HMTB CS C1=C(C(=C(N1)CN)CC(=O)O)CCC(=O)O
DM5HMTB IK QSHWIQZFGQKFMA-UHFFFAOYSA-N
DM5HMTB IU 3-[5-(aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid
DM5HMTB CA CAS 487-90-1
DM5HMTB CB CHEBI:17381
DMH0LM2 ID DMH0LM2
DMH0LM2 DN POT-4
DMH0LM2 HS Phase 2
DMH0LM2 SN AL-78898A; POT-4 EOS Insert; Compstatin complement-inhibiting peptides, Pennsylvania/Potentia; 4(1MeW)7W
DMH0LM2 CP University of Pennsylvania
DMH0LM2 DE Macular degeneration
DMTE8DC ID DMTE8DC
DMTE8DC DN Pozelimab
DMTE8DC HS Phase 2
DMTE8DC SN REGN3918
DMTE8DC CP Regeneron Pharmaceuticals
DMTE8DC DT Antibody
DMTE8DC DE Paroxysmal nocturnal haemoglobinuria
DM4EHVB ID DM4EHVB
DM4EHVB DN PPI-668
DM4EHVB HS Phase 2
DM4EHVB CP Presidio pharmaceuticals
DM4EHVB PC 71665718
DM4EHVB MW 835.8
DM4EHVB FM C42H52Cl2N8O6
DM4EHVB IC InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1
DM4EHVB CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl
DM4EHVB IK JYLMWUZJMRNMDA-SPRBZRACSA-N
DM4EHVB IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride
DM4EHVB CA CAS 1303533-81-4
DM4EHVB DE Hepatitis C virus infection
DMM6J5Z ID DMM6J5Z
DMM6J5Z DN PQ-912
DMM6J5Z HS Phase 2
DMM6J5Z PC 51030870
DMM6J5Z MW 336.4
DMM6J5Z FM C19H20N4O2
DMM6J5Z IC InChI=1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1
DMM6J5Z CS CCCOC1=CC=C(C=C1)[C@H]2CNC(=O)N2C3=CC4=C(C=C3)N=CN4
DMM6J5Z IK XHIKZWOEFZENIX-GOSISDBHSA-N
DMM6J5Z IU (5S)-1-(3H-benzimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one
DMM6J5Z CA CAS 1276021-65-8
DMM6J5Z DE Dementia
DMMCYZ8 ID DMMCYZ8
DMMCYZ8 DN PQR309
DMMCYZ8 HS Phase 2
DMMCYZ8 SN Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)
DMMCYZ8 DT Small molecular drug
DMMCYZ8 PC 58507717
DMMCYZ8 MW 411.4
DMMCYZ8 FM C17H20F3N7O2
DMMCYZ8 IC InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)
DMMCYZ8 CS C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DMMCYZ8 IK ADGGYDAFIHSYFI-UHFFFAOYSA-N
DMMCYZ8 IU 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
DMMCYZ8 CA CAS 1225037-39-7
DMMCYZ8 DE Pain; Squamous head and neck cell carcinom
DM1O0DV ID DM1O0DV
DM1O0DV DN Pradefovir
DM1O0DV HS Phase 2
DM1O0DV SN Remofovir; Pradefovir mesylate; Remofovir mesylate; Hepavir-B; ICN 2001-3; MB-06866; MB-6866; Pradefovir (oral, hepatitis B), Ligand/Chiva
DM1O0DV CP Metabasis Therapeutics Inc
DM1O0DV DT Small molecular drug
DM1O0DV PC 9604654
DM1O0DV MW 423.8
DM1O0DV FM C17H19ClN5O4P
DM1O0DV IC InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)/t14-,28+/m0/s1
DM1O0DV CS C1CO[P@@](=O)(O[C@@H]1C2=CC(=CC=C2)Cl)COCCN3C=NC4=C(N=CN=C43)N
DM1O0DV IK GWNHAOBXDGOXRR-HJFSHJIFSA-N
DM1O0DV IU 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine
DM1O0DV CA CAS 625095-60-5
DM1O0DV DE Hepatitis virus infection
DMIVMR3 ID DMIVMR3
DMIVMR3 DN Prajmaline
DMIVMR3 HS Phase 2
DMIVMR3 SN N(sup 4)-Propylajmalinium; N-Propylajmaline; N-Propylajmalinium; Prajmaline; Prajmalium; Prajmalum; (17R,21-alpha)-17,21-Dihydroxy-4-propylajmalanium; 35080-11-6; 75934UD4GJ; Ajmalanium, 17,21-dihydroxy-4-propyl-, (17R,21-alpha)-; CHEBI:135560; UNII-75934UD4GJ
DMIVMR3 PC 76959818
DMIVMR3 MW 369.5
DMIVMR3 FM C23H33N2O2+
DMIVMR3 IC UAUHEPXILIZYCU-ALHOSYKFSA-N
DMIVMR3 CS CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O
DMIVMR3 IK 1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
DMIVMR3 IU (1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMIVMR3 CA CAS 35080-11-6
DMIVMR3 CB CHEBI:135560
DMIVMR3 DE Atherosclerosis
DM73UTG ID DM73UTG
DM73UTG DN PRALNACASAN
DM73UTG HS Phase 2
DM73UTG SN Pralnacasan; VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG DT Small molecular drug
DM73UTG PC 153270
DM73UTG MW 523.5
DM73UTG FM C26H29N5O7
DM73UTG IC InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1
DM73UTG CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C54
DM73UTG IK CXAGHAZMQSCAKJ-WAHHBDPQSA-N
DM73UTG IU (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG CA CAS 192755-52-5
DM73UTG DE Rheumatoid arthritis
DMBH7XI ID DMBH7XI
DMBH7XI DN Pramiconazole
DMBH7XI HS Phase 2
DMBH7XI SN Azoline; Antifungals, Janssen Research Foundation; R-126638
DMBH7XI CP Barrier Therapeutics
DMBH7XI DT Small molecular drug
DMBH7XI PC 3013050
DMBH7XI MW 659.7
DMBH7XI FM C35H39F2N7O4
DMBH7XI IC InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(4